FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Inyang, AF
   Schwarz, DA
   Jamali, AM
   Buchman, SR
AF Inyang, Alero F.
   Schwarz, Daniel A.
   Jamali, Ameen M.
   Buchman, Steven R.
TI Quantitative Histomorphometric Assessment of Regenerate Cellularity and
   Bone Quality in Mandibular Distraction Osteogenesis After Radiation
   Therapy
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Mandibular distraction osteogenesis; quantitative histomorphometry;
   radiation therapy
ID OSTEOBLAST LIKE CELLS; IONIZING RADIATION; INDUCED IMPAIRMENT; RAT
   FEMUR; IN VITRO; RECONSTRUCTION; SURGERY; DEFECT; HEAD
AB Background: The use of mandibular distraction osteogenesis (MDO) for tissue replacement after oncologic resection in head and neck cancer could have immense therapeutic ramifications. We have previously demonstrated significantly decreased mechanical and microdensitomeric metrics of our MDO regenerate after 36 Gy radiation. Quantitative histomorphometry, a third metric, would permit objective investigation of the effects of radiation on tissue and cellular composition. Our hypothesis is that radiation induced cellular depletion and diminution in function impair optimal bone regeneration.
   Methods: Five rats received radiation to the left mandible; 5 received none. All animals underwent surgical placement of external fixators, creation of mandibular osteotomies, distraction to a 5.1 mm gap width, and consolidation. Point counting and color thresholding were performed.
   Results: There was a significant increase in empty lacunae and a corresponding diminution in osteocytes after radiation. Whereas the volume fraction of mineralized, mature bone was not different, that of nonmineralized, immature osteoid was significantly increased in the radiated group compared with that in the nonradiated group.
   Conclusions: Our findings confirm our prior 2 metrics. Actually, all 3 diverse metrics microdensitometry, biomechanical analysis, and histomorphometry corroborate our hypothesis of cellular depletion and diminution of function as the potential mechanism of radiation induced attenuation in the distracted regenerate. Furthermore, our findings of tissue and cellular changes in the irradiated regenerate elucidate the pathophysiology of decreased bone quality when amalgamated with our previous results. Therapeutic agents may now be introduced, and their effects on the irradiated regenerate critically measured, so that MDO may be used as a viable re constructive option in patients with head and neck cancer.
C1 [Inyang, Alero F.; Schwarz, Daniel A.; Buchman, Steven R.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.
   [Jamali, Ameen M.] Univ Toledo, Coll Med, Toledo, OH 43606 USA.
C3 University of Michigan System; University of Michigan; University System
   of Ohio; University of Toledo
RP Buchman, SR (通讯作者)，Univ Michigan, CS Mott Childrens Hosp, Sch Med, F7859,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM sbuchman@umich.edu
RI Schwarz, Daniel/AAK 6856 2021
OI Buchman, Steven/0000 0001 9742 558X
FU National Institutes of Health [12587 01]
FX Funding supported by the following grants: "Optimization of Bone
   Regeneration in the Irradiated Mandible," National Institutes of Health
   RO1 no. CA 12587 01; PI: Steven R. Buchman, MD.
CR ARNOLD M, 1995, RADIAT RES, V143, P77, DOI 10.2307/3578928
   Arnold M, 1998, RADIOTHER ONCOL, V48, P259, DOI 10.1016/S0167 8140(98)00039 5
   Clark CL, 2006, J ORAL MAXIL SURG, V64, P589, DOI 10.1016/j.joms.2005.12.027
   Dare A, 1997, J DENT RES, V76, P658, DOI 10.1177/00220345970760020601
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Fregene A, 2009, PLAST RECONSTR SURG, V124, P1237, DOI 10.1097/PRS.0b013e3181b5a42f
   GANTOUS A, 1994, PLAST RECONSTR SURG, V93, P164, DOI 10.1097/00006534 199401000 00025
   Gevorgyan A, 2008, PLAST RECONSTR SURG, V122, P1025, DOI 10.1097/PRS.0b013e3181845931
   Gevorgyan A, 2007, J CRANIOFAC SURG, V18, P1044, DOI 10.1097/scs.0b013e31814c916f
   Holmes SB, 2002, J ORAL MAXIL SURG, V60, P305, DOI 10.1053/joms.2002.30581
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278 2391(83)90294 X
   McCarthy J G, 1999, Semin Orthod, V5, P3, DOI 10.1016/S1073 8746(99)80037 1
   MOLINA F, 1995, PLAST RECONSTR SURG, V96, P825, DOI 10.1097/00006534 199509001 00010
   Muhonen A, 2002, INT J ORAL MAX SURG, V31, P519, DOI 10.1054/ijom.2002.0257
   Nakamizo M, 2004, AURIS NASUS LARYNX, V31, P269, DOI 10.1016/j.anl.2004.03.003
   Pelker RR, 1997, CLIN ORTHOP RELAT R, P267
   Raghoebar GM, 2005, J CRANIO MAXILL SURG, V33, P246, DOI 10.1016/j.jcms.2005.02.007
   Ross DA, 2004, LARYNGOSCOPE, V114, P1170, DOI 10.1097/00005537 200407000 00007
   Sawaki Y, 1997, J CRANIO MAXILL SURG, V25, P310, DOI 10.1016/S1010 5182(97)80032 7
   Schwarz DA, 2009, PLAST RECONSTR SURG, V123, p114S, DOI 10.1097/PRS.0b013e318191c5d2
   Shao Z, 2006, J PLAST RECONSTR AES, V59, P181, DOI 10.1016/j.bjps.2005.04.032
   TAKAHASHI S, 1994, INT J RADIAT ONCOL, V30, P1147, DOI 10.1016/0360 3016(94)90322 0
NR 23
TC 15
Z9 18
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1049 2275
EI 1536 3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD SEP
PY 2010
VL 21
IS 5
BP 1438
EP 1442
DI 10.1097/SCS.0b013e3181ec693f
PG 5
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 652JS
UT WOS:000282003300029
PM 20818254
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Berger, L
   Shamai, Y
   Skorecki, KL
   Tzukerman, M
AF Berger, Liron
   Shamai, Yeela
   Skorecki, Karl L.
   Tzukerman, Maty
TI Tumor Specific Recruitment and Reprogramming of Mesenchymal Stem Cells
   in Tumorigenesis
SO STEM CELLS
LA English
DT Article
DE Tumor microenvironment; Tumor derived mesenchymal stem cell; Tumor
   specific recruitment of mesenchymal stem cell; Tumor stromal cell
   interactions; Gastrointestinal cancers; Animal models of cancer
ID INTERNATIONAL SOCIETY; CANCER PROGRESSION; BONE MARROW; IN VITRO;
   MICROENVIRONMENT; MICROVESICLES; FIBROBLASTS; GROWTH; MET; THERAPY
AB Non neoplastic stromal cells harvested from patient tumors were identified as tumor derived mesenchymal stem cells (MSCs) by their multipotential capacity to differentiate into adipocytes, osteoblasts, and chondrocytes and by the expression of MSC specific cell surface markers. These procedures yielded also epithelial cancer cells and their counterpart MSC from gastric carcinoma (GSC1) and lung carcinoma (LC2). While the LC2 cancer cell growth is independent of their LC MSC, the GSC1 cancer cell growth is critically dependent on the presence of their counterpart GSC MSC or their conditioned medium (CM). The fact that none of the various other tumor derived MSCs was able to restore the specific effect of GSC MSC on GSC1 cancer cell growth suggests specificity of tumor derived MSC, which are specifically recruited and educated/reprogrammed by the cancer cells to support tumor growth. Using cytokine array analysis, we were able to demonstrate that GSC1 cell growth is mediated through hepatocyte growth factor (HGF)/c MET signaling pathway which is activated exclusively by HGF secreted from GSC MSC. An innovative approach demonstrates GSC1 mediated specific tropism of naive MSC from the adjacent tissue in a tumor specific manner to support tumor progression. The results suggest that specific tumor tropic naive MSC are reprogrammed in a tumor specific manner to support gastric tumor progression. Understanding the mechanisms involved in the interactions of the tumor cancer cells and tumor derived MSC will constitute the basis for developing multimodal anticancer therapeutic strategies that will also take into account the specific tumor tropism properties of MSC and their reprogramming. Stem Cells2016;34:1011 1026
C1 [Berger, Liron; Shamai, Yeela; Skorecki, Karl L.] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Berger, Liron; Shamai, Yeela; Skorecki, Karl L.] Technion Israel Inst Technol, Res Inst, Haifa, Israel.
   [Skorecki, Karl L.; Tzukerman, Maty] Rambam Med Ctr, Haifa, Israel.
C3 Technion Israel Institute of Technology; Rappaport Faculty of Medicine;
   Technion Israel Institute of Technology; Rambam Health Care Campus
RP Skorecki, KL (通讯作者)，Rambam Med Ctr, Haifa, Israel.; Tzukerman, M (通讯作者)，Rambam Med Ctr, Mol Med, IL 31096 Haifa, Israel.; Skorecki, KL (通讯作者)，Technion Israel Inst Technol, Mol Med Lab, B Rappaport Fac Med, POB 9649, IL 31096 Haifa, Israel.
EM skorecki@techunix.technion.ac.il; bimaty@techunix.technion.ac.il
FU Daniel M. Soref Charitable Trust; Skirball Foundation; Richard D. Satell
   Foundation; Sohnis and Forman families; Israel Science Foundation [62/10
   MT]
FX We thank Ofer Ben Itzhak, Dov Hershkovitz, and Shoshana Ben Eliezer from
   the Pathology Department at Rambam Medical Center for providing the
   tumor tissue samples, Sara Selig for critical reading of the manuscript
   and Irena Reiter for excellent technical assistance. We thank Ilan
   Tsarfaty from Tel Aviv University for the HGF recombinant protein. This
   work was supported by Daniel M. Soref Charitable Trust, the Skirball
   Foundation, the Richard D. Satell Foundation, the Sohnis and Forman
   families, and the Israel Science Foundation (Grant 62/10 MT).
CR Abelson S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083651
   Abelson S, 2012, STEM CELLS, V30, P415, DOI 10.1002/stem.1029
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555 010 9222 7
   Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   Brill A, 2004, CARDIOVASC RES, V63, P226, DOI 10.1016/j.cardiores.2004.04.012
   Bruno S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00382
   Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008 5472.CAN 13 2259
   Camacho L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073790
   Castellana D, 2009, CANCER RES, V69, P785, DOI 10.1158/0008 5472.CAN 08 1946
   Christensen JG, 2003, CANCER RES, V63, P7345
   Chu HY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746 1596 9 123
   Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003
   D'Souza Schorey C, 2012, GENE DEV, V26, P1287, DOI 10.1101/gad.192351.112
   de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Espagnolle N, 2014, J CELL MOL MED, V18, P104, DOI 10.1111/jcmm.12168
   Eyre R, 2014, TUMOR BIOL, V35, P9879, DOI 10.1007/s13277 014 2277 2
   Folkman J, 2004, CANCER BIOL THER, V3, P338, DOI 10.4161/cbt.3.3.708
   Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hoag H, 2014, NATURE, V515, pS118, DOI 10.1038/515S118a
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Imperlini E, 2013, J CELL BIOCHEM, V114, P2577, DOI 10.1002/jcb.24600
   Jamil S, 2013, INT J ONCOL, V43, P831, DOI 10.3892/ijo.2013.2014
   Jamil S, 2014, INT J CANCER, V134, P1630, DOI 10.1002/ijc.28498
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kansy BA, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt484
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Katz E, 2009, CLIN CANCER RES, V15, P70, DOI 10.1158/1078 0432.CCR 08 1233
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001
   Li W, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0172 3
   Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004
   Muralidharan Chari V, 2010, J CELL SCI, V123, P1603, DOI 10.1242/jcs.064386
   Nishimura K, 2012, PATHOBIOLOGY, V79, P290, DOI 10.1159/000337296
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Pap E, 2011, ADV EXP MED BIOL, V714, P183, DOI 10.1007/978 94 007 0782 5_10
   Properzi F, 2013, BIOMARK MED, V7, P769, DOI 10.2217/bmm.13.63
   Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020
   Roson Burgo B, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 910
   Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106
   Schmid R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 349
   Shah K, 2012, ADV DRUG DELIVER REV, V64, P739, DOI 10.1016/j.addr.2011.06.010
   Sun Z, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756 8722 7 14
   Sung SY, 2007, CURR PROB CANCER, V31, P36, DOI 10.1016/j.currproblcancer.2006.12.002
   Thomas GM, 2009, J EXP MED, V206, P1913, DOI 10.1084/jem.20082297
   Tzukerman M, 2006, CANCER RES, V66, P3792, DOI 10.1158/0008 5472.CAN 05 3467
   Tzukerman M, 2003, P NATL ACAD SCI USA, V100, P13507, DOI 10.1073/pnas.2235551100
   Wysoczynski M, 2009, INT J CANCER, V125, P1595, DOI 10.1002/ijc.24479
   Zeng X, 2013, J PROTEOMICS, V89, P51, DOI 10.1016/j.jprot.2013.05.032
NR 52
TC 52
Z9 55
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD APR
PY 2016
VL 34
IS 4
BP 1011
EP 1026
DI 10.1002/stem.2269
PG 16
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA DK1TR
UT WOS:000374697700018
PM 26676563
OA hybrid
DA 2025 08 17
ER

PT J
AU Berti Couto, SA
   Vasconcelos, ACU
   Iglesias, JE
   Figueiredo, MAZ
   Salum, FG
   Cherubini, K
AF Berti Couto, Soraya A.
   Vasconcelos, Ana Carolina U.
   Iglesias, Julia E.
   Figueiredo, Maria Antonia Z.
   Salum, Fernanda G.
   Cherubini, Karen
TI Diabetes mellitus and corticotherapy as risk factors for
   alendronate related osteonecrosis of the jaws: A study in Wistar rats
SO HEAD AND NECK JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE alendronate; bisphosphonates; bisphosphonate related osteonecrosis of
   the jaw (BRONJ); corticotherapy; diabetes mellitus
ID BISPHOSPHONATE INDUCED OSTEONECROSIS; MATRIX METALLOPROTEINASE (MMP) 13;
   BONE MORPHOGENETIC PROTEINS; ZOLEDRONIC ACID; MODEL; OSTEOMYELITIS;
   DEXAMETHASONE; OSTEOPOROSIS; MECHANISMS; EXPRESSION
AB BackgroundThe purpose of this study was to investigate the influence of diabetes and corticotherapy on the development of osteonecrosis of the jaws associated with sodium alendronate.
   MethodsRats were allocated into 4 groups of 11 animals each, representing different treatments: (1) alendronate; (2) alendronate and corticotherapy; (3) alendronate and diabetes; and (4) control. Tooth extractions were performed in all animals, and histological analysis was performed by hematoxylin and eosin staining and immunohistochemistry using anti bone morphogenetic protein (BMP) 4 and anti matrix metalloproteinase (MMP) 13 antibodies.
   ResultsOn hematoxylin and eosin analysis, proportions of inflammatory infiltrate, microbial colonies, and osteonecrosis were significantly greater in the diabetes group. BMP 4 expression in connective tissue was higher in the corticosteroid group than the alendronate group. There were no significant differences between the other groups. MMP 13 expression did not differ between the groups analyzed.
   ConclusionDiabetes but not corticotherapy is associated with jaw osteonecrosis in rats undergoing alendronate therapy and subjected to tooth extractions. (c) 2013 Wiley Periodicals, Inc. Head Neck36: 84 93, 2014
C1 [Berti Couto, Soraya A.; Vasconcelos, Ana Carolina U.; Figueiredo, Maria Antonia Z.; Salum, Fernanda G.; Cherubini, Karen] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Coll Dent, Porto Alegre, RS, Brazil.
   [Iglesias, Julia E.] Pontificia Univ Catolica Rio Grande do Sul, Coll Dent, Porto Alegre, RS, Brazil.
C3 Pontificia Universidade Catolica Do Rio Grande Do Sul; Pontificia
   Universidade Catolica Do Rio Grande Do Sul
RP Cherubini, K (通讯作者)，Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Estomatol, Av Ipiranga 6690 231, BR 90610000 Porto Alegre, RS, Brazil.
EM karen.cherubini@pucrs.br
RI Cherubini, Karen/K 2572 2015; Vasconcelos, Ana Carolina/GXW 3453 2022;
   Eick Iglesias, Julia/HSI 3059 2023
OI Cherubini, Karen/0000 0003 0913 477X; Eick Iglesias,
   Julia/0000 0001 7067 1887
CR Abtahi J, 2012, J ORAL PATHOL MED, V41, P494, DOI 10.1111/j.1600 0714.2011.01125.x
   Adler RA, 2011, J ENDOCRINOL INVEST, V34, P481, DOI [10.1007/BF03346716, 10.3275/7753]
   Aspenberg P, 2011, BONE, V48, P225, DOI 10.1016/j.bone.2010.09.024
   Baltensperger M, 2009, OSTEOMYELITIS JAWS, P316
   Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264
   Bedogni A, 2010, J ORAL MAXIL SURG, V68, P1662, DOI 10.1016/j.joms.2010.02.037
   Bertoldo F, 2007, NAT CLIN PRACT ONCOL, V4, P711, DOI 10.1038/ncponc1000
   Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401
   Brandão Alexandre C., 2002, Braz. Dent. J., V13, P147, DOI 10.1590/S0103 64402002000300001
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Demerjian N, 1999, CLIN RHEUMATOL, V18, P349, DOI 10.1007/s100670050116
   El Miedany YM, 1999, CLIN EXP RHEUMATOL, V17, P561
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   Favus MJ, 2007, J CLIN ENDOCR METAB, V92, P817, DOI 10.1210/jc.2007 0098
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Garimella R, 2008, J HISTOCHEM CYTOCHEM, V56, P569, DOI 10.1369/jhc.2008.950394
   Geoffroy V, 2004, J BONE MINER RES, V19, P811, DOI 10.1359/JBMR.040119
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Greaves P, 2004, NAT REV DRUG DISCOV, V3, P226, DOI 10.1038/nrd1329
   Ríos MH, 2009, J CLIN PERIODONTOL, V36, P1011, DOI 10.1111/j.1600 051X.2009.01488.x
   Hill P A, 1998, Br J Orthod, V25, P101
   Huang RC, 2005, SPINE, V30, P2516, DOI 10.1097/01.brs.0000186470.28070.7b
   Ismael MA, 2008, EUR J PHARMACOL, V589, P66, DOI 10.1016/j.ejphar.2008.05.006
   Jahangiri L, 1997, J PROSTHET DENT, V77, P435, DOI 10.1016/S0022 3913(97)70169 0
   Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495
   Kashii M, 2008, J BONE MINER METAB, V26, P24, DOI 10.1007/s00774 007 0782 8
   Kidambi S, 2008, J AM DENT ASSOC, V139, p8S, DOI 10.14219/jada.archive.2008.0364
   Kumeda Yasuro, 2006, Clin Calcium, V16, P1277
   Lamster IB, 2008, J AM DENT ASSOC, V139, p19S, DOI 10.14219/jada.archive.2008.0363
   Lehnerdt G, 2008, ACTA OTO LARYNGOL, V128, P13, DOI 10.1080/00016480701299659
   Leonardi R, 2005, INT ENDOD J, V38, P297, DOI 10.1111/j.1365 2591.2005.00943.x
   Liu ZD, 2007, ACTA ORTHOP, V78, P46, DOI 10.1080/17453670610013411
   Maahs MP, 2011, HEAD NECK J SCI SPEC, V33, P199, DOI 10.1002/hed.21422
   Manfredi M, 2011, INT J ORAL MAX SURG, V40, P277, DOI 10.1016/j.ijom.2010.11.002
   MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278 2391(83)90294 X
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   McCullough KA, 2007, J ORTHOP RES, V25, P465, DOI 10.1002/jor.20340
   Miazgowski T, 1998, OSTEOPOROSIS INT, V8, P399, DOI 10.1007/s001980050082
   Nannuru KC, 2010, CANCER RES, V70, P3494, DOI 10.1158/0008 5472.CAN 09 3251
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   RAMAMURTHY NS, 1983, J PERIODONTAL RES, V18, P23, DOI 10.1111/j.1600 0765.1983.tb00331.x
   Ruggiero Salvatore L, 2008, Dent Clin North Am, V52, P111, DOI 10.1016/j.cden.2007.09.002
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P1259, DOI 10.14219/jada.archive.2009.0049
   Sharp P.E., 1998, LAB RAT
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Sosa M, 1996, J DIABETES COMPLICAT, V10, P201, DOI 10.1016/1056 8727(95)00062 3
   Spiro AS, 2010, J TRAUMA, V69, P1473, DOI 10.1097/TA.0b013e3181dc59e4
   Vasconcelos ACU, 2012, J ORAL PATHOL MED, V41, P702, DOI 10.1111/j.1600 0714.2012.01140.x
   Wang YJ, 2002, JPN J PHARMACOL, V90, P236, DOI 10.1254/jjp.90.236
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Zhang M, 2008, EXP DIABETES RES, DOI 10.1155/2008/704045
NR 54
TC 25
Z9 26
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1043 3074
EI 1097 0347
J9 HEAD NECK J SCI SPEC
JI Head Neck J. Sci. Spec. Head Neck
PD JAN
PY 2014
VL 36
IS 1
BP 84
EP 93
DI 10.1002/hed.23260
PG 10
WC Otorhinolaryngology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Otorhinolaryngology; Surgery
GA 269CE
UT WOS:000328217300018
PM 23649954
DA 2025 08 17
ER

PT J
AU Heo, JS
   Lim, JY
   Pyo, S
   Yoon, DW
   Lee, D
   Ren, WX
   Lee, SG
   Kim, GJ
   Kim, J
AF Heo, June Seok
   Lim, Ja Yun
   Pyo, Sangshin
   Yoon, Dae Wui
   Lee, Dongsook
   Ren, Wen Xiu
   Lee, Seung Gwan
   Kim, Gi Jin
   Kim, Jinkwan
TI Environmental Benzopyrene Attenuates Stemness of Placenta Derived
   Mesenchymal Stem Cells via Aryl Hydrocarbon Receptor
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID POLYCYCLIC AROMATIC HYDROCARBONS; IN VITRO; OSTEOBLAST DIFFERENTIATION;
   CYCLE CONTROL; ACTIVATION; AHR; BENZO(A)PYRENE; APOPTOSIS; EXTRACT
AB The toxic effects of particulate matter have been linked to polycyclic aromatic hydrocarbons (PAHs) such as benzopyrene. PAHs are potent inducers of the aryl hydrocarbon receptor (AhR), which is an expressed nuclear receptor that senses environmental stimuli and modulates gene expression. Even though several studies have shown that the benzopyrene (BP) of chemical pollutants significantly impaired stem cell activity, the exact molecular mechanisms were not clearly elucidated. In the present study, we aimed to investigate the effects of BP on placenta derived mesenchymal stem cells (PD MSCs) in vitro. We found that the AhR in PD MSCs was expressed under the treatment of BP, and its activation markedly disrupted osteogenic differentiation through the alteration of stemness activity of PD MSCs. Moreover, BP treatment significantly reduced the proliferation activity of PD MSCs and expression of pluripotent markers through the induction of AhR. Treatment with StemRegenin 1 (SR1), a purine derivative that antagonizes the AhR, effectively prevented BP induced reduction of the proliferation and differentiation activity of PD MSCs. In this study, we found that BP treatment in PD MSCs markedly obstructs PD MSC stemness through AhR signaling. Noteworthy, SR1 mediated MSC application will contribute to new perspectives on MSC based therapies for air pollution related bone diseases.
C1 [Heo, June Seok; Lim, Ja Yun; Pyo, Sangshin; Lee, Dongsook] Korea Univ, Coll Hlth Sci, Dept Integrated Biomed & Life Sci, Seoul 03722, South Korea.
   [Yoon, Dae Wui] Seoul Natl Univ, Dept Pharmacol, Obstruct Upper Airway Res Lab, Coll Med, Seoul 03722, South Korea.
   [Ren, Wen Xiu] Southwest Med Univ, Affiliated Hosp, Dept Radiol, Luzhou 400700, Sichuan, Peoples R China.
   [Lee, Seung Gwan] Korea Univ, Coll Hlth Sci, Dept Hlth & Environm Sci, Seoul 03722, South Korea.
   [Kim, Gi Jin] CHA Univ, Dept Biomed Sci, Seongnam 13488, South Korea.
   [Kim, Jinkwan] Jungwon Univ, Dept Biomed Lab Sci, Coll Hlth Sci, Chung Buk 28024, South Korea.
C3 Korea University; Seoul National University (SNU); Southwest Medical
   University; Korea University; Pochon Cha University; Jungwon University
RP Kim, GJ (通讯作者)，CHA Univ, Dept Biomed Sci, Seongnam 13488, South Korea.; Kim, J (通讯作者)，Jungwon Univ, Dept Biomed Lab Sci, Coll Hlth Sci, Chung Buk 28024, South Korea.
EM gjkim@cha.ac.kr; jkkim@jwu.ac.kr
RI ; pyo, sangshin/LQK 7022 2024; Kim, Jinyoung/LFS 2554 2024
OI Kim, Gi Jin/0000 0002 2320 7157; Kim, Jinkwan/0000 0002 7123 1354
FU Jungwon University [2017 050]
FX This work was supported by the Jungwon University Research Grant (number
   2017 050).
CR ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439
   Andrysík Z, 2007, MUTAT RES FUND MOL M, V615, P87, DOI 10.1016/j.mrfmmm.2006.10.004
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524 475X.2008.00410.x
   Bier A, 2018, BIOMATERIALS, V174, P67, DOI 10.1016/j.biomaterials.2018.04.055
   Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536
   Choi YS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172642
   Davila JC, 2004, TOXICOL SCI, V79, P214, DOI 10.1093/toxsci/kfh100
   de Kok TMCM, 2006, MUTAT RES REV MUTAT, V613, P103, DOI 10.1016/j.mrrev.2006.07.001
   Dietrich C, 2010, CARCINOGENESIS, V31, P1319, DOI 10.1093/carcin/bgq028
   Dutta K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009984
   HATTEMERFREY HA, 1991, TOXICOL IND HEALTH, V7, P141, DOI 10.1177/074823379100700303
   Heo JS, 2017, INT J MOL MED, V40, P1486, DOI 10.3892/ijmm.2017.3142
   Herlin M, 2015, TOXICOL IN VITRO, V29, P876, DOI 10.1016/j.tiv.2015.03.006
   Hockley SL, 2007, CHEM RES TOXICOL, V20, P1797, DOI 10.1021/tx700252n
   Kang KS, 2011, TOXICOL SCI, V120, pS269, DOI 10.1093/toxsci/kfq370
   Laberge RM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.199
   Lager S, 2012, J PREGNANCY, V2012, DOI 10.1155/2012/179827
   Lee HJ, 2012, DIFFERENTIATION, V84, P223, DOI 10.1016/j.diff.2012.05.007
   Lee JY, 2016, SCI REP UK, V6, DOI 10.1038/srep33038
   Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024
   Li B, 2015, CELL PHYSIOL BIOCHEM, V35, P433, DOI 10.1159/000369708
   Lin S, 2010, TOXICOL SCI, V118, P202, DOI 10.1093/toxsci/kfq241
   Machala M, 2001, MUTAT RES GEN TOX EN, V497, P49, DOI 10.1016/S1383 5718(01)00240 6
   Matsunawa M, 2009, TOXICOL SCI, V109, P50, DOI 10.1093/toxsci/kfp044
   Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006 2952(99)00310 X
   Page Patrick, 2014, Int J Cell Biol, V2014, P601063, DOI 10.1155/2014/601063
   Podechard N, 2009, TOXICOL IN VITRO, V23, P1139, DOI 10.1016/j.tiv.2009.05.011
   Procházková J, 2011, TOXICOL SCI, V122, P349, DOI 10.1093/toxsci/kfr129
   Rathore K, 2015, RES VET SCI, V103, P34, DOI 10.1016/j.rvsc.2015.09.012
   Ryan EP, 2007, J BONE MINER RES, V22, P1571, DOI 10.1359/JBMR.070615
   Sevastyanova O, 2007, MUTAT RES FUND MOL M, V620, P123, DOI 10.1016/j.mrfmmm.2007.03.002
   Shimada T, 2008, AM J PHYSIOL ENDOC M, V295, pE859, DOI 10.1152/ajpendo.90373.2008
   Speciale A, 2018, ECOTOX ENVIRON SAFE, V150, P96, DOI 10.1016/j.ecoenv.2017.12.038
   Tomokiyo A, 2012, J CELL BIOCHEM, V113, P3093, DOI 10.1002/jcb.24186
   Whitlock JP Jr, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103
   Yu HT, 2014, TOXICOL APPL PHARM, V280, P502, DOI 10.1016/j.taap.2014.08.025
   Zhou YQ, 2017, SCI TOTAL ENVIRON, V587, P305, DOI 10.1016/j.scitotenv.2017.02.152
NR 37
TC 14
Z9 15
U1 1
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2019
VL 2019
AR 7414015
DI 10.1155/2019/7414015
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HJ3RM
UT WOS:000457090300001
PM 30766605
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Rothenbühler, A
   Piquard, C
   Gueorguieva, I
   Lahlou, N
   Linglart, A
   Bougnères, P
AF Rothenbuehler, Anya
   Piquard, Catherine
   Gueorguieva, Iva
   Lahlou, Najiba
   Linglart, Agnes
   Bougneres, Pierre
TI Near Normalization of Adult Height and Body Proportions by Growth
   Hormone in Pycnodysostosis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BONE RESORPTION; CATHEPSIN; PYKNODYSOSTOSIS; OSTEOPETROSIS; DEGRADATION;
   OSTEOCLASTS; MUTATIONS; TURNOVER; CHILDREN; MODEL
AB Context: Mutations in the cathepsin K gene (CTSK) cause a very rare form of short limb dwarfism called pyknodysostosis (online inheritance in man 265800) that reduces adult height to 130 150 cm.
   Objective: To study the effects of GH in children with pyknodysostosis.
   Design and Methods: This was a pilot open study of three children with pyknodysostosis (P1, P2, P3) and 16 age matched children with idiopathic short stature (ISS) treated with a similar IGF I based dosing of GH therapy. P1, P2, and P3 received a mean GH dose of 29, 67, and 120 mu g/kg.d, respectively, during 12, 6.5, and 5 yr, whereas the ISS group received a mean dose of 62 +/  21 mu g/kg.d during 5.4 +/  2 yr.
   Results: P1, P2, and P3 had the typical clinical and radiological features of pyknodysostosis. They were shown to carry three different homozygous missense mutations of the CTSK gene. After onset of GH at 4.5, 5.4, and 10.9 yr of age, respectively, height increased from  2,  4.2, and  3 SD score to  1,  0.5, and  1 SD score after a 12, 6.5, and 5 yr GH treatment. Remarkably, body disproportion was largely corrected by GH treatment. IGF I levels in P1, P2, and P3 were within the range of the ISS group.
   Conclusions: Pyknodysostotic patients can reach near normal stature and skeletal proportions with a personalized GH treatment targeted at appropriate IGF I levels. Given the severity of this rare dwarfism, we propose that GH should be offered to affected children. (J Clin Endocrinol Metab 95: 2827 2831, 2010)
C1 [Bougneres, Pierre] Hop St Vincent de Paul, Ctr Reference Malad Rares Calcium, Serv Endocrinol Pediat, Dept Pediat Endocrinol,AP HP,Fac Med Paris Descar, F 75014 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Cochin   APHP
RP Bougnères, P (通讯作者)，Hop St Vincent de Paul, Ctr Reference Malad Rares Calcium, Serv Endocrinol Pediat, Dept Pediat Endocrinol,AP HP,Fac Med Paris Descar, F 75014 Paris, France.
RI Linglart, agnes/A 8047 2016; Linglart, Agnes/A 8047 2016
OI Linglart, Agnes/0000 0003 3455 002X
FU NovoNordisk
FX We thank an anonymous reviewer for allowing us to improve the discussion
   of specific GH effects in pyknodysostosis. We thank NovoNordisk for long
   term support of the study.
CR AHMED ML, 1990, ARCH DIS CHILD, V65, P1345, DOI 10.1136/adc.65.12.1345
   ANDREN L., 1962, ACTA CHIR SCAND, V124, P496
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Cohen P, 2008, J CLIN ENDOCR METAB, V93, P4210, DOI 10.1210/jc.2008 0509
   Cohen P, 2007, J CLIN ENDOCR METAB, V92, P2480, DOI 10.1210/jc.2007 0204
   Donnarumma Michela, 2007, Hum Mutat, V28, P524, DOI 10.1002/humu.9490
   EDELSON JG, 1992, CLIN ORTHOP RELAT R, P263
   Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219
   EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Fujita Y, 2000, J CLIN ENDOCR METAB, V85, P425, DOI 10.1210/jc.85.1.425
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Hou WS, 1999, J CLIN INVEST, V103, P731, DOI 10.1172/JCI653
   Hunt NP, 1998, J ORAL MAXIL SURG, V56, P497, DOI 10.1016/S0278 2391(98)90722 4
   KAWAHARA K, 1977, ORAL SURG ORAL MED O, V44, P476, DOI 10.1016/0030 4220(77)90419 4
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   MAROTEAUX P, 1962, PRESSE MED, V70, P999
   RANKE MB, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651 2227.1993.tb12936.x
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schilling AF, 2007, OSTEOPOROSIS INT, V18, P659, DOI 10.1007/s00198 006 0311 y
   SEDANO HD, 1968, AM J DIS CHILD, V116, P70, DOI 10.1001/archpedi.1968.02100020072010
   Soliman AT, 1996, ARCH DIS CHILD, V75, P242, DOI 10.1136/adc.75.3.242
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
NR 25
TC 29
Z9 30
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2010
VL 95
IS 6
BP 2827
EP 2831
DI 10.1210/jc.2009 2531
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 606RD
UT WOS:000278444000037
PM 20357177
OA Bronze
DA 2025 08 17
ER

PT J
AU Eckardt, AM
   Lemound, J
   Lindhorst, D
   Rana, M
   Gellrich, NC
AF Eckardt, A. M.
   Lemound, J.
   Lindhorst, D.
   Rana, M.
   Gellrich, N C.
TI Surgical Management of Bisphosphonate related Osteonecrosis of the Jaw
   in Oncologic Patients: A Challenging Problem
SO ANTICANCER RESEARCH
LA English
DT Article
DE Bisphosphonate; osteonecrosis; mandible; BRONJ
ID CANCER PATIENTS; RISK FACTORS; MICROBIAL BIOFILMS; MULTIPLE MYELOMA;
   BONE; RECONSTRUCTION; MECHANISMS; PREVENTION; FREQUENCY; DIAGNOSIS
AB Aim: Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a serious oral complication of supportive cancer therapy and the best method of treatment is still unclear. The purpose of this article is to analyze the type of treatment and outcome in a large patient cohort with BRONJ. Patients and Methods: A total of 142 patients suffering from BRONJ at different sites were studied. All patients had been treated with intravenous bisphosphonates for various oncological disease. A descriptive analysis of all relevant patient data was performed with particular emphasis on surgical outcome. Results: The mandible was affected in 58% of the patients. All but two patients had previous invasive dental procedures. The mean duration of bisphosphonate treatment was 37.1 months. A total of 86% of the patients were treated surgically, including sequestrectomies and mandibular resections. Soft tissue reconstruction was achieved by local closure, myofascial flap using the mylohyoid muscle, and a vascularized fasciocutaneous flap in one patient. No bony reconstruction was performed. Conclusion: Surgical treatment of BRONJ remains challenging. There is only limited evidence that oncologic patients with BRONJ are candidates for vascularized bone reconstruction.
C1 [Eckardt, A. M.; Lemound, J.; Lindhorst, D.; Rana, M.; Gellrich, N C.] Hannover Med Sch, Dept Craniomaxillofacial Surg, D 30625 Hannover, Germany.
C3 Hannover Medical School
RP Eckardt, AM (通讯作者)，Hannover Med Sch, Dept Craniomaxillofacial Surg, Carl Neuberg Str 1, D 30625 Hannover, Germany.
EM eckardt.andre@mh hannover.de
RI Eckardt, Andre/D 5184 2018
OI Eckardt, Andre M./0000 0002 1753 9390; Rana, Majeed/0000 0003 0993 5067
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Abu Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008
   Assael LA, 2009, J ORAL MAXIL SURG, V67, P35, DOI 10.1016/j.joms.2009.01.003
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Chiandussi S, 2006, DENTOMAXILLOFAC RAD, V35, P236, DOI 10.1259/dmfr/27458726
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Engroff SL, 2007, J ORAL MAXIL SURG, V65, P2374, DOI 10.1016/j.joms.2006.07.012
   Fantasia JE, 2009, J ORAL MAXIL SURG, V67, P53, DOI 10.1016/j.joms.2009.01.011
   Fehm T, 2009, BREAST, V18, P213, DOI 10.1016/j.breast.2009.07.001
   Ferrari S, 2008, J ORAL MAXIL SURG, V66, P999, DOI 10.1016/j.joms.2007.06.631
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Hess LM, 2008, AM J MED, V121, P475, DOI 10.1016/j.amjmed.2008.01.047
   Hoefert S, 2010, CLIN ORAL INVEST, V14, P271, DOI 10.1007/s00784 009 0300 6
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   King AE, 2008, PHARMACOTHERAPY, V28, P667, DOI 10.1592/phco.28.5.667
   Knight RJW, 2010, J CRANIOFAC SURG, V21, P25, DOI 10.1097/SCS.0b013e3181c347a0
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Mücke T, 2011, J CANCER RES CLIN, V137, P907, DOI 10.1007/s00432 010 0953 1
   Nocini PF, 2009, EJSO EUR J SURG ONC, V35, P373, DOI 10.1016/j.ejso.2008.05.002
   Rayman S, 2009, INT J DENT HYG, V7, P90, DOI 10.1111/j.1601 5037.2008.00331.x
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2011, ANN NY ACAD SCI, V1218, P38, DOI 10.1111/j.1749 6632.2010.05768.x
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P13, DOI 10.1016/j.joms.2008.10.005
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P1, DOI 10.1016/j.joms.2009.03.001
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Scoletta M, 2010, ORAL SURG ORAL MED O, V110, P46, DOI 10.1016/j.tripleo.2010.02.020
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P1259, DOI 10.14219/jada.archive.2009.0049
   Seth R, 2010, LARYNGOSCOPE, V120, P2165, DOI 10.1002/lary.21062
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Stanton DC, 2009, J ORAL MAXIL SURG, V67, P943, DOI 10.1016/j.joms.2008.12.057
   Stockmann P, 2010, SUPPORT CARE CANCER, V18, P449, DOI 10.1007/s00520 009 0688 1
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Van den Wyngaerta T, 2007, CURR OPIN ONCOL, V19, P315, DOI 10.1097/CCO.0b013e32819f820b
   Vasikaran SD, 2001, ANN CLIN BIOCHEM, V38, P608, DOI 10.1258/0004563011901037
   Walter C, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 11
   Weitzman R, 2007, CRIT REV ONCOL HEMAT, V62, P148, DOI 10.1016/j.critrevonc.2006.12.005
   Wilde F, 2011, ORAL SURG ORAL MED O, V111, P153, DOI 10.1016/j.tripleo.2010.04.015
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 52
TC 25
Z9 26
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2011
VL 31
IS 6
BP 2313
EP 2318
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 791AE
UT WOS:000292631300041
PM 21737657
DA 2025 08 17
ER

PT J
AU Liu, TS
   Yu, H
   Wang, S
   Li, HM
   Du, XYR
   He, XD
AF Liu, Tianshu
   Yu, Hai
   Wang, Shuai
   Li, Huimin
   Du, Xinyiran
   He, Xiaodong
TI Chondroitin sulfate alleviates osteoporosis caused by calcium deficiency
   by regulating lipid metabolism
SO NUTRITION & METABOLISM
LA English
DT Article
DE Osteoporosis; Chondroitin sulfate; Intestinal flora; Metabolomics; Lipid
   metabolism
ID GUT MICROBIOTA; OXIDATIVE STRESS; BONE LOSS; SUPPLEMENTATION;
   ABSORPTION; DIAGNOSIS; ACID; RATS
AB The use of non drug intervention for calcium deficiency has attracted attention in recent years. Although calcium carbonate is the preferred raw material for calcium supplementation, there are few reports on the mechanism of the combined action of chondroitin sulfate and calcium to alleviate osteoporosis from the perspective of gut microbiota and metabolomics. In this study, a rat model of osteoporosis was established by feeding a low calcium diet. The intestinal microbiota abundance, fecal and plasma metabolite expression levels of rats fed a basal diet, a low calcium diet, a low calcium diet plus calcium carbonate, and a low calcium diet plus chondroitin sulfate were compared. The results showed that compared with the low calcium group, the calcium content and bone mineral density of femur were significantly increased in the calcium carbonate and chondroitin sulfate groups. 16 S rRNA sequencing and metabolomics analysis showed that chondroitin sulfate intervention could reduce short chain fatty acid synthesis of intestinal flora, slow down inflammatory response, inhibit osteoclast differentiation, promote calcium absorption and antioxidant mechanism, and alleviate osteoporosis in low calcium feeding rats. Correlation analysis showed that the selected intestinal flora was significantly correlated with metabolites enriched in feces and plasma. This study provides scientific evidence of the potential impact of chondroitin sulfate as a dietary supplement for patients with osteoporosis.
C1 [Liu, Tianshu] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Epidemiol, Jinan 250012, Shandong, Peoples R China.
   [Yu, Hai] Natl Canc Ctr, Div Canc RNA Res, Tokyo 1040045, Japan.
   [Li, Huimin; He, Xiaodong] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Phys & Chem Inspect, Jinan 250012, Shandong, Peoples R China.
   [Liu, Tianshu; Yu, Hai; He, Xiaodong] Shandong Univ, Inst Med Dataol, Natl Inst Hlth Data Sci China, Jinan 250012, Shandong, Peoples R China.
   [Wang, Shuai] Shandong Univ, Inst Toxicol, Cheeloo Coll Med, Sch Publ Hlth, Jining 250012, Shandong, Peoples R China.
   [Du, Xinyiran] Jining Med Univ, Coll Stomatol, Jining 272067, Shandong, Peoples R China.
   [Li, Huimin] Chinese Acad Med Sci & Peking Union Med Coll, Natl Human Genet Resources Ctr, Beijing 100730, Peoples R China.
   [Li, Huimin] Chinese Acad Med Sci & Peking Union Med Coll, Natl Res Inst Hlth & Family Planning, Beijing 100730, Peoples R China.
C3 Shandong University; National Cancer Center   Japan; Shandong
   University; Shandong University; Shandong University; Jining Medical
   University; Chinese Academy of Medical Sciences   Peking Union Medical
   College; Peking Union Medical College; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College
RP He, XD (通讯作者)，Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Phys & Chem Inspect, Jinan 250012, Shandong, Peoples R China.; He, XD (通讯作者)，Shandong Univ, Inst Med Dataol, Natl Inst Hlth Data Sci China, Jinan 250012, Shandong, Peoples R China.
EM xiaodong.he@sdu.edu.cn
RI Liu, Tianshu/H 6879 2019; He, Xiaodong/KQU 1686 2024; WANG,
   Shuai/JBS 3682 2023
FU Program for Changjiang Scholars and Innovative Research Team in
   University [IRT_17R68]; General Project of Shandong Natural Science
   Foundation [ZR2021MC166]
FX This study was supported by the Program for Changjiang Scholars and
   Innovative Research Team in University (IRT_17R68) and General Project
   of Shandong Natural Science Foundation, ZR2021MC166.
CR Al Rawaf HA, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/3719919
   Alonso Pérez A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00504
   Anthamatten A, 2019, J MIDWIFERY WOM HEAL, V64, P265, DOI 10.1111/jmwh.12954
   Beger RD, 2016, METABOLOMICS, V12, DOI 10.1007/s11306 016 1094 6
   Bishnoi M, 2016, GLYCOCONJUGATE J, V33, P693, DOI 10.1007/s10719 016 9665 3
   Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/NMETH.2276, 10.1038/nmeth.2276]
   Bott KN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243933
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Chaplin A, 2016, MOL NUTR FOOD RES, V60, P468, DOI 10.1002/mnfr.201500480
   Cheng M, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.636231
   Chiu YH, 2014, J DAIRY SCI, V97, P2009, DOI 10.3168/jds.2013 7514
   Choi So Young, 2011, Lab Anim Res, V27, P301, DOI 10.5625/lar.2011.27.4.301
   Collins FL, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD 0015 2016
   Di DS, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.765008
   Duscha A, 2022, THER ADV NEUROL DISO, V15, DOI 10.1177/17562864221103935
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   FUJITA T, 1993, OSTEOPOROSIS INT, V3, pS159
   Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   He HT, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.791880
   He JQ, 2020, AGING US, V12, P8583, DOI 10.18632/aging.103168
   Hills RD, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071613
   Hu YM, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02842 3
   Jiang YC, 2020, J CHROMATOGR B, V1152, DOI 10.1016/j.jchromb.2020.122262
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kelly O, 2004, PROSTAG LEUKOTR ESS, V71, P295, DOI 10.1016/j.plefa.2004.04.003
   Kim SM, 2021, ANN NY ACAD SCI, V1487, P21, DOI 10.1111/nyas.14486
   Korotkyi O. H., 2020, Mikrobiologichnii Zhurnal, V82, P64, DOI 10.15407/microbiolj82.06.064
   Korotkyi OH, 2021, MINERVA BIOTECHNOL B, V33, P93, DOI 10.23736/S2724 542X.21.02774 7
   Li C, 2019, OSTEOPOROSIS INT, V30, P1003, DOI 10.1007/s00198 019 04855 5
   Li J, 2021, BONE JOINT RES, V10, P51, DOI 10.1302/2046 3758.101.BJR 2020 0273.R1
   Li M, 2018, EUR J PHARMACOL, V831, P52, DOI 10.1016/j.ejphar.2018.05.003
   Li Y, 2011, J BONE MINER RES, V26, P2656, DOI 10.1002/jbmr.480
   Li ZH, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027442
   Lin H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5307
   Ling CW, 2021, J CLIN ENDOCR METAB, V106, pE3852, DOI 10.1210/clinem/dgab492
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Luo P, 2015, ANAL CHEM, V87, P5050, DOI 10.1021/acs.analchem.5b00615
   Lv HH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122018
   Ma SC, 2021, PEERJ, V9, DOI 10.7717/peerj.12293
   Mastrangelo M, 2019, EXPERT REV NEUROTHER, V19, P1135, DOI 10.1080/14737175.2019.1648212
   McCabe LR, 2019, BONE, V118, P20, DOI 10.1016/j.bone.2018.03.024
   Meiron OE, 2011, J BONE MINER RES, V26, P364, DOI 10.1002/jbmr.196
   Mikami T, 2013, BBA GEN SUBJECTS, V1830, P4719, DOI 10.1016/j.bbagen.2013.06.006
   Mishra S, 2021, DRUG DISCOV TODAY, V26, P1185, DOI 10.1016/j.drudis.2021.01.029
   Ni H, 2022, CONTRAST MEDIA MOL I, V2022, DOI 10.1155/2022/3670007
   Osella G, 2012, EUR J ENDOCRINOL, V166, P855, DOI 10.1530/EJE 11 0957
   Ozaki D, 2021, OSTEOPOROSIS INT, V32, P145, DOI 10.1007/s00198 020 05728 y
   Proal AD, 2017, DISCOV MED, V23, P51
   Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
   Rettedal EA, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10452
   Rizzoli R, 2020, CURR OSTEOPOROS REP, V18, P273, DOI 10.1007/s11914 020 00591 6
   Rubinstein G, 2020, J CLIN ENDOCR METAB, V105, pE12, DOI 10.1210/clinem/dgz136
   Salamanna F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051762
   Sam QH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126453
   Seely KD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179452
   Shang QS, 2016, INT J BIOL MACROMOL, V89, P489, DOI 10.1016/j.ijbiomac.2016.04.091
   Shang QS, 2016, INT J BIOL MACROMOL, V86, P112, DOI 10.1016/j.ijbiomac.2016.01.055
   Shen QS, 2021, CARBOHYD POLYM, V254, DOI 10.1016/j.carbpol.2020.117282
   Shmagel A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020294
   Sisignano M, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082050
   Straub DA, 2007, NUTR CLIN PRACT, V22, P286, DOI 10.1177/0115426507022003286
   Subramanian VS, 2017, HUM GENET, V136, P253, DOI 10.1007/s00439 016 1751 x
   Wallace Louise, 2004, Br J Community Nurs, V9, P102
   Wang JH, 2017, PEERJ, V5, DOI 10.7717/peerj.3450
   Wang MQ, 2013, BMC MED, V11, DOI 10.1186/1741 7015 11 86
   Weaver CM, 2015, CURR OSTEOPOROS REP, V13, P125, DOI 10.1007/s11914 015 0257 0
   Wei MH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.630372
   Whisner CM, 2016, J NUTR, V146, P1298, DOI 10.3945/jn.115.227256
   Wisanwattana W, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.636784
   Xiao CQ, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.682798
   Yang KD, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.840293
   Yatsonsky D, 2019, WORLD J ORTHOP, V10, P123, DOI 10.5312/wjo.v10.i3.123
   Zhang YW, 2021, FOOD FUNCT, V12, P5703, DOI [10.1039/d0fo03468a, 10.1039/D0FO03468A]
   Zhao FL, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00854 w
   Zhao M, 2012, J NUTR, V142, P1791, DOI 10.3945/jn.112.163246
NR 78
TC 10
Z9 10
U1 11
U2 74
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743 7075
J9 NUTR METAB
JI Nutr. Metab.
PD FEB 6
PY 2023
VL 20
IS 1
AR 6
DI 10.1186/s12986 023 00726 3
PG 18
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 8P5YW
UT WOS:000926600100001
PM 36747190
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mady, MF
   Rehman, A
   Kelland, MA
AF Mady, Mohamed F.
   Rehman, Abdur
   Kelland, Malcolm A.
TI Synthesis and Antiscaling Evaluation of Novel Hydroxybisphosphonates for
   Oilfield Applications
SO ACS OMEGA
LA English
DT Article
AB Organophosphorous compounds are still widely used as potential scale inhibitors in the upstream oil and gas industry, particularly in squeeze treatments as they have good adsorption properties on rock and are easily detectable. However, most phosphonate based scale inhibitors have some drawbacks, such as poor biodegradability and various incompatibilities with the production system. The low toxicity of bisphosphonates motivated us to test a series of aliphatic and aromatic hydroxybi sphosphonates as new oilfield scale inhibitors for calcium carbonate (calcite) and barium sulfate (barite) scales. Thus, the well known bone targeting drugs 3 amino 1 hydroxypropane 1,1 bisphosphonic acid (pamidronic acid, SI 1), 4 amino 1 hydroxybutane 1,1 bisphosphonic acid (alendronic acid, SI 2), 5 amino 1 hydroxypentane 1,1 bisphosphonic acid (SI 3), and hydroxyphenylmethylene 1,1 bisphosphonic acid (fenidronic acid, SI 6) are studied along with novel, specially designed bisphosphonates (1,4 dihydroxybutane 1,1,4,4 tetrayl)tetrakisphosphonic acid (SI 4), (1,6 dihydroxyhexane 1,1,6,6 tetrayl)tetrakisphosphonic acid (SI 5), and ((4  aminophenyl)(hydroxy)methylene)bisphosp honic acid (SI 7) in a dynamic tube blocking scale rig at 100 degrees C and 80 bar according to typical North Sea conditions. The scale inhibition performance of the new SIs was compared to that of the commercial 1 hydroxyethylidene bisphosphonic acid (HEDP) and aminotrismethylenephosphonic acid (ATMP). The results indicate that all synthesized hydroxybisphosphonates provide reasonable inhibition performance against calcite scaling and show good thermal stability at 130 degrees C for 7 days under anaerobic conditions.
C1 [Mady, Mohamed F.; Rehman, Abdur; Kelland, Malcolm A.] Univ Stavanger, Dept Chem Biosci & Environm Engn, Fac Sci & Technol, N 4036 Stavanger, Norway.
   [Mady, Mohamed F.] Natl Res Ctr, Dept Green Chem, Cairo 12622, Egypt.
C3 Universitetet i Stavanger; Egyptian Knowledge Bank (EKB); National
   Research Centre (NRC)
RP Mady, MF (通讯作者)，Univ Stavanger, Dept Chem Biosci & Environm Engn, Fac Sci & Technol, N 4036 Stavanger, Norway.; Mady, MF (通讯作者)，Natl Res Ctr, Dept Green Chem, Cairo 12622, Egypt.
EM mohamed.mady@uis.no
RI Mady, Mohamed/AAA 6270 2021; Mady, Mohamed/D 2870 2013
OI Mady, Mohamed/0000 0002 4636 0066
CR Al Roomi YM, 2016, DESALINATION, V393, P186, DOI 10.1016/j.desal.2015.07.025
   Bazin B., 2004, SPE INT S OILF SCAL
   Bott T. R., 1999, P INT C UND HEAT EXC
   BRANDEIS G, 1987, CONTRIB MINERAL PETR, V96, P24, DOI 10.1007/BF00375522
   BROMLEY LA, 1993, LANGMUIR, V9, P3594, DOI 10.1021/la00036a040
   Center JR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115566
   Demadis KD, 2009, INORG CHEM, V48, P4154, DOI 10.1021/ic802400r
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Gruen A, 2014, LETT ORG CHEM, V11, P368
   Igunnu ET, 2014, INT J LOW CARBON TEC, V9, P157, DOI 10.1093/ijlct/cts049
   Jafar Mazumder M. A, 2020, COATINGS, V10
   Kan A. T., 2003, INT S OILF CHEM HOUS
   Kelland M. A., PRODUCTION CHEM OIL
   Kelland MA, 2018, CRYST GROWTH DES, V18, P7441, DOI 10.1021/acs.cgd.8601173
   Kovacs R, 2014, GREEN PROCESS SYNTH, V3, P111, DOI 10.1515/gps 2013 0107
   Kreh R. P., U.S. Patent, Patent No. [5,043,099A, 5043099]
   Mady MF, 2020, IND ENG CHEM RES, V59, P9808, DOI 10.1021/acs.iecr.0c01636
   Mady MF, 2019, ENERG FUEL, V33, P6197, DOI 10.1021/acs.energyfuels.9b01032
   Mady MF, 2019, ENERG FUEL, V33, P228, DOI 10.1021/acs.energyfuels.8b03531
   Mady MF, 2018, ENERG FUEL, V32, P6746, DOI 10.1021/acs.energyfuels.8b01168
   Mady MF, 2017, ENERG FUEL, V31, P5940, DOI 10.1021/acs.energyfuels.7b00508
   Mady MF, 2017, ENERG FUEL, V31, P4603, DOI 10.1021/acs.energyfuels.7b00708
   Mady MF, 2016, ENERG FUEL, V30, P9329, DOI 10.1021/acs.energyfuels.6b02117
   MOEDRITZ.K, 1966, J ORG CHEM, V31, P1603, DOI 10.1021/jo01343a067
   Moshikur RM, 2020, ACS SUSTAIN CHEM ENG, V8, P13660, DOI 10.1021/acssuschemeng.0c03419
   Mpelwa M, 2019, PETROL SCI, V16, P830, DOI 10.1007/s12182 019 0299 5
   Oryan A, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118681
   Oshchepkov A, 2020, SENSOR ACTUAT B CHEM, V314, DOI 10.1016/j.snb.2020.128047
   Oshchepkov M., 2021, SEP PURIF TECHNOL, V255
   Oshchepkov M, 2019, CHEMNANOMAT, V5, P586, DOI 10.1002/cnma.201800660
   Papathanasiou KE, 2019, PURE APPL CHEM, V91, P421, DOI 10.1515/pac 2018 1012
   Plabst M, 2009, INORG CHEM, V48, P4331, DOI 10.1021/ic802294e
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sallis JD, 1995, MINERAL SCALE FORMATION AND INHIBITION, P87
   Smith P. S., 2000, INT S OILF SCAL SOC, P1
   TOMSON MB, 1994, LANGMUIR, V10, P1442, DOI 10.1021/la00017a021
   VANROSMALEN GM, 1980, KRIST TECH, V15, P1269, DOI 10.1002/crat.19800151107
   Wang C, 2009, DESALINATION, V249, P1, DOI 10.1016/j.desal.2009.06.006
   Zhao X, 2013, HEAT TRANSFER ENG, V34, P719, DOI 10.1080/01457632.2012.739482
NR 39
TC 22
Z9 23
U1 2
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470 1343
J9 ACS OMEGA
JI ACS Omega
PD MAR 9
PY 2021
VL 6
IS 9
BP 6488
EP 6497
DI 10.1021/acsomega.1c00379
EA FEB 2021
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA QX0HW
UT WOS:000629031700047
PM 33718740
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pan, W
   Quarles, LD
   Song, LH
   Yu, YH
   Jiao, C
   Tang, HB
   Jiang, CH
   Deng, HW
   Li, YJ
   Zhou, HH
   Xiao, ZS
AF Pan, W
   Quarles, LD
   Song, LH
   Yu, YH
   Jiao, C
   Tang, HB
   Jiang, CH
   Deng, HW
   Li, YJ
   Zhou, HH
   Xiao, ZS
TI Genistein stimulates the osteoblastic differentiation via NO/cGMP in
   bone marrow culture
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE genistein; phytoestrogen; mesenchymal stem cell; osteoblast; estrogen
   receptor; nitric oxide; cyclic GMP
ID HORMONE REPLACEMENT THERAPY; ESTROGEN RECEPTOR ALPHA; NITRIC OXIDE
   SYNTHASE; POSTMENOPAUSAL WOMEN; MC3T3 E1 CELLS; DOUBLE BLIND;
   PHYTOESTROGENS; PROLIFERATION; OSTEOPOROSIS; SPECIFICITY
AB The soybean phytoestrogen, genistein (Gen), has anabolic effects on bone through mechanisms that remain to be elucidated. We examined the role of nitric oxide (NO) and its downstream effector guanylyl cyclase (GC) in mediating the effects of Gen on the proliferation and osteoblastic maturation of primary mouse bone marrow derived mesenchymal stem cells (BMSCs). Gen (10(  8) similar to 10( 6) M) resulted in a dose dependent increase in cell proliferation as measured by increased [H 3]thymidine incorporation, and stimulated osteoblastic maturation as assessed by culture duration dependent increments in alkaline phosphatase (ALP) activity, calcium deposition into extracellular matrix and Runx2/Cbfa1 gene expression in BMSCs cultures. Gen also resulted in a dose dependent increase in NO synthase (NOS) activity, NO formation, and cGMP production in BMSCs cultures. The effects of Gen were minnicked by 17beta estradiol (E 2, 10( 8) M). Concurrent treatment with the estrogen receptor (ER) antagonist ICI182,780 (10( 7) M) or the NOS inhibitor L NAME (3 x 10( 3) M) diminished the Gen (10( 6) M) mediated increase in NOS activity, NO production, and cGMP content. In contrast, a Soluble GC inhibitor 1H [1,2,4]oxadiazolo [4,3, alquinoxal in l one (ODQ 10( 6) M) selectively blocked the Gen (10( 6)M) mediated increase in cGMP content but not in NO production and NOS activity. Moreover, inhibition of ER, NOS activity or cGMP blocked Gen induced proliferation and osteoblastic differentiation of BMSCs and Runx2/Cbfal gene expression in culture. Gen has estrogen like activity and stimulates the proliferation and osteoblastic differentiation of mouse BMSCs at least in part through NO/cGMP pathway. (C) 2004 Wiley Liss, Inc.
C1 Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA.
   Cent S Univ, Inst Clin Pharmacol, Changsha 410078, Peoples R China.
C3 University of Kansas; University of Kansas Medical Center; Central South
   University
RP Univ Kansas, Med Ctr, Kidney Inst, Mail Stop 3018, Kansas City, KS 66160 USA.
EM zxiao@kume.edu
RI Song, Lihua/H 9103 2018
OI Quarles, L. Darryl/0000 0002 5082 7896
FU NIAMS NIH HHS [R01 AR049712, R01 AR049712] Funding Source: Medline
CR Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345, DOI 10.3181/00379727 217 44243
   Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950 351X(98)80003 7
   ARJMANDI BH, 1996, J NUTR, V126, P1161
   Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799
   Chen XW, 2003, J NUTR BIOCHEM, V14, P342, DOI 10.1016/S0955 2863(03)00056 1
   Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347
   Choi EM, 2001, PHYTOCHEMISTRY, V56, P733, DOI 10.1016/S0031 9422(00)00484 2
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Fanti P, 1998, OSTEOPOROSIS INT, V8, P274, DOI 10.1007/s001980050065
   Gao YH, 1999, BIOCHEM PHARMACOL, V58, P767, DOI 10.1016/S0006 2952(99)00162 8
   Grant MKO, 2004, LIFE SCI, V74, P1701, DOI 10.1016/j.lfs.2003.08.029
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003 2697(82)90118 X
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   Horiuchi T, 2000, OSTEOPOROSIS INT, V11, P721, DOI 10.1007/s001980070072
   Ishimi Y, 2000, BIOCHEM BIOPH RES CO, V274, P697, DOI 10.1006/bbrc.2000.3175
   Ishimi Y, 1999, ENDOCRINOLOGY, V140, P1893, DOI 10.1210/en.140.4.1893
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kanno S, 2004, TOXICOLOGY, V196, P137, DOI 10.1016/j.tox.2003.12.002
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Mei J, 2001, J CLIN ENDOCR METAB, V86, P5217, DOI 10.1210/jc.86.11.5217
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297
   O'Shaughnessy MC, 2000, BIOCHEM BIOPH RES CO, V277, P604, DOI 10.1006/bbrc.2000.3714
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   RECKER RR, 1993, J CLIN ENDOCR METAB, V76, P14, DOI 10.1210/jc.76.1.14
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Squadrito F, 2003, AM J MED, V114, P470, DOI 10.1016/S0002 9343(03)00059 7
   Squadrito F, 2000, CARDIOVASC RES, V45, P454, DOI 10.1016/S0008 6363(99)00359 4
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303 7207(01)00594 9
   Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474
   Vihtamäki T, 1999, MATURITAS, V33, P99, DOI 10.1016/S0378 5122(99)00047 X
   Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271
   Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192
   Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200
   Xiao ZS, 2001, KIDNEY INT, V60, P1699, DOI 10.1046/j.1523 1755.2001.00011.x
   Yamamoto S, 2001, J NUTR, V131, P2741, DOI 10.1093/jn/131.10.2741
   Yamazaki T, 2000, MATH INEQUAL APPL, V3, P97
   Yoon HK, 1998, CALCIFIED TISSUE INT, V63, P243, DOI 10.1007/s002239900521
NR 43
TC 86
Z9 99
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB 1
PY 2005
VL 94
IS 2
BP 307
EP 316
DI 10.1002/jcb.20308
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 892HB
UT WOS:000226639800011
PM 15526288
DA 2025 08 17
ER

PT J
AU Li, MY
   Nie, Y
   Zeng, Y
   Wu, YA
   Liu, Y
   Wu, LM
   Xu, JW
   Shen, B
AF Li, Mingyang
   Nie, Yong
   Zeng, Yi
   Wu, Yuangang
   Liu, Yuan
   Wu, Limin
   Xu, Jiawen
   Shen, Bin
TI Does Bisphosphonate Increase the Sclerosis of Tibial Subchondral Bone in
   the Progression of Knee Osteoarthritis A Propensity Score Matching
   Cohort Study Based on Osteoarthritis Initiative
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE bisphosphonate; subchondral bone morphometry; BVF; Tb; N; Sp; Th
ID TIBIOFEMORAL CARTILAGE VOLUME; MINERAL DENSITY; ZOLEDRONIC ACID; MARROW
   LESIONS; DOUBLE BLIND; ALENDRONATE; MICROARCHITECTURE; TURNOVER; CELLS
AB Bisphosphonate has great potential in KOA therapy, but whether the anti resorption mechanism of bisphosphonate aggravates sclerosis of subchondral bone remains unclear. We found that bisphosphonate use did not increase sclerosis of subchondral bone in established KOA, perhaps resolving some concerns about bisphosphonate in patients with KOA.Introduction: Most studies have focused on the protective effect of bisphosphonate on early knee osteoarthritis (KOA) through its anti resorption mechanism in osteoclasts. However, late KOA has a decreased rate of resorption, which is the opposite of early KOA. The risk of subchondral bone sclerosis in late KOA after using bisphosphonate has not been investigated using morphometry.Methods: Forty five patients who had ever used bisphosphonate (or 33 patients with current use) were matched with controls through propensity matching methods, including age, body mass index (BMI), sex, health status (12 Item Short Form Survey physical health score), physical activity level (Physical Activity Scale for the Elderly score), vitamin D use, and calcium use. At the baseline and 12 month (or 18 month) follow up, bone mineral density (BMD) of the tibia and hip was measured by dual energy X ray absorptiometry (DXA), and medial tibial subchondral bone morphometry: bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp) were calculated based on 3 T trabecular MRI. Data were obtained from the Bone Ancillary Study in the Osteoarthritis Initiative (OAI) project.Results: The yearly percentage change in hip BMD of the current bisphosphonate use group was significantly greater than that of the non bisphosphonate use group (0.7% vs.  1%, P = 0.02). The other outcomes (BV/TV, Tb.N, Tb.Sp, Tb.Th, tibia medial BMD, and tibia lateral BMD) between the two groups presented no significant difference. The non bisphosphonate use group experienced a significant increase in Tb.Th [2%, 95% CI = (1%, 4%), P = 0.01], while the bisphosphonate use group presented no significant change [1%, 95% CI = ( 2%, 4%), P = 0.54].Conclusions: Bisphosphonate use did not increase sclerosis of subchondral bone in established KOA. Bisphosphonate might have a stage dependent effect on subchondral bone in KOA initiation and progression.
C1 [Li, Mingyang; Nie, Yong; Zeng, Yi; Wu, Yuangang; Liu, Yuan; Wu, Limin; Xu, Jiawen; Shen, Bin] Sichuan Univ, Orthoped Res Inst, West China Hosp, Dept Orthoped, Chengdu, Peoples R China.
C3 Sichuan University
RP Shen, B (通讯作者)，Sichuan Univ, Orthoped Res Inst, West China Hosp, Dept Orthoped, Chengdu, Peoples R China.
EM shenbin_1971@163.com
RI Xu, Jiawen/NIS 6382 2025
CR Arti HR, 2012, JUNDISHAPUR J NAT PH, V7, P87, DOI 10.17795/jjnpp 3405
   Bainbridge KE, 2004, OSTEOPOROSIS INT, V15, P439, DOI 10.1007/s00198 003 1562 5
   Ballal P, 2020, OSTEOARTHR CARTILAGE, V28, P1325, DOI 10.1016/j.joca.2020.07.006
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Cai GQ, 2021, RHEUMATOLOGY, V60, P2791, DOI 10.1093/rheumatology/keaa716
   Cai GQ, 2020, JAMA J AM MED ASSOC, V323, P1456, DOI 10.1001/jama.2020.2938
   Chen HN, 2016, INT J MORPHOL, V34, P291, DOI 10.4067/S0717 95022016000100042
   Chiba K, 2012, OSTEOPOROSIS INT, V23, P589, DOI 10.1007/s00198 011 1585 2
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097 0258(19981015)17:19<2265::AID SIM918>3.0.CO;2 B
   Daly RM, 2020, J BONE MINER RES, V35, P419, DOI 10.1002/jbmr.3865
   Di Gregorio S, 2015, BONE, V75, P138, DOI 10.1016/j.bone.2014.12.062
   Dillon CF, 2007, AM J PHYS MED REHAB, V86, P12, DOI 10.1097/PHM.0b013e31802ba28e
   Fernández Martín S, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.576212
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Hainan Chen WJ, 2020, KUWAIT MED J, V52, P7
   Hulley S., 2015, Delineando a pesquisa clinica, V4 Edt
   Intema F, 2010, J BONE MINER RES, V25, P1650, DOI 10.1002/jbmr.39
   KAMIBAYASHI L, 1995, BONE, V17, P27, DOI 10.1016/8756 3282(95)00137 3
   Karsdal MA, 2008, OSTEOARTHR CARTILAGE, V16, P638, DOI 10.1016/j.joca.2008.01.014
   Laslett LL, 2014, ANN RHEUM DIS, V73, P824, DOI 10.1136/annrheumdis 2012 202989
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Lo GH, 2012, OSTEOARTHR CARTILAGE, V20, P686, DOI 10.1016/j.joca.2012.03.006
   Lo GH, 2018, SEMIN ARTHRITIS RHEU, V48, P155, DOI 10.1016/j.semarthrit.2018.01.008
   Lv ZY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.725568
   MacKay JW, 2018, EUR RADIOL, V28, P4687, DOI 10.1007/s00330 018 5444 9
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167 010 1054 z
   MAJUMDAR S, 1995, BONE, V17, P417, DOI 10.1016/S8756 3282(95)00263 4
   Mohan G, 2013, OSTEOARTHR CARTILAGE, V21, P1595, DOI 10.1016/j.joca.2013.06.020
   Rossini M, 2015, RHEUMATOL INT, V35, P255, DOI 10.1007/s00296 014 3100 5
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schneider E, 2011, SKELETAL RADIOL, V40, P95, DOI 10.1007/s00256 010 0943 z
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   Tzschentke TM, 2021, BRIT J PHARMACOL, V178, P1973, DOI 10.1111/bph.14799
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Weber A, 2019, PROG BIOPHYS MOL BIO, V148, P21, DOI 10.1016/j.pbiomolbio.2017.12.004
NR 38
TC 2
Z9 2
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD NOV 22
PY 2021
VL 8
AR 781219
DI 10.3389/fmed.2021.781219
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA XJ6YW
UT WOS:000726931700001
PM 34881273
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mossetti, G
   Rendina, D
   De Filippo, G
   Viceconti, R
   Di Domenico, G
   Cioffi, M
   Postiglione, L
   Nunziata, V
AF Mossetti, G
   Rendina, D
   De Filippo, G
   Viceconti, R
   Di Domenico, G
   Cioffi, M
   Postiglione, L
   Nunziata, V
TI Interleukin 6 and osteoprotegerin systems in Paget's disease of bone:
   relationship to risedronate treatment
SO BONE
LA English
DT Article
DE Paget's disease of bone; interleukin 6 system; osteoprotegerin system;
   risedronate
ID ACQUIRED RESISTANCE; IL 6 RECEPTOR; BISPHOSPHONATES; CLODRONATE; LIGAND;
   PAMIDRONATE; MANAGEMENT; MECHANISMS; EXPRESSION
AB Serum concentrations of interleukin 6 (IL 6), IL 6 soluble receptor (sIL 6R), IL 6 gp130 soluble receptor (sgp130), ligand of receptor activator of nuclear factor (NF) kappa B (RANKL), and osteoprotegerin (OPG) were determined in 42 patients with polyostotic Paget's disease of bone (PDB) and acquired resistance to clodronate (M/F ratio 23:19; mean age 58.5 +/  9.4 years) in acute phase of disease and after oral risedronate treatment (30 mg/day for 8 weeks).
   At baseline, pagetic patients showed higher levels of OPG, sIL 6R, and IL 6 with lower levels of sgp130 compared to 24 age  and sex matched controls (respectively, 4.69 +/  1.27 vs. 2.87 +/  0.54 pmol/L; 40.89 +/  8.61 vs. 30.98 +/  4.24 ng/ml; 3.59 +/  0.97 vs. 1.8 +/  0.9 pg/ml; 327.34 +/  43.41 vs. 411.7 +/  79.5 ng/ml). Response to treatment is related to a significant increase of OPG levels in all patients (from 4.69 +/  1.27 to 5.48 +/  1.31 pmol/L). The disease remission, that is, total alkaline phosphatase (tALP) levels within the normal range after therapy, was associated with a simultaneous increase in OPG and sgp130 levels. In patients with tALP higher than the normal range after therapy, the OPG increase was associated with a parallel increase in RANKL levels. Our data suggest that serum levels of components of RANKL/OPG and IL 6 systems, before and after treatment, may be used to better define a therapeutical strategy in pagetic patients. (c) 2004 Elsevier Inc. All rights rserved.
C1 Univ Naples Federico II, Sch Med, Dept Clin & Expt Med, I 80131 Naples, Italy.
   AORN, Unit Pediat Endocrinol, Rummo, Benevento, Italy.
   Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Sch Med, Naples, Italy.
   Univ Naples Federico II, Sch Med, Dept Clin Pathol, Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II;
   University of Naples Federico II
RP Univ Naples Federico II, Sch Med, Dept Clin & Expt Med, Via S Pansini 5, I 80131 Naples, Italy.
EM nunziata@unina.it
RI ; De+Filippo, Gianpaolo/AAE 5584 2019
OI Rendina, Domenico/0000 0002 0331 0392; CIOFFI,
   Michele/0000 0003 3883 111X; 
CR ALTMAN RD, 2002, DISORDERS BONE MINER, P985
   Alvarez L, 2003, ARTHRITIS RHEUM, V48, P824, DOI 10.1002/art.10834
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CLEARY J, 1974, CLIN CHIM ACTA, V57, P217, DOI 10.1016/0009 8981(74)90400 8
   Crandall C, 2001, ARCH INTERN MED, V161, P353, DOI 10.1001/archinte.161.3.353
   Davie M, 1999, BONE, V24, p11S, DOI 10.1016/S8756 3282(99)00027 7
   Dicuonzo G, 2003, J INTERF CYTOK RES, V23, P649, DOI 10.1089/107999003322558782
   Dunn CJ, 2001, DRUGS, V61, P685, DOI 10.2165/00003495 200161050 00013
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Glantz SA, 2001, PRIMER BIOSTATISTICS
   Gutteridge DH, 1999, J BONE MINER RES, V14, P79, DOI 10.1002/jbmr.5650140216
   Hofbauer LC, 2000, J CLIN ENDOCR METAB, V85, P2355, DOI 10.1210/jc.85.7.2355
   HOYLAND JA, 1994, J BONE MINER RES, V9, P75
   Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99 1003rev
   Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432 1327.2001.01867.x
   Kallen KJ, 2002, BBA MOL CELL RES, V1592, P323, DOI 10.1016/S0167 4889(02)00325 7
   Khan SA, 1996, J BONE MINER RES, V11, P178
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133
   PROCKOP DJ, 1960, ANAL BIOCHEM, V1, P228, DOI 10.1016/0003 2697(60)90050 6
   Reddy S V, 2001, Rev Endocr Metab Disord, V2, P195
   Reddy SV, 1999, J BONE MINER RES, V14, P3, DOI 10.1002/jbmr.5650140203
   Rendina D, 2004, CALCIFIED TISSUE INT, V75, P189, DOI 10.1007/s00223 004 0103 3
   Rendina D, 2002, CLIN EXP RHEUMATOL, V20, P359
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Santini D, 2004, BIODRUGS, V18, P269, DOI 10.2165/00063030 200418040 00004
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   Selby PL, 2002, BONE, V31, P366, DOI 10.1016/S8756 3282(02)00817 7
   Singer FR, 1998, J CLIN ENDOCR METAB, V83, P1906, DOI 10.1210/jc.83.6.1906
   Siris ES, 1999, J BONE MINER RES, V14, P49, DOI 10.1002/jbmr.5650140211
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   YATES AJP, 1985, LANCET, V1, P1474
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
NR 37
TC 28
Z9 29
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2005
VL 36
IS 3
BP 549
EP 554
DI 10.1016/j.bone.2004.11.004
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 914AN
UT WOS:000228196900019
PM 15777635
DA 2025 08 17
ER

PT J
AU Kuroshima, S
   Yamashita, J
AF Kuroshima, Shinichiro
   Yamashita, Junro
TI Chemotherapeutic and antiresorptive combination therapy suppressed
   lymphangiogenesis and induced osteonecrosis of the jaw like lesions in
   mice
SO BONE
LA English
DT Article
DE Zoledronic acid; Melphalan; Wound healing; Osteonecrosis of the jaw;
   Lymphangiogenesis
ID BISPHOSPHONATE RELATED OSTEONECROSIS; ZOLEDRONIC ACID; AVASCULAR
   NECROSIS; TOOTH EXTRACTION; CANCER PATIENTS; ORAL CAVITY; OSTEOMYELITIS;
   COMPLICATION; PATHOGENESIS; OSTEOCLASTS
AB Osteonecrosis of the jaw (ONJ) is a serious adverse event that occurs predominantly in patients on both antiresorptive and antineoplastic therapies. However, how these combination therapies are connected to the high frequency of ONJ in this particular patient population is unclear. This study's aim was to determine a mechanism of ONJ associated with the combination therapy of antiresorptives and chemotherapeutics. Mice received zoledronic acid (ZA) in conjunction with melphalan or dexamethasone. The maxillary first molars were extracted 3 weeks after the initiation of treatment and wound healing assessed at 4 weeks post extractions using microcomputed tomography and immunohistochemistry. Mice receiving the combination treatment of ZA and melphalan developed ONJ like lesions, while ONJ like lesions were not found in mice on ZA or melphalan monotherapy, or the combination treatment of ZA and dexamethasone. ONJ lesions were characterized by a lack of epithelium, exposed necrotic bone, severe inflammatory cell infiltration, and minimal bone formation. Fluorescent immunohistochemistry showed that lymphatic vessel formation was significantly suppressed in ONJ like lesions with a concomitant decrease in F4/80(+) macrophages expressing vascular endothelial growth factor C (VEGFC). Interestingly, significantly suppressed lymphatics were also found in the draining lymph nodes of mice on the combination treatment of ZA and melphalan. Thus, suppressed lymphangiogenesis was strongly associated with the development of ONJ like lesions in the current study. Since lymphangiogenesis is critical in the resolution of inflammation during wound healing, inflammation control may serve as a potential strategy to prevent ONJ. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Kuroshima, Shinichiro; Yamashita, Junro] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Yamashita, J (通讯作者)，Univ Michigan, Sch Dent, 1011 North Univ Ave, Ann Arbor, MI 48109 USA.
EM kuroshima@nagasaki u.ac.jp; yamashit@umich.edu
RI ; Yamashita, Junro/D 4787 2019
OI Kuroshima, Shinichiro/0000 0001 9891 9987; Yamashita,
   Junro/0000 0002 5486 1362
CR Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379
   Aksu G, 2001, BONE MARROW TRANSPL, V27, P201, DOI 10.1038/sj.bmt.1702739
   Amler MH., 1960, J AM DENT ASSOC, V61, P32, DOI [DOI 10.14219/JADA.ARCHIVE.1960.0152, 10.14219/jada.archive.1960.0152]
   Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   Cueni Leah N., 2008, Lymphatic Research and Biology, V6, P109, DOI 10.1089/lrb.2008.1008
   Falco P, 2007, EXPERT REV ANTICANC, V7, P945, DOI 10.1586/14737140.7.7.945
   Forner L, 2006, J CLIN PERIODONTOL, V33, P401, DOI 10.1111/j.1600 051X.2006.00924.x
   Francini F, 2011, J AM DENT ASSOC, V142, P506, DOI 10.14219/jada.archive.2011.0220
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   GUNTHEROTH WG, 1984, AM J CARDIOL, V54, P797, DOI 10.1016/S0002 9149(84)80211 8
   HEIMDAHL A, 1989, ORAL SURG ORAL MED O, V68, P711, DOI 10.1016/0030 4220(89)90160 6
   Herlofson BB, 1997, EUR J ORAL SCI, V105, P523, DOI 10.1111/j.1600 0722.1997.tb00239.x
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Hovi L, 1996, J PEDIAT HEMATOL ONC, V18, P90, DOI 10.1097/00043426 199602000 00018
   IIZUKA T, 1992, J ORAL PATHOL MED, V21, P150, DOI 10.1111/j.1600 0714.1992.tb00092.x
   Ji RC, 2005, HISTOL HISTOPATHOL, V20, P155, DOI 10.14670/HH 20.155
   Kataru RP, 2009, BLOOD, V113, P5650, DOI 10.1182/blood 2008 09 176776
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kuroshima S, 2012, ENDOCRINOLOGY, V153, P17, DOI 10.1210/en.2011 1439
   Lenz JH, 2005, J CRANIO MAXILL SURG, V33, P395, DOI 10.1016/j.jcms.2005.07.007
   Li D, 2010, ANN NY ACAD SCI, V1192, P84, DOI 10.1111/j.1749 6632.2009.05210.x
   Marchetti C, 2002, MICROSC RES TECHNIQ, V56, P42, DOI 10.1002/jemt.10010
   Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mawardi H, 2011, J DENT RES, V90, P1339, DOI 10.1177/0022034511420430
   McMillan MD, 1999, J ORAL PATHOL MED, V28, P297
   MEYERS JD, 1980, J INFECT DIS, V142, P338, DOI 10.1093/infdis/142.3.338
   O'Ryan FS, 2012, J ORAL MAXIL SURG, V70, P1844, DOI 10.1016/j.joms.2011.08.033
   Odri GA, 2010, CANCER RES, V70, P7610, DOI 10.1158/0008 5472.CAN 09 4272
   OKABE K, 1995, INT J ORAL MAX SURG, V24, P239, DOI 10.1016/S0901 5027(06)80137 2
   PIETROKO.J, 1971, J PROSTHET DENT, V26, P119, DOI 10.1016/0022 3913(71)90041 2
   Postnov A, 2009, CALCIFIED TISSUE INT, V85, P530, DOI 10.1007/s00223 009 9301 3
   Raber Durlacher JE, 2002, SUPPORT CARE CANCER, V10, P466, DOI 10.1007/s00520 002 0346 3
   RADDEN H G, 1959, Ann R Coll Surg Engl, V24, P366
   Reinholt FP, 1999, EXP CELL RES, V251, P477, DOI 10.1006/excr.1999.4585
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SCHWARTZ HC, 1982, HEAD NECK SURG, V4, P251, DOI 10.1002/hed.2890040313
   Smith N, 1974, Aust Dent J, V19, P250
   Sung Eric C, 2002, Spec Care Dentist, V22, P142, DOI 10.1111/j.1754 4505.2002.tb01178.x
   Tabrizi R, 2010, J CRANIOFAC SURG, V21, P136, DOI 10.1097/SCS.0b013e3181c46df2
   Vardy J, 2006, BRIT J CANCER, V94, P1011, DOI 10.1038/sj.bjc.6603048
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   WOO SB, 1993, CANCER, V72, P1612, DOI 10.1002/1097 0142(19930901)72:5<1612::AID CNCR2820720520>3.0.CO;2 Q
   Yamashita J, 2008, J BONE MINER RES, V23, P621, DOI 10.1359/JBMR.071211
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
   Zhang Q, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2326
   Zhang Q, 2008, J BIOL CHEM, V283, P13491, DOI 10.1074/jbc.M708055200
NR 51
TC 45
Z9 48
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2013
VL 56
IS 1
BP 101
EP 109
DI 10.1016/j.bone.2013.05.013
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 189WS
UT WOS:000322299600016
PM 23727433
DA 2025 08 17
ER

PT J
AU Agis, H
   Blei, J
   Watzek, G
   Gruber, R
AF Agis, H.
   Blei, J.
   Watzek, G.
   Gruber, R.
TI Is Zoledronate Toxic to Human Periodontal Fibroblasts?
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE zoledronate; osteonecrosis; gingival fibroblasts; periodontal ligament
ID BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; ACID; OSTEOCLASTS; JAW;
   DIFFERENTIATION; PROLIFERATION; MECHANISM; THERAPY; BREAST
AB Exposed necrotic alveolar bone is a hallmark of bisphosphonate related osteonecrosis of the jaw. However, it is unknown whether zoledronate causes soft tissue damage via adverse actions toward periodontal fibroblasts. We therefore examined whether zoledronate causes a cytotoxic response in fibroblasts isolated from the gingiva and the periodontal ligament. We report that micromolar concentrations of zoledronate and serum free conditions decreased cell activity, as measured by assays for formazan formation, proliferation, and protein synthesis. Under these conditions, periodontal fibroblasts underwent apoptosis and necrosis, as indicated by cleavage of PARP and membrane disruption, respectively. However, these adverse effects of zoledronate were mitigated by the presence of serum. Moreover, zoledronate bound to calcium phosphate failed to reduce cell activity. Analysis of these data suggests that the cytotoxic responses of periodontal fibroblasts require high concentrations of zoledronate and depend on the in vitro experimental conditions. Whether these findings translate into soft tissue damage will require further investigation.
C1 [Agis, H.; Blei, J.; Watzek, G.; Gruber, R.] Med Univ Vienna, Dept Oral Surg, A 1090 Vienna, Austria.
C3 Medical University of Vienna
RP Gruber, R (通讯作者)，Med Univ Vienna, Dept Oral Surg, Wahringerstr 25A, A 1090 Vienna, Austria.
EM reinhard.gruber@meduniwien.ac.at
RI Gruber, Reinhard/A 8053 2012; Agis, Hermann/O 4596 2016; Watzek,
   Georg/G 7565 2012
OI Agis, Hermann/0000 0001 9509 1555; Gruber, Reinhard/0000 0001 5400 9009;
   
FU Department of Oral Surgery, Medical University of Vienna
FX The authors thank M. Pensch for skillful technical assistance, K.
   Stogerer for preparing the CaP plates, and P. Lysaght for proofreading.
   We acknowledge E. Beran (Novartis Pharma GmbH) for providing us with
   ZOL. This research was supported by the Department of Oral Surgery,
   Medical University of Vienna.
CR ALLEN MR, 2009, J ORAL MAXILLOFAC S, V67, pS61
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Kars MD, 2007, ANTICANCER RES, V27, P4031
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Melisi D, 2005, ENDOCR RELAT CANCER, V12, P1051, DOI 10.1677/erc.1.01061
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Patntirapong S, 2009, BIOMATERIALS, V30, P548, DOI 10.1016/j.biomaterials.2008.09.062
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Schindeler A, 2005, BIOCHEM BIOPH RES CO, V338, P710, DOI 10.1016/j.bbrc.2005.09.198
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   WALTER C, 2009, CLIN ORAL I IN PRESS
NR 29
TC 55
Z9 58
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JAN
PY 2010
VL 89
IS 1
BP 40
EP 45
DI 10.1177/0022034509354298
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 530SG
UT WOS:000272612000006
PM 19948943
DA 2025 08 17
ER

PT J
AU Roberto, J
   Poulin, KL
   Parks, RJ
   Vacratsis, PO
AF Roberto, Justin
   Poulin, Kathy L.
   Parks, Robin J.
   Vacratsis, Panayiotis O.
TI Label free quantitative proteomic analysis of extracellular vesicles
   released from fibroblasts derived from patients with spinal muscular
   atrophy
SO PROTEOMICS
LA English
DT Article
DE data independent acquisition; extracellular vesicles; ion mobility;
   label&#8208; free proteomics; spinal muscular atrophy
ID GROWTH FACTOR I; SMN; IDENTIFICATION; PROTEINS; BODIES
AB Spinal muscular atrophy (SMA) is an autosomal recessive disorder that represents a significant cause of infant mortality. SMA is characterized by reduced levels of the Survival Motor Neuron protein leading to the loss of alpha motor neurons in the spinal cord and brain stem as well as defects in peripheral tissues such as skeletal muscle and liver. With progress in promising therapies such as antisense oligonucleotide and gene replacement, there remains a need to better understand disease subtypes and develop biomarkers for improved diagnostics and therapeutic monitoring. In this study, we have examined the utility of extracellular vesicles as a source of biomarker discovery in patient derived fibroblast cells. Proteome examination utilizing data independent acquisition and ion mobility mass spectrometry identified 684 protein groups present in all biological replicates tested. Label free quantitative analysis identified 116 statistically significant protein alterations compared to control cells, including several known SMA biomarkers. Protein level differences were also observed in regulators of Wnt signaling and Cajal bodies. Finally, levels of insulin growth factor binding protein 3 were validated as being significantly higher in extracellular vesicles isolated from SMA cells. We conclude that extracellular vesicles represent a promising source for SMA biomarker discovery as well as a relevant constituent for advancing our understanding of SMA pathophysiology.
C1 [Roberto, Justin; Vacratsis, Panayiotis O.] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.
   [Poulin, Kathy L.; Parks, Robin J.] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada.
C3 University of Windsor; University of Ottawa; Ottawa Hospital Research
   Institute
RP Vacratsis, PO (通讯作者)，Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.
EM vacratsi@uwindsor.ca
OI Parks, Robin/0000 0002 4959 2233
FU CIHR [MOP 136898, MOP 142316]; NSERC [RGPIN 2014 04810,
   RGPIN 2019 04786, RGPIN 2020 05099]
FX RJP from CIHR, Grant/Award Numbers: MOP 136898, MOP 142316; NSERC,
   Grant/Award Numbers: RGPIN 2014 04810, RGPIN 2019 04786,
   RGPIN 2020 05099; RJP from CIHR, Grant/Award Numbers: MOP 136898,
   MOP 142316; NSERC, Grant/Award Numbers: RGPIN 2014 04810,
   RGPIN 2019 04786; POV from NSERC, Grant/Award Number: RGPIN 2020 05099
CR Allard JB, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00117
   Ando S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74346 9
   Bach JR, 2000, CHEST, V117, P1100, DOI 10.1378/chest.117.4.1100
   BAXTER RC, 1992, J BIOL CHEM, V267, P60
   Chaytow H, 2018, CELL MOL LIFE SCI, V75, P3877, DOI 10.1007/s00018 018 2849 1
   Chen YC, 2012, NEUROL RES, V34, P390, DOI 10.1179/1743132812Y.0000000027
   Finamore F., 2014, EuPA Open Proteomics, V3, P100
   Finkel RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035462
   Freund A, 2014, CELL, V159, P1389, DOI 10.1016/j.cell.2014.10.059
   Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030
   Gross JC, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00010
   Hayes M, 2013, DEVELOPMENT, V140, P1807, DOI 10.1242/dev.090183
   Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401
   Helm D, 2014, MOL CELL PROTEOMICS, V13, P3709, DOI 10.1074/mcp.M114.041038
   Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485
   Jafari E, 2018, RES PHARM SCI, V13, P332, DOI 10.4103/1735 5362.235160
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Kaifer KA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89970
   Kariyawasam DST, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00898
   Knee KM, 2013, CELL STRESS CHAPERON, V18, P137, DOI 10.1007/s12192 012 0357 z
   Kobayashi DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060113
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092 8674(95)90460 3
   Li DK, 2014, SEMIN CELL DEV BIOL, V32, P22, DOI 10.1016/j.semcdb.2014.04.026
   Li Q, 2020, YONSEI MED J, V61, P273, DOI [10.3349/ymj.2020.61.4.273, 10.3349/ymj.2020.61.4273]
   Liang XH, 2014, NUCLEIC ACIDS RES, V42, P7819, DOI 10.1093/nar/gku484
   Lu XW, 2004, NATURE, V430, P93, DOI 10.1038/nature02677
   Millino C, 2009, BMC MED, V7, DOI 10.1186/1741 7015 7 14
   Murdocca M, 2012, MOL MED, V18, P1076, DOI 10.2119/molmed.2012.00056
   Mutsaers CA, 2013, GENOME MED, V5, DOI 10.1186/gm498
   Nery FC, 2019, NEUROL GENET, V5, DOI 10.1212/NXG.0000000000000353
   Ogino S, 2002, HUM GENET, V111, P477, DOI 10.1007/s00439 002 0828 x
   Oprea GE, 2008, SCIENCE, V320, P524, DOI 10.1126/science.1155085
   Peradziryi H, 2011, EMBO J, V30, P3729, DOI 10.1038/emboj.2011.236
   Sakowski SA, 2009, AMYOTROPH LATERAL SC, V10, P63, DOI 10.1080/17482960802160370
   Sawyer IA, 2016, BIOESSAYS, V38, P1197, DOI 10.1002/bies.201600144
   Silva JC, 2006, MOL CELL PROTEOMICS, V5, P144, DOI 10.1074/mcp.M500230 MCP200
   Soltic D, 2019, HUM MOL GENET, V28, P3515, DOI 10.1093/hmg/ddz195
   Tapia O, 2012, HISTOCHEM CELL BIOL, V137, P657, DOI 10.1007/s00418 012 0921 8
   Wadman RI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167087
   Wan B, 2018, HUM MOL GENET, V27, P4061, DOI 10.1093/hmg/ddy300
   Wang Z, 2012, PROTEOMICS, V12, P329, DOI 10.1002/pmic.201100477
NR 41
TC 5
Z9 5
U1 3
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1615 9853
EI 1615 9861
J9 PROTEOMICS
JI Proteomics
PD JUL
PY 2021
VL 21
IS 13 14
SI SI
AR e2000301
DI 10.1002/pmic.202000301
EA MAY 2021
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA TJ3BA
UT WOS:000649257100001
PM 33893753
DA 2025 08 17
ER

PT J
AU Jiang, LJ
   Qiu, WL
   Hedrich, X
   Duan, XR
   Han, XX
   Yu, T
   Wen, SH
   Luo, ZJ
   Feng, RZ
   Teng, Y
   Yin, HF
   Hedrich, CM
   Deng, GM
AF Jiang, Lijuan
   Qiu, Wenlin
   Hedrich, Xuefei
   Duan, Xiaoru
   Han, Xiaoxiao
   Yu, Tong
   Wen, Shenghui
   Luo, Zhijun
   Feng, Ruizhi
   Teng, Yao
   Yin, Haifeng
   Hedrich, Christian M.
   Deng, Guo Min
TI Immunoglobulin G inhibits glucocorticoid induced osteoporosis through
   occupation of FcγRI
SO ISCIENCE
LA English
DT Article
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; MEMBRANE; RANKL; BONE; RECEPTOR;
   INSIGHTS; ORIGIN
AB Glucocorticoid induced osteoporosis (GIOP) is a severe and common complication of long term usage of glucocorticoids (GCs) and lacks of efficient therapy. Here, we investigated the mechanism of anti inflammation effect and osteoclastogenesis side effect of GCs and immunoglobulin G (IgG) treatment against GIOP. GCs inhibited SLE IgG induced inflammation, while IgG inhibited GCs induced osteoclastogenesis. Fc gamma RI and glucocorticoid receptor (GR) were found directly interacted with each other. GCs and IgG could reduce the expression of Fc gamma RI on macrophages. The deficiency of FcyRI affected osteoclastogenesis by GCs and systemic lupus erythematosus (SLE) IgG induced inflammation. Also, IgG efficiently reduced GIOP in mice. These data showed that GCs could induce osteoporosis and inhibit IgG induced inflammation through Fc gamma RI while IgG efficiently suppressed osteoporosis induced by GCs through Fc gamma RI. Hence, our findings may help in developing a feasible therapeutic strategy against osteoporosis, such as GIOP.
C1 [Jiang, Lijuan; Qiu, Wenlin; Hedrich, Xuefei; Duan, Xiaoru; Han, Xiaoxiao; Yu, Tong; Wen, Shenghui; Luo, Zhijun; Feng, Ruizhi; Teng, Yao; Yin, Haifeng; Deng, Guo Min] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan 430022, Peoples R China.
   [Hedrich, Christian M.] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Pediat Rheumatol, Liverpool, England.
C3 Huazhong University of Science & Technology; Alder Hey Children's NHS
   Foundation Trust
RP Deng, GM (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan 430022, Peoples R China.
EM gmdeng@hust.edu.cn
RI ; Hedrich, Christian/AAW 3958 2020; Yin, Haifeng/E 8787 2012; Yu,
   Tong/HGA 7225 2022
OI Hedrich, Christian/0000 0002 1295 6179; Yu, Tong/0000 0002 8061 6600
FU National Natural Science Foundation of China [82171786, 82103731];
   Research Initiating Fund of Union Hospital, Tongji Medical College,
   Huazhong University of Science and Technology, Wuhan, China
   [02.03.2018 41]
FX This study was supported by National Natural Science Foundation of China
   (GM Deng, 82171786) , National Natural Science Foundation of China (XR
   Duan, 82103731) , and Research Initiating Fund (GM Deng, 02.03.2018 41)
   of Union Hospital, Tongji Medical College, Huazhong University of
   Science and Technology, Wuhan, China. We thank doctors and nurses of
   Department of Rheumatology and Immunology in Wuhan Union Hospital for
   their help in this project. We thank the Medical Subcenter of HUST
   Analytical &Testing Center in data acquisition and the Laboratory Animal
   Center of HUST in animal experiment.
CR Angeli A, 2000, Ann Ital Med Int, V15, P47
   AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bultink IEM, 2018, CALCIFIED TISSUE INT, V102, P575, DOI 10.1007/s00223 017 0322 z
   Buttgereit F, 2005, LANCET, V365, P801
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Caplan A, 2017, J AM ACAD DERMATOL, V76, P1, DOI 10.1016/j.jaad.2016.01.062
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Deng GM, 2005, NAT MED, V11, P1066, DOI 10.1038/nm1304
   Deng GM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00078
   Deng GM, 2010, J IMMUNOL, V184, P7154, DOI 10.4049/jimmunol.0902514
   Deng Q, 2015, ENDOCRINOLOGY, V156, P3215, DOI 10.1210/EN.2015 1265
   Fang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01457
   Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis 2019 215089
   Franchin G, 2006, AUTOIMMUN REV, V5, P111, DOI 10.1016/j.autrev.2005.08.003
   Guo XX, 2018, IMMUNOLOGY, V154, P604, DOI 10.1111/imm.12908
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jiang LJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824008
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lai EL, 2019, LUPUS, V28, P945, DOI 10.1177/0961203319855122
   Liu XG, 2011, BLOOD, V117, P2061, DOI 10.1182/blood 2010 07 295477
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Luo QQ, 2020, NEUROGASTROENT MOTIL, V32, DOI 10.1111/nmo.13877
   Rentero ML, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0733 9
   Martínez T, 2019, AUTOIMMUN REV, V18, P279, DOI 10.1016/j.autrev.2018.10.002
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nieto Aristizábal I, 2019, LUPUS, V28, P1566, DOI 10.1177/0961203319883680
   Oppong E, 2014, SMALL, V10, P1991, DOI 10.1002/smll.201303677
   Ozen G, 2019, ANN RHEUM DIS, V78, P1041, DOI 10.1136/annrheumdis 2019 215328
   Panettieri RA, 2019, TRENDS PHARMACOL SCI, V40, P38, DOI 10.1016/j.tips.2018.11.002
   Qiao W, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1174
   Rainville JR, 2019, STEROIDS, V142, P55, DOI 10.1016/j.steroids.2017.12.005
   Scheschowitsch K, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00016
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898
   Strehl C, 2014, ANN NY ACAD SCI, V1318, P1, DOI 10.1111/nyas.12364
   Strehl C, 2011, ARTHRITIS RHEUM US, V63, P3779, DOI 10.1002/art.30637
   Sutter S, 2014, J CLIN ENDOCR METAB, V99, P4231, DOI 10.1210/jc.2014 2177
   Syed AP, 2020, CURR OPIN PHARMACOL, V53, P35, DOI 10.1016/j.coph.2020.03.003
   Vandevyver S, 2013, ENDOCRINOLOGY, V154, P993, DOI 10.1210/en.2012 2045
   Weiss GL, 2019, STEROIDS, V142, P2, DOI 10.1016/j.steroids.2017.09.004
   Zhang Q, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03020
   Zuo YY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.688201
NR 47
TC 3
Z9 3
U1 2
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589 0042
J9 ISCIENCE
JI iScience
PD OCT 20
PY 2023
VL 26
IS 10
AR 107749
DI 10.1016/j.isci.2023.107749
EA SEP 2023
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA T3XQ3
UT WOS:001077353500001
PM 37701568
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Anwikar, SR
   Bandekar, MS
   Patel, TK
   Patel, PB
   Kshirsagar, NA
AF Anwikar, S. R.
   Bandekar, M. S.
   Patel, T. K.
   Patel, P. B.
   Kshirsagar, N. A.
TI Tetany: Possible adverse effect of bevacizumab
SO INDIAN JOURNAL OF CANCER
LA English
DT Article
DE Bevacizumab; adverse effect; tetany; serum calcium
ID ENDOTHELIAL GROWTH FACTOR; BONE RESORPTION; SURVIVAL
AB BACKGROUND: Bevacizumab a recombinant humanized monoclonal antibody was approved in 2004 by US FDA for metastatic colorectal cancer. It is reported to cause potentially serious toxicities including severe hypertension, proteinuria, and congestive heart failure. AIM: To correlate adverse event tetany with the use of bevacizumab. MATERIALS AND METHODS: World Health Organization's Uppsala Monitoring Centre, Sweden, for reporting of adverse drug reactions from all over the world, identified 7 cases with tetany related symptoms to bevacizumab from four different countries. These 7 patients reported to UMC database developed adverse events described as musculoskeletal stiffness (1), muscle spasm (1), muscle cramps (1), lock jaw or jaw stiffness (4), and hypertonia (1), with hypocalcaemia. RESULTS: After detailed study of the possible mechanism of actions of bevacizumab and factors causing tetany, it is proposed that there is a possibility of tetany by bevacizumab, which may occur by interfering with calcium metabolism. Resorption of bone through osteoclasts by affecting VEGF may interfere with calcium metabolism. Another possibility of tetany may be due to associated hypomagnesaemia, hypokalemia, or hyponatremia. CONCLUSIONS: Tetany should be considered as a one of the signs. Patient on bevacizumab should carefully watch for tetany related symptoms and calcium and magnesium levels for their safety.
C1 [Anwikar, S. R.; Bandekar, M. S.; Kshirsagar, N. A.] Maharashtra Univ Hlth Sci, Dept Infect Dis, Bombay, Maharashtra, India.
   [Patel, T. K.; Patel, P. B.] Govt Med Coll, Dept Pharmacol, Bhavnagar, Gujarat, India.
C3 Maharaja Krishnakumar Sinhji Bhavnagar University
RP Kshirsagar, NA (通讯作者)，Maharashtra Univ Hlth Sci, Dept Infect Dis, Bombay, Maharashtra, India.
EM kshirsagarna@yahoo.in
RI Patel, Tejas/E 2100 2012
OI Patel, Tejas/0000 0002 8766 5632; Patel, Parvati/0000 0002 4226 4448
CR [Anonymous], 2006, PHARM BASIS THERAPEU
   Bringhurst FR, 2003, WILLIAMS TXB ENDOCRI, P1303
   Bruder JM, 2001, ENDOCRINOLOGY METABO, V4th, P1079
   Chabner B A., 2006, Goodman and Gilmans Pharmacologic Basis of Therapuetics. Eds, P1315
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12 6 713
   COONEY MM, 2007, J CLIN ONCOL, V18, P15532
   Esbrit P, 2000, J AM SOC NEPHROL, V11, P1085, DOI 10.1681/ASN.V1161085
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Henriksen K, 2003, J BIOL CHEM, V278, P48745, DOI 10.1074/jbc.M309193200
   Kaku M, 2001, J DENT RES, V80, P1880, DOI 10.1177/00220345010800100401
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   Takimoto CH, 2003, J CLIN ONCOL, V21, P2664, DOI 10.1200/JCO.2003.11.015
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   BEVACIZUMAB 4 DOSAGE
   TRAMADOL TRAMADOL HY
   CLEMASTINE ORAL
   DOCETAXEL 4
NR 19
TC 6
Z9 6
U1 10
U2 42
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019 509X
EI 1998 4774
J9 INDIAN J CANCER
JI Indian J. Cancer
PD JAN MAR
PY 2011
VL 48
IS 1
BP 31
EP 33
DI 10.4103/0019 509X.75819
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 723TG
UT WOS:000287529300005
PM 21248449
DA 2025 08 17
ER

PT J
AU Liu, TW
   Akens, MK
   Chen, J
   Wise Milestone, L
   Wilson, BC
   Zheng, G
AF Liu, Tracy W.
   Akens, Margarete K.
   Chen, Juan
   Wise Milestone, Lisa
   Wilson, Brian C.
   Zheng, Gang
TI Imaging of Specific Activation of Photodynamic Molecular Beacons in
   Breast Cancer Vertebral Metastases
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID MATRIX METALLOPROTEINASES; CELL LINES; BONE; THERAPY; EXPRESSION; MODEL;
   MMPS; INVOLVEMENT; OSTEOCLASTS; TECHNOLOGY
AB Breast cancer is the second leading cause of cancer related death in women. Approximately 85% of patients with advanced cases will develop spinal metastases. The vertebral column is the most common site of breast cancer metastases, where overexpression of matrix metalloproteinases (MMPs) promotes the spread of cancer. Current therapies have significant limitations due to the high associated risk of damaging the spinal cord. An attractive alternative is photodynamic therapy providing noninvasive and site selective treatment. However, current photosensitizers are limited by their nonspecific accumulation. Photodynamic molecular beacons (PPMMPB), activated by MMPs, offer another level of PDT selectivity and image guidance preserving criticial tissues, specifically the spinal cord. Metastatic human breast carcinoma cells, MT 1, were used to model the metastatic behavior of spinal lesions. In vitro and in vivo evidence demonstrates MMP specific activation of PPMMPB in MT 1 cells. Using a clinically relevant metastatic model, fluorescent imaging establishes the specific activation of PPMMPB by vertebral metastases versus normal tissue (i.e., spinal cord) demonstrating the specificity of these beacons. Here, we validate that the metastasis selective mechanism of PP(MMP)Bs can specifically image breast cancer vertebral metastases, thereby differentiating tumor and healthy tissue.
C1 [Liu, Tracy W.; Wilson, Brian C.; Zheng, Gang] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada.
   [Liu, Tracy W.; Chen, Juan; Wilson, Brian C.; Zheng, Gang] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada.
   [Akens, Margarete K.; Wise Milestone, Lisa] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto; University Health Network
   Toronto; University of Toronto; Sunnybrook Research Institute;
   Sunnybrook Health Science Center
RP Zheng, G (通讯作者)，S 363 101 Coll St, Toronto, ON M5G 1L7, Canada.
EM gang.zheng@uhnres.utoronto.ca
RI ; zheng, gang/KMX 5568 2024; Akens, Margarete/K 5502 2013
OI Chen, Juan/0000 0001 7515 5072; Wilson, Brian C./0000 0001 5543 666X;
   Zheng, Gang/0000 0002 0705 7398; Akens, Margarete/0000 0003 3523 2381;
   Liu, Tracy/0000 0003 0671 8390
FU Canadian Institutes of Health Research; DOD [W81XWH 10 1 0115]; Joey and
   Toby Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research
FX This work was supported by the Canadian Institutes of Health Research,
   DOD BCRP Predoc Award W81XWH 10 1 0115, and Joey and Toby
   Tanenbaum/Brazilian Ball Chair in Prostate Cancer Research. Partial
   support was provided by the Princess Margaret Hospital Foundation and
   the Ontario Ministry of Health & Long Term care.
CR Akens MK, 2007, PHOTOCHEM PHOTOBIOL, V83, P1034, DOI 10.1111/j.1751 1097.2007.00172.x
   Akens MK, 2010, BREAST CANCER RES TR, V119, P325, DOI 10.1007/s10549 009 0356 7
   American Cancer Society, 2009, BREAST CANC FACTS FI
   Andersen TL, 2004, BONE, V35, P1107, DOI 10.1016/j.bone.2004.06.019
   Bartels RHMA, 2008, CA CANCER J CLIN, V58, P245, DOI 10.3322/CA.2007.0016
   Bogaards A, 2005, PHOTOCH PHOTOBIO SCI, V4, P438, DOI 10.1039/b414829k
   Bord S, 1998, BONE, V23, P7, DOI 10.1016/S8756 3282(98)00064 7
   Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763
   Bullok K, 2005, J MED CHEM, V48, P5404, DOI 10.1021/jm050008p
   Burch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1921887
   Burch S, 2005, J ORTHOP RES, V23, P995, DOI 10.1016/j.orthres.2004.12.014
   Campo MA, 2007, PHOTOCHEM PHOTOBIOL, V83, P958, DOI 10.1111/j.1751 1097.2007.00090.x
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   El Naggar AK, 2009, HEAD NECK ONCOL, V1, DOI [10.1186/1758 3284 1 1, 10.1186/1758 3284 1 25]
   Engebraaten O, 1999, INT J CANCER, V82, P219, DOI 10.1002/(SICI)1097 0215(19990719)82:2<219::AID IJC12>3.0.CO;2 #
   Engebraaten O, 2000, INT J CANCER, V88, P970, DOI 10.1002/1097 0215(20001215)88:6<970::AID IJC21>3.0.CO;2 Q
   Finn Michael A, 2007, Cancer Control, V14, P405
   Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945 053X(98)90019 1
   Gibbs Strauss SL, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3065543
   Guise TA, 2009, GENE DEV, V23, P2117, DOI 10.1101/gad.1854909
   Hou P, 2004, BONE, V34, P37, DOI 10.1016/j.bone.2003.08.011
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Kasper G, 2007, BMC CANCER, V7, DOI 10.1186/1471 2407 7 12
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Klerk CPW, 2007, BIOTECHNIQUES, V43, P7, DOI 10.2144/000112515
   Köhrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 188
   Lee S, 2010, CURR TOP MED CHEM, V10, P1135, DOI 10.2174/156802610791384270
   Lo PC, 2009, J MED CHEM, V52, P358, DOI 10.1021/jm801052f
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   McIntyre JO, 2004, BIOCHEM J, V377, P617, DOI 10.1042/BJ20030582
   Muller PJ, 2006, LASER SURG MED, V38, P384, DOI 10.1002/lsm.20338
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nabha SM, 2008, INT J CANCER, V122, P2482, DOI 10.1002/ijc.23431
   Noë V, 2001, J CELL SCI, V114, P111
   Page McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Pervaiz S, 2006, CLIN EXP PHARMACOL P, V33, P551, DOI 10.1111/j.1440 1681.2006.04406.x
   Sato A, 2004, COMPARATIVE MED, V54, P631
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Stenzl A, 2010, J UROLOGY, V184, P1907, DOI 10.1016/j.juro.2010.06.148
   Troyan SL, 2009, ANN SURG ONCOL, V16, P2943, DOI 10.1245/s10434 009 0594 2
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933
   Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103 123
   Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031 9155/53/9/R01
   Wilson BC, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2795688
   Won E., 2010, BREAST CANC RES TREA
   Won E, 2010, SPINE, V35, P272, DOI 10.1097/BRS.0b013e3181af8360
   Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024
   Yu Q, 2004, CLIN EXP METASTAS, V21, P235, DOI 10.1023/B:CLIN.0000037705.25256.d3
   Zheng G, 2007, P NATL ACAD SCI USA, V104, P8989, DOI 10.1073/pnas.0611142104
NR 51
TC 30
Z9 42
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
EI 1520 4812
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUN
PY 2011
VL 22
IS 6
BP 1021
EP 1030
DI 10.1021/bc200169x
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 776VZ
UT WOS:000291568200006
PM 21585206
DA 2025 08 17
ER

PT J
AU Zuo, WY
   Yu, LJ
   Zhang, HY
   Fei, Q
AF Zuo, Weiyang
   Yu, Lingjia
   Zhang, Haiyan
   Fei, Qi
TI Mineralized collagen scaffold bone graft accelerate the osteogenic
   process of HASCs in proper concentration
SO REGENERATIVE THERAPY
LA English
DT Article
DE Human adipose derived stem cells; Osteogenesis; Cell material
   composition; Polymethylmethacrylate
ID MESENCHYMAL STEM CELLS; ADIPOSE TISSUE; DIFFERENTIATION; MARROW
AB Purpose: To investigate the feasibility and the optimum condition of human adipose derived stem cells cultured on the mineralized collagen material; and to further explore the mechanism of osteogenic differentiation of the human Adipose derived stem cells stimulated by the mineralized collagen material.
   Methods: Primary human adipose derived stem cells (HADSCs) were isolated from human adipose tissue using centrifugal stratification, which had been passed repeatedly to later generations and purified. Human adipose derived stem cells were cultured on the bone graft material and the optimum concentration was explored by Alamar blue colorimetric method. The rest experiment was conducted according to the result. The experimental groups are shown below: group A (HADSCs + bone graft material); group B (HADSCs). Morphological observation was taken by scanning electronic microscope (SEM). Alkaline phosphatase activities were tested by histochemical method. Calcium deposition was investigated by alizarin red staining. The quantity access of osteogenic related mRNA: ALP (alkaline phosphatase), BMP2 (bone morphogenetic protein 2) and RUNX2 (runt related transcription factor 2) were detected using RT PCR.
   Results: The cultured cells grew stably and proliferated rapidly. The optimum condition was 0.5 mg/cm(2) bone graft material coated on the bottom of medium. After culturing on the material 14 days, the alizarin red staining showed that more calcium deposition was detected in group A and alkaline phosphatase activities of group A was higher than group B (p (>) 0.05). Similarly, after culturing for 14 days, the ALP, BMP2 and RUNX2 transcription activity of group A was higher than group B (p (>) 0.05).
   Conclusion: Human adipose derived stem cells cultured on bone graft material were dominantly differentiated into osteoblast in vitro. Thus it provided a new choice for bone tissue engineering. (C) 2021, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Zuo, Weiyang; Yu, Lingjia; Fei, Qi] Capital Med Univ, Beijing Friendship Hosp, Dept Orthoped, Beijing 100050, Peoples R China.
   [Zhang, Haiyan] Capital Med Univ, Dept Cell Biol, Municipal Lab Liver Protect & Regulat Regenerat, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Fei, Q (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Dept Orthoped, Beijing 100050, Peoples R China.
EM spinefei@ccmu.edu.cn
RI Zhang, Haiyan/HPG 4116 2023
CR Clements JR, 2008, J FOOT ANKLE SURG, V47, P350, DOI 10.1053/j.jfas.2008.04.006
   Cowden K, 2019, NANOMED NANOTECHNOL, V17, P380, DOI 10.1016/j.nano.2019.01.008
   Deng BL, 2019, MOL MED REP, V20, P4933, DOI 10.3892/mmr.2019.10764
   Ehnert S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040994
   Fan JB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072474, 10.1371/journal.pone.0076701]
   Farokhi M, 2018, BIOTECHNOL ADV, V36, P68, DOI 10.1016/j.biotechadv.2017.10.001
   Fu XK, 2018, ADV SCI, V5, DOI 10.1002/advs.201700755
   Guo YC, 2018, EMBO J, V37, DOI 10.15252/embj.201899398
   Kargozar S, 2018, J BIOMED MATER RES B, V106, P61, DOI 10.1002/jbm.b.33814
   Kim TH, 2015, ACS NANO, V9, P3780, DOI 10.1021/nn5066028
   Komatsu N, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1085 9
   Li X, 2018, CRIT REV EUKAR GENE, V28, P285, DOI 10.1615/CritRevEukaryotGeneExpr.2018023572
   Maredziak M, 2017, ELECTROMAGN BIOL MED, V36, P45, DOI 10.3109/15368378.2016.1149860
   Mebarki M, 2017, ACTA BIOMATER, V59, P94, DOI 10.1016/j.actbio.2017.06.018
   Myeroff C, 2011, J BONE JOINT SURG AM, V93A, P2227, DOI 10.2106/JBJS.J.01513
   Naruphontjirakul P, 2019, ACTA BIOMATER, V90, P373, DOI 10.1016/j.actbio.2019.03.038
   Perry CR, 1999, CLIN ORTHOP RELAT R, P71
   Rozila I, 2016, J BIOMED MATER RES A, V104, P377, DOI 10.1002/jbm.a.35573
   Thiagarajan L, 2017, STEM CELL TRANSL MED, V6, P2146, DOI 10.1002/sctm.17 0137
   Zhang HT, 2012, CYTOTHERAPY, V14, P1203, DOI 10.3109/14653249.2012.711470
   Zhang HF, 2017, J MATER CHEM B, V5, P1205, DOI 10.1039/c6tb01401a
   Zhang W, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2363917
   Zheng JQ, 2019, MAT SCI ENG C MATER, V105, DOI [10.1016/j.msec.2019.110072, 10.1016/j.rnsec.2019.110072]
   Zhou K, 2019, ACS NANO, V13, P9595, DOI 10.1021/acsnano.9b04723
NR 24
TC 6
Z9 6
U1 0
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2021
VL 18
BP 161
EP 167
DI 10.1016/j.reth.2021.06.001
PG 7
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA WA7TW
UT WOS:000703088900022
PM 34277898
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zheng, WW
   Li, XL
   Liu, DQ
   Li, J
   Yang, S
   Gao, Z
   Wang, ZN
   Yokota, H
   Zhang, P
AF Zheng, Weiwei
   Li, Xinle
   Liu, Daquan
   Li, Jie
   Yang, Shuang
   Gao, Zhe
   Wang, Zhaonan
   Yokota, Hiroki
   Zhang, Ping
TI Mechanical loading mitigates osteoarthritis symptoms by regulating
   endoplasmic reticulum stress and autophagy
SO FASEB JOURNAL
LA English
DT Article
DE OA; eIF2alpha; P62; knee load; non invasive physical therapy
ID UNFOLDED PROTEIN RESPONSE; BONE FORMATION; MURINE TIBIAE; ER STRESS;
   KNEE; CARTILAGE; HISTOPATHOLOGY; STIMULATION; ACTIVATION; FREQUENCY
AB Osteoarthritis (OA) is a disease characterized by cartilage damage and abnormal remodeling of subchondral bone. Our previous study showed that in the early stage of OA, knee loading exerts protective effects by suppressing osteoclastogenesis through Wnt signaling, but little is known about loading effects at the late OA stage. Endoplasmic reticulum (ER) stress and autophagy are known to be involved in the late OA stage. We determined the effects of mechanical loading on ER stress and autophagy in OA mice. One hundred seventy four mice were used for a surgery induced OA model. In the first set of experiments, 60 mice were devoted to evaluation of the role of ER stress and autophagy in the development of OA. In the second set, 114 mice were used to assess the effect of knee loading on OA. Histologic, cellular, microcomputed tomography, and electron microscopic analyses were performed to evaluate morphologic changes, ER stress, and autophagy. Mechanical loading increased phosphorylation of eukaryotic translation initiation factor 2 (eIF2) and regulated expressions of autophagy markers LC3II/I and p62. Osteoarthritic mice also exhibited an elevated ratio of calcified cartilage to total articular cartilage (CC/TAC), and synovial hyperplasia with increased lining cells was found. At the early disease stage, subchondral bone plate thinning and reduced subchondral bone volume fraction (B.Ar/T.Ar) were observed. At the late disease stages, subchondral bone plate thickened concomitant with increased B.Ar/T.Ar. Mice subjected to mechanical loading exhibited resilience to cartilage destruction and a correspondingly reduced Osteoarthritis Research Society International score at 4 and 8 wk, as well as a decrease in synovitis and CC/TAC. While chondrocyte numbers in the OA group was notably decreased, mechanical loading restored chondrogenic differentiation. These results demonstrate that mechanical loading can retard the pathologic progression of OA at its early and late stages. The observed effects of loading are associated with the regulations of ER stress and autophagy.Zheng, W., Li, X., Liu, D., Li, J., Yang, S., Gao, Z., Wang, Z., Yokota, H., Zhang, P. Mechanical loading mitigates osteoarthritis symptoms by regulating endoplasmic reticulum stress and autophagy.
C1 [Zheng, Weiwei; Li, Xinle; Liu, Daquan; Li, Jie; Yang, Shuang; Gao, Zhe; Wang, Zhaonan; Zhang, Ping] Tianjin Med Univ, Sch Basic Med Sci, Dept Anat & Histol, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.
   [Li, Xinle; Liu, Daquan; Zhang, Ping] Tianjin Med Univ, Tianjin Key Lab Metab Dis, Minist Hlth, Key Lab Hormones & Dev, Tianjin, Peoples R China.
   [Li, Xinle; Liu, Daquan; Li, Jie; Yang, Shuang; Zhang, Ping] Chinese Acad Med Sci, Int Cardiovasc Hosp, Tianjin Econ Technol Dev Area, Tianjin, Peoples R China.
   [Li, Xinle; Liu, Daquan; Li, Jie; Yang, Shuang; Zhang, Ping] Peking Union Med Coll, Tianjin, Peoples R China.
   [Yokota, Hiroki; Zhang, Ping] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Tianjin Medical University; Tianjin Medical University; Chinese Academy
   of Medical Sciences   Peking Union Medical College; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Peking Union Medical
   College; Purdue University System; Purdue University; Purdue University
   in Indianapolis
RP Zhang, P (通讯作者)，Tianjin Med Univ, Sch Basic Med Sci, Dept Anat & Histol, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.
EM pizhang2008@163.com
RI zhang, ping/L 3901 2017; Gao, Zhe/HIU 0499 2022; Li, Xinle/B 8285 2016;
   gao, zhe/HIU 0499 2022; Li, Jie/GNP 2561 2022
OI Gao, Zhe/0000 0002 7186 3837; 
FU National Natural Science Foundation of China [81772405, 81572100,
   81601863]; China Postdoctoral Science Foundation [2016M601275]; Tianjin
   Binhai New Area Health and Family Planning Commission [2016BWKL002,
   2016BWKZ005]; Science and Technology Development Fund of Tianjin
   Education Commission for Higher Education [2017KJ223]; U.S. National
   Institutes of Health, National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [AR052144]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81772405 and 81572100 to P.Z.; 81601863 to X.L.),
   China Postdoctoral Science Foundation (2016M601275 to X.L.), Tianjin
   Binhai New Area Health and Family Planning Commission (2016BWKL002 to
   P.Z.; 2016BWKZ005 to D.L.), the Science and Technology Development Fund
   of Tianjin Education Commission for Higher Education (2017KJ223 to
   D.L.), and the U.S. National Institutes of Health, National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (AR052144 to H.Y.). The
   authors declare no conflicts of interest.
CR Binet F, 2015, CELL METAB, V22, P560, DOI 10.1016/j.cmet.2015.07.010
   Binet F, 2013, CELL METAB, V17, P353, DOI 10.1016/j.cmet.2013.02.003
   Caramés B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis 2011 200557
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Denny P, 2018, AUTOPHAGY, V14, P419, DOI 10.1080/15548627.2017.1415189
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring MB, 2015, CURR OPIN PHARMACOL, V22, P51, DOI 10.1016/j.coph.2015.03.004
   Hamamura K, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 312
   Hang DH, 2012, CELLS TISSUES ORGANS, V195, P495, DOI 10.1159/000329502
   Hendrickx G, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007321
   Hilz FM, 2014, BIOELECTROMAGNETICS, V35, P116, DOI 10.1002/bem.21822
   Hirasawa H, 2010, FEBS LETT, V584, P745, DOI 10.1016/j.febslet.2009.12.028
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Hu XH, 2018, J BONE MINER RES, V33, P945, DOI 10.1002/jbmr.3380
   Huang ZY, 2016, NAT REV RHEUMATOL, V12, P123, DOI 10.1038/nrrheum.2015.158
   Jayasuriya CT, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25395 8
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Kaneko H, 2013, MATRIX BIOL, V32, P178, DOI 10.1016/j.matbio.2013.01.004
   Kim JH, 2014, CELL, V156, P730, DOI 10.1016/j.cell.2014.01.007
   Kishino A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02960 1
   Lapane KL, 2015, ARTHRITIS RHEUMATOL, V67, P724, DOI 10.1002/art.38933
   Li CH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18541 1
   Li J, 2017, BONE, V97, P2, DOI 10.1016/j.bone.2016.12.009
   Li XL, 2016, SCI REP UK, V6, DOI 10.1038/srep24668
   Little CB, 2009, ARTHRITIS RHEUM US, V60, P3723, DOI 10.1002/art.25002
   Liu DQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05488 6
   Liu DQ, 2015, BONE, V81, P620, DOI 10.1016/j.bone.2015.09.012
   Lotz MK, 2011, NAT REV RHEUMATOL, V7, P579, DOI 10.1038/nrrheum.2011.109
   MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473
   Moretti J, 2017, CELL, V171, P809, DOI 10.1016/j.cell.2017.09.034
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Oliveira LC, 2016, OSTEOPOROSIS INT, V27, P2913, DOI 10.1007/s00198 016 3618 3
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Rhodes SD, 2013, J BONE MINER RES, V28, P2476, DOI 10.1002/jbmr.1992
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Sun HB, 2012, CONNECT TISSUE RES, V53, P180, DOI 10.3109/03008207.2011.628765
   Tan N, 2018, HEPATOL RES, V48, P839, DOI 10.1111/hepr.13076
   Tower RJ, 2015, BONE, V74, P171, DOI 10.1016/j.bone.2015.01.009
   Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092 8674(00)80835 1
   Vega Rubín de Celis S, 2018, P NATL ACAD SCI USA, V115, P4176, DOI 10.1073/pnas.1717800115
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang CJ, 2012, J SURG RES, V178, P196, DOI 10.1016/j.jss.2012.01.010
   Wang CJ, 2011, ARCH ORTHOP TRAUM SU, V131, P1153, DOI 10.1007/s00402 011 1289 2
   Wang HL, 2014, SHOCK, V41, P324, DOI 10.1097/SHK.0000000000000122
   Yamasaki Y, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0613 3
   Yoboue ED, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0033 4
   Zhang P, 2006, J APPL PHYSIOL, V100, P1452, DOI 10.1152/japplphysiol.00997.2005
   Zhang P, 2007, J BONE MINER METAB, V25, P383, DOI 10.1007/s00774 007 0774 8
   Zhang P, 2007, J BONE MINER RES, V22, P1979, DOI 10.1359/JBMR.070803
   Zhang P, 2007, BONE, V40, P538, DOI 10.1016/j.bone.2006.09.018
   Zhang P, 2011, BONE, V49, P867, DOI 10.1016/j.bone.2011.06.020
   Zhang P, 2009, BONE, V44, P989, DOI 10.1016/j.bone.2009.01.367
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 54
TC 56
Z9 61
U1 2
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAR
PY 2019
VL 33
IS 3
BP 4077
EP 4088
DI 10.1096/fj.201801851R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA HM9HS
UT WOS:000459794800078
PM 30485126
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhou, YH
   Huang, R
   Fan, W
   Prasadam, I
   Crawford, R
   Xiao, Y
AF Zhou, Yinghong
   Huang, Rong
   Fan, Wei
   Prasadam, Indira
   Crawford, Ross
   Xiao, Yin
TI Mesenchymal stromal cells regulate the cell mobility and the immune
   response during osteogenesis through secretion of vascular endothelial
   growth factor A
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE mesenchymal stem cells; macrophages; VEGF; osteoblasts; cell migration;
   bone; immunoregulation
ID STEM CELLS; BONE REGENERATION; RECRUITMENT; MIGRATION; REPAIR; VEGF;
   DIFFERENTIATION; ANGIOGENESIS; MACROPHAGES; CHEMOTAXIS
AB Cell cell interaction is believed to play a critical role in the cell based therapy for bone regeneration. However, the mechanisms involved in the interaction between donor cells and host cells during the bone healing process are still not clear. This study investigated the potential effect of vascular endothelial growth factor A (VEGFA) produced by osteogenically differentiated mesenchymal stem cells (O MSCs) on the recruitment and regulation of undifferentiated MSCs and macrophages during osteogenesis. Factors secreted from MSCs during osteogenic differentiation were monitored by cytokine arrays. Indirect coculture models were applied to study the effect of VEGFA derived from O MSCs on the motility, cell morphology and CXCL12/CXCR4 expression in MSCs as well as the regulation of local immune response. A mouse skull defect model was used to unveil the cell recruitment, macrophage activity and new bone formation following O MSCs transplantation. It was found that VEGFA secretion increased dramatically during the osteogenic differentiation of MSCs. The secreted VEGFA by O MSCs stimulated the expression of CXCL12/CXCR4, resulting in the recruitment of MSCs and macrophages to the bone defects. It was noted that O MSCs could regulate the local inflammation by modulating the expression of proinflammatory cytokines in macrophages and neutralizing VEGFA produced by O MSCs resulted in significant decrease of cell recruitment, cytokine secretion and new bone formation. This study demonstrates that VEGFA secreted by O MSCs plays a pivotal role in the cell recruitment and regulation of local immune response during osteogenesis. Copyright (C) 2016 John Wiley & Sons, Ltd.
C1 [Zhou, Yinghong; Huang, Rong; Prasadam, Indira; Crawford, Ross; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Crawford, Ross] Prince Charles Hosp, Brisbane, Qld, Australia.
   [Fan, Wei] Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, Wuhan, Hubei, Peoples R China.
   [Zhou, Yinghong; Huang, Rong; Fan, Wei; Prasadam, Indira; Crawford, Ross; Xiao, Yin] Queensland Univ Technol, ACCTERM, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Prince Charles Hospital;
   Wuhan University; Queensland University of Technology (QUT)
RP Xiao, Y (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
EM yin.xiao@qut.edu.au
RI ; Xiao, Yin/AAM 4033 2020; Zhou, Yinghong/ABE 6575 2021; Fan,
   Wei/W 3408 2018
OI Zhou, Yinghong/0000 0001 9757 7735; Xiao, Yin/0000 0003 1785 3491;
   Crawford, Ross/0000 0001 6079 1316; Prasadam, Indira/0000 0001 5057 2427
FU Institute of Health and Biomedical Innovation Early Career Researcher
   Internal Grant Scheme Funding; China Scholarship Council
FX The study was supported by the Institute of Health and Biomedical
   Innovation Early Career Researcher Internal Grant Scheme Funding awarded
   to Dr Yinghong Zhou, and the scholarship to Rong Hong from China
   Scholarship Council. The authors would also like to thank the staff at
   the Medical Engineering Research Facility (MERF) for their assistance in
   the in vivo study.
CR Augello A, 2010, EUR CELLS MATER, V20, P121
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Bougioukli S, 2016, BONE, V84, P93, DOI 10.1016/j.bone.2015.12.052
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Choi YY, 2016, SCI REP UK, V6, DOI 10.1038/srep22172
   Chung E, 2014, TISSUE ENG REGEN MED, V11, P431
   COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Dicarlo M, 2015, CELLS TISSUES ORGANS, V201, P333, DOI 10.1159/000445346
   Fan W, 2011, DIFFERENTIATION, V81, P181, DOI 10.1016/j.diff.2010.12.003
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   Hinsenkamp M, 2012, INT ORTHOP, V36, P633, DOI 10.1007/s00264 011 1391 7
   Jin T, 2008, CYTOKINE, V44, P1, DOI 10.1016/j.cyto.2008.06.017
   Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Keeley EC, 2010, ADV CANCER RES, V106, P91, DOI 10.1016/S0065 230X(10)06003 3
   Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004
   Kumar S, 2010, MOL THER, V18, P1026, DOI 10.1038/mt.2009.315
   Li CS, 2016, BIOMATERIALS, V83, P194, DOI 10.1016/j.biomaterials.2016.01.013
   Li F, 2012, BIOCHEM BIOPH RES CO, V426, P475, DOI 10.1016/j.bbrc.2012.08.095
   Long W. J., 2016, ADV ORTHOPEDIC SURG, V2016, DOI DOI 10.1155/2016/1979348
   Michalski MN, 2016, J CELL BIOCHEM, V117, P2697, DOI 10.1002/jcb.25567
   Moghadasali R, 2013, EXP TOXICOL PATHOL, V65, P595, DOI 10.1016/j.etp.2012.06.002
   Perez RA, 2015, MATER TODAY, V18, P573, DOI 10.1016/j.mattod.2015.06.011
   Peris L, 2006, J CELL BIOL, V174, P839, DOI 10.1083/jcb.200512058
   Scheld M, 2016, J NEUROSCI, V36, P1410, DOI 10.1523/JNEUROSCI.2456 15.2016
   Schubert T, 2011, BIOMATERIALS, V32, P8880, DOI 10.1016/j.biomaterials.2011.08.009
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Sulpice E, 2009, BIOL CELL, V101, P525, DOI 10.1042/BC20080221
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053
   Tang WJ, 2012, J BIOL CHEM, V287, P1671, DOI 10.1074/jbc.M111.288472
   TRINDADE R, 2016, CLIN IMPLANT DENT R, V18, P192, DOI DOI 10.1111/cid.12274
   Wang Y, 2007, J TISSUE ENG REGEN M, V1, P39, DOI 10.1002/term.6
   Willems WF, 2011, J ORTHOP RES, V29, P1431, DOI 10.1002/jor.21338
   Wu Andy C, 2013, Bonekey Rep, V2, P373, DOI 10.1038/bonekey.2013.107
   Yamaguchi N, 2015, SCI REP UK, V5, DOI 10.1038/srep07656
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Zhang SJ, 2016, EUR REV MED PHARMACO, V20, P899
   Zhou YH, 2015, J TISSUE ENG REGEN M, V9, P118, DOI 10.1002/term.1619
NR 42
TC 27
Z9 29
U1 0
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JAN
PY 2018
VL 12
IS 1
BP E566
EP E578
DI 10.1002/term.2327
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FT8VL
UT WOS:000423431200052
PM 27696713
OA gold
DA 2025 08 17
ER

PT J
AU Llop Guevara, A
   Porras, M
   Cendón, C
   Di Ceglie, I
   Siracusa, F
   Madarena, F
   Rinotas, V
   Gómez, L
   van Lent, PL
   Douni, E
   Chang, HD
   Kamradt, T
   Román, J
AF Llop Guevara, Alba
   Porras, Monica
   Cendon, Carla
   Di Ceglie, Irene
   Siracusa, Francesco
   Madarena, Federica
   Rinotas, Vagelis
   Gomez, Lluis
   van Lent, Peter L.
   Douni, Eleni
   Chang, Hyun Dong
   Kamradt, Thomas
   Roman, Juan
TI Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and
   destructive arthritis in mice
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Arthritis; JAK; SYK; Small molecule inhibitors; Anti TNF therapy;
   Fibroblast like synoviocytes; Osteoclasts; Memory cells
ID NECROSIS FACTOR ALPHA; DEFECTIVE LYMPHOID DEVELOPMENT; ACTIVE
   RHEUMATOID ARTHRITIS; SPLEEN TYROSINE KINASE; TOFACITINIB CP 690,550;
   DENDRITIC CELLS; PROTECTS MICE; RODENT MODELS; PLASMA CELLS;
   DOUBLE BLIND
AB Introduction: Despite the broad spectrum of antirheumatic drugs, RA is still not well controlled in up to 30 50 % of patients. Inhibition of JAK kinases by means of the pan JAK inhibitor tofacitinib has demonstrated to be effective even in difficult to treat patients. Here, we discuss whether the efficacy of JAK inhibition can be improved by simultaneously inhibiting SYK kinase, since both kinases mediate complementary and non redundant pathways in RA. Methods: Efficacy of dual JAK + SYK inhibition with selective small molecule inhibitors was evaluated in chronic G6PI induced arthritis, a non self remitting and destructive arthritis model in mice. Clinical and histopathological scores, as well as cytokine and anti G6PI antibody production were assessed in both preventive and curative protocols. Potential immunotoxicity was also evaluated in G6PI induced arthritis and in a 28 day TDAR model, by analysing the effects of JAK + SYK inhibition on hematological parameters, lymphoid organs, leukocyte subsets and cell function. Results: Simultaneous JAK + SYK inhibition completely prevented mice from developing arthritis. This therapeutic strategy was also very effective in ameliorating already established arthritis. Dual kinase inhibition immediately resulted in greatly decreased clinical and histopathological scores and led to disease remission in over 70 % of the animals. In contrast, single JAK inhibition and anti TNF therapy (etanercept) were able to stop disease progression but not to revert it. Dual kinase inhibition decreased Treg and NK cell counts to the same extent as single JAK inhibition but overall cytotoxicity remained intact. Interestingly, treatment discontinuation rapidly reversed such immune cell reduction without compromising clinical efficacy, suggesting long lasting curative effects. Dual kinase inhibition reduced the Th1/Th17 cytokine cascade and the differentiation and function of joint cells, in particular osteoclasts and fibroblast like synoviocytes. Conclusions: Concurrent JAK + SYK inhibition resulted in higher efficacy than single kinase inhibition and TNF blockade in a chronic and severe arthritis model. Thus, blockade of multiple immune signals with dual JAK + SYK inhibition represents a reasonable therapeutic strategy for RA, in particular in patients with inadequate responses to current treatments. Our data supports the multiplicity of events underlying this heterogeneous and complex disease.
C1 [Llop Guevara, Alba; Porras, Monica; Cendon, Carla; Gomez, Lluis; Roman, Juan] Draconis Pharma SL, Barcelona, Spain.
   [Cendon, Carla; Siracusa, Francesco; Chang, Hyun Dong] Deutsches Rheuma Forsch Zentrum, Berlin, Germany.
   [Di Ceglie, Irene; van Lent, Peter L.] Radboud Univ Nijmegen, Med Ctr, NL 6525 ED Nijmegen, Netherlands.
   [Madarena, Federica; Kamradt, Thomas] Univ Klinikum, Jena, Germany.
   [Rinotas, Vagelis; Douni, Eleni] Agr Univ Athens, Dept Biotechnol, Lab Genet, GR 11855 Athens, Greece.
   [Douni, Eleni] Biomed Sci Res Ctr Alexander Fleming, Vari, Greece.
C3 Radboud University Nijmegen; Friedrich Schiller University of Jena;
   Agricultural University of Athens; Alexander Fleming Biomedical Sciences
   Research Center
RP Llop Guevara, A (通讯作者)，Draconis Pharma SL, Calle Pallars 179, Barcelona, Spain.
EM alballop@gmail.com
RI ; Siracusa, Francesco/KTH 8772 2024; Chang, Hyun Dong/T 3697 2017; van
   Lent, Peter/A 4047 2014; Di Ceglie, Irene/HGD 5908 2022; Kamradt,
   Thomas/E 9971 2018; Rinotas, Vagelis/KFA 6328 2024
OI DOUNI, ELENI/0000 0003 0004 5121; Rinotas, Vagelis/0000 0002 2390 3136;
   Chang, Hyun Dong/0000 0002 7341 4533; Kamradt,
   Thomas/0000 0001 8443 5893; Siracusa, Francesco/0000 0001 6047 7351;
   Llop Guevara, Alba/0000 0002 7913 9472; Porras,
   Monica/0000 0002 4044 3434; Di Ceglie, Irene/0000 0002 5966 2186; 
FU European Commission [FP7 PEOPLE 2011 ITN 289150]; ITN doctoral
   fellowships; Innovative Medicines Initiative [BTCure 115241]; Leibniz
   Graduate School for Rheumatology
FX We gratefully acknowledge the technical help of Jordi Vilar, Noelia
   Ardanaz, M<SUP>a</SUP> Teresa Gamero, Eva Medina, Jordi Romaguera, Lara
   de Llobet, Juana Pena and Cristina Gerboles. We also thank Dr. Azucena
   Salas for easing the purchase of etanercept. We are indebted to Iren
   Schulz for administrative assistance in the ITN "Osteoimmune". This
   research was supported by the Seventh Framework Programme and Marie
   Curie Actions (European Commission, FP7 PEOPLE 2011 ITN 289150
   "Osteoimmune"). ALG holds an ITN postdoctoral fellowship and IDC, FS and
   FM are supported by ITN doctoral fellowships. Some of this work was also
   funded by Innovative Medicines Initiative (project BTCure 115241) and
   the Leibniz Graduate School for Rheumatology.
CR Bajpai M, 2008, EXPERT OPIN INV DRUG, V17, P641, DOI 10.1517/13543784.17.5.641 
   Baslund B, 2005, ARTHRITIS RHEUM US, V52, P2686, DOI 10.1002/art.21249
   Benson MJ, 2008, J IMMUNOL, V180, P3655, DOI 10.4049/jimmunol.180.6.3655
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burchill MA, 2008, IMMUNITY, V28, P112, DOI 10.1016/j.immuni.2007.11.022
   Burmester GR, 2013, LANCET, V381, P451, DOI 10.1016/S0140 6736(12)61424 X
   CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074 7613(95)90047 0
   Charles Schoeman C, 2016, ANN RHEUM DIS, V75, P1293, DOI 10.1136/annrheumdis 2014 207178
   Clair EWS, 2004, ARTHRITIS RHEUM US, V50, P3432, DOI 10.1002/art.20568
   Coffey G, 2012, J PHARMACOL EXP THER, V340, P350, DOI 10.1124/jpet.111.188441
   Conklyn M, 2004, J LEUKOCYTE BIOL, V76, P1248, DOI 10.1189/jlb.0504282
   Douni E, 2012, HUM MOL GENET, V21, P784, DOI 10.1093/hmg/ddr510
   Fleischmann R, 2012, NEW ENGL J MED, V367, P495, DOI 10.1056/NEJMoa1109071
   Foster JG, 2012, PHARMACOL REV, V64, P1027, DOI 10.1124/pr.110.004051
   Frey O, 2010, ANN RHEUM DIS, V69, P1511, DOI 10.1136/ard.2009.123422
   Fridman JS, 2010, J IMMUNOL, V184, P5298, DOI 10.4049/jimmunol.0902819
   Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668
   Hammaker D, 2010, ANN RHEUM DIS, V69, P77, DOI 10.1136/ard.2009.119479
   Hauser AE, 2002, J IMMUNOL, V169, P1277, DOI 10.4049/jimmunol.169.3.1277
   Heine A, 2013, BLOOD, V122, P1192, DOI 10.1182/blood 2013 03 484642
   Hoyer BF, 2008, ANN RHEUM DIS, V67, P87, DOI 10.1136/ard.2008.098418
   Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504
   Jakus Z, 2010, ARTHRITIS RHEUM US, V62, P1899, DOI 10.1002/art.27438
   Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482
   Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735
   Kremer JM, 2009, ARTHRITIS RHEUM US, V60, P1895, DOI 10.1002/art.24567
   Kudlacz E, 2004, AM J TRANSPLANT, V4, P51, DOI 10.1046/j.1600 6143.2003.00281.x
   Lee EB, 2014, NEW ENGL J MED, V370, P2377, DOI 10.1056/NEJMoa1310476
   LeibundGut Landmann S, 2008, BLOOD, V112, P4971, DOI 10.1182/blood 2008 05 158469
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Lowin T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3464
   Matsumoto I, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2437
   Milici AJ, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2365
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Nosaka T, 1995, BLOOD, V86, P486
   Pap T, 2000, ARTHRITIS RHEUM, V43, P2531, DOI 10.1002/1529 0131(200011)43:11<2531::AID ANR21>3.0.CO;2 V
   Paula FS, 2014, BIOL TARGETS THER, V8, P1, DOI 10.2147/BTT.S35475
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Ranson T, 2003, BLOOD, V101, P4887, DOI 10.1182/blood 2002 11 3392
   Rosengren S, 2012, ANN RHEUM DIS, V71, P440, DOI 10.1136/ard.2011.150284
   Sada K, 2001, J BIOCHEM TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970
   Sallusto F, 2018, J IMMUNOL, V200, P887, DOI 10.1084/jem.179.4.1109
   SAXNE T, 1988, ARTHRITIS RHEUM US, V31, P1041, DOI 10.1002/art.1780310816
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schubert D, 2004, J IMMUNOL, V172, P4503, DOI 10.4049/jimmunol.172.7.4503
   Schweighoffer E, 2013, IMMUNITY, V38, P475, DOI 10.1016/j.immuni.2012.11.015
   Sewgobind VDKD, 2010, AM J TRANSPLANT, V10, P1785, DOI 10.1111/j.1600 6143.2010.03200.x
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140 6736(08)60453 5
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Teitelbaum SL, 2000, J BONE MINER RES, V15, P819
   THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794
   Tokoyoda K, 2009, EUR J IMMUNOL, V39, P2095, DOI 10.1002/eji.200939500
   Townsend RM, 2005, ANN RHEUM DIS, V64, P439
   van der Heijde D, 2013, ARTHRITIS RHEUM US, V65, P559, DOI 10.1002/art.37816
   van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   Yanagi S, 2001, BLOOD, V98, P2869, DOI 10.1182/blood.V98.9.2869
   Yang S, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480 9222 15 8
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
   Zhong JX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009593
   Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832
NR 64
TC 21
Z9 23
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD DEC 10
PY 2015
VL 17
AR 356
DI 10.1186/s13075 015 0866 0
PG 19
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CY4ED
UT WOS:000366360500002
PM 26653844
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tavassoli, P
   Snoek, R
   Ray, M
   Rao, LG
   Rennie, PS
AF Tavassoli, Peyman
   Snoek, Rob
   Ray, Mira
   Rao, Leticia Gomez
   Rennie, Paul S.
TI Rapid, non destructive, cell based screening assays for agents that
   modulate growth, death, and androgen receptor activation in prostate
   cancer cells
SO PROSTATE
LA English
DT Article
DE lentivirus; apoptosis; osteoblast conditioned media; IL 6; dichlorvos;
   EGFP
ID OSTEOBLAST LIKE CELLS; GENE EXPRESSION; IN VITRO; SIGNAL TRANSDUCTION;
   PROBASIN PROMOTER; INTERLEUKIN 6; ESTROGEN; ANTIGEN; PROTEIN; INDUCE
AB BACKGROUND. We developed non invasive, cell based screening assays to rapidly and biologically assess factors that modulate prostate cancer growth and affect androgen receptor (AR) activity.
   METHODS. LNCaP cells, which stably express enhanced green fluorescent protein (EGFP) either constitutively or upon AR activation, were treated with a variety of agents, and then monitored by fluorescence and MTS assays for dose dependent changes in cell number and AR activity.
   RESULTS. The assays were validated for rapid, fluorescence based, quantitative measurement for the presence of growth and AR modulators. Using these assays, we found that osteoblast conditioned media (CM) enhanced prostate cancer cell growth, but not AR activity. After priming with androgen (< 1 nM R1881), forskolin or the pesticide dichlorvos enhanced AR activation, whereas interleukin 6 (IL 6) inhibited it.
   CONCLUSION. These non destructive, cell based assays enable rapid systematic monitoring of the effects of drugs or complex mixtures on prostate cancer cell growth and/or AR activity.
C1 Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada.
   Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
   Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada.
   Univ Western Ontario, Dept Oncol, London Hlth Sci Ctr, London, ON, Canada.
   Univ Toronto, Dept Med, Toronto, ON, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia; Western University (University of
   Western Ontario); London Health Sciences Centre; University of Toronto
RP Rennie, PS (通讯作者)，Vancouver Gen Hosp, Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.
EM prennie@interchange.ubc.ca
CR Andersen HR, 2002, TOXICOL APPL PHARM, V179, P1, DOI 10.1006/taap.2001.9347
   Araki N, 2005, TOXICOL IN VITRO, V19, P335, DOI 10.1016/j.tiv.2004.10.008
   Blaszczyk N, 2004, CLIN CANCER RES, V10, P1860, DOI 10.1158/1078 0432.CCR 0974 3
   Casner PR, 2006, NEW ENGL J MED, V354, P1950
   Chiao JW, 2000, BRIT J CANCER, V83, P360, DOI 10.1054/bjoc.2000.1261
   Cillo JE Jr, 2000, ORAL SURG ORAL MED O, V90, P147, DOI 10.1067/moe.2000.107531
   Culig Z, 2005, J CELL BIOCHEM, V95, P497, DOI 10.1002/jcb.20477
   Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f
   Darbre P, 2006, BEST PRACT RES CL EN, V20, pVII, DOI 10.1016/j.beem.2005.09.010
   Degeorges A, 1996, INT J CANCER, V68, P207, DOI 10.1002/(SICI)1097 0215(19961009)68:2<207::AID IJC12>3.0.CO;2 7
   Di Lorenzo G, 2006, INT J IMMUNOPATH PH, V19, P11
   FEDORUK MN, 2006, EFFLUX TRANSPORTER P, P89
   Fu Z, 2002, PROSTATE, V51, P10, DOI 10.1002/pros.10056
   FURR BJA, 1987, J ENDOCRINOL, V113, pR7, DOI 10.1677/joe.0.113R007
   GHANADIAN R, 1977, UROL RES, V5, P169
   Gioeli D, 2005, CLIN SCI, V108, P293, DOI 10.1042/CS20040329
   GLEAVE M, 1991, CANCER RES, V51, P3753
   HANDELSMAN DJ, 2004, SCI STKE, pPE41
   Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002 0032
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008 5472.CAN 06 0516
   Jia L, 2004, CANCER RES, V64, P2619, DOI 10.1158/0008 5472.CAN 03 3486
   Jiang C, 2006, CANCER RES, V66, P453, DOI 10.1158/0008 5472.CAN 05 1865
   Kavlock R, 2005, CRIT REV TOXICOL, V35, P721, DOI 10.1080/10408440591007377
   Kim HJ, 2005, TOXICOL SCI, V88, P52, DOI 10.1093/toxsci/kfi287
   Kim J, 2005, J MOL ENDOCRINOL, V34, P107, DOI 10.1677/jme.1.01701
   Koeneman KS, 1999, PROSTATE, V39, P246
   Liu WY, 1998, CLIN CANCER RES, V4, P1803
   Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585 005 0056 6
   Michelini E, 2005, CLIN CHEM, V51, P1995, DOI 10.1373/clinchem.2005.053017
   Miyake H, 2001, BRIT J CANCER, V84, P859, DOI 10.1054/bjoc.2000.1686
   Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900
   Nishimura K, 2001, J NATL CANCER I, V93, P1739, DOI 10.1093/jnci/93.22.1739
   Rao LG, 2003, BIOL PHARM BULL, V26, P936, DOI 10.1248/bpb.26.936
   Rao LG, 1996, OSTEOPOROSIS INT, V6, P111, DOI 10.1007/BF01623933
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777
   Setlur SR, 2005, ADV ANAT PATHOL, V12, P265, DOI 10.1097/01.pap.0000184179.50672.f7
   Sonnenschein C, 1998, J STEROID BIOCHEM, V65, P143, DOI 10.1016/S0960 0760(98)00027 2
   Sonneveld E, 2005, TOXICOL SCI, V83, P136, DOI 10.1093/toxsci/kfi005
   Spyrou P, 2002, CLIN ORAL IMPLAN RES, V13, P623, DOI 10.1034/j.1600 0501.2002.130608.x
   Thevis M, 2006, RAPID COMMUN MASS SP, V20, P870, DOI 10.1002/rcm.2389
   Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200
   Van Maele Fabry G, 2000, REGUL TOXICOL PHARM, V31, P13, DOI 10.1006/rtph.1999.1364
   Wang CY, 2004, BIOMATERIALS, V25, P2507, DOI 10.1016/j.biomaterials.2003.09.035
   Wang MH, 2003, UROLOGY, V62, P167, DOI 10.1016/S0090 4295(03)00136 5
   Wetherill YB, 2005, CANCER RES, V65, P54
   Yu D, 2004, PROSTATE, V59, P370, DOI 10.1002/pros.20010
   Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698
   Zhau Haiyen E., 2000, Cancer, V88, P2995, DOI 10.1002/1097 0142(20000615)88:12+<2995::AID CNCR15>3.3.CO;2 P
NR 49
TC 25
Z9 27
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD MAR 1
PY 2007
VL 67
IS 4
BP 416
EP 426
DI 10.1002/pros.20532
PG 11
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 140MS
UT WOS:000244510000010
PM 17219378
DA 2025 08 17
ER

PT J
AU Hosokawa, K
   Arai, F
   Yoshihara, H
   Nakamura, Y
   Gomei, Y
   Iwasaki, H
   Miyamoto, K
   Shima, H
   Ito, K
   Suda, T
AF Hosokawa, Kentaro
   Arai, Fumio
   Yoshihara, Hiroki
   Nakamura, Yuka
   Gomei, Yumiko
   Iwasaki, Hiroko
   Miyamoto, Kana
   Shima, Haruko
   Ito, Keisuke
   Suda, Toshio
TI Function of oxidative stress in the regulation of hematopoietic stem
   cell niche interaction
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE hematopoietic stem cell; oxidative stress; niche; cell adhesion;
   N cadherin; cell cycle
ID BETA CATENIN; SELF RENEWAL; MECHANISM; CADHERIN
AB During postnatal life, the bone marrow (BM) supports both self renewal and differentiation of hematopoietic stem cells (HSCs) in specialized niches, such as osteoblastic niche and vascular niche. A cell adhesion molecule, N cadherin expressed in the HSCs and osteoblasts, suggesting that homophylic binding of N cadherin induce the adhesion of HSCs to the niche cells. Here we demonstrate that an anti cancer drug, 5 fuluorouracil induces reactive oxygen species (ROS) in HSCs, which suppressed N cadherin expression. These events result in the shift of side population (SP) cells to non SP cells, indicating that quiescent HSCs are detached from the niche. Administration of a potent anti oxidant, N acetyl cystein (NAC) suppressed the shift from SP cells. These data suggest that ROS suppressed the N cadherin mediated cell adhesion, and induce the exit of HSCs from the niche. (C) 2007 Published by Elsevier Inc.
C1 Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Dept Cell Differentiat,Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University
RP Suda, T (通讯作者)，Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Dept Cell Differentiat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM sLidato@sc.itc.keio.ac.jp
RI Suda, Toshio/H 6761 2013; Shima, Haruko/NKP 8061 2025; Arai,
   Fumio/J 5241 2013; Iwasaki, Hiroko/D 1702 2009
OI Suda, Toshio/0000 0001 7540 1771; Yoshihara, Hiroki/0000 0001 5128 4515;
   Arai, Fumio/0000 0003 1936 4907; 
CR Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331
   Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172 5183.2004
   Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood 2004 10 4135
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191
   Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989
   Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525
   Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Pearce DJ, 2007, STEM CELLS, V25, P828, DOI 10.1634/stemcells.2006 0405
   Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548
   Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003
   Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104
   Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555 006 9037 8
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 17
TC 94
Z9 115
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 23
PY 2007
VL 363
IS 3
BP 578
EP 583
DI 10.1016/j.bbrc.2007.09.014
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 223HA
UT WOS:000250359400022
PM 17897629
DA 2025 08 17
ER

PT J
AU Andre, F
   Xia, WY
   Conforti, R
   Wei, YK
   Boulet, T
   Tomasic, G
   Spielmann, M
   Zoubir, M
   Berrada, N
   Arriagada, R
   Hortobagyi, GN
   Hung, MC
   Pusztai, L
   Delaloge, S
   Michiels, S
   Cristofanilli, M
AF Andre, Fabrice
   Xia, Weiya
   Conforti, Rosa
   Wei, Yongkun
   Boulet, Thomas
   Tomasic, Gorana
   Spielmann, Marc
   Zoubir, Moustafa
   Berrada, Narjiss
   Arriagada, Rodrigo
   Hortobagyi, Gabriel N.
   Hung, Mien Chie
   Pusztai, Lajos
   Delaloge, Suzette
   Michiels, Stefan
   Cristofanilli, Massimo
TI CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence
SO ONCOLOGIST
LA English
DT Article
DE CXCR4 expression; Breast cancer; Recurrence; Bone metastases
ID 2 RANDOMIZED TRIALS; BONE MARROW; CHEMOKINE RECEPTORS; ZOLEDRONIC ACID;
   PROSTATE CANCER; METASTASIS; CELLS; BISPHOSPHONATES; CHEMOTHERAPY;
   THERAPY
AB Background. Chemokine receptor 4 (CXCR4) has been demonstrated to have a critical role in the early metastatic process. The aim of this study was to evaluate the prognostic value of CXCR4 expression in primary breast tumors and describe correlations with the occurrence of metastasis in organs expressing the CXCR4 ligand stromal cell derived factor 1 (i.e., liver, lung, brain, and bone).
   Patients and Methods. CXCR4 expression in primary breast tumors was evaluated by immunohistochemistry in 823 patients included in two prospective clinical trials. CXCR4 expression was considered positive when >1% of tumor cells were stained. The prognostic value of CXCR4 expression was assessed by a Cox regression model adjusted for clinical characteristics. We assessed the association of CXCR4 expression with the rate of distant metastasis to specific organ sites.
   Results. CXCR4 was expressed in 92 of 794 primary tumors (12%). CXCR4 expression was not associated with clinical characteristics. CXCR4 was not prognostic for overall survival and showed a nonsignificant trend toward a higher risk for distant metastasis. CXCR4(+) tumors showed a significantly higher risk for bone metastasis. The 10 year incidences of bone metastases were 23% (13.6% 32.6%) and 12% (9.7% 15%) in CXCR4(+) and CXCR4( ) tumors, respectively.
   Conclusion. This study suggests that expression of CXCR4 in primary breast tumors is associated with a higher likelihood of developing bone metastases. This finding could open new avenues for the development of novel adjuvant strategies, including bone targeting agents. The Oncologist 2009; 14: 1182 1188
C1 [Cristofanilli, Massimo] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, Houston, TX 77230 USA.
   [Xia, Weiya; Wei, Yongkun; Hung, Mien Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77230 USA.
   [Andre, Fabrice; Conforti, Rosa; Tomasic, Gorana; Spielmann, Marc; Zoubir, Moustafa; Berrada, Narjiss; Arriagada, Rodrigo; Delaloge, Suzette] Univ Paris 06, Dept Radiat Therapy, Dept Pathol, Breast Med Oncol Unit,Inst Gustave Roussy, Villejuif, France.
   [Andre, Fabrice; Conforti, Rosa; Tomasic, Gorana; Spielmann, Marc; Zoubir, Moustafa; Berrada, Narjiss; Arriagada, Rodrigo; Delaloge, Suzette] Univ Paris 06, Translat Res Unit, UPRES EA03535, Inst Gustave Roussy, Villejuif, France.
   [Boulet, Thomas; Michiels, Stefan] Inst Gustave Roussy, Unit Biostat & Epidemiol, Villejuif, France.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Sorbonne Universite;
   UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Sorbonne
   Universite; UNICANCER; Gustave Roussy
RP Cristofanilli, M (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, POB 301439, Houston, TX 77230 USA.
EM mcristof@mdanderson.org
RI ANDRE, Fabrice/AAL 2683 2020; Hung, Mien Chie/ABD 5911 2021; Michiels,
   Stefan/L 1516 2013; Pusztai, Lajos/AAB 2901 2019; CRISTOFANILLI,
   MASSIMO/NUP 7475 2025; Delaloge, Suzette/LIF 9624 2024
OI Cristofanilli, Massimo/0000 0002 4194 7175; andre,
   fabrice/0000 0001 5795 8357; Michiels, Stefan/0000 0002 6963 2968;
   Arriagada, Rodrigo/0000 0002 3134 1735; Hung,
   Mien Chie/0000 0003 4317 4740; 
FU Fondation de France; Fondation Lilly; American Society of Clinical
   Oncology; European Society of Medical Oncology (ESMO); NIH [CA109311];
   DOD Center of Excellence [W81WXH 06 2 0033]; National Breast Cancer
   Foundation, Inc.
FX F. A. is supported by Fondation de France, Fondation Lilly, and a career
   development award from the American Society of Clinical Oncology. R. C.
   is supported by a fellowship from the European Society of Medical
   Oncology (ESMO). M C.H. is supported by NIH CA109311, DOD Center of
   Excellence W81WXH 06 2 0033, and the National Breast Cancer Foundation,
   Inc.
CR Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053
   [Anonymous], LANCET
   Arriagada R, 2005, ACTA ONCOL, V44, P458, DOI 10.1080/02841860510029987
   ARRIAGADA R, 1992, BRIT J CANCER, V66, P951, DOI 10.1038/bjc.1992.391
   Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078 0432.CCR 06 0169
   Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585 005 3222 y
   Conforti R, 2007, ANN ONCOL, V18, P1477, DOI 10.1093/annonc/mdm209
   CONTESSO G, 1987, J CLIN ONCOL, V5, P1378, DOI 10.1200/JCO.1987.5.9.1378
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008 5472.CAN 03 3958
   Lipton Allan, 2008, Curr Opin Support Palliat Care, V2, P197, DOI 10.1097/SPC.0b013e32830baac2
   Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Mystakidou K, 2005, MED ONCOL, V22, P195, DOI 10.1385/MO:22:2:195
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Powles T, 2006, CLIN CANCER RES, V12, p6301S, DOI 10.1158/1078 0432.CCR 06 1211
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Schabath H, 2006, J CELL SCI, V119, P314, DOI 10.1242/jcs.02741
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Taichman RS, 2002, CANCER RES, V62, P1832
   Takenaga M, 2004, BIOCHEM BIOPH RES CO, V320, P226, DOI 10.1016/j.bbrc.2004.05.155
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555 006 9019 x
   Zlotnik A, 2004, SEMIN CANCER BIOL, V14, P181, DOI 10.1016/j.semcancer.2003.10.004
NR 30
TC 55
Z9 62
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1083 7159
EI 1549 490X
J9 ONCOLOGIST
JI Oncologist
PY 2009
VL 14
IS 12
BP 1182
EP 1188
DI 10.1634/theoncologist.2009 0161
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 536BG
UT WOS:000273016500005
PM 19939894
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, LN
   Wang, L
   Li, L
   Wang, H
   Yuan, L
   Kang, L
   Jiang, Q
   Chen, G
   Lv, N
   Cui, XX
   Huang, L
   Wu, HF
   Xu, J
   Li, YL
AF Liu, Linna
   Wang, Lei
   Li, Li
   Wang, Hong
   Yuan, Ling
   Kang, Li
   Jiang, Qian
   Chen, Guan
   Lv, Nan
   Cui, Xiaoxue
   Huang, Lin
   Wu, Huifei
   Xu, Juan
   Li, Yanlin
TI Effects of triangle grass decoction on bone metabolism in rats with
   chronic kidney disease complicated with mineral and bone abnormalities
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Triangle grass (chlorophytumlaxum) decoction; Cardiovascular diseases;
   Chronic kidney disease mineral and bone disorder(CKD MBD);
   Bone cardiovascular axis
ID VASCULAR CALCIFICATION; DISORDERS; PHOSPHATE
AB Ethnopharmacological relevance: Triangle grass is a liliaceous Chlorophytum perennial herb of ChlorophytumlaxumR.Br. It is distributed mainly in Guangdong and Guangxi Provinces of China. The initial use of triangle grass was mainly to treat bone pain and swelling caused by a fall injury. Triangle grass tablets (NO. Z20070544) are also used as a preparation in our hospital because of their analgesic, anti inflammatory, anti snake venom and microcirculation improvement properties and other pharmacological effects (Mei et al., 2006). Triangle grass tablets have been widely used in our hospital to treat patients with bone pain from chronic kidney diseasemineral and bone disorder (CKD MBD). However, the effects and mechanism of triangle grass on bone metabolism in chronic kidney disease complicated with mineral and bone abnormalities are unclear.
   Aim of the study: The aim of the present study was to investigate the effects of a triangle grass decoction on bone metabolism in CKD MBD rats.
   Materials and methods: CKD MBD model rats were subjected to 5/6 nephrectomy combined with 0.5 g NaH2PO4/rat. Serum blood urea nitrogen (BUN), creatinine (Cr), phosphorus (P), calcium (Ca), and intact parathyroid hormone (iPTH) levels were measured with an automatic biochemical analyser. Bone mineral density was determined with a Viva CT 40 system. Bone morphogenetic protein 7(BMP 7),runt related transcription factor 2 (Runx2) and Osterix protein levels were measured by Western blot analysis. Kidney, vertebra and thoracic aorta tissue samples were assessed by histopathology and immunohistochemistry (IHC).
   Results: The degrees of membrane thickening, necrosis, swelling and cast deposition were significantly reduced in high dose rats and Low dose rats. Serum BUN levels were significantly reduced in the Pre H group (P < 0.05). Hypocalcaemia and hyperphos phataemia were detected in triangle grass (P < 0.05, P < 0.05). In addition, iPTH levels were significantly increased in the Pre H group (P < 0.05). Alkaline phosphatase (ALP)levels were significantly decreased in the Pre H group (P < 0.05). The bone mineral density was improved in the Pre H and Pre L groups. BMP 7 protein levels were significantly increased in the Pre H group (P < 0.05). The pathological changes in muscle fibres in the thoracic aorta middle membranes were significantly alleviated in rats in the Pre H and Pre L groups. Changes in SM22 alpha and SM alpha act in protein levels were significantly attenuated in the Pre H group (P < 0.05, P < 0.05). Changes in Runx2 and Osterix protein levels were also significantly attenuated in the Pre H and Pre L groups (P < 0.05, P < 0.05).
   Conclusions: Triangle grass can simultaneously ameliorate vertebral bone loss and abnormal calcification in the thoracic aorta. Triangle grass has a definite effect on bone metabolism disorder in CKD MBD rats.
C1 [Liu, Linna; Huang, Lin; Wu, Huifei; Xu, Juan; Li, Yanlin] Zhongshan Hosp Tradit Chinese Med, Dept Nephrol, Zhongshan 528400, Peoples R China.
   [Wang, Lei; Wang, Hong; Yuan, Ling; Kang, Li; Jiang, Qian; Chen, Guan; Lv, Nan; Cui, Xiaoxue] Tianjin Inst Med & Pharmaceut Sci, Cardiovasc & Cerebrovasc Drugs Res & Dev Ctr, Tianjin 300020, Peoples R China.
   [Li, Li] Univ Guangzhou, Clin Coll Tradit Chinese Med 2, Guangzhou 510405, Peoples R China.
C3 Guangzhou University
RP Li, YL (通讯作者)，Zhongshan Hosp Tradit Chinese Med, Inst Nephrol, Kangxin Rd 3, Zhongshan City 528400, Guangdong, Peoples R China.
EM liulinna_311@126.com; zws9905@sina.com; liligzucm@163.com;
   wh19860906@126.com; 1128sun@163.com; kang437104613@163.com;
   jiangduoxi@163.com; guanchenren@yahoo.com; lihuastar@126.com;
   xiaoxuexue1122@163.com; Huanglin@139.com; 1260136116@qq.com;
   xj1905@126.com; li.yan.lin@126.com
FU Zhongshan Social Welfare Science and Technology Research Project
   [20182166, 20201372]; Scientific research team of Tianjin Institute of
   Medical & Pharmaceutical Sciences (STD 2)
FX Grants from Zhongshan Social Welfare Science and Technology Research
   Project (Grant nos.20182166 and 20201372) and the Scientific research
   team of Tianjin Institute of Medical & Pharmaceutical Sciences (STD 2)
   are gratefully acknowledged.
CR Abramowitz M, 2010, CLIN J AM SOC NEPHRO, V5, P1064, DOI 10.2215/CJN.08621209
   Al Huseini I, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007405
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Hirukawa T, 2015, CLIN EXP NEPHROL, V19, P543, DOI 10.1007/s10157 015 1117 z
   Ikizler TA, 2018, J AM SOC NEPHROL, V29, P250, DOI 10.1681/ASN.2017010020
   Khwaja A, 2010, NEPHRON CLIN PRACT, V116, pC25, DOI 10.1159/000314546
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Lan K, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/819147
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Lau WL, 2010, THROMB HAEMOSTASIS, V104, P464, DOI 10.1160/TH09 12 0814
   Lim K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241976
   Lomashvili KA, 2009, KIDNEY INT, V75, P617, DOI 10.1038/ki.2008.646
   Lundquist AL, 2016, CURR OPIN NEPHROL HY, V25, P120, DOI 10.1097/MNH.0000000000000203
   Mei Q, 2006, CHINESE PHARM J, V17, P301
   Mei Q., 2002, PROPR CHIN MED, V24, P632
   Mei Q.X, 2005, CHINA ACAD J ELECT P, V28, P470
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   Smith ER, 2012, NEPHROL DIAL TRANSPL, V27, P1957, DOI 10.1093/ndt/gfr609
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Vervloet MG, 2014, LANCET DIABETES ENDO, V2, P427, DOI 10.1016/S2213 8587(14)70059 2
   [王庆学 Wang Qingxue], 2019, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V25, P43
   Wu H.F., 2004, CHINA ACAD J ELECT P, V27, P259
   [Wu Huifei 吴惠妃], 2012, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V23, P1788
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
NR 26
TC 5
Z9 5
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 15
PY 2021
VL 275
AR 114126
DI 10.1016/j.jep.2021.114126
EA MAY 2021
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SM5MH
UT WOS:000657648900004
PM 33872749
DA 2025 08 17
ER

PT J
AU Tu, ZB
   Karnoub, AE
AF Tu, Zhenbo
   Karnoub, Antoine E.
TI Mesenchymal stem/stromal cells in breast cancer development and
   management
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE MSC; Breast cancer; Mesenchymal stem; Progression; Therapy
ID STEM CELLS; STROMAL CELLS; BONE MARROW; IN VITRO; TUMOR STROMA;
   MICROENVIRONMENTAL REGULATION; CONDITIONED MEDIUM; TARGETED DELIVERY;
   LYSYL OXIDASE; GROWTH FACTOR
AB Mesenchymal stem/stromal cells (MSCs) encompass a heterogeneous population of fibroblastic progenitor cells that reside in multiple tissues around the body. They are endowed with capacities to differentiate into multiple connective tissue lineages, including chondrocytes, adipocytes, and osteoblasts, and are thought to function as trophic cells recruited to sites of injury and inflammation where they contribute to tissue regeneration. In keeping with these roles, MSCs also to home to sites of breast tumorigenesis, akin to their migration to wounds, and participate in tumor stroma formation. Mounting evidence over the past two decades has described the critical regulatory roles for tumor associated MSCs in various aspects of breast tumor pathogenesis, be it tumor initiation, growth, angiogenesis, tumor microenvironment formation, immune evasion, cancer cell migration, invasion, survival, therapeutic resistance, dissemination, and metastatic colonization. In this review, we present a brief summary of the role of MSCs in breast tumor development and progression, highlight some of the mo lecular frameworks underlying their pro malignant contributions, and present evidence of their promising utility in breast cancer therapy.
C1 [Tu, Zhenbo; Karnoub, Antoine E.] Harvard Med Sch, Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Tu, Zhenbo; Karnoub, Antoine E.] Harvard Med Sch, Dept Pathol, Boston, MA 02215 USA.
   [Karnoub, Antoine E.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
   [Karnoub, Antoine E.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Karnoub, Antoine E.] Boston Vet Affairs Res Inst, West Roxbury, MA 02132 USA.
   [Karnoub, Antoine E.] Ctr Life Sci, 0634 3 Blackfan Circle, Boston, MA 02215 USA.
C3 Harvard University; Harvard University Medical Affiliates; Beth Israel
   Deaconess Medical Center; Harvard Medical School; Harvard University;
   Harvard Medical School; Harvard University; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute
RP Karnoub, AE (通讯作者)，Ctr Life Sci, 0634 3 Blackfan Circle, Boston, MA 02215 USA.
EM akarnoub@bidmc.harvard.edu
RI tu, zhenbo/GYU 7724 2022
OI Tu, Zhenbo/0000 0002 3720 7844
FU USA Department of Defense BCRP [BC160702, BC142139]; USA National
   Institutes of Health NCI [CA207322, CA249223]; USA Veterans Affairs
   [I01BX005980]
FX AEK acknowledges support from the USA Department of Defense BCRP grants
   (BC160702 and BC142139) , the USA National Institutes of Health NCI
   grants (CA207322 and CA249223) , and the USA Veterans Affairs BLRD Merit
   Award (I01BX005980) .
CR Abolghasemi R, 2022, CELL TISSUE BANK, V23, P767, DOI 10.1007/s10561 021 09984 y
   Adelipour M., 2021, J BASIC MED SCI, V24, P98
   Alba Castellón L, 2016, CANCER RES, V76, P6205, DOI 10.1158/0008 5472.CAN 16 0176
   Amey Catherine L, 2017, Oncol Hematol Rev, V13, P45, DOI 10.17925/ohr.2017.13.01.45
   Bagno L, 2018, MOL THER, V26, P1610, DOI 10.1016/j.ymthe.2018.05.009
   Bartosh TJ, 2016, P NATL ACAD SCI USA, V113, pE6447, DOI 10.1073/pnas.1612290113
   Biswas S, 2019, J IMMUNOL, V203, P3447, DOI 10.4049/jimmunol.1900692
   Bliss SA, 2016, CANCER RES, V76, P5832, DOI 10.1158/0008 5472.CAN 16 1092
   Cai YH, 2016, CANCER LETT, V381, P104, DOI 10.1016/j.canlet.2016.07.027
   Casson J, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418810093
   Chaturvedi P, 2014, P NATL ACAD SCI USA, V111, pE2120, DOI 10.1073/pnas.1406655111
   Chaturvedi P, 2013, J CLIN INVEST, V123, P189, DOI 10.1172/JCI64993
   Chen DR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/532161
   Chen YC, 2019, CELL REP, V27, P3916, DOI 10.1016/j.celrep.2019.05.084
   Clarke MR, 2015, MOL CARCINOGEN, V54, P1214, DOI 10.1002/mc.22178
   Conrad C, 2011, ANN SURG, V253, P566, DOI 10.1097/SLA.0b013e3181fcb5d8
   Crigler L, 2007, FASEB J, V21, P2050, DOI 10.1096/fj.06 5880com
   Cuiffo BG, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1019022
   Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001
   Cuiffo BG, 2012, CELL ADHES MIGR, V6, P220, DOI 10.4161/cam.20875
   D'Agostino B, 2010, EXPERT OPIN BIOL TH, V10, P681, DOI 10.1517/14712591003610614
   Daverey A, 2015, SCI REP UK, V5, DOI 10.1038/srep13744
   De Luca A, 2012, J CELL BIOCHEM, V113, P3363, DOI 10.1002/jcb.24212
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580 018 0080 4
   Du L, 2021, BREAST CANCER TOKYO, V28, P829, DOI 10.1007/s12282 021 01218 z
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078 0432.CCR 07 0731
   Dwyer RM, 2011, STEM CELLS, V29, P1149, DOI 10.1002/stem.665
   El Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109
   El Haibi CP, 2010, J MAMMARY GLAND BIOL, V15, P399, DOI 10.1007/s10911 010 9196 7
   Eleuteri S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184597
   Eliopoulos N, 2008, CANCER RES, V68, P4810, DOI 10.1158/0008 5472.CAN 08 0160
   Endo H, 2019, CANCER SCI, V110, P474, DOI 10.1111/cas.13917
   Es HA, 2021, J CELL PHYSIOL, V236, P3918, DOI 10.1002/jcp.30135
   Escobar P, 2015, ONCOTARGET, V6, P29034, DOI 10.18632/oncotarget.4732
   Fakhimi M, 2020, CELL J, V22, P236, DOI 10.22074/cellj.2020.6313
   Ferrer A, 2020, CANCER LETT, V488, P9, DOI 10.1016/j.canlet.2020.05.026
   Friedenstein A J, 1980, Haematol Blood Transfus, V25, P19
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Gallo M, 2012, ANN ONCOL, V23, P597, DOI 10.1093/annonc/mdr159
   Gonçalves MAFV, 2011, MOL THER, V19, P1331, DOI 10.1038/mt.2010.308
   Gonzalez ME, 2017, CELL REP, V18, P1215, DOI 10.1016/j.celrep.2016.12.079
   Halpern JL, 2011, CANCER LETT, V308, P91, DOI 10.1016/j.canlet.2011.04.018
   Hamalian S, 2021, ONCOGENE, V40, P5224, DOI 10.1038/s41388 021 01906 2
   Han J, 2021, ONCOGENE, V40, P833, DOI 10.1038/s41388 020 01574 8
   He NN, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0949 3
   Hen O, 2020, SEMIN CANCER BIOL, V60, P157, DOI 10.1016/j.semcancer.2019.09.002
   Hill BS, 2020, SEMIN CANCER BIOL, V60, P202, DOI 10.1016/j.semcancer.2019.07.028
   Ibragimova M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23095058
   Ishihara S, 2017, CANCER RES, V77, P6179, DOI 10.1158/0008 5472.CAN 17 0569
   Jeong SY, 2013, STEM CELLS, V31, P2136, DOI 10.1002/stem.1471
   Jia XH, 2015, ONCOTARGET, V6, P26018, DOI 10.18632/oncotarget.4658
   Jia ZM, 2020, CANCER MANAG RES, V12, P8733, DOI 10.2147/CMAR.S270200
   Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204
   Kalimuthu S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01116
   Kamat P, 2015, PLAST RECONSTR SURG, V136, P76, DOI 10.1097/PRS.0000000000001321
   Kangari P, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02001 1
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Ke CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069658
   Khatri R, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02173 4
   Kim SH, 2015, TISSUE CELL, V47, P10, DOI 10.1016/j.tice.2014.10.003
   Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kucerova L, 2011, NEOPLASMA, V58, P361, DOI 10.4149/neo_2011_05_361
   Kucerova L, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 535
   Kucerova L, 2012, STEM CELL RES, V8, P247, DOI 10.1016/j.scr.2011.11.006
   Lan TX, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 021 01208 w
   Le HX, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420943839
   Lee JK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084256, 10.1371/journal.pone.0066555]
   Li J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0707 8
   Li QL, 2013, BREAST CANCER RES TR, V141, P317, DOI 10.1007/s10549 013 2672 1
   Li T, 2015, ONCOL REP, V34, P1469, DOI 10.3892/or.2015.4109
   Librizzi M, 2016, CELL BIOCHEM FUNCT, V34, P7, DOI 10.1002/cbf.3157
   Liew A, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt119
   Lin RZ, 2013, MOL CELL BIOCHEM, V383, P13, DOI 10.1007/s11010 013 1746 z
   Lin SY, 2008, EXP CELL RES, V314, P3107, DOI 10.1016/j.yexcr.2008.07.028
   Liu GY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243014
   Liu MC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01453
   Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008 5472.CAN 10 0538
   Liu XY, 2018, ONCOL LETT, V15, P6265, DOI 10.3892/ol.2018.8166
   Liu XY, 2015, EXP THER MED, V9, P1192, DOI 10.3892/etm.2015.2286
   Liubomirski Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00804
   Liubomirski Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00757
   Luo T, 2020, MOL THER ONCOLYTICS, V19, P283, DOI 10.1016/j.omto.2020.10.008
   Maffey A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13460 7
   Mandel K, 2013, STEM CELLS DEV, V22, P3114, DOI 10.1089/scd.2013.0249
   Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549 010 0734 1
   Matuskova M, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0149 2
   McAndrews KM, 2015, SCI REP UK, V5, DOI 10.1038/srep16941
   Meade Kayla J, 2019, Oncotarget, V10, P3027, DOI 10.18632/oncotarget.26903
   Meleshina AV, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0003 7
   Melzer C., 2019, INT J MOL SCI, V20
   Melzer C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115930
   Melzer C, 2019, CANCERS, V11, DOI 10.3390/cancers11060798
   Melzer C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040876
   Melzer C, 2019, CANCERS, V11, DOI 10.3390/cancers11020185
   Melzer C, 2018, STEM CELLS, V36, P977, DOI 10.1002/stem.2819
   Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009
   Mirabdollahi M, 2019, CELL TISSUE BANK, V20, P423, DOI 10.1007/s10561 019 09781 8
   Mohd Ali N., 2020, PHARM BASEL, V14
   Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413
   Nadesh R, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 01878 z
   Nobre AR, 2021, NAT CANCER, V2, P327, DOI 10.1038/s43018 021 00179 8
   Noubissi FK, 2015, FASEB J, V29, P4036, DOI 10.1096/fj.15 271098
   O'Brien KP, 2018, ONCOGENE, V37, P2137, DOI 10.1038/s41388 017 0116 9
   Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231
   Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898
   Orlic D, 2001, ANN NY ACAD SCI, V938, P221
   Pakravan K, 2017, CELL ONCOL, V40, P457, DOI 10.1007/s13402 017 0335 7
   Pasanen I, 2015, ONCOLOGY BASEL, V88, P214, DOI 10.1159/000368556
   Patel SA., 2014, J CANC STEM CELL RES, V2014, DOI [DOI 10.14343/JCSCR.2014.2 1003, DOI 10.14343/JCSCR.2014.2E1003, 10.14343/JCSCR.2014.2e1003]
   Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143
   Plava J, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 02087 2
   Plava J, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020480
   Raj AT, 2021, SAUDI J BIOL SCI, V28, P6556, DOI 10.1016/j.sjbs.2021.07.029
   Rattigan Y, 2010, EXP CELL RES, V316, P3417, DOI 10.1016/j.yexcr.2010.07.002
   Reagan MR, 2012, J BREAST CANCER, V15, P273, DOI 10.4048/jbc.2012.15.3.273
   Rezaie Z, 2019, J CANCER RES THER, V15, P1114, DOI 10.4103/jcrt.JCRT_147_18
   Rubinstein Achiasaf L, 2021, CANCERS, V13, DOI 10.3390/cancers13061472
   Ryan D, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058 019 1131 2
   Samanta S, 2018, ACTA PHARMACOL SIN, V39, P501, DOI 10.1038/aps.2017.162
   Sandiford OA, 2021, CANCER RES, V81, P1567, DOI 10.1158/0008 5472.CAN 20 2434
   Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581
   Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07 8832com
   Sasser AK, 2007, CANCER LETT, V254, P255, DOI 10.1016/j.canlet.2007.03.012
   Schumacher TN, 2022, SCIENCE, V375, P39, DOI 10.1126/science.abf9419
   Segaliny AI, 2019, EBIOMEDICINE, V45, P39, DOI 10.1016/j.ebiom.2019.06.047
   Sepehr KS, 2020, CANCER IMMUNOL IMMUN, V69, P1841, DOI 10.1007/s00262 020 02567 y
   Seshadri M, 2016, CURR OPIN HEMATOL, V23, P339, DOI 10.1097/MOH.0000000000000251
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Shojaei S, 2021, STEM CELL REV REP, V17, P1027, DOI 10.1007/s12015 020 10089 4
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Skolekova S, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964 016 0127 0
   Soufiani KB, 2021, IRAN J ALLERGY ASTHM, V20, P221, DOI 10.18502/ijaai.v20i2.6055
   Soundararajan M, 2018, J CELL PHYSIOL, V233, P9099, DOI 10.1002/jcp.26860
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Suarez NG, 2021, MOLECULES, V26, DOI 10.3390/molecules26061506
   Sudo K, 2007, STEM CELLS, V25, P1610, DOI 10.1634/stemcells.2006 0504
   Sun X, 2021, THERANOSTICS, V11, P5143, DOI 10.7150/thno.58779
   Swamydas M, 2013, CELL ADHES MIGR, V7, P315, DOI 10.4161/cam.25138
   Teufelsbauer M, 2022, MED ONCOL, V39, DOI 10.1007/s12032 022 01655 6
   Thomas C, 2013, ONCOTARGET, V4, P376, DOI 10.18632/oncotarget.919
   Timaner M, 2020, SEMIN CANCER BIOL, V60, P225, DOI 10.1016/j.semcancer.2019.06.003
   TRENTIN JJ, 1971, AM J PATHOL, V65, P621
   Tu ZB, 2019, STEM CELLS, V37, P1281, DOI 10.1002/stem.3055
   Tu ZB, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/s41523 021 00259 z
   Visweswaran M, 2018, INT J BIOCHEM CELL B, V95, P63, DOI 10.1016/j.biocel.2017.12.013
   Wang Y, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.671566
   Wang Y, 2017, STEM CELLS, V35, P2060, DOI 10.1002/stem.2643
   Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088
   Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191
   Wu J, 2016, ACS APPL MATER INTER, V8, P17927, DOI 10.1021/acsami.6b05677
   Xia X, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 134
   Xu C, 2018, ADV SCI, V5, DOI 10.1002/advs.201800382
   Xu HT, 2018, ONCOL LETT, V15, P9142, DOI 10.3892/ol.2018.8463
   Xu RN, 2022, EBIOMEDICINE, V77, DOI 10.1016/j.ebiom.2022.103920
   Yan XL, 2012, BREAST CANCER RES TR, V132, P153, DOI 10.1007/s10549 011 1577 0
   Yang YY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0723 8
   Yao S, 2017, DRUG DELIV, V24, P1372, DOI 10.1080/10717544.2017.1375580
   Yu PF, 2017, ONCOGENE, V36, P840, DOI 10.1038/onc.2016.252
   Yu SY, 2022, GENES GENOM, V44, P539, DOI 10.1007/s13258 021 01200 1
   Yuan L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01076
   Zhang CF, 2013, ONCOL LETT, V6, P1577, DOI 10.3892/ol.2013.1619
   Zhang T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt221
   Zhou XH, 2019, INT J ONCOL, V54, P1843, DOI 10.3892/ijo.2019.4747
NR 167
TC 32
Z9 35
U1 3
U2 32
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044 579X
EI 1096 3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD NOV
PY 2022
VL 86
BP 81
EP 92
DI 10.1016/j.semcancer.2022.09.002
EA SEP 2022
PN 2
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 5F3QX
UT WOS:000866234700001
PM 36087857
OA Bronze
DA 2025 08 17
ER

PT J
AU Yi, H
   Kim, J
   Jung, H
   Rim, YA
   Kim, Y
   Jung, SM
   Park, SH
   Ju, JH
AF Yi, Hyoju
   Kim, Juryun
   Jung, Hyerin
   Rim, Yeri Alice
   Kim, Youngkyun
   Jung, Seung Min
   Park, Sung Hwan
   Ju, Ji Hyeon
TI Induced production of anti etanercept antibody in collagen induced
   arthritis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE etanercept; anti drug antibody; collagen induced arthritis; rheumatoid
   arthritis; tumor necrosis factor alpha
ID EARLY RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN
   LIGAND; CONTROLLED TRIAL; DOUBLE BLIND; TNF ALPHA; ACTIVATION;
   IMMUNOGENICITY; AUTOANTIBODIES; METHOTREXATE
AB Etanercept is a widespread biological drug for the treatment of rheumatoid arthritis, which inhibits tumor necrosis factor alpha (TNF alpha). Recently, the presence of antibodies targeting TNF alpha inhibitors such as infliximab and adalimumab, was reported. However, few reports have studied etanercept in a mouse model of arthritis. We investigated the induction of anti etanercept antibody production, along with the antibody's potential interfering effects on the biological function of etanercept, in mice with collagen induced arthritis (CIA). CIA mice received an intraperitoneal injection of etanercept (25, 100 or 400 mu g per mouse). The degree of inflammation and cartilage erosion was evaluated, and the number of osteoclasts in the ankle joints was assessed by TRAP staining. The level of pro inflammatory cytokines in the serum was measured. To analyze the anti osteoporotic effect of etanercept, microfocal computed tomography analyses of femurs and tibias were performed. Etanercept treatment decreased both the incidence and severity of arthritis in a dose dependent manner, except for the highest dose of 400 mu g. The mice that were treated with 25 and 100 mu g etanercept showed an improvement in inflammation, cartilage damage, and even bone loss. However, mice treated with 400 mu g etanercept showed no significant improvement in any of the tested parameters. Using a customized enzyme linked immunosorbent assay (ELISA), the presence of the anti etanercept antibody was detected in the serum in this treatment refractory group. The therapeutic effect of etanercept was reduced in the CIA mice that developed the anti etanercept antibody. In conclusion, the production of an anti etanercept antibody can be induced in CIA mice, and this antibody can considerably reduce the anti arthritic and anti osteoporotic effects of etanercept.
C1 [Yi, Hyoju; Kim, Juryun; Jung, Hyerin; Rim, Yeri Alice; Kim, Youngkyun; Jung, Seung Min; Park, Sung Hwan; Ju, Ji Hyeon] Catholic Univ Korea, Dept Internal Med, Div Rheumatol, CiSTEM Lab,Seoul St Marys Hosp,Coll Med,CRCID, Seoul 137701, South Korea.
C3 Seoul St. Mary's Hospital; Catholic University of Korea
RP Ju, JH (通讯作者)，Catholic Univ Korea, Dept Internal Med, Div Rheumatol, Seoul St Marys Hosp, 505 Banpodong, Seoul 137701, South Korea.
EM juji@catholic.ac.kr
RI Jung, SeungHyun/HTS 1049 2023
FU Korea Healthcare Technology R&D project, Ministry for Health, Welfare &
   Family Affairs, Republic of Korea [A092258]
FX We are very grateful to Karin for professional proofreading. This study
   was supported by a grant of the Korea Healthcare Technology R&D project,
   Ministry for Health, Welfare & Family Affairs, Republic of Korea
   (A092258).
CR Aikawa NE, 2010, CLIN REV ALLERG IMMU, V38, P82, DOI 10.1007/s12016 009 8140 3
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   Atzeni F, 2008, AUTOIMMUNITY, V41, P87, DOI 10.1080/08916930701620050
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dore RK, 2007, CLIN EXP RHEUMATOL, V25, P40
   Elkayam O, 2005, AUTOIMMUNITY, V38, P155, DOI 10.1080/08916930400021378
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140 6736(94)90628 9
   Finckh A, 2006, ANN RHEUM DIS, V65, P746, DOI 10.1136/ard.2005.045062
   Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308
   Haraoui B, 2006, J RHEUMATOL, V33, P31
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ju JH, 2008, IMMUNOL LETT, V117, P16, DOI 10.1016/j.imlet.2007.09.011
   Kang KY, 2011, JOINT BONE SPINE, V78, P188, DOI 10.1016/j.jbspin.2010.05.010
   Keystone EC, 2004, ARTHRITIS RHEUM, V50, P353, DOI 10.1002/art.20019
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003 4819 130 6 199903160 00004
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   National Institute for Health and Clinical Excellence, AD ET INFL TREATM RH
   O'Dell JR, 2002, ARTHRITIS RHEUM, V46, P283, DOI 10.1002/art.10092
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Taylor PC, 2010, CURR OPIN PHARMACOL, V10, P308, DOI 10.1016/j.coph.2010.01.005
   van den Berg WB, 1999, CLIN EXP RHEUMATOL, V17, pS105
   Wolfe F, 2005, RHEUMATOLOGY, V44, P18, DOI 10.1093/rheumatology/kei056
   Yamaguchi N, 2003, J RHEUMATOL, V30, P22
   Yoon CH, 2008, CLIN RHEUMATOL, V27, P1507, DOI [10.1007/s10067 008 0956 3, 10.1007/s10067 008 0849 5]
NR 28
TC 22
Z9 23
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2014
VL 9
IS 6
BP 2301
EP 2308
DI 10.3892/mmr.2014.2127
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AI0RA
UT WOS:000336555400037
PM 24718553
OA Bronze
DA 2025 08 17
ER

PT J
AU Meikle, ST
   Standen, G
   Salvage, J
   De Santis, R
   Nicolais, L
   Ambrosio, L
   Santin, M
AF Meikle, Steven T.
   Standen, Guy
   Salvage, Jonathan
   De Santis, Roberto
   Nicolais, Luigi
   Ambrosio, Luigi
   Santin, Matteo
TI Synthesis and Characterization of Soybean Based Hydrogels with an
   Intrinsic Activity on Cell Differentiation
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID BIOMATERIALS; SCAFFOLDS; POLYMERS; RELEASE
AB The successful regeneration of large defects in traumatized and diseased tissues depends on the availability of biodegradable and bioactive biomaterials able to guide the tissue during its repair by offering both a physical support and a control of its biological mechanisms. Recently, a novel class of natural, biodegradable biomaterials has been obtained by the thermosetting of defatted soy curd. These biomaterials have been shown to regulate the activity of both tissue and inflammatory cells. Here, soybean based hydrogels with different physicochemical properties and bioactivity have been obtained with a relatively simple and highly reproducible processing method. The content of the different soy components (e.g., the isoflavones) was tuned varying the solvent system during the extraction procedure, while variations in the material crosslinking provided either loose hydrogels or a bioglue. The biomaterials obtained can be used as either bioadhesives or injectable formulations in regenerative medicine as they were shown to stimulate the synthesis of collagen by fibroblasts and the formation of mineralized bone noduli by osteoblasts.
C1 [Meikle, Steven T.; Standen, Guy; Salvage, Jonathan; Santin, Matteo] Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4GJ, E Sussex, England.
   [De Santis, Roberto; Nicolais, Luigi; Ambrosio, Luigi] CNR, Inst Composite & Biomed Mat, Naples, Italy.
C3 University of Brighton; Consiglio Nazionale delle Ricerche (CNR)
RP Santin, M (通讯作者)，Univ Brighton, Sch Pharm & Biomol Sci, Huxley Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
EM m.santin@brighton.ac.uk
RI ; AMBROSIO, LEIRE/K 6381 2017; Meikle, Steven/A 8268 2012
OI Salvage, Jonathan/0000 0002 0627 6249; Santin,
   Matteo/0000 0002 5260 7088; Meikle, Steven/0000 0002 3846 5001;
   AMBROSIO, LUIGI/0000 0002 8367 2405; 
CR Barnes S., US Patent, Patent No. [5,506,211, 5506211]
   Chai C, 2007, MOL THER, V15, P467, DOI 10.1038/sj.mt.6300084
   Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053
   Denavi G, 2009, J FOOD ENG, V90, P341, DOI 10.1016/j.jfoodeng.2008.07.001
   Gelain F, 2010, J CONTROL RELEASE, V145, P231, DOI 10.1016/j.jconrel.2010.04.026
   Giavaresi G, 2010, J MATER SCI MATER M, V21, P615, DOI 10.1007/s10856 009 3870 6
   Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057
   Lakatos PL, 2010, CURR DRUG TARGETS, V11, P179, DOI 10.2174/138945010790309867
   Lykissa ED, 1997, ANAL CHEM, V69, P4912, DOI 10.1021/ac970710w
   Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Nodar MD, 2002, FOOD SCI TECHNOL INT, V8, P337, DOI [10.1177/108201302129174900, 10.1106/108201302031651]
   Pandjaitan N, 2000, J FOOD SCI, V65, P399, DOI 10.1111/j.1365 2621.2000.tb16015.x
   Patterson J, 2010, BIOMATERIALS, V31, P6772, DOI 10.1016/j.biomaterials.2010.05.047
   Reddy N, 2009, BIOTECHNOL PROGR, V25, P1796, DOI 10.1002/btpr.244
   Santin M., Patent International Application Number, Patent No. [PCT/GB01/03464, 0103464]
   Silva SS, 2005, J MATER SCI MATER M, V16, P575, DOI 10.1007/s10856 005 0534 z
   Vaz CM, 2003, J BIOMED MATER RES A, V65A, P60, DOI 10.1002/jbm.a.10416
   WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014 4827(89)90428 X
   Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027
NR 21
TC 16
Z9 18
U1 0
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP
PY 2012
VL 18
IS 17 18
BP 1932
EP 1939
DI 10.1089/ten.tea.2011.0549
PG 8
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 004TS
UT WOS:000308704600019
PM 22616570
DA 2025 08 17
ER

PT J
AU Shih, YRV
   Kingsley, D
   Newman, H
   Hoque, J
   Gupta, A
   Lascelles, BDX
   Varghese, S
AF Shih, Yu Ru V.
   Kingsley, David
   Newman, Hunter
   Hoque, Jiaul
   Gupta, Ankita
   Lascelles, B. Duncan X.
   Varghese, Shyni
TI Multi Functional Small Molecule Alleviates Fracture Pain and Promotes
   Bone Healing
SO ADVANCED SCIENCE
LA English
DT Article
DE adenosine; adenosine receptors; biomaterials; drug delivery; fracture
   healing; fracture pain; phenylboronic acids
ID NERVE GROWTH FACTOR; ADENOSINE RECEPTORS; OSTEOGENIC DIFFERENTIATION;
   STEM CELLS; POSTOPERATIVE PAIN; A(2A) RECEPTORS; MICE LACKING; A(1);
   POPULATION; MANAGEMENT
AB Bone injuries such as fractures are one major cause of morbidities worldwide. A considerable number of fractures suffer from delayed healing, and the unresolved acute pain may transition to chronic and maladaptive pain. Current management of pain involves treatment with NSAIDs and opioids with substantial adverse effects. Herein, we tested the hypothesis that the purine molecule, adenosine, can simultaneously alleviate pain and promote healing in a mouse model of tibial fracture by targeting distinctive adenosine receptor subtypes in different cell populations. To achieve this, a biomaterial assisted delivery of adenosine is utilized to localize and prolong its therapeutic effect at the injury site. The results demonstrate that local delivery of adenosine inhibited the nociceptive activity of peripheral neurons through activation of adenosine A1 receptor (ADORA1) and mitigated pain as demonstrated by weight bearing and open field movement tests. Concurrently, local delivery of adenosine at the fracture site promoted osteogenic differentiation of mesenchymal stromal cells through adenosine A2B receptor (ADORA2B) resulting in improved bone healing as shown by histological analyses and microCT imaging. This study demonstrates the dual role of adenosine and its material assisted local delivery as a feasible therapeutic approach to treat bone trauma and associated pain.
   This study reports a translatable approach for local delivery of adenosine and its sustained release in fracture injury. Adenosine demonstrates unique beneficial features for the treatment of fracture injury by simultaneously providing pain relief and promoting bone healing. Specifically, adenosine activates ADORA1 on peripheral neurons to mitigate pain and ADORA2B on osteoprogenitors to promote osteogenesis. This offers an improved approach to manage bone trauma that is unmatched by current therapeutics.image
C1 [Shih, Yu Ru V.; Kingsley, David; Hoque, Jiaul; Varghese, Shyni] Duke Univ, Sch Med, Dept Orthopaed Surg, Durham, NC 27710 USA.
   [Newman, Hunter; Varghese, Shyni] Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27710 USA.
   [Gupta, Ankita; Lascelles, B. Duncan X.] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Translat Res Pain Program, Raleigh, NC 27607 USA.
   [Lascelles, B. Duncan X.] Univ N Carolina, Thurston Arthrit Ctr, Sch Med, Chapel Hill, NC 27599 USA.
   [Lascelles, B. Duncan X.] Duke Univ, Ctr Translat Pain Med, Dept Anesthesiol, Sch Med, Durham, NC 27710 USA.
   [Lascelles, B. Duncan X.] North Carolina State Univ, Coll Vet Med, Comparat Pain Res & Educ Ctr, Raleigh, NC 27607 USA.
   [Varghese, Shyni] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
C3 Duke University; Duke University; North Carolina State University;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Duke University; North
   Carolina State University; Duke University
RP Shih, YRV; Varghese, S (通讯作者)，Duke Univ, Sch Med, Dept Orthopaed Surg, Durham, NC 27710 USA.; Varghese, S (通讯作者)，Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27710 USA.; Varghese, S (通讯作者)，Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
EM vernon.shih@duke.edu; shyni.varghese@duke.edu
OI Gupta, Ankita/0000 0003 2133 8345; Lascelles, B. Duncan
   X./0000 0002 2950 9009
FU The authors thank Yu Chih D. Shih for help with statistical analyses and
   Courtney Karner for providing the Lepr cre; tdTomato
   mice. This work was funded by National Institutes of Health (R01AR071552
   and R01AR079189). [R01AR071552, R01AR079189]; National Institutes of
   Health
FX The authors thank Yu Chih D. Shih for help with statistical analyses and
   Courtney Karner for providing the <ITALIC>Lepr cre; tdTomato</ITALIC>
   mice. This work was funded by National Institutes of Health (R01AR071552
   and R01AR079189).
CR Aghamohammadi D, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104 020 05133 y
   Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   BELFRAGE M, 1995, ANESTH ANALG, V81, P713, DOI 10.1097/00000539 199510000 00010
   Bernhardt P, 2006, J CARDIOVASC MAGN R, V8, P475, DOI 10.1080/10976640600575270
   Borea PA, 2018, PHYSIOL REV, V98, P1591, DOI 10.1152/physrev.00049.2017
   Bradaschia Correa V, 2017, TISSUE CELL, V49, P545, DOI 10.1016/j.tice.2017.07.001
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Carroll SH, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.2
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Carruthers AM, 2001, MOL PHARMACOL, V59, P1533, DOI 10.1124/mol.59.6.1533
   Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306
   CERQUEIRA MD, 1994, J AM COLL CARDIOL, V23, P384, DOI 10.1016/0735 1097(94)90424 3
   Chang AK, 2017, JAMA J AM MED ASSOC, V318, P1661, DOI 10.1001/jama.2017.16190
   Chartier SR, 2014, PAIN, V155, P2323, DOI 10.1016/j.pain.2014.08.026
   Chen JF, 2013, NAT REV DRUG DISCOV, V12, P265, DOI 10.1038/nrd3955
   Chen ZM, 2012, FASEB J, V26, P1855, DOI 10.1096/fj.11 201541
   Coppi E, 2019, PAIN, V160, P1103, DOI 10.1097/j.pain.0000000000001488
   Corrales LA, 2008, J BONE JOINT SURG AM, V90A, P1862, DOI 10.2106/JBJS.G.01580
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Cronstein BN, 2017, NAT REV RHEUMATOL, V13, P41, DOI 10.1038/nrrheum.2016.178
   Csóka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11 190934
   Duan X, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008241.pub2
   Durante M, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139299
   FELDMAN MD, 1992, CLIN CHEM, V38, P256
   Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074 7742(05)63007 3
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Geusens P, 2013, CURR OPIN RHEUMATOL, V25, P524, DOI 10.1097/BOR.0b013e32836200b8
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Glare P, 2019, LANCET, V393, P1537, DOI 10.1016/S0140 6736(19)30352 6
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gosler MW, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008832.pub2
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hanack C, 2015, CELL, V160, P759, DOI 10.1016/j.cell.2015.01.022
   Haskó G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00085
   Holmes D, 2017, NATURE, V550, pS193, DOI 10.1038/550S193a
   Hooten WM, 2015, MAYO CLIN PROC, V90, P850, DOI 10.1016/j.mayocp.2015.04.012
   Hoque J, 2022, ACS BIOMATER SCI ENG, DOI 10.1021/acsbiomaterials.2c00977
   Hoque J, 2021, BIOMATERIALS, V273, DOI 10.1016/j.biomaterials.2021.120819
   Hu X, 2016, CELL REP, V16, P106, DOI 10.1016/j.celrep.2016.05.080
   Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983
   Jeffery EC, 2022, CELL STEM CELL, V29, P1547, DOI 10.1016/j.stem.2022.10.002
   Jeong HJ, 2003, J NEUROPHYSIOL, V89, P1214, DOI 10.1152/jn.00516.2002
   Jimenez Andrade JM, 2007, PAIN, V133, P183, DOI 10.1016/j.pain.2007.06.016
   Kan HW, 2018, PAIN, V159, P1580, DOI 10.1097/j.pain.0000000000001246
   Kang HM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600691
   Kang H, 2015, BIOMACROMOLECULES, V16, P1050, DOI 10.1021/acs.biomac.5b00099
   Kawarai Y, 2014, YONSEI MED J, V55, P185, DOI 10.3349/ymj.2014.55.1.185
   Khomula EV, 2019, J NEUROSCI, V39, P7061, DOI 10.1523/JNEUROSCI.1191 19.2019
   Li Z, 2019, J CLIN INVEST, V129, P5137, DOI 10.1172/JCI128428
   Little JW, 2015, BRAIN, V138, P28, DOI 10.1093/brain/awu330
   Liu XL, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43834 y
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Magnusdottir R, 2021, OSTEOPOROSIS INT, V32, P2347, DOI 10.1007/s00198 021 05991 7
   Mailhot B, 2020, J EXP MED, V217, DOI 10.1084/jem.20191430
   Majuta LA, 2018, PAIN, V159, P2285, DOI 10.1097/j.pain.0000000000001330
   Majuta LA, 2015, PAIN, V156, P157, DOI 10.1016/j.pain.0000000000000017
   Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE249
   Martin BC, 2011, J GEN INTERN MED, V26, P1450, DOI 10.1007/s11606 011 1771 0
   McCool BA, 2001, BRIT J PHARMACOL, V132, P879, DOI 10.1038/sj.bjp.0703884
   McDougall JJ, 2011, BBA MOL BASIS DIS, V1812, P459, DOI 10.1016/j.bbadis.2010.12.011
   Mediero A, 2015, FASEB J, V29, P1577, DOI 10.1096/fj.14 265066
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Mills LA, 2017, ACTA ORTHOP, V88, P434, DOI 10.1080/17453674.2017.1321351
   Minville V, 2008, ANESTHESIOLOGY, V108, P467, DOI 10.1097/ALN.0b013e3181649333
   Morgan M, 2019, BONE, V123, P168, DOI 10.1016/j.bone.2019.03.040
   Newman H, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121114
   Nguyen Minh Q, 2021, Elife, V10, DOI 10.7554/eLife.71752
   O'Neill KR, 2012, BONE, V50, P1357, DOI 10.1016/j.bone.2012.03.008
   Owen Davina E, 2012, Methods Mol Biol, V846, P179, DOI 10.1007/978 1 61779 536 7_16
   Perner C, 2021, STAR PROTOC, V2, DOI 10.1016/j.xpro.2021.100333
   Petrov T, 2007, J SPINAL CORD MED, V30, P331, DOI 10.1080/10790268.2007.11753948
   Phadke A, 2012, P NATL ACAD SCI USA, V109, P4383, DOI 10.1073/pnas.1201122109
   Prasad A, 2018, J BURN CARE RES, V39, P433, DOI 10.1097/BCR.0000000000000618
   Rao V, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00185
   Rotermund N, 2018, J PHYSIOL LONDON, V596, P717, DOI 10.1113/JP275503
   Sawynok J, 2016, NEUROSCIENCE, V338, P1, DOI 10.1016/j.neuroscience.2015.10.031
   Schaible HG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0470 8
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schulz K, 2018, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00435
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Sun S, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115109
   Tatem KS, 2014, JOVE J VIS EXP, DOI 10.3791/51785
   Tavares Ferreira D, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj8186
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   White PF, 2017, EXPERT OPIN PHARMACO, V18, P329, DOI 10.1080/14656566.2017.1289176
   Wu WP, 2005, PAIN, V113, P395, DOI 10.1016/j.pain.2004.11.020
   Xue Q, 2007, J NEUROCHEM, V101, P212, DOI 10.1111/j.1471 4159.2006.04363.x
   Yasui M, 2012, EUR J PAIN, V16, P953, DOI 10.1002/j.1532 2149.2011.00094.x
   Zeng Y, 2020, ADV MATER, V32, DOI 10.1002/adma.201906022
   Zhang LL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00412
   Zhang XM, 2005, EMBO J, V24, P4211, DOI 10.1038/sj.emboj.7600893
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 96
TC 5
Z9 6
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD DEC
PY 2023
VL 10
IS 36
DI 10.1002/advs.202303567
EA NOV 2023
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA GR5E8
UT WOS:001096884000001
PM 37939302
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Kim, YI
   Tseng, YC
   Ayaz, G
   Wang, SS
   Yan, HL
   du Bois, W
   Yang, HW
   Zhen, T
   Lee, MP
   Liu, PL
   Kaplan, RN
   Huang, J
AF Kim, Young Im
   Tseng, Yu Chou
   Ayaz, Gamze
   Wang, Shasha
   Yan, Hualong
   du Bois, Wendy
   Yang, Howard
   Zhen, Tao
   Lee, Maxwell P. P.
   Liu, Paul
   Kaplan, Rosandra N.
   Huang, Jing
TI SOX9 is a key component of RUNX2 regulated transcriptional circuitry in
   osteosarcoma
SO CELL AND BIOSCIENCE
LA English
DT Article
DE Epigenetics; JMJD1C; Osteosarcoma; RUNX2; SOX9; Transcription
ID OSTEOBLAST DIFFERENTIATION; METHYLATION; OSTERIX; JMJD1C; GENES
AB BackgroundThe absence of prominent, actionable genetic alternations in osteosarcomas (OS) implies that transcriptional and epigenetic mechanisms significantly contribute to the progression of this life threatening form of cancer. Therefore, the identification of potential transcriptional events that promote the survival of OS cells could be key in devising targeted therapeutic approaches for OS. We have previously shown that RUNX2 is a transcription factor (TF) essential for OS cell survival. Unfortunately, the transcriptional network or circuitry regulated by RUNX2 in OS cells is still largely unknown.MethodsThe TFs that are in the RUNX2 transcriptional circuitry were identified by analyzing RNAseq and ChIPseq datasets of RUNX2. To evaluate the effect of SOX9 knockdown on the survival of osteosarcoma cells in vitro, we employed cleaved caspase 3 immunoblotting and propidium iodide staining techniques. The impact of SOX9 and JMJD1C depletion on OS tumor growth was examined in vivo using xenografts and immunohistochemistry. Downstream targets of SOX9 were identified and dissected using RNAseq, pathway analysis, and gene set enrichment analysis. Furthermore, the interactome of SOX9 was identified using BioID and validated by PLA.ResultOur findings demonstrate that SOX9 is a critical TF that is induced by RUNX2. Both in vitro and in vivo experiments revealed that SOX9 plays a pivotal role in the survival of OS. RNAseq analysis revealed that SOX9 activates the transcription of MYC, a downstream target of RUNX2. Mechanistically, our results suggest a transcriptional network involving SOX9, RUNX2, and MYC, with SOX9 binding to RUNX2. Moreover, we discovered that JMJD1C, a chromatin factor, is a novel binding partner of SOX9, and depletion of JMJD1C impairs OS tumor growth.ConclusionThe findings of this study represent a significant advancement in our understanding of the transcriptional network present in OS cells, providing valuable insights that may contribute to the development of targeted therapies for OS.
C1 [Kim, Young Im; Tseng, Yu Chou; Ayaz, Gamze; Wang, Shasha; Yan, Hualong; du Bois, Wendy; Huang, Jing] NCI, Canc & Stem Cell Epigenet Grp, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20814 USA.
   [Yang, Howard; Lee, Maxwell P. P.] NCI, High Dimens Data Anal Grp, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD USA.
   [Zhen, Tao; Liu, Paul] NHGRI, Translat & Funct Genom Branch, Bethesda, MD USA.
   [Kaplan, Rosandra N.] NCI, Tumor Microenvironm Sect, Pediat Oncol Branch, Lab Canc Biol & Genet,Ctr Canc Res, Bethesda, MD USA.
C3 National Institutes of Health (NIH)   USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH)   USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH)   USA; NIH National
   Human Genome Research Institute (NHGRI); National Institutes of Health
   (NIH)   USA; NIH National Cancer Institute (NCI)
RP Huang, J (通讯作者)，NCI, Canc & Stem Cell Epigenet Grp, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20814 USA.
EM huangj3@mail.nih.gov
RI Ayaz, Gamze/CAI 8918 2022; Zhen, T/O 9269 2019; Yan,
   Hualong/JFB 4387 2023
CR Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Byun JS, 2020, J BIOL CHEM, V295, P13677, DOI 10.1074/jbc.RA120.013352
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chen YY, 2020, CANCER RES, V80, P2472, DOI 10.1158/0008 5472.CAN 19 1764
   Chen Y, 2020, ONCOGENE, V39, P6633, DOI 10.1038/s41388 020 01459 w
   Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588 018 0191 z
   Fang S, 2019, ONCOGENE, V38, P4061, DOI 10.1038/s41388 019 0704 y
   GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094 155
   He YL, 2017, STEM CELL REP, V8, P1630, DOI 10.1016/j.stemcr.2017.04.029
   He YL, 2012, ACTA BIOCH BIOPH SIN, V44, P70, DOI 10.1093/abbs/gmr109
   Kim SM, 2010, NUCLEIC ACIDS RES, V38, P6389, DOI 10.1093/nar/gkq491
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Lamora A, 2014, CLIN CANCER RES, V20, P5097, DOI 10.1158/1078 0432.CCR 13 3191
   Li R, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.967000
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Otani S, 2022, ONCOGENE, V41, P683, DOI 10.1038/s41388 021 02120 w
   Otero M, 2017, CONNECT TISSUE RES, V58, P15, DOI 10.1080/03008207.2016.1200566
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200
   Ren L, 2015, ONCOTARGET, V6, P29469, DOI 10.18632/oncotarget.5177
   Roux Kyle J, 2018, Curr Protoc Protein Sci, V91, DOI [10.1002/0471140864.ps1923s74, 10.1002/cpps.51]
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Shin MH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005884
   Sroczynska P, 2014, BLOOD, V123, P1870, DOI 10.1182/blood 2013 08 522094
   Stengel KR, 2021, MOL CELL, V81, DOI 10.1016/j.molcel.2020.12.005
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Whittle SB, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29188
   Yan HL, 2021, EMBO REP, V22, DOI 10.15252/embr.202052122
   Yan J, 2015, MOL MED REP, V12, P498, DOI 10.3892/mmr.2015.3439
   Yin YY, 2022, NAT IMMUNOL, V23, P1342, DOI 10.1038/s41590 022 01287 y
   Yu L, 2019, MOL CANCER RES, V17, P2383, DOI 10.1158/1541 7786.MCR 19 0493
NR 35
TC 7
Z9 7
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045 3701
J9 CELL BIOSCI
JI Cell Biosci.
PD JUL 25
PY 2023
VL 13
IS 1
AR 136
DI 10.1186/s13578 023 01088 2
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA M8XF0
UT WOS:001032981800001
PM 37491298
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huang, YQ
   Chen, N
   Miao, DS
AF Huang, Yuanqing
   Chen, Ning
   Miao, Dengshun
TI Radioprotective effects of pyrroloquinoline quinone on parotid glands in
   C57BL/6J mice
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE oxidative stress; pyrroloquinoline quinone; parotid glands;
   radioprotective; total body irradiation
ID X RAY IRRADIATION; SALIVARY GLANDS; BONE MARROW; 1,25 DIHYDROXYVITAMIN
   D 3; PARATHYROID HORMONE; OXIDATIVE STRESS; NECK CANCER; CELL DEATH;
   ADULT RAT; VITAMIN E
AB The aim of the present study was to investigate whether pyrroloquinoline quinine (PQQ) serve a radioprotective role in parotid gland damage induced by total body irradiation (TBI) in C57BL/6J mice. A total of 15 female 8 week old C57BL/6J mice were randomly assigned into three treatment groups: i) Untreated control (no irradiation); ii) 4 gray (Gy) X ray irradiation; iii) 4 Gy X ray irradiation with additional dietary PQQ (4 mg PQQ/kg in normal diet). Each group included five mice. After 4 weeks, all animals were collected for evaluating the phenotype, body weight, pathological and biochemical parameters. The results indicated that PQQ had biological effects on total body phenotype. PQQ could partially rescue TBI induced damage to parotid glands. In addition, PQQ served radioprotective effects on parotid glands via multiple mechanisms, such as promoting proliferation, inhibiting apoptosis and senescence, upregulating antioxidant ability, scavenging reactive oxygen species and reducing DNA damage. The results of the present study demonstrate that PQQ serves a radioprotective role in parotid gland damage induced by TBI, possibly via inhibiting oxidative stress and participating in DNA damage repair. The study provides experimental and theoretical knowledge for the development of radioprotective clinical drugs.
C1 [Huang, Yuanqing] Hunan Univ Med, Dept Stomatol, 429 Jinxi South Rd, Huaihua 418000, Hunan, Peoples R China.
   [Chen, Ning] Nanjing Med Univ, Inst Stomatol, Nanjing 210029, Jiangsu, Peoples R China.
   [Miao, Dengshun] Nanjing Med Univ, Dept Anat Histol & Embryol, Res Ctr Bone & Stem Cells, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.
C3 Hunan University of Medicine; Nanjing Medical University; Nanjing
   Medical University
RP Huang, YQ (通讯作者)，Hunan Univ Med, Dept Stomatol, 429 Jinxi South Rd, Huaihua 418000, Hunan, Peoples R China.
EM huang1977789@126.com
OI Chen, Ning/0000 0003 4785 5076; Miao, Dengshun/0000 0002 2682 3502
FU Hunan Province Education Department Scientific Research Youth Project of
   China [14B141]
FX The present study was supported by the Hunan Province Education
   Department Scientific Research Youth Project of China (grant no.
   14B141).
CR Bauerly K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021779
   CHERRY CP, 1959, BRIT J RADIOL, V32, P596, DOI 10.1259/0007 1285 32 381 596
   Cotrim AP, 2007, CLIN CANCER RES, V13, P4928, DOI 10.1158/1078 0432.CCR 07 0662
   Di Pietro C, 2006, APOPTOSIS, V11, P57, DOI 10.1007/s10495 005 3346 1
   Dirix P, 2006, CANCER AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302
   Pontual MLD, 2007, J APPL ORAL SCI, V15, P162, DOI 10.1590/S1678 77572007000300003
   Duine JA, 2001, CHEM REC, V1, P74
   FRANK RM, 1965, J AM DENT ASSOC, V70, P868, DOI 10.14219/jada.archive.1965.0220
   Hamlet S, 1997, INT J RADIAT ONCOL, V37, P789, DOI 10.1016/S0360 3016(96)00604 9
   HAUGE JG, 1964, J BIOL CHEM, V239, P3630
   Ishii T, 2010, BIOSCI BIOTECH BIOCH, V74, P663, DOI 10.1271/bbb.90764
   KRESSEL M, 1994, CELL TISSUE RES, V278, P549
   KUMAZAWA T, 1995, BIOCHEM J, V307, P331, DOI 10.1042/bj3070331
   Liem IH, 1996, EUR J NUCL MED, V23, P1485, DOI 10.1007/BF01254473
   Liu H, 2009, J ENDOCRINOL, V203, P203, DOI 10.1677/JOE 09 0247
   Logemann JA, 2003, HEAD NECK J SCI SPEC, V25, P432, DOI 10.1002/hed.10255
   Medina VA, 2011, INT J RADIAT BIOL, V87, P284, DOI 10.3109/09553002.2010.533247
   Misra HS, 2004, FEBS LETT, V578, P26, DOI 10.1016/j.febslet.2004.10.061
   Mitchell AE, 1999, ANAL BIOCHEM, V269, P317, DOI 10.1006/abio.1999.4039
   Mizoe J, 2012, RADIOTHER ONCOL, V103, P32, DOI 10.1016/j.radonc.2011.12.013
   NAGLER RM, 1993, RADIAT RES, V136, P42, DOI 10.2307/3578638
   Nagler RM, 2002, ORAL DIS, V8, P141, DOI 10.1034/j.1601 0825.2002.02838.x
   Nunez MI, 1996, RADIOTHER ONCOL, V39, P155, DOI 10.1016/0167 8140(96)01732 X
   Ohwada K, 2008, J CLIN BIOCHEM NUTR, V42, P29, DOI 10.3164/jcbn.2008005
   Ouchi A, 2009, J AGR FOOD CHEM, V57, P450, DOI 10.1021/jf802197d
   PHILLIPS RM, 1970, J ORAL SURG, V28, P432
   Shankar BS, 2010, REDOX REP, V15, P146, DOI 10.1179/174329210X12650506623762
   SHOLLEY MM, 1974, LAB INVEST, V31, P340
   Steinberg F, 2003, EXP BIOL MED, V228, P160, DOI 10.1177/153537020322800205
   STEINBERG FM, 1994, J NUTR, V124, P744, DOI 10.1093/jn/124.5.744
   Stites T, 2006, J NUTR, V136, P390, DOI 10.1093/jn/136.2.390
   Stites TE, 2000, J NUTR, V130, P719, DOI 10.1093/jn/130.4.719
   Tao R, 2007, BIOCHEM BIOPH RES CO, V363, P257, DOI 10.1016/j.bbrc.2007.08.041
   Taylor SE, 1999, P SOC EXP BIOL MED, V221, P14, DOI 10.1046/j.1525 1373.1999.d01 48.x
   UMEGAKI K, 1995, FREE RADICAL BIO MED, V19, P493, DOI 10.1016/0891 5849(95)00033 T
   UMEGAKI K, 1994, FREE RADICAL BIO MED, V17, P439, DOI 10.1016/0891 5849(94)90170 8
   Wang Y, 2010, FREE RADICAL BIO MED, V48, P348, DOI 10.1016/j.freeradbiomed.2009.11.005
   Xue YB, 2005, HUM MOL GENET, V14, P1515, DOI 10.1093/hmg/ddi160
   ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367
   Zhang YM, 2002, EUR J NEUROSCI, V16, P1015, DOI 10.1046/j.1460 9568.2002.02169.x
   Zhang YH, 2006, BRAIN RES, V1094, P200, DOI 10.1016/j.brainres.2006.03.111
   Zhu BQ, 2006, J CARDIOVASC PHARM T, V11, P119, DOI 10.1177/1074248406288757
NR 42
TC 10
Z9 13
U1 1
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2016
VL 12
IS 6
BP 3685
EP 3693
DI 10.3892/etm.2016.3843
PN A
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EG5IB
UT WOS:000391076400033
PM 28105098
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Holdsworth, G
   Greenslade, K
   Jose, J
   Stencel, Z
   Kirby, H
   Moore, A
   Ke, HZ
   Robinson, MK
AF Holdsworth, Gill
   Greenslade, Kevin
   Jose, Joby
   Stencel, Zofia
   Kirby, Hishani
   Moore, Adrian
   Ke, Hua Zhu
   Robinson, Martyn K.
TI Dampening of the bone formation response following repeat dosing with
   sclerostin antibody in mice is associated with up regulation of Wnt
   antagonists
SO BONE
LA English
DT Article
DE Sclerostin antibody; Bone formation; Wnt antagonists; Osteoporosis
ID POSTMENOPAUSAL WOMEN; OSTEOBLAST LINEAGE; CLINICAL TRIAL; CORTICAL BONE;
   DOUBLE BLIND; ROMOSOZUMAB; DEFICIENCY; DIFFERENTIATION; GENE; MASS
AB Administration of antibodies to sclerostin (Scl Ab) has been shown to increase bone mass, bone mineral density (BMD) and bone strength by increasing bone formation and decreasing bone resorption in both animal studies and human clinical trials. In these studies, the magnitude and rate of increase in bone formation markers is attenuated upon repeat dosing with Scl Ab despite a continuous and progressive increase in BMD.
   Here, we investigated whether the attenuation in the bone formation response following repeated administration of Scl Ab was associated with increased expression of secreted antagonists of Wnt signalling and determined how the circulating marker of bone formation, P1NP, responded to single, or multiple doses, of Scl Ab four days post dosing.
   Female Balb/c mice were treated with Scl Ab and we demonstrated that the large increase in serum P1NP observed following the first dose was reduced following administration of multiple doses of Scl Ab. This dampening of the P1NP response was not due to a change in the kinetics of the bone formation marker response, or differences in exposure to the drug.
   The abundance of transcripts encoding several secreted Wnt antagonists was determined in femurs collected from mice following one or six doses of Scl Ab, or vehicle treatment. Compared with vehicle controls, expression of SOST, SOST DC1, DKK1, DKK2, SFRP1, SFRP2, FRZB, SFRP4 and W1F1 transcripts was significantly increased (approximately 1.5 4.2 fold) following a single dose of Scl Ab. With the exception of SFRP1, these changes were maintained or further increased following six doses of Scl Ab and the abundance of SFRP5 was also increased. Up  regulation of these Wnt antagonists may exert a negative feedback to increased Wnt signalling induced by repeated administration of Scl Ab and could contribute to self regulation of the bone formation response over time.
   After an antibody free period of four weeks or more, the P1NP response was comparable to the naive response, and a second phase of treatment with Scl Ab following an antibody free period elicited additional gains in BMD. Together, these data demonstrate that the rapid dampening of the bone formation response in the immediate post dose period which occurs after repeat dosing of Scl Ab is associated with increased expression of Wnt antagonists, and a treatment free period can restore the full bone formation response to Sd Ab. (C) 2017 The Authors. Published by Elsevier Inc.
C1 [Holdsworth, Gill; Greenslade, Kevin; Jose, Joby; Stencel, Zofia; Kirby, Hishani; Moore, Adrian; Ke, Hua Zhu; Robinson, Martyn K.] UCB Pharma, Slough, Berks, England.
   [Kirby, Hishani] Hishani Kirby Associates Ltd, Reading, Berks, England.
C3 UCB Pharma SA
RP Holdsworth, G (通讯作者)，UCB Pharma, Slough, Berks, England.
EM Gill.Holdsworth@ucb.com
RI JOSE, JOBY/KWT 9709 2024
FU UCB Pharma
FX This work was funded by UCB Pharma.
CR Baker EK, 2015, BONE, V73, P223, DOI 10.1016/j.bone.2014.12.063
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Brommage R, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.34
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Cho SW, 2009, BONE, V44, P1069, DOI 10.1016/j.bone.2009.02.012
   Chouinard L, 2016, REGUL TOXICOL PHARM, V81, P212, DOI 10.1016/j.yrtph.2016.08.010
   Collette NM, 2016, BONE, V88, P20, DOI 10.1016/j.bone.2016.04.005
   Cosman F, 2017, NEW ENGL J MED, V376, P396, DOI 10.1056/NEJMc1615367
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Holdsworth G, 2012, J BIOL CHEM, V287, P26464, DOI 10.1074/jbc.M112.350108
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kendler D.L., 2017, ENDOCR REV, V38
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kiper POS, 2016, NEW ENGL J MED, V374, P2553, DOI 10.1056/NEJMoa1509342
   Kouadjo KE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 127
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Ma Y.L., 2016, BONE, V97, P20
   Maeda A, 2015, J BIOL CHEM, V290, P14004, DOI 10.1074/jbc.M114.628818
   McClung MR, 2015, ANN RHEUM DIS, V74, P166, DOI 10.1136/annrheumdis 2015 eular.2291
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Nioi P, 2015, J BONE MINER RES, V30, P1457, DOI 10.1002/jbmr.2482
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   van Lierop AH, 2014, J CLIN ENDOCR METAB, V99, pE252, DOI 10.1210/jc.2013 3278
   van Lierop AH, 2017, BONE, V96, P51, DOI 10.1016/j.bone.2016.10.010
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 42
TC 44
Z9 49
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2018
VL 107
BP 93
EP 103
DI 10.1016/j.bone.2017.11.003
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FT2XS
UT WOS:000423009900011
PM 29129759
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhao, YD
   Tian, L
   Sheng, WH
   Miao, JC
   Yang, JC
AF Zhao, Yaodong
   Tian, Li
   Sheng, Weihua
   Miao, Jingcheng
   Yang, Jicheng
TI Hypalgesia Effect of IL 24, a Quite New Mechanism for IL 24 Application
   in Cancer Treatment
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID MELANOMA DIFFERENTIATION; GENE THERAPY; BONE PAIN; BISPHOSPHONATES;
   INTERLEUKIN 6; GROWTH; MDA 7/IL 24; SUPPRESSION; APOPTOSIS; DISEASE
AB Tumor suppressor melanoma differentiation associated gene 7/interleukin 24 (mda 7/IL 24) has been extensively regarded as an anti oncogene; however, that whether IL 24, as a member of IL 10 family, is involved in cancer pain was seldom reported before. In this study, we found that IL 24 mediated by adenovirus could significantly increase the plantar mechanical pain threshold in both operation side and contralateral side of the animal models, which were established by injecting 5x103 Walker 256 rat breast cancer ascitic tumor cells into rats' tibia bone medullary canals; IL 24 could also suppress in vitro Walker 256 cells growth by inducing cell apoptosis. Pathologically, IL 24 could protect bone trabecula and substantia corticalis ossium from being completely destructed. Enzyme linked immunosorbent assay (ELISA) showed that IL 24 treatment could increase the  endorphin levels and decrease the IL 6 concentration in plasma of animals. Our study indicated that IL 24 has a potential treatment effect on cancers not only by inhibiting tumor proliferation, but also by the promotion of  endorphin synthesis, inhibition of IL 6 secretion to relieve cancer pain.
C1 [Zhao, Yaodong] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [Zhao, Yaodong; Tian, Li; Sheng, Weihua; Miao, Jingcheng; Yang, Jicheng] Soochow Univ, Cell & Mol Biol Inst, Coll Med, Suzhou 215123, Peoples R China.
   [Tian, Li] Soochow Univ, Affiliated Hosp 1, Suzhou 215123, Peoples R China.
C3 Tongji University; Soochow University   China; Soochow University  
   China
RP Yang, JC (通讯作者)，Soochow Univ, Cell & Mol Biol Inst, Coll Med, Suzhou 215123, Peoples R China.
EM jcyang@suda.edu.cn
OI Zhao, Yaodong/0000 0003 0324 4767
FU National Natural Science Foundation of China [81001016, 81101909]
FX The current research was supported by National Natural Science
   Foundation of China (No. 81001016; 81101909).
CR Body Jean Jacques, 2000, Cancer, V88, P3054, DOI 10.1002/1097 0142(20000615)88:12+<3054::AID CNCR23>3.0.CO;2 Z
   Bonabello A, 2001, PAIN, V91, P269, DOI 10.1016/S0304 3959(00)00447 4
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Bruehl S, 2007, PAIN, V130, P208, DOI 10.1016/j.pain.2006.11.013
   Bruera E, 2003, JAMA J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476
   Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041
   Chang SJ, 2011, MOL BIOL REP, V38, P395, DOI 10.1007/s11033 010 0121 3
   CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476 5381.1992.tb14503.x
   De Jongh RF, 2003, ANESTH ANALG, V96, P1096, DOI 10.1213/01.ANE.0000055362.56604.78
   DORSSERS L, 1987, GENE, V55, P115, DOI 10.1016/0378 1119(87)90254 X
   DRAY A, 1995, BRIT J ANAESTH, V75, P125, DOI 10.1093/bja/75.2.125
   Finegold AA, 1999, HUM GENE THER, V10, P1251, DOI 10.1089/10430349950018238
   Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008 5472.CAN 05 3127
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304 3959(98)00135 3
   Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917
   Huang Y, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/968218
   Jiang HP, 1995, ONCOGENE, V11, P2477
   Lundstrom K, 2003, TRENDS BIOTECHNOL, V21, P117, DOI 10.1016/S0167 7799(02)00042 2
   Mechlin B, 2007, PAIN, V131, P142, DOI 10.1016/j.pain.2006.12.027
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604
   Pohl M, 2008, GENE THER, V15, P953, DOI 10.1038/gt.2008.80
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   Rasmussen Natalie Ann, 2003, Biol Res Nurs, V5, P105, DOI 10.1177/1099800403257166
   Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359 6101(02)00074 6
   Storek B, 2008, P NATL ACAD SCI USA, V105, P1055, DOI 10.1073/pnas.0708003105
   Thurlimann B, 1996, DRUGS, V51, P383
   Walker K, 2002, PAIN, V100, P219, DOI 10.1016/S0304 3959(02)00040 4
   Wang XY, 2007, LUMINESCENCE, V22, P1, DOI 10.1002/bio.917
   Xie YF, 2008, CANCER BIOTHER RADIO, V23, P310, DOI 10.1089/cbr.2007.0453
   YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0
   Yu X, 2010, INT J HEMATOL, V92, P276, DOI 10.1007/s12185 010 0654 1
   Zanjani TM, 2006, EUR J PHARMACOL, V538, P66, DOI 10.1016/j.ejphar.2006.03.063
   Zhu Y, 2011, CANCER GENE THER, V18, P627, DOI 10.1038/cgt.2011.31
NR 35
TC 7
Z9 7
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1079 9907
EI 1557 7465
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD OCT 1
PY 2013
VL 33
IS 10
BP 606
EP 611
DI 10.1089/jir.2012.0146
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 229LT
UT WOS:000325267200008
PM 23869901
DA 2025 08 17
ER

PT J
AU Yildirim, E
   Sezer, G
AF Yildirim, Esma
   Sezer, Gulay
TI Clinical plasma concentration of vinpocetine does not affect osteogenic
   differentiation of mesenchymal stem cells
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Vinpocetine; Mesenchymal stem cells; Osteogenic differentation; NF kappa
   B; Runx2; ALP
ID B DEPENDENT INFLAMMATION; NECROSIS FACTOR ALPHA; KAPPA B;
   BONE FORMATION; OSTEOBLAST DIFFERENTIATION; ISCHEMIC STROKE;
   ADIPOSE TISSUE; INHIBITION; OSTEOPOROSIS; EXPRESSION
AB Aim Vinpocetine (Vin) has long been used as a medicine to treat cerebrovascular disorders and as a dietary supplement to improve cognitive functions. Previous studies have revealed that the transcription factor nuclear factor kappa B (NF kappa B) activity plays an important role in osteogenic differentiation of mesenchymal stem cells (MSC). Vin inhibits NF kappa B dependent inflammatory responses; however, the effect of Vin on the osteogenic differentiation of MSCs has not been reported. In this study, we aimed to the investigate effect of Vin on the osteogenic differentiation of rat bone marrow derived MSCs (BMSCs). Methods We treated BMSCs with clinical plasma (0.17 mu M) or higher concentrations (5 and 20 mu M) of Vin with no significant effect on the cell viability. Alizarin Red S and alkaline phosphatase (ALP) stainings were used to evaluate mineralizations on days 14 and 21. Moreover, expressions of target genes were detected using qRT PCR analysis. Results Osteogenic differentiation of BMSCs did not significantly change with Vin's clinical plasma concentration, but significantly decreased with higher concentrations. Calcium mineralization, ALP staining and mRNA gene expressions ofRunx2andALPwere decreased significantly with high concentrations of Vin, paticularly on day 21. Conclusion Our in vitro findings suggest that clinically relevant concentration of Vin seems safe to use in elderly patients with respect to osteoporosis. On the other hand, Vin at high concentrations appears to be harmful to bone homeostasis.
C1 [Yildirim, Esma] Kayseri City Hosp, Minist Hlth, Pharm Div, TR 38080 Kayseri, Turkey.
   [Sezer, Gulay] Erciyes Univ, Sch Med, Dept Pharmacol, TR 38039 Kayseri, Turkey.
   [Sezer, Gulay] Erciyes Univ, Genkok Genome & Stem Cell Ctr, Kayseri, Turkey.
C3 Ministry of Health   Turkey; Erciyes University; Erciyes University
RP Sezer, G (通讯作者)，Erciyes Univ, Sch Med, Dept Pharmacol, TR 38039 Kayseri, Turkey.; Sezer, G (通讯作者)，Erciyes Univ, Genkok Genome & Stem Cell Ctr, Kayseri, Turkey.
EM gulayszr@erciyes.edu.tr
OI Sezer, Gulay/0000 0001 9365 7746; yildirim derici,
   esma/0000 0002 1371 9175
FU Scientific Research Projects Coordination Unit of Erciyes University
   [TYL 2018 8300]
FX This work was supported by the Scientific Research Projects Coordination
   Unit of Erciyes University (project code: TYL 2018 8300).
CR Ahmad BS, 2016, J CLIN DENSITOM, V19, P450, DOI 10.1016/j.jocd.2016.07.008
   Al Kuraishy HM, 2020, BRAIN CIRC, V6, P1, DOI 10.4103/bc.bc_46_19
   Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Azevedo MF, 2014, ENDOCR REV, V35, P195, DOI 10.1210/er.2013 1053
   Bönöczk P, 2000, BRAIN RES BULL, V53, P245, DOI 10.1016/S0361 9230(00)00354 3
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Carda S, 2009, CEREBROVASC DIS, V28, P191, DOI 10.1159/000226578
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   Choi HD, 2011, J PERIODONTAL IMPLAN, V41, P30, DOI 10.5051/jpis.2011.41.1.30
   Croes M., 2015, PLOS ONE, V7, P10
   Feng XM, 2013, CELL BIOL INT, V37, P1267, DOI 10.1002/cbin.10141
   Gage BF, 2006, ARCH INTERN MED, V166, P241, DOI 10.1001/archinte.166.2.241
   Gómez CD, 2014, J NEUROCHEM, V130, P770, DOI 10.1111/jnc.12784
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Hu XY, 2019, EXP THER MED, V17, P4417, DOI 10.3892/etm.2019.7518
   Jeon KI, 2010, P NATL ACAD SCI USA, V107, P9795, DOI 10.1073/pnas.0914414107
   Jones E, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0144 8
   Kim NJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 018 0198 7
   Lencel P, 2011, BONE, V48, P242, DOI 10.1016/j.bone.2010.09.001
   Li Chao, 2015, Med Sci Monit, V21, P845, DOI 10.12659/MSM.893144
   Li Gui Rong, 2011, World J Stem Cells, V3, P19, DOI 10.4252/wjsc.v3.i3.19
   Lourenco Gonzalez Y, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/6481812
   Lu ZF, 2012, STEM CELLS DEV, V21, P2420, DOI 10.1089/scd.2011.0589
   Ma YY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162295
   Medina AE, 2011, FRONT NEUROSCI SWITZ, V5, DOI 10.3389/fnins.2011.00021
   Munisso MC, 2012, BIOCHIMIE, V94, P2360, DOI 10.1016/j.biochi.2012.05.031
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Patyar S, 2011, PHARMACOL REP, V63, P618, DOI 10.1016/S1734 1140(11)70574 6
   Shen CY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0949 3
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sui YP, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96660
   Tsutsumimoto T, 2002, BONE, V31, P396, DOI 10.1016/S8756 3282(02)00839 6
   VERECZKEY L, 1979, ARZNEIMITTEL FORSCH, V29 1, P957
   Wakabayashi S, 2002, J BONE MINER RES, V17, P249, DOI 10.1359/jbmr.2002.17.2.249
   Wang HX, 2014, NEUROSCI LETT, V566, P247, DOI 10.1016/j.neulet.2014.02.045
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Zhang F, 2018, TRANSL STROKE RES, V9, P174, DOI 10.1007/s12975 017 0549 z
   Zhou XP, 2003, J PHARMACOL EXP THER, V306, P498, DOI 10.1124/jpet.103.051086
   Zhu MP, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109769
NR 43
TC 2
Z9 2
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1734 1140
EI 2299 5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD FEB
PY 2021
VL 73
IS 1
BP 202
EP 210
DI 10.1007/s43440 020 00153 8
EA AUG 2020
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QC5LG
UT WOS:000565931900002
PM 32865810
DA 2025 08 17
ER

PT J
AU Zhang, R
   Kim, AS
   Fox, JM
   Nair, S
   Basore, K
   Klimstra, WB
   Rimkunas, R
   Fong, RH
   Lin, H
   Poddar, S
   Crowe, JE
   Doranz, BJ
   Fremont, DH
   Diamond, MS
AF Zhang, Rong
   Kim, Arthur S.
   Fox, Julie M.
   Nair, Sharmila
   Basore, Katherine
   Klimstra, William B.
   Rimkunas, Rebecca
   Fong, Rachel H.
   Lin, Hueylie
   Poddar, Subhajit
   Crowe, James E., Jr.
   Doranz, Benjamin J.
   Fremont, Daved H.
   Diamond, Michael S.
TI Mxra8 is a receptor for multiple arthritogenic alphaviruses
SO NATURE
LA English
DT Article
ID SCALE CRISPR CAS9 KNOCKOUT; CHIKUNGUNYA VIRUS; MONOCLONAL ANTIBODIES;
   ADHESION MOLECULE; SINDBIS VIRUS; PROTEIN; CELLS; FUSION; DICAM; ENTRY
AB Arthritogenic alphaviruses comprise a group of enveloped RNA viruses that are transmitted to humans by mosquitoes and cause debilitating acute and chronic musculoskeletal disease(1). The host factors required for alphavirus entry remain poorly characterized(2). Here we use a genome wide CRISPR Cas9 based screen to identify the cell adhesion molecule Mxra8 as an entry mediator for multiple emerging arthritogenic alphaviruses, including chikungunya, Ross River, Mayaro and O'nyong nyong viruses. Gene editing of mouse Mxra8 or human MXRA8 resulted in reduced levels of viral infection of cells and, reciprocally, ectopic expression of these genes resulted in increased infection. Mxra8 bound directly to chikungunya virus particles and enhanced virus attachment and internalization into cells. Consistent with these findings, Mxra8 Fc fusion protein or anti Mxra8 monoclonal antibodies blocked chikungunya virus infection in multiple cell types, including primary human synovial fibroblasts, osteoblasts, chondrocytes and skeletal muscle cells. Mutagenesis experiments suggest that Mxra8 binds to a surface exposed region across the A and B domains of chikungunya virus E2 protein, which are a speculated site of attachment. Finally, administration of the Mxra8 Fc protein or anti Mxra8 blocking antibodies to mice reduced chikungunya and O'nyong nyong virus infection as well as associated foot swelling. Pharmacological targeting of Mxra8 could form a strategy for mitigating infection and disease by multiple arthritogenic alphaviruses.
C1 [Zhang, Rong; Kim, Arthur S.; Fox, Julie M.; Nair, Sharmila; Lin, Hueylie; Poddar, Subhajit; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Kim, Arthur S.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Basore, Katherine; Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Klimstra, William B.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Rimkunas, Rebecca; Fong, Rachel H.; Doranz, Benjamin J.] Integral Mol Inc, Philadelphia, PA USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63130 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Vanderbilt University; Vanderbilt
   University; Washington University (WUSTL)
RP Diamond, MS (通讯作者)，Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Diamond, MS (通讯作者)，Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Diamond, MS (通讯作者)，Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Diamond, MS (通讯作者)，Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63130 USA.
EM diamond@wusm.wustl.edu
RI Crowe, James/B 5549 2009; Zhang, Rong/J 5434 2018; Zhang,
   RongZhang/J 5434 2018; Fox, Julie/GLQ 8895 2022; Diamond,
   Michael/AAH 1733 2019
OI Crowe, James/0000 0002 0049 1079; Basore, Katherine/0000 0001 5974 0968;
   Lin, Hueylie/0000 0001 5196 502X; Kim, Arthur/0000 0003 4101 6642;
   Zhang, Rong/0000 0003 2941 4808; Poddar, Subhajit/0000 0002 9764 3242;
   Fremont, Daved/0000 0002 8544 2689; 
FU NIH [R01AI114816, R01AI123348, R01AI095436, HHSN272201400058C]; Defense
   Reduction Threat Agency [HDTRA1 15 1 0013]
FX This study was supported by NIH grants R01AI114816, R01AI123348, and
   R01AI095436, contract HHSN272201400058C, and the Defense Reduction
   Threat Agency HDTRA1 15 1 0013. We thank M. Heise, T. Morrison, M.
   Farzan, J. Miner and T. Dermody for discussions, reagents and comments
   on the manuscript.
CR Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Ashbrook AW, 2014, J VIROL, V88, P12180, DOI 10.1128/JVI.01672 14
   Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092 8674(01)00231 8
   Brien James D, 2013, Curr Protoc Microbiol, V31, DOI 10.1002/9780471729259.mc15d03s31
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Couderc T, 2015, ANTIVIR RES, V121, P120, DOI 10.1016/j.antiviral.2015.07.002
   Doranz BJ, 1997, IMMUNOL RES, V16, P15, DOI 10.1007/BF02786321
   ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197
   Fox JM, 2015, CELL, V163, P1095, DOI 10.1016/j.cell.2015.10.050
   Gardner CL, 2012, VIROLOGY, V425, P103, DOI 10.1016/j.virol.2011.12.020
   Han SW, 2013, CARDIOVASC RES, V98, P73, DOI 10.1093/cvr/cvt019
   Hawman DW, 2013, J VIROL, V87, P13878, DOI 10.1128/JVI.02666 13
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Jemielity S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003232
   Jin J, 2015, CELL REP, V13, P2553, DOI 10.1016/j.celrep.2015.11.043
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016
   Jung YK, 2008, J CELL PHYSIOL, V216, P603, DOI 10.1002/jcp.21438
   Jung YK, 2012, J BONE MINER RES, V27, P2024, DOI 10.1002/jbmr.1632
   Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357 7366.1998
   Lee J, 2017, P NATL ACAD SCI USA, V114, pE7987, DOI 10.1073/pnas.1708052114
   LEVITT NH, 1986, VACCINE, V4, P157, DOI 10.1016/0264 410X(86)90003 4
   Li L, 2010, NATURE, V468, P705, DOI 10.1038/nature09546
   Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0554 4
   Loh J, 2011, J VIROL, V85, P2642, DOI 10.1128/JVI.01661 10
   Lubman OY, 2014, J VIROL, V88, P538, DOI 10.1128/JVI.02729 13
   Oliphant T, 2005, NAT MED, V11, P522, DOI 10.1038/nm1240
   Pal P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003312
   Rose PP, 2011, CELL HOST MICROBE, V10, P97, DOI 10.1016/j.chom.2011.06.009
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Selvarajah S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002423
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Smith SA, 2015, CELL HOST MICROBE, V18, P86, DOI 10.1016/j.chom.2015.06.009
   Sun SY, 2013, ELIFE, V2, DOI 10.7554/eLife.00435
   Taube S, 2010, J VIROL, V84, P5695, DOI 10.1128/JVI.00316 10
   Vancini R, 2015, PROG MOL BIOL TRANSL, V129, P33, DOI 10.1016/bs.pmbts.2014.10.002
   Voss JE, 2010, NATURE, V468, P709, DOI 10.1038/nature09555
   Weaver SC, 2018, ANNU REV MED, V69, P395, DOI 10.1146/annurev med 050715 105122
   Yonezawa T, 2003, GLIA, V44, P190, DOI 10.1002/glia.10279
NR 39
TC 269
Z9 319
U1 6
U2 74
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD MAY 24
PY 2018
VL 557
IS 7706
BP 570
EP +
DI 10.1038/s41586 018 0121 3
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GG6GP
UT WOS:000432794900049
PM 29769725
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ma, WQ
   Jia, KN
   Cheng, HM
   Xu, H
   Li, ZG
   Zhang, H
   Xie, HY
   Sun, H
   Yi, L
   Chen, ZY
   Duan, SZ
   Sano, M
   Fukuda, K
   Lu, L
   Gao, F
   Zhang, RY
   Yan, XX
AF Ma, Wenqi
   Jia, Kangni
   Cheng, Haomai
   Xu, Hong
   Li, Zhigang
   Zhang, Hang
   Xie, Hongyang
   Sun, Hang
   Yi, Lei
   Chen, Zhiyong
   Duan, Shengzhong
   Sano, Motoaki
   Fukuda, Keiichi
   Lu, Lin
   Gao, Fei
   Zhang, Ruiyan
   Yan, Xiaoxiang
TI Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via
   Histone Lactylation
SO CIRCULATION RESEARCH
LA English
DT Article
DE epigenetics; glycolysis; histones; vascular calcification
ID SMOOTH MUSCLE CELLS; GLUCOSE METABOLISM; GENE EXPRESSION; NOR 1; NUR77;
   NURR1; INHIBITION; PHOSPHATE; MOLECULE
AB BACKGROUND:Medial arterial calcification is a chronic systemic vascular disorder distinct from atherosclerosis and is commonly observed in patients with chronic kidney disease, diabetes, and aging individuals. We previously showed that NR4A3 (nuclear receptor subfamily 4 group A member 3), an orphan nuclear receptor, is a key regulator in apo (apolipoprotein) A IV induced atherosclerosis progression; however, its role in vascular calcification is poorly understood.METHODS:We generated NR4A3 /  mice and 2 different types of medial arterial calcification models to investigate the biological roles of NR4A3 in vascular calcification. RNA seq was performed to determine the transcriptional profile of NR4A3 /  vascular smooth muscle cells under beta glycerophosphate treatment. We integrated Cleavage Under Targets and Tagmentation analysis and RNA seq data to further investigate the gene regulatory mechanisms of NR4A3 in arterial calcification and target genes regulated by histone lactylation.RESULTS:NR4A3 expression was upregulated in calcified aortic tissues from chronic kidney disease mice, 1,25(OH)2VitD3 overload induced mice, and human calcified aorta. NR4A3 deficiency preserved the vascular smooth muscle cell contractile phenotype, inhibited osteoblast differentiation related gene expression, and reduced calcium deposition in the vasculature. Further, NR4A3 deficiency lowered the glycolytic rate and lactate production during the calcification process and decreased histone lactylation. Mechanistic studies further showed that NR4A3 enhanced glycolysis activity by directly binding to the promoter regions of the 2 glycolysis genes ALDOA and PFKL and driving their transcriptional initiation. Furthermore, histone lactylation promoted medial calcification both in vivo and in vitro. NR4A3 deficiency inhibited the transcription activation and expression of Phospho1 (phosphatase orphan 1). Consistently, pharmacological inhibition of Phospho1 attenuated calcium deposition in NR4A3 overexpressed vascular smooth muscle cells, whereas overexpression of Phospho1 reversed the anticalcific effect of NR4A3 deficiency in vascular smooth muscle cells.CONCLUSIONS:Taken together, our findings reveal that NR4A3 mediated histone lactylation is a novel metabolome epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.
C1 [Ma, Wenqi; Jia, Kangni; Cheng, Haomai; Xu, Hong; Li, Zhigang; Zhang, Hang; Sun, Hang; Yi, Lei; Chen, Zhiyong; Duan, Shengzhong; Lu, Lin; Zhang, Ruiyan; Yan, Xiaoxiang] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Cardiovasc Med, Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
   [Ma, Wenqi; Jia, Kangni; Cheng, Haomai; Li, Zhigang; Zhang, Hang; Xie, Hongyang] Shanghai Jiao Tong Univ, Inst Cardiovasc Dis, Sch Med, Shanghai, Peoples R China.
   [Xu, Hong] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Cardiovasc Surg, Sch Med, Shanghai, Peoples R China.
   [Duan, Shengzhong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Lab Oral Microbiota & Syst Dis,Sch Med, Shanghai, Peoples R China.
   [Duan, Shengzhong] Shanghai Jiao Tong Univ, Dept Cardiovasc Med, State Key Lab Med Genom,Ruijin Hosp,Sch Med, Shanghai Key Lab Hypertens,Shanghai Inst Hypertens, Shanghai, Peoples R China.
   [Duan, Shengzhong] Natl Clin Res Ctr Oral Dis, Natl Ctr Stomatol, Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Sano, Motoaki; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan.
   [Gao, Fei] Capital Med Univ, Beijing Anzhen Hosp, 2 Anzhen Rd, Beijing 100029, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong
   University; Chinese Academy of Sciences; Keio University; Capital
   Medical University
RP Zhang, RY; Yan, XX (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Cardiovasc Med, Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.; Gao, F (通讯作者)，Capital Med Univ, Beijing Anzhen Hosp, 2 Anzhen Rd, Beijing 100029, Peoples R China.
EM fgaomd@163.com; zhangruiyan@263.net; cardexyanxx@hotmail.com
RI ; Zhang, Ruiyan/HHC 5329 2022; fei, Gao/GQQ 8024 2022; Yi,
   Lei/AAI 6290 2020; Jia, Kangni/HCH 0443 2022; Chen,
   Zhiyong/LRD 1561 2024
OI Hang, Sun/0009 0006 7422 9272; xie, hongyang/0000 0003 1622 9304; Wang,
   Ziyang/0000 0003 4767 2210; YI, LEI/0000 0001 6388 0074; Gao,
   Fei/0000 0003 3633 3133; Cheng, Haomai/0009 0002 4898 4363
FU National Natural Science Foundation of China [82100461, 82070510,
   82325005, 82120108003]; Chinese Postdoctoral Science Foundation
   [2021M702172]; Shanghai Municipal Education Commission Gaofeng Clinical
   Medicine Grant; Shanghai Education Development Foundation; Shanghai
   Municipal Education Commission [20SG15]; Program of Shanghai
   Academic/Technology Research Leader [21XD1422500]
FX This study was supported by the National Natural Science Foundation of
   China (no. 82100461 to W. Ma; no. 82070510 to H. Zhang; no. 82325005 and
   no. 82120108003 to X. Yan), Chinese Postdoctoral Science Foundation (no.
   2021M702172 to W. Ma), a Shanghai Municipal Education Commission Gaofeng
   Clinical Medicine Grant (to X. Yan), the Shuguang Program supported by
   the Shanghai Education Development Foundation and Shanghai Municipal
   Education Commission (no. 20SG15 to X. Yan), and Program of Shanghai
   Academic/Technology Research Leader (no. 21XD1422500).
CR Bobryshev YV, 2014, CURR PHARM DESIGN, V20, P5821, DOI 10.2174/1381612820666140212193011
   Bonta PI, 2006, ARTERIOSCL THROM VAS, V26, P2288, DOI 10.1161/01.ATV.0000238346.84458.5d
   Calvayrac O, 2015, J MOL CELL CARDIOL, V80, P34, DOI 10.1016/j.yjmcc.2014.12.015
   Chao LC, 2007, MOL ENDOCRINOL, V21, P2152, DOI 10.1210/me.2007 0169
   Cheng ZK, 2011, EUR HEART J, V32, P2179, DOI 10.1093/eurheartj/ehq496
   Ciancaglini P, 2010, J BONE MINER RES, V25, P716, DOI 10.1359/jbmr.091023
   Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535 7163.MCT 07 0482
   Close AF, 2013, DIABETES METAB, V39, P478, DOI 10.1016/j.diabet.2013.07.005
   Close AF, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010168
   Cobb AM, 2021, ARTERIOSCL THROM VAS, V41, P1339, DOI 10.1161/ATVBAHA.120.315206
   Crespo J, 2005, CARDIOVASC RES, V67, P333, DOI 10.1016/j.cardiores.2005.03.016
   Cui HC, 2021, AM J RESP CELL MOL, V64, P115, DOI 10.1165/rcmb.2020 0360OC
   Dai Y, 2017, J AM COLL CARDIOL, V70, P2006, DOI 10.1016/j.jacc.2017.08.053
   De Maria GL, 2019, JACC CARDIOVASC INTE, V12, P1465, DOI 10.1016/j.jcin.2019.03.038
   Dillon S, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10202
   Docherty CK, 2018, ATHEROSCLEROSIS, V268, P1, DOI 10.1016/j.atherosclerosis.2017.11.009
   GALLAGHER JC, 1980, J CLIN ENDOCR METAB, V51, P1359, DOI 10.1210/jcem 51 6 1359
   Galle E, 2022, GENOME BIOL, V23, DOI 10.1186/s13059 022 02775 y
   Hou YC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030980
   Hsu SN, 2022, J ENDOCRINOL, V254, P167, DOI 10.1530/JOE 22 0097
   Huang MS, 2008, BIOCHEM BIOPH RES CO, V374, P553, DOI 10.1016/j.bbrc.2008.07.062
   Idelevich A, 2011, ARTERIOSCL THROM VAS, V31, pE55, DOI 10.1161/ATVBAHA.111.230904
   Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008 5472.CAN 04 2134
   Kendrick J, 2011, AM J KIDNEY DIS, V58, P826, DOI 10.1053/j.ajkd.2011.07.020
   Kiffer Moreira T, 2013, J BONE MINER RES, V28, P81, DOI 10.1002/jbmr.1733
   Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003 0247
   Lanzer P, 2021, J AM COLL CARDIOL, V78, P1145, DOI 10.1016/j.jacc.2021.06.049
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Li LP, 2020, NAT METAB, V2, P882, DOI 10.1038/s42255 020 0267 9
   Li RB, 2018, REDOX BIOL, V18, P229, DOI 10.1016/j.redox.2018.07.011
   Li WX, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI150051
   Liu XD, 2019, NATURE, V567, P525, DOI 10.1038/s41586 019 0979 8
   Liu XL, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.972020
   Lu WB, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/2460158
   Ma WQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03162 w
   Martinez Gonzalez J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111371
   Medzikovic L, 2019, TRENDS CARDIOVAS MED, V29, P429, DOI 10.1016/j.tcm.2018.11.015
   Michigami T, 2018, PHYSIOL REV, V98, P2317, DOI 10.1152/physrev.00022.2017
   Nguyen NT, 2020, AM J PHYSIOL HEART C, V319, pH1302, DOI 10.1152/ajpheart.00305.2020
   Nian FG, 2022, BIOCHEM BIOPH RES CO, V615, P31, DOI 10.1016/j.bbrc.2022.05.028
   Niu J, 2021, AGING US, V13, P14355, DOI 10.18632/aging.203050
   Nomiyama T, 2006, J BIOL CHEM, V281, P33467, DOI 10.1074/jbc.M603436200
   Nomiyama T, 2009, CIRCULATION, V119, P577, DOI 10.1161/CIRCULATIONAHA.108.822056
   Pearen MA, 2013, MOL ENDOCRINOL, V27, P1897, DOI 10.1210/me.2013 1205
   Phadwal K, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.611922
   Pirih FQ, 2004, J BIOL CHEM, V279, P53167, DOI 10.1074/jbc.M405677200
   Platko K, 2020, ARTERIOSCL THROM VAS, V40, P1664, DOI 10.1161/ATVBAHA.119.313779
   Ranhotra HS, 2015, J RECEPT SIG TRANSD, V35, P184, DOI 10.3109/10799893.2014.948555
   Rius J, 2004, ARTERIOSCL THROM VAS, V24, P697, DOI 10.1161/01.ATV.0000121570.00515.dc
   Sakata Y, 2004, ARTERIOSCL THROM VAS, V24, P2069, DOI 10.1161/01.ATV.0000143936.77094.a4
   Sekiya T, 2013, NAT IMMUNOL, V14, P230, DOI 10.1038/ni.2520
   Sun Z, 2020, AM J PHYSIOL HEART C, V318, pH1068, DOI 10.1152/ajpheart.00690.2019
   Tani T, 2020, J PATHOL, V250, P30, DOI 10.1002/path.5346
   Wang J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050652
   Wenzl K, 2015, CURR DRUG TARGETS, V16, P38, DOI 10.2174/1389450115666141120112818
   Yan J, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02651 3
   Yang LB, 2017, CIRC RES, V121, P1251, DOI 10.1161/CIRCRESAHA.117.311819
   Zhai XY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abk0490
   Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586 019 1678 1
   Zhao XZ, 2020, ACTA BIOCH BIOPH SIN, V52, P9, DOI 10.1093/abbs/gmz135
   Zhao YX, 2023, MOL CELL, V83, P1093, DOI 10.1016/j.molcel.2023.02.007
   Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163
NR 62
TC 42
Z9 43
U1 15
U2 49
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 7330
EI 1524 4571
J9 CIRC RES
JI Circ.Res.
PD MAY 24
PY 2024
VL 134
IS 11
BP 1427
EP 1447
DI 10.1161/CIRCRESAHA.123.323699
PG 21
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Hematology
GA ZV2R3
UT WOS:001278002000008
PM 38629274
DA 2025 08 17
ER

PT J
AU Schaefer, S
   Detsch, R
   Uhl, F
   Deisinger, U
   Ziegler, G
AF Schaefer, S.
   Detsch, R.
   Uhl, F.
   Deisinger, U.
   Ziegler, G.
TI How Degradation of Calcium Phosphate Bone Substitute Materials is
   influenced by Phase Composition and Porosity
SO ADVANCED ENGINEERING MATERIALS
LA English
DT Article
ID OSTEOCLAST RUFFLED BORDER; BETA TRICALCIUM PHOSPHATE; GRAFT SUBSTITUTES;
   IN VIVO; HYDROXYAPATITE; RESORPTION; SCAFFOLDS; ACIDIFICATION; CERAMICS;
   SECRETION
AB The chemical composition of calcium phosphate (CaP) materials for the regenerative therapy of large bone defects is similar to that of bone. Additionally, calcium phosphates show an excellent biocompatibility. Besides the support of defect healing calcium phosphate implants should be completely degraded within an adequate time period to be replaced by newly formed bone. Although degradation of CaP implants occurs mainly by dissolution of the material, it is important to characterize the osteoclastic resorption as well, which is involved in native bone remodeling. The degradation of bone substitutes made of calcium phosphate ceramics is influenced by various parameters, such as defect size and localization, the general health situation, and age of the patient, but also material properties are important. Especially, the calcium phosphate composition is crucial for the degradation behavior of a calcium phosphate material. Additionally, at the cellular level the micro and macroporosity, including interconnecting pores, influences both, the dissolution and the osteoclastic resorption. In our study, three different calcium phosphate materials (hydroxyapatite, tricalcium phosphate, and a biphasic calcium phosphate) and two different geometries (dense 2D samples and porous 3D scaffolds) are compared regarding their dissolution and resorption behavior. The results show, that the dissolution of CaP ceramics, as examined by the incubation in a degradation solution, depends mainly on the calcium phosphate phase but also on the porosity of the implant. Regarding the resorption, cell proliferation and differentiation of a monocytic cell line as well as the formation of resorption lacunas are analyzed. Cell proliferation is comparable on all phase compositions. Cell differentiation and resorption, however, are influenced by the calcium phosphate phase composition and by the implant porosity as well. By understanding these two mechanisms of degradation, bone substitute materials and, as a result, the bone regeneration of large bone defects using CaP ceramics can be improved.
C1 [Schaefer, S.; Deisinger, U.] Univ Bayreuth, Friedrich Baur Res Inst Biomat, D 95440 Bayreuth, Germany.
   [Detsch, R.; Uhl, F.; Ziegler, G.] BioCer Entwicklungs GmbH, D 95447 Bayreuth, Germany.
C3 University of Bayreuth
RP Schaefer, S (通讯作者)，Univ Bayreuth, Friedrich Baur Res Inst Biomat, POB 101251, D 95440 Bayreuth, Germany.
EM susanne.schaefer@fbi biomaterialien.de; rainer.detsch@ww.uni erlangen.de
OI Uhl, Franziska Elisabeth/0000 0002 0641 4162; Detsch,
   Rainer/0000 0001 9383 428X
FU Federal Ministry of Education and Research (BMBF), Germany [0315019]
FX This study was funded by Federal Ministry of Education and Research
   (BMBF), Germany (no. 0315019).
CR BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521 1878(199810)20:10<837::AID BIES9>3.0.CO;2 D
   Chang BS, 2000, BIOMATERIALS, V21, P1291, DOI 10.1016/S0142 9612(00)00030 2
   DAMIEN CJ, 1991, J APPL BIOMATER, V2, P187, DOI 10.1002/jab.770020307
   Deisinger U, 2010, KEY ENG MATER, V441, P155, DOI 10.4028/www.scientific.net/KEM.441.155
   Detsch R, 2010, ACTA BIOMATER, V6, P3223, DOI 10.1016/j.actbio.2010.03.003
   DETSCH R, 2009, BIOMATERIALIEN, V10, P60
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   FRAYSSINET P, 1993, ORTHOP INT, V1, P308
   Gardner CR, 2007, CELL BIOL INT, V31, P672, DOI 10.1016/j.cellbi.2006.12.008
   Hing KA, 2005, INT J APPL CERAM TEC, V2, P184, DOI 10.1111/j.1744 7402.2005.02020.x
   HULBERT S F, 1970, Journal of Biomedical Materials Research, V4, P433, DOI 10.1002/jbm.820040309
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   Koutsopoulos S, 2002, J BIOMED MATER RES, V62, P600, DOI 10.1002/jbm.10280
   LeGeros R Z, 1988, Adv Dent Res, V2, P164
   Legeros RZ, 2003, J MATER SCI MATER M, V14, P201, DOI 10.1023/A:1022872421333
   Monchau F, 2002, BIOMOL ENG, V19, P143, DOI 10.1016/S1389 0344(02)00023 0
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   NERY EB, 1992, J PERIODONTOL, V63, P729, DOI 10.1902/jop.1992.63.9.729
   PIERCE AM, 1991, ELECTRON MICROSC REV, V4, P1, DOI 10.1016/0892 0354(91)90015 5
   Roldán JC, 2010, J CRANIO MAXILL SURG, V38, P423, DOI 10.1016/j.jcms.2010.01.003
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Rumpel E., 2006, Folia Morphologica, V65, P43
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   von Doernberg MC, 2006, BIOMATERIALS, V27, P5186, DOI 10.1016/j.biomaterials.2006.05.051
   Webster TJ, 2001, BIOMATERIALS, V22, P1327, DOI 10.1016/S0142 9612(00)00285 4
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Yamada S, 1997, BIOMATERIALS, V18, P1037, DOI 10.1016/S0142 9612(97)00036 7
   Yang HY, 2008, J MATER SCI MATER M, V19, P3345, DOI 10.1007/s10856 008 3473 7
   Yuan HP, 2001, BIOMATERIALS, V22, P2617, DOI 10.1016/S0142 9612(00)00450 6
NR 33
TC 43
Z9 47
U1 3
U2 53
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D 69469 WEINHEIM, GERMANY
SN 1438 1656
EI 1527 2648
J9 ADV ENG MATER
JI Adv. Eng. Mater.
PD APR
PY 2011
VL 13
IS 4
BP 342
EP 350
DI 10.1002/adem.201000267
PG 9
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 740IZ
UT WOS:000288787500019
DA 2025 08 17
ER

PT J
AU Lemaire, S
   Kosowska Shick, K
   Appelbaum, PC
   Verween, G
   Tulkens, PM
   Van Bambeke, F
AF Lemaire, Sandrine
   Kosowska Shick, Klaudia
   Appelbaum, Peter C.
   Verween, Gunther
   Tulkens, Paul M.
   Van Bambeke, Francoise
TI Cellular Pharmacodynamics of the Novel Biaryloxazolidinone Radezolid:
   Studies with Infected Phagocytic and Nonphagocytic cells, Using
   Staphylococcus aureus, Staphylococcus epidermidis,
   Listeria monocytogenes, and Legionella pneumophila
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ENDOTHELIAL CELLS; THP 1 MACROPHAGES; INTRACELLULAR PATHOGEN;
   BETA LACTAMS; SUBCELLULAR LOCALIZATION; EPITHELIAL CELLS; ANTIBIOTICS;
   ACCUMULATION; MECHANISMS; INVASION
AB Radezolid is a novel biaryloxazolidinone in clinical development which shows improved activity, including against linezolid resistant strains. In a companion paper (29), we showed that radezolid accumulates about 11 fold in phagocytic cells, with similar to 60% of the drug localized in the cytosol and similar to 40% in the lysosomes of the cells. The present study examines its activity against (i) bacteria infecting human THP 1 macrophages and located in different subcellular compartments (Listeria monocytogenes, cytosol; Legionella pneumophila, vacuoles; Staphylococcus aureus and Staphylococcus epidermidis, mainly phagolysosomal), (ii) strains of S. aureus with clinically relevant mechanisms of resistance, and (iii) isogenic linezolid susceptible and  resistant S. aureus strains infecting a series of phagocytic and nonphagocytic cells. Radezolid accumulated to similar levels (similar to 10 fold) in all cell types (human keratinocytes, endothelial cells, bronchial epithelial cells, osteoblasts, macrophages, and rat embryo fibroblasts). At equivalent weight concentrations, radezolid proved consistently 10 fold more potent than linezolid in all these models, irrespective of the bacterial species and resistance phenotype or of the cell type infected. This results from its higher intrinsic activity and higher cellular accumulation. Time kill curves showed that radezolid's activity was more rapid than that of linezolid both in broth and in infected macrophages. These data suggest the potential interest of radezolid for recurrent or persistent infections where intracellular foci play a determinant role.
C1 [Lemaire, Sandrine; Tulkens, Paul M.; Van Bambeke, Francoise] Catholic Univ Louvain, Unite Pharmacol Cellulaire & Mol, B 1200 Brussels, Belgium.
   [Lemaire, Sandrine; Tulkens, Paul M.; Van Bambeke, Francoise] Catholic Univ Louvain, Louvain Drug Res Inst, B 1200 Brussels, Belgium.
   [Kosowska Shick, Klaudia; Appelbaum, Peter C.] Penn State Univ Hosp, Milton S Hershey Med Ctr, Hershey, PA 17033 USA.
   [Verween, Gunther] Queen Astrid Mil Hosp, Burn Wound Ctr, Keratinocyte Bank, Brussels, Belgium.
C3 Universite Catholique Louvain; Universite Catholique Louvain;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Queen Astrid Military
   Hospital
RP Van Bambeke, F (通讯作者)，Catholic Univ Louvain, Unite Pharmacol Cellulaire & Mol, UCL 73 70,Ave E Mounier 73, B 1200 Brussels, Belgium.
EM francoise.vanbambeke@uclouvain.be
RI Van Bambeke, Françoise/H 5934 2019; Tulkens, Paul/B 2087 2015
OI Tulkens, Paul/0000 0002 7121 3623; Van Bambeke,
   Francoise/0000 0002 0052 7991
CR Barcia Macay M, 2006, ANTIMICROB AGENTS CH, V50, P841, DOI 10.1128/AAC.50.3.841 851.2006
   Baudoux P, 2007, J ANTIMICROB CHEMOTH, V59, P246, DOI 10.1093/jac/dkl489
   Boelens JJ, 2000, J INFECT DIS, V181, P1337, DOI 10.1086/315369
   Bosse MJ, 2005, J BONE JOINT SURG AM, V87A, P1343, DOI 10.2106/JBJS.D.02649
   Brouillette E, 2003, MICROB PATHOGENESIS, V35, P159, DOI 10.1016/S0882 4010(03)00112 8
   CARLIER MB, 1994, INT J TISSUE REACT, V16, P211
   Carryn S, 2003, INFECT DIS CLIN N AM, V17, P615, DOI 10.1016/S0891 5520(03)00066 7
   Carryn S, 2003, J ANTIMICROB CHEMOTH, V51, P1051, DOI 10.1093/jac/dkg189
   Carryn S, 2004, J INFECT DIS, V189, P2101, DOI 10.1086/420848
   Clement S, 2005, J INFECT DIS, V192, P1023, DOI 10.1086/432735
   Ellington JK, 1999, MICROB PATHOGENESIS, V26, P317, DOI 10.1006/mpat.1999.0272
   Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128
   Foster TJ, 2005, NAT REV MICROBIOL, V3, P948, DOI 10.1038/nrmicro1289
   Fowler T, 2003, CELL MICROBIOL, V5, P417, DOI 10.1046/j.1462 5822.2003.00290.x
   Freitag NE, 2009, NAT REV MICROBIOL, V7, P623, DOI 10.1038/nrmicro2171
   Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005
   Giese B, 2009, INFECT IMMUN, V77, P3611, DOI 10.1128/IAI.01478 08
   GLADUE RP, 1990, ANTIMICROB AGENTS CH, V34, P1056, DOI 10.1128/AAC.34.6.1056
   Godding V, 1998, EUR RESPIR J, V11, P1043, DOI 10.1183/09031936.98.11051043
   Isberg RR, 2009, NAT REV MICROBIOL, V7, P12, DOI 10.1038/nrmicro1967
   Joseph B, 2007, MICROBES INFECT, V9, P1188, DOI 10.1016/j.micinf.2007.05.006
   Kahl BC, 2000, INFECT IMMUN, V68, P5385, DOI 10.1128/IAI.68.9.5385 5392.2000
   Kosowska Shick K, 2006, ANTIMICROB AGENTS CH, V50, P765, DOI 10.1128/AAC.50.2.765 769.2006
   Kubica M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001409
   Lawrence L, 2008, ANTIMICROB AGENTS CH, V52, P1653, DOI 10.1128/AAC.01383 07
   Lemaire S, 2008, CLIN MICROBIOL INFEC, V14, P766, DOI 10.1111/j.1469 0691.2008.02035.x
   Lemaire S, 2005, J ANTIMICROB CHEMOTH, V55, P897, DOI 10.1093/jac/dki094
   LEMAIRE S, 2009, 45 INT C ANT AG CHEM
   Lemaire S, 2008, ANTIMICROB AGENTS CH, V52, P2797, DOI 10.1128/AAC.00123 08
   Lemaire S, 2010, ANTIMICROB AGENTS CH, V54, P2540, DOI 10.1128/AAC.01723 09
   Lemaire S, 2009, J ANTIMICROB CHEMOTH, V64, P1035, DOI 10.1093/jac/dkp267
   Lemaire S, 2009, ANTIMICROB AGENTS CH, V53, P3734, DOI 10.1128/AAC.00203 09
   Lemaire S, 2009, ANTIMICROB AGENTS CH, V53, P2289, DOI 10.1128/AAC.01135 08
   Lowy FD, 2000, TRENDS MICROBIOL, V8, P341, DOI 10.1016/S0966 842X(00)01803 5
   Mempel M, 2002, BRIT J DERMATOL, V146, P943, DOI 10.1046/j.1365 2133.2002.04752.x
   Merkel GJ, 2001, MED MICROBIOL IMMUN, V189, P217, DOI 10.1007/s004300100090
   Molmeret M, 2004, MICROBES INFECT, V6, P129, DOI 10.1016/j.micinf.2003.11.004
   Olivier AC, 2009, J INFECT DIS, V200, P1367, DOI 10.1086/606012
   Oviedo Boyso J, 2008, FEMS IMMUNOL MED MIC, V54, P53, DOI 10.1111/j.1574 695X.2008.00447.x
   Park WB, 2007, J MED MICROBIOL, V56, P1290, DOI 10.1099/jmm.0.46765 0
   Portnoy DA, 2002, J CELL BIOL, V158, P409, DOI 10.1083/jcb.200205009
   Qin ZQ, 2007, J MED MICROBIOL, V56, P83, DOI 10.1099/jmm.0.46799 0
   Radtke AL, 2006, CELL MICROBIOL, V8, P1720, DOI 10.1111/j.1462 5822.2006.00795.x
   RENARD C, 1987, ANTIMICROB AGENTS CH, V31, P410, DOI 10.1128/AAC.31.3.410
   RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092 8674(75)80001 8
   Rhen M, 2003, TRENDS MICROBIOL, V11, P80, DOI 10.1016/S0966 842X(02)00038 0
   SAITO A, 1981, J CLIN MICROBIOL, V14, P623, DOI 10.1128/JCM.14.6.623 627.1981
   Sandberg A, 2009, ANTIMICROB AGENTS CH, V53, P1874, DOI 10.1128/AAC.01605 07
   Seral C, 2003, ANTIMICROB AGENTS CH, V47, P2283, DOI 10.1128/AAC.47.7.2283 2292.2003
   Seveau S, 2007, MICROBES INFECT, V9, P1167, DOI 10.1016/j.micinf.2007.05.004
   Sinha B, 2005, THROMB HAEMOSTASIS, V94, P266, DOI 10.1160/TH05 04 0235
   SKRIPKIN E, 2005, 45 INT C ANT AG CHEM
   Skripkin E, 2008, ANTIMICROB AGENTS CH, V52, P3550, DOI 10.1128/AAC.01193 07
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
   TULKENS P, 1974, J CELL BIOL, V63, P383, DOI 10.1083/jcb.63.2.383
   TULKENS P, 1978, BIOCHEM PHARMACOL, V27, P415, DOI 10.1016/0006 2952(78)90370 2
   Van Bambeke F, 2004, ANTIMICROB AGENTS CH, V48, P2853, DOI 10.1128/AAC.48.8.2853 2860.2004
   Van Bambeke F, 2006, CURR OPIN DRUG DISC, V9, P218
   Van de Velde S, 2009, PROTEOMICS, V9, P5484, DOI 10.1002/pmic.200900503
   Zhou JC, 2008, BIOORG MED CHEM LETT, V18, P6179, DOI 10.1016/j.bmcl.2008.10.014
NR 60
TC 43
Z9 48
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2010
VL 54
IS 6
BP 2549
EP 2559
DI 10.1128/AAC.01724 09
PG 11
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA 597KO
UT WOS:000277756000034
PM 20385852
OA Green Published
DA 2025 08 17
ER

PT J
AU Unsworth, J
   Kaneez, S
   Harris, S
   Ridgway, J
   Fenwick, S
   Chenery, D
   Harrison, A
AF Unsworth, Jenny
   Kaneez, Saira
   Harris, Sue
   Ridgway, Jonathan
   Fenwick, Steven
   Chenery, David
   Harrison, Andrew
TI Pulsed low intensity ultrasound enhances mineralisation in preosteoblast
   cells
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE bone; Fracture healing; Low intensity pulsed ultrasound; In vitro
   mineralization
ID CHONDROCYTE DIFFERENTIATION; ALKALINE PHOSPHATASE; RAT; EXPRESSION;
   COLLAGEN; HYPOPHOSPHATASIA; OSTEOBLAST; INDUCTION; EXPOSURE
AB Pulsed low intensity ultrasound has been shown to be highly efficacious in the treatment of nonunion fractures and in the acceleration of fresh fracture healing. MC3T3 E1 subclone 14 cells were cultured for up to 25 days either with or without a daily treatment with low intensity pulsed ultrasound. It was determined that, on day 10 there was a dramatic increase in alkaline phosphatase and MMP 13 mRNA levels detected in ultrasound treated cultures compared with untreated controls. The activity of alkaline phosphatase was significantly increased at days 6, 8 and 10. On day 10, the amount of mineralisation within cultures, assessed using alizarin red staining, was significantly increased in ultrasound treated cultures compared with untreated controls. These results suggest that one of the mechanisms that low intensity pulsed ultrasound has on fracture repair is to enhance the process of endochondral ossification where the soft callus is converted to mineralised hard callus. (E mail: andrew.harrison@smith nephew.com) (c) 2007 World Federation for Ultrasound in Medicine & Biology.
C1 Smith & Nephew Res Ctr, Dept Clin Therapies, York YO10 5DF, N Yorkshire, England.
C3 Smith & Nephew
RP Harrison, A (通讯作者)，Smith & Nephew Res Ctr, Dept Clin Therapies, York Sci Pk, York YO10 5DF, N Yorkshire, England.
EM andrew.harrison@smith nephew.com
RI Harrison, Drew/C 8718 2012
CR Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Anderson HC, 1997, AM J PATHOL, V151, P1555
   ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   D'Alonzo RC, 2002, J BIOL CHEM, V277, P24788, DOI 10.1074/jbc.M202604200
   Ebisawa K, 2004, TISSUE ENG, V10, P921, DOI 10.1089/1076327041348437
   FERNLEY HM, 1971, ENZYMES, P414
   Gebauer D, 2005, ULTRASOUND MED BIOL, V31, P1391, DOI 10.1016/j.ultrasmedbio.2005.06.002
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   HOGAN KA, 2005, TRANSCR ORTH RES SOC, P850
   Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544
   Kokubu T, 1999, BIOCHEM BIOPH RES CO, V256, P284, DOI 10.1006/bbrc.1999.0318
   Korstjens CM, 2004, J ORTHOP RES, V22, P495, DOI 10.1016/j.orthres.2003.09.011
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306
   Leung KS, 2004, CLIN ORTHOP RELAT R, P253
   Leung KS, 2004, ULTRASOUND MED BIOL, V30, P389, DOI 10.1016/j.ultrasmedbio.2003.11.008
   Mayr E, 2002, UNFALLCHIRURG, V105, P108, DOI 10.1007/s001130100301
   MEYER JL, 1984, BIOCHIM BIOPHYS ACTA, V799, P115, DOI 10.1016/0304 4165(84)90284 8
   Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Nolte PA, 2001, J TRAUMA, V51, P693, DOI 10.1097/00005373 200110000 00012
   Parvizi J, 1999, J ORTHOPAED RES, V17, P488, DOI 10.1002/jor.1100170405
   Pilla A A, 1990, J Orthop Trauma, V4, P246, DOI 10.1097/00005131 199004030 00002
   Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286
   Saito M, 2004, CALCIFIED TISSUE INT, V75, P384, DOI 10.1007/s00223 004 0292 9
   Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024
   Sant'Anna EF, 2005, J ORTHOP RES, V23, P646, DOI 10.1016/j.orthres.2004.09.007
   Sena K, 2005, ULTRASOUND MED BIOL, V31, P703, DOI 10.1016/j.ultrasmedbio.2005.01.013
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   Wu CW, 2002, J BONE MINER RES, V17, P639, DOI 10.1359/jbmr.2002.17.4.639
NR 34
TC 61
Z9 74
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD SEP
PY 2007
VL 33
IS 9
BP 1468
EP 1474
DI 10.1016/j.ultrasmedbio.2006.12.003
PG 7
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 208HM
UT WOS:000249310400016
PM 17686570
DA 2025 08 17
ER

PT J
AU Mabrouk, M
   Mostafa, AA
   Oudadesse, H
   Mahmoud, AA
   El Gohary, MI
AF Mabrouk, M.
   Mostafa, A. A.
   Oudadesse, H.
   Mahmoud, A. A.
   El Gohary, M. I.
TI Effect of ciprofloxacin incorporation in PVA and PVA bioactive glass
   composite scaffolds
SO CERAMICS INTERNATIONAL
LA English
DT Article
DE Tissue engineering; Ciprofloxacin; Drug release; Freeze drying;
   Polyvinyl alcohol
ID IN VITRO; FRACTURE TOUGHNESS; OSTEOBLAST PROLIFERATION; HYBRID
   SCAFFOLDS; IONIC PRODUCTS; BONE; DELIVERY; RELEASE; FABRICATION;
   OSTEOMYELITIS
AB Scaffolds are implants used to deliver cells, drugs, and genes into the body in a local controlled release pattern which offers many advantages over systematic drug delivery. Composite scaffolds of polyvinyl alcohol (PVA) and quaternary bioactive glass (46S6 system) with different ratios of glass contents were prepared by the lyophilisation technique. The broad spectrum antibiotic ciprofloxacin (Cip) was impregnated to the scaffold during the fabrication in a concentration of 5, 10 and 20%. Biodegradation rate and in vitro mineralization of the prepared scaffolds were performed by soaking the scaffolds in simulated body fluid (SBF). Phase identification, microstructure, porosity, bioactivity, mechanical properties and drug release pattern in PBS were characterized by XRD, SEM coupled with EDS, Hg porosimeter, inductively coupled plasma optical emission spectroscopy (ICP OES), universal testing machine, fourier transform infrared (FTIR) and UV spectrophotometer, respectively. A porous scaffold has been obtained with porosity up to 85%. By increasing the glass contents in the prepared scaffold the porosity and the degradation rate decrease however, the compressive strength was enhanced. A sustained drug release pattern was observed with a quasi Fickian diffusion mechanism. The formulated ciprofloxacin loaded porous polyvinyl alcohol scaffold gave an acceptable physicochemical properties and was able to deliver the drug in a prolonged release pattern which offers a distinguish treatment for osteomylitis as well as local antibacterial effect. (C) 2013 Elsevier Ltd and Techna Group S.r.l. All rights reserved.
C1 [Mabrouk, M.; Mostafa, A. A.; Oudadesse, H.] Univ Rennes 1, UMR CNRS 6226, F 35042 Rennes, France.
   [Mabrouk, M.; Mostafa, A. A.] Natl Res Ctr NRC, Biomat Dept, Cairo 12622, Egypt.
   [Mahmoud, A. A.] Natl Res Ctr NRC, Dept Pharmaceut Technol, Cairo 12622, Egypt.
   [El Gohary, M. I.] Al Azhar Univ, Fac Sci, Dept Phys, Cairo, Egypt.
C3 Universite de Rennes; Centre National de la Recherche Scientifique
   (CNRS); CNRS   Institute of Chemistry (INC); Egyptian Knowledge Bank
   (EKB); National Research Centre (NRC); Egyptian Knowledge Bank (EKB);
   National Research Centre (NRC); Egyptian Knowledge Bank (EKB); Al Azhar
   University
RP Mostafa, AA (通讯作者)，Natl Res Ctr NRC, Biomat Dept, El Buhouth St, Cairo 12622, Egypt.
EM owka_05@yahoo.com
RI Mahmoud, Azza/AAD 4375 2020; Mostafa, Amany/AAH 5791 2021; Mostafa,
   Amany/O 3929 2014
OI Mabrouk, Mostafa/0000 0003 3330 6762; Mahmoud, Azza/0000 0002 4716 7524;
   Mostafa, Amany/0000 0003 4013 0742
CR ALMEIDA RM, 1990, J APPL PHYS, V68, P4225, DOI 10.1063/1.346213
   Andrade G, 2006, BIOMED MATER, V1, P221, DOI 10.1088/1748 6041/1/4/008
   [Anonymous], 2011, INT J BIOL BIOMED EN
   [Anonymous], 2009, INT J DRUG DEV RES
   Babensee JE, 1998, ADV DRUG DELIVER REV, V33, P111, DOI 10.1016/S0169 409X(98)00023 4
   Bellucci D, 2011, CERAM INT, V37, P1575, DOI 10.1016/j.ceramint.2011.01.023
   BOSTMAN O, 1989, CLIN ORTHOP RELAT R, P195, DOI 10.1097/00003086 198901000 00028
   Brady RA, 2008, FEMS IMMUNOL MED MIC, V52, P13, DOI 10.1111/j.1574 695X.2007.00357.x
   Brook I, 2008, J ORTHOP SCI, V13, P160, DOI 10.1007/s00776 007 1207 1
   Chen RR, 2003, PHARM RES DORDR, V20, P1103, DOI 10.1023/A:1025034925152
   Chiellini E, 2003, PROG POLYM SCI, V28, P963, DOI 10.1016/S0079 6700(02)00149 1
   Choi DH, 2010, J CONTROL RELEASE, V147, P193, DOI 10.1016/j.jconrel.2010.07.103
   Coates J., 2000, ENCY ANAL CHEM, P10815
   Cook RB, 2010, MED ENG PHYS, V32, P991, DOI 10.1016/j.medengphy.2010.06.014
   Dietrich E, 2009, J BIOMED MATER RES A, V88A, P1087, DOI 10.1002/jbm.a.31901
   García Lechuz J, 2009, EXPERT OPIN PHARMACO, V10, P35, DOI [10.1517/14656560802611766, 10.1517/14656560802611766 ]
   Gomes ME, 2008, J TISSUE ENG REGEN M, V2, P243, DOI 10.1002/term.89
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   Gutiérrez MC, 2007, ADV FUNCT MATER, V17, P3505, DOI 10.1002/adfm.200700093
   Han DQ, 2008, MED HYPOTHESES, V71, P374, DOI 10.1016/j.mehy.2008.01.035
   Hench LL., 1996, LIFE CHEM REP, V13, P187
   Hench L.L., 1971, Journal of Biomedical Materials Research Symposium, V36, P117, DOI DOI 10.1002/JBM.820050611
   Hench LL, 2006, J MATER SCI MATER M, V17, P967, DOI 10.1007/s10856 006 0432 z
   Hench LL, 2009, J EUR CERAM SOC, V29, P1257, DOI 10.1016/j.jeurceramsoc.2008.08.002
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Jones JR, 2007, BIOMATERIALS, V28, P1653, DOI 10.1016/j.biomaterials.2006.11.022
   Jones JR, 2009, J EUR CERAM SOC, V29, P1275, DOI 10.1016/j.jeurceramsoc.2008.08.003
   Kanellakopoulou K, 2008, ANTIMICROB AGENTS CH, V52, P2335, DOI 10.1128/AAC.01360 07
   Kaufmann EABE, 2000, J BIOMED MATER RES, V52, P783
   Kesavan S, 2010, ARS PHARM, V51, P1
   KORSMEYER RW, 1983, INT J PHARMACEUT, V15, P25, DOI 10.1016/0378 5173(83)90064 9
   Kretlow JD, 2008, AICHE J, V54, P3048, DOI 10.1002/aic.11610
   Kuruppu MD, 2012, ENG FRACT MECH, V91, P133, DOI 10.1016/j.engfracmech.2012.01.013
   Lazzarini L, 2005, INT J INFECT DIS, V9, P127, DOI 10.1016/j.ijid.2004.09.009
   Leprêtre S, 2009, BIOMATERIALS, V30, P6086, DOI 10.1016/j.biomaterials.2009.07.045
   Mäkinen TJ, 2005, J ANTIMICROB CHEMOTH, V56, P1063, DOI 10.1093/jac/dki366
   Mami M, 2008, APPL SURF SCI, V254, P7386, DOI 10.1016/j.apsusc.2008.05.340
   Mami M, 2008, CERAM SILIKATY, V52, P121
   Mansur HS, 2008, CHEM ENG J, V137, P72, DOI 10.1016/j.cej.2007.09.036
   Mansur HS, 2004, POLYMER, V45, P7193, DOI 10.1016/j.polymer.2004.08.036
   Misra SK, 2007, BIOMACROMOLECULES, V8, P2112, DOI 10.1021/bm0701954
   Misra Superb K., 2008, BIOMATERIALS, V29, P1750
   Nair LS, 2006, ADV BIOCHEM ENG BIOT, V102, P47, DOI 10.1007/b137240
   Nalla RK, 2003, BIOMATERIALS, V24, P3955, DOI 10.1016/S0142 9612(03)00278 3
   Nayak AK, 2011, ACTA PHARMACEUT, V61, P25, DOI 10.2478/v10007 011 0002 x
   Oudadesse H., 2011, Int. J. Biol. Biomed. Eng, V5, P103
   Oudadesse H., 2011, BIOCERAMICS DEV APPL, V1
   Oudadesse H., 2009, BIOCERAMICS, V22, P379
   Peter M, 2010, CHEM ENG J, V158, P353, DOI 10.1016/j.cej.2010.02.003
   Puga AM, 2012, ACTA BIOMATER, V8, P1507, DOI 10.1016/j.actbio.2011.12.020
   Radin S, 2005, J BIOMED MATER RES A, V73A, P21, DOI 10.1002/jbm.a.30241
   Rodríguez Tenreiro C, 2004, J THERM ANAL CALORIM, V77, P403, DOI 10.1023/B:JTAN.0000038981.30494.f4
   Sahoo Subhashree, 2012, Int J Pharma and Bio Sci, V3, P558
   Shin SH, 2001, J IND ENG CHEM, V7, P147
   Silverman LD, 2007, J ORTHOP RES, V25, P23, DOI 10.1002/jor.20284
   Sokolsky Papkov M, 2007, ADV DRUG DELIVER REV, V59, P187, DOI 10.1016/j.addr.2007.04.001
   Sunitha A., 2010, J ADV SCI RES, V1, P24
   Sunitha A., 2010, J PHARM COSMETOLOGY, V1, P1
   Thakre Y. M., 2011, J CHEM PHARM RES, V3, P390
   Unnithan AR, 2012, CARBOHYD POLYM, V90, P1786, DOI 10.1016/j.carbpol.2012.07.071
   Valerio P, 2004, BIOMATERIALS, V25, P2941, DOI 10.1016/j.biomaterials.2003.09.086
   van Gaalen S, 2008, ACAD PR SER BIOM ENG, P559
   Wang Q, 2007, CARBOHYD POLYM, V69, P336, DOI 10.1016/j.carbpol.2006.10.014
   Wang T, 2004, POLYM INT, V53, P911, DOI 10.1002/pi.1461
   Wong SC, 2008, COMPOS PART A APPL S, V39, P579, DOI 10.1016/j.compositesa.2007.09.004
   Wu F, 2012, APPL SURF SCI, V258, P7589, DOI 10.1016/j.apsusc.2012.04.094
   Xu JW, 2009, J ORTHOP RES, V27, P1306, DOI 10.1002/jor.20890
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   YAMAOKA T, 1995, J PHARM PHARMACOL, V47, P479, DOI 10.1111/j.2042 7158.1995.tb05835.x
   Yazdanpanah A, 2012, CERAM INT, V38, P5007, DOI 10.1016/j.ceramint.2012.02.097
   Yilgor P, 2009, BIOMATERIALS, V30, P3551, DOI 10.1016/j.biomaterials.2009.03.024
   Zhang F, 2011, INT J BIOL MACROMOL, V48, P474, DOI 10.1016/j.ijbiomac.2011.01.012
NR 72
TC 61
Z9 62
U1 3
U2 65
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272 8842
EI 1873 3956
J9 CERAM INT
JI Ceram. Int.
PD APR
PY 2014
VL 40
IS 3
BP 4833
EP 4845
DI 10.1016/j.ceramint.2013.09.033
PG 13
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AA3TV
UT WOS:000331017500132
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Reiser, C
   Klotsche, J
   Hospach, A
   Berendes, R
   Schnabel, A
   Jansson, AF
   Hufnagel, M
   Grösch, N
   Niewerth, M
   Minden, K
   Girschick, H
AF Reiser, Christiane
   Klotsche, Jens
   Hospach, Anton
   Berendes, Rainer
   Schnabel, Anja
   Jansson, Annette F.
   Hufnagel, Markus
   Groesch, Nadine
   Niewerth, Martina
   Minden, Kirsten
   Girschick, Hermann
TI First year follow up of children with chronic nonbacterial
   osteomyelitis an analysis of the German National Pediatric Rheumatologic
   Database from 2009 to 2018
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Chronic nonbacterial osteomyelitis; Pediatric rheumatology;
   Autoinflammation; Chronic nonbacterial multifocal osteomyelitis
ID RECURRENT MULTIFOCAL OSTEOMYELITIS; OUTCOMES; CLASSIFICATION; CHILDHOOD;
   OSTEITIS
AB Objective To assess the first year features of patients with chronic nonbacterial osteomyelitis (CNO). Methods Patients with a diagnosis of CNO, disease duration of under 13 months, and first registration in the German National Pediatric Rheumatologic Database (NPRD) between 2009 and 2018 were included in this cross sectional analysis. Results Of 774 documented patients, 62.8% were female, and all patients had a median age of 11 years. The most affected clinical sites were the tibia (29.7%), pelvis (28.0%), and femur (27.8%). HLA B27 was positive in 48 of 314 analyzed patients (15.3%). In 406 patients, an X ray was performed at the first visit; X ray results showed osteosclerosis/ lysis in 34.0% and hyperostosis in 14.5% of the patients. MRI scans (focal and whole body scans) were performed in 648 patients, and 81.5% showed a positive TIRM/STIR signal. A total of 84.7% of the patients were administered nonsteroidal anti inflammatory drugs, 9.6% were administered oral glucocorticoids, 10.8% were administered disease modifying anti rheumatic drugs (DMARDs), and 6.1% were administered bisphosphonates. An evaluation of the patient's questionnaire showed an overall well being (NRS 0 10) of 2.0. The PedCNO disease "activity" score revealed a 70% improvement in variables in 43% of patients in the initial 1 year follow up. Copresentation with diagnostic criteria of pediatric enthesitis related arthritis was rare. Conclusion To our knowledge, the NPRD cohort seemed to be the largest cohort of children and adolescents suffering from CNO worldwide. Most patients were treated effectively with NSAIDs, and only a small group of patients was administered additional medication. The patient defined measures of disease activity had a moderate impact on patients' daily lives.
C1 [Reiser, Christiane] Landeskrankenhaus Bregenz, Dept Pediat, Pediat Rheumatol, Bregenz, Austria.
   [Klotsche, Jens; Groesch, Nadine; Niewerth, Martina; Minden, Kirsten] German Rheumatism Res Ctr, Berlin, Germany.
   [Klotsche, Jens; Minden, Kirsten] Charite Univ Med Berlin, Berlin, Germany.
   [Klotsche, Jens; Minden, Kirsten] Humboldt Univ, Freie Univ Berlin, Berlin, Germany.
   [Klotsche, Jens; Minden, Kirsten] Berlin Inst Hlth, Berlin, Germany.
   [Hospach, Anton] Klinikum Stuttgart, Dept Pediat, Olgahosp, Stuttgart, Germany.
   [Berendes, Rainer] Childrens Hosp St Marien, Pediat Rheumatol, Landshut, Germany.
   [Schnabel, Anja] Gustav Carus Univ, Childrens Hosp, Dresden, Germany.
   [Jansson, Annette F.] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany.
   [Hufnagel, Markus] Univ Freiburg, Div Pediat Infect Dis & Rheumatol, Dept Pediat & Adolescent Med, Univ Med Ctr,Med Fac, Freiburg, Germany.
   [Girschick, Hermann] Childrens Hosp, Vivantes Klinikum Friedrichshain, Berlin, Germany.
   [Girschick, Hermann] Univ Wurzburg, Childrens Hosp, Wurzburg, Germany.
   [Girschick, Hermann] German Ctr Growth & Dev DEUZWEG, Berlin, Germany.
C3 Leibniz Association; Deutsches Rheuma Forschungszentrum (DRFZ); Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Humboldt University of Berlin; Free University of
   Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health;
   General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart; Technische
   Universitat Dresden; University of Munich; University of Freiburg;
   University of Wurzburg
RP Reiser, C (通讯作者)，Landeskrankenhaus Bregenz, Dept Pediat, Pediat Rheumatol, Bregenz, Austria.
EM Christiane.reiser@lkhb.at
RI Schnabel, Anja/NOE 9795 2025; Minden, Kirsten/LFV 1902 2024; Reiser,
   Christiane/ITU 7478 2023
OI Minden, Kirsten/0000 0003 2775 0111; Reiser,
   Christiane/0000 0001 6817 2798
FU German Children Arthritis Foundation (Deutsche Kinder Rheumastiftung);
   AbbVie; Chugai; Pfizer; GSK; Novartis; Projekt DEAL
FX The National Pediatric Rheumatological Database has been funded by the
   German Children Arthritis Foundation (Deutsche Kinder Rheumastiftung),
   AbbVie, Chugai, Pfizer, GSK, and Novartis. Open Access funding enabled
   and organized by Projekt DEAL.
CR Beck C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2992
   Borzutzky A, 2012, PEDIATRICS, V130, pE1190, DOI 10.1542/peds.2011 3788
   Catalano Pons C, 2008, RHEUMATOLOGY, V47, P1397, DOI 10.1093/rheumatology/ken249
   El Shanti HI, 2007, CLIN ORTHOP RELAT R, P11, DOI 10.1097/BLO.0b013e3180986d73
   Foeldvari I, 2001, CLIN EXP RHEUMATOL, V19, pS71
   Girschick H, 2018, RHEUMATOLOGY, V57, P1203, DOI 10.1093/rheumatology/key058
   Girschick HJ, 2007, NAT CLIN PRACT RHEUM, V3, P733, DOI 10.1038/ncprheum0653
   Girschick HJ, 1998, EUR J PEDIATR, V157, P28, DOI 10.1007/s004310050761
   Girschick HJ, 2005, ANN RHEUM DIS, V64, P279, DOI 10.1136/ard.2004.023838
   Hedrich CM, 2020, CURR RHEUMATOL REP, V22, DOI 10.1007/s11926 020 00928 1
   Hofmann SR, 2017, CURR OSTEOPOROS REP, V15, P542, DOI 10.1007/s11914 017 0405 9
   Huber AM, 2002, J PEDIATR US, V141, P198, DOI 10.1067/mpd.2002.126457
   Jansson A, 2007, RHEUMATOLOGY, V46, P154, DOI 10.1093/rheumatology/kel190
   Jansson AF, 2009, ARTHRITIS RHEUM, V60, P1152, DOI 10.1002/art.24402
   Job Deslandre C, 2001, JOINT BONE SPINE, V68, P245, DOI 10.1016/S1297 319X(01)00276 7
   Kaiser D, 2015, PEDIATR RHEUMATOL, V13, DOI 10.1186/s12969 015 0023 y
   Klepper S.E., 2003, Arthritis Care Res, V49, pS5, DOI [DOI 10.1002/ART.11398, 10.1002/art.11398]
   Kromeyer Hauschild K, 2001, MONATSSCHR KINDERH, V149, P807, DOI 10.1007/s001120170107
   Minden K, 2002, ARTHRITIS RHEUM US, V46, P2392, DOI 10.1002/art.10444
   Morbach H, 2012, CLIN EXP RHEUMATOL, V30, P578
   Nentwich J, 2020, PEDIAT RHEUMATOL ONL, P18
   Pastore S, 2016, ACTA PAEDIATR, V105, pE328, DOI 10.1111/apa.13420
   Petty RE, 2004, J RHEUMATOL, V31, P390
   Roderick MR, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969 016 0109 1
   Schnabel A, 2017, J RHEUMATOL, V44, P1058, DOI 10.3899/jrheum.161255
   Schwarz T, 2015, PEDIAT RHEUMATOL, V13
   Vittecoq O, 2000, ARTHRITIS RHEUM, V43, P109, DOI 10.1002/1529 0131(200001)43:1<109::AID ANR14>3.0.CO;2 3
   Wipff J, 2015, ARTHRITIS RHEUMATOL, V67, P1128, DOI 10.1002/art.39013
   Ye W, 2020, J RHEUMATOL
   Zhao YD, 2018, PEDIATR CLIN N AM, V65, P783, DOI 10.1016/j.pcl.2018.04.003
   Zhao Y, 2018, ARTHRIT CARE RES, V70, P1228, DOI 10.1002/acr.23462
   Ziobrowska Bech A, 2013, CLIN EXP RHEUMATOL, V31, P974
NR 32
TC 28
Z9 31
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD NOV 8
PY 2021
VL 23
IS 1
AR 281
DI 10.1186/s13075 021 02658 w
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA WT3IP
UT WOS:000715762100001
PM 34749785
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Khan, FA
   Mishra, H
AF Khan, Farhan Ahmad
   Mishra, Hitesh
TI A comparative study of cyclo oxygenase inhibitors on immune response
   with special reference to Cox 2 inhibitors
SO AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE Non steroidal anti inflammatory drugs (NSAIDS); cost; immunomodulators;
   antibody production
ID RHEUMATOID ARTHRITIS; PROSTAGLANDIN; OSTEOARTHRITIS; LYMPHOCYTES;
   ACTIVATION
AB The object of this study is to observe the in vivo effect of cyclo oxygenase 2 (Cox 2) inhibitors on the humoral response after immunization of rabbits with Salmonella typhi antigen. Albino rabbits of either sex were divided into five groups of six animals each and were administered aspirin (100 mg/kg, (BD), p.o), celecoxib (30 mg/kg O.D, p.o), indomethacin (12.5 mg/kg BD, p.o) and etoricoxib (17 mg/kg O.D, p.o) for seven days starting one day prior to immunization with S. typhi antigen (0.5 ml in each thighs), respectively. The antibody titres were measured weekly for a month using Widal agglutination test. The antibody titres in the first week were augmented in all the groups. The response was more marked in treated group as compared to control group. Later on antibody titre fell markedly in the treated groups. Selective Cox 2 inhibitors administration caused higher antibody suppression in comparison to nonselective Cox inhibitors treatment. These findings support that NSAIDs and the new Cox 2 selective drugs have an unsuspected target, the B cell, and attenuate antibody production.
C1 [Khan, Farhan Ahmad; Mishra, Hitesh] Teerthanker Mahaveer Med Coll & Res Ctr, Dept Pharmacol, Moradabad 244001, India.
C3 Teerthanker Mahaveer University
RP Khan, FA (通讯作者)，Teerthanker Mahaveer Med Coll & Res Ctr, Dept Pharmacol, Moradabad 244001, India.
EM dr.farhan.k@gmail.com
CR Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280
   BETZ M, 1991, J IMMUNOL, V146, P108
   Fedyk ER, 1996, P NATL ACAD SCI USA, V93, P10978, DOI 10.1073/pnas.93.20.10978
   Fung HB, 1999, CLIN THER, V21, P1131, DOI 10.1016/S0149 2918(00)80018 1
   GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791
   Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471 4906(01)02154 8
   He XW, 2002, INT IMMUNOL, V14, P69, DOI 10.1093/intimm/14.1.69
   Iñiguez MA, 1999, J IMMUNOL, V163, P111
   Inoue H, 2001, INFLAMM RES, V50, P65
   ISHIZUKA M, 1974, EXPERIENTIA, V30, P1207, DOI 10.1007/BF01923694
   ROBINSON DR, 1975, J CLIN INVEST, V56, P1181, DOI 10.1172/JCI108195
   Yamamoto H, 1996, J TRAUMA, V41, P612, DOI 10.1097/00005373 199610000 00004
   YOSHIKAWA T, 1993, J RHEUMATOL, V20, P1701
NR 13
TC 1
Z9 1
U1 0
U2 3
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170 00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1996 0816
J9 AFR J PHARM PHARMACO
JI Afr. J. Pharm. Pharmacol.
PD OCT
PY 2011
VL 5
IS 13
BP 1633
EP 1637
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 883OO
UT WOS:000299643800011
DA 2025 08 17
ER

PT J
AU Pieles, O
   Hoering, M
   Adel, S
   Reichert, TE
   Liebisch, G
   Morsczeck, C
AF Pieles, Oliver
   Hoering, Marcus
   Adel, Sadiyeh
   Reichert, Torsten E.
   Liebisch, Gerhard
   Morsczeck, Christian
TI Energy Metabolism and Lipidome Are Highly Regulated during Osteogenic
   Differentiation of Dental Follicle Cells
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID TANDEM MASS SPECTROMETRY; HIGH THROUGHPUT QUANTIFICATION; ACTIVATED
   PROTEIN KINASE; FATTY ACID SYNTHESIS; GENE EXPRESSION; STEM CELLS;
   PHOSPHORYLATION; DEXAMETHASONE; EXTRACTION; STRESS
AB Dental follicle cells (DFCs) are stem/progenitor cells of the periodontium and give rise to alveolar osteoblasts. However, understanding of the molecular mechanisms of osteogenic differentiation, which is required for cell based therapies, is delimited. This study is aimed at analyzing the energy metabolism during the osteogenic differentiation of DFCs. Human DFCs were cultured, and osteogenic differentiation was induced by either dexamethasone or bone morphogenetic protein 2 (BMP2). Previous microarray data were reanalyzed to examine pathways that are regulated after osteogenic induction. Expression and activity of metabolic markers were evaluated by western blot analysis and specific assays, relative amount of mitochondrial DNA was measured by real time quantitative polymerase chain reaction, the oxidative state of cells was determined by a glutathione assay, and the lipidome of cells was analyzed via mass spectrometry (MS). Moreover, osteogenic markers were analyzed after the inhibition of fatty acid synthesis by 5 (tetradecyloxy) 2 furoic acid or C75. Pathway enrichment analysis of microarray data revealed that carbon metabolism was amongst the top regulated pathways after osteogenic induction in DFCs. Further analysis showed that enzymes involved in glycolysis, citric acid cycle, mitochondrial activity, and lipid metabolism are differentially expressed during differentiation, with most markers upregulated and more markedly after induction with dexamethasone compared to BMP2. Moreover, the cellular state was more oxidized, and mitochondrial DNA was distinctly upregulated during the second half of differentiation. Besides, MS of the lipidome revealed higher lipid concentrations after osteogenic induction, with a preference for species with lower numbers of C atoms and double bonds, which indicates a de novo synthesis of lipids. Concordantly, inhibition of fatty acid synthesis impeded the osteogenic differentiation of DFCs. This study demonstrates that energy metabolism is highly regulated during osteogenic differentiation of DFCs including changes in the lipidome suggesting enhanced de novo synthesis of lipids, which are required for the differentiation process.
C1 [Pieles, Oliver; Adel, Sadiyeh; Reichert, Torsten E.; Morsczeck, Christian] Univ Hosp Regensburg, Dept Oral & Maxillofacial Surg, Franz Josef Strauss Allee 11, D 93053 Regensburg, Germany.
   [Hoering, Marcus; Liebisch, Gerhard] Univ Hosp Regensburg, Inst Clin Chem & Lab Med, Franz Josef Strauss Allee 11, D 93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Morsczeck, C (通讯作者)，Univ Hosp Regensburg, Dept Oral & Maxillofacial Surg, Franz Josef Strauss Allee 11, D 93053 Regensburg, Germany.
EM oliver.pieles@ukr.de; marcus.hoering@ukr.de; sadieadel@gmail.com;
   torsten.reichert@ukr.de; gerhard.liebisch@ukr.de;
   christian.morsczeck@ukr.de
RI ; Liebisch, Gerhard/G 6130 2010
OI Horing, Marcus/0000 0002 3651 392X; 
FU Deutsche Forschungsgemeinschaft (DFG) [319390412]
FX AcknowledgmentsThis work was supported by the Deutsche
   Forschungsgemeinschaft (DFG, project number 319390412).
CR Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Berry KAZ, 2004, J AM SOC MASS SPECTR, V15, P1499, DOI 10.1016/j.jasms.2004.07.009
   Bi RY, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070997
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Burdge GC, 2015, WORLD REV NUTR DIET, V112, P1, DOI 10.1159/000365423
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   da Silva CG, 2020, CHEM PHYS LIPIDS, V232, DOI 10.1016/j.chemphyslip.2020.104964
   Felthaus O, 2014, CELL TISSUE RES, V357, P695, DOI 10.1007/s00441 014 1891 z
   HA J, 1994, J BIOL CHEM, V269, P22162
   HALVORSON DL, 1984, LIPIDS, V19, P851, DOI 10.1007/BF02534514
   Höring M, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100050
   Höring M, 2019, ANAL CHEM, V91, P3459, DOI 10.1021/acs.analchem.8b05013
   Hong M, 2020, IN VITRO CELL DEV AN, V56, P480, DOI 10.1007/s11626 020 00467 0
   Hsu SH, 2013, STEM CELLS, V31, P2779, DOI 10.1002/stem.1441
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Husen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079736
   Igumenova TI, 2015, BIOCHEMISTRY US, V54, P4953, DOI 10.1021/acs.biochem.5b00565
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2021, NUCLEIC ACIDS RES, V49, pD545, DOI 10.1093/nar/gkaa970
   Kanehisa M, 2019, PROTEIN SCI, V28, P1947, DOI 10.1002/pro.3715
   Kastaniotis AJ, 2017, BBA MOL CELL BIOL L, V1862, P39, DOI 10.1016/j.bbalip.2016.08.011
   Klontzas ME, 2017, STEM CELLS DEV, V26, P723, DOI 10.1089/scd.2016.0315
   Kwon IK, 2015, BBA MOL CELL RES, V1853, P561, DOI 10.1016/j.bbamcr.2014.12.011
   Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200
   Larsson L, 2016, J DENT RES, V95, P255, DOI 10.1177/0022034515618887
   Liebisch G, 1999, J LIPID RES, V40, P1539
   Liebisch G, 2002, CLIN CHEM, V48, P2217
   Liebisch G, 2004, BBA MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003
   Liebisch G, 2020, J LIPID RES, V61, P1539, DOI 10.1194/jlr.S120001025
   Lipp P, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004556
   Liu J, 2019, CELLS BASEL, V8, DOI 10.3390/cells8060537
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao HM, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/2016809
   Matsuzaka T, 2002, J LIPID RES, V43, P911
   Matyash V, 2008, J LIPID RES, V49, P1137, DOI 10.1194/jlr.D700041 JLR200
   Morsczeck C, 2006, CALCIFIED TISSUE INT, V78, P98, DOI 10.1007/s00223 005 0146 0
   Morsczeck C, 2005, CELL BIOL INT, V29, P567, DOI 10.1016/j.cellbi.2005.03.020
   Morsczeck C, 2005, MATRIX BIOL, V24, P155, DOI 10.1016/j.matbio.2004.12.004
   Morsczeck C, 2018, EXPERT OPIN BIOL TH, V18, P187, DOI 10.1080/14712598.2018.1402004
   PARKER RA, 1977, J MED CHEM, V20, P781, DOI 10.1021/jm00216a009
   Pieles O, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02313 w
   Pieles O, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.104951
   Potapova IA, 2000, BIOCHEMISTRY US, V39, P1169, DOI 10.1021/bi992159y
   RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960
   Rendina Ruedy E, 2017, ADIPOCYTE, V6, P250, DOI 10.1080/21623945.2017.1356505
   Saugspier M, 2010, STEM CELLS DEV, V19, P707, DOI [10.1089/scd.2010.0027, 10.1089/scd.2009.0027]
   Shares BH, 2018, J BIOL CHEM, V293, P16019, DOI 10.1074/jbc.RA118.004102
   Shouhed D, 2005, J CELL BIOCHEM, V95, P1276, DOI 10.1002/jcb.20497
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Skolníková E, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.529421
   Smith CO, 2021, STEM CELLS DEV, V30, P149, DOI 10.1089/scd.2020.0141
   Soto Avellaneda A, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944 020 01389 2
   Venegas V, 2012, METHODS MOL BIOL, V837, P327, DOI 10.1007/978 1 61779 504 6_22
   Viale Bouroncle S, 2012, STEM CELLS DEV, V21, P1936, DOI 10.1089/scd.2011.0422
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Zavan B, 2016, STEM CELLS BIOL REG, P1, DOI 10.1007/978 3 319 33299 4
   Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441
   Zhou T, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9159605
NR 59
TC 8
Z9 9
U1 0
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD JUL 16
PY 2022
VL 2022
AR 3674931
DI 10.1155/2022/3674931
PG 20
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 3H3LT
UT WOS:000831941100001
PM 35903407
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hata, M
   Naruse, K
   Ozawa, S
   Kobayashi, Y
   Nakamura, N
   Kojima, N
   Omi, M
   Katanosaka, Y
   Nishikawa, T
   Naruse, K
   Tanaka, Y
   Matsubara, T
AF Hata, Masaki
   Naruse, Keiko
   Ozawa, Shogo
   Kobayashi, Yasuko
   Nakamura, Nobuhisa
   Kojima, Norinaga
   Omi, Maiko
   Katanosaka, Yuki
   Nishikawa, Toru
   Naruse, Keiji
   Tanaka, Yoshinobu
   Matsubara, Tatsuaki
TI Mechanical Stretch Increases the Proliferation While Inhibiting the
   Osteogenic Differentiation in Dental Pulp Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID IN VITRO; TISSUE; MOVEMENT; RECEPTOR; PATHWAY; DPSCS
AB Dental pulp stem cells (DPSCs), which can differentiate into several types of cells, are subjected to mechanical stress by jaw movement and occlusal forces. In this study, we evaluated how the uniaxial mechanical stretch influences proliferation and differentiation of DPSCs. DPSCs were isolated and cultured from male Sprague Dawley rats. Cultured DPSCs were identified by surface markers and the differentiation capabilities as adipocytes or osteoblasts. To examine the response to mechanical stress, uniaxial stretch was exposed to cultured DPSCs. We evaluated the impact of stretch on the intracellular signaling, proliferation, osteogenic differentiation, and gene expressions of DPSCs. Stretch increased the phosphorylation of Akt, ERK1/2, and p38 MAP kinase as well as the proliferation of DPSCs. The stretch induced proliferation of DPSCs was abolished by the inhibition of the ERK pathway. On the other hand, stretch significantly decreased the osteogenic differentiation of DPSCs, but did not affect the adipogenic differentiation. We also confirmed mRNA expressions of osteocalcin and osteopontin were significantly suppressed by stretch. In conclusion, uniaxial stretch increased the proliferation of DPSCs, while suppressing osteogenic differentiation. These results suggest a crucial role of mechanical stretch in the preservation of DPSCs in dentin. Furthermore, mechanical stretch may be a useful tool for increasing the quantity of DPSCs in vitro for regenerative medicine.
C1 [Hata, Masaki; Ozawa, Shogo; Kojima, Norinaga; Omi, Maiko; Tanaka, Yoshinobu] Aichi Gakuin Univ, Dept Removable Prosthodont, Sch Dent, Nagoya, Aichi 4648651, Japan.
   [Naruse, Keiko; Kobayashi, Yasuko; Nakamura, Nobuhisa; Matsubara, Tatsuaki] Aichi Gakuin Univ, Dept Internal Med, Sch Dent, Nagoya, Aichi 4648651, Japan.
   [Katanosaka, Yuki; Naruse, Keiji] Okayama Univ, Dept Cardiovasc Physiol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Nishikawa, Toru] Aichi Gakuin Univ, Dept Periodontol, Sch Dent, Nagoya, Aichi 4648651, Japan.
C3 Aichi Gakuin University; Aichi Gakuin University; Okayama University;
   Aichi Gakuin University
RP Naruse, K (通讯作者)，Aichi Gakuin Univ, Dept Internal Med, Sch Dent, Chikusa Ku, 2 11 Suemori Dori, Nagoya, Aichi 4648651, Japan.
EM narusek@dpc.agu.ac.jp
RI ; Sokabe, Masahiro/I 1565 2012; Naruse, Keiko/H 3325 2012
OI Omi Sugihara, Maiko/0000 0002 1347 9044; Matsubara,
   Tatsuaki/0000 0002 0647 5475; naruse, keiji/0000 0003 4100 6444
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   [21592506]; MEXT of Japan; Grants in Aid for Scientific Research
   [21592506, 22592322] Funding Source: KAKEN
FX We thank Mr. Brent Bell for reading the manuscript. This research was
   supported, in part, by Grant in Aid for Scientific Research (21592506)
   from the Ministry of Education, Culture, Sports, Science and Technology
   (MEXT) and, in part, by the "Strategic Research AGU Platform Formation
   (2008 2012)'' Project for Private Universities: matching fund subsidy
   from MEXT of Japan.
CR Batouli S, 2003, J DENT RES, V82, P976, DOI 10.1177/154405910308201208
   Botero TM, 2010, J DENT RES, V89, P264, DOI 10.1177/0022034509357556
   Cai XX, 2011, J TISSUE ENG REGEN M, V5, P347, DOI 10.1002/term.319
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Clause KC, 2009, TISSUE ENG PT A, V15, P1373, DOI 10.1089/ten.tea.2008.0169
   Cook B, 2008, NATURE, V452, P361, DOI 10.1038/nature06603
   D'Alimonte I, 2011, J BIOL REG HOMEOS AG, V25, P57
   d'Aquino R, 2008, STEM CELL REV, V4, P21, DOI 10.1007/s12015 008 9013 5
   DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727 80 19661
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Han MJ, 2008, BIOTECHNOL BIOPROC E, V13, P410, DOI [10.1007/s12257 008 0146 9, 10.1007/S12257 008 0146 9]
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Hyun N, 2011, MOL CELLS, V31, P355, DOI 10.1007/s10059 011 0045 3
   Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882
   Kasuya Y, 1999, BIOCHEM BIOPH RES CO, V261, P853, DOI 10.1006/bbrc.1999.1111
   Kawazoe Y, 2008, INT J BIOL SCI, V4, P37, DOI 10.7150/ijbs.4.37
   Koolstra JH, 2002, CRIT REV ORAL BIOL M, V13, P366, DOI 10.1177/154411130201300406
   Kraft DCE, 2010, EUR J ORAL SCI, V118, P29, DOI 10.1111/j.1600 0722.2009.00709.x
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Lee DY, 2010, J BIOL CHEM, V285, P30, DOI 10.1074/jbc.M109.010512
   Lee SK, 2010, LIFE SCI, V86, P107, DOI 10.1016/j.lfs.2009.11.013
   Lindroos B, 2008, BIOCHEM BIOPH RES CO, V368, P329, DOI 10.1016/j.bbrc.2008.01.081
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nakamura H, 2005, J DENT RES, V84, P515, DOI 10.1177/154405910508400606
   Neupane M, 2008, TISSUE ENG PT A, V14, P1007, DOI [10.1089/ten.tea.2007.0207, 10.1089/tea.2007.0207]
   Onishi T, 2003, ANAT REC PART A, V273A, P700, DOI 10.1002/ar.a.10084
   Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667
   Paphangkorakit J, 2000, ARCH ORAL BIOL, V45, P1033, DOI 10.1016/S0003 9969(00)00090 X
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Rimondini L, 2009, Minerva Stomatol, V58, P483
   Sübay RK, 2001, J ENDODONT, V27, P508, DOI 10.1097/00004770 200108000 00003
   Suchanek Jakub, 2007, Acta Medica (Hradec Kralove), V50, P195
   Tu ML, 2011, LIFE SCI, V88, P233, DOI 10.1016/j.lfs.2010.12.001
   Wang JG, 2005, LIFE SCI, V76, P2817, DOI 10.1016/j.lfs.2004.10.050
   Weyts FAA, 2003, CALCIFIED TISSUE INT, V72, P505, DOI 10.1007/s00223 002 2027 0
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Yashiro K, 1999, J DENT RES, V78, P1662, DOI 10.1177/00220345990780101201
   Yu JH, 2007, BIOL CELL, V99, P465, DOI 10.1042/BC20070013
   Yu V, 2009, BIOCHEM BIOPH RES CO, V386, P661, DOI 10.1016/j.bbrc.2009.06.106
   Zhang WB, 2006, TISSUE ENG, V12, P2813, DOI 10.1089/ten.2006.12.2813
NR 41
TC 47
Z9 53
U1 7
U2 31
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAR
PY 2013
VL 19
IS 5 6
BP 625
EP 633
DI 10.1089/ten.tea.2012.0099
PG 9
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 084ZT
UT WOS:000314581100005
PM 23153222
OA Green Published
DA 2025 08 17
ER

PT J
AU Nishikawa, M
   Yanagawa, N
   Kojima, N
   Yuri, S
   Hauser, PV
   Jo, OD
   Yanagawa, N
AF Nishikawa, Masaki
   Yanagawa, Naomi
   Kojima, Nobuhiko
   Yuri, Shunsuke
   Hauser, Peter V.
   Jo, Oak D.
   Yanagawa, Norimoto
TI Stepwise renal lineage differentiation of mouse embryonic stem cells
   tracing in vivo development
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mouse embryonic stem cell; Differentiation; Kidney development;
   Metanephric mesenchyme; Ureteric bud; CD24
ID KIDNEY; EXPRESSION; CULTURE; VITRO; GENE; INDUCTION
AB The in vitro derivation of renal lineage progenitor cells is essential for renal cell therapy and regeneration. Despite extensive studies in the past, a protocol for renal lineage induction from embryonic stem cells remains unestablished. In this study, we aimed to induce renal lineages from mouse embryonic stem cells (mESC) by following in vivo developmental stages, i.e., the induction of mesoderm (Stage I), intermediate mesoderm (Stage II) and renal lineages (Stage III). For stage I induction, in accordance with known signaling pathways involved in mesoderm development in vivo, i.e., Nodal, bone morphogenic proteins (BMPs) and Wnt. we found that the sequential addition of three factors, i.e., Activin A (A), a surrogate for Nodal signaling, during days 0 2, A plus BMP 4 (4) during days 2 4, and A4 plus lithium (L), a surrogate for Wnt signaling, during days 4 6, was most effective to induce the mesodermal marker, Brachyury. For stage II induction, the addition of retinoic acid (R) in the continuous presence of A4L during days 6 8 was most effective to induce nephrogenic intermediate mesodermal markers, such as Pax2 and Lim1. Under this condition, more than 30% of cells were stained positive for Pax2, and there was a concomitant decrease in the expression of non mesodermal markers. For stage III induction, in resemblance to the reciprocal induction between ureteric bud (UB) and metanephric mesenchyme (MM) during kidney development, we found that the exposure to conditioned media derived from UB and MM cells was effective in inducing MM and UB markers, respectively. We also observed the emergence and gradual increase of cell populations expressing progenitor cell marker CD24 from Stage I to Stage III. These CD24(+) cells correlated with higher levels of expression of Brachyury at stage I, Pax2 and Lim1 at stage II and MM markers, such as WT1 and Cadherin 11, after exposure to UB conditioned media at stage III. In conclusion, our results show that stepwise induction by tracing in vivo developmental stages was effective to generate renal lineage progenitor cells from mESC, and CD24 may serve as a useful surface marker for renal lineage cells at stage II and MM cells at stage III. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Nishikawa, Masaki] Greater Los Angeles Vet Affairs Healthcare Syst S, Med Serv, Renal Regenerat Lab, North Hills, CA 91343 USA.
   [Nishikawa, Masaki; Yanagawa, Naomi; Yuri, Shunsuke; Hauser, Peter V.; Jo, Oak D.; Yanagawa, Norimoto] Greater Los Angeles Vet Affairs Healthcare Syst S, Res Serv, North Hills, CA 91343 USA.
   [Nishikawa, Masaki; Yanagawa, Naomi; Yuri, Shunsuke; Hauser, Peter V.; Jo, Oak D.; Yanagawa, Norimoto] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 91343 USA.
   [Kojima, Nobuhiko] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Tokyo
RP Nishikawa, M (通讯作者)，Greater Los Angeles Vet Affairs Healthcare Syst S, Med Serv, Renal Regenerat Lab, Bldg 7,Rm D 101,16111 Plummer St, North Hills, CA 91343 USA.
EM masakiwestriver@gmail.com
RI Hauser, Peter Viktor/D 4255 2009; Yuri, Shunsuke/JSB 9931 2023; YURI,
   Shunsuke/JSB 9931 2023
OI Hauser, Peter Viktor/0000 0003 1168 034X; YURI,
   Shunsuke/0000 0002 9708 3134; Kojima, Nobuhiko/0000 0003 2555 0570
FU Chau Li Foundation
FX The authors would like to thank Dr. Ke Zhan for the assistance with the
   irradiation of feeder cells; Dr. Guoping Fan, Dr. Norihisa Masuyama, and
   Dr. Zhicheng Ma for providing J1 mESCs with advices; and Dr. Steven
   Potter for providing MK3 cells. This study was supported by generous
   funds from the Chau Li Foundation. Parts of this study was presented at
   the American Society of Nephrology meeting in 2009 and published as an
   abstract.
CR Anton R, 2007, FEBS LETT, V581, P5247, DOI 10.1016/j.febslet.2007.10.012
   Batchelder CA, 2009, DIFFERENTIATION, V78, P45, DOI 10.1016/j.diff.2009.05.001
   Bruce SJ, 2007, DIFFERENTIATION, V75, P337, DOI 10.1111/j.1432 0436.2006.00149.x
   Challen GA, 2004, J AM SOC NEPHROL, V15, P2344, DOI 10.1097/01.ASN.0000136779.17837.8F
   DRESSLER GR, 2002, MOUSE DEV PATTERNING, P395
   Dressler GR, 2009, DEVELOPMENT, V136, P3863, DOI 10.1242/dev.034876
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Gadue P, 2005, EXP HEMATOL, V33, P955, DOI 10.1016/j.exphem.2005.06.009
   James RG, 2005, DEV BIOL, V288, P113, DOI 10.1016/j.ydbio.2005.09.025
   Kim D, 2005, J AM SOC NEPHROL, V16, P3527, DOI 10.1681/ASN.2005050544
   Kobayashi T, 2005, BIOCHEM BIOPH RES CO, V336, P585, DOI 10.1016/j.bbrc.2005.08.136
   Kramer J, 2006, DIFFERENTIATION, V74, P91, DOI 10.1111/j.1432 0436.2006.00062.x
   Little MH, 2006, J AM SOC NEPHROL, V17, P2390, DOI 10.1681/ASN.2006030218
   Mae SI, 2010, BIOCHEM BIOPH RES CO, V393, P877, DOI 10.1016/j.bbrc.2010.02.111
   Morizane R, 2009, BIOCHEM BIOPH RES CO, V390, P1334, DOI 10.1016/j.bbrc.2009.10.148
   Nishikawa SI, 2007, NAT REV MOL CELL BIO, V8, P502, DOI 10.1038/nrm2189
   Noon EPB, 2009, DEVELOPMENT, V136, P1995, DOI 10.1242/dev.035592
   Osafune K, 2002, DEV GROWTH DIFFER, V44, P161
   Ren XH, 2010, ACTA BIOCH BIOPH SIN, V42, P464, DOI 10.1093/abbs/gmq046
   Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Steenhard BM, 2005, J AM SOC NEPHROL, V16, P1623, DOI 10.1681/ASN.2004070584
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Vainio S, 2002, NAT REV GENET, V3, P533, DOI 10.1038/nrg842
   Valerius M. Todd, 2002, Mechanisms of Development, V112, P219, DOI 10.1016/S0925 4773(02)00008 4
   Vigneau C, 2007, J AM SOC NEPHROL, V18, P1709, DOI 10.1681/ASN.2006101078
   Weigmann A, 1997, P NATL ACAD SCI USA, V94, P12425, DOI 10.1073/pnas.94.23.12425
   WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0
   Ye P, 2004, KIDNEY INT, V66, P1356, DOI 10.1111/j.1523 1755.2004.00897.x
NR 29
TC 35
Z9 43
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 13
PY 2012
VL 417
IS 2
BP 897
EP 902
DI 10.1016/j.bbrc.2011.12.071
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 883CM
UT WOS:000299610200043
PM 22209845
DA 2025 08 17
ER

PT J
AU Logashina, YA
   Palikova, YA
   Palikov, VA
   Kazakov, VA
   Smolskaya, SV
   Dyachenko, IA
   Tarasova, NV
   Andreev, YA
AF Logashina, Yulia A.
   Palikova, Yulia A.
   Palikov, Viktor A.
   Kazakov, Vitaly A.
   Smolskaya, Sviatlana V.
   Dyachenko, Igor A.
   Tarasova, Nadezhda V.
   Andreev, Yaroslav A.
TI Anti Inflammatory and Analgesic Effects of TRPV1 Polypeptide Modulator
   APHC3 in Models of Osteo  and Rheumatoid Arthritis
SO MARINE DRUGS
LA English
DT Article
DE arthritis; TRPV1; polypeptide modulator; APHC3; cytokines; inflammation;
   non steroidal anti inflammatory drugs; sea anemone; Heteractis crispa
AB Arthritis is a widespread inflammatory disease associated with progressive articular surface degradation, ongoing pain, and hyperalgesia causing the development of functional limitations and disability. TRPV1 channel is one of the high potential targets for the treatment of inflammatory diseases. Polypeptide APHC3 from sea anemone Heteractis crispa is a mode selective TRPV1 antagonist that causes mild hypothermia and shows significant anti inflammatory and analgesic activity in different models of pain. We evaluated the anti inflammatory properties of APHC3 in models of monosodium iodoacetate (MIA) induced osteoarthritis and complete Freund's adjuvant (CFA) induced rheumatoid monoarthritis in comparison with commonly used non steroidal anti inflammatory drugs (NSAIDs) such as diclofenac, ibuprofen, and meloxicam. Subcutaneous administration of APHC3 (0.1 mg/kg) significantly reversed joint swelling, disability, grip strength impairment, and thermal and mechanical hypersensitivity. The effect of APHC3 was equal to or better than that of reference NSAIDs. Protracted treatment with APHC3 decreased IL 1b concentration in synovial fluid, reduced inflammatory changes in joints, and prevented the progression of cartilage degradation. Therefore, polypeptide APHC3 has the potential to be an analgesic and anti inflammatory substance for the alleviation of arthritis symptoms.
C1 [Logashina, Yulia A.; Andreev, Yaroslav A.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16 10, Moscow 117997, Russia.
   [Logashina, Yulia A.; Smolskaya, Sviatlana V.; Tarasova, Nadezhda V.; Andreev, Yaroslav A.] Sechenov First Moscow State Med Univ, Inst Mol Med, Trubetskaya Str 8,Bldg 2, Moscow 119991, Russia.
   [Palikova, Yulia A.; Palikov, Viktor A.; Kazakov, Vitaly A.; Dyachenko, Igor A.] Russian Acad Sci, Branch Shemyakin Ovchinnikov Inst Bioorgan Chem, Prospekt Nauki 6, Pushchino 142290, Russia.
C3 Russian Academy of Sciences; Pushchino Scientific Center for Biological
   Research (PSCBI) of the Russian Academy of Sciences; Institute of
   Bioorganic Chemistry of the Russian Academy of Sciences; Sechenov First
   Moscow State Medical University; Russian Academy of Sciences; Pushchino
   Scientific Center for Biological Research (PSCBI) of the Russian Academy
   of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of
   Sciences
RP Andreev, YA (通讯作者)，Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16 10, Moscow 117997, Russia.; Andreev, YA (通讯作者)，Sechenov First Moscow State Med Univ, Inst Mol Med, Trubetskaya Str 8,Bldg 2, Moscow 119991, Russia.
EM logashina_yu_a@staff.sechenov.ru; yuliyapalikova@bibch.ru;
   vpalikov@bibch.ru; kazakov@bibch.ru; smolskaya_s_v@staff.sechenov.ru;
   dyachenko@bibch.ru; tarasova_n_v@staff.sechenov.ru; aya@ibch.ru
RI ; Logashina, Yulia/AEC 7225 2022; Palikova, Yuliya/Y 4228 2018; DI Igor,
   Dyachenko/K 9060 2017; Kazakov, Vitaly/AAO 7177 2021; Andreev,
   Yaroslav/C 6627 2012; Palikov, Viktor/AIE 3992 2022; Tarasova,
   Nadezhda/I 9892 2016
OI Logashina, Yulia/0000 0002 5739 8326; Andreev,
   Yaroslav/0000 0002 7628 0980; Palikova, Yuliya/0000 0001 9547 0686;
   Tarasova, Nadezhda/0000 0002 2088 6991; Palikov,
   Victor/0000 0003 2989 4477; Smolskaya, Sviatlana/0000 0003 3734 8644
FU Russian Science Foundation [16 15 00167]; Russian Science Foundation
   [16 15 00167] Funding Source: Russian Science Foundation
FX This research was funded by the Russian Science Foundation, grant No.
   16 15 00167.
CR AHMED M, 1995, REGUL PEPTIDES, V55, P85, DOI 10.1016/0167 0115(94)00095 F
   Aitken D, 2018, OSTEOARTHR CARTILAGE, V26, P880, DOI 10.1016/j.joca.2018.02.899
   Alam J, 2017, BIOMED PHARMACOTHER, V92, P615, DOI 10.1016/j.biopha.2017.05.055
   Anand P, 2011, BRIT J ANAESTH, V107, P490, DOI 10.1093/bja/aer260
   Andersson DA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1559
   Andreev YA, 2009, DOKL BIOCHEM BIOPHYS, V424, P46, DOI 10.1134/S160767290901013X
   Andreev YA, 2008, J BIOL CHEM, V283, P23914, DOI 10.1074/jbc.M800776200
   Andreev YA, 2013, MAR DRUGS, V11, P5100, DOI 10.3390/md11125100
   Aspden RM, 2001, LANCET, V357, P1118, DOI 10.1016/S0140 6736(00)04264 1
   Barton NJ, 2006, EXP MOL PATHOL, V81, P166, DOI 10.1016/j.yexmp.2006.04.007
   Bas DB, 2016, PAIN MANAG, V6, P265, DOI 10.2217/pmt.16.4
   Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896 6273(02)00802 4
   Borbély É, 2016, INFLAMM RES, V65, P725, DOI 10.1007/s00011 016 0954 x
   Bressan E, 2016, PAIN, V157, P2504, DOI 10.1097/j.pain.0000000000000669
   Brown PM, 2016, NAT REV RHEUMATOL, V12, P731, DOI 10.1038/nrrheum.2016.175
   Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306
   Choudhary N, 2018, IMMUNOPHARM IMMUNOT, V40, P193, DOI 10.1080/08923973.2018.1434793
   COLPAERT FC, 1983, LIFE SCI, V32, P1827, DOI 10.1016/0024 3205(83)90060 7
   Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023
   Daheshia M, 2008, J RHEUMATOL, V35, P2306, DOI 10.3899/jrheum.080346
   Dux M, 1999, CELL TISSUE RES, V296, P471, DOI 10.1007/s004410051307
   Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4
   Engler A, 2007, BIOCHEM BIOPH RES CO, V359, P884, DOI 10.1016/j.bbrc.2007.05.178
   Esipov RS, 2018, PROTEIN EXPRES PURIF, V145, P71, DOI 10.1016/j.pep.2017.12.011
   Fechtner S, 2017, RHEUMATOLOGY, V56, P1060, DOI 10.1093/rheumatology/kew301
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Finn A, 2014, RHEUMATOLOGY, V53, P2297, DOI 10.1093/rheumatology/keu281
   Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006
   Fleischmann RM, 2019, ARTHRITIS RHEUMATOL, V71, P1056, DOI 10.1002/art.40840
   Galindo T, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040105
   Garami A, 2018, ACTA PHYSIOL, V223, DOI 10.1111/apha.13038
   Garami A, 2020, PHARMACOL THERAPEUT, V208, DOI 10.1016/j.pharmthera.2020.107474
   Garami A, 2010, J NEUROSCI, V30, P1435, DOI 10.1523/JNEUROSCI.5150 09.2010
   Garcia MM, 2019, EUR J PHARMACOL, V854, P109, DOI 10.1016/j.ejphar.2019.04.011
   Gavenis K, 2009, MOL CELL BIOCHEM, V321, P135, DOI 10.1007/s11010 008 9927 x
   Gavva NR, 2007, J PHARMACOL EXP THER, V323, P128, DOI 10.1124/jpet.107.125674
   Gavva NR, 2007, J NEUROSCI, V27, P3366, DOI 10.1523/JNEUROSCI.4833 06.2007
   Grassel Susanne, 2020, F1000Res, V9, DOI 10.12688/f1000research.22115.1
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Gwilym SE, 2009, ARTHRIT RHEUM ARTHR, V61, P1226, DOI 10.1002/art.24837
   Hoffmeister C, 2014, RHEUMATOLOGY, V53, P240, DOI 10.1093/rheumatology/ket352
   Holzer P, 2008, BRIT J PHARMACOL, V155, P1145, DOI 10.1038/bjp.2008.351
   Hsieh WS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09200 6
   Hu F, 2008, BIOCHEM BIOPH RES CO, V369, P989, DOI 10.1016/j.bbrc.2008.02.155
   Huang JH, 2006, CURR NEUROPHARMACOL, V4, P197, DOI 10.2174/157015906778019554
   Alcaraz MJ, 2019, BIOCHEM PHARMACOL, V165, P4, DOI 10.1016/j.bcp.2019.02.034
   Kelly S, 2015, ANN RHEUM DIS, V74, P252, DOI 10.1136/annrheumdis 2013 203413
   Kozlov SA, 2009, RUSS J BIOORG CHEM+, V35, P711, DOI 10.1134/S1068162009060065
   Liu P, 2011, NEUROSCI LETT, V493, P72, DOI 10.1016/j.neulet.2011.01.027
   Liu Bryan R, 2015, NAT REV RHEUMATOL, V11, P35, DOI 10.1038/nrrheum.2014.162
   Lockwood SM, 2019, OSTEOARTHR CARTILAGE, V27, P712, DOI 10.1016/j.joca.2018.12.017
   Logashina YA, 2019, BIOCHEMISTRY MOSCOW+, V84, P101, DOI 10.1134/S0006297919020020
   Logashina YA, 2017, TOXINS, V9, DOI 10.3390/toxins9050154
   Logashina YA, 2017, J BIOL CHEM, V292, P2992, DOI 10.1074/jbc.M116.757369
   Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738
   Marker CL, 2012, METHODS MOL BIOL, V851, P239, DOI 10.1007/978 1 61779 561 9_18
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Materazzi S, 2013, PAIN, V154, P2750, DOI 10.1016/j.pain.2013.08.002
   Möller KÄ, 2015, EUR J PHARMACOL, V756, P75, DOI 10.1016/j.ejphar.2015.02.050
   Montilla García A, 2017, NEUROPHARMACOLOGY, V125, P231, DOI 10.1016/j.neuropharm.2017.07.029
   Moore RA, 2010, ANN RHEUM DIS, V69, P374, DOI 10.1136/ard.2009.107805
   Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Nikolaev MV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177077
   Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Romanovsky AA, 2009, PHARMACOL REV, V61, P228, DOI 10.1124/pr.109.001263
   Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906
   Sames E, 2016, EUR J RHEUMATOL, V3, P91, DOI 10.5152/eurjrheum.2015.0028
   Schatz A, 2016, INT J CARDIOL, V223, P215, DOI 10.1016/j.ijcard.2016.08.131
   Valdes AM, 2011, ANN RHEUM DIS, V70, P1556, DOI 10.1136/ard.2010.148122
   Vincent Tonia L, 2019, F1000Res, V8, DOI 10.12688/f1000research.18831.1
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Weinblatt ME, 2003, ARTHRITIS RHEUM US, V48, P35, DOI 10.1002/art.10697
   Westlund KN, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 46
   Woo YJ, 2011, EXP MOL MED, V43, P561, DOI 10.3858/emm.2011.43.10.062
   Yocum D, 2000, ARCH INTERN MED, V160, P2947, DOI 10.1001/archinte.160.19.2947
NR 80
TC 29
Z9 30
U1 2
U2 48
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 3397
J9 MAR DRUGS
JI Mar. Drugs
PD JAN
PY 2021
VL 19
IS 1
AR 39
DI 10.3390/md19010039
PG 21
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PW1AO
UT WOS:000610408700001
PM 33477357
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cray, JJ
   Durham, EL
   Smalley, MA
   Finegold, DN
   Siegel, MI
   Losee, JE
   Mooney, MP
   Cooper, GM
AF Cray, J. J., Jr.
   Durham, E. L.
   Smalley, M. A.
   Finegold, D. N.
   Siegel, M. I.
   Losee, J. E.
   Mooney, M. P.
   Cooper, G. M.
TI The effects of testosterone on craniosynostotic calvarial cells: a test
   of the gene/environmental model of craniofacial anomalies
SO ORTHODONTICS & CRANIOFACIAL RESEARCH
LA English
DT Article
DE craniosynostosis; gene/environment model; osteoblasts; sex steroids
ID ANTLEY BIXLER SYNDROME; SEX HORMONE DISTURBANCES; GROWTH HORMONE;
   PREGNANCY LUTEOMA; NEWBORN MICE; THERAPY; PATHOLOGY; FEATURES; RECEPTOR;
   RABBITS
AB Authors   Cray JJ Jr, Durham EL, Smalley MA, Finegold DN, Siegel MI, Losee JE, Mooney MP, Cooper GM
   Introduction   The gene environmental interaction model for craniofacial development proposes that if a genetic predisposition for an anomaly is coupled with an environmental factor that can exacerbate this predisposition, more severe phenotypes will result. Here, we utilize cells derived from our non syndromic rabbit model of craniosynostosis to test the hypothesis that an insult, testosterone (TP) administration (exogenous source) will alter the osteogenic activity of these cells.
   Design   Calvarial cells from wild type (WT) (N = 13) or craniosynostotic (CS) rabbits (N = 11) were stimulated with TP, an androgen receptor blocker, flutamide, and combined treatments. Proliferation and differentiation assays were conducted after 7 days. ANOVA and t tests were used to determine differences in stimulation and cell type.
   Results   The CS cells had significantly greater proliferation after TP administration compared to WT. There were no appreciable changes in differentiation after TP stimulation. Flutamide administration or combined TP and flutamide administration decreased both proliferation and differentiation for both cell types similarly.
   Conclusions   Testosterone exposure caused an increase in cell proliferation for CS osteoblast cells. However, a therapy targeted to mitigate this response (flutamide therapy) similarly affected CS and WT cells, suggesting that the administration of flutamide or TP in the presence of flutamide decreases osteogenesis of these cells. Thus, although our data support a mechanism of gene environmental interaction, these results would not support a therapeutic intervention based on this interaction.
C1 [Cray, J. J., Jr.; Durham, E. L.; Smalley, M. A.; Losee, J. E.; Mooney, M. P.; Cooper, G. M.] Univ Pittsburgh, Pediat Craniofacial Biol Lab, Dept Surg, Childrens Hosp Pittsburgh,Div Plast & Reconstruct, Pittsburgh, PA 15201 USA.
   [Finegold, D. N.] Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh, Pittsburgh, PA 15201 USA.
   [Finegold, D. N.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15201 USA.
   [Siegel, M. I.; Mooney, M. P.] Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15201 USA.
   [Siegel, M. I.; Mooney, M. P.] Univ Pittsburgh, Dept Orthodont, Pittsburgh, PA 15201 USA.
   [Mooney, M. P.; Cooper, G. M.] Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA 15201 USA.
   [Cooper, G. M.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15201 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Cooper, GM (通讯作者)，Univ Pittsburgh, Pediat Craniofacial Biol Lab, Dept Surg, Childrens Hosp Pittsburgh,Div Plast & Reconstruct, 3510 Rangos Res Ctr,530,45th St, Pittsburgh, PA 15201 USA.
EM Greg.Cooper@chp.edu
RI Cooper, Gregory/ABI 4744 2022
OI Finegold, David/0000 0001 9901 2578
CR ARNAUD E, 1995, J NEUROSURG, V83, P476, DOI 10.3171/jns.1995.83.3.0476
   Ascoli Paola, 2006, Pituitary, V9, P335, DOI 10.1007/s11102 006 0416 5
   BARRETT RL, 1993, ANGLE ORTHOD, V63, P289
   Bills GC, 2008, EUR J ORTHODONT, V30, P153, DOI 10.1093/ejo/cjm101
   Byron CD, 2008, INTEGR COMP BIOL, V48, P338, DOI 10.1093/icb/icn020
   Camfield P R., 2000, Craniosynostosis, P177
   Carvalho LR, 2005, J PEDIATR US, V146, P295, DOI 10.1016/j.jpeds.2004.08.032
   CHADDUCK WM, 1992, NEUROSURGERY, V30, P867, DOI 10.1227/00006123 199206000 00008
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1403, DOI 10.1097/PRS.0b013e3181d62ad4
   Coussens AK, 2005, GENOMICS, V85, P563, DOI 10.1016/j.ygeno.2005.02.002
   Cragun D, 2005, AM J HUM GENET, V77, P327, DOI 10.1086/432164
   Cray J, 2010, J CRANIOFAC SURG, V21, P711, DOI 10.1097/SCS.0b013e3181d80a36
   ENLOW DH, 1996, ESSENTIALS FACIAL GR
   Fujita T, 2006, EUR J ORTHODONT, V28, P190, DOI 10.1093/ejo/cji093
   Fujita T, 2004, J DENT RES, V83, P250, DOI 10.1177/154405910408300313
   Funatsu M, 2006, ANGLE ORTHOD, V76, P970, DOI 10.2319/011905 17
   HERBST A L, 1973, Clinical Obstetrics and Gynecology, V16, P37, DOI 10.1097/00003081 197312000 00003
   de Faria MEJ, 2009, HORM RES, V71, P173, DOI 10.1159/000197875
   KAPPSIMON KA, 1993, PLAST RECONSTR SURG, V92, P831, DOI 10.1097/00006534 199392050 00008
   Kjellberg H, 2007, EUR J ORTHODONT, V29, P243, DOI 10.1093/ejo/cjm005
   Limbird LE, 1998, CELL, V93, P157, DOI 10.1016/S0092 8674(00)81568 8
   Lin IC, 2004, J CRANIOFAC SURG, V15, P922, DOI 10.1097/00001665 200411000 00006
   Lin IC, 2007, PLAST RECONSTR SURG, V120, P1137, DOI 10.1097/01.prs.0000279527.99734.bf
   Mauceri L, 1997, CLIN DYSMORPHOL, V6, P375, DOI 10.1097/00019605 199710000 00013
   Miller M.T, 2000, CRANIOSYNOSTOSIS DIA, P184
   Mooney MP, 1998, CHILD NERV SYST, V14, P236, DOI 10.1007/s003810050219
   Mooney MP, 1996, J CRAN GENET DEV BIO, V16, P52
   Mooney MP, 1996, CLEFT PALATE CRAN J, V33, P369, DOI 10.1597/1545 1569(1996)033<0369:CSPASP>2.3.CO;2
   MOONEY MP, 1994, CLEFT PALATE J, V3, P8
   Murray JC, 2002, CLIN GENET, V61, P248, DOI 10.1034/j.1399 0004.2002.610402.x
   NODA K, 1994, J MORPHOL, V220, P25, DOI 10.1002/jmor.1052200104
   PERSING JA, 2000, CRANIOSYNOSTOSIS DIA, P209
   PIRINEN S, 1995, ACTA ODONTOL SCAND, V53, P179, DOI 10.3109/00016359509005969
   Ramirez Yañez GO, 2005, EUR J ORTHODONT, V27, P494, DOI 10.1093/ejo/cji028
   Renier D., 1989, SCI FDN SURG TREATME, P263
   RIESENFELD A, 1967, HOMO, V18, P233
   Roth C, 2000, EUR J PEDIATR, V159, P189, DOI 10.1007/s004310050048
   Shackleton C, 2004, AM J MED GENET A, V128A, P223, DOI 10.1002/ajmg.a.30104
   Warmann S, 2000, J PEDIATR SURG, V35, P528, DOI 10.1016/S0022 3468(00)90232 X
   Yamamoto T, 2001, CLIN GENET, V59, P451, DOI 10.1034/j.1399 0004.2001.590611.x
NR 40
TC 6
Z9 6
U1 0
U2 0
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1601 6335
EI 1601 6343
J9 ORTHOD CRANIOFAC RES
JI Orthod. Craniofac. Res.
PD AUG
PY 2011
VL 14
IS 3
BP 149
EP 155
DI 10.1111/j.1601 6343.2011.01520.x
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 794VK
UT WOS:000292929200004
PM 21771269
DA 2025 08 17
ER

PT J
AU Xantus, G
   Zavori, L
   Matheson, C
   Gyarmathy, VA
   Fazekas, LM
   Kanizsai, P
AF Xantus, Gabor
   Zavori, Laszlo
   Matheson, Candice
   Gyarmathy, V. Anna
   Fazekas, Laszlo M.
   Kanizsai, Peter
TI Cannabidiol in low back pain: scientific rationale for clinical trials
   in low back pain
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE Cannabidiol; low back pain; emergency medicine; primary care setting;
   pain reduction; fear reduction; epidiolex; bedriol; CBD; nabiximols
ID MANAGEMENT; RECEPTOR
AB Introduction The pooled worldwide prevalence of low back pain related presentations in primary care varies between 6.8% and 28.4% in the high income countries rendering it a major healthcare/economy problem. To best manage this complex bio psycho social condition a 360 degree approach is needed, as the psycho social components are often more important than the scant pathophysiology. Pattern analysis of cannabis users suggested that attempts to alleviate musculo skeletal pain is often seen as a major drive to use cannabinoids. Areas covered Unlike NSAIDs/opioids, cannabidiol might directly affect more than one modality of pain signaling/perception. The 2019 guideline of the National Institute for Clinical Excellence recommended further studies with cannabidiol in pain medicine because of its excellent safety profile and presumed therapeutic potential. Therefore, we have researched relevant databases for pharmaco physiological papers published between 2000 and 2021 to collate evidence in a narrative fashion to determine the clinical rationale for this cannabinoid in low back pain. Expert opinion Observational research reported good results with CBD in pain and fear reduction, which are both key factors in low back pain. Given the paucity of high quality evidence, further research is needed to determine the efficacy/non inferiority of CBD in primary/emergency care setting, using multimodal assessment of various patient reported outcomes.
C1 [Zavori, Laszlo; Kanizsai, Peter] Cardiff Univ, Sch Med, Cardiff, Wales.
   [Xantus, Gabor] Univ Pecs, Clin Ctr, Univ Emergency Dept, Pecs, Hungary.
   [Matheson, Candice] Dalhouis Univ, Hamilton, ON, Canada.
   [Gyarmathy, V. Anna] Epiconsult Biomed Agcy, Delaware, OH USA.
   [Fazekas, Laszlo M.] Semmelweis Univ Budapest, Budapest, Hungary.
C3 Cardiff University; University of Pecs; Semmelweis University
RP Xantus, G (通讯作者)，Cardiff Univ, Cardiff, Wales.
EM gabor.xantus@gmail.com
RI ; Zavori, Laszlo/GYI 8818 2022; Kanizsai, Peter/I 3741 2014; Xantus,
   Gabor/AAU 7662 2021
OI Zavori, Laszlo/0000 0002 1715 4167; Kanizsai, Peter/0000 0001 7896 2857;
   Fazekas, Laszlo Marton/0000 0002 0626 2357; Gyarmathy, V.
   Anna/0000 0002 9692 2602; 
CR Allan GM, 2018, CAN FAM PHYSICIAN, V64, pE78
   Atalay S, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9010021
   Aviram J, 2017, Pain Physician, V6, pE755, DOI 10.36076/ppj.20.5.E755
   Baron EP, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194 018 0862 2
   Bergamaschi MM, 2011, CURR DRUG SAF, V6, P237, DOI 10.2174/157488611798280924
   Bitencourt RM, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00502
   Boyaji S, 2020, CURR PAIN HEADACHE R, V24, DOI 10.1007/s11916 020 0835 4
   Britch SC, 2021, PSYCHOPHARMACOLOGY, V238, P9, DOI 10.1007/s00213 020 05712 8
   Capano A, 2020, POSTGRAD MED, V132, P56, DOI 10.1080/00325481.2019.1685298
   Cheng Y, 2007, EXPERT OPIN INV DRUG, V16, P951, DOI 10.1517/13543784.16.7.951
   Correa F, 2009, BIOCHEM PHARMACOL, V77, P86, DOI 10.1016/j.bcp.2008.09.014
   Costa B, 2004, BRIT J PHARMACOL, V143, P247, DOI 10.1038/sj.bjp.0705920
   Crippa JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02009
   Crippa JAS, 2019, EUR ARCH PSY CLIN N, V269, P121, DOI 10.1007/s00406 019 00982 6
   Darnall BD, 2017, J PAIN, V18, P1139, DOI 10.1016/j.jpain.2017.05.003
   Edwards J, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1511 7
   **Epidiolex SmPC , EP SMPC
   Espejo Porras F, 2013, NEUROPHARMACOLOGY, V75, P155, DOI 10.1016/j.neuropharm.2013.07.024
   Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776
   Jurkus R, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00454
   Kent Peter M, 2005, Chiropr Osteopat, V13, P13, DOI 10.1186/1746 1340 13 13
   Kim J, 2021, CANNABIS CANNABINOID, V6, P40, DOI 10.1089/can.2019.0102
   Laprairie RB, 2015, BRIT J PHARMACOL, V172, P4790, DOI 10.1111/bph.13250
   Lewis MA, 2018, PLANTA MED, V84, P225, DOI 10.1055/s 0043 122240
   Lvovschi VE, 2019, CLIN J PAIN, V35, P644, DOI 10.1097/AJP.0000000000000715
   MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004
   Morales P, 2017, PROG CHEM ORG NAT PR, V103, P103, DOI 10.1007/978 3 319 45541 9_4
   Morales P, 2016, CANNABIS CANNABINOID, V1, P22, DOI 10.1089/can.2015.0005
   Moulin DE, 2014, PAIN RES MANAG, V19, P328
   Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468 1331.2010.03328.x
   Papagianni EP, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920 019 1026 z
   Phillips Ceri J, 2009, Rev Pain, V3, P2, DOI 10.1177/204946370900300102
   Rock EM, 2012, BRIT J PHARMACOL, V165, P2620, DOI 10.1111/j.1476 5381.2011.01621.x
   Romero Sandoval EA, 2018, PHARMACOTHERAPY, V38, P651, DOI 10.1002/phar.2115
   Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064 005 6978 1
   Sharpe L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02518 2
   Stockings E, 2018, PAIN, V159, P1932, DOI 10.1097/j.pain.0000000000001293
   Tura M, 2019, MOLECULES, V24, DOI 10.3390/molecules24193485
   van de Donk T, 2019, PAIN, V160, P860, DOI 10.1097/j.pain.0000000000001464
   Wideman TH, 2019, CLIN J PAIN, V35, P212, DOI 10.1097/AJP.0000000000000670
   Zis P, 2016, PAIN PHYSICIAN, V19, pE1049
   Zuardi Antonio W, 2017, Front Pharmacol, V8, P259, DOI 10.3389/fphar.2017.00259
NR 42
TC 8
Z9 8
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751 2433
EI 1751 2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD JUN 3
PY 2021
VL 14
IS 6
BP 671
EP 675
DI 10.1080/17512433.2021.1917379
EA APR 2021
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SP5PR
UT WOS:000648142600001
PM 33861675
DA 2025 08 17
ER

PT J
AU Lee, M
   Li, WM
   Siu, RK
   Whang, J
   Zhang, XL
   Soo, C
   Ting, K
   Wu, BM
AF Lee, Min
   Li, Weimin
   Siu, Ronald K.
   Whang, Julie
   Zhang, Xinli
   Soo, Chia
   Ting, Kang
   Wu, Benjamin M.
TI Biomimetic apatite coated alginate/chitosan microparticles as osteogenic
   protein carriers
SO BIOMATERIALS
LA English
DT Article
DE Biomimetic apatite; Alginate; Chitosan; Microparticles; Nell 1;
   Controlled release
ID BONE MORPHOGENETIC PROTEIN 2; DRUG DELIVERY; OSTEOBLAST DIFFERENTIATION;
   GENE DELIVERY; ILIAC BONE; ALGINATE; CHITOSAN; GRAFTS; EXPRESSION;
   COMPLICATIONS
AB Bone morphogenetic proteins (BMPs) are currently approved for spinal fusion, tibial fracture repair, and maxillofacial bone regeneration. However, BMP pleiotropism, paradoxical activities on precursor cells, and unexpected side effects at local and ectopic sites may limit their usage. Thus, the need remains for alternative osteoinductive factors that provide more bone specific activities with fewer adverse effects. Nell 1 [Nel like molecule 1; Nel (a protein highly expressed in neural tissue encoding epidermal growth factor like domain)] is a novel osteogenic protein believed to specifically target cells committed to the osteogenic lineage. The objective of this project is to incorporate Nell 1 into a moldable putty carrier that can adapt to bony defects and deliver Nell 1 to the local microenvironment. We show here that moldability can be achieved by mixing hyaluronan hydrogel with two types of particles: demineralized bone powder for osteoconductivity, and biomimetic apatite coated alginate/chitosan microparticles for controlled Nell 1 delivery. Besides enhancing overall osteoconductivity of the carrier, the biomimetic apatite coating also provides a more sustained release (similar to 15% cumulative release over 30 days) and greatly reduces the initial burst release that is observed with non coated alginate/chitosan microparticles (similar to 40% release after 1 day). The efficacy of Nell 1 delivery from these carriers was evaluated in a rat spinal fusion model against Nell free carriers as controls. At 4 weeks post implantation, Nell 1 enhanced spinal fusion rates as assessed by manual palpation, radiographs, high resolution micro computerized tomography (mu CT), and histology. This moldable putty carrier system appears to be a suitable carrier for promoting osteogenesis, and will be further evaluated in larger animal models over longer periods to follow the remodeling of the regenerated bone. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Siu, Ronald K.; Wu, Benjamin M.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA.
   [Lee, Min; Li, Weimin; Siu, Ronald K.; Whang, Julie; Zhang, Xinli; Ting, Kang; Wu, Benjamin M.] Univ Calif Los Angeles, Dent & Craniofacial Res Inst, Los Angeles, CA 90095 USA.
   [Soo, Chia] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.
   [Wu, Benjamin M.] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Wu, BM (通讯作者)，Univ Calif Los Angeles, Dept Bioengn, 5121 Engn 5, Los Angeles, CA 90095 USA.
EM benwu@ucla.edu
RI Zhang, Xinli/MIN 9371 2025; Wu, Benjamin/JFK 5518 2023; soo,
   chia/JOZ 6461 2023
OI Wu, Benjamin/0000 0001 5236 8534; 
FU UC Discovery grant [Bio 07 10677]; NIH/NIDCR [R01 DE016107]
FX This work was supported by UC Discovery grant Bio 07 10677 and NIH/NIDCR
   R01 DE016107.
CR Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210
   AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Barrere F, 2002, BIOMATERIALS, V23, P1921, DOI 10.1016/S0142 9612(01)00318 0
   Becker TA, 2001, J BIOMED MATER RES, V54, P76, DOI 10.1002/1097 4636(200101)54:1<76::AID JBM9>3.0.CO;2 V
   Cai XX, 2007, CELL BIOL INT, V31, P776, DOI 10.1016/j.cellbi.2007.01.011
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097 4628(19970103)63:1<125::AID APP13>3.0.CO;2 4
   CANADY JW, 1993, CLEFT PALATE CRAN J, V30, P579, DOI 10.1597/1545 1569(1993)030<0579:SOTICA>2.3.CO;2
   Chou YF, 2004, BIOMATERIALS, V25, P5323, DOI 10.1016/j.biomaterials.2003.12.037
   Chou YF, 2005, BIOMATERIALS, V26, P285, DOI 10.1016/j.biomaterials.2004.02.030
   Chou YF, 2005, J BIOMED MATER RES B, V75B, P81, DOI 10.1002/jbm.b.30261
   Coppi G, 2001, DRUG DEV IND PHARM, V27, P393, DOI 10.1081/DDC 100104314
   Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053
   Di Martino A, 2005, BIOMATERIALS, V26, P5983, DOI 10.1016/j.biomaterials.2005.03.016
   Dodane V, 1998, PHARM SCI TECHNOL TO, V1, P246, DOI 10.1016/S1461 5347(98)00059 5
   Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523 1755.2000.00081.x
   González Rodríguez ML, 2002, INT J PHARMACEUT, V232, P225, DOI 10.1016/S0378 5173(01)00915 2
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   KANDORI K, 1995, COLLOID SURFACE B, V5, P81, DOI 10.1016/0927 7765(95)98210 E
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   KLINE RM, 1995, PLAST RECONSTR SURG, V95, P5, DOI 10.1097/00006534 199501000 00002
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P79, DOI 10.1006/bbrc.1999.1638
   Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P752, DOI 10.1006/bbrc.1999.1753
   KURZ LT, 1989, SPINE, V14, P1324, DOI 10.1097/00007632 198912000 00009
   LAURIE SWS, 1984, PLAST RECONSTR SURG, V73, P933, DOI 10.1097/00006534 198406000 00014
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Li ZS, 2005, BIOMATERIALS, V26, P3919, DOI 10.1016/j.biomaterials.2004.09.062
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Matsumoto T, 2004, BIOMATERIALS, V25, P3807, DOI 10.1016/j.biomaterials.2003.10.081
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Olton D, 2007, BIOMATERIALS, V28, P1267, DOI 10.1016/j.biomaterials.2006.10.026
   Ozaki W, 1999, PLAST RECONSTR SURG, V104, P139, DOI 10.1097/00006534 199907000 00020
   RAJAONARIVONY M, 1993, J PHARM SCI, V82, P912, DOI 10.1002/jps.2600820909
   Shen H, 2004, NAT MATER, V3, P569, DOI 10.1038/nmat1179
   Shu X, 2000, INT J PHARM, V201, P51, DOI 10.1016/S0378 5173(00)00403 8
   Strong EB, 2000, OTOLARYNG HEAD NECK, V123, P547, DOI 10.1067/mhn.2000.110541
   Suh JKF, 2000, BIOMATERIALS, V21, P2589
   Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80
   Tonnesen HH, 2002, DRUG DEV IND PHARM, V28, P621, DOI 10.1081/DDC 120003853
   Truong T, 2007, J BONE MINER RES, V22, P7, DOI 10.1359/JBMR.061012
   van den Bergh JPA, 2000, J CLIN PERIODONTOL, V27, P627, DOI 10.1034/j.1600 051x.2000.027009627.x
   Wang JC, 2003, J BONE JOINT SURG AM, V85A, P905, DOI 10.2106/00004623 200305000 00020
   Wolfe SA, 1996, PLAST RECONSTR SURG, V98, P567, DOI 10.1097/00006534 199609000 00039
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375
   Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167
NR 48
TC 105
Z9 125
U1 0
U2 59
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 2009
VL 30
IS 30
BP 6094
EP 6101
DI 10.1016/j.biomaterials.2009.07.046
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 499FY
UT WOS:000270204500023
PM 19674782
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Levin, A
   Li, YC
AF Levin, A
   Li, YC
TI Vitamin D and its analogues: Do they protect against cardiovascular
   disease in patients with kidney disease?
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE vitamin D; vitamin D analogues; chronic kidney disease; cardiovascular
   disease; dialysis; inflammation; cardiac hypertrophy; reninangiotensin
   system; mechanisms
ID PLASMA RENIN ACTIVITY; NEGATIVE ENDOCRINE REGULATOR; PARATHYROID HORMONE
   LEVELS; DENDRITIC CELL MODULATION; BLOOD PRESSURE; D RECEPTOR;
   1,25 DIHYDROXYVITAMIN D 3; RENAL DISEASE; RISK FACTORS; ARTERIAL
   CALCIFICATIONS
AB Background. Patients with chronic kidney disease (CKD) are at high risk for cardiovascular disease, and despite recent advances in hypertension control, anemia management, and dialysis adequacy, mortality remains high. Improved understanding of nontraditional risk factors, including those present at early phases in CKD, may lead to novel therapeutic strategies. CKD has been demonstrated to be an independent risk factor for cardiovascular disease in the general population, but data are lacking as to the associated potential abnormalities that occur in association with reduced glomerular filtration rate (GFR), which may contribute to this increased risk. Data are accumulating regarding the role of abnormalities of calcium, phosphorus, vitamin D, and parathyroid hormone (PTH) in cardiovascular disease. Vitamin D deficiency is present even in the early stages of CKD. Vitamin D plays a central role in calcium phosphorus homeostasis, regulation of PTH, and formation and maintenance of bone. However, until recently, vitamin D has not been considered to have a biologic role in CKD beyond mineral regulation, or has been considered as a negative factor contributing to soft tissue and cardiovascular calcification. In light of recent observational studies showing an association of vitamin D therapy and survival benefit in hemodialysis patients, the effects of vitamin D on cardiovascular system have become a heavily debated issue.
   Methods. A Medline search was performed to identify relevant literature describing the role of vitamin D in the pathogenesis of cardiovascular disease. Both the experimental and clinical literatures in English were reviewed.
   Results. The accumulating published data demonstrate both associative relationships and mechanisms for biologic plausibility. The following three potential mechanisms may be important for the protective effects of vitamin D against cardiovascular disease mortality: vitamin D can inhibit various aspects of inflammation, which have been established as a key pathogenic mechanism in atherosclerosis; vitamin D exerts an antiproliferative effect on myocardial cell hypertrophy and proliferation, which underlies the pathogenesis of congestive heart failure; and vitamin D acts as a negative endocrine regulator for the renin angiotensin system, which itself plays an important independent role in hypertension and cardiovascular health.
   Conclusion. Vitamin D deficiency might be an underestimated nonclassical risk factor for cardiovascular disease in CKD. Based on a review of the evidence, from both basic science and clinical studies, this article supports the possible protective role of vitamin D beyond its effect on mineral metabolism, and suggests the need for ongoing evaluation of the role of vitamin D in cardiovascular health in the CKD population.
C1 Univ British Columbia, Div Nephrol, Vancouver, BC, Canada.
   Univ Chicago, Dept Med, Chicago, IL 60637 USA.
C3 University of British Columbia; University of Chicago
RP Levin, A (通讯作者)，Univ British Columbia, St Pauls Hosp, Div Nephrol, 1081 Burrand,Rm 6010A, Vancouver, BC V6Z 1Y8, Canada.
EM alevin@providencehealth.bc.ca; cyan@medicine.bsd.uchicago.edu
CR Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   BURGESS ED, 1990, AM J HYPERTENS, V3, P903, DOI 10.1093/ajh/3.12.903
   Chertow GM, 2004, NEPHROL DIAL TRANSPL, V19, P1489, DOI 10.1093/ndt/gfh125
   Cheung AK, 2000, KIDNEY INT, V58, P353, DOI 10.1046/j.1523 1755.2000.00173.x
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Culleton BF, 2003, SEMIN DIALYSIS, V16, P95, DOI 10.1046/j.1525 139X.2003.16024.x
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   Fried LP, 1998, JAMA J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092 8674(01)00238 0
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goldsmith DJA, 1997, NEPHRON, V77, P37, DOI 10.1159/000190244
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   Griffin MD, 2001, P NATL ACAD SCI USA, V98, P6800, DOI 10.1073/pnas.121172198
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kong J, 2003, AM J PHYSIOL REG I, V285, pR255, DOI 10.1152/ajpregu.00517.2002
   KristalBoneh E, 1997, HYPERTENSION, V30, P1289, DOI 10.1161/01.HYP.30.5.1289
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003 4819 139 2 200307150 00013
   Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272 6386(98)70145 3
   Levin A, 2001, NEPHROL DIAL TRANSPL, V16, P7, DOI 10.1093/ndt/16.suppl_2.7
   Levin A, 1999, AM J KIDNEY DIS, V34, P125, DOI 10.1016/S0272 6386(99)70118 6
   Li YC, 2004, J STEROID BIOCHEM, V89 90, P387, DOI 10.1016/j.jsbmb.2004.03.004
   Li YC, 2003, J CELL BIOCHEM, V88, P327, DOI 10.1002/jcb.10343
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   LIND L, 1995, AM J HYPERTENS, V8, P894, DOI 10.1016/0895 7061(95)00154 H
   LIND L, 1989, AM J HYPERTENS, V2, P20, DOI 10.1093/ajh/2.1.20
   Liuzzo G, 2001, Rays, V26, P221
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Longenecker JC, 2002, J AM SOC NEPHROL, V13, P1918, DOI 10.1097/01.ASN.0000019641.41496.1E
   MACCARTHY EP, 1989, HYPERTENSION, V13, P954, DOI 10.1161/01.HYP.13.6.954
   Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523 1755.2003.00838.x
   Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471 4914(02)02294 3
   MCGONIGLE RJS, 1984, NEPHRON, V36, P94, DOI 10.1159/000183125
   MILLINER DS, 1990, KIDNEY INT, V38, P931, DOI 10.1038/ki.1990.293
   OConnell TD, 1997, AM J PHYSIOL HEART C, V272, pH1751
   OConnell TD, 1996, CELL BIOL INT, V20, P621, DOI 10.1006/cbir.1996.0081
   Park CW, 1999, AM J KIDNEY DIS, V33, P73, DOI 10.1016/S0272 6386(99)70260 X
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Pfeifer M, 2001, J CLIN ENDOCR METAB, V86, P1633, DOI 10.1210/jc.86.4.1633
   RESNICK LM, 1986, ANN INTERN MED, V105, P649, DOI 10.7326/0003 4819 105 5 649
   Samak MJ, 2002, CLIN NEPHROL, V57, P327
   SANDGREN ME, 1991, BIOCHEM BIOPH RES CO, V181, P611, DOI 10.1016/0006 291X(91)91234 4
   Schwarz U, 2000, NEPHROL DIAL TRANSPL, V15, P218, DOI 10.1093/ndt/15.2.218
   Shlipak MG, 2002, KIDNEY INT, V62, P997, DOI 10.1046/j.1523 1755.2002.00522.x
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F
   Szmitko PE, 2003, CIRCULATION, V108, P2041, DOI 10.1161/01.CIR.0000089093.75585.98
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   TENTORI F, 2003, AM SOC NEPHR M
   TIAN J, 2004, NATL KIDNEY FDN  APR
   Timms PM, 2002, QJM INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   WEISHAAR RE, 1989, ENDOCR REV, V10, P351, DOI 10.1210/edrv 10 3 351
   WEISHAAR RE, 1990, AM J PHYSIOL, V258, pE134, DOI 10.1152/ajpendo.1990.258.1.E134
   Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582
   Xiang W, 2005, AM J PHYSIOL ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004
   Xing NZ, 2002, BIOCHEM BIOPH RES CO, V297, P645, DOI 10.1016/S0006 291X(02)02262 3
   Zittermann A, 2003, J AM COLL CARDIOL, V41, P105, DOI 10.1016/S0735 1097(02)02624 4
NR 62
TC 146
Z9 164
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD NOV
PY 2005
VL 68
IS 5
BP 1973
EP 1981
DI 10.1111/j.1523 1755.2005.00651.x
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 971MQ
UT WOS:000232388800033
PM 16221197
OA Bronze
DA 2025 08 17
ER

PT J
AU Gadzhanova, S
   Ilomäki, J
   Roughead, EE
AF Gadzhanova, Svetla
   Ilomaeki, Jenni
   Roughead, Elizabeth E.
TI COX 2 Inhibitor and Non Selective NSAID Use in Those at Increased Risk
   of NSAID Related Adverse Events
SO DRUGS & AGING
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE MYOCARDIAL INFARCTION;
   RHEUMATOID ARTHRITIS; CARDIOVASCULAR RISK; GASTROINTESTINAL TOXICITY;
   CLINICAL TRIAL; CELECOXIB; OSTEOARTHRITIS; ROFECOXIB; OLDER
AB Background Adverse events related to analgesic use represent a challenge for optimizing treatment of pain in older people.
   Objective The aim of this study was to determine whether non selective non steroidal anti inflammatory drug (NS NSAID) and cyclo oxygenase (COX) 2 inhibitor use is appropriately targeted in those with a prior history of gastrointestinal (GI) events, myocardial infarction (MI) or stroke.
   Methods A retrospective study of pharmacy claims data from the Australian Government Department of Veterans' Affairs was conducted, involving 288,912 veterans aged 55 years and over. Analgesic utilization from 2007 to 2009 was assessed. Three risk cohorts (veterans with prior hospitalization for GI bleed, MI or stroke) and a low risk cohort were identified. Poisson regression was applied to test for a linear trend over the study period.
   Results The prevalence of analgesics dispensed in the overall study population was approximately 34 % between 2007 and 2009. COX 2 inhibitors were more widely dispensed than NS NSAIDs in all those at risk of NSAID related adverse events. At the end of 2009, the ratio was 5.1 % to 2.5 % in the GI cohort, 3.6 % to 3.2 % in the MI cohort and 3.6 % to 2.6 % in the stroke cohort.
   Conclusions Although COX 2 inhibitors appeared to be preferred over NS NSAIDs in those with a prior history of GI events, 2.5 % of patients were still using an NS NSAID at the end of the study period. Consistent with treatment guidelines, in most of these cases, these drugs were co dispensed with proton pump inhibitors. COX 2 inhibitors were used at slightly higher rates than NS NSAIDs in those with a prior history of MI or stroke, which is not consistent with guidelines recommending NS NSAID use.
C1 [Gadzhanova, Svetla; Ilomaeki, Jenni; Roughead, Elizabeth E.] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Qual Use Med & Pharm Res Ctr, Adelaide, SA 5001, Australia.
C3 University of South Australia
RP Ilomäki, J (通讯作者)，Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Qual Use Med & Pharm Res Ctr, GPO Box 2471, Adelaide, SA 5001, Australia.
EM jenni.ilomaki@unisa.edu.au
RI Roughead, Libby/G 4431 2010; Roughead, Elizabeth/G 4431 2010; Ilomaki,
   Jenni/E 7213 2011; Gadzhanova, Svetla/A 3625 2011
OI Roughead, Libby/0000 0002 6811 8991; Gadzhanova,
   Svetla/0000 0002 7493 7387; Ilomaki, Jenni/0000 0002 0348 9441
FU NPS Better choices Better health; Australian Government Department of
   Veterans' Affairs
FX Svetla Gadzhanova and Elizabeth E. Roughead were responsible for study
   design. Svetla Gadzhanova, Jenni Ilomaki and Elizabeth E. Roughead were
   responsible for the analyses, interpretation of the results and
   preparation of the manuscript. This study was funded by NPS Better
   choices Better health. The authors wish to thank Mark Bartlett from NPS
   for his comments on the manuscript. We acknowledge the support of the
   Australian Government Department of Veterans' Affairs, which provided
   data for the conduct of these analyses. The authors have no conflicts of
   interest.
CR Analgesic Expert Group, 2007, THERAPEUTIC GUIDELIN
   Andersohn F, 2006, CIRCULATION, V113, P1950, DOI 10.1161/CIRCULATIONAHA.105.602425
   [Anonymous], 2010, Therapeutic Guidelines, 3 edn
   Australian Bureau of Statistics, 2010, NATIONAL HEALTH SURV
   Australian Bureau of Statistics, 2010, CONTRACT NO ABS CAT
   Australian Government Department of Human Services, 2011, PHARMACEUTICAL BENEF
   Australian Government Department of Veterans' Affairs, 2011, TREATMENT POPULATION
   Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430 000000000 00000
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   Donnelly N, 2000, AUST NZ J PUBL HEAL, V24, P603, DOI 10.1111/j.1467 842X.2000.tb00524.x
   European Medicines Agency, 2005, SCIENTIFIC CONCLUSIO
   Food and Drug Administration, 2005, COX 2 SELECTIVE INCL
   Fosbol EL, 2008, PHARMACOEPIDEM DR S, V17, P822, DOI 10.1002/pds.1592
   Gastroenterological Society of Australia Digestive Health Foundation, 2009, NSAIDS AND THE GASTR
   Hernández Díaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093
   Hernández Díaz S, 2006, BASIC CLIN PHARMACOL, V98, P266, DOI 10.1111/j.1742 7843.2006.pto_302.x
   Hudec R, 2012, J CLIN PHARM THER, V37, P78, DOI 10.1111/j.1365 2710.2011.01256.x
   Lloyd J, 2008, VETERANS USE OF HEAL
   McGettigan P, 2006, JAMA J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011
   Moore RA, 2005, ARTHRITIS RES THER, V7, pR644, DOI 10.1186/ar1704
   Morgan TK, 2012, MED J AUSTRALIA, V196, P50, DOI 10.5694/mja11.10698
   Motsko SP, 2006, DRUG SAFETY, V29, P621, DOI 10.2165/00002018 200629070 00007
   National Centre for Classification in Health, 2005, THE INTERNATIONAL ST
   National Prescribing Service Limited, 2006, REPORT NO 35
   Ray WA, 2009, CIRC CARDIOVASC QUAL, V2, P155, DOI 10.1161/CIRCOUTCOMES.108.805689
   Reville B, 2009, PRIMARY CARE, V36, P781, DOI 10.1016/j.pop.2009.07.010
   Rheumatology Expert Group, 2006, THERAPEUTIC GUIDELIN
   Roughead EE, 2008, DRUG SAFETY, V31, P997, DOI 10.2165/00002018 200831110 00004
   Schnitzer TJ, 2006, CLIN RHEUMATOL, V25, pS22, DOI 10.1007/s10067 006 0203 8
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   The Royal Australian College of General Practitioners, 2009, GUIDELINE FOR THE NO
   Therapeutic Goods Administration Department of Health and Ageing, 2005, REGULATOR TAKES TOUG
   Therapeutic Goods Administration Department of Health and Ageing, 2005, EXPANDED INFORMATION
   Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03 0645rev
   WHO Collaborating Centre for Drug Statistics Methodology, 2012, THE ANATOMICAL THERA
NR 37
TC 8
Z9 8
U1 0
U2 10
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1170 229X
J9 DRUG AGING
JI Drugs Aging
PY 2013
VL 30
IS 1
BP 23
EP 30
DI 10.1007/s40266 012 0037 9
PG 8
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 138TN
UT WOS:000318533000003
PM 23179898
DA 2025 08 17
ER

PT J
AU Laginha, RC
   Silva, JD
   Cinque, G
   de Carvalho, LAEB
   de Carvalho, ALMB
AF Laginha, Raquel C.
   Silva, Jessica D.
   Cinque, Gianfelice
   de Carvalho, Luis A. E. Batista
   de Carvalho, Ana L. M. Batista
TI Vibrational microspectroscopy as a tool to unveil new chemotherapeutic
   strategies against osteosarcoma
SO SPECTROCHIMICA ACTA PART A MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
LA English
DT Article
DE Osteosarcoma; Cisplatin; EURAMOS 1; Raman microspectroscopy; FTIR
   microspectroscopy
ID RAMAN SPECTROSCOPY; ANTICANCER DRUGS; DNA BINDING; CANCER; COMPLEXES;
   PLATINUM; SPERMINE; PATHWAY; CELLS; SALT
AB Over the years, osteosarcoma therapy has had a significative improvement with the use of a multidrug regime strategy, increasing the survival rates from less than 20 % to circa 70 %. Different types of development of new antineoplastic agents are critical to achieve irreversible damage to cancer cells, while preserving the integrity of their healthy counterparts. In the present study, complexes with two and three Pd(II) centres linked by the biogenic polyamines: spermine (Pd2SpmCl4) and spermidine (Pd3Spd2Cl6) were tested against non malignant (osteoblasts, HOb) and cancer (osteosarcoma, MG 63) human cell lines. Either alone or in combination according to the EURAMOS 1 protocol, they were used versus cisplatin as a drug reference. By evaluating the cytotoxic effects of both therapeutic approaches (single and drug combination) in HOb and MG 63 cell lines, the selective anti tumoral potential is assessed. To understand the different treatments at a molecular level, Synchrotron Radiation Fourier Transform Infrared and Raman microspectroscopies were applied. Principal component analysis and hierarchical cluster analysis are applied to the vibrational data, revealing the major metabolic changes caused by each drug, which were found to rely on DNA, lipids, and proteins, acting as biomarkers of drug to cell impact. The main changes were observed for the B DNA native conformation to either ZDNA (higher in the presence of polynuclear complexes) or A DNA (preferably after cisplatin exposure). Additionally, a higher effect upon variation in proteins content was detected in drug combination when compared to single drug administration proving the efficacy of the EURAMOS 1 protocol with the new drugs tested.
C1 [Laginha, Raquel C.; de Carvalho, Luis A. E. Batista; de Carvalho, Ana L. M. Batista] Univ Coimbra, Dept Chem, Mol Phys Chem R&D Unit, P 3004535 Coimbra, Portugal.
   [Silva, Jessica D.; Cinque, Gianfelice] Diamond Light Source, Harwell Sci & Innovat Campus, Didcot OX11 0DE, Oxon, England.
C3 Universidade de Coimbra; Diamond Light Source
RP de Carvalho, LAEB (通讯作者)，Rua Larga, P 3004535 Coimbra, Portugal.
EM labc@ci.uc.pt
RI Batista de Carvalho, Ana/A 2929 2014; Batista de Carvalho,
   Luis/B 5842 2009; Esteves Batista de Carvalho, Luis Alberto/B 5842 2009;
   Laginha, Raquel/JZE 5004 2024
OI Esteves Batista de Carvalho, Luis Alberto/0000 0002 8059 8537; Domingues
   Silva, Jessica/0000 0003 0737 6302; 
FU Portuguese Foundation for Science and Technology (FCT) [SM32861 1]
FX This work was developed within the Molecular Physical Chemistry R&D Unit
   (https://doi.org/10.54499/UIDB/00070/2020 & https://doi
   .org/10.54499/UIDP/00070/2020) and the A.L.M.B.C. employment contract
   (https://doi.org/10.54499/CEECIND/00069/2017/CP1460/CT0029) financed by
   the Portuguese Foundation for Science and Technology (FCT) . Diamond
   Light Source is thanked for access to the IR beamline (SM32861 1)
   through the dedicated call for beamtime at B22/MIRIAM.
CR Baker MJ, 2014, NAT PROTOC, V9, P1771, DOI 10.1038/nprot.2014.110
   de Carvalho ALMB, 2016, FARADAY DISCUSS, V187, P273, DOI 10.1039/c5fd00148j
   de Carvalho ALMB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167218
   Bellisola G, 2013, ANALYST, V138, P3934, DOI 10.1039/c2an36393c
   Bellisola G, 2010, ANALYST, V135, P3077, DOI 10.1039/c0an00509f
   BENEVIDES JM, 1983, NUCLEIC ACIDS RES, V11, P5747, DOI 10.1093/nar/11.16.5747
   Carneiro TJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.590970
   De Gelder J, 2007, J RAMAN SPECTROSC, V38, P1133, DOI 10.1002/jrs.1734
   Farhane Z, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700060
   Farhane Z, 2017, ANAL BIOANAL CHEM, V409, P1333, DOI 10.1007/s00216 016 0065 0
   Farrell NP, 2011, CURR TOP MED CHEM, V11, P2623, DOI 10.2174/156802611798040714
   Ferguson JL, 2018, AM FAM PHYSICIAN, V98, P205
   Fiuza SM, 2006, LETT DRUG DES DISCOV, V3, P149, DOI 10.2174/157018006776286989
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Friedman B, 2019, JOINT BONE SPINE, V86, P301, DOI 10.1016/j.jbspin.2018.07.004
   Gazi E, 2005, BIOPOLYMERS, V77, P18, DOI 10.1002/bip.20167
   Gilad Y, 2021, CANCERS, V13, DOI 10.3390/cancers13040669
   Hu ZG, 2022, CELLS BASEL, V11, DOI 10.3390/cells11213507
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Ivanov AV, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12010014
   Keil Lukas, 2020, FP Essent, V493, P22
   Laginha RC, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24031888
   Lasalvia M, 2022, INFRARED PHYS TECHN, V120, DOI 10.1016/j.infrared.2021.103976
   Lasalvia M, 2021, SENSORS BASEL, V21, DOI 10.3390/s21216992
   Malyutina A, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006752
   Marques M. P. M., 2013, ISRN Spectroscopy, DOI 10.1155/2013/287353
   Martins AS, 2020, CHEMISTRYSELECT, V5, P5993, DOI 10.1002/slct.202001361
   Matos CS, 2012, CURR MED CHEM, V19, P4678
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   NAVARRORANNINGER C, 1993, J INORG BIOCHEM, V52, P37, DOI 10.1016/0162 0134(93)85621 E
   NAVARRORANNINGER C, 1992, J INORG BIOCHEM, V46, P267, DOI 10.1016/0162 0134(92)80037 V
   Nawaz H, 2011, ANALYST, V136, P2450, DOI 10.1039/c1an15104e
   Nawaz H, 2010, ANALYST, V135, P3070, DOI 10.1039/c0an00541j
   Notarstefano V, 2023, ANALYST, V148, P4365, DOI 10.1039/d3an01182h
   Notarstefano V, 2022, SPECTROCHIM ACTA A, V269, DOI 10.1016/j.saa.2021.120735
   Notingher I, 2007, SENSORS BASEL, V7, P1343, DOI 10.3390/s7081343
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Perut F, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050778
   Pilavaki P, 2023, J CLIN MED, V12, DOI 10.3390/jcm12082785
   Santos IP, 2022, CANCERS, V14, DOI 10.3390/cancers14020452
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Silva JD, 2023, MOLECULES, V28, DOI 10.3390/molecules28041698
   Sun W, 2016, DRUG DISCOV TODAY, V21, P1189, DOI 10.1016/j.drudis.2016.05.015
   Taymaz Nikerel H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31939 9
   Toplak M., 2017, Synchrotron Radiation News, V30, P40, DOI 10.1080/08940886.2017.1338424
   Toplak M, 2021, CELLS BASEL, V10, DOI 10.3390/cells10092300
   Torres M, 2018, J PHYS CHEM A, V122, P6934, DOI 10.1021/acs.jpca.8b04023
   Tummala R, 2010, ONCOL REP, V24, P15, DOI 10.3892/or_00000823
   Vojtek M, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15041205
   Vrána O, 2007, J STRUCT BIOL, V159, P1, DOI 10.1016/j.jsb.2007.01.008
   Wang HF, 2022, J PHOTOCH PHOTOBIO B, V226, DOI 10.1016/j.jphotobiol.2021.112366
   Whelan JS, 2015, ANN ONCOL, V26, P407, DOI 10.1093/annonc/mdu526
   Yang JC, 2014, LUNG CANCER, V85, P110, DOI 10.1016/j.lungcan.2014.05.011
   Yu DP, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015582
NR 54
TC 4
Z9 4
U1 1
U2 2
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1386 1425
EI 1873 3557
J9 SPECTROCHIM ACTA A
JI Spectroc. Acta Pt. A Molec. Biomolec. Spectr.
PD SEP 5
PY 2024
VL 317
AR 124389
DI 10.1016/j.saa.2024.124389
EA MAY 2024
PG 15
WC Spectroscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Spectroscopy
GA L2J7R
UT WOS:001349041600001
PM 38710137
OA hybrid
DA 2025 08 17
ER

PT J
AU Bodiga, VL
   Eda, SR
   Chavali, S
   Revur, NN
   Zhang, A
   Thokala, S
   Bodiga, S
AF Bodiga, Vijaya Lakshmi
   Eda, Sasidhar Reddy
   Chavali, Saishashank
   Revur, Nagasaisreelekha Nagavalli
   Zhang, Anita
   Thokala, Sandhya
   Bodiga, Sreedhar
TI In vitro biological evaluation of glyburide as potential inhibitor of
   collagenases
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Collagenases; Glyburide; Zymography
ID RHEUMATOID SYNOVIAL FIBROBLASTS; MATRIX METALLOPROTEINASES; EXPRESSION;
   CLONING; SULFONYLUREAS; HOMOLOGY; GENE
AB In tissues with upregulated MMP activity, MMP inhibition remains one of the key strategies. Potential inhibitors of MMPs have been tested for almost 30 years, but none have reached clinical utility due to bioavailability issues and adverse effects. This study utilized the approach of drug repurposing for exploring glyburide as a potential inhibitor against collagenases. In silico molecular docking studies were carried out to probe the interactions of glyburide with the active site Zn. Collagenase enzyme activity measurements and zymography analyses using conditioned medium from lung fibroblasts, rheumatoid synovial fibroblasts, and osteoblasts were carried out to confirm the inhibitory activity. Glyburide binds and interacts with the catalytic Zn residues of the collagenases, as evidenced by in silico molecular docking studies. Fluorescence enzyme activity measurements reveal that glyburide inhibits peptide substrate cleavage by all three collagenases in a dose dependent manner. Collagen zymography studies validated inhibition of these collagenases by glyburide. These results identify glyburide as a potential inhibitor of collagenases and provide an insight into the mechanism of action of this small molecule. Thus, glyburide may offer additional advantages in diabetics, in controlling MMP activation and collagen degradation and could aid in the treatment of diseases with aberrant MMP activity. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Bodiga, Vijaya Lakshmi] Osmania Univ, Inst Genet, Dept Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Bodiga, Vijaya Lakshmi] Osmania Univ, Hosp Genet Dis, Hyderabad 500007, Andhra Pradesh, India.
   [Eda, Sasidhar Reddy; Chavali, Saishashank; Revur, Nagasaisreelekha Nagavalli] KL Univ, Dept Biotechnol, Green Fields, Vaddeswaram, Andhra Pradesh, India.
   [Zhang, Anita] Med Coll Wisconsin, Dept Med, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA.
   [Thokala, Sandhya; Bodiga, Sreedhar] Kakatiya Univ, Dept Biochem, Warangal 506009, Andhra Pradesh, India.
C3 Osmania University; Osmania University; Koneru Lakshmaiah Education
   Foundation (K L Deemed to be University); Medical College of Wisconsin;
   Kakatiya University
RP Bodiga, S (通讯作者)，Kakatiya Univ, Dept Biochem, Warangal 506009, Andhra Pradesh, India.
EM sbodiga@gmail.com
RI bodiga, sreedhar/B 4991 2009; Bodiga, Vijaya/K 6967 2013
OI Chavali, Sai Shashank/0000 0002 3467 2257; Bodiga,
   Vijaya/0000 0003 3374 8026
CR AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547
   Chiu YC, 2008, J CELL PHYSIOL, V215, P356, DOI 10.1002/jcp.21322
   Cuniasse P, 2005, BIOCHIMIE, V87, P393, DOI 10.1016/j.biochi.2004.09.025
   FREIJE JMP, 1994, J BIOL CHEM, V269, P16766
   GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600
   Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504
   Harrower ADB, 2000, DRUG SAFETY, V22, P313, DOI 10.2165/00002018 200022040 00004
   HASTY KA, 1987, J BIOL CHEM, V262, P10048
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Park HI, 2003, J BIOL CHEM, V278, P51646, DOI 10.1074/jbc.M310109200
   Rao BG, 2005, CURR PHARM DESIGN, V11, P295, DOI 10.2174/1381612053382115
   Riddle MC, 2003, J CLIN ENDOCR METAB, V88, P528, DOI 10.1210/jc.2002 021971
   Shlopov B.V., 2005, ARTHRITIS RHEUM, V40, P2065
   Spurlino J.C., 2004, PROTEIN STRUCT FUNCT, P98
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Tetlow LC, 2001, ARTHRITIS RHEUM US, V44, P585, DOI 10.1002/1529 0131(200103)44:3<585::AID ANR107>3.3.CO;2 3
   UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480
   Vincenti MP, 1998, BIOCHEM J, V331, P341, DOI 10.1042/bj3310341
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Yamamoto T, 2000, J IMMUNOL, V164, P6174, DOI 10.4049/jimmunol.164.12.6174
NR 22
TC 5
Z9 8
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD SEP
PY 2014
VL 70
BP 187
EP 192
DI 10.1016/j.ijbiomac.2014.06.054
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AQ0NA
UT WOS:000342478800026
PM 25008133
DA 2025 08 17
ER

PT J
AU Matteucci, E
   Maroni, P
   Nicassio, F
   Ghini, F
   Bendinelli, P
   Desiderio, MA
AF Matteucci, Emanuela
   Maroni, Paola
   Nicassio, Francesco
   Ghini, Francesco
   Bendinelli, Paola
   Desiderio, Maria Alfonsina
TI 被撤回的出版物: Microenvironment Stimuli HGF and Hypoxia Differently Affected
   miR 125b and Ets 1 Function with Opposite Effects on the Invasiveness of
   Bone Metastatic Cells: A Comparison with Breast Carcinoma Cells
   (Retracted article. See vol. 21, 2020)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article; Retracted Publication
DE Ets 1; HGF; HIF 1; hypoxia; miR 125b; Endothelin 1; bone metastatic
   cells
ID INDUCIBLE FACTOR I; MESENCHYMAL EPITHELIAL TRANSITION; TRANSCRIPTION
   FACTORS; CANCER METASTASIS; DNA METHYLATION; EXPRESSION; BINDING; WWOX;
   REGULATORS; MICRORNAS
AB We examined the influence of microenvironment stimuli on molecular events relevant to the biological functions of 1833 bone metastatic clone and the parental MDA MB231 cells. (i) In both the cell lines, hepatocyte growth factor (HGF) and the osteoblasts' biological products down regulated nuclear Ets 1 protein level in concomitance with endogenous miR 125b accumulation. In contrast, under hypoxia nuclear Ets 1 was unchanged, notwithstanding the miR 125b increase. (ii) Also, the 1833 cell invasiveness and the expression of Endothelin 1, the target gene of Ets 1/HIF 1, showed opposite patterns under HGF and hypoxia. We clarified the molecular mechanism(s) reproducing the high miR 125b levels with the mimic in 1833 cells. Under hypoxia, the miR 125b mimic maintained a basal level and functional Ets 1 protein, as testified by the elevated cell invasiveness. However, under HGF ectopic miR 125b downregulated Ets 1 protein and cell motility, likely involving an Ets 1 dominant negative form sensible to serum conditions; Ets 1 activity inhibition by HGF implicated HIF 1 accumulation, which drugged Ets 1 in the complex bound to the Endothelin 1 promoter. Altogether, 1833 cell exposure to HGF would decrease Endothelin 1 transactivation and protein expression, with the possible impairment of Endothelin 1 dependent induction of E cadherin, and the reversion towards an invasive phenotype: this was favoured by Ets 1 overexpression, which inhibited HIF 1 expression and HIF 1 activity. (iii) In MDA MB231 cells, HGF strongly and rapidly decreased Ets 1, hampering invasiveness and reducing Ets 1 binding to Endothelin 1 promoter; HIF 1 did not form a complex with Ets 1 and Endothelin 1 luciferase activity was unchanged. Overall, depending on the microenvironment conditions and endogenous miR 125b levels, bone metastatic cells might switch from Ets 1 dependent motility towards colonization/growth, regulated by the balance between Ets 1 and HIF 1.
C1 [Matteucci, Emanuela; Bendinelli, Paola; Desiderio, Maria Alfonsina] Univ Milan, Mol Pathol Lab, Dipartimento Sci Biomed Salute, I 20133 Milan, Italy.
   [Maroni, Paola] Sci Inst Res Hospitalizat & Hlth Care IRCCS, Ist Ortoped Galeazzi, I 20161 Milan, Italy.
   [Nicassio, Francesco; Ghini, Francesco] IIT, Ctr Genom Sci IIT SEMM, I 20139 Milan, Italy.
C3 University of Milan; IRCCS Istituto Ortopedico Galeazzi; Istituto
   Italiano di Tecnologia   IIT; Center for Genomic Science IIT
RP Desiderio, MA (通讯作者)，Univ Milan, Mol Pathol Lab, Dipartimento Sci Biomed Salute, I 20133 Milan, Italy.
EM emanuela.matteucci@unimi.it; paola.maroni@grupposandonato.it;
   francesco.nicassio@iit.it; francesco.ghini@iit.it;
   paola.maroni@grupposandonato.it; a.desiderio@unimi.it
RI Maroni, Paola/B 1366 2017; Desiderio, Maria/M 8870 2016
OI Maroni, Paola/0000 0002 3444 9338; nicassio,
   francesco/0000 0002 5954 5318; Ghini, Francesco/0000 0002 6746 4542
FU Ministero della Salute [L4077, L4084, L4101]; Associazione Italiana per
   la Ricerca sul Cancro (AIRC) [IG14085, IG18774]; Cariplo [2015 0590]
FX This work was supported by grants from the Ministero della Salute
   (Ricerca Corrente L4077, L4084 and L4101 to Paola Maroni) and from the
   Associazione Italiana per la Ricerca sul Cancro (AIRC, IG14085 and
   IG18774 to Francesco Nicassio), Cariplo (2015 0590 to Francesco
   Nicassio).
CR Al Rifai O, 2017, J CLIN INVEST, V127, P4104, DOI 10.1172/JCI93437
   Bendinelli P., 2016, INT J MOL SCI, V17, DOI [10. 3390/ijms17050706 27187355, DOI 10.3390/IJMS1705070627187355]
   Bendinelli P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.403
   Bendinelli P, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0389 y
   Bendinelli P, 2014, BBA MOL CELL RES, V1843, P815, DOI 10.1016/j.bbamcr.2013.12.015
   Bendinelli P, 2013, EUR J CANCER, V49, P2608, DOI 10.1016/j.ejca.2013.03.002
   Bill R, 2015, FEBS LETT, V589, P1577, DOI 10.1016/j.febslet.2015.05.002
   Biswas S, 2017, PHARMACOL THERAPEUT, V173, P118, DOI 10.1016/j.pharmthera.2017.02.011
   Chen H. T., 2012, PLOS ONE, V7, DOI [10. 1371/journal. pone. 0038378 22675553, DOI 10.1371/JOURNAL.PONE.003837822675553]
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   DALLAS SL, 1994, J BIOL CHEM, V269, P6815
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968 0004(98)01344 9
   Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010
   Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476 4598 2 29
   Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583
   Furlan A, 2014, INT J CANCER, V135, P2317, DOI 10.1002/ijc.28881
   GEGONNE A, 1992, NEW BIOL, V4, P512
   Gilkes DM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101669
   Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555 012 9377 5
   Hoppe T., 2017, MOL ORAL MICROBIOL, DOI [10. 1111/omi. 12203 28992390, DOI 10.1111/OMI.1220328992390]
   Kanamori Y, 2014, GENE, V551, P119, DOI 10.1016/j.gene.2014.08.037
   KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542
   Laitem C, 2009, ONCOGENE, V28, P2087, DOI 10.1038/onc.2009.72
   Li C, 2017, ONCOTARGET, V8, P12433, DOI 10.18632/oncotarget.14015
   Maroni P, 2017, CARCINOGENESIS, V38, P492, DOI 10.1093/carcin/bgx027
   Maroni P, 2015, INT J MOL SCI, V16, P28108, DOI 10.3390/ijms161225997
   Maroni P, 2015, EXP CELL RES, V330, P287, DOI 10.1016/j.yexcr.2014.10.004
   Maroni P, 2011, BREAST CANCER RES TR, V129, P433, DOI 10.1007/s10549 010 1240 1
   Matteucci E, 2013, EUR J CANCER, V49, P231, DOI 10.1016/j.ejca.2012.05.006
   Mo A, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160273
   Nanduri J, 2017, AM J PHYSIOL LUNG C, V313, pL1096, DOI 10.1152/ajplung.00325.2017
   Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349 7006.2004.tb03320.x
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Prieto García E, 2017, MED ONCOL, V34, DOI 10.1007/s12032 017 0980 8
   Pronina IV, 2017, GENE, V604, P1, DOI 10.1016/j.gene.2016.12.018
   Ridolfi E, 2008, BRIT J CANCER, V99, P1623, DOI 10.1038/sj.bjc.6604726
   Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016
   Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363
   Vallet S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150507
   van der Groep P, 2008, BREAST CANCER RES TR, V111, P475, DOI 10.1007/s10549 007 9817 z
   Xie Y, 2017, J CELL MOL MED, V21, P1033, DOI 10.1111/jcmm.13039
   Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200
   Yin H, 2015, EXP CELL RES, V339, P252, DOI 10.1016/j.yexcr.2015.09.015
   Zhang X, 2017, INT J ONCOL, V50, P232, DOI 10.3892/ijo.2016.3770
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008 5472.CAN 10 2435
   Zhou Y., 2017, J TISSUE ENG REGEN M, DOI [10. 1002/term. 2327 27696713, DOI 10.1002/TERM.232727696713]
NR 47
TC 5
Z9 6
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2018
VL 19
IS 1
AR 258
DI 10.3390/ijms19010258
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FV2OI
UT WOS:000424407200252
PM 29337876
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Rahman, SU
   Ponnusamy, S
   Nagrath, M
   Arany, PR
AF Rahman, Saeed Ur
   Ponnusamy, Sasikumar
   Nagrath, Malvika
   Arany, Praveen R.
TI Precision engineered niche for directed differentiation of MSCs to
   lineage restricted mineralized tissues
SO JOURNAL OF TISSUE ENGINEERING
LA English
DT Article
DE Stem cells; electrospinning; nanofiber scaffolds; dentin; bone; TGF beta
   1; BMP 4
ID ALBUMIN BASED NANOPARTICLES; DENTAL PULP; STEM CELLS; GROWTH FACTORS;
   VASCULARIZATION STRATEGIES; NANOFIBROUS SCAFFOLDS; DRUG DELIVERY;
   EXPRESSION; REGENERATION; TGF BETA 1
AB The major difference between tissue healing and regeneration is the extent of instructional cues available to precisely direct the biological response. A classic example is reparative or osteodentin that is seen in response to physicochemical injury to the pulp dentin complex. Dentin regeneration can direct the differentiation of dental stem cells using concerted actions of both soluble (biomolecules, agonists, and antagonists) and insoluble (matrix topology) cues. The major purpose of this study was to examine the synergistic combination of two discrete biomaterial approaches by utilizing nanofiber scaffolds in discrete configurations (aligned or random) with incorporated polymeric microspheres capable of controlled release of growth factors. Further, to ensure appropriate disinfection for clinical use, Radio Frequency Glow Discharge (RFGD) treatments were utilized, followed by seeding with a mesenchymal stem cell (MSC) line. SEM analysis revealed electrospinning generated controlled architectural features that significantly improved MSC adhesion and proliferation on the aligned nanofiber scaffolds compared to randomly oriented scaffolds. These responses were further enhanced by RFGD pre treatments. These enhanced cell adhesion and proliferative responses could be attributed to matrix induced Wnt signaling that was abrogated by pre treatments with anti Wnt3a neutralizing antibodies. Next, we incorporated controlled release microspheres within these electrospun scaffolds with either TGF beta 1 or BMP4. We observed that these scaffolds could selectively induce dentinogenic or osteogenic markers (DSPP, Runx2, and BSP) and mineralization. This work demonstrates the utility of a novel, modular combinatorial scaffold system capable of lineage restricted differentiation into bone or dentin. Future validation of this scaffold system in vivo as a pulp capping agent represents an innovative dentin regenerative approach capable of preserving tooth pulp vitality.
C1 [Rahman, Saeed Ur; Ponnusamy, Sasikumar; Nagrath, Malvika; Arany, Praveen R.] SUNY Buffalo, Oral Biol Surg & Biomed Engn, B36A Foster Hall,3435 Main St, Buffalo, NY 14214 USA.
   [Rahman, Saeed Ur] Khyber Med Univ, Inst Basic Med Sci, Oral Biol, Peshawar, Pakistan.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   Khyber Medical University
RP Arany, PR (通讯作者)，SUNY Buffalo, Oral Biol Surg & Biomed Engn, B36A Foster Hall,3435 Main St, Buffalo, NY 14214 USA.
EM prarany@buffalo.edu
RI Nagrath, Malvika/HTS 7287 2023; Arany, Praveen/S 5329 2019; Rahman,
   Saeed Ur/H 1957 2018; Perumal, Sasikumar/F 7434 2017
OI Nagrath, Malvika/0000 0002 3757 8792; Rahman, Saeed
   Ur/0000 0003 2234 2274; Arany, Praveen/0000 0002 6116 2340; 
FU University at Buffalo
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   authors wish to acknowledge the financial support (PRA) faculty startup
   funds from University at Buffalo. We thank Dr. Yueling Qin, BioDesign
   Core Facility, University at Buffalo, for help with SEM FIB EDS
   analysis.
CR Aoki Koji, 2008, V468, P307, DOI 10.1007/978 1 59745 249 6_24
   Arany PR, 2014, J DENT RES, V93, P1250, DOI 10.1177/0022034514542272
   Arany PR, 2011, ORAL DIS, V17, P241, DOI 10.1111/j.1601 0825.2010.01735.x
   Arany PR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008234
   Ardeshirylajimi A, 2013, CELL TISSUE RES, V354, P849, DOI 10.1007/s00441 013 1693 8
   Badylak SE, 2002, SEMIN CELL DEV BIOL, V13, P377, DOI 10.1016/S1084952102000940
   Barnes CP, 2007, ADV DRUG DELIVER REV, V59, P1413, DOI 10.1016/j.addr.2007.04.022
   Bertoncelj V, 2014, EUR J PHARM BIOPHARM, V88, P64, DOI 10.1016/j.ejpb.2014.06.001
   Biondi M, 2008, ADV DRUG DELIVER REV, V60, P229, DOI 10.1016/j.addr.2007.08.038
   Chen LF, 2021, BIOENGINEERED, V12, P8031, DOI 10.1080/21655979.2021.1982270
   Cheng G, 2018, INT J PHARMACEUT, V547, P656, DOI 10.1016/j.ijpharm.2018.06.020
   Chiang YC, 2016, DENT MATER, V32, P1197, DOI 10.1016/j.dental.2016.06.013
   D'Souza RN, 1998, EUR J ORAL SCI, V106, P185, DOI 10.1111/j.1600 0722.1998.tb02174.x
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Dobie K, 2002, CONNECT TISSUE RES, V43, P387, DOI 10.1080/03008200290000574
   Elzoghby AO, 2012, J CONTROL RELEASE, V157, P168, DOI 10.1016/j.jconrel.2011.07.031
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gu BK, 2018, J BIOMAT SCI POLYM E, V29, P1053, DOI 10.1080/09205063.2017.1364097
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Gullard A, 2016, J CELL PHYSIOL, V231, P1106, DOI 10.1002/jcp.25207
   Hendrickx B, 2011, TISSUE ENG PART B RE, V17, P13, DOI [10.1089/ten.teb.2010.0315, 10.1089/ten.TEB.2010.0315]
   Hilton TJ, 2013, J DENT RES, V92, pS16, DOI 10.1177/0022034513484336
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Huang GX, 2015, TISSUE ENG PT A, V21, P2228, DOI [10.1089/ten.tea.2015.0089, 10.1089/ten.TEA.2015.0089]
   Hunter DJ, 2015, J BONE MINER RES, V30, P1150, DOI 10.1002/jbmr.2444
   Jin LJ, 2016, ORAL DIS, V22, P609, DOI 10.1111/odi.12428
   Kim JI., 2016, SCI REP UK, V6, P2376
   Kim TH, 2015, BIOCHEM BIOPH RES CO, V459, P706, DOI 10.1016/j.bbrc.2015.03.014
   Kiselev P, 2012, J APPL POLYM SCI, V125, P2433, DOI 10.1002/app.36519
   Kuppan P, 2015, J BIOMED MATER RES A, V103, P2236, DOI 10.1002/jbm.a.35360
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   Leach MK, 2011, JOVE J VIS EXP, DOI 10.3791/2494
   Li WJ, 2002, J BIOMED MATER RES, V60, P613, DOI 10.1002/jbm.10167
   Lin ZF, 2017, J MATER CHEM B, V5, P1015, DOI 10.1039/c6tb02156e
   Lovett M, 2009, TISSUE ENG PART B RE, V15, P353, DOI [10.1089/ten.teb.2009.0085, 10.1089/ten.TEB.2009.0085]
   Ma PX, 2004, MATER TODAY, V7, P30, DOI 10.1016/S1369 7021(04)00233 0
   Martelli G, 2020, BIOMACROMOLECULES, V21, P1157, DOI 10.1021/acs.biomac.9b01550
   Murray PE, 2007, J ENDODONT, V33, P377, DOI 10.1016/j.joen.2006.09.013
   Nie X, 2006, CELL BIOL INT, V30, P295, DOI 10.1016/j.cellbi.2005.12.001
   Nowicka A, 2013, J ENDODONT, V39, P743, DOI 10.1016/j.joen.2013.01.005
   Oliva N, 2020, ADV DRUG DELIVER REV, V161, P22, DOI 10.1016/j.addr.2020.07.021
   Rahman SU, 2018, MATERIALS, V11, DOI 10.3390/ma11081478
   Rahman SU, 2018, ACS APPL MATER INTER, V10, P17526, DOI 10.1021/acsami.7b19782
   Rapuano BE, 2012, J PERIODONTAL IMPLAN, V42, P95, DOI 10.5051/jpis.2012.42.3.95
   Six N, 2002, ARCH ORAL BIOL, V47, P177, DOI 10.1016/S0003 9969(01)00100 5
   Sloan AJ, 2007, ORAL DIS, V13, P151, DOI 10.1111/j.1601 0825.2006.01346.x
   Smith Anthony J, 2003, J Dent Educ, V67, P678
   Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166
   Thesleff I, 1997, MECH DEVELOP, V67, P111, DOI 10.1016/S0925 4773(97)00115 9
   Tzavlaki K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030487
   Wang RJ, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000295
   Wang W, 2016, ACTA BIOMATER, V36, P63, DOI 10.1016/j.actbio.2016.03.015
   Wang Y, 2012, J DENT RES, V91, P690, DOI 10.1177/0022034512448660
   Wartlick O, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001255
   Yamashiro T, 2003, J DENT RES, V82, P172, DOI 10.1177/154405910308200305
   Yang ZH, 2020, DRUG DELIV, V27, P1156, DOI 10.1080/10717544.2020.1797243
   Yao QQ, 2017, BIOMATERIALS, V115, P115, DOI 10.1016/j.biomaterials.2016.11.018
   Yu C, 2007, AUST DENT J, V52, pS4, DOI 10.1111/j.1834 7819.2007.tb00525.x
   Yu HQ, 2017, SCI REP UK, V7, DOI 10.1038/srep44099
   Zhang SF, 2009, BIOMATERIALS, V30, P5143, DOI 10.1016/j.biomaterials.2009.05.060
NR 60
TC 18
Z9 18
U1 0
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2041 7314
J9 J TISSUE ENG
JI J. Tissue Eng.
PD FEB
PY 2022
VL 13
AR 20417314211073934
DI 10.1177/20417314211073934
PG 14
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZN9JC
UT WOS:000765344700001
PM 35237403
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Stuss, M
   Sewerynek, E
   Król, I
   Stepien Klos, W
   Jedrzejczyk, S
AF Stuss, Michal
   Sewerynek, Ewa
   Krol, Iwona
   Stepien Klos, Wioletta
   Jedrzejczyk, Slawomir
TI Assessment of OPG, RANKL, bone turnover markers serum levels, and BMD
   after treatment with strontium ranelate and ibandronate in patients with
   postmenopausal osteoporosis
SO ENDOKRYNOLOGIA POLSKA
LA English
DT Article
DE osteoporosis; osteoprotegerin; RANKL; ibandronate; strontium ranelate
ID FACTOR KAPPA B; OSTEOCLAST DIFFERENTIATION FACTOR; SOLUBLE
   RECEPTOR ACTIVATOR; MINERAL DENSITY; RISEDRONATE TREATMENT;
   RHEUMATOID ARTHRITIS; INHIBITORY FACTOR; GENE EXPRESSION;
   OSTEOPROTEGERIN; WOMEN
AB Introduction: The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after treatment with strontium ranelate (SR) and ibandronate in patients with postmenopausal osteoporosis.
   Material and methods: A total of 89 women with postmenopausal osteoporosis (PO), aged 51 85 years, patients of the Outpatient Clinic of Osteoporosis of the Military Teaching Hospital in Lodz, were enrolled in the study. The patients were randomly assigned to different therapies: ibandronate and (SR). Patients of the control group received only calcium and vitamin D 3 supplements. The patients' visits were repeated after three and six months. Measurements of beta CTX (C terminal Telopeptide of type 1 collagen), osteocalcin, RANKL, osteoprotegerin (OPG), alkaline phosphatase concentrations in serum, as well as of total 24 hour calcium and phosphate levels in serum and urine, were carried out in material collected at baseline and after three and six months of therapy. Left hip and lumbar spine densitometry was done twice (at baseline visit and after six months).
   Results: In all three groups there were no significant differences noted in the concentrations of OPG and RANKL serum protein levels during the study period. Both negative and positive correlations or tendencies of correlations were found between OPG serum concentrations and BMD changes in the SR group.
   Conclusions: Both ibandronate and SR do not seem to cause any significant changes in OPG and RANKL protein serum levels during the first six months of treatment. OPG may play a role in osteoclast activity suppression in the course of treatment with ibandronate in patients with PO. OPG may play an important role in the mechanism of SR therapy and may be viewed as a potentially valuable parameter for monitoring and predicting the course of treatment with SR in PO.
C1 [Stuss, Michal; Sewerynek, Ewa; Stepien Klos, Wioletta] Med Univ Lodz, Dept Endocrine Disorders & Bone Metab, Lodz, Poland.
   [Stuss, Michal; Sewerynek, Ewa] Mil Teaching Hosp, Outpatient Clin Osteoporosis, Lodz, Poland.
   [Krol, Iwona] Poznan Univ Med Sci, Chair & Dept Family Med, Poznan, Poland.
   [Jedrzejczyk, Slawomir] Univ Humanities & Econ, Nonresident Nursing Fac Warsaw, Lodz, Poland.
C3 Medical University Lodz; Poznan University of Medical Sciences
RP Stuss, M (通讯作者)，Med Univ Lodz, Chair Endocrinol, Dept Endocrine Disorders & Bone Metab, Ul Zeligowskiego 7 9, PL 90752 Lodz, Poland.
EM mstuss@wp.pl
OI Stuss, Michal/0000 0002 1469 6526
FU Ministry of Science and Higher Education [KBN 1414/b/P01/2008/34,
   507 12 012]; Servier Polska LLC; Roche Polska LLC
FX This research project was approved by the Bioethical Committee of the
   Medical University of Lodz (Resolution No. RNN/162/06/KE). The studies
   were supported by a grant of the Ministry of Science and Higher
   Education: Contract No. KBN 1414/b/P01/2008/34; Project No. 507 12 012,
   implemented at the Medical University of Lodz. We would like to express
   our highest appreciation for the outstanding generosity and support of
   Servier Polska LLC and Roche Polska LLC, manifested in free of charge
   deliveries of their medicinal products for use in our clinical trial.
CR Anastasilakis AD, 2008, HORM METAB RES, V40, P281, DOI 10.1055/s 2008 1046787
   Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Bashir A, 2005, STEROIDS, V70, P847, DOI 10.1016/j.steroids.2005.04.011
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Chakravarti A, 2008, LAB INVEST, V88, P171, DOI 10.1038/labinvest.3700701
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Choi HJ, 2008, MATURITAS, V60, P170, DOI 10.1016/j.maturitas.2008.05.003
   Crotti TN, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/281287
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   Delgado Calle J, 2012, EPIGENETICS US, V7, P83, DOI 10.4161/epi.7.1.18753
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Drweska Matelska N, 2014, GINEKOL POL, V85, P852
   Duan P, 2015, J HUM HYPERTENS
   Dundar U, 2009, J BONE MINER METAB, V27, P464, DOI 10.1007/s00774 009 0055 9
   Fahrleitner Pammer A, 2003, WIEN KLIN WOCHENSCHR, V115, P291, DOI 10.1007/BF03040334
   Horst Sikorska Wanda, 2005, Reumatologia (Warsaw), V43, P12
   Indridason OS, 2005, OSTEOPOROSIS INT, V16, P417, DOI 10.1007/s00198 004 1699 x
   Karadag Saygi E, 2011, GYNECOL ENDOCRINOL, V27, P1033, DOI 10.3109/09513590.2011.579657
   Kudlacek S, 2003, BONE, V32, P681, DOI 10.1016/S8756 3282(03)00090 5
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Lorenc R, 2013, MEDYCYNA PRKTYCZNA
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Nabipour I, 2009, MENOPAUSE, V16, P950, DOI 10.1097/gme.0b013e3181a181b8
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nishida S, 2005, BIOCH BIOPHYS RES CO, V328, P91
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Peng SL, 2011, J BONE MINER RES, V26, P1272, DOI 10.1002/jbmr.325
   Quinn JMW, 1998, CALCIFIED TISSUE INT, V62, P527, DOI 10.1007/s002239900473
   Reginster JY, 2012, BONE, V50, P1201, DOI 10.1016/j.bone.2011.12.024
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reyes García R, 2010, MENOPAUSE, V17, P140, DOI 10.1097/gme.0b013e3181ac0cc1
   Rogers A, 2002, J CLIN ENDOCR METAB, V87, P4470, DOI 10.1210/jc.2002 020396
   Shen Y, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906 015 0566 y
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stuss M, 2013, J CLIN ENDOCR METAB, V98, pE1007, DOI 10.1210/jc.2012 3885
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P3162, DOI 10.1210/jc.86.7.3162
   Takaoka S, 2010, HORM METAB RES, V42, P627, DOI 10.1055/s 0030 1255091
   Taylan A, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 191
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Uemura H, 2008, J ENDOCRINOL INVEST, V31, P163, DOI 10.1007/BF03345584
   Vanderborght A, 2004, J RHEUMATOL, V31, P1483
   Wheater G, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 201
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasui T, 2011, ANN NY ACAD SCI, V1240, P7, DOI 10.1111/j.1749 6632.2011.06245.x
   Ziolkowska M, 2002, ARTHRITIS RHEUM US, V46, P1744, DOI 10.1002/art.10388
NR 53
TC 15
Z9 18
U1 0
U2 8
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80 180 GDANSK, POLAND
SN 0423 104X
J9 ENDOKRYNOL POL
JI Endokrynol. Pol.
PY 2016
VL 67
IS 2
BP 174
EP 184
DI 10.5603/EP.a2016.0014
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ9PY
UT WOS:000374546600004
PM 26884284
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Klein, C
   Zwick, A
   Kissel, S
   Forster, CU
   Pfeifer, D
   Follo, M
   Illert, AL
   Decker, S
   Benkler, T
   Pahl, H
   Oostendorp, RAJ
   Aumann, K
   Duyster, J
   Dierks, C
AF Klein, Claudius
   Zwick, Anabel
   Kissel, Sandra
   Forster, Christine Ulrike
   Pfeifer, Dietmar
   Follo, Marie
   Illert, Anna Lena
   Decker, Sarah
   Benkler, Thomas
   Pahl, Heike
   Oostendorp, Robert A. J.
   Aumann, Konrad
   Duyster, Justus
   Dierks, Christine
TI Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm
   progression
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID STEM CELL FUNCTION; SONIC HEDGEHOG; PANCREATIC CANCER; MAINTENANCE;
   HEMATOPOIESIS; PROGENITORS; DIFFERENTIATION; ERYTHROPOIESIS; ACTIVATION;
   CARCINOMA
AB JAK2V617F(+) myeloproliferative neoplasms (MPNs) frequently progress into leukemias, but the factors driving this process are not understood. Here, we find excess Hedgehog (HH) ligand secretion and loss of PTCH2 in myeloproliferative disease, which drives canonical and noncanonical HH signaling. Interestingly, Ptch2( / ) mice mimic dual pathway activation and develop a MPN phenotype with leukocytosis (neutrophils and monocytes), strong progenitor and LKS mobilization, splenomegaly, anemia, and loss of lymphoid lineages. HSCs exhibit increased cell cycling with improved stress hematopoiesis after 5 FU treatment, and this results in HSC exhaustion over time. Cytopenias, LKS loss, and mobilization are all caused by loss of Ptch2 in the niche, whereas hematopoietic loss of Ptch2 drives leukocytosis and promotes LKS maintenance and replating capacity in vitro. Ptch2( / ) niche cells show hyperactive noncanonical HH signaling, resulting in reduced production of essential HSC regulators (Scf, Cxcl12, and Jag1) and depletion of osteoblasts. Interestingly, Ptch2 loss in either the niche or in hematopoietic cells dramatically accelerated human JAK2V617F driven pathogenesis, causing transformation of nonlethal chronic MPNs into aggressive lethal leukemias with >30% blasts in the peripheral blood. Our findings suggest HH ligand inhibitors as possible drug candidates that act on hematopoiesis and the niche to prevent transformation of MPNs into leukemias.
C1 [Klein, Claudius; Zwick, Anabel; Kissel, Sandra; Forster, Christine Ulrike; Pfeifer, Dietmar; Follo, Marie; Illert, Anna Lena; Decker, Sarah; Benkler, Thomas; Pahl, Heike; Duyster, Justus; Dierks, Christine] Univ Med Ctr Freiburg, Dept Hematol Oncol, D 79106 Freiburg, Germany.
   [Klein, Claudius] Univ Freiburg, Inst Mol Med & Cell Res, D 79104 Freiburg, Germany.
   [Oostendorp, Robert A. J.] Tech Univ Munich, Med Klin 3, Klinikum Rechts Isar, D 81675 Munich, Germany.
   [Aumann, Konrad] Univ Med Ctr Freiburg, Dept Pathol, D 79104 Freiburg, Germany.
C3 University of Freiburg; University of Freiburg; Technical University of
   Munich; University of Freiburg
RP Dierks, C (通讯作者)，Univ Med Ctr Freiburg, Dept Hematol Oncol, D 79106 Freiburg, Germany.
EM christine.dierks@uniklinik freiburg.de
RI Pahl, Heike/AGM 5260 2022; Oostendorp, Robert A.J./K 9841 2018; Illert,
   Anna/G 8127 2019; Oostendorp, Robert/K 9841 2018; Aumann,
   Konrad/GSN 1821 2022; Dierks, Christine/L 4358 2013
OI Follo, Marie/0000 0002 3090 7442; Oostendorp, Robert
   A.J./0000 0002 4947 0412; 
FU Emmy Noether program of the DFG [DI 1664/1 1, FOR 2033 TP B1]; Deutsche
   Krebshilfe [110670]; EXC [294]; Centre for Biological Signaling Studies
   BIOSS
FX This work was supported by the Emmy Noether program of the DFG (DI
   1664/1 1), FOR 2033 TP B1 (Nichem), and the Deutsche Krebshilfe (grant
   110670). C. Dierks is supported by EXC 294, Centre for Biological
   Signaling Studies BIOSS.
CR Alfaro AC, 2014, DEVELOPMENT, V141, P3331, DOI 10.1242/dev.110056
   Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214
   Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282
   Byrd N, 2002, DEVELOPMENT, V129, P361
   Campaner S, 2013, CELL CYCLE, V12, P3663, DOI 10.4161/cc.26584
   Chan IS, 2012, CANCER RES, V72, P6344, DOI 10.1158/0008 5472.CAN 12 1068
   Chang H, 2010, INT J BIOCHEM CELL B, V42, P1462, DOI 10.1016/j.biocel.2010.04.016
   Datta S, 2006, CELL MOL LIFE SCI, V63, P435, DOI 10.1007/s00018 005 5389 4
   de la Roche M, 2013, SCIENCE, V342, P1247, DOI 10.1126/science.1244689
   Decker S, 2012, BLOOD, V119, P997, DOI 10.1182/blood 2011 06 359075
   Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003
   Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614
   Dyer MA, 2001, DEVELOPMENT, V128, P1717
   Furmanski AL, 2012, EUR J IMMUNOL, V42, P489, DOI 10.1002/eji.201141758
   Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015
   Gering M, 2005, DEV CELL, V8, P389, DOI 10.1016/j.devcel.2005.01.010
   Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896 6273(00)80645 5
   GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792 198703000 00002
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016
   Holtz AM, 2013, DEVELOPMENT, V140, P3423, DOI 10.1242/dev.095083
   Kawamura S, 2008, J BIOL CHEM, V283, P30964, DOI 10.1074/jbc.M806242200
   Kobune M, 2004, BLOOD, V104, P1002, DOI 10.1182/blood 2003 09 3347
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Lau CI, 2012, BLOOD, V119, P4741, DOI 10.1182/blood 2011 10 387266
   Lunardi S, 2014, CANCER LETT, V343, P147, DOI 10.1016/j.canlet.2013.09.039
   Maye P, 2004, DEV BIOL, V265, P276, DOI 10.1016/j.ydbio.2003.09.027
   Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647
   Merchant A, 2010, BLOOD, V115, P2391, DOI 10.1182/blood 2009 09 241703
   Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298 104
   Perry JM, 2009, BLOOD, V113, P911, DOI 10.1182/blood 2008 03 147892
   Poulos MG, 2013, CELL REP, V4, P1022, DOI 10.1016/j.celrep.2013.07.048
   Rowbotham NJ, 2009, BLOOD, V113, P5144, DOI 10.1182/blood 2008 10 185751
   Siggins SL, 2009, BLOOD, V114, P995, DOI 10.1182/blood 2009 03 208330
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Uhmann A, 2007, BLOOD, V110, P1814, DOI 10.1182/blood 2007 02 075648
   Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493
   Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737
NR 39
TC 34
Z9 35
U1 0
U2 4
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022 1007
EI 1540 9538
J9 J EXP MED
JI J. Exp. Med.
PD FEB 8
PY 2016
VL 213
IS 2
BP 273
EP 290
DI 10.1084/jem.20150556
PG 18
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA DI3FK
UT WOS:000373383700012
PM 26834157
OA Green Published
DA 2025 08 17
ER

PT J
AU Xie, CH
   Cao, YM
   Huang, Y
   Shi, QW
   Guo, JH
   Fan, ZW
   Li, JG
   Chen, BW
   Wu, BY
AF Xie, Chu Hai
   Cao, Yan Ming
   Huang, Yan
   Shi, Qun Wei
   Guo, Jian Hong
   Fan, Zi Wen
   Li, Ju Gen
   Chen, Bin Wei
   Wu, Bo Yi
TI Long non coding RNA TUG1 contributes to tumorigenesis of human
   osteosarcoma by sponging miR 9 5p and regulating POU2F1 expression
SO TUMOR BIOLOGY
LA English
DT Article
DE Osteosarcoma; TUG1; miR 9 5p; POU2F1; ceRNA
ID CELL PROLIFERATION; SURVIVAL; CERNA; DIFFERENTIATION; MIGRATION;
   INVASION; NETWORK; CANCER
AB Recent studies have shown that long non coding RNAs (lncRNAs) have critical roles in tumorigenesis, including osteosarcoma. The lncRNA taurine upregulated gene 1 (TUG1) was reported to be involved in the progression of osteosarcoma. Here, we investigated the role of TUG1 in osteosarcoma cells and the underlying mechanism. TUG1 expression was measured in osteosarcoma cell lines and human normal osteoblast cells by quantitative real time PCR (qRT PCR). The effects of TUG1 on osteosarcoma cells were studied by RNA interference in vitro and in vivo. The mechanism of competing endogenous RNA (ceRNA) was determined using bioinformatic analysis and luciferase assays. Our data showed that TUG1 knockdown inhibited cell proliferation and colony formation, and induced G0/G1 cell cycle arrest and apoptosis in vitro, and suppressed tumor growth in vivo. Besides, we found that TUG1 acted as an endogenous sponge to directly bind to miR 9 5p and downregulated miR 9 5p expression. Moreover, TUG1 overturned the effect of miR 9 5p on the proliferation, colony formation, cell cycle arrest, and apoptosis in osteosarcoma cells, which involved the derepression of POU class 2 homeobox 1 (POU2F1) expression. In conclusion, our study elucidated a novel TUG1/miR 9 5p/POU2F1 pathway, in which TUG1 acted as a ceRNA by sponging miR 9 5p, leading to downregulation of POU2F1 and facilitating the tumorigenesis of osteosarcoma. These findings may contribute to the lncRNA targeted therapy for human osteosarcoma.
C1 [Xie, Chu Hai; Cao, Yan Ming; Huang, Yan; Shi, Qun Wei; Guo, Jian Hong; Fan, Zi Wen; Li, Ju Gen; Chen, Bin Wei; Wu, Bo Yi] Guangzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, 250 Chang Gang Dong Rd, Guangzhou 510260, Guangdong, Peoples R China.
C3 Guangzhou Medical University
RP Xie, CH (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, 250 Chang Gang Dong Rd, Guangzhou 510260, Guangdong, Peoples R China.
EM xiechuuhai@sina.com
FU National Natural Science Foundation of China [81574002]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No: 81574002).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Dhamija S, 2016, INT J CANCER, V139, P269, DOI 10.1002/ijc.30039
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Ji TT, 2016, ASIAN PAC J TROP MED, V9, P494, DOI 10.1016/j.apjtm.2016.03.026
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027
   Kobayashi Eisuke, 2012, Sarcoma, V2012, P359739, DOI 10.1155/2012/359739
   Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 92
   Ma B, 2015, DATABASE OXFORD, DOI 10.1093/database/bav004
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Ng MCY, 2010, DIABETIC MED, V27, P1443, DOI 10.1111/j.1464 5491.2010.03124.x
   Sadikovic B, 2009, HUM MOL GENET, V18, P1962, DOI 10.1093/hmg/ddp117
   SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382
   Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008 5472.CAN 05 2399
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Wang F, 2015, ONCOTARGET, V6, P1
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596
   Xie J, 2015, J BIOMATER TISS ENG, V5, P872, DOI 10.1166/jbt.2015.1389
   Xu YT, 2015, TUMOR BIOL, V36, P1643, DOI 10.1007/s13277 014 2763 6
   Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027
   Yuan SX, 2012, HEPATOLOGY, V56, P2231, DOI 10.1002/hep.25895
   Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201
   Zhang Q, 2013, ASIAN PAC J CANCER P, V14, P2311, DOI 10.7314/APJCP.2013.14.4.2311
   Zhou M, 2016, ONCOTARGET, V7, P12598, DOI 10.18632/oncotarget.7181
NR 27
TC 113
Z9 126
U1 0
U2 32
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010 4283
EI 1423 0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2016
VL 37
IS 11
BP 15031
EP 15041
DI 10.1007/s13277 016 5391 5
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA ED4EH
UT WOS:000388799900064
PM 27658774
DA 2025 08 17
ER

PT J
AU Xu, R
   Liu, Y
   Zhou, Y
   Lin, W
   Yuan, Q
   Zhou, X
   Yang, Y
AF Xu, R.
   Liu, Y.
   Zhou, Y.
   Lin, W.
   Yuan, Q.
   Zhou, X.
   Yang, Y.
TI Gnas Loss Causes Chondrocyte Fate Conversion in Cranial Suture
   Formation
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE craniofacial anomalies; craniofacial biology; genetics; developmental
   biology; cell differentiation; signal transduction; translational
   medicine
ID EXPRESSION; CARTILAGE; HEDGEHOG; CELLS; JOINT; BONE; GENE
AB Calvaria development is distinct from limb formation. Craniosynostosis is a skull deformity characterized by premature cranial suture fusion due to the loss of the GNAS gene and, consequently, its encoded protein G alpha(s). This birth defect requires surgery, with potential lethal consequences. So far, hardly any early stage nonsurgical interventions for GNAS loss related craniosynostosis are available. Here, we investigated the role of the Gnas gene in mice in guarding the distinctiveness of intramembranous ossification and how loss of Gnas triggered endochondral like ossification within the cranial sutures. Single cell RNA sequencing (scRNA seq) of normal neonatal mice cranial suture chondrocytes showed a Hedgehog (Hh) inactivation pattern, which was associated with G alpha(s) signaling activation. Loss of Gnas evoked chondrocyte to osteoblast fate conversion and resulted in cartilage heterotopic ossification (HO) within cranial sutures and fontanels of the mouse model, leading to a skull deformity resembling craniosynostosis in patients with loss of GNAS. Activation of ectopic Hh signaling within cranial chondrocytes stimulated the conversion of cell identity through a hypertrophy like stage, which shared features of endochondral ossification in vivo. Reduction of Gli transcription activity by crossing with a loss of function Gli2 allele or injecting GLI1/2 antagonist hindered the progression of cartilage HO in neonatal stage mice. Our study uncovered the role of G alpha(s) in maintaining cranial chondrocyte identity during neonatal calvaria development in mice and how reduction of Hh signaling could be a nonsurgical intervention to reduce skull deformity in craniosynostosis due to loss of GNAS.
C1 [Xu, R.; Liu, Y.; Zhou, Y.; Yang, Y.] Harvard Sch Dent Med, Harvard Stem Cell Inst, Dept Dev Biol, Boston, MA USA.
   [Xu, R.; Lin, W.; Yuan, Q.; Zhou, X.] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14,3rd Sect Ren Min Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
C3 Harvard University; Harvard School of Dental Medicine; Sichuan
   University
RP Xu, R; Zhou, X (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14,3rd Sect Ren Min Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
EM Xurs@scu.edu.cn; Zhouxd@scu.edu.cn
RI ; Liu, Yuchen/AAH 6098 2021; yuan, quan/GZM 5597 2022; Zhou,
   Xuedong/LSL 0410 2024
OI Liu, Yuchen/0000 0001 8922 9976; Zhou, Xuedong/0000 0002 9319 7302;
   Yuan, Quan/0000 0002 2836 1081; 
FU National Institutes of Health grants from the National Institute of
   Dental and Craniofacial Research [R01DE025866]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [R01AR070877]; National
   Natural Science Foundation of China [82001001]; China Postdoctoral
   Science Foundation [BX20190224]; Innovation Program of Chengdu City
   [2019 YF05 01236 SN]; Postdoctoral Foundation of Sichuan University
   [2020SCU12018]; Research Funding of West China Hospital of Stomatology
   [RCDWJS2020 21, RD 02 202101]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [R01AR070877] Funding Source: NIH
   RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by National Institutes of Health grants from the National
   Institute of Dental and Craniofacial Research (R01DE025866) and from
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (R01AR070877) to Y. Yang and National Natural Science Foundation of
   China (82001001), China Postdoctoral Science Foundation (BX20190224),
   Innovation Program of Chengdu City (2019 YF05 01236 SN), Postdoctoral
   Foundation of Sichuan University (2020SCU12018), and Research Funding of
   West China Hospital of Stomatology (RCDWJS2020 21, RD 02 202101) to R.
   Xu.
CR Bai CB, 2002, DEVELOPMENT, V129, P4753
   Chen M, 2005, J CLIN INVEST, V115, P3217, DOI 10.1172/JCI24196
   Cong Q, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb2233
   Cong Q, 2019, CURR TOP DEV BIOL, V133, P281, DOI 10.1016/bs.ctdb.2018.11.019
   Corrales JD, 2006, DEVELOPMENT, V133, P1811, DOI 10.1242/dev.02351
   Drubbel AV, 2021, CELL STEM CELL, V28, P1411, DOI 10.1016/j.stem.2021.03.019
   Fresard L, 2019, NAT MED, V25, P911, DOI 10.1038/s41591 019 0457 8
   Frost ER, 2021, GENE DEV, V35, P619, DOI 10.1101/gad.348151.120
   Gong X, 2018, SCIENCE, V361, DOI 10.1126/science.aas8935
   Graul Neumann LM, 2009, AM J MED GENET A, V149A, P1487, DOI 10.1002/ajmg.a.32889
   Hagelstein Rotman M, 2021, CALCIFIED TISSUE INT, V108, P346, DOI 10.1007/s00223 020 00780 6
   Holmbeck K, 2003, J CELL BIOL, V163, P661, DOI 10.1083/jcb.200307061
   Holmes G, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107871
   Hu Q, 2018, CELL, V173, P1254, DOI 10.1016/j.cell.2018.03.018
   Kaplan FS, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115539
   Kelly NH, 2020, MATRIX BIOL, V89, P1, DOI 10.1016/j.matbio.2019.12.004
   Khan SK, 2018, P NATL ACAD SCI USA, V115, pE418, DOI 10.1073/pnas.1714313114
   Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546
   Leclercq V, 2018, CLIN CASE REP, V6, P1933, DOI 10.1002/ccr3.1739
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Martik ML, 2019, NATURE, V574, P675, DOI 10.1038/s41586 019 1691 4
   Maruyama T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb4416
   Massimi L, 2019, CHILD NERV SYST, V35, P2055, DOI 10.1007/s00381 019 04278 x
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Menon S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24801 6
   Minoux M, 2017, SCIENCE, V355, DOI 10.1126/science.aal2913
   Newton PT, 2019, NATURE, V567, P234, DOI 10.1038/s41586 019 0989 6
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Shore EM, 2002, NEW ENGL J MED, V346, P99, DOI 10.1056/NEJMoa011262
   Shoshani O, 2011, CELL STEM CELL, V8, P10, DOI 10.1016/j.stem.2010.12.004
   Soeda T, 2010, GENESIS, V48, P635, DOI 10.1002/dvg.20667
   Tambuyzer E, 2020, NAT REV DRUG DISCOV, V19, P93, DOI 10.1038/s41573 019 0049 9
   Wang L, 2015, CALCIFIED TISSUE INT, V96, P129, DOI 10.1007/s00223 014 9945 5
   Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545
   Xu RS, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0034 7
   Xu RS, 2018, BONE, V109, P134, DOI 10.1016/j.bone.2017.08.025
   Yu MF, 2021, CELL, V184, P243, DOI 10.1016/j.cell.2020.11.037
NR 38
TC 8
Z9 9
U1 2
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUL
PY 2022
VL 101
IS 8
BP 931
EP 941
AR 00220345221075215
DI 10.1177/00220345221075215
EA FEB 2022
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 3A0WK
UT WOS:000774001000001
PM 35220829
OA Green Published
DA 2025 08 17
ER

PT J
AU Yosofi, C
   Cairon Lejeune, S
   Lefeuvre Plesse, C
   Polard, E
   Briet, M
   Kammerer Jacquet, SF
   Triquet, L
   Scailteux, LM
AF Yosofi, Chabnam
   Cairon Lejeune, Sophie
   Lefeuvre Plesse, Claudia
   Polard, Elisabeth
   Briet, Marie
   Kammerer Jacquet, Solene Florence
   Triquet, Louise
   Scailteux, Lucie Marie
TI Osteonecrosis of the jaw under palbociclib: A case series description
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE Cyclin dependent kinase inhibitor; palbociclib; osteonecrosis of the
   jaw; adverse drug reaction
ID METASTATIC BREAST CANCER; MEDICATION RELATED OSTEONECROSIS; ENDOCRINE
   THERAPY; CDK4/6 INHIBITORS; MULTICENTER; FULVESTRANT; PLACEBO; WOMEN
AB Introduction Cases of osteonecrosis of the jaw have been reported by dental surgeons to the pharmacovigilance center in Rennes, France, occurring among patients treated with palbociclib, a cyclin dependent kinase 4/6 inhibitor. Although this event was not expected with the drug, a safety signal was raised. Describing a local case series, the aim of our study was to identify specific patterns that might suggest a triggering role for these drugs, and to discuss pathophysiological hypotheses. Materials and methods A retrospective case series of patients exposed to cyclin dependent kinase 4/6 inhibitors between 2016 and 2020 with a diagnosis of osteonecrosis of the jaw at the Rennes Dental Care Center was analyzed. The descriptive analysis was conducted on patient demographics, breast cancer characteristics, osteonecrosis of the jaw, biological data, and exposure to cyclin dependent kinase 4/6 inhibitors. Results We identified eight cases, most of them at stages 0 1 (62.5%). Four patients were still exposed to palbociclib at the time of diagnosis and four had discontinued the treatment before the diagnosis. Chronological imputability could not be excluded given the drug's half life and the variable intervals of dental monitoring from one patient to another. All patients had at least one dental osteonecrosis risk factor (including dental extraction, dentures, and denosumab exposure at the time of diagnosis). Neutropenia and mucositis were not systematically reported at the time of diagnosis. The anatomopathological characteristics were nonspecific. Conclusion We did not identify a specific pattern that could suggest a triggering role of palbociclib in the development of ONJ.
C1 [Yosofi, Chabnam; Polard, Elisabeth; Triquet, Louise; Scailteux, Lucie Marie] CHU Rennes, Reg Ctr Pharmacovigilance Pharmacoepidemiol & Drug, Rue Henri Le Guilloux, F 35000 Rennes, France.
   [Cairon Lejeune, Sophie] CHU Rennes, Dent Care Ctr, Rennes, France.
   [Lefeuvre Plesse, Claudia] Eugene Marquis Canc Ctr, Dept Med Oncol, Rennes, France.
   [Briet, Marie] CHRU Angers, Reg Ctr Pharmacovigilance Pharmacoepidemiol & Drug, Angers, France.
   [Kammerer Jacquet, Solene Florence] CHU Rennes, Dept Pathol, Rennes, France.
C3 CHU Rennes; Universite de Rennes; Universite de Rennes; CHU Rennes;
   Universite de Rennes; UNICANCER; Centre Eugene Marquis; Universite
   d'Angers; Centre Hospitalier Universitaire d'Angers; Universite de
   Rennes; CHU Rennes
RP Scailteux, LM (通讯作者)，CHU Rennes, Reg Ctr Pharmacovigilance Pharmacoepidemiol & Drug, Rue Henri Le Guilloux, F 35000 Rennes, France.
EM lucie.scailteux@gmail.com
RI SCAILTEUX, Lucie Marie/AAD 9334 2020; Kammerer Jacquet,
   Solène Florence/ADZ 2030 2022; Briet, Marie/K 7385 2015
CR Agence nationale de securite du medicament et des produits de sante (ANSM), 2020, COMPT REND COM SCI P
   Anesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194925
   Beaudouin S., 2021, J ORAL MED ORAL SURG, V27, P47, DOI DOI 10.1051/MBCB/2021035
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Chang J, 2018, CURR OSTEOPOROS REP, V16, P584, DOI 10.1007/s11914 018 0474 4
   Clark AS, 2016, JAMA ONCOL, V2, P253, DOI 10.1001/jamaoncol.2015.4701
   Clezardin P., 2017, REV RHUMATISME MONOG, V84, P107
   Costa R, 2017, BREAST, V35, P1, DOI 10.1016/j.breast.2017.05.016
   Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470 2045(15)00613 0
   Czarny K., 2020, EMC MED BUCCALE, P17
   Diéras V, 2019, ONCOLOGIST, V24, P1514, DOI 10.1634/theoncologist.2019 0019
   Eguia A, 2020, MED ORAL PATOL ORAL, V25, pE71, DOI 10.4317/medoral.23191
   Elsayed R, 2020, FASEB J, V34, P2595, DOI 10.1096/fj.201901819RR
   Ettl J, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058 020 01263 0
   European Medicines Agency, EMA6526272016 EPAR
   European Medicines Agency, IBR EPAR PROD INF
   Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303
   Finn RS, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058 016 0721 5
   Fusco V, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph181910143
   Georgakopoulou E, 2018, J AM DENT ASSOC, V149, P100, DOI 10.1016/j.adaj.2017.08.046
   George Estee L, 2018, Bone Rep, V8, P104, DOI 10.1016/j.bonr.2018.03.003
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Lombard T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8768162
   Marciano A., INT J ENV RES PUBLIC, V18, P10145
   Marcianò A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249509
   Migliorati Cesar A., 2019, Journal of the National Cancer Institute Monographs, P107, DOI 10.1093/jncimonographs/lgz009
   Moore N, 2019, THERAPIE, V74, P557, DOI 10.1016/j.therap.2019.09.004
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Rugo HS, 2018, EUR J CANCER, V101, P123, DOI 10.1016/j.ejca.2018.05.017
   Serra Francesco, 2019, Drugs Context, V8, P212579, DOI 10.7573/dic.212579
   Spring LM, 2017, ONCOLOGIST, V22, P1039, DOI 10.1634/theoncologist.2017 0142
   Thill M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918793326
   UK Chemotherapy Board, 2019, MED REL OST JAW GUID
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Verma S, 2016, ONCOLOGIST, V21, P1165, DOI 10.1634/theoncologist.2016 0097
   Vermeer JAF, 2016, CURR OSTEOPOROS REP, V14, P219, DOI 10.1007/s11914 016 0318 z
   Zecha JAEM, 2019, SUPPORT CARE CANCER, V27, P3667, DOI 10.1007/s00520 019 04925 8
   Zhang WD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.606043
NR 40
TC 3
Z9 3
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078 1552
EI 1477 092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD DEC
PY 2023
VL 29
IS 8
BP 1990
EP 1997
DI 10.1177/10781552231165434
EA MAR 2023
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA CG7D7
UT WOS:000954666200001
PM 36945877
DA 2025 08 17
ER

PT J
AU Rowe, PSN
AF Rowe, Peter S. N.
TI Regulation of Bone Renal Mineral and Energy Metabolism: The PHEX, FGF23,
   DMP1, MEPE ASARM Pathway
SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
LA English
DT Article
DE MEPE; FGF23; DMP1; KLOTHO; Rickets; PHEX; rickets; osteomalacia; kidney
   disease
ID MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; LINKED HYPOPHOSPHATEMIC
   RICKETS; TUBULAR PHOSPHATE REABSORPTION; BRUSH BORDER MEMBRANES; HUMAN
   OSTEOBLAST CELLS; CHRONIC KIDNEY DISEASE; D DEFICIENT RAT;
   INSULIN SECRETION; HYP MOUSE; IN VIVO
AB More than 300 million years ago, vertebrates emerged from the vast oceans to conquer gravity and the dry land. With this transition, new adaptations occurred that included ingenious changes in reproduction, waste secretion, and bone physiology. One new innovation, the egg shell, contained an ancestral protein (ovocleidin 116) that likely first appeared with the dinosaurs and was preserved through the theropod lineage in modem birds and reptiles. Ovocleidin 116 is an avian homolog of matrix extracellular phosphoglycoprotein (MEPE) and belongs to a group of proteins called short integrin binding ligand interacting glycoproteins (SIBLINGs). These proteins are all localized to a defined region on chromosome 5q in mice and chromosome 4q in humans. A unifying feature of SIBLING proteins is an acidic serine aspartate rich MEPE associated motif (ASARM). Recent research has shown that the ASARM motif and the released ASARM peptide have regulatory roles in mineralization (bone and teeth), phosphate regulation, vascularization, soft tissue calcification, osteoclastogenesis, mechanotransduction, and fat energy metabolism. The MEPE ASARM motif and peptide are physiological substrates for PHEX, a zinc metalloendopeptidase. Defects in PHEX are responsible for X linked hypophosphatemic rickets (HYP). There is evidence that PHEX interacts with another ASARM motif containing SIBLING protein, dentin matrix protein 1 (DMP1). DMP1 mutations cause bone and renal defects that are identical with the defects caused by a loss of PHEX function. This results in autosomal recessive hypophosphatemic rickets (ARHR). In both HYP and ARHR, increased FGF23 expression plays a major role in the disease and in autosomal dominant hypophosphatemic rickets (ADHR), FGF23 half life is increased by activating mutations. ASARM peptide administration in vitro and in vivo also induces increased FGF23 expression. FGF23 is a member of the fibroblast growth factor (FGF) family of cytokines, which surfaced 500 million years ago with the boney fish (i.e., teleosts) that do not contain SIBLING proteins. In terrestrial vertebrates, FGF23, like SIBLING proteins, is expressed in the osteocyte. The boney fish, however, are an osteocytic, so a physiological bone renal link with FGF23 and the SIBLINGs was cemented when life ventured from the oceans to the land during the Triassic period, approximately 300 million years ago. This link has been revealed by recent research that indicates a competitive displacement of a PHEX DMP1 interaction by an ASARM peptide that leads to increased FGF23 expression. This review discusses the new discoveries that reveal a novel PHEX, DMP1, MEPE, ASARM peptide, and FGF23 bone renal pathway. This pathway impacts not only bone formation, bone renal mineralization, and renal phosphate homeostasis but also energy metabolism. The study of this new pathway is relevant for developing therapies for several diseases: bone teeth mineral loss disorders, renal osteodystrophy, chronic kidney disease and bone mineralization disorders (CKD MBD), end stage renal diseases, ectopic arterial calcification, cardiovascular disease renal calcification, diabetes, and obesity.
C1 [Rowe, Peter S. N.] Univ Kansas, Med Ctr, Dept Internal Med, Kidney Inst, Kansas City, KS 66103 USA.
   [Rowe, Peter S. N.] Univ Kansas, Med Ctr, Div Nephrol Hypertens, Kansas City, KS 66103 USA.
C3 University of Kansas; University of Kansas Medical Center; University of
   Kansas; University of Kansas Medical Center
RP Rowe, PSN (通讯作者)，Univ Kansas, Med Ctr, Dept Internal Med, Kidney Inst, Kansas City, KS 66103 USA.
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   National Institutes of Health (NIH, NIAMS) [5R01AR051598]
FX The author acknowledges with gratitude the financial support and awards
   from the National Institute of Arthritis and Musculoskeletal and Skin
   Diseases National Institutes of Health (NIH, NIAMS: Grant No.
   5R01AR051598).
CR Addison WN, 2008, J BONE MINER RES, V23, P1638, DOI 10.1359/JBMR.080601
   Addison WN, 2010, J BONE MINER RES, V25, P695, DOI 10.1359/jbmr.090832
   Alos N, 2005, BONE, V37, P589, DOI 10.1016/j.bone.2005.05.006
   Alvarez Díaz S, 2010, CELL CYCLE, V9, P32, DOI 10.4161/cc.9.1.10266
   Amir LR, 2007, J HISTOCHEM CYTOCHEM, V11, P11
   Argiro L, 2001, GENOMICS, V74, P342, DOI 10.1006/geno.2001.6553
   Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Bao BY, 2006, CARCINOGENESIS, V27, P32, DOI 10.1093/carcin/bgi170
   Bardet C, 2010, CELL MOL LIFE SCI, V67, P305, DOI 10.1007/s00018 009 0185 1
   Baum M, 2005, AM J PHYSIOL RENAL, V288, pF363, DOI 10.1152/ajprenal.00217.2004
   Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372
   Bianchetti L, 2002, PROTEINS, V47, P481, DOI 10.1002/prot.10075
   Bleicher F, 2001, Adv Dent Res, V15, P30
   BONJOUR JP, 1975, AM J PHYSIOL, V229, P402, DOI 10.1152/ajplegacy.1975.229.2.402
   Boskey AL, 2010, CALCIFIED TISSUE INT, V86, P42, DOI 10.1007/s00223 009 9313 z
   BOSKEY AL, 1995, ANN NY ACAD SCI, V760, P249, DOI 10.1111/j.1749 6632.1995.tb44635.x
   Boukpessi T, 2006, CALCIFIED TISSUE INT, V79, P294, DOI 10.1007/s00223 006 0182 4
   Boukpessi T, 2010, AM J PATHOL, V177, P803, DOI 10.2353/ajpath.2010.091231
   Brage M, 2005, CALCIFIED TISSUE INT, V76, P439, DOI 10.1007/s00223 004 0043 y
   Bresler D, 2004, J ENDOCRINOL, V183, pR1, DOI 10.1677/joe.1.05989
   Burland C, 1918, PRACTITIONER, V100, P391
   BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934 8832(11)80030 2
   CADE C, 1987, ENDOCRINOLOGY, V120, P1490, DOI 10.1210/endo 120 4 1490
   CADE C, 1986, ENDOCRINOLOGY, V119, P84, DOI 10.1210/endo 119 1 84
   Campos M, 2003, BIOCHEM J, V373, P271, DOI 10.1042/BJ20030287
   CAPPARELLI AW, 1992, ENDOCRINOLOGY, V130, P328, DOI 10.1210/en.130.1.328
   Chau H, 2003, J BONE MINER RES, V18, P644, DOI 10.1359/jbmr.2003.18.4.644
   Chen S, 2008, ARCH ORAL BIOL, V53, P879, DOI 10.1016/j.archoralbio.2008.05.005
   Cho YD, 2009, J BIOL CHEM, V284, P25230, DOI 10.1074/jbc.M109.008391
   Clemens T.L., 2010, J Bone Miner Res
   Confavreux CB, 2009, MOL CELL ENDOCRINOL, V310, P21, DOI 10.1016/j.mce.2009.04.004
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Danjo A, 2007, BIOCHEM BIOPH RES CO, V360, P199, DOI 10.1016/j.bbrc.2007.06.028
   David V, 2009, J BONE MINER RES S1, V24
   David V, 2011, AM J PHYSIOL RENAL, V300, pF783, DOI 10.1152/ajprenal.00304.2010
   David V, 2009, ENDOCRINOLOGY, V150, P4012, DOI 10.1210/en.2009 0216
   de Borst MH, 2011, J AM SOC NEPHROL, V22, P1603, DOI 10.1681/ASN.2010121251
   DEFRONZO RA, 1980, NEW ENGL J MED, V303, P1259, DOI 10.1056/NEJM198011273032203
   Deshpande AS, 2011, BIOMACROMOLECULES, V12, P2933, DOI 10.1021/bm2005214
   Dobbie H, 2008, NEPHROL DIAL TRANSPL, V23, P730, DOI 10.1093/ndt/gfm535
   Drüeke TB, 2010, KIDNEY INT, V78, P1057, DOI 10.1038/ki.2010.339
   Dubois SG, 2002, AM J PHYSIOL CELL PH, V283, pC1414, DOI 10.1152/ajpcell.00135.2002
   Duret L, 1996, COMPUT APPL BIOSCI, V12, P507
   Eapen AS, 2011, J BIOL CHEM
   Ecarot B, 1999, ENDOCRINOLOGY, V140, P1192, DOI 10.1210/en.140.3.1192
   ECONS MJ, 1994, HUM MOL GENET, V3, P680, DOI 10.1093/hmg/3.4.680
   Elizabeth T.E.C. J. Princess, 1979, PEDIATRICS, V64, P241
   Fedarko Neal S, 2004, FASEB J, V18, P734
   Fedarko NS, 2001, CLIN CANCER RES, V7, P4060
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061
   Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146
   Francis F, 1997, GENOME RES, V7, P573, DOI 10.1101/gr.7.6.573
   FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095 130
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Friedlander G, 2010, NEPHROL DIAL TRANSPL, V25, P3135, DOI 10.1093/ndt/gfq516
   Fukumoto S, 2009, TRENDS ENDOCRIN MET, V20, P230, DOI 10.1016/j.tem.2009.02.001
   Gaucher C, 2009, CELLS TISSUES ORGANS, V189, P219, DOI 10.1159/000151382
   Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382
   Glisson F., 1651, TREATISE RICKETS BEI
   Gluhak Heinrich J, 2007, ARCH ORAL BIOL, V52, P684, DOI 10.1016/j.archoralbio.2006.12.010
   Gluhak Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807
   Goldberg M, 2009, J DENT RES, V88, P396, DOI 10.1177/0022034509337101
   Goldberg Michel, 2006, Dent Clin North Am, V50, P277, DOI 10.1016/j.cden.2005.11.008
   Goltzman D, 2011, J BONE MINER RES, V26, P1997, DOI 10.1002/jbmr.462
   Goobes R, 2007, BIOCHEMISTRY US, V46, P4725, DOI 10.1021/bi602345a
   Gowen LC, 2003, J BIOL CHEM, V278, P1998, DOI 10.1074/jbc.M203250200
   Guo R, 2002, BIOCHEM BIOPH RES CO, V297, P38, DOI 10.1016/S0006 291X(02)02125 3
   Gupta A, 2001, BONE, V29, P467, DOI 10.1016/S8756 3282(01)00601 9
   HARRELL RM, 1985, J CLIN INVEST, V75, P1858, DOI 10.1172/JCI111900
   Harris S. E., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P313
   Hayashibara T, 2004, J BONE MINER RES, V19, P455, DOI 10.1359/JBMR.0301263
   Hayashibara T, 2007, J BONE MINER RES, V22, P1743, DOI 10.1359/JBMR.070709
   Hesse M, 2007, MATRIX BIOL, V26, P75, DOI 10.1016/j.matbio.2006.10.003
   Hines ER, 2004, J BIOL CHEM, V279, P46406, DOI 10.1074/jbc.M404278200
   Hoffman WH, 2008, AM J MED GENET A, V146A, P2164, DOI 10.1002/ajmg.a.32395
   Hoyer JR, 2001, KIDNEY INT, V60, P77, DOI 10.1046/j.1523 1755.2001.00772.x
   HRUSKA KA, 1995, AM J PHYSIOL RENAL, V268, pF357, DOI 10.1152/ajprenal.1995.268.3.F357
   HUANG XQ, 1992, COMPUT APPL BIOSCI, V8, P155
   HUANG XQ, 1990, COMPUT APPL BIOSCI, V6, P373
   Imel EA, 2010, J CLIN ENDOCR METAB, V95, P1846, DOI 10.1210/jc.2009 1671
   Jain A, 2008, BIOCHEMISTRY US, V47, P5986, DOI 10.1021/bi800133n
   Jemtland R, 2011, J BONE MINER RES, V26, P1793, DOI 10.1002/jbmr.396
   Jiang BC, 2010, J BONE MINER RES, V25, P2155, DOI 10.1002/jbmr.117
   Karadag A, 2005, CANCER RES, V65, P11545, DOI 10.1158/0008 5472.CAN 05 2861
   Karadag A, 2004, JNCI J NATL CANCER I, V96, P956, DOI 10.1093/jnci/djh169
   Karsenty G, 2010, J CLIN ENDOCR METAB, V95, P4795, DOI 10.1210/jc.2010 1030
   Kiela PR, 2009, LAB INVEST, V89, P7, DOI 10.1038/labinvest.2008.114
   Kulkarni RN, 2010, CALCIFIED TISSUE INT, V87, P461, DOI 10.1007/s00223 010 9407 7
   KUROKAWA K, 1973, BIOCHIM BIOPHYS ACTA, V313, P59, DOI 10.1016/0304 4165(73)90188 8
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   LAWSONMATTHEW PJ, 1988, CLIN SCI, V74, P101, DOI 10.1042/cs0740101
   Lee NK, 2008, TRENDS ENDOCRIN MET, V19, P161, DOI 10.1016/j.tem.2008.02.006
   Leopold JA, 2007, NAT MED, V13, P189, DOI 10.1038/nm1545
   LINDE A, 1980, J BIOL CHEM, V255, P5931
   Liu H, 2004, J DENT RES, V83, P496, DOI 10.1177/154405910408300612
   Liu SG, 2007, J ENDOCRINOL, V192, P261, DOI 10.1677/joe.1.07059
   LOGHMANADHAM M, 1992, J AM SOC NEPHROL, V3, P1253
   LOGHMANADHAM M, 1987, AM J PHYSIOL, V252, pG244, DOI 10.1152/ajpgi.1987.252.2.G244
   LOGHMANADHAM M, 1992, AM J PHYSIOL, V263, pF301, DOI 10.1152/ajprenal.1992.263.2.F301
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   Lorenzi O, 2010, PFLUG ARCH EUR J PHY, V459, P465, DOI 10.1007/s00424 009 0735 2
   Lu YB, 2011, J BONE MINER RES, V26, P331, DOI 10.1002/jbmr.226
   MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835
   Machado JP, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471 2148 11 342
   MARIE PJ, 1982, ENDOCRINOLOGY, V111, P904, DOI 10.1210/endo 111 3 904
   Marks J, 2008, J AM SOC NEPHROL, V19, P2313, DOI 10.1681/ASN.2008030315
   Marsenic O, 2009, AM J KIDNEY DIS, V53, P875, DOI 10.1053/j.ajkd.2008.12.031
   Martin A, 2008, ENDOCRINOLOGY, V149, P1757, DOI 10.1210/en.2007 1205
   Martin A, 2011, FASEB J, V25, P2551, DOI 10.1096/fj.10 177816
   Matsumoto N, 2005, AM J PHYSIOL ENDOC M, V289, pE123, DOI 10.1152/ajpendo.00562.2004
   Matsumoto N, 2005, BIOCHEM BIOPH RES CO, V332, P248, DOI 10.1016/j.bbrc.2005.04.116
   MCCLOSKEY EV, 1987, BONE, V8, pS35
   MCCLOSKEY EV, 1988, CLIN SCI, V74, P607, DOI 10.1042/cs0740607
   Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B
   MUHLBAUER RC, 1981, CLIN SCI, V60, P171, DOI 10.1042/cs0600171
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nagel DE, 2004, J CELL BIOCHEM, V93, P1107, DOI 10.1002/jcb.20249
   Nakashima M, 2004, HUM GENE THER, V15, P1045, DOI 10.1089/hum.2004.15.1045
   Nampei A, 2004, J BONE MINER METAB, V22, P176, DOI 10.1007/s00774 003 0468 9
   Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200
   Nesbitt T, 1996, ENDOCRINOLOGY, V137, P943, DOI 10.1210/en.137.3.943
   NESBITT T, 1995, J BONE MINER RES, V10, P1327
   O'Riordan JLH, 2006, J BONE MINER RES, V21, P1506, DOI 10.1359/JBMR.060703
   Ogbureke KUE, 2005, KIDNEY INT, V68, P155, DOI 10.1111/j.1523 1755.2005.00389.x
   Palm T.A., 1890, Practitioner, V45, P321
   Paula FJA, 1998, HORM METAB RES, V30, P281, DOI 10.1055/s 2007 978884
   Petersen DN, 2000, J BIOL CHEM, V275, P36172, DOI 10.1074/jbc.M003622200
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Price Sarah, 2011, Nat Rev Rheumatol, V7, P373, DOI 10.1038/nrrheum.2011.84
   Prie D, 2009, KIDNEY INT, V4, P1
   RAFTER GW, 1987, PERSPECT BIOL MED, V30, P527
   Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325
   Rice P, 1995, PROGRAMME MANUAL EGC
   RIFAS L, 1995, CALCIFIED TISSUE INT, V57, P60, DOI 10.1007/BF00298998
   Rifas L, 1997, CALCIFIED TISSUE INT, V61, P256, DOI 10.1007/s002239900331
   RITCHIE HH, 1994, J BIOL CHEM, V269, P3698
   Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Rowe PSN, 2006, BONE, V39, P773, DOI 10.1016/j.bone.2006.04.012
   Rowe PS, 2011, J BONE MINER RES S1, V26
   ROWE PSN, 1993, HUM GENET, V91, P571
   ROWE PSN, 1994, HUM GENET, V94, P457
   Rowe PSN, 1998, CURR OPIN NEPHROL HY, V7, P367, DOI 10.1097/00041552 199807000 00004
   ROWE PSN, 1994, NUCLEIC ACIDS RES, V22, P5135, DOI 10.1093/nar/22.23.5135
   ROWE PSN, 1994, HUM GENET, V93, P291, DOI 10.1007/BF00212025
   Rowe PSN, 2005, BONE, V36, P33, DOI 10.1016/j.bone.2004.09.015
   Rowe PSN, 2004, CRIT REV ORAL BIOL M, V15, P264, DOI 10.1177/154411130401500503
   Rowe PSN, 2004, BONE, V34, P303, DOI 10.1016/j.bone.2003.10.005
   Rowe PSN, 1997, HUM MOL GENET, V6, P539, DOI 10.1093/hmg/6.4.539
   Rowe PSN, 1996, HUM GENET, V97, P345
   Rowe PSN, 1996, BONE, V18, P159, DOI 10.1016/8756 3282(95)00458 0
   Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235
   Rowe PSN, 2000, GENETICS OF OSTEOPOROSIS AND METABOLIC BONE DISEASE, P431
   ROWE PSN, 1992, HUM GENET, V89, P539
   Samadfam R, 2009, ENDOCRINOLOGY, V150, P4835, DOI 10.1210/en.2009 0472
   Schiffrin EL, 2006, HYPERTENSION, V47, P312, DOI 10.1161/01.HYP.0000201443.63240.a7
   SCHLESINGER DH, 1977, J BIOL CHEM, V252, P1689
   Shih NR, 2002, J AM SOC NEPHROL, V13, P394, DOI 10.1681/ASN.V132394
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Shirley DG, 2010, NEPHROL DIAL TRANSPL, V25, P3191, DOI 10.1093/ndt/gfq263
   Six N, 2007, J DENT RES, V86, P780, DOI 10.1177/154405910708600818
   Sprowson AP, 2008, J ORTHOP RES, V26, P1256, DOI 10.1002/jor.20606
   Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200
   STOLL R, 1980, AM J PHYSIOL, V239, pF13, DOI 10.1152/ajprenal.1980.239.1.F13
   Styrkarsdottir U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013217
   SZCZEPANSKAKONKEL M, 1987, J BIOL CHEM, V262, P8000
   SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375
   Tenenhouse HS, 2004, AM J PHYSIOL RENAL, V286, pF675, DOI 10.1152/ajprenal.00362.2003
   TRECHSEL U, 1977, AM J PHYSIOL, V232, pE298, DOI 10.1152/ajpendo.1977.232.3.E298
   Tsuchiya S, 2011, J BONE MINER RES, V26, P220, DOI 10.1002/jbmr.202
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Turner AJ, 2003, BIOCHEM SOC T, V31, P723, DOI 10.1042/bst0310723
   Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521 1878(200103)23:3<261::AID BIES1036>3.0.CO;2 K
   Ubaidus S, 2009, J ELECTRON MICROSC, V58, P381, DOI 10.1093/jmicro/dfp032
   Ullrich KJ, 1997, J PHARMACOL EXP THER, V283, P1223
   Utsugi T, 2000, METABOLISM, V49, P1118, DOI 10.1053/meta.2000.8606
   VANSCOY M, 1988, AM J PHYSIOL, V255, pF984, DOI 10.1152/ajprenal.1988.255.5.F984
   von Marschall Z, 2008, J BIOL CHEM, V283, P32730, DOI 10.1074/jbc.M804283200
   Vordemvenne T, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 263
   WALTON RJ, 1975, CLIN SCI MOL MED, V49, P45, DOI 10.1042/cs0490045
   Wang HG, 2011, J DENT RES, V90, P529, DOI 10.1177/0022034510391057
   Winther K, 2011, SCAND J CLIN LAB INV
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Wu H, 2011, J BIOL CHEM, V286, P29462, DOI 10.1074/jbc.M110.194746
   Xi W, 2002, HORM METAB RES, V34, P288, DOI 10.1055/s 2002 33256
   Xie W, 1999, BIOCHEM J, V343, P393, DOI [10.1042/0264 6021:3430393, 10.1042/bj3430393]
   Xie WS, 2000, BIOCHEM J, V352, P227, DOI 10.1042/0264 6021:3520227
   Yadav VK, 2011, J EXP MED, V208, P41, DOI 10.1084/jem.20101940
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yamakoshi Y, 2005, J BIOL CHEM, V280, P17472, DOI 10.1074/jbc.M413220200
   Yuan B, 2010, J BONE MINER RES S1, V25
   Yuan B, 2011, J BONE MINER RES  S1, V26
   Yuan B, 2011, J BONE MINER RES  S1, V26
   Yuan B, 2008, J CLIN INVEST, V118, P722, DOI 10.1172/JCI32702
   Zeitz U, 2003, FASEB J, V17, P509, DOI 10.1096/fj.02 0424fje
   ZHOU XJ, 1991, KIDNEY INT, V39, P120, DOI 10.1038/ki.1991.15
   Zmuda JM, 2011, OSTEOPOROSIS INT, V22, P1079, DOI 10.1007/s00198 010 1296 0
NR 201
TC 111
Z9 133
U1 0
U2 57
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1045 4403
EI 2162 6502
J9 CRIT REV EUKAR GENE
JI Crit. Rev. Eukaryot. Gene Expr.
PY 2012
VL 22
IS 1
BP 61
EP 86
DI 10.1615/CritRevEukarGeneExpr.v22.i1.50
PG 26
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 901KU
UT WOS:000300966600005
PM 22339660
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, YB
   Yu, X
   Huang, AQ
   Zhang, XX
   Wang, YJ
   Geng, W
   Xu, RJ
   Li, SY
   He, H
   Zheng, B
   Chen, GX
   Xu, YZ
AF Liu, Yubo
   Yu, Xiao
   Huang, Anquan
   Zhang, Xiangxin
   Wang, Yijun
   Geng, Wei
   Xu, Renjie
   Li, Suoyuan
   He, Hui
   Zheng, Bo
   Chen, Guangxiang
   Xu, Yaozeng
TI INTS7 ABCD3 Interaction Stimulates the Proliferation and Osteoblastic
   Differentiation of Mouse Bone Marrow Mesenchymal Stem Cells by
   Suppressing Oxidative Stress
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE bone marrow mesenchymal stem cells (BM MSCs); INTS7; ABCD3;
   proliferation; osteoblastic differentiation; adipogenic differentiation;
   oxidative stress
ID OSTEOGENIC DIFFERENTIATION; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION
   FACTOR; OSTEOPOROSIS; SENESCENCE
AB Increased adipocyte and decreased osteoblast differentiation, combined with the ectopic proliferation of bone marrow mesenchymal stem cells (BM MSCs), represent the primary causes of osteoporosis. The dysregulation of numerous intracellular bioactive factors is responsible for the aberrant differentiation and growth of BM MSCs. In this study, we focused on a new stimulative factor, integrator complex subunit 7 (INTS7), and its cooperative protein ATP binding cassette subfamily D member 3 (ABCD3)/high density lipoprotein binding protein (HDLBP) in mouse BM MSCs. We aimed to uncover the effects of the INTS7 ABCD3/HDLBP interaction on BM MSC biological behaviors and the potential mechanism underlying these effects. Functional in vitro experiments showed that the suppression of the INTS7 ABCD3 interaction rather than HDLBP could impair BM MSC proliferation and induce cell apoptosis. Moreover, Alizarin Red S and Oil Red O staining, respectively, revealed that INTS7 and ABCD3 knockdown but not HDLBP knockdown could decrease osteoblastic differentiation and accelerate the adipogenic differentiation of BM MSCs. Mechanistically, reactive oxygen species (ROS) and histone gamma H2AX quantities significantly increased, whereas the levels of antioxidants declined due to INTS7 and ABCD3 inhibition in BM MSCs. These findings indicated that the suppression of oxidative stress could be involved in the INTS7/ABCD3 co regulatory mechanisms for BM MSC proliferation and differentiation, identifying new potential candidates for osteoporosis therapy.
C1 [Liu, Yubo; Wang, Yijun; Geng, Wei; Xu, Yaozeng] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou, Peoples R China.
   [Liu, Yubo; Yu, Xiao; Huang, Anquan; Zhang, Xiangxin; Xu, Renjie; Li, Suoyuan; He, Hui; Chen, Guangxiang] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Orthopaed, Suzhou, Peoples R China.
   [Zheng, Bo] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Ctr Reprod & Genet,State Key Lab Reprod, Suzhou, Peoples R China.
   [Zheng, Bo] Nanjing Med Univ, Dept Histol & Embryol, State Key Lab Reprod Med, Nanjing, Peoples R China.
C3 Soochow University   China; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Xu, YZ (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou, Peoples R China.; Chen, GX (通讯作者)，Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Orthopaed, Suzhou, Peoples R China.
EM cgx65111799@hotmail.com; xuyaozeng@163.com
RI zhang, xiangxin/AFR 2242 2022; Wang, Yijun/GXW 1763 2022; Zheng,
   Bo/AAC 6993 2022; chen, GX/AAF 5713 2020; Geng, Wei/KYQ 4201 2024; xu,
   renjie/JDM 9087 2023
OI xu, renjie/0000 0002 6147 2453
CR Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Blum M, 2021, NUCLEIC ACIDS RES, V49, pD344, DOI 10.1093/nar/gkaa977
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen QH, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01612 y
   Choo KB, 2014, INT J MED SCI, V11, P1201, DOI 10.7150/ijms.8356
   Colasante C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183150
   Cotta Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   Federico A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050936
   Gao TT, 2020, CELL CYCLE, V19, P1884, DOI 10.1080/15384101.2020.1779471
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Imanaka T, 2000, CELL BIOCHEM BIOPHYS, V32, P131, DOI 10.1385/CBB:32:1 3:131
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanda Y, 2011, LIFE SCI, V89, P250, DOI 10.1016/j.lfs.2011.06.007
   Kawaguchi K, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6786245
   Ko E, 2012, STEM CELLS DEV, V21, P1877, DOI 10.1089/scd.2011.0284
   Kobayashi CI, 2012, J CELL PHYSIOL, V227, P421, DOI 10.1002/jcp.22764
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   Lane MD, 1996, INT J OBESITY, V20, pS91
   Lee JN, 2018, BIOCHEM BIOPH RES CO, V501, P696, DOI 10.1016/j.bbrc.2018.05.050
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liu AR, 2013, J CELL PHYSIOL, V228, P1270, DOI 10.1002/jcp.24282
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mulder JE, 2006, NAT CLIN PRACT ENDOC, V2, P670, DOI 10.1038/ncpendmet0325
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Sargent G, 2016, J CELL BIOL, V214, P677, DOI 10.1083/jcb.201511034
   Shen C., 2019, ASIAN J ANDROL, V21, P345, DOI [10.4103/aja.aja_65_18, DOI 10.4103/aja.aja_65_18]
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 19
   Weng GQ, 2019, NUCLEIC ACIDS RES, V47, pW322, DOI 10.1093/nar/gkz397
   Wu YY, 2021, PEERJ, V9, DOI 10.7717/peerj.10847
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Yang D, 2018, CELL BIOL INT, V42, P403, DOI 10.1002/cbin.10902
   Yang JY, 2020, P NATL ACAD SCI USA, V117, P1496, DOI 10.1073/pnas.1914677117
   Yu J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.665089
   Yu TH, 2018, ONCOL LETT, V16, P48, DOI 10.3892/ol.2018.8668
   Zhao D, 2019, CELL CYCLE, V18, P2800, DOI 10.1080/15384101.2019.1661174
   Zhuang HL, 2016, CURR STEM CELL RES T, V11, P255, DOI 10.2174/1574888X10666150531173309
   Zou XN, 2004, BIOMATERIALS, V25, P5375, DOI 10.1016/j.biomaterials.2003.12.041
NR 45
TC 19
Z9 20
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD NOV 22
PY 2021
VL 12
AR 758607
DI 10.3389/fphys.2021.758607
PG 12
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA XJ7QP
UT WOS:000726977800001
PM 34880777
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, C
   Xu, BW
   Miu, XX
   Deng, ZB
   Liao, H
   Hao, L
AF Li, Chen
   Xu, Binwu
   Miu, Xinxin
   Deng, Zhongbo
   Liao, Hang
   Hao, Liang
TI Inhibition of miRNA 21 attenuates the proliferation and metastasis of
   human osteosarcoma by upregulating PTEN
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE microRNA 21; phosphatase and tensin homolog; osteosarcoma;
   phosphoinositide 3 kinase/RAC alpha serine/threonine protein kinase
   signaling pathway
ID TUMOR SUPPRESSOR PTEN; CANCER CELLS; GENE; LINES; INVOLVEMENT;
   EXPRESSION; RESISTANCE; APOPTOSIS; SURVIVAL; THERAPY
AB The present study aimed to investigate the expression of micro (mi) RNA 21 in osteosarcoma cells, and its role in inhibiting the invasion and metastasis of osteosarcoma. Human osteosarcoma MG 63 cells and osteoblast hFOB1.19 cells were used to compare the expression of miRNA 21 using reverse transcription quantitative polymerase chain reaction analysis. A miRNA 21 mimic or inhibitor were transfected into the MG 63 cells to upregulate and downregulate the expression of miRNA 21, respectively. The present study investigated the proliferation and invasion of transfected MG 63 cells using MTT and Transwell assays. Western blot analyses were used to investigate the regulation of important proteins in the phosphatase and tensin homolog/phosphoinositide 3 kinase/RAC alpha serine/threonine protein kinase (PTEN/PI3K/AKT) signaling pathway. Compared with hFOB1.19 cells, miRNA 21 expression was significantly upregulated in the MG 63 cells (P<0.01), which lead to increased proliferation. Downregulating miRNA 21 expression reduced the proliferation of MG 63 cells compared with hFOB1.19 cells. Invasion assays and western blot analyses revealed that the overexpression of miRNA 21 significantly enhanced the invasion ability of MG 63 cells and the expression of phosphorylated (p ) AKT, while downregulation of miRNA 21 expression reduced the protein level of AKT and p AKT. In the MG 63 cells, miRNA 21 upregulation significantly inhibited the protein level of PTEN, resulting in significantly increased AKT and PI3K protein levels (P<0.01). In conclusion, the results of the present study indicate that the expression of miRNA 21, PI3K and AKT is increased in the osteosarcoma cell line MG 63, which results in reduced expression of PTEN and increased expression of proteins in the PI3K/AKT signaling pathway, and thus increases the aggressiveness of osteosarcoma cells.
C1 [Li, Chen; Xu, Binwu; Miu, Xinxin; Deng, Zhongbo; Liao, Hang; Hao, Liang] Nanchang Univ, Affiliated Hosp 2, Dept Orthoped Surg, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University
RP Hao, L (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Orthoped Surg, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM haollhao96@126.com
RI hao, liang/NBX 8636 2025
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Berner K, 2015, ACTA ONCOL, V54, P25, DOI 10.3109/0284186X.2014.923934
   Chu EC, 2004, MED SCI MONITOR, V10, pRA235
   Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599
   Griffiths Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092 8674(93)90529 Y
   Levine RA, 2002, VET PATHOL, V39, P372, DOI 10.1354/vp.39 3 372
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046
   Liu XL, 2016, TOXICOL LETT, V252, P1, DOI 10.1016/j.toxlet.2016.04.015
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu XD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139582
   Maehama T, 2004, BIOCHEM SOC T, V32, P343, DOI 10.1042/BST0320343
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057
   Nakanishi A, 2014, INT J ONCOL, V44, P1813, DOI 10.3892/ijo.2014.2377
   Rizvi MMA, 2012, PATHOL ONCOL RES, V18, P309, DOI 10.1007/s12253 011 9446 z
   Sarkar S, 2013, AM J CANCER RES, V3, P465
   Venkatramani R, 2016, PEDIATR BLOOD CANCER, V63, P412, DOI 10.1002/pbc.25808
   Wagner A, 2014, INT J MOL SCI, V15, P20134, DOI 10.3390/ijms151120134
   Wu YR, 2016, TUMOR BIOL, V37, P12061, DOI 10.1007/s13277 016 5074 2
   Wu ZH, 2016, TUMOR BIOL, V37, P7245, DOI 10.1007/s13277 015 4604 7
   Xue R, 2016, CLIN SCI, V130, P377, DOI 10.1042/CS20150496
   Yang Feng, 2014, Yichuan, V36, P456, DOI 10.3724/SP.J.1005.2014.0456
   Zhu LH, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00165
   Ziyan W, 2016, IRISH J MED SCI, V185, P85, DOI 10.1007/s11845 014 1225 x
NR 26
TC 28
Z9 30
U1 1
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2018
VL 15
IS 1
BP 1036
EP 1040
DI 10.3892/etm.2017.5477
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FV0WL
UT WOS:000424281600149
PM 29434694
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Miao, TX
   Rao, KS
   Spees, JL
   Oldinski, RA
AF Miao, Tianxin
   Rao, Krithika S.
   Spees, Jeffrey L.
   Oldinski, Rachael A.
TI Osteogenic differentiation of human mesenchymal stem cells through
   alginate graft poly(ethylene glycol) microsphere mediated intracellular
   growth factor delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Alginate; Poly(ethylene glycol); Microspheres; RGD; Mesenchymal stem
   cells; Growth factor delivery
ID DRUG DELIVERY; ALGINATE MICROSPHERES; STROMAL CELLS; RGD; OSTEOBLAST;
   ASSAY; DNA; NANOPARTICLES; PROLIFERATION; MICROCAPSULES
AB The intracellular delivery of growth factors increases opportunities for controlling cell behavior and maintaining tissue homeostasis. Recently, VEGFA was reported to enhance osteogenic differentiation of mesenchymal stem cells (MSCs) through an intracrine mechanism, suggesting a new strategy to promote bone tissue formation in osteoporotic patients. The goal of this study was to design and fabricate ligand conjugated alginate graft poly(ethylene glycol) microspheres for intracellular delivery and release of VEGFA in primary human MSCs to enhance osteogenic differentiation as a potential therapeutic. Three types of microspheres were synthesized and characterized by scanning electron microscopy, in vitro drug release kinetics, MSC uptake and internalization: alginate alone (Alg), alginate graft poly(ethylene glycol) (Alg g PEG) and alginate graft poly(ethylene glycol) S S arginine glycine aspartic acid (Alg g RGD). Each of the different microsphere formulations successfully transported bioactive VEGFA into primary human MSCs within 48 h of culture, and significantly enhanced osteogenic differentiation compared to control treatments with empty microspheres (intracellular control) or non encapsulated VEGFA (extracellular control). Adipogenic differentiation was not affected by the presence of VEGFA intracellularly or extracellularly. These results demonstrating the internalization of alginate based microspheres and intracellular delivery of VEGFA support the efficacy of using this drug delivery and intracrine mechanism to control the fate of human MSCs and enhance osteogenic differentiation. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Miao, Tianxin; Oldinski, Rachael A.] Univ Vermont, Coll Engn & Math Sci, Coll Med, Bioengn Program, Burlington, VT 05405 USA.
   [Rao, Krithika S.; Spees, Jeffrey L.] Univ Vermont, Coll Med, Cell & Mol Biol Grad Program, Burlington, VT 05405 USA.
   [Spees, Jeffrey L.] Univ Vermont, Stem Cell Core, Colchester, VT 05446 USA.
   [Oldinski, Rachael A.] Univ Vermont, Coll Engn & Math Sci, Mech Engn Program, Burlington, VT 05405 USA.
   [Oldinski, Rachael A.] Univ Vermont, Dept Orthopaed & Rehabil, Coll Med, Burlington, VT 05405 USA.
C3 University of Vermont; University of Vermont; University of Vermont;
   University of Vermont; University of Vermont
RP Oldinski, RA (通讯作者)，33 Colchester Ave,Votey 201D, Burlington, VT 05405 USA.
EM tmiao@uvm.edu; krao@uvm.edu; jspees@uvm.edu; oldinski@uvm.edu
FU College of Engineering and Mathematical Sciences at the University of
   Vermont; NIH [R01 HL085210]
FX The authors gratefully acknowledge members of the Engineered
   Biomaterials Research Laboratory at the University of Vermont, the
   visiting NSF REU research assistant Ashleigh Bristol from the University
   of Mississippi for her technical assistance, Alexander Aronshtam, Ph.D.
   for cloning and purification of human VEGFA, and Jianjin Wang for his
   assistance with the statistical analysis. The authors would also like to
   thank members of the University of Vermont Microscopy Imaging Center in
   the College of Medicine for assistance with CLS and SEM imaging. This
   work was supported by the College of Engineering and Mathematical
   Sciences at the University of Vermont and NIH R01 HL085210 (to J.L.S.).
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Aldridge A, 2013, CYTOTHERAPY, V15, P89, DOI 10.1016/j.jcyt.2012.07.001
   [Anonymous], BIOMATERIALS
   Bassyouni F., 2013, RES CHEM INTERMEDIAT, P1
   Chang SJ, 2002, J BIOMED MATER RES, V59, P118, DOI 10.1002/jbm.1223
   Chung HJ, 2007, ADV DRUG DELIVER REV, V59, P249, DOI 10.1016/j.addr.2007.03.015
   Ciofani G, 2008, BIOMED MICRODEVICES, V10, P131, DOI 10.1007/s10544 007 9118 7
   Colombo R, 2012, J MED CHEM, V55, P10460, DOI 10.1021/jm301058f
   Davidovich Pinhas M, 2011, ACTA BIOMATER, V7, P2817, DOI 10.1016/j.actbio.2011.04.001
   Davidovich Pinhas M, 2011, ACTA BIOMATER, V7, P625, DOI 10.1016/j.actbio.2010.09.021
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   García AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502
   Gåserod O, 1999, BIOMATERIALS, V20, P773, DOI 10.1016/S0142 9612(98)00230 0
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Huang SY, 1998, BIOCONJUGATE CHEM, V9, P612, DOI 10.1021/bc980038p
   Iso Y, 2014, STEM CELLS, V32, P674, DOI 10.1002/stem.1546
   Jain S, 2012, BIOMACROMOLECULES, V13, P1074, DOI 10.1021/bm2017993
   Jay SM, 2008, FASEB J, V22, P2949, DOI 10.1096/fj.08 108803
   Jay SM, 2009, J CONTROL RELEASE, V134, P26, DOI 10.1016/j.jconrel.2008.10.019
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kim S, 2009, EUR J PHARM BIOPHARM, V71, P420, DOI 10.1016/j.ejpb.2008.09.021
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092 8674(00)81002 8
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Lee KY, 2004, NANO LETT, V4, P1501, DOI 10.1021/nl0493592
   Lemoine D, 1998, INT J PHARMACEUT, V176, P9, DOI 10.1016/S0378 5173(98)00303 2
   Lin N, 2011, COLLOID SURFACE B, V85, P270, DOI 10.1016/j.colsurfb.2011.02.039
   Liu J, 2012, TISSUE ENG PT A, V18, P2303, DOI [10.1089/ten.tea.2011.0658, 10.1089/ten.TEA.2011.0658]
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Mahou R, 2012, J MATER SCI MATER M, V23, P171, DOI 10.1007/s10856 011 4512 3
   Mahou R, 2010, MACROMOLECULES, V43, P1371, DOI 10.1021/ma902469f
   Meng XW, 2010, CHEM COMMUN, V46, P643, DOI 10.1039/b916224k
   Meng XW, 2011, LANGMUIR, V27, P14401, DOI 10.1021/la2028803
   Midoux P, 2008, CURR GENE THER, V8, P335, DOI 10.2174/156652308786071014
   Mittal SK, 2000, VACCINE, V19, P253, DOI 10.1016/S0264 410X(00)00170 5
   Moshaverinia A, 2014, TISSUE ENG PT A, V20, P611, DOI 10.1089/ten.TEA.2013.0229
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Park JS, 2010, BIOMATERIALS, V31, P6239, DOI 10.1016/j.biomaterials.2010.05.002
   Pawar SN, 2012, BIOMATERIALS, V33, P3279, DOI 10.1016/j.biomaterials.2012.01.007
   Petrie TA, 2008, BIOMATERIALS, V29, P2849, DOI 10.1016/j.biomaterials.2008.03.036
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Salinas CN, 2008, BIOMATERIALS, V29, P2370, DOI 10.1016/j.biomaterials.2008.01.035
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Sinha VR, 2003, J CONTROL RELEASE, V90, P261, DOI 10.1016/S0168 3659(03)00194 9
   Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103
   Temming K, 2005, DRUG RESIST UPDATE, V8, P381, DOI 10.1016/j.drup.2005.10.002
   Tonnesen HH, 2002, DRUG DEV IND PHARM, V28, P621, DOI 10.1081/DDC 120003853
   Wang YN, 2011, BIOMATERIALS, V32, P4903, DOI 10.1016/j.biomaterials.2011.03.027
   WHEATLEY MA, 1991, J APPL POLYM SCI, V43, P2123, DOI 10.1002/app.1991.070431120
   Wu YQ, 2009, BIOMACROMOLECULES, V10, P19, DOI 10.1021/bm801033f
NR 55
TC 51
Z9 62
U1 1
U2 87
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT 28
PY 2014
VL 192
BP 57
EP 66
DI 10.1016/j.jconrel.2014.06.029
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA AQ0GF
UT WOS:000342460400007
PM 24979209
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kritmetapak, K
   Kumar, R
AF Kritmetapak, Kittrawee
   Kumar, Rajiv
TI Phosphatonins: From Discovery to Therapeutics
SO ENDOCRINE PRACTICE
LA English
DT Article
DE fibroblast growth factor 23; hypophosphatemia; osteomalacia;
   phosphatonin; rickets; vitamin D
ID FRIZZLED RELATED PROTEIN 4; STIMULATORY G PROTEIN; X LINKED RICKETS;
   HYPOPHOSPHATEMIC RICKETS; CLINICAL CONSEQUENCES; FIBROUS DYSPLASIA;
   FGF23; TRANSPORT; KIDNEY; OSTEOMALACIA
AB Objective: Phosphate is crucial for cell signaling, energy metabolism, nucleotide synthesis, and bone mineralization. The gut bone parathyroid kidney axis is influenced by parathyroid hormone, 1,25dihydroxyvitamin D, and phosphatonins, especially fibroblast growth factor 23 (FGF23). These hormones facilitate maintenance of phosphate homeostasis. This review summarizes current knowledge regarding the phosphate homeostasis, phosphatonin pathophysiology, and clinical implications of FGF23 related hypophosphatemic disorders, with specific focus on burosumab treatment.Method: A focused literature search of PubMed was conducted. Results: Phosphatonins including FGF23, secreted frizzled related protein 4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 7 play a pathogenic role in several hypophosphatemic disorders. Excess FGF23 inhibits sodium dependent phosphate cotransporters (NaPi 2a and NaPi 2c), resulting in hyperphosphaturia and hypophosphatemia. Additionally, FGF23 suppresses 1,25 dihydroxyvitamin D synthesis in the proximal renal tubule, and thus, it indirectly inhibits intestinal phosphate absorption. Disorders of FGF23 related hypophosphatemia include X linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, fibrous dysplasia/McCune Albright syndrome, and tumor induced osteomalacia (TIO). Complications of conventional therapy with oral phosphate and vitamin D analogs comprise gastrointestinal distress, hypercalcemia, nephrocalcinosis, and secondary/tertiary hyperparathyroidism. In both children and adults with XLH and TIO, the anti FGF23 antibody burosumab exhibits a favorable safety profile and is associated with healing of rickets in affected children and improvement of osteomalacia in both children and adults.Conclusion: The treatment paradigm for XLH and TIO is changing based on data from recent clinical trials. Research suggest that burosumab is effective and safe for pediatric and adult patients with XLH or TIO.(c) 2022 AACE. Published by Elsevier Inc. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Kritmetapak, Kittrawee] Khon Kaen Univ, Fac Med, Khon Kaen, Thailand.
   [Kumar, Rajiv] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA.
   [Kumar, Rajiv] Mayo Clin, Div Nephrol & Hypertens, Med Sci Bldg 1 120,200 1st St Southwest, Rochester, MN 55905 USA.
C3 Khon Kaen University; Mayo Clinic; Mayo Clinic
RP Kumar, R (通讯作者)，Mayo Clin, Div Nephrol & Hypertens, Med Sci Bldg 1 120,200 1st St Southwest, Rochester, MN 55905 USA.
EM rkumar@mayo.edu
OI Kumar, Rajiv/0000 0003 3497 3057
CR Amanzadeh J, 2006, NAT CLIN PRACT NEPHR, V2, P136, DOI 10.1038/ncpneph0124
   Ansermet C, 2017, J AM SOC NEPHROL, V28, P1073, DOI 10.1681/ASN.2016070726
   Bansal S, 2016, CLIN NEPHROL, V85, DOI 10.5414/CN108596
   Zanchetta MB, 2021, J BONE MINER RES, V36, P1502, DOI 10.1002/jbmr.4325
   Berndt T, 2003, J CLIN INVEST, V112, P785, DOI 10.1172/JC1200318563
   Berndt T, 2007, ANNU REV PHYSIOL, V69, P341, DOI 10.1146/annurev.physiol.69.040705.141729
   Berndt TJ, 2006, PFLUG ARCH EUR J PHY, V451, P579, DOI 10.1007/s00424 005 1495 2
   Bhadada SK, 2021, CALCIFIED TISSUE INT, V108, P32, DOI 10.1007/s00223 020 00729 9
   Brandi ML, 2021, BONE, V152, DOI 10.1016/j.bone.2021.116064
   Bresler D, 2004, J ENDOCRINOL, V183, pR1, DOI 10.1677/joe.1.05989
   Breusegem SY, 2009, AM J PHYSIOL RENAL, V297, pF350, DOI 10.1152/ajprenal.90765.2008
   Briot K, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001714
   CAI Q, 1994, NEW ENGL J MED, V330, P1645, DOI 10.1056/NEJM199406093302304
   Carpenter TO, 2018, NEW ENGL J MED, V378, P1987, DOI 10.1056/NEJMoa1714641
   Carpenter TO, 2005, J CLIN ENDOCR METAB, V90, P1012, DOI 10.1210/jc.2004 0357
   Christov M, 2011, ENDOCRINOLOGY, V152, P2031, DOI 10.1210/en.2010 1351
   Cianferotti L, 2022, ENDOCRINE, V76, P709, DOI 10.1007/s12020 022 03039 2
   Clinkenbeard EL, 2017, BONE, V102, P31, DOI 10.1016/j.bone.2017.01.034
   Crotti C, 2021, BONE, V152, DOI 10.1016/j.bone.2021.116077
   De Beur SMJ, 2002, J BONE MINER RES, V17, P1102, DOI 10.1359/jbmr.2002.17.6.1102
   ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310
   Edmonston D, 2020, NAT REV NEPHROL, V16, P7, DOI 10.1038/s41581 019 0189 5
   Endo I, 2008, BONE, V42, P1235, DOI 10.1016/j.bone.2008.02.014
   Farrow EG, 2011, P NATL ACAD SCI USA, V108, pE1146, DOI 10.1073/pnas.1110905108
   Farrow EG, 2010, NAT REV NEPHROL, V6, P207, DOI 10.1038/nrneph.2010.17
   Florenzano P, 2021, CALCIFIED TISSUE INT, V108, P128, DOI 10.1007/s00223 020 00691 6
   Folpe AL, 2019, SEMIN DIAGN PATHOL, V36, P260, DOI 10.1053/j.semdp.2019.07.002
   Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107
   Heijboer AC, 2023, CALCIFIED TISSUE INT, V112, P258, DOI 10.1007/s00223 022 00987 9
   Hernando N, 2021, PHYSIOL REV, V101, P1, DOI 10.1152/physrev.00008.2019
   Hidaka N, 2022, J BONE MINER RES, V37, P1479, DOI 10.1002/jbmr.4620
   Ho BB, 2021, J MOL ENDOCRINOL, V66, pR23, DOI 10.1530/JME 20 0178
   Höppner J, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116111
   Ichida Y, 2021, NEPHROL DIAL TRANSPL, V36, P68, DOI 10.1093/ndt/gfaa156
   Ichikawa S, 2014, ENDOCRINOLOGY, V155, P3891, DOI 10.1210/en.2014 1199
   Imel EA, 2006, J CLIN ENDOCR METAB, V91, P2055, DOI 10.1210/jc.2005 2105
   Imel EA, 2020, J BONE MINER RES, V35, P231, DOI 10.1002/jbmr.3878
   Imel EA, 2019, LANCET, V393, P2416, DOI 10.1016/S0140 6736(19)30654 3
   Imel EA, 2021, CALCIFIED TISSUE INT, V108, P74, DOI 10.1007/s00223 020 00692 5
   Insogna KL, 2019, J BONE MINER RES, V34, P2183, DOI 10.1002/jbmr.3843
   Insogna KL, 2018, J BONE MINER RES, V33, P1383, DOI 10.1002/jbmr.3475
   Ito N, 2010, J INTERN MED, V268, P390, DOI 10.1111/j.1365 2796.2010.02262.x
   Jacquillet G, 2019, PFLUG ARCH EUR J PHY, V471, P83, DOI 10.1007/s00424 018 2231 z
   de Beur SMJ, 2021, J BONE MINER RES, V36, P627, DOI 10.1002/jbmr.4233
   Jiajue R, 2022, FRONT ENDOCRINOL, V13
   Kato H, 2022, J BONE MINER METAB, V40, P101, DOI 10.1007/s00774 021 01258 7
   Khosravi A, 2007, J CLIN ENDOCR METAB, V92, P2374, DOI 10.1210/jc.2006 2865
   Kritmetapak K, 2021, J AM SOC NEPHROL, V32, P1830, DOI 10.1681/ASN.2021050610
   Kritmetapak K, 2021, CALCIFIED TISSUE INT, V108, P16, DOI 10.1007/s00223 019 00636 8
   Kuro O M, 2011, KIDNEY INT, V79, pS20, DOI 10.1038/ki.2011.26
   Lederer E, 2012, CLIN J AM SOC NEPHRO, V7, P1179, DOI 10.2215/CJN.09090911
   Leow MKS, 2021, J CLIN ENDOCR METAB, V106, P2299, DOI DOI 10.1210/clinem/dgaa964
   Levi M, 2019, NAT REV NEPHROL, V15, P482, DOI 10.1038/s41581 019 0159 y
   Liu C, 2021, OSTEOPOROSIS INT, V32, P737, DOI 10.1007/s00198 020 05649 w
   Lotscher M, 1997, J CLIN INVEST, V99, P1302, DOI 10.1172/JCI119289
   LYLES KW, 1985, J CLIN ENDOCR METAB, V60, P711, DOI 10.1210/jcem 60 4 711
   Marcucci G, 2021, CALCIFIED TISSUE INT, V108, P91, DOI 10.1007/s00223 020 00695 2
   Marks J, 2019, PFLUG ARCH EUR J PHY, V471, P165, DOI 10.1007/s00424 018 2221 1
   Michigami T, 2018, PHYSIOL REV, V98, P2317, DOI 10.1152/physrev.00022.2017
   Moe OW, 2009, AM J PHYSIOL RENAL, V296, pF689, DOI 10.1152/ajprenal.00007.2009
   Murali SK, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002427
   Naderi ASA, 2010, NAT REV NEPHROL, V6, P657, DOI 10.1038/nrneph.2010.121
   Ni XL, 2022, J BONE MINER RES, V37, P454, DOI 10.1002/jbmr.4476
   Olauson H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003975
   Olauson H, 2012, J AM SOC NEPHROL, V23, P1641, DOI 10.1681/ASN.2012010048
   Padidela R, 2021, CALCIFIED TISSUE INT, V108, P622, DOI 10.1007/s00223 020 00797 x
   Pande S, 2006, NEPHRON PHYSIOL, V104, P23, DOI 10.1159/000093277
   Piketty ML, 2020, CLIN CHEM LAB MED, V58, pE267, DOI 10.1515/cclm 2020 0460
   Portale AA, 2019, CALCIFIED TISSUE INT, V105, P271, DOI 10.1007/s00223 019 00568 3
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Ritter CS, 2015, KIDNEY INT, V87, P1141, DOI 10.1038/ki.2015.22
   Roszko KL, 2018, NEW ENGL J MED, V379, P1964, DOI 10.1056/NEJMc1808583
   Rowe PSN, 2005, BONE, V36, P33, DOI 10.1016/j.bone.2004.09.015
   Rowe PSN, 2004, BONE, V34, P303, DOI 10.1016/j.bone.2003.10.005
   Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221
   Sabbagh Y, 2005, P NATL ACAD SCI USA, V102, P9637, DOI 10.1073/pnas.0502249102
   Saito T, 2009, INT J PEDIATR ENDOCR, DOI 10.1155/2009/496514
   Saki F, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882 020 01826 5
   SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152
   Trombetti A, 2022, NAT REV ENDOCRINOL, V18, P366, DOI 10.1038/s41574 022 00662 x
   Ward LM, 2022, J CLIN ENDOCR METAB, V107, pE3241, DOI 10.1210/clinem/dgac296
   Weinman EJ, 2011, AM J PHYSIOL RENAL, V300, pF231, DOI 10.1152/ajprenal.00532.2010
   WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403
   Whyte MP, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115300
   Whyte MP, 2019, LANCET DIABETES ENDO, V7, P189, DOI 10.1016/S2213 8587(18)30338 3
   Woeckel VJ, 2010, J CELL PHYSIOL, V225, P593, DOI 10.1002/jcp.22244
   Wolf M, 2020, JAMA J AM MED ASSOC, V323, P432, DOI 10.1001/jama.2019.22450
   Wolf M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124486
   Yuan B, 2008, J CLIN INVEST, V118, P722, DOI 10.1172/JCI32702
   Yuan BZ, 2013, J BONE MINER RES, V28, P56, DOI 10.1002/jbmr.1738
   Zoller H, 2017, CURR OPIN NEPHROL HY, V26, P266, DOI 10.1097/MNH.0000000000000329
NR 91
TC 20
Z9 21
U1 0
U2 7
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1530 891X
EI 1934 2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD JAN
PY 2023
VL 29
IS 1
BP 69
EP 79
DI 10.1016/j.eprac.2022.09.007
EA JAN 2023
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8A5XH
UT WOS:000916311500001
PM 36210014
OA hybrid
DA 2025 08 17
ER

PT J
AU Huang, D
   Zhao, C
   Li, RY
   Chen, BY
   Zhang, YT
   Sun, ZJ
   Wei, JK
   Zhou, HH
   Gu, Q
   Xu, J
AF Huang, Dane
   Zhao, Chao
   Li, Ruyue
   Chen, Bingyi
   Zhang, Yuting
   Sun, Zhejun
   Wei, Junkang
   Zhou, Huihao
   Gu, Qiong
   Xu, Jun
TI Identification of a binding site on soluble RANKL that can be targeted
   to inhibit soluble RANK RANKL interactions and treat osteoporosis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RECEPTOR ACTIVATOR; TNF SUPERFAMILY; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN LIGAND; CRYSTAL STRUCTURE; MOUSE RANK; PEPTIDE;
   TUBERCULOSIS; STRATEGIES; CYTOKINE
AB One of the major challenges for discovering protein protein interaction inhibitors is identifying selective and druggable binding sites at the protein surface. Here, we report an approach to identify a small molecular binding site to selectively inhibit the interaction of soluble RANKL and RANK for designing anti osteoporosis drugs without undesirable immunosuppressive effects. Through molecular dynamic simulations, we discovered a binding site that allows a small molecule to selectively interrupt soluble RANKL RANK interaction and without interfering with the membrane RANKL RANK interaction. We describe a highly potent inhibitor, S3 15, and demonstrate its specificity to inhibit the soluble RANKL RANK interaction with in vitro and in vivo studies. S3 15 exhibits anti osteoporotic effects without causing immunosuppression. Through in silico and in vitro experiments we further confirm the binding model of S3 15 and soluble RANKL. This work might inspire structure based drug discovery for targeting protein protein interactions.
   Huang et al. discover a binding site on soluble RANKL that is not found on its membrane bound homologue. A drug screening identified a small molecule (S3 15) that can target this binding site and has anti osteoporotic but not immunosuppressive effects.
C1 [Huang, Dane; Zhao, Chao; Chen, Bingyi; Zhang, Yuting; Sun, Zhejun; Wei, Junkang; Zhou, Huihao; Gu, Qiong; Xu, Jun] Sun Yat Sen Univ, Sch Pharmaceut Sci, Res Ctr Drug Discovery, Guangzhou 510006, Peoples R China.
   [Huang, Dane; Li, Ruyue] Guangdong Prov Second Hosp Tradit Chinese Med, Guangdong Prov Engn Technol Res Inst Tradit Chine, Guangdong Prov Key Lab Res & Dev Tradit Chinese M, Guangzhou 510095, Peoples R China.
C3 Sun Yat Sen University
RP Zhou, HH; Gu, Q; Xu, J (通讯作者)，Sun Yat Sen Univ, Sch Pharmaceut Sci, Res Ctr Drug Discovery, Guangzhou 510006, Peoples R China.
EM zhuihao@mail.sysu.edu.cn; guqiong@mail.sysu.edu.cn;
   junxu@biochemomes.com
RI ZHOU, HUIHAO/L 6133 2016; ZHANG, YUTING/HOH 4131 2023; Gu,
   Qiong/N 1653 2017; Xu, Jun/AAI 7544 2020
OI ZHOU, HUIHAO/0000 0002 9675 5007; Gu, Qiong/0000 0001 6011 3697; Xu,
   Jun/0000 0002 1075 0337; WEI, JUNKANG/0000 0001 5666 2140; 
FU Natural Science Foundation of China [81573310, 82104473, 22177140];
   GuangDong Basic and Applied Basic Research Foundation [2019A1515110484];
   Science and Technology Planning Project of Guangdong Province
   [2016A020217005]
FX This work was supported by the Natural Science Foundation of China
   (81573310, 82104473, 22177140), GuangDong Basic and Applied Basic
   Research Foundation (2019A1515110484) and the Science and Technology
   Planning Project of Guangdong Province (2016A020217005). We thank Prof.
   J.X. (School of Biomedical Sciences, University of Western Australia)
   for kindly providing full length mouse and human mRANKL plasmids and
   other kindly assistance.
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Arthur KK, 2012, BIOCHEMISTRY US, V51, P795, DOI 10.1021/bi2007806
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Breuil V, 2010, OSTEOPOROSIS INT, V21, P805, DOI 10.1007/s00198 009 1018 7
   Cappariello A, 2015, BIOMATERIALS, V46, P58, DOI 10.1016/j.biomaterials.2014.12.033
   Celià Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556 018 0145 9
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Corbi Verge C, 2017, ANNU REV PHARMACOL, V57, P39, DOI 10.1146/annurev pharmtox 010716 104805
   Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22
   Croft M, 2012, TRENDS IMMUNOL, V33, P144, DOI 10.1016/j.it.2011.10.004
   Delgado Calle J, 2018, FASEB J, V32, P2878, DOI 10.1096/fj.201700919RRR
   Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011
   Elango J, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155559
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   Fouque Aubert A, 2008, JOINT BONE SPINE, V75, P5, DOI 10.1016/j.jbspin.2007.05.004
   Freyer MW, 2008, METHOD CELL BIOL, V84, P79, DOI 10.1016/S0091 679X(07)84004 0
   He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304
   Hong GJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00331
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kanzaki H, 2016, J IMMUNOL, V197, P3871, DOI 10.4049/jimmunol.1601114
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Magni F, 2005, PROTEOMICS, V5, P816, DOI 10.1002/pmic.200401077
   Mancini F, 1999, BIOCHEM PHARMACOL, V58, P851, DOI 10.1016/S0006 2952(99)00150 1
   Martínez ON, 2001, AM J GASTROENTEROL, V96, P1665
   Mashiach E, 2010, NUCLEIC ACIDS RES, V38, pW457, DOI 10.1093/nar/gkq373
   Modell AE, 2016, TRENDS PHARMACOL SCI, V37, P702, DOI 10.1016/j.tips.2016.05.008
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365 2222.1997.tb00690.x
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175
   Phelps DK, 1999, PROTEIN SCI, V8, P2281
   Raje NS, 2019, CLIN CANCER RES, V25, P12, DOI 10.1158/1078 0432.CCR 18 1537
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022 1759(90)90210 M
   Roodman GD, 2007, BONE MARROW TRANSPL, V40, P1139, DOI 10.1038/sj.bmt.1705802
   Sanchez Paulete AR, 2016, EUR J IMMUNOL, V46, P513, DOI 10.1002/eji.201445388
   Scott DE, 2016, NAT REV DRUG DISCOV, V15, P533, DOI 10.1038/nrd.2016.29
   Steeland S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051442
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Touti F, 2019, NAT CHEM BIOL, V15, P410, DOI 10.1038/s41589 019 0245 2
   Walsh MC, 2021, J BONE MINER METAB, V39, P54, DOI 10.1007/s00774 020 01178 y
   Walter TS, 2009, ACTA CRYSTALLOGR F, V65, P597, DOI 10.1107/S1744309109015735
   Xie X, 2014, J MICROBIOL IMMUNOL, V47, P268, DOI 10.1016/j.jmii.2013.03.005
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yan LL, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.190360
   Zhao C, 2019, J MED CHEM, V62, P5885, DOI 10.1021/acs.jmedchem.9b00517
NR 58
TC 33
Z9 36
U1 7
U2 68
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP 12
PY 2022
VL 13
IS 1
AR 5338
DI 10.1038/s41467 022 33006 4
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 4M2UQ
UT WOS:000853182100018
PM 36097003
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jääger, K
   Fatkina, A
   Velts, A
   Orav, E
   Neuman, T
AF Jaeaeger, Kersti
   Fatkina, Angelika
   Velts, Anna
   Orav, Ester
   Neuman, Toomas
TI Variable expression of lineage regulators in differentiated stromal
   cells indicates distinct mechanisms of differentiation towards common
   cell fate
SO GENE
LA English
DT Article
DE Gene expression; Differentiation; Cell to cell variation; Stromal cells
ID MESENCHYMAL STEM CELLS; HUMAN ADIPOSE TISSUE; TRANSCRIPTIONAL
   REGULATION; BONE MARROW; SOX9; GENE; FIBROBLASTS; ENHANCER; COL2A1
AB Mesenchymal stem cells (MSCs) possess a multi lineage differentiation capacity that makes them important players in the field of regenerative medicine. MSC populations derived from different tissues or donors have been shown to exhibit variable gene expression patterns. Further, it is widely acknowledged that MSC isolates are heterogeneous mixtures of cells at different developmental stages. However, the heterogeneity of expression of lineage regulators has not been linked to differentiation potential of different MSC populations towards mesenchymal lineages. Here, we analyzed variation of expression of differentiation markers across whole population and between single differentiating cells of multipotent stromal cell populations derived from adipose tissue (AdMSCs) and skin (FBs) of seven donors. The results of the analyses show that all cell populations exhibit similar differentiation potential towards adipocyte, osteoblast and chondrocyte lineages despite tissue type  and donor specific variations of expression of differentiation associated genes. Further, we detected variable expression of lineage regulators in individual differentiating cells. Together, our data indicate that single cells of stromal cell populations could use distinct molecular mechanisms to reach a common cell fate. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Jaeaeger, Kersti; Neuman, Toomas] Tallinn Univ Technol, Inst Gene Technol, EE 12618 Tallinn, Estonia.
   [Jaeaeger, Kersti; Fatkina, Angelika; Velts, Anna; Orav, Ester] Cellin Technol LLC, Tallinn, Estonia.
   [Neuman, Toomas] Protobios LLC, Tallinn, Estonia.
C3 Tallinn University of Technology; Protobios LLC
RP Jääger, K (通讯作者)，Tallinn Univ Technol, Inst Gene Technol, Akad Tee 15, EE 12618 Tallinn, Estonia.
EM kersti.jaager@cellintechnologies.com;
   angelika.fatkina@cellintechnologies.com; anna.velts@gmail.com;
   ester.orav@gmail.com; tom@protobios.com
RI Jaager, Kersti/G 2786 2017
OI Jaager, Kersti/0000 0002 0503 9292
CR Aigner T, 2003, MATRIX BIOL, V22, P363, DOI 10.1016/S0945 053X(03)00049 0
   Bae S, 2009, CELL TISSUE RES, V335, P565, DOI 10.1007/s00441 008 0729 y
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Blasi A, 2011, VASC CELL, V3, DOI 10.1186/2045 824X 3 5
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Frith J, 2008, TRANSFUS MED HEMOTH, V35, P216, DOI [10.1159/000127448, 000127448]
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138
   Haniffa MA, 2007, J IMMUNOL, V179, P1595, DOI 10.4049/jimmunol.179.3.1595
   Hanson SE, 2010, LARYNGOSCOPE, V120, P546, DOI 10.1002/lary.20797
   Ishii M, 2005, BIOCHEM BIOPH RES CO, V332, P297, DOI 10.1016/j.bbrc.2005.04.118
   Jääger K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038833
   Jääger K, 2011, STEM CELLS DEV, V20, P1327, DOI 10.1089/scd.2010.0258
   Kassis I, 2006, BONE MARROW TRANSPL, V37, P967, DOI 10.1038/sj.bmt.1705358
   Kou I, 2004, J BIOL CHEM, V279, P50942, DOI 10.1074/jbc.M406786200
   Lee JH, 2006, BIOCHEM BIOPH RES CO, V341, P882, DOI 10.1016/j.bbrc.2006.01.038
   Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336
   Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorenz K, 2008, EXP DERMATOL, V17, P925, DOI 10.1111/j.1600 0625.2008.00724.x
   Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005 0234
   Rosen ED, 2005, PROSTAG LEUKOTR ESS, V73, P31, DOI 10.1016/j.plefa.2005.04.004
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738
   Shao HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051459
   Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901 778
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wiper Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218
   Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097 0177(199708)209:4<377::AID AJA5>3.0.CO;2 F
   Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 36
TC 6
Z9 6
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD JAN 1
PY 2014
VL 533
IS 1
BP 173
EP 179
DI 10.1016/j.gene.2013.09.094
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 259YR
UT WOS:000327562700025
PM 24103479
DA 2025 08 17
ER

PT J
AU Liu, S
   Takahashi, M
   Kiyoi, T
   Toyama, K
   Mogi, M
AF Liu, Shuang
   Takahashi, Minae
   Kiyoi, Takeshi
   Toyama, Kensuke
   Mogi, Masaki
TI Genetic Manipulation of Calcium Release Activated Calcium Channel 1
   Modulates the Multipotency of Human Cartilage Derived Mesenchymal Stem
   Cells
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; ARTICULAR CARTILAGE; REPAIR; ORAI1; JOINT;
   TRANSPLANTATION; INHIBITORS; DELIVERY; DEFECTS; THERAPY
AB Calcium is a ubiquitous intracellular messenger that has a crucial role in determining the proliferation, differentiation, and functions of multipotent mesenchymal stem cells (MSCs). Our study is aimed at elucidating the influence of genetically manipulating Ca2+ release activated Ca2+ (CRAC) channel mediated intercellular Ca2+ signaling on the multipotency of MSCs. The abilities of genetically engineered MSCs, including CRAC overexpressing and CRAC knockout MSCs, to differentiate into multiple mesenchymal lineages, including adipogenic, osteogenic, and chondrogenic lineages, were evaluated. CRAC channel mediated Ca2+ influx into these cells was regulated, and the differentiation fate of MSCs was modified. Upregulation of intracellular Ca2+ signals attenuated the adipogenic differentiation ability and slightly increased the osteogenic differentiation potency of MSCs, whereas downregulation of CRACM1 expression promoted chondrogenic differentiation potency. The findings demonstrated the effects of genetically manipulating MSCs by targeting CRACM1. CRAC modified MSCs had distinct differentiation fates to adipocytes, osteoblasts, and chondrocytes. To aid in the clinical implementation of tissue engineering strategies for joint regeneration, these data may allow us to identify prospective factors for effective treatments and could maximize the therapeutic potential of MSC based transplantation.
C1 [Liu, Shuang; Takahashi, Minae; Toyama, Kensuke; Mogi, Masaki] Ehime Univ, Grad Sch Med, Dept Pharmacol, Toon, Ehime 7910295, Japan.
   [Kiyoi, Takeshi] Ehime Univ, Integrated Ctr Sci, Dept Biosci, Toon, Ehime 7910295, Japan.
C3 Ehime University; Ehime University
RP Liu, S (通讯作者)，Ehime Univ, Grad Sch Med, Dept Pharmacol, Toon, Ehime 7910295, Japan.
EM liussmzk@m.ehime u.ac.jp
RI Mogi, Masaki/ABH 2011 2020; Shuang, Liu/AAW 2695 2020
FU Japan Society for the Promotion of Science [25462220, 18K08389];
   Grants in Aid for Scientific Research [18K08389] Funding Source: KAKEN
FX M.M. was funded by KAKENHI Grant 25462220 from the Japan Society for the
   Promotion of Science. S.L. was supported by KAKENHI Grant 18K08389 from
   the Japan Society for the Promotion of Science. We thank M. Arico from
   Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this
   manuscript.
CR Baboolal TG, 2016, ANN RHEUM DIS, V75, P908, DOI 10.1136/annrheumdis 2014 206847
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Catterall WA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003947
   El Jawhari JJ, 2014, QJM INT J MED, V107, P505, DOI 10.1093/qjmed/hcu033
   Fellows CR, 2017, SCI REP UK, V7, DOI 10.1038/srep41421
   Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687
   Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233
   Fodor J, 2013, CELL CALCIUM, V54, P1, DOI 10.1016/j.ceca.2013.03.003
   Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200
   Hayes AJ, 2001, ANAT EMBRYOL, V203, P469, DOI 10.1007/s004290100178
   Joswig AJ, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0503 8
   Kiyoi T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198785
   Lee SH, 2016, BIOCHEM BIOPH RES CO, V473, P1309, DOI 10.1016/j.bbrc.2016.04.068
   Lin FF, 2013, J PHARMACOL EXP THER, V345, P225, DOI 10.1124/jpet.112.202788
   Liu S, 2017, J IMMUNOL, V199, P1584, DOI 10.4049/jimmunol.1700192
   Liu S, 2017, J PHARMACOL SCI, V133, P130, DOI 10.1016/j.jphs.2017.02.001
   Liu S, 2016, SCI REP UK, V6, DOI 10.1038/srep28133
   Liu S, 2015, J IMMUNOL, V194, P76, DOI 10.4049/jimmunol.1401976
   MacDonald GIA, 2011, ARTHRITIS RHEUM US, V63, P2547, DOI 10.1002/art.30474
   McGonagle D, 2017, NAT REV RHEUMATOL, V13, P719, DOI 10.1038/nrrheum.2017.182
   Miyoshi M, 2018, EUR J PHARMACOL, V824, P89, DOI 10.1016/j.ejphar.2018.02.006
   Oh hora M, 2009, IMMUNOL REV, V231, P210, DOI 10.1111/j.1600 065X.2009.00819.x
   Peng HS, 2016, STEM CELLS, V34, P2102, DOI 10.1002/stem.2370
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sadaghiani AM, 2014, CHEM BIOL, V21, P1278, DOI 10.1016/j.chembiol.2014.08.016
   Steward AJ, 2014, EUR CELLS MATER, V28, P358, DOI 10.22203/eCM.v028a25
   Sun YY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29528 x
   Vaeth M, 2015, J IMMUNOL, V195, P1202, DOI 10.4049/jimmunol.1403013
   Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883
   Wakitani S, 2002, OSTEOARTHR CARTILAGE, V10, P199, DOI 10.1053/joca.2001.0504
   Wakitani S, 2007, J TISSUE ENG REGEN M, V1, P74, DOI 10.1002/term.8
NR 31
TC 8
Z9 8
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 8861
EI 2314 7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2019
VL 2019
AR 7510214
DI 10.1155/2019/7510214
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA HN5UD
UT WOS:000460249600001
PM 30906790
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Roth, DE
AF Roth, D. E.
TI Vitamin D supplementation during pregnancy: safety considerations in the
   design and interpretation of clinical trials
SO JOURNAL OF PERINATOLOGY
LA English
DT Article
DE vitamin D; pregnancy; risk assessment; toxicity; dietary supplements;
   review
ID SERUM CALCIOTROPIC HORMONES; D BINDING PROTEIN; PARATHYROID HORMONE;
   CIRCULATING 1 ALPHA,25 DIHYDROXYVITAMIN D; 1,25 DIHYDROXYVITAMIN D
   LEVELS; ERGOCALCIFEROL VITAMIN D 2; D DEFICIENCY; D INGESTION; D
   TOXICITY; D RECEPTOR
AB Maternal child health benefits of optimizing vitamin D status during pregnancy may include a reduced risk of pre eclampsia, improved fetal growth and beneficial effects on infant immune function. These hypotheses require evaluation by randomized controlled antenatal vitamin D supplementation trials using doses that are high enough to elevate serum 25 hydroxyvitamin D concentrations into the range believed to be associated with improved health outcomes. Such doses may be considerably higher than the current recommended dietary allowance (600 IU day( 1)) or standard prenatal supplement dose (400 IU day( 1)), and may even be higher than the tolerable upper intake level (4000 IU day( 1)) advised by the Institute of Medicine (2010). A critical review of the published literature yielded limited data regarding the safety of antenatal vitamin D regimens. There have been no published reports of the teratogenic effects of vitamin D on humans. Some animal studies have suggested the potential for dose dependent fetal toxicities (for example, growth impairment, skeletal malformations and cardiovascular anomalies), but the relevance of these observations to humans is unknown. Antenatal vitamin D supplementation trials should incorporate a range of methods for objectively establishing maternal and fetal safety, and aim to identify the lowest doses of vitamin D required to achieve target outcomes. Journal of Perinatology (2011) 31, 449 459; doi: 10.1038/jp.2010.203; published online 20 January 2011
C1 Hosp Sick Children, Div Pediat Med, Toronto, ON M5G 1X8, Canada.
   [Roth, D. E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Doctoral Program Human Nutr, Baltimore, MD USA.
C3 University of Toronto; Hospital for Sick Children (SickKids); Johns
   Hopkins University; Johns Hopkins Bloomberg School of Public Health
RP Roth, DE (通讯作者)，Hosp Sick Children, Div Pediat Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM daniel.roth@sickkids.ca
RI Roth, Daniel/KFR 3099 2024
FU Canadian Institutes of Health Research; Alberta Heritage Foundation for
   Medical Research
FX DER was supported by training grants from the Canadian Institutes of
   Health Research and the Alberta Heritage Foundation for Medical Research
   during the preparation of this article. Parul Christian (Johns Hopkins
   Bloomberg School of Public Health, Baltimore, MD, USA) is acknowledged
   for her helpful review of an earlier draft of the manuscript.
CR Anderson GW, 1942, AM J OBSTET GYNECOL, V43, P547, DOI 10.1016/S0002 9378(42)91117 7
   ANTIA AU, 1967, J PEDIATR US, V71, P431, DOI 10.1016/S0022 3476(67)80308 1
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004 0360
   Avila E, 2007, J STEROID BIOCHEM, V103, P90, DOI 10.1016/j.jsbmb.2006.07.010
   AVIOLI LV, 1967, J CLIN INVEST, V46, P983, DOI 10.1172/JCI105605
   Bacon CJ, 2009, OSTEOPOROSIS INT, V20, P1407, DOI 10.1007/s00198 008 0814 9
   Barger Lux MJ, 1998, OSTEOPOROSIS INT, V8, P222, DOI 10.1007/s001980050058
   BIKLE DD, 1984, J CLIN INVEST, V74, P1966, DOI 10.1172/JCI111617
   Bischoff Ferrari HA, 2010, OSTEOPOROSIS INT, V21, P1121, DOI 10.1007/s00198 009 1119 3
   Bodnar LM, 2010, OBSTET GYNECOL SURV, V65, P273, DOI 10.1097/OGX.0b013e3181dbc55b
   Bond H, 2008, J PHYSIOL LONDON, V586, P2015, DOI 10.1113/jphysiol.2007.149104
   BOUILLON R, 1981, J CLIN INVEST, V67, P589, DOI 10.1172/JCI110072
   BREHM W, 1937, OHIO STATE MED J, V33, P989
   BROOKE OG, 1980, BMJ BRIT MED J, V280, P751, DOI 10.1136/bmj.280.6216.751
   Brouwer DAJ, 1998, BRIT J NUTR, V79, P527, DOI 10.1079/BJN19980091
   Callies F, 1998, EUR J ENDOCRINOL, V139, P284, DOI 10.1530/eje.0.1390284
   Chen TC, 2000, J NUTR BIOCHEM, V11, P267, DOI 10.1016/S0955 2863(00)00077 2
   Cipriani C, 2010, J CLIN ENDOCR METAB, V95, P4771, DOI 10.1210/jc.2010 0502
   CLEMENTS MR, 1988, J CLIN INVEST, V81, P1768, DOI 10.1172/JCI113518
   CLEMENTS MR, 1984, LANCET, V1, P1376
   COCKBURN F, 1980, BRIT MED J, V281, P11, DOI 10.1136/bmj.281.6232.11
   COE FL, 1978, NEW ENGL J MED, V298, P324, DOI 10.1056/NEJM197802092980608
   CONGDON P, 1983, BMJ BRIT MED J, V286, P1233, DOI 10.1136/bmj.286.6373.1233
   DELVIN EE, 1986, J PEDIATR US, V109, P328, DOI 10.1016/S0022 3476(86)80396 1
   DURAND D, 1983, BRIT J NUTR, V49, P475, DOI 10.1079/BJN19830056
   EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993 11
   FLEISCHMAN AR, 1980, J PEDIATR US, V97, P640, DOI 10.1016/S0022 3476(80)80030 8
   FORBES GB, 1968, PEDIATRICS, V42, P203
   FORFAR JO, 1956, LANCET, V270, P981
   FRASER DR, 1983, LANCET, V1, P969
   GARCIA RE, 1964, NEW ENGL J MED, V271, P117, DOI 10.1056/NEJM196407162710302
   GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002 9343(86)90298 6
   Gezmish O, 2010, REPROD SCI, V17, P168, DOI 10.1177/1933719109349536
   GREER FR, 1984, J PEDIATR US, V105, P61, DOI 10.1016/S0022 3476(84)80361 3
   HADDAD JG, 1993, J CLIN INVEST, V91, P2552, DOI 10.1172/JCI116492
   Harcourt Brown F., 2013, BSAVA manual of rabbit surgery, dentistry and imaging, P423
   Hathcock JN, 2007, AM J CLIN NUTR, V85, P6, DOI 10.1093/ajcn/85.1.6
   Hayes DP, 2008, AM J CLIN NUTR, V88, p578S, DOI 10.1093/ajcn/88.2.578S
   Heaney RP, 2008, AM J CLIN NUTR, V87, P1738, DOI 10.1093/ajcn/87.6.1738
   HOLICK MF, 1975, J BIOL CHEM, V250, P226
   Hollis BW, 2007, J BONE MINER RES, V22, pV39, DOI [10.1359/jbmr.07s215, 10.1359/JBMR.07S215]
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   Hollis BW, 2004, AM J CLIN NUTR, V80, p1752S, DOI 10.1093/ajcn/80.6.1752S
   HOLLIS BW, 1984, J CLIN ENDOCR METAB, V59, P652, DOI 10.1210/jcem 59 4 652
   Houghton LA, 2006, AM J CLIN NUTR, V84, P694, DOI 10.1093/ajcn/84.4.694
   Ilahi M, 2008, AM J CLIN NUTR, V87, P688, DOI 10.1093/ajcn/87.3.688
   Ish Shalom S, 2008, J CLIN ENDOCR METAB, V93, P3430, DOI 10.1210/jc.2008 0241
   Jones G, 2008, AM J CLIN NUTR, V88, p582S, DOI 10.1093/ajcn/88.2.582S
   Kovacs CS, 2005, AM J PHYSIOL ENDOC M, V289, pE133, DOI 10.1152/ajpendo.00354.2004
   Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832
   KUBOTA M, 1982, ENDOCRINOLOGY, V110, P1950, DOI 10.1210/endo 110 6 1950
   Larsson A, 2008, BJOG INT J OBSTET GY, V115, P874, DOI 10.1111/j.1471 0528.2008.01709.x
   LAWSON DEM, 1986, BIOCHEM J, V233, P535, DOI 10.1042/bj2330535
   Leventis P, 2009, SCAND J RHEUMATOL, V38, P149, DOI 10.1080/03009740802419081
   Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028
   Madelenat P, 2001, J Gynecol Obstet Biol Reprod (Paris), V30, P761
   Mahomed K, 1999, Cochrane Database of Systematic Reviews, DOI [10.1002/14651858.CD000228, DOI 10.1002/14651858.CD000228]
   MALLET E, 1986, OBSTET GYNECOL, V68, P300, DOI 10.1097/00006250 198609000 00002
   MARKESTAD T, 1984, AM J CLIN NUTR, V40, P1057, DOI 10.1093/ajcn/40.5.1057
   MARX SJ, 1980, J CLIN ENDOCR METAB, V51, P1138, DOI 10.1210/jcem 51 5 1138
   MARYA RK, 1988, INDIAN J MED RES, V88, P488
   MARYA RK, 1981, GYNECOL OBSTET INVES, V12, P155, DOI 10.1159/000299597
   Masterjohn C, 2007, MED HYPOTHESES, V68, P1026, DOI 10.1016/j.mehy.2006.09.051
   MCCUE CM, 1968, J PEDIATR US, V73, P889, DOI 10.1016/S0022 3476(68)80242 2
   Norman P, 2002, CARDIOVASC RES, V55, P369, DOI 10.1016/S0008 6363(02)00444 3
   Novakovic B, 2009, J BIOL CHEM, V284, P14838, DOI 10.1074/jbc.M809542200
   Pasco JA, 2008, MED HYPOTHESES, V71, P266, DOI 10.1016/j.mehy.2008.01.033
   PAYNE RB, 1990, CLIN CHEM, V36, P142
   PETTIFOR JM, 1995, ANN INTERN MED, V122, P511, DOI 10.7326/0003 4819 122 7 199504010 00006
   Pike JW, 2008, ENDOCRINOLOGY, V149, P3656, DOI 10.1210/en.2008 0042
   REBUTBONNETON C, 1985, REPROD NUTR DEV, V25, P583, DOI 10.1051/rnd:19850410
   Resim S, 2006, UROL RES, V34, P339, DOI 10.1007/s00240 006 0066 0
   ROELOFSEN JMT, 1988, EUR J OBSTET GYN R B, V27, P227, DOI 10.1016/0028 2243(88)90127 X
   Romagnoli E, 2008, J CLIN ENDOCR METAB, V93, P3015, DOI 10.1210/jc.2008 0350
   Sanders KM, 2010, JAMA J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Schnatz PF, 2002, OBSTET GYNECOL SURV, V57, P365, DOI 10.1097/00006254 200206000 00022
   Seamans KM, 2009, AM J CLIN NUTR, V89, p1997S, DOI 10.3945/ajcn.2009.27230D
   SHEPARD RM, 1980, ARCH BIOCHEM BIOPHYS, V202, P43, DOI 10.1016/0003 9861(80)90404 X
   Simmonds CS, 2010, J BONE MINER RES, V25, P594, DOI 10.1359/jbmr.090825
   Slominski A, 2004, EUR J BIOCHEM, V271, P4178, DOI 10.1111/j.1432 1033.2004.04356.x
   STAMP TCB, 1977, LANCET, V1, P1341
   STANDER H. J., 1947, JOUR MT SINAI HOSP, V14, P629
   STERN PH, 1981, J CLIN INVEST, V68, P1374, DOI 10.1172/JCI110386
   STERN PH, 1980, J CLIN INVEST, V66, P852, DOI 10.1172/JCI109924
   TODA T, 1985, TOHOKU J EXP MED, V145, P303, DOI 10.1620/tjem.145.303
   Townsend K, 2005, J STEROID BIOCHEM, V97, P103, DOI 10.1016/j.jsbmb.2005.06.004
   Tuckey RC, 2008, FEBS J, V275, P2585, DOI 10.1111/j.1742 4658.2008.06406.x
   Tukaj C, 2008, INT J EXP PATHOL, V89, P117, DOI 10.1111/j.1365 2613.2008.00578.x
   TURNER M, 1988, MINER ELECTROL METAB, V14, P246
   van Hoof HJC, 2001, EUR J ENDOCRINOL, V144, P391, DOI 10.1530/eje.0.1440391
   vandenBerg H, 1997, EUR J CLIN NUTR, V51, pS76
   VERHAEGHE J, 1992, J STEROID BIOCHEM, V41, P469, DOI 10.1016/0960 0760(92)90372 P
   VIETH R, 1990, AM J PHYSIOL, V258, pE780, DOI 10.1152/ajpendo.1990.258.5.E780
   Vieth R, 2002, CARDIOVASC RES, V56, P323, DOI 10.1016/S0008 6363(02)00641 7
   Vieth R, 2000, J NUTR, V130, P578, DOI 10.1093/jn/130.3.578
   VIETH R, 1994, CLIN CHEM, V40, P435
   Vieth R, 2001, AM J CLIN NUTR, V73, P288
   Vieth R, 2007, J BONE MINER RES, V22, pV64, DOI 10.1359/JBMR.07S221
   Vieth R, 2006, PROG BIOPHYS MOL BIO, V92, P26, DOI 10.1016/j.pbiomolbio.2006.02.003
   Vieth R, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P995
   Viganò P, 2006, J MOL ENDOCRINOL, V36, P415, DOI 10.1677/jme.1.01946
   WAGNER CL, 201026307 EPAS
   WIELAND P, 1980, AM J PHYSIOL, V239, pE385, DOI 10.1152/ajpendo.1980.239.5.E385
   Williams AF, 2007, ARCH DIS CHILD, V92, P740, DOI 10.1136/adc.2007.120774
   WRIGHT AD, 1969, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.5635.23
   Zbytek B, 2008, J INVEST DERMATOL, V128, P2271, DOI 10.1038/jid.2008.62
   ZEGHOUD F, 1988, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V17, P1099
   Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002 9440(10)64162 4
   ,, 2010, Dietary reference intakes for calcium and vitamin D
NR 109
TC 54
Z9 60
U1 0
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0743 8346
EI 1476 5543
J9 J PERINATOL
JI J. Perinatol.
PD JUL
PY 2011
VL 31
IS 7
BP 449
EP 459
DI 10.1038/jp.2010.203
PG 11
WC Obstetrics & Gynecology; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology; Pediatrics
GA 784UC
UT WOS:000292182700001
PM 21252966
DA 2025 08 17
ER

PT J
AU Nafee, N
   Zewail, M
   Boraie, N
AF Nafee, Noha
   Zewail, Mariam
   Boraie, Nabila
TI Alendronate loaded, biodegradable smart hydrogel: a promising injectable
   depot formulation for osteoporosis
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Chitosan; bisphosphonates; beta glycerophosphate; thermogel;
   osteoporosis; intra articular; in situ gelling
ID CHITOSAN BASED HYDROGELS; ABSORPTION ENHANCING MECHANISMS;
   DELIVERY SYSTEM; IN VITRO; THERMOSENSITIVE HYDROGEL; ORTHOPHOSPHATE
   HYDROGEL; SODIUM ALENDRONATE; BONE REGENERATION; LOCAL DELIVERY; ORAL
   DELIVERY
AB Alendronate (ALN) is a BCS III bone resorption inhibitor, with very poor oral bioavailability. Our approach is to develop a minimally invasive thermogelling system for prolonged local delivery of ALN. For this, different chitosan based thermogels were developed and characterised in terms of gelation time, injectability, pH, viscosity and thermoreversibility. Chitosan/beta glycerophosphate (CS/(beta GP) hydrogel pursued temperature dependent, thermoreversible gelation behaviour and was thus selected for drug loading. Increasing ALN concentration resulted in hydrogels with lower porosity and higher density. FTIR and DSC proved interaction between ALN, CS with beta GP. CS/beta GP hydrogel ensured controlled ALN release over 45 65 days depending on initial ALN loading. Freeze drying improved the shelf life stability with minor impact on thermogelling character. In vivo injection of plain and ALN loaded hydrogel in rats rapidly gelled 15 min post injection. Based on histological examination, ALN loaded thermogel showed less inflammatory response, faster proliferation and maturation of granulation tissue relative to plain thermogel. Hydrogels excised 21 days post injection proved the biocompatibility and biodegradability of the system. The presented chitosan based thermogel has significant positive attributes for site specific, time controlled, intra articular delivery of ALN.
C1 [Nafee, Noha; Boraie, Nabila] Alexandria Univ, Fac Pharm, Dept Pharmaceut, El Khartoom Sq, Alexandria 21521, Egypt.
   [Zewail, Mariam] Damanhour Univ, Fac Pharm, Dept Pharmaceut, Damanhour, Egypt.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Damanhour University
RP Nafee, N (通讯作者)，Alexandria Univ, Fac Pharm, Dept Pharmaceut, El Khartoom Sq, Alexandria 21521, Egypt.
EM nnafe3@gmail.com
RI Zewail, Mariam/AAW 4635 2021; Nafee, Noha/JLM 3827 2023
CR Achim M, 2009, FARMACIA, V57, P703
   Alama T, 2016, INT J PHARMACEUT, V515, P476, DOI 10.1016/j.ijpharm.2016.10.046
   Aminabhavi TM, 2017, WOODH PUBL SER BIOM, V122, P295, DOI 10.1016/B978 0 08 100230 8.00012 1
   [Anonymous], ORTHOPEDICS
   Bae J, 2015, INT J PHARMACEUT, V480, P37, DOI 10.1016/j.ijpharm.2015.01.020
   Baek JS, 2011, J DRUG TARGET, V19, P37, DOI 10.3109/10611861003667599
   Beck SC, 2017, WOODH PUBL SER BIOM, V123, P33, DOI 10.1016/B978 0 08 100228 5.00002 X
   Calvo Fernández T, 2010, EUR CELLS MATER, V20, P260
   Chenite A, 2001, CARBOHYD POLYM, V46, P39, DOI 10.1016/S0144 8617(00)00281 2
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Cruz L, 2011, J CONTROL RELEASE, V152, P370, DOI 10.1016/j.jconrel.2011.02.030
   Depani BP, 2013, ACTA PHARMACEUT, V63, P479, DOI 10.2478/acph 2013 0033
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ganji F, 2007, J SOL GEL SCI TECHN, V42, P47, DOI 10.1007/s10971 006 9007 1
   Gordon S, 2010, EUR J PHARM SCI, V41, P360, DOI 10.1016/j.ejps.2010.07.004
   Han HK, 2012, EUR J PHARM SCI, V46, P500, DOI 10.1016/j.ejps.2012.04.002
   Hur W, 2016, J CONTROL RELEASE, V222, P97, DOI 10.1016/j.jconrel.2015.12.007
   Jarry C, 2001, J BIOMED MATER RES, V58, P127, DOI 10.1002/1097 4636(2001)58:1<127::AID JBM190>3.0.CO;2 G
   Karamustafa F., 2006, Fabad J. Pharm. Sci, V31, P31
   Kempe S, 2008, EUR J PHARM BIOPHARM, V68, P26, DOI 10.1016/j.ejpb.2007.05.020
   Kempe S, 2012, J CONTROL RELEASE, V161, P668, DOI 10.1016/j.jconrel.2012.04.016
   Khodaverdi E, 2012, AAPS PHARMSCITECH, V13, P460, DOI 10.1208/s12249 012 9764 9
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Kusamori K, 2010, J BONE MINER RES, V25, P2306, DOI 10.1002/jbmr.147
   Li NY, 2016, COLLOID SURFACE B, V142, P344, DOI 10.1016/j.colsurfb.2016.03.015
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   LIN JH, 1994, J PHARM SCI US, V83, P1741, DOI 10.1002/jps.2600831218
   Ma X, 2016, COLLOID SURFACE B, V143, P81, DOI 10.1016/j.colsurfb.2016.03.025
   Miladi K, 2015, J DRUG DELIV SCI TEC, V30, P391, DOI 10.1016/j.jddst.2015.04.007
   Miladi K, 2015, IND CROP PROD, V72, P24, DOI 10.1016/j.indcrop.2015.01.079
   Molinaro G, 2002, BIOMATERIALS, V23, P2717, DOI 10.1016/S0142 9612(02)00004 2
   Nakaya Y, 2016, J PHARM SCI US, V105, P3680, DOI 10.1016/j.xphs.2016.09.004
   Ngoenkam J, 2010, INT J PHARMACEUT, V391, P115, DOI 10.1016/j.ijpharm.2010.02.028
   Ochiuz L, 2008, MATER PLAST, V45, P372
   Posadowska U, 2015, INT J PHARMACEUT, V485, P31, DOI 10.1016/j.ijpharm.2015.03.003
   Ruel Gariépy E, 2004, EUR J PHARM BIOPHARM, V57, P53, DOI 10.1016/S0939 6411(03)00095 X
   Samiei N, 2017, INT J PHARMACEUT, V527, P184, DOI 10.1016/j.ijpharm.2017.05.042
   Schuetz YB, 2008, EUR J PHARM BIOPHARM, V68, P19, DOI 10.1016/j.ejpb.2007.06.020
   Shen ZH, 2014, MAT SCI ENG C MATER, V42, P303, DOI 10.1016/j.msec.2014.05.043
   Sparidans RW, 1998, PHARM WORLD SCI, V20, P206, DOI 10.1023/A:1008626026484
   Strampel W, 2007, DRUG SAFETY, V30, P755, DOI 10.2165/00002018 200730090 00003
   Sun JL, 2010, J BIOMED MATER RES A, V95A, P1019, DOI 10.1002/jbm.a.32923
   SUTTON SC, 1993, PHARMACEUT RES, V10, P924, DOI 10.1023/A:1018981832261
   Ta HT, 2009, BIOMATERIALS, V30, P3605, DOI 10.1016/j.biomaterials.2009.03.022
   Ta HT, 2009, INT J PHARMACEUT, V371, P134, DOI 10.1016/j.ijpharm.2009.01.018
   Taherian AR, 2017, FOOD HYDROCOLLOID, V63, P635, DOI 10.1016/j.foodhyd.2016.09.031
   Tian M, 2012, ACTA BIOMATER, V8, P753, DOI 10.1016/j.actbio.2011.10.030
   Wang LM, 2010, BIOMATERIALS, V31, P3976, DOI 10.1016/j.biomaterials.2010.01.131
   Wu J, 2006, INT J PHARMACEUT, V315, P1, DOI 10.1016/j.ijpharm.2006.01.045
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
   Zhao QS, 2009, J SOL GEL SCI TECHN, V50, P111, DOI 10.1007/s10971 008 1891 0
   Zhou HY, 2008, CARBOHYD POLYM, V73, P265, DOI 10.1016/j.carbpol.2007.11.026
NR 53
TC 52
Z9 55
U1 4
U2 81
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061 186X
EI 1029 2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2018
VL 26
IS 7
BP 563
EP 575
DI 10.1080/1061186X.2017.1390670
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GI2LJ
UT WOS:000434201500004
PM 29073792
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Kishi, S
   Fujiwara Tani, R
   Honoki, K
   Sasaki, R
   Mori, S
   Ohmori, H
   Sasaki, T
   Miyagawa, Y
   Kawahara, I
   Kido, A
   Tanaka, Y
   Kuniyasu, H
AF Kishi, Shingo
   Fujiwara Tani, Rina
   Honoki, Kanya
   Sasaki, Rika
   Mori, Shiori
   Ohmori, Hitoshi
   Sasaki, Takamitsu
   Miyagawa, Yoshihiro
   Kawahara, Isao
   Kido, Akira
   Tanaka, Yasuhito
   Kuniyasu, Hiroki
TI Oxidized high mobility group B 1 enhances metastability of colorectal
   cancer via modification of mesenchymal stem/stromal cells
SO CANCER SCIENCE
LA English
DT Article
DE cancer metastasis; colorectal cancer; HMGB1; mesenchymal stem cell;
   stemness
ID GLYCATION END PRODUCTS; NUCLEAR FACTOR HMGB1; STEM CELLS; PROTEIN HMGB1;
   EXPRESSION; RECRUITMENT; METASTASIS; MIGRATION; DIFFERENTIATION;
   PROLIFERATION
AB High mobility group box 1 (HMGB1) is known to be a chemotactic factor for mesenchymal stem/stromal cells (MSCs), but the effect of post translational modification on its function is not clear. In this study, we hypothesized that differences in the oxidation state of HMGB1 would lead to differences in the function of MSCs in cancer. In human colorectal cancer, MSCs infiltrating into the stroma were correlated with liver metastasis and serum HMGB1. In animal models, oxidized HMGB1 mobilized three fold fewer MSCs to subcutaneous tumors compared with reduced HMGB1. Reduced HMGB1 inhibited the proliferation of mouse bone marrow MSCs (BM MSCs) and induced differentiation into osteoblasts and vascular pericytes, whereas oxidized HMGB1 promoted proliferation and increased stemness, and no differentiation was observed. When BM MSCs pretreated with oxidized HMGB1 were co cultured with syngeneic cancer cells, cell proliferation and stemness of cancer cells were increased, and tumorigenesis and drug resistance were promoted. In contrast, co culture with reduced HMGB1 pretreated BM MSCs did not enhance stemness. In an animal orthotopic transplantation colorectal cancer model, oxidized HMGB1, but not reduced HMGB1, promoted liver metastasis with intratumoral MSC chemotaxis. Therefore, oxidized HMGB1 reprograms MSCs and promotes cancer malignancy. The oxidized HMGB1 MSC axis may be an important target for cancer therapy.
C1 [Kishi, Shingo; Fujiwara Tani, Rina; Sasaki, Rika; Mori, Shiori; Ohmori, Hitoshi; Sasaki, Takamitsu; Miyagawa, Yoshihiro; Kawahara, Isao; Kuniyasu, Hiroki] Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
   [Honoki, Kanya; Kido, Akira; Tanaka, Yasuhito] Nara Med Univ, Dept Orthoped, Nara, Japan.
C3 Nara Medical University; Nara Medical University
RP Kuniyasu, H (通讯作者)，Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.
EM cooninh@zb4.so net.ne.jp
RI Honoki, Kanya/C 8814 2009
FU MEXT KAKENHI [19 K16564, 20 K21659, 20 K19349, 20 K11260, 21 K10143];
   Grants in Aid for Scientific Research [22H04922, 22K09341, 22K11396,
   22K11423, 20K19349, 20K21659, 20K11260] Funding Source: KAKEN
FX This work was supported by MEXT KAKENHI Grant Numbers 19 K16564 (RFT),
   20 K21659 (HK), 20 K19349 (SK), 20 K11260 (HO), 21 K10143 (SM) and 20
   K19349 (IK)
CR Ananthula S, 2016, ONCOTARGET, V7, P20869, DOI 10.18632/oncotarget.8029
   Atiya H, 2020, ADV EXP MED BIOL, V1234, P31, DOI 10.1007/978 3 030 37184 5_3
   Barbato L, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080926
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Ding DC, 2011, CELL TRANSPLANT, V20, P5, DOI 10.3727/096368910X
   Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood 2003 04 1193
   Engstrand J, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3925 x
   Feng L, 2016, EXP THER MED, V12, P3941, DOI 10.3892/etm.2016.3857
   Fong Y, 1996, SEMIN SURG ONCOL, V12, P219, DOI 10.1002/(SICI)1098 2388(199607/08)12:4<219::AID SSU3>3.3.CO;2 O
   Frank MG, 2016, BRAIN BEHAV IMMUN, V51, P99, DOI 10.1016/j.bbi.2015.08.001
   Fujii K, 2009, CELL PROLIFERAT, V42, P701, DOI 10.1111/j.1365 2184.2009.00624.x
   Fujimoto Y, 2005, DIS COLON RECTUM, V48, P1883, DOI 10.1007/s10350 005 0141 6
   Fujiwara Tani Rina, 2020, Oncotarget, V11, P2982, DOI 10.18632/oncotarget.27674
   Fujiwara Tani Rina, 2018, Oncotarget, V9, P37367, DOI 10.18632/oncotarget.26427
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo reports/kvf198
   Griess B, 2017, FREE RADICAL BIO MED, V112, P464, DOI 10.1016/j.freeradbiomed.2017.08.013
   He YF, 2015, CHEM SCI, V6, P2074, DOI 10.1039/c4sc03650f
   Janko C, 2014, ANTIOXID REDOX SIGN, V20, P1075, DOI 10.1089/ars.2013.5179
   Jayaraman H, 2021, CURR STEM CELL RES T, V16, P443, DOI 10.2174/1574888X15666201022111942
   Jiang MY, 2020, MOL MED REP, V22, P3255, DOI 10.3892/mmr.2020.11422
   Kang HJ, 2009, LAB INVEST, V89, P948, DOI 10.1038/labinvest.2009.47
   Kishi S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105185
   Koliaraki V, 2017, GASTROENTEROLOGY, V152, P964, DOI 10.1053/j.gastro.2016.11.049
   Kumar A, 2020, ARCH BONE JT SURG AB, V8, P560, DOI 10.22038/abjs.2020.42536.2155
   Kuniyasu H, 2003, ONCOL REP, V10, P445
   Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031
   Kuniyasu H, 2010, GUT, V59, P348, DOI 10.1136/gut.2009.178376
   Kwak MS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01189
   Kwak MS, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101203
   Lau TT, 2011, EXPERT OPIN BIOL TH, V11, P189, DOI 10.1517/14712598.2011.546338
   Li B, 2021, IMMUN INFLAMM DIS, V9, P8, DOI 10.1002/iid3.370
   Li JH, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1484 9
   Lin F, 2016, INT J MOL MED, V37, P789, DOI 10.3892/ijmm.2016.2479
   Lotfi R, 2011, EUR J IMMUNOL, V41, P2021, DOI 10.1002/eji.201041324
   Lou GH, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.63
   Luo Y, 2010, EUR J CANCER, V46, P791, DOI 10.1016/j.ejca.2009.11.011
   Meng ER, 2008, STEM CELLS DEV, V17, P805, DOI 10.1089/scd.2008.0276
   Meng XH, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0827 z
   Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008 5472.CAN 08 0943
   Mori S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249347
   Notsu M, 2014, ENDOCRINOLOGY, V155, P2402, DOI 10.1210/en.2013 1818
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Ohmori H, 2010, PATHOBIOLOGY, V77, P210, DOI 10.1159/000296305
   Ozaki Y, 2007, STEM CELLS DEV, V16, P119, DOI 10.1089/scd.2006.0032
   Papaccio F, 2017, STEM CELL TRANSL MED, V6, P2115, DOI 10.1002/sctm.17 0138
   Qiao L, 2008, ACTA PHARMACOL SIN, V29, P333, DOI 10.1111/j.1745 7254.2008.00751.x
   Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0597 8
   Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739
   Shimomoto T, 2012, CLIN EXP METASTAS, V29, P915, DOI 10.1007/s10585 012 9480 6
   Shimomoto T, 2012, J GASTROENTEROL, V47, P1073, DOI 10.1007/s00535 012 0572 5
   SIEGELR, 2014, CA CANCER J CLIN, V64, P9, DOI DOI 10.3322/CAAC.21208)
   Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031
   Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189
   Wakao F., 2021, CANC STAT JAPAN 2021, P146
   Xie HL, 2014, CELL BIOL INT, V38, P892, DOI 10.1002/cbin.10279
   Xue JM, 2021, J CELL PHYSIOL, V236, P3406, DOI 10.1002/jcp.30125
   Zhou XN, 2020, CANCER SCI, V111, P3100, DOI 10.1111/cas.14563
   Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662
   Yang SM, 2015, CLIN GENITOURIN CANC, V13, pE347, DOI 10.1016/j.clgc.2015.04.004
NR 61
TC 7
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD AUG
PY 2022
VL 113
IS 8
BP 2904
EP 2915
DI 10.1111/cas.15400
EA MAY 2022
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 3O9NT
UT WOS:000799009200001
PM 35570394
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Choi, KD
   Vodyanik, MA
   Slukvin, II
AF Choi, Kyung Dal
   Vodyanik, Maxim A.
   Slukvin, Igor I.
TI Generation of mature human myelomonocytic cells through expansion and
   differentiation of pluripotent stem cell derived
   lin<SUP> </SUP>CD34<SUP>+</SUP>CD43<SUP>+</SUP>CD45<SUP>+</SUP>
   progenitors
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID EX VIVO EXPANSION; DENDRITIC CELLS; DIRECTED DIFFERENTIATION;
   HEMATOPOIETIC PROGENITORS; CD34(+) CELLS; IN VITRO; NEUTROPHILS; LINES;
   EOSINOPHILS; ACTIVATION
AB Basic research into human mature myelomonocytic cell function, myeloid lineage diversification and leukemic transformation, and assessment of myelotoxicity in preclinical drug development requires a constant supply of donor blood or bone marrow samples and laborious purification of mature myeloid cells or progenitors, which are present in very small quantities. To overcome these limitations, we have developed a protocol for efficient generation of neutrophils, eosinophils, macrophages, osteoclasts, DCs, and Langerhans cells from human embryonic stem cells (hESCs). As a first step, we generated lin( )CD34(+)CD43(+)CD45(+) hematopoietic cells highly enriched in myeloid progenitors through coculture of hESCs with OP9 feeder cells. After expansion in the presence of GM CSF, these cells were directly differentiated with specific cytokine combinations toward mature cells of particular types. Morphologic, phenotypic, molecular, and functional analyses revealed that hESC derived myelomonocytic cells were comparable to their corresponding somatic counterparts. In addition, we demonstrated that a similar protocol could be used to generate myelomonocytic cells from induced pluripotent stem cells (iPSCs). This technology offers an opportunity to generate large numbers of patient specific myelomonocytic cells for in vitro studies of human disease mechanisms as well as for drug screening.
C1 [Slukvin, Igor I.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Dept Pathol & Lab Med, Madison, WI 53715 USA.
   [Vodyanik, Maxim A.; Slukvin, Igor I.] Univ Wisconsin, Natl Primate Res Ctr, Madison, WI 53715 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Slukvin, II (通讯作者)，Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Dept Pathol & Lab Med, 1220 Capitol Court, Madison, WI 53715 USA.
EM islukvin@wisc.edu
FU NIH [HL085223, P51 RR000167]
FX We thank James Thomson for providing hiPSC cell lines, Toru Nakano for
   providing OP9 cells, Alexey Pereverzev for the helpful discussion on
   evaluation of osteoclast function, and Joan Larson for editorial
   assistance. This work is supported by NIH grants HL085223 (to I.I.
   Slukvin) and NIH grant P51 RR000167 to the National Primate Research
   Center, University of Wisconsin Madison.
CR Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912
   AntalSzalmas P, 1997, J LEUKOCYTE BIOL, V61, P721, DOI 10.1002/jlb.61.6.721
   Arock M, 2002, J LEUKOCYTE BIOL, V71, P557
   Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016
   BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453
   Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695
   Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008 0922
   Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677
   Fairchild PJ, 2000, CURR BIOL, V10, P1515, DOI 10.1016/S0960 9822(00)00824 1
   FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145 2126(88)90103 8
   Hamaguchi Tsuru E, 2004, BRIT J HAEMATOL, V124, P819, DOI 10.1111/j.1365 2141.2004.04850.x
   HAYLOCK DN, 1992, BLOOD, V80, P1405
   Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114
   Hino M, 2000, BRIT J HAEMATOL, V109, P314, DOI 10.1046/j.1365 2141.2000.02054.x
   Karlsson KR, 2008, EXP HEMATOL, V36, P1167, DOI 10.1016/j.exphem.2008.04.009
   KHANNAGUPTA A, 1994, BLOOD, V84, P294
   Lieber JG, 2004, BLOOD, V103, P852, DOI 10.1182/blood 2003 04 1030
   MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo 120 6 2326
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Muller PY, 2002, BIOTECHNIQUES, V32, P1372
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   RADO TA, 1987, BLOOD, V70, P989
   Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024
   Rosenberg HF, 1996, EXP HEMATOL, V24, P888
   Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015
   Saeki K, 2009, STEM CELLS, V27, P59, DOI 10.1634/stemcells.2007 0980
   Santegoets SJAM, 2008, J LEUKOCYTE BIOL, V84, P143, DOI 10.1189/jlb.1107750
   Senju S, 2003, BLOOD, V101, P3501, DOI 10.1182/blood 2002 07 2254
   Senju S, 2007, STEM CELLS, V25, P2720, DOI 10.1634/stemcells.2007 0321
   Slukvin II, 2006, J IMMUNOL, V176, P2924, DOI 10.4049/jimmunol.176.5.2924
   SMITH SL, 1993, EXP HEMATOL, V21, P870
   Su Z, 2008, CLIN CANCER RES, V14, P6207, DOI 10.1158/1078 0432.CCR 08 0309
   Tachimoto H, 2000, CHEM IMMUNOL, V76, P45
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757
   THAVARAJAH M, 1991, BIOCHEM BIOPH RES CO, V176, P1189, DOI 10.1016/0006 291X(91)90411 Y
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Valladeau J, 2005, SEMIN IMMUNOL, V17, P273, DOI 10.1016/j.smim.2005.05.009
   Vodyanik MA, 2005, BLOOD, V105, P617, DOI 10.1182/blood 2004 04 1649
   Vodyanik MA, 2006, BLOOD, V108, P2095, DOI 10.1182/blood 2006 02 003327
   Vodyanik Maxim A, 2007, Curr Protoc Cell Biol, VChapter 23, DOI 10.1002/0471143030.cb2306s36
   Vodyanik Maxim A., 2007, V407, P275, DOI 10.1007/978 1 59745 536 7_19
   WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281
   Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
NR 47
TC 166
Z9 197
U1 0
U2 15
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2009
VL 119
IS 9
BP 2818
EP 2829
DI 10.1172/JCI38591
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 493BR
UT WOS:000269708600039
PM 19726877
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Bakhit, A
   Kawashima, N
   Hashimoto, K
   Noda, S
   Nara, K
   Kuramoto, M
   Tazawa, K
   Okiji, T
AF Bakhit, Alamuddin
   Kawashima, Nobuyuki
   Hashimoto, Kentaro
   Noda, Sonoko
   Nara, Keisuke
   Kuramoto, Masashi
   Tazawa, Kento
   Okiji, Takashi
TI Strontium ranelate promotes odonto /osteogenic
   differentiation/mineralization of dental papillae cells in vitro
   and mineralized tissue formation of the dental pulp in vivo
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CALCIUM SENSING RECEPTOR; TRIOXIDE AGGREGATE; OSTEOBLAST
   DIFFERENTIATION; ACTIVATION; REPLICATION; HYDROXIDE; DEFECTS; KINASE;
   CAR; RAT
AB This study examined the effects and mechanisms of strontium ranelate (SrRn) a drug used to treat osteoporosis on the proliferation and differentiation/mineralization of cloned dental pulp like cells (mouse dental papillae cells; MDPs). It also determined whether topical application of SrRn to exposed dental pulp tissue promotes the formation of mineralized tissue in vivo. The MDPs were cultured with or without SrRn, and cell proliferation, odonto /osteoblastic gene expression, mineralized nodule formation, and Akt phosphorylation were evaluated. The formation of mineralized tissue in SrRn treated pulp tissue in rat upper first molars was evaluated histologically. The SrRn up regulated cell proliferation and expression of Alp (alkaline phosphatase), Bsp (bone sialoprotein), Dmp (dentin matrix acidic phosphoprotein) 1, Dspp (dentin sialophosphoprotein), and Oc (osteocalcin) in a dose dependent manner. Mineralized nodule formation was also enhanced by SrRn. NPS 2143, a calcium sensing receptor (CaSR) antagonist, and siRNA against the CaSR gene blocked SrRn induced proliferation, odonto /osteoblastic gene expression, and mineralized nodule formation. SrRn induced Akt phosphorylation, and this was blocked by NPS 2143. Topical application of SrRn to exposed rat molar pulps induced the formation of osteodentin like mineralized tissue. Our study revealed for the first time that SrRn promotes proliferation and odonto /osteogenic differentiation/mineralization of MDPs via PI3K/Akt signaling activated by CaSR in vitro; mineralized tissue forms from the dental pulp in vivo.
C1 [Bakhit, Alamuddin; Kawashima, Nobuyuki; Hashimoto, Kentaro; Noda, Sonoko; Nara, Keisuke; Kuramoto, Masashi; Tazawa, Kento; Okiji, Takashi] TMDU, Grad Sch Med & Dent Sci, Div Oral Hlth Sci, Dept Pulp Biol & Endodont, Tokyo 1138510, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Kawashima, N (通讯作者)，TMDU, Grad Sch Med & Dent Sci, Div Oral Hlth Sci, Dept Pulp Biol & Endodont, Tokyo 1138510, Japan.
EM kawashima.n.endo@tmd.ac.jp
RI Okiji, Takashi/W 3841 2019
OI Okiji, Takashi/0000 0002 9791 4508
FU Japan Society for the Promotion of Science [25293386, 16K15795,
   17H04380]; Grants in Aid for Scientific Research [16K15795, 25293386,
   17H04380] Funding Source: KAKEN
FX This work was supported by a Grant in Aid from the Japan Society for the
   Promotion of Science (#25293386 and #16K15795 to N.K., #17H04380 to
   T.O.). We thank Prof. Masahiro Saito for his offer to provide MDPs and
   Dr. Kayoko Ohnishi for her technical support.
CR Abrahamsen B, 2014, OSTEOPOROSIS INT, V25, P757, DOI 10.1007/s00198 013 2469 4
   Accorinte MDR, 2008, J ENDODONT, V34, P1, DOI 10.1016/j.joen.2007.09.012
   Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756 8722 6 88
   Almeida MM, 2016, TISSUE CELL, V48, P183, DOI 10.1016/j.tice.2016.03.009
   Andelin WE, 2003, J ENDODONT, V29, P646, DOI 10.1097/00004770 200310000 00008
   Aral H, 2008, ECOTOX ENVIRON SAFE, V70, P349, DOI 10.1016/j.ecoenv.2008.02.026
   Arthur JM, 2000, BIOCHEM BIOPH RES CO, V275, P538, DOI 10.1006/bbrc.2000.3226
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Barbara A, 2004, METABOLISM, V53, P532, DOI 10.1016/j.metabol.2003.10.022
   Bergenholtz Gunnar, 2013, Singapore Dent J, V34, P1, DOI 10.1016/j.sdj.2013.11.001
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Silva GAB, 2018, J BONE MINER METAB, V36, P73, DOI 10.1007/s00774 017 0822 y
   Brennan SC, 2013, BBA MOL CELL RES, V1833, P1732, DOI 10.1016/j.bbamcr.2012.12.011
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Camilleri J, 2006, INT ENDOD J, V39, P747, DOI 10.1111/j.1365 2591.2006.01135.x
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Caverzasio J, 2011, CELL PHYSIOL BIOCHEM, V27, P243, DOI 10.1159/000327950
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Cox CF, 1996, OPER DENT, V21, P4
   da Rosa WLO, 2018, J BIOMED MATER RES B, V106, P1358, DOI 10.1002/jbm.b.33934
   Dammaschke Till, 2008, J Hist Dent, V56, P9
   Dvorak Ewell MM, 2011, J BONE MINER RES, V26, P2935, DOI 10.1002/jbmr.520
   Elgali I, 2016, ACTA BIOMATER, V29, P409, DOI 10.1016/j.actbio.2015.10.005
   FITZGERALD M, 1979, J DENT RES, V58, P2198, DOI 10.1177/002203457905800411011
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Isaac J, 2011, EUR CELLS MATER, V21, P130, DOI 10.22203/eCM.v021a11
   Ishimoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121938
   Kifor O, 2001, AM J PHYSIOL RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291
   Koizumi Y, 2013, CONGENIT ANOM, V53, P101, DOI 10.1111/cga.12011
   Komabayashi T, 2016, DENT MATER J, V35, P1, DOI 10.4012/dmj.2015 013
   Marie PJ, 2006, CURR OPIN RHEUMATOL, V18, pS11, DOI 10.1097/01.bor.0000229522.89546.7b
   Masalskas BF, 2018, J BIOMED MATER RES A, V106, P333, DOI 10.1002/jbm.a.36237
   Matsumoto S, 2013, J ENDODONT, V39, P68, DOI 10.1016/j.joen.2012.10.006
   McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114
   Mente J, 2014, J ENDODONT, V40, P1746, DOI 10.1016/j.joen.2014.07.019
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Okiji T, 2009, INT J DENT, V2009, DOI 10.1155/2009/464280
   Parisay Iman, 2015, Iran Endod J, V10, P6
   Pilmane M, 2017, MAT SCI ENG C MATER, V78, P1222, DOI 10.1016/j.msec.2017.05.042
   Roberts HW, 2008, DENT MATER, V24, P149, DOI 10.1016/j.dental.2007.04.007
   Rosa Jucely Aparecida da, 2016, Braz. Dent. J., V27, P502, DOI 10.1590/0103 6440201600693
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   SCHRODER U, 1972, Odontologisk Revy, V23, P211
   Tenti S, 2014, MOD RHEUMATOL, V24, P881, DOI 10.3109/14397595.2014.888156
   TORABINEJAD M, 1995, J ENDODONT, V21, P109, DOI 10.1016/S0099 2399(06)80433 4
   Torabinejad M, 2010, J ENDODONT, V36, P190, DOI 10.1016/j.joen.2009.09.010
   Tsubakimoto T., 2007, Japanese Journal of Conservative Dentistry, V50, P292
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Yamamoto M, 2014, ARCH ORAL BIOL, V59, P310, DOI 10.1016/j.archoralbio.2013.12.006
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Zhu CX, 2015, INT J CLIN EXP MED, V8, P17055
NR 54
TC 27
Z9 30
U1 1
U2 21
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 15
PY 2018
VL 8
AR 9224
DI 10.1038/s41598 018 27461 7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GJ4GQ
UT WOS:000435338900064
PM 29907831
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Frazier, R
   Hodakowski, A
   Cai, X
   Lee, J
   Zakarija, A
   Stein, B
   David, V
   Wolf, M
   Isakova, T
   Mehta, R
AF Frazier, Rebecca
   Hodakowski, Alexander
   Cai, Xuan
   Lee, Jungwha
   Zakarija, Anaadriana
   Stein, Brady
   David, Valentin
   Wolf, Myles
   Isakova, Tamara
   Mehta, Rupal
TI Effects of ferric carboxymaltose on markers of mineral and bone
   metabolism: A single center prospective observational study of women
   with iron deficiency
SO BONE
LA English
DT Article
DE Hypophosphatemia; Iron deficiency anemia; Ferric carboxymaltose;
   Fibroblast growth factor 23; Bone specific alkaline phosphatase
ID INFLAMMATORY BOWEL DISEASE; GROWTH FACTOR 23; SEVERE HYPOPHOSPHATEMIA;
   ANEMIA; OSTEOMALACIA
AB Background: Two weekly infusions of ferric carboxymaltose (FCM) are commonly prescribed for treatment of iron deficiency anemia. However, administration of FCM increases intact levels of fibroblast growth factor 23 (FGF23), which causes hypophosphatemia due to renal phosphate wasting, calcitriol deficiency and secondary hyperparathyroidism. The adverse effects of FCM on mineral metabolism and bone health emerged from case reports and secondary analyses of trials. Data on these safety signals with FCM in clinical practice are limited because markers of mineral and bone metabolism are not routinely checked.
   Methods: To obtain real world experience with effects of FCM on mineral and bone metabolism, we conducted a prospective observational study of 16 women who were managed at a single center hematology clinic for iron deficiency anemia. From October 2016 to February 2018, all participants received two weekly infusions of FCM at a hematology infusion clinic. We hypothesized that FCM would decrease phosphate, increase intact FGF23 (iFGF23), and decrease c terminal FGF23 (cFGF23). Secondary outcomes were changes in hemoglobin, iron indices, urine fractional excretion of phosphate (FePi), parathyroid hormone (PTH), calcitriol, calcium, osteocalcin, and bone specific alkaline phosphatase (BAP). FCM was administered at weeks zero and one, and we measured laboratory values at weeks zero, one, two, and five of the study. We used linear mixed models to analyze the significance of the changes in laboratory values over time.
   Results: After two FCM infusions, nearly all (14 of 16) participants developed hypophosphatemia. iFGF23 increased, cFGF23 decreased, and phosphate decreased significantly from week zero to week two (iFGF23 increased by +134.0% [40.6, 305.8], p < 0.001; cFGF23 decreased by  516.3% [ 1332.7,  142.7], p = 0.002; phosphate decreased by  49.8 15.4%, p < 0.001). There was also a significant increase in FePi, PTH, and BAP and a significant decrease in calcitriol and calcium from week zero to week two. There was no significant change in osteocalcin during this time period. iFGF23, but not PTH, was independently associated with decreased phosphate. iFGF23 was also significantly associated with decrease in calcitriol from week zero to week two. Elevation in BAP suggests disordered bone mineralization in response to FCM therapy.
   Conclusion: In this prospective observational study of women with iron deficiency anemia, two FCM infusions significantly altered markers of bone mineralization and mineral metabolism. The results suggest that FCM should be used cautiously in the treatment of iron deficiency anemia.
C1 [Frazier, Rebecca; David, Valentin; Isakova, Tamara; Mehta, Rupal] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Nephrol & Hypertens, Chicago, IL 60611 USA.
   [Frazier, Rebecca; Hodakowski, Alexander; Cai, Xuan; David, Valentin; Isakova, Tamara; Mehta, Rupal] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Translat Metab & Hlth, Chicago, IL 60611 USA.
   [Lee, Jungwha] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Div Biostat, Chicago, IL 60611 USA.
   [Frazier, Rebecca; Mehta, Rupal] Jesse Brown Vet Adm Med Ctr, Chicago, IL 60612 USA.
   [Wolf, Myles] Duke Univ, Sch Med, Dept Med, Div Nephrol,Duke Clin Res Inst, Durham, NC 27701 USA.
   [Zakarija, Anaadriana; Stein, Brady] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol,Robert H Lurie Comprehens Canc, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine; Northwestern University;
   Feinberg School of Medicine; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Jesse Brown VA Medical Center; Duke
   University; Northwestern University; Feinberg School of Medicine; Robert
   H. Lurie Comprehensive Cancer Center
RP Frazier, R (通讯作者)，633 N St Clair,Suite 18, Chicago, IL 60611 USA.
EM Rebecca.frazier@northwestern.edu
OI David, Valentin/0000 0001 9527 2364; Mehta, Rupal/0000 0001 5848 4325
FU National Kidney Foundation of Illinois Young Investigator Grant;
   National Institutes of Health's National Center for Advancing
   Translational Sciences [KL2TR001424, UL1TR001422];  [P30DK114857]; 
   [R01DK102438];  [T32DK108738]
FX This study was supported by grants P30DK114857, R01DK102438 (TI),
   T32DK108738 (RF), and a National Kidney Foundation of Illinois Young
   Investigator Grant (RM). Research reported in this publication was also
   supported, in part, by the National Institutes of Health's National
   Center for Advancing Translational Sciences, Grant Number KL2TR001424
   and by the National Institutes of Health's National Center for Advancing
   Translational Sciences, Grant Number UL1TR001422. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The views expressed
   in this article are those of the authors and do not necessarily reflect
   the position or policy of the Department of Veterans Affairs or the
   United States government.
CR Amarnani R, 2020, RHEUMATOLOGY, V59, P2166, DOI 10.1093/rheumatology/kez627
   [Anonymous], 2007, Assessing the Iron Status of Populations
   [Anonymous], 2008, PRIMER METABOLIC BON
   Auerbach M, 2017, HEMODIAL INT, V21, pS83, DOI 10.1111/hdi.12560
   Bartko J, 2018, J BONE MINER RES, V33, P534, DOI 10.1002/jbmr.3319
   Bermejo F, 2009, WORLD J GASTROENTERO, V15, P4638, DOI 10.3748/wjg.15.4638
   Blazevic A, 2014, NETH J MED, V72, P49
   Derosa G, 2016, BIOMARK DIS, P3, DOI 10.1007/978 94 007 7678 4_27
   Detlie TE, 2019, ALIMENT PHARM THER, V50, P397, DOI 10.1111/apt.15386
   Fierz YC, 2014, EUR J CLIN NUTR, V68, P531, DOI 10.1038/ejcn.2014.20
   Keating GM, 2015, DRUGS, V75, P101, DOI 10.1007/s40265 014 0332 3
   Klein K., 2018, BMJ CASE REPORTS, V2018
   Laha TJ, 2012, CLIN CHEM, V58, P1711, DOI 10.1373/clinchem.2012.185827
   Mani LY, 2010, TRANSPLANTATION, V90, P804, DOI 10.1097/TP.0b013e3181f00a18
   McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401
   Moore Kari Lenita Falck, 2013, Tidsskr Nor Laegeforen, V133, P165, DOI 10.4045/tidsskr.12.0494
   Ross PD, 1998, J BONE MINER RES, V13, P297, DOI 10.1359/jbmr.1998.13.2.297
   Schaefer B, 2017, GASTROENTEROLOGY, V152, pE5, DOI 10.1053/j.gastro.2016.09.050
   Song L, 2017, ADV CLIN CHEM, V82, P1, DOI 10.1016/bs.acc.2017.06.005
   Takashi Y, 2018, TRENDS ENDOCRIN MET, V29, P755, DOI 10.1016/j.tem.2018.08.006
   Urbina T, 2018, J BONE MINER RES, V33, P540, DOI 10.1002/jbmr.3369
   US Food and Drug Administration, 2007, GUID IND TOX GRAD SC
   Van Wyck DB, 2009, TRANSFUSION, V49, P2719, DOI 10.1111/j.1537 2995.2009.02327.x
   Wolf M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124486
   Wolf M, 2014, CURR OPIN NEPHROL HY, V23, P411, DOI 10.1097/01.mnh.0000447020.74593.6f
   Wolf M, 2013, J BONE MINER RES, V28, P1793, DOI 10.1002/jbmr.1923
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
   Zimmermann MB, 2007, LANCET, V370, P511, DOI 10.1016/S0140 6736(07)61235 5
NR 28
TC 12
Z9 13
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2020
VL 141
AR 115559
DI 10.1016/j.bone.2020.115559
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PK3CN
UT WOS:000602327700010
PM 32730929
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mazzocca, AD
   McCarthy, MBR
   Chowaniec, DM
   Dugdale, EM
   Hansen, D
   Cote, MP
   Bradley, JP
   Romeo, AA
   Arciero, RA
   Beitzel, K
AF Mazzocca, Augustus D.
   McCarthy, Mary Beth R.
   Chowaniec, David M.
   Dugdale, Evan M.
   Hansen, Derek
   Cote, Mark P.
   Bradley, James P.
   Romeo, Anthony A.
   Arciero, Robert A.
   Beitzel, Knut
TI The Positive Effects of Different Platelet Rich Plasma Methods on Human
   Muscle, Bone, and Tendon Cells
SO AMERICAN JOURNAL OF SPORTS MEDICINE
LA English
DT Article
DE PRP; bone; muscle; tendon
ID RANDOMIZED CONTROLLED TRIAL; IN VITRO; HUMAN OSTEOBLASTS; AUTOLOGOUS
   BONE; PROLIFERATION; PRP; AUGMENTATION; SURGERY; CULTURE; REPAIR
AB Background: Clinical application of platelet rich plasma (PRP) in the realm of orthopaedic sports medicine has yielded variable results. Differences in separation methods and variability of the individual may contribute to these variable results.
   Purpose: To compare the effects of different PRP separation methods on human bone, muscle, and tendon cells in an in vitro model.
   Study Design: Controlled laboratory study.
   Methods: Blood collected from 8 participants (mean +/  SD age 31.6 +/  10.9 years) was used to obtain PRP preparations. Three different PRP separation methods were used: a single spin process yielding a lower platelet concentration (PRPLP), a single spin process yielding high platelet and white blood cell concentrations (PRPHP), and a double spin that produces a higher platelet concentration and lower white blood cell concentration (PRPDS). Human bone, muscle, and tendon cells obtained from discarded tissue samples during shoulder surgery were placed into culture and treated with the 3 PRP preparations, control media (2% fetal bovine serum [FBS] and 10% FBS), and native blood. Radioactive thymidine assays were obtained to examine cell proliferation, and testing with enzyme linked immunosorbent assay was used to determine growth factor concentrations.
   Results: Addition of PRPLP to osteocytes, myocytes, and tenocytes significantly increased cell proliferation (P <= .05) compared with the controls. Adding PRPDS to osteoblasts and tenocytes increased cell proliferation significantly (P <= .05), but no significance was shown for its addition to myocytes. The addition of PRPHP significantly increased cell proliferation compared with the controls only when added to tenocytes (P <= .05). Osteoblasts: Proliferation was significantly increased by addition of PRPLP compared with all controls (2% FBS, 10% FBS, native blood) (P <= .05). Addition of PRPDS led to significantly increased proliferation compared with all controls, native blood, and PRPHP (P <= .05). Proliferation was significantly less when PRPHP was added compared with PRPDS (P <= .05). Myocytes: Proliferation was significantly increased by addition of PRPLP compared with native blood (P <= .05). Adding PRPHP or PRPDS to myocytes showed no significant increase in proliferation compared with the controls or the other separations. Tenocytes: Proliferation was significantly increased by addition of PRPLP compared with all controls (2% FBS, 10% FBS, native blood) (P <= .05). Addition of PRPDS showed a significant increase compared with the controls and native blood. For tenocytes, there was a significant increase (P <= .05) seen when PRPHP was added compared with the controls and native blood but not compared with the other separations.
   Conclusion: The primary findings of this study suggest the application of different PRP separations may result in a potential beneficial effect on the clinically relevant target cells in vitro. However, it is unclear which platelet concentration or PRP preparation may be optimal for the treatment of various cell types. In addition, a "more is better" theory for the use of higher platelet concentrations cannot be supported. This study was not intended to prove efficacy but to provide a platform for future research to be built upon.
C1 [Mazzocca, Augustus D.; McCarthy, Mary Beth R.; Chowaniec, David M.; Dugdale, Evan M.; Hansen, Derek; Cote, Mark P.; Bradley, James P.; Romeo, Anthony A.; Arciero, Robert A.; Beitzel, Knut] Univ Connecticut, Dept Orthopaed Surg, Ctr Hlth, Farmington, CT 06034 USA.
C3 University of Connecticut
RP Mazzocca, AD (通讯作者)，Univ Connecticut, Dept Orthopaed Surg, Ctr Hlth, 263 Farmington Ave,MARB 4th Floor, Farmington, CT 06034 USA.
EM admazzocca@yahoo.com
RI Mazzocca, Augustus/AAD 7507 2021; McCarthy, Mary/IUM 4856 2023
OI Romeo, Anthony/0000 0003 4848 3411; Dugdale, Evan/0000 0002 6747 4177
CR Alsousou J, 2009, J BONE JOINT SURG BR, V91B, P987, DOI 10.1302/0301 620X.91B8.22546
   ALTMAN J, 1962, EXP NEUROL, V5, P302, DOI 10.1016/0014 4886(62)90040 7
   Anitua E, 2005, J ORTHOP RES, V23, P281, DOI 10.1016/j.orthres.2004.08.015
   Bir SC, 2009, J VASC SURG, V50, P870, DOI 10.1016/j.jvs.2009.06.016
   Carofino B, ARTHROSCOPY
   Castricini R, 2011, AM J SPORT MED, V39, P258, DOI 10.1177/0363546510390780
   Chatterjee M, 2002, SCIENCE, V298, P1432, DOI 10.1126/science.1074883
   Cheng Wenjun, 2007, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V21, P386
   Christenson JT, 2004, THORAC CARDIOV SURG, V52, P225, DOI 10.1055/s 2004 821078
   Clausen C, 2006, CELLS TISSUES ORGANS, V184, P68, DOI 10.1159/000098948
   Consolo U, 2007, CLIN ORAL IMPLAN RES, V18, P252, DOI 10.1111/j.1600 0501.2006.01330.x
   de Mos M, 2008, AM J SPORT MED, V36, P1171, DOI 10.1177/0363546508314430
   de Vos RJ, 2010, JAMA J AM MED ASSOC, V303, P144, DOI 10.1001/jama.2009.1986
   Del Bue M, 2008, VET RES COMMUN, V32, pS51, DOI 10.1007/s11259 008 9093 3
   Ehrenfest DMD, 2009, TRENDS BIOTECHNOL, V27, P158, DOI 10.1016/j.tibtech.2008.11.009
   Fallouh L, 2010, J BONE JOINT SURG AM, V92A, P2909, DOI 10.2106/JBJS.I.01158
   Foster TE, 2009, AM J SPORT MED, V37, P2259, DOI 10.1177/0363546509349921
   GANDHI A, 2005, FOOT ANKLE CLIN, V10, pR8
   Gandhi Ankur, 2005, Foot Ankle Clin, V10, P621, DOI 10.1016/j.fcl.2005.06.009
   GAVOSTO F, 1964, NATURE, V203, P92, DOI 10.1038/203092a0
   Gerard D, 2006, J ORAL MAXIL SURG, V64, P443, DOI 10.1016/j.joms.2005.11.016
   Graziani F, 2006, CLIN ORAL IMPLAN RES, V17, P212, DOI 10.1111/j.1600 0501.2005.01203.x
   Griffin XL, 2009, INJURY, V40, P158, DOI 10.1016/j.injury.2008.06.025
   Hamdan AAS, 2009, CLIN ORAL IMPLAN RES, V20, P616, DOI 10.1111/j.1600 0501.2008.01687.x
   Kanno T, 2005, J ORAL MAXIL SURG, V63, P362, DOI 10.1016/j.joms.2004.07.016
   Lopez Vidriero E, 2010, ARTHROSCOPY, V26, P269, DOI 10.1016/j.arthro.2009.11.015
   Markopoulou CE, 2009, J MUSCULOSKEL NEURON, V9, P167
   Mazzocca AD, 2012, J BONE JOINT SURG AM, V94A, P308, DOI 10.2106/JBJS.K.00430
   Picard F, 1999, CLIN CHEM LAB MED, V37, P681, DOI 10.1515/CCLM.1999.106
   Rutkowski JL, 2010, J ORAL IMPLANTOL, V36, P11, DOI 10.1563/AAID JOI 09 00063
   Schepull T, 2011, AM J SPORT MED, V39, P38, DOI 10.1177/0363546510383515
   Slapnicka J, 2008, J ORAL MAXIL SURG, V66, P297, DOI 10.1016/j.joms.2007.05.022
   Spang JT, 2011, KNEE SURG SPORT TR A, V19, P495, DOI 10.1007/s00167 010 1291 1
   SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111
   Tumia NS, 2004, AM J SPORT MED, V32, P915, DOI 10.1177/0363546503261710
   Uggeri J, 2007, J PERIODONTOL, V78, P1985, DOI 10.1902/jop.2007.070116
   Weibrich G, 2002, INT J ORAL MAX IMPL, V17, P184
   Zhang H, 2004, J ORTHOP RES, V22, P30, DOI 10.1016/S0736 0266(03)00155 4
NR 38
TC 138
Z9 147
U1 0
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0363 5465
EI 1552 3365
J9 AM J SPORT MED
JI Am. J. Sports Med.
PD AUG
PY 2012
VL 40
IS 8
BP 1742
EP 1749
DI 10.1177/0363546512452713
PG 8
WC Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences
GA 984FO
UT WOS:000307175700008
PM 22802273
DA 2025 08 17
ER

PT J
AU Bantumilli, S
   Zhu, LC
   Sakthivel, M
   Dodd, L
AF Bantumilli, Surekha
   Zhu, Lee Ching
   Sakthivel, Muthukumar
   Dodd, Leslie
TI A case of osteoclastic variant of anaplastic thyroid carcinoma:
   Diagnostic and prognostic marker studies by cytology
SO DIAGNOSTIC CYTOPATHOLOGY
LA English
DT Article
DE anaplastic carcinoma; cytology diagnosis of thyroid carcinoma;
   osteoclastic variant; osteoclast like giant cells; PD L1 in thyroid
   carcinoma
AB Anaplastic thyroid carcinoma is an infrequent, but aggressive fatal subtype of thyroid cancer. The osteoclastic variant of anaplastic carcinoma is a rare subtype of anaplastic carcinoma with rare cases reported in the literature. Molecular targeted therapies have emerged for the anaplastic carcinoma, necessitating accurate pathologic diagnosis with additional ancillary testing for directing clinical management. We present here the cytological diagnosis of an anaplastic thyroid carcinoma osteoclastic variant on fine needle aspiration (FNA), with emphasis on the novelty of utilizing the least invasive procedure (aspiration cytology) for rendering pathological diagnosis as well as identifying potential prognostic markers for targeted immunotherapy.
C1 [Bantumilli, Surekha; Zhu, Lee Ching; Dodd, Leslie] Univ N Carolina, Dept Pathol & Lab Med, 160 North Med Dr,CB 7525, Chapel Hill, NC 27599 USA.
   [Sakthivel, Muthukumar] Univ N Carolina, Dept Radiol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Zhu, LC (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, 160 North Med Dr,CB 7525, Chapel Hill, NC 27599 USA.
EM leeching.zhu@unchealth.unc.edu
OI Bantumilli, Surekha/0000 0002 3213 6688; SAKTHIVEL, MUTHU
   KUMAR/0000 0002 6257 884X
CR Abe I, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912 021 01019 9
   Abe I, 2021, HISTOL HISTOPATHOL, V36, P239, DOI 10.14670/HH 18 277
   Begum S, 2004, MODERN PATHOL, V17, P1359, DOI 10.1038/modpathol.3800198
   Besaw RJ, 2021, J NATL COMPR CANC NE, V19, P247, DOI 10.6004/jnccn.2021.7001
   Bible KC, 2021, THYROID, V31, P337, DOI 10.1089/thy.2020.0944
   Capdevila J, 2019, ANN ONCOL, V30, P1843, DOI 10.1093/annonc/mdz216
   Dong WL, 2018, GENE CHROMOSOME CANC, V57, P645, DOI 10.1002/gcc.22678
   ESMAILI JH, 1983, CANCER AM CANCER SOC, V52, P2122, DOI 10.1002/1097 0142(19831201)52:11<2122::AID CNCR2820521125>3.0.CO;2 3
   Han KM, 2010, KOREAN J PATHOL, V44, P682, DOI 10.4132/KoreanJPathol.2010.44.6.682
   Hrudka J, 2020, VIRCHOWS ARCH, V477, P687, DOI 10.1007/s00428 020 02830 8
   Lopes Ventura S, 2019, J ENDOCRINOL INVEST, V42, P527, DOI 10.1007/s40618 018 0947 4
   Luchini C, 2018, HUM PATHOL, V81, P157, DOI 10.1016/j.humpath.2018.07.006
   Obayashi M, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876 020 01362 4
   Paulsson JO, 2020, J PATHOL, V250, P183, DOI 10.1002/path.5359
   Paulsson JO, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902 018 0275 x
   Pozdeyev N, 2018, CLIN CANCER RES, V24, P3059, DOI 10.1158/1078 0432.CCR 18 0373
   Rosai J., 2011, ROSAI ACKERMANS SURG, P487
   Scheffel RS, 2022, CURR OPIN ONCOL, V34, P9, DOI 10.1097/CCO.0000000000000797
   Silver Karcioglu Amanda, 2022, Cancer Cytopathol, V130, P174, DOI 10.1002/cncy.22519
   Stenman A, 2021, CANCERS, V13, DOI 10.3390/cancers13246340
   Zhang LX, 2022, HEAD NECK PATHOL, V16, P716, DOI 10.1007/s12105 022 01428 7
NR 21
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 8755 1039
EI 1097 0339
J9 DIAGN CYTOPATHOL
JI Diagn. Cytopathol.
PD DEC
PY 2022
VL 50
IS 12
BP E357
EP E360
DI 10.1002/dc.25028
EA AUG 2022
PG 4
WC Medical Laboratory Technology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology; Pathology
GA 5V3BF
UT WOS:000836413200001
PM 35929756
DA 2025 08 17
ER

PT J
AU Ferrie, L
   Premnath, P
   Olsen, A
   Larijani, L
   Besler, BA
   Rancourt, DE
   Duncan, NA
   Underhill, TM
   Krawetz, RJ
AF Ferrie, Leah
   Premnath, Priyatha
   Olsen, Alexandra
   Larijani, Leila
   Besler, Bryce A.
   Rancourt, Derrick E.
   Duncan, Neil A.
   Underhill, T. Michael
   Krawetz, Roman J.
TI Exogenously delivered iPSCs disrupt the natural repair response of
   endogenous MPCs after bone injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; SERUM OSTEOPONTIN LEVELS; MINERAL DENSITY;
   MOUSE; EFFICIENCY; MARROW; MODEL
AB Promoting bone healing including fracture non unions are promising targets for bone tissue engineering due to the limited success of current clinical treatment methods. There has been significant research on the use of stem cells with and without biomaterial scaffolds to treat bone fractures due to their promising regenerative capabilities. However, the relative roles of exogenous vs. endogenous stem cells and their overall contribution to in vivo fracture repair is not well understood. The purpose of this study was to determine the interaction between exogenous and endogenous stem cells during bone healing. This study was conducted using a standardized burr hole bone injury model in a mesenchymal progenitor cell (MPC) lineage tracing mouse under normal homeostatic and osteoporotic conditions. Burr hole injuries were treated with a collagen I biomaterial loaded with and without labelled induced pluripotent stem cells (iPSCs). Using lineage tracing, the roles of exogenous and endogenous stem cells during bone healing were examined. It was observed that treatment with iPSCs resulted in muted healing compared to untreated controls in intact mice post injury. When the cell populations were examined histologically, iPSC treated burr hole defects presented with a dramatic reduction in endogenous MPCs and cell proliferation throughout the injury site. However, when the ovaries were removed and an osteoporotic like phenotype induced in the mice, iPSCs treatment resulted in increased bone formation relative to untreated controls. In the absence of iPSCs, endogenous MPCs demonstrated robust proliferative and osteogenic capacity to undertake repair and this behaviour was disrupted in the presence of iPSCs which instead took on an osteoblast fate but with little proliferation. This study clearly demonstrates that exogenously delivered cell populations can impact the normal function of endogenous stem/progenitor populations during the normal healing cascade. These interactions need to be better understood to inform cell and biomaterial therapies to treat fractures.
C1 [Ferrie, Leah; Premnath, Priyatha; Olsen, Alexandra; Larijani, Leila; Besler, Bryce A.; Rancourt, Derrick E.; Duncan, Neil A.; Krawetz, Roman J.] Univ Calgary, McCaig Inst Bone & Joint Hlth, Calgary, AB, Canada.
   [Ferrie, Leah; Olsen, Alexandra; Besler, Bryce A.; Rancourt, Derrick E.; Duncan, Neil A.; Krawetz, Roman J.] Univ Calgary, Biomed Engn Grad Program, Calgary, AB, Canada.
   [Premnath, Priyatha] Univ Wisconsin Milwaukee, Coll Engn & Appl Sci, Milwaukee, WI USA.
   [Larijani, Leila; Rancourt, Derrick E.] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB, Canada.
   [Duncan, Neil A.] Univ Calgary, Schulich Sch Engn, Dept Civil Engn, Calgary, AB, Canada.
   [Underhill, T. Michael] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada.
   [Krawetz, Roman J.] Univ Calgary, Cumming Sch Med, Dept Cell Biol & Anat, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; University of Wisconsin
   System; University of Wisconsin Milwaukee; University of Calgary;
   University of Calgary; University of British Columbia; University of
   Calgary
RP Krawetz, RJ (通讯作者)，Univ Calgary, McCaig Inst Bone & Joint Hlth, Calgary, AB, Canada.; Krawetz, RJ (通讯作者)，Univ Calgary, Biomed Engn Grad Program, Calgary, AB, Canada.; Krawetz, RJ (通讯作者)，Univ Calgary, Cumming Sch Med, Dept Cell Biol & Anat, Calgary, AB, Canada.
EM rkrawetz@ucalgary.ca
RI Duncan, Neil/C 8260 2009; Besler, Bryce/AAH 6837 2020
OI Olsen, Alexandra/0000 0001 9980 3468
FU Osteoporosis Canada Studentship; Alberta Innovates Health Solutions
   Fellowship; NSERC; Tier 2 Canada Research Chair; CIHR
FX Leah Ferrie was supported by an Osteoporosis Canada Studentship.
   Priyatha Premnath was supported by an Alberta Innovates Health Solutions
   Fellowship. Alexandra Olsen was supported by an NSERC studentship. Roman
   Krawetz is supported by a Tier 2 Canada Research Chair. This work from
   supported by grants from NSERC and CIHR. We would like to thank the
   Cumming School of Medicine ARC staff for assistance with animal
   husbandry; and Kent Paulson for assistance with the biomechanical
   testing.
CR Abbasi S, 2020, CELL STEM CELL, V27, P396, DOI 10.1016/j.stem.2020.07.008
   Alfred R, 2011, BIOMATERIALS, V32, P6006, DOI 10.1016/j.biomaterials.2011.04.015
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Cho EH, 2013, J KOREAN MED SCI, V28, P1496, DOI 10.3346/jkms.2013.28.10.1496
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Frölke JPM, 2007, INJURY, V38, pS19, DOI 10.1016/S0020 1383(07)80005 2
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Huang S, 2015, CELL TRANSPLANT, V24, P2643, DOI 10.3727/096368915X687219
   Jeon OH, 2016, SCI REP UK, V6, DOI 10.1038/srep26761
   Krawetz RJ, 2012, TISSUE ENG PT A, V18, P1014, DOI [10.1089/ten.TEA.2011.0174, 10.1089/ten.tea.2011.0174]
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Lowekamp BC, 2013, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00045
   Nandra R, 2016, TRAUMA, V18, P3, DOI 10.1177/1460408615591625
   Obermeyer TS, 2012, J ORTHOP TRAUMA, V26, P712, DOI 10.1097/BOT.0b013e3182724298
   Pereira TA, 2016, INT J PARASITOL, V46, P829, DOI 10.1016/j.ijpara.2016.08.004
   Premnath P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215018
   Premnath P, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1790 z
   Roderburg C, 2015, CRIT CARE, V19, DOI 10.1186/s13054 015 0988 4
   Schlundt C, 2018, CURR OSTEOPOROS REP, V16, P155, DOI 10.1007/s11914 018 0432 1
   Scott RW, 2019, CELL STEM CELL, V25, P797, DOI 10.1016/j.stem.2019.11.004
   Soliman H, 2020, CELL STEM CELL, V26, P205, DOI 10.1016/j.stem.2019.12.008
   Sui SR, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.28
   Taha MA, 2013, J MAGN RESON IMAGING, V38, P231, DOI 10.1002/jmri.23876
   Taiani JT, 2014, BONE, V64, P263, DOI 10.1016/j.bone.2014.04.019
   Taiani JT, 2013, CELL TRANSPLANT, V22, P1453, DOI 10.3727/096368912X658755
   Taiani JT, 2010, STEM CELLS DEV, V19, P989, DOI 10.1089/scd.2009.0297
   Tseng SS, 2008, J BONE JOINT SURG AM, V90A, P92, DOI 10.2106/JBJS.G.01192
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   Wei QS, 2016, SCAND J CLIN LAB INV, V76, P33, DOI 10.3109/00365513.2015.1087045
   Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015
   Zhu W, 2016, P NATL ACAD SCI USA, V113, pE3492, DOI 10.1073/pnas.1604153113
NR 33
TC 0
Z9 0
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 9
PY 2023
VL 13
IS 1
DI 10.1038/s41598 023 36609 z
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA J0OQ8
UT WOS:001006690200086
PM 37296277
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ren, L
   Li, QY
   Zhang, LW
   Wang, RY
   Qin, F
   Zhao, LS
   Wei, XY
   Xiong, ZL
AF Ren, Li
   Li, Qiuyu
   Zhang, Liwei
   Wang, Ruoyao
   Qin, Feng
   Zhao, Longshan
   Wei, Xiuyan
   Xiong, Zhili
TI Integrated serum pharmacochemistry, network pharmacology and
   pharmacokinetics to explore bioactive components of Gushudan in the
   treatment of osteoporosis
SO JOURNAL OF CHROMATOGRAPHY B ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE Gushudan; Osteoporosis; Bioactive components; Serum pharmacochemistry;
   Network pharmacology; Pharmacokinetics
ID TANSHINONE IIA; RAT PLASMA; ICARIIN; CHROMATOGRAPHY; OSTHOLE;
   DIFFERENTIATION; OSTEOBLASTS; METABOLISM; ACTIVATION; INSIGHT
AB Gushudan (GSD), a compound prescription on the basis of traditional Chinese medicine (TCM) theory and clinical practice, has been used in the treatment of osteoporosis (OP) for many years. Although studies have shown that GSD can treat OP, there is a lack of systematic screening method to explore the bioactive components, which are still unclear. Therefore, this study was aimed to establish an integrated method to screen and determine bioactive ingredients of GSD in the treatment of OP by serum pharmacochemistry, network pharmacology and pharmacokinetics. Firstly, 112 components of the GSD extract and 90 serum migrating constituents were identified by the ultra high performance liquid chromatography hybrid quadrupole Orbitrap highresolution mass spectrometry (UHPLC Q Orbitrap HRMS), most of which were derived from flavonoids, tanshinones, coumarins and organic acids. Secondly, based on the network pharmacological analysis of the serum migrating constituents, 37 core targets and 20 main pathways related to both GSD and OP were obtained. More importantly, 7 bioactive ingredients were further screened as the PK markers by the network topology parameters including icariin, icariside II, isopimpinellin, bergapten, imperatorin, osthole and tanshinone IIA. Finally, a sensitive and accurate quantitative method based on ultra high performance liquid chromatography tandem mass spectrometry (UHPLC MS/MS) was established and validated for simultaneous determination of the 7 bioactive ingredients in the rat plasma after oral administration of GSD extract, which was then applied to pharmacokinetic study. Besides, the overall pharmacokinetic characteristics were further calculated: Cmax was 180.52 +/  31.18 ng/mL, T max was 0.46 +/  0.20 h, t(1/2) was 4.09 +/  0.39 h, AUC0 8 was 567.24 +/  65.29 ng.h/mL, which displayed quick absorption and medium elimination in rats after oral administration of GSD extract. This study provided a new and holistic insight for exploring bioactive constituents and main targets to decode the therapeutic material basis of GSD against OP.
C1 [Ren, Li; Li, Qiuyu; Zhang, Liwei; Wang, Ruoyao; Qin, Feng; Zhao, Longshan; Xiong, Zhili] Shenyang Pharmaceut Univ, Sch Pharm, Benxi 117004, Peoples R China.
   [Wei, Xiuyan] Shenyang Pharmaceut Univ, Sch Life Sci & Biopharmaceut Sci, Shenyang 110016, Liaoning, Peoples R China.
   [Xiong, Zhili] Shenyang Pharmaceut Univ, 26 Huatuo Rd, High &New Tech Dev Zone, Benxi 117004, Liaoning, Peoples R China.
C3 Shenyang Pharmaceutical University; Shenyang Pharmaceutical University;
   Shenyang Pharmaceutical University
RP Xiong, ZL (通讯作者)，Shenyang Pharmaceut Univ, 26 Huatuo Rd, High &New Tech Dev Zone, Benxi 117004, Liaoning, Peoples R China.
EM bearry200@126.com
RI Ren, Li/LRT 1157 2024; Qin, Feng/JWP 5386 2024
FU National Natural Sci ence Foundation of China [82174235, 81773694];
   Science Foundation of Shenyang Pharmaceutical University [GGJJ2021107]
FX Acknowledgements This work was supported by funding from the National
   Natural Sci ence Foundation of China (Grant No. 82174235 and No.
   81773694) and Science Foundation of Shenyang Pharmaceutical University
   GGJJ2021107.
CR Asafo Adjei TA, 2016, CURR OSTEOPOROS REP, V14, P226, DOI 10.1007/s11914 016 0321 4
   Cheatham SW, 2017, STRENGTH COND J, V39, P2, DOI 10.1519/SSC.0000000000000302
   Cheng L, 2018, AM J TRANSL RES, V10, P1457
   Feng QS, 2021, J PHARMACEUT BIOMED, V199, DOI 10.1016/j.jpba.2021.114054
   Geiker NRW, 2020, OSTEOPOROSIS INT, V31, P601, DOI 10.1007/s00198 019 05229 7
   Hu JH, 2017, BIOCHEM PHARMACOL, V136, P109, DOI 10.1016/j.bcp.2017.04.010
   Huang SQ, 2020, DRUG DES DEV THER, V14, P2725, DOI 10.2147/DDDT.S250991
   Huang Y, 2016, J CHROMATOGR B, V1027, P119, DOI 10.1016/j.jchromb.2016.05.019
   Jin ZX, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02228 6
   Li J, 2005, J CHROMATOGR B, V826, P26, DOI 10.1016/j.jchromb.2005.07.048
   Li J, 2015, INT J CLIN EXP PATHO, V8, P13695
   Li XJ, 2016, INT J MOL MED, V38, P1661, DOI 10.3892/ijmm.2016.2794
   Li Ye, 2015, Zhongguo Zhong Yao Za Zhi, V40, P1038
   Liu M, 2007, J CHROMATOGR B, V860, P113, DOI 10.1016/j.jchromb.2007.10.019
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep38437
   Liu WD, 2017, ONCOTARGET, V8, P2594, DOI 10.18632/oncotarget.13732
   Lu YJ, 2015, J CHROMATOGR B, V993, P75, DOI 10.1016/j.jchromb.2015.04.021
   Meng F, 2004, PHARMAZIE, V59, P643
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ruiz Garcia A, 2008, J PHARM SCI US, V97, P654, DOI 10.1002/jps.21009
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tang W, 2009, CURR PHARM DESIGN, V15, P2170, DOI 10.2174/138161209788682451
   Wang C, 2012, CHROMATOGRAPHIA, V75, P1129, DOI 10.1007/s10337 012 2319 0
   Wang KS, 2017, ONCOL REP, V37, P3397, DOI 10.3892/or.2017.5581
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Xiao JJ, 2015, MOL CELL BIOCHEM, V409, P113, DOI 10.1007/s11010 015 2517 9
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Xue QQ, 2021, CHEMOMETR INTELL LAB, V210, DOI 10.1016/j.chemolab.2021.104254
   Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915
   Yu Y, 2021, ACTA PHARM SIN B, V11, P1469, DOI 10.1016/j.apsb.2021.02.017
   Yuan HD, 2017, MOLECULES, V22, DOI 10.3390/molecules22071135
   Yuan XM, 2020, ANAL BIOCHEM, V591, DOI 10.1016/j.ab.2019.113559
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang WJ, 2016, CURR PHARM DESIGN, V22, P3171, DOI 10.2174/1381612822666160224142812
NR 35
TC 6
Z9 7
U1 1
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1570 0232
EI 1873 376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD JUN 1
PY 2023
VL 1225
AR 123762
DI 10.1016/j.jchromb.2023.123762
EA MAY 2023
PG 13
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA K4JV1
UT WOS:001016126200001
PM 37247535
DA 2025 08 17
ER

PT J
AU Wang, ZH
   Liu, NC
   Zhou, G
   Shi, TG
   Wang, ZZ
   Gan, JJ
   Wang, R
   Qian, HB
   Bao, NR
   Guo, T
   Zhao, JN
AF Wang, Zhenheng
   Liu, Naicheng
   Zhou, Gang
   Shi, Tongguo
   Wang, Zhenzhen
   Gan, Jingjing
   Wang, Rui
   Qian, Hongbo
   Bao, Nirong
   Guo, Ting
   Zhao, Jianning
TI Expression of XBP1s in Fibroblasts is Critical for
   TiAl6V4 Particle Induced RANKL Expression and
   Osteolysis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE TiAl6V4 particles; XBP1s; RANKL; osteolysis; fibroblasts
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC RETICULUM STRESS; PLASMA CELL
   DIFFERENTIATION; TRANSCRIPTION FACTOR XBP 1; NF KAPPA B; OSTEOCLAST
   FORMATION; PERIPROSTHETIC OSTEOLYSIS; JNK ACTIVATION; STROMAL CELLS;
   IRE1 ALPHA XBP1
AB Wear particle induced osteolysis is a major cause of aseptic loosening, which is one of the most common reasons for total hip arthroplasty (THA) failure. Previous studies have shown that the expression of Receptor activation of nuclear factor (NF) kB (RANKL) by fibroblasts in periprosthetic membrane played a crucial role in wear particle induced osteolysis. However, the underlying mechanism of RANKL expression remains largely unknown. In the present study, we investigated the effect of TiAl6V4 particle (TiPs) induced XBP1s (spliced form of X box binding protein 1) on RANKL expression and osteoclastogenesis both in vitro and in vivo. The levels of XBP1s in peri implant membrane, animal models, and TiPs stimulated fibroblasts were determined by western blots. To assess the effect of XBP1s on RANKL expression, fibroblasts were treated with both a small interfering RNA (siRNA) and an inhibitor of XBP1 prior to exposure to TiPs. The effect of XBP1s on osteoclasts formation was determined by tartrate resistant acid phosphatase (TRAP) staining in vitro osteoclastogenesis assay and in animal models. The resorption of bone was assessed by micro computed tomography (micro CT) with three dimensional reconstruction. Our results demonstrated that XBP1s was activated in periprosthetic membrane, mouse calvaria models, and TiPs stimulated human synovial fibroblasts. Further, inhibition of XBP1s decreased the expression of RANKL and osteoclasts formation in vitro. In mouse calvaria models, both of the osteoclastogenesis and osteolysis were inhibited XBP1s inhibitor. Our results suggested that XBP1s mediated TiPs induced of RANKL expression in fibroblasts, and down regulating XBP1s may represent a potential therapy for wear particle induced osteolysis. (C) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
C1 [Wang, Zhenheng; Liu, Naicheng; Wang, Rui; Qian, Hongbo; Bao, Nirong; Guo, Ting; Zhao, Jianning] Nanjing Univ, Jinling Hosp, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
   [Zhou, Gang; Shi, Tongguo; Wang, Zhenzhen; Gan, Jingjing] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Sch Life Sci, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University
RP Bao, NR; Guo, T; Zhao, JN (通讯作者)，Nanjing Univ, Jinling Hosp, Dept Orthopaed, Nanjing, Jiangsu, Peoples R China.
EM bnrbnr@sina.com; guotingli@vip.sina.com; zhaojianning. 0207@163.com
RI zhou, gang/Z 3014 2019; Shi, Tongguo/AAS 3460 2021
FU National Natural Science Foundation of China [81572111]; Graduate
   Education Innovation Project of Jiangsu Province [KYZZ15_0045];
   Scientific Research Foundation of Graduate School of Nanjing University
   [2015CL12]; Department of Orthopedics Clinical Research Center
   [BL2012002]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   number: 81572111; Grant sponsor: Graduate Education Innovation Project
   of Jiangsu Province; Grant number: KYZZ15_0045; Grant sponsor:
   Scientific Research Foundation of Graduate School of Nanjing University;
   Grant number: 2015CL12; Grant sponsor: Department of Orthopedics
   Clinical Research Center; Grant number: BL2012002.
CR Chung YH, 2012, INT J BIOCHEM CELL B, V44, P989, DOI 10.1016/j.biocel.2012.03.007
   Crockett JC, 2011, OSTEOPOROSIS INT, V22, P1, DOI 10.1007/s00198 010 1272 8
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu CCA, 2009, EMBO J, V28, P1624, DOI 10.1038/emboj.2009.117
   Huo YZ, 2013, VIROLOGY, V444, P233, DOI 10.1016/j.virol.2013.06.015
   Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907
   Koreny T, 2006, ARTHRITIS RHEUM, V54, P3221, DOI 10.1002/art.22134
   Lenna S, 2013, ARTHRITIS RHEUM US, V65, P1357, DOI 10.1002/art.37891
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Maly DJ, 2014, NAT CHEM BIOL, V10, P892, DOI 10.1038/nchembio.1664
   Overley Adamson B, 2014, CANCER BIOL THER, V15, P452, DOI 10.4161/cbt.27820
   Ramage SC, 2007, J BONE JOINT SURG AM, V89A, P841, DOI 10.2106/JBJS.F.00655
   Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509
   Sakai H, 2002, ANN RHEUM DIS, V61, P103, DOI 10.1136/ard.61.2.103
   Sanches M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5202
   Sha HB, 2011, TRENDS ENDOCRIN MET, V22, P374, DOI 10.1016/j.tem.2011.05.002
   Shinohara Y, 2013, BIOCHEM BIOPH RES CO, V432, P326, DOI 10.1016/j.bbrc.2013.01.103
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Volkmann K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199737
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang R, 2013, BIOMATERIALS, V34, P2611, DOI 10.1016/j.biomaterials.2013.01.025
   Wang Y, 2013, BIOMATERIALS, V34, P150, DOI 10.1016/j.biomaterials.2012.09.059
   Wei XC, 2005, J BONE MINER RES, V20, P1136, DOI 10.1359/JBMR.050206
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wu R, 2015, DNA CELL BIOL, V34, P6, DOI 10.1089/dna.2014.2552
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Xu GS, 2012, BLOOD, V119, P4205, DOI 10.1182/blood 2011 05 353300
   Zeng L, 2010, J IMMUNOL, V185, P2324, DOI 10.4049/jimmunol.0903052
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
NR 35
TC 2
Z9 4
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD APR
PY 2017
VL 35
IS 4
BP 752
EP 759
DI 10.1002/jor.23056
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA ES7KG
UT WOS:000399728400003
PM 26403762
OA Bronze
DA 2025 08 17
ER

PT J
AU Fizazi, K
   Herrmann, K
   Krause, BJ
   Rahbar, K
   Chi, KN
   Morris, MJ
   Sartor, O
   Tagawa, ST
   Kendi, AT
   Vogelzang, N
   Calais, J
   Nagarajah, J
   Wei, XX
   Koshkin, VS
   Beauregard, JM
   Chang, B
   Ghouse, R
   DeSilvio, M
   Messmann, RA
   de Bono, J
AF Fizazi, Karim
   Herrmann, Ken
   Krause, Bernd J.
   Rahbar, Kambiz
   Chi, Kim N.
   Morris, Michael J.
   Sartor, Oliver
   Tagawa, Scott T.
   Kendi, Ayse T.
   Vogelzang, Nicholas
   Calais, Jeremie
   Nagarajah, James
   Wei, Xiao X.
   Koshkin, Vadim S.
   Beauregard, Jean Mathieu
   Chang, Brian
   Ghouse, Ray
   DeSilvio, Michelle
   Messmann, Richard A.
   de Bono, Johann
TI Health related quality of life and pain outcomes with [177Lu]
   Lu PSMA 617 plus standard of care versus standard of care in patients
   with metastatic castration resistant prostate cancer (VISION): a
   multicentre, open label, randomised, phase 3 trial
SO LANCET ONCOLOGY
LA English
DT Article
ID BONE METASTASES; MEN; IMPACT; ENZALUTAMIDE; CABAZITAXEL; ABIRATERONE;
   MANAGEMENT; SURVIVAL; EVENTS
AB Background In VISION, the prostate specific membrane antigen (PSMA) targeted radioligand therapy lutetium 177 [(1)77Lu]Lu PSMA 617 (vipivotide tetraxetan) improved radiographic progression free survival and overall survival when added to protocol permitted standard of care in patients with metastatic castration resistant prostate cancer. Here, we report additional health related quality of life (HRQOL), pain, and symptomatic skeletal event results. Methods This multicentre, open label, randomised, phase 3 trial was conducted at 84 cancer centres in nine countries in North America and Europe. Eligible patients were aged 18 years or older; had progressive PSMA positive metastatic castration resistant prostate cancer; an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 2; and had previously received of at least one androgen receptor pathway inhibitor and one or two taxanecontaining regimens. Patients were randomly assigned (2:1) to receive either [(1)77Lu]Lu PSMA 617 plus protocolpermitted standard of care ([(1)77Lu]Lu PSMA 617 group) or standard of care alone (control group) using permuted blocks. Randomisation was stratified by baseline lactate dehydrogenase concentration, liver metastases, ECOG performance status, and androgen receptor pathway inhibitor inclusion in standard of care. Patients in the [(1)77Lu] Lu PSMA 617 group received intravenous infusions of 7 center dot 4 gigabecquerel (GBq; 200 millicurie [mCi]) [(1)77Lu] Lu PSMA 617 every 6 weeks for four cycles plus two optional additional cycles. Standard of care included approved hormonal treatments, bisphosphonates, and radiotherapy. The alternate primary endpoints were radiographic progression  free survival and overall survival, which have been reported. Here we report the key secondary endpoint of time to first symptomatic skeletal event, and other secondary endpoints of HRQOL assessed with the Functional Assessment of Cancer Therapy Prostate (FACT P) and EQ 5D 5L, and pain assessed with the Brief Pain InventoryShort Form (BPI SF). Patient reported outcomes and symptomatic skeletal events were analysed in all patients who were randomly assigned after implementation of measures designed to reduce the dropout rate in the control group (on or after March 5, 2019), and safety was analysed according to treatment received in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, NCT03511664, and is active but not recruiting. Findings Between June 4, 2018, and Oct 23, 2019, 831 patients were enrolled, of whom 581 were randomly assigned to the [(1)77Lu]Lu PSMA 617 group (n=385) or control group (n=196) on or after March 5, 2019, and were included in analyses of HRQOL, pain, and time to first symptomatic skeletal event. The median age of patients was 71 years (IQR 65 75) in the [(1)77Lu]Lu PSMA 617 group and 72 center dot 0 years (66 76) in the control group. Median time to first symptomatic skeletal event or death was 11 center dot 5 months (95% CI 10 center dot 3 13 center dot 2) in the [(1)77Lu]Lu PSMA 617 group and 6 center dot 8 months (5 center dot 2 8 center dot 5) in the control group (hazard ratio [HR] 0 center dot 50, 95% CI 0 center dot 40 0 center dot 62). Time to worsening was delayed in the [(1)77Lu]Lu PSMA 617 group versus the control group for FACT P score (HR 0 center dot 54, 0 center dot 45 0 center dot 66) and subdomains, BPI SF pain intensity score (0 center dot 52, 0 center dot 42 0 center dot 63), and EQ 5D 5L utility score (0 center dot 65, 0 center dot 54 0 center dot 78).
   Grade 3 or 4 haematological adverse events included decreased haemoglobin (80 [15%] of 529 assessable patients who received [(1)77Lu]Lu PSMA 617 plus standard of care vs 13 [6%] of 205 who received standard of care only), lymphocyte concentrations (269 [51%] vs 39 [19%]), and platelet counts (49 [9%] vs five [2%]). Treatment related adverse events leading to death occurred in five (1%) patients who received [(1)77Lu]Lu PSMA 617 plus standard of care (pancytopenia [n=2], bone marrow failure [n=1], subdural haematoma [n=1], and intracranial haemorrhage [n=1]) and no patients who received standard of care only. Interpretation [(1)77Lu]Lu PSMA 617 plus standard of care delayed time to worsening in HRQOL and time to skeletal events compared with standard of care alone. These findings support the use of [(1)77Lu]Lu PSMA 617 in patients with metastatic castration  resistant prostate cancer who received previous androgen receptor pathway inhibitor and taxane treatment.
C1 [Fizazi, Karim] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France.
   [Herrmann, Ken] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany.
   [Herrmann, Ken] Univ Hosp Essen, German Canc Consortium, Essen, Germany.
   [Krause, Bernd J.] Rostock Univ, Dept Nucl Med, Med Ctr, Rostock, Germany.
   [Rahbar, Kambiz] Univ Hosp Munster, Dept Nucl Med, Munster, Germany.
   [Chi, Kim N.] British Columbia Canc Agcy, Med Oncol Dept, Vancouver, BC, Canada.
   [Morris, Michael J.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Sartor, Oliver] Tulane Univ, Tuland Canc Ctr, Sch Med, New Orleans, LA USA.
   [Tagawa, Scott T.] Weill Cornell Med, Dept Urol Hematol & Med Oncol, New York, NY USA.
   [Kendi, Ayse T.] Mayo Clin, Dept Radiol, Rochester, MN USA.
   [Vogelzang, Nicholas] Comprehens Canc Ctr, Las Vegas, NV USA.
   [Calais, Jeremie] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA.
   [Nagarajah, James] Radboud Univ Nijmegen Med Ctr, Dept Med Imaging, Nijmegen, Netherlands.
   [Wei, Xiao X.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
   [Koshkin, Vadim S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA.
   [Beauregard, Jean Mathieu] CHU Quebec Univ Laval, Dept Med Imaging, Quebec City, PQ, Canada.
   [Chang, Brian] Parkview Hosp, Radiat Oncol Associates, Ft Wayne, IN USA.
   [Ghouse, Ray] Adv Accelerator Applicat Novartis, Geneva, Switzerland.
   [DeSilvio, Michelle; Messmann, Richard A.] Novartis, E Hanover, NJ USA.
   [de Bono, Johann] Inst Canc Res, London, England.
   [de Bono, Johann] Royal Marsden Hosp, London, England.
   [Fizazi, Karim] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, F 94805 Villejuif, France.
C3 Universite Paris Saclay; UNICANCER; Gustave Roussy; University of
   Duisburg Essen; Helmholtz Association; German Cancer Research Center
   (DKFZ); University of Duisburg Essen; University of Rostock; University
   of Munster; British Columbia Cancer Agency; Memorial Sloan Kettering
   Cancer Center; Tulane University; Cornell University; Weill Cornell
   Medicine; Mayo Clinic; University of California System; University of
   California Los Angeles; Radboud University Nijmegen; Harvard University;
   Harvard University Medical Affiliates; Dana Farber Cancer Institute;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; Laval University; Novartis; Novartis USA; University of London;
   Institute of Cancer Research   UK; Royal Marsden NHS Foundation Trust;
   Royal Marsden NHS Foundation Trust; UNICANCER; Gustave Roussy;
   Universite Paris Saclay
RP Fizazi, K (通讯作者)，Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, F 94805 Villejuif, France.
EM karim.fizazi@gustaveroussy.fr
RI Rahbar, Kambiz/H 7935 2012; Beauregard, Jean Mathieu/AAE 4989 2020;
   Nagarajah, James/X 5804 2019; CALAIS, JEREMIE/AAG 7119 2020; wei,
   xiaoxue/GSD 8234 2022
OI de Bono, Johann S/0000 0002 2034 595X; CALAIS,
   JEREMIE/0000 0002 8839 4379; 
FU Advanced Accelerator Applications (Novartis); MRC [MR/W018217/1] Funding
   Source: UKRI
FX Advanced Accelerator Applications (Novartis).
CR Boyle HJ, 2019, EUR J CANCER, V116, P116, DOI 10.1016/j.ejca.2019.04.031
   Cathomas R, 2014, UROL INT, V92, P377, DOI 10.1159/000358258
   Cella D, 2015, ANN ONCOL, V26, P179, DOI 10.1093/annonc/mdu510
   Cleeland C., 1991, The Brief Pain Inventory
   Devlin N, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955 017 0704 y
   Esper P, 1997, UROLOGY, V50, P920, DOI 10.1016/S0090 4295(97)00459 7
   Fizazi K, 2020, LANCET ONCOL, V21, P1513, DOI 10.1016/S1470 2045(20)30449 6
   Fizazi K, 2015, EUR UROL, V68, P42, DOI 10.1016/j.eururo.2014.10.001
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039
   Gillessen S, 2022, EUR UROL, V82, P115, DOI 10.1016/j.eururo.2022.04.002
   Gillessen S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.5002
   Halabi S, 2008, J CLIN ONCOL, V26, P2544, DOI 10.1200/JCO.2007.15.0367
   Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270
   Hofman MS, 2021, LANCET, V397, P797, DOI 10.1016/S0140 6736(21)00237 3
   Hussain A, 2019, CRIT REV ONCOL HEMAT, V139, P108, DOI 10.1016/j.critrevonc.2019.04.020
   Joly F, 2020, CLIN GENITOURIN CANC, V18, pE510, DOI 10.1016/j.clgc.2020.02.003
   McKay R, 2017, PROSTATE CANCER P D, V20, P276, DOI 10.1038/pcan.2017.4
   Minner S, 2011, PROSTATE, V71, P281, DOI 10.1002/pros.21241
   Nuhn P, 2019, EUR UROL, V75, P88, DOI 10.1016/j.eururo.2018.03.028
   Nussbaum N, 2016, PROSTATE CANCER P D, V19, P111, DOI 10.1038/pcan.2015.42
   Parker C, 2020, ANN ONCOL, V31, P1119, DOI 10.1016/j.annonc.2020.06.011
   Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477 7525 5 70
   Rathkopf DE, 2014, EUR UROL, V66, P815, DOI 10.1016/j.eururo.2014.02.056
   Rowe SP, 2019, ANNU REV MED, V70, P461, DOI 10.1146/annurev med 062117 073027
   Saad F, 2015, EUR UROL, V68, P570, DOI 10.1016/j.eururo.2015.04.032
   Sartor O, 2021, NEW ENGL J MED, V385, P1091, DOI 10.1056/NEJMoa2107322
   Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597
   Terrisse S, 2020, JAMA ONCOL, V6, P206, DOI 10.1001/jamaoncol.2019.4097
   Violet J, 2019, J NUCL MED, V60, P517, DOI 10.2967/jnumed.118.219352
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 33
TC 61
Z9 62
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470 2045
EI 1474 5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD JUN
PY 2023
VL 24
IS 6
BP 597
EP 610
DI 10.1016/S1470 2045(23)00158 4
EA MAY 2023
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA K9MN2
UT WOS:001019604800001
PM 37269841
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Nakamura, R
   Nakamura, F
   Fukunaga, S
AF Nakamura, Ryosuke
   Nakamura, Fumio
   Fukunaga, Shigeharu
TI Perlecan Diversely Regulates the Migration and Proliferation of Distinct
   Cell Types in vitro
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Basement membrane; Cell culture; Extracellular matrix; Heparan sulfate;
   Proteoglycan
ID FIBROBLAST GROWTH FACTOR; HEPARAN SULFATE PROTEOGLYCAN; MESENCHYMAL
   STEM CELLS; DOMAIN V; SCATTER FACTOR; TUMOR GROWTH; RECEPTOR; CULTURE;
   BINDING; ANGIOGENESIS
AB Perlecan is a multifunctional component of the extracellular matrix. It shows different effects on distinct cell types, and therefore it is thought to show potential for therapies targeting multiple cell types. However, the full range of multifunctionality of perlecan remains to be elucidated. We cultured various cell types, which were derived from epithelial/endothelial, connective and muscle tissues, in the presence of either antiserum against perlecan or exogenous perlecan, and examined the effects of perlecan on cell migration and proliferation. Cell migration was determined using a scratch assay. Blocking of perlecan by anti perlecan antiserum inhibited the migration of vascular endothelial cells (VECs) and bone marrow derived mesenchymal stem cells, and exogenous perlecan added to the culture medium promoted the migration of these cell types. The migration of other cell types was inhibited or was not promoted by exogenous perlecan. Cell proliferation was measured using a water soluble tetrazolium dye. When cells were cultured at low densities, perlecan blocking inhibited the proliferation of VECs, and exogenous perlecan promoted the proliferation of keratinocytes. In contrast, the proliferation of fibroblasts, pre adipocytes and vascular smooth muscle cells cultured at low densities was inhibited by exogenous perlecan. When cells were cultured at high densities, perlecan blocking promoted the proliferation of most cell types, with the exception of skeletal system derived cells (chondrocytes and osteoblasts), which were inhibited by exogenous perlecan. Our results provide an overview of the multiple functions of perlecan in various cell types, and implicate a potential role of perlecan to inhibit undesirable activities, such as fibrosis, obesity and intimal hyperplasia. (C) 2015 S. Karger AG, Basel
C1 [Nakamura, Ryosuke; Nakamura, Fumio; Fukunaga, Shigeharu] Hokkaido Univ, Res Fac Agr, Lab Anim By Prod Sci, Sapporo, Hokkaido 0608589, Japan.
C3 Hokkaido University
RP Fukunaga, S (通讯作者)，Hokkaido Univ, Res Fac Agr, Lab Anim By Prod Sci, Kita Ku, Kita 9,Nishi 9, Sapporo, Hokkaido 0608589, Japan.
EM kamui@anim.agr.hokudai.ac.jp
OI Nakamura, Ryosuke/0000 0003 0061 2114
CR Abuharbeid S, 2006, INT J BIOCHEM CELL B, V38, P1463, DOI 10.1016/j.biocel.2005.10.017
   Al Ahmad AJ, 2011, GLIA, V59, P1822, DOI 10.1002/glia.21227
   Arikawa Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537
   AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092 8674(94)90031 0
   Bajanca F, 2006, DEVELOPMENT, V133, P1635, DOI 10.1242/dev.02336
   Baker AB, 2008, CIRC RES, V103, P289, DOI 10.1161/CIRCRESAHA.108.179465
   Belleudi F, 2007, TRAFFIC, V8, P1854, DOI 10.1111/j.1600 0854.2007.00651.x
   BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003 2697(62)90095 7
   Bix GJ, 2013, ACS CHEM NEUROSCI, V4, P370, DOI 10.1021/cn300197y
   Botta A, 2012, J CELL SCI, V125, P4241, DOI 10.1242/jcs.096289
   Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432 1033.1997.t01 1 00039.x
   Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523
   Cailhier JF, 2008, J BIOL CHEM, V283, P27220, DOI 10.1074/jbc.M801164200
   CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205
   Chen JH, 2001, CELL BIOL INT, V25, P567, DOI 10.1006/cbir.2000.0688
   Chen Q, 2007, NAT PROTOC, V2, P1197, DOI 10.1038/nprot.2007.118
   Clark RAF, 1996, AM J PATHOL, V148, P1407
   Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA
   Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109
   De Wit J, 2005, MOL CELL NEUROSCI, V29, P40, DOI 10.1016/j.mcn.2004.12.009
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168 8278(00)80412 2
   French MM, 2002, J BONE MINER RES, V17, P48, DOI 10.1359/jbmr.2002.17.1.48
   Garl PJ, 2004, CIRC RES, V94, P175, DOI 10.1161/01.RES.0000109791.69181.B6
   Girós A, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471 213X 7 29
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Govindraj P, 2002, J BIOL CHEM, V277, P19461, DOI 10.1074/jbc.M200786200
   GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625
   HANTAZAMBROISE D, 1987, J NEUROSCI, V7, P2293
   HASSELL JR, 1980, P NATL ACAD SCI BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494
   Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467 789X.2001.00042.x
   Hausman Dorothy B., 2008, V456, P201, DOI 10.1007/978 1 59745 245 8_15
   HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945
   Henry MD, 2001, J CELL SCI, V114, P1137
   HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524
   Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582 4934.2010.01236.x
   Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702
   Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006 291X(03)01500 6
   Iruela Arispe ML, 2009, DEV CELL, V16, P222, DOI 10.1016/j.devcel.2009.01.013
   Kimura Kuniko, 2009, Nihon Rinsho Meneki Gakkai Kaishi, V32, P160
   Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200
   Knox SM, 2006, CELL MOL LIFE SCI, V63, P2435, DOI 10.1007/s00018 006 6162 z
   Laplante P, 2006, J BIOL CHEM, V281, P30383, DOI 10.1074/jbc.M606412200
   Lee B, 2011, J CLIN INVEST, V121, P3005, DOI 10.1172/JCI46358
   Lee Seung Won, 2000, Animal Science Journal, V71, P501
   Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097 4652(199808)176:2<255::AID JCP4>3.0.CO;2 N
   Metz RP, 2012, METHODS MOL BIOL, V843, P169, DOI 10.1007/978 1 61779 523 7_16
   Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200
   Moore BB, 2003, AM J PHYSIOL LUNG C, V284, pL342, DOI 10.1152/ajplung.00168.2002
   MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142
   Nakajima I, 2003, BIOCHEM BIOPH RES CO, V309, P702, DOI 10.1016/j.bbrc.2003.08.057
   Nakamura Fumio, 2000, Animal Science Journal, V71, P486
   Nakamura H, 1992, SHIN SEIKAAGKU JIKKE, V12, P13
   Nakamura R, 2014, ANIM SCI J, V85, P706, DOI 10.1111/asj.12187
   Nakamura R, 2014, ANIM SCI J, V85, P262, DOI 10.1111/asj.12116
   NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460 2075.1991.tb07836.x
   Nath B, 2012, HEPATOLOGY, V55, P622, DOI 10.1002/hep.25497
   NOONAN DM, 1991, J BIOL CHEM, V266, P22939
   Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323 06.2006
   OLSON NE, 1992, AM J PATHOL, V140, P1017
   RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275
   Ritchey ER, 2011, MOL VIS, V17, P2440
   Roberts J, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00155
   RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415
   RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092 8674(94)90209 7
   Sakai K, 2010, BIOCHEM BIOPH RES CO, V392, P403, DOI 10.1016/j.bbrc.2010.01.035
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Santiago B, 2012, ARTHRITIS RHEUM US, V64, P409, DOI 10.1002/art.33345
   Sasse P, 2008, CARDIOVASC RES, V80, P435, DOI 10.1093/cvr/cvn225
   Seppanen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062662
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793
   Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910
   SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092 8674(94)90032 9
   Stratman AN, 2009, BLOOD, V114, P5091, DOI 10.1182/blood 2009 05 222364
   Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887
   SUNDARRAJ N, 1995, J CELL SCI, V108, P2663
   Sureshbabu A, 2011, INT J DEV BIOL, V55, P781, DOI 10.1387/ijdb.113364as
   Tran PK, 2004, CIRC RES, V94, P550, DOI 10.1161/01.RES.0000117772.86853.34
   Voelkel NF, 2013, AM J PHYSIOL LUNG C, V304, pL457, DOI 10.1152/ajplung.00335.2012
   Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079
   Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945 053X(99)00014 1
   Whitelock JM, 2008, BIOCHEMISTRY US, V47, P11174, DOI 10.1021/bi8013938
   Zhou ZJ, 2004, CANCER RES, V64, P4699, DOI 10.1158/0008 5472.CAN 04 0810
NR 86
TC 16
Z9 19
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2014
VL 200
IS 6
BP 374
EP 393
DI 10.1159/000440950
PG 20
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA CY9PO
UT WOS:000366739000002
PM 26562025
DA 2025 08 17
ER

PT J
AU Fu, JN
   Li, Y
   Zhang, Y
   Liang, YQ
   Zheng, YF
   Li, ZY
   Zhu, SL
   Li, CY
   Cui, ZD
   Wu, SL
AF Fu, Jieni
   Li, Yuan
   Zhang, Yu
   Liang, Yanqin
   Zheng, Yufeng
   Li, Zhaoyang
   Zhu, Shengli
   Li, Changyi
   Cui, Zhenduo
   Wu, Shuilin
TI An Engineered Pseudo Macrophage for Rapid Treatment of Bacteria Infected
   Osteomyelitis via Microwave Excited Anti Infection and Immunoregulation
SO ADVANCED MATERIALS
LA English
DT Article
DE antibacterial properties; engineered macrophages; immunoregulation;
   microwave therapy; osteomyelitis
ID NANOPARTICLES; ANTIBIOTICS; MANAGEMENT; MECHANISM; DAMAGE; OXIDE
AB Preventing deep bacterial infection and simultaneously enhancing osteogenic differentiation are in great demand for osteomyelitis. Microwave (MW) dynamic therapy is attracting attention due to its excellent penetration ability, but the mechanism of MW induced reactive oxygen species (ROS) is still unknown. Herein, MW responsive engineered pseudo macrophages (M Fe3O4/Au nanoparticles (NPs)) are fabricated to clear Staphylococcus aureus infections and induce M2 polarization of macrophages to improve osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs) under MW irradiation. Fe3O4/Au NPs can generate center dot O 2( ) and heat under MW irradiation in a saline solution, and the mechanism is put forward via finite element modeling and density functional theory calculations. Due to the gap plasmon, electromagnetic hotspots are produced at Fe3O4 Au interface at 2.45 GHz. Because of these induced electromagnetic hotspots, the sodium species is field ionized and subsequently reacts with oxygen to produce center dot O 2( ). Meanwhile, the Fe3O4/Au NPs have a stronger ability than Fe3O4 NPs to fix oxygen, favoring the production of ROS. Additionally, MW treated macrophages diminish to secrete inflammatory cytokines, resulting in the decrease of ROS production in MSCs and thus enhancing their osteogenic differentiation. These engineered pseudo macrophages will be promising for effectively treating bacterial infections and promoting osteoblast differentiation simultaneously in deep tissues under MW irradiation.
C1 [Fu, Jieni; Li, Yuan; Liang, Yanqin; Li, Zhaoyang; Zhu, Shengli; Cui, Zhenduo; Wu, Shuilin] Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ China, Tianjin 300072, Peoples R China.
   [Zhang, Yu; Zheng, Yufeng] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Orthoped, Guangzhou 510080, Peoples R China.
   [Zheng, Yufeng] Peking Univ, Coll Engn, State Key Lab Turbulence & Complex Syst, Beijing 100871, Peoples R China.
   [Zheng, Yufeng] Peking Univ, Coll Engn, Dept Mat Sci & Engn, Beijing 100871, Peoples R China.
   [Li, Changyi] Tianjin Med Univ, Stomatol Hosp, 12 Qixiangtai Rd, Tianjin 300070, Peoples R China.
C3 Tianjin University; Southern Medical University   China; Guangdong
   Academy of Medical Sciences & Guangdong General Hospital; Peking
   University; Peking University; Tianjin Medical University
RP Li, ZY; Wu, SL (通讯作者)，Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ China, Tianjin 300072, Peoples R China.; Zhang, Y; Zheng, YF (通讯作者)，Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Orthoped, Guangzhou 510080, Peoples R China.; Zheng, YF (通讯作者)，Peking Univ, Coll Engn, State Key Lab Turbulence & Complex Syst, Beijing 100871, Peoples R China.; Zheng, YF (通讯作者)，Peking Univ, Coll Engn, Dept Mat Sci & Engn, Beijing 100871, Peoples R China.
EM zhangyu@gdph.org.cn; yfzheng@pku.edu.cn; zyli@tju.edu.cn;
   shuilinwu@tju.edu.cn
RI Li, Zhaoyang/JPA 0792 2023; wu, shuilin/LUZ 0692 2024; WU,
   Shuilin/F 7897 2010; YAN, Zheng Guang/HGC 8374 2022; Li,
   Changyi/GVS 6654 2022; Zhu, Shengli/D 5281 2009
OI Fu, Jieni/0000 0002 4850 8482; wu, shuilin/0000 0002 1270 1870; Zhu,
   Shengli/0000 0002 0190 2626; Zheng, Y.F./0000 0002 7402 9979
FU China National Funds for Distinguished Young Scientists [51925104];
   National Natural Science Foundation of China [51871162]
FX This work was jointly supported by the China National Funds for
   Distinguished Young Scientists (no. 51925104), and the National Natural
   Science Foundation of China (no. 51871162).
CR BLOCHL PE, 1994, PHYS REV B, V49, P16223, DOI 10.1103/PhysRevB.49.16223
   Boniakowski AE, 2018, EUR J IMMUNOL, V48, P1445, DOI 10.1002/eji.201747400
   Carek PJ, 2001, AM FAM PHYSICIAN, V63, P2413
   Chen XW, 2018, NANOSCALE, V10, P15677, DOI 10.1039/c8nr03927e
   Courtney CM, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701776
   Daniel P.L., 2004, LANCET, V364, P369
   Deng XR, 2017, ADV MATER, V29, DOI 10.1002/adma.201701266
   Deng Y, 2008, J AM CHEM SOC, V130, P28, DOI 10.1021/ja0777584
   Ding GH, 2015, SENSOR ACTUAT B CHEM, V221, P1084, DOI 10.1016/j.snb.2015.07.074
   Dudarev SL, 1998, PHYS REV B, V57, P1505, DOI 10.1103/PhysRevB.57.1505
   Ezraty B, 2017, NAT REV MICROBIOL, V15, P385, DOI 10.1038/nrmicro.2017.26
   Ford CA, 2017, EXPERT REV ANTI INFE, V15, P851, DOI 10.1080/14787210.2017.1372192
   Fu CH, 2018, ACS NANO, V12, P2201, DOI 10.1021/acsnano.7b08868
   Fu JN, 2020, ACTA BIOMATER, V101, P152, DOI 10.1016/j.actbio.2019.10.041
   Ginhoux F, 2016, IMMUNITY, V44, P439, DOI 10.1016/j.immuni.2016.02.024
   Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092 8674(02)01201 1
   Hu CMJ, 2015, NATURE, V526, P118, DOI 10.1038/nature15373
   Hu CMJ, 2013, NAT NANOTECHNOL, V8, P336, DOI [10.1038/nnano.2013.54, 10.1038/NNANO.2013.54]
   Hu DF, 2017, ACS NANO, V11, P9330, DOI 10.1021/acsnano.7b04731
   Huang DL, 2019, CHEM ENG J, V361, P353, DOI 10.1016/j.cej.2018.12.098
   Jeng HT, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.195115
   Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030
   Khattak HK, 2019, P NATL ACAD SCI USA, V116, P4000, DOI 10.1073/pnas.1818350116
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   Lam SJ, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.162, 10.1038/nmicrobiol.2016.162]
   Li JX, 2018, ADV MATER, V30, DOI [10.1002/adma.201801043, 10.1002/adma.201704800]
   Li M, 2016, ADV HEALTHC MATER, V5, P557, DOI 10.1002/adhm.201500712
   Li RX, 2019, NANO LETT, V19, P124, DOI 10.1021/acs.nanolett.8b03439
   Li Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202000023
   Li YA, 2020, ACS NANO, V14, P8157, DOI 10.1021/acsnano.0c01486
   Li Y, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201900946
   Li Y, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201800299
   Lin L, 2015, NAT NANOTECHNOL, V10, P465, DOI [10.1038/NNANO.2015.28, 10.1038/nnano.2015.28]
   Lin W, 2020, NATL SCI REV, V7, P472, DOI 10.1093/nsr/nwz065
   Liu Y, 2017, ANGEW CHEM INT EDIT, V56, P1486, DOI 10.1002/anie.201609277
   Lodziana Z, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.206402
   Ma XY, 2019, BIOMATERIALS, V214, DOI 10.1016/j.biomaterials.2019.119223
   Nakayama M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00103
   Parodi A, 2013, NAT NANOTECHNOL, V8, P61, DOI 10.1038/nnano.2012.212
   Perdew JP, 1997, PHYS REV LETT, V78, P1396, DOI 10.1103/PhysRevLett.77.3865
   Qiao YQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18268 0
   Rao NL, 2011, PLAST RECONSTR SURG, V127, p177S, DOI 10.1097/PRS.0b013e3182001f0f
   Schnaider L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01447 x
   Sun Z., 2020, SPRINGER SERIES MAT
   Tan L, 2018, ADV MATER, V30, DOI 10.1002/adma.201801808
   Tang JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13724
   Thamphiwatana S, 2017, P NATL ACAD SCI USA, V114, P11488, DOI 10.1073/pnas.1714267114
   Towse A, 2017, HEALTH POLICY, V121, P1025, DOI 10.1016/j.healthpol.2017.07.011
   Ventola C Lee, 2015, P T, V40, P277
   Wang C, 2018, ADV MATER, V30, DOI 10.1002/adma.201804023
   Wei SB, 2021, NANO TODAY, V37, DOI 10.1016/j.nantod.2021.101090
   Wu B, 2019, NANO LETT, V19, P5277, DOI 10.1021/acs.nanolett.9b01735
   Xu C, 2017, FOOD CONTROL, V73, P1445, DOI 10.1016/j.foodcont.2016.10.048
   Yang JH, 2017, CELL HOST MICROBE, V22, P757, DOI 10.1016/j.chom.2017.10.020
   Zhang QZ, 2018, NAT NANOTECHNOL, V13, P1182, DOI 10.1038/s41565 018 0254 4
   Zheng QY, 2021, CHEM SOC REV, V50, P5086, DOI 10.1039/d1cs00056j
   Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009 1082
NR 57
TC 144
Z9 146
U1 22
U2 321
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD OCT
PY 2021
VL 33
IS 41
AR 2102926
DI 10.1002/adma.202102926
EA AUG 2021
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA WF6FR
UT WOS:000685406800001
PM 34396595
DA 2025 08 17
ER

PT J
AU Patnaik, R
   Varghese, R
   Jannati, S
   Naidoo, N
   Banerjee, Y
AF Patnaik, Rajashree
   Varghese, Riah
   Jannati, Shirin
   Naidoo, Nerissa
   Banerjee, Yajnavalka
TI Targeting PAR2 mediated inflammation in osteoarthritis: a comprehensive
   in vitro evaluation of oleocanthal's potential as a functional food
   intervention for chondrocyte protection and anti inflammatory effects
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Osteoarthritis; Protease activated receptor 2 (PAR 2); Oleocanthal;
   Anti inflammatory agents; Chondrocytes; In vitro techniques; Cartilage;
   Signal transduction; Phenols; Inflammation mediators; Extracellular
   matrix; Mitochondrial membrane potential
ID ACTIVATED RECEPTOR 2; NF KAPPA B; MONOCYTE CHEMOATTRACTANT; ARTICULAR
   CHONDROCYTES; CHONDROITINS 4; II COLLAGEN; TNF ALPHA; 6 SULFATE; MATRIX;
   DEGRADATION
AB BackgroundOsteoarthritis (OA) is a prevalent degenerative joint disease characterized by chronic inflammation and progressive cartilage degradation, ultimately leading to joint dysfunction and disability. Oleocanthal (OC), a bioactive phenolic compound derived from extra virgin olive oil, has garnered significant attention due to its potent anti inflammatory properties, which are comparable to those of non steroidal anti inflammatory drugs (NSAIDs). This study pioneers the investigation into the effects of OC on the Protease Activated Receptor 2 (PAR 2) mediated inflammatory pathway in OA, aiming to validate its efficacy as a functional food based therapeutic intervention.MethodsTo simulate cartilage tissue in vitro, human bone marrow derived mesenchymal stem cells (BMSCs) were differentiated into chondrocytes. An inflammatory OA like environment was induced in these chondrocytes using lipopolysaccharide (LPS) to mimic the pathological conditions of OA. The therapeutic effects of OC were evaluated by treating these inflamed chondrocytes with various concentrations of OC. The study focused on assessing key inflammatory markers, catabolic enzymes, and mitochondrial function to elucidate the protective mechanisms of OC. Mitochondrial function, specifically mitochondrial membrane potential (Delta Psi m), was assessed using Rhodamine 123 staining, a fluorescent dye that selectively accumulates in active mitochondria. The integrity of Delta Psi m serves as an indicator of mitochondrial and bioenergetic function. Additionally, Western blotting was employed to analyze protein expression levels, while real time polymerase chain reaction (RT PCR) was used to quantify gene expression of inflammatory cytokines and catabolic enzymes. Flow cytometry was utilized to measure cell viability and apoptosis, providing a comprehensive evaluation of OC's therapeutic effects on chondrocytes.ResultsThe results demonstrated that OC significantly downregulated PAR 2 expression in a dose dependent manner, leading to a substantial reduction in pro inflammatory cytokines, including TNF alpha, IL 1 beta, and MCP 1. Furthermore, OC attenuated the expression of catabolic markers such as SOX4 and ADAMTS5, which are critically involved in cartilage matrix degradation. Importantly, OC was found to preserve mitochondrial membrane potential (Delta Psi m) in chondrocytes subjected to inflammatory stress, as evidenced by Rhodamine 123 staining, indicating a protective effect on cellular bioenergetics. Additionally, OC modulated the Receptor Activator of Nuclear Factor Kappa Beta Ligand (RANKL)/Receptor Activator of Nuclear Factor Kappa Beta (RANK) pathway, suggesting a broader therapeutic action against the multifactorial pathogenesis of OA.ConclusionsThis study is the first to elucidate the modulatory effects of OC on the PAR 2 mediated inflammatory pathway in OA, revealing its potential as a multifaceted therapeutic agent that not only mitigates inflammation but also protects cartilage integrity. The preservation of mitochondrial function and modulation of the RANKL/RANK pathway further underscores OC's comprehensive therapeutic potential in counteracting the complex pathogenesis of OA. These findings position OC as a promising candidate for integration into nutritional interventions aimed at managing OA. However, further research is warranted to fully explore OC's therapeutic potential across different stages of OA and its long term effects in musculoskeletal disorders.
C1 [Patnaik, Rajashree; Varghese, Riah; Jannati, Shirin; Naidoo, Nerissa; Banerjee, Yajnavalka] MBRU, Dubai Hlth, Dubai, U Arab Emirates.
RP Banerjee, Y (通讯作者)，MBRU, Dubai Hlth, Dubai, U Arab Emirates.
EM Yajnavalka.Banerjee@dubaihealth.ae
RI ; Banerjee, Yajnavalka/AGR 7812 2022
OI Naidoo, Nerissa/0000 0002 0924 8796; 
FU Mohammed Bin Rashid University of Medicine and Health Sciences; Al
   Jalila Foundation
FX The authors wish to express their sincere appreciation to Ms. Monisha
   Varghese for her invaluable support in conducting the RT PCR
   experiments. The authors also extend their deep gratitude to the Al
   Jalila Foundation for their magnanimous support, which was crucial in
   providing the necessary laboratory space and state of the art equipment
   needed to carry out this research.
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022 2836(05)80360 2
   Amiable N, 2009, BONE, V44, P1143, DOI 10.1016/j.bone.2009.02.015
   arthritis, Eat Right for Your Type of Arthritis
   arthritis, Benefits of Olive Oil for Arthritis
   Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a
   Bergholt NL, 2019, CARTILAGE, V10, P370, DOI 10.1177/1947603518764262
   Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369 5274(99)00046 6
   Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316
   Blanco FJ, 2011, NAT REV RHEUMATOL, V7, P161, DOI 10.1038/nrrheum.2010.213
   Blewett HJH, 2008, CRIT REV FOOD SCI, V48, P458, DOI 10.1080/10408390701429526
   Boe Chelsea, 2015, Am J Orthop (Belle Mead NJ), V44, P302
   Buckland Jenny, 2013, Nat Rev Rheumatol, V9, P566, DOI 10.1038/nrrheum.2013.135
   Buhrmann C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147645
   CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652
   Castrogiovanni P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122042
   Chen TL, 2011, J BIOMED SCI, V18, DOI 10.1186/1423 0127 18 43
   Chin KY, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101060
   Chin KY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13080755
   Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930
   DIEFFENBACH CW, 1993, PCR METH APPL, V3, pS30
   Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/NEJMoa1200303, 10.1056/nejmoa1800389]
   Fan HX, 2023, DIABETOL METAB SYNDR, V15, DOI 10.1186/s13098 023 01052 7
   Fari G, 2023, Med (Kaunas), V59
   Fari G, 2023, BIOLOGY BASEL, V12, DOI 10.3390/biology12081061
   Fennema E, 2013, TRENDS BIOTECHNOL, V31, P108, DOI 10.1016/j.tibtech.2012.12.003
   Ferrell WR, 2010, ANN RHEUM DIS, V69, P2051, DOI 10.1136/ard.2010.130336
   Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913
   Fields JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01412
   Geng RZ, 2023, EXP THER MED, V26, DOI 10.3892/etm.2023.12180
   González Rodríguez M, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12122112
   Grishko VI, 2009, OSTEOARTHR CARTILAGE, V17, P107, DOI 10.1016/j.joca.2008.05.009
   Han GT, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5558066
   Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004
   Henrotin Y, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3657
   Huang XJ, 2019, AGING US, V11, P12532, DOI 10.18632/aging.102586
   Iacono A, 2010, ARTHRITIS RHEUM US, V62, P1675, DOI 10.1002/art.27437
   Jannati S, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25168727
   Jiang LJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703110
   JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526
   Jones K, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.789349
   Kahan A, 2009, ARTHRITIS RHEUM US, V60, P524, DOI 10.1002/art.24255
   Kalogera S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 03346 0
   Kan SY, 2021, CARTILAGE, V13, p1102S, DOI 10.1177/19476035211063858
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950
   Kwak Sanggyu, 2023, J Lipid Atheroscler, V12, P89, DOI 10.12997/jla.2023.12.2.89
   Latourte A, 2022, OSTEOARTHR CARTILAGE, V30, P175, DOI 10.1016/j.joca.2021.09.012
   LAZARUS GS, 1968, J CLIN INVEST, V47, P2622, DOI 10.1172/JCI105945
   Lippiello L, 2008, EVID BASED COMPL ALT, V5, P191, DOI 10.1093/ecam/nem132
   Liu JT, 2010, OSTEOARTHR CARTILAGE, V18, P1218, DOI 10.1016/j.joca.2010.07.003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lozano Castellón J, 2020, CRIT REV FOOD SCI, V60, P2532, DOI 10.1080/10408398.2019.1650715
   Lu Qinglie, 2017, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V31, P1517, DOI 10.7507/1002 1892.201705025
   Lu TJ, 2017, CELL TRANSPLANT, V26, P417, DOI 10.3727/096368916X693464
   Ma RF, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 154
   Mailhot B, 2020, J EXP MED, V217, DOI 10.1084/jem.20191430
   McCulloch K, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00257
   Michel BA, 2005, ARTHRITIS RHEUM US, V52, P779, DOI 10.1002/art.20867
   Milner JM, 2010, ARTHRITIS RHEUM US, V62, P1955, DOI 10.1002/art.27476
   Mishra P, 2019, ANN CARD ANAESTH, V22, P407, DOI 10.4103/aca.ACA_94_19
   Molnar V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179208
   Montoya T, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10050650
   Ni FF, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 02045 2
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Patnaik R, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0290739
   Patnaik R, 2023, JMIR RES PROTOC, V12, DOI 10.2196/42964
   Patti AM, 2020, METABOLITES, V10, DOI 10.3390/metabo10100392
   Qu RZ, 2018, FASEB J, V32, P1044, DOI 10.1096/fj.201700265R
   Ramey Ward AN, 2024, WOUND REPAIR REGEN, V32, P257, DOI 10.1111/wrr.13137
   Scanzello CR, 2017, J ORTHOP RES, V35, P735, DOI 10.1002/jor.23471
   Scotece M, 2018, CELL PHYSIOL BIOCHEM, V49, P2414, DOI 10.1159/000493840
   Scotece M, 2012, LIFE SCI, V91, P1229, DOI 10.1016/j.lfs.2012.09.012
   Struglics A, 2006, OSTEOARTHR CARTILAGE, V14, P101, DOI 10.1016/j.joca.2005.07.018
   Takahata Y, 2019, FASEB J, V33, P619, DOI 10.1096/fj.201800259R
   Tang H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.999851
   Veronese N, 2019, CLIN NUTR, V38, P2735, DOI 10.1016/j.clnu.2018.11.032
   Veronese N, 2017, CLIN NUTR, V36, P1609, DOI 10.1016/j.clnu.2016.09.035
   Weissgerber TL, 2018, ELIFE, V7, DOI 10.7554/eLife.36163
   Wilkinson DJ, 2019, BRIT J PHARMACOL, V176, P38, DOI 10.1111/bph.14173
   Wu Z, 2021, Biomater Biosyst, V4, P100030, DOI 10.1016/j.bbiosy.2021.100030
   Xiang W, 2023, BMC MUSCULOSKEL DIS, V24, DOI 10.1186/s12891 022 05949 8
   Xiang Y, 2006, OSTEOARTHR CARTILAGE, V14, P1163, DOI 10.1016/j.joca.2006.04.015
   Xu F, 2022, CYTOKINE, V152, DOI 10.1016/j.cyto.2022.155805
   Xu YK, 2015, BIOL RES, V48, DOI [10.1186/s40659 015 0057 0, 10.1186/S40659 015 0057 0]
   Ye XK, 2021, EXP GERONTOL, V156, DOI 10.1016/j.exger.2021.111616
   Yoshitomi H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06187 0
   Zhao YP, 2015, ANN RHEUM DIS, V74, P2244, DOI 10.1136/annrheumdis 2014 205779
   Zhao YP, 2019, EBIOMEDICINE, V41, P556, DOI 10.1016/j.ebiom.2019.02.035
   Zhu P, 2007, CLIN IMMUNOL, V122, P75, DOI 10.1016/j.clim.2006.08.004
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 90
TC 4
Z9 4
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD OCT 1
PY 2024
VL 25
IS 1
AR 769
DI 10.1186/s12891 024 07888 y
PG 23
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA H9P8Z
UT WOS:001326689800007
PM 39354427
OA gold
DA 2025 08 17
ER

PT J
AU Ma, YY
   Sun, L
   Chen, XJ
   Wang, N
   Yi, PF
   Song, M
   Zhang, B
   Wang, YZ
   Liang, QH
AF Ma, Yun Yun
   Sun, Lin
   Chen, Xiu Juan
   Wang, Na
   Yi, Peng Fei
   Song, Min
   Zhang, Bo
   Wang, Yu Zhong
   Liang, Qiu Hua
TI Vinpocetine Attenuates the Osteoblastic Differentiation of Vascular
   Smooth Muscle Cells
SO PLOS ONE
LA English
DT Article
ID CEREBROVASCULAR DISEASES; OXIDATIVE STRESS; IN VIVO; CALCIFICATION;
   EXPRESSION; MECHANISMS; MICE
AB Vascular calcification is an active process of osteoblastic differentiation of vascular smooth muscle cells; however, its definite mechanism remains unknown. Vinpocetine, a derivative of the alkaloid vincamine, has been demonstrated to inhibit the high glucose induced proliferation of vascular smooth muscle cells; however, it remains unknown whether vinpocetine can affect the osteoblastic differentiation of vascular smooth muscle cells. We hereby investigated the effect of vinpocetine on vascular calcification using a beta glycerophosphate induced cell model. Our results showed that vinpocetine significantly reduced the osteoblast like phenotypes of vascular smooth muscle cells including ALP activity, osteocalcin, collagen type I, Runx2 and BMP 2 expression as well as the formation of mineralized nodule. Vinpocetine, binding to translocation protein, induced phosphorylation of extracellular signal related kinase and Akt and thus inhibited the translocation of nuclear factor kappa B into the nucleus. Silencing of translocator protein significantly attenuated the inhibitory effect of vinpocetine on osteoblastic differentiation of vascular smooth muscle cells. Taken together, vinpocetine may be a promising candidate for the clinical therapy of vascular calcification.
C1 [Ma, Yun Yun; Sun, Lin; Wang, Na; Yi, Peng Fei; Song, Min; Zhang, Bo; Liang, Qiu Hua] Jining Med Univ, Affiliated Hosp, Dept Endocrinol, Jining, Shandong, Peoples R China.
   [Ma, Yun Yun; Chen, Xiu Juan] Jining Med Univ, Jining, Shandong, Peoples R China.
   [Wang, Yu Zhong] Jining Med Univ, Affiliated Hosp, Dept Neurol, Jining, Shandong, Peoples R China.
   [Wang, Yu Zhong] Jining Med Univ, Affiliated Hosp, Cent Lab, Jining, Shandong, Peoples R China.
C3 Jining Medical University; Jining Medical University; Jining Medical
   University; Jining Medical University
RP Liang, QH (通讯作者)，Jining Med Univ, Affiliated Hosp, Dept Endocrinol, Jining, Shandong, Peoples R China.
EM huaqiuliang@sohu.com
RI Ma, Yunyun/MIP 5131 2025; Zhang, Bo/GMW 6146 2022
FU National Natural Science Foundation of China [81400860]
FX This study was supported by the National Natural Science Foundation of
   China (81400860).
CR Bagoly Edit, 2007, Orvosi Hetilap, V148, P1353, DOI 10.1556/OH.2007.28115
   Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013
   Cai YJ, 2012, J PHARMACOL EXP THER, V343, P479, DOI 10.1124/jpet.112.195446
   Deshmukh R, 2009, EUR J PHARMACOL, V620, P49, DOI 10.1016/j.ejphar.2009.08.027
   Grainger DJ, 1998, J CELL SCI, V111, P2977
   Jayalath RW, 2005, EUR J VASC ENDOVASC, V30, P476, DOI 10.1016/j.ejvs.2005.04.030
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Liang QH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033126
   Liu GY, 2014, ENDOCRINOLOGY, V155, P558, DOI 10.1210/en.2013 1298
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Patyar S, 2011, PHARMACOL REP, V63, P618, DOI 10.1016/S1734 1140(11)70574 6
   Ruiz Miyazawa KW, 2015, CHEM BIOL INTERACT, V237, P9, DOI 10.1016/j.cbi.2015.05.007
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Wang K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096894
   Wu MT, 2013, CALCIFIED TISSUE INT, V93, P365, DOI 10.1007/s00223 013 9712 z
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Zhao Yan Yin, 2011, Neuron Glia Biol, V7, P187, DOI 10.1017/S1740925X12000129
NR 18
TC 7
Z9 7
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 2
PY 2016
VL 11
IS 9
AR e0162295
DI 10.1371/journal.pone.0162295
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DV4EJ
UT WOS:000382877800047
PM 27589055
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Engel, N
   Oppermann, C
   Falodun, A
   Kragl, U
AF Engel, N.
   Oppermann, C.
   Falodun, A.
   Kragl, U.
TI Proliferative effects of five traditional Nigerian medicinal plant
   extracts on human breast and bone cancer cell lines
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Plant extracts; Herbal medicine; Anticancer; Flow cytometry
ID PERSEA AMERICANA; MENOPAUSAL SYMPTOMS; AQUEOUS EXTRACT; SOY; PREVENTION;
   TAMOXIFEN; ESTROGEN; LEAVES
AB Ethnopharmacological relevance: The medicinal plants Hunteria umbellata (HUL), Cola lepidota (CCL), Persea americana leaf (PAL), Root bark of Persea americana (RPA) and Plukenetia conophora (PCL) are used in Nigerian traditional medicine for the treatment of cancer and cancer related diseases.
   Aim of the study: To scientifically evaluate the cell proliferative and apoptotic effects of the plants extracts using breast and osteocarcinoma cell lines, and also to identify the possible components via LC MS to have a kind of chemical fingerprint.
   Materials and methods: The antiproliferative and apoptotic effects of methanolic extracts (10 mu g/ml) of the five medicinal plants were subjected to in vitro evaluation using four cancer cell lines (breast MCF 7 and BT 20; Osteocarcinoma MG 63 and Saos 2) measured by flow cytometry. Non tumorigenic controls MCF 12A and primary isolated osteoblasts (POB) were chosen to eliminate negative influence on healthy tissue.
   Results: Of the five extracts RPA demonstrated a significant (P < 0.05) anti proliferative activity against estrogen receptor positive breast cancer cell lines (MCF 7). The proliferative phase was decreased by 18%, whereas, a significant increase in cell proliferation (about 27%) was observed for RPA at a concentration of 10 mu g/ml. PCL, CCL, HUL and PAL did not show marked inhibition of the proliferation of cell line MCF 7.
   Conclusion: These results give suggestive evidence that the plant extracts exhibit some correlation between the claimed ethnomedicinal uses and the cell proliferative activity. RPA extract includes chemical compounds with estrogen like activity and validates its potential use as anticancer agent, particularly against breast carcinoma; provided important information potentially helpful in drug designing and discovery. Further studies will involve the isolation of anti tumour compounds in RPA by LC MS and detailed mechanism of anticancer activities. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Falodun, A.] Univ Benin, Dept Pharmaceut Chem, Fac Pharm, Benin, Nigeria.
   [Engel, N.] Univ Rostock, Dept Cell Biol, Biomed Res Ctr, D 18057 Rostock, Germany.
   [Oppermann, C.; Kragl, U.] Univ Rostock, Inst Chem, D 18059 Rostock, Germany.
C3 University of Benin; University of Rostock; University of Rostock
RP Falodun, A (通讯作者)，Univ Benin, Dept Pharmaceut Chem, Fac Pharm, Benin, Nigeria.
EM faloabi@uniben.edu
RI Falodun, Abiodun/O 9972 2017; Kragl, Udo/A 3691 2015
OI Falodun, Abiodun/0000 0003 2929 3305; Kragl, Udo/0000 0002 2507 7472
FU DFG TWAS; Deutsche Krebshilfe [FKZ: 107821]
FX We are grateful to DFG TWAS (2010/11) for the award of a visiting
   scientist to Dr. A. Falodun. Special appreciation to Institute of
   Chemie, University of Rostock, Germany. University of Benin, Benin City,
   Nigeria is also acknowledged. We would like to thank Deutsche Krebshilfe
   (FKZ: 107821) for the funding of our work as well. We acknowledge the
   technical help of Petra Seidel, Dept. of Cell Biology, University of
   Rostock.
CR Adeboye JO, 1999, FITOTERAPIA, V70, P15, DOI 10.1016/S0367 326X(98)00015 X
   Adeyemi OO, 2002, FITOTERAPIA, V73, P375, DOI 10.1016/S0367 326X(02)00118 1
   Antia B. S., 2005, Indian Journal of Pharmacology, V37, P325
   CASTLES CG, 1993, CANCER RES, V53, P5934
   CORDELL GA, 1991, J ETHNOPHARMACOL, V32, P117, DOI 10.1016/0378 8741(91)90110 Y
   CRAGG GM, 1994, CIBA F SYMP, V185, P178
   Dingfa Wang, 2010, Molecular & Cellular Toxicology, V6, P25
   EJIMADU IM, 2002, INT J CHEM, V12, P241
   Falodun A, 2006, Pak J Pharm Sci, V19, P256
   Fisher B, 2005, JNCI J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372
   Gupta PB, 2006, J STEROID BIOCHEM, V102, P71, DOI 10.1016/j.jsbmb.2006.09.025
   Howes LG, 2006, MATURITAS, V55, P203, DOI 10.1016/j.maturitas.2006.03.008
   Hu R, 2004, NUTRITION, V20, P83, DOI 10.1016/j.nut.2003.09.015
   Hunter MS, 2004, PSYCHO ONCOL, V13, P769, DOI 10.1002/pon.793
   HUTCHINSON J, 1958, FLORA W TROPICAL A 2, V1, P365
   Igbe I, 2010, ACTA POL PHARM, V67, P81
   Iwu M.W., 1999, NEW ANTIMICROBIALS P
   IWU MM, 1993, HDB AFRICAN MED PLAN
   Johnson T., 1999, Ethnobotany Desk Reference
   Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829
   LANGER AS, 1996, TAMOXIFEN GUIDE CLIN, P127
   LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842
   Messina MJ, 2003, NUTR REV, V61, P117, DOI [10.1301/nr.2003.apr.117 131, 10.1301/nr.2003.apr.117–131]
   Munro IC, 2003, NUTR REV, V61, P1, DOI 10.1301/nr.2003.janr.1 33
   Nebe B, 2006, EUR J CANCER PREV, V15, P405, DOI 10.1097/00008469 200610000 00005
   Nunez R, 2001, Curr Issues Mol Biol, V3, P67
   Owolabi MA, 2005, FITOTERAPIA, V76, P567, DOI 10.1016/j.fitote.2005.04.020
   Sirtori CR, 2001, DRUG SAFETY, V24, P665, DOI 10.2165/00002018 200124090 00003
   Somekawa Y, 2001, OBSTET GYNECOL, V97, P109, DOI 10.1016/S0029 7844(00)01080 2
   Tomida A, 1999, ANTI CANCER DRUG DES, V14, P169
   Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271
NR 31
TC 49
Z9 52
U1 1
U2 45
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD SEP 2
PY 2011
VL 137
IS 2
BP 1003
EP 1010
DI 10.1016/j.jep.2011.07.023
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 823HK
UT WOS:000295112900009
PM 21782919
DA 2025 08 17
ER

PT J
AU Karademir, U
   Gokbulut, C
   Akar, F
AF Karademir, Umit
   Gokbulut, Cengiz
   Akar, Ferda
TI Comparative Plasma Dispositions of Meloxicam and Carprofen Following
   Oral Administration in Dogs
SO ACTA SCIENTIAE VETERINARIAE
LA English
DT Article
DE carprofen; dog; meloxicam; NSAIDs; pharmacokinetics
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PHARMACOKINETICS; CYCLOOXYGENASE;
   PHARMACODYNAMICS; PHARMACOLOGY; INHIBITORS
AB Background: Nonsteroidal anti inflammatory drugs (NSAIDs) are used extensively in several domestic animal species for the treatment of a range of musculo skeletal disorders and soft tissue injuries or inflammatory conditions. These drugs have antipyretic, anti inflammatory and analgesic properties. Meloksikam (MLX) and carprofen (CRP) are two of the NSAIDs most commonly used by oral administration, which is the preferred route for the treatment of chronic pain and inflammation in dogs. The aim of the present study was to determine the pharmacokinetic properties of CRP and MLX in healthy dogs following oral administration at the doses of 2 mg/kg and 0.2 mg/kg bodyweight, respectively.
   Materials, Methods & Results: A total of 12 client owned, cross bred bitches, 2 5 years old and weighing 15 20 kg were used in the study. The animals were allocated into two groups of six such that the mean weight of animals in each group was similar. In Group I, CRP was given orally at a dose of 2 mg/kg and in Group II, MLX was given orally at a dose of 0.2 mg/kg. Blood samples were collected one day prior to drug administration and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32, 40, 48, 56, 72 and 96 h post treatment. Samples were centrifuged at 3000 g for 20 min and plasma was transferred to plastic tubes. Heparinized drug free blood samples for analytical method development and validation process were collected from dogs not included in the study. All the plasma samples were stored at  20 degrees C until estimation of drug concentrations with all analyses completed within one month of sampling and they were analysed by high performance liquid chromatography (HPLC). The terminal half life of MLX (t(1/2) = 37.91 +/  9.15 h) was significantly longer compared with that of CRP (t(1/2) = 17.02 +/  6.95 h). In addition, CRP was absorbed faster (t(max) = 2.20 h) from gastrointestinal system and reached the peak plasma concentration significantly earlier than MLX (t(max) = 5.00 h). Moreover, the results indicated that Cmax (1.31 +/  0.33 mu g/mL) and AUC (33.73 +/  15.25 mu g.h/mL) for CRP values were significantly higher and larger compared with those observed for MLX (C max = 0.39 +/  0.13 mu g/mL and AUC = 17.99 +/  4.97 mu g.h/mL), respectively following dose proportionality comparisons for C max and AUC values of both molecules done after dose normalization.
   Discussion: The pharmacokinetic parameters of CPR were significantly different from those of MLX following oral administration. The results of the present study suggest that, although the systemic availability of CPR was higher, its absorption and elimination phases were significantly faster compared with those of MLX. Though, as the earlier and higher C max of CRP than MLX suggests that CRP seems to display anti inflammatory effect faster than MLX in the treatment of the acute inflammatory disorders in dogs following oral administration, the anti inflammatory effect is not necessarily directly related only to C max and t max, especially when the pharmacodynamic characteristics of the drugs may be different. The present study indicates that there are significant differences between pharmacokinetic parameters of MLX and CRP after oral administration in dogs. Because of the relatively slow absorption from gastrointestinal system after oral administration, MLX should be given intramuscular or subcutaneous routes in acute cases with respect of the time for onset of action.
C1 [Karademir, Umit; Akar, Ferda] Adnan Menderes Univ, Fac Vet Med, Dept Pharmacol & Toxicol, Isikli Koyu, Aydin, Turkey.
   [Gokbulut, Cengiz] Balikesir Univ, Fac Med, Dept Med Pharmacol, Balikesir, Turkey.
C3 Adnan Menderes University; Balikesir University
RP Karademir, U (通讯作者)，Adnan Menderes Univ, Fac Vet Med, Dept Pharmacol & Toxicol, TR 09100 Aydin, Turkey.
EM umitkarademir@yahoo.com
RI karademir, umit/LNL 1130 2024; Gokbulut, Cengiz/B 1956 2016
OI Gokbulut, Cengiz/0000 0002 4912 7307
CR Botting RM, 2006, J THERM BIOL, V31, P208, DOI 10.1016/j.jtherbio.2005.11.008
   Busch U, 1998, DRUG METAB DISPOS, V26, P576
   Clark TP, 2003, J VET PHARMACOL THER, V26, P187, DOI 10.1046/j.1365 2885.2003.00475.x
   Engelhardt G, 1995, INFLAMM RES, V44, P548, DOI 10.1007/BF01757360
   Euller Ziegler L., 2001, INFLAMM RES, V50, P5
   Fiorucci S, 2001, BIOCHEM PHARMACOL, V62, P1433, DOI 10.1016/S0006 2952(01)00747 X
   Kay Mugford P, 2000, AM J VET RES, V61, P802, DOI 10.2460/ajvr.2000.61.802
   KuKanich B, 2012, VET ANAESTH ANALG, V39, P69, DOI 10.1111/j.1467 2995.2011.00675.x
   Lees P, 2004, J VET PHARMACOL THER, V27, P491, DOI 10.1111/j.1365 2885.2004.00618.x
   Lees P, 2004, J VET PHARMACOL THER, V27, P479, DOI 10.1111/j.1365 2885.2004.00617.x
   Mathews KA, 2002, J VET EMERG CRIT CAR, V12, P89, DOI 10.1046/j.1435 6935.2002.00007.x
   MCKELLAR QA, 1994, J VET PHARMACOL THER, V17, P447, DOI 10.1111/j.1365 2885.1994.tb00276.x
   Montoya L, 2004, VET RES COMMUN, V28, P415, DOI 10.1023/B:VERC.0000034995.81994.49
   NIELSENKUDSK F, 1980, ACTA PHARMACOL TOX, V47, P267
   Shrivastava A., 2011, Chron. Young Sci, P21, DOI [DOI 10.4103/2229 5186.79345, 10.4103/2229 5186.79345]
   Taketo MM, 1998, JNCI J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609
   Toutain PL, 2001, J VET PHARMACOL THER, V24, P43, DOI 10.1046/j.1365 2885.2001.00304.x
   Velpandian T, 2000, J CHROMATOGR B, V738, P431, DOI 10.1016/S0378 4347(99)00537 X
NR 18
TC 0
Z9 0
U1 0
U2 11
PU UNIV FED RIO GRANDE DO SUL
PI PORTO ALEGRE RS
PA FAC VET, CAIXA POSTAL 15017, PORTO ALEGRE RS, 91501 570, BRAZIL
SN 1678 0345
EI 1679 9216
J9 ACTA SCI VET
JI Acta Sci. Vet.
PD JUN 30
PY 2015
VL 43
AR 1293
PG 6
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA CN7MX
UT WOS:000358619800008
DA 2025 08 17
ER

PT J
AU Florczyk, SJ
   Kim, DJ
   Wood, DL
   Zhang, MQ
AF Florczyk, Stephen J.
   Kim, Dae Joon
   Wood, David L.
   Zhang, Miqin
TI Influence of processing parameters on pore structure of 3D porous
   chitosan alginate polyelectrolyte complex scaffolds
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE chitosan; alginate; polyelectrolyte complex; scaffold; tissue
   engineering
ID DRUG DELIVERY; TISSUE; BIOMATERIALS; HYDROGELS
AB Fabrication of porous polymeric scaffolds with controlled structure can be challenging. In this study, we investigated the influence of key experimental parameters on the structures and mechanical properties of resultant porous chitosan alginate (CA) polyelectrolyte complex (PEC) scaffolds, and on proliferation of MG 63 osteoblast like cells, targeted at bone tissue engineering. We demonstrated that the porous structure is largely affected by the solution viscosity, which can be regulated by the acetic acid and alginate concentrations. We found that the CA PEC solutions with viscosity below 300 Pa.s yielded scaffolds of uniform pore structure and that more neutral pH promoted more complete complexation of chitosan and alginate, yielding stiffer scaffolds. CA PEC scaffolds produced from solutions with viscosities below 300 Pa.s also showed enhanced cell proliferation compared with other samples. By controlling the key experimental parameters identified in this study, CA PEC scaffolds of different structures can be made to suit various tissue engineering applications. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 98A: 614 620, 2011.
C1 [Florczyk, Stephen J.; Wood, David L.; Zhang, Miqin] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA.
   [Kim, Dae Joon] Sejong Univ, Dept Adv Mat Engn, Seoul, South Korea.
C3 University of Washington; University of Washington Seattle; Sejong
   University
RP Zhang, MQ (通讯作者)，Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA.
EM djkim@sejong.ac.kr; mzhang@u.washington.edu
RI ; Florczyk, Stephanie/ABC 9922 2020; Zhang, Miqin/F 5537 2010
OI Florczyk, Stephanie/0000 0001 7151 7857; Zhang,
   Miqin/0000 0001 8974 1494; 
FU University of Washington; Basic Research in Science and Engineering
   Program [2110 0024260]
FX Contract grant sponsors: University of Washington: Technology Gap
   Innovation Fund (to M. Zhang); Basic Research in Science and Engineering
   Program administered by the National Research Foundation of Korea (to
   D. J. Kim); contract grant number: 2110 0024260
CR Berger J, 2004, EUR J PHARM BIOPHARM, V57, P35, DOI 10.1016/s0939 6411(03)00160 7
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Chung TW, 2002, BIOMATERIALS, V23, P2827, DOI 10.1016/S0142 9612(01)00399 4
   Dado D, 2009, SEMIN CELL DEV BIOL, V20, P656, DOI 10.1016/j.semcdb.2009.02.001
   Han J, 2010, INT J BIOL MACROMOL, V46, P199, DOI 10.1016/j.ijbiomac.2009.11.004
   Hutmacher DW, 2007, J TISSUE ENG REGEN M, V1, P245, DOI 10.1002/term.24
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Lankalapalli S, 2009, INDIAN J PHARM SCI, V71, P481, DOI 10.4103/0250 474X.58165
   Li ZS, 2010, BIOMATERIALS, V31, P404, DOI 10.1016/j.biomaterials.2009.09.070
   Li ZS, 2005, J BIOMED MATER RES A, V75A, P485, DOI 10.1002/jbm.a.30449
   Li ZS, 2005, BIOMATERIALS, V26, P3919, DOI 10.1016/j.biomaterials.2004.09.062
   Rinaudo M, 2008, POLYM INT, V57, P397, DOI 10.1002/pi.2378
   Shapiro L, 1997, BIOMATERIALS, V18, P583, DOI 10.1016/S0142 9612(96)00181 0
   Vauthier C, 2009, PHARM RES DORDR, V26, P1025, DOI 10.1007/s11095 008 9800 3
   Yin YJ, 2003, J BIOMED MATER RES A, V67A, P844, DOI 10.1002/jbm.a.10153
   Zhang Y, 2004, J MATER SCI MATER M, V15, P255, DOI 10.1023/B:JMSM.0000015485.94665.25
   Zhang Y, 2001, J NON CRYST SOLIDS, V282, P159, DOI 10.1016/S0022 3093(01)00345 3
NR 17
TC 81
Z9 92
U1 0
U2 64
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1549 3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD SEP
PY 2011
VL 98A
IS 4
BP 614
EP 620
DI 10.1002/jbm.a.33153
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 806XJ
UT WOS:000293850500015
PM 21721118
DA 2025 08 17
ER

PT J
AU Campos, T
   Uchoa, E
   Santos, V
   Zatarin, R
   Benicio, R
   Gomes, C
   da Cruz, A
AF Campos, Talyta
   Uchoa, Elza
   Santos, Victor
   Zatarin, Raffael
   Benicio, Rosenelle
   Gomes, Clayson
   da Cruz, Aparecido
TI Phenotypic Variability in Camurati Engelmann Disease: A Case Report of a
   Family with the c.653G>A Pathogenic Variant in the TGFB1 Gene
SO GENES
LA English
DT Article
DE hyperostosis; autosomal dominant; bone metabolism; rare disease
AB Camurati Engelmann Disease (CED), or Progressive Diaphyseal Dysplasia, is a rare autosomal dominant disorder caused by heterozygous mutations in the TGFB1 Gene, essential for bone regeneration. This study examines the genotype phenotype relationship in a family diagnosed with CED, specifically focusing on a missense variant (c.653G>A, p.Arg218Cys). The family comprised a mother and her two children, all of whom were found to carry the same disease causing variant. The second child exhibited severe symptoms by age six, including progressive weakness and joint pain, leading to wheelchair dependency. The mother displayed milder symptoms with preserved independence. The firstborn son, initially asymptomatic, developed gait abnormalities and pain during adolescence. Clinical evaluations revealed characteristic hyperostosis of long bones, with significant variability in symptom onset and severity among family members, potentially indicative of genetic anticipation. This case underscores the importance of genetic testing and interdisciplinary management in CED, as traditional treatments, including corticosteroids and NSAIDs, often yield limited efficacy and notable side effects. Our findings contribute to the understanding of CED's pathophysiology and highlight the necessity for tailored therapeutic approaches. The identification of the common TGFB1 variant in this family reinforces the critical role of TGFB1 in bone metabolism and suggests avenues for further research into targeted therapies. Such reports enhance awareness and provide valuable insights for healthcare professionals managing rare genetic disorders.
C1 [Campos, Talyta; Gomes, Clayson; da Cruz, Aparecido] Pontifical Catholic Univ Goias, Sch Med & Life Sci, Grad Program Genet, Replicon Res Nucl, BR 74605050 Goiania, GO, Brazil.
   [Campos, Talyta; Uchoa, Elza; Santos, Victor; Zatarin, Raffael; Benicio, Rosenelle; da Cruz, Aparecido] State Hlth Secretary Goias, Ctr Rehabil & Readaptat Dr Henr Santillo, Clin Genet Serv, BR 74605050 Goiania, GO, Brazil.
   [Uchoa, Elza; Santos, Victor; da Cruz, Aparecido] Univ Fed Goias, Grad Program Genet & Mol Biol, BR 74605050 Goiania, GO, Brazil.
C3 Universidade Federal de Goias
RP da Cruz, A (通讯作者)，Pontifical Catholic Univ Goias, Sch Med & Life Sci, Grad Program Genet, Replicon Res Nucl, BR 74605050 Goiania, GO, Brazil.; da Cruz, A (通讯作者)，State Hlth Secretary Goias, Ctr Rehabil & Readaptat Dr Henr Santillo, Clin Genet Serv, BR 74605050 Goiania, GO, Brazil.; da Cruz, A (通讯作者)，Univ Fed Goias, Grad Program Genet & Mol Biol, BR 74605050 Goiania, GO, Brazil.
EM campostalytabmd@gmail.com; acruz@pucgoias.edu.br
RI da Cruz, Aparecido D./K 6701 2015
OI da Cruz, Aparecido D./0000 0003 0753 3814; Alves da Silva Campos,
   Talyta/0009 0000 0540 570X
CR Agarwal K, 2022, AACE CLIN CASE REP, V8, P54, DOI 10.1016/j.aace.2021.08.002
   Charoenngam N, 2022, GENES BASEL, V13, DOI 10.3390/genes13101880
   Chen Q, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.913979
   ClinVar, US
   Cui LJ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.882144
   Das L, 2022, AACE CLIN CASE REP, V8, P58, DOI 10.1016/j.aace.2021.10.002
   Damiá AD, 2017, REUMATOL CLIN, V13, P48, DOI 10.1016/j.reuma.2015.12.004
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Janssens K, 2003, J BIOL CHEM, V278, P7718, DOI 10.1074/jbc.M208857200
   Klemm P, 2023, EUR J RHEUMATOL, V10, P34, DOI 10.5152/eurjrheum.2023.21115
   Li Q, 2022, J BONE MINER RES, V37, P78, DOI 10.1002/jbmr.4436
   Liang HT, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1041061
   McGowan NWA, 2003, J CLIN ENDOCR METAB, V88, P3321, DOI 10.1210/jc.2002 020564
   Moreira S., 2017, BMJ Case Rep., DOI [10.1136/bcr 2017 221760, DOI 10.1136/BCR 2017 221760]
   omim, Camurati Engelmann Disease
   R Madhumathi, 2023, J Assoc Physicians India, V71, P1
   Restrepo Juan Pablo, 2016, Rev.Colomb.Reumatol., V23, P218, DOI 10.1016/j.rcreu.2016.03.002
   Sun ZK, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12040910
   Tao XH, 2022, MOL GENET GENOM MED, V10, DOI 10.1002/mgg3.1922
   Van Hul W, 2019, CALCIFIED TISSUE INT, V104, P554, DOI 10.1007/s00223 019 00532 1
   Wallace S.E., 2024, GeneReviews Internet
NR 21
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD NOV
PY 2024
VL 15
IS 11
AR 1354
DI 10.3390/genes15111354
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA O0F1J
UT WOS:001367977400001
PM 39596554
OA gold
DA 2025 08 17
ER

PT J
AU Puliani, G
   Hasenmajer, V
   Sciarra, F
   Barbagallo, F
   Sbardella, E
   Pofi, R
   Gianfrilli, D
   Romagnoli, E
   Venneri, MA
   Isidori, AM
AF Puliani, Giulia
   Hasenmajer, Valeria
   Sciarra, Francesca
   Barbagallo, Federica
   Sbardella, Emilia
   Pofi, Riccardo
   Gianfrilli, Daniele
   Romagnoli, Elisabetta
   Venneri, Mary Anna
   Isidori, Andrea M.
TI Impaired Immune Function in Patients With Chronic Postsurgical
   Hypoparathyroidism: Results of the EMPATHY Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE parathyroid related disorders; osteoimmunology; clinical trials; immune
   function; disorders of calcium/phosphate metabolism; PTH
ID PARATHYROID HORMONE; T CELLS; QUESTIONNAIRE; EPIDEMIOLOGY; BIOMARKERS;
   CATARACT; DISEASES; RECEPTOR; RISK
AB Context: Despite the pivotal role of calcium signaling in immune response, little is known about immune function in patients affected by hypoparathyroidism.
   Objective: This work aimed to evaluate immune function in hypoparathyroidism.
   Methods: The Evaluation of iMmune function in Postsurgical and AuToimmune HYpoparathyroidism (NCT04059380) is a case control, cross sectional study set in an Italian referral center. Participants included 20 patients with postsurgical hypoparathyroidism (12 females) and 20 age  and sex matched controls. Main outcome measures included calcium metabolism assessment, peripheral blood mononuclear cells (PBMC) profiling via flow cytometry, parathyroid hormone receptor 1 (PTHr1) expression analysis using immunofluorescence and PrimeFlow RNA assay, gene expression analysis via real time polymerase chain reaction, cytokine measurement, and evaluation of infectious disease frequency and severity.
   Results: Immune cell profiling revealed decreased monocytes, regulatory, naive, and total CD4(+) T lymphocytes, which correlated with total calcium, ionized calcium, and PTH levels, in patients with hypoparathyroidism. Patients with hypoparathyroidism had a higher CD3 CD56(+) natural killer (NK) cell count, which inversely correlated with calcium, PTH, and vitamin D levels. Furthermore, they exhibited decreased tumor necrosis factor (TNF) and granulocyte macrophage colony stimulating factor gene expression and decreased circulating TNF levels. Gene expression and immunofluorescence analysis confirmed PTHr1 expression in all PBMC lineages; however, the percentage of cells expressing PTHr1 was lower, whereas the intensity of PTHr1 expression in monocytes, total T lymphocytes, CD8(+)CD4(+) and CD4(+) T lymphocytes, and total NK cells was higher in patients with hypoparathyroidism.
   Conclusions: This study describes for the first time the immune alterations in patients with hypoparathyroidism receiving conventional therapies, supporting the immunoregulatory role of PTH and proposing an explanation for the increased susceptibility to infections observed in epidemiological studies.
C1 [Puliani, Giulia; Hasenmajer, Valeria; Sciarra, Francesca; Barbagallo, Federica; Sbardella, Emilia; Pofi, Riccardo; Gianfrilli, Daniele; Romagnoli, Elisabetta; Venneri, Mary Anna; Isidori, Andrea M.] Sapienza Univ Rome, Dept Expt Med, I 00161 Rome, Italy.
   [Puliani, Giulia] IRCCS Regina Elena Natl Canc Inst, Oncol Endocrinol Unit, I 00144 Rome, Italy.
C3 Sapienza University Rome
RP Venneri, MA; Isidori, AM (通讯作者)，Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I 00166 Rome, Italy.
EM maryanna.venneri@uniroma1.it; andrea.isidori@uniroma1.it
RI ; Pofi, Riccardo/AAE 2378 2020; Isidori, Andrea/F 3062 2010; Puliani,
   Giulia/ABH 8785 2020; Barbagallo, Federica/K 1185 2018; Barbagallo,
   Federica/AAD 4903 2022; Sbardella, Emilia/AAC 3684 2022
OI Gianfrilli, Daniele/0000 0002 2682 8266; Hasenmajer,
   Valeria/0000 0003 4301 6662; Pofi, Riccardo/0000 0001 7808 5735;
   VENNERI, MARY ANNA/0000 0002 0687 8135; Barbagallo,
   Federica/0000 0002 2972 370X; Isidori, Andrea/0000 0002 9037 5417;
   Puliani, Giulia/0000 0003 2899 9146
FU Takeda Pharmaceuticals [IIR ITA 002304]
FX This spontaneous study was partially supported by Takeda Pharmaceuticals
   (investigator initiated research grant agreement IIR ITA 002304).
CR Alemzadeh R, 2012, METAB SYNDR RELAT D, V10, P422, DOI 10.1089/met.2012.0056
   Bollerslev J, 2015, EUR J ENDOCRINOL, V173, pEG1, DOI 10.1530/EJE 15 0628
   Borie R, 2011, EUR RESPIR REV, V20, P98, DOI 10.1183/09059180.00001311
   Brown RL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01803 x
   Castell S, 2014, BUNDESGESUNDHEITSBLA, V57, P1300, DOI 10.1007/s00103 014 2045 x
   Cheng SP, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/709024
   Christensen MHE, 2015, EUR J ENDOCRINOL, V173, P9, DOI 10.1530/EJE 14 1038
   Christensen MHE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020481
   Clarke BL, 2018, ENDOCRIN METAB CLIN, V47, P771, DOI 10.1016/j.ecl.2018.07.004
   Clarke BL, 2016, J CLIN ENDOCR METAB, V101, P2284, DOI 10.1210/jc.2015 3908
   Cusano NE, 2016, J BONE MINER RES, V31, P308, DOI 10.1002/jbmr.2609
   Eleftheriadis T, 2007, INT UROL NEPHROL, V39, P595, DOI 10.1007/s11255 006 9100 y
   Francisco R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072092
   Goswami R, 2012, CLIN ENDOCRINOL, V77, P200, DOI 10.1111/j.1365 2265.2012.04353.x
   Heine GH, 2008, KIDNEY INT, V73, P622, DOI 10.1038/sj.ki.5002744
   Isidori AM, 2018, LANCET DIABETES ENDO, V6, P173, DOI 10.1016/S2213 8587(17)30398 4
   Jafari M, 2019, CELL J, V20, P604, DOI 10.22074/cellj.2019.5992
   KLINGER M, 1990, KIDNEY INT, V37, P1543, DOI 10.1038/ki.1990.147
   Mahon MJ, 2011, CELL SIGNAL, V23, P1659, DOI 10.1016/j.cellsig.2011.05.020
   Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55
   MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300
   Medrano M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092663
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Oh Hora M, 2008, CURR OPIN IMMUNOL, V20, P250, DOI 10.1016/j.coi.2008.04.004
   Olson NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071498
   Ozanska A, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12883
   PERRY HM, 1984, J BIOL CHEM, V259, P5531
   Peter H. H., 2014, British Journal of Medicine and Medical Research, V4, P4751, DOI 10.9734/BJMMR/2014/10823
   Puliani G, SUPPLEMENTARY DATA I, DOI [10.6084/m9.figshare.13297877.v1, DOI 10.6084/M9.FIGSHARE.13297877.V1]
   Roberts CA, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00571
   Rodríguez Muñoz Y, 2011, ALIMENT PHARM THER, V34, P960, DOI 10.1111/j.1365 2036.2011.04807.x
   Saha S, 2017, J BONE MINER METAB, V35, P405, DOI 10.1007/s00774 016 0767 6
   SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167 5699(88)91212 1
   Seeliger S, 2003, CLIN NEPHROL, V59, P429
   Sievers C, 2014, BUNDESGESUNDHEITSBLA, V57, P1283, DOI 10.1007/s00103 014 2052 y
   Silva BC, 2017, OSTEOPOROSIS INT, V28, P463, DOI 10.1007/s00198 016 3750 0
   Silva BC, 2021, REV ENDOCR METAB DIS, V22, P789, DOI 10.1007/s11154 020 09614 0
   SIMPSON KM, 1991, P SOC EXP BIOL MED, V197, P44
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Tzanno Martins C, 2000, CLIN NEPHROL, V54, P22
   Ulrich C, 2010, NEPHROL DIAL TRANSPL, V25, P2265, DOI 10.1093/ndt/gfq012
   Underbjerg L, 2018, J BONE MINER RES, V33, P822, DOI 10.1002/jbmr.3368
   Underbjerg L, 2015, J BONE MINER RES, V30, P1738, DOI 10.1002/jbmr.2501
   Underbjerg L, 2014, J BONE MINER RES, V29, P2504, DOI 10.1002/jbmr.2273
   Vadiveloo T, 2019, CLIN ENDOCRINOL, V90, P285, DOI 10.1111/cen.13895
   Venneri MA, 2019, J CLIN ENDOCR METAB, V104, P2623, DOI 10.1210/jc.2018 02525
   Young N, 2005, J IMMUNOL, V175, P8287, DOI 10.4049/jimmunol.175.12.8287
   Yu MC, 2018, EMBO REP, V19, P156, DOI 10.15252/embr.201744421
NR 48
TC 19
Z9 19
U1 1
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2021
VL 106
IS 5
BP E2215
EP E2227
DI 10.1210/clinem/dgab038
EA JAN 2021
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA SN4KN
UT WOS:000658260400025
PM 33484559
OA Bronze
DA 2025 08 17
ER

PT J
AU Ceballos, A
   Mas, R
   Castaño, G
   Fernández, L
   Mendoza, S
   Menéndez, R
   Gonzalez, JJ
   Illnait, J
   Gámez, R
   Mesa, M
   Fernández, J
AF Ceballos, A
   Mas, R
   Castaño, G
   Fernández, L
   Mendoza, S
   Menéndez, R
   Gonzalez, JJ
   Illnait, J
   Gámez, R
   Mesa, M
   Fernández, J
TI The effect of D 003 (10 mg/day) on biochemical parameters of bone
   remodelling in postmenopausal women:: A randomized, double blind study
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH
LA English
DT Article
ID HMG COA REDUCTASE; PYRIDINIUM CROSS LINKS; MINERAL DENSITY; LIPID
   PROFILE; GALACTOSYL HYDROXYLYSINE; CARDIOVASCULAR DISEASE;
   CONTROLLED TRIAL; IN VITRO; MARKERS; SIMVASTATIN
AB Biphosphonates, which are antiresorptive agents used to treat osteoporosis, inhibit the mevalonate pathway, preventing protein prenylation and inhibiting osteoclast activity Statins decrease cholesterol biosynthesis by blocking the mevalonate pathway and have been reported to have beneficial effects on bone. D 003 is a mixture of high molecular weight acids purified from sugarcane wax that inhibits cholesterol biosynthesis before mevalonate production. D 003 prevents bone loss and resorption in rats with osteoporosis induced with ovariectomy or corticoids. Biochemical markers of bone turnover are used to monitor the short term efficacy of antiosteoporotic therapy. This randomized, double blind, placebo controlled study was undertaken to investigate the short term effects of D 003 (10 mg/day) on biochemical markers of bone turnover in postmenopausal women with low bone mineral density (BMD). After 4 weeks on a low fat diet, 34 women were randomized to D 003 (10 mg/day) or placebo for 6 months. Pre  and post treatment samples were analyzed for urinary excretion of deoxypyridinoline (DPD)/creatinine (Cr), a marker of bone resorption, and serum bone specific alkaline phosphatase (BSAP), a marker of bone formation. The effects on lipid profile and safety indicators, as well as adverse events (AE), were investigated. D 003 (10 mg/day) lowered urinary excretion of tDPD/Cr versus baseline (20.601.) (p < 0. 001) and placebo (33.701.) (p < 0.01), but did not modify serum BSAP D 003 decreased low density lipoprotein cholesterol (LDL C) (32.8%), total cholesterol (TC) (16.401.) and the TC/high density lipoprotein cholesterol (HDL C) ratio (34.7%), increased HDL C (30.301.) (p < 0.001) and did not modify triglycerides. The effects on these variables were significant as early as 3 months after treatment initiation. D 003 was well tolerated. Three patients (one in the placebo group and two in the D 003 group) withdrew from the study. Two of these withdrawals were due to AE: abdominal pain (placebo) and heartburn (D 003). Five patients (four in the placebo group [22.2%] and one in the D 003 group [6.3%.]) reported mild AE. In conclusion, D 003 (10mg/day) reduced urinary excretion of tDPD/Cr, a bone resorption marker and did not change serum BSAP a bone formation marker while it lowered cholesterol in study patients. These preliminary results suggest that D 003 could be useful in treating postmenopausal women with low BMD. However, the potential value of D 003 in treating or preventing osteoporosis deserves further clinical investigation.
C1 Natl Ctr Sci Res, Ctr Nat Prod, Havana, Cuba.
   Med Surg Res Ctr, Havana, Cuba.
RP Natl Ctr Sci Res, Ctr Nat Prod, POB 6990, Havana, Cuba.
RI Mendoza Castaño, Sarahi/IQR 9004 2023; , Rafael Gamez
   Menendeza/IQT 0595 2023
OI , Rafael Gamez Menendeza/0000 0002 6633 8771
CR Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Bauer DC, 2003, OSTEOPOROSIS INT, V14, P273, DOI 10.1007/s00198 002 1323 x
   Bauer DC, 1999, J BONE MINER RES, V14, pS179
   Berthold HK, 2004, OSTEOPOROSIS INT, V15, P459, DOI 10.1007/s00198 004 1598 1
   BETTICA P, 1992, CLIN CHEM, V38, P2313
   Bettica P, 1996, J CLIN ENDOCR METAB, V81, P542, DOI 10.1210/jc.81.2.542
   Bettica P, 1997, J CLIN ENDOCR METAB, V82, P3034, DOI 10.1210/jc.82.9.3034
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P380, DOI 10.1007/s001980170106
   Braatvedt GD, 2004, BONE, V35, P766, DOI 10.1016/j.bone.2004.05.001
   Burnett JR, 2002, ANN CLIN BIOCHEM, V39, P203, DOI 10.1258/0004563021902134
   Castaño G, 2003, CLIN DRUG INVEST, V23, P789, DOI 10.2165/00044011 200323120 00004
   Castaño G, 2003, CLIN DRUG INVEST, V23, P193, DOI 10.2165/00044011 200323030 00005
   Castano Gladys, 2002, Drugs R D, V3, P337, DOI 10.2165/00126839 200203050 00008
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gámez R, 2000, CURR THER RES CLIN E, V61, P460, DOI 10.1016/S0011 393X(00)80029 6
   Garrett IR, 2000, J BONE MINER RES, V15, pS225
   Garrett IR, 2002, ARTHRITIS RES, V4, P237, DOI 10.1186/ar413
   HARRIS ST, 1993, J CLIN ENDOCR METAB, V76, P1399, DOI 10.1210/jc.76.6.1399
   HORCAJADAMOITEN.MN, 1997, J BONE MINER RES, V15, P2251
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010
   MALLMIN H, 1991, UPSALA J MED SCI, V96, P205, DOI 10.3109/03009739109179272
   Más R, 2004, DRUG FUTURE, V29, P773, DOI 10.1358/dof.2004.029.08.828449
   McFarlane SI, 2004, ENDOCRINE, V23, P1, DOI 10.1385/ENDO:23:1:01
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Mendoza S, 2001, CURR THER RES CLIN E, V62, P209, DOI 10.1016/S0011 393X(01)80032 1
   Menéndez R, 2004, CAN J PHYSIOL PHARM, V82, P22, DOI [10.1139/y03 123, 10.1139/Y03 123]
   Menéndez R, 2002, CAN J PHYSIOL PHARM, V80, P13, DOI 10.1139/Y01 088
   MENENDEZ R, 2001, PHARM RES, V44, P300
   Meunier PJ, 1999, CLIN THER, V21, P1025, DOI 10.1016/S0149 2918(99)80022 8
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mostaza JM, 2001, CLIN CHIM ACTA, V308, P133, DOI 10.1016/S0009 8981(01)00476 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Noa M, 2004, DRUG EXP CLIN RES, V30, P35
   Noa Miriam, 2004, Drugs R D, V5, P281, DOI 10.2165/00126839 200405050 00004
   OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025 6196(12)65511 6
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140 6736(00)04042 3
   Rejnmark L, 2004, J BONE MINER RES, V19, P737, DOI 10.1359/JBMR.040209
   SEIBEL MJ, 1992, TRENDS ENDOCRIN MET, V3, P263, DOI 10.1016/1043 2760(92)90129 O
   Seifert MF, 1997, NUTR RES, V17, P1209, DOI 10.1016/S0271 5317(97)00090 0
   SEIGLER L, 1981, CLIN CHEM, V27, P838
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stein EA, 2001, NUTR METAB CARDIOVAS, V11, P84
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Tikiz C, 2004, J BONE MINER METAB, V22, P365, DOI 10.1007/s00774 004 0496 0
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   VONSTECHOW D, 2003, BMC MUSCULOSKEL DIS, V4, P1471
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   XU H, 1995, CALCIFIED TISSUE INT, V57, P293, DOI 10.1007/BF00298885
   Yang T S, 1998, Zhonghua Yi Xue Za Zhi (Taipei), V61, P568
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 62
TC 7
Z9 10
U1 0
U2 2
PU BIOSCIENCE EDIPRINT INC
PI CAROUGE
PA RUE ALEXANDRE GAVARD 16, 1227 CAROUGE, SWITZERLAND
SN 0251 1649
J9 INT J CLIN PHARM RES
JI Int. J. Clin. Pharmacol. Res.
PY 2005
VL 25
IS 4
BP 175
EP 186
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 999ZD
UT WOS:000234429800004
PM 16402634
DA 2025 08 17
ER

PT J
AU Stage, TB
   Christensen, MMH
   Jorgensen, NR
   Beck Nielsen, H
   Brosen, K
   Gram, J
   Frost, M
AF Stage, Tore Bjerregaard
   Christensen, Mette Marie Hougaard
   Jorgensen, Niklas Rye
   Beck Nielsen, Henning
   Brosen, Kim
   Gram, Jeppe
   Frost, Morten
TI Effects of metformin, rosiglitazone and insulin on bone metabolism in
   patients with type 2 diabetes
SO BONE
LA English
DT Article
DE Type 2 diabetes; Bone turnover markers; Insulin; Metformin;
   Rosiglitazone
ID MINERAL DENSITY; BIOCHEMICAL MARKERS; REFERENCE INTERVALS; FRACTURE
   RISK; GLUCOSE; MELLITUS; DIFFERENTIATION; METAANALYSIS; OSTEOBLASTS;
   EXPRESSION
AB Background: Fracture risk is increased in individuals with type 2 diabetes (T2D). The pathophysiological mechanisms accentuating fracture risk in T2D are convoluted, incorporating factors such as hyperglycaemia, insulinopenia, and antidiabetic drugs. The objectives of this study were to assess whether different insulin regimens, metformin and rosiglitazone influence bone metabolism. We explored if the concentration of metformin and rosiglitazone in blood or improved glycaemic control altered bone turnover.
   Methods: Two year clinical trial designed to investigate effects of antidiabetic treatment in 371 T2D patients. Participants were randomized to short or long acting human insulin (non blinded) and then further randomized to metformin + placebo, rosiglitazone + placebo, metformin + rosiglitazone or placebo + placebo (blinded). Fasting bone turnover markers (BTM) representing bone resorption (CTX) and formation (PINP) including HbA1c were measured at baseline and after 3, 12 and 24 months. Trough steady state plasma concentrations of metformin and rosiglitazone were measured after 3, 6 and 9 months of treatment. Associations between treatments and BTMs during the follow up of the trial were analysed in mixed effects models that included adjustments for age, gender, BMI, renal function and repeated measures of HbA1c.
   Results: BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively. Allocation of insulin regimens was not associated with different levels of BTMs. Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP). Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs. HbA1c was inversely associated with CTX but not P1NP.
   Conclusions: The choice of insulin treatment is not influencing BTMs, metformin treatment may decrease BTMs, and improvement of glycaemic control may influence bone resorption activity.
C1 [Stage, Tore Bjerregaard; Brosen, Kim] Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, Odense, Denmark.
   [Stage, Tore Bjerregaard] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Christensen, Mette Marie Hougaard] Odense Univ Hosp, Dept Clin Biochem & Pharmacol, Odense, Denmark.
   [Jorgensen, Niklas Rye] Univ Southern Denmark, Odense Univ Hosp, Inst Clin Res, OPEN,Odense Patient Data Explorat Network, Odense, Denmark.
   [Jorgensen, Niklas Rye] Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Beck Nielsen, Henning; Frost, Morten] Odense Univ Hosp, Dept Endocrinol, Kloevervaenget 6, DK 5000 Odense C, Denmark.
   [Gram, Jeppe] Hosp Southwest Denmark, Dept Endocrinol, Esbjerg, Denmark.
C3 University of Southern Denmark; University of California System;
   University of California San Francisco; University of Southern Denmark;
   Odense University Hospital; University of Southern Denmark; Odense
   University Hospital; University of Copenhagen; Copenhagen University
   Hospital; Rigshospitalet; University of Southern Denmark; Odense
   University Hospital
RP Frost, M (通讯作者)，Odense Univ Hosp, Dept Endocrinol, Kloevervaenget 6, DK 5000 Odense C, Denmark.
EM morten.munk.frost.nielsen@rsyd.dk
RI Frost, Morten/G 9410 2011; Stage, Tore/AGO 2526 2022; Brosen,
   Kim/F 6023 2011; Christensen, Mette/IXN 3215 2023; Jørgensen,
   Niklas/B 6003 2012
OI Stage, Tore Bjerregaard/0000 0002 4698 4389; Jorgensen, Niklas
   Rye/0000 0001 9624 5210; Christensen, Mette Marie
   Hougaard/0000 0001 9797 276X; Brosen, Kim/0000 0001 8444 7835; Gram,
   Jeppe/0000 0003 2584 1132; 
FU Danish Council for Independent Research [DFF1333 00283]; Region of
   Southern Denmark [13/7659]; Danish Independent Research Council; Steno
   Diabetes Center Odense (SDCO) [SDCO Research 005, SDCO Research 001]
   Funding Source: researchfish
FX This study was supported by grants from the Danish Council for
   Independent Research (DFF1333 00283) and the Region of Southern Denmark
   (13/7659). TS and MF hold grants from the Danish Independent Research
   Council.
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Basu R, 2011, J CLIN ENDOCR METAB, V96, P1450, DOI 10.1210/jc.2010 2877
   Berberoglu Z, 2007, J CLIN ENDOCR METAB, V92, P3523, DOI 10.1210/jc.2007 0431
   Bornstein S, 2017, ENDOCRINOLOGY, V158, P3369, DOI 10.1210/en.2017 00299
   Botolin S, 2006, J CELL BIOCHEM, V99, P411, DOI 10.1002/jcb.20842
   Christensen MMH, 2011, PHARMACOGENET GENOM, V21, P837, DOI 10.1097/FPC.0b013e32834c0010
   Clowes JA, 2002, J CLIN ENDOCR METAB, V87, P3324, DOI 10.1210/jc.87.7.3324
   DELMAS PD, 1992, BONE, V13, pS17, DOI 10.1016/S8756 3282(09)80005 7
   Fajardo RJ, 2014, J BONE MINER RES, V29, P1025, DOI 10.1002/jbmr.2210
   Frost M, 2013, CLIN ENDOCRINOL, V78, P743, DOI 10.1111/cen.12042
   Gormsen LC, 2016, J NUCL MED, V57, P1920, DOI 10.2967/jnumed.116.177774
   Gram J, 2011, DIABETES CARE, V34, P27, DOI 10.2337/dc10 0531
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Hamilton EJ, 2012, ACTA DIABETOL, V49, P153, DOI 10.1007/s00592 011 0324 7
   Harslof T, 2011, J CLIN ENDOCR METAB, V96, P1541, DOI 10.1210/jc.2010 2077
   Ivaska KK, 2015, ENDOCR CONNECT, V4, P155, DOI 10.1530/EC 15 0022
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jorgensen NR, 2017, OSTEOPOROSIS INT, V28, P2103, DOI 10.1007/s00198 017 4026 z
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Lecka Czernik B, 2017, DIABETOLOGIA, V60, P1163, DOI 10.1007/s00125 017 4269 4
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Manavalan JS, 2012, J CLIN ENDOCR METAB, V97, P3240, DOI 10.1210/jc.2012 1546
   Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797
   Mercer N, 2007, MOL CELL BIOCHEM, V306, P87, DOI 10.1007/s11010 007 9557 8
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Pacifici R, 2016, ANN NY ACAD SCI, V1364, P11, DOI 10.1111/nyas.12969
   Pastor MMC, 2000, OSTEOPOROSIS INT, V11, P455, DOI 10.1007/s001980070114
   Pedersen RS, 2005, CHROMATOGRAPHIA, V62, P197, DOI 10.1365/s10337 005 0593 9
   Schwartz AV, 2008, DIABETES CARE, V31, P391, DOI 10.2337/dc07 1152
   Schwartz AV, 2017, DIABETOLOGIA, V60, P1170, DOI 10.1007/s00125 017 4283 6
   Shao XY, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/453940
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Stage TB, 2013, PHARMACOGENET GENOM, V23, P219, DOI 10.1097/FPC.0b013e32835f91fc
   Starup Linde J, 2014, OSTEOPOROSIS INT, V25, P1697, DOI 10.1007/s00198 014 2676 7
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Wei JW, 2014, J CLIN INVEST, V124, P1781, DOI 10.1172/JCI72323
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   Yang JH, 2010, CELL BIOCHEM FUNCT, V28, P334, DOI 10.1002/cbf.1668
   Zhu ZN, 2014, BONE, V68, P115, DOI 10.1016/j.bone.2014.08.010
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 42
TC 59
Z9 64
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2018
VL 112
BP 35
EP 41
DI 10.1016/j.bone.2018.04.004
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GI4WE
UT WOS:000434371100005
PM 29654849
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Runzer, CD
   Anand, S
   Mota, C
   Moroni, L
   Plank, C
   van Griensven, M
   Balmayor, ER
AF Runzer, Claudia Del Toro
   Anand, Shivesh
   Mota, Carlos
   Moroni, Lorenzo
   Plank, Christian
   van Griensven, Martijn
   Balmayor, Elizabeth R.
TI Cellular uptake of modified mRNA occurs via caveolae mediated
   endocytosis, yielding high protein expression in slow dividing cells
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID INTRACELLULAR FATE; GENE DELIVERY; INTERNALIZATION; CLATHRIN;
   OSTEOGENESIS; TRANSFECTION; PATHWAYS; MATRIX; COMPLEXES; LIPOSOMES
AB Nucleic acids have clear clinical potential for gene therapy. Plasmid DNA (pDNA) was the first nucleic acid to be pursued as a therapeutic molecule. Recently, mRNA came into play as it offers improved safety and affordability. In this study, we investigated the uptake mechanisms and efficiencies of genetic material by cells. We focused on three main variables (1) the nucleic acid (pDNA, or chemically modified mRNA), (2) the delivery vector (Lipofectamine 3000 or 3DFect), and (3) human primary cells (mesenchymal stem cells, dermal fibroblasts, and osteoblasts). In addition, transfections were studied in a 3D environment using electrospun scaffolds. Cellular internalization and intracellular trafficking were assessed by using enhancers or inhibitors of endocytosis and endosomal escape. The polymeric vector TransIT X2 was included for comparison purposes. While lipoplexes utilized several entry routes, uptake via caveolae served as the main route for gene delivery. pDNA yielded higher expression levels in fast dividing fibroblasts, whereas, in slow dividing osteoblasts, cmRNA was responsible for high protein production. In the case of mesenchymal stem cells, which presented an intermediate doubling time, the combination vector/nucleic acid seemed more relevant than the nucleic acid per se. In all cases, protein expression was higher when the cells were seeded on 3D scaffolds.
C1 [Runzer, Claudia Del Toro; van Griensven, Martijn] MERLN Inst Technol Inspired Regenerat Med, Dept Cell Biol Inspired Tissue Engn, NL 6229 ER Maastricht, Netherlands.
   [Anand, Shivesh; Mota, Carlos; Moroni, Lorenzo] MERLN Inst Technol Inspired Regenerat Med, Dept Complex Tissue Regenerat, NL 6229 ER Maastricht, Netherlands.
   [Plank, Christian] Ethris GmbH, D 82152 Planegg, Germany.
   [van Griensven, Martijn; Balmayor, Elizabeth R.] Mayo Clinic, Rehabil Med Res Ctr, Musculoskeletal Gene Therapy Lab, Rochester, MN 55905 USA.
   [Balmayor, Elizabeth R.] RWTH Aachen Univ Hosp, D 52074 Aachen, Germany.
   [Balmayor, Elizabeth R.] RWTH Aachen Univ Hosp, Dept Orthopaed, Expt Orthopaed & Trauma Surg, D 52074 Aachen, Germany.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Maastricht University; Maastricht University Medical Centre (MUMC); Mayo
   Clinic; RWTH Aachen University; RWTH Aachen University Hospital; RWTH
   Aachen University; RWTH Aachen University Hospital
RP Balmayor, ER (通讯作者)，RWTH Aachen Univ Hosp, Dept Orthopaed, Expt Orthopaed & Trauma Surg, D 52074 Aachen, Germany.
EM erosadobalma@ukaachen.de
RI Balmayor, E./N 9283 2015; Mota, Carlos/N 2472 2013; Rosado Balmayor,
   Elizabeth/N 9283 2015; Anand, Shivesh/AAM 6221 2020; Moroni,
   Lorenzo/D 2826 2014; van Griensven, Martijn/F 5808 2012; Mota,
   Carlos/AAI 1825 2020
OI Mota, Carlos/0000 0001 5935 6245; Rosado Balmayor,
   Elizabeth/0000 0002 0484 4847; Anand, Shivesh/0000 0001 9662 2039;
   Moroni, Lorenzo/0000 0003 1298 6025; van Griensven,
   Martijn/0000 0001 5104 9881; 
FU European Union [874790]; 4Nano EARDRM project, under the Frame of
   EuroNanoMed III; ERA NET Cofund Scheme of the Horizon 2020 Research and
   Innovation Framework Programme of the European Commission; Netherlands
   Organization for Scientific Research (NWO) [OND1365231]
FX This work has been performed as part of the cmRNAbone project funded by
   the European Union's Horizon 2020 research and innovation programme
   under the grant agreement no. 874790, the 4Nano EARDRM project, funded
   under the Frame of EuroNanoMed III, an ERA NET Cofund Scheme of the
   Horizon 2020 Research and Innovation Framework Programme of the European
   Commission, and the Netherlands Organization for Scientific Research
   (NWO, grant no. OND1365231) . The authors thank the Microscopy CORE Lab
   (M4I Maastricht University) , especially to Hans Duimel and Kevin Knoops
   for their help in TEM and confocal imaging.
CR Akita H, 2007, J GENE MED, V9, P197, DOI 10.1002/jgm.1010
   Anand S., 2023, Carbohydrate Polymers, V310
   Anand S, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202002082
   Badieyan ZS, 2016, J CONTROL RELEASE, V239, P137, DOI 10.1016/j.jconrel.2016.08.037
   Balmayor ER, 2017, STEM CELLS DEV, V26, P25, DOI 10.1089/scd.2016.0171
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Balmayor ER, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00009
   Bettinger T, 2001, NUCLEIC ACIDS RES, V29, P3882, DOI 10.1093/nar/29.18.3882
   Both SK, 2007, TISSUE ENG, V13, P3, DOI 10.1089/ten.2005.0513
   Cervia LD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171699
   Chakraborty A, 2015, J PHYS CHEM LETT, V6, P3688, DOI 10.1021/acs.jpclett.5b01739
   Chan CL, 2012, BIOMATERIALS, V33, P4928, DOI 10.1016/j.biomaterials.2012.03.038
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Conwell CC, 2005, ADV GENET, V53, P3, DOI 10.1016/S0065 2660(05)53001 3
   Danti S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091440
   De Haes W, 2012, MOL PHARMACEUT, V9, P2942, DOI 10.1021/mp3003336
   El Sayed A, 2013, MOL THER, V21, P1118, DOI 10.1038/mt.2013.54
   Escriou V, 1998, BBA BIOMEMBRANES, V1368, P276, DOI 10.1016/S0005 2736(97)00194 6
   Evans CH, 2015, NAT REV RHEUMATOL, V11, P234, DOI 10.1038/nrrheum.2015.28
   Ewert Kai K., 2008, V433, P159, DOI 10.1007/978 1 59745 237 3_10
   Fayed O, 2021, MOL PHARMACEUT, V18, P1121, DOI 10.1021/acs.molpharmaceut.0c01042
   Freund I, 2019, GENES BASEL, V10, DOI 10.3390/genes10020092
   Günday C, 2020, DRUG DELIV TRANSL RE, V10, P706, DOI 10.1007/s13346 020 00736 1
   Hajj KA, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.56
   Hou XC, 2021, NAT REV MATER, V6, P1078, DOI 10.1038/s41578 021 00358 0
   Karikó K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kasputis T, 2012, J BIOL ENG, V6, DOI 10.1186/1754 1611 6 17
   Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733
   Kulkarni JA, 2018, NUCLEIC ACID THER, V28, P146, DOI 10.1089/nat.2018.0721
   Leonhardt C, 2014, NANOMED NANOTECHNOL, V10, P679, DOI 10.1016/j.nano.2013.11.008
   Mazumdar S, 2021, ACTA PHARM SIN B, V11, P903, DOI 10.1016/j.apsb.2021.02.019
   Muiznieks LD, 2013, BBA MOL BASIS DIS, V1832, P866, DOI 10.1016/j.bbadis.2012.11.022
   Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818
   PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199
   Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600 0854.2002.30501.x
   Raj A, 2006, PLOS BIOL, V4, P1707, DOI 10.1371/journal.pbio.0040309
   Reautschnig P, 2017, RNA BIOL, V14, P651, DOI 10.1080/15476286.2016.1208323
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Resina S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006058
   Romieu Mourez R, 2009, J IMMUNOL, V182, P7963, DOI 10.4049/jimmunol.0803864
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Salameh JW, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1598
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Simoes S, 1998, GENE THER, V5, P955, DOI 10.1038/sj.gt.3300674
   SORIANO P, 1983, P NATL ACAD SCI BIOL, V80, P7128, DOI 10.1073/pnas.80.23.7128
   Stanton M.G, 2017, RNA THERAPEUTICS, P237
   Tavitian B, 2002, PHARM RES DORDR, V19, P367, DOI 10.1023/A:1015133205457
   THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960
   Vercauteren D, 2010, MOL THER, V18, P561, DOI 10.1038/mt.2009.281
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Webb K, 1998, J BIOMED MATER RES, V41, P422, DOI 10.1002/(SICI)1097 4636(19980905)41:3<422::AID JBM12>3.0.CO;2 K
   Zhang W, 2019, TISSUE ENG PT A, V25, P131, DOI [10.1089/ten.TEA.2018.0112, 10.1089/ten.tea.2018.0112]
NR 52
TC 10
Z9 10
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD JUN 13
PY 2023
VL 32
BP 960
EP 979
DI 10.1016/j.omtn.2023.05.019
EA JUN 2023
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA O3NO9
UT WOS:001042920700001
PM 37305166
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Güler Yüksel, M
   Allaart, CF
   Goekoop Ruiterman, YPM
   de Vries Bouwstra, JK
   van Groenendael, JHLM
   Mallée, C
   de Bois, MHW
   Breedveld, FC
   Dijkmans, BAC
   Lems, WF
AF Gueler Yueksel, M.
   Allaart, C. F.
   Goekoop Ruiterman, Y. P. M.
   de Vries Bouwstra, J. K.
   van Groenendael, J. H. L. M.
   Mallee, C.
   de Bois, M. H. W.
   Breedveld, F. C.
   Dijkmans, B. A. C.
   Lems, W. F.
TI Changes in hand and generalised bone mineral density in patients with
   recent onset rheumatoid arthritis
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID X RAY RADIOGRAMMETRY; DISEASE ACTIVITY; ABSORPTIOMETRY; METABOLISM;
   THERAPY; RISK; MASS; CORTICOSTEROIDS; PREDNISOLONE; DESTRUCTION
AB Objectives: To evaluate changes in bone mineral density (BMD) in the hands, hip and spine after 1 and 2 years of follow up, in relation to antirheumatic and antiresorptive therapies and disease and demographic variables in patients with recent onset rheumatoid arthritis ( RA).
   Methods: Changes in BMD measured in metacarpals 2 4 by digital x ray radiogrammetry and in the hip and spine by dual energy x ray absorptiometry were assessed at baseline and after 1 and 2 years of follow up in 218 patients with recent onset RA from the BeSt study, who received one of four treatment strategies: sequential monotherapy ( group 1); step up combination therapy ( group 2); initial combination therapy with tapered high dose prednisone ( group 3); or initial combination therapy with infliximab (group 4).
   Results: After 1 and 2 years, there was significant BMD loss in all locations, with significantly greater BMD loss in the hands than generalised BMD loss in the hip and spine. Initial combination therapy with prednisone or infliximab were associated with less hand BMD loss compared with initial monotherapy after 1 and 2 years ( 0.9 and  1.6%,  0.6 and  1.4%,  1.7 and  3.3%, and  2.6 and  3.6% for group 4 1 after 1 and 2 years, overall p = 0.001 and p = 0.014, respectively). Progression in erosions was independently associated with increased BMD loss both in the hands and hip after 1 year. The use of bisphosphonates protected only against generalised BMD loss in the hip and spine.
   Conclusions: The association between joint damage progression and both hand and generalised BMD loss in RA suggests common pathways between these processes, with hand BMD loss occurring earlier in the disease course than generalised BMD loss.
C1 [Gueler Yueksel, M.; Allaart, C. F.; Goekoop Ruiterman, Y. P. M.; Breedveld, F. C.] Leiden Univ, Med Ctr, Dept Rheumatol, NL 2300 RC Leiden, Netherlands.
   [de Vries Bouwstra, J. K.; Dijkmans, B. A. C.; Lems, W. F.] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
   [van Groenendael, J. H. L. M.] Franciscus Hosp, Dept Rheumatol, Roosendaal, Netherlands.
   [Mallee, C.] Kennemer Gasthuis, Dept Rheumatol, Haarlem, Netherlands.
   [de Bois, M. H. W.] Med Ctr Haaglanden, Dept Rheumatol, The Hague, Netherlands.
   [Dijkmans, B. A. C.; Lems, W. F.] Jan van Breemen Inst, Dept Rheumatol, Amsterdam, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC; Vrije Universiteit Amsterdam; VU UNIVERSITY
   MEDICAL CENTER; Spaarne Hospital; Haaglanden Medical Center
RP Güler Yüksel, M (通讯作者)，Leiden Univ, Med Ctr, Dept Rheumatol, POB 9600, NL 2300 RC Leiden, Netherlands.
EM m.yuksel@lumc.nl
RI de Vries Bouwstra, Jeska/GLT 3945 2022
FU Dutch College of Health Insurances (College Voor Zorgverzekeringen);
   Schering Plough BV and Centocor Inc
FX This study was supported by a government grant from the Dutch College of
   Health Insurances (College Voor Zorgverzekeringen). Schering Plough BV
   and Centocor Inc. provided additional grants and supplied the study
   medication for patients in group 4.
CR Adachi JD, 1999, CALCIFIED TISSUE INT, V65, P332, DOI 10.1007/s002239900707
   Ardicoglu O, 2001, J CLIN DENSITOM, V4, P263, DOI 10.1385/JCD:4:3:263
   Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140 6736(97)01300 7
   Böttcher J, 2005, ARTHRITIS RHEUM US, V52, P3850, DOI 10.1002/art.21606
   Brown AK, 2006, ARTHRITIS RHEUM, V54, P3761, DOI 10.1002/art.22190
   *CLIN PRACT GUID D, 1996, CAN MED ASSOC J, V155, P1113
   de Nijs RNJ, 2006, NEW ENGL J MED, V355, P675, DOI 10.1056/NEJMoa053569
   Deodhar AA, 2003, ANN RHEUM DIS, V62, P767, DOI 10.1136/ard.62.8.767
   Deodhar AA, 1996, BRIT J RHEUMATOL, V35, P309
   Devlin J, 1996, BRIT J RHEUMATOL, V35, P1256
   Forslind K, 2003, J RHEUMATOL, V30, P2590
   Goekoop Ruiterman YPM, 2007, ANN INTERN MED, V146, P406, DOI 10.7326/0003 4819 146 6 200703200 00005
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Gravallese EM, 2000, ARTHRITIS RHEUM US, V43, P2143, DOI 10.1002/1529 0131(200010)43:10<2143::AID ANR1>3.3.CO;2 J
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Green MJ, 2001, BEST PRACT RES CL RH, V15, P105, DOI 10.1053/berh.2000.0129
   Güler Yüksel M, 2008, ANN RHEUM DIS, V67, P823, DOI 10.1136/ard.2007.073817
   Habib GS, 2005, CLIN RHEUMATOL, V24, P129, DOI 10.1007/s10067 004 0989 1
   HALL GM, 1993, ARTHRITIS RHEUM, V36, P1510, DOI 10.1002/art.1780361105
   Haugeberg G, 2005, ARCH INTERN MED, V165, P1293, DOI 10.1001/archinte.165.11.1293
   Haugeberg G, 2006, ANN RHEUM DIS, V65, P736, DOI 10.1136/ard.2005.043869
   Haugeberg G, 2003, CURR OPIN RHEUMATOL, V15, P469, DOI 10.1097/00002281 200307000 00016
   Hoff M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2280
   Huusko TM, 2001, ANN RHEUM DIS, V60, P521, DOI 10.1136/ard.60.5.521
   Hyldstrup L, 2001, CALCIFIED TISSUE INT, V68, P135, DOI 10.1007/s002230001204
   Jensen T, 2005, SCAND J RHEUMATOL, V34, P27, DOI 10.1080/03009740510017986
   Jensen T, 2004, ANN RHEUM DIS, V63, P15, DOI 10.1136/ard.2003.013888
   Lange U, 2005, RHEUMATOLOGY, V44, P1546, DOI 10.1093/rheumatology/kei082
   Lems WF, 2006, OSTEOPOROSIS INT, V17, P716, DOI 10.1007/s00198 005 0037 2
   PEEL NFA, 1994, ARTHRITIS RHEUM, V37, P983, DOI 10.1002/art.1780370702
   Pocock NA, 1997, J BONE MINER RES, V12, P2113, DOI 10.1359/jbmr.1997.12.12.2113
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Rosholm A, 2001, OSTEOPOROSIS INT, V12, P961, DOI 10.1007/s001980170026
   SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535
   Sambrook PN, 2005, ANN RHEUM DIS, V64, P176, DOI 10.1136/ard.2003.018556
   Seriolo B, 2006, ANN NY ACAD SCI, V1069, P420, DOI 10.1196/annals.1351.040
   SHEPHERD JA, 2001, J BONE MINER RES, V16, pM103
   SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   VANDERHEIJDE DMFM, 1993, J RHEUMATOL, V20, P579
   Verhoeven AC, 1997, J RHEUMATOL, V24, P1495
   Vis M, 2006, ANN RHEUM DIS, V65, P1495, DOI 10.1136/ard.2005.044198
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Westhovens R, 2000, Z RHEUMATOL, V59, P33
NR 45
TC 130
Z9 141
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD MAR
PY 2009
VL 68
IS 3
BP 330
EP 336
DI 10.1136/ard.2007.086348
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 406TQ
UT WOS:000263318200007
PM 18375540
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Fallarini, S
   Paoletti, T
   Battaglini, NO
   Lombardi, G
AF Fallarini, S.
   Paoletti, T.
   Battaglini, N. Orsi
   Lombardi, G.
TI Invariant NKT cells increase drug induced osteosarcoma cell death
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE iNKT cells; osteosarcoma; cisplatin; doxorubicin; methotrexate;
   combination therapy
ID KILLER T CELLS; ALPHA GALACTOSYLCERAMIDE KRN7000; IN VITRO; INDOLEAMINE
   2,3 DIOXYGENASE; ANTITUMOR ACTIVITY; PROGNOSTIC FACTORS; DENDRITIC
   CELLS; CANCER PATIENTS; CUTTING EDGE; PHASE I
AB BACKGROUND AND PURPOSE
   In osteosarcoma (OS) patients, only a limited number of drugs are active and the regimens currently in use include a combination of at least two of these drugs: doxorubicin, cisplatin, methotrexate and ifosfamide. Today, 30 40% of patients still die of OS highlighting the urgent need for new treatments. Invariant NKT (iNKT) cells are a lymphocyte lineage with features of both T and NK cells, playing important roles in tumour suppression. Our aim was to test whether the cytoxicity induced by cisplatin, doxorubicin and methotrexate against OS cells can be enhanced by iNKT cell treatment.
   EXPERIMENTAL APPROACH
   iNKT cells were purified from human peripheral blood mononuclear cells by cell sorting (V alpha 24V beta 11(+) cells) and used as effector cells against OS cells (U2 OS, HOS, MG 63). Cell death (calcein AM method), perforin/granzyme B and Fas/FasL expressions were determined by flow cytometry. CD1d expression was analysed at both the gene and protein level.
   KEY RESULTS
   iNKT cells were cytotoxic against OS cells through a CD1d dependent mechanism. This activity was specific for tumour cells, because human CD1d(+) mesenchymal stem cells and CD1d( ) osteoblasts were not affected. iNKT cell treatment enhanced drug induced OS cell death in a concentration dependent manner and this effect was reduced in CD1d silenced OS cells.
   CONCLUSION AND IMPLICATIONS
   iNKT cells kill malignant, but not non malignant, cells. iNKT cell treatment enhances the cytotoxicity of anti neoplastic drugs against OS cells in a CD1d dependent manner. The present data encourage further studies on the use of iNKT cells in OS therapy.
C1 [Fallarini, S.; Paoletti, T.; Lombardi, G.] Univ Piemonte Orientale Amedeo Avogadro, Dept Pharmaceut Sci, Novara, Italy.
   [Battaglini, N. Orsi] Univ Florence, Dept Clin Physiopathol, Nucl Med Unit, Florence, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; University of Florence
RP Lombardi, G (通讯作者)，Univ Piemonte Orientale, Dept Pharmaceut Sci, Largo Donegani 2, I 28100 Novara, Italy.
EM grazia.lombardi@pharm.unipmn.it
RI Fallarini, Silvia/ABF 3249 2020
FU University of 'Piemonte Orientale Amedeo Avogadro'; 'Regione Piemonte',
   Italy
FX This study was supported by grants from University of 'Piemonte
   Orientale Amedeo Avogadro' and 'Regione Piemonte', Italy.
CR Bagnara D, 2009, HAEMATOL HEMATOL J, V94, P967, DOI 10.3324/haematol.2008.001339
   Bourgeois E, 2009, EUR J IMMUNOL, V39, P1046, DOI 10.1002/eji.200838575
   Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521
   Buddingh EP, 2011, CANCER IMMUNOL IMMUN, V60, P575, DOI 10.1007/s00262 010 0965 3
   Carnaud C, 1999, J IMMUNOL, V163, P4647
   Chávez Galán L, 2009, CELL MOL IMMUNOL, V6, P15, DOI 10.1038/cmi.2009.3
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   Cole PD, 2002, CANCER CHEMOTH PHARM, V50, P111, DOI 10.1007/s00280 002 0478 7
   Croudace JE, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471 2172 9 71
   Crough T, 2004, BRIT J CANCER, V91, P1880, DOI 10.1038/sj.bjc.6602218
   Crowe NY, 2005, J EXP MED, V202, P1279, DOI 10.1084/jem.20050953
   Decker S, 1999, J BONE JOINT SURG BR, V81B, P545, DOI 10.1302/0301 620X.81B3.9167
   Dhodapkar MV, 2011, CLIN IMMUNOL, V140, P160, DOI 10.1016/j.clim.2010.12.010
   Dhodapkar MV, 2003, J EXP MED, V197, P1667, DOI 10.1084/jem.20021650
   Duan XP, 2004, CLIN CANCER RES, V10, P777, DOI 10.1158/1078 0432.CCR 1245 02
   Eberl G, 2000, EUR J IMMUNOL, V30, P985, DOI 10.1002/(SICI)1521 4141(200004)30:4<985::AID IMMU985>3.0.CO;2 E
   Exley MA, 2001, J IMMUNOL, V167, P5531, DOI 10.4049/jimmunol.167.10.5531
   Exley MA, 2011, CLIN IMMUNOL, V140, P184, DOI 10.1016/j.clim.2011.04.017
   Fais F, 2004, INT J CANCER, V109, P402, DOI 10.1002/ijc.11723
   Fallarini S, 2009, BRIT J PHARMACOL, V157, P1072, DOI 10.1111/j.1476 5381.2009.00213.x
   Fallarini S, 2008, BIOCHEM PHARMACOL, V76, P738, DOI 10.1016/j.bcp.2008.07.001
   Fallarini S, 2010, BIOCHEM BIOPH RES CO, V398, P420, DOI 10.1016/j.bbrc.2010.06.091
   Fellenberg J, 2000, J ORTHOPAED RES, V18, P10, DOI 10.1002/jor.1100180103
   Ferrari S, 2005, J CLIN ONCOL, V23, P8845, DOI 10.1200/JCO.2004.00.5785
   Fujii S, 2008, TRENDS IMMUNOL, V29, P242, DOI 10.1016/j.it.2008.02.002
   Giaccone G, 2002, CLIN CANCER RES, V8, P3702
   Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309
   Hogendoorn PCW, 2010, ANN ONCOL, V21, pv204, DOI 10.1093/annonc/mdq223
   Ishihara S, 2000, J IMMUNOL, V165, P1659, DOI 10.4049/jimmunol.165.3.1659
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Johnstone EC, 2000, CANCER CHEMOTH PHARM, V46, P433, DOI 10.1007/s002800000185
   Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742
   Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Lesterhuis WJ, 2011, MOL IMMUNOL, V49, P1, DOI 10.1016/j.molimm.2011.09.014
   Lin H, 2004, EUR J IMMUNOL, V34, P2664, DOI 10.1002/eji.200324834
   Lisbonne M, 2004, EUR J IMMUNOL, V34, P1381, DOI 10.1002/eji.200324828
   Luksch R, 2003, TUMORI, V89, P263, DOI 10.1177/030089160308900306
   Marina N, 2009, CANCER BIOL THER, V8, P981, DOI 10.4161/cbt.8.10.8602
   Mattarollo SR, 2006, INT J CANCER, V119, P1630, DOI 10.1002/ijc.22019
   Metelitsa LS, 2011, CLIN IMMUNOL, V140, P119, DOI 10.1016/j.clim.2010.10.005
   Metelitsa LS, 2004, CLIN IMMUNOL, V110, P267, DOI 10.1016/j.clim.2003.11.005
   Metelitsa LS, 2003, LEUKEMIA, V17, P1068, DOI 10.1038/sj.leu.2402943
   Molano A, 2008, IMMUNOL LETT, V117, P81, DOI 10.1016/j.imlet.2007.12.013
   Molling JW, 2008, CLIN IMMUNOL, V129, P182, DOI 10.1016/j.clim.2008.07.025
   Montoya CJ, 2007, IMMUNOLOGY, V122, P1, DOI 10.1111/j.1365 2567.2007.02647.x
   Mori K, 2006, ONCOL REP, V15, P693
   Morris ES, 2005, J CLIN INVEST, V115, P3093, DOI 10.1172/JCI25249
   Motohashi S, 2006, CLIN CANCER RES, V12, P6079, DOI 10.1158/1078 0432.CCR 06 0114
   Nicol A, 2000, IMMUNOLOGY, V99, P229, DOI 10.1046/j.1365 2567.2000.00952.x
   Nieda M, 2001, BLOOD, V97, P2067, DOI 10.1182/blood.V97.7.2067
   Nowak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011311
   Paoletti T, 2009, EUR J PHARMACOL, V620, P120, DOI 10.1016/j.ejphar.2009.08.015
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Robson H, 2002, MED PEDIATR ONCOL, V39, P573, DOI 10.1002/mpo.10076
   Rogers PR, 2004, J IMMUNOL METHODS, V285, P197, DOI 10.1016/j.jim.2003.12.003
   SERRA M, 1993, ANTICANCER RES, V13, P323
   Smyth MJ, 2001, INT IMMUNOL, V13, P459, DOI 10.1093/intimm/13.4.459
   Song LP, 2009, J CLIN INVEST, V119, P1524, DOI 10.1172/JCI37869
   Sun J, 2007, CHINESE MED J PEKING, V120, P400, DOI 10.1097/00029330 200703010 00010
   Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555 009 9186 7
   Takahashi T, 2002, J IMMUNOL, V168, P3140, DOI 10.4049/jimmunol.168.7.3140
   Taniguchi M, 2010, INT IMMUNOL, V22, P1, DOI 10.1093/intimm/dxp104
   Terabe M, 2006, CANCER RES, V66, P3869, DOI 10.1158/0008 5472.CAN 05 3421
   Terabe M, 2008, ADV CANCER RES, V101, P277, DOI 10.1016/S0065 230X(08)00408 9
   Théoleyre S, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 123
   Tsuda N, 2001, J ORTHOP RES, V19, P346, DOI 10.1016/S0736 0266(00)90031 7
   van den Heuvel MJ, 2011, TRENDS MOL MED, V17, P65, DOI 10.1016/j.molmed.2010.10.007
   van der Vliet HJJ, 2004, CLIN IMMUNOL, V112, P8, DOI 10.1016/j.clim.2004.03.003
   van der Vliet HJJ, 2001, CLIN IMMUNOL, V100, P144, DOI 10.1006/clim.2001.5060
   Whelan JS, 2012, ANN ONCOL, V23, P1607, DOI 10.1093/annonc/mdr491
   Wingender G, 2010, J IMMUNOL, V185, P2721, DOI 10.4049/jimmunol.1001018
   Zitvogel L, 2008, B ACAD NAT MED PARIS, V192, P1469, DOI 10.1016/S0001 4079(19)32694 9
NR 74
TC 27
Z9 30
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD DEC
PY 2012
VL 167
IS 7
BP 1533
EP 1549
DI 10.1111/j.1476 5381.2012.02108.x
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 032QK
UT WOS:000310733800012
PM 22817659
OA Green Published
DA 2025 08 17
ER

PT J
AU Thompson, MS
   Epari, DR
   Bieler, F
   Duda, GN
AF Thompson, M. S.
   Epari, D. R.
   Bieler, F.
   Duda, G. N.
TI In vitro models for bone mechanobiology: applications in bone
   regeneration and tissue engineering
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H JOURNAL OF
   ENGINEERING IN MEDICINE
LA English
DT Article
DE bone regeneration; mechanobiology; in vitro models; fluid shear stress;
   substrate stretch
ID OSTEOBLAST LIKE CELLS; MECHANICAL STRAIN; SHEAR STRESS; ENDOCHONDRAL
   OSSIFICATION; FLUID FLOW; PROSTAGLANDIN E 2; SCAFFOLDS; SYSTEM;
   MECHANOTRANSDUCTION; DIFFERENTIATION
AB Healthy bone healing is a remarkable, mechanically sensitive, scar free process that leads rapidly to repair tissue of high mechanical quality and functionality, and knowledge of this process is essential for driving advances in bone tissue engineering and regeneration. Gaining this knowledge requires the use of models to probe and understand the detailed mechanisms of healing, and the tight coupling of biology and mechanics make it essential that both of these aspects are controlled and analysed together, using a mechanobiological approach. This article reviews the literature on in vitro models used for this purpose, beginning with two dimensional (2D) cell culture models used for applying controlled mechanical stimuli to relevant cells, and detailing the analysis techniques required for understanding both substrate strain and fluid flow stimuli in sufficient detail to relate them to biological response. The additional complexity of three dimensional (3D) models, enabling more faithful representation of the healing situation, can require correspondingly more sophisticated tools for mechanical and biological analysis, but has recently uncovered exciting evidence for the mechanical sensitivity of angiogenesis, essential for successful healing. Studies using explanted tissue continue to be vital in informing these approaches, providing additional evidence for the relevance of effects in biological and mechanical environments close to those in the living organism. Mechanobiology is essential for the proper analysis of models for bone regeneration, and has an exciting integrative role to play not only in advancing knowledge in this area, but also in ensuring successful translation of new tissue engineering and regenerative therapies to the clinic.
C1 [Thompson, M. S.] Univ Oxford, Dept Engn Sci, Inst Biomed Engn, Oxford OX1 3PJ, England.
   [Thompson, M. S.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Biomed Res Unit, Oxford OX1 3PJ, England.
   [Epari, D. R.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia.
   [Bieler, F.; Duda, G. N.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, Julius Wolff Inst, D 13353 Berlin, Germany.
   [Bieler, F.; Duda, G. N.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, Ctr Musculoskeletal Surg, D 13353 Berlin, Germany.
C3 University of Oxford; University of Oxford; Queensland University of
   Technology (QUT); Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin
RP Thompson, MS (通讯作者)，Univ Oxford, Dept Engn Sci, Inst Biomed Engn, Parks Rd, Oxford OX1 3PJ, England.
EM mark.thompson@eng.ox.ac.uk
RI Epari, Devakar/J 1204 2012; Thompson, Mark/B 9261 2009; Duda,
   Georg/H 2085 2016
OI Thompson, Mark/0000 0001 8958 0336; Epari, Devakar/0000 0002 9306 709X;
   Duda, Georg/0000 0001 7605 3908
FU German Research Foundation (DFG) [SFB 760]
FX This work was partially supported by funding through the German Research
   Foundation (DFG SFB 760).
CR Abercrombie Stuart, 2008, Journal of Biomechanics, V41, DOI 10.1016/S0021 9290(08)70346 4
   Alsousou J, 2009, J BONE JOINT SURG BR, V91B, P987, DOI 10.1302/0301 620X.91B8.22546
   Anderson EJ, 2006, BIOMED ENG ONLINE, V5, DOI 10.1186/1475 925X 5 27
   Baas E, 2010, J BIOMECH, V43, P733, DOI 10.1016/j.jbiomech.2009.10.016
   Bacabac RG, 2005, ANN BIOMED ENG, V33, P104, DOI 10.1007/s10439 005 8968 5
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   BENES AJ, 1985, J CELL SCI, V75, P35
   Bieler FH, 2009, J BIOMECH, V42, P1692, DOI 10.1016/j.jbiomech.2009.04.013
   Boschetti F, 2006, J BIOMECH, V39, P418, DOI 10.1016/j.jbiomech.2004.12.022
   Bottlang M, 1997, BIOMED TECH, V42, P305, DOI 10.1515/bmte.1997.42.11.305
   Brown THOMAS D., 2000, Comput Methods Biomech Biomed Engin, V3, P65, DOI 10.1080/10255840008915254
   Chan ME, 2009, CELL MOL BIOENG, V2, P405, DOI 10.1007/s12195 009 0075 5
   Chung S, 2009, LAB CHIP, V9, P269, DOI 10.1039/b807585a
   Datta N, 2006, P NATL ACAD SCI USA, V103, P2488, DOI 10.1073/pnas.0505661103
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   ELHAJ AJ, 1990, J BONE MINER RES, V5, P923
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Grabner B, 2000, REV SCI INSTRUM, V71, P3522, DOI 10.1063/1.1287623
   Harvey A., 2009, ANN BRIT MACHINE VIS, P1
   Hoffler CE, 2006, J ORTHOP RES, V24, P1687, DOI 10.1002/jor.20207
   Huang CH, 2009, J CELL BIOCHEM, V108, P1263, DOI 10.1002/jcb.22356
   Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333
   Isaksson H, 2006, J BIOMECH, V39, P1507, DOI 10.1016/j.jbiomech.2005.01.037
   Kadow Romacker A, 2009, CELLS TISSUES ORGANS, V190, P61, DOI 10.1159/000178022
   Kaspar D, 2002, J BIOMECH, V35, P873, DOI 10.1016/S0021 9290(02)00058 1
   Kaspar D, 2000, J BIOMECH, V33, P45, DOI 10.1016/S0021 9290(99)00171 2
   Kasper G, 2007, STEM CELLS, V25, P903, DOI 10.1634/stemcells.2006 0432
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Lazopoulos KA, 2008, J BIOMECH, V41, P1289, DOI 10.1016/j.jbiomech.2008.01.008
   Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102
   Liedert A, 2004, BIOCHEM BIOPH RES CO, V319, P951, DOI 10.1016/j.bbrc.2004.05.087
   Lienau J, 2008, BIOMED TECH, V53, P300, DOI 10.1515/BMT.2008.047
   Lim CT, 2006, J BIOMECH, V39, P195, DOI 10.1016/j.jbiomech.2004.12.008
   Maes F, 2009, BIOTECHNOL BIOENG, V103, P621, DOI 10.1002/bit.22277
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Martin I, 2007, J BIOMECH, V40, P750, DOI 10.1016/j.jbiomech.2006.03.008
   Matheson LA, 2006, BIOMATERIALS, V27, P226, DOI 10.1016/j.biomaterials.2005.05.070
   Matziolis G, 2006, TISSUE ENG, V12, P201, DOI 10.1089/ten.2006.12.201
   Merryman WD, 2010, J BIOMECH, V43, P1, DOI 10.1016/j.jbiomech.2009.09.001
   Myers KA, 2007, BIOCHEM BIOPH RES CO, V364, P214, DOI 10.1016/j.bbrc.2007.09.109
   NEIDLINGERWILKE C, 1994, J ORTHOP RES, V12, P70, DOI 10.1002/jor.1100120109
   Nolte PA, 2001, J ORTHOP RES, V19, P301, DOI 10.1016/S0736 0266(00)00027 9
   Nowlan NC, 2008, J BIOMECH, V41, P249, DOI 10.1016/j.jbiomech.2007.09.031
   Ott CE, 2009, J BONE MINER RES, V24, P1247, DOI [10.1359/JBMR.090206, 10.1359/jbmr.090206]
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Perala M, 1997, BIOCHEM J, V324, P209, DOI 10.1042/bj3240209
   Pitsillides AA, 2006, J ANAT, V208, P417, DOI 10.1111/j.1469 7580.2006.00556.x
   REICH KM, 1991, AM J PHYSIOL, V261, pC428, DOI 10.1152/ajpcell.1991.261.3.C428
   Reilly GC, 2010, J BIOMECH, V43, P55, DOI 10.1016/j.jbiomech.2009.09.009
   Sandino C, 2008, J BIOMECH, V41, P1005, DOI 10.1016/j.jbiomech.2007.12.011
   Schwartz Z, 2007, J BIOMED MATER RES A, V83A, P20, DOI 10.1002/jbm.a.31185
   Schwarz US, 2005, MED ENG PHYS, V27, P763, DOI 10.1016/j.medengphy.2005.04.007
   Sittichockechaiwut A, 2009, BONE, V44, P822, DOI 10.1016/j.bone.2008.12.027
   Smalt R, 1997, AM J PHYSIOL ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751
   Stops AJF, 2010, J BIOMECH, V43, P618, DOI 10.1016/j.jbiomech.2009.10.037
   Thompson MS, 2007, TISSUE ENG, V13, P1378
   Thompson MS, 2007, MED ENG PHYS, V29, P820, DOI 10.1016/j.medengphy.2006.08.012
   Trepczik B, 2007, BONE, V40, P597, DOI 10.1016/j.bone.2006.10.011
   Ugryumova N, 2009, OSTEOARTHR CARTILAGE, V17, P33, DOI 10.1016/j.joca.2008.05.005
   van Oers RFM, 2008, BONE, V42, P250, DOI 10.1016/j.bone.2007.10.009
   Wall ME, 2007, J BIOMECH, V40, P173, DOI 10.1016/j.jbiomech.2005.10.032
   Wilson CJ, 2009, MICROVASC RES, V78, P358, DOI 10.1016/j.mvr.2009.08.002
   You J, 2000, J BIOMECH ENG T ASME, V122, P387, DOI 10.1115/1.1287161
NR 64
TC 11
Z9 12
U1 0
U2 23
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954 4119
EI 2041 3033
J9 P I MECH ENG H
JI Proc. Inst. Mech. Eng. Part H J. Eng. Med.
PY 2010
VL 224
IS H12
SI SI
BP 1533
EP 1541
DI 10.1243/09544119JEIM807
PG 9
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 687CS
UT WOS:000284752600015
PM 21287836
DA 2025 08 17
ER

PT J
AU Lucchi, L
   Carboni, C
   Stipo, L
   Malaguti, V
   Ferrari, F
   Graziani, R
   Arletti, S
   Graziosi, C
AF Lucchi, Leonardo
   Carboni, Chiara
   Stipo, Lucia
   Malaguti, Vittoria
   Ferrari, Federica
   Graziani, Romina
   Arletti, Silvia
   Graziosi, Catia
TI Early Initiation of Cinacalcet for the Treatment of Secondary
   Hyperparathyroidism in Hemodialysis Patients: A Three Year Clinical
   Experience
SO ARTIFICIAL ORGANS
LA English
DT Article
DE Cinacalcet; Hemodialysis; Secondary hyperparathyroidism; Kidney Disease
   Outcomes Quality Initiative of the National Kidney Foundation targets
ID STAGE RENAL DISEASE; LONG TERM TREATMENT; PARATHYROID HYPERPLASIA;
   MINERAL METABOLISM; BONE METABOLISM; KIDNEY DISEASE; RECEPTOR; OUTCOMES;
   CALCIUM; DIALYSIS
AB Despite the availability of standard therapy (vitamin D sterols and phosphate binders) for the treatment of secondary hyperparathyroidism (SHPT) in hemodialyzed (HD) patients, a significant percentage of patients still fail to achieve targets recommended by the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation for parathyroid hormone (PTH), calcium, and phosphorus. The calcimimetic cinacalcet (CN) has been shown to be an effective treatment for SHPT, significantly reducing serum PTH while simultaneously lowering calcium, phosphorus, and calciumphosphorus product levels, thus increasing the proportion of patients achieving the K/DOQI targets for bone mineral parameters. The aim of this study was to evaluate if early treatment with CN had beneficial effects in HD patients with mild to moderate SHPT in whom conventional treatments had failed to achieve NKF K/DOQI targets for PTH, serum corrected calcium, and phosphorus while minimizing the risk of paradoxical hypercalcemia and/or hyperphosphatemia. Clinical practice data were collected monthly, starting from 6 months prior to, and up to 36 months after, the start of CN therapy. CN was started at a dose of 30 mg daily or every other day, and titrated thereafter to achieve intact PTH (iPTH) <300 pg/mL. The dose of concomitant vitamin D and phosphate binders were also adjusted in order to achieve K/DOQI targets. Data from 32 patients were collected, 28 of whom had been treated with CN for at least 36 months at the time of data analysis. At baseline, patients had serum iPTH >300 pg/mL (570 +/  295 pg/mL) and/or serum corrected calcium >9.5 mg/dL. CN induced significant decreases in iPTH, calcium, and calciumphosphorus product with respect to baseline levels. The percentage of patients within K/DOQI target levels at baseline, 12, 24, and 36 months was 0, 81.2, 83.3, and 86.2% for iPTH; 34.4, 65.6, 86.6, and 89.6% for serum corrected calcium; 40.6, 56.2, 69.6, and 72.4% for phosphorus; and 37.5, 62.5, 80, and 82.7% for calciumphosphorus product. The mean dose of CN at the end of the observation period was 38 mg/day. The mean dose of concomitant medication (calcitriol, Al containing phosphate binders, and sevelamer) decreased from baseline to 36 months. Early treatment with CN in HD patients with SHPT increases the proportion of patients achieving and maintaining K/DOQI targets with a low dose of CN (38 mg/day). These results suggest that the metabolic control obtained with low dose CN administered early in the course of SHPT can be maintained or increased over time.
C1 [Lucchi, Leonardo; Carboni, Chiara; Stipo, Lucia; Malaguti, Vittoria; Ferrari, Federica; Graziani, Romina; Arletti, Silvia; Graziosi, Catia] Azienda Policlin, I 41124 Modena, Italy.
RP Lucchi, L (通讯作者)，Azienda Policlin, Via Pozzo 71, I 41124 Modena, Italy.
EM lucchi.leonardo@policlinico.mo.it
CR Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523 1755.2000.00178.x
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Charytan C, 2005, AM J KIDNEY DIS, V46, P58, DOI 10.1053/j.ajkd.2005.04.013
   Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Danese MD, 2008, CLIN J AM SOC NEPHRO, V3, P1423, DOI 10.2215/CJN.01060308
   Arenas MD, 2007, NEPHROL DIAL TRANSPL, V22, P1639, DOI 10.1093/ndt/gfl840
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Lazar E, 2007, AM J NEPHROL, V27, P274, DOI 10.1159/000101727
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771
   Meola M, 2009, NEPHROL DIAL TRANSPL, V24, P982, DOI 10.1093/ndt/gfn654
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Moe SM, 2003, AM J NEPHROL, V23, P369, DOI 10.1159/000073945
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Owda A, 2003, RENAL FAILURE, V25, P595, DOI 10.1081/JDI 120022551
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Rodriguez M, 2005, AM J PHYSIOL RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004
   Souberbielle JC, 2006, KIDNEY INT, V70, P345, DOI 10.1038/sj.ki.5001606
   Sprague SM, 2009, CLIN J AM SOC NEPHRO, V4, P1465, DOI 10.2215/CJN.06141108
   Tarrass F, 2006, NEPHROLOGY, V11, P494, DOI 10.1111/j.1440 1797.2006.00696.x
   Torres PU, 2004, NEPHROL DIAL TRANSPL, V19, P27, DOI 10.1093/ndt/gfh1053
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 31
TC 7
Z9 8
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0160 564X
EI 1525 1594
J9 ARTIF ORGANS
JI Artif. Organs
PD DEC
PY 2011
VL 35
IS 12
BP 1186
EP 1193
DI 10.1111/j.1525 1594.2011.01270.x
PG 8
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Transplantation
GA 862IU
UT WOS:000298085200008
PM 21848793
DA 2025 08 17
ER

PT J
AU Passeri, E
   Mazzaccaro, D
   Sanson, V
   Perego, S
   Nano, G
   Verdelli, C
   Lombardi, G
   Corbetta, S
AF Passeri, Elena
   Mazzaccaro, Daniela
   Sanson, Veronica
   Perego, Silvia
   Nano, Giovanni
   Verdelli, Chiara
   Lombardi, Giovanni
   Corbetta, Sabrina
TI Effects of 12 months treatment with zoledronate or teriparatide on
   intimamedia thickness of carotid artery in women with postmenopausal
   osteoporosis: A pilot study
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Article
DE carotid atherosclerosis; intima media thickness; osteopontin;
   osteoprotegerin; teriparatide; zoledronate
ID VASCULAR CALCIFICATION; MEDIA THICKNESS; PARATHYROID HORMONE
AB Atherosclerosis and osteoporosis are interrelated entities and share similar pathogenic mechanisms. Recent studies showed that key proteins of bone metabolism, such as osteoprotegerin (OPG) and osteopontin (OPN), are also involved in vascular atherosclerosis and calcifications. The carotid intima media thickness (CA IMT) is an early quantitative marker of generalized atherosclerosis. Aim of study was to investigate whether I 2 months treatment with zoledronate (ZLN) or teriparatide (TPT) affects CA IMT and circulating OPG and OPN levels. In this study, 11 postmenopausal osteoporotic women (aged 73, 70.5 74.5 years; median, range interquartile) treated with 5 mg/year iv ZLN; 9 postmenopausal osteoporotic women (aged 70, 62.5 73.5 years) treated with 20 mu g/day sc TPT; and 10 aged , body mass index (BMI) , glycemic, and lipid profiles matched, free from anti osteoporotic and hypocholesterolemic drugs, controls were prospectively investigated at baseline and after 12 months. At baseline, median CA IMT was similar in the three groups and increased after 12 months. CA IMT increased significantly in TPT treated patients (1.0, 0.8 1.2 vs 1.1, 0.9 15 mm, P= 0.04), though the change was minimal. After 12 months of treatment, CA IMT positively correlated with alkaline phosphatase (ALP) levels (r = 0.767, P= 0.008) and negatively with high density lipoprotein (HDL) cholesterol levels (r =  0.65, P=0.03), suggesting interplay between active bone remodeling and lipid profile. At baseline and after 12 months, median serum OPG and OPN levels did not differ among the groups and did not correlate with changes in CA IMT. In conclusion, ZLN and TPT treatments are safe on carotid walls in osteoporotic women with subclinical atherosclerosis; circulating OPG and OPN are not affected by long term anti osteoporotic treatments and do not correlate with CA IMT.
C1 [Passeri, Elena; Corbetta, Sabrina] IRCCS Ist Ortoped Galeazzi, Endocrinol & Diabetol Serv, Milan, Italy.
   [Mazzaccaro, Daniela; Nano, Giovanni] IRCCS Policlin San Donato, Operat Unit Vasc Surg 1, Milan, Italy.
   [Sanson, Veronica; Perego, Silvia; Lombardi, Giovanni] IRCCS Ist Ortoped Galeazzi, Lab Expt Biochem & Mol Biol, Milan, Italy.
   [Nano, Giovanni; Corbetta, Sabrina] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
   [Verdelli, Chiara] IRCCS Ist Ortoped Galeazzi, Lab Expt Endocrinol, Milan, Italy.
C3 IRCCS Istituto Ortopedico Galeazzi; IRCCS Policlinico San Donato; IRCCS
   Istituto Ortopedico Galeazzi; University of Milan; IRCCS Istituto
   Ortopedico Galeazzi
RP Corbetta, S (通讯作者)，Univ Milan, Endocrinol & Diabetol Serv, IRCCS Ist Ortoped Galeazzi, Dept Biomed sci Hlth, Via R Galeazzi 4, I 20161 Milan, Italy.
EM sabrina.corbetta@unimi.it
RI Lombardi, Giovanni/I 2414 2012; Sansoni, Veronica/B 1375 2017;
   Mazzaccaro, Daniela/J 6604 2016; Mazzaccaro, Daniela/AAA 7535 2021;
   Verdelli, Chiara/E 4042 2014; Corbetta, Sabrina/H 5457 2011; nano,
   giovanni/AAB 2063 2021; Perego, Silvia/B 1340 2017
OI Sansoni, Veronica/0000 0003 0337 975X; Mazzaccaro,
   Daniela/0000 0002 7414 642X; Verdelli, Chiara/0000 0002 6644 5163;
   Corbetta, Sabrina/0000 0001 8140 3175; Lombardi,
   Giovanni/0000 0002 8365 985X; Perego, Silvia/0000 0002 4996 8130; nano,
   giovanni/0000 0001 9680 6014
FU Italian Ministry of Health
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This paper
   was supported by the Italian Ministry of Health.
CR Anastasilakis AD, 2008, HORM METAB RES, V40, P281, DOI 10.1055/s 2008 1046787
   Caffarelli C, 2017, CLIN INTERV AGING, V12, P1819, DOI 10.2147/CIA.S138002
   Choi HS, 2008, INT J CLIN PRACT, V62, P1352, DOI 10.1111/j.1742 1241.2008.01801.x
   Ciccone MM, 2011, EUR J CARDIOV PREV R, V18, P650, DOI 10.1177/1741826711398841
   Gonnelli S, 2014, BONE, V61, P27, DOI 10.1016/j.bone.2013.12.017
   Kim DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122646
   Shao JS, 2003, J BIOL CHEM, V278, P50195, DOI 10.1074/jbc.M308825200
   Vassalle C, 2016, VASC PHARMACOL, V86, P77, DOI 10.1016/j.vph.2016.07.003
   Walker MD, 2009, J CLIN ENDOCR METAB, V94, P3849, DOI 10.1210/jc.2009 1086
   Ye CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154740
   Yoda M, 2015, CALCIFIED TISSUE INT, V97, P32, DOI 10.1007/s00223 015 0007 4
NR 11
TC 8
Z9 9
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394 6320
EI 2058 7384
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD JAN 7
PY 2019
VL 33
DI 10.1177/2058738418822439
PG 7
WC Immunology; Pathology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pathology; Pharmacology & Pharmacy
GA HR6HA
UT WOS:000463249200001
PM 30791743
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, JH
   Xu, K
   Wen, GB
   Guo, H
   Li, S
   Wu, XP
   Dai, RC
   Sheng, ZF
   Liao, EY
AF Liu, Jianghua
   Xu, Kang
   Wen, Gebo
   Guo, Hui
   Li, San
   Wu, Xianping
   Dai, Ruchun
   Sheng, Zhifeng
   Liao, Eryuan
TI Comparison of the effects of genistein and zoledronic acid on the bone
   loss in OPG deficient mice
SO BONE
LA English
DT Article
DE osteoprotegerin; genistein; bone microstructure; bone biomechanics;
   biochemical markets
ID HORMONE REPLACEMENT THERAPY; EARLY POSTMENOPAUSAL WOMEN;
   ESTROGEN RECEPTOR ALPHA; CONTROLLED TRIAL; DOUBLE BLIND; PHYTOESTROGEN
   GENISTEIN; OSTEOPROTEGERIN LIGAND; OSTEOLYTIC LESIONS; MINERAL DENSITY;
   SEX STEROIDS
AB Using osteoprotegerin (OPG) knockout mice, we demonstrated that in vivo the effects of both genistein and 17 beta estradiot (E 2) on bone metabolism were completely abolished. In contrast, zoledronic acid could effectively suppress bone resorption and prevent bone loss. Introduction: The anti resorptive effects of E 2 on bone metabolism are considered to be mediated via modulation of the osteoblast derived paracrine factor OPG. Recently, the phytoestrogen genistein was found to suppress bone resorption by enhancing osteoblastic production of OPG. However, the mechanism underlying the in vivo effects of E 2 and genistein on bone is not entirely understood, and a central question in this regard is whether E 2 regulates bone metabolism via an OPG dependent pathway.
   Methods: After mating heterozygous (OPG(+/ )) mice, homozygous (OPG( / )) and wild type (WT) with a mixed C57BL/6J x 129/SV background were obtained. The study involved 6 week old female OPG( / ) (it =40) and WT mice (it = 8). The OPG( / ) mice were randomly divided into 5 groups (n = 8 per group) as follows: (1) genistein treated mice (Gen) that were subcutaneously injected with genistein at a maximal dose (0.8 mg/day); (2) E 2 treated mice (E 2) that were subcutaneously injected with E2 at a dose (0.03 mu g/day); (3) DMSO control mice (DMSO) that were subcutaneously injected with a mixture of dimethylsulfoxide (DMSO) and polyethyleneglycol 300; (4) zoledronic acid treated mice (Zol) that were subcutaneously injected with zoledronic acid at a dose of (150 mu g/kg) twice per week; and (5) H2O control mice that were subcutaneously injected with sterilized water twice per week. The doses of genistein, estrogen and zoledronic acid were selected based on the results of dose response effect of agents on bone versus uterus in OPG /  mice. The mice were sacrificed 6 weeks after this intervention. The microarchitecture of the trabecular and cortical bone was assessed by performing microcomputed tomography (micro CT) for the right proximal tibia. The bone mineral density (BMD) of the left femur was measured by dual energy X ray absorptiometry (DXA). The biomechanical parameters of the right femur were determined by a three point bend testing. Serum levels of bone alkaline phosphatase (B ALP), tartarate resistant acid phosphatase 5b (TRACP 5b), and receptor activator of nuclear factor kappa B ligand (RANKL) were determined by performing ELISA.
   Results: DXA analysis revealed that the total BMD of the femur was not significantly altered in the Gen, E 2, H2O, and DMSO groups. The three point bending test revealed no significant differences in the biomechanical parameters, including ultimate loading, ultimate stress, stiff index, and elastic modulus, and micro CT analysis revealed that the microarchitectural parameters of the trabecular bone (vBMD, tBMD, BVF, BSF, SMI, Tb.N, Conn.D, Tb.Sp, and Tb.Th) and cortical bone (Ct.Th, Mm, In.Pm, Ot.Pm, Ma.Ar, Ct.Ar, Tt.Ar, Ct.BMD, and Ct. BMC) did not differ among the groups. Genistein and E2 treatment did not alter the serum TRACP 5b, B ALP, or RANKL levels. However, in addition to increasing the bone mass, zoledronic acid could effectively improve biomechanical parameters and could completely prevent deterioration of the bone architecture in the OPG( / ) mice. Conclusions: The effects of genistein and E, on bone metabolism in vivo were lost completely in OPG deficient mice, suggesting that the effect of these agents on bone metabolism seems to be entirely dependent on OPG. In contrast, zoledronic acid could effectively suppress bone resorption and completely prevent the bone loss in the OPG( / ) mice an effect that is likely to be independent of the OPG pathway. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Liu, Jianghua; Xu, Kang; Wu, Xianping; Dai, Ruchun; Sheng, Zhifeng; Liao, Eryuan] Cent S Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, Changsha 410011, Hunan, Peoples R China.
C3 Central South University
RP Liao, EY (通讯作者)，Cent S Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, Changsha 410011, Hunan, Peoples R China.
EM eyliao@21cn.com
RI XU, KANG/HNR 4619 2023
CR Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950 351X(98)80003 7
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   CAO YH, 1999, BIOL PHARM BULL, V22, P805
   Chanawirat A, 2006, CLIN HEMORHEOL MICRO, V34, P309
   Chen XW, 2002, BIOCHEM BIOPH RES CO, V295, P417, DOI 10.1016/S0006 291X(02)00667 8
   Chen YM, 2004, MENOPAUSE, V11, P246, DOI 10.1097/01.GME.0000094394.59028.46
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Crisafulli A, 2004, J CLIN ENDOCR METAB, V89, P188, DOI 10.1210/jc.2003 030891
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Erlandsson MC, 2005, APMIS, V113, P317, DOI 10.1111/j.1600 0463.2005.apm_113502.x
   HEE KY, 2002, EXP MOL MED, V34, P145
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ishimi Y, 2000, BIOCHEM BIOPH RES CO, V274, P697, DOI 10.1006/bbrc.2000.3175
   Ishimi Y, 1999, ENDOCRINOLOGY, V140, P1893, DOI 10.1210/en.140.4.1893
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Lee YP, 2002, CANCER RES, V62, P5564
   Li BB, 2003, BIOL PHARM BULL, V26, P780, DOI 10.1248/bpb.26.780
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Mazess RB, 2000, J CLIN DENSITOM, V3, P133, DOI 10.1385/JCD:3:2:133
   Michael H, 2005, J BONE MINER RES, V20, P2224, DOI 10.1359/JBMR.050803
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Nikander E, 2005, FERTIL STERIL, V83, P137, DOI 10.1016/j.fertnstert.2004.09.003
   Oreffo ROC, 1999, HISTOCHEM CELL BIOL, V111, P125, DOI 10.1007/s004180050342
   Oursler M. J., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P363
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosen LS, 2001, CANCER J, V7, P377
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Saika M, 2001, ENDOCRINOLOGY, V142, P2205, DOI 10.1210/en.142.6.2205
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   Wu J, 2006, METABOLISM, V55, P423, DOI 10.1016/j.metabol.2005.10.002
   Wu J, 2001, J BONE MINER RES, V16, P1829, DOI 10.1359/jbmr.2001.16.10.1829
NR 43
TC 17
Z9 21
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2008
VL 42
IS 5
BP 950
EP 959
DI 10.1016/j.bone.2008.01.010
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 292IQ
UT WOS:000255260100014
PM 18337202
DA 2025 08 17
ER

PT J
AU Zheng, TY
   Zhang, ZZ
   Zhu, R
   Sun, D
AF Zheng, Tianyang
   Zhang, Zhizhong
   Zhu, Rong
   Sun, Dong
TI A microelectrode array chip for osteogenic differentiation of
   mesenchymal stem cells under electrical stimulation
SO LAB ON A CHIP
LA English
DT Article
ID BONE MARROW; SUBSTRATE CONDUCTIVITY; ELECTROMAGNETIC FIELDS;
   PROLIFERATION; MECHANISM; CUES
AB Electrical stimulation (ES) as an easy and effective inducing method has been widely used in induction differentiation of stem cells, e.g. osteogenic differentiation of mesenchymal stem cells (MSCs) for bone healing and bone tissue therapies. However, the micro effect of an inhomogeneous electric field has rarely been investigated for ES in induction differentiation, and conventionally used ex situ assays may preclude accurate assessment due to variation from cell inoculation and treatments. Here, a novel electrical stimulation method with a microelectrode array chip is proposed for osteogenic differentiation of MSCs. The electric field applied onto the MSCs by the microelectrode array is designed similarly with a natural aggregation distribution of differentiated MSCs. The proposed ES method accelerates osteoblast proliferation and differentiation in the electrode array region and generates a larger amount of mineralized deposits, which are assayed via in situ alizarin red staining and morphology observation as well as immunocytochemistry. In addition, this method allows a direct in situ assessment to compare the osteogenic differentiation of MSCs with and without ES on a single chip to avoid culture environment difference. The method provides a fundamental platform for investigating induced differentiation of stem cells and allows integration with multifunctional cell assays to achieve in situ tracking for the differentiation process of stem cells.
C1 [Zheng, Tianyang; Zhang, Zhizhong; Zhu, Rong] Tsinghua Univ, Dept Precis Instrument, State Key Lab Precis Measurement Technol & Instru, Beijing 100084, Peoples R China.
   [Sun, Dong] City Univ Hong Kong, Dept Mech & Biomed Engn, Hong Kong, Peoples R China.
C3 Tsinghua University; City University of Hong Kong
RP Zhu, R (通讯作者)，Tsinghua Univ, Dept Precis Instrument, State Key Lab Precis Measurement Technol & Instru, Beijing 100084, Peoples R China.
EM zr_gloria@mail.tsinghua.edu.cn
OI SUN, Dong/0000 0003 3945 4037; Zheng, Tianyang/0000 0003 2733 5479
FU National Natural Science Foundation of China [61531166001]; National
   Instrumentation Program [2011YQ030134]
FX This work was financially supported by the National Natural Science
   Foundation of China (61531166001) and the National Instrumentation
   Program (2011YQ030134). The authors would like to thank Prof. Peng Liu
   at the School of Medicine of Tsinghua University for providing MSCs as a
   gift.
CR Abeed RI, 1998, J ORTHOP TRAUMA, V12, P510, DOI 10.1097/00005131 199809000 00015
   Balint R, 2013, TISSUE ENG PART B RE, V19, P48, DOI [10.1089/ten.teb.2012.0183, 10.1089/ten.TEB.2012.0183]
   Chiu CY, 2015, ULTRASOUND MED BIOL, V41, P1842, DOI 10.1016/j.ultrasmedbio.2015.03.017
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Ding S, 2017, BIOTECHNOL BIOENG, V114, P260, DOI 10.1002/bit.26075
   Eischen Loges M, 2018, PEERJ, V6, DOI 10.7717/peerj.4959
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Griffin M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072978
   Guo XL, 2015, J APPL PHYS, V117, DOI 10.1063/1.4921871
   Guo XL, 2015, BIOSENS BIOELECTRON, V68, P529, DOI 10.1016/j.bios.2015.01.052
   Haddad JB, 2007, J ALTERN COMPLEM MED, V13, P485, DOI 10.1089/acm.2007.5270
   Hammerick KE, 2010, TISSUE ENG PT A, V16, P917, DOI [10.1089/ten.tea.2009.0267, 10.1089/ten.TEA.2009.0267]
   Hronik Tupaj M, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475 925X 10 9
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jin L, 2018, ACS APPL MATER INTER, V10, P18543, DOI 10.1021/acsami.8b04136
   Jing D, 2016, SCI REP UK, V6, DOI 10.1038/srep32045
   Kang KS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.11
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim IS, 2006, BBA MOL CELL RES, V1763, P907, DOI 10.1016/j.bbamcr.2006.06.007
   Kim IS, 2009, TISSUE ENG PT A, V15, P2411, DOI 10.1089/ten.tea.2008.0554
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kuo YC, 2015, STEM CELLS, V33, P429, DOI 10.1002/stem.1860
   Kushibiki T, 2009, PHOTOMED LASER SURG, V27, P493, DOI 10.1089/pho.2008.2343
   Lee J, 2009, J MOL BIOL, V393, P113, DOI 10.1016/j.jmb.2009.08.026
   Luo F, 2012, ORTHOPEDICS, V35, pE526, DOI 10.3928/01477447 20120327 11
   Malgieri A, 2010, INT J CLIN EXP MED, V3, P248
   Mitchell AC, 2016, ACTA BIOMATER, V30, P1, DOI 10.1016/j.actbio.2015.11.007
   Mobini S, 2017, PEERJ, V5, DOI 10.7717/peerj.2821
   Nuttelman CR, 2006, J BIOMED MATER RES A, V76A, P183, DOI 10.1002/jbm.a.30537
   Ongaro A, 2014, BIOELECTROMAGNETICS, V35, P426, DOI 10.1002/bem.21862
   Pek YS, 2010, BIOMATERIALS, V31, P385, DOI 10.1016/j.biomaterials.2009.09.057
   Pittenger M., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P309
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ravikumar K, 2017, BIOELECTROCHEMISTRY, V116, P52, DOI 10.1016/j.bioelechem.2017.03.004
   Sim WY, 2007, LAB CHIP, V7, P1775, DOI 10.1039/b712361m
   Song MY, 2014, CELL BIOCHEM BIOPHYS, V69, P47, DOI 10.1007/s12013 013 9764 8
   Thrivikraman G, 2015, ACS APPL MATER INTER, V7, P23015, DOI 10.1021/acsami.5b06390
   Xiong K, 2017, ACS APPL MATER INTER, V9, P44356, DOI 10.1021/acsami.7b16206
   Zheng TY, 2019, ANAL CHEM, V91, P4479, DOI 10.1021/acs.analchem.8b05228
NR 39
TC 16
Z9 17
U1 1
U2 53
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473 0197
EI 1473 0189
J9 LAB CHIP
JI Lab Chip
PD JAN 21
PY 2020
VL 20
IS 2
BP 373
EP 383
DI 10.1039/c9lc01081e
PG 11
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology  
   Other Topics; Instruments & Instrumentation
GA KE9CH
UT WOS:000508846700013
PM 31850469
DA 2025 08 17
ER

PT J
AU Fornai, M
   Colucci, R
   Pellegrini, C
   Benvenuti, L
   Natale, G
   Ryskalin, L
   Blandizzi, C
   Antonioli, L
AF Fornai, Matteo
   Colucci, Rocchina
   Pellegrini, Carolina
   Benvenuti, Laura
   Natale, Gianfranco
   Ryskalin, Larisa
   Blandizzi, Corrado
   Antonioli, Luca
TI Role of proteinase activated receptors 1 and 2 in nonsteroidal
   anti inflammatory drug enteropathy
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Nonsteroidal anti inflammatory drugs (NSAIDs); Enteropathy;
   Proteinase activated receptors (PAR); Fecal calprotectin; Intestinal
   epithelial barrier; Intestinal inflammation
ID INTESTINAL INFLAMMATION; GASTROINTESTINAL TRACT; RISK FACTORS; COLITIS;
   INJURY; DAMAGE; BLOOD; OSTEOARTHRITIS; IDENTIFICATION; PERMEABILITY
AB Background The use of nonsteroidal anti inflammatory drugs (NSAIDs) can promote lower gastrointestinal detrimental effects. Proteinase activated receptors 1 (PAR1) and PAR2 are involved in the pathophysiology of several digestive disorders. This study examines the contribution of PAR1 and PAR2 in NSAID induced small intestinal injury, and to investigate the underlying mechanisms. Methods Male Wistar rats (40 weeks old) were treated with indomethacin (1.5 mg/kg BID) for 14 days. Subgroups of animals were treated intraperitoneally with TFFLR NH2 (PAR1 agonist), AC55541 (PAR2 agonist), SCH79797 (PAR1 antagonist) or ENMD 1068 (PAR2 antagonist). After treatments, blood and feces were collected for the assessment of hemoglobin and calprotectin, respectively. The ileum was processed for the evaluation of myeloperoxidase (MPO), malondialdehyde (MDA), and the protein expression of occludin and activated caspase 3. Results Indomethacin elicited a significant intestinal damage, associated with a decrease in blood hemoglobin and an increase in tissue MPO, MDA and fecal calprotectin. In this setting, either the PAR1 agonist or PAR2 antagonist counteracted these changes, with the exception of MDA, which was unaffected. By contrast, the PAR1 antagonist or PAR2 agonist did not exert any effect on all the parameters. Indomethacin also decreased occludin and increased activated caspase 3 expression in ileal tissues. The PAR1 agonist or PAR2 antagonist prevented the reduced occludin expression, while the PAR2 antagonist also decreased the levels of activated caspase 3. Conclusions PAR2 is involved in the pathogenesis of indomethacin enteropathy, through pro inflammatory mechanisms and an impairment of the intestinal epithelial barrier. PAR1 activation and PAR2 inhibition could represent suitable strategies for the prevention of NSAID enteropathy.
C1 [Fornai, Matteo; Benvenuti, Laura; Blandizzi, Corrado; Antonioli, Luca] Univ Pisa, Dept Clin & Expt Med, Via Roma 55, I 56126 Pisa, Italy.
   [Colucci, Rocchina] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I 35100 Padua, Italy.
   [Pellegrini, Carolina] Univ Pisa, Dept Pharm, I 56126 Pisa, Italy.
   [Natale, Gianfranco; Ryskalin, Larisa] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
C3 University of Pisa; University of Padua; University of Pisa; University
   of Pisa
RP Fornai, M (通讯作者)，Univ Pisa, Dept Clin & Expt Med, Via Roma 55, I 56126 Pisa, Italy.
EM matteo.fornai@unipi.it
RI ; Ryskalin, Larisa/ISR 9458 2023; Blandizzi, Corrado/AAB 8736 2019;
   Pellegrini, Carolina/ABE 3462 2021
OI BLANDIZZI, CORRADO/0000 0001 9927 5386; COLUCCI, ROCCHINA
   LUCIA/0000 0002 2593 5457; FORNAI, MATTEO/0000 0002 0812 3959
FU BMS/Pfizer European Thrombosis Investigator Initiated Research Program
   (ERISTA) [2014 API 0020]
FX This study received funding from the BMS/Pfizer European Thrombosis
   Investigator Initiated Research Program (ERISTA). Award number:
   2014 API 0020. The funder was not involved in the study design,
   collection, analysis, interpretation of data, the writing of this
   article or the decision to submit it for publication.
CR Antonioli L, 2010, J PHARMACOL EXP THER, V335, P434, DOI 10.1124/jpet.110.171223
   Arisan ED, 2018, MOL BIOL REP, V45, P2175, DOI 10.1007/s11033 018 4378 2
   BJARNASON I, 1987, LANCET, V2, P711
   BJARNASON I, 1992, GUT, V33, P1204, DOI 10.1136/gut.33.9.1204
   Bjarnason I, 2018, GASTROENTEROLOGY, V154, P500, DOI 10.1053/j.gastro.2017.10.049
   Bonnart C, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12489
   Bueno L, 2008, NEUROGASTROENT MOTIL, V20, P580, DOI 10.1111/j.1365 2982.2008.01139.x
   Cenac N, 2005, INFLAMM BOWEL DIS, V11, P792, DOI 10.1097/01.mib.0000177506.71784.bd
   Chami B, 2018, ARCH BIOCHEM BIOPHYS, V645, P61, DOI 10.1016/j.abb.2018.03.012
   Colucci R, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01340
   de Garavilla L, 2001, BRIT J PHARMACOL, V133, P975, DOI 10.1038/sj.bjp.0704152
   Dugina TN, 2002, BIOCHEMISTRY MOSCOW+, V67, P65, DOI 10.1023/A:1013952114485
   El Eter EA, 2012, SHOCK, V37, P639, DOI 10.1097/SHK.0b013e3182507774
   Fornai M, 2020, NUTRITION, V70, DOI 10.1016/j.nut.2019.110583
   Fornai M, 2016, PHARMACOL RES, V104, P186, DOI 10.1016/j.phrs.2015.12.031
   Fornai M, 2014, J PHARMACOL EXP THER, V348, P86, DOI 10.1124/jpet.113.207118
   Fornai M, 2011, PHARMACOL RES, V63, P59, DOI 10.1016/j.phrs.2010.10.013
   Fukui A, 2012, AM J PHYSIOL GASTR L, V303, pG927, DOI 10.1152/ajpgi.00236.2012
   Gardell LR, 2008, J PHARMACOL EXP THER, V327, P799, DOI 10.1124/jpet.108.142570
   Hansen KK, 2005, P NATL ACAD SCI USA, V102, P8363, DOI 10.1073/pnas.0409535102
   Hawkey CJ, 2006, J CARDIOVASC PHARM, V47, pS72, DOI 10.1097/00005344 200605001 00013
   Kahn M, 1996, MOL MED, V2, P349, DOI 10.1007/BF03401632
   Kelso EB, 2006, J PHARMACOL EXP THER, V316, P1017, DOI 10.1124/jpet.105.093807
   Kuramoto T, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471 230X 13 85
   Lai Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132031
   Lanas A, 2012, ALIMENT PHARM THER, V36, P485, DOI 10.1111/j.1365 2036.2012.05213.x
   Li S, 2015, MOL MED REP, V12, P7181, DOI 10.3892/mmr.2015.4325
   Lohman RJ, 2012, J PHARMACOL EXP THER, V340, P256, DOI 10.1124/jpet.111.187062
   Ma L, 2005, P NATL ACAD SCI USA, V102, P216, DOI 10.1073/pnas.0406682102
   Mallen SR, 2011, CURR MED RES OPIN, V27, P1359, DOI 10.1185/03007995.2011.581274
   Manceau H, 2017, CLIN CHEM LAB MED, V55, P474, DOI 10.1515/cclm 2016 0522
   Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03 080
   Niikura R, 2018, DIGEST ENDOSC, V30, P79, DOI 10.1111/den.12922
   Pereira Leite C, 2017, MED RES REV, V37, P802, DOI 10.1002/med.21424
   Pontarollo G, 2020, FEBS J, V287, P645, DOI 10.1111/febs.15055
   Rendek Z, 2016, SCAND J GASTROENTERO, V51, P28, DOI 10.3109/00365521.2015.1066421
   Ricciuto A, 2019, CRIT REV CL LAB SCI, V56, P307, DOI 10.1080/10408363.2019.1619159
   Ryu DG, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017080
   Saeed MA, 2017, INFLAMM BOWEL DIS, V23, P593, DOI 10.1097/MIB.0000000000001045
   Scarpignato C, 2010, GASTROENTEROL CLIN N, V39, P433, DOI 10.1016/j.gtc.2010.08.010
   Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061
   Sébert M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00717
   Sostres C, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4175
   Svistunov AA, 2018, TERAPEVT ARKH, V90, P95, DOI [10.26442/terarkh201890895 100, https//doi.org/10.26442/terarkh201890895 100]
   Syer SD, 2015, J GASTROENTEROL, V50, P387, DOI 10.1007/s00535 014 1032 1
   Tai FWD, 2018, CURR OPIN GASTROEN, V34, P175, DOI 10.1097/MOG.0000000000000427
   Van Spaendonk H, 2017, WORLD J GASTROENTERO, V23, P2106, DOI 10.3748/wjg.v23.i12.2106
   Vergnolle N, 2005, GUT, V54, P867, DOI 10.1136/gut.2004.048876
   Vergnolle N, 2008, INT J BIOCHEM CELL B, V40, P1219, DOI 10.1016/j.biocel.2008.01.016
   Vyas D, 2007, HISTOL HISTOPATHOL, V22, P623, DOI 10.14670/HH 22.623
   Walker C, 2019, INT J RHEUMATOL, V2019, DOI 10.1155/2019/8635073
   Wallace JL, 2013, WORLD J GASTROENTERO, V19, P1861, DOI 10.3748/wjg.v19.i12.1861
   Wang X, 2011, EUR J GASTROEN HEPAT, V23, P876, DOI 10.1097/MEG.0b013e328349de81
   Watanabe T, 2020, J GASTROENTEROL, V55, P481, DOI 10.1007/s00535 019 01657 8
   Watanabe T, 2013, DIGEST LIVER DIS, V45, P390, DOI 10.1016/j.dld.2012.12.005
   Wongrakpanich S, 2018, AGING DIS, V9, P1, DOI 10.14336/AD.2017.0304
   Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642
   Yoshida N, 2011, MOL MED REP, V4, P81, DOI 10.3892/mmr.2010.386
   Zhao JH, 2012, DIGEST DIS SCI, V57, P58, DOI 10.1007/s10620 011 1827 3
NR 59
TC 4
Z9 4
U1 0
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1734 1140
EI 2299 5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD OCT
PY 2020
VL 72
IS 5
BP 1347
EP 1357
DI 10.1007/s43440 020 00119 w
EA JUN 2020
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OI4ND
UT WOS:000544268700001
PM 32583327
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Roth, M
   Barris, DM
   Piperdi, S
   Kuo, V
   Everts, S
   Geller, D
   Houghton, P
   Kolb, EA
   Hawthorne, T
   Gill, J
   Gorlick, R
AF Roth, Michael
   Barris, David M.
   Piperdi, Sajida
   Kuo, Vicky
   Everts, Stephanie
   Geller, David
   Houghton, Peter
   Kolb, E. Anders
   Hawthorne, Thomas
   Gill, Jonathan
   Gorlick, Richard
TI Targeting Glycoprotein NMB With Antibody Drug Conjugate, Glembatumumab
   Vedotin, for the Treatment of Osteosarcoma
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE antibody drug conjugate; glembatumumab vedotin; GPNMB; osteosarcoma
ID PRECLINICAL TESTING PROGRAM; HIGH DOSE METHOTREXATE; METASTATIC
   BREAST CANCER; THERAPEUTIC TARGET; OSTEOBLAST DIFFERENTIATION;
   NONMETASTATIC OSTEOSARCOMA; MICROARRAY ANALYSIS; PHASE I/II; STAGE 1;
   CHEMOTHERAPY
AB BackgroundCure rates for children and young adults with osteosarcoma have remained stagnant over the past three decades. Targeting glycoprotein non metastatic b (GPNMB) with the antibody drug conjugate glembatumumab vedotin has improved outcomes for patients with melanoma and breast cancer. The potential utility of targeting GPNMB in osteosarcoma was explored.
   MethodsGPNMB protein expression was evaluated by immunohistochemistry in human osteosarcoma tumor samples and by enzyme linked immunosorbent assay (ELISA) in osteosarcoma cell lines. mRNA expression was measured by quantitative PCR in primary osteosarcoma samples and cell lines. Surface GPNMB expression was evaluated by flow cytometry and correlated with in vitro and in vivo cytotoxicity of glembatumumab vedotin.
   ResultsSixty seven human osteosarcoma samples were evaluated by immunohistochemistry, including 12 samples from initial biopsy, 38 samples from definitive surgery, and 17 from the time of disease recurrence. GPNMB was expressed in 92.5% (62/67) of osteosarcoma samples. All primary osteosarcoma samples expressed high levels of GPNMB mRNA. Glembatumumab induced cytotoxic effects in 74% (14/19) of osteosarcoma cell lines, and GPNMB protein levels correlated with glembatumumab in vitro cytotoxicity (r= 0.46, P=0.04). All osteosarcoma cell lines demonstrated surface GPNMB expression.
   ConclusionsGPNMB is expressed in osteosarcoma and targeting GPNMB with the antibody drug conjugate glembatumumab vedotin demonstrates osteosarcoma cytotoxic activity. Clinical trials are indicated to assess the efficacy of targeting GPNMB in patients with osteosarcoma. Pediatr Blood Cancer 2015; 9999:1 7 (c) 2015 Wiley Periodicals, Inc.
C1 [Roth, Michael; Barris, David M.; Piperdi, Sajida; Kuo, Vicky; Everts, Stephanie; Gill, Jonathan; Gorlick, Richard] Albert Einstein Coll Med, Div Pediat Hematol Oncol, Childrens Hosp Montefiore, Bronx, NY 10467 USA.
   [Geller, David] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Orthopaed Surg, Bronx, NY 10467 USA.
   [Geller, David] Albert Einstein Coll Med, Childrens Hosp Montefiore, Bronx, NY 10467 USA.
   [Houghton, Peter] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
   [Kolb, E. Anders] Alfred I DuPont Hosp Children, Div Pediat Hematol Oncol, Wilmington, DE USA.
   [Hawthorne, Thomas] Celldex Therapeut, Branford, CT USA.
   [Gorlick, Richard] Albert Einstein Coll Med, Dept Pediat & Mol Pharmacol, Bronx, NY 10467 USA.
C3 Yeshiva University; Montefiore Medical Center; Albert Einstein College
   of Medicine; Childrens Hospital at Montefiore; Montefiore Medical
   Center; Albert Einstein College of Medicine; Yeshiva University;
   Montefiore Medical Center; Albert Einstein College of Medicine;
   Childrens Hospital at Montefiore; Yeshiva University; University of
   Texas System; University of Texas Health Science Center at San Antonio;
   Nemours Alfred I. duPont Hospital for Children; Celldex Therapeutics,
   Inc.; Yeshiva University; Montefiore Medical Center; Albert Einstein
   College of Medicine
RP Gorlick, R (通讯作者)，Childrens Hosp Montefiore, Pediat Hematol Oncol, 3415 Bainbridge Ave,Rosenthal Pavil,Room 300, Bronx, NY 10467 USA.
EM RGorlick@montefiore.org
RI ; Geller, David/AAV 8082 2020
OI Barris, David/0000 0001 8656 1666; Kolb, E. Anders/0000 0003 2854 9014;
   GORLICK, RICHARD/0000 0001 8995 2929; 
FU Foster Foundation; Swim Across America; Barbara Epstein Foundation;
   National Cancer Institute [K12 CA 132783 04]
FX Grant sponsor: Foster Foundation; Grant sponsor: Swim Across America;
   Grant sponsor: Barbara Epstein Foundation; Grant sponsor: National
   Cancer Institute; Grant number: K12 CA 132783 04
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Ahn JH, 2002, BLOOD, V100, P1742, DOI 10.1182/blood.V100.5.1742.h81702001742_1742_1754
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683
   Chou AJ, 2009, CANCER AM CANCER SOC, V115, P5339, DOI 10.1002/cncr.24566
   Ebb D, 2012, J CLIN ONCOL, V30, P2545, DOI 10.1200/JCO.2011.37.4546
   EDMONSON JH, 1984, J CLIN ONCOL, V2, P152, DOI 10.1200/JCO.1984.2.3.152
   Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140 6736(13)61719 5
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984
   GOORIN AM, 1987, J CLIN ONCOL, V5, P1178, DOI 10.1200/JCO.1987.5.8.1178
   Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078
   Kolb EA, 2014, PEDIATR BLOOD CANCER, V61, P1816, DOI 10.1002/pbc.25099
   Kolb EA, 2013, PEDIATR BLOOD CANCER, V60, P1325, DOI 10.1002/pbc.24517
   KRAILO M, 1987, MED PEDIATR ONCOL, V15, P69, DOI 10.1002/mpo.2950150205
   Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078 0432.CCR 05 2797
   Kubista B, 2011, INT ORTHOP, V35, P401, DOI 10.1007/s00264 010 0996 6
   LaPointe NE, 2013, NEUROTOXICOLOGY, V37, P231, DOI 10.1016/j.neuro.2013.05.008
   Lexell JE, 2005, AM J PHYS MED REHAB, V84, P719, DOI 10.1097/01.phm.0000176452.17771.20
   Onaga M, 2003, J HEPATOL, V39, P779, DOI 10.1016/S0168 8278(03)00361 1
   Ott PA, 2014, J CLIN ONCOL, V32, P3659, DOI 10.1200/JCO.2013.54.8115
   Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76
   Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200
   Ripoll VM, 2008, GENE, V413, P32, DOI 10.1016/j.gene.2008.01.014
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078 0432.CCR 09 1611
   Roth M, 2014, CANCER AM CANCER SOC, V120, P548, DOI 10.1002/cncr.28461
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Selim AA, 2003, CRIT REV EUKAR GENE, V13, P265, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
   Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030
   Souhami RL, 1997, LANCET, V350, P911, DOI 10.1016/S0140 6736(97)02307 6
   Sowers Rebecca, 2011, Sarcoma, V2011, P834170, DOI 10.1155/2011/834170
   Sutherland MSK, 2006, J BIOL CHEM, V281, P10540, DOI 10.1074/jbc.M510026200
   Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600 0625.2008.00830.x
   Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078 0432.CCR 05 2018
   Yardley D, 2013, BREAST CANC SABCS 20
   Yardley DA, 2012, CANC RES 35 ANN C S3, V72
   Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959
NR 38
TC 46
Z9 52
U1 1
U2 15
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1545 5009
EI 1545 5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JAN
PY 2016
VL 63
IS 1
BP 32
EP 38
DI 10.1002/pbc.25688
PG 7
WC Oncology; Hematology; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology; Pediatrics
GA CZ4UH
UT WOS:000367097800006
PM 26305408
DA 2025 08 17
ER

PT J
AU Laowanitwattana, T
   Aungsuchawan, S
   Narakornsak, S
   Markme, R
   Tancharoen, W
   Keawdee, J
   Boonma, N
   Tasuya, W
   Peerapapong, L
   Pangjaidee, N
   Pothacharoen, P
AF Laowanitwattana, Tanongsak
   Aungsuchawan, Sirinda
   Narakornsak, Suteera
   Markme, Runchana
   Tancharoen, Waleephan
   Keawdee, Junjira
   Boonma, Nonglak
   Tasuya, Witoon
   Peerapapong, Lamaiporn
   Pangjaidee, Nathaporn
   Pothacharoen, Peeraphan
TI Osteoblastic differentiation potential of human amniotic fluid derived
   mesenchymal stem cells in different culture conditions
SO ACTA HISTOCHEMICA
LA English
DT Article
DE Differentiation; Mesenchymal stem cells; Human amniotic fluid;
   Osteoblastic like cells; Scaffold
ID CHONDROGENIC DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; IN VITRO;
   SIGNALING PATHWAYS; SCAFFOLD; OSTEOCYTE; SESAMIN; VIVO
AB Osteoporosis is a bone degenerative disease characterized by a decrease in bone strength and an alteration in the osseous micro architecture causing an increase in the risk of fractures. These diseases usually happen in postmenopausal women and elderly men. The most common treatment involves anti resorptive agent drugs. However, the inhibition of bone resorption alone is not adequate for recovery in patients at the severe stage of osteoporosis who already have a fracture. Therefore, the combination of utilizing osteoblast micro mimetic scaffold in cultivation with the stimulation of osteoblastic differentiations to regain bone formation is a treatment strategy of considerable interest. The aims of this current study are to investigate the osteoblastic differentiation potential of mesenchymal stem cells derived from human amniotic fluid and to compare the monolayer culture and scaffold culture conditions. The results showed the morphology of cells in human amniotic fluid as (type, which is a typical cell shape of mesenchymal stem cells. In addition, the proliferation rate of cells in human amniotic fluid reached the highest peak after 14 days of culturing. After which time, the growth rate slowly decreased. Moreover, the positive expression of specific mesenchymal cell surface markers including CD44, CD73, CD90, and also HLA ABC (MHC class I) were recorded. On the other hand, the negative expressions of the endothelial stem cells markers (CD31), the hematopoietic stem cells markers (CD34, 45), the amniotic stem cells markers (CD117), and also the HLA DR (MHC class II) were also recorded. The expressions of osteoblastogenic related genes including OCN, COL1A1, and ALP were higher in the osteogenic induced group when compared to the control group. Interestingly, the osteoblastogenic related gene expressions that occurred under scaffold culture conditions were superior to the monolayer culture conditions. Additionally, higher ALP activity and greater calcium deposition were recorded in the extracellular matrix in the osteogenic induced group than in the culture in the scaffold group. In summary, the mesenchymal stem cells derived from human amniotic fluid can be induced to be differentiated into osteoblastic like cells and can promote osteoblastic differentiation using the applied scaffold.
C1 [Laowanitwattana, Tanongsak; Aungsuchawan, Sirinda; Narakornsak, Suteera; Markme, Runchana; Tancharoen, Waleephan; Keawdee, Junjira; Boonma, Nonglak; Tasuya, Witoon; Peerapapong, Lamaiporn; Pangjaidee, Nathaporn] Chiang Mai Univ, Fac Med, Dept Anat, Chiang Mai, Thailand.
   [Pothacharoen, Peeraphan] Chiang Mai Univ, Fac Med, Dept Biochem, Chiang Mai, Thailand.
C3 Chiang Mai University; Chiang Mai University
RP Aungsuchawan, S (通讯作者)，Chiang Mai Univ, Maharaj Nakom Chiang Mai Hosp 110, Fac Med, Dept Anat, Intawarorose Rd, Chiang Mai 50200, Thailand.
EM sirinda001@hotmail.com
FU Faculty of Medicine Research Fund, Chiang Mai University, Chiang Mai,
   Thailand
FX This research study was supported by the Faculty of Medicine Research
   Fund, Chiang Mai University, Chiang Mai, Thailand.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   [Anonymous], 2011, EMBRYONIC STEM CELLS
   [Anonymous], 2012, REGENER RES
   [Anonymous], COLOR TXB HISTOLOGY
   [Anonymous], CELL DEATH DIS
   [Anonymous], KOBE J MED SCI
   [Anonymous], POLYM RES J
   [Anonymous], PEDIAT BONE
   Appasani K, 2011, STEM CELLS BIOL REG, P3, DOI 10.1007/978 1 60761 860 7_1
   Azami M, 2013, TISSUE CELL, V45, P328, DOI 10.1016/j.tice.2013.05.002
   Balderas Cejudo M.A., 2017, OAJ Gerontol Geriatric Med, V1, DOI DOI 10.19080/OAJGGM.2017.01.555563
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Cananzi M, 2012, ORGANOGENESIS, V8, DOI 10.4161/org.22426
   Castrén E, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0162 6
   Chen SW, 2016, TISSUE ENG PART C ME, V22, P189, DOI [10.1089/ten.tec.2015.0281, 10.1089/ten.TEC.2015.0281]
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Elabd C, 2007, BIOCHEM BIOPH RES CO, V361, P342, DOI 10.1016/j.bbrc.2007.06.180
   Evans ND, 2006, MATER TODAY, V9, P26, DOI 10.1016/S1369 7021(06)71740 0
   Galli D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/762695
   George J, 2006, BIOTECHNOL BIOENG, V95, P404, DOI 10.1002/bit.20939
   Iñiguez Ariza NM, 2015, MATURITAS, V82, P245, DOI 10.1016/j.maturitas.2015.07.003
   Jain KG, 2015, INDIAN J MED RES, V142, P746, DOI 10.4103/0971 5916.174568
   Janeczek AA, 2016, STEM CELLS, V34, P418, DOI 10.1002/stem.2241
   Kim EY, 2014, HUM CELL, V27, P51, DOI 10.1007/s13577 013 0080 9
   Kim J, 2007, CELL PROLIFERAT, V40, P75
   Lanza R, 2009, ESSENTIALS OF STEM CELL BIOLOGY, 2ND EDITION, pXV, DOI 10.1016/B978 0 12 374729 7.00073 1
   Liu MM, 2014, STEM CELLS DEV, V23, P146, DOI 10.1089/scd.2013.0261
   Maclaughlin Eric J, 2006, Ther Clin Risk Manag, V2, P281
   Markmee R, 2017, MOL MED REP, V16, P6068, DOI 10.3892/mmr.2017.7333
   Menssen A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471 2164 12 461
   Mescher A.L., 2016, Junqueira's basic histology, VFourteenth, P138
   Mokry J, 2015, STEM CELL BIOLOGY AND TISSUE ENGINEERING IN DENTAL SCIENCES, P237, DOI 10.1016/B978 0 12 397157 9.00019 9
   Morabito C, 2015, CELL PHYSIOL BIOCHEM, V36, P259, DOI 10.1159/000374069
   Narakornsak S, 2017, ACTA HISTOCHEM, V119, P451, DOI 10.1016/j.acthis.2017.04.006
   Petrochenko Peter, 2010, J Long Term Eff Med Implants, V20, P303
   Pipino C, 2015, WORLD J STEM CELLS, V7, P681, DOI 10.4252/wjsc.v7.i4.681
   Pipino C, 2014, STEM CELLS DEV, V23, P2959, DOI 10.1089/scd.2013.0627
   Pittenger Mark F., 2008, V449, P27, DOI 10.1007/978 1 60327 169 1_2
   Prins HJ, 2014, STEM CELL RES, V12, P428, DOI 10.1016/j.scr.2013.12.001
   Ramos TL, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964 015 0124 8
   Ratanavaraporn J, 2006, J MET MATER MINER, V16, P31
   Rodrigues MT, 2012, TISSUE ENG PT A, V18, P2518, DOI 10.1089/ten.tea.2011.0672
   Savickiene J, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/319238
   Si JW, 2014, STEM CELL TRANSL MED, V3, P1504, DOI 10.5966/sctm.2014 0118
   Solchaga LA, 2011, METHODS MOL BIOL, V698, P253, DOI 10.1007/978 1 60761 999 4_20
   Somoza RA, 2014, TISSUE ENG PART B RE, V20, P596, DOI [10.1089/ten.teb.2013.0771, 10.1089/ten.TEB.2013.0771]
   Stevenson J.C., 2007, ATLAS OSTEOPOROSIS, V3a
   Sun HL, 2010, BIOMATERIALS, V31, P1133, DOI 10.1016/j.biomaterials.2009.10.030
   Trohatou O, 2013, CURR STEM CELL RES T, V8, P125, DOI 10.2174/1574888X11308020003
   Vadasz S, 2014, J PEDIATR SURG, V49, P1554, DOI 10.1016/j.jpedsurg.2014.04.006
   Vellasamy Shalini, 2012, World J Stem Cells, V4, P53
   Wanachewin O, 2015, J FUNCT FOODS, V14, P395, DOI [10.1016/j.jff.2015.01.046, 10.1016/j.jff.2015.]
   Wei DG, 2011, STEM CELLS BIOL REG, P89, DOI 10.1007/978 1 60761 860 7_6
   Xie XJ, 2006, ACTA PHARMACOL SIN, V27, P1153, DOI 10.1111/j.1745 7254.2006.00436.x
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Zhao XN, 2017, SCI REP UK, V7, DOI 10.1038/srep44076
   Zhou J, 2014, ARCH GYNECOL OBSTET, V290, P223, DOI 10.1007/s00404 014 3231 7
NR 60
TC 11
Z9 11
U1 0
U2 2
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0065 1281
EI 1618 0372
J9 ACTA HISTOCHEM
JI Acta Histochem.
PY 2018
VL 120
IS 8
BP 701
EP 712
DI 10.1016/j.acthis.2018.07.006
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HJ3KB
UT WOS:000457068700001
PM 30078494
DA 2025 08 17
ER

PT J
AU Cho, HJ
   Lee, JW
   Cho, HJ
   Lee, CS
   Kim, HS
AF Cho, Hyun Jai
   Lee, Jin Woo
   Cho, Hyun Ju
   Lee, Choon Soo
   Kim, Hyo Soo
TI Identification of Adult Mesodermal Progenitor Cells and Hierarchy in
   Atherosclerotic Vascular Calcification
SO STEM CELLS
LA English
DT Article
DE Bone marrow; Differentiation; Hematopoietic stem cells; Mesenchymal stem
   cells; Osteoblast
ID MESENCHYMAL STROMAL CELLS; HEMATOPOIETIC STEM CELLS; BONE MARROW;
   PDGFR ALPHA; MECHANISMS; EXPRESSION; PURIFICATION; MACROPHAGES;
   PHYSIOLOGY; SELECTION
AB The nature of calcifying progenitor cells remains elusive. In this study, we investigated the developmental hierarchy and dynamics of progenitor cells. In vitro and in vivo reconstitution assays demonstrated that Sca 1+/PDGFR alpha  cells in the bone marrow (BM) are the ancestors of Sca 1+/PDGFR alpha+ cells. Cells of CD29+Sca 1+/PDGFR alpha  lineage in the BM showed both hematopoietic potential with osteoclastic differentiation ability as well as mesenchymal stem cell like properties with osteoblastic differentiation potential. Clonally isolated BM derived artery infiltrated Sca 1+/PDGFR alpha  cells maintained osteoblastic/osteoclastic bipotency but lost hematopoietic activity. In hypercholesterolemic apolipoprotein E deficient (Apoe / ) mice, the mobilization from BM to peripheral circulation, followed by migration into atherosclerotic plaques of Sca 1+/PDGFR alpha  cells, but not Sca 1+/PDGFR alpha+ cells, were significantly decreased, and Interleukin 1 beta (IL 1 beta) and Interleukin 5 (IL 5) mediated this response. Here, we demonstrated that Sca 1+/PDGFR alpha  cells are mesodermal progenitor cells in adults, and the dynamics of progenitor cells were regulated by atherosclerosis related humoral factors. These results may contribute to better understanding of vascular homeostasis and assist in the development of novel therapies for atherosclerosis.
C1 [Cho, Hyun Jai; Kim, Hyo Soo] Seoul Natl Univ Hosp, Dept Internal Med, 101 Daehak Ro, Seoul 110744, South Korea.
   [Lee, Jin Woo; Cho, Hyun Ju; Lee, Choon Soo; Kim, Hyo Soo] Seoul Natl Univ Hosp, Strateg Ctr Cell & Bio Therapy, Seoul, South Korea.
   [Lee, Jin Woo; Cho, Hyun Ju; Lee, Choon Soo; Kim, Hyo Soo] Seoul Natl Univ, Natl Res Lab Stem Cell Niche, Coll Med, Seoul, South Korea.
   [Lee, Choon Soo; Kim, Hyo Soo] Seoul Natl Univ, World Class Univ Program, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU)
RP Kim, HS (通讯作者)，Seoul Natl Univ Hosp, Dept Internal Med, 101 Daehak Ro, Seoul 110744, South Korea.
EM hyosoo@snu.ac.kr
RI choi, jo/O 5940 2014; CHO, HYUNJU/W 9672 2019; Lee,
   Choon Soo/KIA 6810 2024; Kim, Hyo/J 2753 2012; Lee, Jin/AAK 6959 2020
FU Korea Health Technology R & D Project "Strategic Center of Cell and Bio
   Therapy for Heart, Diabetes & Cancer" through the Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health Welfare (MHW) [HI 17
   C 2085]; Bio & Medical Technology Development Program of the National
   Research Foundation (NRF)   Korean government (MSIP), Republic of Korea
   [NRF 2015M3A9B4051041]
FX This study was supported by a grant of the Korea Health Technology R & D
   Project "Strategic Center of Cell and Bio Therapy for Heart, Diabetes &
   Cancer" through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health & Welfare (MHW) (HI 17 C 2085), and the
   Bio & Medical Technology Development Program of the National Research
   Foundation (NRF), funded by the Korean government (MSIP)
   (NRF 2015M3A9B4051041), Republic of Korea.
CR Anam K, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt323
   Andrade J, 2011, BIOL BLOOD MARROW TR, V17, P608, DOI 10.1016/j.bbmt.2010.12.697
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594
   Ball SG, 2014, STEM CELLS, V32, P694, DOI 10.1002/stem.1538
   Bergman P, 2005, NAT CLIN PRACT CARD, V2, P246, DOI 10.1038/ncpcardio0192
   Brunelli S, 2004, CIRC RES, V94, P1571, DOI 10.1161/01.RES.0000132747.12860.10
   Cho HJ, 2013, EXPERT REV CARDIOVAS, V11, P937, DOI 10.1586/14779072.2013.814875
   Cho HJ, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001534
   Cohen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7709
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eghbali Fatourechi GZ, 2007, BONE, V40, P1370, DOI 10.1016/j.bone.2006.12.064
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Ema M, 2006, BLOOD, V107, P111, DOI 10.1182/blood 2005 05 1970
   Fadini GP, 2012, CIRCULATION, V125, P2772, DOI 10.1161/CIRCULATIONAHA.112.090860
   Fadini GP, 2011, CIRC RES, V108, P1112, DOI 10.1161/CIRCRESAHA.110.234088
   Fazzi R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025600
   Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620
   Gössl M, 2008, J AM COLL CARDIOL, V52, P1314, DOI 10.1016/j.jacc.2008.07.019
   Hjortnaes J, 2013, TRENDS CARDIOVAS MED, V23, P71, DOI 10.1016/j.tcm.2012.09.003
   Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kramann R, 2016, CELL STEM CELL, V19, P628, DOI 10.1016/j.stem.2016.08.001
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Kueanjinda P, 2015, SCI REP UK, V5, DOI 10.1038/srep12784
   Li HZ, 2014, STEM CELL REP, V3, P965, DOI 10.1016/j.stemcr.2014.09.018
   Ma JJ, 2015, DIS MODEL MECH, V8, P385, DOI 10.1242/dmm.018887
   Marinou K, 2012, TRENDS ENDOCRIN MET, V23, P628, DOI 10.1016/j.tem.2012.06.001
   Miller Cindy L, 2005, Methods Mol Biol, V290, P71
   Nakayama N, 2003, J CELL SCI, V116, P2015, DOI 10.1242/jcs.00417
   Ng HP, 2015, ARTERIOSCL THROM VAS, V35, P1101, DOI 10.1161/ATVBAHA.115.305290
   Passman JN, 2008, P NATL ACAD SCI USA, V105, P9349, DOI 10.1073/pnas.0711382105
   Petrini M, 2009, STEM CELLS DEV, V18, P857, DOI 10.1089/scd.2008.0291
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Sage AP, 2010, NAT REV CARDIOL, V7, P528, DOI 10.1038/nrcardio.2010.115
   Sakurai H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047078
   SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810
   Tintut Y, 2003, CIRCULATION, V108, P2505, DOI 10.1161/01.CIR.0000096485.64373.C5
   Weissman IL, 2008, BLOOD, V112, P3543, DOI 10.1182/blood 2008 08 078220
NR 42
TC 7
Z9 7
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2018
VL 36
IS 7
BP 1075
EP 1096
DI 10.1002/stem.2814
PG 22
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA GN9UA
UT WOS:000439553100010
PM 29484798
OA Bronze
DA 2025 08 17
ER

PT J
AU Knychala, J
   Bouropoulos, N
   Catt, CJ
   Katsamenis, OL
   Please, CP
   Sengers, BG
AF Knychala, J.
   Bouropoulos, N.
   Catt, C. J.
   Katsamenis, O. L.
   Please, C. P.
   Sengers, B. G.
TI Pore Geometry Regulates Early Stage Human Bone Marrow Cell Tissue
   Formation and Organisation
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Tissue engineering; Human bone marrow cells; Actin; Calcium phosphate
   cements; Mathematical modelling; Porous scaffolds
ID OSTEOBLAST LIKE CELLS; SURFACE ROUGHNESS; STEM CELL; MATRIX PRODUCTION;
   TITANIUM ALLOY; SCAFFOLDS; ADHESION; GROWTH; SIZE; PROLIFERATION
AB Porous architecture has a dramatic effect on tissue formation in porous biomaterials used in regenerative medicine. However, the wide variety of 3D structures used indicates there is a clear need for the optimal design of pore architecture to maximize tissue formation and ingrowth. Thus, the aim of this study was to characterize initial tissue growth solely as a function of pore geometry. We used an in vitro system with well defined open pore slots of varying width, providing a 3D environment for neo tissue formation while minimizing nutrient limitations. Results demonstrated that initial tissue formation was strongly influenced by pore geometry. Both velocity of tissue invasion and area of tissue formed increased as pores became narrower. This is associated with distinct patterns of actin organisation and alignment depending on pore width, indicating the role of active cell generated forces. A mathematical model based on curvature driven growth successfully predicted both shape of invasion front and constant rate of growth, which increased for narrower pores as seen in experiments. Our results provide further evidence for a front based, curvature driven growth mechanism depending on pore geometry and tissue organisation, which could provide important clues for 3D scaffold design.
C1 [Knychala, J.; Katsamenis, O. L.; Sengers, B. G.] Univ Southampton, Fac Engn & Environm, Bioengn Sci Res Grp, Southampton SO17 1BJ, Hants, England.
   [Bouropoulos, N.; Katsamenis, O. L.] Univ Patras, Dept Mat Sci, Patras 26504, Greece.
   [Bouropoulos, N.] Fdn Res & Technol, Hellas Inst Chem Engn & High Temp Chem Proc FORTH, Patras 26504, Greece.
   [Catt, C. J.; Please, C. P.] Univ Southampton, Sch Math, Southampton SO17 1BJ, Hants, England.
C3 University of Southampton; University of Patras; Foundation for Research
   & Technology   Hellas (FORTH); Institute of Chemical Engineering
   Sciences (ICE HT); University of Southampton
RP Knychala, J (通讯作者)，Univ Southampton, Fac Engn & Environm, Bioengn Sci Res Grp, Southampton SO17 1BJ, Hants, England.
EM jonathan.knychala@gmail.com
RI ; Katsamenis, Orestis/KHD 4205 2024; Please, Colin/G 6247 2011
OI Sengers, Bram/0000 0001 5859 6984; Katsamenis,
   Orestis/0000 0003 4367 4147; Please, Colin/0000 0001 8917 8574
FU EPSRC [EP/F032994/1]; Engineering and Physical Sciences Research Council
   [EP/F032994/1, EP/H028277/1] Funding Source: researchfish; EPSRC
   [EP/H028277/1] Funding Source: UKRI
FX We would like to thank Dr R. Tare and the Bone and Joint Research Group
   in Southampton for their assistance and for providing the cell sample.
   Dr C. Catt was supported by Symbiosis project funding, EPSRC
   EP/F032994/1.
CR Andriotis O, 2010, CRYST RES TECHNOL, V45, P239, DOI 10.1002/crat.200900551
   Aratyn Schaus Y, 2011, MOL BIOL CELL, V22, P1330, DOI 10.1091/mbc.E10 11 0891
   Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532
   Bidan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036336
   Biton YY, 2009, PHYS BIOL, V6, DOI 10.1088/1478 3975/6/4/046010
   Blankenship JT, 2006, DEV CELL, V11, P459, DOI 10.1016/j.devcel.2006.09.007
   Bohner M, 2011, ACTA BIOMATER, V7, P478, DOI 10.1016/j.actbio.2010.08.008
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   Buxboim A, 2010, J CELL SCI, V123, P297, DOI 10.1242/jcs.041186
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dawson JI, 2008, ARCH BIOCHEM BIOPHYS, V473, P124, DOI 10.1016/j.abb.2008.03.024
   Deligianni DD, 2001, BIOMATERIALS, V22, P1241, DOI 10.1016/S0142 9612(00)00274 X
   Deshpande VS, 2007, P ROY SOC A MATH PHY, V463, P787, DOI 10.1098/rspa.2006.1793
   Ducheyne P, 1999, BIOMATERIALS, V20, P2287, DOI 10.1016/S0142 9612(99)00181 7
   Elaine N, 2010, HUMAN ANATOMY PHYSL
   Engelmayr GC, 2006, J BIOMECH, V39, P1819, DOI 10.1016/j.jbiomech.2005.05.020
   Frosch KH, 2004, J BIOMED MATER RES A, V68A, P325, DOI 10.1002/jbm.a.20010
   Frosch KH, 2002, CELLS TISSUES ORGANS, V170, P214, DOI 10.1159/000047925
   Galbraith CG, 1997, P NATL ACAD SCI USA, V94, P9114, DOI 10.1073/pnas.94.17.9114
   Han SJ, 2011, COMPUT METHOD BIOMEC, V14, P459, DOI 10.1080/10255842.2011.554412
   Hollister SJ, 2002, BIOMATERIALS, V23, P4095, DOI 10.1016/S0142 9612(02)00148 5
   HULBERT S F, 1970, Journal of Biomedical Materials Research, V4, P433, DOI 10.1002/jbm.820040309
   Kapfer SC, 2011, BIOMATERIALS, V32, P6875, DOI 10.1016/j.biomaterials.2011.06.012
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kong HJ, 2005, P NATL ACAD SCI USA, V102, P4300, DOI 10.1073/pnas.0405873102
   Lamolle SF, 2009, BIOMATERIALS, V30, P736, DOI 10.1016/j.biomaterials.2008.10.052
   Li B, 2009, J BIOMECH, V42, P1622, DOI 10.1016/j.jbiomech.2009.04.033
   Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142 9612(98)00144 6
   Lohmann CH, 2000, J BONE MINER RES, V15, P1169, DOI 10.1359/jbmr.2000.15.6.1169
   Lossdörfer S, 2004, J BIOMED MATER RES A, V70A, P361, DOI 10.1002/jbm.a.30025
   Lu JX, 1999, J MATER SCI MATER M, V10, P111, DOI 10.1023/A:1008973120918
   Mathur A, 2012, ACTA BIOMATER, V8, P2595, DOI 10.1016/j.actbio.2012.03.025
   Mège RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004
   Melchels FPW, 2010, ACTA BIOMATER, V6, P4208, DOI 10.1016/j.actbio.2010.06.012
   Montell DJ, 2008, SCIENCE, V322, P1502, DOI 10.1126/science.1164073
   Moroni L, 2006, BIOMATERIALS, V27, P974, DOI 10.1016/j.biomaterials.2005.07.023
   Murray J. D., 2003, MATH BIOL, V18, P468
   Nathan AS, 2011, ACTA BIOMATER, V7, P57, DOI 10.1016/j.actbio.2010.08.007
   Nelson CM, 2009, BBA MOL CELL RES, V1793, P903, DOI 10.1016/j.bbamcr.2008.12.014
   Nelson CM, 2005, P NATL ACAD SCI USA, V102, P11594, DOI 10.1073/pnas.0502575102
   Pamula E, 2008, J MATER SCI MATER M, V19, P425, DOI 10.1007/s10856 007 3001 1
   Peyton SR, 2007, CELL BIOCHEM BIOPHYS, V47, P300, DOI 10.1007/s12013 007 0004 y
   Ruiz SA, 2008, STEM CELLS, V26, P2921, DOI 10.1634/stemcells.2008 0432
   Rumpler M, 2008, J R SOC INTERFACE, V5, P1173, DOI 10.1098/rsif.2008.0064
   Sabetrasekh R, 2010, BIOMED MATER, V5, DOI 10.1088/1748 6041/5/1/015003
   Sanz Herrera JA, 2009, BIOMATERIALS, V30, P6674, DOI 10.1016/j.biomaterials.2009.08.053
   Sengers BG, 2009, ANN BIOMED ENG, V37, P1165, DOI 10.1007/s10439 009 9676 3
   Sundelacruz S, 2009, SEMIN CELL DEV BIOL, V20, P646, DOI 10.1016/j.semcdb.2009.03.017
   Tambe D. T., NAT MAT
   Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100
   Tare RS, 2008, MOL CELL ENDOCRINOL, V288, P11, DOI 10.1016/j.mce.2008.02.017
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Tsuruga E, 1997, J BIOCHEM TOKYO, V121, P317
   Wang JHC, 2003, J BIOMECH, V36, P97, DOI 10.1016/S0021 9290(02)00233 6
   Yang SF, 2008, MATER DESIGN, V29, P1802, DOI 10.1016/j.matdes.2008.03.024
   Zeltinger J, 2001, TISSUE ENG, V7, P557, DOI 10.1089/107632701753213183
NR 56
TC 107
Z9 113
U1 0
U2 69
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090 6964
EI 1573 9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD MAY
PY 2013
VL 41
IS 5
BP 917
EP 930
DI 10.1007/s10439 013 0748 z
PG 14
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 124LJ
UT WOS:000317465000005
PM 23404072
DA 2025 08 17
ER

PT J
AU Huang, W
   Shang, WL
   Li, DH
   Wu, WW
   Hou, SX
AF Huang, Wei
   Shang, Wei lin
   Li, De hao
   Wu, Wen wen
   Hou, Shu xun
TI Simvastatin protects osteoblast against
   H2O2 induced oxidative damage via inhibiting the
   upregulation of Nox4
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Simvastatin; Hydrogen peroxide; NADPH oxidase; Nox4
ID BONE MINERAL DENSITY; STRESS; DIFFERENTIATION; EXPRESSION; PROTEINS;
   STATINS; ENZYMES; CELLS; GENE
AB Statins, 3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors, have been used clinically as a cholesterol lowering drug to treat hyperlipidemia. In recent years, accumulating evidence indicates the possible beneficial effect of statins on osteoporosis. However, the underlying molecular mechanism remains to be elucidated. In the present study, we investigated the therapeutic effects of simvastatin on cell viability, apoptosis, and alkaline phosphatase activity in murine osteoblastic MC3T3 E1 cells treated by hydrogen peroxide (H2O2, 100 mu M). It was shown that simvastatin suppressed H2O2 induced oxidative stress and attenuated H2O2 induced cell injury including increasing osteoblastic viability, inhibiting apoptosis, and promoting differentiation. Then, we examined the effects of simvastatin (10( 7) M) on Nox1, Nox2, and Nox4 expressions in osteoblastic cells treated by H2O2 (100 mu M). We found that in MC3T3 E1 cells, H2O2 induced upregulation of Nox4 expression was inhibited by simvastatin, which was restored by farnesyl pyrophosphate (5 mu M) as well as geranylgeranyl pyrophosphate (5 mu M). RNAi approach was used to reduce Nox4 protein levels in osteoblastic cells to explore its biological effects against H2O2 induced oxidative damage. When Nox4 expression was reduced in osteoblastic cells, H2O2 induced cell injury was attenuated markedly. We concluded that simvastatin protected osteoblast against H2O2 induced oxidative damage, at least in part, via inhibiting the upregulation of Nox4.
C1 [Huang, Wei; Shang, Wei lin; Li, De hao; Wu, Wen wen; Hou, Shu xun] PLA, Affiliated Hosp 1, Dept Orthopaed Surg, Gen Hosp, Beijing 100048, Peoples R China.
RP Huang, W (通讯作者)，PLA, Affiliated Hosp 1, Dept Orthopaed Surg, Gen Hosp, 51 Fucheng Rd, Beijing 100048, Peoples R China.
EM huangwei201105@hotmail.com
CR [Anonymous], 2000, NIH Consens Statement, V17, P1
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Bloom HL, 2010, CARDIOL RES PRACT, V2010, DOI 10.4061/2010/253803
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Grcevic D, 2001, CROAT MED J, V42, P384
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Hwang R, 2004, J BIOL CHEM, V279, P21239, DOI 10.1074/jbc.M312771200
   Kakehi T, 2008, SEMIN IMMUNOPATHOL, V30, P301, DOI 10.1007/s00281 008 0122 7
   Kanazawa I, 2009, INTERNAL MED, V48, P1869, DOI 10.2169/internalmedicine.48.2645
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027
   Liberman M, 2008, ARTERIOSCL THROM VAS, V28, P463, DOI 10.1161/ATVBAHA.107.156745
   Lim LS, 2009, AM J PREV MED, V36, P366, DOI 10.1016/j.amepre.2009.01.013
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Manfredini V, 2010, CELL BIOCHEM FUNCT, V28, P360, DOI 10.1002/cbf.1654
   Manolagas SC, 2008, ENDOCRINOLOGY, V149, P3264, DOI 10.1210/en.2008 0402
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Monjo M, 2010, CELL PHYSIOL BIOCHEM, V26, P647, DOI 10.1159/000322332
   Morton DJ, 2001, J BONE MINER RES, V16, P135, DOI 10.1359/jbmr.2001.16.1.135
   Muteliefu G, 2009, NEPHROL DIAL TRANSPL, V24, P2051, DOI 10.1093/ndt/gfn757
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Park YH, 2003, CELL BIOL TOXICOL, V19, P325, DOI 10.1023/B:CBTO.0000004986.51081.c5
   Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537
   Polidori MC, 2001, FREE RADICAL BIO MED, V30, P456, DOI 10.1016/S0891 5849(00)00345 2
   Salido M, 2009, HISTOL HISTOPATHOL, V24, P1275, DOI 10.14670/HH 24.1275
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Wang XD, 2003, ARCH BIOCHEM BIOPHYS, V415, P6, DOI 10.1016/S0003 9861(03)00213 3
   Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081
   Whaley Connell A, 2008, HYPERTENSION, V51, P474, DOI 10.1161/HYPERTENSIONAHA.107.102467
   Yang YM, 2010, INFLAMM RES, V59, P151, DOI 10.1007/s00011 009 0082 y
   Zhong ZM, 2009, CELL PHYSIOL BIOCHEM, V24, P105, DOI 10.1159/000227818
   Zhou MS, 2008, AM J PHYSIOL RENAL, V295, pF53, DOI 10.1152/ajprenal.00041.2008
NR 34
TC 36
Z9 43
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2012
VL 360
IS 1 2
BP 71
EP 77
DI 10.1007/s11010 011 1045 5
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 857MO
UT WOS:000297722800009
PM 21904947
DA 2025 08 17
ER

PT J
AU Li, YC
   Liang, WN
   Li, XH
   Gao, BZ
   Gan, HJ
   Yin, LH
   Shen, JY
   Kang, J
   Ding, SS
   Lin, XJ
   Liao, LH
   Li, CD
AF Li, Yachan
   Liang, Wenna
   Li, Xihai
   Gao, Bizhen
   Gan, Huijuan
   Yin, Lianhua
   Shen, Jianying
   Kang, Jie
   Ding, Shanshan
   Lin, Xuejuan
   Liao, Linghong
   Li, Candong
TI Effect of serum from postmenopausal women with osteoporosis exhibiting
   the Kidney Yang deficiency pattern on bone formation in an hFOB 1.19
   human osteoblastic cell line
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE bone formation; osteoblast; postmenopausal osteoporosis; Kidney Yang
   deficiency pattern
ID TRADITIONAL CHINESE MEDICINE; SEX STEROIDS; DIFFERENTIATION; DENSITY;
   ASSOCIATION; OSTEOCALCIN; EXPRESSION; IGF 1; ZHENG; MASS
AB The aim of the present study was to investigate the underlying mechanism of the Kidney Yang deficiency (KYD) pattern of osteoporosis in postmenopausal women of a certain age range by comparing the effect of serum from postmenopausal women with osteoporosis exhibiting the KYD pattern with that of serum from postmenopausal women without osteoporosis on bone formation in an hFOB 1.19 human osteoblastic cell line. A random selection of 30 female, postmenopausal volunteers aged 60 70 years, including 15 cases without osteoporosis and 15 cases with the KYD pattern of osteoporosis, were enrolled at the Physical Examination Center of the Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine. Venous blood was extracted and the serum was separated. The hFOB 1.19 cells were treated with 10% KYD pattern serum or control serum from postmenopausal women of the same age range without osteoporosis. It was found that the KYD pattern serum significantly decreased the cell viability, activity of alkaline phosphatase and number of calcified nodules, as well as downregulated the expression of osteocalcin and osteoprotegerin (OPG) and upregulated that of receptor activator of nuclear factor kappa B ligand (RANKL) in the hFOB 1.19 cells. In addition, the present results showed that the concentrations of estradiol (E 2), OPG and insulin like factor 1 (IGF 1) in the KYD pattern serum were lower than those in the control serum. In combination, these findings suggest that the downregulation of E 2, OPG and IGF 1 in the KYD pattern serum inhibits the OPG/RANKL system, leading to a decrease in bone formation in the hFOB 1.19 cells. This indicates that the alterations in E 2, OPG and IGF 1 may account for the susceptibility of certain postmenopausal women to the KYD pattern of osteoporosis.
C1 [Li, Yachan; Liang, Wenna; Gao, Bizhen; Gan, Huijuan; Shen, Jianying; Kang, Jie; Ding, Shanshan; Lin, Xuejuan; Liao, Linghong; Li, Candong] Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndromes, Fuzhou 350122, Fujian, Peoples R China.
   [Li, Xihai] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Fujian, Peoples R China.
   [Yin, Lianhua] Fujian Univ Tradit Chinese Med, Affiliated Hosp 2, Fuzhou 350004, Fujian, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine; Fujian University of Traditional Chinese
   Medicine
RP Li, CD (通讯作者)，Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndromes, 1 Qiuyang Rd, Fuzhou 350122, Fujian, Peoples R China.
EM fjzylcd@126.com
RI Li, Xihai/NUQ 4105 2025
FU National Natural Science Foundation of China [81202645, 81230087];
   Natural Science Foundation of Fujian Province [2015J01339]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81202645 and 81230087), and the Natural Science
   Foundation of Fujian Province (grant no. 2015J01339).
CR An S, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P907
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Baek KH, 2006, BONE, V39, P1352, DOI 10.1016/j.bone.2006.06.011
   Botella S, 2013, J CLIN ENDOCR METAB, V98, pE1740, DOI 10.1210/jc.2013 2264
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Coelho MJ, 2000, BIOMATERIALS, V21, P1095, DOI 10.1016/S0142 9612(99)00192 1
   Damiani G, 2007, RIV BIOL BIOL FORUM, V100, P361
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   Gao Z, 2013, CHIN J INTEGR MED, V19, P862, DOI 10.1007/s11655 013 1328 z
   Hayden RS, 2014, BIOMATERIALS, V35, P3794, DOI 10.1016/j.biomaterials.2014.01.034
   Huang S, 2014, BONE, V60, P235, DOI 10.1016/j.bone.2013.12.023
   Jiang M, 2012, J ETHNOPHARMACOL, V140, P634, DOI 10.1016/j.jep.2012.01.033
   Jiang M, 2011, COMPLEMENT THER MED, V19, P115, DOI 10.1016/j.ctim.2011.05.002
   Lagari VS, 2013, J CLIN DENSITOM, V16, P445, DOI 10.1016/j.jocd.2013.08.011
   Leung Ping Chung, 2013, J Tradit Complement Med, V3, P82, DOI 10.4103/2225 4110.110407
   Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet syb:20060032
   Liang WN, 2013, INT J MOL MED, V32, P1069, DOI 10.3892/ijmm.2013.1485
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Lu AP, 2012, J ETHNOPHARMACOL, V141, P549, DOI 10.1016/j.jep.2011.08.045
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Mazière C, 2013, BBA MOL BASIS DIS, V1832, P1756, DOI 10.1016/j.bbadis.2013.05.033
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Mozaffari Khosravi Hassan, 2012, Journal of Dietary Supplements, V9, P262, DOI 10.3109/19390211.2012.726703
   Oh SM, 2008, ARCH PHARM RES, V31, P216, DOI 10.1007/s12272 001 1144 z
   Méndez JP, 2013, MENOPAUSE, V20, P568, DOI [10.1097/gme.0b013e318277694f, 10.1097/GME.0b013e318277694f]
   Papierska L, 2012, ADV MED SCI POLAND, V57, P51, DOI 10.2478/v10039 011 0060 9
   Parker BD, 2010, CALCIFIED TISSUE INT, V86, P185, DOI 10.1007/s00223 010 9332 9
   Reid Ian R, 2014, J Bone Metab, V21, P21, DOI 10.11005/jbm.2014.21.1.21
   Sapir Koren R, 2013, OSTEOPOROSIS INT, V24, P1771, DOI 10.1007/s00198 012 2208 2
   Shoji S, 2010, CALCIFIED TISSUE INT, V87, P181, DOI 10.1007/s00223 010 9384 x
   Stuss M, 2013, J CLIN ENDOCR METAB, V98, pE1007, DOI 10.1210/jc.2012 3885
   Wang P, 2013, OMICS, V17, P451, DOI 10.1089/omi.2012.0057
   Xu Hong, 2004, J Tradit Chin Med, V24, P88
   Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463
   Yasuda H, 2013, WORLD J ORTHOP, V4, P207, DOI 10.5312/wjo.v4.i4.207
   Zhao RQ, 2013, EUR J CLIN INVEST, V43, P1195, DOI 10.1111/eci.12158
NR 36
TC 16
Z9 18
U1 0
U2 31
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2015
VL 10
IS 3
BP 1089
EP 1095
DI 10.3892/etm.2015.2616
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CR2HR
UT WOS:000361148800043
PM 26622445
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Spadari, GS
   Zaniboni, E
   Vedovello, SAS
   Santamaria, MP
   do Amaral, MEC
   dos Santos, GMT
   Esquisatto, MAM
   Mendonca, FAS
   Santamaria, M
AF Spadari, Gisele Sampaio
   Zaniboni, Ewerton
   Scudeler Vedovello, Silvia Amelia
   Santamaria, Mauro Pedrine
   Corezola do Amaral, Maria Esmeria
   Tech dos Santos, Glaucia Maria
   Marretto Esquisatto, Marcelo Augusto
   Sampaio Mendonca, Fernanda Aparecida
   Santamaria , Milton, Jr.
TI Electrical stimulation enhances tissue reorganization during orthodontic
   tooth movement in rats
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Microcurrent application; Low intensity electric current; Orthodontic
   tooth movement
ID ENDOTHELIAL GROWTH FACTOR; MICROCURRENT STIMULATION;
   ELECTROMAGNETIC FIELDS; CYTOKINE EXPRESSION; CARTILAGE REPAIR; BONE;
   MECHANISMS; CELLS; BETA; L.
AB This study evaluated the effects of a low intensity electric current on tissue reorganization during experimental orthodontic tooth movement.
   Thirty two animals were divided into two groups evaluated on days 3 and 7: OTM orthodontic tooth movement and OTM + MC orthodontic tooth movement and microcurrent application (10 mu A/5 min). The samples were processed for histological, morphometric, and Western blotting analysis.
   Analysis of the periodontal ligament (PL) showed a significantly smaller number of granulocytes in the OTM + MC group on day 7.The number of fibroblasts was significantly higher in the OTM + MC group on days 3 and 7. The area of birefringent collagen fibers was more organized in the OTM + MC group on days 3 and 7. The number of blood vessels was significantly higher in the OTM + MC group on day 7. Microcurrent application significantly increased the number of osteoclasts in the compression region of the PL. In the OTM + MC group on day 7 of tooth movement, the expression of TGF beta 1 and VEGF was significantly reduced whereas the expression of bFGF was increased in PL.
   Electrical stimulation enhances tissue responses, reducing the number of granulocytes and increasing the number of fibroblasts, blood vessels, and osteoclasts and modulates the expression of TGF beta 1, VEFG, and bFGF.
   This technique is used in many areas of medicine, but poorly explored in dentistry and orthodontics. This treatment is cheap and non invasive and can be applied by own orthodontist, and it can improve the treatment with a faster and safe tooth movement, without pain.
C1 [Spadari, Gisele Sampaio; Scudeler Vedovello, Silvia Amelia; Santamaria , Milton, Jr.] UNIARARAS, Heminio Ometto Univ Ctr, Grad Program Orthodont, Dr Maximiliano Baruto 500, BR 13607339 Araras, SP, Brazil.
   [Zaniboni, Ewerton] UNIARARAS, Heminio Ometto Univ Ctr, Sch Dent, Dr Maximiliano Baruto 500, BR 13607339 Araras, SP, Brazil.
   [Corezola do Amaral, Maria Esmeria; Tech dos Santos, Glaucia Maria; Marretto Esquisatto, Marcelo Augusto; Sampaio Mendonca, Fernanda Aparecida; Santamaria , Milton, Jr.] UNIARARAS, Heminio Ometto Univ Ctr, Grad Program Biomed Sci, Dr Maximiliano Baruto 500, BR 13607339 Araras, SP, Brazil.
   [Santamaria, Mauro Pedrine] State Univ Sao Paulo, Div Periodont, Coll Dent, UNESP, Ave Engn Francisco Jose Longo 777, BR 12245000 Sao Jose Dos Campos, SP, Brazil.
C3 Centro Universitario Herminio Ometto; Centro Universitario Herminio
   Ometto; Centro Universitario Herminio Ometto; Universidade Estadual
   Paulista
RP Santamaria, M (通讯作者)，UNIARARAS, Heminio Ometto Univ Ctr, Grad Program Orthodont, Dr Maximiliano Baruto 500, BR 13607339 Araras, SP, Brazil.; Santamaria, M (通讯作者)，UNIARARAS, Heminio Ometto Univ Ctr, Grad Program Biomed Sci, Dr Maximiliano Baruto 500, BR 13607339 Araras, SP, Brazil.
EM santamariajr@mailcity.com
RI Santamaria Jr, Milton/B 4843 2013; S. Vedovello, Silvia A./D 4355 2014;
   Corezola do Amaral, Maria Esmeria/E 6263 2012; Esquisatto,
   Marcelo/HNP 1112 2023; do Amaral, Maria/E 6263 2012; Santamaria,
   Mauro/L 7852 2013
OI Santamaria Jr, Milton/0000 0002 3490 5030; Vedovello,
   Silvia/0000 0002 7203 2867; Corezola do Amaral, Maria
   Esmeria/0000 0001 5128 2202; Santamaria, Mauro/0000 0001 9468 0729;
   Marretto Esquisatto, Marcelo Augusto/0000 0002 2588 619X
FU National Council for Scientific and Technological Development  
   CAPES/PNPD [23038.008192/2013 01]; Heminio Ometto University Center
FX This study was funded by the National Council for Scientific and
   Technological Development   CAPES/PNPD (process no.
   23038.008192/2013 01) and Heminio Ometto University Center.
CR Agren Magnus S, 2007, Int J Low Extrem Wounds, V6, P82, DOI 10.1177/1534734607301394
   Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   Asadi MR, 2013, J REHABIL RES DEV, V50, P489, DOI 10.1682/JRRD.2012.04.0074
   BALAKATOUNIS A. B., 2008, EPLASTY, V16, P8
   Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023
   BASSETT CAL, 1993, J CELL BIOCHEM, V51, P387, DOI 10.1002/jcb.2400510402
   Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   Becker R., 1985, THE BODY ELECT
   Bismar H, 1999, BONE, V24, P565, DOI 10.1016/S8756 3282(99)00082 4
   Blumenthal NC, 1997, BIOELECTROMAGNETICS, V18, P264, DOI 10.1002/(SICI)1521 186X(1997)18:3<264::AID BEM10>3.0.CO;2 P
   Castro FCB, 2012, HOMEOPATHY, V101, P147, DOI 10.1016/j.homp.2012.05.006
   Chao PHG, 2000, J BIOMECH ENG T ASME, V122, P261, DOI 10.1115/1.429661
   Cheng K, 1998, BIOELECTROMAGNETICS, V19, P68, DOI 10.1002/(SICI)1521 186X(1998)19:2<68::AID BEM2>3.0.CO;2 1
   CHENG N, 1982, CLIN ORTHOP RELAT R, P264
   Ciccone CD, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 17
   Dahl J, 2007, J ORTHOP RES, V25, P1185, DOI 10.1002/jor.20390
   DAVIDOVITCH Z, 1980, AM J ORTHOD DENTOFAC, V77, P33, DOI 10.1016/0002 9416(80)90222 5
   de Gaspi FOD, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/950347
   DEANGELIS V, 1970, AMER J ORTHODONTICS, V58, P284, DOI 10.1016/0002 9416(70)90092 8
   Derringer KA, 2004, ARCH ORAL BIOL, V49, P631, DOI 10.1016/j.archoralbio.2004.02.011
   Di Domenico M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/201689
   Dominici M., 1902, COMPT REND SOC BIOL, V54, P221
   Fracalossi Ana Carolina Cuzzuol, 2009, Rev. Dent. Press Ortodon. Ortop. Facial, V14, P143, DOI 10.1590/S1415 54192009000100014
   FUJITA M, 1992, J HAND SURG BRIT EUR, V17B, P94, DOI 10.1016/0266 7681(92)90021 S
   Funk RHW, 2006, CELLS TISSUES ORGANS, V182, P59, DOI 10.1159/000093061
   Garlet TP, 2007, EUR J ORAL SCI, V115, P355, DOI 10.1111/j.1600 0722.2007.00469.x
   GORNALL AG, 1949, J BIOL CHEM, V177, P751
   Hashimoto H, 1990, Nihon Kyosei Shika Gakkai Zasshi, V49, P352
   HELLER IJ, 1979, AM J ORTHOD DENTOFAC, V75, P239, DOI 10.1016/0002 9416(79)90272 0
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Feito MJ, 2011, J MATER SCI MATER M, V22, P405, DOI 10.1007/s10856 010 4193 3
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Kim DH, 2008, KOREAN J ORTHOD, V38, P337, DOI 10.4041/kjod.2008.38.5.337
   Kloth Luther C, 2005, Int J Low Extrem Wounds, V4, P23
   Krishnan V, 2009, J DENT RES, V88, P597, DOI 10.1177/0022034509338914
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Lara VS, 2003, J DENT RES, V82, P460, DOI 10.1177/154405910308200611
   Lee BY, 2007, ADV THER, V24, P1202, DOI 10.1007/BF02877766
   Lee H, 2009, EURASIP J ADV SIG PR, DOI 10.1155/2009/384384
   Lin YL, 2006, AM J VET RES, V67, P271, DOI 10.2460/ajvr.67.2.271
   MARTIN RB, 1978, CALC TISS RES, V25, P23, DOI 10.1007/BF02010747
   McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004
   Mendonca F A S, 2005, RGO REV GAUC ODONTOL, V53, P193
   Mendonça JS, 2013, LASER PHYS, V23, DOI 10.1088/1054 660X/23/3/035605
   Migliato KF, 2011, WOUNDS, V23, P111
   Murakami M, 2008, CURR OPIN HEMATOL, V15, P215, DOI 10.1097/MOH.0b013e3282f97d98
   Neves LMG, 2013, LASER PHYS, V23, DOI 10.1088/1054 660X/23/3/035604
   Poltawski L, 2009, PHYS THER REV, V14, P104, DOI 10.1179/174328809X405973
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Ren YJ, 2008, EUR J ORAL SCI, V116, P89, DOI 10.1111/j.1600 0722.2007.00511.x
   Ripamonti U, 2009, J CRANIOFAC SURG, V20, P1544, DOI 10.1097/SCS.0b013e3181b09ca6
   Rossetto A, 2013, MINERVA STOMATOL, V11
   Sako E, 2010, ANGLE ORTHOD, V80, P904, DOI 10.2319/011910 38.1
   Salomão Milene Freitas Lima, 2014, Dental Press J. Orthod., V19, P67, DOI 10.1590/2176 9451.19.3.067 074.oar
   Mendonca FAS, 2009, ACTA CIR BRAS, V24, P150, DOI 10.1590/S0102 86502009000200013
   Santamaria M, 2006, EUR J ORTHODONT, V28, P217, DOI 10.1093/ejo/cji117
   Seifi M, 2013, CELL J, V15, P230
   Souza T. D. de, 2001, Ciencia Rural, V31, P819, DOI 10.1590/S0103 84782001000500013
   Teixeira CC, 2010, J DENT RES, V89, P1135, DOI 10.1177/0022034510373764
   Thakral G, 2013, DIABET FOOT ANKLE, V4, DOI 10.3402/dfa.v4i0.22081
   Van Schepdael A, 2013, BIOMECH MODEL MECHAN, V12, P249, DOI 10.1007/s10237 012 0396 5
   Watson T, 2002, HAEMOPHILIA, V8, P413, DOI 10.1046/j.1365 2516.2002.00613.x
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Wong VW, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/190486
   Zhao LM, 2010, TISSUE ENG PT A, V16, P725, DOI 10.1089/ten.TEA.2009.0495
   Zuzzi DC, 2013, TISSUE CELL, V45, P275, DOI 10.1016/j.tice.2013.02.003
NR 66
TC 32
Z9 49
U1 1
U2 28
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JAN
PY 2017
VL 21
IS 1
BP 111
EP 120
DI 10.1007/s00784 016 1759 6
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EG9OL
UT WOS:000391388300012
PM 26917494
DA 2025 08 17
ER

PT J
AU Kazmi, SMR
   Siddiqui, HK
   Khan, FR
   Khan, SRA
AF Kazmi, Syed Murtaza Raza
   Siddiqui, Humayun Kaleem
   Khan, Farhan Raza
   Khan, Shah Rukh Ali
TI Knowledge, attitudes and practices of physicians and dentists on
   medication related osteonecrosis of the jaw: a cross sectional survey
SO BRITISH DENTAL JOURNAL
LA English
DT Article; Early Access
ID BISPHOSPHONATE RELATED OSTEONECROSIS; SURGEONS POSITION PAPER;
   RISK FACTORS; MULTIPLE MYELOMA; AMERICAN ASSOCIATION; CANCER PATIENTS;
   PREVALENCE; MANAGEMENT; DIAGNOSIS; AWARENESS
AB Background Bisphosphonate medication can cause osteonecrosis of the jaw, which is an uncommon but serious complication. This survey explores the knowledge, attitudes and practices of dentists and physicians regarding medication related osteonecrosis of the jaw (MRONJ).Methods A cross sectional study was conducted among physicians and dentists of Pakistan's secondary and tertiary care hospitals between March and June 2021. Data were collected through a web based questionnaire distributed among the eligible clinicians involved in prescribing bisphosphonates to patients or management of osteonecrosis. SPSS Statistics 23.0 was used for the data analysis. The frequencies and proportions of the descriptive variables were reported.Results A response rate of 29% was achieved. Only six dentists (n = 6/61; 9.8%) were aware that mammalian target of rapamycin inhibitors could lead to osteonecrosis. Only one third (n = 9/26; 34.6%) of physicians informed their patients about the possible side effects of bisphosphonates. The most commonly identified risk factor among them was the duration of the drug (n = 77/87; 88.5%) and the least identified was gender (n = 34/87; 39.0%).Conclusions Our study revealed insufficient knowledge among the respondents about the recently updated established guidelines available on MRONJ. The majority of physicians don't refer patients to dentists before prescribing bisphosphonates and other associated medications.
C1 [Kazmi, Syed Murtaza Raza] Aga Khan Univ, Prosthodont, Dent Sect, Dept Surg, Karachi, Pakistan.
   [Siddiqui, Humayun Kaleem] Aga Khan Univ, Dept Surg, Dent Sect, Oral & Maxillofacial Surg, Karachi, Pakistan.
   [Khan, Farhan Raza] Aga Khan Univ, Dept Surg, Dent Sect, Operat Dent & Endodont, Karachi, Pakistan.
   [Khan, Shah Rukh Ali] Aga Khan Univ, Dept Surg, Dent Sect, Karachi, Pakistan.
C3 Aga Khan University; Aga Khan University; Aga Khan University; Aga Khan
   University
RP Kazmi, SMR (通讯作者)，Aga Khan Univ, Prosthodont, Dent Sect, Dept Surg, Karachi, Pakistan.
EM syed.murtaza@aku.edu
RI ; Kazmi, Syed Murtaza Raza/IST 1947 2023; Khan, Farhan/W 5461 2019
OI Kazmi, Syed Murtaza Raza/0000 0002 6934 6945; 
CR Al Maweri Sadeq Ali, 2020, Eur J Dent, V14, P144, DOI 10.1055/s 0040 1701542
   Alhussain A, 2015, J ORAL MAXIL SURG, V73, P1095, DOI 10.1016/j.joms.2014.12.040
   Allegra A, 2019, TOHOKU J EXP MED, V248, P27, DOI 10.1620/tjem.248.27
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bonacina R, 2011, J CAN DENT ASSOC, V77, P1
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Campisi G, 2022, J ORAL MAXIL SURG, V80, P1723, DOI 10.1016/j.joms.2022.07.149
   de Lima PB, 2015, SUPPORT CARE CANCER, V23, P3421, DOI 10.1007/s00520 015 2689 6
   El Osta L, 2015, SUPPORT CARE CANCER, V23, P2825, DOI 10.1007/s00520 015 2649 1
   Fehm T, 2009, GYNECOL ONCOL, V112, P605, DOI 10.1016/j.ygyno.2008.11.029
   Fosnacht K, 2017, REV HIGH EDUC, V40, P245, DOI 10.1353/rhe.2017.0003
   Irshad Abeer, 2010, J Ayub Med Coll Abbottabad, V22, P126
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317, DOI [10.1002/jlac.18651330307, DOI 10.1002/JLAC.18651330307]
   Migliorati CA, 2010, SUPPORT CARE CANCER, V18, P1099, DOI 10.1007/s00520 010 0882 1
   Miranda Silva W, 2020, SUPPORT CARE CANCER, V28, P5397, DOI 10.1007/s00520 020 05374 4
   Nazir M A, 2015, PAK ORAL DENT J, V35, P466
   Pimolbutr K, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8071579
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Riaz H, 2015, J PHARM HEALTH SERV, V6, P111, DOI 10.1111/jphs.12091
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero Salvatore L, 2008, Dent Clin North Am, V52, P111, DOI 10.1016/j.cden.2007.09.002
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Salesi N, 2006, ANTICANCER RES, V26, P3111
   Scottish Dental Clinical Effectiveness Programme, 2017, OR HLTH MAN PAT RISK
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P61, DOI 10.14219/jada.archive.2009.0019
   TA161 NI, 2008, ALENDRONATE ETIDRONA
   Tanna N, 2017, BRIT DENT J, V222, P121, DOI 10.1038/sj.bdj.2017.79
   Tsao C, 2013, J ORAL MAXIL SURG, V71, P1360, DOI 10.1016/j.joms.2013.02.016
   Vandone AM, 2012, ANN ONCOL, V23, P193, DOI 10.1093/annonc/mdr039
   Vinitzky Brener I, 2017, MED ORAL PATOL ORAL, V22, pE84, DOI 10.4317/medoral.21433
   Walter C, 2008, EUR UROL, V54, P1066, DOI 10.1016/j.eururo.2008.06.070
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 40
TC 1
Z9 1
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0007 0610
EI 1476 5373
J9 BRIT DENT J
JI Br. Dent. J.
PD 2023 MAY 24
PY 2023
DI 10.1038/s41415 023 5852 3
EA MAY 2023
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA H2BN1
UT WOS:000994070700001
PM 37225843
DA 2025 08 17
ER

PT J
AU Reim, NS
   Breig, B
   Stahr, K
   Eberle, J
   Hoeflich', A
   Wolf, E
   Erben, RG
AF Reim, Natascha S.
   Breig, Bianca
   Stahr, Kerstin
   Eberle, Johannes
   Hoeflich', Andreas
   Wolf, Eckhard
   Erben, Reinhold G.
TI Cortical bone loss in androgen deficient aged male rats is mainly caused
   by increased endocortical bone remodeling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoporosis; cortical bone; histomorphometry; testosterone; BMD;
   orchiectomy
ID IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; OSTEOBLAST LIKE CELLS; SEX
   STEROIDS; OVARIECTOMIZED RATS; MINERAL METABOLISM; INVOLUTIONAL
   OSTEOPOROSIS; GROWTH HORMONE; F344 RATS; MALE MICE; DENSITY
AB Introduction: Hypogonadism is considered to be one of the major risk factors for osteoporosis in men. Here, we sequentially studied the effects of androgen deficiency on cortical bone in aged orchiectomy (ORX) rats.
   Materials and Methods: One hundred seventy 13 mo old male Fischer 344 rats were either ORX or shamoperated. After in vivo fluorochrome labeling, groups of 8 15 SHAM and ORX rats each were killed at 2 wk and 1, 2, 3, 4 6, and 9 mo after surgery. To examine the effects of testosterone replacement therapy, 9 mo old ORX rats were supplemented with testosterone undecanoate at a weekly dose of 6 mg/kg for 4 mo. Cortical bone changes in the tibial shaft were monitored by pQCT analysis and by bone histomorphometry.
   Results: SHAM rats did not show age related bone loss at the tibial diaphysis. pQCT analysis and bone histomorphometry showed cortical bone osteopenia in ORX rats, beginning from 2 mo after surgery until the end of the study. Androgen deficiency induced a sustained decrease in periosteal bone formation during the first 4 mo after ORX. However, although periosteal expansion of the tibial shaft tended to be slower in ORX rats compared with SHAM controls, the reduction in total cross sectional area in ORX animals reached statistical significance only at 4 mo after surgery. The major mechanism for cortical bone loss in aged ORX rats was a progressive expansion of the marrow cavity, which was associated with an initial increase in endocortical eroded perimeter at 1 and 2 mo after surgery, followed by a sustained increase in endocortical bone formation until the end of the study. All these changes were prevented in aged ORX rats receiving testosterone supplementation in an insulin like growth factor system independent fashion.
   Conclusions: We conclude that androgen deficiency induced cortical bone loss in aged, nongrowing rats is mainly caused by augmented endocortical bone remodeling.
C1 [Reim, Natascha S.; Breig, Bianca; Stahr, Kerstin; Eberle, Johannes; Erben, Reinhold G.] Univ Munich, Inst Physiol Physiol Chem & Anim Nutr, Munich, Germany.
   [Hoeflich', Andreas; Wolf, Eckhard] Univ Munich, Inst Mol Anim Breeding, Munich, Germany.
C3 University of Munich; University of Munich
RP Reim, NS (通讯作者)，Univ Munich, Inst Physiol Physiol Chem & Anim Nutr, Marchioninistr 15, Munich, Germany.
RI ; Erben, Reinhold/AAG 8007 2020; Wolf, Elmar/AAY 8493 2021
OI Wolf, Eckhard/0000 0002 0430 9510; Hoeflich,
   Andreas/0000 0003 2018 2836; Erben, Reinhold/0000 0003 0801 6958
CR ARISAKA O, 1995, METABOLISM, V44, P419, DOI 10.1016/0026 0495(95)90046 2
   Banu J, 2002, BONE, V30, P125, DOI 10.1016/S8756 3282(01)00636 6
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756 3282(98)00104 5
   Bouillon R, 2004, J CLIN ENDOCR METAB, V89, P6025, DOI 10.1210/jc.2004 0602
   COLVARD DS, 1989, P NATL ACAD SCI USA, V86, P854, DOI 10.1073/pnas.86.3.854
   Daniell HW, 1997, J UROLOGY, V157, P439, DOI 10.1016/S0022 5347(01)65165 6
   DANIELSEN CC, 1992, CALCIFIED TISSUE INT, V50, P169, DOI 10.1007/BF00298796
   DEVOGELAER JP, 1992, MATURITAS, V15, P17, DOI 10.1016/0378 5122(92)90057 B
   Diamond T, 1998, CANCER, V83, P1561, DOI 10.1002/(SICI)1097 0142(19981015)83:8<1561::AID CNCR11>3.0.CO;2 Z
   Duan YB, 2003, J BONE MINER RES, V18, P1766, DOI 10.1359/jbmr.2003.18.10.1766
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   Erben RG, 2000, J BONE MINER RES, V15, P1085, DOI 10.1359/jbmr.2000.15.6.1085
   Erben RG, 2003, ENDOCRINOLOGY, V144, P40, DOI 10.1210/en.2002 220513
   FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003 4819 106 3
   FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem 69 4 776
   FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904
   GILSANZ V, 1988, AM J PHYSIOL, V255, pE416, DOI 10.1152/ajpendo.1988.255.4.E416
   GUNNESS M, 1995, J BONE MINER RES, V10, P1735
   Hoeflich A, 2004, GEN COMP ENDOCR, V136, P248, DOI 10.1016/j.ygcen.2003.12.019
   IBBOTSON KJ, 1992, J BONE MINER RES, V7, P425
   Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358
   Ke H. Z., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P215
   LAURITZEN DB, 1993, J BONE MINER RES, V8, P871
   MUNOZTORRES M, 1995, CALCIFIED TISSUE INT, V57, P94, DOI 10.1007/BF00298426
   ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87
   Oxlund BS, 2003, BONE, V32, P69, DOI 10.1016/S8756 3282(02)00916 X
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Petit MA, 2004, BONE, V35, P750, DOI 10.1016/j.bone.2004.05.008
   Prakasam G, 1999, BONE, V24, P491, DOI 10.1016/S8756 3282(99)00018 6
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002 9343(83)90860 4
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330
   Schenk RK., 1984, METHODS CALCIFIED TI, P1
   Seeman E, 2001, Rev Endocr Metab Disord, V2, P45
   Seeman E, 2003, NEW ENGL J MED, V349, P320, DOI 10.1056/NEJMp038101
   Shozu M, 1998, MOL CELL ENDOCRINOL, V139, P117, DOI 10.1016/S0303 7207(98)00069 0
   Smithson G, 1998, J IMMUNOL, V161, P27
   SMITHSON G, 1995, J IMMUNOL, V155, P3409
   STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523
   TUREK FW, 1979, JNCI J NATL CANCER I, V63, P969
   TURNER RT, 1990, J ORTHOP RES, V8, P612, DOI 10.1002/jor.1100080418
   TURNER RT, 1987, J BONE MINER RES, V2, P115
   UESUGI Y, 1992, ANAT REC, V234, P541, DOI 10.1002/ar.1092340409
   UZAWA T, 1995, BONE, V16, P477
   Vandenput L, 2004, J BONE MINER RES, V19, P1462, DOI 10.1359/JBMR.040505
   VANDERSCHUEREN D, 1993, CALCIFIED TISSUE INT, V53, P342, DOI 10.1007/BF01351841
   VANDERSCHUEREN D, 1992, ENDOCRINOLOGY, V130, P2906, DOI 10.1210/en.130.5.2906
   VANDERSCHUEREN D, 1993, J BONE MINER RES, V8, P801
   VANDERSCHUEREN D, 1992, J BONE MINER RES, V7, P1407
   Venken K, 2007, J BONE MINER RES, V22, P72, DOI 10.1359/JBMR.060911
   Viselli SM, 1997, CELL IMMUNOL, V182, P99, DOI 10.1006/cimm.1997.1227
   Weber K, 2004, BONE, V35, P704, DOI 10.1016/j.bone.2004.04.011
   Weinstein RS, 1997, ENDOCRINOLOGY, V138, P4013, DOI 10.1210/en.138.9.4013
   WEISSBERGER AJ, 1993, J CLIN ENDOCR METAB, V76, P1407, DOI 10.1210/jc.76.6.1407
   WINK CS, 1980, CALCIFIED TISSUE INT, V32, P77, DOI 10.1007/BF02408524
NR 57
TC 48
Z9 53
U1 0
U2 0
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2008
VL 23
IS 5
BP 694
EP 704
DI 10.1359/JBMR.080202
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 291NC
UT WOS:000255203100012
PM 18433303
OA Bronze
DA 2025 08 17
ER

PT J
AU Nakaya, Y
   Takaya, M
   Hinatsu, Y
   Alama, T
   Kusamori, K
   Katsumi, H
   Sakane, T
   Yamamoto, A
AF Nakaya, Yuka
   Takaya, Mayu
   Hinatsu, Yuta
   Alama, Tammam
   Kusamori, Kosuke
   Katsumi, Hidemasa
   Sakane, Toshiyasu
   Yamamoto, Akira
TI Enhanced Oral Delivery of Bisphosphonate by Novel Absorption Enhancers:
   Improvement of Intestinal Absorption of Alendronate by N Acyl
   Amino Acids and N Acyl Taurates and Their Absorption Enhancing
   Mechanisms
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE intestinal absorption; absorption enhancer; tight junction; Caco 2
   cells; membrane transport
ID NITROGEN CONTAINING BISPHOSPHONATE; POORLY ABSORBABLE DRUGS;
   BRUSH BORDER MEMBRANE; POSTMENOPAUSAL OSTEOPOROSIS; MUCOSAL TOXICITY;
   TIGHT JUNCTIONS; RATS; PERMEABILITY; SAFETY; INSULIN
AB Bisphosphonates (BPs) are carbon substituted pyrophosphate analogs that exhibit a high affinity to hydroxyapatite and specifically inhibit bone resorption. Alendronate sodium (sodium 4 amino 1 hydroxybutylidene 1,1 bisphosphonate trihydrate) is a typical BP compound in clinical use. BPs have very low bioavailability, typically <1% after their oral administration, and their intestinal absorption is further reduced by co administered drugs or food. In this study, we examined the effects of N acyl amino acids and N acyl taurates on the small intestinal absorption of alendronate. All N acyl amino acids and N acyl taurates increased the small intestinal absorption of alendronate, especially 1% (wt/vol) sodium palmitoyl sarcosinate (PN), which elicited a 14 fold increase. In addition, the absorption enhancing effects of these enhancers were reversible and they may not cause continuous and irreversible membrane toxicity in the rat small intestine. Furthermore, we examined the absorption promoting mechanisms of PN and found that it increased the membrane fluidity of the lipid bilayers. In addition, it was found that PN may open the tight junctions by reducing the expression level of claudin 4, which is a major tight junction protein. These findings indicate that these enhancers are useful for promoting the intestinal absorption of alendronate. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Nakaya, Yuka; Takaya, Mayu; Hinatsu, Yuta; Alama, Tammam; Kusamori, Kosuke; Katsumi, Hidemasa; Sakane, Toshiyasu; Yamamoto, Akira] Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan.
C3 Kyoto Pharmaceutical University
RP Yamamoto, A (通讯作者)，Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan.
EM yamamoto@mb.kyoto phu.ac.jp
OI Kusamori, Kosuke/0000 0003 2065 6122; Alama, Tammam/0000 0002 4294 4988
CR Alama T, 2016, INT J PHARMACEUT, V499, P58, DOI 10.1016/j.ijpharm.2015.12.043
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   CASSIDY MM, 1967, J CELL BIOL, V32, P685, DOI 10.1083/jcb.32.3.685
   Del Vecchio G, 2012, MOL PHARMACEUT, V9, P2523, DOI 10.1021/mp3001414
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gao Y, 2008, INT J PHARM, V359, P70, DOI 10.1016/j.ijpharm.2008.03.016
   Gao Y, 2008, INT J PHARMACEUT, V354, P126, DOI 10.1016/j.ijpharm.2007.11.061
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   González Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079 6107(02)00037 8
   GORDON GS, 1985, P NATL ACAD SCI USA, V82, P7419, DOI 10.1073/pnas.82.21.7419
   Graham DY, 1999, ALIMENT PHARM THER, V13, P515
   Graham DY, 2002, DIGEST DIS SCI, V47, P1665, DOI 10.1023/A:1016495221567
   Han HK, 2012, EUR J PHARM SCI, V46, P500, DOI 10.1016/j.ejps.2012.04.002
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   ISHIZAWA T, 1987, J PHARM PHARMACOL, V39, P892, DOI 10.1111/j.2042 7158.1987.tb03124.x
   JANNER M, 1991, CALCIFIED TISSUE INT, V49, P280, DOI 10.1007/BF02556218
   KAJII H, 1986, J PHARM SCI US, V75, P475, DOI 10.1002/jps.2600750511
   KAJII H, 1988, J PHARM SCI US, V77, P390, DOI 10.1002/jps.2600770506
   Katsumi H, 2012, J PHARM SCI US, V101, P3230, DOI 10.1002/jps.23136
   Katsumi H, 2011, J PHARM SCI US, V100, P3783, DOI 10.1002/jps.22620
   Katsumi H, 2010, INT J PHARMACEUT, V400, P124, DOI 10.1016/j.ijpharm.2010.08.041
   Kim MH, 2016, J PHYS THER SCI, V28, P725, DOI 10.1589/jpts.28.725
   Koga K, 2006, EUR J PHARM BIOPHARM, V64, P82, DOI 10.1016/j.ejpb.2006.03.011
   Kusamori K, 2010, J BONE MINER RES, V25, P2306, DOI 10.1002/jbmr.147
   Lee KJ, 2004, INT J PHARMACEUT, V285, P43, DOI 10.1016/j.ijpharm.2004.07.022
   Lin YL, 2011, J CONTROL RELEASE, V149, P21, DOI 10.1016/j.jconrel.2010.02.017
   Ma TY, 1999, AM J PHYSIOL GASTR L, V276, pG965, DOI 10.1152/ajpgi.1999.276.4.G965
   Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143
   Meng JA, 2011, J PHARM PHARMACOL, V63, P400, DOI 10.1111/j.2042 7158.2010.01229.x
   Naniwa T, 2008, INTERNAL MED, V47, P2083, DOI 10.2169/internalmedicine.47.1457
   Pazianas M, 2010, THER CLIN RISK MANAG, V6, P325
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Prabhu R, 2001, ANAL BIOCHEM, V289, P157, DOI 10.1006/abio.2000.4908
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Satoh H, 2013, J PHARMACOL EXP THER, V344, P189, DOI 10.1124/jpet.112.199182
   SIEGEL IA, 1985, TOXICOL LETT, V26, P153, DOI 10.1016/0378 4274(85)90160 2
   Uchiyama T, 1999, J PHARM PHARMACOL, V51, P1241, DOI 10.1211/0022357991776976
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Vazquez CM, 1996, BIOSCIENCE REP, V16, P217, DOI 10.1007/BF01207336
   Wong JA, 2004, BIOMED CHROMATOGR, V18, P98, DOI 10.1002/bmc.298
   Yamamoto A, 1996, J PHARM PHARMACOL, V48, P1285, DOI 10.1111/j.2042 7158.1996.tb03937.x
   YAMAMOTO A, 1994, PHARMACEUT RES, V11, P1496, DOI 10.1023/A:1018968611962
   Yamamoto A, 2001, J PHARMACOL EXP THER, V296, P84
NR 44
TC 17
Z9 17
U1 1
U2 37
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD DEC
PY 2016
VL 105
IS 12
BP 3680
EP 3690
DI 10.1016/j.xphs.2016.09.004
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA ED7FO
UT WOS:000389027800023
PM 27771051
DA 2025 08 17
ER

PT J
AU Zhou, P
   Kasuga, T
AF Zhou, P.
   Kasuga, T.
TI Dissolution behavior of Mg/Si doped vaterite particles in biodegradable
   polymer composites
SO EXPRESS POLYMER LETTERS
LA English
DT Article
DE polymer composites; biodegradable polymers; calcium carbonate; ion
   release; biomaterials
ID MARROW STROMAL CELLS; BIOACTIVE GLASS; DRUG DELIVERY; BONE MARROW;
   IN VITRO; OSTEOGENIC SUPPLEMENTS; CALCIUM CARBONATE; FETAL OSTEOBLASTS;
   SOFT TISSUE; MAGNESIUM
AB Tuning the ion release ability of bioactive materials is one of the key factors for bone repair and regeneration. Calcium (Ca2+), magnesium (Mg2+), and silicate ions were reported to enhance the activity of bone forming cells. In this work, the dissolution behavior of magnesium and silicate doped calcium carbonate (vaterite), denoted as MgSiV, embedded in three kinds of biodegradable polymers in Tris buffer solutions (TBS) were examined to find an effective ion releasing system. Poly(L lactic acid) (PLLA) and poly(D, L lactide co glycolide) (PDLLG, lactide: glycolide = 75: 25 or 50: 50; denoted as PDLLG75 and PDLLG50, respectively) were chosen as the matrix polymers. The Mg2+ and silicate ions were released rapidly within 3 d of soaking. Continuous release of Ca2+ ions from the composites induced the formation of aragonite on the film surfaces in the presence of Mg2+ ions. The amount of ions released from the MgSiV PLLA composite was lesser than those released from the PDLLG based composites. The fast degradation of PDLLG50 induced a decrease in the pH of TBS. The MgSiV PDLLG75 composite exhibited a rapid release of Mg2+ ions, a continuous release of Ca2+ ions, and a controlled release of silicate ions with no reduction in the pH of TBS. Such release phenomena are caused by the formation of pathways for ion release, originating from the water uptake ability of PDLLG75.
C1 [Zhou, P.; Kasuga, T.] Nagoya Inst Technol, Dept Frontier Mat, Showa Ku, Gokiso Cho, Nagoya, Aichi 4668555, Japan.
   [Kasuga, T.] Nagoya Inst Technol, Div Adv Ceram, Showa Ku, Gokiso Cho, Nagoya, Aichi 4668555, Japan.
C3 Nagoya Institute of Technology; Nagoya Institute of Technology
RP Kasuga, T (通讯作者)，Nagoya Inst Technol, Dept Frontier Mat, Showa Ku, Gokiso Cho, Nagoya, Aichi 4668555, Japan.; Kasuga, T (通讯作者)，Nagoya Inst Technol, Div Adv Ceram, Showa Ku, Gokiso Cho, Nagoya, Aichi 4668555, Japan.
EM kasuga.toshihiro@nitech.ac.jp
FU JSPS Program for Advancing Strategic International Networks
FX The present work was conducted in the framework of the Academic Unit
   Cooperation Program between Nagoya Institute of Technology (NITech) and
   Imperial College, London (ICL). The authors are indebted to Dr. Anthony
   L. B. Macon (NITech and ICL) for his valuable input. The present work
   was supported in part by the JSPS Program for Advancing Strategic
   International Networks to Accelerate the Circulation of Talented
   Researchers.
CR Alexis F, 2005, POLYM INT, V54, P36, DOI 10.1002/pi.1697
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Anderson JM, 2012, ADV DRUG DELIVER REV, V64, P72, DOI 10.1016/j.addr.2012.09.004
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Carmagnola I, 2015, INT J POLYM MATER PO, V64, P90, DOI 10.1080/00914037.2014.886247
   Damadzadeh B, 2010, J MATER SCI MATER M, V21, P2523, DOI 10.1007/s10856 010 4110 9
   De Choudens Sánchez V, 2009, J SEDIMENT RES, V79, P363, DOI 10.2110/jsr.2009.043
   Fan RR, 2014, INT J NANOMED, V9, P615, DOI 10.2147/IJN.S52689
   FernandezDiaz L, 1996, J SEDIMENT RES, V66, P482
   Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Kalliola S, 2017, COLLOID SURFACE B, V153, P229, DOI 10.1016/j.colsurfb.2017.02.025
   Kontoyannis CG, 2000, ANALYST, V125, P251, DOI 10.1039/a908609i
   Kudryavtseva VL, 2017, COLLOID SURFACE B, V157, P481, DOI 10.1016/j.colsurfb.2017.06.011
   Loste E, 2003, J CRYST GROWTH, V254, P206, DOI 10.1016/S0022 0248(03)01153 9
   Ma PX, 2004, MATER TODAY, V7, P30, DOI 10.1016/S1369 7021(04)00233 0
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Mastrogiacomo M, 2007, BIOMATERIALS, V28, P1376, DOI 10.1016/j.biomaterials.2006.10.001
   Mei L, 2016, EXPERT OPIN DRUG DEL, V13, P741, DOI 10.1517/17425247.2016.1142525
   Nakamura J, 2013, J MATER CHEM B, V1, P4446, DOI 10.1039/c3tb20589d
   Obata A, 2017, J MATER SCI, V52, P8942, DOI 10.1007/s10853 017 1057 y
   OTA Y, 1995, J AM CERAM SOC, V78, P1983, DOI 10.1111/j.1151 2916.1995.tb08924.x
   Tsigkou O, 2007, J BIOMED MATER RES A, V80A, P837, DOI 10.1002/jbm.a.30910
   Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019
   Vergnol G, 2016, J BIOMED MATER RES B, V104, P180, DOI 10.1002/jbm.b.33364
   Verrier S, 2004, BIOMATERIALS, V25, P3013, DOI 10.1016/j.biomaterials.2003.09.081
   Wu XS, 2004, ARTIF CELL BLOOD SUB, V32, P575, DOI 10.1081/BIO 200039635
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Yamada S, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00195
   Yamada S, 2014, J CERAM SOC JPN, V122, P1010, DOI 10.2109/jcersj2.122.1010
   Yang HY, 2017, INT J NANOMED, V12, P839, DOI 10.2147/IJN.S128792
   Yoshizawa S, 2014, ACTA BIOMATER, V10, P2834, DOI 10.1016/j.actbio.2014.02.002
   Zhou P, 2017, RSC ADV, V7, P3992, DOI 10.1039/c6ra25645g
   Zreiqat H, 2002, J BIOMED MATER RES, V62, P175, DOI 10.1002/jbm.10270
NR 36
TC 2
Z9 2
U1 0
U2 23
PU BUDAPEST UNIV TECHNOL & ECON
PI BUDAPEST
PA DEPT POLYMER ENG, MUEGYETEM RKP 3, BUDAPEST, H 1111, HUNGARY
SN 1788 618X
J9 EXPRESS POLYM LETT
JI Express Polym. Lett.
PD FEB
PY 2018
VL 12
IS 2
BP 171
EP 179
DI 10.3144/expresspolymlett.2018.15
PG 9
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA FR6CO
UT WOS:000419153200007
OA gold
DA 2025 08 17
ER

PT J
AU Gray, RS
   Wilm, TP
   Smith, J
   Bagnat, M
   Dale, RM
   Topczewski, J
   Johnson, SL
   Solnica Krezel, L
AF Gray, Ryan S.
   Wilm, Thomas P.
   Smith, Jeff
   Bagnat, Michel
   Dale, Rodney M.
   Topczewski, Jacek
   Johnson, Stephen L.
   Solnica Krezel, Lilianna
TI Loss of col8a1a function during zebrafish embryogenesis results
   in congenital vertebral malformations
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Notochord; Vertebral malformations; Collagen; Osteoblast
ID NOTOCHORD DEVELOPMENT; IDIOPATHIC SCOLIOSIS; LINKAGE MAP; DANIO RERIO;
   GENE; MINERALIZATION; MORPHOGENESIS; SEGMENTATION; ROLES;
   DIFFERENTIATION
AB Congenital vertebral malformations (CVM) occur in 1 in 1000 live births and in many cases can cause spinal deformities, such as scoliosis, and result in disability and distress of affected individuals. Many severe forms of the disease, such as spondylocostal dystostosis, are recessive monogenic traits affecting somitogenesis, however the etiologies of the majority of CVM cases remain undetermined. Here we demonstrate that morphological defects of the notochord in zebrafish can generate congenital type spine defects. We characterize three recessive zebrafish leviathan/col8a1a mutant alleles ((m531), (vu41), (vu105)) that disrupt collagen type VIII alpha1a (col8a1a), and cause folding of the embryonic notochord and consequently adult vertebral column malformations. Furthermore, we provide evidence that a transient loss of col8a1a function or inhibition of Lysyl oxidases with drugs during embryogenesis was sufficient to generate vertebral fusions and scoliosis in the adult spine. Using periodic imaging of individual zebrafish, we correlate focal notochord defects of the embryo with vertebral malformations (VM) in the adult. Finally, we show that bends and kinks in the notochord can lead to aberrant apposition of osteoblasts normally confined to well segmented areas of the developing vertebral bodies. Our results afford a novel mechanism for the formation of VM, independent of defects of somitogenesis, resulting from aberrant bone deposition at regions of misshapen notochord tissue. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Gray, Ryan S.; Solnica Krezel, Lilianna] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Wilm, Thomas P.; Smith, Jeff; Solnica Krezel, Lilianna] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Bagnat, Michel] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Dale, Rodney M.; Topczewski, Jacek] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA.
   [Johnson, Stephen L.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Vanderbilt University; Duke University;
   Northwestern University; Feinberg School of Medicine; Washington
   University (WUSTL)
RP Gray, RS (通讯作者)，Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
EM grayr@wustl.edu
RI Gray, Ryan/G 2187 2010; Gray, Ryan/L 3923 2019; Smith, Jeff/C 3484 2012;
   Topczewski, Jacek/D 5895 2016
OI Gray, Ryan/0000 0001 9668 6497; Smith, Jeffrey/0000 0001 8424 910X;
   Bagnat, Michel/0000 0002 3829 0168; Dale, Rodney/0000 0003 4255 4741;
   Topczewski, Jacek/0000 0001 6023 9556
FU Children's Discovery Institute [MD F 201I 143, NRSA F32, NIMAS NIH
   1F32AR063001 01]; Washington University Musculoskeletal Research Center
   [NIH P30 AR057235]
FX The authors would like to thank the Zebrafish Consortium for excellent
   care of fish stocks as well as members of the Solnica Krezel and
   Johnson's groups for helpful discussions during the evolution of this
   work. We are very thankful to Stephen Canter for technical assistance.
   We are grateful to Drs. Diane Sepich, Margot Kossman Williams, Jonathan
   Gitlin, Philip Giampietro and Christina Gurnett for critical commentary
   on this manuscript. This work is dedicated to Howard Gray and the 06010
   for inspiration and good humor. This work was funded by a Children's
   Discovery Institute fellowship grant (MD F 201I 143) and an NRSA F32
   (NIMAS NIH 1F32AR063001 01) to RSG and a Pilot and Feasibility from the
   Washington University Musculoskeletal Research Center (NIH P30 AR057235)
   to LSK.
CR ADAMS DS, 1990, DEVELOPMENT, V110, P115
   Bensimon Brito A, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 28
   Bradley KM, 2011, G3 GENES GENOM GENET, V1, P3, DOI 10.1534/g3.111.000190
   Bradley KM, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 4 r55
   Bruggeman BJ, 2012, DEV DYNAM, V241, P675, DOI 10.1002/dvdy.23750
   Christiansen HE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008481
   Dale RM, 2011, DEV BIOL, V357, P518, DOI 10.1016/j.ydbio.2011.06.020
   DeLaurier A, 2010, GENESIS, V48, P505, DOI 10.1002/dvg.20639
   Distel M, 2009, P NATL ACAD SCI USA, V106, P13365, DOI 10.1073/pnas.0903060106
   Eckalbar W.L., 2012, REV DEV BIOL, V1, P401
   Ellis K, 2013, J CELL BIOL, V200, P667, DOI 10.1083/jcb.201212095
   Fleming A, 2004, DEVELOPMENT, V131, P873, DOI 10.1242/dev.00952
   Gansner JM, 2008, DEV DYNAM, V237, P2844, DOI 10.1002/dvdy.21705
   Gansner JM, 2007, DEV BIOL, V307, P202, DOI 10.1016/j.ydbio.2007.04.029
   Gansner JM, 2008, DEV DYNAM, V237, P3715, DOI 10.1002/dvdy.21779
   Giampietro PF, 2009, ANN NY ACAD SCI, V1151, P38, DOI 10.1111/j.1749 6632.2008.03452.x
   Glickman NS, 2003, DEVELOPMENT, V130, P873, DOI 10.1242/dev.00314
   Grotmol S, 2003, ANAT EMBRYOL, V207, P263, DOI 10.1007/s00429 003 0349 y
   Grotmol S, 2006, J ANAT, V209, P339, DOI 10.1111/j.1469 7580.2006.00618.x
   Hawkins TA, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 42
   Hedequist D, 2007, J PEDIATR ORTHOPED, V27, P106, DOI 10.1097/BPO.0b013e31802b4993
   Higgins DG, 1996, METHOD ENZYMOL, V266, P383
   Jülich D, 2009, DEVELOPMENT, V136, P2913, DOI 10.1242/dev.038935
   Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Kimmel CB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009475
   Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149
   Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498 338
   Koehl MAR, 2000, AM ZOOL, V40, P28, DOI 10.1668/0003 1569(2000)040[0028:MDOFWH]2.0.CO;2
   Madsen EC, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000261
   Mellgren EM, 2004, DEV GENES EVOL, V214, P493, DOI 10.1007/s00427 004 0428 y
   Mendelsohn BA, 2006, CELL METAB, V4, P155, DOI 10.1016/j.cmet.2006.05.001
   Morin Kensicki EM, 2002, DEVELOPMENT, V129, P3851
   Odenthal J, 1996, DEVELOPMENT, V123, P103
   Pagnon Minot A, 2008, DEV BIOL, V316, P21, DOI 10.1016/j.ydbio.2007.12.033
   Parichy DM, 2009, DEV DYNAM, V238, P2975, DOI 10.1002/dvdy.22113
   Parsons MJ, 2002, DEVELOPMENT, V129, P3137
   Pourquié O, 2011, CELL, V145, P650, DOI 10.1016/j.cell.2011.05.011
   Renn J., 2013, DEV BIOL
   Ricard Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978
   Scott A, 2005, CURR TOP DEV BIOL, V65, P229
   Sepich DS, 2005, DEV DYNAM, V234, P279, DOI 10.1002/dvdy.20507
   Sparrow DB, 2012, CELL, V149, P295, DOI 10.1016/j.cell.2012.02.054
   Stemple DL, 1996, DEVELOPMENT, V123, P117
   STERN CD, 1987, DEVELOPMENT, V99, P261
   Stickney HL, 2000, DEV DYNAM, V219, P287
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   VERBOUT A J, 1976, Acta Biotheoretica, V25, P219, DOI 10.1007/BF00046818
   Wang S., 2013, J ANAT
   Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140 6736(08)60658 3
   WESTERFIELD M, 1993, ZEBRAFISH BOOK GUIDE
   Wilson L, 2005, DEV BIOL, V282, P1, DOI 10.1016/j.ydbio.2005.02.027
   Wise CA, 2008, CURR GENOMICS, V9, P51, DOI 10.2174/138920208783884874
   Yamamoto M, 2010, DEVELOPMENT, V137, P2527, DOI 10.1242/dev.051011
NR 54
TC 77
Z9 99
U1 0
U2 21
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0012 1606
EI 1095 564X
J9 DEV BIOL
JI Dev. Biol.
PD FEB 1
PY 2014
VL 386
IS 1
BP 72
EP 85
DI 10.1016/j.ydbio.2013.11.028
PG 14
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA 297LX
UT WOS:000330258000008
PM 24333517
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Karami, N
   Razeghi, M
AF Karami, Nazanin
   Razeghi, Mehdi
TI Structural Evaluation of the Effect of Bone Quality on the Mechanical
   Interaction between Dental Implants and Bone
SO SHOCK AND VIBRATION
LA English
DT Article
ID FINITE ELEMENT; PRIMARY STABILITY; STRESS ANALYSIS; BEHAVIOR
AB When one or more teeth are lost for any reason such as accident, caries, and gum disease, they should be replaced with dentures. Researchers discovered that titanium successfully bonds to bone because of the development of osteoblasts on its rough surface. However, the success of dental implants depends on biological, mechanical, and chemical factors. Each of these factors is itself a function of different parameters that, any changes in these factors affect the mechanism of transfering from the prosthesis to the implant and from implant to bone. The role determinant in the success of implant therapy is the function of the geometry and mechanical properties of the implant, jaw and bone implant joint. Now, due to the increasing use of dental implants, various companies are constantly launching their new products and, as a result, express many benefits of these products, which in most cases are based on their claims. It is not a long term study, and therefore it is not possible to make an accurate judgment on the designs, macroscopic and microscopic properties, and benefits offered, due to the lack of accurate and practical comparisons between systems. It will not be possible to prove the effectiveness of each of them. Therefore, understanding the design method and its philosophy, along with familiarity with the types of systems available in the market, is a determining factor in the clinical success of dental implant treatment. The presence of threads prevents overload on the surface of the cortical bone and reduces this load by up to 36%. Reducing the thread pitch contributes to the stability of the implant, and increasing the depth of the thread stabilizes patients with poor bone quality. The behavior of the bone and its relation to the implant with regard to applied loads with a maximum inclination angle of 15 degrees have been evaluated by evaluating the tension in the bony areas of the cortex and trabecular bone.
C1 [Karami, Nazanin; Razeghi, Mehdi] Islamic Azad Univ, Fac Med Engn, Dept Med Engn, Res Sci Branch, Tehran, Iran.
C3 Islamic Azad University
RP Karami, N (通讯作者)，Islamic Azad Univ, Fac Med Engn, Dept Med Engn, Res Sci Branch, Tehran, Iran.
EM nazanin.karami@srbiau.ac.ir; razeghi.ac@gmail.com
CR Asim M., 2021, PREDICTION RUTTING F, V2, P212
   Bicudo P, 2016, PROCEDIA STRUCT INTE, V1, P26, DOI 10.1016/j.prostr.2016.02.005
   Chrcanovic BR, 2017, INT J PROSTHODONT, V30, P219, DOI 10.11607/ijp.5142
   da Cunha AC, 2015, AM J ORTHOD DENTOFAC, V147, P45, DOI 10.1016/j.ajodo.2014.09.011
   Demenko V, 2014, COMPUT METHOD BIOMEC, V17, P1751, DOI 10.1080/10255842.2013.766173
   El Anwar Mohamed I, 2017, Eur J Dent, V11, P186, DOI 10.4103/1305 7456.208432
   Eskenati A.R., 2021, Journal of Southwest Jiaotong University, V56, DOI [10.35741/issn.0258 2724.56.4.69, DOI 10.35741/ISSN.0258 2724.56.5.49]
   Faverani LP, 2014, MAT SCI ENG C MATER, V37, P164, DOI 10.1016/j.msec.2014.01.013
   Geramizadeh M, 2018, DENT MED PROBL, V55, P17, DOI 10.17219/dmp/85077
   Gurler G, 2017, SAUDI MED J, V38, P1207, DOI 10.15537/smj.2017.12.21462
   Hariri Ardebili MA, 2022, INT J GEOMECH, V22, DOI 10.1061/(ASCE)GM.1943 5622.07022006
   Jeong MA, 2015, IMPLANT DENT, V24, P263, DOI 10.1097/ID.0000000000000239
   Khorshid HEA, 2014, IMPLANT DENT, V23, P125, DOI 10.1097/ID.0000000000000027
   Ko YC, 2017, CLIN IMPLANT DENT R, V19, P440, DOI 10.1111/cid.12468
   Kuroshima S, 2017, J PROSTHODONT RES, V61, P353, DOI 10.1016/j.jpor.2017.05.006
   Kuroshima S, 2017, ACTA BIOMATER, V48, P433, DOI 10.1016/j.actbio.2016.11.021
   Li J, 2017, J DENT RES, V96, P822, DOI 10.1177/0022034517700131
   Linetskiy I, 2017, COMPUT BIOL MED, V91, P318, DOI 10.1016/j.compbiomed.2017.09.016
   Luo CQ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3503152
   Marcián P, 2018, COMPUT BIOL MED, V96, P157, DOI 10.1016/j.compbiomed.2018.03.012
   Munjal Sumit, 2015, Contemp Clin Dent, V6, P40, DOI 10.4103/0976 237X.149290
   Ntintakis I., 2020, HighTech and Innovation Journal, V1, P161, DOI [10.28991/HIJ 2020 01 04 03, DOI 10.28991/HIJ 2020 01 04 03]
   Priya MP, 2022, CIV ENG J TEHRAN, V8, P472, DOI 10.28991/CEJ 2022 08 03 05
   Romanos GE, 2018, CLIN ORAL IMPLAN RES, V29, P649, DOI 10.1111/clr.12792
   Romanos GE, 2014, CLIN IMPLANT DENT R, V16, P166, DOI 10.1111/j.1708 8208.2012.00470.x
   Rupp F, 2018, DENT MATER, V34, P40, DOI 10.1016/j.dental.2017.09.007
   Sun W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100424
   Tavafzadeh SS, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/938782
   Uto Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189893
   Voumard B, 2019, J MECH BEHAV BIOMED, V92, P24, DOI 10.1016/j.jmbbm.2018.12.035
   Wang SH, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10090710
   Yeler D.Y., 2016, CUMHUR DENT J, V19, P73
   Zia Shamami D, 2014, J BIOMATER TISS ENG, V4, P632, DOI 10.1166/jbt.2014.1212
NR 33
TC 1
Z9 1
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1070 9622
EI 1875 9203
J9 SHOCK VIB
JI Shock Vib.
PD AUG 31
PY 2022
VL 2022
AR 1667838
DI 10.1155/2022/1667838
PG 9
WC Acoustics; Engineering, Mechanical; Mechanics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Engineering; Mechanics
GA 4L5NJ
UT WOS:000852676800001
OA gold
DA 2025 08 17
ER

PT J
AU Ma, B
   Li, XT
   Zhang, Q
   Wu, D
   Wang, GJ
   Jiye, A
   Sun, JG
   Li, J
   Liu, YH
   Wang, YL
   Ying, HJ
AF Ma, Bo
   Li, Xiaotian
   Zhang, Qi
   Wu, Di
   Wang, Guangji
   Jiye, A.
   Sun, Jianguo
   Li, Jing
   Liu, Yinhui
   Wang, Yonglu
   Ying, Hanjie
TI Metabonomic profiling in studying anti osteoporosis effects of strontium
   fructose 1,6 diphosphate on estrogen deficiency induced osteoporosis in
   rats by GC/TOF MS
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Metabonomic; GC/TOF MS; Osteoporosis; Strontium fructose 1;
   6 diphosphate (FDP Sr)
ID PROSTAGLANDIN E 2 PGE(2); PREVENTS BONE LOSS; OSTEOBLAST
   DIFFERENTIATION; FATTY ACIDS; RANELATE; MASS; METABOLOMICS; RESORPTION;
   FRACTURE; RECEPTOR
AB A novel strontium salt compound strontium fructose 1, 6 diphosphate (FDP Sr) has been proved to have highly effective for bone loss via dual effects of stimulating bone formation and suppressing bone absorption. In the present study, metabolomic approach was used to identify and study potential biomarkers associated with the effect and safety of FDP Sr. The metabolomic profiles of bone loss induced by estrogen deficiency in a rat model was described to attain a system level map of the shift on the metabolic response in plasma using GC/TOF MS, after FDP Sr was orally administered at the dose of 110 mg/kg/day for the prevention and 220 mg/kg/day for the treatment. Meanwhile, bone turnover biomarkers and bone mineral density were investigated to identify the specific changes of potential anti osteoporosis effects of FDP Sr. The differences in metabolic profiles between osteoporosis rats and FDP Sr treated rats were well observed by the partial least squares discriminant analysis (PLS DA) to the MS spectra. Some metabolites including homocysteine, arachidonic acid, alanine, and hydroxyproline, which significantly changed during osteoporosis progression could be effectively reversed after FDP Sr therapy. Of course some metabolites such as uric acid, glyceric acid, octadecadienoic acid, docosahexaenoic acid, oleic acid, and hexadecanoic acid were not found to reverse significantly after FDP Sr administration. These results delineated the FDP Sr effects related metabolic alterations in the bone loss rats, suggesting that metabonomic analysis could provide helpful information on the new potential biomarkers relating to the mechanism of anti osteoporosis action and side effects of FDP Sr against estrogen deficiency induced bone loss. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Ma, Bo; Zhang, Qi; Li, Jing; Liu, Yinhui; Wang, Yonglu] Nanjing Univ Technol, Sch Pharmaceut Sci, Nanjing 210009, Jiangsu, Peoples R China.
   [Li, Xiaotian] Zhengzhou Univ, Sch Pharm, Zhengzhou 450001, Peoples R China.
   [Wu, Di] Univ Penn, Childrens Hosp Philadelphia, Div Clin Pharmacol & Therapeut,Inst Translat Med, Lab Syst Biol,Kinet Modeling & Simulat KMAS Core, Philadelphia, PA 19104 USA.
   [Wang, Guangji; Jiye, A.; Sun, Jianguo] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Jiangsu, Peoples R China.
   [Ying, Hanjie] Nanjing Univ Technol, Sch Life Sci & Pharmaceut Engn, Nanjing 210009, Jiangsu, Peoples R China.
C3 Nanjing Tech University; Zhengzhou University; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   China Pharmaceutical University; Nanjing Tech University
RP Zhang, Q (通讯作者)，Nanjing Univ Technol, Sch Pharmaceut Sci, Nanjing 210009, Jiangsu, Peoples R China.
EM nancyzhang03@hotmail.com; wudi@email.chop.edu
RI ; Sun, Jianguo/AFQ 7455 2022
OI Ying, Hanjie/0000 0002 4061 0001; Sun, Jianguo/0000 0003 4417 7644
FU program for Changjiang Scholars and Innovative Research Team in
   University [IRT1066]; China Postdoctoral Science Foundation
   [2013M5302520]; "333 High Level Talent Cultivation Project" of Jiangsu
   Province
FX The study was supported by a grant from a program for Changjiang
   Scholars and Innovative Research Team in University (Grant no. IRT1066),
   the China Postdoctoral Science Foundation funded Project (2013M5302520)
   and the "333 High Level Talent Cultivation Project" of Jiangsu Province
   (2012).
CR AKAMINE T, 1992, BONE, V13, P11, DOI 10.1016/8756 3282(92)90356 2
   Bayhan I, 2009, RHEUMATOL INT, V29, P263, DOI 10.1007/s00296 008 0693 6
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Dimitrova KR, 2002, CARDIOVASC RES, V53, P577, DOI 10.1016/S0008 6363(01)00462 X
   Durand M, 2008, J BONE MINER RES, V23, P1097, DOI 10.1359/JBMR.080228
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Griffin JL, 2003, CURR OPIN CHEM BIOL, V7, P648, DOI 10.1016/j.cbpa.2003.08.008
   Gullberg J, 2005, PLOS ONE, V77, P8086
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Iwamoto J, 2006, CALCIFIED TISSUE INT, V79, P318, DOI 10.1007/s00223 006 0092 5
   JEE WSS, 1992, BONE, V13, P153, DOI 10.1016/8756 3282(92)90005 H
   Jonsson P, 2005, ANAL CHEM, V77, P5635, DOI 10.1021/ac050601e
   Kanatani M, 2002, J CELL PHYSIOL, V190, P306, DOI 10.1002/jcp.10067
   KATZ IA, 1992, J BONE MINER RES, V7, P1191
   Koek MM, 2011, METABOLOMICS, V7, P1, DOI 10.1007/s11306 010 0219 6
   Lu YH, 2008, RAPID COMMUN MASS SP, V22, P2882, DOI 10.1002/rcm.3670
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Ma B, 2011, ACTA PHARMACOL SIN, V32, P270, DOI 10.1038/aps.2010.196
   Ma B, 2011, J INORG BIOCHEM, V105, P563, DOI 10.1016/j.jinorgbio.2011.01.001
   McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Meves H, 2008, BRIT J PHARMACOL, V155, P4, DOI 10.1038/bjp.2008.216
   Mo A, 2002, BONE, V31, P402, DOI 10.1016/S8756 3282(02)00835 9
   Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a
   Qi W, 2011, BIOL TRACE ELEM RES, V143, P302, DOI 10.1007/s12011 010 8829 4
   Qian S, 2010, PLOS ONE, V5
   Ramautar R, 2011, ELECTROPHORESIS, V32, P52, DOI 10.1002/elps.201000378
   Ramirez Yañez GO, 2004, BONE, V35, P1361, DOI 10.1016/j.bone.2004.08.006
   Requirand P, 2000, CLIN NUTR, V19, P271, DOI 10.1054/clnu.2000.0107
   Sacco SM, 2009, MENOPAUSE, V16, P545, DOI 10.1097/gme.0b013e31818fc00a
   van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546
   Watkins BA, 2000, J NUTR, V130, P2274, DOI 10.1093/jn/130.9.2274
   Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014
   Weinreb M, 2006, PROSTAG LEUKOTR ESS, V75, P81, DOI 10.1016/j.plefa.2006.06.004
   Weiss LA, 2005, AM J CLIN NUTR, V81, P934, DOI 10.1093/ajcn/81.4.934
   Wilson ID, 2005, J CHROMATOGR B, V817, P67, DOI 10.1016/j.jchromb.2004.07.045
   Yan B, 2009, J APPL PHYSIOL, V106, P531, DOI 10.1152/japplphysiol.90816.2008
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
NR 41
TC 29
Z9 33
U1 0
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2013
VL 718
IS 1 3
BP 524
EP 532
DI 10.1016/j.ejphar.2013.06.030
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 242HM
UT WOS:000326229700065
PM 23872379
DA 2025 08 17
ER

PT J
AU Keibl, C
   Fügl, A
   Zanoni, G
   Tangl, S
   Wolbank, S
   Redl, H
   van Griensven, M
AF Keibl, Claudia
   Fuegl, Alexander
   Zanoni, Gerald
   Tangl, Stefan
   Wolbank, Susanne
   Redl, Heinz
   van Griensven, Martijn
TI Human adipose derived stem cells reduce callus volume upon BMP 2
   administration in bone regeneration
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Bone regeneration; Drill hole model; Tissue Engineering; Human adipose
   derived stem cells; BMP 2; Fibrin; Micro Computer Tomography
ID TISSUE ENGINEERED BONE; MORPHOGENETIC PROTEINS; CLINICAL APPLICATIONS;
   DEFECTS; THERAPY; OSTEOGENESIS; FRACTURES; REPAIR
AB Introduction: The demand for new therapeutic approaches to treat bone defects and fractures is increasing in trauma surgery and orthopaedics because the number of patients with degenerative diseases is continuously growing. "Tissue Engineering'' offers promising new technologies that combine the three components   cells, growth factors and matrix. Efforts are targeted at improving and accelerating recovery, especially for long bone fractures, and reducing the risk of delayed bone healing or pseudoarthrosis. Adult human adipose derived stem cells (ASC) can differentiate into osteoblasts in an osteogenic surrounding. Bone morphogenetic protein 2 (BMP 2) accelerates and initiates this differentiation. Fibrin, a matrix that promotes wound healing, is a promising carrier for ASCs and BMP 2.
   Materials and methods: In this study, a 2 mm transcortical drill hole in the femur of male rats served as a small non critical size defect model for fracture simulation. In vivo bone healing was investigated upon administration of the growth factor BMP 2 embedded with ASCs in a locally applied fibrin matrix. Groups with the components alone were also investigated. After 2 and 4 weeks, mu CT and histology were performed to determine the bone and callus volume.
   Results and discussion: After only a short period of time (2 and 4 weeks), this animal model discloses comparative information about the osteogenetic potential and bone regeneration with little effort (no osteosynthesis necessary). The most significant result found in this model is that the combination of ASCs and BMP 2 in a fibrin matrix significantly reduces callus formation after 2 weeks compared to BMP 2 alone. BMP 2 alone significantly increased callus formation. ASCs embedded alone in the fibrin matrix did not lead to increased bone regeneration.
   Conclusion: Transplantation of ASC modulated the callus induction by BMP 2 to a normal volume. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Keibl, Claudia; Zanoni, Gerald; Wolbank, Susanne; Redl, Heinz; van Griensven, Martijn] AUVA Res Ctr, Ludwig Boltzmann Inst Expt & Clin Traumatol, A 1200 Vienna, Austria.
   [Fuegl, Alexander; Tangl, Stefan] Med Univ Vienna, Dept Oral Surg, A 1090 Vienna, Austria.
   [Keibl, Claudia; Fuegl, Alexander; Zanoni, Gerald; Tangl, Stefan; Wolbank, Susanne; Redl, Heinz; van Griensven, Martijn] Baxter Innovat GmbH, A 1220 Vienna, Austria.
C3 Ludwig Boltzmann Institute; Ludwig Boltzmann Institute for Experimental
   & Clinical Traumatology; Medical University of Vienna; Baxter
   International Inc; Baxter Innovations GmbH
RP Keibl, C (通讯作者)，AUVA Res Ctr, Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A 1200 Vienna, Austria.
EM claudia.keibl@trauma.lbg.ac.at
RI ; van Griensven, Martijn/F 5808 2012; Redl, Heinz/AAD 8157 2019; Tangl,
   Stefan/AAS 6367 2020
OI Wolbank, Susanne/0000 0002 1244 5854; van Griensven,
   Martijn/0000 0001 5104 9881; Tangl, Stefan/0000 0002 9023 4745; 
CR Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539
   BERGEL S, 1907, DEUT MED WOCHENSCHR, V9, P663
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Cancedda R, 2003, STEM CELLS, V21, P610, DOI 10.1634/stemcells.21 5 610
   CARLORI GM, 2009, INJURY S3, V40, pS67
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Dragoo JL, 2003, J ORTHOP RES, V21, P622, DOI 10.1016/S0736 0266(02)00238 3
   Dragoo JL, 2005, PLAST RECONSTR SURG, V115, P1665, DOI 10.1097/01.PRS.0000161459.90856.AB
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82, DOI 10.2106/00004623 200300003 00014
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS160
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Giannoudis P, 2007, INJURY, V38, pS81, DOI 10.1016/j.injury.2007.02.013
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(08)70003 2
   Giannoudis PV, 2007, INJURY, V38, pS1, DOI 10.1016/j.injury.2007.02.004
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Hasharoni A, 2005, J NEUROSURG SPINE, V3, P47, DOI 10.3171/spi.2005.3.1.0047
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Kalpakcioglu BB, 2008, J BONE JOINT SURG AM, V90A, P68, DOI 10.2106/JBJS.G.01506
   LACZKO J, 1975, MIKROSKOPIE, V31, P1
   Lane JM, 2005, J ORTHOP TRAUMA, V19, pS17, DOI 10.1097/00005131 200511101 00006
   Lendeckel S, 2004, J CRANIO MAXILL SURG, V32, P370, DOI 10.1016/j.jcms.2004.06.002
   Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006
   McIntosh KR, 2009, TISSUE ENG PT A, V15, P2677, DOI 10.1089/ten.TEA.2008.0566
   MINUTH WW, 2002, TISSUE ENG
   MOHYEDDIN BM, 2007, IRAN J IMMUNOL, V4, P50, DOI DOI 10.1016/J.JNEUROIM.2010.07.013
   Mohyeddin Bonab M, 2007, ARCH IRAN MED, V10, P467
   Niemeyer P, 2010, BIOMATERIALS, V31, P3572, DOI 10.1016/j.biomaterials.2010.01.085
   Patterson TE, 2008, J BONE JOINT SURG AM, V90A, P111, DOI 10.2106/JBJS.G.01572
   Pereira AC, 2007, ARQ BRAS CARDIOL, V88, P104, DOI 10.1590/S0066 782X2007000100017
   Peterson B, 2005, TISSUE ENG, V11, P120, DOI 10.1089/ten.2005.11.120
   Pountos I, 2005, INJURY, V36, P8, DOI 10.1016/j.injury.2005.07.028
   Pountos I, 2007, INJURY, V38, pS23, DOI 10.1016/S0020 1383(08)70006 8
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Redl H, 1987, Rev Laryngol Otol Rhinol (Bord), V108, P9
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Rueger JM, 1998, ORTHOPADE, V27, P72, DOI 10.1007/PL00003481
   Runyan CM, 2010, PLAST RECONSTR SURG, V125, P1372, DOI 10.1097/PRS.0b013e3181d7032f
   Schmidmaier G, 2007, INJURY, V38, pS35, DOI 10.1016/S0020 1383(08)70007 X
   Schmoekel HG, 2005, BIOTECHNOL BIOENG, V89, P253, DOI 10.1002/bit.20168
   SEELICH T, 1979, DTSCH Z MUND KIEFER, V3, P22
   Shoji T, 2010, LAB INVEST, V90, P637, DOI 10.1038/labinvest.2010.39
   Stutzle H, 1998, ORTHOPADE, V27, P118, DOI 10.1007/PL00003477
   Tasso R, 2010, BIOMATERIALS, V31, P2121, DOI 10.1016/j.biomaterials.2009.11.064
   Termaat MF, 2005, J BONE JOINT SURG AM, V87A, P1367, DOI 10.2106/JBJS.D.02585
   Tortelli F, 2010, BIOMATERIALS, V31, P242, DOI 10.1016/j.biomaterials.2009.09.038
   Westerhuis RJ, 2005, INJURY, V36, P1405, DOI 10.1016/j.injury.2005.02.047
   Wolbank S, 2007, TISSUE ENG, V13, P1173, DOI 10.1089/ten.2006.0313
   Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 51
TC 33
Z9 40
U1 0
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD AUG
PY 2011
VL 42
IS 8
BP 814
EP 820
DI 10.1016/j.injury.2011.03.007
PG 7
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 786DS
UT WOS:000292284100015
PM 21457972
DA 2025 08 17
ER

PT J
AU Ralston, MR
   Stevenson, KS
   Mark, PB
   Geddes, CC
AF Ralston, Maximilian R.
   Stevenson, Karen S.
   Mark, Patrick B.
   Geddes, Colin C.
TI Clinical factors associated with severe hypophosphataemia after kidney
   transplant
SO BMC NEPHROLOGY
LA English
DT Article
DE Kidney transplantation; Hypophosphataemia; Hyperparathyroidism; Graft
   function
ID GROWTH FACTOR 23; POSTTRANSPLANT HYPOPHOSPHATEMIA;
   RENAL TRANSPLANTATION; MINERAL METABOLISM; PHOSPHATE REABSORPTION;
   PARATHYROID HORMONE; CALCIUM METABOLISM; GRAFT FAILURE; DONOR AGE; FGF23
AB Background The mechanism by which hypophosphataemia develops following kidney transplantation remains debated, and limited research is available regarding risk factors. This study aimed to assess the association between recipient and donor variables, and the severity of post transplantation hypophosphataemia. Methods We performed a single centre retrospective observational study. We assessed the association between demographic, clinical and biochemical variables and the development of hypophosphataemia. We used linear regression analysis to assess association between these variables and phosphate nadir. Results 87.6% of patients developed hypophosphataemia. Patients developing hypophosphataemia were younger, had a shorter time on renal replacement therapy, were less likely to have had a parathyroidectomy or to experience delayed graft function, were more likely to have received a living donor transplant, from a younger donor. They had higher pre transplantation calcium levels, and lower alkaline phosphatase levels. Receipt of a living donor transplant, lower donor age, not having had a parathyroidectomy, receiving a transplant during the era of tacrolimus based immunosuppression, not having delayed graft function, higher pre transplantation calcium, and higher pre transplantation phosphate were associated with lower phosphate nadir by multiple linear regression. Conclusions This analysis demonstrates an association between variables relating to better graft function and hypophosphataemia. The links with biochemical measures of mineral bone disease remain less clear.
C1 [Ralston, Maximilian R.; Stevenson, Karen S.; Mark, Patrick B.; Geddes, Colin C.] Queen Elizabeth Univ Hosp, Glasgow Renal & Transplant Unit, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.
   [Mark, Patrick B.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
C3 Queen Elizabeth University Hospital (QEUH); University of Glasgow
RP Ralston, MR (通讯作者)，Queen Elizabeth Univ Hosp, Glasgow Renal & Transplant Unit, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.
EM Maximilian.Ralston@ggc.scot.nhs.uk
RI ; Ralston, Maximilian/MIP 6964 2025; Mark, Patrick/N 5536 2014
OI Stevenson, Karen/0000 0002 2170 511X; Mark, Patrick/0000 0003 3387 2123
CR Baia LC, 2015, NAT REV NEPHROL, V11, P656, DOI 10.1038/nrneph.2015.153
   Barros X, 2012, TRANSPLANTATION, V94, P830, DOI 10.1097/TP.0b013e318264fc08
   Benavente D, 2012, EXP CLIN TRANSPLANT, V10, P119, DOI 10.6002/ect.2011.0110
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bhan I, 2006, KIDNEY INT, V70, P1486, DOI 10.1038/sj.ki.5001788
   Bonewald LF, 2013, PEDIATR NEPHROL, V28, P563, DOI 10.1007/s00467 012 2309 3
   Brunelli SM, 2007, J AM SOC NEPHROL, V18, P1999, DOI 10.1681/ASN.2007020143
   Canalejo R, 2010, J AM SOC NEPHROL, V21, P1125, DOI 10.1681/ASN.2009040427
   Chevarria J, 2021, CLIN KIDNEY J, V14, P1106, DOI 10.1093/ckj/sfaa061
   Connolly GM, 2009, TRANSPLANTATION, V87, P1040, DOI 10.1097/TP.0b013e31819cd122
   Dhayat NA, 2016, KIDNEY INT, V90, P648, DOI 10.1016/j.kint.2016.04.024
   Doyle Maire E, 2008, Curr Osteoporos Rep, V6, P134, DOI 10.1007/s11914 008 0024 6
   Ekberg H, 2007, NEW ENGL J MED, V357, P2562, DOI 10.1056/NEJMoa067411
   Evenepoel P, 2007, AM J TRANSPLANT, V7, P1193, DOI 10.1111/j.1600 6143.2007.01753.x
   Evenepoel P, 2004, NEPHROL DIAL TRANSPL, V19, P1281, DOI 10.1093/ndt/gfh128
   Evenepoel P, 2008, CLIN J AM SOC NEPHRO, V3, P1829, DOI 10.2215/CJN.01310308
   Evenepoel P, 2013, SEMIN NEPHROL, V33, P191, DOI 10.1016/j.semnephrol.2012.12.019
   Falkiewicz K, 2003, TRANSPL P, V35, P2213, DOI 10.1016/S0041 1345(03)00765 6
   Ghanekar H, 2006, CURR OPIN NEPHROL HY, V15, P97, DOI 10.1097/01.mnh.0000203187.49890.cc
   Green J, 2001, KIDNEY INT, V60, P1182, DOI 10.1046/j.1523 1755.2001.0600031182.x
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Hamdy NAT, 2007, ENDOCRIN METAB CLIN, V36, P923, DOI 10.1016/j.ecl.2007.07.009
   Han SY, 2012, TRANSPL P, V44, P657, DOI 10.1016/j.transproceed.2011.11.046
   HIGGINS RM, 1990, NEPHROL DIAL TRANSPL, V5, P62, DOI 10.1093/ndt/5.1.62
   Huber L, 2013, TRANSPL INT, V26, pE94, DOI 10.1111/tri.12145
   Jeon HJ, 2017, CLIN J AM SOC NEPHRO, V12, P653, DOI 10.2215/CJN.07090716
   Kawarazaki H, 2011, NEPHROL DIAL TRANSPL, V26, P2691, DOI 10.1093/ndt/gfq777
   Kim YJ, 2012, TRANSPL P, V44, P651, DOI 10.1016/j.transproceed.2011.12.050
   Levi M, 2001, KIDNEY INT, V59, P2377
   Lindeman R.H., 1980, Introduction to Bivariate and Multivariate Analysis
   Mandal AK, 2003, TRANSPLANTATION, V75, P494, DOI 10.1097/01.TP.0000048381.48473.D1
   Manghat P, 2014, ANN CLIN BIOCHEM, V51, P631, DOI 10.1177/0004563214521399
   Meier Kriesche HU, 2002, J AM GERIATR SOC, V50, P14, DOI 10.1046/j.1532 5415.2002.50002.x
   Merhi B, 2017, AM J KIDNEY DIS, V70, P377, DOI 10.1053/j.ajkd.2017.04.014
   Miles CD, 2020, CLIN J AM SOC NEPHRO, V15, P412, DOI 10.2215/CJN.09470819
   Miyamoto KI, 2007, AM J NEPHROL, V27, P503, DOI 10.1159/000107069
   Moreso F, 1999, NEPHROL DIAL TRANSPL, V14, P930, DOI 10.1093/ndt/14.4.930
   Nakai K, 2019, CLIN EXP NEPHROL, V23, P1161, DOI 10.1007/s10157 019 01756 z
   Negri AL, 2009, NEFROLOGIA, V29, P196, DOI 10.3265/Nefrologia.2009.29.3.5290.en.full
   Pochineni V, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00261
   Prasad N, 2016, CLIN KIDNEY J, V9, P669, DOI 10.1093/ckj/sfw065
   Ramezani M, 2007, TRANSPL P, V39, P1033, DOI 10.1016/j.transproceed.2007.03.025
   Resende L, 2009, TRANSPL P, V41, P794, DOI 10.1016/j.transproceed.2009.01.064
   Rodríguez Ortiz ME, 2019, SEMIN DIALYSIS, V32, P444, DOI 10.1111/sdi.12772
   ROSENBAUM RW, 1981, KIDNEY INT, V19, P568, DOI 10.1038/ki.1981.54
   Fructuoso AIS, 2012, TRANSPL P, V44, P2551, DOI 10.1016/j.transproceed.2012.09.070
   Schwarz C, 2001, NEPHROL DIAL TRANSPL, V16, P378, DOI 10.1093/ndt/16.2.378
   Seeherunvong W, 2011, PEDIATR TRANSPLANT, V15, P37, DOI 10.1111/j.1399 3046.2010.01405.x
   Seifi S, 2003, TRANSPL P, V35, P2645, DOI 10.1016/j.transproceed.2003.08.056
   Shimada T., 2009, J BONE MINER RES, V19, P435
   Silver J, 2010, PEDIATR NEPHROL, V25, P2241, DOI 10.1007/s00467 010 1565 3
   Taweesedt Pahnwat T, 2015, World J Transplant, V5, P231, DOI 10.5500/wjt.v5.i4.231
   Tomida K, 2012, BONE, V51, P729, DOI 10.1016/j.bone.2012.06.027
   Torres A, 2002, J AM SOC NEPHROL, V13, P551, DOI 10.1681/ASN.V132551
   Trombetti A, 2011, EUR J ENDOCRINOL, V164, P839, DOI 10.1530/EJE 10 1150
   van Londen M, 2017, CLIN J AM SOC NEPHRO, V12, P1301, DOI 10.2215/CJN.10270916
   Wolf M, 2016, TRANSPLANTATION, V100, P184, DOI 10.1097/TP.0000000000000823
NR 57
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD DEC 9
PY 2021
VL 22
IS 1
AR 407
DI 10.1186/s12882 021 02624 3
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA XM0RV
UT WOS:000728545400001
PM 34886802
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU He, WG
   Ji, X
   Song, CC
   Song, SS
   Liu, LX
AF He, Wenguang
   Ji, Xiao
   Song, Congcong
   Song, Shanshan
   Liu, Lixia
TI Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory
   myofibroblastic tumor with a rare GCC2 ALK fusion
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE inflammatory myofibroblastic tumors; GCC2 ALK; ensartinib; case report;
   partial response
ID CRIZOTINIB; LANDSCAPE; PATIENT
AB BackgroundInflammatory myofibroblastic tumors (IMTs) are rare with distal metastasis. Approximately 50% of patients have anaplastic lymphoma kinase (ALK) fusion. Patients with non small cell lung cancer with ALK fusion are usually highly sensitive to ALK tyrosine kinase inhibitors (TKIs), but the application of TKI in IMT needs further exploration. Case presentationA 66 year old man was diagnosed with IMT with bone metastasis, cT4N0M1c, IVB stage. Immunohistochemistry results showed that he was ALK positive, and next generation sequencing revealed GCC2 ALK fusion in the IMT. The patient was administered first line ensartinib 225 mg QD, which targeted GCC2 ALK fusion, and denosumab 120 mg Q4w anti bone metastasis therapy. The patient developed a grade III rash, and the ensartinib dose was reduced to 125 mg QD; consequently, he achieved a partial response (PR), and the side effects significantly reduced. Computed tomography results showed that the patient maintained PR after 7 months of follow up, and he was still in a state of progression free survival without obvious side effects after 11 months of follow up. ConclusionTo our knowledge, this is the first case of the GCC2 ALK fusion type in IMT and the first report showing that the use of ensartinib as a TKI in IMT has clinical benefits.
C1 [He, Wenguang; Ji, Xiao; Liu, Lixia] Shanxi Med Univ, Shanxi Prov Canc Hosp, Shanxi Hosp,Affiliated Canc Hosp, Tradit Chinese Med Dept,Canc Hosp Affiliated,Chine, Taiyuan, Peoples R China.
   [Song, Congcong; Song, Shanshan] YuceBio Technol Co Ltd, Dept Translat Med, Shenzhen, Peoples R China.
C3 Shanxi Medical University
RP Liu, LX (通讯作者)，Shanxi Med Univ, Shanxi Prov Canc Hosp, Shanxi Hosp,Affiliated Canc Hosp, Tradit Chinese Med Dept,Canc Hosp Affiliated,Chine, Taiyuan, Peoples R China.
EM liulixia8402@163.com
CR Christopoulos P, 2019, INT J CANCER, V144, P190, DOI 10.1002/ijc.31893
   du Tertre MC, 2019, MOL CANCER THER, V18, P1628, DOI 10.1158/1535 7163.MCT 19 0105
   Elktaibi A, 2020, HEAD NECK PATHOL, V14, P454, DOI 10.1007/s12105 019 01061 x
   Horn L, 2021, JAMA ONCOL, V7, P1617, DOI 10.1001/jamaoncol.2021.3523
   Horn L, 2018, CLIN CANCER RES, V24, P2771, DOI 10.1158/1078 0432.CCR 17 2398
   Jiang JH, 2018, LUNG CANCER, V115, P5, DOI 10.1016/j.lungcan.2017.10.011
   Kerr DA, 2021, AM J SURG PATHOL, V45, P1707, DOI 10.1097/PAS.0000000000001735
   Lee Jessica, 2019, Acta Med Acad, V48, P116, DOI 10.5644/ama2006 124.248
   Li WH, 2022, BMC MED, V20, DOI 10.1186/s12916 022 02362 9
   Liu WF, 2021, INVEST NEW DRUG, V39, P278, DOI 10.1007/s10637 020 00984 5
   Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159 8290.CD 14 0377
   Mai SJ, 2019, LUNG CANCER, V128, P101, DOI 10.1016/j.lungcan.2018.12.016
   Mansfield AS, 2016, ANN ONCOL, V27, P2111, DOI 10.1093/annonc/mdw405
   Matter MS, 2020, TRANSL LUNG CANCER R, V9, P2645, DOI 10.21037/tlcr 20 676
   Noh KW, 2017, J PATHOL, V243, P307, DOI 10.1002/path.4950
   Qin J, 2019, TRANSL CANCER RES, V8, P2187, DOI 10.21037/tcr.2019.08.26
   Rao N, 2018, J NATL COMPR CANC NE, V16, P115, DOI 10.6004/jnccn.2017.7031
   Schöffski P, 2021, EUR J CANCER, V156, P12, DOI 10.1016/j.ejca.2021.07.016
   Schöffski P, 2018, LANCET RESP MED, V6, P431, DOI 10.1016/S2213 2600(18)30116 4
   Shash H, 2016, J PEDIAT HEMATOL ONC, V38, P642, DOI 10.1097/MPH.0000000000000594
   Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0160 2
   Tateishi Y, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000 016 0586 z
   Vendrell JA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12679 8
   Villalobos VM, 2018, LANCET RESP MED, V6, P405, DOI 10.1016/S2213 2600(18)30147 4
   Wong HH, 2020, ANTI CANCER DRUG, V31, P1106, DOI 10.1097/CAD.0000000000000994
   Xia PY, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 02982 4
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
NR 27
TC 7
Z9 7
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 8
PY 2022
VL 12
AR 934887
DI 10.3389/fonc.2022.934887
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 3X9IE
UT WOS:000843345500001
PM 36003768
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wagner, F
   Holzapfel, BM
   McGovern, JA
   Shafiee, A
   Baldwin, JG
   Martine, LC
   Lahr, CA
   Wunner, FM
   Friis, T
   Bas, O
   Boxberg, M
   Prodinger, PM
   Shokoohmand, A
   Moi, D
   Mazzieri, R
   Loessner, D
   Hutmacher, DW
AF Wagner, Ferdinand
   Holzapfel, Boris M.
   McGovern, Jacqui A.
   Shafiee, Abbas
   Baldwin, Jeremy G.
   Martine, Laure C.
   Lahr, Christoph A.
   Wunner, Felix M.
   Friis, Thor
   Bas, Onur
   Boxberg, Melanie
   Prodinger, Peter M.
   Shokoohmand, Ali
   Moi, Davide
   Mazzieri, Roberta
   Loessner, Daniela
   Hutmacher, Dietmar W.
TI Humanization of bone and bone marrow in an orthotopic site reveals new
   potential therapeutic targets in osteosarcoma
SO BIOMATERIALS
LA English
DT Article
ID HUMAN PROSTATE CANCER; HUMAN HEMATOPOIETIC NICHE; BREAST CANCER;
   IN VIVO; MOUSE MODELS; TUMOR MICROENVIRONMENT; METASTASIS MODEL;
   XENOGRAFT MODEL; MURINE MODEL; HUMAN TISSUE
AB Background: Existing preclinical murine models often fail to predict effects of anti cancer drugs. In order to minimize interspecies differences between murine hosts and human bone tumors of in vivo xenograft platforms, we tissue engineered a novel orthotopic humanized bone model.
   Methods: Orthotopic humanized tissue engineered bone constructs (ohTEBC) were fabricated by 3D printing of medical grade polycaprolactone scaffolds, which were seeded with human osteoblasts and embedded within polyethylene glycol based hydrogels containing human umbilical vein endothelial cells (HUVECs). Constructs were then implanted at the femur of NOD scid and NSG mice. NSG mice were then bone marrow transplanted with human CD34(+) cells. Human osteosarcoma (OS) growth was induced within the ohTEBCs by direct injection of Luc SAOS 2 cells. Tissues were harvested for bone matrix and marrow morphology analysis as well as tumor biology investigations. Tumor marker expression was analyzed in the humanized OS and correlated with the expression in 68 OS patients utilizing tissue micro arrays (TMA).
   Results: After harvesting the femurs micro computed tomography and immunohistochemical staining showed an organ, which had all features of human bone. Around the original mouse femur new bone trabeculae have formed surrounded by a bone cortex. Staining for human specific (hs) collagen type I (hs Col I) showed human extracellular bone matrix production. The presence of nuclei staining positive for human nuclear mitotic apparatus protein 1 (hs NuMa) proved the osteocytes residing within the bone matrix were of human origin. Flow cytometry verified the presence of human hematopoietic cells. After injection of Luc SAOS 2 cells a primary tumor and lung metastasis developed. After euthanization histological analysis showed pathognomic features of osteoblastic OS. Furthermore, the tumor utilized the previously implanted HUVECS for angiogenesis. Tumor marker expression was similar to human patients. Moreover, the recently discovered musculoskeletal gene C12orf29 was expressed in the most common subtypes of OS patient samples.
   Conclusion: OhTEBCs represent a suitable orthotopic microenvironment for humanized OS growth and offers a new translational direction, as the femur is the most common location of OS. The newly developed and validated preclinical model allows controlled and predictive marker studies of primary bone tumors and other bone malignancies. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wagner, Ferdinand; Holzapfel, Boris M.; McGovern, Jacqui A.; Shafiee, Abbas; Baldwin, Jeremy G.; Martine, Laure C.; Lahr, Christoph A.; Wunner, Felix M.; Friis, Thor; Bas, Onur; Shokoohmand, Ali; Loessner, Daniela; Hutmacher, Dietmar W.] QUT, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.
   [Wagner, Ferdinand] Ludwig Maximilians Univ Munchen, Dept Pediat Surg, Dr Von Hauner Childrens Hosp, Lindwurmstr 4, D 80337 Munich, Germany.
   [Wagner, Ferdinand] Univ Regensburg, Asklepios Klinikum Bad Abbach, Dept Orthoped, Kaiser Karl V Allee 3, D 93077 Bad Abbach, Germany.
   [Holzapfel, Boris M.] Univ Wurzburg, Orthoped Ctr Musculoskeletal Res, Koenig Ludwig Haus, Brettreichstr 11, D 97074 Wurzburg, Germany.
   [Boxberg, Melanie] Tech Univ Munich, Inst Pathol, Klinikum Rechts Isar, Trogerstr 18, D 81675 Munich, Germany.
   [Prodinger, Peter M.] Tech Univ Munich, Dept Orthoped Surg, Klinikum Rechts Isar, Ismaningerstr 22, D 81675 Munich, Germany.
   [Moi, Davide; Mazzieri, Roberta] Univ Queensland, Diamantina Inst, Translat Res Inst, Woolloongabba, Qld, Australia.
   [Loessner, Daniela] Queen Mary Univ London, Barts Canc Inst, Charterhouse Sq, London EC1M 6BQ, England.
   [Hutmacher, Dietmar W.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, 801 Ferst Dr Northwest, Atlanta, GA 30332 USA.
   [Hutmacher, Dietmar W.] Tech Univ Munich, Inst Adv Study, Lichtenbergstr 2a, D 85748 Garching, Germany.
C3 Queensland University of Technology (QUT); University of Munich;
   University of Regensburg; University of Wurzburg; Technical University
   of Munich; Technical University of Munich; University of Queensland;
   University of London; Queen Mary University London; University System of
   Georgia; Georgia Institute of Technology; Technical University of Munich
RP Hutmacher, DW (通讯作者)，Queensland Univ Technol, Ctr Regenerat Med, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM dietmar.hutmacher@qut.edu.au
RI shafiee, Abbas/H 9230 2019; Baldwin, Jeremy/ABA 3910 2021; Bas,
   Onur/B 5373 2016; Mazzieri, Roberta/C 9773 2015; Holzapfel,
   Boris/LCE 4882 2024; Loessner, Daniela/L 2265 2017; Prodinger,
   Peter/AAL 3665 2021; Shafiee, Abbas/H 9230 2019; Hutmacher,
   Dietmar/AEO 9578 2022; Friis, Thor/HTN 2970 2023
OI Bas, Onur/0000 0001 8841 5443; Mazzieri, Roberta/0000 0002 5172 0927;
   McGovern, Jacqui/0000 0002 4993 6745; Shokoohmand,
   Ali/0009 0005 9182 2054; Loessner, Daniela/0000 0001 5891 3441; Shafiee,
   Abbas/0000 0002 8885 9025; Hutmacher, Dietmar Werner/0000 0001 5678 2134
FU National Health and Medical Research Council of Australia [1082313];
   Worldwide Cancer Research Project [1082313]; German Research Foundation
   (DFG) [HO 5068/1 1, WA 3606/1 1]; National Breast Cancer Foundation
   [IN 15 047]
FX We kindly thank the Central Analytical Research Facility (CARF) at the
   Institute of Health and Biomedical Innovation, Queensland University of
   Technology, for providing assistance with histological analyses. We
   thank Dr. Christina Theodoropoulos, and Cosmo Orlando Hutmacher for
   their excellent technical assistance. Fibrin glue (TISSEEL) was kindly
   provided by Baxter Healthcare Australia. Mark Wellard kindly provided
   MRI utilities and assisted in MRI analysis of the samples at the School
   of Chemistry, Physics and Mechanical Engineering, Science and
   Engineering Faculty, Queensland University of Technology. The following
   funding to the authors existed when performing the study: National
   Health and Medical Research Council of Australia (Project Grant 1082313
   to BMH and DWH), Worldwide Cancer Research (Project Grant 1082313 to
   B.M.H. and D.W.H.), German Research Foundation (DFG HO 5068/1 1 to
   B.M.H. and DFG WA 3606/1 1 to F.Wa.) and National Breast Cancer
   Foundation (IN 15 047 to B.M.H. and D.W.H.).
CR Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Baldwin JG, 2017, BIOMATERIALS, V121, P193, DOI 10.1016/j.biomaterials.2016.11.016
   Baptista AM, 2014, ACTA ORTOP BRAS, V22, P250, DOI 10.1590/1413 78522014220500978
   BERLIN O, 1993, CANCER RES, V53, P4890
   Bersani F, 2014, CANCER RES, V74, P7229, DOI 10.1158/0008 5472.CAN 14 1809
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Blache U, 2016, ADV HEALTHC MATER, V5, P489, DOI 10.1002/adhm.201500795
   Bland JM, 2003, ULTRASOUND OBST GYN, V22, P85, DOI 10.1002/uog.122
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown TD, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 011 0013 7
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Chan MWC, 2010, METHOD CELL BIOL, V98, P179, DOI 10.1016/S0091 679X(10)98008 4
   Chen Y, 2012, BLOOD, V119, P4971, DOI 10.1182/blood 2011 11 389957
   Covassin L, 2013, CLIN EXP IMMUNOL, V174, P372, DOI 10.1111/cei.12180
   Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008 5472.CAN 04 3246
   Ek ETH, 2006, CRIT REV ONCOL HEMAT, V60, P1, DOI 10.1016/j.critrevonc.2006.03.006
   Epari DR, 2010, P I MECH ENG H, V224, P1543, DOI 10.1243/09544119JEIM808
   Fernández Pérez J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06898 2
   FIDLER IJ, 1990, CANCER METAST REV, V9, P149, DOI 10.1007/BF00046341
   FOGH J, 1977, JNCI J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Freudenberg U, 2009, BIOMATERIALS, V30, P5049, DOI 10.1016/j.biomaterials.2009.06.002
   Friis TE, 2014, TISSUE ENG PART C ME, V20, P780, DOI [10.1089/ten.tec.2013.0099, 10.1089/ten.TEC.2013.0099]
   Fürstenberger G, 2005, BRIT J CANCER, V93, P793, DOI 10.1038/sj.bjc.6602782
   Green JT, 2014, SEMIN DIAGN PATHOL, V31, P21, DOI 10.1053/j.semdp.2014.01.001
   Groen RWJ, 2012, BLOOD, V120, pE9, DOI 10.1182/blood 2012 03 414920
   Haas AR, 1999, DIFFERENTIATION, V64, P77, DOI 10.1046/j.1432 0436.1999.6420077.x
   Harland B, 2011, PHYS BIOL, V8, DOI 10.1088/1478 3975/8/1/015011
   Hesami P., 2014, CLIN EXP METASTAS, P1
   Holzapfel BM, 2015, BIOMATERIALS, V61, P103, DOI 10.1016/j.biomaterials.2015.04.057
   Holzapfel BM, 2014, BIOMATERIALS, V35, P4108, DOI 10.1016/j.biomaterials.2014.01.062
   Holzapfel BM, 2015, STEM CELLS, V33, P1696, DOI 10.1002/stem.1978
   Holzapfel BM, 2013, CANCER METAST REV, V32, P129, DOI 10.1007/s10555 013 9437 5
   Hutmacher DW, 2015, CURR OPIN BIOTECH, V35, P127, DOI 10.1016/j.copbio.2015.06.001
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Ito R, 2012, CELL MOL IMMUNOL, V9, P208, DOI 10.1038/cmi.2012.2
   Ivey JW, 2016, CANCER LETT, V380, P330, DOI 10.1016/j.canlet.2015.12.019
   Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Khanna C, 2001, CANCER RES, V61, P3750
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Lee J, 2012, P NATL ACAD SCI USA, V109, P19638, DOI 10.1073/pnas.1208384109
   Macchiarini Francesca, 2005, J Exp Med, V202, P1307, DOI 10.1084/jem.20051547
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Martine LC, 2017, NAT PROTOC, V12, P639, DOI 10.1038/nprot.2017.002
   McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870
   Morton JJ, 2016, ONCOGENE, V35, P290, DOI 10.1038/onc.2015.94
   Nemeth JA, 1999, CANCER RES, V59, P1987
   PosthumaDeBoer J, 2013, BRIT J CANCER, V109, P2142, DOI 10.1038/bjc.2013.578
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   Reinisch A, 2016, NAT MED, V22, P812, DOI 10.1038/nm.4103
   Reinisch A, 2015, BLOOD, V125, P249, DOI 10.1182/blood 2014 04 572255
   Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858
   Rongvaux A, 2013, ANNU REV IMMUNOL, V31, P635, DOI 10.1146/annurev immunol 032712 095921
   SALZERKUNTSCHIK M, 1983, J CANCER RES CLIN, V106, P21, DOI 10.1007/BF00625047
   Santos GC, 2009, MODERN PATHOL, V22, P1321, DOI 10.1038/modpathol.2009.99
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110
   Shafiee A, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700414
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890
   Thibaudeau L, 2015, CELL CYCLE, V14, P2191, DOI 10.1080/15384101.2015.1062327
   Thibaudeau L, 2015, ONCOTARGET, V6, P332, DOI 10.18632/oncotarget.2788
   Thibaudeau L, 2014, DIS MODEL MECH, V7, P299, DOI 10.1242/dmm.014076
   Wagner F, 2016, J BONE JOINT SURG AM, V98, P916, DOI 10.2106/JBJS.15.00920
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Werner Klein M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097860
   Xia TS, 2012, BREAST CANCER RES TR, V132, P471, DOI 10.1007/s10549 011 1496 0
   Xia TS, 2010, ONCOL REP, V24, P203, DOI 10.3892/or_00000847
   Yonou H, 2001, CANCER RES, V61, P2177
   Zhong GX, 2017, ONCOTARGETS THER, V10, P527, DOI 10.2147/OTT.S125589
   Zieris A, 2010, BIOMATERIALS, V31, P7985, DOI 10.1016/j.biomaterials.2010.07.021
NR 74
TC 39
Z9 39
U1 0
U2 59
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2018
VL 171
BP 230
EP 246
DI 10.1016/j.biomaterials.2018.04.030
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GH7OJ
UT WOS:000433643000020
PM 29705656
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Ozaki, T
   Nakamura, M
   Ogata, T
   Sang, MJ
   Yoda, H
   Hiraoka, K
   Sang, MX
   Shimozato, O
AF Ozaki, Toshinori
   Nakamura, Mizuyo
   Ogata, Takehiro
   Sang, Meijie
   Yoda, Hiroyuki
   Hiraoka, Kiriko
   Sang, Meixiang
   Shimozato, Osamu
TI Depletion of pro oncogenic RUNX2 enhances gemcitabine (GEM)
   sensitivity of p53 mutated pancreatic cancer Panc 1 cells through
   the induction of pro apoptotic TAp63
SO ONCOTARGET
LA English
DT Article
DE gemcitabine; mutant p53; pancreatic cancer; RUNX2; TAp63
ID WILD TYPE P53; REGULATES OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION
   FACTOR 2; DNA DAMAGE; P53 DEPENDENT APOPTOSIS; TUMOR SUPPRESSOR;
   UBIQUITIN LIGASE; MUTANT P53; HISTONE H3; BONE
AB Recently, we have described that siRNA mediated silencing of runt related transcription factor 2 (RUNX2) improves anti cancer drug gemcitabine (GEM) sensitivity of p53 deficient human pancreatic cancer AsPC 1 cells through the augmentation of p53 family TAp63 dependent cell death pathway. In this manuscript, we have extended our study to p53 mutated human pancreatic cancer Panc 1 cells. According to our present results, knockdown of mutant p53 alone had a marginal effect on GEM mediated cell death of Panc 1 cells. We then sought to deplete RUNX2 using siRNA in Panc 1 cells and examined its effect on GEM sensitivity. Under our experimental conditions, RUNX2 knockdown caused a significant enhancement of GEM sensitivity of Panc 1 cells. Notably, GEM mediated induction of TAp63 but not of TAp73 was further stimulated in RUNX2 depleted Panc 1 cells, indicating that, like AsPC 1 cells, TAp63 might play a pivotal role in the regulation of GEM sensitivity of Panc 1 cells. Consistent with this notion, forced expression of TAp63a in Panc 1 cells promoted cell cycle arrest and/or cell death, and massively increased luciferase activities driven by TAp63 target gene promoters such as p21(WAF1) and NOXA. In addition, immunoprecipitation experiments indicated that RUNX2 forms a complex with TAp63 in Panc 1 cells. Taken together, our current observations strongly suggest that depletion of RUNX2 enhances the cytotoxic effect of GEM on p53 mutated Panc 1 cells through the stimulation of TAp63 dependent cell death pathway even in the presence of a large amount of pro oncogenic mutant p53, and might provide an attractive strategy to treat pancreatic cancer patients with p53 mutations.
C1 [Ozaki, Toshinori; Nakamura, Mizuyo; Ogata, Takehiro; Sang, Meijie; Sang, Meixiang; Shimozato, Osamu] Chiba Canc Ctr, Lab DNA Damage Signaling, Res Inst, Chiba, Japan.
   [Sang, Meijie] Toyama Univ, Dept Regenerat Med, Grad Sch Med & Pharmatheut Sci, Toyama, Japan.
   [Yoda, Hiroyuki; Hiraoka, Kiriko] Chiba Canc Ctr, Res Inst, Lab Canc Genet, Chiba, Japan.
   [Sang, Meixiang] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang, Peoples R China.
C3 Chiba Cancer Center; University of Toyama; Chiba Cancer Center; Hebei
   Medical University
RP Ozaki, T (通讯作者)，Chiba Canc Ctr, Lab DNA Damage Signaling, Res Inst, Chiba, Japan.
EM tozaki@chiba cc.jp
RI ; Yoda, Hiroyuki/HNI 2020 2023
OI Yoda, Hiroyuki/0000 0002 5528 8940; 
FU JSPS (MEXT) KAKENHI [23501278]; Grants in Aid for Scientific Research
   [23501278, 15K08412] Funding Source: KAKEN
FX We thank Dr. Hiroki Nagase (Laboratory of Cancer Genetics, Chiba Cancer
   Center) for his valuable discussion. This work was supported in part by
   JSPS (MEXT) KAKENHI Grant Number 23501278.
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Brusgard JL, 2015, ONCOTARGET, V6, P28132, DOI 10.18632/oncotarget.4654
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092 8674(00)00118 5
   Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008 5472.CAN 05 0197
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a
   Ge QQ, 2016, ONCOTARGETS THER, V9, P231, DOI 10.2147/OTT.S96710
   Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555 010 9235 2
   HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193 225
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631
   Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732
   Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614
   Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535 6108(03)00078 3
   ISAACS WB, 1991, CANCER RES, V51, P4716
   Janes RH, 1996, ANN SURG, V223, P261, DOI 10.1097/00000658 199603000 00006
   Ji SR, 2015, CELL RES, V25, P561, DOI 10.1038/cr.2015.30
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092 8674(00)80540 1
   Kayed H, 2007, BRIT J CANCER, V97, P1106, DOI 10.1038/sj.bjc.6603984
   Kim HG, 2008, CANCER RES, V68, P2538, DOI 10.1158/0008 5472.CAN 07 6597
   Kleger A, 2014, ANN ONCOL, V25, P1260, DOI 10.1093/annonc/mdu013
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kumar Y, 2015, J BIOL CHEM, V290, P30975, DOI 10.1074/jbc.M115.669531
   Kuo YH, 2009, BLOOD, V113, P3323, DOI 10.1182/blood 2008 06 162248
   Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665
   Li Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104346
   Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044
   Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128
   Moss RA, 2010, ONCOTARGETS THER, V3, P111
   Nakaya N, 2013, MOL CLIN ONCOL, V1, P100, DOI 10.3892/mco.2012.8
   Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ozaki T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.127
   Ozaki T, 2015, FEBS J, V282, P114, DOI 10.1111/febs.13108
   Pan YL, 2015, MOL CANCER THER, V14, P407, DOI 10.1158/1535 7163.MCT 14 0485
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Rödicker F, 2003, CANCER RES, V63, P2737
   Serres MP, 2012, J CLIN INVEST, V122, P844, DOI 10.1172/JCI60376
   Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200
   Smeenk HG, 2005, LANGENBECK ARCH SURG, V390, P94, DOI 10.1007/s00423 004 0476 9
   Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617
   Sugimoto H, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.10
   Tandon M, 2016, ONCOGENE, V35, P4730, DOI 10.1038/onc.2015.518
   Trotter TN, 2015, BLOOD, V125, P3598, DOI 10.1182/blood 2014 12 613968
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290
   Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097 2765(00)80275 0
   Zhu HB, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477 7819 11 22
NR 56
TC 11
Z9 12
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 1
PY 2016
VL 7
IS 44
BP 71937
EP 71950
DI 10.18632/oncotarget.12433
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EB5VQ
UT WOS:000387449100073
PM 27713122
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Brennan, MA
   Monahan, DS
   Brulin, B
   Gallinetti, S
   Humbert, P
   Tringides, C
   Canal, C
   Ginebra, MP
   Layrolle, P
AF Brennan, Meadhbha
   Monahan, David S.
   Brulin, Benedicte
   Gallinetti, Sara
   Humbert, Paul
   Tringides, Christina
   Canal, Cristina
   Ginebra, Maria Pau
   Layrolle, Pierre
TI Biomimetic versus sintered macroporous calcium phosphate scaffolds
   enhanced bone regeneration and human mesenchymal stromal cell
   engraftment in calvarial defects
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Calcium deficient hydroxyapatite; Beta tricalcium phosphate; Bone
   regeneration; Human bone marrow mesenchymal stromal cells; Engraftment
ID BETA TRICALCIUM PHOSPHATE; STEM CELLS; HYDROXYAPATITE SCAFFOLDS;
   SURFACE TOPOGRAPHY; IN VITRO; OSTEOINDUCTION; TISSUE; DIFFERENTIATION;
   OSTEOGENESIS; INHIBITION
AB In contrast to sintered calcium phosphates (CaPs) commonly employed as scaffolds to deliver mesenchymal stromal cells (MSCs) targeting bone repair, low temperature setting conditions of calcium deficient hydroxyapatite (CDHA) yield biomimetic topology with high specific surface area. In this study, the healing capacity of CDHA administering MSCs to bone defects is evaluated for the first time and compared with sintered beta tricalcium phosphate (beta TCP) constructs sharing the same interconnected macroporosity. Xeno free expanded human bone marrow MSCs attached to the surface of the hydrophobic beta TCP constructs, while infiltrating the pores of the hydrophilic CDHA. Implantation of MSCs on CaPs for 8 weeks in calvaria defects of nude mice exhibited complete healing, with bone formation aligned along the periphery of beta TCP, and conversely distributed within the pores of CDHA. Human monocyte osteoclast differentiation was inhibited in vitro by direct culture on CDHA compared to beta TCP biomaterials and indirectly by administration of MSC conditioned media generated on CDHA, while MSCs increased osteoclastogenesis in both CaPs in vivo. MSC engraftment was significantly higher in CDHA constructs, and also correlated positively with bone in growth in scaffolds. These findings demonstrate that biomimetic CDHA are favorable carriers for MSC therapies and should be explored further towards clinical bone regeneration strategies.
   Statement of significance
   Delivery of mesenchymal stromal cells (MSCs) on calcium phosphate (CaP) biomaterials enhances reconstruction of bone defects. Traditional CaPs are produced at high temperature, but calcium deficient hydroxyapatite (CDHA) prepared at room temperature yields a surface structure more similar to native bone mineral. The objective of this study was to compare the capacity of biomimetic CDHA scaffolds with sintered P TCP scaffolds for bone repair mediated by MSCs for the first time. In vitro, greater cell infiltration occurred in CDHA scaffolds and following 8 weeks in vivo, MSC engraftment was higher in CDHA compared to beta TCP, as was bone in growth. These findings demonstrate the impact of material features such as surface structure, and highlight that CDHA should be explored towards clinical bone regeneration strategies. (C) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Brennan, Meadhbha; Brulin, Benedicte; Humbert, Paul; Layrolle, Pierre] Univ Nantes, Fac Med, PHY OS, INSERM,UMR 1238, 1 Rue Gaston Veil, F 44035 Nantes, France.
   [Brennan, Meadhbha; Brulin, Benedicte; Humbert, Paul; Layrolle, Pierre] Univ Paul Sabatier, CHU Purpan, ToNIC, INSERM,UMR 1214, F 31024 Toulouse, France.
   [Brennan, Meadhbha; Tringides, Christina] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
   [Brennan, Meadhbha; Monahan, David S.] Natl Univ Ireland NUIG, Sch Med, Biomed Engn Sch Engn, Galway, Ireland.
   [Brennan, Meadhbha; Monahan, David S.] Natl Univ Ireland NUIG, Regenerat Med Inst REMEDI, Sch Med, Galway, Ireland.
   [Gallinetti, Sara; Canal, Cristina; Ginebra, Maria Pau] Univ Politecn Catalunya UPC, Dept Mat Sci & Engn, Biomat Biomech & Tissue Engn Grp, Av Eduard Maristany 10 14, Barcelona 08019, Spain.
   [Gallinetti, Sara; Canal, Cristina; Ginebra, Maria Pau] Univ Politecn Cataluna, Res Ctr Multiscale Sci & Engn, Barcelona, Spain.
   [Tringides, Christina] Harvard Univ, Harvard Program Biophys, Cambridge, MA 02138 USA.
   [Ginebra, Maria Pau] Barcelona Inst Sci & Technol, Inst Bioengn Catalonia IBEC, Baldiri & Reixach 10 12, Barcelona 08028, Spain.
C3 Nantes Universite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Institut National de la Sante et de la Recherche
   Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite
   Toulouse III   Paul Sabatier; Harvard University; Ollscoil na
   Gaillimhe University of Galway; Ollscoil na Gaillimhe University of
   Galway; Universitat Politecnica de Catalunya; Universitat Politecnica de
   Catalunya; Harvard University; University of Barcelona; Barcelona
   Institute of Science & Technology; Institut de Bioenginyeria de
   Catalunya
RP Layrolle, P (通讯作者)，Univ Nantes, Fac Med, PHY OS, INSERM,UMR 1238, 1 Rue Gaston Veil, F 44035 Nantes, France.; Layrolle, P (通讯作者)，Univ Paul Sabatier, CHU Purpan, ToNIC, INSERM,UMR 1214, F 31024 Toulouse, France.
EM pierre.layrolle@inserm.fr
RI Layrolle, Pierre/K 9257 2015; Canal, Cristina/AGJ 6002 2022; Humbert,
   Paul/JLL 4419 2023; Ginebra, Maria Pau/J 8149 2017
OI Layrolle, Pierre/0000 0001 9800 5210; Humbert, Paul/0000 0003 1208 5550;
   Tringides, Christina/0000 0003 2747 1200; Monahan,
   David/0000 0002 1232 3101; Ginebra, Maria Pau/0000 0002 4700 5621;
   Canal, Cristina/0000 0002 3039 7462
FU European Commission [REBORNE 241879]; Spanish Government (MINECO/FEDER,
   EU) [MAT2015 65601 R]; European Union [708711]; Generalitat de
   Catalunya; European Research Council [852152]; Marie Curie Actions
   (MSCA) [708711] Funding Source: Marie Curie Actions (MSCA); European
   Research Council (ERC) [852152] Funding Source: European Research
   Council (ERC)
FX The research leading to these results has received funding from the
   European Commission Seventh Framework Program (FP7/20072013) under the
   Grant agreement REBORNE 241879. Authors acknowledge the Spanish
   Government for financial support through Project MAT2015 65601 R project
   (MINECO/FEDER,EU). This project has received funding from the European
   Union's Horizon 2020 research and innovation program under the Marie
   Sklodowska Curie Individual Fellowship of Meadhbh Brennan, grant
   agreement PARAGEN, 708711. Support for the research of Maria Pau Ginebra
   and Cristina Canal was received through the "ICREA Academia" prize for
   excellence in research, funded by the Generalitat de Catalunya. Authors
   are grateful to K. Khurana, J. Konka and A. Renaud for their technical
   support. Mesenchymal stromal cells derived from human bone marrow were
   kindly supplied by Frederic Deschaseaux, STROMA lab, Toulouse, and by
   Professor Hubert Schrezenmeier of the German Red Cross and Ulm
   University. Cristina Canal and Maria Pau Ginebra belong to the 2017 SGR
   1165 of Generalitat de Catalunya. David Monahan is funded as a
   postdoctoral researcher under the European Research Council Starting
   Grant (EVEREST, Grant agreement ID: 852152). The authors acknowledge the
   facilities, scientific, and technical assistance of the centre for
   Microscopy & Imaging at the National University of Ireland Galway
   (www.imaging.nuigalway.ie).
CR Abagnale G, 2015, BIOMATERIALS, V61, P316, DOI 10.1016/j.biomaterials.2015.05.030
   Abe T, 2018, J DENT SCI, V13, P354, DOI 10.1016/j.jds.2018.08.001
   Almirall A, 2004, BIOMATERIALS, V25, P3671, DOI 10.1016/j.biomaterials.2003.10.066
   Avril P, 2016, J BONE ONCOL, V5, P5, DOI 10.1016/j.jbo.2015.11.002
   Barba A, 2019, ACS APPL MATER INTER, V11, P8818, DOI 10.1021/acsami.8b20749
   Barba A, 2018, ACTA BIOMATER, V79, P135, DOI 10.1016/j.actbio.2018.09.003
   Barba A, 2017, ACS APPL MATER INTER, V9, P41722, DOI 10.1021/acsami.7b14175
   Becquart P, 2012, TISSUE ENG PT A, V18, P2084, DOI [10.1089/ten.TEA.2011.0690, 10.1089/ten.tea.2011.0690]
   Bohner M, 2019, MATER TODAY, V22, P132, DOI 10.1016/j.mattod.2018.10.036
   Brennan MA, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 86147 9
   Brennan MA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909125
   Brennan MA, 2017, STEM CELL TRANSL MED, V6, P2160, DOI 10.1002/sctm.17 0133
   Brennan MA, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045019
   Brennan MA, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt504
   Canal C, 2016, POLYMER, V92, P170, DOI 10.1016/j.polymer.2016.03.069
   Cerletti M, 2008, CELL, V134, P37, DOI 10.1016/j.cell.2008.05.049
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Ciapetti G, 2017, ACTA BIOMATER, V50, P102, DOI 10.1016/j.actbio.2016.12.013
   Clark AY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14000 9
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2007, J CELL BIOCHEM, V100, P326, DOI 10.1002/jcb.21058
   Davison NL, 2014, EUR CELLS MATER, V27, P281, DOI 10.22203/eCM.v027a20
   Davison NL, 2014, BIOMATERIALS, V35, P5088, DOI 10.1016/j.biomaterials.2014.03.013
   Deschepper M, 2013, STEM CELLS, V31, P526, DOI 10.1002/stem.1299
   Diez Escudero A, 2019, J TISSUE ENG REGEN M, V13, P1217, DOI 10.1002/term.2872
   Diez Escudero A, 2017, TISSUE ENG PART C ME, V23, P118, DOI [10.1089/ten.tec.2016.0361, 10.1089/ten.TEC.2016.0361]
   Engel E, 2008, TISSUE ENG PT A, V14, P1341, DOI 10.1089/ten.tea.2007.0287
   Fang DJ, 2007, STEM CELLS, V25, P1021, DOI 10.1634/stemcells.2006 0576
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   García Sánchez D, 2019, WORLD J STEM CELLS, V11, P748, DOI 10.4252/wjsc.v11.i10.748
   Giannoni P, 2010, TISSUE ENG PT A, V16, P489, DOI [10.1089/ten.tea.2009.0041, 10.1089/ten.TEA.2009.0041]
   Ginebra MP, 2010, ACTA BIOMATER, V6, P2863, DOI 10.1016/j.actbio.2010.01.036
   Gómez Barrena E, 2019, BIOMATERIALS, V196, P100, DOI 10.1016/j.biomaterials.2018.03.033
   Granchi D, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3674045
   Habibovic P, 2006, J ORTHOP RES, V24, P867, DOI 10.1002/jor.20115
   Habibovic P, 2005, BIOMATERIALS, V26, P3565, DOI 10.1016/j.biomaterials.2004.09.056
   Habraken W, 2016, MATER TODAY, V19, P69, DOI 10.1016/j.mattod.2015.10.008
   Ho SS, 2018, STEM CELLS, V36, P1393, DOI 10.1002/stem.2853
   Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   HoWangYin KY, 2014, STEM CELLS, V32, P231, DOI 10.1002/stem.1540
   Humbert P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00663
   Janvikul W, 2013, PROCEDIA ENGINEER, V59, P158, DOI 10.1016/j.proeng.2013.05.106
   Khurana K, 2020, J BIOMED MATER RES B, V108, P760, DOI 10.1002/jbm.b.34430
   Kiernan J, 2016, STEM CELL TRANSL MED, V5, P683, DOI 10.5966/sctm.2015 0231
   Klar RM, 2013, J CELL MOL MED, V17, P1444, DOI 10.1111/jcmm.12125
   Knabe C, 2000, J BIOMED MATER RES, V52, P498, DOI 10.1002/1097 4636(20001205)52:3<498::AID JBM8>3.0.CO;2 P
   Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001
   Liu YK, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/2/025004
   Mankani MH, 2007, EXP HEMATOL, V35, P995, DOI 10.1016/j.exphem.2007.01.051
   Mankani MH, 2006, STEM CELLS, V24, P2140, DOI 10.1634/stemcells.2005 0567
   Mao AS, 2019, P NATL ACAD SCI USA, V116, P15392, DOI 10.1073/pnas.1819415116
   Sadowska JM, 2018, ACTA BIOMATER, V76, P319, DOI 10.1016/j.actbio.2018.06.025
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mebarki M, 2017, ACTA BIOMATER, V59, P94, DOI 10.1016/j.actbio.2017.06.018
   Montufar EB, 2010, ACTA BIOMATER, V6, P876, DOI 10.1016/j.actbio.2009.10.018
   Nasu T, 2009, J BIOMED MATER RES A, V89A, P601, DOI 10.1002/jbm.a.31984
   Osugi M, 2012, TISSUE ENG PT A, V18, P1479, DOI [10.1089/ten.tea.2011.0325, 10.1089/ten.TEA.2011.0325]
   Othman Z, 2019, BIOMATERIALS, V210, P12, DOI 10.1016/j.biomaterials.2019.04.021
   Pastorino D, 2015, ACTA BIOMATER, V12, P250, DOI 10.1016/j.actbio.2014.10.031
   Quevedo HC, 2009, P NATL ACAD SCI USA, V106, P14022, DOI 10.1073/pnas.0903201106
   Ripamonti U, 2010, BIOMATERIALS, V31, P6400, DOI 10.1016/j.biomaterials.2010.04.037
   Roche ET, 2014, BIOMATERIALS, V35, P6850, DOI 10.1016/j.biomaterials.2014.04.114
   Sadowska JM, 2019, ACTA BIOMATER, V96, P605, DOI 10.1016/j.actbio.2019.06.057
   Sadowska JM, 2017, TISSUE ENG PT A, V23, P1297, DOI [10.1089/ten.tea.2016.0406, 10.1089/ten.TEA.2016.0406]
   Salazar Noratto GE, 2020, STEM CELLS, V38, P22, DOI 10.1002/stem.3079
   Sharaf Eldin WE, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1908365
   Stanovici J, 2016, CURR RES TRANSL MED, V64, P83, DOI 10.1016/j.retram.2016.04.006
   Tanaka T, 2008, J BIOMED MATER RES B, V86B, P453, DOI 10.1002/jbm.b.31041
   Tanaka T, 2010, J BIOMED MATER RES A, V93A, P469, DOI 10.1002/jbm.a.32560
   Vandecandelaere N, 2012, J MATER SCI MATER M, V23, P2593, DOI 10.1007/s10856 012 4719 y
   Vidal L, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 63742 w
   Vidal L, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00061
   Wang WG, 2016, MATERIALS, V9, DOI 10.3390/ma9120992
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
   Zhao MH, 2014, SCI REP UK, V4, DOI 10.1038/srep05376
NR 76
TC 19
Z9 19
U1 1
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2021
VL 135
BP 689
EP 704
DI 10.1016/j.actbio.2021.09.007
EA NOV 2021
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA WW4YY
UT WOS:000717925100005
PM 34520883
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Song, YM
   Lee, HJ
   Min, SK
   Park, YH
   Oh, JK
   Kim, JY
   Park, JB
AF Song, Young Min
   Lee, Hyun Jin
   Min, Sae Kyung
   Park, Yoon Hee
   Oh, Jae Kwen
   Kim, Ji Youn
   Park, Jun Beom
TI Effects of noni on cellular viability and osteogenic differentiation of
   gingiva derived stem cells demonstrated by RNA sequencing and
   quantitative PCR
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE cell differentiation; cell survival; herbal medicine; medical plants;
   Morinda citrifolia; osteogenesis; stem cells
ID MORINDA CITRIFOLIA JUICE; OSTEOBLAST DIFFERENTIATION; EXPRESSION;
   ACTIVATION; EXTRACT; PATHWAY; L.
AB Noni fruit (Morinda citrifolia) has been widely used in traditional medicine across tropical and subtropical regions, and is now being paid more attention in Western medicine. The present study aimed to investigate the effects of noni extract on the change in the cellular morphology, maintenance of cellular viability and enhancement of osteogenic differentiation of stem cells. Stem cells obtained from gingiva were cultured where noni extracts existed at concentrations ranging from 10 200 ng/ml. Evaluations of cell morphology and cellular viability were performed. Alkaline phosphatase activity assays were performed to assess the osteogenic differentiation. Alizarin Red S staining was performed to evaluate the calcium deposits in the culture, with the addition of noni extract. Global gene expression was analyzed via next generation mRNA sequencing. Gene ontology and pathway analyses were performed to determine the associated mechanisms. Validation procedures were performed via quantitative (q)PCR analysis. The addition of noni at concentrations ranging from 10 200 ng/ml did not produce significant morphological changes. There were significantly higher values of cellular viability, with the highest value at 100 ng/ml compared with the control (P<0.05). Furthermore, significantly higher values of alkaline phosphatase activity was noted in the 10 and 100 ng/ml groups compared with the 0 ng/ml group on day 7 (P<0.05). Alizarin Red S staining revealed calcium deposits in each group. In addition, the highest value for Alizarin Red S staining was observed at 100 ng/ml compared with the unloaded control (P<0.05). qPCR analysis demonstrated that the mRNA expression levels of RUNX2, BSP, OCN and COL1A1 increased following treatment with noni. Taken together, the results of the present study suggest that noni extract has enhancing effects on gingiva derived mesenchymal stem cells, by enhancing cellular viability and osteogenic differentiation.
C1 [Song, Young Min; Lee, Hyun Jin; Min, Sae Kyung; Park, Jun Beom] Catholic Univ Korea, Dept Periodont, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea.
   [Park, Yoon Hee] Ebiogen, Seoul 04785, South Korea.
   [Oh, Jae Kwen] Merden Dent Hosp, Bucheon Si 14544, Gyeonggi, South Korea.
   [Kim, Ji Youn] Catholic Univ Korea, Div Oral & Maxillofacial Surg, Dept Dent, Coll Med,St Vincents Hosp, 222 Banpo Daero, Seoul 06591, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Park, JB (通讯作者)，Catholic Univ Korea, Dept Periodont, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea.; Kim, JY (通讯作者)，Catholic Univ Korea, Div Oral & Maxillofacial Surg, Dept Dent, Coll Med,St Vincents Hosp, 222 Banpo Daero, Seoul 06591, South Korea.
EM kimjy@catholic.ac.kr; jbassoon@catholic.ac.kr
RI Song, Young min/AAC 5075 2020; Park, Jun Beom/I 8201 2019
FU National Research Foundation of Korea   Korea government (MSIT)
   [2020R1A2C4001624]
FX The present study was supported by the National Research Foundation of
   Korea grant funded by the Korea government (MSIT, grant no.
   2020R1A2C4001624).
CR Algenstaedt P, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/3565427
   Chan Blanco Y, 2007, J SCI FOOD AGR, V87, P1710, DOI 10.1002/jsfa.2894
   Choudhary Ekta, 2018, J Conserv Dent, V21, P443, DOI 10.4103/JCD.JCD_58_18
   Garcia Vilas JA, 2015, MOL IMMUNOL, V65, P86, DOI 10.1016/j.molimm.2015.01.008
   García Vilas JA, 2015, SCI REP UK, V5, DOI 10.1038/srep08021
   Garrido Gallego Francisco, 2015, Rev. esp. enferm. dig., V107, P247
   Glang J., 2013, Mod Res Inflamm, V2, P21, DOI [DOI 10.4236/MRI.2013.22003, 10.4236/mri.2013.22003]
   Gu H, 2018, J MED FOOD, V21, P57, DOI 10.1089/jmf.2017.3933
   Gupta Rakesh Kumar, 2015, Asian Pac J Cancer Prev, V16, P3457
   Huang HL, 2015, J MED FOOD, V18, P663, DOI 10.1089/jmf.2014.3213
   Hussain S, 2016, INT J STEM CELLS, V9, P221, DOI 10.15283/ijsc16024
   Jin SH, 2015, J PERIODONTAL RES, V50, P461, DOI 10.1111/jre.12228
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kang SH, 2019, J PERIODONTAL IMPLAN, V49, P258, DOI 10.5051/jpis.2019.49.4.258
   Kang Yu Chan, 2015, Acta Neurol Taiwan, V24, P43
   Kannan S, 2020, BIOL OPEN, V9, DOI 10.1242/bio.053280
   Kim BB, 2019, EXP THER MED, V18, P3425, DOI 10.3892/etm.2019.7971
   Kim BB, 2017, J INT MED RES, V45, P993, DOI 10.1177/0300060517701035
   Kim YT, 2021, J PERIODONTAL IMPLAN, V51, P179, DOI 10.5051/jpis.2006360318
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kumarasamy Barani, 2014, J Dent (Tehran), V11, P703
   Langford J, 2004, J ALTERN COMPLEM MED, V10, P737, DOI 10.1089/1075553042476605
   Lee HJ, 2021, COATINGS, V11, DOI 10.3390/coatings11060642
   Lee H, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57010038
   Lee H, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10165471
   Lee H, 2019, ADV CLIN EXP MED, V28, P699, DOI 10.17219/acem/94162
   Lee SI, 2017, EXP THER MED, V13, P1757, DOI 10.3892/etm.2017.4194
   Liu Y, 2018, MUTAGENESIS, V33, P203, DOI 10.1093/mutage/gey010
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Min SK, 2020, MEDICINA LITHUANIA, V56, DOI 10.3390/medicina56080389
   Needleman IG, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001724.pub2
   Osman WNW, 2018, PHYTOTHER RES, V32, P2078, DOI 10.1002/ptr.6151
   Palu A, 2010, PHYTOTHER RES, V24, P1437, DOI 10.1002/ptr.3150
   Panditrao MM, 2014, W INDIAN MED J, V63, P814, DOI 10.7727/wimj.2013.109
   Pandy V, 2018, BIOMED PHARMACOTHER, V107, P368, DOI 10.1016/j.biopha.2018.08.008
   Park JB, 2013, J BIOMAT SCI POLYM E, V24, P2045, DOI 10.1080/09205063.2013.823071
   Pieles O, 2020, HISTOCHEM CELL BIOL, V154, P397, DOI 10.1007/s00418 020 01904 7
   Pratap UP, 2018, J INTEGR MED JIM, V16, P199, DOI 10.1016/j.joim.2018.04.002
   Pratap UP, 2016, J RECEPT SIG TRANSD, V36, P139, DOI 10.3109/10799893.2015.1061001
   Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb 2011 12 3 r22
   Sharma K, 2016, DRUG RES, V66, P141, DOI 10.1055/s 0035 1555804
   Singh B, 2020, PHYTOTHER RES, V34, P924, DOI 10.1002/ptr.6579
   Stuss M, 2021, BOSNIAN J BASIC MED, V21, P461, DOI 10.17305/bjbms.2020.5179
   Tae JY, 2020, COATINGS, V10, DOI 10.3390/coatings10111055
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Wall MM, 2018, J SCI FOOD AGR, V98, P3391, DOI 10.1002/jsfa.8850
   Wang MY, 2020, MOLECULES, V25, DOI 10.3390/molecules25010160
   Wang X, 2013, INT ORTHOP, V37, P2491, DOI 10.1007/s00264 013 2059 2
   West BJ, 2018, FOODS, V7, DOI 10.3390/foods7040058
   Whittle AJ, 2012, CELL, V149, P871, DOI 10.1016/j.cell.2012.02.066
   Xia B, 2011, BIOLOGICALS, V39, P217, DOI 10.1016/j.biologicals.2011.04.004
NR 51
TC 5
Z9 5
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2022
VL 23
IS 1
AR 32
DI 10.3892/etm.2021.10954
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA XC9FP
UT WOS:000722316800001
PM 34824640
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dellinger, AL
   Cunin, P
   Lee, D
   Kung, AL
   Brooks, DB
   Zhou, ZG
   Nigrovic, PA
   Kepley, CL
AF Dellinger, Anthony L.
   Cunin, Pierre
   Lee, David
   Kung, Andrew L.
   Brooks, D. Bradford
   Zhou, Zhiguo
   Nigrovic, Peter A.
   Kepley, Christopher L.
TI Inhibition of Inflammatory Arthritis Using Fullerene Nanomaterials
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; COLLAGEN INDUCED ARTHRITIS; SYNOVIAL MAST CELLS; REACTIVE
   OXYGEN; RHEUMATOID ARTHRITIS; IN VITRO; PATHOGENESIS; LOCALIZATION;
   ANTIOXIDANTS; FIBROBLASTS
AB Inflammatory arthritis (e.g. rheumatoid arthritis; RA) is a complex disease driven by the interplay of multiple cellular lineages. Fullerene derivatives have previously been shown to have anti inflammatory capabilities mediated, in part, by their ability to prevent inflammatory mediator release by mast cells (MC). Recognizing that MC can serve as a cellular link between autoantibodies, soluble mediators, and other effector populations in inflammatory arthritis, it was hypothesized that fullerene derivatives might be used to target this inflammatory disease. A panel of fullerene derivatives was tested for their ability to affect the function of human skin derived MC as well as other lineages implicated in arthritis, synovial fibroblasts and osteoclasts. It is shown that certain fullerene derivatives blocked Fc gamma R and TNF alpha induced mediator release from MC; TNF alpha induced mediator release from RA synovial fibroblasts; and maturation of human osteoclasts. MC inhibition by fullerene derivatives was mediated through the reduction of mitochondrial membrane potential and Fc gamma R mediated increases in cellular reactive oxygen species and NF kappa B activation. Based on these in vitro data, two fullerene derivatives (ALM and TGA) were selected for in vivo studies using K/BxN serum transfer arthritis in C57BL/6 mice and collagen induced arthritis (CIA) in DBA/1 mice. Dye conjugated fullerenes confirmed localization to affected joints in arthritic animals but not in healthy controls. In the K/BxN moldel, fullerenes attenuated arthritis, an effect accompanied by reduced histologic inflammation, cartilage/bone erosion, and serum levels of TNF alpha. Fullerenes remained capable of attenuating K/BxN arthritis in mast cell deficient mice Cre Master mice, suggesting that lineages beyond the MC represent relevant targets in this system. These studies suggest that fullerene derivatives may hold promise both as an assessment tool and as anti inflammatory therapy of arthritis.
C1 [Dellinger, Anthony L.; Kepley, Christopher L.] Univ N Carolina, Joint Sch Nanosci & Nanoengn, Greensboro, NC 27412 USA.
   [Cunin, Pierre; Nigrovic, Peter A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA USA.
   [Cunin, Pierre; Nigrovic, Peter A.] Harvard Univ, Sch Med, Div Immunol, Boston Childrens Hosp, Boston, MA USA.
   [Lee, David] Novartis Inst Biomed Res, Basel, Switzerland.
   [Kung, Andrew L.] Dana Farber Inst, Boston, MA USA.
   [Brooks, D. Bradford; Zhou, Zhiguo] Luna Innovat Inc, Danville, VA USA.
C3 University of North Carolina; University of North Carolina Greensboro;
   Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Boston Children's Hospital; Harvard
   Medical School; Novartis; Harvard University; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute
RP Kepley, CL (通讯作者)，Univ N Carolina, Joint Sch Nanosci & Nanoengn, Greensboro, NC 27412 USA.
EM clkepley@uncg.edu
RI Kung, Andrew/AEU 0826 2022; Zhou, Zhiguo/S 4260 2018
OI Kung, Andrew/0000 0002 9091 488X; 
FU Novartis Institutes for Biomedical Research; Luna Innovations
   Incorporated
FX Novartis Institutes for Biomedical Research and Luna Innovations
   Incorporated provided support in the form of salaries for authors DL,
   DBB and ZZ, but did not have any additional role in the study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of these authors are articulated in the
   'author contributions' section.
CR Adiseshaiah P, 2013, INVEST RADIOL, V48, P745, DOI 10.1097/RLI.0b013e318294de5d
   Arab HH, 2013, TOXICOL APPL PHARM, V27, P00040
   Avnet S, 2007, INT J ONCOL, V30, P469
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bamborough P, 2010, DRUG NEWS PERSPECT, V23, P483, DOI 10.1358/dnp.2010.23.8.1447844
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Castor W., 2007, ARTHRITIS RHEUMATISM, V3, P140
   Chirico F, 2007, EXP DERMATOL, V16, P429, DOI 10.1111/j.1600 0625.2007.00545.x
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438
   Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001
   Dellinger A, 2013, J CARDIOVASC MAGN R, V15, DOI 10.1186/1532 429X 15 7
   Dellinger A, 2010, NANOMED NANOTECHNOL, V6, P575, DOI 10.1016/j.nano.2010.01.008
   Dellinger A, 2009, EXP DERMATOL, V18, P1079, DOI 10.1111/j.1600 0625.2009.00904.x
   Dellinger Anthony., 2012, J Nanomed Nanotechol, V3, P8, DOI [10.4172/2157 7439.1000153, DOI 10.4172/2157 7439.1000153]
   Drafi Frantisek, 2012, Interdiscip Toxicol, V5, P84, DOI 10.2478/v10102 012 0015 4
   Ehrich M, 2011, TOXICOL IN VITRO, V25, P301, DOI 10.1016/j.tiv.2010.09.010
   Eklund KK, 2007, IMMUNOL REV, V217, P38, DOI 10.1111/j.1600 065X.2007.00504.x
   Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015
   Foley S, 2002, BIOCHEM BIOPH RES CO, V294, P116, DOI 10.1016/S0006 291X(02)00445 X
   Fumelli C, 2000, J INVEST DERMATOL, V115, P835, DOI 10.1046/j.1523 1747.2000.00140.x
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0
   GRUBER B, 1988, CLIN EXP IMMUNOL, V71, P289
   GRUBER B, 1986, ARTHRITIS RHEUM US, V29, P944, DOI 10.1002/art.1780290802
   Handel ML, 2000, CLIN EXP PHARMACOL P, V27, P139, DOI 10.1046/j.1440 1681.2000.03216.x
   Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524
   Holmdahl R, 2002, AGEING RES REV, V1, P135, DOI 10.1016/S0047 6374(01)00371 2
   Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065
   IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273
   Jaswal S, 2003, CLIN CHIM ACTA, V338, P123, DOI 10.1016/j.cccn.2003.08.011
   Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898 6568(98)00037 0
   Kepley CL, 2005, INT ARCH ALLERGY IMM, V138, P29, DOI 10.1159/000087355
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Majumdar S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/jimmunol.167.5.2911
   Malbec O, 2007, IMMUNOL REV, V217, P206, DOI 10.1111/j.1600 065X.2007.00510.x
   Marcu KB, 2010, CURR DRUG TARGETS, V11, P599, DOI 10.2174/138945010791011938
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Nam NH, 2006, MINI REV MED CHEM, V6, P945, DOI 10.2174/138955706777934937
   Niedermeier M, 2010, BEST PRACT RES CL RH, V24, P527, DOI 10.1016/j.berh.2010.02.002
   Nigrovic PA, 2005, ARTHRITIS RES THER, V7, P1, DOI 10.1186/ar1446
   Nigrovic PA, 2007, IMMUNOL REV, V217, P19, DOI 10.1111/j.1600 065X.2007.00506.x
   Nigrovic PA, 2007, P NATL ACAD SCI USA, V104, P2325, DOI 10.1073/pnas.0610852103
   Nigrovic PA, 2010, ARTHRITIS RHEUM US, V62, P3322, DOI 10.1002/art.27659
   Norton SK, 2012, J ALLERGY CLIN IMMUN, V130, P761, DOI 10.1016/j.jaci.2012.04.023
   Norton SK, 2010, CTS CLIN TRANSL SCI, V3, P158, DOI 10.1111/j.1752 8062.2010.00212.x
   Noss EH, 2008, IMMUNOL REV, V223, P252, DOI 10.1111/j.1600 065X.2008.00648.x
   Park H, 2012, NAT REV IMMUNOL, V12, P570, DOI 10.1038/nri3261
   Park MK, 2012, IMMUNOL LETT, V148, P59, DOI 10.1016/j.imlet.2012.05.008
   Phillips DC, 2010, ANTIOXID REDOX SIGN, V12, P743, DOI 10.1089/ars.2009.2607
   Pitman N, 2011, ANN RHEUM DIS, V70, P1170, DOI 10.1136/ard.2010.134528
   Porter AE, 2006, ACTA BIOMATER, V2, P409, DOI 10.1016/j.actbio.2006.02.006
   Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076 6879(95)60154 6
   Roman Blas JA, 2008, INT REV IMMUNOL, V27, P351, DOI 10.1080/08830180802295740
   Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665
   Schubert N, 2015, ARTHRITIS RHEUMATOL, V67, P903, DOI 10.1002/art.38996
   Schwartz LB, 1993, BIOL MAST CELLS BASO, P135
   Sköldstam L, 2003, ANN RHEUM DIS, V62, P208, DOI 10.1136/ard.62.3.208
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Solomon S, 2005, ARTHRITIS RES THER, V7, P129, DOI 10.1186/ar1761
   STEINITZ K, 1947, Harefuah, V32, P174
   Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600 065X.2011.01088.x
   Swindle EJ, 2004, J BIOL CHEM, V279, P48751, DOI 10.1074/jbc.M409738200
   Swindle EJ, 2007, J IMMUNOL, V179, P7059, DOI 10.4049/jimmunol.179.10.7059
   Winyard PG, 2011, BIOCHEM SOC T, V39, P1226, DOI 10.1042/BST0391226
   Wruck CJ, 2011, ANN RHEUM DIS, V70, P844, DOI 10.1136/ard.2010.132720
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914
   Zhang W, 2012, INT IMMUNOPHARMACOL, V14, P27, DOI 10.1016/j.intimp.2012.06.001
   Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694
   Zhou ZG, 2010, BIOCONJUGATE CHEM, V21, P1656, DOI 10.1021/bc1001664
   Zorov DB, 2006, BBA BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029
NR 72
TC 44
Z9 46
U1 0
U2 40
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2015
VL 10
IS 4
AR e0126290
DI 10.1371/journal.pone.0126290
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CG1ES
UT WOS:000353016500120
PM 25879437
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Song, W
   Ye, L
   Tang, Q
   Lu, X
   Huang, X
   Xie, M
   Yu, S
   Yuan, Z
   Chen, L
AF Song, W.
   Ye, L.
   Tang, Q.
   Lu, X.
   Huang, X.
   Xie, M.
   Yu, S.
   Yuan, Z.
   Chen, L.
TI Rev erbα attenuates refractory periapical periodontitis via M1
   polarization: An in vitro and in vivo study
SO INTERNATIONAL ENDODONTIC JOURNAL
LA English
DT Article
DE endodontics; Enterococcus faecalis; immunity; inflammation; macrophages;
   periapical periodontitis
ID ENTEROCOCCUS FAECALIS; CLOCK
AB Aim: Rev erb alpha has been reported to regulate the healing of inflammatory lesions through its effect on the immune system in a variety of inflammatory disease. Moreover, the balance of macrophages polarization plays a crucial role in immune response and inflammatory progression. However, in refractory periapical periodontitis (RAP), the role of Rev erb alpha in inflammatory response and bone resorption by regulating macrophage polarization remains unclarified. The aims of the present study were to investigate the expression of Rev erb alpha in experimental RAP and to explore the relationship between Rev erb alpha and macrophage polarization through the application of its pharmacological agonist SR9009 into the in vivo and in vitro experiments. Methodology: Enterococcus faecalis induced RAP models were established in SD rats. Histological staining and micro computed tomography scanning were used to evaluate osteoclastogenesis and alveolar bone resorption. The expression of Rev erb alpha and macrophage polarization were detected in the periapical tissues from rats by immunofluorescence, flow cytometry, and western blots. Furthermore, immunohistochemical staining and enzyme linked immunosorbent assay were performed to explore the relationship between Rev erb alpha and inflammatory cytokines related to macrophage polarization. Result: Compared to healthy periapical tissue, the expression of Rev erb alpha was significantly down regulated in macrophages from inflammatory periapical area, especially in Enterococcus faecalis induced periapical lesions, with obvious type 1 macrophage (M1) like dominance and the production of pro inflammatory cytokines. In addition, Rev erb alpha activation by SR9009 could induce type 2 macrophage (M2) like polarization in periapical tissue and THP1 cell line, followed by increased secretion of anti inflammatory cytokines IL 10 and TGF beta. Furthermore, intracanal application of SR9009 reduced the lesion size and promoted the repair of RAP by decreasing the number of osteoclasts and enhancing the formation of mineralized tissue in periapical inflammatory lesions. Conclusions: Rev erb alpha played an essential role in the pathogenesis of RAP through its effect on macrophage polarization. Targeting Rev erb alpha might be a promising and prospective therapy method for the prevention and management of RAP.
C1 [Song, W.; Ye, L.; Tang, Q.; Lu, X.; Huang, X.; Xie, M.; Yu, S.; Yuan, Z.; Chen, L.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Stomatol, Wuhan, Peoples R China.
   [Song, W.; Ye, L.; Tang, Q.; Lu, X.; Huang, X.; Xie, M.; Yu, S.; Yuan, Z.; Chen, L.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan, Peoples R China.
   [Song, W.; Ye, L.; Tang, Q.; Lu, X.; Huang, X.; Xie, M.; Yu, S.; Yuan, Z.; Chen, L.] Hubei Prov Key Lab Oral & Maxillofacial Dev & Rege, Wuhan, Peoples R China.
   [Yuan, Z.; Chen, L.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Stomatol, Wuhan 430022, Peoples R China.
   [Yuan, Z.; Chen, L.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan 430030, Peoples R China.
   [Yuan, Z.; Chen, L.] Hubei Prov Key Lab Oral & Maxillofacial Dev & Rege, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology
RP Yuan, Z; Chen, L (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Stomatol, Wuhan 430022, Peoples R China.; Yuan, Z; Chen, L (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan 430030, Peoples R China.; Yuan, Z; Chen, L (通讯作者)，Hubei Prov Key Lab Oral & Maxillofacial Dev & Rege, Wuhan 430022, Peoples R China.
EM yuanzhenglin@hust.edu.cn; chenlili1030@hust.edu.cn
FU National Outstanding Youth Science Fund Project of National Natural
   Science Foundation of China
FX No Statement Availabler No Statement Availabler No Statement Available
CR Amir M, 2018, CELL REP, V25, P3733, DOI 10.1016/j.celrep.2018.11.101
   Bakhsh A, 2022, INT ENDOD J, V55, P923, DOI 10.1111/iej.13786
   Cavalla F, 2021, J DENT RES, V100, P29, DOI 10.1177/0022034520952341
   Chen XM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02531 y
   Choi JE, 2018, EXP NEUROBIOL, V27, P344, DOI 10.5607/en.2018.27.5.344
   Cui LY, 2021, AM J REPROD IMMUNOL, V86, DOI 10.1111/aji.13436
   Dai XZ, 2022, MICROBIOL SPECTR, V10, DOI 10.1128/spectrum.01045 22
   Elashiry MM, 2021, J ORAL MICROBIOL, V13, DOI 10.1080/20002297.2020.1868152
   Gentry Weeks CR, 1999, INFECT IMMUN, V67, P2160, DOI 10.1128/IAI.67.5.2160 2165.1999
   Griepentrog JE, 2020, J LEUKOCYTE BIOL, V107, P11, DOI 10.1002/JLB.4HI0519 155R
   Griffin P, 2019, P NATL ACAD SCI USA, V116, P5102, DOI 10.1073/pnas.1812405116
   Kao PHN, 2019, J MOL BIOL, V431, P2932, DOI 10.1016/j.jmb.2019.05.030
   Kou L, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02494 y
   Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209
   Lin DJ, 2018, BIOCHEM BIOPH RES CO, V498, P1028, DOI 10.1016/j.bbrc.2018.03.109
   Liu H, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2314 6
   Liu JM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.707844
   Mohammadi Z, 2011, INT ENDOD J, V44, P697, DOI 10.1111/j.1365 2591.2011.01886.x
   Momenijavid M, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11780 x
   Morioka N, 2019, BRAIN BEHAV IMMUN, V78, P116, DOI 10.1016/j.bbi.2019.01.014
   Nagendrababu V, 2021, INT ENDOD J, V54, P848, DOI 10.1111/iej.13477
   Polak D, 2021, INT ENDOD J, V54, P1840, DOI 10.1111/iej.13574
   Pourcet B, 2018, GASTROENTEROLOGY, V154, P1449, DOI 10.1053/j.gastro.2017.12.019
   Ramakrishnan Sathiya N, 2006, Nucl Recept Signal, V4, pe009
   Sakko Marjut, 2016, Prim Dent J, V5, P84, DOI 10.1308/205016816819304231
   Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030
   Song C, 2018, FASEB J, V32, P3215, DOI 10.1096/fj.201600825RRR
   Stuart CH, 2006, J ENDODONT, V32, P93, DOI 10.1016/j.joen.2005.10.049
   Sunde PT, 2002, J ENDODONT, V28, P304, DOI 10.1097/00004770 200204000 00011
   Wang HW, 2020, J ENDODONT, V46, P65, DOI 10.1016/j.joen.2019.10.001
   Wang LN, 2019, ORAL DIS, V25, P1769, DOI 10.1111/odi.13169
   Xu RS, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0058 x
   Zhang CJ, 2015, J ENDODONT, V41, P1207, DOI 10.1016/j.joen.2015.04.008
   Zhou ZY, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113773
NR 34
TC 3
Z9 3
U1 7
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0143 2885
EI 1365 2591
J9 INT ENDOD J
JI Int. Endod. J.
PD APR
PY 2024
VL 57
IS 4
BP 451
EP 463
DI 10.1111/iej.14024
EA JAN 2024
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA KM5N6
UT WOS:001152204700001
PM 38279698
DA 2025 08 17
ER

PT J
AU Hatt, LP
   Thompson, K
   Müller, WEG
   Stoddart, MJ
   Armiento, AR
AF Hatt, Luan Phelipe
   Thompson, Keith
   Mueller, Werner E. G.
   Stoddart, Martin James
   Armiento, Angela Rita
TI Calcium Polyphosphate Nanoparticles Act as an Effective Inorganic
   Phosphate Source during Osteogenic Differentiation of Human Mesenchymal
   Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteogenic differentiation; mesenchymal stem cells;
   beta glycerolphosphate; inorganic polyphosphate; Ca polyphosphate
   nanoparticles
ID EXPRESSION; MINERALIZATION
AB The ability of bone marrow derived mesenchymal stem/stromal cells (BM MSCs) to differentiate into osteoblasts makes them the ideal candidate for cell based therapies targeting bone diseases. Polyphosphate (polyP) is increasingly being studied as a potential inorganic source of phosphate for extracellular matrix mineralisation. The aim of this study is to investigate whether polyP can effectively be used as a phosphate source during the in vitro osteogenic differentiation of human BM MSCs. Human BM MSCs are cultivated under osteogenic conditions for 28 days with phosphate provided in the form of organic beta glycerolphosphate (BGP) or calcium polyP nanoparticles (polyP NP). Mineralisation is demonstrated using Alizarin red staining, cellular ATP content, and free phosphate levels are measured in both the cells and the medium. The effects of BGP or polyP NP on alkaline phosphatase (ALP) activity and gene expression of a range of osteogenic related markers are also assessed. PolyP NP supplementation displays comparable effects to the classical BGP containing osteogenic media in terms of mineralisation, ALP activity and expression of osteogenesis associated genes. This study shows that polyP NP act as an effective source of phosphate during mineralisation of BM MSC. These results open new possibilities with BM MSC based approaches for bone repair to be achieved through doping of conventional biomaterials with polyP NP.
C1 [Hatt, Luan Phelipe; Thompson, Keith; Stoddart, Martin James; Armiento, Angela Rita] AO Res Inst Davos, CH 7270 Davos, Switzerland.
   [Mueller, Werner E. G.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, D 55131 Mainz, Germany.
C3 AO Foundation; Johannes Gutenberg University of Mainz
RP Armiento, AR (通讯作者)，AO Res Inst Davos, CH 7270 Davos, Switzerland.
EM phelipe.hatt@aofoundation.org; keith.thompson@aofoundation.org;
   wmueller@uni mainz.de; martin.stoddart@aofoundation.org;
   angela.armiento@aofoundation.org
RI ; Wang, Xiaohong/AAR 5526 2020; Armiento, Angela/AAE 6362 2021;
   Stoddart, Martin/E 3240 2013
OI Muller, Werner E.G./0000 0002 8223 3689; Stoddart,
   Martin/0000 0002 9538 1517; Thompson, Keith/0000 0002 9167 5147; Hatt,
   Luan Phelipe/0000 0001 5278 2209; Armiento, Angela
   Rita/0000 0002 3285 0419
FU AO Foundation; AO CMF RD award
FX This research was funded by AO Foundation by way of an AO CMF R&D award.
CR Beck GR, 2003, J CELL BIOCHEM, V90, P234, DOI 10.1002/jcb.10622
   BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169 6009(92)90707 K
   CASSELLA JP, 1995, CALCIFIED TISSUE INT, V56, P118, DOI 10.1007/BF00296342
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Fatherazi S, 2009, J DENT RES, V88, P39, DOI 10.1177/0022034508328072
   Foster BL, 2006, CALCIFIED TISSUE INT, V78, P103, DOI 10.1007/s00223 005 0184 7
   Gardner OFW, 2015, METHODS MOL BIOL, V1340, P41, DOI 10.1007/978 1 4939 2938 2_3
   GRONOWICZ G, 1989, J BONE MINER RES, V4, P313
   Hacchou Y, 2007, J DENT RES, V86, P893, DOI 10.1177/154405910708600917
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kato K, 2018, IN VITRO CELL DEV AN, V54, P449, DOI 10.1007/s11626 018 0257 3
   Kawazoe Y, 2008, INT J BIOL SCI, V4, P37, DOI 10.7150/ijbs.4.37
   Leyhausen G, 1998, J BONE MINER RES, V13, P803, DOI 10.1359/jbmr.1998.13.5.803
   Loebel C, 2015, TISSUE ENG PT A, V21, P115, DOI [10.1089/ten.tea.2014.0096, 10.1089/ten.TEA.2014.0096]
   Morimoto D, 2010, J BONE MINER METAB, V28, P418, DOI 10.1007/s00774 010 0157 4
   Müller WEG, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201905220
   Müller WEG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020427
   Müller WEG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188977
   Müller WEG, 2016, ACTA BIOMATER, V31, P358, DOI 10.1016/j.actbio.2015.11.060
   Müller WEG, 2015, MATER LETT, V148, P163, DOI 10.1016/j.matlet.2015.02.070
   Müller WEG, 2015, J CELL SCI, V128, P2202, DOI 10.1242/jcs.170605
   Schäck LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065943
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Tada H, 2011, BONE, V48, P1409, DOI 10.1016/j.bone.2011.03.675
   Usui Y, 2010, J DENT RES, V89, P504, DOI 10.1177/0022034510363096
   Wu ATH, 2015, BIOMACROMOLECULES, V16, P166, DOI 10.1021/bm501356c
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 29
TC 20
Z9 20
U1 1
U2 25
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2019
VL 20
IS 22
AR 5801
DI 10.3390/ijms20225801
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JW0YW
UT WOS:000502786800283
PM 31752206
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, HC
   Liu, SW
   Li, W
   Zhao, XF
   Zhao, X
   Cheng, M
   Qiu, L
   Ma, J
AF Cheng, Huan Chen
   Liu, Sheng Wei
   Li, Wei
   Zhao, Xue Fei
   Zhao, Xu
   Cheng, Mei
   Qiu, Lin
   Ma, Jun
TI Arsenic trioxide regulates adipogenic and osteogenic differentiation in
   bone marrow MSCs of aplastic anemia patients through BMP4 gene
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE arsenic trioxide; mesenchymal stem cells; differentiation; BMP4
ID ACUTE PROMYELOCYTIC LEUKEMIA; MESENCHYMAL STROMAL CELLS
AB The typical pathological feature of aplastic anemia (AA) is the rise in the number of fat cells and the reduction of osteoblasts in bone marrow. However, both fat cells and osteobalsts in bone marrow are derived from the mesenchymal stem cells (MSCs). Generally, the adipogenic and osteogenic differentiation is a dynamic and balanceable process. The imbalance of the adipogenic and osteogenic differentiation may participate in the occurrence and progress of many diseases. Arsenic trioxide (ATO) could induce differentiation and apoptosis in tumor cells. In this study, Oil Red O and Alizarin red were used to detect the adipogenic and osteogenic differentiation. The ability of adipogenic differentiation is much higher, whereas the osteogenic differentiation is much lower in the MSCs of AA patients compared with healthy controls. ATO inhibits adipogenic differentiation and promotes osteogenic differentiation in the MSC of AA patients. The expression of BMP4 is increased with ATO treatment. The ability of adipogenic differentiation is decreased, whereas the osteogenic differentiation is increased after transfection of BMP4 gene into the MSCs of AA patients. This study shows that ATO regulates the adipogenic and osteogenic differentiation balance of MSCs in AA, which provides a theoretical basis for the adjunctive therapy of ATO on AA. The BMP4 gene is involved in the ATO regulation of adipogenic and osteogenic differentiation balance, which provides a new target for the treatment of AA.
C1 [Cheng, Huan Chen; Liu, Sheng Wei; Li, Wei; Zhao, Xue Fei; Zhao, Xu; Cheng, Mei; Qiu, Lin; Ma, Jun] First Hosp Harbin, Inst Hematol & Oncol, Harbin 150010, Peoples R China.
RP Ma, J (通讯作者)，First Hosp Harbin, Inst Hematol & Oncol, Harbin 150010, Peoples R China.
EM haerbinxys@126.com
RI zhao, xuefei/N 5237 2017
FU China Postdoctoral Fund [20110491102]
FX The work was supported by a grant from the China Postdoctoral Fund (No.
   20110491102).
CR Arai Fumio, 2005, Clin Calcium, V15, P73
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Bakrania P, 2008, AM J HUM GENET, V82, P304, DOI 10.1016/j.ajhg.2007.09.023
   Chao YH, 2010, ANN HEMATOL, V89, P715, DOI 10.1007/s00277 009 0892 6
   Cheng HC, 2011, ACTA BIOCH BIOPH SIN, V43, P204, DOI 10.1093/abbs/gmq130
   Galimberti S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 53
   Gottschling S, 2007, STEM CELLS, V25, P798, DOI 10.1634/stemcells.2006 0513
   KACHINSKAS DJ, 1994, CELL GROWTH DIFFER, V5, P1235
   Li N, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 61
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qian SW, 2013, P NATL ACAD SCI USA, V110, pE798, DOI 10.1073/pnas.1215236110
   Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901
   Trouba KJ, 2000, TOXICOL APPL PHARM, V168, P25, DOI 10.1006/taap.2000.9012
   Walenda T, 2010, J CELL MOL MED, V14, P337, DOI 10.1111/j.1582 4934.2009.00776.x
   Wang GJ, 2004, HEMATOL ONCOL, V22, P63, DOI 10.1002/hon.728
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762
NR 18
TC 18
Z9 21
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD SEP
PY 2015
VL 47
IS 9
BP 673
EP 679
DI 10.1093/abbs/gmv065
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CQ0VR
UT WOS:000360316400002
PM 26215597
DA 2025 08 17
ER

PT J
AU Gabay, C
   Msihid, J
   Zilberstein, M
   Paccard, C
   Lin, Y
   Graham, NMH
   Boyapati, A
AF Gabay, Cem
   Msihid, Jerome
   Zilberstein, Moshe
   Paccard, Caroline
   Lin, Yong
   Graham, Neil M. H.
   Boyapati, Anita
TI Identification of sarilumab pharmacodynamic and predictive markers in
   patients with inadequate response to TNF inhibition: a biomarker
   substudy of the phase 3 TARGET study
SO RMD OPEN
LA English
DT Article
ID ACTIVE RHEUMATOID ARTHRITIS; SOLUBLE INTERLEUKIN 6; OSTEOCLAST
   FORMATION; SYNOVIAL FLUID; IL 6 RECEPTOR; SERUM LEVELS; METHOTREXATE;
   TOCILIZUMAB; INDUCTION; ALPHA
AB Introduction Interleukin 6 (IL 6) orchestrates formation of an inflammatory pannus, leading to joint damage in rheumatoid arthritis (RA). Sarilumab is a human monoclonal antibody blocking the IL 6R alpha. In TARGET (NCT01709578), a phase 3 study in adults with moderate to severe RA and inadequate response or intolerance to tumour necrosis factor inhibitors, subcutaneous sarilumab 200 mg or 150 mg every 2 weeks (q2w) plus conventional synthetic disease modifying antirheumatic drugs (csDMARDs) significantly reduced disease activity versus placebo plus csDMARDs.
   Methods Circulating levels of biomarkers associated with synovial inflammation (matrix metalloproteinase 3 (MMP 3), collagen type I MMP cleaved fragment (C1M), collagen type III MMP cleaved fragment (C3M)), myeloid (soluble intercellular adhesion molecule 1 (sICAM 1), IL 8 and calprotectin) and lymphoid activation (chemokine, CXC motif, ligand 13 (CXCL13), CXCL10, B cell activating factor) and bone remodelling (receptor activator of nuclear factor kappa B ligand (RANKL), osteoprotegerin and osteocalcin) were evaluated in patients from a TARGET substudy.
   Results Sarilumab significantly decreased C1M, C3M, CXCL13, MMP 3 and total RANKL levels at week 24 versus placebo; some markers were significantly suppressed at week 2 and normalised to levels in healthy controls. Levels of sICAM 1 were predictive of disease activity score by C reactive protein and clinical disease activity index low disease activity (LDA) response in the sarilumab 200 mg q2w group at week 12. A trend was observed in which patients with lower sICAM 1 levels at baseline had better response compared with patients with higher sICAM 1.
   Conclusions Sarilumab plus csDMARDs decreased circulating biomarkers of synovial inflammation and bone resorption; sICAM 1 was predictive of achieving LDA with sarilumab.
C1 [Gabay, Cem] Univ Hosp Geneva, Geneva, Switzerland.
   [Msihid, Jerome; Paccard, Caroline] Sanofi R&D, Chilly Mazarin, France.
   [Zilberstein, Moshe] Sanofi R&D, Bridgewater, NJ USA.
   [Lin, Yong] Sanofi Genzyme, Bridgewater, NJ USA.
   [Graham, Neil M. H.; Boyapati, Anita] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
C3 University of Geneva; Sanofi Aventis; Sanofi France; Sanofi Aventis;
   Sanofi USA; Sanofi Aventis; Genzyme Corporation; Regeneron
RP Boyapati, A (通讯作者)，Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
EM anita.boyapati@regeneron.com
RI Gabay, Cem/LJM 4539 2024
FU Sanofi Genzyme; Regeneron Pharmaceuticals, Inc.
FX This study was sponsored by Sanofi Genzyme and Regeneron
   Pharmaceuticals, Inc.
CR BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Boumans MJH, 2012, ANN RHEUM DIS, V71, P108, DOI 10.1136/annrheumdis 2011 200198
   Boyapati A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1132 9
   Chastek B, 2017, J MED ECON, V20, P464, DOI 10.1080/13696998.2016.1275653
   Choi IY, 2015, ANN RHEUM DIS, V74, P499, DOI 10.1136/annrheumdis 2013 203923
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555
   Desgeorges A, 1997, J RHEUMATOL, V24, P1510
   Ferraccioli G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040362
   Fleischmann R, 2017, ARTHRITIS RHEUMATOL, V69, P277, DOI 10.1002/art.39944
   Genovese MC, 2015, ARTHRITIS RHEUMATOL, V67, P1424, DOI 10.1002/art.39093
   Han BK, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0995 0
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Huizinga TWJ, 2014, ANN RHEUM DIS, V73, P1626, DOI 10.1136/annrheumdis 2013 204405
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Karsdal MA, 2012, SEMIN ARTHRITIS RHEU, V42, P131, DOI 10.1016/j.semarthrit.2012.01.004
   Koczan D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2419
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   SACK U, 1993, RHEUMATOL INT, V13, P45, DOI 10.1007/BF00307733
   Sebba A, 2008, AM J HEALTH SYST PH, V65, P1413, DOI 10.2146/ajhp070449
   Srirangan S, 2010, THER ADV MUSCULOSKEL, V2, P247, DOI 10.1177/1759720X10378372
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Uson J, 1997, J RHEUMATOL, V24, P2069
   Yasunori K, 2008, CLIN RHEUMATOL, V27, P1093, DOI 10.1007/s10067 008 0870 8
NR 25
TC 26
Z9 28
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2056 5933
J9 RMD OPEN
JI RMD Open
PD FEB
PY 2018
VL 4
IS 1
AR UNSP e000607
DI 10.1136/rmdopen 2017 000607
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA JM3UZ
UT WOS:000496144900009
PM 29556418
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tabatabaei, FS
   Jazayeri, M
   Ghahari, P
   Haghighipour, N
AF Tabatabaei, F. S.
   Jazayeri, M.
   Ghahari, P.
   Haghighipour, N.
TI Effects of Equiaxial Strain on the Differentiation of Dental Pulp Stem
   Cells without Using Biochemical Reagents
SO MOLECULAR & CELLULAR BIOMECHANICS
LA English
DT Article
ID PERIODONTAL LIGAMENT FIBROBLASTS; ORTHODONTIC TOOTH MOVEMENT; OSTEOGENIC
   DIFFERENTIATION; IN VITRO; TENSILE STRAIN; EXPRESSION; MECHANOBIOLOGY;
   PATHWAY; STRESS; TISSUE
AB During orthodontic treatments, applied mechanical forces create strain and result in tooth movement through the alveolar bone. This response to mechanical strain is a fundamental biological reaction. The present study evaluated the effect of equiaxial strain within the range of orthodontic forces on the osteogenic differentiation of human dental pulp stem cells (hDPSCs). Following isolation and culture of hDPSCs, 3rd passage cells were transferred on a silicone membrane covered with collagen. Cell adhesion to the membrane was evaluated under scanning electron microscope (SEM). Cells were divided into three groups: the first group was placed in a conventional culture medium, transferred to an equiaxial stretching device (3% strain for 2 weeks). The positive control was placed in an osteogenic medium with no mechanical strain. The negative control group was placed in the conventional culture medium with no mechanical strain either. Study groups were evaluated for expression of osteogenic markers (Alkaline phosphatase and Osteopontin) with immunofluorescence and real time PCR. SEM images revealed optimal adhesion of cells to the silicone membrane. Immunofluorescence study demonstrated that osteocalcin expression occurred after 2 weeks in the two groups under mechanical and chemical signals. After application of equiaxial strain, level of expression of osteogenic markers was significantly higher than in the negative and positive control groups. Based on the study results, static equiaxial strain which mimics the types of orthodontic forces can result in differentiation of hDPSCs to osteoblasts. The results obtained may be used in cell therapy and tissue engineering.
C1 [Tabatabaei, F. S.] Shahid Beheshti Univ Med Sci, Sch Dent, Dept Dent Mat, Tehran, Iran.
   [Jazayeri, M.; Haghighipour, N.] Pasteur Inst Iran, Natl Cell Bank Iran, Tehran, Iran.
   [Ghahari, P.] Shahid Beheshti Univ Med Sci, Sch Dent, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Pasteur Network; Pasteur
   Institute of Iran; Shahid Beheshti University Medical Sciences
RP Haghighipour, N (通讯作者)，Pasteur Inst Iran, Natl Cell Bank Iran, 12 Farvardin Ave,Pasteur Ave, Tehran, Iran.
EM haghighipour@pasteur.ac.ir
RI Jazayeri, Maryam/KCY 5297 2024; Tabatabaei, Fahimeh/P 4766 2017;
   haghighipour, nooshin/K 9617 2017; Haghighipour, Nooshin/K 9617 2017
OI Tabatabaei, Fahimeh/0000 0002 5951 4853; haghighipour,
   nooshin/0000 0003 3605 6770; Jazayeri, Maryam/0000 0001 6144 8691; 
FU Shahid Beheshti university of Medical Science [89 01 92 7038]
FX This study is a revised version of a doctoral thesis submitted by
   Parastoo Ghahari, supported by the Shahid Beheshti university of Medical
   Science (project number 89 01 92 7038).
CR Aarden EM, 1996, BONE, V18, P305, DOI 10.1016/8756 3282(96)00010 5
   Cai XX, 2011, J TISSUE ENG REGEN M, V5, P347, DOI 10.1002/term.319
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Dado D, 2012, REGEN MED, V7, P101, DOI [10.2217/RME.11.99, 10.2217/rme.11.99]
   Field C, 2009, AM J ORTHOD DENTOFAC, V135, P174, DOI 10.1016/j.ajodo.2007.03.032
   Haghighipour N, 2010, ARTIF ORGANS, V34, P481, DOI 10.1111/j.1525 1594.2010.01003.x
   Han MJ, 2008, BIOTECHNOL BIOPROC E, V13, P410, DOI [10.1007/s12257 008 0146 9, 10.1007/S12257 008 0146 9]
   Henneman S, 2008, EUR J ORTHODONT, V30, P299, DOI 10.1093/ejo/cjn020
   Howard PS, 1998, J PERIODONTAL RES, V33, P500
   Huang GTJ, 2006, CELL TISSUE RES, V324, P225, DOI 10.1007/s00441 005 0117 9
   Jang JY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/860652
   Kearney EM, 2010, ANN BIOMED ENG, V38, P1767, DOI 10.1007/s10439 010 9979 4
   Kook SH, 2009, J CELL BIOCHEM, V106, P1060, DOI 10.1002/jcb.22085
   Lee SK, 2010, LIFE SCI, V86, P107, DOI 10.1016/j.lfs.2009.11.013
   Ma DD, 2012, J ENDODONT, V38, P796, DOI 10.1016/j.joen.2012.02.014
   Mao Jeremy J, 2010, Semin Orthod, V16, P143
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mori G, 2011, ANN NY ACAD SCI, V1237, P47, DOI 10.1111/j.1749 6632.2011.06234.x
   Pereira LO, 2012, INT ENDOD J, V45, P1080, DOI 10.1111/j.1365 2591.2012.02068.x
   Ren YJ, 2003, ANGLE ORTHOD, V73, P86
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Sübay RK, 2001, J ENDODONT, V27, P508, DOI 10.1097/00004770 200108000 00003
   Sumanasinghe RD, 2006, TISSUE ENG, V12, P3459, DOI 10.1089/ten.2006.12.3459
   Wang JHC, 2006, BIOMECH MODEL MECHAN, V5, P1, DOI 10.1007/s10237 005 0012 z
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Yamamoto E, 2002, J BIOMECH ENG T ASME, V124, P85, DOI 10.1115/1.1427924
   Yu V, 2009, BIOCHEM BIOPH RES CO, V386, P661, DOI 10.1016/j.bbrc.2009.06.106
   Zhang WB, 2006, TISSUE ENG, V12, P2813, DOI 10.1089/ten.2006.12.2813
NR 29
TC 20
Z9 22
U1 1
U2 10
PU TECH SCIENCE PRESS
PI HENDERSON
PA 871 CORONADO CENTER DR, SUTE 200, HENDERSON, NV 89052 USA
SN 1556 5297
EI 1556 5300
J9 MOL CELL BIOMECH
JI Mol. Cell. Biomech.
PD SEP
PY 2014
VL 11
IS 3
BP 209
EP 220
PG 12
WC Cell Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA CD2YQ
UT WOS:000350945300003
PM 25831861
DA 2025 08 17
ER

PT J
AU Purswani, MU
   Jacobson, DL
   Dimeglio, LA
   Yao, TJ
   Kopp, JB
   Van Dyke, RB
   Yu, WY
   Siberry, GK
AF Purswani, Murli U.
   Jacobson, Denise L.
   Dimeglio, Linda A.
   Yao, Tzy Jyun
   Kopp, Jeffrey B.
   Van Dyke, Russell B.
   Yu, Wendy
   Siberry, George K.
CA Pediat HIV
TI Phosphaturia in HIV Exposed Uninfected Neonates Associated with Maternal
   Use of Tenofovir Disoproxil Fumarate in Late Pregnancy
SO JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
LA English
DT Article
DE HEU; in utero exposure; 25 OH vitamin D; percent tubular reabsorption of
   phosphate; renal; TDF
ID BONE MINERAL DENSITY; BETA TRACE PROTEIN; PHOSPHONOAMIDATE PRODRUGS;
   ANTIRETROVIRAL THERAPY; INFANTS; CHILDREN; WOMEN; PHARMACOKINETICS;
   ADOLESCENTS; POPULATION
AB Background Tenofovir disoproxil fumarate (TDF) is often used in treating pregnant women living with HIV. Third trimester TDF exposure is associated with a 12% reduction in bone mineral content in HIV exposed uninfected (HEU) neonates. The potential mechanisms underlying this observation are unknown.Methods The TDF study enrolled newborns of gestational age >= 36 weeks from the Surveillance Monitoring for Antiretroviral Therapy and Toxicities study based on in utero TDF exposure (TDF use >= 8 weeks in the third trimester vs none). Blood and urine samples were collected cross sectionally within 30 days of birth to assess renal function (serum creatinine, serum phosphate, eGFR, percent tubular reabsorption of phosphate [PTRP]), and bone turnover (serum parathyroid hormone, 25 OH vitamin D [25(OH)D], and urinary cross linked N telopeptide of type 1 collagen). For each biomarker, a LOESS plot was fit using values at age at specimen collection; regression lines over age were fit among samples collected from 4 to 30 days, to compare slopes by TDF exposure.Results Among 141 neonates, 77 were TDF exposed and 64 TDF unexposed. Between age 4 and 30 days, PTRP decreased more rapidly in the TDF exposed compared to the unexposed group with slopes of  0.58 vs  0.08/day (difference  0.50/day [95% CI  0.88,  0.11]). Slopes for 25(OH)D were similar in both groups, but serum levels were lower in TDF exposed neonates (median [IQR]: 22 [19, 29] vs 26 [22, 37] ng/mL). No differences were observed for other biomarkers.Conclusions Third trimester in utero exposure to TDF is associated with increased urinary loss of phosphate and lower serum concentrations of 25(OH)D in HEU neonates.
   TDF use during the third trimester of pregnancy in women living with HIV is associated with lower serum 25 OH vitamin D levels and increased urinary phosphate loss in their exposed but uninfected offspring within the first 30 days of life.
C1 [Purswani, Murli U.] Icahn Sch Med Mt Sinai, Div Pediat Infect Dis, BronxCare Hlth Syst, Bronx, NY USA.
   [Jacobson, Denise L.; Yao, Tzy Jyun; Yu, Wendy] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA.
   [Dimeglio, Linda A.] Indiana Univ Sch Med, Riley Hosp Children IU Hlth, Div Pediat Endocrinol & Diabetol, Indianapolis, IN USA.
   [Kopp, Jeffrey B.] NIDDK, Kidney Dis Sect, NIH, Bethesda, MD USA.
   [Van Dyke, Russell B.] Tulane Univ, Sch Med, Sect Pediat Infect Dis, New Orleans, LA USA.
   [Siberry, George K.] United States Agcy Int Dev USAID, Prevent Care & Treatment Div, Off HIV AIDS, Washington, DC USA.
C3 Icahn School of Medicine at Mount Sinai; BronxCare Health System;
   Harvard University; Harvard T.H. Chan School of Public Health; Indiana
   University System; Indiana University Bloomington; Indiana University
   Health; James Whitcomb Riley Hospital Children; National Institutes of
   Health (NIH)   USA; NIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK); Tulane University
RP Purswani, MU (通讯作者)，BronxCare Hlth Syst, Dept Pediat, Div Pediat Infect Dis, 1685 Morris Ave,Suite 1G, Bronx, NY 10457 USA.
EM mpurswan@bronxcare.org
RI ; Kopp, Jeffrey/O 2681 2015; Purswani, Murli/F 7995 2019; DiMeglio,
   Linda/F 9277 2019
OI Kohlhoff, Stephan/0000 0001 9561 0407; Purswani,
   Murli/0000 0001 6902 7779; Siberry, George/0000 0002 5999 1596; 
FU Eunice Kennedy Shriver National Institute of Child Health & Human
   Development; Office of the Director, National Institutes of Health;
   National Institute of Dental and Craniofacial Research; National
   Institute of Allergy and Infectious Diseases; National Institute of
   Neurological Disorders and Stroke; National Institute on Deafness and
   Other Communication Disorders; National Institute of Mental Health;
   National Institute on Drug Abuse; National Cancer Institute; National
   Institute on Alcohol Abuse and Alcoholism; National Heart, Lung, and
   Blood Institute; Harvard T.H. Chan School of Public Health [HD052102];
   Tulane University School of Medicine [HD052104]; Harvard T.H. Chan
   School of Public Health [P01HD103133]; Intramural Research Program,
   National Institute of Diabetes and Digestive and Kidney Diseases
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health & Human Development, Office of the Director, National
   Institutes of Health, National Institute of Dental and Craniofacial
   Research, National Institute of Allergy and Infectious Diseases,
   National Institute of Neurological Disorders and Stroke, National
   Institute on Deafness and Other Communication Disorders, National
   Institute of Mental Health, National Institute on Drug Abuse, National
   Cancer Institute, National Institute on Alcohol Abuse and Alcoholism,
   and National Heart, Lung, and Blood Institute through co operative
   agreements with the Harvard T.H. Chan School of Public Health (grant
   number HD052102) (Principal Investigator: George R Seage III; Program
   Director: Liz Salomon) and the Tulane University School of Medicine
   (grant number HD052104) (Principal Investigator: Russell Van Dyke*;
   Co Principal Investigator: Ellen Chadwick; Project Director: Patrick
   Davis), and through Harvard T.H. Chan School of Public Health for the
   Pediatric HIV/AIDS Cohort Study 2020 (grant number P01HD103133)
   (Multiple Principal Investigators: Ellen Chadwick, Sonia Hernandez Diaz,
   Jennifer Jao, Paige Williams; Program Director: Liz Salomon). Data
   management services were provided by Frontier Science (Data Management
   Center Director: Suzanne Siminski), and regulatory services and
   logistical support were provided by Westat, Inc. (Project Directors:
   Julie Davidson, Tracy Wolbach). Jeffrey Kopp is supported by the
   Intramural Research Program, National Institute of Diabetes and
   Digestive and Kidney Diseases. The conclusions and opinions expressed in
   this article are those of the authors and do not necessarily reflect
   those of the United States Agency for International Development,
   National Institutes of Health, or U.S. Department of Health and Human
   Services.
CR Allegaert K, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00366
   [Anonymous], Prevention of Mother to Child HIV Transmission
   [Anonymous], Preexposure prophylaxis for the prevention of HIV in the United States   2017
   Bariciak E, 2011, CLIN BIOCHEM, V44, P1156, DOI 10.1016/j.clinbiochem.2011.06.987
   Best BM, 2015, HIV MED, V16, P502, DOI 10.1111/hiv.12252
   Birkus G, 2008, MOL PHARMACOL, V74, P92, DOI 10.1124/mol.108.045526
   Birkus G, 2007, ANTIMICROB AGENTS CH, V51, P543, DOI 10.1128/AAC.00968 06
   Calza L, 2019, NEW MICROBIOL, V42, P145
   Fernandez Fernandez B, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/354908
   Filler G, 2016, CURR OPIN PEDIATR, V28, P173, DOI 10.1097/MOP.0000000000000318
   Filler G, 2014, CLIN NEPHROL, V81, P269, DOI 10.5414/CN108089
   Fioroti CEA, 2022, REV INST MED TROP SP, V64, DOI [10.1590/S1678 9946202264010, 10.1590/s1678 9946202264010]
   Floridia M, 2016, J ANTIMICROB CHEMOTH, V71, P3206, DOI 10.1093/jac/dkw268
   Gafni RI, 2006, PEDIATRICS, V118, pE711, DOI 10.1542/peds.2005 2525
   Gattineni J, 2015, PEDIATR NEPHROL, V30, P2085, DOI 10.1007/s00467 013 2666 6
   Grant PM, 2016, CURR OPIN HIV AIDS, V11, P326, DOI 10.1097/COH.0000000000000248
   Havens PL, 2018, ANTIVIR THER, V23, P623, DOI 10.3851/IMP3269
   Himes SK, 2015, PEDIATR INFECT DIS J, V34, P851, DOI 10.1097/INF.0000000000000747
   Hirt D, 2009, CLIN PHARMACOL THER, V85, P182, DOI 10.1038/clpt.2008.201
   Huang JS, 2013, HIV CLIN TRIALS, V14, P224, DOI 10.1310/hct1405 224
   Jacobson DL, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115515
   Kourtis AP, 2018, PEDIATR INFECT DIS J, V37, pE264, DOI [10.1097/INF.0000000000002152, 10.1097/inf.0000000000002152]
   Kovacs CS, 2014, PHYSIOL REV, V94, P1143, DOI 10.1152/physrev.00014.2014
   Kuczmarski RJ., 2002, Vital Health Stat 11, P1
   Labcorp, ENDOCRINOLOGY EXPECT
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898 1906.2005
   Conesa Buendía FM, 2019, J BONE MINER RES, V34, P923, DOI 10.1002/jbmr.3665
   Mills A, 2016, LANCET INFECT DIS, V16, P43, DOI 10.1016/S1473 3099(15)00348 5
   Mohamed M, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.546544
   Nachega JB, 2017, JAIDS J ACQ IMM DEF, V76, P1, DOI 10.1097/QAI.0000000000001359
   Noe S, 2018, ADV PHARMACOL SCI, V2018, DOI 10.1155/2018/6069131
   Office of AIDS Research Advisory Council, 2022, GUIDELINES USE ANTIR
   Office of AIDS Research Advisory Council, 2024, RECOMMENDATIONS USE
   Osorio LE, 2017, PEDIATR INFECT DIS J, V36, P184, DOI 10.1097/INF.0000000000001386
   Pintye J, 2021, AIDS, V35, P267, DOI 10.1097/QAD.0000000000002730
   Pintye J, 2021, J INFECT DIS, V223, P638, DOI 10.1093/infdis/jiaa398
   Prieto Alhambra D, 2014, JAIDS J ACQ IMM DEF, V66, P90, DOI 10.1097/QAI.0000000000000112
   Purswani M, 2013, PEDIATR INFECT DIS J, V32, P495, DOI 10.1097/INF.0b013e31827f4eff
   Ryom L, 2019, J INFECT DIS, V220, P1629, DOI 10.1093/infdis/jiz369
   Salvadori N, 2019, CLIN INFECT DIS, V69, P144, DOI 10.1093/cid/ciy982
   Sato J, 2010, PEDIATR INT, V52, P398, DOI 10.1111/j.1442 200X.2010.03086.x
   Sax Paul E, 2014, J Acquir Immune Defic Syndr, V67, P52, DOI 10.1097/QAI.0000000000000225
   Siberry GK, 2015, CLIN INFECT DIS, V61, P996, DOI 10.1093/cid/civ437
   Siberry GK, 2012, AIDS, V26, P1151, DOI 10.1097/QAD.0b013e328352d135
   Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156
   The John Hopkins Hospital, 2020, HARRIET LANE HDB
   Tourret J, 2013, J AM SOC NEPHROL, V24, P1519, DOI 10.1681/ASN.2012080857
   Ustianowski A, 2015, INFECT DIS THER, V4, P145, DOI 10.1007/s40121 015 0070 1
   Van Dyke RB, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00199
   Vhembo T, 2023, JAIDS J ACQ IMM DEF, V93, P431, DOI 10.1097/QAI.0000000000003218
   World Health Organization (WHO), 2022, Stanford Report
   ,, 2014, Pediatrics, V134, pe1229, DOI 10.1542/peds.2014 2173
NR 52
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048 7193
EI 2048 7207
J9 J PEDIAT INF DIS SOC
JI J. Pediatr. Infect. Dis. Soc.
PD JUN 19
PY 2024
VL 13
IS 8
BP 396
EP 405
DI 10.1093/jpids/piae054
EA MAY 2024
PG 10
WC Infectious Diseases; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases; Pediatrics
GA D5W1Z
UT WOS:001249357200001
PM 38820092
OA Green Published
DA 2025 08 17
ER

PT J
AU Reis, AMS
   Ocarino, ND
   Boeloni, JN
   Gomes, DA
   Goes, AM
   Ferreira, AD
   Serakides, R
AF Sena Reis, Amanda Maria
   Ocarino, Natalia de Melo
   Boeloni, Jankerle Neves
   Gomes, Dawidson Assis
   Goes, Alfredo Miranda
   Ferreira, Andrea da Fonseca
   Serakides, Rogeria
TI Inhibition of the osteogenic differentiation of mesenchymal stem cells
   derived from the offspring of rats treated with caffeine during
   pregnancy and lactation
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Caffeine; lactation; pregnancy; stem cell; rat
ID OSTEOBLAST LIKE CELLS; VITAMIN D RECEPTOR; BONE MARROW; PROGRESSIVE
   DEVELOPMENT; HEMATOPOIETIC CELLS; STROMAL CELLS; EXPRESSION;
   PROLIFERATION; GROWTH; MINERALIZATION
AB Caffeine is an alkaloid that is widely consumed due to its presence in drugs, coffee, tea, and chocolate. This compound passes to offspring through the placenta and milk; can cause teratogenic mutations; and reduces the formation, growth, and mass of bone. Because mesenchymal stem cells (MSCs) are responsible for generating the entire skeleton, we hypothesized that these cells are targets of caffeine. This study evaluated the osteogenic differentiation of MSCs derived from the offspring of rats treated with caffeine during pregnancy and lactation. Twenty four adult Wistar rats were randomly divided into four groups, including one control group and three experimental groups treated with 25, 50, or 100 mg/kg of caffeine. At weaning, three 21 day old pups from each dam in each group were euthanized for extraction of bone marrow cells for in vitro tests. Caffeine doses of 50 and 100 mg/kg significantly reduced the activity of alkaline phosphatase at 7, 14, and 21 days and the expression of collagen I at 21 days. However, the expression of gene transcripts for alkaline phosphatase, Runx 2, and bone sialoprotein, as well as the synthesis of mineralization nodules, decreased significantly in all groups treated with caffeine. The expression of osteocalcin was significantly reduced only in the group treated with 50 mg/kg caffeine. The caffeine that passes from the mother to the offspring during pregnancy and lactation reduces the osteogenic differentiation of MSCs. We propose that this reduction in the osteogenic potential of MSCs may be involved in the pathogenesis of osteopenia resulting from caffeine consumption.
C1 [Sena Reis, Amanda Maria; Ocarino, Natalia de Melo; Boeloni, Jankerle Neves; Serakides, Rogeria] Univ Fed Minas Gerais, NCT TCA, Dept Clin & Cirurgia Vet, Escola Vet, Ave Presidente Antonio Carlos 6627, BR 31270901 Belo Horizonte, MG, Brazil.
   [Gomes, Dawidson Assis; Goes, Alfredo Miranda; Ferreira, Andrea da Fonseca] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Lab Imunol Celular & Biol Mol, BR 31270901 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais
RP Serakides, R (通讯作者)，Univ Fed Minas Gerais, NCT TCA, Dept Clin & Cirurgia Vet, Escola Vet, Ave Presidente Antonio Carlos 6627, BR 31270901 Belo Horizonte, MG, Brazil.
EM serakidesufmg@gmail.com
RI Boeloni, Jankerle/AGI 7942 2022; Reis, Amanda/AAQ 5039 2020; Assis
   Gomes, Dawidson/O 1372 2013; Serakides, Rogéria/C 7571 2016; Gomes,
   Dawidson/O 1372 2013; Ocarino, Natalia/H 3241 2018
OI Assis Gomes, Dawidson/0000 0001 7714 991X; 
FU Fundacao de Amparo a Pesquisa de Minas Gerais (Fapemig); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (Capes); Pro reitoria de
   Pesquisa da Universidade Federal de Minas Gerais (PRPQ)
FX This work was supported by grants from the Fundacao de Amparo a Pesquisa
   de Minas Gerais (Fapemig), the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes), and Pro reitoria de Pesquisa da
   Universidade Federal de Minas Gerais (PRPQ).
CR Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08 0180
   Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458
   ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203
   Ballesteros Yanez Inmaculada, 2012, J Caffeine Res, V2, P90, DOI 10.1089/jcr.2012.0011
   Birket MJ, 2011, J CELL SCI, V124, P348, DOI 10.1242/jcs.072272
   Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215
   Boeloni JN, 2013, PATHOL RES PRACT, V209, P44, DOI 10.1016/j.prp.2012.10.004
   Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Cook DG, 1996, BRIT MED J, V313, P1358, DOI 10.1136/bmj.313.7069.1358
   Cowles EA, 1998, CALCIFIED TISSUE INT, V62, P74, DOI 10.1007/s002239900397
   DEWS PB, 1982, ANNU REV NUTR, V2, P323, DOI 10.1146/annurev.nu.02.070182.001543
   Dragicevic N, 2012, NEUROPHARMACOLOGY, V63, P1368, DOI 10.1016/j.neuropharm.2012.08.018
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Egawa T, 2011, J APPL PHYSIOL, V111, P1629, DOI 10.1152/japplphysiol.00249.2011
   EGRISE D, 1992, CALCIFIED TISSUE INT, V50, P336, DOI 10.1007/BF00301631
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Föcking M, 2005, BIOCHEM BIOPH RES CO, V337, P435, DOI 10.1016/j.bbrc.2005.09.067
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   Huang TH, 2002, BONE, V30, P293, DOI 10.1016/S8756 3282(01)00659 7
   Jones FS, 2008, MOL PHARMACOL, V74, P673, DOI 10.1124/mol.108.046888
   Kamagata Kiyoura Y, 1999, J PERIODONTOL, V70, P283, DOI 10.1902/jop.1999.70.3.283
   Khairnar A, 2010, NEUROTOX RES, V17, P435, DOI 10.1007/s12640 009 9125 y
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 60
   Liu SH, 2011, J ORTHOP RES, V29, P954, DOI 10.1002/jor.21326
   Lu PZ, 2008, INT J MOL SCI, V9, P698, DOI 10.3390/ijms9050698
   Macedo R. M., 2012, Journal of Caffeine Research, V2, P140, DOI 10.1089/jcr.2012.0027
   MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519 69842002000400008
   MAZZONE A, 1995, HAEMATOLOGICA, V80, P161
   Minguell JJ, 2000, BRAZ J MED BIOL RES, V33, P881, DOI 10.1590/S0100 879X2000000800003
   Moioli EK, 2007, WOUND REPAIR REGEN, V15, P413, DOI 10.1111/j.1524 475X.2007.00244.x
   NAROD SA, 1991, AM J OBSTET GYNECOL, V164, P1109, DOI 10.1016/0002 9378(91)90597 K
   NEFUSSI JR, 1985, DIFFERENTIATION, V29, P160, DOI 10.1111/j.1432 0436.1985.tb00310.x
   Ocarino NM, 2008, NITRIC OXIDE BIOL CH, V19, P320, DOI 10.1016/j.niox.2008.08.004
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Palacios N, 2010, PARKINSONISM RELAT D, V16, P370, DOI 10.1016/j.parkreldis.2010.02.012
   Payushina OV, 2006, BIOL BULL+, V33, P2, DOI 10.1134/S106235900601002X
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079
   Rapuri PB, 2007, J STEROID BIOCHEM, V103, P368, DOI 10.1016/j.jsbmb.2006.12.037
   Reissig CJ, 2009, DRUG ALCOHOL DEPEN, V99, P1, DOI 10.1016/j.drugalcdep.2008.08.001
   Ribeiro JA, 2010, J ALZHEIMERS DIS, V20, pS3, DOI 10.3233/JAD 2010 1379
   Sampaio IBM, 1998, Estatistica aplicada a experimentacao animal
   Sarobo C, 2012, INT J EXP PATHOL, V93, P429, DOI 10.1111/j.1365 2613.2012.00843.x
   Schäffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006 0589
   SCOTT WJ, 1983, TERATOLOGY, V28, P427, DOI 10.1002/tera.1420280314
   Reis AMS, 2014, ACTUAL OSTEOL, V10, P20
   Shih YRV, 2006, STEM CELLS, V24, P2391, DOI 10.1634/stemcells.2006 0253
   Su SJ, 2013, INT J FOOD SCI NUTR, V64, P429, DOI 10.3109/09637486.2012.759184
   Tan Y, 2012, TOXICOL LETT, V214, P279, DOI 10.1016/j.toxlet.2012.09.007
   TASSINARI MS, 1991, J BONE MINER RES, V6, P1029
   Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875
   Tsuang Yang Hwei, 2006, J Orthop Surg Res, V1, P7, DOI 10.1186/1749 799X 1 7
   TYRALA EE, 1979, ARCH DIS CHILD, V54, P787, DOI 10.1136/adc.54.10.787
   Vaes BLT, 2006, BONE, V39, P724, DOI 10.1016/j.bone.2006.04.024
   Varkey M, 2007, TISSUE ENG, V13, P809, DOI 10.1089/ten.2006.0348
   Wang YJ, 2014, J BONE MINER RES, V29, P685, DOI 10.1002/jbmr.2081
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
   Xu X, 2013, CELL METAB, V18, P1
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Zhou Y, 2010, BRIT J PHARMACOL, V161, P1542, DOI 10.1111/j.1476 5381.2010.00998.x
NR 61
TC 13
Z9 13
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD MAR 3
PY 2016
VL 57
IS 2
BP 131
EP 142
DI 10.3109/03008207.2015.1117075
PG 12
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA DH5PQ
UT WOS:000372844400006
PM 26634797
DA 2025 08 17
ER

PT J
AU Palasiewicz, K
   Umar, S
   Romay, B
   Zomorrodi, RK
   Shahrara, S
AF Palasiewicz, Karol
   Umar, Sadiq
   Romay, Bianca
   Zomorrodi, Ryan K.
   Shahrara, Shiva
TI Tofacitinib therapy intercepts macrophage metabolic reprogramming
   instigated by SARS CoV 2 Spike protein
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Macrophages; Osteoclasts; RA FLS; Spike protein; Tofacitinib
ID RHEUMATOID ARTHRITIS; TNF ALPHA; LIGATION; RECEPTOR; PATHOGENESIS;
   COVID 19; TLR5; RA
AB The molecular mechanism of severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) Spike protein was characterized to identify novel therapies. The impact of tofacitinib, IL 6R Ab, or TNFi therapy was determined on Spike protein or LPS/IFN gamma induced signaling, inflammation, and metabolic reprogramming in M phi s and/or rheumatoid arthritis (RA) fibroblast like synoviocyte (FLS). ACE2 frequency was markedly expanded in M phi s compared to T cells and RA FLS. Tofacitinib suppresses Spike protein potentiated STAT1 signaling, whereas this function was unchanged by TNFi. Tofacitinib impairs IL 6/IFN/LPS induced STAT1 and STAT3 phosphorylation in RA M phi s and FLS. Interestingly, tofacitinib had a broader inhibitory effect on the monokines, glycolytic regulators, or oxidative metabolites compared to IL 6R Ab and TNFi in Spike protein activated M phi s. In contrast, all three therapies disrupted IFN alpha and IFN beta secretion in response to Spike protein; nonetheless, the IFN gamma was only curtailed by tofacitinib or IL 6R Ab. While tofacitinib counteracted M phi metabolic rewiring instigated by Spike protein, it was inconsequential on the glycolysis expansion mediated via HK2 and/or LDHA in the activated RA M phi and FLS. Nevertheless, the potentiated inflammatory response and the diminished oxidative phosphorylation modulated by Spike protein and/or LPS/IFN gamma stimulation in M phi s or RA FLS were reversed by tofacitinib. In conclusion, tofacitinib suppresses M phi inflammation and immunometabolism triggered by Spike protein and may provide a promising strategy for COVID 19 patients.
C1 [Palasiewicz, Karol; Umar, Sadiq; Shahrara, Shiva] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.
   [Palasiewicz, Karol; Umar, Sadiq; Romay, Bianca; Zomorrodi, Ryan K.; Shahrara, Shiva] Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL 60607 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Jesse Brown VA Medical Center; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital
RP Shahrara, S (通讯作者)，Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.; Shahrara, S (通讯作者)，Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL 60607 USA.
EM shahrara@uic.edu
RI ; Umar, Sadiq/H 3769 2019
OI Shahrara, Shiva/0000 0002 6698 8491; Palasiewicz,
   Karol/0000 0002 2894 6047; Zomorrodi, Ryan/0009 0003 6417 5985; Umar,
   Sadiq/0000 0002 4733 5751; 
FU Department of Veteran's Affairs MERIT Award [BX002286]; National
   Institutes of Health NIH [AI147697, AR056099, AR065778]; Pfizer
   Investigator Initiated award; National Psoriasis Foundation (NPF);
   Chicago Biomedical Consortium (CBC) Accelerator Award; National
   Institute of Allergy and Infectious Diseases [R41AI147697] Funding
   Source: NIH RePORTER
FX This work was supported in part by awards from the Department of
   Veteran's Affairs MERIT Award BX002286, the National Institutes of
   Health NIH AI147697, AR056099, and AR065778, Pfizer
   Investigator Initiated award, the National Psoriasis Foundation (NPF),
   and Chicago Biomedical Consortium (CBC) Accelerator Award. The contents
   do not represent the views of the U.S. Department of Veterans Affairs or
   the United States Government.
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], NATURE
   Antwi Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bagca BG, 2020, CYTOKINE GROWTH F R, V54, P51, DOI 10.1016/j.cytogfr.2020.06.013
   Barile E, 2020, MOLECULES, V25, DOI 10.3390/molecules25102424
   Catanzaro M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0191 1
   Chamberlain ND, 2013, ANN RHEUM DIS, V72, P418, DOI 10.1136/annrheumdis 2011 201203
   Chamberlain ND, 2012, J IMMUNOL, V189, P475, DOI 10.4049/jimmunol.1102977
   Chen ZL, 2015, ANN RHEUM DIS, V74, P1898, DOI 10.1136/annrheumdis 2013 204530
   Chen Z, 2013, J IMMUNOL, V190, P5256, DOI 10.4049/jimmunol.1201675
   Chikugo M, 2018, J MED INVESTIG, V65, P166, DOI 10.2152/jmi.65.166
   Codo AC, 2020, CELL METAB, V32, P437, DOI 10.1016/j.cmet.2020.07.007
   Conaghan PG, 2016, ANN RHEUM DIS, V75, P1024, DOI 10.1136/annrheumdis 2015 208267
   Elshabrawy H, 2018, ANGIOGENESIS, V21, P215, DOI 10.1007/s10456 017 9589 y
   Eshleman EM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006388
   Ferrari D, 2020, CLIN CHEM LAB MED, V58, P1095, DOI 10.1515/cclm 2020 0398
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Israelow Benjamin, 2020, J Exp Med, V217, DOI [10.1084/jem.20201241, 10.1101/2020.05.27.118893]
   Kim SJ, 2020, CELL MOL IMMUNOL, V17, P728, DOI 10.1038/s41423 019 0235 z
   Kim SJ, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209206
   Kim SJ, 2016, ARTHRITIS RHEUMATOL, V68, P1099, DOI 10.1002/art.39544
   Kim SJ, 2014, J IMMUNOL, V193, P3902, DOI 10.4049/jimmunol.1302998
   La Rosée F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375 020 0891 0
   Lee AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02061
   Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591 020 0901 9
   McGarry T, 2018, ARTHRITIS RHEUMATOL, V70, P1959, DOI 10.1002/art.40569
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140 6736(20)30628 0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577 020 0331 4
   Netland J, 2010, VIROLOGY, V399, P120, DOI 10.1016/j.virol.2010.01.004
   O'Callaghan KP, 2020, JAMA J AM MED ASSOC, V324, P437, DOI 10.1001/jama.2020.12190
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P914, DOI 10.1002/art.30232
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P2884, DOI 10.1002/art.30493
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Simmons DP, 2012, J IMMUNOL, V188, P3116, DOI 10.4049/jimmunol.1101313
   Umar S, 2021, CELL MOL IMMUNOL, V18, P2199, DOI 10.1038/s41423 020 0433 8
   Van Raemdonck K, 2020, CELL MOL LIFE SCI, V77, P1387, DOI 10.1007/s00018 019 03235 w
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421 020 0168 9
   Xiong Y, 2020, INVEST RADIOL, V55, P332, DOI 10.1097/RLI.0000000000000674
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 44
TC 13
Z9 14
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0014 2980
EI 1521 4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD SEP
PY 2021
VL 51
IS 9
BP 2330
EP 2340
DI 10.1002/eji.202049159
EA JUN 2021
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA UJ9KM
UT WOS:000664916100001
PM 34107055
OA Green Published
DA 2025 08 17
ER

PT J
AU Feng, SM
   Cai, M
   Liu, PC
   Wei, L
   Wang, JS
   Qi, J
   Deng, LF
AF Feng, Shengmei
   Cai, Ming
   Liu, Pengcheng
   Wei, Li
   Wang, Jinshen
   Qi, Jin
   Deng, Lianfu
TI Atp6v1c1 May Regulate Filament Actin Arrangement in Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID VACUOLAR H+ ATPASE; V ATPASE; SUBUNIT C; F ACTIN; INVASION; PH;
   INVADOPODIA; OSTEOCLASTS; EXPRESSION; CARCINOMA
AB Previous studies have shown that the rate of breast cancer metastasis correlates with the expression of vacuolar H+ ATPases (V ATPases). However, how V ATPase is involved in breast cancer metastasis remains unknown. Our previous study showed that Atp6v1c1 depleted osteoclasts did not form organized actin rings and that Atp6v1c1 co localizes with F actin. In this study, we found that the normal arrangement of filamentous actin is disrupted in Atp6v1c1 depleted 4T1 mouse breast cancer cells and in the ATP6V1C1 depleted human breast cancer cell lines MDA MB 231 and MDA MB 435s. We further found that Atp6v1c1 co localizes with F actin in 4T1 cells. The results of our study suggest that high expression of Atp6v1c1 affects the actin structure of cancer cells such that it facilitates breast cancer metastasis. The findings also indicate that Atp6v1c1 could be a novel target for breast cancer metastasis therapy.
C1 [Feng, Shengmei; Wei, Li; Wang, Jinshen; Qi, Jin; Deng, Lianfu] Jiao Tong Univ, Sch Med, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Traumatol & Orthopaed,Ruijin Hosp, Shanghai 200030, Peoples R China.
   [Cai, Ming; Liu, Pengcheng] Tongji Univ, Sch Med, Shanghai Peoples 10, Dept Orthopaed, Shanghai 200092, Peoples R China.
C3 Shanghai Jiao Tong University; Tongji University
RP Feng, SM (通讯作者)，Jiao Tong Univ, Sch Med, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Traumatol & Orthopaed,Ruijin Hosp, Shanghai 200030, Peoples R China.
EM fengshengmei@yahoo.com.cn; lfdeng@msn.com
RI cai, ming/HPF 1404 2023; Liu, Pengcheng/L 5274 2016
FU National Natural Science Foundation of China [30901525]; Shanghai
   Natural Science Foundation [09ZR1428900]; Shanghai Education Commission
   Foundation [10YZ39]; Talents Cultivation Plan of Shanghai Health System
   [XYQ2011050]; Science and Technology Grant from the Medical School of
   Shanghai, Jiaotong University
FX This work was supported by the National Natural Science Foundation of
   China (Grant 30901525), Shanghai Natural Science Foundation (Grant
   09ZR1428900), Shanghai Education Commission Foundation (Grant 10YZ39),
   Talents Cultivation Plan of Shanghai Health System (XYQ2011050), and a
   Science and Technology Grant from the Medical School of Shanghai,
   Jiaotong University. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Desai B, 2008, J BIOL CHEM, V283, P13856, DOI 10.1074/jbc.M709401200
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951
   Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272
   Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200
   KANE PM, 1995, J BIOL CHEM, V270, P17025
   Martínez Zaguilán R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006 2952(99)00022 2
   Mijatovic T, 2007, BBA REV CANCER, V1776, P32, DOI 10.1016/j.bbcan.2007.06.002
   Otero Rey EM, 2008, ORAL ONCOL, V44, P193, DOI 10.1016/j.oraloncology.2007.02.011
   Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200
   Sennoune SR, 2004, AM J PHYSIOL CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003
   Sennoune SR, 2004, CELL BIOCHEM BIOPHYS, V40, P185, DOI 10.1385/CBB:40:2:185
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649
   Vitavska O, 2005, J BIOL CHEM, V280, P1070, DOI 10.1074/jbc.M406797200
   Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200
   Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH 22.443
   Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909
   Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004
   Yang SY, 2007, J CELL SCI, V120, P3362, DOI 10.1242/jcs.008300
NR 20
TC 22
Z9 28
U1 1
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2014
VL 9
IS 1
AR e84833
DI 10.1371/journal.pone.0084833
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 297DH
UT WOS:000330235100036
PM 24454753
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, L
   Zhou, Q
   Zhang, N
   Li, WX
   Ying, MD
   Ding, WJ
   Yang, B
   He, QJ
AF Zhang, Lei
   Zhou, Qian
   Zhang, Ning
   Li, Weixu
   Ying, Meidan
   Ding, Wanjing
   Yang, Bo
   He, Qiaojun
TI E2F1 impairs all trans retinoic acid induced osteogenic differentiation
   of osteosarcoma via promoting ubiquitination mediated degradation of
   RARα
SO CELL CYCLE
LA English
DT Article
DE E2F1; osteosarcoma; ATRA; all trans retinoic acid; RAR alpha; osteogenic
   differentiation
ID MESENCHYMAL STEM CELLS; MYELOID LEUKEMIA CELLS; CANCER CELLS;
   PROTEOLYTIC DEGRADATION; DOWN REGULATION; MELANOMA CELLS; EXPRESSION;
   APOPTOSIS; THERAPY; OSTEOBLASTS
AB All trans retinoic acid (ATRA) is a widely used differentiation drug that can effectively induce osteogenic differentiation of osteosarcoma cells, but the underlying mechanism remains elusive, which limits the clinical application for ATRA in osteosarcoma patients. In this study, we identified E2F1 as a novel regulator involved in ATRA induced osteogenic differentiation of osteosarcoma cells. We observed that osteosarcoma cells are coupled with individual differences in the expression levels of E2F1 in patients, and E2F1 impairs ATRA induced differentiation of osteosarcoma cells. Moreover, remarkable anti proliferative and differentiation inducing effects of ATRA treatment are only observed in E2F1 low to negative expressed primary osteosarcoma cultures. These results strongly suggested that E2F1 may serve as a potent indicator for the effectiveness of ATRA treatment in osteosarcoma. Interestingly, E2F1 is found to downregulate retinoic acid receptor alpha (RAR alpha), a key factor determines the effectiveness of ATRA. E2F1 specifically binds to RAR alpha and promotes its ubiquitination mediated degradation; as a consequence, RAR alpha mediated differentiation is inhibited in osteosarcoma. Therefore, our studies present E2F1 as a potent biomarker, as well as a therapeutic target for ATRA based differentiation therapeutics, and raise the hope of using differentiation based approaches for osteosarcoma patients.
C1 [Zhang, Lei; Zhou, Qian; Ying, Meidan; Ding, Wanjing; Yang, Bo; He, Qiaojun] Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhang, Ning; Li, Weixu] Zhejiang Univ, Dept Orthoped, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP He, QJ (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310003, Zhejiang, Peoples R China.
EM yang924@zju.edu.cn; qiaojunhe@zju.edu.cn
RI Zhang, Ning/LEM 5455 2024; he, qiaojun/F 3198 2010
FU National Natural Science Foundation of China [81273534, 81202558];
   Program for New Century Excellent Talents in University; Zhejiang
   Province Program for the Cultivation of High level Innovative Health
   Talents; Zhejiang Provincial Program for Qianjiang Talents [2013R10025];
   Fundamental Research Funds for the Central Universities
FX This work was supported by grants from National Natural Science
   Foundation of China (No. 81273534 and No. 81202558), Program for New
   Century Excellent Talents in University, Zhejiang Province Program for
   the Cultivation of High level Innovative Health Talents, Zhejiang
   Provincial Program for Qianjiang Talents (2013R10025), the Fundamental
   Research Funds for the Central Universities.
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Cao J, 2009, FREE RADICAL BIO MED, V47, P536, DOI 10.1016/j.freeradbiomed.2009.05.024
   Connolly RM, 2013, CLIN CANCER RES, V19, P1651, DOI 10.1158/1078 0432.CCR 12 3175
   Dai X, 2011, MED SCI MONITOR, V17, pRA177, DOI 10.12659/MSM.881893
   Dani N, 2012, J BONE MINER RES, V27, P1322, DOI 10.1002/jbmr.1578
   DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643
   Diao HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052319
   Dingwall M, 2011, DIFFERENTIATION, V82, P57, DOI 10.1016/j.diff.2011.05.003
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097 0142(19950101)75:1+<203::AID CNCR2820751308>3.0.CO;2 V
   Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534 5807(02)00190 9
   Fang YF, 2011, MOL CARCINOGEN, V50, P24, DOI 10.1002/mc.20687
   Ferrari N, 2003, CLIN CANCER RES, V9, P6020
   Fukuda K, 2005, KIDNEY INT, V68, P1940, DOI 10.1111/j.1523 1755.2005.00624.x
   Garattini E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3245
   Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004
   Gianni M, 2012, LEUKEMIA, V26, P1850, DOI 10.1038/leu.2012.50
   Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121
   Guy CT, 1996, MOL CELL BIOL, V16, P685
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Hisada K, 2013, J BONE MINER METAB, V31, P53, DOI 10.1007/s00774 012 0385 x
   Itoshima T, 2000, CLIN CANCER RES, V6, P2851
   Kadowaki S, 2004, MOL CELL BIOCHEM, V262, P51, DOI 10.1023/B:MCBI.0000038215.89821.7f
   Kelly WK, 2000, CLIN CANCER RES, V6, P838
   Laue K, 2008, DEVELOPMENT, V135, P3775, DOI 10.1242/dev.021238
   Lee JL, 2007, CANCER RES, V67, P2089, DOI 10.1158/0008 5472.CAN 06 3625
   Liu PPL, 1996, ONCOLOGY, V53, P275
   Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Ozaki T, 2009, BIOCHEM BIOPH RES CO, V387, P143, DOI 10.1016/j.bbrc.2009.06.141
   Paik JC, 2010, J BIOL CHEM, V285, P6348, DOI 10.1074/jbc.M109.072074
   Pützer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582 4934.2007.00030.x
   Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304 3835(03)00108 3
   Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535
   SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839
   SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749 6632.1995.tb44633.x
   Stender JD, 2007, MOL ENDOCRINOL, V21, P2112, DOI 10.1210/me.2006 0474
   Strachan GD, 2001, J BIOL CHEM, V276, P45677, DOI 10.1074/jbc.M103765200
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Verhaegen M, 2012, ONCOGENE, V31, P828, DOI 10.1038/onc.2011.277
   Vuaroqueaux V, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1681
   WANG J, 1995, CELL GROWTH DIFFER, V6, P1299
   Ying MD, 2013, MOL CANCER THER, V12, P195, DOI 10.1158/1535 7163.MCT 12 0433
   Zanardi S, 2006, ENDOCR RELAT CANCER, V13, P51, DOI 10.1677/erc.1.00938
   Zhang H, 2003, CARCINOGENESIS, V24, P185, DOI 10.1093/carcin/24.2.185
   Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807
NR 50
TC 25
Z9 28
U1 0
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PD APR 15
PY 2014
VL 13
IS 8
BP 1277
EP 1287
DI 10.4161/cc.28190
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AF0YA
UT WOS:000334439800009
PM 24608861
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Lin, TK
   Chou, P
   Lin, CH
   Hung, YJ
   Jong, GP
AF Lin, Tsung Kun
   Chou, Pesus
   Lin, Ching Heng
   Hung, Yi Jen
   Jong, Gwo Ping
TI Long term effect of statins on the risk of new onset osteoporosis: A
   nationwide population based cohort study
SO PLOS ONE
LA English
DT Article
ID COA REDUCTASE INHIBITORS; BONE MINERAL DENSITY; SCANDINAVIAN SIMVASTATIN
   SURVIVAL; OSTEOBLAST DIFFERENTIATION; FRACTURE RISK; IN VITRO;
   METAANALYSIS; PATHWAY; TRIAL; EXPRESSION
AB Background
   Several observational cohort and meta analytical studies in humans have shown that statin users have a lower risk of fractures or greater bone mineral densities (BMD) than nonusers. However, some studies including randomized clinical trials have the opposite results, particularly in Asian populations.
   Objective
   This study investigates the impacts of statins on new onset osteoporosis in Taiwan.
   Methods
   In a nationwide retrospective population based cohort study, 45,342 subjects aged between 50 90 years having received statin therapy (statin users) since January 1 2001, and observed through December 31 2013 were selected from the National Health Insurance Research Database of Taiwan. Likewise, 115,594 patients had no statin therapy (statin non users) were included as controls in this study. Multivariable Cox proportional hazards analysis for drug exposures was employed to evaluate the association between statin treatment and new onset of osteoporosis risk. We also used the long rank test to evaluate the difference of probability of osteoporosis free survival.
   Results
   During the 13 year follow up period, 16,146 of all enrolled subjects (10.03%) developed osteoporosis, including 3097 statin users (6.83%) and 13,049 statin non users (11.29%). Overall, statin therapy reduced the risk of new onset osteoporosis by 48% (adjusted hazard ratio [HR] 0.52; 95% CI 0.50 to 0.54). A dose response relationship between statin treatment and the risk of new onset osteoporosis was observed. The adjusted hazard ratios for new onset osteoporosis were 0.84 (95% CI, 0.78 to 0.90), 0.56 (95% CI, 0.52 to 0.60) and 0.23 (95% CI, 0.21 to 0.25) when cumulative defined daily doses (cDDDs) ranged from 28 to 90, 91 to 365, and more than 365, respectively, relative to nonusers. Otherwise, high potency statins (rosuvastatin and atorvastatin) and moderate potency statin (simvastatin) seemed to have a potential protective effect for osteoporosis.
   Conclusions
   In this population based cohort study, we found that statin use is associated with a decreased risk of osteoporosis in both genders. The osteoprotective effect of statins seemed to be more prominent with a dependency on the cumulative dosage and statin intensity.
C1 [Lin, Tsung Kun] Taoyuan Armed Forces Gen Hosp, Taoyuan, Taiwan.
   [Lin, Tsung Kun; Chou, Pesus] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Lin, Tsung Kun; Chou, Pesus] Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan.
   [Lin, Ching Heng] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.
   [Hung, Yi Jen] Natl Def Med Ctr, Triserv Gen Hosp, Div Endocrinol & Metab, Dept Internal Med,Sch Med, Taipei, Taiwan.
   [Jong, Gwo Ping] Chung Shan Med Univ Hosp, Div Internal Cardiol, Taichung, Taiwan.
   [Jong, Gwo Ping] Chung Shan Med Univ, Taichung, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Taichung Veterans General Hospital; Tri Service General
   Hospital; National Defense Medical University; Chung Shan Medical
   University; Chung Shan Medical University Hospital; Chung Shan Medical
   University
RP Jong, GP (通讯作者)，Chung Shan Med Univ Hosp, Div Internal Cardiol, Taichung, Taiwan.; Jong, GP (通讯作者)，Chung Shan Med Univ, Taichung, Taiwan.
EM cgp8009@yahoo.com.tw
OI Jong, Gwo Ping/0000 0002 7786 5497
FU Taichung Veterans General Hospital, Taiwan [TCVGH NHR110603,
   TCVGH 1067310C, TCVGH FCU1068205, TCVGH YM1060201, TCVGH VTA106PREM1]
FX This study was supported in part by grants from Taichung Veterans
   General Hospital, Taiwan (TCVGH NHR110603, TCVGH 1067310C,
   TCVGH FCU1068205, TCVGH YM1060201, TCVGH VTA106PREM1). The authors would
   like to thank the Healthcare Service Research Center (HSRC) of Taichung
   Veterans General Hospital for statistical support. There was no
   additional external funding received for this study.
CR Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   An T, 2017, OSTEOPOROSIS INT, V28, P47, DOI 10.1007/s00198 016 3844 8
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P380, DOI 10.1007/s001980170106
   Cannon CP, 2015, NEW ENGL J MED, V373, P1476, DOI 10.1056/NEJMc1509363
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   Chrysant SG, 2017, POSTGRAD MED, V129, P430, DOI 10.1080/00325481.2017.1292107
   Erlandson KM, 2015, AIDS, V29, P175, DOI 10.1097/QAD.0000000000000526
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165 6147(97)01147 4
   Hatzigeorgiou C, 2005, OSTEOPOROSIS INT, V16, P990, DOI 10.1007/s00198 004 1793 0
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Helin Salmivaara A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048095
   Hughes A, 2007, CALCIFIED TISSUE INT, V81, P403, DOI 10.1007/s00223 007 9078 1
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P1451, DOI 10.1211/jpp.58.11.0005
   LaCroix AZ, 2003, ANN INTERN MED, V139, P97, DOI 10.7326/0003 4819 139 2 200307150 00009
   Liu J, 2013, BONE, V54, P151, DOI 10.1016/j.bone.2013.01.044
   Majima T, 2007, INTERNAL MED, V46, P1967, DOI 10.2169/internalmedicine.46.0419
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Monjo M, 2010, CELL PHYSIOL BIOCHEM, V26, P647, DOI 10.1159/000322332
   Morse LR, 2016, OSTEOPOROSIS INT, V27, P3503, DOI 10.1007/s00198 016 3678 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002 9149(00)00910 3
   Peña JM, 2015, JAMA INTERN MED, V175, P171, DOI 10.1001/jamainternmed.2014.6388
   Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140 6736(00)04042 3
   Rejnmark L, 2004, OSTEOPOROSIS INT, V15, P452, DOI 10.1007/s00198 003 1568 z
   Ridker PM, 2010, AM J CARDIOL, V106, P1351, DOI 10.1016/j.amjcard.2010.08.025
   Roy Satyajeet, 2017, J Clin Med Res, V9, P638, DOI 10.14740/jocmr3066w
   Scranton RE, 2005, ARCH INTERN MED, V165, P2007, DOI 10.1001/archinte.165.17.2007
   Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002
   Swiger KJ, 2013, MAYO CLIN PROC, V88, P1213, DOI 10.1016/j.mayocp.2013.07.013
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019
   Wada Y, 2000, ARCH INTERN MED, V160, P2865, DOI 10.1001/archinte.160.18.2865
   Weivoda MM, 2011, J CELL BIOCHEM, V112, P1506, DOI 10.1002/jcb.23087
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
NR 36
TC 44
Z9 46
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 3
PY 2018
VL 13
IS 5
AR e0196713
DI 10.1371/journal.pone.0196713
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GE6AF
UT WOS:000431305100057
PM 29723231
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Yang, C
   Liu, W
   Shan, HJ
   Yu, XW
   Zhang, XL
   Zeng, BF
   Qian, YB
AF Yang, Chao
   Liu, Wei
   Shan, Haojie
   Yu, Xiaowei
   Zhang, Xianlong
   Zeng, Bingfang
   Qian, Yebin
TI Naringin inhibits titanium particles induced up regulation of TNF α and
   IL 6 via the p38 MAPK pathway in fibroblasts from hip periprosthetic
   membrane
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Naringin; titanium particles; TNF alpha; IL 6; fibroblasts
ID NECROSIS FACTOR ALPHA; OSTEOCLAST FORMATION; WEAR DEBRIS; IN VITRO;
   KAPPA B; INTERLEUKIN 6; OSTEOLYSIS; EXPRESSION; ARTHROPLASTY;
   INFLAMMATION
AB Aims Inflammatory responses to wear debris cause osteolysis that leads to aseptic loosening and hip arthroplasty failure. Wear debris stimulate macrophages and fibroblasts to secret proinflammatory cytokines, including TNF alpha and IL 6, which have been specifically implicated in periprosthetic osteolysis and osteoclast differentiation. Naringin has anti inflammatory effect in macrophages. Moreover, naringin inhibited osteoclastogenesis and wear particles induced osteolysis. In this study, we examined the potential inhibitory effects of naringin on titanium (Ti) particle induced proinflammatory cytokines secretion in fibroblasts and the possible underlying molecular mechanisms. Materials and methods Fibroblasts were isolated from periprosthetic membrane at the time of revision surgery performed due to aseptic loosening after hip arthroplasty and were cultured in the presence or absence of Ti particles, naringin and mitogen activated protein kinase (MAPK) inhibitors, PD98059 (a selective inhibitor of ERK), SP600125 (a selective inhibitor of JNK), and SB203580 (a selective inhibitor of p38). TNF alpha and IL 6 assays were performed using enzyme linked immunosorbent assay kits. The phosphorylation levels of p38 and nuclear factor kappa B p65 (NF kappa B p65) were examined by western blot. Results Naringin or SB203580 pretreatment significantly suppressed the secretion of TNF alpha and IL 6 induced by titanium particles in fibroblasts, while inhibition of ERK or JNK pathways showed no effect on production of TNF alpha and IL 6. Moreover, naringin inhibited Ti particle induced phosphorylation of p38 and p65. Conclusions These results indicated that naringin could inhibit Ti particle induced inflammation in fibroblasts by inhibiting p38 MAPK/NF kappa B p65 activity and might be a potential drug for the treatment of inflammatory periprosthetic osteolysis after arthroplasty.
C1 [Yang, Chao; Liu, Wei; Shan, Haojie; Yu, Xiaowei; Zhang, Xianlong; Zeng, Bingfang; Qian, Yebin] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China.
   [Qian, Yebin] Shanghai Univ Med & Hlth Sci, Shanghai Peoples Hosp East 6, Dept Orthoped, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai University of Medicine & Health
   Sciences
RP Qian, YB (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China.
EM yebinqian@aliyun.com
RI Wu, yanxia/HGA 0318 2022
FU National Natural Science Foundation of China [81673998]; Scientific
   Research Project of Shanghai Municipal Health Commission [201540151];
   Science and Technology Development Fund of Shanghai Pudong New Area
   [PKJ2015 Y07]; Research Fund of Shanghai Sixth People's Hospital East
   [2016041]
FX This work was supported by the National Natural Science Foundation of
   China [Grant Number 81673998]; Scientific Research Project of Shanghai
   Municipal Health Commission [Grant Number 201540151]; Science and
   Technology Development Fund of Shanghai Pudong New Area [Grant Number
   PKJ2015 Y07] and Research Fund of Shanghai Sixth People's Hospital East
   [Grant Number 2016041].
CR Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bi C, 2016, CYTOTECHNOLOGY, V68, P1473, DOI 10.1007/s10616 015 9908 3
   Bukata SV, 2004, J ORTHOP RES, V22, P6, DOI 10.1016/S0736 0266(03)00153 0
   Catelas Isabelle, 2010, Instr Course Lect, V59, P3
   Chen DS, 2012, INFLAMMATION, V35, P1798, DOI 10.1007/s10753 012 9500 3
   CHIBA J, 1994, CLIN ORTHOP RELAT R, P304
   Ding HW, 2017, FITOTERAPIA, V121, P212, DOI 10.1016/j.fitote.2017.07.016
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   El Mihi KA, 2017, LIFE SCI, V187, P50, DOI 10.1016/j.lfs.2017.08.019
   Feng MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108502
   Fritz EA, 2005, J ORTHOP RES, V23, P1249, DOI 10.1016/j.orthres.2005.03.013
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623 198365050 00001
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Inoue M, 2000, ENDOCRINOLOGY, V141, P284, DOI 10.1210/en.141.1.284
   Irshad M, 2013, J CLIN PERIODONTOL, V40, P841, DOI 10.1111/jcpe.12136
   Kandhare AD, 2014, CHEM BIOL INTERACT, V219, P101, DOI 10.1016/j.cbi.2014.05.012
   Kanno S, 2006, LIFE SCI, V78, P673, DOI 10.1016/j.lfs.2005.04.051
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Li NH, 2014, DRUG DES DEV THER, V8, P1, DOI 10.2147/DDDT.S52714
   Li WS, 2014, CURR PHARM BIOTECHNO, V15, P1173, DOI 10.2174/1389201015666141111114442
   Li ZL, 2018, BIOMED PHARMACOTHER, V103, P50, DOI 10.1016/j.biopha.2018.03.163
   Liang J, 2016, PHARMAZIE, V71, P101, DOI 10.1691/ph.2016.5629
   Liu H, 2019, J CELL PHYSIOL, V234, P11009, DOI 10.1002/jcp.27924
   Liu LH, 2017, IRAN J BASIC MED SCI, V20, P813, DOI 10.22038/IJBMS.2017.9017
   Liu XC, 2016, ENVIRON TOXICOL PHAR, V48, P1, DOI 10.1016/j.etap.2016.09.005
   Liu Y, 2012, MOL MED REP, V6, P1343, DOI 10.3892/mmr.2012.1072
   Lv ZH, 2018, INT IMMUNOPHARMACOL, V65, P140, DOI 10.1016/j.intimp.2018.09.019
   Mahon OR, 2018, ACTA BIOMATER, V65, P426, DOI 10.1016/j.actbio.2017.10.041
   Meng JH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01053
   Nam JS, 2017, J BIOMED MATER RES A, V105, P912, DOI 10.1002/jbm.a.36004
   Ninomiya JT, 2001, J ORTHOPAED RES, V19, P621, DOI 10.1016/S0736 0266(00)00061 9
   Qian YB, 2008, J ARTHROPLASTY, V23, P581, DOI 10.1016/j.arth.2007.06.010
   Qian Y, 2007, J BIOMED MATER RES A, V83A, P401, DOI 10.1002/jbm.a.31318
   Qian YB, 2013, CONNECT TISSUE RES, V54, P361, DOI 10.3109/03008207.2013.823953
   Rakshit DS, 2006, J BONE JOINT SURG AM, V88A, P788, DOI 10.2106/JBJS.E.00711
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Sabokbar A, 2005, J ORTHOP RES, V23, P511, DOI 10.1016/j.orthres.2004.10.006
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   SHANBHAG AS, 1995, J ARTHROPLASTY, V10, P498, DOI 10.1016/S0883 5403(05)80152 4
   Shi L, 2017, NEUROBIOL AGING, V56, P115, DOI 10.1016/j.neurobiolaging.2017.04.014
   Sun SG, 2006, ACTA ORTHOP, V77, P320, DOI 10.1080/17453670610046091
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Xu Q, 2017, MED SCI MONITOR, V23, P3746, DOI 10.12659/MSM.902396
   Xu T, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/8981650
   Yu XW, 2013, INT ORTHOP, V37, P137, DOI 10.1007/s00264 012 1668 5
   Zhang L, 2018, BIOMED PHARMACOTHER, V104, P300, DOI 10.1016/j.biopha.2018.05.030
   Zhang Q, 2019, MOL MED REP, V19, P41, DOI 10.3892/mmr.2018.9622
NR 50
TC 15
Z9 17
U1 0
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD SEP 3
PY 2021
VL 62
IS 5
BP 485
EP 494
DI 10.1080/03008207.2020.1778680
EA JUN 2020
PG 10
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA UN1SS
UT WOS:000546487300001
PM 32500755
DA 2025 08 17
ER

PT J
AU Rossini, M
   Viapiana, O
   Gatti, D
   de Terlizzi, F
   Adami, S
AF Rossini, Maurizio
   Viapiana, Ombretta
   Gatti, Davide
   de Terlizzi, Francesca
   Adami, Silvano
TI Capacitively Coupled Electric Field for Pain Relief in Patients with
   Vertebral Fractures and Chronic Pain
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID LOW BACK PAIN; NERVE STIMULATION; DOUBLE BLIND; HORIZONTAL THERAPIES;
   RANDOMIZED CROSSOVER; SPINAL FUSIONS; BONE CELLS; OSTEOPOROSIS;
   DEFORMITIES; PATHWAY
AB Fragility vertebral fractures often are associated with chronic back pain controlled by analgesic compounds. Capacitive coupling electrical stimulation is a type of electrical stimulation technology approved by the US FDA to noninvasively enhance fracture repair and spinal fusion. These uses suggest it would be a possible treatment for patients with back pain attributable to vertebral fractures. We therefore randomized 51 postmenopausal women with multiple fractures and chronic pain to the use of one of two indistinguishable devices delivering either the standard capacitive coupling electrical stimulation by Osteospine (TM) (active group) or low intensity pulse (control group). Twenty patients of the active group and 21 of the control group (80%) completed the study for a total duration of 3 months. The mean visual analog scale values for pain and the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) scores improved in both groups. We observed a relationship between hours of treatments and reductions in pain intensity only in the active group. Capacitive coupling electrical stimulation was not more effective than control treatment when comparing mean visual analog scale pain and QALEFFO scores in the two groups and when adjusting for the hours of treatment. However, the proportion of patients able to discontinue NSAIDs owing to elimination or reduction of pain was greater in the active group than in the control group. We interpret these findings as suggesting capacitive coupling electrical stimulation controls pain in some patients and reduces the use of NSAIDs.
   Level of Evidence: Level I, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
C1 [Rossini, Maurizio; Viapiana, Ombretta; Gatti, Davide; Adami, Silvano] Univ Verona, Rheumatol Unit, Dept Biomed & Surg Sci, OCM Borgo Trento, I 37126 Verona, Italy.
   [de Terlizzi, Francesca] IGEA Srl, Biophys Lab, Carpi, Modena, Italy.
C3 University of Verona; Azienda Ospedaliera Universitaria Integrata Verona
RP Rossini, M (通讯作者)，Univ Verona, Rheumatol Unit, Dept Biomed & Surg Sci, OCM Borgo Trento, Ple Stefani 1, I 37126 Verona, Italy.
EM maurizio.rossini@univr.it
RI Davide, Gatti/ABP 6506 2022; de Rosa, Francesco/AAC 5935 2022; rossini,
   maurizio/D 6610 2011
OI Rossini, Maurizio/0000 0001 9692 2293; gatti,
   davide/0000 0002 7471 3076; VIAPIANA, Ombretta/0000 0003 1917 5655
CR BRIGHTON CT, 1985, J BONE JOINT SURG AM, V67A, P577, DOI 10.2106/00004623 198567040 00012
   BRIGHTON CT, 1985, J ORTHOP RES, V3, P331, DOI 10.1002/jor.1100030310
   BRIGHTON CT, 1989, J BONE JOINT SURG AM, V71A, P228, DOI 10.2106/00004623 198971020 00009
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   Edmond SL, 2005, OSTEOPOROSIS INT, V16, P1086, DOI 10.1007/s00198 004 1815 y
   Francis RM, 2008, OSTEOPOROSIS INT, V19, P895, DOI 10.1007/s00198 007 0530 x
   FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506
   Gadsby JG, 2000, COCHRANE DB SYST REV, V2
   Gan JC, 2006, EUR SPINE J, V15, P1301, DOI 10.1007/s00586 006 0087 y
   Ghoname ESA, 1999, JAMA J AM MED ASSOC, V281, P818, DOI 10.1001/jama.281.9.818
   Goodwin CB, 1999, SPINE, V24, P1349, DOI 10.1097/00007632 199907010 00013
   Huang C, 1996, ARCH INTERN MED, V156, P2469, DOI 10.1001/archinte.156.21.2469
   Hurley DA, 2001, ARCH PHYS MED REHAB, V82, P485, DOI 10.1053/apmr.2001.21934
   Johnson MI, 2002, CLIN PHYSIOL FUNCT I, V22, P187, DOI 10.1046/j.1475 097X.2002.00416.x
   Köke AJA, 2004, PAIN, V108, P36, DOI 10.1016/j.pain.2003.11.013
   Lips P, 1999, OSTEOPOROSIS INT, V10, P150, DOI 10.1007/s001980050210
   Lorich DG, 1998, CLIN ORTHOP RELAT R, P246
   MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271
   MELZACK R, 1983, PHYS THER, V63, P489, DOI 10.1093/ptj/63.4.489
   Pluijm SMF, 2000, J BONE MINER RES, V15, P1564, DOI 10.1359/jbmr.2000.15.8.1564
   SCOTT G, 1994, J BONE JOINT SURG AM, V76A, P820, DOI 10.2106/00004623 199406000 00005
   Weiner DK, 2003, J AM GERIATR SOC, V51, P599, DOI 10.1034/j.1600 0579.2003.00202.x
   Zambito A, 2007, OSTEOPOROSIS INT, V18, P1541, DOI 10.1007/s00198 007 0391 3
   Zambito A, 2006, CLIN EXP RHEUMATOL, V24, P534
   Zhuang HM, 1997, BIOCHEM BIOPH RES CO, V237, P225, DOI 10.1006/bbrc.1997.7118
NR 25
TC 19
Z9 21
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009 921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2010
VL 468
IS 3
BP 735
EP 740
DI 10.1007/s11999 009 1088 z
PG 6
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 558HM
UT WOS:000274731700013
PM 19756902
OA Green Published
DA 2025 08 17
ER

PT J
AU Hari, P
   DeFor, TE
   Vesole, DH
   Bredeson, CN
   Burns, LJ
AF Hari, Parameswaran
   DeFor, Todd E.
   Vesole, David H.
   Bredeson, Christopher N.
   Burns, Linda J.
TI Intermittent Zoledronic Acid Prevents Bone Loss in Adults after
   Allogeneic Hematopoietic Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Osteoporosis; Zoledronic acid; Bisphosphonates; Allogeneic hematopoietic
   cell transplantation
ID LONG TERM SURVIVORS; MARROW STROMAL CELLS; MINERAL DENSITY;
   BISPHOSPHONATE THERAPY; VITAMIN D; OSTEOPOROSIS; MASS; MALIGNANCIES;
   PAMIDRONATE; MECHANISMS
AB Bone mineral density (BMD) loss is common in survivors of allogeneic hematopoietic cell transplantation (alloHCT). We performed a multicenter, phase II, randomized open label trial of intravenous zoledronic acid (ZA) to prevent BMD loss in adult recipients of alloHCT with osteopenia before HCT. The treatment group received ZA 4 mg intravenously within 28 days pre HCT and at 3 and 6 months after HCT. Both treatment and control groups received calcium carbonate and vitamin D supplements. Of 61 patients, 32 were randomized to the ZA cohort and 29 to the control cohorts. More patients in the ZA group had an HCT comorbidity index high risk score of >= 3 (50% versus 21%, P < .01). Baseline BMD, T scores, serum osteocalcin, bone alkaline phosphatase, and urine N telopeptide (UNTX) levels were similar in both cohorts. Thirty patients were evaluable for outcomes (11 from the treatment and 19 from the control group). At 12 months, subjects in the treatment group had an improvement in BMD at the femoral neck (mean change, .018 for ZA group versus  .054 for controls; P = .04) and a significant decline in levels of UNTX ( 56 for ZA group versus  9 for control; P = .04) compared with baseline. ZA was well tolerated and not associated with any cases of osteonecrosis of jaw or renal impairment. Lower survival observed in the ZA cohort was likely related to baseline imbalance in HCT CI scores. Intermittent ZA is effective in preserving long term bone health in adult alloHCT recipients at risk for osteoporosis. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
   [DeFor, Todd E.] Univ Minnesota, Minneapolis, MN USA.
   [Vesole, David H.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
   [Bredeson, Christopher N.] Univ Ottawa, Div Haematol, Ottawa, ON, Canada.
   [Burns, Linda J.] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA.
C3 Medical College of Wisconsin; University of Minnesota System; University
   of Minnesota Twin Cities; Hackensack University Medical Center;
   University of Ottawa; University of Minnesota System; University of
   Minnesota Twin Cities
RP Hari, P (通讯作者)，Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
EM phari@mcw.edu
RI Hari, Parameswaran/A 7271 2009
OI Hari, Parameswaran/0000 0002 8800 297X
FU Janie Lymphoma Fund
FX We thank the patients and their families, as well as the medical and
   nursing staffs at the Medical College of Wisconsin and the University of
   Minnesota for their dedication and support. We also thank Judy Witte and
   Marilee Larkin at the University of Minnesota and Sharon Vine and
   Deborah Pastorek at the Medical College of Wisconsin for data collection
   and management. Zoledronic acid for this study and a portion of patient
   care costs was provided by Novartis Pharmaceuticals Corporation. The
   work was also supported by the Janie Lymphoma Fund (L.J.B.).
CR Banfi A, 2001, CANCER, V92, P2419, DOI 10.1002/1097 0142(20011101)92:9<2419::AID CNCR1591>3.0.CO;2 K
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Carpenter PA, 2007, BIOL BLOOD MARROW TR, V13, P683, DOI 10.1016/j.bbmt.2007.02.001
   Chae YS, 2009, BONE MARROW TRANSPL, V44, P35, DOI 10.1038/bmt.2008.414
   D'Souza AB, 2006, INTERN MED J, V36, P600, DOI 10.1111/j.1445 5994.2006.01154.x
   Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342
   Gandhi MK, 2003, BRIT J HAEMATOL, V121, P462, DOI 10.1046/j.1365 2141.2003.04303.x
   Ganguly S, 2012, CLIN TRANSPLANT, V26, P447, DOI 10.1111/j.1399 0012.2011.01527.x
   Grigg AP, 2006, J CLIN ENDOCR METAB, V91, P3835, DOI 10.1210/jc.2006 0684
   Kananen K, 2005, J CLIN ENDOCR METAB, V90, P3877, DOI 10.1210/jc.2004 2161
   Kananen K, 2002, BONE MARROW TRANSPL, V29, P33, DOI 10.1038/sj.bmt.1703317
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kashyap A, 2000, BIOL BLOOD MARROW TR, V6, P344, DOI 10.1016/S1083 8791(00)70061 9
   Kintzel PE, 2001, DRUG SAFETY, V24, P19, DOI 10.2165/00002018 200124010 00003
   Lee WY, 2002, J CLIN ENDOCR METAB, V87, P329, DOI 10.1210/jc.87.1.329
   Li EC, 2003, CLIN THER, V25, P2669, DOI 10.1016/S0149 2918(03)80327 2
   Lin DY, 1997, STAT MED, V16, P901, DOI 10.1002/(SICI)1097 0258(19970430)16:8<901::AID SIM543>3.0.CO;2 M
   Massenkeil G, 2001, LEUKEMIA, V15, P1701, DOI 10.1038/sj.leu.2402264
   McClung M, 2009, OBSTET GYNECOL, V114, P999, DOI 10.1097/AOG.0b013e3181bdce0a
   Schulte C, 2000, OSTEOPOROSIS INT, V11, P344, DOI 10.1007/s001980070124
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Snedecor G. W., 1989, Ames Iowa State Univ Press Iowa, V8th
   Sorror ML, 2005, BLOOD, V106, P2912, DOI 10.1182/blood 2005 05 2004
   Sorror ML, 2011, JAMA J AM MED ASSOC, V306, P1874, DOI 10.1001/jama.2011.1558
   Sorror ML, 2009, BIOL BLOOD MARROW TR, V15, P757, DOI 10.1016/j.bbmt.2009.02.007
   Stern JM, 2001, BIOL BLOOD MARROW TR, V7, P257, DOI 10.1053/bbmt.2001.v7.pm11400947
   Tauchmanovà L, 2006, BONE MARROW TRANSPL, V37, P81, DOI 10.1038/sj.bmt.1705196
   Tauchmanovà L, 2005, J CLIN ENDOCR METAB, V90, P627, DOI 10.1210/jc.2004 0509
   Tauchmanovà L, 2003, OSTEOPOROSIS INT, V14, P1013, DOI 10.1007/s00198 003 1520 2
   Tauchmanovà L, 2002, J CLIN ENDOCR METAB, V87, P5058, DOI 10.1210/jc.2002 020800
   Tauchmanová L, 2007, J CLIN ENDOCR METAB, V92, P4536, DOI 10.1210/jc.2006 2870
   Välimäki MJ, 1999, BONE MARROW TRANSPL, V23, P355, DOI 10.1038/sj.bmt.1701586
   Weilbaecher KN, 2000, BIOL BLOOD MARROW TR, V6, P165, DOI 10.1016/S1083 8791(00)70039 5
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yao S, 2008, BONE MARROW TRANSPL, V41, P393, DOI 10.1038/sj.bmt.1705918
   Yao S, 2010, BIOL BLOOD MARROW TR, V16, P1130, DOI 10.1016/j.bbmt.2010.02.017
NR 36
TC 20
Z9 23
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1083 8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD SEP
PY 2013
VL 19
IS 9
BP 1361
EP 1367
DI 10.1016/j.bbmt.2013.06.015
PG 7
WC Hematology; Immunology; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Immunology; Transplantation
GA 212WT
UT WOS:000324014200012
PM 23806773
OA hybrid
DA 2025 08 17
ER

PT J
AU Tabatabaei, SN
   Hodjat, M
   Hakimiha, N
   Akhoundi, MSA
   Kharazifard, MJ
AF Tabatabaei, Seyyedeh Niloufar
   Hodjat, Mahshid
   Hakimiha, Neda
   Akhoundi, Mohammad Sadegh Ahmad
   Kharazifard, Mohammad Javad
TI In Vitro Effect of Photobiomodulation Therapy with 980 nm
   Diode Laser on Gene Expression of Key Regulators of Bone Remodeling by
   Human Periodontal Ligament Cells under Mild Orthodontic Forces
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID LOW LEVEL LASER; EXPERIMENTAL TOOTH MOVEMENT; OSTEOCLAST
   DIFFERENTIATION; STEM CELLS; IRRADIATION; MECHANISMS; RANK; OPG;
   STIMULATION; METABOLISM
AB This study investigated the effect of photobiomodulation (PBM) with 980 nm diode laser as monotherapy and in combination with compressive and tensile orthodontic forces on expression of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), sclerostin (SOST) and periostin (POSTN), by human periodontal ligament cells. Isolated cells were cultured and subjected to either tensile (10% elongation) or compressive forces (25 g cm( 2)) for 24 and 48 h. Subsequently, the cells received PBM (100 mW power, 3 or 6 J cm( 2) energy density) immediately after load cycle. RT PCR was applied to assess the genes expression. Data were analyzed by one way ANOVA, followed by post hoc Tukey test (P <= 0.05). We found that PBM in combination with orthodontic forces led to upregulation of bone resorption genes (RANKL and SOST) at the pressure side and their downregulation at the tension side. The expression of osteogenic genes (OPG and POSTN) increased at the tension side and decreased at the pressure side. PBM alone did not affect gene expression. In conclusion, these findings suggest that this PBM protocol may be effective in enhancement of the gene expression in favor of bone remodeling acceleration that should be confirmed in future animal and human studies.
C1 [Tabatabaei, Seyyedeh Niloufar; Akhoundi, Mohammad Sadegh Ahmad] Univ Tehran Med Sci, Sch Dent, Dept Orthodont, Tehran, Iran.
   [Hodjat, Mahshid; Kharazifard, Mohammad Javad] Univ Tehran Med Sci, Dent Res Inst, Dent Res Ctr, Tehran, Iran.
   [Hakimiha, Neda] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Shahid Beheshti University Medical Sciences
RP Akhoundi, MSA (通讯作者)，Univ Tehran Med Sci, Sch Dent, Dept Orthodont, Tehran, Iran.; Hakimiha, N (通讯作者)，Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran.
EM ned.hakimiha@gmail.com; ahmadakh@tums.ac.ir
RI Hodjat, Mahshid/M 4557 2018; Hakimiha, Neda/AAZ 1927 2021
OI Hakimiha, Neda/0000 0001 5188 0325; 
FU Dentistry Research Institute of Tehran University of Medical Sciences
   [1400 3 133 55172]
FX Acknowledgement This study was part of a post graduate thesis in
   orthodontics supported by the Dentistry Research Institute of Tehran
   University of Medical Sciences (Grant no. 1400 3 133 55172).
CR Aihara N, 2006, LASER MED SCI, V21, P24, DOI 10.1007/s10103 005 0368 4
   Alhadlaq Adel M, 2015, J Contemp Dent Pract, V16, P578
   Alhashimi N, 2001, AM J ORTHOD DENTOFAC, V119, P307, DOI 10.1067/mod.2001.110809
   Altan BA, 2012, LASER MED SCI, V27, P131, DOI 10.1007/s10103 010 0853 2
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   BAUMRIND S, 1969, AMER J ORTHODONTICS, V55, P12, DOI 10.1016/S0002 9416(69)90170 5
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   BRUDVIK P, 1991, EUR J ORTHODONT, V13, P255, DOI 10.1093/ejo/13.4.255
   Carvalho Lobato P, 2014, PHOTOMED LASER SURG, V32, P302, DOI 10.1089/pho.2012.3439
   Coluzzi DJ, 2008, J Laser Dent, V16, P4
   Cossetin E, 2013, ANGLE ORTHOD, V83, P1015, DOI 10.2319/100812 789.1
   DAVIDOVITCH Z, 1991, CRIT REV ORAL BIOL M, V2, P411, DOI 10.1177/10454411910020040101
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   Elkattan Aya Ehab, 2019, Open Access Maced J Med Sci, V7, P412, DOI 10.3889/oamjms.2019.089
   Fujita S, 2008, ORTHOD CRANIOFAC RES, V11, P143, DOI 10.1111/j.1601 6343.2008.00423.x
   Ge MK, 2015, LASER MED SCI, V30, P1609, DOI 10.1007/s10103 014 1538 z
   Gunji H, 2018, LASER SURG MED, V50, P772, DOI 10.1002/lsm.22797
   Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864
   Hamblin MR, 2017, AIMS BIOPHYS, V4, P337, DOI 10.3934/biophy.2017.3.337
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hsu LF, 2018, J PHOTOCH PHOTOBIO B, V186, P41, DOI 10.1016/j.jphotobiol.2018.05.011
   Kanzaki H, 2004, J DENT RES, V83, P920, DOI 10.1177/154405910408301206
   Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801
   Kapoor P, 2014, PROG ORTHOD, V15, DOI 10.1186/s40510 014 0065 6
   Kasai S, 1996, J Clin Laser Med Surg, V14, P107
   Kau CH, 2013, PROG ORTHOD, V14, DOI 10.1186/2196 1042 14 30
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Kim YD, 2007, LASER PHYS LETT, V4, P616, DOI 10.1002/lapl.200710032
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Kucher U, 2014, INT J ORAL SCI, V6, P70, DOI 10.1038/ijos.2014.12
   Leethanakul C, 2014, ANGLE ORTHOD, V84, P839, DOI 10.2319/100613 737.1
   LEIKER BJ, 1995, AM J ORTHOD DENTOFAC, V108, P380, DOI 10.1016/S0889 5406(95)70035 8
   Lim WH, 2014, J PERIODONTAL RES, V49, P751, DOI 10.1111/jre.12158
   Maiya GA, 2005, PHOTOMED LASER SURG, V23, P187, DOI 10.1089/pho.2005.23.187
   Marquezan M, 2010, PHOTOMED LASER SURG, V28, P757, DOI 10.1089/pho.2009.2694
   Mayahara K, 2010, LASER SURG MED, V42, P489, DOI 10.1002/lsm.20871
   Milligan M, 2017, ARCH ORAL BIOL, V80, P62, DOI 10.1016/j.archoralbio.2017.03.016
   Na S, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.7.075008
   Odagaki N, 2018, J DENT RES, V97, P1374, DOI 10.1177/0022034518771331
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889 5406(97)70152 5
   Sedky Y, 2019, Laser Dent Sci, V3, P99, DOI DOI 10.1007/S41547 019 00055 W
   Seifi M, 2007, LASER MED SCI, V22, P261, DOI 10.1007/s10103 007 0447 9
   Silva AN, 2002, J CLIN LASER MED SUR, V20, P83, DOI 10.1089/104454702753768061
   Sousa MVS, 2014, PHOTOMED LASER SURG, V32, P592, DOI 10.1089/pho.2014.3789
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tang N, 2012, ARCH MED SCI, V8, P422, DOI 10.5114/aoms.2012.28810
   Tsuka Y, 2020, J LASERS MED SCI, V11, P138, DOI 10.34172/jlms.2020.24
   Wang YG, 2017, BBA GEN SUBJECTS, V1861, P441, DOI 10.1016/j.bbagen.2016.10.008
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Yamaguchi M, 2009, ORTHOD CRANIOFAC RES, V12, P113, DOI 10.1111/j.1601 6343.2009.01444.x
   Yassaei Soghra, 2013, J Dent (Tehran), V10, P264
   Yoshida T, 2009, ORTHOD CRANIOFAC RES, V12, P289, DOI 10.1111/j.1601 6343.2009.01464.x
   Youssef M, 2008, LASER MED SCI, V23, P27, DOI 10.1007/s10103 007 0449 7
   Zhang F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14667 4
   Zheng JY, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01684 z
   Zhou GJ, 2019, INT J CLIN EXP MED, V12, P11360
NR 57
TC 5
Z9 6
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0031 8655
EI 1751 1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD NOV
PY 2023
VL 99
IS 6
BP 1448
EP 1455
DI 10.1111/php.13787
EA FEB 2023
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CG7Y9
UT WOS:000934840100001
PM 36718580
OA Bronze
DA 2025 08 17
ER

PT J
AU Chang, B
   Qiu, HX
   Zhao, HY
   Yang, X
   Wang, Y
   Ji, TD
   Zhang, YX
   Quan, Q
   Li, YQ
   Zeng, J
   Meng, HY
   Gu, Y
AF Chang, Biao
   Qiu, Haixia
   Zhao, Hongyou
   Yang, Xi
   Wang, Ying
   Ji, Tengda
   Zhang, Yuxuan
   Quan, Qi
   Li, Yunqi
   Zeng, Jing
   Meng, Haoye
   Gu, Ying
TI The Effects of Photobiomodulation on MC3T3 E1 Cells via 630 nm and 810
   nm Light Emitting Diode
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Laser Therapy, Low Level; Osteoblasts; Osteoporosis
ID LEVEL LASER THERAPY; BIPHASIC DOSE RESPONSE; EXPERIMENTAL OSTEOPOROSIS;
   BIOMECHANICAL PROPERTIES; WNT/BETA CATENIN; STEM CELLS; RED LIGHT;
   MECHANISMS; PROLIFERATION; IRRADIATION
AB Background: Photobiomodulation (PBM) has been explored as a promising therapeutic strategy to regulate bone cell growth; however, the effects of PBM on osteoblast cell lines remains poorly understood. In addition, as a light source of PBM, the light uniformity of light emitting diode (LED) devices has not been given enough attention.
   Material/Methods: Here, we sought to investigate the effects of PBM on MC3T3 E1 cells via 630 nm and 810 nm light from a newly designed LED with high uniformity of light. Cell proliferation, flow cytometric analysis, alkaline phosphatase (ALP) staining, ALP activity, Alizarin Red 5 staining, and quantitative real time polymerase chain reaction (qRT PCR) were carried out to assess treatment response. MC3T3 E1 cells were irradiated with LED devices (630 +/  5 nm and 810 +/  10 nm, continuous wave) for 200 seconds at a power density of 5 mW/cm(2) once daily.
   Results: Increases in cell proliferation and decreases in cell apoptosis were evident following irradiation. ALP staining intensity and activity were also significantly increased following irradiation. Level of mineralization was obviously enhanced in irradiated groups compared with non irradiated controls. qRT PCR also showed significant increases in mRNA expression of osteocalcin (OCN) and osteoprotegerin (OPG) in the irradiated groups.
   Conclusions: Our results showed that LED PBM could promote the proliferation, ALP staining intensity and activity, level of mineralization, gene expression of OCN and OPG of MC3T3 E1 cells, with no significant difference between the 630 nm  and 810 nm irradiated groups.
C1 [Chang, Biao; Qiu, Haixia; Zhao, Hongyou; Wang, Ying; Ji, Tengda; Li, Yunqi; Zeng, Jing; Gu, Ying] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing, Peoples R China.
   [Yang, Xi] Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing, Peoples R China.
   [Yang, Xi] Gen Hosp Xinjiang Mil Command, Urumqi, Xinjiang, Peoples R China.
   [Zhang, Yuxuan; Quan, Qi; Meng, Haoye] Chinese Peoples Liberat Army Gen Hosp, Inst Orthoped, Beijing, Peoples R China.
   [Zhang, Yuxuan; Quan, Qi; Meng, Haoye] Beijing Key Lab Regenerat Med Orthoped, Beijing, Peoples R China.
   [Zhang, Yuxuan; Quan, Qi; Meng, Haoye] Peoples Liberat Army, Key Lab Musculoskeletal Trauma & War Injuries, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Gu, Y (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing, Peoples R China.
EM goyinglaser301@163.com
RI meng, hao/JHT 3327 2023; QUAN, QI/LDG 0376 2024; zeng,
   jing/JDW 4350 2023
FU National Key R&D Program of China [2017YFB0403801]
FX This work was supported by the National Key R&D Program of China
   (2017YFB0403801)
CR Aras MH, 2015, PHOTOMED LASER SURG, V33, P136, DOI 10.1089/pho.2014.3820
   Asai T., 2014, Kobe J Med Sci, V60, P12
   Barikbin B, 2017, J COSMET LASER THER
   Bayat M, 2016, LASER MED SCI, V31, P305, DOI 10.1007/s10103 015 1842 2
   Bayram H, 2013, INT J ORAL MAX SURG, V42, P140, DOI 10.1016/j.ijom.2012.03.026
   Bingöl Ü, 2005, PHOTOMED LASER SURG, V23, P459, DOI 10.1089/pho.2005.23.459
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chan AS, 2019, INT J GERIATR PSYCH, V34, P369, DOI 10.1002/gps.5039
   Chang B, 2018, MED SCI MONITOR, V24, P8758, DOI 10.12659/MSM.912309
   Chang B, 2016, EUR J NEUROSCI, V44, P2040, DOI 10.1111/ejn.13250
   Choi SH, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201900063
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2014, CURR OSTEOPOROS REP, V12, P385, DOI 10.1007/s11914 014 0237 9
   Cotler HB, 2015, MOJ Orthop Rheumatol, V2, DOI [DOI 10.15406/MOJOR.2015.02.00068, 10.15406/mojor.2015.02.00068]
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Deana AM, 2018, LASER MED SCI, V33, P1147, DOI 10.1007/s10103 018 2486 9
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fallahnezhad S, 2018, J CELL BIOCHEM, V119, P983, DOI 10.1002/jcb.26265
   Fridoni M, 2015, LASER MED SCI, V30, P1117, DOI 10.1007/s10103 014 1706 1
   Gál P, 2009, LASER MED SCI, V24, P539, DOI 10.1007/s10103 008 0604 9
   Golovynskyi S, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201800141
   Han L, 2018, LASER MED SCI, V33, P637, DOI 10.1007/s10103 018 2455 3
   Heiskanen V, 2018, PHOTOCH PHOTOBIO SCI, V17, P1003, DOI [10.1039/c8pp00176f, 10.1039/c8pp90049c]
   Hemmer E, 2016, NANOSCALE HORIZ, V1, P168, DOI 10.1039/c5nh00073d
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Huang YY, 2011, DOSE RESPONSE, V9, P602, DOI 10.2203/dose response.11 009.Hamblin
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Joo HJ, 2017, ANN DERMATOL, V29, P747, DOI 10.5021/ad.2017.29.6.747
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kim H, 2013, DERMATOL SURG, V39, P1177, DOI 10.1111/dsu.12200
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103 008 0550 6
   Kim JE, 2017, LASER SURG MED, V49, P940, DOI 10.1002/lsm.22736
   Kobayashi FY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017193
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Lim HJ, 2014, LASER MED SCI, V29, P659, DOI 10.1007/s10103 013 1363 9
   Liu DB, 2018, MED SCI MONITOR, V24, P4363, DOI 10.12659/MSM.905958
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mostafavinia A, 2017, J PHOTOCH PHOTOBIO B, V175, P29, DOI 10.1016/j.jphotobiol.2017.08.021
   Pagin MT, 2014, LASER MED SCI, V29, P55, DOI 10.1007/s10103 012 1238 5
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103 011 1005 z
   Poppi RR, 2011, LASER MED SCI, V26, P515, DOI 10.1007/s10103 010 0867 9
   Pyo SJ, 2013, LASER MED SCI, V28, P543, DOI 10.1007/s10103 012 1109 0
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rosa CB, 2017, LASER MED SCI, V32, P263, DOI 10.1007/s10103 016 2108 3
   RYDEN H, 1994, SWED DENT J, V18, P35
   Scalize PH, 2015, LASER MED SCI, V30, P1599, DOI 10.1007/s10103 015 1773 y
   Skopin MD, 2009, PHOTODERMATOL PHOTO, V25, P75, DOI 10.1111/j.1600 0781.2009.00406.x
   Sohn HM, 2017, LASER MED SCI, V32, P189, DOI 10.1007/s10103 016 2101 x
   Sohn H, 2015, LASER SURG MED, V47, P745, DOI 10.1002/lsm.22413
   Sorbellini E, 2018, LASER MED SCI, V33, P1431, DOI 10.1007/s10103 018 2584 8
   Tani A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071946
   Tatmatsu Rocha JC, 2018, J PHOTOCH PHOTOBIO B, V187, P41, DOI 10.1016/j.jphotobiol.2018.07.032
   de Paiva PRV, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015317
   Wang YG, 2017, BBA GEN SUBJECTS, V1861, P441, DOI 10.1016/j.bbagen.2016.10.008
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   Yun SH, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 016 0008
   Zhao Y, 2007, BIOMATERIALS, V28, P3063, DOI 10.1016/j.biomaterials.2007.03.003
NR 58
TC 23
Z9 25
U1 1
U2 17
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD NOV 19
PY 2019
VL 25
BP 8744
EP 8752
DI 10.12659/MSM.920396
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JQ6PX
UT WOS:000499066100003
PM 31743330
OA Green Published
DA 2025 08 17
ER

PT J
AU Ramaraju, H
   Miller, SJ
   Kohn, DH
AF Ramaraju, Harsha
   Miller, Sharon J.
   Kohn, David H.
TI Dual functioning peptides discovered by phage display increase the
   magnitude and specificity of BMSC attachment to mineralized biomaterials
SO BIOMATERIALS
LA English
DT Article
DE Biomimetic apatite; Peptides; Phage display; MSCs; Adhesion strength
ID MARROW STROMAL FIBROBLASTS; BONE GRAFT SUBSTITUTE; MEDIATE
   CELL ADHESION; HYDROXYAPATITE SURFACES; RGD PEPTIDES; IN VITRO; BINDING;
   ADSORPTION; PHOSPHORYLATION; DIFFERENTIATION
AB Design of biomaterials for cell based therapies requires presentation of specific physical and chemical cues to cells, analogous to cues provided by native extracellular matrices (ECM). We previously identified a peptide sequence with high affinity towards apatite (VTKHLNQISQSY, VTK) using phage display. The aims of this study were to identify a human MSC specific peptide sequence through phage display, combine it with the apatite specific sequence, and verify the specificity of the combined dual functioning peptide to both apatite and human bone marrow stromal cells. In this study, a combinatorial phage display identified the cell binding sequence (DPIYALSWSGMA, DPI) which was combined with the mineral binding sequence to generate the dual peptide DPI VTK. DPI VTK demonstrated significantly greater binding affinity (1/K D) to apatite surfaces compared to VTK, phosphorylated VTK (VTKphos), DPI VTKphos, RGD VTK, and peptide free apatite surfaces (p < 0.01), while significantly increasing hBMSC adhesion strength (tau(50), p < 0.01). MSCs demonstrated significantly greater adhesion strength to DPI VTK compared to other cell types, while attachment of MC3T3 pre osteoblasts and murine fibroblasts was limited (p < 0.01). MSCs on DPI VTK coated surfaces also demonstrated increased spreading compared to pre osteoblasts and fibroblasts. MSCs cultured on DPI VTK coated apatite films exhibited significantly greater proliferation compared to controls (p < 0.001). Moreover, early and late stage osteogenic differentiation markers were elevated on DPI VTK coated apatite films compared to controls. Taken together, phage display can identify non obvious cell and material specific peptides to increase human MSC adhesion strength to specific biomaterial surfaces and subsequently increase cell proliferation and differentiation. These new peptides expand biomaterial design methodology for cell based regeneration of bone defects. This strategy of combining cell and material binding phage display derived peptides is broadly applicable to a variety of systems requiring targeted adhesion of specific cell populations, and may be generalized to the engineering of any adhesion surface. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Ramaraju, Harsha; Miller, Sharon J.; Kohn, David H.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Kohn, David H.] Univ Michigan, Dept Biol & Mat Sci, 1011 N Univ Ave,Room 2213, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Kohn, DH (通讯作者)，Univ Michigan, Dept Biol & Mat Sci, 1011 N Univ Ave,Room 2213, Ann Arbor, MI 48109 USA.
EM dh.kohn@umich.edu
RI Ramaraju, Harsha/HGE 1406 2022; Kohn, David/AAJ 4131 2020
OI Miller, Sharon/0000 0002 1768 5945; Ramaraju, Harsha/0000 0001 9452 9228
FU NIH [DE015411, R01 DE026116]
FX We would like to thank Dr. Sergei Kuznetsov for the generous
   contribution of primary human bone marrow stromal cells and Dr. Paul
   Krebsbach for the induced pluripotent mesenchymal cells. Funded by NIH
   DE015411, R01 DE026116.
CR Addison WN, 2010, BIOMATERIALS, V31, P9422, DOI 10.1016/j.biomaterials.2010.08.064
   Addison WN, 2010, J BONE MINER RES, V25, P695, DOI 10.1359/jbmr.090832
   Artzi Z, 2008, INT J ORAL MAX IMPL, V23, P1063
   Bhatnagar RS, 1999, TISSUE ENG, V5, P53, DOI 10.1089/ten.1999.5.53
   Emam H, 2011, INT J ORAL MAX IMPL, V26, P561
   Eyckmans J, 2011, DEV CELL, V21, P35, DOI 10.1016/j.devcel.2011.06.015
   Feng YZ, 2004, BIOCHEMISTRY US, V43, P15811, DOI 10.1021/bi049174+
   Fujisawa R, 1997, MATRIX BIOL, V16, P21, DOI 10.1016/S0945 053X(97)90113 X
   Garcia AJ, 2003, CELL BIOCHEM BIOPHYS, V39, P61, DOI 10.1385/CBB:39:1:61
   García AJ, 2002, BIOCHEMISTRY US, V41, P9063, DOI 10.1021/bi025752f
   Gilbert M, 2000, J BIOL CHEM, V275, P16213, DOI 10.1074/jbc.M001773200
   Gomar F, 2007, INT ORTHOP, V31, P93, DOI 10.1007/s00264 006 0087 x
   Hennessy KM, 2008, BIOMATERIALS, V29, P3075, DOI 10.1016/j.biomaterials.2008.04.014
   Hennessy KM, 2009, BIOMATERIALS, V30, P1898, DOI 10.1016/j.biomaterials.2008.12.053
   Hsiong SX, 2009, TISSUE ENG PT A, V15, P263, DOI 10.1089/ten.tea.2007.0411
   Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05 5424rev
   Itoh D, 2002, J BIOMED MATER RES, V62, P292, DOI 10.1002/jbm.10338
   Kantlehner M, 2000, CHEMBIOCHEM, V1, P107, DOI 10.1002/1439 7633(20000818)1:2<107::AID CBIC107>3.0.CO;2 4
   Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890 199704270 00003
   Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335
   Kuznetsov SA, 2013, J TISSUE ENG REGEN M, V7, P226, DOI 10.1002/term.515
   Lebaron RG, 2000, TISSUE ENG, V6, P85, DOI 10.1089/107632700320720
   Lee JS, 2009, ANGEW CHEM INT EDIT, V48, P6266, DOI 10.1002/anie.200901618
   Lee JS, 2010, ADV MATER, V22, P5494, DOI 10.1002/adma.201002970
   Luck K, 2011, BIOINFORMATICS, V27, P899, DOI 10.1093/bioinformatics/btr060
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   Makowski L, 2003, BIOINFORMATICS, V19, P483, DOI 10.1093/bioinformatics/btg013
   Mandava S, 2004, PROTEOMICS, V4, P1439, DOI 10.1002/pmic.200300680
   Mankani MH, 2006, STEM CELLS, V24, P2140, DOI 10.1634/stemcells.2005 0567
   McClay D.R., 2001, CURR PROTOC CELL BIO, P2
   Meder F, 2013, J AM CHEM SOC, V135, P6307, DOI 10.1021/ja401590c
   Mobbs RJ, 2014, J NEUROSURG SPINE, V21, P867, DOI 10.3171/2014.9.SPINE131151
   Murphy WL, 2000, J BIOMED MATER RES, V50, P50, DOI 10.1002/(SICI)1097 4636(200004)50:1<50::AID JBM8>3.0.CO;2 F
   Petrie TA, 2006, BIOMATERIALS, V27, P5459, DOI 10.1016/j.biomaterials.2006.06.027
   Ramaswamy J, 2011, ADV MAT SCI ENG BOCA, P1
   Segvich S.J., 2008, BIOMATERIALS BIOMEDI, P325
   Segvich SJ, 2009, BIOMATERIALS, V30, P1287, DOI 10.1016/j.biomaterials.2008.11.008
   Shekaran A, 2011, J BIOMED MATER RES A, V96A, P261, DOI 10.1002/jbm.a.32979
   Stayton PS, 2003, CRIT REV ORAL BIOL M, V14, P370, DOI 10.1177/154411130301400507
   Tsai TM, 1996, INT J PHARM, V127, P31, DOI 10.1016/0378 5173(95)04111 7
   Villarreal Ramirez E, 2014, CONNECT TISSUE RES, V55, P134, DOI 10.3109/03008207.2014.923870
   YOUNG BR, 1988, J COLLOID INTERF SCI, V124, P28, DOI 10.1016/0021 9797(88)90321 9
NR 42
TC 36
Z9 39
U1 0
U2 69
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2017
VL 134
BP 1
EP 12
DI 10.1016/j.biomaterials.2017.04.034
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EV4GS
UT WOS:000401717500001
PM 28453953
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Petruzzella, A
   Bruand, M
   Santamaria Martinez, A
   Katanayeva, N
   Reymond, L
   Wehrle, S
   Georgeon, S
   Inel, D
   van Dalen, FJ
   Viertl, D
   Lau, K
   Pojer, F
   Schottelius, M
   Zoete, V
   Verdoes, M
   Arber, C
   Correia, BE
   Oricchio, E
AF Petruzzella, Aaron
   Bruand, Marine
   Santamaria Martinez, Albert
   Katanayeva, Natalya
   Reymond, Luc
   Wehrle, Sarah
   Georgeon, Sandrine
   Inel, Damla
   van Dalen, Floris J.
   Viertl, David
   Lau, Kelvin
   Pojer, Florence
   Schottelius, Margret
   Zoete, Vincent
   Verdoes, Martijn
   Arber, Caroline
   Correia, Bruno E.
   Oricchio, Elisa
TI Antibody peptide conjugates deliver covalent inhibitors blocking
   oncogenic cathepsins
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID CYSTEINE CATHEPSINS; S INHIBITOR; K INHIBITOR; POSTMENOPAUSAL WOMEN;
   CANCER PROGRESSION; PROGNOSTIC IMPACT; DOUBLE BLIND; ODANACATIB;
   PHARMACOKINETICS; MICROENVIRONMENT
AB Cysteine cathepsins are a family of proteases that are relevant therapeutic targets for the treatment of different cancers and other diseases. However, no clinically approved drugs for these proteins exist, as their systemic inhibition can induce deleterious side effects. To address this problem, we developed a modular antibody based platform for targeted drug delivery by conjugating non natural peptide inhibitors (NNPIs) to antibodies. NNPIs were functionalized with reactive warheads for covalent inhibition, optimized with deep saturation mutagenesis and conjugated to antibodies to enable cell type specific delivery. Our antibody peptide inhibitor conjugates specifically blocked the activity of cathepsins in different cancer cells, as well as osteoclasts, and showed therapeutic efficacy in vitro and in vivo. Overall, our approach allows for the rapid design of selective cathepsin inhibitors and can be generalized to inhibit a broad class of proteases in cancer and other diseases.
   Cathepsins are relevant therapeutic targets in cancer and other diseases. Here, the authors developed a different approach to block the activity of cathepsins in specific cellular contexts by combining non natural peptide inhibitors with antibodies, enhancing therapeutic efficacy while reducing side effects.
C1 [Petruzzella, Aaron; Bruand, Marine; Santamaria Martinez, Albert; Katanayeva, Natalya; Oricchio, Elisa] Swiss Fed Inst Technol Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland.
   [Petruzzella, Aaron; Bruand, Marine; Santamaria Martinez, Albert; Katanayeva, Natalya; Zoete, Vincent; Oricchio, Elisa] Swiss Canc Ctr Leman SCCL, Lausanne, Switzerland.
   [Reymond, Luc] Swiss Fed Inst Technol EPFL, Inst Chem Sci & Engn ISIC, Inst Bioengn, Lausanne, Switzerland.
   [Wehrle, Sarah; Georgeon, Sandrine; Correia, Bruno E.] Swiss Fed Inst Technol Lausanne EPFL, Sch Engn, Lab Prot Design & Immunoengn, Lausanne, Switzerland.
   [Inel, Damla; Zoete, Vincent; Arber, Caroline] Ludwig Inst Canc Res, Lausanne Branch, Lausanne, Switzerland.
   [Inel, Damla; Zoete, Vincent; Arber, Caroline] Lausanne Univ Hosp CHUV, Dept Oncol, Lausanne, Switzerland.
   [Inel, Damla; Viertl, David; Schottelius, Margret; Zoete, Vincent] Univ Lausanne UNIL, Lausanne, Switzerland.
   [van Dalen, Floris J.; Verdoes, Martijn] Radboud Univ Nijmegen, Med Ctr, Dept Med BioSci, Nijmegen, Netherlands.
   [van Dalen, Floris J.; Verdoes, Martijn] Inst Chem Immunol, Nijmegen, Netherlands.
   [Viertl, David; Schottelius, Margret] Lausanne Univ Hosp CHUV, Translat Radiopharmaceut Sci, Dept Nucl Med, Lausanne, Switzerland.
   [Viertl, David; Schottelius, Margret] Lausanne Univ Hosp CHUV, Dept Mol Imaging, Translat Radiopharmaceut Sci, Lausanne, Switzerland.
   [Viertl, David; Schottelius, Margret] Lausanne Univ Hosp CHUV, Dept Oncol, Translat Radiopharmaceut Sci, Lausanne, Switzerland.
   [Viertl, David] Univ Lausanne UNIL, Dept Res & Training, Vivo Imaging Facil, Lausanne, Switzerland.
   [Lau, Kelvin; Pojer, Florence] Swiss Fed Inst Technol Lausanne EPFL, Sch Life Sci, Prot Prod & Struct Core Facil, Lausanne, Switzerland.
   [Schottelius, Margret] AGORA Pole Rech Canc, Lausanne, Switzerland.
C3 Swiss School of Public Health (SSPH+); Swiss Federal Institutes of
   Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss
   Institute Experimental Cancer Research; Swiss Federal Institutes of
   Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss
   Federal Institutes of Technology Domain; Ecole Polytechnique Federale de
   Lausanne; Ludwig Institute for Cancer Research; University of Lausanne;
   Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne;
   Radboud University Nijmegen; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); University of Lausanne; Swiss School of
   Public Health (SSPH+); Swiss Federal Institutes of Technology Domain;
   Ecole Polytechnique Federale de Lausanne
RP Oricchio, E (通讯作者)，Swiss Fed Inst Technol Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland.; Oricchio, E (通讯作者)，Swiss Canc Ctr Leman SCCL, Lausanne, Switzerland.; Correia, BE (通讯作者)，Swiss Fed Inst Technol Lausanne EPFL, Sch Engn, Lab Prot Design & Immunoengn, Lausanne, Switzerland.
EM bruno.correia@epfl.ch; elisa.oricchio@epfl.ch
RI Lau, Kelvin/M 2639 2019; van Dalen, Floris/M 8813 2017;
   Santamaria Martínez, Albert/IXN 3985 2023; Verdoes, Martijn/A 4911 2015;
   Zoete, Vincent/HOH 2800 2023
OI Georgeon, Sandrine/0000 0002 8158 4508; Bruand,
   Marine/0000 0001 8651 4800; Arber, Caroline/0000 0001 6440 9970; Zoete,
   Vincent/0000 0002 2336 6537; Petruzzella, Aaron/0000 0002 7616 2271;
   REYMOND, Luc/0000 0001 5282 9273
FU SNF [CRSK 3_190639]; Leenaards Foundation; Swiss Cancer League
   [KFS 5000 02 2020]; Fondation Aclon; Swiss National Science Foundation
   (SNF) [CRSK 3_190639] Funding Source: Swiss National Science Foundation
   (SNF)
FX We thank the EPFL and University of Lausanne (UNIL) facilities,
   particularly the Protein Production and Structure Core Facility, the
   Biomolecular Screening Facility, the Institute of Chemical Sciences and
   Engineering (ISIC) Mass Spectrometry Facility and the FC Core Facility
   of EPFL. We also thank M. Santin, A. Buu Hoang, E. Simkova, A.
   Pellegrino and G. Dienes from EPFL for their technical support with in
   vitro assay optimization. This work was supported by the SNF (Spark
   grant CRSK 3_190639, to E.O.), Leenaards Foundation (to E.O., B.E.C. and
   C.A.), Swiss Cancer League (KFS 5000 02 2020, to E.O.) and Fondation
   Aclon (to E.O.). We thank ARRONAX (Saint Herblain, France) for [64Cu]
   production. We thank Creoptix (Waedenswil, Switzerland) and A. Moretti
   for support with the Creoptix WAVE system.
CR Bararia D, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107522
   BARRETT AJ, 1981, ACTA BIOL MED GER, V40, P1513
   Baugh M, 2011, J AUTOIMMUN, V36, P201, DOI 10.1016/j.jaut.2011.01.003
   Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078 0432.CCR 08 0121
   Bentley D, 2023, RHEUMATOLOGY, V62, P3644, DOI 10.1093/rheumatology/kead092
   Bertosin E, 2021, ACS NANO, V15, P9391, DOI 10.1021/acsnano.0c10137
   Biniossek ML, 2011, J PROTEOME RES, V10, P5363, DOI 10.1021/pr200621z
   Boike L, 2022, NAT REV DRUG DISCOV, V21, P881, DOI 10.1038/s41573 022 00542 z
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bratkovic T, 2005, BIOCHEM BIOPH RES CO, V332, P897, DOI 10.1016/j.bbrc.2005.05.028
   Chalouni C, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 017 0667 1
   Chen RJ, 2023, ARCH OSTEOPOROS, V18, DOI 10.1007/s11657 023 01261 7
   Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   Delage JA, 2021, CANCERS, V13, DOI 10.3390/cancers13235936
   Dheilly E, 2020, CANCER CELL, V37, P674, DOI 10.1016/j.ccell.2020.03.016
   Diao L, 2013, CLIN PHARMACOKINET, V52, P855, DOI 10.1007/s40262 013 0079 0
   Edgington Mitchell LE, 2017, METHODS MOL BIOL, V1491, P145, DOI 10.1007/978 1 4939 6439 0_11
   Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood 2003 07 2469
   England RM, 2020, BIOMACROMOLECULES, V21, P3332, DOI 10.1021/acs.biomac.0c00768
   Flygare JA, 2013, CHEM BIOL DRUG DES, V81, P113, DOI 10.1111/cbdd.12085
   Fonovic M, 2014, BBA GEN SUBJECTS, V1840, P2560, DOI 10.1016/j.bbagen.2014.03.017
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Frlan R, 2006, CURR MED CHEM, V13, P2309, DOI 10.2174/092986706777935122
   Fujise N, 2000, LUNG CANCER J IASLC, V27, P19, DOI 10.1016/S0169 5002(99)00088 4
   Gaieb Z, 2019, J COMPUT AID MOL DES, V33, P1, DOI 10.1007/s10822 018 0180 4
   GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406
   Gopinathan A, 2012, GUT, V61, P877, DOI 10.1136/gutjnl 2011 300850
   Hamilton GS, 2015, BIOLOGICALS, V43, P318, DOI 10.1016/j.biologicals.2015.05.006
   Hargreaves P, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1955 2
   Heidtmann HH, 1997, CLIN EXP METASTAS, V15, P368, DOI 10.1023/A:1018494020001
   Kramer L, 2017, TRENDS PHARMACOL SCI, V38, P873, DOI 10.1016/j.tips.2017.06.003
   Lah TT, 1998, BIOL CHEM, V379, P125
   Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008 5472.CAN 06 3940
   Lee Dutra A, 2011, EXPERT OPIN THER PAT, V21, P311, DOI 10.1517/13543776.2011.553800
   Lindström E, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1497 4
   López Otín C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200
   McClung MR, 2019, LANCET DIABETES ENDO, V7, P899, DOI 10.1016/S2213 8587(19)30346 8
   McGlinchey RP, 2015, P NATL ACAD SCI USA, V112, P9322, DOI 10.1073/pnas.1500937112
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Mullard A, 2013, NAT REV DRUG DISCOV, V12, P329, DOI 10.1038/nrd4009
   Naftaly A, 2021, ACS BIOMATER SCI ENG, V7, P3179, DOI 10.1021/acsbiomaterials.1c00387
   Narayanan A, 2022, BIOCHEM SOC T, V50, P151, DOI 10.1042/BST20211180
   Niedergethmann M, 2004, PANCREAS, V29, P204, DOI 10.1097/00006676 200410000 00005
   Nouh MA, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 1
   Novinec Marko, 2013, Biomol Concepts, V4, P287, DOI 10.1515/bmc 2012 0054
   Olson OC, 2015, NAT REV CANCER, V15, P712, DOI 10.1038/nrc4027
   Pauly TA, 2003, BIOCHEMISTRY US, V42, P3203, DOI 10.1021/bi027308i
   Payne CD, 2014, BRIT J CLIN PHARMACO, V78, P1334, DOI 10.1111/bcp.12470
   Podgorski I, 2007, BIOCHEM SOC T, V35, P701, DOI 10.1042/BST0350701
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074 7613(00)80249 6
   Saegusa K, 2002, J CLIN INVEST, V110, P361, DOI 10.1172/JCI200214682
   Segal E, 2015, CHEM BIOL, V22, P148, DOI 10.1016/j.chembiol.2014.11.008
   Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011
   SHI GP, 1994, J BIOL CHEM, V269, P11530
   Smyth P, 2022, MOL ASPECTS MED, V88, DOI 10.1016/j.mam.2022.101106
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Sudhan DR, 2016, INT J CANCER, V138, P2665, DOI 10.1002/ijc.29992
   Theron M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00806
   Turk V, 2012, BBA PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   van Dalen FJ, 2021, FRONT CHEM, V8, DOI 10.3389/fchem.2020.628433
   Verdoes M, 2013, J AM CHEM SOC, V135, P14726, DOI 10.1021/ja4056068
   Victor BC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3058
   Vidak E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8030264
   Woo JT, 1996, EUR J PHARMACOL, V300, P131, DOI 10.1016/0014 2999(95)00858 6
   Young G, 2018, SCIENCE, V360, P423, DOI 10.1126/science.aar5839
   Zoete V, 2016, J COMPUT CHEM, V37, P437, DOI 10.1002/jcc.24249
NR 71
TC 11
Z9 13
U1 7
U2 29
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1552 4450
EI 1552 4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD SEP
PY 2024
VL 20
IS 9
BP 1188
EP 1198
DI 10.1038/s41589 024 01627 z
EA MAY 2024
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA E0K5Y
UT WOS:001234568400001
PM 38811854
DA 2025 08 17
ER

PT J
AU Han, XN
   Gilbert, S
   Groschwitz, K
   Hogan, S
   Jurickova, I
   Trapnell, B
   Samson, C
   Gully, J
AF Han, Xiaonan
   Gilbert, Shila
   Groschwitz, Katherine
   Hogan, Simon
   Jurickova, Ingrid
   Trapnell, Bruce
   Samson, Charles
   Gully, Jonathan
TI Loss of GM CSF signalling in non haematopoietic cells increases NSAID
   ileal injury
SO GUT
LA English
DT Article
ID COLONY STIMULATING FACTOR; PEDIATRIC CROHNS DISEASE; GENOME WIDE
   ASSOCIATION; MARROW DERIVED CELLS; EPITHELIAL CELLS; GM CSF/IL 3/IL 5
   RECEPTORS; INTESTINAL PERMEABILITY; GENE EXPRESSION; TRANSDUCER;
   ACTIVATION
AB Background Administration of granulocyte macrophage colony stimulating factor (GM CSF) relieves symptoms in Crohn's disease (CD). It has been reported that reduced GM CSF bioactivity is associated with more aggressive ileal behaviour and that GM CSF null mice exhibit ileal barrier dysfunction and develop a transmural ileitis following exposure to non steroidal anti inflammatory drugs (NSAIDs). STAT5 signalling is central to GM CSF action. It was therefore hypothesised that GM CSF signalling in non haematopoietic cells is required for ileal homeostasis.
   Methods Bone marrow (BM) chimeras were generated by reconstituting irradiated GM CSF receptor (gm csfr) beta chain or GM CSF (gm csf) deficient mice with wild type BM (WTBM  > GMRKO and WTBM  > GMKO). Intestinal barrier function and the response to NSAID induced ileal injury were examined. Expression of gm csf, gm csfr or stat5 in Caco 2 and HT 29 intestinal epithelial cell (IEC) lines was knocked down and the effect of GMCSF signalling on IEC survival and proliferation was determined.
   Results Elevated levels of GM CSF autoantibodies in ileal CD were found to be associated with dysregulation of IEC survival and proliferation. GM CSF receptor deficient mice and WTBM  > GMRKO chimeras exhibited ileal hyperpermeability. NSAID exposure induced a transmural ileitis in GM CSF receptor deficient mice and WTBM  > GMRKO chimeras. Transplantation of wild type BM into GM CSF deficient mice prevented NSAID ileal injury and restored ileal barrier function. Ileal crypt IEC proliferation was reduced in WTBM  > GMRKO chimeras, while STAT5 activation in ileal IEC following NSAID exposure was abrogated in WTBM  > GMRKO chimeras. Following knock down of gm csf, gm csfr a or b chain or stat5a/b expression in Caco 2 cells, basal proliferation was suppressed. GM CSF normalised proliferation of Caco 2 cells exposed to NSAID, which was blocked by stat5a/b RNA interference.
   Conclusions Loss of GM CSF signalling in non haematopoietic cells increases NSAID ileal injury; furthermore, GM CSF signalling in non haematopoietic cells regulates ileal epithelial homeostasis via the STAT5 pathway. The therapeutic use of GM CSF may therefore be beneficial in chronic ileitis associated with CD.
C1 [Han, Xiaonan; Gilbert, Shila; Jurickova, Ingrid; Samson, Charles; Gully, Jonathan] Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA.
   [Han, Xiaonan; Gilbert, Shila; Groschwitz, Katherine; Hogan, Simon; Jurickova, Ingrid; Trapnell, Bruce; Samson, Charles; Gully, Jonathan] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA.
   [Trapnell, Bruce] Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA.
   [Groschwitz, Katherine; Hogan, Simon] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA.
C3 Cincinnati Children's Hospital Medical Center; University System of
   Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical
   Center; University System of Ohio; University of Cincinnati; Cincinnati
   Children's Hospital Medical Center
RP Han, XN (通讯作者)，Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, MLC 2010,3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM xiaonan.han@cchmc.org
OI Han, Xiaonan/0000 0001 5368 6489
FU Crohns and Colitis Foundation of America; Cincinnati Children's Hospital
   Research Foundation Digestive Health Center (PHS) [P30 DK0789392];
   Cincinnati Children's Hospital Medical Center; NIH [KL2 RR026315]
FX Crohns and Colitis Foundation of America (XH), Cincinnati Children's
   Hospital Research Foundation Digestive Health Center (PHS Grant P30
   DK0789392) and Cincinnati Children's Hospital Medical Center Trustee
   Award (XH). NIH clinical and translational research award KL2 RR026315
   (XH).
CR Beauchamp RD, 1996, ANN SURG, V223, P620, DOI 10.1097/00000658 199605000 00018
   Bernasconi E, 2010, INFLAMM BOWEL DIS, V16, P428, DOI 10.1002/ibd.21072
   Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132
   Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774
   Chidlow J.H., 2009, GASTROENTEROLOGY, V136, pe2
   Chidlow JH, 2009, GASTROENTEROLOGY, V136, P575, DOI 10.1053/j.gastro.2008.10.085
   Cui Y, 2007, HEPATOLOGY, V46, P504, DOI 10.1002/hep.21713
   Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678
   Drudy D, 2001, J MED MICROBIOL, V50, P526, DOI 10.1099/0022 1317 50 6 526
   Drumm B, 2003, LANCET, V361, P1830, DOI 10.1016/S0140 6736(03)13435 6
   Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796
   Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768
   Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046
   Golaz JL, 2007, IN VITRO CELL DEV AN, V43, P176, DOI 10.1007/s11626 007 9034 4
   Guthridge MA, 2004, BLOOD, V103, P820, DOI 10.1182/blood 2003 06 1999
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han X, 2007, GUT, V56, P73, DOI 10.1136/gut.2006.094490
   Han X, 2009, GUT, V58, P49, DOI 10.1136/gut.2007.145094
   Han XN, 2006, AM J PATHOL, V169, P1999, DOI 10.2353/ajpath.2006.060186
   Han XN, 2009, GASTROENTEROLOGY, V136, P1261, DOI 10.1053/j.gastro.2008.12.046
   Han XN, 2005, GASTROENTEROLOGY, V129, P185, DOI 10.1053/j.gastro.2005.05.018
   Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10
   Hansen G, 2008, CELL, V134, P496, DOI 10.1016/j.cell.2008.05.053
   Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002
   HOLLANDER D, 1986, ANN INTERN MED, V105, P883, DOI 10.7326/0003 4819 105 6 883
   HYAMS JS, 1991, J PEDIATR GASTR NUTR, V12, P439, DOI 10.1097/00005176 199105000 00005
   Joshi PC, 2006, AM J PHYSIOL LUNG C, V291, pL1150, DOI 10.1152/ajplung.00150.2006
   JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676
   Korzenik JR, 2005, NEW ENGL J MED, V352, P2193, DOI 10.1056/NEJMoa041109
   Lehtonen A, 2002, J LEUKOCYTE BIOL, V71, P511
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Mann A, 2001, CANCER RES, V61, P2311
   Meddings J, 2000, ANN NY ACAD SCI, V915, P333
   Paine R, 2003, AM J PATHOL, V163, P2397, DOI 10.1016/S0002 9440(10)63594 8
   Panja A, 1998, J IMMUNOL, V161, P3675
   Ramshaw HS, 2007, BLOOD, V110, P3582, DOI 10.1182/blood 2007 01 070391
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103
   Sainathan SK, 2008, INFLAMM BOWEL DIS, V14, P88, DOI 10.1002/ibd.20279
   Schorr K, 2000, CANCER RES, V60, P5950
   Sennikov SV, 2002, J GASTROENTEROL, V37, P1048, DOI 10.1007/s005350200176
   Takeuchi K, 2006, CLIN GASTROENTEROL H, V4, P196, DOI 10.1016/S1542 3565(05)00980 8
   Trapnell BC, 2009, CURR OPIN IMMUNOL, V21, P514, DOI 10.1016/j.coi.2009.09.004
NR 43
TC 25
Z9 26
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017 5749
EI 1468 3288
J9 GUT
JI Gut
PD AUG
PY 2010
VL 59
IS 8
BP 1066
EP 1078
DI 10.1136/gut.2009.203893
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 626PA
UT WOS:000279976700013
PM 20584783
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Murugesan, V
   Liu, J
   Yang, RH
   Lin, HQ
   Lischuk, A
   Pastores, G
   Zhang, XK
   Chuang, WL
   Mistry, PK
AF Murugesan, Vagishwari
   Liu, Jun
   Yang, Ruhua
   Lin, Haiquin
   Lischuk, Andrew
   Pastores, Gregory
   Zhang, Xiaokui
   Chuang, Wei Lien
   Mistry, Pramod K.
TI Validating glycoprotein non metastatic melanoma B (gpNMB, osteoactivin),
   a new biomarker of Gaucher disease
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE gpNMB; Osteoactivin; Biomarker; Gaucher disease
ID OSTEOBLAST DIFFERENTIATION; MARKED ELEVATION; GENE EXPRESSION; TYPE 1;
   CHITOTRIOSIDASE; MACROPHAGES; REGULATOR; MUTATION; ACTS
AB In the spleens of Gaucher disease mice and patients, there is a striking elevation of expression of glycoprotein non Metastatic Melanoma B (gpNMB). We conducted a study in a large cohort of patients with Gaucher disease to assess the utility of serum levels of soluble fragment of gpNMB as a biomarker of disease activity. There was N 15 fold elevation of gpNMB in sera of untreated patients with Gaucher disease. gpNMB levels correlated with overall disease severity as well as the severity of individual organ compartments: liver, spleen, bone and hematological disease. Imiglucerase enzyme replacement therapy resulted in significant reduction of gpNMB. Serum levels of gpNMB were highly correlated with accumulation of bioactive lipid substrate of Gaucher disease, glucosylsphingosine as well as established biomarkers, chitotriosidase and chemokine, CCL18. Our results suggest utility of gpNMB as a biomarker of Gaucher disease to monitor individual patients and cohorts of patients for disease progression or response to therapy. Investigation of gpNMB in Gaucher disease pathophysiology is likely to illuminate our understanding disease mechanisms. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Murugesan, Vagishwari; Liu, Jun; Yang, Ruhua] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
   [Lin, Haiquin] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA.
   [Lischuk, Andrew] Yale Univ, Sch Med, Dept Radiol, New Haven, CT 06510 USA.
   [Pastores, Gregory] Mater Misericordiae Univ Hosp, Dept Metab Dis, Dublin, Ireland.
   [Zhang, Xiaokui; Chuang, Wei Lien] Sanofi Genzyme, Framingham, MA USA.
   [Mistry, Pramod K.] Yale Univ, Sch Med, Dept Internal Med & Pediat, New Haven, CT USA.
C3 Yale University; Yale University; Yale University; University College
   Dublin; Mater Misericordiae University Hospital; Sanofi Aventis; Genzyme
   Corporation; Yale University
RP Mistry, PK (通讯作者)，Yale Lysosomal Dis Treatment Ctr, Dept Med & Pediat, 333 Cedar St,LMP 1080,POB 208019, New Haven, CT 06520 USA.
EM pramod.mistry@yale.edu
RI ; Pastores, Gregory/AAE 8647 2020; zhang, xiaokui/KVB 0390 2024
OI Murugesan, Vagishwari/0000 0001 9223 4637; Lin,
   Haiqun/0000 0002 3114 9671; 
FU National Institutes of Arthritis, Musculoskeletal and Skin Diseases [AR
   65932]; Center of Excellence Grant in Clinical Translational Research
   from Genzyme, a Sanofi Company; Genzyme
FX We thank patients for their generous participation in the study. PKM is
   supported by a grant from the National Institutes of Arthritis,
   Musculoskeletal and Skin Diseases AR 65932 and Center of Excellence
   Grant in Clinical Translational Research from Genzyme, a Sanofi Company.
   He has received research support, honoraria and consulting fees from
   Genzyme.
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841
   Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Abdelmagid SM, 2014, AM J PATHOL, V184, P697, DOI 10.1016/j.ajpath.2013.11.031
   Aerts JM, 2008, ACTA PAEDIATR, V97, P7, DOI 10.1111/j.1651 2227.2007.00641.x
   Boot RG, 2004, BLOOD, V103, P33, DOI 10.1182/blood 2003 05 1612
   Chung JS, 2007, BLOOD, V109, P4320, DOI 10.1182/blood 2006 11 053769
   Dekker N, 2011, BLOOD, V118, pE118, DOI 10.1182/blood 2011 05 352971
   Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036
   Gabriel TL, 2014, DIABETES, V63, P3310, DOI 10.2337/db13 1720
   Grabowski GA, 2015, AM J HEMATOL, V90, pS12, DOI 10.1002/ajh.24063
   HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084
   Hruska KS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/78549
   Kramer G, 2016, FEBS OPEN BIO, V6, P902, DOI 10.1002/2211 5463.12078
   Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10 154757
   Liu J, 2012, P NATL ACAD SCI USA, V109, P10018, DOI 10.1073/pnas.1200941109
   Marques ARA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147208
   Mistry PK, 2015, AM J HEMATOL, V90, pS6, DOI 10.1002/ajh.24055
   Mistry PK, 2014, P NATL ACAD SCI USA, V111, P4934, DOI 10.1073/pnas.1400768111
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Moran MT, 2000, BLOOD, V96, P1969, DOI 10.1182/blood.V96.5.1969.h8001969_1969_1978
   Murugesan V., 2016, Am J Hematol
   Myerowitz R, 2004, MOL GENET METAB, V83, P288, DOI 10.1016/j.ymgme.2004.06.020
   Parente MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032419
   Pastores GM, 2010, WIEN MED WOCHENSCHR, V160, P605, DOI 10.1007/s10354 010 0850 x
   Ripoll VM, 2008, GENE, V413, P32, DOI 10.1016/j.gene.2008.01.014
   Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557
   Rolfs A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079732
   Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093
   Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259
   Taddei TH, 2009, AM J HEMATOL, V84, P208, DOI 10.1002/ajh.21362
   Weinreb NJ, 2004, SEMIN HEMATOL, V41, P15, DOI 10.1053/j.seminhematol.2004.07.010
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
   Yildiz Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 151
   Zigdon H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120194
NR 35
TC 41
Z9 46
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1079 9796
EI 1096 0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD FEB
PY 2018
VL 68
SI SI
BP 47
EP 53
DI 10.1016/j.bcmd.2016.12.002
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA FO8OR
UT WOS:000417147400011
PM 28003098
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Moynihan, E
   Panseri, S
   Bassi, G
   Rossi, A
   Campodoni, E
   Dempsey, E
   Montesi, M
   Velasco Torrijos, T
   Montagner, D
AF Moynihan, Eoin
   Panseri, Silvia
   Bassi, Giada
   Rossi, Arianna
   Campodoni, Elisabetta
   Dempsey, Eithne
   Montesi, Monica
   Velasco Torrijos, Trinidad
   Montagner, Diego
TI Development of Novel Pt(IV) Carbohydrate Derivatives as Targeted
   Anticancer Agents against Osteosarcoma
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Pt(IV) pro drugs; cisplatin; carbohydrate; selective targeting;
   osteosarcoma; healthy cell; click chemistry
ID GLYCOSYLATED PLATINUM(IV) COMPLEXES; CRYSTAL STRUCTURE; CANCER CELLS;
   IN VITRO; METABOLISM; RESISTANCE; SERUM
AB Despite the enormous importance of cisplatin as a chemotherapeutic agent, its application is impacted by dose limiting side effects and lack of selectivity for cancer cells. Researchers can overcome these issues by taking advantage of the pro drug nature of the platinum(IV) oxidation state, and by modifying the coordination sphere of the metal centre with specific vectors whose receptors are overexpressed in tumour cell membranes (e.g., carbohydrates). In this paper we report the synthesis of four novel carbohydrate modified Pt(IV) pro drugs, based on the cisplatin scaffold, and their biological activity against osteosarcoma (OS), a malignant tumour which is most common in adolescents and young adults. The carbohydrate targeting vectors and Pt scaffold are linked using copper catalysed azide alkyne cycloaddition (CuAAC) chemistry, which is synonymous with mild and robust reaction conditions. The novel complexes are characterised using multinuclear 1D 2D NMR (H 1, C 13 and Pt 195), IR, HR MS, Elem. Analyses, and CV. Cytotoxicity on 2D and 3D and cell morphology studies on OS cell lines, as well as non cancerous human foetal osteoblasts (hFOBs), are discussed.
C1 [Moynihan, Eoin; Dempsey, Eithne; Velasco Torrijos, Trinidad; Montagner, Diego] Maynooth Univ, Dept Chem, Maynooth W23 F2H6, Ireland.
   [Panseri, Silvia; Bassi, Giada; Rossi, Arianna; Campodoni, Elisabetta; Montesi, Monica] CNR, Inst Sci Technol & Sustainabil Ceram, Natl Res Council, I 48018 Faenza, Italy.
   [Bassi, Giada] Univ Studies G Annunzio, Dept Neurosci Imaging & Clin Sci, I 66100 Chieti, Italy.
   [Rossi, Arianna] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, I 98166 Messina, Italy.
   [Dempsey, Eithne; Velasco Torrijos, Trinidad; Montagner, Diego] Maynooth Univ, Kathleen Londsdale Inst Human Hlth Res, Maynooth W23F2H6, Ireland.
C3 Consiglio Nazionale delle Ricerche (CNR); University of Messina
RP Montagner, D (通讯作者)，Maynooth Univ, Dept Chem, Maynooth W23 F2H6, Ireland.; Montesi, M (通讯作者)，CNR, Inst Sci Technol & Sustainabil Ceram, Natl Res Council, I 48018 Faenza, Italy.; Montagner, D (通讯作者)，Maynooth Univ, Kathleen Londsdale Inst Human Hlth Res, Maynooth W23F2H6, Ireland.
EM monica.montesi@issmc.cnr.it; diego.montagner@mu.ie
RI Campodoni, Elisabetta/AFM 6799 2022; Velasco Torrijos,
   Trinidad/LZG 4663 2025; Panseri, Silvia/AAW 2856 2020; Montesi,
   Monica/J 8861 2018; Dempsey, Eithne/AAA 2688 2020
OI Bassi, Giada/0000 0001 8496 5077; Montagner, Diego/0000 0002 1034 9623;
   Velasco Torrijos, Trinidad/0000 0002 0701 8268; Panseri,
   Silvia/0000 0002 8099 7132; Dempsey, Eithne/0000 0003 3607 5015; Rossi,
   Arianna/0000 0001 9863 7701; Campodoni, Elisabetta/0000 0001 8931 2921;
   Montesi, Monica/0000 0002 9192 8554; 
FU European Project Horizon 2020 NANO4TARMED (H2020  WIDESPREAD 2020 5)
   [952063]
FX This work was funded by the European Project Horizon 2020 NANO4TARMED
   (H2020  WIDESPREAD 2020 5; GA number 952063).
CR Arponen M, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.1035516
   Bassi G, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 79448 y
   Bhargava A, 2009, EXPERT OPIN INV DRUG, V18, P1787, DOI 10.1517/13543780903362437
   BRANDON RJ, 1984, J MED CHEM, V27, P861, DOI 10.1021/jm00373a009
   Chen CKJ, 2020, DALTON T, V49, P7722, DOI 10.1039/d0dt01622e
   Cifuentes M, 2011, J CELL PHYSIOL, V226, P1425, DOI 10.1002/jcp.22668
   Deng D, 2014, NATURE, V510, P121, DOI 10.1038/nature13306
   Dhara S.C., 1970, INDIAN J CHEM, V8, P193
   Dozio SM, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6346 3
   EASTMAN A, 1987, BIOCHEM PHARMACOL, V36, P4177, DOI 10.1016/0006 2952(87)90581 8
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   Fronik P, 2022, COMMUN CHEM, V5, DOI 10.1038/s42004 022 00661 z
   HARRAP KR, 1991, ADV ENZYME REGUL, V31, P31, DOI 10.1016/0065 2571(91)90007 9
   Heymann MF, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.011
   Holman GD, 2020, PFLUG ARCH EUR J PHY, V472, P1155, DOI 10.1007/s00424 020 02411 3
   Horvath P, 2016, NAT REV DRUG DISCOV, V15, P751, DOI 10.1038/nrd.2016.175
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kenny RG, 2019, CHEM REV, V119, P1058, DOI 10.1021/acs.chemrev.8b00271
   Krishnakumar GS, 2018, INT J BIOL MACROMOL, V106, P739, DOI 10.1016/j.ijbiomac.2017.08.076
   Li CY, 2018, INT J MOL MED, V42, P1799, DOI 10.3892/ijmm.2018.3753
   Liu C, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.698023
   Liu X, 2022, CHEM BIODIVERS, V19, DOI 10.1002/cbdv.202200695
   Ma J, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00386
   Ma J, 2017, J MED CHEM, V60, P5736, DOI 10.1021/acs.jmedchem.7b00433
   Ma J, 2017, EUR J MED CHEM, V128, P45, DOI 10.1016/j.ejmech.2017.01.032
   Ma J, 2016, DALTON T, V45, P11830, DOI 10.1039/c6dt02207c
   Ma LL, 2015, CHEM COMMUN, V51, P6301, DOI 10.1039/c4cc10409a
   Malik MS, 2020, RSC MED CHEM, V11, P327, DOI 10.1039/c9md00458k
   Mortensen ACL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.532285
   Moynihan E, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.795997
   Patra M, 2016, J AM CHEM SOC, V138, P12541, DOI 10.1021/jacs.6b06937
   PENDYALA L, 1989, CANCER CHEMOTH PHARM, V25, P10, DOI 10.1007/BF00694331
   Rischin D, 1996, BRIT J CANCER, V74, P590, DOI 10.1038/bjc.1996.406
   Sun LF, 2012, NATURE, V490, P361, DOI 10.1038/nature11524
   Upadhyaya K, 2016, ORG BIOMOL CHEM, V14, P1338, DOI 10.1039/c5ob02113h
   Valle S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18954 z
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang QP, 2016, DALTON T, V45, P10366, DOI 10.1039/c6dt01562j
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Zhang CY, 2022, THERANOSTICS, V12, P2115, DOI 10.7150/thno.69424
   Zheng DQ, 2020, J CELL SCI, V133, DOI 10.1242/jcs.239277
NR 42
TC 5
Z9 5
U1 1
U2 31
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2023
VL 24
IS 7
AR 6028
DI 10.3390/ijms24076028
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA D6PS1
UT WOS:000969935600001
PM 37047001
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Bedoui, Y
   Septembre Malaterre, A
   Giry, C
   Jaffar Bandjee, MC
   Selambarom, J
   Guiraud, P
   Gasque, P
AF Bedoui, Yosra
   Septembre Malaterre, Axelle
   Giry, Claude
   Jaffar Bandjee, Marie Christine
   Selambarom, Jimmy
   Guiraud, Pascale
   Gasque, Philippe
TI Robust COX 2 mediated prostaglandin response may drive arthralgia and
   bone destruction in patients with chronic inflammation post chikungunya
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
AB Patients following infection by chikungunya virus (CHIKV) can suffer for months to years from arthralgia and arthritis. Interestingly, methotrexate (MTX) a major immune regulatory drug has proved to be of clinical benefit. We have previously shown that CHIKV can persist in the joint of one patient 18 months post infection and plausibly driving chronic joint inflammation but through ill characterized mechanisms. We have pursued our investigations and report novel histological and in vitro data arguing for a plausible role of a COX 2 mediated inflammatory response post CHIKV. In the joint, we found a robust COX 2 staining on endothelial cells, synovial fibroblasts and more prominently on multinucleated giant cells identified as CD11c+ osteoclasts known to be involved in bone destruction. The joint tissue was also strongly stained for CD3, CD8, CD45, CD14, CD68, CD31, CD34, MMP2, and VEGF (but not for NO synthase and two B cell markers). Dendritic cells were rarely detected. Primary human synovial fibroblasts were infected with CHIKV or stimulated either by the synthetic molecule polyriboinosinic:polyribocytidylic acid (PIC) to mimic chronic viral infection or cytokines. First, we found that PIC and CHIKV enhanced mRNA expression of COX 2. We further found that PIC but not CHIKV increased the mRNA levels of cPLA2 alpha and of mPGES 1, two other central enzymes in PGE2 production. IFN beta upregulated cPLA2 alpha and COX 2 transcription levels but failed to modulated mPGES 1 mRNA expression. Moreover, PIC, CHIKV and IFN beta decreased mRNA expression of the PGE2 degrading enzyme 15 PGDH. Interestingly, MTX failed to control the expression of all these enzymes. In sharp contrast, dexamethasone was able to control the capacity of pro inflammatory cytokines, IL 1 beta as well as TNF alpha, to stimulate mRNA levels of cPLA2 alpha, COX 2 and mPGES 1. These original data argue for a concerted action of CHIKV (including viral RNA) and cytokines plausibly released from recruited leukocytes to drive a major COX 2 mediated PGE2 proinflammatory responses to induce viral arthritis.
   Author summary
   It is important to have a better understanding of the immuno pathogenesis of Chikungunya virus (CHIKV) and particularly focusing on the chronic phase associated to arthralgia and arthritis. Benefiting from our prospective cohort studies, we herein provide novel in vivo data identifying for the first time the implication of COX 2 and several other enzymes involved in prostaglandin biosynthesis and the persistence of the virus of the joint. Prostaglandin has major activities in inflammation and joint destruction. In vitro, we have used a model of human synovial fibroblasts to decipher the regulatory mechanisms of prostaglandin biosynthesis pathway. We have made important observations showing that the virus itself as well as major inflammatory cytokines can dramatically control the expression of all enzymes involved in the metabolism of prostaglandin. Interestingly, pharmacological investigations further revealed that dexamethasone, but not methotrexate (currently used to treat patients with chikungunya) may be of clinical values.
C1 [Bedoui, Yosra; Selambarom, Jimmy; Guiraud, Pascale; Gasque, Philippe] Univ La Reunion, Plateforme Technol CYROI St Clotilde, Unite Mixte Rech Proc Infect Milieu Insulaire Tro, INSERM U1187,CNRS 9192,IRD 249, Ile De La Reunion, France.
   [Bedoui, Yosra; Gasque, Philippe] CHU La Reunion, Lab Immunol Clin & Expt Zone Ocean Indien, Site Felix Guyon,Allee Topazes, St Denis De La Reunion, France.
   [Septembre Malaterre, Axelle] Univ La Reunion, CHU La Reunion, Unite Rech Etud Pharmacoimmunol, Site Felix Guyon,Allee Topazes, St Denis De La Reunion, France.
   [Giry, Claude; Jaffar Bandjee, Marie Christine] CHU La Reunion, CNR Associe Arbovirus, Lab Biol, Site Felix Guyon,Allee Topazes, St Denis De La Reunion, France.
   [Gasque, Philippe] CHU La Reunion, Lab Immunol Clin & Expt Zone Ocean Indien LICE OI, Site Felix Guyon,Allee Topazes,CS11021, F 97400 St Denis De La Reunion, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   University of La Reunion; CHU Reunion; University of La Reunion; CHU
   Reunion; CHU Reunion; CHU Reunion
RP Gasque, P (通讯作者)，Univ La Reunion, Plateforme Technol CYROI St Clotilde, Unite Mixte Rech Proc Infect Milieu Insulaire Tro, INSERM U1187,CNRS 9192,IRD 249, Ile De La Reunion, France.; Gasque, P (通讯作者)，CHU La Reunion, Lab Immunol Clin & Expt Zone Ocean Indien, Site Felix Guyon,Allee Topazes, St Denis De La Reunion, France.; Gasque, P (通讯作者)，CHU La Reunion, Lab Immunol Clin & Expt Zone Ocean Indien LICE OI, Site Felix Guyon,Allee Topazes,CS11021, F 97400 St Denis De La Reunion, France.
EM philippe.gasque@gmail.com
OI SELAMBAROM, JIMMY/0000 0001 9950 2542; Septembre Malaterre,
   Axelle/0000 0003 4335 9016
FU Regional Council of La Reunion [234277]; Regional Council of la Reunion,
   Europe; French state through the Viropam research program [D2017024696,
   GURDTI 2017 1198 0002583, RE0002583]
FX YB is a fellow of the Regional Council of La Reunion (ref 234277)
   (https://regionreunion.com). This study was funded by the Regional
   Council of la Reunion, Europe and the French state through the Viropam
   research program reference D2017024696, POE FEDER
   (https://regionreunion.com/sites/feder/). 2014 2020 1.09, Grant number:
   GURDTI 2017 1198 0002583, No Synergie RE0002583 to PGu and JS. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akhrymuk I, 2012, J VIROL, V86, P7180, DOI 10.1128/JVI.00541 12
   Amaral JK, 2018, ARTHRIT CARE RES, V70, P1501, DOI 10.1002/acr.23519
   Bedoui Y, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006634
   Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537
   Chalaem P, 2016, VIROL J, V13, DOI 10.1186/s12985 016 0606 3
   Dupuis Maguiraga L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001446
   Feuerherm AJ, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 018 1794 6
   Fitzpatrick FA, 2004, CURR PHARM DESIGN, V10, P577, DOI 10.2174/1381612043453144
   FITZPATRICK FA, 1980, J IMMUNOL, V125, P431
   Fros JJ, 2010, J VIROL, V84, P10877, DOI 10.1128/JVI.00949 10
   Gheorghe KR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3851
   GITTER BD, 1989, IMMUNOLOGY, V66, P196
   Gutiérrez Venegas G, 2012, CELL IMMUNOL, V273, P150, DOI 10.1016/j.cellimm.2011.12.005
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   HULKOWER KI, 1994, ARTHRITIS RHEUM US, V37, P653, DOI 10.1002/art.1780370508
   HUSBY G, 1977, ARTHRITIS RHEUM US, V20, P785, DOI 10.1002/art.1780200304
   Inoue H, 2002, BRIT J PHARMACOL, V136, P287, DOI 10.1038/sj.bjp.0704705
   Inoue H, 2001, INFLAMM RES, V50, P65
   Ito S, 2001, NEUROSCI RES, V41, P299, DOI 10.1016/S0168 0102(01)00289 9
   Javelle E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003603
   Kang RY, 1996, BRIT J RHEUMATOL, V35, P711
   Amaral JK, 2019, VIRUSES BASEL, V11, DOI 10.3390/v11030289
   Kim HJ, 2015, MOL MED REP, V12, P4141, DOI 10.3892/mmr.2015.3931
   Kojima F, 2005, FUND CLIN PHARMACOL, V19, P255, DOI 10.1111/j.1472 8206.2005.00316.x
   Koki A, 2002, ADV EXP MED BIOL, V507, P177
   Korotkova M, 2005, ARTHRITIS RHEUM US, V52, P3439, DOI 10.1002/art.21390
   Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104
   Leistad L, 2011, SCAND J RHEUMATOL, V40, P308, DOI 10.3109/03009742.2010.547872
   Martel Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049 0172(03)00134 3
   Michaels RM, 1996, J RHEUMATOL, V23, P226
   Mitchell MD, 2000, PROSTAG LEUKOTR ESS, V62, P1, DOI 10.1054/plef.1999.0117
   Novaes GS, 1996, J RHEUMATOL, V23, P2092
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Pindado J, 2007, J IMMUNOL, V179, P4821, DOI 10.4049/jimmunol.179.7.4821
   de Oliveira ACP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 015 0473 7
   Ruipérez V, 2009, J IMMUNOL, V182, P3877, DOI 10.4049/jimmunol.0804003
   SALMON JA, 1987, BRIT MED BULL, V43, P285, DOI 10.1093/oxfordjournals.bmb.a072183
   Silva LA, 2017, J CLIN INVEST, V127, P737, DOI 10.1172/JCI84417
   Simon Fabrice, 2011, Curr Infect Dis Rep, V13, P218, DOI 10.1007/s11908 011 0180 1
   Sissoko D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000389
   Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469
   Suhrbier A, 2012, NAT REV RHEUMATOL, V8, P420, DOI 10.1038/nrrheum.2012.64
   Sutaria RB, 2018, CURR OPIN RHEUMATOL, V30, P256, DOI 10.1097/BOR.0000000000000486
   Swierkot J, 2006, PHARMACOL REP, V58, P473
   Tai HH, 2002, PROSTAG OTH LIPID M, V68 9, P483, DOI 10.1016/S0090 6980(02)00050 3
   Thorén S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432 1327.2000.01735.x
   Tong M, 2005, ARCH BIOCHEM BIOPHYS, V435, P50, DOI 10.1016/j.abb.2004.11.031
   Tong M, 2006, CARCINOGENESIS, V27, P2170, DOI 10.1093/carcin/bgl053
   Vergne P, 1998, J RHEUMATOL, V25, P433
   Waggoner JJ, 2015, EXPERT REV ANTI INFE, V13, P291, DOI 10.1586/14787210.2015.995634
   WILLIAMS TJ, 1979, BRIT J PHARMACOL, V65, P517, DOI 10.1111/j.1476 5381.1979.tb07860.x
   Wong KZ, 2018, VIRUSES BASEL, V10, DOI 10.3390/v10060294
   YARON M, 1981, ARTHRITIS RHEUM, V24, P1582, DOI 10.1002/art.1780241221
   YARON M, 1978, ARTHRITIS RHEUM US, V21, P694, DOI 10.1002/art.1780210614
   YARON M, 1979, INFLAMMATION, V3, P243, DOI 10.1007/BF00914181
   YARON M, 1977, NATURE, V267, P457, DOI 10.1038/267457a0
   Yucel Lindberg T, 2000, INFLAMMATION, V24, P207, DOI 10.1023/A:1007057312325
   Zhao XY, 2014, STEM CELLS, V32, P521, DOI 10.1002/stem.1543
   Zhu AS, 2017, J INVEST DERMATOL, V137, P1562, DOI 10.1016/j.jid.2017.03.023
   ZOR U, 1982, J GEN VIROL, V63, P359, DOI 10.1099/0022 1317 63 2 359
NR 60
TC 13
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935 2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2021
VL 15
IS 2
AR e0009115
DI 10.1371/journal.pntd.0009115
PG 23
WC Infectious Diseases; Parasitology; Tropical Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases; Parasitology; Tropical Medicine
GA QK8NO
UT WOS:000620636900003
PM 33596205
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Eckert, D
   Evic, M
   Schang, J
   Isbruch, M
   Er, M
   Dörrschuck, L
   Rapp, F
   Donaubauer, AJ
   Gaipl, US
   Frey, B
   Fournier, C
AF Eckert, Denise
   Evic, Megi
   Schang, Jasmin
   Isbruch, Maike
   Er, Melissa
   Doerrschuck, Lea
   Rapp, Felicitas
   Donaubauer, Anna Jasmina
   Gaipl, Udo S.
   Frey, Benjamin
   Fournier, Claudia
TI Osteo immunological impact of radon spa treatment: due to radon or spa
   alone? Results from the prospective, thermal bath placebo controlled
   RAD ON02 trial
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE osteoclastogenesis; radon and thermal spa treatment; bone metabolism;
   Th17/Treg cells; biomarker and degenerative musculoskeletal diseases
ID RHEUMATOID ARTHRITIS; IMMUNE SYSTEM; THERAPY; DISEASES; LEPTIN;
   OSTEOIMMUNOLOGY; OSTEOARTHRITIS; BALNEOTHERAPY
AB Musculoskeletal disorders (MSDs) are associated with pain and lead to reduced mobility and quality of life for patients. Radon therapy is used as alternative or complementary to pharmaceutical treatments. According to previous reports, radon spa leads to analgesic and anti inflammatory effects, but the cellular and molecular mechanisms are widely unknown. A previous study (RAD ON01) revealed, that bone erosion markers like collagen fragments (C terminal telopeptide, CTX) are reduced after radon spa treatment in serum of patients with degenerative MSDs. Within the scope of the prospective, placebo controlled RAD ON02 trial presented here, we analyzed the influence of radon and thermal spa treatment on osteoclastogenesis. From patient blood, we isolate monocytes, seeded them on bone slices and differentiated them in the presence of growth factors into mature osteoclasts (mOCs). Subsequent analysis showed a smaller fraction of mOCs after both treatments, which was even smaller after radon spa treatment. A significantly reduced resorbed area on bone slices reflects this result. Only after radon spa treatment, we detected in the serum of patients a significant decrease of receptor activator of NF kappa B ligand (RANKL), which indicates reduced differentiation of OCs. However, other markers for bone resorption (CTX) and bone formation (OPG, OCN) were not altered after both treatments. Adipokines, such as visfatin and leptin that play a role in some MSD types by affecting osteoclastogenesis, were not changed after both treatments. Further, also immune cells have an influence on osteoclastogenesis, by inhibiting and promoting terminal differentiation and activation of OCs, respectively. After radon treatment, the fraction of Treg cells was significantly increased, whereas Th17 cells were not altered. Overall, we observed that both treatments had an influence on osteoclastogenesis and bone resorption. Moreover, radon spa treatment affected the Treg cell population as well as the Th17/Treg ratio were affected, pointing toward a contribution of the immune system after radon spa. These data obtained from patients enrolled in the RAD ON02 trial indicate that radon is not alone responsible for the effects on bone metabolism, even though they are more pronounced after radon compared to thermal spa treatment.
C1 [Eckert, Denise; Evic, Megi; Schang, Jasmin; Isbruch, Maike; Er, Melissa; Doerrschuck, Lea; Rapp, Felicitas; Fournier, Claudia] Dept Biophys, GSI Helmholtzzentrum Schwerionenforschung, Darmstadt, Germany.
   [Donaubauer, Anna Jasmina; Gaipl, Udo S.; Frey, Benjamin] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Radiat Oncol, Translat Radiobiol, Univ Klinikum Erlangen, Erlangen, Germany.
C3 Helmholtz Association; GSI Helmholtz Center for Heavy Ion Research;
   University of Erlangen Nuremberg
RP Fournier, C (通讯作者)，Dept Biophys, GSI Helmholtzzentrum Schwerionenforschung, Darmstadt, Germany.
EM c.fournier@gsi.de
RI Donaubauer, Anna Jasmina/AAM 5529 2021; Frey, Benjamin/D 9565 2017;
   Gaipl, Udo/AAE 1060 2020
OI Rapp, Felicitas/0000 0003 0968 1546; 
FU Bundesministerium fr Bildung und Forschung (GREWIS) [02NUK017G,
   02NUK050A, 02NUK050E]; Bayerisches Staatsministerium; Oberfranken
   Stiftung Bayreuth; Kurortforschungsverein Bad Steben e.V., Bad Steben
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work is funded by
   the Bundesministerium fur Bildung und Forschung (GREWIS and
   GREWIS alpha, 02NUK017G, 02NUK050A and 02NUK050E), by the Bayerisches
   Staatsministerium fur Gesundheitund Pflege im Rahmen des Forderprogramms
   zur Steigerung dermedizinischen Qualitat in denbayerischen Kurorten, by
   the Oberfranken Stiftung Bayreuth, by EURADON Verein Europaeischer
   Radonheilbader e.V., Bad Steben and by the Kurortforschungsverein Bad
   Steben e.V., Bad Steben.r The author(s) declare financial support was
   received for the research, authorship, and/or publication of this
   article. This work is funded by the Bundesministerium fur Bildung und
   Forschung (GREWIS and GREWIS alpha, 02NUK017G, 02NUK050A and 02NUK050E),
   by the Bayerisches Staatsministerium fur Gesundheit und Pflege im Rahmen
   des Forderprogramms zur Steigerung der medizinischen Qualitat in den
   bayerischen Kurorten, by the Oberfranken Stiftung Bayreuth, by EURADON  
   Verein Europaischer Radonheilbader e.V., Bad Steben and by the
   Kurortforschungsverein Bad Steben e.V., Bad Steben.
CR Annegret F, 2013, RHEUMATOL INT, V33, P2839, DOI 10.1007/s00296 013 2819 8
   Bindu S, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114147
   Chen WP, 2010, CLIN CHEM LAB MED, V48, P1141, DOI 10.1515/CCLM.2010.230
   Christensen Jon, 2015, BMC Res Notes, V8, P322, DOI 10.1186/s13104 015 1284 8
   Cucu A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00882
   Davis A, 2016, BRIT J GEN PRACT, V66, P172, DOI 10.3399/bjgp16X684433
   Deloch L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103197
   Deloch L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01834
   Di Nicola V, 2020, REGEN THER, V15, P149, DOI 10.1016/j.reth.2020.07.007
   Donaubauer AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740742
   Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165854
   Eckert D, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.817281
   Ehnert S, 2021, WORLD J STEM CELLS, V13, P1667, DOI 10.4252/wjsc.v13.i11.1667
   Falkenbach A, 2005, RHEUMATOL INT, V25, P205, DOI 10.1007/s00296 003 0419 8
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Franke A, 2000, RHEUMATOLOGY, V39, P894, DOI 10.1093/rheumatology/39.8.894
   Gaisberger M, 2021, INT J BIOMETEOROL, V65, P1151, DOI 10.1007/s00484 021 02095 z
   Ghobadi H, 2021, J RES MED SCI, V26, DOI 10.4103/jrms.JRMS_626_19
   Ginaldi L, 2016, CURR MED CHEM, V23, P3754, DOI 10.2174/0929867323666160907162546
   Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156
   Hofmann W, 2019, RADIAT ENVIRON BIOPH, V58, P513, DOI 10.1007/s00411 019 00807 z
   Kleinhans C, 2015, J BIOTECHNOL, V205, P101, DOI 10.1016/j.jbiotec.2014.11.039
   Kume K, 2002, J HISTOCHEM CYTOCHEM, V50, P159, DOI 10.1177/002215540205000204
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lange U, 2016, CLIN RHEUMATOL, V35, P2783, DOI 10.1007/s10067 016 3236 7
   Liu CZ, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.889257
   Maier A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010316
   Moder Angelika, 2010, International Journal of Low Radiation, V7, P423, DOI 10.1504/IJLR.2010.037663
   Mort JS, 2001, ARTHRITIS RES, V3, P337, DOI 10.1186/ar325
   Naito K, 1999, RHEUMATOLOGY, V38, P510, DOI 10.1093/rheumatology/38.6.510
   Nakamura I, 1999, J CELL SCI, V112, P3985
   OGATA Y, 1992, J BIOL CHEM, V267, P3581
   OKADA Y, 1995, LAB INVEST, V72, P311
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Papenfuss F, 2022, RADIAT ENVIRON BIOPH, V61, P279, DOI 10.1007/s00411 022 00972 8
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Rühle PF, 2019, MOD RHEUMATOL, V29, P165, DOI 10.1080/14397595.2018.1442640
   Rühle PF, 2017, AUTOIMMUNITY, V50, P133, DOI 10.1080/08916934.2017.1284819
   Sanjon EP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47236 y
   Santos I, 2016, ISR MED ASSOC J, V18, P474
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   Schumacher M SG., 2008, Methodik klinischer Studien. Methodische Grundlagen der Planung, P310
   Seegenschmiedt MH, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150080
   Shao TY, 2016, SCI REP UK, V6, DOI 10.1038/srep32415
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140 6736(14)61704 9
   Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167 0115(00)00152 X
   STRACKE H, 1985, DEUT MED WOCHENSCHR, V110, P1442, DOI 10.1055/s 2008 1069025
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   van der Zee neuen A, 2023, INT J PUBLIC HEALTH, V68, DOI 10.3389/ijph.2023.1605931
   Van Tubergen A, 2001, ARTHRIT RHEUM ARTHR, V45, P430, DOI 10.1002/1529 0131(200110)45:5<430::AID ART362>3.0.CO;2 F
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Winklmayr M, 2015, RADIAT ENVIRON BIOPH, V54, P123, DOI 10.1007/s00411 014 0568 z
   Xie CX, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0868 z
   Yammani RR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3705
   Yan MQ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010257
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zaiss MM, 2010, J IMMUNOL, V184, P7238, DOI 10.4049/jimmunol.0903841
   Zhu L, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979 020 00202 z
NR 61
TC 1
Z9 1
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 16
PY 2024
VL 14
AR 1284609
DI 10.3389/fimmu.2023.1284609
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA GF4S4
UT WOS:001151243400001
PM 38292488
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kharazmi, M
   Michaëlsson, K
   Schilcher, J
   Eriksson, N
   Melhus, H
   Wadelius, M
   Hallberg, P
AF Kharazmi, Mohammad
   Michaelsson, Karl
   Schilcher, Jorg
   Eriksson, Niclas
   Melhus, Hakan
   Wadelius, Mia
   Hallberg, Par
TI A Genome Wide Association Study of Bisphosphonate Associated Atypical
   Femoral Fracture
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Genome wide association study; Atypical fractures; Bisphosphonate;
   Drug related side effects and adverse reactions; Pharmacogenetics
ID POSTMENOPAUSAL WOMEN; BONE TURNOVER; CORTICAL BONE; RISK; OSTEONECROSIS;
   OSTEOPOROSIS; POLYMORPHISM; POWER; HETEROGENEITY; JAW
AB Atypical femoral fracture is a well documented adverse reaction to bisphosphonates. It is strongly related to duration of bisphosphonate use, and the risk declines rapidly after drug withdrawal. The mechanism behind bisphosphonate associated atypical femoral fracture is unclear, but a genetic predisposition has been suggested. With the aim to identify common genetic variants that could be used for preemptive genetic testing, we performed a genome wide association study. Cases were recruited mainly through reports of adverse drug reactions sent to the Swedish Medical Products Agency on a nation wide basis. We compared atypical femoral fracture cases (n=51) with population based controls (n=4891), and to reduce the possibility of confounding by indication, we also compared with bisphosphonate treated controls without a current diagnosis of cancer (n=324). The total number of single nucleotide polymorphisms after imputation was 7,585,874. A genome wide significance threshold of p<5x10( 8) was used to correct for multiple testing. In addition, we performed candidate gene analyses for a panel of 29 genes previously implicated in atypical femoral fractures (significance threshold of p<5.7x10( 6)). Compared with population controls, bisphosphonate associated atypical femoral fracture was associated with four isolated, uncommon single nucleotide polymorphisms. When cases were compared with bisphosphonate treated controls, no statistically significant genome wide association remained. We conclude that the detected associations were either false positives or related to the underlying disease, i.e., treatment indication. Furthermore, there was no significant association with single nucleotide polymorphisms in the 29 candidate genes. In conclusion, this study found no evidence of a common genetic predisposition for bisphosphonate associated atypical femoral fracture. Further studies of larger sample size to identify possible weakly associated genetic traits, as well as whole exome or whole genome sequencing studies to identify possible rare genetic variation conferring a risk are warranted.
C1 [Kharazmi, Mohammad; Michaelsson, Karl] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
   [Schilcher, Jorg] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Linkoping, Sweden.
   [Eriksson, Niclas; Melhus, Hakan; Wadelius, Mia; Hallberg, Par] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
   [Eriksson, Niclas] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden.
C3 Uppsala University; Linkoping University; Uppsala University; Uppsala
   University
RP Kharazmi, M (通讯作者)，Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
EM kharazmi.mohammad@gmail.com
RI ; Michaelsson, Karl/AAM 9094 2021; Wadelius, Mia/C 7740 2016
OI Melhus, Hakan/0000 0002 6857 5973; Hallberg, Par/0000 0003 3465 3280;
   Schilcher, Jorg/0000 0003 0677 9265; Eriksson,
   Niclas/0000 0002 2152 4343; Michaelsson, Karl/0000 0003 2815 1217;
   Wadelius, Mia/0000 0002 6368 2622
FU Swedish Research Council [521 2011 2440, 521 2014 3370, 2015 03527];
   Swedish Heart and Lung Foundation [20120557, 20140291, 20170711];
   Selander's foundation; Thureus' foundation; Swedish Medical Products
   Agency; Clinical Research Support (ALF) at Uppsala University;
   Ostergotland County Council [LIO 698411]; Science for Life Laboratory;
   Uppsala University; Research Council Swedish [2017 00641]; Swedish
   Research Council; Swedish Research Council [2017 00641] Funding Source:
   Swedish Research Council
FX This work was supported by the Swedish Research Council (Medicine
   521 2011 2440, 521 2014 3370 and 2015 03527); Swedish Heart and Lung
   Foundation (20120557, 20140291 and 20170711); Selander's foundation;
   Thureus' foundation; the Swedish Medical Products Agency; the Clinical
   Research Support (ALF) at Uppsala University; and Ostergotland County
   Council (LIO 69841T1). We thank research nurses Ulrica Ramqvist,
   Elisabeth Stjernberg, Charlotta Haglund and Elisabeth Balcom, and
   research assistants Sofie Collin, Eva Prado Lopez, Agnes Kataja Knight,
   Agnes Wadelius, and Martha Wadelius, Department of Medical Sciences,
   Clinical Pharmacology, Uppsala University, Uppsala, Sweden, for
   recruiting and interviewing cases and for database administration. We
   are grateful to Tomas Axelsson for SNP array genotyping at the
   Department of Medical Sciences, SNP&SEQ Technology Platform, which is
   funded by the Science for Life Laboratory, Swedish Research Council, and
   Uppsala University. Computations were performed on resources provided by
   SNIC through Uppsala Multidisciplinary Center for Advanced Computational
   Science (UPPMAX). We acknowledge Patrik Magnusson and Barbro Sandin at
   the Department of Medical Epidemiology and Biostatistics, Karolinska
   Institutet for access to data from the Swedish Twin Registry, which is
   managed by Karolinska Institutet and receives funding through the
   Research Council Swedish under Grant No. 2017 00641.
CR Adler RA, 2018, EUR J ENDOCRINOL, V178, pR81, DOI 10.1530/EJE 17 1002
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Aspenberg P, 2014, CURR OSTEOPOROS REP, V12, P189, DOI 10.1007/s11914 014 0200 9
   Carr DF, 2018, EXP BIOL MED, V243, P291, DOI 10.1177/1535370217733425
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742 015 0047 8
   Choi HJ, 2010, YONSEI MED J, V51, P231, DOI 10.3349/ymj.2010.51.2.231
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Donnelly E, 2012, J BONE MINER RES, V27, P672, DOI 10.1002/jbmr.560
   Durbin R, 2014, BIOINFORMATICS, V30, P1266, DOI 10.1093/bioinformatics/btu014
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Funck Brentano T, 2017, JOINT BONE SPINE, V84, P715, DOI 10.1016/j.jbspin.2016.11.014
   Iwata K, 2014, BONE, V64, P183, DOI 10.1016/j.bone.2014.04.012
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P496, DOI 10.1038/nrrheum.2016.118
   Kharazmi M, 2014, RHEUMATOLOGY, V53, P1911, DOI 10.1093/rheumatology/keu286
   Kharazmi M, 2014, ANN RHEUM DIS, V73, P1594, DOI 10.1136/annrheumdis 2013 205080
   Khosla S, 2017, J BONE MINER RES, V32, P424, DOI 10.1002/jbmr.3074
   Liu Y, 2014, CHINESE MED J PEKING, V127, P662, DOI 10.3760/cma.j.issn.0366 6999.20132382
   Lo JC, 2016, BONE, V85, P142, DOI 10.1016/j.bone.2016.01.002
   Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679
   Magnusson PKE, 2013, TWIN RES HUM GENET, V16, P317, DOI 10.1017/thg.2012.104
   Marini F, 2008, CURR MED RES OPIN, V24, P2609, DOI [10.1185/03007990802352894, 10.1185/03007990802352894 ]
   McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643
   McRae AF, 2017, METHODS MOL BIOL, V1526, P161, DOI 10.1007/978 1 4939 6613 4_9
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Nguyen HH, 2018, J BONE MINER RES PLU, V2, P2
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Olmos JM, 2012, PHARMACOGENOMICS J, V12, P227, DOI 10.1038/tpj.2010.88
   Pérez Núñez I, 2015, MOL CELL BIOCHEM, V409, P45, DOI 10.1007/s11010 015 2510 3
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Ragnarsson O, 2015, EUR J ENDOCRINOL, V172, DOI 10.1530/EJE 14 0747
   Rivadeneira F, 2016, TRENDS ENDOCRIN MET, V27, P262, DOI 10.1016/j.tem.2016.03.006
   Roca Ayats N, 2017, NEW ENGL J MED, V376, P1794, DOI 10.1056/NEJMc1612804
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Schilcher J, 2015, INJURY, V46, P2468, DOI 10.1016/j.injury.2015.09.031
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Sham PC, 2014, NAT REV GENET, V15, P335, DOI 10.1038/nrg3706
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Szappanos A, 2009, CLIN ENDOCRINOL, V71, P636, DOI 10.1111/j.1365 2265.2009.03528.x
   Teo YY, 2008, CURR OPIN LIPIDOL, V19, P133, DOI 10.1097/MOL.0b013e3282f5dd77
   *WEIZM I SCI, GENECARDS
NR 42
TC 15
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUL
PY 2019
VL 105
IS 1
BP 51
EP 67
DI 10.1007/s00223 019 00546 9
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IA3QI
UT WOS:000469477400005
PM 31006051
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Cui, LX
   Tian, XY
   Yan, L
   Guan, XY
   Dong, B
   Zhao, M
   Lv, A
   Liu, DN
   Wu, JH
   Hao, CY
AF Cui, Lixuan
   Tian, Xiuyun
   Yan, Liang
   Guan, Xiaoya
   Dong, Bin
   Zhao, Min
   Lv, Ang
   Liu, Daoning
   Wu, Jianhui
   Hao, Chunyi
TI Expression and function of Siglec 15 in RLPS and its correlation with
   PD L1: Bioinformatics Analysis and Clinicopathological Evidence
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Siglec 15; PD L1; Retroperitoneal liposarcoma; Prognosis
ID OSTEOCLAST DIFFERENTIATION; OPEN LABEL; CANCER; IMMUNOTHERAPY; SARCOMA
AB Purpose: Retroperitoneal liposarcoma (RLPS) is a rare malignancy without effective treatment. Since current treatment for unresectable RLPS is unsatisfactory, immunotherapy and targeted therapy are urgently needed. Siglec 15 is a transmembrane protein highly homologous to PD L1 and is involved in tumor immune escape. The biological function of Siglec 15 in RLPS, its prognostic relevance and its relationship with PD L1 need to be further clarified. In this study, we aimed to explore the biological function of Siglec 15 in sarcomas through bioinformatics analysis, and we also evaluated Siglec 15 and PD L1 expression in RLPS samples. The relationship between the expression of Siglec 15 and PD L1 and their clinicopathological relevance and prognostic value were also investigated in clinical RLPS patients.Methods: The RNA sequencing data of 259 sarcoma cases and 48 RLPS cases from TCGA were used to analyze the Siglec 15 expression and the differentially expressed genes (DEG) related with Siglec 15 expression. In addition, DEGs were subsequently analyzed through the gene ontology (GO)/ Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein protein interaction (PPI) network. Tumor specimens were obtained from 91 RLPS patients of our sarcoma center, and Siglec 15 and PD L1 expression were evaluated using immunohistochemistry. The correlation between the expression level of these two markers as well as their correlation with clinicopathological factors and prognosis of RLPS patients was also assessed.Results: GEPIA analysis showed that the high expression of Siglec 15 was associated with poor sarcoma OS (P=0.034). A total of 682 differential genes were identified between the high and low expression groups of Siglec 15 in RLPS. Enrichment analysis of the KEGG pathway showed that Siglec 15 was related to the Hippo signaling pathway and the neuroactive ligand receptor interaction. GO annotation analysis showed that the expression of Siglec 15 may thus be able to affect serine hydrolase activity, alongside signal receptor activator activity. The top 5 genes with the largest number of connection points are APOA1, F2, AHSG, AMBP, SERPINC1. In subsequent studies, we used 91 liposarcoma samples from our center for verification. Siglec 15 was expressed in 84.6% of RLPS cases, whereas PD L1 was expressed in 17.6% of RLPS cases. A negative correlation was observed between Siglec 15 and PD L1 expression (P=0.020). In this group of RLPS patients, high Siglec 15 expression was correlated with poorer disease free survival (DFS) (P=0.021), and it was an independent predictor of DFS (hazard ratio: 2.298; 95% confidence interval: 1.154 4.576; P=0.018). However, we did not find a correlation between PD L1 expression and overall survival or DFS in RLPS patients.Conclusion: The DEG and signaling pathways identified in the study could provide a preliminary understanding of the underlying molecular mechanisms of Siglec 15 in the development and progression of RLPS. High expression of Siglec 15 was a negative independent predictive factor for DFS of RLPS. The negative relationship between Siglec 15 and PD L1 expression suggested that the Siglec 15 pathway might be an important supplement to PD L1 treatment.
C1 [Cui, Lixuan; Tian, Xiuyun; Yan, Liang; Guan, Xiaoya; Lv, Ang; Liu, Daoning; Wu, Jianhui; Hao, Chunyi] Peking Univ Canc Hosp & Inst, Dept Hepatopancreato Biliary Surg, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China.
   [Cui, Lixuan] Peking Univ Canc Hosp & Inst, Dept Crit Care Med, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China.
   [Dong, Bin] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Cent Lab, Minist Educ, Beijing, Peoples R China.
   [Zhao, Min] Peking Univ Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.
   [Wu, Jianhui; Hao, Chunyi] Peking Univ Canc Hosp & Inst, Dept Hepatopancreato Biliary Surg, Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing, Peoples R China.
C3 Ministry of Education   China; Ministry of Education   China; Ministry
   of Education   China
RP Wu, JH; Hao, CY (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Hepatopancreato Biliary Surg, Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing, Peoples R China.
EM wujianhui@bjmu.edu.cn; haochunyi@bjmu.edu.cn
RI Liu, Dao Ning/GZA 9122 2022
OI Liu, Dao ning/0000 0003 3287 5592
FU National Natural Science Foundation of China [91959120]; Capital Health
   Research and Development of Special Funds [2020 1 1021]; Beijing
   Municipal Natural Science Foundation [Z190022]; Beijing excellent talent
   training project [2018000021469G269]; Beijing Municipal Administration
   of Hospital's Ascent Plan [DFL20181104]; Science Foundation of Peking
   University Cancer Hospital [2022 4, 2021 2, 2021 15]; China Postdoctoral
   Science Foundation [2020M680260]; Beijing Municipal Administration of
   Hospitals Youth Programm [QML20181104]
FX This study was supported by National Natural Science Foundation of China
   (approval No. 91959120) , Capital Health Research and Development of
   Special Funds (approval No. 2020 1 1021) , Beijing Municipal Natural
   Science Foundation (approval No. Z190022) , Beijing excellent talent
   training project (approval No. 2018000021469G269) , Beijing Municipal
   Administration of Hospital's Ascent Plan (approval No. DFL20181104) ,
   Science Foundation of Peking University Cancer Hospital (approval No.
   2022 4, 2021 2, 2021 15) , China Postdoctoral Science Foundation
   (approval No. 2020M680260) , and Beijing Municipal Administration of
   Hospitals Youth Programm (approval No. QML20181104) .
CR BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bougarne N, 2018, ENDOCR REV, V39, P760, DOI 10.1210/er.2018 00064
   Cissé MY, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay2163
   Crago AM, 2011, CURR OPIN ONCOL, V23, P373, DOI 10.1097/CCO.0b013e32834796e6
   D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470 2045(18)30006 8
   Ding JY, 2020, PEERJ, V8, DOI 10.7717/peerj.10419
   Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013
   Fudaba H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 79742 9
   Guo XC, 2017, GENE DEV, V31, P247, DOI 10.1101/gad.294348.116
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014
   Lee S, 2006, METHOD ENZYMOL, V414, P468, DOI 10.1016/S0076 6879(06)14025 2
   Li BH, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1807291
   Lim J, 2015, CLIN CANCER RES, V21, P4753, DOI 10.1158/1078 0432.CCR 15 0831
   Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737
   McKinley Sophia K, 2020, Adv Surg, V54, P273, DOI 10.1016/j.yasu.2020.05.003
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140 6736(18)32409 7
   Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005
   Murciano Goroff YR, 2020, CELL RES, V30, P507, DOI 10.1038/s41422 020 0337 2
   Park HK, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1658 5
   Pollack SM, 2017, CANCER AM CANCER SOC, V123, P3291, DOI 10.1002/cncr.30726
   Sassa N, 2020, INT J UROL, V27, P1058, DOI 10.1111/iju.14361
   Shanes ED, 2019, AM J SURG PATHOL, V43, P792, DOI 10.1097/PAS.0000000000001254
   Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108
   Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014
   Sun JW, 2021, CLIN CANCER RES, V27, P680, DOI 10.1158/1078 0432.CCR 19 2925
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470 2045(17)30624 1
   Teng FF, 2018, CANCER LETT, V414, P166, DOI 10.1016/j.canlet.2017.11.014
   TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108
   Tropea S, 2021, EJSO EUR J SURG ONC, V47, P1201, DOI 10.1016/j.ejso.2020.08.030
   van Erp AEM, 2017, ONCOTARGET, V8, P71371, DOI 10.18632/oncotarget.19071
   van Rensburg HJJ, 2018, CANCER RES, V78, P1457, DOI 10.1158/0008 5472.CAN 17 3139
   Vilanova JC., 2017, WHO classification of soft tissue tumors, DOI [10.1007/978 3 319 46679 8_11, DOI 10.1007/978 3 319 46679 8]
   Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159 8290.CD 15 0224
   Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591 019 0374 x
   Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449
   Wilky BA, 2019, LANCET ONCOL, V20, P837, DOI 10.1016/S1470 2045(19)30153 6
   Yan L, 2019, CANCER SCI, V110, P3038, DOI 10.1111/cas.14161
   Yi M, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 020 01027 5
   Zhang S, 2020, ONCOTARGETS THER, V13, P6523, DOI 10.2147/OTT.S246613
   Zhang S, 2020, ONCOL REP, V44, P565, DOI 10.3892/or.2020.7635
   Zhu MMT, 2020, CANCER TREAT REV, V91, DOI 10.1016/j.ctrv.2020.102115
   Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118
NR 47
TC 4
Z9 4
U1 1
U2 7
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2022
VL 19
IS 13
BP 1977
EP 1988
DI 10.7150/ijms.77193
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 7E2EW
UT WOS:000900989200015
PM 36438917
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hosseinpour, S
   Xu, C
   Walsh, LJ
AF Hosseinpour, Sepanta
   Xu, Chun
   Walsh, Laurence J.
TI Impact of photobiomodulation using four diode laser wavelengths of on
   cationic liposome gene transfection into pre osteoblast cells
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY
LA English
DT Article
DE Photobiomodulation; Low level laser therapy; Gene transfection; Gene
   delivery; Plasmid DNA; Lipofectamine; Cationic liposome
ID TARGETED TRANSFECTION; MAMMALIAN CELLS; THERAPY; DNA; EFFICIENCY;
   DELIVERY
AB Gene therapy can be an effective treatment modality for some severe genetic diseases. Despite efforts to improve their performance, non viral gene delivery methods remain inefficient and costly. As an alternative to viral vectors, cationic liposomes have a good safety profile and low immunogenicity, but relatively low transfection efficiency. They may also be toxic to cells at high concentrations. Given these challenges, the present study explored the impact of photobiomodulation (PBM) on cationic liposome plasmid DNA transfection in terms of its efficiency and toxicity, using Lipofectamine 2000 to carry green fluorescent protein (GFP) encoding plasmid DNA, with the pre osteoblast MC3T3 E1 cell line as the target. Cultures were irradiated using diode lasers (445, 685, 810, or 970 nm) at 200 mW using pulsed mode (50 Hz), with a power density of 104.64 mW/cm(2), and irradiance from 6 to 18 joules. To determine transfection efficiency, expression of GFP was assessed using confocal laser scanning microscopy and flow cytometry. Cell viability was evaluated using the MTT assay. PBM using 810 nm and 970 nm lasers significantly enhanced transfection efficiency for GFP, indicating more efficient uptake of plasmid DNA. Conversely, laser irradiation at 445 nm and 685 nm wavelengths reduced the GFP transfection efficiency. Treatment using 685, 810, and 970 nm lasers at 12 J maintained cell viability and prevented toxicity of cationic liposomes. Overall, these findings support the concept that PBM using near infrared laser wavelengths can enhance transfection efficiency and support cell viability when cationic liposomes are used as the vector in gene therapy.
C1 [Hosseinpour, Sepanta; Xu, Chun; Walsh, Laurence J.] Univ Queensland, Sch Dent, Herston, Qld 4006, Australia.
C3 University of Queensland
RP Walsh, LJ (通讯作者)，Univ Queensland, Sch Dent, UQ Oral Hlth Ctr, 288 Herston Rd, Herston, Qld 4006, Australia.
EM sp.hosseinpour@uqconnect.edu.au; chun.xu@uq.edu.au; l.walsh@uq.edu.au
RI Walsh, Laurence/F 1210 2010; Xu, Chun/C 3649 2017; Hosseinpour,
   Sepanta/K 8114 2019
OI Xu, Chun/0000 0001 8831 3607; Hosseinpour, Sepanta/0000 0002 6503 4223
CR Antkowiak M, 2010, BIOMED OPT EXPRESS, V1, P414, DOI 10.1364/BOE.1.000414
   Balazs DA, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/326497
   Brown MD, 2001, INT J PHARMACEUT, V229, P1, DOI 10.1016/S0378 5173(01)00861 4
   Chang SY, 2019, LASER MED SCI, V34, P367, DOI 10.1007/s10103 018 2605 7
   FARHOOD H, 1995, BBA BIOMEMBRANES, V1235, P289, DOI 10.1016/0005 2736(95)80016 9
   FRALEY R, 1980, J BIOL CHEM, V255, P431
   Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015
   Hosseinpour S, 2019, CALCIFIED TISSUE INT, V105, P223, DOI 10.1007/s00223 019 00571 8
   Jere SW, 2020, J PHOTOCH PHOTOBIO B, V204, DOI 10.1016/j.jphotobiol.2020.111791
   Kara C, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12417
   Kim TK, 2010, ANAL BIOANAL CHEM, V397, P3173, DOI 10.1007/s00216 010 3821 6
   Kim YD, 2009, LASER MED SCI, V24, P577, DOI 10.1007/s10103 008 0614 7
   Kreisler M, 2002, LASER SURG MED, V30, P365, DOI 10.1002/lsm.10060
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897
   Mali Shrikant, 2013, Indian J Hum Genet, V19, P3, DOI 10.4103/0971 6866.112870
   Mokoena D, 2018, J PHOTOCH PHOTOBIO B, V189, P138, DOI 10.1016/j.jphotobiol.2018.10.011
   Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818
   Nathwani AC, 2019, HEMATOL AM SOC HEMAT, P1, DOI 10.1182/hematology.2019000007
   Nishimura N, 2006, NAT METHODS, V3, P99, DOI 10.1038/NMETH844
   Nissan J, 2006, J ORAL REHABIL, V33, P619, DOI 10.1111/j.1365 2842.2006.01601.x
   Oskuee RK, 2016, ADV PHARM BULL, V6, P515, DOI 10.15171/apb.2016.065
   Parker S, 2007, BRIT DENT J, V202, P131, DOI 10.1038/bdj.2007.75
   Pigatto GR, 2019, J PHOTOCH PHOTOBIO B, V196, DOI 10.1016/j.jphotobiol.2019.111513
   Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728 200503000 00016
   Rahimi P, 2018, BRATISL MED J, V119, P701, DOI 10.4149/BLL_2018_125
   Ramaswamy S, 2012, NEUROBIOL DIS, V48, P243, DOI 10.1016/j.nbd.2011.12.030
   Vitor LLR, 2020, J PHOTOCH PHOTOBIO B, V203, DOI 10.1016/j.jphotobiol.2019.111738
   Riss TL., 2016, CELL VIABILITY ASSAY
   Shakouri SK, 2010, LASER MED SCI, V25, P73, DOI 10.1007/s10103 009 0670 7
   Shirahata Y, 2001, J INVEST MED, V49, P184, DOI 10.2310/6650.2001.34045
   Silva AD, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37759 1
   Simoes Sergio, 2005, Expert Opin Drug Deliv, V2, P237, DOI 10.1517/17425247.2.2.237
   Sommer AP, 2019, PHOTOBIOMODULATION P, V37, P336, DOI 10.1089/photob.2018.4606
   Sommer AP, 2011, J PHYS CHEM LETT, V2, P562, DOI 10.1021/jz2001503
   Sommer AP, 2010, J CONTROL RELEASE, V148, P131, DOI 10.1016/j.jconrel.2010.10.010
   Stevenson DJ, 2010, J R SOC INTERFACE, V7, P863, DOI 10.1098/rsif.2009.0463
   Terakawa M, 2004, OPT LETT, V29, P1227, DOI 10.1364/OL.29.001227
   Tirlapur UK, 2002, NATURE, V418, P290, DOI 10.1038/418290a
   Trelles M.A., 2015, ANN TRANSL MED, V3
   TSUKAKOSHI M, 1984, APPL PHYS B PHOTO, V35, P135, DOI 10.1007/BF00697702
   Uchugonova A, 2008, OPT EXPRESS, V16, P9357, DOI 10.1364/OE.16.009357
   Wang WX, 2017, SCI REP UK, V7, DOI 10.1038/srep43036
   Yao CP, 2008, IEEE T NANOBIOSCI, V7, P111, DOI 10.1109/TNB.2008.2000742
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081
NR 45
TC 7
Z9 7
U1 0
U2 21
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011 1344
EI 1873 2682
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B Biol.
PD FEB
PY 2021
VL 215
AR 112108
DI 10.1016/j.jphotobiol.2020.112108
EA JAN 2021
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA QH9OE
UT WOS:000618602500003
PM 33418241
DA 2025 08 17
ER

PT J
AU Luboshits, G
   Benayahu, D
AF Luboshits, G.
   Benayahu, D.
TI MS KIF18A, a kinesin is associated with estrogen receptor
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE kinesin; estrogen receptor; protein interaction; imaging; signaling
ID TRANSPORT PATHWAYS; PLASMA MEMBRANE; ALPHA; IDENTIFICATION; MOTOR;
   EXPRESSION; TRANSCRIPTION; OSTEOBLASTS; ACTIVATION; CAVEOLAR
AB The study of MS KIF18A kinesin protein is focused on its cellular distribution and association with a cargo protein. Indirect immunofluorescence (IF) analyzed the intracellular distribution of endogenous MS KIF18A and the transfected enhanced green fluorescence protein (eGFP) MS KIF18A in osteogenic cells. In both cases, the proteins were localized at the plasma membrane, cytosol, and nucleus. Bioinformatics analysis suggested interactions between MSKIF18A and estrogen receptor(ER alpha) which were further elucidated by immunoprecipitation (IP). We identified interaction between endogenous MS KIF18A with 66 and 46 kDa isoforms of ER alpha in MBA 15 cells. Moreover, MS KIF18A and 66 kDa ERa complex has been demonstrated between ectopically expressed proteins in COS 7 cells. We have shown that anti MS KIF18A antibody immunoprecipitated the ER alpha and pERK in cells challenged with 17 beta estrogen (17 beta E2). The hormone activation induced mitogen activated protein kinases (MAPK) pathway and increased p ERK. The activation was interfered when cells were pre treated with either ICI 182,780 or MAPK inhibitor PD98059 prior the challenge with 17 beta E2 that resulted in a decrease in association between MS KIF18A and p ERK1/2. The obtained results suggest a role for the proteins in a non genomic response of MBA 15 cells challenged with 17 beta E2. This study presents a novel interaction between MS KIF18A and ER that may have important physiological and pharmacological implications for estrogen action in various cells.
C1 Tel Aviv Univ, Dept Cell & Dev Biol, Sackler Sch Med, IL 66978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Benayahu, D (通讯作者)，Tel Aviv Univ, Dept Cell & Dev Biol, Sackler Sch Med, IL 66978 Tel Aviv, Israel.
EM dafnab@post.tau.ac.il
CR Baker SA, 2003, J BIOL CHEM, V278, P34211, DOI 10.1074/jbc.M300156200
   BENAYAHU D, 1989, J CELL PHYSIOL, V140, P1, DOI 10.1002/jcp.1041400102
   Benayahu D, 1997, BIOCHEM BIOPH RES CO, V233, P30, DOI 10.1006/bbrc.1997.6401
   Braidman I, 2000, BONE, V26, P423, DOI 10.1016/S8756 3282(00)00246 5
   Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003
   Chaban VV, 2004, ENDOCRINOLOGY, V145, P3788, DOI 10.1210/en.2004 0149
   Chambliss KL, 2002, STEROIDS, V67, P413, DOI 10.1016/S0039 128X(01)00177 5
   Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453
   COLVARD D, 1989, CONNECT TISSUE RES, V20, P33, DOI 10.3109/03008208909023872
   deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250
   Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064
   Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688
   Gandhi R, 2004, MOL BIOL CELL, V15, P121, DOI 10.1091/mbc.E03 05 0342
   Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298
   Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319
   Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A
   Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779
   Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257
   Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039 128X(99)00107 5
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960 0760(00)00108 4
   Li HY, 2004, AM J PHYSIOL RENAL, V286, pF711, DOI 10.1152/ajprenal.00308.2003
   LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365
   Luboshits G, 2005, GENE, V351, P19, DOI 10.1016/j.gene.2005.02.009
   Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265
   Mak HY, 1999, MOL CELL BIOL, V19, P3895
   Martini PGV, 2003, J STEROID BIOCHEM, V85, P117, DOI 10.1016/S0960 0760(03)00207 3
   Massas R, 1998, J CELL BIOCHEM, V69, P282, DOI 10.1002/(SICI)1097 4644(19980601)69:3<282::AID JCB6>3.0.CO;2 N
   Mavlyutov TA, 2002, TRAFFIC, V3, P630, DOI 10.1034/j.1600 0854.2002.30905.x
   Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo reports/kve185
   MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305
   Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117
   Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092 8674(00)00161 6
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Oreffo ROC, 1999, HISTOCHEM CELL BIOL, V111, P125, DOI 10.1007/s004180050342
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633 1646.2003
   Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004 0115
   Ruff M, 2000, BREAST CANCER RES, V2, P353, DOI 10.1186/bcr80
   Savoian MS, 2004, J CELL SCI, V117, P3669, DOI 10.1242/jcs.01213
   Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796
   Shamay A, 1996, CELL BIOL INT, V20, P401, DOI 10.1006/cbir.1996.0050
   Shur I, 2002, J CELL BIOCHEM, V87, P51, DOI 10.1002/jcb.10267
   Solomon KR, 2000, J BONE MINER RES, V15, P2380, DOI 10.1359/jbmr.2000.15.12.2380
   Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88
   Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092 8674(03)00111 9
   WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889
   Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200
   Zafar A, 1995, BIOCHEM MOL BIOL INT, V36, P1197
   ZHU C, 2005, MOL BIOL CELL
NR 50
TC 9
Z9 13
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB 15
PY 2007
VL 100
IS 3
BP 693
EP 702
DI 10.1002/jcb.21000
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 130CB
UT WOS:000243775700012
PM 17006958
DA 2025 08 17
ER

PT J
AU Kabiri, M
   Kul, B
   Lott, WB
   Futrega, K
   Ghanavi, P
   Upton, Z
   Doran, MR
AF Kabiri, Mahboubeh
   Kul, Betul
   Lott, William B.
   Futrega, Kathryn
   Ghanavi, Parisa
   Upton, Zee
   Doran, Michael R.
TI 3D mesenchymal stem/stromal cell osteogenesis and autocrine signalling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mesenchymal stem cells; Osteogenesis; Microaggregate; BMP 2 signalling;
   BMP 2 autocrine signalling; Three dimensional culture
ID STEM CELLS; IN VITRO; STROMAL CELLS; DIFFERENTIATION; OSTEOBLASTS;
   GENERATION; SPHEROIDS; SURFACES; ADHESION; MATRIX
AB Mesenchymal stem/stromal cells (MSC) are rapidly becoming a leading candidate for use in tissue regeneration, with first generation of therapies being approved for use in orthopaedic repair applications. Capturing the full potential of MSC will likely require the development of novel in vitro culture techniques and devices. Herein we describe the development of a straightforward surface modification of an existing commercial product to enable the efficient study of three dimensional (3D) human bone marrow derived MSC osteogenic differentiation. Hundreds of 3D microaggregates, of either 42 or 168 cells each, were cultured in osteogenic induction medium and their differentiation was compared with that occurring in traditional two dimensional (2D) monolayer cultures. Osteogenic gene expression and matrix composition was significantly enhanced in the 3D microaggregate cultures. Additionally, BMP 2 gene expression was significantly up regulated in 3D cultures at day 3 and 7 by approximately 25  and 30 fold, respectively. The difference in BMP 2 gene expression between 2D and 3D cultures was negligible in the more mature day 14 osteogenic cultures. These data support the notion that BMP 2 autocrine signalling is up regulated in 3D MSC cultures, enhancing osteogenic differentiation. This study provides both mechanistic insight into MSC differentiation, as well as a platform for the efficient generation of microtissue units for further investigation or use in tissue engineering applications. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kabiri, Mahboubeh; Kul, Betul; Futrega, Kathryn; Ghanavi, Parisa; Doran, Michael R.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Stem Cell Therapies Lab, Brisbane, Qld 4001, Australia.
   [Kabiri, Mahboubeh] Univ Tehran, Coll Sci, Dept Biotechnol, Tehran, Iran.
   [Upton, Zee] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld 4001, Australia.
   [Doran, Michael R.] Mater Med Res Inst, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); University of Tehran;
   Queensland University of Technology (QUT); Mater Research
RP Doran, MR (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Stem Cell Therapies Lab, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM michael.doran@qut.edu.au
RI ; Kabiri, Mahboubeh/ABE 1182 2021; Upton, Zee/ABC 4642 2021; Lott,
   William/J 1062 2012; Doran, Michael/F 6059 2014; Futrega,
   Kathryn/AAX 1303 2021
OI Futrega, Kathryn/0000 0003 3411 6768; Doran, Michael
   Robert/0000 0001 5876 4757; Lott, William/0000 0001 7118 7560; Upton,
   Zee/0000 0002 9928 5864
FU National Health and Medical Research Council (NHMRC) of Australia; QUT
   Vice Chancellor's Fellowship Scheme
FX The Authors would like to thank the QUT Vice Chancellor's Fellowship
   Scheme and the National Health and Medical Research Council (NHMRC) of
   Australia for funding this work.
CR Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429
   Cheng MT, 2009, CELL PROLIFERAT, V42, P448, DOI 10.1111/j.1365 2184.2009.00611.x
   Croll TI, 2006, BIOMACROMOLECULES, V7, P1610, DOI 10.1021/bm060044l
   de Barros APDN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009093
   DEKKER A, 1991, BIOMATERIALS, V12, P130, DOI 10.1016/0142 9612(91)90191 C
   Doran MR, 2010, BIOMATERIALS, V31, P5137, DOI 10.1016/j.biomaterials.2010.03.015
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Friedenstein A J, 1980, Haematol Blood Transfus, V25, P19
   Frith JE, 2010, TISSUE ENG PART C ME, V16, P735, DOI [10.1089/ten.tec.2009.0432, 10.1089/ten.TEC.2009.0432]
   García AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502
   Haase HR, 2003, J PERIODONTAL RES, V38, P366, DOI 10.1034/j.1600 0765.2003.00655.x
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092 8674(02)01229 1
   Jähn K, 2010, EUR CELLS MATER, V20, P149
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kelm JM, 2006, TISSUE ENG, V12, P2151, DOI 10.1089/ten.2006.12.2151
   Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655
   Kong HJ, 2005, P NATL ACAD SCI USA, V102, P4300, DOI 10.1073/pnas.0405873102
   Markway BD, 2010, CELL TRANSPLANT, V19, P29, DOI 10.3727/096368909X478560
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Parson AB, 2008, CELL, V132, P511, DOI 10.1016/j.cell.2008.02.004
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Timmins NE, 2005, CELL TISSUE RES, V320, P207, DOI 10.1007/s00441 004 1064 6
   Timmins Nicholas E., 2004, Angiogenesis, V7, P97, DOI 10.1007/s10456 004 8911 7
   Toquet J, 1999, J BIOMED MATER RES, V44, P98, DOI 10.1002/(SICI)1097 4636(199901)44:1<98::AID JBM11>3.0.CO;2 P
   Ungrin MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001565
   Wang WJ, 2009, BIOMATERIALS, V30, P2705, DOI 10.1016/j.biomaterials.2009.01.030
   Ye CP, 2007, CELL BIOCHEM FUNCT, V25, P267, DOI 10.1002/cbf.1330
NR 29
TC 61
Z9 66
U1 1
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 9
PY 2012
VL 419
IS 2
BP 142
EP 147
DI 10.1016/j.bbrc.2012.01.017
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 913XP
UT WOS:000301911000002
PM 22266317
DA 2025 08 17
ER

PT J
AU Kim, JS
   Lee, HK
   Kim, MR
   Kim, PK
   Kim, CW
AF Kim, Ji Soo
   Lee, Hyun Kyung
   Kim, Mi Ryung
   Kim, Pan Kyeorn
   Kim, Chan Wha
TI Differentially expressed proteins of mesenchymal stem cells derived from
   human cord blood (hUCB) during osteogenic differentiation
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE osteogenesis; mesenchymal stem cells; human umbillical cord blood;
   proteomics
ID 2 DIMENSIONAL GEL ELECTROPHORESIS; UNRELATED BONE MARROW;
   HEAT SHOCK PROTEIN; PROGENITOR CELLS; ACTIN POLYMERIZATION; PROTEOMIC
   ANALYSIS; STROMAL CELLS; IDENTIFICATION; MECHANISM; APOPTOSIS
AB Multipotent mesenchymal stem cells (MSCs) derived from human umbilical cord blood (hUCB) represent promising candidates for the development of future cellular therapy strategies. MSCs have been found to be able to differentiate into various tissues. One of the primary limitations in our understanding of the biology of human MSCs is the absence of prospective markers required for the monitoring of lineage specific differentiation. hUCB derived MSCs have been found to have significantly greater osteogenic potential. In this study, we focused on proteins that were differentially expressed during osteogenic differentiation of hUCB MSCs. And we analyzed the protein expression inherent to osteogenic differentiation by two dimensional gel electrophoresis, ESI Q TOF, and Western blotting. Eleven differentially expressed spots were observed between the two groups (before and after differentiation) on the 2 DE map. These might also be proved as useful cytosolic biomarker proteins for osteogenesis, and might be employed in quality control of osteoblasts in cell therapy applications.
C1 [Kim, Ji Soo; Lee, Hyun Kyung; Kim, Mi Ryung; Kim, Pan Kyeorn; Kim, Chan Wha] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.
C3 Korea University
RP Kim, CW (通讯作者)，Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.
EM cwkim@korea.ac.kr
RI Kim, Dong Ki/J 5389 2012; Kim, Yeon Ju/AAE 5919 2019
CR Arrigo AP, 2005, J CELL BIOCHEM, V94, P241, DOI 10.1002/jcb.20349
   Barker JN, 2002, BIOL BLOOD MARROW TR, V8, P257, DOI 10.1053/bbmt.2002.v8.pm12064362
   Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602 7612.2000
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200
   Goodwin HS, 2001, BIOL BLOOD MARROW TR, V7, P581, DOI 10.1053/bbmt.2001.v7.pm11760145
   Grewal SS, 2003, BLOOD, V101, P4233, DOI 10.1182/blood 2002 08 2510
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097 4652(199603)166:3<585::AID JCP13>3.0.CO;2 6
   Hwang SH, 2007, BIOTECHNOL BIOPROC E, V12, P32, DOI 10.1007/BF02931800
   Joo WA, 2003, PROTEOMICS, V3, P2402, DOI 10.1002/pmic.200300616
   Joo WA, 2003, BIOSCI BIOTECH BIOCH, V67, P1574, DOI 10.1271/bbb.67.1574
   Kakinuma S, 2003, STEM CELLS, V21, P217, DOI 10.1634/stemcells.21 2 217
   Kassis I, 2006, BONE MARROW TRANSPL, V37, P967, DOI 10.1038/sj.bmt.1705358
   Kondoh H, 2007, HISTOL HISTOPATHOL, V22, P85, DOI 10.14670/HH 22.85
   Kondoh H, 2005, CANCER RES, V65, P177
   Lee HK, 2006, PROTEOMICS, V6, P1223, DOI 10.1002/pmic.200500385
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Lee SH, 2005, J PROTEOME RES, V4, P335, DOI 10.1021/pr049830s
   Levchenko A, 2005, NAT BIOTECHNOL, V23, P828, DOI 10.1038/nbt0705 828
   Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097 4652(199807)176:1<57::AID JCP7>3.0.CO;2 7
   MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255
   Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501
   Rocha V, 2001, BLOOD, V97, P2962, DOI 10.1182/blood.V97.10.2962
   RUBINSTEIN P, 1993, BLOOD, V81, P1679
   Son WK, 2003, PROTEOMICS, V3, P2393, DOI 10.1002/pmic.200300605
   STRAUCH AR, 1986, J BIOL CHEM, V261, P849
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Sun HJ, 2006, J ORTHOP RES, V24, P2059, DOI 10.1002/jor.20273
   Tsuchiya H, 1996, CANCER RES, V56, P2881
   Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092 8674(00)81446 4
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wieske M, 2001, EUR J BIOCHEM, V268, P2083, DOI 10.1046/j.1432 1327.2001.02082.x
   Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519
   Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623 199812000 00004
   Zenzmaier C, 2005, BIOCHEM BIOPH RES CO, V328, P968, DOI 10.1016/j.bbrc.2005.01.044
NR 39
TC 19
Z9 26
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916 8451
EI 1347 6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD SEP
PY 2008
VL 72
IS 9
BP 2309
EP 2317
DI 10.1271/bbb.80224
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA 356HU
UT WOS:000259770100008
PM 18776689
OA Bronze
DA 2025 08 17
ER

PT J
AU Xie, HG
   Wang, QQ
   Zhang, XY
   Wang, T
   Hu, W
   Manicum, T
   Chen, H
   Sun, LJ
AF Xie, Huanguang
   Wang, Qingqing
   Zhang, Xinyue
   Wang, Te
   Hu, Wei
   Manicum, Theasha
   Chen, Hua
   Sun, Liaojun
TI Possible therapeutic potential of berberine in the treatment of STZ plus
   HFD induced diabetic osteoporosis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Berberine; Diabetic osteoporosis; Microarchitecture; Bone mineral
   density; Oxidative stress
ID NF KAPPA B; OXIDATIVE STRESS; HIGH GLUCOSE; OSTEOBLAST DIFFERENTIATION;
   BONE MASS; CELLS; RATS; INSULIN; MECHANISMS; EXPRESSION
AB Diabetic osteoporosis is a complication of diabetes mellitus, and can result in an increased incidence of bone fractures and a delay in fracture healing. Berberine is one of the most widely distributed isoquinoline alkaloid in plants and possesses antioxidant properties. These properties can reduce the high glucose mediated in the dysfunction of human bone marrow stem cells. Therefore, the present study was designed to investigate the apparent beneficial effect of berberine on bone characteristics in streptozotocin plus HFD induced diabetic rats. Rats were selected at random and divided into four groups: (A) control group (CG) (n = 10); (B) diabetic group (DG) (n = 10); (C) diabetic group with 50 mg kg( 1)day( 1) of berberine (Brb 50) (n = 10); and (D) diabetic group with 100 mg kg( 1)day( 1) of berberine (Brb 100) (n = 10). After 12 weeks of being treated with berberine, the femora from all rats were assessed and other blood biochemistries evaluated. Berberine at 50 mg/kg showed little effect and significance on diabetic osteopenia, while berberine at 100 mg/kg was significantly increased in diabetic rats. The same group also displayed a significantly decreased serum osteocalcin and serum alkaline phosphatase activity in diabetic rats. The impaired micro architecture of the femurs in diabetic rats could partially be prevented by berberine with 100 mg/kg. In addition, berberine could to an extent restore the decreased bone formation and reabsorption of the femurs in diabetic rats through the histomorphometric analysis. Berberine could not only significantly lower the oxidative level of DNA damage, but also up regulate the activity of serum antioxidants. According to our investigations and discoveries, we have found, that berberine may be a potential drug for controlling bone loss in diabetic osteoporosis.
C1 [Xie, Huanguang; Wang, Qingqing; Wang, Te; Hu, Wei; Manicum, Theasha; Chen, Hua; Sun, Liaojun] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou 325000, Peoples R China.
   [Xie, Huanguang; Wang, Qingqing; Wang, Te; Hu, Wei; Manicum, Theasha; Chen, Hua; Sun, Liaojun] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.
   [Zhang, Xinyue] Fujian Prov Govt Hosp, Dept Radiol, Fuzhou 350003, Fujian, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Sun, LJ (通讯作者)，109 XueYuan West Rd, Wenzhou, Zhejiang, Peoples R China.
EM 576374928@qq.com; 314019077@qq.com; 342823703@qq.com;
   15067702212@163.com; huweifey@126.com; theashamanicum@yahoo.com;
   chenhua_fey@163.com; sunljfey@126.com
RI Wang, Qingqing/E 7972 2014; Sun, liaojun/L 2978 2019
CR Adil M, 2017, BIOMED PHARMACOTHER, V94, P1010, DOI 10.1016/j.biopha.2017.08.001
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Balint E, 2001, BONE, V28, P21, DOI 10.1016/S8756 3282(00)00426 9
   Chen CH, 2010, BIOCHEM BIOPH RES CO, V397, P543, DOI 10.1016/j.bbrc.2010.05.153
   Chen DL, 2017, J CELL BIOCHEM, V118, P4349, DOI 10.1002/jcb.26089
   Cok A, 2011, BIOCHIMIE, V93, P1187, DOI 10.1016/j.biochi.2011.04.013
   Coskun O, 2005, PHARMACOL RES, V51, P117, DOI 10.1016/j.phrs.2004.06.002
   DeVries JH, 2009, NEW ENGL J MED, V361, P1408
   Forsén L, 1999, DIABETOLOGIA, V42, P920, DOI 10.1007/s001250051248
   Hamada Y, 2007, BONE, V40, P1408, DOI 10.1016/j.bone.2006.12.057
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Imenshahidi M, 2016, PHYTOTHER RES, V30, P1745, DOI 10.1002/ptr.5693
   INABA M, 1995, J BONE MINER RES, V10, P1050
   KAKKAR P, 1984, INDIAN J BIOCHEM BIO, V21, P130
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06 0006
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125 007 0886 7
   LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502
   Li HY, 2003, BIOL PHARM BULL, V26, P110, DOI 10.1248/bpb.26.110
   Liu WH, 2008, ARCH BIOCHEM BIOPHYS, V475, P128, DOI 10.1016/j.abb.2008.04.022
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Ni Y X, 1988, Zhong Xi Yi Jie He Za Zhi, V8, P711
   Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845
   Pfisterer ME, 2009, NEW ENGL J MED, V361, P1407, DOI 10.1056/NEJMc091419
   Rahigude AB, 2012, MED HYPOTHESES, V79, P440, DOI 10.1016/j.mehy.2012.06.016
   SEINO Y, 1995, DIABETES METAB REV, V11, P21, DOI 10.1002/dmr.5610110103
   Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891 5849(00)00224 0
   Slater AFG, 1995, TOXICOL LETT, V82 3, P149, DOI 10.1016/0378 4274(95)03474 9
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Suzuki K, 2003, BONE, V33, P108, DOI 10.1016/S8756 3282(03)00169 8
   TENNISWOOD M, 1976, CAN J BIOCHEM CELL B, V54, P350, DOI 10.1139/o76 051
   Terada M, 1998, BONE, V22, P17, DOI 10.1016/S8756 3282(97)00220 2
   Wang T, 2017, BIOMED PHARMACOTHER, V89, P681, DOI 10.1016/j.biopha.2017.02.018
   Xu DH, 2010, PLANTA MED, V76, P1809, DOI 10.1055/s 0030 1250040
   Yi P, 2008, WORLD J GASTROENTERO, V14, P876, DOI 10.3748/wjg.14.876
   Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097 4644(20001101)79:2<301::AID JCB130>3.0.CO;2 0
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
   Zhou JY, 2011, FITOTERAPIA, V82, P184, DOI 10.1016/j.fitote.2010.08.019
   Zhou JY, 2009, EUR J PHARMACOL, V606, P262, DOI 10.1016/j.ejphar.2008.12.056
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
NR 40
TC 43
Z9 49
U1 0
U2 48
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2018
VL 108
BP 280
EP 287
DI 10.1016/j.biopha.2018.08.131
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HA2UZ
UT WOS:000450101800034
PM 30223099
OA hybrid
DA 2025 08 17
ER

PT J
AU Li, RJ
   Cai, YR
   Yang, Y
   Fang, SB
   Su, XP
   Sun, YQ
   Yao, JM
AF Li, Ruijing
   Cai, Yurong
   Yang, Ying
   Fang, Shunbin
   Su, Xiuping
   Sun, Yunqing
   Yao, Juming
TI Dimensionally and morphologically controlled growth of calcium phosphate
   crystals by an organic free hydrothermal process
SO CERAMICS INTERNATIONAL
LA English
DT Article
DE Calcium phosphate; Nanowire; Microsphere; Crystal growth
ID DRUG DELIVERY SYSTEM; STRONTIUM HYDROXYAPATITE; NANOSIZED
   HYDROXYAPATITE; NANOPARTICLES; PROLIFERATION; LUMINESCENT
AB Calcium phosphate (CaP) materials are optimal candidate biomaterials for bone tissue engineering because of their bioactivity and biocompatibility. The controlled fabrication of CaP materials draws great interest because the size, shape and composition of CaP crystals play critical roles in biological response. In this study, CaP nanowires and microspheres were synthesised via an organic free hydrothermal process without the assistance of any surfactant or template. The effect of the reaction condition on CaP crystal growth was investigated. Experimental results showed that the size, shape and composition of the obtained CaP crystals could be manipulated by changing nucleation temperature, reaction temperature, pH value and reaction time. The chemical composition of the obtained crystals had a common change process from dicalcium phosphate dihydrate and dicalcium phosphate anhydrous to hydroxyapatite with the elongation of reaction time. The prenucleation and nucleation temperature before hydrothermal treatment were critical for the growth of CaP crystal. Two typical morphologies of nanowire and microsphere were fabricated under the given reaction condition. The growth mechanisms of the crystals were also discussed in this paper. In vitro results showed that both nanowires and microspheres of CaP exhibited exceptional performance to improve osteoblast proliferation, which endowed them with interesting potential for bone repair. The findings are highly important to develop excellent materials suitable for bone tissue engineering. (C) 2016 Elsevier Ltd and Techna Group S.r.l. All rights reserved.
C1 [Li, Ruijing; Cai, Yurong; Yang, Ying; Fang, Shunbin; Su, Xiuping; Yao, Juming] Zhejiang Sci Tech Univ, Coll Mat & Text, Key Lab Adv Text Mat & Mfg Technol, Natl Engn Lab Text Fiber Mat & Proc Technol,Minis, Hangzhou 310018, Peoples R China.
   [Sun, Yunqing] Liaocheng Univ, Sch Chem & Chem Engn, Liaocheng 252000, Peoples R China.
C3 Zhejiang Sci Tech University; Liaocheng University
RP Cai, YR (通讯作者)，Zhejiang Sci Tech Univ, Coll Mat & Text, Key Lab Adv Text Mat & Mfg Technol, Natl Engn Lab Text Fiber Mat & Proc Technol,Minis, Hangzhou 310018, Peoples R China.
EM caiyr@zstu.edu.cn
RI Yao, Juming/N 7886 2014
FU Program for National Natural Science Foundation of China [51202219,
   51372226]; Zhejiang Provincial Natural Science Foundation of China
   [LY16E020013]; Zhejiang Top Priority Discipline of Textile Science and
   Engineering [2015KF23]
FX The work is financially supported by the Program for National Natural
   Science Foundation of China (51202219 and 51372226), Zhejiang Provincial
   Natural Science Foundation of China (LY16E020013) and Zhejiang Top
   Priority Discipline of Textile Science and Engineering (2015KF23).
CR Bohner Marc, 2013, Biomatter, V3, DOI 10.4161/biom.25103
   Brand M, 2008, NAT PROTOC, V3, P398, DOI 10.1038/nprot.2008.8
   Cao MH, 2004, LANGMUIR, V20, P4784, DOI 10.1021/la0498197
   Chandanshive B, 2010, J MATER CHEM, V20, P6923, DOI 10.1039/c0jm00145g
   Dorozhkin SV, 2009, MATERIALS, V2, P1975, DOI 10.3390/ma2041975
   Dorozhkin SV, 2009, MATERIALS, V2, P221, DOI 10.3390/ma2010221
   Giger EV, 2011, J CONTROL RELEASE, V150, P87, DOI 10.1016/j.jconrel.2010.11.012
   Guo XK, 2014, J MATER CHEM B, V2, P1760, DOI 10.1039/c3tb21652g
   Guo YP, 2011, CHEM COMMUN, V47, P12215, DOI [10.1039/c1cc15190h, 10.1039/c1c15190h]
   Hansen TW, 2013, ACCOUNTS CHEM RES, V46, P1720, DOI 10.1021/ar3002427
   Hong YL, 2010, MAT SCI ENG R, V70, P225, DOI 10.1016/j.mser.2010.06.010
   Iafisco M, 2015, CRYSTENGCOMM, V17, P507, DOI 10.1039/c4ce01415d
   Ito H, 2008, CRYST GROWTH DES, V8, P1055, DOI 10.1021/cg070443f
   Kim YY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5341
   Koirala MB, 2015, ACS APPL MATER INTER, V7, P27382, DOI 10.1021/acsami.5b09042
   Kozlova D, 2012, J MATER CHEM, V22, P396, DOI 10.1039/c1jm14683a
   Li J, 2012, J CONTROL RELEASE, V158, P108, DOI 10.1016/j.jconrel.2011.10.020
   Li WH, 2016, J MATER CHEM B, V4, P340, DOI 10.1039/c5tb02328a
   Lin KL, 2013, ACS APPL MATER INTER, V5, P8008, DOI 10.1021/am402089w
   Mao CB, 2003, P NATL ACAD SCI USA, V100, P6946, DOI 10.1073/pnas.0832310100
   Meldrum FC, 2008, CHEM REV, V108, P4332, DOI 10.1021/cr8002856
   Niu N, 2012, CRYSTENGCOMM, V14, P1744, DOI 10.1039/c1ce06265d
   Sadat Shojai M, 2013, ACTA BIOMATER, V9, P7591, DOI 10.1016/j.actbio.2013.04.012
   Shao FW, 2012, J MATER SCI, V47, P1054, DOI 10.1007/s10853 011 5894 9
   Su P, 2011, CARBOHYD POLYM, V84, P239, DOI 10.1016/j.carbpol.2010.11.031
   Su Y.C., 2016, ACS BIOMATER SCI ENG
   Tamimi F, 2010, BIOMATERIALS, V31, P2762, DOI 10.1016/j.biomaterials.2009.12.039
   Tampieri A, 2014, ACS APPL MATER INTER, V6, P15697, DOI 10.1021/am5050967
   Tang YX, 2014, ADV MATER, V26, P6111, DOI 10.1002/adma.201402000
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Vallet Regí M, 2004, PROG SOLID STATE CH, V32, P1, DOI 10.1016/j.progsolidstchem.2004.07.001
   Wang HX, 2010, ACTA BIOMATER, V6, P1743, DOI 10.1016/j.actbio.2009.12.009
   Wu J, 2013, MINI REV MED CHEM, V13, P1501
   Wu L, 2011, CHEM COMMUN, V47, P11674, DOI 10.1039/c1cc14709a
   Xia LG, 2013, J MATER CHEM B, V1, P5403, DOI 10.1039/c3tb20945h
   Xu ZL, 2012, J APPL TOXICOL, V32, P429, DOI 10.1002/jat.1745
   Ye F, 2010, ACTA BIOMATER, V6, P2212, DOI 10.1016/j.actbio.2009.12.014
   Yoshida K, 2012, J ELECTRON MICROSC, V61, P99, DOI 10.1093/jmicro/dfr100
   Zhang CM, 2010, BIOMATERIALS, V31, P3374, DOI 10.1016/j.biomaterials.2010.01.044
   Zhang J, 2010, NANOSCALE, V2, P18, DOI 10.1039/b9nr00047j
   Zhuang Z, 2013, ACTA BIOMATER, V9, P6732, DOI 10.1016/j.actbio.2013.02.001
NR 41
TC 7
Z9 8
U1 1
U2 61
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272 8842
EI 1873 3956
J9 CERAM INT
JI Ceram. Int.
PD NOV 15
PY 2016
VL 42
IS 15
BP 17387
EP 17397
DI 10.1016/j.ceramint.2016.08.038
PG 11
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA DY0JW
UT WOS:000384784100124
DA 2025 08 17
ER

PT J
AU Murphy, DJ
   Ou, YS
   Euler, DH
   Wessner, K
   Adamski, S
   Luo, B
   Wesolowski, GA
   Vogel, R
   Glantschnig, H
   Lubbers, LS
   Carroll, SS
   Lai, MT
AF Murphy, Dennis J.
   Ou, Yangsi
   Euler, Danielle H.
   Wessner, Keith
   Adamski, Sharon
   Luo, Bin
   Wesolowski, Gregg A.
   Vogel, Robert
   Glantschnig, Helmut
   Lubbers, Laura S.
   Carroll, Stephen S.
   Lai, Ming Tain
TI Determination of in Vivo Enzyme Occupancy Utilizing Inhibitor
   Dissociation Kinetics
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID TARGET RESIDENCE TIME; CATHEPSIN K; RECEPTOR OCCUPANCY; IMPACT
AB During drug discovery, assessment of in vivo target occupancy by therapeutic candidates is often required for predicting clinical efficacy. Current strategies for determining target occupancy include using radiolabeled or irreversible surrogates, which can be technically challenging, and the results are often not sufficiently quantitative. We developed a straightforward method by applying slow dissociation kinetics to quantitatively determine enzyme occupancy without using specialized reagents. We applied this method to determine occupancy of Cathepsin K inhibitors in bone tissues harvested from rabbit femurs. Tissues from dosed animals were harvested, flash frozen, lysed, then analyzed by a jump dilution assay with substrate. The rate of substrate turnover was monitored continuously until reaching steady state and progress curves were fit with the equation [product] = v(s)t divided by ((vi   vs)/k(obs))(1   exp( k(obs)t)). The initial rate v(i) represents the residual activity of the enzyme before inhibitor dissociation; v(s), is the reaction rate after dissociation of the inhibitor. Occupancy is derived from the ratio of v(i)/v(s). A significant benefit of the method is that data from both the occupied and unoccupied states are obtained in the same assay under identical conditions, which provides greater consistency between studies. The Cat K inhibitor MK 0674 (in vitro IC50 1 nM) was tested in young rabbits (<6 month old) and showed a dosedependent increase in occupancy, reaching essentially complete occupancy at 1.0 mg/kg. In addition the method enables measurement of the total Cat K in the target tissue. Results confirmed complete occupancy even as the osteoclasts responded to higher doses with increased enzyme production.
C1 [Murphy, Dennis J.; Ou, Yangsi; Carroll, Stephen S.; Lai, Ming Tain] Merck Res Labs, In Vitro Pharmacol, West Point, PA 19486 USA.
   [Wesolowski, Gregg A.; Vogel, Robert; Glantschnig, Helmut] Merck Res Labs, Bone Biol, West Point, PA 19486 USA.
   [Euler, Danielle H.; Wessner, Keith; Adamski, Sharon; Luo, Bin; Lubbers, Laura S.] Merck Res Labs, In Vivo Pharmacol, West Point, PA 19486 USA.
C3 Merck & Company; Merck & Company; Merck & Company
RP Murphy, DJ (通讯作者)，Merck Res Labs, In Vitro Pharmacol, West Point, PA 19486 USA.
EM dennis.murphy@merck.com; mingtain_lai@merck.com
RI Lai, Ming/KQU 8970 2024
CR Copeland RA, 2013, EVALUATION OF ENZYME INHIBITORS IN DRUG DISCOVERY: A GUIDE FOR MEDICINAL CHEMISTS AND PHARMACOLOGISTS, 2ND EDITION, P1, DOI 10.1002/9781118540398
   Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082
   Copeland RA, 2011, ANAL BIOCHEM, V416, P206, DOI 10.1016/j.ab.2011.05.029
   Copeland RA, 2010, EXPERT OPIN DRUG DIS, V5, P305, DOI 10.1517/17460441003677725
   Crane SN, 2006, J MED CHEM, V49, P1066, DOI 10.1021/jm051059p
   Desmarais S, 2009, BIOL CHEM, V390, P941, DOI 10.1515/BC.2009.092
   Gabrielsson J, 2009, DRUG DISCOV TODAY, V14, P358, DOI 10.1016/j.drudis.2008.12.011
   Isabel E, 2010, BIOORG MED CHEM LETT, V20, P887, DOI 10.1016/j.bmcl.2009.12.083
   James ML, 2012, PHYSIOL REV, V92, P897, DOI 10.1152/physrev.00049.2010
   Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647 200003000 00001
   Le SY, 2008, J PHARMACOL EXP THER, V325, P902, DOI 10.1124/jpet.107.135343
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Lindström E, 2007, J PHARMACOL EXP THER, V322, P1286, DOI 10.1124/jpet.107.124958
   Lu H, 2010, CURR OPIN CHEM BIOL, V14, P467, DOI 10.1016/j.cbpa.2010.06.176
   Malany S, 2009, J RECEPT SIG TRANSD, V29, P84, DOI 10.1080/10799890902721339
   Methot N, 2008, MOL PHARMACOL, V73, P1857, DOI 10.1124/mol.108.045682
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   Ploeger BA, 2009, DRUG METAB PHARMACOK, V24, P3, DOI 10.2133/dmpk.24.3
   Robichaud J, 2003, J MED CHEM, V46, P3709, DOI 10.1021/jm0301078
   Skorey K, 2006, ANAL BIOCHEM, V349, P49, DOI 10.1016/j.ab.2005.11.018
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Tillotson B, 2010, J BIOL CHEM, V285, P39835, DOI 10.1074/jbc.M110.141580
   Weissleder R, 2008, NATURE, V452, P580, DOI 10.1038/nature06917
NR 23
TC 3
Z9 3
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002 7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 9
PY 2015
VL 137
IS 35
BP 11230
EP 11233
DI 10.1021/jacs.5b06518
PG 4
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA CR3RU
UT WOS:000361251600007
PM 26301491
DA 2025 08 17
ER

PT J
AU Luo, Z
   Wu, G
   Zhang, DY
   Liu, J
   Ran, RG
AF Luo, Zheng
   Wu, Gang
   Zhang, Daiyang
   Liu, Jun
   Ran, Renguo
TI microRNA 625 targets Yes associated protein 1 to suppress cell
   proliferation and invasion of osteosarcoma
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteosarcoma; Yes associated protein 1; microRNA 625; proliferation;
   invasion
ID POOR PROGNOSIS; DECREASED EXPRESSION; GASTRIC CANCER; METASTASIS;
   PROMOTES; MIGRATION
AB Osteosarcoma (OS) is the leading cause of cancer associated mortality in adolescents and children. MicroRNAs (miRNAs) have critical roles in cancer, particularly in the initiation and progression of OS. Therefore, OS associated miRNAs should be identified for use as therapeutic targets for treatment of OS. This study aimed to investigate the expression pattern, potential roles and underlying mechanism of microRNA 625 (miR 625) in OS. miR 625 was markedly downregulated in OS tissues and cell lines compared with that in associated adjacent non tumor tissues and human normal osteoblasts, respectively. The enforced expression of miR 625 using miRNA mimics significantly reduced the proliferation and invasion of OS cells. Bioinformatics analysis and luciferase reporter assays indicated that miR 625 targeted the 3 untranslated region of Yes associated protein 1 (YAP 1). Furthermore, upregulation of miR 625 reduced endogenous YAP1 expression at the mRNA and protein levels. The upregulated expression of YAP1 in OS tissues was inversely correlated with miR 625 expression. YAP1 restoration using a recombinant plasmid rescued the miR 625 mediated tumor suppressive effects in OS cells. In conclusion, miR 625 attenuated the cell proliferation and invasion of OS by suppressing YAP1. Thus, miR 625 may be a potential target for OS therapy.
C1 [Luo, Zheng; Zhang, Daiyang; Liu, Jun; Ran, Renguo] Cent Hosp Enshi Autonomous Prefecture, Dept Spinal Surg, Enshi 445000, Hubei, Peoples R China.
   [Wu, Gang] Cent Hosp Enshi Autonomous Prefecture, Dept Inspect, 158 Wuyang Rd, Enshi 445000, Hubei, Peoples R China.
RP Wu, G (通讯作者)，Cent Hosp Enshi Autonomous Prefecture, Dept Inspect, 158 Wuyang Rd, Enshi 445000, Hubei, Peoples R China.
EM wu1044156103@163.com
CR Bacci G, 2003, ANN ONCOL, V14, P1126, DOI 10.1093/annonc/mdg286
   Benjamin RS, 2015, LANCET ONCOL, V16, P12, DOI 10.1016/S1470 2045(14)71186 6
   Fenger JM, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2837 5
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood 2008 07 170589
   Griffiths Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Guillon MAM, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 407
   Haghikia Arash, 2012, JAKSTAT, V1, P143, DOI 10.4161/jkst.19573
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Iorio MV, 2012, CANCER J, V18, P215, DOI 10.1097/PPO.0b013e318250c001
   Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078 0432.CCR 10 2467
   Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078 0432.CCR 14 1374
   Letson G D, 2001, Cancer Control, V8, P239
   Li C, 2015, INT J CLIN EXP MED, V8, P9560
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078 0432.CCR 10 1800
   Li S, 2015, UROL ONCOL SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.06.003
   Li Z, 2015, ONCOTARGET, V6, P17559, DOI 10.18632/oncotarget.2755
   Li Z, 2015, ONCOTARGET, V6, P13914, DOI 10.18632/oncotarget.4227
   Li Z, 2015, ONCOTARGET, V6, P4562, DOI 10.18632/oncotarget.2923
   Liu H, 2015, TUMOR BIOL, V36, P6313, DOI 10.1007/s13277 015 3317 2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou XL, 2013, J SURG ONCOL, V108, P230, DOI 10.1002/jso.23380
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Orr BA, 2011, J NEUROPATH EXP NEUR, V70, P568, DOI 10.1097/NEN.0b013e31821ff8d8
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Shin JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085205
   Tu YF, 2015, SCI REP UK, V5, DOI 10.1038/srep13827
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Wang M, 2012, FEBS LETT, V586, P2382, DOI 10.1016/j.febslet.2012.05.050
   Wang ZQ, 2014, FEBS LETT, V588, P915, DOI 10.1016/j.febslet.2014.01.035
   Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040
   Yang T, 2015, TUMOR BIOL, V36, P4357, DOI 10.1007/s13277 015 3075 1
   Yang Z, 2014, ONCOL REP, V32, P1265, DOI 10.3892/or.2014.3305
   Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011
   Zhang YH, 2013, INT J IMMUNOPATH PH, V26, P157, DOI 10.1177/039463201302600115
   Zhou WB, 2016, BIOCHEM BIOPH RES CO, V470, P838, DOI 10.1016/j.bbrc.2016.01.122
   Zhou X, 2015, ONCOGENE, V34, P965, DOI 10.1038/onc.2014.35
NR 37
TC 10
Z9 10
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2018
VL 17
IS 1
BP 2005
EP 2011
DI 10.3892/mmr.2017.8079
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT8WG
UT WOS:000423433300255
PM 29257207
OA Bronze
DA 2025 08 17
ER

PT J
AU Jiang, WT
   Xu, T
   Song, ZM
   Wang, XK
   Yuan, SS
   Li, QQ
   Wei, YP
   Wang, C
   Yang, G
   Cao, J
   Mo, YQ
   Liu, ZT
   Li, N
   Li, SQ
   Lv, P
   Zhang, Y
   Wang, Y
   Hu, WJ
AF Jiang, Wenting
   Xu, Tao
   Song, Zhanming
   Wang, Xuekang
   Yuan, Shasha
   Li, Qingqing
   Wei, Yiping
   Wang, Cui
   Yang, Gang
   Cao, Jie
   Mo, Yaqian
   Liu, Zhongtian
   Li, Ning
   Li, Siqi
   Lv, Ping
   Zhang, Yu
   Wang, Ying
   Hu, Wenjie
TI CCL2 is a key regulator and therapeutic target for periodontitis
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE bindarit; CCL2; monocytes/macrophages; periodontitis; targeted therapy
ID MONOCYTE CHEMOATTRACTANT PROTEIN 1; CHEMOKINE RECEPTORS; BINDARIT;
   DIFFERENTIATION; PATHOGENESIS; INHIBITION
AB Aim: Our previous study revealed that the C C motif chemokine receptor 2 (CCR2) is a promising target for periodontitis prevention and treatment. However, CCR2 is a receptor with multiple C C motif chemokine ligands (CCLs), including CCL2, CCL7, CCL8, CCL13 and CCL16, and which of these ligands plays a key role in periodontitis remains unclear. The aim of the present study was to explore the key functional ligand of CCR2 in periodontitis and to evaluate the potential of the functional ligand as a therapeutic target for periodontitis.
   Materials and Methods: The expression levels and clinical relevance of CCR2, CCL2, CCL7, CCL8, CCL13 and CCL16 were studied using human samples. The role of CCL2 in periodontitis was evaluated by using CCL2 knockout mice and overexpressing CCL2 in the periodontium. The effect of local administration of bindarit in periodontitis was evaluated by preventive and therapeutic medication in a mouse periodontitis model. Microcomputed tomography, haematoxylin and eosin staining, tartrate resistant acid phosphatase staining, real time quantitative polymerase chain reaction, enzyme linked immunosorbent assay, bead based immunoassays and flow cytometry were used for histomorphology, molecular biology and cytology analysis.
   Results: Among different ligands of CCR2, only CCL2 was significantly up regulated in periodontitis gingival tissues and was positively correlated with the severity of periodontitis. Mice lacking CCL2 showed milder inflammation and less bone resorption than wild type mice, which was accompanied by a reduction in monocyte/ macrophage recruitment. Adeno associated virus 2 vectors overexpressing CCL2 in Ccl2( / ) mice gingiva reversed the attenuation of periodontitis in a CCR2 dependent manner. In ligation induced experimental periodontitis, preventive or therapeutic administration of bindarit, a CCL2 synthesis inhibitor, significantly inhibited the production of CCL2, decreased the osteoclast number and bone loss and reduced the expression levels of proinflammatory cytokines TNF a, IL 6 and IL 1 beta.
   Conclusions: CCL2 is a pivotal chemokine that binds to CCR2 during the progression of periodontitis, and targeting CCL2 may be a feasible option for controlling periodontitis.
C1 [Jiang, Wenting; Yuan, Shasha; Wei, Yiping; Wang, Cui; Yang, Gang; Cao, Jie; Li, Siqi; Hu, Wenjie] Peking Univ Sch & Hosp Stomatol, Dept Periodontol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Natl Engn Lab Digital &, Beijing, Peoples R China.
   [Xu, Tao] Peking Univ Sch & Hosp Stomatol, Dept Emergency, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Natl Engn Lab Digital &, Beijing, Peoples R China.
   [Song, Zhanming; Wang, Xuekang; Li, Qingqing; Mo, Yaqian; Liu, Zhongtian; Li, Ning; Lv, Ping; Zhang, Yu; Wang, Ying] Peking Univ, Dept Immunol, Sch Basic Med Sci, Beijing, Peoples R China.
   [Song, Zhanming; Wang, Xuekang; Li, Qingqing; Mo, Yaqian; Liu, Zhongtian; Li, Ning; Lv, Ping; Zhang, Yu; Wang, Ying] Peking Univ, NHC Key Lab Med Immunol, Beijing, Peoples R China.
   [Lv, Ping; Wang, Ying] Peking Univ, Ctr Human Dis Genom, Beijing, Peoples R China.
   [Hu, Wenjie] Peking Univ, NHC Res Ctr Engn & Technol Computerized Dent, Beijing, Peoples R China.
   [Wang, Ying] Peking Univ, Sch Basic Med Sci, Dept Immunol, 38,Coll Rd, Beijing, Peoples R China.
   [Wang, Ying] Peking Univ, NHC Key Lab Med Immunol, 38,Coll Rd, Beijing, Peoples R China.
   [Hu, Wenjie] Peking Univ Sch & Hosp Stomatol, Dept Periodontol, Natl Clin Res Ctr Oral Dis, Natl Engn Lab Digital & Mat Technol Stomatol,Beiji, 22,Zhongguancun South St, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Peking University; Peking University
RP Wang, Y (通讯作者)，Peking Univ, Sch Basic Med Sci, Dept Immunol, 38,Coll Rd, Beijing, Peoples R China.; Wang, Y (通讯作者)，Peking Univ, NHC Key Lab Med Immunol, 38,Coll Rd, Beijing, Peoples R China.; Hu, WJ (通讯作者)，Peking Univ Sch & Hosp Stomatol, Dept Periodontol, Natl Clin Res Ctr Oral Dis, Natl Engn Lab Digital & Mat Technol Stomatol,Beiji, 22,Zhongguancun South St, Beijing, Peoples R China.
EM yw@bjmu.edu.cn; huwenjie@pkuss.bjmu.edu.cn
RI Yang, Gang/B 2616 2008; Liu, Zhongtian/ABE 5037 2021; Cao,
   Xiaodong/D 6045 2011
OI Wei, Yiping/0000 0002 8517 3757; WANG, YING/0000 0001 5224 6692
FU Peking University Clinical Scientist Program [BMU2019LCKXJ010]; National
   Natural Science Foundation of China [81970536]; Research Foundation of
   Peking University School and Hospital of Stomatology [PKUSS20220114]
FX Peking University Clinical Scientist Program, Grant/Award Number:
   BMU2019LCKXJ010; National Natural Science Foundation of China,
   Grant/Award Number: 81970536; Research Foundation of Peking University
   School and Hospital of Stomatology, Grant/Award Number: PKUSS20220114
CR Abusleme L, 2021, PERIODONTOL 2000, V86, P57, DOI 10.1111/prd.12362
   Almubarak A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00330
   Attwood MM, 2020, NAT REV DRUG DISCOV, V19, P695, DOI 10.1038/s41573 020 0078 4
   Bhusal RP, 2020, PROTEIN SCI, V29, P420, DOI 10.1002/pro.3744
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Ble A, 2011, AM J NEPHROL, V34, P367, DOI 10.1159/000330685
   Boström EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134608
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Colombo A, 2016, EUROINTERVENTION, V12, pE1385, DOI 10.4244/EIJY15M12_03
   Festing Michael F W, 2002, ILAR J, V43, P244
   Ge SJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 171
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev immunol 032713 120145
   Gulbrandsen TR, 2021, J KNEE SURG, V34, P913, DOI 10.1055/s 0039 3402076
   Gupta M, 2013, CYTOKINE, V61, P892, DOI 10.1016/j.cyto.2012.12.012
   Hajishengallis G, 2020, PERIODONTOL 2000, V84, P14, DOI 10.1111/prd.12331
   Hughes CE, 2018, FEBS J, V285, P2944, DOI 10.1111/febs.14466
   Hyde Georgia, 2020, BJR Open, V2, P20200032, DOI 10.1259/bjro.20200032
   Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28
   Jiang WT, 2022, J CLIN PERIODONTOL, V49, P1203, DOI 10.1111/jcpe.13699
   Kinane DF., 2017, NAT REV DIS PRIM, V3, P1, DOI DOI 10.1038/NRDP.2017.38
   Kurtis B, 2005, J PERIODONTOL, V76, P1849, DOI 10.1902/jop.2005.76.11.1849
   Lira Junior R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00086
   Liu SH, 2018, ARCH IMMUNOL THER EX, V66, P221, DOI 10.1007/s00005 017 0497 z
   Ma SB, 2020, MOL BRAIN, V13, DOI 10.1186/s13041 020 00701 6
   Mirolo M, 2008, EUR CYTOKINE NETW, V19, P119, DOI 10.1684/ecn.2008.0133
   Mombelli A, 2018, PERIODONTOL 2000, V76, P85, DOI 10.1111/prd.12147
   Mora E, 2012, CELL CYCLE, V11, P159, DOI 10.4161/cc.11.1.18559
   Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49
   Pradeep AR, 2009, ARCH ORAL BIOL, V54, P503, DOI 10.1016/j.archoralbio.2009.02.007
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Seo SU, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9010
   Shen ZS, 2021, CELL MOL IMMUNOL, V18, P2224, DOI 10.1038/s41423 020 0500 1
   Shi M, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00124
   Souto FO, 2011, AM J RESP CRIT CARE, V183, P234, DOI 10.1164/rccm.201003 0416OC
   Steinberg D, 2020, PERIODONTOL 2000, V84, P176, DOI 10.1111/prd.12341
   Takeuchi T, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102884
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   White GE, 2013, PHARMACOL REV, V65, P47, DOI 10.1124/pr.111.005074
   Xu MS, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13115
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Zhang D, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.105003
   Zhao LP, 2018, CLIN IMPLANT DENT R, V20, P333, DOI 10.1111/cid.12585
   Zidar A, 2021, EXPERT OPIN DRUG DEL, V18, P1229, DOI 10.1080/17425247.2021.1908260
NR 43
TC 11
Z9 11
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD DEC
PY 2023
VL 50
IS 12
BP 1644
EP 1657
DI 10.1111/jcpe.13872
EA SEP 2023
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA Y4YF0
UT WOS:001066481200001
PM 37697486
DA 2025 08 17
ER

PT J
AU Ma, ZR
   Sun, J
   Jiang, Q
   Zhao, Y
   Jiang, HZ
   Sun, P
   Feng, W
AF Ma, Zheru
   Sun, Jing
   Jiang, Qi
   Zhao, Yao
   Jiang, Haozhuo
   Sun, Peng
   Feng, Wei
TI Identification and analysis of mitochondria related central genes in
   steroid induced osteonecrosis of the femoral head, along with drug
   prediction
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE steroid induced femoral head necrosis; weighted gene co expression
   network analysis; differentially expressed genes; mitochondrial related
   genes; immune cell infiltration; diagnostic biomarkers; bioinformatics
   analysis; DrugBank
ID OXIDATIVE STRESS; STEM CELLS; ROS; OSTEOCLASTS; MECHANISM; DAMAGE; SOD2
AB Purpose Steroid induced osteonecrosis of the femoral head (SONFH) is a refractory orthopedic hip joint disease that primarily affects middle aged and young individuals. SONFH may be caused by ischemia and hypoxia of the femoral head, where mitochondria play a crucial role in oxidative reactions. Currently, there is limited literature on whether mitochondria are involved in the progression of SONFH. Here, we aim to identify and validate key potential mitochondrial related genes in SONFH through bioinformatics analysis. This study aims to provide initial evidence that mitochondria play a role in the progression of SONFH and further elucidate the mechanisms of mitochondria in SONFH.Methods The GSE123568 mRNA expression profile dataset includes 10 non SONFH (non steroid induced osteonecrosis of the femoral head) samples and 30 SONFH samples. The GSE74089 mRNA expression profile dataset includes 4 healthy samples and 4 samples with ischemic necrosis of the femoral head. Both datasets were downloaded from the Gene Expression Omnibus (GEO) database. The mitochondrial related genes are derived from MitoCarta3.0, which includes data for all 1136 human genes with high confidence in mitochondrial localization based on integrated proteomics, computational, and microscopy approaches. By intersecting the GSE123568 and GSE74089 datasets with a set of mitochondrial related genes, we screened for mitochondrial related genes involved in SONFH. Subsequently, we used the good Samples Genes method in R language to remove outlier genes and samples in the GSE123568 dataset. We further used WGCNA to construct a scale free co expression network and selected the hub gene set with the highest connectivity. We then intersected this gene set with the previously identified mitochondrial related genes to select the genes with the highest correlation. A total of 7 mitochondrial related genes were selected. Next, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis on the selected mitochondrial related genes using R software. Furthermore, we performed protein network analysis on the differentially expressed proteins encoded by the mitochondrial genes using STRING. We used the GSEA software to group the genes within the gene set in the GSE123568 dataset based on their coordinated changes and evaluate their impact on phenotype changes. Subsequently, we grouped the samples based on the 7 selected mitochondrial related genes using R software and observed the differences in immune cell infiltration between the groups. Finally, we evaluated the prognostic significance of these features in the two datasets, consisting of a total of 48 samples, by integrating disease status and the 7 gene features using the cox method in the survival R package. We performed ROC analysis using the roc function in the pROC package and evaluated the AUC and confidence intervals using the ci function to obtain the final AUC results.Results Identification and analysis of 7 intersecting DEGs (differentially expressed genes) were obtained among peripheral blood, cartilage samples, hub genes, and mitochondrial related genes. These 7 DEGs include FTH1, LACTB, PDK3, RAB5IF, SOD2, and SQOR, all of which are upregulated genes with no intersection in the downregulated gene set.
   Subsequently, GO and KEGG pathway enrichment analysis revealed that the upregulated DEGs are primarily involved in processes such as oxidative stress, release of cytochrome C from mitochondria, negative regulation of intrinsic apoptotic signaling pathway, cell apoptosis, mitochondrial metabolism, p53 signaling pathway, and NK cell mediated cytotoxicity. GSEA also revealed enriched pathways associated with hub genes. Finally, the diagnostic value of these key genes for hormone related ischemic necrosis of the femoral head (SONFH) was confirmed using ROC curves.Conclusion BID, FTH1, LACTB, PDK3, RAB5IF, SOD2, and SQOR may serve as potential diagnostic mitochondrial related biomarkers for SONFH. Additionally, they hold research value in investigating the involvement of mitochondria in the pathogenesis of ischemic necrosis of the femoral head.
C1 [Ma, Zheru; Zhao, Yao; Jiang, Haozhuo; Sun, Peng; Feng, Wei] First Hosp Jilin Univ, Orthopaed Ctr, Dept Bone & Joint Surg, Changchun, Peoples R China.
   [Sun, Jing] First Hosp Jilin Univ, Dept Otolaryngol Head & Neck Surg, Changchun, Jilin, Peoples R China.
   [Jiang, Qi] First Hosp Jilin Univ, Dept Resp Med, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Feng, W (通讯作者)，First Hosp Jilin Univ, Orthopaed Ctr, Dept Bone & Joint Surg, Changchun, Peoples R China.
EM feng_wei@jlu.edu.cn
RI ; Sun, Peng/KDO 4243 2024
OI wang, haoyu/0009 0001 2467 5331; 
CR Abate M, 2020, SEMIN CELL DEV BIOL, V98, P139, DOI 10.1016/j.semcdb.2019.05.022
   Alam MM, 2023, REDOX BIOL, V60, DOI 10.1016/j.redox.2023.102624
   Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Arosio P, 2015, BIOCHEM J, V472, P1, DOI 10.1042/BJ20150787
   Bennett JA, 2022, PLOS BIOL, V20, DOI 10.1371/journal.pbio.3001899
   Bigarella CL, 2014, DEVELOPMENT, V141, P4206, DOI 10.1242/dev.107086
   Billen LP, 2008, ONCOGENE, V27, pS93, DOI 10.1038/onc.2009.47
   Cascone A, 2022, CELLS BASEL, V11, DOI 10.3390/cells11101703
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Chen LD, 2023, SLEEP BREATH, V27, P2069, DOI 10.1007/s11325 023 02801 8
   Chen XB, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9271595
   Chen YH, 2019, CHINESE J PHYSIOL, V62, P70, DOI 10.4103/CJP.CJP_7_19
   Cucchi D, 2017, CELL DEATH DIFFER, V24, P1137, DOI 10.1038/cdd.2017.60
   Damerau A, 2022, METAB ENG, V72, P116, DOI 10.1016/j.ymben.2022.03.006
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Fang J, 2009, ADV DRUG DELIVER REV, V61, P290, DOI 10.1016/j.addr.2009.02.005
   Flynn JM, 2013, FREE RADICAL BIO MED, V62, P4, DOI 10.1016/j.freeradbiomed.2013.05.027
   Gahl RF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.320
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gonzalez Morena JM, 2023, APOPTOSIS, V28, P186, DOI 10.1007/s10495 022 01775 4
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673 5374.2013.21.009
   Hirata H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186892
   Huang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.777697
   Jackson MR, 2015, METHOD ENZYMOL, V554, P255, DOI 10.1016/bs.mie.2014.11.037
   Jeoung NH, 2006, BIOCHEM J, V397, P417, DOI 10.1042/BJ20060125
   Jiang J, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2778 7
   Jiang L, 2022, CANCER BIOTHER RADIO, V37, P527, DOI 10.1089/cbr.2020.4052
   Ju J, 2023, J BIOMED SCI, V30, DOI 10.1186/s12929 023 00927 1
   Kim WS, 2017, FREE RADICAL BIO MED, V112, P567, DOI 10.1016/j.freeradbiomed.2017.09.001
   Kokkinopoulou I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116054
   Koo JI, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110718
   Li RJ, 2015, J HAZARD MATER, V287, P392, DOI 10.1016/j.jhazmat.2015.02.006
   Li XP, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1199751
   Liu XJ, 2023, FRONT MED LAUSANNE, V10, DOI 10.3389/fmed.2023.1181286
   Lu BY, 2023, MOL METAB, V80, DOI 10.1016/j.molmet.2024.101871
   Luo Y, 2023, MOL CARCINOGEN, V62, P907, DOI 10.1002/mc.23533
   Lv HH, 2023, FASEB J, V37, DOI 10.1096/fj.202202131RR
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Melov S, 1999, MUTAT RES DNA REPAIR, V434, P233, DOI 10.1016/S0921 8777(99)00031 2
   Meng KR, 2023, BIOMED PHARMACOTHER, V162, DOI 10.1016/j.biopha.2023.114403
   Nie ZG, 2019, MOL MED REP, V20, P401, DOI 10.3892/mmr.2019.10267
   Nie ZG, 2019, BIOCHEM BIOPH RES CO, V511, P693, DOI 10.1016/j.bbrc.2019.02.118
   Peng PJ, 2021, FEBS OPEN BIO, V11, P312, DOI 10.1002/2211 5463.13037
   Powell C, 2011, CLIN REV ALLERG IMMU, V41, P102, DOI 10.1007/s12016 010 8217 z
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Rensvold JW, 2022, NATURE, V606, P382, DOI 10.1038/s41586 022 04765 3
   Rigoulet M, 2011, ANTIOXID REDOX SIGN, V14, P459, DOI 10.1089/ars.2010.3363
   Schoppa AM, 2022, DIS MODEL MECH, V15, DOI 10.1242/dmm.049392
   Shi XY, 2023, FRONT BIOSCI LANDMRK, V28, DOI 10.31083/j.fbl2808182
   Silvestrini G, 1999, ENDOCR RES, V25, P117, DOI 10.1080/07435809909066134
   Star BS, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12030587
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474 9726.2006.00213.x
   Sun F, 2022, BIOCHEM BIOPH RES CO, V602, P149, DOI 10.1016/j.bbrc.2022.02.112
   Sun MH, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04472 6
   Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011
   Velarde MC, 2012, AGING US, V4, P3, DOI 10.18632/aging.100423
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang GJ, 2000, CLIN ORTHOP RELAT R, P295, DOI 10.1097/00003086 200001000 00030
   Wang SQ, 2020, MOL MED REP, V22, P257, DOI 10.3892/mmr.2020.11094
   Xu JY, 2019, THERANOSTICS, V9, P2999, DOI 10.7150/thno.31301
   Xue C, 2018, AM J TRANSL RES, V10, P4152
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Yao XD, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01658 y
   Younus H, 2018, INT J HEALTH SCI IJH, V12, P88
   Yu HC, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03225 1
   Zhang F, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04226 1
   Zhang F, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2238 1
   Zhang J, 2018, CANCER MED US, V7, P3351, DOI 10.1002/cam4.1576
   Zhang MJ, 2016, BIOMED REP, V5, P57, DOI 10.3892/br.2016.679
   Zhang XF, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/4540124
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhou W, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4019619
   Zhu ZH, 2011, FRONT BIOSCI LANDMRK, V16, P2747, DOI 10.2741/3883
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 76
TC 6
Z9 6
U1 5
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD FEB 7
PY 2024
VL 15
AR 1341366
DI 10.3389/fendo.2024.1341366
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA II2B3
UT WOS:001165621100001
PM 38384969
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kassahun, K
   McIntosh, I
   Koeplinger, K
   Sun, L
   Talaty, JE
   Miller, DL
   Dixon, R
   Zajic, S
   Stoch, SA
AF Kassahun, Kelem
   McIntosh, Ian
   Koeplinger, Kenneth
   Sun, Li
   Talaty, Jennifer E.
   Miller, Deborah L.
   Dixon, Russell
   Zajic, Stefan
   Stoch, S. Aubrey
TI Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in
   Humans
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; MASS SPECTROMETRY; BONE DENSITY; OSTEOPOROSIS;
   PHARMACOKINETICS; TURNOVER; MONKEYS
AB Odanacatib is a selective inhibitor of the cathepsin K enzyme that is expressed in osteoclasts involved in the degradation of bone organic matrix, and is being developed as a novel treatment of osteoporosis. Odanacatib has demonstrated increases in bone mineral density in postmenopausal women and is undergoing a pivotal phase III trial. The absorption, metabolism, and excretion of [C 14]odanacatib were studied in healthy male volunteers (n = 6) after a single oral dose of 25 mg (100 mu Ci). Plasma, urine, and fecal samples were collected at intervals up to 34 days postdose. The pharmacokinetics of odanacatib were characterized by slow absorption (mean time to achieve maximum plasma concentration of 14.2 hours) and long apparent elimination half life (mean t(1/2) 96.7 hours); 74.5% of the dose was recovered in feces and 16.9% in urine, resulting in a total recovery of 91.4%. Seven metabolites were identified in urine; the major pathway (methyl hydroxylation producing M8 and its derivatives) was largely dependent on CYP3A. Metabolites and odanacatib accounted for 77% and 23% of urinary radioactivity, respectively. In fecal extracts, the only radioactive components identified were odanacatib (60.9%) and M8 (9.5%). The fraction of odanacatib in feces derived from absorbed drug was estimated using a bioavailability value obtained from the results of a separate intravenous study. Collectively, the data indicate that odanacatib has a long t(1/2) on account of its low metabolic intrinsic clearance, and that metabolism (principally mediated by CYP3A) and excretion of intact parent compound account for similar to 70% and similar to 30% of the clearance of odanacatib in humans.
C1 [Kassahun, Kelem; McIntosh, Ian; Koeplinger, Kenneth; Sun, Li; Talaty, Jennifer E.; Zajic, Stefan] Merck Res Labs, West Point, PA 19486 USA.
   [Miller, Deborah L.; Stoch, S. Aubrey] Merck Res Labs, Rahway, NJ USA.
   [Dixon, Russell] Covance Clin Res, Madison, WI USA.
C3 Merck & Company; Merck & Company
RP Kassahun, K (通讯作者)，Merck Res Labs, Dept Drug Metab, WP75B 200,POB 4, West Point, PA 19486 USA.
EM kassahun310@comcast.net
OI Zajic, Stefan/0000 0002 9844 9951
FU Merck & Co., Inc., Whitehouse Station, NJ
FX This study was sponsored by Merck & Co., Inc., Whitehouse Station, NJ.
   Editorial assistance was provided by Gary Dever, Ph.D., of Complete
   Medical Communications, Parsippany, NJ. This assistance was funded by
   Merck & Co., Inc., Whitehouse Station, NJ.
CR Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Compston J, 2010, RADIOL CLIN N AM, V48, P477, DOI 10.1016/j.rcl.2010.02.010
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gu JK, 1999, FRESEN J ANAL CHEM, V365, P553, DOI 10.1007/s002160051521
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Iki Masayuki, 2012, Clin Calcium, V22, P797, DOI CliCa1206797803
   Kassahun K, 2011, DRUG METAB DISPOS, V39, P1079, DOI 10.1124/dmd.110.037184
   KRIMMER HP, 1987, CHEM ZTG, V111, P357
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Stoch SA, 2013, J POPUL THER CLIN PH, V20, pE312
   Stoch SA, 2013, INT J CLIN PHARM TH, V51, P688, DOI 10.5414/CP201864
   Stoch SA, 2013, BRIT J CLIN PHARMACO, V75, P1240, DOI 10.1111/j.1365 2125.2012.04471.x
   Sun L, 2012, J CHROMATOGR B, V885, P15, DOI 10.1016/j.jchromb.2011.12.004
NR 20
TC 28
Z9 29
U1 0
U2 6
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0090 9556
EI 1521 009X
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD MAY
PY 2014
VL 42
IS 5
BP 818
EP 827
DI 10.1124/dmd.113.056580
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AE9VV
UT WOS:000334360200002
PM 24553380
DA 2025 08 17
ER

PT J
AU Torii, D
   Kobayashi, T
   Horie, T
   Tsutsui, TW
AF Torii, Daisuke
   Kobayashi, Tomoko
   Horie, Tetsuro
   Tsutsui, Takeo W.
TI Characterization of dental pulp stem cells isolated from a patient
   diagnosed with Crouzon syndrome
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE Crouzon syndrome; dental pulp stem cells; fibroblast growth factor
   receptor 2; mitogen&#8208; activated protein kinase; osteocalcin
ID GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE C; MUTATION; FGFR2; GENE;
   DIFFERENTIATION; OSTEOBLASTS; ACTIVATION; EXPRESSION; BONE
AB Stem cells isolated from patients with rare diseases are important to elucidate their pathogeny and mechanisms to enable regenerative therapy. However, the mechanisms underlying tissue regeneration using patient derived dental pulp stem cells (DPSCs) are unclear. In this study, we investigated the levels of mRNA and protein expression related to cellular differentiation of Crouzon syndrome patient derived DPSCs (CS DPSCs) with a Gly338Arg fibroblast growth factor receptor 2 mutation. Multipotency related gene expression levels were equivalent in both healthy donor DPSCs and CS DPSCs. CS DPSCs showed higher osteocalcin (OCN) expression than healthy donor DPSCs. CS DPSCs showed a lower increase in the rate of OCN expression among phorbol 12 myristate 13 acetate (PMA) treated cells than healthy donor DPSCs compared with untreated control cells. CS DPSCs showed a lower phosphorylation rate of p38 and p44/42 in PMA treated cells than healthy donor DPSCs compared with untreated control cells. These results demonstrate that CS DPSCs have higher OCN expression and lower PMA stimulation responsiveness than healthy donor DPSCs.
C1 [Torii, Daisuke; Tsutsui, Takeo W.] Nippon Dent Univ Tokyo, Sch Life Dent, Dept Pharmacol, Tokyo, Japan.
   [Kobayashi, Tomoko; Horie, Tetsuro] Nippon Dent Univ Tokyo, Sch Life Dent, Res Ctr Odontol, Tokyo, Japan.
   [Kobayashi, Tomoko] Nippon Dent Univ Tokyo, Sch Life Dent, Dept Dev & Regenerat Dent, Tokyo, Japan.
   [Horie, Tetsuro] Nippon Dent Univ Tokyo, Sch Life Dent, Dept Oral Hlth, Tokyo, Japan.
C3 Nippon Dental University; Nippon Dental University; Nippon Dental
   University; Nippon Dental University
RP Tsutsui, TW (通讯作者)，Nippon Dent Univ Tokyo, Sch Life Dent, Dept Pharmacol, Chiyoda Ku, 1 9 20 Fujimi, Tokyo 1028159, Japan.
EM ryuryu@tky.ndu.ac.jp
RI ; , 堀江哲郎/AAV 2371 2020; Tsutsui, Takeo/ABB 4046 2020; Torii,
   Daisuke/AAV 3019 2020; Kobayashi, Tomoko/AAV 2007 2020
OI Torii, Daisuke/0000 0001 7411 2556; Horie, Tetsuro/0000 0002 6713 6725; 
FU Japan Society for the Promotion of Science [18K09626]; Grants in Aid for
   Scientific Research [18K09626] Funding Source: KAKEN
FX Japan Society for the Promotion of Science, Grant/Award Number:
   Scientific Research (C) Number 18K09626
CR Azoury SC, 2017, INT J BIOL SCI, V13, P1479, DOI 10.7150/ijbs.22373
   Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999
   Cheung WMW, 2006, FEBS LETT, V580, P121, DOI 10.1016/j.febslet.2005.11.062
   De Ravin SS, 2016, NAT BIOTECHNOL, V34, P424, DOI 10.1038/nbt.3513
   Dessels C, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00115
   Fan J.R., 2018, ACAD J PEOPLES PUBLI, V1, P19
   Fang TJ, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 6001 9
   Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002 9440(10)65401 6
   GORRY MC, 1995, HUM MOL GENET, V4, P1387, DOI 10.1093/hmg/4.8.1387
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Guenou H, 2005, HUM MOL GENET, V14, P1429, DOI 10.1093/hmg/ddi152
   Kan S, 2002, AM J HUM GENET, V70, P472, DOI 10.1086/338758
   Keller MD, 2018, J PEDIAT INF DIS SOC, V7, pS40, DOI 10.1093/jpids/piy011
   Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611
   Le Blanc K, 2005, TRANSPLANTATION, V79, P1607, DOI 10.1097/01.TP.0000159029.48678.93
   Lee KKL, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035311
   Lemonnier J, 2001, J BONE MINER RES, V16, P832, DOI 10.1359/jbmr.2001.16.5.832
   Lemonnier J, 2000, EXP CELL RES, V256, P158, DOI 10.1006/excr.2000.4820
   Liu J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/292506
   Liu J, 2013, CALCIFIED TISSUE INT, V92, P451, DOI 10.1007/s00223 013 9701 2
   Lomri A, 2001, J BONE MINER RES, V16, P705, DOI 10.1359/jbmr.2001.16.4.705
   Luo FT, 2018, MOL THER NUCL ACIDS, V13, P291, DOI 10.1016/j.omtn.2018.09.012
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Matsui M, 2018, HUM CELL, V31, P127, DOI 10.1007/s13577 017 0198 2
   Morita J, 2014, DEV DYNAM, V243, P560, DOI 10.1002/dvdy.24099
   Pfaff MJ, 2016, DEV BIOL, V415, P242, DOI 10.1016/j.ydbio.2016.03.026
   Sethi A, 2011, INVEST OPHTH VIS SCI, V52, P5251, DOI 10.1167/iovs.11 7587
   Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601 6343.2005.00331.x
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Shih IM, 1998, J CELL SCI, V111, P2655
   Suzuki H, 2012, J CELL PHYSIOL, V227, P3267, DOI 10.1002/jcp.24021
   Tan SM, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm704
   Zhang YZ, 1999, GENE, V230, P69, DOI 10.1016/S0378 1119(99)00047 5
NR 34
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2021
VL 236
IS 7
BP 5317
EP 5324
DI 10.1002/jcp.30241
EA JAN 2021
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA RI3KP
UT WOS:000604032200001
PM 33386632
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Lo, JC
   Hui, RL
   Grimsrud, CD
   Chandra, M
   Neugebauer, RS
   Gonzalez, JR
   Budayr, A
   Lau, G
   Ettinger, B
AF Lo, Joan C.
   Hui, Rita L.
   Grimsrud, Christopher D.
   Chandra, Malini
   Neugebauer, Romain S.
   Gonzalez, Joel R.
   Budayr, Amer
   Lau, Gene
   Ettinger, Bruce
TI The association of race/ethnicity and risk of atypical femur fracture
   among older women receiving oral bisphosphonate therapy
SO BONE
LA English
DT Article
DE Femur fracture; Subtrochanter; Femoral shaft; Atypical fracture;
   Bisphosphonates
ID FEMORAL FRACTURES; HIP
AB Purpose: Several epidemiologic studies suggest that compared to white women, Asians have a greater propensity to suffer an atypical femur fracture (AFF) while taking bisphosphonate therapy. This study examines the relative risk of AFF following bisphosphonate initiation for Asian compared to white women.
   Methods: Using data from a large integrated northern California healthcare delivery system, we examined diaphyseal femur fracture outcomes among women age >= 50 years old who initiated oral bisphosphonate therapy during 2002 2007. An AFF was defined by the 2013 American Society of Bone and Mineral Research Task Force criteria. The risk of radiographically confirmed AFF was examined for Asian compared to white women, adjusting for differences in bisphosphonate exposure and other potential risk factors.
   Results: Among 48,390 women (65.3% white, 17.1% Asian) who newly initiated bisphosphonate therapy and were followed for a median of 7.7 years, 68 women experienced an AFF. The rate of AFF was 18.7 per 100,000 person years overall and eight fold higher among Asian compared to white women (64.2 versus 7.6 per 100,000 person years). Asians were also more likely to have longer bisphosphonate treatment duration compared to whites (median 3.8 versus 2.7 years). The age adjusted relative hazard for AFF was 8.5 (95% confidence interval 4.9 14.9) comparing Asian to white women, and was only modestly reduced to 6.6 (3.7 11.5) after adjusting for bisphosphonate duration and current use.
   Conclusions: Our study confirms marked racial disparity in AFF risk that should be further investigated, particularly the mechanisms accounting for this difference. These findings also underscore the need to further examine the association of bisphosphonate duration and AFF in women of Asian race, as well as differential risk across Asian subgroups. In the interim, counseling of Asian women about osteoporosis drug continuation should include consideration of their potentially higher AFF risk. (C) 2016 Published by Elsevier Inc.
C1 [Lo, Joan C.; Chandra, Malini; Neugebauer, Romain S.; Gonzalez, Joel R.; Ettinger, Bruce] Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
   [Lo, Joan C.; Budayr, Amer] Kaiser Permanente Oakland Med Ctr, Dept Med, Oakland, CA USA.
   [Hui, Rita L.] Kaiser Permanente Calif, Pharm Outcomes Res Grp, Oakland, CA USA.
   [Grimsrud, Christopher D.] Kaiser Permanente Oakland Med Ctr, Dept Orthoped Surg, Oakland, CA USA.
   [Lau, Gene] Kaiser Permanente San Francisco Med Ctr, Dept Med, Oakland, CA USA.
   [Ettinger, Bruce] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
C3 Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser
   Permanente; University of California System; University of California
   San Francisco
RP Lo, JC (通讯作者)，Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM Joan.C.Lo@kp.org
OI Gonzalez, Joel/0000 0002 1859 6856
FU Kaiser Permanente Community Benefit Program; National Institutes of
   Health [1R01AG047230 01 A1]
FX The authors would like to acknowledge Drs. Patricia Zheng and Maureen
   Baur for their assistance with data collection. This study was supported
   by a grant from the Kaiser Permanente Community Benefit Program and in
   part by a grant from the National Institutes of Health, 1R01AG047230 01
   A1. The opinions expressed in this publication are solely the
   responsibility of the authors and do not represent the official views of
   Kaiser Permanente or the National Institutes of Health.
CR Chen LP, 2014, CALCIFIED TISSUE INT, V95, P240, DOI 10.1007/s00223 014 9887 y
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Gordon N.P., 2011, INTERNAL REPORT
   Hoeffel E.M., 2012, The Asian Population: 2010. 2010 Census Briefs
   Kang JS, 2014, INT ORTHOP, V38, P1247, DOI 10.1007/s00264 013 2259 9
   Koh JSB, 2011, SINGAP MED J, V52, P77
   Lo JC, 2014, OSTEOPOROSIS INT, V25, P2313, DOI 10.1007/s00198 014 2750 1
   Lo JC, 2012, BONE, V51, P181, DOI 10.1016/j.bone.2012.02.632
   Marcano A, 2014, CLIN ORTHOP RELAT R, V472, P1020, DOI 10.1007/s11999 013 3352 5
   Martelli S, 2014, CLIN BIOMECH, V29, P869, DOI 10.1016/j.clinbiomech.2014.08.001
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Ng AC, 2014, CURR OSTEOPOROS REP, V12, P65, DOI 10.1007/s11914 014 0198 z
   Orimo Hajime, 2012, Arch Osteoporos, V7, P3
   Saita Y, 2015, J BONE MINER METAB, V33, P311, DOI 10.1007/s00774 014 0591 9
   Saita Y, 2014, BONE, V66, P105, DOI 10.1016/j.bone.2014.06.008
   Sasaki S, 2012, J BONE MINER METAB, V30, P561, DOI 10.1007/s00774 012 0358 0
   Schilcher J, 2015, ACTA ORTHOP, V86, P100, DOI 10.3109/17453674.2015.1004149
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Taormina DP, 2014, BONE, V63, P1, DOI 10.1016/j.bone.2014.02.006
   U.S. Census Bureau, 2010, 2010 CENS SUMM FIL 1
   Unnanuntana Aasis, 2013, J Bone Joint Surg Am, V95, P1, DOI 10.2106/JBJS.L.00568
NR 23
TC 85
Z9 90
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2016
VL 85
BP 142
EP 147
DI 10.1016/j.bone.2016.01.002
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DH4QJ
UT WOS:000372770200019
PM 26769007
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Dereka, XE
   Markopoulou, CE
   Fanourakis, G
   Tseleni Balafouta, S
   Vrotsos, IA
AF Dereka, Xanthippi E.
   Markopoulou, Cleopatra E.
   Fanourakis, Galinos
   Tseleni Balafouta, Sofia
   Vrotsos, Ioannis A.
TI RANKL and OPG mRNA Level after Non Surgical Periodontal Treatment
SO INFLAMMATION
LA English
DT Article
DE RANKL; OPG; periodontitis; non surgical periodontal treatment
ID KAPPA B LIGAND; GINGIVAL CREVICULAR FLUID; ALVEOLAR BONE DESTRUCTION;
   RECEPTOR ACTIVATOR; OSTEOPROTEGERIN LIGAND; OSTEOCLAST DIFFERENTIATION;
   EXPRESSION; DISEASE; MECHANISMS; CYTOKINE
AB Recent research evidence shows that the receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) play an important role in osteoclastogenesis and the inflammatory bone loss during periodontitis. Bone remodeling process is dependent on the balance of these two proteins while a high ratio of RANKL/OPG characterizes the increased osteolytic process and it has been reported in inflammatory diseases including the periodontal disease. The purpose of this study was to determine the OPG and RANKL mRNA levels in periodontal tissues derived from patients with advanced chronic periodontitis after non surgical periodontal therapy (SRP) and to compare the RANKL/OPG ration with that in healthy persons. Gingival biopsies were obtained from subjects with clinically healthy periodontium (H) (N = 11) and patients with advanced chronic periodontitis (CP) (N = 14). Total RNA was isolated from the gingival samples and 1 mu g RNA was reverse transcribed to cDNA, followed by polymerase chain reaction (PCR) using specific primers for OPG and RANKL. The efficiency of reverse transcription was verified by the amplification of the GAPDH gene. The intensity of RT PCR products was analyzed by a densitometer and was normalized to the intensity of the band for the housekeeping gene GAPDH. Immunohistochemical evaluation of the RANKL and OPG expression was also performed. The expression of RANKL as well as of OPG was reduced in CP specimens in comparison to that of healthy persons in a statistical significant way. However, the RANKL/OPG ratio showed to be slightly elevated in CP compared to H specimens but this finding was not of statistical significance. The immunohistochemical analysis revealed a non uniform expression pattern for both proteins. Although further investigation is needed to identify the specific role of RANKL and OPG protein in periodontitis progression, our data after SRP might indicate the possible involvement of these proteins in the activation of pathways, which regulate the repair of the periodontal tissues.
C1 [Dereka, Xanthippi E.; Markopoulou, Cleopatra E.; Vrotsos, Ioannis A.] Univ Athens, Dept Periodontol, Sch Dent, Athens 11527, Greece.
   [Fanourakis, Galinos] Univ Athens, DDS, Athens 11527, Greece.
   [Tseleni Balafouta, Sofia] Univ Athens, Dept Oral Pathol & Med, Sch Dent, Athens 11527, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; National & Kapodistrian University of Athens
RP Dereka, XE (通讯作者)，Univ Athens, Dept Periodontol, Sch Dent, 2 Thivon Str, Athens 11527, Greece.
EM dereka@otenet.gr
OI TSELENI BALAFOUTA, SOFIA/0000 0002 1772 406X; Fanourakis,
   Galinos/0000 0003 3866 0429
CR Anandarajah AP, 2006, J CELL BIOCHEM, V97, P226, DOI 10.1002/jcb.20674
   Belibasakis GN, 2005, INFECT IMMUN, V73, P342, DOI 10.1128/IAI.73.1.342 351.2005
   Bostanci N, 2007, J PERIODONTAL RES, V42, P287, DOI 10.1111/j.1600 0765.2006.00946.x
   Bostanci N, 2007, J CLIN PERIODONTOL, V34, P370, DOI 10.1111/j.1600 051X.2007.01061.x
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Buduneli N, 2009, J PERIODONTOL, V80, P1274, DOI 10.1902/jop.2009.090106
   Chen R, 2008, J PERIODONTAL RES, V43, P237, DOI 10.1111/j.1600 0765.2007.01021.x
   Cobb CM, 2002, J CLIN PERIODONTOL, V29, P6
   Crotti T, 2003, J PERIODONTAL RES, V38, P380, DOI 10.1034/j.1600 0765.2003.00615.x
   Garlet GP, 2004, J CLIN PERIODONTOL, V31, P671, DOI 10.1111/j.1600 051X.2004.00545.x
   GRAHAM LS, 2009, CLIN IMMUNOLOGY
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu D, 2003, INT J MOL MED, V11, P17
   Lu HK, 2006, J PERIODONTAL RES, V41, P354, DOI 10.1111/j.1600 0765.2006.00883.x
   Mogi M, 2004, J DENT RES, V83, P166, DOI 10.1177/154405910408300216
   Puiu L, 2003, CANCER LETT, V194, P91, DOI 10.1016/S0304 3835(03)00049 1
   Reddi D, 2008, MICROBES INFECT, V10, P1459, DOI 10.1016/j.micinf.2008.08.007
   Schwartz Z, 1997, PERIODONTOL 2000, V14, P158, DOI 10.1111/j.1600 0757.1997.tb00196.x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Taubman MA, 2007, J CLIN PERIODONTOL, V34, P367, DOI 10.1111/j.1600 051X.2007.01065.x
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Wara aswapati N, 2007, J PERIODONTOL, V78, P1062, DOI 10.1902/jop.2007.060398
NR 24
TC 21
Z9 25
U1 0
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360 3997
J9 INFLAMMATION
JI Inflammation
PD JUN
PY 2010
VL 33
IS 3
BP 200
EP 206
DI 10.1007/s10753 009 9174 7
PG 7
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA 585ZV
UT WOS:000276870900008
PM 20033478
DA 2025 08 17
ER

PT J
AU Hochheuser, C
   van Zogchel, LMJ
   Kleijer, M
   Kuijk, C
   Tol, S
   van der Schoot, CE
   Voermans, C
   Tytgat, GAM
   Timmerman, I
AF Hochheuser, Caroline
   van Zogchel, Lieke M. J.
   Kleijer, Marion
   Kuijk, Carlijn
   Tol, Simon
   van der Schoot, C. Ellen
   Voermans, Carlijn
   Tytgat, Godelieve A. M.
   Timmerman, Ilse
TI The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and
   Function of Mesenchymal Stromal Cells
SO CANCERS
LA English
DT Article
DE neuroblastoma; mesenchymal stromal cell; bone marrow; microenvironment;
   metastasis
ID MINIMAL RESIDUAL DISEASE; STEM CELLS; CHEMOTHERAPY; MARKER;
   PROLIFERATION; TRANSITION; RESISTANCE; EXPRESSION; PREDICTOR; CHILDREN
AB Simple Summary
   Patients with metastatic neuroblastoma are at risk for relapse after conventional therapy. It is believed that residual neuroblastoma cells in the bone marrow (BM) are responsible for this process after becoming resistant to chemotherapy. Studies in various tumor types suggest that cells in the BM environment (specifically the so called mesenchymal stromal cells (MSCs)) can promote survival and chemoresistance of tumor cells. We characterized the MSC compartment within the BM of patients with neuroblastoma, with and without metastases. Our data indicate that the quantity and functionality of the MSC population is altered in the presence of tumor cells. We furthermore identify a specific MSC subpopulation which is exclusively detected in the presence of tumor cells. These data contribute to the understanding of the interactions between neuroblastoma cells and the environment, which is essential in order to target the tumor cells in the BM more effectively, thereby improving therapy success and preventing relapse.
   Background: The bone marrow (BM) is the main site of metastases and relapse in patients with neuroblastoma (NB). BM residing mesenchymal stromal cells (MSCs) were shown to promote tumor cell survival and chemoresistance. Here we characterize the MSC compartment of the metastatic NB BM niche. Methods: Fresh BM of 62 NB patients (all stages), and control fetal and adult BM were studied by flow cytometry using well established MSC markers (CD34 , CD45 , CD90+, CD105+), and CD146 and CD271 subtype markers. FACS sorted BM MSCs and tumor cells were validated by qPCR. Moreover, isolated MSCs were tested for multilineage differentiation and Colony forming unit fibroblasts (CFU Fs) capacity. Results: Metastatic BM contains a higher number of MSCs (p < 0.05) with increased differentiation capacity towards the osteoblast lineage. Diagnostic BM contains a MSC subtype (CD146+CD271 ), only detected in BM of patients with metastatic NB, determined by flow cytometry. FACS sorting clearly discriminated MSC( subtypes) and NB fractions, validated by mRNA and DNA qPCR. Overall, the CD146+CD271  subtype decreased during therapy and was detected again in the majority of patients at relapse. Conclusions: We demonstrate that the neuroblastoma BM MSC compartment is different in quantity and functionality and contains a metastatic niche specific MSC subtype. Ultimately, the MSCs contribution to tumor progression could provide targets with potential for eradicating resistant metastatic disease.
C1 [Hochheuser, Caroline; Kleijer, Marion; Kuijk, Carlijn; Voermans, Carlijn; Tytgat, Godelieve A. M.; Timmerman, Ilse] Univ Amsterdam, Sanquin Res & Landsteiner Lab, Dept Hematopoiesis, Amsterdam UMC, NL 1066 CX Amsterdam, Netherlands.
   [Hochheuser, Caroline; van Zogchel, Lieke M. J.; Tytgat, Godelieve A. M.; Timmerman, Ilse] Princess Maxima Ctr Pediat Oncol, Dept Pediat Oncol, NL 3584 CS Utrecht, Netherlands.
   [van Zogchel, Lieke M. J.; van der Schoot, C. Ellen] Univ Amsterdam, Amsterdam UMC, Dept Expt Immunohematol, Sanquin Res & Landsteiner Lab, NL 1066 CX Amsterdam, Netherlands.
   [Tol, Simon] Univ Amsterdam, Amsterdam UMC, Dept Mol & Cellular Hemostasis, Sanquin Res & Landsteiner Lab, NL 1066 CX Amsterdam, Netherlands.
C3 University of Amsterdam; Princess Maxima Center; University of
   Amsterdam; University of Amsterdam
RP Timmerman, I (通讯作者)，Univ Amsterdam, Sanquin Res & Landsteiner Lab, Dept Hematopoiesis, Amsterdam UMC, NL 1066 CX Amsterdam, Netherlands.; Timmerman, I (通讯作者)，Princess Maxima Ctr Pediat Oncol, Dept Pediat Oncol, NL 3584 CS Utrecht, Netherlands.
EM c.h.hochheuser@prinsesmaximacentrum.nl;
   L.M.J.vanZogchel@prinsesmaximacentrum.nl; m.kleijer@sanquin.nl;
   c.kuijk@sanquin.nl; s.tol@sanquin.nl; e.vanderschoot@sanquin.nl;
   c.voermans@sanquin.nl; g.a.m.tytgat@prinsesmaximacentrum.nl;
   I.Timmerman@sanquin.nl
RI ; Voermans, Carlijn/GPP 3405 2022; tytgat, g/ABF 6481 2020
OI Tytgat, Lieve/0000 0003 4452 0748; van Zogchel,
   Lieke/0000 0003 3557 7195; Hochheuser, Caroline/0000 0002 2672 6980
FU Stichting Kinderen Kankervrij [303]; Landsteiner Foundation for Blood
   Transfusion Research (LSBR) [F1101]; Koningin Wilhelmina Fund; KWF
   Kankerbestrijding TRANSCAN [8352/TRS 2018 00000715]; Prinses Maxima
   Center [P0104]
FX This research was funded by Stichting Kinderen Kankervrij, grant number
   303 (I.T.); Landsteiner Foundation for Blood Transfusion Research
   (LSBR), grant number F1101 (I.T. and C.V.); Liquidhope, a TranScan 2
   project by Koningin Wilhelmina Fund, KWF Kankerbestrijding TRANSCAN
   8352/TRS 2018 00000715 (L.M.J.v.Z); Prinses Maxima Center grant P0104
   (G.A.M.T., C.H.)
CR [Anonymous], **NON TRADITIONAL**
   Ara T, 2013, CANCER RES, V73, P3852, DOI 10.1158/0008 5472.CAN 12 2353
   Baglio SR, 2017, CLIN CANCER RES, V23, P3721, DOI 10.1158/1078 0432.CCR 16 2726
   Bate Eya LT, 2014, EUR J CANCER, V50, P628, DOI 10.1016/j.ejca.2013.11.015
   Battula VL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90036
   Berthold F, 2020, ANN ONCOL, V31, P422, DOI 10.1016/j.annonc.2019.11.011
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Bliss SA, 2016, CANCER RES, V76, P5832, DOI 10.1158/0008 5472.CAN 16 1092
   Borriello L, 2017, CANCER RES, V77, P5142, DOI 10.1158/0008 5472.CAN 16 2586
   Bozzi F, 2008, ANTICANCER RES, V28, P1565
   Bühring HJ, 2009, ANN NY ACAD SCI, V1176, P124, DOI 10.1111/j.1749 6632.2009.04564.x
   Burchill SA, 2017, CANCER AM CANCER SOC, V123, P1095, DOI 10.1002/cncr.30380
   Cheung NKV, 2015, J CLIN ONCOL, V33, P755, DOI 10.1200/JCO.2014.57.6777
   Conforti A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076989
   Cordeiro Spinetti E, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00007
   Correa D, 2016, INT J CANCER, V138, P417, DOI 10.1002/ijc.29709
   Debruyne DN, 2016, ONCOGENE, V35, P3681, DOI 10.1038/onc.2015.434
   Desbourdes L, 2017, STEM CELLS DEV, V26, P709, DOI 10.1089/scd.2016.0295
   Domenech J, 1998, LEUKEMIA LYMPHOMA, V29, P533, DOI 10.3109/10428199809050913
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Forest A.E., 2013, MADAME CURIE BIOSCIE
   FRIED W, 1976, EXP HEMATOL, V4, P310
   Guo J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0545 6
   HaDuong JH, 2015, INT J CANCER, V137, P797, DOI 10.1002/ijc.29465
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Kamga PT, 2016, ONCOTARGET, V7, P21713, DOI 10.18632/oncotarget.7964
   Kamran N, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1408750
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Korn C, 2017, BLOOD, V129, P811, DOI 10.1182/blood 2016 09 670224
   Kraal KCJM, 2019, CLIN CANCER RES, V25, P1012, DOI 10.1158/1078 0432.CCR 18 1904
   Kucerova L, 2015, CANCER MICROENVIRON, V8, P1, DOI 10.1007/s12307 014 0151 9
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Lifshitz V, 2017, MOL CANCER THER, V16, P2516, DOI 10.1158/1535 7163.MCT 17 0379
   Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585 005 0056 6
   Maijenburg MW, 2012, HAEMATOL HEMATOL J, V97, P179, DOI 10.3324/haematol.2011.047753
   Maijenburg MW, 2010, BRIT J HAEMATOL, V148, P428, DOI 10.1111/j.1365 2141.2009.07960.x
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Méhes G, 2001, CLIN CANCER RES, V7, P1969
   Nakata R, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1332941
   Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011
   Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648
   Piskareva O, 2015, CANCER LETT, V364, P142, DOI 10.1016/j.canlet.2015.05.004
   Prata KD, 2010, EXP HEMATOL, V38, P292, DOI 10.1016/j.exphem.2010.01.006
   Price TT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4059
   Reagan MR, 2016, NAT REV RHEUMATOL, V12, P154, DOI 10.1038/nrrheum.2015.160
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Schelker RC, 2018, HEMATOLOGY, V23, P337, DOI 10.1080/10245332.2017.1402455
   Schiano C, 2012, MED ONCOL, V29, P2998, DOI 10.1007/s12032 012 0158 3
   SEEGER RC, 1982, J IMMUNOL, V128, P983
   Seeger RC, 2000, J CLIN ONCOL, V18, P4067, DOI 10.1200/JCO.2000.18.24.4067
   Shankar V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120069
   Shiozawa Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.57
   Silverman AM, 2012, CANCER RES, V72, P2228, DOI 10.1158/0008 5472.CAN 11 2165
   Somaiah C, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0407 7
   Stutterheim J, 2012, CLIN CANCER RES, V18, P808, DOI 10.1158/1078 0432.CCR 11 0849
   Stutterheim J, 2008, J CLIN ONCOL, V26, P5443, DOI 10.1200/JCO.2007.13.6531
   Stutterheim J, 2009, CLIN CHEM, V55, P1316, DOI 10.1373/clinchem.2008.117945
   Tormin A, 2011, BLOOD, V117, P5067, DOI 10.1182/blood 2010 08 304287
   van Groningen T, 2017, NAT GENET, V49, P1261, DOI 10.1038/ng.3899
   van Nes J, 2013, CLIN CANCER RES, V19, P3485, DOI 10.1158/1078 0432.CCR 12 3021
   van Wezel EM, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00413
   Van Zogchel L.M.J., 2018, P ADV NEUR RES ASS M
   Viprey VF, 2014, J CLIN ONCOL, V32, P1074, DOI 10.1200/JCO.2013.53.3604
   Wessely A, 2019, FASEB J, V33, P11884, DOI 10.1096/fj.201900925R
   Wu HW, 2019, CLIN CANCER RES, V25, P4761, DOI 10.1158/1078 0432.CCR 18 3358
NR 66
TC 18
Z9 19
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD NOV
PY 2020
VL 12
IS 11
AR 3231
DI 10.3390/cancers12113231
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OW5HZ
UT WOS:000592918800001
PM 33147765
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chan, WH
   Wu, HY
   Chang, WH
AF Chan, Wen Hsiung
   Wu, Hsiao Yun
   Chang, Walter H.
TI Dosage effects of curcumin on cell death types in a human osteoblast
   cell line
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE curcumin; apoptosis; necrosis; oxidative stress; ATP levels
ID CARCINOMA A431 CELLS; INDUCED OXIDATIVE STRESS; HUMAN BREAST CANCER;
   N TERMINAL KINASE; AK 5 TUMOR CELLS; INDUCED APOPTOSIS; CYTOCHROME C;
   PHOTODYNAMIC THERAPY; MEDIATED APOPTOSIS; HYDROGEN PEROXIDE
AB Curcumin, the yellow pigment of Curcuma longa, is known to have antioxidant and anti inflammatory properties, as well as their ability to either induce or prevent cell apoptosis. However, the precise molecular mechanisms of these effects are unknown. Here, we demonstrate that curcumin can induce apoptotic changes, including JNK activation, caspase 3 activation, and cleavage of PARP and PAK2, at treatment concentrations lower than 25 mu M in human osteoblast cells. In contrast, treatment with 50 200 mu M of curcumin does not induce apoptosis, but rather triggers necrotic cell death in human osteoblasts. Using the cell permeable dye 2',7' dichlorofluorescin diacetate (DCF DA) as an indicator of reactive oxygen species (ROS) generation, we found that while treatment with 12.525 mu M curcumin directly increased intracellular oxidative stress, 50 200 mu M curcumin had far less effect. Pretreatment of cells with N acetyl cysteine or alpha tocopherol, two well known ROS scavengers, attenuated the intracellular ROS levels increases and converted the apoptosis to necrosis induced by 12.5 25 mu M curcumin. Moreover, we observed a dose dependent decrease in intracellular ATP levels after treatment of osteoblast cells with curcumin and pretreatment of cells with antimycin or 2 deoxyglucose to cause ATP depletion significantly converted 12.5 25 mu M curcumin induced apoptosis to necrosis, indicating that ATP (a known mediator of apoptotic versus necrotic death) is most likely involved in the switching mechanism. Overall, our results signify that curcumin dosage treatment determines the possible effect on ROS generation, intracellular ATP levels, and cell apoptosis or necrosis in osteoblast cells. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Chung Yuan Christian Univ, Dept Biomed Engn, Bone Tissue Engn Res Ctr, Chungli 32023, Taiwan.
   Chung Yuan Christian Univ, Coll Biosci Technol, Chungli 32023, Taiwan.
   Chung Yuan Christian Univ, Ctr Nanotechnol, Chungli 32023, Taiwan.
C3 Chung Yuan Christian University; Chung Yuan Christian University; Chung
   Yuan Christian University
RP Chang, WH (通讯作者)，Chung Yuan Christian Univ, Dept Biomed Engn, Bone Tissue Engn Res Ctr, Chungli 32023, Taiwan.
EM whchang@cycu.edu.tw
RI ; Chang, Wen Hao/C 4906 2013
OI /0000 0003 3636 5506; Chang, Wen Hao/0000 0003 4880 6006
CR ALDER V, 1995, J BIOL CHEM, V270, P26071
   ALISON MR, 1994, GUT, V35, P577, DOI 10.1136/gut.35.5.577
   Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143
   Barthelemy S, 1998, RES VIROLOGY, V149, P43, DOI 10.1016/S0923 2516(97)86899 9
   BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092 8674(94)90131 7
   Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014 5793(99)00969 2
   BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162
   Bush RL, 2001, J ENDOVASC THER, V8, P53, DOI 10.1583/1545 1550(2001)008<0053:ESPACE>2.0.CO;2
   BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167 5699(94)90018 3
   Chan WH, 2000, BIOCHEM J, V351, P221, DOI 10.1042/0264 6021:3510221
   Chan WH, 2003, J CELL BIOCHEM, V90, P327, DOI 10.1002/jcb.10638
   Chan WH, 2004, J CELL BIOCHEM, V92, P200, DOI 10.1002/jcb.20059
   Chan WH, 1999, J CELL PHYSIOL, V178, P397, DOI 10.1002/(SICI)1097 4652(199903)178:3<397::AID JCP14>3.3.CO;2 U
   Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014 5793(02)02292 5
   Chung JY, 2002, ONCOGENE, V21, P1539, DOI 10.1038/sj.onc.1205023
   Eguchi Y, 1997, CANCER RES, V57, P1835
   Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0
   Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097 4652(200001)182:1<41::AID JCP5>3.0.CO;2 7
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014 5793(97)01068 5
   Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273
   Hsuuw YD, 2005, J CELL PHYSIOL, V205, P379, DOI 10.1002/jcp.20408
   HUANG MT, 1994, CANCER RES, V54, P5841
   Jaruga E, 1998, BIOCHEM PHARMACOL, V56, P961, DOI 10.1016/S0006 2952(98)00144 0
   Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523 1747.1998.00352.x
   Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468
   Kass GEN, 1996, BIOCHEM J, V318, P749, DOI 10.1042/bj3180749
   Khar A, 1999, FEBS LETT, V445, P165, DOI 10.1016/S0014 5793(99)00114 3
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167 5699(97)80014 X
   Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165 2478(96)02642 9
   Kuo ML, 1996, BBA MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925 4439(96)00032 4
   KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304 3835(85)90159 4
   Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092 8674(00)80434 1
   Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921
   MAJNO G, 1995, AM J PATHOL, V146, P3
   Nadkami K.M., 1976, INDIAN MAT MED, P414
   Oshimi S, 1996, J PHYSIOL LONDON, V495, P319, DOI 10.1113/jphysiol.1996.sp021596
   Ramírez Tortosa MC, 1999, ATHEROSCLEROSIS, V147, P371, DOI 10.1016/S0021 9150(99)00207 5
   Ramsewak RS, 2000, PHYTOMEDICINE, V7, P303, DOI 10.1016/S0944 7113(00)80048 3
   Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014 5793(95)01431 4
   SCHWARTZ SM, 1995, AM J PATHOL, V147, P229
   Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631
   Somasundaram S, 2002, CANCER RES, V62, P3868
   Takadera T, 2004, EUR J PHARMACOL, V499, P239, DOI 10.1016/j.ejphar.2004.07.115
   Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0
   Weber T, 2003, BIOCHEMISTRY US, V42, P4277, DOI 10.1021/bi020527j
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092 8674(00)80501 2
NR 51
TC 90
Z9 95
U1 0
U2 18
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278 6915
EI 1873 6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD AUG
PY 2006
VL 44
IS 8
BP 1362
EP 1371
DI 10.1016/j.fct.2006.03.001
PG 10
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Toxicology
GA 076QF
UT WOS:000239972100023
PM 16624471
DA 2025 08 17
ER

PT J
AU Shang, H
   Zhou, AN
   Jiang, J
   Liu, YP
   Xie, J
   Li, SY
   Chen, YT
   Zhu, XF
   Tan, H
   Li, JS
AF Shang, Hui
   Zhou, Anna
   Jiang, Jian
   Liu, Yanpeng
   Xie, Jing
   Li, Sheyu
   Chen, Yantao
   Zhu, Xiaofeng
   Tan, Hong
   Li, Jianshu
TI Inhibition of the fibrillation of highly amyloidogenic human calcitonin
   by cucurbit[7]uril with improved bioactivity
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Human calcitonin; Amyloid beta peptides; Cucurbit[7]uril; Inhibitor;
   Supramolecular chemistry
ID PROTEIN AGGREGATION; COMMON MECHANISM; RECOGNITION; TOXICITY; FIBRILS;
   INSULIN; GROMACS; IMPLIES
AB Protein/peptide fibrillation is an important challenge for biotechnological drug development. Salmon calcitonin (sCT) is currently used in the clinical treatment of bone related diseases such as osteoporosis and hypercalcemia, but it still has the risk of immune responses. Although human calcitonin (hCT) would be a better choice in terms of immunogenicity, it has a strong tendency to irreversibly aggregate in aqueous solutions and form long amyloid fibrils, which significantly reduces its bioavailability and therapeutic potency. Here, we demonstrate that cucurbit[7]uril (CB[7]) can inhibit hCT fibrillation by supramolecular interaction with its aromatic groups (affinity: Phe16 > Tyr12 > Phe19 > Phe22). The hCT CB[7] complex exhibits low cytotoxicity, even promotes osteoblast proliferation and osteogenic capacity of MC3T3 cells. Meanwhile the hCT CB[7] complexes shows higher bioactivity compared to hCT in reducing blood calcium levels in rats, and also decreases the immunogenicity of hCT. These results suggest that CB[7] has the potential to improve the therapeutic potency of amyloidogenic protein/peptide drugs such as hCT. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Shang, Hui; Zhou, Anna; Liu, Yanpeng; Xie, Jing; Chen, Yantao; Zhu, Xiaofeng; Tan, Hong; Li, Jianshu] Sichuan Univ, Coll Polymer Sci & Engn, Dept Biomed Polymers & Artificial Organs, Chengdu 610065, Sichuan, Peoples R China.
   [Chen, Yantao] Shenzhen Univ, Coll Chem & Environm Engn, Shenzhen Key Lab Funct Polymer, Shenzhen 518060, Peoples R China.
   [Jiang, Jian; Zhu, Xiaofeng] Sichuan Univ, Coll Life Sci, Chengdu 610065, Sichuan, Peoples R China.
   [Li, Sheyu] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu 610065, Sichuan, Peoples R China.
   [Li, Jianshu] Sichuan Univ, State Key Lab Polymer Mat Engn, Chengdu 610065, Sichuan, Peoples R China.
C3 Sichuan University; Shenzhen University; Sichuan University; Sichuan
   University; Sichuan University
RP Chen, YT; Zhu, XF; Li, JS (通讯作者)，Sichuan Univ, Coll Polymer Sci & Engn, Dept Biomed Polymers & Artificial Organs, Chengdu 610065, Sichuan, Peoples R China.
EM ytchen@szu.edu.cn; zhuxiaofeng@scu.edu.cn; jianshu_li@scu.edu.cn
RI Li, Sheyu/O 3242 2016; Zhu, Xiaofeng/ABH 5003 2020; Xie,
   Jing/AAJ 5073 2021; Shang, Hui/JVD 9210 2023; CHEN, Yantao/E 6074 2012
OI jiang, jian/0000 0002 1922 7489; 
FU National Natural Science Foundation of China [21534008, 51773128,
   51703138, 21174088]; State Key Laboratory of Polymer Materials
   Engineering [sklpme2017 2 02]; MOE Key Laboratory of Macromolecular
   Synthesis and Functionalization, Zhejiang University [2017MSF04];
   Program for Changjiang Scholars and Innovative Research Team in
   University [IRT_15R48]
FX This work was supported by National Natural Science Foundation of China
   (21534008, 51773128, 51703138 and 21174088), State Key Laboratory of
   Polymer Materials Engineering (Grant No. sklpme2017 2 02), the MOE Key
   Laboratory of Macromolecular Synthesis and Functionalization, Zhejiang
   University (2017MSF04) and Program for Changjiang Scholars and
   Innovative Research Team in University (IRT_15R48).
CR Andreotti G, 2011, J BIOL CHEM, V286, P2707, DOI 10.1074/jbc.M110.182014
   ARVINTE T, 1993, J BIOL CHEM, V268, P6415
   Barrow SJ, 2015, CHEM REV, V115, P12320, DOI 10.1021/acs.chemrev.5b00341
   Bédos JP, 1998, J PHARMACOL EXP THER, V286, P29
   Bendotti C, 2012, PROG NEUROBIOL, V97, P101, DOI 10.1016/j.pneurobio.2011.10.001
   BERGER G, 1988, VIRCHOWS ARCH A, V412, P543, DOI 10.1007/BF00844290
   Bian YQ, 2015, MOL SIMULAT, V41, P752, DOI 10.1080/08927022.2014.931680
   Bian YQ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003562
   Bonomi M, 2009, COMPUT PHYS COMMUN, V180, P1961, DOI 10.1016/j.cpc.2009.05.011
   Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a
   Cao SQ, 2017, J CONTROL RELEASE, V256, P182, DOI 10.1016/j.jconrel.2017.04.014
   Chinai JM, 2011, J AM CHEM SOC, V133, P8810, DOI 10.1021/ja201581x
   Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901
   Fändrich M, 2007, CELL MOL LIFE SCI, V64, P2066, DOI 10.1007/s00018 007 7110 2
   Fenley AT, 2014, J CHEM THEORY COMPUT, V10, P4069, DOI 10.1021/ct5004109
   FOSTER GV, 1968, POSTGRAD MED J, V44, P411, DOI 10.1136/pgmj.44.511.411
   Gillmore JD, 2013, NAT REV NEPHROL, V9, P574, DOI 10.1038/nrneph.2013.171
   Guo CA, 2015, SCI REP UK, V5, DOI 10.1038/srep13556
   Haataja L, 2008, ENDOCR REV, V29, P303, DOI 10.1210/er.2007 0037
   Hermeling S, 2004, PHARM RES DORDR, V21, P897, DOI 10.1023/B:PHAM.0000029275.41323.a6
   Huang R, 2012, J MOL BIOL, V416, P108, DOI 10.1016/j.jmb.2011.12.023
   Iconomidou VA, 2000, FEBS LETT, V479, P141, DOI 10.1016/S0014 5793(00)01888 3
   Jacobs TP, 2005, J CLIN ENDOCR METAB, V90, P6316, DOI 10.1210/jc.2005 0675
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Kim EJ, 2013, BIOL TRACE ELEM RES, V152, P105, DOI 10.1007/s12011 012 9593 4
   Kubota R, 2015, CHEM SOC REV, V44, P4454, DOI 10.1039/c4cs00381k
   Lagona J, 2005, ANGEW CHEM INT EDIT, V44, P4844, DOI 10.1002/anie.200460675
   Laio A, 2008, REP PROG PHYS, V71, DOI 10.1088/0034 4885/71/12/126601
   Lee HH, 2014, ANGEW CHEM INT EDIT, V53, P7461, DOI 10.1002/anie.201402496
   Lee JW, 2015, J AM CHEM SOC, V137, P15322, DOI 10.1021/jacs.5b10648
   Lindorff Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lumachi F, 2009, ANTICANCER RES, V29, P1551
   McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289
   Muff R, 1991, Osteoporos Int, V1, P72, DOI 10.1007/BF01880446
   Mulinacci F, 2011, EUR J PHARM BIOPHARM, V78, P229, DOI 10.1016/j.ejpb.2010.12.038
   Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680
   NIALL HD, 1969, P NATL ACAD SCI USA, V64, P771, DOI 10.1073/pnas.64.2.771
   Piana S, 2007, J PHYS CHEM B, V111, P4553, DOI 10.1021/jp067873l
   Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200
   Rekharsky MV, 2008, CHEM COMMUN, P2236, DOI 10.1039/b719902c
   Rosenberg AS, 2006, AAPS J, V8, pE501, DOI 10.1208/aapsj080359
   Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149 2918(02)80075 3
   Shan Q, 2015, J VET PHARMACOL THER, V38, P537, DOI 10.1111/jvp.12214
   Shang H, 2017, INT J PHARMACEUT, V527, P52, DOI 10.1016/j.ijpharm.2017.05.006
   Shtainfeld A, 2010, BIOCHEMISTRY US, V49, P5299, DOI 10.1021/bi1002713
   Sieber P., 1970, SYNTHESE YON CALCITO, V53, P2135
   SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044
   Figueira Thais Rezende e Silva, 2012, BMC Res Notes, V5, P185, DOI [10.1186/1756 0500 5 367, 10.1186/1756 0500 5 185]
   Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109 003 0464 5
   Susa AC, 2014, J AM CHEM SOC, V136, P12912, DOI 10.1021/ja504031d
   Tang Y, 2010, PHARM RES DORDR, V27, P272, DOI 10.1007/s11095 009 0015 z
   Tribello GA, 2014, COMPUT PHYS COMMUN, V185, P604, DOI 10.1016/j.cpc.2013.09.018
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang W, 2010, INT J PHARMACEUT, V390, P89, DOI 10.1016/j.ijpharm.2010.02.025
   Yan XZ, 2014, TISSUE ENG PART C ME, V20, P198, DOI 10.1089/ten.tec.2012.0412
   Yu GC, 2015, CHEM REV, V115, P7240, DOI 10.1021/cr5005315
   Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756 3282(02)00688 9
NR 59
TC 29
Z9 31
U1 0
U2 63
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD SEP 15
PY 2018
VL 78
BP 178
EP 188
DI 10.1016/j.actbio.2018.07.045
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GV3JM
UT WOS:000445990200015
PM 30076991
DA 2025 08 17
ER

PT J
AU Ye, JJ
   Gong, M
   Song, J
   Chen, S
   Meng, QH
   Shi, R
   Zhang, LQ
   Xue, JJ
AF Ye, Jingjing
   Gong, Min
   Song, Jian
   Chen, Shu
   Meng, Qinghan
   Shi, Rui
   Zhang, Liqun
   Xue, Jiajia
TI Integrating Inflammation Responsive Prodrug with Electrospun Nanofibers
   for Anti Inflammation Application
SO PHARMACEUTICS
LA English
DT Article
DE enzyme responsive drug release; anti inflammatory; prodrug; electrospun
   nanofiber scaffold
ID DUAL DRUG DELIVERY; CONTROLLED RELEASE; ANTIBACTERIAL;
   FUNCTIONALIZATION; BIODEGRADATION; NANOTUBES; MEMBRANE; SCAFFOLD;
   NSAIDS; BONE
AB Chronic inflammation plays a side effect on tissue regeneration, greatly inhibiting the repair or regeneration of tissues. Conventional local delivery of anti inflammation drugs through physical encapsulation into carriers face the challenges of uncontrolled release. The construction of an inflammation responsive prodrug to release anti inflammation drugs depending on the occurrence of inflammation to regulate chronic inflammation is of high need. Here, we construct nanofiber based scaffolds to regulate the inflammation response of chronic inflammation during tissue regeneration. An inflammation sensitive prodrug is synthesized by free radical polymerization of the indomethacin containing precursor, which is prepared by the esterification of N (2 hydroxyethyl) acrylamide with the anti inflammation drug indomethacin. Then, anti inflammation scaffolds are constructed by loading the prodrug in poly(epsilon caprolactone)/gelatin electrospun nanofibers. Cholesterol esterase, mimicking the inflammation environment, is adopted to catalyze the hydrolysis of the ester bonds, both in the prodrug and the nanofibers matrix, leading to the generation of indomethacin and the subsequent release to the surrounding. In contrast, only a minor amount of the drug is released from the scaffold, just based on the mechanism of hydrolysis in the absence of cholesterol esterase. Furthermore, the inflammation responsive nanofiber scaffold can effectively inhibit the cytokines secreted from RAW264.7 macrophage cells induced by lipopolysaccharide in vitro studies, highlighting the great potential of these electrospun nanofiber scaffolds to be applied for regulating the chronic inflammation in tissue regeneration.
C1 [Ye, Jingjing; Gong, Min; Song, Jian; Chen, Shu; Zhang, Liqun; Xue, Jiajia] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
   [Ye, Jingjing; Gong, Min; Song, Jian; Chen, Shu; Zhang, Liqun; Xue, Jiajia] Beijing Univ Chem Technol, Beijing Lab Biomed Mat, Beijing 100029, Peoples R China.
   [Meng, Qinghan] Beijing Univ Chem Technol, Coll Mat Sci & Engn, Beijing 100029, Peoples R China.
   [Shi, Rui] Beijing Jishuitan Hosp, Beijing Res Inst Traumatol & Orthopaed, Beijing 100035, Peoples R China.
C3 Beijing University of Chemical Technology; Beijing University of
   Chemical Technology; Beijing University of Chemical Technology
RP Zhang, LQ; Xue, JJ (通讯作者)，Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.; Zhang, LQ; Xue, JJ (通讯作者)，Beijing Univ Chem Technol, Beijing Lab Biomed Mat, Beijing 100029, Peoples R China.; Shi, R (通讯作者)，Beijing Jishuitan Hosp, Beijing Res Inst Traumatol & Orthopaed, Beijing 100035, Peoples R China.
EM 2017400077@mail.buct.edu.cn; gongmin@ustb.edu.cn;
   2021210312@buct.edu.cn; 2017020580@mail.buct.edu.cn;
   qhmeng@mail.buct.edu.cn; shirui@jst hosp.com.cn;
   zhanglq@mail.buct.edu.cn; jiajiaxue@mail.buct.edu.cn
RI Xue, Jiajia/A 4079 2019; Zhang, Liqun/Q 7646 2019; XUE,
   JIAJIA/A 4079 2019
OI XUE, JIAJIA/0000 0002 7209 7935
FU National Natural Science Foundation of China [52073014, 82002049,
   82072406]; Key Program of Beijing Natural Science Foundation [Z200025];
   Fundamental Research Funds for the Central Universities [buctrc202020];
   Beijing Municipal Health Commission [PXM2020 026275 000003, BMHC 2021 6]
FX This research was funded by the National Natural Science Foundation of
   China (Grant No. 52073014 and 82002049; to J.X. Grant No. 82072406 to
   R.S.), Key Program of Beijing Natural Science Foundation (Z200025),
   Fundamental Research Funds for the Central Universities (buctrc202020),
   and Beijing Municipal Health Commission (PXM2020 026275 000003;
   BMHC 2021 6).
CR Almasian A, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6646702
   Askari VR, 2020, DRUG CHEM TOXICOL, V43, P353, DOI 10.1080/01480545.2019.1572182
   Badri W, 2016, INT J PHARMACEUT, V515, P757, DOI 10.1016/j.ijpharm.2016.11.002
   Barkin RL, 2015, AM J THER, V22, P388, DOI 10.1097/MJT.0b013e3182459abd
   Blaudez F, 2022, ACTA BIOMATER, V140, P116, DOI 10.1016/j.actbio.2021.11.047
   Chao MY, 2021, ACS NANO, V15, P9746, DOI 10.1021/acsnano.1c00472
   Chen L, 2021, BIOACT MATER, V6, P3218, DOI 10.1016/j.bioactmat.2021.02.022
   Chen R, 2016, ADV FUNCT MATER, V26, P8810, DOI 10.1002/adfm.201603197
   Chen ZJ, 2021, ADV SCI, V8, DOI 10.1002/advs.202004793
   Chung MF, 2015, J AM CHEM SOC, V137, P12462, DOI 10.1021/jacs.5b08057
   Deng MY, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000353
   Ding HX, 2021, ACS APPL BIO MATER, V4, P6167, DOI 10.1021/acsabm.1c00493
   Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401
   Gong M, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201902127
   Gong M, 2019, NANOMED NANOTECHNOL, V17, P124, DOI 10.1016/j.nano.2019.01.002
   Gong M, 2018, COLLOID SURFACE B, V170, P201, DOI 10.1016/j.colsurfb.2018.06.012
   Hadisi Z, 2018, INT J BIOL MACROMOL, V107, P2008, DOI 10.1016/j.ijbiomac.2017.10.061
   Haley RM, 2019, EXP BIOL MED, V244, P433, DOI 10.1177/1535370218787770
   Hao MZ, 2018, IND ENG CHEM RES, V57, P7486, DOI 10.1021/acs.iecr.8b00622
   Hao MZ, 2016, COMPOS PART B ENG, V95, P395, DOI 10.1016/j.compositesb.2016.03.084
   Huang YP, 2021, POLYM TEST, V97, DOI 10.1016/j.polymertesting.2021.107129
   Jeong D, 2016, J CONTROL RELEASE, V233, P72, DOI 10.1016/j.jconrel.2016.04.039
   Jervis PJ, 2020, SOFT MATTER, V16, P10001, DOI 10.1039/d0sm01198c
   Kaur G, 2018, BIOORG CHEM, V80, P24, DOI 10.1016/j.bioorg.2018.05.014
   Khan AUR, 2021, BIOACT MATER, V6, P2783, DOI 10.1016/j.bioactmat.2021.01.040
   Labow RS, 1999, J BIOMATER APPL, V13, P187, DOI 10.1177/088532829901300302
   Li RT, 2022, ADV SCI, V9, DOI 10.1002/advs.202105152
   Liu S, 2017, J CONTROL RELEASE, V264, P1, DOI 10.1016/j.jconrel.2017.08.011
   Liu WF, 2015, MEDCHEMCOMM, V6, P2129, DOI 10.1039/c5md00308c
   Liu WF, 2015, BIOORG MED CHEM LETT, V25, P3044, DOI 10.1016/j.bmcl.2015.04.077
   Lu YF, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202105749
   Norouzi M, 2015, ADV HEALTHC MATER, V4, P1114, DOI 10.1002/adhm.201500001
   Pan GQ, 2015, BIOMATERIALS, V53, P202, DOI 10.1016/j.biomaterials.2015.02.078
   Porrelli D, 2021, ACS APPL MATER INTER, V13, P17255, DOI 10.1021/acsami.1c01016
   Pu HL, 2014, ACS NANO, V8, P1213, DOI 10.1021/nn4058787
   Sadek KM, 2021, ACS OMEGA, V6, P34447, DOI 10.1021/acsomega.1c04608
   Sarhane KA, 2019, ACTA BIOMATER, V88, P332, DOI 10.1016/j.actbio.2019.02.034
   Shi J, 2019, ACTA BIOMATER, V97, P360, DOI 10.1016/j.actbio.2019.07.037
   Su YC, 2021, SMALL SCI, V1, DOI 10.1002/smsc.202100003
   Tan JJ, 2018, BIOMATERIALS, V178, P608, DOI 10.1016/j.biomaterials.2018.03.035
   Wang XY, 2021, APPL ORGANOMET CHEM, V35, DOI 10.1002/aoc.6269
   Wei YJ, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120237
   Wen ML, 2020, ACS APPL MATER INTER, V12, P6863, DOI 10.1021/acsami.9b19452
   Wen SH, 2019, MAT SCI ENG C MATER, V100, P514, DOI 10.1016/j.msec.2019.02.076
   Xi K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18265 3
   Xue JJ, 2020, SMALL METHODS, V4, DOI 10.1002/smtd.202000125
   Xue JJ, 2015, ACS NANO, V9, P1600, DOI 10.1021/nn506255e
   Xue S, 2021, BIOACT MATER, V6, P2372, DOI 10.1016/j.bioactmat.2021.01.017
   Yan FL, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00675 6
   Ye JJ, 2020, MACROMOL BIOSCI, V20, DOI 10.1002/mabi.202000116
   Zhang RS, 2021, CHEM ENG J, V421, DOI 10.1016/j.cej.2021.129623
   Zhao G, 2021, J CONTROL RELEASE, V339, P484, DOI 10.1016/j.jconrel.2021.10.007
   Zhao X, 2015, COLLOID SURFACE B, V130, P1, DOI 10.1016/j.colsurfb.2015.03.058
NR 53
TC 17
Z9 17
U1 8
U2 55
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JUN
PY 2022
VL 14
IS 6
AR 1273
DI 10.3390/pharmaceutics14061273
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 2N1OL
UT WOS:000818157400001
PM 35745845
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Vidal, SA
   Skorupski, KA
   Willcox, JL
   Palm, CA
   Burton, JH
AF Vidal, Sarah A.
   Skorupski, Katherine A.
   Willcox, Jennifer L.
   Palm, Carrie A.
   Burton, Jenna H.
TI Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid
   Administration to Dogs With Malignant Osteolysis
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE aminobisphosphonate; azotemia; canine; pain management; zoledronate
ID MULTIPLE MYELOMA; DOUBLE BLIND; PAMIDRONATE; BISPHOSPHONATES; CANCER
AB Zoledronic acid (ZOL) is an intravenous bisphosphonate indicated for the use of hypercalcemia of malignancy and management of bony metastases. Its therapeutic effect lies in the targeting of malignant osteoclasts; however, administration can be associated with renal toxicity. The objective of this retrospective study was to evaluate the frequency and severity of acute kidney injury (AKI) following ZOL administration in a cohort of cancer bearing dogs. A pharmacy search was conducted to identify dogs that received a dose of ZOL between June 2016 and July 2019. Inclusion criteria included baseline and post treatment chemistry panels. Medical records were reviewed to obtain clinical data including signalment, dose, dosage, number of treatments administered, and changes in renal function. Forty four dogs met the inclusion criteria. Median number of doses administered was three [interquartile range (IQR), 2 5]. The median highest creatinine value occurred after a median of one dose (IQR, 1 2 doses) compared with the median highest value of blood urea nitrogen, phosphorus, and potassium, which occurred after a median of two doses (IQR, 1 3). Six (13.6%) dogs developed an AKI, and one dog (2.3%) had progression of an existing azotemia after treatment with ZOL was initiated. Two dogs (4.5%) had ZOL treatment discontinued secondary to development of azotemia. Use of concurrent administration of non steroidal anti inflammatory drugs or anesthesia did not significantly increase the risk of AKI in this cohort of dogs. Acute kidney injury is observed infrequently in cancer bearing dogs treated with ZOL and is generally mild to moderate in severity; discontinuation of ZOL due to AKI is uncommon.
C1 [Vidal, Sarah A.] Univ Calif Davis, William R Pritchard Vet Med Teaching Hosp, Sch Vet Med, Davis, CA 95616 USA.
   [Skorupski, Katherine A.; Willcox, Jennifer L.; Burton, Jenna H.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.
   [Palm, Carrie A.] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA.
   [Burton, Jenna H.] Colorado State Univ, Coll Vet Med & Biomed Sci, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   Colorado State University System; Colorado State University Fort Collins
RP Burton, JH (通讯作者)，Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.; Burton, JH (通讯作者)，Colorado State Univ, Coll Vet Med & Biomed Sci, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA.
EM jenna.burton@colostate.edu
RI ; Skorupski, Katherine/AAP 7753 2021; Burton, Jenna/KYP 0715 2024
OI Willcox, Jennifer/0000 0003 2107 6226; Skorupski,
   Katherine/0000 0003 0324 445X; 
CR [Anonymous], 2016, VET COMP ONCOL, V14, P417, DOI 10.1111/vco.283
   [Anonymous], 2018, ZOMETA ZOLEDRONIC AC
   [Anonymous], 2014, PAMIDRONATE DISODIUM
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Body JJ, 2005, ONCOLOGIST, V10, P3, DOI 10.1634/theoncologist.10 90001 3
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Fan TM, 2008, J VET INTERN MED, V22, P380, DOI 10.1111/j.1939 1676.2008.0046.x
   Fan TM, 2009, J VET INTERN MED, V23, P152, DOI 10.1111/j.1939 1676.2008.0221.x
   Fan TM, 2007, VET CLIN N AM SMALL, V37, P1091, DOI 10.1016/j.cvsm.2007.08.002
   Fan TM, 2007, J VET INTERN MED, V21, P431, DOI 10.1892/0891 6640(2007)21[431:SPFPTO]2.0.CO;2
   Fan TM, 2005, J VET INTERN MED, V19, P74, DOI 10.1892/0891 6640(2005)19<74:EOIPAI>2.0.CO;2
   Green JR, 1997, PHARMACOL TOXICOL, V80, P225, DOI 10.1111/j.1600 0773.1997.tb01964.x
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   International Renal Interest Society, 2016, GRAD AC KIDN INJ
   Kozicki AR, 2015, VET COMP ONCOL, V13, P229, DOI 10.1111/vco.12040
   Kravets I, 2018, AM J MED, V131, P1298, DOI 10.1016/j.amjmed.2018.04.028
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Milner RJ, 2004, J VET INTERN MED, V18, P597, DOI 10.1892/0891 6640(2004)18<597:BAC>2.0.CO;2
   Munier A, 2005, ANN PHARMACOTHER, V39, P1194, DOI 10.1345/aph.1E589
   Oblak ML, 2012, VET SURG, V41, P430, DOI 10.1111/j.1532 950X.2012.00968.x
   Ott SM, 2015, SEMIN DIALYSIS, V28, P363, DOI 10.1111/sdi.12388
   Rosen LS, 2001, CANCER J, V7, P377
   Saad Fred, 2002, Clin Prostate Cancer, V1, P145, DOI 10.3816/CGC.2002.n.016
   Schenk A, 2018, J AM ANIM HOSP ASSOC, V54, DOI [10.5326/JAAHA MS 6681, 10.5326/jaaha ms 6681]
NR 24
TC 5
Z9 5
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2297 1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD JUL 2
PY 2021
VL 8
AR 647846
DI 10.3389/fvets.2021.647846
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA TJ9AS
UT WOS:000673765700001
PM 34277751
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sedik, AS
   Kawana, KY
   Koura, AS
   Mehanna, RA
AF Sedik, Aya S. S.
   Kawana, Khadiga Y. Y.
   Koura, Azza S. S.
   Mehanna, Radwa A. A.
TI Biological effect of bone marrow mesenchymal stem cell  derived
   extracellular vesicles on the structure of alveolar bone in rats with
   glucocorticoid induced osteoporosis
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Glucocorticoids; Osteoporosis; Mesenchymal stem cells; Extracellular
   vesicles
ID MOLECULAR MECHANISMS; EXOSOMES; DIFFERENTIATION; TRANSCRIPTION;
   OSTEONECROSIS; MICROVESICLES; REGENERATION; EXPRESSION; OSTEOBLAST;
   THERAPY
AB BackgroundGlucocorticoids are used for the treatment of autoimmune disorders; however, they can elicit several side effects such as osteoporosis. Several approaches can be made to treat glucocorticoid induced osteoporosis, including the use of stem cells. However, the therapeutic effect of mesenchymal stem cells depends on its released factors, including extracellular vesicles. Extracellular vesicles have been recognized as important mediators of intercellular communication as they participate in many physiological processes. The present study was designed to investigate the effect of bone marrow mesenchymal stem cells derived extracellular vesicles on the structure of alveolar bone in rats with glucocorticoid induced osteoporosis.MethodsThirty adult albino male rats were divided into 3 groups: control group (CG), glucocorticoid induced osteoporosis (GOG) and extracellular vesicles treated group (ExTG). Rats in the GOG and ExTG groups were injected with methylprednisolone acetate (40 mg/kg) intramuscularly in the quadriceps muscle 3 times per week for three weeks in the early morning. Afterwards, the rats in GOG group received a single vehicle injection (PBS) while each rat in the ExTG group received a single injection of extracellular vesicles (400 mu g/kg suspended in 0.2 ml PBS) in the tail vein. Rats were euthanized 1 month after injection. Mandibles were dissected and the molar segments were prepared for histological preparation, scanning electron microscopy (SEM), and energy dispersive x ray (EDX).ResultsHistology and scanning electron microscopyof bone tissue showed alveolar bone loss and bone resorption in the GOG group. while in the ExTG group, alveolar bone demostrated normal bone architecture. EDX showed that calcium percentage in GOG group was lower than ExTG group,which showed no statistically significant difference from the control group.ConclusionsExtracellular vesicles may be a promising treatment modality in the treatment of bone diseases and in bone regeneration. However, further research is needed before stating that extracellular vesicles s can be used to treat bone disorders especially when translating to humans.
C1 [Sedik, Aya S. S.; Kawana, Khadiga Y. Y.; Koura, Azza S. S.] Alexandria Univ, Fac Dent, Dept Oral Biol, Alexandria, Egypt.
   [Mehanna, Radwa A. A.] Alexandria Univ, Fac Med, Dept Physiol, Alexandria, Egypt.
   [Mehanna, Radwa A. A.] Alexandria Univ, Fac Med, Ctr Excellence Res Regenerat Med & Applicat CERRMA, Alexandria, Egypt.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB);
   Alexandria University
RP Sedik, AS (通讯作者)，Alexandria Univ, Fac Dent, Dept Oral Biol, Alexandria, Egypt.
EM Aya.sedik@alexu.edu.eg
RI Dentistry, Faculty/KHT 2332 2024; Mehanna, Radwa/J 6885 2019
OI Mehanna, Radwa/0000 0001 9048 4464; Sedik, Aya/0009 0009 7137 4230
FU Science, Technology & Innovation Funding Authority (STDF); Egyptian
   Knowledge Bank (EKB)
FX Open access funding provided by The Science, Technology & Innovation
   Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank
   (EKB). The authors received no specific funding for this work.
CR Abolgheit S, 2021, J BIOMATER APPL, V36, P128, DOI 10.1177/0885328220963920
   Almawi WY, 2002, J LEUKOCYTE BIOL, V71, P9
   Ashour AA, 2022, DRUG DELIV, V29, P3270, DOI 10.1080/10717544.2022.2142700
   Bagi CM, 2011, COMPARATIVE MED, V61, P76
   Battistelli M, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9010021
   Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Bronckers ALJJ, 2003, MICROSC RES TECHNIQ, V61, P540, DOI 10.1002/jemt.10377
   Bryda Elizabeth C, 2013, Mo Med, V110, P207
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Castillo Cardiel G, 2017, DENT TRAUMATOL, V33, P38, DOI 10.1111/edt.12303
   Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Choumerianou DM, 2008, TISSUE ENG PART B RE, V14, P53, DOI 10.1089/teb.2007.0216
   Chrousos George P., 1998, Annals of Internal Medicine, V129, P229
   Cocucci E, 2015, TRENDS CELL BIOL, V25, P364, DOI 10.1016/j.tcb.2015.01.004
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Cooper MS, 2012, J BONE MINER RES, V27, P2238, DOI 10.1002/jbmr.1753
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Efird J, 2011, INT J ENV RES PUB HE, V8, P15, DOI 10.3390/ijerph8010015
   Ericson Neilsen W, 2014, OCHSNER J, V14, P203
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Furuta T, 2016, STEM CELL TRANSL MED, V5, P1620, DOI 10.5966/sctm.2015 0285
   Goldstein J.I., 2017, Scanning electron microscopy and X ray microanalysis
   Gomes PS, 2011, LAB ANIM UK, V45, P14, DOI 10.1258/la.2010.010085
   Grad W, 2007, MOL CELL ENDOCRINOL, V275, P2, DOI 10.1016/j.mce.2007.05.018
   Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799
   Hofer HR, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0394 0
   Hu MD, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.819651
   Ishaq M, 2007, J IMMUNOL, V179, P3851, DOI 10.4049/jimmunol.179.6.3851
   JOWSEY J, 1966, J ANAT, V100, P857
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   Khodashenas S, 2019, BIOTECHNOL LETT, V41, P523, DOI 10.1007/s10529 019 02667 5
   Kovacs JZ, 2007, CARBON, V45, P1279, DOI 10.1016/j.carbon.2007.01.012
   Lewiecki EM, 2010, MATURITAS, V66, P182, DOI 10.1016/j.maturitas.2010.02.008
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Mayourian J, 2018, CIRC RES, V122, P933, DOI 10.1161/CIRCRESAHA.118.312420
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Motomura G, 2008, J RHEUMATOL, V35, P2395, DOI 10.3899/jrheum.080324
   Narayanan R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3808674
   Oz HS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/754857
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Pérez AV, 2008, DIGESTION, V77, P22, DOI 10.1159/000116623
   Properzi F, 2013, BIOMARK MED, V7, P769, DOI 10.2217/bmm.13.63
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Rosner M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00661 x
   Schäcke H, 2006, EXP DERMATOL, V15, P565, DOI 10.1111/j.1600 0625.2006.00453.x
   Scimeca M, 2018, EUR J HISTOCHEM, V62, P88, DOI 10.4081/ejh.2018.2841
   Silva WA, 2003, STEM CELLS, V21, P661, DOI 10.1634/stemcells.21 6 661
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003 2697(85)90442 7
   Smyth TJ, 2014, BBA BIOMEMBRANES, V1838, P2954, DOI 10.1016/j.bbamem.2014.07.026
   Song IH, 2005, J RHEUMATOL, V32, P1199
   Stillwell W, 2013, INTRO BIOL MEMBRANCE
   Takeuchi R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225472
   Thabet E, 2020, MOL HUM REPROD, V26, P906, DOI 10.1093/molehr/gaaa068
   Timmermans S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01545
   Toh WS, 2018, BIOCHEM SOC T, V46, P843, DOI 10.1042/BST20180079
   van der Pol E, 2010, J THROMB HAEMOST, V8, P2596, DOI 10.1111/j.1538 7836.2010.04074.x
   van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Xu R, 2016, J CLIN INVEST, V126, P1152, DOI 10.1172/JCI81129
   Yang YJ, 2018, ACTA PHARMACOL SIN, V39, P633, DOI 10.1038/aps.2017.134
   Yoon HY, 2012, J BONE MINER METAB, V30, P509, DOI 10.1007/s00774 012 0350 8
   Yuan N, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6655225
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1562 9
   Zhou DA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 239
   Zhou SR, 2018, J CRANIOFAC SURG, V29, P1216, DOI 10.1097/SCS.0000000000004395
NR 72
TC 6
Z9 6
U1 3
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAR 17
PY 2023
VL 24
IS 1
AR 205
DI 10.1186/s12891 023 06276 2
PG 14
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA A1QK5
UT WOS:000952944200001
PM 36932362
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jie, SS
   Sun, HJ
   Liu, JX
   Gao, Y
   Bai, D
   Zhu, LL
   Zhao, HY
   Zeng, H
   Ma, YL
AF Jie, Shan shan
   Sun, Hui juan
   Liu, Jian xin
   Gao, Yan
   Bai, Dong
   Zhu, Liu luan
   Zhao, Hong yan
   Zeng, Hui
   Ma, Ya luan
TI Simiao Yong'an decoction ameliorates murine collagen induced arthritis
   by modulating neutrophil activities: An in vitro and
   in vivo study
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE SimiaoYong?an decoction; Rheumatoid arthritis; Collagen induced
   arthritis; Inflammation; Neutrophils; Acknowledgments The study was
   supported by Research project of China Academy of Chinese Medical
   Sciences (No; YZ 202016; China)
ID RHEUMATOID ARTHRITIS; INHIBITION; ACTIVATION; PROTECTS; THERAPY; IMMUNE;
   ACID; DRUG
AB Ethnopharmacological relevance: Rheumatoid arthritis (RA) is a common systemic autoimmune disease with high morbidity and disability rate. Currently, there is no effective allopathic treatment for RA, and most of the drugs provoke many adverse effects. Simiao Yong'an decoction (SMYAD) is a traditional Chinese prescription for the treatment of sore and gangrene caused by hot poison. With the development of pharmacology and clinical research, SMYAD has remarkable anti inflammatory properties and has been used for RA treatments for years.Aim of the study: This study aimed to investigate the anti arthritic effect of SMYAD and further explore the immunopharmacological mechanisms.Materials and methods: Arthritis was induced in DBA/1 mice by two time immunizations. Collagen induced rheumatoid arthritis (CIA) mice were divided into 4 groups: control, model, methotrexate (MTX), and SMYAD group (n = 6). The administration groups were given MTX (0.5 mg/kg/3 d) and SMYAD (4.5 g/kg/d) by gavage from day 14. The arthritis index (AI) score was evaluated every 3 days after the second immunization. Hema toxylin and eosin (H&E) staining, Safranin O fast green staining, Trap staining, and Micro CT were used to measure the histopathology injuries and bone destruction of joints. Granulocyte changes in the spleen, bone marrow, and period blood were analyzed by flow cytometry. The expression of inflammatory cytokines and chemokines in joints were detected by qRT PCR. SMYAD containing serum was obtained from SD rats gavaged with SMYAD. Neutrophils were isolated from peripheral blood and bone marrow for the in vitro experiments of transwell cell assay, apoptosis assay, reactive oxygen species (ROS) generation and neutrophil extracellular traps (NETs) formation.Results: SMYAD significantly relieved arthritis severity in CIA mice. The AI score was significantly decreased in the SMYAD group compared with the model group. Additionally, SMYAD alleviated inflammatory infiltration, cartilage damage, osteoclast formation, and bone damage in the ankle joints. In the flow cytometry assay, SMYAD significantly reduced granulocytes number in the spleen and bone marrow, while increased in peripheral blood. Furthermore, compared with the CIA group, SMYAD suppressed the mRNA levels of inflammatory factors including TNF alpha, IL 1 beta, IL 6 and chemokines CXCL1, CXCL2, and IL 8 in the inflamed joints. In the in vitro studies, 20% SMYAD containing serum effectively inhibited the migration of neutrophils, promoted neutrophils apoptosis, reduced ROS production and NETs formation. Conclusion: Collectively, our results demonstrated that SMYAD effectively restrained arthritis in CIA mice by modulating neutrophil activities.
C1 [Jie, Shan shan; Sun, Hui juan; Liu, Jian xin; Bai, Dong; Ma, Ya luan] China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing 100700, Peoples R China.
   [Gao, Yan; Zeng, Hui] Capital Med Univ, Beijing Shijitan Hosp, Beijing 100038, Peoples R China.
   [Zhu, Liu luan] Capital Med Univ, Affiliated Beijing Ditan Hosp, Beijing 100015, Peoples R China.
   [Zhao, Hong yan] China Acad Chinese Med Sci, Expt Res Ctr, Beijing 100700, Peoples R China.
C3 Institute of Basic Theory for Chinese Medicine, CACMS; China Academy of
   Chinese Medical Sciences; Capital Medical University; Capital Medical
   University; Experimental Research Center, CACMS; China Academy of
   Chinese Medical Sciences
RP Ma, YL (通讯作者)，China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing 100700, Peoples R China.; Zeng, H (通讯作者)，Capital Med Univ, Beijing Shijitan Hosp, Beijing 100038, Peoples R China.
EM jss010210@163.com; 18519283726@163.com; jianxinliu@163.com;
   gaoyantalentback@126.com; baidong2000@126.com; zhuliuluan@aliyun.com;
   zhaohongyan1997@163.com; zenghui@ccmu.edu.cn; mayaluan@mail.cintcm.ac.cn
RI Bai, Dong/K 2622 2018; Gao, Yan/IST 0188 2023
OI Gao, Yan/0000 0003 3698 1413
FU Research project of China Academy of Chinese Medical Sciences
   [YZ 202016]
FX Acknowledgments The study was supported by Research project of China
   Academy of Chinese Medical Sciences (No. YZ 202016, China) .
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Al Gareeb A, 2019, ARCH RHEUMATOL, V34, P426, DOI 10.5606/ArchRheumatol.2019.7100
   Aldayel AM, 2018, J CONTROL RELEASE, V283, P280, DOI 10.1016/j.jconrel.2018.05.035
   Apel F, 2018, NAT REV RHEUMATOL, V14, P467, DOI 10.1038/s41584 018 0039 z
   Bertolotto M, 2014, BRIT J PHARMACOL, V171, P3376, DOI 10.1111/bph.12670
   Burgener SS, 2019, CELL REP, V27, P3646, DOI 10.1016/j.celrep.2019.05.065
   Chen WQ, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/8549329
   [迟森森 Chi Sensen], 2016, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V39, P933
   Chowdhury K, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 017 1505 8
   Croia C, 2019, CLIN EXP RHEUMATOL, V37, P347
   Cross A, 2006, J LEUKOCYTE BIOL, V80, P521, DOI 10.1189/jlb.0306178
   Cui Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1428 1
   Du A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.763163
   Du X.H., 2015, CHINESE PHARM J, V26, P2158
   Duan WF, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0382 x
   Alarcon MF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649693
   Haikal SM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080823
   He K., 2014, J PRACT TRADIT CHIN, V28, P58, DOI [10.13729/j.issn.1671 7813.2014.11.27, DOI 10.13729/J.ISSN.1671 7813.2014.08.62,08]
   Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568 020 0281 y
   Jia B, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7521701
   Kanlaya R, 2016, SCI REP UK, V6, DOI 10.1038/srep30233
   Kaundal U, 2021, CLIN EXP RHEUMATOL, V39, P479, DOI 10.55563/clinexprheumatol/4h5onh
   Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580
   Kienle K, 2021, SCIENCE, V372, P1303, DOI 10.1126/science.abe7729
   [李彩霞 Li Caixia], 2018, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V41, P329
   Li JL, 2016, J INVEST DERMATOL, V136, P416, DOI 10.1038/JID.2015.410
   Liu C, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4069032
   Liu YY, 2017, MOLECULES, V22, DOI 10.3390/molecules22111937
   [刘忠第 Liu Zhongdi], 2015, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V30, P3191
   Ma W.G., 2017, TIANJIN J TRADITIONA, V34, P43
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024
   Miyabe Y, 2019, NAT REV RHEUMATOL, V15, P731, DOI 10.1038/s41584 019 0323 6
   Németh T, 2020, NAT REV DRUG DISCOV, V19, P253, DOI 10.1038/s41573 019 0054 z
   Nie B., 2016, 2016 P 6 ANN NATL C, V223
   Paglia MD, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248866
   Pérez Sánchez C, 2017, J AUTOIMMUN, V82, P31, DOI 10.1016/j.jaut.2017.04.007
   Rubin SJS, 2019, NAT REV RHEUMATOL, V15, P303, DOI 10.1038/s41584 019 0211 0
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Shimoyama AT, 2013, N S ARCH PHARMACOL, V386, P5, DOI 10.1007/s00210 012 0807 2
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Sun Y, 2017, ONCOL LETT, V13, P4849, DOI 10.3892/ol.2017.6045
   Tak PP, 1997, ARTHRITIS RHEUM, V40, P217, DOI 10.1002/art.1780400206
   Tanaka D, 2006, IMMUNOLOGY, V119, P195, DOI 10.1111/j.1365 2567.2006.02424.x
   Tsai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051351
   Vorobjeva N, 2020, BBA MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165664
   Walia MK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0944 8
   Wang L.D., 2019, INF TRADIT CHIN MED, V26, P04
   Weyand CM, 2006, NAT CLIN PRACT RHEUM, V2, P201, DOI 10.1038/ncprheum0142
   Wittkowski H, 2007, ANN RHEUM DIS, V66, P1020, DOI 10.1136/ard.2006.061507
   Wright HL, 2014, NAT REV RHEUMATOL, V10, P593, DOI 10.1038/nrrheum.2014.80
   Xie PP, 2021, DRUG DES DEV THER, V15, P629, DOI 10.2147/DDDT.S294849
   Xu DY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12824
   Xu HB, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 239
   Yang G.L., 2016, INTERNAL MED INTEGRA, P998
   杨怡坤, 2011, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V17, P1161
   Yu JY, 2015, MOLECULES, V20, P13041, DOI 10.3390/molecules200713041
   Zabel BA, 2015, ANNU REV PATHOL MECH, V10, P51, DOI 10.1146/annurev pathol 012513 104640
   [张可兴 Zhang Keixing], 2019, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V28, P415
   Zhu YJ, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/3990607
NR 59
TC 9
Z9 10
U1 0
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD APR 6
PY 2023
VL 305
AR 116119
DI 10.1016/j.jep.2022.116119
EA JAN 2023
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 7Z2MK
UT WOS:000915397800001
PM 36596398
DA 2025 08 17
ER

PT J
AU Huseynova, F
   Ionescu, C
   Cuisinier, F
   Huseynova, I
   Mammadov, A
   Barragan Montero, V
AF Huseynova, Fidan
   Ionescu, Catalina
   Cuisinier, Frederic
   Huseynova, Irada
   Mammadov, Alamdar
   Barragan Montero, Veronique
TI Could CH3 M6P Be a Potential Dual Functioning Candidate for
   Bone Regeneration?
SO BIOMEDICINES
LA English
DT Article
DE CH3 M6P; stem cell; DPSC; bone formation; angiogenesis; gene expression
ID GROWTH FACTOR BETA; PULP STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   FACTOR II; OSTEOGENIC DIFFERENTIATION; TGF BETA; MANNOSE 6 PHOSPHATE;
   ANGIOGENESIS; PHOSPHATE; CALCIUM
AB Background: CI RM6P has different binding sites with affinities for both M6P and IGF2, plays a role in the regulation of the TGF beta and IGF pathways that is important for controlling cell growth and differentiation. We hypothesize that previously synthesised derivative of M6P could be an alternative candidate for bone tissue regeneration in terms of higher binding affinity, stability in human serum, low cost and temporal delivery. Methods: CH3 M6P is synthesised based on previously described protocol; mesenchymal origin of isolated DPSCs was assessed by flow cytometry and AR staining prior to alkaline phosphatase (ALP) activity test, qPCR to evaluate differentiation specific marker expression, immunofluoresence, and SEM/EDS to evaluate organic and inorganic matrix formation; and rat aortic ring model to evaluate angiogenic effect of molecule. Results: CH3 M6P upregulated ALP activity, the expression of the ALP, Col1, RunX2, Mef2C, TGF beta 1, TGF beta 1R, TGF beta 2, and Smad3 genes under osteogenic conditions. The results of immunofluorescence and SEM/EDS studies did not show enhancing effect on matrix formation. As we observed, the induction effect of CH3 M6P on the expression of angiogenic genes such as SMAD3 and TGF beta 1R, even under osteogenic conditions, within the scope of research, we checked the angiogenic effect of the molecule and compared it to VEGF, showing that the CH3 M6P is really angiogenic. Conclusions: Our findings provide an important clue for the further exploration of the molecule, which can be necessary to enhance the capability of the commonly used osteomedium, possibly leading to the development of bone forming drugs and has the potential to be a dual functioning molecule for bone tissue engineering.
C1 [Huseynova, Fidan; Cuisinier, Frederic; Barragan Montero, Veronique] Montpellier Univ, LBN, F 34193 Montpellier, France.
   [Huseynova, Fidan; Huseynova, Irada; Mammadov, Alamdar] Minstry Sci & Educ Republ Azerbaian, Inst Mol Biol & Biotechnol, AZ 1073 Baku, Azerbaijan.
   [Huseynova, Fidan] Azerbaijan Med Univ, Dept Cytol Embryol & Histol, AZ 1078 Baku, Azerbaijan.
   [Ionescu, Catalina] Univ Craiova, Fac Sci, Dept Chem, 107i Calea Bucure?ti, Craiova 200144, Romania.
   [Cuisinier, Frederic] CHU Montpellier, Ctr Soins & Rech Dentaire, F 34000 Montpellier, France.
   [Cuisinier, Frederic] Montpellier Univ, Fac Odontol, F 34295 Montpellier, France.
C3 Universite de Montpellier; Ministry of Education of Azerbaijan Republic;
   Azerbaijan Medical University; University of Craiova; Universite de
   Montpellier; CHU de Montpellier; Universite de Montpellier
RP Huseynova, F; Barragan Montero, V (通讯作者)，Montpellier Univ, LBN, F 34193 Montpellier, France.; Huseynova, F (通讯作者)，Minstry Sci & Educ Republ Azerbaian, Inst Mol Biol & Biotechnol, AZ 1073 Baku, Azerbaijan.; Huseynova, F (通讯作者)，Azerbaijan Med Univ, Dept Cytol Embryol & Histol, AZ 1078 Baku, Azerbaijan.
EM fidan.huseynova92@gmail.com; catalinagurgui@yahoo.co.uk;
   veronique.montero@umontpellier.fr
RI Huseynova, Fidan/LXW 5611 2024; Ionescu, Catalina/AAT 3845 2021;
   cuisinier, frederic/ABD 4152 2020; Mammadov, Alamdar/MCK 3478 2025;
   Huseynova, Irada/Y 6141 2019
OI Huseynova, Fidan/0000 0003 2013 0286; Huseynova,
   Irada/0000 0003 3336 2203; 
CR Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Arpornmaeklong P, 2018, ANN ANAT, V215, P52, DOI 10.1016/j.aanat.2017.09.008
   Barragan Montero V, 2011, CHEMMEDCHEM, V6, P1771, DOI 10.1002/cmdc.201100293
   Bekes I, 2016, MOL CANCER, V15, DOI 10.1186/s12943 016 0497 3
   BERNLIND C, 1994, CARBOHYD RES, V263, P173, DOI 10.1016/0008 6215(94)00169 3
   Bohner M, 2020, ACTA BIOMATER, V113, P23, DOI 10.1016/j.actbio.2020.06.022
   Bonjour JP, 2011, J AM COLL NUTR, V30, p438S, DOI 10.1080/07315724.2011.10719988
   Borowiak M, 2009, CELL STEM CELL, V4, P348, DOI 10.1016/j.stem.2009.01.014
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   Bronckaers A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071104
   Butera A, 2022, APPL SCI BASEL, V12, DOI 10.3390/app12073250
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603 653
   d'Aquino R, 2009, J EXP ZOOL PART B, V312B, P408, DOI 10.1002/jez.b.21263
   DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580
   DuBose KB, 2012, BIOCHEM BIOPH RES CO, V422, P488, DOI 10.1016/j.bbrc.2012.05.020
   Fendi F, 2024, POLYM BULL, V81, P1097, DOI 10.1007/s00289 023 04794 6
   Gary Bobo M, 2007, CURR MED CHEM, V14, P2945, DOI 10.2174/092986707782794005
   Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050
   Hwang HS, 2023, GELS BASEL, V9, DOI 10.3390/gels9070588
   Ielo I, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23179721
   Ionescu C, 2022, MEDICINA LITHUANIA, V58, DOI 10.3390/medicina58070903
   Ionescu C, 2022, CHEM PHYS LIPIDS, V242, DOI 10.1016/j.chemphyslip.2021.105161
   Ionescu C, 2016, BIOORG MED CHEM LETT, V26, P636, DOI 10.1016/j.bmcl.2015.11.059
   JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo 126 2 1014
   Kaji H, 2006, HORM METAB RES, V38, P740, DOI 10.1055/s 2006 955085
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kawashima N, 2012, ARCH ORAL BIOL, V57, P1439, DOI 10.1016/j.archoralbio.2012.08.010
   KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432 1033.1990.tb15547.x
   Kumar P, 2018, Cold Spring Harbor Protocols, V2018, DOI DOI 10.1101/PDB.PROT095505
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee OH, 2000, BRIT J CANCER, V82, P385
   Lin Q, 1998, DEVELOPMENT, V125, P4565
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo 128 1 413
   Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462
   Montero J. L., 2009, Patent No. [WO 2009138600 A219, 2009138600219]
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Munakata M, 2024, BIOENGINEERING BASEL, V11, DOI 10.3390/bioengineering11020192
   NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo 124 2 612
   Patel H, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.48943
   Rather HA, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109761
   Scimeca JC, 2017, DRUG DISCOV TODAY, V22, P1084, DOI 10.1016/j.drudis.2017.04.007
   Seong JM, 2010, BIOMED MATER, V5, DOI 10.1088/1748 6041/5/6/062001
   SHERBINA NV, 1992, BONE, V13, P197, DOI 10.1016/8756 3282(92)90012 L
   Shi XM, 2013, INT J MOL SCI, V14, P14321, DOI 10.3390/ijms140714321
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Stephens AS, 2011, J BIOL CHEM, V286, P30071, DOI 10.1074/jbc.M111.253518
   Suzuki E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112566
   Vladulescu D, 2024, BIOMEDICINES, V12, DOI 10.3390/biomedicines12010007
   Xu JJ, 2020, J BONE MINER RES, V35, P167, DOI 10.1002/jbmr.3871
   Yang LJ, 2000, WOUND REPAIR REGEN, V8, P538, DOI 10.1046/j.1524 475x.2000.00538.x
   Zaichick V, 2002, APPL RADIAT ISOTOPES, V56, P781, DOI 10.1016/S0969 8043(02)00066 0
   Zhang WH, 2020, INT J MOL MED, V45, P1501, DOI 10.3892/ijmm.2020.4525
   Zhu SY, 2011, ANNU REV BIOMED ENG, V13, P73, DOI 10.1146/annurev bioeng 071910 124715
   Zisch AH, 2003, CARDIOVASC PATHOL, V12, P295, DOI 10.1016/S1054 8807(03)00089 9
NR 56
TC 0
Z9 0
U1 9
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD DEC
PY 2024
VL 12
IS 12
AR 2697
DI 10.3390/biomedicines12122697
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA Q9T2W
UT WOS:001388003200001
PM 39767604
OA gold
DA 2025 08 17
ER

PT J
AU Deng, ZT
   Jin, JW
   Wang, ZH
   Wang, Y
   Gao, Q
   Zhao, JN
AF Deng, Zhantao
   Jin, Jiewen
   Wang, Zhenheng
   Wang, Yong
   Gao, Qian
   Zhao, Jianning
TI The metal nanoparticle induced inflammatory response is regulated by
   SIRT1 through NF κB deacetylation in aseptic loosening
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE metal nanoparticle; inflammatory response; SIRT1; NF kappa B; aseptic
   loosening
ID ENDOPLASMIC RETICULUM STRESS; PARTICLE INDUCED OSTEOLYSIS; TNF ALPHA;
   WEAR; PROTEIN; OSTEOBLASTS; TRANSCRIPTION; MACROPHAGES; EXPRESSION;
   TITANIUM
AB Aseptic loosening is the most common cause of total hip arthroplasty (THA) failure, and osteolysis induced by wear particles plays a major role in aseptic loosening. Various pathways in multiple cell types contribute to the pathogenesis of osteolysis, but the role of Sirtuin 1 (SIRT1), which can regulate inflammatory responses through its deacetylation, has never been investigated. We hypothesized that the downregulation of SIRT1 in macrophages induced by metal nanoparticles was one of the reasons for osteolysis in THA failure. In this study, the expression of SIRT1 was examined in macrophages stimulated with metal nanoparticles from materials used in prosthetics and in specimens from patients suffering from aseptic loosening. To address whether SIRT1 downregulation triggers these inflammatory responses, the effects of the SIRT1 activator resveratrol on the expression of inflammatory cytokines in metal nanoparticle stimulated macrophages were tested. The results demonstrated that SIRT1 expression was significantly downregulated in metal nanoparticle stimulated macrophages and clinical specimens of prosthesis loosening. Pharmacological activation of SIRT1 dramatically reduced the particle induced expression of inflammatory cytokines in vitro and osteolysis in vivo. Furthermore, SIRT1 regulated particle induced inflammatory responses through nuclear factor kappa B (NF kappa B) acetylation. Thus, the results of this study suggest that SIRT1 plays a key role in metal nanoparticle induced inflammatory responses and that targeting the SIRT1 pathway may lead to novel therapeutic approaches for the treatment of aseptic prosthesis loosening.
C1 [Deng, Zhantao; Wang, Zhenheng; Zhao, Jianning] Nanjing Univ, Sch Med, Jinling Hosp, Dept Orthoped, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.
   [Deng, Zhantao; Jin, Jiewen; Wang, Yong; Gao, Qian] Nanjing Univ, Med Sch, Ctr Translat Med, Nanjing, Jiangsu, Peoples R China.
   [Deng, Zhantao; Jin, Jiewen; Wang, Yong; Gao, Qian] Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, 22 Hankou Rd, Nanjing 210002, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Zhao, JN (通讯作者)，Nanjing Univ, Sch Med, Jinling Hosp, Dept Orthoped, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.; Gao, Q (通讯作者)，Nanjing Univ, Med Sch, Jiangsu Key Lab Mol Med, 22 Hankou Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM qian_gao@nju.edu.cn; zhaojianning.0207@163.com
FU National Natural Science Foundation of China [81572111]; Clinical
   Science and Technology Project Foundation of Jiangsu Province
   [BL2012002]; Scientific Research Project of Nanjing [201402007]; Natural
   Science Foundation of Jiangsu Province [BK20161385]
FX First, we thank all the patients and family members who participated in
   our study. This study was supported by the National Natural Science
   Foundation of China (81572111), the Clinical Science and Technology
   Project Foundation of Jiangsu Province (BL2012002), the Scientific
   Research Project of Nanjing (201402007), and the Natural Science
   Foundation of Jiangsu Province (BK20161385).
CR [Anonymous], J ORTHOP RES
   [Anonymous], ARTHRITIS RES THER
   [Anonymous], J BIOL CHEM
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200
   Cherian JJ, 2015, CLIN ORTHOP RELAT R, V473, P2700, DOI 10.1007/s11999 015 4220 2
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Deng ZT, 2017, ACTA BIOMATER, V49, P541, DOI 10.1016/j.actbio.2016.11.051
   Dong J, 2010, GENE DEV, V24, P1709, DOI 10.1101/gad.1958410
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962 8924(00)01745 1
   Fujii J, 2011, HIP INT, V21, P231, DOI 10.5301/HIP.2011.7977
   Fusco S, 2012, CELL CYCLE, V11, P4135, DOI 10.4161/cc.22074
   Gallo J, 2008, PHYSIOL RES, V57, P339, DOI 10.33549/physiolres.931140
   Gambhir S, 2015, WORLD J GASTROENTERO, V21, P3174, DOI 10.3748/wjg.v21.i11.3174
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Goodman SB, 1998, J BONE JOINT SURG BR, V80B, P531, DOI 10.1302/0301 620X.80B3.8158
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Gülçin I, 2003, J ETHNOPHARMACOL, V86, P51, DOI 10.1016/S0378 8741(03)00036 9
   Guo R, 2015, INT J CARDIOL, V191, P36, DOI 10.1016/j.ijcard.2015.04.245
   Hallab NJ, 2009, BULL HOSP JT DIS, V67, P182
   Hao HN, 2010, J BIOMED MATER RES A, V92A, P1373, DOI 10.1002/jbm.a.32474
   Hoenders CSM, 2008, J BIOMED MATER RES B, V86B, P291, DOI 10.1002/jbm.b.30992
   Huang W, 2012, ACTA PHARMACOL SIN, V33, P668, DOI 10.1038/aps.2011.189
   Kaufman AM, 2008, J BIOMED MATER RES A, V84A, P464, DOI 10.1002/jbm.a.31467
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim KJ, 1998, CLIN ORTHOP RELAT R, P46
   Kotas ME, 2013, ADIPOCYTE, V2, P113, DOI 10.4161/adip.23437
   Kwon HS, 2008, CELL HOST MICROBE, V3, P158, DOI 10.1016/j.chom.2008.02.002
   Lee J, 2014, CELL STRESS CHAPERON, V19, P649, DOI 10.1007/s12192 013 0490 3
   Li Y, 2011, FASEB J, V25, P1664, DOI 10.1096/fj.10 173492
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Lou Y, 2015, INT J MOL MED, V36, P873, DOI 10.3892/ijmm.2015.2291
   Melhem H, 2016, GUT, V65, P595, DOI 10.1136/gutjnl 2014 307030
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   MURRAY DW, 1990, J BONE JOINT SURG BR, V72, P988, DOI 10.1302/0301 620X.72B6.2246303
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Pearl JI, 2011, BIOMATERIALS, V32, P5535, DOI 10.1016/j.biomaterials.2011.04.046
   Prokopovich P, 2014, ADV COLLOID INTERFAC, V213, P36, DOI 10.1016/j.cis.2014.09.001
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   RAE T, 1986, BIOMATERIALS, V7, P30, DOI 10.1016/0142 9612(86)90085 2
   Rai E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048621
   Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708 1269OC
   Shanbhag AS, 1998, J BIOMED MATER RES, V41, P497, DOI 10.1002/(SICI)1097 4636(19980905)41:3<497::AID JBM21>3.3.CO;2 G
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Takeda Watanabe A, 2012, BIOCHEM BIOPH RES CO, V427, P191, DOI 10.1016/j.bbrc.2012.09.042
   Takei H, 2000, J BIOMED MATER RES, V52, P382, DOI 10.1002/1097 4636(200011)52:2<382::AID JBM19>3.0.CO;2 V
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Wang R, 2013, BIOMATERIALS, V34, P2611, DOI 10.1016/j.biomaterials.2013.01.025
   Wang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137774
   Wang ZH, 2015, ACTA BIOMATER, V24, P352, DOI 10.1016/j.actbio.2015.06.024
   Wooley PH, 2004, GENE THER, V11, P402, DOI 10.1038/sj.gt.3302202
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yang HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046364
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yin HQ, 2014, GASTROENTEROLOGY, V146, P801, DOI 10.1053/j.gastro.2013.11.008
NR 61
TC 44
Z9 45
U1 0
U2 16
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2017
VL 12
BP 3617
EP 3636
DI 10.2147/IJN.S124661
PG 20
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA EU4MG
UT WOS:000401003100002
PM 28553103
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Bimonte, VM
   Catanzaro, G
   Po, A
   Trocchianesi, S
   Besharat, ZM
   Spinello, Z
   Curreli, M
   Fabi, A
   Bei, R
   Milella, M
   Vacca, A
   Ferretti, E
   Migliaccio, S
AF Bimonte, Viviana M.
   Catanzaro, Giuseppina
   Po, Agnese
   Trocchianesi, Sofia
   Besharat, Zein Mersini
   Spinello, Zaira
   Curreli, Mariaignazia
   Fabi, Alessandra
   Bei, Roberto
   Milella, Michele
   Vacca, Alessandra
   Ferretti, Elisabetta
   Migliaccio, Silvia
TI The endocrine disruptor cadmium modulates the androgen estrogen
   receptors ratio and induces inflammatory cytokines in luminal (A) cell
   models of breast cancer
SO ENDOCRINE
LA English
DT Article
DE Cadmium; Endocrine disruptors; Breast cancer; Estrogen receptors;
   Androgen receptor; Cytokines
ID ACTIVATED PROTEIN KINASE; ALPHA; MECHANISM; INTERLEUKIN 6; OSTEOBLASTS;
   HOMEOSTASIS; BETA
AB PurposeBreast cancer (BC) is the most common malignancy that affects women, and it is, to date, their leading cause of death. Luminal A molecular subtype accounts for 40% of BC and is characterized by hormone receptors positive/human epidermal growth factor 2 expression and current treatment consists of surgery plus aromatase inhibitor therapy. Interestingly, several studies demonstrated that the heavy metal cadmium (Cd), classified as a group 1 human carcinogen and widely spread in the environment, exerts estrogen like activities in several tissues and suggested an intriguing relationship between increased Cd exposure and BC incidence. Thus, aim of this study was to evaluate effects of Cd on Luminal A BC estrogen receptor (ER) positive/progesterone receptor positive cell models in vitro to characterize the mechanism(s) involved in breast cell homeostasis disruption.MethodsT47D and MCF7 were exposed to Cd (0.5 1 mu M) for 6 24 h to evaluate potential alterations in: cells viability, steroid receptors and intracellular signaling by western blot. Moreover, we evaluated the expression of inflammatory cytokines interleukin by RT PCR.ResultsOur results showed a significant induction of androgen receptor (AR) and an increased AR/ER ratio. Further, Cd exposure increased pro inflammatory cytokines interleukin (IL)6, IL8 and tumor necrosis factor alpha levels. Finally, as previously demonstrated by our group, Cd alters pathways such as mitogen activated protein kinase family and protein kinase B.ConclusionIn conclusion, our study demonstrates that Cd modifies the expression and pattern of ERs and AR in BC cell lines, suggesting an alteration of BC cells homeostasis, likely predisposing to a carcinogenetic microenvironment.
C1 [Bimonte, Viviana M.; Curreli, Mariaignazia; Migliaccio, Silvia] Univ Foro Italico, Dept Movement Human & Hlth Sci, I 00195 Rome, Italy.
   [Catanzaro, Giuseppina; Besharat, Zein Mersini; Spinello, Zaira; Vacca, Alessandra; Ferretti, Elisabetta] Sapienza Univ Rome, Dept Expt Med, I 00161 Rome, Italy.
   [Po, Agnese; Trocchianesi, Sofia] Sapienza Univ Rome, Dept Mol Med, I 00161 Rome, Italy.
   [Fabi, Alessandra] Fdn Policlin Univ A Gemelli IRCCS, Precis Med Senol Unit, I 00168 Rome, Italy.
   [Bei, Roberto] Univ Roma Tor Vergata, Dept Clin Sci & Translat Med, I 00133 Rome, Italy.
   [Milella, Michele] Univ Verona, Dept Oncol, I 37134 Verona, Italy.
C3 Foro Italico University of Rome; Sapienza University Rome; Sapienza
   University Rome; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli; University of Rome Tor Vergata; University of
   Verona
RP Migliaccio, S (通讯作者)，Univ Foro Italico, Dept Movement Human & Hlth Sci, I 00195 Rome, Italy.
EM silvia.migliaccio@uniroma4.it
RI Besharat, Zein Mersini/G 5413 2013; Curreli, Mariaignazia/GYA 2481 2022;
   Milella, Michele/ABH 8606 2020; Po, Agnese/G 8754 2015; catanzaro,
   giuseppina/AGZ 8080 2022; Bei, Roberto/W 8023 2019; Fabi,
   Alessandra/AAC 1021 2019; Spinello, Zaira/AIB 7587 2022
OI Spinello, Zaira/0000 0002 7016 6538; Bimonte, Viviana
   Maria/0000 0003 4345 9033; 
FU Ministero dell'Universit e della Ricerca
FX The authors would like to acknowledge all the support staff at the
   participating institutions for their contributions to this study.
CR Aka JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031532
   Anestis A, 2020, MOLECULES, V25, DOI 10.3390/molecules25020358
   Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
   Bakr AG, 2022, LIFE SCI, V311, DOI 10.1016/j.lfs.2022.121152
   Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078 0432.CCR 04 0812
   Bimonte VM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020754
   Bimonte VM, 2017, ENDOCRINE, V58, P340, DOI 10.1007/s12020 016 1193 1
   Brama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013
   Byrne C, 2009, TOXICOL APPL PHARM, V238, P266, DOI 10.1016/j.taap.2009.03.025
   Darbre PD, 2021, ADV PHARMACOL, V92, P485, DOI 10.1016/bs.apha.2021.04.006
   Dwyer AR, 2020, J MOL ENDOCRINOL, V65, pT35, DOI 10.1530/JME 19 0274
   Elbalka Saleh S, 2022, Breast Dis, V41, P495, DOI 10.3233/BD 220037
   Esquivel Velázquez M, 2015, J INTERF CYTOK RES, V35, P1, DOI 10.1089/jir.2014.0026
   Fiocchetti M, 2021, TOXICS, V9, DOI 10.3390/toxics9100237
   Fittipaldi S, 2019, J ENDOCRINOL INVEST, V42, P727, DOI 10.1007/s40618 018 0982 1
   Florez Garcia V, 2023, ENVIRON RES, V219, DOI 10.1016/j.envres.2022.115109
   Folgiero V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.179
   GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896
   Gomes LR, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 26
   Goyer RA, 1997, ANNU REV NUTR, V17, P37, DOI 10.1146/annurev.nutr.17.1.37
   Habanjar O, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24044002
   Hassanein EHM, 2022, LIFE SCI, V308, DOI 10.1016/j.lfs.2022.120971
   Hirao Suzuki M, 2021, BIOL PHARM BULL, V44, P1594, DOI 10.1248/bpb.b21 00468
   Ibrahim AS, 2022, LIPIDS HEALTH DIS, V21, DOI 10.1186/s12944 022 01678 y
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Joseph P, 2009, TOXICOL APPL PHARM, V238, P272, DOI 10.1016/j.taap.2009.01.011
   Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821
   Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014
   Limoge M, 2017, ONCOTARGET, V8, P61969, DOI 10.18632/oncotarget.18755
   Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007
   Luevano J, 2014, J ENVIRON PATHOL TOX, V33, P183, DOI 10.1615/JEnvironPatholToxicolOncol.2014011075
   Ma JH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0527 z
   Manore SG, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.866014
   Michmerhuizen AR, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523 020 00190 9
   Migliaccio S, 2003, CALCIFIED TISSUE INT, V72, P181, DOI 10.1007/s00223 002 1042 5
   Migliaccio S, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12010044
   Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097 0215(20000720)89:4<384::AID IJC11>3.0.CO;2 R
   Nita Irina, 2021, Med Pharm Rep, V94, P273, DOI 10.15386/mpr 1842
   Ostrovsky O, 2020, ADV EXP MED BIOL, V1221, P231, DOI 10.1007/978 3 030 34521 1_8
   Papa V, 2015, J ENDOCRINOL INVEST, V38, P1345, DOI 10.1007/s40618 015 0380 x
   Peana M, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13010036
   Po A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70871 9
   Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07 8832com
   Shen K, 2023, PHARMACOL THERAPEUT, V242, DOI 10.1016/j.pharmthera.2023.108350
   Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309
   Starek Swiechowicz B, 2021, PHARMACOL REP, V73, P1497, DOI 10.1007/s43440 021 00317 0
   Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545
   Strumylaite L, 2011, BREAST CANCER RES TR, V125, P511, DOI 10.1007/s10549 010 1007 8
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Tahtamouni L, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0279746
   Tarhonska K, 2022, TOXICOL LETT, V361, P29, DOI 10.1016/j.toxlet.2022.03.003
   Todorovic Rakovic N, 2013, J INTERF CYTOK RES, V33, P563, DOI 10.1089/jir.2013.0023
   Trapani D, 2022, CANCER TREAT REV, V104, DOI 10.1016/j.ctrv.2022.102339
   Waalkes MP, 2003, MUTAT RES FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011
   WELSHONS WV, 1988, MOL CELL ENDOCRINOL, V57, P169, DOI 10.1016/0303 7207(88)90072 X
   Xie Q, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0744 3
   Yasar P, 2017, REPROD MED BIOL, V16, P4, DOI 10.1002/rmb2.12006
   You CP, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232315342
   Yu S, 2017, BIOCHEM BIOPH RES CO, V486, P752, DOI 10.1016/j.bbrc.2017.03.114
   Zhang F, 2019, J CELL BIOCHEM, V120, P10342, DOI 10.1002/jcb.28318
NR 60
TC 3
Z9 3
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD MAR
PY 2024
VL 83
IS 3
BP 798
EP 809
DI 10.1007/s12020 023 03594 2
EA NOV 2023
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LC7N1
UT WOS:001120921200002
PM 37979099
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Anandi, P
   Jain, NA
   Tian, X
   Wu, CO
   Pophali, PA
   Koklanaris, E
   Ito, S
   Savani, BN
   Barrett, J
   Battiwalla, M
AF Anandi, P.
   Jain, N. A.
   Tian, X.
   Wu, C. O.
   Pophali, P. A.
   Koklanaris, E.
   Ito, S.
   Savani, B. N.
   Barrett, J.
   Battiwalla, M.
TI Factors influencing the late phase of recovery after bone mineral
   density loss in allogeneic stem cell transplantation survivors
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
ID LONG TERM SURVIVORS; ZOLEDRONIC ACID; AVASCULAR NECROSIS; FRACTURE RISK;
   FOLLOW UP; OSTEOPOROSIS; RECIPIENTS; PAMIDRONATE; MECHANISMS; PREVENTION
AB Accelerated bone mineral density loss (BMDL) occurs early after allogeneic stem cell transplantation (SCT) and is related to factors such as steroids and chronic GvHD. In order to understand the natural history of BMDL of SCT in the longer term, we evaluated a longitudinal cohort of 148 survivors with a median follow up of 12 years (range 3 22 years). All women received hormone replacement therapy, and routine calcium/vitamin D supplementation was recommended but similar to 50% of patients still had suboptimal vitamin D levels and bisphosphonates were rarely utilized. BMD significantly improved from 5 to 20+ years but the femoral neck and forearm remained vulnerable sites. Younger age, higher pretransplant body mass index (BMI) and increment in BMI post transplant were significantly associated with increased BMD and protected against osteopenia/osteoporosis. These findings support consideration of BMD loss in SCT survivors in two phases, an early phase of BMD loss (3 5 years) followed by a later phase of BMD recovery, with different protective and aggravating factors. Treatment and transplant related factors (such as steroids, immunosuppressives, chronic GvHD, vitamin D) are known to impact the early phase of BMD loss but age and BMI are more influential in the late phase of BMD recovery.
C1 [Anandi, P.; Jain, N. A.; Pophali, P. A.; Koklanaris, E.; Ito, S.; Barrett, J.; Battiwalla, M.] NHLBI, Hematol Branch, NIH, Bldg 10 CRC,Room 5 3581,10 Ctr Dr MSC 1202, Bethesda, MD 20892 USA.
   [Tian, X.; Wu, C. O.] NHLBI, Off Biostat Res, NIH, Bldg 10 CRC,Room 5 3581,10 Ctr Dr MSC 1202, Bethesda, MD 20892 USA.
   [Savani, B. N.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
C3 National Institutes of Health (NIH)   USA; NIH National Heart Lung &
   Blood Institute (NHLBI); National Institutes of Health (NIH)   USA; NIH
   National Heart Lung & Blood Institute (NHLBI); Vanderbilt University
RP Battiwalla, M (通讯作者)，NHLBI, Stem Cell Allogene Transplantat Sect, Hematol Branch, NIH, Bldg 10 CRC,Room 5 3581,10 Ctr Dr MSC 1202, Bethesda, MD 20892 USA.
EM minoo.battiwalla@nih.gov
RI Savani, Bipin/LZH 1365 2025; Pophali, Priyanka/P 8646 2016; Jain,
   Natasha/AAO 1108 2020
OI Ito, Sawa/0000 0002 6076 0234; Jain, Natasha/0000 0002 8638 6754
FU NHLBI, NIH
FX This work was supported by the Intramural Research Program of the NHLBI,
   NIH.
CR [Anonymous], RINSHO KETSUEKI
   Chae YS, 2009, BONE MARROW TRANSPL, V44, P35, DOI 10.1038/bmt.2008.414
   D'Souza AB, 2006, INTERN MED J, V36, P600, DOI 10.1111/j.1445 5994.2006.01154.x
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Duncan CN, 2011, BIOL BLOOD MARROW TR, V17, P749, DOI 10.1016/j.bbmt.2010.10.009
   Ebeling PR, 2009, J CLIN ENDOCR METAB, V94, P1483, DOI 10.1210/jc.2009 0205
   Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342
   Faulhaber GAM, 2009, BONE MARROW TRANSPL, V43, P953, DOI 10.1038/bmt.2009.70
   Gandhi MK, 2003, BRIT J HAEMATOL, V121, P462, DOI 10.1046/j.1365 2141.2003.04303.x
   Ganguly S, 2012, CLIN TRANSPLANT, V26, P447, DOI 10.1111/j.1399 0012.2011.01527.x
   Grigg AP, 2006, J CLIN ENDOCR METAB, V91, P3835, DOI 10.1210/jc.2006 0684
   GROUP W, 2004, J CLIN DENSITOM, V7, P17
   Hari P, 2013, BIOL BLOOD MARROW TR, V19, P1361, DOI 10.1016/j.bbmt.2013.06.015
   Kananen K, 2005, J CLIN ENDOCR METAB, V90, P3877, DOI 10.1210/jc.2004 2161
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281
   Kodama M, 2011, FERTIL STERIL, V95, P731, DOI 10.1016/j.fertnstert.2010.09.037
   McClune BL, 2011, BONE MARROW TRANSPL, V46, P1, DOI 10.1038/bmt.2010.198
   McClune B, 2012, SEMIN HEMATOL, V49, P59, DOI 10.1053/j.seminhematol.2011.10.007
   Pundole XN, 2015, J CLIN ONCOL, V33, P1364, DOI 10.1200/JCO.2014.57.8195
   Savani BN, 2007, BIOL BLOOD MARROW TR, V13, P517, DOI 10.1016/j.bbmt.2007.01.085
   Schulte C, 2000, OSTEOPOROSIS INT, V11, P344, DOI 10.1007/s001980070124
   Schulte CMS, 2004, BLOOD, V103, P3635, DOI 10.1182/blood 2003 09 3081
   Shuler FD, 2012, ORTHOPEDICS, V35, P798, DOI 10.3928/01477447 20120822 12
   Stern JM, 2001, BIOL BLOOD MARROW TR, V7, P257, DOI 10.1053/bbmt.2001.v7.pm11400947
   Tauchmanovà L, 2006, BONE MARROW TRANSPL, V37, P81, DOI 10.1038/sj.bmt.1705196
   Tauchmanovà L, 2005, J CLIN ENDOCR METAB, V90, P627, DOI 10.1210/jc.2004 0509
   Tauchmanovà L, 2003, OSTEOPOROSIS INT, V14, P1013, DOI 10.1007/s00198 003 1520 2
   Tauchmanovà L, 2003, CANCER, V97, P2453, DOI 10.1002/cncr.11373
   Tauchmanovà L, 2002, J CLIN ENDOCR METAB, V87, P5058, DOI 10.1210/jc.2002 020800
   Välimäki MJ, 1999, BONE MARROW TRANSPL, V23, P355, DOI 10.1038/sj.bmt.1701586
   van der Voort DJM, 2001, OSTEOPOROSIS INT, V12, P630, DOI 10.1007/s001980170062
   Weilbaecher KN, 2000, BIOL BLOOD MARROW TR, V6, P165, DOI 10.1016/S1083 8791(00)70039 5
   Yao S, 2008, BONE MARROW TRANSPL, V41, P393, DOI 10.1038/sj.bmt.1705918
   Yao S, 2010, BIOL BLOOD MARROW TR, V16, P1130, DOI 10.1016/j.bbmt.2010.02.017
NR 34
TC 18
Z9 20
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268 3369
EI 1476 5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD AUG
PY 2016
VL 51
IS 8
BP 1101
EP 1106
DI 10.1038/bmt.2016.85
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA DS4WB
UT WOS:000380781200014
PM 27042843
OA Bronze
DA 2025 08 17
ER

PT J
AU Brown, AJ
AF Brown, Alex J.
TI Vitamin D analogs for secondary hyperparathyroidism: What does the
   future hold?
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 13th Workshop on Vitamin D
CY APR 07 12, 2006
CL Victoria, CANADA
SP Novacea Inc, Solvay Pharmaceut BV, Teijin Ltd
ID PARATHYROID HORMONE SECRETION; MODERATE RENAL FAILURE; CHRONIC
   KIDNEY DISEASE; HEMODIALYSIS PATIENTS; DIALYSIS PATIENTS;
   1 ALPHA HYDROXYVITAMIN D 2; BINDING PROPERTIES; UREMIC RATS;
   PARICALCITOL; CALCITRIOL
AB Secondary hyperparathyroidism (2 degrees HPT) commonly develops in patients with chronic kidney disease (CKD) in response to high phosphate, low calcium and low 1,25 dihydroxyvitamin D 3 [1 alpha,25(OH)(2)D 3]. High PTH levels increase the rate of bone turnover, with a net efflux of calcium and phosphate leading to vascular calcification and coronary artery disease. Treatment of 2 degrees HPT with 1 alpha,25(OH)(2)D 3 and calciumbased phosphate binders often produces hypercalcemia and over suppression of PTH, resulting in adynamic bone that cannot buffer excess calcium and phosphate, which increases the risk of vascular calcification. It is essential, then, to reduce PTH levels to a range that supports normal bone turnover and minimizes ectopic calcification. Vitamin D analogs that inhibit PTH gene transcription and parathyroid hyperplasia, and that have less calcemic activity than 1 alpha,25(OH)(2)D 3, have provided a greater safety margin for the treatment of 2'HPT, as well as enhancing the survival of CKD patients. Although several analogs with less calcemic activity are now used in patients (paricalcitol and doxercalciferol in the USA, and OCT and falecalcitriol in Japan), efforts to develop even more selective analogs continue. Parathyroid glands express both 25 hydroxylase and 1 alpha hydroxylase and may be capable of activating prohormones or prodrugs to suppress PTH and parathyroid growth by an autocrine mechanism. Moreover, the introduction of non calcium based phosphate binders (sevelamer and lanthanum carbonate) and cinacalcet (an allosteric activator of the calcium receptor that reduces PTH and the serum calcium x phosphate product) may reduce the risk of hypercalcernia with vitamin D therapy. Combining these agents with higher doses of vitamin D compounds may achieve greater suppression of PTH and possibly enhance survival in patients with chronic kidney disease. (c) 2007 Published by Elsevier Ltd.
C1 Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Brown, AJ (通讯作者)，Washington Univ, Sch Med, Div Renal, Box 8126,660 S Euclid, St Louis, MO 63110 USA.
EM abrown@im.wustl.edu
CR Akizawa T, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_10.28
   Albaaj F, 2005, INT J CLIN PRACT, V59, P1091, DOI 10.1111/j.1368 5031.2005.00592.x
   BAKER LRI, 1989, KIDNEY INT, V35, P661, DOI 10.1038/ki.1989.36
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Brown AJ, 2005, J CELL BIOCHEM, V96, P569, DOI 10.1002/jcb.20553
   BROWN AJ, 1993, ENDOCRINOLOGY, V133, P1158, DOI 10.1210/en.133.3.1158
   Coburn JW, 2004, AM J KIDNEY DIS, V43, P877, DOI 10.1053/j.ajkd.2004.01.012
   Correa P, 2002, J CLIN ENDOCR METAB, V87, P5826, DOI 10.1210/jc.2002 021356
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Coyne DW, 2002, AM J KIDNEY DIS, V40, P1283, DOI 10.1053/ajkd.2002.36899
   Dobrez DG, 2004, NEPHROL DIAL TRANSPL, V19, P1174, DOI 10.1093/ndt/gfh123
   DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo 128 4 1687
   Frazao JM, 1998, NEPHROL DIAL TRANSPL, V13, P68, DOI 10.1093/ndt/13.suppl_3.68
   Goodman WG, 2005, CURR OPIN NEPHROL HY, V14, P355, DOI 10.1097/01.mnh.0000172722.52499.71
   Hayashi M, 2004, NEPHROL DIAL TRANSPL, V19, P2067, DOI 10.1093/ndt/gfh329
   HEALY MD, 1980, ARCH INTERN MED, V140, P1030, DOI 10.1001/archinte.140.8.1030
   Ho LT, 2002, SEMIN NEPHROL, V22, P488, DOI 10.1053/snep.2002.35965
   KOBAYASHI T, 1994, J BIOCHEM TOKYO, V115, P373, DOI 10.1093/oxfordjournals.jbchem.a124346
   Koike N, 2002, NEPHROL DIAL TRANSPL, V17, P53, DOI 10.1093/ndt/17.suppl_10.53
   Komuro S, 2003, DRUG METAB DISPOS, V31, P973, DOI 10.1124/dmd.31.8.973
   Lippuner K, 2004, HORM RES, V61, P7, DOI 10.1159/000075191
   Llach F, 2001, AM J KIDNEY DIS, V38, pS45, DOI 10.1053/ajkd.2001.28114
   Martin KJ, 1998, AM J KIDNEY DIS, V32, pS61, DOI 10.1053/ajkd.1998.v32.pm9808145
   Martin KJ, 2004, AM J KIDNEY DIS, V43, P558, DOI 10.1053/j.ajkd.2003.12.003
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Martinez I, 1996, NEPHROL DIAL TRANSPL, V11, P22, DOI 10.1093/ndt/11.supp3.22
   Maung HM, 2001, AM J KIDNEY DIS, V37, P532
   OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529
   Plum LA, 2004, P NATL ACAD SCI USA, V101, P6900, DOI 10.1073/pnas.0401656101
   REINHART GA, 2005, J AM SOC NEPHROL, V16, pA495
   RITTER CS, 2005, J AM SOC NEPHROL, V16, pA750
   ROWN AJ, 1990, KIDNEY INT       S29, V29, pS22
   Segersten U, 2002, J CLIN ENDOCR METAB, V87, P2967, DOI 10.1210/jc.87.6.2967
   SJODEN G, 1985, P SOC EXP BIOL MED, V178, P432
   Slatopolsky E, 2002, KIDNEY INT, V62, P1277, DOI 10.1111/j.1523 1755.2002.kid573.x
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   SLATOPOLSKY E, 2003, J AM SOC NEPHROL, V14
   Slatopolsky EA, 1999, KIDNEY INT, V55, P299, DOI 10.1046/j.1523 1755.1999.00240.x
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Sprague SM, 2001, AM J KIDNEY DIS, V38, pS51, DOI 10.1053/ajkd.2001.28110
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   Tan AU, 1997, KIDNEY INT, V51, P317, DOI 10.1038/ki.1997.39
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   TENTORI F, 2005, J AM SOC NEPHROL, V16, pA279
   Zisman AL, 2005, AM J NEPHROL, V25, P591, DOI 10.1159/000089707
NR 46
TC 23
Z9 24
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAR
PY 2007
VL 103
IS 3 5
SI SI
BP 578
EP 583
DI 10.1016/j.jsbmb.2006.12.089
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 158WU
UT WOS:000245826800070
PM 17368185
DA 2025 08 17
ER

PT J
AU Shao, F
   Panahipour, L
   Gruber, R
AF Shao, Feng
   Panahipour, Layla
   Gruber, Reinhard
TI Flavonoids from Dalbergia cochinchinensis: Impact on osteoclastogenesis
SO JOURNAL OF DENTAL SCIENCES
LA English
DT Article
DE Flavonoids; Dalbergia cochinchinensis; Osteoclastogenesis
ID DIFFERENTIATION; OSTEOPOROSIS; HEARTWOOD; ISOLIQUIRITIGENIN; MODEL;
   CONSTITUENTS; INHIBITION; MECHANISMS; COLITIS
AB Background/purpose: Dalbergia cochinchinensi has been widely used in traditional medicine because of its flavonoids. This study examined which components in D. cochinchinen sis were capable of reducing or even stimulating the formation of bone resorbing osteoclasts.Materials and methods: We have isolated subfamilies of chalcones (isoliquiritigenin, butein), flavones (7 hydroxy 6 methoxyflavone) and neoflavanoids (5 methoxylatifolin), and performed an in vitro bioassay on osteoclastogenesis. The flavonoids were tested for their potential to change the expression of tartrate resistant acid phosphatase (TRAP) and cathepsin K (CTSK) in murine bone marrow cultures being exposed to RANKL, M CSF and TGF b1 using RT PCR, histochemistry and immunoassay.Results: We could confirm that isoliquiritigenin and butein significantly lower the expression of TRAP and CTSK in this setting. Moreover, histochemistry supported the decrease of TRAP by the chalcones. We further observed a trend towards an increase of osteoclastogenesis in the pres ence of 5 methoxylatifolin and 7 hydroxy 6 methoxyflavone, particular in bone marrow cul tures being exposed to RANKL and M CSF. Consistently, the anti inflammatory activity was restricted to isoliquiritigenin and butein in murine RAW 264.7 inflammatory macrophages stim ulated by lipopolysaccharide (LPS). With respect to osteoblastogenesis, neither of the flavo noids but butyrate, a short chain fatty acid, increased the osteogenic differentiation marker alkaline phosphatase activity in ST2 murine mesenchymal cells.Conclusion: We have identified two flavonoids from D. cochinchinensis with a potential pro osteoclastogenic activity and confirm the anti osteoclastogenic activity of isoliquiritigenin and butein. 2022 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY NC ND license (http://creativecommons. org/licenses/by nc nd/4.0/).
C1 [Shao, Feng; Panahipour, Layla; Gruber, Reinhard] Med Univ Vienna, Univ Clin Dent, Dept Oral Biol, Sensengasse 2a, A 1090 Vienna, Austria.
   [Shao, Feng] Jiangxi Univ Tradit Chinese Med, Key Lab Modern Preparat Tradit Chinese Med, Minist Educ, Nanchang, Peoples R China.
   [Shao, Feng] Jiangxi Univ Tradit Chinese Med, Key Lab Innovat Drug & Efficient Energy saving Pha, Nanchang, Peoples R China.
   [Gruber, Reinhard] Univ Bern, Sch Dent Med, Dept Periodontol, Bern, Switzerland.
   [Gruber, Reinhard] Austrian Cluster Tissue Regenerat, Vienna, Austria.
C3 Medical University of Vienna; Jiangxi University of Traditional Chinese
   Medicine; Jiangxi University of Traditional Chinese Medicine; University
   of Bern
RP Gruber, R (通讯作者)，Med Univ Vienna, Univ Clin Dent, Dept Oral Biol, Sensengasse 2a, A 1090 Vienna, Austria.
EM reinhard.gruber@meduniwien.ac.at
RI Gruber, Reinhard/A 8053 2012; SHAO, Feng/HKO 9182 2023
OI Shao, Feng/0000 0002 4306 6451
FU National Natural Science Foundation of China [82160733, 81760094];
   Chinese Government Scholarship [202008360031]; Science and Technology
   Project of Depart  ment Education of Jiangxi Province [GJJ201203];
   Science and Technology Planning of Health Commission of Jiangxi Province
   [202131043]
FX This project was supported by the National Natural Science Foundation of
   China (Grant numbers 82160733, 81760094) , the Chinese Government
   Scholarship (Grant numbers 202008360031) , Science and Technology
   Project of Depart  ment Education of Jiangxi Province (Grant numbers
   GJJ201203) , Science and Technology Planning of Health Commission of
   Jiangxi Province (Grant numbers 202131043) .
CR Al Mamun MA, 2015, BIOL RES, V48, DOI [10.1186/s40659 015 0056 1, 10.1186/S40659 015 0056 1]
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P515, DOI 10.1016/j.tem.2021.03.008
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Carnovali M, 2020, J PHARMACOL SCI, V143, P300, DOI 10.1016/j.jphs.2020.06.001
   Chan SC, 1998, PLANTA MED, V64, P153, DOI 10.1055/s 2006 957394
   Choi YH, 2016, INT IMMUNOPHARMACOL, V31, P223, DOI 10.1016/j.intimp.2015.12.024
   Choudhary D, 2016, BIOMED PHARMACOTHER, V83, P942, DOI 10.1016/j.biopha.2016.08.010
   Ebetino FH, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116289
   Florczyk Soluch U, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29122 1
   Fuller K, 2000, J CELL SCI, V113, P2445
   Gautam J, 2015, MENOPAUSE, V22, P1246, DOI 10.1097/GME.0000000000000453
   Gruber R, 2006, CLIN ORAL IMPLAN RES, V17, P188, DOI 10.1111/j.1600 0501.2005.01216.x
   Huan Y, 2009, CHEM NAT COMPD+, V45, P239, DOI 10.1007/s10600 009 9291 4
   Im NK, 2013, BIOL PHARM BULL, V36, P796, DOI 10.1248/bpb.b12 00964
   Jeong S, 2020, MOLECULES, V25, DOI 10.3390/molecules25173908
   Ji BC, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19162 y
   Joyce KM, 2022, MOL NUTR FOOD RES, V66, DOI 10.1002/mnfr.202100974
   Karvande A, 2017, J PHARM PHARMACOL, V69, P1381, DOI 10.1111/jphp.12764
   Kim EN, 2019, PHYTOTHER RES, V33, P2948, DOI 10.1002/ptr.6468
   Kim JY, 2014, INT IMMUNOPHARMACOL, V20, P213, DOI 10.1016/j.intimp.2014.03.001
   Lee SH, 2009, INFLAMM RES, V58, P257, DOI 10.1007/s00011 008 8183 6
   Lee SD, 2015, WORLD J GASTROENTERO, V21, P465, DOI 10.3748/wjg.v21.i2.465
   Lin TH, 2010, J CELL PHYSIOL, V222, P757, DOI 10.1002/jcp.22008
   Liu RH, 2016, CHIN HERB MED, V8, P89, DOI 10.1016/S1674 6384(16)60014 X
   Liu S, 2016, BIOCHEM PHARMACOL, V106, P82, DOI 10.1016/j.bcp.2016.03.002
   Martiniakova M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14030523
   MUANGNOICHAROEN N, 1982, PHYTOCHEMISTRY, V21, P767, DOI 10.1016/0031 9422(82)83184 1
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460 2075.1988.tb02949.x
   Panahipour Layla, 2019, Cytokine X, V1, P100009, DOI 10.1016/j.cytox.2019.100009
   Panahipour L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134694
   Pathak V, 1997, PHYTOCHEMISTRY, V46, P1219, DOI 10.1016/S0031 9422(97)80015 5
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ramesh P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.779638
   Rodríguez V, 2022, CURR MED CHEM, V29, P2913, DOI 10.2174/0929867328666210921143644
   Saulacic N, 2015, CLIN ORAL IMPLAN RES, V26, P383, DOI 10.1111/clr.12357
   Schett G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05800 6
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Srivastava S, 2013, PHYTOMEDICINE, V20, P683, DOI 10.1016/j.phymed.2013.03.001
   Sung B, 2011, INT J CANCER, V129, P2062, DOI 10.1002/ijc.25868
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Vasak C, 2014, CLIN ORAL IMPLAN RES, V25, P1378, DOI 10.1111/clr.12277
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zheng WH, 2017, INT IMMUNOPHARMACOL, V42, P1, DOI 10.1016/j.intimp.2016.11.009
   Zhu LX, 2012, INT J BIOCHEM CELL B, V44, P1139, DOI 10.1016/j.biocel.2012.04.003
NR 48
TC 1
Z9 1
U1 0
U2 8
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1991 7902
EI 2213 8862
J9 J DENT SCI
JI J. Dental Sci.
PD JAN
PY 2023
VL 18
IS 1
BP 112
EP 119
DI 10.1016/j.jds.2022.06.026
EA JAN 2023
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 7Z2OB
UT WOS:000915402100001
PM 36643234
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xu, H
   Shen, MY
   Shang, H
   Xu, WX
   Zhang, SH
   Yang, HR
   Zhou, DM
   Hakkarainen, M
AF Xu, Huan
   Shen, Mengyuan
   Shang, Han
   Xu, Wenxuan
   Zhang, Shenghui
   Yang, Hao Ran
   Zhou, Dongmei
   Hakkarainen, Minna
TI Osteoconductive and Antibacterial Poly(lactic acid) Fibrous Membranes
   Impregnated with Biobased Nanocarbons for Biodegradable Bone
   Regenerative Scaffolds
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID GRAPHENE OXIDE; ELECTROSPUN NANOFIBERS; CARBON NANOTUBES; COMPOSITES;
   CYTOTOXICITY; EFFICACY; FIBERS
AB Carbonaceous nanostructures featuring unique structural characteristics and high cytocompatibility offer a wealth of possibilities to impart enhancements of mechanical properties and biological activities for osteogenic tissue scaffolds. Here, we unveil the fabrication of osteoconductive and antibacterial porous poly(lactic acid) (PLA) membranes by direct electrospinning of microfibers impregnated with coffee ground derived quantum dots (QDs). It enabled a straightforward pathway to regulate the diameter and its distribution for the electrospun PLA microfibers, as well as the improved hydrophilicity. The QDs exhibited high affinity to the PLA matrix, permitting remarkable promotion of tensile strength and elastic modulus for the QD modified PLA membranes while maintaining comparable extensibility. More importantly, osteoblast adhesion and stretching on the electrospun membranes were significantly enhanced with the existence of QDs, as exemplified by the nearly 1.8 fold increase in cell viability cultured onto the composite membrane loaded with 1.5% QDs compared to that of pure PLA. This was accompanied by rapid biomimetic mineralization and uniform apatite formation in an osteofriendly manner. Unexpectedly, immediate and broad spectrum antibacterial performance was achieved for the composite membranes, likely arising from the synergistic effects of QD imparted membrane stress and oxidative stress. The unusual combination of mechanical, biomineralization, biological, and antibacterial performances makes the biodegradable membrane scaffolds promising for guided bone/tissue regeneration therapy.
C1 [Xu, Huan; Shang, Han; Xu, Wenxuan; Zhang, Shenghui] China Univ Min & Technol, Sch Mat Sci & Phys, Xuzhou 221116, Jiangsu, Peoples R China.
   [Shen, Mengyuan; Zhou, Dongmei] Xuzhou Med Univ, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China.
   [Yang, Hao Ran] Zhengzhou Univ Light Ind, State Lab Surface & Interface Sci & Technol, Sch Mat & Chem Engn, Zhengzhou 450002, Peoples R China.
   [Hakkarainen, Minna] KTH Royal Inst Technol, Dept Fibre & Polymer Technol, S 10044 Stockholm, Sweden.
C3 China University of Mining & Technology; Xuzhou Medical University;
   Zhengzhou University of Light Industry; Royal Institute of Technology
RP Xu, H (通讯作者)，China Univ Min & Technol, Sch Mat Sci & Phys, Xuzhou 221116, Jiangsu, Peoples R China.; Zhou, DM (通讯作者)，Xuzhou Med Univ, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China.; Hakkarainen, M (通讯作者)，KTH Royal Inst Technol, Dept Fibre & Polymer Technol, S 10044 Stockholm, Sweden.
EM hihuan@cumt.edu.cn; zdm@xzhmu.edu.cn; minna@kth.se
RI Xu, Huan/JYQ 6346 2024; Hakkarainen, Minna/L 5127 2016; Xu,
   Huan/C 2592 2017; Xu, Wenxuan/LOS 1887 2024; shen,
   mengyuan/NMK 0302 2025
OI Hakkarainen, Minna/0000 0002 7790 8987; Xu, Huan/0000 0002 4468 5019; 
FU National Natural Science Foundation of China [52003292, 51803192];
   Jiangsu Provincial Research Foundation for Basic Research [BK20200661];
   China Postdoctoral Science Foundation [2020M681763]; Fundamental
   Research Funds for the Central Universities [2021QN1115]
FX The authors acknowledge the financial support from the National Natural
   Science Foundation of China (Nos. 52003292 and 51803192), the Jiangsu
   Provincial Research Foundation for Basic Research (No. BK20200661), the
   China Postdoctoral Science Foundation (No. 2020M681763), and the
   Fundamental Research Funds for the Central Universities (No.
   2021QN1115).
CR Abdelaziz D, 2021, J ADV RES, V28, P51, DOI 10.1016/j.jare.2020.06.014
   Adolfsson KH, 2019, ADV SUSTAIN SYST, V3, DOI 10.1002/adsu.201800148
   Al Enizi AM, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8040259
   Andersson SR, 2010, BIOMACROMOLECULES, V11, P3617, DOI 10.1021/bm101075p
   Bai JJ, 2015, PROG NAT SCI MATER, V25, P327, DOI 10.1016/j.pnsc.2015.07.004
   Cai N, 2014, FIBER POLYM, V15, P2544, DOI 10.1007/s12221 014 2544 2
   Ding JX, 2019, PROG POLYM SCI, V90, P1, DOI 10.1016/j.progpolymsci.2019.01.002
   Feng XR, 2019, J CONTROL RELEASE, V302, P19, DOI 10.1016/j.jconrel.2019.03.020
   Gu B, 2021, CARBOHYD POLYM, V260, DOI 10.1016/j.carbpol.2021.117835
   Hu WB, 2010, ACS NANO, V4, P4317, DOI 10.1021/nn101097v
   Huo SH, 2021, APPL SURF SCI, V551, DOI 10.1016/j.apsusc.2021.149444
   Jahanmard F, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110163
   Jiang T, 2015, PROG POLYM SCI, V46, P1, DOI 10.1016/j.progpolymsci.2014.12.001
   Kang S, 2008, LANGMUIR, V24, P6409, DOI 10.1021/la800951v
   Kikuchi M, 2004, BIOMATERIALS, V25, P5979, DOI 10.1016/j.biomaterials.2004.02.001
   Kim HD, 2017, ACS APPL MATER INTER, V9, P21639, DOI 10.1021/acsami.7b04114
   Kim KH, 2005, J BIOTECHNOL, V120, P327, DOI 10.1016/j.jbiotec.2005.06.033
   Lee JKY, 2018, PROG POLYM SCI, V86, P40, DOI 10.1016/j.progpolymsci.2018.07.002
   Li XR, 2009, NANO LETT, V9, P2763, DOI 10.1021/nl901582f
   Liao GY, 2012, COMPOS SCI TECHNOL, V72, P248, DOI 10.1016/j.compscitech.2011.11.009
   Liu C, 2017, ACS BIOMATER SCI ENG, V3, P471, DOI 10.1021/acsbiomaterials.6b00766
   Liu C, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8080287
   Liu K, 2021, ACS SUSTAIN CHEM ENG, V9, P4440, DOI 10.1021/acssuschemeng.0c08240
   Liu SB, 2011, ACS NANO, V5, P6971, DOI 10.1021/nn202451x
   Manavitehrani I, 2017, BIOMACROMOLECULES, V18, P1736, DOI 10.1021/acs.biomac.7b00078
   McCann JT, 2006, J AM CHEM SOC, V128, P1436, DOI 10.1021/ja056810y
   McCullen SD, 2007, J APPL POLYM SCI, V105, P1668, DOI 10.1002/app.26288
   Mydeen SS, 2020, CHEM PHYS LETT, V761, DOI 10.1016/j.cplett.2020.138009
   Patel DK, 2019, RSC ADV, V9, P36040, DOI 10.1039/c9ra06260b
   Qian YZ, 2019, ACS APPL MATER INTER, V11, P37381, DOI 10.1021/acsami.9b07053
   Qian YZ, 2018, ACS APPL MATER INTER, V10, P3248, DOI 10.1021/acsami.7b14524
   Qu Y, 2018, ACS APPL MATER INTER, V10, P4462, DOI 10.1021/acsami.7b17020
   Rahmati M, 2021, PROG MATER SCI, V117, DOI 10.1016/j.pmatsci.2020.100721
   Safari N, 2020, ACS BIOMATER SCI ENG, V6, P6253, DOI 10.1021/acsbiomaterials.0c00613
   Saini P, 2016, ADV DRUG DELIVER REV, V107, P47, DOI 10.1016/j.addr.2016.06.014
   Song XF, 2013, COMPOS SCI TECHNOL, V79, P8, DOI 10.1016/j.compscitech.2013.02.014
   Swider E, 2018, ACTA BIOMATER, V73, P38, DOI 10.1016/j.actbio.2018.04.006
   Vecitis CD, 2010, ACS NANO, V4, P5471, DOI 10.1021/nn101558x
   Wang JL, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8040115
   Wang MZ, 2021, J HAZARD MATER, V412, DOI 10.1016/j.jhazmat.2021.125333
   Wu D, 2018, MATERIALS, V11, DOI 10.3390/ma11040566
   Wu D, 2017, BIOMACROMOLECULES, V18, P1582, DOI 10.1021/acs.biomac.7b00195
   Xiao DM, 2021, ACS SUSTAIN CHEM ENG, V9, P4139, DOI 10.1021/acssuschemeng.0c09348
   Xie JW, 2008, MACROMOL RAPID COMM, V29, P1775, DOI 10.1002/marc.200800381
   Xu H, 2017, ACS SUSTAIN CHEM ENG, V5, P11607, DOI 10.1021/acssuschemeng.7b02963
   Xu H, 2017, ACS APPL MATER INTER, V9, P27972, DOI 10.1021/acsami.7b09401
   Xu H, 2017, ACS SUSTAIN CHEM ENG, V5, P5360, DOI 10.1021/acssuschemeng.7b00663
   Xu H, 2016, ACS SUSTAIN CHEM ENG, V4, P5618, DOI 10.1021/acssuschemeng.6b01524
   Xu XY, 2006, EUR POLYM J, V42, P2081, DOI 10.1016/j.eurpolymj.2006.03.032
   Xue JJ, 2017, ACCOUNTS CHEM RES, V50, P1976, DOI 10.1021/acs.accounts.7b00218
   Xue JJ, 2014, BIOMATERIALS, V35, P9395, DOI 10.1016/j.biomaterials.2014.07.060
   Yoshimoto I, 2018, DENT MATER, V34, P538, DOI 10.1016/j.dental.2017.12.011
   Zhang CM, 2016, J MECH BEHAV BIOMED, V53, P403, DOI 10.1016/j.jmbbm.2015.08.043
   Zhang YB, 2010, ACS NANO, V4, P3181, DOI 10.1021/nn1007176
   Zia I, 2020, ACS APPL BIO MATER, V3, P7133, DOI 10.1021/acsabm.0c00948
NR 55
TC 33
Z9 33
U1 3
U2 74
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888 5885
EI 1520 5045
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD AUG 18
PY 2021
VL 60
IS 32
BP 12021
EP 12031
DI 10.1021/acs.iecr.1c02165
EA AUG 2021
PG 11
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA UD4IJ
UT WOS:000687171300014
DA 2025 08 17
ER

PT J
AU Liu, C
   Dong, JY
   Yue, LL
   Liu, SH
   Wan, Y
   Liu, H
   Tan, WY
   Guo, QQ
   Zhang, D
AF Liu, Chao
   Dong, Jian Yong
   Yue, Lin Lin
   Liu, Shao Hua
   Wan, Yi
   Liu, Hong
   Tan, Wan Ye
   Guo, Qian Qian
   Zhang, Dong
TI Rapamycin/sodium hyaluronate binding on nano hydroxyapatite coated
   titanium surface improves MC3T3 E1 osteogenesis
SO PLOS ONE
LA English
DT Article
ID OSTEOBLAST; DRUG; DIFFERENTIATION; APOPTOSIS
AB Endosseous titanium (Ti) implant failure due to poor biocompatibility of implant surface remains a major problem for osseointegration. Improving the topography of Ti surface may enhance osseointegration, however, the mechanism remains unknown. To investigate the effect of modified Ti surface on osteogenesis, we loaded rapamycin (RA) onto nano hydroxyapatite (HAp) coated Ti surface which was acid etched, alkali heated and HAp coated sequentially. Sodium hyaluronate (SH) was employed as an intermediate layer for the load of RA, and a steady release rate of RA was maintained. Cell vitality of MC3T3 E1 was assessed by MTT. Osteogenesis of MC3T3 E1 on this modified Ti surface was evaluated by alkaline phosphatase (ALP) activity, mineralization and related osteogenesis genes osteocalcin (OCN), osteopontin (OPN), Collagen I and Runx2. The result revealed that RA/SH loaded nano HAp Ti surface was innocent for cell vitality and even more beneficial for cell osteogenesis in vitro. Furthermore, osteogenesis of MC3T3 E1 showed significant association with the mammalian target of rapamycin (mTOR) phosphorylation by RA, which required further study about the mechanism. The approach to this modified Ti surface presented in this paper has high research value for the development of Ti based implant.
C1 [Liu, Chao; Liu, Shao Hua; Tan, Wan Ye; Zhang, Dong] Shandong Univ, Qilu Hosp, Dept Oral & Maxillofacial Surg, Jinan, Peoples R China.
   [Liu, Chao; Liu, Shao Hua; Tan, Wan Ye; Zhang, Dong] Shandong Univ, Qilu Hosp, Inst Dent Med, Jinan, Peoples R China.
   [Dong, Jian Yong; Yue, Lin Lin; Guo, Qian Qian] Shandong Univ, Sch Stomotol, Jinan, Peoples R China.
   [Wan, Yi] Shandong Univ, Sch Mech Engn, Key Lab High Efficiency & Clean Mech Manufacture, Minist Educ, Jinan, Peoples R China.
   [Liu, Hong] Shandong Univ, Ctr Bio & Micro Nano Funct Mat, State Key Lab Crystal Mat, Jinan, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Shandong
   University; Shandong University
RP Zhang, D (通讯作者)，Shandong Univ, Qilu Hosp, Dept Oral & Maxillofacial Surg, Jinan, Peoples R China.; Zhang, D (通讯作者)，Shandong Univ, Qilu Hosp, Inst Dent Med, Jinan, Peoples R China.
EM qiluzhangdong@163.com
RI ; Liu, Hong/D 7288 2019
OI Dong, Jianyong/0000 0002 1147 176X; Liu, Hong/0000 0003 1640 9620
FU Natural Science Foundation of Shandong Provience, China [BS2015SW028]
FX This work was supported by the Natural Science Foundation of Shandong
   Provience, China (BS2015SW028), http://ww.sdnsf.gov.cn/portal/ The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.This work was
   supported by the Natural Science Foundation of Shandong Province, China
   (BS2015SW028). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Avila G, 2009, IMPLANT DENT, V18, P17, DOI 10.1097/ID.0b013e318192cb7d
   Cai KY, 2010, ACTA BIOMATER, V6, P2314, DOI 10.1016/j.actbio.2009.11.034
   Chua PH, 2008, BIOMATERIALS, V29, P1412, DOI 10.1016/j.biomaterials.2007.12.019
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960
   Fukuda A, 2005, J BONE MINER RES, V20, P2245, DOI 10.1359/JBMR.050816
   Hao XH, 2015, ACS NANO, V9, P9614, DOI 10.1021/nn507485j
   Huang Y, 2014, BIOMED MATER, V9, DOI 10.1088/1748 6041/9/6/065007
   Hwang DS, 2010, BIOMATERIALS, V31, P1080, DOI 10.1016/j.biomaterials.2009.10.041
   Jiang PL, 2015, ACS APPL MATER INTER, V7, P14384, DOI 10.1021/acsami.5b03172
   Jonásová L, 2004, BIOMATERIALS, V25, P1187, DOI 10.1016/j.biomaterials.2003.08.009
   Kim HM, 1997, J BIOMED MATER RES, V38, P121
   Kirmanidou Y, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2908570
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Lai W, 2016, MAT SCI ENG C MATER, V62, P166, DOI 10.1016/j.msec.2016.01.055
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Li GL, 2016, ACS APPL MATER INTER, V8, P3840, DOI 10.1021/acsami.5b10633
   Liu C, 2014, ANN HEMATOL, V93, P1177, DOI 10.1007/s00277 014 2024 1
   Luo Y, 2010, J CONTROL RELEASE, V147, P278, DOI 10.1016/j.jconrel.2010.07.108
   Mainardes RM, 2004, CURR DRUG TARGETS, V5, P449, DOI 10.2174/1389450043345407
   Oshida Y, 2010, INT J MOL SCI, V11, P1580, DOI 10.3390/ijms11041580
   Rupp F, 2006, J BIOMED MATER RES A, V76A, P323, DOI 10.1002/jbm.a.30518
   Sato M, 2008, J BIOMED MATER RES A, V84A, P265, DOI 10.1002/jbm.a.31469
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Svanborg LM, 2014, INT J DENT, V2014, DOI 10.1155/2014/197581
   Tan WY, 2013, ULTRASON SONOCHEM, V20, P216, DOI 10.1016/j.ultsonch.2012.07.020
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Wang M, 2012, J NANOSCI NANOTECHNO, V12, P7692, DOI 10.1166/jnn.2012.6624
   Wu JM, 2006, J AM CERAM SOC, V89, P2660, DOI 10.1111/j.1551 2916.2006.01104.x
   Xuereb M, 2015, INT J PROSTHODONT, V28, P51, DOI 10.11607/ijp.4124
   Zhao YY, 2015, J SHANDONG U HLTH SC, V53, P41
NR 32
TC 10
Z9 10
U1 1
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 9
PY 2017
VL 12
IS 2
AR e0171693
DI 10.1371/journal.pone.0171693
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EK9GJ
UT WOS:000394231800091
PM 28182765
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Mariano, KCF
   do Nascimento, MHM
   Querobino, SM
   Campos, EVR
   de Oliveira, JL
   Yokaichiya, F
   Franco, MKKD
   Alberto Silva, C
   de Paula, E
   Lombello, CB
   de Lima, R
   Fraceto, LF
   de Araujo, DR
AF Freitas Mariano, Kelli C.
   Monteiro do Nascimento, Monica H.
   Querobino, Samyr M.
   Ramos Campos, Estefania, V
   de Oliveira, Jhones L.
   Yokaichiya, Fabiano
   Franco, Margareth K. K. D.
   Alberto Silva, Carlos
   de Paula, Eneida
   Lombello, Christiane B.
   de Lima, Renata
   Fraceto, Leonardo F.
   de Araujo, Daniele R.
TI Influence of chitosan tripolyphosphate nanoparticles on thermosensitive
   polymeric hydrogels: structural organization, drug release mechanisms
   and cytotoxicity
SO INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
LA English
DT Article
DE Arthritis; chitosan nanoparticles; hydrogels; naproxen; poloxamer
ID IN VITRO EVALUATION; TRANSFECTION EFFICIENCY; ANTIINFLAMMATORY DRUGS;
   COPOLYMER MICELLES; AQUEOUS SOLUTION; DELIVERY; NAPROXEN; CARRIER; GEL;
   OPTIMIZATION
AB Chitosan tripolyphosphate (CS TPP) nanoparticles containing naproxen (NPX) were dispersed in poloxamer (PL) as unique (PL407) or binary (PL407 PL403) systems. Nanoparticles presented diameter of similar to 250 nm and zeta potential of similar to 35 mV with drug loading and encapsulation efficiency of 98.4 +/  0.3% and 36.9 +/  0.12%, respectively. NPX CS TPP shifted the sol gel transition and micellization temperatures. PL407 PL403 systems presented G ' > G '' compared to PL407. SAXS patterns revealed transitions from lamellar to hexagonal phase organizations with low drug release rates, in the presence of CS TPP nanoparticles. NPX CS TPP PL407 induced lower cytotoxicity compared to PL407 PL403 in fibroblasts and osteoblasts, making them promising systems for intra articular delivery.
   [GRAPHICS]
   .
C1 [Freitas Mariano, Kelli C.; Monteiro do Nascimento, Monica H.; Querobino, Samyr M.; Alberto Silva, Carlos; de Araujo, Daniele R.] Fed Univ ABC, Human & Nat Sci Ctr, Santo Andre, SP, Brazil.
   [Ramos Campos, Estefania, V; de Oliveira, Jhones L.; Fraceto, Leonardo F.] State Univ Julio de Mesquita Filho, Dept Environm Engn, Sorocaba, SP, Brazil.
   [Yokaichiya, Fabiano] Helmholtz Zentrum Berlin Mat, Dept Quantum Phenomena Novel Mat, Berlin, Germany.
   [Franco, Margareth K. K. D.] Nucl & Energy Res Inst, Sao Paulo, SP, Brazil.
   [de Paula, Eneida] Univ Estadual Campinas, Dept Biochem & Tissue Biol, Inst Biol, Campinas, SP, Brazil.
   [Lombello, Christiane B.] Fed Univ ABC, Engn Modelling & Appl Social Sci Ctr, Santo Andre, SP, Brazil.
   [de Lima, Renata] Univ Sorocaba, Dept Biotechnol, Sorocaba, Brazil.
C3 Universidade Federal do ABC (UFABC); Comissao Nacional de Energia
   Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN);
   Universidade de Sao Paulo; Universidade Estadual de Campinas;
   Universidade Federal do ABC (UFABC); Universidade de Sorocaba
RP de Araujo, DR (通讯作者)，Univ Federa ABC, Human & Nat Sci Ctr, Ctr Ciencias Naturais & Humanas, Av Estados 5001,Bloco A,Torre 3,Lab 503 3, BR 09021058 Santo Andre, SP, Brazil.
EM daniele.araujo@ufabc.edu.br
RI ; Fraceto, Leonardo/C 4468 2012; Yokaichiya, Fabiano/D 3620 2012; Lima,
   Renata/AAC 6777 2020; Lima, Renata/B 9107 2012; de Araujo,
   Daniele/L 1153 2016; de Oliveira, Jhones/P 8065 2018; Oliveira, Jhones
   Luiz/P 8065 2018; Alberto Silva, Carlos/F 2972 2012; Ribeiro de Araujo,
   Daniele/L 1153 2016; Franco, Margareth/N 5506 2016; Campos,
   Estefânia/K 9319 2014; Lombello, Christiane Bertachini/G 4128 2014;
   querobino, samyr/M 7894 2019; de Paula, Eneida/C 3031 2013; Nascimento,
   Monica/LMO 8531 2024
OI Alberto Silva, Carlos/0000 0003 4519 8930; Lima,
   Renata/0000 0001 8712 1144; Ramos Campos, Estefania
   Vangelie/0000 0002 9420 7461; Oliveira, Jhones Luiz/0000 0002 9664 0349;
   Ribeiro de Araujo, Daniele/0000 0002 9289 4229; Mariano,
   Kelli/0000 0002 5660 2890; de Paula, Eneida/0000 0003 4504 5723; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   Fundacao de Amparoa Pesquisa do Estado de Sao Paulo [FAPESP
   2014/26200 9, 2014/14457 5, 2014/12653 1]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico [CNPq 309207/2016 9,
   402838/2016 5]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [14/14457 5, 14/26200 9] Funding Source: FAPESP
FX This research work was supported by Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Fundacao de Amparoa Pesquisa do
   Estado de Sao Paulo [FAPESP 2014/26200 9, 2014/14457 5, 2014/12653 1]
   and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [CNPq
   309207/2016 9, 402838/2016 5]. Authors are also grateful to the
   Brazilian Synchrotron Light Laboratory for SAXS facilities (SAXS 1
   beamline) and UFABC Multiuser Central Facilities (CEM UFABC).
CR Ahmad R, 2018, J BIOMED NANOTECHNOL, V14, P20, DOI 10.1166/jbn.2018.2476
   Al Kassas R, 2016, CARBOHYD POLYM, V153, P176, DOI 10.1016/j.carbpol.2016.06.096
   Asasutjarit R, 2011, INT J PHARMACEUT, V411, P128, DOI 10.1016/j.ijpharm.2011.03.054
   Bahreini E, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556 276X 9 340
   Bhat PA, 2009, J PHYS CHEM B, V113, P997, DOI 10.1021/jp807229c
   Botting RM, 2006, J PHYSIOL PHARMACOL, V57, P113
   Bozdag S, 2001, J MICROENCAPSUL, V18, P443, DOI 10.1080/02652040010018641
   Cerchiara T, 2015, EUR J PHARM BIOPHARM, V92, P112, DOI 10.1016/j.ejpb.2015.03.004
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Cirri M, 2006, J PHARMACEUT BIOMED, V42, P126, DOI 10.1016/j.jpba.2005.11.029
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928 0987(01)00095 1
   Dorraj G, 2015, IRAN J PHARM RES, V14, P347
   Ege MA., 2014, INT J PHARMACEUT, V4, P33
   Essving P, 2009, ACTA ORTHOP, V80, P213, DOI 10.3109/17453670902930008
   Grespan R, 2008, ARTHRITIS RHEUM, V58, P2030, DOI 10.1002/art.23597
   Grillo R, 2014, J HAZARD MATER, V278, P163, DOI 10.1016/j.jhazmat.2014.05.079
   Gu JJ, 2016, COLLOID SURFACE B, V140, P83, DOI 10.1016/j.colsurfb.2015.12.023
   Gustafsson J, 1999, J COLLOID INTERF SCI, V211, P326, DOI 10.1006/jcis.1998.5996
   Jaffré B, 2003, ARTHRITIS RHEUM, V48, P1594, DOI 10.1002/art.11023
   Ji XY, 2013, J BIOMED NANOTECHNOL, V9, P1672, DOI 10.1166/jbn.2013.1665
   Jin L, 2014, THERANOSTICS, V4, P240, DOI 10.7150/thno.6914
   Kang ML, 2014, BIOMATERIALS, V35, P9984, DOI 10.1016/j.biomaterials.2014.08.042
   Konecsni K, 2012, FOOD CHEM, V134, P1775, DOI 10.1016/j.foodchem.2012.03.070
   Kumar SP, 2015, INT J BIOL MACROMOL, V78, P87, DOI 10.1016/j.ijbiomac.2015.03.045
   Kuntsche J, 2011, INT J PHARMACEUT, V417, P120, DOI 10.1016/j.ijpharm.2011.02.001
   Larsen SW, 2006, EUR J PHARM SCI, V29, P348, DOI 10.1016/j.ejps.2006.07.002
   Li F, 2015, SCI ADV MATER, V7, P2103, DOI 10.1166/sam.2015.1982
   Lin FY, 2004, BMJ BRIT MED J, V329, P324, DOI 10.1136/bmj.38159.639028.7C
   Liu TB, 2000, J APPL CRYSTALLOGR, V33, P727, DOI 10.1107/S0021889899013369
   Lu ZX, 2017, NANOSCI NANOTECH LET, V9, P184, DOI 10.1166/nnl.2017.2277
   Morgen M, 2013, PHARM RES DORDR, V30, P257, DOI 10.1007/s11095 012 0870 x
   Nascimento MHM, 2018, INT J BIOL MACROMOL, V111, P1245, DOI 10.1016/j.ijbiomac.2018.01.064
   Le NH, 2017, NANOSCI NANOTECH LET, V9, P496, DOI 10.1166/nnl.2017.2348
   Oshiro A, 2014, LANGMUIR, V30, P13689, DOI 10.1021/la503021c
   Qu Y, 2017, J BIOMED NANOTECHNOL, V13, P1598, DOI 10.1166/jbn.2017.2475
   Ravani L, 2013, INT J PHARMACEUT, V454, P695, DOI 10.1016/j.ijpharm.2013.06.015
   Ricardo NMPS, 2005, INT J PHARMACEUT, V300, P22, DOI 10.1016/j.ijpharm.2005.04.023
   Roques C, 2009, J CONTROL RELEASE, V138, P71, DOI 10.1016/j.jconrel.2009.04.030
   Russo E, 2016, COLLOID SURFACE B, V143, P88, DOI 10.1016/j.colsurfb.2016.03.028
   Ryan SM, 2013, J CONTROL RELEASE, V167, P120, DOI 10.1016/j.jconrel.2013.01.027
   Salim M, 2016, LANGMUIR, V32, P5552, DOI 10.1021/acs.langmuir.6b01007
   Akkari ACS, 2016, COLLOID SURFACE B, V138, P138, DOI 10.1016/j.colsurfb.2015.11.048
   Saxena V, 2013, COLLOID SURFACE B, V112, P350, DOI 10.1016/j.colsurfb.2013.07.031
   Seed M. P., 2005, Inflammopharmacology, V12, P551
   Sharma PK, 2004, INT J PHARMACEUT, V278, P361, DOI 10.1016/j.ijpharm.2004.03.029
   Su YL, 2002, LANGMUIR, V18, P5370, DOI 10.1021/la020007p
   Teng YW, 2016, J NANOSCI NANOTECHNO, V16, P12154, DOI 10.1166/jnn.2016.12965
   Thing M, 2012, EUR J PHARM SCI, V45, P351, DOI 10.1016/j.ejps.2011.12.006
   Thing M, 2013, INT J PHARMACEUT, V451, P34, DOI 10.1016/j.ijpharm.2013.04.056
   Tian J, 2017, CHINESE CHEM LETT, V28, P798, DOI 10.1016/j.cclet.2017.01.010
   Tian QP, 2012, INT J PHARMACEUT, V426, P202, DOI 10.1016/j.ijpharm.2012.01.019
   Yang Y, 2016, J BIOMED NANOTECHNOL, V12, P1963, DOI 10.1166/jbn.2016.2298
   Zhang LM, 2012, POLYM CHEM UK, V3, P1958, DOI 10.1039/c2py20201h
   Zhang M, 2013, INT J PHARMACEUT, V454, P599, DOI 10.1016/j.ijpharm.2013.01.043
   Zhang Y, 2005, J COLLOID INTERF SCI, V285, P74, DOI 10.1016/j.jcis.2004.12.033
   Zhou GY, 2016, J BIOMED MATER RES A, V104, P493, DOI 10.1002/jbm.a.35587
NR 56
TC 17
Z9 17
U1 0
U2 22
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO 0154 OSLO, NORWAY
SN 0091 4037
EI 1563 535X
J9 INT J POLYM MATER PO
JI Int. J. Polym. Mater. Polym. Biomat.
PD JUN 12
PY 2020
VL 69
IS 9
BP 592
EP 603
DI 10.1080/00914037.2019.1596909
EA APR 2019
PG 12
WC Materials Science, Biomaterials; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Polymer Science
GA KO4ZL
UT WOS:000466625400001
DA 2025 08 17
ER

PT J
AU Navarrete, F
   Wong, YS
   Cabezas, J
   Riadi, G
   Manríquez, J
   Rojas, D
   Mançanares, ACF
   Rodriguez Alvarez, L
   Saravia, F
   Castro, FO
AF Navarrete, Felipe
   Wong, Yat Sen
   Cabezas, Joel
   Riadi, Gonzalo
   Manriquez, Jose
   Rojas, Daniela
   Furlanetto Mancanares, Ana Carolina
   Rodriguez Alvarez, Lleretny
   Saravia, Fernando
   Castro, Fidel Ovidio
TI Distinctive Cellular Transcriptomic Signature and MicroRNA Cargo of
   Extracellular Vesicles of Horse Adipose and Endometrial Mesenchymal Stem
   Cells from the Same Donors
SO CELLULAR REPROGRAMMING
LA English
DT Article
DE endometrium; gene expression; differentiation; bioinformatics;
   regenerative therapies
ID STROMAL CELLS; IN VITRO; DIFFERENTIATION; PROLIFERATION; GROWTH; BLOOD;
   EXPRESSION; OSTEOBLAST; AMNION
AB Equine endometrial and adipose mesenchymal stem cells (eMSCs and aMSCs, respectively) were isolated from the same donors of thoroughbred mares. The cells displayed characteristic features of MSCs, including trilineage mesodermal and also neurogenic differentiation. We evaluated the influence of cellular origin on their transcriptome profile. Cellular RNA was isolated and sequenced and extracellular vesicles (EVs) were obtained from conditioned medium of cells cultured in medium depleted of EVs, and their microRNA (miRNA) cargo analyzed by sequencing. Differential expression of mRNAs and EV miRNA was analyzed, as well as pathways and processes most represented in each cell origin. mRNA reads from all expressed genes clustered according to the cellular origin. A total of 125 up  and 51 downregulated genes were identified and 31 differentially expressed miRNAs. Based on mRNA sequencing, endometrial MSCs strongly upregulated genes involved in the Hippo, transforming growth factor beta, and pluripotency signaling pathways. Alongside with this, pathways involved in extracellular matrix reorganization were the most represented in the miRNA cargo of EVs secreted by eMSCs. The niche from which MSCs originated defined the transcriptomic signature of the cells, including the secretion of lineage specific loaded EV to ensure proper communication and homeostasis. Identification and testing their biological functions can provide new tools for the therapeutic use of horse MSC.
C1 [Navarrete, Felipe; Wong, Yat Sen; Cabezas, Joel; Manriquez, Jose; Rojas, Daniela; Furlanetto Mancanares, Ana Carolina; Rodriguez Alvarez, Lleretny; Saravia, Fernando; Castro, Fidel Ovidio] Univ Concepcion, Dept Anim Sci, Fac Vet Sci, Ave Vicente Mendez, Chillan 3801061, Chile.
   [Riadi, Gonzalo] Univ Talca, Ctr Bioinformat Simulat & Modeling CBSM, Dept Bioinformat, Fac Engn, Talca, Chile.
C3 Universidad de Concepcion; Universidad de Talca
RP Castro, FO (通讯作者)，Univ Concepcion, Dept Anim Sci, Fac Vet Sci, Ave Vicente Mendez, Chillan 3801061, Chile.
EM fidcastro@udec.cl
RI Villa Manriquez, Jose Fabian/ACM 7105 2022; Mançanares, Ana
   Carolina/C 1683 2012; Furlanetto Mancanares, Ana Carolina/C 1683 2012;
   Riadi, Gonzalo/ABG 2144 2020; Rodriguez Alvarez, Lleretny/AAH 9420 2019
OI Riadi, Gonzalo/0000 0002 7633 2365; Cabezas Salazar, Joel
   Gustavo/0000 0001 8931 2630; Furlanetto Mancanares, Ana
   Carolina/0000 0003 3382 579X; Wong Alvaro, Yat Sen/0000 0001 5126 6325; 
FU FONDECYT REGULAR [1150757, 11140869]; Ministry of Education of Chile
FX This research was granted by FONDECYT REGULAR 1150757 to Fidel Ovidio
   Castro and 11140869 to Gonzalo Riadi, from the Ministry of Education of
   Chile, to Fidel Ovidio Castro.
CR Aupperle H, 2000, EQUINE VET J, V32, P228, DOI 10.2746/042516400776563554
   Azami M, 2013, TISSUE CELL, V45, P328, DOI 10.1016/j.tice.2013.05.002
   Barturen G., 2014, Meth, Next Gen. Seq, V1, P21, DOI DOI 10.2478/MNGS 2014 0001
   Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168
   Bourzac C, 2010, EQUINE VET J, V42, P519, DOI 10.1111/j.2042 3306.2010.00098.x
   Branly T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020435
   Bruno S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033115
   Cabezas J, 2018, THERIOGENOLOGY, V106, P93, DOI 10.1016/j.theriogenology.2017.09.035
   Capomaccio S, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4957806
   Cardoso TC, 2017, CELL TISSUE RES, V367, P243, DOI 10.1007/s00441 016 2504 9
   Carrade DD, 2013, COMPARATIVE MED, V63, P207
   Castro FO, 2014, RES VET SCI, V96, P95, DOI 10.1016/j.rvsc.2013.12.005
   Chan RWS, 2004, BIOL REPROD, V70, P1738, DOI 10.1095/biolreprod.103.024109
   Choi EK, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21464 0
   Corradetti B, 2013, REPRODUCTION, V145, P391, DOI 10.1530/REP 12 0437
   Dangi Garimella S, 2011, ONCOGENE, V30, P1002, DOI 10.1038/onc.2010.485
   den Hartogh SC, 2016, SCI REP UK, V6, DOI 10.1038/srep19386
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dong L, 2019, MOL ONCOL, V13, P1605, DOI 10.1002/1878 0261.12527
   Donofrio G, 2008, REPROD BIOL ENDOCRIN, V6, DOI 10.1186/1477 7827 6 65
   Dueñas F, 2014, BMC VET RES, V10, DOI 10.1186/1746 6148 10 154
   Ebrahimi Barough S, 2013, J MOL NEUROSCI, V51, P265, DOI 10.1007/s12031 013 9957 z
   Fortier LA, 1998, AM J VET RES, V59, P1182
   Fu T, 2012, P NATL ACAD SCI USA, V109, P16137, DOI 10.1073/pnas.1205951109
   Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105
   Gargett CE, 2007, CURR OPIN OBSTET GYN, V19, P377, DOI 10.1097/GCO.0b013e328235a5c6
   Gargett CE, 2012, FERTIL STERIL, V98, DOI 10.1016/j.fertnstert.2012.05.004
   Gargett CE, 2010, MOL HUM REPROD, V16, P818, DOI 10.1093/molehr/gaq061
   Gómez MC, 2015, CELL REPROGRAM, V17, P376, DOI 10.1089/cell.2015.0040
   Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115
   Hossini AM, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864 015 1262 5
   Jin GZ, 2008, J VET MED SCI, V70, P723, DOI 10.1292/jvms.70.723
   Jing LJ, 2011, NEUROREPORT, V22, P206, DOI 10.1097/WNR.0b013e328344a666
   Khanmohammadi M, 2012, INT J HEMATOL, V95, P484, DOI 10.1007/s12185 012 1067 0
   Khatun M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175986
   Lander AD, 2012, BMC BIOL, V10, DOI 10.1186/1741 7007 10 19
   Lange Consiglio A, 2013, EQUINE VET J, V45, P737, DOI 10.1111/evj.12052
   Lange Consiglio A, 2012, J TISSUE ENG REGEN M, V6, P622, DOI 10.1002/term.465
   Lara E, 2017, REPROD DOMEST ANIM, V52, P707, DOI 10.1111/rda.12969
   Lara Evelyn, 2018, Bioengineering Basel, V5, P75, DOI 10.3390/bioengineering5030075
   Lee JK, 2007, CELL TRANSPLANT, V16, P849, DOI 10.3727/000000007783465271
   Liu H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1285 y
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Lou GH, 2017, J CELL MOL MED, V21, P2963, DOI 10.1111/jcmm.13208
   Makino K, 2013, J IMMUNOL, V190, P3905, DOI 10.4049/jimmunol.1200822
   Martino NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111533
   Miernik K, 2012, REPRODUCTION, V143, P203, DOI 10.1530/REP 11 0202
   Mischen BT, 2008, PLAST RECONSTR SURG, V122, P725, DOI 10.1097/PRS.0b013e318180ec9f
   Misso G, 2014, MOL THER NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47
   Omwandho COA, 2010, HUM REPROD, V25, P101, DOI 10.1093/humrep/dep382
   PAN Y, 2018, DIABETES S1, V67, DOI DOI doi.org/10.2337/db18 2025 P
   Patel AN, 2011, STEM CELLS CLONING, V4, P61, DOI 10.2147/SCCAA.S11991
   Perrini C, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0429 6
   Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   Pramanik S, 2017, MOL NEUROBIOL, V54, P7401, DOI 10.1007/s12035 016 0214 7
   Qian DH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00629 3
   Rink BE, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0616 0
   Shi ST, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3816256
   Shoae Hassani A, 2011, MED HYPOTHESES, V76, P843, DOI 10.1016/j.mehy.2011.02.033
   Su HY, 2017, INT J CLIN EXP PATHO, V10, P1331
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Yang HF, 2014, FEBS LETT, V588, P192, DOI 10.1016/j.febslet.2013.11.036
   Zaminy Arash, 2008, Iran Biomed J, V12, P133
   Zeng CX, 2015, ONCOTARGET, V6, P12224, DOI 10.18632/oncotarget.3652
   Zhang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1059 5
   Zhu HY, 2017, CHINESE MED J PEKING, V130, P2732, DOI 10.4103/0366 6999.218013
   Zhu HY, 2015, GYNECOL ENDOCRINOL, V31, P796, DOI 10.3109/09513590.2015.1069268
   Zhu LP, 2018, CANCER MANAG RES, V10, P2337, DOI 10.2147/CMAR.S168594
NR 71
TC 5
Z9 6
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152 4971
EI 2152 4998
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD DEC 1
PY 2020
VL 22
IS 6
BP 311
EP 327
DI 10.1089/cell.2020.0026
EA SEP 2020
PG 17
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA OZ9TN
UT WOS:000574577100001
PM 32991224
DA 2025 08 17
ER

PT J
AU Dai, QS
   Zhou, HY
   Wu, ZH
   Long, JT
   Shao, N
   Cheang, TY
   Wang, SM
AF Dai, Qiang Sheng
   Zhou, Hong Yan
   Wu, Zhuang Hong
   Long, Jian Ting
   Shao, Nan
   Cheang, Tuck Yun
   Wang, Shen Ming
TI Osterix transcriptional factor is involved in the metastasis of human
   breast cancers
SO ONCOLOGY LETTERS
LA English
DT Article
DE Osterix; breast cancer; metastasis
ID ENDOTHELIAL GROWTH FACTOR; MATRIX METALLOPROTEINASE INHIBITORS;
   OSTEOBLAST DIFFERENTIATION; GASTRIC CARCINOMA; BONE FORMATION; MMP 9;
   INVASION; THERAPY; DISEASE; CATENIN
AB The transcriptional factor Osterix is specifically expressed in bone tissues to regulate the differentiation and maturation of osteoblasts. Recent studies have also identified the expression of Osterix in a number of cancer tissues, such as kidney and lung cancers. However, the association of Osterix with the metastasis of breast cancers has never been reported. The present study, for the first time, provides evidence supporting the involvement of Osterix in breast cancer metastasis. Western blotting was employed to investigate the expression of Osterix in a number of human breast cancer cell lines with different metastatic features. Gain of function and loss of function experiments were performed in MCF7 cells (low level of metastasis) and MDA MB 361 cells (high level of metastasis). The expression of several metastasis associated genes was analyzed by western blotting and quantitative polymerase chain reaction. A firefly luciferase based reporter gene assay was conducted in order to study whether Osterix regulated the promoter activities of the MMP2 and MMP9 genes, which play critical roles in cancer metastasis. The results showed that Osterix was highly expressed in the MDA MB 231 and MDA MB 361 cells, but was not detectable in the MCF7 cells. The overexpression of Osterix in the MCF7 cells promoted the expression of VEGF, MMP9 and beta catenin, while downregulating the expression of E cadherin. In addition, suppression of Osterix expression in the MDA MB 361 cells reversed the alteration of VEGF, MMP9, beta catenin and E cadherin expression. A reporter gene assay suggested that Osterix activated MMP2 and MMP9 promoter activity. In conclusion, Osterix is involved in the metastasis of human breast cancer and may be a target for the efficient treatment of human breast cancers.
C1 [Dai, Qiang Sheng; Long, Jian Ting] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhou, Hong Yan] Sun Yat Sen Univ, Affiliated Hosp 1, Neurol Intens Care Unit, Guangzhou 510080, Guangdong, Peoples R China.
   [Wu, Zhuang Hong; Shao, Nan; Cheang, Tuck Yun; Wang, Shen Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc Surg, Guangzhou 510080, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Cheang, TY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc Surg, 58 Zhongshan Second Rd, Guangzhou 510080, Guangdong, Peoples R China.
EM cheangtuckyun818@163.com; wangshenming2789@163.com
RI Shao, Nan/AAX 7528 2020; long, jianting/JCE 8178 2023
FU Science and Technology Planning Project of Guangdong Province
   [2012B031800032]; National Natural Science Foundation of China
   [81372821]
FX This study was supported by grants from the Science and Technology
   Planning Project of Guangdong Province (no. 2012B031800032) and the
   National Natural Science Foundation of China (no. 81372821).
CR Berns EMJJ, 2003, CLIN CANCER RES, V9, P1253
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959 8049(00)00156 8
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208
   Hoekstra R, 2001, ONCOLOGIST, V6, P415, DOI 10.1634/theoncologist.6 5 415
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Liabakk NB, 1996, CANCER RES, V56, P190
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003 2697(87)90587 2
   Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Yang D, 2010, SUZHON U J MED SCI, V3, P6
   Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364
   Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434 999 0373 0
   Zheng HC, 2006, ANTICANCER RES, V26, P3579
NR 21
TC 11
Z9 12
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2015
VL 10
IS 3
BP 1870
EP 1874
DI 10.3892/ol.2015.3448
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CQ9GZ
UT WOS:000360923000113
PM 26622767
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU McInnes, IB
   Liew, FY
   Gracie, JA
AF McInnes, IB
   Liew, FY
   Gracie, JA
TI Interleukin 18: A therapeutic target in rheumatoid arthritis? Commentary
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE cytokine; IL 18; inflammation rheumatoid arthritis
ID COLLAGEN INDUCED ARTHRITIS; GAMMA INDUCING FACTOR; OSTEOCLAST FORMATION;
   INTERFERON GAMMA; SYNOVIAL TISSUE; IL 18; EXPRESSION; RECEPTOR; ALPHA;
   JOINT
AB Interleukin 18 (IL 18), a member of the IL 1 superfamily of cytokines has been demonstrated to be an important mediator of both innate and adaptive immune responses. Several reports have implicated its role in the pathogenesis of rheumatoid arthritis (RA). Although biologic therapy is firmly established in the treatment of a number of inflammatory diseases including RA, partial and non responder patients constitute residual unmet clinical need. The aim of this article is to briefly review the biology of, and experimental approaches to IL 18 neutralisation, together with speculation as to the relative merits of IL 18 as an alternative to existing targets.
C1 Univ Glasgow, Div Immunol, Infection & Inflammation, Glasgow G12 8QQ, Lanark, Scotland.
C3 University of Glasgow
RP Univ Glasgow, Div Immunol, Infection & Inflammation, Glasgow G12 8QQ, Lanark, Scotland.
EM i.b.mcinnes@clinmed.gla.ac.uk
RI McInnes, Iain/ACS 0958 2022
OI McInnes, Iain/0000 0002 6462 4280
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Banda NK, 2003, J IMMUNOL, V170, P2100, DOI 10.4049/jimmunol.170.4.2100
   Bombardieri M, 2004, ARTHRITIS RES THER, V6, pR447, DOI 10.1186/ar1209
   Braddock M, 2004, EXPERT OPIN BIOL TH, V4, P847, DOI 10.1517/14712598.4.6.847
   Bufler P, 2002, P NATL ACAD SCI USA, V99, P13723, DOI 10.1073/pnas.212519099
   Choe JY, 2003, J EXP MED, V197, P537, DOI 10.1084/jem.20021850
   Dai SM, 2004, ANN RHEUM DIS, V63, P1379, DOI 10.1136/ard.2003.018481
   Dinarello CA, 2004, RHEUM DIS CLIN N AM, V30, P417, DOI 10.1016/j.rdc.2004.02.001
   DINARELLO CA, 2003, J INFECT DIS     S2, V2, P370
   Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317
   Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313
   Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333
   Joosten LAB, 2004, AM J PATHOL, V165, P959, DOI 10.1016/S0002 9440(10)63357 3
   Joosten LAB, 2003, ARTHRITIS RHEUM, V48, P339, DOI 10.1002/art.10814
   KANE D, 2004, RHEUMATOLOGY     S2, P2
   Leung BP, 2000, J IMMUNOL, V164, P6495, DOI 10.4049/jimmunol.164.12.6495
   Leung BP, 2001, J IMMUNOL, V167, P2879, DOI 10.4049/jimmunol.167.5.2879
   McInnes Iain B, 2004, Curr Rheumatol Rep, V6, P336, DOI 10.1007/s11926 004 0007 2
   Möller B, 2002, ARTHRITIS RES, V4, P139, DOI 10.1186/ar390
   MOREI HC, 2001, J BIOL CHEM, V276, P37069
   Morel JCM, 2001, LAB INVEST, V81, P1371, DOI 10.1038/labinvest.3780351
   Plater Zyberk C, 2001, J CLIN INVEST, V108, P1825, DOI 10.1172/JCI12097
   Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379
   Rooney T, 2004, ANN RHEUM DIS, V63, P1393, DOI 10.1136/ard.2003.016428
   Smeets RL, 2003, GENE THER, V10, P1004, DOI 10.1038/sj.gt.3301986
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Van den Berg Wim B, 2002, Curr Rheumatol Rep, V4, P232
   Verri WA, 2004, J PHARMACOL EXP THER, V310, P710, DOI 10.1124/jpet.103.063990
   Wei XQ, 2001, J IMMUNOL, V166, P517, DOI 10.4049/jimmunol.166.1.517
   Yamamura M, 2001, ARTHRITIS RHEUM, V44, P275, DOI 10.1002/1529 0131(200102)44:2<275::AID ANR44>3.3.CO;2 2
NR 30
TC 49
Z9 56
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2005
VL 7
IS 1
BP 38
EP 41
DI 10.1186/ar1497
PG 4
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 878DM
UT WOS:000225626700026
PM 15642152
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lv, DW
   Zhao, XD
AF Lv, Dawei
   Zhao, Xiaodong
TI Evaluation of the anti RANKL monoclonal antibody in rheumatoid arthritis
   rats
SO ARCHIVES OF RHEUMATOLOGY
LA English
DT Article
DE Anti RANKL; monoclonal antibody; rheumatoid arthritis; treatment
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; ARTICULAR CHONDROCYTES; BONE;
   BLOCKING; EROSION; RISK
AB Objectives: In this study, we aimed to investigate the therapeutic effect of anti receptor activator of nuclear factor kappa kappa B ligand (RANKL) monoclonal antibodies R748 1 1 1, R748 1 1 2 and R748 1 1 3 on rheumatoid arthritis (RA) in a rat model.
   Materials and methods: Gene cloning, hybridoma technology, affinity purification, enzyme linked immunosorbent assay, general observation, hematoxylin eosin staining, X ray, and many other experimental techniques were used in this study.
   Results: Improved collagen induced arthritis (CIA) modeling was successfully constructed. The RANKL gene was cloned and the anti RANKL monoclonal antibody was prepared. Following treatment with the anti RANKL monoclonal antibody, the soft tissue swelling of the hind paws, the joint thickening, the narrowed joint gap, and the blurred edge of the bone joint were improved. The pathological changes such as synovial hyperplasia of fibrous tissue, cartilage and bone destruction were significantly decreased in the anti RANKL monoclonal antibody treated CIA group. Compared to the normal control group and phosphate buffer saline (PBS) treated CIA group, the expression of tumor necrosis factor alpha (TNF alpha) and interleukin 1 (IL 1) in antibody treated CIA group, positive drug treated CIA group, and IgG treated CIA group were decreased (p<0.05).
   Conclusion: The anti  RANKL monoclonal antibody can promote the therapeutic effect of RA rats, indicating that the anti RANKL monoclonal antibody has a certain potential value and may be beneficial to the further study of the mechanism of RA treatment.
C1 [Lv, Dawei; Zhao, Xiaodong] Fourth Med Ctr PLA Gen Hosp, Dept Emergency, Beijing, Peoples R China.
RP Zhao, XD (通讯作者)，Fourth Med Ctr PLA Gen Hosp, Dept Emergency, Beijing 100048, Peoples R China.
EM xdzhao@tom.com
FU National Natural Science Foundation of China [61335011, 31300691]
FX This study was supported by the National Natural Science Foundation of
   China (no. 61335011 & 31300691).
CR Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592
   Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10
   Bugatti S, 2007, AUTOIMMUN REV, V6, P482, DOI 10.1016/j.autrev.2007.02.008
   Crotti TN, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/281287
   Du FH, 2017, AUTOIMMUN HIGHLIGHTS, V8, DOI 10.1007/s13317 017 0100 y
   Feehan LM, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1888 3
   Hairul Islam MI, 2017, INT IMMUNOPHARMACOL, V53, P114, DOI 10.1016/j.intimp.2017.10.022
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Jahid M, 2018, GENE, V641, P63, DOI 10.1016/j.gene.2017.10.051
   Judge Andy, 2017, Alzheimers Dement (N Y), V3, P612, DOI 10.1016/j.trci.2017.10.002
   Jutley GS, 2017, BEST PRACT RES CL RH, V31, P59, DOI 10.1016/j.berh.2017.09.016
   Kalden JR, 2017, NAT REV RHEUMATOL, V13, P707, DOI 10.1038/nrrheum.2017.187
   Kim D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009616
   Kinslow JD, 2016, ARTHRITIS RHEUMATOL, V68, P2372, DOI 10.1002/art.39771
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Lac P, 2018, J AUTOIMMUN, V89, P75, DOI 10.1016/j.jaut.2017.12.002
   Lewiecki EM, 2010, MATURITAS, V66, P182, DOI 10.1016/j.maturitas.2010.02.008
   Little CB, 2007, J CLIN INVEST, V117, P1627, DOI 10.1172/JCI30765
   Liu GW, 2017, BIOCHEM BIOPH RES CO, V491, P388, DOI 10.1016/j.bbrc.2017.07.091
   [刘曦 Liu Xi], 2010, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V14, P3666
   Naidu VGM, 2013, CHEM BIOL INTERACT, V203, P467, DOI 10.1016/j.cbi.2012.12.016
   Ohmura Koichiro, 2009, Nihon Rinsho Meneki Gakkai Kaishi, V32, P484
   Pál I, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen 2017 000485
   Suzuki T, 2017, CLIN MED INSIGHTS AR, V10, DOI 10.1177/1179544117745851
   Tang CH, 2008, CARCINOGENESIS, V29, P1483, DOI 10.1093/carcin/bgn045
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wailoo A, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21710
   王乐禹, 2010, [中国病理生理杂志, Chinese Journal of Pathophysiology], V26, P1217
   Wang Yu, 2010, J Med Res, V39, P117
   [肖静 Xiao Jing], 2010, [中华肾脏病杂志, Chinese Journal of Nephrology], V26, P708
   Yang J, 2010, J Oral Sci Res, V26, P359
   Yuasa T, 2008, LAB INVEST, V88, P264, DOI 10.1038/labinvest.3700747
   Zhang L, 2010, Mod Oncol, V18, P1051
   Zhu M, 2008, ARTHRITIS RHEUM US, V58, P2053, DOI 10.1002/art.23614
NR 36
TC 0
Z9 0
U1 1
U2 4
PU TURKISH LEAGUE AGAINST RHEUMATISM
PI ANKARA
PA TALATPASA BULVARI DUMLUPINAR CAD 40 3 CEBECI DORTYOL, ANKARA, 06100,
   Turkiye
EI 2618 6500
J9 ARCH RHEUMATOL
JI Arch. Rheumatol.
PD MAR
PY 2023
VL 38
IS 1
BP 22
EP 31
DI 10.46497/ArchRheumatol.2023.9240
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA X9WK8
UT WOS:001101876400003
PM 37235123
OA gold
DA 2025 08 17
ER

PT J
AU Dawes, JM
   Kiesewetter, H
   Perkins, JR
   Bennett, DLH
   McMahon, SB
AF Dawes, John M.
   Kiesewetter, Hannes
   Perkins, James R.
   Bennett, David L. H.
   McMahon, Stephen B.
TI Chemokine expression in peripheral tissues from the Monosodium
   Iodoacetate model of chronic joint pain
SO MOLECULAR PAIN
LA English
DT Article
DE Pain; Chemokine; Osteoarthritis; Monosodium iodoacetate; Macrophages;
   Neutrophils
ID MONOCYTE CHEMOATTRACTANT PROTEIN 1; INFRAPATELLAR FAT PAD; NEUROPATHIC
   PAIN; INDUCED OSTEOARTHRITIS; SENSORY NEURONS; SKELETAL PAIN; NERVE
   GROWTH; RODENT MODEL; RAT MODEL; BEHAVIOR
AB Background: Chronic pain arising from degenerative diseases of the joint such as osteoarthritis (OA) has a strong peripheral component which is likely to be mediator driven. Current treatments which reduce the production of such mediators i.e. non steroidal anti inflammatory drugs (NSAIDs), can help to lessen pain in OA patients. However, this is not always the case and complete pain relief is rarely achieved, suggesting that additional unidentified mediators play a role. Here we have investigated the notion that chemokines might act as such pain mediators in OA.
   Results: Using the monosodium iodoacetate (MIA) model of chronic joint pain the expression of over 90 different inflammatory mediators, mainly cytokines and chemokines, were measured in tissues taken from the femorotibial joint (cartilage, subchondral bone, fat pad) using custom made quantitative real time polymerase chain reaction (qPCR) array cards. At both the day 3 and 14 time points, numerous inflammatory mediators were significantly up regulated in these tissues, although it was clear that the largest transcriptional dysregulation occurred in the cartilage. Using individual qPCR to measure immune cell markers, a significant infiltration of macrophages was measured in the cartilage and fat pad at day 3. Neutrophil infiltration was also measured in the fat pad at the same time point, but no infiltration was observed at day 14. Combination of mRNA expression data from different time points and tissues identified the chemokines, CCL2, 7 and 9 as being consistently up regulated. The overall increase in CCL2 expression was also measured at the protein level.
   Conclusion: Chemokines in general and CCL2, 7 and 9 in particular, represent promising targets for further studies into the identification of new pain mediators in chronic joint pain.
C1 [Dawes, John M.; Bennett, David L. H.] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England.
   [Kiesewetter, Hannes; McMahon, Stephen B.] Kings Coll London, Wolfson Ctr Age Related Dis, London, England.
   [Perkins, James R.] UCL, Dept Struct & Mol Biol, London, England.
C3 University of Oxford; University of London; King's College London;
   University of London; University College London
RP Dawes, JM (通讯作者)，John Radcliffe Hosp, Nuffield Dept Clin Neurosci, West Wing,Level 6, Oxford OX3 9DU, England.
EM john.dawes@ndcn.ox.ac.uk
RI ; bennett, david/ABG 1184 2020; Perkins, James/H 8629 2017; Perkins,
   James Richard/H 8629 2017
OI Bennett, David/0000 0002 7996 2696; Dawes, John/0000 0003 4179 3492;
   McMahon, Stephen/0000 0003 4656 5536; Perkins, James
   Richard/0000 0003 4108 096X
FU Wellcome Trust; Innovative Medicines Initiative (IMI); Innovative
   Medicines Initiative Joint Undertakings (IMI JU) [115007]
FX SBM and DLHB are members of the Wellcome Trust funded London Pain
   Consortium. SBM is a Wellcome Trust Senior Investiga tor. DLHB is a
   Wellcome Trust Clinical Scientist. JMD is funded by the Innovative
   Medicines Initiative (IMI). HK and JRP are students of the London Pain
   Consortium and funded by the Wellcome Trust. This work is part of the
   Europain project and funded by the Innovative Medicines Initiative Joint
   Undertakings (IMI JU) grant no. 115007.
CR Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100
   Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140 6736(96)07524 1
   Alaaeddine N, 2001, ARTHRITIS RHEUM US, V44, P1633, DOI 10.1002/1529 0131(200107)44:7<1633::AID ART286>3.0.CO;2 Z
   Aley KO, 1998, J NEUROSCI, V18, P7008
   Bacon K, 2002, J INTERF CYTOK RES, V22, P1067
   Belkouch M, 2011, J NEUROSCI, V31, P18381, DOI 10.1523/JNEUROSCI.3386 11.2011
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Bhangoo S, 2007, MOL PAIN, V3, DOI 10.1186/1744 8069 3 38
   Bogen O, 2009, NEUROSCIENCE, V159, P780, DOI 10.1016/j.neuroscience.2008.12.049
   Bohnsack M, 2005, ARCH ORTHOP TRAUM SU, V125, P592, DOI 10.1007/s00402 005 0796 4
   Borzì RM, 2004, CLIN ORTHOP RELAT R, pS53, DOI 10.1097/01.blo.0000143805.64755.4f
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Clements KM, 2009, OSTEOARTHR CARTILAGE, V17, P805, DOI 10.1016/j.joca.2008.11.002
   Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023
   Creamer P, 1996, J RHEUMATOL, V23, P1031
   Crichton B, 2002, CURR MED RES OPIN, V18, P92, DOI 10.1185/030079902125000345
   CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476 5381.1992.tb14503.x
   Cunha TM, 2008, BRIT J PHARMACOL, V154, P460, DOI 10.1038/bjp.2008.94
   DASILVA JAP, 1990, J RHEUMATOL, V17, P1592
   Dawes JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002193
   Felson DT, 2005, CURR OPIN RHEUMATOL, V17, P624, DOI 10.1097/01.bor.0000172800.49120.97
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Goldring MB, 2000, ARTHRITIS RHEUM US, V43, P1916, DOI 10.1002/1529 0131(200009)43:9<1916::AID ANR2>3.0.CO;2 I
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Haider S, 2013, CURR GENOMICS, V14, P91, DOI 10.2174/1389202911314020003
   Hancock CM, 2008, CLIN J PAIN, V24, P353, DOI 10.1097/AJP.0b013e31815e5418
   Harvey VL, 2009, MOL PAIN, V5, DOI 10.1186/1744 8069 5 18
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   Jung H, 2008, J NEUROCHEM, V104, P254, DOI 10.1111/j.1471 4159.2007.04969.x
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kiefer F, 2011, CELL MOL LIFE SCI, V68, P2811, DOI 10.1007/s00018 011 0677 7
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   Lean JM, 2002, J CELL BIOCHEM, V87, P386, DOI 10.1002/jcb.10319
   Liu T, 2000, PAIN, V86, P25, DOI 10.1016/S0304 3959(99)00306 1
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Macule Francisco, 2005, Acta Orthop Belg, V71, P714
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Mason L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 28
   Miller RE, 2012, P NATL ACAD SCI USA, V109, P20602, DOI 10.1073/pnas.1209294110
   Ng SC, 2010, CURR OPIN GASTROEN, V26, P611, DOI 10.1097/MOG.0b013e32833e91eb
   Ogbonna AC, 2013, EUR J PAIN, V17, P514, DOI 10.1002/j.1532 2149.2012.00223.x
   Oh SB, 2001, J NEUROSCI, V21, P5027, DOI 10.1523/JNEUROSCI.21 14 05027.2001
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 134
   Perkins JR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471 2164 13 296
   Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67
   Qin XM, 2005, J NEUROSCI RES, V82, P51, DOI 10.1002/jnr.20612
   Schuelert N, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3553
   SOZZANI S, 1994, J IMMUNOL, V152, P3615
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Sun JH, 2006, J NEUROPHYSIOL, V96, P2189, DOI 10.1152/jn.00222.2006
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Thacker MA, 2007, ANESTH ANALG, V105, P838, DOI 10.1213/01.ane.0000275190.42912.37
   Thakur M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033730
   Ushiyama T, 2003, ANN RHEUM DIS, V62, P108, DOI 10.1136/ard.62.2.108
   Vassiliou EK, 2008, J IMMUNOL, V181, P4534, DOI 10.4049/jimmunol.181.7.4534
   Vermeirsch H, 2007, PHARMACOL BIOCHEM BE, V87, P349, DOI 10.1016/j.pbb.2007.05.010
   Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001
   White FA, 2005, P NATL ACAD SCI USA, V102, P14092, DOI 10.1073/pnas.0503496102
   Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148
   Wylde V, 2011, PAIN, V152, P566, DOI 10.1016/j.pain.2010.11.023
   Zhang N, 2004, J IMMUNOL, V173, P594, DOI 10.4049/jimmunol.173.1.594
   Zhang N, 2005, P NATL ACAD SCI USA, V102, P4536, DOI 10.1073/pnas.0406030102
NR 66
TC 31
Z9 33
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
EI 1744 8069
J9 MOL PAIN
JI Mol. Pain
PD NOV 8
PY 2013
VL 9
DI 10.1186/1744 8069 9 57
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 280NX
UT WOS:000329038500001
PM 24206615
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pietrovito, L
   Comito, G
   Parri, M
   Giannoni, E
   Chiarugi, P
   Taddei, ML
AF Pietrovito, Laura
   Comito, Giuseppina
   Parri, Matteo
   Giannoni, Elisa
   Chiarugi, Paola
   Taddei, Maria Letizia
TI Zoledronic Acid Inhibits the RhoA mediated Amoeboid Motility o Prostate
   Cancer Cells
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Prostate cancer; zoledronic acid; amoeboid motility; RhoA; metastasis;
   endothelium
ID BREAST CANCER; MULTIPLE MYELOMA; BISPHOSPHONATES; ADHESION; PATHWAY;
   POLARIZATION; FIBROBLASTS; TRANSITION; METASTASES; MIGRATION
AB Background: The bisphosphonate Zoledronic acid (ZA) is a potent osteoclast inhibitor currently used in the clinic to reduce osteoporosis and cancer induced osteolysis. Moreover, ZA exerts an anti tumor effect in several tumors. Despite this evidence, the relevance of ZA in prostate cancer (PCa) is not completely understood.
   Objective: To investigate the effect of ZA administration on the invasive properties of PC3 cells, which are characterised by RhoA dependent amoeboid motility.
   Methods: The effect of ZA administration on the in vitro invasive properties of PC3 cells was evaluated by cell migration in 3D collagen matrices, immunofluorescence and Boyden assays or transendothelial migration. Lung retention and colonization assays were performed to assess the efficacy of ZA administration in vivo.
   Results: PC3 cells are characterised by RhoA dependent amoeboid motility. We now report a clear inhibition of in vitro PC3 cell invasion and RhoA activity upon ZA treatment. Moreover, to confirm a specific role of ZA in the inhibition of amoeboid motility of PC3 cells, we demonstrate that ZA interferes only partially with PC3 cells showing a mesenchymal phenotype due to both treatment with conditioned medium of cancer associated fibroblasts or to the acquisition of chemoresistance. Furthermore, we demonstrate that ZA impairs adhesion to endothelial cells and the trans endothelial cell migration, two essential properties characterising amoeboid motility and PC3 metastatic dissemination. In vivo experiments prove the ability of ZA to inhibit the metastatic process of PC3 cells as shown by the decrease in lung colonization.
   Conclusion: This study demonstrates that ZA inhibits Rho dependent amoeboid motility of PC3 cells, thus suggesting ZA as a potential therapy to impede the metastatic dissemination of PC3 cells.
C1 [Pietrovito, Laura; Comito, Giuseppina; Parri, Matteo; Giannoni, Elisa; Chiarugi, Paola; Taddei, Maria Letizia] Univ Firenze, Dipartimento Sci Biomed Sperimentali & Clin, Viale Morgagni 50, I 50142 Florence, Italy.
   [Taddei, Maria Letizia] Univ Firenze, Dipartimento Med Sperimentale & Clin, Viale Morgagni 50, I 50142 Florence, Italy.
   [Taddei, Maria Letizia] Tuscany Tumor Inst, I 50134 Florence, Italy.
   [Taddei, Maria Letizia] Ctr Res Transfer & High Educ DeNoTHE, I 50134 Florence, Italy.
C3 University of Florence; University of Florence
RP Taddei, ML (通讯作者)，Univ Florence, Dept Expt & Clin Med, Viale Morgagni 50, I 50134 Florence, Italy.
EM marialetizia.taddei@unifi.it
RI Giannoni, Elisa/AAE 2092 2020; Chiarugi, Paola/CDD 7988 2022
OI Chiarugi, Paola/0000 0001 7655 2969
FU Associazione Italiana Ricerca sul Cancro (AIRC) [8797]; Istituto Toscano
   Tumori [0203607]
FX The work was supported by Associazione Italiana Ricerca sul Cancro
   (AIRC) (grant #8797 to P.C.) and Istituto Toscano Tumori (grant #0203607
   to P.C.)
CR Adjei AA, 2001, CURR PHARM DESIGN, V7, P1581, DOI 10.2174/1381612013397258
   Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191
   Comito G, 2017, ONCOTARGET, V8, P118, DOI 10.18632/oncotarget.9497
   Conte P, 2004, SEMIN ONCOL, V31, P59, DOI 10.1053/j.seminoncol.2004.07.024
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   El Amm J, 2016, CLIN MED INSIGHTS ON, V10, P11, DOI 10.4137/CMO.S30751
   Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959 8049(00)00091 5
   Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008 5472.CAN 12 1949
   Giannoni E, 2013, J MOL MED, V91, P103, DOI 10.1007/s00109 012 0941 9
   Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008 5472.CAN 10 0785
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Ippolito L., 2016, ONCOTARGET
   Jiang PF, 2016, ONCOTARGET, V7, P57932, DOI 10.18632/oncotarget.10773
   Laggner U, 2009, CLIN IMMUNOL, V131, P367, DOI 10.1016/j.clim.2009.01.008
   Lipton A, 2002, CANCER INVEST, V20, P45, DOI 10.1081/CNV 120014886
   Mani J, 2012, PROSTATE CANCER P D, V15, P250, DOI 10.1038/pcan.2012.9
   McCubrey JA, 2007, BBA MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Naoe M, 2010, ONCOL RES, V18, P493, DOI 10.3727/096504010X12671222663638
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Parri M, 2007, J BIOL CHEM, V282, P19619, DOI 10.1074/jbc.M701319200
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Pietrovito L, 2018, MOL ONCOL, V12, P659, DOI 10.1002/1878 0261.12189
   Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169
   Riganti C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060975
   Rosen LS, 2001, CANCER J, V7, P377
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2014, LANCET ONCOL, V15, P1041, DOI 10.1016/S1470 2045(14)70363 8
   Sackmann E, 2015, BBA MOL CELL RES, V1853, P3132, DOI 10.1016/j.bbamcr.2015.06.012
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Santini D, 2009, CANCER IMMUNOL IMMUN, V58, P31, DOI 10.1007/s00262 008 0521 6
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Song ZB, 2014, MED ONCOL, V31, DOI 10.1007/s12032 014 0898 3
   Taddei M.L., 2018, J CELL PHYSL, P8274
   Taddei ML, 2013, CANCER LETT, V341, P80, DOI 10.1016/j.canlet.2013.01.042
   Taddei ML, 2011, MOL CANCER RES, V9, P149, DOI 10.1158/1541 7786.MCR 10 0298
   Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473
   Wolf K, 2006, BRIT J DERMATOL, V154, P11, DOI 10.1111/j.1365 2133.2006.07231.x
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zameer S, 2018, PHARMACOL REP, V70, P900, DOI 10.1016/j.pharep.2018.03.011
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 45
TC 7
Z9 7
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568 0096
EI 1873 5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2019
VL 19
IS 10
BP 807
EP 816
DI 10.2174/1568009619666190115142858
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA JX9MB
UT WOS:000504049800004
PM 30648509
OA Green Published
DA 2025 08 17
ER

PT J
AU Huang, S
   Xu, LL
   Sun, YX
   Zhang, YF
   Li, G
AF Huang, Shuo
   Xu, Liangliang
   Sun, Yuxin
   Zhang, Yifeng
   Li, Gang
TI The fate of systemically administrated allogeneic mesenchymal stem cells
   in mouse femoral fracture healing
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Allogeneic mesenchymal stem cells (MSCs); systemic injection; local
   injection; fracture healing
ID ACUTE MYOCARDIAL INFARCTION; MULTIPOTENT STROMAL CELLS;
   VERSUS HOST DISEASE; BONE MARROW; TRANSGENIC MICE; MODEL;
   TRANSPLANTATION; REGENERATION; OSTEOGENESIS; DELIVERY
AB Introduction: The fate and whereabouts of the allogenic mesenchymal stem cells (MSCs) following their transplantation are not well understood. The present study investigated the fate of systemically administrated allogeneic MSCs in mouse fracture healing by using in vivo imaging and immunohistochemistry methods.
   Methods: Open femoral fracture with internal fixation was established in 30 FVB mice, which were assigned to three groups receiving phosphate buffered saline (PBS) injection, MSC systemic injection, or MSC local injection. Luc MSCs (5 x 10(5)) isolated from the luciferase transgenic mice with FVB background were injected at 4 days after fracture. All animals were terminated at 5 weeks after fracture; examinations included bioluminescence based in vivo imaging, micro computer tomography, mechanical testing, histology, immunohistochemistry, and double immunofluorescence staining.
   Results: The bioluminescence signals of the Luc MSCs at the fracture site could be detected for 12 14 days following their injection in the Luc MSC local injection group, whereas in the Luc MSC systemic injection group, Luc MSCs were initially trapped in lungs for about 8 9 days and then gradually redistributed to the fracture site. Bone mineral density, bone volume/tissue volume, ultimate load, and E modulus in the MSC injection groups were significantly higher than those in the PBS group. Double immunostaining demonstrated that the MSC local injection group had more Luc positive cells, and there was a higher apoptotic rate at the fracture site than the MSC systemic injection group. Both Luciferase positive MSCs and osteoblasts were present in the callus in the MSC injection groups at 5 weeks after fracture, suggesting that some of allogenic Luc MSCs contributed to the new bone formation. Only less than 3 % of injected Luc MSCs remained at the fracture site in the MSC injection groups at 5 weeks following the fracture, and the rest of the injected Luc MSCs disappeared.
   Conclusions: Our data showed that both systemic and local injection of allogeneic MSCs promoted fracture healing through enhancing biomechanical properties, bone content, and enlarged callus sizes. Immunohistochemistry confirmed that the injected MSCs are still present in the fracture site and can differentiate into osteoblasts to participate in fracture healing even at 5 weeks following the fracture. These findings provide useful information for the use of allogenic MSCs for cell therapy applications.
C1 [Huang, Shuo; Xu, Liangliang; Sun, Yuxin; Zhang, Yifeng; Li, Gang] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Fac Med, Li Ka Shing Inst,Hlth Inst,Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   [Huang, Shuo; Xu, Liangliang; Sun, Yuxin; Li, Gang] Chinese Univ Hong Kong, Stem Cells & Regenerat Med Lab, Li Ka Shing Inst Hlth Sci, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Key Lab Regenerat Med, Minist Educ, Sch Biomed Sci,Fac Med, Shatin, Hong Kong, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Shenzhen Res Inst, CUHK ACC Space Med Ctr Hlth Maintenance Musculosk, Shenzhen 518057, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Fac Med, Lui Che Woo Inst Innovat Med, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; Chinese University of
   Hong Kong; CUHK Shenzhen Research Institute; The Chinese University of
   Hong Kong, Shenzhen; Chinese University of Hong Kong
RP Li, G (通讯作者)，Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Fac Med, Li Ka Shing Inst,Hlth Inst,Prince Wales Hosp, Room 904,9 F,30 32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.
EM gangli@cuhk.edu.hk
RI ; Li, Gang/J 7830 2018; SUN, Yuxin/B 5440 2016; Liangliang,
   XU/K 9185 2019
OI Xu, Liangliang/0000 0002 5249 7480; Li, Gang/0000 0002 3981 2239; 
FU Hong Kong Government Research Grant Council, General Research Fund
   [CUHK470813]; China Shenzhen City Science and Technology Bureau under
   the Shenzhen City Knowledge Innovation Plan, Basic Research Project
   [JCYJ20130401171935811]; SMART program, Lui Che Woo Institute of
   Innovative Medicine, Faculty of Medicine, the Chinese University of Hong
   Kong
FX This work is supported by a grant from Hong Kong Government Research
   Grant Council, General Research Fund (CUHK470813), and a grant from
   China Shenzhen City Science and Technology Bureau under the Shenzhen
   City Knowledge Innovation Plan, Basic Research Project
   (JCYJ20130401171935811) to Gang Li. This study was also supported in
   part by SMART program, Lui Che Woo Institute of Innovative Medicine,
   Faculty of Medicine, the Chinese University of Hong Kong. This research
   project was made possible by resources donated by Lui Che Woo Foundation
   Limited.
CR [Anonymous], NEUROSURGERY
   Block GJ, 2009, STEM CELLS, V27, P670, DOI [10.1002/stem.20080742, 10.1634/stemcells.stemcells.2008 0742]
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Bruder SP, 1998, J BONE JOINT SURG AM, V80A, P985, DOI 10.2106/00004623 199807000 00007
   Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Cole JH, 2011, CLIN ORTHOP RELAT R, V469, P2139, DOI 10.1007/s11999 011 1784 3
   Devine MJ, 2002, J ORTHOP RES, V20, P1232, DOI 10.1016/S0736 0266(02)00051 7
   Falanga V, 2007, TISSUE ENG, V13, P1299, DOI 10.1089/ten.2006.0278
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hall B, 2007, INT J HEMATOL, V86, P8, DOI 10.1532/IJH97.06230
   Hashemi SM, 2008, EUR HEART J, V29, P251, DOI 10.1093/eurheartj/ehm559
   Henriques C, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756 3305 7 89
   Imanishi Y, 2008, J MOL CELL CARDIOL, V44, P662, DOI 10.1016/j.yjmcc.2007.11.001
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood 2004 04 1488
   Kim SO, 2011, UROL INT, V86, P110, DOI 10.1159/000317322
   Koç ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365 3083.2003.01176.x
   Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103
   Li H, 2008, STEM CELLS, V26, P2531, DOI 10.1634/stemcells.2008 0146
   Livingston TL, 2003, J MATER SCI MATER M, V14, P211, DOI 10.1023/A:1022824505404
   Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA
   McFarlin K, 2006, WOUND REPAIR REGEN, V14, P471, DOI 10.1111/j.1743 6109.2006.00153.x
   Murphy JM, 2003, ARTHRITIS RHEUM US, V48, P3464, DOI 10.1002/art.11365
   Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sanchez Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337
   SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406
   Shirley D, 2005, J ORTHOP RES, V23, P1013, DOI 10.1016/j.orthres.2005.01.013
   Zhang T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt221
NR 34
TC 41
Z9 46
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD OCT 26
PY 2015
VL 6
AR 206
DI 10.1186/s13287 015 0198 7
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CU4OK
UT WOS:000363509100003
PM 26503505
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kozlowska, AK
   Kaur, K
   Topchyan, P
   Jewett, A
AF Kozlowska, Anna K.
   Kaur, Kawaljit
   Topchyan, Paytsar
   Jewett, Anahid
TI Novel strategies to target cancer stem cells by NK cells; studies in
   humanized mice
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE Osteoclast expanded Super Charged NK Cells; Cancer Immunotherapy; BLT
   Humanized Mice; CSCs; Review
ID NATURAL KILLER CELLS; SEVERE COMBINED IMMUNODEFICIENCY; HEMATOPOIETIC
   PROGENITOR CELLS; MOUSE MODEL; IN VIVO; TNF ALPHA; BLT MICE; LYMPHOID
   ORGANS; DENDRITIC CELLS; MELANOMA CELLS
AB We have previously shown, that following selection, natural killer (NK) cells differentiate cancer stem like cells (CSCs)/poorly differentiated tumors via secreted and membrane bound IFN gamma and TNF alpha, leading to prevention of tumor growth and remodeling of the tumor microenvironment. Since conventional therapeutic strategies, including chemotherapy and radiotherapy remain unsuccessful in treating stem like tumors, there has been increasing interest in NK cell targeted immunotherapy for the treatment of aggressive malignacies. In our recent studies, we used a humanized (hu BLT) mouse model with transplanted human bone marrow, liver and thymus to demonstrate the efficacy of adoptive transfer of ex vivo expanded, super charged NK cells in selection and differentiation of stem like tumors within the context of a fully reconstituted human immune system. We have also shown that CSCs differentiated with split anergized NK cells prior to implantation in humanized mice did not grow or metastasize. In this review, we present current advances in NK cell detection, expansion and therapeutic delivery methods, and discuss the utility of different humanized mouse models in studying NK cell based therapies in the preclinical setting.
C1 [Kozlowska, Anna K.; Kaur, Kawaljit; Topchyan, Paytsar; Jewett, Anahid] Univ Calif Los Angeles, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Oral Biol & Oral Med, Los Angeles, CA USA.
   [Jewett, Anahid] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med & Dent, Los Angeles, CA 90024 USA.
   [Kozlowska, Anna K.] Poznan Univ Med Sci, Dept Tumor Immunol, Chair Med Biotechnol, Poznan, Poland.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   UCLA Jonsson Comprehensive Cancer Center; Poznan University of Medical
   Sciences
RP Jewett, A (通讯作者)，Univ Calif Los Angeles, Sch Dent, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM ajewett@ucla.edu
RI ; Kozlowska, Anna/P 1620 2015
OI Kozlowska, Anna Karolina/0000 0003 2465 217X; Topchyan,
   Paytsar/0000 0002 3902 7652; 
FU Polish Ministry of Sciences and Higher Education; Mobility Plus award
FX The authors declare no conflicts of interest. Anna K. Kozlowska was
   supported by the Polish Ministry of Sciences and Higher Education and
   the Mobility Plus award.
CR Akkina R, 2013, CURR OPIN IMMUNOL, V25, P403, DOI 10.1016/j.coi.2013.03.009
   André MC, 2010, J IMMUNOL, V185, P2710, DOI 10.4049/jimmunol.1000583
   BAXTER AG, 1993, DIABETES, V42, P1574, DOI 10.2337/diabetes.42.11.1574
   BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0
   Brehm MA, 2010, CLIN IMMUNOL, V135, P84, DOI 10.1016/j.clim.2009.12.008
   Bui VT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00576
   Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106
   Cojoc M, 2015, SEMIN CANCER BIOL, V31, P16, DOI 10.1016/j.semcancer.2014.06.004
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471 4906(01)02060 9
   Cooper MA, 2004, TRENDS IMMUNOL, V25, P47, DOI 10.1016/j.it.2003.10.012
   Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106
   Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120 11
   DORSHKIND K, 1985, J IMMUNOL, V134, P3798
   Ferlazzo G, 2004, P NATL ACAD SCI USA, V101, P16606, DOI 10.1073/pnas.0407522101
   Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455
   Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105 2896.2005.00223.x
   GANICK DJ, 1980, INT ARCH ALLER A IMM, V62, P330, DOI 10.1159/000232530
   Garcia Iglesias T, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 186
   Garg H, 2011, VIROL J, V8, DOI 10.1186/1743 422X 8 34
   Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166
   Huntington ND, 2009, J EXP MED, V206, P25, DOI 10.1084/jem.20082013
   Isaacson C. B., 1962, MOUSE NEWS LETT, V27, P31
   Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood 2005 02 0516
   Ito A, 2009, CANCER IMMUNOL IMMUN, V58, P1195, DOI 10.1007/s00262 008 0632 0
   Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood 2001 12 0207
   JAX Laboratory, 2015, HUM NSGTM MIC IMM
   Jewett A, 2006, CLIN CANCER RES, V12, P1994, DOI 10.1158/1078 0432.CCR 05 2306
   Jewett A, 1996, J IMMUNOL, V156, P907
   JEWETT A, 1995, CELL IMMUNOL, V160, P91, DOI 10.1016/0008 8749(95)80013 9
   Jewett A, 1996, J CLIN IMMUNOL, V16, P46, DOI 10.1007/BF01540972
   Jewett A, 1997, J IMMUNOL, V159, P4815
   Jewett A, 2000, CLIN IMMUNOL, V96, P19, DOI 10.1006/clim.2000.4871
   Jewett A, 2008, CANCER IMMUNOL IMMUN, V57, P1053, DOI 10.1007/s00262 007 0437 6
   Jewett A, 2013, J CANCER, V4, P12, DOI 10.7150/jca.5519
   Jewett A, 2012, CURR DRUG DELIV, V9, P5, DOI 10.2174/156720112798375989
   Jewett A, 2012, CANCER IMMUNOL IMMUN, V61, P265, DOI 10.1007/s00262 011 1163 7
   KATAOKA S, 1983, DIABETES, V32, P247, DOI 10.2337/diabetes.32.3.247
   King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365 2249.2009.03933.x
   Koka R, 2003, J EXP MED, V197, P977, DOI 10.1084/jem.20021836
   Kuss I, 1999, CLIN CANCER RES, V5, P329
   Kwant Mitchell A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008379
   Lai P, 1996, CLIN CANCER RES, V2, P161
   LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131
   LEVY EM, 1977, PREP BIOCHEM, V7, P467, DOI 10.1080/00327487708065514
   Livaditi O, 2006, CYTOKINE, V36, P283, DOI 10.1016/j.cyto.2007.02.007
   Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006
   Mamessier E, 2011, CANCER RES, V71, P6621, DOI 10.1158/0008 5472.CAN 11 0792
   Manz MG, 2007, IMMUNITY, V26, P537, DOI 10.1016/j.immuni.2007.05.001
   McDermott SP, 2010, BLOOD, V116, P193, DOI 10.1182/blood 2010 02 271841
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Mizrahi S, 2007, J LEUKOCYTE BIOL, V82, P1095, DOI 10.1189/jlb.0407205
   Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632
   Nixon CC, 2013, BLOOD, V122, P2195, DOI 10.1182/blood 2013 04 496950
   Nomura Tatsuji, 2008, Curr Top Microbiol Immunol, V324, pv
   Olesen R, 2011, J REPROD IMMUNOL, V88, P195, DOI 10.1016/j.jri.2010.11.005
   Onoe T, 2011, J IMMUNOL, V187, P3895, DOI 10.4049/jimmunol.1100394
   Pek EA, 2011, IMMUNOBIOLOGY, V216, P218, DOI 10.1016/j.imbio.2010.04.008
   Peng YP, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 738
   PERUSSIA B, 1992, J IMMUNOL, V149, P3495
   PHILLIPS RA, 1989, CURR TOP MICROBIOL, V152, P259
   Pietra G, 2012, CANCER RES, V72, P1407, DOI 10.1158/0008 5472.CAN 11 2544
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Rongvaux A, 2013, ANNU REV IMMUNOL, V31, P635, DOI 10.1146/annurev immunol 032712 095921
   Sato T, 1999, EXP HEMATOL, V27, P726, DOI 10.1016/S0301 472X(99)00005 3
   Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood 2009 04 215855
   Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017
   Shultz Leonard D, 2014, Cold Spring Harb Protoc, V2014, P694, DOI 10.1101/pdb.top073585
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Stoddart CA, 2011, VIROLOGY, V417, P154, DOI 10.1016/j.virol.2011.05.013
   Stonier SW, 2010, IMMUNOL LETT, V127, P85, DOI 10.1016/j.imlet.2009.09.009
   Strowig T, 2010, BLOOD, V116, P4158, DOI 10.1182/blood 2010 02 270678
   Takenaka K, 2007, NAT IMMUNOL, V8, P1313, DOI 10.1038/ni1527
   Tian XH, 2006, STEM CELLS, V24, P1370, DOI 10.1634/stemcells.2005 0340
   Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Tseng HC, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00259
   Tseng HC, 2015, ONCOTARGET, V6, P8947, DOI 10.18632/oncotarget.3250
   Tseng HC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00269
   Tseng HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011590
   Tseng HC, 2010, PLOS ONE, V5
   Vatakis DN, 2012, JOVE J VIS EXP, DOI 10.3791/4181
   Vatakis DN, 2011, P NATL ACAD SCI USA, V108, pE1408, DOI 10.1073/pnas.1115050108
   Vosshenrich CAJ, 2005, J IMMUNOL, V174, P1213, DOI 10.4049/jimmunol.174.3.1213
   Wege AK, 2011, INT J CANCER, V129, P2194, DOI 10.1002/ijc.26159
   WESTERMANN J, 1992, CLIN INVESTIGATOR, V70, P539
   Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711
   Yoshizawa K, 2011, J IMMUNOL, V187, P5162, DOI 10.4049/jimmunol.1101561
   Zhang LG, 2012, CELL MOL IMMUNOL, V9, P237, DOI 10.1038/cmi.2012.7
   Zhou GJ, 2012, J CLIN INVEST, V122, P4727, DOI 10.1172/JCI66056
   Zhu L, 2010, ANTIVIR THER, V15, P1107, DOI 10.3851/IMP1673
NR 93
TC 21
Z9 24
U1 0
U2 12
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093 9946
EI 1093 4715
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2017
VL 22
BP 370
EP 384
DI 10.2741/4489
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EQ2OQ
UT WOS:000397909800009
PM 27814619
DA 2025 08 17
ER

PT J
AU Dereka, XE
   Markopoulou, CE
   Vrotsos, IA
AF Dereka, X. E.
   Markopoulou, C. E.
   Vrotsos, I. A.
TI Role of growth factors on periodontal repair
SO GROWTH FACTORS
LA English
DT Article
DE growth factors; periodontal repair; periodontal tissues; periodontal
   defects; therapeutic application
ID LIGAMENT FIBROBLASTIC CELLS; FACTORS REGULATE EXPRESSION;
   PROTEASE ACTIVATED LIGAND; GINGIVAL CREVICULAR FLUID; II FURCATION
   DEFECTS; BB RHPDGF BB; IN VITRO; FACTOR RECEPTORS; TRANSFORMING
   GROWTH FACTOR BETA 1; IMMUNOHISTOCHEMICAL LOCALIZATION
AB Regeneration of periodontal structures lost during periodontal diseases constitutes a complex biological process regulated among others by interactions between cells and growth factors. Growth factors are biologically active polypeptides affecting the proliferation, chemotaxis and differentiation of cells from epithelium, bone and connective tissue. They express their action by binding to specific cell surface receptors present on various target cells including osteoblasts, cementoblasts and periodontal ligament fibroblasts. The observation that growth factors participate in all cell functions led to exogenous application during periodontal tissue repair aiming to their use as an alternative therapeutic approach to periodontal therapy. Cell types and cultures conditions, dose, carrier materials, application requirements are of critical importance in the outcome of periodontal repair. The purpose of this article is to review the literature with respect to the biological actions of PDGF, TGF, FGF, IGF and EGF on periodontal cells and tissues, which are involved in periodontal regeneration.
C1 Univ Athens, Sch Dent, Dept Periodont, Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Dereka, XE (通讯作者)，XE Dereka 110 Vas Sofias Str, Athens, Greece.
EM dereka@otenet.gr
CR Baird Andrew, 2000, P167
   Bartold PM, 2000, PERIODONTOL 2000, V24, P253, DOI 10.1034/j.1600 0757.2000.2240113.x
   Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588
   Boltchi FE, 1999, QUINTESSENCE INT, V30, P775
   BOYAN LA, 1994, J DENT RES, V73, P1593, DOI 10.1177/00220345940730100301
   Brady TA, 1998, J DENT RES, V77, P1779, DOI 10.1177/00220345980770100501
   Camelo M, 2003, INT J PERIODONT REST, V23, P213
   Chang KM, 1996, ARCH ORAL BIOL, V41, P719, DOI 10.1016/S0003 9969(96)00024 6
   Chien HH, 2000, CALCIFIED TISSUE INT, V67, P141, DOI 10.1007/s00223001128
   Clemmons David R., 2000, P79
   Cochran DL, 1999, PERIODONTOL 2000, V19, P40, DOI 10.1111/j.1600 0757.1999.tb00146.x
   Cooke JW, 2006, TISSUE ENG, V12, P1441, DOI 10.1089/ten.2006.12.1441
   Cornelini R, 2003, J PERIODONTOL, V74, P446, DOI 10.1902/jop.2003.74.4.446
   Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200
   DEREKA X, 2004, CLIN ORAL IMPLANTS R, V15
   Derynck R, 1997, BBA REV CANCER, V1333, pF105, DOI 10.1016/S0304 419X(97)00017 6
   Fujimura K, 2002, ARCH ORAL BIOL, V47, P577, DOI 10.1016/S0003 9969(02)00046 8
   Fujita T, 2004, CELL BIOL INT, V28, P281, DOI 10.1016/j.cellbi.2003.12.007
   Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb 75 6 669
   Gamal AY, 2000, J CLIN PERIODONTOL, V27, P347, DOI 10.1034/j.1600 051x.2000.027005347.x
   Gao J, 1998, J DENT RES, V77, P1708, DOI 10.1177/00220345980770090701
   Gao J, 1999, J PERIODONTAL RES, V34, P113, DOI 10.1111/j.1600 0765.1999.tb02230.x
   Gao J, 1996, J PERIODONTAL RES, V31, P260, DOI 10.1111/j.1600 0765.1996.tb00491.x
   Garant PhiliasR., 2003, ORAL CELLS TISSUES
   Giannobile WV, 2001, J PERIODONTOL, V72, P815, DOI 10.1902/jop.2001.72.6.815
   Giannobile WV, 1997, J DENT RES, V76, P1569, DOI 10.1177/00220345970760090901
   Giannobile WV, 1996, J PERIODONTAL RES, V31, P301, DOI 10.1111/j.1600 0765.1996.tb00497.x
   Götz W, 2006, EUR J ORAL SCI, V114, P318
   Götz W, 2001, CONNECT TISSUE RES, V42, P291, DOI 10.3109/03008200109016843
   Green RJ, 1997, J PERIODONTAL RES, V32, P209, DOI 10.1111/j.1600 0765.1997.tb00526.x
   Haase HR, 1998, J CELL PHYSIOL, V174, P353, DOI 10.1002/(SICI)1097 4652(199803)174:3<353::AID JCP9>3.0.CO;2 N
   Han X, 2003, J DENT RES, V82, P454, DOI 10.1177/154405910308200610
   Han XZ, 2003, J PERIODONTOL, V74, P1176, DOI 10.1902/jop.2003.74.8.1176
   Howell T H, 1996, Curr Opin Periodontol, V3, P149
   Howell TH, 1997, J PERIODONTOL, V68, P1186, DOI 10.1902/jop.1997.68.12.1186
   Inaba H, 2004, J PERIODONTOL, V75, P858, DOI 10.1902/jop.2004.75.6.858
   IRWIN CR, 1991, J PERIODONTAL RES, V26, P388, DOI 10.1111/j.1600 0765.1991.tb01727.x
   Ivanovski S, 2001, ARCH ORAL BIOL, V46, P679, DOI 10.1016/S0003 9969(01)00036 X
   Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357 2725(03)00255 3
   Jin QM, 2004, MOL THER, V9, P519, DOI 10.1016/j.ymthe.2004.01.016
   Kuru L, 2004, J CLIN PERIODONTOL, V31, P527, DOI 10.1111/j.1600 051X.2004.00521.x
   Lee MB, 1997, J CLIN PERIODONTOL, V24, P355, DOI 10.1111/j.1600 051X.1997.tb00198.x
   Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579
   MARKOPOULOU CE, 2003, J INT ACAD PERIODONT, V5, P63
   Matsuda N, 1998, ARCH ORAL BIOL, V43, P987, DOI 10.1016/S0003 9969(98)00079 X
   MATSUDA N, 1992, J PERIODONTOL, V63, P515, DOI 10.1902/jop.1992.63.6.515
   Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151
   MATSUDA N, 1993, ARCH ORAL BIOL, V38, P559, DOI 10.1016/0003 9969(93)90120 B
   Mohammed S, 1998, J PERIODONTAL RES, V33, P335, DOI 10.1111/j.1600 0765.1998.tb02208.x
   Momose M, 2002, J PERIODONTOL, V73, P748, DOI 10.1902/jop.2002.73.7.748
   Mott David A, 2002, J Oral Implantol, V28, P57, DOI 10.1563/1548 1336(2002)028<0057:EOOPIV>2.3.CO;2
   Mumford JH, 2001, J PERIODONTOL, V72, P331, DOI 10.1902/jop.2001.72.3.331
   Murakami S, 2003, J PERIODONTAL RES, V38, P97, DOI 10.1034/j.1600 0765.2003.00640.x
   Murakami S, 1999, J PERIODONTAL RES, V34, P425, DOI 10.1111/j.1600 0765.1999.tb02277.x
   Nemoto E, 2005, J DENT RES, V84, P629, DOI 10.1177/154405910508400709
   Nemoto E, 2004, J PERIODONTAL RES, V39, P388, DOI 10.1111/j.1600 0765.2004.00750.x
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282
   Nishimura F, 1996, J DENT RES, V75, P986, DOI 10.1177/00220345960750041401
   NORDLUND L, 1991, J PERIODONTAL RES, V26, P333, DOI 10.1111/j.1600 0765.1991.tb02071.x
   OATES TW, 1993, J PERIODONTOL, V64, P142, DOI 10.1902/jop.1993.64.2.142
   Ojima Y, 2003, ORAL DIS, V9, P144, DOI 10.1034/j.1601 0825.2003.02906.x
   Okamoto T, 1997, IN VITRO CELL DEV AN, V33, P302
   Oxford GE, 1998, J PERIODONTOL, V69, P479, DOI 10.1902/jop.1998.69.4.479
   Oxford GE, 1999, J ORAL MAXIL SURG, V57, P154, DOI 10.1016/S0278 2391(99)90230 6
   Palioto DB, 2004, J PERIODONTOL, V75, P498, DOI 10.1902/jop.2004.75.4.498
   Palmon A, 2000, J PERIODONTOL, V71, P974, DOI 10.1902/jop.2000.71.6.974
   Papadopoulos CE, 2003, J PERIODONTOL, V74, P451, DOI 10.1902/jop.2003.74.4.451
   Parkar MH, 2001, ARCH ORAL BIOL, V46, P275, DOI 10.1016/S0003 9969(00)00099 6
   Pinheiro MLB, 2003, J PERIODONTOL, V74, P323, DOI 10.1902/jop.2003.74.3.323
   Reynolds MA, 2005, J PERIODONTOL, V76, P2330, DOI 10.1902/jop.2005.76.12.2330
   Roberts Anita B., 2000, P221
   Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130
   Rossa C, 2000, J PERIODONTOL, V71, P775, DOI 10.1902/jop.2000.71.5.775
   Sae Lim V, 2004, J PERIODONTOL, V75, P1570, DOI 10.1902/jop.2004.75.12.1570
   Sarment DP, 2006, J CLIN PERIODONTOL, V33, P135, DOI 10.1111/j.1600 051X.2005.00870.x
   Saygin NE, 2000, J PERIODONTOL, V71, P1591, DOI 10.1902/jop.2000.71.10.1591
   Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092 8674(02)00966 2
   Shigeno K, 2002, INT J ARTIF ORGANS, V25, P1095, DOI 10.1177/039139880202501109
   Shimabukuro Y, 2005, J CELL PHYSIOL, V203, P557, DOI 10.1002/jcp.20256
   Shroff B, 1996, ARCH ORAL BIOL, V41, P613, DOI 10.1016/0003 9969(96)00147 1
   Skaleric U, 1997, EUR J ORAL SCI, V105, P136, DOI 10.1111/j.1600 0722.1997.tb00192.x
   Smith PC, 2004, J PERIODONTAL RES, V39, P380, DOI 10.1111/j.1600 0765.2004.00753.x
   Soares FP, 2005, J PERIODONTOL, V76, P1681, DOI 10.1902/jop.2005.76.10.1681
   Strayhorn CL, 1999, J PERIODONTOL, V70, P1345, DOI 10.1902/jop.1999.70.11.1345
   TAJIMA Y, 1992, J PERIODONTAL RES, V27, P299, DOI 10.1111/j.1600 0765.1992.tb01681.x
   Takayama S, 1998, J PERIODONTAL RES, V33, P315, DOI 10.1111/j.1600 0765.1998.tb02205.x
   Takayama S, 2002, J PERIODONTOL, V73, P1467, DOI 10.1902/jop.2002.73.12.1467
   Takayama S, 2001, J DENT RES, V80, P2075, DOI 10.1177/00220345010800121001
   Terranova V P, 1989, Adv Dent Res, V3, P69
   TERRANOVA VP, 1987, J PERIODONTOL, V58, P371, DOI 10.1902/jop.1987.58.6.371
   Tozum Tolga Fikret, 2003, J Can Dent Assoc, V69, P664
   Trasatti C, 2004, J ENDODONT, V30, P213, DOI 10.1097/00004770 200404000 00007
   Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523 1747.2002.01641.x
   Wikesjo UME, 1998, J CLIN PERIODONTOL, V25, P475, DOI 10.1111/j.1600 051X.1998.tb02476.x
   Winter S, 2005, CELL TISSUE RES, V319, P467, DOI 10.1007/s00441 004 1026 z
   Ye P, 2003, PATHOLOGY, V35, P384, DOI 10.1080/00313020310001602585
   Zaman KU, 1999, J PERIODONTAL RES, V34, P244, DOI 10.1111/j.1600 0765.1999.tb02250.x
   Zhu Z, 2001, J DENT RES, V80, P892, DOI 10.1177/00220345010800030901
NR 99
TC 102
Z9 112
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0897 7194
EI 1029 2292
J9 GROWTH FACTORS
JI Growth Factors
PD DEC
PY 2006
VL 24
IS 4
BP 260
EP 267
DI 10.1080/08977190601060990
PG 8
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 133GY
UT WOS:000244002600005
PM 17381067
DA 2025 08 17
ER

PT J
AU Bahmaee, H
   Owen, R
   Boyle, L
   Perrault, CM
   Garcia Granada, AA
   Reilly, GC
   Claeyssens, F
AF Bahmaee, Hossein
   Owen, Robert
   Boyle, Liam
   Perrault, Cecile M.
   Garcia Granada, Andres A.
   Reilly, Gwendolen C.
   Claeyssens, Frederik
TI Design and Evaluation of an Osteogenesis on a Chip Microfluidic Device
   Incorporating 3D Cell Culture
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE organ on a chip; mechanotransduction; polyHIPE; additive manufacture;
   bioreactor; computational fluid dynamics; tissue engineering
ID TUNABLE MECHANICAL PROPERTIES; FLUID SHEAR STRESS; IN VITRO MODEL;
   POLYHIPE SCAFFOLDS; RECOVERY PERIODS; BONE; FLOW; OSTEOBLASTS;
   INCREASES; STIMULUS
AB Microfluidic based tissue on a chip devices have generated significant research interest for biomedical applications, such as pharmaceutical development, as they can be used for small volume, high throughput studies on the effects of therapeutics on tissue mimics. Tissue on a chip devices are evolving from basic 2D cell cultures incorporated into microfluidic devices to complex 3D approaches, with modern designs aimed at recapitulating the dynamic and mechanical environment of the native tissue. Thus far, most tissue on a chip research has concentrated on organs involved with drug uptake, metabolism and removal (e.g., lung, skin, liver, and kidney); however, models of the drug metabolite target organs will be essential to provide information on therapeutic efficacy. Here, we develop an osteogenesis on a chip device that comprises a 3D environment and fluid shear stresses, both important features of bone. This inexpensive, easy to fabricate system based on a polymerized High Internal Phase Emulsion (polyHIPE) supports proliferation, differentiation and extracellular matrix production of human embryonic stem cell derived mesenchymal progenitor cells (hES MPs) over extended time periods (up to 21 days). Cells respond positively to both chemical and mechanical stimulation of osteogenesis, with an intermittent flow profile containing rest periods strongly promoting differentiation and matrix formation in comparison to static and continuous flow. Flow and shear stresses were modeled using computational fluid dynamics. Primary cilia were detectable on cells within the device channels demonstrating that this mechanosensory organelle is present in the complex 3D culture environment. In summary, this device aids the development of 'next generation' tools for investigating novel therapeutics for bone in comparison with standard laboratory and animal testing.
C1 [Bahmaee, Hossein; Owen, Robert; Boyle, Liam; Reilly, Gwendolen C.; Claeyssens, Frederik] Univ Sheffield, Kroto Res Inst, Dept Mat Sci & Engn, Sheffield, S Yorkshire, England.
   [Bahmaee, Hossein; Owen, Robert; Boyle, Liam; Perrault, Cecile M.; Reilly, Gwendolen C.; Claeyssens, Frederik] Univ Sheffield, INSIGNEO Inst Silico Med, Sheffield, S Yorkshire, England.
   [Owen, Robert] Univ Nottingham, Sch Pharm, Regenerat Med & Cellular Therapies, Biodiscovery Inst, Nottingham, England.
   [Perrault, Cecile M.] Eden Microfluid, Paris, France.
   [Garcia Granada, Andres A.] Univ Ramon Llull, Grp Engn Prod Ind, IQS, Barcelona, Spain.
C3 University of Sheffield; University of Sheffield; University of
   Nottingham; Universitat Ramon Llull; Institut Quimic de Sarria
RP Owen, R (通讯作者)，Univ Sheffield, Kroto Res Inst, Dept Mat Sci & Engn, Sheffield, S Yorkshire, England.; Owen, R (通讯作者)，Univ Sheffield, INSIGNEO Inst Silico Med, Sheffield, S Yorkshire, England.; Owen, R (通讯作者)，Univ Nottingham, Sch Pharm, Regenerat Med & Cellular Therapies, Biodiscovery Inst, Nottingham, England.
EM robert.owen@nottingham.ac.uk
RI Perrault, Cecile M./A 2982 2011; Reilly, Gwendolen/C 3456 2009;
   Garcia Granada, Andres/M 7252 2013; Garcia Granada, Andres
   Amador/M 7252 2013; Claeyssens, Frederik/E 4781 2011; Owen,
   Robert/J 2553 2019; Perrault, Cecile/A 2982 2011
OI Perrault, Cecile M./0000 0003 2230 6994; Reilly,
   Gwendolen/0000 0003 1456 1071; Garcia Granada, Andres
   Amador/0000 0002 6271 2594; Owen, Robert/0000 0003 1961 0733; 
FU Engineering and Physical Sciences Research Council [EP/N509735/1,
   EP/L505055/1]; Biotechnology and Biological Sciences Research Council
   [BB/F016840/1]; EPSRC Henry Royce Institute [EP/P02470X/1]; EPSRC
   [EP/I007695/1]; Medical Research Council [MR/L012669/1]; EPSRC
   [EP/S019367/1, EP/P02470X/1, EP/I007695/1] Funding Source: UKRI; MRC
   [MR/L012669/1] Funding Source: UKRI; Engineering and Physical Sciences
   Research Council [EP/S019367/1, EP/R00661X/1, EP/I007695/1,
   EP/P02470X/1] Funding Source: researchfish; Medical Research Council
   [MR/L012669/1] Funding Source: researchfish
FX We acknowledge funding from the Engineering and Physical Sciences
   Research Council (Grant Nos. EP/N509735/1 and EP/L505055/1) and
   Biotechnology and Biological Sciences Research Council (Grant No.
   BB/F016840/1) for studentships for RO and LB. We also acknowledge the
   EPSRC Henry Royce Institute funding (Grant No. EP/P02470X/1) for the
   light sheet microscope, and funding from the EPSRC (Grant No.
   EP/I007695/1) and the Medical Research Council (MR/L012669/1) for
   establishing the laser laboratory. Confocal imaging was performed at the
   Kroto Imaging Facility.
CR Dikici BA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00875
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Barbetta A, 2004, MACROMOLECULES, V37, P3188, DOI 10.1021/ma0359436
   Batra NN, 2005, J BIOMECH, V38, P1909, DOI 10.1016/j.jbiomech.2004.08.009
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Brauchle E, 2013, BIOMATERIALS, V34, P7401, DOI 10.1016/j.biomaterials.2013.06.016
   Cartmell SH, 2003, TISSUE ENG, V9, P1197, DOI 10.1089/10763270360728107
   Case N, 2011, CALCIFIED TISSUE INT, V88, P189, DOI 10.1007/s00223 010 9448 y
   Chao P, 2009, BIOCHEM PHARMACOL, V78, P625, DOI 10.1016/j.bcp.2009.05.013
   Delaine Smith RM, 2012, EUR CELLS MATER, V24, P162, DOI 10.22203/eCM.v024a12
   Delaine Smith Robin M, 2012, Muscles Ligaments Tendons J, V2, P169
   Delaine Smith RM, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.97
   Dikici BA, 2019, MATERIALS, V12, DOI 10.3390/ma12162643
   Donahue SW, 2003, J BIOMECH, V36, P35, DOI 10.1016/S0021 9290(02)00318 4
   Du DJ, 2009, BIOTECHNOL BIOENG, V102, P1670, DOI 10.1002/bit.22214
   Esch MB, 2014, ADV DRUG DELIVER REV, V69, P158, DOI 10.1016/j.addr.2013.12.003
   Esch MB, 2012, BIOMED MICRODEVICES, V14, P895, DOI 10.1007/s10544 012 9669 0
   Ferrell N, 2012, BIOTECHNOL BIOENG, V109, P797, DOI 10.1002/bit.24339
   Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136
   Genthial R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03548 5
   Gong XY, 2014, BIOSCI BIOTECH BIOCH, V78, P565, DOI 10.1080/09168451.2014.895657
   Hadida M, 2020, BIOTECHNOL BIOENG, V117, P251, DOI 10.1002/bit.27171
   Hao SJ, 2018, SMALL, V14, DOI 10.1002/smll.201702787
   Hinderer S, 2012, BIOMATERIALS, V33, P5259, DOI 10.1016/j.biomaterials.2012.03.075
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Huh D, 2011, TRENDS CELL BIOL, V21, P745, DOI 10.1016/j.tcb.2011.09.005
   Jaasma MJ, 2008, TISSUE ENG PT A, V14, P1213, DOI 10.1089/tea.2007.0321
   Johnson DL, 1996, AM J PHYSIOL ENDOC M, V271, pE205, DOI 10.1152/ajpendo.1996.271.1.E205
   Kimmins SD, 2011, ADV FUNCT MATER, V21, P211, DOI 10.1002/adfm.201001330
   Knight E, 2011, METHODS MOL BIOL, V695, P323, DOI 10.1007/978 1 60761 984 0_20
   Kreke MR, 2008, TISSUE ENG PT A, V14, P529, DOI 10.1089/tea.2007.0068
   Lee A, 2017, BIOMATER SCI UK, V5, P2035, DOI 10.1039/c7bm00292k
   Li W, 2010, BONE, V47, P353, DOI 10.1016/j.bone.2010.05.005
   Malayeri A, 2016, INT J BIOPRINTING, V2, P67, DOI 10.18063/IJB.2016.02.005
   Malfait AM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0747 6
   Maschmeyer I, 2015, LAB CHIP, V15, P2688, DOI 10.1039/c5lc00392j
   McGonigle P, 2014, BIOCHEM PHARMACOL, V87, P162, DOI 10.1016/j.bcp.2013.08.006
   Melchels FPW, 2010, BIOMATERIALS, V31, P6121, DOI 10.1016/j.biomaterials.2010.04.050
   Mukhopadhyay R., 2007, PDMS ISNT BEST
   Neuzil P, 2012, NAT REV DRUG DISCOV, V11, P620, DOI 10.1038/nrd3799
   Novik E, 2010, BIOCHEM PHARMACOL, V79, P1036, DOI 10.1016/j.bcp.2009.11.010
   Owen R, 2020, INT J BIOPRINTING, V6, P99, DOI 10.18063/ijb.v6i2.265
   Owen R, 2020, BIOENGINEERING BASEL, V7, DOI 10.3390/bioengineering7010012
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Owen R, 2015, DATA BRIEF, V5, P616, DOI 10.1016/j.dib.2015.09.051
   Owen R, 2016, J MECH BEHAV BIOMED, V54, P159, DOI 10.1016/j.jmbbm.2015.09.019
   Paterson TE, 2018, APL BIOENG, V2, DOI 10.1063/1.5008556
   Plunkett NA, 2010, TISSUE ENG PT A, V16, P943, DOI [10.1089/ten.tea.2009.0345, 10.1089/ten.TEA.2009.0345]
   Pusch J, 2011, BIOMATERIALS, V32, P7469, DOI 10.1016/j.biomaterials.2011.06.035
   Puwanun S, 2018, J TISSUE ENG REGEN M, V12, P370, DOI 10.1002/term.2462
   Robinson JL, 2016, TISSUE ENG PT A, V22, P403, DOI [10.1089/ten.tea.2015.0370, 10.1089/ten.TEA.2015.0370]
   Robling AG, 2001, J EXP BIOL, V204, P3389
   Robling AG, 2000, J BONE MINER RES, V15, P1596, DOI 10.1359/jbmr.2000.15.8.1596
   Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Scheinpflug J, 2018, GENES BASEL, V9, DOI 10.3390/genes9050247
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sherborne C, 2018, MATER DESIGN, V156, P494, DOI 10.1016/j.matdes.2018.06.061
   Sieber S, 2018, J TISSUE ENG REGEN M, V12, P479, DOI 10.1002/term.2507
   Sikavitsas VI, 2003, P NATL ACAD SCI USA, V100, P14683, DOI 10.1073/pnas.2434367100
   Srinivasan S, 2007, J APPL PHYSIOL, V102, P1945, DOI 10.1152/japplphysiol.00507.2006
   Temiyasathit S, 2010, ANN NY ACAD SCI, V1192, P422, DOI 10.1111/j.1749 6632.2009.05243.x
   Torisawa YS, 2014, NAT METHODS, V11, P663, DOI [10.1038/NMETH.2938, 10.1038/nmeth.2938]
   Wagner I, 2013, LAB CHIP, V13, P3538, DOI 10.1039/c3lc50234a
   Wang AJ, 2016, MAT SCI ENG C MATER, V67, P51, DOI 10.1016/j.msec.2016.04.087
   Wang LY, 2003, J BIOMECH, V36, P1439, DOI 10.1016/S0021 9290(03)00241 0
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Wu CC, 2006, J CELL BIOCHEM, V98, P632, DOI 10.1002/jcb.20697
   Zhou JW, 2010, ELECTROPHORESIS, V31, P2, DOI 10.1002/elps.200900475
NR 71
TC 63
Z9 66
U1 5
U2 98
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD SEP 8
PY 2020
VL 8
AR 557111
DI 10.3389/fbioe.2020.557111
PG 17
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA NW2CD
UT WOS:000574816900001
PM 33015017
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, RH
   Fu, CJ
   Sun, JB
   Wang, XM
   Geng, S
   Wang, XY
   Zou, JL
   Yang, CL
   Bi, ZG
AF Liu, Renhao
   Fu, Chunjiang
   Sun, Jiabing
   Wang, Xvming
   Geng, Shuo
   Wang, Xiaoyu
   Zou, Jilong
   Yang, Chenglin
   Bi, Zhenggang
TI A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by
   MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and
   Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Osteosarcoma (OS); Protein homeostasis; Proteasome; Proteasome
   inhibitor; MLN9708/2238; Mitochondria; Apoptosis; Cell cycle arrest;
   Cell invasion
ID NF KAPPA B; CANCER CELLS; MEMBRANE PERMEABILIZATION; ANTITUMOR ACTIVITY;
   PROSTATE CANCER; MITOTIC ENTRY; DEATH; PROTEIN; BCL 2; BAX
AB Background: The proteasome exists in all eukaryotic cells and provides the main route of intracellular proteins degradation involved in cell growth and apoptosis. Proteasome inhibition could block protein degradation pathways and disturb regulatory networks, possibly leading to profound effects on cell growth, particularly in cancer cells. A proteasome inhibitor with an appropriate toxicity index for malignant cells rather than normal cells would be an attractive anticancer therapy. Methods: The human osteosarcoma (OS) cell lines MG 63 and Saos 2 and normal osteoblast cells were used to study the antitumour activity of the proteasome inhibitor MLN9708/2238. Results: MLN2238 inhibited cell growth, induced cell cycle arrest and apoptosis, and attenuated the invasion abilities of MG 63 and Saos 2 cells, with little cytotoxicity to normal cells. In addition, MLN2238 promoted antitumour mechanisms including the accumulation of E2F1, P53, P21 and other negative G2/M checkpoint proteins; up regulated the relative expression ratio of BAX/BCL 2, APAF 1 and pro apoptotic proteins of the BCL 2 family; triggered mitochondrial outer membrane permeabilization (MOMP); down regulated BCL 2 and XIAP; activated caspase3/8/9; and suppressed MMP2/9 expression and secretion levels. Conclusions: The proteasome may be a novel biochemical target for OS treatment in vitro. Our study provides a promising mechanistic framework for MLN9708/2238 in OS treatment, supporting its clinical development. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Liu, Renhao; Fu, Chunjiang; Sun, Jiabing; Wang, Xvming; Geng, Shuo; Wang, Xiaoyu; Zou, Jilong; Yang, Chenglin; Bi, Zhenggang] Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 23 Youzheng St, Harbin 150001, Peoples R China.
C3 Harbin Medical University
RP Bi, ZG (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 23 Youzheng St, Harbin 150001, Peoples R China.
EM zhenggangbi_dr@163.com
OI Zou, Jilong/0000 0002 8037 5077
FU National Natural Science Foundation of China [81171692]
FX The work was supported by National Natural Science Foundation of China
   (No. 81171692).
CR Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159 8290.CD 11 0320
   Adams J, 1999, CANCER RES, V59, P2615
   Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361
   Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535 6108(03)00080 1
   Cater MA, 2011, BIOCHEM J, V436, P481, DOI 10.1042/BJ20110123
   Chauhan D, 2011, CLIN CANCER RES, V17, P5311, DOI 10.1158/1078 0432.CCR 11 0476
   Chou WM, 2010, TOXICON, V55, P353, DOI 10.1016/j.toxicon.2009.08.012
   Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092 8674(04)00046 7
   Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50
   Dick LR, 2010, DRUG DISCOV TODAY, V15, P243, DOI 10.1016/j.drudis.2010.01.008
   Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092 8674(00)00008 8
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599
   Jung T, 2009, MOL ASPECTS MED, V30, P191, DOI 10.1016/j.mam.2009.04.001
   Kim Y, 2011, CELL PHYSIOL BIOCHEM, V28, P175, DOI 10.1159/000331729
   Kupperman E, 2010, CANCER RES, V70, P1970, DOI 10.1158/0008 5472.CAN 09 2766
   Lee EC, 2011, CLIN CANCER RES, V17, P7313, DOI 10.1158/1078 0432.CCR 11 0636
   Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384
   Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045
   Ling YH, 2002, MOL CANCER THER, V1, P841
   Liu WH, 2014, J CELL PHYSIOL, V229, P588, DOI 10.1002/jcp.24481
   Liu XJ, 2015, MOL CELL, V58, P284, DOI 10.1016/j.molcel.2015.03.003
   Liu Y, 2013, SCI REP UK, V3, DOI 10.1038/srep03098
   Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010
   MacLaren AP, 2001, CELL DEATH DIFFER, V8, P210, DOI 10.1038/sj.cdd.4400801
   Masdehors P, 1999, BRIT J HAEMATOL, V105, P752, DOI 10.1046/j.1365 2141.1999.01388.x
   Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527
   Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868
   Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078 0432.CCR 07 2218
   Raffoul JJ, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 107
   Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365 2141.2001.02683.x
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Thompson R, 2013, BRIT J CLIN PHARMACO, V76, P358, DOI 10.1111/bcp.12139
   Wang Y, 2015, INT J CLIN EXP PATHO, V8, P63
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wu HM, 2015, SCI REP UK, V5, DOI 10.1038/srep12291
   Xu W, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912 016 0524 y
   Yang LZ, 2015, CELL PHYSIOL BIOCHEM, V35, P237, DOI 10.1159/000369691
   Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097 2765(01)00213 1
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092 8674(00)81382 3
NR 50
TC 22
Z9 23
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 41
IS 2
BP 451
EP 465
DI 10.1159/000456598
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA EU3EC
UT WOS:000400910400003
PM 28214890
OA gold
DA 2025 08 17
ER

PT J
AU Bonicelli, A
   Tay, T
   Cobb, JP
   Boughton, OR
   Hansen, U
   Abel, RL
   Zioupos, P
AF Bonicelli, Andrea
   Tay, Tabitha
   Cobb, Justin P.
   Boughton, Oliver R.
   Hansen, Ulrich
   Abel, Richard L.
   Zioupos, Peter
TI Association between nanoscale strains and tissue level nanoindentation
   properties in age related hip fractures
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Bone properties; Synchrotron; Nanoindentation; Fracture; Ageing
ID HUMAN CORTICAL BONE; TERM BISPHOSPHONATE THERAPY; TRABECULAR BONE;
   ELASTIC PROPERTIES; STRENGTH; MINERALIZATION; HETEROGENEITY; MECHANISMS;
   TOUGHNESS; MODULUS
AB Measurement of the properties of bone as a material can happen in various length scales in its hierarchical and composite structure. The aim of this study was to test the tissue level properties of clinically relevant human bone samples which were collected from donors belonging to three groups: ageing donors who suffered no fractures (Control); untreated fracture patients (Fx Untreated) and patient who experienced hip fracture despite being treated with bisphosphonates (Fx BisTreated). Tissue level properties were assessed by (a) nanoindentation and (b) synchrotron tensile tests (STT) where strains were measured at the 'tissue', 'fibril' and 'mineral' levels by using simultaneous Wide angle   (WAXD) and Small angle  X ray diffraction (SAXD). The composition was analysed by thermogravimetric analysis and material level endo  and exo thermic reactions by differential scanning calorimetry (TGA/DSC3+). Irrespective of treatment fracture donors exhibited significantly lower tissue, fibril and mineral strain at the micro and nanoscale respectively and had a higher mineral content than controls. In nanoindentation only nanohardness was significantly greater for Controls and Fx BisTreated versus Fx Untreated. The other nanoindentation parameters did not vary significantly across the three groups. There was a highly significant positive correlation (p < 0.001) between organic content and tissue level strain behaviour. Overall hip fractures were associated with lower STT nanostrains and it was behaviour measured by STT which proved to be a more effective approach for predicting fracture risk because evidently it was able to demonstrate the mechanical deficit for the bone tissue of the donors who had experienced fractures.
C1 [Bonicelli, Andrea] Univ Cent Lancashire, Sch Nat Sci, Preston PR1 2HE, England.
   [Bonicelli, Andrea; Zioupos, Peter] Def Acad UK, Cranfield Forens Inst, Musculoskeletal & Medicolegal Res Grp, Shrivenham SN6 8LA, Swindon, England.
   [Tay, Tabitha; Cobb, Justin P.; Abel, Richard L.] Imperial Coll London, Fac Med, Dept Surg & Canc, MSk Lab, London W6 8PR, England.
   [Hansen, Ulrich] Imperial Coll London, Fac Engn, Dept Mech Engn, Biomech Grp, London SW7 2AZ, England.
C3 University of Lancashire; Imperial College London; Imperial College
   London
RP Zioupos, P (通讯作者)，Def Acad UK, Cranfield Forens Inst, Musculoskeletal & Medicolegal Res Grp, Shrivenham SN6 8LA, Swindon, England.
EM p.zioupos@hotmail.co.uk
RI ; cobb, justin/AAS 9814 2020; Boughton, Oliver/AAM 8012 2020; Bonicelli,
   Andrea/GNW 6422 2022; ZIOUPOS, PETER/S 4342 2019
OI Bonicelli, Andrea/0000 0002 9518 584X; ZIOUPOS,
   PETER/0000 0002 0123 2706; Bonicelli, Andrea/0009 0007 9104 8788; 
FU Michael Uren Foundation; Royal Osteoporosis Society; EPSRC [EP/K020196];
   Dr Mortimer & Theresa Sackler Foundation; National Institute for Health
   Research [ACF 2012 21 019] Funding Source: researchfish
FX We acknowledge Diamond Light Source for time on Beamline I22 under
   Proposals SM17664 and SM13337, and the beamline scientists who supported
   the data collection including Dr Nick Terrill, Dr Andy Smith, Dr Olga
   Shebanova and Dr Timothy Snow. Funding was also provided by The Royal
   Osteoporosis Society, The Michael Uren Foundation and The Dr Mortimer &
   Theresa Sackler Foundation and the EPSRC (EP/K020196: Point of Care High
   Accuracy Fracture Risk Prediction). The authors would like to thank
   Professor Anthony Bull for the loan of camera equipment.
CR Abel RL, 2021, CURR OSTEOPOROS REP, V19, P318, DOI 10.1007/s11914 021 00678 8
   Acevedo C, 2015, BONE, V81, P352, DOI 10.1016/j.bone.2015.08.002
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Bonicelli A, 2022, BONE, V155, DOI 10.1016/j.bone.2021.116265
   Boskey A, 2003, OSTEOPOROSIS INT, V14, pS16, DOI 10.1007/s00198 003 1468 2
   Boskey AL, 2017, ANN NY ACAD SCI, V1410, P93, DOI 10.1111/nyas.13572
   Boughton OR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200475
   Burr DB, 2019, BONE, V120, P85, DOI 10.1016/j.bone.2018.10.010
   Chevalier Y, 2007, J BIOMECH, V40, P3333, DOI 10.1016/j.jbiomech.2007.05.004
   Currey JD, 2004, J BIOMECH, V37, P549, DOI 10.1016/j.jbiomech.2003.08.008
   Donnelly E, 2010, J BIOMED MATER RES A, V92A, P1048, DOI 10.1002/jbm.a.32442
   Durchschlag E, 2006, J BONE MINER RES, V21, P1581, DOI 10.1359/JBMR.060701
   Eanes ED, 2000, CALCIFIED TISSUE INT, V66, P449, DOI 10.1007/s002230010090
   Fratzl Zelman N, 2009, CALCIFIED TISSUE INT, V85, P335, DOI 10.1007/s00223 009 9289 8
   Gallant MA, 2013, BONE, V53, P301, DOI 10.1016/j.bone.2012.12.015
   Gourion Arsiquaud S, 2010, BONE, V46, P666, DOI 10.1016/j.bone.2009.11.011
   Gupta HS, 2005, NANO LETT, V5, P2108, DOI 10.1021/nl051584b
   Hengsberger S, 2002, BONE, V30, P178, DOI 10.1016/S8756 3282(01)00624 X
   Jin A, 2017, BONE JOINT RES, V6, P602, DOI 10.1302/2046 3758.610.BJR 2016 0321.R1
   Karim L, 2018, BONE, V106, P90, DOI 10.1016/j.bone.2015.03.021
   Larrue A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021297
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Ma SC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 69783 5
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Nyman JS, 2016, CURR OSTEOPOROS REP, V14, P138, DOI 10.1007/s11914 016 0314 3
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   Pienkowski D, 2019, OSTEOPOROSIS INT, V30, P277, DOI 10.1007/s00198 018 4760 x
   Qian TB, 2020, J MECH BEHAV BIOMED, V112, DOI 10.1016/j.jmbbm.2020.103989
   Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142 9612(97)00073 2
   Rho JY, 2001, ANN BIOMED ENG, V29, P1082, DOI 10.1114/1.1424913
   Rho JY, 2002, J BIOMECH, V35, P189, DOI 10.1016/S0021 9290(01)00199 3
   Saito M, 2008, OSTEOPOROSIS INT, V19, P1343, DOI 10.1007/s00198 008 0585 3
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Schoeb M, 2020, OSTEOPOROSIS INT, V31, P1683, DOI 10.1007/s00198 020 05375 3
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Vanleene M, 2012, BONE, V50, P1317, DOI 10.1016/j.bone.2012.03.007
   Wen XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127973
   Wu ZH, 2012, J ORTHOP RES, V30, P693, DOI 10.1002/jor.22001
   Zimmermann EA, 2016, SCI REP UK, V6, DOI 10.1038/srep21072
   Zimmermann EA, 2011, P NATL ACAD SCI USA, V108, P14416, DOI 10.1073/pnas.1107966108
   Zioupos P, 2008, J BIOMED MATER RES A, V86A, P627, DOI 10.1002/jbm.a.31576
   Zioupos P., 2005, European Journal of Morphology, V42, P31
   Zioupos P, 2001, J BIOMATER APPL, V15, P187, DOI 10.1106/5JUJ TFJ3 JVVA 3RJ0
   ZIOUPOS P, 1994, MED ENG PHYS, V16, P203, DOI 10.1016/1350 4533(94)90039 6
NR 44
TC 5
Z9 5
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1751 6161
EI 1878 0180
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD FEB
PY 2023
VL 138
AR 105573
DI 10.1016/j.jmbbm.2022.105573
EA DEC 2022
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 7O9KK
UT WOS:000908333700004
PM 36525874
OA Green Accepted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Carinci, F
   Pezzetti, F
   Spina, AM
   Palmieri, A
   Carls, F
   Laino, G
   De Rosa, A
   Farina, E
   Illiano, F
   Stabellini, G
   LoMuzio, L
   Perrotti, V
   Piattelli, A
AF Carinci, F
   Pezzetti, F
   Spina, AM
   Palmieri, A
   Carls, F
   Laino, G
   De Rosa, A
   Farina, E
   Illiano, F
   Stabellini, G
   LoMuzio, L
   Perrotti, V
   Piattelli, A
TI An in vitro model for dissecting distraction osteogenesis
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE distraction osteogenesis; equibiaxial stretch device; gene profiling;
   mesenchymal cell; preosteoblast
ID BONE MORPHOGENETIC PROTEINS; ENDOTHELIAL GROWTH FACTOR; MATRIX PROTEINS;
   GENE EXPRESSION; MESSENGER RNA; RABBIT; CONSOLIDATION; OSTEOBLASTS;
   OSTEOCALCIN; COMMITMENT
AB Distraction osteogenesis (DO) is a mechanotransduction process capable of generating viable osseous tissue by the gradual separation of osteotomized bone edges. Several variables are implicated in DO: magnitude of mechanical strain, distraction rate, and type of distracted bone. The combination of these factors acts on different types of cells inducing apoptosis, cell proliferation, and differentiation. The elucidation of the molecular mechanisms has important clinical implications because it may facilitate the use of recombinant proteins or gene therapy to accelerate bone regeneration. Previous reports have analyzed several molecules such as extracellular matrix proteins, cytokines, bone morphogenetic proteins, hormones, and angiogenic factors. Moreover, a single protein can have multifunctional roles. With such a huge number of mechanical, histologic, cellular, and molecular variables, there is the need to have a cell culture model that enables the selection of the effect of a specific strength to a single cell type at different time points and with or without cytokines. The analysis of the genetic profiling of a cell line cultured on an equibiaxial stretch device has such characteristic. Because there is a recruitment and commitment of preosteoblastic cells during bone lengthening and no previous report has focus on them, the authors used a preosteoblast MC3T3 E1 cell line to detect the early molecular effects of distraction on mesenchymal cells. By using DNA microarrays containing 15,000 clones, the authors identified several genes the expression of which was significantly up  or down regulated. The differentially expressed genes cover a broad range of biological processes: cell growth, metabolism, morphogenesis, cell communication, response to stress, and cell death. The data reported are the first genetic portrait of stretched preosteoblasts. They can be relevant in the better understanding of the molecular mechanism of DO and as a model for comparing the effect of distraction on different cell lines and primary cultures, rate and strength of distraction, and with or without cytokines.
C1 Univ Ferrara, Sch Med, Dept Maxillofacial Surg, I 44100 Ferrara, Italy.
   Univ Bologna, Inst Histol, Bologna, Italy.
   Univ Naples 2, Dept Biochem, Naples, Italy.
   JRH, Dept Maxillofacial Surg, Oxford, England.
   Univ Naples 2, Dept Oral Surg, Dent Clin, Naples, Italy.
   Univ Naples 2, Dept Oral Pathol, Naples, Italy.
   Univ Milan, Dept Histol, Milan, Italy.
   Univ Ancona, Dept Oral Pathol, Ancona, Italy.
   Univ G dAnnunzio, Dent Clin, Chieti, Italy.
C3 University of Ferrara; University of Bologna; Universita della Campania
   Vanvitelli; Universita della Campania Vanvitelli; Universita della
   Campania Vanvitelli; University of Milan; Marche Polytechnic University;
   G d'Annunzio University of Chieti Pescara
RP Univ Ferrara, Sch Med, Dept Maxillofacial Surg, Corso Giovecca 203, I 44100 Ferrara, Italy.
EM crc@.unife.it
RI perrotti, vittoria/L 1028 2016; Muzio, Lorenzo/C 8533 2011; Lo Muzio,
   Lorenzo/C 8533 2011
OI perrotti, vittoria/0000 0001 7652 1660; SPINA,
   Annamaria/0000 0002 2877 3158; Lo Muzio, Lorenzo/0000 0003 4633 4893
CR Bail H. J., 2001, Growth Hormone and IGF Research, V11, P314, DOI 10.1054/ghir.2001.0246
   Campisi P, 2003, PLAST RECONSTR SURG, V111, P201, DOI 10.1097/01.PRS.0000034932.99249.34
   Carinci F, 2003, J DENT RES, V82, P551, DOI 10.1177/154405910308200713
   Carinci F, 2003, ORAL ONCOL, V39, P69, DOI 10.1016/S1368 8375(02)00027 1
   Cho BC, 2003, J CRANIOFAC SURG, V14, P417, DOI 10.1097/00001665 200305000 00025
   Eckardt H, 2003, J ORTHOP RES, V21, P335, DOI 10.1016/S0736 0266(02)00159 6
   Farhadieh RD, 1999, J CRANIOFAC SURG, V10, P80, DOI 10.1097/00001665 199901000 00016
   Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6
   Fong KD, 2003, J CRANIOFAC SURG, V14, P348, DOI 10.1097/00001665 200305000 00013
   Hu J, 2003, J CRANIO MAXILL SURG, V31, P238, DOI 10.1016/S1010 5182(03)00034 9
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Li G, 2002, J ORTHOP RES, V20, P779, DOI 10.1016/S0736 0266(01)00166 8
   Li G, 2000, CELL BIOL INT, V24, P25, DOI 10.1006/cbir.1999.0449
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Marucci DD, 2002, J CRANIO MAXILL SURG, V30, P208, DOI 10.1054/jcms.2002.0289
   Mehrara BJ, 1999, PLAST RECONSTR SURG, V103, P536, DOI 10.1097/00006534 199902000 00026
   Mizumoto Y, 2003, J BONE JOINT SURG AM, V85A, P124, DOI 10.2106/00004623 200300003 00019
   Pacicca DM, 2003, BONE, V33, P889, DOI 10.1016/j.bone.2003.06.002
   Parfitt AM, 2000, BONE, V27, P487, DOI 10.1016/S8756 3282(00)00353 7
   Sato M, 1999, J BONE MINER RES, V14, P1084, DOI 10.1359/jbmr.1999.14.7.1084
   Sato M, 1998, J BONE MINER RES, V13, P1221, DOI 10.1359/jbmr.1998.13.8.1221
   Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200
   Steinbrech DS, 2000, PLAST RECONSTR SURG, V105, P2028, DOI 10.1097/00006534 200005000 00018
   Tavakoli K, 1999, BRIT J PLAST SURG, V52, P434, DOI 10.1054/bjps.1999.3157
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Yazawa M, 2003, J ORAL MAXIL SURG, V61, P587, DOI 10.1053/joms.2003.50116
NR 26
TC 9
Z9 12
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1049 2275
EI 1536 3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD JAN
PY 2005
VL 16
IS 1
BP 71
EP 78
DI 10.1097/00001665 200501000 00014
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 886GR
UT WOS:000226215400014
PM 15699648
DA 2025 08 17
ER

PT J
AU Wang, J
   Wang, Y
   Zhang, H
   Chang, J
   Lu, M
   Gao, WL
   Liu, WD
   Li, YT
   Yin, L
   Wang, XH
   Wang, YJ
   Gao, MR
   Yin, ZS
AF Wang, Jun
   Wang, Yin
   Zhang, Hui
   Chang, Jun
   Lu, Ming
   Gao, Weilu
   Liu, Wendong
   Li, Yetian
   Yin, Li
   Wang, Xiaohe
   Wang, Yuejun
   Gao, Mengru
   Yin, Zongsheng
TI Identification of a novel microRNA 141 3p/Forkhead box C1/β catenin axis
   associated with rheumatoid arthritis synovial fibroblast function in
   vivo and in vitro
SO THERANOSTICS
LA English
DT Article
DE rheumatoid arthritis; FoxC1; miR 141 3p; synovial fibroblasts;
   collagen induced arthritis
ID COLLAGEN INDUCED ARTHRITIS; WNT SIGNALING PATHWAY;
   TUMOR NECROSIS FACTOR; BETA CATENIN; INDUCED INFLAMMATION; MICRORNA
   REGULATION; JOINT DESTRUCTION; EXPRESSION; FOXC1; ACTIVATION
AB Rationale: Rheumatoid arthritis (RA) is a prototype of inflammatory arthritis in which synovial fibroblasts (SFs) play key roles in cartilage and bone destruction through tumor like proliferation, migration, invasion and inflammation. This study aimed to research forkhead box protein C1 (FoxC1) and microRNA (miR) 141 3p, which modulate pathological changes in the synovial membrane, to find possible strategies for treating RA.
   Methods: FoxC1,beta catenin and miR 141 3p gene expression in synovial tissues and SFs was quantified by real time PCR; FoxC1 and beta catenin protein levels were evaluated by immunohistochemistry, immunofluorescence, and Western blotting. We transiently transfected human SFs with FoxC1 and beta catenin overexpression and silencing vectors and assessed proliferation, migration, invasion and inflammation by cell function and enzyme linked immunosorbent assays. We also assessed downstream signaling activation using immunofluorescence, real time PCR and Western blotting. Double luciferase, coimmunoprecipitation and chromatin immunoprecipitation assays were used to verify miR 141 3p, FoxC1 and beta catenin gene and protein combinations. Finally, the therapeutic effects of FoxC1 silencing and miR 141 3p overexpression were evaluated in type II collagen induced arthritis (CIA) rats.
   Results: We found that FoxC1 expression was significantly upregulated in synovium and SFs in both RA patients and rats with collagen induced arthritis (CIA). FoxCl overexpression increased beta catenin messenger RNA (mRNA) and protein levels and upregulated cyclin D1, c Myc, fibronectin and matrix metalloproteinase 3 (MMP3) mRNA and protein expression in RA SFs (RASFs). In contrast, FoxC1 knockdown reduced beta catenin mRNA and protein levels as well as cyclin Di, c Myc, and fibronectin mRNA and protein levels in RASFs. Furthermore, altering FoxC1 expression did not significantly change GSK3 beta and pGSK3 beta levels. FoxC1 overexpression promoted proliferation, migration, invasion and proinflammatory cytokine (interleukin (IL) 1 beta, IL 6, and tumor necrosis factor a (TNF a)) production and reduced anti inflammatory cytokine (IL 10) levels in RASFs. FoxC1 bound to the beta catenin promoter, and beta catenin mediated the FoxC1 induced pathological changes. We also observed downregulated microRNA (miR) 141 3p expression in SFs from both RA patients and CIA rats and further found that miR 141  3p bound to the FoxC1 3'UTR and suppressed FoxC1 expression. Intra ankle miR 141 3p agomir or FoxC 1  specific siRNA injection hindered CIA development in rats.
   Conclusions: FoxC1 and miR 141 3p participate in RA pathogenesis by mediating inflammation and SF proliferation, migration, and invasion and thus could be novel targets for RA therapy as a nonimmunosuppressive approach.
C1 [Wang, Jun; Zhang, Hui; Lu, Ming; Gao, Weilu; Li, Yetian; Yin, Li; Wang, Xiaohe; Yin, Zongsheng] Anhui Med Univ, Affiliated Hosp 1, Dept Orthopaed, 218 JiXi Rd, Hefei 230022, Anhui, Peoples R China.
   [Wang, Yin] Anhui Med Univ, Affiliated Hosp 4, Dept Plast Surg, Hefei, Anhui, Peoples R China.
   [Chang, Jun] Anhui Med Univ, Affiliated Hosp 4, Dept Orthopaed, Hefei, Anhui, Peoples R China.
   [Liu, Wendong] Anhui Med Univ, Affiliated Hosp 1, Dept Radiol, Hefei, Anhui, Peoples R China.
   [Wang, Yuejun; Gao, Mengru] Anhui Med Univ, Affiliated Hosp 4, Dept Pathol, Hefei, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University; Anhui Medical University; Anhui Medical University
RP Yin, ZS (通讯作者)，Anhui Med Univ, Affiliated Hosp 1, Dept Orthopaed, 218 JiXi Rd, Hefei 230022, Anhui, Peoples R China.
EM yinzongsheng@ahmu.edu.cn
RI wang, yue/ISA 4119 2023; Lu, Ming/MVV 6688 2025; Gao, Weilu/O 7521 2016;
   Zhou, Hong/JKJ 1067 2023
FU National Natural Science Foundation of China [81672161, 81871785]
FX This study was supported by combined grants from the National Natural
   Science Foundation of China (Nos. 81672161 and 81871785).
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   [Anonymous], J NATL CANC I
   Araki Y, 2016, ARTHRITIS RHEUMATOL, V68, P1111, DOI 10.1002/art.39563
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Campo GM, 2010, BIOCHIMIE, V92, P204, DOI 10.1016/j.biochi.2009.10.006
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Chen SY, 2015, ARTHRITIS RHEUMATOL, V67, P39, DOI 10.1002/art.38899
   Dulos J, 2013, CLIN EXP RHEUMATOL, V31, P515
   Falconer J, 2018, ARTHRITIS RHEUMATOL, V70, P984, DOI 10.1002/art.40504
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Firestein GS, 2002, ARTHRITIS RHEUM, V46, P298, DOI 10.1002/art.502
   Früh M, 2012, TRANSL LUNG CANCER R, V1, P145, DOI 10.3978/j.issn.2218 6751.2012.03.01
   Gough NR, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002806
   Green MJ, 2003, RHEUMATOLOGY, V42, P83, DOI 10.1093/rheumatology/keg037
   Hao F, 2019, THERANOSTICS, V9, P5282, DOI 10.7150/thno.32268
   Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058
   Imai K, 2006, BIOCHEM BIOPH RES CO, V345, P1615, DOI 10.1016/j.bbrc.2006.05.075
   Janczi T, 2019, ARTHRITIS RHEUMATOL, V71, P63, DOI 10.1002/art.40667
   Kim YH, 2015, BIOMOL THER, V23, P195, DOI 10.4062/biomolther.2014.125
   Klimiuk PA, 1997, AM J PATHOL, V151, P1311
   Koga T, 2011, CLIN EXP RHEUMATOL, V29, P906
   Kontny E, 2015, SCAND J RHEUMATOL, V44, P363, DOI 10.3109/03009742.2015.1025833
   Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092 8674(00)81204 0
   Kurimoto S, 2015, NEUROSCIENCE, V294, P101, DOI 10.1016/j.neuroscience.2015.02.049
   Kurowska Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108
   Lee SM, 2013, ACS NANO, V7, P50, DOI 10.1021/nn301215q
   Li GQ, 2019, HUM GENE THER, V30, P1008, DOI 10.1089/hum.2018.212
   Li J, 2014, INT J ONCOL, V45, P1547, DOI 10.3892/ijo.2014.2559
   Li YT, 2012, ARTHRITIS RHEUM US, V64, P3240, DOI 10.1002/art.34550
   Liang HY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06603 5
   Lin JC, 2017, CELL MOL BIOL, V63, P17, DOI 10.14715/cmb/2017.63.1.4
   Liu XZ, 2017, ONCOTARGET, V8, P12649, DOI 10.18632/oncotarget.15172
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu Z, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00937
   Luo XB, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4194
   Maclean K, 2005, AM J MED GENET A, V132A, P381, DOI 10.1002/ajmg.a.30274
   Malemud Charles J, 2013, J Clin Cell Immunol, V4, P160
   Manwani B, 2013, EXP NEUROL, V249, P120, DOI 10.1016/j.expneurol.2013.08.011
   Marinova Mutafchieva L, 2002, ARTHRITIS RHEUM, V46, P507, DOI 10.1002/art.10126
   Mehta BB, 2018, INT IMMUNOPHARMACOL, V58, P15, DOI 10.1016/j.intimp.2018.02.022
   Miao CG, 2018, J MOL MED, V96, P495, DOI 10.1007/s00109 018 1635 8
   Montgomery RL, 2010, CURR DRUG TARGETS, V11, P936
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168 9525(97)01093 7
   Müller Ladner U, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2337
   Müller Ladner U, 2005, NAT CLIN PRACT RHEUM, V1, P102, DOI 10.1038/ncprheum0047
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493
   Noss EH, 2008, IMMUNOL REV, V223, P252, DOI 10.1111/j.1600 065X.2008.00648.x
   O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev immunol 020711 075013
   Philippe L, 2013, ANN RHEUM DIS, V72, P1071, DOI 10.1136/annrheumdis 2012 201654
   Rabelo FD, 2010, AUTOIMMUN REV, V9, P207, DOI 10.1016/j.autrev.2009.08.003
   Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008 5472.CAN 09 4120
   Santiago L, 2017, ARTHRITIS RHEUMATOL, V69, P320, DOI 10.1002/art.39857
   Schneider S, 2016, EUR ARCH OTO RHINO L, V273, P1283, DOI 10.1007/s00405 015 3609 6
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529 0131(200104)44:4<772::AID ANR133>3.3.CO;2 C
   Sen M, 2002, ARTHRITIS RHEUM, V46, P2867, DOI 10.1002/art.10593
   Shen WS, 2017, GENE THER, V24, P353, DOI 10.1038/gt.2017.28
   Shi QQ, 2016, ONCOL REP, V36, P2059, DOI 10.3892/or.2016.5033
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Tan P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2017 z
   Thomas RS, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3536
   Turner JD, 2015, CURR OPIN RHEUMATOL, V27, P175, DOI 10.1097/BOR.0000000000000148
   Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635
   Wei LX, 2013, TUMOR BIOL, V34, P941, DOI 10.1007/s13277 012 0629 3
   Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029
   Xiao LX, 2016, J AM SOC NEPHROL, V27, P1727, DOI 10.1681/ASN.2015040449
   Yamanaka H, 2000, ARTHRITIS RHEUM, V43, P852, DOI 10.1002/1529 0131(200004)43:4<852::AID ANR16>3.0.CO;2 7
   Yan X, 2016, SCI REP UK, V6, DOI 10.1038/srep28915
   Yeremenko N, 2015, ARTHRITIS RHEUMATOL, V67, P2071, DOI 10.1002/art.39183
   Yu ZH, 2018, TISSUE CELL, V53, P15, DOI 10.1016/j.tice.2018.05.011
   Zhang HJ, 2017, INT IMMUNOPHARMACOL, V50, P283, DOI 10.1016/j.intimp.2017.06.021
   Zhang JG, 2015, SCI REP UK, V5, DOI 10.1038/srep08087
   Zhou LL, 2019, KIDNEY INT, V95, P830, DOI 10.1016/j.kint.2018.10.032
NR 79
TC 37
Z9 39
U1 0
U2 14
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 12
BP 5412
EP 5434
DI 10.7150/thno.45214
PG 23
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA LD5PV
UT WOS:000526083000017
PM 32373221
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hsiong, SX
   Huebsch, N
   Fischbach, C
   Kong, HJ
   Mooney, DJ
AF Hsiong, Susan X.
   Huebsch, Nathaniel
   Fischbach, Claudia
   Kong, Hyun Joon
   Mooney, David J.
TI Integrin adhesion ligand bond formation of preosteoblasts and stem cells
   in three dimensional RGD presenting matrices
SO BIOMACROMOLECULES
LA English
DT Article
ID RESONANCE ENERGY TRANSFER; MARROW STROMAL CELLS; OSTEOBLAST
   DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR MATRIX;
   SIGNALING PATHWAYS; ALGINATE HYDROGELS; COLLAGEN SYNTHESIS;
   GENE EXPRESSION; MC3T3 E1 CELLS
AB Cell interactive polymers have been widely used as synthetic extracellular matrices to regulate cell function and promote tissue regeneration. However, there is a lack of quantitative understanding of the cell material interface. In this study, integrin adhesion ligand bond formation of preosteoblasts and D1 stem cells with RGD presenting alginate matrices were examined using FRET and flow cytometry. Bond number increased with adhesion ligand density but did not change with RGD island spacing for both cell types. Integrin expression varied with cell type and substrate in 2D culture, but the integrin expression profiles of both cell types were similar when cultured in 3D RGD presenting substrates and distinct from 2D culture. In summary, combining a FRET technique to quantify bond formation with flow cytometry to elucidate integrin expression can define specific cell material interactions for a given material system and may be useful for informing biomaterial design strategies for cell based therapies.
C1 [Mooney, David J.] Harvard Univ, Engn Sci Lab, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
   [Hsiong, Susan X.] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.
   [Huebsch, Nathaniel] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Fischbach, Claudia] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA.
   [Kong, Hyun Joon] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.
C3 Harvard University; University of Michigan System; University of
   Michigan; Harvard University; Massachusetts Institute of Technology
   (MIT); Cornell University; University of Illinois System; University of
   Illinois Urbana Champaign
RP Mooney, DJ (通讯作者)，Harvard Univ, Engn Sci Lab, Sch Engn & Appl Sci, SEAS 325 Pierce Hall Cambridge, Cambridge, MA 02138 USA.
EM mooneyd@seas.harvard.edu
RI Fischbach, Claudia/C 8550 2009
OI Fischbach, Claudia/0000 0002 9368 0150; Huebsch,
   Nathaniel/0000 0002 3329 0214; Mooney, David/0000 0001 6299 1194
FU NIDCR NIH HHS [R37 DE013033, R37 DE13033] Funding Source: Medline; NIGMS
   NIH HHS [T32 GM145304] Funding Source: Medline
CR Alsberg E, 2001, J DENT RES, V80, P2025, DOI 10.1177/00220345010800111501
   Bennett JH, 2001, ARCH ORAL BIOL, V46, P229, DOI 10.1016/S0003 9969(00)00114 X
   Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006 3495(03)75126 1
   Chen HF, 2007, BIOPHYS J, V92, P1399, DOI 10.1529/biophysj.106.094896
   Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   Dai JW, 1999, BIOPHYS J, V77, P3363, DOI 10.1016/S0006 3495(99)77168 7
   Devine MJ, 2002, J ORTHOP RES, V20, P1232, DOI 10.1016/S0736 0266(02)00051 7
   DIDUCH DR, 1993, J BONE JOINT SURG AM, V75A, P92, DOI 10.2106/00004623 199301000 00012
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   Fromigue O, 1997, CYTOKINE, V9, P613, DOI 10.1006/cyto.1997.0209
   Gilbert M, 2003, J BIOMED MATER RES A, V67A, P69, DOI 10.1002/jbm.a.10053
   Goennenwein S, 2003, BIOPHYS J, V85, P646, DOI 10.1016/S0006 3495(03)74508 1
   Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264
   HSIONG SX, 2007, J BIOMED MATER RES A, V4, P1501
   Kong HJ, 2006, P NATL ACAD SCI USA, V103, P18534, DOI 10.1073/pnas.0605960103
   KUBITSCHECK U, 1991, BIOPHYS J, V60, P307, DOI 10.1016/S0006 3495(91)82055 0
   Kundu AK, 2006, BIOCHEM BIOPH RES CO, V347, P347, DOI 10.1016/j.bbrc.2006.06.110
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lee KY, 2004, NANO LETT, V4, P1501, DOI 10.1021/nl0493592
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Moursi AM, 1997, J CELL SCI, V110, P2187
   NAKATANI Y, 1984, BIOCHEM BIOPH RES CO, V123, P894, DOI 10.1016/S0006 291X(84)80219 3
   Oyajobi BO, 1999, J BONE MINER RES, V14, P351, DOI 10.1359/jbmr.1999.14.3.351
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Petrie TA, 2006, BIOMATERIALS, V27, P5459, DOI 10.1016/j.biomaterials.2006.06.027
   Pistone M, 1996, CELL BIOL INT, V20, P471, DOI 10.1006/cbir.1996.0062
   PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766
   Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142 9612(98)00107 0
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Simmons CA, 2004, BONE, V35, P562, DOI 10.1016/j.bone.2004.02.027
   Smalley KSM, 2006, IN VITRO CELL DEV AN, V42, P242
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sun S, 2006, BIOELECTROCHEMISTRY, V69, P133, DOI 10.1016/j.bioelechem.2005.11.007
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Titushkin I, 2006, BIOPHYS J, V90, P2582, DOI 10.1529/biophysj.105.073775
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
NR 39
TC 55
Z9 66
U1 0
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JUL
PY 2008
VL 9
IS 7
BP 1843
EP 1851
DI 10.1021/bm8000606
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 326DX
UT WOS:000257639500018
PM 18540674
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Münz, S
   Feger, M
   Edemir, B
   Föller, M
AF Muenz, Sina
   Feger, Martina
   Edemir, Bayram
   Foeller, Michael
TI Up Regulation of Fibroblast Growth Factor 23 Gene Expression in UMR106
   Osteoblast like Cells with Reduced Viability
SO CELLS
LA English
DT Article
DE cisplatin; apoptosis; 1; 25(OH)(2)D 3; klotho; inflammation
ID KAPPA B ACTIVATION; INDUCED APOPTOSIS; FGF23 PRODUCTION; CISPLATIN;
   CANCER; DOXORUBICIN; PROLIFERATION; INHIBITION; MECHANISMS; RECEPTOR
AB Fibroblast growth factor 23 (FGF23) controls vitamin D and phosphate homeostasis in the kidney and has additional paracrine effects elsewhere. As a biomarker, its plasma concentration is associated with progression of inflammatory, renal, and cardiovascular diseases. Major stimuli of FGF23 synthesis include active vitamin D and inflammation. Antineoplastic chemotherapy treats cancer by inducing cellular damage ultimately favoring cell death (apoptosis and necrosis) and causing inflammation. Our study explored whether chemotherapeutics and other apoptosis inducers impact on Fgf23 expression. Experiments were performed in osteoblast like UMR106 cells, Fgf23 gene expression and protein synthesis were determined by qRT PCR and ELISA, respectively. Viability was assessed by MTT assay and NF kappa B activity by Western Blotting. Antineoplastic drugs cisplatin and doxorubicin as well as apoptosis inducers procaspase activating compound 1 (PAC 1), a caspase 3 activator, and serum depletion up regulated Fgf23 transcripts while reducing cell proliferation and viability. The effect of cisplatin on Fgf23 transcription was paralleled by Il 6 up regulation and NF kappa B activation and attenuated by Il 6 and NF kappa B signaling inhibitors. To conclude, cell viability decreasing chemotherapeutics as well as apoptosis stimulants PAC 1 and serum depletion up regulate Fgf23 gene expression. At least in part, Il 6 and NF kappa B may contribute to this effect.
C1 [Muenz, Sina; Feger, Martina; Foeller, Michael] Univ Hohenheim, Dept Physiol, D 70599 Stuttgart, Germany.
   [Edemir, Bayram] Martin Luther Univ Halle Wittenberg, Dept Hematol & Oncol, D 06120 Halle, Germany.
C3 University Hohenheim; Martin Luther University Halle Wittenberg
RP Föller, M (通讯作者)，Univ Hohenheim, Dept Physiol, D 70599 Stuttgart, Germany.
EM s.muenz@uni hohenheim.de; martina.feger@uni hohenheim.de;
   bayram.edemir@uk halle.de; michael.foeller@uni hohenheim.de
RI ; Edemir, Bayram/AAF 6845 2020
OI Foller, Michael/0000 0003 2074 4827; 
CR Abuna RPF, 2019, J CELL PHYSIOL, V234, P749, DOI 10.1002/jcp.26886
   Andrukhova O, 2012, BONE, V51, P621, DOI 10.1016/j.bone.2012.05.015
   Bär L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211309
   Bär L, 2018, P NATL ACAD SCI USA, V115, P5804, DOI 10.1073/pnas.1800160115
   Bai JA, 2015, WORLD J GASTROENTERO, V21, P6180, DOI 10.3748/wjg.v21.i20.6180
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960 7404(97)00015 7
   Bonewald LF, 2013, PEDIATR NEPHROL, V28, P563, DOI 10.1007/s00467 012 2309 3
   Chanakul A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072816
   Chang HM, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03693 w
   Chu C, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882 021 02329 7
   Daryadel A, 2018, PFLUG ARCH EUR J PHY, V470, P1569, DOI 10.1007/s00424 018 2171 7
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   David V, 2016, KIDNEY INT, V89, P135, DOI 10.1038/ki.2015.290
   di Giuseppe R, 2015, EUR J EPIDEMIOL, V30, P131, DOI 10.1007/s10654 014 9982 4
   Durlacher Betzer K, 2018, KIDNEY INT, V94, P315, DOI 10.1016/j.kint.2018.02.026
   Esparza López J, 2013, J CANCER RES CLIN, V139, P1625, DOI 10.1007/s00432 013 1476 3
   Feng S, 2015, ONCOTARGET, V6, P17291, DOI 10.18632/oncotarget.4174
   Figurek A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10051266
   Fitzpatrick EA, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00320
   Glosse P, 2018, NUTR DIABETES, V8, DOI 10.1038/s41387 018 0037 x
   González Bermúdez L, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50035 0
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Higuchi A, 2006, BRIT J OPHTHALMOL, V90, P760, DOI 10.1136/bjo.2005.088203
   Hu MC, 2019, PFLUG ARCH EUR J PHY, V471, P99, DOI 10.1007/s00424 018 2238 5
   Hu MC, 2013, ANNU REV PHYSIOL, V75, P503, DOI 10.1146/annurev physiol 030212 183727
   Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090
   Isakova T, 2012, CURR OPIN NEPHROL HY, V21, P334, DOI 10.1097/MNH.0b013e328351a391
   Kim SB, 2006, FEBS LETT, V580, P311, DOI 10.1016/j.febslet.2005.12.012
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Leifheit Nestler M, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00278
   Li F, 2013, CHINESE MED J PEKING, V126, P3276, DOI 10.3760/cma.j.issn.0366 6999.20123391
   Ludwig T, 2004, KIDNEY INT, V66, P196, DOI 10.1111/j.1523 1755.2004.00720.x
   Ma LL, 2018, CELL BIOL INT, V42, P1270, DOI 10.1002/cbin.10997
   Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160
   Mason EF, 2011, BBA MOL CELL RES, V1813, P645, DOI 10.1016/j.bbamcr.2010.08.011
   Masuyama R, 2006, J CLIN INVEST, V116, P3150, DOI 10.1172/JCI29463
   Medici D, 2008, J CELL BIOL, V182, P459, DOI 10.1083/jcb.200803024
   Meir T, 2014, KIDNEY INT, V86, P1106, DOI 10.1038/ki.2014.215
   Mirza MAI, 2009, NEPHROL DIAL TRANSPL, V24, P3125, DOI 10.1093/ndt/gfp205
   Mytych J, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020261
   Oflazoglu U, 2020, SUPPORT CARE CANCER, V28, P3965, DOI 10.1007/s00520 020 05477 y
   Ozkok A, 2016, TOXICOL LETT, V240, P105, DOI 10.1016/j.toxlet.2015.10.028
   Peterson QP, 2009, J MOL BIOL, V388, P144, DOI 10.1016/j.jmb.2009.03.003
   Razzaque MS, 2006, TRENDS MOL MED, V12, P298, DOI 10.1016/j.molmed.2006.05.002
   Rusinek K, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051231
   Saini RK, 2013, CALCIFIED TISSUE INT, V92, P339, DOI 10.1007/s00223 012 9683 5
   Samadfam R, 2009, ENDOCRINOLOGY, V150, P4835, DOI 10.1210/en.2009 0472
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Takashi Y, 2019, P NATL ACAD SCI USA, V116, P11418, DOI 10.1073/pnas.1815166116
   Vervloet MG, 2011, CLIN J AM SOC NEPHRO, V6, P383, DOI 10.2215/CJN.04730510
   Vidal A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 58663 7
   Volkova M, 2011, CURR CARDIOL REV, V7, P214, DOI 10.2174/157340311799960645
   Vyas D, 2014, ONCOTARGETS THER, V7, P1015, DOI 10.2147/OTT.S60114
   Wahl P, 2012, ADV EXP MED BIOL, V728, P107, DOI 10.1007/978 1 4614 0887 1_8
   Wallach D, 2014, ELIFE, V3, DOI 10.7554/eLife.02583
   Wang CW, 2015, INTEGR CANCER THER, V14, P546, DOI 10.1177/1534735415588826
   Wang SW, 2002, BIOCHEM J, V367, P729, DOI 10.1042/BJ20020752
   Xiao YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072545
   Yang F, 2015, MUTAT RES FUND MOL M, V773, P9, DOI 10.1016/j.mrfmmm.2015.01.007
   Zhang BB, 2016, J MOL MED, V94, P557, DOI 10.1007/s00109 015 1370 3
NR 63
TC 2
Z9 2
U1 1
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JAN
PY 2022
VL 11
IS 1
AR 40
DI 10.3390/cells11010040
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZE2BL
UT WOS:000758693600001
PM 35011602
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Khan, MR
   Mordan, N
   Parkar, M
   Salih, V
   Donos, N
   Brett, PM
AF Khan, Mohammad R.
   Mordan, Nicola
   Parkar, Mohamed
   Salih, Vehid
   Donos, Nikolaos
   Brett, Peter M.
TI Atypical Mesenchymal Stromal Cell Responses to Topographic Modifications
   of Titanium Biomaterials Indicate Cytoskeletal  and Genetic
   Plasticity Based Heterogeneity of Cells
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID ACID ETCHED SURFACE; EARLY OSSEOINTEGRATION; BONE INTEGRATION; IMPLANT
   SURFACES; SLA SURFACE; ENERGY; OSTEOBLASTS; EXPRESSION; MAXILLA
AB Titanium (Ti) is widely used as a biomaterial for endosseous implants due to its relatively inert surface oxide layer that enables implanted devices the ability of assembling tissue reparative components that culminate in osseointegration. Topographic modifications in the form of micro  and nanoscaled structures significantly promote osseointegration and enhance the osteogenic differentiation of adult mesenchymal stromal cells (MSCs). While the biological mechanisms central to the differential responses of tissues and cells to Ti surface modifications remain unknown, adhesion and morphological adaptation are amongst the earliest events at the cell biomaterial interface that are highly influenced by surface topography and profoundly impact the regulation of stem cell fate determination. This study correlated the effects of Ti topographic modifications on adhesion and morphological adaptation of human MSCs with phenotypic change. The results showed that modified Ti topographies precluded the adhesion of a subset of MSCs while incurring distinct morphological constraints on adherent cells. These effects anomalously corresponded with a differential expression of stem cell pluripotency and Wnt signalling associated markers on both modified surfaces while additionally differing between hydrophobic and hydrophilic surface modifications though extent of osteogenic differentiation induced by both modified topographies yielded similarly significant higher levels of cellular mineralisation in contrast to polished Ti. These results suggest that in the absence of deposited proteins and soluble factors, both modified topographies incur the selective adhesion of a subpopulation of progenitors with relatively higher cytoskeletal plasticity. While the presence of deposited proteins and soluble factors does not significantly affect adherence of cells, nanotopographic modifications enhance expression of pluripotency markers in proliferative conditions, which are conversely overridden by both modified topographies in osteogenic inductive conditions. Further deciphering the mechanisms underlying cellular selectivity and Ti topographic responsiveness will improve our understanding of stem cell heterogeneity and advance the potential of MSCs in regenerative medicine.
C1 [Khan, Mohammad R.; Mordan, Nicola; Parkar, Mohamed; Salih, Vehid; Donos, Nikolaos; Brett, Peter M.] UCL, UCL Eastman Dent Inst, Biomat & Tissue Engn, 256 Grays Inn Rd, London WC1X 8LD, England.
   [Salih, Vehid] Univ Plymouth, Fac Med & Dent, Plymouth PL4 8AA, Devon, England.
   [Donos, Nikolaos] Queen Mary Univ London, Inst Dent, Turner St, London E1 2AD, England.
   [Brett, Peter M.] Univ Surrey, Guildford GU2 7XH, Surrey, England.
C3 University of London; University College London; University of Plymouth;
   University of London; Queen Mary University London; University of Surrey
RP Khan, MR (通讯作者)，UCL, UCL Eastman Dent Inst, Biomat & Tissue Engn, 256 Grays Inn Rd, London WC1X 8LD, England.
EM m.r.khan@ucl.ac.uk
RI Salih, Vehid/AAG 8171 2020
OI Salih, Vehid/0000 0003 3776 2941; Khan, Mohammad
   Ramine/0000 0002 3728 011X
FU ITI Foundation [491/2006]; University of London, Central Research Fund
   Grant
FX The authors extend their gratitude to the ITI Foundation for funding
   this research (grant code (491/2006)) and the University of London,
   Central Research Fund Grant, for funding the gene array experiments. The
   authors further extend their gratitude to the Institut Straumann AG
   Switzerland for providing the valuable titanium biomaterials. The
   authors also extend their gratitude to Dr. Shahzia Anjum from the UCL
   Institute of Child Health for her analysis of the gene expression
   miniarray derived data. The authors also extend their gratitude to Prof.
   Tim Arnett from the University College London and Prof. Matt Dalby from
   the University of Glasgow for their review and insights towards the data
   presented in this paper. The publication of this article was self funded
   by the authors.
CR Alayan J, 2017, CLIN ORAL IMPLAN RES, V28, P1325, DOI 10.1111/clr.12988
   Atta W, 2009, BIOMATERIALS, V30, P5352, DOI 10.1016/j.biomaterials.2009.06.040
   Bornstein MM, 2010, J PERIODONTOL, V81, P809, DOI 10.1902/jop.2010.090727
   Bornstein MM, 2003, INT J ORAL MAX IMPL, V18, P659
   Brett PM, 2004, BONE, V35, P124, DOI 10.1016/j.bone.2004.03.009
   Buser D, 1998, INT J ORAL MAX IMPL, V13, P611
   Buser D, 1999, J BIOMED MATER RES, V45, P75, DOI 10.1002/(SICI)1097 4636(199905)45:2<75::AID JBM1>3.0.CO;2 P
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Buser D, 2004, J DENT RES, V83, P529, DOI 10.1177/154405910408300704
   Calciolari E, 2018, J PERIODONTAL RES, V53, P174, DOI 10.1111/jre.12498
   Cochran DL, 1996, CLIN ORAL IMPLAN RES, V7, P240, DOI 10.1034/j.1600 0501.1996.070306.x
   Di L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1130 2
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Donos N, 2011, CLIN ORAL IMPLAN RES, V22, P365, DOI 10.1111/j.1600 0501.2010.02113.x
   Galli C, 2012, ACTA BIOMATER, V8, P2963, DOI 10.1016/j.actbio.2012.04.043
   Huang C, 2015, BBA GEN SUBJECTS, V1850, P1261, DOI 10.1016/j.bbagen.2015.02.011
   Ivanovski S, 2011, CLIN ORAL IMPLAN RES, V22, P373, DOI 10.1111/j.1600 0501.2010.02112.x
   Khan MR, 2012, BONE, V50, P1, DOI 10.1016/j.bone.2011.07.040
   Khan MTS, 2014, AKADEMEIA, V4
   Lagonegro P, 2018, DENT MATER J, V37, P278, DOI 10.4012/dmj.2017 008
   Lai HC, 2010, J BIOMED MATER RES A, V93A, P289, DOI 10.1002/jbm.a.32542
   Lang NP, 2011, CLIN ORAL IMPLAN RES, V22, P349, DOI 10.1111/j.1600 0501.2011.02172.x
   London R, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00070
   LUMETTI S, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/401859
   McLeod CM, 2017, EUR CELLS MATER, V34, P217, DOI 10.22203/eCM.v034a14
   Miron RJ, 2010, BIOMATERIALS, V31, P449, DOI 10.1016/j.biomaterials.2009.09.075
   Prowse PDH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058898
   Qu Z, 2007, J BIOMED MATER RES A, V82A, P658, DOI 10.1002/jbm.a.31023
   Rupp F, 2006, J BIOMED MATER RES A, V76A, P323, DOI 10.1002/jbm.a.30518
   Schwarz F, 2009, J BIOMED MATER RES B, V88B, P544, DOI 10.1002/jbm.b.31233
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Uggeri J, 2010, MICRON, V41, P210, DOI 10.1016/j.micron.2009.10.013
   van Velzen FJJ, 2015, CLIN ORAL IMPLAN RES, V26, P1121, DOI 10.1111/clr.12499
   Wall I, 2009, BONE, V45, P17, DOI 10.1016/j.bone.2009.03.662
   Wennerberg A, 2009, CLIN ORAL IMPLAN RES, V20, P172, DOI 10.1111/j.1600 0501.2009.01775.x
   Zhao G, 2007, BIOMATERIALS, V28, P2821, DOI 10.1016/j.biomaterials.2007.02.024
   Zhao G, 2005, J BIOMED MATER RES A, V74A, P49, DOI 10.1002/jbm.a.30320
NR 38
TC 5
Z9 5
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD JUL 1
PY 2019
VL 2019
AR 5214501
DI 10.1155/2019/5214501
PG 16
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IJ1IN
UT WOS:000475652100001
PM 31354840
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Hao, W
   Yang, R
   Yang, Y
   Jin, S
   Li, YQ
   Yuan, F
   Guo, Q
   Xiao, L
   Wang, X
   Wang, FW
   Wu, YM
   Teng, X
AF Hao, Wei
   Yang, Rui
   Yang, Yang
   Jin, Sheng
   Li, Yanqing
   Yuan, Fang
   Guo, Qi
   Xiao, Lin
   Wang, Xin
   Wang, Fuwei
   Wu, Yuming
   Teng, Xu
TI Stellate ganglion block ameliorates vascular calcification by inhibiting
   endoplasmic reticulum stress
SO LIFE SCIENCES
LA English
DT Article
DE Vascular calcification; Stellate ganglion block; Endoplasmic reticulum
   stress; Sympathetic activity; Norepinephrine
ID MUSCLE CELL CALCIFICATION; MEDIATED APOPTOSIS; OXIDATIVE STRESS; PLUS
   NICOTINE; IN VITRO; NOREPINEPHRINE; RATS; ACTIVATION; MECHANISM; PATHWAY
AB Aims: Vascular calcification (VC) underlies substantial cardiovascular morbidity and mortality. No clinically therapies have emerged presently. Stellate ganglion block (SGB) is one of the most often used sympathetic blockade procedure, and regulates vascular dilation. However, the effect of SGB on VC is still unknown. Therefore, we aimed to identify the ameliorative effect of SGB on VC.
   Key finding: In vivo VC was induced in rats by administering vitamin D3 plus nicotine (VDN), and in vitro calcification of rat aortic vascular smooth muscle cells (VSMC) was induced by beta glycerophosphate. In VDN rats, alkaline phosphatase (ALP) activity and Calcium contents were higher than that in control rats. The transformation of VSMC from contractile to osteoblast  like phenotype was observed in calcified aorta. SGB ameliorated the increase of ALP activity and Calcium content, and the transformation of VSMC in calcified aorta. The stimulation of endoplasmic reticulum stress (ERS) in calcified aorta was also attenuated by SGB treatment. The inducer of ERS, tunicamycin could block the beneficial effect of SGB on VC, and the ERS inhibitor, 4 PBA could mimic the amelioration of SGB. Furthermore, SGB attenuated the increased plasma levels of norepinephrine in VDN rats. In vitro experiments, norepinephrine exaggerated VSMC calcification, phenotype transformation and ERS.
   Significance: These results demonstrate that SGB could inhibit sympathetic nervous activity, and then prevent the activation of ERS followed by ameliorating VC. Sympathetic over activation might play critical role in the pathogenesis of VC, which provides new strategy and target for therapy and prevention of VC.
C1 [Yang, Rui; Jin, Sheng; Yuan, Fang; Guo, Qi; Xiao, Lin; Wang, Xin; Wang, Fuwei; Wu, Yuming; Teng, Xu] Hebei Med Univ, Dept Physiol, Shijiazhuang 050017, Hebei, Peoples R China.
   [Hao, Wei] Hebei Prov Hosp Tradit Chinese Med, Dept Anesthesiol, Shijiazhuang 050011, Hebei, Peoples R China.
   [Li, Yanqing] Hebei Prov Hosp Tradit Chinese Med, Dept Gynaecol, Shijiazhuang 050011, Hebei, Peoples R China.
   [Teng, Xu] Hebei Key Lab Lab Anim Sci, Shijiazhuang 050017, Hebei, Peoples R China.
   [Yang, Yang] Cangzhou Hosp People, Dept Orthopaed 3, Cangzhou 061000, Peoples R China.
   [Wu, Yuming] Hebei Collaborat Innovat Ctr Cardiocerebrovasc Di, Shijiazhuang 050017, Hebei, Peoples R China.
   [Wu, Yuming] Key Lab Vasc Med Hebei Prov, Shijiazhuang 050017, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei University of Chinese Medicine; Hebei
   University of Chinese Medicine
RP Wu, YM; Teng, X (通讯作者)，361 Zhongshan East Rd, Shijiazhuang 050017, Hebei, Peoples R China.
EM wuyum@yahoo.com; tengxu78@163.com
RI Wu, Yuming/LMP 5267 2024; Jin, Sheng/H 1254 2014; LI,
   YANQING/HKF 0151 2023; Guo, Qi/U 5576 2019
OI Teng, Xu/0000 0003 2206 8308; 
FU National Natural Science Foundation of China [81100229, 81770499];
   Province Natural Science Foundation of Hebei [C2012206063, H2016206264]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81100229, 81770499), and the Province Natural Science
   Foundation of Hebei (Nos. C2012206063, H2016206264).
CR Cai Y, 2010, ACTA PHARMACOL SIN, V31, P1359, DOI 10.1038/aps.2010.89
   Cai Y, 2010, CARDIOVASC RES, V85, P864, DOI 10.1093/cvr/cvp366
   Chang JR, 2013, EXP BIOL MED, V238, P1136, DOI 10.1177/1535370213502619
   Chen Yong quan, 2012, Zhejiang Da Xue Xue Bao Yi Xue Ban, V41, P65
   Chen Yongquan, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P896, DOI 10.3969/j.issn.1672 7347.2013.09.005
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   Dönmez A, 2005, J CARDIOTHOR VASC AN, V19, P729, DOI 10.1053/j.jvca.2004.10.008
   Duan XH, 2013, APOPTOSIS, V18, P1132, DOI 10.1007/s10495 013 0861 3
   Duan XH, 2009, BIOCHEM BIOPH RES CO, V387, P694, DOI 10.1016/j.bbrc.2009.07.085
   El Asmar Margueritta S, 2014, Oman Med J, V29, P172, DOI 10.5001/omj.2014.44
   Elias M, 2000, Pain Physician, V3, P294
   Ewence AE, 2008, CIRC RES, V103, pE28, DOI 10.1161/CIRCRESAHA.108.181305
   Gan XT, 2014, MOL CELL BIOCHEM, V394, P237, DOI 10.1007/s11010 014 2100 9
   Gopal D, 2013, ANN CARD ANAESTH, V16, P238, DOI 10.4103/0971 9784.119161
   Gulcu N, 2009, ANESTH ANALG, V108, P1701, DOI 10.1213/ane.0b013e31819c6018
   Guttuso T, 2013, MATURITAS, V76, P221, DOI 10.1016/j.maturitas.2013.08.001
   Kitajima T, 2001, REGION ANESTH PAIN M, V26, P41, DOI 10.1053/rapm.2001.16163
   Kumar N, 2014, ANAESTHESIA, V69, P954, DOI 10.1111/anae.12774
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Li YM, 2014, ACTA BIOCH BIOPH SIN, V46, P629, DOI 10.1093/abbs/gmu048
   Liberman M, 2011, BIOCHEM BIOPH RES CO, V413, P436, DOI 10.1016/j.bbrc.2011.08.114
   Liu HM, 2014, J BIOL INORG CHEM, V19, P375, DOI 10.1007/s00775 013 1078 1
   Mao W, 2007, AM J PHYSIOL HEART C, V293, pH1636, DOI 10.1152/ajpheart.01377.2006
   Mao WK, 2005, AM J PHYSIOL HEART C, V288, pH2381, DOI 10.1152/ajpheart.00904.2004
   Masuda M, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000238
   Miyazaki Anzai S, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000949
   Niederhoffer N, 1997, J VASC RES, V34, P386, DOI 10.1159/000159247
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Shioi A, 2002, CIRC RES, V91, P9, DOI 10.1161/01.RES.0000026421.61398.F2
   Shroff RC, 2008, CIRCULATION, V118, P1748, DOI 10.1161/CIRCULATIONAHA.108.783738
   Sugimoto M, 1999, REGION ANESTH PAIN M, V24, P30, DOI 10.1016/S1098 7339(99)90162 1
   Tseng W, 2010, J BIOL CHEM, V285, P29925, DOI 10.1074/jbc.M110.117366
   Wang QX, 2005, EUR J ANAESTH, V22, P913, DOI 10.1017/S0265021505001559
   WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009 8981(84)90162 1
   Yang C, 2011, J SURG RES, V168, P262, DOI 10.1016/j.jss.2009.10.002
   Yokoyama M, 2000, ANESTHESIOLOGY, V92, P109, DOI 10.1097/00000542 200001000 00021
   Zhang LL, 2013, MED HYPOTHESES, V80, P158, DOI 10.1016/j.mehy.2012.11.017
   Zhou YB, 2012, EXP BIOL MED, V237, P50, DOI 10.1258/ebm.2011.011252
   Zhou YB, 2009, EXP BIOL MED, V234, P908, DOI 10.3181/0811 RM 346
NR 39
TC 22
Z9 26
U1 0
U2 22
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JAN 15
PY 2018
VL 193
BP 1
EP 8
DI 10.1016/j.lfs.2017.12.002
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4HV
UT WOS:000419027200001
PM 29208463
DA 2025 08 17
ER

PT J
AU Yu, WW
   Zheng, Y
   Li, HY
   Lin, HB
   Chen, Z
   Tian, Y
   Chen, HS
   Zhang, PP
   Xu, XW
   Shen, YQ
AF Yu, Wenwen
   Zheng, Yi
   Li, Hongyan
   Lin, Hongbing
   Chen, Zhen
   Tian, Yue
   Chen, Huishan
   Zhang, Peipei
   Xu, Xiaowei
   Shen, Yuqin
TI The Toll like receptor ligand, CpG oligodeoxynucleotides, regulate
   proliferation and osteogenic differentiation of osteoblast
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Periodontitis; CpG ODN; Osteoblast; Proliferation; Differentiation
ID CELL CYCLE; TRANSCRIPTION FACTOR; RUNX2; OLIGONUCLEOTIDES;
   PHOSPHORYLATION; MODULATION; ACTIVATION; MECHANISMS; EXPRESSION;
   RESPONSES
AB Background This study aimed to investigate the regulation of CpG oligodeoxynucleotides (ODNs) on proliferation and osteogenic differentiation of MC3T3 cells. Methods The laser co focusing and flow cytometry assay were employed to detect cell uptake of CpG ODN 2006. Twelve ODNs were sythesized, and their effects on proliferation and differentiation were detected by MTT and alkaline phosphatase (ALP) activity assay. Flow cytometry assay was used to examine the regulation of CpG ODN on cell cycle. Quantitative real time PCR (qRT PCR) and western blot were used to evaluate the regulation of CpG ODN on mRNA and protein expression of osteogenic differentiation genes. Results The phosphorothioate CpG ODN 2006 could efficiently enter the MC3T3 cells in 1 h and locate in the cytoplasm. The MTT assay demonstrated CpG ODNs could promote MC3T3 cell proliferation and differentiation in the early stage, and gradually attenuated along with the increase of treating time, except for BW001 and FC001. qRT PCR assay demonstrated that all the 12 CpG ODNs could promote the relative expression level of osteogenic differentiated genes, SP7 and OCN. In addition, western blot analysis suggested the CpG ODNs of BW001 and FC001 could increase the protein expression of P27(Kip1)and Runx2 and decrease the protein expression of cyclin D1. Conclusion The selected CpGODNs may be a potential gene therapy for bone regeneration of periodontitis.
C1 [Yu, Wenwen; Zheng, Yi; Li, Hongyan; Lin, Hongbing; Chen, Zhen; Tian, Yue; Chen, Huishan; Zhang, Peipei; Xu, Xiaowei; Shen, Yuqin] Jilin Univ, Sch & Hosp Stomatol, Dept Periodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
   [Yu, Wenwen] Nankai Univ, Dept Orthodont, Tianjin Key Lab Oral & Maxillofacial Funct Recons, 75 Dagu North Rd, Tianjin 300041, Peoples R China.
   [Yu, Wenwen] Nankai Univ, Tianjin Stomatol Hosp, 75 Dagu North Rd, Tianjin 300041, Peoples R China.
   [Yu, Wenwen] Nankai Univ, Hosp Stomatol, 75 Dagu North Rd, Tianjin 300041, Peoples R China.
C3 Jilin University; Nankai University; Nankai University; Tianjin Medical
   University; Nankai University
RP Shen, YQ (通讯作者)，Jilin Univ, Sch & Hosp Stomatol, Dept Periodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
EM shenyqjlu@126.com
RI Yu, Wenwen/LCE 3187 2024
FU Medical Support Program of the Jilin University [20170311032YY]; Science
   and Technology Project of the Jilin Provincial Department of Finance
   [jcsz2020304 9]; National Natural Science Foundation of China [81970946,
   81600879]; 13th Five Year for Key Clinical Medical Subjects Construction
   of Tianjin [jmse268]
FX This research was supported by grants from the Medical Support Program
   of the Jilin University (No. 20170311032YY), Science and Technology
   Project of the Jilin Provincial Department of Finance
   (No.jcsz2020304 9), National Natural Science Foundation of China (No.
   81970946 and No. 81600879) and the 13th Five Year for Key Clinical
   Medical Subjects Construction of Tianjin (No. jmse268).
CR Amcheslavsky A, 2005, J BONE MINER RES, V20, P1692, DOI 10.1359/JBMR.050515
   Amcheslavsky A, 2004, J BIOL CHEM, V279, P54039, DOI 10.1074/jbc.M409138200
   Azuma M, 2006, J PERIODONTAL RES, V41, P361, DOI 10.1111/j.1600 0765.2006.00896.x
   Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498
   Farrokhi S, 2017, IMMUNOTHERAPY UK, V9, P339, DOI 10.2217/imt 2016 0104
   Feng ZY, 2011, INT J MOL SCI, V12, P2543, DOI 10.3390/ijms12042543
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014
   Jakob T, 1998, J IMMUNOL, V161, P3042
   Kim IY, 2012, J SURG RES, V174, P284, DOI 10.1016/j.jss.2010.12.021
   Klinman Dennis M, 2004, Nat Rev Immunol, V4, P249, DOI 10.1038/nri1329
   Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774 002 0408 0
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703 831
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432 1033.2003.03555.x
   Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001
   Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200
   Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065
   Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200
   Shen YQ, 2012, INT J MOL SCI, V13, P2877, DOI 10.3390/ijms13032877
   Tane S, 2014, BIOCHEM BIOPH RES CO, V443, P1105, DOI 10.1016/j.bbrc.2013.12.109
   Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097 2765(01)00327 6
   Wang YF, 2017, INT J MOL MED, V40, P1991, DOI 10.3892/ijmm.2017.3155
   Yu XQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165862
   Zhang HJ, 2017, MAT SCI ENG C MATER, V73, P144, DOI 10.1016/j.msec.2016.12.072
   Zhang M, 2009, J CELL SCI, V122, P1382, DOI 10.1242/jcs.040709
   Zheng Y, 2017, RSC ADV, V7, P27121, DOI 10.1039/c6ra27182k
   Zou W, 2002, FASEB J, V16, P274, DOI 10.1096/fj.01 0586com
NR 32
TC 12
Z9 12
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD AUG 14
PY 2020
VL 15
IS 1
AR 327
DI 10.1186/s13018 020 01844 x
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA NE7VZ
UT WOS:000562813200001
PM 32795334
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Scotto di Carlo, F
   Divisato, G
   Iacoangeli, M
   Esposito, T
   Gianfrancesco, F
AF Scotto di Carlo, Federica
   Divisato, Giuseppina
   Iacoangeli, Maurizio
   Esposito, Teresa
   Gianfrancesco, Fernando
TI The identification of H3F3A mutation in giant cell tumour of the
   clivus and the histological diagnostic algorithm of other clival lesions
   permit the differential diagnosis in this location
SO BMC CANCER
LA English
DT Article
DE Giant cell tumour; Clivus; H3F3A gene; Diagnostic algorithm;
   Differential diagnosis
ID SKULL BASE; SPHENOID BONE; PAGET DISEASE; CHONDROSARCOMA; EXPRESSION;
   MIMICKING; CHORDOMA; SARCOMA
AB Background: Giant Cell Tumour of Bone (GCT) is a locally aggressive primary bone tumour that usually occurs at the epiphyses of the long bones of the appendicular skeleton with a tendency to recurrence. Recurrent somatic H3F3A mutations have been described in 92% of GCT cases. GCTs involving the Clivus are extremely rare lesions and less than 15 cases are described in the literature. They represent a surgery challenge and are easily misdiagnosed. Our aim was to reveal if the genetic bases underlying Clival GCTs were the same of GCTs of long bones to improve the diagnosis and treatment.
   Methods: The targeted somatic sequencing of GCT related genes (H3F3A, H3F3B, IDH1, IDH2 and ZNF687) was performed on Clival GCT biopsies of two different cases. Histological analyses on the same tissues were used to detect the neoplastic population and its expression profile.
   Results: Sanger sequencing revealed that both patients were positive for the p.Gly34Trp mutation in the H3F3A gene. Immunofluorescence assay using monoclonal antibody, specifically detecting the mutant H3.3, highlighted that the mutation only involved the mononuclear cell population and not the multinucleated giant cells. Moreover, immunohistochemistry assay showed that RANKL was highly expressed by the stromal cells within Clival GCT, mimicking what happens in GCT of the long bones. In addition, systematic literature review allowed us to generate a histology based diagnostic algorithm of the most common clival lesions.
   Conclusions: We conclude that the Clival GCT is genetically defined by somatic mutation in the H3F3A gene, linking it to the GCT of long bones. The similarity with GCTs of long bones let us to hypothesize the utility of Denosumab therapy (already effective for GCTs) in these surgically challenging cases. Moreover, H3F3A genetic screening can be combined to the histological analysis to differentiate GCTs from morphologically similar giant cell rich sarcomas, while the histological diagnostic algorithm could help the differential diagnosis of other clival lesions.
C1 [Scotto di Carlo, Federica; Divisato, Giuseppina; Esposito, Teresa; Gianfrancesco, Fernando] Natl Res Council Italy, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy.
   [Scotto di Carlo, Federica] Univ Campania Luigi Vanvitelli, Dept Environm Biol & Pharmaceut Sci & Technol DiS, Caserta, Italy.
   [Iacoangeli, Maurizio] Umberto I Gen Hosp, Dept Neurosurg, Ancona, Italy.
   [Esposito, Teresa] IRCCS INM Neuromed, Pozzilli, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e
   Biofisica "Adriano Buzzati Traverso" (IGB CNR); Universita della
   Campania Vanvitelli; IRCCS Neuromed
RP Gianfrancesco, F (通讯作者)，Natl Res Council Italy, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy.
EM fernando.gianfrancesco@igb.cnr.it
RI ; Gianfrancesco, Fernando/P 6853 2014; Scotto di Carlo,
   Federica/IQX 0519 2023; Esposito, Teresa/AAA 5488 2019
OI IACOANGELI, Maurizio/0000 0002 3629 5301; Gianfrancesco,
   Fernando/0000 0002 3812 2471; Scotto di Carlo,
   Federica/0000 0003 1797 9051; Divisato, Giuseppina/0000 0003 4014 1716
FU Italian Association for Cancer Research (AIRC) [15707]
FX This work was supported by the Italian Association for Cancer Research
   (AIRC), Grant IG 2014 n. 15707 (F.G.).
CR Agrawal Amit, 2014, Asian J Neurosurg, V9, P48, DOI 10.4103/1793 5482.131078
   Almefty K, 2007, CANCER AM CANCER SOC, V110, P2457, DOI 10.1002/cncr.23073
   Alzarei A, 2017, INT J OTORHINOLARYNG, V3, P725
   Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Aragao MD, 2007, J APPL ORAL SCI, V15, P310, DOI 10.1590/S1678 77572007000400013
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   BERTONI F, 1992, CANCER, V70, P1124, DOI 10.1002/1097 0142(19920901)70:5<1124::AID CNCR2820700517>3.0.CO;2 P
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Billingsley JT, 2014, J NEUROL SURG REP, V75, pE175, DOI 10.1055/s 0034 1378153
   Boyd SD, 2013, APPL IMMUNOHISTO M M, V21, P116, DOI 10.1097/PAI.0b013e31825d550a
   Brackmann DE, 2006, OTOL NEUROTOL, V27, P981, DOI 10.1097/01.mao.0000233812.48800.b4
   Buter JJ, 1997, EUR ARCH OTO RHINO L, V254, P298, DOI 10.1007/BF02905992
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chambers KJ, 2014, LARYNGOSCOPE, V124, P1097, DOI 10.1002/lary.24420
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   DAHLIN DC, 1985, AM J ROENTGENOL, V144, P955, DOI 10.2214/ajr.144.5.955
   DeConde AS, 2013, J NEUROL SURG PART B, V74, P292, DOI 10.1055/s 0033 1348027
   Divisato G, 2017, ONCOTARGET, V8, P63121, DOI 10.18632/oncotarget.18670
   Divisato G, 2016, AM J HUM GENET, V98, P275, DOI 10.1016/j.ajhg.2015.12.016
   DOSHI R, 1977, CAN J NEUROL SCI, V4, P213, DOI 10.1017/S0317167100025257
   Erdem E, 2003, RADIOGRAPHICS, V23, P995, DOI 10.1148/rg.234025176
   Gaston CL, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0056 0
   GOLDENBERG RR, 1970, J BONE JOINT SURG AM, VA 52, P619, DOI 10.2106/00004623 197052040 00001
   Goto Y, 2017, J NEUROSURG, V126, P431, DOI 10.3171/2016.3.JNS152802
   Gouin F, 2013, ORTHOP TRAUMATOL SUR, V99, pS313, DOI 10.1016/j.otsr.2013.07.006
   Grau S, 2010, WORLD NEUROSURG, V74, P513, DOI 10.1016/j.wneu.2010.06.020
   Gray H., 1918, ANATOMY HUMAN BODY
   Guo ZF, 2017, J CLIN NEUROSCI, V44, P133, DOI 10.1016/j.jocn.2017.06.014
   Gupta R, 2008, BRIT J NEUROSURG, V22, P447, DOI 10.1080/02688690701818943
   Hsu SW, 2013, FORMOS J SURG, V46, P30, DOI 10.1016/j.fjs.2012.10.006
   Iacoangeli Maurizio, 2013, Cancer Manag Res, V5, P21, DOI 10.2147/CMAR.S38768
   Inoue A, 2016, WORLD NEUROSURG, V91, DOI [10.1016/J.WNEU.2016.04.054, 10.1016/j.wneu.2016.04.054]
   June Ho B, 2015, J INT ADV OTOL, V11, P88, DOI 10.5152/iao.2015.797
   Kalwani N, 2015, J NEUROL SURG REP, V76, P156, DOI 10.1055/s 0035 1554930
   Kaneko MK, 2014, CANCER SCI, V105, P744, DOI 10.1111/cas.12413
   Karras CL, 2016, CASE REP NEUROL MED, V2016, DOI 10.1155/2016/8371697
   Kattner KA, 1998, SKULL BASE SURG, V8, P93, DOI 10.1055/s 2008 1058582
   Kawase Takeshi, 1996, Neurologia Medico Chirurgica, V36, P1, DOI 10.2176/nmc.36.1
   Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212
   Korten AGGC, 1998, J NEUROL NEUROSUR PS, V65, P88, DOI 10.1136/jnnp.65.1.88
   Krishnan G, 2016, OTORHINOLARYNGOLOGY, V8, P68
   LARSSON SE, 1975, J BONE JOINT SURG AM, VA 57, P167, DOI 10.2106/00004623 197557020 00007
   Le Julie, 2015, Surg Neurol Int, V6, P26, DOI 10.4103/2152 7806.151393
   Liu YL, 2004, MODERN PATHOL, V17, P1129, DOI 10.1038/modpathol.3800162
   Lu ZH, 2011, BRIT J RADIOL, V84, pE206, DOI 10.1259/bjr/20601291
   Lüke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190
   Mahale M, 2013, J CLIN DIAGN RES, V7, P1197, DOI 10.7860/JCDR/2013/2725.3021
   Modkovski R, 2009, INTERNET J NEUROSURG, V7, P1
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   MOTOMOCHI M, 1985, SURG NEUROL, V23, P25, DOI 10.1016/0090 3019(85)90155 7
   NG HK, 1993, HISTOPATHOLOGY, V22, P113, DOI 10.1111/j.1365 2559.1993.tb00089.x
   Pallini R, 2009, ACTA NEUROCHIR, V151, P291, DOI 10.1007/s00701 009 0229 1
   Patibandla Mohana Rao, 2017, Asian J Neurosurg, V12, P78, DOI 10.4103/1793 5482.145112
   Pazzaglia L, 2010, HISTOPATHOLOGY, V57, P59, DOI 10.1111/j.1365 2559.2010.03597.x
   Picci P., 2014, Atlas of musculoskeletal tumors and tumorlike lesions: the Rizzoli case archive
   POTTER GD, 1970, CANCER AM CANCER SOC, V25, P167, DOI 10.1002/1097 0142(197001)25:1<167::AID CNCR2820250124>3.0.CO;2 P
   Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13
   Ralston SH, 2012, CALCIFIED TISSUE INT, V91, P97, DOI 10.1007/s00223 012 9599 0
   Righi A, 2017, HUM PATHOL, V68, P128, DOI 10.1016/j.humpath.2017.08.033
   Rosenberg AE, 1999, AM J SURG PATHOL, V23, P1370, DOI 10.1097/00000478 199911000 00007
   Roy S, 2013, EUR ARCH OTO RHINO L, V270, P1167, DOI 10.1007/s00405 012 2249 3
   홍상원, 2004, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V36, P324
   Sasagawa Y, 2012, CLIN NEUROL NEUROSUR, V114, P786, DOI 10.1016/j.clineuro.2011.12.041
   Shibao Shunsuke, 2015, Surg Neurol Int, V6, pS623, DOI 10.4103/2152 7806.170459
   Tamura R, 2016, J NEUROL SURG PART A, V77, P239, DOI 10.1055/s 0035 1554808
   Tang PH, 2017, OPHTHALMOL THER, V6, P215, DOI 10.1007/s40123 017 0081 y
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tsai Y F., 2000, CHIN J RADIOL, V25, P223
   Uslu GH, 2014, ONCOL LETT, V8, P151, DOI 10.3892/ol.2014.2086
   Venkatesh M D, 2012, Med J Armed Forces India, V68, P392, DOI 10.1016/j.mjafi.2012.06.004
   Weber AL, 1997, SKULL BASE SURG, V7, P163, DOI 10.1055/s 2008 1058592
   WILBUR AC, 1986, AM J NEURORADIOL, V7, P361
   Wülling M, 2001, J CANCER RES CLIN, V127, P467, DOI 10.1007/s004320100234
   YOSHIDA H, 1988, ACTA PATHOL JAPON, V38, P325
   Yu WYH, 2015, INT CANCER CONF J, V4, P181, DOI 10.1007/s13691 014 0195 1
   Zhao J, 2014, ONCOL LETT, V8, P2782, DOI 10.3892/ol.2014.2528
   Zorlu F, 2006, J NEURO ONCOL, V76, P149, DOI 10.1007/s11060 005 4343 5
NR 77
TC 13
Z9 14
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD APR 2
PY 2018
VL 18
AR 358
DI 10.1186/s12885 018 4291 z
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GC5JN
UT WOS:000429823500006
PM 29609578
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kazek Kesik, A
   Nosol, A
   Plonka, J
   Smiga Matuszowicz, M
   Golda Cepa, M
   Krok Borkowicz, M
   Brzychczy Wloch, M
   Pamula, E
   Simka, W
AF Kazek Kesik, Alicja
   Nosol, Agnieszka
   Plonka, Joanna
   Smiga Matuszowicz, Monika
   Golda Cepa, Monika
   Krok Borkowicz, Malgorzata
   Brzychczy Wloch, Monika
   Pamula, Elzbieta
   Simka, Wojciech
TI PLGA amoxicillin loaded layer formed on anodized Ti alloy as a hybrid
   material for dental implant applications
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Amoxicillin; Titanium alloy; Hybrid coatings; Bacteria;
   Cytocompatibility; Implant
ID PLASMA ELECTROLYTIC OXIDATION; CONTROLLED RELEASE; TITANIUM ALLOY;
   SURFACE; ACID); MICROSTRUCTURE; ANTIBACTERIAL; RESISTANCE; HYDROGELS;
   CORROSION
AB In this paper, the preparation of a functional hybrid coating loaded with a drug (amoxicillin) on a promising titanium alloy   Ti 15Mo alloy is presented. The titanium alloy surface was anodized in solution with bioactive compounds to obtain a porous oxide layer favorable for MG 63 osteoblast like cell adhesion. Then, a poly(lactide co glycolide) (PLGA) loaded with amoxicillin layer was formed using a dip coating technique to cover the oxide layer, without filling in all of the pores. The morphology of the surface was evaluated using scanning electron microscopy supported by 3D Roughness Reconstruction software. The surface treatment of the Ti 15Mo alloy surface caused the surface roughness to increase up to 1.71 mu m. The anodization process caused the Ti 15Mo alloy surface to become slightly more hydrophilic; however, the formation of the PLGA layer loaded with drug increased the contact angle to 96.5 degrees +/  2.2 degrees, respectively. After 4 weeks of polymer layer degradation, the registered signals on the H 1 NMR spectrum were identical to the signals registered for lactic acid (LAc), which confirms that the polymer layer was degraded within a short period of time. The concentration of drug released into the artificial saliva was investigated using high performance liquid chromatography (HPLC) up to 12 h of coatings immersion. During the first hour of coating degradation in artificial saliva, and the concentration of the drug (13 mu g/ml) was enough to inhibit bacterial growth of S. aureus and S. epidermidis. These results were confirmed by agar plate diffusion method and evaluation of the minimal inhibitory concentration (MIC). The cytocompatibility of the materials was determined using the osteoblast like cells MG 63, and the viability and cell morphology (live/dead staining) were also evaluated. The results showed that amoxicillin influences the osteoblast like MG 63 cells' behavior during cell culture, especially for the first few hours. The influence on the type of surface treatment on MG 63 cell behavior during 7 days of culture is discussed in this paper. To the best of our knowledge, this is the first time that a fast degrading layer with amoxicillin has been deposited on previously anodized Ti surface. The formation of functional coating may find application as a cytocompatible coating to prevent bacterial adhesion on long term implant surfaces.
C1 [Kazek Kesik, Alicja; Nosol, Agnieszka; Plonka, Joanna; Simka, Wojciech] Silesian Tech Univ, Fac Chem, B Krzywoustego St 6, PL 44100 Gliwice, Poland.
   [Smiga Matuszowicz, Monika] Silesian Tech Univ, Fac Chem, M Strzody 9 St, PL 44100 Gliwice, Poland.
   [Golda Cepa, Monika] Jagiellonian Univ, Fac Chem, Gronostajowa St 2, PL 30387 Krakow, Poland.
   [Krok Borkowicz, Malgorzata; Pamula, Elzbieta] AGH Univ Sci & Technol, Fac Mat Sci & Ceram, Mickiewicza Av 30, PL 30059 Krakow, Poland.
   [Brzychczy Wloch, Monika] Jagiellonian Univ, Dept Microbiol, Med Coll, Czysta 18 St, PL 31121 Krakow, Poland.
C3 Silesian University of Technology; Silesian University of Technology;
   Jagiellonian University; AGH University of Krakow; Jagiellonian
   University; Collegium Medicum Jagiellonian University
RP Kazek Kesik, A (通讯作者)，Silesian Tech Univ, Fac Chem, B Krzywoustego St 6, PL 44100 Gliwice, Poland.
EM alicja.kazek kesik@polsl.pl
RI Simka, Wojciech/AAW 9951 2020; Płonka, Joanna/S 7456 2018;
   Śmiga Matuszowicz, Monika/R 9838 2018; Kazek Kesik, Alicja/C 5610 2017;
   Golda Cepa, Monika/E 2860 2015; Smiga Matuszowicz, Monika/R 9838 2018;
   Plonka, Joanna/S 7456 2018; Pamula, Elzbieta/A 2813 2017; Pamuła,
   Elżbieta/A 2813 2017
OI Kazek Kesik, Alicja/0000 0001 9971 7279; Golda Cepa,
   Monika/0000 0001 9054 4682; Smiga Matuszowicz,
   Monika/0000 0003 4651 5619; Plonka, Joanna/0000 0002 2507 2508; Pamula,
   Elzbieta/0000 0002 0464 6189; Krok Borkowicz,
   Malgorzata/0000 0002 9415 0282; 
FU National Science Centre, Poland [UMO 2016/21/D/ST5/01652]
FX This work was supported by the National Science Centre, Poland
   (UMO 2016/21/D/ST5/01652).
CR Altinisik A, 2014, POLYM BULL, V71, P759, DOI 10.1007/s00289 013 1090 1
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169 409X(97)00048 3
   [Anonymous], 1999, Paediatr Child Health, V4, P321
   [Anonymous], J CONTROL RELEASE
   [Anonymous], 2017, The Egyptian Journal of Hospital Medicine
   Asri RIM, 2016, J MECH BEHAV BIOMED, V57, P95, DOI 10.1016/j.jmbbm.2015.11.031
   Babiarczuk B, 2016, SURF COAT TECH, V285, P134, DOI 10.1016/j.surfcoat.2015.11.030
   Baqain ZH, 2012, BRIT J ORAL MAX SURG, V50, P239, DOI 10.1016/j.bjoms.2011.04.074
   Brook I, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471 2334 9 202
   Cardea S, 2011, J SUPERCRIT FLUID, V59, P149, DOI 10.1016/j.supflu.2011.07.022
   Chen WZ, 2018, ACTA BIOMATER, V74, P489, DOI 10.1016/j.actbio.2018.04.043
   Choi JW, 2017, J ALLOY COMPD, V726, P930, DOI 10.1016/j.jallcom.2017.08.004
   Cipriano AaronF., 2013, Journal of Biomedical Nanotechnology, V9, P1, DOI DOI 10.1166/JBN.2013.1760
   Darband GB, 2017, J MAGNES ALLOY, V5, P74, DOI 10.1016/j.jma.2017.02.004
   Santis R, 2013, POLYM COMPOSITE, V34, P1413, DOI 10.1002/pc.22446
   Doadrio AL, 2015, INT J PHARMACEUT, V492, P207, DOI 10.1016/j.ijpharm.2015.07.046
   Duewelhenke N, 2007, ANTIMICROB AGENTS CH, V51, P54, DOI 10.1128/AAC.00729 05
   Geetha M, 2009, PROG MATER SCI, V54, P397, DOI 10.1016/j.pmatsci.2008.06.004
   Habazaki H, 2012, APPL SURF SCI, V259, P711, DOI 10.1016/j.apsusc.2012.07.104
   Han YQ, 2017, J ALLOY COMPD, V729, P1145, DOI 10.1016/j.jallcom.2017.09.267
   Jarosz M, 2016, COLLOID SURFACE B, V143, P447, DOI 10.1016/j.colsurfb.2016.03.073
   Kalita S, 2016, MAT SCI ENG C MATER, V61, P720, DOI 10.1016/j.msec.2015.12.078
   Karaji ZG, 2017, MAT SCI ENG C MATER, V76, P406, DOI 10.1016/j.msec.2017.03.079
   Kazek Kesik A, 2014, ARCH CIV MECH ENG, V14, P671, DOI 10.1016/j.acme.2013.10.008
   Kazek Kesik A, 2016, SURF COAT TECH, V302, P158, DOI 10.1016/j.surfcoat.2016.05.073
   Kazek Kesik A, 2015, SURF COAT TECH, V276, P59, DOI 10.1016/j.surfcoat.2015.06.034
   Kazek Kesik A, 2014, MAT SCI ENG C MATER, V39, P259, DOI 10.1016/j.msec.2014.03.008
   Khorasanian M, 2011, SURF COAT TECH, V206, P1495, DOI 10.1016/j.surfcoat.2011.09.038
   Liu HH, 2017, MAT SCI ENG A STRUCT, V704, P10, DOI 10.1016/j.msea.2017.07.078
   Lode HM, 2008, INT J ANTIMICROB AG, V32, P10, DOI 10.1016/j.ijantimicag.2008.02.004
   Makadia HK, 2011, POLYMERS BASEL, V3, P1377, DOI 10.3390/polym3031377
   Manam NS, 2017, J ALLOY COMPD, V701, P698, DOI 10.1016/j.jallcom.2017.01.196
   Melhus Å, 2004, CYTOKINE, V25, P254, DOI 10.1016/j.cyto.2003.11.009
   Nabavi HF, 2017, SURF COAT TECH, V322, P59, DOI 10.1016/j.surfcoat.2017.05.035
   Truc NT, 2018, SURF COAT TECH, V344, P664, DOI 10.1016/j.surfcoat.2018.03.038
   Pereira BL, 2018, J MECH BEHAV BIOMED, V77, P347, DOI 10.1016/j.jmbbm.2017.08.010
   Pritchard EM, 2013, ADV FUNCT MATER, V23, P854, DOI 10.1002/adfm.201201636
   Ribeiro Marta, 2012, Biomatter, V2, P176, DOI 10.4161/biom.22905
   Rodríguez Félix DE, 2012, POLYM BULL, V68, P197, DOI 10.1007/s00289 011 0549 1
   Shin KR, 2016, SURF ENG, V32, P418, DOI 10.1179/1743294415Y.0000000026
   Shirai T, 2011, ACTA BIOMATER, V7, P1928, DOI 10.1016/j.actbio.2010.11.036
   Snoddy B, 2016, MAT SCI ENG C MATER, V67, P822, DOI 10.1016/j.msec.2016.04.062
   Sood S, 2017, INT J BIOL MACROMOL, V101, P612, DOI 10.1016/j.ijbiomac.2017.03.103
   Spriano S, 2018, ACTA BIOMATER, V79, P1, DOI 10.1016/j.actbio.2018.08.013
   Tapia Albarran M, 2004, INT J PHARMACEUT, V273, P121, DOI 10.1016/j.ijpharm.2003.12.019
   Tatullo Marco, 2017, J Bone Jt Infect, V2, P84, DOI 10.7150/jbji.17507
   Weszl M, 2017, MAT SCI ENG C MATER, V78, P69, DOI 10.1016/j.msec.2017.04.032
   Zhao G, 2014, SURF COAT TECH, V251, P38, DOI 10.1016/j.surfcoat.2014.02.028
   Zheng FY, 2013, BIOMATERIALS, V34, P1402, DOI 10.1016/j.biomaterials.2012.10.071
   Zolnik BS, 2006, J CONTROL RELEASE, V112, P293, DOI 10.1016/j.jconrel.2006.02.015
NR 50
TC 53
Z9 56
U1 4
U2 72
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD JAN 1
PY 2019
VL 94
BP 998
EP 1008
DI 10.1016/j.msec.2018.10.049
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA HB8SF
UT WOS:000451360300099
PM 30423788
DA 2025 08 17
ER

PT J
AU Koivisto, K
   Kyllönen, E
   Haapea, M
   Niinimäki, J
   Sundqvist, K
   Pehkonen, T
   Seitsalo, S
   Tervonen, O
   Karppinen, J
AF Koivisto, Katri
   Kyllonen, Eero
   Haapea, Marianne
   Niinimaki, Jaakko
   Sundqvist, Kaj
   Pehkonen, Timo
   Seitsalo, Seppo
   Tervonen, Osmo
   Karppinen, Jaro
TI Efficacy of zoledronic acid for chronic low back pain associated with
   Modic changes in magnetic resonance imaging
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Low back pain; Magnetic resonance imaging; Modic changes; Randomized
   trial; Zoledronic acid
ID ACUTE PHASE RESPONSE; SIGNAL CHANGES; BONE EDEMA; END PLATES;
   BISPHOSPHONATES; CELLS; DISC; TYPE 1; MRI; PREVALENCE
AB Background: Modic changes (MC) are associated with low back pain (LBP), but effective treatments are lacking. The aim of this randomized, placebo controlled, double blinded trial was to evaluate the efficacy of zoledronic acid (ZA) for chronic LBP among patients with MC in magnetic resonance imaging (MRI).
   Methods: Inclusion criteria were LBP lasting >= 3 months, with an intensity of >= 6 on a 10 cm VAS or an Oswestry Disability Index (ODI) of >= 30%, and MC in MRI. Patients were randomized into single intravenous infusion of ZA 5 mg (n = 20), or placebo (n = 20) groups. The primary outcome was LBP intensity, secondary outcomes leg pain intensity, ODI, health related quality of life (RAND 36), lumbar flexibility, sick leaves and use of pain medication. The treatment differences at one month and one year were analysed using ANCOVA with adjustment for the baseline score.
   Results: The mean difference (MD) between the groups in the primary outcome, intensity of LBP, was 1.4 (95% confidence intervals (CI) 0.01 to 2.9) in favour of ZA at one month. We observed no significant between group difference in the intensity of LBP at one year (MD 0.7; 95% CI  1.0 to 2.4) or in secondary outcomes at any time point except that 20% of patients in the ZA group used non steroidal anti inflammatory drugs at one year compared to 60% in the placebo group (P = 0.022). Acute phase reactions (fever, flu like symptoms, arthralgia) emerged in 95% of the patients in the ZA group, compared to 35% in the placebo group.
   Conclusions: ZA was effective in reducing the intensity of LBP in the short term and in reducing the use of NSAIDs within the time span of one year among patients with chronic LBP and MC confirmed in MRI. Although the results seem encouraging, larger studies are required to analyse the effectiveness and safety of ZA for patients with MC.
C1 [Koivisto, Katri; Kyllonen, Eero; Sundqvist, Kaj; Karppinen, Jaro] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
   [Koivisto, Katri; Kyllonen, Eero; Sundqvist, Kaj; Karppinen, Jaro] Univ Oulu, Oulu, Finland.
   [Haapea, Marianne; Niinimaki, Jaakko; Tervonen, Osmo] Oulu Univ Hosp, Dept Diagnost Radiol, Inst Diagnost, Oulu, Finland.
   [Haapea, Marianne] Oulu Univ Hosp, Dept Psychiat, Oulu, Finland.
   [Pehkonen, Timo] Oulu Healthcare Ctr, Rehabilitat Unit, Oulu, Finland.
   [Seitsalo, Seppo] ORTON Orthopaed Hosp, Helsinki, Finland.
   [Karppinen, Jaro] Finnish Inst Occupat Hlth, Oulu, Finland.
   [Karppinen, Jaro] Finnish Inst Occupat Hlth, Disabil Prevent Ctr, Oulu, Finland.
   [Karppinen, Jaro] Univ Oulu, Dept Phys & Rehabil Med, Inst Clin Med, Oulu 90014, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; Finnish Institute of Occupational Health; Finnish Institute of
   Occupational Health; University of Oulu
RP Karppinen, J (通讯作者)，Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
EM jaro.karppinen@ttl.fi
RI ; Niinimäki, Jaakko/O 2186 2014; Haapea, Marianne/I 3291 2016
OI Karppinen, Jaro/0000 0002 2158 6042; Niinimaki,
   Jaakko/0000 0002 5591 3726; Haapea, Marianne/0000 0002 3989 9354
FU Novartis Pharma
FX Novartis Pharma provided investigational medications for the study, and
   supported the conduct of the trial (< 10 000$). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Albert HB, 2008, MED HYPOTHESES, V70, P361, DOI 10.1016/j.mehy.2007.05.014
   Albert HB, 2013, EUR SPINE J, V22, P690, DOI 10.1007/s00586 013 2674 z
   Albert HB, 2013, EUR SPINE J, V22, P697, DOI 10.1007/s00586 013 2675 y
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Braithwaite I, 1998, Eur Spine J, V7, P363, DOI 10.1007/s005860050091
   Buttermann Glenn R, 2004, Spine J, V4, P495, DOI 10.1016/j.spinee.2004.03.024
   Carbonare LD, 2010, DRUG HEALTHC PATIENT, V2, P121, DOI 10.2147/DHPS.S6285
   Carbone LD, 2004, ARTHRITIS RHEUM US, V50, P3516, DOI 10.1002/art.20627
   Nguyen C, 2011, ARTHRITIS RHEUM US, V63, P2828, DOI 10.1002/art.30443
   Cocco R, 1999, Boll Soc Ital Biol Sper, V75, P71
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Esposito P, 2006, NEUROCHIRURGIE, V52, P315, DOI 10.1016/S0028 3770(06)71225 5
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632 200011150 00017
   Fayad F, 2007, EUR SPINE J, V16, P925, DOI 10.1007/s00586 006 0301 y
   Hancock M, 2012, EUR SPINE J, V21, P240, DOI 10.1007/s00586 011 1955 7
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Jensen RK, 2012, EUR SPINE J, V21, P2271, DOI 10.1007/s00586 012 2309 9
   Jensen RK, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 22
   Jensen TS, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 81
   Jensen TS, 2008, EUR SPINE J, V17, P1407, DOI 10.1007/s00586 008 0770 2
   Kääpä E, 2012, SPINE, V37, P134, DOI 10.1097/BRS.0b013e3182188a90
   Keller A, 2012, EUR SPINE J, V21, P418, DOI 10.1007/s00586 011 1964 6
   Kjaer P, 2005, SPINE, V30, P1173, DOI 10.1097/01.brs.0000162396.97739.76
   Kuisma M, 2007, SPINE, V32, P1116, DOI 10.1097/01.brs.0000261561.12944.ff
   Kuisma M, 2006, SPINE, V31, P1714, DOI 10.1097/01.brs.0000224167.18483.14
   Kuisma M, 2009, SKELETAL RADIOL, V38, P141, DOI 10.1007/s00256 008 0590 9
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Maksymowych WP, 2001, J RHEUMATOL, V28, P144
   McQueen F, 2011, ANN RHEUM DIS, V70, P1091, DOI 10.1136/ard.2010.142539
   Mitra D, 2004, EUR RADIOL, V14, P1574, DOI 10.1007/s00330 004 2314 4
   MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678
   Ohtori S, 2006, SPINE, V31, P1026, DOI 10.1097/01.brs.0000215027.87102.7c
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Rossini M, 2012, J BONE MINER RES, V27, P227, DOI 10.1002/jbmr.521
   Siepe CJ, 2006, SPINE, V31, P1923, DOI 10.1097/01.brs.0000228780.06569.e8
   TOYONE T, 1994, J BONE JOINT SURG BR, V76B, P757, DOI 10.1302/0301 620X.76B5.8083266
   Tubach F, 2012, ARTHRIT CARE RES, V64, P1699, DOI 10.1002/acr.21747
   Vital JM, 2003, SPINE, V28, P715
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650 199206000 00002
   Wedderkopp N, 2009, ACTA RADIOL, V50, P65, DOI 10.1080/02841850802524485
   Wilkens P, 2013, SPINE, V38, P65, DOI 10.1097/BRS.0b013e318263bb7b
NR 44
TC 37
Z9 96
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAR 4
PY 2014
VL 15
AR 64
DI 10.1186/1471 2474 15 64
PG 9
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA AG1LJ
UT WOS:000335176400001
PM 24588905
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gupta, RR
   Achenie, LEK
AF Gupta, Rishi R.
   Achenie, Luke E. K.
TI A network model for gene regulation
SO COMPUTERS & CHEMICAL ENGINEERING
LA English
DT Article; Proceedings Paper
CT 7th World Congress of Chemical Engineering
CY JUL 10 14, 2005
CL Glasgow, SCOTLAND
DE microarray; Boolean algebra; network; time series; gene regulation
ID TRANSCRIPTIONAL PROGRAM; BACTERIOPHAGE LAMBDA; PHAGE LAMBDA; EXPRESSION;
   SIMULATION; PROTEINS; CLUSTER
AB Advances in microarray technology have resulted in an exponential rise in gene expression data. Partially as a result of this, full genome sequences have been reported for many organisms. In addition several methods have been developed (a) for assigning functionality to previously unknown genes and (b) for measuring the output (i.e. gene expression) of the gene regulatory network. The knowledge of the gene regulatory network further gives insights about gene pathways. This information leads to many potential applications in medicine and molecular biology, examples of which are identification of metabolic pathways, complex genetic diseases, drug discovery and toxicology analysis. Also, gene regulatory networks allow comparison of expression patterns of many uncharacterized genes; this comparison provides clues to gene function. A variety of models (such as neural networks, Boolean networks, and Bayesian) have been proposed in recent times. Although each of these models have individual strengths, none of them addresses important issues such as time delay, or make use of available biological information. In the work presented here we demonstrate that networks can efficiently model natural biological processes, specifically gene regulatory systems. Through the modeling approach, we have inferred gene regulatory networks using a time course data set for (a) lambda bacteriophage infection, (b) osteoblast study, and (c) rat central nervous system (CNS) development. The results compare favorably with experimental results from the literature. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.
C3 University of Connecticut
RP Gupta, RR (通讯作者)，Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.
EM rishi@engr.uconn.edu; achenie@engr.uconn.edu
CR Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   BROWNSTEIN MJ, 1998, FUNCTIONAL GENOMICS, P27
   Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699
   ColladoVides J, 1996, INTEGRATIVE APPROACHES TO MOLECULAR BIOLOGY, P179
   D'haeseleer P, 1999, Pac Symp Biocomput, P41
   D'haeseleer P, 2000, BIOINFORMATICS, V16, P707, DOI 10.1093/bioinformatics/16.8.707
   DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711 6716.1992
   DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680
   Dodd IB, 2005, CURR OPIN GENET DEV, V15, P145, DOI 10.1016/j.gde.2005.02.001
   ECHOLS H, 1976, GENETICS, V83, P5
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fields S, 1999, P NATL ACAD SCI USA, V96, P8825, DOI 10.1073/pnas.96.16.8825
   Garg S, 2003, BIOTECHNOL PROGR, V19, P1142, DOI 10.1021/bp025648p
   Gross C.A., 1996, ESCHERICHIA COLI SAL, V2nd
   GUPTA RR, 2006, UNPUB COMPUTATIONAL
   Hasty J, 2001, CHAOS, V11, P207, DOI 10.1063/1.1345702
   HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151
   Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83
   Kalajzic I, 2005, J BIOL CHEM, V280, P24618, DOI 10.1074/jbc.M413834200
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022 5193(69)90015 0
   Kiehl TR, 2004, BIOINFORMATICS, V20, P316, DOI 10.1093/bioinformatics/btg409
   Kobiler O, 2005, P NATL ACAD SCI USA, V102, P4470, DOI 10.1073/pnas.0500670102
   KOURILSKY P, 1973, MOL GEN GENET, V122, P183, DOI 10.1007/BF00435190
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   LOOMIS WF, 1995, SCIENCE, V269, P649, DOI 10.1126/science.7624792
   MARNELLOS G, 1998, PAC S BIOC, V5, P30
   MARNELLOS G, 2000, PAC S BIOC, V12, P329
   MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793
   McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168 9525(98)01659 X
   Narberhaus F, 1999, MOL MICROBIOL, V31, P1, DOI 10.1046/j.1365 2958.1999.01166.x
   Newton MA, 2004, BIOSTATISTICS, V5, P155, DOI 10.1093/biostatistics/5.2.155
   NOWAK R, 1995, SCIENCE, V270, P368, DOI 10.1126/science.270.5235.368
   Palsson BO, 1997, NAT BIOTECHNOL, V15, P3, DOI 10.1038/nbt0197 3
   Ptashne M., 1992, A genetic switch: phage l and higher organisms
   Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273
   STADEN R, 1984, NUCLEIC ACIDS RES, V12, P521, DOI 10.1093/nar/12.1Part2.521
   Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397 194
   Thieffry D, 1999, BIOESSAYS, V21, P895, DOI 10.1002/(SICI)1521 1878(199911)21:11<895::AID BIES1>3.0.CO;2 F
   Tian TH, 2004, J THEOR BIOL, V227, P229, DOI 10.1016/j.jtbi.2003.11.003
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Vohradsky J, 2001, FASEB J, V15, P846, DOI 10.1096/fj.00 0361com
   Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334
   Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369 5274(99)80027 7
   YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.micro.47.1.321
NR 45
TC 11
Z9 14
U1 0
U2 2
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0098 1354
EI 1873 4375
J9 COMPUT CHEM ENG
JI Comput. Chem. Eng.
PD AUG 15
PY 2007
VL 31
IS 8
BP 950
EP 961
DI 10.1016/j.compchemeng.2006.08.008
PG 12
WC Computer Science, Interdisciplinary Applications; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Computer Science; Engineering
GA 178LS
UT WOS:000247222800008
DA 2025 08 17
ER

PT J
AU Li, YS
   Wagner, ER
   Yan, ZJ
   Wang, ZL
   Luther, G
   Jiang, W
   Ye, JX
   Wei, Q
   Wang, J
   Zhao, LG
   Lu, S
   Wang, X
   Mohammed, MK
   Tang, SL
   Liu, H
   Fan, JM
   Zhang, FG
   Zou, YL
   Song, DZ
   Liao, JY
   Haydon, RC
   Luu, HH
   He, TC
AF Li, Yasha
   Wagner, Eric R.
   Yan, Zhengjian
   Wang, Zhonliang
   Luther, Gaurav
   Jiang, Wei
   Ye, Jixing
   Wei, Qiang
   Wang, Jing
   Zhao, Lianggong
   Lu, Shun
   Wang, Xin
   Mohammed, Maryam K.
   Tang, Shengli
   Liu, Hao
   Fan, Jiaming
   Zhang, Fugui
   Zou, Yulong
   Song, Dongzhe
   Liao, Junyi
   Haydon, Rex C.
   Luu, Hue H.
   He, Tong Chuan
TI The Calcium Binding Protein S100A6 Accelerates Human Osteosarcoma Growth
   by Promoting Cell Proliferation and Inhibiting Osteogenic
   Differentiation
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Osteosarcoma; Bone tumor; S100A6; Apoptosis; S100 proteins; BMP9;
   Osteoblastic differentiation; Mesenchymal stem cells
ID BONE MORPHOGENETIC PROTEINS; SUPPRESSES TUMOR GROWTH; STEM CELLS;
   OSTEO/ODONTOBLASTIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION;
   INCREASED EXPRESSION; METASTASIS; MIGRATION; CATENIN; CHEMOTHERAPY
AB Background/Aims: Although osteosarcoma (OS) is the most common primary malignancy of bone, its molecular pathogenesis remains to be fully understood. We previously found the calcium binding protein S100A6 was expressed in similar to 80% of the analyzed OS primary and/or metastatic tumor samples. Here, we investigate the role of S100A6 in OS growth and progression. Methods: S100A6 expression was assessed by qPCR and Western blotting. Overexpression or knockdown of S100A6 was carried out to determine S100A6's effect on proliferation, cell cycle, apoptosis, tumor growth, and osteogenic differentiation. Results: S100A6 expression was readily detected in human OS cell lines. Exogenous S100A6 expression promoted cell proliferation in vitro and tumor growth in an orthotopic xenograft model of human OS. S100A6 overexpression reduced the numbers of OS cells in G1 phase and increased viable cells under serum starvation condition. Conversely, silencing S100A6 expression induced the production of cleaved caspase 3, and increased early stage apoptosis. S100A6 knockdown increased osteogenic differentiation activity of mesenchymal stem cells, while S100A6 overexpression inhibited osteogenic differentiation. BMP9 induced bone formation was augmented by S100A6 knockdown. Conclusion: Our findings strongly suggest that S100A6 may promote OS cell proliferation and OS tumor growth at least in part by facilitating cell cycle progression, preventing apoptosis, and inhibiting osteogenic differentiation. Thus, it is conceivable that targeting S100A6 may be exploited as a novel anti OS therapy. (C) 2015 The Author(s) Published by S. Karger AG, Basel
C1 [Li, Yasha; Wang, Zhonliang; He, Tong Chuan] Chongqing Med Univ, Stem Cell Biol & Therapy Lab, Key Lab Child Dev & Disorders, Minist Educ,Childrens Hosp, Chongqing, Peoples R China.
   [Li, Yasha; Wagner, Eric R.; Yan, Zhengjian; Wang, Zhonliang; Luther, Gaurav; Jiang, Wei; Ye, Jixing; Wei, Qiang; Wang, Jing; Zhao, Lianggong; Lu, Shun; Wang, Xin; Mohammed, Maryam K.; Tang, Shengli; Liu, Hao; Fan, Jiaming; Zhang, Fugui; Zou, Yulong; Song, Dongzhe; Liao, Junyi; Haydon, Rex C.; Luu, Hue H.; He, Tong Chuan] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Orthopaed Surg & Rehabil Med, Chicago, IL 60637 USA.
   [Yan, Zhengjian; Wei, Qiang; Wang, Jing; Liu, Hao; Fan, Jiaming; Zhang, Fugui; Zou, Yulong; Liao, Junyi; He, Tong Chuan] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   [Yan, Zhengjian; Wei, Qiang; Wang, Jing; Liu, Hao; Fan, Jiaming; Zhang, Fugui; Zou, Yulong; Liao, Junyi; He, Tong Chuan] Chongqing Med Univ, Affiliated Hosp, Chongqing, Peoples R China.
   [Ye, Jixing] Chongqing Univ, Sch Bioengn, Chongqing 630044, Peoples R China.
   [Zhao, Lianggong] Lanzhou Univ, Dept Orthopaed Surg, Affiliated Hosp 2, Lanzhou 730000, Peoples R China.
   [Lu, Shun] Shandong Prov Hosp, Dept Orthopaed Surg, Jinan, Peoples R China.
   [Lu, Shun] Shandong Univ, Sch Med, Jinan 250100, Peoples R China.
   [Wang, Xin; Song, Dongzhe] Sichuan Univ, Dept Surg, West China Hosp, Chengdu 610064, Peoples R China.
   [Tang, Shengli] Wuhan Univ, Dept Surg, Zhongnan Hosp, Wuhan 430072, Peoples R China.
C3 Chongqing Medical University; University of Chicago; University of
   Chicago Medical Center; Chongqing Medical University; Chongqing Medical
   University; Chongqing University; Lanzhou University; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Shandong
   University; Sichuan University; Wuhan University
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, 5841 South Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM hluu@bsd.uchicago.edu; tche@bsd.uchicago.edu
RI Ye, Jixing/JAX 5357 2023; Wang, Qiang/B 3068 2012
OI Wagner, Eric/0000 0001 9241 5702; ZHANG, FUGUI/0000 0002 5298 2160
FU National Institutes of Health [AT004418, AR50142, AR054381]; Ministry of
   Science and Technology (MOST) of China [2011CB707900]; Howard Hughes
   Medical Institute Medical Research Fellowship; University of Chicago
   Core Facility Subsidy grant from the National Center for Advancing
   Translational Sciences (NCATS) of the National Institutes of Health [UL1
   TR000430]
FX The reported work was supported in part by research grants from the
   National Institutes of Health (AT004418, AR50142, AR054381 to TCH, RCH
   and HHL), and the 973 Program of Ministry of Science and Technology
   (MOST) of China (#2011CB707900 to TCH). MKM was a recipient of Howard
   Hughes Medical Institute Medical Research Fellowship. This work was also
   supported in part by The University of Chicago Core Facility Subsidy
   grant from the National Center for Advancing Translational Sciences
   (NCATS) of the National Institutes of Health through Grant UL1 TR000430.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ando Kosei, 2013, Cancers (Basel), V5, P591, DOI 10.3390/cancers5020591
   Basu Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028
   Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chen X, 2013, CELL PHYSIOL BIOCHEM, V32, P1083, DOI 10.1159/000354508
   Chen X, 2015, GENES DIS, V2, P96, DOI 10.1016/j.gendis.2014.12.001
   Chen X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121319
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113064
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Duan L, 2014, INT J ONCOL, V44, P781, DOI 10.3892/ijo.2013.2231
   Emberley ED, 2004, BIOCHEM CELL BIOL, V82, P508, DOI 10.1139/O04 052
   Fernandez Fernandez MR, 2008, PROTEIN SCI, V17, P1663, DOI 10.1110/ps.035527.108
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Gross SR, 2014, CELL MOL LIFE SCI, V71, P1551, DOI 10.1007/s00018 013 1400 7
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He T. C., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P363
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Hua Z, 2011, SURGERY, V149, P783, DOI 10.1016/j.surg.2010.12.007
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Hwang R, 2004, J BIOL CHEM, V279, P21239, DOI 10.1074/jbc.M312771200
   Ji YF, 2014, INT J MOL MED, V33, P769, DOI 10.3892/ijmm.2014.1633
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kilanczyk E, 2012, CELL CALCIUM, V51, P470, DOI 10.1016/j.ceca.2012.04.005
   Kuijjer ML, 2013, INT J CANCER, V133, P2512, DOI 10.1002/ijc.28124
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lesniak W, 2009, BIOCHEM BIOPH RES CO, V390, P1087, DOI 10.1016/j.bbrc.2009.10.150
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Li ZQ, 2014, J MOL MED, V92, P291, DOI 10.1007/s00109 013 1104 3
   Liu X, 2013, J CELL MOL MED, V17, P1160, DOI 10.1111/jcmm.12097
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luther GA, 2013, CANCER LETT, V336, P222, DOI 10.1016/j.canlet.2013.05.002
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Lyu XJ, 2015, ONCOTARGET, V6, P6656, DOI 10.18632/oncotarget.3169
   Lyu XJ, 2015, CELL BIOCHEM BIOPHYS, V71, P279, DOI 10.1007/s12013 014 0196 x
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Moore Drew D, 2014, Cancer Treat Res, V162, P65, DOI 10.1007/978 3 319 07323 1_4
   Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713
   Muramatsu Y, 1997, ONCOL REP, V4, P49
   Nataraj V, 2015, J SURG ONCOL, V112, P662, DOI 10.1002/jso.24045
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Rastegar F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014182
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165 4608(03)00105 5
   Santamaria Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195
   Sato Y, 2013, J GASTROEN HEPATOL, V28, P1422, DOI 10.1111/jgh.12247
   Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968 0004(96)80167 8
   Sleijfer S, 2014, CURR OPIN ONCOL, V26, P434, DOI 10.1097/CCO.0000000000000093
   Slomnicki LP, 2009, INT J BIOCHEM CELL B, V41, P784, DOI 10.1016/j.biocel.2008.08.007
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Tsoporis JN, 2008, J BIOL CHEM, V283, P30174, DOI 10.1074/jbc.M805318200
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093608
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang T, 2016, TUMOR BIOL, V37, P2299, DOI 10.1007/s13277 015 4057 z
   Wang XH, 2010, AM J PATHOL, V177, P586, DOI 10.2353/ajpath.2010.091217
   Wen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094397
   WETERMAN MAJ, 1992, CANCER RES, V52, P1291
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yamamoto N, 2013, EXPERT OPIN PHARMACO, V14, P2183, DOI 10.1517/14656566.2013.827171
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Yang YQ, 2007, J DIGEST DIS, V8, P186, DOI 10.1111/j.1751 2980.2007.00311.x
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang JL, 2014, DIGEST DIS SCI, V59, P2136, DOI 10.1007/s10620 014 3137 z
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhang YY, 2014, ONCOL REP, V32, P1013, DOI 10.3892/or.2014.3308
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhou WY, 2014, DISCOV MED, V17, P301
NR 98
TC 80
Z9 88
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 37
IS 6
BP 2375
EP 2392
DI 10.1159/000438591
PG 18
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA DA8RC
UT WOS:000368072800026
PM 26646427
OA gold
DA 2025 08 17
ER

PT J
AU Sophocleous, A
   Börjesson, AE
   Salter, DM
   Ralston, SH
AF Sophocleous, A.
   Boerjesson, A. E.
   Salter, D. M.
   Ralston, S. H.
TI The type 2 cannabinoid receptor regulates susceptibility to
   osteoarthritis in mice
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE CB2; Cnr2; Cannabinoids; Osteoarthritis; Cartilage; Mouse model
ID INDUCED BONE LOSS; ARTICULAR CHONDROCYTES; CB2; MASS; DIFFERENTIATION;
   EXPRESSION; OSTEOBLAST; AGONIST
AB Objective: Cannabinoid receptors and their ligands have been implicated in the regulation of various physiological processes but their role in osteoarthritis has not been investigated. The aim of this study was to evaluate the role of the type 2 cannabinoid receptor (Cnr2) in regulating susceptibility to osteoarthritis in mice.
   Methods: We analysed the severity of knee osteoarthritis as assessed by the Osteoarthritis Research Society International (OARSI) scoring system in mice with targeted deletion of Cnr2 (Cnr2( / )) and wild type (WT) littermates. Studies were conducted in mice subjected to surgical destabilisation of the medial meniscus (DMM) and in those with spontaneous age related osteoarthritis (OA).
   Results: Osteoarthritis was more severe following DMM in the medial compartment of the knee in Cnr2( / ) compared with WT mice (mean +/  sem score = 4.9 +/  0.5 vs 3.6 +/  0.3; P = 0.017). Treatment of WT mice with the CB2 selective agonist HU308 following DMM reduced the severity of OA in the whole joint (HU308 = 8.4 +/  0.2 vs vehicle = 10.4 +/  0.6; P = 0.007). Spontaneous age related osteoarthritis was also more severe in the medial compartment of the knee in 12 month old Cnr2( / ) mice compared with WT (5.6 +/  0.5 vs 3.5 +/  0.3, P = 0.008). Cultured articular chondrocytes from Cnr2( / ) mice produced less proteoglycans in vitro than wild type chondrocytes.
   Conclusion: These studies demonstrate that the Cnr2 pathway plays a role in the pathophysiology of osteoarthritis in mice and shows that pharmacological activation of CB2 has a protective effect. Further studies of the role of cannabinoid receptors in the pathogenesis of osteoarthritis in man are warranted. (C) 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Sophocleous, A.; Boerjesson, A. E.; Ralston, S. H.] Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, Rheumatol & Bone Dis Unit,Ctr Genom & Expt Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Salter, D. M.] Univ Edinburgh, MRC Inst Genet & Mol Med, Ctr Genom & Expt Med, Osteoarticular Res Grp, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh
RP Ralston, SH (通讯作者)，Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, Rheumatol & Bone Dis Unit,Ctr Genom & Expt Med, Edinburgh EH4 2XU, Midlothian, Scotland.
EM antonia.sophocleous@ed.ac.uk; anna.borjesson@igmm.ed.ac.uk;
   donald.salter@ed.ac.uk; stuart.ralston@ed.ac.uk
OI Sophocleous, Antonia/0000 0003 0854 1429; Tornqvist,
   Anna/0000 0003 2621 9038
FU Arthritis Research UK [17713]; Swedish Research Council [2013 455];
   Versus Arthritis [17713] Funding Source: researchfish
FX This research was funded by a programme grant to SHR from Arthritis
   Research UK (reference 17713). AEB was supported by a fellowship from
   the Swedish Research Council 2013 455.
CR Adolphe M, 1997, IN VITRO METHODS PHA, P182
   AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022 1759(94)90396 4
   Buckley NE, 2008, BRIT J PHARMACOL, V153, P309, DOI 10.1038/sj.bjp.0707527
   Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014 2999(00)00211 9
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Burston JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080440
   Dequeker J, 2008, ANN RHEUM DIS, V67, P5, DOI 10.1136/ard.2007.079764
   Dunn SL, 2012, FUTURE MED CHEM, V4, P713, DOI [10.4155/fmc.12.20, 10.4155/FMC.12.20]
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Glasson SS, 2007, CURR DRUG TARGETS, V8, P367, DOI 10.2174/138945007779940061
   Gui H, 2014, RHEUMATOLOGY, V53, P802, DOI 10.1093/rheumatology/ket447
   Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P285, DOI 10.1007/s00223 010 9378 8
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Inglis JJ, 2008, ARTHRITIS RHEUM US, V58, P3110, DOI 10.1002/art.23870
   Kim BJ, 2013, TISSUE ENG REGEN MED, V10, P211, DOI 10.1007/s13770 013 0008 1
   La Porta C, 2013, PAIN, V154, P160, DOI 10.1016/j.pain.2012.10.009
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897
   Mbvundula EC, 2006, J PHARM PHARMACOL, V58, P351, DOI 10.1211/jpp.58.3.0009
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004
   Review Manager (RevMan), 2014, REV MAN REVMAN
   Richardson D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2401
   Salvat C, 2005, OSTEOARTHR CARTILAGE, V13, P243, DOI 10.1016/j.joca.2004.11.008
   Sophocleous A, 2014, CALCIFIED TISSUE INT, V94, P423, DOI 10.1007/s00223 013 9823 6
   Sophocleous A, 2011, ENDOCRINOLOGY, V152, P2141, DOI 10.1210/en.2010 0930
   Sumariwalla PF, 2004, ARTHRITIS RHEUM US, V50, P985, DOI 10.1002/art.20050
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Yao BB, 2008, BRIT J PHARMACOL, V153, P390, DOI 10.1038/sj.bjp.0707568
NR 35
TC 46
Z9 50
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD SEP
PY 2015
VL 23
IS 9
BP 1586
EP 1594
DI 10.1016/j.joca.2015.04.020
PG 9
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA CQ5ON
UT WOS:000360655000017
PM 25937028
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Fierabracci, A
AF Fierabracci, Alessandra
TI The putative role of proteolytic pathways in the pathogenesis of Type 1
   diabetes mellitus: The 'autophagy' hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
ID GENOME WIDE ASSOCIATION; ANKYLOSING SPONDYLITIS; AUTOIMMUNITY; GENE;
   EXPRESSION; MECHANISM; IMMUNE; ERAP1; LOCI
AB Autoimmune diseases are a heterogeneous group of disorders affecting different organs and tissues. New tools, such as genome wide association studies, have provided evidence for new susceptibility loci and candidate genes in the disease process including common susceptibility genes involved in the immunological synapse and T cell activation. Close linkages have been found in a number of diseases, including ankylosing spondylitis, multiple sclerosis, Crohn's disease and insulin dependent diabetes mellitus (Type 1 diabetes mellitus). Evidence for some association with Type I diabetes was previously found in the region containing 5q15/ERAP1 (endoplasmic reticulum aminopeptidase 1) (rs30187, ARTS1).
   Recent data suggest that in eukaryotic cells in addition to the ubiquitin/proteasome system another proteolytic pathway may have a significant role in the autoimmunity process, i.e. the autophagic pathway which constitutes the principal regulated catabolic process mediated by lysosomes. Autophagy could play a role in MHC class I and class II self antigen presentation at the basis of the autoimmunity process. Furthermore cross talk among different proteolytic pathways was recently highlighted i.e. components processed in the ubiquitin/proteasome system possibly engaged in autophagic pathways.
   T1D is an autoimmune disease characterised by the destruction of pancreatic beta cells by autoreactive T cells. Immunological abnormalities can precede months to years the initial symptoms and clinical diagnosis. Our hypothesis suggests that in the autoimmune process autophagy can intervene at different levels, during the thymic selection process of T lymphocytes causing escape of autoreactive T cells, at the initiation stage of the disease, in the preclinical period or subsequently to the disease onset having a role at the level of perpetuation of the autoimmunity process.
   Supporting evidence derives from the already reported discovery of polymorphisms in autophagy related genes in patients affected by several autoimmune conditions such as Systemic Lupus Erithematosus. In addition deregulated autophagy was detected in T cells from lupus prone mice and also found in T cells from patients. Autophagy was found activated in osteoclasts from RA patients as demonstrated by the increased expression of Atg7 and Beclin 1.
   Our hypothesis to be unraveled could have, if correct, relevant implications for the management of autoimmune conditions such as Type 1 diabetes. In principle, novel therapeutic approaches could be established by targeting deregulated autophagy offering novel opportunities to personalized medicine in patients affected by the disease. (C) 2014 Elsevier Ltd. All rights reserved.
C1 Bambino Gesu Childrens Hosp IRCCS, Autoimmun Lab, Immunol Area, I 00165 Rome, Italy.
C3 IRCCS Bambino Gesu
RP Fierabracci, A (通讯作者)，Bambino Gesu Childrens Hosp IRCCS, Autoimmun Lab, Immunol Area, Piazza S Onofrio 4, I 00165 Rome, Italy.
EM alessandra.fierabracci@opbg.net
RI Fierabracci, Alessandra/K 5930 2016
OI Fierabracci, Alessandra/0000 0003 3078 9754
FU Italian Ministry of Health
FX This study was supported by the Italian Ministry of Health.
CR Aichinger M, 2013, J EXP MED, V210, P287, DOI 10.1084/jem.20122149
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Bluestone JA, 2010, NATURE, V464, P1293, DOI 10.1038/nature08933
   Bottazzo GF, 2004, ACTA PAEDIATR, V93, P38, DOI 10.0180/08035320310021237
   Dittmar M, 2010, THYROID, V20, P737, DOI 10.1089/thy.2010.1639
   Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873
   Fierabracci A, 2009, CURR MOL MED, V9, P1024, DOI 10.2174/156652409789839134
   Fierabracci A, 2012, AUTOIMMUN REV, V12, P281, DOI 10.1016/j.autrev.2012.04.007
   Fierabracci A, 2011, CURR PHARM DESIGN, V17, P3094, DOI 10.2174/138161211798157586
   Fujitani Y, 2009, ISLETS, V1, P151, DOI 10.4161/isl.1.2.9057
   Fung EYMG, 2009, GENES IMMUN, V10, P188, DOI 10.1038/gene.2008.99
   Garg G, 2012, J IMMUNOL, V188, P4644, DOI 10.4049/jimmunol.1100272
   Gianchecchi E., 2013, Health, V5, P2150, DOI 10.4236/health.2013.512293
   Gianchecchi E., 2013, Auto immun. Rev
   Gianchecchi E, 2013, AUTOIMMUN REV, V12, P717, DOI 10.1016/j.autrev.2012.12.003
   Gregersen PK, 2012, CURR OPIN IMMUNOL, V24, P538, DOI 10.1016/j.coi.2012.09.003
   Gros F, 2012, AUTOPHAGY, V8, P1113, DOI 10.4161/auto.20275
   Guerini FR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029931
   Hughes AL, 1998, ANNU REV GENET, V32, P415, DOI 10.1146/annurev.genet.32.1.415
   Kovacs JR, 2012, CELL DEATH DIFFER, V19, P144, DOI 10.1038/cdd.2011.78
   Lam Tse WK, 2002, SPRINGER SEMIN IMMUN, V24, P297, DOI 10.1007/s00281 002 0110 2
   Lapaquette P, 2012, J MOL MED, V90, P987, DOI 10.1007/s00109 012 0934 8
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084
   Palma A, 2013, GENOMICS, V102, P163, DOI 10.1016/j.ygeno.2013.04.016
   Park C, 2013, CELL BIOCHEM BIOPHYS, V67, P3, DOI 10.1007/s12013 013 9623 7
   Pedersen OB, 2008, SCAND J RHEUMATOL, V37, P120, DOI 10.1080/03009740701824613
   Pierdominici M, 2012, FASEB J, V26, P1400, DOI 10.1096/fj.11 194175
   Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513
   Santiago JL, 2008, DIABETOLOGIA, V51, P1653, DOI 10.1007/s00125 008 1070 4
   Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208
   Shapira Y, 2010, J AUTOIMMUN, V34, pJ168, DOI 10.1016/j.jaut.2009.11.018
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   Tykocinski LO, 2010, P NATL ACAD SCI USA, V107, P19426, DOI 10.1073/pnas.1009265107
   Villaseñor J, 2008, P NATL ACAD SCI USA, V105, P15854, DOI 10.1073/pnas.0808069105
   Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573
   Zhou XJ, 2011, ANN RHEUM DIS, V70, P1330, DOI 10.1136/ard.2010.140111
NR 37
TC 15
Z9 19
U1 0
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAY
PY 2014
VL 82
IS 5
BP 553
EP 557
DI 10.1016/j.mehy.2014.02.010
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AG0KT
UT WOS:000335105100009
PM 24582332
DA 2025 08 17
ER

PT J
AU Kozhevnikov, E
   Qiao, SP
   Han, FT
   Yan, W
   Zhao, YF
   Hou, XL
   Acharya, A
   Shen, YJ
   Tian, H
   Zhang, HJ
   Chen, XB
   Zheng, YC
   Yan, HJ
   Guo, M
   Tian, WM
AF Kozhevnikov, Evgeny
   Qiao, Shupei
   Han, Fengtong
   Yan, Wei
   Zhao, Yufang
   Hou, Xiaolu
   Acharya, Alaka
   Shen, Yijun
   Tian, Hui
   Zhang, Haijiao
   Chen, Xiongbiao
   Zheng, Yuanchuan
   Yan, Hongji
   Guo, Mian
   Tian, Weiming
TI A dual transduction integrated biosensing system to examine the 3D
   cell culture for bone regeneration
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Electrical impedance; Fluorescence imaging; Bone regeneration
ID IMPEDANCE; DESIGN
AB Three dimensional (3D) cell cultures developed with living cells and scaffolds have demonstrated outstanding potential for tissue engineering and regenerative medicine applications. However, no suitable tools are available to monitor dynamically variable cell behavior in such a complex microenvironment. In particular, simultaneously assessing cell behavior, cell secretion, and the general state of a 3D culture system is of a really challenging task. This paper presents our development of a dual transduction integrated biosensing system that assesses electrical impedance in conjunction with imaging techniques to simultaneously investigate the 3D cell culture for bone regeneration. First, we created models to mimic the dynamic deposition of the extracellular matrix (ECM) in 3D culture, which underwent osteogenesis by incorporating different amounts of bone ECM components (collagen, hydroxyapatite [HAp], and hyaluronic acid [HA]) into alginate based hydrogels. The formed models were investigated by means of electrical impedance spectroscopy (EIS), with the results showing that the impedances increased linearly with collagen and hyaluronan, but changed in a more complex manner with HAp. Thereafter, we created two models that consisted of primary osteoblast cells (OBs), which expressed the enhanced green fluorescent protein (EGFP), and 4T1 cells, which secreted the EGFP HA, in the alginate hydrogel. We found the capacitance (associated with impedance and measured by EIS) increased with the increases in initial embedded OBs, and also confirmed the cell proliferation over 3 days with the EGFP signal as monitored by the fluorescent imaging component in our system. Interestingly, the change in capacitance is found to be associated with OB migration following stimulation. Also, we show higher capacitance in 4T1 cells that secret HA when compared to control 4T1 cells after a 3 day culture. Taken together, we demonstrate that our biosensing system is able to investigate the dynamic process of 3D culture in a non invasive and real time manner.
C1 [Kozhevnikov, Evgeny; Qiao, Shupei; Han, Fengtong; Zhao, Yufang; Hou, Xiaolu; Acharya, Alaka; Shen, Yijun; Tian, Hui; Zhang, Haijiao; Tian, Weiming] Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Heilongjiang, Peoples R China.
   [Yan, Wei] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China.
   [Chen, Xiongbiao] Univ Saskatchewan, Dept Mech Engn, Saskatoon, SK, Canada.
   [Zheng, Yuanchuan] Harbin Inst Technol, Sch Chem & Chem Engn, Harbin, Heilongjiang, Peoples R China.
   [Yan, Hongji] KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Div Glycosci, Dept Chem, Stockholm, Sweden.
   [Guo, Mian] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Institute of Technology; Harbin Medical University; University of
   Saskatchewan; Harbin Institute of Technology; Royal Institute of
   Technology; Harbin Medical University
RP Tian, WM (通讯作者)，Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Heilongjiang, Peoples R China.; Guo, M (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Heilongjiang, Peoples R China.
EM guomian@hrbmu.edu.cn; tianweiming@hit.edu.cn
RI Tian, Weiming/AGY 1338 2022; Yan, Hongji/AAL 7040 2021
OI Tian, Weiming/0000 0003 4958 4118; Chen, Xiongbiao
   (Daniel)/0000 0002 4716 549X; Qiao, Shupei/0000 0002 4555 7190; Acharya,
   Alaka/0000 0003 4701 3346; /0000 0001 7257 5522; 
FU National Natural Science Foundation of China [51773050, 21407036,
   81773161, 81572472]; Natural Science Foundation of Heilongjiang Province
   of China [B2015005]; Natural Science and Engineering Research Council of
   Canada
FX Research is supported by National Natural Science Foundation of China
   (grants 51773050, 21407036, 81773161, 81572472), Natural Science
   Foundation of Heilongjiang Province of China (No. B2015005), Natural
   Science and Engineering Research Council of Canada.
CR Alford AI, 2015, INT J BIOCHEM CELL B, V65, P20, DOI 10.1016/j.biocel.2015.05.008
   [Anonymous], 1995, HDB BIOL EFFECTS ELE
   Arias LR, 2010, BIOSENS BIOELECTRON, V25, P2225, DOI 10.1016/j.bios.2010.02.029
   Arndt S, 2004, BIOSENS BIOELECTRON, V19, P583, DOI 10.1016/S0956 5663(03)00269 0
   Currey J. D., 2013, BONES STRUCTURE MECH
   Danikas D, 2002, PLAST RECONSTR SURG, V110, P1612, DOI 10.1097/00006534 200211000 00057
   Doblare Manuel, 2003, Acta Cientifica Venezolana, V54, P58
   Jeong SH, 2012, BIOSENS BIOELECTRON, V35, P128, DOI 10.1016/j.bios.2012.02.039
   Kozhevnikov E, 2016, J MATER CHEM B, V4, P2757, DOI 10.1039/c5tb02707a
   Lee EJ, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475 925X 13 142
   Lee SM, 2016, BIOSENS BIOELECTRON, V77, P56, DOI 10.1016/j.bios.2015.09.005
   Saffitz JE, 2004, CIRC RES, V94, P585, DOI 10.1161/01.RES.0000121575.34653.50
   Yan HJ, 2018, BIOMATERIALS, V161, P190, DOI 10.1016/j.biomaterials.2018.01.041
   Zhang N, 2018, BIOSENS BIOELECTRON, V112, P149, DOI 10.1016/j.bios.2018.04.037
NR 14
TC 11
Z9 12
U1 0
U2 69
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956 5663
EI 1873 4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD SEP 15
PY 2019
VL 141
AR 111481
DI 10.1016/j.bios.2019.111481
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology   Other Topics
GA IY1DW
UT WOS:000486132800070
PM 31260904
DA 2025 08 17
ER

PT J
AU Ho, YT
   Shimbo, T
   Wijaya, E
   Ouchi, Y
   Takaki, E
   Yamamoto, R
   Kikuchi, Y
   Kaneda, Y
   Tamai, K
AF Ho, Yen Ting
   Shimbo, Takashi
   Wijaya, Edward
   Ouchi, Yuya
   Takaki, Eiichi
   Yamamoto, Ryoma
   Kikuchi, Yasushi
   Kaneda, Yasufumi
   Tamai, Katsuto
TI Chromatin accessibility identifies diversity in mesenchymal stem cells
   from different tissue origins
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STROMAL CELLS; RNA SEQ; LANDSCAPE; ELEMENTS; MARROW; LUNG
AB Mesenchymal stem cells (MSCs), which can differentiate into tri lineage (osteoblast, adipocyte, and chondrocyte) and suppress inflammation, are promising tools for regenerative medicine. MSCs are phenotypically diverse based on their tissue origins. However, the mechanisms underlying cell typespecific gene expression patterns are not fully understood due to the lack of suitable strategy to identify the diversity. In this study, we investigated gene expression programs and chromatin accessibilities of MSCs by whole transcriptome RNA seq analysis and an assay for transposase accessible chromatin using sequencing (ATAC seq). We isolated MSCs from four tissues (femoral and vertebral bone marrow, adipose tissue, and lung) and analysed their molecular signatures. RNA seq identified the expression of MSC markers and both RNA seq and ATAC seq successfully clustered the MSCs based on their tissue origins. Interestingly, clustering based on tissue origin was more accurate with chromatin accessibility signatures than with transcriptome profiles. Furthermore, we identified transcription factors potentially involved in establishing cell type specific chromatin structures. Thus, epigenome analysis is useful to analyse MSC identity and can be utilized to characterize these cells for clinical use.
C1 [Ho, Yen Ting; Shimbo, Takashi; Wijaya, Edward; Ouchi, Yuya; Takaki, Eiichi; Yamamoto, Ryoma; Kikuchi, Yasushi; Tamai, Katsuto] Osaka Univ, Grad Sch Med, Dept Stem Cell Therapy Sci, Suita, Osaka, Japan.
   [Wijaya, Edward; Ouchi, Yuya; Takaki, Eiichi; Yamamoto, Ryoma] StemRIM Co Ltd, Ibaraki, Osaka, Japan.
   [Kaneda, Yasufumi] Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Suita, Osaka, Japan.
C3 University of Osaka; University of Osaka
RP Shimbo, T; Tamai, K (通讯作者)，Osaka Univ, Grad Sch Med, Dept Stem Cell Therapy Sci, Suita, Osaka, Japan.
EM shimbot@sts.med.osaka u.ac.jp; tamai@gts.med.osaka u.ac.jp
RI ; Edward, Wijaya/G 6209 2013; Tamai, Keiichi/AAQ 9358 2020
OI Wijaya, Edward/0000 0002 1234 0761; Ho, Yen Ting/0000 0002 1687 3995; 
FU AMED [JP18bk0104055, JP18lm0203018]; JSPS KAKENHI [JP16H05369]
FX We thank for Machika Kawamura for helpful comments on the manuscript.
   This study was supported by AMED under Grant Number JP18bk0104055 and
   JP18lm0203018, and JSPS KAKENHI Grant Number JP16H05369.
CR Bakopoulou A, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0705 0
   Bao XM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0840 9
   Bonev B, 2016, NAT REV GENET, V17, P661, DOI 10.1038/nrg.2016.112
   Bortolotti F, 2015, STEM CELL REP, V4, P332, DOI 10.1016/j.stemcr.2015.01.001
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/nmeth.2688, 10.1038/NMETH.2688]
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chen FX, 2018, NAT REV MOL CELL BIO, V19, P464, DOI 10.1038/s41580 018 0010 5
   Cho KA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16788 2
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097 2765(02)00459 8
   Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646
   Davie K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004994
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Foronjy Robert F, 2012, Cells, V1, P874
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Ghazanfari R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09449 x
   Gonzalez Blas C. B., 2018, 370346 BIORXIV
   Hansen KD, 2012, BIOSTATISTICS, V13, P204, DOI 10.1093/biostatistics/kxr054
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Hayashi T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02866 0
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Huang W, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 1
   Introna Martino, 2015, Curr Opin Organ Transplant, V20, P72, DOI 10.1097/MOT.0000000000000158
   Kelsey G, 2017, SCIENCE, V358, P69, DOI 10.1126/science.aan6826
   Khan A, 2018, NUCLEIC ACIDS RES, V46, pD260, DOI [10.1093/nar/gkx1126, 10.1093/nar/gkx1188]
   Kwon A, 2016, SCI REP UK, V6, DOI 10.1038/srep23544
   Lama VN, 2007, J CLIN INVEST, V117, P989, DOI 10.1172/JCI29713
   Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r25
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140 6736(08)60690 X
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681
   Mo MH, 2016, CELL MOL LIFE SCI, V73, P3311, DOI 10.1007/s00018 016 2229 7
   Moon GJ, 2018, CELL TRANSPLANT, V27, P485, DOI 10.1177/0963689718755404
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Olsson A, 2016, NATURE, V537, P698, DOI 10.1038/nature19348
   Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006
   PROCKOP DJ, 1997, SCIENCE, V276, P71, DOI [DOI 10.1126/SCIENCE.276.5309.71, 10.1126/science.276.5309.71]
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Schep AN, 2017, NAT METHODS, V14, P975, DOI [10.1038/NMETH.4401, 10.1038/nmeth.4401]
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sood R, 2017, BLOOD, V129, P2070, DOI 10.1182/blood 2016 10 687830
   Su YJ, 2017, NAT NEUROSCI, V20, P476, DOI 10.1038/nn.4494
   Summer R, 2007, AM J RESP CELL MOL, V37, P152, DOI 10.1165/rcmb.2006 0386OC
   Tamai K, 2011, P NATL ACAD SCI USA, V108, P6609, DOI 10.1073/pnas.1016753108
   Nora CCV, 2012, STEM CELLS DEV, V21, P1761, DOI 10.1089/scd.2011.0030
   Weng JY, 2010, BONE MARROW TRANSPL, V45, P1732, DOI 10.1038/bmt.2010.195
   Wislet Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004 0149
   Wu JJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0437 6
   Yamamoto N, 2007, J DERMATOL SCI, V48, P43, DOI 10.1016/j.jdermsci.2007.05.015
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
NR 50
TC 27
Z9 31
U1 0
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 10
PY 2018
VL 8
AR 17765
DI 10.1038/s41598 018 36057 0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HD6RP
UT WOS:000452673800014
PM 30531792
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lomashvili, KA
   Manning, KE
   Weitzmann, MN
   Nelea, V
   McKee, MD
   O'Neill, WC
AF Lomashvili, Koba A.
   Manning, Kelly E.
   Weitzmann, M. Neale
   Nelea, Valentin
   McKee, Marc D.
   O'Neill, W. Charles
TI Persistence of Vascular Calcification after Reversal of Uremia
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID GENERALIZED ARTERIAL CALCIFICATION; MEDIAL ELASTOCALCINOSIS;
   CARBONIC ANHYDRASE; ETIDRONATE THERAPY; VITAMIN D; REGRESSION; INFANCY;
   RATS; PHOSPHATE; SURVIVAL
AB The extent to which vascular calcification is reversible and the possible mechanisms are unclear. To address this, calcified aortas from uremic mice were transplanted orthotopically into normal mice, and the calcium content, histology, and minerals of the allografts were compared with the nontransplanted donor aorta. Calcium content decreased immediately after transplantation but remained constant thereafter, with 68%+/  12% remaining after 34 weeks. X ray diffraction showed the presence of apatite in both donor aortas and allografts. Osteoclasts were absent in the allografts and there was no expression of the macrophage marker CD11b, the osteoclast marker tartrate resistant acid phosphatase, or carbonic anhydrase II. The initial loss of calcium was Less in heavily calcified aortas and was associated with an increase in the Ca/P ratio from 1.49 to 1.63, consistent with a Loss of nonapatitic calcium. The results indicate that vascular calcification persists after reversal of uremia, because of a lack of active resorption of apatite. This failure to resorb established calcifications may contribute to the severity of vascular calcification and suggests that therapy should be aimed at prevention.
C1 [Lomashvili, Koba A.; Manning, Kelly E.; O'Neill, W. Charles] Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol & Metab, Dept Med, Atlanta, GA USA.
   [Weitzmann, M. Neale] Atlanta Dept Vet Affairs Med Ctr, Decatur, GA USA.
   [Nelea, Valentin; McKee, Marc D.] McGill Univ, Fac Dent, Montreal, PQ, Canada.
   [McKee, Marc D.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada.
C3 Emory University; Emory University; McGill University; McGill University
EM woneill@emory.edu
RI McKee, Marc/E 2187 2011
OI McKee, Marc D/0000 0001 8349 965X; Manning, Kelly/0000 0002 6262 1190
FU NIH [K08 DK079176]
FX Supported by NIH grant K08 DK079176 (K.A.L.).
CR Abedi SA, 2009, TRANSPL P, V41, P2829, DOI 10.1016/j.transproceed.2009.07.037
   Abou Hassan N, 2012, CLIN J AM SOC NEPHRO, V7, P275, DOI 10.2215/CJN.06490711
   Bas A, 2006, J BONE MINER RES, V21, P484, DOI 10.1359/JBMR.051211
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Chowdhury UK, 2004, ANN THORAC SURG, V78, P1614, DOI 10.1016/j.athoracsur.2004.03.105
   Ciana G, 2006, EUR J PEDIATR, V165, P258, DOI 10.1007/s00431 005 0035 6
   Cogan EB, 1999, ANAL BIOCHEM, V271, P29, DOI 10.1006/abio.1999.4100
   Essalihi R, 2005, CIRCULATION, V112, P1628, DOI 10.1161/CIRCULATIONAHA.104.528984
   EVERHART JE, 1988, DIABETOLOGIA, V31, P16
   Ferreira CR, 2016, AM J MED GENET A, V170, P1308, DOI 10.1002/ajmg.a.37574
   Han KH, 2015, VASC MED, V20, P527, DOI 10.1177/1358863X15597076
   Iribarren C, 2004, J WOMENS HEALTH, V13, P381, DOI 10.1089/154099904323087060
   JOHNSSON MSA, 1992, CRIT REV ORAL BIOL M, V3, P61, DOI 10.1177/10454411920030010601
   LEGEROS RZ, 1973, CALC TISS RES, V13, P173, DOI 10.1007/BF02015408
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   Lomashvili KA, 2004, J AM SOC NEPHROL, V15, P1392, DOI 10.1097/01.ASN.0000128955.83129.9C
   Lomashvili KA, 2014, KIDNEY INT, V85, P1351, DOI 10.1038/ki.2013.521
   Lomashvili KA, 2014, ARTERIOSCL THROM VAS, V34, P146, DOI 10.1161/ATVBAHA.113.302525
   Lopez I, 2009, AM J PHYSIOL RENAL, V296, pF1376, DOI 10.1152/ajprenal.90737.2008
   Maréchal C, 2012, AM J KIDNEY DIS, V59, P258, DOI 10.1053/j.ajkd.2011.07.019
   MARROTT PK, 1984, PEDIATR CARDIOL, V5, P119, DOI 10.1007/BF02424963
   Mathew S, 2007, J AM SOC NEPHROL, V18, P122, DOI 10.1681/ASN.2006050490
   Miyai Kentaro, 2015, Bone Rep, V3, P57, DOI 10.1016/j.bonr.2015.09.001
   Moe SM, 2004, NEPHROL DIAL TRANSPL, V19, P2387, DOI 10.1093/ndt/gfh303
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Nakamura S, 2009, CLIN J AM SOC NEPHRO, V4, P1892, DOI 10.2215/CJN.04320709
   Neuman WilliamF., 1958, The Chemical Dynamics of Bone Mineral
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   O'Neill WC, 2007, KIDNEY INT, V71, P282, DOI 10.1038/sj.ki.5002119
   Otero JE, 2013, J BONE MINER RES, V28, P419, DOI 10.1002/jbmr.1752
   Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002 9440(10)63996 X
   Schurgers LJ, 2007, BLOOD, V109, P2823, DOI 10.1182/blood 2006 07 035345
   SHOLLER GF, 1984, J PEDIATR US, V105, P257, DOI 10.1016/S0022 3476(84)80123 7
   Shuvy M, 2008, CARDIOVASC RES, V79, P492, DOI 10.1093/cvr/cvn088
   SPICER SS, 1989, AM J PATHOL, V134, P947
   VERBERCKMOES R, 1975, ANN INTERN MED, V82, P529, DOI 10.7326/0003 4819 82 4 529
   Verberckmoes SC, 2007, KIDNEY INT, V71, P298, DOI 10.1038/sj.ki.5002028
NR 37
TC 10
Z9 10
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2017
VL 187
IS 2
BP 332
EP 338
DI 10.1016/j.ajpath.2016.10.006
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA EI5XQ
UT WOS:000392570000010
PM 27939134
OA Green Published
DA 2025 08 17
ER

PT J
AU Pan, KH
   Lu, YY
   Cao, DN
   Peng, J
   Zhang, YQ
   Li, XM
AF Pan, Kaihua
   Lu, Yuanyuan
   Cao, Daning
   Peng, Jiang
   Zhang, Yunqing
   Li, Xiaoming
TI Long Non coding RNA SNHG1 Suppresses the Osteogenic Differentiation of
   Bone Marrow Mesenchymal Stem Cells by Binding with HMGB1
SO BIOCHEMICAL GENETICS
LA English
DT Article
DE Osteogenic differentiation; SNHG1; Pyroptosis; Osteoporosis; HMGB1
ID OSTEOPOROSIS
AB Osteoporosis (OP) has a significant detrimental impact on the health of the elder. Long term clinical effectiveness of current drugs used for OP treatment is limited. Therefore, it is very important to explore novel treatment targets for OP. The expression of SNHG1, HMGB1, OCN and OPN in gene level was measured using RT qPCR, and the protein expression was determined by Western blotting assay. The concentration of IL 1 beta and IL 18 in supernatant of the bone marrow mesenchymal stem cells (BMSCs) was measured by ELISA. The interaction between SNHG1 and HMGB1 was confirmed by RNA pull down. Besides, alizarin red staining was performed to evaluate the differentiation of BMSCs into osteoblast. SNHG1 and HMGB1 were found to be upregulated in the serum of OP patients. During the osteogenic differentiation of BMSCs, the expression of osteoblastogenesis markers (OCN and OPN) and the activity of ALP were upregulated, while the expression levels of SNHG1 and HMGB1 were decreased in a time dependent manner. In addition, the interaction between SNHG1 and HMGB1, expression of pyroptosis associated factors (caspase 1 p20 and GSDMD N), and secretion of IL 1 beta and IL 18 were also decreased during osteogenic differentiation. Interestingly, increasing SNHG1 promoted HMGB1 expression, activated pyroptosis, but inhibited osteogenic differentiation. Silencing HMGB1 or inhibiting caspase 1 partially rescued the inhibitory effect of SNHG1 on osteogenic differentiation. Our findings indicate that SNHG1 suppresses the osteogenic differentiation of BMSCs by activating pyroptosis through interaction with HMGB1 and promotion of HMGB1 expression. Our work provides further evidence supporting SNHG1 acts as a potential target for OP treatment, and reveals for the first time that SNHG1 regulates osteogenic differentiation by affecting pyroptosis.
C1 [Pan, Kaihua; Lu, Yuanyuan; Cao, Daning; Peng, Jiang; Zhang, Yunqing; Li, Xiaoming] First Hosp Changsha, Dept Orthopaed, 311 Yingpan Rd, Changsha 410005, Hunan, Peoples R China.
RP Li, XM (通讯作者)，First Hosp Changsha, Dept Orthopaed, 311 Yingpan Rd, Changsha 410005, Hunan, Peoples R China.
EM lixiaoming221@163.com
FX We would like to give our sincere gratitude to the reviewers for their
   constructive comments.
CR Aibar Almazán A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169465
   Burdette BE, 2021, ACTA PHARM SIN B, V11, P2768, DOI 10.1016/j.apsb.2021.02.006
   Chen GQ, 2004, J INTERF CYTOK RES, V24, P329, DOI 10.1089/107999004323142187
   Chen HL, 2023, J BIOCHEM MOL TOXIC, V37, DOI 10.1002/jbt.23373
   Chen RC, 2022, EXP MOL MED, V54, P91, DOI 10.1038/s12276 022 00736 w
   Fang Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109595
   Feng L, 2016, EXP THER MED, V12, P3941, DOI 10.3892/etm.2016.3857
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Fu Y, 2021, BIOENGINEERED, V12, P7714, DOI 10.1080/21655979.2021.1982323
   He FL, 2019, J CELL PHYSIOL, V234, P17314, DOI 10.1002/jcp.28351
   Hu CL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.820718
   Jiang YP, 2019, LIFE SCI, V228, P208, DOI 10.1016/j.lfs.2019.05.002
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Ko NY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144886
   Li MS, 2021, THERANOSTICS, V11, P9397, DOI 10.7150/thno.57037
   McKenzie BA, 2018, P NATL ACAD SCI USA, V115, pE6065, DOI 10.1073/pnas.1722041115
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Reginster JY, 2014, BEST PRACT RES CL EN, V28, P809, DOI 10.1016/j.beem.2014.09.003
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Sun Q, 2022, CELL CYCLE, V21, P1267, DOI 10.1080/15384101.2022.2046984
   Tan X, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03413 4
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tao ZB, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.548812
   Wang CG, 2020, EXP MOL MED, V52, P1310, DOI 10.1038/s12276 020 0475 0
   Wang QJ, 2017, BIOMED PHARMACOTHER, V89, P1178, DOI 10.1016/j.biopha.2017.02.090
   Wang Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12829
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Xiang J, 2020, MOL MED REP, V22, P3715, DOI 10.3892/mmr.2020.11489
   Xu M, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0894 x
   Xu YJ, 2018, CLIN CHIM ACTA, V476, P28, DOI 10.1016/j.cca.2017.11.005
   Yang XH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44766 3
   Yang Y, 2020, BIOL RES, V53, DOI 10.1186/s40659 020 00309 z
   Yu HT, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03110 8
   Yu X, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00392 2
   Zhang LJ, 2023, CELL SIGNAL, V102, DOI 10.1016/j.cellsig.2022.110554
   Zhang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1005665
NR 36
TC 8
Z9 9
U1 0
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0006 2928
EI 1573 4927
J9 BIOCHEM GENET
JI Biochem. Genet.
PD AUG
PY 2024
VL 62
IS 4
BP 2869
EP 2883
DI 10.1007/s10528 023 10564 w
EA DEC 2023
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA L4X1O
UT WOS:001111041400002
PM 38038773
DA 2025 08 17
ER

PT J
AU Bottini, N
   Firestein, GS
AF Bottini, Nunzio
   Firestein, Gary S.
TI Epigenetics in Rheumatoid Arthritis: A Primer for Rheumatologists
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Rheumatoid arthritis; DNAmethylation; Histone acetylation; microRNA;
   Epigenetics; Histonemodification
ID HISTONE DEACETYLASE INHIBITORS; SYSTEMIC LUPUS ERYTHEMATOSUS;
   FIBROBLAST LIKE SYNOVIOCYTES; COLLAGEN INDUCED ARTHRITIS; BLOOD
   MONONUCLEAR CELLS; DNA METHYLATION; SYNOVIAL FIBROBLASTS; T CELLS;
   AUTOIMMUNE INFLAMMATION; METHYLOME SIGNATURE
AB Epigenetic anomalies are emerging as key pathogenic features of rheumatoid arthritis (RA). The effect of epigenetics in RA ranges from contributing to complex disease mechanisms to identifying biomarkers for early diagnosis and response to therapy. This review focuses on three key epigenetic areas in RA, namely DNA methylation, histone modification, and expression and/or function of microRNAs. Epigenomics studies of DNA methylation have identified alterations of genome wide DNA methylation in cells from patients with rheumatoid arthritis. Histone modification studies have focused on histone acetylation, which tends to be increased in RA. Preclinical studies show that inhibitors of histone deacetylases are effective in cellular and animal models of RA. Genome wide and candidate microRNA surveys identified increased or reduced expression of selected microRNAs in rheumatoid arthritis. These microRNA are either pro or anti inflammatory in multiple cell types or affect osteoclast physiology and the pathogenesis of bone erosion. Defining epigenetic contributions to the pathogenesis of RA, especially in combination with understanding genetic associations, could lead to novel therapy and a clearer understanding of disease risk.
C1 [Bottini, Nunzio] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Bottini, Nunzio; Firestein, Gary S.] Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA.
C3 La Jolla Institute for Immunology; University of California System;
   University of California San Diego
RP Bottini, N (通讯作者)，Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA.
EM nunzio@liai.org; gfirestein@ucsd.edu
RI Ingegnoli, Francesca/B 6226 2017
OI Ingegnoli, Francesca/0000 0002 6727 1273
FU Rheumatology Research Foundation Disease Targeted Innovative Research
   Award
FX Funding was provided, in part, by the Rheumatology Research Foundation
   Disease Targeted Innovative Research Award. This is manuscript #1647
   from the La Jolla Institute for Allergy and Immunology.
CR Alsaleh G, 2009, J IMMUNOL, V182, P5088, DOI 10.4049/jimmunol.0801613
   Baxter D, 2012, IMMUNOL CELL BIOL, V90, P288, DOI 10.1038/icb.2011.114
   Bergman Y, 2013, NAT STRUCT MOL BIOL, V20, P274, DOI 10.1038/nsmb.2518
   Blüml S, 2011, ARTHRITIS RHEUM US, V63, P1281, DOI 10.1002/art.30281
   Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190
   Chatzikyriakidou A, 2010, JOINT BONE SPINE, V77, P411, DOI 10.1016/j.jbspin.2010.05.013
   Choo QY, 2010, RHEUMATOLOGY, V49, P1447, DOI 10.1093/rheumatology/keq108
   Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525 0016(03)00235 1
   CORVETTA A, 1991, J CHROMATOGR BIOMED, V566, P481, DOI 10.1016/0378 4347(91)80265 E
   Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103
   de la Rica L, 2013, J AUTOIMMUN, V41, P6, DOI 10.1016/j.jaut.2012.12.005
   Duroux Richard I, 2012, ARTHRITIS RHEUM US, V64, P11, DOI 10.1002/art.30651
   Fulci V, 2010, HUM IMMUNOL, V71, P206, DOI 10.1016/j.humimm.2009.11.008
   Gantier MP, 2012, NUCLEIC ACIDS RES, V40, P8048, DOI 10.1093/nar/gks521
   Gillespie J, 2012, ARTHRITIS RHEUM US, V64, P418, DOI 10.1002/art.33382
   Grabiec AM, 2013, NAT REV RHEUMATOL, V9, P311, DOI 10.1038/nrrheum.2013.17
   Grabiec AM, 2012, ANN RHEUM DIS, V71, P424, DOI 10.1136/ard.2011.154211
   Grabiec AM, 2010, J IMMUNOL, V184, P2718, DOI 10.4049/jimmunol.0901467
   Hancock WW, 2012, ANN RHEUM DIS, V71, P46, DOI 10.1136/annrheumdis 2011 200593
   Hawtree S, 2013, BIOCHEM SOC T, V41, P783, DOI 10.1042/BST20130053
   Horiuchi M, 2009, J RHEUMATOL, V36, P1580, DOI 10.3899/jrheum.081115
   Huber LC, 2007, ARTHRITIS RHEUM, V56, P1087, DOI 10.1002/art.22512
   Ishida K, 2012, J PERIODONTOL, V83, P917, DOI 10.1902/jop.2011.110356
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Jiménez Morales S, 2012, TISSUE ANTIGENS, V80, P317, DOI 10.1111/j.1399 0039.2012.01929.x
   Joosten LAB, 2011, MOL MED, V17, P391, DOI 10.2119/molmed.2011.00058
   Karouzakis E, 2011, GENES IMMUN, V12, P643, DOI 10.1038/gene.2011.45
   Karouzakis E, 2012, ARTHRITIS RHEUM US, V64, P1809, DOI 10.1002/art.34340
   Karouzakis E, 2009, ARTHRITIS RHEUM US, V60, P3613, DOI 10.1002/art.25018
   Kawabata Tomoko, 2010, Arthritis Res Ther, V12, pR133, DOI 10.1186/ar3071
   Kim YI, 1996, J LAB CLIN MED, V128, P165, DOI 10.1016/S0022 2143(96)90008 6
   Klareskog L, 2010, ANN RHEUM DIS, V69, P2062, DOI 10.1136/ard.2010.142109
   Kloster MM, 2013, INT J ONCOL, V42, P1815, DOI 10.3892/ijo.2013.1853
   Kuchen S, 2004, AUTOIMMUNITY, V37, P57, DOI 10.1080/08916930310001637977
   Kurowska Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108
   Li JY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3006
   Li YT, 2012, ARTHRITIS RHEUM US, V64, P3240, DOI 10.1002/art.34550
   Liao J, 2012, CLIN IMMUNOL, V145, P13, DOI 10.1016/j.clim.2012.07.006
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Liu CC, 2011, IMMUNOL LETT, V135, P96, DOI 10.1016/j.imlet.2010.10.003
   Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487
   Maciejewska Rodrigues H, 2010, J AUTOIMMUN, V35, P15, DOI 10.1016/j.jaut.2009.12.010
   Miao CG, 2013, CELL SIGNAL, V25, P598, DOI 10.1016/j.cellsig.2012.11.023
   Murata K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3013
   Nagata Y, 2009, ARTHRITIS RHEUM US, V60, P2677, DOI 10.1002/art.24762
   Nakamachi Y, 2009, ARTHRITIS RHEUM US, V60, P1294, DOI 10.1002/art.24475
   Nakamura C, 2008, RHEUMATOLOGY, V47, P418, DOI 10.1093/rheumatology/ken003
   Nakano K, 2013, J IMMUNOL, V190, P1297, DOI 10.4049/jimmunol.1202572
   Nakano K, 2013, ANN RHEUM DIS, V72, P110, DOI 10.1136/annrheumdis 2012 201526
   Nakasa T, 2008, ARTHRITIS RHEUM US, V58, P1284, DOI 10.1002/art.23429
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Neidhart M, 2000, ARTHRITIS RHEUM US, V43, P2634, DOI 10.1002/1529 0131(200012)43:12<2634::AID ANR3>3.0.CO;2 1
   Niederer F, 2012, ARTHRITIS RHEUM US, V64, P1771, DOI 10.1002/art.34334
   Niederer F, 2011, ANN RHEUM DIS, V70, P1866, DOI 10.1136/ard.2010.148957
   Niimoto T, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 209
   Nile CJ, 2008, ARTHRITIS RHEUM, V58, P2686, DOI 10.1002/art.23758
   O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009
   Pandis I, 2012, ANN RHEUM DIS, V71, P1716, DOI 10.1136/annrheumdis 2011 200803
   Pauley KM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2493
   Philippe L, 2012, J IMMUNOL, V188, P454, DOI 10.4049/jimmunol.1102348
   Plenge Robert M, 2009, Curr Rheumatol Rep, V11, P351, DOI 10.1007/s11926 009 0050 0
   RICHARDSON B, 1990, ARTHRITIS RHEUM US, V33, P1665, DOI 10.1002/art.1780331109
   Saouaf SJ, 2009, EXP MOL PATHOL, V87, P99, DOI 10.1016/j.yexmp.2009.06.003
   Semaan N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019827
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386
   Stanczyk J, 2011, ARTHRITIS RHEUM US, V63, P373, DOI 10.1002/art.30115
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Takami N, 2006, ARTHRITIS RHEUM US, V54, P779, DOI 10.1002/art.21637
   Trenkmann M, 2013, ARTHRITIS RHEUM US, V65, P916, DOI 10.1002/art.37834
   Trenkmann M, 2011, ANN RHEUM DIS, V70, P1482, DOI 10.1136/ard.2010.143040
   Vojinovic J, 2011, ARTHRITIS RHEUM US, V63, P1452, DOI 10.1002/art.30238
   Whitaker JW, 2013, GENOME MED, V5, DOI 10.1186/gm444
   Wittmann J, 2011, ANN RHEUM DIS, V70, pI92, DOI 10.1136/ard.2010.140152
   Xiao Y, 2010, CURR OPIN IMMUNOL, V22, P583, DOI 10.1016/j.coi.2010.08.013
   Yang B, 2012, HUM IMMUNOL, V73, P101, DOI 10.1016/j.humimm.2011.10.005
   Zhu S, 2012, NAT MED, V18, P1077, DOI 10.1038/nm.2815
NR 77
TC 63
Z9 65
U1 0
U2 28
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD NOV
PY 2013
VL 15
IS 11
AR 372
DI 10.1007/s11926 013 0372 9
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 243AG
UT WOS:000326287900003
PM 24072602
DA 2025 08 17
ER

PT J
AU Endo, S
   Nishiyama, T
   Matuoka, T
   Miura, T
   Nishinaka, T
   Matsunaga, T
   Ikari, A
AF Endo, Satoshi
   Nishiyama, Tsubasa
   Matuoka, Tomoe
   Miura, Takeshi
   Nishinaka, Toru
   Matsunaga, Toshiyuki
   Ikari, Akira
TI Loxoprofen enhances intestinal barrier function via generation of its
   active metabolite by carbonyl reductase 1 in differentiated Caco 2 cells
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Loxoprofen; Nonsteroidal anti inflammatory drug; Epithelial barrier
   function; Claudin; Carbonyl reductase 1
ID INFLAMMATORY BOWEL DISEASE; TIGHT JUNCTION BARRIER; NITRIC OXIDE
   SYNTHASE; TNF ALPHA MODULATION; CLAUDIN 2 EXPRESSION; UP REGULATION;
   KINASE; PERMEABILITY; INCREASE; INJURY
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are used worldwide as antipyretic analgesics and agents for rheumatoid arthritis and osteoarthritis, but known to cause damage to the gastrointestinal mucosae as their serious adverse effects. Few studies showed the impairment of intestinal epithelial barrier function (EBF) by high concentrations (0.5 1 mM) of NSAIDs, but the underlying mechanism is not fully understood. This study is aimed at clarifying effects at a low concentration (50 mu M) of three NSAIDs, loxoprofen (Lox), ibuprofen and indomethacin, on intestinal EBF using human intestinal epithelial like Caco 2 cells. Among those NSAIDs, Lox increased the transepithelial electric resistance (TER) value, decreased the paracellular Lucifer yellow CH (LYCH) permeability, and upregulated claudin (CLDN) 1, 3 and 5, indicating that low doses of Lox enhanced EBF through increasing expression of CLDNs. Lox is known to be metabolized to a pharmacologically active metabolite, (2S,1'R,2'S) loxoprofen alcohol (Lox RS), by carbonyl reductase 1 (CBR1), which is highly expressed in human intestine. CBR1 was expressed in the Caco 2 cells, and the pretreatment with a CBR1 inhibitor suppressed both the Lox evoked CLDN upregulation and EBF enhancement. In addition, the treatment of the cells with Lox RS resulted in higher TER value and lower LYCH permeability than those with Lox. Thus, Lox RS synthesized by CBR1 may greatly contribute to the improving efficacy of Lox on the barrier function. Since EBF is decreased in inflammatory bowel disease, we finally examined the effect of Lox on EBF using the Caco 2/ THP 1 co culture system, which is used as an in vitro inflammatory bowel disease model. Lox significantly recovered EBF which was impaired by inflammatory cytokines secreted from THP 1 macrophages. These in vitro observations suggest that Lox enhances intestinal EBF, for which the metabolism of Lox to Lox RS by CBR1 has an important role.
C1 [Endo, Satoshi; Nishiyama, Tsubasa; Matuoka, Tomoe; Ikari, Akira] Gifu Pharmaceut Univ, Dept Biopharmaceut Sci, Lab Biochem, Gifu 5011196, Japan.
   [Miura, Takeshi] Mukogawa Womens Univ, Pharmaceut Educ Support Ctr, Sch Pharm & Pharmaceut Sci, Nishinomiya, Hyogo 6638184, Japan.
   [Nishinaka, Toru] Osaka Ohtani Univ, Fac Pharm, Lab Biochem, Tondabayashi 5848540, Japan.
   [Matsunaga, Toshiyuki] Gifu Pharmaceut Univ, Educ Ctr Green Pharmaceut Sci, Gifu 5028585, Japan.
C3 Gifu Pharmaceutical University; Mukogawa Women's University; Gifu
   Pharmaceutical University
RP Ikari, A (通讯作者)，Gifu Pharmaceut Univ, Lab Biochem, 1 25 4 Daigaku Nishi, Gifu 5011196, Japan.
EM ikari@gifu pu.ac.jp
RI Miura, Takeshi/MDT 5772 2025; Endo, Satoshi/F 8059 2011
OI Endo, Satoshi/0000 0003 0578 9672
FU Japan Society for the Promotion of Science [17K11151]; Self medication
   Research Foundation; Grants in Aid for Scientific Research [17K11151]
   Funding Source: KAKEN
FX This work was supported in part by a grant in aid for scientific
   research (C) (17K11151) from the Japan Society for the Promotion of
   Science (S.E.), and Self medication Research Foundation (A.I.).
CR Al Sadi R, 2013, AM J PATHOL, V183, P1871, DOI 10.1016/j.ajpath.2013.09.001
   Alexandre MD, 2005, J CELL SCI, V118, P2683, DOI 10.1242/jcs.02406
   Alexandre MD, 2007, BIOCHEM BIOPH RES CO, V357, P87, DOI 10.1016/j.bbrc.2007.03.078
   Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165
   Amasheh S, 2005, CELL TISSUE RES, V321, P89, DOI 10.1007/s00441 005 1101 0
   Bains OS, 2009, DRUG METAB DISPOS, V37, P1107, DOI 10.1124/dmd.108.024711
   Carson J L, 1993, Drugs, V46 Suppl 1, P243
   Cheatum DE, 1999, CLIN THER, V21, P992, DOI 10.1016/S0149 2918(99)80020 4
   Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719
   Cunningham KE, 2012, ANN NY ACAD SCI, V1258, P34, DOI 10.1111/j.1749 6632.2012.06526.x
   Endo S, 2020, J MED CHEM, V63, P10396, DOI 10.1021/acs.jmedchem.0c00939
   Endo S, 2019, NUTR RES, V72, P92, DOI 10.1016/j.nutres.2019.10.010
   Fujii N, 2016, J BIOL CHEM, V291, P24787, DOI 10.1074/jbc.M116.728196
   Fujimori S, 2010, DIGESTION, V82, P167, DOI 10.1159/000308361
   Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122
   Goldstein JL, 2007, ALIMENT PHARM THER, V25, P1211, DOI 10.1111/j.1365 2036.2007.03312.x
   Gonzalez Covarrubias V, 2007, DRUG METAB DISPOS, V35, P973, DOI 10.1124/dmd.107.014779
   Günzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012
   Hou JH, 2006, J BIOL CHEM, V281, P36117, DOI 10.1074/jbc.M608853200
   Hou JH, 2010, P NATL ACAD SCI USA, V107, P18010, DOI 10.1073/pnas.1009399107
   Hu DW, 2015, ORG BIOMOL CHEM, V13, P7487, DOI 10.1039/c5ob00847f
   Hua WY, 2017, J PHARM SCI US, V106, P1405, DOI 10.1016/j.xphs.2017.01.024
   Jo H, 2017, FOOD CHEM TOXICOL, V108, P203, DOI 10.1016/j.fct.2017.08.002
   Kämpfer AAM, 2017, TOXICOL IN VITRO, V45, P31, DOI 10.1016/j.tiv.2017.08.011
   Konrad M, 2006, AM J HUM GENET, V79, P949, DOI 10.1086/508617
   Lameris AL, 2013, SCAND J GASTROENTERO, V48, P58, DOI 10.3109/00365521.2012.741616
   Lazzaroni M, 2004, ALIMENT PHARM THER, V20, P48, DOI 10.1111/j.1365 2036.2004.02037.x
   Lejeune M, 2011, AM J PATHOL, V179, P807, DOI 10.1016/j.ajpath.2011.05.001
   Ma TY, 2005, AM J PHYSIOL GASTR L, V288, pG422, DOI 10.1152/ajpgi.00412.2004
   Ma TY, 2004, AM J PHYSIOL GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003
   Maiden L, 2005, GASTROENTEROLOGY, V128, P1172, DOI 10.1053/j.gastro.2005.03.020
   Malátková P, 2010, CURR DRUG METAB, V11, P639, DOI 10.2174/138920010794233530
   Manabe A, 2017, BIOL PHARM BULL, V40, P1299, DOI 10.1248/bpb.b17 00244
   MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228
   Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040
   Noguchi M, 2005, BIOL PHARM BULL, V28, P2075, DOI 10.1248/bpb.28.2075
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432 1327.2000.01606.x
   OHARA H, 1995, BIOCHEM PHARMACOL, V50, P221, DOI 10.1016/0006 2952(95)00124 I
   Oshima T, 2008, AM J PHYSIOL CELL PH, V295, pC800, DOI 10.1152/ajpcell.00157.2008
   Oshima T, 2008, J GASTROEN HEPATOL, V23, pS146, DOI 10.1111/j.1440 1746.2008.05405.x
   Poritz LS, 2011, DIGEST DIS SCI, V56, P2802, DOI 10.1007/s10620 011 1688 9
   Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316
   Quiñones Lombraña A, 2018, BIOPHARM DRUG DISPOS, V39, P315, DOI 10.1002/bdd.2135
   Rosenthal R, 2010, J CELL SCI, V123, P1913, DOI 10.1242/jcs.060665
   Ryu WI, 2018, J DERMATOL SCI, V90, P313, DOI 10.1016/j.jdermsci.2018.02.017
   Samak G, 2011, AM J PHYSIOL GASTR L, V301, pG50, DOI 10.1152/ajpgi.00494.2010
   Satoh H, 2014, J PHARMACOL EXP THER, V348, P227, DOI 10.1124/jpet.113.208991
   Satoh H, 2012, J PHARMACOL EXP THER, V343, P270, DOI 10.1124/jpet.112.197475
   Satsu H, 2006, EXP CELL RES, V312, P3909, DOI 10.1016/j.yexcr.2006.08.018
   Shanahan F, 2001, GASTROENTEROLOGY, V120, P622, DOI 10.1053/gast.2001.22122
   Takeuchi K, 2006, DIGEST DIS SCI, V51, P1250, DOI 10.1007/s10620 006 8045 4
   Takeuchi K, 2015, DIGESTION, V91, P218, DOI 10.1159/000374106
   Tamura A, 2011, GASTROENTEROLOGY, V140, P913, DOI 10.1053/j.gastro.2010.08.006
   Tanaka MN, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 63
   Thakre Nighot M, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1187325
   Vivinus Nébot M, 2014, GUT, V63, P744, DOI 10.1136/gutjnl 2012 304066
   Wang YX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040765
   Weber CR, 2008, LAB INVEST, V88, P1110, DOI 10.1038/labinvest.2008.78
   Weber CR, 2010, J BIOL CHEM, V285, P12037, DOI 10.1074/jbc.M109.064808
   WHITTLE BJR, 1995, BRIT J PHARMACOL, V116, P2286, DOI 10.1111/j.1476 5381.1995.tb15066.x
   YAMADA T, 1993, INFLAMMATION, V17, P641, DOI 10.1007/BF00920471
   Yu ASL, 2009, J GEN PHYSIOL, V133, P111, DOI 10.1085/jgp.200810154
   Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375
NR 63
TC 6
Z9 6
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD OCT 1
PY 2021
VL 348
AR 109634
DI 10.1016/j.cbi.2021.109634
EA SEP 2021
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA WD5AL
UT WOS:000704953200007
PM 34506768
DA 2025 08 17
ER

PT J
AU Onizuka, S
   Iwata, T
   Park, SJ
   Nakai, K
   Yamato, M
   Okano, T
   Izumi, Y
AF Onizuka, Satoru
   Iwata, Takanori
   Park, Sung Joon
   Nakai, Kenta
   Yamato, Masayuki
   Okano, Teruo
   Izumi, Yuichi
TI ZBTB16 as a Downstream Target Gene of Osterix Regulates
   Osteoblastogenesis of Human Multipotent Mesenchymal Stromal Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BIOINFORMATICS; CELL DIFFERENTIATION; PERIODONTAL LIGAMENT (PDL); STEM
   CELL(S); OSTEOGENESIS; MOLECULAR BIOLOGY
ID TRANSCRIPTION FACTOR OSTERIX; BONE MORPHOGENETIC PROTEIN 2; STEM CELLS;
   OSTEOGENIC DIFFERENTIATION; EXPRESSION; PLZF; REGENERATION;
   PHOSPHORYLATION; CBFA1; LIMB
AB Human multipotent mesenchymal stromal cells (hMSCs) possess the ability to differentiate into osteoblasts, and they can be utilized as a source for bone regenerative therapy. Osteoinductive pretreatment, which induces the osteoblastic differentiation of hMSCs in vitro, has been widely used for bone tissue engineering prior to cell transplantation. However, the molecular basis of osteoblastic differentiation induced by osteoinductive medium (OIM) is still unknown. Therefore, we used a next generation sequencer to investigate the changes in gene expression during the osteoblastic differentiation of hMSCs. The hMSCs used in this study possessed both multipotency and self renewal ability. Whole transcriptome analysis revealed that the expression of zinc finger and BTB domain containing 16 (ZBTB16) was significantly increased during the osteoblastogenesis of hMSCs. ZBTB16 mRNA and protein expression was enhanced by culturing the hMSCs with OIM. Small interfering RNA (siRNA) mediated gene silencing of ZBTB16 decreased the activity of alkaline phosphatase (ALP); the expression of osteogenic genes, such as osteocalcin (OCN) and bone sialoprotein (BSP), and the mineralized nodule formation induced by OIM. siRNA mediated gene silencing of Osterix (Osx), which is known as an essential regulator of osteoblastic differentiation, markedly downregulated the expression of ZBTB16. In addition, chromatin immunoprecipitation (ChIP) assays showed that Osx associated with the ZBTB16 promoter region containing the GC rich canonical Sp1 sequence, which is the specific Osx binding site. These findings suggest that ZBTB16 acts as a downstream transcriptional regulator of Osx and can be useful as a late marker of osteoblastic differentiation. J. Cell. Biochem. 117: 2423 2434, 2016. (c) 2016 Wiley Periodicals, Inc.
C1 [Onizuka, Satoru; Izumi, Yuichi] Tokyo Med Dent Univ, Dept Periodontol, Grad Sch Med Dent Sci, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
   [Onizuka, Satoru; Iwata, Takanori; Yamato, Masayuki; Okano, Teruo] Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, 8 1 Kawada Cho, Tokyo 1628666, Japan.
   [Park, Sung Joon; Nakai, Kenta] Univ Tokyo, Human Genome Ctr, Inst Med Sci, Minato Ku, 4 6 1 Shirokanedai, Tokyo 1088639, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Tokyo Women's Medical University; University of Tokyo
RP Iwata, T; Okano, T (通讯作者)，Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, 8 1 Kawada Cho, Tokyo 1628666, Japan.
EM iwata.takanori@twmu.ac.jp; tokano@twmu.ac.jp
RI ; Nakai, Kenta/B 7293 2009; Okano, Teruo/J 4028 2012; Park,
   Sung Joon/JDM 8242 2023; Iwata, Takanori/AAT 3219 2020
OI Park, Sung Joon/0000 0002 1774 9590; Okano, Teruo/0000 0002 4470 9842; 
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   Japan; Japan Society for the Promotion of Science; JSPS KAKENHI
   [15K11224]; Japan Agency for Medical Research and Development (AMED);
   Grants in Aid for Scientific Research [15K11224] Funding Source: KAKEN
FX Grant sponsor: Ministry of Education, Culture, Sports, Science and
   Technology (MEXT) of Japan; Grant sponsor: Japan Society for the
   Promotion of Science; Grant sponsor: JSPS KAKENHI; Grant number:
   15K11224; Grant sponsor: Japan Agency for Medical Research and
   Development (AMED).
CR Acampora D, 1999, DEVELOPMENT, V126, P3795
   Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014
   Barna M, 2005, NATURE, V436, P277, DOI 10.1038/nature03801
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367
   Di Bella C, 2008, TISSUE ENG PT A, V14, P483, DOI 10.1089/tea.2007.0137
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Felthaus O, 2014, CELL TISSUE RES, V357, P695, DOI 10.1007/s00441 014 1891 z
   Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719
   Gay IC, 2007, ORTHOD CRANIOFAC RES, V10, P149, DOI 10.1111/j.1601 6343.2007.00399.x
   Hakki SS, 2014, J BIOMED MATER RES B, V102, P119, DOI 10.1002/jbm.b.32988
   Ikeda R, 2005, J BIOL CHEM, V280, P8523, DOI 10.1074/jbc.M409442200
   Iwata T, 2010, J CLIN PERIODONTOL, V37, P1088, DOI 10.1111/j.1600 051X.2010.01597.x
   Iwata T, 2009, BIOMATERIALS, V30, P2716, DOI 10.1016/j.biomaterials.2009.01.032
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Niger C, 2011, BONE, V49, P683, DOI 10.1016/j.bone.2011.07.027
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Park SJ, 2016, ORAL DIS, V22, P353, DOI 10.1111/odi.12403
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Savage AK, 2008, IMMUNITY, V29, P391, DOI 10.1016/j.immuni.2008.07.011
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332
   Skovrlj B, 2014, SPINE J, V14, P2763, DOI 10.1016/j.spinee.2014.05.024
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Trubiani O, 2008, J BIOMED MATER RES A, V87A, P986, DOI 10.1002/jbm.a.31837
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467
   Yamada A, 2013, BIOMATERIALS, V34, P3270, DOI 10.1016/j.biomaterials.2013.01.066
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422
   Zhu FC, 2012, J CELL PHYSIOL, V227, P2677, DOI 10.1002/jcp.23010
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 50
TC 31
Z9 33
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2016
VL 117
IS 10
BP 2423
EP 2434
DI 10.1002/jcb.25634
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DS6LE
UT WOS:000380892500023
PM 27335174
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Si, JQ
   Guo, RB
   Zhang, L
   Liu, WY
   Kong, L
   Liu, Y
   Yu, Y
   Zang, J
   Chen, WW
   Li, XY
   Li, XT
AF Si, Jiaqi
   Guo, Ruibo
   Zhang, Lu
   Liu, Wanying
   Kong, Liang
   Liu, Yang
   Yu, Yang
   Zang, Juan
   Chen, Weiwei
   Li, Xiuying
   Li, Xuetao
TI Mannose modified celastrol liposomes targeted activated macrophages for
   rheumatoid arthritis treatment in vitro and in
   vivo evaluation
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Rheumatoid arthritis; Mannose; Celastrol; Macrophages; Anti inflammatory
ID MANNOSYLATED LIPOSOMES; NANOPARTICLES; POLARIZATION; DELIVERY; PEG
AB Rheumatoid arthritis (RA) is an autoimmune illness characterized by symmetrical polyarthritis as the primary clinical symptom. A substantial number of synovial macrophages are activated in RA patients, resulting in sy novial inflammation, joint inflammation, and cartilage degradation. The goal of this study is to develop a novel therapy for the effective treatment of RA. We prepared mannose modified celastrol liposomes (MAN CSL lips) by thin film hydration method. The particle size of the prepared liposomes was (95.37 +/  0.16) nm, and the zeta potential was ( 5.4 +/  0.40) mV. The experimental results showed that MAN CSL lips had low cytotoxicity and could be efficiently taken up by macrophages, suppress osteoclast formation, and reduce the level of inflam matory factors. In addition, in vivo animal experiments, liposomes can prolong the systemic circulation time of drugs, reduce the joint score and serum inflammatory factor expression in arthritic rats, and have significant cartilage protection and anti inflammatory effects, making it a promising therapeutic method for treating RA.
C1 [Si, Jiaqi; Guo, Ruibo; Zhang, Lu; Liu, Wanying; Kong, Liang; Liu, Yang; Yu, Yang; Zang, Juan; Li, Xuetao] Liaoning Univ Tradit Chinese Med, Sch Pharm, Dalian 116600, Peoples R China.
   [Chen, Weiwei; Li, Xiuying] Shanxi Univ Chinese Med, Jinzhong 030619, Peoples R China.
   [Li, Xuetao] Liaoning Univ Tradit Chinese Med, Sch Pharm, Shengming 1 Rd 77, Double D port, Dalian 116600, Peoples R China.
   [Li, Xiuying] Shanxi Univ Chinese Med, Shanxi Key Lab Innovat Drug Treatment Serious Dis, Jinzhong 030619, Peoples R China.
C3 Liaoning University of Traditional Chinese Medicine; Shanxi University
   of Chinese Medicine; Liaoning University of Traditional Chinese
   Medicine; Shanxi University of Chinese Medicine
RP Li, XT (通讯作者)，Liaoning Univ Tradit Chinese Med, Sch Pharm, Shengming 1 Rd 77, Double D port, Dalian 116600, Peoples R China.; Li, XY (通讯作者)，Shanxi Univ Chinese Med, Shanxi Key Lab Innovat Drug Treatment Serious Dis, Jinzhong 030619, Peoples R China.
EM lixiuying@sxtcm.edu.cn; lixuetao1979@163.com
RI Li, Xiuying/F 6544 2017; Li, Xue tao/AAH 2890 2020
FU China Postdoctoral Science Foundation [2022MD723796, 2022MD713762];
   Doctoral Start up Foundation of Liaoning Province [2022  BS  197, 2023
    BS 139]
FX This work was supported by the China Postdoctoral Science Foundation
   (2022MD723796, 2022MD713762) , the Doctoral Start up Foundation of
   Liaoning Province (2022 BS 197, 2023  BS 139) .
CR Abutorabi ES, 2023, MOL BIOL REP, V50, P4073, DOI 10.1007/s11033 023 08255 1
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Alvarado Vazquez PA, 2017, IMMUNOBIOLOGY, V222, P900, DOI 10.1016/j.imbio.2017.05.011
   An LM, 2020, NANO LETT, V20, P7728, DOI 10.1021/acs.nanolett.0c03279
   Bergholt NL, 2019, CARTILAGE, V10, P370, DOI 10.1177/1947603518764262
   Bhardwaj U, 2022, RHEUMATOLOGY, V61, P3370, DOI 10.1093/rheumatology/keab914
   Boutet MA, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102758
   Chen XH, 2021, J SCI FOOD AGR, V101, P2014, DOI 10.1002/jsfa.10819
   Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090
   Choudhary N, 2018, IMMUNOPHARM IMMUNOT, V40, P193, DOI 10.1080/08923973.2018.1434793
   Conforti A, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102735
   Cutolo M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867260
   Dedmon LE, 2020, RHEUMATOLOGY, V59, P2661, DOI 10.1093/rheumatology/keaa232
   Fang HH, 2022, ACS APPL MATER INTER, V14, P8824, DOI 10.1021/acsami.1c23429
   Fang JQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11172674
   Feldman AT, 2014, METHODS MOL BIOL, V1180, P31, DOI 10.1007/978 1 4939 1050 2_3
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Gao Q, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106527
   Guo RB, 2022, BIOMATER SCI UK, V10, P499, DOI 10.1039/d1bm01520f
   Hagert C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00114
   Han JF, 2023, MOLECULES, V28, DOI 10.3390/molecules28020591
   Hou W, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2020.112081
   Ibaraki H, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010104
   Ibrahim M, 2022, J CONTROL RELEASE, V351, P215, DOI 10.1016/j.jconrel.2022.09.031
   Iwamoto N, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.998554
   Kellogg C, 2021, HUM VACC IMMUNOTHER, V17, P638, DOI 10.1080/21645515.2020.1818519
   Kong L, 2020, INT J NANOMED, V15, P2841, DOI 10.2147/IJN.S239608
   Kozma GT, 2020, ADV DRUG DELIVER REV, V154, P163, DOI 10.1016/j.addr.2020.07.024
   Leber N, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900162
   Ledinski M, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14091751
   Lim MA, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00818
   Lin YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040880
   Liu CF, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113039
   Liu GM, 2023, ANIMAL, V17, DOI 10.1016/j.animal.2023.100714
   Lok B, 2023, LIFE BASEL, V13, DOI 10.3390/life13020346
   Mueller AL, 2021, CELLS BASEL, V10, DOI 10.3390/cells10113017
   Nan F, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.877543
   Null Null M. M., 2023, StatPearls
   Put S, 2013, J NUCL MED, V54, P807, DOI 10.2967/jnumed.112.111781
   Radu AF, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112857
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Smith Melanie H, 2022, JAMA, V327, P1194, DOI 10.1001/jama.2022.0786
   Song XQ, 2020, MOL MED REP, V21, P2303, DOI 10.3892/mmr.2020.11052
   Song XQ, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105725
   Sultana F, 2017, EUR J PHARM BIOPHARM, V115, P229, DOI 10.1016/j.ejpb.2017.03.009
   Ta W, 2023, INT J NANOMED, V18, P1823, DOI 10.2147/IJN.S394953
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   van Alem CMA, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13071004
   Wagh PR, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.673209
   Wang KZ, 2023, FEBS J, V290, P209, DOI 10.1111/febs.16589
   Wang Q, 2021, ACTA PHARM SIN B, V11, P1158, DOI 10.1016/j.apsb.2021.03.013
   Wang YJ, 2023, J LIPOSOME RES, V33, P197, DOI 10.1080/08982104.2022.2153138
   Wu D, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1051082
   Xi L, 2022, ACTA PHARM SIN B, V12, P339, DOI 10.1016/j.apsb.2021.07.019
   Xue LP, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119642
   Yang JJ, 2022, INT IMMUNOPHARMACOL, V112, DOI 10.1016/j.intimp.2022.109241
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Zheng X, 2022, DRUG DELIV, V29, P1025, DOI 10.1080/10717544.2022.2057616
   Zhou X, 2021, DRUG DELIV, V28, P2447, DOI 10.1080/10717544.2021.2000679
   Zhu YT, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.938849
NR 60
TC 2
Z9 2
U1 2
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773 2247
EI 2588 8943
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD JAN
PY 2024
VL 91
AR 105185
DI 10.1016/j.jddst.2023.105185
EA DEC 2023
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DQ6M7
UT WOS:001133563800001
DA 2025 08 17
ER

PT J
AU Cho, HJ
   Cho, HJ
   Lee, HJ
   Song, MK
   Seo, JY
   Bae, YH
   Kim, JY
   Lee, HY
   Lee, W
   Koo, BK
   Oh, BH
   Park, YB
   Kim, HS
AF Cho, Hyun Ju
   Cho, Hyun Jai
   Lee, Ho Jae
   Song, Myung Kang
   Seo, Ji Yun
   Bae, Yeon Hee
   Kim, Ju Young
   Lee, Hae Young
   Lee, Whal
   Koo, Bon Kwon
   Oh, Byung Hee
   Park, Young Bae
   Kim, Hyo Soo
TI Vascular Calcifying Progenitor Cells Possess Bidirectional
   Differentiation Potentials
SO PLOS BIOLOGY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; SMOOTH MUSCLE CELLS; BONE MARROW; GROWTH FACTOR;
   CALCIFICATION; OSTEOCLASTOGENESIS; ATHEROSCLEROSIS; MECHANISMS;
   CONTRIBUTE; MICE
AB Vascular calcification is an advanced feature of atherosclerosis for which no effective therapy is available. To investigate the modulation or reversal of calcification, we identified calcifying progenitor cells and investigated their calcifying/decalcifying potentials. Cells from the aortas of mice were sorted into four groups using Sca 1 and PDGFR alpha markers. Sca 1(+) (Sca 1(+)/PDGFR alpha(+) and Sca 1(+)/PDGFR alpha( )) progenitor cells exhibited greater osteoblastic differentiation potentials than Sca 1( ) (Sca 1( )/PDGFR alpha(+) and Sca 1( )/PDGFR alpha( )) progenitor cells. Among Sca 1(+) progenitor populations, Sca 1(+)/PDGFR alpha( ) cells possessed bidirectional differentiation potentials towards both osteoblastic and osteoclastic lineages, whereas Sca 1(+)/PDGFR alpha(+) cells differentiated into an osteoblastic lineage unidirectionally. When treated with a peroxisome proliferator activated receptor gamma (PPAR gamma) agonist, Sca 1(+)/PDGFR alpha( ) cells preferentially differentiated into osteoclast like cells. Sca 1(+) progenitor cells in the artery originated from the bone marrow (BM) and could be clonally expanded. Vessel resident BM derived Sca 1(+) calcifying progenitor cells displayed nonhematopoietic, mesenchymal characteristics. To evaluate the modulation of in vivo calcification, we established models of ectopic and atherosclerotic calcification. Computed tomography indicated that Sca 1(+) progenitor cells increased the volume and calcium scores of ectopic calcification. However, Sca 1(+)/PDGFR alpha( ) cells treated with a PPAR gamma agonist decreased bone formation 2 fold compared with untreated cells. Systemic infusion of Sca 1(+)/PDGFR alpha( ) cells into Apoe( / ) mice increased the severity of calcified atherosclerotic plaques. However, Sca 1(+)/PDGFR alpha( ) cells in which PPAR gamma was activated displayed markedly decreased plaque severity. Immunofluorescent staining indicated that Sca 1(+)/PDGFR alpha( ) cells mainly expressed osteocalcin; however, activation of PPAR gamma triggered receptor activator for nuclear factor kappa B (RANK) expression, indicating their bidirectional fate in vivo. These findings suggest that a subtype of BM derived and vessel resident progenitor cells offer a therapeutic target for the prevention of vascular calcification and that PPAR gamma activation may be an option to reverse calcification.
C1 [Cho, Hyun Ju; Cho, Hyun Jai; Lee, Ho Jae; Song, Myung Kang; Seo, Ji Yun; Bae, Yeon Hee; Kim, Ju Young; Kim, Hyo Soo] Seoul Natl Univ, Coll Med, Natl Res Lab Stem Cell Niche, Seoul, South Korea.
   [Cho, Hyun Ju; Cho, Hyun Jai; Lee, Hae Young; Koo, Bon Kwon; Oh, Byung Hee; Park, Young Bae; Kim, Hyo Soo] Seoul Natl Univ Hosp, Ctr Cardiovasc, Seoul 110744, South Korea.
   [Cho, Hyun Ju; Cho, Hyun Jai; Lee, Hae Young; Koo, Bon Kwon; Oh, Byung Hee; Park, Young Bae; Kim, Hyo Soo] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   [Cho, Hyun Ju; Cho, Hyun Jai; Lee, Ho Jae; Song, Myung Kang; Bae, Yeon Hee; Kim, Ju Young; Park, Young Bae; Kim, Hyo Soo] Seoul Natl Univ Hosp, Innovat Res Inst Cell Therapy, Seoul 110744, South Korea.
   [Lee, Whal] Seoul Natl Univ, Coll Med, Dept Radiol, Seoul, South Korea.
   [Kim, Hyo Soo] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, World Class Univ Program, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU)
RP Cho, HJ (通讯作者)，Seoul Natl Univ, Coll Med, Natl Res Lab Stem Cell Niche, Seoul, South Korea.
EM hyosoo@snu.ac.kr
RI Oh, Byung Hee/G 9875 2011; Koo, Bon Kwon/J 5374 2012; Lee,
   Hye Young/JEP 8044 2023; Lee, Hyo Suk/J 5618 2012; Kim,
   Juhee/KFS 3069 2024; choi, jo/O 5940 2014; LEE, HYUN/ABC 6119 2021; Kim,
   Hyo/J 2753 2012; Park, Young Bae/J 5490 2012
OI Oh, Byung Hee/0000 0002 9945 4306; Lee, Hae Young/0000 0002 9521 4102; 
FU National Research Foundation; Korean Government (MEST), Republic of
   Korea [2010 0020258]
FX This study was supported by the National Research Foundation, funded by
   the Korean Government (MEST) (2010 0020258), Republic of Korea. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594
   Boucher J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1905
   Bradfute SB, 2005, EXP HEMATOL, V33, P836, DOI 10.1016/j.exphem.2005.04.001
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cho HJ, 2009, CURR ATHEROSCLER REP, V11, P206, DOI 10.1007/s11883 009 0032 8
   Cho Youngjin, 2011, J Am Coll Cardiol, V57, P99, DOI 10.1016/j.jacc.2010.07.035
   Collett GDM, 2005, CIRC RES, V96, P930, DOI 10.1161/01.RES.0000163634.51301.0d
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Doherty TM, 2003, P NATL ACAD SCI USA, V100, P11201, DOI 10.1073/pnas.1932554100
   Doherty TM, 2002, FASEB J, V16, DOI 10.1096/fj.01 0898hyp
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Fadini GP, 2012, CIRCULATION, V125, P2772, DOI 10.1161/CIRCULATIONAHA.112.090860
   Finkenzeller G, 2006, TISSUE ENG, V12, P2889, DOI 10.1089/ten.2006.12.2889
   Gössl M, 2007, ATHEROSCLEROSIS, V192, P246, DOI 10.1016/j.atherosclerosis.2006.07.004
   Hahn JY, 2008, J AM COLL CARDIOL, V51, P933, DOI 10.1016/j.jacc.2007.11.040
   Halade GV, 2011, EXP GERONTOL, V46, P43, DOI 10.1016/j.exger.2010.09.014
   Hardouin SN, 2011, DEVELOPMENT, V138, P203, DOI 10.1242/dev.054916
   Hiramatsu K, 2011, J CLIN INVEST, V121, P640, DOI 10.1172/JCI44605
   Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628
   Ilvesaro J, 2005, LIFE SCI, V77, P1351, DOI 10.1016/j.lfs.2005.01.027
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Joo I, 2011, INT J CARDIOVASC IMA
   Kanda N, 2003, J INVEST DERMATOL, V121, P570, DOI 10.1046/j.1523 1747.2003.12428.x
   Kim HS, 2004, J MOL CELL CARDIOL, V37, P871, DOI 10.1016/j.yjmcc.2004.06.017
   Maiellaro K, 2007, CARDIOVASC RES, V75, P640, DOI 10.1016/j.cardiores.2007.06.023
   Masuda R, 2001, CELL TISSUE RES, V304, P351, DOI 10.1007/s004410100347
   Moon JH, 2011, KOREAN J RADIOL, V12, P308, DOI 10.3348/kjr.2011.12.3.308
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883 001 0065 0
   Naik V, 2012, CARDIOVASC RES, V94, P545, DOI 10.1093/cvr/cvs126
   Nelson WD, 2007, CIRC RES, V101, P1319, DOI 10.1161/CIRCRESAHA.107.155564
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Park EA, 2011, CIRCULATION, V123, pE262, DOI 10.1161/CIRCULATIONAHA.110.006254
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Sage AP, 2010, NAT REV CARDIOL, V7, P528, DOI 10.1038/nrcardio.2010.115
   Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Tintut Y, 2005, J MOL CELL CARDIOL, V39, P389, DOI 10.1016/j.yjmcc.2005.03.019
   Trion A, 2004, AM HEART J, V147, P808, DOI 10.1016/j.ahj.2003.10.047
   Vattikuti R, 2004, AM J PHYSIOL ENDOC M, V286, pE686, DOI 10.1152/ajpendo.00552.2003
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wei W, 2011, MOL CELL BIOL, V31, P4692, DOI 10.1128/MCB.05979 11
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wildemann Britt, 2007, J Orthop Surg Res, V2, P27, DOI 10.1186/1749 799X 2 27
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636
   Yoshida S, 2012, BIOCHEM BIOPH RES CO, V421, P785, DOI 10.1016/j.bbrc.2012.04.084
NR 56
TC 33
Z9 37
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1544 9173
EI 1545 7885
J9 PLOS BIOL
JI PLoS. Biol.
PD APR
PY 2013
VL 11
IS 4
AR e1001534
DI 10.1371/journal.pbio.1001534
PG 15
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA 140WT
UT WOS:000318687800012
PM 23585735
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhou, DA
   Deng, YN
   Liu, L
   Li, JJ
AF Zhou, Da An
   Deng, Yue Ning
   Liu, Lei
   Li, Jian Jun
TI Effect of kidney reinforcing and marrow beneficial traditional Chinese
   medicine intervened serum on the proliferation and osteogenic
   differentiation of bone marrow stromal cells
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE kidney reinforcing and marrow beneficial traditional Chinese
   Medicine intervened serum; bone marrow mesenchymal stem cells;
   osteogenic differentiation capacity
ID MESENCHYMAL STEM CELLS; OSTEOPOROSIS; TGF BETA 1; OSTEONECROSIS;
   ADIPOGENESIS; OSTEOBLASTS; EXPRESSION; HEPCIDIN; MARKERS; LIVER
AB The present study aimed to investigate the effect of kidney reinforcing and marrow beneficial traditional Chinese medicine (TCM) intervened (KRMBTI) serum on the proliferation and osteogenic differentiation of bone marrow stromal cells (BMSCs) in rats. Rat BMSCs were isolated and cultured in vitro with various concentrations of serum obtained from rats at different time points following treatment with low, medium and high doses of KRMBT. The alkaline phosphatase (ALP) activity and proliferation of the BMCSs was assessed to determine the optimal serum sampling time point and serum concentration. Transforming growth factor (TGF) 1 expression of the BMSCs was detected using enzyme linked immunosorbent assay (ELISA), and hepcidin mRNA expression in the rat livers was detected using reverse transcription polymerase chain reaction. The proliferation of BMCSs treated with serum obtained l h after dosing was observed to be significantly higher than that for BMCSs treated with serum obtained at the four other time points (P<0.05). Furthermore, the proliferation following treatment with 25% KRMBTI serum was significantly higher than that for the other KRMBTI serum concentrations (P<0.01). For a 25% concentration of the serum collected at l h, the proliferation in the high  and low dose KRMBTI serum groups was significantly higher than that of the medium dose and control groups (P<0.01) and no statistical significance was observed between the high  and low dose groups. In the osteogenic differentiation process of the high dose group, the ALP activity at every time point was significantly higher than that of the low dose group and the peak value of the former was achieved at concentrations between 20 and 30%. KRMBTI serum was shown to promote the expression of TGF 1. Furthermore, hepcidin was observed to be expressed at significantly higher levels in the high dose group than in the control group, and hepcidin expression was significantly higher after 10 weeks compared with that after five weeks. These findings suggest that KRMBTI serum increases TGF 1 and hepcidin expression levels, which may be the mechanism underlying the promotion of osteogenic differentiation induced by KRMBTI serum in BMSCs.
C1 [Zhou, Da An; Li, Jian Jun] Capital Med Univ, Sch Rehabil Med, China Rehabil Res Ctr, Dept Spinal & Neural Funct Reconstruct, Beijing 100068, Peoples R China.
   [Zhou, Da An; Deng, Yue Ning; Liu, Lei] Liaoning Med Univ, Dept Rehabil, Affiliated Hosp 3, Jinzhou 121000, Liaoning, Peoples R China.
C3 Capital Medical University; Jinzhou Medical University
RP Li, JJ (通讯作者)，Capital Med Univ, Sch Rehabil Med, China Rehabil Res Ctr, Dept Spinal & Neural Funct Reconstruct, 10 Jiaomen Rd, Beijing 100068, Peoples R China.
EM dajjcn@163.com
CR Anic Branimir, 2006, Reumatizam, V53, P63
   Arnott JA, 2008, BONE, V42, P871, DOI 10.1016/j.bone.2008.01.006
   [陈克明 CHEN Keming], 2008, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V14, P642
   Cui QJ, 1997, CLIN ORTHOP RELAT R, P8
   Fujita T, 1996, CALCIFIED TISSUE INT, V58, P226
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   Houtkooper LB, 2007, ACSMS HEALTH FIT J, V11, P21, DOI 10.1249/01.FIT.0000257708.14987.38
   Inoue Shigehiro, 2003, J Orthop Sci, V8, P751
   [吉静娴 JI Jing xian], 2009, [中国生化药物杂志, Chinese Journal of Biochemical Pharmaceutics], V30, P141
   Kazama T, 2008, BIOCHEM BIOPH RES CO, V377, P780, DOI 10.1016/j.bbrc.2008.10.046
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kim KH, 2005, J ETHNOPHARMACOL, V96, P497, DOI 10.1016/j.jep.2004.09.039
   Liu GW, 2013, ZHONGGUO GU ZHI SHU, V19, P324
   [刘媛 Liu Yuan], 2010, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V16, P713
   [罗晓 LUO Xiao], 2008, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V14, P818
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Nesti LJ, 2007, J CELL BIOCHEM, V101, P348, DOI 10.1002/jcb.21180
   Özmen B, 2007, EUR CYTOKINE NETW, V18, P148
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Qian GF, 2006, ENDOCR J, V53, P87, DOI 10.1507/endocrj.53.87
   Schilling T, 2007, MOL CELL ENDOCRINOL, V271, P1, DOI 10.1016/j.mce.2007.03.004
   Shin MK, 2008, CELL SIGNAL, V20, P613, DOI 10.1016/j.cellsig.2007.11.012
   Wang Xin xiang, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P1119
   Zeng Jian chun, 2010, Zhongguo Gu Shang, V23, P606
NR 25
TC 5
Z9 7
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2015
VL 9
IS 1
BP 191
EP 196
DI 10.3892/etm.2014.2062
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AX1HS
UT WOS:000346699000034
PM 25452801
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Li, WH
   Zhang, XL
   Xi, XH
   Li, YF
   Quan, H
   Liu, SF
   Wu, LQ
   Wu, PH
   Lan, WX
   Shao, YJ
   Li, HM
   Chen, KB
   Hu, ZB
AF Li, Wenhu
   Zhang, Xianliao
   Xi, Xinhua
   Li, Yufa
   Quan, Hong
   Liu, Shifeng
   Wu, Liqi
   Wu, Penghuan
   Lan, Wenxing
   Shao, Yongjun
   Li, Haomiao
   Chen, Kebing
   Hu, Zhengbo
TI PLK2 modulation of enriched TAp73 affects osteogenic differentiation and
   prognosis in human osteosarcoma
SO CANCER MEDICINE
LA English
DT Article
DE osteogenic differentiation; Osteosarcoma; PDX; PLK2; TAp73
ID TRANS RETINOIC ACID; OSTEOBLASTIC DIFFERENTIATION; GENE EXPRESSION;
   HUMAN CANCER; CELL LINE; P73; SURVIVAL; THERAPY; MG 63; RECEPTOR
AB There are three subtypes of undifferentiated human conventional osteosarcoma (HCOS): osteoblastic osteosarcoma (OOS), chondroblastic osteosarcoma (COS), and fibroblastic osteosarcoma (FOS). HCOS also exhibits heterogeneous pathological maldifferentiation in individual patients. Currently, the mechanism regulating HCOS differentiation remains unclear, and therapies are ineffective. Osteopontin (OPN) and osteocalcin (OCN) are markers of osteoblast maturation, and their expression is inhibited in HCOS. A previous study found that PLK2 inhibited TAp73 phosphorylation and consequent anti OS function of TAp73 in OS cells with enriched TAp73. TAp73 was also reported to regulate bone cell calcification. Here, OOS was found to have higher TAp73 levels and PLK2 expression than those in COS, which is correlated with HCOS maldifferentiation according to Spearman analysis and affects patient prognosis according to Kaplan Meier survival analysis. In the conventional OS cell line Saos2 and in patient derived xenograft OS (PDX OS) cells, increased PLK2 expression owing to abundant TAp73 levels affected OPN and OCN content as measured by RT PCR and Western blotting, and alizarin red staining showed that PLK2 affected calcium deposition in OS cells. In addition, PLK2 inhibition in PDX OS cells prohibited clone formation, as indicated by a clonogenic assay, and sensitized OS cells to cisplatin (CDDP) (which consequently limited proliferation), as shown by the CCK 8 assay. In an established PDX animal model with abundant TAp73 levels, PLK2 inhibition or CDDP treatment prevented tumor growth and prolonged median survival. The combined therapeutic effect of PLK2 inhibition with CDDP treatment was better than that of either monotherapy. These results indicate that increased PLK2 levels due to enriched TAp73 affect osteogenic differentiation and maturation and OS prognosis. In conclusion, PLK2 is a potential target for differentiation therapy of OS with enriched TAp73.
C1 [Li, Wenhu; Quan, Hong; Wu, Liqi; Wu, Penghuan; Lan, Wenxing; Shao, Yongjun; Hu, Zhengbo] Southern Med Univ, Dept Orthoped, Shaoguan First Peoples Hosp, Shaoguan 512000, Guangdong, Peoples R China.
   [Zhang, Xianliao; Wu, Penghuan] Southern Med Univ, Orthoped Ctr, Zhujiang Hosp, Guangzhou, Peoples R China.
   [Xi, Xinhua] Shantou Univ, Dept Orthopaed, Affiliated Yuebei Peoples Hosp, Med Coll, Shaoguan, Peoples R China.
   [Li, Yufa] Southern Med Univ, Second Sch Clin Med, Guangzhou, Peoples R China.
   [Li, Yufa] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China.
   [Li, Yufa] Guangdong Acad Med Sci, Guangzhou, Peoples R China.
   [Liu, Shifeng] Dongguan Eighth Peoples Hosp, Orthoped Ctr, Dongguan, Peoples R China.
   [Li, Haomiao; Chen, Kebing] Southern Med Univ, Orthoped Ctr, Orthoped Inst Guangdong Prov, Affiliated Hosp 3, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Shantou University; Southern Medical University   China;
   Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Southern Medical University   China
RP Hu, ZB (通讯作者)，Southern Med Univ, Dept Orthoped, Shaoguan First Peoples Hosp, Shaoguan 512000, Guangdong, Peoples R China.
EM 407822759@qq.com
RI Chan, kevin/JSK 6298 2023; wu, penghuan/GZL 3738 2022; QUAN,
   Hong/GQQ 5435 2022
OI Chen, Kebing/0000 0003 3490 3411; 
FU National Natural Science Foundation of China [81201434]; Natural Science
   Foundation of Guangdong Province [2017A030307012, 2018A0303070013,
   S2012040007947]; Scientific Research Foundation for Youth Scholars of
   Southern Medical University [B1012045]
FX National Natural Science Foundation of China, Grant/Award Number:
   81201434; Natural Science Foundation of Guangdong Province, Grant/Award
   Number: 2017A030307012, 2018A0303070013 and S2012040007947; The
   Scientific Research Foundation for Youth Scholars of Southern Medical
   University, Grant/Award Number: B1012045
CR Ashraf S, 2017, J TISSUE ENG REGEN M, V11, P2503, DOI 10.1002/term.2148
   Berner K, 2015, ACTA ONCOL, V54, P25, DOI 10.3109/0284186X.2014.923934
   Blattmann C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0497 x
   Bunch B, 2019, CELL CYCLE, V18, P2055, DOI 10.1080/15384101.2019.1638693
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Castillo Tandazo W, 2019, CURR OSTEOPOROS REP, V17, P343, DOI 10.1007/s11914 019 00534 w
   Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008
   Chen YN, 2015, ANN DIAGN PATHOL, V19, P33, DOI 10.1016/j.anndiagpath.2014.12.004
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Dancsok AR, 2017, ONCOTARGET, V8, P7068, DOI 10.18632/oncotarget.12548
   de Thé H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103
   DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643
   Ding XP, 2019, REGEN THER, V11, P17, DOI 10.1016/j.reth.2019.03.007
   Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789
   Duchman KR, 2015, CANCER EPIDEMIOL, V39, P593, DOI 10.1016/j.canep.2015.05.001
   Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226
   Finch JL, 2001, J AM SOC NEPHROL, V12, P1468, DOI 10.1681/ASN.V1271468
   Forni C, 2009, MOL CANCER THER, V8, P449, DOI 10.1158/1535 7163.MCT 08 0848
   Gao F X, 1993, Zhonghua Bing Li Xue Za Zhi, V22, P285
   Guilhamon P, 2014, GENOME MED, V6, DOI 10.1186/s13073 014 0116 0
   Hainaut P, 2000, ADV CANCER RES, V77, P81
   Han D, 2019, JOVE J VIS EXP, DOI 10.3791/57011
   Hasegawa T, 1997, CANCER DETECT PREV, V21, P280
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   Hu ZB, 2016, CANCER MED US, V5, P74, DOI 10.1002/cam4.558
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Jemal A., 2010, CA CANCER J CLIN, V60, P277, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050
   Kallio A, 2008, MOL CELL ENDOCRINOL, V289, P38, DOI 10.1016/j.mce.2008.03.005
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kommagani R, 2010, CELL DEATH DIFFER, V17, P398, DOI 10.1038/cdd.2009.135
   KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501
   Liang JT, 2017, ONCOTARGET, V8, P101832, DOI 10.18632/oncotarget.21762
   Liu WJ, 2019, J CELL PHYSIOL, V234, P22972, DOI 10.1002/jcp.28858
   Lu H, 2014, NEOPLASIA, V16, P789, DOI 10.1016/j.neo.2014.08.014
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luther Gaurav, 2010, Trends Cancer Res, V6, P69
   Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936 6943.2003
   Matthew EM, 2007, CELL CYCLE, V6, P2571, DOI 10.4161/cc.6.20.5079
   Mimori K, 2018, ANN GASTROENT SURG, V2, P332, DOI 10.1002/ags3.12182
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Moll UM, 2004, MOL CANCER RES, V2, P371
   Mortus JR, 2014, ADV EXP MED BIOL, V804, P93, DOI 10.1007/978 3 319 04843 7_5
   Ni XL, 2019, CRIT REV FOOD SCI, V59, pS71, DOI 10.1080/10408398.2018.1509201
   Niklison Chirou MV, 2013, P NATL ACAD SCI USA, V110, P18952, DOI 10.1073/pnas.1221172110
   Nozaki K, 1999, J VET MED SCI, V61, P649, DOI 10.1292/jvms.61.649
   Ou BC, 2016, CANCER LETT, V380, P457, DOI 10.1016/j.canlet.2016.07.004
   Paredes R, 2004, J STEROID BIOCHEM, V89 90, P269, DOI 10.1016/j.jsbmb.2004.03.076
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Pellegrino R, 2010, HEPATOLOGY, V51, P857, DOI 10.1002/hep.23467
   Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304
   RODAN SB, 1987, CANCER RES, V47, P4961
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200
   Shen T, 2017, INT J BIOCHEM CELL B, V89, P207, DOI 10.1016/j.biocel.2017.06.012
   Shin DM, 2001, J CLIN ONCOL, V19, P3010, DOI 10.1200/JCO.2001.19.12.3010
   Siolas D, 2013, CANCER RES, V73, P5315, DOI 10.1158/0008 5472.CAN 13 1069
   Sioletic S, 2013, HISTOPATHOLOGY, V62, P287, DOI 10.1111/j.1365 2559.2012.04348.x
   Smeland S, 2019, EUR J CANCER, V109, P36, DOI 10.1016/j.ejca.2018.11.027
   Staals EL, 2006, CANCER AM CANCER SOC, V106, P2682, DOI 10.1002/cncr.21936
   Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647
   Subbiah V, 2015, ONCOTARGET, V6, P40642, DOI 10.18632/oncotarget.5841
   Symon A, 2017, INT J BIOCHEM CELL B, V87, P18, DOI 10.1016/j.biocel.2017.03.005
   Tan LB, 2010, WORLD J UROL, V28, P117, DOI 10.1007/s00345 009 0432 y
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Toumi AA, 2010, APPL IMMUNOHISTO M M, V18, P128, DOI 10.1097/PAI.0b013e3181bcb2da
   Vassilev LT, 2005, J MED CHEM, V48, P4491, DOI 10.1021/jm058174k
   Wan L, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1487 6
   Wang D, 2019, CANCER RES, V79, P7, DOI 10.1158/0008 5472.CAN 18 1086
   Wang YC, 2011, ACTA HISTOCHEM, V113, P402, DOI 10.1016/j.acthis.2010.03.002
   Xia X, 2019, PEERJ, V7, P7974
   Xie YQ, 2018, INT J ONCOL, V52, P1401, DOI 10.3892/ijo.2018.4328
   [许遵营 Xu Zunying], 2016, [中国临床解剖学杂志, Chinese Journal of Clinical Anatomy], V34, P68
   Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607
   Ye H, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190095
   Ying M, 2016, ONCOGENE, V35, P4358, DOI [10.1038/onc.2015.503, 10.1038/onc.2016.29]
   Zenmyo M, 2001, HUM PATHOL, V32, P410, DOI 10.1053/hupa.2001.23524
   Zhao W, 2014, CANCER BIOMARK, V14, P197, DOI 10.3233/CBM 140393
NR 83
TC 12
Z9 13
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2045 7634
J9 CANCER MED US
JI Cancer Med.
PD JUN
PY 2020
VL 9
IS 12
BP 4371
EP 4385
DI 10.1002/cam4.3066
EA APR 2020
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA LY7RF
UT WOS:000529298400001
PM 32349184
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Antunes, LMG
   Bueno, RDE
   Dias, FD
   Bianchi, MDP
AF Greggi Antunes, Lusania Maria
   e Lima Bueno, Rafaela de Barros
   Dias, Francisca da Luz
   Pires Bianchi, Maria de Lourdes
TI Acetylsalicylic acid exhibits anticlastogenic effects on cultured human
   lymphocytes exposed to doxorubicin
SO MUTATION RESEARCH GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
LA English
DT Article
DE acetylsalicylic acid; anticlastogenicity; antimutagenesis; doxorubicin;
   lymphocytes; chromosome aberrations
ID BONE MARROW CELLS; CHROMOSOMAL ABERRATIONS; GENOTOXICITY; CANCER;
   CLASTOGENICITY; ANTHRACYCLINES; ANTIOXIDANTS; ADRIAMYCIN; MECHANISMS;
   ASPIRIN
AB Acetylsalicylic acid (ASA) is a non steroidal anti inflammatory drug (NSAID) with many pharmacological properties, such as anti inflammatory, antipyretic and analgesic. Many studies have suggested the possible efficiency of ASA and other NSAIDs in preventing cancer. ASA could also have antimutagenic and antioxidant properties. The aim of this study was to investigate the possible clastogenic and anticlastogenic effects of different concentrations of ASA on doxorubicin induced chromosomal aberrations in human lymphocytes. Human blood samples were obtained from six healthy, non smoking volunteers; and the chromosomal aberration assay was carried out using conventional techniques. The parameters analyzed were mitotic index, total number of chromosomal aberrations and percentage of aberrant metaphases. The concentrations of ASA (25, 50 or 100 mu g/mL) tested in combination with DXR (0.2 mu g/mL) were established on the basis of the results of the mitotic index. The treatment with ASA alone was neither cytotoxic nor clastogenic (p > 0.01). In lymphocyte cultures treated with different combinations of ASA and DXR, a significant decrease in the total number of chromosome aberrations was observed compared with DXR alone (P < 0.01). This protective effect of ASA on DXR induced chromosomal damage was obtained for all combinations, and it was most evident when ASA was at 25.0 mu g/mL. In our experiments, ASA may have acted as an antioxidant and inhibited the chromosomal damage induced by the free radicals generated by DXR. The identification of compounds that could counteract the free radicals produced by doxorubicin could be of possible benefits against the potential harmful effects of anthracyclines. The results of this study show that there is a relevant need for more investigations in order to elucidate the mechanisms underlying the anticlastogenic effect of ASA. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin Toxicol & Bromatol, BR 05508 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Antunes, LMG (通讯作者)，Av Do Cafe S N, BR 14040903 Ribeirao Preto, SP, Brazil.
EM lusania@fcfrp.usp.br
RI Antunes, Lusânia/B 8040 2012; Antunes, Lusania/B 8040 2012; de Lourdes
   Bianchi, Maria/F 3209 2011
OI Antunes, Lusania/0000 0002 3079 4388; 
CR Ajith TA, 2005, CLIN EXP PHARMACOL P, V32, P888, DOI 10.1111/j.1440 1681.2010.04280.x
   Antunes LMG, 2005, MUTAT RES GEN TOX EN, V585, P113, DOI 10.1016/j.mrgentox.2005.04.006
   Antunes LMG, 1999, TERATOGEN CARCIN MUT, V19, P53
   Arkhipchuk VV, 2004, J APPL TOXICOL, V24, P401, DOI 10.1002/jat.1027
   Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511
   Conklin KA, 2004, J NUTR, V134, p3201S, DOI 10.1093/jn/134.11.3201S
   Costa WF, 2006, ENVIRON MOL MUTAGEN, V47, P18, DOI 10.1002/em.20160
   DeAtley SM, 1999, CANCER LETT, V136, P41, DOI 10.1016/S0304 3835(98)00306 1
   Dhawan A, 2003, MUTAGENESIS, V18, P487, DOI 10.1093/mutage/geg024
   Drew JE, 2005, BIOCHEM PHARMACOL, V70, P888, DOI 10.1016/j.bcp.2005.06.011
   DUNN TL, 1987, MUTAT RES, V189, P299, DOI 10.1016/0165 1218(87)90061 9
   Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006 2952(98)00307 4
   Giri AK, 1996, MUTAT RES GENET TOX, V370, P1, DOI 10.1016/S0165 1218(96)90121 4
   Gülkaç MD, 2004, MUTAGENESIS, V19, P231, DOI 10.1093/mutage/geh021
   Hare LG, 2003, J CLIN PATHOL, V56, P649, DOI 10.1136/jcp.56.9.649
   Heng HHQ, 2006, GENOME, V49, P195, DOI 10.1139/G06 023
   Hsu CS, 2002, BIOCHEM BIOPH RES CO, V293, P705
   INCHIOSA MA, 1990, RES COMMUN CHEM PATH, V67, P63
   Islaih M, 2005, MUTAT RES FUND MOL M, V578, P100, DOI 10.1016/j.mrfmmm.2005.04.012
   JARVIK LF, 1971, SCIENCE, V171, P829
   Karahalil B, 2002, MUTAT RES GEN TOX EN, V515, P135, DOI 10.1016/S1383 5718(02)00003 7
   KARGER S, 1985, INT SYSTEM HUMAN CYT, P66
   MAUER I, 1970, SCIENCE, V169, P198, DOI 10.1126/science.169.3941.198
   Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6
   MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014 4827(60)90138 5
   MULLER L, 1991, MUTAT RES, V263, P83, DOI 10.1016/0165 7992(91)90064 B
   Niikawa M, 2001, BIOL PHARM BULL, V24, P964, DOI 10.1248/bpb.24.964
   OLDHAM JW, 1986, J APPL TOXICOL, V6, P237, DOI 10.1002/jat.2550060403
   Peek RM, 2004, CANCER CHEMOTH PHARM, V54, pS50, DOI 10.1007/s00280 004 0887 x
   Resende FA, 2006, LIFE SCI, V79, P1268, DOI 10.1016/j.lfs.2006.03.038
   SIMPSON C, 2003, CLIN J ONCOL NURS, V8, P497
   Surh YJ, 1999, MUTAT RES FUND MOL M, V428, P305, DOI 10.1016/S1383 5742(99)00057 5
   Weijl NI, 1997, CANCER TREAT REV, V23, P209, DOI 10.1016/S0305 7372(97)90012 8
   WEISS RB, 1992, SEMIN ONCOL, V19, P670
   Zeiger E, 2003, MUTAT RES REV MUTAT, V543, P191, DOI 10.1016/S1383 5742(02)00111 4
NR 35
TC 16
Z9 17
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1383 5718
EI 1879 3592
J9 MUTAT RES GEN TOX EN
JI Mutat. Res. Genet. Toxicol. Environ. Mutagen.
PD JAN 10
PY 2007
VL 626
IS 1 2
BP 155
EP 161
DI 10.1016/j.mrgentox.2006.09.009
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 128FR
UT WOS:000243644100019
PM 17097912
DA 2025 08 17
ER

PT J
AU Sato, K
   Osaka, E
   Fujiwara, K
   Fujii, R
   Takayama, T
   Tokuhashi, Y
   Nakanishi, K
AF Sato, Kentaro
   Osaka, Eiji
   Fujiwara, Kyoko
   Fujii, Ryota
   Takayama, Tadateru
   Tokuhashi, Yasuaki
   Nakanishi, Kazuyoshi
TI miRNA 218 targets multiple oncogenes and is a therapeutic target for
   osteosarcoma
SO ONCOLOGY REPORTS
LA English
DT Article
DE osteosarcoma; miR 218; survivin; YM155; targeted therapy
ID SQUAMOUS CELL CARCINOMA; SURVIVIN MESSENGER RNA; LUNG CANCER;
   OPEN LABEL; EXPRESSION; GENE; METASTASIS; APOPTOSIS; PROLIFERATION;
   MULTICENTER
AB Survivin is overexpressed in various cancers and is correlated with treatment resistance and prognosis. MicroRNAs (miRNAs) directly regulate several target genes and are potential therapeutic agents for various cancers. The present study evaluated multiple gene targets of miR 218, including survivin, in osteosarcoma and compared the anti tumor effects of miR 218 with those of YM155, an anti survivin agent. It assessed the expression levels of miR 218 and survivin in osteosarcoma and osteoblast cell lines, as well as the proliferative, migratory and invasive capacities of cells following treatment with miR 218 or YM155. The form of cell death was assessed using fluorescence activated cell sorting analysis to examine the expression of invasion ability related genes. Osteosarcoma cell lines were subcutaneously injected into immunodeficient mice; the mice were then treated with miR 218 or YM155 to assess the anti tumor effects of these agents. The results showed that miR 218 was downregulated, whereas survivin was overexpressed in the osteosarcoma cell line compared with normal osteoblast cells. The expression of survivin was suppressed upon overexpression of miR 218 (miR 218 group) or administration of YM155 (YM155 group), leading to apoptosis and inhibition of osteosarcoma cell proliferation. Invasion and migration abilities were inhibited in the miR 218 group, but not in the YM155 group. In the animal model, both the miR 218 and YM155 groups showed a reduced tumor volume and decreased survivin expression. In osteosarcoma, miR 218 showed a wider range of therapeutic efficacy compared with YM155, suggesting that miR 218 should be evaluated as a treatment target.
C1 [Sato, Kentaro] Nihon Univ Hosp, Dept Orthoped Surg, Tokyo, Tokyo 1018309, Japan.
   [Osaka, Eiji; Fujii, Ryota; Nakanishi, Kazuyoshi] Nihon Univ Sch Med, Dept Orthoped Surg, Tokyo, Tokyo, Japan.
   [Fujiwara, Kyoko; Takayama, Tadateru] Nihon Univ Sch Med, Dept Internal Med, Tokyo, Tokyo 1738610, Japan.
   [Fujiwara, Kyoko] Nihon Univ Sch Dent, Dept Anat, Tokyo, Tokyo 1018310, Japan.
   [Tokuhashi, Yasuaki] Tachikawa Kinen Hosp, Dept Orthoped Surg, Kasama City, Ibaraki 3091736, Japan.
C3 Nihon University; Nihon University; Nihon University; Nihon University
RP Osaka, E (通讯作者)，Nihon Univ Sch Med, Dept Orthoped Surg, 30 1 Oyaguchikami cho, Tokyo, Tokyo 1738610, Japan.
EM osaka.eiji@nihon u.ac.jp
CR Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Chen X, 2016, J CANCER, V7, P1057, DOI 10.7150/jca.15061
   Clemens MR, 2015, BREAST CANCER RES TR, V149, P171, DOI 10.1007/s10549 014 3238 6
   Dai G, 2018, CELL PHYSIOL BIOCHEM, V46, P1134, DOI 10.1159/000488842
   Deng WW, 2013, NANOMED NANOTECHNOL, V9, P1181, DOI 10.1016/j.nano.2013.05.008
   Di Leva G, 2014, ANNU REV PATHOL MECH, V9, P287, DOI 10.1146/annurev pathol 012513 104715
   Eaton BR, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28352
   Fernández JG, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 209
   Gao JZ, 2015, EUR REV MED PHARMACO, V19, P2062
   Huang JC, 2015, AM J CANCER RES, V5, P20
   Imai M, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 319
   Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096 911X(20001201)35:6<550::AID MPO12>3.0.CO;2 Y
   Italiano A, 2020, LANCET ONCOL, V21, P446, DOI [10.1016/51470 2045(19)30825 3, 10.1016/S1470 2045(19)30825 3]
   Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026
   Kami K, 2004, SURGERY, V136, P443, DOI 10.1016/j.surg.2004.05.023
   Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097 0215(20011120)95:6<360::AID IJC1063>3.0.CO;2 1
   Kataoka K, 2016, THORAC CANCER, V7, P676, DOI 10.1111/1759 7714.12366
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kogo R, 2015, ONCOTARGET, V6, P1090, DOI 10.18632/oncotarget.2836
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Li YJ, 2017, FUTURE ONCOL, V13, P2571, DOI 10.2217/fon 2017 0398
   Lin CH, 2014, ADV EXP MED BIOL, V804, P33, DOI 10.1007/978 3 319 04843 7_2
   Liu JG, 2017, MOL MED REP, V16, P7949, DOI 10.3892/mmr.2017.7660
   Liu Y, 2020, J BUON, V25, P2708
   Liu YG, 2015, MED SCI MONITOR, V21, P2877, DOI 10.12659/MSM.894448
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu YF, 2015, EXP CELL RES, V334, P173, DOI 10.1016/j.yexcr.2015.03.027
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078 0432.CCR 08 0746
   Miyachi Kazuhito, 2003, Gastric Cancer, V6, P217, DOI 10.1007/s10120 003 0255 2
   Monzó M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100
   Osaka E, 2007, J ORTHOP RES, V25, P116, DOI 10.1002/jor.20291
   Pakkala S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120858
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645
   Shaikh AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040506
   Szuhai K, 2012, CANCER GENET NY, V205, P193, DOI 10.1016/j.cancergen.2012.04.001
   Tong XZ, 2019, ONCOL LETT, V18, P359, DOI 10.3892/ol.2019.10335
   Tutar L, 2015, DRUG DEVELOP RES, V76, P382, DOI 10.1002/ddr.21273
   van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470 2045(17)30621 6
   Waller CF., 2018, CANCER RES, V212, DOI [10.1007/978 3 319 91439 8_1, DOI 10.1007/978 3 319 91439 8_1]
   Wang HD, 2004, J CANCER RES CLIN, V130, P487, DOI 10.1007/s00432 004 0561 z
   Xuan CM, 2019, ONCOL LETT, V17, P571, DOI 10.3892/ol.2018.9576
   Zarogoulidis P, 2015, CELL SIGNAL, V27, P1576, DOI 10.1016/j.cellsig.2015.04.009
   Zhang W, 2016, CELL PHYSIOL BIOCHEM, V38, P2426, DOI 10.1159/000445594
   Zhang Z, 2015, ONCOL REP, V34, P1074, DOI 10.3892/or.2015.4067
NR 46
TC 6
Z9 6
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2022
VL 47
IS 5
AR 92
DI 10.3892/or.2022.8303
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 0H2WB
UT WOS:000778596500001
PM 35293593
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Choudhary, S
   Halbout, P
   Alander, C
   Raisz, L
   Pilbeam, C
AF Choudhary, Shilpa
   Halbout, Philippe
   Alander, Cynthia
   Raisz, Lawrence
   Pilbeam, Carol
TI Strontium ranelate promotes osteoblastic differentiation and
   mineralization of murine bone marrow stromal cells: Involvement of
   prostaglandins
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE cyclooxygenase 2; osteoblast; osteocalcin; dexamethasone; alkaline
   phosphatase
ID ANTIFRACTURE EFFICACY; ALVEOLAR BONE; IN VITRO; RESORPTION; E 2;
   CYCLOOXYGENASE 2; INCREASES; CULTURES; E(2); RATS
AB Strontium ranelate is a new anti osteoporosis treatment. This study showed that strontium ranelate stimulated PGE(2) production and osteoblastic differentiation in murine marrow stromal cells, which was markedly reduced by inhibition of COX 2 activity or disruption of COX 2 gene expression. Hence, some anabolic effects of strontium ranelate may be mediated by the induction of COX 2 and PGE2 production.
   Introduction: Strontium ranelate is an orally active drug that reduces vertebral and hip fracture risk by increasing bone formation and reducing bone resorption. Strontium ranelate effects on bone formation are the result of increased osteoblastic differentiation and activity, but the mechanisms governing these effects are unknown. Based on previous work, we hypothesized that strontium ranelate increases cyclooxygenase (COX) 2 expression and that, consequently, the prostaglandin E 2 (PGE2) produced could mediate some effects of strontium ranelate on osteoblasts.
   Materials and Methods: Marrow stromal cells (MSCs) from COX 2 wildtype (WT) and knockout (KO) mice were cultured with and without low dose dexamethasone. Osteoblastic differentiation was characterized by alkaline phosphatase (ALP) activity, real time PCR for ALP and osteocalcin (OCN) mRNA expression, and alizarin red staining for mineralization. Medium PGE2 was measured by radioimmunoassay or enzyme immunoassay.
   Results and Conclusions: In MSCs from COX 2 WT mice, strontium ranelate significantly increased ALP activity, ALP and OCN mRNA expression, and mineralization after 14 or 21 days of culture. A short treatment at the beginning of the culture (0 7 days) with strontium ranelate was as effective as continuous treatment. Strontium ranelate (1 and 3 mM Sr+2) dose dependently increased PGE2 production, with maximum PGE2 production occurring during the first week of culture. NS 398, a selective COX 2 inhibitor, blocked the strontium ranelate stimulation of PGE2 production and significantly inhibited the strontium ranelate stimulation of ALP activity. In MSCs from COX 2 KO mice, the strontium ranelate stimulation of ALP and OCN mRNA expression and mineralization were markedly reduced compared with COX 2 WT cultures. Similar effects of strontium ranelate on osteoblastic markers and on PGE2 production were seen when MSCs were cultured with or without low dose dexamethasone (10 nM). We conclude that PGE2 produced by the strontium ranelate induction of COX 2 expression plays a role in strontium ranelate induced osteoblastic differentiation in MSCs in vitro.
C1 Univ Connecticut, Ctr Hlth, MARB, Dept Med, Farmington, CT 06030 USA.
   Inst Rech Int Servier, F 92415 Courbevoie, France.
C3 University of Connecticut; Servier; Institut de Recherches
   Internationales Servier
RP Pilbeam, C (通讯作者)，Univ Connecticut, Ctr Hlth, MARB, Dept Med, Room N4051,263 Farmington Ave, Farmington, CT 06030 USA.
EM pilbeam@nso.uchc.edu
FU NIAMS NIH HHS [R01AR18063] Funding Source: Medline; NIDDK NIH HHS [R01
   DK048361, R01DK48361] Funding Source: Medline
CR Adami S, 2006, BONE, V38, P23, DOI 10.1016/j.bone.2005.08.028
   Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097 4644(19990301)72:3<396::AID JCB9>3.3.CO;2 Y
   Barbara A, 2004, METABOLISM, V53, P532, DOI 10.1016/j.metabol.2003.10.022
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Brennan T., 2006, Calcified Tissue International, V78, pS129
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019
   Cheng SL, 1996, J CELL BIOCHEM, V61, P182, DOI 10.1002/(SICI)1097 4644(19960501)61:2<182::AID JCB3>3.0.CO;2 Q
   Chikazu D, 2005, J BONE MINER RES, V20, P1887, DOI 10.1359/jbmr.2005.20.10.1887
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Delannoy P, 2002, METABOLISM, V51, P906, DOI 10.1053/meta.2002.33360
   Einhorn TA, 2003, ARTHRITIS RES THER, V5, P5, DOI 10.1186/ar607
   FayePetersen OM, 1996, PEDIATR PATHOL LAB M, V16, P489, DOI 10.1080/15513819609168686
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   Fromigue O., 2006, Calcified Tissue International, V78, pS145
   Hott M, 2003, BONE, V33, P115, DOI 10.1016/S8756 3282(03)00115 7
   JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834
   Ke HZ, 1998, BONE, V23, P249, DOI 10.1016/S8756 3282(98)00102 1
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   MILLER SC, 1993, BONE, V14, P587, DOI 10.1016/8756 3282(93)90198 J
   NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559
   NORRDIN RW, 1988, CALCIFIED TISSUE INT, V42, P363, DOI 10.1007/BF02556354
   Okada Y, 2000, J BONE MINER RES, V15, pS217
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Ortolani S, 2006, BONE, V38, P19, DOI 10.1016/j.bone.2005.10.030
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   PILBEAM CC, 1993, J BIOL CHEM, V268, P25643
   PILBEAM CC, 2002, PRINCIPLES BONE BIOL, V2, P979
   Purpura KA, 2003, J CELL BIOCHEM, V90, P109, DOI 10.1002/jcb.10596
   RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1076, DOI 10.1210/endo 126 2 1076
   Raisz LG, 2003, PROSTAG OTH LIPID M, V71, P287, DOI 10.1016/S1098 8823(03)00049 2
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reginster JY, 2002, CURR PHARM DESIGN, V8, P1907, DOI 10.2174/1381612023393639
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Takiguchi T, 1999, J PERIODONTAL RES, V34, P431
   Tang LY, 1996, J CELL PHYSIOL, V166, P76
   UEDA K, 1980, J PEDIATR US, V97, P834, DOI 10.1016/S0022 3476(80)80282 4
   VANVLASSELAER P, 1994, BLOOD, V84, P753, DOI 10.1182/blood.V84.3.753.bloodjournal843753
   Weinreb M, 1999, AM J PHYSIOL ENDOC M, V276, pE376, DOI 10.1152/ajpendo.1999.276.2.E376
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 50
TC 146
Z9 176
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2007
VL 22
IS 7
BP 1002
EP 1010
DI 10.1359/JBMR.070321
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 181QQ
UT WOS:000247451600006
PM 17371157
DA 2025 08 17
ER

PT J
AU Georgaki, M
   Delli, K
   Paschalidi, P
   Gkizani, S
   Tsiklakis, K
   Nikitakis, NG
AF Georgaki, Maria
   Delli, Konstantina
   Paschalidi, Polytimi
   Gkizani, Sotiria
   Tsiklakis, Konstantinos
   Nikitakis, Nikolaos G.
TI Chronic Osteomyelitis With Proliferative Periostitis of the Mandible in
   a Child Report of a Case Managed by Immunosuppressive Treatment
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE osteomyelitis with proliferative periostitis; primary chronic
   osteomyelitis; chronic recurrent multifocal osteomyelitis;
   immunosuppressive therapy; anti TNF
ID RECURRENT MULTIFOCAL OSTEOMYELITIS; DIFFUSE SCLEROSING OSTEOMYELITIS;
   OSSIFICANS GARRES OSTEOMYELITIS; RETROSPECTIVE ANALYSIS; FIBROUS
   DYSPLASIA; CLASSIFICATION; DIAGNOSIS; CRMO
AB Background: Osteomyelitis with proliferative periostitis is a relatively uncommon inflammatory condition of the jaws, mainly characterized by periosteal formation of reactive bone. It primarily affects children and adolescences, also referred to as Garre's osteomyelitis, more frequently involving the molar region of the mandible. Cases lacking an obvious source of infection may have an immunologically mediated etiopathogenesis, falling under the spectrum of primary chronic osteomyelitis or chronic recurrent multifocal osteomyelitis (CRMO).
   Case report: Herein, we present a case of chronic osteomyelitis in a 6.5 year old girl, who suffered from recurrent painful episodes of swelling of the mandible for the last 2 years, previously requiring hospitalization and administration of intravenous (IV) antibiotics and NSAIDs with limited responsiveness. The biopsy showed features consistent with osteomyelitis with proliferative periostitis. The patient was initially managed with an IV combination antibiotic regimen with only partial improvement. The possibility of an autoimmune mechanism in the context of primary chronic osteomyelitis or CRMO was considered, and immunosuppressive therapy (TNF inhibitor etanercept along with corticosteroids and methotrexate) was administered, resulting in clinical resolution.
   Conclusions: Osteomyelitis and its childhood variants are relatively rare and their management presents several challenges. Although typically treated with administration of antibiotics, possibly along with surgical intervention, other treatment modalities may be necessary for resilient and persistent cases. In a subset of cases, especially in the absence of local infectious factors, immunologically mediated mechanisms may play an important role and appropriate immunosuppressive therapy may be effective.
C1 [Georgaki, Maria] Natl & Kapodistrian Univ Athens, Dept Oral Med & Pathol, Sch Dent, Athens, Greece.
   [Georgaki, Maria] Natl & Kapodistrian Univ Athens, Hosp Dent, Sch Dent, Athens, Greece.
   [Delli, Konstantina] Univ Groningen, Univ Med Ctr Groningen, Dept Oral Dis Oral & Maxillofacial Surg, Groningen, Netherlands.
   [Paschalidi, Polytimi] Natl & Kapodistrian Univ Athens, Sch Dent, Dept Oral & Maxillofacial Surg, Athens, Greece.
   [Gkizani, Sotiria] Natl & Kapodistrian Univ Athens, Sch Dent, Dept Paediat Dent, Athens, Greece.
   [Tsiklakis, Konstantinos] Natl & Kapodistrian Univ Athens, Sch Dent, Dept Oral Diag & Radiol, Athens, Greece.
   [Nikitakis, Nikolaos G.] Natl & Kapodistrian Univ Athens, Dept Oral Med & Pathol & Hosp Dent, Sch Dent, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; University of Groningen; National & Kapodistrian
   University of Athens; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens
RP Georgaki, M (通讯作者)，Univ Athens, Dept Oral Med & Pathol, Sch Dent, 2 Thivon St Goudi, Athens 11527, Greece.; Georgaki, M (通讯作者)，Univ Athens, Hosp Dent, Sch Dent, 2 Thivon St Goudi, Athens 11527, Greece.
EM mar1georgaki@gmail.com
RI ; Delli, Konstantina/AAF 2270 2019
OI Georgaki, Maria/0000 0002 0734 8857; Delli,
   Konstantina/0000 0003 3115 3977; 
CR Ahuja Upasana S, 2019, Int J Clin Pediatr Dent, V12, P470, DOI 10.5005/jp journals 10005 1665
   Allen, 2016, ORAL MAXILLOFACIAL P, P128
   Audu GK, 2015, J PEDIATR GASTR NUTR, V60, P586, DOI 10.1097/MPG.0000000000000663
   Baltensperger M, 2004, J CRANIO MAXILL SURG, V32, P43, DOI 10.1016/j.jcms.2003.07.008
   Berglund C, 2015, CASE REP DENT, V2015, DOI 10.1155/2015/152717
   Bertrand K, 2018, EUR J CLIN MICROBIOL, V37, P1071, DOI 10.1007/s10096 018 3219 5
   Bevin CR, 2008, J ORAL MAXIL SURG, V66, P2073, DOI 10.1016/j.joms.2008.06.029
   Buch K, 2019, CALCIFIED TISSUE INT, V104, P544, DOI 10.1007/s00223 018 0495 0
   Dushnicky MJ, 2021, J PEDIATR GASTR NUTR, V73, P626, DOI 10.1097/MPG.0000000000003225
   Dym Harry, 2017, Dent Clin North Am, V61, P271, DOI 10.1016/j.cden.2016.12.001
   Eyrich GKH, 2003, J ORAL MAXIL SURG, V61, P561, DOI 10.1053/joms.2003.50110
   Flygare L, 1997, ORAL SURG ORAL MED O, V83, P300, DOI 10.1016/S1079 2104(97)90020 2
   Frid P, 2009, ORAL SURG ORAL MED O, V107, P641, DOI 10.1016/j.tripleo.2009.01.020
   Gaal A, 2020, PEDIATR RHEUMATOL, V18, DOI 10.1186/s12969 019 0384 8
   Gaetti Jardim E, 2010, BRAZ J MICROBIOL, V41, P1056, DOI [10.1590/S1517 83822010000400025, 10.1590/S1517 838220100004000025]
   GROOT RH, 1992, ORAL SURG ORAL MED O, V74, P557, DOI 10.1016/0030 4220(92)90342 N
   Hameed M, 2020, HEAD NECK PATHOL, V14, P70, DOI 10.1007/s12105 019 01094 2
   Hofmann SR, 2015, CLIN IMMUNOL, V161, P300, DOI 10.1016/j.clim.2015.09.013
   Jia KK, 2021, J ORAL MAXIL SURG, V79, P1053, DOI 10.1016/j.joms.2020.11.014
   Kannan SK, 2006, INT J PAEDIATR DENT, V16, P59, DOI 10.1111/j.1365 263X.2006.00630.x
   Kawai T, 1996, ORAL SURG ORAL MED O, V82, P704, DOI 10.1016/S1079 2104(96)80447 1
   Lentrodt S, 2007, J ORAL MAXIL SURG, V65, P186, DOI 10.1016/j.joms.2005.11.106
   Liu D, 2019, ANN ROY COLL SURG, V101, P328, DOI 10.1308/rcsann.2019.0021
   Lukosiunas A, 2011, MEDICINA LITHUANIA, V47, P380, DOI 10.3390/medicina47070054
   MALMSTROM M, 1983, INT J ORAL MAXILLOF, V12, P6, DOI 10.1016/S0300 9785(83)80074 X
   Martin Granizo R, 1999, OTOLARYNG HEAD NECK, V121, P828, DOI 10.1053/hn.1999.v121.a94999
   Marx RE, 2012, ORAL AND MAXILLOFACIAL PATHOLOGY: A RATIONALE FOR DIAGNOSIS AND TREATMENT, VOL I AND II, SECOND EDITION, P1
   Moratin J, 2021, CLIN ORAL INVEST, V25, P1395, DOI 10.1007/s00784 020 03447 6
   Moreno Mateo F, 2021, CURR OPIN PEDIATR, V33, P90, DOI 10.1097/MOP.0000000000000970
   Oulis C, 2000, Int J Paediatr Dent, V10, P240, DOI 10.1046/j.1365 263x.2000.00199.x
   Petrikowski CG, 1995, ORAL SURG ORAL MED O, V80, P744, DOI 10.1016/S1079 2104(05)80260 4
   Robertsson C, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101089
   Schuknecht BF, 1997, J CRANIO MAXILL SURG, V25, P24, DOI 10.1016/S1010 5182(97)80021 2
   STEWART A, 1994, SKELETAL RADIOL, V23, P225
   Suei Y, 2005, ORAL SURG ORAL MED O, V100, P207, DOI 10.1016/j.tripleo.2004.11.006
   SUEI Y, 1994, ORAL SURG ORAL MED O, V78, P156, DOI 10.1016/0030 4220(94)90139 2
   Taddio A, 2017, PEDIATR DRUGS, V19, P165, DOI 10.1007/s40272 017 0226 4
   Tlougan BE, 2009, PEDIATR DERMATOL, V26, P497, DOI 10.1111/j.1525 1470.2009.00984.x
   Tong Antonio C K, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V102, pe14, DOI 10.1016/j.tripleo.2006.03.025
   VANDENBOSSCHE LH, 1993, J PERIODONTOL, V64, P60, DOI 10.1902/jop.1993.64.1.60
   Walsh P, 2015, RHEUMATOLOGY, V54, P1688, DOI 10.1093/rheumatology/kev013
   Wood N K., 1997, Differential diagnosis of oral lesions, V5
   WOOD RE, 1988, ORAL SURG ORAL MED O, V65, P773, DOI 10.1016/0030 4220(88)90028 X
   Zuluaga AF, 2006, ARCH INTERN MED, V166, P95, DOI 10.1001/archinte.166.1.95
NR 44
TC 1
Z9 3
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891 3668
EI 1532 0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JAN
PY 2022
VL 41
IS 1
BP E10
EP E15
DI 10.1097/INF.0000000000003368
PG 6
WC Immunology; Infectious Diseases; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Pediatrics
GA XM4GA
UT WOS:000728786600005
PM 34711782
OA Green Published
DA 2025 08 17
ER

PT J
AU Henriksen, K
   Byrjalsen, I
   Nielsen, RH
   Madsen, AN
   Larsen, LK
   Christiansen, C
   Beck Nielsen, H
   Karsdal, MA
AF Henriksen, Kim
   Byrjalsen, Inger
   Nielsen, Rasmus H.
   Madsen, Andreas N.
   Larsen, Leif K.
   Christiansen, Claus
   Beck Nielsen, Henning
   Karsdal, Morten A.
TI A comparison of glycemic control, water retention, and musculoskeletal
   effects of balaglitazone and pioglitazone in diet induced obese rats
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Diabetes; Pioglitazone; Balaglitazone; Oedema; Bone formation; Oral
   glucose tolerance test
ID PROLIFERATOR ACTIVATED RECEPTOR; IMPAIRED GLUCOSE TOLERANCE; PPAR GAMMA
   AGONIST; BONE FORMATION; OSTEOBLAST DIFFERENTIATION; THERAPEUTIC
   TARGETS; INSULIN RESISTANCE; METABOLIC DISEASE; IN VITRO; ROSIGLITAZONE
AB Agonists of Perioxisome Proliferator Activator Receptor gamma (PPAR gamma), which work as insulin sensitizers, are approved for type 2 diabetes. However. adverse effects, such as oedemas, infarctions, and increased fracture rates, limit their applicability.
   We performed a head to head comparison of equipotent glucose lowering concentrations of the partial PPAR gamma agonist balaglitazone and the full agonist pioglitazone in male diet induced obese rats, to investigate effects on bone formation, fluid retention and fat accumulation.
   Sixty male dio induced obese rats were divided into five categories: vehicle, pioglitazone 10 mg/kg, pioglitazone 30 mg/kg, balaglitazone 5 mg/kg, balaglitazone 10 mg/kg. At day  7, 21 and 42 fasting serum samples were collected and whole body tissue composition was evaluated by MR scanning. Food intake and bodyweights were monitored during the study period. At day 42, an oral glucose tolerance test was performed to evaluate glucose homeostasis in the rats.
   During oral glucose tolerance test both pioglitazone and balaglitazone lowered baseline glucose and maintained the suppression during the oral glucose tolerance test. Both lowered basal insulin, peak insulin secretion and total insulin during oral glucose tolerance test Both drugs increased bodyweight, although this was more pronounced in the pioglitazone 30 group. MR scans of body fat and water showed that all treatment groups increased their fat mass, whereas only the pioglitazone 30 group accumulated water. Pioglitazone treatment led to reduction of the bone formation marker osteocalcin, whereas balaglitazone treatment did not affect it.
   Balaglitazone is a novel PPAR gamma agonist. which potently lowers glucose levels, while it neither affects fluid retention nor bone formation parameters. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Henriksen, Kim; Byrjalsen, Inger; Nielsen, Rasmus H.; Madsen, Andreas N.; Larsen, Leif K.; Karsdal, Morten A.] Nord Biosci AS, DK 2730 Herlev, Denmark.
   [Christiansen, Claus] CCBR, Ballerup, Denmark.
   [Beck Nielsen, Henning] Univ Hosp So Denmark, Odense, Denmark.
C3 Nordic Bioscience; Synarc; Center Clinical & Basic Research; University
   of Southern Denmark; University of Southern Denmark Hospital
RP Henriksen, K (通讯作者)，Nord Biosci AS, Herlev Hovedgade 207, DK 2730 Herlev, Denmark.
EM kh@nordicbioscience.com
OI Karsdal, Morten/0000 0001 5026 8740
FU Danske Forskningsfond
FX We thank the "Danske Forskningsfond" for support to work by Rasmus H.
   Nielsen.
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002 0217
   Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003
   Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005 0171
   Deeg MA, 2008, PPAR RES, V2008, DOI 10.1155/2008/520465
   Diep QN, 2002, CIRCULATION, V105, P2296, DOI 10.1161/01.CIR.0000016049.86468.23
   Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471 4914(02)02385 7
   Eguchi K, 2007, HYPERTENS RES, V30, P23, DOI 10.1291/hypres.30.23
   Einstein M, 2008, MOL PHARMACOL, V73, P62, DOI 10.1124/mol.107.041202
   Froment P, 2006, PPAR RES, V2006, DOI 10.1155/PPAR/2006/73986
   Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433
   Glintborg D, 2008, DIABETES CARE, V31, P328, DOI 10.2337/dc07 1424
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Guan YF, 2005, NAT MED, V11, P861, DOI 10.1038/nm1278
   Khan E, 2003, J LAB CLIN MED, V142, P29, DOI 10.1016/S0022 2143(03)00058 1
   Kintscher U, 2000, EUR J PHARMACOL, V401, P259, DOI 10.1016/S0014 2999(00)00461 1
   Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003 0036
   Larsen PJ, 2008, EUR J PHARMACOL, V596, P173, DOI 10.1016/j.ejphar.2008.08.004
   Larsen PJ, 2003, DIABETES, V52, P2249, DOI 10.2337/diabetes.52.9.2249
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Levin BE, 1997, AM J PHYSIOL REG I, V273, pR725, DOI 10.1152/ajpregu.1997.273.2.R725
   Li M, 2006, BONE, V39, P796, DOI 10.1016/j.bone.2006.04.008
   LOKE YK, 2008, CMAJ
   McDonough AK, 2008, NAT CLIN PRACT ENDOC, V4, P507, DOI 10.1038/ncpendmet0920
   Rahman S, 2007, EUR J CLIN PHARMACOL, V63, P733, DOI 10.1007/s00228 007 0315 3
   Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167
   Rosen CJ, 2008, J BONE MINER RES, V23, P1881, DOI 10.1359/JBMR.081001
   Schaller S, 2005, ASSAY DRUG DEV TECHN, V3, P553, DOI 10.1089/adt.2005.3.553
   Schaller S, 2004, J BONE MINER RES, V19, P1144, DOI 10.1359/JBMR.040302
   Schwartz AV, 2008, PPAR RES, V2008, DOI 10.1155/2008/297893
   Singh S, 2007, JAMA J AM MED ASSOC, V298, P1189, DOI 10.1001/jama.298.10.1189
   Song J, 2004, J PHARMACOL EXP THER, V308, P426, DOI 10.1124/jpet.103.058008
   Sorensen MG, 2007, BIOMARKERS, V12, P266, DOI 10.1080/13547500601070842
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   TAKADA L, 2007, ANN NY ACAD SCI, V1116, P182
   Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341
   Yokoyama J, 2007, HEART VESSELS, V22, P146, DOI 10.1007/s00380 006 0951 z
   Zanchi A, 2004, J CLIN ENDOCR METAB, V89, P1140, DOI 10.1210/jc.2003 031526
NR 39
TC 17
Z9 19
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 15
PY 2009
VL 616
IS 1 3
BP 340
EP 345
DI 10.1016/j.ejphar.2009.06.051
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 495YT
UT WOS:000269933100051
PM 19595686
DA 2025 08 17
ER

PT J
AU Young, EW
   Albert, JM
   Satayathum, S
   Goodkin, DA
   Pisoni, RL
   Akiba, T
   Akizawa, T
   Kurokawa, K
   Bommer, J
   Piera, L
   Port, FK
AF Young, EW
   Albert, JM
   Satayathum, S
   Goodkin, DA
   Pisoni, RL
   Akiba, T
   Akizawa, T
   Kurokawa, K
   Bommer, J
   Piera, L
   Port, FK
TI Predictors and consequences of altered mineral metabolism: The Dialysis
   Outcomes and Practice Patterns Study
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE mineral metabolism; vitamin D; phosphorus binders; calcium phosphorus
   product; parathyroid hormone; DOPPS
ID STAGE RENAL DISEASE; HEMODIALYSIS PATIENTS; PARATHYROID HORMONE;
   MORTALITY RISK; CALCIFICATION; ASSOCIATION; CORONARY; PRODUCT; CALCIUM;
   DOPPS
AB Background. Altered mineral metabolism contributes to bone disease, cardiovascular disease, and other clinical problems in patients with end stage renal disease.
   Methods. This study describes the recent status, significant predictors, and potential consequences of abnormal mineral metabolism in representative groups of hemodialysis facilities (N = 307) and patients (N = 17,236) participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS) in the United States, Europe, and Japan from 1996 to 2001.
   Results. Many patients fell out of the recommended guideline range for serum concentrations of phosphorus (8% of patients below lower target range, 52% of patients above upper target range), albumin corrected calcium (9% below, 50% above), calcium phosphorus product (44% above), and intact PTH (51% below, 27% above). All cause mortality was significantly and independently associated with serum concentrations of phosphorus (RR 1.04 per 1 mg/dL, P = 0.0003), calcium (RR 1.10 per 1 mg/dL, P < 0.0001), calcium phosphorus product (RR 1.02 per 5 mg(2)/dL(2), p = 0.0001), PTH (1.01 per 100 pg/dL, P = 0.04), and dialysate calcium (RR 1.13 per 1 mEq/L, P = 0.01). Cardiovascular mortality was significantly associated with the serum concentrations of phosphorus (RR 1.09, P < 0.0001) calcium (RR 1.14, P < 0.0001), calcium phosphorus produc; (RR 1.05, P < 0.0001), and PTH (RR 1.02, P = 0.03). The adjusted rate of parathyroidectomy varied 4 fold across the DOPPS countries, and was significantly associated with baseline concentrations of phosphorus (RR 1.17, P < 0.0001), calcium (RR 1.58, P < 0.0001), calcium phosphorus product (RR 1.11, P < 0.0001), PTH (RR 1.07, P < 0.0001), and dialysate calcium concentration (RR 0.57, P = 0.03). Overall, 52% of patients received some form of vitamin D therapy, with parenteral forms almost exclusively restricted to the United States. Vitamin D was potentially underused in up to 34% of patients with high PTH, and overused in up to 46% of patients with low PTH. Phosphorus binders (mostly calcium salts during the study period) were used by 81% of patients, with potential overuse in up to 77% patients with low serum phosphorus concentration, and potential underused in up to 18% of patients with a high serum phosphorus concentration.
   Conclusion. This study expands our understanding of the relationship between altered mineral metabolism and outcomes and identifies several potential opportunities for improved practice in this area.
C1 URREA, Ann Arbor, MI 48103 USA.
   Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA.
   Hosp Gen Valle Hebron, Serv Nephrol, Barcelona, Spain.
   Heidelberg Univ, Heidelberg, Germany.
   Tokai Univ, Inst Med Sci, Kanagawa 2591100, Japan.
   Wakayama Med Univ, Ctr Blood Purificat Therap, Wakayama, Japan.
   Tokyo Womens Med Univ, Dept Blood Purificat & Internal Med, Tokyo, Japan.
   ICOS Corp, Bothell, WA USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Hospital Universitari Vall
   d'Hebron; Ruprecht Karls University Heidelberg; Tokai University;
   Wakayama Medical University; Tokyo Women's Medical University; Icos
   Corporation
RP URREA, 315 W Huron, Ann Arbor, MI 48103 USA.
EM DOPPS@urrea.org
OI Albert, Justin/0000 0001 5330 1892
CR Atsumi K, 1999, AM J KIDNEY DIS, V33, P287, DOI 10.1016/S0272 6386(99)70302 1
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Foley RN, 1996, AM J NEPHROL, V16, P386, DOI 10.1159/000169030
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Gupta A, 2000, J AM SOC NEPHROL, V11, P330, DOI 10.1681/ASN.V112330
   Hsu CH, 1997, AM J KIDNEY DIS, V29, P641, DOI 10.1016/S0272 6386(97)90352 8
   Kessler M, 2002, NEPHROL DIAL TRANSPL, V17, P2, DOI 10.1093/ndt/17.suppl_7.2
   Port FK, 2003, BLOOD PURIFICAT, V21, P85, DOI 10.1159/000067859
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Rayner HC, 2004, NEPHROL DIAL TRANSPL, V19, P108, DOI 10.1093/ndt/gfg483
   Sawaya BP, 2002, CLIN NEPHROL, V57, P51
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tokuyama T, 2002, AM J KIDNEY DIS, V39, P291, DOI 10.1053/ajkd.2002.30548
   Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523 1755.2000.07413.x
NR 17
TC 632
Z9 676
U1 2
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2005
VL 67
IS 3
BP 1179
EP 1187
DI 10.1111/j.1523 1755.2005.00185.x
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 897OC
UT WOS:000227013500041
PM 15698460
OA Bronze
DA 2025 08 17
ER

PT J
AU Savic, A
   Matijevic, R
   Savic, D
   Miok, J
   Glavcic, A
AF Savic, Aleksandra
   Matijevic, Radmila
   Savic, Dragan
   Miok, Jelena
   Glavcic, Aleksandra
TI Bilateral atypical femoral fracture related to bisphosphonate therapy
SO SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO
LA English
DT Article
DE osteoporosis; antiresorptive treatment; intramedullary nailing
ID FEMUR FRACTURE
AB Introduction Although bisphosphonates represent the most commonly prescribed antiresorptive therapy for the treatment of osteoporosis and fracture prevention, paradoxically, their continuous use in some patients can lead to an atypical femoral fracture. This type of fracture is characterized by specific features regarding clinical presentation, mechanism of injury and radiological manifestations. The objective of this article was to present a case of a bilateral femoral fracture associated with bisphosphonate usage.
   Case outline A 70 year old female patient was admitted to the emergency department with a severe, throbbing pain in both thighs after a ground level fall. Radiographs of both femurs verified bilateral complete fracture localized in the diaphyseal region. Prior to hospitalization, she had continuously been taking ibandronate for three years. The patient underwent percutaneous osteosynthesis with intramedullary nailing with interlocking screws of both femurs. Six weeks after the surgical treatment, radiographic findings indicated the presence of early signs of healing on both femurs. At the four month follow up, the complete union of the bone fragments was achieved and she managed to walk without any pain and walking aids.
   Conclusion Physicians still face doubts regarding optimal duration of bisphosphonate therapy. Although atypical femoral fracture represents a rare adverse event related to bisphosphonate use, all patients receiving this antiresorptive treatment who are complaining of new onset unexplained pain in the thighs for more than two weeks should be completely diagnostically evaluated in term of atypical femoral fracture. Patients with confirmed atypical femoral fracture should undergo surgical treatment.
C1 [Savic, Aleksandra; Glavcic, Aleksandra] Special Hosp Rheumat Dis, Futoska 68, Novi Sad 21112, Serbia.
   [Savic, Aleksandra; Matijevic, Radmila; Savic, Dragan; Glavcic, Aleksandra] Univ Novi Sad, Fac Med, Novi Sad, Serbia.
   [Matijevic, Radmila; Savic, Dragan] Clin Ctr Vojvodina, Clin Orthoped Surg & Traumatol, Novi Sad, Serbia.
   [Miok, Jelena] Dr Milicev Internal Med Practice, Novi Sad, Serbia.
C3 University of Novi Sad
RP Savic, A (通讯作者)，Special Hosp Rheumat Dis, Futoska 68, Novi Sad 21112, Serbia.
EM aleksandra_savic@uns.ac.rs
RI Savic, Aleksandra/ACS 5886 2022
OI Matijevic, Radmila/0000 0002 4993 9399
CR Bégin MJ, 2022, J BONE MINER RES, V37, P87, DOI 10.1002/jbmr.4461
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Curtis JR, 2020, MED CARE, V58, P419, DOI 10.1097/MLR.0000000000001294
   Hagino H, 2021, J BONE MINER METAB, V39, P668, DOI 10.1007/s00774 021 01208 3
   Kang JS, 2014, INT ORTHOP, V38, P1247, DOI 10.1007/s00264 013 2259 9
   Kim KH, 2022, GERIATR ORTHOP SURG, V13, DOI 10.1177/21514593211070130
   Koh JH, 2017, OSTEOPOROSIS INT, V28, P3251, DOI 10.1007/s00198 017 4169 y
   Lee Kyung Jae, 2018, Hip Pelvis, V30, P202, DOI 10.5371/hp.2018.30.4.202
   Lim HS, 2016, J BONE JOINT SURG AM, V98, P1978, DOI 10.2106/JBJS.15.01422
   Lim SJ, 2018, OSTEOPOROSIS INT, V29, P2427, DOI 10.1007/s00198 018 4640 4
   Lo JC, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03672 w
   Papapoulos S, 2021, J BONE MINER RES, V36, P1225, DOI 10.1002/jbmr.4284
   Sahemey R, 2020, J ORTHOP TRAUMA REHA, V27, P192, DOI 10.1177/2210491720952444
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Tile L, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X20916983
   Zenke Yukichi, 2016, Journal of UOEH, V38, P207, DOI 10.7888/juoeh.38.207
NR 16
TC 0
Z9 0
U1 0
U2 0
PU SRPSKO LEKARSKO DRUSTVO
PI BEOGRAD
PA UREDNISTVO CASOPISA SRPSKI ARHIV, UL DZORDZA VASINGTONA 19, BEOGRAD,
   11000, SERBIA
SN 0370 8179
J9 SRP ARK CELOK LEK
JI Srp. Ark. Celok. Lek.
PD SEP OCT
PY 2022
VL 150
IS 9 10
BP 598
EP 601
DI 10.2298/SARH211203066S
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA E8HC2
UT WOS:000977878300016
OA gold
DA 2025 08 17
ER

PT J
AU Hegner, B
   Schaub, T
   Janke, D
   Zickler, D
   Lange, C
   Girndt, M
   Jankowski, J
   Schindler, R
   Dragun, D
AF Hegner, Bjoern
   Schaub, Theres
   Janke, Daniel
   Zickler, Daniel
   Lange, Claudia
   Girndt, Matthias
   Jankowski, Joachim
   Schindler, Ralf
   Dragun, Duska
TI Targeting proinflammatory cytokines ameliorates calcifying phenotype
   conversion of vascular progenitors under uremic conditions in vitro
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HIGH CUTOFF HEMOFILTRATION; MESENCHYMAL STROMAL CELLS; STEM CELLS;
   ARTERIAL CALCIFICATION; INTERLEUKIN 1; TOXINS; MECHANISMS; INITIATION;
   MEMBRANES; SURVIVAL
AB Severe vascular calcification develops almost invariably in chronic kidney patients posing a substantial risk to quality of life and survival. This unmet medical need demands identification of novel therapeutic modalities. We aimed to pinpoint components of the uremic microenvironment triggering differentiation of vascular progenitors to calcifying osteoblast like cells. In an unbiased approach, assessing the individual potency of 63 uremic retention solutes to enhance calcific phenotype conversion of vascular progenitor cells, the pro inflammatory cytokines IL 1 beta and TNF alpha were identified as the strongest inducers followed by FGF 2, and PTH. Pharmacologic targeting of these molecules alone or in combination additively antagonized pro calcifying properties of sera from uremic patients. Our findings stress the importance of pro inflammatory cytokines above other characteristic components of the uremic microenvironment as key mediators of calcifying osteoblastic differentiation in vascular progenitors. Belonging to the group of "middle sized molecules", they are neither effectively removed by conventional dialysis nor influenced by established supportive therapies. Specific pharmacologic interventions or novel extracorporeal approaches may help preserve regenerative capacity and control vascular calcification due to uremic environment.
C1 [Hegner, Bjoern; Schaub, Theres; Janke, Daniel; Zickler, Daniel; Jankowski, Joachim; Schindler, Ralf; Dragun, Duska] Charite Univ Med Berlin, Freie Univ Berlin, Humboldt Univ Berlin, Berlin, Germany.
   [Hegner, Bjoern; Schaub, Theres; Janke, Daniel; Zickler, Daniel; Schindler, Ralf; Dragun, Duska] Campus Virchow Clin, Clin Nephrol & Intens Care Med, Berlin Inst Hlth, Berlin, Germany.
   [Hegner, Bjoern; Dragun, Duska] Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany.
   [Hegner, Bjoern; Dragun, Duska] Charite, CCR, Berlin, Germany.
   [Schaub, Theres] Berlin Inst Hlth, Inst Chem & Biochem, Berlin, Germany.
   [Lange, Claudia] Univ Med Ctr Hamburg Eppendorf, Dept Cell & Gene Therapy, Clin Stem Cell Transplantat, Hamburg, Germany.
   [Girndt, Matthias] Martin Luther Univ Halle Wittenberg, Dept Internal Med 2, Halle, Germany.
   [Jankowski, Joachim] Charite, Clin Nephrol, Berlin Inst Hlth, Campus Benjamin Franklin, Berlin, Germany.
   [Hegner, Bjoern] Vivantes Ida Wolff Hosp Geriatr Med, Berlin, Germany.
   [Schaub, Theres] Berlin Inst Hlth, Inst Cell & Neurobiol, Campus Mitte, Berlin, Germany.
   [Jankowski, Joachim] Univ Hosp RWTH, Inst Mol Cardiovasc Res, Aachen, Germany.
   [Jankowski, Joachim] Maastricht Univ, Sch Cardiovasc Dis, Maastricht, Netherlands.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Humboldt University of Berlin; Free
   University of Berlin; Charite Universitatsmedizin Berlin; Berlin
   Institute of Health; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Humboldt University of
   Berlin; Free University of Berlin; Charite Universitatsmedizin Berlin;
   Berlin Institute of Health; University of Hamburg; University Medical
   Center Hamburg Eppendorf; Martin Luther University Halle Wittenberg;
   Humboldt University of Berlin; Free University of Berlin; Charite
   Universitatsmedizin Berlin; Berlin Institute of Health; Humboldt
   University of Berlin; Free University of Berlin; Charite
   Universitatsmedizin Berlin; Berlin Institute of Health; RWTH Aachen
   University; RWTH Aachen University Hospital; Maastricht University
RP Hegner, B (通讯作者)，Charite Univ Med Berlin, Freie Univ Berlin, Humboldt Univ Berlin, Berlin, Germany.; Hegner, B (通讯作者)，Campus Virchow Clin, Clin Nephrol & Intens Care Med, Berlin Inst Hlth, Berlin, Germany.; Hegner, B (通讯作者)，Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany.; Hegner, B (通讯作者)，Charite, CCR, Berlin, Germany.; Hegner, B (通讯作者)，Vivantes Ida Wolff Hosp Geriatr Med, Berlin, Germany.
EM bjoern.hegner@gmx.de
RI ; Lange, Claudia/KMY 3570 2024; Girndt, Matthias/M 1436 2019
OI Dragun, Duska/0000 0002 0310 9269; Hegner, Bjorn/0000 0003 3524 1165;
   Girndt, Matthias/0000 0003 2823 0847; 
FU EU through SysKID [HEALTH F2 2009 241544]
FX The authors thank Adrian Schreiber for providing Anakinra. This work was
   supported in part by EU funding through SysKID (HEALTH F2 2009 241544).
CR Abbate A, 2013, AM J CARDIOL, V111, P1394, DOI 10.1016/j.amjcard.2013.01.287
   Abedin M, 2004, CIRC RES, V95, P671, DOI 10.1161/01.RES.0000143421.27684.12
   Bautch VL, 2011, NAT MED, V17, P1437, DOI 10.1038/nm.2539
   Cheung Richard Y, 2004, Health Law J, V12, P183
   Cohen G, 2007, NEPHROL DIAL TRANSPL, V22, P3381, DOI 10.1093/ndt/gfm210
   Collett GDM, 2005, CIRC RES, V96, P930, DOI 10.1161/01.RES.0000163634.51301.0d
   Collins AJ, 2010, AM J KIDNEY DIS, V55, pVI, DOI 10.1053/j.ajkd.2009.10.009
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175
   Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882
   Gondouin B, 2011, ADV CHRONIC KIDNEY D, V18, P180, DOI 10.1053/j.ackd.2011.02.006
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Herrington WG, 2016, LANCET DIABETES ENDO, V4, P829, DOI 10.1016/S2213 8587(16)30156 5
   Ikonomidis I, 2014, CIRC CARDIOVASC IMAG, V7, P619, DOI 10.1161/CIRCIMAGING.113.001193
   Jankowski V, 2007, ARTERIOSCL THROM VAS, V27, P297, DOI 10.1161/01.ATV.0000253889.09765.5f
   Jankowski V, 2011, FASEB J, V25, P2987, DOI 10.1096/fj.11 185470
   Kimmel PL, 1998, KIDNEY INT, V54, P236, DOI 10.1046/j.1523 1755.1998.00981.x
   Kirsch AH, 2017, NEPHROL DIAL TRANSPL, V32, P165, DOI 10.1093/ndt/gfw310
   Koleganova N, 2009, NEPHROL DIAL TRANSPL, V24, P2488, DOI 10.1093/ndt/gfp137
   Kramann R., 2013, J BONE MINER RES
   Kramann R, 2012, NEPHROL DIAL TRANSPL, V27, P2693, DOI 10.1093/ndt/gfr656
   Kramann R, 2011, ARTERIOSCL THROM VAS, V31, pE45, DOI 10.1161/ATVBAHA.111.228601
   Lange C, 2007, J CELL PHYSIOL, V213, P18, DOI 10.1002/jcp.21081
   Lim WH, 2007, KIDNEY INT, V72, P1138, DOI 10.1038/sj.ki.5002425
   Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590
   Malard B., 2016, ARTIF ORGANS
   Meert N, 2007, ARTIF ORGANS, V31, P600, DOI 10.1111/j.1525 1594.2007.00434.x
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Morgera S, 2006, CRIT CARE MED, V34, P2099, DOI 10.1097/01.CCM.0000229147.50592.F9
   Nair J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094328
   Naka T, 2010, CONTRIB NEPHROL, V166, P181, DOI 10.1159/000314871
   Neirynck N, 2013, INT UROL NEPHROL, V45, P139, DOI 10.1007/s11255 012 0258 1
   Neven E, 2011, KIDNEY INT, V79, P1166, DOI 10.1038/ki.2011.59
   Noh H, 2012, NEPHROL DIAL TRANSPL, V27, P218, DOI 10.1093/ndt/gfr267
   Palmer SC, 2016, AM J KIDNEY DIS, V68, P691, DOI 10.1053/j.ajkd.2016.05.015
   Pavlenko D, 2016, SCI REP UK, V6, DOI 10.1038/srep34429
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656
   Rogers NM, 2008, CURR OPIN NEPHROL HY, V17, P629, DOI 10.1097/MNH.0b013e32830f4566
   Sage AP, 2010, NAT REV CARDIOL, V7, P528, DOI 10.1038/nrcardio.2010.115
   Schepers E, 2011, CLIN J AM SOC NEPHRO, V6, P2374, DOI 10.2215/CJN.01720211
   Schepers E, 2010, BLOOD PURIFICAT, V29, P130, DOI 10.1159/000245639
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   van Breukelen van der Stoep DF, 2013, ATHEROSCLEROSIS, V231, P163, DOI 10.1016/j.atherosclerosis.2013.09.006
   Van Tassell BW, 2013, CIRCULATION, V128, P1910, DOI 10.1161/CIRCULATIONAHA.113.003199
   Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523 1755.2003.00924.x
   Vanholder R, 2008, J AM SOC NEPHROL, V19, P863, DOI 10.1681/ASN.2007121377
   Vanholder R, 2007, NEPHROL DIAL TRANSPL, V22, P3115, DOI 10.1093/ndt/gfm151
   Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018 008 8064 8
   Watt FE, 2013, ARTHRITIS RHEUM US, V65, P397, DOI 10.1002/art.37765
   Weidle UH, 2013, CANCER GENOM PROTEOM, V10, P1
   Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636
   Zickler D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169024
NR 55
TC 14
Z9 14
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 14
PY 2018
VL 8
AR 12087
DI 10.1038/s41598 018 30626 z
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GQ3CC
UT WOS:000441536700006
PM 30108259
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Maroni, P
   Brini, AT
   Arrigoni, E
   de Girolamo, L
   Niada, S
   Matteucci, E
   Bendinelli, P
   Desiderio, MA
AF Maroni, Paola
   Brini, Anna Teresa
   Arrigoni, Elena
   de Girolamo, Laura
   Niada, Stefania
   Matteucci, Emanuela
   Bendinelli, Paola
   Desiderio, Maria Alfonsina
TI Chemical and genetic blockade of HDACs enhances osteogenic
   differentiation of human adipose tissue derived stem cells by oppositely
   affecting osteogenic and adipogenic transcription factors
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE hASCs; HDACs; Runx2; PPAR gamma; Osteo differentiation
ID HISTONE DEACETYLASE INHIBITORS; OSTEOBLAST DIFFERENTIATION; RUNX2;
   INTERACTS; PROTEINS; SMRT
AB The human adipose tissue derived stem/stromal cells (hASCs) are an interesting source for hone tissue engineering applications. Our aim was to clarify in hASCs the role of acetylation in the control of Run trelated transcription factor 2 (Runx2) and Peroxisome proliferator activated receptor (PPAR) y. These key osteogenic and adipogenic transcription factors are oppositely involved in osteo differentiation. The hASCs, committed or not towards bone lineage with osteoinductive medium, were exposed to HDACs chemical blockade with Trichostatin A (TSA) or were genetically silenced for HDACs. Alkaline phosphatase (ALP) and collagen/calcium deposition, considered as early and late osteogenic markers, were evaluated concomitantly as index of osteo differentiation. TSA pretreatment, useful experimental protocol to analyse pan HDAC chemical inhibition, and switch to osteogenic medium induced early osteoblast maturation gene Runx2, while transiently decreased PPARy and scarcely affected late differentiation markers. Timedependent effects were observed after knocking down of HDAC1 and 3: Runx2 and ALP underwent early activation, followed by late osteogenic markers increase and by PPARVALP activity diminutions mostly after HDAC3 silencing. HDAC1 and 3 genetic blockade increased and decreased Runx2 and PPARy target genes, respectively. Noteworthy, HDACs knocking down favoured the commitment effect of osteogenic medium. Our results reveal a role for HDACs in orchestrating osteo differentiation of hASCs at transcriptional level, and might provide new insights into the modulation of hASCs based regenerative therapy. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Matteucci, Emanuela; Bendinelli, Paola; Desiderio, Maria Alfonsina] Univ Milan, Dipartimento Sci Biomed Salute, Mol Pathol Lab, I 20133 Milan, Italy.
   [Maroni, Paola; Brini, Anna Teresa; de Girolamo, Laura; Niada, Stefania] Ist Ortoped Galeazzi, Milan, Italy.
   [Brini, Anna Teresa; Arrigoni, Elena; Niada, Stefania] Univ Milan, Dipartimento Sci Biomed Chirurg & Odontoiatr, I 20133 Milan, Italy.
C3 University of Milan; IRCCS Istituto Ortopedico Galeazzi; University of
   Milan
RP Desiderio, MA (通讯作者)，Univ Milan, Dipartimento Sci Biomed Salute, Mol Pathol Lab, Via Luigi Mangiagalli 31, I 20133 Milan, Italy.
EM a.desiderio@unimi.it
RI Bendinelli, Paola/M 7324 2016; Brini, Anna Teresa/C 2610 2017; DE
   GIROLAMO, LAURA/C 6274 2011; niada, stefania/C 5517 2017; Desiderio,
   Maria/M 8870 2016; Maroni, Paola/B 1366 2017; Brini, Anna/C 2610 2017
OI Brini, Anna Teresa/0000 0002 7848 8099; DE GIROLAMO,
   LAURA/0000 0002 9979 3092; niada, stefania/0000 0003 3655 9968; Maroni,
   Paola/0000 0002 3444 9338; Arrigoni, Elena/0000 0002 7149 2845; 
FU CARIPLO Foundation [2010 0737]; Ministero della Salute, Ricerca Corrente
   [4029, 4064]
FX Authors thank Dr. Alessandro Degrate for his contribution to the
   statistical analysis. Grants: CARIPLO Foundation, 2010 0737: Ministero
   della Salute, Ricerca Corrente 4029 and 4064.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Abe T, 2006, J BONE MINER METAB, V24, P283, DOI 10.1007/s00774 006 0685 0
   Bendinelli P, 2009, MOL CANCER RES, V7, P1328, DOI 10.1158/1541 7786.MCR 08 0548
   Carey N, 2006, CURR OPIN PHARMACOL, V6, P369, DOI 10.1016/j.coph.2006.03.010
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   De Girolamo L, 2008, INT J ARTIF ORGANS, V31, P467, DOI 10.1177/039139880803100602
   de Girolamo L, 2011, J ORTHOP RES, V29, P100, DOI 10.1002/jor.21184
   de Girolamo L, 2009, CYTOTHERAPY, V11, P793, DOI 10.3109/14653240903079393
   Ge WS, 2011, STEM CELLS, V29, P1112, DOI 10.1002/stem.663
   Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091 6101.2001
   Harrison BC, 2010, FEBS LETT, V584, P1103, DOI 10.1016/j.febslet.2010.02.057
   Hatch NE, 2009, J BONE MINER RES, V24, P652, DOI 10.1359/JBMR.081213
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Kakudo N, 2008, J BIOMED MATER RES A, V84A, P191, DOI 10.1002/jbm.a.31311
   Kakudo N, 2007, BIOCHEM BIOPH RES CO, V359, P239, DOI 10.1016/j.bbrc.2007.05.070
   Kawai M, 2009, NAT REV RHEUMATOL, V5, P365, DOI 10.1038/nrrheum.2009.102
   Pham L, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.216853
   Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004
   Lee W.H., 2006, MOL ENDOCRINOL, V20, P2431
   Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Nakagami H, 2006, J ATHEROSCLER THROMB, V13, P77, DOI 10.5551/jat.13.77
   Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078 0432.CCR 03 0709
   Patra SK, 2007, ONCOL REP, V17, P1279
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Santos A, 2010, CYTOTHERAPY, V12, P924, DOI 10.3109/14653241003774011
   Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 362
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494 07
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Wu L, 2007, MOL CELL BIOCHEM, V301, P83, DOI 10.1007/s11010 006 9399 9
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
NR 35
TC 38
Z9 43
U1 1
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 16
PY 2012
VL 428
IS 2
BP 271
EP 277
DI 10.1016/j.bbrc.2012.10.044
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 055QQ
UT WOS:000312431900012
PM 23085045
OA Green Published
DA 2025 08 17
ER

PT J
AU Ouellet, C
   Maltais, R
   Ouellet, E
   Barbeau, X
   Lagüe, P
   Poirier, D
AF Ouellet, Charles
   Maltais, Rene
   Ouellet, Etienne
   Barbeau, Xavier
   Lague, Patrick
   Poirier, Donald
TI Discovery of a sulfamate based steroid sulfatase inhibitor with
   intrinsic selective estrogen receptor modulator properties
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Sulfatase; Enzyme; Inhibitor; Estrogen; Cancer; SERM
ID BREAST CANCER; AROMATASE INHIBITORS; DERIVATIVES; THERAPY; MECHANISM;
   PROGRESS; TARGET
AB Steroid sulfatase (STS), the enzyme which converts inactive sulfated steroid precursors into active hormones, is a promising therapeutic target for the treatment of estrogen sensitive breast cancer. We report herein the synthesis and in vitro study of dual action STS inhibitors with selective estrogen receptor modulator (SERM) effects. A library of tetrahydroisoquinoline N substituted derivatives (phenolic compounds) was synthesized by solid phase chemistry and tested on estrogen sensitive breast cancer T 47D cells. Three phenolic compounds devoid of estrogenic activity and toxicity emerged from this screening. Their sulfamate analogs were then synthesized, tested in STS transfected HEK 293 cells, and found to be potent inhibitors of the enzyme (IC50 of 3.9, 8.9, and 16.6 nM). When tested in T 47D cells they showed no estrogenic activity and produced a moderate antiestrogenic activity. The compounds were further tested on osteoblast like Saos 2 cells and found to significantly stimulate their proliferation as well as their alkaline phosphatase activity, thus suggesting a SERM activity. These results are supported by molecular docking experiments. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Ouellet, Charles; Maltais, Rene; Ouellet, Etienne; Poirier, Donald] CHUL, CHU Quebec, Res Ctr, Med Chem Lab, T4,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.
   [Barbeau, Xavier] Univ Laval, Dept Chim, IBIS, Ctr Rech Fonct Struct & Ingn Prot PROTEO, Quebec City, PQ G1K 7P4, Canada.
   [Lague, Patrick] Univ Laval, Dept Biochim Microbiol & Bioinformat, IBIS, Ctr Rech Fonct Struct & Ingn Prot PROTEO, Quebec City, PQ, Canada.
   [Poirier, Donald] Univ Laval, Fac Med, Dept Mol Med, Quebec City, PQ G1K 7P4, Canada.
C3 Laval University; Laval University Hospital; Laval University; Laval
   University; Laval University
RP Poirier, D (通讯作者)，CHUL, CHU Quebec, Res Ctr, Med Chem Lab, T4,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.
EM donald.poirier@crchul.ulaval.ca
OI Lague, Patrick/0000 0002 5236 4979
CR Agnusdei D., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P127
   Ahmad I, 2015, EUR J MED CHEM, V102, P375, DOI 10.1016/j.ejmech.2015.08.010
   Ahmed S, 2002, CURR MED CHEM, V9, P263, DOI 10.2174/0929867023371210
   Aidoo Gyamfi K, 2009, ANTI CANCER AGENT ME, V9, P599, DOI 10.2174/187152009788679985
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bérubé M, 2010, MOLECULES, V15, P1590, DOI 10.3390/molecules15031590
   Bojarová P, 2008, CHEMBIOCHEM, V9, P613, DOI 10.1002/cbic.200700579
   Bojarová P, 2008, CURR OPIN CHEM BIOL, V12, P573, DOI 10.1016/j.cbpa.2008.06.018
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Chetrite GS, 2000, J STEROID BIOCHEM, V72, P23, DOI 10.1016/S0960 0760(00)00040 6
   Ciobanu LC, 2003, CANCER RES, V63, P6442
   Ciobanu LC, 2003, J ENZYM INHIB MED CH, V18, P15, DOI 10.1080/1475636031000069282
   Ciobanu LC, 2002, J STEROID BIOCHEM, V80, P339, DOI 10.1016/S0960 0760(02)00024 9
   Ciobanu LC, 2000, ORG LETT, V2, P445, DOI 10.1021/ol990381p
   Ciobanu LC, 1999, J MED CHEM, V42, P2280, DOI 10.1021/jm980677l
   Ciobanu LC, 2006, CHEMMEDCHEM, V1, P1249, DOI 10.1002/cmdc.200600071
   Duggan C, 2003, J CLIN ONCOL, V21, P3588, DOI 10.1200/JCO.2003.10.111
   Foster PA, 2008, ANTI CANCER AGENT ME, V8, P732, DOI 10.2174/187152008785914815
   Ghosh D, 2007, CELL MOL LIFE SCI, V64, P2013, DOI 10.1007/s00018 007 7175 y
   Guedes G, 2015, CHEMMEDCHEM, V10, P1403, DOI 10.1002/cmdc.201500148
   Hanson SR, 2004, ANGEW CHEM INT EDIT, V43, P5736, DOI 10.1002/anie.200300632
   Hernandez Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200
   Horvath A, 2005, EXPERT OPIN THER PAT, V15, P1541, DOI 10.1517/13543776.15.11.1541
   Imai Y, 2009, J BONE MINER METAB, V27, P127, DOI 10.1007/s00774 008 0021 y
   Jha A, 2015, EUR J MED CHEM, V92, P103, DOI 10.1016/j.ejmech.2014.12.037
   Jonat W, 2006, J CANCER RES CLIN, V132, P275, DOI 10.1007/s00432 006 0082 z
   Lin SX, 2010, NAT REV ENDOCRINOL, V6, P485, DOI 10.1038/nrendo.2010.92
   Lv W, 2016, J MED CHEM, V59, P157, DOI 10.1021/acs.jmedchem.5b01677
   Maltais R, 2011, STEROIDS, V76, P929, DOI 10.1016/j.steroids.2011.03.010
   McDonnell DP, 2010, CURR OPIN PHARMACOL, V10, P620, DOI 10.1016/j.coph.2010.09.007
   Mostafa YA, 2013, J STEROID BIOCHEM, V137, P183, DOI 10.1016/j.jsbmb.2013.01.013
   Musa MA, 2007, CURR MED CHEM, V14, P1249, DOI 10.2174/092986707780598023
   Nussbaumer P, 2004, MED RES REV, V24, P529, DOI 10.1002/med.20008
   Obiorah I, 2011, MATURITAS, V70, P315, DOI 10.1016/j.maturitas.2011.09.006
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Ouellet C, 2015, INVEST NEW DRUG, V33, P95, DOI 10.1007/s10637 014 0187 1
   Ouellet E, 2013, MEDCHEMCOMM, V4, P681, DOI 10.1039/c3md20354a
   Pasqualini JR, 1996, J CLIN ENDOCR METAB, V81, P1460, DOI 10.1210/jc.81.4.1460
   PASQUALINI JR, 1989, J STEROID BIOCHEM, V34, P155, DOI 10.1016/0022 4731(89)90077 0
   Poirier D, 1999, EXPERT OPIN THER PAT, V9, P1083, DOI 10.1517/13543776.9.8.1083
   Poirier D., 2015, CURR ENZYM INHIB, V11, P65, DOI [10.2174/157340801101150707124626, DOI 10.2174/157340801101150707124626]
   Purohit A, 2012, J ENDOCRINOL, V212, P99, DOI 10.1530/JOE 11 0266
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rasmussen LM, 2007, BREAST CANCER RES TR, V106, P191, DOI 10.1007/s10549 007 9494 y
   Reed MJ, 2005, ENDOCR REV, V26, P171, DOI 10.1210/er.2004 0003
   Roy J, 2013, MOL CELL ENDOCRINOL, V376, P148, DOI 10.1016/j.mce.2013.06.022
   SANTNER SJ, 1984, J CLIN ENDOCR METAB, V59, P29, DOI 10.1210/jcem 59 1 29
   Shah R, 2016, EUR J MED CHEM, V114, P170, DOI 10.1016/j.ejmech.2016.02.054
   Tripathi RP, 2008, CURR ORG CHEM, V12, P1093, DOI 10.2174/138527208785740283
   Wang TL, 2009, MINI REV MED CHEM, V9, P1191, DOI 10.2174/138955709789055207
   Winum JY, 2004, EXPERT OPIN THER PAT, V14, P1273, DOI 10.1517/13543776.14.9.1273
   Woo LWL, 2013, CHEMMEDCHEM, V8, P779, DOI 10.1002/cmdc.201300015
   Woo LWL, 2005, CRC ENZYM INHIB SER, P221
NR 53
TC 19
Z9 19
U1 0
U2 30
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD AUG 25
PY 2016
VL 119
BP 169
EP 182
DI 10.1016/j.ejmech.2016.04.044
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DP3YZ
UT WOS:000378433600012
PM 27155470
DA 2025 08 17
ER

PT J
AU Yaquelo, CM
AF Martinez Yaquelo, Cesar
TI Action of calcium binders. Formation of calcium salts in the intestinal
   tract and the blood circulatory system
SO ACTA BIOQUIMICA CLINICA LATINOAMERICANA
LA English
DT Article
DE calcium binders; osteopenia; osteoporosis; atherosclerosis;
   mephrosclerosis; urotithyasis; calcinosis; vascular calcification
ID PHOSPHORUS; OXALATE
AB Calcium binders are water soluble substances whose anionic part can possibly react with calcium cations present in any part of the human body. Some examples of calcium binders are phosphoric, oxalic and phytic acids and their alkaline salts present in many natural foods, in some foods containing additives, and in some medicines. There are also uric and lactic acids that are the result of normal metabolism. The first negative action of calcium binders takes place in the intestinal tract when they react with calcium of dairy food. The latter produces a combination of calcium binder anions with calcium cations, and then an insoluble salt that precipitates as small solid particles that cannot be assimilated and which are eliminated in the faeces. The second negative action of calcium binders takes place when soluble calcium binders are assimilated into the blood circulatory system and, get in contact with the free ionized calcium in serum, which gives rise to complexed calcium with inorganic and organic anions. Immediately the free ionized normal level of calcium in blood serum decays, and the parathyroid hormone comes into action (secondary hyperparathyroidism) extracting free ionized calcium from bones (bone resorption). The soluble complexed calcium circulates in the serum through the whole blood circulatory system, and because it is ultra filtrable, it freely filters through the glomerulus and is excreted in urine. The final result is the formation of the corresponding salts in a metastable state, concentrated near the point where the precipitation of these salts occurs. This special condition is due to the fact that certain proteins are inhibiting the precipitation. In some soft tissues with chronic inflammation, the above mentioned metastable state is affected because the inhibitory mechanism is blocked, causing the formation of calcium phosphate salts nuclei in the tissue and the build up of calcium phosphate crystals. This triggers causes many serious diseases. Finally, it is suggested that a start can be made on preventing the action of calcium binders by controlling diet, especially by avoiding high intakes of phosphates, oxalates and phytates.
C1 Univ Republ Oriental, Fac Quim & Farm, Montevideo, Uruguay.
C3 Universidad de la Republica, Uruguay
RP Yaquelo, CM (通讯作者)，San Carlos Bolivar 6282, Montevideo, Uruguay.
EM martyaq@montevideo.com.uy
CR Alfrey AC, 2004, KIDNEY INT, V66, pS13, DOI 10.1111/j.1523 1755.2004.09003.x
   Block GA, 2001, CURR OPIN NEPHROL HY, V10, P741, DOI 10.1097/00041552 200111000 00003
   BRACACCIO D, 2002, NEPHROL DIAL TRANSPL, V17, P201
   Brancaccio D, 2005, CONTRIB NEPHROL, V149, P279, DOI 10.1159/000085689
   Cappuccio FP, 2000, J NEPHROL, V13, P169
   Cozzolino M, 2003, KIDNEY INT, V64, P1653, DOI 10.1046/j.1523 1755.2003.00284.x
   Cozzolino Mario, 2005, Ital Heart J Suppl, V6, P25
   Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003 0015
   Endres D.B., 1994, Textbook of Clinical Chemistry, P1887
   Fiorino AS, 1996, YALE J BIOL MED, V69, P517
   Friedman EA, 2005, KIDNEY INT, V68, pS2, DOI 10.1016/S0085 2538(15)51226 X
   HENRY J, 1997, DIAGNOSTICO TRATAMIE
   Holmes RP, 2000, KIDNEY INT, V57, P1662, DOI 10.1046/j.1523 1755.2000.00010.x
   Horner HT, 2005, J AGR FOOD CHEM, V53, P7870, DOI 10.1021/jf051193i
   Ma D, 2004, CALCIFIED TISSUE INT, V75, P286, DOI 10.1007/s00223 004 0274 y
   NORD E, 2005, NEPHROLITHIASIS
   Nunes JPL, 2005, MED HYPOTHESES, V65, P521, DOI 10.1016/j.mehy.2005.03.024
   PALMIERI G, 2003, PATHOPHYSIOLOGY MINE
   Ritz E, 2005, J NEPHROL, V18, P221
   SANTHI K, 2001, J AM SOC NEPHROL, P2131
   Sax L, 2001, J AM COLL NUTR, V20, P271, DOI 10.1080/07315724.2001.10719047
   Slatopolsky E, 2003, J AM SOC NEPHROL, V14, pS297, DOI 10.1097/01.ASN.0000081668.41546.2B
   Stary HC, 2000, Z KARDIOL, V89, P28
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
   Uribarri J, 2003, SEMIN DIALYSIS, V16, P186, DOI 10.1046/j.1525 139X.2003.16037.x
   VALENTINE J, 2005, SOFT DRINKS AM OTHER
   Vieth R, 2005, ANN MED, V37, P278, DOI 10.1080/07853890510007313
NR 27
TC 1
Z9 1
U1 0
U2 3
PU FEDERACION BIOQUIMICA PROVINCIA BUENOS AIRES
PI LA PLATA, BUENOS AIRES
PA CALLE 6, NO. 1344, 1900 LA PLATA, BUENOS AIRES, ARGENTINA
SN 0325 2957
EI 1851 6114
J9 ACTA BIOQUIM CLIN L
JI Acta Bioquim. Clin. Latinoam.
PD JUN
PY 2006
VL 40
IS 2
BP 213
EP 217
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA 092KM
UT WOS:000241095500008
DA 2025 08 17
ER

PT J
AU Damrongsri, D
   Geva, S
   Salvi, GE
   Williams, RC
   Limwongse, V
   Offenbacher, S
AF Damrongsri, D
   Geva, S
   Salvi, GE
   Williams, RC
   Limwongse, V
   Offenbacher, S
TI Cyclooxygenase 2 inhibition selectively attenuates bone morphogenetic
   protein 6 synthesis and bone formation during guided tissue regeneration
   in a rat model
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article
DE bone morphogenetic proteins; cyclooxygenase 2; guided bone regeneration;
   insulin like growth factor; non steroidal anti inflammatory drugs;
   platelet derived growth factor; prostaglandins
ID GROWTH FACTOR I; GENE EXPRESSION; PROSTAGLANDIN E(2); TRANSCRIPTION
   FACTORS; MESENCHYMAL CELLS; FRACTURE REPAIR; MESSENGER RNA;
   DIFFERENTIATION; VITRO; OSTEOBLASTS
AB Objectives: Bone formation during guided tissue regeneration is a tightly regulated process involving cells, extracellular matrix and growth factors. The aims of this study were (i) to examine the expression of cyclooxygenase 2 (COX 2) during bone regeneration and (ii) the effects of selective COX 2 inhibition on osseous regeneration and growth factor expression in the rodent femur model.
   Material and methods: A standardized transcortical defect of 5 x 1.5 mm was prepared in the femur of 12 male rats and a closed half cylindrical titanium chamber was placed over the defect. The expression of COX 2 and of platelet derived growth factor B (PDGF B), bone morphogenetic protein 6 (BMP 6) and insulin like growth factor I/II (IGF I/II) was analyzed at Days 3, 7, 21 and 28 semiquantitatively by reverse transcriptase polymerase chain reaction and immunohistochemistry. The effects of COX 2 inhibition by intraperitoneal injection of NS 398 (3 mg/kg/day) were analyzed in five additional animals sacrificed at Day 14.
   Results: Histomorphometry revealed that new bone formation occurred in the cortical defect area as well as in the supracortical region, i.e. region within the chamber by Day 7 and increased through Day 28. Immunohistochemical evidence of COX 2 and PDGF B levels were observed early (i.e. Day 3) and decreased rapidly by Day 7. BMP 6 expression was maximal at Day 3 and slowly declined by Day 28. In contrast, IGF I/II expression gradually increased during the 28 day period. Systemic administration NS 398 caused a statistically significant reduction (P < 0.05) in new bone formation (25 30%) and was associated with a statistically significant reduction in BMP 6 protein and mRNA expression (50% and 65% at P < 0.05 and P < 0.01, respectively). PDGF B mRNA or protein expression was not affected by NS 398 treatment.
   Conclusion: COX 2 inhibition resulted in reduced BMP 6 expression and impaired osseous regeneration suggesting an important role for COX 2 induced signaling in BMP synthesis and new bone formation.
C1 Univ N Carolina, Sch Dent, Ctr Oral & System Dis, Chapel Hill, NC 27599 USA.
   Chulalongkorn Univ, Sch Dent, Dept Anat, Bangkok, Thailand.
   Univ Bern, Sch Dent Med, Dept Periodontol & Fixed Prosthodont, Bern, Switzerland.
   Univ N Carolina, Sch Dent, Dept Periodontol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Chulalongkorn University; University of Bern; University of North
   Carolina; University of North Carolina Chapel Hill
RP Univ N Carolina, Sch Dent, Ctr Oral & System Dis, Chapel Hill, NC 27599 USA.
EM steve_offenbacher@dentistry.unc.edu
FU PHS HHS [P01 08917] Funding Source: Medline
CR ANDREW JG, 1993, CALCIFIED TISSUE INT, V53, P97, DOI 10.1007/BF01321886
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   BAB IA, 1994, J CELL BIOCHEM, V55, P358, DOI 10.1002/jcb.240550313
   Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401
   Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   BOURQUE WT, 1993, INT J DEV BIOL, V37, P573
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Castaño E, 2000, J PHARMACOL EXP THER, V293, P509
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097 4547(19991015)58:2<254::AID JNR5>3.3.CO;2 L
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   GITELMAN SE, 1995, CELL GROWTH DIFFER, V6, P827
   GRONOWICZ GA, 1994, EXP CELL RES, V212, P314, DOI 10.1006/excr.1994.1149
   Hammerle CHF, 1996, CLIN ORAL IMPLAN RES, V7, P38, DOI 10.1034/j.1600 0501.1996.070105.x
   Horner A, 1996, BONE, V19, P353, DOI 10.1016/S8756 3282(96)00217 7
   HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671
   Kamata A, 1998, BIOCHEM BIOPH RES CO, V246, P404, DOI 10.1006/bbrc.1998.8632
   Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715
   KOSHIHARA Y, 1989, BIOCHEM BIOPH RES CO, V159, P1206, DOI 10.1016/0006 291X(89)92238 9
   Kössi J, 2001, ARCH DERMATOL RES, V293, P126, DOI 10.1007/s004030000197
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Kunnel JG, 2004, CONNECT TISSUE RES, V45, P40, DOI 10.1080/03008200490278133
   Lammens J, 1998, J BONE MINER RES, V13, P279, DOI 10.1359/jbmr.1998.13.2.279
   Lee SJ, 2001, J BIOMED MATER RES, V55, P295, DOI 10.1002/1097 4636(20010605)55:3<295::AID JBM1017>3.0.CO;2 W
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   LINDE A, 1993, J ORAL MAXIL SURG, V51, P892, DOI 10.1016/S0278 2391(10)80111 9
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   MCCARTHY TL, 1989, CONNECT TISSUE RES, V20, P277, DOI 10.3109/03008208909023897
   Meinel L, 2003, BONE, V33, P660, DOI 10.1016/S8756 3282(03)00207 2
   PFEILSCHIFTER J, 1990, ENDOCRINOLOGY, V127, P69, DOI 10.1210/endo 127 1 69
   Plant A, 2002, J BONE MINER RES, V17, P782, DOI 10.1359/jbmr.2002.17.5.782
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Rys Sikora KE, 2000, AM J PHYSIOL CELL PH, V278, pC822, DOI 10.1152/ajpcell.2000.278.4.C822
   Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672
   Schmid J, 1991, CLIN ORAL IMPLAN RES, V2, P199, DOI 10.1034/j.1600 0501.1991.020407.x
   Schmid J, 1997, CLIN ORAL IMPLAN RES, V8, P244, DOI 10.1034/j.1600 0501.1997.080311.x
   Scutt A, 1996, CALCIFIED TISSUE INT, V59, P154, DOI 10.1007/s002239900102
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Solheim E, 1998, INT ORTHOP, V22, P410, DOI 10.1007/s002640050290
   Steinbrech DS, 1999, ANN PLAS SURG, V42, P481, DOI 10.1097/00000637 199905000 00004
   TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090 6980(91)90001 V
   Vikjaer D, 1997, EUR J ORAL SCI, V105, P59, DOI 10.1111/j.1600 0722.1997.tb00181.x
   Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606
   Wakisaka A, 1998, J BONE MINER RES, V13, P13, DOI 10.1359/jbmr.1998.13.1.13
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Wong RWK, 1999, EUR J ORTHODONT, V21, P119, DOI 10.1093/ejo/21.2.119
   Woodiel FN, 1996, J BONE MINER RES, V11, P1249
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
   Yamamoto N, 2002, BIOL PHARM BULL, V25, P509, DOI 10.1248/bpb.25.509
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 60
TC 7
Z9 9
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0905 7161
EI 1600 0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD FEB
PY 2006
VL 17
IS 1
BP 38
EP 47
DI 10.1111/j.1600 0501.2005.01187.x
PG 10
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Engineering
GA 005WA
UT WOS:000234854400005
PM 16441783
DA 2025 08 17
ER

PT J
AU Ryan, DA
   Cheng, JJ
   Masuda, K
   Cashman, JR
AF Ryan, Daniel A.
   Cheng, Jiongjia
   Masuda, Koichi
   Cashman, John R.
TI Role of Curcuminoids and Tricalcium Phosphate Ceramic in Rat Spinal
   Fusion
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE bone marrow derived mesenchymal stem cells; curcumins; tricalcium
   phosphate ceramic; bone growth
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; BONE FORMATION; OSTEOGENIC
   DIFFERENTIATION; ALZHEIMERS DISEASE; SMALL MOLECULE; OSTEOBLAST
   DIFFERENTIATION; DEXAMETHASONE; TRANSCRIPTION; REGENERATION
AB Despite considerable research effort, there is a significant need for safe agents that stimulate bone formation. Treatment of large or complex bone defects remains a challenge. Implantation of small molecule induced human bone marrow derived mesenchymal stromal cells (hBMSCs) on an appropriate tricalcium phosphate (TCP) scaffold offers a robust system for noninvasive therapy for spinal fusion. To show the efficacy of this approach, we identified a small molecule curcuminoid that when combined with TCP ceramic in the presence of hBMSCs selectively induced growth of bone cells: after 8  or 25 day incubations, alkaline phosphatase was elevated. Treatment of hBMSCs with curcuminoid 1 and TCP ceramic increased osteogenic target gene expression (i.e., Runx2, BMP2, Osteopontin, and Osteocalcin) over time. In the presence of curcuminoid 1 and TCP ceramic, osteogenesis of hBMSCs, including proliferation, differentiation, and mineralization, was observed. No evidence of chondrogenic or adipogenic potential using this protocol was observed. Transplantation of curcuminoid 1 treated hBMSC/TCP mixtures into the spine of immunodeficient rats showed that it achieved spinal fusion and provided greater stability of the spinal column than untreated hBMSC TCP implants or TCP alone implants. On the basis of histological analysis, greater bone formation was associated with curcuminoid 1 treated hBMSC implants manifested as contiguous growth plates with extensive hematopoietic territories. Stimulation of hBMSCs by administration of small molecule curcuminoid 1 in the presence of TCP ceramic afforded an effective noninvasive strategy that increased spinal fusion repair and provided greater stability of the spinal column after 8 weeks in immunodeficient rats.
   Impact statement
   Bone defects only slowly regenerate themselves in humans. Current procedures to restore spinal defects are not always effective. Some have side effects. In this article, a new method to produce bone growth within 8 weeks in rats is presented. In the presence of tricalcium phosphate ceramic, curcuminoid 1 small molecule stimulated human bone marrow derived mesenchymal stromal cells showed robust bone cell growth in vitro. Transplantation of this mixture into the spine showed efficient spinal fusion in rats. The approach presented herein provides an efficient biocompatible scaffold for delivery of a potentially clinically useful system that could be applicable in patients.
C1 [Ryan, Daniel A.; Cheng, Jiongjia; Cashman, John R.] Human BioMol Res Inst, 5310 Eastgate Mall, San Diego, CA 92121 USA.
   [Masuda, Koichi] Univ Calif San Diego, Dept Orthoped Surg, San Diego, CA 92103 USA.
C3 University of California System; University of California San Diego
RP Cashman, JR (通讯作者)，Human BioMol Res Inst, 5310 Eastgate Mall, San Diego, CA 92121 USA.
EM jcashman@hbri.org
RI Cheng, Jiongjia/AAM 9464 2020
FU Human BioMolecular Research Institute
FX No external funding was received. Funding was from the Human
   BioMolecular Research Institute.
CR Aggarwal B.B., 2007, The molecular targets and therapeutic uses of curcumin in health and disease
   Ahn J, 2010, AM J PHYSIOL CELL PH, V298, pC1510, DOI 10.1152/ajpcell.00369.2009
   Akiyama H, 2008, MOD RHEUMATOL, V18, P213, DOI 10.1007/s10165 008 0048 x
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   [Anonymous], 2013, INT J RES PHARM SCI
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Betz RR, 2002, ORTHOPEDICS, V25, pS561
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Blackwood KA, 2012, INT J POLYM SCI, V2012, DOI 10.1155/2012/174942
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Cashman JR, 2012, NEURODEGENER DIS, V10, P274, DOI 10.1159/000333123
   Chen SG, 2014, BONE, V67, P109, DOI 10.1016/j.bone.2014.06.032
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   DelaRosa O, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00182
   DelaRosa O, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/865601
   DiMarino AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00201
   Eniwumide JO, 2007, EUR CELLS MATER, V14, P30, DOI 10.22203/eCM.v014a03
   Fiala M, 2007, P NATL ACAD SCI USA, V104, P12849, DOI 10.1073/pnas.0701267104
   Fukui D, 2017, EUR SPINE J, V26, P2014, DOI 10.1007/s00586 016 4920 7
   Funk JL, 2006, J NAT PROD, V69, P351, DOI 10.1021/np050327j
   Gellynck K, 2013, BONE, V57, P405, DOI 10.1016/j.bone.2013.09.012
   Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959
   Giuliani N, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/312501
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973 1296.99285
   Holtzclaw D, 2008, J AM DENT ASSOC, V139, P1192, DOI 10.14219/jada.archive.2008.0334
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jin GZ, 2012, J MATER SCI MATER M, V23, P1739, DOI 10.1007/s10856 012 4646 y
   Jin QM, 2000, J BIOMED MATER RES, V51, P491, DOI 10.1002/1097 4636(20000905)51:3<491::AID JBM25>3.3.CO;2 T
   Kang YQ, 2012, BIOMATERIALS, V33, P6998, DOI 10.1016/j.biomaterials.2012.06.061
   Kang YQ, 2011, BIOMATERIALS, V32, P6119, DOI 10.1016/j.biomaterials.2011.05.015
   Kim CH, 1999, J ENDOCRINOL, V162, P371, DOI 10.1677/joe.0.1620371
   Kim HN, 2011, BMB REP, V44, P446, DOI 10.5483/BMBRep.2011.44.7.446
   Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890 199704270 00003
   Kuznetsov SA, 2013, J TISSUE ENG REGEN M, V7, P226, DOI 10.1002/term.515
   Lanier M, 2012, J MED CHEM, V55, P697, DOI 10.1021/jm2010223
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864
   Mankani MH, 2008, TISSUE ENG PT A, V14, P1949, DOI 10.1089/ten.tea.2007.0348
   Mankani MH, 2001, BIOTECHNOL BIOENG, V72, P96, DOI 10.1002/1097 0290(20010105)72:1<96::AID BIT13>3.0.CO;2 A
   Masoumi A, 2009, J ALZHEIMERS DIS, V17, P703, DOI 10.3233/JAD 2009 1080
   Mishra S, 2008, ANN INDIAN ACAD NEUR, V11, P13, DOI 10.4103/0972 2327.40220
   Naito M, 2013, CELL TISSUE RES, V354, P761, DOI 10.1007/s00441 013 1696 5
   Nishizuka M, 2008, FEBS LETT, V582, P3201, DOI 10.1016/j.febslet.2008.08.011
   Okada M, 2009, CELL BIOCHEM FUNCT, V27, P526, DOI 10.1002/cbf.1615
   Pape HC, 2010, J ORTHOP TRAUMA, V24, pS36, DOI 10.1097/BOT.0b013e3181cec4a1
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Ravindran J, 2010, BIOCHEM PHARMACOL, V79, P1658, DOI 10.1016/j.bcp.2010.01.033
   Robey PG, 2011, TISSUE ENG PART B RE, V17, P423, DOI 10.1089/ten.teb.2011.0199
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476 9255 2 8
   Schmöle AC, 2013, CURR PHARM BIOTECHNO, V14, P36
   Song IH, 2009, J ORTHOP RES, V27, P916, DOI 10.1002/jor.20838
   Strathmann J., 2012, NATURAL COMPOUNDS IN, VVolume 47, P95, DOI [10.1007/978 94 007 4575 9_5, DOI 10.1007/978 94 007 4575 9_5]
   Volak LP, 2008, DRUG METAB DISPOS, V36, P1594, DOI 10.1124/dmd.108.020552
   Wang YK, 2013, J CELL MOL MED, V17, P823, DOI 10.1111/jcmm.12061
   Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088
   Wu X, 2002, J AM CHEM SOC, V124, P14520, DOI 10.1021/ja0283908
   Yamaguchi T, 2014, TISSUE ENG PART C ME, V20, P578, DOI [10.1089/ten.tec.2013.0439, 10.1089/ten.TEC.2013.0439]
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zhang X, 2011, EUR J PHARM SCI, V42, P540, DOI 10.1016/j.ejps.2011.02.009
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 67
TC 2
Z9 2
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD NOV 1
PY 2020
VL 26
IS 11
BP 577
EP 589
DI 10.1089/ten.tec.2020.0217
EA NOV 2020
PG 13
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA OS1BI
UT WOS:000592283600001
PM 33086948
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU León, IE
   Porro, V
   Astrada, S
   Egusquiza, MG
   Cabello, CI
   Bollati Fogolin, M
   Etcheverry, SB
AF Leon, I. E.
   Porro, V.
   Astrada, S.
   Egusquiza, M. G.
   Cabello, C. I.
   Bollati Fogolin, M.
   Etcheverry, S. B.
TI Polyoxometalates as antitumor agents: Bioactivity of a new
   polyoxometalate with copper on a human osteosarcoma model
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Anticancer drug; MG 63 human osteosarcoma cells; Mechanisms of action;
   Polyoxometalates; Copper
ID APOPTOTIC CELL DEATH; IN VITRO; REDUCED GLUTATHIONE; OXIDATIVE STRESS;
   GROWTH FACTOR; INHIBITORS; VANADIUM; PROLIFERATION; MITOCHONDRIAL;
   POLYOXOMOLYBDATE
AB Polyoxometalates (POMs) are early transition metal oxygen anion clusters. They display interesting biological effects mainly related to their antiviral and antitumor properties. On the other hand, copper compounds also show different biological and pharmacological effects in cell culture and in animal models. We report herein for the first time, a detailed study of the mechanisms of action of a copper(II) compound of the group of HPOMs with the formula K7Na3[Cu 4(H2O)(2)(PW9O34)(2)]20H(2)O (PW9Cu), in a model of human osteosarcoma derived cell line, MG 63. The compound inhibited selectively the viability of the osteosarcoma cells in the range of 25 100 mu M (p < 0.01). Besides, we have clearly shown a more deleterious action of PW9Cu on tumor osteoblasts than in normal cells. Cytotoxicity studies also showed deleterious effects for PW9Cu. The increment of reactive oxygen species (ROS) and the decrease of the GSH/GSSG ratio were involved in the antiproliferative effects of PW9Cu. Moreover, the compound caused cell cycle arrest in G(2) phase, triggering apoptosis as determined by flow cytometry. As a whole, these results showed the main mechanisms of the deleterious effects of PW9Cu in the osteosarcoma cell line MG 63, demonstrating that this compound is a promissory agent for cancer treatments. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Leon, I. E.; Etcheverry, S. B.] Univ Nacl La Plata, Fac Ciencias Exactas, CONICET, Ctr Quim Inorgan, RA 1900 La Plata, Argentina.
   [Porro, V.; Astrada, S.; Bollati Fogolin, M.] Inst Pasteur, Unidad Biol Celular, Montevideo 11400, Uruguay.
   [Egusquiza, M. G.; Cabello, C. I.] CINDECA, La Plata, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of La Plata; Pasteur Network; Institut Pasteur de
   Montevideo; Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); National University of La Plata; Cindeca
RP Etcheverry, SB (通讯作者)，Univ Nacl La Plata, Fac Ciencias Exactas, CONICET, Ctr Quim Inorgan, RA 1900 La Plata, Argentina.
EM etcheverry@biol.unlp.edu.ar
RI leon, i/GZL 2093 2022
OI leon, ignacio/0000 0003 1010 3997
FU UNLP [11X/554]; CONICET [PIP 1125]; ANPCyT from Argentina [PICT
   2008 2218, PICT 2010  0981]; ANPCyT, Argentina; AMSUD  PASTEUR
FX This work was partly supported by UNLP (11X/554), CONICET, (PIP 1125),
   ANPCyT (PICT 2008 2218 and PICT 2010  0981) from Argentina. SBE is
   member of the Carrera del Investigador, CONICET, Argentina. CIC is
   member of the Carrera del Investigador, CIC, PBA. IEL has a fellowship
   from ANPCyT, Argentina and a fellowship from AMSUD  PASTEUR. MBF is
   member of the Sistema Nacional de Investigadores (SNI) of the Agencia
   Nacional de Investigacion e Innovacion (ANII) from Uruguay. The authors
   would like to thank Ines Tiscornia for the management work with the
   cells and Prof Dr Gerardo Vasta for purchasing the Rhodamine 123 probe
   for the mitochondrial activity assay. Moreover, the authors would like
   to thank Prof. Maria del Carmen Bernal for her careful revision of the
   manuscript.
CR Alemón Medina R, 2008, TOXICOL IN VITRO, V22, P710, DOI 10.1016/j.tiv.2007.11.011
   Baumgartner HK, 2007, AM J PHYSIOL GASTR L, V293, pG296, DOI 10.1152/ajpgi.00103.2007
   BERTHON G, 1993, AGENTS ACTIONS, V39, P210, DOI 10.1007/BF01998975
   Bisceglie F, 2012, J INORG BIOCHEM, V116, P195, DOI 10.1016/j.jinorgbio.2012.07.006
   Borenfreund E., 1984, Journal of Tissue Culture Methods, V9, P7, DOI [10.1007/BF01666038, DOI 10.1007/BF01666038]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   BUSSEREAU F, 1983, ANN INST PASTEUR VIR, V134, P127, DOI 10.1016/S0769 2617(83)80048 3
   Capella MAM, 2007, CELL BIOL TOXICOL, V23, P413, DOI 10.1007/s10565 007 9003 4
   Casuscelli S, 2005, CATAL TODAY, V107 08, P230, DOI 10.1016/j.cattod.2005.07.093
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   Delgado O., 1994, POLYOXOMETALATES PLA
   Dianat S, 2013, J PHOTOCH PHOTOBIO B, V124, P27, DOI 10.1016/j.jphotobiol.2013.04.001
   Egusquiza MG, 2012, CATAL COMMUN, V26, P117, DOI 10.1016/j.catcom.2012.04.030
   El Gendy KS, 2009, CHEMOSPHERE, V77, P339, DOI 10.1016/j.chemosphere.2009.07.015
   Etcheverry SB, 2009, NEW DEVELOPMENTS IN MEDICINAL CHEMISTRY, P105
   Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899 9007(02)00916 4
   Farrell N.P., 1999, The Uses of Inorganic Chemistry in Medicine
   FINKE RG, 1987, INORG CHEM, V26, P3886, DOI 10.1021/ic00270a014
   FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11
   Grebenová D, 2003, J PHOTOCH PHOTOBIO B, V69, P71, DOI 10.1016/S1011 1344(02)00410 4
   Guo ZJ, 2000, ADV INORG CHEM, V49, P183
   Hasenknopf B, 2005, FRONT BIOSCI LANDMRK, V10, P275, DOI 10.2741/1527
   Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003 2697(76)90326 2
   Huang X, 2005, CELL PROLIFERAT, V38, P223, DOI 10.1111/j.1365 2184.2005.00344.x
   Hurley A.A., 1997, CURR PROTOC CYTOM
   HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409
   JASMIN C, 1973, BIOMEDICINE, V18, P319
   Jelikic Stankov M, 2007, J TRACE ELEM MED BIO, V21, P8, DOI 10.1016/j.jtemb.2006.11.004
   Kramarova E, 1996, INT J CANCER, V68, P759
   Krejsa CM, 1997, J BIOL CHEM, V272, P11541
   León IE, 2012, METALLOMICS, V4, P1287, DOI 10.1039/c2mt20091k
   Lever A.B.P., 1968, INORGANIC ELECT SPEC
   Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002
   Mitsui S, 2006, BIOMED PHARMACOTHER, V60, P353, DOI 10.1016/j.biopha.2006.02.009
   Mohseny Alexander B., 2012, Sarcoma, V2012, P417271, DOI 10.1155/2012/417271
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nagai M, 2012, FREE RADICAL BIO MED, V52, P2142, DOI 10.1016/j.freeradbiomed.2012.03.017
   Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834
   Ogata A, 2008, BRIT J CANCER, V98, P399, DOI 10.1038/sj.bjc.6604133
   Ogata A, 2005, BIOMED PHARMACOTHER, V59, P240, DOI 10.1016/j.biopha.2004.11.008
   OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201
   POPE MT, 1991, ANGEW CHEM INT EDIT, V30, P34, DOI 10.1002/anie.199100341
   POPE MT, 1983, HETEROPOLY ISOPOLY O
   Pozarowski P., 2003, CURR PROTOC CYTOM
   Pu F, 2013, MOL BIOSYST, V9, P113, DOI 10.1039/c2mb25389e
   RAYNAUD M, 1971, CR ACAD SCI D NAT, V272, P347
   Raza R, 2012, DALTON T, V41, P14329, DOI 10.1039/c2dt31784b
   Rehder D, 1999, COORDIN CHEM REV, V182, P297, DOI 10.1016/S0010 8545(98)00194 5
   Rhule JT, 1998, CHEM REV, V98, P327, DOI 10.1021/cr960396q
   Sherr C.J., 2000, Cancer Res, V60, P3695
   SO H, 1972, INORG CHEM, V11, P1441, DOI 10.1021/ic50112a061
   Sorenson J.R.J., 1989, COPPER ZINC INFLAMMA, P69
   Sorenson J.R.J., 1987, BIOL COPPER COMPLEXE
   SOUYRICAPORALE M, 1984, J GEN VIROL, V65, P831, DOI 10.1099/0022 1317 65 4 831
   Stankiewicz P.J., 1995, METAL IONS BIOL SYST, V31
   TAJIMA Y, 2001, CURR TOP BIOCH RES, V4, P129
   Wang CCC, 2008, CANCER LETT, V259, P82, DOI 10.1016/j.canlet.2007.10.005
   Weder JE, 2002, COORDIN CHEM REV, V232, P95, DOI 10.1016/S0010 8545(02)00086 3
   WU EY, 1990, ARCH BIOCHEM BIOPHYS, V282, P358, DOI 10.1016/0003 9861(90)90129 M
   Yamase T, 1996, BIOL PHARM BULL, V19, P459
   Yamase Toshihiro, 2013, Prog Mol Subcell Biol, V54, P65, DOI 10.1007/978 3 642 41004 8_4
   Zhai FY, 2009, BIOMED PHARMACOTHER, V63, P51, DOI 10.1016/j.biopha.2008.01.006
   Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464
NR 65
TC 42
Z9 50
U1 1
U2 119
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD OCT 5
PY 2014
VL 222
BP 87
EP 96
DI 10.1016/j.cbi.2014.10.012
PG 10
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA AW7RI
UT WOS:000346461800011
PM 25451568
OA Green Published
DA 2025 08 17
ER

PT J
AU An, XL
   Ma, KY
   Zhang, ZR
   Zhao, TC
   Zhang, XM
   Tang, B
   Li, ZY
AF An, Xinglan
   Ma, Kuiying
   Zhang, Zhiren
   Zhao, Tianchuang
   Zhang, Xueming
   Tang, Bo
   Li, Ziyi
TI miR 17, miR 21, and miR 143 Enhance Adipogenic Differentiation from
   Porcine Bone Marrow Derived Mesenchymal Stem Cells
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID ADIPOSE TISSUE; ADIPOCYTE DIFFERENTIATION; EXPRESSION; MICRORNAS;
   C3H10T1/2; TARGETS; MODEL; BETA
AB Bone marrow derived mesenchymal stem cells (BMSCs) have multilineage differentiation abilities toward adipocytes and osteoblasts. Recently, numerous studies have focused on the roles of microRNAs (miRNAs) in the process of adipogenic differentiation of human and mouse cells. However, the role of miRNAs in adipogenic differentiation process of porcine BMSCs (pBMSCs) remains unclear. In this study, pBMSCs were induced to differentiate into adipocytes using a chemical approach, and the roles of miR 17, miR 21, and miR 143 in this process were investigated. Our results showed that pBMSCs could be chemically induced to differentiate into adipocytes and that the expression of miR 17, miR 21, and miR 143 increased during differentiation. Then, overexpression of mimics of miR 17, miR 21, and miR 143 increased the number of oil red O positive cells of adipocyte differentiation. The expression levels of CCAAT/enhancer binding protein alpha (C/EBPa) mRNA showed increases of 1.8 , 1.5 , and 1.2 fold in the groups expressing mimics of miR 21, miR 17, and miR 143, respectively, at day 20. These results demonstrate that miR 17, miR 21, and miR 143 are involved in and promote the adipogenic differentiation of pBMSCs. This study provides an experimental basis for establishing a stable and efficient adipogenic differentiation model for applications in cell therapy and tissue engineering.
C1 [An, Xinglan; Ma, Kuiying; Zhang, Zhiren; Li, Ziyi] Jilin Univ, Coll Anim Sci, Changchun, Peoples R China.
   [An, Xinglan; Li, Ziyi] Jilin Univ, Hosp 1, Acad Translat Med, State & Local Joint Engn Lab Anim Models Human Di, Changchun 130061, Peoples R China.
   [Zhao, Tianchuang; Zhang, Xueming; Tang, Bo] Jilin Univ, Coll Vet Med, Changchun 130062, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Li, ZY (通讯作者)，Jilin Univ, Hosp 1, Acad Translat Med, State & Local Joint Engn Lab Anim Models Human Di, Changchun 130061, Peoples R China.; Tang, B (通讯作者)，Jilin Univ, Coll Vet Med, Changchun 130062, Peoples R China.
EM tang_bo@jlu.edu.cn; ziyi@jlu.edu.cn
RI MA, Kuiying/H 7941 2017
OI MA, Kuiying/0000 0002 6971 0954
CR Alexander R, 2011, EXPERT OPIN THER TAR, V15, P623, DOI 10.1517/14728222.2011.561317
   Casado JG, 2012, VET IMMUNOL IMMUNOP, V147, P104, DOI 10.1016/j.vetimm.2012.03.015
   Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815
   CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531
   Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200
   Esquela Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Hamam D, 2015, STEM CELLS DEV, V24, P417, DOI 10.1089/scd.2014.0331
   Jin WW, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471 2199 11 29
   Kang M, 2013, MOL BIOL REP, V40, P5027, DOI 10.1007/s11033 013 2603 6
   Kim EK, 2011, PLAST RECONSTR SURG, V128, P387, DOI 10.1097/PRS.0b013e31821e6de2
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Li GX, 2011, J CELL BIOCHEM, V112, P1318, DOI 10.1002/jcb.23045
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Liu Y, 2013, BIOSCIENCE REP, V33, P351, DOI 10.1042/BSR20120023
   Noort WA, 2012, J CELL MOL MED, V16, P1827, DOI 10.1111/j.1582 4934.2011.01455.x
   Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008 5472.CAN 08 1305
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rho GJ, 2009, FRONT BIOSCI LANDMRK, V14, P3942, DOI [10.2735/3503, 10.2741/3503]
   Ringe J, 2002, CELL TISSUE RES, V307, P321, DOI 10.1007/s00441 002 0525 z
   Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101
   Yi C, 2011, FEBS LETT, V585, P3303, DOI 10.1016/j.febslet.2011.09.015
   Zhao L, 2009, CALCIFIED TISSUE INT, V84, P56, DOI 10.1007/s00223 008 9189 3
   Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200
NR 23
TC 32
Z9 37
U1 0
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044 5498
EI 1557 7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD AUG
PY 2016
VL 35
IS 8
BP 410
EP 416
DI 10.1089/dna.2015.3182
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA DS5JH
UT WOS:000380817500006
PM 27093346
DA 2025 08 17
ER

PT J
AU Jiang, HY
   Lin, CH
   Cai, TW
   Jiang, LT
   Lou, C
   Lin, SD
   Wang, WD
   Yan, ZJ
   Pan, XY
   Xue, XH
AF Jiang, Hongyi
   Lin, Chihao
   Cai, Tingwen
   Jiang, Liting
   Lou, Chao
   Lin, Shida
   Wang, Weidan
   Yan, Zijian
   Pan, Xiaoyun
   Xue, Xinghe
TI Taxifolin mediated Nrf2 activation ameliorates oxidative stress and
   apoptosis for the treatment of glucocorticoid induced osteonecrosis of
   the femoral head
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE apoptosis; glucocorticoid induced osteonecrosis of the femoral head
   (GIONFH); Nrf2 pathway; oxidative stress; taxifolin
ID IN VITRO; NECROSIS; PATHWAY; CELLS
AB Glucocorticoid induced osteonecrosis of the femoral head (GIONFH) is the main complication secondary to long term or excessive use of glucocorticoids (GCs). Taxifolin (TAX) is a natural antioxidant with various pharmacological effects, such as antioxidative stress and antiapoptotic properties. The purpose of this study was to explore whether TAX could regulate oxidative stress and apoptosis in GIONFH by activating the nuclear factor erythroid 2 related factor 2 (Nrf2) pathway. We conducted qRT PCR, Western blotting, TUNEL assays, flow cytometry, and other experiments in vitro. Microcomputed tomography analysis, hematoxylin eosin staining, and immunohistochemical staining were performed to determine the therapeutic effect of TAX in vivo. TAX mitigated the overexpression of ROS and NOX gene expression induced by DEX, effectively reducing oxidative stress. Additionally, TAX could alleviate DEX induced osteoblast apoptosis, as evidenced by qRT PCR, Western blotting, and other experimental techniques. Our in vivo studies further demonstrated that TAX mitigates the progression of GIONFH in rats by combating oxidative stress and apoptosis. Mechanistic exploration revealed that TAX thwarts the progression of GIONFH through the activation of the Nrf2 pathway. Overall, our research herein reports that TAX mediated Nrf2 activation ameliorates oxidative stress and apoptosis for the treatment of GIONFH.
C1 [Jiang, Hongyi; Lin, Chihao; Cai, Tingwen; Jiang, Liting; Lou, Chao; Lin, Shida; Wang, Weidan; Yan, Zijian; Pan, Xiaoyun; Xue, Xinghe] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.
   [Jiang, Hongyi; Lin, Chihao; Cai, Tingwen; Jiang, Liting; Lou, Chao; Lin, Shida; Wang, Weidan; Yan, Zijian; Pan, Xiaoyun; Xue, Xinghe] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Jiang, Hongyi; Lin, Chihao; Cai, Tingwen; Jiang, Liting; Lou, Chao; Lin, Shida; Wang, Weidan; Yan, Zijian] Key Lab Orthoped Zhejiang Prov, Wenzhou, Peoples R China.
   [Jiang, Hongyi; Lin, Chihao; Cai, Tingwen; Jiang, Liting; Lou, Chao; Lin, Shida; Wang, Weidan; Yan, Zijian] Wenzhou Med Univ, Sch Clin Med 2, Wenzhou, Peoples R China.
   [Pan, Xiaoyun] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou 325000, Zhejiang, Peoples R China.
   [Pan, Xiaoyun; Xue, Xinghe] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Zhejiang, Peoples R China.
   [Xue, Xinghe] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University; Wenzhou Medical University;
   Wenzhou Medical University
RP Pan, XY (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou 325000, Zhejiang, Peoples R China.; Pan, XY; Xue, XH (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Zhejiang, Peoples R China.; Xue, XH (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
EM xiaoyunpan@126.com; xinghe901130@163.com
RI ; Jiang, Liting/MBI 1801 2025; Lin, ChiHao/HZK 8189 2023; Lou,
   Chao/JPL 0980 2023; Jiang, Hongyi/GLR 0971 2022
OI Xue, Xinghe/0000 0003 3300 7287; 
FU This work was funded by Wenzhou Municipal Science and Technology Bureau
   (Y20210400), Medical and Health Technology Program of Zhejiang Province
   (No. 2020KY187), and The Yuying Program of the Second Affiliated
   Hospital of Wenzhou Medical University (No. 813 [Y20210400]; Wenzhou
   Municipal Science and Technology Bureau [2020KY187]; Medical and Health
   Technology Program of Zhejiang Province [813386]; Yuying Program of the
   Second Affiliated Hospital of Wenzhou Medical University
FX This work was funded by Wenzhou Municipal Science and Technology Bureau
   (Y20210400), Medical and Health Technology Program of Zhejiang Province
   (No. 2020KY187), and The Yuying Program of the Second Affiliated
   Hospital of Wenzhou Medical University (No. 813386).
CR Ahiskali I, 2019, CUTAN OCUL TOXICOL, V38, P384, DOI 10.1080/15569527.2019.1637348
   Bai SC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9192413
   Baird L, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00099 20
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chen J, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04300 8
   Chen L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9102012
   Cohen Rosenblum A, 2019, ORTHOP CLIN N AM, V50, P139, DOI 10.1016/j.ocl.2018.10.001
   Cui Y, 2021, SCI TOTAL ENVIRON, V764, DOI 10.1016/j.scitotenv.2020.142880
   Das A, 2021, BIOMED PHARMACOTHER, V142, DOI 10.1016/j.biopha.2021.112004
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Ding LZ, 2018, INT J MOL MED, V41, P2517, DOI 10.3892/ijmm.2018.3506
   Dovio A, 2008, J Endocrinol Invest, V31, P7
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978 94 007 2869 1_7
   Fan ZQ, 2021, ORTHOP SURG, V13, P2145, DOI 10.1111/os.13127
   Feng YL, 2014, CHEM BIOL INTERACT, V207, P26, DOI 10.1016/j.cbi.2013.11.004
   Hines JT, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e177
   Hong L, 2009, J STEROID BIOCHEM, V114, P180, DOI 10.1016/j.jsbmb.2009.02.001
   Huang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.777697
   Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006
   Islam J, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107566
   Kovac S, 2015, BBA GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021
   Kuang HX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071546
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee SB, 2007, BIOL PHARM BULL, V30, P1074, DOI 10.1248/bpb.30.1074
   Li MY, 2009, J CELL BIOCHEM, V107, P944, DOI 10.1002/jcb.22197
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092 8674(00)80434 1
   Liu XL, 2021, FOOD FUNCT, V12, P12142, DOI [10.1039/d1fo01349a, 10.1039/D1FO01349A]
   Liu XL, 2021, DRUG DES DEV THER, V15, P871, DOI 10.2147/DDDT.S281369
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396
   Lu Y, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba3613
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev pharmtox 011112 140320
   Makena PS, 2009, ENVIRON MOL MUTAGEN, V50, P451, DOI 10.1002/em.20487
   Manigandan K, 2015, BIOCHIMIE, V119, P103, DOI 10.1016/j.biochi.2015.10.014
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nan BY, 2022, ACTA PHARM SIN B, V12, P167, DOI 10.1016/j.apsb.2021.07.002
   Nan K, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02390 x
   Okkay U, 2022, METAB BRAIN DIS, V37, P1541, DOI 10.1007/s11011 022 00952 3
   Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010 010 0709 x
   Perkins CL, 2000, CANCER RES, V60, P1645
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Sun X, 2014, FOOD CHEM TOXICOL, V63, P221, DOI 10.1016/j.fct.2013.11.013
   Sunil C, 2019, PHYTOCHEMISTRY, V166, DOI 10.1016/j.phytochem.2019.112066
   Tao SC, 2017, THERANOSTICS, V7, P733, DOI 10.7150/thno.17450
   Tarafdar A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123824
   Vermot A, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060890
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Xu X., 2021, EVID BASED COMPL ALT, V2021, P8002111
   Yan ZJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01195
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Yu C, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6635460
   Zhan JD, 2020, FOOD FUNCT, V11, P7830, DOI [10.1039/d0fo00837k, 10.1039/D0FO00837K]
   Zhang F, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04226 1
   Zhang SQ, 2021, DRUG DES DEV THER, V15, P983, DOI 10.2147/DDDT.S298691
   Zhang XY, 2018, BIOCHEM BIOPH RES CO, V503, P2255, DOI 10.1016/j.bbrc.2018.06.146
   Zhu CY, 2019, BIOCHEM BIOPH RES CO, V516, P645, DOI 10.1016/j.bbrc.2019.06.073
   Zhu X, 2020, CALCIFIED TISSUE INT, V106, P518, DOI 10.1007/s00223 020 00660 z
   Zuo RT, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1426 3
NR 63
TC 12
Z9 14
U1 2
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JAN
PY 2024
VL 38
IS 1
BP 156
EP 173
DI 10.1002/ptr.8031
EA OCT 2023
PG 18
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GP7Q2
UT WOS:001083404300001
PM 37846877
OA Bronze
DA 2025 08 17
ER

PT J
AU Xue, YF
   St Hilaire, C
   Hortells, L
   Phillippi, JA
   Sant, V
   Sant, S
AF Xue, Yingfei
   St Hilaire, Cynthia
   Hortells, Luis
   Phillippi, Julie A.
   Sant, Vinayak
   Sant, Shilpa
TI Shape Specific Nanoceria Mitigate Oxidative Stress Induced Calcification
   in Primary Human Valvular Interstitial Cell Culture
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE Nanoceria; Reactive oxygen species (ROS); Valve calcification;
   Patient derived valvular interstitial cells (hVICs); Cerium oxide
   nanoparticle; Nanoparticle shape
ID CERIUM OXIDE NANOPARTICLES; AORTIC VALVE DISEASE; OSTEOGENIC
   DIFFERENTIATION; VASCULAR CALCIFICATION; EMERGING ROLE; MECHANISMS;
   STENOSIS; PROLIFERATION; PHOSPHATE; NANORODS
AB Lack of effective pharmacological treatment makes valvular calcification a significant clinical problem in patients with valvular disease and bioprosthetic/mechanical valve replacement therapies. Elevated levels of reactive oxygen species (ROS) in valve tissue have been identified as a prominent hallmark and driving factor for valvular calcification. However, the therapeutic value of ROS modulating agents for valvular calcification remains elusive. We hypothesized that ROS modulating shape specific cerium oxide nanoparticles (CNPs) will inhibit oxidative stress induced valvular calcification. CNPs are a class of self regenerative ROS modulating agents, which can switch between Ce3+ and Ce4+ in response to oxidative microenvironment. In this work, we developed oxidative stress induced valve calcification model using two patient derived stenotic valve interstitial cells (hVICs) and investigated the therapeutic effect of shape specific CNPs to inhibit hVIC calcification.
   Human valvular interstitial cells (hVICs) were obtained from a normal healthy donor and two patients with calcified aortic valves. hVICs were characterized for their phenotypic (mesenchymal, myofibroblast and osteoblast) marker expression by qRT PCR and antioxidant enzymes activity before and after exposure to hydrogen peroxide (H2O2) induced oxidative stress. Four shape specific CNPs (sphere, short rod, long rod, and cube) were synthesized via hydrothermal or ultra sonication method and characterized for their biocompatibility in hVICs by alamarBlue(A (R)) assay, and ROS scavenging ability by DCFH DA assay. H2O2 and inorganic phosphate (Pi) were co administrated to induce hVIC calcification in vitro as demonstrated by Alizarin Red S staining and calcium quantification. The effect of CNPs on inhibiting H2O2 induced hVIC calcification was evaluated.
   hVICs isolated from calcified valves exhibited elevated osteoblast marker expression and decreased antioxidant enzyme activities compared to the normal hVICs. Due to the impaired antioxidant enzyme activities, acute H2O2 induced oxidative stress resulted in higher ROS levels and osteoblast marker expression in both diseased hVICs when compared to the normal hVICs. Shape specific CNPs exhibited shape dependent abiotic ROS scavenging ability, and excellent cytocompatibility. Rod and sphere CNPs scavenged H2O2 induced oxidative stress in hVICs in a shape  and dose dependent manner by lowering intracellular ROS levels and osteoblast marker expression. Further, CNPs also enhanced activity of antioxidant enzymes in hVICs to combat oxidative stress. Cube CNPs were not effective ROS scavengers. The addition of H2O2 in the Pi induced calcification model further increased calcium deposition in vitro in a time dependent manner. Co administration of rod CNPs with Pi and H2O2 mitigated calcification in the diseased hVICs.
   We demonstrated that hVICs derived from calcified valves exhibited impaired antioxidant defense mechanisms and were more susceptible to oxidative stress than normal hVICs. CNPs scavenged H2O2 induced oxidative stress in hVICs in a shape dependent manner. The intrinsic ROS scavenging ability of CNPs and their ability to induce cellular antioxidant enzyme activities may confer protection from oxidative stress exacerbated calcification. CNPs represent promising antioxidant therapy for treating valvular calcification and deserve further investigation.
C1 [Xue, Yingfei; Sant, Vinayak; Sant, Shilpa] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
   [St Hilaire, Cynthia; Hortells, Luis] Univ Pittsburgh, Dept Med, Div Cardiol, Pittsburgh, PA 15219 USA.
   [St Hilaire, Cynthia; Hortells, Luis] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15219 USA.
   [Phillippi, Julie A.; Sant, Shilpa] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA 15261 USA.
   [Phillippi, Julie A.] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA 15219 USA.
   [Phillippi, Julie A.; Sant, Shilpa] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
   [Sant, Shilpa] 808A Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Sant, S (通讯作者)，Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.; Sant, S (通讯作者)，808A Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.
EM shs149@pitt.edu
RI Xue, Yingfei/J 7504 2019; Sant, Shilpa/G 4086 2010; Phillippi,
   Julie/AAW 3205 2021; St. Hilaire, Cynthia/R 8205 2017
OI Sant, Shilpa/0000 0002 2017 9584; Xue, Yingfei/0000 0002 4551 3702;
   Sant, Vinayak/0000 0003 2903 1276
FU School of Pharmacy, University of Pittsburgh; NHLBI [HL117917]
FX We acknowledge funding support from the School of Pharmacy, University
   of Pittsburgh (SS) and HL117917, NHLBI (CSH). YX acknowledges Graduate
   Student Research Scholarship from the School of Pharmacy, University of
   Pittsburgh. We thank Dr. Thomas Gleason, Center for Thoracic Aortic
   Disease, University of Pittsburgh for providing us with valve cusp
   tissue to collect the valve cells and Jennifer Hill for isolating valve
   cells. We thank Dr. Donna Stolz, Center for Biologic Imaging, University
   of Pittsburgh for access to TEM facility and Akhil Patel, School of
   Pharmacy, University of Pittsburgh for acquiring the TEM images. We
   thank Dr. Paul Johnston, School of Pharmacy, University of Pittsburgh
   for access to the spectrophotometer.
CR Aikawa E., 2012, PLOS ONE, V7
   Boström KI, 2011, CIRC RES, V109, P564, DOI 10.1161/CIRCRESAHA.110.234278
   Bowler MA, 2015, CARDIOVASC PATHOL, V24, P1, DOI 10.1016/j.carpath.2014.08.003
   Branchetti E, 2013, ARTERIOSCL THROM VAS, V33, pE66, DOI 10.1161/ATVBAHA.112.300177
   Butcher JT, 2011, ADV DRUG DELIVER REV, V63, P242, DOI 10.1016/j.addr.2011.01.008
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Cox RF, 2012, BRIT J CANCER, V106, P525, DOI 10.1038/bjc.2011.583
   Esmerats JF, 2016, ANTIOXID REDOX SIGN, V25, P401, DOI 10.1089/ars.2015.6554
   Gaharwar AK, 2013, ADV MATER, V25, P3329, DOI 10.1002/adma.201300584
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Gough DR, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.96
   Gould R. A., 2010, JOVE J VIS EXP, V23, P12
   Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4
   Heistad DD, 2009, CIRC J, V73, P201, DOI 10.1253/circj.CJ 08 1082
   Hjortnaes J, 2016, J MOL CELL CARDIOL, V94, P13, DOI 10.1016/j.yjmcc.2016.03.004
   Hutcheson JD, 2017, CIRC RES, V120, P270, DOI 10.1161/CIRCRESAHA.116.310060
   Hutcheson JD, 2014, NAT REV CARDIOL, V11, P218, DOI 10.1038/nrcardio.2014.1
   Jo DH, 2015, NANOMED NANOTECHNOL, V11, P1603, DOI 10.1016/j.nano.2015.04.015
   KIM KM, 1976, FED PROC, V35, P156
   Kobayashi Seiichi, 2002, J Atheroscler Thromb, V9, P184
   Kolli MB, 2014, BIOMATERIALS, V35, P9951, DOI 10.1016/j.biomaterials.2014.08.037
   Lai CF, 2012, ENDOCRINOLOGY, V153, P3897, DOI 10.1210/en.2012 1216
   Li Y, 2015, NANOSCALE, V7, P16631, DOI 10.1039/c5nr02970h
   Liberman M., 2007, THROMB VASC BIOL, V28, P463
   Liu AC, 2007, AM J PATHOL, V171, P1407, DOI 10.2353/ajpath.2007.070251
   Mai HX, 2005, J PHYS CHEM B, V109, P24380, DOI 10.1021/jp055584b
   Mason D, 2015, J CONTROL RELEASE, V215, P101, DOI 10.1016/j.jconrel.2015.08.001
   Matés JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009 9120(99)00075 2
   Mathieu P, 2014, CAN J CARDIOL, V30, P982, DOI 10.1016/j.cjca.2014.03.029
   Mazière C, 2010, BBA MOL BASIS DIS, V1802, P1013, DOI 10.1016/j.bbadis.2010.07.010
   Miller JD, 2008, J AM COLL CARDIOL, V52, P843, DOI 10.1016/j.jacc.2008.05.043
   Miller JD, 2011, CIRC RES, V108, P1392, DOI 10.1161/CIRCRESAHA.110.234138
   Miller JD, 2009, CIRCULATION, V119, P2693, DOI 10.1161/CIRCULATIONAHA.108.834614
   Monzack EL, 2011, J HEART VALVE DIS, V20, P449
   Mozaffarian D, 2016, CIRCULATION, V133, P447, DOI 10.1161/CIR.0000000000000366
   Mulholland DL, 1996, CAN J CARDIOL, V12, P231
   Nelson BC, 2016, ANTIOXIDANTS BASEL, V5, DOI 10.3390/antiox5020015
   Niu JL, 2007, CARDIOVASC RES, V73, P549, DOI 10.1016/j.cardiores.2006.11.031
   Niu JL, 2011, J PHARMACOL EXP THER, V338, P53, DOI 10.1124/jpet.111.179978
   Otto CM, 2008, NEW ENGL J MED, V359, P1395, DOI 10.1056/NEJMe0807001
   Pagliari F, 2012, ACS NANO, V6, P3767, DOI 10.1021/nn2048069
   Pesce M., 2015, PLOS ONE, V10
   Pirmohamed T, 2010, CHEM COMMUN, V46, P2736, DOI 10.1039/b922024k
   Popov AL, 2016, MAT SCI ENG C MATER, V68, P406, DOI 10.1016/j.msec.2016.05.103
   Pulido Reyes G, 2015, SCI REP UK, V5, DOI 10.1038/srep15613
   Rzigalinski BA, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1444
   Sakthivel T, 2013, CHEMPLUSCHEM, V78, P1446, DOI 10.1002/cplu.201300302
   Schoen FJ, 2005, ANN THORAC SURG, V79, P1072, DOI 10.1016/j.athoracsur.2004.06.033
   Schoen FJ, 2012, ANNU REV PATHOL MECH, V7, P161, DOI 10.1146/annurev pathol 011110 130257
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   Sverdlov AL, 2011, AM J CARDIOVASC DIS, V1, P185
   Walkey C, 2015, ENVIRON SCI NANO, V2, P33, DOI 10.1039/c4en00138a
   Xue Y, 2018, DRUG DELIV TRANSL RE, V8, P357, DOI 10.1007/s13346 017 0396 1
   Xue YF, 2017, ACTA BIOMATER, V48, P2, DOI 10.1016/j.actbio.2016.10.032
   Yip CYY, 2011, CARDIOVASC PATHOL, V20, P177, DOI 10.1016/j.carpath.2010.12.001
   Zhang DS, 2007, INORG CHEM, V46, P2446, DOI 10.1021/ic061697d
   Zhang Q, 2015, J NANOSCI NANOTECHNO, V15, P6444, DOI 10.1166/jnn.2015.10709
NR 57
TC 10
Z9 16
U1 1
U2 46
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1865 5025
EI 1865 5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD OCT
PY 2017
VL 10
IS 5
BP 483
EP 500
DI 10.1007/s12195 017 0495 6
PG 18
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biophysics; Engineering
GA FG9AP
UT WOS:000410730900011
PM 30319717
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, YY
   Yao, YD
   Chen, F
   Guo, X
   Kang, JL
   Huang, YF
   He, F
   Dong, Y
   Xie, Y
   Wu, P
   Zhou, H
AF Zhang, Yan Yu
   Yao, Yun Da
   Chen, Fang
   Guo, Xin
   Kang, Jun Li
   Huang, Yu Feng
   He, Fan
   Dong, Yan
   Xie, Ying
   Wu, Peng
   Zhou, Hua
TI (9S,13R) 12 oxo phytodienoic acid attenuates inflammation
   by inhibiting mPGES 1 and modulating macrophage polarization via NF κB
   and Nrf2/HO 1 pathways
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE (9S,13R) 12 oxo phytodienoic acid; MPGES 1; NF kappa B; Nrf2;
   Inflammation, Macrophage polarization
ID PROSTAGLANDIN E 2 SYNTHASE 1; UP REGULATION; EXPRESSION; MAPK;
   CYCLOOXYGENASE 2; OSTEOARTHRITIS; SUPPRESSION; CARRAGEENAN; PREVENTION;
   CARTILAGE
AB Non steroidal anti inflammatory drugs (NSAIDs) relieve inflammation by suppressing prostaglandin E 2/cyclooxygenase 2 (PGE(2)/COX 2) with cardiovascular and gastrointestinal bleeding risk. Theoretically, suppressing PGE(2) through inhibiting the terminal synthase microsomal prostaglandin E 2 synthase 1 (mPGES 1) instead of upstream COX 2 is ideal for inflammation. Here, (9S,13R) 12 oxo phytodienoic acid (AA 24) extracted from Artemisia anomala was first screened as an anti inflammatory candidate and decreased inducible nitric oxide synthase (iNOS), nitric oxide (NO), mPGES 1, and PGE(2) without affecting COX 1/2, thromboxane A(2) (TXA(2)) and prostaglandin I 2 (PGI(2)). Besides, AA 24 suppressed the differentiation of M0 macrophages to M1 phenotype but enhanced it to M2 phenotype, blocked the activation of NF kappa B pathway, and increased the activation of Nrf2 and heme oxygenase 1 (HO 1). Moreover, AA 24 selectively inhibited mPGES 1 and reduced inflamed paw edema in carrageenan induced mice. In conclusion, AA 24 attenuates inflammation by inhibiting mPGES 1 and modulating macrophage polarization via the NF kappa B and Nrf2/HO 1 pathways and could be a promising candidate for developing anti inflammatory drugs.
C1 [Huang, Yu Feng; He, Fan; Xie, Ying; Zhou, Hua] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, State Key Lab Dampness Syndrome Chinese Med,Guang, Affiliated Hosp 2,Guangdong Prov Hosp Tradit Chin, Guangzhou 510006, Guangdong, Peoples R China.
   [Zhang, Yan Yu; Yao, Yun Da; Guo, Xin; Kang, Jun Li; Huang, Yu Feng; He, Fan; Xie, Ying; Zhou, Hua] Macau Univ Sci & Technol, Fac Chinese Med, Taipa, Macao, Peoples R China.
   [Zhang, Yan Yu; Yao, Yun Da; Guo, Xin; Kang, Jun Li; Huang, Yu Feng; He, Fan; Xie, Ying; Zhou, Hua] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macao, Peoples R China.
   [Chen, Fang; Wu, Peng] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Joint Lab Translat Canc Res Chinese Med, Minist Educ, Guangzhou 510006, Guangdong, Peoples R China.
   [Dong, Yan] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Macau University of Science &
   Technology; Macau University of Science & Technology; Guangzhou
   University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Xie, Y; Zhou, H (通讯作者)，Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, State Key Lab Dampness Syndrome Chinese Med,Guang, Affiliated Hosp 2,Guangdong Prov Hosp Tradit Chin, Guangzhou 510006, Guangdong, Peoples R China.; Wu, P (通讯作者)，Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Joint Lab Translat Canc Res Chinese Med, Minist Educ, Guangzhou 510006, Guangdong, Peoples R China.; Dong, Y (通讯作者)，Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Guangdong, Peoples R China.
EM 1462523594@qq.com; leoxieying16@outlook.com; wupeng@gzucm.edu.cn;
   gutcmzhs@hotmail.com
RI Zhou, Hua/IQS 0555 2023
OI Xie, Ying/0000 0003 3223 1797
FU Joint Research Fund for Overseas Chinese, Hong Kong and Macao Young
   Scholars of National Science Foundation of China [81929003, 81628016];
   2020 Hunan Province Science and Technology Innovation Key Projects
   [2020SK1020]; National Key Research and Development Program of China
   [2017YFE0119900]; Science and Technology Development Fund, Macao SAR
   [0027/2017/AMJ, 0001/2020/AKP]
FX This research was funded by the Joint Research Fund for Overseas
   Chinese, Hong Kong and Macao Young Scholars of National Science
   Foundation of China (Project No.: 81929003, 81628016), the 2020 Hunan
   Province Science and Technology Innovation Key Projects (Project No.:
   2020SK1020), the National Key Research and Development Program of China
   (Project No.: 2017YFE0119900), and the Science and Technology
   Development Fund, Macao SAR (File no.: 0027/2017/AMJ, 0001/2020/AKP).
CR Ahmed SMU, 2017, BBA MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Amaro Luis Juan Manuel, 1997, Acta Cientifica Venezolana, V48, P91
   Atherton C, 2004, CLIN GASTROENTEROL H, V2, P113, DOI 10.1016/S1542 3565(03)00318 5
   Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801
   Båge T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 241
   Bahia MS, 2014, MED RES REV, V34, P825, DOI 10.1002/med.21306
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Bogdan D, 2018, J BIOL CHEM, V293, P5295, DOI 10.1074/jbc.RA118.001593
   Boniakowski AE, 2017, J IMMUNOL, V199, P17, DOI 10.4049/jimmunol.1700223
   Capodanno D, 2016, CIRCULATION, V134, P1579, DOI 10.1161/CIRCULATIONAHA.116.023164
   Chen LH, 2013, PROSTAG OTH LIPID M, V104, P58, DOI 10.1016/j.prostaglandins.2012.08.006
   Chen SB, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1193 6
   Chen TT, 2019, KIDNEY INT, V95, P760, DOI 10.1016/j.kint.2018.10.041
   Chopra S, 2019, SCIENCE, V365, P248, DOI 10.1126/science.aau6499
   Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218
   D'Agostino G, 2007, J PHARMACOL EXP THER, V322, P1137, DOI 10.1124/jpet.107.123265
   Das S, 2007, CHEM REV, V107, P3286, DOI 10.1021/cr068365a
   Davies NM, 2000, CLIN PHARMACOKINET, V38, P377, DOI 10.2165/00003088 200038050 00001
   Díaz Muñoz MD, 2010, CELL SIGNAL, V22, P1427, DOI 10.1016/j.cellsig.2010.05.011
   DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103
   Feng R, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0262 x
   Ferrer MD, 2019, CURR MED CHEM, V26, P3225, DOI 10.2174/0929867325666180514112124
   Floková K, 2014, PHYTOCHEMISTRY, V105, P147, DOI 10.1016/j.phytochem.2014.05.015
   Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910
   Gao ZS, 2021, ACTA BIOMATER, V126, P211, DOI 10.1016/j.actbio.2021.03.018
   Genin M, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1546 9
   Gomez I, 2013, PROSTAG LEUKOTR ESS, V89, P55, DOI 10.1016/j.plefa.2013.04.004
   Gonçalves ECD, 2020, J NAT PROD, V83, P1190, DOI 10.1021/acs.jnatprod.9b01134
   Gong J, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2710 6
   GRUBB BD, 1991, EXP BRAIN RES, V84, P383
   Guay J, 2004, J BIOL CHEM, V279, P24866, DOI 10.1074/jbc.M403106200
   Hara S, 2017, P JPN ACAD B PHYS, V93, P703, DOI 10.2183/pjab.93.044
   Huang GR, 2008, AFR J BIOTECHNOL, V7, P1335
   Huang JR, 2008, IMMUNOL INVEST, V37, P263, DOI 10.1080/08820130802083622
   Huang YL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20082023
   Idriss NK, 2008, J AM COLL CARDIOL, V52, P971, DOI 10.1016/j.jacc.2008.06.019
   Ikeda Matsuo Y, 2017, BIOL PHARM BULL, V40, P557, DOI 10.1248/bpb.b16 01026
   Jia ZJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/147894
   Jiang M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1124 6
   Kawanishi N, 2010, EXERC IMMUNOL REV, V16, P105
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kotwal GJ, 2017, RESULTS PROBL CELL D, V62, P353, DOI 10.1007/978 3 319 54090 0_14
   KRUGER G, 1985, TETRAHEDRON LETT, V26, P6027, DOI 10.1016/S0040 4039(00)95116 5
   KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151
   Lahey KA, 2004, MOL PLANT MICROBE IN, V17, P1394, DOI 10.1094/MPMI.2004.17.12.1394
   Lee AS, 2013, GENE, V527, P440, DOI 10.1016/j.gene.2013.05.069
   Lee HW, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882 020 01921 7
   Lio CK, 2020, BIOCHEM PHARMACOL, V173, DOI 10.1016/j.bcp.2019.113639
   Liu JX, 2016, PHARMACOL RES, V111, P303, DOI 10.1016/j.phrs.2016.06.022
   Luo D, 2017, AGING US, V9, P2068, DOI 10.18632/aging.101302
   Lv HM, 2016, FOOD FUNCT, V7, P355, DOI 10.1039/c5fo00807g
   Lv HM, 2016, INT J BIOL SCI, V12, P72, DOI 10.7150/ijbs.13188
   Lv ZY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03792 8
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   Masuko Hongo K, 2004, ARTHRITIS RHEUM US, V50, P2829, DOI 10.1002/art.20437
   Murad F., 2008, P 14 BIENNIAL M SOC
   Naito Y, 2014, ARCH BIOCHEM BIOPHYS, V564, P83, DOI 10.1016/j.abb.2014.09.005
   Nakano M, 2007, EUR J PHARMACOL, V559, P210, DOI 10.1016/j.ejphar.2006.11.080
   Newson J, 2017, CELL REP, V20, P3162, DOI 10.1016/j.celrep.2017.08.098
   Nguyen TD, 2009, PLANTA MED, V75, P803, DOI 10.1055/s 0029 1185386
   Pan Yi feng, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2597
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Patrono C, 2005, NEW ENGL J MED, V353, P2373, DOI 10.1056/NEJMra052717
   Plóciennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018 014 1762 5
   Robb CT, 2020, BRIT J PHARMACOL, V177, P4899, DOI 10.1111/bph.15206
   Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1
   Schaller F, 1997, EUR J BIOCHEM, V245, P294, DOI 10.1111/j.1432 1033.1997.t01 1 00294.x
   Siemoneit U, 2011, BRIT J PHARMACOL, V162, P147, DOI 10.1111/j.1476 5381.2010.01020.x
   Starr T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193601
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tan RZ, 2019, PHYTOMEDICINE, V52, P284, DOI 10.1016/j.phymed.2018.09.210
   Tan X, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/681352
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Wang C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.803037
   Wenrui W., 2020, PROG BIOMED ENG, V41
   Wu CL, 2020, OSTEOARTHR CARTILAGE, V28, P544, DOI 10.1016/j.joca.2019.12.007
   Xue J, 2010, BIOMED PHARMACOTHER, V64, P118, DOI 10.1016/j.biopha.2009.04.033
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914
   Yang JH, 2021, MOLECULES, V26, DOI 10.3390/molecules26175427
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Yao CC, 2019, BRIT J PHARMACOL, V176, P337, DOI 10.1111/bph.14530
   Yu J, 2017, APOPTOSIS, V22, P1431, DOI 10.1007/s10495 017 1418 7
   Yuri I.M., 2010, J NEUROCHEM, V94, P13
   Zappavigna S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072605
   Zhang P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01455
   Zhang X, 2019, J HEPATOL, V71, P163, DOI 10.1016/j.jhep.2019.03.014
   Zhang XY, 2020, CARDIOL RES PRACT, V2020, DOI 10.1155/2020/5695723
   Zhang YY, 2022, BMC PHARMACOL TOXICO, V23, DOI 10.1186/s40360 021 00541 7
   Zhou H, 2017, BIOCHEM PHARMACOL, V142, P133, DOI 10.1016/j.bcp.2017.07.010
NR 89
TC 19
Z9 20
U1 3
U2 29
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD AUG
PY 2022
VL 182
AR 106310
DI 10.1016/j.phrs.2022.106310
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3J5HF
UT WOS:000833425200003
PM 35714824
DA 2025 08 17
ER

PT J
AU Zhang, YR
   Lapidos, KA
   Gal Moscovici, A
   Sprague, SM
   Ameer, GA
AF Zhang, Yangrong
   Lapidos, Karen A.
   Gal Moscovici, Anca
   Sprague, Stuart M.
   Ameer, Guillermo A.
TI A Receptor Based Bioadsorbent to Target Advanced Glycation End Products
   in Chronic Kidney Disease
SO ARTIFICIAL ORGANS
LA English
DT Article
DE Advanced glycation end products; Receptor for advanced glycation end
   products; Inflammation; End stage renal disease; Extracorporeal; Hollow
   fiber device
ID POSSIBLE INVOLVEMENT; WHOLE BLOOD; PROTEINS; LIGANDS; ENDPRODUCTS;
   EXPRESSION; DEVICE; RAGE; MORTALITY; PATHWAYS
AB The accumulation of advanced glycation end products (AGEs) has been reported to be a major contributor to chronic systemic inflammation. AGEs are not efficiently removed by hemodialysis or the kidney of a chronic kidney disease (CKD) patient. The goal of this study was to develop a receptor for AGEs (RAGE) based bioadsorbent device that was capable of removing endogenous AGEs from human blood. The extracellular domain of RAGE was immobilized onto agarose beads to generate the bioadsorbent. The efficacy of AGE removal from saline, serum, and whole blood; biological effects of AGE reduction; and hemocompatibility and stability of the bioadsorbent were investigated. The bioadsorbent bound AGE modified bovine serum albumin (AGE BSA) with a binding capacity of 0.73 +/  0.07mg AGE BSA/mL bioadsorbent. The bioadsorbent significantly reduced the concentration of total AGEs in serum isolated from end stage kidney disease patients by 57%. AGE removal resulted in a significant reduction of vascular cell adhesion molecule 1 expression in human endothelial cells and abolishment of osteoclast formation in osteoclast progenitor cells. A hollow fiber device loaded with bioadsorbent reduced endogenous AGEs from recirculated blood to 36% of baseline levels with no significant changes in total protein or albumin concentration. The bioadsorbent maintained AGE specific binding capacity after freeze drying and storage for 1 year. This approach provides the foundation for further development of soluble RAGE based extracorporeal therapies to selectively deplete serum AGEs from human blood and decrease inflammation in patients with diabetes and/or CKD.
C1 [Zhang, Yangrong; Lapidos, Karen A.; Ameer, Guillermo A.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Gal Moscovici, Anca; Sprague, Stuart M.] Northwestern Univ, NorthShore Univ HealthSyst, Div Nephrol & Hypertens, Evanston, IL 60208 USA.
   [Ameer, Guillermo A.] Northwestern Univ, Chem Life Proc Inst, Evanston, IL 60208 USA.
   [Sprague, Stuart M.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Ameer, Guillermo A.] Univ Chicago, Feinberg Sch Med, Dept Surg, Chicago, IL 60637 USA.
   [Gal Moscovici, Anca] Hadassah Univ Hosp Ein Karem, Dept Nephrol, Jerusalem, Israel.
   [Gal Moscovici, Anca] Hadassah Univ Hosp Ein Karem, Hypertens Serv, Jerusalem, Israel.
C3 Northwestern University; NorthShore University Health System;
   Northwestern University; Northwestern University; University of Chicago;
   University of Chicago; Northwestern University; Feinberg School of
   Medicine
RP Ameer, GA (通讯作者)，Northwestern Univ, Dept Biomed Engn, 2145 Sheridan Rd E310, Evanston, IL 60208 USA.
EM g ameer@northwestern.edu
RI Ameer, Guillermo/B 6765 2009
FU National Institutes of Health (NIDDK)
FX We thank Rosemarie Wilton from Argonne National Laboratory for the
   generous gift of the pASK40 RAGE plasmid. This work was funded by the
   National Institutes of Health (NIDDK).
CR Ameer GA, 2001, KIDNEY INT, V59, P1544, DOI 10.1046/j.1523 1755.2001.0590041544.x
   Ameer GA, 1999, BIOTECHNOL BIOENG, V62, P602, DOI 10.1002/(SICI)1097 0290(19990305)62:5<602::AID BIT12>3.0.CO;2 M
   [Anonymous], ANN DAT REP ATL CHRO
   Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125 009 1458 9
   Busch M, 2010, EUR J CLIN INVEST, V40, P742, DOI 10.1111/j.1365 2362.2010.02317.x
   Daniels CM, 2005, BLOOD PURIFICAT, V23, P287, DOI 10.1159/000086207
   Ekong U, 2006, J GASTROEN HEPATOL, V21, P682, DOI 10.1111/j.1440 1746.2006.04225.x
   Engelen L, 2013, DIABETES OBES METAB, V15, P677, DOI 10.1111/dom.12058
   Fowers KD, 2001, BIOMATERIALS, V22, P1749, DOI 10.1016/S0142 9612(00)00335 5
   Grovender EA, 2002, AICHE J, V48, P2357, DOI 10.1002/aic.690481025
   HOLMES CJ, 1995, ARTIF ORGANS, V19, P1126, DOI 10.1111/j.1525 1594.1995.tb02274.x
   Ikeda K, 1996, BIOCHEMISTRY US, V35, P8075, DOI 10.1021/bi9530550
   Kilhovd BK, 2007, DIABETOLOGIA, V50, P1409, DOI 10.1007/s00125 007 0687 z
   Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740
   Meerwaldt R, 2009, AM J KIDNEY DIS, V53, P138, DOI 10.1053/j.ajkd.2008.08.031
   Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133
   Mitsuhashi T, 1997, J CLIN INVEST, V100, P847, DOI 10.1172/JCI119600
   Miyata T, 1996, NEPHROL DIAL TRANSPL, V11, P54
   Nin JW, 2011, DIABETES CARE, V34, P442, DOI 10.2337/dc10 1087
   Penfold SA, 2010, KIDNEY INT, V78, P287, DOI 10.1038/ki.2010.134
   Reichelt P, 2006, PROTEIN EXPRES PURIF, V46, P483, DOI 10.1016/j.pep.2005.09.027
   SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987
   Semba RD, 2010, J RENAL NUTR, V20, P74, DOI 10.1053/j.jrn.2009.08.001
   Takeuchi M, 2004, MED HYPOTHESES, V63, P449, DOI 10.1016/j.mehy.2004.02.042
   Takeuchi M, 2008, CURR PHARM DESIGN, V14, P973, DOI 10.2174/138161208784139693
   Valencia JV, 2004, ANAL BIOCHEM, V324, P68, DOI 10.1016/j.ab.2003.09.013
   Wendt T, 2006, ATHEROSCLEROSIS, V185, P70, DOI 10.1016/j.atherosclerosis.2005.06.013
   Williams ME, 2003, AM J KIDNEY DIS, V41, pS42, DOI 10.1053/ajkd.2003.50083
   Wilton R, 2006, PROTEIN EXPRES PURIF, V47, P25, DOI 10.1016/j.pep.2006.01.008
   Yan SF, 2009, J MOL MED, V87, P235, DOI 10.1007/s00109 009 0439 2
NR 30
TC 9
Z9 10
U1 0
U2 9
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0160 564X
EI 1525 1594
J9 ARTIF ORGANS
JI Artif. Organs
PD JUN
PY 2014
VL 38
IS 6
BP 474
EP 483
DI 10.1111/aor.12203
PG 10
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Transplantation
GA AJ2SU
UT WOS:000337513600008
PM 24206165
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zeng, XX
   Wang, ST
   Gui, P
   Wu, H
   Li, ZX
AF Zeng, Xinxin
   Wang, Shengtao
   Gui, Peng
   Wu, Hao
   Li, Zhaoxu
TI Expression and significance of Annexin A3 in the osteosarcoma cell lines
   HOS and U2OS
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteosarcoma; Annexin A3; apoptosis; molecular targeted therapy
ID IN VITRO; CANCER; RESISTANCE; TUMORIGENESIS; ACTIVATION; BIOMARKER;
   BIOLOGY; TARGET; GROWTH; JNK
AB Annexin A3 (ANXA3) is highly expressed in different types of cancers, but the impact of ANXA3 in bone tumors is still not clear. In the present study, the expression of ANXA3 in osteosarcoma cells was first confirmed by cellular immunofluorescence. Reverse transcription quantitative polymerase chain reaction (RT qPCR) and western blot analysis were used to detect the expression of ANXA3 in osteoblasts in the osteosarcoma cell lines U2OS and HOS. Furthermore, small interfering (si) RNA were transfected into U2OS and HOS cells via a liposome mediated method. Then once ANXA3 had been successfully downregulated in U2OS and HOS cells, the cells were collected and total protein was extracted after 48 h of transfection. Western blot analysis was used to confirm successful ANXA3 transfection into osteosarcoma cells and the apoptotic rate of HOS and U2OS was detected by flow cytometry. The expression of ANXA3 in the osteosarcoma cell lines HOS and U2OS were first observed by confocal laser scanning microscopy, and was then detected by RT qPCR and western blotting. The mRNA and protein levels of ANXA3 in the osteosarcoma cell lines HOS and U2OS were significantly increased compared with osteoblasts, particularly in HOS cells. When siRNA was transfected into HOS and U2OS cells, the protein expression level of ANXA3 was measured via western blotting. The results indicated that the expression of ANXA3 was significantly decreased. In addition, to determine whether ANXA3 knockdown induced cell apoptosis, the present study analyzed the apoptotic rate by flow cytometry. The results revealed that ANXA3 knockdown markedly increased HOS and U2OS cell apoptosis. To the best of our knowledge, the present study is the first to confirm that ANXA3 is highly expressed in the osteosarcoma cell lines HOS and U2OS. In addition, downregulation of ANXA3 expression in HOS and U2OS cells could increase apoptotic ability.
C1 [Zeng, Xinxin; Gui, Peng; Wu, Hao] Guilin Med Univ, Affiliated Hosp, Dept Orthopaed, Guilin 541001, Guangxi, Peoples R China.
   [Wang, Shengtao] Guilin Med Univ, Affiliated Hosp, Dept Emergency & Trauma Surg, Guilin 541001, Guangxi, Peoples R China.
   [Li, Zhaoxu] Nanxishan Hosp Guangxi Zhuang Autonomous Reg, Dept Orthopaed, 46 Chongxin Rd, Guilin 541002, Guangxi, Peoples R China.
C3 Guilin Medical University; Guilin Medical University
RP Li, ZX (通讯作者)，Nanxishan Hosp Guangxi Zhuang Autonomous Reg, Dept Orthopaed, 46 Chongxin Rd, Guilin 541002, Guangxi, Peoples R China.
EM 2240411900@qq.com
RI ; li, zhaoxu/MEO 7338 2025
OI , li chao xu/0000 0002 4239 8075; 
FU National Natural Science Foundation of China [81360400]
FX The present study was supported by National Natural Science Foundation
   of China (grant no. 81360400).
CR Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Hagiwara S, 2012, BRIT J CANCER, V106, P1997, DOI 10.1038/bjc.2012.145
   Hamelin Peyron C, 2014, CLIN BIOCHEM, V47, P901, DOI 10.1016/j.clinbiochem.2014.05.063
   Jeun M, 2017, ADV HEALTHC MATER, P6
   Jin YL, 2013, BIOMED PHARMACOTHER, V67, P337, DOI 10.1016/j.biopha.2013.02.006
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kim JB, 2018, ONCOL LETT, V15, P8723, DOI 10.3892/ol.2018.8441
   Li J, 2018, PATHOL RES PRACT, V214, P1719, DOI 10.1016/j.prp.2018.09.009
   Li ZX, 2016, ONCOTARGET, V7, P84388, DOI 10.18632/oncotarget.12756
   [李朝旭 Li Zhaoxu], 2016, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V33, P154
   [李朝旭 Li Zhaoxu], 2014, [中国免疫学杂志, Chinese Journal of Immunology], V30, P1533
   Li ZX, 2013, MOL BIOL REP, V40, P427, DOI 10.1007/s11033 012 2077 y
   Li ZX, 2012, J ORTHOP RES, V30, P824, DOI 10.1002/jor.21579
   Li ZX, 2011, INT IMMUNOPHARMACOL, V11, P496, DOI 10.1016/j.intimp.2011.01.001
   Li ZC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1012 z
   李朝旭, 2016, [中国免疫学杂志, Chinese Journal of Immunology], V32, P1777
   Liu YF, 2009, J PATHOL, V217, P54, DOI 10.1002/path.2429
   Liu YF, 2016, ANAL CELL PATHOL, V2016, DOI 10.1155/2016/4131403
   Liu YF, 2012, MED ONCOL, V29, P174, DOI 10.1007/s12032 010 9761 3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MICHAELIS J, 1988, LANCET, V1, P1174
   Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 4 219
   Mussunoor S, 2008, J PATHOL, V216, P131, DOI 10.1002/path.2400
   Pan QZ, 2015, MOL CARCINOGEN, V54, P598, DOI 10.1002/mc.22126
   Pan QZ, 2015, STEM CELLS, V33, P354, DOI 10.1002/stem.1850
   Pénzváltó Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059503
   Perron B, 1997, J BIOL CHEM, V272, P11321
   Shao P, 2017, AM J TRANSL RES, V9, P4300
   Tong M, 2015, STEM CELL REP, V5, P45, DOI 10.1016/j.stemcr.2015.05.013
   Tong SW, 2012, J CELL BIOCHEM, V113, P1671, DOI 10.1002/jcb.24036
   Wu N, 2013, CLIN TRANSL ONCOL, V15, P106, DOI 10.1007/s12094 012 0928 6
   Yan XD, 2010, CANCER RES, V70, P1616, DOI 10.1158/0008 5472.CAN 09 3215
   Yang YM, 2019, SEMIN LIVER DIS, V39, P26, DOI 10.1055/s 0038 1676806
   Zeidan B, 2015, ONCOTARGET, V6, P21421, DOI 10.18632/oncotarget.4070
   Zeng C, 2013, EXP MOL PATHOL, V95, P23, DOI 10.1016/j.yexmp.2013.04.002
   Zhou T, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2603685
   Zhou T, 2017, ONCOL REP, V37, P388, DOI 10.3892/or.2016.5251
NR 39
TC 8
Z9 8
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2019
VL 20
IS 3
BP 2583
EP 2590
DI 10.3892/mmr.2019.10513
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA IS8YL
UT WOS:000482435500060
PM 31524248
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Neto, R
   Frazao, J
AF Neto, Ricardo
   Frazao, Joao
TI Efficacy and safety of calcium carbonate in normophosphataemic patients
   with chronic kidney disease Stages 3 and 4
SO CLINICAL KIDNEY JOURNAL
LA English
DT Article
DE calcium carbonate; phosphate binders; pre dialysis patients; urinary
   fractional excretion of phosphate; vascular calcification
ID VASCULAR CALCIFICATION SCORE; GROWTH FACTOR 23; PHOSPHATE BINDERS;
   PHOSPHORUS; PROGRESSION; MORTALITY; BALANCE; PEOPLE; TARGET; RISK
AB Background. Disordered bone and mineral metabolism are a common complication of chronic kidney disease (CKD). Phosphate binders are often prescribed in advanced CKD, when hyperphosphataemia develops. Little is known about the role of these drugs in earlier stages, when serum phosphorus levels are kept in the normal range by increased urinary excretion.
   Methods. A retrospective, controlled observational study was conducted on a cohort of 78 pre dialysis patients. Subjects had CKD Stage 3 or 4, normal serum phosphorus levels and increased urinary fractional excretion of phosphate. Thirty eight patients receiving calcium carbonate for 24 months were compared with 40 patients under no phosphate binders, regarding mineral metabolism parameters and vascular calcification scores.
   Results. Calcium carbonate decreased mean urinary fractional excretion of phosphate and median 24 h urine phosphorus, whereas no significant change was seen in the control group. Mean serum phosphorus and median serum intact parathyroid hormone (iPTH) remained stable in treated patients but increased in the control group. Vascular calcification, assessed by Kauppila and AdragAo scores, worsened under calcium carbonate with no significant change in the control group.
   Conclusions. Calcium carbonate reduced urinary phosphate excretion and prevented the rise in phosphorus and iPTH serum levels in a cohort of normophosphataemic pre dialysis patients. However, treatment was associated with increased vascular calcification, suggesting that calcium based phosphate binders are not a safe option for CKD patients.
C1 [Neto, Ricardo; Frazao, Joao] Univ Porto, INEB I3S, Nephrol & Infect Dis Res & Dev Grp, Porto, Portugal.
   [Neto, Ricardo; Frazao, Joao] Univ Porto, Porto Med Sch, Dept Med, Porto, Portugal.
   [Neto, Ricardo; Frazao, Joao] Ctr Hosp Univ Sao Joao, Dept Nephrol, Porto, Portugal.
C3 Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto
RP Neto, R (通讯作者)，Univ Porto, INEB I3S, Nephrol & Infect Dis Res & Dev Grp, Porto, Portugal.; Neto, R (通讯作者)，Univ Porto, Porto Med Sch, Dept Med, Porto, Portugal.; Neto, R (通讯作者)，Ctr Hosp Univ Sao Joao, Dept Nephrol, Porto, Portugal.
EM ricardoneto76@gmail.com
RI Frazao, Joao/J 9811 2013; Frazão, João/J 9811 2013
OI Frazao, Joao/0000 0002 8081 5474; 
CR Adragao T, 2004, NEPHROL DIAL TRANSPL, V19, P1480, DOI 10.1093/ndt/gfh217
   Adragao T, 2009, NEPHROL DIAL TRANSPL, V24, P997, DOI 10.1093/ndt/gfn584
   Becker GJ, 2009, NEPHROL DIAL TRANSPL, V24, P2321, DOI 10.1093/ndt/gfp220
   Bellasi A, 2006, KIDNEY INT, V70, P1623, DOI 10.1038/sj.ki.5001820
   Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   Drüeke TB, 2012, J AM SOC NEPHROL, V23, P1277, DOI 10.1681/ASN.2012060569
   García Canton C, 2011, NEPHROL DIAL TRANSPL, V26, P2250, DOI 10.1093/ndt/gfq650
   Hill KM, 2013, KIDNEY INT, V83, P959, DOI 10.1038/ki.2012.403
   Isakova T, 2015, J AM SOC NEPHROL, V26, P2328, DOI 10.1681/ASN.2015020117
   Kauppila LI, 1997, ATHEROSCLEROSIS, V132, P245, DOI 10.1016/S0021 9150(97)00106 8
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, Kidney Int, V3, P1, DOI [DOI 10.1016/J.KINT.2023.10.018, DOI 10.1038/KISUP.2012.73]
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003 4819 150 9 200905050 00006
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Oliveira RB, 2010, CLIN J AM SOC NEPHRO, V5, P286, DOI 10.2215/CJN.05420709
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   Scialla JJ, 2014, NAT REV NEPHROL, V10, P268, DOI 10.1038/nrneph.2014.49
   Spiegel DM, 2012, KIDNEY INT, V81, P1116, DOI 10.1038/ki.2011.490
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
   Toussaint ND, 2012, NEPHROLOGY, V17, P433, DOI 10.1111/j.1440 1797.2012.01618.x
   Vervloet MC, 2017, NAT REV NEPHROL, V13, P27, DOI 10.1038/nrneph.2016.164
   Vervloet MG, 2018, KIDNEY INT, V93, P1060, DOI 10.1016/j.kint.2017.11.036
NR 24
TC 6
Z9 6
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048 8505
EI 2048 8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD FEB
PY 2021
VL 14
IS 2
BP 550
EP 555
DI 10.1093/ckj/sfz181
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA RQ3CB
UT WOS:000642298900012
PM 33623678
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gupta, KK
   Pal, N
   Mishra, PK
   Srivastava, P
   Mohanty, S
   Maiti, P
AF Gupta, Kamal K.
   Pal, Namrata
   Mishra, Pradeep K.
   Srivastava, Pradeep
   Mohanty, Sujata
   Maiti, Pralay
TI 5 Florouracil loaded poly(lactic acid) poly(caprolactone) hybrid
   scaffold: Potential chemotherapeutic implant
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE poly(lactic acid); polycaprolactone; 5 florouracil; hybrid; nanofibers;
   osteoblast cell
ID DRUG RELEASE; BLENDS; 5 FLUOROURACIL; HYDROCHLORIDE; NANOPARTICLES;
   FIBERS; DEGRADATION; COPOLYMERS; DELIVERY; CHITOSAN
AB Hybrid nanofibers of poly(lactic acid) and polycaprolactone have been developed by embedding cancerous drug through electrospinning technique. The composition of polymer has been varied to check the compositional effect on properties. The quality of nanofibers has been testified through surface morphology, wetting properties using contact angle and mechanical strength under uniaxial elongation. The compatibility of drug (5 fluorourasil) with matrix fiber has been verified using Fourier transform infrared, X ray diffraction, Raman spectroscopy, and differential scanning calorimetry. The drug release study has been performed showing greater release in hybrid fibers when compared with pure polymers as a result of synergism of two immiscible polymers and quasi Fickian diffusion mechanism in hybrid nanofiber as implants showing compositional effect on drug release. A model has been proposed showing faster release of drugs in hybrid systems. Biological responses through fluorescence imaging and MTT assay confirm the release of drug from hybrid nanofibers showing potential use of hybrid scaffolds as chemotherapeutic implant. (C) 2013 Wiley Periodicals, Inc.
C1 [Gupta, Kamal K.; Pal, Namrata; Mishra, Pradeep K.] Banaras Hindu Univ, Dept Chem Engn, Indian Inst Technol, Varanasi 221005, Uttar Pradesh, India.
   [Srivastava, Pradeep] Banaras Hindu Univ, Sch Biochem Engn, Indian Inst Technol, Varanasi 221005, Uttar Pradesh, India.
   [Mohanty, Sujata] All India Inst Med Sci, Stem Cell Facil, New Delhi 110029, India.
   [Maiti, Pralay] Banaras Hindu Univ, Sch Mat Sci & Technol, Indian Inst Technol, Varanasi 221005, Uttar Pradesh, India.
C3 Banaras Hindu University (BHU); Indian Institute of Technology System
   (IIT System); Indian Institute of Technology BHU Varanasi (IIT BHU
   Varanasi); Banaras Hindu University (BHU); Indian Institute of
   Technology System (IIT System); Indian Institute of Technology BHU
   Varanasi (IIT BHU Varanasi); All India Institute of Medical Sciences
   (AIIMS) New Delhi; Indian Institute of Technology System (IIT System);
   Indian Institute of Technology BHU Varanasi (IIT BHU Varanasi); Banaras
   Hindu University (BHU)
RP Maiti, P (通讯作者)，Banaras Hindu Univ, Sch Mat Sci & Technol, Indian Inst Technol, Varanasi 221005, Uttar Pradesh, India.
EM pmaiti.mst@itbhu.ac.in
RI Mishra, Pradeep/AAT 6747 2021; Srivastava, Pratap/AAC 4095 2019
FU University Grant Commission (UGC)
FX Contract grant sponsor: University Grant Commission (UGC)
CR Abdelkader H, 2007, AAPS PHARMSCITECH, V8, pE1
   Alexis F, 2005, POLYM INT, V54, P36, DOI 10.1002/pi.1697
   Amna T, 2012, INT J NANOMED, V7, P1659, DOI 10.2147/IJN.S24467
   Bertram U, 2012, DRUG DEV IND PHARM, V38, P659, DOI 10.3109/03639045.2011.598536
   Cai Q, 2002, POLYM ADVAN TECHNOL, V13, P534, DOI 10.1002/pat.222
   Can E, 2011, AAPS PHARMSCITECH, V12, P1442, DOI 10.1208/s12249 011 9714 y
   Chen CC, 2003, BIOMATERIALS, V24, P1167, DOI 10.1016/S0142 9612(02)00466 0
   Chu CY, 2010, MACROMOLECULES, V43, P3376, DOI 10.1021/ma9025509
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928 0987(01)00095 1
   Davies JH, 2002, BONE, V31, P319, DOI 10.1016/S8756 3282(02)00822 0
   Emami J, 2008, DARU, V16, P60
   Farquharson S, 2005, J RAMAN SPECTROSC, V36, P208, DOI 10.1002/jrs.1277
   Fukushima M, 2012, US Pat, Patent No. [0232103 A1, 0232103]
   Fundador N.G. V., 2010, Macromol. Mater. Eng, V295, P865, DOI [10.1002/mame.201000197, DOI 10.1002/MAME.201000197]
   Gang J, 2007, J DRUG TARGET, V15, P445, DOI 10.1080/10611860701453901
   Gupta KK, 2012, PHYS CHEM CHEM PHYS, V14, P12844, DOI 10.1039/c2cp41789h
   Hirvikorpi T, 2011, APPL SURF SCI, V257, P9451, DOI 10.1016/j.apsusc.2011.06.031
   Hou JW, 2011, DRUG DEV IND PHARM, V37, P1068, DOI 10.3109/03639045.2011.559658
   Inai R, 2005, NANOTECHNOLOGY, V16, P208, DOI 10.1088/0957 4484/16/2/005
   Jain S, 2010, MACROMOL MATER ENG, V295, P750, DOI 10.1002/mame.201000063
   KIM TH, 1989, CANCER AM CANCER SOC, V63, P1922, DOI 10.1002/1097 0142(19890515)63:10<1922::AID CNCR2820631009>3.0.CO;2 R
   KISTER G, 1995, J RAMAN SPECTROSC, V26, P307, DOI 10.1002/jrs.1250260409
   Kister G, 2000, POLYMER, V41, P925, DOI 10.1016/S0032 3861(99)00223 2
   Lebourg M, 2008, EUR POLYM J, V44, P2207, DOI 10.1016/j.eurpolymj.2008.04.033
   Lei L, 2010, J CONTROL RELEASE, V146, P45, DOI 10.1016/j.jconrel.2010.05.017
   Liu LJ, 2000, BIOMACROMOLECULES, V1, P350, DOI 10.1021/bm000046k
   Liu TY, 2006, J CONTROL RELEASE, V112, P88, DOI 10.1016/j.jconrel.2006.01.017
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu LL, 2012, IND ENG CHEM RES, V51, P3682, DOI 10.1021/ie2028969
   Nagarwal RC, 2011, COLLOID SURFACE B, V86, P28, DOI 10.1016/j.colsurfb.2011.03.023
   Park CG, 2011, MACROMOL RES, V19, P1210, DOI 10.1007/s13233 011 1112 5
   Rastogi VK, 2000, J RAMAN SPECTROSC, V31, P595
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   Sanna V, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556 276X 6 260
   Song M, 2008, APPL SURF SCI, V255, P610, DOI 10.1016/j.apsusc.2008.06.131
   Varaprasad K, 2012, J POLYM ENVIRON, V20, P573, DOI 10.1007/s10924 012 0412 y
   Xian CJ, 2004, BONE, V35, P739, DOI 10.1016/j.bone.2004.04.027
   Xu XL, 2008, EUR J PHARM BIOPHARM, V70, P165, DOI 10.1016/j.ejpb.2008.03.010
   Xu XL, 2006, J CONTROL RELEASE, V114, P307, DOI 10.1016/j.jconrel.2006.05.031
   Yang XD, 2008, COLLOID SURFACE B, V61, P125, DOI 10.1016/j.colsurfb.2007.07.012
   Zahedi P, 2012, J APPL POLYM SCI, V124, P4174, DOI 10.1002/app.35372
   Zeng J, 2005, J CONTROL RELEASE, V105, P43, DOI 10.1016/j.jconrel.2005.02.024
   Zhou HJ, 2006, POLYMER, V47, P7497, DOI 10.1016/j.polymer.2006.08.042
NR 43
TC 43
Z9 44
U1 0
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD AUG
PY 2014
VL 102
IS 8
BP 2600
EP 2612
DI 10.1002/jbm.a.34932
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AM6HH
UT WOS:000339964300013
PM 24038786
DA 2025 08 17
ER

PT J
AU Li, SQ
   Wang, J
AF Li, Shuangqing
   Wang, Juan
TI Salvianolic acid B prevents steroid induced osteonecrosis of the femoral
   head via PPARγ expression in rats
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Proceedings Paper
CT 2nd Workshop on Paediatric Virology
CY OCT 08, 2016
CL Athens, GREECE
DE salvianolic acid B; steroid induced osteonecrosis; femoral head;
   peroxisome proliferator activated receptor gamma
ID MESENCHYMAL STEM CELLS; FIBRIL FORMATION; BREAST CANCER; IN VITRO;
   PATHOGENESIS; MICRORNAS
AB Salvianolic acid B (Sal B) is a water soluble phenolic compound derived from Salvia Miltiorrhiza. Recent studies show Sal B has a clear function of anti cerebral ischemia injury, which is closely related to antioxidation, free radical scavenging, neuroprotection and the blood brain barrier. The aim of the present study was to verify whether Sal B prevents steroid induced osteonecrosis of the femoral head and to investigate its underlying pharmacological mechanisms. Steroid induced osteonecrosis rat models were established to evaluate the effects of Sal B on osteonecrotic changes and repair processes. The use of Sal B improved steroid induced histopathological scores and inhibited osteoclast differentiation in rats. Notably, Sal B induced bone marrow derived mesenchymal stem cells into osteogenesis. Moreover, Sal B treatment suppressed peroxisome proliferator activated receptor (PPAR)gamma and AP2 protein expression levels and increased runt related transcription factor 2 and Collagen I protein expression levels in steroid induced rats. osteocalcin and alkaline phosphatase content in steroid induced rats was enhanced by treatment with Sal B. These results suggest that Sal B prevents steroid induced osteonecrosis of the femoral head via PPAR gamma expression in rats. The present pilot study provides a brief insight into the effect of Sal B on steroid induced osteonecrosis.
C1 [Li, Shuangqing] Cangzhou Cent Hosp Hebei, Dept Orthoped, 201 Xinhua Rd, Cangzhou 061001, Hebei, Peoples R China.
   [Wang, Juan] Cangzhou Med Coll Hebei, Dept Educ Adm, Cangzhou 061001, Hebei, Peoples R China.
RP Li, SQ (通讯作者)，Cangzhou Cent Hosp Hebei, Dept Orthoped, 201 Xinhua Rd, Cangzhou 061001, Hebei, Peoples R China.
EM lianzikan5137@126.com
CR Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
   Bender TS, 2015, NEUROSCIENCE, V303, P569, DOI 10.1016/j.neuroscience.2015.07.016
   Cao W, 2012, CHIN J INTEGR MED, V18, P316, DOI [10.1007/s11655 011 012 1052 8, 10.1007/s11655 012 1052 8]
   Cui L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034647
   de Carvalho SN, 2013, CELLS TISSUES ORGANS, V198, P139, DOI 10.1159/000353215
   Dumont N, 2014, EXP HEMATOL, V42, P741, DOI 10.1016/j.exphem.2014.04.009
   Durairajan SSK, 2008, NEUROCHEM INT, V52, P741, DOI 10.1016/j.neuint.2007.09.006
   Emamghoreishi M, 2015, IRAN J BASIC MED SCI, V18, P240
   Fan SH, 2015, J CELL BIOCHEM, V116, P502, DOI 10.1002/jcb.24978
   Herzog DPE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/320123
   Hoban DB, 2015, NEUROSCIENCE, V303, P402, DOI 10.1016/j.neuroscience.2015.07.014
   Liu Yan fei, 2007, Zhongguo Zhong Yao Za Zhi, V32, P1128
   Maxwell GL, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.08.028
   Pan CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126640
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Saracoglu I, 2012, PHYTOTHER RES, V26, P148, DOI 10.1002/ptr.3546
   Seven M, 2014, FUTURE ONCOL, V10, P1027, DOI 10.2217/fon.13.259
   Tang CL, 2013, INT J CLIN EXP PATHO, V6, P2441
   Tang MK, 2001, ACTA PHARMACOL SIN, V22, P380
   Tian JW, 2009, PHYTOMEDICINE, V16, P726, DOI 10.1016/j.phymed.2009.01.007
   Wang L, 2016, OSTEOPOROSIS INT, V27, P153, DOI 10.1007/s00198 015 3225 8
   Wang PJ, 2014, CELL PHYSIOL BIOCHEM, V34, P288, DOI 10.1159/000362999
   Xiao M, 2015, HISTOL HISTOPATHOL, V30, P1171
   Xie MY, 2014, MOL VIS, V20, P921
   Xu DH, 2014, INT J BIOCHEM CELL B, V51, P1, DOI 10.1016/j.biocel.2014.03.005
   Yang TL, 2011, J SCI FOOD AGR, V91, P134, DOI 10.1002/jsfa.4163
   Yarbro Connie Henke, 2003, Breast J, V9 Suppl 2, pS98, DOI 10.1046/j.1524 4741.9.s2.12.x
   Yi JJ, 2010, BBA PROTEINS PROTEOM, V1804, P1684, DOI 10.1016/j.bbapap.2010.05.002
NR 28
TC 10
Z9 12
U1 2
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD FEB
PY 2017
VL 13
IS 2
BP 651
EP 656
DI 10.3892/etm.2016.4008
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Research & Experimental Medicine
GA EL9GH
UT WOS:000394927900045
PM 28352346
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Alonso, N
   Albagha, OME
   Azfer, A
   Larraz Prieto, B
   Berg, K
   Riches, PL
   Ostanek, B
   Kocjan, T
   Marc, J
   Langdahl, BL
   Ralston, SH
AF Alonso, Nerea
   Albagha, Omar M. E.
   Azfer, Asim
   Larraz Prieto, Beatriz
   Berg, Kathryn
   Riches, Philip L.
   Ostanek, Barbara
   Kocjan, Tomaz
   Marc, Janja
   Langdahl, Bente L.
   Ralston, Stuart H.
TI Genome wide association study identifies genetic variants which predict
   the response of bone mineral density to teriparatide therapy
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
DE pharmacogenetics; osteoporosis; therapeutics
ID POSTMENOPAUSAL WOMEN; SEVERE OSTEOPOROSIS; DOUBLE BLIND; ALENDRONATE;
   FRACTURES; BISPHOSPHONATES; CXCL12/CXCR4; BMD
AB ObjectivesTeriparatide (TPTD) is an effective treatment for osteoporosis but the individual response to therapy is variable for reasons that are unclear. This study aimed to determine whether the response to TPTD might be influenced by genetic factors. MethodsWe searched for predictors of the response of bone mineral density (BMD) to TPTD using a two stage genome wide association study in 437 patients with osteoporosis from three referral centres. Demographic and clinical data including the response of BMD to treatment at the lumbar spine and hip were extracted from the medical records of each participant. ResultsAllelic variation at rs6430612 on chromosome 2, close to the CXCR4 gene was associated with the response of spine BMD to TPTD at a genome wide significant level (p=9.2x10( 9) beta= 0.35 ( 0.47 to  0.23)). The increase in BMD was almost twice as great in AA homozygotes at rs6430612 as compared with GG homozygotes with intermediate values in heterozygotes. The same variant was also associated with response of femoral neck and total hip BMD (p=0.007). An additional locus on chromosome 19 tagged by rs73056959 was associated with the response of femoral neck BMD to TPTD (p=3.5x10( 9), beta= 1.61 ( 2.14 to  1.07)). ConclusionsGenetic factors influence the response to TPTD at the lumbar spine and hip with a magnitude of effect that is clinically relevant. Further studies are required to identify the causal genetic variants and underlying mechanisms as well as to explore how genetic testing for these variants might be implemented in clinical practice.
C1 [Ralston, Stuart H.] Univ Edinburgh, Ctr Genom & Expt Med, Edinburgh EH4 2XU, Scotland.
   [Alonso, Nerea; Albagha, Omar M. E.; Azfer, Asim; Larraz Prieto, Beatriz; Berg, Kathryn; Riches, Philip L.; Ralston, Stuart H.] Univ Edinburgh, Inst Genet & Canc, Ctr Genom & Expt Med, Edinburgh, Scotland.
   [Alonso, Nerea] Med Univ Graz, Clin Inst Med, Chem Lab Diagnost, Graz, Austria.
   [Albagha, Omar M. E.] Hamad Bin Khalifa Univ, Coll Hlth & Life Sci, Doha, Qatar.
   [Riches, Philip L.; Ralston, Stuart H.] Western Gen Hosp, Rheumat Dis Unit, Edinburgh, Scotland.
   [Ostanek, Barbara; Marc, Janja] Univ Ljubljana, Fac Pharm, Dept Clin Biochem, Ljubljana, Slovenia.
   [Kocjan, Tomaz] Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Ljubljana, Slovenia.
   [Kocjan, Tomaz] Univ Ljubljana, Fac Med, Dept Internal Med, Ljubljana, Slovenia.
   [Langdahl, Bente L.] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
C3 University of Edinburgh; University of Edinburgh; Medical University of
   Graz; Qatar Foundation (QF); Hamad Bin Khalifa University Qatar;
   University of Edinburgh; University of Ljubljana; University Medical
   Centre Ljubljana; University of Ljubljana; Aarhus University
RP Ralston, SH (通讯作者)，Univ Edinburgh, Ctr Genom & Expt Med, Edinburgh EH4 2XU, Scotland.
EM stuart.ralston@ed.ac.uk
RI Berg, Kathryn/MEO 5284 2025; Albagha, Omar/LVR 3478 2024; Riches,
   Philip/C 7308 2013
OI Kocjan, Tomaz/0000 0001 8606 6825; Riches, Philip/0000 0003 3029 7098
CR Bergmann PJM, 2019, J BONE MINER RES, V34, P1976, DOI [10.1002/jbmr.3835, 10.1002/jbmr.3641]
   Burge R.T., 2001, Journal of Medical Economics, V4, P51
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen L, 2016, CELL, V167, P1398, DOI 10.1016/j.cell.2016.10.026
   Gregson CL, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01061 5
   Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139
   Hadji P, 2012, OSTEOPOROSIS INT, V23, P2141, DOI 10.1007/s00198 011 1856 y
   Heaney RP, 2011, OSTEOPOROSIS INT, V22, P1703, DOI 10.1007/s00198 010 1376 1
   Hirbe AC, 2007, P NATL ACAD SCI USA, V104, P14062, DOI 10.1073/pnas.0705203104
   Jakob F, 2012, EUR J ENDOCRINOL, V166, P87, DOI 10.1530/EJE 11 0740
   Joseph VR, 2022, STAT ANAL DATA MIN, V15, P531, DOI 10.1002/sam.11583
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P496, DOI 10.1038/nrrheum.2016.118
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Kraft P, 2009, STAT SCI, V24, P561, DOI 10.1214/09 STS290
   Langdahl Bente L, 2017, Lancet, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Little J, 2009, ANN INTERN MED, V150, P206, DOI 10.7326/0003 4819 150 3 200902030 00011
   Maranville JC, 2016, PHARMACOGENOMICS J, V16, P388, DOI 10.1038/tpj.2015.47
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niimi R, 2014, OSTEOPOROSIS INT, V25, P377, DOI 10.1007/s00198 013 2426 2
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Oswald AJ, 2019, CALCIFIED TISSUE INT, V105, P148, DOI 10.1007/s00223 019 00563 8
   Oswald AJ, 2014, CALCIFIED TISSUE INT, V94, P176, DOI 10.1007/s00223 013 9788 5
   Ralston KAP, 2022, CALCIFIED TISSUE INT, V110, P698, DOI 10.1007/s00223 022 00948 2
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Scottish Intercollegiate Guidelines Network, 2021, SCOTTISH LAND COMMIS, P1
   Shahnazari M, 2013, FASEB J, V27, P3505, DOI 10.1096/fj.12 225763
   Shirakawa J, 2016, CALCIFIED TISSUE INT, V98, P306, DOI 10.1007/s00223 015 0083 5
   Zhu W, 2011, J BIOL CHEM, V286, P26794, DOI 10.1074/jbc.M111.250985
NR 32
TC 7
Z9 7
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUL
PY 2023
VL 82
IS 7
BP 985
EP 991
DI 10.1136/ard 2022 223618
EA MAR 2023
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA L3JB1
UT WOS:000954021500001
PM 36941031
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Robert, AW
   Angulski, ABB
   Spangenberg, L
   Shigunov, P
   Pereira, IT
   Bettes, PSL
   Naya, H
   Correa, A
   Dallagiovanna, B
   Stimamiglio, MA
AF Robert, Anny Waloski
   Batti Angulski, Addeli Bez
   Spangenberg, Lucia
   Shigunov, Patricia
   Pereira, Isabela Tiemy
   Loiacono Bettes, Paulo Sergio
   Naya, Hugo
   Correa, Alejandro
   Dallagiovanna, Bruno
   Stimamiglio, Marco Augusto
TI Gene expression analysis of human adipose tissue derived stem cells
   during the initial steps of in vitro osteogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYSOME PROFILING SHOWS; OSTEOBLAST DIFFERENTIATION; PROLIFERATION;
   REGULATOR; FAK; THERAPY; ROLES; FOXO1; PKA
AB Mesenchymal stem cells (MSCs) have been widely studied with regard to their potential use in cell therapy protocols and regenerative medicine. However, a better comprehension about the factors and molecular mechanisms driving cell differentiation is now mandatory to improve our chance to manipulate MSC behavior and to benefit future applications. In this work, we aimed to study gene regulatory networks at an early step of osteogenic differentiation. Therefore, we analyzed both the total mRNA and the mRNA fraction associated with polysomes on human adipose tissue derived stem cells (hASCs) at 24 h of osteogenesis induction. The RNA seq results evidenced that hASC fate is not compromised with osteogenesis at this time and that 21 days of continuous cell culture stimuli are necessary for full osteogenic differentiation of hASCs. Furthermore, early stages of osteogenesis induction involved gene regulation that was linked to the management of cell behavior in culture, such as the control of cell adhesion and proliferation. In conclusion, although discrete initial gene regulation related to osteogenesis occur, the first 24 h of induction is not sufficient to trigger and drive in vitro osteogenic differentiation of hASCs.
C1 [Robert, Anny Waloski; Batti Angulski, Addeli Bez; Shigunov, Patricia; Pereira, Isabela Tiemy; Correa, Alejandro; Dallagiovanna, Bruno; Stimamiglio, Marco Augusto] Fiocruz Parana, Inst Carlos Chagas, Rua Prof Algacyr Munhoz Mader 3775, BR 81350010 Curitiba, PR, Brazil.
   [Spangenberg, Lucia; Naya, Hugo] Inst Pasteur Montevideo, Unidad Bioinformat, Mataojo 2020, Montevideo 11400, Uruguay.
   [Loiacono Bettes, Paulo Sergio] Cirurgia Plast Dr Paulo Bettes, Rua Francisco Rocha 1312, BR 80730390 Curitiba, PR, Brazil.
C3 Fundacao Oswaldo Cruz; Pasteur Network; Institut Pasteur de Montevideo
RP Stimamiglio, MA (通讯作者)，Fiocruz Parana, Inst Carlos Chagas, Rua Prof Algacyr Munhoz Mader 3775, BR 81350010 Curitiba, PR, Brazil.
EM mstimamiglio@fiocruz.br
RI ; Dallagiovanna, Bruno/AAA 3603 2019; Stimamiglio, Marco/AAA 8129 2019;
   Shigunov, Patrícia/AAQ 1948 2020; Kulig, Anny/AAE 2529 2020; Pereira,
   Isabela/AAW 5731 2021
OI Dallagiovanna, Bruno/0000 0001 6992 7048; Pereira,
   Isabela/0000 0001 8951 9965; Robert, Anny/0000 0002 7837 2790;
   Stimamiglio, Marco Augusto/0000 0001 8537 2812; Naya,
   Hugo/0000 0001 6982 4399; SHIGUNOV, PATRICIA/0000 0001 6443 1529; 
FU Fundacao Araucaria; CNPq
FX We would like to thank all the staff of the Carlos Chagas Institute
   (Fiocruz PR) for the laboratory and administrative support; the staff of
   the Bioinformatics Unit (Institut Pasteur Montevideo) for RNA seq data
   analysis; and the staff of Cirurgia Plastica Dr. Paulo Bettes for tissue
   collection. We thank the Program for Technological Development in Tools
   for Health PDTIS FIOCRUZ for use of its facilities. This study was
   supported by Fundacao Araucaria and CNPq.
CR Aenlle KK, 2014, MOL ENDOCRINOL, V28, P722, DOI 10.1210/me.2013 1286
   [Anonymous], MOL BIOSYST
   [Anonymous], PLOS ONE
   [Anonymous], 2017, CURR CONTENTS, DOI DOI 10.1371/JOURNAL.PONE
   Bionaz M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137644
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Choi WI, 2014, J BIOL CHEM, V289, P18625, DOI 10.1074/jbc.M113.538751
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Drabek K, 2011, J BONE MINER RES, V26, P2045, DOI 10.1002/jbmr.435
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fathi E, 2017, EXP BIOL MED, V242, P482, DOI 10.1177/1535370216685432
   Fosbrink M, 2009, EXP MOL PATHOL, V86, P87, DOI 10.1016/j.yexmp.2008.12.005
   Fromm Dornieden C, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471 2199 13 9
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Liang Y, 2009, CRIT REV EUKAR GENE, V19, P289, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.30
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Maeda A, 2015, J BIOL CHEM, V290, P14004, DOI 10.1074/jbc.M114.628818
   Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mizrahi O, 2013, GENE THER, V20, P370, DOI 10.1038/gt.2012.45
   Monaco E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032481
   Munekata K, 2009, IN VITRO CELL DEV AN, V45, P642, DOI 10.1007/s11626 009 9230 5
   Nguyen PK, 2016, JAMA CARDIOL, V1, P831, DOI 10.1001/jamacardio.2016.2225
   Ono M, 2011, J BONE MINER RES, V26, P193, DOI 10.1002/jbmr.205
   Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Ruijtenberg S, 2016, CELL CYCLE, V15, P196, DOI 10.1080/15384101.2015.1120925
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Shao J, 2015, BIOL RES, V48, DOI [10.1186/s40659 015 0053 4, 10.1186/S40659 015 0053 4]
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Siqueira MF, 2011, BONE, V48, P1043, DOI 10.1016/j.bone.2011.01.019
   Sisakhtnezhad S, 2017, EUR J CELL BIOL, V96, P13, DOI 10.1016/j.ejcb.2016.11.003
   Spangenberg L, 2013, STEM CELL RES, V11, P902, DOI 10.1016/j.scr.2013.06.002
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Tegla CA, 2015, EXP MOL PATHOL, V98, P328, DOI 10.1016/j.yexmp.2015.03.011
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Thysen S, 2016, LAB INVEST, V96, P570, DOI 10.1038/labinvest.2016.38
   Üren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374
   van de Peppel J, 2017, STEM CELL REP, V8, P947, DOI 10.1016/j.stemcr.2017.02.018
   Wang H, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0277 4
   Yang J., 2014, Food Science and Human Wellness, V3, P127, DOI DOI 10.1016/J.FSHW.2014.12.002
   Yong Y, 2016, J TISSUE ENG REGEN M, V10, pE537, DOI 10.1002/term.1864
   Zhang P, 2012, INT J MOL MED, V29, P1083, DOI 10.3892/ijmm.2012.934
   Zych J, 2014, STEM CELLS DEV, V23, P2791, DOI 10.1089/scd.2013.0496
NR 56
TC 21
Z9 21
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 16
PY 2018
VL 8
AR 4739
DI 10.1038/s41598 018 22991 6
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FZ4VC
UT WOS:000427589100016
PM 29549281
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, SC
   Lee, YJ
   Shin, MK
   Sung, JS
AF Lee, Seung Cheol
   Lee, Yoo Jung
   Shin, Min Kyoung
   Sung, Jung Suk
TI Regulation of CXCR6 Expression on Adipocytes and Osteoblasts
   Differentiated from Human Adipose Tissue Derived Mesenchymal Stem Cells
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID PROTEIN COUPLED RECEPTORS; VITRO MIGRATION CAPACITY; CHEMOKINE
   RECEPTORS; CXCL16; INTERNALIZATION; UBIQUITINATION; TRAFFICKING;
   DISINTEGRIN; MECHANISMS; PATHWAYS
AB Human mesenchymal stem cells derived from adipose tissue (hADMSCs) are a desirable candidate in regenerative medicine. hADMSCs secrete growth factors, cytokines, and chemokines and also express various receptors that are important in cell activation, differentiation, and migration to injured tissue. We showed that the expression level of chemokine receptor CXCR6 was significantly increased by similar to 2.5 fold in adipogenic differentiated cells (Ad), but not in osteogenic differentiated cells (Os) when compared with hADMSCs. However, regulation of CXCR6 expression on hADMSCs by using lentiviral particles did not affect the differentiation potential of hADMSCs. Increased expression of CXCR6 on Ad was mediated by both receptor recycling, which was in turn regulated by secretion of CXCL16, and de novo synthesis. The level of soluble CXCL16 was highly increased in both Ad and Os in particular, which inversely correlates with the expression on a transmembrane bound form of CXCL16 that is cleaved by disintegrin and metalloproteinase. We concluded that the expression of CXCR6 is regulated by receptor degradation or recycling when it is internalized by interaction with CXCL16 and by de novo synthesis of CXCR6. Overall, our study may provide an insight into the molecular mechanisms of the CXCR6 reciprocally expressed on differentiated cells from hADMSCs.
C1 [Lee, Seung Cheol; Lee, Yoo Jung; Shin, Min Kyoung; Sung, Jung Suk] Dongguk Univ Seoul, Dept Life Sci, Goyang 10326, Gyeonggi Do, South Korea.
C3 Dongguk University
RP Sung, JS (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Goyang 10326, Gyeonggi Do, South Korea.
EM hen4118@gmail.com; wjdyd85@naver.com; samantha1994@naver.com;
   sungjs@dongguk.edu
OI Lee, Seung Cheol/0000 0003 4310 5112
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [NRF 2017R1D1A1B03030983]; Dongguk University research fund of 2019
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT)
   (NRF 2017R1D1A1B03030983) and Dongguk University research fund of 2019.
CR Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362
   Ahmadian Kia N, 2011, J MOL NEUROSCI, V44, P178, DOI 10.1007/s12031 010 9446 6
   Baek SJ, 2011, EXP MOL MED, V43, P596, DOI 10.3858/emm.2011.43.10.069
   Bennett LD, 2011, IMMUNOLOGY, V134, P246, DOI 10.1111/j.1365 2567.2011.03485.x
   Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200
   Chen EEM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.429
   Croitoru Lamoury J, 2007, J INTERF CYTOK RES, V27, P53, DOI 10.1089/jir.2006.0037
   Dores MR, 2012, MOL PHARMACOL, V82, P563, DOI 10.1124/mol.112.079418
   Ghanemi A, 2015, SAUDI PHARM J, V23, P115, DOI 10.1016/j.jsps.2013.07.007
   Gir P, 2012, PLAST RECONSTR SURG, V129, P1277, DOI 10.1097/PRS.0b013e31824ecae6
   Gooden MJM, 2014, BRIT J CANCER, V110, P1535, DOI 10.1038/bjc.2014.55
   Gough PJ, 2004, J IMMUNOL, V172, P3678, DOI 10.4049/jimmunol.172.6.3678
   Huang Y, 2006, HUM REPROD, V21, P1083, DOI 10.1093/humrep/dei436
   Ichida M, 2011, FEBS LETT, V585, P4018, DOI 10.1016/j.febslet.2011.11.014
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jopling HM, 2014, CELLS BASEL, V3, P363, DOI 10.3390/cells3020363
   Kasina S, 2009, CELL PROLIFERAT, V42, P799, DOI 10.1111/j.1365 2184.2009.00645.x
   Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902
   Konno M, 2013, DEV GROWTH DIFFER, V55, P309, DOI 10.1111/dgd.12049
   Lehrke M, 2007, J AM COLL CARDIOL, V49, P442, DOI 10.1016/j.jacc.2006.09.034
   Lin P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023891
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007 0054
   Luttrell LM, 2002, J CELL SCI, V115, P455
   Marchese A, 2009, METHOD ENZYMOL, V460, P413, DOI 10.1016/S0076 6879(09)05221 5
   Meiser A, 2008, J IMMUNOL, V180, P6713, DOI 10.4049/jimmunol.180.10.6713
   Minteer D, 2013, ADV BIOCHEM ENG BIOT, V129, P59, DOI 10.1007/10_2012_146
   Mueller A, 2004, EUR J BIOCHEM, V271, P243, DOI 10.1046/j.1432 1033.2003.03918.x
   Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785
   Oksvold MP, 2012, FEBS LETT, V586, P3575, DOI 10.1016/j.febslet.2012.08.022
   Olson TS, 2002, AM J PHYSIOL REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001
   Perez Diaz S, 2017, AM J PHYSIOL CELL PH, V312, pC83, DOI 10.1152/ajpcell.00246.2016
   Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722
   Schramme A, 2008, KIDNEY INT, V74, P328, DOI 10.1038/ki.2008.181
   Skieterska K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050923
   Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763
   Solari R, 2015, EUR J PHARMACOL, V746, P363, DOI 10.1016/j.ejphar.2014.06.060
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748
   Yang JL, 2020, J BIOL CHEM, V295, P6641, DOI 10.1074/jbc.RA119.011192
   Yoshie Osamu, 2013, Nihon Rinsho Meneki Gakkai Kaishi, V36, P189
   Zhang Yu, 2012, ScientificWorldJournal, V2012, P793823, DOI 10.1100/2012/793823
NR 41
TC 4
Z9 4
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD AUG 19
PY 2020
VL 2020
AR 8870133
DI 10.1155/2020/8870133
PG 14
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA NQ6AV
UT WOS:000570952200001
PM 32922452
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Diamond, T
   Wong, YK
   Golombick, T
AF Diamond, T.
   Wong, Y. K.
   Golombick, T.
TI Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D,
   PTH, bone and muscle strength in patients with vitamin D deficiency
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone turnover; Muscle strength; Vitamin D deficiency
AB Treatment of vitamin D deficiency for 3 months with oral cholecalciferol 5,000 IU daily was more effective than 2,000 IU daily in achieving optimal serum 25 hydroxyvitamin D (25OHD) concentrations. Optimal 25OHD serum level calculated to be 63.8 nmol/L. All parameters of muscle strength improved following administration of cholecalciferol for 3 months.
   The aim of this study was to determine the optimal dose of cholecalciferol required to achieve target serum 25OHD level a parts per thousand yen75 nmol/L and its relationship to both bone turnover and muscle strength.
   Thirty deficient patients (serum 25OHD a parts per thousand currency sign50 nmol/L) were randomly assigned into two groups i.e. 2,000 and 5,000 IU/day. Data were collected at baseline, at 2 and 3 months post therapy: (a) clinical demographics, (b) dietary calcium recall, (c) physical tests of muscle function and (d) biochemistry. Statistical analysis used paired student t test and analysis of variance. Regression analysis was used to determine relationship between serum 25OHD and parathyroid hormone (PTH).
   Twenty six (87%) patients completed 3 months of therapy. The percent increase in serum 25OHD (compared to baseline) was 82.7% in 2,000 IU group and 219.5% in 5,000 IU group. All participants (100%) achieved a serum 25OHD concentration > 50 nmol/L; only 5 subjects (45.4%) in 2,000 IU group compared to 14 subjects (93.3%) in 5,000 IU group achieved final 25OHD concentration a parts per thousand yen75 nmol/L (p < 0.01). In the regression analysis, the reflexion point at which the PTH level increased above the normal range was calculated to be 63.8 nmol/L 25OHD. All parameters of muscle strength showed trends in improvements following the administration of both the 2,000 and 5,000 IU doses. No patient reported untoward side effects and no patient developed hypercalcaemia.
   Treatment for 3 months with oral cholecalciferol 5,000 IU daily may be more effective than 2,000 IU daily in achieving optimal serum 25OHD concentrations in vitamin D deficient patients.
C1 [Diamond, T.; Wong, Y. K.; Golombick, T.] St George Hosp, Dept Endocrinol, Kogarah, NSW 2211, Australia.
C3 St George Hospital
RP Diamond, T (通讯作者)，St George Hosp, Dept Endocrinol, Level 3 Prichard Wing,Gray St, Kogarah, NSW 2211, Australia.
EM terrydiamond@optusnet.com.au
CR Bischoff Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   DeLuca HF, 2008, NUTR REV, V56, P4
   Diamond T, 2009, MED TODAY, V10, P18
   Fess E.E., 1987, Journal of Hand Therapy, V1, P28, DOI [DOI 10.1016/S0894 1130(87)80009 1, 10.1016/S0894 1130(87)80009 1]
   Hackman KL, 2010, MED J AUSTRALIA, V192, P686, DOI 10.5694/j.1326 5377.2010.tb03702.x
   Holick MF, 2008, AM J CLIN NUTR, V87, p1080S
   Kuchuk NO, 2009, J CLIN ENDOCR METAB, V94, P1244, DOI 10.1210/jc.2008 1832
   McCarthy EK, 2004, J GERONTOL A BIOL, V59, P1207, DOI 10.1093/gerona/59.11.1207
   Prabhala A, 2000, ARCH INTERN MED, V160, P1199, DOI 10.1001/archinte.160.8.1199
   Van der Mei IAF, 2007, ENV HEAL PERSPECT, V56, P4
   Wark JD, 2003, AUST PRESER, V26, P126
NR 11
TC 38
Z9 41
U1 0
U2 20
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2013
VL 24
IS 3
BP 1101
EP 1105
DI 10.1007/s00198 012 1944 7
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 089DH
UT WOS:000314889100038
PM 22422304
DA 2025 08 17
ER

PT J
AU Wielage, RC
   Bansal, M
   Andrews, JS
   Wohlreich, MM
   Klein, RW
   Happich, M
AF Wielage, Ronald C.
   Bansal, Megha
   Andrews, J. Scott
   Wohlreich, Madelaine M.
   Klein, Robert W.
   Happich, Michael
TI The Cost Effectiveness of Duloxetine in Chronic Low Back Pain: A US
   Private Payer Perspective
SO VALUE IN HEALTH
LA English
DT Article
DE chronic low back pain; cost effectiveness; cost utility analysis;
   duloxetine; pharmacoeconomic model
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTON PUMP INHIBITORS; DIABETIC
   PERIPHERAL NEUROPATHY; THERAPEUTIC ARTHRITIS RESEARCH; MARK 3 UTILITY
   SCORES; ACUTE RENAL FAILURE; WOMAC INDEX SCORES; EVENT TRIAL TARGET;
   DOUBLE BLIND; PRIMARY PREVENTION
AB Objective: To assess the cost effectiveness of duloxetine in the treatment of chronic low back pain (CLBP) from a US private payer perspective. Methods: A cost utility analysis was undertaken for duloxetine and seven oral post first line comparators, including nonsteroidal anti inflammatory drugs (NSAIDs), weak and strong opioids, and an anticonvulsant. We created a Markov model on the basis of the National Institute for Health and Clinical Excellence model documented in its 2008 osteoarthritis clinical guidelines. Health states included treatment, death, and 12 states associated with serious adverse events (AEs). We estimated treatment specific utilities by carrying out a meta analysis of pain scores from CLBP clinical trials and developing a transfer to utility equation using duloxetine CLBP patient level data. Probabilities of AEs were taken from the National Institute for Health and Clinical Excellence model or estimated from osteoarthritis clinical trials by using a novel maximum likelihood simulation technique. Costs were gathered from Red Book, Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project database, the literature, and, for a limited number of inputs, expert opinion. The model performed one way and probabilistic sensitivity analyses and generated incremental cost effectiveness ratios (ICERs) and cost acceptability curves. Results: The model estimated an ICER of $59,473 for duloxetine over naproxen. ICERs under $30,000 were estimated for duloxetine over non NSAIDs, with duloxetine dominating all strong opioids. In subpopulations at a higher risk of NSAID related AEs, the ICER over naproxen was $33,105 or lower. Conclusions: Duloxetine appears to be a cost effective post first line treatment for CLBP compared with all but generic NSAIDs. In subpopulations at risk of NSAID related AEs, it is particularly cost effective.
C1 [Wielage, Ronald C.; Bansal, Megha; Klein, Robert W.] Med Decis Modeling Inc, Indianapolis, IN 46268 USA.
   [Andrews, J. Scott; Wohlreich, Madelaine M.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
   [Happich, Michael] Lilly Deutschland GmbH, Bad Homburg, Germany.
C3 Medical Decision Modeling Inc. (MDM); Eli Lilly; Eli Lilly; Lilly
   Deutschland GmbH
RP Wielage, RC (通讯作者)，Med Decis Modeling Inc, 8909 Purdue Rd,Suite 550, Indianapolis, IN 46268 USA.
EM rwielage@mdm inc.com
RI Wielage, Ronald/AAW 2002 2021
FU Eli Lilly and Company, Indianapolis, IN, USA
FX This research was supported by Eli Lilly and Company, Indianapolis, IN,
   USA.
CR Agency for Healthcare Research and Quality, 2011, HCUPNET TOOL ID TRAC
   Agency for Healthcare Research and Quality, 2011, INP QUAL IND IQIS AH
   American Medical Association, 2011, AMA COD ONL CPT COD
   [Anonymous], COST EFFECTIVENESS C
   [Anonymous], 2000, 20998S009 NDA US FOO
   [Anonymous], OST NAT CLIN GUID CA
   [Anonymous], HLTH TECHNOL ASSESS
   [Anonymous], 2011, Health, United States, 2010: With Special feature on death and dying
   [Anonymous], HLTH TECHNOL ASSESS
   Arezzo JC, 2008, BMC NEUROL, V8, DOI 10.1186/1471 2377 8 33
   Arias E., 2006, US LIFE TABLES 2006
   Avalere Health, 2009, AV HLTH AN AM HOSP A
   Balhara YPS, 2007, J POSTGRAD MED, V53, P44, DOI 10.4103/0022 3859.30328
   Barton GR, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477 7525 6 51
   Bohnert ASB, 2011, JAMA J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370
   Brunton S, 2010, DRUG SAFETY, V33, P393, DOI 10.2165/11319200 000000000 00000
   Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895 4356(97)00049 8
   Bureau of Labor Statistics, 2012, CONS PRIC IND MED SE
   Canadian Institute for Health Information, 2009, PROT PUMP INH US SEN
   Chappell J, 2009, J CLIN PHARMACOL, V49, P1456, DOI 10.1177/0091270009344335
   Charlot M, 2010, ANN INTERN MED, V153, P378, DOI 10.7326/0003 4819 153 6 201009210 00005
   Currie SR, 2004, PAIN, V107, P54, DOI 10.1016/j.pain.2003.09.015
   Curtiss FR, 2010, J MANAGE CARE PHARM, V16, P492, DOI 10.18553/jmcp.2010.16.7.492
   Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005
   Dagenais Simon, 2005, Spine J, V5, P357, DOI 10.1016/j.spinee.2005.03.001
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197 2456(86)90046 2
   Eddy D., 1998, OSTEOPOROS INT, V8, pS1
   Eli Lilly and Company, 2011, MARK SHAR DUL COMP
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   Fihn SD, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471 2261 9 44
   Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526 4637.2007.00370.x
   Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543
   Freynhagen R, 2005, PAIN, V115, P254, DOI 10.1016/j.pain.2005.02.032
   Freynhagen R, 2009, CURR PAIN HEADACHE R, V13, P185, DOI 10.1007/s11916 009 0032 y
   Fryback DG, 2007, MED CARE, V45, P1162, DOI 10.1097/MLR.0b013e31814848f1
   Galbreath AD, 2004, CIRCULATION, V110, P3518, DOI 10.1161/01.CIR.0000148957.62328.89
   Goeree R, 2006, CURR MED RES OPIN, V22, P1425, DOI 10.1185/030079906X115568
   Greiner W, 2006, Eur J Health Econ, V7, P290, DOI 10.1007/s10198 006 0376 8
   Griffin MR, 2000, AM J EPIDEMIOL, V151, P488
   Grootendorst P, 2007, J RHEUMATOL, V34, P534
   Hippisley Cox J, 2005, BMJ BRIT MED J, V331, P1310, DOI 10.1136/bmj.331.7528.1310
   Hippisley Cox J, 2007, BMJ BRIT MED J, V335, P136, DOI 10.1136/bmj.39261.471806.55
   Hjalte F, 2010, J PAIN SYMPTOM MANAG, V40, P696, DOI 10.1016/j.jpainsymman.2010.02.019
   Huerta C, 2005, AM J KIDNEY DIS, V45, P531, DOI 10.1053/j.ajkd.2004.12.005
   Ivanova JI, 2012, PHARMACOECONOMICS, V30, P595, DOI 10.2165/11598130 000000000 00000
   Jetté N, 2011, ARCH NEUROL CHICAGO, V68, P107, DOI 10.1001/archneurol.2010.341
   Kanis J A, 2007, Health Technol Assess, V11, piii
   Kanis JA, 2007, HEALTH TECHNOL ASSES, V11, P1
   Kelly JP, 2008, PAIN, V138, P507, DOI 10.1016/j.pain.2008.01.027
   Kleindorfer D, 2006, STROKE, V37, P2473, DOI 10.1161/01.STR.0000242766.65550.92
   Ko CW, 2000, J GEN INTERN MED, V15, P400, DOI 10.1046/j.1525 1497.2000.03459.x
   Kroenke K, 2009, GEN HOSP PSYCHIAT, V31, P206, DOI 10.1016/j.genhosppsych.2008.12.006
   Kuijpers T, 2011, EUR SPINE J, V20, P40, DOI 10.1007/s00586 010 1541 4
   Lafrance JP, 2009, PHARMACOEPIDEM DR S, V18, P923, DOI 10.1002/pds.1798
   Laine L, 2007, LANCET, V369, P465, DOI 10.1016/S0140 6736(07)60234 7
   Lakshminarayan K, 2009, AM J EPIDEMIOL, V169, P1070, DOI 10.1093/aje/kwp029
   Lange B, 2010, ADV THER, V27, P381, DOI 10.1007/s12325 010 0036 3
   Lee KK, 2010, CIRCULATION, V122, P1478, DOI 10.1161/CIRCULATIONAHA.110.947960
   Maetzel A, 2003, ARTHRIT RHEUM ARTHR, V49, P283, DOI 10.1002/art.11121
   Marshall D, 2008, VALUE HEALTH, V11, P470, DOI 10.1111/j.1524 4733.2007.00258.x
   McNeil JM, 2001, JAMA J AM MED ASSOC, V285, P1571
   Meadows Eric S, 2007, BMC Womens Health, V7, P6, DOI 10.1186/1472 6874 7 6
   Montano CB, 2008, CLIN STUDY REPORT DU
   Mortimer D, 2008, MED DECIS MAKING, V28, P66, DOI 10.1177/0272989X07309642
   Mortimer D, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477 7525 7 33
   Mulder H, 2008, CLIN STUDY REPORT EF
   Mullins C Daniel, 2003, J Manag Care Pharm, V9, P150
   Neighbors DM, 2001, J PAIN SYMPTOM MANAG, V21, P129, DOI 10.1016/S0885 3924(00)00247 5
   Nucynta ER, 2011, PRESCRIBING INFORM
   Pai S, 2004, ORTHOP CLIN N AM, V35, P1, DOI 10.1016/S0030 5898(03)00101 9
   Patrick K, 2009, EFFECT DULOXETINE 60
   PDR Network, 2011, RED BOOK PHARM FUND
   Pignone M, 2006, ANN INTERN MED, V144, P326, DOI 10.7326/0003 4819 144 5 200603070 00007
   Rahme E, 2007, ARTHRIT RHEUM ARTHR, V57, P748, DOI 10.1002/art.22764
   Remmers A, 2000, 19 ANN M AM PAIN SOC
   Roger VL, 2004, JAMA J AM MED ASSOC, V292, P344, DOI 10.1001/jama.292.3.344
   Rosenstock J, 2004, PAIN, V110, P628, DOI 10.1016/j.pain.2004.05.001
   Rubin DI, 2007, NEUROL CLIN, V25, P353, DOI 10.1016/j.ncl.2007.01.004
   Sauerland S, 2009, VALUE HEALTH, V12, P364, DOI 10.1111/j.1524 4733.2008.00442.x
   Savigny P., 2009, Low Back Pain: early management of persistent non specific low back pain
   Schneider V, 2006, AM J EPIDEMIOL, V164, P881, DOI 10.1093/aje/kwj331
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Segal L, 2004, MED J AUSTRALIA, V180, pS11
   Siegel JE, 1996, JAMA J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339
   Skljarevski V, 2009, EUR J NEUROL, V16, P1041, DOI 10.1111/j.1468 1331.2009.02648.x
   Skljarevski V, 2010, J PAIN, V11, P1282, DOI 10.1016/j.jpain.2010.03.002
   Skljarevski V, 2010, SPINE, V35, pE578, DOI 10.1097/BRS.0b013e3181d3cef6
   Skljarevski V, 2010, PAIN MED, V11, P648, DOI 10.1111/j.1526 4637.2010.00836.x
   Spiegel BMR, 2005, ARTHRIT RHEUM ARTHR, V53, P185, DOI 10.1002/art.21065
   Stevenson M, 2007, HEALTH TECHNOL ASSES, V11, P1
   Strombom I, 2008, CURR DRUG SAF, V3, P154, DOI 10.2174/157488608784529215
   van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586 006 1071 2
   van Zanten SJOV, 2005, AM J GASTROENTEROL, V100, P1477, DOI 10.1111/j.1572 0241.2005.40280.x
   Vestergaard P, 2006, J INTERN MED, V260, P76, DOI 10.1111/j.1365 2796.2006.01667.x
   Vestergaard P, 2008, CALCIFIED TISSUE INT, V82, P92, DOI 10.1007/s00223 007 9099 9
   Vestergaard P, 2008, CURR DRUG SAF, V3, P199, DOI 10.2174/157488608785699504
   VONKORFF M, 1994, SPINE, V19, pS2041
   Wang GJ, 2010, AM J MANAG CARE, V16, P769
   Washington State Department of Social & Health Services, 2009, CALC TAP PLAN CLIENT
   Wernicke J, 2008, CURR DRUG SAF, V3, P132, DOI 10.2174/157488608784529189
   Wernicke J, 2008, CURR DRUG SAF, V3, P143, DOI 10.2174/157488608784529198
   Yang M, 2007, CURR MED RES OPIN, V23, P2269, DOI 10.1185/030079907X210796
   Yu EW, 2011, AM J MED, V124, P519, DOI 10.1016/j.amjmed.2011.01.007
   Zhang JJ, 2006, JAMA J AM MED ASSOC, V296, P1619, DOI 10.1001/jama.296.13.jrv60015
NR 104
TC 23
Z9 24
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1098 3015
EI 1524 4733
J9 VALUE HEALTH
JI Value Health
PD MAR APR
PY 2013
VL 16
IS 2
BP 334
EP 344
DI 10.1016/j.jval.2012.12.006
PG 11
WC Economics; Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA 144AC
UT WOS:000318910400014
PM 23538186
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhou, YC
   Liu, Y
   Cheng, L
AF Zhou, Yingchuan
   Liu, Yi
   Cheng, Li
TI miR 21 expression is related to particle induced osteolysis pathogenesis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE miR 21; particle induced osteolysis; AP 1; PDCD4
ID TNF ALPHA; BONE; POLYETHYLENE; MACROPHAGES; TISSUES
AB Previous studies have found that microRNA 21 (miR 21) is an important functional factor during osteoclast differentiation. Abnormal osteoclastogenesis induced by wear particles is the main cause of aseptic loosening in joint replacements. The aim of the present study is to investigate the possible role of miR 21 in the pathogenesis of particle induced osteolysis (PIO). miR 21 expression was examined in a PIO mouse model using real time (RT PCR). Osteoclastogenesis was determined by a tartrate resistant acid phosphatase (TRAP) quantification method. A toluidine blue staining assay was used to examine calvarial osteolysis. The results demonstrated that miR 21 was significantly upregulated in the PIO animal model. Knocking out miR 21 in the particle stimulated tissue could ameliorate osteolysis symptoms. Additionally, through our analysis of PDCD4 and AP 1 expression, we suggest that the feedback loop of AP 1, miR 21, and PDCD4 might have an important influence on the development of PIO and that miR 21 is a potential target for implant loosening therapies. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:18371842, 2012
C1 [Zhou, Yingchuan; Liu, Yi; Cheng, Li] Wuxi Peoples Hosp, Dept Orthoped, Wuxi, Peoples R China.
C3 Jiangnan University
RP Cheng, L (通讯作者)，Wuxi Peoples Hosp, Dept Orthoped, Wuxi, Peoples R China.
EM chengliwph@gmail.com
FU scientific foundation of Wuxi People's Hospital
FX This study was funded by the scientific foundation of Wuxi People's
   Hospital.
CR Aspenberg P, 1998, CLIN ORTHOP RELAT R, P75
   Blüml S, 2011, ARTHRITIS RHEUM US, V63, P1281, DOI 10.1002/art.30281
   Böhler M, 2002, J BONE JOINT SURG BR, V84B, P128, DOI 10.1302/0301 620X.84B1.11324
   Campbell PA, 2002, ACTA ORTHOP SCAND, V73, P506, DOI 10.1080/000164702321022767
   Catelas I, 2003, BIOMATERIALS, V24, P4785, DOI 10.1016/S0142 9612(03)00378 8
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Davies AP, 2005, J BONE JOINT SURG AM, V87A, P18, DOI 10.2106/JBJS.C.00949
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Gallo Jiri, 2002, Biomedical Papers (Olomouc), V146, P21
   Green TR, 2000, J BIOMED MATER RES, V53, P490, DOI 10.1002/1097 4636(200009)53:5<490::AID JBM7>3.0.CO;2 7
   HOROWITZ SM, 1995, J BIOMED MATER RES, V29, P477, DOI 10.1002/jbm.820290407
   Ingham E, 2000, BIOMATERIALS, V21, P1005, DOI 10.1016/S0142 9612(99)00261 6
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582 4934.2008.00556.x
   Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414 424.2001
   MacQuarrie RA, 2004, J BIOMED MATER RES B, V69B, P104, DOI 10.1002/jbm.b.20031
   Maruotti N, 2011, CLIN EXP MED, V11, P137, DOI 10.1007/s10238 010 0117 2
   Miscia S, 2002, CELL GROWTH DIFFER, V13, P13
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Ren WP, 2006, BIOMATERIALS, V27, P5161, DOI 10.1016/j.biomaterials.2006.04.004
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828
   Sugatani T, 2007, J CELL BIOCHEM, V101, P996, DOI 10.1002/jcb.21335
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   von Knoch M, 2005, BIOMATERIALS, V26, P1803, DOI 10.1016/j.biomaterials.2004.06.010
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Yang SY, 2002, BIOMATERIALS, V23, P3535, DOI 10.1016/S0142 9612(02)00032 7
   Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200
NR 28
TC 29
Z9 29
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD NOV
PY 2012
VL 30
IS 11
BP 1837
EP 1842
DI 10.1002/jor.22128
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 015OL
UT WOS:000309455700020
PM 22508494
DA 2025 08 17
ER

PT J
AU Kang, HM
   Zhang, KY
   Pan, Q
   Lin, SE
   Wong, DSH
   Li, JM
   Lee, WYW
   Yang, BG
   Han, FX
   Li, G
   Li, B
   Bian, LM
AF Kang, Heemin
   Zhang, Kunyu
   Pan, Qi
   Lin, Sien
   Wong, Dexter Siu Hong
   Li, Jinming
   Lee, Wayne Yuk Wai
   Yang, Boguang
   Han, Fengxuan
   Li, Gang
   Li, Bin
   Bian, Liming
TI Remote Control of Intracellular Calcium Using Upconversion
   Nanotransducers Regulates Stem Cell Differentiation In Vivo
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE in vivo stem cell differentiation; intracellular calcium regulation;
   photocaging; upconversion nanotransducers
ID PHOTODYNAMIC THERAPY; CARTILAGE REGENERATION; NANOPARTICLES; BONE;
   CANCER; HYDROGELS; FATE; PLURIPOTENCY; DEGENERATION; CHONDROCYTES
AB Remote control of stem cell differentiation in vivo by stimuli responsive nanomaterials with the use of tissue penetrative stimuli is an appealing strategy for versatile regulation in stem cell therapy. In this study, an upconversion nanotransducer (UCNT) based nanocomplex with photolabile caging of chondro inductive kartogenin (KGN) and/or either calcium chelator or calcium supplier (caged calcium), and subsequent coupling of integrin binding ligand via cyclodextrin adamantine supramolecular complexation is utilized. Near infrared (NIR) to ultraviolet light conversion by UCNT nanocomplex triggered intracellular photo uncaging and release of cargo molecules, thereby allowing direct regulation of real time intracellular calcium levels. While intracellular KGN delivery led to the differentiation of human mesenchymal stem cells (hMSCs) into hypertrophic chondrocytes, NIR regulated intracellular calcium decrease and KGN delivery induced their differentiation into chondrocytes by inhibiting hypertrophy. Conversely, intracellular calcium increase and KGN delivery promoted the differentiation of hMSCs into osteoblasts via endochondral pathway. To the best of knowledge, this is the first demonstration of utilizing NIR controllable nanomaterials for regulating stem cell differentiation by controlling intracellular calcium, both in vitro and in vivo. This versatile control can facilitate the translation of stem cells to remotely controlled treatment of diseases in composite tissues involving various cell types.
C1 [Kang, Heemin; Zhang, Kunyu; Wong, Dexter Siu Hong; Li, Jinming; Yang, Boguang; Bian, Liming] Chinese Univ Hong Kong, Dept Biomed Engn, Shatin 999077, Hong Kong, Peoples R China.
   [Pan, Qi; Lin, Sien; Lee, Wayne Yuk Wai; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China.
   [Pan, Qi; Lin, Sien; Lee, Wayne Yuk Wai; Li, Gang] Chinese Univ Hong Kong, Lui Che Woo Inst Innovat Med, Stem Cells & Regenerat Med Lab, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Lin, Sien; Bian, Liming] Guangdong Med Univ, Guangdong Key Lab Res & Dev Nat Drugs, Dept Pharmacol, Zhanjiang 524023, Guangdong, Peoples R China.
   [Han, Fengxuan; Li, Bin] Soochow Univ, Affiliated Hosp 1, Orthopaed Inst, Dept Orthopaed Surg, Suzhou 215006, Jiangsu, Peoples R China.
   [Li, Bin; Bian, Liming] China Orthopaed Regenerat Med Grp CORMed, Hangzhou 310058, Zhejiang, Peoples R China.
   [Li, Gang; Bian, Liming] Chinese Univ Hong Kong, Shenzhen Res Inst, CUHKACC Space Med Ctr Hlth Maintenance Musculoske, Shenzhen 518172, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Chinese University of Hong Kong; Guangdong Medical
   University; Soochow University   China; CUHK Shenzhen Research
   Institute; The Chinese University of Hong Kong, Shenzhen
RP Bian, LM (通讯作者)，Chinese Univ Hong Kong, Dept Biomed Engn, Shatin 999077, Hong Kong, Peoples R China.; Bian, LM (通讯作者)，Guangdong Med Univ, Guangdong Key Lab Res & Dev Nat Drugs, Dept Pharmacol, Zhanjiang 524023, Guangdong, Peoples R China.; Li, B (通讯作者)，Soochow Univ, Affiliated Hosp 1, Orthopaed Inst, Dept Orthopaed Surg, Suzhou 215006, Jiangsu, Peoples R China.; Li, B; Bian, LM (通讯作者)，China Orthopaed Regenerat Med Grp CORMed, Hangzhou 310058, Zhejiang, Peoples R China.; Li, B; Bian, LM (通讯作者)，Chinese Univ Hong Kong, Shenzhen Res Inst, CUHKACC Space Med Ctr Hlth Maintenance Musculoske, Shenzhen 518172, Peoples R China.
EM binli@suda.edu.cn; lbian@cuhk.edu.hk
RI ; Lin, Sien/J 7773 2018; Bian, Liming/A 7183 2011; Li, Bin/B 7802 2012;
   Wong, Siu Hong Dexter/AAT 9831 2021; Lee, Wayne YW/H 8298 2013; Li,
   Gang/J 7830 2018; Lee, Wayne/H 8298 2013; Zhang, Kunyu/AAG 3278 2021;
   Han, Fengxuan/IZP 9512 2023; 李, 金明/GWZ 6274 2022
OI Bian, Liming/0000 0003 4739 0918; Lin, Sien/0000 0002 7292 7062; Lee,
   Wayne YW/0000 0002 0486 360X; Li, Gang/0000 0002 3981 2239; Wong, Siu
   Hong Dexter/0000 0001 7920 4599; Zhang, Kunyu/0000 0003 2481 4781; Li,
   Bin/0000 0001 8516 9953; Kang, Heemin/0000 0003 2694 9882; 
FU National Natural Science Foundation of China [31570979, 31530024,
   81772404, 81430049, 81772322]; National Key R&D Program of China
   [2016YFC1100203]; Research Grants Council of Hong Kong [14202215,
   14220716]; Health and Medical Research Fund; Food and Health Bureau;
   Government of the Hong Kong Special Administrative Region [04152836];
   Hong Kong Research Grants Council Theme based Research Scheme
   [T13 402/17 N]; Chow Yuk Ho Technology Centre for Innovative Medicine,
   The Chinese University of Hong Kong; Research Grants Council of the Hong
   Kong Special Administrative Region, China [T13 402/17 N, 14119115,
   14160917, 9054014 N_CityU102/15]; Hong Kong Innovation Technology
   Commission Funds [ITS/UIM 305]; SMART program, Lui Che Woo Institute of
   Innovative Medicine
FX H.K. and K.Z. contributed equally to this work. Projects 31570979 and
   31530024 are supported by the National Natural Science Foundation of
   China. This work is supported by National Key R&D Program of China
   (2016YFC1100203). The work described in this paper is supported by a
   General Research Fund grant from the Research Grants Council of Hong
   Kong (project nos 14202215 and 14220716). This work is supported by the
   Health and Medical Research Fund, the Food and Health Bureau, the
   Government of the Hong Kong Special Administrative Region (04152836).
   The work was partially supported by Hong Kong Research Grants Council
   Theme based Research Scheme (Ref. T13 402/17 N). This research is
   supported by the Chow Yuk Ho Technology Centre for Innovative Medicine,
   The Chinese University of Hong Kong. The authors are grateful for
   technical support from Josie Lai, Samuel Wong, and Anny Cheung in the
   School of Biomedical Sciences, The Chinese University of Hong Kong. The
   authors also thank Prof. Feng Wang and Ms. Tianying Sun in the
   Department of Materials Science and Engineering, City University of Hong
   Kong, for the help with the photoluminescence characterization of the
   UCNTs. The work was partially supported by grants from Research Grants
   Council of the Hong Kong Special Administrative Region, China (project
   nos 14119115, 14160917, 9054014 N_CityU102/15, and T13 402/17 N);
   National Natural Science Foundation of China (81772404, 81430049, and
   81772322); Hong Kong Innovation Technology Commission Funds
   (ITS/UIM 305). This study was also supported in part by SMART program,
   Lui Che Woo Institute of Innovative Medicine. The animal experiments in
   this work were approved by the Institutional Animal Care and Use
   Committee at the Chinese University of Hong Kong.
CR Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Bhumiratana S, 2014, P NATL ACAD SCI USA, V111, P6940, DOI 10.1073/pnas.1324050111
   Bian LM, 2013, P NATL ACAD SCI USA, V110, P10117, DOI 10.1073/pnas.1214100110
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chaudhuri O, 2016, NAT MATER, V15, P326, DOI [10.1038/NMAT4489, 10.1038/nmat4489]
   Chen GY, 2014, CHEM REV, V114, P5161, DOI 10.1021/cr400425h
   Chen PJ, 2015, ADV MATER, V27, P6488, DOI 10.1002/adma.201502784
   Cheng L, 2013, ADV FUNCT MATER, V23, P272, DOI 10.1002/adfm.201201733
   Chien YH, 2013, ACS NANO, V7, P8516, DOI 10.1021/nn402399m
   Cui SS, 2013, ACS NANO, V7, P676, DOI 10.1021/nn304872n
   Devlin MJ, 2015, LANCET DIABETES ENDO, V3, P141, DOI 10.1016/S2213 8587(14)70007 5
   Diba M, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703438
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Du V, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00543 2
   Fedoryshin LL, 2014, ACS APPL MATER INTER, V6, P13600, DOI 10.1021/am503039f
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Huey DJ, 2012, SCIENCE, V338, P917, DOI 10.1126/science.1222454
   Idris NM, 2012, NAT MED, V18, P1580, DOI 10.1038/nm.2933
   Jayakumar MKG, 2012, P NATL ACAD SCI USA, V109, P8483, DOI 10.1073/pnas.1114551109
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Kakuta T, 2013, ADV MATER, V25, P2849, DOI 10.1002/adma.201205321
   Kang H, 2018, BIOMATERIALS, V178, P681, DOI 10.1016/j.biomaterials.2018.03.007
   Kang H, 2017, ACS NANO, V11, P9636, DOI 10.1021/acsnano.7b02857
   Khademhosseini A, 2016, NAT PROTOC, V11, P1775, DOI 10.1038/nprot.2016.123
   Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]
   Kim T, 2011, J AM CHEM SOC, V133, P2955, DOI 10.1021/ja1084095
   Li JM, 2016, BIOMATERIALS, V110, P1, DOI 10.1016/j.biomaterials.2016.09.011
   Liu CQ, 2017, BIOMATERIALS, V139, P151, DOI 10.1016/j.biomaterials.2017.06.008
   Lu Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10066
   Min YZ, 2014, ANGEW CHEM INT EDIT, V53, P1012, DOI 10.1002/anie.201308834
   Pacardo DB, 2015, NANOSCALE, V7, P12096, DOI 10.1039/c5nr01568e
   Park JS, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201700396
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rutges JPHJ, 2010, OSTEOARTHR CARTILAGE, V18, P1487, DOI 10.1016/j.joca.2010.08.006
   Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110
   Seidi A, 2011, ACTA BIOMATER, V7, P1441, DOI 10.1016/j.actbio.2011.01.011
   Shi DQ, 2016, ACS NANO, V10, P1292, DOI 10.1021/acsnano.5b06663
   Shi P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13088
   Shih YR, 2017, P NATL ACAD SCI USA, V114, P5419, DOI 10.1073/pnas.1702576114
   Sun S, 2007, FASEB J, V21, P1472, DOI 10.1096/fj.06 7153com
   Thomas D, 2018, ADV MATER, V30, DOI 10.1002/adma.201703948
   Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]
   van der Kraan PM, 2012, OSTEOARTHR CARTILAGE, V20, P223, DOI 10.1016/j.joca.2011.12.003
   Vankayala R, 2018, ADV MATER, V30, DOI 10.1002/adma.201706320
   Wang BY, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7090269
   Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200
   Wang FM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03617 x
   Wang F, 2011, NAT MATER, V10, P968, DOI [10.1038/nmat3149, 10.1038/NMAT3149]
   Wong DSH, 2017, NANO LETT, V17, P1685, DOI 10.1021/acs.nanolett.6b04958
   Wu S, 2016, ADV MATER, V28, P1208, DOI 10.1002/adma.201502843
   Xie J, 2008, J AM CHEM SOC, V130, P7542, DOI 10.1021/ja802003h
   Xu J, 2017, ACS NANO, V11, P4463, DOI 10.1021/acsnano.7b00715
   Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Yang H, 2014, ADV FUNCT MATER, V24, P1738, DOI 10.1002/adfm.201302433
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Yoon JK, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703853
   Zhang KY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701642
   Zhang Q, 2012, ADV FUNCT MATER, V22, P5144, DOI 10.1002/adfm.201201316
   Zhao H, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201702592
   Zhao N, 2017, BIOMATERIALS, V141, P40, DOI 10.1016/j.biomaterials.2017.06.031
   Zuscik MJ, 2002, EXP CELL RES, V276, P310, DOI 10.1006/excr.2002.5527
NR 65
TC 64
Z9 66
U1 3
U2 249
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD OCT 10
PY 2018
VL 28
IS 41
AR 1802642
DI 10.1002/adfm.201802642
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA GW0JQ
UT WOS:000446550700005
DA 2025 08 17
ER

PT J
AU Zayed, N
   Afif, H
   Chabane, N
   Mfuna Endam, L
   Benderdour, M
   Martel Pelletier, J
   Pelletier, JP
   Motiani, RK
   Trebak, M
   Duval, N
   Fahmi, H
AF Zayed, Nadia
   Afif, Hassan
   Chabane, Nadir
   Mfuna Endam, Leandra
   Benderdour, Mohamed
   Martel Pelletier, Johanne
   Pelletier, Jean Pierre
   Motiani, Rajender K.
   Trebak, Mohamed
   Duval, Nicolas
   Fahmi, Hassan
TI Inhibition of Interleukin 1β Induced Matrix Metalloproteinases 1 and 13
   Production in Human Osteoarthritic Chondrocytes by Prostaglandin
   D2
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED RECEPTOR GAMMA;
   PROGRESSIVE JOINT DESTRUCTION; HUMAN ARTICULAR CHONDROCYTES; IN VITRO;
   HUMAN OSTEOBLASTS; INDUCED ARTHRITIS; DP RECEPTORS; COLLAGENASE;
   CARTILAGE
AB Objective. To investigate the effects of prostaglandin D 2 (PGD(2)) on interieukin 1 beta (IL 1 beta) induced matrix metalloproteinase 1 (MMP 1) and MMP 13 expression in human chondrocytes and the signaling pathways involved in these effects.
   Methods. Chondrocytes were stimulated with IL 1 in the presence or absence of PGD(2), and expression of MMP 1. and MMP 13 proteins was evaluated by enzyme linked immunosorbent assay. Messenger RNA (mRNA) expression and promoter activity were analyzed by real time reverse transcription polymerase chain reaction and transient transfections, respectively. The role of the PGD(2) receptors D prostanoid receptor 1 (DP1) and chemoattractant receptor like molecule expressed on Th2 cells (CRTH2) was evaluated using specific agonists and antibody blocking experiments. The contribution of the cAMP/protein kinase A (PKA) pathway was determined using cAMP elevating agents and PKA inhibitors.
   Results. PGD(2) decreased in a dose dependent manner IL 1 induced MMP 1 and MMP 13 protein and mRNA expression as well as their promoter activation. DP1 and CRTH2 were expressed and functional in chondrocytes. The effect of PGD(2) was mimicked by BW245C, a selective agonist of DP1, but not by 13,14 dihydro 15 keto PGD(2), a selective agonist of CRTH2. Furthermore, treatment with an anti DP1 antibody reversed the effect of PGD(2) indicating that the inhibitory effect of PGD(2) is mediated by DP1. The cAMP elevating agents 8 Br cAMP and forskolin suppressed IL 1 induced MMP 1 and MMP 13 expression, and the PKA inhibitors KT5720 and H89 reversed the inhibitory effect of PGD(2) suggesting that the effect of PGD(2) is mediated by the cAMP/PKA pathway.
   Conclusion. PGD(2) inhibits IL 1 induced production of MMP 1 and MMP 13 by chondrocytes through the DP1/cAMP/PKA signaling pathway. These data also suggest that modulation of PGD(2) levels in the joint may have therapeutic potential in the prevention of cartilage degradation.
C1 [Fahmi, Hassan] Univ Montreal, Notre Dame Hosp, Osteoarthrit Res Unit, Ctr Rech,Ctr Hosp, Montreal, PQ H2L 4M1, Canada.
   [Benderdour, Mohamed] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada.
   [Motiani, Rajender K.; Trebak, Mohamed] Albany Med Coll, Albany, NY 12208 USA.
   [Duval, Nicolas] Ctr Convalescence, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Albany Medical College
RP Fahmi, H (通讯作者)，Univ Montreal, Notre Dame Hosp, Osteoarthrit Res Unit, Ctr Rech,Ctr Hosp, 1560 Sherbrooke E,Pavillon JA DeSseve,Y 2628, Montreal, PQ H2L 4M1, Canada.
EM h.fahmi@umontreal.ca
RI Trebak, Mohamed/E 7405 2014; Pelletier, Jean Pierre/AAG 2896 2019;
   Martel Pelletier, Johanne/AAG 2928 2019
OI Motiani, Rajender K/0000 0002 8971 9008
FU Canadian Institutes of Health Research [MOP 84282]; Fonds de la
   Recherche du Centre de Recherche du Centre Hospitalier de I'Universite
   de Montreal; NIH [K22 ES 014729]; Albany Medical College; Fonds de la
   Recherche en Sante du Quebec
FX Supported by the Canadian Institutes of Health Research (grant
   MOP 84282) and the Fonds de la Recherche du Centre de Recherche du
   Centre Hospitalier de I'Universite de Montreal. Dr. Trebak's work was
   supported by the NIH (Early Career grant K22 ES 014729) and by start LIP
   funds from Albany Medical College. Dr. Fahmi is a Research Scholar of
   the Fonds de la Recherche en Sante du Quebec.
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577
   Brewster M, 1998, ARTHRITIS RHEUM, V41, P1639, DOI 10.1002/1529 0131(199809)41:9<1639::AID ART15>3.0.CO;2 0
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Crider JY, 1999, BRIT J PHARMACOL, V127, P204, DOI 10.1038/sj.bjp.0702490
   dePaulis A, 1996, ARTHRITIS RHEUM US, V39, P1222, DOI 10.1002/art.1780390723
   Dingle JT, 1999, OSTEOARTHR CARTILAGE, V7, P313, DOI 10.1053/joca.1998.0176
   EGG D, 1984, Z RHEUMATOL, V43, P89
   Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529 0131(200103)44:3<595::AID ANR108>3.3.CO;2 #
   Francois M, 2004, J BIOL CHEM, V279, P28411, DOI 10.1074/jbc.M312708200
   Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211
   Gencosmanoglu BE, 2001, RES EXP MED, V200, P215
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255
   HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192
   Hutchinson JW, 1998, J BONE JOINT SURG BR, V80B, P907, DOI 10.1302/0301 620X.80B5.8464
   Ianaro A, 2001, FEBS LETT, V508, P61, DOI 10.1016/S0014 5793(01)03035 6
   Ishikawa T, 2005, BRIT J PHARMACOL, V144, P133, DOI 10.1038/sj.bjp.0706054
   Ishikawa T, 2005, EUR J PHARMACOL, V508, P239, DOI 10.1016/j.ejphar.2004.12.014
   Jakob M, 2004, RHEUMATOLOGY, V43, P852, DOI 10.1093/rheumatology/keh197
   Kapoor M, 2007, PROSTAG LEUKOTR ESS, V76, P103, DOI 10.1016/j.plefa.2006.11.006
   Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544
   LEFF P, 1992, BRIT J PHARMACOL, V106, P996, DOI 10.1111/j.1476 5381.1992.tb14447.x
   Martel Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049 0172(03)00134 3
   Monneret G, 2003, J PHARMACOL EXP THER, V304, P349, DOI 10.1124/jpet.102.042937
   Murakami Y, 2003, ARTHRITIS RHEUM, V48, P2931, DOI 10.1002/art.11271
   PIETILA P, 1984, SCAND J RHEUMATOL, V13, P243, DOI 10.3109/03009748409100393
   RASHAD S, 1989, LANCET, V2, P519
   Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636
   Reijman M, 2005, ARTHRITIS RHEUM US, V52, P3137, DOI 10.1002/art.21357
   Relic B, 2004, J BIOL CHEM, V279, P22399, DOI 10.1074/jbc.M314118200
   Sabatini M, 2005, ARTHRITIS RHEUM US, V52, P171, DOI 10.1002/art.20900
   Serni U, 1999, OSTEOARTHR CARTILAGE, V7, P351, DOI 10.1053/joca.1998.0195
   Shan ZZ, 2004, J BIOL CHEM, V279, P37939, DOI 10.1074/jbc.M402424200
   Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200
   TASAKI Y, 1991, PROSTAGLANDINS, V41, P303, DOI 10.1016/0090 6980(91)90001 V
   Thabet MM, 2006, CURR OPIN INVEST DR, V7, P1014
   TOWN MH, 1983, PROSTAG OTH LIPID M, V25, P13
   Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200
   Trivedi SG, 2006, P NATL ACAD SCI USA, V103, P5179, DOI 10.1073/pnas.0507175103
   WELGUS HG, 1981, J BIOL CHEM, V256, P9511
NR 42
TC 56
Z9 63
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD NOV
PY 2008
VL 58
IS 11
BP 3530
EP 3540
DI 10.1002/art.23958
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 374JO
UT WOS:000261039800029
PM 18975308
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Pachón Peña, G
   Yu, G
   Tucker, A
   Wu, X
   Vendrell, J
   Bunnell, BA
   Gimble, JM
AF Pachon Pena, G.
   Yu, G.
   Tucker, A.
   Wu, X.
   Vendrell, J.
   Bunnell, B. A.
   Gimble, J. M.
TI Stromal Stem Cells From Adipose Tissue and Bone Marrow of Age Matched
   Female Donors Display Distinct Immunophenotypic Profiles
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID CIRCADIAN MECHANISMS; HUMAN ADIPOCYTES; GENE EXPRESSION; TNF ALPHA;
   DIFFERENTIATION; PROTEIN; OBESITY; CULTURE; FAT; GLUCOCORTICOIDS
AB Adipose tissue is composed of lipid filled mature adipocytes and a heterogeneous stromal vascular fraction (SVF) population of cells. Similarly, the bone marrow (BM) is composed of multiple cell types including adipocytes, hematopoietic, osteoprogenitor, and stromal cells necessary to support hematopoiesis. Both adipose and BM contain a population of mesenchymal stromalstem cells with the potential to differentiate into multiple lineages, including adipogenic, chondrogenic, and osteogenic cells, depending on the culture conditions. In this study we have shown that human adipose derived stem cells (ASCs) and bone marrow mesenchymal stem cells (BMSCs) populations display a common expression profile for many surface antigens, including CD29, CD49c, CD147, CD166, and HLA abc. Nevertheless, significant differences were noted in the expression of CD34 and its related protein, PODXL, CD36, CD 49f, CD106, and CD146. Furthermore, ASCs displayed more pronounced adipogenic differentiation capability relative to BMSC based on Oil Red staining (7 fold vs. 2.85 fold induction). In contrast, no difference between the stem cell types was detected for osteogenic differentiation based on Alizarin Red staining. Analysis by RT PCR demonstrated that both the ASC and BMSC differentiated adipocytes and osteoblast displayed a significant upregulation of lineage specific mRNAs relative to the undifferentiated cell populations; no significant differences in fold mRNA induction was noted between ASCs and BMSCs. In conclusion, these results demonstrate human ASCs and BMSCs display distinct immunophenotypes based on surface positivity and expression intensity as well as differences in adipogenic differentiation. The findings support the use of both human ASCs and BMSCs for clinical regenerative medicine. J. Cell. Physiol. 226: 843 851, 2011. (C) 2010 Wiley Liss, Inc.
C1 [Pachon Pena, G.; Vendrell, J.] Univ Rovira & Virgili, IISPV, Univ Hosp Tarragona Joan XXIII, CIBERDEM, Tarragona, Spain.
   [Yu, G.; Wu, X.; Gimble, J. M.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Stem Cell Biol Lab, Baton Rouge, LA USA.
   [Tucker, A.; Bunnell, B. A.] Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA.
   [Bunnell, B. A.] Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA.
C3 Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere
   Virgili (IISPV); CIBER   Centro de Investigacion Biomedica en Red;
   CIBERDEM; Louisiana State University System; Louisiana State University;
   Pennington Biomedical Research Center; Tulane University; Tulane
   University
RP Bunnell, BA (通讯作者)，Tulane Ctr Stem Cell Res & Regenerat Med, J Bennett Johnston Bldg,1324 Tulane Ave,SL 99, New Orleans, LA 70112 USA.
EM bbunnell@tulane.edu
RI Vendrell, Joan/V 4034 2018; Vendrell Ortega, Joan Josep/V 4034 2018
OI Bunnell, Bruce/0000 0001 6196 3722; Vendrell Ortega, Joan
   Josep/0000 0002 6994 6115
FU Pennington Biomedical Research Center; Clinical Nutrition Research Unit
   [P30 DK072476]; NIDDK; NHLBI [P01 HL75161]; Louisiana Gene Therapy
   Research Consortium; Tulane University
FX Contract grant sponsor: Pennington Biomedical Research Center. Contract
   grant sponsor: Clinical Nutrition Research Unit; Contract grant number:
   P30 DK072476. Contract grant sponsor: NIDDK. Contract grant sponsor:
   NHLBI; Contract grant number: P01 HL75161. Contract grant sponsor:
   Louisiana Gene Therapy Research Consortium. Contract grant sponsor:
   Tulane University
CR ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665
   Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Bunnell Bruce A., 2008, V456, P155, DOI 10.1007/978 1 59745 245 8_12
   Cousin S, 2001, J CELL PHYSIOL, V186, P380, DOI 10.1002/1097 4652(2001)9999:9999<000::AID JCP1038>3.0.CO;2 T
   Dawn B, 2005, BASIC RES CARDIOL, V100, P494, DOI 10.1007/s00395 005 0552 5
   De Ugarte DA, 2003, CELLS TISSUES ORGANS, V174, P101, DOI 10.1159/000071150
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dubois S GHY D., 2005, Adipocytes, V1, P139
   Dubois Severine G., 2008, V449, P69, DOI 10.1007/978 1 60327 169 1_5
   Eilertsen KJ, 2008, CRIT REV EUKAR GENE, V18, P189, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.10
   Estes BT, 2004, CURR TOP DEV BIOL, V60, P91
   Flegal KM, 2010, JAMA J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074 7696(08)60092 3
   Gimble JM, 2009, OBES REV, V10, P46, DOI 10.1111/j.1467 789X.2009.00661.x
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Gimble JM, 2003, EXPERT OPIN BIOL TH, V3, P705, DOI 10.1517/eobt.3.5.705.21230
   Goh BC, 2007, BIOCHEM BIOPH RES CO, V360, P828, DOI 10.1016/j.bbrc.2007.06.136
   Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138
   Guilak F, 2006, J CELL PHYSIOL, V206, P229, DOI 10.1002/jcp.20463
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Halvorsen YDC, 2001, METABOLISM, V50, P407, DOI 10.1053/meta.2001.21690
   Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068
   Koç ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791
   Larson BL, 2008, STEM CELLS, V26, P193, DOI 10.1634/stemcells.2007 0524
   Lee RH, 2009, BLOOD, V113, P816, DOI 10.1182/blood 2007 12 128702
   McIntosh K, 2006, STEM CELLS, V24, P1246, DOI 10.1634/stemcells.2005 0235
   Mesimäki K, 2009, INT J ORAL MAX SURG, V38, P201, DOI 10.1016/j.ijom.2009.01.001
   Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005 0234
   Morrison RF, 1999, J CELL BIOCHEM, P59
   Nie J, 2009, J BIOL CHEM, V284, P1279, DOI 10.1074/jbc.M808285200
   Ozkurt IC, 2004, ENDOCRINOLOGY, V145, P3696, DOI 10.1210/en.2003 1436
   Ozkurt IC, 2003, J BIOL CHEM, V278, P26803, DOI 10.1074/jbc.M212652200
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Sen A, 2001, J CELL BIOCHEM, V81, P312, DOI 10.1002/1097 4644(20010501)81:2<312::AID JCB1046>3.0.CO;2 Q
   Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805
   Strem Brian M., 2005, Keio Journal of Medicine, V54, P132, DOI 10.2302/kjm.54.132
   Wang BH, 2005, AM J PHYSIOL ENDOC M, V288, pE731, DOI 10.1152/ajpendo.00475.2004
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Wolfe Margaret, 2008, V449, P3, DOI 10.1007/978 1 60327 169 1_1
   Wood IS, 2005, BIOCHEM BIOPH RES CO, V337, P422, DOI 10.1016/j.bbrc.2005.09.068
   Wu XY, 2008, BONE, V42, P861, DOI 10.1016/j.bone.2007.12.226
   Wu XY, 2007, OBESITY, V15, P2560, DOI 10.1038/oby.2007.308
   Wu ZD, 1996, MOL CELL BIOL, V16, P4128
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yu G, 2010, CYTOTHERAPY, V12, P538, DOI 10.3109/14653241003649528
   Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
   Zvonic S, 2006, DIABETES, V55, P962, DOI 10.2337/diabetes.55.04.06.db05 0873
NR 56
TC 142
Z9 154
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2011
VL 226
IS 3
BP 843
EP 851
DI 10.1002/jcp.22408
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 720CP
UT WOS:000287258100029
PM 20857424
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Attar Schneider, O
   Pasmanik Chor, M
   Tartakover Matalon, S
   Drucker, L
   Lishner, M
AF Attar Schneider, Oshrat
   Pasmanik Chor, Metsada
   Tartakover Matalon, Shelly
   Drucker, Liat
   Lishner, Michael
TI eIF4E and eIF4GI have distinct and differential imprints on multiple
   myeloma's proteome and signaling
SO ONCOTARGET
LA English
DT Article
DE Multiple Myeloma; Translation initiation; eIF4GI; eIF4E; Bioinformatics
ID TRANSLATION INITIATION FACTOR; INTERNAL RIBOSOME ENTRY;
   CELL PROLIFERATION; MESSENGER RNA; OSTEOBLAST DIFFERENTIATION;
   EPITHELIAL CELLS; VACCINIA VIRUS; CANCER THERAPY; BREAST CANCER;
   IN VITRO
AB Accumulating data indicate translation plays a role in cancer biology, particularly its rate limiting stage of initiation. Despite this evolving recognition, the function and importance of specific translation initiation factors is unresolved. The eukaryotic translation initiation complex eIF4F consists of eIF4E and eIF4G at a 1:1 ratio. Although it is expected that they display interdependent functions, several publications suggest independent mechanisms.
   This study is the first to directly assess the relative contribution of eIF4F components to the expressed cellular proteome, transcription factors, microRNAs, and phenotype in a malignancy known for extensive protein synthesis multiple myeloma (MM). Previously, we have shown that eIF4E/eIF4GI attenuation (siRNA/Avastin) deleteriously affected MM cells' fate and reduced levels of eIF4E/eIF4GI established targets. Here, we demonstrated that eIF4E/eIF4GI indeed have individual influences on cell proteome. We used an objective, high throughput assay of mRNA microarrays to examine the significance of eIF4E/eIF4GI silencing to several cellular facets such as transcription factors, microRNAs and phenotype. We showed different imprints for eIF4E and eIF4GI in all assayed aspects. These results promote our understanding of the relative contribution and importance of eIF4E and eIF4GI to the malignant phenotype and shed light on their function in eIF4F translation initiation complex.
C1 [Attar Schneider, Oshrat; Tartakover Matalon, Shelly; Drucker, Liat; Lishner, Michael] Meir Med Ctr, Oncogenet Lab, Kefar Sava, Israel.
   [Lishner, Michael] Meir Med Ctr, Dept Internal Med, Kefar Sava, Israel.
   [Attar Schneider, Oshrat; Tartakover Matalon, Shelly; Drucker, Liat; Lishner, Michael] Tel Aviv Univ, Sackler Fac Med, IL 69978 Tel Aviv, Israel.
   [Pasmanik Chor, Metsada] Tel Aviv Univ, Bioinformat Unit, GSW Fac Life Sci, IL 69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv University
RP Drucker, L (通讯作者)，Meir Med Ctr, Oncogenet Lab, Kefar Sava, Israel.
EM druckerl@clalit.org.il
CR Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004
   Attar Schneider O, 2014, CELL SIGNAL, V26, P1878, DOI 10.1016/j.cellsig.2014.05.005
   Attar Schneider O, 2012, LAB INVEST, V92, P178, DOI 10.1038/labinvest.2011.162
   Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806
   Barnhart BC, 2007, J CLIN INVEST, V117, P2385, DOI 10.1172/JCI33107
   Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Boras Granic K, 2006, DEV BIOL, V295, P219, DOI 10.1016/j.ydbio.2006.03.030
   Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019
   Cenci S, 2007, FEBS LETT, V581, P3652, DOI 10.1016/j.febslet.2007.04.031
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025
   Damiano F, 2010, BIOCHEM J, V429, P603, DOI 10.1042/BJ20091827
   Gilbert WV, 2010, J BIOL CHEM, V285, P29033, DOI 10.1074/jbc.R110.150532
   Hanson PJ, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00092
   Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078 0432.CCR 08 2822
   Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471 4892(03)00071 7
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kentsis A, 2005, RNA, V11, P1762, DOI 10.1261/rna.2238705
   KOEFFLER HP, 1980, BLOOD, V56, P344
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Kovacs E, 2006, THESCIENTIFICWORLDJO, V6, P888, DOI 10.1100/tsw.2006.178
   Larsson O, 2007, CANCER RES, V67, P6814, DOI 10.1158/0008 5472.CAN 07 0752
   Larsson O, 2006, NUCLEIC ACIDS RES, V34, P4375, DOI 10.1093/nar/gkl558
   Li XS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 26
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lin CJ, 2008, CANCER RES, V68, P5326, DOI 10.1158/0008 5472.CAN 07 5876
   Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242
   Martin SK, 2011, LEUKEMIA, V25, P1533, DOI 10.1038/leu.2011.122
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Montanaro L, 2004, CELL CYCLE, V3, P1387, DOI 10.4161/cc.3.11.1251
   Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Osadchy A, 2004, EUR J HAEMATOL, V73, P183, DOI 10.1111/j.1600 0609.2004.00284.x
   Piccirillo CA, 2014, NAT IMMUNOL, V15, P503, DOI 10.1038/ni.2891
   Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573
   Ramírez Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Semenza GL, 2006, NOVART FDN SYMP, V272, p[2, 8, 33]
   Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954
   Sevilla L, 1999, MOL CELL BIOL, V19, P2624
   Sharan R, 2003, BIOINFORMATICS, V19, P1787, DOI 10.1093/bioinformatics/btg232
   Shatsky IN, 2014, CRIT REV BIOCHEM MOL, V49, P164, DOI 10.3109/10409238.2014.887051
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502 e131
   Shiroki K, 2002, NUCLEIC ACIDS RES, V30, P2851, DOI 10.1093/nar/gkf408
   Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900
   Sterpetti P, 2006, AM J PHYSIOL GASTR L, V290, pG624, DOI 10.1152/ajpgi.00128.2005
   Tao L, 2006, CANCER CHEMOTH PHARM, V58, P24, DOI 10.1007/s00280 005 0137 x
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Welnowska E, 2009, J MOL BIOL, V394, P506, DOI 10.1016/j.jmb.2009.09.036
   Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369
   Xu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079752
   Yanagiya A, 2009, MOL CELL BIOL, V29, P1661, DOI 10.1128/MCB.01187 08
   Yang Yu Jie, 2003, Ai Zheng, V22, P1023
   Zaborowska I, 2012, VIROLOGY, V425, P11, DOI 10.1016/j.virol.2011.12.022
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhao JN, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746 1596 9 76
   Zhou YM, 2010, P NATL ACAD SCI USA, V107, P7904, DOI 10.1073/pnas.0908441107
   Zismanov V, 2009, BRIT J CANCER, V101, P1402, DOI 10.1038/sj.bjc.6605291
   Zismanov V, 2015, INT J ONCOL, V46, P860, DOI 10.3892/ijo.2014.2774
NR 60
TC 11
Z9 12
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2015
VL 6
IS 6
BP 4315
EP 4329
DI 10.18632/oncotarget.3008
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CF6WB
UT WOS:000352696200067
PM 25717031
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Elsaadany, M
   Subramanian, G
   Ayan, H
   Yildirim Ayan, E
AF Elsaadany, Mostafa
   Subramanian, Gayathri
   Ayan, Halim
   Yildirim Ayan, Eda
TI Exogenous nitric oxide (NO) generated by NO plasma treatment modulates
   osteoprogenitor cells early differentiation
SO JOURNAL OF PHYSICS D APPLIED PHYSICS
LA English
DT Article
DE bone regeneration; nitric oxide; plasma medicine; osteoprogenitor cells
ID MESENCHYMAL STEM CELLS; DIELECTRIC BARRIER DISCHARGE; SUB SONIC
   VIBRATION; PULSED ELECTROMAGNETIC FIELDS; OSTEOBLAST LIKE CELLS;
   BONE MINERAL DENSITY; OSTEOGENIC DIFFERENTIATION; NEURAL
   DIFFERENTIATION; NEURONAL DIFFERENTIATION; SYNTHASE EXPRESSION
AB In this study, we investigated whether nitric oxide (NO) generated using a non thermal plasma system can mediate osteoblastic differentiation of osteoprogenitor cells without creating toxicity. Our objective was to create an NO delivery mechanism using NO dielectric barrier discharge (DBD) plasma that can generate and transport NO with controlled concentration to the area of interest to regulate osteoprogenitor cell activity. We built a non thermal atmospheric pressure DBD plasma nozzle system based on our previously published design and similar designs in the literature. The electrical and spectral analyses demonstrated that N 2 dissociated into NO under typical DBD voltage current characteristics. We treated osteoprogenitor cells (MC3T3 E1) using NO plasma treatment system. Our results demonstrated that we could control NO concentration within cell culture media and could introduce NO into the intracellular space using NO plasma treatment with various treatment times. We confirmed that NO plasma treatment maintained cell viability and did not create any toxicity even with prolonged treatment durations. Finally, we demonstrated that NO plasma treatment induced early osteogenic differentiation in the absence of pro osteogenic growth factors/proteins. These findings suggest that through the NO plasma treatment system we are able to generate and transport tissue specific amounts of NO to an area of interest to mediate osteoprogenitor cell activity without subsequent toxicity. This opens up the possibility to develop DBD plasma assisted tissue specific NO delivery strategies for therapeutic intervention in the prevention and treatment of bone diseases.
C1 [Elsaadany, Mostafa; Subramanian, Gayathri; Ayan, Halim; Yildirim Ayan, Eda] Univ Toledo, Coll Engn, Dept Bioengn, Toledo, OH 43606 USA.
   [Ayan, Halim] Univ Toledo, Coll Engn, Dept Mech Ind & Mfg Engn, Toledo, OH 43606 USA.
   [Yildirim Ayan, Eda] Univ Toledo, Med Ctr, Dept Orthopaed Surg, Toledo, OH 43614 USA.
C3 University System of Ohio; University of Toledo; University System of
   Ohio; University of Toledo; University System of Ohio; University of
   Toledo
RP Elsaadany, M (通讯作者)，Univ Toledo, Coll Engn, Dept Bioengn, Toledo, OH 43606 USA.
EM eda.yildirimayan@utoledo.edu
RI Elsaadany, Mostafa/I 1596 2019
OI Elsaadany, Mostafa/0000 0001 9388 8149
FU deArce Koch Memorial Endowment Fund in Support of Medical Research and
   Development
FX This work is supported by deArce Koch Memorial Endowment Fund in Support
   of Medical Research and Development.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Arjunan KP, 2011, PLASMA PROCESS POLYM, V8, P1154, DOI 10.1002/ppap.201100078
   Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799
   Ayan H, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022 3727/42/12/125202
   Ayan H, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3638062
   Ayan H, 2009, IEEE T PLASMA SCI, V37, P113, DOI 10.1109/TPS.2008.2006899
   Baylan N, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/4/045011
   Bialorucki C, 2014, J MECH BEHAV BIOMED, V38, P143, DOI 10.1016/j.jmbbm.2014.06.018
   Cho H, 2012, J TISSUE ENG REGEN M, V6, P411
   Cho H, 2012, LIFE SCI, V90, P591, DOI 10.1016/j.lfs.2012.02.014
   Choi YK, 2012, J TISSUE ENG REGEN M, V6, P411
   Choi YK, 2014, APPL BIOCHEM BIOTECH, V174, P1233, DOI 10.1007/s12010 014 1091 z
   Choi YK, 2012, LIFE SCI, V91, P329, DOI 10.1016/j.lfs.2012.07.022
   Coleman JW, 2002, CLIN EXP IMMUNOL, V129, P4, DOI 10.1046/j.1365 2249.2002.01918.x
   Corbett SA, 1999, J BONE JOINT SURG BR, V81B, P531, DOI 10.1302/0301 620X.81B3.8852
   Daeschlein G, 2012, J HOSP INFECT, V81, P177, DOI 10.1016/j.jhin.2012.02.012
   Ding HW, 2012, J CELL SCI, V125, P5564, DOI 10.1242/jcs.081703
   Dobrynin D, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022 3727/44/7/075201
   Esposito M, 2013, IN VIVO, V27, P495
   Graves DB, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022 3727/45/26/263001
   Gutiérrez OM, 2011, OSTEOPOROSIS INT, V22, P1745, DOI 10.1007/s00198 010 1383 2
   Hall CN, 2008, J PHYSIOL LONDON, V586, P3597, DOI 10.1113/jphysiol.2008.154724
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Hukkanen MVJ, 1999, J BONE MINER RES, V14, P868, DOI 10.1359/jbmr.1999.14.6.868
   Jamal SA, 2013, OSTEOPOROSIS INT, V24, P763, DOI 10.1007/s00198 012 2262 9
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   JUDD HL, 1981, OBSTET GYNECOL, V58, P267
   Kalghatgi S, 2010, ANN BIOMED ENG, V38, P748, DOI 10.1007/s10439 009 9868 x
   Kanamaru Yuichi, 2001, Kobe Journal of Medical Sciences, V47, P1
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Khatun H, 2008, INDIAN J PURE AP PHY, V46, P889
   Kim MO, 2015, INT J MOL MED, V35, P153, DOI 10.3892/ijmm.2014.1978
   Lestinská L, 2011, J QUANT SPECTROSC RA, V112, P2779, DOI 10.1016/j.jqsrt.2011.09.006
   Li Y, 2011, CELL BIOL INT, V35, P757, DOI 10.1042/CBI20100832
   Liebmann J, 2011, NITRIC OXIDE BIOL CH, V24, P8, DOI 10.1016/j.niox.2010.09.005
   Lin IC, 2008, PLAST RECONSTR SURG, V121, P1554, DOI 10.1097/PRS.0b013e31816c3bd7
   Ma QL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090041
   Machala Z, 2007, J MOL SPECTROSC, V243, P194, DOI 10.1016/j.jms.2007.03.001
   Morrison A, 2013, CLINICOECONOMIC OUTC, V5, P9, DOI 10.2147/CEOR.S38721
   Nichols SP, 2012, ADV DRUG DELIVER REV, V64, P1177, DOI 10.1016/j.addr.2012.03.002
   Nie DX, 2011, SPECTROCHIM ACTA A, V79, P1896, DOI 10.1016/j.saa.2011.05.083
   Olivier S, 2005, BIOCHEM PHARMACOL, V69, P891, DOI 10.1016/j.bcp.2004.11.030
   Pacifici R, 2008, CELL IMMUNOL, V252, P68, DOI 10.1016/j.cellimm.2007.06.008
   Pal UN, 2010, J PHYS CONF SER, V208, DOI 10.1088/1742 6596/208/1/012142
   Pan W, 2005, J CELL BIOCHEM, V94, P307, DOI 10.1002/jcb.20308
   Park JK, 2012, J TISSUE ENG REGEN M, V6, P409
   Park JE, 2013, NEUROCHEM INT, V62, P418, DOI 10.1016/j.neuint.2013.02.002
   Park JW, 2008, J BIOMED MATER RES A, V86A, P117, DOI 10.1002/jbm.a.31618
   Prè D, 2011, BONE, V49, P295, DOI 10.1016/j.bone.2011.04.013
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   Saura M, 2010, THESCIENTIFICWORLDJO, V10, P624, DOI 10.1100/tsw.2010.58
   Schappe RS, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.042701
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Sensenig R, 2011, ANN BIOMED ENG, V39, P674, DOI 10.1007/s10439 010 0197 x
   Song MY, 2014, CELL BIOCHEM BIOPHYS, V69, P47, DOI 10.1007/s12013 013 9764 8
   Song MY, 2014, BIOELECTROMAGNETICS, V35, P479, DOI 10.1002/bem.21867
   Stacey E, 1998, J CLIN ENDOCR METAB, V83, P3056, DOI 10.1210/jc.83.9.3056
   Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Steinbeck MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082143
   Stephens Alexandre S, 2011, BMC Res Notes, V4, P410, DOI 10.1186/1756 0500 4 410
   Thomas DD, 2008, FREE RADICAL BIO MED, V45, P18, DOI 10.1016/j.freeradbiomed.2008.03.020
   Tian Y, 2012, CELL BIOCHEM BIOPHYS, V64, P169, DOI 10.1007/s12013 012 9369 7
   Tirkkonen L, 2011, J R SOC INTERFACE, V8, P1736, DOI 10.1098/rsif.2011.0211
   Valassi E, 2012, ENDOCR PRACT, V18, P209, DOI 10.4158/EP11134.OR
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   Wimalawansa SJ, 2010, ANN NY ACAD SCI, V1192, P391, DOI 10.1111/j.1749 6632.2009.05230.x
   Wu AS, 2013, J SURG RES, V179, pE1, DOI 10.1016/j.jss.2012.02.039
   Xia Y, 2004, ENDOCRINOLOGY, V145, P4550, DOI 10.1210/en.2004 0327
   Xiao ZS, 2001, KIDNEY INT, V60, P1699, DOI 10.1046/j.1523 1755.2001.00011.x
   Xiong Z, 2014, STEM CELL RES, V12, P387, DOI 10.1016/j.scr.2013.11.003
   Yan QA, 2010, ARTHRITIS RHEUM US, V62, P2013, DOI 10.1002/art.27486
   Yang LQ, 2013, INT IMMUNOPHARMACOL, V17, P383, DOI 10.1016/j.intimp.2013.06.021
   Zhang CC, 2012, ARCH ORAL BIOL, V57, P1395, DOI 10.1016/j.archoralbio.2012.04.010
NR 75
TC 17
Z9 19
U1 0
U2 37
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0022 3727
EI 1361 6463
J9 J PHYS D APPL PHYS
JI J. Phys. D Appl. Phys.
PD SEP 4
PY 2015
VL 48
IS 34
AR 345401
DI 10.1088/0022 3727/48/34/345401
PG 14
WC Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physics
GA CP1XJ
UT WOS:000359670600014
DA 2025 08 17
ER

PT J
AU Mele, C
   Maggioni, G
   Giordano, A
   Lunardon, C
   Balsamo, F
   Mazzone, A
   Pistarini, C
AF Mele, Chiara
   Maggioni, Giorgio
   Giordano, Andrea
   Lunardon, Clara
   Balsamo, Francesca
   Mazzone, Alessandra
   Pistarini, Caterina
TI A Retrospective Study on Statins and Post stroke Patients: What About
   Functional Outcome and Follow Up in a Stroke Rehabilitation Cohort?
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE statin; stroke; disability; functional outcome; follow up
ID ACUTE ISCHEMIC STROKE; OSTEOBLAST DIFFERENTIATION; REDUCTASE INHIBITORS;
   SIMVASTATIN; FRACTURE; RISK; PREVENTION; NEUROPROTECTION;
   CLASSIFICATION; ACTIVATOR
AB Objective: Statins exert pleiotropic effects by influencing several mechanisms, including synaptogenesis, neurogenesis, cerebral flow regulation, and angiogenesis. Results from in vitro and animal models suggest that statins could have beneficial effect on functional recovery and outcome after stroke events. However, results in human studies are still controversial. The aim of our study was to evaluate the role of statin in influencing functional outcome and subsequent clinical follow up in a large cohort of post stroke rehabilitation patients.
   Methods: This retrospective study consecutively enrolled 413 adult patients with stroke event, admitted to the division of Neurorehabilitation of the IRCCS ICS Maugeri, Veruno (Italy), for an individual rehabilitation program between 2015 and 2017. Follow up lasted 3 5 years after discharge. Demographic data, etiology, classification, and anatomical site of stroke lesion, functional assessment, use and duration of statin therapy, and death during hospitalization were collected at baseline and on discharge. Clinical data on subsequent follow up were also evaluated, considering these as variables: stroke recurrence, bone fractures, cardiovascular complications, and death.
   Results: In our cohort, 177 patients (42.9%) were prescribed statin therapy, of whom 50 (28.2%) before the stroke event and 127 (71.8%) at the beginning of the rehabilitation process. The use and type of statin therapy as well as the duration of treatment were not associated with recovery and functional outcome, regardless of confounders including sex, age, etiology, and site of stroke lesion, and initial functional level. For what concern post discharge clinical follow up, the use of statin therapy was significantly associated with a lower risk of bone fractures (OR = 0.095, CI 95%: 0.012 0.743, p = 0.01) independently from age, sex, initial and final functional level, and comorbidities.
   Conclusions: The use of statins does not seem to influence the functional outcome in post stroke patients. However, they could exert a protective role against bone fractures during post discharge follow up, suggesting further evaluation on this topic.
C1 [Mele, Chiara] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
   [Maggioni, Giorgio; Lunardon, Clara; Balsamo, Francesca] Ist Ricovero & Cura Carattere Sci IRCCS, Neurorehabil Div, Ist Clin Sci Maugeri SPA SB, Inst Veruno, Novara, Italy.
   [Giordano, Andrea; Mazzone, Alessandra] Ist Ricovero & Cura Carattere Sci IRCCS, Bioengn Div, Ist Clin Sci Maugeri SPA SB, Inst Veruno, Novara, Italy.
   [Pistarini, Caterina] Ist Ricovero & Cura Carattere Sci IRCCS, Dept Phys & Rehabil Med, Inst Genoa Nervi, Ist Clin Sci Maugeri SPA SB, Genoa, Italy.
C3 University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS;
   Istituti Clinici Scientifici Maugeri IRCCS; Istituti Clinici Scientifici
   Maugeri IRCCS
RP Mele, C (通讯作者)，Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
EM chiara.mele1989@gmail.com
RI Pistarini, CATERINA/K 5234 2018; Giordano, Andrea/E 8442 2019;
   Pistarini, Caterina/K 5234 2018; Mele, Chiara/ABG 2902 2020
OI Mele, Chiara/0000 0003 2880 9373; Pistarini,
   Caterina/0000 0001 8925 0484; 
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Amarenco P, 2006, NEW ENGL J MED, V355, P549
   Amin Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980
   Arboix A, 2010, BMC NEUROL, V10, DOI 10.1186/1471 2377 10 47
   Aslanyan S, 2005, EUR J NEUROL, V12, P493, DOI 10.1111/j.1468 1331.2005.01049.x
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140 6736(05)67394 1
   BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140 6736(91)93206 O
   Berger C, 2008, BRAIN RES REV, V58, P48, DOI 10.1016/j.brainresrev.2007.10.010
   Biffi A, 2011, STROKE, V42, P1314, DOI 10.1161/STROKEAHA.110.605923
   Callaly EL, 2015, AGE AGEING, V44, P882, DOI 10.1093/ageing/afv093
   Carda S, 2009, CEREBROVASC DIS, V28, P191, DOI 10.1159/000226578
   Chen CJ, 2019, NEUROLOGY, V93, P1056, DOI 10.1212/WNL.0000000000008627
   Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555
   Chou R, 2016, JAMA J AM MED ASSOC, V316, P2008, DOI 10.1001/jama.2015.15629
   Chróinín DN, 2011, STROKE, V42, P1021, DOI 10.1161/STROKEAHA.110.596734
   Cimino A, 2005, NEUROTOXICOLOGY, V26, P929, DOI 10.1016/j.neuro.2005.03.009
   Cummings SR, 2016, J BONE MINER RES, V31, P2069, DOI 10.1002/jbmr.3030
   Elkind MSV, 2005, NEUROLOGY, V65, P253, DOI 10.1212/01.WNL.0000171746.63844.6a
   Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880
   Goldstein LB, 2009, STROKE, V40, P3526, DOI 10.1161/STROKEAHA.109.557330
   Grefkes C, 2020, NEUROL RES PRACT, V2, DOI 10.1186/s42466 020 00060 6
   HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003 9993(93)90153 2
   Helin Salmivaara A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048095
   Hudon C, 2005, J CLIN EPIDEMIOL, V58, P603, DOI 10.1016/j.jclinepi.2004.10.017
   Huo Kang, 2016, World J Exp Med, V6, P1, DOI 10.5493/wjem.v6.i1.1
   Jin SL, 2015, INT J CLIN EXP MED, V8, P8269
   Kennedy J, 2007, LANCET NEUROL, V6, P961, DOI 10.1016/S1474 4422(07)70250 8
   LaCroix AZ, 2003, ANN INTERN MED, V139, P97, DOI 10.7326/0003 4819 139 2 200307150 00009
   Lin SM, 2018, J CLIN ENDOCR METAB, V103, P3439, DOI 10.1210/jc.2018 00652
   LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127
   LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532 5415.1968.tb02103.x
   Mackintosh S, 2009, AUST J PHYSIOTHER, V55, P65, DOI 10.1016/S0004 9514(09)70066 2
   Marques JS, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.14421
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Miedema I, 2010, CEREBROVASC DIS, V29, P263, DOI 10.1159/000275500
   Monjo M, 2010, CELL PHYSIOL BIOCHEM, V26, P647, DOI 10.1159/000322332
   Montaner J, 2008, EUR J NEUROL, V15, P82, DOI 10.1111/j.1468 1331.2007.02015.x
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Peña JM, 2015, JAMA INTERN MED, V175, P171, DOI 10.1001/jamainternmed.2014.6388
   Reeves MJ, 2008, STROKE, V39, P1779, DOI 10.1161/STROKEAHA.107.501700
   Silva SM, 2020, DISABIL REHABIL, V42, P156, DOI 10.1080/09638288.2018.1496149
   Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B
   Vaughan CJ, 2003, AM J CARDIOL, V91, p23B, DOI 10.1016/S0002 9149(02)03270 8
   Wada Y, 2000, ARCH INTERN MED, V160, P2865, DOI 10.1001/archinte.160.18.2865
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
NR 46
TC 4
Z9 4
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2295
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 21
PY 2021
VL 12
AR 744732
DI 10.3389/fneur.2021.744732
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA WU6DK
UT WOS:000716633900001
PM 34744982
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lapi, F
   Cipriani, F
   Caputi, AP
   Corrao, G
   Vaccheri, A
   Sturkenboom, MC
   Di Bari, M
   Gregori, D
   Carle, F
   Staniscia, T
   Vestri, A
   Brandi, M
   Fusco, V
   Campisi, G
   Mazzaglia, G
AF Lapi, F.
   Cipriani, F.
   Caputi, A. P.
   Corrao, G.
   Vaccheri, A.
   Sturkenboom, M. C.
   Di Bari, M.
   Gregori, D.
   Carle, F.
   Staniscia, T.
   Vestri, A.
   Brandi, M.
   Fusco, V.
   Campisi, G.
   Mazzaglia, G.
CA Bisphosphonates Efficacy Safety
TI Assessing the risk of osteonecrosis of the jaw due to bisphosphonate
   therapy in the secondary prevention of osteoporotic fractures
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bisphosphonates; Nested case control study; Osteonecrosis of the jaw;
   Osteoporotic fractures
ID ORAL BISPHOSPHONATES; ASSOCIATION; SURGERY; PROFILE
AB There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized.
   The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ.
   An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case control study within a cohort of individuals aged 55+ years old, who were discharged from hospitals with a primary diagnosis of incident osteoporotic fracture. The date related to the discharge diagnosis of ONJ was the index date. Conditional logistic regression for matched data was fitted to estimate the odds ratio (OR) along with 95 % confidence intervals (95 % CI) for the likely association between use of BPs and the risk of ONJ.
   Any one of the 61 ascertained cases of ONJ (incidence rate, 36.6 per 100,000 person years) was matched to 20 controls for a total of 1120 controls. When the exposure to BPs was modeled according to recency (i.e., exposure time window prior to the index date) of use, the adjusted OR (95 % CI) for current users was 2.8 (1.3 5.9) against never users. The cumulative use of BPs has shown to increase the incidence of ONJ among patients with primary osteoporotic fractures, although not statistically significant risk has been observed.
   Although the risk of BP related ONJ appears low in non oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.
C1 [Lapi, F.; Cipriani, F.; Mazzaglia, G.] Reg Agcy Healthcare Serv Tuscany, Florence, Italy.
   [Lapi, F.] Univ Florence, Dept Preclin & Clin Pharmacol, I 50139 Florence, Italy.
   [Lapi, F.] McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada.
   [Caputi, A. P.] Univ Messina, Dept Med & Pharmacol, Messina, Italy.
   [Corrao, G.] Univ Milano Bicocca, Unit Biostat & Epidemiol, Dept Stat, Milan, Italy.
   [Vaccheri, A.] Univ Bologna, Dept Pharmacol, Bologna, Italy.
   [Sturkenboom, M. C.; Mazzaglia, G.] Erasmus MC, Pharmacoepidemiol Unit, Dept Med Informat, Rotterdam, Netherlands.
   [Di Bari, M.] Univ Florence, Unit Gerontol & Geriatr, Dept Crit Care Med & Surg, Florence, Italy.
   [Gregori, D.] Univ Padua, Dept Publ Hlth & Environm Med, Padua, Italy.
   [Carle, F.] Polytech Univ Marche, Ctr Epidemiol Biostat & Med Informat Technol, Ancona, Italy.
   [Staniscia, T.] Univ G DAnnunzio, Dept Med & Aging, Chieti, Italy.
   [Vestri, A.] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, Rome, Italy.
   [Brandi, M.] Univ Florence, Dept Internal Med, Florence, Italy.
   [Fusco, V.] Alessandria Hosp, Oncol Unit, Alessandria, Italy.
   [Campisi, G.] Univ Palermo, Dept Surg & Oncol Disciplines, Sect Oral Med, Palermo, Italy.
C3 University of Florence; McGill University; Jewish General Hospital  
   Montreal; University of Messina; University of Milano Bicocca;
   University of Bologna; Erasmus University Rotterdam; Erasmus MC;
   University of Florence; University of Padua; Marche Polytechnic
   University; G d'Annunzio University of Chieti Pescara; Sapienza
   University Rome; University of Florence; University of Palermo
RP Lapi, F (通讯作者)，Univ Florence, Dept Preclin & Clin Pharmacol, Viale G Pieraccini 6, I 50139 Florence, Italy.
EM francesco.lapi@unifi.it
RI ; Fusco, Vittorio/HIR 5269 2022; Gregori, Dario/F 9974 2012; DI BARI,
   MAURO/J 1524 2012
OI campisi, giuseppina/0000 0002 9443 0495; Fusco,
   Vittorio/0000 0003 0263 9820; brandi, maria luisa/0000 0002 8741 0592;
   Mazzaglia, Giampiero/0000 0003 4933 2148; Gregori,
   Dario/0000 0001 7906 0580; Di Bari, Mauro/0000 0002 5514 0524;
   Sturkenboom, Miriam/0000 0003 1360 2388
FU Agenzia Italiana del Farmaco (AIFA), Rome, Italy [FARM06R9YY]
FX The study was supported by Agenzia Italiana del Farmaco (AIFA grant
   FARM06R9YY), Rome, Italy. We would like to thank Dr. Laurent Azoulay
   (Department of Oncology, McGill University, Montreal, Canada) for the
   paper revision which he conducted according to the standard peer review
   process. We would also like to thank all the other components of the
   BEST study group who have contributed to the scientific content or
   provided technical support: Emiliano Sessa (Regional Agency for
   Healthcare Services of Tuscany, Florence, Italy); Vincenzo Arcoraci
   (Department of Medicine and Pharmacology, University of Messina, Italy);
   Arianna Ghirardi, Lorenza Scotti, Andrea Parodi, Antonella Zambon (Unit
   of Biostatistics and Epidemiology, Department of Statistics, University
   of Milan Bicocca, Milan, Italy); Carlo Piccinni, Caterina Suzzi, Aurora
   Puccini, Alberto Vaccheri (Department of Pharmacology, University of
   Bologna, Bologna, Italy); Pierangelo Geppetti (Head Unit; Center of
   Pharmacoutilization, Pharmacoepidemiology, Pharmacovigilance, and
   Pharmacoeconomics, University of Florence, Florence, Italy), Lavinia
   Sati (Center of Pharmacoutilization, Pharmacoepidemiology,
   Pharmacovigilance, and Pharmacoeconomics, University of Florence,
   Florence, Italy); Francesca Forlan (Department of Public Health and
   Environmental Medicine, University of Padua, Padua, Italy); Rosaria
   Gesuita (Center of Epidemiology, Biostatistics, and Medical Information
   Technology, Polytechnic University of Marche, Ancona, Italy); Angelo
   Menna (Regional Agency of Healthcare Services of Abruzzi, Chieti,
   Italy); Alessandra Mingarelli, Gianluca Di Tanna (Department of Public
   health and Infectious Disease, University "La Sapienza", Rome, Italy);
   and Marco Valenti (Head Unit; Department of Medicine and Public Health,
   University of L'Aquila, L'Aquila, Italy).
CR Assael LA, 2009, J ORAL MAXIL SURG, V67, P35, DOI 10.1016/j.joms.2009.01.003
   Barasch A, 2011, J DENT RES, V90, P439, DOI 10.1177/0022034510397196
   Beiderbeck AB, 2004, J CLIN EPIDEMIOL, V57, P973, DOI 10.1016/j.jclinepi.2003.12.017
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Curtis JR, 2009, OSTEOPOROSIS INT, V20, P1969, DOI 10.1007/s00198 009 0840 2
   Curtis JR, 2009, MED CARE, V47, P69, DOI 10.1097/MLR.0b013e3181808c05
   Delmas PD, 2008, BONE, V42, P16, DOI 10.1016/j.bone.2007.10.020
   Devold HM, 2010, EUR J CLIN PHARMACOL, V66, P299, DOI 10.1007/s00228 009 0746 0
   Diel IJ, 2007, CRIT REV ONCOL HEMAT, V64, P198, DOI 10.1016/j.critrevonc.2007.07.005
   Edwards BJ, 2008, LANCET ONCOL, V9, P1166, DOI 10.1016/S1470 2045(08)70305 X
   Etminan M, 2008, J RHEUMATOL, V35, P691
   Fusco V, 2010, BREAST, V19, P432, DOI 10.1016/j.breast.2010.03.008
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Jung TI, 2007, J BONE MINER RES, V22, pS113
   Khan AA, 2008, J RHEUMATOL, V35, P1391
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Lapi F, 2012, BONE, V50, P85, DOI 10.1016/j.bone.2011.09.048
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Marini Francesca, 2011, Front Biosci (Elite Ed), V3, P364, DOI 10.2741/e251
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Patrick AR, 2011, PHARMACOEPIDEM DR S, V20, P551, DOI 10.1002/pds.2098
   Pazianas M, 2008, OSTEOPOROSIS INT, V19, P773, DOI 10.1007/s00198 007 0502 1
   Piscitelli P, 2010, OSTEOPOROSIS INT, V21, P1323, DOI 10.1007/s00198 009 1084 x
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sarasquete ME, 2009, ORAL DIS, V15, P382, DOI 10.1111/j.1601 0825.2009.01568.x
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Zavras AI, 2006, J ORAL MAXIL SURG, V64, P917, DOI 10.1016/j.joms.2006.02.011
NR 35
TC 31
Z9 31
U1 0
U2 15
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD FEB
PY 2013
VL 24
IS 2
BP 697
EP 705
DI 10.1007/s00198 012 2013 y
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 080WI
UT WOS:000314274400032
PM 22618266
DA 2025 08 17
ER

PT J
AU Wang, YG
   Huang, YY
   Wang, Y
   Lyu, PJ
   Hamblin, MR
AF Wang, Yuguang
   Huang, Ymg Ying
   Wang, Yong
   Lyu, Peijun
   Hamblin, Michael R.
TI Photobiomodulation of human adipose derived stem cells using 810 nm and
   980 nm lasers operates via different mechanisms of action
SO BIOCHIMICA ET BIOPHYSICA ACTA GENERAL SUBJECTS
LA English
DT Article
DE Photobiomodulation; Adipose derived stem cells; 810 nm; 980 nm;
   Cytochrome c oxidase; Heat gated ion channels
ID DIFFERENT WAVELENGTHS 660; ANIMAL MODEL; IN VITRO; THERAPY; IRRADIATION;
   WATER; OSTEOBLASTS; MUCOSITIS; MEMBRANE; CHANNEL
AB Photobiomodulation (PBM) using red or near infrared (NIR) light has been used to stimulate the proliferation and differentiation of adipose derived stem cells. The use of NIR wavelengths such as 810 nm is reasonably well accepted to stimulate mitochondrial activity and ATP production via absorption of photons by cytochrome c oxidase. However, the mechanism of action of 980 nm is less well understood. Here we study the effects of both wavelengths (810 nm and 980 nm) on adipose derived stem cells in vitro. Both wavelengths showed a biphasic dose response, but 810 nm had a peak dose response at 3 J/cm(2) for stimulation of proliferation at 24 h, while the peak dose for 980 nm was 10 100 times lower at 0.03 or 0.3 J/cm(2). Moreover, 980 nm (but not 810 nm) increased cytosolic calcium while decreasing mitochondrial calcium. The effects of 980 nm could be blocked by calcium channel blockers (capsazepine for TRPV1 and SKF96365 for TRPC channels), which had no effect on 810 nm. To test the hypothesis that the chromophore for 980 nm was intracellular water, which could possibly form a microscopic temperature gradient upon laser irradiation, we added cold medium (4 degrees C) during the light exposure, or pre incubated the cells at 42 degrees C, both of which abrogated the effect of 980 nm but not 810 nm. We conclude that 980 nm affects temperature gated calcium ion channels, while 810 nm largely affects mitochondrial cytochrome c oxidase. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Wang, Yuguang; Wang, Yong; Lyu, Peijun] Peking Univ, Sch & Hosp Stomatol, Ctr Digital Dent, Beijing, Peoples R China.
   [Wang, Yuguang; Wang, Yong; Lyu, Peijun] Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China.
   [Wang, Yuguang; Huang, Ymg Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Wang, Yuguang; Huang, Ymg Ying; Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.
   [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
C3 Peking University; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   Medical School; Harvard University
RP Lyu, PJ (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Ctr Digital Dent, Beijing, Peoples R China.; Hamblin, MR (通讯作者)，Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM kqlpj@bjmu.edu.cn; hamblin@helix.mgh.harvard.edu
RI Hamblin, Michael/H 2758 2019; Huang, Yingying/G 3153 2011; Wang,
   Yu/K 6558 2014; Huang, yingying/J 7329 2012
OI Huang, Yingying/0000 0003 3066 6981; Hamblin, Michael
   R/0000 0001 6431 4605
FU US NIH [R01AI050875]; Air Force Office of Scientific Research
   [FA9550 13 1 0068]; US Army Medical Research Acquisition Activity
   [W81XWH 09 1 0514]; US Army Medical Research and Materiel Command
   [W81XWH 13 2 0067]; PKUSS [PKUSS20140208]; Ministry of Education
   [113002A]
FX This work was supported by US NIH R01AI050875 and by Air Force Office of
   Scientific Research grant FA9550 13 1 0068, US Army Medical Research
   Acquisition Activity grant W81XWH 09 1 0514, and US Army Medical
   Research and Materiel Command grant W81XWH 13 2 0067. Yuguang Wang was
   funded by PKUSS grant PKUSS20140208 and Ministry of Education grant
   113002A.
CR Abramovitch Gottlib L, 2005, LASER MED SCI, V20, P138, DOI 10.1007/s10103 005 0355 9
   Anders JJ, 2015, PHOTOMED LASER SURG, V33, P183, DOI 10.1089/pho.2015.9848
   Anders JJ, 2014, LASER SURG MED, V46, P34, DOI 10.1002/lsm.22212
   Bostanciklioglu M, 2015, LASER MED SCI, V30, P1289, DOI 10.1007/s10103 015 1727 4
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Cafaro A, 2014, LASER MED SCI, V29, P185, DOI 10.1007/s10103 013 1313 6
   Chai BH, 2009, J PHYS CHEM B, V113, P13953, DOI 10.1021/jp908163w
   Choi K, 2013, J BIOMED MATER RES B, V101B, P919, DOI 10.1002/jbm.b.32897
   Choudhery MS, 2015, CYTOTHERAPY, V17, P359, DOI 10.1016/j.jcyt.2014.11.003
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439 011 0454 7
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   de Villiers JA, 2011, STEM CELL REV REP, V7, P869, DOI 10.1007/s12015 011 9244 8
   Ding J, 2012, NEUROSCI BULL, V28, P173, DOI 10.1007/s12264 012 1213 y
   Dukic W, 2013, J PERIODONTOL, V84, P1111, DOI 10.1902/jop.2012.110708
   Eduardo FD, 2008, LASER SURG MED, V40, P433, DOI 10.1002/lsm.20646
   Ferrante M, 2013, LASER MED SCI, V28, P845, DOI 10.1007/s10103 012 1174 4
   Barboza CAG, 2014, EINSTEIN SAO PAULO, V12, P75, DOI 10.1590/S1679 45082014AO2824
   Gu QB, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/857123
   Gupta A, 2013, LASERS MED SCI
   Henderson Theodore A, 2015, Adv Mind Body Med, V29, P27
   Isman E, 2015, LASER MED SCI, V30, P1489, DOI 10.1007/s10103 015 1750 5
   Kushibiki T, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/974864
   Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a
   Lavi R, 2012, PHOTOMED LASER SURG, V30, P14, DOI 10.1089/pho.2011.3083
   Morimoto RI, 2011, COLD SH Q B, V76, P91, DOI 10.1101/sqb.2012.76.010637
   Pal M, 2009, CURR PHARM DESIGN, V15, P1008, DOI 10.2174/138161209787581995
   Park IS, 2014, BIOMATERIALS, V35, P9280, DOI 10.1016/j.biomaterials.2014.07.061
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103 011 1005 z
   Plapler H, 2016, LASER MED SCI, V31, P421, DOI 10.1007/s10103 016 1865 3
   Romanovsky AA, 2009, PHARMACOL REV, V61, P228, DOI 10.1124/pr.109.001263
   Saita E, 2016, BBA MOL CELL BIOL L, V1861, P837, DOI 10.1016/j.bbalip.2016.01.003
   Santana Blank LA, 2005, PHOTOMED LASER SURG, V23, P416, DOI 10.1089/pho.2005.23.416
   Santana Blank L, 2010, PHOTOMED LASER SURG, V28, pS41, DOI 10.1089/pho.2009.2647
   Skopin MD, 2009, PHOTODERMATOL PHOTO, V25, P75, DOI 10.1111/j.1600 0781.2009.00406.x
   Slot DE, 2014, J CLIN PERIODONTOL, V41, P681, DOI 10.1111/jcpe.12233
   Sommer AP, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305 5839.2015.09.18
   Sommer AP, 2015, SCI REP UK, V5, DOI 10.1038/srep12029
   Sydnor M., 2016, PHLEBOLOGY
   Usumez A, 2014, LASER MED SCI, V29, P1807, DOI 10.1007/s10103 013 1336 z
   Vatansever Fatma, 2012, Photonics Lasers Med, V4, P255
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wang Lina, 2014, Cells, V3, P662, DOI 10.3390/cells3030662
   Wong Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003
   Wu ZH, 2010, LASER SURG MED, V42, P503, DOI 10.1002/lsm.20924
   Ytteborg E, 2010, BBA MOL CELL BIOL L, V1801, P127, DOI 10.1016/j.bbalip.2009.10.001
NR 46
TC 157
Z9 165
U1 1
U2 52
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304 4165
EI 1872 8006
J9 BBA GEN SUBJECTS
JI Biochim. Biophys. Acta Gen. Subj.
PD FEB
PY 2017
VL 1861
IS 2
BP 441
EP 449
DI 10.1016/j.bbagen.2016.10.008
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EI7LU
UT WOS:000392680200041
PM 27751953
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Cuscino, N
   Raimondi, L
   De Luca, A
   Carcione, C
   Russelli, G
   Conti, L
   Baldi, J
   Conaldi, PG
   Giavaresi, G
   Gallo, A
AF Cuscino, Nicola
   Raimondi, Lavinia
   De Luca, Angela
   Carcione, Claudia
   Russelli, Giovanna
   Conti, Laura
   Baldi, Jacopo
   Conaldi, Pier Giulio
   Giavaresi, Gianluca
   Gallo, Alessia
TI Gathering Novel Circulating Exosomal microRNA in Osteosarcoma Cell Lines
   and Possible Implications for the Disease
SO CANCERS
LA English
DT Article
DE microRNAs; exosomes; liquid biopsy
ID CANCER; BIOMARKERS; DIAGNOSIS
AB One of the goals of personalized medicine is to understand and treat diseases with greater precision through the molecular profile of the patient. This profiling is becoming a powerful tool for the discovery of novel biomarkers that can guide physicians in assessing, in advance, the disease stage, and monitoring disease progression. Circulating miRNAs and exosomal miRNAs, a group of small non coding RNAs, are considered the gold standard diagnostic biomarkers for human diseases. We have previously demonstrated that osteosarcoma derived exosomes are able to influence crucial mechanisms inside tumor niches, inducing osteoclast differentiation, and sustaining bone resorption activity. Here we discovered, through Next Generation Sequencing (NGS), eight novel microRNAs in three different osteosarcoma cell lines, and assessed the selective packaging into the exosomes released. We then investigated, as proof of principle, the presence of the novel microRNAs in osteosarcoma patient samples, and found that 5 of the 8 novel microRNAs were more present in circulating exosomes of osteosarcoma patients compared with the controls. These results raise a question: Could the 8 novel microRNAs play a role for osteosarcoma pathogenesis? Although still premature, the results are encouraging, and further studies with a validation in a larger cohort are needed.
C1 [Cuscino, Nicola; Russelli, Giovanna; Conaldi, Pier Giulio; Gallo, Alessia] IRCCS ISMETT Ist Mediterraneo & Trapianti & Terap, Res Dept, I 90127 Palermo, Italy.
   [Raimondi, Lavinia; De Luca, Angela; Giavaresi, Gianluca] IRCCS ISTITUTO ORTOPEDICO RIZZOLI, I 40136 Bologna, Italy.
   [Carcione, Claudia] Fdn RiMED, I 90133 Palermo, Italy.
   [Conti, Laura] IRCCS Regina Elena Canc Natl Inst, Clin Pathol, Body Fluids Biobank, I 00100 Rome, Italy.
   [Baldi, Jacopo] IRCCS Regina Elena Natl Canc Inst, Dept Orthopaed Oncol, I 00100 Rome, Italy.
C3 IRCCS Istituto Mediterraneo per i Trapianti e Terapie ad Alta
   Specializzazione (ISMETT)
RP Gallo, A (通讯作者)，IRCCS ISMETT Ist Mediterraneo & Trapianti & Terap, Res Dept, I 90127 Palermo, Italy.
EM ncuscino@ismett.edu; lavinia.raimondi@ior.it; angela.deluca@ior.it;
   ccarcione@fondazionerimed.com; grusselli@ismett.edu;
   laura.conti@ifo.gov.it; jacopo.baldi@ifo.gov.it; pgconaldi@ismett.edu;
   gianluca.giavaresi@ior.it; agallo@ismett.edu
RI ; Conaldi, Pier/AAC 1573 2019; deluca, angela/ABD 3384 2020; De Luca,
   Angela/ABD 3384 2020; Raimondi, Lavinia/K 4085 2016; Giavaresi,
   Gianluca/J 5583 2016; Baldi, Jacopo/AAC 2111 2019
OI , Jacopo/0000 0002 2387 5286; De Luca, Angela/0000 0001 5493 9441;
   Raimondi, Lavinia/0000 0001 9394 2002; Giavaresi,
   Gianluca/0000 0001 7843 5969; cuscino, nicola/0000 0002 2790 7257;
   Conaldi, Pier Giulio/0000 0003 1994 8005; Carcione,
   Claudia/0000 0002 0305 1781
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brase JC, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 306
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 128
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Coulter SJ, 2018, BIOTECHNIQUES, V65, P86, DOI 10.2144/btn 2018 0058
   Friedländer MR, 2012, NUCLEIC ACIDS RES, V40, P37, DOI 10.1093/nar/gkr688
   Hamam R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.440
   Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32
   Li XY, 2018, CANCER LETT, V439, P66, DOI 10.1016/j.canlet.2018.09.012
   Li YS, 2019, AM J MED SCI, V357, P280, DOI 10.1016/j.amjms.2018.12.004
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mohseny AB, 2012, EUR J CANCER, V48, P3429, DOI 10.1016/j.ejca.2012.06.018
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   Palmirotta R, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918794630
   Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008 5472.CAN 13 2030
   Raimondi L, 2020, CARCINOGENESIS, V41, P666, DOI 10.1093/carcin/bgz130
   Raimondi L, 2017, ONCOTARGET, V8, P100831, DOI 10.18632/oncotarget.19852
   Sarver AL, 2010, LAB INVEST, V90, P753, DOI 10.1038/labinvest.2010.53
   Sholl LM, 2017, J THORAC ONCOL, V12, P1464, DOI 10.1016/j.jtho.2017.08.004
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
NR 22
TC 19
Z9 20
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD DEC
PY 2019
VL 11
IS 12
AR 1924
DI 10.3390/cancers11121924
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KC7VZ
UT WOS:000507382100101
PM 31816885
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, CZ
   Fu, YC
   Jian, SC
   Wang, YH
   Liu, PL
   Ho, ML
   Wang, CK
AF Wang, Chau Zen
   Fu, Yin Chih
   Jian, Shih Ciang
   Wang, Yan Hsiung
   Liu, Po Len
   Ho, Mei Ling
   Wang, Chih Kuang
TI Synthesis and characterization of cationic polymeric nanoparticles as
   simvastatin carriers for enhancing the osteogenesis of bone marrow
   mesenchymal stem cells
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Simvastatin; Osteogenesis; Cationic copolymers; Nanoparticles; Bone
   marrow mesenchymal stem cells
ID BLOCK COPOLYMER MICELLES; CONTROLLED RELEASE; SURFACE CHARGE; DELIVERY;
   CHITOSAN; PLGA; DRUG; PROTEINS
AB Simvastatin (SIM) can increase osteoblast activity and enhance osteogenesis. However, some limitations of SIM have been noted, such as statin associated rhabdomyolysis and its poor solubility in water. In this study, we fabricated new cationic nanoparticles (NPs) designed for the controlled release of hydrophobic SIM and endocytosis by cells with the aim of reducing the total required amount of SIM administered and enhancing the osteogenesis of bone marrow mesenchymal stem cells (BMSCs). New copolymers of bis(poly(lactic co glycolic acid) phenylalanine polyethylene glycol) quaternary ammonium grafted diethyltriamine (bis(PLGA phe PEG) qDETA; BPPD) were created using a diethyltriamine quaternary ammonium (qDETA) moiety, hetero bifunctional polyethylene glycol (COOH PEG NH2), phenylalanine (phe) and poly(lactic co glycolic acid) (PLGA). SIM encapsulated in BPPD NPs (SIM/BPPD) was fabricated using a water miscible solvent. The size distributions of BPPD NPs and SIM/BPPD NPs, the encapsulation efficacy and the in vitro release profile of SIM in SIM/BPPD NPs over 6 days were investigated. Based on the results of Alizarin Red S staining, alkaline phosphatase (ALP) activity assays and quantitative polymerase chain reaction (Q PCR) results, we propose that SIM/BPPD NPs may induce osteogenesis in BMSCs by enhancing the expression of an osteogenic gene, which subsequently elevates ALP activity and mineralization, resulting in enhanced BMSC osteogenesis. These results suggest that the SIM/BPPD NPs may be used as hydrophobic drug carriers to reduce the total required amount of SIM administered and to provide an effective SIM release mechanism for enhancing BMSC osteogenesis. Surprisingly, BPPD NPs were also shown to have the ability to promote osteogenesis in BMSCs by enhancing the expression of osteogenic genes, especially osteocalcin (OC), and subsequently elevating ALP activity and mineralization. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Wang, Chau Zen; Ho, Mei Ling] Kaohsiung Med Univ, Dept Physiol, Kaohsiung 807, Taiwan.
   [Fu, Yin Chih] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Fu, Yin Chih] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung 807, Taiwan.
   [Jian, Shih Ciang; Wang, Chih Kuang] Kaohsiung Med Univ, Dept Med & Appl Chem, Kaohsiung 807, Taiwan.
   [Wang, Yan Hsiung] Kaohsiung Med Univ, Sch Dent, Kaohsiung 807, Taiwan.
   [Liu, Po Len] Kaohsiung Med Univ, Dept Resp Therapy, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University
RP Wang, CK (通讯作者)，Kaohsiung Med Univ, Dept Med & Appl Chem, Kaohsiung 807, Taiwan.
EM cicwang@kmu.edu.tw
RI ; Ho, Mei Ling/D 5515 2009; Liu, Po Len/D 4873 2009; Fu,
   Yin Chih/D 5035 2009; Wang, Chau Zen/D 4868 2009; Wang,
   Yan Hsiung/ABD 4004 2020; Wang, Chih Kuang/D 4440 2009
OI Wang, Yan Hsiung/0000 0001 8161 7472; Wang,
   Chih Kuang/0000 0002 4398 6979; Ho, Mei Ling/0000 0001 8064 8488; 
FU Ministry of Economic Affairs; National Science Council in Taiwan
   [101 EC 17 A 17 S1 041, NSC 101 2628 E 037  002]; Kaohsiung Medical
   University Hospital [KMUH100 0R40]
FX The authors gratefully acknowledge the support for this research by the
   Ministry of Economic Affairs, and National Science Council in Taiwan
   under the grant numbers 101 EC 17 A 17 S1 041, NSC 101 2628 E 037  002,
   and the Kaohsiung Medical University Hospital (KMUH100 0R40),
   respectively.
CR Ashjari M, 2012, J MATER SCI MATER M, V23, P943, DOI 10.1007/s10856 012 4562 1
   Chen Y, 2003, LETT PEPT SCI, V10, P621, DOI 10.1007/BF02442596
   Cheng TL, 2005, BIOCONJUGATE CHEM, V16, P1225, DOI 10.1021/bc050133f
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Garrett IR, 2007, J ORTHOP RES, V25, P1351, DOI 10.1002/jor.20391
   Gasper S.R., 2000, U.S. Patent, Patent No. [6,022,887, 6022887]
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   Harush Frenkel O, 2008, BIOMACROMOLECULES, V9, P435, DOI 10.1021/bm700535p
   Harush Frenkel O, 2007, BIOCHEM BIOPH RES CO, V353, P26, DOI 10.1016/j.bbrc.2006.11.135
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Ho ML, 2008, J CONTROL RELEASE, V128, P142, DOI 10.1016/j.jconrel.2008.02.012
   Jokerst JV, 2011, NANOMEDICINE UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169 409X(00)00124 1
   Kim YH, 2001, BIOCONJUGATE CHEM, V12, P932, DOI 10.1021/bc015510c
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   KWON GS, 1995, ADV DRUG DELIVER REV, V16, P295, DOI 10.1016/0169 409X(95)00031 2
   Labhasetwar V, 1998, J PHARM SCI, V87, P1229, DOI 10.1021/js980021f
   Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010
   Lee JY, 2004, J CONTROL RELEASE, V94, P323, DOI 10.1016/j.jconrel.2003.10.012
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168 3659(98)00097 2
   Malaekah Nikouei B., 2005, IRAN J PHARM SCI, V1, P195
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Pauly S, 2009, BONE, V45, P505, DOI 10.1016/j.bone.2009.05.010
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378 5173(02)00315 0
   Qaddoumi MG, 2004, PHARM RES DORDR, V21, P641, DOI 10.1023/B:PHAM.0000022411.47059.76
   Rabinovich Guilatt L, 2004, J DRUG TARGET, V12, P623, DOI 10.1080/10611860400015910
   Shekunov BY, 2006, PHARM RES DORDR, V23, P196, DOI 10.1007/s11095 005 8635 4
   Tai IC, 2013, INT J NANOMED, V8, P3895, DOI 10.2147/IJN.S48694
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Wang CK, 2009, BIOMATERIALS, V30, P4178, DOI 10.1016/j.biomaterials.2009.04.029
   WANG GJ, 1995, J FORMOS MED ASSOC, V94, P589
   Wang YH, 2013, J NANOPART RES, V15, DOI 10.1007/s11051 013 2077 4
   Webber MA, 2004, J PSYCHOPHARMACOL, V18, P432, DOI 10.1177/026988110401800316
   Yue ZG, 2011, BIOMACROMOLECULES, V12, P2440, DOI 10.1021/bm101482r
   Zhang Y., 2011, INT J PHARMACEUT, V30, P118
   Zhou YS, 2010, BIOMATERIALS, V31, P5325, DOI 10.1016/j.biomaterials.2010.03.037
NR 37
TC 42
Z9 48
U1 0
U2 79
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0021 9797
EI 1095 7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD OCT 15
PY 2014
VL 432
BP 190
EP 199
DI 10.1016/j.jcis.2014.06.037
PG 10
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA AO1KC
UT WOS:000341070000026
PM 25086394
DA 2025 08 17
ER

PT J
AU Yang, BC
   Li, M
   Lei, HG
   Xu, YD
   Li, HX
   Gao, ZZ
   Guan, RL
   Xin, ZC
AF Yang, Bicheng
   Li, Meng
   Lei, Hongen
   Xu, Yongde
   Li, Huixi
   Gao, Zhezhu
   Guan, Ruili
   Xin, Zhongcheng
TI Low Intensity Pulsed Ultrasound Influences the Myogenic Differentiation
   of Muscle Satellite Cells in a Stress Urinary Incontinence Rat Model
SO UROLOGY
LA English
DT Article
ID STEM; EXPRESSION; OSTEOBLAST; THERAPY; PATHWAY
AB OBJECTIVE To investigate the therapeutic effect of low intensity pulsed ultrasound (LIPUS) in a stress urinary incontinence (SUI) rat model and its influence on myogenic satellite cells.
   METHODS Fifty Sprague Dawley rats underwent vaginal distension and bilateral ovariectomy mimicking par  tum injury and menopause to construct SUI models, which were further randomized into 100 mW/cm(2) LIPUS, 200 mW/cm(2) LIPUS, 300 mW/cm(2) LIPUS, and none treatment control sub groups with 10 rats per subgroup. Ten rats served as mock operation control. Leak point pressure and bladder capacity were recorded 1 week after LIPUS treatment. Immunofluorescence staining and Western blot were performed to examine histological changes, myodifferentiation, and signaling pathway.
   RESULTS Here, we found the leak point pressure and bladder capacity were restored in 200 mW/cm(2) LIPUS and 300 mW/cm(2) LIPUS groups, but not in 100 mW/cm(2) LIPUS group. More robust striated muscle regeneration was observed in 200 mW/cm(2) LIPUS group comparing with the SUI none treatment group. Moreover, we found LIPUS activated the myodifferentiation of muscle satellite cells, which is correlated to p38 phosphorylation level.
   CONCLUSION LIPUS restored the leak point pressure and bladder capacity, and activated satellite cell myodifferentiation in SUI rat model. (C) 2018 Published by Elsevier Inc.
RI Yang, Bicheng/JED 9933 2023; lei, hongen/C 5684 2008; zhang,
   chen/JES 0371 2023
OI Guan, Ruili/0000 0003 0422 846X; 
FU National Natural Science Foundation of China [81470921, 81671450]
FX This work was supported by the National Natural Science Foundation of
   China (nos. 81470921 and 81671450).
CR Agur W, 2013, EUR UROL, V64, P323, DOI 10.1016/j.eururo.2013.04.034
   Appleford MR, 2007, BIOMATERIALS, V28, P4788, DOI 10.1016/j.biomaterials.2007.06.010
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Bernal A, 2015, STEM CELL REV REP, V11, P852, DOI 10.1007/s12015 015 9608 6
   de Gusmao CVB, 2010, CLIN ORTHOP RELAT R, V468, P1149, DOI 10.1007/s11999 009 1146 6
   Cox A, 2013, NAT REV UROL, V10, P78, DOI 10.1038/nrurol.2012.243
   Hanawa K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104863
   Hijaz AK, 2013, FEMALE PELVIC MED RE, V19, P356, DOI 10.1097/SPV.0b013e3182a331a9
   Ikai H, 2008, J PERIODONTAL RES, V43, P212, DOI 10.1111/j.1600 0765.2007.01016.x
   Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Lei HG, 2015, UROLOGY, V86, DOI 10.1016/j.urology.2015.07.026
   Li M, 2016, UROLOGY, V97, DOI 10.1016/j.urology.2016.08.009
   Lin CS, 2012, STEM CELLS DEV, V21, P834, DOI 10.1089/scd.2011.0621
   Lluís F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002
   Lluís F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528
   Motohashi N, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00001
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Perdiguero E, 2011, J CELL BIOL, V195, P307, DOI 10.1083/jcb.201104053
   Peyrat L, 2002, BJU INT, V89, P61, DOI 10.1046/j.1464 4096.2001.01813.x
   Ren LX, 2013, ULTRASONICS, V53, P686, DOI 10.1016/j.ultras.2012.10.008
   Rutten S, 2016, JBJS REV, V4, DOI 10.2106/JBJS.RVW.O.00027
   Sena K, 2011, ULTRASONICS, V51, P639, DOI 10.1016/j.ultras.2011.01.007
   Shi H, 2013, J CLIN INVEST, V123, P2064, DOI 10.1172/JCI64375
   Shindo T, 2016, ARTERIOSCL THROM VAS, V36, P1220, DOI 10.1161/ATVBAHA.115.306477
   Tedesco FS, 2010, J CLIN INVEST, V120, P11, DOI 10.1172/JCI40373
   Urita A, 2013, J HAND SURG AM, V38A, P498, DOI 10.1016/j.jhsa.2012.11.032
   Wei FY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106722
   Wu AK, 2018, TRANSL ANDROL UROL, V7, pS7, DOI 10.21037/tau.2017.12.36
   Xu YD, 2015, STEM CELLS DEV, V24, P747, DOI 10.1089/scd.2014.0380
NR 30
TC 16
Z9 19
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0090 4295
EI 1527 9995
J9 UROLOGY
JI Urology
PD JAN
PY 2019
VL 123
AR 297.e1
DI 10.1016/j.urology.2018.09.020
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA HF9BF
UT WOS:000454535600088
PM 30273612
DA 2025 08 17
ER

PT J
AU Ming, WL
   Xie, H
   Hu, ZX
   Chen, YY
   Zhu, YH
   Bai, YF
   Liu, HD
   Sun, X
   Liu, Y
   Gu, WJ
AF Ming, Wenlong
   Xie, Hui
   Hu, Zixi
   Chen, Yuanyuan
   Zhu, Yanhui
   Bai, Yunfei
   Liu, Hongde
   Sun, Xiao
   Liu, Yun
   Gu, Wanjun
TI Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer
   Patients With an Unsupervised Analysis
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE peripheral blood mononuclear cells; immune gene signature; unsupervised
   analysis; breast cancer subtype; breast cancer survival
ID AMERICAN SOCIETY; CELL MIGRATION; EXPRESSION; PATHWAY; RECOMMENDATIONS;
   ASSOCIATION; CONSENSUS; SURVIVAL; THERAPY
AB Background: Breast cancer (BC) is a highly heterogeneous cancer. The interaction between immune system and BC is complex, widespread yet unclear. In this study, we aimed to reveal the heterogeneity of host systemic immune response to BC and understand the possible mechanisms that may drive the heterogeneity using transcriptomic data from peripheral blood mononuclear cells (PBMCs).
   Methods: Transcriptome wide gene expressions of PBMCs in 33 BC patients were generated by RNA sequencing. An unsupervised clustering algorithm was employed to discover PBMC transcriptome subtypes among BC patients. Association analysis between PBMC subtypes and age, clinical stage, abundance of immune cells, and other clinical factors was performed to understand the underlying biological processes that may drive this heterogeneity. Immune gene signature identification and in silico survival analysis were performed to investigate the potential clinical implications of these PBMC subtypes. The findings were validated using the whole blood transcriptomes of an independent cohort.
   Results: We observed that established BC subtypes were not associated with PBMC gene expression profiles. Instead, we discovered and validated two new BC subtypes using PBMC transcriptome, which have distinct immune cell proportions, especially for lymphocytes (P = 5.22 x 10( 12)) and neutrophils (P = 1.13 x 10( 14)). Enrichment analysis of differentially expressed genes revealed that these two subtypes had distinct patterns of immune responses, including osteoclast differentiation and interleukin 10 signaling pathway. We developed two immune gene signatures that can differentiate these two BC PBMC subtypes. Further analysis suggested they had the ability to predict the clinical outcome of BC patients.
   Conclusions: PBMC transcriptome profiles can classify BC patients into two distinct subtypes. These two subtypes are mainly shaped by different immune cell abundance, which may have implications on clinical outcomes.
C1 [Ming, Wenlong; Hu, Zixi; Chen, Yuanyuan; Bai, Yunfei; Liu, Hongde; Sun, Xiao; Gu, Wanjun] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing, Jiangsu, Peoples R China.
   [Xie, Hui; Zhu, Yanhui; Liu, Yun] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
C3 Southeast University   China; Nanjing Medical University
RP Gu, WJ (通讯作者)，Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing, Jiangsu, Peoples R China.; Liu, Y (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
EM liuyun@njmu.edu.cn; wanjungu@gmail.com
RI Liu, Hongde/K 2029 2013; zhu, yanhui/MIK 4881 2025; Chen,
   Yuanyuan/GXG 2130 2022; Gu, Wanjun/B 3998 2010
FU National Key R&D Program of China [2018YFC1314900, 2018YFC1314902]; Key
   Research & Development Program of Jiangsu Province [BE2016002 3];
   National Natural Science Foundation of China [61571109]; Fundamental
   Research Funds for the Central Universities [2242017K3DN04]
FX This work was funded by grants from National Key R&D Program of China
   (2018YFC1314900, 2018YFC1314902), Key Research & Development Program of
   Jiangsu Province (BE2016002 3), National Natural Science Foundation of
   China (61571109), and the Fundamental Research Funds for the Central
   Universities (2242017K3DN04).
CR Aaroe J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2472
   Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Azab B, 2012, ANN SURG ONCOL, V19, P217, DOI 10.1245/s10434 011 1814 0
   Baine MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017014
   Baranzini SE, 2009, HUM MOL GENET, V18, P2078, DOI 10.1093/hmg/ddp120
   Bonassi S, 2007, CARCINOGENESIS, V28, P625, DOI 10.1093/carcin/bgl177
   Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125
   Ciarloni L, 2016, CLIN CANCER RES, V22, P4604, DOI 10.1158/1078 0432.CCR 15 2057
   Dumeaux V, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005680
   Dumeaux V, 2015, INT J CANCER, V136, P656, DOI 10.1002/ijc.29030
   Esquivel Velázquez M, 2015, J INTERF CYTOK RES, V35, P1, DOI 10.1089/jir.2014.0026
   Ethier JL, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 016 0794 1
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI 10.1093/nar/gkx1132
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470 2045(13)70567 9
   Foulds GA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02028
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Grecian R, 2018, BRIT MED BULL, V128, P5, DOI 10.1093/bmb/ldy029
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549 009 0674 9
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48
   Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289
   Hensler M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1102827
   Jia WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143061
   Kapp AV, 2007, BIOSTATISTICS, V8, P9, DOI 10.1093/biostatistics/kxj029
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Koh CH, 2015, BRIT J CANCER, V113, P150, DOI 10.1038/bjc.2015.183
   Lappalainen I, 2015, NAT GENET, V47, P692, DOI 10.1038/ng.3312
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Lee M, 2017, IMMUNE NETW, V17, P214, DOI 10.4110/in.2017.17.4.214
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu ZG, 2005, CELL RES, V15, P24, DOI 10.1038/sj.cr.7290259
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Mishra S, 2015, CANCER LETT, V369, P67, DOI 10.1016/j.canlet.2015.07.045
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Nagarajan D, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010020
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Ocana A, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0707 7
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   R Core Team, 2017, R LANG ENV STAT COMP
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450
   Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07 8832com
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Standish Leanna J, 2008, J Soc Integr Oncol, V6, P158
   Suzuki E, 2019, BREAST CANCER TOKYO, V26, P282, DOI 10.1007/s12282 018 0920 2
   Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581
   Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284
   Waning DL, 2013, CANCER CELL, V24, P407, DOI 10.1016/j.ccr.2013.10.001
   Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140
   Wolczyk D, 2016, CELL ONCOL, V39, P353, DOI 10.1007/s13402 016 0280 x
   Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530
   Zhang XC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09762 1
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zu XY, 2012, CELL TISSUE RES, V347, P73, DOI 10.1007/s00441 011 1225 3
NR 58
TC 17
Z9 18
U1 1
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 1
PY 2019
VL 9
AR 985
DI 10.3389/fonc.2019.00985
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA JO4JQ
UT WOS:000497546300001
PM 31632916
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ogawa, K
   Mukai, T
   Arano, Y
   Otaka, A
   Ueda, M
   Uebara, T
   Magata, Y
   Hashimoto, K
   Saji, H
AF Ogawa, Kazuma
   Mukai, Takahiro
   Arano, Yasushi
   Otaka, Akira
   Ueda, Masashi
   Uebara, Tomoya
   Magata, Yasuhiro
   Hashimoto, Kazuyuki
   Saji, Hideo
TI Rhemium 186 monoaminemonoamidedithiol conjugated bisphosphonate
   derivatives for bone pain palliation
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE rhenium 186; monoaminemonoamidedithiols; bisphosphonate; bone;
   palliation
ID RE 186 HYDROXYETHYLIDENE DIPHOSPHONATE; OSSEOUS METASTASES;
   BREAST CANCER; RE 186 HEDP; PROSTATE; THERAPY; RHENIUM 186 HEDP;
   HYDROXYAPATITE; MECHANISMS; AGENTS
AB To develop a radiopharmaceutical for the palliation of painful bone metastases based on the concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative labeled with rhenium 186 (Re 186) that contains a hydroxyl group at the central carbon of its bisphosphonate structure, we attached a stable Re 186 MAMA chelate to the amino group of a 4 amino butylidene phosphonate derivative [N [2 [[4 [(4 hydroxy 4,4 diphosphonobutyl)amino] 4 oxobutyl] 2 thioethylamino]acetyl] 2 aminoethanethiolate] oxorhenium (V) (Re 186 MAMA HBP) and we investigated the effect of a hydroxyl group at the central carbon of its bisphosphonate structure on affinity for hydroxyapatite and on biodistribution by conducting a comparative study with [N [2 [[3 (3,3 diphosphonopropylcarbamoyl)propyl] 2 thioethylamino]acetyl] 2 aminoethanethiolate] oxorhenium (V) (Re 186 MAMA BP). The precursor of Re 186 MAMA HBP, trityl (Tr) MAMA HBP, was obtained by coupling a Tr MAMA derivative to 4 amino 1 hydroxybutylidene 1,1 bisphosphonate. Re 186 MAMA HBP was prepared by a reaction with (ReO4 ) Re 186 and SnCl2 in citrate buffer after the deprotection of the Tr groups of Tr MAMA HBP. After reversed phase high performance liquid chromatography, Re 186 MAMA HBP had a radiochemical purity of over 95%. Compared with Re 186 MAMA BP, Re 186 MAMA HBP showed a greater affinity for hydroxyapatite beads in vitro and accumulated a significantly higher level in the femur in vivo. Thus, the introduction of a hydroxyl group into Re 186 complex conjugated bisphosphonates would be effective in enhancing accumulation in bones. These findings provide useful information oil the design of bone seeking therapeutic radiopharmaceuticals. (c) 2006 Elsevier Inc. All rights reserved.
C1 Kyoto Univ, Dept Pathofunct Bioanal, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.
   Kanazawa Univ, Adv Sci Res Ctr, Kanazawa, Ishikawa 9208640, Japan.
   Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan.
   Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan.
   Hamamatsu Univ Sch Med, Photon Med Res Ctr, Hamamatsu, Shizuoka 4313192, Japan.
   Japan Atom Energy Res Inst, Tokai, Ibaraki 3191195, Japan.
C3 Kyoto University; Kanazawa University; Kyushu University; Chiba
   University; Hamamatsu University School of Medicine; Japan Atomic Energy
   Agency
RP Saji, H (通讯作者)，Kyoto Univ, Dept Pathofunct Bioanal, Grad Sch Pharmaceut Sci, Sakyo Ku, Shimoadachi Cho, Kyoto 6068501, Japan.
EM hsaji@pharm.kyoto u.ac.jp
RI Ogawa, Kazuma/D 8406 2015; Arano, Yasushi/AFQ 8631 2022; Ueda,
   Masashi/K 4096 2013
OI Ogawa, Kazuma/0000 0002 1691 7302; Arano, Yasushi/0000 0001 6091 5382;
   Ueda, Masashi/0000 0001 7027 1568
CR Arano Yasushi, 1995, Radioisotopes, V44, P514
   De Winter F, 1999, CLIN NUCL MED, V24, P898, DOI 10.1097/00003072 199911000 00022
   DEKLERK JMH, 1992, J NUCL MED, V33, P646
   Elder RC, 1997, INORG CHEM, V36, P3055, DOI 10.1021/ic960980h
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FOGELMAN I, 1981, J NUCL MED, V22, P880
   FUJISAWA R, 1991, BIOCHIM BIOPHYS ACTA, V1075, P56
   GOECKELER WF, 1987, J NUCL MED, V28, P495
   JURISSON SS, 1983, INORG CHEM, V22, P1332, DOI 10.1021/ic00151a013
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   KETRING AR, 1987, NUCL MED BIOL, V14, P223, DOI 10.1016/0883 2897(87)90046 8
   KIECZYKOWSKI GR, 1992, Patent No. 2248061
   KOBAYASHI K, 2000, RADIOCHEMISTRY, V42, P551
   Kolesnikov Gauthier H, 2000, J NUCL MED, V41, P1689
   Limouris GS, 1997, ANTICANCER RES, V17, P1767
   McEwan AJB, 2000, SEMIN RADIAT ONCOL, V10, P103, DOI 10.1016/S1053 4296(00)80047 8
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   MEYER JL, 1973, CALC TISS RES, V13, P295, DOI 10.1007/BF02015419
   O'Sullivan JM, 2002, BRIT J CANCER, V86, P1715, DOI 10.1038/sj.bjc.6600348
   Ogawa K, 2004, J LABELLED COMPD RAD, V47, P753, DOI 10.1002/jlcr.864
   Pandit Taskar N, 2004, J NUCL MED, V45, P1358
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   SUBRAMANIAN G, 1983, RADIOLOGY, V149, P823, DOI 10.1148/radiology.149.3.6316414
   UPPELSCHOTEN JM, 1995, RADIOTHER ONCOL, V36, P198, DOI 10.1016/0167 8140(95)01587 7
   VanAswegen A, 1997, NUCL MED COMMUN, V18, P582, DOI 10.1097/00006231 199706000 00015
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208
NR 27
TC 57
Z9 62
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0969 8051
EI 1872 9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD MAY
PY 2006
VL 33
IS 4
BP 513
EP 520
DI 10.1016/j.nucmedbio.2006.03.006
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 051DZ
UT WOS:000238142400009
PM 16720243
DA 2025 08 17
ER

PT J
AU Mundy, L
AF Mundy, Linda
TI Platelet rich plasma: a case study for the identification of
   disinvestment opportunities using horizon scanning
SO AUSTRALIAN HEALTH REVIEW
LA English
DT Article
ID VALUE HEALTH CARE; KNEE OSTEOARTHRITIS; HYALURONIC ACID; INJECTION;
   TRIAL
AB Objective. This paper discusses the potential for horizon scanning to identify low value, inappropriate clinical practices that deliver minimal benefit to patients and represent a considerable financial burden on the health system.
   Methods. Platelet rich plasma (PRP) was identified by routine horizon scanning as a potentially innovative treatment alternative for osteoarthritis of the knee. A rapid, non systematic assessment of the evidence pertaining to the safety and effectiveness of PRP compared with nonsteroidal anti inflammatory drugs (NSAIDs) for the treatment of osteoarthritis of the knee was conducted.
   Results. The evidence base supporting the use of PRP for the treatment of osteoarthritis was poor. No comparative studies were identified that compared the use of PRP to NSAIDs, the current treatment option for osteoarthritis of the knee in Australia. Despite the lack of effectiveness evidence, the use of PRP injections was rapidly increasing in the private sector using an inappropriate Medicare Benefits Schedule item number.
   Conclusions. This assessment highlights the potential of using established horizon scanning methodologies to identify targets for full or partial disinvestment of ineffective, inefficient or harmful clinical practices.
C1 [Mundy, Linda] HealthPACT, Hlth Improvement Unit, Clin Excellence Div, Dept Hlth, Level 2,15 Butterfield St, Herston, Qld 4006, Australia.
C3 Queensland Health
RP Mundy, L (通讯作者)，HealthPACT, Hlth Improvement Unit, Clin Excellence Div, Dept Hlth, Level 2,15 Butterfield St, Herston, Qld 4006, Australia.
EM linda.mundy@health.qld.gov.au
CR [Anonymous], MED US ARTHR OST
   [Anonymous], 2013, NAT HLTH PRIOR AR
   Australian Institute of Health and Welfare, 2010, SNAPSH ARTHR AUSTR 2
   Burnouf T, 2013, BLOOD REV, V27, P77, DOI 10.1016/j.blre.2013.02.001
   Caloundra Spinal and Sports Medicine Clinic, 2015, PLAT RICH PLASM INJ
   Cheng OT, 2012, PAIN MED, V13, P740, DOI 10.1111/j.1526 4637.2012.01394.x
   Directory of PRP Practitioners, 2015, PLAT RICH PLASM INJ
   Dr Jones and Partners, 2014, PLAT RICH PLASM INJ
   Elshaug AG, 2012, MED J AUSTRALIA, V197, P556, DOI 10.5694/mja12.11083
   Filardo G, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 229
   Filardo G, 2011, KNEE SURG SPORT TR A, V19, P528, DOI 10.1007/s00167 010 1238 6
   Halpern B, 2013, CLIN J SPORT MED, V23, P238, DOI 10.1097/JSM.0b013e31827c3846
   Jang SJ, 2012, EUROPEAN J ORTHOPAED
   Ju H., 2013, REPLACEMENT PERIPHER
   Laupaffarakasem W, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005118.pub2
   Lee KS, 2013, SEMIN MUSCULOSKEL R, V17, P91, DOI 10.1055/s 0033 1333943
   Mazzocca AD, 2012, J BONE JOINT SURG AM, V94A, P308, DOI 10.2106/JBJS.K.00430
   Medical Services Advisory Committee, 2011, APPL 1176R ASS APPL
   Medical Services Advisory Committee, 2003, INTR VISC TREATM OST
   Medicare Australia Statistics, 2015, MED IT REP
   Merlin T, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471 2288 9 34
   Mundy L., 2013, INFERIOR VENA CAVA F
   Mundy L., 2014, CATHETER ABLATION AT
   Mundy Linda, 2005, Aust Health Rev, V29, P395
   Norwood Day Surgery, 2015, PLAT RICH PLASM CAN
   Patel S, 2013, AM J SPORT MED, V41, P356, DOI 10.1177/0363546512471299
   Platelet Rich Plasma (PRP), 2013, PLATELET RICH PLASMA
   Sampson S, 2010, AM J PHYS MED REHAB, V89, P961, DOI 10.1097/PHM.0b013e3181fc7edf
   Schmajuk G, 2014, JAMA INTERN MED, V174, P1702, DOI 10.1001/jamainternmed.2014.3926
   Spaková T, 2012, AM J PHYS MED REHAB, V91, P411, DOI 10.1097/PHM.0b013e3182aab72
   Tinsley BA, 2012, OPER TECHN SPORT MED, V20, P192, DOI 10.1053/j.otsm.2012.04.002
   Torrero J.I., 2012, Journal of Biological Regulators and Homeostatic Agents, V26, P71
   Wang Saegusa A, 2011, ARCH ORTHOP TRAUM SU, V131, P311, DOI 10.1007/s00402 010 1167 3
NR 33
TC 7
Z9 7
U1 0
U2 2
PU CSIRO PUBLISHING
PI CLAYTON
PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC
   3168, AUSTRALIA
SN 0156 5788
EI 1449 8944
J9 AUST HEALTH REV
JI Aust. Health Rev.
PY 2017
VL 41
IS 1
BP 33
EP 37
DI 10.1071/AH15075
PG 5
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA EM7RR
UT WOS:000395510500006
PM 27007328
OA hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Mizerska Kowalska, M
   Slawinska Brych, A
   Niedziela, E
   Brodovskiy, V
   Zdzisinska, B
AF Mizerska Kowalska, Magdalena
   Slawinska Brych, Adrianna
   Niedziela, Emilia
   Brodovskiy, Viktor
   Zdzisinska, Barbara
TI Alpha Ketoglutarate Downregulates the Neutral Endopeptidase and Enhances
   the Growth Inhibitory Activity of Thiorphan in Highly Aggressive
   Osteosarcoma Cells
SO MOLECULES
LA English
DT Article
DE neutral endopeptidase; alpha ketoglutarate; epigenetic regulation;
   natural anticancer products; enhancer of zeste homolog 2 (EZH2)
   methyltransferase; combination therapies
ID MECHANISMS; LINES
AB Since natural substances are widely explored as epigenetic modulators of gene expression and epigenetic abnormalities are important causes of cancerogenesis, factors with pro tumor activities subjected to epigenetic control, e.g., neutral endopeptidase (NEP, neprilysin), are promising anticancer targets for potential therapies acting via epigenetic regulation of gene expression. Alpha ketoglutarate (AKG) is a naturally occurring co substrate for enzymes involved in histone and DNA demethylation with suggested anti cancer activity. Hence, we investigated a potential effect of AKG on the NEP expression in cells derived from various cancers (cervical, colon, osteosarcoma) and normal epithelial cells and osteoblasts. Moreover, the overall methylation status of histone H3 was explored to establish the molecular target of AKG activity. Additionally, it was investigated whether AKG in combination with thiorphan (NEP specific inhibitor) exhibited enhanced anticancer activity. The results revealed that AKG downregulated the expression of NEP at the protein level only in highly aggressive osteosarcoma HOS cells (flow cytometry and fluorometric assays), and this protease was found to be involved in AKG induced growth inhibition in osteosarcoma cells (siRNA NEP silencing, BrdU assay, flow cytometry). Unexpectedly, AKG induced hypermethylation of H3K27 in HOS cells, which was partially dependent on EZH2 activity. However, this effect was not implicated in the AKG induced NEP downregulation (flow cytometry). Finally, the combined treatment with AKG and thiorphan was shown to significantly enhance the growth inhibitory potential of each one towards HOS cells (BrdU assay). These preliminary studies have shown for the first time that the downregulation of NEP expression is a promising target in therapies of NEP implicating HOS cells. Moreover, this therapeutic goal can be achieved via AKG induced downregulation of NEP and synergistic activity of AKG with thiorphan, i.e., a NEP specific inhibitor. Furthermore, this study has reported for the first time that exogenous AKG can influence the activity of histone methyltransferase, EZH2. However, this issue needs further investigation to elucidate the mechanisms of this phenomenon.
C1 [Mizerska Kowalska, Magdalena; Niedziela, Emilia; Brodovskiy, Viktor; Zdzisinska, Barbara] Marie Curie Sklodowska Univ, Fac Biol & Biotechnol, Dept Virol & Immunol, Akademicka 19 St, PL 20033 Lublin, Poland.
   [Slawinska Brych, Adrianna] Marie Curie Sklodowska Univ, Fac Biol & Biotechnol, Dept Cell Biol, Akademicka 19 St, PL 20033 Lublin, Poland.
C3 Maria Curie Sklodowska University; Maria Curie Sklodowska University
RP Mizerska Kowalska, M (通讯作者)，Marie Curie Sklodowska Univ, Fac Biol & Biotechnol, Dept Virol & Immunol, Akademicka 19 St, PL 20033 Lublin, Poland.
EM magdalena.mizerska kowalska@mail.umcs.pl
RI ; Mizerska Kowalska, Magdalena/AAG 9713 2020
OI Mizerska Kowalska, Magdalena/0000 0003 2364 6181; Zdzisinska,
   Barbara/0000 0002 0920 3192; 
FU National Science Center, Poland;  [2018/02/X/NZ5/01504]
FX This research was funded by research Grant No. 2018/02/X/NZ5/01504 from
   the National Science Center, Poland.
CR Bayes Genis A, 2016, J AM COLL CARDIOL, V68, P639, DOI 10.1016/j.jacc.2016.04.060
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Carl McGrath S, 2006, HISTOL HISTOPATHOL, V21, P1339, DOI 10.14670/HH 21.1339
   Chin RM, 2014, NATURE, V510, P397, DOI 10.1038/nature13264
   Eberlin M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00093
   Fala Loretta, 1 IN CLASS ANGIOTENS
   GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526
   Gyanwali B, 2022, TRENDS ENDOCRIN MET, V33, P136, DOI 10.1016/j.tem.2021.11.003
   Kalawaj K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249406
   Kale VP, 2021, SEMIN CANCER BIOL, V68, P242, DOI 10.1016/j.semcancer.2020.03.005
   Klieser E, 2015, WORLD J GASTRO ONCOL, V7, P473, DOI 10.4251/wjgo.v7.i12.473
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Maguer Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592
   Mancarella D, 2021, GENOME MED, V13, DOI 10.1186/s13073 021 00837 7
   Mizerska Kowalska M, 2021, CLIN TRANSL ONCOL, V23, P1405, DOI 10.1007/s12094 020 02537 x
   Mizerska Kowalska M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126716
   Mizerska Kowalska M, 2019, CHEM BIOL INTERACT, V307, P105, DOI 10.1016/j.cbi.2019.04.033
   Mizerska Kowalska M, 2016, TUMOR BIOL, V37, P13355, DOI 10.1007/s13277 016 5248 y
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Nalivaeva NN, 2020, MECH AGEING DEV, V192, DOI 10.1016/j.mad.2020.111363
   Nalivaeva N N, 2012, Int J Alzheimers Dis, V2012, P383796, DOI 10.1155/2012/383796
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198 050
   Parker SJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25228 9
   Peters GJ, 2000, PHARMACOL THERAPEUT, V87, P227, DOI 10.1016/S0163 7258(00)00086 3
   Plana D, 2022, CANCER DISCOV, V12, P606, DOI 10.1158/2159 8290.CD 21 0212
   Ratovitski EA, 2017, CURR GENOMICS, V18, P175, DOI 10.2174/1389202917666160803165229
   Rougeot C, 2003, P NATL ACAD SCI USA, V100, P8549, DOI 10.1073/pnas.1431850100
   Rouillard AD, 2016, DATABASE OXFORD, DOI 10.1093/database/baw100
   Sankhe R, 2021, EUR J PHARMACOL, V891, DOI 10.1016/j.ejphar.2020.173727
   Sankhe R, 2021, J MOL STRUCT, V1224, DOI 10.1016/j.molstruc.2020.129073
   Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111
   Shahmirzadi AA, 2020, CELL METAB, V32, P447, DOI 10.1016/j.cmet.2020.08.004
   Sobocinska M, 2019, AMINO ACIDS, V51, P1201, DOI 10.1007/s00726 019 02760 z
   Sonaye HV, 2021, BIOMED PHARMACOTHER, V141, DOI 10.1016/j.biopha.2021.111638
   Stephen HM, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.16
   Sui XB, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020683
   Talib WH, 2022, MOLECULES, V27, DOI 10.3390/molecules27175452
   TeSlaa T, 2016, CELL METAB, V24, P485, DOI 10.1016/j.cmet.2016.07.002
   Torlakovic E, 2005, J PATHOL, V205, P311, DOI 10.1002/path.1705
   Usmani BA, 2000, CLIN CANCER RES, V6, P1664
   Wang HH, 2005, WORLD J GASTROENTERO, V11, P1540
   Wang Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019229
   Watson Maria, 2015, Curr Protoc Cytom, V71, DOI 10.1002/0471142956.cy0636s71
   Watson M, 2014, CYTOM PART A, V85A, P78, DOI 10.1002/cyto.a.22344
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005 016 0406 x
   Zhang HT, 2013, MED ONCOL, V30, DOI 10.1007/s12032 013 0608 6
   Zhang TR, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148 020 00862 0
   Zhang ZZ, 2019, REPRODUCTION, V158, P123, DOI 10.1530/REP 19 0018
   Zhuravin I A, 2011, Dokl Biol Sci, V438, P145, DOI 10.1134/S001249661103015X
   Zurek A, 2019, TOXICOL APPL PHARM, V374, P53, DOI 10.1016/j.taap.2019.04.024
NR 53
TC 1
Z9 1
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2023
VL 28
IS 1
AR 97
DI 10.3390/molecules28010097
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 7Q9TN
UT WOS:000909724600001
PM 36615293
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, MQ
   Lai, HB
   Deng, Q
   Peng, X
   Shen, JS
   Zhou, X
   Peng, W
   Zhu, LY
   Tu, H
   Li, X
AF Wu, Mingquan
   Lai, Huabing
   Deng, Qing
   Peng, Xi
   Shen, Jingshou
   Zhou, Xu
   Peng, Wei
   Zhu, Liyang
   Tu, He
   Li, Xia
TI The Evaluation of Xiaozeng Qianggu Tablets for Treating Postmenopausal
   Osteoporosis via up Regulated Autophagy
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID BONE MINERAL DENSITY; OSTEOCYTE AUTOPHAGY; OXIDATIVE STRESS;
   OVARIECTOMY; OSTEOCLASTOGENESIS; OSTEOBLAST; APOPTOSIS; THERAPY; WOMEN
AB Objective. Postmenopausal osteoporosis (PMOP) is a common age associated disease in the life course. Clinically, Xiaozeng Qianggu Tablets (XQT) have a potent therapeutic e"ect on the PMOP. However, the bioactive components and the mechanism of XQTunderlying the PMOP treatment were unclear and it should be explored to discover the scienti c connotation in traditional medical practice. Methods. The components in XQT were identi ed by UPLC Q TOF/MS. The animal model of PMOP was established by surgical ovariectomy in the female Sprague Dawley rats. After treatment of XQT, the therapeutic e"ect was assessed by the determination of bone metabolism biomarkers in serum and histopathological examination. The e"ect of XQT on the autophagy and bone micro situation were tested using western blot, RT qPCR, and transmission electron microscope. Results. There were 27 compounds identi ed in XQT, including catalpol, monotropein, verbascoside, cryptochlorogenic acid, 5,7dihydroxychromone 7 rutinoside, biorobin, and so on. The bone metabolism markers (alkaline phosphatase, bone alkaline phosphatase, procollagen type I intact N terminal propeptide, cross linked carboxy terminal telopeptide of type I collagen, and tartrate resistant acid phosphatase) were signi cantly increased in the PMOP rats and reversed by XQTadministration. Moreover, the width of bone trabeculae and the ratio of the area of calcium deposition to bone trabeculae were also improved after treating the middle dose of XQT. Meanwhile, the bone micro structure was improved by XQT. The mRNA and protein expression of unc51 like kinase 1, beclin 1, and microtubule associated protein 1B light chain 3 in PMOP rats were down regulated and upregulated by XQT administration. Conclusions. The compounds in XQT, including catalpol, monotropein, verbascoside cryptochlorogenic acid, and so on, were valuable for further pharmacy evaluation. The pathological changes and bone micro structure were improved by XQT, and the down regulated autophagy level was also restored, which suggested a potent e"ect of XQT on treating PMOP, corresponding to its clinic use.
C1 [Wu, Mingquan; Zhou, Xu; Peng, Wei; Zhu, Liyang; Tu, He] Sichuan Orthoped Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China.
   [Lai, Huabing] Sichuan Orthoped Hosp, Dept Rehabil, Chengdu, Sichuan, Peoples R China.
   [Lai, Huabing] Sichuan Orthoped Hosp, Prosthet Orthoped Ctr, Chengdu, Sichuan, Peoples R China.
   [Deng, Qing; Peng, Xi] China West Normal Univ, Coll Life Sci, Nanchong, Sichuan, Peoples R China.
   [Shen, Jingshou] Sichuan Orthoped Hosp, Dept Hands & Wrists, Chengdu, Sichuan, Peoples R China.
   [Li, Xia] Sichuan Orthoped Hosp, Dept Internal Med, Chengdu, Sichuan, Peoples R China.
C3 China West Normal University
RP Wu, MQ (通讯作者)，Sichuan Orthoped Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China.
EM 18782976939@163.com
OI WU, MINGQUAN/0000 0003 4145 9531
FU Technology Innovation Project for Young Plants [2019048]; Cadre Health
   Care Project of Sichuan Province [2019 606]; Research Project for Young
   of Sichuan Orthopedic Hospital [2019QN05]
FX This work was supported by Technology Innovation Project for Young
   Plants (no. 2019048), The Cadre Health Care Project of Sichuan Province
   (2019 606), and The Research Project for Young of Sichuan Orthopedic
   Hospital (2019QN05).
CR Abdi F, 2017, IRAN J PHARM RES, V16, P380
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm 2012 0095
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen YQ, 2018, BIOMED PHARMACOTHER, V107, P1175, DOI 10.1016/j.biopha.2018.08.069
   Collaborative Grp Hormonal Factors, 2019, LANCET, V394, P1159, DOI 10.1016/S0140 6736(19)31709 X
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ezzat S, 2019, J CELL BIOCHEM, V120, P2560, DOI 10.1002/jcb.27552
   Florencio Silva R, 2018, BIOMED PHARMACOTHER, V98, P406, DOI 10.1016/j.biopha.2017.12.089
   Fontenot HB, 2014, JOGNN J OBST GYN NEO, V43, P236, DOI 10.1111/1552 6909.12285
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Han DD, 2017, ONCOTARGET, V8, P14680, DOI 10.18632/oncotarget.14747
   He YQ, 2018, CHEM BIOL INTERACT, V291, P128, DOI 10.1016/j.cbi.2018.06.015
   Jang SA, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7280342
   Kiem PV, 2008, ARCH PHARM RES, V31, P823, DOI 10.1007/s12272 001 1232 3
   Lavrador P, 2018, DRUG DISCOV TODAY, V23, P1293, DOI 10.1016/j.drudis.2018.05.012
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li F, 2013, PHYTOMEDICINE, V20, P549, DOI 10.1016/j.phymed.2013.01.001
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li WL, 2013, CHIN HERB MED, V5, P292, DOI [10.1016/S1674 6384(13)60043 X, 10.1016/s1674 6384(13)60043 x]
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Li YT, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110747
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Liu C, 2019, OSTEOPOROSIS INT, V30, P491, DOI 10.1007/s00198 018 4670 y
   Lobo RA, 2016, ATHEROSCLEROSIS, V254, P282, DOI 10.1016/j.atherosclerosis.2016.10.005
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Lupsa BC, 2015, ENDOCRIN METAB CLIN, V44, P517, DOI 10.1016/j.ecl.2015.05.002
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Osteoporosis and Bone Mineral Research Branch of Chinese Medical Association, 2019, Chin J Osteoporosis Bone Mineral Metabolic Disorders, V12, P317, DOI [10. 3969/j.issn.1674 2591.2019.04.001, DOI 10.3969/J.ISSN.1674 2591.2019.04.001]
   Park E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010233
   Park SH, 2016, PHYTOTHER RES, V30, P604, DOI 10.1002/ptr.5565
   Prior JC, 2017, J MUSCULOSKEL NEURON, V17, P146
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Stuenkel CA, 2015, J CLIN ENDOCR METAB, V100, P3975, DOI 10.1210/jc.2015 2236
   Tran O, 2021, OSTEOPOROSIS INT, V32, P1195, DOI 10.1007/s00198 020 05769 3
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wu YX, 2016, BIOMED PHARMACOTHER, V82, P399, DOI 10.1016/j.biopha.2016.05.008
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yang YH, 2014, BIOCHEM BIOPH RES CO, V451, P86, DOI 10.1016/j.bbrc.2014.07.069
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
NR 48
TC 4
Z9 4
U1 0
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD SEP 19
PY 2022
VL 2022
AR 3960834
DI 10.1155/2022/3960834
PG 17
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 6A1QJ
UT WOS:000880435300009
PM 36193128
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Güler Yüksel, M
   Bijsterbosch, J
   Goekoop Ruiterman, YPM
   de Vries Bouwstra, JK
   Hulsmans, HMJ
   de Beus, WM
   Han, KH
   Breedveld, FC
   Dijkmans, BAC
   Allaart, CF
   Lems, WF
AF Gueler Yueksel, M.
   Bijsterbosch, J.
   Goekoop Ruiterman, Y. P. M.
   de Vries Bouwstra, J. K.
   Hulsmans, H. M. J.
   de Beus, W. M.
   Han, K. H.
   Breedveld, F. C.
   Dijkmans, B. A. C.
   Allaart, C. F.
   Lems, W. F.
TI Changes in bone mineral density in patients with recent onset, active
   rheumatoid arthritis
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID LOW DOSE CORTICOSTEROIDS; VERTEBRAL FRACTURE; RECEPTOR ACTIVATOR; JOINT
   DAMAGE; DOUBLE BLIND; THERAPY; RISK; OSTEOPROTEGERIN; METHOTREXATE;
   MULTICENTER
AB Objectives: We examined the effects of four different treatment strategies on bone mineral density (BMD) in patients with recently diagnosed, active rheumatoid arthritis (RA) and the influence of disease related and demographic factors on BMD loss after 1 year of follow up in the BeSt trial.
   Methods: BMD measurements of the lumbar spine and total hip were performed in 342 patients with recent onset RA at baseline and after 1 year. Multivariable regression analyses were performed to determine independent associations between disease and demographic parameters and BMD loss after 1 year.
   Results: Median BMD loss after 1 year was 0.8% and 1.0% of baseline in the spine and the hip, respectively. No significant differences between the treatment groups, including corticosteroids and the anti tumour necrosis factor a infliximab, were observed with regard to BMD loss after 1 year of treatment. Joint damage at baseline and joint damage progression according to the Sharp van der Heijde score were independently associated with more BMD loss after 1 year. The use of bisphosphonates independently protected against BMD loss.
   Conclusions: After 1 year of follow up in the BeSt study, we did not find differences in BMD loss between the four treatment strategies, including high doses of corticosteroids and anti tumour necrosis factor a. Joint damage and joint damage progression are associated with high BMD loss, which emphasises that BMD loss and erosive RA have common pathways in their pathogenesis.
C1 [Gueler Yueksel, M.; Bijsterbosch, J.; Goekoop Ruiterman, Y. P. M.; Breedveld, F. C.; Allaart, C. F.] Leiden Univ, Med Ctr, Dept Rheumatol, NL 2300 RC Leiden, Netherlands.
   [de Vries Bouwstra, J. K.; Dijkmans, B. A. C.; Lems, W. F.] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
   [Hulsmans, H. M. J.] Haga Hosp, Dept Rheumatol, The Hague, Netherlands.
   [de Beus, W. M.] Med Ctr Haaglanden, Dept Rheumatol, The Hague, Netherlands.
   [Han, K. H.] Med Ctr Rijnmond Zuid, Dept Rheumatol, Rotterdam, Netherlands.
   [Dijkmans, B. A. C.; Lems, W. F.] Slotervaart Hosp, Dept Rheumatol, Amsterdam, Netherlands.
   [Dijkmans, B. A. C.; Lems, W. F.] Jan van Breemen Inst, Dept Rheumatol, Amsterdam, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Vrije Universiteit Amsterdam; VU UNIVERSITY
   MEDICAL CENTER; Haga Hospital; Haaglanden Medical Center; Slotervaart
   Hospital
RP Güler Yüksel, M (通讯作者)，Leiden Univ, Med Ctr, Dept Rheumatol, POB 9600, NL 2300 RC Leiden, Netherlands.
EM m.yuksel@lumc.nl
RI de Vries Bouwstra, Jeska/GLT 3945 2022
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   Adachi JD, 1999, CALCIFIED TISSUE INT, V65, P332, DOI 10.1007/s002239900707
   Åman S, 1998, SCAND J RHEUMATOL, V27, P188
   Boulos P, 2000, CLIN EXP RHEUMATOL, V18, pS79
   Buckley LM, 1997, J RHEUMATOL, V24, P1489
   Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003 4819 125 12 199612150 00004
   Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Cortet B, 2000, CLIN EXP RHEUMATOL, V18, P683
   Di Munno O, 2004, J RHEUMATOL, V31, P1305
   Dolan AL, 2002, RHEUMATOLOGY, V41, P1047, DOI 10.1093/rheumatology/41.9.1047
   Forslind K, 2003, J RHEUMATOL, V30, P2590
   Geusens PP, 2006, ARTHRITIS RHEUM US, V54, P1772, DOI 10.1002/art.21896
   Goekoop Ruiterman YPM, 2005, ARTHRITIS RHEUM US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Green MJ, 2001, BEST PRACT RES CL RH, V15, P105, DOI 10.1053/berh.2000.0129
   Habib GS, 2005, CLIN RHEUMATOL, V24, P129, DOI 10.1007/s10067 004 0989 1
   HALL GM, 1993, ARTHRITIS RHEUM, V36, P1510, DOI 10.1002/art.1780361105
   Haugeberg G, 2005, ARCH INTERN MED, V165, P1293, DOI 10.1001/archinte.165.11.1293
   Haugeberg G, 2002, ARTHRITIS RHEUM US, V46, P1720, DOI 10.1002/art.10408
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Huusko TM, 2001, ANN RHEUM DIS, V60, P521, DOI 10.1136/ard.60.5.521
   Jensen T, 2004, ANN RHEUM DIS, V63, P15, DOI 10.1136/ard.2003.013888
   Josse R, 1996, CAN MED ASSOC J, V155, P1113
   Kroot EJJA, 2001, ARTHRITIS RHEUM, V44, P1254, DOI 10.1002/1529 0131(200106)44:6<1254::AID ART216>3.0.CO;2 G
   Lange U, 2005, RHEUMATOLOGY, V44, P1546, DOI 10.1093/rheumatology/kei082
   Minaur NJ, 2002, RHEUMATOLOGY, V41, P741, DOI 10.1093/rheumatology/41.7.741
   PEEL NFA, 1995, ANN RHEUM DIS, V54, P801, DOI 10.1136/ard.54.10.801
   Pocock NA, 1997, J BONE MINER RES, V12, P2113, DOI 10.1359/jbmr.1997.12.12.2113
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535
   Sambrook PN, 2000, J RHEUMATOL, V27, P2541
   Sambrook PN, 2005, ANN RHEUM DIS, V64, P176, DOI 10.1136/ard.2003.018556
   Seriolo B, 2006, ANN NY ACAD SCI, V1069, P420, DOI 10.1196/annals.1351.040
   SHENSTONE BD, 1994, BRIT J RHEUMATOL, V33, P541
   SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   Verhoeven AC, 1997, J RHEUMATOL, V24, P1495
   Verhoeven AC, 2001, RHEUMATOLOGY, V40, P1231, DOI 10.1093/rheumatology/40.11.1231
   Vis M, 2006, ANN RHEUM DIS, V65, P1495, DOI 10.1136/ard.2005.044198
   Westhovens R, 2000, Z RHEUMATOL, V59, P33
   Zhang J, 1998, JAMA J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 45
TC 75
Z9 78
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2008
VL 67
IS 6
BP 823
EP 828
DI 10.1136/ard.2007.073817
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 299SD
UT WOS:000255774400015
PM 17644545
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Yang, CD
   Wang, KP
   Liu, XF
   Liu, Q
AF Zhou, Yong
   Yang, Chuandong
   Wang, Kunpeng
   Liu, Xuefeng
   Liu, Quan
TI MicroRNA 33b Inhibits the Proliferation and Migration of Osteosarcoma
   Cells via Targeting Hypoxia Inducible Factor 1α
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Osteosarcoma; MicroRNA; Proliferation; Migration; Hypoxia inducible
   factor 1 alpha
ID MESENCHYMAL TRANSITION; EXPRESSION; INVASION; MELANOMA; METASTASIS;
   METABOLISM; CARCINOMA; APOPTOSIS; THERAPY; PROTEIN
AB Recently, microRNA (miR) 33b has been demonstrated to act as a tumor suppressor in osteosarcoma. However, the regulatory mechanism of miR 33b in osteosarcoma cell proliferation and migration remains largely unknown. In this study, real time PCR showed that miR 33b was significantly downregulated in osteosarcoma tissues compared to their matched adjacent nontumor tissues. Its expression was also decreased in several common osteosarcoma cell lines, including Saos 2, MG63, U2OS, and SW1353, when compared to normal osteoblast cell line hFOB. Overexpression of miR 33b suppressed U2OS cell proliferation and migration. HIF 1 alpha was further identified as a target of miR 33b, and its protein levels were reduced after overexpression of miR33b in U2OS cells. Moreover, overexpression of HIF 1 alpha significantly reversed the suppressive effect of miR33b on U2OS cell proliferation and migration. In addition, HIF 1 alpha was found to be significantly upregulated in osteosarcoma tissues compared to adjacent nontumor tissues, and their expression levels were inversely correlated to the miR 33b levels in osteosarcoma tissues. According to these findings, miR 33b plays a suppressive role in the regulation of osteosarcoma cell proliferation and migration via directly targeting HIF 1 alpha. Therefore, we suggest that the miR 33b/HIF 1 alpha axis may become a promising therapeutic target for osteosarcoma.
C1 [Zhou, Yong; Yang, Chuandong; Wang, Kunpeng; Liu, Xuefeng; Liu, Quan] Harbin Med Univ, Affiliated Hosp 4, Dept Orthoped 2, 37 Yiyuan Rd, Harbin 150001, Heilongjiang, Peoples R China.
C3 Harbin Medical University
RP Liu, XF (通讯作者)，Harbin Med Univ, Affiliated Hosp 4, Dept Orthoped 2, 37 Yiyuan Rd, Harbin 150001, Heilongjiang, Peoples R China.
EM liuxuefengdoctor@sina.com
RI Liu, xuefeng/IUP 1483 2023
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Antaramian A, 2015, J SEX MED, V12, P2267, DOI 10.1111/jsm.13073
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Costa Pinheiro P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148 015 0076 2
   Duan ZF, 2011, MOL CANCER THER, V10, P1337, DOI 10.1158/1535 7163.MCT 11 0096
   Fan L, 2012, ACTA BIOCH BIOPH SIN, V44, P407, DOI 10.1093/abbs/gms019
   Guo MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090518
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008 5472.CAN 12 0979
   Liang D, 2012, J CANCER RES CLIN, V138, P1865, DOI 10.1007/s00432 012 1256 5
   Lin S, 2014, J HUAZHONG U SCI MED, V34, P889, DOI 10.1007/s11596 014 1369 y
   Lin YC, 2015, SCI REP UK, V5, DOI 10.1038/srep09995
   Marín Hernández A, 2009, MINI REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Qu JJ, 2015, INT J ONCOL, V47, P2141, DOI 10.3892/ijo.2015.3187
   Schönenberger MJ, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00042
   Shi ZC, 2015, TUMOR BIOL, V36, P8579, DOI 10.1007/s13277 015 3614 9
   Slominski A, 2014, ARCH BIOCHEM BIOPHYS, V563, P79, DOI 10.1016/j.abb.2014.06.030
   Summerer I, 2015, BRIT J CANCER, V113, P76, DOI 10.1038/bjc.2015.111
   Sun QQ, 2015, MOL MED REP, V11, P3330, DOI 10.3892/mmr.2015.3221
   Sun YM, 2015, MOL MED REP, V11, P1975, DOI 10.3892/mmr.2014.2913
   Thompson LDR, 2013, ENT EAR NOSE THROAT, V92, P288
   Wu TY, 2014, INT J CLIN EXP PATHO, V7, P56
   Wu XY, 2013, INT J MED SCI, V10, P676, DOI 10.7150/ijms.5528
   Xu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115300
   Zhang JF, 2015, ONCOL LETT, V10, P2135, DOI 10.3892/ol.2015.3503
   Zhang P, 2015, TOXICOL LETT, V234, P151, DOI 10.1016/j.toxlet.2015.02.018
   Zhang RY, 2016, TUMOR BIOL, V37, P3479, DOI 10.1007/s13277 015 4086 7
   Zhao CF, 2016, J BONE ONCOL, V5, P22, DOI 10.1016/j.jbo.2016.01.002
   Zimna A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/549412
NR 31
TC 44
Z9 45
U1 0
U2 5
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965 0407
EI 1555 3906
J9 ONCOL RES
JI Oncol. Res.
PY 2017
VL 25
IS 3
BP 397
EP 405
DI 10.3727/096504016X14743337535446
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EQ3MT
UT WOS:000397977700010
PM 27662380
OA Green Published
DA 2025 08 17
ER

PT J
AU Jewett, A
   Kos, J
   Kaur, K
   Turnsek, TL
   Breznik, B
   Senjor, E
   Wong, P
   Nguyen, KY
   Ko, MW
AF Jewett, Anahid
   Kos, Janko
   Kaur, Kawaljit
   Turnsek, Tamara Lah
   Breznik, Barbara
   Senjor, Emanuela
   Wong, Paul
   Nguyen, Kristin Y.
   Ko, Meng Wei
TI Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy,
   Dysregulated Systemic Immunity, and Immunosuppression in Metastatic
   Cancer
SO CRITICAL REVIEWS IN IMMUNOLOGY
LA English
DT Article
DE NK cells; cancer stem cells; differentiation; cancer immunotherapy;
   probiotics; osteoclasts; supercharged NK cells; humanized BLT mice;
   preneoplastic; KRAS; cytotoxicity
ID NF KAPPA B; PERIPHERAL BLOOD LYMPHOCYTES; HUMAN GLIOBLASTOMA CELLS;
   ONCOLYTIC VIRAL THERAPY; ZETA CHAIN EXPRESSION; NK CELLS; STEM CELLS;
   CYSTATIN F; TUMOR MICROENVIRONMENT; INFLAMMATORY RESPONSE
AB We have previously demonstrated that natural killer (NK) cells are the main immune effectors that can mediate selection and differentiation of different cancer stem cells and undifferentiated tumors via lysis and secreted or membrane bound interferon gamma and tumor necrosis factor alpha, respectively. This leads to growth inhibition and tumor metastasis curtailment. In this review, we present an overview of our findings on NK cell biology and its significance in selection and differentiation of stem like tumors using in vitro and in vivo studies conducted in nonobese diabetic/severe combined immunodeficiency (scid)/interleukin R gamma(   ), humanized bone marrow/liver/thymus (hu BLT) mice, and those of human cancer patients. Moreover, we present recent advances in NK cell expansion and therapeutic delivery and discuss the superiority of allogeneic supercharged NK cells over their autologous counterparts for cancer treatment. We review potential loss of NK cell numbers and function at neoplastic and preneoplastic stages of tumorigenesis as a potential mechanism for pancreatic cancer induction and progression. We believe that NK cells should be placed highly in the armamentarium of tumor immunotherapy due to their indispensable role in targeting cancer stem like/poorly differentiated tumors and a variety of other key NK cell functions that are discussed in this report, including their role in CD8(+) T cell expansion and targeting gene knockout or dedifferentiated tumors. The combination of allogeneic supercharged NK cells and other immunotherapeutic strategies such as oncolytic viruses, antibody dependent cellular cytotoxicity inducing antibodies, checkpoint inhibitors, chimeric antigen receptor (CAR) T cells and CAR NK cells, chemotherapeutics, and radiotherapeutic strategies can be used for optimal eradication of tumors.
C1 [Jewett, Anahid; Kaur, Kawaljit; Breznik, Barbara; Senjor, Emanuela; Wong, Paul; Nguyen, Kristin Y.; Ko, Meng Wei] Univ Calif Los Angeles, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Oral Biol & Med, Los Angeles, CA USA.
   [Jewett, Anahid] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med & Dent, Los Angeles, CA 90024 USA.
   [Kos, Janko; Senjor, Emanuela] Jozef Stefan Inst, Dept Biotechnol, Ljubljana, Slovenia.
   [Kos, Janko; Senjor, Emanuela] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia.
   [Turnsek, Tamara Lah; Breznik, Barbara] Natl Inst Biol, Dept Genet Toxicol & Canc Biol, Ljubljana, Slovenia.
C3 University of California System; University of California Los Angeles;
   UCLA Jonsson Comprehensive Cancer Center; University of California
   System; University of California Los Angeles; Slovenian Academy of
   Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana;
   National Institute of Biology   Slovenia
RP Jewett, A (通讯作者)，Univ Calif Los Angeles, Sch Med & Dent, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM ajewett@dentistry.ucla.edu
RI Barbara, Breznik/ABE 7972 2020; Kos, Janko/AAX 6462 2021; Kaur,
   Kawaljit/A 3222 2013
OI Senjor, Emanuela/0000 0002 1040 5365; Breznik,
   Barbara/0000 0003 0247 5811; Wong, Paul/0000 0002 5833 0331; Kaur,
   Kawaljit/0000 0003 1936 5985
CR Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869
   Ady JW, 2014, ONCOLYTIC VIROTHER, V3, P35, DOI 10.2147/OV.S53858
   Alderson KL, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/379123
   Alex P, 2010, J IMMUNOL, V184, P3988, DOI 10.4049/jimmunol.0901657
   Ames E, 2015, J IMMUNOL, V195, P4010, DOI 10.4049/jimmunol.1500447
   Aoukaty A, 2005, J IMMUNOL, V174, P4551, DOI 10.4049/jimmunol.174.8.4551
   Baker GJ, 2014, CANCER RES, V74, P5079, DOI 10.1158/0008 5472.CAN 14 1203
   Barak H, 2012, DEV CELL, V22, P1191, DOI 10.1016/j.devcel.2012.04.018
   Barta P, 2012, MOL CANCER, V11, DOI 10.1186/1476 4598 11 4
   Bedel R, 2011, CANCER RES, V71, P1615, DOI 10.1158/0008 5472.CAN 09 4540
   Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200
   Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood 2010 02 271874
   Beraza N, 2009, J EXP MED, V206, P1727, DOI 10.1084/jem.20082152
   Bergström I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174177
   Bhat R, 2011, INT J CANCER, V128, P908, DOI 10.1002/ijc.25415
   Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030668
   Bochem AE, 2015, ARTERIOSCL THROM VAS, V35, P1663, DOI 10.1161/ATVBAHA.114.304959
   Bognar P, 2014, J INVEST DERMATOL, V134, P105, DOI 10.1038/jid.2013.307
   Bonamichi BD, 2017, DIABETES METAB J, V41, P229, DOI 10.4093/dmj.2017.41.4.229
   BONAVIDA B, 1993, NAT IMMUN, V12, P194
   Breznik B, 2017, ONCOTARGET, V8, P25482, DOI 10.18632/oncotarget.16041
   Bücklein V, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1178421
   Bugide S, 2018, P NATL ACAD SCI USA, V115, pE3509, DOI 10.1073/pnas.1802691115
   Bui VT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00576
   Burke S, 2010, TRENDS IMMUNOL, V31, P339, DOI 10.1016/j.it.2010.06.003
   Cacalano N, 2008, APOPTOSIS, V13, P1439, DOI 10.1007/s10495 008 0270 1
   Carlens S, 2001, HUM IMMUNOL, V62, P1092, DOI 10.1016/S0198 8859(01)00313 5
   Ochoa MC, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1393597
   Carrega P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00347
   Castriconi R, 2013, J IMMUNOL, V190, P5321, DOI 10.4049/jimmunol.1202693
   Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845
   Cekic C, 2014, CANCER RES, V74, P7250, DOI 10.1158/0008 5472.CAN 13 3583
   Chan CB, 2009, P NATL ACAD SCI USA, V106, P468, DOI 10.1073/pnas.0809824105
   Chanvillard C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00063
   Chaurasiya S, 2018, CURR OPIN IMMUNOL, V51, P83, DOI 10.1016/j.coi.2018.03.008
   Chiu J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00267
   Cichocki F, 2017, CANCER RES, V77, P5664, DOI 10.1158/0008 5472.CAN 17 0799
   Cifaldi L, 2015, ARTHRITIS RHEUMATOL, V67, P3037, DOI 10.1002/art.39295
   Ciszak L, 2009, ONCOL REP, V21, P173, DOI 10.3892/or_00000205
   Colbert JD, 2011, J BIOL CHEM, V286, P42082, DOI 10.1074/jbc.M111.253914
   Colbert JD, 2009, TRAFFIC, V10, P425, DOI 10.1111/j.1600 0854.2009.00881.x
   Concha Benavente F, 2018, CANCER IMMUNOL RES, V6, P1548, DOI 10.1158/2326 6066.CIR 18 0062
   Cook KD, 2014, CRIT REV IMMUNOL, V34, P359, DOI 10.1615/CritRevImmunol.2014010604
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471 4906(01)02060 9
   Cortés Vieyra R, 2012, J INFLAMM LOND, V9, DOI 10.1186/1476 9255 9 23
   Costa D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01150
   Coutu DL, 2011, AGING US, V3, P920, DOI 10.18632/aging.100369
   D'Angelo ME, 2010, J BIOL CHEM, V285, P20514, DOI 10.1074/jbc.M109.094573
   Daniel S, 2004, BLOOD, V104, P2376, DOI 10.1182/blood 2003 02 0635
   Deng JO, 2010, CANCER PREV RES, V3, P424, DOI 10.1158/1940 6207.CAPR 10 0032
   DeSanctis JB, 1996, CELL IMMUNOL, V167, P18, DOI 10.1006/cimm.1996.0003
   Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424
   Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201
   Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008 5472.CAN 06 3974
   Dong L, 2016, CNS NEUROSCI THER, V22, P661, DOI 10.1111/cns.12557
   Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001
   Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215
   Fang F, 2017, SEMIN IMMUNOL, V31, P37, DOI 10.1016/j.smim.2017.07.009
   Finocchiaro G, 2014, CURR OPIN ONCOL, V26, P608, DOI 10.1097/CCO.0000000000000135
   Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008
   Fu XY, 2006, CELL RES, V16, P214, DOI 10.1038/sj.cr.7310029
   Fujisaki H, 2009, CANCER RES, V69, P4010, DOI 10.1158/0008 5472.CAN 08 3712
   Furutani E, 2010, BLOOD, V116, P446, DOI 10.1182/blood.V116.21.1015.1015
   Galland S, 2017, CELL REP, V20, P2891, DOI 10.1016/j.celrep.2017.08.089
   Gironella M, 2007, GUT, V56, P1091, DOI 10.1136/gut.2006.116087
   Gogali F, 2013, THYROID, V23, P1561, DOI 10.1089/thy.2012.0560
   Golan I, CANCERS BASEL
   Goumas FA, 2015, INT J CANCER, V137, P1035, DOI 10.1002/ijc.29445
   Guedes RP, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742 2094 11 122
   Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205
   Guo Z, 2014, ENDOCR RELAT CANCER, V21, pT285, DOI 10.1530/ERC 14 0002
   Hamilton G, 2008, EMBO J, V27, P499, DOI 10.1038/sj.emboj.7601979
   Han X, 1997, GYNECOL ONCOL, V65, P391, DOI 10.1006/gyno.1997.4668
   Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200
   Haspels HN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01345
   He YK, 2017, J AUTOIMMUN, V81, P1, DOI 10.1016/j.jaut.2017.04.001
   Hinrichs CS, 2019, SCI TRANSL MED, V11
   Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317
   Hu ZW, 2017, ONCOTARGET, V8, P1481, DOI 10.18632/oncotarget.13644
   Ichise H, 2017, STEM CELL REP, V9, P853, DOI 10.1016/j.stemcr.2017.07.020
   Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008 5472.CAN 11 4062
   Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140 6736(00)03231 1
   Jarahian M, 2009, J VIROL, V83, P8108, DOI 10.1128/JVI.00211 09
   Jewett A, 2006, CANCER IMMUNOL IMMUN, V55, P1052, DOI 10.1007/s00262 005 0093 7
   Jewett A, 2006, CLIN CANCER RES, V12, P1994, DOI 10.1158/1078 0432.CCR 05 2306
   Jewett A, 1996, J IMMUNOL, V156, P907
   Jewett A, 2003, HUM IMMUNOL, V64, P505, DOI 10.1016/S0198 8859(03)00039 9
   JEWETT A, 1995, CELL IMMUNOL, V160, P91, DOI 10.1016/0008 8749(95)80013 9
   Jewett A, 1997, J IMMUNOL, V159, P4815
   Jewett A, TUMOR IMMUNOENVIRONM
   Jewett A, 2008, CANCER IMMUNOL IMMUN, V57, P1053, DOI 10.1007/s00262 007 0437 6
   Jewett A, 2020, MOL THER ONCOLYTICS, V16, P41, DOI 10.1016/j.omto.2019.11.002
   Jewett A, 2018, SEMIN CANCER BIOL, V53, P178, DOI 10.1016/j.semcancer.2018.08.001
   Jewett A, 2014, J IMMUNOTOXICOL, V11, P297, DOI 10.3109/1547691X.2013.877104
   Jewett A, 2013, J CANCER, V4, P12, DOI 10.7150/jca.5519
   Jewett A, 2012, CURR DRUG DELIV, V9, P5, DOI 10.2174/156720112798375989
   Jewett A, 2011, J CANCER, V2, P443, DOI 10.7150/jca.2.443
   Jewett A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009874
   Jurisic V, 2007, MED ONCOL, V24, P312, DOI 10.1007/s12032 007 0007 y
   Kamiya T, 2019, J CLIN INVEST, V129, P2094, DOI 10.1172/JCI123955
   Kaur G, 2013, BRAIN, V136, P2657, DOI 10.1093/brain/aws159
   Kaur K, 2020, CANCERS, V12, DOI 10.3390/cancers12010063
   Kaur K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01229
   Kaur K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426518
   Kaur K, 2018, CURR OPIN IMMUNOL, V51, P170, DOI 10.1016/j.coi.2018.03.022
   Kaur K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01606
   Kaur K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00297
   Kim HS, 2010, IMMUNITY, V32, P175, DOI 10.1016/j.immuni.2010.02.004
   Kim HW, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005926
   Kim N, 2019, ARCH PHARM RES, V42, P591, DOI 10.1007/s12272 019 01143 y
   Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847
   Kohga K, 2010, J HEPATOL, V52, P872, DOI 10.1016/j.jhep.2009.12.030
   Konjar S, 2010, IMMUNOLOGY, V131, P257, DOI 10.1111/j.1365 2567.2010.03299.x
   Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325
   Kozlowska AK, 2017, FRONT BIOSCI LANDMRK, V22, P370, DOI 10.2741/4489
   Kozlowska AK, 2016, CANCER IMMUNOL IMMUN, V65, P1085, DOI 10.1007/s00262 016 1866 x
   Kozlowska AK, 2017, J CANCER, V8, P537, DOI 10.7150/jca.15989
   Krneta T, 2016, CELL MOL IMMUNOL, V13, P628, DOI 10.1038/cmi.2015.42
   Kuss I, 1999, CLIN CANCER RES, V5, P329
   Lah TT, 2019, SEMIN CANC BIOL
   Lai P, 1996, CLIN CANCER RES, V2, P161
   Lamano JB, 2019, CLIN CANCER RES, V25, P3643, DOI 10.1158/1078 0432.CCR 18 2402
   Lametschwandtner G, 2015, J IMMUNOTHER CANC S2, V3, pP230
   Langerholc T, 2005, FEBS J, V272, P1535, DOI 10.1111/j.1742 4658.2005.04594.x
   Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600 065X.2008.00720.x
   Lee BC, 2016, CELL METAB, V23, P685, DOI 10.1016/j.cmet.2016.03.002
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Lee YS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01379
   Leivas A, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1250051
   Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009
   Liu B, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935 015 0260 7
   Lokody I, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3707
   Long KB, 2017, MOL CANCER THER, V16, P1898, DOI 10.1158/1535 7163.MCT 16 0899
   Long YP, 2018, CANCER MED US, V7, P4690, DOI 10.1002/cam4.1713
   López Cobo S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1392426
   López Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009
   Lv YF, 2012, INFLAMM BOWEL DIS, V18, P1950, DOI 10.1002/ibd.22887
   Magister S, 2015, ONCOTARGET, V6, P22310, DOI 10.18632/oncotarget.4208
   Magister S, 2013, J CANCER, V4, P45, DOI 10.7150/jca.5044
   Maher K, 2014, PROTEIN PEPTIDE LETT, V21, P957, DOI 10.2174/0929866521666140403124146
   Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078 0432.CCR 14 0635
   Melsen JE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00262
   Mendez Huergo SP, 2018, FRONT IMMUNOL, V93057
   Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590 018 0251 7
   MIESCHER S, 1988, CANCER RES, V48, P6992
   Miranda D, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9605253
   Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632
   Muinao T, 2018, EXP CELL RES, V362, P1, DOI 10.1016/j.yexcr.2017.10.018
   Murray S, 2016, HUM VACC IMMUNOTHER, V12, P607, DOI 10.1080/21645515.2015.1096458
   Nagathihalli NS, 2016, ONCOTARGET, V7, P65982, DOI 10.18632/oncotarget.11786
   Nakazawa T, 2014, J NEURO ONCOL, V116, P31, DOI 10.1007/s11060 013 1258 4
   Nanut MP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01459
   Nanut MP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00616
   O'Brien KL, 2019, NAT REV IMMUNOL, V19, P282, DOI 10.1038/s41577 019 0139 2
   Ogbomo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066825
   Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858
   Pallmer K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00251
   Parameswaran R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11154
   Pasero C, 2016, CANCER RES, V76, P2153, DOI 10.1158/0008 5472.CAN 15 1965
   Pazina T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00369
   Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78
   Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627
   Pham DH, 2017, ANTICANCER RES, V37, P5507, DOI 10.21873/anticanres.11981
   Nguyen PH, 2017, CLIN CANCER RES, V23, P1586, DOI 10.1158/1078 0432.CCR 15 2157
   Poli A, 2013, ONCOTARGET, V4, P1527, DOI 10.18632/oncotarget.1291
   Poli A, 2013, J IMMUNOL, V190, P5355, DOI 10.4049/jimmunol.1203401
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Prunk M, 2019, RADIOL ONCOL, V53, P57, DOI 10.2478/raon 2019 0007
   Purdy AK, 2009, J IMMUNOL, V183, P7234, DOI 10.4049/jimmunol.0900088
   Qin J, 1997, Zhonghua Yi Xue Za Zhi, V77, P167
   Radosavljevic G, 2011, CLIN EXP METASTAS, V28, P451, DOI 10.1007/s10585 011 9383 y
   Rahal A, 2017, J SURG ONCOL, V116, P94, DOI 10.1002/jso.24626
   Ramakrishnan S, 2019, CELL DEATH DIFFER, V26, P2100, DOI 10.1038/s41418 019 0278 9
   Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604
   Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027
   Ricci Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Romero Reyes M, 2007, APOPTOSIS, V12, P2063, DOI 10.1007/s10495 007 0112 6
   Roviezzo F, 2002, J PHYSIOL PHARMACOL, V53, P541
   Sasaki A, 2001, Brain Tumor Pathol, V18, P13, DOI 10.1007/BF02478920
   Scheller J, 2011, BBA MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Schmid JMP, 2006, PEDIATRICS, V117, pE1049, DOI 10.1542/peds.2005 2062
   Schmohl JU, 2016, TARGET ONCOL, V11, P353, DOI 10.1007/s11523 015 0391 8
   Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110
   Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434 007 9583 5
   Shan YZ, 2015, INT J CLIN EXP MED, V8, P9114
   Shurin MR, 3 CANC IMM IMM CITIM
   Spanholtz J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009221
   Suárez Fueyo A, 2018, J IMMUNOL, V200, P3077, DOI 10.4049/jimmunol.1700588
   Sutton VR, 2007, J CELL BIOL, V176, P425, DOI 10.1083/jcb.200609077
   TADA M, 1993, J NEURO ONCOL, V16, P25, DOI 10.1007/BF01324831
   Tai LH, 2013, CANCER RES, V73, P97, DOI 10.1158/0008 5472.CAN 12 1993
   Tato CM, 2006, INT IMMUNOL, V18, P505, DOI 10.1093/intimm/dxh391
   Thompson TW, 2017, ELIFE, V6, DOI 10.7554/eLife.30881
   Thompson WL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742 2094 5 35
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Toden S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21478 8
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Tseng HC, 2015, J CANCER, V6, P866, DOI 10.7150/jca.11527
   Tseng HC, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00259
   Tseng HC, 2015, ONCOTARGET, V6, P8947, DOI 10.18632/oncotarget.3250
   Tseng HC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00269
   Tseng HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011590
   TSUBOI I, 1995, CYTOKINE, V7, P372, DOI 10.1006/cyto.1995.0047
   Tsukerman P, 2015, ONCOTARGET, V6, P44151, DOI 10.18632/oncotarget.6629
   van Helden YGJ, 2010, CELL MOL LIFE SCI, V67, P2039, DOI 10.1007/s00018 010 0341 7
   VAN MEIR E, 1992, CANCER RES, V52, P4297
   Verdeil G, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.958951
   Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884
   Vitale M, 2014, EUR J IMMUNOL, V44, P1582, DOI 10.1002/eji.201344272
   Wang B, 2014, CANCER RES, V74, P5746, DOI 10.1158/0008 5472.CAN 13 2563
   Wang W, 2014, J BIOL CHEM, V289, P33311, DOI 10.1074/jbc.M114.603464
   Woroniecka K, 2018, CLIN CANCER RES, V24, P4175, DOI 10.1158/1078 0432.CCR 17 1846
   Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059
   Wu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1310 0
   Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359 6101(01)00016 8
   Xu F, 2017, CANCER IMMUNOL IMMUN, V66, P1367, DOI 10.1007/s00262 017 2031 x
   Xu LJ, 2018, MOL ONCOL, V12, P269, DOI 10.1002/1878 0261.12135
   Xu XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041869
   Xu YB, 2013, CANCER IMMUNOL IMMUN, V62, P1637, DOI 10.1007/s00262 013 1466 y
   Yin J, 2015, P NATL ACAD SCI USA, V112, P15988, DOI 10.1073/pnas.1521740112
   Yin K, 2010, MOL MED, V16, P438, DOI 10.2119/molmed.2010.00004
   Young A, 2018, CANCER RES, V78, P1003, DOI 10.1158/0008 5472.CAN 17 2826
   Zamarin D, 2018, J CLIN INVEST, V128, P1413, DOI 10.1172/JCI98047
   Zamarin D, 2014, MOL THER ONCOLYTICS, V1, DOI 10.1038/mto.2014.4
   Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095
   Zhang CC, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv375
   Zhu X, 2008, J BIOL CHEM, V283, P22930, DOI 10.1074/jbc.M801408200
NR 227
TC 15
Z9 20
U1 1
U2 14
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1040 8401
EI 2162 6472
J9 CRIT REV IMMUNOL
JI Crit. Rev. Immunol.
PY 2020
VL 40
IS 2
BP 93
EP 133
DI 10.1615/CritRevImmunol.2020033391
PG 41
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA MG8VS
UT WOS:000546311900001
PM 32749091
DA 2025 08 17
ER

PT J
AU Zhang, ZH
   Wang, L
   Zhang, FY
   Jing, SC
   Cen, MN
AF Zhang, Zhihan
   Wang, Li
   Zhang, Fangyuan
   Jing, Shaochun
   Cen, Meini
TI Functional mechanism and clinical implications of mir 1271 5p in pilon
   fracture healing processes
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE miR 1271 5p; ZBTB7A; Pilon fracture
ID INHIBITS CELL PROLIFERATION; OSTEOBLAST DIFFERENTIATION
AB BackgroundPilon fractures are challenging to treat and carry a risk of delayed healing. MicroRNA (miRNA) is closely associated with various diseases due to its ability to regulate gene expression. Consequently, this study aimed to examine the connection between miR 1271 5p expression levels and pilon fracture healing processes, while also exploring the underlying mechanisms. The objective of this research was to provide valuable insights for the future clinical treatment of pilon fractures.MaterialsVenous blood samples were obtained for RNA extraction from patients with normal healing (n = 107) or delayed healing (n = 45) of pilon fractures. The expression levels of miR 1271 5p were measured using qRT PCR. MiR 1271 5p and ZBTB7A biological functions in MC3T3 E1 cells were examined using the Cell Counting Kit 8 (CCK 8), flow cytometry, and qRT PCR. Finally, an investigation into the underlying mechanisms was carried out using a dual luciferase reporter assay.ResultsThis study found that, compared to those who healed normally, patients who experienced delayed healing of pilon fractures had significantly higher expression of miR 1271 5p. This suggests that miR 1271 5p may be an indicator for delayed healing in pilon fractures. Moreover, the upregulation of miR 1271 5p may result in a reduction of ZBTB7A expression, which is thought to mediate the effects of miR 1271 5p on MC3T3 E1 cell activities.ConclusionsMiR 1271 5p was involved in the healing processes of pilon fractures via targeting ZBTB7A. MiR 1271 5p was a possible target for the therapy of pilon fractures.
C1 [Zhang, Zhihan] Wuhan Univ, Zhongnan Hosp, Dept Orthopaed Trauma & Microsurg, Wuhan 430071, Peoples R China.
   [Wang, Li] Shenzhen Univ Gen Hosp, Dept Joint & Trauma Surg, Shenzhen 518055, Peoples R China.
   [Zhang, Fangyuan] First Hosp Qinhuangdao, Dept Trauma Surg, Qinhuangdao 066000, Peoples R China.
   [Jing, Shaochun] Second Hosp Qinhuangdao, Dept Traumat Arthropathy, 133,Chaoyang South St, Qinhuangdao 066000, Hebei, Peoples R China.
   [Cen, Meini] Youjiang Med Univ Nationalities, Dept Rehabil Med, Affiliated Hosp, 18 Zhongshan 2nd Rd, Baise 533000, Guangxi, Peoples R China.
C3 Wuhan University; Youjiang Medical University for Nationalities
RP Jing, SC (通讯作者)，Second Hosp Qinhuangdao, Dept Traumat Arthropathy, 133,Chaoyang South St, Qinhuangdao 066000, Hebei, Peoples R China.; Cen, MN (通讯作者)，Youjiang Med Univ Nationalities, Dept Rehabil Med, Affiliated Hosp, 18 Zhongshan 2nd Rd, Baise 533000, Guangxi, Peoples R China.
EM shaochunjing96@163.com; cenmeini96@163.com
RI Zhang, Fangyuan/IZE 0121 2023
FU Hebei Province Medical Science research project
FX Not applicable.
CR Ali Syeda Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051723
   Aliç T, 2022, INDIAN J ORTHOP, V56, P2119, DOI 10.1007/s43465 022 00743 z
   Aliç T, 2016, ACTA ORTHOP TRAUMATO, V50, P103, DOI 10.3944/AOTT.2016.15.0211
   [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053
   Bowers KM, 2024, BIOENGINEERING BASEL, V11, DOI 10.3390/bioengineering11060525
   Cai Yimei, 2009, Genomics Proteomics & Bioinformatics, V7, P147, DOI 10.1016/S1672 0229(08)60044 3
   Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224
   Chen XH, 2019, MOL MED REP, V19, P508, DOI 10.3892/mmr.2018.9680
   Costoya Jose A., 2007, Briefings in Functional Genomics & Proteomics, V6, P8, DOI 10.1093/bfgp/elm002
   Feng L, 2019, PHARM BIOL, V57, P586, DOI 10.1080/13880209.2019.1657153
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Gargano G, 2023, BRIT MED BULL, V148, P58, DOI 10.1093/bmb/ldad023
   Gargano G, 2022, BRIT MED BULL, V142, P34, DOI 10.1093/bmb/ldac012
   Gargano G, 2021, BRIT MED BULL, V138, P58, DOI 10.1093/bmb/ldaa040
   Giordano L, 2020, BRIT MED BULL, V133, P79, DOI 10.1093/bmb/ldaa002
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Gong J, 2017, MOL MED REP, V16, P143, DOI 10.3892/mmr.2017.6610
   Gupta S, 2020, Cancer Lett, P48322
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Ho PTB, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23137167
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Izumiya M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147752
   Jeong JH, 2023, EXP MOL MED, V55, P43, DOI 10.1038/s12276 022 00908 8
   Khanna A, 2008, BRIT MED BULL, V88, P147, DOI 10.1093/bmb/ldn024
   Kim T, 2023, EXP MOL MED, V55, P1314, DOI 10.1038/s12276 023 01050 9
   Kodama H, 1981, Establishment of a clonal osteogenic cell line from newborn mouse calvaria, P23899
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Kottmeier SA, 2018, J AM ACAD ORTHOP SUR, V26, P640, DOI 10.5435/JAAOS D 17 00160
   Kugach KA, 2024, CLIN PODIATR MED SUR, V41, P503, DOI 10.1016/j.cpm.2024.01.007
   Li Z, 2021, Mol Med Rep, V23
   Lin MF, 2017, INT J BIOCHEM CELL B, V88, P155, DOI 10.1016/j.biocel.2017.05.019
   Liu JQ, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 022 02596 w
   Ma X, 2019, Front Bioeng Biotechnol, P7330
   de Albornoz PM, 2011, BRIT MED BULL, V100, P39, DOI 10.1093/bmb/ldr006
   Migliorini F, 2023, EXPERT OPIN INV DRUG, V32, P855, DOI 10.1080/13543784.2023.2263352
   Nelson Fred R T, 2003, J Am Acad Orthop Surg, V11, P344
   Oliviero A, 2019, BRIT MED BULL, V130, P137, DOI 10.1093/bmb/ldz015
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486
   Singh AK, 2021, MOL BIOL REP, V48, P4703, DOI 10.1007/s11033 021 06405 x
   Tian Y, 2019, EUR REV MED PHARMACO, V23, P5648, DOI 10.26355/eurrev_201907_18300
   Tsuji Takechi K, 2012, P NATL ACAD SCI USA, V109, P2561, DOI 10.1073/pnas.1116042109
   Vishnoi A., 2023, Methods Mol Biol, V25951, P12
   Waki T, 2016, BMC Musculoskelet Disord, P1783
   Wiebking U, 2017, UNFALLCHIRURG, V120, P632, DOI 10.1007/s00113 017 0363 9
   Yang QN, 2021, CELL BIOL INT, V45, P1468, DOI 10.1002/cbin.11585
   Yeh LY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00047
   Zhou KN, 2021, DNA CELL BIOL, V40, P740, DOI 10.1089/dna.2021.0100
   Zhu ZJ, 2017, BIOCHEM BIOPH RES CO, V486, P49, DOI 10.1016/j.bbrc.2017.02.121
   Zou W, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10613
NR 51
TC 5
Z9 5
U1 2
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD NOV 22
PY 2024
VL 19
IS 1
AR 782
DI 10.1186/s13018 024 05291 w
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA N1Z0O
UT WOS:001362385400006
PM 39578827
OA gold
DA 2025 08 17
ER

PT J
AU Igawa, K
   Ohara, N
   Kawakubo, A
   Sugimoto, K
   Yanagiguchi, K
   Ikeda, T
   Yamada, S
   Hayashi, Y
AF Igawa, Kazunari
   Ohara, Naoko
   Kawakubo, Atsushi
   Sugimoto, Kouji
   Yanagiguchi, Kajiro
   Ikeda, Takeshi
   Yamada, Shizuka
   Hayashi, Yoshihiko
TI D Glucosamine Promotes Transfection Efficiency during Electroporation
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID PROTON SPONGE; GENE TRANSFER; DNA; CELLS
AB D Glucosamine is a useful medicament in various fields of medicine and dentistry. With respect to stability of the cell membrane, it has been reported that bradykinin induced nociceptive responses are significantly suppressed by the direct application of D glucosamine. Electroporation is usually used to effectively introduce foreign genes into tissue culture cells. Buffers for electroporation with or without D glucosamine are used in experiments of transfection vectors. This is the first study to indirectly observe the stability and protection of the osteoblast membrane against both electric stress and gene uptake (the proton sponge hypothesis: osmotic rupture during endosomes prior to fusion with lysosomes) in electroporation with D glucosamine application. The transfection efficiency was evaluated as the fluorescence intensity of the transfected green fluorescent protein (GFP) in the cultured cells (osteoblasts; NOS 1 cells). The transfection efficiency increased over 30% in the electroporation samples treated with D glucosamine supplemented buffer after one day. The membrane absorption of D glucosamine is the primary mechanism of membrane stress induced by electric stress. This new function of D glucosamine is useful and meaningful for developing more effective transformation procedures.
C1 [Igawa, Kazunari; Kawakubo, Atsushi; Sugimoto, Kouji; Yanagiguchi, Kajiro; Ikeda, Takeshi; Yamada, Shizuka; Hayashi, Yoshihiko] Nagasaki Univ, Sch Biomed Sci, Dept Cariol, Nagasaki 8528588, Japan.
   [Ohara, Naoko] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Conservat Dent, Okayama 7008558, Japan.
C3 Nagasaki University; Okayama University
RP Hayashi, Y (通讯作者)，Nagasaki Univ, Sch Biomed Sci, Dept Cariol, Nagasaki 8528588, Japan.
EM hayashi@nagasaki u.ac.jp
FU Japan Society; Ministry of Education, Science, Sports and Culture of
   Japan [16390547]; Grants in Aid for Scientific Research [16390547,
   24592875] Funding Source: KAKEN
FX This work was supported by a Grant in Aid for Challenging Exploratory
   Research from the Japan Society, contract grant sponsor: Ministry of
   Education, Science, Sports and Culture of Japan, Contract Grant no.
   16390547.
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Behr JP, 1997, CHIMIA, V51, P34
   Borer JS, 2007, EUR HEART J, V28, P1904, DOI 10.1093/eurheartj/ehm209
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   CROLLE G, 1980, CURR MED RES OPIN, V7, P104, DOI 10.1185/03007998009112035
   Godbey WT, 2000, J BIOMED MATER RES, V51, P321, DOI 10.1002/1097 4636(20000905)51:3<321::AID JBM5>3.0.CO;2 R
   HOTTA T, 1992, ACTA PATHOL JAPON, V42, P595
   Hua J, 2002, J LEUKOCYTE BIOL, V71, P632
   Kaida K, 2013, J DENT SCI, V8, P68, DOI 10.1016/j.jds.2012.09.022
   Lohmander LS, 2007, LANCET, V370, P2082, DOI 10.1016/S0140 6736(07)61879 0
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Muzzarelli R. A. A., 1999, CHITIN CHITINASES, P285
   Pack DW, 2000, BIOTECHNOL BIOENG, V67, P217, DOI 10.1002/(SICI)1097 0290(20000120)67:2<217::AID BIT11>3.3.CO;2 H
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021
   Shigemasa Y, 1996, BIOTECHNOL GENET ENG, V13, P383, DOI 10.1080/02648725.1996.10647935
   Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454
NR 17
TC 6
Z9 6
U1 0
U2 20
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 485867
DI 10.1155/2014/485867
PG 4
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AB4EB
UT WOS:000331741100001
PM 24678506
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kulesza, A
   Zielniok, K
   Hawryluk, J
   Paczek, L
   Burdzinska, A
AF Kulesza, Agnieszka
   Zielniok, Katarzyna
   Hawryluk, Jakub
   Paczek, Leszek
   Burdzinska, Anna
TI Ibuprofen in Therapeutic Concentrations Affects the Secretion of Human
   Bone Marrow Mesenchymal Stromal Cells, but Not Their Proliferative and
   Migratory Capacity
SO BIOMOLECULES
LA English
DT Article
DE ibuprofen; human mesenchymal stromal cells; bone marrow; secretion;
   prostaglandin E2; cyclooxygenase; immunomodulation; regeneration
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STEM CELLS; DIFFERENTIATION;
   MECHANISMS; INHIBITION; EFFICACY; MUSCLE; NSAIDS; PROSTAGLANDIN E2;
   MEDICATION
AB Mesenchymal stromal cells (MSCs) are able to modulate the immune system activity and the regeneration processes mainly through the secretion of multiple soluble factors, including prostaglandin E2 (PGE(2)). PGE(2) is produced as a result of cyclooxygenases (COX) activity. In the present study, we investigated how ibuprofen, a nonselective COX inhibitor, affects the proliferation, migration and secretion of human bone marrow MSCs (hBM MSCs). For this purpose, six hBM MSCs populations were treated with ibuprofen at doses which do not differ from maximum serum concentrations during standard pharmacotherapy. Ibuprofen treatment (25 or 50 mu g/mL) substantially reduced the secretion of PGE(2) in all tested populations. Following ibuprofen administration, MSCs were subjected to proliferation (BrdU), transwell migration, and scratch assays, while its effect on MSCs secretome was evaluated by Proteome Profiler and Luminex immunoassays. Ibuprofen did not cause statistically significant changes in the proliferation rate and migration ability of MSCs (p > 0.05). However, ibuprofen (25 mu g/mL for 3 days) significantly decreased mean secretion of: CCL2 (by 44%), HGF (by 31%), IL 6 (by 22%), VEGF (by 20%) and IL 4 (by 8%) compared to secretion of control MSCs (p < 0.05). Our results indicate that ibuprofen at therapeutic concentrations may impair the pro regenerative properties of hBM MSCs.
C1 [Kulesza, Agnieszka; Hawryluk, Jakub; Paczek, Leszek; Burdzinska, Anna] Med Univ Warsaw, Fac Med, Dept Immunol Transplantol & Internal Dis, Nowogrodzka 59, PL 02006 Warsaw, Poland.
   [Zielniok, Katarzyna] Med Univ Warsaw, Fac Med, Dept Clin Immunol, Nowogrodzka 59, PL 02006 Warsaw, Poland.
   [Paczek, Leszek] Polish Acad Sci, Inst Biochem & Biophys, Dept Bioinformat, Pawinskiego 5A, PL 02106 Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Warsaw; Polish
   Academy of Sciences; Institute of Biochemistry & Biophysics   Polish
   Academy of Sciences
RP Burdzinska, A (通讯作者)，Med Univ Warsaw, Fac Med, Dept Immunol Transplantol & Internal Dis, Nowogrodzka 59, PL 02006 Warsaw, Poland.
EM akulesza@wum.edu.pl; katarzyna.zielniok@wum.edu.pl;
   jakub.m.hawryluk@gmail.com; leszek.paczek@wum.edu.pl;
   anna.burdzinska@wum.edu.pl
RI Burdzinska, Anna/Q 2402 2016; Zielniok, Katarzyna/AAN 9954 2021
OI Burdzinska, Anna/0000 0001 7148 5971; Paczek,
   Leszek/0000 0003 0160 3009; Zielniok, Katarzyna/0000 0002 9984 6721
FU National Science Centre, Poland [2018/29/N/NZ6/02771]
FX FundingThis study was funded by the National Science Centre, Poland.
   Grant number: 2018/29/N/NZ6/02771.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Andreeva E, 2017, CYTOTHERAPY, V19, P1152, DOI 10.1016/j.jcyt.2017.07.001
   Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359 6101(00)00014 9
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   Brooks G, 2003, J PHARM PHARMACOL, V55, P519, DOI 10.1211/002235702775
   Burdzinska A, 2017, ANAT REC, V300, P577, DOI 10.1002/ar.23498
   Chen MR, 2013, KNEE SURG SPORT TR A, V21, P540, DOI 10.1007/s00167 012 2095 2
   Christensen B, 2011, J APPL PHYSIOL, V110, P137, DOI 10.1152/japplphysiol.00942.2010
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Damian S, 2020, TISSUE CELL, V67, DOI 10.1016/j.tice.2020.101427
   Davies NM, 1998, CLIN PHARMACOKINET, V34, P101, DOI 10.2165/00003088 199834020 00002
   de Girolamo L, 2013, CURR PHARM DESIGN, V19, P2459, DOI 10.2174/1381612811319130015
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duffy MM, 2011, EUR J IMMUNOL, V41, P2840, DOI 10.1002/eji.201141499
   Dymowska M, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13111822
   English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56
   Gallelli L, 2013, OSTEOARTHR CARTILAGE, V21, P1400, DOI 10.1016/j.joca.2013.06.026
   Han JB, 2016, HUM GENE THER, V27, P621, DOI 10.1089/hum.2016.003
   Hirano T, 2021, INT IMMUNOL, V33, P127, DOI 10.1093/intimm/dxaa078
   Jang MW, 2012, J CELL PHYSIOL, V227, P3756, DOI 10.1002/jcp.24084
   Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood 2004 02 0586
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Kleiveland CR, 2008, EXP CELL RES, V314, P1831, DOI 10.1016/j.yexcr.2008.02.004
   Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Lee BC, 2016, SCI REP UK, V6, DOI 10.1038/srep26298
   Lee S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207795
   Lee S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/632902
   Li LP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9682757
   Lu XM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8178643
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mallick Emad, 2009, J Orthop Surg Res, V4, P9, DOI 10.1186/1749 799X 4 9
   Matheakakis A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810132
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   Müller M, 2011, CELL BIOL INT, V35, P235, DOI 10.1042/CBI20090211
   Nakamura T, 2011, J GASTROEN HEPATOL, V26, P188, DOI 10.1111/j.1440 1746.2010.06549.x
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Németh K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Oh N, 2014, J VET MED SCI, V76, P629, DOI 10.1292/jvms.13 0482
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Perrott DA, 2004, ARCH PEDIAT ADOL MED, V158, P521, DOI 10.1001/archpedi.158.6.521
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pojda Zygmunt, 2013, Postepy Biochem, V59, P187
   Potthast H, 2005, J PHARM SCI US, V94, P2121, DOI 10.1002/jps.20444
   Pountos I, 2011, J CELL MOL MED, V15, P525, DOI 10.1111/j.1582 4934.2010.01006.x
   Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62
   Rennert RC, 2012, REGEN MED, V7, P833, DOI [10.2217/RME.12.82, 10.2217/rme.12.82]
   Scutera S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01207
   Song N, 2020, TRENDS PHARMACOL SCI, V41, P653, DOI 10.1016/j.tips.2020.06.009
   Sotiropoulou PA, 2006, STEM CELLS, V24, P462, DOI 10.1634/stemcells.2004 0331
   Styner M, 2010, J CELL BIOCHEM, V111, P1042, DOI 10.1002/jcb.22793
   Szala S, 2014, POSTEP HIG MED DOSW, V68, P1287
   Tsai WC, 2006, J ORTHOP RES, V24, P551, DOI 10.1002/jor.20069
   Varrassi G, 2020, ADV THER, V37, P61, DOI 10.1007/s12325 019 01144 9
   Zarychta Wisniewska W, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/1613701
   Zielniok K, 2020, CELLS BASEL, V9, DOI 10.3390/cells9112396
NR 58
TC 10
Z9 10
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD FEB
PY 2022
VL 12
IS 2
AR 287
DI 10.3390/biom12020287
PG 19
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA ZL9FL
UT WOS:000763975000001
PM 35204788
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ding, H
   Chang, WJ
   Yao, J
   Liu, FD
   Zeng, QL
   He, ZX
AF Ding, Hai
   Chang, Wenju
   Yao, Jian
   Liu, Fendou
   Zeng, Qingliang
   He, Zhenxing
TI Effect and Mechanism of Tetrandrine on Osteoclastogenesis in Rheumatoid
   Arthritis
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Tetrandrine; Rheumatoid Arthritis; Osteoclasts; Mechanism of MAPKs
ID PROINFLAMMATORY CYTOKINES
AB Background: To investigate the effects and mechanism of Tetrandrine on osteoclastogenesis in rheumatoid arthritis (RA) by in vitro induction culture. Material and methods: Peripheral blood mononuclear cells (PBMCs) from RA patients were cultured in vitro. Tetrandrine toxicity, TRAP staining and acid phosphatase activity were measured by CCK 8 assay. The contents of CatK were measured by ELISA assay. The expressions of c Fos, NFATcl and ERK1/2, P ERK1/2, p38, p p38, JNK and P JNK genes were detected by WB. TNF a, RANKL and M CSF were jointly used to induce PBMCs of RA patients. TRAP staining was performed after Tetrandrine intervention. WB assay were used to detect the expressions of RANK and TRAP6. Results: After Tetrandrine intervention, the number of TRAP positive cells and RNAK mRNA and protein levels were reduced, and the inhibitory effect increased with drug concentration. Tetrandrine could significantly reduce the number of TRAP positive cells, decrease the activity of acid phosphatase and the contents of CatK, and reduce the expressions of c Fos, NFATcl and ERK1/2, P ERK1/2, p38, JNK, and P JNK. Conclusion: Tetrandrine can inhibit osteoclastogenesis and TRAP expressions, as well as the cell activities of Cathepsin K (CatK) in PBMCs of RA patients. The mechanism may be related to the decrease of the expressions of p ERK1/2, p p38, p JNK proteins, thereby its phosphorylation rate was reduced, then c Fos and NFATcl expressions were inhibited, which suggested that Tetrandrine can play an important role in inhibiting osteoclastogenesis and activation by phosphorylating MAPKs pathway.
C1 [Ding, Hai; Chang, Wenju; Yao, Jian; Liu, Fendou; Zeng, Qingliang; He, Zhenxing] Bengbu Med Coll, Dept Orthoped, Affiliated Hosp 1, 287 Changhuai Rd, Bengbu 233004, Anhui, Peoples R China.
C3 Bengbu Medical University
RP Ding, H (通讯作者)，Bengbu Med Coll, Dept Orthoped, Affiliated Hosp 1, 287 Changhuai Rd, Bengbu 233004, Anhui, Peoples R China.
RI , YAO JIAN/JMQ 3831 2023
CR Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   de Vries TJ, 2016, J PERIODONTAL RES, V51, P186, DOI 10.1111/jre.12297
   Gulcubuk A, 2013, PANCREATOLOGY, V13, P347, DOI 10.1016/j.pan.2013.05.005
   Hoff M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 54
   Jules J, 2015, J BIOL CHEM, V290, P23738, DOI 10.1074/jbc.M115.667535
   Jules J, 2014, METHODS MOL BIOL, V1155, P109, DOI 10.1007/978 1 4939 0669 7_10
   Komatsu N, 2012, ADV IMMUNOL, V115, P45, DOI 10.1016/B978 0 12 394299 9.00002 3
   Li ZG, 2015, NAT REV RHEUMATOL, V11, P313, DOI 10.1038/nrrheum.2014.218
   Lin YC, 2015, OSTEOPOROSIS INT, V26, P811, DOI 10.1007/s00198 014 2968 y
   Mclnnes I. B., 2016, NATURE REV RHEUMATOL, V12, P63
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
NR 11
TC 0
Z9 0
U1 2
U2 13
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD APR
PY 2019
VL 9
IS 4
BP 517
EP 521
DI 10.1166/jbt.2019.1998
PG 5
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IT2CL
UT WOS:000482655400015
DA 2025 08 17
ER

PT J
AU Dikmen, G
AF Dikmen, Gokhan
TI Host guest interaction of anti carcinogenic drug zoledronic acid with
   ? cyclodextrin in solid and solution forms
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE Zoledronic acid; Beta cyclodextrin; Chemical interaction; Complex
   formation; Spectroscopic and thermal characterization
ID HYDROXYPROPYL BETA CYCLODEXTRIN; AMINO ACIDS; COMPLEX; BONE;
   BISPHOSPHONATES; MECHANISM; PLGA
AB Zoledronic acid (ZA) molecule is very important drug used in the treatment of cancer such as prostate, renal and lung cancers. However, it has some disadvantages such as stability and solubility, as well as the disadvantages of many other cancer drugs such as release and undesirable side effects. Therefore, a complex was formed between ZA molecule and beta cyclodextrin ( a CD) which is a good drug carrier system to eliminate the disadvantages of ZA molecule. In this study, complex formed by host ( a CD) and guest (ZA) molecules was obtained and the binding of ZA with a CD was examined using UV Vis, FTIR, NMR spectroscopic methods, powder XRD and thermal analysis methods. Absorption measurements indicated that any chemical shift in UV Vis spectrum of ZA molecule was not observed after interacting with a CD molecule. Moreover, as the concentration of a CD molecule increased, absorbance value of ZA molecule decreased in the solution form. NMR and FT IR spectra showed that chemical interactions between ZA and a CD molecules were observed. These interactions were observed especially between the P OH, C OH and CN groups of the ZA molecule and the groups in the inner cavity of a CD. On the other hand, according to thermal analysis results, thermal stability of complex molecule (ZA/ a CD) was increased when it was compared with ZA and a CD molecules.
C1 [Dikmen, Gokhan] Eskisehir Osmangazi Univ, Cent Res Lab Applicat & Res Ctr ARUM, TR 26040 Eskisehir, Turkey.
C3 Eskisehir Osmangazi University
RP Dikmen, G (通讯作者)，Eskisehir Osmangazi Univ, Cent Res Lab Applicat & Res Ctr ARUM, TR 26040 Eskisehir, Turkey.
EM gdikmen@ogu.edu.tr
RI DİKMEN, Gökhan/I 8969 2019
CR Arti S, 2021, J MOL LIQ, V329, DOI 10.1016/j.molliq.2021.115431
   Aydin M, 2013, J ACAD RES MED, V3, P5, DOI 10.5152/jarem.2013.06
   Basha RY, 2019, CARBOHYD POLYM, V218, P53, DOI 10.1016/j.carbpol.2019.04.056
   Bender M.L., 1978, Cyclodextrin chemistry
   Bilensoy E, 2007, J INCL PHENOM MACRO, V57, P363, DOI 10.1007/s10847 006 9259 y
   Caso JV, 2015, AMINO ACIDS, V47, P2215, DOI 10.1007/s00726 015 2003 4
   Ceborska M, 2016, J MOL STRUCT, V1109, P114, DOI 10.1016/j.molstruc.2015.12.082
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Crini G, 2014, CHEM REV, V114, P10940, DOI 10.1021/cr500081p
   Dikmen G, 2021, J MOL LIQ, V335, DOI 10.1016/j.molliq.2021.116278
   Dodziuk H., 2006, CYCLODEXTRINS THEIR
   Dotsikas Y, 2000, J PHARMACEUT BIOMED, V23, P997, DOI 10.1016/S0731 7085(00)00392 7
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   EVANS CE, 1994, BONE MINER, V26, P95, DOI 10.1016/S0169 6009(08)80055 4
   Giordano F, 2001, THERMOCHIM ACTA, V380, P123, DOI 10.1016/S0040 6031(01)00665 7
   Gomes C, 2011, J FOOD SCI, V76, pE479, DOI 10.1111/j.1750 3841.2011.02264.x
   González Gaitano G, 2004, J PHYS CHEM B, V108, P14154, DOI 10.1021/jp0484231
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Green SB, 2014, AM J HEALTH SYST PH, V71, P2029, DOI 10.2146/ajhp140041
   He YF, 2008, J PHOTOCH PHOTOBIO A, V197, P253, DOI 10.1016/j.jphotochem.2008.01.001
   Job P, 1928, ANN CHIM FRANCE, V9, P113
   Kocherlakota C., 2009, U.S. Patent Application, Patent No. [12/173, 871, 12173871]
   Kundu M, 2017, J MOL LIQ, V240, P570, DOI 10.1016/j.molliq.2017.05.123
   Kundu M, 2017, SPECTROCHIM ACTA A, V183, P332, DOI 10.1016/j.saa.2017.04.030
   Li EC, 2003, CLIN THER, V25, P2669, DOI 10.1016/S0149 2918(03)80327 2
   Loftsson T, 2004, J PHARM SCI US, V93, P1091, DOI 10.1002/jps.20047
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Ondo D, 2016, J CHEM THERMODYN, V97, P242, DOI 10.1016/j.jct.2016.01.027
   Prabhu AAM, 2010, J FLUORESC, V20, P1199, DOI 10.1007/s10895 010 0669 2
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Salvatierra D, 1996, J ORG CHEM, V61, P9578, DOI 10.1021/jo9612032
   Sankaranarayanan RK, 2011, J MOL LIQ, V161, P107, DOI 10.1016/j.molliq.2011.04.016
   Sarveiya V, 2004, J INCL PHENOM MACRO, V49, P275, DOI 10.1007/s10847 004 6098 6
   Sinha VR, 2005, J PHARM SCI US, V94, P676, DOI 10.1002/jps.20287
   Szejtli J, 2004, PURE APPL CHEM, V76, P1825, DOI 10.1351/pac200476101825
   Tian BR, 2020, CARBOHYD POLYM, V232, DOI 10.1016/j.carbpol.2019.115805
   Trindade GGG, 2019, FOOD CHEM TOXICOL, V125, P198, DOI 10.1016/j.fct.2019.01.003
   Trotta F, 2000, POLYM DEGRAD STABIL, V69, P373, DOI 10.1016/S0141 3910(00)00084 7
   Vaidya B, 2019, INT J BIOL MACROMOL, V122, P338, DOI 10.1016/j.ijbiomac.2018.10.181
   Vega E, 2012, INT J NANOMED, V7, P1357, DOI 10.2147/IJN.S28481
   Venkatesh G, 2013, J INCL PHENOM MACRO, V77, P309, DOI 10.1007/s10847 012 0248 z
   Wang J, 2011, FOOD CHEM, V127, P1680, DOI 10.1016/j.foodchem.2011.02.036
   Zhang XQ, 2012, J MATER CHEM, V22, P18505, DOI 10.1039/c2jm33140c
   Zhao R, 2016, MOLECULES, V21, DOI 10.3390/molecules21040372
   Zhao R, 2011, J BIOL PHYS, V37, P387, DOI 10.1007/s10867 011 9221 0
   Zhu GY, 2014, CARBOHYD POLYM, V105, P75, DOI 10.1016/j.carbpol.2014.01.060
NR 47
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022 2860
EI 1872 8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD AUG 5
PY 2022
VL 1261
AR 132897
DI 10.1016/j.molstruc.2022.132897
EA APR 2022
PG 9
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 1L3MX
UT WOS:000799196800012
DA 2025 08 17
ER

PT J
AU Zhang, JY
   Li, M
   Kang, ET
   Neoh, KG
AF Zhang, Jieyu
   Li, Min
   Kang, En Tang
   Neoh, Koon Gee
TI Electrical stimulation of adipose derived mesenchymal stem cells in
   conductive scaffolds and the roles of voltage gated ion channels
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Electrical stimulation; Polypyrrole; Adipose derived mesenchymal stem
   cells; Polycaprolactone scaffold; Voltage gated ion channels
ID IN VITRO; OSTEOGENIC DIFFERENTIATION; BIOMATERIAL SCAFFOLDS; NA+
   CHANNELS; POLYPYRROLE; TISSUE; PROLIFERATION; EXPRESSION; COMPOSITE;
   FIELDS
AB Since electrical stimulation (ES) can significantly accelerate bone healing, a conductive scaffold that can deliver ES locally at the defect site is desirable for bone defect therapy. Herein, an electrically conductive scaffold was prepared via incorporation of polypyrrole (PPY) in a polycaprolactone (PCL) template scaffold. In vitro tests with mouse osteoblasts indicate that the PPY/PCL scaffold has good biocompatibility, and is suitable for use as an ES substrate. When human adipose derived mesenchymal stem cells (AD MSCs) were cultured in the PPY/PCL scaffold and subjected to 200 mu A of direct current for 4 h per day for 21 days, the amount of calcium deposited was 100% higher than that without ES. When these cells were subjected to ES together with blockers of voltage gated calcium (Ca v(2+)), sodium (Na v(+)), potassium (K v(+)), or chloride (Cl v( )) channels, the ES induced enhancement of AD MSCs' functions was reduced with Na v(+), K v(+), or Cl v( ) blockers and completely nullified with Cev(2+) blocker. These results indicate that ion fluxes through these channels activated by ES induce different cascades of reactions in the cells, which subsequently regulate AD MSCs' functions, and Cav(2+) plays a more critical role than the other three channels. Our results further the current understanding of the mechanisms by which ES regulates stem cells' behavior, and also showed that the conductive PPY/PCL scaffold with application of ES has good potential in bone defect therapy.
   Statement of Significance In this work, an electrically conductive and biocompatible scaffold was prepared by incorporating polypyrrole in a polycaprolactone template scaffold. Application of 200 A direct current for 4 h per day to human adipose derived mesenchymal stem cells cultured on this scaffold promoted migration of these cells into the inner region of the scaffold and enhanced their osteogenic differentiation. The roles of voltage gated ion channels (Ca v(2+), Na v(+), K v(+), and Cl v( )) in osteogenic differentiation stimulated by the electric current were investigated. The results from these experiments further the current understanding of the mechanisms by which electrical stimulation regulates stem cells' behavior, and also show that the polypyr role polycaprolactone scaffold with application of electrical stimulation has good potential in bone defect therapy. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Zhang, Jieyu; Kang, En Tang; Neoh, Koon Gee] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Kent Ridge 117576, Singapore.
   [Li, Min; Kang, En Tang; Neoh, Koon Gee] Natl Univ Singapore, Dept Chem & Biomol Engn, Kent Ridge 117576, Singapore.
C3 National University of Singapore; National University of Singapore
RP Neoh, KG (通讯作者)，Blk E5,4 Engn Dr 4,02 34, Singapore 117576, Singapore.
EM zhangjieyu@u.nus.edu; chelim@nus.edu.sg; cheket@nus.edu.sg;
   chenkg@nus.edu.sg
RI ; Zhang, Jieyu/AAG 1339 2019; Kang, En Tang/G 8522 2012; Neoh,
   KG/I 2912 2013
OI Zhang, Jieyu/0000 0002 2827 3487; Kang, En Tang/0000 0003 0599 7834;
   Neoh, Koon Gee/0000 0002 2700 1914; 
FU National Medical Research Council of Singapore [NMRC EDG09 nov024]
FX This work was financially supported by the National Medical Research
   Council of Singapore (Grant number NMRC EDG09 nov024). We thank Dr.
   Yaw Chyn Lim from Department of Physiology, National University of
   Singapore, for providing us the cell culture facilities.
CR Aronin CEP, 2008, ACTA BIOMATER, V4, P1187, DOI 10.1016/j.actbio.2008.02.029
   Bai XW, 2007, AM J PHYSIOL CELL PH, V293, pC1539, DOI 10.1152/ajpcell.00089.2007
   Banu SK, 2008, ENDOCRINOLOGY, V149, P219, DOI 10.1210/en.2007 1087
   Benders KEM, 2013, TRENDS BIOTECHNOL, V31, P169, DOI 10.1016/j.tibtech.2012.12.004
   Bergh JJ, 2004, ENDOCRINOLOGY, V145, P426, DOI 10.1210/en.2003 0319
   Björninen M, 2014, ANN BIOMED ENG, V42, P1889, DOI 10.1007/s10439 014 1023 7
   Boiko N, 2013, J BIOL CHEM, V288, P9418, DOI 10.1074/jbc.M112.449413
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Diykov D, 2013, INVERTEBR NEUROSCI, V13, P57, DOI 10.1007/s10158 012 0143 8
   Fassina L, 2010, J BIOMED MATER RES A, V93A, P1272, DOI 10.1002/jbm.a.32620
   Filardo G, 2013, AM J SPORT MED, V41, P1786, DOI 10.1177/0363546513490658
   Gabriel S, 2007, CHEM MATER, V19, P2364, DOI 10.1021/cm062450h
   Galár P, 2013, INT J ELECTROCHEM SC, V8, P57
   Goldstein C, 2010, J ORTHOP TRAUMA, V24, pS62, DOI 10.1097/BOT.0b013e3181cdde1b
   Hammerick KE, 2010, BIOCHEM BIOPH RES CO, V397, P12, DOI 10.1016/j.bbrc.2010.05.003
   Hardy JG, 2013, CURR OPIN BIOTECH, V24, P847, DOI 10.1016/j.copbio.2013.03.011
   Hess R, 2012, BIOMATERIALS, V33, P8975, DOI 10.1016/j.biomaterials.2012.08.056
   Holzwarth JM, 2011, BIOMATERIALS, V32, P9622, DOI 10.1016/j.biomaterials.2011.09.009
   Hong S, 2011, CARBOHYD POLYM, V83, P940, DOI 10.1016/j.carbpol.2010.09.002
   Hu CL, 2006, NEUROPHARMACOLOGY, V51, P737, DOI 10.1016/j.neuropharm.2006.05.013
   Hu WW, 2014, MAT SCI ENG C MATER, V37, P28, DOI 10.1016/j.msec.2013.12.019
   Isaacson BM, 2010, J BIOMED MATER RES A, V95A, P1270, DOI 10.1002/jbm.a.32905
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kawai T, 2014, TISSUE ENG PT A, V20, P1336, DOI [10.1089/ten.TEA.2013.0508, 10.1089/ten.tea.2013.0508]
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04 1814fje
   Kon E, 2010, INJURY, V41, P693, DOI 10.1016/j.injury.2009.11.014
   Koori K, 2014, CELL TISSUE RES, V357, P707, DOI 10.1007/s00441 014 1918 5
   Lefebvre M., 2006, APPL PROBABILITY STA
   Lian Kai, 2013, Biomatter, V3, DOI 10.4161/biom.27250
   Lin YH, 2011, LIFE SCI, V89, P886, DOI 10.1016/j.lfs.2011.09.011
   Liu AR, 2012, THIN SOLID FILMS, V520, P6307, DOI 10.1016/j.tsf.2012.06.039
   Meng SY, 2013, BIOELECTROMAGNETICS, V34, P189, DOI 10.1002/bem.21766
   Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125
   Olsen ML, 2003, J NEUROSCI, V23, P5572
   Pappalardo LW, 2014, GLIA, V62, P1162, DOI 10.1002/glia.22671
   Pelto J, 2013, TISSUE ENG PT A, V19, P882, DOI [10.1089/ten.tea.2012.0111, 10.1089/ten.TEA.2012.0111]
   Pereira C, 2015, BIOMATERIALS, V56, P36, DOI 10.1016/j.biomaterials.2015.03.054
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Radford R, 2012, AM J PHYSIOL RENAL, V302, pF905, DOI 10.1152/ajprenal.00427.2011
   Russell TA, 2008, J BONE JOINT SURG AM, V90A, P2057, DOI 10.2106/JBJS.G.01191
   Saadoun S, 2011, J NEUROL NEUROSUR PS, V82, DOI 10.1136/jnnp.2010.232371
   Shao SJ, 2011, BIOMATERIALS, V32, P2821, DOI 10.1016/j.biomaterials.2011.01.051
   Shi ZL, 2009, BIOMACROMOLECULES, V10, P1603, DOI 10.1021/bm900203w
   Shrestha B, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt480
   Sun WJ, 2010, J NEUROPHYSIOL, V103, P469, DOI 10.1152/jn.00154.2009
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Wu WKK, 2008, MOL CELL BIOCHEM, V308, P219, DOI 10.1007/s11010 007 9631 2
   Xiao YH, 2012, J MATER CHEM, V22, P8076, DOI 10.1039/c2jm30601h
   Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang JY, 2013, BIOTECHNOL BIOENG, V110, P1466, DOI 10.1002/bit.24796
   Zhang X, 2003, LANGMUIR, V19, P10703, DOI 10.1021/la034893v
   Zheng LQ, 2011, BIOMATERIALS, V32, P7053, DOI 10.1016/j.biomaterials.2011.06.004
   Zheng XF, 2011, J MATER SCI MATER M, V22, P693, DOI 10.1007/s10856 011 4248 0
   Zhu HB, 2011, BIOMATERIALS, V32, P4744, DOI 10.1016/j.biomaterials.2011.03.030
   Zuk PA, 2010, MOL BIOL CELL, V21, P1783, DOI 10.1091/mbc.E09 07 0589
NR 59
TC 149
Z9 163
U1 3
U2 170
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 1
PY 2016
VL 32
BP 46
EP 56
DI 10.1016/j.actbio.2015.12.024
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DF8ZF
UT WOS:000371649100005
PM 26703122
DA 2025 08 17
ER

PT J
AU Ramirez, JG
   Smit, DJ
   Viol, F
   Schrader, J
   Ghadban, T
   Pantel, K
   Izbicki, JR
   Reeh, M
AF Ramirez, Jose Giron
   Smit, Daniel J.
   Viol, Fabrice
   Schrader, Joerg
   Ghadban, Tarik
   Pantel, Klaus
   Izbicki, Jakob R.
   Reeh, Matthias
TI High Serum Levels of Wnt Signaling Antagonist Dickkopf Related Protein 1
   Are Associated with Impaired Overall Survival and Recurrence in
   Esophageal Cancer Patients
SO CANCERS
LA English
DT Article
DE esophageal carcinoma; DKK1; prognostic marker; biomarker; precision
   medicine; circulating tumor cells; disseminated tumor cells
ID DISSEMINATED TUMOR CELLS; PERIPHERAL BLOOD; BREAST CANCER; BONE MARROW;
   BIOMARKER; PHOSPHORYLATION; PROGRESSION; DKK1
AB Dickkopf related protein 1 (DKK1), an antagonist of the canonical Wnt pathway has been the subject of research for many years. Especially in gastrointestinal cancers, research suggests a pivotal role of DKK1. In order to understand the role of DKK1 in esophageal cancer, we analyzed blood samples of esophageal cancer patients for their DKK1 levels and retrospectively analyzed the clinicopathological data. In our study cohort, we observed a negative prognostic role of high DKK1 serum levels with respect to overall survival in esophageal cancer patients. These data may suggest serum DKK1 as a novel biomarker for improved risk stratification and treatment monitoring in esophageal cancer patients.
   Dickkopf related protein 1 (DKK1), an antagonist of the canonical Wnt pathway, has received tremendous attention over the past years as its dysregulation is said to be critically involved in a wide variety of gastrointestinal cancers. However, the potential clinical implications of DKK1 remain poorly understood. Although multimodal treatment options have been implemented over the past years, esophageal cancer (EC) patients still suffer from poor five year overall survival rates ranging from 15% to 25%. Especially prognostic factors and biomarkers for risk stratification are lacking to choose the most beneficial treatment out of the emerging landscape of different treatment options. In this study, we analyzed the serum DKK1 (S DKK1) levels of 91 EC patients prior to surgery in a single center study at the University Medical Center Hamburg Eppendorf by enzyme linked immunosorbent assay. High levels of S DKK1 could be especially observed in patients suffering from esophageal adenocarcinoma which may promote the hypothesis of a crucial role of DKK1 in inflammation. S DKK1 levels of >= 5800 pg/mL were shown to be associated with unfavorable five year survival rates and the presence of CTCs. Interestingly, significantly lower S DKK1 levels were detected in patients after neoadjuvant treatment, implying that S DKK1 may serve as a useful biomarker for treatment monitoring. Multivariate analysis identified S DKK1 as an independent prognostic marker with respect to overall survival in EC patients with a hazard ratio of 2.23. In conclusion, our data implicate a negative prognostic role of DKK1 with respect to the clinical outcome in EC patients. Further prospective studies should be conducted to implement S DKK1 into the clinical routine for risk stratification and treatment monitoring.
C1 [Ramirez, Jose Giron; Schrader, Joerg; Ghadban, Tarik; Izbicki, Jakob R.; Reeh, Matthias] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, D 20246 Hamburg, Germany.
   [Smit, Daniel J.] Univ Med Ctr Hamburg Eppendorf, Inst Biochem & Signal Transduct, D 20246 Hamburg, Germany.
   [Viol, Fabrice; Schrader, Joerg] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, D 20246 Hamburg, Germany.
   [Pantel, Klaus] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, D 20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Reeh, M (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, D 20246 Hamburg, Germany.
EM j.giron ramirez@uke.de; d.smit@uke.de; f.viol@uke.de; jschrader@uke.de;
   t.ghadban@uke.de; pantel@uke.de; izbicki@uke.de; mreeh@uke.de
RI ; Smit, Dr. Daniel J./AFH 3933 2022; Reeh, Matthias/AAB 6917 2022
OI Ghadban, Tarik/0000 0002 1894 9893; Reeh, Matthias/0000 0001 9111 3905;
   Smit, Daniel J./0000 0002 3190 9511; Pantel, Klaus/0000 0001 5736 2772
FU "Gunther Haenisch Preissitzung" from the "Vereinigung Norddeutscher
   Chirurgen
FX J.G.R. received funding from the "Gunther Haenisch Preissitzung" from
   the "Vereinigung Norddeutscher Chirurgen".
CR Abdel Latif MMM, 2009, CURR OPIN PHARMACOL, V9, P396, DOI 10.1016/j.coph.2009.06.010
   Alix Panabières C, 2021, CANCER DISCOV, V11, P858, DOI 10.1158/2159 8290.CD 20 1311
   Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078 0432.CCR 04 0378
   Borgen E, 1999, CYTOTHERAPY, V1, P377, DOI 10.1080/0032472031000141283
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Darlavoix T, 2009, VIRCHOWS ARCH, V454, P629, DOI 10.1007/s00428 009 0769 z
   Effenberger KE, 2012, INT J CANCER, V131, pE475, DOI 10.1002/ijc.26439
   Fehm T, 2006, CANCER AM CANCER SOC, V107, P885, DOI 10.1002/cncr.22076
   Gaur Puja, 2014, J Carcinog, V13, P11, DOI 10.4103/1477 3163.143720
   Goyal L, 2020, CLIN CANCER RES, V26, P6158, DOI 10.1158/1078 0432.CCR 20 1310
   Han SX, 2015, ONCOTARGET, V6, P19907, DOI 10.18632/oncotarget.4529
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Jaeger BAS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/491459
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276 020 0380 6
   Kagey MH, 2017, BRIT J PHARMACOL, V174, P4637, DOI 10.1111/bph.13894
   Karstens KF, 2021, CANCERS, V13, DOI 10.3390/cancers13010109
   Keller L, 2019, NAT REV CANCER, V19, P553, DOI 10.1038/s41568 019 0180 2
   Koch C, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911908
   Li Y, 2019, CANCER MED US, V8, P3782, DOI 10.1002/cam4.2286
   Lin EW, 2016, ONCOGENE, V35, P5337, DOI 10.1038/onc.2016.34
   Liu YQ, 2014, TUMOR BIOL, V35, P3145, DOI 10.1007/s13277 013 1411 x
   Lordick F, 2013, LANGENBECK ARCH SURG, V398, P177, DOI 10.1007/s00423 012 1001 1
   Lyros O, 2019, AM J CANCER RES, V9, P330
   Lyros O, 2014, AM J PHYSIOL GASTR L, V306, pG557, DOI 10.1152/ajpgi.00153.2013
   Mazon M, 2016, CANCERS, V8, DOI 10.3390/cancers8070062
   Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112
   Niu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 0883 1
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140 6736(12)60643 6
   Reeh M, 2015, ANN SURG, V261, P1124, DOI 10.1097/SLA.0000000000001130
   Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078 0432.CCR 06 1695
   Sakane H, 2010, J CELL SCI, V123, P360, DOI 10.1242/jcs.058008
   Shao YC, 2017, AM J CANCER RES, V7, P1754
   Smit DJ, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114589
   Smit DJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092129
   Vashist YK, 2012, ANN SURG, V255, P1105, DOI 10.1097/SLA.0b013e3182565b0b
   Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008 5472.CAN 06 3369
   Yan WT, 2017, SCI REP UK, V7, DOI 10.1038/srep43464
   Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00323 3
   Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533
   Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008 5472.CAN 05 4081
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116951
NR 42
TC 7
Z9 8
U1 0
U2 4
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD OCT
PY 2021
VL 13
IS 19
AR 4980
DI 10.3390/cancers13194980
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA WI0KL
UT WOS:000708056400001
PM 34638464
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Novello, C
   Pazzaglia, L
   Cingolani, C
   Conti, A
   Quattrini, I
   Manara, MC
   Tognon, M
   Picci, P
   Benassi, MS
AF Novello, Chiara
   Pazzaglia, Laura
   Cingolani, Chiara
   Conti, Amalia
   Quattrini, Irene
   Manara, Maria Cristina
   Tognon, Mauro
   Picci, Piero
   Benassi, Maria Serena
TI miRNA expression profile in human osteosarcoma: Role of miR 1 and
   miR 133b in proliferation and cell cycle control
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE microRNA microarray; osteosarcoma; cell proliferation; apoptosis; Met
   expression
ID MICRORNAS; GROWTH; CANCER; SURVIVAL; RNA
AB miRNA profile deregulation affecting downstream signaling pathways activates endpoints that represent potential biomarkers for prognosis and treatment of tumor patients. In the past 20 years conventional therapy for osteosarcoma (OS) reached a survival plateau, highlighting the need for new therapeutic approaches. In this study, microarray unsupervised and supervised analysis identified, respectively, 100 and 40 differentially expressed miRNAs in OS samples with different grades of malignancy compared to normal bone. When analyzing low grade and high grade OS by unsupervised analysis, 12 miRNAs were found to be differentially expressed. Real time PCR performed on a larger series of OS confirmed a significant lower expression of miR 1, miR 133b and miR 378* in tumors with respect to control, also showing lower mRNA levels in 31 high grade OS than in 25 low grade and in metastatic versus non metastatic patients. We demonstrated that miR 1 and miR133b were downregulated in OS cell lines compared to normal osteoblasts. Secondly, by transfection with miRNA precursor molecules, we demonstrated that the ectopic expression of miR 1 and miR 133b in U2 OS cell lines significantly reduced cell proliferation and MET protein expression and negatively regulated cell invasiveness and motility in a short term assay. Cell cycle distribution revealed block in G, and delay of cell cycle progression associated with increased apoptosis in miR 1  and miR 133b transfected cells, respectively. Our data assessed specific miRNA profiling deregulation in OS clinical samples and suggest that the expression of miR 1 and miR 133b may control cell proliferation and cell cycle through MET protein expression modulation.
C1 [Novello, Chiara; Pazzaglia, Laura; Cingolani, Chiara; Conti, Amalia; Quattrini, Irene; Manara, Maria Cristina; Picci, Piero; Benassi, Maria Serena] Rizzoli Orthopaed Inst, Expt Oncol Lab, I 40136 Bologna, Italy.
   [Tognon, Mauro] Univ Ferrara, Dept Morphol & Embryol, Sect Cell Biol & Mol Genet, Sch Med, I 44100 Ferrara, Italy.
   [Tognon, Mauro] Univ Ferrara, Ctr Biotechnol, I 44100 Ferrara, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; University of Ferrara; University of
   Ferrara
RP Benassi, MS (通讯作者)，Rizzoli Orthopaed Inst, Expt Oncol Lab, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM mariaserena.benassi@ior.it
RI Manara, Maria/K 3366 2018; Quattrini, Irene/C 6672 2019; Conti,
   Amalia/AAC 5159 2022; Manara, Maria Cristina/K 3366 2018; Pazzaglia,
   Laura/C 7918 2019; Cingolani, Chiara/AAS 9178 2021; Picci,
   Piero/J 5979 2016; Novello, Chiara/K 2569 2016
OI Quattrini, Irene/0000 0003 2221 3376; Manara, Maria
   Cristina/0000 0001 5686 720X; Pazzaglia, Laura/0000 0001 5937 4953; ,
   IRCCS Istituto Ortopedico Rizzoli/0000 0001 5680 1286; Picci,
   Piero/0000 0002 8519 4101; Novello, Chiara/0000 0001 5405 0300
FU Istituto Superiore della Sanita (ITALIA USA project)
FX The authors wish to thank Dr Alba Balladelli for editing the manuscript,
   Ms. Cristina Ghinelli for her graphic work, Dr Roberto Mirabella and Dr
   Paola Poggi for statistical support. This study was supported by
   Istituto Superiore della Sanita (ITALIA USA project) and 5 parts per
   thousand donation (Italy).
CR Bar N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010859
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Crawford M, 2009, BIOCHEM BIOPH RES CO, V388, P483, DOI 10.1016/j.bbrc.2009.07.143
   Esquela Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gorlick R, 2010, J BONE MINER RES, V25, P683, DOI 10.1002/jbmr.77
   Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715
   Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603
   He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101
   Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186
   Huang ZH, 2011, CANCER RES, V71, P2582, DOI 10.1158/0008 5472.CAN 10 3032
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Kauppinen S, 2006, HANDB EXP PHARM, V173, P405
   Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218
   Lagos Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960 9822(02)00809 6
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403
   Montanini L, 2012, CELL ONCOL, V35, P29, DOI 10.1007/s13402 011 0059 z
   Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 3 r13
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 96
   Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075
   Wu W, 2007, INT J CANCER, V120, P953, DOI 10.1002/ijc.22454
   Wu ZY, 2011, MED ONCOL, V28, P1469, DOI 10.1007/s12032 010 9563 7
   Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Zhang H, 2010, ONCOL REP, V24, P1363, DOI 10.3892/or_00000994
NR 28
TC 107
Z9 113
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2013
VL 42
IS 2
BP 667
EP 675
DI 10.3892/ijo.2012.1717
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 077AT
UT WOS:000314001000032
PM 23229283
OA Bronze
DA 2025 08 17
ER

PT J
AU Matsubara, N
   Uemura, H
   Nagamori, S
   Suzuki, H
   Uemura, H
   Kimura, G
AF Matsubara, Nobuaki
   Uemura, Hirotsugu
   Nagamori, Satoshi
   Suzuki, Hiroyoshi
   Uemura, Hiroji
   Kimura, Go
TI A Phase II, Randomized, Open Label, Multi arm Study of TAS 115 for
   Castration Resistant Prostate Cancer Patients With Bone Metastases
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Bone scan index; Brief Pain Inventory; Multikinase inhibitor; MET
   proto oncogene; Vascular endothelial growth factor receptor
ID CABOZANTINIB; OSTEOBLASTS; SURVIVAL; MET
AB New treatments to improve quality of life and survival for castration resistant prostate cancer patients with bone metastases are needed. We evaluated the safety and efficacy of the oral multikinase inhibitor TAS 115 in 50 patients. Overall, we observed improvements in bone metastasis and pain measures, and acceptable safety profiles with TAS 115. TAS 115 may be a useful treatment for these patients. Introduction: TAS 115 is an oral multikinase inhibitor targeting the MET proto oncogene, vascular endothelial growth factor receptor, and colony stimulating factor 1 receptor. We evaluated the efficacy and safety of TAS 115 in castration resistant prostate cancer (CRPC) patients with bone metastases. Patients and Methods: This phase II study, conducted in Japan, comprised 2 cohorts of CRPC patients. Cohort A included patients with bone metastasis and no history of docetaxel; TAS 115 200 to 400 mg/d was administered with abiraterone and prednisone. Cohort B included patients with symptomatic multiple bone metastases, post or unfit for docetaxel, randomized 1:1 to receive TAS 115 400 or 600 mg/d orally, once daily, in a repeated weekly schedule of 5 days on/2 days off. The primary endpoint was bone scan index (BSI) response rate at Week 12 in each dose group. Results: Cohorts A and B included 24 and 26 patients, respectively. The 12 week BSI response rates for 200, 300, and 400 mg were 0%, 33.3%, and 16.7% in Cohort A, and for 400 and 600 mg were 7.1% and 25.0% in Cohort B. The best BSI response rates for 200, 300, and 400 mg were 0%, 66.7%, and 16.7% in Cohort A, and for 400 and 600 mg were 7.1% and 33.3% in Cohort B. A > 30% reduction in BPI SF score was shown in 57.7% of patients in Cohort B. The most frequent Grade > 3 adverse drug reactions were hypophosphatemia (20.8%) in Cohort A and anemia (23.1%) in Cohort B. Conclusion: TAS 115 appears to demonstrate anti tumor activity and acceptable tolerability in CRPC patients with bone metastases.
C1 [Matsubara, Nobuaki] Natl Canc Ctr Hosp East, Div Breast & Med Oncol, 6 5 1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.
   [Uemura, Hirotsugu] Kindai Univ Fac Med, Dept Urol, Osaka, Osaka, Japan.
   [Nagamori, Satoshi] Natl Hosp Org, Hokkaido Canc Ctr, Dept Urol, Sapporo, Hokkaido, Japan.
   [Suzuki, Hiroyoshi] Toho Univ Sakura Med Ctr, Dept Urol, Sakura, Chiba, Japan.
   [Uemura, Hiroji] Yokohama City Univ Med Ctr, Dept Urol & Renal Transplantat, Yokohama, Kanagawa, Japan.
   [Kimura, Go] Nippon Med Sch, Dept Urol, Bunkyo Ku, Tokyo, Japan.
C3 National Cancer Center   Japan; Yokohama City University; Nippon Medical
   School
RP Matsubara, N (通讯作者)，Natl Canc Ctr Hosp East, Div Breast & Med Oncol, 6 5 1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.
EM nmatsuba@east.ncc.go.jp
RI KIMURA, GO/Y 7843 2018; Kimura, Go/Y 7843 2018
OI KIMURA, GO/0000 0003 0088 9324; 
FU Taiho Pharmaceutical Co, Ltd.
FX The authors thank the patients who participated in this trial and their
   families, all the investigators, and the members of the Data Monitoring
   Committee, as well as the coordinators and study site personnel. They
   also acknowledge Marion Barnett, BSc, and Keyra Martinez Dunn, MD, of
   Edanz Pharma for providing medical writing assistance, which was funded
   by Taiho Pharmaceutical Co, Ltd. This study was supported by Taiho
   Pharmaceutical Co, Ltd. The sponsor was involved in the design and
   conduct of the study, analysis of data, and approval of the manuscript.
   No grant numbers are applicable.
CR Aftab DT, 2011, CLIN TRANSL ONCOL, V13, P703, DOI 10.1007/s12094 011 0719 5
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   Doi T, 2020, INVEST NEW DRUG, V38, P1175, DOI 10.1007/s10637 019 00859 4
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Fujita H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164830
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Kakehi Y, 2017, INT J UROL, V24, P648, DOI 10.1111/iju.13380
   Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
   Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090 4295(02)01954 4
   Lee CRH, 2020, CELL BIOL TOXICOL, V36, P115, DOI 10.1007/s10565 019 09483 7
   Lowrance WT, 2018, J UROLOGY, V200, P1264, DOI 10.1016/j.juro.2018.07.090
   NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Prostate Cancer. Version 1.2024
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Parker CC, 2013, EUR UROL, V63, P189, DOI 10.1016/j.eururo.2012.09.008
   Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597
   Smith MR, 2014, J CLIN ONCOL, V32, P3391, DOI 10.1200/JCO.2013.54.5954
   Zhang SM, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 9
NR 23
TC 2
Z9 2
U1 0
U2 0
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD DEC
PY 2021
VL 19
IS 6
BP 491
EP 500
DI 10.1016/j.clgc.2021.07.013
EA DEC 2021
PG 10
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA XQ2EE
UT WOS:000731363100013
PM 34493431
OA hybrid
DA 2025 08 17
ER

PT J
AU Bigham, A
   Foroughi, F
   Motamedi, M
   Rafienia, M
AF Bigham, Ashkan
   Foroughi, Firoozeh
   Motamedi, Mehdi
   Rafienia, Mohammad
TI Multifunctional nanoporous magnetic zinc
   silicate ZnFe204 core shell composite for bone
   tissue engineering applications
SO CERAMICS INTERNATIONAL
LA English
DT Article
DE Zinc silicate; Magnetic composite; Core shell; Sustained release;
   Hyperthermia; Antibacterial
ID DRUG DELIVERY SYSTEM; BIOMEDICAL APPLICATIONS; OXIDE NANOPARTICLES;
   MAGNESIUM SILICATE; TEMPERATURE; SCAFFOLDS; NANOCOMPOSITE; HYPERTHERMIA;
   BEHAVIOR
AB Multifunctional materials have recently gained substantial attraction in bone tissue engineering because of their capabilities to solve essential problems after implantation including inflammation and osteomyelitis and also bone cancerous tissues through hyperthermia treatment.The aim of this study was to design and develop a new multifunctional composite containing a magnetic zinc ferrite as a core, and nanoporous zinc silicate as a shell via a two step synthesis strategy to meet all above targets simultaneously. ZnFe(2)0(4) particles are synthesized via solvothermal method and then coated through surfactant assisted sol gel method to obtain zinc silicate ZnFe(2)0(4) composite using cetyltrimethylammoniumbromide (CTAB) as a surfactant. The XRD results show that the composite has a glass ceramic structure. The FESEM micrographs indicate the increase in the size of ZnFe(2)0(4) particles because of zinc silicate formation around them. The vibrating sample magnetometer (VSM) results reveal that the formation of zinc silicate over ZnFe(2)0(4) particles caused the magnetization saturation (Ms) to be reduced from 43 to 30 emu g( 1). The antibacterial activity of the composite is evaluated against S.aureus and E. coli bacteria. Heat generation capability of the composite is assessed in vitro and results show that the composite reached the saturation temperature of 45 degrees C up to 510 s with 200 Oe magnetic field and constant 200 kHz frequency. Potential application of the composite as a controlled release system is assessed in vitro up to 240 h. The cell compatibility of the composite with different concentrations is assessed using osteoblast like cells (MG63) up to 48 h.
C1 [Bigham, Ashkan; Foroughi, Firoozeh; Motamedi, Mehdi] Islamic Azad Univ, Adv Mat Res Ctr, Dept Mat Engn, Najafabad Branch, Najafabad, Iran.
   [Rafienia, Mohammad] Isfahan Univ Med Sci, Biosensor Res Ctr, Esfahan, Iran.
C3 Islamic Azad University; Isfahan University of Medical Sciences
RP Bigham, A (通讯作者)，Islamic Azad Univ, Adv Mat Res Ctr, Dept Mat Engn, Najafabad Branch, Najafabad, Iran.
EM ashkanbigham@smt.iaun.ac.ir
RI ; rafienia, mohamamd/V 3848 2017; rafienia, mohammad/V 3848 2017;
   Bigham, Ashkan/ABA 7104 2021
OI Bigham, Ashkan/0000 0001 7442 3549; rafienia,
   mohammad/0000 0001 6030 5082; Foroughi, Firoozeh/0000 0002 3564 0118
CR Ansari M, 2018, J AM CERAM SOC, V101, P3649, DOI 10.1111/jace.15510
   Ansari M, 2017, J MAGN MAGN MATER, V439, P67, DOI 10.1016/j.jmmm.2017.04.084
   Arcos D, 2013, ACTA MATER, V61, P890, DOI 10.1016/j.actamat.2012.10.039
   Bigham A, 2016, CERAM INT, V42, P17185, DOI 10.1016/j.ceramint.2016.08.009
   Bock N, 2010, ACTA BIOMATER, V6, P786, DOI 10.1016/j.actbio.2009.09.017
   Diba M, 2014, CURR OPIN SOLID ST M, V18, P147, DOI 10.1016/j.cossms.2014.02.004
   Foroughi F, 2016, MAT SCI ENG C MATER, V68, P774, DOI 10.1016/j.msec.2016.07.028
   Ghadiri S, 2017, J SOL GEL SCI TECHN, V83, P229, DOI 10.1007/s10971 017 4404 1
   Goldstein LS, 2003, INT J HYPERTHER, V19, P373, DOI 10.1080/0265673031000090701
   Gu J, 2007, SMALL, V3, P1740, DOI 10.1002/smll.200700311
   Habash Riadh W. Y., 2006, Critical Reviews in Biomedical Engineering, V34, P491, DOI 10.1615/CritRevBiomedEng.v34.i6.30
   Hadidi M, 2017, SURF COAT TECH, V321, P171, DOI 10.1016/j.surfcoat.2017.04.055
   Hassanzadeh Tabrizi SA, 2016, MAT SCI ENG C MATER, V58, P737, DOI 10.1016/j.msec.2015.09.020
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040 8428(01)00179 2
   Iqbal Y, 2016, J KOREAN PHYS SOC, V68, P587, DOI 10.3938/jkps.68.587
   Khamsehashari N, 2018, MATER CHEM PHYS, V205, P283, DOI 10.1016/j.matchemphys.2017.11.034
   Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e
   Manzano M, 2008, CHEM ENG J, V137, P30, DOI 10.1016/j.cej.2007.07.078
   Marques C, 2014, INT J NANOMED, V9, P2713, DOI 10.2147/IJN.S55943
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   RADKE LL, 1994, CLIN IMMUNOL IMMUNOP, V73, P344, DOI 10.1006/clin.1994.1208
   Sirelkhatim A, 2015, NANO MICRO LETT, V7, P219, DOI 10.1007/s40820 015 0040 x
   Sun C, 2008, ADV DRUG DELIVER REV, V60, P1252, DOI 10.1016/j.addr.2008.03.018
   WILKINS TD, 1972, ANTIMICROB AGENTS CH, V1, P451, DOI 10.1128/AAC.1.6.451
   Wu CT, 2011, ACTA BIOMATER, V7, P3563, DOI 10.1016/j.actbio.2011.06.028
   Zhang ML, 2010, J MATER SCI MATER M, V21, P1169, DOI 10.1007/s10856 010 3985 9
NR 26
TC 47
Z9 48
U1 1
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272 8842
EI 1873 3956
J9 CERAM INT
JI Ceram. Int.
PD JUL
PY 2018
VL 44
IS 10
BP 11798
EP 11806
DI 10.1016/j.ceramint.2018.03.264
PG 9
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GG5XD
UT WOS:000432768200097
DA 2025 08 17
ER

PT J
AU Brown, AJ
   Ritter, CS
   Weiskopf, AS
   Vouros, P
   Sasso, GJ
   Uskokovic, MR
   Wang, GC
   Reddy, GS
AF Brown, AJ
   Ritter, CS
   Weiskopf, AS
   Vouros, P
   Sasso, GJ
   Uskokovic, MR
   Wang, GC
   Reddy, GS
TI Isolation and identification of 1α hydroxy 3 epi vitamin D3,
   a potent suppressor of parathyroid hormone secretion
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE metabolism; 1 alpha,25(OH)(2)D 3; C 3 epimerization pathway; 1 alpha
   OHD3; 1 alpha OH 3 epi D 3; 1 alpha,25(OH)(2) 3 epi D 3; parathyroid
   hormone; chronic renal failure; secondary hyperparathyroidism
ID C 24 OXIDATION PATHWAY; SENSING RECEPTOR EXPRESSION; C 3 EPIMERIZATION
   PATHWAY; 1 ALPHA,25 DIHYDROXY 3 EPI VITAMIN D 3;
   1 ALPHA,25 DIHYDROXYVITAMIN D 3; HUMAN KERATINOCYTES; UREMIC RATS;
   METABOLISM; ANALOGS; CELLS
AB Since our original demonstration of the metabolism of 1 alpha,25(OH)(2)D 3 into 1 alpha,25(OH)(2) 3 epi D 3 in human keratinocytes, there have been several reports indicating that epimerization of the 3 hydroxyl group of vitamin D compounds is a common metabolic process. Recent studies reported the metabolism of 25OHD(3) and 24(R),25(OH)(2)D 3 into their respective C 3 epimers, indicating that the presence of 1 alpha hydroxyl group is not necessary for the 3 epimerization of vitamin D compounds. To determine whether the presence of a 25 hydroxyl group is required for 3 epimerization of vitamin D compounds, we investigated the metabolism of 1 alpha OHD3, a non 25 hydroxylated vitamin D compound, in rat osteosarcoma cells (ROS 17/2.8). We noted metabolism of 1 alpha OHD3 into a less polar metabolite which was unequivocally identified as 1 alpha OH 3 epi D 3 using the techniques of HPLC, GC/MS, and H 1 NMR analysis. We also identified 1 alpha OH 3 epi D 3 as a circulating metabolite in rats treated with pharmacological concentrations of 1 alpha OHD3. Thus, these results indicated that the presence of a 25 hydroxyl group is not required for 3 epimerization of vitamin D compounds. Furthermore, the results from the same studies also provided evidence to indicate that 1 alpha OH 3 epi D 3, like 1 alpha OHD3, is hydroxylated at C 25. We then evaluated the biological activities of 1 alpha OH 3 epi D3. Treatment of normal rats every other day for 7 days with 2.5 nmol/kg of 1 alpha OH 3 epi D3 did not raise serum calcium, while the same close of 1 alpha OHD3 increased serum calcium by 3.39 +/  0.52 mg/dl. Interestingly, in the same rats which received 1 alpha OH 3 epi D 3 we also noted a reduction in circulating PTH levels by 65 +/  7%. This ability of 1 alpha OH 3 epi D 3 to suppress PTH levels in normal rats without altering serum calcium was further tested in rats with reduced renal function. The results indicated that the ED50 of 1 alpha OH 3 epi D 3 for suppression of PTH was only slightly higher than that of 1 alpha,25(OH)(2)D 3, but that the threshold dose of the development of hypercalcemia (total serum Ca > 10.5 mg/dl) was nearly 80 times higher. These findings indicate that 1 alpha OH 3 epi D 3 is a highly selective vitamin D analog with tremendous potential for treatment of secondary hyperparathyroidism in chronic renal failure patients.
C1 Brown Univ, Dept Chem, Providence, RI 02912 USA.
   Brown Univ, Dept Biomed Engn, Providence, RI 02905 USA.
   Cetek Corp, Marlborough, MA 01752 USA.
   Northeastern Univ, Barnett Inst, Dept Chem, Boston, MA 02115 USA.
   Hoffmann La Roche Inc, Nutley, NJ 07110 USA.
   Bioxell Inc, Nutley, NJ 07110 USA.
   Washington Univ, Sch Med, St Louis, MO 63110 USA.
C3 Brown University; Brown University; Northeastern University; Roche
   Holding; Roche Holding USA; Washington University (WUSTL)
RP Reddy, GS (通讯作者)，Brown Univ, Dept Chem, 324 Brook St,Box H, Providence, RI 02912 USA.
EM Satya_Reddy@Brown.edu
CR Astecker N, 2000, MOL CELL ENDOCRINOL, V170, P91, DOI 10.1016/S0303 7207(00)00330 0
   Bischof MG, 1998, EXP CELL RES, V241, P194, DOI 10.1006/excr.1998.4044
   Brown AJ, 1999, KIDNEY INT, V55, P1284, DOI 10.1046/j.1523 1755.1999.00386.x
   Brown AJ, 2000, CURR PHARM DESIGN, V6, P701, DOI 10.2174/1381612003400416
   Brown AJ, 1999, J CELL BIOCHEM, V73, P106, DOI 10.1002/(SICI)1097 4644(19990401)73:1<106::AID JCB12>3.0.CO;2 Q
   Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P41, DOI 10.1093/ndt/17.suppl_10.41
   Kamao M, 2004, J BIOL CHEM, V279, P15897, DOI 10.1074/jbc.M311473200
   Kamao M, 2001, J NUTR SCI VITAMINOL, V47, P108, DOI 10.3177/jnsv.47.108
   Masuda S, 2000, DES MONOMERS POLYM, V3, P25, DOI 10.1163/156855500750198708
   Plum LA, 2004, P NATL ACAD SCI USA, V101, P6900, DOI 10.1073/pnas.0401656101
   Reddy G., 1997, VITAMIN D CHEM BIOL, P139
   Reddy GS, 2000, ARCH BIOCHEM BIOPHYS, V383, P197, DOI 10.1006/abbi.2000.2074
   REDDY GS, 1994, VITAMIN D, P172
   Reddy GS, 2001, STEROIDS, V66, P441, DOI 10.1016/S0039 128X(00)00228 2
   REDDY GS, 1989, BIOCHEMISTRY US, V28, P1763, DOI 10.1021/bi00430a051
   Ritter CS, 2002, J BONE MINER RES, V17, P2206, DOI 10.1359/jbmr.2002.17.12.2206
   Sekimoto H, 1999, FEBS LETT, V448, P278, DOI 10.1016/S0014 5793(99)00377 4
   Siu Caldera ML, 1999, BONE, V24, P457, DOI 10.1016/S8756 3282(99)00019 8
   SLATOPOLSKY E, 1995, AM J KIDNEY DIS, V26, P852, DOI 10.1016/0272 6386(95)90455 7
NR 19
TC 43
Z9 47
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 15
PY 2005
VL 96
IS 3
BP 569
EP 578
DI 10.1002/jcb.20553
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 969VG
UT WOS:000232262800012
PM 16088954
DA 2025 08 17
ER

PT J
AU Ding, LJ
   Wang, SD
   Qu, XZ
   Wang, JF
AF Ding, Lijuan
   Wang, Shudong
   Qu, Xiaozhang
   Wang, Jiafeng
TI Tanshinone IIA sensitizes oral squamous cell carcinoma to radiation due
   to an enhanced autophagy
SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Tanshinone IIA; Radiation; Apoptosis; Autophagy; SCC090
ID OXIDATIVE STRESS; IN VITRO; HEPATOCELLULAR CARCINOMA; INDUCED APOPTOSIS;
   BREAST CANCER; LUNG CANCER; STEM CELLS; DAMAGE; PROLIFERATION;
   OSTEOBLASTS
AB Purpose: Tanshinone IIA (TanIIA), which is derived from the roots of Salvia miltiorrhiza (Danshen), has multiple pharmacological activities. However, the radiosensitivezing activity of TanIIA in oral cancer cells has not been studied extensively. The purpose of this study is to investigate the radiosensitizing effects of TanIIA in human oral squamous cell carcinoma SCC090 and examined the underlying mechanisms.
   Methods: Clonogenic assay was used to investigate the radiosensitizing effect of TanIIA on SCC090. And then, apoptosis and reactive oxygen species (ROS) induced by the combination of TanIIA with radiation were analyzed by Flow cytometry. Finally, autophagy was detected by monodansylcadervarine (MDC) staining.
   Results: TanIIA could significantly sensitize SCC090 to radiation. Meanwhile, an increase ROS generation after exposed to the combination treatment was found. In addition, the protein levels of Beclin 1, Atg5 and LC3 II, three important proteins involved in autophagy were increased in cells.
   Conclusions: TanIIA exerted a strong radiosensitizing effect on SCC090 comparing with the simple drug or single radiation treatment, which was due to an enhanced ROS generation and autophagy. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Ding, Lijuan] Jilin Univ, Dept Radiat Oncol, Hosp 1, Changchun 130021, Peoples R China.
   [Wang, Shudong] Jilin Univ, Dept Cardiol, Hosp 1, Changchun 130021, Peoples R China.
   [Qu, Xiaozhang] Jilin Univ, Hosp 1, Dept Endocrinol, Changchun 130021, Peoples R China.
   [Wang, Jiafeng] Jilin Univ, Sch & Hosp Stomatol, Dept Endodont, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University
RP Wang, JF (通讯作者)，1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
EM jiafeng_wang88@126.com
RI Wang, Jiafeng/LZE 8700 2025
CR BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Cadet J, 1999, MUTAT RES FUND MOL M, V424, P9, DOI 10.1016/S0027 5107(99)00004 4
   Chen Fen yan, 2015, Zhongguo Zhong Yao Za Zhi, V40, P1649
   Chen YZ, 2014, ANTI CANCER DRUG, V25, P983, DOI 10.1097/CAD.0000000000000127
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   Dong XR, 2009, CANCER BIOTHER RADIO, V24, P681, DOI 10.1089/cbr.2009.0640
   Dong YZ, 2011, NAT PROD REP, V28, P529, DOI 10.1039/c0np00035c
   Eckert AW, 2010, J ORAL PATHOL MED, V39, P313, DOI 10.1111/j.1600 0714.2009.00829.x
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Filomeni G, 2010, AUTOPHAGY, V6, P999, DOI 10.4161/auto.6.7.12754
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08 01 0080
   Jang NY, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1090 7
   Jeon YJ, 2015, EUR J PHARMACOL, V764, P480, DOI 10.1016/j.ejphar.2015.07.047
   Johnson NW, 2011, PERIODONTOL 2000, V57, P19, DOI 10.1111/j.1600 0757.2011.00401.x
   Karagiannis TC, 2004, CELL MOL LIFE SCI, V61, P2137, DOI 10.1007/s00018 004 4174 0
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Leveque L, 2015, IMMUNOL CELL BIOL, V93, P43, DOI 10.1038/icb.2014.95
   Li J, 2015, INT J CLIN EXP PATHO, V8, P13695
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6
   Martin CL, 2008, ORAL ONCOL, V44, P369, DOI 10.1016/j.oraloncology.2007.05.003
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Niu XL, 2000, FREE RADICAL RES, V33, P305, DOI 10.1080/10715760000301471
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Schrijvers D, 1998, J CLIN ONCOL, V16, P1054, DOI 10.1200/JCO.1998.16.3.1054
   Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233
   Song Yi, 2005, Zhongguo Zhongyao Zazhi, V30, P207
   Tang Zhongzhi, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P166
   van Genderen H, 2006, NAT PROTOC, V1, P363, DOI 10.1038/nprot.2006.55
   Velalopoulou A., 2015, INT J MOL SCI, V17
   Wan L, 2015, ARCH GYNECOL OBSTET, V292, P1301, DOI 10.1007/s00404 015 3766 2
   Wang SX, 2015, J ETHNOPHARMACOL, V164, P247, DOI 10.1016/j.jep.2015.01.042
   Wang WQ, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 69
   Wang Y, 2010, FREE RADICAL BIO MED, V48, P348, DOI 10.1016/j.freeradbiomed.2009.11.005
   Wei B, 2014, ATHEROSCLEROSIS, V235, P318, DOI 10.1016/j.atherosclerosis.2014.05.924
   White JS, 2007, ORAL ONCOL, V43, P701, DOI 10.1016/j.oraloncology.2006.09.001
   Xi S, 2003, J DENT RES, V82, P11, DOI 10.1177/154405910308200104
   Xie J, 2015, ACTA PHARM SIN B, V5, P554, DOI 10.1016/j.apsb.2015.07.008
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007 1102
   Yamazaki S, 2014, ARCH BIOCHEM BIOPHYS, V557, P18, DOI 10.1016/j.abb.2014.05.030
   Yan Q, 2005, J BIOTECHNOL, V119, P416, DOI 10.1016/j.jbiotec.2005.04.020
   Yang IH, 2016, J CLIN BIOCHEM NUTR, V58, P40, DOI 10.3164/jcbn.15 7
   Yoon Y, 1999, J ETHNOPHARMACOL, V68, P121, DOI 10.1016/S0378 8741(99)00059 8
NR 44
TC 23
Z9 24
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1382 6689
EI 1872 7077
J9 ENVIRON TOXICOL PHAR
JI Environ. Toxicol. Pharmacol.
PD SEP
PY 2016
VL 46
BP 264
EP 269
DI 10.1016/j.etap.2016.07.021
PG 6
WC Environmental Sciences; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Pharmacology & Pharmacy; Toxicology
GA DW7II
UT WOS:000383824000034
PM 27521571
DA 2025 08 17
ER

PT J
AU Chevalier, Y
   Quek, E
   Borah, B
   Gross, G
   Stewart, J
   Lang, T
   Zysset, P
AF Chevalier, Yan
   Quek, Evelyn
   Borah, Babul
   Gross, Gary
   Stewart, John
   Lang, Thomas
   Zysset, Philippe
TI Biomechanical effects of teriparatide in women with osteoporosis treated
   previously with alendronate and risedronate: Results from quantitative
   computed tomography based finite element analysis of the vertebral body
SO BONE
LA English
DT Article
DE Bisphosphonate; Teriparatide; Finite element analysis; Osteoporosis;
   Vertebra
ID BONE STRENGTH; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; FRACTURE RISK;
   DENSITY; BISPHOSPHONATES; MECHANISMS; RALOXIFENE; INCREASES; TURNOVER
AB Previous antiresorptive treatment may influence the anabolic response to teriparatide. The OPTAMISE (Open label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment. The objective of this study was to use quantitative computed tomography (CT) based nonlinear finite element modeling to evaluate how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the biomechanical effectiveness of teriparatide. Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study. These models were subjected to uniaxial compression. Total BMD derived bone volume fraction (BV/TV(d), i.e., bone volume [BV]/total volume [TV]), estimated from quantitative CT based volumetric BMD, vertebral stiffness, and failure load (strength) were calculated for each time measurement point. The results of this study demonstrated that 12 months of treatment with teriparatide following prior treatment with either risedronate or alendronate increased BMD derived BV/TV(d), the predicted vertebral stiffness, and failure load. However, the effects of teriparatide were more pronounced in patients treated previously with risedronate, which is consistent with the findings of the OPTAMISE study. The mean (+/  standard error) increase in stiffness was greater in the prior risedronate group than the prior alendronate group (24.6 +/  3.2% versus 14.4 +/  2.8%, respectively: p = 0.0073). Similarly, vertebral failure load increased by 27.2 +/  3.5% in the prior risedronate group versus 15.3 +/  3.1% in the prior alendronate group (p=0.0042). The mechanical variables increased in greater proportion than BV/TV(d), which increased by 6.9 +/  0.9% versus 4.6 +/  0.8% in the prior risedronate and prior alendronate groups, respectively (p = 0.0290). Our finding indicated that while teriparatide can be used with success on patients who have previously undergone treatment with risedronate and alendronate, it demonstrated greater anabolic effect on biomechanical properties in prior risedronate patients in the first year of teriparatide treatment. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Chevalier, Yan] Vienna Univ Technol, Inst Lightweight Design & Struct Biomech, A 1040 Vienna, Austria.
   [Stewart, John] Sanofi Aventis, Laval, PQ, Canada.
   [Quek, Evelyn; Lang, Thomas] Univ Calif San Francisco, Dept Radiol, Ctr Mol & Funct Imaging, San Francisco, CA 94143 USA.
   [Borah, Babul; Gross, Gary] Procter & Gamble Pharmaceut Inc, Hlth Care Res Ctr, Mason, OH USA.
C3 Technische Universitat Wien; Sanofi Aventis; Sanofi Canada; University
   of California System; University of California San Francisco; Procter &
   Gamble
RP Chevalier, Y (通讯作者)，Vienna Univ Technol, Inst Lightweight Design & Struct Biomech, Gusshausstr 27 29, A 1040 Vienna, Austria.
EM yan@ilsb.tuwien.ac.at
RI Lang, Thomas/B 2685 2012; Zysset, Philippe/B 2997 2018
OI Lang, Thomas/0000 0002 3720 8038; Zysset, Philippe/0000 0002 4712 7047
FU Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and
   Sanofi aventis)
FX We would like to acknowledge the Clinical Investigators of the OPTAMISE
   study (Drs. Miller, Delmas, Lindsay, Watts, Luckey, Aclachi, Saag,
   Greenspan, Seeman, Boonen, Meeves and Bilezikian) for their kind review
   of the manuscript and for providing helpful suggestions.We would also
   like to thank Dr. Dieter Pahr for the software tools used to create the
   finite element models and Dr. Mathieu Charlebois for the implementation
   of the constitutive laws for bone in the nonlinear FE simulations.This
   project, including editorial assistance, was supported by funding from
   the Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals
   and Sanofi aventis).
CR [Anonymous], 2013, Technical Report 202
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Boonen S, 2007, J CLIN ENDOCR METAB, V92, P1415, DOI 10.1210/jc.2006 1404
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Chevalier Y, 2008, COMPUT METHOD BIOMEC, V11, P477, DOI 10.1080/10255840802078022
   Chevalier Y, 2009, J BIOMECH ENG T ASME, V131, DOI 10.1115/1.3212097
   Crawford RP, 2004, SPINE, V29, P2248, DOI 10.1097/01.brs.0000142435.90314.3b
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   EASTELL R, 1991, J BONE MINER RES, V6, P207
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Garcia D, 2009, BIOMECH MODEL MECHAN, V8, P149, DOI 10.1007/s10237 008 0125 2
   Graeff C, 2009, J BONE MINER RES, V24, P1672, DOI [10.1359/JBMR.090416, 10.1359/jbmr.090416]
   Hernandez CJ, 2001, BONE, V29, P74, DOI 10.1016/S8756 3282(01)00467 7
   Imai K, 2009, OSTEOPOROSIS INT, V20, P801, DOI 10.1007/s00198 008 0750 8
   Imai K, 2008, SPINE, V33, P27, DOI 10.1097/BRS.0b013e31815e3993
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Lang TF, 1997, BONE, V21, P101, DOI 10.1016/S8756 3282(97)00072 0
   Lang TF, 1999, J COMPUT ASSIST TOMO, V23, P130, DOI 10.1097/00004728 199901000 00027
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   PARFITT AM, 1992, BONE, V13, pS41, DOI 10.1016/8756 3282(92)90196 4
   Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Wang X, 2008, BONE, V43, P775, DOI 10.1016/j.bone.2008.05.023
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
NR 30
TC 53
Z9 57
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JAN
PY 2010
VL 46
IS 1
BP 41
EP 48
DI 10.1016/j.bone.2009.09.032
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 550LN
UT WOS:000274129400006
PM 19800436
DA 2025 08 17
ER

PT J
AU Bergemann, D
   Massoz, L
   Bourdouxhe, J
   Pardo, CAC
   Voz, ML
   Peers, B
   Manfroid, I
AF Bergemann, David
   Massoz, Laura
   Bourdouxhe, Jordane
   Pardo, Claudio A. Carril
   Voz, Marianne L.
   Peers, Bernard
   Manfroid, Isabelle
TI Nifurpirinol: A more potent and reliable substrate compared to
   metronidazole for nitroreductase mediated cell ablations
SO WOUND REPAIR AND REGENERATION
LA English
DT Article
ID ESCHERICHIA COLI NITROREDUCTASE; TARGETED ABLATION; ZEBRAFISH LARVAE;
   REGENERATION; EXPRESSION; ENZYME; SYSTEM
AB The zebrafish is a popular animal model with well known regenerative capabilities. To study regeneration in this fish, the nitroreductase/metronidazole mediated system is widely used for targeted ablation of various cell types. Nevertheless, we highlight here some variability in ablation efficiencies with the metronidazole prodrug that led us to search for a more efficient and reliable compound. Herein, we present nifurpirinol, another nitroaromatic antibiotic, as a more potent prodrug compared to metronidazole to trigger cell ablation in nitroreductase expressing transgenic models. We show that nifurpirinol induces robust and reliable ablations at concentrations 2,000 fold lower than metronidazole and three times below its own toxic concentration. We confirmed the efficiency of nifurpirinol in triggering massive ablation of three different cell types: the pancreatic beta cells, osteoblasts, and dopaminergic neurons. Our results identify nifurpirinol as a very potent prodrug for the nitroreductase mediated ablation system and suggest that its use could be extended to many other cell types, especially if difficult to ablate, or when combined pharmacological treatments are desired.
C1 [Bergemann, David; Massoz, Laura; Bourdouxhe, Jordane; Pardo, Claudio A. Carril; Voz, Marianne L.; Peers, Bernard; Manfroid, Isabelle] Univ Liege, Zebrafish Dev & Dis Models Lab GIGA, Liege, Belgium.
C3 University of Liege
RP Manfroid, I (通讯作者)，Ave Hop 1,B34, B 4000 Liege, Belgium.
EM isabelle.manfroid@uliege.be
OI Carril Pardo, Claudio/0009 0002 9943 7730
FU Universite de Liege, Fonds Speciaux de la Recherche Credit classique
   [0000005312]; Belgian Fonds pour la Formation a la Recherche dans
   l'Industrie et dans l'Agriculture (FRIA) [0000009232]; Belgian Fonds De
   La Recherche Scientifique FRS  FNRS [0000006539, qualifie 0000009017];
   FRIA (Fonds pour la Formation a la Recherche dans l'Industrie et dans
   l'Agriculture); Leon Fredericq Funds (University of Liege); doctoral
   Becas Chile fellowship from CONYCIT; ARC program of the University of
   Liege (Action de Recherches Concertees)
FX Universite de Liege, Fonds Speciaux de la Recherche Credit classique
   0000005312; Belgian Fonds pour la Formation a la Recherche dans
   l'Industrie et dans l'Agriculture (FRIA), 0000009232; Belgian Fonds De
   La Recherche Scientifique FRS  FNRS, Credit de recherche 0000006539,
   Mandat chercheur qualifie 0000009017. D. Bergemann was supported by FRIA
   (Fonds pour la Formation a la Recherche dans l'Industrie et dans
   l'Agriculture) and the Leon Fredericq Funds (University of Liege). I.
   Manfroid, M. Voz and B. Peers are "Chercheur Qualifie" at FRS FNRS. C.
   Carril Pardo is supported by a doctoral Becas Chile fellowship from
   CONYCIT. This work was also supported by the ARC program of the
   University of Liege (Action de Recherches Concertees).
CR Anderson RM, 2009, DEV BIOL, V334, P213, DOI 10.1016/j.ydbio.2009.07.017
   Becker T, 1997, J COMP NEUROL, V377, P577, DOI 10.1002/(SICI)1096 9861(19970127)377:4<577::AID CNE8>3.0.CO;2 #
   Bridgewater JA, 1995, EUR J CANCER, V31A, P2362, DOI 10.1016/0959 8049(95)00436 X
   Bridgewater JA, 1997, HUM GENE THER, V8, P709, DOI 10.1089/hum.1997.8.6 709
   Clark AJ, 1997, GENE THER, V4, P101, DOI 10.1038/sj.gt.3300367
   Curado S, 2007, DEV DYNAM, V236, P1025, DOI 10.1002/dvdy.21100
   Ghaye AP, 2015, BMC BIOL, V13, DOI 10.1186/s12915 015 0179 4
   Godoy R, 2015, J NEUROCHEM, V135, P249, DOI 10.1111/jnc.13214
   Hsu CC, 2010, MAR BIOTECHNOL, V12, P466, DOI 10.1007/s10126 009 9248 4
   Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343
   Lambert AM, 2012, J NEUROSCI, V32, P13488, DOI 10.1523/JNEUROSCI.1638 12.2012
   Mathias JR, 2014, ZEBRAFISH, V11, P85, DOI 10.1089/zeb.2013.0937
   Pisharath H, 2007, MECH DEVELOP, V124, P218, DOI 10.1016/j.mod.2006.11.005
   Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857
   Provost E, 2007, GENESIS, V45, P625, DOI 10.1002/dvg.20338
   Singh SP, 2012, DEV CELL, V22, P879, DOI 10.1016/j.devcel.2012.03.006
   Takase Y, 1968, B JAP SOC FISH, V34, P1118
   van Ham TJ, 2014, DIS MODEL MECH, V7, P857, DOI 10.1242/dmm.014886
   White DT, 2013, METHODS, V62, P232, DOI 10.1016/j.ymeth.2013.03.017
NR 19
TC 29
Z9 31
U1 2
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1067 1927
EI 1524 475X
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD MAR APR
PY 2018
VL 26
IS 2
BP 238
EP 244
DI 10.1111/wrr.12633
PG 7
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA GY0GK
UT WOS:000448193100178
PM 29663654
DA 2025 08 17
ER

PT J
AU Giallongo, C
   Tibullo, D
   Parrinello, NL
   La Cava, P
   Di Rosa, M
   Bramanti, V
   Di Raimondo, C
   Conticello, C
   Chiarenza, A
   Palumbo, GA
   Avola, R
   Romano, A
   Di Raimondo, F
AF Giallongo, Cesarina
   Tibullo, Daniele
   Parrinello, Nunziatina L.
   La Cava, Piera
   Di Rosa, Michelino
   Bramanti, Vincenzo
   Di Raimondo, Cosimo
   Conticello, Concetta
   Chiarenza, Annalisa
   Palumbo, Giuseppe A.
   Avola, Roberto
   Romano, Alessandra
   Di Raimondo, Francesco
TI Granulocyte like myeloid derived suppressor cells (G MDSC) are increased
   in multiple myeloma and are driven by dysfunctional mesenchymal stem
   cells (MSC)
SO ONCOTARGET
LA English
DT Article
DE MM microenvironemnt; mesenchymal stem cells; G MDSC; immune suppression
ID BONE MARROW MICROENVIRONMENT; STROMAL CELLS; IMMUNE SYSTEM; T CELLS;
   SERUM LEVELS; PROGRESSION; ACTIVATION; OSTEOCLAST; EXPRESSION; DISEASE
AB Granulocytic Myeloid derived suppressor cells (G MDSC) are increased in Multiple Myeloma (MM) patients but the mechanisms of G MDSC generation are still unknown. There are many evidences of the role of mesenchymal stem cells (MSC) in promoting MM cell growth, survival and drug resistance. We here used a specific experimental model in vitro to evaluate the ability of MSC to induce G MDSC. We found that although MSC derived from healthy donors (HD), MGUS and MM were able to generate the same amount of MDSC, only MM MSC educated G MDSC exhibited suppressive ability. In addition, in comparison with MSC derived from HD, MM MSC produce higher amount of immune modulatory factors that could be involved in MDSC induction. Compared to G MDSC obtained from co culture models with MSC from healthy subjects, both MGUS and MM MSC educated G MDSC showed increase of immune modulatory factors. However, only MM MSC educated G MDSC 1) up regulated immune suppressive factors as ARG1 and TNF alpha, 2) expressed higher levels of PROK2, important in angiogenesis and inflammatory process, and 3) showed ability to digest bone matrix.
   Our data demonstrate that MM MSC are functionally different from healthy subjects and MGUS MSC, supporting an evolving concept regarding the contribution of MM MSC to tumor development and progression.
C1 [Giallongo, Cesarina; Tibullo, Daniele; Parrinello, Nunziatina L.; La Cava, Piera; Di Raimondo, Cosimo; Conticello, Concetta; Chiarenza, Annalisa; Palumbo, Giuseppe A.; Romano, Alessandra; Di Raimondo, Francesco] Univ Catania, AOU, Policlin OVE, Div Hematol, I 95124 Catania, Italy.
   [Giallongo, Cesarina; Di Rosa, Michelino; Bramanti, Vincenzo; Avola, Roberto] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Tibullo, Daniele] Univ Catania, Dept Biol Geol & Environm Sci, Catania, Italy.
C3 University of Catania; University of Catania; University of Catania
RP Tibullo, D (通讯作者)，Univ Catania, AOU, Policlin OVE, Div Hematol, I 95124 Catania, Italy.; Tibullo, D (通讯作者)，Univ Catania, Dept Biol Geol & Environm Sci, Catania, Italy.
EM d.tibullo@unict.it
RI Romano, Alessandra/I 9201 2012; Tibullo, Daniele/J 3946 2016; Bramanti,
   Vincenzo/L 8828 2019; ROMANO, ALESSANDRA/I 9201 2012; Chiarenza,
   Annalisa/AAC 2013 2019; TIBULLO, Daniele/J 3946 2016; Conticello,
   Concetta/K 4596 2018; Giallongo, Cesarina/J 7225 2016; Palumbo,
   Giuseppe/W 7072 2019; Di Rosa, Michelino/B 5807 2013; Di Raimondo,
   Cosimo/AEP 9505 2022; Di Raimondo, Francesco/K 7965 2016; parrinello,
   nunziatina/J 4099 2016; PALUMBO, Giuseppe Alberto Maria/W 7072 2019
OI Conticello, Concetta/0000 0003 0862 3598; Bramanti,
   Vincenzo/0000 0002 9380 8062; ROMANO, ALESSANDRA/0000 0002 6333 4433;
   TIBULLO, Daniele/0000 0002 4416 8556; Giallongo,
   Cesarina/0000 0002 7667 6088; Di Rosa, Michelino/0000 0002 1837 9325;
   Chiarenza, Annalisa/0000 0002 8759 4854; Di Raimondo,
   Francesco/0000 0002 7749 0293; Di Raimondo, Cosimo/0000 0003 4691 9381;
   PALUMBO, Giuseppe Alberto Maria/0000 0003 1859 6319
FU Ministero della Salute, Ricerca Finalizzata [PE 2011 02350147]
FX Financial support (Prof. Francesco Di Raimondo) Ministero della Salute,
   Ricerca Finalizzata 2011 2012 (PE 2011 02350147).
CR André T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059756
   Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   Botta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00348
   Brandau S, 2011, J LEUKOCYTE BIOL, V89, P311, DOI 10.1189/jlb.0310162
   Chen Siqi, 2015, Oncoscience, V2, P910
   Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   De Veirman K, 2015, ONCOTARGET, V6, P10532
   De Veirman K, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00349
   Duffy A, 2013, CANCER IMMUNOL IMMUN, V62, P299, DOI 10.1007/s00262 012 1332 3
   Favaloro J, 2014, LEUKEMIA LYMPHOMA, V55, P2893, DOI 10.3109/10428194.2014.904511
   Ferrara N, 2010, CURR OPIN HEMATOL, V17, P219, DOI 10.1097/MOH.0b013e3283386660
   Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828
   Garayoa M, 2009, LEUKEMIA, V23, P1515, DOI 10.1038/leu.2009.65
   Garcia Gomez A, 2014, ONCOTARGET, V5, P8284, DOI 10.18632/oncotarget.2058
   Garderet L, 2007, LEUKEMIA LYMPHOMA, V48, P2032, DOI 10.1080/10428190701593644
   Giallongo C, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00107
   Giallongo C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101848
   Görgün GT, 2013, BLOOD, V121, P2975, DOI 10.1182/blood 2012 08 448548
   Guglielmelli Tommasina, 2015, Oncoscience, V2, P382
   Hu JS, 2012, DIS MODEL MECH, V5, P763, DOI 10.1242/dmm.008961
   Huss R, 2002, BRIT J HAEMATOL, V118, P305, DOI 10.1046/j.1365 2141.2002.03587.x
   Köffel R, 2014, BLOOD, V124, P2713, DOI 10.1182/blood 2014 07 588178
   LeCouter J, 2003, TRENDS CARDIOVAS MED, V13, P276, DOI 10.1016/S1050 1738(03)00110 5
   Li BZ, 2010, ARCH MED RES, V41, P623, DOI 10.1016/j.arcmed.2010.11.008
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   Montero AJ, 2012, J IMMUNOTHER, V35, P107, DOI 10.1097/CJI.0b013e318242169f
   Mougiakakos D, 2011, BLOOD, V117, P4826, DOI 10.1182/blood 2010 12 324038
   Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood 2007 07 099226
   Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476 5381.2009.00291.x
   Nagaraj S, 2012, SEMIN CANCER BIOL, V22, P282, DOI 10.1016/j.semcancer.2012.01.010
   Nagaraj S, 2010, J IMMUNOL, V184, P3106, DOI 10.4049/jimmunol.0902661
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Pfreundschuh M, 2015, ONCOTARGET, V6, P32287, DOI 10.18632/oncotarget.5960
   Poggi A, 2014, IMMUNOL LETT, V159, P55, DOI 10.1016/j.imlet.2014.03.001
   Qu XP, 2012, J BIOL CHEM, V287, P19574, DOI 10.1074/jbc.M111.326801
   Ramachandran IR, 2013, J IMMUNOL, V190, P3815, DOI 10.4049/jimmunol.1203373
   Romano A, 2014, BIOMED RES INT UK, V2014, DOI 10.1155/2014/198539
   Sade Feldman M, 2013, IMMUNITY, V38, P541, DOI 10.1016/j.immuni.2013.02.007
   Sánchez N, 2014, CELL IMMUNOL, V289, P174, DOI 10.1016/j.cellimm.2014.04.007
   Sawant A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24064
   Sawant A, 2013, CANCER RES, V73, P4606, DOI 10.1158/0008 5472.CAN 13 0305
   SIMMONS PJ, 1991, BLOOD, V78, P55
   Soleymaninejadian E, 2012, AM J REPROD IMMUNOL, V67, P1, DOI 10.1111/j.1600 0897.2011.01069.x
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tibullo D, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00226
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Van Valckenborgh E, 2012, LEUKEMIA, V26, P2424, DOI 10.1038/leu.2012.113
   Wang GY, 2013, CELL BIOL INT, V37, P137, DOI 10.1002/cbin.10024
   Wang JH, 2015, ONCOTARGET, V6, P43992, DOI 10.18632/oncotarget.6083
   Wang L, 2015, ONCOTARGET, V6, P41228, DOI 10.18632/oncotarget.5682
   Wang ZT, 2015, CANCER IMMUNOL IMMUN, V64, P389, DOI 10.1007/s00262 014 1646 4
   Yan B, 2013, J IMMUNOL, V190, P5882, DOI 10.4049/jimmunol.1201881
   Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008 5472.CAN 04 1687
   Zhang W, 1999, ANN HEMATOL, V78, P305, DOI 10.1007/s002770050520
   Zhuang JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048871
NR 59
TC 78
Z9 81
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 27
PY 2016
VL 7
IS 52
BP 85764
EP 85775
DI 10.18632/oncotarget.7969
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EG9ZT
UT WOS:000391422500009
PM 26967390
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Xu, R
   Xing, JY
   Wei, RY
   Lv, JW
   Liu, SC
   Shi, JH
   Liu, ZH
AF Zhang, Yu
   Xu, Ran
   Xing, Jianyu
   Wei, Renyue
   Lv, Jiawei
   Liu, Shichao
   Shi, Jiuhui
   Liu, Zhonghua
TI Osteogenic Differentiation from Induced Pluripotent Stem Cells via a
   Three Dimensional Culture Method
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Osteogenesis; iPS; 3D Culture; Gelfoam Sponge; BMP7
ID MESENCHYMAL STEM; BONE FORMATION; FIBROBLASTS; COMBINATION; PROGENITORS;
   STRATEGY; SCAFFOLD
AB Induced pluripotent stem cells (iPSCs) generated by somatic cell reprogramming have opened a promising gateway for personalized cell replacement therapy, and efficient in vitro expansion and differentiation into specialized cells are prerequisites for their clinical applications. Previous studies have described several strategies for osteoinduction from iPSCs; however, all of them were based on short or long period of two dimensional (2D) culture. Given that three dimensional (3D) culture system is more similar to the in vivo osteogenic environment, in this study, we explored an entirely 3D based method for iPSC osteogenic differentiation and investigated the effects of D glucose level and BMP7 on the process. Our results showed that during embryoid body formation, ATRA/bFGF treatment promoted the derivation of mesenchymal stem cells (MSCs) from iPSCs via neuroectodermal differentiation pathway. When the derived cells were loaded onto biodegradable gelfoam scaffolds, they not only attached and proliferated along the gelfoam fibers upon maintenance, but also underwent matrix mineralization upon osteoinduction. Although high D glucose negatively affected osteogenic differentiation of the cells by suppressing osteoblast maturation, it significantly potentiated BMP7 induced osteogenesis. Our study provides an efficient 3D based method for iPSC osteoinduction and suggests the synergistic effect of D glucose level and BMP7 on the osteogenic process, which contributes to the optimization of iPSC directed induction for bone tissue engineering.
C1 [Zhang, Yu; Wei, Renyue; Lv, Jiawei; Liu, Shichao; Liu, Zhonghua] Northeast Agr Univ, Coll Life Sci, Harbin 150030, Peoples R China.
   [Xu, Ran; Xing, Jianyu; Shi, Jiuhui] Harbin Med Univ, Affiliated Hosp 1, Harbin 150006, Peoples R China.
C3 Northeast Agricultural University   China; Harbin Medical University
RP Liu, ZH (通讯作者)，Northeast Agr Univ, Coll Life Sci, Harbin 150030, Peoples R China.; Shi, JH (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Harbin 150006, Peoples R China.
RI ; Xu, Ran/KMY 2774 2024; wei, renyue/NKP 6623 2025; Liu,
   Shichao/J 2954 2019; Liu, Zhonghua/AAO 3590 2021
OI Liu, Shichao/0000 0002 4156 3876; Zhang, Yu/0000 0002 2291 2022; 
FU National Natural Science Foundation of China [31301211]; University
   Nursing Program for Young Scholars with Creative Talents in Heilongjiang
   Province [UNPYSCT2016010]; Young Talents Project of NEAU [14QC01]
FX This work was supported by the National Natural Science Foundation of
   China (31301211), the University Nursing Program for Young Scholars with
   Creative Talents in Heilongjiang Province (UNPYSCT2016010) and the Young
   Talents Project of NEAU (14QC01).
CR Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a
   Ishiy FAA, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/249098
   BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085
   Bianchi G, 2003, EXP CELL RES, V287, P98, DOI 10.1016/S0014 4827(03)00138 1
   Bilousova G, 2011, STEM CELLS, V29, P206, DOI 10.1002/stem.566
   de Peppo GM, 2013, P NATL ACAD SCI USA, V110, P8680, DOI 10.1073/pnas.1301190110
   Dienelt A, 2011, STEM CELLS DEV, V20, P465, DOI 10.1089/scd.2010.0205
   Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987
   Grayson WL, 2008, TRENDS BIOTECHNOL, V26, P181, DOI 10.1016/j.tibtech.2007.12.009
   Hayashi T, 2012, CELL TRANSPLANT, V21, P591, DOI 10.3727/096368911X605529
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Lou XX, 2015, STEM CELL REV REP, V11, P645, DOI 10.1007/s12015 015 9594 8
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Maegawa N, 2007, J TISSUE ENG REGEN M, V1, P306, DOI 10.1002/term.41
   Marolt D, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt10
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Ogawa N, 2007, HORM METAB RES, V39, P871, DOI 10.1055/s 2007 991157
   Peter SJ, 1998, J BIOMED MATER RES, V43, P422, DOI 10.1002/(SICI)1097 4636(199824)43:4<422::AID JBM9>3.3.CO;2 T
   Rohanizadeh R, 2008, J MATER SCI MATER M, V19, P1173, DOI 10.1007/s10856 007 3154 y
   Rose LC, 2013, J TISSUE ENG REGEN M, V7, P371, DOI 10.1002/term.532
   Sakurai H, 2008, STEM CELLS, V26, P1865, DOI 10.1634/stemcells.2008 0173
   Sakurai H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047078
   Seeherman HJ, 2010, J BONE JOINT SURG AM, V92A, P411, DOI 10.2106/JBJS.H.01732
   Shan ZY, 2014, CELL REPROGRAM, V16, P77, DOI 10.1089/cell.2013.0067
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Tang MH, 2014, TISSUE ENG PT A, V20, P1295, DOI [10.1089/ten.tea.2013.0211, 10.1089/ten.TEA.2013.0211]
   Tashiro K, 2009, STEM CELLS, V27, P1802, DOI 10.1002/stem.108
   Tsiridis E, 2006, INJURY, V37, pS25, DOI 10.1016/j.injury.2006.08.021
   Villa Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Vunjak Novakovic G, 2011, CELL STEM CELL, V8, P252, DOI 10.1016/j.stem.2011.02.014
   Wang WW, 2010, MOL CELL BIOCHEM, V338, P115, DOI 10.1007/s11010 009 0344 6
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zheng Z, 2012, J BIOL CHEM, V287, P19949, DOI 10.1074/jbc.M112.355099
   Zou LJ, 2013, SCI REP UK, V3, DOI 10.1038/srep02243
NR 41
TC 0
Z9 0
U1 0
U2 49
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD JUN
PY 2017
VL 7
IS 6
BP 448
EP 457
DI 10.1166/jbt.2017.1589
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ER6QE
UT WOS:000398930300003
DA 2025 08 17
ER

PT J
AU Guan, XX
   Zhou, Y
   Chen, H
   Wang, CW
   Wang, HM
AF Guan, Xiaoxu
   Zhou, Yi
   Chen, Hui
   Wang, Chaowei
   Wang, Huiming
TI Antibacterial, anti inflammatory, and anti osteoclastogenesis roles of
   allicin in periodontitis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Periodontitis; Porphyromonas gingivalis; allicin; growth; biofilm;
   osteoclastic activity
ID PORPHYROMONAS GINGIVALIS; EXPRESSION; MODULATION; MECHANISMS; EXTRACT;
   DISEASE; IL 10; AGENT; CELLS
AB Periodontitis is an infectious inflammatory immune disease. Allicin, because of its antibacterial, antiinflammatory and immunomodulation properties, appears to be a promising drug for treating periodontitis. In this study, the antimicrobial activity of allicin against Porphyromonas gingivalis (P. gingivalis) and its effects on inflammatory cytokine expression in experimental periodontitis and osteoclast activity in vitro were investigated. Allicin inhibited P. gingivalis growth, with a minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of 4 mg/I and 8 mg/I, respectively. Allicin showed inhibitory effects on P.gingivalis biofilm formation, with a minimum biofilm inhibition concentration (MBIC50/MBIC90) of 4 mg/I and 16 mg/I, respectively, and affected the viability of 1 day old biofilms with a minimum biofilm reduction concentration (MBRC50) of 32 mg/I. Confocal laser scanning microscopy (CSLM) revealed that treatment with 32 mg/I allicin resulted in a lower bacteria number, fewer live bacteria, and a thinner biofilm. In gingivomucosal tissues around first right molar teeth undergoing ligatureinduced periodontitis, allicin substantially inhibited periodontal destructive cytokines, including TNF alpha, IL 1 beta, IL 6, INF gamma, and IL 12, but promoted protective cytokines such as IL 4 and IL 10. By affecting the cytokine framework and the secretion of M CSF and RNAKL from osteoblasts, allicin suppressed osteoclastogenesis by modulating the RANK RANKL system, as demonstrated by a decrease in NF kB p65 levels. These results suggested that allicin is a potential natural product for treating periodontitis.
C1 [Guan, Xiaoxu; Zhou, Yi; Chen, Hui; Wang, Chaowei; Wang, Huiming] Zhejiang Univ, Coll Med, Affiliated Hosp Stomatol, Yanan Rd 395, Hangzhou 310000, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Zhou, Y; Wang, HM (通讯作者)，Zhejiang Univ, Coll Med, Affiliated Hosp Stomatol, Dept Oral Implantat, Yanan Rd 395, Hangzhou 310000, Zhejiang, Peoples R China.
EM zyuth scsa@zju.edu.cn; hmwang1960@hotmail.com
RI Wang, Chaowei/KUD 9852 2024
FU National Science Foundation of China [81 400480]
FX This study was supported by the National Science Foundation of China
   (grant No. 81 400480).
CR Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379
   Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643
   Bluestone JA, 2009, NAT REV IMMUNOL, V9, P811, DOI 10.1038/nri2654
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cellini L, 1996, FEMS IMMUNOL MED MIC, V13, P273, DOI 10.1111/j.1574 695X.1996.tb00251.x
   Cronstein BN, 2007, BULL HOSP JT DIS, V65, pS11
   Cutler RR, 2004, BRIT J BIOMED SCI, V61, P71, DOI 10.1080/09674845.2004.11732646
   Di Paola R, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/787159
   Donati M, 2009, J PERIODONTAL RES, V44, P683, DOI 10.1111/j.1600 0765.2008.01178.x
   Eilat Adar S, 2013, NUTRIENTS, V5, P3646, DOI 10.3390/nu5093646
   Fonseca JE, 2009, AUTOIMMUN REV, V8, P538, DOI 10.1016/j.autrev.2009.01.012
   Fridman S, 2014, VET PARASITOL, V203, P51, DOI 10.1016/j.vetpar.2014.02.002
   Fu E, 2015, J PERIODONTAL RES, V50, P380, DOI 10.1111/jre.12217
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Han X, 2009, ORAL MICROBIOL IMMUN, V24, P190, DOI 10.1111/j.1399 302X.2008.00494.x
   Ho CY, 2014, MOL NUTR FOOD RES, V58, P1069, DOI 10.1002/mnfr.201300617
   Hodge G, 2002, CYTOMETRY, V48, P209, DOI 10.1002/cyto.10133
   Kador PF, 2011, J PERIODONTOL, V82, P926, DOI 10.1902/jop.2010.100442
   Khatua TN, 2013, CAN J PHYSIOL PHARM, V91, P448, DOI 10.1139/cjpp 2012 0315
   Kim SR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073877
   Koutouzis T, 2009, J PERIODONTOL, V80, P625, DOI 10.1902/jop.2009.080422
   Lappin DF, 2001, CLIN EXP IMMUNOL, V123, P294, DOI 10.1046/j.1365 2249.2001.01448.x
   Musacchio E, 2009, J RHEUMATOL, V36, P1575, DOI 10.3899/jrheum.081321
   Nakayama K, 2003, CURR PROTEIN PEPT SC, V4, P389, DOI 10.2174/1389203033486983
   Niederman R, 2001, J CLIN PERIODONTOL, V28, P569, DOI 10.1034/j.1600 051x.2001.028006569.x
   Oft M, 2014, CANCER IMMUNOL RES, V2, P194, DOI 10.1158/2326 6066.CIR 13 0214
   Palombo EA, 2011, EVID BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep067
   Pereira AL, 2012, QUINTESSENCE INT, V43, P777
   Peterson BW, 2015, FEMS MICROBIOL REV, V39, P234, DOI 10.1093/femsre/fuu008
   Preshaw PM, 2008, PERIODONTOL 2000, V48, P92, DOI 10.1111/j.1600 0757.2008.00252.x
   Reinhart KM, 2009, NUTR RES REV, V22, P39, DOI 10.1017/S0954422409350003
   Repeke CE, 2010, BONE, V46, P1122, DOI 10.1016/j.bone.2009.12.030
   Sasaki H, 2004, J PERIODONTAL RES, V39, P432, DOI 10.1111/j.1600 0765.2004.00760.x
   Sharma S, 2009, ANTIMICROB AGENTS CH, V53, P216, DOI 10.1128/AAC.00045 08
   Silva N, 2015, J APPL ORAL SCI, V23, P329
   Spelman K, 2006, ALTERN MED REV, V11, P128
   Teles R, 2013, PERIODONTOL 2000, V62, P95, DOI 10.1111/prd.12010
   You SX, 2013, MOL NUTR FOOD RES, V57, P2049, DOI 10.1002/mnfr.201200843
   Zhou Y, 2015, BONE, V71, P17, DOI 10.1016/j.bone.2014.09.026
NR 39
TC 7
Z9 9
U1 2
U2 15
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 7
BP 6721
EP 6730
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GO8WE
UT WOS:000440379700033
DA 2025 08 17
ER

PT J
AU Karimzadeh, A
   Esmaily, H
   Raeissadat, SA
   Esmaelzade, M
   Aghamiri, SH
   Bolandnazar, NS
AF Karimzadeh, Afshin
   Esmaily, Hadi
   Raeissadat, Seyed Ahmad
   Esmaelzade, Maryam
   Aghamiri, Seyed Hossein
   Bolandnazar, Najmeh Sadat
TI Comparison of the Effect of Intracarpal Injection of Ketorolac With
   Triamcinolone in Carpal Tunnel Syndrome: A Randomized Controlled Trial
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE ketorolac; carpal tunnel syndrome; triamcinolone; injection site
   reaction; analgesic; functional status
ID GUIDED INTRAARTICULAR KETOROLAC; ULTRASOUND; OSTEOARTHRITIS
AB Background: The most prevalent entrapment neuropathy is carpal tunnel syndrome (CTS). Although nonsteroidal antiinflammatory drugs (NSAIDs) are frequently prescribed for musculoskeletal disorders, oral NSAIDs do not provide any additional benefits for CTS. Nevertheless, the use of NSAID phonophoresis has shown significant improvement, possibly due to increased concentration in the target tissue. The effects of intracarpal injection of NSAIDs on CTS have not been studied. Objective: We conducted a controlled trial to compare the efficacy of ketorolac and triamcinolone in treating CTS. Methods: Mild to moderate CTS patients were randomly assigned to receive either a local injection of 30 mg ketorolac or 40 mg triamcinolone. Patients were evaluated using visual analog scale (VAS) for pain, severity, function, electrodiagnostic findings, patient satisfaction, and any complications at the injection site, at baseline and 12 weeks after the procedures. Results: Fifty patients participated, and 43 completed the study. Both groups showed significant improvement in the VAS, severity, function, and electrodiagnostic scores at 3 months compared with the baseline. A comparison of the groups showed significant differences in VAS, severity, and function, with the improvement being significantly higher in the triamcinolone group. Conclusion and Relevance: The present study showed that injection of triamcinolone or ketorolac into the carpal tunnel relieved pain, increased function, and improved electrodiagnostic findings in patients with mild to moderate CTS. It also showed that triamcinolone was superior to ketorolac in terms of analgesic effect and resulted in greater improvement in symptom severity and function.
C1 [Karimzadeh, Afshin; Esmaelzade, Maryam; Bolandnazar, Najmeh Sadat] Shahid Beheshti Univ Med Sci, Phys Med & Rehabil Res Ctr, Tehran, Iran.
   [Karimzadeh, Afshin; Esmaily, Hadi; Aghamiri, Seyed Hossein] Shahid Beheshti Univ Med Sci, Tehran, Iran.
   [Esmaily, Hadi] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Valiasr Ave, Tehran 1996835113, Iran.
   [Raeissadat, Seyed Ahmad] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Clin Res Dev Ctr, Phys Med & Rehabil Res Ctr,Dept Phys Med & Rehabil, Tehran, Iran.
   [Aghamiri, Seyed Hossein] Shahid Beheshti Univ Med Sci, Sch Med, Dept Neurol, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Shahid Beheshti University Medical Sciences; Shahid
   Beheshti University Medical Sciences; Shahid Beheshti University Medical
   Sciences
RP Esmaily, H (通讯作者)，Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Valiasr Ave, Tehran 1996835113, Iran.
EM Esmaily_hadi@sbmu.ac.ir
RI ; Karimzadeh, Afshin/AAG 2210 2021; Esmaily, Hadi/K 9027 2019;
   raeissadat, ahmad/AAV 6187 2020; Aghamiri, seyed/AAB 2880 2020
OI Esmaily, Hadi/0000 0001 6915 6028; 
FU Shahid Beheshti University of Medical Sciences [11375]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: Shahid
   Beheshti University of Medical Sciences funded this study (grant number:
   11375).
CR Aboonq MS, 2015, NEUROSCIENCES, V20, P4
   Ahn JK, 2015, J BACK MUSCULOSKELET, V28, P497, DOI 10.3233/BMR 140546
   Babaei Ghazani A, 2018, AM J PHYS MED REHAB, V97, P407, DOI 10.1097/PHM.0000000000000877
   Calandruccio JH, 2018, ORTHOP CLIN N AM, V49, P223, DOI 10.1016/j.ocl.2017.11.009
   Chammas Michel, 2014, Rev. bras. ortop., V49, P437, DOI 10.1016/j.rboe.2014.08.002
   Dumitru D, 2002, Electrodiagnostic medicine
   Graham B, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.16.00719
   Hassankhani GG, 2018, ARCH BONE JT SURG AB, V6, P71
   Jablecki CK, 2002, NEUROLOGY, V58, P1589, DOI 10.1212/WNL.58.11.1589
   Kang H, 2021, J EDUC EVAL HEALTH P, V18
   Karimzadeh A, 2019, J PAIN RES, V12, P579, DOI 10.2147/JPR.S190652
   Koh SH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015506
   Kwon HK, 2014, J CLIN NEUROL, V10, P348, DOI 10.3988/jcn.2014.10.4.348
   이승아, 2011, [The Journal of Oriental Obstetrics ＆ Gynecology, 대한한방부인과학회지], V24, P31
   Leite JCD, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 78
   Ostergaard PJ, 2020, CURR REV MUSCULOSKE, V13, P141, DOI 10.1007/s12178 020 09616 0
   Park KD, 2015, SKELETAL RADIOL, V44, P1333, DOI 10.1007/s00256 015 2174 9
   Raeissadat SA, 2014, J LASERS MED SCI, V5, P39
   Rezazadeh A., 1392, KOOMESH, V15, P138
   Soyupek F, 2012, RHEUMATOL INT, V32, P3235, DOI 10.1007/s00296 011 2171 9
   Urits I, 2019, CURR PAIN HEADACHE R, V23, DOI 10.1007/s11916 019 0811 z
   Wilder Smith EP, 2006, NAT CLIN PRACT NEURO, V2, P366, DOI 10.1038/ncpneuro0216
   Yildiz N, 2011, J BACK MUSCULOSKELET, V24, P39, DOI 10.3233/BMR 2011 0273
NR 23
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060 0280
EI 1542 6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD MAR
PY 2024
VL 58
IS 3
BP 205
EP 213
DI 10.1177/10600280231175146
EA JUN 2023
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HP8Z7
UT WOS:001008352500001
PM 37278013
DA 2025 08 17
ER

PT J
AU Karakeçili, A
   Topuz, B
   Ersoy, FS
   Sahin, T
   Günyakti, A
   Demirtas, TT
AF Karakecili, Ayse
   Topuz, Berna
   Ersoy, Feriha Sevval
   Sahin, Toygun
   Gunyakti, Ayse
   Demirtas, Tugrul Tolga
TI UiO 66 metal organic framework as a double actor in chitosan scaffolds:
   Antibiotic carrier and osteogenesis promoter
SO BIOMATERIALS ADVANCES
LA English
DT Article
DE UiO 66; Wet spinning; Chitosan scaffold; Osteogenic differentiation;
   Fosfomycin carrier; Osteomyelitis
ID ANTIBACTERIAL; DIFFERENTIATION; MECHANISMS; MEMBRANES; DELIVERY; CELLS
AB Metal organic frameworks (MOFs) have recently emerged as a useful class of nanostructures with well suited characteristics for drug delivery applications, due to the high surface area and pore size for efficient loading. Despite their use as a nano carrier for controlled delivery of various types of drugs, the inherent osteo conductive properties have stolen a great attention as a growing area of investigation. Here, we evaluated the double function of UiO 66 MOF structure as a carrier for fosfomycin antibiotic and also as an osteogenic differentiation promoter when introduced in 3D chitosan scaffolds, for the first time. Our results revealed that the wet spun chitosan scaffolds containing fosfomycin loaded UiO 66 nanocrystals (CHI/UiO 66/FOS) possessed fiber mesh structure with integrated micro scale fibers and increased mechanical strength. In vitro antibacterial studies indicated that CHI/UiO 66/FOS scaffolds showed bactericidal activity against Staphylococcus aureus. Moreover, the scaffolds were biocompatible to MC3T3 E1 pre osteoblasts and significantly up regulated the expression of osteogenesis related genes and facilitated the extracellular matrix mineralization, in vitro. Taken together, our results demonstrate UiO 66 MOFs can present double functionality and CHI/UiO 66/FOS scaffolds hold a significant potential to be further explored as an alternative approach in treating infected bone defects like osteomyelitis.
C1 [Karakecili, Ayse; Topuz, Berna; Ersoy, Feriha Sevval; Sahin, Toygun] Ankara Univ, Dept Chem Engn, Fac Engn, TR 06100 Ankara, Turkey.
   [Gunyakti, Ayse] Ankara Univ, Inst Biotechnol, Gumusdere 60 Yil Yerleskesi, TR 06135 Ankara, Turkey.
   [Demirtas, Tugrul Tolga] Erciyes Univ, Dept Basic Pharmaceut Sci, Fac Pharm, TR 38039 Kayseri, Turkey.
   [Demirtas, Tugrul Tolga] Erciyes Univ, Genome & Stem Cell Ctr, TR 38039 Kayseri, Turkey.
C3 Ankara University; Ankara University; Erciyes University; Erciyes
   University
RP Karakeçili, A (通讯作者)，Ankara Univ, Dept Chem Engn, Fac Engn, TR 06100 Ankara, Turkey.
EM akarakecili@eng.ankara.edu.tr
RI ; Şahin, Toygun/GQI 4463 2022; Günyaktı, Ayşe/HTM 9605 2023; Topuz,
   Berna/AAH 3164 2020; DEMİRTAŞ, Tuğrul/C 9785 2015; Gunyakti Mujtaba,
   Ayse/AAI 4852 2021
OI Topuz, Berna/0000 0002 6980 3296; Gunyakti Mujtaba,
   Ayse/0000 0001 9301 8928
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [218M324]
FX This research was supported by The Scientific and Technological Research
   Council of Turkey (TUBITAK) with grant no: 218M324.
CR Chen H, 2020, RSC ADV, V10, P40157, DOI 10.1039/d0ra06873j
   Chen JY, 2017, J BIOMED MATER RES A, V105, P834, DOI 10.1002/jbm.a.35960
   Chen YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113426
   Chicatun F, 2011, BIOMACROMOLECULES, V12, P2946, DOI 10.1021/bm200528z
   Chowdhuri AR, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361 6528/aa57af
   Demirtas TT, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5626 9
   DeStefano MR, 2017, CHEM MATER, V29, P1357, DOI 10.1021/acs.chemmater.6b05115
   Dorati R, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10040096
   Duewelhenke N, 2007, ANTIMICROB AGENTS CH, V51, P54, DOI 10.1128/AAC.00729 05
   Fardjahromi MA, 2022, MATER TODAY CHEM, V23, DOI 10.1016/j.mtchem.2021.100670
   Fardjahromi MA, 2021, MAT SCI ENG C MATER, V123, DOI 10.1016/j.msec.2021.111972
   Hatakeyama W, 2013, INT J MOL MED, V32, P1255, DOI 10.3892/ijmm.2013.1516
   Hoseinpour V, 2021, TISSUE CELL, V72, DOI 10.1016/j.tice.2021.101588
   Izquierdo Barba I, 2011, ACTA BIOMATER, V7, P2977, DOI 10.1016/j.actbio.2011.03.005
   Jafary F, 2017, INT J TRANSPLANT MED, V8, P195
   Karakeçili A, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110098
   Kim CH, 2018, ADV EXP MED BIOL, V1077, P475, DOI 10.1007/978 981 13 0947 2_25
   Korpayev S, 2020, INT J BIOL MACROMOL, V156, P681, DOI 10.1016/j.ijbiomac.2020.04.109
   Kyriacou H, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10072244
   Lawson HD, 2021, ACS APPL MATER INTER, V13, P7004, DOI 10.1021/acsami.1c01089
   Liu YH, 2020, ACS APPL MATER INTER, V12, P36978, DOI 10.1021/acsami.0c12090
   Lu MP, 2016, SCI REP UK, V6, DOI 10.1038/srep39174
   Malheiro VN, 2010, ACTA BIOMATER, V6, P418, DOI 10.1016/j.actbio.2009.07.012
   Nasrabadi M, 2019, NEW J CHEM, V43, P16033, DOI 10.1039/c9nj03216a
   Onat B, 2016, ACTA BIOMATER, V40, P293, DOI 10.1016/j.actbio.2016.04.033
   Ran JB, 2018, CHEM ENG J, V333, P20, DOI 10.1016/j.cej.2017.09.145
   Ren N, 2022, J RARE EARTH, V40, P161, DOI 10.1016/j.jre.2020.11.007
   Shen MF, 2020, COMPR REV FOOD SCI F, V19, P1397, DOI 10.1111/1541 4337.12515
   Singh N, 2021, J MATER CHEM B, V9, P5925, DOI 10.1039/d1tb01044a
   Suck K, 2007, J BIOMED MATER RES A, V80A, P268, DOI 10.1002/jbm.a.30965
   Tabassum N, 2021, MATER TODAY COMMUN, V26, DOI 10.1016/j.mtcomm.2021.102156
   Taheri M, 2021, CHEM ENG J, V413, DOI 10.1016/j.cej.2020.127511
   Toprak Ö, 2021, MAT SCI ENG C MATER, V120, DOI 10.1016/j.msec.2020.111738
   Tsegka KG, 2022, EXPERT REV ANTI INFE, V20, P33, DOI 10.1080/14787210.2021.1932463
   Ucar S, 2013, J APPL POLYM SCI, V130, P3759, DOI 10.1002/app.39629
   Vallet Regí M, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000310
   Wang Y, 2021, J SOLID STATE CHEM, V293, DOI 10.1016/j.jssc.2020.121805
   Wang Y, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119619
   Weng WX, 2021, J MATER SCI, V56, P8309, DOI 10.1007/s10853 021 05824 2
   Winarta J, 2020, CRYST GROWTH DES, V20, P1347, DOI 10.1021/acs.cgd.9b00955
   Wyszogrodzka G, 2016, DRUG DISCOV TODAY, V21, P1009, DOI 10.1016/j.drudis.2016.04.009
   Xie CG, 2021, NANOTECHNOLOGY, V32, DOI 10.1088/1361 6528/abf7ea
   Xue YY, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001369
   Yang YW, 2020, MATER CHEM FRONT, V4, P973, DOI 10.1039/c9qm00772e
   Yüksel E, 2016, INT J BIOL MACROMOL, V86, P162, DOI 10.1016/j.ijbiomac.2016.01.061
   Yüksel E, 2014, MAT SCI ENG C MATER, V45, P510, DOI 10.1016/j.msec.2014.10.004
   Zhong LN, 2020, NANOSCALE, V12, P24437, DOI 10.1039/d0nr06297a
   Zhu XY, 2014, CHEM COMMUN, V50, P8779, DOI 10.1039/c4cc02570a
NR 48
TC 37
Z9 37
U1 10
U2 94
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2772 9508
J9 BIOMATER ADV
JI Biomater. Adv.
PD MAY
PY 2022
VL 136
AR 212757
DI 10.1016/j.bioadv.2022.212757
EA MAY 2022
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 1W2NB
UT WOS:000806613100004
PM 35929303
DA 2025 08 17
ER

PT J
AU Chan, DC
   Yang, RS
   Ho, CH
   Tsai, YS
   Wang, JJ
   Tsai, KT
AF Chan, Ding Cheng
   Yang, Rong Sen
   Ho, Chung Han
   Tsai, Yau Sheng
   Wang, Jhi Joung
   Tsai, Kang Ting
TI The Use of Alendronate Is Associated with a Decreased Incidence of Type
   2 Diabetes Mellitus A Population Based Cohort Study in Taiwan
SO PLOS ONE
LA English
DT Article
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; UNDERCARBOXYLATED
   OSTEOCALCIN; OLDER MEN; MARKERS; SUPPLEMENTATION; OSTEOPOROSIS;
   PREVALENCE; TURNOVER; THERAPY
AB Purpose
   Bone remodeling has been linked to glucose metabolism in animal studies, but the results of human trials were inconclusive. Bisphosphonates may play a role in glucose metabolism through their impacts on bone remodeling enzymes. In this study, we aimed to examine the influence of alendronate usage on the incidence of type 2 diabetes mellitus (DM) among osteoporotic patients.
   Methods
   A retrospective cohort study was designed to include osteoporotic patients without DM from a population based cohort containing 1,000,000 subjects. Patients treated with alendronate (exposed group, N=1,011) were compared with those who received no treatment (age and gender matched non exposed group, N=3,033). Newly diagnosed DM was identified from medical records by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD 9CM) code. The incidence of DM in both groups was calculated for comparison.
   Results
   The non exposed group had a significantly higher incidence of DM (Odds ratio 1.21, 95% confidence interval 1.03 similar to 1.41) when compared with the exposed group. In subgroup analysis, the DM risk reduction in exposed group was only significant among those younger than 65 years and those without hypertension or dyslipidemia. Patients who were prescribed alendronate more than or equal to 3 times had demonstrated a significant reduction in DM risk.
   Conclusions
   Our study showed alendronate might yield a protective effect for incident DM. This effect became insignificant in patients with older age, dyslipidemia or hypertension. The underlying mechanism needs further exploration with prospective data for confirmation of the observed findings.
C1 [Chan, Ding Cheng] Natl Taiwan Univ Hosp, Dept Gerontol & Geriatr, Taipei, Taiwan.
   [Chan, Ding Cheng] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Chan, Ding Cheng] Natl Taiwan Univ Hosp, Superintendent Off, JinShan Branch, New Taipei City, Taiwan.
   [Yang, Rong Sen] Natl Taiwan Univ Hosp, Dept Orthoped, Taipei, Taiwan.
   [Ho, Chung Han; Wang, Jhi Joung] Chi Mei Med Ctr, Inst Med Res, Tainan, Taiwan.
   [Tsai, Yau Sheng] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 70101, Taiwan.
   [Tsai, Kang Ting] Chi Mei Med Ctr, Dept Geriatr, Tainan, Taiwan.
   [Tsai, Kang Ting] Chi Mei Med Ctr, Dept Family Med, Tainan, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University Hospital; Chi Mei
   Hospital; National Cheng Kung University; Chi Mei Hospital; Chi Mei
   Hospital
RP Tsai, KT (通讯作者)，Chi Mei Med Ctr, Dept Geriatr, Tainan, Taiwan.
EM irised57@yahoo.com.tw
RI ; Ting, Tsai/J 1468 2019; Chen, Pau Chung/H 5686 2011
OI CHAN, DING CHENG/0000 0003 2215 2243; Yang,
   Rong Sen/0000 0002 0553 4779; Ho, Chung Han/0000 0001 5925 8477; 
CR Abdelazim IA, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0189 9
   Carter AA, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f2610
   Chan WP, 2004, ACTA RADIOL, V45, P59, DOI 10.1080/02841850310003221
   Chang CH, 2010, DIABETIC MED, V27, P636, DOI 10.1111/j.1464 5491.2010.03007.x
   Choi HJ, 2008, MATURITAS, V60, P170, DOI 10.1016/j.maturitas.2008.05.003
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fukumoto S, 2009, TRENDS ENDOCRIN MET, V20, P230, DOI 10.1016/j.tem.2009.02.001
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   Hirao M, 2008, J BONE MINER METAB, V26, P260, DOI 10.1007/s00774 007 0823 3
   Kumar R, 2010, AM J CLIN NUTR, V92, P1528, DOI 10.3945/ajcn.2010.30108
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Maugeri D, 2002, ARCH GERONTOL GERIAT, V34, P117, DOI 10.1016/S0167 4943(01)00202 3
   Perifanis V, 2007, ANN HEMATOL, V86, P23, DOI 10.1007/s00277 006 0180 7
   Pittas AG, 2009, J CLIN ENDOCR METAB, V94, P827, DOI 10.1210/jc.2008 1422
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V89, P265, DOI 10.1007/s00223 011 9515 z
   Yang NP, 2006, HEALTH POLICY, V75, P329, DOI 10.1016/j.healthpol.2005.04.009
   Yeap BB, 2010, EUR J ENDOCRINOL, V163, P265, DOI 10.1530/EJE 10 0414
   Yoshida M, 2008, DIABETES CARE, V31, P2092, DOI 10.2337/dc08 1204
NR 20
TC 25
Z9 27
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2015
VL 10
IS 4
AR e0123279
DI 10.1371/journal.pone.0123279
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CF8XK
UT WOS:000352845100159
PM 25874962
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Boopalan, T
   Arumugam, A
   Parada, J
   Saltzstein, E
   Lakshmanaswamy, R
AF Boopalan, Thiyagarajan
   Arumugam, Arunkumar
   Parada, Jacqueline
   Saltzstein, Edward
   Lakshmanaswamy, Rajkumar
TI Receptor activator for nuclear factor κB ligand signaling promotes
   progesterone mediated estrogen induced mammary carcinogenesis
SO CANCER SCIENCE
LA English
DT Article
DE Estradiol; GLI 1; mifepristone; progesterone; RANKL
ID HORMONE REPLACEMENT THERAPY; BREAST CANCER RISK; CELL SURVIVAL;
   OSTEOCLAST DIFFERENTIATION; EPITHELIAL PROLIFERATION; GLAND DEVELOPMENT;
   PLUS PROGESTIN; TNF RECEPTOR; ACI RATS; RANKL
AB Breast cancer is a leading cause of cancer related death in women. Prolonged exposure to the ovarian hormones estrogen and progesterone increases the risk of breast cancer. Although estrogen is known as a primary factor in mammary carcinogenesis, very few studies have investigated the role of progesterone. Receptor activator for nuclear factor B (NF B) ligand (RANKL) plays an important role in progesterone induced mammary carcinogenesis. However, the molecular mechanism underlying RANKL induced mammary carcinogenesis remains unknown. In our current study, we show that RANKL induces glioma associated oncogene homolog 1 (GLI 1) in estrogen induced progesterone mediated mammary carcinogenesis. In vivo experiments were carried out using ACI rats and in vitro experiments were carried out in MCF 7 cells. In ACI rats, mifepristone significantly reduced the incidence of mammary tumors. Likewise, mifepristone also inhibited the proliferation of MCF 7 cells. Hormone treatments induced RANKL, receptor activator of NF B (RANK), and NF B in a protein kinase B dependent manner and inhibited apoptosis by activation of anti apoptotic protein Bcl2 in mammary tumors and MCF 7 cells. Mechanistic studies in MCF 7 cells reveal that RANKL induced upstream stimulatory factor 1 and NF B, resulting in subsequent activation of their downstream target GLI 1. We have identified that progesterone mediates estrogen induced mammary carcinogenesis through activation of GLI 1 in a RANKL dependent manner.
C1 [Boopalan, Thiyagarajan; Arumugam, Arunkumar; Parada, Jacqueline; Saltzstein, Edward; Lakshmanaswamy, Rajkumar] Texas Tech Univ Hlth Sci Ctr, Ctr Excellence Canc Res, El Paso, TX USA.
C3 Texas Tech University System; Texas Tech University Health Sciences
   Center El Paso
RP Lakshmanaswamy, R (通讯作者)，Dept Biomed Sci, 5001 El Paso Dr, El Paso, TX 79905 USA.
EM rajkumar.lakshmanaswamy@ttuhsc.edu
RI ARUMUGAM, ARUNKUMAR/HCI 6286 2022
FU Texas Tech University Health Sciences Center Paul L. Foster School of
   Medicine
FX Texas Tech University Health Sciences Center Paul L. Foster School of
   Medicine
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Beral Valerie, 2003, Lancet, V362, P419
   BERG K, 1994, PARASITOL RES, V80, P235, DOI 10.1007/BF00932680
   BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505
   Blank EW, 2008, P NATL ACAD SCI USA, V105, P3527, DOI 10.1073/pnas.0710535105
   Bratton MR, 2010, INT J ONCOL, V37, P541, DOI 10.3892/ijo_00000703
   Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092 8674(01)00599 2
   Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151
   Fernandez Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   González Suárez E, 2011, CLIN TRANSL ONCOL, V13, P222, DOI 10.1007/s12094 011 0646 5
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505
   HASLAM SZ, 1979, BIOCHEM J, V182, P127, DOI 10.1042/bj1820127
   Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102
   HOCKENBERY DM, 1994, J CELL SCI, P51
   HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709
   Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kenemans P, 2003, BEST PRACT RES CL EN, V17, P123, DOI 10.1016/S1521 690X(02)00084 2
   Kim HH, 2003, FASEB J, V17, P2163, DOI 10.1096/fj.03 0215fje
   Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097 0215(19990505)81:3<339::AID IJC5>3.0.CO;2 6
   Moorman PG, 2000, AM J PUBLIC HEALTH, V90, P966, DOI 10.2105/AJPH.90.6.966
   Nakashima H, 2006, CANCER RES, V66, P7041, DOI 10.1158/0008 5472.CAN 05 4588
   NANDI S, 1958, JNCI J NATL CANCER I, V21, P1039
   Papanastasiou AD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3234
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761
   Rajkumar L, 2001, P NATL ACAD SCI USA, V98, P11755, DOI 10.1073/pnas.201393798
   Ross RK, 2000, JNCI J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Shull JD, 1997, CARCINOGENESIS, V18, P1595, DOI 10.1093/carcin/18.8.1595
   Travis RC, 2003, BREAST CANCER RES, V5, P239, DOI 10.1186/bcr628
   Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175
   Villavicencio EH, 2002, GENESIS, V32, P247, DOI 10.1002/gene.10078
   Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131
NR 38
TC 16
Z9 20
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2015
VL 106
IS 1
BP 25
EP 33
DI 10.1111/cas.12571
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AZ9XG
UT WOS:000348567000004
PM 25412610
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xue, Z
   Niu, LY
   An, G
   Guo, YS
   Lv, SC
   Ren, XP
AF Xue, Z.
   Niu, L.  Y.
   An, G.
   Guo, Y.  S.
   Lv, S.  C.
   Ren, X.  P.
TI Expression of recombinant BMP 7 gene increased ossification activity in
   the rabbit bone mesenchymal stem cells
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Bone morphogenetic protein 7; Mesenchymal stem cells; Gene transfection;
   Alkaline phosphatase activity; Collagen
ID IN VITRO; MORPHOGENETIC PROTEIN 7; OSTEOGENIC PROTEIN 1; MARROW;
   DIFFERENTIATION; REGENERATION; DEFECTS; CHONDROGENESIS; PROGENITORS;
   CARTILAGE
AB OBJECTIVE: The mesenchymal stem cells (MSCs), which were distributed in the bone marrow stroma, become ideal progenitor cells in bone tissue engineering because of their convenient isolation, small injury when obtained, and strong osteogenic capacity. The osteogenic differentiation of MSCs, which is indicated by the increased alkaline phosphatase (ALP) activity and the enhanced accumulation of collagen, could be induced by a strong osteogenic capacity biological factor termed bone morphogenetic protein 7 (BMP 7). Although the chemically synthesized BMP 7 was widely applied to study the osteogenic differentiation of MSCs, transferring and expressing BMP 7 gene in target cells is more desirable, especially for gene therapy, given the advantages and convenience on the stable expression of BMP 7. The aim of this study was to determine whether recombinant BMP 7 expressing MSCs would induce bone formation in vitro.
   MATERIALS AND METHODS: BMP 7 gene was cloned from human placental tissue to construct a recombinant eukaryotic expression plasmid carrying BMP 7 gene by conjugating with eukaryotic expression vector pcDNA3.1. MSCs were isolated from rabbit bone marrow and cultured in vitro. Then they were divided into 3 groups: pcDNA3.1 BMP 7 transfected, pcD NA3.1 transfected, and untransfected. Human healthy fresh placental tissue was provided by the Department of Gynaecology and Obstetrics, Second Affiliated Hospital of Harbin Medical University. Written informed consent was obtained from the women. One healthy male New Zealand rabbit was provided by the Laboratory Animal Center, Harbin Medical University.
   RESULTS: A significant increase of ALP activity was detected in the supernatant of pcD NA3.1 BMP 7 transfected MSCs, and the enhanced collagen accumulation, which was inferred by the increased hydroxyproline content and RT PCR.
   CONCLUSIONS: These results implied that BMP 7 gene was expressed in MSCs sufficiently and was involved in inducing differentiation of MSCs into osteoblast.
C1 [Xue, Z.; Niu, L.  Y.; An, G.; Guo, Y.  S.; Lv, S.  C.; Ren, X.  P.] Harbin Med Univ, Hosp 2, Harbin, Peoples R China.
C3 Harbin Medical University
RP Lv, SC (通讯作者)，Harbin Med Univ, Hosp 2, Harbin, Peoples R China.
EM lvsongcen@yahoo.com
FU Science and Technology Research Foundation of the Education Department
   of Heilongjiang Province of China [12511202]
FX The authors were grateful to colleagues in the Laboratory Animal Center
   and the Biochemical Department of Harbin Medical University for their
   generous help. The study was supported by grant (No. 12511202) from the
   Science and Technology Research Foundation of the Education Department
   of Heilongjiang Province of China.
CR Anjos Afonso F, 2007, BRIT J HAEMATOL, V139, P373, DOI 10.1111/j.1365 2141.2007.06827.x
   Ballas CB, 2002, J CELL BIOCHEM, P20, DOI 10.1002/jcb.10127
   Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247
   Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585 007 9118 2
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chubinskaya S, 2007, INT ORTHOP, V31, P773, DOI 10.1007/s00264 007 0423 9
   Dang Hong sheng, 2007, Sichuan Da Xue Xue Bao Yi Xue Ban, V38, P929
   Dorai H, 2000, J CELL PHYSIOL, V184, P37, DOI 10.1002/(SICI)1097 4652(200007)184:1<37::AID JCP4>3.0.CO;2 M
   Franceschi RT, 2004, CELLS TISSUES ORGANS, V176, P95, DOI 10.1159/000075031
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Hsu WK, 2007, BONE, V40, P931, DOI 10.1016/j.bone.2006.10.030
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Lee SY, 2008, BIOCHEM BIOPH RES CO, V376, P148, DOI 10.1016/j.bbrc.2008.08.138
   Li TT, 2004, CURR OPIN NEPHROL HY, V13, P417, DOI 10.1097/01.mnh.0000133974.24935.fe
   Long Hua, 2006, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V20, P1224
   Ma HB, 2007, WORLD J GASTROENTERO, V13, P4214, DOI 10.3748/wjg.v13.i31.4214
   Ma Hong Bing, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1183
   Majewski M, 2008, GENE THER, V15, P1139, DOI 10.1038/gt.2008.48
   Miyamoto C, 2007, J ORTHOP SCI, V12, P555, DOI 10.1007/s00776 007 1176 4
   Park J, 2007, BIOMATERIALS, V28, P2772, DOI 10.1016/j.biomaterials.2007.02.009
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reyes M, 2001, ANN NY ACAD SCI, V938, P231
   SAKANO S, 1993, CLIN ORTHOP RELAT R, P337
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Seol YJ, 2008, BIOTECHNOL APPL BIOC, V49, P85, DOI 10.1042/BA20060247
   Star GP, 2009, VASC PHARMACOL, V50, P45, DOI 10.1016/j.vph.2008.09.001
   Takigami H, 2007, J ORTHOP RES, V25, P1333, DOI 10.1002/jor.20411
   Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432 0436.2004.07207003.x
   Vinge LE, 2008, CIRC RES, V102, P1458, DOI 10.1161/CIRCRESAHA.108.173195
   Xiao Rui, 2002, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V19, P703
   Zhang YF, 2007, BIOMATERIALS, V28, P4635, DOI 10.1016/j.biomaterials.2007.07.009
NR 33
TC 10
Z9 12
U1 0
U2 6
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD AUG
PY 2015
VL 19
IS 16
BP 3056
EP 3062
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CR8HC
UT WOS:000361590800020
PM 26367729
DA 2025 08 17
ER

PT J
AU Chen, K
   Wu, DJ
   Bai, YS
   Zhu, XD
   Chen, ZQ
   Wang, CF
   Zhao, YC
   Li, M
AF Chen, Kai
   Wu, Dajiang
   Bai, Yushu
   Zhu, Xiaodong
   Chen, Ziqiang
   Wang, Chuanfeng
   Zhao, Yingchuan
   Li, Ming
TI Fuzzy Clustering Analysis of Osteosarcoma Related Genes
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Osteosarcoma; Gene sequences; Fuzzy clustering; Runx2
ID ONCOSTATIN M; DIFFERENTIAL REGULATION; OSTEOBLAST PHENOTYPE; CELL LINES;
   IN VITRO; EXPRESSION; GROWTH; INTERLEUKIN 6; INFLAMMATION; RESORPTION
AB Osteosarcoma is the most common malignant bone tumor with a peak manifestation during the second and third decade of life. In order to explore the influence of genetic factors on the mechanism of osteosarcoma by analyzing the inter relationship between osteosarcoma and its related genes, and then provide potential genetic references for the prevention, diagnosis and treatment of osteosarcoma, we collected osteosarcoma related gene sequences in Genebank of National Center for Biotechnology Information (NCBI) and local alignment analysis for a pair of sequences was carried out to identify the measurement association among related sequences. Then fuzzy clustering method was used for clustering analysis so as to contact the unknown genes through the consistent osteosarcoma related genes in one class. From the result of fuzzy clustering analysis, we could classify the osteosarcoma related genes into two groups and deduced that the genes clustered into one group had similar function. Based on this knowledge, we found more genes related to the pathogenesis of osteosarcoma and these genes could exert similar function as Runx2, a risk factor confirmed in osteosarcoma, this study may help better understand the genetic mechanism and provide new molecular markers and therapies for osteosarcoma.
C1 [Chen, Kai; Wu, Dajiang; Bai, Yushu; Zhu, Xiaodong; Chen, Ziqiang; Wang, Chuanfeng; Zhao, Yingchuan; Li, Ming] Changhai Hosp, Dept Orthoped, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Li, M (通讯作者)，Changhai Hosp, Dept Orthoped, Shanghai 200433, Peoples R China.
EM minglil@hotmail.com
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022 2836(05)80360 2
   [Anonymous], DEC CONTR INCL 17 S
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   BEZDEK JC, 1981, PATTERN RECOGNITION
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Casey R.M., 2005, Business Intelligence Network
   CHAMBERS TJ, 1985, J CELL SCI, V76, P155
   Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498
   de Hooge ASK, 2002, AM J PATHOL, V160, P1733, DOI 10.1016/S0002 9440(10)61120 0
   Dembélé D, 2003, BIOINFORMATICS, V19, P973, DOI 10.1093/bioinformatics/btg119
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ek ETH, 2007, CLIN EXP METASTAS, V24, P93, DOI 10.1007/s10585 007 9062 1
   Fletcher ChristopherDM., 2002, PATHOLOGY GENETICS T, V4
   FULLER K, 1991, BIOCHEM BIOPH RES CO, V181, P67, DOI 10.1016/S0006 291X(05)81382 8
   Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357 4310(99)01540 3
   GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168 9525(00)89142 8
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Halfter H, 1998, GROWTH FACTORS, V15, P135, DOI 10.3109/08977199809117189
   Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502
   Iida K, 2003, ONCOL REP, V10, P1961
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707
   Langdon C, 2000, AM J PATHOL, V157, P1187, DOI 10.1016/S0002 9440(10)64634 2
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092 8674(00)81871 1
   Liu F, 2002, BONE, V31, P212, DOI 10.1016/S8756 3282(02)00806 2
   Mohammed RAA, 2007, BRIT J CANCER, V96, P1092, DOI 10.1038/sj.bjc.6603678
   Pickert L, 1998, BIOINFORMATICS, V14, P244, DOI 10.1093/bioinformatics/14.3.244
   Ping G, 1996, SPE GAS TECHN S
   Pratap J, 2003, CANCER RES, V63, P5357
   Rozen N, 2000, BONE, V26, P469, DOI 10.1016/S8756 3282(00)00263 5
   Saeidi L. Handy, 1974, SPE CAL REG M
   Sjin RTT, 2006, CANCER GENE THER, V13, P619, DOI 10.1038/sj.cgt.7700938
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646
   Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wang Z. Q., 1992, Bone and haematopoietic defects in mice lacking c fos
NR 38
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2014
VL 20
IS 3
BP 535
EP 539
DI 10.1007/s12253 013 9725 y
PG 5
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA AK2UL
UT WOS:000338274900007
PM 24293382
DA 2025 08 17
ER

PT J
AU Nie, MZ
   Zhang, J
   Bal, M
   Duran, C
   An, SW
   Zigman, JM
   Baum, M
   Hiremath, C
   Marciano, DK
   Wolf, MTF
AF Nie, Mingzhu
   Zhang, Jing
   Bal, Manjot
   Duran, Claudia
   An, Sung Wan
   Zigman, Jeffrey M.
   Baum, Michel
   Hiremath, Chitkale
   Marciano, Denise K.
   Wolf, Matthias T. F.
TI Ghrelin enhances tubular magnesium absorption in the kidney
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE magnesium; TRPM6/7; Ghrelin; GHSR; protein kinase A
ID DES ACYL GHRELIN; INTENSIVE MEDICAL THERAPY; GASTRIC BYPASS SURGERY;
   METABOLIC BONE DISEASE; BARIATRIC SURGERY; SODIUM REABSORPTION;
   PARATHYROID HORMONE; SLEEVE GASTRECTOMY; SURGICAL TREATMENT; TRPM7
   CHANNEL
AB Osteoporosis after bariatric surgery is an increasing health concern as the rate of bariatric surgery has risen. In animal studies mimicking bariatric procedures, bone disease, together with decreased serum levels of Ca2+, Mg2+ and the gastric hormone Ghrelin were described. Ghrelin regulates metabolism by binding to and activating the growth hormone secretagogue receptor (GHSR) which is also expressed in the kidney. As calcium and magnesium are key components of bone, we tested the hypothesis that Ghrelin deficiency contributes to osteoporosis via reduced upregulation of the renal calcium channel TRPV5 and the heteromeric magnesium channel TRPM6/7. We expressed GHSR with TRPV5 or TRPM6/7 channel in HEK293 cells and treated them with purified Ghrelin. Whole cell current density was analyzed by patch clamp recording. Nephron specific gene expression was performed by tubular microdissection followed by qPCR in wild type (WT) mice, and immunofluorescent imaging of GHSR eGFP mice. Tubular magnesium homeostasis was analyzed in GHSR null and WT mice at baseline and after caloric restriction. After Ghrelin exposure, whole cell current density did not change for TRPV5 but increased for TRPM6/7 in a dose dependent fashion. Applying the Ghrelin mimetic (D Trp7, Ala8,D Phe10) alpha MSH (6 11) amide without and with the GHSR antagonist (D Lys3) GHRP6, we confirmed the stimulatory role of Ghrelin towards TRPM6/7. As GHSR initiates downstream signaling via protein kinase A (PKA), we found that the PKA inhibitor H89 abrogated TRPM6/7 stimulation by Ghrelin. Similarly, transfected G alpha s, but not the G alpha s mutant Q227L, nor G alpha i2, G alpha q, or G alpha 13 upregulated TRPM6/7 current density. In microdissected TALs and DCTs similar levels of GHSR mRNA were detected. In contrast, TRPM6 mRNA was expressed in the DCT and also detected in the TAL at 25% expression compared to DCT. Immunofluorescent studies using reporter GHSR eGFP mice showed a strong eGFP signal in the TAL but surprisingly displayed no eGFP signal in the DCT. In 3 , 6 , and 9 month old GHSR null and WT mice, baseline serum magnesium was not significantly different, but 24 h urinary magnesium excretion was elevated in 9 month old GHSR null mice. In calorically restricted GHSR null mice, we detected excess urinary magnesium excretion and reduced serum magnesium levels compared to WT mice. The kidneys from calorically restricted WT mice showed upregulated gene expression of magnesiotropic genes Hnf1b, Cldn 16, Cldn 19, Fxyd 2b, and Parvalbumin compared to GHSR null mice. Our in vitro studies show that Ghrelin stimulates TRPM6/7 via GHSR and G alpha s PKA signaling. The murine studies are consistent with Ghrelin GHSR signaling inducing reduced urinary magnesium excretion, particularly in calorically restricted mice when Ghrelin levels are elevated. This effect may be mediated by Ghrelin upregulation of TRPM6 in the TAL and/or upregulation of other magnesiotropic genes. We postulate that rising Ghrelin levels with hunger contribute to increased renal Mg2+ reabsorption to compensate for lack of enteral Mg2+ uptake.
C1 [Nie, Mingzhu; Zhang, Jing; Bal, Manjot; Duran, Claudia; An, Sung Wan; Baum, Michel; Wolf, Matthias T. F.] Univ Texas Southwestern Med Ctr, Dept Pediat, Pediat Nephrol, Dallas, TX 75235 USA.
   [An, Sung Wan; Wolf, Matthias T. F.] Univ Michigan, Dept Pediat, Pediat Nephrol, Ann Arbor, MI 48109 USA.
   [Zigman, Jeffrey M.] UTSW Med Ctr, Ctr Hypothalam Res, Dept Internal Med, Dallas, TX USA.
   [Hiremath, Chitkale; Marciano, Denise K.] UTSW Med Ctr, Dept Internal Med, Nephrol, Dallas, TX USA.
   [Hiremath, Chitkale; Marciano, Denise K.] UTSW Med Ctr, Dept Cell Biol, Dallas, TX USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; University of Michigan System; University of Michigan;
   University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center
RP Wolf, MTF (通讯作者)，Univ Texas Southwestern Med Ctr, Dept Pediat, Pediat Nephrol, Dallas, TX 75235 USA.; Wolf, MTF (通讯作者)，Univ Michigan, Dept Pediat, Pediat Nephrol, Ann Arbor, MI 48109 USA.
EM matwolf@med.umich.edu
RI Duran, Claudia/S 1175 2019; Hiremath, Chitkale/LNP 8193 2024
OI Marciano, Denise K./0000 0003 0612 4664
FU U.S. Department of Defense10.13039/100000005 [Galpha12/13, Q227L];
   O'Brien Kidney Center Dallas
FX We are grateful to Richard T. Miller (UT Southwestern Medical School,
   Dallas), who was so friendly to provide the plasmids for G alpha s, G
   alpha i2, G alpha q, G alpha 12/13, and the G alpha s mutant Q227L.
   Touchstone Center for analyzing serum and urine electrolytes. O'Brien
   Kidney Center Dallas. We thank Drs. Chubanov and Gudermann from the
   Ludwig Maximilians University Munich for providing us with human TRPM6
   and TRPM7 plasmids. We thank Dr. J. Hou from Wahington University, St.
   Louis, for providing us with anti Claudin 16 antibody.
CR ALFREY AC, 1974, J CLIN INVEST, V54, P1074, DOI 10.1172/JCI107851
   Ariyasu H, 2001, J CLIN ENDOCR METAB, V86, P4753, DOI 10.1210/jc.86.10.4753
   Aydin S, 2008, BIOMED CHROMATOGR, V22, P1354, DOI 10.1002/bmc.1065
   Bano G, 1999, INT J OBESITY, V23, P361, DOI 10.1038/sj.ijo.0800827
   Barbagallo M, 2009, MAGNESIUM RES, V22, P235, DOI 10.1684/mrh.2009.0187
   Barrera G, 2004, NUTRITION, V20, P769, DOI 10.1016/j.nut.2004.05.014
   Benso A, 2012, EUR J ENDOCRINOL, V166, P911, DOI 10.1530/EJE 11 0982
   Berarducci A, 2009, APPL NURS RES, V22, P35, DOI 10.1016/j.apnr.2007.03.004
   BISBALLE S, 1991, GUT, V32, P1303, DOI 10.1136/gut.32.11.1303
   Blanchard MG, 2016, J AM SOC NEPHROL, V27, P804, DOI 10.1681/ASN.2014121228
   BOSKEY AL, 1992, J ORTHOP RES, V10, P774, DOI 10.1002/jor.1100100605
   Broglio F, 2004, J CLIN ENDOCR METAB, V89, P3062, DOI 10.1210/jc.2003 031964
   Choi HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065505
   COSTANZO LS, 1978, AM J PHYSIOL, V235, pF492, DOI 10.1152/ajprenal.1978.235.5.F492
   Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714
   Dagli AF, 2009, PATHOL RES PRACT, V205, P165, DOI 10.1016/j.prp.2008.10.002
   de Baaij JHF, 2015, PHYSIOL REV, V95, P1, DOI 10.1152/physrev.00012.2014
   De Prisco C, 2005, AM J MED SCI, V329, P57, DOI 10.1097/00000441 200502000 00001
   De Souza MJ, 2004, J CLIN ENDOCR METAB, V89, P3536, DOI 10.1210/jc.2003 032007
   Delhanty PJD, 2014, FRONT HORM RES, V42, P163, DOI 10.1159/000358345
   Folli F, 2012, INT J OBESITY, V36, P1373, DOI 10.1038/ijo.2012.115
   Frick KK, 2003, J AM SOC NEPHROL, V14, P1082, DOI 10.1097/01.ASN.0000062960.26868.17
   Fujimura K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094373
   Fukushima N, 2005, J BONE MINER RES, V20, P790, DOI 10.1359/JBMR.041237
   Gautam S, 2021, J NEPAL MED ASSOC, V59, P35, DOI 10.31729/jnma.5764
   Geloneze B, 2003, OBES SURG, V13, P17, DOI 10.1381/096089203321136539
   Groenestege WMT, 2006, J AM SOC NEPHROL, V17, P1035, DOI 10.1681/ASN.2005070700
   GULLESTAD L, 1994, J AM COLL NUTR, V13, P45
   Gupta D, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqab148
   Hamoui N, 2003, ARCH SURG CHICAGO, V138, P891, DOI 10.1001/archsurg.138.8.891
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140 6736(05)67483 1
   Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826
   Hoenderop JGJ, 2008, PHYSIOLOGY, V23, P32, DOI 10.1152/physiol.00039.2007
   Hoorn EJ, 2011, NAT MED, V17, P1304, DOI 10.1038/nm.2497
   Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039
   Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974
   Janssen JAMJL, 2001, EUR J ENDOCRINOL, V145, P711, DOI 10.1530/eje.0.1450711
   Kemp BA, 2019, J ENDOCR SOC, V3, P2088, DOI 10.1210/js.2019 00121
   Kemp BA, 2018, AM J PHYSIOL RENAL, V315, pF1058, DOI 10.1152/ajprenal.00010.2018
   Kemp BA, 2014, ENDOCRINOLOGY, V155, P2658, DOI 10.1210/en.2013 2177
   Kemp BA, 2013, KIDNEY INT, V84, P501, DOI 10.1038/ki.2013.187
   Khosla S, 1996, J BONE MINER RES, V11, P857
   KLEIN KB, 1987, GASTROENTEROLOGY, V92, P608, DOI 10.1016/0016 5085(87)90008 4
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Kotidis EV, 2006, OBES SURG, V16, P554, DOI 10.1381/096089206776944940
   Liang QH, 2013, TOXICOL APPL PHARM, V272, P591, DOI 10.1016/j.taap.2013.07.018
   Loffing J, 2003, AM J PHYSIOL RENAL, V284, pF628, DOI 10.1152/ajprenal.00217.2002
   Maccarinelli G, 2005, J ENDOCRINOL, V184, P249, DOI 10.1677/joe.1.05837
   Malkani S, 2015, CURR OPIN ENDOCRINOL, V22, P98, DOI 10.1097/MED.0000000000000143
   Mori K, 2000, FEBS LETT, V486, P213, DOI 10.1016/S0014 5793(00)02308 5
   Nair AV, 2012, P NATL ACAD SCI USA, V109, P11324, DOI 10.1073/pnas.1113811109
   Nie MZ, 2018, J BIOL CHEM, V293, P16488, DOI 10.1074/jbc.RA118.003950
   Nie MZ, 2016, J AM SOC NEPHROL, V27, P3447, DOI 10.1681/ASN.2015101100
   Ogden CL, 2006, JAMA J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Pacifico L, 2009, EUR J ENDOCRINOL, V161, P861, DOI 10.1530/EJE 09 0375
   Quercia I, 2014, DIABETES METAB, V40, P87, DOI 10.1016/j.diabet.2013.11.003
   Rude RK, 2004, J NUTR BIOCHEM, V15, P710, DOI 10.1016/j.jnutbio.2004.08.001
   Rude RK, 2004, J NUTR, V134, P79, DOI 10.1093/jn/134.1.79
   Rude RK, 2003, CALCIFIED TISSUE INT, V72, P32, DOI 10.1007/s00223 001 1091 1
   Rümenapf G, 1998, CALCIFIED TISSUE INT, V63, P433
   Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781
   Schauer PR, 2014, NEW ENGL J MED, V371, P682, DOI 10.1056/NEJMc1407393
   Schauer PR, 2012, NEW ENGL J MED, V366, P1567, DOI 10.1056/NEJMoa1200225
   Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889
   Shimada T, 2014, METABOLISM, V63, P469, DOI 10.1016/j.metabol.2013.12.011
   Sivertsen B, 2013, BRIT J PHARMACOL, V170, P1349, DOI 10.1111/bph.12361
   Smith JT, 2013, PEPTIDES, V47, P45, DOI 10.1016/j.peptides.2013.06.012
   Stemmer K, 2013, ENDOCRINOLOGY, V154, P2015, DOI 10.1210/en.2012 2130
   Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101
   Tatara MR, 2007, EXP BIOL MED, V232, P1449, DOI 10.3181/0608 RM 196
   Thomas S, 2010, NUTR CLIN PRACT, V25, P175, DOI 10.1177/0884533610361739
   Ullman Culleré MH, 1999, LAB ANIM SCI, V49, P319
   van Angelen AA, 2013, NEPHROL DIAL TRANSPL, V28, P2983, DOI 10.1093/ndt/gft358
   van der Velde M, 2012, ENDOCRINOLOGY, V153, P3593, DOI 10.1210/en.2012 1277
   Velásquez DA, 2011, DIABETES, V60, P1177, DOI 10.2337/db10 0802
   Venables G, 2011, CELL TISSUE RES, V346, P135, DOI 10.1007/s00441 011 1240 4
   Vilarrasa N, 2009, OBES SURG, V19, P860, DOI 10.1007/s11695 009 9843 5
   Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200
   von Mach MA, 2004, METABOLISM, V53, P918, DOI 10.1016/j.metabol.2004.01.015
   Walder RY, 2009, HUM MOL GENET, V18, P4367, DOI 10.1093/hmg/ddp392
   Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901
   Xie YH, 2023, J BONE MINER RES, V38, P1015, DOI 10.1002/jbmr.4820
   Yang J, 2008, P NATL ACAD SCI USA, V105, P10750, DOI 10.1073/pnas.0805353105
   Yu EW, 2014, J BONE MINER RES, V29, P1507, DOI 10.1002/jbmr.2226
   Zhang YY, 2015, P NATL ACAD SCI USA, V112, P1226, DOI 10.1073/pnas.1423643112
   Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823
NR 86
TC 2
Z9 2
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD APR 4
PY 2024
VL 15
AR 1363708
DI 10.3389/fphys.2024.1363708
PG 15
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA OA8P0
UT WOS:001204632900001
PM 38638279
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Seo, DK
   Kim, JH
   Min, J
   Yoon, HH
   Shin, ES
   Kim, SW
   Jeon, SR
AF Seo, Dong Kwang
   Kim, Jeong Hoon
   Min, Joongkee
   Yoon, Hyung Ho
   Shin, Eun Sil
   Kim, Seong Who
   Jeon, Sang Ryong
TI Enhanced axonal regeneration by transplanted Wnt3a secreting human
   mesenchymal stem cells in a rat model of spinal cord injury
SO ACTA NEUROCHIRURGICA
LA English
DT Article
DE Wnt3a; Mesenchymal stem cell; Transfection; Spinal cord injury; Spinal
   cord regeneration; Functional recovery
ID MARROW STROMAL CELLS; WNT SIGNALING PATHWAY; BONE MARROW; FUNCTIONAL
   RECOVERY; GENE THERAPY; NERVOUS SYSTEM; LENTIVIRAL VECTORS; CAVITY
   FORMATION; GROWTH; EXPRESSION
AB While pure mesenchymal stem cell (MSC) treatment for spinal cord injury (SCI) is known to be safe, its efficacy is insufficient. Therefore, gene modified stem cells are being developed to enhance the effect of pure MSCs. We investigated the effect of stem cell therapy through the transfection of a Wnt3a producing gene that stimulates axonal regeneration.
   MSCs obtained from the human umbilical cord blood (hMSCs) were multiplied, cultivated, and transfected with the pLenti Wnt3a GFP viral vector to produce Wnt3a secreting hMSCs. A total of 50 rats were injured with an Infinite Horizon impactor at the level of the T7 8 vertebrae. Rats were divided into five groups according to the transplanted material: (1) phosphate buffered saline injection group (sham group, n = 10); (Pertz et al. Proc Natl Acad Sci USA 105:1931 1936, 39) Wnt3a protein injection group (Wnt3a protein group, n = 10); (3) hMSC transplantation group (MSC group, n = 10); (4) hMSCs transfected with the pLenti vector transplantation group (pLenti MSC group, n = 10); (5) hMSCs transfected with the pLenti+Wnt3a vector transplantation group (Wnt3a MSC group, n = 10). Behavioral tests were performed daily for the first 3 days after injury and then weekly for 8 weeks. The injured spinal cords were extracted, and axonal regeneration markers including choline acetyltransferase (ChAT), growth associated protein 43 (GAP43), and microtubule associated protein 2 (MAP2) were investigated by immunofluorescence, RT PCR, and western blotting.
   Seven weeks after the transplantation (8 weeks after SCI), rats in the Wnt3a MSC group achieved significantly higher average scores in the motor behavior tests than those in the other groups (p < 0.05). Immunofluorescent stains showed greater immunoreactivity of ChAT, GAP43, and MAP2 in the Wnt3a MSC group than in the other groups. RT PCR and western blots revealed greater expression of these proteins in the Wnt3a MSC group than in the other groups (p < 0.05).
   Wnt3a secreting hMSC transplantation considerably improved neurological recovery and axonal regeneration in a rat SCI model.
C1 [Seo, Dong Kwang; Kim, Jeong Hoon; Min, Joongkee; Yoon, Hyung Ho; Shin, Eun Sil; Jeon, Sang Ryong] Univ Ulsan, Coll Med, Dept Neurol Surg, Asan Med Ctr, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Kim, Seong Who] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan
RP Jeon, SR (通讯作者)，Univ Ulsan, Coll Med, Dept Neurol Surg, Asan Med Ctr, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM srjeon@amc.seoul.kr
OI Yoon, Hyung Ho/0000 0003 4123 0112
FU Asan Medical Center [13 176]
FX The Asan Medical Center provided financial support in the form of the
   Asan Life Science Institute Grant (13 176). The sponsor played no role
   in the design or conduct of this research.
CR Akiyama Y, 2002, J NEUROSCI, V22, P6623
   ARBEIT JM, 1987, J CLIN ONCOL, V5, P480, DOI 10.1200/JCO.1987.5.3.480
   Arévalo JC, 2005, CURR OPIN CELL BIOL, V17, P112, DOI 10.1016/j.ceb.2005.01.004
   Barde Isabelle, 2011, Curr Protoc Mouse Biol, V1, P169, DOI 10.1002/9780470942390.mo100169
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Blesch A, 2002, PROG BRAIN RES, V137, P415
   Cavazzana Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328
   Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078
   Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665
   Cízková D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571 006 9093 1
   Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064 007 9368 z
   De Miguel MP, 2012, CURR MOL MED, V12, P574
   De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856
   Diaz RM, 2000, GENE THER, V7, P1656, DOI 10.1038/sj.gt.3301277
   Einstein O, 2008, ARCH NEUROL CHICAGO, V65, P452, DOI 10.1001/archneur.65.4.452
   Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370
   GOSLIN K, 1990, J NEUROSCI, V10, P588
   Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976
   Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165
   Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089
   Im J, 2007, BIOCHEM BIOPH RES CO, V354, P296, DOI 10.1016/j.bbrc.2006.12.205
   Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311 05.2005
   Kumagai G, 2013, EXP NEUROL, V248, P369, DOI 10.1016/j.expneurol.2013.06.028
   Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004
   Lee HJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000156
   Li YQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060970
   [刘娅 LIU Ya], 2008, [现代化工, Modern Chemical Industry], V28, P28
   Mansilla Soto J, 2016, HUM GENE THER, V27, P295, DOI 10.1089/hum.2016.037
   Metz Gerlinde A, 2009, J Vis Exp, DOI 10.3791/1204
   Miyashita T, 2009, J NEUROTRAUM, V26, P955, DOI 10.1089/neu.2008.0776
   Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301 0082(97)00043 9
   Oh SK, 2016, NEUROSURGERY, V78, P436, DOI 10.1227/NEU.0000000000001056
   Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021
   Osaka M, 2010, BRAIN RES, V1343, P226, DOI 10.1016/j.brainres.2010.05.011
   Park JH, 2013, ACTA NEUROCHIR, V155, P809, DOI 10.1007/s00701 013 1663 7
   Park JH, 2012, NEUROSURGERY, V70, P1238, DOI 10.1227/NEU.0b013e31824387f9
   PARR BA, 1993, DEVELOPMENT, V119, P247
   Pertz OC, 2008, P NATL ACAD SCI USA, V105, P1931, DOI 10.1073/pnas.0706545105
   Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023
   Sakai D, 2003, BIOMATERIALS, V24, P3531, DOI 10.1016/S0142 9612(03)00222 9
   Salmon P, 2002, CURR TOP MICROBIOL, V261, P211
   Samdani AF, 2009, SPINE, V34, P2605, DOI 10.1097/BRS.0b013e3181bdca87
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19 14 05731.1999
   Suh HI, 2011, ACTA NEUROCHIR, V153, P1003, DOI 10.1007/s00701 011 0945 1
   Tashiro S, 2016, SCI REP UK, V6, DOI 10.1038/srep30898
   Touzot F, 2014, EXPERT OPIN BIOL TH, V14, P789, DOI 10.1517/14712598.2014.895811
   Van Damme A, 2006, STEM CELLS, V24, P896, DOI 10.1634/stemcells.2003 0106
   Woods NB, 2001, J INTERN MED, V249, P339, DOI 10.1046/j.1365 2796.2001.00806.x
   Xue F, 2015, NEURAL REGEN RES, V10, P104, DOI 10.4103/1673 5374.150715
   YANG KH, 2007, J KOR NEUROTRAUMATOL, V3, P99
   Yang XT, 2014, J NEUROSCI RES, V92, P148, DOI 10.1002/jnr.23314
   Yin ZS, 2008, NEUROL RES, V30, P480, DOI 10.1179/174313208X284133
   Yun S, 2007, BIOCHEM BIOPH RES CO, V363, P727, DOI 10.1016/j.bbrc.2007.09.033
   Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873 9880.1998
NR 55
TC 16
Z9 22
U1 0
U2 17
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4 6, PO BOX 89, A 1201 WIEN, AUSTRIA
SN 0001 6268
EI 0942 0940
J9 ACTA NEUROCHIR
JI Acta Neurochir.
PD MAY
PY 2017
VL 159
IS 5
BP 947
EP 957
DI 10.1007/s00701 017 3097 0
PG 11
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA ER9WG
UT WOS:000399177300032
PM 28160063
DA 2025 08 17
ER

PT J
AU Gevorgyan, AM
   La Scala, GC
   Sukhu, B
   Leung, IT
   Ashrafpour, H
   Yeung, I
   Neligan, PC
   Pang, CY
   Forrest, CR
AF Gevorgyan, Artur M.
   La Scala, Giorgio C.
   Sukhu, Balram
   Leung, Iona T.
   Ashrafpour, Homa
   Yeung, Ivan
   Neligan, Peter C.
   Pang, Cho Y.
   Forrest, Christopher R.
TI Radiation induced craniofacial bone growth inhibition: In vitro
   cytoprotection in the rabbit orbitozygomatic complex periosteum derived
   cell culture
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID DIFFERENTIAL GENE EXPRESSION; OSTEOBLAST LIKE CELLS; IONIZING RADIATION;
   AMINOTHIOL WR1065; NECK CANCER; AMIFOSTINE; HEAD; RADIOTHERAPY;
   CHILDREN; THERAPY
AB Background: Radiotherapy for the management of head and neck cancer in pediatric patients results in severe inhibition of craniofacial bone growth. Previously, the infant rabbit orbitozygomatic complex was established as an experimental model. Amifostine, a cytoprotective agent, was found effective in preventing radiation induced bone growth inhibition. This study was designed to investigate the effects radiation on osteogenic cells from infant rabbit orbitozygomatic complex periostea and to assess the effects of cytoprotection in vitro.
   Methods: Infant New Zealand White rabbits (n = 18) were randomized into three groups and received radiation (0, 10, or 15 Gy) to both orbitozygomatic complexes. Cell cultures were developed from orbitozygomatic complex periostea, and cell numbers, proliferation, alkaline phosphatase, and collagen type I expression and mineralization were assessed. Subsequently, rabbits (n = 18) were randomized into three groups to receive either radiation at the effective dose, pretreatment with amifostine (300 mg/kg, intravenously, 20 minutes before irradiation) with the effective radiation close, or no treatment. Cell cultures were developed and tested for proliferation and alkaline phosphatase expression.
   Results: Irradiation resulted in a significant inhibition of cell numbers (p < 0.001) and proliferation (p < 0.01) at the 15 Gy dose and no statistically significant changes in alkaline phosphatase activity. Collagen type I expression and mineralization were also significantly reduced at the 15 Gy dose. Pretreatment with amifostine significantly (p < 0.05) enhanced the number of surviving cells.
   Conclusions: Amifostine is capable of protecting orbitozygomatic complex periosteum derived osteogenic cells from the deleterious effects of radiation. This study provides the basis for understanding the cellular mechanisms of radiation induced craniofacial bone growth inhibition and cytoprotection by amifostine.
C1 [Forrest, Christopher R.] Hosp Sick Children, Ctr Craniofacial Care & Res, Div Plast Surg, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada.
   Univ Geneva, Childrens Hosp, Pediat Surg Clin, Geneva, Switzerland.
   Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
   Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada.
   Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Dept Clin Phys, Toronto, ON, Canada.
   Univ Hlth Network, Div Plast Surg, Toronto, ON, Canada.
   Univ Toronto, Toronto, ON, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; Hospital for Sick Children (SickKids); University of Geneva;
   University of Toronto; Sinai Health System Toronto; Lunenfeld Tanenbaum
   Research Institute; University of Toronto; Sinai Health System Toronto;
   Lunenfeld Tanenbaum Research Institute; University of Toronto;
   University Health Network Toronto; Princess Margaret Cancer Centre;
   University of Toronto; University Health Network Toronto; University of
   Toronto
RP Forrest, CR (通讯作者)，Hosp Sick Children, Ctr Craniofacial Care & Res, Div Plast Surg, 555 Univ Ave,Room 5430, Toronto, ON M5G 1X8, Canada.
EM christopher.forrest@sickkids.ca
RI Neligan, Peter/ABD 7219 2020; La Scala, Giorgio/AAM 8031 2020
CR BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339
   Capizzi RL, 2000, INT J HEMATOL, V72, P425
   CAPIZZI RL, 1996, EUR J CANCER, V32, P5
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Dahllöf G, 1998, ACTA ODONTOL SCAND, V56, P378, DOI 10.1080/000163598428365
   Dare A, 1997, J DENT RES, V76, P658, DOI 10.1177/00220345970760020601
   Denys D, 1998, INT J PEDIATR OTORHI, V45, P7, DOI 10.1016/S0165 5876(98)00028 7
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   FARKAS LG, 1992, CLEFT PALATE CRAN J, V29, P301, DOI 10.1597/1545 1569(1992)029<0301:GADORU>2.3.CO;2
   Forrest CR, 2002, PLAST RECONSTR SURG, V109, P1311, DOI 10.1097/00006534 200204010 00015
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   Grdina DJ, 2002, ONCOLOGY BASEL, V63, P2, DOI 10.1159/000067146
   GUYURON B, 1983, ANN PLAS SURG, V11, P423, DOI 10.1097/00000637 198311000 00010
   Hatoum GF, 2004, INT J RADIAT ONCOL, V59, P844, DOI 10.1016/j.ijrobp.2004.01.046
   Karsila Tenovuo S, 2001, ORAL ONCOL, V37, P586, DOI 10.1016/S1368 8375(01)00002 1
   Kataoka Y, 2002, INT J RADIAT ONCOL, V53, P180, DOI 10.1016/S0360 3016(01)02820 6
   Khodarev NN, 2004, INT J RADIAT ONCOL, V60, P553, DOI 10.1016/j.ijrobp.2004.04.060
   La Scala GC, 2005, PLAST RECONSTR SURG, V115, P1973, DOI 10.1097/01.PRS.0000163322.22436.3B
   LARSON DL, 1990, AM J SURG, V160, P348, DOI 10.1016/S0002 9610(05)80540 9
   Mann K, 2005, ONCOGENE, V24, P3964, DOI 10.1038/sj.onc.1208563
   Matsumura S, 1996, CALCIFIED TISSUE INT, V59, P307, DOI 10.1007/s002239900129
   MEADOWS AT, 1985, CA CANCER J CLIN, V35, P271, DOI 10.3322/canjclin.35.5.271
   *MEDIMMUNE ONC, 2001, ETH AM INJ
   North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413
   O'Donovan DA, 2001, J CRANIOFAC SURG, V12, P533, DOI 10.1097/00001665 200111000 00006
   Orditura M, 1999, ONCOL REP, V6, P1357
   Paulino AC, 2000, INT J RADIAT ONCOL, V48, P1489, DOI 10.1016/S0360 3016(00)00799 9
   Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006 2952(02)01655 6
   Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200
   Potter Bryan O, 2003, Surg Oncol Clin N Am, V12, P379, DOI 10.1016/S1055 3207(03)00005 X
   Raney RB, 1999, MED PEDIATR ONCOL, V33, P362, DOI 10.1002/(SICI)1096 911X(199910)33:4<362::AID MPO4>3.0.CO;2 I
   Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   TENENBAUM HC, 1992, BONE, V13, P129, DOI 10.1016/8756 3282(92)90002 E
   Toljanic JA, 1998, ONCOL REP, V5, P345
   Vissink A, 2003, CRIT REV ORAL BIOL M, V14, P199, DOI 10.1177/154411130301400305
   Zackrisson B, 2003, ACTA ONCOL, V42, P443, DOI 10.1080/02841860310014886
NR 38
TC 7
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0032 1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD MAR
PY 2008
VL 121
IS 3
BP 763
EP 771
DI 10.1097/01.prs.0000299908.66658.82
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 268GA
UT WOS:000253566000007
PM 18317126
DA 2025 08 17
ER

PT J
AU Albalate, M
   de la Piedra, C
   Ortiz, A
   Pérez, JH
   Rubert, M
   Garcia, RP
   Zazo, P
   Nieto, L
   de Sequera, P
   Egido, J
AF Albalate, M.
   de la Piedra, C.
   Ortiz, A.
   Hernandez Perez, J.
   Rubert, M.
   Perez Garcia, R.
   Zazo, P.
   Nieto, L.
   de Sequera, P.
   Egido, J.
TI Risk in Dosing Regimens for 25 OH Vitamin D Supplementation in Chronic
   Haemodialysis Patients
SO NEPHRON CLINICAL PRACTICE
LA English
DT Article
DE Haemodialysis; 25 hydroxyvitamin D; Calcium; Phosphorus; PTH
ID CHRONIC KIDNEY DISEASE; HIGH DOSE CHOLECALCIFEROL; MINERAL METABOLISM; D
   DEFICIENCY; ERGOCALCIFEROL; BONE
AB Introduction: 25 OH vitamin D (25 OHvitD) insufficiency or deficiency should be treated in haemodialysis (HD) patients, although the 25 OHvitD target, drug or dosing regimens are unclear. Aims: To describe factors associated with 25 OHvitD levels in HD patients and to assess the effect of three dosing regimens to supplement 25 OHvitD (calcifediol) on serum calcium (Ca), phosphate (P), parathyroid hormone (PTH), 25 OHvitD and 1,25 OHvitD. Methods: Two hundred and seventeen patients from three HD units were studied. Demographic and biochemical data were collected at baseline. Two different 25 OHvitD assays were used. One hundred and sixty seven patients were treated with various calcifediol dosing regimens. The same biochemical determinations were repeated after 3 months of treatment. Results: At baseline, 12.9% of patients had 25 OHvitD < 10 ng/ml. In multivariate linear regression, the season (lower in winter) and the assay method were determinants of 25 OHvitD concentration. Following calcifediol supplementation, 25 OHvitD, calcium and phosphate increased, while PTH diminished with statistical significance. After treatment, there were positive correlations between 25 OHvitD and Ca (r = 0.28, p < 0.0001) or 1,25 OHvitD (r = 0.75, p < 0.0001) that were not observed in the baseline dataset. High concentrations of post treatment 25 OHvitD were associated with higher 1,25 OHvitD levels. Calcemia increased more in those treated with concomitant active vitamin D or those having suppressed baseline PTH, while PTH decreased more in those having above target PTH levels. Conclusions: Standardisation of methods to determine 25 OHvitD blood levels is needed. In HD patients, calcifediol increased 25 OHvitD, calcemia and phosphatemia and lowered PTH. Caution should be exercised with the higher calcifediol dosing regimens, especially in patients with suppressed PTH or on vitamin D receptor activators. Copyright (C) 2012 S. Karger AG, Basel
C1 [Albalate, M.; Perez Garcia, R.; de Sequera, P.] Hosp Univ Infanta Leonor, Serv Nefrol, ES 28031 Madrid, Spain.
   [de la Piedra, C.; Rubert, M.; Zazo, P.] Autonoma Univ IIS Fdn Jimenez Diaz, Serv Bioquim, Madrid, Spain.
   [Ortiz, A.; Hernandez Perez, J.; Egido, J.] Autonoma Univ IIS Fdn Jimenez Diaz, Serv Nefrol, Madrid, Spain.
   [Nieto, L.] Ctr Dialisis Santa Engracia FRIAT, Madrid, Spain.
C3 Hospital Universitario Infanta Leonor; Fundacion Jimenez Diaz; Fundacion
   Jimenez Diaz
RP Albalate, M (通讯作者)，Hosp Univ Infanta Leonor, Serv Nefrol, Gran Via Este 80, ES 28031 Madrid, Spain.
EM malbalater@senefro.org
RI Ortiz Arduan, Alberto/Y 7582 2018; ortiz, alberto/Y 7582 2018;
   de Sequera, Patricia/HZH 5681 2023
OI Ortiz Arduan, Alberto/0000 0002 9805 9523; 
FU FIS [PI10/00072, PS09/00447]; RECAVA [RD06/0014/0035]; Fundacion Lilly;
   ISCIII RETIC [REDinREN/RD06/0016]; Comunidad de Madrid/CIFRA/S
   [BIO0283/2006]; Sociedad Espanola de Nefrologia; ERA EDTA; Programa
   Intensificacion Actividad Investigadora (ISCIII/Agencia
   Lain Entralgo/CM);  [S2010/BMD 2378]
FX The work of the senior authors was supported by the following grants:
   FIS (PI10/00072) RECAVA (RD06/0014/0035) Fundacion Lilly (J.E.). FIS
   PS09/00447, ISCIII RETIC REDinREN/RD06/0016, Comunidad de
   Madrid/CIFRA/S BIO0283/2006, S2010/BMD 2378, Sociedad Espanola de
   Nefrologia, ERA EDTA, and Programa Intensificacion Actividad
   Investigadora (ISCIII/Agencia Lain Entralgo/CM) to A.O.
CR [Anonymous], REV ESP ENFER MET S1
   Blair D, 2008, J RENAL NUTR, V18, P375, DOI 10.1053/j.jrn.2008.04.008
   Clayton P, 2009, NEPHROLOGY, V14, P554, DOI 10.1111/j.1440 1797.2009.01145.x
   Dusso AS, 2011, KIDNEY INT, V79, P715, DOI 10.1038/ki.2010.543
   Farrell CJL, 2012, CLIN CHEM, V58, P531, DOI 10.1373/clinchem.2011.172155
   Food and Nutrition Board Institute of Medicine National Academies., 2010, DIETARY REFERENCE IN
   HALLORAN BP, 1984, J CLIN ENDOCR METAB, V59, P1063, DOI 10.1210/jcem 59 6 1063
   Heaney RP, 2009, J BONE MINER RES, V24, P755, DOI 10.1359/JBMR.081219
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick Michael F, 2011, J Clin Endocrinol Metab, V96, P1, DOI 10.1210/jc.2011 0385
   Jean G, 2008, NEPHRON CLIN PRACT, V110, pC58, DOI 10.1159/000151534
   Jean G, 2008, NEPHROL DIAL TRANSPL, V23, P3670, DOI 10.1093/ndt/gfn339
   Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P3799, DOI 10.1093/ndt/gfp370
   Jean G, 2009, NEPHROL THER, V5, P520, DOI 10.1016/j.nephro.2009.07.010
   Kandula P, 2011, CLIN J AM SOC NEPHRO, V6, P50, DOI 10.2215/CJN.03940510
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   LAMBERT PW, 1982, J CLIN INVEST, V69, P722, DOI 10.1172/JCI110501
   Matias PJ, 2010, CLIN J AM SOC NEPHRO, V5, P905, DOI 10.2215/CJN.06510909
   Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629
   Nigwekar SU, 2012, AM J KIDNEY DIS, V60, P139, DOI 10.1053/j.ajkd.2011.12.035
   Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092 8674(00)80655 8
   Pérez García R, 2012, NEFROLOGIA, V32, P459, DOI 10.3265/Nefrologia.pre2012.Jan.11189
   Rojas Rivera J, 2010, NEPHROL DIAL TRANSPL, V25, P2850, DOI 10.1093/ndt/gfq313
   Tokmak F, 2008, NEPHROL DIAL TRANSPL, V23, P4016, DOI 10.1093/ndt/gfn367
   Tolouian R, 2010, CLIN NEPHROL, V74, P19
   Torregrosa JV, 2011, NEFROLOGIA, V31, P3, DOI 10.3265/Nefrologia.pre2011.Jan.10816
   Wagner D, 2009, CLIN BIOCHEM, V42, P1549, DOI 10.1016/j.clinbiochem.2009.07.013
   Wasse H, 2012, AM J CLIN NUTR, V95, P522, DOI 10.3945/ajcn.111.025502
   Zerwekh JE, 2008, AM J CLIN NUTR, V87, p1087S, DOI 10.1093/ajcn/87.4.1087S
NR 29
TC 5
Z9 5
U1 0
U2 14
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1660 2110
J9 NEPHRON CLIN PRACT
JI Nephron. Clin. Pract.
PY 2012
VL 121
IS 3 4
BP C112
EP C119
DI 10.1159/000345148
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 080JW
UT WOS:000314239100003
PM 23221739
DA 2025 08 17
ER

PT J
AU Krishnan, B
   Smith, TL
   Dubey, P
   Zapadka, ME
   Torti, FM
   Willingham, MC
   Tallant, EA
   Gallagher, PE
AF Krishnan, Bhavani
   Smith, Thomas L.
   Dubey, Purnima
   Zapadka, Michael E.
   Torti, Frank M.
   Willingham, Mark C.
   Tallant, E. Ann
   Gallagher, Patricia E.
TI Angiotensin (1 7) attenuates metastatic prostate cancer and reduces
   osteoclastogenesis
SO PROSTATE
LA English
DT Article
DE angiotensin (1 7); metastatic prostate cancer; vascular endothelial
   growth factor; osteoclasts
ID ENDOTHELIAL GROWTH FACTOR; COLONY STIMULATING FACTOR; BONE METASTASIS;
   FACTOR CONTRIBUTES; EXPRESSION; MICROENVIRONMENT; PATHOGENESIS;
   XENOGRAFTS; MECHANISMS; REDUCTION
AB BACKGROUND Angiotensin (1 7) [Ang (1 7)] is an endogenous, heptapeptide hormone with anti proliferative and anti angiogenic properties. The primary objective of this study was to determine whether Ang (1 7) effectively reduces prostate cancer metastasis in mice.
   METHODS Human PC3 prostate cancer cells were injected into the aortic arch via the carotid artery of SCID mice pre treated with Ang (1 7) or injected into the tibia of athymic mice, administered Ang (1 7) for 5 weeks beginning 2 weeks post injection. Tumor growth and volume were determined by bioluminescent and magnetic resonance imaging. The presence of tumors was confirmed by hematoxylin and eosin staining; TRAP histochemistry was used to identify osteolytic lesions. The effect of Ang (1 7) on osteoclastogenesis was assessed in differentiated bone marrow cells.
   RESULTS Pre treatment with Ang (1 7) prevented metastatic tumor formation following intra aortic injection of PC3 cells, while 83% of untreated mice developed tumors in metastatic sites. Circulating VEGF was significantly higher in control mice compared to mice administered Ang (1 7). A 5 week regimen of the heptapeptide hormone attenuated intra tibial tumor growth; Ang (1 7) was significantly higher in the tibia of treated mice than in control animals. Osteoclastogenesis was reduced by 50% in bone marrow cells differentiated in the presence of Ang (1 7), suggesting that the heptapeptide hormone prevents the formation of osteolytic lesions to reduce tumor survival in the bone microenvironment.
   CONCLUSIONS These findings suggest that Ang (1 7) may serve as an anti angiogenic and anti metastatic agent for advanced prostate cancer. By extension, the heptapeptide hormone may provide effective therapy for bone metastasis produced from primary tumors of the lung and breast. Prostate 73: 7182, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Krishnan, Bhavani; Tallant, E. Ann; Gallagher, Patricia E.] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA.
   [Krishnan, Bhavani; Tallant, E. Ann] Wake Forest Univ, Bowman Gray Sch Med, Mol Genet & Genom Program, Winston Salem, NC 27157 USA.
   [Smith, Thomas L.] Wake Forest Univ, Bowman Gray Sch Med, Dept Orthoped Surg, Winston Salem, NC 27157 USA.
   [Dubey, Purnima; Willingham, Mark C.] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA.
   [Zapadka, Michael E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiol, Winston Salem, NC 27157 USA.
   [Torti, Frank M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.
C3 Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest
   University; Wake Forest Baptist Medical Center; Wake Forest University;
   Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest
   Baptist Medical Center; Wake Forest University; Wake Forest Baptist
   Medical Center; Wake Forest University; Wake Forest Baptist Medical
   Center
RP Gallagher, PE (通讯作者)，Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM pgallagh@wakehealth.edu
RI Dubey, Purnima/AAY 2462 2021
FU National Institute of Health [HL051952]; GT Cancer Fund, Wake Forest
   University Comprehensive Cancer Center, Golfers Against Cancer
   (Greensboro, NC); Farley Hudson Foundation (Jacksonville, NC)
FX Grant sponsor: The National Institute of Health; Grant number: HL051952;
   Grant sponsor: GT Cancer Fund, Wake Forest University Comprehensive
   Cancer Center, Golfers Against Cancer (Greensboro, NC); Grant sponsor:
   Farley Hudson Foundation (Jacksonville, NC).
CR [Anonymous], 2010, Facts and Figures 2010, P22
   Body JJ, 2011, CURR OPIN ONCOL, V23, P338, DOI 10.1097/CCO.0b013e328347918b
   Brosnihan KB, 2003, HYPERTENSION, V42, P749, DOI 10.1161/01.HYP.0000085220.53285.11
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Chappell MC, 1998, HYPERTENSION, V31, P362, DOI 10.1161/01.HYP.31.1.362
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Coenegrachts L, 2010, CANCER RES, V70, P6537, DOI 10.1158/0008 5472.CAN 09 4092
   Cook KL, 2010, CANCER RES, V70, P8319, DOI 10.1158/0008 5472.CAN 10 1136
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Foley R, 2011, PROSTATE, V71, P550, DOI 10.1002/pros.21266
   Gallagher PE, 2004, CARCINOGENESIS, V25, P2045, DOI 10.1093/carcin/bgh236
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Häggström S, 2000, PROSTATE, V45, P42, DOI 10.1002/1097 0045(20000915)45:1<42::AID PROS5>3.0.CO;2 E
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   Kirby R, 2009, BJU INT, V103, P146, DOI 10.1111/j.1464 410X.2008.08078.x
   Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008 5472.CAN 05 1809
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Macfarlane RJ, 2010, CURR ONCOL, V17, pS80
   Macfarlane RJ, 2010, UROL CLIN N AM, V37, P105, DOI 10.1016/j.ucl.2009.11.011
   Machado RDP, 1999, LIFE SCI, V66, P67
   Matsumoto Y, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 85
   Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462
   Menon J, 2007, CANCER RES, V67, P2809, DOI 10.1158/0008 5472.CAN 06 3614
   Mohamedali KA, 2011, CLIN CANCER RES, V17, P2328, DOI 10.1158/1078 0432.CCR 10 2943
   Molina A, 2011, J UROLOGY, V185, P787, DOI 10.1016/j.juro.2010.10.042
   Morrissey C, 2007, J CELL BIOCHEM, V101, P873, DOI 10.1002/jcb.21214
   Msaouel P, 2008, BEST PRACT RES CL EN, V22, P341, DOI 10.1016/j.beem.2008.01.011
   Neville Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305 7372(02)00095 6
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   Petty WJ, 2009, CLIN CANCER RES, V15, P7398, DOI 10.1158/1078 0432.CCR 09 1957
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rove KO, 2010, ONCOLOGY NY, V24, P1308
   Siegel RL., 2019, J Clin, V69, P7, DOI DOI 10.3322/CAAC.21772
   Soto Pantoja DR, 2009, MOL CANCER THER, V8, P1676, DOI 10.1158/1535 7163.MCT 09 0161
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Storey JA, 2007, CURR OPIN ONCOL, V19, P254, DOI 10.1097/CCO.0b013e32805e8787
   Street John, 2009, J Orthop Surg Res, V4, P19, DOI 10.1186/1749 799X 4 19
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 41
TC 63
Z9 67
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD JAN
PY 2013
VL 73
IS 1
BP 71
EP 82
DI 10.1002/pros.22542
PG 12
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 050VH
UT WOS:000312081900009
PM 22644942
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Roberts, MS
   Gafni, RI
   Brillante, B
   Guthrie, LC
   Streit, J
   Gash, D
   Gelb, J
   Krusinska, E
   Brennan, SC
   Schepelmann, M
   Riccardi, D
   Bin Khayat, ME
   Ward, DT
   Nemeth, EF
   Rosskamp, R
   Collins, MT
AF Roberts, Mary Scott
   Gafni, Rachel, I
   Brillante, Beth
   Guthrie, Lori C.
   Streit, Jamie
   Gash, David
   Gelb, Jeff
   Krusinska, Eva
   Brennan, Sarah C.
   Schepelmann, Martin
   Riccardi, Daniela
   Bin Khayat, Mohd Ezuan
   Ward, Donald T.
   Nemeth, Edward F.
   Rosskamp, Ralf
   Collins, Michael T.
TI Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic
   NPSP795 (SHP635)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PTH; HYPOPARATHYROIDISM; HYPOCALCEMIA; CALCIUM SENSING RECEPTOR;
   CALCILYTIC
ID CALCIUM SENSING RECEPTOR; CA2+ SENSING RECEPTOR; MUTATIONS;
   HYPOPARATHYROIDISM; PATHOPHYSIOLOGY; HYPERCALCEMIA; MOUSE; PTH
AB Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused by heterozygous, gain of function mutations of the calcium sensing receptor gene (CAR). Individuals are hypocalcemic with inappropriately low parathyroid hormone (PTH) secretion and relative hypercalciuria. Calcilytics are negative allosteric modulators of the extracellular calcium receptor (CaR) and therefore may have therapeutic benefits in ADH1. Five adults with ADH1 due to four distinct CAR mutations received escalating doses of the calcilytic compound NPSP795 (SHP635) on 3 consecutive days. Pharmacokinetics, pharmacodynamics, efficacy, and safety were assessed. Parallel in vitro testing with subject CaR mutations assessed the effects of NPSP795 on cytoplasmic calcium concentrations (Ca i(2+)), and ERK and p38(MAPK) phosphorylation. These effects were correlated with clinical responses to administration of NPSP795. NPSP795 increased plasma PTH levels in a concentration dependent manner up to 129% above baseline (p = 0.013) at the highest exposure levels. Fractional excretion of calcium (FECa) trended down but not significantly so. Blood ionized calcium levels remained stable during NPSP795 infusion despite fasting, no calcitriol supplementation, and little calcium supplementation. NPSP795 was generally safe and well tolerated. There was significant variability in response clinically across genotypes. In vitro, all mutant CaRs were half maximally activated (EC50) at lower concentrations of extracellular calcium (Ca o(2+)) compared to wild type (WT) CaR; NPSP795 exposure increased the EC50 for all CaR activity readouts. However, the in vitro responses to NPSP795 did not correlate with any clinical parameters. NPSP795 increased plasma PTH levels in subjects with ADH1 in a dose dependent manner, and thus, serves as proof of concept that calcilytics could be an effective treatment for ADH1. Albeit all mutations appear to be activating at the CaR, in vitro observations were not predictive of the in vivo phenotype or the response to calcilytics, suggesting that other parameters impact the response to the drug. (c) 2019 American Society for Bone and Mineral Research.
C1 [Roberts, Mary Scott; Gafni, Rachel, I; Brillante, Beth; Guthrie, Lori C.; Streit, Jamie; Collins, Michael T.] NIDCR, Skeletal Disorders & Mineral Homeostasis Sect, NIH, Bldg 30,Room 228,30 Convent Dr,MSC 4320, Bethesda, MD 20892 USA.
   [Gash, David; Gelb, Jeff; Krusinska, Eva; Rosskamp, Ralf] NPS Pharmaceut Inc, Bedminster, NJ USA.
   [Brennan, Sarah C.; Schepelmann, Martin; Riccardi, Daniela] Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales.
   [Brennan, Sarah C.] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia.
   [Schepelmann, Martin; Ward, Donald T.] Med Univ Vienna, Inst Pathophysiol & Allergy Res, Vienna, Austria.
   [Bin Khayat, Mohd Ezuan] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Bin Khayat, Mohd Ezuan] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Serdang, Malaysia.
   [Nemeth, Edward F.] MetisMedica, Toronto, ON, Canada.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Dental & Craniofacial Research (NIDCR); Cardiff University; University
   of Sydney; Medical University of Vienna; University of Manchester;
   Universiti Putra Malaysia
RP Collins, MT (通讯作者)，NIDCR, Skeletal Disorders & Mineral Homeostasis Sect, NIH, Bldg 30,Room 228,30 Convent Dr,MSC 4320, Bethesda, MD 20892 USA.
EM Mc247k@nih.gov
RI ; khayat, mohd/W 2255 2018; Riccardi, Daniela/A 4674 2010; Brennan,
   Sarah/L 3011 2013; Schepelmann, Martin/C 7007 2016
OI /0000 0002 2493 9093; Riccardi, Daniela/0000 0002 7322 3163; Brennan,
   Sarah/0000 0002 8719 4367; Ward, Donald/0000 0003 1342 9458; Gafni,
   Rachel/0000 0002 7970 3491; bin khayat, mohd ezuan/0000 0002 4876 6385; 
FU Intramural NIH HHS [Z01 DE000649] Funding Source: Medline; Shire
   Pharmaceutical Funding Source: Medline; NPS Pharmaceuticals Funding
   Source: Medline
CR Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359
   Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Clarke BL, 2014, CLIN THER, V36, P722, DOI 10.1016/j.clinthera.2014.04.001
   Dong BZ, 2015, J BONE MINER RES, V30, P1980, DOI 10.1002/jbmr.2551
   Goolam MA, 2014, FEBS LETT, V588, P3340, DOI 10.1016/j.febslet.2014.07.022
   Gorvin CM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91103
   Hannan FM, 2015, ENDOCRINOLOGY, V156, P3114, DOI 10.1210/en.2015 1269
   Hebert SC, 1997, J EXP BIOL, V200, P295
   Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Letz S, 2010, J CLIN ENDOCR METAB, V95, pE229, DOI 10.1210/jc.2010 0651
   Loupy A, 2012, J CLIN INVEST, V122, P3355, DOI 10.1172/JCI57407
   Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   NEMETH EF, 1987, J BIOL CHEM, V262, P5188
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Piret SE, 2016, J BONE MINER RES, V31, P1207, DOI 10.1002/jbmr.2797
   Riccardi D, 2010, AM J PHYSIOL RENAL, V298, pF485, DOI 10.1152/ajprenal.00608.2009
   Roszko KL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91079
   Roszko KL, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00458
   Ward DT, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015623.73739.B8
NR 24
TC 35
Z9 39
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2019
VL 34
IS 9
BP 1609
EP 1618
DI 10.1002/jbmr.3747
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IX9FJ
UT WOS:000485992800007
PM 31063613
OA Green Accepted, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Fallahnezhad, S
   Khodaverdi, E
   Forqani, MA
   Rezae, FA
   Karimi, M
   Kamali, H
AF Fallahnezhad, Somaye
   Khodaverdi, Elham
   Forqani, Mohammad Amin
   Rezae, Fatemeh Asgharian
   Karimi, Malihe
   Kamali, Hossein
TI Preparation and evaluation of injectable sustained release
   Alendronate loaded lipid liquid crystal on ovariectomy induced
   osteoporosis in rats
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Lipid liquid crystal; Sustained release; Alendronate;
   Ovariectomy induced osteoporosis; In situ gel
ID DELIVERY; MECHANISMS; SYSTEM; WOMEN
AB Alendronate, a bisphosphonate compound, is used to treat osteoporosis by inhibiting bone resorption. However, oral consumption of Alendronate can cause severe gastrointestinal side effects, such as heartburn, difficulty swallowing, constipation or diarrhea, flatulence, and esophageal irritation or pain. To overcome this problem, an injectable sustained release formulation of alendronate based on lipid liquid crystal (LLC) using phosphatidylcholine (PC), sorbitan monooleate (SMO), glycerol di oleate (GDO), and N methyl 2 pyrrolidone (NMP) or ethanol solvents was recommended. This compound was added as a base to one side of a coupling syringe, while alendronate powder was added to the other. After combining the two syringes, the resulting formulations were transferred into tubes containing PBS for in vitro evaluation. In formulations containing ethanol, the cumulative percentage of drug release, water content, and degradation were higher than in those with NMP. Furthermore, LLC gel formulations with ethanol solvent had lower viscosity and a cubic structure, whereas LLC containing NMP had a hexagonal structure, indicating slower and longer release of alendronate in LLC NMP formulations. In vivo evaluations of subcutaneous injections of alendronate based on LLC formulation in rats with ovariectomyinduced osteoporosis showed significant advancements in osteogenesis markers, including RUNX2, OPG, VEGF, and Type 1 Collagen, according to Western blot analysis. These finding highlight alendronate's potential not only as a bone resorption inhibitor but also as a bone formation stimulator. Additionally, histopathology results revealed no osteoclast activity or osteoarthritis reactions in the LLC formulation group. Hence, an injectable LLC formulation containing PC, SMO and NMP could be a suitable option for developing a sustained release LLC formulation of alendronate for osteoporosis treatment.
C1 [Fallahnezhad, Somaye] Semnan Univ Med Sci, Nervous Syst Stem Cells Res Ctr, Semnan, Iran.
   [Fallahnezhad, Somaye] Semnan Univ Med Sci, Sch Med, Dept Anat Sci, Semnan, Iran.
   [Khodaverdi, Elham; Karimi, Malihe; Kamali, Hossein] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Targeted Drug Delivery Res Ctr, Mashhad, Iran.
   [Khodaverdi, Elham; Karimi, Malihe; Kamali, Hossein] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut, Mashhad, Iran.
   [Forqani, Mohammad Amin] Mashhad Univ Med Sci, Neurosci Res Ctr, Mashhad, Iran.
   [Rezae, Fatemeh Asgharian] Mashhad Univ Med Sci, Student Res Comm, Mashhad, Iran.
C3 Semnan University of Medical Sciences; Semnan University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences; Mashhad University of Medical Sciences; Mashhad
   University of Medical Sciences
RP Karimi, M; Kamali, H (通讯作者)，Mashhad Univ Med Sci, Pharmaceut Technol Inst, Targeted Drug Delivery Res Ctr, Mashhad, Iran.; Karimi, M; Kamali, H (通讯作者)，Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut, Mashhad, Iran.
EM karimidm971@mums.ac.ir; kamalih@mums.ac.ir
RI khodaverdi, elham/A 8010 2018; khodaverdi, elham/S 7960 2019
OI khodaverdi, elham/0000 0002 1084 6603; 
FU Mashhad University of Medical Sciences [4000661]
FX The authors are grateful for the financial support provided by Mashhad
   University of Medical Sciences with 4000661 number.
CR Babaei H, 2018, J CELL BIOCHEM, V119, P6575, DOI 10.1002/jcb.26777
   Báez Santos YM, 2016, INT J PHARMACEUT, V514, P314, DOI 10.1016/j.ijpharm.2016.06.138
   Blanco Fernández G, 2023, ADV COLLOID INTERFAC, V313, DOI 10.1016/j.cis.2023.102867
   Camurus A., 2018, Buvidal Weekly and Buvidal Monthly (CAM2038) Approved in Australia as the First Long Acting Treatment of Opioid Dependence
   Clarkin CE, 2013, CELL BIOCHEM FUNCT, V31, P1, DOI 10.1002/cbf.2911
   Dong JL, 2018, INT J BIOL MACROMOL, V116, P1268, DOI 10.1016/j.ijbiomac.2018.05.116
   Fallahnezhad S, 2018, J PHOTOCH PHOTOBIO B, V182, P77, DOI 10.1016/j.jphotobiol.2018.03.015
   Gisbert Garzarán M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010083
   Guo CY, 2010, DRUG DISCOV TODAY, V15, P1032, DOI 10.1016/j.drudis.2010.09.006
   He QBR, 2023, FRONT BIOSCI LANDMRK, V28, DOI 10.31083/j.fbl2801010
   Jabarpour M, 2018, MICROVASC RES, V118, P49, DOI 10.1016/j.mvr.2018.02.005
   Jeong B, 2000, J BIOMED MATER RES, V50, P171, DOI 10.1002/(SICI)1097 4636(200005)50:2<171::AID JBM11>3.3.CO;2 6
   Kamali H, 2022, INT J PHARMACEUT, V611, DOI 10.1016/j.ijpharm.2021.121275
   Kanis JA, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00871 9
   Karadag Saygi E, 2011, GYNECOL ENDOCRINOL, V27, P1033, DOI 10.3109/09513590.2011.579657
   Karimi M, 2024, J DRUG DELIV SCI TEC, V96, DOI 10.1016/j.jddst.2024.105640
   Karimi M, 2024, INT J PHARMACEUT, V654, DOI 10.1016/j.ijpharm.2024.123973
   Karimi M, 2023, INT J PHARMACEUT, V639, DOI 10.1016/j.ijpharm.2023.122947
   Khodaverdi E, 2022, INT J PHARMACEUT, V618, DOI 10.1016/j.ijpharm.2022.121649
   Khosravipour A, 2022, J LASERS MED SCI, V13, DOI 10.34172/jlms.2022.10
   Ki MH, 2014, J CONTROL RELEASE, V185, P62, DOI 10.1016/j.jconrel.2014.04.034
   Kim Dong Hwan, 2015, Journal of Pharmaceutical Investigation, V45, P1, DOI 10.1007/s40005 014 0165 9
   Klara J, 2022, INT J NANOMED, V17, P6065, DOI 10.2147/IJN.S388430
   Lim JL, 2015, INT J PHARMACEUT, V490, P265, DOI 10.1016/j.ijpharm.2015.05.049
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Mei LL, 2018, ACTA BIOMATER, V67, P99, DOI 10.1016/j.actbio.2017.11.057
   Miao Y, 2016, MOL CRYST LIQ CRYST, V633, P110, DOI 10.1080/15421406.2016.1177899
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   Nagira K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 66979 7
   Negrini R., 2014, PhD diss
   Negrini R, 2015, CHEM COMMUN, V51, P6671, DOI 10.1039/c4cc10274f
   Negrini R, 2011, LANGMUIR, V27, P5296, DOI 10.1021/la200591u
   Otte A, 2017, INT J PHARMACEUT, V532, P345, DOI 10.1016/j.ijpharm.2017.08.098
   Pedroncelli A.M, Camurus Receives EU Approval for Weekly and Monthly Buvidal(CAM2038) for Opioid Dependence
   Perez M.O., 2023, Osteoporosis and Fracture Risk Assessment: Improving Outcomes in Postmenopausal Women
   Pothiwala P, 2006, J WOMENS HEALTH, V15, P709, DOI 10.1089/jwh.2006.15.709
   Pretel H, 2007, LASER SURG MED, V39, P788, DOI 10.1002/lsm.20585
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Russu A, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13089
   Sànchez Riera L, 2010, BEST PRACT RES CL RH, V24, P793, DOI 10.1016/j.berh.2010.10.003
   Shen XK, 2016, J MATER CHEM B, V4, P1423, DOI 10.1039/c5tb01956g
   Siavashi V, 2016, J CELL BIOCHEM, V117, P1934, DOI 10.1002/jcb.25492
   Siris E.S., 2002, Obstet. Gynecol. Surv., V57, P220
   Tiemann A., 2014, GMS Interdiscipl. Plast Reconstr. Surg. DGPW, V3
   Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303 7207(03)00151 5
   Tu Kristie N, 2018, P T, V43, P92
   Usach I, 2019, ADV THER, V36, P2986, DOI 10.1007/s12325 019 01101 6
   Zabara A, 2014, J CONTROL RELEASE, V188, P31, DOI 10.1016/j.jconrel.2014.05.052
NR 53
TC 0
Z9 0
U1 3
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773 2247
EI 2588 8943
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD DEC
PY 2024
VL 102
AR 106373
DI 10.1016/j.jddst.2024.106373
EA NOV 2024
PN A
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA L7Z4J
UT WOS:001352866600001
DA 2025 08 17
ER

PT J
AU Rici, REG
   Alcântara, D
   Fratini, P
   Wenceslau, CV
   Ambrósio, CE
   Miglino, MA
   Maria, DA
AF Grassi Rici, Rose Eli
   Alcantara, Dayane
   Fratini, Paula
   Wenceslau, Cristiane Valverde
   Ambrosio, Carlos Eduardo
   Miglino, Maria Angelica
   Maria, Durvanei Augusto
TI Mesenchymal stem cells with rhBMP 2 inhibits the growth of canine
   osteosarcoma cells
SO BMC VETERINARY RESEARCH
LA English
DT Article
DE Osteosarcoma; rhBMP 2; Mesenchymal stem cell; Canine
ID BONE MORPHOGENETIC PROTEINS; EXPRESSION; CANCER
AB Background: The bone morphogenetic proteins (BMPs) belong to a unique group of proteins that includes the growth factor TGF beta. BMPs play important roles in cell differentiation, cell proliferation, and inhibition of cell growth. They also participate in the maturation of several cell types, depending on the microenvironment and interactions with other regulatory factors. Depending on their concentration gradient, the BMPs can attract various types of cells and act as chemotactic, mitogenic, or differentiation agents. BMPs can interfere with cell proliferation and the formation of cartilage and bone. In addition, BMPs can induce the differentiation of mesenchymal progenitor cells into various cell types, including chondroblasts and osteoblasts. The aim of this study was to analyze the effects of treatment with rhBMP 2 on the proliferation of canine mesenchymal stem cells (cMSCs) and the tumor suppression properties of rhBMP 2 in canine osteocarcoma (OST) cells. Osteosarcoma cell lines were isolated from biopsies and excisions of animals with osteosarcoma and were characterized by the Laboratory of Biochemistry and Biophysics, Butantan Institute. The mesenchymal stem cells were derived from the bone marrow of canine fetuses (cMSCs) and belong to the University of Sao Paulo, College of Veterinary Medicine (FMVZ USP) stem cell bank. After expansion, the cells were cultured in a 12 well Transwell system; cells were treated with bone marrow mesenchymal stem cells associated with rhBMP2. Expression of the intracytoplasmic and nuclear markers such as Caspase 3, Bax, Bad, Bcl 2, Ki 67, p53, Oct3/4, Nanog, Stro 1 were performed by flow citometry.
   Results: We evaluated the regenerative potential of in vitro treatment with rhBMP 2 and found that both osteogenic induction and tumor regression occur in stem cells from canine bone marrow. rhBMP 2 inhibits the proliferation capacity of OST cells by mechanisms of apoptosis and tumor suppression mediated by p53.
   Conclusion: We propose that rhBMP 2 has great therapeutic potential in bone marrow cells by serving as a tumor suppressor to increase p53 and the pro apoptotic proteins Bad and Bax, as well as by increasing the activity of phosphorylated caspase 3.
   Study design: Canine bone marrow mesenchymal stem cells associated with rhBMP2 in canine osteosarcoma treatment: "in vitro" study
C1 [Grassi Rici, Rose Eli; Alcantara, Dayane; Fratini, Paula; Miglino, Maria Angelica] Univ Sao Paulo, Dept Surg, Fac Vet Med & Zootecny, BR 05508270 Sao Paulo, Brazil.
   [Wenceslau, Cristiane Valverde] Octavio Bastos Educ Fdn, Lab Anim Morphol, Univ Ctr, Sao Joao Da Boa Vista, Brazil.
   [Ambrosio, Carlos Eduardo] Univ Sao Paulo, Lab Anim Anat, Fac Zootecny & Food Engn, BR 05508270 Sao Paulo, Brazil.
   [Maria, Durvanei Augusto] Butantan Inst, Lab Biochem & Biophis, Sao Paulo, Brazil.
   [Grassi Rici, Rose Eli] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Cirugia, BR 05508270 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Instituto
   Butantan; Universidade de Sao Paulo
RP Rici, REG (通讯作者)，Univ Sao Paulo, Dept Surg, Fac Vet Med & Zootecny, BR 05508270 Sao Paulo, Brazil.
EM roseeli@usp.br
RI ALCANTARA, DAYANE/B 4138 2016; Ambrosio, Carlos/F 3402 2010; Rici,
   Rose/I 2083 2012; Alcantara, Dayane/B 4138 2016; Fratini,
   Paula/C 4084 2014; Miglino, Maria/B 9519 2012; Ambrosio, Carlos
   Eduardo/F 3402 2010
OI Fratini, Paula/0000 0002 4780 4829; Alcantara,
   Dayane/0000 0003 4932 8245; Ambrosio, Carlos Eduardo/0000 0002 8224 5022
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Beck SE, 2006, AM J PHYSIOL GASTR L, V291, pG135, DOI 10.1152/ajpgi.00482.2005
   Ben Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679
   Chang SCN, 2003, GENE THER, V10, P2013, DOI 10.1038/sj.gt.3302106
   Daleck C. R., 2002, Revista de Educacao Continuada do CRMV SP, V5, P233
   Eichhorn ME, 2007, LANGENBECK ARCH SURG, V392, P371, DOI 10.1007/s00423 007 0150 0
   Eliseev RA, 2008, ONCOGENE, V27, P3605, DOI 10.1038/sj.onc.1211020
   Fossum TW, 2001, CIRURGIA PEQUENOS AN
   GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164
   Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067
   Heckler MCT, 2004, ANCL AN 25 C CLIN VE, P66
   Hsu MY, 2005, CANCER METAST REV, V24, P251, DOI 10.1007/s10555 005 1575 y
   Johnson KA, 2004, TRATADO MED INTERNA, V2, P1988
   Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011
   KLEINER J.A., 2003, REV CIENT MED VET, V1, P193
   Kuznetsov S, 1996, CALCIFIED TISSUE INT, V59, P265, DOI 10.1007/s002239900121
   Langenfeld EM, 2005, ANN THORAC SURG, V80, P1028, DOI 10.1016/j.athoracsur.2005.03.094
   Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005 0234
   Murakami N, 2002, J BIOMED MATER RES, V62, P169, DOI 10.1002/jbm.10236
   Oya N, 2001, INT J RADIAT ONCOL, V51, P87, DOI 10.1016/S0360 3016(01)01603 0
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Pool RR., 1990, Tumors in Domestic Animals, V3rd, P157
   REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959 437X(94)90141 O
   Sandhu HS, 2003, SPINE, V28, pS64, DOI 10.1097/00007632 200308011 00012
   Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a
   SILVEIRA P.R., 2008, CIENCIA ANIMAL BRAS, V9, P487
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793
   WANG EA, 1993, TRENDS BIOTECHNOL, V11, P379, DOI 10.1016/0167 7799(93)90096 R
   Wang L, 2011, CANCER BIOL THER, V11, P457, DOI 10.4161/cbt.11.5.14372
   Wen XZ, 2004, BIOCHEM BIOPH RES CO, V316, P100, DOI 10.1016/j.bbrc.2004.02.016
   WITHROW SJ, 1991, CLIN ORTHOP RELAT R, P159
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
NR 34
TC 16
Z9 17
U1 1
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746 6148
J9 BMC VET RES
JI BMC Vet. Res.
PD FEB 22
PY 2012
VL 8
AR 17
DI 10.1186/1746 6148 8 17
PG 9
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 911US
UT WOS:000301745700001
PM 22356869
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Safavi, AS
   Rouhi, G
   Haghighipour, N
   Bagheri, F
   Eslaminejad, MB
   Sayahpour, FA
AF Safavi, Atiyeh Sadat
   Rouhi, Gholamreza
   Haghighipour, Nooshin
   Bagheri, Fatemeh
   Eslaminejad, Mohamadreza Baghaban
   Sayahpour, Frough Azam
TI Efficacy of mechanical vibration in regulating mesenchymal stem cells
   gene expression
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE Mesenchymal stem cells; Differentiation; Gene regulation; Mechanical
   vibration; Tissue engineering
ID HIGH FREQUENCY VIBRATION; OSTEOGENIC DIFFERENTIATION; STROMAL CELLS;
   LOW AMPLITUDE; SIGNALS; PROLIFERATION; STRETCH
AB This study aimed at investigating the expression of osteoblast and chondrocyte related genes in mesenchymal stem cells (MSCs), derived from rabbit adipose tissue, under mechanical vibration. The cells were placed securely on a vibrator's platform and subjected to 300Hz of sinusoidal vibration, with a maximum amplitude of 10m, for 45min per day, and for 14 consequent days, in the absence of biochemical reagents. The negative control group was placed in the conventional culture medium with no mechanical loading. The expression of osteoblast and chondrocyte related genes was investigated using real time polymerase chain reaction (real time PCR). In addition, F actin fiber structure and alignment with the help of actin filament fluorescence staining were evaluated, and the level of metabolic activity of MSCs was determined by the methyl thiazolyl tetrazolium assay. The real time PCR study showed a significant increase of bone gene expression in differentiated cells, compared with MSCs (P<0.05). On the other hand, the level of chondrocyte gene expression was not remarkable. Applying mechanical vibration enhanced F actin fiber structure and made them aligned in a specific direction. It was also found that during the differentiation process, the metabolic activity of the cells increased (P<0.05). The results of this work are in agreement with the well accepted fact that the MSCs, in the absence of growth factors, are sensitive to low amplitude, high frequency vibration. Outcomes of this work can be applied in cell therapy and tissue engineering, when regulation of stem cells is required.
C1 [Safavi, Atiyeh Sadat; Rouhi, Gholamreza] Amirkabir Univ Technol, Fac Biomed Engn, POB 1591634311, Tehran, Iran.
   [Haghighipour, Nooshin] Pasteur Inst Iran, Natl Cell Bank Iran, Tehran, Iran.
   [Bagheri, Fatemeh] Tarbiat Modares Univ, Dept Chem Engn, Biotechnol Grp, Tehran, Iran.
   [Eslaminejad, Mohamadreza Baghaban; Sayahpour, Frough Azam] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran.
C3 Amirkabir University of Technology; Pasteur Network; Pasteur Institute
   of Iran; Tarbiat Modares University; Academic Center for Education,
   Culture & Research (ACECR)
RP Rouhi, G (通讯作者)，Amirkabir Univ Technol, Fac Biomed Engn, POB 1591634311, Tehran, Iran.
EM atiyehsafavi@gmail.com; grouhi@aut.ac.ir; haghighipour@pasteur.ac.ir;
   f.bagheri@modares.ac.ir; eslami@royaninstitute.org; fa_rosacea@yahoo.com
RI ; Safavi, Atiyeh/AAL 5433 2021; Haghighipour, Nooshin/K 9617 2017;
   Bagheri, Fatemeh/JUU 6250 2023; Rouhi, Gholamreza/R 2295 2019; Baghaban
   Eslaminejad, Mohamadreza/S 3645 2017
OI Bagheri, Fatemeh/0000 0002 9920 338X; Safavi, Atiyeh
   Sadat/0000 0002 6510 1318; Baghaban Eslaminejad,
   Mohamadreza/0000 0002 1036 0072
CR Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01 0656fje
   Amin S, 2014, CELL BIOL INT, V38, P219, DOI 10.1002/cbin.10194
   Atala A., 2010, Foundations of regenerative medicine
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Butler DL, 2000, J BIOMECH ENG T ASME, V122, P570, DOI 10.1115/1.1318906
   Cashion AT, 2014, BIORESEARCH OPEN ACC, V3, P19, DOI 10.1089/biores.2013.0048
   Delaine Smith Robin M, 2012, Muscles Ligaments Tendons J, V2, P169
   Dumas V, 2010, CALCIFIED TISSUE INT, V87, P351, DOI 10.1007/s00223 010 9394 8
   Edwards JH, 2015, WORLD J STEM CELLS, V7, P568, DOI 10.4252/wjsc.v7.i3.568
   Eslaminejad MB., 2007, Iran J Basic Med Sci, V10, P146
   Estes BT, 2010, NAT PROTOC, V5, P1294, DOI 10.1038/nprot.2010.81
   Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908
   Ghazanfari S, 2009, BIOCHEM BIOPH RES CO, V388, P601, DOI 10.1016/j.bbrc.2009.08.072
   Guilak F, 2001, CLIN ORTHOP RELAT R, pS295, DOI 10.1097/00003086 200110001 00027
   Haghighipour N, 2012, CELL BIOL INT, V36, P669, DOI 10.1042/CBI20110400
   Hooshiar SA, 2008, 56 ANN M ORTH RES SO
   Jafarabadi MR, 2016, LASER MED SCI, V31, P1827, DOI 10.1007/s10103 016 2058 9
   Judex S, 2005, J CELL BIOCHEM, V94, P982, DOI 10.1002/jcb.20363
   Kim IS, 2012, J DENT RES, V91, P1135, DOI 10.1177/0022034512465291
   Kulkarni RN, 2013, BONE, V57, P493, DOI 10.1016/j.bone.2013.08.020
   Lau E, 2011, J ORTHOP RES, V29, P1075, DOI 10.1002/jor.21334
   Lau E, 2010, BONE, V46, P1508, DOI 10.1016/j.bone.2010.02.031
   Li D, 2011, REGEN MED, V6, P229, DOI 10.2217/RME.11.2
   Litwack G, 2011, EFFECTS MECH LOADING
   Liu J, 2001, RES EXP MED, V200, P183
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacQueen L, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0179
   Marycz K, 2016, PEERJ, V4, DOI 10.7717/peerj.1637
   Meier E, 2016, JSM BIOTECHNOL BIOME, V3, P1060
   Mohajeri S, 2010, TISSUE ENG PT A, V16, P3821, DOI [10.1089/ten.tea.2009.0520, 10.1089/ten.TEA.2009.0520]
   O'Conor CJ, 2013, STEM CELL RES THER, V4, P1, DOI DOI 10.1186/SCRT211
   Orbay H, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/461718
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Prè D, 2013, BONE MARROW RES, DOI 10.1155/2013/803450
   Prè D, 2011, BONE, V49, P295, DOI 10.1016/j.bone.2011.04.013
   Pre D., 2008, 2008 2nd International Conference on Bioinformatics and Biomedical Engineering (ICBBE '08), P884, DOI 10.1109/ICBBE.2008.217
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Safavi AS, 2013, IR Patent, Patent No. 81111
   Safshekan F, 2014, J MECH MED BIOL, V14, DOI 10.1142/S0219519414500547
   Sen B, 2011, J BIOMECH, V44, P593, DOI 10.1016/j.jbiomech.2010.11.022
   Steward AJ, 2015, J ANAT, V227, P717, DOI 10.1111/joa.12243
   Takeuchi R, 2006, ARTHRITIS RHEUM US, V54, P1897, DOI 10.1002/art.21895
   Tan SL, 2013, J ANAT, V222, P437, DOI 10.1111/joa.12032
   Tirkkonen L, 2011, J R SOC INTERFACE, V8, P1736, DOI 10.1098/rsif.2011.0211
   Wang CZ, 2010, J APPL PHYSIOL, V109, P840, DOI 10.1152/japplphysiol.00115.2010
   Wang Liang, 2015, Chinese Medical Sciences Journal, V30, P108
   Wescoe KE, 2008, CELL BIOCHEM BIOPHYS, V52, P85, DOI 10.1007/s12013 008 9029 0
   Zaminy A, 2008, YAKHTEH, V10, P25
   Zhang AX, 2007, MOL CELL BIOCHEM, V304, P167, DOI 10.1007/s11010 007 9497 3
   Zhang CC, 2012, ARCH ORAL BIOL, V57, P1395, DOI 10.1016/j.archoralbio.2012.04.010
   Zhou Y, 2011, EUR CELLS MATER, V22, P12, DOI 10.22203/eCM.v022a02
NR 51
TC 8
Z9 9
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD MAY
PY 2019
VL 55
IS 5
BP 387
EP 394
DI 10.1007/s11626 019 00340 9
PG 8
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA HX5ZV
UT WOS:000467484300008
PM 30993556
DA 2025 08 17
ER

PT J
AU Qin, W
   Gao, XL
   Ma, T
   Weir, MD
   Zou, J
   Song, B
   Lin, ZM
   Schneider, A
   Xu, HHK
AF Qin, Wei
   Gao, Xianling
   Ma, Tao
   Weir, Michael D.
   Zou, Jing
   Song, Bing
   Lin, Zhengmei
   Schneider, Abraham
   Xu, Hockin H. K.
TI Metformin Enhances the Differentiation of Dental Pulp Cells into
   Odontoblasts by Activating AMPK Signaling
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE AMPK; metformin; odontoblast; proliferation
ID MESENCHYMAL STEM CELLS; IN VITRO; UMBILICAL CORD; EXPRESSION; VIVO;
   INHIBITION; OSTEOBLAST; PHENOTYPE; PATHWAY; LESIONS
AB Introduction: Metformin is a first line drug for treating type 2 diabetes that regulates the differentiation of mesenchymal stem cells. Its effects on human dental pulp cells (DPCs) remain unknown. This study aimed to investigate the effects of metformin on the proliferation and differentiation of DPCs. Methods: A live/dead viability assay kit was used to examine the effects of metformin on the cell viability of DPCs. Cell proliferation was analyzed using a cell counting kit (CCK 8; Dojindo, Tokyo, Japan). Levels of phosphorylated and unphosphorylated adenosine 5' monophosphate activated protein kinase (AMPK) were quantified by Western blot analysis in response to metformin and the AMPK signaling inhibitor Compound C (EMD Chemicals, San Diego, CA). The effects of Compound C on the metformin induced odontoblast differentiation of DPCs were determined by alkaline phosphatase activity assay and von Kossa staining, and the expression of odontoblastic markers was evaluated by reverse transcription polymerase chain reaction analysis. Results: DPCs exhibited mesenchymal stem cell characteristics using flow cytometry. Different doses of metformin were shown to be cytocompatible with DPCs, yielding >90% cell viability. None of the concentrations of metformin up to 50 mu mol/L affected cell proliferation. The Western blot assay showed that DPCs express functional organic cation transporter 1, a transmembrane protein that mediates the intracellular uptake of metformin. Metformin significantly activated the AMPK pathway in a dose dependent manner. In addition, it stimulated alkaline phosphatase activity; enhanced mineralized nodule formation; and increased the expression of odontoblastic markers including dentin sialophosphoprotein, dentin matrix protein 1, runt related transcription factor 2, and osteocalcin. Moreover, pretreatment with Compound C, a specific AMPK inhibitor, markedly reversed metformin induced odontoblastic differentiation and cell mineralization. Conclusions: This study shows that metformin can induce DPC differentiation and mineralization in an AMPK dependent manner and that this well tolerated antidiabetic drug has potential in regenerative endodontics as well as in other regenerative applications.
C1 [Qin, Wei; Gao, Xianling; Lin, Zhengmei] Sun Yat Sen Univ, Guanghua Sch Stomatol, Dept Operat Dent & Endodont, Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Qin, Wei; Gao, Xianling; Weir, Michael D.; Song, Bing; Xu, Hockin H. K.] Univ Maryland, Sch Med, Dept Adv Oral Sci & Therapeut, Baltimore, MD 21201 USA.
   [Ma, Tao; Zou, Jing; Schneider, Abraham] Univ Maryland, Sch Med, Dept Oncol & Diagnost Sci, 650 West Baltimore St, Baltimore, MD 21201 USA.
   [Xu, Hockin H. K.] Univ Maryland, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA.
   [Xu, Hockin H. K.] Univ Maryland Baltimore Cty, Dept Mech Engn, Baltimore, MD 21201 USA.
C3 Sun Yat Sen University; University System of Maryland; University of
   Maryland Baltimore; University System of Maryland; University of
   Maryland Baltimore; University System of Maryland; University of
   Maryland Baltimore; University System of Maryland; University of
   Maryland Baltimore County
RP Schneider, A (通讯作者)，Univ Maryland, Sch Med, Dept Oncol & Diagnost Sci, 650 West Baltimore St, Baltimore, MD 21201 USA.; Lin, ZM (通讯作者)，Sun Yat Sen Univ, Guanghua Sch Stomatol, Dept Operat Dent & Endodont, 56 Lingyuanxi Rd, Guangzhou 510055, Guangdong, Peoples R China.; Xu, HHK (通讯作者)，Univ Maryland, Sch Dent, Dept Endodont Periodont & Prosthodont, 650 West Baltimore St, Baltimore, MD 21201 USA.
EM linzhm@mail.sysu.edu.cn; schneider66@umaryland.edu; hxu@umaryland.edu
RI Schneider, Abraham/AAR 5941 2021; Weir, Michael/M 7729 2013; Gao,
   Xianling/ITU 4818 2023
FU National Institutes of Health/National Institute of Dental and
   Craniofacial Research Grant [R01 DE023578, R01 DE14190]; University of
   Maryland School of Dentistry bridge grant
FX Supported by the National Institutes of Health/National Institute of
   Dental and Craniofacial Research Grant R01 DE023578 (AS.), R01 DE14190
   (H.X.), and the University of Maryland School of Dentistry bridge grant
   (H.X).
CR Abou Neel EA, 2014, J DENT, V42, P915, DOI 10.1016/j.jdent.2014.05.008
   Baba O, 2004, EUR J ORAL SCI, V112, P163, DOI 10.1111/j.0909 8836.2004.00110.x
   Balic A, 2011, BONE, V48, P927, DOI 10.1016/j.bone.2010.12.008
   Blas García A, 2010, HEPATOLOGY, V52, P115, DOI 10.1002/hep.23647
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Catón J, 2011, J CELL MOL MED, V15, P1054, DOI 10.1111/j.1582 4934.2010.01251.x
   Chidiac JJ, 2009, CYTOKINE, V46, P194, DOI 10.1016/j.cyto.2009.01.008
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Egbuniwe O, 2011, CELL CYCLE, V10, P3912, DOI 10.4161/cc.10.22.18093
   Fisher LW, 2011, CELLS TISSUES ORGANS, V194, P113, DOI 10.1159/000324254
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Goto N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8035759
   Griss T, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002309
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Guo J, 2017, J CELL PHYSIOL, V232, P3158, DOI 10.1002/jcp.25769
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Hwang YC, 2008, J MOL HISTOL, V39, P153, DOI 10.1007/s10735 007 9148 8
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Jin B, 2016, TISSUE ENG PT A, V22, P721, DOI 10.1089/ten.tea.2015.0273
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kim IS, 2010, J DENT RES, V89, P1129, DOI 10.1177/0022034510375283
   Kim JK, 2010, J DENT RES, V89, P1433, DOI 10.1177/0022034510384870
   Kim JY, 2017, J ENDODONT, V43, P417, DOI 10.1016/j.joen.2016.10.013
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679
   Lymperi S, 2013, OPEN DENT J, V7, P76, DOI 10.2174/1874210601307010076
   Min KS, 2010, J ENDODONT, V36, P447, DOI 10.1016/j.joen.2009.11.021
   Nies AT, 2011, HANDB EXP PHARMACOL, V201, P105, DOI 10.1007/978 3 642 14541 4_3
   Papagerakis P, 2002, BONE, V30, P377, DOI 10.1016/S8756 3282(01)00683 4
   Patel H, 2013, J ORAL PATHOL MED, V42, P250, DOI 10.1111/j.1600 0714.2012.01196.x
   Paula Silva FWG, 2009, J DENT RES, V88, P339, DOI 10.1177/0022034509334070
   Posa F, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9150819
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Tang J, 2017, J ENDODONT, V43, P263, DOI 10.1016/j.joen.2016.10.028
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Vitale Cross L, 2012, CANCER PREV RES, V5, P562, DOI 10.1158/1940 6207.CAPR 11 0502
   Volponi AA, 2010, TRENDS CELL BIOL, V20, P715, DOI 10.1016/j.tcb.2010.09.012
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Wang P, 2015, ACTA BIOMATER, V18, P236, DOI 10.1016/j.actbio.2015.02.011
   Yang DZ, 2016, SCI REP UK, V6, DOI 10.1038/srep37370
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Zhao LA, 2010, BIOMATERIALS, V31, P6502, DOI 10.1016/j.biomaterials.2010.05.017
   Zou HR, 2017, J ENDODONT, V43, P745, DOI 10.1016/j.joen.2016.12.019
NR 44
TC 34
Z9 38
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0099 2399
EI 1878 3554
J9 J ENDODONT
JI J. Endod.
PD APR
PY 2018
VL 44
IS 4
BP 576
EP 584
DI 10.1016/j.joen.2017.11.017
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GC8IA
UT WOS:000430035800010
PM 29306537
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, WJ
   Du, ZY
   Yan, JQ
   Ma, D
   Shi, MM
   Zhang, MJ
   Peng, CH
   Li, HW
AF Wang, Weijie
   Du, Zhiyong
   Yan, Jiqi
   Ma, Di
   Shi, Minmin
   Zhang, Mingjun
   Peng, Chenghong
   Li, Hongwei
TI Mesenchymal Stem Cells Promote Liver Regeneration and Prolong Survival
   in Small For Size Liver Grafts: Involvement of C Jun N Terminal Kinase,
   Cyclin D1, and NF κB
SO PLOS ONE
LA English
DT Article
ID IN VITRO; HEPATOCYTE PROLIFERATION; ISCHEMIA REPERFUSION;
   TRANSPLANTATION; INJURY; HEPATECTOMY; MECHANISMS; FIBROSIS; THERAPY
AB Background: The therapeutic potential of mesenchymal stem cells (MSCs) has been highlighted recently for treatment of acute or chronic liver injury, by possibly differentiating into hepatocyte like cells, reducing inflammation, and enhancing tissue repair. Despite recent progress, exact mechanisms of action are not clearly elucidated. In this study, we attempted to explore whether and how MSCs protected hepatocytes and stimulated allograft regeneration in small for size liver transplantation (SFSLT).
   Methods: SFSLT model was established with a 30% partial liver transplantation (30PLT) in rats. The differentiation potential and characteristics of bone marrow derived MSCs were explored in vitro. MSCs were infused transvenously immediately after graft implantation in therapy group. Expressions of apoptosis , inflammatory , anti inflammatory , and growth factor related genes were measured by RT PCR, activities of transcription factors AP 1 and NF kappa B were analyzed by EMSA, and proliferative responses of the hepatic graft were evaluated by immunohistochemistry and western blot.
   Results: MSCs were successfully induced into hepatocyte like cells, osteoblasts and adipocytes in vitro. MSCs therapy could not only alleviate ischemia reperfusion injury and acute inflammation to promote liver regeneration, but also profoundly improve one week survival rate. It markedly up regulated the mRNA expressions of HGF, Bcl 2, Bcl XL, IL 6, IL 10, IP 10, and CXCR2, however, down regulated TNF alpha. Increased activities of AP 1 and NF kappa B, as well as elevated expressions of p c Jun, cyclin D1, and proliferating cell nuclear antigen (PCNA), were also found in MSCs therapy group.
   Conclusion: These data suggest that MSCs therapy promotes hepatocyte proliferation and prolongs survival in SFSLT by reducing ischemia reperfusion injury and acute inflammation, and sustaining early increased expressions of c Jun N terminal Kinase, Cyclin D1, and NF kappa B.
C1 [Wang, Weijie; Yan, Jiqi; Ma, Di; Shi, Minmin; Zhang, Mingjun; Peng, Chenghong; Li, Hongwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China.
   [Wang, Weijie] Zhengzhou Univ, Sch Med, Affiliated Hosp 1, Dept Surg, Zhengzhou 450052, Henan Province, Peoples R China.
   [Du, Zhiyong] Cent Hosp Wuhan, Dept Hepatobiliary Surg, Wuhan, Hubei Province, Peoples R China.
C3 Shanghai Jiao Tong University; Zhengzhou University
RP Yan, JQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China.
EM jiqiyan@yahoo.com
RI Sohan, H.M./GXF 6326 2022
OI Peng, Chenghong/0000 0002 5573 7873
FU National Natural Science Foundation of China [81070358]; Municipal
   Natural Science Foundation of Shanghai Municipality [09ZR1418600]
FX This study was supported by grants from The National Natural Science
   Foundation of China (81070358) and Municipal Natural Science Foundation
   of Shanghai Municipality (09ZR1418600). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aurich I, 2007, GUT, V56, P405, DOI 10.1136/gut.2005.090050
   Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782
   Bishi DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092397
   Bone Larson CL, 2001, J IMMUNOL, V167, P7077, DOI 10.4049/jimmunol.167.12.7077
   Du ZY, 2013, J SURG RES, V183, P907, DOI 10.1016/j.jss.2013.02.009
   Fouraschen SMG, 2012, STEM CELLS DEV, V21, P2410, DOI 10.1089/scd.2011.0560
   Fu WY, 2013, HEPATOL RES, V43, P300, DOI 10.1111/j.1872 034X.2012.01071.x
   Holden NS, 2011, J PHARMACOL TOX MET, V63, P7, DOI 10.1016/j.vascn.2010.03.002
   Jeon H, 2010, CURR OPIN ORGAN TRAN, V15, P283, DOI 10.1097/MOT.0b013e32833983ee
   Jiang SM, 2009, LIVER TRANSPLANT, V15, P1043, DOI 10.1002/lt.21797
   Jin X, 2007, HEPATOLOGY, V46, P802, DOI 10.1002/hep.21728
   KAMADA N, 1983, SURGERY, V93, P64
   Kanazawa H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019195
   Kubo N, 2012, J GASTROEN HEPATOL, V27, P165, DOI 10.1111/j.1440 1746.2011.06798.x
   Kuo TK, 2008, GASTROENTEROLOGY, V134, P2111, DOI 10.1053/j.gastro.2008.03.015
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Luk JM, 2005, J IMMUNOL METHODS, V305, P39, DOI 10.1016/j.jim.2005.07.006
   Ma T, 2012, AM J TRANSPLANT, V12, P620, DOI 10.1111/j.1600 6143.2011.03870.x
   Malato Y, 2012, GASTROENTEROLOGY, V143, P1597, DOI 10.1053/j.gastro.2012.08.030
   Mangnall D, 2003, LIVER INT, V23, P124, DOI 10.1034/j.1600 0676.2003.00812.x
   Meier RPH, 2013, STEM CELL RES, V11, P1348, DOI 10.1016/j.scr.2013.08.011
   Nesher E, 2011, TRANSPL P, V43, P1736, DOI 10.1016/j.transproceed.2010.11.031
   Niu J, 2014, CLIN EXP IMMUNOL, V176, P473, DOI 10.1111/cei.12283
   Njoku DB, 2009, J AUTOIMMUN, V32, P52, DOI 10.1016/j.jaut.2008.11.003
   Pan GZ, 2012, J SURG RES, V178, P935, DOI 10.1016/j.jss.2012.04.070
   Pan QW, 2011, LIVER TRANSPLANT, V17, P596, DOI 10.1002/lt.22260
   Puglisi MA, 2011, J BIOMED BIOTECHNOL, V2011, P1
   Rabani V, 2010, CELL BIOL INT, V34, P601, DOI 10.1042/CBI20090386
   Salomone F, 2013, STEM CELL RES, V11, P1037, DOI 10.1016/j.scr.2013.07.003
   Schwabe RF, 2006, AM J PHYSIOL GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005
   Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135
   Seki T, 2012, J SURG RES, V178, P63, DOI 10.1016/j.jss.2012.02.014
   Shao CH, 2014, J SURG RES, V186, P408, DOI 10.1016/j.jss.2013.08.016
   Stock P, 2010, NAT PROTOC, V5, P617, DOI 10.1038/nprot.2010.7
   Tiberio L, 2006, CYTOKINE, V34, P131, DOI 10.1016/j.cyto.2006.04.009
   van Poll D, 2008, HEPATOLOGY, V47, P1634, DOI 10.1002/hep.22236
   Wang WJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0083908, 10.1371/journal.pone.0084654]
   Xia XF, 2012, LIVER TRANSPLANT, V18, P696, DOI 10.1002/lt.23414
   Yang ZF, 2007, LIVER TRANSPLANT, V13, P558, DOI 10.1002/lt.21094
   Yu Y, 2007, MOL THER, V15, P1382, DOI 10.1038/sj.mt.6300202
   Yu Y, 2010, STEM CELLS DEV, V19, P903, DOI 10.1089/scd.2009.0254
   Zhang HY, 2012, TRANSFUS MED REV, V26, P129, DOI 10.1016/j.tmrv.2011.09.002
   Zhao W, 2012, WORLD J GASTROENTERO, V18, P1048, DOI 10.3748/wjg.v18.i10.1048
   Zhong Z, 2006, TRANSPLANTATION, V82, P241, DOI 10.1097/01.tp.0000228867.98158.d2
NR 44
TC 39
Z9 46
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2014
VL 9
IS 12
AR e112532
DI 10.1371/journal.pone.0112532
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AX4MS
UT WOS:000346907200011
PM 25479410
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Smrzová, J
   Urbánek, T
AF Smrzova, Jana
   Urbanek, Tomas
TI Cinacalcet   Clinical and Laboratory Effectiveness, Concomitant
   Treatment Patterns and Treatment Cost: Could We Do Better and How?
SO KIDNEY & BLOOD PRESSURE RESEARCH
LA English
DT Article
DE Cinacalcet; Itching; Phosphate binders; Hyperparathyroidism, secondary;
   Vitamin D; Dialysis, cost of; Chronic kidney failure
ID CHRONIC KIDNEY DISEASE; LONG TERM TREATMENT; SECONDARY
   HYPERPARATHYROIDISM; PARATHYROID HORMONE; MINERAL METABOLISM; BONE
   METABOLISM; HEMODIALYSIS; THERAPY; MANAGEMENT; MORTALITY
AB Background: The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. Methods: 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical (hospitalization rate, clinical complaints questionnaire) responses to 12 month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. Results: The mean s Ca dropped significantly from 2.36 +/  0.24 to 2.21 +/  0.20 mmol/l, s P from 2.45 +/  0.54 to 2.01 +/  0.53 mmol/l, Ca x P from 5.79 +/  1.25 to 4.42 +/  1.13 mmol(2)/l(2), and iPTH dropped from 919.0 +/  465.6 to 372.1 +/  294.6 pg/ml. The mean cinacalcet dose reached 44.1 +/  23.0 mg/day after 12 months. Itching intensity decreased significantly. No change in hospitalization rate was observed. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 +/  9.59 to 20.62 +/  9.22. Conclusions: Cinacalcet decreased elevated s Ca, s P, Ca x P, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT. Copyright (C) 2010 S. Karger AG, Basel
C1 [Smrzova, Jana] Univ Hosp, Dialysis & Nephrol Ctr, Brno, Czech Republic.
   [Smrzova, Jana] INMED, Svitavy, Czech Republic.
   [Urbanek, Tomas] Acad Sci Czech Republ, Inst Psychol, Brno, Czech Republic.
C3 University Hospital Brno; Czech Academy of Sciences; Institute of
   Psychology of the Czech Academy of Sciences
RP Smrzová, J (通讯作者)，Vychodilova 16, CZ 61600 Brno, Czech Republic.
EM jsmrzova@gmail.com
RI Urbanek, Tomas/G 9427 2014
FU Institute of Psychology, Academy of Sciences of the Czech Republic
   [AV0Z70250504]
FX Tomas Urbanek, assist. prof., PhD was supported by the research plan of
   the Institute of Psychology, Academy of Sciences of the Czech Republic
   (No. AV0Z70250504).
CR Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Cannata Andia JB, 2008, NDT PLUS S1, V1, P2
   Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206
   Couttenye MM, 1999, KIDNEY INT, V56, pS70, DOI 10.1046/j.1523 1755.1999.07308.x
   CUNNINGHAM J, 2008, NDT PLUS S1, V1, P29
   CUNNINGHAM J, 2005, KIDNEY INT, V67, P467
   Danese MD, 2008, CLIN J AM SOC NEPHRO, V3, P1423, DOI 10.2215/CJN.01060308
   Arenas MD, 2007, NEPHROL DIAL TRANSPL, V22, P1639, DOI 10.1093/ndt/gfl840
   FRAZAO J, 2008, NDT PLUS S1, V1, P12
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Garside R, 2007, HEALTH TECHNOL ASSES, V11, P1
   Gibney EM, 2003, AM J KIDNEY DIS, V42, P1, DOI 10.1016/S0272 6386(03)00403 7
   Joy MS, 2007, J MANAGE CARE PHARM, V13, P397, DOI 10.18553/jmcp.2007.13.5.397
   Lazar E, 2007, AM J NEPHROL, V27, P274, DOI 10.1159/000101727
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Meola M, 2009, NEPHROL DIAL TRANSPL, V24, P982, DOI 10.1093/ndt/gfn654
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Mix TCH, 2003, AM J KIDNEY DIS, V42, P972, DOI 10.1016/j.ajkd.2003.06.001
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Moe SM, 2003, AM J NEPHROL, V23, P369, DOI 10.1159/000073945
   Narayan R, 2007, AM J KIDNEY DIS, V49, P801, DOI 10.1053/j.ajkd.2007.03.009
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   OLGAARD K, 2006, CLIN GUIDE BONE MINE
   Peter WLS, 2009, CLIN J AM SOC NEPHRO, V4, P354, DOI 10.2215/CJN.05241008
   Riccardi D., 2008, NDT PLUS, V1, pi7
   RYCHLIK I, 2008, STAT YEARLY REPORT D
   SMRZOVA J, 2005, VNITR LEK, V51, P327
   Ureña P, 2009, NEPHROL DIAL TRANSPL, V24, P2852, DOI 10.1093/ndt/gfp144
NR 30
TC 7
Z9 7
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1420 4096
EI 1423 0143
J9 KIDNEY BLOOD PRESS R
JI Kidney Blood Pressure Res.
PY 2010
VL 33
IS 5
BP 333
EP 342
DI 10.1159/000317935
PG 10
WC Physiology; Urology & Nephrology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology; Cardiovascular System & Cardiology
GA 685QW
UT WOS:000284644200001
PM 20714162
OA Bronze
DA 2025 08 17
ER

PT J
AU Cozzolino, M
   Ureña Torres, P
   Vervloet, MG
   Brandenburg, V
   Bover, J
   Goldsmith, D
   Larsson, TE
   Massy, ZA
   Mazzaferro, S
AF Cozzolino, Mario
   Urena Torres, Pablo
   Vervloet, Marc G.
   Brandenburg, Vincent
   Bover, Jordi
   Goldsmith, David
   Larsson, Tobias E.
   Massy, Ziad A.
   Mazzaferro, Sandro
CA ERA EDTA
TI Is chronic kidney disease mineral bone disorder (CKD MBD) really a
   syndrome?
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE syndrome; chronic kidney disease; parathyroid hormone; cardiovascular
   outcome; renal osteodystrophy
ID METABOLIC SYNDROME; DIALYSIS PATIENTS; PRACTICE PATTERNS; CALCIUM;
   MORTALITY; PHOSPHATE; OUTCOMES; PHOSPHORUS; RISK; PTH
AB The concept of chronic kidney disease mineral bone disorder (CKD MBD) does not appear to fulfil the requirements for a syndrome at first glance, but its definition has brought some clear cut benefits for clinicians and patients, including wider and more complex diagnostic and therapeutic approaches to the management of this challenging set of issues. Admittedly, not all components of CKD MBD are present in all patients at all times, but these are highly interrelated, involving mineral and bone laboratory abnormalities, clinical and histological bone disease and finally, cardiovascular disease. The presence of typical biological bone ossification processes in an ectopic anatomical location in CKD has helped to define the existence of an unprecedented bone vascular relationship, extending its interest even to other medical specialities. For now, we believe that CKD MBD does not reach full criteria to be defined as a syndrome. However, this novel concept has clearly influenced current clinical guidelines. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF/KDOQI (TM)) guidelines in 2003 for instance recommended that calcium based phosphate binders should be avoided to treat hyperphosphataemia in the presence of cardiovascular calcifications. In 2009, the KDIGO and other guidelines reinforced and extended this recommendation by stating that it is reasonable to choose oral phosphate binder therapy by taking into consideration other components of CKD MBD. Similarly, it is also considered reasonable to use information on vascular/valvular calcification to guide the management of CKD MBD. Our current assumption as a working group 'CKD MBD' is that CKD MBD has the potential to be defined a true syndrome, such as a constellation of concurrent signs and symptoms that suggest a common underlying mechanism for these components as opposed to the term disease. The term 'syndrome' also implies that in any patient at risk due to the presence of one or a few components of the entire syndrome, the screening for additional components is highly recommended. However, it has not currently been demonstrated that there is an additive predictive value, which can be derived from identifying individual components. Despite all we have learned about this putative syndrome, we have been left with only a hypothetical framework about how to treat patients. So while we agree that the concept of CKD MBD has influenced, and continues to influence, our current clinical hypotheses, definitive proof of a benefit of interventions in CKD MBD is still lacking and a global multiple therapeutic approach to treat simultaneously several components of CKD MBD should be tested by well designed new randomized controlled trials.
C1 [Cozzolino, Mario] Univ Milan, Dept Hlth Sci, Div Renal, San Paolo Hosp, Milan, Italy.
   [Cozzolino, Mario] Univ Milan, Lab Expt Nephrol, San Paolo Hosp, Milan, Italy.
   [Urena Torres, Pablo] Univ Paris 05, Dept Nephrol & Dialysis, Clin Landy, Necker Hosp, Paris, France.
   [Urena Torres, Pablo] Univ Paris 05, Dept Renal Physiol, Necker Hosp, Paris, France.
   [Vervloet, Marc G.] Vrije Univ Amsterdam, Med Ctr, Dept Nephrol, Amsterdam, Netherlands.
   [Brandenburg, Vincent] RWTH Univ Hosp Aachen, Dept Cardiol & Intens Care Med, Aachen, Germany.
   [Bover, Jordi] REDinREN, Dept Nephrol, Fundacio Puigvert, IIB St Pau, Barcelona, Spain.
   [Goldsmith, David] Kings Hlth Partners AHSC London, London, England.
   [Larsson, Tobias E.] Karolinska Inst, Renal Unit, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
   [Larsson, Tobias E.] Karolinska Univ Hosp, Dept Nephrol, Stockholm, Sweden.
   [Massy, Ziad A.] Paris Ile France Ouest Univ UVSQ, Div Nephrol, Hop Ambroise Pare, Paris, France.
   [Massy, Ziad A.] UPJV, INSERM, U1088, Amiens, France.
   [Mazzaferro, Sandro] Univ Roma La Sapienza, Dept Cardiovasc Resp Nephrol & Geriatr Sci, I 00185 Rome, Italy.
C3 University of Milan; San Paolo Polo Universitaria Hospital; University
   of Milan; San Paolo Polo Universitaria Hospital; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Necker Enfants Malades   APHP; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Necker Enfants
   Malades   APHP; Vrije Universiteit Amsterdam; RWTH Aachen University;
   RWTH Aachen University Hospital; Fundacio Puigvert; Karolinska
   Institutet; Karolinska Institutet; Karolinska University Hospital;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Ambroise Pare   APHP; Universite Paris Saclay; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Picardie Jules
   Verne (UPJV); Sapienza University Rome
RP Cozzolino, M (通讯作者)，Univ Milan, Dept Hlth Sci, Div Renal, San Paolo Hosp, Milan, Italy.
EM mario.cozzolino@unimi.it
RI ; Cozzolino, Mario/AAB 9965 2022; Mazzaferro, Sandro/E 9321 2012;
   Goldsmith, David/H 6965 2018; Torres, Pablo/LBH 6671 2024; Vervoort,
   G.M.M./L 4718 2015; Bover, Jordi/AAZ 6797 2020
OI Bover, Jordi/0000 0003 3577 2273; Cozzolino, Mario/0000 0002 8494 6252;
   Mazzaferro, Sandro/0000 0003 3071 1893; Vervloet,
   Marc/0000 0003 4607 9415; Goldsmith, David/0000 0002 4349 9193; 
FU Abbvie; Shire; Dutch Kidney Foundation; Sanofi; Amgen; Fresenius; Bayer;
   Sanofi/Genzyme; FMC; Baxter; Genzyme/Sanofi; Novo Nordisk Fonden
   [NNF13OC0004951] Funding Source: researchfish
FX Mario Cozzolino: Lecture honoraria from Abbvie, Shire, Amgen, Genzyme,
   Roche. Research Grants from Abbvie, Shire. Pablo Urena Torres: honoraria
   from Abbvie, Amgen, Fresenius, Shire, Genzyme/Sanofi. Marc Vervloet:
   research grants from Dutch Kidney Foundation, Shire, Abbvie, Sanofi.
   Speaking fees form Amgen, Fresenius. Consultant for Astellas, Amgen.
   Vincent Brandenburg: current Grants from Amgen, Bayer, Sanofi. Honoraria
   2013 from Bayer, Sanofi, Fresenius, Synlap. Jordi Bover: speaking fees
   from Abbvie, Amgen, Sanofi/Genzyme, Shire. David Goldsmith: honoraria
   from Abbvie, Amgen, Fresenius, Keryx, Sandoz. Tobias Larsson: part time
   employee of Astellas. Ziad Massy: speaking honoraria from
   Genzyme/Sanofi, Amgen, FMC, Vifor, Abbvie, Chugai research grants from
   FMC, Baxter, Amgen, Genzyme/Sanofi. Sandro Mazzaferro: Lecture honoraria
   from Shire and Amgen.
CR [Anonymous], 2013, KIDNEY INT S, V3, P8
   Cannata Andía B, 2013, KIDNEY INT, V84, P998, DOI 10.1038/ki.2013.185
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Cozzolino M, 2012, NEPHROL DIAL TRANSPL, V27, P3588, DOI 10.1093/ndt/gfs108
   Cozzolino M, 2011, NEPHROL DIAL TRANSPL, V26, P402, DOI 10.1093/ndt/gfq691
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Ford ES, 2002, JAMA J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goldsmith DJA, 2010, NEPHROL DIAL TRANSPL, V25, P3823, DOI 10.1093/ndt/gfq513
   Grundy SM, 2006, AM J CLIN NUTR, V83, P1248, DOI 10.1093/ajcn/83.6.1248
   Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609
   Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140 6736(13)60897 1
   Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289
   London GM, 2009, CLIN J AM SOC NEPHRO, V4, P254, DOI 10.2215/CJN.06661208
   Lopes AA, 2012, AM J KIDNEY DIS, V60, P90, DOI 10.1053/j.ajkd.2011.12.025
   Manns BJ, 2010, AM J KIDNEY DIS, V55, P800, DOI 10.1053/j.ajkd.2010.02.339
   Martin KJ, 2011, CLIN J AM SOC NEPHRO, V6, P440, DOI 10.2215/CJN.05130610
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Naves Díaz M, 2011, NEPHROL DIAL TRANSPL, V26, P1938, DOI 10.1093/ndt/gfq304
   Shlipak MG, 2013, NEW ENGL J MED, V369, P932, DOI 10.1056/NEJMoa1214234
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Thompson B, 2012, NAT REV ENDOCRINOL, V8, P529, DOI 10.1038/nrendo.2012.36
   Uhlig K, 2010, AM J KIDNEY DIS, V55, P773, DOI 10.1053/j.ajkd.2010.02.340
   Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295
NR 24
TC 90
Z9 93
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD OCT
PY 2014
VL 29
IS 10
BP 1815
EP 1820
DI 10.1093/ndt/gft514
PG 6
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA AQ6SE
UT WOS:000342943300006
PM 24516228
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Yang, DW
   Moon, JS
   Ko, HM
   Shin, YK
   Fukumoto, S
   Kim, SH
   Kim, MS
AF Yang, Dong Wook
   Moon, Jung Sun
   Ko, Hyun Mi
   Shin, Yeo Kyeong
   Fukumoto, Satoshi
   Kim, Sun Hun
   Kim, Min Seok
TI Direct reprogramming of fibroblasts into diverse lineage cells by DNA
   demethylation followed by differentiating cultures
SO KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
LA English
DT Article
DE Cell lineage; Cellular reprogramming; DNA demethylation; Epigenesis,
   genetic
ID HUMAN GENOME; STEM CELLS; MECHANISMS; EXPRESSION; GENERATION; CONVERSION
AB Direct reprogramming, also known as a trans differentiation, is a technique to allow mature cells to be converted into other types of cells without inducing a pluripotent stage. It has been suggested as a major strategy to acquire the desired type of cells in cell based therapies to repair damaged tissues. Studies related to switching the fate of cells through epigenetic modification have been progressing and they can bypass safety issues raised by the virus based transfection methods. In this study, a protocol was established to directly convert fully differentiated fibroblasts into diverse mesenchymal lineage cells, such as osteoblasts, adipocytes, chondrocytes, and ectodermal cells, including neurons, by means of DNA demethylation, immediately followed by culturing in various differentiating media. First, 24 h exposure of 5 azacytidine (5 aza CN), a well characterized DNA methyl transferase inhibitor, to NIH 3T3 murine fibroblast cells induced the expression of stem cell markers, that is, increasing cell plasticity. Next, 5 aza CN treated fibroblasts were cultured in osteogenic, adipogenic, chondrogenic, and neurogenic media with or without bone morphogenetic protein 2 for a designated period. Differentiation of each desired type of cell was verified by quantitative reverse transcriptase polymerase chain reaction/western blot assays for appropriate marker expression and by various staining methods, such as alkaline phosphatase/alizarin red S/oil red 0/alcian blue. These proposed procedures allowed easier acquisition of the desired cells without any transgenic modification, using direct reprogramming technology, and thus may help make it more available in the clinical fields of regenerative medicine.
C1 [Yang, Dong Wook; Moon, Jung Sun; Ko, Hyun Mi; Shin, Yeo Kyeong; Kim, Sun Hun; Kim, Min Seok] Chonnam Natl Univ, Sch Dent, Dent Sci Res Inst, Gwangju 61186, South Korea.
   [Fukumoto, Satoshi] Tohoku Univ, Dept Oral Hlth & Dev Sci, Div Pediat Dent, Grad Sch Dent, Sendai, Miyagi 9808575, Japan.
C3 Chonnam National University; Tohoku University
RP Kim, MS (通讯作者)，Chonnam Natl Univ, Sch Dent, Dent Sci Res Inst, Gwangju 61186, South Korea.
EM greatone@jnu.ac.kr
RI ; Yang, Dongwook/NRB 5370 2025; Kim, Min Seok/LZH 3686 2025
OI Yang, Dongwook/0000 0002 9030 597X; Fukumoto,
   Satoshi/0000 0002 5046 6891; 
FU National Research Foundation of Korea (NRF)   Korea government
   [NRF 2018R1A2B6006373]; National Research Foundation of Korea (NRF)  
   Korea government (MSIT) [2019R1A5A2027521]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (NRF 2018R1A2B6006373) and
   National Research Foundation of Korea (NRF) grant funded by the Korea
   government (MSIT) (No.2019R1A5A2027521).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Avgustinova A, 2016, NAT REV MOL CELL BIO, V17, P643, DOI 10.1038/nrm.2016.76
   Baubec T, 2015, NATURE, V520, P243, DOI 10.1038/nature14176
   Bushman F, 2005, NAT REV MICROBIOL, V3, P848, DOI 10.1038/nrmicro1263
   Chanda S, 2014, STEM CELL REP, V3, P282, DOI 10.1016/j.stemcr.2014.05.020
   Cheng L, 2015, CELL RES, V25, P645, DOI 10.1038/cr.2015.55
   Cho YD, 2014, J BIOL CHEM, V289, P20120, DOI 10.1074/jbc.M114.558064
   Cohen DE, 2011, NAT REV GENET, V12, P243, DOI 10.1038/nrg2938
   DARMON M, 1984, EMBO J, V3, P961, DOI 10.1002/j.1460 2075.1984.tb01914.x
   DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092 8674(87)90585 X
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533
   Guo C, 2017, CURR OPIN GENET DEV, V46, P50, DOI 10.1016/j.gde.2017.06.011
   Heng JCD, 2010, COLD SH Q B, V75, P237, DOI 10.1101/sqb.2010.75.003
   Hua J, 2014, CELL BIOL INT, V38, P198, DOI 10.1002/cbin.10188
   Kurakazu I, 2019, J BIOL CHEM, V294, P17555, DOI 10.1074/jbc.RA119.009409
   Li D, 2019, STEM CELL REV REP, V15, P67, DOI 10.1007/s12015 018 9854 5
   MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021
   Maza I, 2015, NAT BIOTECHNOL, V33, P769, DOI 10.1038/nbt.3270
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Pennarossa G, 2013, P NATL ACAD SCI USA, V110, P8948, DOI 10.1073/pnas.1220637110
   Raciti M, 2013, MOL CELL NEUROSCI, V57, P42, DOI 10.1016/j.mcn.2013.10.004
   Riemens RJM, 2018, PROG NEUROBIOL, V168, P42, DOI 10.1016/j.pneurobio.2018.04.003
   Schröder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092 8674(02)00864 4
   Song KH, 2012, NATURE, V485, P599, DOI 10.1038/nature11139
   Spada F, 2007, J CELL BIOL, V176, P565, DOI 10.1083/jcb.200610062
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Waddington C.H, 1957, during a theoretical discussion between two characters about the different aspects
   Whitelaw E, 2000, METH MOL B, V158, P351
   Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413
   Xu J, 2015, CELL STEM CELL, V16, P119, DOI 10.1016/j.stem.2015.01.013
NR 32
TC 3
Z9 3
U1 0
U2 7
PU KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
PI SEOUL
PA C/O EDITORIAL OFFICE, 448 13 SEOKYO DONG, SEOUL, SOUTH KOREA
SN 1226 4512
EI 2093 3827
J9 KOREAN J PHYSIOL PHA
JI KOREAN J. PHYSIOL. PHARMACOL.
PD NOV
PY 2020
VL 24
IS 6
BP 463
EP 472
DI 10.4196/kjpp.2020.24.6.463
PG 10
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA OH2JQ
UT WOS:000582396000003
PM 33093268
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU He, PC
   Yu, HJ
   Jiang, L
   Chen, ZY
   Wang, SY
   Macrae, VE
   Fu, XD
   Zhu, DX
AF He, Pengcheng
   Yu, Hongjiao
   Jiang, Lei
   Chen, Ziying
   Wang, Siying
   Macrae, Vicky E.
   Fu, Xiaodong
   Zhu, Dongxing
TI Hdac9 inhibits medial artery calcification through
   down regulation of Osterix
SO VASCULAR PHARMACOLOGY
LA English
DT Article
DE Hdac9; Medial artery calcification; Vascular smooth muscle cell;
   Osterix; Chronic kidney disease
ID SMOOTH MUSCLE CELLS; VASCULAR CALCIFICATION; EMERGING ROLE;
   UP REGULATION; EXPRESSION; ATHEROSCLEROSIS; ASSOCIATION; PHOSPHATE;
   DISEASE
AB Backgrounds: Medial artery calcification (MAC) significantly contributes to the increased cardiovascular death in patients with chronic kidney disease (CKD). Previous genome wide association studies have shown that various genetic variants of the histone deacetylase Hdac9 are associated with cardiovascular disease, but the role of Hdac9 in MAC under CKD conditions remains unclear.
   Methods: High phosphate induced vascular smooth muscle cell (VSMC) calcification and MAC in mice administered with vitamin D 3 (vD) were used in the present study. Alizarin red staining, calcium quantitative assay, qPCR, western blotting and histology were performed.
   Results: Hdac9 expression was significantly down regulated during high phosphate induced vascular smooth muscle cell (VSMC) calcification and MAC in mice administered with vitamin D 3 (vD). Furthermore, high phosphate treatment inhibited phosphorylation of Akt, and pharmacological inhibition of Akt signaling reduced Hdac9 expression in cultured VSMCs. Knockdown of Hdac9 significantly enhanced calcium deposition in VSMCs. Conversely, adenovirus mediated overexpression of Hdac9 inhibited high phosphate induced VSMC in vitro calcification. Our subsequent mechanistic studies revealed that the anti calcific effect of Hdac9 was mediated through down regulation of osteoblast specific transcription factor Osterrix.
   Conclusion: These data suggest that Hdac9 is a novel inhibitor of MAC and may represent a potential therapeutic target for MAC in CKD patients.
C1 [He, Pengcheng; Jiang, Lei] Guangdong Acad Med Sci, Guangdong Prov Key Lab Coronary Heart Dis Prevent, Guangdong Prov Peoples Hosp, Dept Cardiol,Guangdong Cardiovasc Inst, Guangzhou 510100, Peoples R China.
   [Yu, Hongjiao] Univ Aberdeen, Inst Med Sci, Sch Med Sci, Forester Hill, Aberdeen AB25 2ZD, Scotland.
   [Chen, Ziying; Wang, Siying; Fu, Xiaodong; Zhu, Dongxing] Guangzhou Med Univ, Guangdong Key Lab Vasc Dis, State Key Lab Resp Dis, Guangzhou Inst Cardiovasc Dis,Affiliated Hosp 2, Guangzhou 510260, Guangdong, Peoples R China.
   [Macrae, Vicky E.] Univ Edinburgh, Roslin Inst, RDSVS, Easter Bush Campus, Edinburgh EH25 9RG, Midlothian, Scotland.
C3 Southern Medical University   China; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital; University of Aberdeen; State Key
   Laboratory of Respiratory Disease; Guangzhou Medical University;
   University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology
   and Biological Sciences Research Council (BBSRC); Roslin Institute
RP Fu, XD; Zhu, DX (通讯作者)，Guangzhou Med Univ, Guangdong Key Lab Vasc Dis, State Key Lab Resp Dis, Guangzhou Inst Cardiovasc Dis,Affiliated Hosp 2, Guangzhou 510260, Guangdong, Peoples R China.
EM fuxiaod@mail.gzhmu.edu.cn; dongxing.zhu@gzhmu.edu.cn
RI ; He, Pengcheng/GYJ 6459 2022
OI zhu, dongxing/0000 0001 5419 438X; Jiang, Lei/0000 0002 3505 4020;
   Jiang, Lei/0000 0002 9509 370X; 
FU National Natural Science Foundation for Young Scientists of China
   [81800428]; Innovation Project of Department of Education of Guangdong
   Province [2017KTSCX158]; Innovative Research Team of Department of
   Education of Guangdong Province [2019KCXTD015]; Guangdong Natural
   Science Foundation [2018A030310178]; Science and Technology Projects of
   Guangzhou [201904010289]; National Natural Science Foundation
   [81871137]; Project of Department of Education of Guangdong Province
   [2015KTSCX109]; National Funds of Developing Local Colleges and
   Universities [B16056001]; Science and Technology Program of Guangzhou
   [201804010376]; Guangzhou 121 Talent Program; BBSRC [BBS/E/D/10002071]
   Funding Source: UKRI; Biotechnology and Biological Sciences Research
   Council [BBS/E/D/10002071] Funding Source: researchfish
FX This work was supported by funding from the National Natural Science
   Foundation for Young Scientists of China (No. 81800428), The Innovation
   Project of Department of Education of Guangdong Province (No.
   2017KTSCX158), The Innovative Research Team of Department of Education
   of Guangdong Province (NO.2019KCXTD015), Guangdong Natural Science
   Foundation (No. 2018A030310178), Science and Technology Projects of
   Guangzhou (No. 201904010289) to Dr. Dongxing Zhu. Dr. Xiaodong Fu is
   supported by the National Natural Science Foundation (81871137), The
   Project of Department of Education of Guangdong Province (2015KTSCX109),
   National Funds of Developing Local Colleges and Universities
   (B16056001), Science and Technology Program of Guangzhou (201804010376),
   Guangzhou 121 Talent Program
CR Abend A, 2017, EMBO REP, V18, P1166, DOI 10.15252/embr.201643686
   Azechi T, 2013, J ATHEROSCLER THROMB, V20, P538, DOI 10.5551/jat.15826
   Azghandi S, 2015, STROKE, V46, P197, DOI 10.1161/STROKEAHA.114.007213
   Benerofe SA, 2017, FASEB J, V31
   Cao Q, 2014, ARTERIOSCL THROM VAS, V34, P1871, DOI 10.1161/ATVBAHA.114.303393
   Cui LW, 2016, CLIN EXP HYPERTENS, V38, P451, DOI 10.3109/10641963.2016.1163366
   Deng L, 2015, ARTERIOSCL THROM VAS, V35, P175, DOI 10.1161/ATVBAHA.114.304786
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Gong YC, 2016, MOL MED REP, V14, P2111, DOI 10.3892/mmr.2016.5484
   GRONOWICZ G, 1989, J BONE MINER RES, V4, P313
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Kwon DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10492
   Lau WL, 2010, THROMB HAEMOSTASIS, V104, P464, DOI 10.1160/TH09 12 0814
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   Lu JL, 2016, ONCOTARGET, V7, P37471, DOI 10.18632/oncotarget.9650
   Malhotra R, 2019, NAT GENET, V51, P1580, DOI 10.1038/s41588 019 0514 8
   Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588 018 0058 3
   Markus HS, 2013, STROKE, V44, P1220, DOI 10.1161/STROKEAHA.111.000217
   Matsukura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139262
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Nelson CP, 2017, NAT GENET, V49, P1385, DOI 10.1038/ng.3913
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Paloian NJ, 2014, AM J PHYSIOL RENAL, V307, pF891, DOI 10.1152/ajprenal.00163.2014
   Ponnusamy A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196232
   Prestel M, 2019, STROKE, V50, P2651, DOI 10.1161/STROKEAHA.119.026112
   Sage AP, 2011, KIDNEY INT, V79, P414, DOI 10.1038/ki.2010.390
   Schäck LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065943
   SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003
   Song Y, 2017, EUR J PHARMACOL, V794, P45, DOI 10.1016/j.ejphar.2016.11.029
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Towler DA, 2006, ANN NY ACAD SCI, V1068, P327, DOI 10.1196/annals.1346.036
   Voelkl J, 2019, CELL MOL LIFE SCI, V76, P2077, DOI 10.1007/s00018 019 03054 z
   Voelkl J, 2018, J CLIN INVEST, V128, P3024, DOI 10.1172/JCI96477
   Zhu DX, 2013, MOL CELL ENDOCRINOL, V372, P1, DOI 10.1016/j.mce.2013.03.008
   Zhu Dongxing, 2012, Front Endocrinol (Lausanne), V3, P95, DOI 10.3389/fendo.2012.00095
   Zhu DX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019595
NR 37
TC 10
Z9 11
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1537 1891
EI 1879 3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD SEP
PY 2020
VL 132
AR 106775
DI 10.1016/j.vph.2020.106775
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OE6HV
UT WOS:000580630600001
PM 32702412
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Yoon, BS
   Moon, JH
   Jun, EK
   Kim, J
   Maeng, I
   Kim, JS
   Lee, JH
   Baik, CS
   Kim, A
   Cho, KS
   Lee, JH
   Lee, HH
   Whang, KY
   You, S
AF Yoon, Byung Sun
   Moon, Jai Hee
   Jun, Eun Kyoung
   Kim, Jonggun
   Maeng, Isaac
   Kim, Jun Sung
   Lee, Jung Han
   Baik, Cheong Soon
   Kim, Aeree
   Cho, Kyoung Shik
   Lee, Jang Ho
   Lee, Hwang Heui
   Whang, Kwang Youn
   You, Seungkwon
TI Secretory Profiles and Wound Healing Effects of Human Amniotic
   Fluid Derived Mesenchymal Stem Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID UMBILICAL CORD BLOOD; HEPATOCYTE GROWTH FACTOR; BONE MARROW; STROMAL
   CELLS; IN VITRO; EXPRESSION; DIFFERENTIATION; ADULT; CYTOKINES; GENES
AB Recent evidence shows that amniotic fluid (AF) contains multiple cell types derived from the developing fetus, and may represent a novel source of stem cells for cell therapy. In this study, we examined the paracrine factors released by human amniotic fluid derived mesenchymal stem cells (AF MSCs) and their ability to accelerate the wound healing process by stimulating proliferation and migration of dermal fibroblasts. AF MSCs expressed the typical MSC marker proteins CD13, CD29, and CD44 and differentiated into adipocytes, osteoblasts, and chondrocytes when exposed to the appropriate differentiation media. In addition, AF MSC conditioned media (AF MSC CM) significantly enhanced proliferation of dermal fibroblasts. Antibody based protein array and enzyme linked immunosorbent assay (ELISA) indicated that AF MSC CM contains various cytokines and chemokines that are known to be important in normal wound healing, including IL 8, IL 6, TGF beta, TNFRI, VEGF, and EGF. Application of AF MSC CM significantly enhanced wound healing by dermal fibroblasts via the TGF beta/SMAD2 pathway. Levels of p SMAD2 were increased by AF MSC CM, and both the increase in p SMAD2 and migration of dermal fibroblasts were blocked by inhibiting the TGF beta/SMAD2 pathway. Moreover, in a mouse excisional wound model, AF MSC CM accelerated wound healing. These data provide the first evidence of the potential for AF MSC CM in the treatment of skin wounds.
C1 [Yoon, Byung Sun; Moon, Jai Hee; Jun, Eun Kyoung; Maeng, Isaac; Kim, Jun Sung; Lee, Jung Han; You, Seungkwon] Korea Univ, Lab Cell Funct Regulat, Coll Life Sci & Biotechnol, Seoul 136701, South Korea.
   [Yoon, Byung Sun] Korea Univ, Inst Life Sci & Nat Resources, Seoul 136701, South Korea.
   [Kim, Jonggun; Whang, Kwang Youn] Korea Univ, Div Biotechnol, Coll Life Sci & Biotechnol, Seoul 136701, South Korea.
   [Jun, Eun Kyoung; Lee, Jung Han; Cho, Kyoung Shik; Lee, Jang Ho; Lee, Hwang Heui] Stemmedience Corp, Div Stem Cell, Res Inst, Seoul, South Korea.
   [Baik, Cheong Soon] SamKwang Med Labs, Seoul, South Korea.
   [Kim, Aeree] Korea Univ, Guro Hosp, Dept Pathol, Coll Med, Seoul 136701, South Korea.
   [Lee, Hwang Heui] ChungDam NB Clin, Seoul, South Korea.
C3 Korea University; Korea University; Korea University; Korea University;
   Korea University Medicine (KU Medicine)
RP You, S (通讯作者)，Korea Univ, Lab Cell Funct Regulat, Coll Life Sci & Biotechnol, Seoul 136701, South Korea.
EM bioseung@korea.ac.kr
RI You, Seungkwon/H 3067 2015; Kim, Jun Sung/AAI 1673 2020
FU Ministry of Education, Science and Technology, Republic of Korea
   [SC 5150]; Stemmedience, Republic of Korea; Brain Korea 21 project,
   Republic of Korea; Korea University Grant, Republic of Korea
FX This research was supported by a grant (SC 5150) from the Stem Cell
   Research Center of the 21st Century Frontier Research Program, funded by
   the Ministry of Education, Science and Technology, Republic of Korea; a
   grant from Stemmedience, Republic of Korea; a grant from the second
   phase of Brain Korea 21 project, Republic of Korea; and a Korea
   University Grant, Republic of Korea.
CR Agren Magnus S, 2007, Int J Low Extrem Wounds, V6, P82, DOI 10.1177/1534734607301394
   Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524 475X.2008.00410.x
   Battula VL, 2007, DIFFERENTIATION, V75, P279, DOI 10.1111/j.1432 0436.2006.00139.x
   Blakytny Robert, 2000, Journal of Pathology, V190, P589, DOI 10.1002/(SICI)1096 9896(200004)190:5<589::AID PATH553>3.0.CO;2 T
   BRAUCHLE M, 1994, ONCOGENE, V9, P3199
   Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744
   Carrington LM, 2005, J CATARACT REFR SURG, V31, P412, DOI 10.1016/j.jcrs.2004.04.072
   Cha JS, 2007, CLIN DERMATOL, V25, P73, DOI 10.1016/j.clindermatol.2006.10.002
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Del Rio M, 1999, GENE THER, V6, P1734, DOI 10.1038/sj.gt.3300986
   Enoch S, 2006, BRIT MED J, V332, P900, DOI 10.1136/bmj.332.7546.900
   Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001
   Feugate JE, 2002, J CELL BIOL, V156, P161, DOI 10.1083/jcb.200103062
   Finnerty CC, 2006, SHOCK, V26, P13, DOI 10.1097/01.shk.0000223120.26394.7d
   Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514
   Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067 1927.2004.12404.x
   Handgretinger R, 2003, ANN NY ACAD SCI, V996, P141, DOI 10.1111/j.1749 6632.2003.tb03242.x
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Hosokawa R, 2005, J INVEST DERMATOL, V125, P1302, DOI 10.1111/j.0022 202X.2005.23963.x
   in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood 2003 04 1291
   KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kho Y, 2008, BIOSCI BIOTECH BIOCH, V72, P70, DOI 10.1271/bbb.70374
   Kim WS, 2007, J DERMATOL SCI, V48, P15, DOI 10.1016/j.jdermsci.2007.05.018
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002 9440(10)65287 X
   Li HH, 2006, CELL TISSUE RES, V326, P725, DOI 10.1007/s00441 006 0270 9
   Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514
   Liu CH, 2005, CYTOKINE, V32, P270, DOI 10.1016/j.cyto.2005.11.003
   Mairet Coello G, 2009, J NEUROSCI, V29, P775, DOI 10.1523/JNEUROSCI.1700 08.2009
   MASSAGUE J, 1999, WOUNDING SMAD NAT CE, V1, pE117
   Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060
   MATSUSHIMA K, 1989, CYTOKINE, V1, P1
   Meckmongkol TT, 2007, BIOCHEM BIOPH RES CO, V360, P709, DOI 10.1016/j.bbrc.2007.06.121
   Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103
   Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391
   Moon JH, 2008, STEM CELLS DEV, V17, P713, DOI 10.1089/scd.2007.0210
   Nagaya N, 2004, AM J PHYSIOL HEART C, V287, pH2670, DOI 10.1152/ajpheart.01071.2003
   Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447
   Nakanishi C, 2008, BIOCHEM BIOPH RES CO, V374, P11, DOI 10.1016/j.bbrc.2008.06.074
   Neuhoff S, 2007, EXP HEMATOL, V35, P1119, DOI 10.1016/j.exphem.2007.03.019
   Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129
   Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898
   Park G, 2008, J INVEST DERMATOL, V128, P2429, DOI 10.1038/jid.2008.103
   Patel KM, 2007, J SURG RES, V143, P281, DOI 10.1016/j.jss.2006.11.006
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279
   PRUSA AR, 2002, MED SCI MONITOR, V8, P253, DOI DOI 10.1016/J.STEM.2007.05.013
   Re MC, 2000, J HEMATOTH STEM CELL, V9, P481, DOI 10.1089/152581600419143
   Richardson Marion, 2004, Nurs Times, V100, P50
   Riedel K, 2007, ARCH MED RES, V38, P45, DOI 10.1016/j.arcmed.2006.04.010
   Rosch R, 2006, SURG ENDOSC, V20, P1892, DOI 10.1007/s00464 005 0816 z
   Shih NR, 2002, J AM SOC NEPHROL, V13, P394, DOI 10.1681/ASN.V132394
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565
   Tögel F, 2005, AM J PHYSIOL RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279
   van Poll D, 2008, HEPATOLOGY, V47, P1634, DOI 10.1002/hep.22236
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Yoo SJ, 2005, EXP MOL MED, V37, P399, DOI 10.1038/emm.2005.50
   Yoon BS, 2006, DIFFERENTIATION, V74, P149, DOI 10.1111/j.1432 0436.2006.00063.x
   You S, 2004, MOL CELLS, V18, P261
   Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128
   Zhao Y, 2006, EXP CELL RES, V312, P2454, DOI 10.1016/j.yexcr.2006.04.008
NR 68
TC 165
Z9 179
U1 1
U2 29
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JUN
PY 2010
VL 19
IS 6
BP 887
EP 902
DI 10.1089/scd.2009.0138
PG 16
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 614CX
UT WOS:000279033900013
PM 19686050
DA 2025 08 17
ER

PT J
AU Martinelli, N
   Bianchi, A
   Sartorelli, E
   Dondi, A
   Bonifacini, C
   Malerba, F
AF Martinelli, Nicolo
   Bianchi, Alberto
   Sartorelli, Elena
   Dondi, Alessandra
   Bonifacini, Carlo
   Malerba, Francesco
TI Treatment of Bone Marrow Edema of the Talus with Pulsed Electromagnetic
   Fields Outcomes in Six Patients
SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION
LA English
DT Article
ID FEMORAL HEAD; TRANSIENT OSTEOPOROSIS; CORE DECOMPRESSION; CONSERVATIVE
   TREATMENT; OSTEONECROSIS; ILOPROST; KNEE; STIMULATION; MRI;
   BISPHOSPHONATES
AB Background: Bone marrow edema (BME) of the talus is a rare, mostly self limiting cause of foot and ankle pain. We sought to investigate in patients with idiopathic BME of the talus the effectiveness of pulsed electromagnetic fields and to determine the effect of this therapy on magnetic resonance imaging findings.
   Methods: Six patients with BME of the talus confirmed by magnetic resonance imaging were enrolled. Pain was quantified with a visual analog scale from 0 (no pain) to 10 (the worst pain imaginable). The clinical outcome was assessed using the American Orthopaedic Foot and Ankle Society scoring system. Treatment consisted of pulsed electromagnetic field stimulation 8 h/d for 30 days. The device used generated pulses 1.3 milliseconds in duration, with a frequency of 75 Hz and a mean +/  SD induced electric field of 3.5 +/  0.5 mV.
   Results: The mean American Orthopaedic Foot and Ankle Society score improved from 59.4 (range, 40 66) before treatment to 94 (range, 80 100) at the last follow up. The visual analog scale score decreased significantly from 5.6 (range, 4 7) before treatment to 1 (range, 0 2) at the last follow up. Magnetic resonance imaging showed that BME improved after 1 month of treatment and resolved completely within 3 months in 5 patients, with normal signal intensity and no signs of progression to avascular necrosis.
   Conclusions: A significant reduction in BME area was associated with a significant decrease in pain within 3 months of beginning treatment.
C1 [Martinelli, Nicolo; Bianchi, Alberto; Sartorelli, Elena; Dondi, Alessandra; Bonifacini, Carlo; Malerba, Francesco] IRCCS Galeazzi, Dept Ankle & Foot Surg, I 20100 Milan, Italy.
C3 IRCCS Istituto Ortopedico Galeazzi
RP Martinelli, N (通讯作者)，IRCCS Galeazzi, Dept Ankle & Foot Surg, Via R Galeazzi 4, I 20100 Milan, Italy.
EM n.martinelli@unicampus.it
RI Martinelli, Nicolo/T 3537 2017
OI Martinelli, Nicolo/0000 0001 6857 0729
CR AARON RK, 1989, CLIN ORTHOP RELAT R, P209
   Aigner N, 2001, J BONE JOINT SURG BR, V83B, P855, DOI 10.1302/0301 620X.83B6.11377
   Baier C, 2013, RHEUMATOL INT, V33, P1397, DOI 10.1007/s00296 012 2584 0
   Bartl C, 2012, ARCH ORTHOP TRAUM SU, V132, P1781, DOI 10.1007/s00402 012 1617 1
   Ciombor DM, 2003, OSTEOARTHR CARTILAGE, V11, P455, DOI 10.1016/S1063 4584(03)00083 9
   De Mattei M, 2003, CONNECT TISSUE RES, V44, P154, DOI 10.1080/03008200390208546
   De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521 186X(1999)20:3<177::AID BEM4>3.0.CO;2 #
   Disch AC, 2005, J BONE JOINT SURG BR, V87B, P560, DOI 10.1302/0301 620X.87B4.15658
   DOURY P, 1994, J BONE JOINT SURG BR, V76B, P993, DOI 10.1302/0301 620X.76B6.7983140
   Elder GJ, 2006, NEPHROLOGY, V11, P560, DOI 10.1111/j.1440 1797.2006.00708.x
   GRANT SM, 1992, DRUGS, V43, P889, DOI 10.2165/00003495 199243060 00008
   GRIMM J, 1991, ARCH ORTHOP TRAUM SU, V110, P98, DOI 10.1007/BF00393882
   Hofmann S, 2004, ORTHOP CLIN N AM, V35, P321, DOI 10.1016/j.ocl.2004.04.005
   HOFMANN S, 1993, J BONE JOINT SURG BR, V75, P210, DOI 10.1302/0301 620X.75B2.8444939
   KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349, DOI 10.1177/107110079401500701
   Lecouvet FE, 1998, AM J ROENTGENOL, V170, P71, DOI 10.2214/ajr.170.1.9423603
   MAMMI GI, 1993, CLIN ORTHOP RELAT R, P246
   Massari L, 2006, J BONE JOINT SURG AM, V88A, P56, DOI 10.2106/JBJS.F.00536
   Mayerhoefer ME, 2007, RHEUMATOLOGY, V46, P1460, DOI 10.1093/rheumatology/kem172
   Mont MA, 2004, CLIN ORTHOP RELAT R, P131, DOI 10.1097/01.blo.0000150128.57777.8e
   Muccioli GMM, 2013, EUR J RADIOL, V82, P530, DOI 10.1016/j.ejrad.2012.11.011
   SAVINI R, 1990, J BIOELECTRICITY, V9, P9, DOI 10.3109/15368379009027756
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Tonbul M, 2011, J AM PODIAT MED ASSN, V101, P430, DOI 10.7547/1010430
   TRAINA GC, 1991, J BIOELECTRICITY, V10, P101, DOI 10.3109/15368379109031402
   VANDEBERG BE, 1993, RADIOGRAPHICS, V13, P501, DOI 10.1148/radiographics.13.3.8316660
   Varani K, 2002, BRIT J PHARMACOL, V136, P57, DOI 10.1038/sj.bjp.0704695
   Zorzi C, 2007, KNEE SURG SPORT TR A, V15, P830, DOI 10.1007/s00167 007 0298 8
NR 28
TC 15
Z9 16
U1 0
U2 4
PU AMER PODIATRIC MED ASSOC
PI BETHESDA
PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814 1621 USA
SN 8750 7315
EI 1930 8264
J9 J AM PODIAT MED ASSN
JI J. Am. Podiatr. Med. Assoc.
PD JAN FEB
PY 2015
VL 105
IS 1
BP 27
EP 32
DI 10.7547/8750 7315 105.1.27
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA DA3CP
UT WOS:000367673800005
PM 25675223
DA 2025 08 17
ER

PT J
AU Corobea, MS
   Albu, MG
   Ion, R
   Cimpean, A
   Miculescu, F
   Antoniac, IV
   Raditoiu, V
   Sirbu, I
   Stoenescu, M
   Voicu, SI
   Ghica, MV
AF Corobea, Marijana Simina
   Albu, Madalina Georgiana
   Ion, Raluca
   Cimpean, Anisoara
   Miculescu, Florin
   Antoniac, Iulian Vasile
   Raditoiu, Valentin
   Sirbu, Ioan
   Stoenescu, Mihai
   Voicu, Stefan Ioan
   Ghica, Mihaela Violeta
TI Modification of titanium surface with collagen and doxycycline as a new
   approach in dental implants
SO JOURNAL OF ADHESION SCIENCE AND TECHNOLOGY
LA English
DT Article
DE titanium; collagen; doxycycline; drug delivery; osseointegration
ID IN VITRO; DELIVERY SYSTEMS; DRUG DELIVERY; RELEASE; OSSEOINTEGRATION;
   ALLOY; VIVO
AB In this work, we investigate for the first time several issues involved in bio adhesion process for a new type of chemically modified titanium surfaces (in their initial form and after collagen deposition), in order to assess their potential in dental implant surface modification. For this purpose, we studied the following: collagen adhesion, cytotoxicity, osteoblast cytomorphology, cell adhesion and proliferation, doxycycline embedding and modifications in the collagen film deposed on the metal surfaces, drug release from the collagen films. The improvement of adhesion between collagen film and titanium substrate, when hydroxyl and amino functional groups are assisting the surfaces was presented, all materials showing no cytotoxic effects as revealed by lactate dehydrogenase based assay. The drug release from titanium coll doxy systems offers a dual mechanism of the delivery profile (burst release followed by moderate discharge of the antibiotic), with perspectives in soft tissue recovery postoperative stage.
C1 [Corobea, Marijana Simina; Sirbu, Ioan; Stoenescu, Mihai] Carol Davila Univ Med & Pharm, Fac Med Dent, Bucharest 010209, Romania.
   [Albu, Madalina Georgiana] Leather & Footwear Res Inst, Collagen Dept, Bucharest 031215, Romania.
   [Ion, Raluca; Cimpean, Anisoara] Univ Bucharest, Dept Biochem & Mol Biol, Bucharest 050095, Romania.
   [Miculescu, Florin; Antoniac, Iulian Vasile] Univ Politehn Bucuresti, Fac Mat Sci & Engn, Bucharest 060042, Romania.
   [Raditoiu, Valentin] Natl Inst Res & Dev Chem & Petrochem, Bucharest 060021, Romania.
   [Voicu, Stefan Ioan] Univ Politehn Bucuresti, Fac Appl Chem & Mat Sci, Dept Analyt Chem & Environm Engn, Bucharest 011061, Romania.
   [Ghica, Mihaela Violeta] Carol Davila Univ Med & Pharm, Dept Phys Chem, Fac Pharm, Bucharest 020956, Romania.
C3 Carol Davila University of Medicine & Pharmacy; National Research &
   Development Institute Textiles & Leather INCDTP; University of
   Bucharest; National University of Science & Technology POLITEHNICA
   Bucharest; National Institute Research & Development in Chemistry &
   Petrochemistry; National University of Science & Technology POLITEHNICA
   Bucharest; University of Bucharest; Carol Davila University of Medicine
   & Pharmacy
RP Voicu, SI (通讯作者)，Univ Politehn Bucuresti, Fac Appl Chem & Mat Sci, Dept Analyt Chem & Environm Engn, 1 Polizu St, Bucharest 011061, Romania.
EM svoicu@gmail.com
RI Raditoiu, Valentin/C 4095 2011; Antoniac, Iulian/D 4802 2014; Ion,
   Rodica Mariana/B 2839 2008; Sirbu, Ioan/AAL 3741 2020; Cimpean,
   Anisoara/C 2101 2011; Ghica, Mihaela Violeta/ABH 1952 2021; Iulian,
   Antoniac/D 4802 2014; Voicu, Stefan/AAP 4984 2020; Miculescu,
   Florin/A 4524 2011
OI GHICA, Mihaela Violeta/0000 0001 6853 9203; Cimpean,
   Anisoara/0000 0002 5833 3110; Raditoiu, Valentin/0000 0002 7708 4420;
   Iulian, Antoniac/0000 0003 0112 3494; Miculescu,
   Florin/0000 0001 6757 5616; Ion, Raluca/0000 0001 9871 4981; Albu,
   Madalina Georgiana/0000 0001 9960 2244
FU 'Parteneriate in domenii prioritare   PNII'   MEN UEFISCDI [155/2014]
FX This work was supported by the 'Parteneriate in domenii prioritare  
   PNII', supported by MEN UEFISCDI [project no. 155/2014].
CR Aaron JE, 2012, FRONT ENDOCRINOL, V3, P1
   Albu MG, 2009, REV ROUM CHIM, V54, P373
   Alla RamaKrishna., 2011, Trends in Biomaterials Artificial Organs, V25, P112
   Barbaresso RC, 2014, CR CHIM, V17, P12, DOI 10.1016/j.crci.2013.07.007
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Branemark P. I., 1969, J PLAST RECONSTR SUR, V3, P81, DOI [10.3109/028443169090366994924041, DOI 10.3109/02844316909036699]
   Choi J, 2014, INT J NANOMED, V9, P5189, DOI 10.2147/IJN.S71304
   Chrcanovic BR, 2015, J DENT, V43, P16, DOI 10.1016/j.jdent.2014.11.007
   Corobea MS, 2014, DIG J NANOMATER BIOS, V9, P1339
   Esposito M, 2013, COCHRANE DB SYST REV, V7, P1
   Ghica MV, 2013, PHARMAZIE, V68, P340, DOI 10.1691/ph.2013.2101
   Guo CY, 2012, J ADHES SCI TECHNOL, V26, P189, DOI 10.1163/016942411X569390
   Heitz Mayfield LJA, 2008, J CLIN PERIODONTOL, V35, P292, DOI 10.1111/j.1600 051X.2008.01275.x
   Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168 3659(01)00248 6
   John V, 2007, AUST DENT J, V52, pS138, DOI 10.1111/j.1834 7819.2007.tb00521.x
   Lyndon JA, 2014, J CONTROL RELEASE, V179, P63, DOI 10.1016/j.jconrel.2014.01.026
   Metoki N, 2014, LANGMUIR, V30, P6791, DOI 10.1021/la404829b
   Nagai M, 2002, DENT MATER J, V21, P250, DOI 10.4012/dmj.21.250
   Roehlecke C, 2001, CELLS TISSUES ORGANS, V168, P178, DOI 10.1159/000047833
   Singh B, 2013, INT J PHARMACEUT, V457, P82, DOI 10.1016/j.ijpharm.2013.09.028
   Stadlinger B, 2013, EUR CELLS MATER, V25, P326, DOI 10.22203/eCM.v025a23
   Sung JH, 2010, INT J PHARMACEUT, V392, P232, DOI 10.1016/j.ijpharm.2010.03.024
   Sverzut AT, 2012, BIOMED MATER, V2012, P1
   Torabinejad M, 2015, J ENDODONT, V41, P1, DOI 10.1016/j.joen.2014.09.002
   Walter MS, 2014, DENT MATER, V30, P200, DOI 10.1016/j.dental.2013.11.006
   Yeo In Sung, 2014, Open Biomed Eng J, V8, P114, DOI 10.2174/1874120701408010114
NR 26
TC 35
Z9 35
U1 1
U2 94
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0169 4243
EI 1568 5616
J9 J ADHES SCI TECHNOL
JI J. Adhes. Sci. Technol.
PD DEC 2
PY 2015
VL 29
IS 23
BP 2537
EP 2550
DI 10.1080/01694243.2015.1073661
PG 14
WC Engineering, Chemical; Materials Science, Multidisciplinary; Mechanics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science; Mechanics
GA CQ5CL
UT WOS:000360620800003
DA 2025 08 17
ER

PT J
AU Plá, SMC
   D'Urso, A
   Fernández Sánchez, JF
   Colangelo, D
   Choquesillo Lazarte, D
   Ferracini, R
   Bosetti, M
   Prat, M
   Gómez Morales, J
AF Cano Pla, Sandra Maria
   D'Urso, Annarita
   Fernandez Sanchez, Jorge Fernando
   Colangelo, Donato
   Choquesillo Lazarte, Duane
   Ferracini, Riccardo
   Bosetti, Michela
   Prat, Maria
   Gomez Morales, Jaime
TI Biomimetic Citrate Coated Luminescent Apatite Nanoplatforms for
   Diclofenac Delivery in Inflammatory Environments
SO NANOMATERIALS
LA English
DT Article
DE inflammation treatment; diclofenac loaded nanoparticles; apatite;
   Tb3+ doped apatite; luminescence; cytocompatibility
ID HYDROXYAPATITE NANOPARTICLES; ADSORPTION; PH; CRYSTALLIZATION; IONS;
   CYTOCOMPATIBILITY; CYCLOOXYGENASE 2; NANOCRYSTALS; DOXORUBICIN;
   MECHANISM
AB Luminescent nanoparticles are innovative tools for medicine, allowing the imaging of cells and tissues, and, at the same time, carrying and releasing different types of molecules. We explored and compared the loading/release ability of diclofenac (COX 2 antagonist), in both undoped  and luminescent Terbium(3+) (Tb3+) doped citrate coated carbonated apatite nanoparticles at different temperatures (25, 37, 40 degrees C) and pHs (7.4, 5.2). The cytocompatibility was evaluated on two osteosarcoma cell lines and primary human osteoblasts. Biological effects of diclofenac loaded nanoparticles were monitored in an in vitro osteoblast's cytokine induced inflammation model by evaluating COX 2 mRNA expression and production of PGE(2). Adsorption isotherms fitted the multilayer Langmuir Freundlich model. The maximum adsorbed amounts at 37 degrees C were higher than at 25 degrees C, and particularly when using the Tb3+  doped particles. Diclofenac release efficiencies were higher at pH 5.2, a condition simulating a local inflammation. The luminescence properties of diclofenac loaded Tb3+  doped particles were affected by pH, being the relative luminescence intensity higher at pH 5.2 and the luminescence lifetime higher at pH 7.4, but not influenced either by the temperature or by the diclofenac loaded amount. Both undoped and Tb3+ doped nanoparticles were cytocompatible. In addition, diclofenac release increased COX 2 mRNA expression and decreased PGE(2) production in an in vitro inflammation model. These findings evidence the potential of these nanoparticles for osteo localized delivery of anti inflammatory drugs and the possibility to localize the inflammation, characterized by a decrease in pH, by changes in luminescence.
C1 [Cano Pla, Sandra Maria; Choquesillo Lazarte, Duane; Gomez Morales, Jaime] IACT, Lab Estudios Cristalog, Avda Palmeras 4, Granada 18100, Spain.
   [D'Urso, Annarita; Colangelo, Donato; Prat, Maria] Univ Piemonte Orientale, Dipartimento Sci Salute, A Avogadro Via Solaroli 17, I 28100 Novara, Italy.
   [Fernandez Sanchez, Jorge Fernando] Univ Granada, Dept Analyt Chem, Fac Sci, Avda Fuentenueva S N, Granada 18071, Spain.
   [Ferracini, Riccardo] Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate, Viale Benedetto 15 6, I 16132 Genoa, Italy.
   [Ferracini, Riccardo] Osped Koelliker, Corso Galileo Ferraris 247 255, I 10134 Turin, Italy.
   [Bosetti, Michela] Univ Piemonte Orientale, Via Bovio 4, I 28100 Novara, Italy.
   [Prat, Maria] Ctr Biotecnol Ric Med Applicata BRMA, Via Solaroli 17, I 28100 Novara, Italy.
   [Prat, Maria] Consorzio Interuniv Biotecnol CIB, Local Padriciano 99, I 34149 Area Riccerca, Italy.
   [Prat, Maria] Consorzio Interuniv Nazl Sci & Tecnol Mat INSTM, Via Giuseppe Giusti 9, I 50121 Florence, Italy.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Instituto
   Andaluz de Ciencias de la Tierra (IACT); University of Eastern Piedmont
   Amedeo Avogadro; University of Granada; University of Genoa; University
   of Eastern Piedmont Amedeo Avogadro
RP Gómez Morales, J (通讯作者)，IACT, Lab Estudios Cristalog, Avda Palmeras 4, Granada 18100, Spain.; Prat, M (通讯作者)，Univ Piemonte Orientale, Dipartimento Sci Salute, A Avogadro Via Solaroli 17, I 28100 Novara, Italy.; Prat, M (通讯作者)，Ctr Biotecnol Ric Med Applicata BRMA, Via Solaroli 17, I 28100 Novara, Italy.; Prat, M (通讯作者)，Consorzio Interuniv Biotecnol CIB, Local Padriciano 99, I 34149 Area Riccerca, Italy.; Prat, M (通讯作者)，Consorzio Interuniv Nazl Sci & Tecnol Mat INSTM, Via Giuseppe Giusti 9, I 50121 Florence, Italy.
EM sandra@lec.csic.es; annarita.durso@med.uniupo.it; jffernan@ugr.es;
   donato.colangelo@med.uniupo.it; duane.choquesillo@csic.es;
   ferracini@edu.unige.it; michela.bosetti@uniupo.it;
   maria.prat@med.uniupo.it; jaime@lec.csic.es
RI Gómez Morales, Jaime/M 3985 2014; Ferracini, Riccardo/AAL 4622 2020;
   Colangelo, Donato/ABB 2772 2020; Lazarte, Duane/D 3090 2014; Prat,
   Maria/AAG 5905 2020; Choquesillo Lazarte, Duane/D 3090 2014; D'Urso,
   Annarita/LWI 6963 2024; Bosetti, Michela/AAR 9556 2021; Gomez Morales,
   Jaime/M 3985 2014; Fernandez Sanchez, Jorge/B 6086 2017
OI Colangelo, Donato/0000 0003 2277 3226; Prat, Maria/0000 0003 0262 9729;
   Fernandez Sanchez, Jorge/0000 0002 6181 2833; Ferracini,
   Riccardo/0000 0001 7654 0327; Choquesillo Lazarte,
   Duane/0000 0002 7077 8972; Bosetti, Michela/0000 0002 3682 8702; D'URSO,
   ANNARITA/0000 0002 8290 9677; Gomez Morales, Jaime/0000 0002 9395 7797; 
FU Spanish Agencia Estatal de Investigacion (AEI) of the Ministerio de
   Ciencia e Innovacion (MCI); FEDER, UE [PGC2018 102047 B I00]
FX This research was funded by Spanish Agencia Estatal de Investigacion
   (AEI) of the Ministerio de Ciencia e Innovacion (MCI) and co funded with
   FEDER, UE, Project No. PGC2018 102047 B I00 (MCIU/AEI/FEDER, UE). M.P.
   acknowledges the Progetto di Ricerca Fondi di Ateneo per la Ricerca FAR
   2018 "Development of innovative biological materials for the functional
   regeneration of cardiac tissue models".
CR Abbas A.M.B., 2018, IRAQI J CHEM PET ENG, V19, P29
   ADAMSON AW, 1967, PHYS CHEM SURFACES
   Agotegaray M, 2014, J NANOSCI NANOTECHNO, V14, P3343, DOI 10.1166/jnn.2014.8256
   Ain Q, 2019, J BIOMED MATER RES A, V107, P2595, DOI 10.1002/jbm.a.36765
   Al Lawati H, 2020, MOL PHARMACEUT, V17, P1377, DOI 10.1021/acs.molpharmaceut.0c00069
   Arias JL, 2010, COLLOID SURFACE B, V75, P204, DOI 10.1016/j.colsurfb.2009.08.032
   Azizian S., 2021, Interface Science and Technology, V33, P445, DOI [DOI 10.1016/B978 0 12 818805 7.00011 4, 10.1016/B978 0 12818805 7.00011 4, DOI 10.1016/B978 0 12818805 7.00011 4]
   Ramírez Rodríguez GB, 2013, CRYSTENGCOMM, V15, P2206, DOI 10.1039/c2ce26556g
   Bosetti M, 2010, J CELL PHYSIOL, V225, P466, DOI 10.1002/jcp.22225
   Bystrova AV, 2015, FERROELECTRICS, V475, P135, DOI 10.1080/00150193.2015.995580
   Chen MH, 2014, SCI TECHNOL ADV MAT, V15, DOI 10.1088/1468 6996/15/5/055005
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cohen Y, 2020, ACS APPL BIO MATER, V3, P2209, DOI 10.1021/acsabm.0c00048
   Curtis EM, 2016, CLIN MED, V16, P360, DOI 10.7861/clinmedicine.16 4 360
   Ding ZZ, 2016, J MATER CHEM B, V4, P3555, DOI 10.1039/c6tb00509h
   Dutta B, 2021, ADV COLLOID INTERFAC, V296, DOI 10.1016/j.cis.2021.102509
   Etter EL, 2021, ADV DRUG DELIVER REV, V179, DOI 10.1016/j.addr.2021.113994
   Fasolino I, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10091743
   Fenton OS, 2018, ADV MATER, V30, DOI 10.1002/adma.201705328
   Fornai M, 2005, GUT, V54, P608, DOI 10.1136/gut.2004.053322
   Gan TJ, 2010, CURR MED RES OPIN, V26, P1715, DOI 10.1185/03007995.2010.486301
   Gera S, 2017, CURR DRUG DELIV, V14, P904, DOI 10.2174/1567201813666161230142123
   Gómez Morales J, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11020322
   Gómez Morales J, 2019, J COLLOID INTERF SCI, V538, P174, DOI 10.1016/j.jcis.2018.11.083
   Gómez Morales J, 2013, PROG CRYST GROWTH CH, V59, P1, DOI 10.1016/j.pcrysgrow.2012.11.001
   Gouda AA, 2013, ARAB J CHEM, V6, P145, DOI 10.1016/j.arabjc.2010.12.006
   Grässel S, 2021, J CLIN MED, V10, DOI 10.3390/jcm10091938
   Hanninen P., 2011, LANTHANIDE LUMINESCE, DOI [10.1007/978 3 642 21023 5, DOI 10.1007/978 3 642 21023 5]
   Haque ST, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186721
   HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003 2697(84)90095 2
   Hu YY, 2010, P NATL ACAD SCI USA, V107, P22425, DOI 10.1073/pnas.1009219107
   Hughes FJ, 1999, J BIOL CHEM, V274, P1776, DOI 10.1074/jbc.274.3.1776
   Iafisco M, 2013, SMALL, V9, P3834, DOI 10.1002/smll.201202843
   ISO, 2009, 109935 ISO, P34
   Jabalera Y, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10020199
   Jelinkova P, 2019, J CONTROL RELEASE, V307, P166, DOI 10.1016/j.jconrel.2019.06.013
   Kaur A, 2020, TRAC TREND ANAL CHEM, V123, DOI 10.1016/j.trac.2019.115777
   Khalifehzadeh R, 2020, ADV COLLOID INTERFAC, V279, DOI 10.1016/j.cis.2020.102157
   Kolodziejska Justyna, 2018, Reumatologia (Warsaw), V56, P174, DOI 10.5114/reum.2018.76816
   Lakowicz J. R., 2006, Principles of Fluorescence Spectroscopy, P27, DOI [DOI 10.1007/978 0 387 46312 4, DOI 10.1007/978 0 387 46312 4_21]
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Larous S, 2016, INT J HYDROGEN ENERG, V41, P10380, DOI 10.1016/j.ijhydene.2016.01.096
   Liu DD, 2014, J BIOL INORG CHEM, V19, P879, DOI 10.1007/s00775 014 1119 4
   Lopez Macipe A, 1998, J COLLOID INTERF SCI, V200, P114, DOI 10.1006/jcis.1997.5343
   Low KL, 2010, J BIOMED MATER RES B, V94B, P273, DOI 10.1002/jbm.b.31619
   Macedo LD, 2021, EUR J PHARM SCI, V158, DOI 10.1016/j.ejps.2020.105654
   Delgado López JM, 2012, ACTA BIOMATER, V8, P3491, DOI 10.1016/j.actbio.2012.04.046
   Medina Velazquez DY, 2019, OPT MATER, V87, P3, DOI 10.1016/j.optmat.2018.08.021
   Munir MU, 2021, ARTIF CELL NANOMED B, V49, P717, DOI 10.1080/21691401.2021.2016785
   Oltolina F, 2015, LANGMUIR, V31, P1766, DOI 10.1021/la503747s
   Ozawa T, 2013, ANAL CHEM, V85, P590, DOI 10.1021/ac3031724
   Pereira MBB, 2020, CARBOHYD POLYM, V236, DOI 10.1016/j.carbpol.2020.116036
   Pietrzykowska E, 2022, MATERIALS, V15, DOI 10.3390/ma15010184
   Rainsford K. D., 1999, American Journal of Medicine, V107, p27S
   REED BE, 1993, SEP SCI TECHNOL, V28, P2179, DOI 10.1080/01496399308016742
   RICHARDSON FS, 1982, CHEM REV, V82, P541, DOI 10.1021/cr00051a004
   Roato I, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4126379
   Rodríguez Ruiz I, 2013, LANGMUIR, V29, P8213, DOI 10.1021/la4008334
   Rojas A, 2019, EXPERT OPIN THER TAR, V23, P1, DOI 10.1080/14728222.2019.1554056
   Romero Castillo I, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202000319
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Shang HB, 2014, RSC ADV, V4, P53122, DOI 10.1039/c4ra09902h
   Sidney LE, 2015, TISSUE ENG PT A, V21, P362, DOI [10.1089/ten.tea.2014.0100, 10.1089/ten.TEA.2014.0100]
   Subramaniam S, 2021, ADV DRUG DELIVER REV, V177, DOI 10.1016/j.addr.2021.113948
   Do TNT, 2012, THER DELIV, V3, P623, DOI 10.4155/TDE.12.39
   van der Meel R, 2019, NAT NANOTECHNOL, V14, P1007, DOI 10.1038/s41565 019 0567 y
   Wang YN, 2019, J MATER CHEM B, V7, P538, DOI 10.1039/c8tb02679c
   Wong CY, 2017, J CONTROL RELEASE, V264, P247, DOI 10.1016/j.jconrel.2017.09.003
   Zamperone A, 2013, STEM CELLS DEV, V22, P2873, DOI 10.1089/scd.2012.0718
   Zhang YX, 2018, NANOMED NANOTECHNOL, V14, P353, DOI 10.1016/j.nano.2017.11.012
NR 70
TC 11
Z9 11
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4991
J9 NANOMATERIALS BASEL
JI Nanomaterials
PD FEB
PY 2022
VL 12
IS 3
AR 562
DI 10.3390/nano12030562
PG 23
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA ZG3AG
UT WOS:000760130900001
PM 35159907
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pan, SN
   Chen, AL
   Han, ZH
   Wang, YL
   Lu, X
   Yang, YX
AF Pan, Sina
   Chen, Ali
   Han, Zhihui
   Wang, Yaling
   Lu, Xin
   Yang, Yongxia
TI <SUP>1</SUP>H NMR based metabonomic study on the effects of Epimedium on
   glucocorticoid induced osteoporosis
SO JOURNAL OF CHROMATOGRAPHY B ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE Metabonomics; Osteoporosis; Epimedium; H 1 NMR; Multivariate data
   analysis
ID BONE MINERAL DENSITY; RHIZOMA DRYNARIAE; DIETARY TAURINE;
   DIFFERENTIATION; EXTRACT; APOPTOSIS; SUPPLEMENTATION; OSTEOBLASTS;
   CORTISOL; RATS
AB Glucocorticoids are widely used in clinical practice for the treatment of many immune mediated and inflammatory diseases, and glucocorticoid induced osteoporosis (GIO) is the most common type of secondary osteoporosis. Epimedium is one of the most commonly used traditional Chinese medicines for treating osteoporosis. In the present study, we systematically analysed the metabonomic characteristics of GIO model rats and elucidated the therapeutic effect of Epimedium by using a H 1 NMR based metabonomic approach in conjunction with multivariate data analysis. Rats in treatment and model groups were injected with dexamethasone (0.1 mg/kg/day) for 5 weeks. Simultaneously, two treatment groups were orally administered Epimedium (10 g/kg/day) or Alendronate (1.2 mg/kg/day) for 5 weeks. In GIO model rats, lipid and lactate levels in serum were increased, while creatine/creatinine, PC/GPC, taurine, glycine and beta glucose levels were decreased. In urine, GIO rats had higher levels of phenylacetylglycine but lower levels of 2 oxoglutarate, citrate, creatine/creatinine, taurine, PC/GPC and hippurate than controls. Epimedium reversed the aforementioned metabolic alterations in multiple metabolic pathways involved in energy, lipid, amino acid and phospholipid metabolism and gut microbiota derangement. Our results indicated that Epimedium had significant effects in the prevention and treatment of osteoporosis. It is concluded that(1)H NMR metabonomics is a useful method for studying the metabolic effects of traditional Chinese medicine from a systematic and holistic view. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Pan, Sina; Han, Zhihui; Wang, Yaling; Lu, Xin; Yang, Yongxia] Guangdong Pharmaceut Univ, Sch Basic Courses, Guangzhou 510006, Guangdong, Peoples R China.
   [Pan, Sina; Han, Zhihui; Wang, Yaling] Guangdong Pharmaceut Univ, Dept Tradit Chinese Med, Guangzhou 510006, Guangdong, Peoples R China.
   [Chen, Ali] Guangdong Pharmaceut Univ, Sch Med & Chem Ind, Guangzhou 510006, Guangdong, Peoples R China.
C3 Guangdong Pharmaceutical University; Guangdong Pharmaceutical
   University; Guangdong Pharmaceutical University
RP Yang, YX (通讯作者)，Guangdong Pharmaceut Univ, Sch Basic Courses, Guangzhou 510006, Guangdong, Peoples R China.
EM sheepma@163.com
FU Science and Technology Planning Project of Guangdong Province
   [2015A020211033, 2016A030303062]
FX We acknowledge the financial supports from the Science and Technology
   Planning Project of Guangdong Province (no. 2015A020211033,
   2016A030303062).
CR Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Chao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096969
   Chen SY, 2015, J NUTR BIOCHEM, V26, P696, DOI 10.1016/j.jnutbio.2015.01.006
   Chen SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106559
   Chen WF, 2011, BRIT J NUTR, V105, P180, DOI 10.1017/S0007114510003247
   Choi MJ, 2013, ADV EXP MED BIOL, V776, P335, DOI 10.1007/978 1 4614 6093 0_31
   Choi MJ, 2009, ADV EXP MED BIOL, V643, P341, DOI 10.1007/978 0 387 75681 3_35
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Lucinda LMF, 2013, PHYTOTHER RES, V27, P515, DOI 10.1002/ptr.4747
   Gennari L, 2015, EXPERT OPIN DRUG DIS, V10, P1201, DOI 10.1517/17460441.2015.1080685
   Huang Y, 2014, BIOMED CHROMATOGR, V28, P878, DOI 10.1002/bmc.3194
   Jeon SH, 2007, FEBS LETT, V581, P5929, DOI 10.1016/j.febslet.2007.11.035
   Jiang CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066786
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu Yi Heng, 2006, Zhongguo Zhong Yao Za Zhi, V31, P487
   Lu XM, 2011, TALANTA, V83, P700, DOI 10.1016/j.talanta.2010.09.026
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Moghadam Kia S, 2010, INT J DERMATOL, V49, P239, DOI 10.1111/j.1365 4632.2009.04322.x
   Monteiro N, 2014, J INT AIDS SOC, V17, P52, DOI 10.7448/IAS.17.4.19565
   NICHOLSON JK, 1995, ANAL CHEM, V67, P793, DOI 10.1021/ac00101a004
   Pechlivanis A, 2010, J PROTEOME RES, V9, P6405, DOI 10.1021/pr100684t
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Pozzi S, 2007, LEUKEMIA LYMPHOMA, V48, P56, DOI 10.1080/10428190600977690
   Psihogios NG, 2008, NMR BIOMED, V21, P195, DOI 10.1002/nbm.1176
   Ren ZZ, 2013, BIOL TRACE ELEM RES, V152, P396, DOI 10.1007/s12011 013 9634 7
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   Wallimann T, 2011, AMINO ACIDS, V40, P1271, DOI 10.1007/s00726 011 0877 3
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang Q. P., 2001, Foreign Medicine, V21, P451
   Wei L, 2009, TOXICOL APPL PHARM, V234, P314, DOI 10.1016/j.taap.2008.11.010
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wu B, 2008, MOL BIOSYST, V4, P855, DOI 10.1039/b800923f
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   [叶纯 YE Chun], 2008, [中国临床解剖学杂志, Chinese Journal of Clinical Anatomy], V26, P87
   Zhang DW, 2012, BIOCHIMIE, V94, P2514, DOI 10.1016/j.biochi.2012.06.033
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhao YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059617
NR 42
TC 23
Z9 28
U1 4
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570 0232
EI 1873 376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD DEC 1
PY 2016
VL 1038
BP 118
EP 126
DI 10.1016/j.jchromb.2016.10.015
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EC3YS
UT WOS:000388063600016
PM 27810280
DA 2025 08 17
ER

PT J
AU Griebeler, ML
   Kearns, AE
   Ryu, E
   Hathcock, MA
   Melton, LJ
   Wermers, RA
AF Griebeler, Marcio L.
   Kearns, Ann E.
   Ryu, Euijung
   Hathcock, Matthew A.
   Melton, L. Joseph, III
   Wermers, Robert A.
TI Secular trends in the incidence of primary hyperparathyroidism over five
   decades (1965 2010)
SO BONE
LA English
DT Article
DE Primary hyperparathyroidism; Hypercalcemia; Osteoporosis; Epidemiology;
   Incidence
ID ROCHESTER EPIDEMIOLOGY PROJECT; MEDICAL RECORDS LINKAGE; POSTMENOPAUSAL
   HORMONE THERAPY; CALCIUM INTAKE; INCREASING INCIDENCE; THYROID CANCER;
   UNITED STATES; POPULATION; WOMEN; OSTEOPOROSIS
AB Introduction of automated serum calcium measurements in the 1970s resulted in a sharp rise in primary hyperparathyroidism (PHPT) incidence. However, recent investigations suggest a significant rise in PHPT incidence for unclear reasons. Our objective was to update our population based secular trends in PHPT incidence, to determine if there has been a significant rise in PHPT incidence as suggested by others, and, if possible, to identify changes in clinical practice that might be responsible. Rochester, Minnesota, residents who met the criteria for PHPT from 2002 through 2010 were identified through the medical records linkage system of the Rochester Epidemiology Project and added to the historical cohort beginning in 1965. Incidence rates were adjusted to the 2010 US white population. Altogether, 1142 Rochester residents have been diagnosed with PHPT since 1965, including 341 in 2002 2010. Over time, two periods of increased PHPT incidence occurred, one beginning in 1974 (121.7 per 100,000 person years) and a second peak (86.2 per 100,000 person years) starting in 1998. The median age of PHPT subjects has increased significantly from 55 years in 1985 1997 to 60 years of age in 1998 2010 and more patients (36%) had a parathyroidectomy in 1998 2010. Although serum calcium measurement has declined since 1996, there was a progressive increase in parathyroid hormone testing between 1994 and 2008. There was also a rise in orders for bone mineral density measurements in women since 1998, which peaked in 2003 2004. A second sharp rise in PHPT incidence occurred in our community in 1998, simultaneously with the introduction of national osteoporosis screening guidelines, Medicare coverage for bone density measurement, and new medications for the treatment of osteoporosis. Case ascertainment bias from targeted PHPT screening in patients being evaluated for osteoporosis is the most likely explanation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Griebeler, Marcio L.; Kearns, Ann E.; Wermers, Robert A.] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Dept Med, Rochester, MN 55905 USA.
   [Ryu, Euijung; Hathcock, Matthew A.] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA.
   [Melton, L. Joseph, III] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Wermers, RA (通讯作者)，Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Dept Med, 200 First St SW, Rochester, MN 55905 USA.
EM wermers.robert@mayo.edu
RI Griebeler, Marcio/AAN 9987 2021
FU National Institute on Aging [R01AG034676]
FX This study was made possible using the resources of the Rochester
   Epidemiology Project, which is supported by the National Institute on
   Aging (R01AG034676). The content is solely the responsibility of the
   authors and does not necessarily represent official views of the
   National Institutes of Health.
CR Abood A, 2013, DAN MED J, V60
   [Anonymous], 1997, Precision Agriculture in the 21st Century: Geospatial and Information Technologies in Crop Management, DOI [DOI 10.17226/5491, 10.17226/5491]
   Bailey RL, 2010, J NUTR, V140, P817, DOI 10.3945/jn.109.118539
   Bilezikian JP, 2002, J BONE MINER RES, V17, pN2
   Bolland MJ, 2005, J CLIN ENDOCR METAB, V90, P1525, DOI 10.1210/jc.2004 1891
   Davies L, 2006, JAMA J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164
   Farley JF, 2009, AM J HEALTH SYST PH, V66, P1191, DOI 10.2146/ajhp080248
   Fraser WD, 2009, LANCET, V374, P145, DOI 10.1016/S0140 6736(09)60507 9
   Grey A, 2005, J CLIN ENDOCR METAB, V90, P2122, DOI 10.1210/jc.2004 1772
   Haas JS, 2004, ANN INTERN MED, V140, P184, DOI 10.7326/0003 4819 140 3 200402030 00009
   HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402
   Hersh AL, 2004, JAMA J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47
   INSOGNA KL, 1985, NEW ENGL J MED, V313, P1126, DOI 10.1056/NEJM198510313131805
   Jaglal SB, 2000, CAN MED ASSOC J, V163, P1139
   Jorde R, 2000, J CLIN EPIDEMIOL, V53, P1164, DOI 10.1016/S0895 4356(00)00239 0
   KHOSLA S, 1993, J CLIN ENDOCR METAB, V76, P715, DOI 10.1210/jc.76.3.715
   Leenhardt L, 2004, EUR J ENDOCRINOL, V150, P133, DOI 10.1530/eje.0.1500133
   Mangano KM, 2011, J AM DIET ASSOC, V111, P687, DOI 10.1016/j.jada.2011.02.014
   MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003 4819 100 5 633
   Melton LJ, 2002, J BONE MINER RES, V17, pN12
   Paik JM, 2012, BMJ BRIT MED J, V345, DOI 10.1136/bmj.e6390
   Rao DS, 2000, J CLIN ENDOCR METAB, V85, P1054, DOI 10.1210/jc.85.3.1054
   Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195
   St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482
   Stafford RS, 2004, ARCH INTERN MED, V164, P1525, DOI 10.1001/archinte.164.14.1525
   Tannenbaum C, 2002, J CLIN ENDOCR METAB, V87, P4431, DOI 10.1210/jc.2002 020275
   TOHME JF, 1990, J CLIN ENDOCR METAB, V70, P951, DOI 10.1210/jcem 70 4 951
   Wermers RA, 2006, J BONE MINER RES, V21, P171, DOI 10.1359/JBMR.050910
   Wermers RA, 1997, ANN INTERN MED, V126, P433, DOI 10.7326/0003 4819 126 6 199703150 00003
   Yeh MW, 2013, J CLIN ENDOCR METAB, V98, P1122, DOI 10.1210/jc.2012 4022
   Yoo JW, 2012, J WOMENS HEALTH, V21, P1144, DOI 10.1089/jwh.2012.3517
   Yu N, 2009, CLIN ENDOCRINOL, V71, P485, DOI 10.1111/j.1365 2265.2008.03520.x
NR 34
TC 114
Z9 121
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2015
VL 73
BP 1
EP 7
DI 10.1016/j.bone.2014.12.003
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CC7FJ
UT WOS:000350532800001
PM 25497786
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cheung, MC
   Kao, PLH
   Lee, N
   Sivathasan, D
   Vong, CW
   Zhu, J
   Polster, A
   Darby, I
AF Cheung, M. C.
   Kao, P. L. H.
   Lee, N.
   Sivathasan, D.
   Vong, C. W.
   Zhu, J.
   Polster, A.
   Darby, I.
TI Interest in dental implantology and preferences for implant therapy: a
   survey of Victorian dentists
SO AUSTRALIAN DENTAL JOURNAL
LA English
DT Article
DE Dental implants; implant training; questionnaire; survey; treatment
   preferences
ID PARTIALLY EDENTULOUS PATIENTS; OF THE LITERATURE; FOLLOW UP;
   PERI IMPLANTITIS; COMPLICATION RATES; PERIODONTAL CARE; SINGLE CROWNS;
   BONE LOSS; PRACTITIONERS; DISEASE
AB BackgroundThe purpose of this study was to gauge dentists' interest, knowledge and training in implantology, and to compare their treatment preferences with current literature. Subsequently, this information may be used to evaluate implantology education pathways.
   MethodsA cross sectional postal survey of 600 randomly selected dentists registered with the Dental Practice Board of Victoria was conducted. Respondents were asked about background, interest and training in implantology, and implant treatment preferences. Results were analysed according to primary practice location, decade of graduation and attendance at continuing professional development (CPD) programmes.
   ResultsOne hundred and seventy six questionnaires were included for analysis. In general, dentists rate their implant knowledge, interest and enjoyment in restoring implants favourably. No differences were found between city and country practitioners, and different graduation decades. The level of CPD significantly influenced treatment preferences. Practitioners were generally unwilling to treat patients taking bisphosphonates, or to perform grafting procedures. Most dentists provide common services to treat peri implant conditions. Direct to fixture is the most popular fixture abutment connection.
   ConclusionsOverall, there is a high level of implant knowledge corresponding to current evidence in the literature. Level of CPD attendance is the most important factor in dentists' willingness to provide more implant therapy options.
C1 [Cheung, M. C.; Kao, P. L. H.; Lee, N.; Sivathasan, D.; Vong, C. W.; Zhu, J.; Polster, A.; Darby, I.] Univ Melbourne, Melbourne Dent Sch, Melbourne, Vic 3010, Australia.
C3 University of Melbourne
RP Darby, I (通讯作者)，Univ Melbourne, Melbourne Dent Sch, Periodont, 720 Swanston St, Carlton, Vic 3052, Australia.
EM idarby@unimelb.edu.au
OI Cheung, Monique/0000 0001 5326 3048
FU Melbourne Dental School, The University of Melbourne, Victoria
FX We gratefully acknowledge the support of the Melbourne Dental School,
   The University of Melbourne, Victoria.
CR Aghaloo TL, 2007, INT J ORAL MAX IMPL, V22, P49
   American Dental Association, 2008, 2007 SURV CURR ISS D
   Andersen E, 2001, INT J ORAL MAX IMPL, V16, P217
   [Anonymous], THESIS
   [Anonymous], 2007, 2005 06 SURV DENT SE
   Bornstein MM, 2009, INT J ORAL MAX IMPL, V24, P12
   Brennan D, 2007, AUST J RURAL HEALTH, V15, P189, DOI 10.1111/j.1440 1584.2007.00883.x
   Costa FO, 2012, J CLIN PERIODONTOL, V39, P173, DOI 10.1111/j.1600 051X.2011.01819.x
   Curran Vernon R, 2006, Aust J Rural Health, V14, P51, DOI 10.1111/j.1440 1584.2006.00763.x
   Darby IB, 2005, AUST DENT J, V50, P37, DOI 10.1111/j.1834 7819.2005.tb00083.x
   Ferreira SD, 2006, J CLIN PERIODONTOL, V33, P929, DOI 10.1111/j.1600 051X.2006.01001.x
   Flemmig TF, 2013, PERIODONTOL 2000, V62, P287, DOI 10.1111/prd.12009
   Gibson RL, 2006, BRIT DENT J, V201, P367, DOI 10.1038/sj.bdj.4814043
   Heitz Mayfield LJA, 2008, J CLIN PERIODONTOL, V35, P292, DOI 10.1111/j.1600 051X.2008.01275.x
   Heitz Mayfield LJA, 2004, INT J ORAL MAX IMPL, V19, P128
   Hill P, 1996, Aust J Rural Health, V4, P275, DOI 10.1111/j.1440 1584.1996.tb00223.x
   Hopcraft MS, 2008, AUST DENT J, V53, P133, DOI 10.1111/j.1834 7819.2008.00022.x
   Hultin M, 2007, CLIN ORAL IMPLAN RES, V18, P50, DOI 10.1111/j.1600 0501.2007.01447.x
   Ivanovski S, 2010, AUST DENT J, V55, P339, DOI 10.1111/j.1834 7819.2010.01247.x
   Jung RE, 2008, CLIN ORAL IMPLAN RES, V19, P119, DOI 10.1111/j.1600 0501.2007.01453.x
   Jung RE, 2012, CLIN ORAL IMPLAN RES, V23, P2, DOI 10.1111/j.1600 0501.2012.02547.x
   Karoussis IK, 2007, CLIN ORAL IMPLAN RES, V18, P669, DOI 10.1111/j.1600 0501.2007.01406.x
   Klokkevold PR, 2007, INT J ORAL MAX IMPL, V22, P173
   Kotsovilis S, 2006, CLIN ORAL IMPLAN RES, V17, P587, DOI 10.1111/j.1600 0501.2005.01245.X
   Kruger Estie, 2005, Aust J Rural Health, V13, P321, DOI 10.1111/j.1440 1584.2005.00724.x
   Lambert P M, 2000, Ann Periodontol, V5, P79, DOI 10.1902/annals.2000.5.1.79
   Lee JCY, 2012, CLIN ORAL IMPLAN RES, V23, P325, DOI 10.1111/j.1600 0501.2011.02264.x
   Lewis MB, 2011, AUST DENT J, V56, P181, DOI 10.1111/j.1834 7819.2011.01322.x
   Lindquist LW, 1997, J DENT RES, V76, P1667, DOI 10.1177/00220345970760100801
   Louropoulou A, 2014, J EVID BASED DENT PR, V14, P60, DOI 10.1016/j.jebdp.2014.03.008
   Maalhagh Fard Ahmad, 2002, J Prosthodont, V11, P202, DOI 10.1053/jpro.2002.126726
   Mattheos N, 2010, AUST DENT J, V55, P333, DOI 10.1111/j.1834 7819.2010.01246.x
   Mattheos N, 2010, AUST DENT J, V55, P329, DOI 10.1111/j.1834 7819.2010.01245.x
   Michalakis KX, 2003, INT J ORAL MAX IMPL, V18, P719
   Mombelli A, 2012, CLIN ORAL IMPLAN RES, V23, P67, DOI 10.1111/j.1600 0501.2012.02541.x
   Moy PK, 2005, INT J ORAL MAX IMPL, V20, P569
   Ng PCH, 2011, IMPLANT DENT, V20, P95, DOI 10.1097/ID.0b013e31820031fa
   Quirynen M, 2007, J CLIN PERIODONTOL, V34, P805, DOI 10.1111/j.1600 051X.2007.01106.x
   Reid D, 2004, NZ DENT J, V101, P12
   Rinke S, 2011, CLIN ORAL IMPLAN RES, V22, P826, DOI 10.1111/j.1600 0501.2010.02061.x
   Robertson PB, 2002, PERIODONTOL 2000, V30, P104, DOI 10.1034/j.1600 0757.2002.03010.x
   Roccuzzo M, 2010, CLIN ORAL IMPLAN RES, V21, P490, DOI 10.1111/j.1600 0501.2009.01886.x
   Roos Jansåker AM, 2006, J CLIN PERIODONTOL, V33, P290, DOI 10.1111/j.1600 051X.2006.00906.x
   Roos Jansåker AM, 2003, J CLIN PERIODONTOL, V30, P467, DOI 10.1034/j.1600 051X.2003.00296.x
   Sailer I, 2012, CLIN ORAL IMPLAN RES, V23, P163, DOI 10.1111/j.1600 0501.2012.02538.x
   Sambrook RJ, 2012, AUST DENT J, V57, P409, DOI 10.1111/j.1834 7819.2012.01731.x
   Scully Crispian, 2006, Implant Dent, V15, P212, DOI 10.1097/01.id.0000236120.22719.02
   Serino G, 2009, CLIN ORAL IMPLAN RES, V20, P169, DOI 10.1111/j.1600 0501.2008.01627.x
   Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
   Wennström JL, 2004, J CLIN PERIODONTOL, V31, P713, DOI 10.1111/j.1600 051X.2004.00568.x
   Wilcox C W, 1997, J Prosthodont, V6, P61, DOI 10.1111/j.1532 849X.1997.tb00066.x
   Wilson TG, 1999, J PERIODONTOL, V70, P724, DOI 10.1902/jop.1999.70.7.724
   Wilson TG, 2009, J PERIODONTOL, V80, P1388, DOI 10.1902/jop.2009.090115
NR 53
TC 8
Z9 8
U1 1
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0045 0421
EI 1834 7819
J9 AUST DENT J
JI Aust. Dent. J.
PD DEC
PY 2016
VL 61
IS 4
BP 455
EP 463
DI 10.1111/adj.12411
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EF9QK
UT WOS:000390664500010
PM 26800641
OA Bronze
DA 2025 08 17
ER

PT J
AU Rawat, P
   Ahmad, I
   Vohora, D
   Ahmad, FJ
   Talegaonkar, S
AF Rawat, Purnima
   Ahmad, Iqbal
   Vohora, Divya
   Ahmad, Farhan Jalees
   Talegaonkar, Sushama
TI Three Ply Walled Microcapsules for Enhanced Pharmacokinetics of Poorly
   Absorbed Risedronate Sodium: Novel Stratagem Toward Osteoporosis
SO JOURNAL OF PHARMACEUTICAL INNOVATION
LA English
DT Article
DE Risedronate sodium; Bisphosphonates; Microcapsules; Osteoporosis;
   Box Behnken design
ID DELIVERY SYSTEMS; RESORPTION; BISPHOSPHONATES; MICROSPHERES;
   FORMULATION; AGENTS
AB Effective and optimized drug delivery has always been one of the major challenge for the researchers in the last few decades and is still a very active field of research. The present investigation focuses on the development of a novel strategy to enhance the bioavailability of risedronate sodium which shows very poor and erratic absorption. A multiple emulsion technique has been used to prepare the three ply walled microcapsules needed for targeting the specific sites. Box Behnken model has been selected to optimize the effect of various process variables on particle size and entrapment efficiency. Optimized microcapsules (PN F) were found to have a particle size of 3.97 +/  0.29 mu m (PDI = 0.19 +/  0.09), entrapment efficiency of 79.12 +/  2.19 %, and maximum release of 96.34 +/  3.426 and 97.32 +/  2.486 % in simulated gastric and intestinal fluid, respectively, over the period of 24 h. In vivo pharmacokinetic study exhibits a substantial increase in the absolute bioavailability of the microcapsules (F = 40.68 +/  2.636 %) as compared to marketed formulation, RISOFOSA (R), CIPLA (F = 0.98 A +/  0.086 %) (p < 0.01) leading to a more effective drug transport. A stability analysis has also been carried out and is found to be quite promising for the present formulation. The obtained outcomes strongly support the fact that the present formulation not only plays a vital role in the optimized delivery of risedronate sodium in osteoporosis management but also depicts negligible pitfalls.
C1 [Rawat, Purnima; Ahmad, Iqbal; Ahmad, Farhan Jalees; Talegaonkar, Sushama] Jamia Hamdard, Nanomed Res Lab, Dept Pharmaceut, Fac Pharm, New Delhi 110062, India.
   [Vohora, Divya] Jamia Hamdard, Dept Pharmacol, Fac Pharm, New Delhi 110062, India.
C3 Jamia Hamdard University; Jamia Hamdard University
RP Talegaonkar, S (通讯作者)，Jamia Hamdard, Nanomed Res Lab, Dept Pharmaceut, Fac Pharm, New Delhi 110062, India.
EM purrnimanegi@hotmail.com; iqbal_ahmad2@yahoo.co.in;
   divyavohora@hotmail.com; farhanja_2000@yahoo.com; stalegaonkar@gmail.com
RI ; Ahmad, Farhan/HMO 6565 2023; Vohora, Divya/H 4245 2019; Ahmad,
   Iqbal/AAS 3169 2021; Talegoankar, Sushama/AAW 8374 2020; Rawat,
   Purnima/ABC 6345 2020
OI Vohora, Divya/0000 0003 1852 9191; /0000 0003 3323 018X; Ahmad,
   Iqbal/0000 0002 2425 6217; Talegaonkar, sushama/0000 0003 2211 5119;
   Ahmad, Farhan/0000 0002 0740 8573; 
FU Indian Council of Medical Research
FX The authors would like to thank the Indian Council of Medical Research
   for their financial support.
CR Ahmad I, 2014, PHARM DEV TECHNOL, V19, P460, DOI 10.3109/10837450.2013.795167
   Ahmad N, 2016, DRUG DELIV, V23, P2095, DOI 10.3109/10717544.2014.941076
   Åkesson K, 2003, B WORLD HEALTH ORGAN, V81, P677
   BHATNAGAR S, 1995, J MICROENCAPSUL, V12, P13, DOI 10.3109/02652049509051123
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928 0987(01)00095 1
   ELORZA B, 1993, J MICROENCAPSUL, V10, P237, DOI 10.3109/02652049309104390
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Food Drug Administration HHS, 2001, FED REGISTER, V66, P56332
   HAYDEN JM, 1995, BONE, V17, pS93, DOI 10.1016/8756 3282(95)00186 H
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142 9612(00)00115 0
   Jia HJ, 2006, ANAL CHIM ACTA, V562, P171, DOI 10.1016/j.aca.2006.01.077
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Malhotra N, 2008, INDIAN J MED RES, V127, P263
   Mirza MA, 2011, DRUG DEV IND PHARM, V37, P310, DOI 10.3109/03639045.2010.512011
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Neuprez A, 2008, BEST PRACT RES CL EN, V22, P869, DOI 10.1016/j.beem.2008.06.003
   NORDIN B. E. C., 1966, CLIN ORTHO RELAT RES, V45, P17
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   Patashnik S, 1997, J DRUG TARGET, V4, P371, DOI 10.3109/10611869709017894
   Simanjuntak R, 2014, Drug Res (Stuttg), V64, P136, DOI 10.1055/s 0033 1354365
   Singh A, 2013, COLLOID SURFACE B, V102, P822, DOI 10.1016/j.colsurfb.2012.08.038
   Zaghloul AA, 2001, J MICROENCAPSUL, V18, P651
NR 24
TC 6
Z9 7
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1872 5120
EI 1939 8042
J9 J PHARM INNOV
JI J. Pharm. Innov.
PD JUN
PY 2015
VL 10
IS 2
BP 130
EP 139
DI 10.1007/s12247 015 9213 x
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CH7KD
UT WOS:000354214100004
DA 2025 08 17
ER

PT J
AU Bladé, J
   Cibeira, MT
   de Larrea, CF
   Rosiñol, L
AF Blade, J.
   Teresa Cibeira, M.
   Fernandez de Larrea, C.
   Rosinol, L.
TI Multiple myeloma
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE allogeneic stem cell transplantation; beta 2 microglobulin; monoclonal
   gammopathy; multiple myeloma
ID STEM CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; HIGH DOSE
   THERAPY; PHASE III; ELDERLY PATIENTS; MONOCLONAL GAMMOPATHY; GENETIC
   ABNORMALITIES; COMPLETE RESPONSE; PROGNOSTIC FACTOR; FOLLOW UP
AB Multiple myeloma (MM) constitutes 1% of malignant diseases and 15% of haematological malignancies. In virtually all patients MM is preceded by monoclonal gammopathy of undetermined significance (MGUS). The cause of monoclonal gammopathies and the mechanisms of progression are unknown. The diagnosis of MM requires the presence of an M protein in serum and/or urine, increased bone marrow plasma cells and related organ or tissue impairment. Cytogenetic status, serum beta 2 microglobulin and response to therapy are the key prognostic factors. The treatment of younger patients with MM should include a triple agent induction regimen (i.e. bortezomib/thalidomide/dexamethasone), autologous stem cell transplantation (ASCT) and consolidation and maintenance incorporating novel agents along with sequential minimal residual disease studies to determine for how long treatment is still of benefit. Allogeneic transplantation with reduced intensity conditioning is promising but remains experimental. For patients not eligible for ASCT the best initial regimens are melphalan/prednisone/thalidomide (MPT), melphalan/prednisone/bortezomib (MPV) and lenalidomide/dexamethasone. In relapsing patients, the choice of salvage therapy should depend on: (i) the components of initial therapy, (ii) the degree and duration of response, (iii) type of relapse: aggressive versus indolent, (iv) previous toxicities and (v) age and performance status. A sequential approach is preferred over combination of multiple agents. Supportive measures include the use of bisphosphonates and erythropoietin according to the updated guidelines.
C1 [Blade, J.; Teresa Cibeira, M.; Fernandez de Larrea, C.; Rosinol, L.] Hosp Clin Barcelona, Hematol & Oncol Inst, Dept Hematol, IDIBAPS, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS
RP Bladé, J (通讯作者)，Villarroel 170, Barcelona 08036, Spain.
EM jblade@clinic.ub.es
RI de Larrea, Carlos/ABG 9608 2020; Rosinol, Laura/CAH 3175 2022
OI Fernandez de Larrea Rodriguez, Carlos/0000 0003 4930 9255; 
FU Instituto Carlos III (Spanish Institute of Health) [RD06/0020/0005, FIS
   08/0147, CM07/108]
FX This work has been supported in part by Spanish Grants RD06/0020/0005,
   FIS 08/0147 and CM07/108 from Instituto Carlos III (Spanish Institute of
   Health).
CR ALEXANIAN R, 1972, CANCER AM CANCER SOC, V30, P382, DOI 10.1002/1097 0142(197208)30:2<382::AID CNCR2820300213>3.0.CO;2 C
   Alexanian R, 2001, BONE MARROW TRANSPL, V27, P1037, DOI 10.1038/sj.bmt.1703035
   Attal M, 2006, BLOOD, V108, P3289, DOI 10.1182/blood 2006 05 022962
   Avet Loiseau H, 2007, BLOOD, V109, P3489, DOI 10.1182/blood 2006 08 040410
   Avet Loiseau H, 2009, J CLIN ONCOL, V27, P4585, DOI 10.1200/JCO.2008.20.6136
   Bensinger W, 2008, J CLIN ONCOL, V26, P480, DOI 10.1200/JCO.2007.11.6863
   Bladé J, 2000, BONE MARROW TRANSPL, V26, P845, DOI 10.1038/sj.bmt.1702622
   Bladé J, 2008, LEUKEMIA, V22, P1651, DOI 10.1038/leu.2008.203
   Bladé J, 2008, ANN ONCOL, V19, P117, DOI 10.1093/annonc/mdn437
   Blade J, 1996, BRIT J HAEMATOL, V93, P345, DOI 10.1046/j.1365 2141.1996.5191061.x
   Bladé J, 2008, CURR OPIN ONCOL, V20, P697, DOI 10.1097/CCO.0b013e3283136984
   Bladé J, 2010, HAEMATOL HEMATOL J, V95, P702, DOI 10.3324/haematol.2009.021550
   Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365 2141.1998.00930.x
   Bladé J, 2010, BLOOD, V115, P3655, DOI 10.1182/blood 2009 08 238196
   Bladé J, 2010, J CLIN ONCOL, V28, P690, DOI 10.1200/JCO.2009.22.2257
   Bladé J, 2009, BLOOD, V113, P5370, DOI 10.1182/blood 2009 03 207241
   Bladé J, 2009, HAEMATOL HEMATOL J, V94, P163, DOI 10.3324/haematol.2008.002766
   Bruno B, 2009, BLOOD, V113, P3375, DOI 10.1182/blood 2008 07 167379
   Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019
   Cavo M, 2009, BLOOD, V114, P148
   *CHORN LEUK MEYL T, 1973, CANC CHEMOTHER REP, V4, P145
   DELFORGE M, 2010, LANCET ONCO IN PRESS
   Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594
   Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284
   Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140 6736(07)61537 2
   Garban F, 2006, BLOOD, V107, P3474, DOI 10.1182/blood 2005 09 3869
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Gutiérrez NC, 2007, LEUKEMIA, V21, P143, DOI 10.1038/sj.leu.2404413
   Harousseau JL, 2006, HAEMATOLOGICA, V91, P1498
   Hulin C, 2009, J CLIN ONCOL, V27, P3664, DOI 10.1200/JCO.2008.21.0948
   Jagannath S, 2007, LEUKEMIA, V21, P151, DOI 10.1038/sj.leu.2404442
   Lahuerta JJ, 2008, J CLIN ONCOL, V26, P5775, DOI 10.1200/JCO.2008.17.9721
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Ladetto M, 2010, J CLIN ONCOL, V28, P2077, DOI 10.1200/JCO.2009.23.7172
   Landgren O, 2009, BLOOD, V113, P5412, DOI 10.1182/blood 2008 12 194241
   Ludwig H, 2009, BLOOD, V113, P3435, DOI 10.1182/blood 2008 07 169565
   Nadal E, 2004, BONE MARROW TRANSPL, V33, P61, DOI 10.1038/sj.bmt.1704313
   OCIO EM, 2008, LANCET ONCOL, V27, P120
   Orlowski RZ, 2007, J CLIN ONCOL, V25, P3892, DOI 10.1200/JCO.2006.10.5460
   Paiva B, 2008, BLOOD, V112, P4017, DOI 10.1182/blood 2008 05 159624
   Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062
   Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140 6736(06)68338 4
   Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood 2007 10 117457
   Palumbo A, 2009, BLOOD, V114, P253
   Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259
   Popat R, 2008, BRIT J HAEMATOL, V141, P512, DOI 10.1111/j.1365 2141.2008.06997.x
   Rajkumar SV, 2008, J CLIN ONCOL, V26, P2171, DOI 10.1200/JCO.2007.14.1853
   Rajkumar SV, 2010, LANCET ONCOL, V11, P29, DOI 10.1016/S1470 2045(09)70284 0
   Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221
   Richardson P, 2009, BLOOD, V114, P772, DOI 10.1182/blood 2008 12 196238
   Richardson PG, 2007, BLOOD, V110, P3557, DOI 10.1182/blood 2006 08 036947
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Rizzo JD, 2008, J CLIN ONCOL, V26, P132, DOI 10.1200/JCO.2007.14.3396
   Rosinol L, 2004, HAEMATOLOGICA, V89, P832
   Rosiñol L, 2008, BLOOD, V112, P3591, DOI 10.1182/blood 2008 02 141598
   Rosiñol L, 2007, J CLIN ONCOL, V25, P4452, DOI 10.1200/JCO.2007.12.3323
   Rosinol L, 2009, BLOOD, V114, P59
   San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479
   Spencer A, 2009, J CLIN ONCOL, V27, P1788, DOI 10.1200/JCO.2008.18.8573
   Stewart AK, 2009, BLOOD, V114, P5436, DOI 10.1182/blood 2009 07 204651
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   van de Velde HJK, 2007, HAEMATOLOGICA, V92, P1399, DOI 10.3324/haematol.11534
   Waage A, 2007, BLOOD, V110, p32A, DOI 10.1182/blood.V110.11.78.78
   Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596
   Weiss BM, 2009, BLOOD, V113, P5418, DOI 10.1182/blood 2008 12 195008
   Wijermans P, 2008, BLOOD, V112, P241
NR 67
TC 36
Z9 43
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923 7534
EI 1569 8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2010
VL 21
SU 7
BP 313
EP 319
DI 10.1093/annonc/mdq363
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 666FK
UT WOS:000283099200045
PM 20943635
OA Bronze
DA 2025 08 17
ER

PT J
AU Migliario, M
   Rizzi, M
   Rocchetti, V
   Pittarella, P
   Renò, F
AF Migliario, Mario
   Rizzi, Manuela
   Rocchetti, Vincenzo
   Pittarella, Pamela
   Reno, Filippo
TI Low Zoledronate Concentrations Stimulate Human Keratinocyte
   Proliferation
SO PHARMACOLOGY
LA English
DT Article
DE Aminobisphosphonates; Human keratinocytes; Wound healing
ID IN VITRO; CLINICAL PRACTICE; AMERICAN SOCIETY; BISPHOSPHONATES;
   MECHANISMS; MIGRATION; ONCOLOGY; DISEASE; BONE; OSTEOPOROSIS
AB Aim: To evaluate, in an in vitro wound healing model, the effect of zoledronate on keratinocyte cellular behavior. Materials and Methods: Human spontaneously immortalized keratinocytes (HaCaT) were treated with low zoledronate concentrations (10 nmol/l to 10 mu mol/l) and its effect on cell proliferation was evaluated by means of a fluorescent assay (Tox 8), along with the analysis of cytokeratin 5 and filaggrin gene expression. Moreover, zoledronate effects on cell migration were evaluated by in vitro wound healing, and matrix metalloproteinase (MMP) activity was investigated by gelatin zymography. Results: At the tested concentrations, zoledronate stimulated keratinocyte proliferation, upregulating cytokeratin 5 while downregulating filaggrin expression and wound healing ability, without any significant effect on MMP 9 activity. The lack of zoledronate effects on MMP 9 activity indicates that, in our experimental model, wound closure is mainly due to an increase in cell proliferation rather than an increase in cell migration. Moreover, the observed increase in cell proliferation could be ascribed to a zoledronate mediated reduction of farnesyl pyrophosphate endogenous levels. Conclusions: These results could foster new clinical applications for this 'old' drug in the field of epithelial regeneration. Copyright (C) 2013 S. Karger AG, Basel
C1 [Migliario, Mario; Rocchetti, Vincenzo] Univ Eastern Piedmont Amedeo Avogadro, Dept Hlth Sci, Dent Clin, IT 28100 Novara, Italy.
   [Rizzi, Manuela; Pittarella, Pamela; Reno, Filippo] Univ Eastern Piedmont Amedeo Avogadro, Dept Hlth Sci, Human Anat Lab, IT 28100 Novara, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; University of Eastern
   Piedmont Amedeo Avogadro
RP Renò, F (通讯作者)，Univ Eastern Piedmont Amedeo Avogadro, Dept Hlth Sci, Via Solaroli 17, IT 28100 Novara, Italy.
EM filippo.reno@med.unipmn.it
RI ; Rizzi, Manuela/AAE 9202 2021; Migliario, Mario/AAB 3945 2019; Renò,
   Filippo/AAA 5591 2019
OI ROCCHETTI, Vincenzo/0000 0002 3186 7008; Migliario,
   Mario/0000 0003 1627 4164; RIZZI, Manuela/0000 0002 6174 7111; 
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Bensadoun RJ, 2008, B CANCER, V95, P413, DOI [10.1068/bdc.2008.0617, 10.1684/bdc.2008.0617]
   Berenson JR, 1999, ANNU REV MED, V50, P237
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Landesberg R, 2009, J ORAL MAXIL SURG, V67, P27, DOI 10.1016/j.joms.2008.12.006
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Mehrotra Bhoomi, 2006, Hematology Am Soc Hematol Educ Program, P356
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101
   Renò F, 2012, INT WOUND J, V9, P442, DOI 10.1111/j.1742 481X.2011.00905.x
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Vukelic S, 2010, J BIOL CHEM, V285, P1980, DOI 10.1074/jbc.M109.016741
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wu Shenhong, 2007, Acta Oncol, V46, P581
NR 34
TC 1
Z9 2
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0031 7012
EI 1423 0313
J9 PHARMACOLOGY
JI Pharmacology
PY 2013
VL 91
IS 3 4
BP 201
EP 206
DI 10.1159/000346918
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 146JD
UT WOS:000319086500011
PM 23428615
DA 2025 08 17
ER

PT J
AU Touati, N
   Tryfonidis, K
   Caramia, F
   Bonnefoi, H
   Cameron, D
   Slaets, L
   Parker, BS
   Loi, S
AF Touati, Nathan
   Tryfonidis, Konstantinos
   Caramia, Franco
   Bonnefoi, Herve
   Cameron, David
   Slaets, Leen
   Parker, Belinda S.
   Loi, Sherene
TI Correlation between severe infection and breast cancer metastases in the
   EORTC 10994/BIG 1 00 trial: Investigating innate immunity as a tumour
   suppressor in breast cancer
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE IRF7 signature; Severe infection; Breast cancer; Bone metastases; Immune
   response; Neo adjuvant chemotherapy
ID NEOADJUVANT CHEMOTHERAPY; BONE DISEASE; THERAPY; STRATEGIES; SURVIVAL
AB Background: Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones.
   Methods: Clinical data of the European Organisation for Research and Treatment of Cancer 10994/BIG 1 00 phase III trial which randomised 1856 patients treated with NACT between 2001 and 2006, were used. Severe infection was febrile neutropenia or any other grade III IV infective adverse event during NACT. The IRF7 signature was calculated from gene expression data available for 160 patients on a pre NACT biopsy. Cox models for distant relapse free interval (DRFI) investigated the effect of the severe infection and IRF7. Fine and Gray models studied the occurrence of bone metastases as first distant relapse.
   Results: Median follow up was 4.8 years. No association between severe infection and DFRI was observed in the entire population (n = 1615 eligible patients) hazard ratio [(HR] = 0.99, 90% CI, confidence interval [CI] = 0.81 1.20). For IRF7 (N = 160), a trend towards an association with DRFI was observed (HR = 0.89 for a 50 unit increase, 90% CI = 0.78 1.02, p = 0.081). Higher levels of the IRF7 signature were significantly associated with a decreased bone metastases risk: (HR = 0.76 for a 50 unit increase, 95% CI, 0.62 0.94, p = 0.012).
   Conclusions: In this study it was shown that severe infection during NACT was not associated with decreased DRFI while high expression of the IRF7 gene signature was significantly associated with reduced bone relapse. This result may be useful for future adjuvant bisphosphonate/denosumab use. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Touati, Nathan; Slaets, Leen] EORTC, Dept Stat, Ave Emmanuel Mounier 83b11, B 1200 Brussels, Belgium.
   [Tryfonidis, Konstantinos] EORTC, Dept Med, Ave Emmanuel Mounier 83b11, B 1200 Brussels, Belgium.
   [Caramia, Franco; Loi, Sherene] Univ Melbourne, Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia.
   [Bonnefoi, Herve] Inst Bergonie Unicanc, Dept Med Oncol, INSERM CIC1401, Bordeaux, France.
   [Cameron, David] Western Gen Hosp, Edinburgh Canc Ctr, Crewe Rd South, Gb Edinburgh EH4 2XU, Midlothian, Scotland.
   [Parker, Belinda S.] La Trobe Univ, Dept Biochem & Genet, La Trobe Inst Mol Sci, Melbourne, Vic, Australia.
C3 European Organisation for Research & Treatment of Cancer; European
   Organisation for Research & Treatment of Cancer; Peter Maccallum Cancer
   Center; University of Melbourne; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); University of
   Edinburgh; La Trobe University
RP Touati, N (通讯作者)，EORTC, Dept Stat, Ave Emmanuel Mounier 83b11, B 1200 Brussels, Belgium.; Loi, S (通讯作者)，Univ Melbourne, Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia.
EM nathan.touati@eortc.be; Konstantinos.tryfonidis@eortc.be;
   Franco.Caramia@petermac.org; H.Bonnefoi@bordeaux.unicancer.fr;
   D.Cameron@ed.ac.uk; leen.slaets@eortc.be; Belinda.Parker@Iatrobe.edu.uk;
   sherene.loi@petermac.org
RI Parker, Belinda/A 8759 2013; Loi, Sherene/H 1979 2016; Loi,
   Sherene/ITT 3863 2023; Cameron, David/C 7781 2013
OI Loi, Sherene/0000 0001 6137 9171; Parker, Belinda/0000 0002 8333 1926;
   Cameron, David/0000 0002 2717 7979
FU European Organisation for Research and Treatment of Cancer (EORTC)
   Cancer Research fund; EORTC Breast Cancer Group; John Colebatch Cancer
   Council Victoria Fellowship; Breast Cancer Research Foundation, BCRF NY
FX This work was supported by the European Organisation for Research and
   Treatment of Cancer (EORTC) Cancer Research fund. Nathan Touati's
   fellowship at EORTC is supported by the EORTC Breast Cancer Group.
   Sherene Loi is supported by the John Colebatch Cancer Council Victoria
   Fellowship and the Breast Cancer Research Foundation, BCRF NY.
   Furthermore the authors would like to thank the Fondation pour la lutte
   contre le cancer et pour des recherches medicobiologiques and Prof.
   Richard Iggo (INSERM U1218) as well as all patients, doctors and nurses
   involved in the EORTC 10994/BIG 1 00 study.
CR Anderson JR, 2008, J CLIN ONCOL, V26, P3913, DOI 10.1200/JCO.2008.16.1000
   Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830
   Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470 2045(11)70094 8
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963
   Giobbie Hurder A, 2013, J CLIN ONCOL, V31, P2963, DOI 10.1200/JCO.2013.49.5283
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523
   Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14
   Perry AK, 2005, CELL RES, V15, P407, DOI 10.1038/sj.cr.7290309
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Savas P, 2016, NAT REV CLIN ONCOL, V13, P228, DOI 10.1038/nrclinonc.2015.215
   Sisirak V, 2012, CANCER RES, V72, P5188, DOI 10.1158/0008 5472.CAN 11 3468
   Van Poznak C, 2005, CANCER AM CANCER SOC, V104, P443, DOI 10.1002/cncr.21201
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Zardavas D, 2016, EXPERT REV ANTICANC, V16, P1263, DOI 10.1080/14737140.2016.1247698
NR 19
TC 5
Z9 6
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD FEB
PY 2017
VL 72
BP 95
EP 102
DI 10.1016/j.ejca.2016.11.015
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EK6YK
UT WOS:000394072000012
PM 28027521
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Chellini, F
   Sassoli, C
   Nosi, D
   Deledda, C
   Tonelli, P
   Zecchi Orlandini, S
   Formigli, L
   Giannelli, M
AF Chellini, Flaminia
   Sassoli, Chiara
   Nosi, Daniele
   Deledda, Cristiana
   Tonelli, Paolo
   Zecchi Orlandini, Sandra
   Formigli, Lucia
   Giannelli, Marco
TI Low Pulse Energy Nd:YAG Laser Irradiation Exerts a Biostimulative Effect
   on Different Cells of the Oral Microenvironment: "An In Vitro Study"
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE alkaline phosphatase (ALP); calcium transients; endothelial cells;
   fibroblasts; osteoblasts; osteopontin; peri implantitis; periodontitis;
   Runt related transcription factor 2 (Runx2); transient receptor
   potential canonical channel 1 (TRPC1)
ID ND YAG LASER; CARDIOVASCULAR DISEASE; CALCIUM; PROLIFERATION;
   PERIODONTITIS; EXPRESSION; PATHOGENS; RECEPTOR; THERAPY; GROWTH
AB Background and Objectives: Dental lasers represent a promising therapeutic tool in the treatment of periodontal and pen implant diseases However, their clinical application remains still limited. Here, we Investigated the potential biostimulatory effect of low pulse energy neodymium:yttrium aluminum garnet (Nd.YAG) laser irradiation on different cells representative of the oral microenvironment and elucidated the underlying molecular mechanisms.
   Materials and Methods: Saos 2 osteoblasts, H end endothelial cells, and NIH/3T3 fibroblasts pre treated or not with photosensitizing dye methylene blue (MB), were irradiated with low pulse energy (20 mJ) and high repetition rate (50 70 Hz) Nd YAG laser, and evaluated for cell viability and proliferation as well as for the expression of specific differentiation markers by confocal immunofluorescence and real time RT PCR. Changes in intracellular Ca2+ levels after laser exposure were also evaluated in living osteoblasts.
   Results: Nd:YAG laser irradiation did not affect cell viability in all the tested cell types, even when combined with pre treatment with MB, and efficiently stimulated cell growth in the non sensitized osteoblasts Moreover, a significant induction in the expression of osteopontin. ALP, and Runx2 in osteoblasts, type I collagen in fibroblasts, and vinculin in endothelial cells could be observed in the irradiated cells Pre treatment with MB negatively affected cell differentiation in the unstimulated and laser stimulated cells. Notably, laser irradiation also caused an increase in the intracellular Ca2+ in osteoblasts through the activation of TRPC1 ion channels. Moreover, the pharmacologic or genetic inhibition of these channels strongly attenuated laser induced osteopontin expression, suggesting a role for the laser mediated Ca2+ influx in regulating osteoblast differentiation
   Conclusion: Low pulse energy and high repetition rate Nd.YAG laser irradiation may exert a biostimulative effect on different cells representative of the oral microenvironment, particularly osteoblasts. Pre treatment with MB prior to irradiation hampers this effect and limits the potential clinical application of photosensitizing dyes in dental practice Lasers Surg. Med 42:527 539, 2010 (C) 2010 Wiley Liss, Inc.
C1 [Chellini, Flaminia; Sassoli, Chiara; Nosi, Daniele; Zecchi Orlandini, Sandra; Formigli, Lucia] Univ Florence, Dept Anat Histol & Forens Med, I 50134 Florence, Italy.
   [Deledda, Cristiana] Univ Florence, Dept Clin Physiopathol, Endocrine Unit, I 50134 Florence, Italy.
   [Tonelli, Paolo; Giannelli, Marco] Univ Florence, Dept Oral Surg, I 50134 Florence, Italy.
C3 University of Florence; University of Florence; University of Florence
RP Chellini, F (通讯作者)，Univ Florence, Dept Anat Histol & Forens Med, Viale Morgagni 85, I 50134 Florence, Italy.
RI SASSOLI, CHIARA/AAC 4023 2019; Giannelli, Marco/F 4100 2017; Deledda,
   Cristiana/AAB 8976 2019
OI CHELLINI, FLAMINIA/0000 0002 8974 1299; TONELLI,
   PAOLO/0000 0002 6534 8345; 
FU Italian Ministry for Education, University and Research, Rome, Italy
FX Contract grant sponsor The Italian Ministry for Education, University
   and Research, Rome, Italy
CR Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Amabile N, 2008, J INTERN MED, V263, P644, DOI 10.1111/j.1365 2796.2007.01916.x
   Aoki Akira, 2008, General Dentistry, V56, P674
   Arisu HD, 2006, LASER MED SCI, V21, P175, DOI 10.1007/s10103 006 0398 6
   Bergmans L, 2006, INT ENDOD J, V39, P547, DOI 10.1111/j.1365 2591.2006.01115.x
   Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962 8924(97)01127 6
   Chen CH, 2008, LASER SURG MED, V40, P46, DOI 10.1002/lsm.20589
   Cheng HP, 2008, PHYSIOL REV, V88, P1491, DOI 10.1152/physrev.00030.2007
   Cobb CM, 2006, J PERIODONTOL, V77, P545, DOI 10.1902/jop.2006.050417
   COBB CM, 1992, J PERIODONTOL, V63, P701, DOI 10.1902/jop.1992.63.8.701
   De Benedittis M, 2007, J ORAL MAXIL SURG, V65, P314, DOI 10.1016/j.joms.2006.05.011
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Formigli L, 2009, J CELL SCI, V122, P1322, DOI 10.1242/jcs.035402
   Fujihara S, 2006, J BONE MINER RES, V21, P956, DOI 10.1359/JBMR.060315
   Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200
   Giannelli M, 2009, J PERIODONTOL, V80, P977, DOI 10.1902/jop.2009.080648
   Giannini R, 2006, CLIN ORAL IMPLAN RES, V17, P638, DOI 10.1111/j.1600 0501.2006.01278.x
   Heitz Mayfield LJA, 2008, J CLIN PERIODONTOL, V35, P292, DOI 10.1111/j.1600 051X.2008.01275.x
   Kirszberg C, 2005, CANCER CHEMOTH PHARM, V56, P659, DOI 10.1007/s00280 005 1014 3
   Luciani P, 2004, J CLIN ENDOCR METAB, V89, P1332, DOI 10.1210/jc.2003 031065
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Meisel P, 2005, J PHOTOCH PHOTOBIO B, V79, P159, DOI 10.1016/j.jphotobiol.2004.11.023
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Papapanagiotou D, 2009, ATHEROSCLEROSIS, V202, P605, DOI 10.1016/j.atherosclerosis.2008.05.035
   Parker S, 2007, BRIT DENT J, V202, P131, DOI 10.1038/bdj.2007.75
   Persson GR, 2008, J CLIN PERIODONTOL, V35, P362, DOI 10.1111/j.1600 051X.2008.01281.x
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Pussinen PJ, 2007, ARTERIOSCL THROM VAS, V27, P1433, DOI 10.1161/ATVBAHA.106.138743
   Sbrana F, 2008, AM J PHYSIOL CELL PH, V295, pC160, DOI 10.1152/ajpcell.00014.2008
   Schoop U, 2004, LASER SURG MED, V35, P111, DOI 10.1002/lsm.20026
   Schwarz F, 2008, J CLIN PERIODONTOL, V35, P29, DOI 10.1111/j.1600 051X.2008.01259.x
   Sharan K, 2008, INDIAN J MED RES, V127, P274
   Slot DE, 2009, J PERIODONTOL, V80, P1041, DOI 10.1902/jop.2009.080571
   Socransky SS, 2005, PERIODONTOL 2000, V38, P135, DOI 10.1111/j.1600 0757.2005.00107.x
   Vassalli Massimo, 2003, Italian Journal of Anatomy and Embryology, V108, P195
   Vescovi P, 2008, PHOTOMED LASER SURG, V26, P37, DOI 10.1089/pho.2007.2181
   Vescovi P, 2007, BRIT J ORAL MAX SURG, V45, P628, DOI 10.1016/j.bjoms.2007.03.016
   Vladimirov YA, 2004, BIOCHEMISTRY MOSCOW+, V69, P81, DOI 10.1023/B:BIRY.0000016356.93968.7e
   Walsh LJ, 2003, AUST DENT J, V48, P146, DOI 10.1111/j.1834 7819.2003.tb00025.x
   Yang WZ, 2007, PHOTOCHEM PHOTOBIOL, V83, P979, DOI 10.1111/j.1751 1097.2007.00116.x
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
NR 42
TC 46
Z9 55
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0196 8092
EI 1096 9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD AUG
PY 2010
VL 42
IS 6
BP 527
EP 539
DI 10.1002/lsm.20861
PG 13
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Surgery
GA 639XC
UT WOS:000281009400011
PM 20662029
DA 2025 08 17
ER

PT J
AU Wen, P
   Zhang, W
   Wang, P
   Zhang, Y
   Zhang, W
   Zhao, Y
   Guo, H
AF Wen, P.
   Zhang, W.
   Wang, P.
   Zhang, Y.
   Zhang, W.
   Zhao, Y.
   Guo, H.
TI Osteogenic effects of the peptide fraction derived from
   pepsin hydrolyzed bovine lactoferrin
SO JOURNAL OF DAIRY SCIENCE
LA English
DT Article
DE lactoferrin; enzyme hydrolysis; peptide synthesis; osteoblast;
   osteogenic
AB Osteoporosis is a common disease that frequently occurs in the older population, particularly in postmenopausal women. It severely compromises the health of the older population, and the drugs commonly used to treat osteoporosis have a variety of adverse effects. Lactoferrin (LF) is a protein present in milk that has recently been found to exhibit osteogenic activity. Lactoferrin is nontoxic and harmless, suggesting that it may have excellent biocompatibility and tolerability after human consumption. Oral consumption of LF in an ovariectomized rat model has been found to ameliorate osteoporosis. However, the mechanism underlying this effect remains to be clarified. In this study, bovine LF (bLF) was first hydrolyzed by pepsin for 1 h, and the hydrolyzed mixture was freeze dried and collected. The hydrolyzed mixture was then separated into 5 components (E1 E5), of which E3 had the greatest effect in promoting proliferation of osteoblasts (MC3T3 E1). Component E3 was further isolated into 21 components with preparative reversed phase HPLC, and the E3 15 component had maximal bioactivity. With HPLC mass spectrometry and peptide sequencing, E3 15 was identified to contain amino acids 97 to 208 from the bLF N terminus. Then, E3 15 was divided into 6 different peptide segments (P1 P6), and the corresponding segments were generated by solid phase synthesis. Only the P1 peptide (amino acids 97 122 from the N terminus of bLF) significantly promoted osteoblast proliferation. The bioactivity of P1 toward osteoblast cells and alkaline phosphatase activity were tested as a function of P1 concentration, and a nonlinear effect was observed.
C1 [Wen, P.; Zhang, Y.; Zhang, W.; Guo, H.] Gansu Agr Univ, Coll Food Sci & Engn, Lanzhou 730070, Peoples R China.
   [Zhang, W.; Wang, P.; Guo, H.] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Lab Food Qual & Safety, Key Lab Funct Dairy, Beijing 100083, Peoples R China.
   [Zhao, Y.] Kansas State Univ, Dept Grain Sci & Ind, Manhattan, KS 66506 USA.
C3 Gansu Agricultural University; China Agricultural University; Kansas
   State University
RP Guo, H (通讯作者)，Gansu Agr Univ, Coll Food Sci & Engn, Lanzhou 730070, Peoples R China.; Guo, H (通讯作者)，China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Lab Food Qual & Safety, Key Lab Funct Dairy, Beijing 100083, Peoples R China.; Zhao, Y (通讯作者)，Kansas State Univ, Dept Grain Sci & Ind, Manhattan, KS 66506 USA.
EM yuzhao1016@ksu.edu; guohuiyuan@cau.edu.cn
OI Guo, Huiyuan/0000 0003 0792 177X; ZHANG, WEI/0000 0001 8353 9674
FU FUXI talents program of Gansu Agricultural University (Lanzhou, China)
   [Gaufx 02Y01]; National Natural Science Foundation of China (Beijing)
   [NSFC 331301457, 31772014, 31972202]; Natural Science Foundation of
   Gansu Province (Lanzhou, China) [20JR10RA532]; Key R&D and
   transformation projects of science and technology of Qinghai Province
   (Qinghai, China) [2018 SF C29]
FX Financial support from the FUXI talents program (Gaufx 02Y01) of Gansu
   Agricultural University (Lanzhou, China), the National Natural Science
   Foundation of China (NSFC 331301457, 31772014, 31972202; Beijing), the
   Natural Science Foundation of Gansu Province (grant no. 20JR10RA532,
   Lanzhou, China), and Key R&D and transformation projects of science and
   technology of Qinghai Province (2018 SF C29; Qinghai, China) is
   gratefully acknowledged. The authors declare that they have no conflicts
   of interest.
CR BELLAMY W, 1992, J APPL BACTERIOL, V73, P472, DOI 10.1111/j.1365 2672.1992.tb05007.x
   Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247
   Cornish J, 2006, BIOCHEM CELL BIOL, V84, P297, DOI 10.1139/O06 057
   Cornish J, 2004, BIOMETALS, V17, P331, DOI 10.1023/B:BIOM.0000027713.18694.91
   Cornish J, 2004, ENDOCRINOLOGY, V145, P4366, DOI 10.1210/en.2003 1307
   Eriksen EK, 2010, BRIT J NUTR, V104, P374, DOI 10.1017/S0007114510000577
   Fan FJ, 2017, J AGR FOOD CHEM, V65, P7179, DOI 10.1021/acs.jafc.7b02067
   Farley JR, 2001, CALCIFIED TISSUE INT, V68, P43, DOI 10.1007/BF02685002
   Gass M, 2006, AM J MED, V119, p3S, DOI 10.1016/j.amjmed.2005.12.017
   Gavish H, 1997, BIOCHEMISTRY US, V36, P14883, DOI 10.1021/bi971670t
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Greenberg Z, 1997, J CELL BIOCHEM, V65, P359, DOI 10.1002/(SICI)1097 4644(19970601)65:3<359::AID JCB6>3.3.CO;2 T
   Grey A, 2006, MOL CELL ENDOCRINOL, V251, P96, DOI 10.1016/j.mce.2006.03.002
   Grey A, 2004, MOL ENDOCRINOL, V18, P2268, DOI 10.1210/me.2003 0456
   Guo HY, 2009, J NUTR, V139, P958, DOI 10.3945/jn.108.100586
   HEANEY RP, 1989, JAMA J AM MED ASSOC, V261, P2986, DOI 10.1001/jama.261.20.2986
   HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   JOHANSEN JS, 1989, BONE MINER, V6, P77, DOI 10.1016/0169 6009(89)90025 1
   Kaphalia BS, 2014, BIOMARKERS IN TOXICOLOGY, P279, DOI 10.1016/B978 0 12 404630 6.00016 6
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuwata H, 1998, BBA PROTEIN STRUCT M, V1429, P129, DOI 10.1016/S0167 4838(98)00224 6
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Le Potier I, 2001, CHROMATOGRAPHIA, V53, P563, DOI 10.1007/BF02491624
   LIN P, 1993, J HISTOCHEM CYTOCHEM, V41, P1435, DOI 10.1177/41.9.8354883
   Lorget F, 2002, BIOCHEM BIOPH RES CO, V296, P261, DOI 10.1016/S0006 291X(02)00849 5
   Malet A, 2011, BONE, V48, P1028, DOI 10.1016/j.bone.2011.02.002
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   McCormick RK, 2007, ALTERN MED REV, V12, P113
   Miura T, 2010, INT DAIRY J, V20, P67, DOI 10.1016/j.idairyj.2009.09.004
   Naot D, 2005, CLIN MED RES, V3, P93, DOI 10.3121/cmr.3.2.93
   Naot D, 2011, BONE, V49, P217, DOI 10.1016/j.bone.2011.04.002
   Onishi H, 2011, EXPERT OPIN DRUG DEL, V8, P1469, DOI 10.1517/17425247.2011.615829
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shi PJ, 2020, J DAIRY SCI, V103, P3950, DOI 10.3168/jds.2019 17425
   Shi PJ, 2018, FOOD BIOSCI, V22, P19, DOI 10.1016/j.fbio.2017.12.011
   TOMITA M, 1991, J DAIRY SCI, V74, P4137, DOI 10.3168/jds.S0022 0302(91)78608 6
   Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000
   Ying XZ, 2012, INT ORTHOP, V36, P647, DOI 10.1007/s00264 011 1303 x
NR 42
TC 6
Z9 6
U1 0
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022 0302
EI 1525 3198
J9 J DAIRY SCI
JI J. Dairy Sci.
PD APR
PY 2021
VL 104
IS 4
BP 3853
EP 3862
DI 10.3168/jds.2020 19138
EA MAR 2021
PG 10
WC Agriculture, Dairy & Animal Science; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Food Science & Technology
GA QY4MD
UT WOS:000630014700007
PM 33551166
OA Bronze
DA 2025 08 17
ER

PT J
AU Park, SY
   Cho, W
   Abd El Aty, AM
   Hacimuftuoglu, A
   Jeong, JH
   Jung, TW
AF Park, Seung Yeon
   Cho, Wonjun
   Abd El Aty, A. M.
   Hacimuftuoglu, Ahmet
   Jeong, Ji Hoon
   Jung, Tae Woo
TI Valdecoxib attenuates lipid induced hepatic steatosis through
   autophagy mediated suppression of endoplasmic reticulum stress
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Valdecoxib; ER stress; NAFLD; AMPK; SIRT6; Autophagy
ID FATTY LIVER DISEASE; UNFOLDED PROTEIN RESPONSE; INSULIN RESISTANCE;
   ACTIVATION; SIRT6; AMPK; MANAGEMENT; OBESITY; ACCUMULATION; INFLAMMATION
AB Valdecoxib (VAL) is one of the non steroidal anti inflammatory drugs (NSAIDs) used to treat inflammatory disorders, such as rheumatoid arthritis, osteoarthritis, and menstrual cramps. Recently, VAL ameliorates skeletal muscle insulin resistance via suppression of inflammation. However, the effects of VAL on lipid metabolism in hepatocytes have not been seen yet. This study investigated the effects of VAL on lipid accumulation and lipogenesis in human primary hepatocytes. Treatment with VAL suppressed lipid accumulation and expressions of lipogenic genes, such as processed sterol regulatory element binding proteins (SREBP1) and stearoyl CoA desaturase 1 (SCD1) in palmitate treated hepatocytes. Furthermore, VAL ameliorated dose dependently palmitate induced ER stress markers. Treatment of hepatocytes with VAL increased AMPK phosphorylation and SIRT6 expression. siRNA mediated suppression of AMPK or SIRT6 abolished the effects of VAL on lipid accumulation, lipogenesis, and endoplasmic reticulum (ER) stress in palmitate treated hepatocytes. Administration of VAL ameliorated hepatic lipid accumulation and lipogenic protein expression in HFD fed mice. Moreover, in vivo AMPK siRNA transfection abolished the effects of VAL on hepatic steatosis and lipid metabolism. These results suggest that VAL suppresses ER stress through the AMPK/SIRT6 pathway, thereby attenuating hepatic steatosis under hyperlipidemic conditions. Using VAL, the current study results provide clues for developing a novel therapeutic agent for treating non alcoholic fatty liver disease.
C1 [Park, Seung Yeon; Jeong, Ji Hoon] Grad Sch Chung Ang Univ, Dept Global Innovat Drugs, Seoul, South Korea.
   [Park, Seung Yeon; Cho, Wonjun; Jeong, Ji Hoon; Jung, Tae Woo] Chung Ang Univ, Coll Med, Dept Pharmacol, 221 Heuksuk dong, Seoul 156756, South Korea.
   [Abd El Aty, A. M.] Cairo Univ, Fac Vet Med, Dept Pharmacol, Giza 12211, Egypt.
   [Abd El Aty, A. M.; Hacimuftuoglu, Ahmet] Ataturk Univ, Med Fac, Dept Med Pharmacol, Erzurum, Turkey.
C3 Chung Ang University; Chung Ang University Hospital; Egyptian Knowledge
   Bank (EKB); Cairo University; Ataturk University
RP Jung, TW (通讯作者)，Chung Ang Univ, Coll Med, Dept Pharmacol, 221 Heuksuk dong, Seoul 156756, South Korea.; Abd El Aty, AM (通讯作者)，Cairo Univ, Fac Vet Med, Dept Pharmacol, Giza 12211, Egypt.
EM abdelaty44@hotmail.com; twjung@cau.ac.kr
RI Hacimuftuoglu, Ahmet/U 9109 2018; Abd El Aty, A. M./H 8216 2018
OI Abd El Aty, A. M./0000 0001 6596 7907
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2022R1A2B5B01001453, NRF 2021R1F1A1050004]
FX Acknowledgements This study was supported by the National Research
   Foundation of Korea (NRF) grant funded by the Korea government (MSIT) .
   (No. 2022R1A2B5B01001453) and (No. NRF 2021R1F1A1050004) .
CR Alkhouri N, 2011, EXPERT REV GASTROENT, V5, P201, DOI [10.1586/egh.11.6, 10.1586/EGH.11.6]
   Amen OM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00977
   Bachar Wikstrom E, 2013, DIABETES, V62, P1227, DOI 10.2337/db12 1474
   Bang In Hyuk, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276 019 0309 0
   Cheng Yan, 2011, World J Biol Chem, V2, P226, DOI 10.4331/wjbc.v2.i10.226
   Daniels SE, 2005, J GEN INTERN MED, V20, P62, DOI 10.1111/j.1525 1497.2004.30052.x
   Duvnjak M, 2007, WORLD J GASTROENTERO, V13, P4539, DOI 10.3748/wjg.v13.i34.4539
   Edwards JE, 2004, PAIN, V111, P286, DOI 10.1016/j.pain.2004.07.004
   Goldstein J.L., 2004, VALDECOXIB ALIMENT P, V20, P527
   González Ortiz M, 2005, METAB SYNDR RELAT D, V3, P95, DOI 10.1089/met.2005.3.95
   Gregor MF, 2009, DIABETES, V58, P693, DOI 10.2337/db08 1220
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Iachettini S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1065 0
   Jang M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 30977 7
   Jo H, 2013, HEPATOLOGY, V57, P1366, DOI 10.1002/hep.26126
   Kanfi Y, 2010, AGING CELL, V9, P162, DOI 10.1111/j.1474 9726.2009.00544.x
   Kapuy O, 2014, FEBS OPEN BIO, V4, P704, DOI 10.1016/j.fob.2014.07.006
   Kawasaki N, 2012, SCI REP UK, V2, DOI 10.1038/srep00799
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim TJ, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114557
   Kuang JY, 2017, DIABETES, V66, P1159, DOI 10.2337/db16 1225
   Kwon C, 2020, BIOCHEM BIOPH RES CO, V526, P539, DOI 10.1016/j.bbrc.2020.03.128
   Leese PT, 2002, AM J EMERG MED, V20, P275, DOI 10.1053/ajem.2002.32635
   Li YL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01150
   Lin JH, 2008, ANNU REV PATHOL MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434
   Liu C, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22339 0
   Luo PC, 2018, HEPATOLOGY, V68, P1786, DOI 10.1002/hep.30062
   Mao YQ, 2016, HEPATIC MED EVID RES, V8, P27, DOI 10.2147/HMER.S98120
   Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]
   Munch D, 2014, AUTOPHAGY, V10, P1579, DOI 10.4161/auto.29406
   Puri P, 2008, GASTROENTEROLOGY, V134, P568, DOI 10.1053/j.gastro.2007.10.039
   Pyun D.H., J CELL PHYSL, V236, P4902
   Rinella ME, 2016, NAT REV GASTRO HEPAT, V13, P196, DOI 10.1038/nrgastro.2016.3
   Shao JX, 2016, PROTEIN CELL, V7, P281, DOI 10.1007/s13238 016 0257 6
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Song LL, 2013, ONCOL LETT, V6, P1031, DOI 10.3892/ol.2013.1498
   Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748 1716.2009.01970.x
   Viollet B, 2006, J PHYSIOL LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506
   Woods A, 2017, CELL REP, V18, P3043, DOI 10.1016/j.celrep.2017.03.011
   Xin Y, 2021, BIOCHEM BIOPH RES CO, V544, P44, DOI 10.1016/j.bbrc.2021.01.061
   Xu G, 2018, CURR MED CHEM, V25, P889, DOI 10.2174/0929867324666170404142450
   Yin J., 2015, Mediators of Inflammation, V2015, P272313, DOI DOI 10.1155/2015/272313
NR 42
TC 24
Z9 24
U1 0
U2 11
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY
PY 2022
VL 199
AR 115022
DI 10.1016/j.bcp.2022.115022
EA MAR 2022
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1B1YB
UT WOS:000792237300003
PM 35358477
DA 2025 08 17
ER

PT J
AU Li, W
   Cheong, YK
   Wang, H
   Ren, GG
   Yang, Z
AF Li, Wen
   Cheong, Yuen Ki
   Wang, Hui
   Ren, Guogang
   Yang, Zhuo
TI Neuroprotective Effects of Etidronate and 2,3,3 Trisphosphonate Against
   Glutamate Induced Toxicity in PC12 Cells
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE Etidronate; 2,3,3 Trisphosphonate; PC12 cells; Glutamate;
   Neuroprotection
ID DELTA T CELLS; INDUCED APOPTOSIS; ALZHEIMERS DISEASE; OXIDATIVE STRESS;
   BISPHOSPHONATES; MECHANISMS; RISK; OSTEOPOROSIS; STIMULATION;
   PAMIDRONATE
AB Etidronate is one of the best known bisphosphonates (BP) derivatives. It is often used as a reference drug in research related to hypercalcaemia and other common bone diseases. 2,3,3 trisphosphonate (TrisPP) is brand new analogue of BP, that also contains a 'germinal bisphosphonate' unit with an additional phosphoryl group attached in proximity to the BP unit. It is known that BPs bind to calcium by chemisorptions to form Ca BP complexes through (O)P C P(O) moiety and hydrogen coordinations, and so they suppress calcium flow by interfering with Ca2+ channel operations. The mechanistic actions of BP, involving interactions and regulations of Ca2+, are somewhat similar to the pathogenesis of well known neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. To investigate if neuroprotective effects are exhibited by the compounds of interests, we used a rat adrenal pheochromocytoma cell line (PC12) as our in vitro model to observe any occurrence of neuron inter reflection. We pre treated these PC12 cells with etidronate and TrisPP before challenging the cells with a high concentration of the neurotoxin, glutamate. Our data showed that pre treatment with 100 mu M etidronate partially ameliorated the glutamate induced decrease in cell viability (47 %), whereas pre treating cells with 10 100 mu M TrisPP showed remarkable cell protection (78 86 %). Moreover, pre treatments of the cells with etidronate or TrisPP attenuated cell apoptosis, reactive oxygen species generation, Ca2+ overloading and caspase 3 protein expression, which were associated with a remarkable increase in superoxide dismutase activity in our glutamate injured PC12 cells. Therefore, this study supports the notion that etidronate and TrisPP may be promising neuroprotective agents.
C1 [Li, Wen; Yang, Zhuo] Nankai Univ, Sch Med, State Key Lab Med Chem Biol, Key Lab Tumor Microenvironm & Neurovasc Regulat, 94 Weijin Rd, Tianjin 300071, Peoples R China.
   [Cheong, Yuen Ki; Ren, Guogang] Univ Hertfordshire, Sci & Technol Res Inst, Hatfield AL10 9AB, Herts, England.
   [Wang, Hui] Nankai Univ, Coll Life Sci, 94 Weijin Rd, Tianjin 300071, Peoples R China.
C3 Nankai University; University of Hertfordshire; Nankai University
RP Yang, Z (通讯作者)，Nankai Univ, Sch Med, State Key Lab Med Chem Biol, Key Lab Tumor Microenvironm & Neurovasc Regulat, 94 Weijin Rd, Tianjin 300071, Peoples R China.
EM zhuoyang@nankai.edu.cn
RI Ren, Guogang/P 4540 2017; Cheong, Yuen Ki/W 5617 2019
OI Ren, Guogang/0000 0001 8865 1526; Cheong, Yuen Ki/0000 0002 3737 6285
FU Tianjin Research Program of Application Foundation and Advanced
   Technology [14JCZDJC35000]; National Natural Science Foundation of China
   [81571804]; UK Royal Academy of Engineering [RAEng. 1213RECI052]; EPSRC
   [EP/D07942X/1] Funding Source: UKRI; Engineering and Physical Sciences
   Research Council [EP/D07942X/1] Funding Source: researchfish
FX This work was supported by grant from Tianjin Research Program of
   Application Foundation and Advanced Technology (14JCZDJC35000), the
   National Natural Science Foundation of China (81571804) and the UK Royal
   Academy of Engineering (RAEng. 1213RECI052).
CR Chang KH, 2014, AGE, V36, P967, DOI 10.1007/s11357 013 9608 x
   Cheong YK, 2010, NUCL MED BIOL, V37, P677, DOI 10.1016/j.nucmedbio.2010.04.079
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304 3959(98)00135 3
   Han YG, 2011, CELL MOL NEUROBIOL, V31, P65, DOI 10.1007/s10571 010 9554 4
   Hausenloy DJ, 2003, J MOL CELL CARDIOL, V35, P339, DOI 10.1016/S0022 2828(03)00043 9
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Kunzmann V, 2000, BLOOD, V96, P384
   Lane RK, 2015, BBA BIOENERGETICS, V1847, P1387, DOI 10.1016/j.bbabio.2015.05.021
   Li N, 2007, J ETHNOPHARMACOL, V111, P458, DOI 10.1016/j.jep.2006.12.015
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lin SS, 2014, NEUROCHEM RES, V39, P922, DOI 10.1007/s11064 014 1288 0
   Liu SC, 2011, BRAIN RES BULL, V84, P183, DOI 10.1016/j.brainresbull.2010.12.008
   Liu SB, 2012, J NEUROSCI, V32, P4887, DOI 10.1523/JNEUROSCI.5828 11.2012
   Liu XY, 2010, MOL CELL BIOCHEM, V344, P277, DOI 10.1007/s11010 010 0552 0
   Lyell V, 2015, AGE AGEING, V44, P34, DOI 10.1093/ageing/afu122
   Ma SW, 2012, NEUROTOXICOLOGY, V33, P59, DOI 10.1016/j.neuro.2011.11.003
   Oldfield E, 2010, ACCOUNTS CHEM RES, V43, P1216, DOI 10.1021/ar100026v
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Paterson R, 2002, LANCET INFECT DIS, V2, P515, DOI 10.1016/S1473 3099(02)00390 0
   Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471 4159.2004.02796.x
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Roos PM, 2014, J TRACE ELEM MED BIO, V28, P418, DOI 10.1016/j.jtemb.2014.08.010
   Rudy CC, 2015, AGING DIS, V6, P131, DOI 10.14336/AD.2014.0423
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sato Y, 2013, J MUSCULOSKEL NEURON, V13, P346
   Sousa SC, 2003, FEBS LETT, V543, P179, DOI 10.1016/S0014 5793(03)00421 6
   Sun R, 2012, FOLIA NEUROPATHOL, V50, P270, DOI 10.5114/fn.2012.30527
   Torsney KM, 2014, J NEUROL NEUROSUR PS, V85, P1159, DOI 10.1136/jnnp 2013 307307
   van den Bos F, 2013, AGE AGEING, V42, P156, DOI 10.1093/ageing/afs161
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Xia WF, 2013, J BONE MINER RES, V28, P2122, DOI 10.1002/jbmr.1954
   Xu LJ, 2014, J APPL TOXICOL, V34, P651, DOI 10.1002/jat.2890
   Xu PJ, 2012, J NANOPART RES, V14, DOI 10.1007/s11051 012 0906 5
   Yamada K, 2014, J EXP MED, V211, P387, DOI 10.1084/jem.20131685
   Yan FG, 2011, EUR J PHARMACOL, V652, P23, DOI 10.1016/j.ejphar.2010.11.018
   Yang XF, 2011, CELL MOL NEUROBIOL, V31, P303, DOI 10.1007/s10571 010 9622 9
   Yu LC, 2014, NEUROCHEM INT, V70, P10, DOI 10.1016/j.neuint.2014.03.003
   Zhou R, 2011, J ALZHEIMERS DIS, V24, P101, DOI 10.3233/JAD 2010 101467
NR 44
TC 22
Z9 22
U1 0
U2 25
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364 3190
EI 1573 6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD APR
PY 2016
VL 41
IS 4
BP 844
EP 854
DI 10.1007/s11064 015 1761 4
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DI9ZD
UT WOS:000373860300023
PM 26559687
DA 2025 08 17
ER

PT J
AU Dong, BJ
   Liu, XH
   Li, JW
   Wang, B
   Yin, J
   Zhang, HL
   Liu, W
AF Dong, Bingjiang
   Liu, Xinhui
   Li, Jiwei
   Wang, Bin
   Yin, Jian
   Zhang, Hailong
   Liu, Wei
TI Berberine Encapsulated in Exosomes Derived from Platelet Rich Plasma
   Promotes Chondrogenic Differentiation of the Bone Marrow Mesenchymal
   Stem Cells via the Wnt/β Catenin Pathway
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE platelet rich plasma; exosome; berberine; cartilage regeneration;
   beta catenin
ID CULTURE; PROLIFERATION; APOPTOSIS; EFFICACY; PROTOCOL; KNEE
AB Cartilage regenerative medicine, wherein the stem cells from adults exert a crucial role, has high potential in the treatment of defective articular cartilage. Recently, Bone marrow mesenchymal stem cells (BMSCs) are being increasingly recognized as an alternative source of adult stem cells, which are capable of differentiating into several cell types (e.g., adipocytes, chondrocytes, and osteoblasts). However, their proliferative properties and tendency to dedifferentiate restrict their use in clinical settings. Recently, a possible bioactive material PRP exos (exosomes derived from platelet rich plasma), has emerged, which can effectively facilitate the differentiation and proliferation of cells. Recent studies have reported that berberine (Ber), known to have anti inflammatory properties, plays a role in osteogenesis. Since biological molecules are used in combinations, we attempted to assess the effect of Exos Ber (PRP exos in combination with Ber) on the chondrogenic differentiation of BMSCs in vitro. In this study, Exos Ber was observed to promote the proliferation of BMSCs and cause their chondrogenic differentiation in vitro. Additionally, Exos Ber could promote the migration of BMSCs and increase the protein expression of the chondrogenic genes (Collagen II, SOX9, Aggrecan). After treatment with Exos Ber, significant induction of beta catenin expression was observed, which could be repressed successfully by adding beta catenin inhibitor XAV 939. Interestingly, the repression of the Wnt/beta catenin axis also resulted in reduced gene expression levels of Collagen II, SOX9, and Aggrecan. These observations indicated that Exos Ber facilitated the differentiation of chondrogenic BMSCs by modulating the Wnt/beta catenin axis, which offers innovative insights into the reconstruction of cartilage.
C1 [Dong, Bingjiang; Liu, Xinhui; Wang, Bin; Yin, Jian; Zhang, Hailong; Liu, Wei] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Orthopaed, Nanjing 211100, Jiangsu, Peoples R China.
   [Li, Jiwei] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Clin Lab, Nanjing 211100, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, XH (通讯作者)，Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Orthopaed, Nanjing 211100, Jiangsu, Peoples R China.; Li, JW (通讯作者)，Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Clin Lab, Nanjing 211100, Jiangsu, Peoples R China.
EM liuxinhuijnyy@163.com; 624965607@qq.com
RI Yin, Jian/JBN 1938 2023; liu, wei/AAH 2406 2019
FU Key Projects of Youth Innovation and Scientific Research Fund of the
   Affiliated Jiangning Hospital with Nanjing Medical Uni versity; 
   [JNYYZXKY202017]
FX Acknowledgments This work was supported by the Key Projects of Youth
   Innovation and Scientific Research Fund of the Affiliated Jiangning
   Hospital with Nanjing Medical Uni versity (JNYYZXKY202017) .
CR Alzhrani GN, 2021, CELL BIOL INT, V45, P1807, DOI 10.1002/cbin.11620
   Ba RK, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/5492059
   Bornes TD, 2015, BIOPROTOC, V5, P1693
   Cho YJ, 2006, BIOL PHARM BULL, V29, P1408, DOI 10.1248/bpb.29.1408
   Chopra R N, 1932, Ind Med Gaz, V67, P194
   Chung MJ, 2019, CELL CYCLE, V18, P2954, DOI 10.1080/15384101.2019.1664224
   Farr J, 2011, CLIN ORTHOP RELAT R, V469, P2696, DOI 10.1007/s11999 010 1764 z
   Gao ZS, 2021, ACTA BIOMATER, V126, P211, DOI 10.1016/j.actbio.2021.03.018
   Guo SC, 2017, THERANOSTICS, V7, P81, DOI 10.7150/thno.16803
   Habtemariam S, 2016, PHARMACOL RES, V113, P592, DOI 10.1016/j.phrs.2016.09.041
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Jin L, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/ab49e2
   Jing H, 2017, FASEB J, V31, P4422, DOI 10.1096/fj.201700118R
   Kim KH, 2020, ANIMALS BASEL, V10, DOI 10.3390/ani10101723
   Korpershoek JV, 2020, TRIALS, V21, DOI 10.1186/s13063 020 04771 8
   Krüger JP, 2012, J ORTHOP RES, V30, P845, DOI 10.1002/jor.22005
   Lei H, 2009, J BIOMED MATER RES B, V91B, P679, DOI 10.1002/jbm.b.31444
   Li JS, 2020, J ORTHOP RES, V38, P670, DOI 10.1002/jor.24497
   Li WY, 2016, EXP THER MED, V12, P4041, DOI 10.3892/etm.2016.3866
   Liu XC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1529 7
   Ma L, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 79734 9
   Oichi T, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115368
   Orr MB, 2017, J NEUROTRAUM, V34, P2342, DOI 10.1089/neu.2016.4915
   Peterson L, 2000, CLIN ORTHOP RELAT R, P212, DOI 10.1097/00003086 200005000 00020
   Qi H, 2019, IN VITRO CELL DEV AN, V55, P203, DOI 10.1007/s11626 019 00330 x
   Ren BL, 2021, INT ORTHOP, V45, P2773, DOI 10.1007/s00264 021 05163 6
   Schmitt LC, 2014, J ORTHOP SPORT PHYS, V44, P565, DOI 10.2519/jospt.2014.4844
   Shen J, 2015, MOL MED REP, V11, P1298, DOI 10.3892/mmr.2014.2875
   Shi YX, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923328
   Torreggiani E, 2014, EUR CELLS MATER, V28, P137, DOI 10.22203/eCM.v028a11
   van Buul GM, 2011, AM J SPORT MED, V39, P2362, DOI 10.1177/0363546511419278
   Wang BA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1060 5
   Wang DH, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab022
   Wang SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep36400
   Wang XZ, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00081
   Xia Changsuo, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P997
   Xie Q, 2012, J ENDODONT, V38, P1114, DOI 10.1016/j.joen.2012.04.023
   Xin BC, 2020, PATHOL ONCOL RES, V26, P1677, DOI 10.1007/s12253 019 00746 6
   Yin WJ, 2016, MED SCI MONITOR, V22, P1280, DOI 10.12659/MSM.898218
   Yu T, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198735, 10.1590/1414 431x20198735]
   Yuan T, 2008, TRANSFUS APHER SCI, V38, P167, DOI 10.1016/j.transci.2008.01.006
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhang W, 2009, BIOL PHARM BULL, V32, P1335, DOI 10.1248/bpb.32.1335
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 44
TC 11
Z9 12
U1 2
U2 15
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
EI 1347 5215
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD OCT
PY 2022
VL 45
IS 10
BP 1444
EP 1451
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 7K1HX
UT WOS:000905037400008
PM 35858798
OA gold
DA 2025 08 17
ER

PT J
AU Oh, SH
   Hwang, YC
   Yang, H
   Kang, JH
   Hur, SW
   Jung, NR
   Jang, WG
   Lee, KN
   Oh, WM
   Park, JC
   Kim, SH
   Koh, JT
AF Oh, S. H.
   Hwang, Y. C.
   Yang, H.
   Kang, J. H.
   Hur, S. W.
   Jung, N. R.
   Jang, W. G.
   Lee, K. N.
   Oh, W. M.
   Park, J. C.
   Kim, S. H.
   Koh, J. T.
TI SHP is Involved in BMP2 induced Odontoblast Differentiation
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE orphan nuclear receptor; matrix mineralization; dentin matrix; dental
   pulp; DSPP; Dlx5
ID BONE MORPHOGENETIC PROTEINS; DENTIN SIALOPHOSPHOPROTEIN EXPRESSION;
   RUNX2; REGENERATION; PATTERNS; THERAPY; CELLS; DSPP; BSP
AB Small Heterodimer Partner (SHP) interacts with diverse transcription factors such as Runx2 and regulates many cellular events including differentiation, proliferation, and energy metabolism. SHP is reported to be a positive regulator of BMP2 induced bone formation. This study aimed to clarify the role of SHP in odontoblast differentiation and matrix mineralization. Rat tooth germs were isolated, and gene expression was determined by RT PCR and real time PCR. Localization of SHP protein expression was identified by immunofluorescent analysis. Primary human dental pulp cells (HDPCs) were cultured with BMP2 and/or Ad siSHP. Matrix mineralization was evaluated by Alizarin red staining. Transient transfection experiment was performed with the SHP or Dlx5 expressional plasmids and the DSPP gene. In tooth germs from post natal days 3 to 9, BMP 2 and SHP expression increased with DSPP and DMP1 mRNA expression. In an immunostaining study, SHP was expressed in odontoblasts and surrounding osteoblasts. When HDPCs were cultured with BMP2 in mineralization inducing medium, SHP expression also increased with an increase in DSPP expression. Down regulation of SHP by Ad siSHP inhibited matrix mineralization. In transient transfection experiments, overexpression of SHP was shown to enhance DSPP promoter activity through interactions between SHP and Dlx5. These results suggest that SHP may mediate BMP2 signaling to promote mineralization of the dentin matrix.
C1 [Oh, S. H.; Hwang, Y. C.; Yang, H.; Kang, J. H.; Hur, S. W.; Jung, N. R.; Jang, W. G.; Lee, K. N.; Oh, W. M.; Kim, S. H.; Koh, J. T.] Chonnam Natl Univ, Dental Sci Res Inst, Kwangju 500757, South Korea.
   [Oh, S. H.; Hwang, Y. C.; Yang, H.; Kang, J. H.; Hur, S. W.; Jung, N. R.; Jang, W. G.; Lee, K. N.; Oh, W. M.; Kim, S. H.; Koh, J. T.] Chonnam Natl Univ, Project BK21, Kwangju 500757, South Korea.
   [Oh, S. H.; Hwang, Y. C.; Yang, H.; Kang, J. H.; Hur, S. W.; Jung, N. R.; Jang, W. G.; Lee, K. N.; Kim, S. H.; Koh, J. T.] Chonnam Natl Univ, Sch Dent, Res Ctr Biomineralizat Disorders, Kwangju 500757, South Korea.
   [Park, J. C.] Seoul Natl Univ, Sch Dent, Dept Oral Histol Dev Biol, Seoul, South Korea.
   [Park, J. C.] Seoul Natl Univ, Sch Dent, Dent Res Inst, Seoul, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Seoul National University (SNU); Seoul National
   University (SNU)
RP Koh, JT (通讯作者)，Chonnam Natl Univ, Dental Sci Res Inst, Kwangju 500757, South Korea.
EM jtkoh@chonnam.ac.kr
RI Park, Joo Cheol/D 6437 2012
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2011 0030757]
FX The authors thank Dr. H.M. Ryoo for a gift of Dlx5 construct and Dr.
   J.E. Nor for supplying MDPC 23 cells. This study was supported by a
   grant from the National Research Foundation of Korea (NRF), funded by
   the Korea government (MEST) (No. 2011 0030757). The authors declare no
   potential conflicts of interest with respect to the authorship and/or
   publication of this article.
CR Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097 0177(199712)210:4<383::AID AJA3>3.0.CO;2 C
   Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600 0722.1998.tb02177.x
   Camilleri S, 2006, EUR J ORAL SCI, V114, P361, DOI 10.1111/j.1600 0722.2006.00399.x
   Chanda D, 2008, ENDOCR J, V55, P253, DOI 10.1507/endocrj.K07E 103
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen S, 2005, J BIOL CHEM, V280, P29717, DOI 10.1074/jbc.M502929200
   Chen S, 2009, J DENT RES, V88, P904, DOI 10.1177/0022034509342873
   Chen S, 2008, J BIOL CHEM, V283, P19359, DOI 10.1074/jbc.M709492200
   Cho YD, 2010, J BIOL CHEM, V285, P36369, DOI 10.1074/jbc.M110.103093
   DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040
   Heng NHM, 2007, J PERIODONTOL, V78, P2369, DOI 10.1902/jop.2007.070130
   Hwang YC, 2008, J MOL HISTOL, V39, P153, DOI 10.1007/s10735 007 9148 8
   Iohara K, 2004, J DENT RES, V83, P590, DOI 10.1177/154405910408300802
   Jeong BC, 2010, J BONE MINER RES, V25, P262, DOI 10.1359/jbmr.090718
   Kim HJ, 2009, ARCH ORAL BIOL, V54, P563, DOI 10.1016/j.archoralbio.2009.03.003
   Mukherjee S, 2010, PHARM RES DORDR, V27, P1439, DOI 10.1007/s11095 010 0117 7
   Nakashima M, 2005, CYTOKINE GROWTH F R, V16, P369, DOI 10.1016/j.cytogfr.2005.02.011
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Thesleff I, 2003, J CELL SCI, V116, P1647, DOI 10.1242/jcs.00410
   Thomadakis G, 1999, EUR J ORAL SCI, V107, P368, DOI 10.1046/j.0909 8836.1999.eos107508.x
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   Yamashiro T, 2003, J DENT RES, V82, P172, DOI 10.1177/154405910308200305
   Yang X, 2009, J DENT RES, V88, P1020, DOI 10.1177/0022034509346258
NR 25
TC 8
Z9 14
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
J9 J DENT RES
JI J. Dent. Res.
PD DEC
PY 2012
VL 91
IS 12
BP 1124
EP 1129
DI 10.1177/0022034512461916
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 036OQ
UT WOS:000311037600006
PM 23010719
DA 2025 08 17
ER

PT J
AU Shahabi, S
   Treccani, L
   Rezwan, K
AF Shahabi, Shakiba
   Treccani, Laura
   Rezwan, Kurosch
TI Amino acid catalyzed seed regrowth synthesis of photostable high
   fluorescent silica nanoparticles with tunable sizes for intracellular
   studies
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Fluorescence; Nanotoxicology; Osteoblast; Osteosarcoma; Seeds regrowth;
   Silica nanoparticle; Nanomedicine; Environmental and health effects
ID NANOSPHERES; OPTIMIZATION; OSTEOBLASTS; DELIVERY; SPHERES; PROBES; CELLS
AB Size controlled fluorescence silica nanoparticles (NPs) are widely used for nanotoxicological studies, and diagnostic and targeted therapies. Such particles can be easily visualized and localized within cell environments and their interactions with cellular components can be monitored. We developed an amino acid catalyzed seed regrowth technique (ACSRT) to synthesize spherical rhodamine doped silica NPs with tunable sizes, low polydispersity index as well as high labeling efficiency and enhanced fluorescence photostability. Via ACSRT, fluorescent silica NPs can be obtained by introducing the fluorophore in seed formation step, while a precise control over particle size can be achieved by simply adjusting the concentration of reactants in the regrowth step. Unlike the conventional methods, the proposed ACSRT permits the synthesis of fluorescent silicaNPs in awater based system, without the use of any surfactants and co surfactants. By this approach, additional linkers for covalent coupling of the fluorophore to silica matrix can be omitted, while a remarkable doping efficiency is achieved. The suitability of these particles for biomedical application is demonstrated by in vitro testswith normal andmalignant bone cells. We show that the particles can be easily and unambiguously visualized by a conventional fluorescence microscope, localized, and distinguished within intracellular components. In addition, it is presented that the cellular uptake and cytotoxic profile of silica NPs are strongly correlated to the particle size, concentration, and cell line. The results of in vitro experiments demonstrate that tunable fluorescent silica NPs synthesized with ACSRT can be potentially used for toxicological assessments and nanomedical studies.
C1 [Shahabi, Shakiba; Treccani, Laura; Rezwan, Kurosch] Univ Bremen, Adv Ceram, D 28359 Bremen, Germany.
C3 University of Bremen
RP Treccani, L (通讯作者)，Univ Bremen, Adv Ceram, Biol Garten 2, D 28359 Bremen, Germany.
EM treccani@uni bremen.de
RI Treccani, Laura/R 1725 2016; Rezwan, Kurosch/K 9451 2013
OI Rezwan, Kurosch/0000 0002 7318 1119
FU European Research Council [205509]; European Research Council (ERC)
   [205509] Funding Source: European Research Council (ERC); Academy of
   Finland (AKA) [205509] Funding Source: Academy of Finland (AKA)
FX We greatly thank Dr. Jan Koser of Zentrale Analytik, University of
   Bremen for DLS measurements, Eike Volkmann and Tobias Bollhorst of
   Advanced Ceramics, University Bremen for helping with statistical
   analysis and for scientific discussion, respectively. This work was
   supported by the European Research Council within the SIRG Project
   "BiocerEng" Project No. 205509.
CR Al Rawi M, 2011, ARCH TOXICOL, V85, P813, DOI 10.1007/s00204 010 0642 5
   Bagwe RP, 2004, LANGMUIR, V20, P8336, DOI 10.1021/la049137j
   BAUMLER W, 1990, CHEM PHYS, V140, P75, DOI 10.1016/0301 0104(90)89051 Q
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Bollhorst T, 2014, ANGEW CHEM, V127, P120
   BRINKER CJ, 1990, SOL GEL SCI
   Chang JS, 2007, ENVIRON SCI TECHNOL, V41, P2064, DOI 10.1021/es062347t
   Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385 299X(97)00047 0
   Febvay S, 2010, NANO LETT, V10, P2211, DOI 10.1021/nl101157z
   Finnie KS, 2007, LANGMUIR, V23, P3017, DOI 10.1021/la0624283
   Fuller JE, 2008, BIOMATERIALS, V29, P1526, DOI 10.1016/j.biomaterials.2007.11.025
   Gao F, 2007, SPECTROCHIM ACTA A, V67, P517, DOI 10.1016/j.saa.2006.08.009
   Gao XQ, 2009, OPT MATER, V31, P1715, DOI 10.1016/j.optmat.2009.05.004
   Guarnieri D, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 013 2229 6
   Guo YS, 2013, TRAC TREND ANAL CHEM, V42, P168, DOI 10.1016/j.trac.2012.09.018
   Ha SW, 2009, CHEM COMMUN, P2881, DOI 10.1039/b902195g
   Hartlen KD, 2008, LANGMUIR, V24, P1714, DOI 10.1021/la7025285
   He XX, 2012, ANAL CHEM, V84, P9056, DOI 10.1021/ac301461s
   Holthaus MG, 2012, ACTA BIOMATER, V8, P394, DOI 10.1016/j.actbio.2011.07.031
   Hornig S, 2008, SOFT MATTER, V4, P1169, DOI 10.1039/b800276b
   Imhof A, 1999, J PHYS CHEM B, V103, P1408, DOI 10.1021/jp983241q
   Jia TT, 2009, BIOSENS BIOELECTRON, V25, P263, DOI 10.1016/j.bios.2009.06.030
   Jin YH, 2008, CHEM MATER, V20, P4411, DOI 10.1021/cm8007478
   Kumar R, 2008, ACS NANO, V2, P449, DOI 10.1021/nn700370b
   Labéguerie Egéa J, 2011, J NANOPART RES, V13, P6455, DOI 10.1007/s11051 011 0539 0
   Larson DR, 2008, CHEM MATER, V20, P2677, DOI 10.1021/cm7026866
   Latterini L, 2009, LANGMUIR, V25, P4767, DOI 10.1021/la803934f
   Liang JL, 2013, COLLOID SURFACE A, V426, P33, DOI 10.1016/j.colsurfa.2013.02.064
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Lu CW, 2007, NANO LETT, V7, P149, DOI 10.1021/nl0624263
   Lu F, 2009, SMALL, V5, P1408, DOI 10.1002/smll.200900005
   Nakamura M, 2007, ANAL CHEM, V79, P6507, DOI 10.1021/ac070394d
   Nan AJ, 2008, NANO LETT, V8, P2150, DOI 10.1021/nl0802741
   Nooney RI, 2009, ANAL BIOANAL CHEM, V393, P1143, DOI 10.1007/s00216 008 2418 9
   PARKS GA, 1965, CHEM REV, V65, P177, DOI 10.1021/cr60234a002
   Peng JF, 2007, ANAL BIOANAL CHEM, V388, P645, DOI 10.1007/s00216 007 1244 9
   Qian J, 2008, OPT EXPRESS, V16, P19568, DOI 10.1364/OE.16.019568
   Rosenholm JM, 2010, NANOSCALE, V2, P1870, DOI 10.1039/c0nr00156b
   Shi H, 2010, ANAL CHEM, V82, P2213, DOI 10.1021/ac902417s
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Tansub W., 2012, Journal of Nanomaterials, V2012, P60
   Tao GP, 2011, COLLOID SURFACE B, V86, P106, DOI 10.1016/j.colsurfb.2011.03.026
   VANBLAADEREN A, 1993, J COLLOID INTERF SCI, V156, P1, DOI 10.1006/jcis.1993.1073
   VANBLAADEREN A, 1992, LANGMUIR, V8, P2921, DOI 10.1021/la00048a013
   Watanabe R, 2011, J COLLOID INTERF SCI, V360, P1, DOI 10.1016/j.jcis.2010.09.001
   Xia TA, 2009, ACS NANO, V3, P3273, DOI 10.1021/nn900918w
   Yokoi T, 2010, CHEM MATER, V22, P3900, DOI 10.1021/cm9037846
   Yokoi T, 2009, CHEM MATER, V21, P3719, DOI 10.1021/cm900993b
   Zhao BZ, 2009, TOXICOL APPL PHARM, V241, P163, DOI 10.1016/j.taap.2009.08.010
   Zhao XJ, 2004, ADV MATER, V16, P173, DOI 10.1002/adma.200305622
NR 50
TC 18
Z9 18
U1 2
U2 51
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388 0764
EI 1572 896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD JUN 18
PY 2015
VL 17
IS 6
AR 270
DI 10.1007/s11051 015 3072 8
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA CK8MS
UT WOS:000356492900001
DA 2025 08 17
ER

PT J
AU Danila, MI
   Outman, RC
   Rahn, EJ
   Mudano, AS
   Redden, DT
   Li, P
   Allison, JJ
   Anderson, FA
   Wyman, A
   Greenspan, SL
   LaCroix, AZ
   Nieves, JW
   Silverman, SL
   Siris, ES
   Watts, NB
   Miller, MJ
   Curtis, JR
   Warriner, AH
   Wright, NC
   Saag, KG
AF Danila, Maria I.
   Outman, Ryan C.
   Rahn, Elizabeth J.
   Mudano, Amy S.
   Redden, David T.
   Li, Peng
   Allison, Jeroan J.
   Anderson, Fred A.
   Wyman, Allison
   Greenspan, Susan L.
   LaCroix, Andrea Z.
   Nieves, Jeri W.
   Silverman, Stuart L.
   Siris, Ethel S.
   Watts, Nelson B.
   Miller, Michael J.
   Curtis, Jeffrey R.
   Warriner, Amy H.
   Wright, Nicole C.
   Saag, Kenneth G.
TI Evaluation of a Multimodal, Direct to Patient Educational Intervention
   Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; NONBISPHOSPHONATES; BEHAVIORAL INTERVENTION; FRACTURE
   PREVENTION; BISPHOSPHONATES
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; HIP FRACTURE; HEALTH
   BEHAVIOR; MULTIFACETED INTERVENTION; ACTIVATING PATIENTS; WRIST
   FRACTURE; RISK; IMPROVE; THERAPY
AB Osteoporosis treatment rates are declining, even among those with past fractures. Novel, low cost approaches are needed to improve osteoporosis care. We conducted a parallel group, controlled, randomized clinical trial evaluating a behavioral intervention for improving osteoporosis medication use. A total of 2684 women with self reported fracture history after age 45 years not using osteoporosis therapy from US Global Longitudinal Study of Osteoporosis in Women (GLOW) sites were randomized 1:1 to receive a multimodal, tailored, direct to patient, video intervention versus usual care. The primary study outcome was self report of osteoporosis medication use at 6 months. Other outcomes included calcium and vitamin D supplementation, bone mineral density (BMD) testing, readiness for behavioral change, and barriers to treatment. In intent to treat analyses, there were no significant differences between groups (intervention versus control) in osteoporosis medication use (11.7% versus 11.4%, p=0.8), calcium supplementation (31.8% versus 32.6%, p=0.7), vitamin D intake (41.3% versus 41.9%, p=0.8), or BMD testing (61.8% versus 57.1%, p=0.2). In the intervention group, fewer women were in the precontemplative stage of behavior change, more women reported seeing their primary care provider, had concerns regarding osteonecrosis of the jaw, and difficulty in taking/remembering to take osteoporosis medications. We found differences in BMD testing among the subgroup of women with no prior osteoporosis treatment, those who provided contact information, and those with no past BMD testing. In per protocol analyses, women with appreciable exposure to the online intervention (n=257) were more likely to start nonbisphosphonates (odds ratio [OR]=2.70; 95% confidence interval [CI] 1.26 5.79) compared with the usual care group. Although our intervention did not increase the use of osteoporosis therapy at 6 months, it increased nonbisphosphonate medication use and BMD testing in select subgroups, shifted participants' readiness for behavior change, and altered perceptions of barriers to osteoporosis treatment. Achieving changes in osteoporosis care using patient activation approaches alone is challenging. (C) 2018 American Society for Bone and Mineral Research.
C1 [Danila, Maria I.; Outman, Ryan C.; Rahn, Elizabeth J.; Mudano, Amy S.; Redden, David T.; Li, Peng; Curtis, Jeffrey R.; Warriner, Amy H.; Wright, Nicole C.; Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Allison, Jeroan J.; Anderson, Fred A.; Wyman, Allison] Univ Massachusetts, Med Sch, Worcester, MA USA.
   [Greenspan, Susan L.] Univ Pittsburgh, Pittsburgh, PA USA.
   [LaCroix, Andrea Z.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA.
   [LaCroix, Andrea Z.] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Nieves, Jeri W.] Helen Hayes Hosp, W Haverstraw, NY USA.
   [Silverman, Stuart L.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Siris, Ethel S.] Columbia Univ, Med Ctr, New York, NY USA.
   [Watts, Nelson B.] Mercy Hlth Osteoporosis & Bone Hlth Serv, Cincinnati, OH USA.
   [Miller, Michael J.] Texas A&M Univ, Irma Lerma Rangel Coll Pharm, Dept Pharmaceut Sci, College Stn, TX USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Massachusetts System; University of Massachusetts
   Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Group Health Cooperative; University of
   California System; University of California San Diego; Cedars Sinai
   Medical Center; Columbia University; Texas A&M University System; Texas
   A&M University College Station
RP Saag, KG (通讯作者)，Univ Alabama Birmingham, Dept Med, Div Rheumatol & Immunol, FOT 820,510 20th St South, Birmingham, AL 35294 USA.
EM ksaag@uab.edu
RI ; LaCroix, Andrea/N 9880 2018; Curtis, Jeffrey/I 6723 2015; Miller,
   Michael/K 6928 2017
OI Nieves, Jeri/0000 0001 8593 343X; Li, Peng/0000 0002 9026 9999; Miller,
   Michael/0000 0002 6026 6279; Curtis, Jeffrey R/0000 0002 8907 8976
FU NIAMS/NIH [R01 AR060240, K23 AR062100]; Agency for Healthcare Research
   and Quality [K12HS023009]
FX Trial registration: clinicaltrials.gov, identifier NCT01907269. This
   work was supported by R01 AR060240 (KGS) from the NIAMS/NIH. MID is
   supported by a K23 AR062100 award from NIAMS/NIH. NCW is supported by
   grant number K12HS023009 from the Agency for Healthcare Research and
   Quality. The NIAMS/NIH had no role in the design and conduct of the
   study; collection, management, analysis, and interpretation of data;
   preparation, review, or approval of the manuscript; or decision to
   submit the manuscript for publication.
CR Alami S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158365
   [Anonymous], HEDIS QUAL MEAS
   Ashton CM, 2010, PATIENT EDUC COUNS, V81, P275, DOI 10.1016/j.pec.2010.01.019
   Ball LK, 1998, PEDIATRICS, V101, P453, DOI 10.1542/peds.101.3.453
   Bennett AT, 2015, J WOMENS HEALTH, V24, P950, DOI 10.1089/jwh.2015.5251
   Bessette L, 2011, OSTEOPOROSIS INT, V22, P2963, DOI 10.1007/s00198 011 1533 1
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Campbell MK, 1998, OSTEOPOROSIS INT, V8, P584, DOI 10.1007/s001980050103
   Ciaschini PM, 2010, BMC GERIATR, V10, DOI 10.1186/1471 2318 10 60
   Cline RR, 2005, MATURITAS, V50, P196, DOI 10.1016/j.maturitas.2004.05.004
   Cole RE, 2011, POSTGRAD MED, V123, P131, DOI 10.3810/pgm.2011.03.2271
   Cram P, 2016, OSTEOPOROSIS INT, V27, P3513, DOI 10.1007/s00198 016 3681 9
   Cranney A, 2008, OSTEOPOROSIS INT, V19, P1733, DOI 10.1007/s00198 008 0669 0
   Danila MI, 2016, CONT CLIN TRIAL COMM, V4, P14, DOI 10.1016/j.conctc.2016.06.010
   Dell R, 2011, OSTEOPOROSIS INT, V22, pS457, DOI 10.1007/s00198 011 1712 0
   DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277 9536(92)90206 6
   Eberth JM, 2014, J ADOLESCENT HEALTH, V54, P289, DOI 10.1016/j.jadohealth.2013.09.005
   Feldstein AC, 2008, OSTEOPOROSIS INT, V19, P1527, DOI 10.1007/s00198 008 0605 3
   FISHER JD, 1992, PSYCHOL BULL, V111, P455, DOI 10.1037/0033 2909.111.3.455
   Freed GL, 1996, JAMA J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869
   Gadkari AS, 2010, CURR MED RES OPIN, V26, P683, DOI 10.1185/03007990903550586
   Ganda K, 2013, OSTEOPOROSIS INT, V24, P393, DOI 10.1007/s00198 012 2090 y
   Gardner MJ, 2005, J BONE JOINT SURG AM, V87A, P3, DOI 10.2106/JBJS.D.02289
   Giangregorio L, 2006, SEMIN ARTHRITIS RHEU, V35, P293, DOI 10.1016/j.semarthrit.2005.11.001
   Giangregorio L, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 38
   Gleason LJ, 2012, GERIATR ORTHOP SURG, V3, P79, DOI 10.1177/2151458512454878
   Gregson CL, 2014, OSTEOPOROSIS INT, V25, P85, DOI 10.1007/s00198 013 2438 y
   Grover ML, 2014, WOMEN HEALTH ISS, V24, pE69, DOI 10.1016/j.whi.2013.11.007
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hinyard LJ, 2007, HEALTH EDUC BEHAV, V34, P777, DOI 10.1177/1090198106291963
   Hogan KN, 2013, J AM GERIATR SOC, V61, P2046, DOI 10.1111/jgs.12521
   Hooven FH, 2009, OSTEOPOROSIS INT, V20, P1107, DOI 10.1007/s00198 009 0958 2
   Ivers RQ, 2002, J CLIN EPIDEMIOL, V55, P452, DOI 10.1016/S0895 4356(01)00518 2
   Jennings LA, 2010, J AM GERIATR SOC, V58, P650, DOI 10.1111/j.1532 5415.2010.02769.x
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Kingwell E, 2010, OSTEOPOROSIS INT, V21, P307, DOI 10.1007/s00198 009 0966 2
   Laliberté MC, 2011, OSTEOPOROSIS INT, V22, P2743, DOI 10.1007/s00198 011 1557 6
   Leslie WD, 2012, CAN MED ASSOC J, V184, P290, DOI 10.1503/cmaj.111158
   Majumdar SR, 2007, OSTEOPOROSIS INT, V18, P261, DOI 10.1007/s00198 006 0248 1
   Majumdar SR, 2004, ANN INTERN MED, V141, P366, DOI 10.7326/0003 4819 141 5 200409070 00011
   Majumdar SR, 2008, CAN MED ASSOC J, V178, P569, DOI 10.1503/cmaj.070981
   Majumdar SR, 2012, AM J MED, V125, P929, DOI 10.1016/j.amjmed.2012.02.021
   Mauck KF, 2002, OSTEOPOROSIS INT, V13, P560, DOI 10.1007/s001980200073
   McHorney CA, 2011, HEALTH EXPECT, V14, P307, DOI 10.1111/j.1369 7625.2010.00619.x
   McLeod KM, 2007, J NUTR, V137, P1968, DOI 10.1093/jn/137.8.1968
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P852, DOI 10.1210/jc.2015 3156
   Morris Nancy S, 2006, BMC Fam Pract, V7, P21, DOI 10.1186/1471 2296 7 21
   Nahum Shani I, 2015, HEALTH PSYCHOL, V34, P1209, DOI 10.1037/hea0000306
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315
   Newman ED, 2011, OSTEOPOROSIS INT, V22, pS451, DOI 10.1007/s00198 011 1695 x
   Orwoll E, 2005, CONTEMP CLIN TRIALS, V26, P569, DOI 10.1016/j.cct.2005.05.006
   Outman RC, 2012, CONTEMP CLIN TRIALS, V33, P206, DOI 10.1016/j.cct.2011.09.020
   Ownby Raymond L, 2012, Neurobehav HIV Med, V4, P113
   Siris ES, 2011, OSTEOPOROSIS INT, V22, P27, DOI 10.1007/s00198 010 1211 8
   Slater MD, 2002, COMMUN THEOR, V12, P173, DOI 10.1111/j.1468 2885.2002.tb00265.x
   Smith DH, 2008, ARCH INTERN MED, V168, P477, DOI 10.1001/archinternmed.2007.132
   Solomon DH, 2006, OSTEOPOROSIS INT, V17, P760, DOI 10.1007/s00198 005 0049 y
   Stuurman Bieze AGG, 2014, OSTEOPOROSIS INT, V25, P1807, DOI 10.1007/s00198 014 2659 8
   Tran AN, 2004, PATIENT EDUC COUNS, V52, P113, DOI 10.1016/S0738 3991(03)00002 8
   van Boven JFM, 2014, J MANAG CARE SPEC PH, V20, P786, DOI 10.18553/jmcp.2014.20.8.786
   Warriner AH, 2015, J RHEUMATOL, V42, P1478, DOI 10.3899/jrheum.141238
   Warriner AH, 2014, MED CARE, V52, P743, DOI 10.1097/MLR.0000000000000170
   Warriner AH, 2012, J BONE MINER RES, V27, P2603, DOI 10.1002/jbmr.1720
   Watts NB, 2014, NAT REV ENDOCRINOL, V10, P412, DOI 10.1038/nrendo.2014.55
   Weinstein N.D., 2008, Health behavior and health education: Theory, research, and practice, P123, DOI DOI 10.1002/9781119057840.CH100
   Weinstein ND, 1998, HEALTH PSYCHOL, V17, P290, DOI 10.1037/0278 6133.17.3.290
   WEINSTEIN ND, 1987, J BEHAV MED, V10, P481, DOI 10.1007/BF00846146
   WEINSTEIN ND, 1988, HEALTH PSYCHOL, V7, P355, DOI 10.1037/0278 6133.7.4.355
   Winzenberg T, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471 2458 6 12
   Wolinsky FD, 2017, J CLIN DENSITOM, V20, P464, DOI 10.1016/j.jocd.2016.08.012
   Wu FT, 2014, J CLIN DENSITOM, V17, P466, DOI 10.1016/j.jocd.2014.07.008
   Yood RA, 2008, J GEN INTERN MED, V23, P1815, DOI 10.1007/s11606 008 0772 0
   Yu JB, 2015, PATIENT PREFER ADHER, V9, P821, DOI 10.2147/PPA.S81963
NR 75
TC 27
Z9 29
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2018
VL 33
IS 5
BP 763
EP 772
DI 10.1002/jbmr.3395
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Endocrinology & Metabolism
GA GF5KU
UT WOS:000432006800002
PM 29377378
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Zameer, S
   Alam, M
   Hussain, S
   Vohora, D
   Ali, J
   Najmi, A
   Akhtar, M
AF Zameer, Saima
   Alam, Mahtab
   Hussain, Salman
   Vohora, Divya
   Ali, Javed
   Najmi, Abul Kalam
   Akhtar, Mohd
TI Neuroprotective role of alendronate against APP processing and
   neuroinflammation in mice fed a high fat diet
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE Alzheimer's disease; Isoprenoids; Cholesterol; Alendronate; BACE 1
ID INDUCED OXIDATIVE STRESS; ALZHEIMERS DISEASE; A BETA;
   ACETYLCHOLINESTERASE INHIBITORS; COGNITIVE IMPAIRMENT; MOUSE MODEL;
   IN VITRO; BRAIN; CHOLESTEROL; MEMORY
AB Obesity and consumption of diet rich in fat are known to contribute to the development of Alzheimer's disease (AD) which is a complex and multifactorial neurodegenerative disease and a leading cause of mortality with unmet medical needs. Hypercholesterolemia was discovered to increase neuropathological changes along with cognitive decline in AD mouse models but still the underlying mechanism is elusive. Furthermore, isoprenoids, the crucial products of Mevalonate pathway produced by the action of farnesyl pyrophosphate synthase (FPPS) enzyme, are also demonstrated to play a key role in AD. Nevertheless, bisphosphonates target this enzyme in order to treat osteoporosis and also found to alleviate dementia in such patients. As per the cited inhibitory action of alendronate, against acetylcholinesterase and cholesterol level, we hypothesized to explore the potential of alendronate against high fat diet (HFD) induced neuropathologies and cognitive disabilities in AD mouse model. Here we noticed that in mice provided with HFD for 14 weeks, spatial memory was compromised as interpreted in different behavioral paradigms. Together with cognitive depletion, there was observed a provoking effect on amyloid precursor protein (APP) processing via amyloidogenic pathway due to enhanced beta site APP cleaving enzyme 1 (BACE 1) level which in turn leads to augmented release of amyloid beta (A beta) in hippocampus of HFD mice. Relevant to these, significant elevation in hippocampal level of neuroinflammatory cytokines, oxidative stress markers and isoprenoids and serum cholesterol were also found after HFD exposure. Marked reversal of cognitive impairment, enhanced APP processing, neuroinflammation along with other neuropathological alterations in hippocampus was demonstrated following oral administration of alendronate (1.76 mg/kg) for 15 days despite of HFD treatment. These changes were noted to be due to modulation of isoprenoids and cholesterol level by alendronate. Supporting these, histopathological analysis done by congo red revealed the reduced A beta deposition in hippocampus of drug treated HFD mice The current outcomes provide important implications for the contribution of Mevalonate pathway and HFD for the onset of AD and also support alendronate as a prominent intervention for amelioration of AD like pathologies.
C1 [Zameer, Saima; Alam, Mahtab; Hussain, Salman] Jamia Hamdard, Dept Pharmacol, Pharmaceut Med, Sch Pharmaceut Educ & Res, New Delhi, India.
   [Vohora, Divya; Najmi, Abul Kalam; Akhtar, Mohd] Jamia Hamdard, Dept Pharmacol, Sch Pharmaceut Educ & Res, New Delhi, India.
   [Ali, Javed] Jamia Hamdard, Dept Pharmaceut, Sch Pharmaceut Educ & Res, New Delhi, India.
C3 Jamia Hamdard University; Jamia Hamdard University; Jamia Hamdard
   University
RP Akhtar, M (通讯作者)，Jamia Hamdard, Dept Pharmacol, Sch Pharmaceut Educ & Res, New Delhi, India.
EM fiatakhtar@hotmail.com
RI Ali, Javed/S 3180 2017; Zameer, Saima/ACY 4824 2022; Akhtar,
   Mohd/G 1709 2012; Vohora, Divya/H 4245 2019; Ali, Javed/ABH 1485 2020;
   Hussain, Salman/AAN 9202 2021
OI Ali, Javed/0000 0001 5308 0655; Najmi, Abul/0000 0002 9299 414X;
   Hussain, Salman/0000 0002 1691 8428; Vohora, Divya/0000 0003 1852 9191; 
FU Sun Pharmaceutical Industries Ltd; Council of Scientific and Industrial
   Research (CSIR), India
FX This study was supported by Sun Pharmaceutical Industries Ltd and
   Council of Scientific and Industrial Research (CSIR), India. The
   experimental work was carried out in the Neurobehavioral Pharmacology
   lab, Jamia Hamdard. The authors are thankful to Prof. Suhel Parvez for
   providing the necessary facilities of Department of Medical Elementology
   and Toxicology, School of Chemical and Life Sciences (SCLS), Jamia
   Hamdard, New Delhi.
CR Ayyub M, 2017, DRUG RES, V67, P59, DOI 10.1055/s 0042 118172
   Beydoun MA, 2008, OBES REV, V9, P204, DOI 10.1111/j.1467 789X.2008.00473.x
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Tung BT, 2017, J ETHNOPHARMACOL, V198, P24, DOI 10.1016/j.jep.2016.12.037
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   Celis Munoz T., 2016, J SYST INTEGR NEUROS, V2, P166
   Chang KH, 2014, AGE, V36, P967, DOI 10.1007/s11357 013 9608 x
   Chavez Valdez R, 2018, HIPPOCAMPUS, V28, P617, DOI 10.1002/hipo.22965
   Chu CS, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24248 8
   Cibicková L, 2007, PHYSIOL RES, V56, P765, DOI 10.33549/physiolres.931121
   Cibicková L, 2009, PHYSIOL RES, V58, P455, DOI 10.33549/physiolres.931382
   Costa AC, 2018, EUR ARCH PSY CLIN N, V268, P501, DOI 10.1007/s00406 017 0838 2
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eckert GP, 2009, NEUROBIOL DIS, V35, P251, DOI 10.1016/j.nbd.2009.05.005
   Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113
   ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006 2952(61)90145 9
   Eskelinen MH, 2008, INT J GERIATR PSYCH, V23, P741, DOI 10.1002/gps.1969
   Ferreira Vieira TH, 2016, CURR NEUROPHARMACOL, V14, P101, DOI 10.2174/1570159X13666150716165726
   Gazdzinski S, 2008, ANN NEUROL, V63, P652, DOI 10.1002/ana.21377
   Ghribi O, 2006, EXP NEUROL, V200, P460, DOI 10.1016/j.expneurol.2006.03.019
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Hampel H, 2018, BRAIN, V141, P1917, DOI 10.1093/brain/awy132
   Hardy J, 2006, J ALZHEIMERS DIS, V9, P151
   Herculano B, 2013, J ALZHEIMERS DIS, V33, P983, DOI 10.3233/JAD 2012 121324
   Hooff GP, 2010, ANAL BIOANAL CHEM, V398, P1801, DOI 10.1007/s00216 010 4088 7
   Husain I, 2018, HUM EXP TOXICOL, V37, P399, DOI 10.1177/0960327117705431
   Julien C, 2010, NEUROBIOL AGING, V31, P1516, DOI 10.1016/j.neurobiolaging.2008.08.022
   Kandimalla R, 2017, J ALZHEIMERS DIS, V57, P1049, DOI 10.3233/JAD 161118
   Kaundal M, 2018, EUR J PHARMACOL, V832, P56, DOI 10.1016/j.ejphar.2018.05.015
   Knight EM, 2014, NEUROBIOL AGING, V35, P1821, DOI 10.1016/j.neurobiolaging.2014.02.010
   Kosak U, 2016, SCI REP UK, V6, DOI 10.1038/srep39495
   Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068
   Lee Hyoung gon, 2006, Current Alzheimer Research, V3, P75, DOI 10.2174/156720506775697124
   Levin Allerhand J A, 2002, J Nutr Health Aging, V6, P315
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Magalingam KB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3740461
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   Neha, 2014, N S ARCH PHARMACOL, V387, P777, DOI 10.1007/s00210 014 0990 4
   Ohta Y, 2017, GERIATR GERONTOL INT, V17, P1843, DOI 10.1111/ggi.12971
   Orta Salazar E, 2016, UPDATE ON DEMENTIA, P191, DOI 10.5772/64619
   Pandey A, 2018, CYTOKINE, V102, P211, DOI 10.1016/j.cyto.2017.10.019
   Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032
   Petrov D, 2015, BBA MOL BASIS DIS, V1852, P1687, DOI 10.1016/j.bbadis.2015.05.004
   Phaniendra A, 2015, INDIAN J CLIN BIOCHE, V30, P11, DOI 10.1007/s12291 014 0446 0
   Rahman SO, 2019, BIOMED PHARMACOTHER, V110, P47, DOI 10.1016/j.biopha.2018.11.043
   Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870
   Regen F, 2017, CURR ALZHEIMER RES, V14, P1140, DOI 10.2174/1567205014666170203141717
   Remya C, 2014, INDIAN J PHARM SCI, V76, P567
   Richa R, 2017, NEUROCHEM INT, V104, P64, DOI 10.1016/j.neuint.2016.12.008
   Sachdeva AK, 2015, J NUTR BIOCHEM, V26, P736, DOI 10.1016/j.jnutbio.2015.01.012
   Santos DB, 2012, EXP NEUROL, V233, P767, DOI 10.1016/j.expneurol.2011.11.036
   Sathya M, 2017, J ALZHEIMERS DIS, V60, pS3, DOI 10.3233/JAD 161034
   Sodhi RK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070487
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Tabrizian K, 2016, BIOL TRACE ELEM RES, V169, P106, DOI 10.1007/s12011 015 0399 z
   Thirumangalakudi L, 2008, J NEUROCHEM, V106, P475, DOI 10.1111/j.1471 4159.2008.05415.x
   Walker JM, 2017, NEUROBIOL DIS, V100, P87, DOI 10.1016/j.nbd.2017.01.004
   Wang DM, 2018, COGN NEURODYNAMICS, V12, P303, DOI 10.1007/s11571 017 9471 z
   Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200
   Wu N, 2013, BBA MOL BASIS DIS, V1832, P1560, DOI 10.1016/j.bbadis.2013.04.024
   Zameer S, 2019, NEUROTOXICOLOGY, V70, P122, DOI 10.1016/j.neuro.2018.11.012
   Zameer S, 2018, PHARMACOL REP, V70, P900, DOI 10.1016/j.pharep.2018.03.011
   Zameer S, 2017, PHARMACOL REP, V69, P1300, DOI 10.1016/j.pharep.2017.06.002
   Zhou XH, 2018, BBA MOL BASIS DIS, V1864, P488, DOI 10.1016/j.bbadis.2017.11.009
NR 64
TC 18
Z9 19
U1 2
U2 25
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361 9230
EI 1873 2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD AUG
PY 2020
VL 161
BP 197
EP 212
DI 10.1016/j.brainresbull.2020.04.010
PG 16
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA MB4WG
UT WOS:000542603900020
PM 32389800
DA 2025 08 17
ER

PT J
AU Inoue, Y
   Tenshin, H
   Teramachi, J
   Sumitani, R
   Oda, A
   Maeda, Y
   Oura, M
   Sogabe, K
   Maruhashi, T
   Takahashi, M
   Fujii, S
   Nakamura, S
   Miki, H
   Hara, T
   Endo, I
   Kagawa, K
   Ozaki, S
   Hiasa, M
   Harada, T
   Abe, M
AF Inoue, Yusuke
   Tenshin, Hirofumi
   Teramachi, Jumpei
   Sumitani, Ryohei
   Oda, Asuka
   Maeda, Yusaku
   Oura, Masahiro
   Sogabe, Kimiko
   Maruhashi, Tomoko
   Takahashi, Mamiko
   Fujii, Shiro
   Nakamura, Shingen
   Miki, Hirokazu
   Hara, Tomoyo
   Endo, Itsuro
   Kagawa, Kumiko
   Ozaki, Shuji
   Hiasa, Masahiro
   Harada, Takeshi
   Abe, Masahiro
TI Elotuzumab mediated ADCC with Th1 like Vγ9Vδ2 T cells to disrupt
   myeloma osteoclast interaction
SO CANCER SCIENCE
LA English
DT Article
DE Elotuzumab; multiple myeloma; osteoclast; SLAMF7; V gamma 9V delta 2 T
   cell
AB Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1 like V gamma 9V delta 2 (gamma delta) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL 2. We previously reported that the expanded gamma delta T cells effectively targeted and killed OCs as well as MM cells. Because the expanded gamma delta T cells expressed CD16 on their surface, we investigated the utilization of the expanded gamma delta T cells for antibody dependent cellular cytotoxicity (ADCC). Although the expanded gamma delta T cells alone induced cell death in MM cell lines, the addition of the anti SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7 expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance gamma delta T cell induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor kappa B ligand and M CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo expanded gamma delta T cells can exert ELO mediated ADCC against SLAMF7 expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of gamma delta T cells.
C1 [Inoue, Yusuke] Tokushima Univ Hosp, Dept Med Technol, Tokushima, Japan.
   [Tenshin, Hirofumi; Hiasa, Masahiro] Tokushima Univ, Grad Sch Biomed Sci, Dept Orthodont & Dentofacial Orthoped, Tokushima, Japan.
   [Teramachi, Jumpei] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Funct & Anat, Okayama, Japan.
   [Sumitani, Ryohei; Oda, Asuka; Maeda, Yusaku; Oura, Masahiro; Sogabe, Kimiko; Maruhashi, Tomoko; Takahashi, Mamiko; Fujii, Shiro; Hara, Tomoyo; Harada, Takeshi] Tokushima Univ, Grad Sch Biomed Sci, Dept Hematol Endocrinol & Metab, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
   [Nakamura, Shingen] Tokushima Univ, Grad Sch Biomed Sci, Dept Community Med & Med Sci, Tokushima, Japan.
   [Miki, Hirokazu] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Japan.
   [Endo, Itsuro] Tokushima Univ Hosp, Dept Bioregulatory Sci, Tokushima, Japan.
   [Kagawa, Kumiko; Ozaki, Shuji] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Japan.
   [Abe, Masahiro] Kawashima Hosp, Dept Hematol, Tokushima, Japan.
C3 Tokushima University; Tokushima University; Okayama University;
   Tokushima University; Tokushima University; Tokushima University;
   Tokushima University
RP Harada, T (通讯作者)，Tokushima Univ, Grad Sch Biomed Sci, Dept Hematol Endocrinol & Metab, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM takeshi_harada@tokushima u.ac.jp
RI 日浅, 雅博/S 1537 2019; Nakamura, Shingen/GPX 5438 2022
FU Japan Society for the Promotion of Science
FX We thank the Support Center for Advanced Medical Sciences in Tokushima
   University Graduate School of Biomedical Sciences.
CR Castella B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01492
   Costa F, 2017, ONCOTARGET, V8, P56598, DOI 10.18632/oncotarget.17896
   Cui Q, 2011, INT J HEMATOL, V94, P63, DOI 10.1007/s12185 011 0885 9
   Giannotta C, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1167443
   Harada T, 2017, LEUKEMIA, V31, P258, DOI 10.1038/leu.2016.273
   Mensurado S, 2023, NAT REV CLIN ONCOL, V20, P178, DOI 10.1038/s41571 022 00722 1
   Nakamura K, 2020, BLOOD, V136, P2731, DOI 10.1182/blood.2020006540
   Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood 2007 08 107292
   Tenshin H, 2017, BLOOD ADV, V1, P2124, DOI 10.1182/bloodadvances.2017008813
   Teramachi J, 2023, J BONE MINER METAB, V41, P388, DOI 10.1007/s00774 023 01403 4
   Thompson K, 2006, BLOOD, V107, P651, DOI 10.1182/blood 2005 03 1025
NR 11
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD FEB
PY 2025
VL 116
IS 2
BP 559
EP 563
DI 10.1111/cas.16401
EA NOV 2024
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 1PC3T
UT WOS:001357858400001
PM 39557586
OA gold
DA 2025 08 17
ER

PT J
AU Cotter, EJ
   Chew, N
   Powderly, WG
   Doran, PP
AF Cotter, Eoin J.
   Chew, Nicholas
   Powderly, William G.
   Doran, Peter P.
TI HIV 1 Alters Mesenchymal Stem Cell Differentiation Potential and Cell
   Phenotype ex Vivo
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID BONE MARROW; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; INFECTED
   PATIENTS; TAT PROTEIN; RECEPTOR; TYPE 1; ADIPOGENESIS; OSTEOPOROSIS;
   PREVALENCE
AB An increased incidence of bone and lipid toxicities is associated with HIV 1' infection and its treatment. Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into both osteoblasts (OB) and adipocytes (AC). We hypothesize that the interaction of MSC and HIV 1 underlie these toxicities. Serum was collected from uninfected control and HIV infected, antiviral naive patients. Sera were divided into three groups: HIV negative sera (n = 5), HIV positive low viral load (LVL) (VL range 120; 4000, n=5) or high viral load (HVL) (VL range 100,000; 500,000, n = 5). MSCs were exposed to these sera (5%) in an adipogenic/osteogenic condition and in nondifferentiating conditions in acute and chronic exposure models. Markers of adipogenesis/osteogenesis were examined in both MSCs induced to differentiated and nondifferentiating cells. Sera from HVL HIV 1 infected individuals induced a clear proadipogenic phenotype, as evidenced by an increase in adipocyte formation and the induction of increased expression of adipogenic markers including LPL and PPAR gamma. Both CD4 receptor blockade and treatment with the antiretroviral AZT attenuated these proadipogenic effects, suggesting that an infection event may underlie the observed phenomena. Finally, inhibition of COUP TF 1 by HIV 1 TAT was identified as a potential molecular mechanism for these effects. These results suggest that HIV 1 directly interacts with and may infect MSCs resulting in alterations of their differentiation potential, findings that significantly enhance our understanding of HIV 1 associated bone and fat toxicities.
C1 [Cotter, Eoin J.] Univ Coll Dublin, Clin Res Ctr, Catherine Macauley Ctr, Dublin 7, Ireland.
   [Powderly, William G.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 7, Ireland.
C3 University College Dublin; University College Dublin
RP Cotter, EJ (通讯作者)，Univ Coll Dublin, Clin Res Ctr, Catherine Macauley Ctr, Nelson St, Dublin 7, Ireland.
EM eoin.cotter@ucd.ie
OI Doran, Peter/0000 0003 2064 5335; cotter, eoin/0000 0001 6506 3254;
   Powderly, William/0000 0001 7808 3086
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296 1371
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Barillari G, 1999, BLOOD, V94, P663
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Cotter EJ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 33
   Craig DH, 2009, AM J PHYSIOL CELL PH, V296, pC193, DOI 10.1152/ajpcell.00355.2008
   DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   Gregory CA, 2005, EXP CELL RES, V306, P330, DOI 10.1016/j.yexcr.2005.03.018
   GUO L, 1994, ANTIMICROB AGENTS CH, V38, P2483, DOI 10.1128/AAC.38.10.2483
   Hamrick M.W., 2007, Bonekey Osteovision, V4, P99, DOI 10.1138/20070254
   Hamrick MW, 2005, J BONE MINER RES, V20, P994, DOI 10.1359/JBMR.050103
   Huang JL, 2007, NAT MED, V13, P1241, DOI 10.1038/nm1639
   Jain RG, 2002, J BIOL CHEM, V277, P19247, DOI 10.1074/jbc.C200069200
   Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667
   Kim SH, 2006, TOXICOL APPL PHARM, V215, P198, DOI 10.1016/j.taap.2006.03.001
   Knobel H, 2001, AIDS, V15, P807, DOI 10.1097/00002030 200104130 00022
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030 200305020 00005
   Meunier P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086 197110000 00021
   MILLINKOVIC A, 2006, COLL ANTROPOL S2, V2, P59
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   O'Doherty U, 2002, J VIROL, V76, P10942, DOI 10.1128/JVI.76.21.10942 10950.2002
   Ou XM, 2009, INT IMMUNOPHARMACOL, V9, P70, DOI 10.1016/j.intimp.2008.10.002
   Richardson J, 2008, J BONE JOINT SURG BR, V90B, P988, DOI 10.1302/0301 620X.90B8.20861
   Rohr O, 2000, J BIOL CHEM, V275, P2654, DOI 10.1074/jbc.275.4.2654
   Scheideler M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 340
   SHI X, 2007, PPAR RES, V92, P501
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wang LX, 2002, AIDS RES HUM RETROV, V18, P917, DOI 10.1089/088922202760265597
   Xu Z, 2008, P NATL ACAD SCI USA, V105, P2421, DOI 10.1073/pnas.0707082105
   Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood 2002 02 0531
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
NR 41
TC 44
Z9 46
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889 2229
EI 1931 8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB
PY 2011
VL 27
IS 2
BP 187
EP 199
DI 10.1089/aid.2010.0114
PG 13
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA 716XG
UT WOS:000287006200013
PM 20929345
DA 2025 08 17
ER

PT J
AU Kim, TH
   Hong, JM
   Oh, B
   Cho, YS
   Lee, JY
   Kim, HL
   Lee, JE
   Ha, MH
   Park, EK
   Kim, SY
AF Kim, Tae Ho
   Hong, Jung Min
   Oh, Bermseok
   Cho, Yoon Shin
   Lee, Jong Young
   Kim, Hyung Lae
   Lee, Jong Eun
   Ha, Mi Hyun
   Park, Eui Kyun
   Kim, Shin Yoon
TI Association of polymorphisms in the interleukin 23 receptor gene with
   osteonecrosis of femoral head in Korean population
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
DE femur head; interleukin 23; osteonecrosis; polymorphism, single
   nucleotide
ID GENOME WIDE ASSOCIATION; CROHNS DISEASE; IL23R; IL 23; SUSCEPTIBILITY;
   OSTEOCLASTS; MECHANISM; CYTOKINE; THERAPY; INSIGHT
AB Osteonecrosis of the femoral head (ONFH) is known as death of the cellular portion of the femoral head due to an interruption in the vascular supply. The underlying pathophysiology regarding bone cell death remains uncertain. Recently, several studies have shown that autoimmune disorders were related to the development of osteonecrosis. This study investigated the genetic effects of Interleukin 23 receptor (IL23R) polymorphisms regarding the risk of ONFH. Ten SNPs were selected and genotyped in 443 ONFH patients and 273 control subjects in order to perform the genetic association analysis. It was found that polymorphisms of the IL23R gene (rs4655686, rs1569922 and rs7539625) were significantly associated with an increased risk of ONFH (P values; 0.0198 0.0447, OR; 1.30 1.49). Particularly, a stratified analysis based on etiology (alcohol, steroid or idiopathic) showed that the associations between these polymorphisms and ONFH were most significant in idiopathic ONFH patients (P values; 0.0001 0.0150, OR; 1.45 2.17). These results suggest that IL23R polymorphisms may play an important role in the development of ONFH.
C1 [Kim, Tae Ho; Hong, Jung Min; Ha, Mi Hyun; Park, Eui Kyun; Kim, Shin Yoon] Kyungpook Natl Univ Hosp, Skeletal Dis Genome Res Ctr, Taegu 700412, South Korea.
   [Kim, Tae Ho] Kyungpook Natl Univ, Sch Med, Dept Med, Taegu 700412, South Korea.
   [Kim, Shin Yoon] Kyungpook Natl Univ, Sch Med, Dept Orthoped Surg, Taegu 700412, South Korea.
   [Park, Eui Kyun] Kyungpook Natl Univ, Sch Dent, Dept Pathol & Regenerat Med, Taegu 700412, South Korea.
   [Oh, Bermseok; Cho, Yoon Shin; Lee, Jong Young; Kim, Hyung Lae] Natl Inst Hlth, Natl Genome Res Inst, Seoul 122701, South Korea.
   [Lee, Jong Eun] DNA Link Inc, Seoul 120110, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   Hospital (KNUH); Kyungpook National University (KNU); Kyungpook National
   University (KNU); Kyungpook National University (KNU); Korea Disease
   Control & Prevention Agency (KDCA); Korea National Institute of Health
   (KNIH); DNA Link, Inc.
RP Kim, SY (通讯作者)，Kyungpook Natl Univ Hosp, Skeletal Dis Genome Res Ctr, Taegu 700412, South Korea.
EM syukim@knu.ac.kr
RI Lee, Jong Young/M 6319 2013; kim, nayoung/IWV 4038 2023; Lee,
   Jung Seok/L 6826 2019
OI Kim, Shin Yoon/0000 0002 5445 648X; 
FU Korea Health 21 RD Project; Ministry of Health and Welfare, Republic of
   Korea [A010252]; Korea National Institute of Health, Korea; Center for
   Disease Control, Republic of Korea
FX This work was supported by a grant from the Korea Health 21 R&D Project,
   Ministry of Health and Welfare, Republic of Korea (Project No.:
   A010252), and intramural grants from the Korea National Institute of
   Health, Korea Center for Disease Control, Republic of Korea.
CR Abu Shakra M, 2003, CLIN REV ALLERG IMMU, V25, P13, DOI 10.1385/CRIAI:25:1:13
   ATSUMI T, 1992, CLIN ORTHOP RELAT R, P22
   Boss JH, 2004, MED HYPOTHESES, V62, P958, DOI 10.1016/j.mehy.2003.12.036
   Capon F, 2007, HUM GENET, V122, P201, DOI 10.1007/s00439 007 0397 0
   Cardon LR, 2006, SCIENCE, V314, P1403, DOI 10.1126/science.1136668
   Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051
   Childs SG, 2005, ORTHOP NURS, V24, P295
   Cummings JAF, 2007, INFLAMM BOWEL DIS, V13, P1063, DOI 10.1002/ibd.20180
   DECAMARGO FP, 1984, CLIN ORTHOP RELAT R, P216
   Dubinsky MC, 2007, INFLAMM BOWEL DIS, V13, P511, DOI 10.1002/ibd.20126
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Glas J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000819
   Glueck C J, 2003, Curr Hematol Rep, V2, P417
   GOLD EW, 1979, CLIN ORTHOP RELAT R, P222
   Goldring SR, 1996, CLIN ORTHOP RELAT R, P13
   HEDRICK PW, 1987, GENETICS, V117, P331
   Jones J P Jr, 1999, Acta Orthop Belg, V65 Suppl 1, P5
   Kamiya S, 2007, J BONE MINER METAB, V25, P277, DOI 10.1007/s00774 007 0766 8
   Kerachian MA, 2006, ENDOTHELIUM J ENDOTH, V13, P237, DOI 10.1080/10623320600904211
   Kim DJ, 2006, EXP MOL MED, V38, P519, DOI 10.1038/emm.2006.61
   Kim TH, 2007, MOL CELLS, V24, P388
   Lane NE, 2006, NAT CLIN PRACT RHEUM, V2, P562, DOI 10.1038/ncprheum0298
   MIGLIARESI S, 1994, LUPUS, V3, P37, DOI 10.1177/096120339400300108
   Mohamed SGK, 2005, BIOCHEM BIOPH RES CO, V329, P839, DOI 10.1016/j.bbrc.2005.02.049
   Mont MA, 1998, CLIN ORTHOP RELAT R, pS314
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   Mundy GR, 1996, CLIN ORTHOP RELAT R, P24, DOI 10.1097/00003086 199603000 00004
   Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074 7613(00)00070 4
   Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699
   Qin ZHS, 2002, AM J HUM GENET, V71, P1242, DOI 10.1086/344207
   Raelson JV, 2007, P NATL ACAD SCI USA, V104, P14747, DOI 10.1073/pnas.0706645104
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Roberts RL, 2007, AM J GASTROENTEROL, V102, P2754, DOI 10.1111/j.1572 0241.2007.01525.x
   Sánchez E, 2007, TISSUE ANTIGENS, V70, P233, DOI 10.1111/j.1399 0039.2007.00881.x
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Tektonidou MG, 2004, ORTHOP CLIN N AM, V35, P259, DOI 10.1016/j.ocl.2004.02.003
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
NR 40
TC 20
Z9 22
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD AUG 31
PY 2008
VL 40
IS 4
BP 418
EP 426
DI 10.3858/emm.2008.40.4.418
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 346SF
UT WOS:000259088800007
PM 18779654
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mastbergen, SC
   Bijlsma, JW
   Lafeber, FP
AF Mastbergen, SC
   Bijlsma, JW
   Lafeber, FP
TI Selective COX 2 inhibition is favorable to human early and late stage
   osteoarthritic cartilage:: a human in vitro study
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE human cartilage; Osteoarthritis; COX 2 inhibition
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HUMAN ARTICULAR CARTILAGE;
   PROTEOGLYCAN SYNTHESIS; CYCLOOXYGENASE; METABOLISM; CHONDROCYTES;
   MECHANISMS; EXPLANT; DISEASE; CULTURE
AB Objective: Nonsteroidal anti inflammatory drugs (NSAIDs) are widely used in the treatment of osteoarthritis (OA). For the outcome of treatment the direct effects of NSAIDs on cartilage may be more important than indirect effects on inflammation, considered being secondary in OA. For clinical practice, it is relevant to study effects of NSAIDs on early stages of OA. Therefore we studied the direct effects of celecoxib on human degenerated OA cartilage and compared the effects with those on human healthy cartilage and human end stage CA cartilage.
   Methods: Degenerated, late stage OA, and healthy human articular cartilage were exposed (7 days of culture) to celecoxib (0.1 10 mu M). Changes in cartilage proteoglycan turnover (synthesis, retention, and release), proteoglycan content, prostaglandin E 2 (PGE(2)) and nitric oxide (NO) production were determined.
   Results: Both degenerated and established OA cartilage showed its characteristic changes in proteoglycan turnover (all P < 0.05). Celecoxib at 1 mu M was able to increase synthesis of degenerated cartilage and normalize both releases of newly formed and resident proteoglycans. Importantly, 1 mu M celecoxib influenced matrix integrity by enhancing proteoglycan content. Similar results were found for end stage OA cartilage. Enhanced PGE(2) production in degenerative and OA cartilage could be decreased by celecoxib, whereas no effect on enhanced NO production was found. No significant effects of celecoxib on normal cartilage were found.
   Discussion: Celecoxib, in a clinical relevant concentration, showed in vitro a significant beneficial effect, not only on late stage CA but also on more early stages of OA, whereas healthy cartilage remained unaffected, suggesting chondroprotective properties of celecoxib in the treatment of degenerative joint disorders. (C) 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 Univ Med Ctr Utrecht, NL 3508 GA Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center
RP Mastbergen, SC (通讯作者)，Univ Med Ctr Utrecht, Room F02 127,POB 85500, NL 3508 GA Utrecht, Netherlands.
EM s.mastbergen@azu.nl
CR ABRAMSON S, 1989, CLIN EXP RHEUMATOL, V7, pS163
   Abramson SB, 2001, BEST PRACT RES CL RH, V15, P831, DOI 10.1053/berh.2001.0196
   Amin A R, 2000, Curr Rheumatol Rep, V2, P447, DOI 10.1007/s11926 000 0019 5
   Aspden RM, 2001, LANCET, V357, P1118, DOI 10.1016/S0140 6736(00)04264 1
   Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118
   COLLIER S, 1991, BIOCHEM PHARMACOL, V41, P1375, DOI 10.1016/0006 2952(91)90111 H
   Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140 6736(97)07226 7
   Cryer B, 1998, PROSTAG OTH LIPID M, V56, P341, DOI 10.1016/S0090 6980(98)00064 1
   Ding CH, 2002, INFLAMMATION, V26, P139, DOI 10.1023/A:1015504632021
   Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161
   Dingle JT, 1999, OSTEOARTHR CARTILAGE, V7, P313, DOI 10.1053/joca.1998.0176
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   El Hajjaji H, 2003, J RHEUMATOL, V30, P2444
   Fung HB, 1999, CLIN THER, V21, P1131, DOI 10.1016/S0149 2918(00)80018 1
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   Harris RC, 2002, AM J CARDIOL, V89, p10D
   Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140 6736(98)12154 2
   Henrotin YE, 1999, CLIN EXP RHEUMATOL, V17, P151
   Jacques C, 1999, REV RHUM, V66, P701
   Johnston SA, 1997, J AM VET MED ASSOC, V210, P1486
   LAFEBER FPJG, 1993, BRIT J RHEUMATOL, V32, P281
   LAFEBER FPJG, 1993, CONNECT TISSUE RES, V29, P287, DOI 10.3109/03008209309016834
   LAFEBER FPJG, 1992, AM J PATHOL, V140, P1421
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Mastbergen SC, 2002, RHEUMATOLOGY, V41, P801, DOI 10.1093/rheumatology/41.7.801
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P308
   Poole A. Robin, 1999, Frontiers in Bioscience, V4, pd662, DOI 10.2741/Poole
   Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140 6736(02)11131 7
   Siegle I, 1998, ARTHRITIS RHEUM US, V41, P122, DOI 10.1002/1529 0131(199801)41:1<122::AID ART15>3.3.CO;2 #
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   SMITH RL, 1995, J RHEUMATOL, V22, P1130
   vanValburg AA, 1997, J RHEUMATOL, V24, P358
   WHITEMAN P, 1973, BIOCHEM J, V131, P351, DOI 10.1042/bj1310351
NR 33
TC 67
Z9 73
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1063 4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JUN
PY 2005
VL 13
IS 6
BP 519
EP 526
DI 10.1016/j.joca.2005.02.004
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 935NZ
UT WOS:000229790300008
PM 15922186
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, AQ
   Qu, SX
   Chao, MM
   Zhu, MH
   Weng, J
   Zhou, ZR
AF Liu, Aiqin
   Qu, Shuxin
   Chao, Mengmeng
   Zhu, Minhao
   Weng, Jie
   Zhou, Zhongrong
TI UHMWPE carrying estradiol to treat the particle induced
   osteolysis Processing and characterizing
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE ultra high molecular weight polyethylene (UHMWPE); 17 beta estradiol
   (E2); hot press processing characterization; wear
ID MOLECULAR WEIGHT POLYETHYLENE; WEAR PERFORMANCE; BONE RESORPTION;
   DRUG DELIVERY; IN VITRO; BISPHOSPHONATE; OSTEOBLASTS; COMPOSITES;
   FRICTION; BEHAVIOR
AB The objective of this study was to explore the possibility of UHMWPE implant used as the drug carrier to treat particle induced osteolysis. 17 beta estradiol (E2), which had. the potential application on osteolysis treatment and the high melting point, was added into UHMWPE powder to produce UHMWPE E2 composites through hot press processing. The hydrophobicity, crystallinity, mechanical properties, and wear performance of the UHMWPE E2 were characterized compared with the control UHMWPE. The thermal analysis and Fourier Transform Infrared Spectroscopy results demonstrated that the hot press processing Would not alter the functional groups of E2 in this study. There were no significant differences in the hydrophobicity and crystallinity between the UHMWPE E2 and UHMWPE. The UHMWPE E2 showed satisfying mechanical properties, including ultimate tensile strength (47.2 +/  3.6 MPa), yield strength (25.0 +/  0.6 MPa) and elongation at break (320 +/  25.5%), which were similar with the control UHMWPE. The friction coefficients and worn scars were similar between the UHMWPE E2 and the control UHMWPE. The wear mechanism of the UHMWPE E2 and UHMWPE both were abrasive wear under dry friction. The UHMWPE E2 possesses the approving mechanical properties and wear performance compared with the control UHMWPE, which might be used as the potential implanted drug carrier to prevent the particle induced osteolysis in joint replacements. (C) 2008 Wiley Periodicals, Inc. J Biomed Mater Res 90A: 496 505, 2009
C1 [Qu, Shuxin; Zhu, Minhao; Zhou, Zhongrong] SW Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat,Tribol Res Inst, Chengdu 610031, Peoples R China.
C3 Southwest Jiaotong University
RP Qu, SX (通讯作者)，SW Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat,Tribol Res Inst, Chengdu 610031, Peoples R China.
EM qushuxin@home.swjtu.edu.cn
RI Zhou, Zhong/H 3199 2011; liu, Aiqin/AGK 2956 2022; Weng,
   Jie/B 3005 2010; QU, Shuxin/H 3036 2011
OI Weng, Jie/0000 0002 7034 3215; Liu, Aiqin/0000 0001 6524 1698
FU National Natural Science Foundation of China [50535050]; Ministry of
   Education, China [NCET 05 0797]
FX Contract grant sponsor: National Natural Science Foundation of China;
   contract grant number: Key Project 50535050Contract grant sponsor:
   Program for New Century Excellent Talents in University, Ministry of
   Education, China; contract grant number: NCET 05 0797
CR AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, V276, P18
   Anderson BC, 2002, BIOMATERIALS, V23, P1761, DOI 10.1016/S0142 9612(01)00301 5
   Anissian HL, 1999, ACTA ORTHOP SCAND, V70, P578, DOI 10.3109/17453679908997845
   Åstrand J, 2004, J ORTHOP RES, V22, P244, DOI 10.1016/j.orthres.2003.08.008
   Buford A, 2004, MATER DESIGN, V25, P385, DOI 10.1016/j.matdes.2003.11.010
   Chiesa R, 2000, J BIOMED MATER RES, V50, P381, DOI 10.1002/(SICI)1097 4636(20000605)50:3<381::AID JBM12>3.0.CO;2 P
   DiSilvio L, 2006, INJURY, V37, pS33, DOI 10.1016/j.injury.2006.08.022
   Duan K, 2005, J BIOMED MATER RES B, V72B, P43, DOI 10.1002/jbm.b.30112
   Firkins PJ, 2001, J BIOMECH, V34, P1291, DOI 10.1016/S0021 9290(01)00096 3
   Fruh HJ, 1997, BIOMATERIALS, V18, P873, DOI 10.1016/S0142 9612(97)00005 7
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   Harris Steven A., 1996, P507
   HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46
   Holzer G, 2002, J ORTHOP RES, V20, P281, DOI 10.1016/S0736 0266(01)00092 4
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Iwase M, 2002, J ORTHOPAED RES, V20, P499, DOI 10.1016/S0736 0266(01)00155 3
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Johnson K.L., 1985, Contact Mechanics, P90
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kurtz SM, 1999, BIOMATERIALS, V20, P1659, DOI 10.1016/S0142 9612(99)00053 8
   MARTI E, 2000, NETZSCH ANN 2000 THE, P90
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Mohr D, 1999, J CONTROL RELEASE, V61, P203, DOI 10.1016/S0168 3659(99)00118 2
   NUSBAUM HJ, 1979, J APPL POLYM SCI, V23, P777, DOI 10.1002/app.1979.070230313
   Otsuka M, 2000, ADV DRUG DELIVER REV, V42, P249, DOI 10.1016/S0169 409X(00)00065 X
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Pruitt LA, 2005, BIOMATERIALS, V26, P905, DOI 10.1016/j.biomaterials.2004.03.022
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Ren WP, 2004, J ORTHOP RES, V22, P21, DOI 10.1016/S0736 0266(03)00130 X
   RIEU J, 1991, BIOMATERIALS, V12, P139, DOI 10.1016/0142 9612(91)90192 D
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   Shi W, 2003, SURF ENG, V19, P279, DOI 10.1179/026708403225006221
   Shirong G., 2003, WEAR, V255, P1069
   Spiegelberg S, 2004, UHMWPE HDB ULTRAHIGH, P266
   Thadani PJ, 2002, ORTHOPEDICS, V25, P59
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tong J, 2006, COMPOS PART A APPL S, V37, P38, DOI 10.1016/j.compositesa.2005.05.023
   von Knoch F, 2005, BIOMATERIALS, V26, P3549, DOI 10.1016/j.biomaterials.2004.09.043
   Wang A, 1998, TRIBOL INT, V31, P17, DOI 10.1016/S0301 679X(98)00005 X
   WILLERT HG, 1990, CLIN ORTHOP RELAT R, P95
   Xie XL, 2003, BIOMATERIALS, V24, P1889, DOI 10.1016/S0142 9612(02)00610 5
   Xiong DS, 2005, MATER LETT, V59, P175, DOI 10.1016/j.matlet.2004.09.011
   Zenios M, 2004, J BIOMED MATER RES B, V71B, P322, DOI 10.1002/jbm.b.30101
   Zheng J, 2007, TRIBOL INT, V40, P278, DOI 10.1016/j.triboint.2005.09.025
NR 45
TC 8
Z9 10
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD AUG
PY 2009
VL 90A
IS 2
BP 496
EP 505
DI 10.1002/jbm.a.32120
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 468JP
UT WOS:000267814100022
PM 18563828
DA 2025 08 17
ER

PT J
AU Umar, S
   Palasiewicz, K
   Van Raemdonck, K
   Volin, MV
   Romay, B
   Amin, MA
   Zomorrodi, RK
   Arami, S
   Gonzalez, M
   Rao, V
   Zanotti, B
   Fox, DA
   Sweiss, N
   Shahrara, S
AF Umar, Sadiq
   Palasiewicz, Karol
   Van Raemdonck, Katrien
   Volin, Michael V.
   Romay, Bianca
   Amin, M. Asif
   Zomorrodi, Ryan K.
   Arami, Shiva
   Gonzalez, Mark
   Rao, Vikram
   Zanotti, Brian
   Fox, David A.
   Sweiss, Nadera
   Shahrara, Shiva
TI IRAK4 inhibition: a promising strategy for treating RA joint
   inflammation and bone erosion
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE TLR7; M phi s; RA FLSs; osteoclasts; T cells; IRAK4
ID COLLAGEN INDUCED ARTHRITIS; TOLL LIKE RECEPTORS; RHEUMATOID ARTHRITIS;
   KINASE ACTIVITY; TNF ALPHA; NECROSIS FACTOR; LIGATION; BLOCKADE; CELLS;
   TLR7
AB Flares of joint inflammation and resistance to currently available biologic therapeutics in rheumatoid arthritis (RA) patients could reflect activation of innate immune mechanisms. Herein, we show that a TLR7 GU rich endogenous ligand, miR Let7b, potentiates synovitis by amplifying RA monocyte and fibroblast (FLS) trafficking. miR Let7b ligation to TLR7 in macrophages (M phi s) and FLSs expanded the synovial inflammatory response. Moreover, secretion of M1 monokines triggered by miR Let7b enhanced Th1/Th17 cell differentiation. We showed that IRAK4 inhibitor (i) therapy attenuated RA disease activity by blocking TLR7 induced M1 M phi or FLS activation, as well as monokine modulated Th1/Th17 cell polarization. IRAK4i therapy also disrupted RA osteoclastogenesis, which was amplified by miR Let7b ligation to joint myeloid TLR7. Hence, the effectiveness of IRAK4i was compared with that of a TNF inhibitor (i) or anti IL 6R treatment in collagen induced arthritis (CIA) and miR Let7b mediated arthritis. We found that TNF or IL 6R blocking therapies mitigated CIA by reducing the infiltration of joint F480(+)iNOS(+) M phi s, the expression of certain monokines, and Th1 cell differentiation. Unexpectedly, these biologic therapies were unable to alleviate miR Let7b induced arthritis. The superior efficacy of IRAK4i over anti TNF or anti IL 6R therapy in miR Let7b induced arthritis or CIA was due to the ability of IRAK4i therapy to restrain the migration of joint F480(+)iNOS(+) M phi s, vimentin(+) fibroblasts, and CD3(+) T cells, in addition to negating the expression of a wide range of monokines, including IL 12, MIP2, and IRF5 and Th1/Th17 lymphokines. In conclusion, IRAK4i therapy may provide a promising strategy for RA therapy by disconnecting critical links between inflammatory joint cells.
C1 [Umar, Sadiq; Palasiewicz, Karol; Van Raemdonck, Katrien; Arami, Shiva; Shahrara, Shiva] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.
   [Umar, Sadiq; Palasiewicz, Karol; Van Raemdonck, Katrien; Romay, Bianca; Zomorrodi, Ryan K.; Arami, Shiva; Sweiss, Nadera; Shahrara, Shiva] Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL 60612 USA.
   [Volin, Michael V.; Zanotti, Brian] Midwestern Univ, Dept Microbiol & Immunol, Downers Grove, IL 60515 USA.
   [Amin, M. Asif; Fox, David A.] Univ Michigan, Ctr Excellence, Div Rheumatol & Clin Autoimmun, Ann Arbor, MI 48109 USA.
   [Gonzalez, Mark] Univ Illinois, Dept Orthoped Surg, Chicago, IL 60612 USA.
   [Rao, Vikram] Pfizer Res, Cambridge, MA 02139 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Jesse Brown VA Medical Center; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital; Midwestern
   University; Midwestern University   Downers Grove; University of
   Michigan System; University of Michigan; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   Pfizer; Pfizer USA
RP Shahrara, S (通讯作者)，Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.; Shahrara, S (通讯作者)，Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL 60612 USA.
EM shahrara@uic.edu
RI ; Umar, Sadiq/H 3769 2019
OI Umar, Sadiq/0000 0002 4733 5751; Zomorrodi, Ryan/0009 0003 6417 5985;
   Shahrara, Shiva/0000 0002 6698 8491; Palasiewicz,
   Karol/0000 0002 2894 6047
FU Department of Veteran's Affairs MERIT Award [1I01BX002286]; National
   Institutes of Health [AR056099, AR065778]; National Psoriasis Foundation
   (NPF); Pfizer Investigator Initiated Research (IIR) Program; Chicago
   Biomedical Consortium (CBC) Accelerator Award
FX This work was supported in part by awards from the Department of
   Veteran's Affairs MERIT Award (1I01BX002286), the National Institutes of
   Health (AR056099 and AR065778), the National Psoriasis Foundation (NPF),
   the Pfizer Investigator Initiated Research (IIR) Program, and the
   Chicago Biomedical Consortium (CBC) Accelerator Award.
CR Alzabin S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3875
   Alzabin S, 2012, ANN RHEUM DIS, V71, P1741, DOI 10.1136/annrheumdis 2011 201024
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Balak DMW, 2017, CLIN IMMUNOL, V174, P63, DOI 10.1016/j.clim.2016.09.015
   Chamberlain ND, 2013, ANN RHEUM DIS, V72, P418, DOI 10.1136/annrheumdis 2011 201203
   Chamberlain ND, 2012, J IMMUNOL, V189, P475, DOI 10.4049/jimmunol.1102977
   Chen SY, 2012, GENE THER, V19, P752, DOI 10.1038/gt.2011.173
   Chen ZL, 2015, ANN RHEUM DIS, V74, P1898, DOI 10.1136/annrheumdis 2013 204530
   Chen Z, 2013, J IMMUNOL, V190, P5256, DOI 10.4049/jimmunol.1201675
   Cho JH, 2017, ONCOTARGET, V8, P24932, DOI 10.18632/oncotarget.15326
   Cushing L, 2017, J BIOL CHEM, V292, P18689, DOI 10.1074/jbc.M117.796912
   Cushing L, 2014, J BIOL CHEM, V289, P10865, DOI 10.1074/jbc.M113.544809
   Danto SI, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2008 6
   Dayer JM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00293
   Dépis F, 2012, ARTHRITIS RHEUM US, V64, P3189, DOI 10.1002/art.34497
   Duffau P, 2015, ARTHRITIS RHEUMATOL, V67, P3146, DOI 10.1002/art.39321
   Elshabrawy H, 2018, ANGIOGENESIS, V21, P215, DOI 10.1007/s10456 017 9589 y
   Elshabrawy HA, 2017, AUTOIMMUN REV, V16, P103, DOI 10.1016/j.autrev.2016.12.003
   Fujimoto M, 2008, ARTHRITIS RHEUM US, V58, P3710, DOI 10.1002/art.24126
   Genung N E, 2017, Prog Med Chem, V56, P117, DOI 10.1016/bs.pmch.2016.11.004
   Giménez N, 2020, LEUKEMIA, V34, P100, DOI 10.1038/s41375 019 0507 8
   Hasham MG, 2017, DIS MODEL MECH, V10, P259, DOI 10.1242/dmm.027409
   Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118
   Kim H, 2018, BIOMATERIALS, V164, P38, DOI 10.1016/j.biomaterials.2018.02.034
   Kim SJ, 2020, CELL MOL IMMUNOL, V17, P728, DOI 10.1038/s41423 019 0235 z
   Kim SJ, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209206
   Kim SJ, 2016, ARTHRITIS RHEUMATOL, V68, P1099, DOI 10.1002/art.39544
   Kim SJ, 2014, J IMMUNOL, V193, P3902, DOI 10.4049/jimmunol.1302998
   Kim SJ, 2013, ARTHRITIS RHEUM US, V65, P2024, DOI 10.1002/art.37992
   Kim TW, 2007, J EXP MED, V204, P1025, DOI 10.1084/jem.20061825
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Koziczak Holbro M, 2007, J BIOL CHEM, V282, P13552, DOI 10.1074/jbc.M700548200
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990
   Lee KL, 2017, J MED CHEM, V60, P5521, DOI 10.1021/acs.jmedchem.7b00231
   Li QC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048278
   Miyamoto A, 2012, CYTOTECHNOLOGY, V64, P331, DOI 10.1007/s10616 012 9442 5
   Morgan R, 2015, ARTHRITIS RHEUMATOL, V67, P74, DOI 10.1002/art.38878
   Negishi H, 2019, P NATL ACAD SCI USA, V116, P23653, DOI 10.1073/pnas.1915326116
   Notley CA, 2008, J EXP MED, V205, P2491, DOI 10.1084/jem.20072707
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P914, DOI 10.1002/art.30232
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P2884, DOI 10.1002/art.30493
   Pickens SR, 2011, ARTHRITIS RHEUM US, V63, P2289, DOI 10.1002/art.30324
   Salvi V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98204
   Spinetti T, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1230578
   Suárez Fariñas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084634
   Thiolat A, 2014, ARTHRITIS RHEUMATOL, V66, P273, DOI 10.1002/art.38246
   Van Raemdonck K, 2020, CELL MOL LIFE SCI, V77, P1387, DOI 10.1007/s00018 019 03235 w
   Weiss M, 2015, P NATL ACAD SCI USA, V112, P11001, DOI 10.1073/pnas.1506254112
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Xiao Q, 2016, J IMMUNOL, V197, P3820, DOI 10.4049/jimmunol.1600333
   Ye J, 2017, J IMMUNOL, V199, P941, DOI 10.4049/jimmunol.1601890
   Ye XJ, 2004, CLIN EXP IMMUNOL, V136, P440, DOI 10.1111/j.1365 2249.2004.02430.x
   Zhu FG, 2013, AUTOIMMUNITY, V46, P419, DOI 10.3109/08916934.2013.798651
   Zhu W, 2015, INFLAMMATION, V38, P2067, DOI 10.1007/s10753 015 0188 z
NR 54
TC 35
Z9 37
U1 0
U2 18
PU CHIN SOCIETY IMMUNOLOGY
PI BEING
PA 5 DONGDAN SANTIAO, DONGCHEN DISTRICT, BEING, 100005, PEOPLES R CHINA
SN 1672 7681
EI 2042 0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD SEP
PY 2021
VL 18
IS 9
BP 2199
EP 2210
DI 10.1038/s41423 020 0433 8
EA MAY 2020
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA UO7YI
UT WOS:000533048500001
PM 32415262
OA Green Published
DA 2025 08 17
ER

PT J
AU Kozlova, D
   Chernousova, S
   Knuschke, T
   Buer, J
   Westendorf, AM
   Epple, M
AF Kozlova, Diana
   Chernousova, Svitlana
   Knuschke, Torben
   Buer, Jan
   Westendorf, Astrid M.
   Epple, Matthias
TI Cell targeting by antibody functionalized calcium phosphate
   nanoparticles
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID NONVIRAL VECTORS; DRUG DELIVERY; GENE DELIVERY; QUANTUM DOTS;
   TRANSFECTION; FLUORESCENT; SHELL; HYDROXYAPATITE; NANOMEDICINE
AB Calcium phosphate nanoparticles were coated with a shell of silica and covalently functionalized by silanization, either with thiol or with amino groups. This permits the covalent attachment of molecules like dyes or antibodies. Between the calcium phosphate surface and the outer silica shell, biomolecules like nucleic acids (DNA or siRNA) can be incorporated as cargo. This leads to cell specific carriers of biomolecules into cells, e.g. for transfection, gene silencing or cell activation. The cellular uptake of antibody coated calcium phosphate nanoparticles was demonstrated on two cell lines: He La (epithelial cell line) and MG 63 (osteoblast like cell line). Furthermore, the functionalization of calcium phosphate nanoparticles with a dendritic cell specific antibody (CD11c) led to a cell specific targeting as shown with primary murine splenocytes. Thus, the successful coating of calcium phosphate nanoparticles with cell specific antibodies makes them suitable for many clinical applications.
C1 [Kozlova, Diana; Chernousova, Svitlana; Epple, Matthias] Univ Duisburg Essen, Inst Inorgan Chem, D 45117 Essen, Germany.
   [Knuschke, Torben; Buer, Jan; Westendorf, Astrid M.] Univ Duisburg Essen, Inst Med Microbiol, Univ Hosp Essen, D 45147 Essen, Germany.
   [Kozlova, Diana; Chernousova, Svitlana; Epple, Matthias] Univ Duisburg Essen, Ctr Nanointegrat Duisburg Essen CeNIDE, D 45117 Essen, Germany.
C3 University of Duisburg Essen; University of Duisburg Essen; University
   of Duisburg Essen
RP Epple, M (通讯作者)，Univ Duisburg Essen, Inst Inorgan Chem, Univ Str 5 7, D 45117 Essen, Germany.
EM matthias.epple@uni due.de
RI Knuschke, Torben/ABH 2933 2020; Westendorf, Astrid/AAX 1937 2020; Epple,
   Matthias/AAX 9694 2020
OI Knuschke, Torben/0000 0002 2273 1475; Epple,
   Matthias/0000 0002 1641 7068; Buer, Jan/0000 0002 7602 1698; 
FU Deutsche Forschungs gemeinschaft [SFB/Transregio 60]
FX This work was supported by the Deutsche Forschungs gemeinschaft
   (SFB/Transregio 60) to A.M.W., J.B. and M.E. We thank Dr V. Sokolova for
   helpful discussions.
CR Ackerson CJ, 2006, J AM CHEM SOC, V128, P2635, DOI 10.1021/ja0555668
   Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Azarmi S, 2006, J PHARM PHARM SCI, V9, P124
   Balasubramanian SK, 2010, BIOMATERIALS, V31, P9023, DOI 10.1016/j.biomaterials.2010.08.012
   Barth BM, 2010, ACS NANO, V4, P1279, DOI 10.1021/nn901297q
   BECK P, 1990, J MICROENCAPSUL, V7, P491, DOI 10.3109/02652049009040471
   BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003 2697(89)90662 3
   Claesson EM, 2007, COLLOID SURFACE A, V297, P46, DOI 10.1016/j.colsurfa.2006.10.019
   Cui Y, 2011, CHEM SCI, V2, P1463, DOI 10.1039/c1sc00242b
   Epple M, 2010, J MATER CHEM, V20, P18, DOI 10.1039/b910885h
   Fernando LP, 2010, BIOMACROMOLECULES, V11, P2675, DOI 10.1021/bm1007103
   Fukumori Y, 2006, ADV POWDER TECHNOL, V17, P1, DOI 10.1163/156855206775123494
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Goesmann H, 2010, ANGEW CHEM INT EDIT, V49, P1362, DOI 10.1002/anie.200903053
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Ibrahim I.A., 2010, AM SCI, V6, P985
   Jun YW, 2008, ACCOUNTS CHEM RES, V41, P179, DOI 10.1021/ar700121f
   Kievit FM, 2011, ADV MATER, V23, pH217, DOI 10.1002/adma.201102313
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Klesing J, 2010, J MATER SCI MATER M, V21, P887, DOI 10.1007/s10856 009 3934 7
   Kurreck J, 2009, ANGEW CHEM INT EDIT, V48, P1378, DOI 10.1002/anie.200802092
   Laroui H, 2011, AM J PHYSIOL GASTR L, V300, pG371, DOI 10.1152/ajpgi.00466.2010
   Liu YC, 2011, INT J NANOMED, V6, P721, DOI 10.2147/IJN.S17096
   Mailänder V, 2009, BIOMACROMOLECULES, V10, P2379, DOI 10.1021/bm900266r
   Maitra A, 2005, EXPERT REV MOL DIAGN, V5, P893, DOI 10.1586/14737159.5.6.893
   Neumann S, 2009, BIOMATERIALS, V30, P6794, DOI 10.1016/j.biomaterials.2009.08.043
   Neumeier M, 2011, J MATER CHEM, V21, P1250, DOI 10.1039/c0jm02264k
   Olton D, 2007, BIOMATERIALS, V28, P1267, DOI 10.1016/j.biomaterials.2006.10.026
   Ow H, 2005, NANO LETT, V5, P113, DOI [10.1021/nl0482478, 10.1012/nl0482478]
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022 3727/42/22/224001
   Park I, 2009, J NANOSCI NANOTECHNO, V9, P7224, DOI 10.1166/jnn.2009.1636
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Reischl D, 2009, NANOMED NANOTECHNOL, V5, P8, DOI 10.1016/j.nano.2008.06.001
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Roy I, 2003, INT J PHARMACEUT, V250, P25, DOI 10.1016/S0378 5173(02)00452 0
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Schmidt HT, 2006, J MICROENCAPSUL, V23, P769, DOI 10.1080/09687860600945792
   Sokolova V, 2006, MATERIALWISS WERKST, V37, P441, DOI 10.1002/mawe.200600017
   Sokolova V, 2011, ACTA BIOMATER, V7, P4029, DOI 10.1016/j.actbio.2011.07.010
   Sokolova V, 2008, ANGEW CHEM INT EDIT, V47, P1382, DOI 10.1002/anie.200703039
   Sokolova V, 2007, J BIOL INORG CHEM, V12, P174, DOI 10.1007/s00775 006 0177 7
   Sokolova V, 2011, NANOSCALE, V3, P1957, DOI 10.1039/c1nr00002k
   Sokolova V, 2010, J MATER SCI, V45, P4952, DOI 10.1007/s10853 009 4159 3
   Sokolova V, 2010, BIOMATERIALS, V31, P5627, DOI 10.1016/j.biomaterials.2010.03.067
   Sokolova VV, 2006, BIOMATERIALS, V27, P3147, DOI 10.1016/j.biomaterials.2005.12.030
   Urch H, 2009, J MATER CHEM, V19, P2166, DOI 10.1039/b810026h
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   VANBLAADEREN A, 1992, LANGMUIR, V8, P2921, DOI 10.1021/la00048a013
   Wolcott A, 2006, J PHYS CHEM B, V110, P5779, DOI 10.1021/jp057435z
   Wu C, 2008, ACS NANO, V2, P2415, DOI 10.1021/nn800590n
   Yamaura M, 2004, J MAGN MAGN MATER, V279, P210, DOI 10.1016/j.jmmm.2004.01.094
   Yang LL, 2009, SMALL, V5, P235, DOI 10.1002/smll.200800714
NR 53
TC 88
Z9 95
U1 1
U2 92
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959 9428
EI 1364 5501
J9 J MATER CHEM
JI J. Mater. Chem.
PD JAN 14
PY 2012
VL 22
IS 2
BP 396
EP 404
DI 10.1039/c1jm14683a
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 875HC
UT WOS:000299020000018
DA 2025 08 17
ER

PT J
AU Hong, I
   Joo, JM
   Kwon, YH
   Wu, DT
   Sanz, M
   Jung, UW
   Cha, JK
AF Hong, Inpyo
   Joo, Jeung Min
   Kwon, Yoon Hee
   Wu, David T.
   Sanz, Mariano
   Jung, Ui Won
   Cha, Jae Kook
TI Local delivery of pamidronate with collagen matrix mitigates buccal bone
   resorption following immediate implant placement   An experimental in
   vivo study
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE animal experiment; bisphosphonate; collagen matrix; extraction;
   histology; immediate implant; preclinical study
ID BIPHASIC CALCIUM PHOSPHATE; FRESH EXTRACTION SOCKETS; BISPHOSPHONATES;
   MECHANISM; DEFECTS
AB AimsThe aim of this experimental in vivo pilot study was to evaluate the effect of the local delivery of pamidronate within a collagen membrane on the changes in the buccal soft and hard tissue dimensions at the time of immediate implant placement and whether this effect was influenced by the placement of bone substitutes.MethodsIn six beagle dogs, the distal roots of the third and fourth premolars were extracted, and immediate implants were placed. Treatment groups were randomly allocated to each socket: (i) covering the buccal bone with pamidronate soaked collagen membrane (BP group), (ii) filling the gap defect with synthetic bone substitute (BS group), (iii) filling the gap defect with synthetic bone substitute and covering the buccal bone with pamidronate soaked collagen membrane (BP/BS group), (iv) no treatment (control group). Intraoral scanning was performed immediately after the surgery and at 20 weeks. Histomorphometric and micro computed tomography (CT) outcomes were evaluated at 20 weeks.ResultsThe micro CT analysis demonstrated that the BP group showed no apparent difference in vertical bone level with residual mesial root area, while control group showed significant buccal bone resorption at the implant site. The histomorphometric analysis demonstrated that the vertical bone level of buccal plate was significantly differed between the BP and control group (0.34 +/  0.93 and 1.27 +/  0.56 mm, respectively; p = .041). There was no statistically significant difference in the horizontal ridge width (HRW 1, 2, 3) among the groups. Also, the thickness, height and buccal contours of the soft tissue did not reveal significant changes among the groups.ConclusionThe local delivery of pamidronate to the outer surface of the buccal wall at the time of immediate implant placement effectively limits buccal bone resorption. The results from the present investigation should be interpreted with caution, as well as its clinical translatability. Further investigation is needed to understand the pamidronate binding and releasing kinetic, as well as the ideal carrier of this drug for its topical application.
   Local delivery of pamidronate with collagen matrix mitigates buccal bone resorption following immediate implant placement. The group with pamidronate soaked collagen membrane showed significantly reduced buccal bone resorption.image
C1 [Hong, Inpyo; Joo, Jeung Min; Kwon, Yoon Hee; Jung, Ui Won; Cha, Jae Kook] Yonsei Univ, Coll Dent, Res Inst Periodontal Regenerat, Dept Periodontol, Seoul, South Korea.
   [Wu, David T.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Div Periodontol, Boston, MA USA.
   [Sanz, Mariano] Univ Complutense Madrid, Fac Odontol, Dept Periodontol, E 28040 Madrid, Spain.
C3 Yonsei University; Yonsei University Health System; Harvard University;
   Harvard School of Dental Medicine; Complutense University of Madrid
RP Jung, UW; Cha, JK (通讯作者)，Yonsei Univ, Coll Dent, Dept Periodontol, 50 1 Yonsei Ro, Seoul 03722, South Korea.
EM drjew@yuhs.ac; chajaekook@gmail.com
RI ; wu, david/LLK 2024 2024; Jung, Ui Won/R 1631 2019; Sanz,
   Mariano/G 8244 2017; Cha, Jae Kook/KQT 9083 2024
OI Jung, Ui Won/0000 0001 6371 4172; Sanz, Mariano/0000 0002 6293 5755; Oh,
   Sang Yeob/0000 0001 6817 9834; Hong, Inpyo/0000 0002 0486 9593; Wu,
   David/0000 0002 9752 5377
FU Korea Health Industry Development Institute
FX Korea Health Industry Development Institute
CR Altundal H, 2004, INT J ORAL MAX SURG, V33, P286, DOI 10.1006/ijom.2002.0472
   Araújo MG, 2011, CLIN ORAL IMPLAN RES, V22, P1, DOI 10.1111/j.1600 0501.2010.01920.x
   Araújo MG, 2005, J CLIN PERIODONTOL, V32, P212, DOI 10.1111/j.1600 051X.2005.00642.x
   Avila Ortiz G, 2019, J CLIN PERIODONTOL, V46, P195, DOI 10.1111/jcpe.13057
   Bouler JM, 2017, ACTA BIOMATER, V53, P1, DOI 10.1016/j.actbio.2017.01.076
   Cha JK, 2019, CLIN ORAL IMPLAN RES, V30, P515, DOI 10.1111/clr.13436
   Cha JK, 2018, CLIN ORAL IMPLAN RES, V29, P688, DOI 10.1111/clr.13260
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI [10.1186/s12917 020 02451 y, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823]
   Fischer KR, 2015, CLIN ORAL IMPLAN RES, V26, P1135, DOI 10.1111/clr.12483
   GRUBER HE, 1992, BIOTECH HISTOCHEM, V67, P30, DOI 10.3109/10520299209110002
   Hong JY, 2014, CLIN ORAL IMPLAN RES, V25, pE30, DOI 10.1111/clr.12041
   Jung UW, 2017, J CLIN PERIODONTOL, V44, P1172, DOI 10.1111/jcpe.12802
   Kauffmann F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103616
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kitayama S, 2016, CLIN ORAL IMPLAN RES, V27, pE206, DOI 10.1111/clr.12605
   Lee JS, 2018, J CLIN PERIODONTOL, V45, P1388, DOI 10.1111/jcpe.13014
   Mardas N, 2023, PERIODONTOL 2000, V93, P289, DOI 10.1111/prd.12508
   Mazzocco F, 2017, CLIN ORAL IMPLAN RES, V28, P495, DOI 10.1111/clr.12826
   Miron RJ, 2016, CLIN ORAL IMPLAN RES, V27, P668, DOI 10.1111/clr.12647
   Park JY, 2023, J CLIN PERIODONTOL, V50, P358, DOI 10.1111/jcpe.13742
   Park SH, 2020, J CLIN PERIODONTOL, V47, P382, DOI 10.1111/jcpe.13231
   Park WB, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59010176
   Qahash M, 2008, CLIN ORAL IMPLAN RES, V19, P166, DOI 10.1111/j.1600 0501.2007.01428.x
   Sanz M, 2017, CLIN ORAL IMPLAN RES, V28, P902, DOI 10.1111/clr.12896
   Sanz Martín I, 2019, CLIN IMPLANT DENT R, V21, P145, DOI 10.1111/cid.12696
   Seyssens L, 2022, CLIN IMPLANT DENT R, V24, P339, DOI 10.1111/cid.13079
   Slagter KW, 2021, J PERIODONTOL, V92, P1738, DOI 10.1002/JPER.20 0845
   Sun YY, 2023, INT J IMPLANT DENT, V9, DOI 10.1186/s40729 023 00491 1
   Tsigarida A, 2020, J CLIN PERIODONTOL, V47, P1326, DOI 10.1111/jcpe.13347
   Vignoletti F, 2019, CLIN ORAL IMPLAN RES, V30, P353, DOI 10.1111/clr.13421
   Vignoletti F, 2012, CLIN ORAL IMPLAN RES, V23, P22, DOI 10.1111/j.1600 0501.2011.02331.x
   Vignoletti F, 2009, J CLIN PERIODONTOL, V36, P265, DOI 10.1111/j.1600 051X.2008.01363.x
NR 34
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD MAR
PY 2025
VL 60
IS 3
BP 255
EP 264
DI 10.1111/jre.13342
EA AUG 2024
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 1YC1C
UT WOS:001297472800001
PM 39187450
OA hybrid
DA 2025 08 17
ER

PT J
AU van Vliet, EI
   de Herder, WW
   de Rijke, YB
   Zillikens, MC
   Kam, BLR
   Teunissen, JJM
   Peeters, RP
   Krenning, EP
   Kwekkeboom, DJ
AF van Vliet, Esther I.
   de Herder, Wouter W.
   de Rijke, Yolanda B.
   Zillikens, M. Carola
   Kam, Boen L. R.
   Teunissen, Jaap J. M.
   Peeters, Robin P.
   Krenning, Eric P.
   Kwekkeboom, Dik J.
TI Hypocalcaemia after treatment with
   [<SUP>177</SUP>Lu DOTA<SUP>0</SUP>,Tyr<SUP>3</SUP>]octreotate
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE Neuroendocrine tumour; [Lu 177 DOTA(0), Tyr(3)] octreotate; Side
   effects; Hypocalcaemia
ID RADIOLABELED SOMATOSTATIN ANALOG; RECEPTOR RADIONUCLIDE THERAPY;
   NEUROENDOCRINE TUMORS; Y 90 DOTATOC; SURVIVAL; TOXICITY
AB The aim of this study was to explore the possible mechanisms involved in an observed decline in serum calcium levels in patients with a neuroendocrine tumour (NET) treated with [Lu 177 DOTA(0),Tyr(3)]octreotate (Lu 177 octreotate).
   In 47 patients with NET who were normocalcaemic at baseline, serum calcium, albumin, creatinine, alkaline phosphatase, gamma glutamyl transpeptidase, magnesium, phosphate and 25 hydroxyvitamin D were prospectively analysed at baseline and up to 6 months after treatment. Parathyroid hormone (PTH), 1,25 dihydroxyvitamin D 3, type 1 aminoterminal propeptide of procollagen, bone specific alkaline phosphatase, carboxyterminal crosslinking telopeptide of bone collagen, collagen type I crosslinked N telopeptide, and creatinine and calcium in 24 h urine samples, were evaluated at baseline and at 3 and 6 months. Another 153 patients with NET were included in a retrospective study to estimate the occurrence of hypocalcaemia in a larger patient group.
   In the prospectively included patients, the mean serum calcium level decreased significantly after treatment (2.31 +/  0.01 to 2.26 +/  0.02 mmol/l, p = 0.02). Eight patients (17 %) showed a marked decrease in serum calcium levels with a nadir of a parts per thousand currency sign2.10 mmol/l. In five patients (11 %), calcium substitution therapy was prescribed. PTH increased significantly (5.9 +/  0.6 to 6.7 +/  0.8 pmol/l, p = 0.02), presumably in response to the decreasing serum calcium levels. 25 Hydroxyvitamin D remained stable after treatment. Creatinine levels increased significantly (73 +/  3 to 77 +/  3 mu mol/l, p = 0.01), but not enough to explain the hypocalcaemia. Phosphate levels remained unaffected. In the retrospectively analysed patients, the mean serum calcium level decreased significantly from 2.33 +/  0.01 at baseline to a nadir of 2.24 +/  0.01 mmol/l at 18 months after treatment (p < 0.001). Of the 153 patients, 33 (22 %) showed a serum calcium nadir of a parts per thousand currency sign2.10 mmol/l, and 11 (7 %) received calcium substitution therapy.
   The mean serum calcium level decreased significantly after treatment with Lu 177 octreotate, resulting in mild hypocalcaemia in about 20 % of patients. We excluded several potential causes of this hypocalcaemia, so the cause remains unknown. Serum calcium levels should be monitored after peptide receptor radionuclide therapy, and calcium substitution therapy should be initiated if appropriate.
C1 [van Vliet, Esther I.; Kam, Boen L. R.; Teunissen, Jaap J. M.; Krenning, Eric P.; Kwekkeboom, Dik J.] Erasmus MC, Univ Med Ctr, Dept Nucl Med, NL 3015 CE Rotterdam, Netherlands.
   [de Herder, Wouter W.; Zillikens, M. Carola; Peeters, Robin P.] Erasmus MC, Univ Med Ctr, Dept Internal Med, NL 3015 CE Rotterdam, Netherlands.
   [de Rijke, Yolanda B.] Erasmus MC, Univ Med Ctr, Dept Clin Chem, NL 3015 CE Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP van Vliet, EI (通讯作者)，Erasmus MC, Univ Med Ctr, Dept Nucl Med, S Gravendijkwal 230, NL 3015 CE Rotterdam, Netherlands.
EM e.i.vanvliet@erasmusmc.nl
RI de Rijke, Yolanda/AAQ 5497 2020; Peeters, Robin/P 3603 2014; Krenning,
   Eric/L 1064 2013; de+Herder, Wouter/AAN 8429 2021
OI Peeters, Robin/0000 0001 7732 9371
CR Bodei L, 2003, EUR J NUCL MED MOL I, V30, P207, DOI 10.1007/s00259 002 1023 y
   Bodei L, 2008, EUR J NUCL MED MOL I, V35, P1847, DOI 10.1007/s00259 008 0778 1
   Druckenthaner M, 2007, REGUL PEPTIDES, V138, P32, DOI 10.1016/j.regpep.2006.08.005
   GLAZEBROOK GA, 1987, AM J SURG, V154, P368, DOI 10.1016/0002 9610(89)90006 8
   Guven A, 2009, ANN NUCL MED, V23, P437, DOI 10.1007/s12149 009 0270 4
   Imhof A, 2011, J CLIN ONCOL, V29, P2416, DOI 10.1200/JCO.2010.33.7873
   Kwekkeboom DJ, 2008, J CLIN ONCOL, V26, P2124, DOI 10.1200/JCO.2007.15.2553
   Kwekkeboom DJ, 2010, ENDOCR RELAT CANCER, V17, pR53, DOI 10.1677/ERC 09 0078
   Kwekkeboom DJ, 2001, EUR J NUCL MED, V28, P1319, DOI 10.1007/s002590100574
   Michaud LB, 2006, AM J HEALTH SYST PH, V63, P419, DOI 10.2146/ajhp050045.p1
   Teunissen JJM, 2009, EUR J NUCL MED MOL I, V36, P1758, DOI 10.1007/s00259 009 1151 8
   Valkema R, 2006, SEMIN NUCL MED, V36, P147, DOI 10.1053/j.semnuclmed.2006.01.001
   Valkema R, 2005, J NUCL MED, V46, p83S
   Waldherr C, 2002, J NUCL MED, V43, P610
   Waldherr C, 2001, ANN ONCOL, V12, P941, DOI 10.1023/A:1011160913619
NR 15
TC 5
Z9 5
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619 7070
EI 1619 7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD DEC
PY 2013
VL 40
IS 12
BP 1843
EP 1852
DI 10.1007/s00259 013 2503 y
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 248HZ
UT WOS:000326690600008
PM 23877632
DA 2025 08 17
ER

PT J
AU Heinecke, LF
   Grzanna, MW
   Au, AY
   Mochal, CA
   Rashmir Raven, A
   Frondoza, CG
AF Heinecke, L. F.
   Grzanna, M. W.
   Au, A. Y.
   Mochal, C. A.
   Rashmir Raven, A.
   Frondoza, C. G.
TI Inhibition of cyclooxygenase 2 expression and prostaglandin
   E2 production in chondrocytes by avocado soybean
   unsaponifiables and epigallocatechin gallate
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Chondrocytes; COX 2; PGE(2); ASU; EGCG; NF kappa B
ID NITRIC OXIDE; GREEN TEA; SYNOVIAL FLUID; JOINT DISEASE; ARTICULAR
   CHONDROCYTES; CHONDROITIN SULFATE; SIGNALING PATHWAYS; SUBCHONDRAL BONE;
   GENE EXPRESSION; KAPPA B
AB Objective To evaluate the anti inflammatory effect of the combination of avocado soybean unsaponifiables (ASU) and epigallocatechin gallate (EGCG) on cyclooxygenase 2 (COX 2) expression and prostaglandin E 2 (PGE(2)) production in cytokine activated equine chondrocytes
   Methods Production of type II collagen and aggrecan was verified by immunohistochemistry and Western blot Chondrocytes were incubated with (1) control media alone, (2) ASU (4 mu g/ml, 8 3 mu g/ml), (3) EGCG (4, 40, 400 ng/ml), or (4) the combination of ASU and EGCG for 24 h Cells were next incubated with control medium alone or with IL 1 beta (10 ng/ml) and TNF alpha (1 ng/ml) COX 2 gene expression by real time PCR analysis and NF kappa B nuclear translocation by immunohistochemistry were performed after 1 h of incubation PGE2 production was determined by immunoassay after 24 h of incubation
   Results Equine chondrocytes responded to cytokine activation by up regulated gene expression of COX 2 and increased PGE2 production Activation was associated with NF kappa B translocation Individually, ASU and EGCG marginally inhibited COX 2 expression and PGE2 production in activated chondrocytes In contrast, the combination of ASU and EGCG reduced COX 2 expression close to non activated control levels and significantly inhibited PGE2 production These reductions were statistically greater than those of ASU or EGCG alone The inhibition of COX 2 expression and PGE2 production was associated with inhibition of NF kappa B translocation.
   Conclusion The present study demonstrates that the anti inflammatory activity of ASU and EGCG is potentiated when used in combination This combination may offer an attractive supplement or alternative to non steroidal anti inflammatory drugs (NSAIDs) in the management of osteoarthritis. (C) 2009 Osteoarthntis Research Society International Published by Elsevier Ltd. All rights reserved
C1 [Heinecke, L. F.; Grzanna, M. W.; Au, A. Y.; Frondoza, C. G.] Nutramax Labs Inc, Edgewood, MD 21040 USA.
   [Au, A. Y.; Frondoza, C. G.] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD 21239 USA.
   [Au, A. Y.] Syracuse Univ, Dept Biomed & Chem Engn, Syracuse, NY 13210 USA.
   [Mochal, C. A.; Rashmir Raven, A.; Frondoza, C. G.] Mississippi State Univ, Coll Vet Med, Mississippi State, MS 39762 USA.
C3 Johns Hopkins University; Syracuse University; Mississippi State
   University
RP Frondoza, CG (通讯作者)，Nutramax Labs Inc, 2208 Lakeside Blvd, Edgewood, MD 21040 USA.
RI Au, Angela/U 4131 2019
FU Nutramax Laboratories, Inc
FX We would like to acknowledge: Nutramax Laboratories, Inc for funding,
   Mississippi State College of Veterinary Medicine for providing tissue,
   Reinhard Grzanna, Ph.D. for the immunohistochemical experiments,
   microscopic analyses, and Stacy Ownby for editing and constructive
   critique of the manuscript
CR Afonso V, 2007, JOINT BONE SPINE, V74, P324, DOI 10.1016/j.jbspin.2007.02.002
   Ahmed S, 2002, FREE RADICAL BIO MED, V33, P1097, DOI 10.1016/S0891 5849(02)01004 3
   Ameye LG, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2016
   Annabi B, 2002, BBA MOL CELL RES, V1542, P209, DOI 10.1016/S0167 4889(01)00187 2
   Asada S, 2001, INFLAMM RES, V50, P19, DOI 10.1007/s000110050719
   Au RY, 2007, OSTEOARTHR CARTILAGE, V15, P1249, DOI 10.1016/j.joca.2007.07.009
   Beluche LA, 2001, AM J VET RES, V62, P1916, DOI 10.2460/ajvr.2001.62.1916
   Bertone AL, 2001, VET SURG, V30, P528, DOI 10.1053/jvet.2001.28430
   Brama PAJ, 2000, ANN RHEUM DIS, V59, P155, DOI 10.1136/ard.59.2.155
   Cake MA, 2000, OSTEOARTHR CARTILAGE, V8, P404, DOI 10.1053/joca.1999.0315
   Chow HHS, 2003, CLIN CANCER RES, V9, P3312
   Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83
   Clegg PD, 2003, VET J, V166, P3, DOI 10.1016/S1090 0233(02)00270 8
   Crofford LJ, 1999, OSTEOARTHR CARTILAGE, V7, P406, DOI 10.1053/joca.1999.0226
   Dannhardt G, 2001, EUR J MED CHEM, V36, P109, DOI 10.1016/S0223 5234(01)01197 7
   Demeule Michel, 2002, Current Medicinal Chemistry   Anti Cancer Agents, V2, P441, DOI 10.2174/1568011023353930
   Einhorn TA, 2003, ARTHRITIS RES THER, V5, P5, DOI 10.1186/ar607
   FRISBIE DD, 2006, 52 ANN CONV AM ASS E
   Gabay O, 2008, OSTEOARTHR CARTILAGE, V16, P373, DOI 10.1016/j.joca.2007.06.016
   Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524
   Harper KA, 2008, BIOCHEM SOC T, V36, P543, DOI 10.1042/BST0360543
   Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471 4906(01)02154 8
   Henrotin Y, 2005, OSTEOARTHR CARTILAGE, V13, P643, DOI 10.1016/j.joca.2005.04.002
   Henrotin YE, 2003, OSTEOARTHR CARTILAGE, V11, P747, DOI 10.1016/S1063 4584(03)00150 X
   Henrotin YE, 2006, J RHEUMATOL, V33, P1668
   Jang D, 1998, FREE RADICAL BIO MED, V24, P1511, DOI 10.1016/S0891 5849(97)00459 0
   Jomphe C, 2008, BASIC CLIN PHARMACOL, V102, P59, DOI 10.1111/j.1742 7843.2007.00158.x
   Kawcak CE, 2001, EQUINE VET J, V33, P120, DOI 10.1111/j.2042 3306.2001.tb00589.x
   Kawcak CE, 2007, AM J VET RES, V68, P598, DOI 10.2460/ajvr.68.6.598
   Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407
   Krasnokutsky S, 2008, OSTEOARTHR CARTILAGE, V16, pS1, DOI 10.1016/j.joca.2008.06.025
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Kut Lasserre C, 2001, J PERIODONTOL, V72, P1685, DOI 10.1902/jop.2001.72.12.1685
   Largo R, 2003, OSTEOARTHR CARTILAGE, V11, P290, DOI 10.1016/S1063 4584(03)00028 1
   Lippiello L, 2000, CLIN ORTHOP RELAT R, P229, DOI 10.1097/00003086 200012000 00027
   Lippiello L, 2008, EVID BASED COMPL ALT, V5, P191, DOI 10.1093/ecam/nem132
   Lo MY, 2004, J ORTHOP RES, V22, P1120, DOI 10.1016/j.orthres.2003.12.022
   Mastbergen SC, 2002, RHEUMATOLOGY, V41, P801, DOI 10.1093/rheumatology/41.7.801
   McIlwraith CW, 2005, EQUINE VET J, V37, P473, DOI 10.2746/042516405774480102
   Miller SB, 2006, SEMIN ARTHRITIS RHEU, V36, P37, DOI 10.1016/j.semarthrit.2006.03.005
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   Morinobu A, 2008, ARTHRITIS RHEUM, V58, P2012, DOI 10.1002/art.23594
   Morton AJ, 2005, RES VET SCI, V78, P189, DOI 10.1016/j.rvsc.2004.07.006
   Nieminen R, 2005, MEDIAT INFLAMM, P249, DOI 10.1155/MI.2005.249
   ROSSDALE PD, 1985, VET REC, V116, P66, DOI 10.1136/vr.116.3.66
   Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009
   Sarkar FH, 2004, MUTAT RES FUND MOL M, V555, P53, DOI 10.1016/j.mrfmmm.2004.04.015
   Scharstuhl A, 2002, J IMMUNOL, V169, P507, DOI 10.4049/jimmunol.169.1.507
   Schindler JF, 2007, J DENT RES, V86, P800, DOI 10.1177/154405910708600902
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Sung WS, 2008, BIOL PHARM BULL, V31, P1798, DOI 10.1248/bpb.31.1798
   Tallarida RJ, 2003, J PHARMACOL EXP THER, V307, P699, DOI 10.1124/jpet.103.054320
   Tardieu D, 2000, CARCINOGENESIS, V21, P973, DOI 10.1093/carcin/21.5.973
   Tekle C, 2008, BRIT J CANCER, V99, P750, DOI 10.1038/sj.bjc.6604566
   Trumble TN, 2005, VET CLIN N AM EQUINE, V21, P575, DOI 10.1016/j.cveq.2005.08.004
   Tung JT, 2002, AM J VET RES, V63, P987, DOI 10.2460/ajvr.2002.63.987
   Ullmann U, 2005, PHYTOMEDICINE, V12, P410, DOI 10.1016/j.phymed.2004.07.001
   Yudoh K, 2005, ARTHRITIS RES THER, V7, pR380, DOI 10.1186/ar1499
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 59
TC 60
Z9 64
U1 0
U2 18
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1063 4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD FEB
PY 2010
VL 18
IS 2
BP 220
EP 227
DI 10.1016/j.joca.2009.08.015
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 566HK
UT WOS:000275360500010
PM 19748608
OA Bronze
DA 2025 08 17
ER

PT J
AU Sieper, J
   Braun, J
   Dougados, M
   Baeten, D
AF Sieper, Joachim
   Braun, Juergen
   Dougados, Maxime
   Baeten, Dominique
TI Axial spondyloarthritis
SO NATURE REVIEWS DISEASE PRIMERS
LA English
DT Article
ID QUALITY OF LIFE; ACTIVE ANKYLOSING SPONDYLITIS; SOCIETY CLASSIFICATION
   CRITERIA; UNFOLDED PROTEIN RESPONSE; NECROSIS FACTOR BLOCKERS;
   INFLAMMATORY BACK PAIN; ANTI TNF THERAPY; RHEUMATOID ARTHRITIS;
   PSORIATIC ARTHRITIS; DISEASE ACTIVITY
AB The term axial spondyloarthritis covers both non radiographic disease and radiographic disease (also known as ankylosing spondylitis). Some studies have been performed to investigate the prevalence of axial spondyloarthritis, although most are limited to patients with radiographic disease. A strong genetic association has been shown between axial spondyloarthritis and human leukocyte antigen B27 (HLA B27), but the pathogenetic role of HLA B27 has not yet been clarified. Tumour necrosis factor (TNF), IL 17, IL 23 and downstream pathways also seem to be important   based on the good results of therapies directed against these molecules   but their exact role in the inflammatory process is also not yet clear. Elucidating the interaction between osteoproliferation and inflammation will be crucial for the prevention of long term structural damage of the bone. The development of new criteria for classification, diagnosis and screening of patients with axial spondyloarthritis will enable earlier intervention for this chronic inflammatory disease. MRI has become an important tool for the early detection of axial spondyloarthritis. NSAIDs and TNF blockers are effective therapies, including in the early non radiographic stage. Therapeutic blockade of IL 17 or IL 23 seems to be a promising new treatment option. Tools for measuring quality of life in axial spondyloarthritis have become relevant to assess the impact that the disease has on patients. These diagnostic and therapeutic advances will continue to change the management of axial spondyloarthritis, and new insights into the disease pathogenesis will hopefully accelerate this process. For an illustrated summary of this Primer, visit: http://go.nature.com/51b1af
C1 [Sieper, Joachim] Charite Campus Benjamin Franklin, Rheumatol, Hindenburgdamm 30, D 12200 Berlin, Germany.
   [Braun, Juergen] Rheumazentrum Ruhrgebiet, Herne, Germany.
   [Dougados, Maxime] Paris Descartes Univ, Hop Cochin, AP HP,INSERM U1153,Dept Rheumatol, Fac Med,Clin Epidemiol & Biostat,PRES Sorbonne Pa, Paris, France.
   [Baeten, Dominique] Univ Amsterdam, Acad Med Ctr, Clin Immunol & Rheumatol, Amsterdam, Netherlands.
   [Baeten, Dominique] Univ Amsterdam, Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Ruhr University Bochum; Rheumazentrum
   Ruhrgebiet; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Cochin   APHP; University of Amsterdam;
   Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam
RP Sieper, J (通讯作者)，Charite Campus Benjamin Franklin, Rheumatol, Hindenburgdamm 30, D 12200 Berlin, Germany.
EM joachim.sieper@charite.de
RI Braun, Jürgen/AFT 8107 2022; Dougados, Maxime/P 5287 2016
FU AbbVie; Boehringer Ingelheim; Janssen; Lilly; Merck; Novartis; Pfizer;
   UCB; MSD; Roche; Bristol Myers Squibb; Glenmark; Zymetech; FivePrime
FX J.S. has received honoraria for being a member of speaker's bureau
   and/or consulting fees from the following companies: AbbVie, Boehringer
   Ingelheim, Janssen, Lilly, Merck, Novartis, Pfizer and UCB; and research
   grants from the following companies: AbbVie, Janssen, Merck and Pfizer.
   J.B. discloses no financial conflicts. M.D. has received honouraria for
   being a member of speaker's bureau and/or consulting fees from the
   following companies: AbbVie, Boehringer Ingelheim, Janssen, Lilly,
   Merck, Novartis, Pfizer and UCB; and his department has received
   research grants from the following companies: AbbVie, Janssen, Lilly,
   Merck, Pfizer, Novartis and UCB. D.B. has received honouraria for being
   a member of speaker's bureau and/or consulting fees from the following
   companies: AbbVie, Pfizer, MSD, UCB, Novartis, Lilly, Boehringer
   Ingelheim, Roche, Bristol Myers Squibb, Janssen, Glenmark, Zymetech and
   FivePrime.
CR Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Akkoc N, 2005, ARTHRITIS RHEUM, V52, P4048, DOI 10.1002/art.21492
   Ambarus C, 2012, CURR OPIN RHEUMATOL, V24, P351, DOI 10.1097/BOR.0b013e3283534df4
   AMOR B, 1990, REV RHUM, V57, P85
   AMOR B, 1992, REV RHUM, V59, pS3
   AMOR B, 1995, REV RHUM, V62, P10
   Appel H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3370
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Arends S, 2015, CLIN EXP RHEUMATOL, V33, P174
   Ariza Ariza R, 2003, ARTHRIT RHEUM ARTHR, V49, P483, DOI 10.1002/art.11197
   Armaka M, 2008, J EXP MED, V205, P331, DOI 10.1084/jem.20070906
   Asquith M, 2014, BEST PRACT RES CL RH, V28, P687, DOI 10.1016/j.berh.2014.10.018
   Atagunduz P, 2005, ARTHRITIS RHEUM US, V52, P892, DOI 10.1002/art.20948
   Baerlecken NT, 2014, ANN RHEUM DIS, V73, P1211, DOI 10.1136/annrheumdis 2012 202208
   Baeten D, 2005, ARTHRITIS RES THER, V7, pR359, DOI 10.1186/ar1501
   Baeten D, 2004, ARTHRITIS RHEUM US, V50, P1611, DOI 10.1002/art.20174
   Baeten D. L., 2014, AM COLL RHEUMATOL AB
   Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140 6736(13)61134 4
   Baraliakos X, 2007, ANN RHEUM DIS, V66, P910, DOI 10.1136/ard.2006.066415
   Baraliakos X, 2005, ARTHRITIS RES THER, V7, pR439, DOI 10.1186/ar1693
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P1079, DOI 10.1136/annrheumdis 2012 202177
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Benham H, 2014, ARTHRITIS RHEUMATOL, V66, P1755, DOI 10.1002/art.38638
   Boonen A, 2010, ANN RHEUM DIS, V69, P102, DOI 10.1136/ard.2008.104117
   Boonen A, 2008, J RHEUMATOL, V35, P662
   Bowness P, 2011, J IMMUNOL, V186, P2672, DOI 10.4049/jimmunol.1002653
   Brandt J, 2000, ARTHRITIS RHEUM US, V43, P1346, DOI 10.1002/1529 0131(200006)43:6<1346::AID ANR18>3.0.CO;2 E
   Braun A, 2013, RHEUMATOLOGY, V52, P1418, DOI 10.1093/rheumatology/ket115
   Braun J, 2006, ANN RHEUM DIS, V65, P1147, DOI 10.1136/ard.2006.052878
   Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140 6736(02)08215 6
   Braun J, 2005, RHEUMATOLOGY, V44, P670, DOI 10.1093/rheumatology/keh584
   Braun J, 2011, ANN RHEUM DIS, V70, P896, DOI 10.1136/ard.2011.151027
   Braun J, 2003, ARTHRITIS RHEUM US, V48, P1126, DOI 10.1002/art.10883
   BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407
   Braun J, 2015, J RHEUMATOL, V42, P31, DOI 10.3899/jrheum.130959
   Breban M, 2008, ARTHRITIS RHEUM US, V58, P88, DOI 10.1002/art.23167
   Carmona L, 2011, RHEUMATOLOGY, V50, P85, DOI 10.1093/rheumatology/keq207
   Chan AT, 2005, ARTHRITIS RHEUM, V52, P3586, DOI 10.1002/art.21395
   Chorus AMJ, 2003, ANN RHEUM DIS, V62, P1178, DOI 10.1136/ard.2002.004861
   Chung HY, 2012, ANN RHEUM DIS, V71, P809, DOI 10.1136/annrheumdis 2011 200180
   Chung HY, 2011, ANN RHEUM DIS, V70, P1930, DOI 10.1136/ard.2011.152975
   Ciurea A, 2014, ANN RHEUM DIS, V73, P1908, DOI 10.1136/annrheumdis 2014 205613
   Claudepierre P, 1995, BRIT J RHEUMATOL, V34, P1139
   Coffre M, 2013, ARTHRITIS RHEUM US, V65, P1510, DOI 10.1002/art.37936
   Cortes A, 2013, NAT GENET, V45, P730, DOI 10.1038/ng.2667
   Dagfinrud H, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002822.pub3
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   Dean LE, 2014, RHEUMATOLOGY, V53, P650, DOI 10.1093/rheumatology/ket387
   Delay ML, 2009, ARTHRITIS RHEUM US, V60, P2633, DOI 10.1002/art.24763
   Deodhar A, 2014, ANN RHEUM DIS, V73, P198, DOI 10.1136/annrheumdis 2014 eular.1135
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
   Dougados M, 2012, ARTHRIT CARE RES, V64, P290, DOI 10.1002/acr.20671
   Dougados M, 2011, JOINT BONE SPINE, V78, P598, DOI 10.1016/j.jbspin.2011.01.013
   Dougados M, 2011, LANCET, V377, P2127, DOI 10.1016/S0140 6736(11)60071 8
   Dougados M, 2011, ANN RHEUM DIS, V70, P249, DOI 10.1136/ard.2010.133488
   Doward LC, 2003, ANN RHEUM DIS, V62, P20, DOI 10.1136/ard.62.1.20
   Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873
   François RJ, 2000, ARTHRITIS RHEUM US, V43, P2011, DOI 10.1002/1529 0131(200009)43:9<2011::AID ANR12>3.0.CO;2 Y
   GILL TM, 1994, JAMA J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619
   GOFTON JP, 1966, ANN RHEUM DIS, V25, P525, DOI 10.1136/ard.25.6.525
   Goodall JC, 2010, P NATL ACAD SCI USA, V107, P17698, DOI 10.1073/pnas.1011736107
   Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664
   Gossec L, 2014, ANN RHEUM DIS, V73, P1012, DOI 10.1136/annrheumdis 2014 205207
   GRAN JT, 1985, ANN RHEUM DIS, V44, P359, DOI 10.1136/ard.44.6.359
   Gran JT, 1997, BRIT J RHEUMATOL, V36, P766
   Guillemin F, 2005, ANN RHEUM DIS, V64, P1427, DOI 10.1136/ard.2004.029199
   GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003 4819 118 8 199304150 00009
   Haibel H, 2014, ANN RHEUM DIS, V73, P243, DOI 10.1136/annrheumdis 2012 203055
   Haibel H, 2013, ARTHRITIS RHEUM US, V65, P2211, DOI 10.1002/art.38014
   Haibel H, 2005, ANN RHEUM DIS, V64, P296, DOI 10.1136/ard.2004.023176
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092 8674(90)90512 D
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Helmick CG, 2008, ARTHRITIS RHEUM US, V58, P15, DOI 10.1002/art.23177
   Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001
   HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140 6736(93)91760 J
   Hermann J, 2009, RHEUMATOLOGY, V48, P812, DOI 10.1093/rheumatology/kep119
   Heuft Dorenbosch L, 2006, ANN RHEUM DIS, V65, P804, DOI 10.1136/ard.2005.044206
   Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl 2011 301668
   Inman RD, 2008, ARTHRITIS RHEUM US, V58, P3402, DOI 10.1002/art.23969
   Jacques P, 2014, ANN RHEUM DIS, V73, P437, DOI 10.1136/annrheumdis 2013 203643
   Jacques P, 2010, CURR OPIN RHEUMATOL, V22, P368, DOI 10.1097/BOR.0b013e3283393807
   Jandus C, 2008, ARTHRITIS RHEUM, V58, P2307, DOI 10.1002/art.23655
   Kenna TJ, 2012, ARTHRITIS RHEUM US, V64, P1420, DOI 10.1002/art.33507
   Khan MA, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0362 y
   Khan Muhammad Asim, 1995, Current Opinion in Rheumatology, V7, P263, DOI 10.1097/00002281 199507000 00001
   Khanna D, 2007, AM J MANAG CARE, V13, pS218
   Kiltz U, 2015, ANN RHEUM DIS, V74, P830, DOI 10.1136/annrheumdis 2013 203967
   Kiltz U, 2009, CLIN EXP RHEUMATOL, V27, pS108
   Kollnberger S, 2002, ARTHRITIS RHEUM, V46, P2972, DOI 10.1002/art.10605
   Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074 7613(00)80038 2
   Kotsis K, 2014, EXPERT REV PHARM OUT, V14, P857, DOI 10.1586/14737167.2014.957679
   Landewé R, 2014, ANN RHEUM DIS, V73, P39, DOI 10.1136/annrheumdis 2013 204231
   Lin P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105684
   Lories RJU, 2008, RHEUMATOLOGY, V47, P605, DOI 10.1093/rheumatology/ken082
   Lories RJU, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2642
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Lories RJU, 2004, ANN RHEUM DIS, V63, P595, DOI 10.1136/ard.2003.013599
   Lukas C, 2009, ANN RHEUM DIS, V68, P18, DOI 10.1136/ard.2008.094870
   Mandl P, 2015, ANN RHEUM DIS, V74, P1327, DOI 10.1136/annrheumdis 2014 206971
   Martindale J, 2006, RHEUMATOLOGY, V45, P1288, DOI 10.1093/rheumatology/kel115
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   McGonagle D, 1998, LANCET, V352, P1137, DOI 10.1016/S0140 6736(97)12004 9
   McGonagle D, 1998, ARTHRITIS RHEUM, V41, P694, DOI 10.1002/1529 0131(199804)41:4<694::AID ART17>3.0.CO;2 #
   McGonagle D, 2002, ANN RHEUM DIS, V61, P534, DOI 10.1136/ard.61.6.534
   McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297
   Mear JP, 1999, J IMMUNOL, V163, P6665
   Mijiyawa M, 2000, CURR OPIN RHEUMATOL, V12, P281, DOI 10.1097/00002281 200007000 00008
   MOLL JMH, 1974, MEDICINE, V53, P343, DOI 10.1097/00005792 197409000 00002
   Neerinckx B, 2014, ANN RHEUM DIS, V73, P629, DOI 10.1136/annrheumdis 2013 204170
   NISSILA M, 1988, ARTHRITIS RHEUM US, V31, P1111, DOI 10.1002/art.1780310905
   Noordenbos T, 2012, ARTHRITIS RHEUM US, V64, P99, DOI 10.1002/art.33396
   Paramarta JE, 2014, ANN RHEUM DIS, V73, P735, DOI 10.1136/annrheumdis 2012 203155
   Park H, 2012, NAT REV IMMUNOL, V12, P570, DOI 10.1038/nri3261
   PODDUBNYY D, ARTHRITIS RHEUMATOL, V66, P1133
   Poddubnyy D, 2014, ANN RHEUM DIS, V73, P817, DOI 10.1136/annrheumdis 2013 204248
   Poddubnyy D, 2013, ANN RHEUM DIS, V72, P1430, DOI 10.1136/annrheumdis 2012 203148
   Poddubnyy D, 2011, ANN RHEUM DIS, V70, P1369, DOI 10.1136/ard.2010.145995
   Ramiro S, 2015, ANN RHEUM DIS, V74, P52, DOI 10.1136/annrheumdis 2013 204055
   Reveille JD, 2012, ARTHRIT CARE RES, V64, P905, DOI 10.1002/acr.21621
   Reveille JD, 2012, ARTHRITIS RHEUM US, V64, P1407, DOI 10.1002/art.33503
   Robinson PC, 2014, MOL IMMUNOL, V57, P2, DOI 10.1016/j.molimm.2013.06.013
   Robinson PC, 2012, RHEUM DIS CLIN N AM, V38, P539, DOI 10.1016/j.rdc.2012.08.018
   Rudwaleit M, 2004, ANN RHEUM DIS, V63, P665, DOI 10.1136/ard.2003.016386
   Rudwaleit M, 2005, ARTHRITIS RHEUM, V52, P1000, DOI 10.1002/art.20990
   Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P1520, DOI 10.1136/ard.2009.110767
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233
   Rudwaleit M, 2012, NAT REV RHEUMATOL, V8, P262, DOI 10.1038/nrrheum.2012.39
   Rudwaleit M, 2009, ARTHRITIS RHEUM US, V60, P717, DOI 10.1002/art.24483
   Ruutu M, 2012, ARTHRITIS RHEUM US, V64, P2211, DOI 10.1002/art.34423
   Sahlberg AS, 2009, ADV EXP MED BIOL, V649, P235
   Salaffi F, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477 7525 7 25
   Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014
   Saraux A, 2005, ANN RHEUM DIS, V64, P1431, DOI 10.1136/ard.2004.029207
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Sieper J, 2005, ANN RHEUM DIS, V64, P659, DOI 10.1136/ard.2004.028753
   Sieper J, 2014, ANN RHEUM DIS, V73, P101, DOI 10.1136/annrheumdis 2012 203201
   Sieper J, 2002, ANN RHEUM DIS, V61, P8
   Sieper J, 2009, ANN RHEUM DIS, V68, P784, DOI 10.1136/ard.2008.101501
   Sieper J, 2009, ANN RHEUM DIS, V68, P1, DOI 10.1136/ard.2008.104018
   Sieper J., 2014, AM COLL RHEUMATOL AB
   Sieper J, 2008, ARTHRITIS RHEUM US, V58, P649, DOI 10.1002/art.23260
   Sieper J, 2015, ANN RHEUM DIS, V74, P1051, DOI 10.1136/annrheumdis 2013 204963
   Sieper J, 2014, ANN RHEUM DIS, V73, P95, DOI 10.1136/annrheumdis 2013 203559
   Sieper J, 2013, ANN RHEUM DIS, V72, P1621, DOI 10.1136/annrheumdis 2012 201777
   Sieper J, 2013, ANN RHEUM DIS, V72, P815, DOI 10.1136/annrheumdis 2012 201766
   Sieper J, 2013, ARTHRITIS RHEUM US, V65, P543, DOI 10.1002/art.37803
   Smolen JS, 2014, ANN RHEUM DIS, V73, P3, DOI 10.1136/annrheumdis 2013 204317
   Smolen JS, 2014, ANN RHEUM DIS, V73, P6, DOI 10.1136/annrheumdis 2013 203419
   Song IH, 2010, ARTHRITIS RHEUM US, V62, P1290, DOI 10.1002/art.27383
   Song I. H., 2009, ARTHRITIS RHEUM S10, V60, P1769
   Song IH, 2011, ANN RHEUM DIS, V70, P1108, DOI 10.1136/ard.2010.145946
   Stolwijk C, 2012, RHEUM DIS CLIN N AM, V38, P441, DOI 10.1016/j.rdc.2012.09.003
   Taurog JD, 2009, ARTHRITIS RHEUM, V60, P1977, DOI 10.1002/art.24599
   Tran TM, 2006, ARTHRITIS RHEUM US, V54, P1317, DOI 10.1002/art.21740
   Turner MJ, 2005, J IMMUNOL, V175, P2438, DOI 10.4049/jimmunol.175.4.2438
   van den Berg R, 2014, ARTHRITIS RHEUMATOL, V66, P2403, DOI 10.1002/art.38738
   van den Berg R, 2013, ANN RHEUM DIS, V72, P1646, DOI 10.1136/annrheumdis 2012 201884
   van der Heijde D, 2005, ARTHRITIS RHEUM US, V52, P1205, DOI 10.1002/art.20985
   van der Heijde D, 2009, ANN RHEUM DIS, V68, P922, DOI 10.1136/ard.2007.087270
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2014, J RHEUMATOL, V41, P1095, DOI 10.3899/jrheum.131003
   van der Heijde D, 2011, ANN RHEUM DIS, V70, P905, DOI 10.1136/ard.2011.151563
   van der Horst Bruinsma IE, 2002, CLIN EXP RHEUMATOL, V20, pS67
   van Duivenvoorde L. M., 2009, ARTHRITIS RHEUM S10, V65, P536
   van Duivenvoorde LM, 2012, ARTHRITIS RHEUM US, V64, P3210, DOI 10.1002/art.34600
   van Duivenvoorde LM, 2011, ARTHRITIS RHEUM US, V63, pS387
   van Echteld I, 2006, J RHEUMATOL, V33, P2475
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   VANDERLINDEN SM, 1984, ARTHRITIS RHEUM, V27, P241
   Vandooren B, 2009, ARTHRITIS RHEUM US, V60, P3534, DOI 10.1002/art.27251
   Vastesaeger N, 2011, ANN RHEUM DIS, V70, P973, DOI 10.1136/ard.2010.147744
   Videm Vibeke, 2014, J Rheumatol, V41, P2041, DOI 10.3899/jrheum.140353
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Ward MM, 2008, ARTHRIT RHEUM ARTHR, V59, P497, DOI 10.1002/art.23523
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650 199206000 00002
   Weber U, 2010, ARTHRIT CARE RES, V62, P1763, DOI 10.1002/acr.20312
   Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001
   Yeremenko N, 2013, ARTHRITIS RHEUM US, V65, P174, DOI 10.1002/art.37704
   Zeidler H, 2014, ANN RHEUM DIS, V73, P637, DOI 10.1136/annrheumdis 2013 204110
NR 182
TC 161
Z9 167
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2056 676X
J9 NAT REV DIS PRIMERS
JI Nat. Rev. Dis. Primers
PD JUL 9
PY 2015
VL 1
AR 15013
DI 10.1038/nrdp.2015.13
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA DT2KB
UT WOS:000381308100001
PM 27188328
DA 2025 08 17
ER

PT J
AU Jiang, H
   Jia, PZ
AF Jiang, Hao
   Jia, Peizeng
TI MiR 153 3p inhibits osteogenic differentiation of periodontal ligament
   stem cells through KDM6A induced demethylation of H3K27me3
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE KDM6A; miR&#8208; 153&#8208; 3p; osteogenic differentiation; PDLSCs
ID EZH2; PROLIFERATION; REGENERATION
AB Background and objective Periodontal ligament stem cells (PDLSCs) have potential for osteogenic differentiation and show a great foreground in treating bone diseases. Histone three lysine 27 (H3K27) demethylase lysine demethylase 6A (KDM6A) is a critical epigenetic modifier and plays an important role in regulating osteogenic differentiation. Multiple microRNAs have been found to play important roles in osteogenesis. The aim of this study was to explore the mechanisms underlying the roles of miR 153 3p and KDM6A in PDLSC osteogenesis.
   Methods The levels of the osteogenic markers alkaline phosphatase (ALP), runt related transcription factor 2 (Runx2), and osteopontin (OPN) were measured by western blotting. Osteoblast activity and mineral deposition were detected by ALP and Alizarin red S (ARS) staining. The levels of miR 153 3p and KDM6A were measured by quantitative real time PCR (qRT PCR). A luciferase reporter assay was used to confirm the interaction between KDM6A and miR 153 3p. Gain of function and loss of function assays were performed to identify the roles of miR 153 3p and KDM6A in the osteogenic differentiation of PDLSCs.
   Results In osteogenic PDLSCs, the expression of KDM6A, ALP, Runx2, and OPN was upregulated, whereas that of miR 153 3p was downregulated. miR 153 3p downregulation or KDM6A overexpression promoted the osteogenic differentiation of PDLSCs, as demonstrated by increases in ALP activity, matrix mineralization, and ALP, Runx2, and OPN expression. KDM6A was confirmed to be a target of miR 153 3p, and KDM6A overexpression reversed the inhibitory effect of miR 153 3p mimic on PDLSC osteogenesis. KDM6A promoted ALP, Runx2, and OPN expression through the demethylation of H3K27me3 on the promoter regions of these genes.
   Conclusion miR 153 3p inhibited PDLSC osteogenesis by targeting KDM6A and inhibiting ALP, Runx2, and OPN transcription. These findings provide latent hope for PDLSCs application in periodontal therapy.
C1 [Jiang, Hao] Fifth Cent Hosp Tianjin, Dept Stomatol, 41 Zhejiang Rd, Tianjin 300450, Peoples R China.
   [Jia, Peizeng] Peking Univ, Dept Orthodont, Sch Stomatol, Beijing, Peoples R China.
C3 Peking University
RP Jiang, H (通讯作者)，Fifth Cent Hosp Tianjin, Dept Stomatol, 41 Zhejiang Rd, Tianjin 300450, Peoples R China.
EM jianghao20083030@163.com
RI Jia, Peizeng/HPM 9563 2023
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   BORDIN S, 1984, SCIENCE, V223, P171, DOI 10.1126/science.6691142
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cao YJ, 2015, INT J MOL MED, V36, P760, DOI 10.3892/ijmm.2015.2275
   Chen Z, 2017, J ORAL PATHOL MED, V46, P313, DOI 10.1111/jop.12492
   Du J, 2014, J DENT RES, V93, P183, DOI 10.1177/0022034513513026
   Gay I, 2014, J PERIODONTAL RES, V49, P110, DOI 10.1111/jre.12086
   Han J, 2014, J PERIODONTAL RES, V49, P333, DOI 10.1111/jre.12111
   Hemming S, 2016, STEM CELLS DEV, V25, P909, DOI 10.1089/scd.2015.0384
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Hu L, 2018, ORAL DIS, V24, P696, DOI 10.1111/odi.12703
   Iwata T, 2009, BIOMATERIALS, V30, P2716, DOI 10.1016/j.biomaterials.2009.01.032
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Li D, 2019, J CELL PHYSIOL, V234, P21316, DOI 10.1002/jcp.28736
   Liu HX, 2018, INT J MOL MED, V41, P3379, DOI 10.3892/ijmm.2018.3526
   Liu J, 2020, J DENT, V92, DOI 10.1016/j.jdent.2019.103259
   Mang T, 2020, J CELL SCI, V133, DOI 10.1242/jcs.246934
   Merkel A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01175
   Mrozik KM, 2013, REGEN MED, V8, P711, DOI 10.2217/rme.13.66
   Nazir MA, 2017, INT J HEALTH SCI IJH, V11
   Nuñez J, 2019, PERIODONTOL 2000, V79, P107, DOI 10.1111/prd.12250
   Qiao J, 2020, CELL DEATH DIFFER, V27, P808, DOI 10.1038/s41418 019 0388 4
   Qin WW, 2019, ENDOCRINE, V65, P426, DOI 10.1007/s12020 019 01952 7
   Qiu W, 2020, WORLD J STEM CELLS, V12, P251, DOI 10.4252/wjsc.v12.i4.251
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sun DY, 2018, BIOL RES, V51, DOI 10.1186/s40659 018 0203 6
   Tonetti MS, 2017, J CLIN PERIODONTOL, V44, P456, DOI 10.1111/jcpe.12732
   Tsuyama J, 2015, STEM CELL REP, V5, P365, DOI 10.1016/j.stemcr.2015.06.006
   Wang PT, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12413
   Xu M, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0894 x
   Yao FH, 2017, INT J CLIN EXP PATHO, V10, P11536
   Zeng HF, 2017, BIOCHEM BIOPH RES CO, V487, P140, DOI 10.1016/j.bbrc.2017.04.032
NR 35
TC 29
Z9 32
U1 1
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD APR
PY 2021
VL 56
IS 2
BP 379
EP 387
DI 10.1111/jre.12830
EA DEC 2020
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA QU7EC
UT WOS:000601328400001
PM 33368310
DA 2025 08 17
ER

PT J
AU Bradaschia Correa, V
   Casado Gomez, I
   Moreira, MM
   Ferreira, LB
   Arana Chavez, VE
AF Bradaschia Correa, Vivian
   Casado Gomez, Inmaculada
   Matheus Moreira, Mariana
   Ferreira, Lorraine Braga
   Arana Chavez, Victor E.
TI Immunolocalization of Smad 4 in developing molar roots of
   alendronate treated rats
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Root formation; Alendronate; Smad 4; Cementoblasts;
   Immunohistochemistry; Cementogenesis
ID TOOTH ERUPTION; EXPRESSION; BISPHOSPHONATES; RESORPTION; AMELOGENIN;
   CHILDREN; TISSUES; CELLS
AB Introduction: During root formation, Smad 4 plays a key role during the epithelial mesenchymal interactions and the Hertwig's epithelial root sheath (HERS) apical proliferation. The root formation and eruption of rat molars is impeded by alendronate treatment due to the inhibition of bone resortion by this drug. The present study aimed to examine the structures affected in the developing root and immunodetect the presence of Smad 4 in rats treated with alendronate.
   Methods: Newborn Wistar rats were daily injected 2.5 mg/kg alendronate (ALN) during 9, 12 and 30 days. The controls (CON) were injected with saline. The maxillae were fixed and embedded in paraffin or Spun resin. Paraffin sections were incubated in Smad 4 antibody that was labelled with DAB. The ultrathin sections were examined in a transmission electron microscope.
   Results: In ALN, a short portion of root dentine was formed; the epithelial diaphragm (ED) and the dental follicle (DF) were disorganized by the contact of bone trabeculae. The (CON) molar roots developed normally. Smad 4 labelling was detected in the cytoplasm of fibroblasts and cementoblasts adjacent to the cementum in CON; in ALN group, few ED cells presented weak immunolabelling. Ultrastructurally, the ED and DF appeared disrupted due to the presence of thin bone trabeculae between its cells. It resulted in the lack of apical proliferation of HERS and, consequently, arrest of root formation.
   Conclusion: The immunodetection of Smad 4 in the DF cells of ALN specimens indicates that the signalling for the differentiation of these cells into cementum forming fibroblasts and cementoblasts occurs, despite the impairment of root elongation. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Bradaschia Correa, Vivian; Matheus Moreira, Mariana; Ferreira, Lorraine Braga; Arana Chavez, Victor E.] Univ Sao Paulo, Dept Biomat & Oral Biol, Sch Dent, BR 05508000 Sao Paulo, Brazil.
   [Casado Gomez, Inmaculada] Univ Complutense Madrid, Sch Dent, E 28040 Madrid, Spain.
C3 Universidade de Sao Paulo; Complutense University of Madrid
RP Arana Chavez, VE (通讯作者)，Univ Sao Paulo, Dept Biomat & Oral Biol, Sch Dent, Ave Prof Lineu Prestes 2227, BR 05508000 Sao Paulo, Brazil.
EM vearana@usp.br
RI Arana Chavez, V/G 4948 2012; Casado, Inma/AAO 9678 2020;
   Bradaschia Correa, Vivian/N 7452 2013
OI Bradaschia Correa, Vivian/0000 0002 4395 3106
FU Sao Paulo Research Foundation (FAPESP) [06/60094 5, 09/54853 9];
   National Council for Scientific and Technological Development (CNPq)  
   Brazil
FX This research was supported by the Sao Paulo Research Foundation (FAPESP
     grants 06/60094 5 and 09/54853 9) and the National Council for
   Scientific and Technological Development (CNPq)   Brazil.
CR Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097 0177(199712)210:4<383::AID AJA3>3.0.CO;2 C
   Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125
   Arana Chavez VE, 2009, INT J BIOCHEM CELL B, V41, P446, DOI 10.1016/j.biocel.2008.09.007
   Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008 1531
   Boabaid F, 2001, TISSUE CELL, V33, P318, DOI 10.1054/tice.2001.0179
   Bradaschia Correa V, 2012, EUR J HISTOCHEM, V56, P149, DOI 10.4081/ejh.2012.e24
   Bradaschia Correa V, 2007, CELL TISSUE RES, V330, P475, DOI 10.1007/s00441 007 0499 y
   Chai Y, 2006, DEV DYNAM, V235, P2353, DOI 10.1002/dvdy.20833
   Hiraga T, 2010, CALCIFIED TISSUE INT, V86, P502, DOI 10.1007/s00223 010 9366 z
   Hosoya A, 2006, J HISTOCHEM CYTOCHEM, V54, P1371, DOI 10.1369/jhc.6A6980.2006
   Huang XF, 2010, J BONE MINER RES, V25, P1167, DOI 10.1359/jbmr.091103
   Janones DS, 2005, ARCH ORAL BIOL, V50, P527, DOI 10.1016/j.archoralbio.2004.10.004
   Kamoun Goldrat A, 2008, EUR J ORAL SCI, V116, P195, DOI 10.1111/j.1600 0722.2008.00529.x
   Maasalu K, 2003, ACTA PAEDIATR, V92, P452
   Marks SC, 1996, ANAT RECORD, V245, P374, DOI 10.1002/(SICI)1097 0185(199606)245:2<374::AID AR18>3.0.CO;2 M
   Massa LF, 2000, EUR J ORAL SCI, V108, P74, DOI 10.1034/j.1600 0722.2000.00753.x
   Massa LF, 2006, J HISTOCHEM CYTOCHEM, V54, P713, DOI 10.1369/jhc.5A6853.2006
   Moriguchi M, 2011, ANAT SCI INT, V86, P69, DOI 10.1007/s12565 010 0089 z
   Oikawa T, 2011, EUR J ORTHODONT, V33, P221, DOI 10.1093/ejo/cjq053
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Swanson EC, 2006, EUR J ORAL SCI, V114, P239, DOI 10.1111/j.1600 0722.2006.00321.x
   Wise GE, 2009, ORTHOD CRANIOFAC RES, V12, P67, DOI 10.1111/j.1601 6343.2009.01439.x
   Wise GE, 2006, EUR J ORAL SCI, V114, P512, DOI 10.1111/j.1600 0722.2006.00406.x
   Xu X, 2008, DEV CELL, V15, P322, DOI 10.1016/j.devcel.2008.06.004
   Xu X, 2006, DEV BIOL, V297, P238, DOI 10.1016/j.ydbio.2006.05.014
   Zeichner David M, 2006, PERIODONTOL 2000, V41, P196, DOI 10.1111/j.1600 0757.2006.00162.x
   Zhang H, 2010, ARCH ORAL BIOL, V55, P417, DOI 10.1016/j.archoralbio.2010.03.009
NR 28
TC 4
Z9 7
U1 0
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD NOV
PY 2013
VL 58
IS 11
BP 1744
EP 1750
DI 10.1016/j.archoralbio.2013.06.002
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 244BW
UT WOS:000326363100022
PM 23827715
OA hybrid
DA 2025 08 17
ER

PT J
AU Bouard, C
   Terreux, R
   Honorat, M
   Manship, B
   Ansieau, S
   Vigneron, AM
   Puisieux, A
   Payen, L
AF Bouard, Charlotte
   Terreux, Raphael
   Honorat, Mylene
   Manship, Brigitte
   Ansieau, Stephane
   Vigneron, Arnaud M.
   Puisieux, Alain
   Payen, Lea
TI Deciphering the molecular mechanisms underlying the binding of the
   TWIST1/E12 complex to regulatory E box sequences
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID SAETHRE CHOTZEN SYNDROME; EPITHELIAL MESENCHYMAL TRANSITION; BHLH
   TRANSCRIPTION FACTORS; LOOP HELIX PROTEINS; DNA BINDING;
   PROSTATE CANCER; OSTEOBLAST DIFFERENTIATION; UP REGULATION; MUTATIONS;
   DOMAIN
AB The TWIST1 bHLH transcription factor controls embryonic development and cancer processes. Although molecular and genetic analyses have provided a wealth of data on the role of bHLH transcription factors, very little is known on the molecular mechanisms underlying their binding affinity to the E box sequence of the promoter. Here, we used an in silico model of the TWIST1/E12 (TE) heterocomplex and performed molecular dynamics (MD) simulations of its binding to specific (TE box) and modified E box sequences. We focused on (i) active E box and inactive E box sequences, on (ii) modified active E box sequences, as well as on (iii) two box sequences with modified adjacent bases the AT  and TA boxes. Our in silico models were supported by functional in vitro binding assays. This exploration highlighted the predominant role of protein side chain residues, close to the heart of the complex, at anchoring the dimer to DNA sequences, and unveiled a shift towards adjacent (( 1) and ( 1*)) bases and conserved bases of modified E box sequences. In conclusion, our study provides proof of the predictive value of these MD simulations, which may contribute to the characterization of specific inhibitors by docking approaches, and their use in pharmacological therapies by blocking the tumoral TWIST1/E12 function in cancers.
C1 [Bouard, Charlotte; Vigneron, Arnaud M.; Puisieux, Alain; Payen, Lea] Ctr Rech Cancerol Lyon, Inserm UMR S1052, F 69373 Lyon, France.
   [Bouard, Charlotte; Ansieau, Stephane; Vigneron, Arnaud M.; Puisieux, Alain; Payen, Lea] Ctr Rech Cancerol Lyon, CNRS UMR5286, F 69373 Lyon, France.
   [Bouard, Charlotte; Ansieau, Stephane; Vigneron, Arnaud M.; Puisieux, Alain; Payen, Lea] LabEX DEVweCAN, Lyon, France.
   [Bouard, Charlotte; Ansieau, Stephane; Vigneron, Arnaud M.; Puisieux, Alain; Payen, Lea] UNIV, UMR1052, F 69008 Lyon, France.
   [Bouard, Charlotte; Manship, Brigitte; Ansieau, Stephane; Vigneron, Arnaud M.; Puisieux, Alain; Payen, Lea] Ctr Leon Berard, F 69373 Lyon, France.
   [Bouard, Charlotte; Terreux, Raphael; Puisieux, Alain; Payen, Lea] Univ Lyon 1, ISPB, F 69008 Lyon, France.
   [Terreux, Raphael; Honorat, Mylene] Inst Biochim Prot IBCP, F 69007 Lyon, France.
   [Terreux, Raphael] CNRS, UMR 5305, F 69007 Lyon, France.
   [Puisieux, Alain] Inst Univ France, F 75231 Paris, France.
   [Payen, Lea] Hosp Civils Lyon, Lab Biochim & Biol Mol CHLS, F 69003 Lyon, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UNICANCER; Centre Leon Berard; Universite Claude Bernard Lyon 1;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Centre National de la Recherche
   Scientifique (CNRS); CNRS   National Institute for Biology (INSB);
   UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; Universite
   Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1; Centre National
   de la Recherche Scientifique (CNRS); CNRS   National Institute for
   Biology (INSB); Institut Universitaire de France; CHU Lyon
RP Payen, L (通讯作者)，Ctr Rech Cancerol Lyon, Inserm UMR S1052, F 69373 Lyon, France.; Payen, L (通讯作者)，Ctr Rech Cancerol Lyon, CNRS UMR5286, F 69373 Lyon, France.; Payen, L (通讯作者)，LabEX DEVweCAN, Lyon, France.; Payen, L (通讯作者)，UNIV, UMR1052, F 69008 Lyon, France.; Payen, L (通讯作者)，Ctr Leon Berard, F 69373 Lyon, France.; Payen, L (通讯作者)，Univ Lyon 1, ISPB, F 69008 Lyon, France.; Payen, L (通讯作者)，Hosp Civils Lyon, Lab Biochim & Biol Mol CHLS, F 69003 Lyon, France.
EM Lea.payen gay@univ lyon1.fr
RI ; Vigneron, Arnaud/ABC 7306 2021; terreux, raphael/IXX 2489 2023;
   Ansieau, Stephane/I 6195 2016; payen, lea/LOR 4616 2024
OI terreux, raphael/0000 0003 1243 7413; ANSIEAU,
   Stephane/0000 0003 0989 2108; Vigneron, Arnaud/0000 0003 4161 0676;
   PUISIEUX, Alain/0000 0002 9938 3798; payen, lea/0000 0002 1599 5886
FU LabEX DEVweCAN [ANR 10 LABX 61]; LyRIC (Lyon Recherche Integree en
   Cancerologie, Institut National contre le Cancer) [INCa_4664]; Ligue
   Nationale contre le Cancer
FX LabEX DEVweCAN [ANR 10 LABX 61]; LyRIC (Lyon Recherche Integree en
   Cancerologie, Institut National contre le Cancer [INCa_4664]; Ligue
   Nationale contre le Cancer (to C.B.). Funding for open access charge:
   LabEX DEVweCAN [ANR 10 LABX 61]; LyRIC (Lyon Recherche Integree en
   Cancerologie, Institut National contre le Cancer [INCa_4664]; Ligue
   Nationale contre le Cancer (to C.B.).
CR Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bouard C, 2014, J BIOMOL STRUCT DYN, V32, P226, DOI 10.1080/07391102.2012.762722
   Castanon I, 2001, DEVELOPMENT, V128, P3145
   Chang AT, 2015, GENE DEV, V29, P603, DOI 10.1101/gad.242842.114
   Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717
   Corsi AK, 2002, DEVELOPMENT, V129, P2761
   De Masi F, 2011, NUCLEIC ACIDS RES, V39, P4553, DOI 10.1093/nar/gkr070
   El Ghouzzi V, 1999, EUR J HUM GENET, V7, P27, DOI 10.1038/sj.ejhg.5200240
   El Ghouzzi V, 2001, FEBS LETT, V492, P112, DOI 10.1016/S0014 5793(01)02238 4
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525
   Firulli BA, 2007, J BIOL CHEM, V282, P27536, DOI 10.1074/jbc.M702613200
   Fong AP, 2012, DEV CELL, V22, P721, DOI 10.1016/j.devcel.2012.01.015
   Gajula RP, 2015, NEOPLASIA, V17, P16, DOI 10.1016/j.neo.2014.10.009
   Gordan R, 2013, CELL REP, V3, P1093, DOI 10.1016/j.celrep.2013.03.014
   Gripp KW, 2001, GENET MED, V3, P102, DOI 10.1097/00125817 200103000 00003
   Grove CA, 2009, CELL, V138, P314, DOI 10.1016/j.cell.2009.04.058
   Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197 36
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122
   Jones S, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 6 226
   Knöfler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264 6021:3610641
   Kosty J, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.2.FOCUS155
   Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008 5472.CAN 04 3785
   Li S, 2012, BMC BIOL, V10, DOI 10.1186/1741 7007 10 73
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Longo A, 2008, BIOCHEMISTRY US, V47, P218, DOI 10.1021/bi701527r
   Maia AM, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 184
   Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429 440.2000
   Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723
   MURRE C, 1994, BBA GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167 4781(94)90001 9
   Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057
   Ohno K, 2003, HUM MOL GENET, V12, P739, DOI 10.1093/hmg/ddg089
   Ozdemir A, 2011, GENOME RES, V21, P566, DOI 10.1101/gr.104018.109
   Paznekas WA, 1998, AM J HUM GENET, V62, P1370, DOI 10.1086/301855
   Piccinin S, 2012, CANCER CELL, V22, P404, DOI 10.1016/j.ccr.2012.08.003
   Raatikainen S, 2015, SCAND J UROL, V49, P51, DOI 10.3109/21681805.2014.909529
   Ren KQ, 2013, INT J ONCOL, V43, P1719, DOI 10.3892/ijo.2013.2071
   Rose CSP, 1997, HUM MOL GENET, V6, P1369, DOI 10.1093/hmg/6.8.1369
   Sauvé S, 2007, J MOL BIOL, V365, P1163, DOI 10.1016/j.jmb.2006.10.044
   Seo SK, 2014, BIOCHEM BIOPH RES CO, V449, P490, DOI 10.1016/j.bbrc.2014.05.030
   Seto ML, 2007, AM J MED GENET A, V143A, P678, DOI 10.1002/ajmg.a.31630
   Slovák J, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1906217
   Song XJ, 2001, MAGN RESON CHEM, V39, pS30, DOI 10.1002/mrc.956
   Teng Y, 2014, CLIN EXP METASTAS, V31, P367, DOI 10.1007/s10585 013 9621 6
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tran PT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002650
   Valsesia Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033
   Wushou A, 2014, INT J MOL SCI, V15, P21621, DOI 10.3390/ijms151221621
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Zhang Y, 2008, J CELL BIOCHEM, V105, P487, DOI 10.1002/jcb.21844
NR 55
TC 18
Z9 22
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305 1048
EI 1362 4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN 20
PY 2016
VL 44
IS 11
BP 5470
EP 5489
DI 10.1093/nar/gkw334
PG 20
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA DR2SB
UT WOS:000379753100050
PM 27151200
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Pleniceanu, O
   Shukrun, R
   Omer, D
   Vax, E
   Kanter, I
   Dziedzic, K
   Pode Shakked, N
   Mark Daniei, M
   Pri Chen, S
   Gnatek, Y
   Alfandary, H
   Varda Bloom, N
   Bar Lev, DD
   Bollag, N
   Shtainfeld, R
   Armon, L
   Urbach, A
   Kalisky, T
   Nagler, A
   Harari Steinberg, O
   Arbiser, JL
   Dekel, B
AF Pleniceanu, Oren
   Shukrun, Racheli
   Omer, Dorit
   Vax, Einav
   Kanter, Itamar
   Dziedzic, Klaudyna
   Pode Shakked, Naomi
   Mark Daniei, Michal
   Pri Chen, Sara
   Gnatek, Yehudit
   Alfandary, Hadas
   Varda Bloom, Nira
   Bar Lev, Dekel D.
   Bollag, Naomi
   Shtainfeld, Rachel
   Armon, Leah
   Urbach, Achia
   Kalisky, Tomer
   Nagler, Arnon
   Harari Steinberg, Orit
   Arbiser, Jack L.
   Dekel, Benjamin
TI PPARG is central to the initiation and propagation of human
   angiomyolipoma, suggesting its potential as a therapeutic target
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE angiomyolipoma; cancer stem cells; mesenchymal stem cells; PPARG;
   tuberous sclerosis complex
ID ACTIVATED RECEPTOR GAMMA; TUBEROUS SCLEROSIS COMPLEX; MESENCHYMAL
   STEM CELLS; TISSUE GROWTH FACTOR; PDGF B; MAMMALIAN TARGET;
   BREAST CANCER; TGF BETA; EPITHELIOID ANGIOMYOLIPOMA; TERMINAL
   DIFFERENTIATION
AB Angiomyolipoma (AML), the most common benign renal tumor, can result in severe morbidity from hemorrhage and renal failure. While mTORC1 activation is involved in its growth, mTORC1 inhibitors fail to eradicate AML, highlighting the need for new therapies. Moreover, the identity of the AML cell of origin is obscure. AML research, however, is hampered by the lack of in vivo models. Here, we establish a human AML xenograft (Xn) model in mice, recapitulating AML at the histological and molecular levels. Microarray analysis demonstrated tumor growth in vivo to involve robust PPARG pathway activation. Similarly, immunostaining revealed strong PPARG expression in human AML specimens. Accordingly, we demonstrate that while PPARG agonism accelerates AML growth, PPARG antagonism is inhibitory, strongly suppressing AML proliferation and tumor initiating capacity, via a TGFB mediated inhibition of PDGFB and CTGF. Finally, we show striking similarity between AML cell lines and mesenchymal stem cells (MSCs) in terms of antigen and gene expression and differentiation potential. Altogether, we establish the first in vivo human AML model, which provides evidence that AML may originate in a PPARG activated renal MSC lineage that is skewed toward adipocytes and smooth muscle and away from osteoblasts, and uncover PPARG as a regulator of AML growth, which could serve as an attractive therapeutic target.
C1 [Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit; Vax, Einav; Dziedzic, Klaudyna; Pode Shakked, Naomi; Mark Daniei, Michal; Pri Chen, Sara; Gnatek, Yehudit; Bar Lev, Dekel D.; Harari Steinberg, Orit; Dekel, Benjamin] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Stem Cell Res Inst, Ramat Gan, Israel.
   [Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit; Vax, Einav; Dziedzic, Klaudyna; Pode Shakked, Naomi; Mark Daniei, Michal; Pri Chen, Sara; Gnatek, Yehudit; Bar Lev, Dekel D.; Harari Steinberg, Orit; Dekel, Benjamin] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Div Pediat Nephrol, Ramat Gan, Israel.
   [Pleniceanu, Oren; Varda Bloom, Nira; Nagler, Arnon] Sheba Med Ctr, Div Hematol, Ramat Gan, Israel.
   [Pleniceanu, Oren; Varda Bloom, Nira; Nagler, Arnon] Sheba Med Ctr, Cord Blood Bank, Ramat Gan, Israel.
   [Pleniceanu, Oren; Shukrun, Racheli; Vax, Einav; Dziedzic, Klaudyna; Pode Shakked, Naomi; Alfandary, Hadas; Nagler, Arnon; Dekel, Benjamin] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Kanter, Itamar; Kalisky, Tomer] Bar Ilan Univ, Inst Nanotechnol, Fac Engn, Ramat Gan, Israel.
   [Alfandary, Hadas] Schneider Childrens Med Ctr Israel, Inst Nephrol, Petah Tiqwa, Israel.
   [Bollag, Naomi; Shtainfeld, Rachel; Armon, Leah; Urbach, Achia] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel.
   [Arbiser, Jack L.] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA.
   [Arbiser, Jack L.] Atlanta Vet Adm Hosp, Winship Canc Inst, Atlanta, GA USA.
C3 Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University;
   Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv
   University; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv
   University; Sackler Faculty of Medicine; Bar Ilan University; Tel Aviv
   University; Bar Ilan University; Emory University
RP Dekel, B (通讯作者)，Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Pediat Stem Cell Res Inst, Ramat Gan, Israel.; Dekel, B (通讯作者)，Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Div Pediat Nephrol, Ramat Gan, Israel.; Dekel, B (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
EM benjamin.dekel@gmail.com
RI ; Urbach, Achia/GLR 9975 2022
OI /0000 0003 0537 4469; Urbach, Achia/0000 0001 9393 4504; Armon,
   Leah/0009 0001 6858 5338
FU Ziering Foundation; Israel Cancer Association [20150916]; Israel Cancer
   Research Fund (ICRF) project [PG 14 112]; Emory Skin Disease Research
   Core Center Grant from the National Institutes of Health [RO1 AR47901,
   P30 AR42687]; Robert Margolis Foundation; Rabinowitch Davis Foundation
   for Melanoma Research; Betty Minsk Foundation for Melanoma Research;
   Reynolds Sarcoma Foundation
FX BD is supported by the Ziering Foundation, the Israel Cancer Association
   (grant no 20150916), and the Israel Cancer Research Fund (ICRF) project
   grant (grant number PG 14 112). JLA is supported by the grant RO1
   AR47901 and P30 AR42687 Emory Skin Disease Research Core Center Grant
   from the National Institutes of Health, the Robert Margolis Foundation,
   as well as funds from the Rabinowitch Davis Foundation for Melanoma
   Research and the Betty Minsk Foundation for Melanoma Research, and the
   Reynolds Sarcoma Foundation. We thank Dr. Jasmin Jacob of the Cancer
   Research Center, Sheba Medical Center, Tel Hashomer, Israel, for her
   assistance with bioinformatic analysis. We also wish to express our
   gratitude to Prof. Iris Barshack of the Department of Pathology, Sheba
   Medical Center, Tel Hashomer, Israel, for providing AML histology
   specimens, and assistance with stainings. We dedicate this work to our
   beloved friend and colleague, Klaudyna Dziedzic.
CR Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549
   Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   [Anonymous], 2013, CELL REPORTS
   Arbiser JL, 2001, AM J PATHOL, V159, P483, DOI 10.1016/S0002 9440(10)61720 8
   Assaad AM, 2007, CHEST, V131, P850, DOI 10.1378/chest.06 1680
   Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007 0166
   Battula VL, 2013, BLOOD, V122, P357, DOI 10.1182/blood 2012 06 437988
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564
   Bissler JJ, 2013, LANCET, V381, P817, DOI 10.1016/S0140 6736(12)61767 X
   Boeuf S, 2008, J PATHOL, V216, P158, DOI 10.1002/path.2389
   BONETTI F, 1994, PATHOLOGY, V26, P230, DOI 10.1080/00313029400169561
   Brannon AR, 2010, CANCER RES, V70, DOI 10.1158/1538 7445.AM10 1996
   Bühring HJ, 2009, ANN NY ACAD SCI, V1176, P124, DOI 10.1111/j.1749 6632.2009.04564.x
   Buzhor E, 2013, AM J PATHOL, V183, P1621, DOI 10.1016/j.ajpath.2013.07.034
   Cao YH, 2014, NAT REV ENDOCRINOL, V10, P530, DOI 10.1038/nrendo.2014.114
   Cao YH, 2013, TRENDS MOL MED, V19, P460, DOI 10.1016/j.molmed.2013.05.002
   Cao YH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003149
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Cheng JW, 2013, J CELL BIOCHEM, V114, P1510, DOI 10.1002/jcb.24492
   Cibas ES, 2001, AM J SURG PATHOL, V25, P121, DOI 10.1097/00000478 200101000 00014
   Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Danielson LS, 2010, AM J PATHOL, V177, P908, DOI 10.2353/ajpath.2010.091150
   Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099
   Dekel B, 2006, J AM SOC NEPHROL, V17, P3300, DOI 10.1681/ASN.2005020195
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49
   Dziedzic K, 2014, SEMIN CELL DEV BIOL, V36, P57, DOI 10.1016/j.semcdb.2014.08.003
   Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254
   FITZPATRICK JE, 1990, J AM ACAD DERMATOL, V23, P1093, DOI 10.1016/0190 9622(90)70339 J
   Fogelgren B, 2008, DEV DYNAM, V237, P1767, DOI 10.1002/dvdy.21587
   Folpe AL, 2010, HUM PATHOL, V41, P1, DOI 10.1016/j.humpath.2009.05.011
   Furuhashi M, 2004, CANCER RES, V64, P2725, DOI 10.1158/0008 5472.CAN 03 1489
   Gao PS, 2014, J IMMUNOL, V192, P4560, DOI 10.4049/jimmunol.1303461
   GOODMAN ZD, 1984, AM J SURG PATHOL, V8, P745, DOI 10.1097/00000478 198410000 00003
   Hall Glenn F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030562
   Harari Steinberg O, 2013, EMBO MOL MED, V5, P1556, DOI 10.1002/emmm.201201584
   Harari Steinberg O, 2011, ORGANOGENESIS, V7, P123, DOI 10.4161/org.7.2.15783
   Hellström M, 1999, DEVELOPMENT, V126, P3047
   Iwamoto H, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1400244
   Ji H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5944
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kale S, 2004, FASEB J, V18, P270, DOI 10.1096/fj.04 1604fje
   Kattar MM, 1999, HUM PATHOL, V30, P295, DOI 10.1016/S0046 8177(99)90008 4
   Kenerson HL, 2002, CANCER RES, V62, P5645
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kobayashi T, 1999, CANCER RES, V59, P1206
   KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195 70
   Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798
   Konosu Fukaya S, 2014, PATHOL INT, V64, P133, DOI 10.1111/pin.12142
   Kourtidis A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2240
   Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200
   Leesnitzer LM, 2002, BIOCHEMISTRY US, V41, P6640, DOI 10.1021/bi0159581
   Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026
   Liang N, 2014, J EXP MED, V211, P2249, DOI 10.1084/jem.20140341
   Lim SD, 2007, MOL MED, V13, P160, DOI 10.2119/2006 00070.Lim
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luo HL, 2012, BIOMATERIALS, V33, P4277, DOI 10.1016/j.biomaterials.2012.02.042
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mendel TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065691
   Meng QQ, 2011, NEUROSCI LETT, V503, P191, DOI 10.1016/j.neulet.2011.08.033
   Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097 2765(00)80047 7
   Nadal JA, 2002, AM J PHYSIOL HEART C, V282, pH739, DOI 10.1152/ajpheart.00656.2001
   Nakajima A, 2008, CANCER SCI, V99, P1892, DOI 10.1111/j.1349 7006.2008.00904.x
   Nakano R, 2006, BIOCHEM PHARMACOL, V72, P42, DOI 10.1016/j.bcp.2006.03.023
   Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353
   Pi LY, 2011, INVEST OPHTH VIS SCI, V52, P8701, DOI 10.1167/iovs.11 7870
   Pleniceanu O, 2010, STEM CELLS, V28, P1649, DOI 10.1002/stem.486
   Pode Shakked N, 2016, SCI REP UK, V6, DOI 10.1038/srep23562
   Pode Shakked N, 2013, EMBO MOL MED, V5, P18, DOI 10.1002/emmm.201201516
   Pode Shakked N, 2009, J CELL MOL MED, V13, P1792, DOI 10.1111/j.1582 4934.2008.00607.x
   Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710
   Schaefer KL, 2005, CANCER RES, V65, P2251, DOI 10.1158/0008 5472.CAN 04 3037
   SHIMIZU M, 1994, AM J SURG PATHOL, V18, P1164, DOI 10.1097/00000478 199411000 00011
   Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200
   Shukrun R, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.05.013
   Siroky BJ, 2014, AM J PHYSIOL RENAL, V307, pF560, DOI 10.1152/ajprenal.00569.2013
   Stricker S, 2012, STEM CELLS DEV, V21, P623, DOI 10.1089/scd.2011.0154
   Takahashi H, 2006, CANCER SCI, V97, P854, DOI 10.1111/j.1349 7006.2006.00250.x
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008 5472.CAN 09 2067
   Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237
   Trelinska J, 2015, ANTI CANCER DRUG, V26, P437, DOI 10.1097/CAD.0000000000000207
   Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192
   Varda Bloom N, 2014, ISR MED ASSOC J, V16, P774
   Wada K, 2006, J BIOL CHEM, V281, P12673, DOI 10.1074/jbc.M513786200
   Wang X, 2013, ONCOGENE, V32, P5512, DOI 10.1038/onc.2013.217
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575
   Yan XL, 2012, ONCOL LETT, V4, P398, DOI 10.3892/ol.2012.760
   Yang XJ, 2013, P NATL ACAD SCI USA, V110, P13932, DOI 10.1073/pnas.1309629110
   Yang YL, 2013, P NATL ACAD SCI USA, V110, P12018, DOI 10.1073/pnas.1301331110
   Yu WH, 2008, MOL CELL BIOCHEM, V310, P11, DOI 10.1007/s11010 007 9661 9
   Yuan HY, 2012, ONCOTARGET, V3, P345
NR 101
TC 9
Z9 10
U1 0
U2 11
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1757 4676
EI 1757 4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD APR
PY 2017
VL 9
IS 4
BP 508
EP 530
DI 10.15252/emmm.201506111
PG 23
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EQ4HZ
UT WOS:000398038200011
PM 28275008
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Strand, V
   Bloch, DA
   Leff, R
   Peloso, PM
   Simon, LS
AF Strand, V.
   Bloch, D. A.
   Leff, R.
   Peloso, P. M.
   Simon, L. S.
TI Safety issues in the development of treatments for osteoarthritis:
   recommendations of the Safety Considerations Working Group
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Safety assessments; Serious adverse events; Cardiovascular risks;
   NSAIDs; COX 2
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CORONARY HEART DISEASE;
   CARDIOVASCULAR RISK; PRIMARY CARE; RHEUMATIC CONDITIONS; KNEE
   OSTEOARTHRITIS; MANAGEMENT; INHIBITORS; ARTHRITIS; EVENTS
AB Objective: The symptomatic treatment of osteoarthritis (OA) remains to be improved, as many patients do not respond well to current palliative therapies and/or suffer unacceptable adverse events. Given the unmet need for innovative, effective and well tolerated therapies, it is important to develop the means to estimate the ongoing safety profile of novel therapeutic agents over short  and longer term use.
   Design: Methods are presented to estimate the number of serious adverse events (SAEs) of interest considered as "acceptable" per 1000 patient years exposure and to estimate the numbers of patient years needed in a randomized controlled trial (RCT) to meet objectives. As exposure is increased, more evidence is accrued that the overall risk is within study limits. It is equally important that requirements for delineating the safety of promising new therapies not create barriers that would preclude their development. Therefore, ongoing surveillance of occurrence of SAEs of interest during clinical development is proposed, for example after every incremental 500 patient years exposure are accrued.
   Results: This paper and others in this special issue focus on identification of safety signals for symptomatic treatments of OA. Much less information is available for agents aimed at slowing/preventing structural progression but it is expected that a higher risk profile might be considered acceptable in the context of more promising benefit.
   Conclusion: This paper provides a proposal and supporting data for a comprehensive approach for assessing ongoing safety during clinical development of both palliative and disease modifying therapies for OA. (C) 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Strand, V.] Stanford Univ, Sch Med, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA.
   [Bloch, D. A.] Stanford Univ, Sch Med, Dept Biostat, Palo Alto, CA 94304 USA.
   [Leff, R.] AstraZeneca, Wilmington, DE USA.
   [Peloso, P. M.] Merck Res Labs, Clin Res Analgesia & Inflammat, Rahway, NJ USA.
   [Simon, L. S.] SDG LLC, Boston, MA USA.
C3 Stanford University; Stanford University; AstraZeneca; Merck & Company
RP Strand, V (通讯作者)，Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA.
EM vstrand@stanford.edu; dbloch@stanford.edu; Richard.leff@astrazeneca.com;
   Paul_peloso@merck.com
FU American College of Rheumatology; Amgen; ArthroLab; AstraZeneca; Bayer
   Healthcare; Chondrometrics; CombinatoRx; Cypress BioScience; DePuy
   Mitek; Expanscience; 4QImaging; Genevrier/IBSA; Genzyme; King
   (Alpharma); Merck; Merck Serono; NicOx; Pfizer; Rottapharm; Smith
   Nephew; Wyeth
FX The OARSI FDA OA Initiative received financial support from the
   following professional organization:American College of
   RheumatologyAdditionally the OARSI FDA OA Initiative received financial
   support from the following companies:AmgenArthroLabAstraZenecaBayer
   HealthcareChondrometricsCombinatoRxCypress BioScienceDePuy
   MitekExpanscience4QImagingGenevrier/IBSAGenzymeKing (Alpharma)MerckMerck
   SeronoNicOxPfizerRottapharmSmith & NephewWyeth
CR Altman Roy Davis, 2009, Am J Manag Care, V15, pS236
   [Anonymous], 2008, GUID IND DIAB MELL E
   [Anonymous], 2008, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention
   Beaulieu M, 2004, AM J MANAG CARE, V10, P569
   Becker MC, 2009, AM HEART J, V157, P606, DOI 10.1016/j.ahj.2008.12.014
   Berlin JA, 2008, AM J PUBLIC HEALTH, V98, P1366, DOI 10.2105/AJPH.2007.124537
   Beyth RJ, 1999, DRUG AGING, V14, P231, DOI 10.2165/00002512 199914030 00005
   BLACKSHEAR JL, 1983, ARCH INTERN MED, V143, P1130, DOI 10.1001/archinte.143.6.1130
   Brewster W, 2006, CURR DRUG SAF, V1, P127, DOI 10.2174/157488606776930599
   BROUWERS JRBJ, 1994, CLIN PHARMACOKINET, V27, P462, DOI 10.2165/00003088 199427060 00005
   BUOMINEN U, 2007, HEALTH QUAL LIFE OUT, V5, P16, DOI DOI 10.1186/1477 7525 5 16
   Chan AT, 2006, CIRCULATION, V113, P1578, DOI 10.1161/CIRCULATIONAHA.105.595793
   Cimmino MA, 2005, SEMIN ARTHRITIS RHEU, V35, P17, DOI 10.1016/j.semarthrit.2005.01.015
   Cunnington M, 2008, PHARMACOEPIDEM DR S, V17, P601, DOI 10.1002/pds.1590
   Curhan GC, 2002, ARCH INTERN MED, V162, P2204, DOI 10.1001/archinte.162.19.2204
   Di YM, 2008, CURR PHARM DESIGN, V14, P1723, DOI 10.2174/138161208784746798
   Dziedzic KS, 2009, PHYS THER, V89, P1371, DOI 10.2522/ptj.20090003
   Erb N, 2004, SCAND J RHEUMATOL, V33, P293, DOI 10.1080/03009740410006899
   *FDA, FDA PROD LAB TOC
   *FDA, 1999, FDA GUID IND CLIN DE
   *FDA, FDA PROD LAB AD
   Figueiras A, 1999, MED CARE, V37, P809, DOI 10.1097/00005650 199908000 00010
   Fosbol EL, 2009, CLIN PHARMACOL THER, V85, P190, DOI 10.1038/clpt.2008.204
   Fosbol EL, 2010, CIRC CARDIOVASC QUAL, V3, P395, DOI 10.1161/CIRCOUTCOMES.109.861104
   Furst DE, 2010, SEMIN ARTHRITIS RHEU, V39, P327, DOI 10.1016/j.semarthrit.2008.10.002
   Glasser SP, 2007, J CLIN PHARMACOL, V47, P1074, DOI 10.1177/0091270007304776
   Hammond IW, 2007, EXPERT OPIN DRUG SAF, V6, P705, DOI 10.1517/14740338.6.6.705
   Hernández Díaz S, 2006, BASIC CLIN PHARMACOL, V98, P266, DOI 10.1111/j.1742 7843.2006.pto_302.x
   Hochberg M C, 1996, Arthritis Care Res, V9, P170, DOI 10.1002/1529 0131(199606)9:3<170::AID ANR1790090304>3.0.CO;2 K
   *ICH, ICH GUID EXT POP EXP
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Lanas A, 2010, ANN RHEUM DIS, V69, P1453, DOI 10.1136/ard.2009.123166
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Lee JH, 2002, ARTHRITIS RHEUM US, V46, P2565, DOI 10.1002/art.10583
   Lipscomb ER, 2009, DIABETES CARE, V32, P394, DOI 10.2337/dc08 1622
   Lopez Gonzalez E, 2009, DRUG SAFETY, V32, P19, DOI 10.2165/00002018 200932010 00002
   Mazer M, 2008, J MED TOXICOL, V4, P2, DOI 10.1007/BF03160941
   McClain C J, 1999, Curr Gastroenterol Rep, V1, P42, DOI 10.1007/s11894 999 0086 3
   McGettigan P, 2006, JAMA J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011
   *NAT COLL CTR CHRO, 2008, OS NAT CLIN GUID CAR
   Niculescu L, 2009, CURR MED RES OPIN, V25, P729, DOI [10.1185/03007990802714382, 10.1185/03007990802714382 ]
   Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533 2500.2008.00204.x
   Ray WA, 2009, CIRC CARDIOVASC QUAL, V2, P155, DOI 10.1161/CIRCOUTCOMES.108.805689
   Rosemann T, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 79
   Rosemann T, 2008, PAIN MED, V9, P903, DOI 10.1111/j.1526 4637.2008.00498.x
   ROUJEAU JC, 1987, SCAND J RHEUMATOL, P131
   Roumie CL, 2009, PHARMACOEPIDEM DR S, V18, P1053, DOI 10.1002/pds.1820
   Sacks JJ, 2010, ARTHRIT CARE RES, V62, P460, DOI 10.1002/acr.20041
   Sharma L, 2003, ARTHRITIS RHEUM US, V48, P3359, DOI 10.1002/art.11420
   Solomon DH, 2008, ARTHRIT RHEUM ARTHR, V59, P1097, DOI 10.1002/art.23911
   Strand V, 2007, LANCET, V370, P2138, DOI 10.1016/S0140 6736(07)61909 6
   THOMPSON MS, 1986, AM J PUBLIC HEALTH, V76, P392, DOI 10.2105/AJPH.76.4.392
   van Dijk GM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 95
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
NR 55
TC 3
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD MAY
PY 2011
VL 19
IS 5
SI SI
BP 493
EP 499
DI 10.1016/j.joca.2011.02.019
PG 7
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 774IM
UT WOS:000291378900004
PM 21396471
OA Bronze
DA 2025 08 17
ER

PT J
AU Endo, N
   Fujino, K
   Doi, T
   Akai, M
   Hoshino, Y
   Nakano, T
   Iwaya, T
AF Endo, Naoto
   Fujino, Keiji
   Doi, Tokuhide
   Akai, Masami
   Hoshino, Yuichi
   Nakano, Tetsuo
   Iwaya, Tsutomu
TI Effect of elcatonin versus nonsteroidal anti inflammatory medications
   for acute back pain in patients with osteoporotic vertebral fracture: a
   multiclinic randomized controlled trial
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Calcitonin (or elcatonin); Osteoporosis; Vertebral fracture; Lumbar
   pain; Randomized controlled trial
ID OVARIECTOMY INDUCED HYPERALGESIA; QUALITY OF LIFE; POSTMENOPAUSAL WOMEN;
   BIOCHEMICAL MARKERS; CALCITONIN; RAT; PARTICIPATION; COMBINATION;
   RISEDRONATE; MECHANISMS
AB The aim of this study was to compare the efficacy of elcatonin injections and oral nonsteroidal anti inflammatory drugs (NSAIDs) for patients with osteoporosis who have acute lumbar pain after experiencing new vertebral compression fractures. Two hundred twenty eight Japanese female patients (mean age 77.3 years) with acute lumbar pain from osteoporotic vertebral fractures were randomly divided into two groups. Patients in one group were given an NSAID (NSAIDs group) and patients in the other group were given weekly intramuscular injections of 20 units of elcatonin (elcatonin group). All patients underwent follow up examinations up to 6 weeks from the start of the trial. Outcome measures were the level of functional impairment according to the Japan Questionnaire for Osteoporotic Pain (JQ22), the Roland Morris Disability Questionnaire (RDQ), and a visual analog scale (VAS) of pain intensity. Statistical analyses focused on (1) the time course of pain and functional level using linear mixed effects models to analyze the longitudinal data and (2) the effectiveness of elcatonin injection with mean difference values and 95 % confidence intervals. Significant differences were seen over time between the initial values and the postintervention values (4 and 6 weeks) in JQ22, RDQ, and VAS scores (effect size d > 0.4) in each group. The mean differences between the elcatonin group and the NSAIDs group in each measure at 4 and 6 weeks were  4.8 and  8.3 for the JQ22,  1.3 and  2.6 for the RDQ, and  11.3 and  11.5 for the VAS, shifted to elcatonin. Once weekly elcatonin injection was more effective than NSAIDs for treating acute lumbar pain and improving mobility in Japanese women with osteoporotic vertebral fractures.
C1 [Endo, Naoto] Niigata Univ, Grad Sch Med & Dent Sci, Dept Regenerat & Transplant Med, Div Orthoped Surg, Niigata, Japan.
   [Fujino, Keiji] Fujino Orthopaed Clin, Fujino, Japan.
   [Doi, Tokuhide] Fukuoka Clin, Fukuoka, Japan.
   [Akai, Masami; Iwaya, Tsutomu] Natl Rehabil Ctr Persons Disabil, Tokyo, Japan.
   [Hoshino, Yuichi] Jichi Med Sch, Dept Orthopaed Surg, Shimotsuke, Japan.
   [Nakano, Tetsuo] Tamana Cent Hosp, Tamana, Japan.
C3 Niigata University; Jichi Medical University
RP Endo, N (通讯作者)，Niigata Univ, Grad Sch Med & Dent Sci, Dept Regenerat & Transplant Med, Div Orthoped Surg, Niigata, Japan.
EM endless@med.niigata u.ac.jp
CR Altman DG., 2000, STAT CONFIDENCE
   Chow S C, 2007, SAMPLE SIZE CALCULAT, P355, DOI [10.1201/9781584889830, DOI 10.1201/9781584889830.CH14]
   COPP DH, 1961, SCIENCE, V134, P2038, DOI 10.1126/science.134.3495.2038
   Doi T, 2013, J BONE MINER METAB, V31, P663, DOI 10.1007/s00774 013 0458 5
   FORMAN LJ, 1989, LIFE SCI, V45, P447, DOI 10.1016/0024 3205(89)90631 0
   HAYASHI T, 1989, BONE, V10, P25, DOI 10.1016/8756 3282(89)90143 9
   Hedström M, 2001, ACTA ORTHOP SCAND, V72, P248, DOI 10.1080/00016470152846565
   Hoesel LM, 2005, CLIN ORTHOP RELAT R, P226, DOI 10.1097/01.blo.0000180891.03042.8d
   Hongo M, 2015, J BONE MINER METAB, V33, P432, DOI 10.1007/s00774 014 0603 9
   HORI M, 1984, FOLIA PHARMACOL JPN, V84, P91, DOI 10.1254/fpj.84.91
   Iba K, 2012, MB ORTHOP, V25, P117
   Ito A, 2000, J NEUROSCI, V20, P6302, DOI 10.1523/JNEUROSCI.20 16 06302.2000
   Ito A, 2012, MOL PAIN, V8, DOI 10.1186/1744 8069 8 42
   Ivaska KK, 2007, J BONE MINER RES, V22, P1155, DOI 10.1359/JBMR.070505
   Karachalios T, 2004, J BONE JOINT SURG BR, V86B, P350, DOI 10.1302/0301 620X.86B3.14300
   Katae Y, 2009, J ORTHOP RES, V27, P1652, DOI 10.1002/jor.20920
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Knopp JA, 2005, OSTEOPOROSIS INT, V16, P1281, DOI 10.1007/s00198 004 1798 8
   Lozano Ondoua AN, 2013, NEUROSCI LETT, V557, P52, DOI 10.1016/j.neulet.2013.08.003
   McGuire Jr RA, 2010, TREATING SPINAL COMP
   Ohishi T, 1998, ARCH ORTHOP TRAUM SU, V118, P126, DOI 10.1007/s004020050331
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Orimo H, 1996, J BONE MINER METAB, V14, P73
   ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632 198303000 00004
   Shibata K, 1998, PHARMACOL BIOCHEM BE, V60, P371, DOI 10.1016/S0091 3057(98)00015 X
   Suzukamo Yoshimi, 2003, J Orthop Sci, V8, P543, DOI 10.1007/s00776 003 0679 x
   Takakuwa M, 2012, BIOL PHARM BULL, V35, P1159, DOI 10.1248/bpb.b12 00200
   Yoh K, 2005, J BONE MINER METAB, V23, P167, DOI 10.1007/s00774 004 0556 5
   Yoshimura N, 2010, INT J EPIDEMIOL, V39, P988, DOI 10.1093/ije/dyp276
   Yoshimura T, 2012, FUND CLIN PHARMACOL, V26, P315, DOI 10.1111/j.1472 8206.2011.00934.x
NR 30
TC 9
Z9 13
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2017
VL 35
IS 4
BP 375
EP 384
DI 10.1007/s00774 016 0765 8
PG 10
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA EZ4EO
UT WOS:000404665600003
PM 27465912
DA 2025 08 17
ER

PT J
AU Wang, WJ
   Fu, WZ
   He, JW
   Wang, C
   Zhang, ZL
AF Wang, W J
   Fu, W Z
   He, J W
   Wang, C.
   Zhang, Z L
TI Association between SOST gene polymorphisms and response to
   alendronate treatment in postmenopausal Chinese women with low bone
   mineral density
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
ID TARGETED DELETION; BUCHEM DISEASE; SCLEROSTIN; OSTEOPOROSIS;
   DIFFERENTIATION; OSTEOBLASTS; METABOLISM; RESORPTION; THERAPY; CATENIN
AB The aim of this study was to explore the allelic association between SOST polymorphisms and the variance of clinical effects of alendronate in postmenopausal Chinese women with osteoporosis or osteopenia. In the study, 500 postmenopausal women in Shanghai area with osteoporosis or osteopenia were included. All participants were treated with weekly oral alendronate 70 mg, daily calcium 600 mg and vitamin D 125 IU for 12 months. Nine tagging single nucleotide polymorphisms (SNPs) in SOST gene were genotyped. Bone mineral density of lumbar spine (L1 L4), left femoral neck and total hip were measured at baseline and after 1 year of treatment, respectively. In the study, 450 subjects completed the 1 year follow up. The rs865429 was significantly associated with the % change of BMD at the femoral neck (P = 0.007). GG carriers seemed to be at an advantage after treatment of alendronate. Compared with AG and AA heterozygote, GG homozygote had the highest % change of BMD (3.100 +/  2.899%) at femoral neck. The odds ratio (95% confidence) of GG homozygote to be responders at femoral neck was 1.921 (1.211 3.048). Two haplotypes GG and AC constituted by rs865429 and rs851057 were associated with the % change of BMD at femoral neck and total hip, respectively. Therefore, the common variation of SOST gene contribute to the therapeutic response to alendronate treatment in Chinese women with osteoporosis or osteopenia.
C1 [Wang, W J; Fu, W Z; He, J W; Wang, C.; Zhang, Z L] Shanghai Jiao Tong Univ, Dept Osteoporosis & Bone Dis, Metab Bone Dis & Genet Res Unit, Affiliated Peoples Hosp 6, Shanghai, Peoples R China.
   [Wang, W J; Fu, W Z; He, J W; Wang, C.; Zhang, Z L] Shanghai Key Clin Ctr Metab Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, ZL (通讯作者)，Shanghai Jiao Tong Univ, Dept Osteoporosis & Bone Dis, Metab Bone Dis & Genet Res Unit, Affiliated Peoples Hosp 6, Shanghai, Peoples R China.; Zhang, ZL (通讯作者)，Shanghai Key Clin Ctr Metab Dis, Shanghai, Peoples R China.
EM zzl2002@medmail.com.cn
OI Zhang, zhenlin/0000 0002 4339 1617
CR Balemans W, 2002, BONE, V31, P515, DOI 10.1016/S8756 3282(02)00844 X
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Collette NM, 2012, P NATL ACAD SCI USA, V109, P14092, DOI 10.1073/pnas.1207188109
   Conti V, 2015, INT J MOL SCI, V16, P5452, DOI 10.3390/ijms16035452
   Creatsa M, 2011, J OBSTET GYNAECOL RE, V37, P1415, DOI 10.1111/j.1447 0756.2011.01557.x
   Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gao G, 2008, J CLIN DENSITOM, V11, P360, DOI 10.1016/j.jocd.2008.04.005
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   He JW, 2014, J CLIN ENDOCR METAB, V99, pE665, DOI 10.1210/jc.2013 2086
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Iwamoto J, 2005, J BONE MINER METAB, V23, P238, DOI 10.1007/s00774 004 0590 3
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee DO, 2014, GYNECOL OBSTET INVES, V77, P186, DOI 10.1159/000358389
   Lewiecki EM, 2008, BONE, V43, P1115, DOI 10.1016/j.bone.2008.08.106
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Palomba S, 2003, CLIN ENDOCRINOL, V58, P365, DOI 10.1046/j.1365 2265.2003.01724.x
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qureshi AM, 2002, CALCIFIED TISSUE INT, V70, P158, DOI 10.1007/s00223 001 1035 9
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Uitterlinden AG, 2004, AM J HUM GENET, V75, P1032, DOI 10.1086/426458
   Wang C, 2015, PHARMACOGENOMICS J, V15, P158, DOI 10.1038/tpj.2014.52
   Wang JY, 2016, PHARMACOGENOMICS, V17, P209, DOI 10.2217/pgs.15.167
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xia WB, 2012, J BONE MINER RES, V27, P125, DOI 10.1002/jbmr.519
   Zhang H, 2014, OSTEOPOROSIS INT, V25, P2797, DOI 10.1007/s00198 014 2832 0
   Zhang H, 2012, ACTA PHARMACOL SIN, V33, P490, DOI 10.1038/aps.2011.172
   Zheng H, 2016, PHARMACOGENET GENOM, V26, P12, DOI 10.1097/FPC.0000000000000181
   Zhou PR, 2014, PHARMACOGENOMICS, V15, P821, DOI [10.2217/PGS.14.12, 10.2217/pgs.14.12]
   Zhou PR, 2015, PHARMACOGENOMICS, V16, P1077, DOI [10.2217/PGS.15.76, 10.2217/pgs.15.76]
NR 42
TC 5
Z9 5
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470 269X
EI 1473 1150
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD OCT
PY 2019
VL 19
IS 5
BP 490
EP 498
DI 10.1038/s41397 018 0059 8
PG 9
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA IZ7DZ
UT WOS:000487249100010
PM 30287911
DA 2025 08 17
ER

PT J
AU Haney, SL
   Chhonker, YS
   Varney, ML
   Talmon, G
   Smith, LM
   Murry, DJ
   Holstein, SA
AF Haney, Staci L.
   Chhonker, Yashpal S.
   Varney, Michelle L.
   Talmon, Geoffrey
   Smith, Lynette M.
   Murry, Daryl J.
   Holstein, Sarah A.
TI In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of
   Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on
   Toxicity and Biodistribution
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID MURINE MODEL; TRANSFERASE; PRENYLATION; OSTEOCLASTS; PROTEINS; VITRO
AB The enzyme geranylgeranyl diphosphate synthase (GGDPS) synthesizes the 20 carbon isoprenoid geranylgeranyl pyrophosphate, which is used in geranylgeranylation reactions. We have demonstrated that GGDPS inhibitors in multiple myeloma (MM) cells disrupt Rab geranylgeranylation, leading to inhibition of monoclonal protein trafficking, induction of the unfolded protein response pathway (UPR), and apoptosis. We have previously reported preclinical studies with the GGDPS inhibitor VSW1198, which is a mixture of homogeranyl/homoneryl triazole bisphosphonates. Additional structure function efforts have led to development of the alpha methylated derivatives RAM2093 (homogeranyl) and RAM2061 (homoneryl). As little is known regarding the impact of olefin stereochemistry on drug properties in vivo, we pursued additional preclinical evaluation of RAM2093 and RAM2061. In MM cell lines, both isomers induce activation of UPR/apoptotic markers in a concentration dependent manner and with similar potency. Single dose testing in CD 1 mice identified a maximum tolerated i.v. dose of 0.5 mg/kg for RAM2061 and 0.3 mg/kg for RAM2093. Liver toxicity was the primary barrier to dose escalation for both compounds. Disruption of geranylgeranylation in vivo was confirmed after multidose administration of either compound. Pharmacokinetic studies revealed plasma terminal half lives of 29.2 +/  6 (RAM2061) and 22.1 +/  4 hours (RAM2093). Relative to RAM2061, RAM2093 levels were significantly higher in liver tissue but not in other tissues. Using MM.1S flank xenografts, we observed a significant reduction in tumor growth in mice treated with RAM2061 relative to controls. Collectively, these studies reveal olefin stereochemistry dependent effects on GGDPS inhibitor biodistribution and confirm the in vivo efficacy of this novel therapeutic approach.
   SIGNIFICANCE STATEMENT
   These studies reveal olefin stereochemistry dependent effects on the in vivo properties of two novel triazole bisphosphonate inhibitors of geranylgeranyl diphosphate synthase and demonstrate the therapeutic potential of this class of inhibitors for the treatment of multiple myeloma.
C1 [Haney, Staci L.; Varney, Michelle L.; Holstein, Sarah A.] Univ Nebraska Med Ctr, Dept Internal Med, 986840 Nebraska Med Ctr, Omaha, NE 68198 USA.
   [Chhonker, Yashpal S.; Murry, Daryl J.] Univ Nebraska Med Ctr, Clin Pharmacol Lab, Dept Pharm Practice, Omaha, NE 68198 USA.
   [Talmon, Geoffrey] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
   [Murry, Daryl J.; Holstein, Sarah A.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.
   [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Holstein, SA (通讯作者)，Univ Nebraska Med Ctr, Dept Internal Med, 986840 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM sarah.holstein@unmc.edu
RI ; Holstein, Sarah/H 6033 2019
OI Varney, Michelle/0000 0001 5339 2077; Murry, DJ/0000 0002 4169 5027
FU National Institutes of Health [R01CA172070, P30 CA036727]; Nebraska
   Department of Health Human Services [LB 506]
FX This work was supported by the National Institutes of Health [Grants
   R01CA172070, P30 CA036727] and the Nebraska Department of Health & Human
   Services [LB 506].
CR Allen C, 2017, MOL PHARMACOL, V91, P229, DOI 10.1124/mol.116.107326
   Born EJ, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.64
   Chhonker YS, 2018, J PHARMACEUT BIOMED, V153, P22, DOI 10.1016/j.jpba.2018.02.010
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   ERIKSSON T, 1995, CHIRALITY, V7, P44, DOI 10.1002/chir.530070109
   Eriksson T, 2001, EUR J CLIN PHARMACOL, V57, P365, DOI 10.1007/s002280100320
   Fischer ES, 2014, NATURE, V512, P49, DOI 10.1038/nature13527
   Foust BJ, 2016, BIOORGAN MED CHEM, V24, P3734, DOI 10.1016/j.bmc.2016.06.019
   Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02 10 0639
   Haney SL, 2019, ONCOGENE, V38, P5308, DOI 10.1038/s41388 019 0794 6
   Haney SL, 2018, INVEST NEW DRUG, V36, P810, DOI 10.1007/s10637 018 0571 3
   Haney SL, 2017, MOLECULES, V22, DOI 10.3390/molecules22060886
   Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200
   Holstein SA, 2011, LEUKEMIA RES, V35, P551, DOI 10.1016/j.leukres.2010.08.008
   Lacbay CM, 2018, J MED CHEM, V61, P6904, DOI 10.1021/acs.jmedchem.8b00886
   Lawson MA, 2008, BIOCHEM BIOPH RES CO, V377, P453, DOI 10.1016/j.bbrc.2008.09.157
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lu J, 2009, MOL CANCER THER, V8, P1218, DOI 10.1158/1535 7163.MCT 08 1122
   Matthiesen RA, 2018, BIOORGAN MED CHEM, V26, P376, DOI 10.1016/j.bmc.2017.10.023
   Matthiesen RA, 2016, J ORG CHEM, V81, P9438, DOI 10.1021/acs.joc.6b01693
   O'Dwyer PJ, 2010, ANN ONCOL, V21, P42
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood 2005 08 3531
   Ramalho JS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471 2121 3 26
   Reilly JE, 2017, CANCER BIOL THER, V18, P872, DOI 10.1080/15384047.2016.1219817
   Reilly JE, 2015, CLIN EXP METASTAS, V32, P555, DOI 10.1007/s10585 015 9727 0
   Wills VS, 2017, BIOORGAN MED CHEM, V25, P2437, DOI 10.1016/j.bmc.2017.02.066
   Wills VS, 2015, ACS MED CHEM LETT, V6, P1195, DOI 10.1021/acsmedchemlett.5b00334
   Zhou X, 2014, BIOORGAN MED CHEM, V22, P2791, DOI 10.1016/j.bmc.2014.03.014
NR 31
TC 18
Z9 20
U1 0
U2 8
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD NOV 1
PY 2019
VL 371
IS 2
BP 327
EP 338
DI 10.1124/jpet.119.258624
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA JM0OA
UT WOS:000495922100011
PM 31420526
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Pan, JH
   Ma, ZH
   Liu, B
   Qian, HY
   Shao, XG
   Liu, JZ
   Wang, Q
   Xue, W
AF Pan, Jiahua
   Ma, Zehua
   Liu, Bo
   Qian, Hongyang
   Shao, Xiaoguang
   Liu, Jiazhou
   Wang, Qi
   Xue, Wei
TI Identification of cancer associated fibroblasts subtypes in prostate
   cancer
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE cancer associated fibroblasts; heterogeneity; castration resistance;
   prognosis; prostate cancer
ID TUMOR MICROENVIRONMENT; ANDROGEN RECEPTOR; SINGLE CELL; GENE EXPRESSION;
   RESISTANCE; MYOFIBROBLASTS; HETEROGENEITY; FEATURES; THERAPY
AB IntroductionCancer associated fibroblasts (CAFs) are one of the most abundant cell types in tumor microenvironment. However, the phenotypic and functional heterogeneities among CAFs have not been sufficiently investigated in prostate cancer. MethodsWe obtained and analyzed the single cell RNA sequencing data from 26 hormone sensitive prostate cancer samples and 8 castration resistant prostate cancer samples, along with the analysis of bulk sequencing datasets. Furthermore, we performed multicolor immunofluorescence staining to verify the findings from the data analysis. ResultsWe identified two major CAFs subtypes with distinct molecular characteristics and biological functions in prostate cancer microenvironment, namely alpha SMA+ CAV1+ CAFs C0 and FN1+ FAP+ CAFs C1. Another single cell RNA sequencing dataset containing 7 bone metastatic prostate cancer samples demonstrated that osteoblasts in the bone metastatic lesions comprised two subtypes with molecular characteristics and biological functions similar to CAFs C0 and CAFs C1 in the primary tumor sites. In addition, we discovered a transcriptional factor regulatory network depending on CAFs C1. CAFs C1, but not CAFs C0, was associated with castration resistance and poor prognosis. We also found that CAFs C1 signature was involved in treatment resistance to immune checkpoint inhibitors. DiscussionIn summary, our results identified the presence of heterogeneous CAFs subtypes in prostate cancer microenvironment and the potential of specific CAFs subtype as therapeutic target for castration resistant prostate cancer.
C1 [Pan, Jiahua; Ma, Zehua; Liu, Bo; Qian, Hongyang; Shao, Xiaoguang; Liu, Jiazhou; Wang, Qi; Xue, Wei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China.
   [Wang, Qi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Wang, Q; Xue, W (通讯作者)，Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China.; Wang, Q (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai, Peoples R China.
EM wqi@sjtu.edu.cn; xuewei@renji.com
RI Liu, Jiazhou/MGB 6199 2025
FU National Natural Science Foundation of China [82072847, 81772742];
   Science and Technology Commission of Shanghai Municipality [21Y11904100,
   19XD1402300]; Shanghai Municipal Health Commission [2019LJ11,
   2020CXJQ03]; Shanghai Shenkang Hospital Development Center
   [SHDC2020CR3014A]; Shanghai Municipal Education Commission Gaofeng
   Clinical Medicine Grant Support [20191906, 20152215]; Renji Hospital
   [LYZXHXKT220845, 2020LYRJ 002, PNO 0106, RJKY18 02]
FX The work was supported by National Natural Science Foundation of China
   (No 82072847, 81772742), Science and Technology Commission of Shanghai
   Municipality (21Y11904100, 19XD1402300), Shanghai Municipal Health
   Commission (2019LJ11, 2020CXJQ03), Shanghai Shenkang Hospital
   Development Center (SHDC2020CR3014A), Shanghai Municipal Education
   Commission Gaofeng Clinical Medicine Grant Support (20191906, 20152215),
   Renji Hospital (LYZXHXKT220845, 2020LYRJ 002, PNO 0106, RJKY18 02). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or manuscript preparation.
CR Affo S, 2021, CANCER CELL, V39, P866, DOI 10.1016/j.ccell.2021.03.012
   Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078 0432.CCR 05 0585
   Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573 019 0044 1
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666
   Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001
   Chen SJ, 2021, NAT CELL BIOL, V23, DOI 10.1038/s41556 020 00613 6
   Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007
   Chen ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18916 5
   Cornford P, 2021, EUR UROL, V79, P263, DOI 10.1016/j.eururo.2020.09.046
   Delaine Smith RM, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102674
   Dong BJ, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01476 1
   Eckert MA, 2019, NATURE, V569, P723, DOI 10.1038/s41586 019 1173 8
   Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596 020 0292 x
   Foster DS, 2022, CANCER CELL, V40, P1392, DOI 10.1016/j.ccell.2022.09.015
   Galbo PM, 2021, CLIN CANCER RES, V27, P2636, DOI 10.1158/1078 0432.CCR 20 4226
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587 020 0546 8
   Graham MK, 2023, PROSTATE, V83, P286, DOI 10.1002/pros.24460
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Haldar S, 2020, P NATL ACAD SCI USA, V117, P8515, DOI 10.1073/pnas.1910952117
   Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115
   Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039
   Hirz T, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36325 2
   Huang HC, 2022, CANCER CELL, V40, P659, DOI 10.1016/j.ccell.2022.04.011
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Jain S, 2018, ANN ONCOL, V29, P215, DOI 10.1093/annonc/mdx637
   Joseph DB, 2021, J PATHOL, V255, P141, DOI 10.1002/path.5751
   Kfoury Y, 2021, CANCER CELL, V39, P1464, DOI 10.1016/j.ccell.2021.09.005
   Kwon OJ, 2019, ISCIENCE, V13, P328, DOI 10.1016/j.isci.2019.02.032
   Lakins MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03347 0
   Lin YL, 2022, HEPATOLOGY, V75, P28, DOI 10.1002/hep.32099
   Liu DY, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64073 6
   Luo H, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34395 2
   Ma XS, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01264 9
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501
   McAndrews KM, 2022, CANCER DISCOV, V12, P1580, DOI 10.1158/2159 8290.CD 20 1484
   McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003
   Mizutani Y, 2019, CANCER RES, V79, P5367, DOI 10.1158/0008 5472.CAN 19 0454
   Mottet N, 2021, EUR UROL, V79, P243, DOI 10.1016/j.eururo.2020.09.042
   Nicolas AM, 2022, CANCER CELL, V40, P168, DOI 10.1016/j.ccell.2022.01.004
   Öhlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Song HB, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27322 4
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008 5472.CAN 06 4040
   Tashireva LA, 2017, IMMUNOBIOLOGY, V222, P631, DOI 10.1016/j.imbio.2016.11.012
   Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008 5472.CAN 09 2984
   Uchihara T, 2020, CANCER RES, V80, P3222, DOI 10.1158/0008 5472.CAN 19 3803
   van de Sande B, 2020, NAT PROTOC, V15, P2247, DOI 10.1038/s41596 020 0336 2
   Wanjala J, 2015, MOL CANCER THER, V14, P278, DOI 10.1158/1535 7163.MCT 14 0542 T
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008 5472.CAN 15 2973
   Yu GY, 2022, CANCER RES, V82, P3158, DOI 10.1158/0008 5472.CAN 22 0170
   Zhang M, 2020, J HEPATOL, V73, P1118, DOI 10.1016/j.jhep.2020.05.039
   Zhang ZD, 2020, CANCER CELL, V38, P279, DOI 10.1016/j.ccell.2020.06.005
   Zhu Y, 2021, NAT REV UROL, V18, P282, DOI 10.1038/s41585 021 00442 8
NR 58
TC 18
Z9 19
U1 2
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 24
PY 2023
VL 14
AR 1133160
DI 10.3389/fimmu.2023.1133160
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA C7UX4
UT WOS:000963935900001
PM 37033924
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, JH
   Mao, Z
   Shang, W
   Yue, HT
   Wang, YW
   Wu, LL
   Liu, W
   Yang, J
AF Hu Jinhua
   Mao Zhao
   Shang Wei
   Yue Haitao
   Wang Yuwen
   Wu Lili
   Liu Wei
   Yang Jian
TI Down Regulation of Differentiated Embryo Chondrocyte Expressed Gene 1 is
   Related to the Decrease of Osteogenic Capacity
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Differentiated embryo chondrocyte expressed gene 1 (DEC1); dexamethasone
   (DEX); 17 beta estradiol (E2); alkaline phosphatase (ALP);
   mineralization; osteogenic activity
ID HELIX TRANSCRIPTION FACTORS; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   POSTMENOPAUSAL WOMEN; ALKALINE PHOSPHATASE; IN VITRO; DEC1; BONE;
   ESTROGEN; RECEPTOR; SAOS 2
AB Differentiated embryo chondrocyte expressed gene 1 (DEC1) is associated with chondrogenesis, neurogenesis, immune response, biological rhythm, lipogenesis, cell differentiation and carcinogenesis. However, there is little information about its contribution to osteoblast osteogenesis. In the present study, we report that DEC1 expression increases along with the degree of mineralization, which parallells with the increase of osteogenesis induction time in SaoS 2 cells. Dexamethasone (DEX) decreases the osteogenesis capacity such as alkaline phosphatase (ALP) activity and mineralization along with decreasing the DEC1 expression. On the contrary, 17 beta estradiol (E2) increases the osteogenesis along with increasing the DEC1 expression. Moreover, the overexpression of DEC1 alone increases the ALP activity and mineralization synchronously, and it not only partially reverses the decrease of ALP activity induced by DEX, but almost abolishes the decrease of mineralized nodules induced by DEX. On the other hand, the DEC1 expression decreases in tibia bone marrow side of ovariectomy mice compared with that in sham operated mice, and E2 treatment ameliorates the decrease of DEC1 expression induced by bilateral ovariectomy and prevents osteoporosis in ovariectomized mice. Taken together, downregulation of DEC1 expression is related to the decrease of osteogenic capacity. The findings provide a novel target for the therapy of osteoporosis.
C1 [Hu Jinhua; Shang Wei; Yue Haitao; Wang Yuwen; Wu Lili; Liu Wei; Yang Jian] Nanjing Med Univ, Dept Pharmacol, Nanjing 21029, Jiangsu, Peoples R China.
   [Mao Zhao] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing University
RP Yang, J (通讯作者)，Nanjing Med Univ, Dept Pharmacol, Nanjing 21029, Jiangsu, Peoples R China.
EM jianyang@njmu.edu.cn
RI Liu, Guanfeng/KHV 9757 2024
FU Natural Science Foundation of China [81173128, 81373443]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   [2012323411000]; Jiangsu Provincial Department of Education
   [13KJA310003]; Ministry and Education of PRC [20123234110005]
FX The authors thank Dr. Bingfang Yan of University of Rhode Island for
   kindly providing the DEC1 construct and antibody. This study was
   supported by the Natural Science Foundation of China (Nos. 81173128,
   81373443), the Project Funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (2012323411000),
   the Major Project of Jiangsu Provincial Department of Education (No.
   13KJA310003), and the Ministry and Education of PRC (20123234110005).
CR Abnosi MH, 2012, IRAN J BASIC MED SCI, V15, P1131
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   BERESFORD JN, 1986, ENDOCRINOLOGY, V119, P1776, DOI 10.1210/endo 119 4 1776
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen FP, 2009, TAIWAN J OBSTET GYNE, V48, P350, DOI 10.1016/S1028 4559(09)60323 5
   Chen WF, 2006, BRIT J NUTR, V95, P1039, DOI 10.1079/BJN20061735
   Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133
   Fukui M, 2011, BIOCHEM BIOPH RES CO, V415, P252, DOI 10.1016/j.bbrc.2011.10.025
   Hong YD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023046
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Iwata T, 2006, EUR J CELL BIOL, V85, P423, DOI 10.1016/j.ejcb.2005.12.007
   Jiang HX, 2005, J BONE MINER RES, V20, P494, DOI 10.1359/JBMR.041133
   Kharlap MS, 2006, ANN NY ACAD SCI, V1091, P205, DOI 10.1196/annals.1378.067
   Kon N, 2008, NAT CELL BIOL, V10, P1463, DOI 10.1038/ncb1806
   Lei J, 2010, J IMMUNOL, V185, P7186, DOI 10.4049/jimmunol.1001437
   Li YH, 2006, INT J MOL MED, V18, P713
   Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200
   Lindley C, 2002, DRUG METAB DISPOS, V30, P814, DOI 10.1124/dmd.30.7.814
   Liu YF, 2013, STAT INTERFACE, V6, P1
   Lu L, 2012, CELL BIOL TOXICOL, V28, P279, DOI 10.1007/s10565 012 9222 1
   Ma WS, 2013, ONCOL REP, V30, P2957, DOI 10.3892/or.2013.2774
   MacLean HE, 2004, GENE EXPR PATTERNS, V4, P633, DOI 10.1016/j.modgep.2004.04.011
   Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154
   Morales Torres J, 2004, OSTEOPOROSIS INT, V15, P625, DOI 10.1007/s00198 004 1596 3
   Nakashima A, 2008, MOL CELL BIOL, V28, P4080, DOI 10.1128/MCB.02168 07
   Nam SH, 2012, BONE, V50, P149, DOI 10.1016/j.bone.2011.10.017
   Park YK, 2012, MOL CELLS, V33, P575, DOI 10.1007/s10059 012 0002 9
   Paterni I, 2013, EXPERT OPIN THER PAT, V23, P1247, DOI 10.1517/13543776.2013.805206
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Piek E, 2010, BONE, V46, P613, DOI 10.1016/j.bone.2009.10.024
   Pinkerton JV, 2013, CLIN OBSTET GYNECOL, V56, P711, DOI 10.1097/GRF.0b013e3182a9fb02
   Qian YJ, 2012, P NATL ACAD SCI USA, V109, P11300, DOI 10.1073/pnas.1203185109
   Ren Y, 2012, CHINESE J CANCER RES, V24, P151, DOI 10.1007/s11670 012 0151 6
   RODAN SB, 1987, CANCER RES, V47, P4961
   Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sanders S, 2013, SOUTH MED J, V106, P698, DOI 10.1097/SMJ.0b013e3182a0df8b
   Seamon J, 2013, BONE MARROW RES, DOI 10.1155/2013/737580
   Seimiya M, 2004, EUR J IMMUNOL, V34, P1322, DOI 10.1002/eji.200324700
   Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960
   Shen M, 2002, J BIOL CHEM, V277, P50112, DOI 10.1074/jbc.M206771200
   Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171 9335 00167
   Shi XH, 2011, WORLD J GASTROENTERO, V17, P2037, DOI 10.3748/wjg.v17.i15.2037
   Solakidi S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P240
   Sterling RS, 2011, CLIN ORTHOP RELAT R, V469, P1913, DOI 10.1007/s11999 010 1736 3
   Stucki U, 2001, CLIN ORAL IMPLAN RES, V12, P121, DOI 10.1034/j.1600 0501.2001.012002121.x
   Thompson L, 2012, J ORTHOP RES, V30, P831, DOI 10.1002/jor.21585
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Visentini M, 2012, EUR J IMMUNOL, V42, P1468, DOI 10.1002/eji.201142313
   Wang QP, 2012, BONE, V51, P515, DOI 10.1016/j.bone.2012.05.011
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Wu T, 2011, J EXP BIOL, V214, P1257, DOI 10.1242/jeb.052100
   Yamada K, 2005, FRONT BIOSCI LANDMRK, V10, P3151, DOI 10.2741/1772
   Yamada K, 2003, J BIOL CHEM, V278, P30719, DOI 10.1074/jbc.M301597200
   Yin XX, 2012, BRAZ J MED BIOL RES, V45, P693, DOI 10.1590/S0100 879X2012007500060
   Yuen HF, 2010, BRIT J CANCER, V102, P332, DOI 10.1038/sj.bjc.6605480
   Zhang Y, 2008, J CELL BIOCHEM, V105, P487, DOI 10.1002/jcb.21844
   Zhao Q, 2013, CALCIFIED TISSUE INT, V93, P172, DOI 10.1007/s00223 013 9739 1
NR 60
TC 6
Z9 8
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD APR
PY 2014
VL 15
IS 4
BP 432
EP 441
DI 10.2174/1389450114666140102133719
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AE9SW
UT WOS:000334351300005
PM 24397494
DA 2025 08 17
ER

PT J
AU Alberto, LCA
   Georgina, CCE
   Miryam, MH
   Gabriel, TCL
   Adrian, EG
   Arelly, CAB
   Lena, RA
   Antonio, APM
   Manuel, MAV
AF Alexis Alberto, Larios Cervantes
   Elda Georgina, Chavez Cortez
   Miryam, Martinez Hernandez
   Luis Gabriel, Talavera Contreras
   Adrian, Espinoza Guillen
   Bertha Arelly, Carrillo Avila
   Lena, Ruiz Azuara
   Marco Antonio, Alvarez Perez
   Victor Manuel, Martinez Aguilar
TI Antimicrobial effect of Casiopeinas® copper  and ruthenium based
   compounds on Aggregatibacter actinomycetemcomitans and in vitro
   cell viability onto osteoblasts cells
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Casiopeinas (R); Copper; Ruthenium; Aggregatibacter
   actinomycetemcomitans; Antimicrobial effect
ID PERI IMPLANT DISEASES; 2017 WORLD WORKSHOP; ANTIBACTERIAL ACTIVITY;
   SILVER NANOPARTICLES; CONSENSUS REPORT; COMPLEXES; CLASSIFICATION;
   TRANSITION; MECHANISM
AB Objectives The present study aims to evaluate the antimicrobial property of Casiopeinas (R) copper  and ruthenium based compounds against Aggregatibacter actinomycetemcomitans serotype b (ATCC (R) 43,718 (TM)), as well as the cytotoxicity on an osteoblasts cell line of both compounds.
   Material and methods The antibacterial effect of the copper based compounds (CasII gly, CasIII ia) and the ruthenium based compound (RuN 6) at four different concentrations was evaluated as the inhibition ratio of the bacterial growth after 48 h under anaerobic conditions, and the cell viability was measured through resazurin assay.
   Results The copper  and ruthenium based compounds used for this assay were (CasII gly, CasIII ia, and RuN 6), showing inhibitory activity between 39 and 62% compared to the antibiotic employed as control 66%. Cell viability was established between 61 and 96%.
   Conclusions Casiopeinas (R) and ruthenium showed dose and time dependent, inhibitory activity on A. actinomycetemcomitans, and low toxicity on cells (osteoblast) underexposure. The compound CasII gly showed the best antimicrobial effect, and it could be considered a possible antimicrobial agent in periodontal therapy.
C1 [Alexis Alberto, Larios Cervantes; Elda Georgina, Chavez Cortez; Bertha Arelly, Carrillo Avila; Victor Manuel, Martinez Aguilar] Univ Autonoma Yucatan, Sch Dent, Specializat Periodont, Merida, Mexico.
   [Miryam, Martinez Hernandez] Univ Nacl Autonoma Mexico, Fac Dent, DEPeI, Lab Mol Genet, Mexico City, DF, Mexico.
   [Luis Gabriel, Talavera Contreras; Adrian, Espinoza Guillen; Lena, Ruiz Azuara] Univ Nacl Autonoma Mexico, Fac Chem, Dept Inorgan & Nucl Chem, Mexico City, DF, Mexico.
   [Marco Antonio, Alvarez Perez] Univ Nacl Autonoma Mexico, Fac Dent, DEPeI, Tissue Bioengn Lab, Mexico City, Mexico.
C3 Universidad Autonoma de Yucatan; Universidad Nacional Autonoma de
   Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional
   Autonoma de Mexico
RP Miryam, MH (通讯作者)，Univ Nacl Autonoma Mexico, Fac Dent, DEPeI, Lab Mol Genet, Mexico City, DF, Mexico.
EM victor.martinez@correo.uady.mx
RI ; Martínez Hernández, Miryam/KDP 2584 2024
OI Martinez Aguilar, Victor/0000 0003 2188 5293; Talavera Contreras, Luis
   Gabriel/0000 0001 6230 6548; Martinez Hernandez,
   Miryam/0000 0002 1589 8605; Larios Cervantes, Alexis
   Alberto/0000 0002 8648 9075
FU DGAPA UNAM [PAPIIT IT203618, IN230020]
FX The financial support by the DGAPA UNAM: PAPIIT IT203618 and IN230020
   projects.
CR [Anonymous], 2004, J PERIODONTOL, V75, P1553
   Asikainen S, 1999, PERIODONTOL 2000, V20, P65, DOI 10.1111/j.1600 0757.1999.tb00158.x
   Barbosa AR, 2015, CHEMOTHERAPY, V61, P249, DOI 10.1159/000443496
   Benoit DSW, 2019, ACS NANO, V13, P4869, DOI 10.1021/acsnano.9b02816
   García Ramos JC, 2014, CHEM EUR J, V20, P13730, DOI 10.1002/chem.201402775
   García Ramos JC, 2012, DALTON T, V41, P10164, DOI 10.1039/c2dt30224a
   Chapple ILC, 2018, J CLIN PERIODONTOL, V45, pS68, DOI 10.1111/jcpe.12940
   Chen PL, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aae15b
   Correia I, 2017, J INORG BIOCHEM, V175, P284, DOI 10.1016/j.jinorgbio.2017.07.025
   de Anda Jáuregui G, 2019, COMPUT BIOL CHEM, V78, P127, DOI 10.1016/j.compbiolchem.2018.11.021
   Deng ZQ, 2017, BIOMATERIALS, V129, P111, DOI 10.1016/j.biomaterials.2017.03.017
   Dorati R, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10040096
   Feres M, 2015, PERIODONTOL 2000, V67, P131, DOI 10.1111/prd.12075
   Fernandes JS, 2017, ACTA BIOMATER, V59, P2, DOI 10.1016/j.actbio.2017.06.046
   Galindo Murillo R, 2015, NUCLEIC ACIDS RES, V43, P5364, DOI 10.1093/nar/gkv467
   Gholizadeh P, 2017, MICROB PATHOGENESIS, V113, P303, DOI 10.1016/j.micpath.2017.11.001
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   Herbert BA, 2016, MOL ORAL MICROBIOL, V31, P207, DOI 10.1111/omi.12119
   Valencia Cruz AI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054664
   Lia SJ, 2019, INT J NANOMED, V14, P1469, DOI 10.2147/IJN.S191340
   Marín Hernández A, 2012, ARCH TOXICOL, V86, P753, DOI 10.1007/s00204 012 0809 3
   MARSH PD, 1992, J DENT RES, V71, P1431, DOI 10.1177/00220345920710071501
   MCLEAN RJC, 1993, CAN J MICROBIOL, V39, P895, DOI 10.1139/m93 134
   Miranda Calderón JE, 2011, CARBOHYD RES, V346, P121, DOI 10.1016/j.carres.2010.07.007
   Oberoi SS, 2015, INT DENT J, V65, P4, DOI 10.1111/idj.12146
   Pal M, 2018, EUR J MED CHEM, V150, P419, DOI 10.1016/j.ejmech.2018.03.015
   Papapanou PN, 2018, J CLIN PERIODONTOL, V45, pS162, DOI 10.1111/jcpe.12946
   Andere NMRB, 2018, PHOTODIAGN PHOTODYN, V24, P115, DOI 10.1016/j.pdpdt.2018.09.002
   Silva Platas C, 2016, J BIOENERG BIOMEMBR, V48, P43, DOI 10.1007/s10863 015 9640 x
   Toledano Magaña Y, 2017, J MED CHEM, V60, P899, DOI 10.1021/acs.jmedchem.6b00795
   Urbina Guti?rrez J., 2018, NOVASINERGIA, V1, P14, DOI [10.37135/unach.ns.001.01.02, DOI 10.37135/UNACH.NS.001.01.02]
   Vargas Reus MA, 2012, INT J ANTIMICROB AG, V40, P135, DOI 10.1016/j.ijantimicag.2012.04.012
   Yin IX, 2020, INT J NANOMED, V15, P2555, DOI 10.2147/IJN.S246764
NR 33
TC 1
Z9 1
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1517 8382
EI 1678 4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD MAR
PY 2022
VL 53
IS 1
BP 179
EP 184
DI 10.1007/s42770 021 00648 3
EA NOV 2021
PG 6
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA ZI4KX
UT WOS:000714831800001
PM 34741282
OA Green Published
DA 2025 08 17
ER

PT J
AU Tsekoura, EK
   Dick, T
   Pankongadisak, P
   Graf, D
   Boluk, Y
   Uludag, H
AF Tsekoura, Eleni K.
   Dick, Teo
   Pankongadisak, Porntipa
   Graf, Daniel
   Boluk, Yaman
   Uludag, Hasan
TI Delivery of Bioactive Gene Particles via Gelatin Collagen PEG Based
   Electrospun Matrices
SO PHARMACEUTICALS
LA English
DT Article
DE electrospun matrices; gelatin; collagen; gene delivery; plasmid DNA;
   Bone Morphogenetic Protein
ID CHITOSAN NANOPARTICLES; GROWTH FACTORS; REGENERATION; SCAFFOLDS;
   CARTILAGE; SYSTEM; CELLS
AB The fabrication of fiber mats via electrospinning has been adopted in the last decades to produce high quality scaffolds for tissue engineering. However, an effective combination of electrospinning methods with gene delivery therapies remains a challenge. In this study, we describe how the delivery of gene complexes via electrospun mats that contain different volumes of gelatin (Gel), collagen (Col), and polyethylene glycol (PEG) can affect gene expression by transfected cells. Non viral complexes were formulated by using lipid modified polyethylenimine (PEI) polymer and plasmid DNAs (pDNA) like the reporter Green Fluorescent Protein (GFP) and the therapeutically relevant Bone Morphogenetic Protein 2 (BMP 2) and electrospuned after being mixed with different volumes of Gel Col PEG mats and delivered to human myoblast (C2C12) and mouse osteoblast cells (MC3T3). The entrapment of GFP complexes via different homogeneous electrospun fiber mats revealed that a high fraction of collagen in the mats affected the quality of the fibers and led to reduced transfection efficiency on target cells. On the other hand, the fabrication of double layered mats that contained collagen without complexes as a first layer and gelatin collagen PEG with complexes as a second layer successfully induced GFP expression and ALP activity in C2C12 cells. We conclude that this study has established the advantage of formulating multilayered bioactive collagen based mats for gene delivery applications.
C1 [Tsekoura, Eleni K.; Dick, Teo; Uludag, Hasan] Univ Alberta, Fac Engn, Dept Chem & Mat Engn, Edmonton, AB T6G 1H9, Canada.
   [Pankongadisak, Porntipa] Mae Fah Luang Univ, Sch Sci, Muang 57100, Chiang Rai, Thailand.
   [Graf, Daniel] Univ Alberta, Fac Med & Dent, Dept Dent, Edmonton, AB T6G 2R7, Canada.
   [Boluk, Yaman] Univ Alberta, Fac Engn, Dept Civil & Environm Engn, Edmonton, AB T6G 1H9, Canada.
   [Uludag, Hasan] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2H7, Canada.
   [Uludag, Hasan] Univ Alberta, Fac Med & Dent, Dept Biomed Engn, Edmonton, AB T6G 2V2, Canada.
C3 University of Alberta; Mae Fah Luang University; University of Alberta;
   University of Alberta; University of Alberta; University of Alberta
RP Uludag, H (通讯作者)，Univ Alberta, Fac Engn, Dept Chem & Mat Engn, Edmonton, AB T6G 1H9, Canada.; Uludag, H (通讯作者)，Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2H7, Canada.; Uludag, H (通讯作者)，Univ Alberta, Fac Med & Dent, Dept Biomed Engn, Edmonton, AB T6G 2V2, Canada.
EM tsekoura@ualberta.ca; tadick@ualberta.ca; pankongadisak.p@gmail.com;
   dgraf@ualberta.ca; yaman@ualberta.ca; huludag@ualberta.ca
RI ; Graf, Daniel/H 1214 2011; Boluk, Yaman/ABD 9009 2020
OI Graf, Daniel/0000 0003 1163 8117; Atz Dick, Teo/0000 0003 1599 7889
CR Anguela XM, 2019, ANNU REV MED, V70, P273, DOI 10.1146/annurev med 012017 043332
   Bleich NK, 2012, ADV DRUG DELIVER REV, V64, P1320, DOI 10.1016/j.addr.2012.03.007
   Echave MC, 2019, EXPERT OPIN BIOL TH, V19, P773, DOI 10.1080/14712598.2019.1610383
   Cen L, 2008, PEDIATR RES, V63, P492, DOI 10.1203/PDR.0b013e31816c5bc3
   Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586 008 0745 3
   Chen JN, 2011, BIOMATERIALS, V32, P4793, DOI 10.1016/j.biomaterials.2011.03.041
   Choktaweesap N, 2007, POLYM J, V39, P622, DOI 10.1295/polymj.PJ2006190
   D'Mello S, 2017, AAPS J, V19, P43, DOI 10.1208/s12248 016 9982 2
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Erencia M, 2016, POLYM ADVAN TECHNOL, V27, P382, DOI 10.1002/pat.3678
   Foox M, 2015, EXPERT OPIN DRUG DEL, V12, P1547, DOI 10.1517/17425247.2015.1037272
   Janani G, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa5510
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kwak S, 2016, NANOSCALE RES LETT, V11, P1, DOI 10.1186/s11671 016 1532 4
   Li H, 2017, J BIOMED MATER RES A, V105, P265, DOI 10.1002/jbm.a.35900
   Li MY, 2005, P ANN INT IEEE EMBS, P5858
   Needham CJ, 2014, ACTA BIOMATER, V10, P4103, DOI 10.1016/j.actbio.2014.05.011
   Nezarati RM, 2013, TISSUE ENG PART C ME, V19, P810, DOI [10.1089/ten.tec.2012.0671, 10.1089/ten.TEC.2012.0671]
   Pandey, 2014, J PHARM RES, V8, P1387
   Pankongadisak P, 2020, INT J BIOL MACROMOL, V149, P296, DOI 10.1016/j.ijbiomac.2020.01.252
   Pillay V, 2013, J NANOMATER, V2013, DOI 10.1155/2013/789289
   Raftery RM, 2018, J CONTROL RELEASE, V283, P20, DOI 10.1016/j.jconrel.2018.05.022
   Rajesh Mishra J.M., 2018, NANOTECHNOLOGY TEXTI, P1
   Saraf A, 2010, J CONTROL RELEASE, V143, P95, DOI 10.1016/j.jconrel.2009.12.009
   Shahriar SMS, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9040532
   Shapiro G, 2018, CURR OSTEOPOROS REP, V16, P504, DOI 10.1007/s11914 018 0459 3
   Shih YRV, 2006, STEM CELLS, V24, P2391, DOI 10.1634/stemcells.2006 0253
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Tierney EG, 2013, ORGANOGENESIS, V9, P22, DOI 10.4161/org.24329
   Tierney EG, 2012, J CONTROL RELEASE, V158, P304, DOI 10.1016/j.jconrel.2011.11.026
   Vázquez N, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/ab1741
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Wang CY, 2017, MAT SCI ENG C MATER, V79, P507, DOI 10.1016/j.msec.2017.05.075
   Zhang CL, 2014, CHEM SOC REV, V43, P4423, DOI 10.1039/c3cs60426h
NR 34
TC 13
Z9 13
U1 6
U2 27
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD JUL
PY 2021
VL 14
IS 7
AR 666
DI 10.3390/ph14070666
PG 17
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TO1CN
UT WOS:000676659200001
PM 34358092
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fung, PL
   Nicoletti, P
   Shen, Y
   Porter, S
   Fedele, S
AF Fung, P. L.
   Nicoletti, P.
   Shen, Y.
   Porter, S.
   Fedele, S.
TI Pharmacogenetics of Bisphosphonate associated Osteonecrosis of the Jaw
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Jaw osteonecrosis; Bisphosphonates; Pharmacogenetics; Pharmacogenomics;
   Genes; Single nucleotide polymorphisms
ID GENOME WIDE ASSOCIATION; HYPERSENSITIVITY REACTIONS; MULTIPLE MYELOMA;
   STAGING SYSTEM; FEMORAL HEAD; POLYMORPHISM; GENE; CYP2C8;
   HLA B ASTERISK 5701; MECHANISMS
AB Osteonecrosis of the jaws (ONJ) is a potentially severe disorder that develops in a subgroup of individuals who have used bisphosphonate (BP) medications. Several clinical risk factors have been associated with the risk of ONJ development, but evidence is limited and in most instances ONJ remains an unpredictable adverse drug reaction. Interindividual genetic variability can contribute to explaining ONJ development in a subset of BP users, and the discovery of relevant associated gene variants could lead to the identification of individuals at higher risk. No genetic variant has been found to be robustly associated with susceptibility to ONJ.
C1 [Fung, P. L.; Porter, S.; Fedele, S.] UCL, UCL Eastman Dent Inst, London WC1X 8LD, England.
   [Nicoletti, P.; Shen, Y.] Columbia Univ, Dept Syst Biol, Irving Canc Res Ctr, New York, NY 10032 USA.
   [Shen, Y.] Columbia Univ, Dept Biomed Informat, Irving Canc Res Ctr, New York, NY 10032 USA.
   [Fedele, S.] Univ Coll London Hosp, NIHR Biomed Res Ctr, London W1T 7DN, England.
C3 University of London; University College London; Columbia University;
   Columbia University; University of London; University College London;
   University College London Hospitals NHS Foundation Trust
RP Fedele, S (通讯作者)，UCL, Univ Coll London Hosp Trust, Eastman Dent Inst & Hosp, 256 Grays Inn Rd, London WC1X 8LD, England.
EM s.fedele@ucl.ac.uk
RI ; Porter, Stephen/B 3519 2009
OI Porter, Stephen/0000 0002 3328 2759; Fedele,
   Stefano/0000 0001 9006 9412; 
CR Allen MR, 2011, ODONTOLOGY, V99, P8, DOI 10.1007/s10266 010 0153 0
   Arduino PG, 2011, J ORAL PATHOL MED, V40, P510, DOI 10.1111/j.1600 0714.2010.01004.x
   Bagan JV, 2012, ORAL ONCOL, V48, P753, DOI 10.1016/j.oraloncology.2012.02.009
   Balla B, 2012, ORAL DIS, V18, P580, DOI 10.1111/j.1601 0825.2012.01912.x
   Bedogni A, 2012, ORAL DIS, V18, P621, DOI 10.1111/j.1601 0825.2012.01903.x
   Bush WS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002822
   Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Daly AK, 2001, BRIT J CLIN PHARMACO, V52, P489, DOI 10.1046/j.0306 5251.2001.01510.x
   Daly AK, 2013, GENOME MED, V5, DOI 10.1186/gm409
   Daly AK, 2012, ANNU REV PHARMACOL, V52, P21, DOI 10.1146/annurev pharmtox 010611 134743
   Daly AK, 2010, NAT REV GENET, V11, P241, DOI 10.1038/nrg2751
   Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379
   Di Martino MT, 2011, BRIT J HAEMATOL, V154, P529, DOI 10.1111/j.1365 2141.2011.08622.x
   English BC, 2010, THER CLIN RISK MANAG, V6, P579, DOI 10.2147/TCRM.S14303
   Fedele S, 2015, BRIT J ORAL MAX SURG, V53, P13, DOI 10.1016/j.bjoms.2014.09.001
   Fedele S, 2010, AM J MED, V123, P1060, DOI 10.1016/j.amjmed.2010.04.033
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304
   Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140 6736(02)08158 8
   Katz J, 2011, INT J ORAL MAX SURG, V40, P605, DOI 10.1016/j.ijom.2011.02.002
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim TH, 2008, OSTEOARTHR CARTILAGE, V16, P287, DOI 10.1016/j.joca.2007.06.017
   Kraft P, 2009, STAT SCI, V24, P561, DOI 10.1214/09 STS290
   Kühl S, 2012, ORAL ONCOL, V48, P938, DOI 10.1016/j.oraloncology.2012.03.028
   La Ferla F, 2012, BIOMARK MED, V6, P201, DOI [10.2217/BMM.12.14, 10.2217/bmm.12.14]
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Leckband SG, 2013, CLIN PHARMACOL THER, V94, P324, DOI 10.1038/clpt.2013.103
   Lee YJ, 2012, J ORTHOP RES, V30, P21, DOI 10.1002/jor.21492
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140 6736(02)07873 X
   Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135
   Marini Francesca, 2011, Front Biosci (Elite Ed), V3, P364, DOI 10.2741/e251
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Nicoletti P, 2012, ONCOLOGIST, V17, P279, DOI 10.1634/theoncologist.2011 0202
   Phillips KA, 2001, JAMA J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270
   Rice TK, 2008, ADV GENET, V60, P293, DOI 10.1016/S0065 2660(07)00412 9
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sambrook Philip, 2006, Aust Fam Physician, V35, P801
   Sarasquete ME, 2009, ORAL DIS, V15, P382, DOI 10.1111/j.1601 0825.2009.01568.x
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632
   Stockmann P, 2013, J CRANIO MAXILL SURG, V41, P71, DOI 10.1016/j.jcms.2012.10.018
   Such E, 2011, HAEMATOL HEMATOL J, V96, P1557, DOI 10.3324/haematol.2011.042572
   Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796
   Zhong DN, 2013, ACTA HAEMATOL BASEL, V129, P90, DOI 10.1159/000342120
NR 55
TC 22
Z9 28
U1 0
U2 11
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1042 3699
EI 1558 1365
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD NOV
PY 2015
VL 27
IS 4
BP 537
EP +
DI 10.1016/j.coms.2015.06.005
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CX1OV
UT WOS:000365466400008
PM 26299425
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cirak, Y
   Varol, U
   Atmaca, H
   Kisim, A
   Sezgin, C
   Karabulut, B
   Uzunoglu, S
   Uslu, R
   Karaca, B
AF Cirak, Yalcin
   Varol, Umut
   Atmaca, Harika
   Kisim, Asli
   Sezgin, Canfeza
   Karabulut, Bulent
   Uzunoglu, Selim
   Uslu, Ruchan
   Karaca, Burcak
TI Zoledronic acid in combination with serine/threonine phosphatase
   inhibitors induces enhanced cytotoxicity and apoptosis in
   hormone refractory prostate cancer cell lines by decreasing the
   activities of PP1 and PP2A
SO BJU INTERNATIONAL
LA English
DT Article
DE zoledronic acid; phosphatase inhibitors; combination; phosphatase 1;
   phosphatase 2A
ID MEVALONATE PATHWAY; BONE DISEASE; BISPHOSPHONATES; PYROPHOSPHATE
AB OBJECTIVES
   To investigate if the cytotoxic and apoptotic effect of zoledronic acid (ZA) can be enhanced by the addition of the serine/threonine protein phosphatase inhibitors calyculin A (CA) and okadaic acid (OA) in hormone and drug refractory prostate cancer cells, PC 3 and DU 145.
   To discover the effect of these combination treatments on phosphatase 1 (PP1) and PP2A protein expression levels in prostate cancer cells.
   MATERIALS AND METHODS
   An XTT cell viability assay was used to determine cytotoxicity.
   Apoptosis was evaluated by enzyme linked immunosorbent assay (ELISA) using a Cell Death Detection ELISA Plus Kit and verified by measuring caspase 3/7 enzyme activity.
   The PP1 and PP2A enzyme activities were evaluated by serine/threonine phosphatase ELISA and expression levels of PP1 and PP2A proteins were then re assessed by Western blot analysis.
   RESULTS
   Combination of ZA with either CA or OA showed synergistic cytotoxicity and apoptosis compared with any agent alone in both PC 3 and DU 145 prostate cancer cells.
   The combination of ZA with phosphatase inhibitors resulted in enhanced suppression of both PP1 and PP2A enzyme activity and protein levels, which was more overt with the ZA/CA combination.
   CONCLUSION
   Results from our study increase the translational potential of our in vitro findings and offer the basic rationale for the design of new combinatory strategies with ZA and phosphatase inhibitors for the treatment of prostate cancer, which may become resistant to conventional therapy.
C1 [Cirak, Yalcin; Varol, Umut; Sezgin, Canfeza; Karabulut, Bulent; Uslu, Ruchan; Karaca, Burcak] Ege Univ, Sch Med, Tulay Aktas Oncol Hosp, Div Med Oncol, Izmir, Turkey.
   [Atmaca, Harika; Kisim, Asli; Uzunoglu, Selim] Celal Bayar Univ, Fac Sci & Arts, Dept Biol, Mol Biol Sect, Muradiye, Manisa, Turkey.
C3 Ege University; Celal Bayar University
RP Karaca, B (通讯作者)，Ege Univ Sch Med, Tulay Aktas Oncol Hosp, TR 35100 Izmir, Turkey.
EM burcak.karaca@ege.edu.tr
RI Uzunoglu, Selim/Y 9285 2019; Uslu, Ruchan/C 6855 2008; atmaca,
   harika/AAX 8164 2021
OI Uslu, Ruchan/0000 0002 9584 6134; atmaca, harika/0000 0002 8459 4373;
   Kisim, Asli/0000 0002 5245 1706; Karaca, Burcak/0000 0003 2638 1625;
   Sezgin, Veliddin Canfeza/0000 0003 2840 3218
CR ALBERTSEN PC, 1995, JAMA J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Body JJ, 2006, SUPPORT CARE CANCER, V14, P408, DOI 10.1007/s00520 005 0913 5
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856
   Garnick MB, 1997, UROLOGY, V49, P5, DOI 10.1016/S0090 4295(97)00163 5
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014 5793(91)80745 O
   Islam MM, 2002, CANCER CHEMOTH PHARM, V49, P111, DOI 10.1007/s00280 001 0397 z
   Jayaraj R, 2009, TOXICOLOGY, V256, P118, DOI 10.1016/j.tox.2008.11.013
   Jemal A, 2008, CA CANCER J CLIN, V55, P10
   Karabulut B, 2009, CELL BIOL INT, V33, P239, DOI 10.1016/j.cellbi.2008.11.011
   Karabulut B, 2011, MOL BIOL REP, V38, P249, DOI 10.1007/s11033 010 0102 6
   Kennedy NJ, 1998, J IMMUNOL, V160, P4881
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saydam G, 2003, LEUKEMIA RES, V27, P709, DOI 10.1016/S0145 2126(02)00347 8
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699
   Sonnemann J, 2007, MOL CANCER THER, V6, P2976, DOI 10.1158/1535 7163.MCT 07 0221
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
NR 30
TC 14
Z9 14
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1464 4096
EI 1464 410X
J9 BJU INT
JI BJU Int.
PD DEC
PY 2012
VL 110
IS 11C
BP E1147
EP E1154
DI 10.1111/j.1464 410X.2012.11392.x
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 091DQ
UT WOS:000315029700064
PM 22882676
DA 2025 08 17
ER

PT J
AU Garnier, D
   Milsom, C
   Magnus, N
   Meehan, B
   Weitz, J
   Yu, J
   Rak, J
AF Garnier, Delphine
   Milsom, Chloe
   Magnus, Nathalie
   Meehan, Brian
   Weitz, Jeffrey
   Yu, Joanne
   Rak, Janusz
TI Role of the tissue factor pathway in the biology of tumor initiating
   cells
SO THROMBOSIS RESEARCH
LA English
DT Article; Proceedings Paper
CT 5th International Conference on Thrombosis and Hemostasis Issues in
   Cancer
CY APR 23 25, 2010
CL Stresa, ITALY
DE Tissue factor; Oncogenes; Cancer; Angiogenesis; Cancer stem cells;
   Coagulation; Cancer stem cell niche
ID GROWTH FACTOR RECEPTOR; BLOOD MONONUCLEAR CELLS; STEM CELLS;
   SELF RENEWAL; FACTOR EXPRESSION; FACTOR VIIA; OSTEOBLAST
   DIFFERENTIATION; MESENCHYMAL TRANSITIONS; COLORECTAL CANCER;
   ENDOTHELIAL CELLS
AB Oncogenic transformation and aberrant cellular differentiation are regarded as key processes leading to malignancy. They produce heterogenous cellular populations including subsets of tumour initiating cells (TICs), also known as cancer stem cells (CSCs). Intracellular events involved in these changes profoundly impact the extracellular and systemic constituents of cancer progression, including those dependent on the vascular system. This includes angiogenesis, vasculogenesis, activation of the coagulation system and formation of CSC related and premetastatic niches. Tissue factor (TF) is a unique cell associated receptor for coagulation factor VIIa, initiator of blood coagulation, and mediator of cellular signalling, all of which influence vascular homeostasis.
   Our studies established a link between oncogenic events, angiogenesis and the elevated expression of TF in several types of cancer cells. The latter suggests that cancer coagulopathy and cellular events attributed to the coagulation system may have cancer specific and genetic causes. Indeed, in human glioma cells, a transforming mutant of the epidermal growth factor receptor (EGFRvIII) triggers not only the expression of TF, but also of its ligand (factor VII) and protease activated receptors (PAR 1 and PAR 2). Consequently, tumour cells expressing EGFRvIII become hypersensitive to contact with blood borne proteases (VIIa, thrombin), which upregulate their production of angiogenic factors (VEGF and IL 8), and contribute to formation of the growth promoting microenvironment (niche). Moreover, TF overexpression accompanies features of cellular aggressiveness such as markers of CSCs (CD133), epithelial to mesenchymal transition (EMT) and expression of the angiogenic and prometastatic phenotype. Conversely, TF blocking antibodies inhibit tumour growth, angiogenesis, and especially tumour initiation upon injection of threshold numbers of tumourigenic cells. Likewise, TF depletion in the host compartment (e. g. in low TF mice) perturbs tumour initiation.
   These observations suggest that both cancer cells and their adjacent host stroma contribute TF activity to the tumour microenvironment. We postulate that the TF pathway may play an important role in formation of the vascular niche for tumour initiating CSCs, through its procoagulant and signalling effects. Therapeutic blockade of these mechanisms could hamper tumour initiation processes, which are dependent on CSCs and participate in tumour onset, recurrence, drug resistance and metastasis. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Rak, Janusz] McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3Z 3Z2, Canada.
   [Milsom, Chloe; Yu, Joanne] Univ Toronto, Toronto, ON, Canada.
   [Weitz, Jeffrey] McGill Univ, Henderson Res Ctr, Montreal, PQ H3Z 3Z2, Canada.
C3 McGill University; University of Toronto; McGill University
RP Rak, J (通讯作者)，McGill Univ, Montreal Childrens Hosp, Res Inst, 4060 Ste Catherine W, Montreal, PQ H3Z 3Z2, Canada.
EM janusz.rak@mcgill.ca
RI Weitz, Jeffrey/AAD 1929 2019; Garnier, Delphine/ABC 0065 2022
OI Garnier, Delphine/0000 0002 5744 5612; 
FU Canadian Institutes of Health Research Funding Source: Medline
CR Aharon A, 2009, BEST PRACT RES CL HA, V22, P61, DOI 10.1016/j.beha.2008.11.002
   Ahmed TAE, 2008, TISSUE ENG B
   Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725
   Al Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988
   Albrektsen T, 2007, J THROMB HAEMOST, V5, P1588, DOI 10.1111/j.1538 7836.2007.02603.x
   Baker CH, 2002, CANCER RES, V62, P1996
   Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008 5472.CAN 06 1010
   Bauer S, 2006, J NEUROSCI, V26, P12089, DOI 10.1523/JNEUROSCI.3047 06.2006
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Bhattacharjee G, 2005, ARTERIOSCL THROM VAS, V25, P1737, DOI 10.1161/01.ATV.0000173419.31242.56
   Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357
   Brat DJ, 2004, LAB INVEST, V84, P397, DOI 10.1038/labinvest.3700070
   Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88
   Buller HR, 2007, J THROMB HAEMOST, V5, P246, DOI 10.1111/j.1538 7836.2007.02497.x
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580
   Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0
   Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296 209
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   Davey RE, 2007, FASEB J, V21, P2020, DOI 10.1096/fj.06 7852com
   Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood 2008 08 077941
   Dicklert A, 2009, EXPERT REV MED DEVIC, V6, P27, DOI 10.1586/17434440.6.1.27
   Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792
   Dvorak F., 2006, Hemostasis and thrombosis: basic principles and clinical practice, P851
   DVORAK HF, 1981, SCIENCE, V212, P923, DOI 10.1126/science.7195067
   Ema M, 2008, CELL STEM CELL, V3, P555, DOI 10.1016/j.stem.2008.09.003
   Falanga A, 2005, SEMIN THROMB HEMOST, V31, P104, DOI 10.1055/s 2005 863812
   Folkins C, 2007, CANCER RES, V67, P3560, DOI 10.1158/0008 5472.CAN 06 4238
   Folkman J., 2003, HOLLAND FREI CANC ME, P161
   Francis JL, 2002, SEMIN THROMB HEMOST, V28, P29, DOI 10.1055/s 2002 20562
   Furie B, 2004, TRENDS MOL MED, V10, P171, DOI 10.1016/j.molmed.2004.02.008
   GESSLER F, 2009, NEUROSCIENCE
   Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246
   Grassinger J, 2009, BLOOD, V114, P49, DOI 10.1182/blood 2009 01 197988
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Hembrough TA, 2003, CANCER RES, V63, P2997
   HEPPNER GH, 1984, CANCER RES, V44, P2259
   HEPPNER GH, 1989, J NATL CANCER I, V81, P648, DOI 10.1093/jnci/81.9.648
   Hill RP, 2007, JNCI J NATL CANCER I, V99, P1435, DOI 10.1093/jnci/djm136
   Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Lee AYY, 2005, J CLIN ONCOL, V23, P2123, DOI 10.1200/JCO.2005.03.133
   Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118
   Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018
   Liu TM, 2009, STEM CELLS DEV, V18, P1013, DOI 10.1089/scd.2008.0335
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Mackman N, 2008, J THROMB HAEMOST, V6, P303, DOI 10.1111/j.1538 7836.2008.02873.x
   Mackman N, 2008, NATURE, V451, P914, DOI 10.1038/nature06797
   MAGNUS N, 2009, ROLE TISSUE FACTOR P, P1
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin K, 2009, CIRC RES, V105, P214, DOI 10.1161/CIRCRESAHA.109.199984
   Milsom C, 2007, J THROMB HAEMOST, V5, P2550, DOI 10.1111/j.1538 7836.2007.02766.x
   Milsom C, 2005, BIOCHEM BIOPH RES CO, V337, P1267, DOI 10.1016/j.bbrc.2005.09.187
   MILSOM C, 2009, ARTERIOSCLE IN PRESS
   MILSOM CC, 2009, THESIS MCMASTER U, P1
   Milsom CC, 2008, CANCER RES, V68, P10068, DOI 10.1158/0008 5472.CAN 08 2067
   Moldovan NI, 2003, TRENDS CARDIOVAS MED, V13, P265, DOI 10.1016/S1050 1738(03)00108 7
   MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832
   Ngo CV, 2007, INT J CANCER, V120, P1261, DOI 10.1002/ijc.22426
   NGO CV, 2005, P AM ASS CANC RES, V46
   NICOSIA RF, 1983, CANCER RES, V43, P2159
   Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood 2007 01 065995
   Parisi S, 2008, J CELL SCI, V121, P2629, DOI 10.1242/jcs.027599
   Parry GCN, 1998, J CLIN INVEST, V101, P560, DOI 10.1172/JCI814
   Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632
   Petersen LC, 2008, THROMB RES, V122, pS11, DOI 10.1016/S0049 3848(08)70011 2
   Petralia GA, 2005, NAT CLIN PRACT ONCOL, V2, P356, DOI 10.1038/ncponc0225
   PROVENCAL M, 2009, CARCINOGENESIS
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Rak J, 2000, CANCER METAST REV, V19, P93, DOI 10.1023/A:1026516920119
   Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959 8049(96)00396 6
   Rak J, 2006, MED HYPOTHESES, V66, P601, DOI 10.1016/j.mehy.2005.09.004
   Rak J, 2003, CANC DRUG DISC DEV, P171
   Rak J, 2008, CURR OPIN HEMATOL, V15, P522, DOI 10.1097/MOH.0b013e3283063a3e
   Rak J, 2006, CANCER RES, V66, P10643, DOI 10.1158/0008 5472.CAN 06 2350
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rickles FR, 2006, PATHOPHYSIOL HAEMO T, V35, P103, DOI 10.1159/000093551
   Rong Y, 2005, CANCER RES, V65, P1406, DOI 10.1158/0008 5472.CAN 04 3376
   Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072 200606000 00001
   Rong Y, 2009, CANCER RES, V69, P2540, DOI 10.1158/0008 5472.CAN 08 1547
   Ruf W, 2007, J THROMB HAEMOST, V5, P1584, DOI 10.1111/j.1538 7836.2007.02622.x
   Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031
   Tallman MS, 2004, J THROMB HAEMOST, V2, P1341, DOI 10.1111/j.1538 7836.2004.00787.x
   Tarzami ST, 2006, J THROMB HAEMOST, V4, P656, DOI 10.1111/j.1538 7836.2006.01788.x
   Tesselaar MET, 2007, J THROMB HAEMOST, V5, P520, DOI 10.1111/j.1538 7836.2007.02369.x
   Theodorou E, 2009, GENE DEV, V23, P575, DOI 10.1101/gad.1772509
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922
   TROUSSEAU A, 1865, CLIN MED HOTEL DIEU, P654
   Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood 2006 10 053736
   Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood 2007 07 101048
   Viloria Petit A, 2003, EMBO J, V22, P4091, DOI 10.1093/emboj/cdg408
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang XL, 2004, INT J CANCER, V112, P994, DOI 10.1002/ijc.20527
   Yu JL, 2005, BLOOD, V105, P1734, DOI 10.1182/blood 2004 05 2042
   Yu JL, 2004, J THROMB HAEMOST, V2, P2065, DOI 10.1111/j.1538 7836.2004.00972.x
   Yu JL, 2004, SEMIN THROMB HEMOST, V30, P21
   Yu J, 2008, ARTERIOSCL THROM VAS, V28, P1975, DOI 10.1161/ATVBAHA.108.175083
   Zhao JS, 2009, CLIN CANCER RES, V15, P208, DOI 10.1158/1078 0432.CCR 08 0407
   Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589
   Zwicker JI, 2007, CRIT REV ONCOL HEMAT, V62, P126, DOI 10.1016/j.critrevonc.2007.01.001
NR 104
TC 36
Z9 42
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049 3848
J9 THROMB RES
JI Thromb. Res.
PD APR
PY 2010
VL 125
SU 2
BP S44
EP S50
DI 10.1016/S0049 3848(10)70012 8
PG 7
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Hematology; Cardiovascular System & Cardiology
GA 590FX
UT WOS:000277211400011
PM 20434004
DA 2025 08 17
ER

PT J
AU Hu, XJ
   Wang, ZR
   Chen, MK
   Chen, XR
   Liang, WQ
AF Hu, Xujun
   Wang, Zirui
   Chen, Meikai
   Chen, Xuerong
   Liang, Wenqing
TI The anti osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES 529
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteosarcoma; mTOR; RES 529; Akt and molecularly targeted therapy
ID REDUCES TUMOR GROWTH; PALOMID 529; TORC1/TORC2 INHIBITOR; CANCER;
   APOPTOSIS; PATHWAY
AB mTOR over activation is important for human osteosarcoma (OS) tumorigenesis and progression. RES 529 is a mTORC1/2 dual inhibitor. Here, our results show that RES 529 inhibited viability, cell cycle progression and proliferation of the established (U2OS line) and primary human OS cells. RES 529 induced apoptosis activation in OS cells. It was yet non cytotoxic to OB 6 osteoblastic cells and the primary human osteoblasts. RES 529 disrupted assembling of mTORC1 (mTOR Raptor association) and mTORC2 (mTOR Rictor mLST8 association) in human OS cells, blocking mTORC1/2 activation. Significantly, RES 529 induced reactive oxygen species (ROS) production and mitochondria! depolarization in U2OS cells as well. RES 529 induced anti OS cell activity was more potent than other known Akt mTOR inhibitors. In vivo, RES 529 intraperitoneal injection significantly inhibited U2OS xenograft tumor growth in severe combined immunodeficiency (SCID) mice. mTORC1/2 activation in RES 529 treated tumor tissues was largely inhibited. Collectively, the mTOR inhibitor RES 529 efficiently inhibits human OS cell growth in vitro and in vivo. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Hu, Xujun; Chen, Meikai; Chen, Xuerong; Liang, Wenqing] Zhejiang Univ, Shaoxing Hosp, Shaoxing Peoples Hosp, Dept Orthopaed, 568 Zhongxing North Rd, Shaoxing 312000, Zhejiang, Peoples R China.
   [Wang, Zirui] Linyi Peoples Hosp, East Med Area, Internal Med Ward, Linyi, Shandong, Peoples R China.
C3 Zhejiang University
RP Liang, WQ (通讯作者)，Zhejiang Univ, Shaoxing Hosp, Shaoxing Peoples Hosp, Dept Orthopaed, 568 Zhongxing North Rd, Shaoxing 312000, Zhejiang, Peoples R China.
EM liangwqgk9@163.com
OI Liang, Wen Qing/0000 0001 9770 882X
FU Nature Science Foundation of Zhejiang Province [LY18H060013];
   Construction and Cultivation Project of Zhejiang Province [2015PYA012];
   Foundation of Zhejiang Province medical health [2016RCA029]; Medical and
   Health Research Project of Zhejiang, Province [2017KY662]
FX This study was supported by Nature Science Foundation of Zhejiang
   Province (LY18H060013), Construction and Cultivation Project of Zhejiang
   Province (2015PYA012), Foundation of Zhejiang Province medical health
   (2016RCA029), Medical and Health Research Project of Zhejiang, Province
   (2017KY662).
CR Bishop M.W., 2016, F1000Res, V5
   Bishop MW, 2016, CURR OPIN PEDIATR, V28, P26, DOI 10.1097/MOP.0000000000000298
   Brooks MM, 2013, MOL VIS, V19, P1406
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417 013 2375 7
   Fei HD, 2017, ONCOTARGET, V8, P49646, DOI 10.18632/oncotarget.17911
   Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226
   García García C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078 0432.CCR 11 2750
   Gravina GL, 2011, ENDOCR RELAT CANCER, V18, P385, DOI 10.1530/ERC 11 0045
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Ito K, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.13
   Ji DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085116
   Kabiraj P, 2015, PROTEIN J, V34, P349, DOI 10.1007/s10930 015 9629 7
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li X, 2011, LIFE SCI, V88, P314, DOI 10.1016/j.lfs.2010.12.006
   Lin F, 2013, INT J CANCER, V133, P1222, DOI 10.1002/ijc.28126
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Wang YL, 2016, CELL PHYSIOL BIOCHEM, V38, P2401, DOI 10.1159/000445592
   Weinberg MA, 2016, ANTI CANCER DRUG, V27, P475, DOI 10.1097/CAD.0000000000000354
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008 5472.CAN 08 2058
   Yang JY, 2006, APOPTOSIS, V11, P1371, DOI 10.1007/s10495 006 7691 5
   Yao C, 2013, CELL BIOCHEM BIOPHYS, V65, P217, DOI 10.1007/s12013 012 9423 5
   Yin G, 2017, ONCOTARGET, V8, P82027, DOI 10.18632/oncotarget.18303
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434 009 0555 9
   Zhao S, 2017, ONCOTARGET, V8, P104867, DOI 10.18632/oncotarget.20452
   Zheng B, 2015, CANCER LETT, V357, P468, DOI 10.1016/j.canlet.2014.11.012
   Zhou QA, 2010, MED ONCOL, V27, P1239, DOI 10.1007/s12032 009 9365 y
   Zhou RP, 2011, J ORTHOP RES, V29, P846, DOI 10.1002/jor.21311
   Zhu YR, 2016, ONCOTARGET, V7, P49527, DOI 10.18632/oncotarget.10389
   Zhu YR, 2015, CANCER BIOL THER, V16, P602, DOI 10.1080/15384047.2015.1017155
NR 31
TC 8
Z9 9
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 4
PY 2018
VL 497
IS 2
BP 499
EP 505
DI 10.1016/j.bbrc.2018.02.050
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GA3LE
UT WOS:000428229400006
PM 29432734
DA 2025 08 17
ER

PT J
AU Yamamoto, K
   Tanaka, S
AF Yamamoto, Kenta
   Tanaka, Shunichi
TI Survey on Actual Management of Osteoporosis with the Japanese Medical
   Data Vision Database in Elderly Patients Undergoing Spinal Fusion
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE spinal fusion; osteoporosis; real world data; peri operative;
   assessment; DXA; treatment
ID BONE HEALTH OPTIMIZATION; LUMBAR INTERBODY FUSION; POSTMENOPAUSAL
   OSTEOPOROSIS; SURGERY; INCREASES; FAILURE; WOMEN; RISK
AB Background: No actual data on spinal fusion and management of osteoporosis in Japan have been reported. The aim of the survey was to investigate pre  and post operative management of osteoporosis, including testing and prescription, in elderly patients undergoing spinal fusion in Japan. Methods: Medical data on patients aged 65 years or older undergoing spinal fusion from April 2018 to March 2022 were extracted from the medical data vision (MDV) database containing health insurance claims data from Japanese acute care hospitals to investigate fusion area, pre  and post operative osteoporosis tests (bone mineral density and osteoporosis markers), prescriptions of osteoporosis medications, and other information. Results: The analysis set consisted of 26,959 patients. Annual pre operative BMD testing rates and osteoporosis markers testing rates were higher than the post operative rates without significant annual changes. The post operative prescription rate of osteoporosis medications throughout the target period was approximately two times higher than the preoperative rate. The drug with highest pre  and post operative prescription rates was teriparatide (TPTD) followed by bisphosphonates, showing that the prescription rate of TPTD proportionally increased with the length of fusion area. Conclusions: It was suggested that patients aged 65 years or older undergoing spinal fusion might receive insufficient osteoporosis tests. Despite no trend in the testing rate with the length of fusion area, some tendency was observed in the selection of osteoporosis medications. In patients with osteoporosis undergoing spinal fusion, early examination, diagnosis, and therapeutic intervention may improve the prognoses, and solid testing and prescriptions are therefore expected.
C1 [Yamamoto, Kenta; Tanaka, Shunichi] Asahi Kasei Pharm Corp, Musculoskeletal Pharmaceut Brand Strategy, Pharmaceut R&D Business & Strategy Div, 1 1 2 Yurakucho,Chiyoda Ku, Tokyo 1000006, Japan.
RP Yamamoto, K (通讯作者)，Asahi Kasei Pharm Corp, Musculoskeletal Pharmaceut Brand Strategy, Pharmaceut R&D Business & Strategy Div, 1 1 2 Yurakucho,Chiyoda Ku, Tokyo 1000006, Japan.
EM yamamoto.kgv@om.asahi kasei.co.jp; tanaka.scq@om.asahi kasei.co.jp
CR Aizawa T, 2016, TOHOKU J EXP MED, V238, P153, DOI 10.1620/tjem.238.153
   Anderson PA, 2023, SPINE, V48, P782, DOI 10.1097/BRS.0000000000004618
   Ayub N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10133002
   Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003 4819 137 6 200209170 00014
   Bow CH, 2012, OSTEOPOROSIS INT, V23, P879, DOI 10.1007/s00198 011 1627 9
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Díaz Romero R, 2021, INT J SPINE SURG, V15, P376, DOI 10.14444/8049
   Dimar J, 2021, NEUROSURGERY, V89, pS19, DOI 10.1093/neuros/nyab317
   Ebata S, 2017, J BONE JOINT SURG AM, V99, P365, DOI 10.2106/JBJS.16.00230
   Fan ZQ, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0286110
   Fuggle NR, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115833
   Gupta Anmol, 2021, J Spine Surg, V7, P1, DOI 10.21037/jss 20 668
   Gupta A, 2021, SPINE J, V21, P134, DOI 10.1016/j.spinee.2020.08.002
   Hyakkan R, 2021, SPINE, V46, P1645, DOI 10.1097/BRS.0000000000004075
   Innovation Translation Center (Switzerland), 2022, Update from the Osteoporotic Spine Surgery Task Force
   Inose H, 2018, SPINE, V43, pE29, DOI 10.1097/BRS.0000000000001995
   Inoue G, 2014, J NEUROSURG SPINE, V21, P425, DOI 10.3171/2014.5.SPINE13656
   Japan Osteoporosis Foundation, 2021, CURRENT STATUS OSTEO
   Kadri A, 2020, J BONE JOINT SURG AM, V102, P574, DOI 10.2106/JBJS.19.00999
   Khalid SI, 2020, NEUROSURG FOCUS, V49, DOI 10.3171/2020.5.FOCUS20289
   Kim TH, 2013, PAIN PHYSICIAN, V16, P165
   Kobayashi K, 2022, NAGOYA J MED SCI, V84, P155, DOI 10.18999/nagjms.84.1.155
   Lim SY, 2013, AM J MENS HEALTH, V7, P350, DOI 10.1177/1557988313478826
   Matsumoto T, 2011, BONE, V49, P605, DOI 10.1016/j.bone.2011.07.011
   Medical Data Vision Co. Ltd., MDV Database Overview
   Ministry of Health Labour and Welfare, 2022, GUIDELINES IMPLEMENT
   Ministry of Health Labour and Welfare, Medical fee revision
   Mo XY, 2021, BMC GERIATR, V21, DOI 10.1186/s12877 021 02313 8
   Mohanty S, 2024, J BONE JOINT SURG AM, V106, P206, DOI 10.2106/JBJS.23.00272
   Mugge L, 2022, SPINE, V47, P1435, DOI 10.1097/BRS.0000000000004418
   Nakatoh S, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00993 8
   Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003 4819 137 6 200209170 00015
   Nishida K, 2024, SPINE SURG RELAT RES, V8, P163, DOI 10.22603/ssrr.2023 0175
   Ogiri M, 2023, SPINE SURG RELAT RES, V7, P200, DOI 10.22603/ssrr.2022 0198
   Ohtori S, 2012, SPINE, V37, pE1464, DOI 10.1097/BRS.0b013e31826ca2a8
   Pantoja S, 2019, GLOB SPINE J, V9, P169, DOI 10.1177/2192568218785369
   Raad M, 2022, SPINE, V47, P1121, DOI 10.1097/BRS.0000000000004409
   Ravindra VM, 2015, WORLD NEUROSURG, V83, P1114, DOI 10.1016/j.wneu.2014.12.031
   Sardar ZM, 2022, SPINE, V47, P128, DOI 10.1097/BRS.0000000000004268
   Sato M, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0199 7
   Sawakami K, 2022, J NEUROSURG SPINE, V36, P429, DOI 10.3171/2021.5.SPINE202003
   Stoker GE, 2013, SPINE, V38, P507, DOI 10.1097/BRS.0b013e3182739ad1
   The Japanese Orthopaedic Association, National Registry JOANR Annual Report in FY2022
   The Japanese Society of Periodontology, 2015, Japanese Clinical Guidelines for Psychosomatic Pediatrics: Five Guidelines for Daily Clinical Practice, P26
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Wolfert AJ, 2022, J AM ACAD ORTHOP SUR, V30, P573, DOI 10.5435/JAAOS D 21 01258
   Yagi M, 2016, OSTEOPOROSIS INT, V27, P3495, DOI 10.1007/s00198 016 3676 6
   Yoshimura N, 2022, J BONE MINER METAB, V40, P829, DOI 10.1007/s00774 022 01352 4
NR 48
TC 4
Z9 4
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2077 0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2024
VL 13
IS 10
AR 2806
DI 10.3390/jcm13102806
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA SE6P0
UT WOS:001232823600001
PM 38792348
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Septembre Malaterre, A
   Boina, C
   Douanier, A
   Gasque, P
AF Septembre Malaterre, Axelle
   Boina, Chailas
   Douanier, Audrey
   Gasque, Philippe
TI Deciphering the Antifibrotic Property of Metformin
SO CELLS
LA English
DT Article
DE mesenchymal stem cells; myofibroblast; transdifferentiation;
   inflammation; miRs; oxidative stress; fibrosis; metformin
ID IDIOPATHIC PULMONARY FIBROSIS; EPITHELIAL MESENCHYMAL TRANSITION;
   TGF BETA; MOLECULAR MECHANISMS; THERAPEUTIC TARGETS; HYDROGEN PEROXIDE;
   OXIDATIVE STRESS; GENE EXPRESSION; TISSUE REPAIR; LUNG FIBROSIS
AB Fibrosis is a chronic progressive and incurable disease leading to organ dysfunction. It is characterized by the accumulation of extracellular matrix proteins produced by mesenchymal stem cells (MSCs) differentiating into myofibroblasts. Given the complexity of its pathophysiology, the search for effective treatments for fibrosis is of paramount importance. Metformin, a structural dimethyl analog of the galegine guanide extracted from the "French Lilac" (Fabaceae Galega officinalis), is the most widely used antidiabetic drug, recently recognized for its antifibrotic effects through ill characterized mechanisms. The in vitro model of TGF beta 1 induced fibrosis in human primary pulmonary mesenchymal stem cells (HPMSCs), identified as CD248+ and CD90+ cells, was used to study the effects of metformin extracts. These effects were tested on the expression of canonical MSC differentiation markers, immune/inflammatory factors and antioxidative stress molecules using qRT PCR (mRNA, miRNA), immunofluorescence and ELISA experiments. Interestingly, metformin is able to reduce/modulate the expression of different actors involved in fibrosis. Indeed, TGF beta 1 effects were markedly attenuated by metformin, as evidenced by reduced expression of three collagen types and Acta2 mRNAs. Furthermore, metformin attenuated the effects of TGF beta 1 on the expression of PDGF, VEGF, erythropoietin, calcitonin and profibrotic miRs, possibly by controlling the expression of several key TGF/Smad factors. The expression of four major fibrogenic MMPs was also reduced by metformin treatment. In addition, metformin controlled MSC differentiation into lipofibroblasts and osteoblasts and had the ability to restore redox balance via the Nox4/Nrf2, AMP and Pi3K pathways. Overall, these results show that metformin is a candidate molecule for antifibrotic effect and/or aiming to combat the development of chronic inflammatory diseases worldwide.
C1 [Septembre Malaterre, Axelle; Boina, Chailas; Douanier, Audrey; Gasque, Philippe] Univ Reunion, Un Rech, EPI Etudes Pharmaco Immunol, CS11021, Allee Topazes, F 97400 Saint Denis, France.
   [Septembre Malaterre, Axelle; Boina, Chailas; Douanier, Audrey; Gasque, Philippe] CHU Reunion, CS11021, Lab immunol Clin & Experimentale Zone ocean Indie, S Felix Guyon Allee Topazes, F 97400 Saint Denis, France.
C3 University of La Reunion; CHU Reunion
RP Septembre Malaterre, A (通讯作者)，Univ Reunion, Un Rech, EPI Etudes Pharmaco Immunol, CS11021, Allee Topazes, F 97400 Saint Denis, France.; Septembre Malaterre, A (通讯作者)，CHU Reunion, CS11021, Lab immunol Clin & Experimentale Zone ocean Indie, S Felix Guyon Allee Topazes, F 97400 Saint Denis, France.
EM axelle.malaterre septembre@univ reunion.fr
OI Septembre Malaterre, Axelle/0000 0003 4335 9016; GASQUE,
   Philippe/0000 0003 1837 8063
CR Amano H, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109067
   Andersson Sjöland A, 2008, INT J BIOCHEM CELL B, V40, P2129, DOI 10.1016/j.biocel.2008.02.012
   Antomou KM, 2007, PULM PHARMACOL THER, V20, P453, DOI 10.1016/j.pupt.2006.01.002
   Asada N, 2011, J CLIN INVEST, V121, P3981, DOI 10.1172/JCI57301
   Audousset C, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.727806
   Bedoui Y, 2020, J NEUROIMMUNE PHARM, V15, P838, DOI 10.1007/s11481 020 09958 z
   Boutten A, 2010, EXPERT OPIN THER TAR, V14, P329, DOI 10.1517/14728221003629750
   Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492 5505.2002
   Cardenas CLL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003291
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Choi SM, 2016, J KOREAN MED SCI, V31, P1419, DOI 10.3346/jkms.2016.31.9.1419
   Corvol P, 2008, B ACAD NAT MED PARIS, V192, P289, DOI 10.1016/S0001 4079(19)32831 6
   Crunkhorn Sarah, 2022, Nat Rev Drug Discov, V21, P20, DOI 10.1038/d41573 021 00199 0
   Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010 0323OC
   da Silva Neto PV, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12050604
   Dees C, 2021, EXP DERMATOL, V30, P121, DOI 10.1111/exd.14193
   Desai O, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00043
   Duffield JS, 2014, J CLIN INVEST, V124, P2299, DOI 10.1172/JCI72267
   Duffield JS, 2013, ANNU REV PATHOL MECH, V8, P241, DOI 10.1146/annurev pathol 020712 163930
   El Agha E, 2017, CELL STEM CELL, V21, P166, DOI 10.1016/j.stem.2017.07.011
   Eming SA, 2017, SCIENCE, V356, P1026, DOI 10.1126/science.aam7928
   Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203 023AW
   Gasque P, 2016, J INFECT DIS, V214, pS446, DOI 10.1093/infdis/jiw362
   Giannandrea M, 2014, DIS MODEL MECH, V7, P193, DOI 10.1242/dmm.012062
   Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200
   Hardie DG, 2016, ACTA PHARM SIN B, V6, P1, DOI 10.1016/j.apsb.2015.06.002
   Hecker L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008182
   Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005
   Henry TW, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102396
   Ji Y, 2016, ACTA PHARMACOL SIN, V37, P794, DOI 10.1038/aps.2016.36
   Kheirollahi V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10839 0
   Kim Suji, 2020, Cell Physiol Biochem, V54, P195, DOI 10.33594/000000214
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154
   Kuninty PR, 2016, ONCOTARGET, V7, P16396, DOI 10.18632/oncotarget.7651
   Lakshmi SP, 2017, BIOCHEM J, V474, P1531, DOI 10.1042/BCJ20160943
   Lim DH, 2006, AM J PHYSIOL LUNG C, V291, pL265, DOI 10.1152/ajplung.00305.2005
   Lim JY, 2012, J CELL PHYSIOL, V227, P1081, DOI 10.1002/jcp.22824
   Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035
   Liu YY, 2022, INT IMMUNOPHARMACOL, V108, DOI 10.1016/j.intimp.2022.108728
   Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158
   Mazur W, 2010, APMIS, V118, P703, DOI 10.1111/j.1600 0463.2010.02646.x
   Mehrad B, 2009, INT J BIOCHEM CELL B, V41, P1708, DOI 10.1016/j.biocel.2009.02.020
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Meng XM, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00082
   Moreira LM, 2020, NATURE, V587, P460, DOI 10.1038/s41586 020 2890 8
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nakahira K, 2016, AM J RESP CRIT CARE, V194, P1196, DOI 10.1164/rccm.201512 2468SO
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140 6736(11)60405 4
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264 6021:3480607
   Pandit KV, 2011, TRANSL RES, V157, P191, DOI 10.1016/j.trsl.2011.01.012
   Plantier L, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0062 2017
   Rangarajan S, 2018, NAT MED, V24, P1121, DOI 10.1038/s41591 018 0087 6
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Roderburg C, 2011, HEPATOLOGY, V53, P209, DOI 10.1002/hep.23922
   Samah M, 2012, EUR J PHARMACOL, V689, P186, DOI 10.1016/j.ejphar.2012.05.026
   Samarakoon R, 2013, CELL SIGNAL, V25, P264, DOI 10.1016/j.cellsig.2012.10.003
   Sato N, 2016, RESP RES, V17, DOI 10.1186/s12931 016 0420 x
   Savary G, 2019, AM J RESP CRIT CARE, V200, P184, DOI 10.1164/rccm.201807 1237OC
   Savary G, 2014, EUR RESPIR J, V44
   Schurgers LJ, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00036
   Scruggs AM, 2020, AM J RESP CELL MOL, V62, P191, DOI 10.1165/rcmb.2019 0163OC
   Sgalla G, 2018, RESP RES, V19, DOI 10.1186/s12931 018 0730 2
   Spagnolo P, 2017, LANCET RESP MED, V5, P372, DOI 10.1016/S2213 2600(17)30122 4
   Steinberg GR, 2019, NAT REV DRUG DISCOV, V18, P527, DOI 10.1038/s41573 019 0019 2
   Stijn W, 2013, ANN THORAC MED, V8, P38, DOI 10.4103/1817 1737.105718
   Strieter RM, 2007, J CLIN INVEST, V117, P549, DOI 10.1172/JCI30562
   Strieter RM, 2009, CHEST, V136, P1364, DOI 10.1378/chest.09 0510
   Swigris JJ, 2010, BIODRUGS, V24, P49, DOI 10.2165/11319550 000000000 00000
   Takagi K., 2019, ROLE MIRNAS IDIOPATH
   Tampe D, 2014, NAT REV NEPHROL, V10, P226, DOI 10.1038/nrneph.2014.14
   Thannickal Victor J, 2006, Proc Am Thorac Soc, V3, P350, DOI 10.1513/pats.200601 001TK
   Tomos IP, 2017, EXPERT REV RESP MED, V11, P299, DOI 10.1080/17476348.2017.1300533
   Tu Y, 2017, SCI REP UK, V7, DOI 10.1038/srep43790
   Waghray M, 2005, FASEB J, V19, P854, DOI 10.1096/fj.04 2882fje
   Wang JY, 2017, ONCOTARGET, V8, P98029, DOI 10.18632/oncotarget.20442
   Wang K, 2018, AUTOPHAGY, V14, P269, DOI 10.1080/15548627.2017.1409405
   Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536
   Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002 9440(10)62351 6
   Wolters PJ, 2014, ANNU REV PATHOL MECH, V9, P157, DOI 10.1146/annurev pathol 012513 104706
   Wu B, 2021, SEMIN ARTHRITIS RHEU, V51, P310, DOI 10.1016/j.semarthrit.2020.12.003
   Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200
   Xin XB, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108870
   Yamamoto T, 2009, LEUKEMIA, V23, P761, DOI 10.1038/leu.2008.353
   Yamashita CM, 2011, AM J PATHOL, V179, P1733, DOI 10.1016/j.ajpath.2011.06.041
   Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200
   Zhou Y, 2013, J CLIN INVEST, V123, P1096, DOI 10.1172/JCI66700
   Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099
NR 89
TC 4
Z9 4
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD DEC
PY 2022
VL 11
IS 24
AR 4090
DI 10.3390/cells11244090
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 7D5QN
UT WOS:000900544900001
PM 36552855
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Militsakh, O
   Lydiatt, W
   Lydiatt, D
   Interval, E
   Lindau, R
   Coughlin, A
   Panwar, A
AF Militsakh, Oleg
   Lydiatt, William
   Lydiatt, Daniel
   Interval, Erik
   Lindau, Robert
   Coughlin, Andrew
   Panwar, Aru
TI Development of Multimodal Analgesia Pathways in Outpatient Thyroid and
   Parathyroid Surgery and Association With Postoperative Opioid
   Prescription Patterns
SO JAMA OTOLARYNGOLOGY HEAD & NECK SURGERY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American Head and Neck Society (AHNS) at the
   Combined Otolaryngology Spring Meetings
CY APR 18 19, 2018
CL National Harbor, MD
SP Amer Head & Neck Soc
ID PERIOPERATIVE CARE; ENHANCED RECOVERY; NECK; HEAD; COMPLICATIONS;
   ANESTHESIA; SOCIETY; EVENTS; RISK; PAIN
AB IMPORTANCE Prescription opioid use contributes to drug related adverse effects and risk for dependence and abuse. Multimodal analgesia (MMA) has been shown to be useful in reducing opioid use following orthopedic, gynecologic, and colorectal surgery, but adoption in head and neck surgery has lagged. Recently, we published findings related to the feasibility of MMA protocols in same day thyroid, parathyroid, and parotid surgery. However, whether such strategies lead to effective and durable reduction in frequency of opioid prescriptions, and affect physician prescribing practices, remains unclear.
   OUJECTIVE To observe trends in adoption and adherence to institutional MMA protocols following thyroid and parathyroid surgery, and to assess the association of institutional multimodal (nonopioid) analgesia protocols with opioid use and physician prescribing patterns following outpatient thyroid and parathyroid surgery.
   DESIGN, SETTING, AND PARTICIPANTS Cohort study at a head and neck surgery service at a tertiary care hospital of prescription patterns and retrospective review of patient medical records following implementation of an optional institutional MMA protocol in 2015, based on preoperative administration of acetaminophen, nonsteroidal anti inflammatory drugs (NSAIDs), and gabapentin, and postoperative use of acetaminophen and ibuprofen for analgesia after thyroid and parathyroid surgery. There were 528 adult patients who underwent thyroid and parathyroid surgery between January 1, 2015, and June 30, 2017.
   MAIN OUTCOMES AND MEASURES We report on adherence to the MMA protocol over the study period as measure of physician buy in and adoption of the technique. The frequency of opioid use and physician prescription patterns following thyroid and parathyroid surgery is reported over the study period to study the association of the available MMA pathway with these variables.
   RESULTS A total of 528 patients (mean [SD] age, 53.1[15.7] years; 80.3% female) underwent outpatient thyroid and parathyroid surgery. The frequency of postoperative opioid prescriptions decreased during the study period (16 of 122 [13.1%] in 2015, 22 of 244 [9.0%] in 2016, 3 of 162 [1.9%] in 2017). Adherence to the MMA protocol increased (0 of 122 cases in 2015,106 of 244 [43.4%] cases in 2016, 142 of 162 [87.7%] cases in 2017), with reduced likelihood of opioid prescription on discharge (2017 vs 2015 odds ratio, 0.13; 95% Cl, 0.04 0.44). Only 1 postoperative hematoma was recorded in the study cohort, and 352 (66.7%) patients achieved same day discharge, whereas 176 (33.3%) maintained outpatient status but received overnight observation prior to discharge.
   CONCLUSIONS AND RELEVANCE Adoption and adherence to the MMA protocol increased substantially over the study period for patients undergoing thyroid and parathyroid surgery and was associated with a simultaneous significant decline in prescription of postoperative opioid analgesics. Use of nonopioid multimodal agents, incorporating NSAIDs, was safe and did not lead to increased incidence of bleeding. Availability of effective nonopioid MMA pathways may favorably influence physician prescribing practices and avoid unnecessary opioid prescriptions.
C1 [Militsakh, Oleg; Lydiatt, William; Lydiatt, Daniel; Interval, Erik; Lindau, Robert; Coughlin, Andrew; Panwar, Aru] Nebraska Methodist Hosp, Dept Head & Neck Surg Oncol, Methodist Estabrook Canc Ctr, 8303 Dodge St,Ste 304, Omaha, NE 68114 USA.
RP Panwar, A (通讯作者)，Nebraska Methodist Hosp, Dept Head & Neck Surg Oncol, Methodist Estabrook Canc Ctr, 8303 Dodge St,Ste 304, Omaha, NE 68114 USA.
EM aru.panwar@nmhs.org
RI Lydiatt, William/ACA 5095 2022
CR Baker DW, 2017, JAMA J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935
   Batchelder A, 2015, EUR J VASC ENDOVASC, V50, P412, DOI 10.1016/j.ejvs.2015.07.019
   Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105
   Centers for disease control and prevention, Opioid overdose
   Chin CJ, 2011, J OTOLARYNGOL HEAD N, V40, P196, DOI 10.2310/7070.2011.100146
   Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008
   Clarke H, 2014, BMJ BRIT MED J, V348, DOI 10.1136/bmj.g1251
   Dort JC, 2017, JAMA OTOLARYNGOL, V143, P292, DOI 10.1001/jamaoto.2016.2981
   Eichhorn W, 2014, BRIT J ORAL MAX SURG, V52, P527, DOI 10.1016/j.bjoms.2014.02.020
   Feldheiser A, 2016, ACTA ANAESTH SCAND, V60, P289, DOI 10.1111/aas.12651
   Mudd PA, 2017, JAMA OTOLARYNGOL, V143, P712, DOI 10.1001/jamaoto.2016.3839
   Oderda GM, 2007, ANN PHARMACOTHER, V41, P400, DOI 10.1345/aph.1H386
   Oltman J, 2017, JAMA OTOLARYNGOL, V143, P1207, DOI 10.1001/jamaoto.2017.1773
   Page AJ, 2016, BRIT J SURG, V103, P564, DOI 10.1002/bjs.10087
NR 14
TC 63
Z9 66
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611 5885 USA
SN 2168 6181
EI 2168 619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol Head Neck Surg.
PD NOV
PY 2018
VL 144
IS 11
BP 1023
EP 1029
DI 10.1001/jamaoto.2018.0987
PG 7
WC Otorhinolaryngology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Otorhinolaryngology; Surgery
GA HA4SX
UT WOS:000450255000010
PM 30027221
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Lee, YC
AF Lee, Yvonne C.
TI Effect and Treatment of Chronic Pain in Inflammatory Arthritis
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Arthritis; Rheumatoid arthritis; Psoriatic arthritis; Fibromyalgia;
   Pain; Chronic pain; Quality of life; Comorbidity; Treatment;
   Non steroidal anti inflammatory agents; NSAIDs; Opioid analgesics;
   Neurotransmitter agents; Antidepressive agents
ID QUALITY OF LIFE; DISEASE ACTIVITY SCORE; RHEUMATOID ARTHRITIS;
   DOUBLE BLIND; BACK PAIN; 28 JOINTS; OSTEOARTHRITIS; FIBROMYALGIA;
   HEALTH; TRIAL
AB Pain is the most common reason patients with inflammatory arthritis see a rheumatologist. Patients consistently rate pain as one of their highest priorities, and pain is the single most important determinant of patient global assessment of disease activity. Although pain is commonly interpreted as a marker of inflammation, the correlation between pain intensity and measures of peripheral inflammation is imperfect. The prevalence of chronic, non inflammatory pain syndromes such as fibromyalgia is higher among patients with inflammatory arthritis than in the general population. Inflammatory arthritis patients with fibromyalgia have higher measures of disease activity and lower quality of life than inflammatory patients who do not have fibromyalgia. This review article focuses on current literature involving the effects of pain on disease assessment and quality of life for patients with inflammatory arthritis. It also reviews non pharmacologic and pharmacologic options for treatment of pain for patients with inflammatory arthritis, focusing on the implications of comorbidities and concurrent disease modifying antirheumatic drug therapy. Although several studies have examined the effects of reducing inflammation for patients with inflammatory arthritis, very few clinical trials have examined the safety and efficacy of treatment directed specifically towards pain pathways. Most studies have been small, have focused on rheumatoid arthritis or mixed populations (e. g., rheumatoid arthritis plus osteoarthritis), and have been at high risk of bias. Larger, longitudinal studies are needed to examine the mechanisms of pain in inflammatory arthritis and to determine the safety and efficacy of analgesic medications in this specific patient population.
C1 Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital
RP Lee, YC (通讯作者)，Brigham & Womens Hosp, Div Rheumatol, 75 Francis St,PBB B3, Boston, MA 02115 USA.
EM ylee9@partners.org
RI Lee, Yvonne/AAL 4826 2021
FU Forest Laboratories
FX Dr Lee has received grant support from Forest Laboratories and has owned
   stock/stock options in Merck and Co., Novartis, and Elan Corp.
CR [Anonymous], COCHRANE DATABASE SY
   [Anonymous], COCHRANE DATABASE SY
   Arendt Nielsen L, 2010, PAIN
   Arnold LM, 2007, ARTHRITIS RHEUM US, V56, P1336, DOI 10.1002/art.22457
   Aviel YB, 2011, RHEUMATOLOGY, V50, P2051, DOI 10.1093/rheumatology/ker256
   Borenstein D, 2010, ARTHRIT CARE RES, V62, P590, DOI 10.1002/acr.20005
   Chan FKL, 2010, LANCET, V376, P173, DOI 10.1016/S0140 6736(10)60673 3
   Colebatch AN, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008872.pub2
   Courvoisier DS, 2012, ARTHRIT CARE RES, V64, P190, DOI 10.1002/acr.20652
   Crofford LJ, 2008, PAIN, V136, P419, DOI 10.1016/j.pain.2008.02.027
   Crofford LJ, 2010, NAT REV RHEUMATOL, V6, P191, DOI 10.1038/nrrheum.2010.24
   Gaskin, 2011, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research
   GERECZSIMON EM, 1989, CLIN RHEUMATOL, V8, P467, DOI 10.1007/BF02032098
   Haverman L, 2012, ARTHRIT CARE RES, V64, P694, DOI 10.1002/acr.21609
   Heiberg T, 2005, ANN RHEUM DIS, V64, P191, DOI 10.1136/ard.2004.022699
   HELLIWELL PS, 1993, BRIT J RHEUMATOL, V32, P216
   HUSKISSON EC, 1972, BMJ BRIT MED J, V4, P193, DOI 10.1136/bmj.4.5834.193
   Husted JA, 2012, ARTHRIT CARE RES, V64, P758, DOI 10.1002/acr.21602
   Irwin MR, 2012, SLEEP, V35, P537, DOI 10.5665/sleep.1742
   Kawaguchi Y, 2003, J SPINAL DISORD TECH, V16, P38, DOI 10.1097/00024720 200302000 00007
   Khan NA, 2012, ARTHRIT CARE RES, V64, P206, DOI 10.1002/acr.20685
   Knittle K, 2010, ARTHRIT CARE RES, V62, P1460, DOI 10.1002/acr.20251
   Knittle KP, 2011, ARTHRIT CARE RES, V63, P1613, DOI 10.1002/acr.20587
   Kosek E, 2000, PAIN, V88, P69, DOI 10.1016/S0304 3959(00)00310 9
   Laine L, 2008, GASTROENTEROLOGY, V135, P1517, DOI 10.1053/j.gastro.2008.07.067
   LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304 3959(79)90049 6
   Lee YC, 2013, ANN RHEUM DIS, V72, P949, DOI 10.1136/annrheumdis 2012 201506
   Lee YC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3353
   Lee YC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3306
   Lee YC, 2011, ARTHRIT CARE RES, V63, P320, DOI 10.1002/acr.20373
   Lee YC, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2842
   Marks JL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008952.pub2
   Mease PJ, 2008, J RHEUMATOL, V35, P502
   Murphy SL, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3449
   Murphy SL, 2011, ARTHRIT CARE RES, V63, P1543, DOI 10.1002/acr.20583
   Neva MH, 2011, RHEUMATOLOGY, V50, P1635, DOI 10.1093/rheumatology/ker173
   Nicassio PM, 2012, PAIN, V153, P107, DOI 10.1016/j.pain.2011.09.024
   Pollard LC, 2012, J RHEUMATOL, V39, P28, DOI 10.3899/jrheum.110668
   Pollard LC, 2010, RHEUMATOLOGY, V49, P924, DOI 10.1093/rheumatology/kep458
   Ranzolin A, 2009, ARTHRIT RHEUM ARTHR, V61, P794, DOI 10.1002/art.24430
   Richards BL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008921.pub2
   Richards BL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008922.pub2
   Richards BL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008920.pub2
   ROTH SH, 1975, J CLIN PHARMACOL, V15, P378, DOI 10.1002/j.1552 4604.1975.tb01468.x
   Strand V, 2012, RHEUMATOLOGY, V51, P1860, DOI 10.1093/rheumatology/kes131
   Studenic P, 2012, ARTHRITIS RHEUM US, V64, P2814, DOI 10.1002/art.34543
   ten Klooster PM, 2007, ANN RHEUM DIS, V66, P1485, DOI 10.1136/ard.2007.069765
   Ton E, 2012, J RHEUMATOL, V39, P22, DOI 10.3899/jrheum.110072
   van der Goes MC, 2010, ANN RHEUM DIS, V69, P1913, DOI 10.1136/ard.2009.124958
   Whittle SL, 2012, RHEUMATOLOGY, V51, P1416, DOI 10.1093/rheumatology/kes032
   Whittle SL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003113.pub3
   Wilder Smith CH, 2007, WORLD J GASTROENTERO, V13, P3699
   WOLFE F, 1990, ARTHRITIS RHEUM US, V33, P160, DOI 10.1002/art.1780330203
   WOLFE F, 1984, J RHEUMATOL, V11, P814
   Wolfe F, 2007, J RHEUMATOL, V34, P1674
   Wolfe F, 2011, PAIN, V152, P291, DOI 10.1016/j.pain.2010.09.027
   WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0
NR 57
TC 108
Z9 126
U1 2
U2 35
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD JAN
PY 2013
VL 15
IS 1
AR 300
DI 10.1007/s11926 012 0300 4
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 225VM
UT WOS:000324992900004
PM 23292816
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Blahnova, VH
   Dankova, J
   Rampichova, M
   Filova, E
AF Blahnova, V. Hefka
   Dankova, J.
   Rampichova, M.
   Filova, E.
TI Combinations of growth factors for human mesenchymal stem cell
   proliferation and osteogenic differentiation
SO BONE & JOINT RESEARCH
LA English
DT Article
DE Mesenchymal stem cell; Growth factor; Osteogenic differentiation;
   Regenerative medicine
ID OSTEOBLAST DIFFERENTIATION; ALKALINE PHOSPHATASE; BONE FORMATION; BETA;
   MINERALIZATION; MODULATION; PROMOTE; ADIPOSE; VEGF
AB Aims
   Here we introduce a wide and complex study comparing effects of growth factors used alone and in combinations on human mesenchymal stem cell (hMSC) proliferation and osteogenic differentiation. Certain ways of cell behaviour can be triggered by specific peptides   growth factors, influencing cell fate through surface cellular receptors.
   Methods
   In our study transforming growth factor beta (TGF beta), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin like growth factor 1 (IGF 1), and vascular endothelial growth factor (VEGF) were used in order to induce osteogenesis and proliferation of hMSCs from bone marrow. These cells are naturally able to differentiate into various mesodermal cell lines. Effect of each factor itself is pretty well known. We designed experimental groups where two and more growth factors were combined. We supposed cumulative effect would appear when more growth factors with the same effect were combined. The cellular metabolism was evaluated using MTS assay and double stranded DNA (dsDNA) amount using PicoGreen assay. Alkaline phosphatase (ALP) activity, as early osteogenesis marker, was observed. Phase contrast microscopy was used for cell morphology evaluation.
   Results
   TGF beta and bFGF were shown to significantly enhance cell proliferation. VEGF and IGF 1 supported ALP activity. Light microscopy showed initial extracellular matrix mineralization after VEGF/IGF 1 supply.
   Conclusion
   A combination of more than two growth factors did not support the cellular metabolism level and ALP activity even though the growth factor itself had a positive effect. This is probably caused by interplay of various messengers shared by more growth factor signalling cascades.
C1 [Blahnova, V. Hefka; Dankova, J.; Rampichova, M.; Filova, E.] Czech Acad Sci, Inst Expt Med, Prague, Czech Republic.
   [Filova, E.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic.
C3 Czech Academy of Sciences; Institute of Experimental Medicine of the
   Czech Academy of Sciences; Charles University Prague; Motol University
   Hospital
RP Blahnova, VH (通讯作者)，Czech Acad Sci, Inst Expt Med, Prague, Czech Republic.
EM veronika.blahnova@iem.cas.cz
RI Rampichova, Michala/H 3121 2014; Filova, Eva/H 3126 2014
FU Grant Agency of Charles University [448218]; Ministry of Education,
   Youth and Sports of the Czech Republic within National Sustainability
   Programme I [RP NPUI:LO1508, RP NPU I:LO1309, CZ.2.16/3.1.00/24006];
   Czech Science Foundation [18 to 09306 S]; Internal Grant Agency of the
   Ministry of Health of the Czech Republic [NV18 05 00379, 16 28637A,
   17 32285A]
FX This work was supported by: the Grant Agency of Charles University,
   Grant number 448218; the Ministry of Education, Youth and Sports of the
   Czech Republic within National Sustainability Programme I: project
   number RP NPUI:LO1508 and RP NPU I:LO1309, CZ.2.16/3.1.00/24006; the
   Czech Science Foundation, project number 18 to 09306 S; and the Internal
   Grant Agency of the Ministry of Health of the Czech Republic project
   number NV18 05 00379, 16 28637A, 17 32285A.
CR Aenlle KK, 2014, MOL ENDOCRINOL, V28, P722, DOI 10.1210/me.2013 1286
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Benavente CA, 2003, GROWTH FACTORS, V21, P87, DOI 10.1080/08977190310001613789
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Bosetti M, 2007, BIOMOL ENG, V24, P613, DOI 10.1016/j.bioeng.2007.08.019
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   Frisch RN, 2016, EXPERT OPIN THER TAR, V20, P1087, DOI 10.1517/14728222.2016.1162293
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Gurkan UA, 2010, TISSUE ENG PT A, V16, P2295, DOI [10.1089/ten.tea.2009.0565, 10.1089/ten.TEA.2009.0565]
   Hankemeier S, 2005, TISSUE ENG, V11, P41, DOI 10.1089/ten.2005.11.41
   Havlas V, 2011, ACTA CHIR ORTHOP TR, V78, P138
   Hu K, 2017, DEV DYNAM, V246, P227, DOI 10.1002/dvdy.24463
   Huang Z, 2010, CYTOKINE, V51, P305, DOI 10.1016/j.cyto.2010.06.002
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   KIELTY CM, 2002, CONNECTIVE TISSUE IT, P159, DOI DOI 10.1002/0471221929.CH2
   Kong Xia, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P1292
   Lee JH, 2012, CELL TISSUE RES, V348, P475, DOI 10.1007/s00441 012 1392 x
   Li LN, 2019, BBA GEN SUBJECTS, V1863, P199, DOI 10.1016/j.bbagen.2018.10.003
   Li PP, 2014, J BONE MINER METAB, V32, P627, DOI 10.1007/s00774 013 0538 6
   Locatelli V, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/235060
   Long MW, 2001, BLOOD CELL MOL DIS, V27, P677, DOI 10.1006/bcmd.2001.0431
   Marie PJ, 2012, GENE, V498, P1, DOI 10.1016/j.gene.2012.01.086
   Meng X, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 80
   Meyers EA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022244
   MOHAN S, 1991, CLIN ORTHOP RELAT R, P30
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Osagie Clouard L, 2019, BONE JOINT RES, V8, P397, DOI 10.1302/2046 3758.88.BJR 2019 0018.R1
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rodeo SA, 2019, BONE JOINT J, V101B, P361, DOI 10.1302/0301 620X.101B4.BJJ 2019 0013.R1
   Rodrigues M, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt32
   Shu C, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa 2016 0034
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Sulpice E, 2009, BIOL CELL, V101, P525, DOI 10.1042/BC20080221
   Vater C, 2011, ACTA BIOMATER, V7, P463, DOI 10.1016/j.actbio.2010.07.037
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Wen Q, 2012, J CELL MOL MED, V16, P1260, DOI 10.1111/j.1582 4934.2011.01407.x
   Wu JF, 2014, BMC DEV BIOL, V14, DOI 10.1186/1471 213X 14 21
   Xie X, 2019, BONE JOINT RES, V8, P323, DOI [10.1302/2046 3758.87.BJR 2018 0223.R2, 10.1302/2046 3758.87BJR 2018 0223.R2]
   Yoshikawa M, 2017, BONE JOINT RES, V6, P277, DOI 10.1302/2046 3758.65.BJR 2016 0187.R1
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Zhou CH, 2014, AMINO ACIDS, V46, P1673, DOI 10.1007/s00726 014 1729 8
NR 44
TC 28
Z9 28
U1 1
U2 12
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD JUL
PY 2020
VL 9
IS 7
BP 412
EP 420
DI 10.1302/2046 3758.97.BJR 2019 0183.R2
PG 9
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA MY8HU
UT WOS:000558658400009
PM 32864112
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Boneva, B
   Marchev, A
   Amirova, K
   Ganova, P
   Georgiev, M
   Tchorbanov, A
   Mihaylova, N
AF Boneva, Blagovesta
   Marchev, Andrey
   Amirova, Kristiana
   Ganova, Petya
   Georgiev, Milen
   Tchorbanov, Andrey
   Mihaylova, Nikolina
TI Crocus sativus Extract as a Biological Agent for
   Disease Modifying Therapy of Collagenase Induced Mouse Model of
   Osteoarthritis
SO LIFE BASEL
LA English
DT Article
DE collagenase; experimental osteoarthritis; inflammation; Crocus sativus L
ID CARTILAGE DESTRUCTION; ANIMAL MODELS; FOLLOW UP; SAFFRON; ARTHRITIS;
   KNEE; QUALITY; RECOMMENDATIONS; INTERLEUKIN 10; CONSTITUENTS
AB Objectives: Osteoarthritis (OA) is an age related joint disease that involves the degeneration of cartilage and is the most prevalent form of arthritis, affecting a large part of the population. OA is a multifactorial disorder, and no single etiological mechanism has been found to be common to all forms of the disease. Currently used therapies for control of the disease are mainly nonsteroidal anti inflammatory drugs (NSAIDs) and corticosteroid medications. The aim of this study was to investigate the extract from Crocus sativus as a biological disease suppressing therapy agent. Methods: Balb/c mice were injected intra articularly with Clostridium histolyticum type IA for induction of osteoarthritis. The mice were randomized to five groups: control group, I group (CIOA untreated), II group (CIOA + 100 mg/kg/daily saffron), III group (CIOA + 50 mg/kg/daily saffron), IV group (CIOA + 25 mg/kg/daily saffron). Flow cytometry analysis was used to study the splenocytes' phenotype isolated from the treated animals. The serum levels of inflammatory and anti inflammatory cytokines were analyzed with ELISA. The histological assessment was used to analyze the saffron extract effect on histopathological alterations. Results: Saffron treatment significantly decreased osteoarthritis associated joint histological manifestations and decreased serum TNF alpha levels. The flow cytometry analysis showed a decrease in pro inflammatory immune cell subtypes in the spleen. Conclusions: The results obtained suggest that saffron affected the disease progression and could be a potential therapeutic approach in osteoarthritic patients' therapy.
C1 [Boneva, Blagovesta; Tchorbanov, Andrey] Bulgarian Acad Sci, Inst Microbiol, Lab Expt Immunol, Sofia 1113, Bulgaria.
   [Marchev, Andrey; Amirova, Kristiana; Georgiev, Milen] Bulgarian Acad Sci, Stephan Angeloff Inst Microbiol, Lab Metabol, 139 Ruski Blvd, Plovdiv 4000, Bulgaria.
   [Ganova, Petya; Mihaylova, Nikolina] Bulgarian Acad Sci, Inst Microbiol, Lab Immunohistochem & Immunopathol, Sofia 1113, Bulgaria.
C3 Bulgarian Academy of Sciences; Bulgarian Academy of Sciences; Stephan
   Angeloff Institute of Microbiology, Bulgarian Academy of Sciences;
   Bulgarian Academy of Sciences
RP Mihaylova, N (通讯作者)，Bulgarian Acad Sci, Inst Microbiol, Lab Immunohistochem & Immunopathol, Sofia 1113, Bulgaria.
EM mihaylova_n@microbio.bas.bg
RI Mihaylova, Nikolina/HHM 8871 2022; Georgiev, Milen/P 6948 2015
OI Mihaylova, Nikolina/0000 0001 8582 9296; Georgiev, Milen
   I./0000 0001 5248 6135
FU The Bulgarian National Science Fund (BNSF)
FX The work was supported by grant KP 06 H33/8 from The Bulgarian National
   Science Fund (BNSF) and the European Fund for regional development
   through Operational Program Science and Education for Smart Growth
   2014 2020, Grant BG05M2OP001 1.002 0001 C04 "Fundamental Translational
   and Clinical Investigations on Infections and Immunity".
CR Adaes S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4436
   Ahrazem O, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00971
   Alaaeddine N, 1999, ARTHRITIS RHEUM US, V42, P710, DOI 10.1002/1529 0131(199904)42:4<710::AID ANR14>3.0.CO;2 4
   Aljuhani WS, 2021, KNEE SURG RELAT RES, V33, DOI 10.1186/s43019 021 00095 2
   Asbaghi O, 2021, PHYTOTHER RES, V35, P20, DOI 10.1002/ptr.6748
   Ayati Z, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 03102 3
   Benazzo F, 2016, EUR REV MED PHARMACO, V20, P959
   Bondeson J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2099
   Bondeson J, 2010, ARTHRITIS RHEUM US, V62, P647, DOI 10.1002/art.27290
   Boneva B, 2022, LIFE BASEL, V12, DOI 10.3390/life12111938
   Broadhead GK, 2016, CRIT REV FOOD SCI, V56, P2767, DOI 10.1080/10408398.2013.879467
   Cagliani LR, 2015, FOOD CONTROL, V50, P342, DOI 10.1016/j.foodcont.2014.09.017
   Cai XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645842
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chevalier X, 2015, ANN RHEUM DIS, V74, P1697, DOI 10.1136/annrheumdis 2014 205348
   Chevalier X, 2009, ARTHRIT RHEUM ARTHR, V61, P344, DOI 10.1002/art.24096
   Choi HJ, 2001, DYES PIGMENTS, V49, P15, DOI 10.1016/S0143 7208(01)00007 9
   Clynes MA, 2019, AGING CLIN EXP RES, V31, P1049, DOI 10.1007/s40520 019 01163 0
   Coaccioli S, 2022, J CLIN MED, V11, DOI 10.3390/jcm11206013
   Cohen SB, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3430
   Dowlatabadi R, 2017, METABOLOMICS, V13, DOI 10.1007/s11306 016 1155 x
   Dubin A, 2016, MED CLIN N AM, V100, P147, DOI 10.1016/j.mcna.2015.08.008
   Fang H, 2014, NAT REV RHEUMATOL, V10, P413, DOI 10.1038/nrrheum.2014.46
   Festuccia C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/135048
   Fujimoto K, 2019, PHARMACOGN RES, V11, P98, DOI 10.4103/pr.pr_152_18
   Gezici S, 2019, J FOOD SCI TECH MYS, V56, P5435, DOI 10.1007/s13197 019 04014 y
   Harrell CR, 2019, BIOMED PHARMACOTHER, V109, P2318, DOI 10.1016/j.biopha.2018.11.099
   Hemshekhar M, 2012, BIOCHIMIE, V94, P2723, DOI 10.1016/j.biochi.2012.08.013
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Kabiri M, 2017, LWT FOOD SCI TECHNOL, V84, P1, DOI 10.1016/j.lwt.2017.05.033
   Katz Jeffrey N, 2020, Osteoarthr Cartil Open, V2, P100059, DOI 10.1016/j.ocarto.2020.100059
   Koski C, 2020, J MATER CHEM B, V8, P2048, DOI 10.1039/c9tb01462d
   Koycheva IK, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.680168
   Lampropoulou Adamidou Kalliopi, 2014, Eur J Orthop Surg Traumatol, V24, P263, DOI 10.1007/s00590 013 1205 2
   Li X, 2017, BIOSCI BIOTECH BIOCH, V81, P891, DOI 10.1080/09168451.2016.1263145
   Lindler Breanna N, 2020, Medicines (Basel), V7, DOI 10.3390/medicines7110067
   Little CB, 2008, CURR RHEUMATOL REV, V4, P175, DOI 10.2174/157339708785133523
   Liu JD, 2018, FOOD CHEM, V253, P284, DOI 10.1016/j.foodchem.2018.01.140
   Liu W, 2018, PHARM BIOL, V56, P209, DOI 10.1080/13880209.2018.1448874
   Long HB, 2022, ARTHRITIS RHEUMATOL, V74, P1172, DOI 10.1002/art.42089
   Lorenz J, 2014, METHODS MOL BIOL, V1194, P401, DOI 10.1007/978 1 4939 1215 5_23
   Lubberts E, 1998, CYTOKINE, V10, P361, DOI 10.1006/cyto.1997.0298
   Marshall M, 2018, NAT REV RHEUMATOL, V14, P641, DOI 10.1038/s41584 018 0095 4
   Marx W, 2019, NUTR REV, V77, P557, DOI 10.1093/nutrit/nuz023
   Miller RE, 2014, CYTOKINE, V70, P185, DOI 10.1016/j.cyto.2014.06.019
   Moos V, 1999, J RHEUMATOL, V26, P870
   Mostafavinia SE, 2016, DNA CELL BIOL, V35, P340, DOI 10.1089/dna.2015.3208
   Parizad S, 2019, FOOD CHEM, V295, P387, DOI 10.1016/j.foodchem.2019.05.116
   Rahaiee S, 2015, J FOOD SCI TECH MYS, V52, P1881, DOI 10.1007/s13197 013 1238 x
   Rathore B, 2015, INT J PHARM SCI RES, V6, P1473, DOI 10.13040/IJPSR.0975 8232.6(4).1473 78
   Reynard LN, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.4
   Sarfarazi M, 2020, IND CROP PROD, V145, DOI 10.1016/j.indcrop.2019.111978
   Schmitz N, 2010, OSTEOARTHR CARTILAGE, V18, pS113, DOI 10.1016/j.joca.2010.05.026
   Setayesh L, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082736
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Silverwood V, 2015, OSTEOARTHR CARTILAGE, V23, P507, DOI 10.1016/j.joca.2014.11.019
   Singh G, 2022, DIGEST DIS SCI, V67, P2922, DOI 10.1007/s10620 021 07163 3
   Sobolev AP, 2014, FOODS, V3, P403, DOI 10.3390/foods3030403
   Sohaei S, 2020, INT J FOOD PROP, V23, P1386, DOI 10.1080/10942912.2020.1807567
   Tan HY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2795090
   Teeple E, 2013, AAPS J, V15, P438, DOI 10.1208/s12248 013 9454 x
   García Rodríguez MV, 2014, J AGR FOOD CHEM, V62, P8068, DOI 10.1021/jf5019356
   VANDERKRAAN PM, 1990, J EXP PATHOL, V71, P19
   Vincent TL, 2012, RHEUMATOLOGY, V51, P1931, DOI 10.1093/rheumatology/kes035
   Wang ECY, 2014, ARTHRITIS RHEUMATOL, V66, P2762, DOI 10.1002/art.38770
   Wang Y, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114368
   Watson R.R, 2014, Bioactive nutraceuticals and dietary supplements in neurological and brain disease: prevention and therapy
   Wu XQ, 2016, IMMUNOLOGY, V148, P237, DOI 10.1111/imm.12608
   Xing BC, 2021, J ETHNOPHARMACOL, V281, DOI 10.1016/j.jep.2021.114555
   Yamin R, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37448 z
   Yoo JH, 2018, CLIN ORTHOP SURG, V10, P315, DOI 10.4055/cios.2018.10.3.315
   Zare M., 2018, COCHRANE DB SYST REV, V2018, pCD012950, DOI [10.1002/14651858.CD012950, DOI 10.1002/14651858.CD012950]
   Zeinali M, 2019, IRAN J BASIC MED SCI, V22, P334, DOI 10.22038/ijbms.2019.34365.8158
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
NR 74
TC 6
Z9 6
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2075 1729
J9 LIFE BASEL
JI Life Basel
PD APR
PY 2023
VL 13
IS 4
AR 894
DI 10.3390/life13040894
PG 20
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Microbiology
GA E7ZZ8
UT WOS:000977693600001
PM 37109424
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Candelario, J
   Chachisvilis, M
AF Candelario, Jose
   Chachisvilis, Mirianas
TI Real time detection of G protein activation using monomolecular Gγ FRET
   sensors
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE Fluorescence resonance energy transfer; G gamma subunit; G protein
   sensor; G protein coupled receptors; mechanosensing; shear stress
ID FLUID SHEAR STRESS; PLASMA MEMBRANE; LIVING CELLS; COMPLEX
   TRANSLOCATION; FLUORESCENT PROTEINS; PARATHYROID HORMONE;
   COUPLED RECEPTORS; GOLGI COMPLEX; BONE CELLS; DISSOCIATION
AB G protein coupled receptors (GPCRs) are involved in many diseases, and are the target of a large percentage of modern drugs. While only a few fluorescence resonance energy transfer (FRET) sensors have been made for real time detection of GPCR activation, the human genome encodes roughly 950 GPCRs and a need for a broad real time detection system is needed. In this study, we developed and characterized a new type of G protein sensor based on the G gamma subunit containing an intra molecular FRET pair to allow detection of real time G protein activation in multiple cell lines using time resolved fluorescence spectroscopy. Our G gamma sensors were able to detect G protein activation to aluminum fluoride, a G protein activator, in human embryonic kidney 293 cells (HEK293). Moreover, our sensors were able to couple to the bradykinin B 2, parathyroid type 1 and adrenergic 2A GPCRs and detect G protein activation in response to the cognate ligands; bradykinin, parathyroid and noradrenaline hormones, respectively. Furthermore, our sensors also detected ligand independent G protein activation by fluid shear stress. G protein inhibitors, pertussis toxin and guanosine 5' [beta thio] diphosphate, inhibited the FRET response to G protein stimulants indicating that the sensor response is specific to G protein activation. These findings suggest that the described G gamma sensors can be used to monitor real time G protein activation by a variety of G protein stimulants or inhibitors.
C1 [Candelario, Jose; Chachisvilis, Mirianas] La Jolla Bioengn Inst, San Diego, CA 92121 USA.
C3 La Jolla Bioengineering Institute
RP Chachisvilis, M (通讯作者)，La Jolla Bioengn Inst, 3535 Gen Atom Court,Ste 210, San Diego, CA 92121 USA.
EM mirianas@ljbi.org
FU National Science Foundation [MCB 0721396]; TeraGrid resources
   [TG MCB090202]; National Institutes of Health [HL86943, HL86943 S1]
FX JC is grateful for Postdoctoral Research Supplement from the National
   Institutes of Health. This work was supported by grants to MC from the
   National Science Foundation (MCB 0721396), TeraGrid resources
   (TG MCB090202) and the National Institutes of Health (HL86943 and
   HL86943 S1). The authors declare no competing financial interests.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Akgoz M, 2004, J BIOL CHEM, V279, P51541, DOI 10.1074/jbc.M410639200
   Akgoz M, 2006, CELL SIGNAL, V18, P1758, DOI 10.1016/j.cellsig.2006.01.016
   Azpiazu I, 2006, CELL SIGNAL, V18, P1190, DOI 10.1016/j.cellsig.2005.09.007
   Bergaya S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593
   BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014 5793(85)80004 1
   BORJIGIN J, 1994, J BIOL CHEM, V269, P14715
   Bünemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100
   BURNS DL, 1988, MICROBIOL SCI, V5, P285
   Cabrera Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000 0026
   Candelario J, 2012, CELL MOL BIOENG, V5, P277, DOI 10.1007/s12195 012 0232 0
   Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103
   Chisari M, 2009, PLOS ONE, V4, pA181, DOI 10.1371/journal.pone.0007797
   DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749
   Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103
   Filmore D., 2004, MOD DRUG DISCOV, V7, P24
   GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151
   Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200
   Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515
   Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835
   Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534 5807(03)00060 1
   Miyawaki A, 2011, ANNU REV BIOCHEM, V80, P357, DOI 10.1146/annurev biochem 072909 094736
   MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49
   Myung CS, 2006, MOL PHARMACOL, V69, P877, DOI 10.1124/mol.105.018994
   Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550
   Nguyen AW, 2005, NAT BIOTECHNOL, V23, P355, DOI 10.1038/nbt1066
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756 3282(96)00008 7
   Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653
   Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945
   Saini DK, 2007, J BIOL CHEM, V282, P24099, DOI 10.1074/jbc.M701191200
   SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986
   Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014 5793(02)02775 8
   Tu X, 2011, AM SOC BON MIN RES A
   Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838
   Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125
   Wittinghofer A, 1997, CURR BIOL, V7, pR682, DOI 10.1016/S0960 9822(06)00355 1
   Zhang YL, 2009, AM J PHYSIOL CELL PH, V296, pC1391, DOI 10.1152/ajpcell.00549.2008
   Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137
NR 39
TC 1
Z9 2
U1 0
U2 16
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69 77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1079 9893
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PY 2013
VL 33
IS 1
BP 63
EP 72
DI 10.3109/10799893.2012.759589
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 080UM
UT WOS:000314269400010
PM 23336397
DA 2025 08 17
ER

PT J
AU Beck, GR
   Khazai, NB
   Bouloux, GF
   Camalier, CE
   Lin, YM
   Garneys, LM
   Siqueira, J
   Peng, LM
   Pasquel, F
   Umpierrez, D
   Smiley, D
   Umpierrez, GE
AF Beck, George R., Jr.
   Khazai, Natasha B.
   Bouloux, Gary F.
   Camalier, Corinne E.
   Lin, Yiming
   Garneys, Laura M.
   Siqueira, Joselita
   Peng, Limin
   Pasquel, Francisco
   Umpierrez, Denise
   Smiley, Dawn
   Umpierrez, Guillermo E.
TI The effects of thiazolidinediones on human bone marrow stromal cell
   differentiation in vitro and in thiazolidinedione treated patients with
   type 2 diabetes
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID FAT DISTRIBUTION; INSULIN RESISTANCE; GLUCOSE TOLERANCE; MINERAL
   DENSITY; BODY FAT; ROSIGLITAZONE; PIOGLITAZONE; OSTEOBLASTOGENESIS;
   ADIPOGENESIS; MECHANISMS
AB Thiazolidinedione (TZD) therapy has been associated with an increased risk of bone fractures. Studies in rodents have led to a model in which decreased bone quality in response to TZDs is due to a competition of lineage commitment between osteoblasts (OBs) and adipocytes (ADs) for a common precursor cell, resulting in decreased OB numbers. Our goal was to investigate the effects of TZD exposure on OB AD lineage determination from primary human bone marrow stromal cells (hBMSCs) both in vitro and in vivo from nondiabetic subjects and patients with type 2 diabetics. Our experimental design included 2 phases. Phase 1 was an in vitro study of TZD effects on the differentiation of hBMSCs into OBs and ADs in nondiabetic subjects. Phase 2 was a randomized, placebo controlled trial to determine the effects of 6 month pioglitazone treatment in vivo on hBMSC differentiation using AD/OB colony forming unit assays in patients with type 2 diabetes. In vitro, TZDs (pioglitazone and rosiglitazone) enhanced the adipogenesis of hBMSCs, whereas neither altered OB differentiation or function as measured by alkaline phosphatase activity, gene expression, and mineralization. The ability of TZDs to enhance adipogenesis occurred at a specific time/stage of the differentiation process, and pretreating with TZDs did not further enhance adipogenesis. In vivo, 6 month TZD treatment decreased OB precursors, increased AD precursors, and increased total colony number in patients with type 2 diabetes. Our results indicate that TZD exposure in vitro potently stimulates adipogenesis but does not directly alter OB differentiation/mineralization or lineage commitment from hBMSCs. However, TZD treatment in type 2 diabetic patients results in decreased osteoblastogenesis from hBMSCs compared with placebo, indicating an indirect negative effect on OBs and suggesting an alternative model by which TZDs might negatively regulate bone quality. (Translational Research 2013;161:145 155)
C1 [Beck, George R., Jr.] Emory Univ, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA.
   Emory Univ, Dept Surg, Div Oral & Maxillofacial Surg, Atlanta, GA 30322 USA.
   Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University; Rollins School
   Public Health
RP Beck, GR (通讯作者)，Emory Univ, Dept Med, Div Endocrinol, 101 Woodruff Circle WMRB 1026, Atlanta, GA 30322 USA.
EM george.beck@emory.edu
RI Beck, George/AAO 2117 2020
FU Emory Medical Care Foundation Grant from Emory University; NIH/NIAMS
   [AR056090]; NIH/NCI [CA136059, CA136716]; NIH [UL1 RR025008]; American
   Diabetes Association [7 03 CR 35]
FX The authors thank all of the patients who contributed to the study; Anum
   Ghazipura and Gonzalo Robalino, MD, for assistance with patient
   recruitment; and Jane Caudell for screening the Grady Diabetes clinic
   database for eligible patients. This study was supported in part by a
   grant from the Emory Medical Care Foundation Grant from Emory University
   (NBK). GRB, CEC, YL, and LMG were also supported by grants from
   NIH/NIAMS (AR056090) and NIH/NCI (CA136059 and CA136716) and GEU was
   supported by grants from NIH UL1 RR025008 and American Diabetes
   Association 7 03 CR 35.
CR Abdallah BM, 2012, BONE, V50, P540, DOI 10.1016/j.bone.2011.06.030
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Bajaj M, 2004, J CLIN ENDOCR METAB, V89, P4649, DOI 10.1210/jc.2004 0224
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   BERESFORD JN, 1989, CLIN ORTHOP RELAT R, P270
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bruedigam C, 2010, STEM CELLS, V28, P916, DOI 10.1002/stem.405
   Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796
   Crossno JT, 2006, J CLIN INVEST, V116, P3220, DOI 10.1172/JCI28510
   DeFronzo RA, 2011, NEW ENGL J MED, V364, P1104, DOI 10.1056/NEJMoa1010949
   Di Iorgi N, 2008, INT J OBESITY, V32, P1854, DOI 10.1038/ijo.2008.170
   Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140 6736(06)69420 8
   Gimble JM, 1996, MOL PHARMACOL, V50, P1087
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Grey A, 2012, EUR J ENDOCRINOL, V166, P1087, DOI 10.1530/EJE 11 1075
   Grey A, 2009, DIABETES OBES METAB, V11, P275, DOI 10.1111/j.1463 1326.2008.00931.x
   Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393
   Harslof T, 2011, J CLIN ENDOCR METAB, V96, P1541, DOI 10.1210/jc.2010 2077
   Johnson TE, 1999, ENDOCRINOLOGY, V140, P3245, DOI 10.1210/en.140.7.3245
   Justesen J, 2004, ENDOCRINOLOGY, V145, P1916, DOI 10.1210/en.2003 1427
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kawai M, 2009, NAT REV RHEUMATOL, V5, P365, DOI 10.1038/nrrheum.2009.102
   Kelly IE, 1999, DIABETES CARE, V22, P288, DOI 10.2337/diacare.22.2.288
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Mancini T, 2009, BONE, V45, P784, DOI 10.1016/j.bone.2009.06.006
   McDonough AK, 2008, NAT CLIN PRACT ENDOC, V4, P507, DOI 10.1038/ncpendmet0920
   Meier C, 2008, ARCH INTERN MED, V168, P820, DOI 10.1001/archinte.168.8.820
   Miyazaki Y, 2002, J CLIN ENDOCR METAB, V87, P2784, DOI 10.1210/jc.87.6.2784
   Mori Y, 1999, DIABETES CARE, V22, P908, DOI 10.2337/diacare.22.6.908
   NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803
   OWEN M, 1988, CIBA F SYMP, V136, P42
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145
   Rotolin S, 2006, J CELL PHYSIOL, V209, P967, DOI 10.1002/jcp.20804
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Schwartz AV, 2006, PPAR RES, V2006, DOI 10.1155/PPAR/2006/24502
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Schwartz AV, 2008, PPAR RES, V2008, DOI 10.1155/2008/297893
   Siersbaek R, 2012, TRENDS ENDOCRIN MET, V23, P56, DOI 10.1016/j.tem.2011.10.001
   Solomon DH, 2009, J CLIN ENDOCR METAB, V94, P2792, DOI 10.1210/jc.2008 2157
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   Werner C, 2007, DIABETES, V56, P2609, DOI 10.2337/db07 0069
   Willson TM, 1996, ANN NY ACAD SCI, V804, P276, DOI 10.1111/j.1749 6632.1996.tb18622.x
   Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a
   Wren TAL, 2011, J CLIN ENDOCR METAB, V96, P782, DOI 10.1210/jc.2010 1922
   Yaturu S, 2007, DIABETES CARE, V30, P1574, DOI 10.2337/dc06 2606
   Yki Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Yki Järvinen H, 2005, LANCET, V366, P1241, DOI 10.1016/S0140 6736(05)67504 6
NR 53
TC 48
Z9 52
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1931 5244
EI 1878 1810
J9 TRANSL RES
JI Transl. Res.
PD MAR
PY 2013
VL 161
IS 3
BP 145
EP 155
DI 10.1016/j.trsl.2012.08.006
PG 11
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA 096SW
UT WOS:000315425600003
PM 23022285
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sanjurjo Rodriguez, C
   Altaie, A
   Mastbergen, S
   Baboolal, T
   Welting, T
   Lafeber, F
   Pandit, H
   McGonagle, D
   Jones, E
AF Sanjurjo Rodriguez, Clara
   Altaie, Ala
   Mastbergen, Simon
   Baboolal, Thomas
   Welting, Tim
   Lafeber, Floris
   Pandit, Hemant
   McGonagle, Dennis
   Jones, Elena
TI Gene Expression Signatures of Synovial Fluid Multipotent Stromal Cells
   in Advanced Knee Osteoarthritis and Following Knee Joint Distraction
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE multipotent stromal cells; synovial fluid; osteoarthritis; knee joint
   distraction; subchondral bone; chondrocytes
ID MESENCHYMAL STEM CELLS; CHONDROGENIC PROGENITOR CELLS; ENDOTHELIAL
   GROWTH FACTOR; CARTILAGE REPAIR; BONE; RECEPTORS; INCREASE; TISSUE;
   DIFFERENTIATION; IDENTIFICATION
AB Osteoarthritis (OA) is the most common musculoskeletal disorder. Although joint replacement remains the standard of care for knee OA patients, knee joint distraction (KJD), which works by temporarily off loading the joint for 6 8 weeks, is becoming a novel joint sparing alternative for younger OA sufferers. The biological mechanisms behind KJD structural improvements remain poorly understood but likely involve joint resident regenerative cells including multipotent stromal cells (MSCs). In this study, we hypothesized that KJD leads to beneficial cartilage anabolic and anti catabolic changes in joint resident MSCs and investigated gene expression profiles of synovial fluid (SF) MSCs following KJD as compared with baseline. To obtain further insights into the effects of local biomechanics on MSCs present in late OA joints, SF MSC gene expression was studied in a separate OA arthroplasty cohort and compared with subchondral bone (SB) MSCs from medial (more loaded) and lateral (less loaded) femoral condyles from the same joints. In OA arthroplasty cohort (n = 12 patients), SF MSCs expressed lower levels of ossification  and hypotrophy related genes [bone sialoprotein (IBSP), parathyroid hormone 1 receptor (PTH1R), and runt related transcription factor 2 (RUNX2)] than did SB MSCs. Interestingly, SF MSCs expressed 5  to 50 fold higher levels of transcripts for classical extracellular matrix turnover molecules matrix metalloproteinase 1 (MMP1), a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), and tissue inhibitor of metalloproteinase 3 (TIMP3), all (p < 0.05) potentially indicating greater cartilage remodeling ability of OA SF MSCs, compared with SB MSCs. In KJD cohort (n = 9 patients), joint off loading resulted in sustained, significant increase in SF MSC colonies' sizes and densities and a notable transcript upregulation of key cartilage core protein aggrecan (ACAN) (weeks 3 and 6), as well as reduction in pro inflammatory C C motif chemokine ligand 2 (CCL2) expression (weeks 3 and 6). Additionally, early KJD changes (week 3) were marked by significant increases in MSC chondrogenic commitment markers gremlin 1 (GREM1) and growth differentiation factor 5 (GDF5). In combination, our results reveal distinct transcriptomes on joint resident MSCs from different biomechanical environments and show that 6 week joint off loading leads to transcriptional changes in SF MSCs that may be beneficial for cartilage regeneration. Biomechanical factors should be certainly considered in the development of novel MSC based therapies for OA.
C1 [Sanjurjo Rodriguez, Clara; Altaie, Ala; Baboolal, Thomas; McGonagle, Dennis; Jones, Elena] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
   [Sanjurjo Rodriguez, Clara] Univ A Coruna, Ctr Adv Sci Res CICA, Inst Biomed Res A Coruna INIBIC, Physiotherapy Med & Biomed Sci Dept CIBER BBN, La Coruna, Spain.
   [Mastbergen, Simon; Lafeber, Floris] Univ Utrecht, Regenerat Med Ctr Utrecht, Univ Med Ctr Utrecht, Rheumatol & Clin Immunol, Utrecht, Netherlands.
   [Welting, Tim] Maastricht Univ, Med Ctr, Dept Orthoped Surg, Lab Expt Orthoped, Maastricht, Netherlands.
   [Pandit, Hemant; McGonagle, Dennis] NIHR Leeds Musculoskeletal Biomed Res Ctr, Leeds, W Yorkshire, England.
C3 University of Leeds; Universidade da Coruna; Centro interdisciplinar de
   Quimica e Bioloxia CICA; Instituto de Investigacion Biomedica de A
   Coruna (INIBIC); Utrecht University; Utrecht University Medical Center;
   Maastricht University
RP Jones, E (通讯作者)，Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
EM e.jones@leeds.ac.uk
RI ; Sanjurjo Rodríguez, Clara/T 2580 2017; Jones, Elena/AAL 2818 2021;
   Pandit, Hemant/D 5529 2011; Baboolal, Thomas/IWE 3593 2023;
   Sanjurjo Rodriguez, Clara/T 2580 2017
OI Pandit, Hemant/0000 0001 7392 8561; Altaie, Ala/0000 0002 9203 1490;
   Jones, Elena/0000 0001 9365 2283; Sanjurjo Rodriguez,
   Clara/0000 0003 2702 7804
FU FOREUM: foundation for research in rheumatology [104929]; Dutch
   Arthritis Society [LLP 9, LLP 14]
FX This study was supported by FOREUM: foundation for research in
   rheumatology grant number 104929. The institution of SC Mastbergen and
   FPJG Lafeber has, during the study period, received funding from Dutch
   Arthritis Society (ReumaNederland), project number LLP 9,
   https://reumanederland.nl/.The institution of TJM Welting received
   funding from Dutch Arthritis Society (ReumaNederland), project number
   LLP 14, https://reumanederland.nl/.The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Affan A, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2495 2
   Ahmad N, 2020, J CELL PHYSIOL, V235, P6366, DOI 10.1002/jcp.29607
   Alaaeddine N, 2015, INFLAMM RES, V64, P721, DOI 10.1007/s00011 015 0854 5
   Altaie A, 2018, CYTOTHERAPY, V20, P375, DOI 10.1016/j.jcyt.2017.12.003
   Amemiya M, 2020, BIOCHEM BIOPH RES CO, V523, P465, DOI 10.1016/j.bbrc.2019.12.068
   Ayyaz A, 2019, NATURE, V569, P121, DOI 10.1038/s41586 019 1154 y
   Baboola TG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4574
   Baboolal TG, 2016, ANN RHEUM DIS, V75, P908, DOI 10.1136/annrheumdis 2014 206847
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Carluccio S, 2020, CELLS BASEL, V9, DOI 10.3390/cells9041052
   Cassano JM, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0840 2
   Chahal J, 2019, STEM CELL TRANSL MED, V8, P746, DOI 10.1002/sctm.18 0183
   Chen Y, 2015, OSTEOARTHR CARTILAGE, V23, P1728, DOI 10.1016/j.joca.2015.05.018
   Choi WS, 2017, OSTEOARTHR CARTILAGE, V25, P401, DOI 10.1016/j.joca.2016.07.009
   Churchman SM, 2012, ARTHRITIS RHEUM US, V64, P2632, DOI 10.1002/art.34434
   Coutu DL, 2011, BLOOD, V117, P6801, DOI 10.1182/blood 2010 12 321539
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Daghestani HN, 2015, ARTHRITIS RHEUMATOL, V67, P956, DOI 10.1002/art.39006
   De Luca P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040423
   Djouad F, 2005, ARTHRITIS RES THER, V7, pR1304, DOI 10.1186/ar1827
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dwivedi G., 2018, CARTILAGE, V2018, DOI 10.1177/1947603518812555
   Endres M, 2007, J ORTHOP RES, V25, P1299, DOI 10.1002/jor.20394
   Fahy N, 2014, OSTEOARTHR CARTILAGE, V22, P1167, DOI 10.1016/j.joca.2014.05.021
   Fang W, 2021, J KNEE SURG, V34, P1476, DOI 10.1055/s 0040 1710366
   Fellows CR, 2017, SCI REP UK, V7, DOI 10.1038/srep41421
   Fellows CR, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00213
   Ganguly P, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5197983
   Garcia J, 2016, SCI REP UK, V6, DOI 10.1038/srep24295
   Goh EL, 2019, ORTHOP RES REV, V11, P79, DOI 10.2147/ORR.S211060
   Goldring MB, 2000, ARTHRITIS RHEUM US, V43, P1916, DOI 10.1002/1529 0131(200009)43:9<1916::AID ANR2>3.0.CO;2 I
   Grandi FC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5352
   Hamilton JL, 2016, J BONE MINER RES, V31, P911, DOI 10.1002/jbmr.2828
   Harris Q, 2013, STEM CELLS, V31, P2253, DOI 10.1002/stem.1477
   Hissnauer TN, 2010, OSTEOARTHR CARTILAGE, V18, P1630, DOI 10.1016/j.joca.2010.10.002
   Hyodo Akinobu, 2019, JB JS Open Access, V4, pe0010, DOI 10.2106/JBJS.OA.19.00010
   Iijima H, 2016, OSTEOARTHR CARTILAGE, V24, P354, DOI 10.1016/j.joca.2015.09.001
   Ilas DC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67998 0
   Ilas DC, 2019, RHEUMATOLOGY, V58, P1777, DOI 10.1093/rheumatology/kez130
   Intema F, 2011, OSTEOARTHR CARTILAGE, V19, P668, DOI 10.1016/j.joca.2011.02.005
   Jansen MP, 2018, OSTEOARTHR CARTILAGE, V26, P1604, DOI 10.1016/j.joca.2018.08.004
   Jansen M. P., 2019, CARTILAGE, V2019, DOI 10.1177/1947603519828432
   Jansen MP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227975
   Jayasuriya CT, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25395 8
   Ji QB, 2019, ANN RHEUM DIS, V78, P100, DOI 10.1136/annrheumdis 2017 212863
   Jones EA, 2004, ARTHRITIS RHEUM US, V50, P817, DOI 10.1002/art.20203
   Jones EA, 2008, ARTHRITIS RHEUM US, V58, P1731, DOI 10.1002/art.23485
   Kang H, 2012, TISSUE ENG PT A, V18, P331, DOI [10.1089/ten.TEA.2011.0074, 10.1089/ten.tea.2011.0074]
   Kania K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57011 8
   Katagiri K, 2017, ARTHROSCOPY, V33, P800, DOI 10.1016/j.arthro.2016.09.033
   Kim YS, 2015, AM J SPORT MED, V43, P399, DOI 10.1177/0363546514559822
   Koelling S, 2009, CELL STEM CELL, V4, P324, DOI 10.1016/j.stem.2009.01.015
   Kohno Y, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 1998 6
   Kouroupis D, 2019, TISSUE ENG PART B RE, V25, P55, DOI [10.1089/ten.teb.2018.0118, 10.1089/ten.TEB.2018.0118]
   Lee DH, 2012, OSTEOARTHR CARTILAGE, V20, P106, DOI 10.1016/j.joca.2011.11.010
   Leijs MJC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00231
   Leijten JCH, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4306
   Ludin A, 2013, OSTEOARTHR CARTILAGE, V21, P491, DOI 10.1016/j.joca.2012.12.003
   Maria CS, 2016, SEMIN CELL DEV BIOL, V49, P11, DOI 10.1016/j.semcdb.2015.12.004
   Mastbergen SC, 2013, NAT REV RHEUMATOL, V9, P277, DOI 10.1038/nrrheum.2013.29
   Matas J, 2019, STEM CELL TRANSL MED, V8, P215, DOI 10.1002/sctm.18 0053
   Matsukura Y, 2014, CLIN ORTHOP RELAT R, V472, P1357, DOI 10.1007/s11999 013 3418 4
   McGonagle D, 2017, NAT REV RHEUMATOL, V13, P719, DOI 10.1038/nrrheum.2017.182
   Mikel S., 2012, Innovations in biotechnology, P6, DOI DOI 10.5772/28908
   Mizuno M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0870 9
   Monibi F, 2016, J KNEE SURG, V29, P242, DOI 10.1055/s 0035 1549022
   Morito T, 2008, RHEUMATOLOGY, V47, P1137, DOI 10.1093/rheumatology/ken114
   Muiños López E, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1247950
   Neybecker P, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1071 2
   O'Brien K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040774
   Paavonen K, 2002, J RHEUMATOL, V29, P39
   Pineiro Ramil M., 2018, Cartil. Repair Regen, DOI DOI 10.5772/INTECHOPEN.70406
   Roelofs AJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15040
   Roughley Peter J, 2014, J Exp Orthop, V1, P8, DOI 10.1186/s40634 014 0008 7
   Sánchez M, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4868613
   Sanjurjo Rodriguez C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45820 w
   Schminke B, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 014 0461 4
   Schreurs BW, 2017, LANCET, V389, P1374, DOI 10.1016/S0140 6736(17)30190 3
   Sekiya I, 2012, J ORTHOP RES, V30, P943, DOI 10.1002/jor.22029
   Seol D, 2012, ARTHRITIS RHEUM US, V64, P3626, DOI 10.1002/art.34613
   Shariatzadeh M, 2019, CELL TISSUE RES, V378, P399, DOI 10.1007/s00441 019 03069 9
   SIVASUBRAMANIYA.K, 2012, ANN NY ACAD SCI, V0008, P00094
   Takahashi T, 2019, J KNEE SURG, V32, P788, DOI 10.1055/s 0038 1669447
   Tricoire L, 2019, METHODS MOL BIOL, V1941, P139, DOI 10.1007/978 1 4939 9077 1_10
   van der Woude JAD, 2017, BONE JOINT J, V99B, P51, DOI [10.1302/0301 620X.99B1.BJJ 2016 0099.R3, 10.1302/0301 620X.99B1.BJJ 2016 0099]
   van der Woude JTAD, 2017, CARTILAGE, V8, P263, DOI 10.1177/1947603516665442
   Wang ZM, 2013, MOL MED REP, V8, P877, DOI 10.3892/mmr.2013.1570
   WATANABE N, 2020, STEM CELL REV R 0930, DOI DOI 10.21203/rs.3.rs 42459/v1
   Watt FE, 2020, OSTEOARTHR CARTILAGE, V28, P324, DOI 10.1016/j.joca.2019.12.005
   Westacott CI, 1997, ARTHRITIS RHEUM, V40, P1282, DOI 10.1002/1529 0131(199707)40:7<1282::AID ART13>3.0.CO;2 E
   Wiegant K, 2013, OSTEOARTHR CARTILAGE, V21, P1660, DOI 10.1016/j.joca.2013.08.006
   Wiegant K, 2015, ARTHRITIS RHEUMATOL, V67, P465, DOI 10.1002/art.38906
   Wiegertjes R, 2019, OSTEOARTHR CARTILAGE, V27, P1197, DOI 10.1016/j.joca.2019.04.014
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Zarebska JM, 2017, OSTEOARTHR CARTILAGE, V25, P406, DOI 10.1016/j.joca.2016.10.008
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou WY, 2019, AM J SPORT MED, V47, P1722, DOI 10.1177/0363546519848678
NR 97
TC 21
Z9 22
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD OCT 14
PY 2020
VL 8
AR 579751
DI 10.3389/fbioe.2020.579751
PG 17
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA OH5YX
UT WOS:000582663700001
PM 33178674
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Barcelos, RP
   Lima, FD
   Courtes, AA
   da Silva, IK
   Vargas, JE
   Royes, LFF
   Trindade, C
   González Gallego, J
   Soares, FAA
AF Barcelos, Romulo Pillon
   Lima, Frederico Diniz
   Courtes, Aline Alves
   da Silva, Ingrid Kich
   Vargas, Jose Eduardo
   Freire Royes, Luiz Fernando
   Trindade, Cristiano
   Gonzalez Gallego, Javier
   Antunes Soares, Felix Alexandre
TI Diclofenac Administration after Physical Training Blunts Adaptations of
   Peripheral Systems and Leads to Losses in Exercise Performance: In Vivo
   and In Silico Analyses
SO ANTIOXIDANTS
LA English
DT Article
DE NSAIDs; physical training; rat; diclofenac; inflammation; oxidative
   stress; systems biology; systems pharmacology; adaptation
ID SKELETAL MUSCLE; RESISTANCE EXERCISE; INTERLEUKIN 6; INFLAMMATION;
   GLUTATHIONE; RATS; SUPPLEMENTS; MECHANISMS; IL 6
AB Recovery in athletes is hampered by soreness and fatigue. Consequently, nonsteroidal anti inflammatory drugs are used as an effective strategy to maintain high performance. However, impact of these drugs on adaptations induced by training remains unknown. This study assessed the effects of diclofenac administration (10 mg/kg/day) on rats subjected to an exhaustive test, after six weeks of swimming training. Over the course of 10 days, three repeated swimming bouts were performed, and diclofenac or saline were administered once a day. Trained animals exhibited higher muscle citrate synthase and lower plasma creatinine kinase activities as compared to sedentary animals, wherein diclofenac had no impact. Training increased time to exhaustion, however, diclofenac blunted this effect. It also impaired the increase in plasma and liver interleukin 6 levels. The trained group exhibited augmented catalase, glutathione peroxidase, and glutathione reductase activities, and a higher ratio of reduced to oxidized glutathione in the liver. However, diclofenac treatment blunted all these effects. Systems biology analysis revealed a close relationship between diclofenac and liver catalase. These results confirmed that regular exercise induces inflammation and oxidative stress, which are crucial for tissue adaptations. Altogether, diclofenac treatment might be helpful in preventing pain and inflammation, but its use severely affects performance and tissue adaptation.
C1 [Barcelos, Romulo Pillon; Courtes, Aline Alves; da Silva, Ingrid Kich; Antunes Soares, Felix Alexandre] Univ Fed Santa Maria, Ctr Ciencias Nat & Exatas, Dept Bioquim & Biol Mol, Programa Posgrad Bioquim Toxicol, BR 97105900 Santa Maria, RS, Brazil.
   [Barcelos, Romulo Pillon] Univ Passo Fundo UPF, Programa Posgrad Bioexperimentacao PPGBioexp, BR 285, BR 99052900 Passo Fundo, RS, Brazil.
   [Lima, Frederico Diniz; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Ctr Educ Fis & Desportos, Lab Bioquim Exercicio, BR 97105900 Santa Maria, RS, Brazil.
   [Vargas, Jose Eduardo] Univ Passo Fundo UPF, Inst Ciencias Biol ICB, Lab Biol Mol, BR 99052900 Passo Fundo, RS, Brazil.
   [Vargas, Jose Eduardo] Univ Fed Rio Grande do Sul UFRGS, Hosp Clin Porto Alegre, Programa Posgrad Ciencias Gastroenterol & Hepatol, BR 90035003 Porto Alegre, RS, Brazil.
   [Trindade, Cristiano] Univ Simon Bolivar, Fac Ciencias Basicas & Biomed, Barranquilla 080002, Colombia.
   [Gonzalez Gallego, Javier] Univ Leon, Inst Biomed IBIOMED, Leon 24071, Spain.
   [Gonzalez Gallego, Javier] Univ Leon, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Leon 24071, Spain.
C3 Universidade Federal de Santa Maria (UFSM); Universidade de Passo Fundo;
   Universidade Federal de Santa Maria (UFSM); Universidade de Passo Fundo;
   Universidade Federal do Rio Grande do Sul; Hospital de Clinicas de Porto
   Alegre; Universidad de Leon; Universidad de Leon; CIBER   Centro de
   Investigacion Biomedica en Red; CIBEREHD
RP Barcelos, RP (通讯作者)，Univ Fed Santa Maria, Ctr Ciencias Nat & Exatas, Dept Bioquim & Biol Mol, Programa Posgrad Bioquim Toxicol, BR 97105900 Santa Maria, RS, Brazil.; Barcelos, RP (通讯作者)，Univ Passo Fundo UPF, Programa Posgrad Bioexperimentacao PPGBioexp, BR 285, BR 99052900 Passo Fundo, RS, Brazil.; Trindade, C (通讯作者)，Univ Simon Bolivar, Fac Ciencias Basicas & Biomed, Barranquilla 080002, Colombia.
EM romulopillon@upf.br; profred@gmail.com; alinecourtes@bol.com.br;
   ingrid.ksilva@gmail.com; josevargas@upf.br; nandoroyes@yahoo.com.br;
   cristiano.trindade@unisimonbolivar.edu.co; jgonga@unileon.es;
   felix@ufsm.br
RI Trindade, Cristiano/CAA 5369 2022; Soares, Félix/AAE 6251 2020; royes,
   luiz/T 3581 2019; Vargas, José/P 3916 2017; Soares, Felix/K 7611 2012;
   Lima, Frederico/P 8479 2015; Barcelos, Romulo/J 8231 2015;
   Gonzalez Gallego, Javier/D 8219 2012; Barcelos, Rômulo/J 8231 2015
OI Trindade, Cristiano/0000 0002 6128 5025; Gonzalez Gallego,
   Javier/0000 0002 4386 9342; Soares, Felix/0000 0002 6453 7902; royes,
   luiz/0000 0003 4045 4827; Barcelos, Romulo/0000 0002 6366 6366; 
FU Instituto de Salud Carlos III, Spain; CNPQ;  [PRONEM/CNPq/FAPERGS
   16/25510000248 7];  [CAPES/PROEX 23038.005848/2018 31]
FX The work was supported by the PRONEM/CNPq/FAPERGS 16/25510000248 7 and
   CAPES/PROEX 23038.005848/2018 31 research grants. FAAS received a
   fellowship from CNPQ. CIBERehd is funded by Instituto de Salud Carlos
   III, Spain.
CR Al dossari MH, 2020, BIOL TRACE ELEM RES, V196, P173, DOI 10.1007/s12011 019 01910 4
   [Anonymous], 1984, METHOD ENZYMOL
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Barcelos RP, 2017, APPL PHYSIOL NUTR ME, V42, P757, DOI 10.1139/apnm 2016 0593
   Barcelos RP, 2017, FREE RADICAL RES, V51, P222, DOI 10.1080/10715762.2017.1291942
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   CARLBERG I, 1985, METHOD ENZYMOL, V113, P484
   de Araujo GG, 2007, COMP BIOCHEM PHYS A, V148, P888, DOI 10.1016/j.cbpa.2007.09.002
   Deng XM, 2006, J PHARMACOL EXP THER, V319, P1191, DOI 10.1124/jpet.106.110247
   Deshmukh AS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20556 8
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Fischer CP, 2006, EXERC IMMUNOL REV, V12, P6
   FLOHE L, 1984, METHOD ENZYMOL, V105, P114
   Francaux M, 2009, APPL PHYSIOL NUTR ME, V34, P454, DOI 10.1139/H09 036
   Georgakouli K, 2015, EXP THER MED, V10, P2015, DOI 10.3892/etm.2015.2792
   Georgiou CD, 2009, NAT PROTOC, V4, P125, DOI 10.1038/nprot.2008.222
   Gonzalez Gil AM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061899
   Harrold JM, 2013, CLIN PHARMACOL THER, V94, P651, DOI 10.1038/clpt.2013.176
   Higgins MR, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17228452
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003 2697(76)90326 2
   Huang SH, 2006, CLIN J SPORT MED, V16, P27, DOI 10.1097/01.jsm.0000194766.35443.9c
   Kiran TR, 2004, COMP BIOCHEM PHYS B, V137, P187, DOI 10.1016/j.cbpc.2003.11.002
   Lima FD, 2016, SCAND J MED SCI SPOR, V26, P1160, DOI 10.1111/sms.12549
   Lima FD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055668
   Lubiana P, 2016, COMP BIOCHEM PHYS C, V185, P147, DOI 10.1016/j.cbpc.2016.04.003
   Lundby AKM, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12905
   Magherini F, 2019, FREE RADICAL RES, V53, P1155, DOI 10.1080/10715762.2019.1697438
   Merry TL, 2016, J PHYSIOL LONDON, V594, P5135, DOI 10.1113/JP270654
   Mikkelsen UR, 2011, SCAND J MED SCI SPOR, V21, P630, DOI 10.1111/j.1600 0838.2010.01170.x
   Moghetti P, 2016, FRONT HORM RES, V47, P44, DOI 10.1159/000445156
   Murton AJ, 2013, INT J BIOCHEM CELL B, V45, P2209, DOI 10.1016/j.biocel.2013.07.005
   Pal M, 2014, IMMUNOL CELL BIOL, V92, P331, DOI 10.1038/icb.2014.16
   Parry HA, 2020, INT J SPORTS MED, V41, P349, DOI 10.1055/a 1121 7851
   Barcelos RP, 2016, LIFE SCI, V148, P247, DOI 10.1016/j.lfs.2016.02.006
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Ruegsegger GN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029694
   Scardoni G, 2009, BIOINFORMATICS, V25, P2857, DOI 10.1093/bioinformatics/btp517
   SCHINDLER R, 1990, BLOOD, V75, P40
   Schreijenberg M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1432 5
   SRERE PAUL A., 1968, P11
   Steckling FM, 2020, SCAND J MED SCI SPOR, V30, P264, DOI 10.1111/sms.13579
   Steensberg A, 2003, AM J PHYSIOL ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003
   Vargas JE, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5432651
   Vargas JE, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/301635
   Vaso M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen 2015 007608
   Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351
   Zhang WJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00743
   Ziltener J.  L., 2010, Annals of Physical and Rehabilitation Medicine, V53, P278, DOI 10.1016/j.rehab.2010.03.001
NR 49
TC 1
Z9 1
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD AUG
PY 2021
VL 10
IS 8
AR 1246
DI 10.3390/antiox10081246
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA UF6OM
UT WOS:000688691300001
PM 34439494
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qu, Z
   Laky, M
   Ulm, C
   Matejka, M
   Dard, M
   Andrukhov, O
   Rausch fan, X
AF Qu, Zhe
   Laky, Markus
   Ulm, Christian
   Matejka, Michael
   Dard, Michel
   Andrukhov, Oleh
   Rausch fan, Xiaohui
TI Effect of Emdogain on proliferation and migration of different
   periodontal tissue associated cells
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article
ID ENAMEL MATRIX PROTEINS; HUMAN ALVEOLAR OSTEOBLASTS; IN VITRO; STIMULATES
   PROLIFERATION; DERIVATIVE EMDOGAIN(R); REGENERATIVE THERAPY; DEFECTS;
   AMELOGENIN; EXPRESSION; MOLECULES
AB Objectives. Although Emdogain is widely used as a gel in periodontal therapy, the exact mechanisms underlying its regenerative ability still need to be further investigated. Therefore, we tested in vitro the effect of the product Emdogain on proliferation, viability, and migration of various human cell types of periodontium.
   Study design. Proliferation and viability of alveolar osteoblasts (AOBs), epithelial cell line HSC 2, and human umbilical vein endothelial cells (HUVECs) were measured using [(3)H] thymidine uptake and 3,4,5 dimethylthiazol 2 yl  2,5 diphenyl tetrazolium bromide (MTT) assay, respectively. Cell migration was investigated in microchemotaxis chamber.
   Results. The proliferation and viability of AOB, HSC 2, and HUVECs were significantly stimulated by Emdogain (12.5 250 mu g/mL) in direct relationship with the amount of product present in the cell culture medium. Cell migration was stimulated in AOB and HUVECs depending on Emdogain amount. In contrast, in HSC 2 cells the migration was stimulated only by less than 50 mu g/mL of Emdogain, whereas at higher amounts this stimulating effect was either diminished or absent.
   Conclusion. Emdogain stimulates proliferation, viability, and migration of AOB, HSC 2, and HUVECs in vitro. This biological versatility of Emdogain could correspond to an essential mechanism underlying its ability to promote periodontal regeneration. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:924 931)
C1 [Qu, Zhe; Laky, Markus; Ulm, Christian; Matejka, Michael; Andrukhov, Oleh; Rausch fan, Xiaohui] Med Univ Vienna, Dept Periodontol, Bernhard Gottlieb Univ Clin Dent, A 1090 Vienna, Austria.
   [Qu, Zhe] Dalian Univ Technol, Dalian Stomatol Hosp, Dalian, Peoples R China.
   [Dard, Michel] Inst Straumann AG, Basel, Switzerland.
C3 Medical University of Vienna; Dalian University of Technology; Institut
   Straumann AG
RP Andrukhov, O (通讯作者)，Med Univ Vienna, Dept Periodontol, Bernhard Gottlieb Univ Clin Dent, Wahringerstr 25 A, A 1090 Vienna, Austria.
EM oleh.andrukhov@meduniwien.ac.at
RI ; Andrukhov, Oleh/H 9851 2018
OI Rausch Fan, Xiaohui/0000 0002 8010 1914; Laky,
   Markus/0000 0001 7801 0995; Andrukhov, Oleh/0000 0002 0485 2142
CR Bertl K, 2009, J PERIODONTOL, V80, P1622, DOI 10.1902/jop.2009.090157
   Bosshardt DD, 2008, J CLIN PERIODONTOL, V35, P87, DOI 10.1111/j.1600 051X.2008.01264.x
   Galli C, 2006, J PERIODONTOL, V77, P1223, DOI 10.1902/jop.2006.050304
   Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P669, DOI 10.1111/j.1600 051X.1997.tb00248.x
   Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600 051X.1997.tb00247.x
   Hoang AM, 2002, J DENT RES, V81, P497, DOI 10.1177/154405910208100713
   Jiang J, 2006, ORAL SURG ORAL MED O, V102, P698, DOI 10.1016/j.tripleo.2006.02.011
   Johnson DL, 2009, J PERIODONTOL, V80, P648, DOI 10.1902/jop.2009.070420
   Kawase T, 2002, J PERIODONTAL RES, V37, P255, DOI 10.1034/j.1600 0765.2002.01615.x
   Kawase T, 2001, J PERIODONTAL RES, V36, P367, DOI 10.1034/j.1600 0765.2001.360604.x
   Kawase T, 2000, J PERIODONTAL RES, V35, P291, DOI 10.1034/j.1600 0765.2000.035005291.x
   Kawashima Y, 2002, J PERIODONTAL RES, V37, P223, DOI 10.1034/j.1600 0765.2002.01608.x
   Klein MO, 2007, CLIN ORAL IMPLAN RES, V18, P40, DOI 10.1111/j.1600 0501.2006.01279.x
   Koike Y, 2005, J PERIODONTAL RES, V40, P385, DOI 10.1111/j.1600 0765.2005.00819.x
   Lee AZ, 2008, ORAL SURG ORAL MED O, V106, P133, DOI 10.1016/j.tripleo.2008.01.030
   Lyngstadaas SP, 2001, J CLIN PERIODONTOL, V28, P181, DOI 10.1034/j.1600 051x.2001.028002181.x
   Maycock J, 2002, CONNECT TISSUE RES, V43, P472, DOI 10.1080/03008200290000880
   Mizutani S, 2003, ORAL DIS, V9, P210, DOI 10.1034/j.1601 0825.2003.02876.x
   Mumulidu A, 2007, J CHROMATOGR B, V857, P210, DOI 10.1016/j.jchromb.2007.07.017
   Nagano T, 2004, J PERIODONTAL RES, V39, P249, DOI 10.1111/j.1600 0765.2004.00733.x
   Pischon N, 2006, ORAL SURG ORAL MED O, V102, P551, DOI 10.1016/j.tripleo.2005.08.040
   Rausch fan XH, 2008, DENT MATER, V24, P102, DOI 10.1016/j.dental.2007.03.001
   Rincon JC, 2005, ARCH ORAL BIOL, V50, P1047, DOI 10.1016/j.archoralbio.2005.04.006
   Sakallioglu U, 2004, BIOMATERIALS, V25, P1831, DOI 10.1016/S0142 9612(03)00468 X
   Schlueter SR, 2007, J PERIODONTOL, V78, P141, DOI 10.1902/jop.2007.060111
   Schwartz Z, 2000, J PERIODONTOL, V71, P1287, DOI 10.1902/jop.2000.71.8.1287
   Sculean A, 2008, J CLIN PERIODONTOL, V35, P817, DOI 10.1111/j.1600 051X.2008.01295.x
   Tonetti MS, 2004, J CLIN PERIODONTOL, V31, P1092, DOI 10.1111/j.1600 051X.2004.00615.x
   Veis A, 2003, CELL MOL LIFE SCI, V60, P38, DOI 10.1007/s000180300003
   Venezia E, 2004, CRIT REV ORAL BIOL M, V15, P382, DOI 10.1177/154411130401500605
   Yuan K, 2003, J CLIN PERIODONTOL, V30, P732, DOI 10.1034/j.1600 051X.2003.00413.x
   Yukna RA, 2000, J PERIODONTOL, V71, P752, DOI 10.1902/jop.2000.71.5.752
NR 32
TC 12
Z9 13
U1 0
U2 7
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1079 2104
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD JUN
PY 2010
VL 109
IS 6
BP 924
EP 931
DI 10.1016/j.tripleo.2010.01.007
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 592UH
UT WOS:000277405500035
PM 20399692
DA 2025 08 17
ER

PT J
AU Aldea, M
   Potara, M
   Soritau, O
   Florian, IS
   Florea, A
   Nagy Simone, T
   Pileczki, V
   Brie, I
   Maniu, D
   Kacso, G
AF Aldea, Mihaela
   Potara, Monica
   Soritau, Olga
   Florian, Ioan Stefan
   Florea, Adrian
   Nagy Simone, Timea
   Pileczki, Valentina
   Brie, Ioana
   Maniu, Dana
   Kacso, Gabriel
TI Chitosan capped gold nanoparticles impair radioresistant glioblastoma
   stem like cells
SO JOURNAL OF BUON
LA English
DT Article
DE cancer stem cells; chitosan; glioblastoma; gold nanoparticles;
   radiotherapy
ID CANCER; CHEMOTHERAPY; TEMOZOLOMIDE; ENHANCEMENT; METFORMIN; DELIVERY;
   TARGETS; THERAPY
AB Purpose: Glioblastoma is a rapidly evolving lethal disease mainly due to its highly chemo  and radioresistant glioblastoma stem cells (GSCs). Herein, we tested if chitosan capped gold nanoparticles (Chit GNPs) may overcome the limitations of drug concentrations by increased cell internalization in GSCs and if such GNPs could enhance the response to irradiation.
   Methods: Chitosan was used for Chit GNP synthesis as a reducing and stabilizing agent. Chit GNPs were characterized by spectroscopy, dark field, transmission electron microscopy and zeta potential measurements. Patient derived GSCs and human osteoblasts were treated with increasing concentrations of nanoparticles and irradiated The uptake and cytotoxicity of Chit GNPs were compared to that of uncoated GNPs.
   Results: The positively charged, 26 nm sized, spherical Chit GNPs, showed a huge intracellular accumulation into the cytosol, lysosomes and near the nucleus, whereas no uncoated GNPs were internalized within GSCs. Surprisingly, Chit GNPs were highly cytotoxic for GSCs irrespective of cell irradiation, that failed to add an additional benefit when combined with Chit GNPs/GNPs. Moreover, Chit GNPs were selectively cytotoxic for GSCs and did not affect the normal cells, despite an increased nanoparticle internalization.
   Conclusions: The important Chit GNP internalization and their selective cytotoxicity for GSCs make this compound a potential novel anticancer agent and a promising backbone for drug delivery in glioblastoma.
C1 [Aldea, Mihaela; Brie, Ioana; Kacso, Gabriel] Iuliu Hatieganu Univ Med & Pharm, Dept Med Oncol & Radiotherapy, Cluj Napoca, Romania.
   [Potara, Monica; Nagy Simone, Timea] Babes Bolyai Univ, Nanobiophoton & Laser Microscopy Ctr, Interdisciplinary Res Bionanosci, Cluj Napoca, Romania.
   [Potara, Monica; Nagy Simone, Timea] Babes Bolyai Univ, Fac Phys, Cluj Napoca, Romania.
   [Soritau, Olga; Brie, Ioana] Ion Chiricuta Canc Inst, Dept Tumor Biol, Cluj Napoca, Romania.
   [Florian, Ioan Stefan] Iuliu Hatieganu Univ Med & Pharm, Dept Neurosurg, Cluj Napoca, Romania.
   [Florea, Adrian] Iuliu Hatieganu Univ Med & Pharm, Dept Cell & Mol Biol, Cluj Napoca, Romania.
   [Pileczki, Valentina] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania.
   [Maniu, Dana] Babes Bolyai Univ, Dept Biomol Phys, Fac Phys, Cluj Napoca, Romania.
   [Kacso, Gabriel] Amethyst Radiotherapy Ctr, Cluj Napoca, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy; Babes Bolyai
   University from Cluj; Babes Bolyai University from Cluj; Oncology
   Institute Prof. Dr. Ion Chiricuta; Iuliu Hatieganu University of
   Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy;
   Iuliu Hatieganu University of Medicine & Pharmacy; Babes Bolyai
   University from Cluj
RP Aldea, M (通讯作者)，Republicii Str 34 36, Cluj Napoca 400012, Romania.
EM mihaela.aldea1@gmail.com
RI Florian, Ioan Stefan/D 5934 2016; Aldea, Mihaela/MDT 8065 2025; Potara,
   Monica/C 6317 2012; Kacso, Gabriel/AEE 3611 2022; Pileczki,
   Valentina/ABB 6273 2020; Maniu, Dana/GQP 1378 2022; Florea,
   Adrian/L 2600 2019; Florian, Ioan/D 5934 2016
OI Florian, Ioan Stefan/0000 0001 7127 0946; Aldea,
   Mihaela/0000 0001 7685 051X; Potara, Monica/0000 0003 4901 2400; KACSO,
   Gabriel/0000 0003 2245 3302; Florea, Adrian/0000 0002 0898 7626; Maniu,
   Dana/0000 0002 3759 6544; 
FU EUFISCDI National Grant [PNII RU TE 2014 4 0225]; University of Medicine
   and Pharmacy (Cluj Napoca) [7690/2/15.04.2016]
FX This research was financially supported by an EUFISCDI National Grant  
   PNII RU TE 2014 4 0225 (ENERGY), Competition for Young Teams, Program
   for Human Resources. M.A. was also financed by a research grant for PhD
   Fellows (contract number 7690/2/15.04.2016) offered by the University of
   Medicine and Pharmacy (Cluj Napoca).
CR Aldea M, 2016, PHARM RES DORDR, V33, P2059, DOI 10.1007/s11095 016 1947 8
   Aldea M, 2014, TUMOR BIOL, V35, P5101, DOI 10.1007/s13277 014 1676 8
   Aldea MD, 2014, J BUON, V19, P502
   Amidi M, 2010, ADV DRUG DELIVER REV, V62, P1, DOI 10.1016/j.addr.2009.12.006
   Auffinger B, 2014, CELL DEATH DIFFER, V21, P1119, DOI 10.1038/cdd.2014.31
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bhumkar DR, 2007, PHARM RES DORDR, V24, P1415, DOI 10.1007/s11095 007 9257 9
   Boyles MSP, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0146 9
   Butterworth KT, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/29/295101
   Chen HY, 2016, ONCOTARGET, V7, P42485, DOI 10.18632/oncotarget.9890
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chithrani DB, 2010, RADIAT RES, V173, P719, DOI 10.1667/RR1984.1
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510
   Jain S, 2014, RADIOTHER ONCOL, V110, P342, DOI 10.1016/j.radonc.2013.12.013
   Joh DY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062425
   Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115
   Liu CJ, 2010, PHYS MED BIOL, V55, P931, DOI 10.1088/0031 9155/55/4/002
   McMahon SJ, 2011, SCI REP UK, V1, DOI 10.1038/srep00018
   Munthe S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155106
   Potara M, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957 4484/20/31/315602
   Rahman WN, 2009, NANOMED NANOTECHNOL, V5, P136, DOI 10.1016/j.nano.2009.01.014
   Rao W, 2015, ACS NANO, V9, P5725, DOI 10.1021/nn506928p
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470 2045(09)70025 7
   Tomuleasa C, 2010, J BUON, V15, P583
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
NR 26
TC 7
Z9 7
U1 0
U2 11
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107 0625
EI 2241 6293
J9 J BUON
JI J. BUON
PD MAY JUN
PY 2018
VL 23
IS 3
BP 800
EP 813
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GJ3BZ
UT WOS:000435151300039
PM 30003755
DA 2025 08 17
ER

PT J
AU Haydock, SF
   Appleyard, AN
   Mironenko, T
   Lester, J
   Scott, N
   Leadlay, PF
AF Haydock, SF
   Appleyard, AN
   Mironenko, T
   Lester, J
   Scott, N
   Leadlay, PF
TI Organization of the biosynthetic gene cluster for the macrolide
   concanamycin A In Streptomyces neyagawaensis ATCC 27449
SO MICROBIOLOGY SGM
LA English
DT Article
ID SUBSTRATE SPECIFICITY; GENOME SEQUENCE; DOMAINS; AVERMITILIS; INHIBITOR;
   CLONING; ACID; DNA
AB The macrolide antibiotic concanamycin A has been identified as an exceptionally potent inhibitor of the vacuolar (V type) ATPase. Such compounds have been mooted as the basis of a potential drug treatment for osteoporosis, since the V ATPase is involved in the osteoclast mediated bone resorption that underlies this common condition. To enable combinatorial engineering of altered concanamycins, the biosynthetic gene cluster governing the biosynthesis of concanamycin A has been cloned from Streptomyces neyagawaensis and shown to span a region of over 100 kbp of contiguous DNA. An efficient transformation system has been developed for S. neyagawaensis and used to demonstrate the role of the cloned locus in the formation of concanamycin A. Sequence analysis of the 28 ORFs in the region has revealed key features of the biosynthetic pathway, in particular the biosynthetic origin of portions of the backbone, which arise from the unusual polyketide building blocks ethylmalonyl CoA and methoxymalonyl ACP, and the origin of the pendant deoxysugar moiety 4' O carbamoyl 2' deoxyrhamnose, as well as the presence of a modular polyketide synthase (PKS) encoded by six giant ORFs. Examination of the methoxymalonyl specific acyltransferase (AT) domains has led to recognition of an amino acid sequence motif which can be used to distinguish methylmalonyl CoA  from methoxymalonyl ACP specific AT domains in natural PKSs.
C1 Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England.
C3 University of Cambridge
RP Haydock, SF (通讯作者)，Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.
EM stephen.haydock@addenbrookes.nhs.uk
OI Leadlay, Peter/0000 0002 3247 509X
CR ARCAMONE F. M., 1959, GIORN MICROBIOL, V7, P207
   Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a
   BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378 1119(92)90627 2
   BINDSEIL KH, 1984, LIEBIGS ANN CHEM, P305
   Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992
   Butler AR, 2001, MICROBIOL UK, V147, P795, DOI 10.1099/00221287 147 4 795
   Caffrey P, 2003, CHEMBIOCHEM, V4, P654, DOI 10.1002/cbic.200300581
   Decker H, 1996, FEMS MICROBIOL LETT, V141, P195, DOI 10.1111/j.1574 6968.1996.tb08384.x
   Del Vecchio F, 2003, J IND MICROBIOL BIOT, V30, P489, DOI 10.1007/s10295 003 0062 0
   Dröse S, 2001, BIOCHEMISTRY US, V40, P2816, DOI 10.1021/bi001759q
   GOETZ MA, 1985, J ANTIBIOT, V38, P161, DOI 10.7164/antibiotics.38.161
   HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378 1119(94)00750 M
   Haydock SF, 2004, J BIOTECHNOL, V113, P55, DOI 10.1016/j.jbiotec.2004.03.022
   HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014 5793(95)01119 Y
   KIESER T, 2000, PRACTICAL STREPTOMYC
   KINASHI H, 1984, J ANTIBIOT, V37, P1333, DOI 10.7164/antibiotics.37.1333
   Laitala Leinonen T, 1999, J CELL SCI, V112, P3657
   Lau J, 1999, BIOCHEMISTRY US, V38, P1643, DOI 10.1021/bi9820311
   LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461
   Liras P, 2000, APPL MICROBIOL BIOT, V54, P467, DOI 10.1007/s002530000420
   MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378 1119(92)90603 M
   MUROI M, 1993, CELL STRUCT FUNCT, V18, P139, DOI 10.1247/csf.18.139
   Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198
   OMURA S, 1982, J ANTIBIOT, V35, P1632, DOI 10.7164/antibiotics.35.1632
   Paget MSB, 1999, J BACTERIOL, V181, P204, DOI 10.1128/JB.181.1.204 211.1999
   Rascher A, 2003, FEMS MICROBIOL LETT, V218, P223, DOI 10.1016/S0378 1097(02)01148 5
   Reeves CD, 2001, BIOCHEMISTRY US, V40, P15464, DOI 10.1021/bi015864r
   Reeves CD, 2002, J BIOL CHEM, V277, P9155, DOI 10.1074/jbc.M111915200
   Ruan XA, 1997, GENE, V203, P1, DOI 10.1016/S0378 1119(97)00450 2
   SAMBROOK J, 1989, MOL CLONING LAB MANU, V1
   Schuhmann T, 2004, J ANTIBIOT, V57, P655, DOI 10.7164/antibiotics.57.655
   SEKIASANO M, 1994, J ANTIBIOT, V47, P1226, DOI 10.7164/antibiotics.47.1226
   Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g
   Steffensky M, 2000, ANTIMICROB AGENTS CH, V44, P1214, DOI 10.1128/AAC.44.5.1214 1222.2000
   Summers RG, 1997, MICROBIOL UK, V143, P3251, DOI 10.1099/00221287 143 10 3251
   WESTLEY JW, 1984, J ANTIBIOT, V37, P1738, DOI 10.7164/antibiotics.37.1738
   Wu K, 2000, GENE, V251, P81, DOI 10.1016/S0378 1119(00)00171 2
   Yu TW, 2002, P NATL ACAD SCI USA, V99, P7968, DOI 10.1073/pnas.092697199
NR 38
TC 76
Z9 85
U1 0
U2 13
PU MICROBIOLOGY SOC
PI LONDON
PA 14 16 MEREDITH ST, LONDON, ENGLAND
SN 1350 0872
EI 1465 2080
J9 MICROBIOL SGM
JI Microbiology (UK)
PD OCT
PY 2005
VL 151
BP 3161
EP 3169
DI 10.1099/mic.0.28194 0
PN 10
PG 9
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA 973VS
UT WOS:000232551300004
PM 16207901
OA Bronze
DA 2025 08 17
ER

PT J
AU Veltman, JD
   Lambers, MEH
   van Nimwegen, M
   Hendriks, RW
   Hoogsteden, HC
   Hegmans, JPJJ
   Aerts, JGJV
AF Veltman, J. D.
   Lambers, M. E. H.
   van Nimwegen, M.
   Hendriks, R. W.
   Hoogsteden, H. C.
   Hegmans, J. P. J. J.
   Aerts, J. G. J. V.
TI Zoledronic acid impairs myeloid differentiation to tumour associated
   macrophages in mesothelioma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE Zoledronic acid; myeloid differentiation; macrophages; myeloid derived
   suppressor cells; malignant mesothelioma
ID DELTA T CELLS; LIPOSOME MEDIATED DEPLETION; CHORIONIC GONADOTROPIN;
   SUPPRESSOR CELLS; NITRIC OXIDE; BREAST; BONE; BISPHOSPHONATES; PROSTATE;
   INHIBITION
AB BACKGROUND: Suppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper efficacy of antitumour therapies. The amino bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent studies showed that ZA prolongs disease free survival in cancer patients. The exact mechanism is a topic of debate; it has been suggested that ZA targets tumour associated macrophages (TAMs).
   METHODS: We investigate the role of ZA on the myeloid differentiation to TAMs in murine mesothelioma in vivo and in vitro. Mice were intraperitoneally inoculated with a lethal dose of mesothelioma tumour cells and treated with ZA to determine the effects on myeloid differentiation and survival.
   RESULTS: We show that ZA impaired myeloid differentiation. Inhibition of myeloid differentiation led to a reduction in TAMs, but the number of immature myeloid cells with myeloid derived suppressor cell (MDSC) characteristics was increased. In addition, ZA affects the phenotype of macrophages leading to reduced level of TAM associated cytokines in the tumour microenvironment. No improvement of survival was observed.
   CONCLUSION: We conclude that ZA leads to a reduction in macrophages and impairs polarisation towards an M2 phenotype, but this was associated with an increase in the number of immature myeloid cells, which might diminish the effects of ZA on survival. British Journal of Cancer (2010) 103, 629 641. doi:10.1038/sj.bjc.6605814 www.bjcancer.com Published online 27 July 2010 (C) 2010 Cancer Research UK
C1 [Veltman, J. D.; Lambers, M. E. H.; van Nimwegen, M.; Hendriks, R. W.; Hoogsteden, H. C.; Hegmans, J. P. J. J.; Aerts, J. G. J. V.] Erasmus MC, Dept Pulm Med, NL 3000 CA Rotterdam, Netherlands.
   [Aerts, J. G. J. V.] Amphia Hosp, Dept Pulm Dis, NL 4818 CK Breda, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Amphia Hospital
RP Aerts, JGJV (通讯作者)，Erasmus MC, Dept Pulm Med, POB 2040, NL 3000 CA Rotterdam, Netherlands.
EM JAerts@amphia.nl
RI Aerts, Joachim/I 7885 2018
FU Stichting Asbestkanker Rotterdam
FX This study was financially supported by 'Stichting Asbestkanker
   Rotterdam'.
CR Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004
   Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600 065X.2008.00607.x
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668
   Bronte V, 2001, J IMMUNOTHER, V24, P431, DOI 10.1097/00002371 200111000 00001
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Chen YJ, 2009, IMMUNOPHARM IMMUNOT, V31, P499, DOI 10.1080/08923970902814103
   CLAASSEN E, 1992, RES IMMUNOL, V143, P235, DOI 10.1016/S0923 2494(92)80173 I
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Coffelt SB, 2009, BBA REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   COSCIA M, 2009, J CELL MOL IN PRESS
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097 0142(20000615)88:12+<3080::AID CNCR27>3.0.CO;2 W
   Dolcetti L, 2010, EUR J IMMUNOL, V40, P22, DOI 10.1002/eji.200939903
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gainford MC, 2005, BMJ BRIT MED J, V330, P769, DOI 10.1136/bmj.330.7494.769
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2009, CURR CANCER DRUG TAR, V9, P824, DOI 10.2174/156800909789760267
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Greifenberg V, 2009, EUR J IMMUNOL, V39, P2865, DOI 10.1002/eji.200939486
   Hegmans JPJJ, 2006, EUR RESPIR J, V27, P1086, DOI 10.1183/09031936.06.00135305
   Hegmans LPJJ, 2005, AM J RESP CRIT CARE, V171, P1168, DOI 10.1164/rccm.200501 0570C
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Kunzmann V, 2000, BLOOD, V96, P384
   Kusmartsev S, 2002, CANCER IMMUNOL IMMUN, V51, P293, DOI 10.1007/s00262 002 0280 8
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   MILLS CD, 1992, J IMMUNOL, V149, P2709
   Miselis NR, 2008, MOL CANCER THER, V7, P788, DOI 10.1158/1535 7163.MCT 07 0579
   Miyagawa F, 2001, J IMMUNOL, V166, P5508, DOI 10.4049/jimmunol.166.9.5508
   Montague R, 2004, EUR UROL, V46, P389, DOI 10.1016/j.eururo.2004.04.022
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nagaraj S, 2007, ADV EXP MED BIOL, V601, P213
   Ohtsuka Y, 2005, BLOOD, V106, P3134, DOI 10.1182/blood 2005 03 0972
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Pandya KJ, 2010, LUNG CANCER, V67, P330, DOI 10.1016/j.lungcan.2009.04.020
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   RAJPAR S, 2010, ANN ONCOL IN PRESS
   Rössner S, 2005, EUR J IMMUNOL, V35, P3533, DOI 10.1002/eji.200526172
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Sakaguchi S, 2009, INT IMMUNOL, V21, P1105, DOI 10.1093/intimm/dxp095
   Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008 5472.CAN 08 1327
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Santini D, 2010, CURR CANCER DRUG TAR, V10, P46, DOI 10.2174/156800910790980223
   Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011
   Stathopoulos GT, 2008, AM J RESP CRIT CARE, V178, P50, DOI 10.1164/rccm.200710 1513OC
   Tsagozis P, 2008, CANCER IMMUNOL IMMUN, V57, P1451, DOI 10.1007/s00262 008 0482 9
   Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Wan H, 2007, J LEUKOCYTE BIOL, V82, P926, DOI 10.1189/jlb.0207092
   Wan H, 2009, J LEUKOCYTE BIOL, V86, P361, DOI 10.1189/jlb.0208126
   Weigert A, 2008, NITRIC OXIDE BIOL CH, V19, P95, DOI 10.1016/j.niox.2008.04.021
   Wolf AM, 2006, HAEMATOLOGICA, V91, P1165
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
   ZAGHLOUL MS, 2010, INT J CLIN IN PRESS
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
NR 71
TC 88
Z9 92
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 24
PY 2010
VL 103
IS 5
BP 629
EP 641
DI 10.1038/sj.bjc.6605814
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 643IB
UT WOS:000281287700006
PM 20664588
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhou, F
   Han, SY
   Zhou, N
   Zheng, WX
   Li, PP
AF Zhou, Fei
   Han, Shuyan
   Zhou, Ning
   Zheng, Wenxian
   Li, Pingping
TI Effects of modified Shu Gan Liang Xue decoction combined with
   anastrozole on osteoblastic proliferation and differentiation of
   MC3T3 E1 cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE modified Shu Gan Liang Xue decoction; osteoblast like cell; alkaline
   phosphatase; osteocalcin; mineralization
ID EARLY BREAST CANCER; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITORS; BONE
   LOSS; ZOLEDRONIC ACID; BIOCHEMICAL MARKERS; GENE EXPRESSION; IN VIVO;
   ZO FAST; THERAPY
AB Aromatase inhibitors (AIs) are widely used in the treatment of hormone dependent breast cancer and as a result, aromatase inhibitor associated bone loss (AIBL) has become a major concern amongst patients receiving AT treatment. Modified Shu Gan Liang Xue decoction (mSGLXD), a clinical prescription, has been used for ameliorating AIBL in patients with breast cancer for decades and has achieved good clinical efficacy. However, the mechanism underlying how mSGLXD influences bone homeostasis and alleviates AIBL has remained elusive. In the present study, mSGLXD was supplemented with Rhizoma Drynariae containing phytoestrogens, and the safety of mSGLXD was evaluated. mSGLXD did not possess estrogenic activity and significantly inhibited the proliferation of estrogen receptor positive breast cancer cell line MCF 7, which suggested that mSGLXD was safe for postmenopausal patients with breast cancer. Subsequently, the effects of mSGLXD alone or in combination with anastrozole on osteoblastic MC3T3 E1 cell proliferation and differentiation were investigated. Cell counting kit 8, reverse transcription polymerase chain reaction and biochemical methods, such as ELISA and alizarin red S staining, were used in the present study. It was revealed that mSGLXD not only stimulated MC3T3 E1 cell proliferation, but also upregulated alkaline phosphatase and osteocalcin gene and protein expression levels. High concentrations of anastrozole (10 or 100 mu mol/l) markedly inhibited MC3T3 E1 cell proliferation, but this inhibitory effect was attenuated by mSGLXD. Furthermore, mSGLXD increased MC3T3 E1 cell mineralization following beta glycerophosphate and ascorbic acid induction. Therefore, the results of the present study suggested that mSGLXD may be a promising adjuvant therapy, with high safety and efficacy, for the prevention and treatment of AIBL in patients with breast cancer who receive AT treatment.
C1 [Zhou, Fei; Han, Shuyan; Zhou, Ning; Zheng, Wenxian; Li, Pingping] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Tradit Res, Dept Integrated Tradit Chinese & Western Med, Beijing 100142, Peoples R China.
C3 Peking University
RP Li, PP (通讯作者)，Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Tradit Res, Dept Integrated Tradit Chinese & Western Med, 52 Fucheng Rd, Beijing 100142, Peoples R China.
EM lppmal@163.com
FU Beijing Natural Science Foundation (Beijing, China) [7112026]
FX The present study was funded by the Beijing Natural Science Foundation
   (grant no. 7112026; Beijing, China).
CR Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470 2045(02)00777 5
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Brueggemeier RW, 2005, ENDOCR REV, V26, P331, DOI 10.1210/er.2004 0015
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   Chang EJ, 2003, ARCH PHARM RES, V26, P620, DOI 10.1007/BF02976711
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470 2045(10)70257 6
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307
   Ettinger B, 1998, J CLIN ENDOCR METAB, V83, P2239, DOI 10.1210/jc.83.7.2239
   Fu XS, 2011, CHINESE J CANCER RES, V23, P208, DOI 10.1007/s11670 011 0208 y
   Geisler J, 1998, CLIN CANCER RES, V4, P2089
   Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751
   Hlaing TT, 2014, ANN CLIN BIOCHEM, V51, P189, DOI 10.1177/0004563213515190
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Keinan Boker L, 2004, AM J CLIN NUTR, V79, P282
   Kenny AM, 2002, J REPROD MED, V47, P63
   Kim EJ, 2013, BIOL TRACE ELEM RES, V152, P105, DOI 10.1007/s12011 012 9593 4
   Kwong A, 2008, BREAST, V17, P42, DOI 10.1016/j.breast.2007.06.005
   Lee SH, 2014, OSTEOPOROSIS INT, V25, P1131, DOI 10.1007/s00198 013 2575 3
   Lester JE, 2008, CLIN CANCER RES, V14, P6336, DOI 10.1158/1078 0432.CCR 07 5101
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Llombart A, 2012, CLIN BREAST CANCER, V12, P40, DOI 10.1016/j.clbc.2011.08.002
   McCloskey E, 2006, EUR J CANCER, V42, P1044, DOI 10.1016/j.ejca.2005.10.028
   Miller WR, 2001, J STEROID BIOCHEM, V79, P93, DOI 10.1016/S0960 0760(01)00148 0
   Nabholtz JM, 2003, EUR J CANCER, V39, P1684, DOI 10.1016/S0959 8049(03)00326 5
   Pang WY, 2012, J FOOD DRUG ANAL, V20, P265
   Pant S, 2008, DRUGS, V68, P2591, DOI 10.2165/0003495 200868180 00005
   Peeters PHM, 2003, BREAST CANCER RES TR, V77, P171, DOI 10.1023/A:1021381101632
   Perez EA, 2007, ANN ONCOL, V18, P26, DOI 10.1093/annonc/mdm263
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246
   Speirs V, 1999, BRIT J CANCER, V81, P690, DOI 10.1038/sj.bjc.6690749
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   Trock BJ, 2006, JNCI J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Wu CX, 2008, CHINESE J EXPT TRADI, V14, P31
   Xue D, 2011, CHINESE J CANCER RES, V23, P74, DOI 10.1007/s11670 011 0074 7
   Zhang Y, 2009, J ETHNOPHARMACOL, V126, P345, DOI 10.1016/j.jep.2009.08.016
NR 45
TC 2
Z9 3
U1 0
U2 22
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2015
VL 11
IS 3
BP 1639
EP 1646
DI 10.3892/mmr.2014.2962
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CD2OA
UT WOS:000350917700012
PM 25405542
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Anthwal, N
   Urban, DJ
   Luo, ZX
   Sears, KE
   Tucker, AS
AF Anthwal, Neal
   Urban, Daniel J.
   Luo, Zhe Xi
   Sears, Karen E.
   Tucker, Abigail S.
TI Meckel's cartilage breakdown offers clues to mammalian middle ear
   evolution
SO NATURE ECOLOGY & EVOLUTION
LA English
DT Article
ID BONE; OSTEOCLASTS; EXPRESSION; FOS
AB A key transformation in mammalian ear evolution was incorporation of the primary jaw Joint of premammalian synapsids into the definitive mammalian middle ear of living mammals. This evolutionary transition occurred in two steps, starting with a partial or 'transitional' mammalian middle ear in which the ectotympanic and malleus were still connected to the mandible by an ossified Meckel's cartilage (MC), as observed in many Mesozoic mammals. This was followed by MC breakdown, freeing the ectotympanic and the malleus from the mandible and creating the definitive mammalian middle ear. Here we report new findings on the role of chondroclasts in MC breakdown, shedding light on how therian mammals lost the part of the MC connecting the ear to the Jaw. Genetic or pharmacological loss of clast cells in mice and opossums leads to persistence of embryonic MC beyond Juvenile stages, with MC ossification in mutant mice. The persistent MC causes a distinctive groove on the postnatal mouse dentary. This morphology phenocopies the ossified MC and Meckelian groove observed in Mesozoic mammals. Clast cell recruitment to MC is not observed in reptiles, where MC persists as a cartilaginous structure. We hypothesize that ossification of MC is an ancestral feature of mammaliaforms, and that a shift in the timing of clast cell recruitment to MC prior to its ossification is a key developmental mechanism for the evolution of the definitive mammalian middle ear in extant therians.
C1 [Anthwal, Neal; Tucker, Abigail S.] Kings Coll London, Guys Hosp, Dept Craniofacial Dev & Stem Cell Biol, Floor 27,Guys Tower, London SE1 9RT, England.
   [Urban, Daniel J.; Sears, Karen E.] Univ Illinois, Sch Integrat Biol, 505 South Goodwin Ave, Urbana, IL 61801 USA.
   [Luo, Zhe Xi] Univ Chicago, Dept Organismal Biol & Anat, 1025 E 57Th St, Chicago, IL 60637 USA.
   [Sears, Karen E.] Univ Illinois, Carl Woese Inst Genom Biol, 1206 West Gregory Dr, Urbana, IL 61801 USA.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; University of Illinois System; University of Illinois
   Urbana Champaign; University of Chicago; University of Illinois System;
   University of Illinois Urbana Champaign
RP Tucker, AS (通讯作者)，Kings Coll London, Guys Hosp, Dept Craniofacial Dev & Stem Cell Biol, Floor 27,Guys Tower, London SE1 9RT, England.
EM abigail.tucker@kcl.ac.uk
RI ; Tucker, Abigail/K 1788 2016; Luo, Zhe XI/AAU 2263 2021
OI Sears, Karen/0000 0001 9744 9602; Urban, Daniel/0000 0002 2672 8468;
   Tucker, Abigail/0000 0001 8871 6094; 
FU Leverhulme Trust [RPG 2013 070]; Wellcome Trust [102889/Z/13/2,
   102889/Z/13/Z]; NSF/EDEN Research Exchange Grant [IOS 0955517]; NSF
   Graduate Research Fellowship [2013136301]; Doctoral Dissertation
   Improvement Grant [1406802]
FX We thank C. Healy (KCL) and L. Yin (UIUC) for support with mu CT, E.
   Popa (King's College London, KCL) for assistance in processing tissue,
   J.M. Fons (KCL) for injection of newborn mice. A. Neander (University of
   Chicago) for graphics assistance, A. Grigoriadis (KCL) (or supplying the
   c Fos mutant mice and in situ probes, and J. Turner and E. Decarpentrie
   (Francis Crick Institute) for supplying opossum pups. For this project,
   N.A. was supported by the Leverhulme Trust (RPG 2013 070) and the
   Wellcome Trust (102889/Z/13/2) and NSF/EDEN Research Exchange Grant (IOS
   0955517) A.S.T. is funded by the Wellcome Trust (102889/Z/13/Z). D.J.U.
   was supported by a NSF Graduate Research Fellowship (2013136301) and
   K.E.S. by a Doctoral Dissertation Improvement Grant (1406802).
CR Abzhanov A, 2013, TRENDS GENET, V29, P712, DOI 10.1016/j.tig.2013.09.004
   ALLIN EF, 1992, EVOLUTIONARY BIOLOGY OF HEARING, P587
   Amano O, 2010, J ORAL BIOSCI, V52, P125, DOI 10.2330/joralbiosci.52.125
   Amin S, 2006, DEV DYNAM, V235, P1326, DOI 10.1002/dvdy.20666
   Anthwal N., 2012, CLONE BONE SYNERGY M, P207
   Anthwal N, 2013, J ANAT, V222, P147, DOI 10.1111/j.1469 7580.2012.01526.x
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Ealba EL, 2015, DEV BIOL, V408, P151, DOI 10.1016/j.ydbio.2015.10.001
   Gaupp E., 1913, ARCH ANATOMIE ENTWIC
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hall Hall BK. BK., Bones and cartilage: Developmental and evolutionary skeletal biology
   Holliday CM, 2013, GEOL SOC SPEC PUBL, V379, P555, DOI 10.1144/SP379.2
   Ji Q, 2009, SCIENCE, V326, P278, DOI 10.1126/science.1178501
   Knowles HJ, 2012, VIRCHOWS ARCH, V461, P205, DOI 10.1007/s00428 012 1274 3
   LEWINSON D, 1992, ANAT REC, V233, P504, DOI 10.1002/ar.1092330403
   Luo ZX, 2007, NATURE, V450, P1011, DOI 10.1038/nature06277
   Luo ZX, 2015, P NATL ACAD SCI USA, V112, pE7101, DOI 10.1073/pnas.1519387112
   Luo ZX, 2011, ANNU REV ECOL EVOL S, V42, P355, DOI 10.1146/annurev ecolsys 032511 142302
   Maier W, 2016, J ANAT, V228, P270, DOI 10.1111/joa.12379
   Martin T, 2015, NATURE, V526, P380, DOI 10.1038/nature14905
   Meng J, 2003, ZOOL J LINN SOC LOND, V138, P431, DOI 10.1046/j.1096 3642.2003.00064.x
   Meng J, 2011, NATURE, V472, P181, DOI 10.1038/nature09921
   Popa E. M., 2016, J ANAT
   Raff RA, 2007, NAT REV GENET, V8, P911, DOI 10.1038/nrg2225
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rowe T, 1996, SCIENCE, V273, P651, DOI 10.1126/science.273.5275.651
   Royce BF, 2007, ANN NY ACAD SCI, V1116, P245, DOI 10.1196/annals.1402.084
   Sakakura Y, 2005, J ANAT, V207, P325, DOI 10.1111/j.1469 7580.2005.00466.x
   Sakakura Y, 2010, J ORAL BIOSCI, V52, P143, DOI 10.2330/joralbiosci.52.143
   Sánchez Villagra MR, 2002, J MORPHOL, V251, P219, DOI 10.1002/jmor.1085
   Smith KK, 2006, DEV DYNAM, V235, P1181, DOI 10.1002/dvdy.20676
   Takechi M, 2010, J EXP ZOOL PART B, V314B, P417, DOI 10.1002/jez.b.21347
   Urban D. J. U., P R SOC B IN PRESS
   Wang Y, 2013, DEV BIOL, V381, P301, DOI 10.1016/j.ydbio.2013.07.016
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wilson J, 2004, DEV BIOL, V266, P138, DOI 10.1016/j.ydbio.2003.10.012
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
NR 37
TC 45
Z9 47
U1 0
U2 33
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2397 334X
J9 NAT ECOL EVOL
JI Nat. Ecol. Evol.
PD APR
PY 2017
VL 1
IS 4
AR 0093
DI 10.1038/s41559 017 0093
PG 6
WC Ecology; Evolutionary Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Evolutionary Biology
GA FO8XM
UT WOS:000417171500015
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, YB
   Wang, ZM
   Wang, YK
   Huang, Q
   Ren, C
   Sun, L
   Wang, Q
   Li, M
   Liu, HL
   Li, Z
   Zhang, K
   Ma, T
   Lu, Y
AF Xu, Yibo
   Wang, Zhimeng
   Wang, Yakang
   Huang, Qiang
   Ren, Cheng
   Sun, Liang
   Wang, Qian
   Li, Ming
   Liu, Hongliang
   Li, Zhong
   Zhang, Kun
   Ma, Teng
   Lu, Yao
TI Identification of differentially expressed autophagy genes associated
   with osteogenic differentiation in human bone marrow mesenchymal stem
   cells
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Autophagy; differentially expressed genes; mesenchymal stem cells;
   osteoblast differentiation
ID R PACKAGE; PATTERNS; NDRG4
AB Background: Mesenchymal stem cells derived from human tissues have been widely used for tissue re generation because of their strong self renewal capacity and multi potential properties. Autophagy plays a vital role in maintaining bone homeostasis. However, the mechanism underlying this role for autophagy in the osteogenic differentiation of mesenchymal stem cells remains to be elucidated. Methods: Two microarray datasets were down loaded from the GEO database. Fourteen bone marrow mesenchymal stem cell samples comprising control and induction groups were selected to identify differentially expressed autophagy related genes via multiple bioinformatics approaches, followed by functional analysis. Interactions among differentially expressed autophagy genes, miRNAs, and transcription factors were analyzed and visualized using Cytoscape software. The association between hub differentially expressed genes and autophagy was validated by qRT PCR. Results: Ten autophagy related genes (including VPS8, NDRG4, and CYBB) were identified as osteogenic hub genes. Correlation analysis revealed that CYBB was highly correlated with the sensitivity to multiple drugs, such as imexon, megestrol acetate, and isotretinoin. The regulatory network displayed a complex connection among miRNAs, transcription factors, and differentially expressed autophagy genes. Friends' analysis showed that NDRG4 was highly closely related to other hub genes (P < 0.05). Furthermore, NDRG4 expression was downregulated in the induction group (P < 0.01). NDRG4 was significantly correlated with infiltrating immune cells, including monocytes, eosinophils, type 17 T helper cells, neutrophils, activated CD8 T cells, and immature B cells. Levels of the 10 autophagy related genes (including VPS8, NDRG4, and CYBB) were successfully validated based on in vitro experiments. Conclusion: We identified candidate molecules to further investigate their functions in osteogenesis, providing novel insights into the role of autophagy in mesenchymal stem cell differentiation.
C1 [Xu, Yibo; Wang, Zhimeng; Wang, Yakang; Huang, Qiang; Ren, Cheng; Sun, Liang; Wang, Qian; Li, Ming; Liu, Hongliang; Li, Zhong; Zhang, Kun; Ma, Teng; Lu, Yao] Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthopaed Surg, Xian 710054, Shaanxi, Peoples R China.
   [Xu, Yibo; Ren, Cheng; Lu, Yao] Xi An Jiao Tong Univ, Bioinspired Engn & Biomech Ctr BEBC, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China.
   [Ma, Teng; Lu, Yao] Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthopaed Surg, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Lu, Y (通讯作者)，Xi An Jiao Tong Univ, Bioinspired Engn & Biomech Ctr BEBC, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China.; Ma, T; Lu, Y (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthopaed Surg, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
EM gukemt@163.com; drluyao@163.com
RI Liu, Hongliang/P 3444 2014; Zhang, Kun/S 5005 2019
FU Scientific Research Program   Xian Health Commission [2021yb26]; Xian
   Science and Technology Project [2019114613YX001SF038 (14)]
FX This work was supported by a project grant from the Scientific Research
   Program Funded by the Xian Health Commission (2021yb26) and Xian Science
   and Technology Project (2019114613YX001SF038 (14) ) .
CR Aghali A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112993
   Aly M, 2019, BLOOD ADV, V3, P2164, DOI 10.1182/bloodadvances.2018028423
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bahraminasab M, 2020, BIOMED ENG ONLINE, V19, DOI 10.1186/s12938 020 00810 2
   Baptista LS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051285
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Chen M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02628 8
   Chen XD, 2020, WORLD J STEM CELLS, V12, P776, DOI 10.4252/wjsc.v12.i8.776
   Croes M, 2016, BONE, V84, P262, DOI 10.1016/j.bone.2016.01.010
   Fan TY, 2020, J CELL MOL MED, V24, P7968, DOI 10.1111/jcmm.15429
   Granchi D, 2010, TISSUE ENG PART C ME, V16, P511, DOI [10.1089/ten.tec.2009.0405, 10.1089/ten.TEC.2009.0405]
   Wiktorin HG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7095902
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kapor S, 2021, J PERS MED, V11, DOI 10.3390/jpm11111048
   Lee DJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13326 y
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Liao CS, 2020, J CELL PHYSIOL, V235, P4466, DOI 10.1002/jcp.29323
   Liu Y, 2021, BMC GENOMICS, V22, DOI 10.1186/s12864 021 07584 4
   Liu YC, 2014, BIOSCI TRENDS, V8, P138, DOI 10.5582/bst.2014.01047
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Melotte V, 2009, JNCI J NATL CANCER I, V101, P916, DOI 10.1093/jnci/djp131
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Noronha NCND, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1224 y
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Ozaki K, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw3921
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   Rahman MM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6054361
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008 5472.CAN 12 1370
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Somaiah C, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0407 7
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tan JL, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.3
   Wan YX, 2017, BIOCHEM BIOPH RES CO, V488, P46, DOI 10.1016/j.bbrc.2017.05.004
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Wang Z, 2018, INFLAMMATION, V41, P959, DOI 10.1007/s10753 018 0750 6
   Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Yang L, 2021, TISSUE ENG PT A, DOI [10.1089/ten.tea.2021.0015, 10.1089/ten.TEA.2021.0015]
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064
   Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900
   Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094
   Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496
NR 49
TC 2
Z9 2
U1 0
U2 2
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2022
VL 14
IS 8
BP 5326
EP 5342
PG 17
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 5C2FS
UT WOS:000864082000007
PM 36105058
DA 2025 08 17
ER

PT J
AU Huang, JY
   Bi, Y
   Zhu, GH
   He, Y
   Su, YX
   He, BC
   Wang, Y
   Kang, Q
   Chen, L
   Zuo, GW
   Luo, Q
   Shi, Q
   Zhang, BQ
   Huang, AL
   Zhou, L
   Feng, T
   Luu, HH
   Haydon, RC
   He, TC
   Tang, N
AF Huang, Jiayi
   Bi, Yang
   Zhu, Gao Hui
   He, Yun
   Su, Yuxi
   He, Bai Cheng
   Wang, Yi
   Kang, Quan
   Chen, Liang
   Zuo, Guo Wei
   Luo, Qing
   Shi, Qiong
   Zhang, Bing Qiang
   Huang, Ailong
   Zhou, Lan
   Feng, Tao
   Luu, Hue H.
   Haydon, Rex C.
   He, Tong Chuan
   Tang, Ni
TI Retinoic acid signalling induces the differentiation of mouse fetal
   liver derived hepatic progenitor cells
SO LIVER INTERNATIONAL
LA English
DT Article
DE hepatic differentiation; hepatic progenitor cells; nuclear receptors;
   retinoid signalling; signalling transduction
ID STEM CELLS; OSTEOBLAST DIFFERENTIATION; NUCLEAR RECEPTORS;
   CANCER THERAPY; CHEMOPREVENTION; REGENERATION; GROWTH; SPECIFICATION;
   HNF 3 ALPHA; MECHANISMS
AB Background
   Hepatic progenitor cells (HPCs) can be isolated from fetal liver and extrahepatic tissues. Retinoic acid (RA) signalling plays an important role in development, although the role of RA signalling in liver specific progenitors is poorly understood.
   Aims
   We sought to determine the role of RA in regulating hepatic differentiation.
   Methods
   RNA was isolated from liver tissues of various developmental stages. Liver marker expression was assessed by reverse transcriptase polymerase chain reaction and immunofluorescence staining. Reversibly immortalized HPCs derived from mouse embryonic day 14.5 (E14.5) liver (aka, HP14.5) were established. Albumin promoter driven reporter (Alb GLuc) was used to monitor hepatic differentiation. Glycogen synthesis was assayed as a marker for terminal hepatic differentiation.
   Results
   Retinoic acid receptor (RAR) alpha, retinoid X receptor (RXR) alpha and RXR gamma expressed in E12.5 to postnatal day 28 liver samples. Expression of RAR beta and RXR beta was low perinatally, whereas RAR gamma was undetectable in prenatal tissues and increased postnatally. Retinal dehydrogenase 1 and 2 (Raldh1 and Raldh2) were expressed in all tissues, while Raldh3 was weakly expressed in prenatal samples but was readily detected postnatally. Nuclear receptor corepressors were highly expressed in all tissues, while expression of nuclear co activators decreased in perinatal tissues and increased after birth. HP14.5 cells expressed high levels of early liver stem cell markers. Expression of RA signalling components and coregulators was readily detected in HP14.5. RA was shown to induce Alb GLuc activity and late hepatocyte markers. RA was further shown to induce glycogen synthesis in HP14.5 cells, an important function of mature hepatocytes.
   Conclusions
   Our results strongly suggest that RA signalling may play an important role in regulating hepatic differentiation.
C1 [Huang, Jiayi; Bi, Yang; Zhu, Gao Hui; He, Yun; Su, Yuxi; He, Bai Cheng; Wang, Yi; Kang, Quan; Chen, Liang; Zuo, Guo Wei; Luo, Qing; Shi, Qiong; Zhang, Bing Qiang; Huang, Ailong; Zhou, Lan; Feng, Tao; He, Tong Chuan; Tang, Ni] Chongqing Med Univ, Affiliated Hosp, Minist Educ China, Key Lab Diagnost Med Designated, Chongqing, Peoples R China.
   [Huang, Jiayi; Bi, Yang; Zhu, Gao Hui; He, Yun; Su, Yuxi; He, Bai Cheng; Wang, Yi; Kang, Quan; Chen, Liang; Zuo, Guo Wei; Luo, Qing; Shi, Qiong; Zhang, Bing Qiang; Zhou, Lan; Feng, Tao; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan; Tang, Ni] Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
C3 Chongqing Medical University; University of Chicago; University of
   Chicago Medical Center
RP Tang, N (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis Res, Chongqing, Peoples R China.
EM nitang809@hotmail.com
RI Tang, Ni/Z 5133 2019; huang, jiayi/AAR 3913 2021
OI Bi, Yang/0000 0001 7263 1002; 
FU American Cancer Society; The Brinson Foundation; Orthopaedic Research
   and Education Foundation; Natural Science Foundation of China; Ministry
   of Science and Technology of China [30771925]; National Institutes of
   Health
FX We thank Dr Philippe Leboulch of MIT for the generous provision of SSR
   #69 vector. The reported work was supported, in part, by research grants
   from the American Cancer Society (T. C. H. and H. H. L.), The Brinson
   Foundation (T. C. H.), the Orthopaedic Research and Education Foundation
   (H. H. L.), the Natural Science Foundation of China and the Ministry of
   Science and Technology of China (B. C. H., J. H., Y. W., Q. K., L. C.,
   Q. S., A. H., L. Z., T. C. H. and N. T., and #30771925 to T. F.), and
   the National Institutes of Health (R. C. H., T. C. H. and H. H. L.).
CR Alison MR, 2007, SEMIN CELL DEV BIOL, V18, P819, DOI 10.1016/j.semcdb.2007.09.016
   Cantz T, 2008, CELL TISSUE RES, V331, P271, DOI 10.1007/s00441 007 0483 6
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255
   Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399
   Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002
   Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925 4773(02)00338 6
   Fiegel HC, 2006, J CELL MOL MED, V10, P577, DOI 10.1111/j.1582 4934.2006.tb00422.x
   Fields AL, 2007, J CELL BIOCHEM, V102, P886, DOI 10.1002/jcb.21530
   Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936
   Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a
   Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320 7330.2001
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   Hirano K, 2008, PATHOL RES PRACT, V204, P799, DOI 10.1016/j.prp.2008.05.002
   HU ZY, 1994, CELL GROWTH DIFFER, V5, P503
   Ijpenberg A, 2007, DEV BIOL, V312, P157, DOI 10.1016/j.ydbio.2007.09.014
   JACOB A, 1994, NUCLEIC ACIDS RES, V22, P2126, DOI 10.1093/nar/22.11.2126
   Jacob A, 1999, EXP CELL RES, V250, P1, DOI 10.1006/excr.1999.4512
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Karamouzis MV, 2007, CELL ONCOL, V29, P183
   Kitisin K., 2007, Cancer Biomarkers, V3, P251
   Ledda Columbano GM, 2004, CARCINOGENESIS, V25, P2061, DOI 10.1093/carcin/bgh221
   Lévesque E, 2007, HEPATOLOGY, V45, P128, DOI 10.1002/hep.21464
   Libbrecht L, 2006, WORLD J GASTROENTERO, V12, P6261, DOI 10.3748/wjg.v12.i39.6261
   Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168 9525(99)01710 2
   LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655
   Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156
   Mic FA, 2002, DEVELOPMENT, V129, P2271
   Monga SPS, 2001, CELL TRANSPLANT, V10, P81
   Moon YJ, 2008, CELL BIOL INT, V32, P1293, DOI 10.1016/j.cellbi.2008.07.017
   Niederreither K, 2008, NAT REV GENET, V9, P541, DOI 10.1038/nrg2340
   Oertel M, 2008, BBA MOL BASIS DIS, V1782, P61, DOI 10.1016/j.bbadis.2007.12.004
   Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023
   Park BH, 2001, CURR OPIN ONCOL, V13, P78, DOI 10.1097/00001622 200101000 00015
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pérez Pomares JM, 2004, DEV DYNAM, V229, P465, DOI 10.1002/dvdy.10455
   Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558
   SATO T, 1995, EXP CELL RES, V217, P72, DOI 10.1006/excr.1995.1065
   Schmelzer E, 2006, STEM CELLS, V24, P1852, DOI 10.1634/stemcells.2006 0036
   Schmitt TM, 2004, J EXP MED, V200, P469, DOI 10.1084/jem.20040394
   Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900
   Sgodda M, 2007, EXP CELL RES, V313, P2875, DOI 10.1016/j.yexcr.2007.05.020
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shen PF, 2004, FRONT BIOSCI LANDMRK, V9, P2663, DOI 10.2741/1425
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   SOPRANO DR, 1995, ANNU REV NUTR, V15, P111, DOI 10.1146/annurev.nu.15.070195.000551
   Strick Marchand H, 2002, HEPATOLOGY, V36, P794, DOI 10.1053/jhep.2002.36123
   SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040 8428(01)00144 5
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651
   Verma AK, 2003, J BIOL REG HOMEOS AG, V17, P92
   Walkup MH, 2006, STEM CELLS, V24, P1833, DOI 10.1634/stemcells.2006 0063
   Wang K, 2008, BIOCHEM PHARMACOL, V75, P2204, DOI 10.1016/j.bcp.2008.02.030
   Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971
   Yoshida Y, 2007, AM J PHYSIOL GASTR L, V293, pG1089, DOI 10.1152/ajpgi.00187.2007
   Zaret KS, 2008, SCIENCE, V322, P1490, DOI 10.1126/science.1161431
   Zaret KS, 2008, NAT REV GENET, V9, P329, DOI 10.1038/nrg2318
   Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837
   Ziouzenkova O, 2007, NAT MED, V13, P695, DOI 10.1038/nm1587
   Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359 6446(02)02526 6
NR 68
TC 70
Z9 91
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1478 3223
EI 1478 3231
J9 LIVER INT
JI Liver Int.
PD NOV
PY 2009
VL 29
IS 10
BP 1569
EP 1581
DI 10.1111/j.1478 3231.2009.02111.x
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 502BM
UT WOS:000270429000019
PM 19737349
DA 2025 08 17
ER

PT J
AU Qin, D
   Zhang, HJ
   Zhang, HF
   Sun, TY
   Zhao, HB
   Lee, WH
AF Qin, Di
   Zhang, Huijie
   Zhang, Hongfei
   Sun, Tongyi
   Zhao, Hongbin
   Lee, Wen Hui
TI Anti osteoporosis effects of osteoking via reducing reactive oxygen
   species
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Osteoking; Reactive oxygen species; Osteoblast; Osteoclast
ID KAPPA B LIGAND; OXIDATIVE STRESS; RECEPTOR ACTIVATOR; ANTIOXIDANT
   SYSTEM; INJURY; RANKL; CELLS; WOMEN
AB Ethnopharmacological relevance: Osteoking is a Traditional Chinese Medicine consisting of seven types of medicinal herbs originated from Yi nationality and has been used in clinic to treat bone diseases for thousands of years in China. Osteoking shows excellent clinical therapeutic effects on osteoporosis, but it is not clear whether Osteoking could exhibit beneficial effects against osteoporosis via reducing reactive oxygen species (ROS).
   Aim of the study: To explore whether the protective effects of Osteoking on osteoporosis related to ROS, we investigated the effects of Osteoking on osteogenesis differentiation under oxidative stress.
   Materials and methods: The ovariectomized (OVX) osteoporosis model was established by ovarian surgery, and Osteoking was orally administrated for 84 days. Then the pathogenesis changes of femur were analyzed by Hematoxylin and eosin (H&E) and Masson's trichrome staining. The levels of ROS, malondialdehyde (MDA)and superoxide dismutase (SOD) from rats' serum were further measured. In vitro, mouse pre osteoblastic MC3T3 E1 cells pre treated with or without 0.25 mM tert butyl hydroperoxide (t BHP) for 2 h were cultured and treated with different dilutions of Osteoking or 20 mu M N Acetyl L cysteine for another 24 h, respectively. The intracellular ROS production and markers of oxidative damage of the MC3T3 E1 cells were determined using corresponding kits, respectively. The expressions of alkaline phosphatase (ALP), collagen type I, osteoprotegerin (OPG), TGF beta 1, beta catenin, receptor activator of nuclear factor kappa B ligand (RANKL) and interleukin 6 (IL 6) were further analyzed by qRT PCR and western blotting upon treatment.
   Results: Our results showed that Osteoking significantly improving trabecular microstructure by promoting collagen fiber repair and new bone or cartilage regeneration was demonstrated in OVX osteoporosis rat models by micro CT analysis and histological staining results. Osteoking supplementation reduced the levels of ROS and MDA in OVX rat serum and increased SOD activities. In addition, Osteoking could also up regulate the proteins expression levels of Runx2, osteocalcin (BGP) and osteoprotegerin (OPG) but reducing the expression of tartrate resistant acid phosphatase (TRAP). In vitro, Osteoking could effectively inhibit the t BHP induced intracellular excessive ROS production and protect cells from oxidative stress in mouse pre osteoblastic MC3T3 E1 cells. Meanwhile, the mRNA expressions of ALP, collagen type I, OPG, TGF beta 1 and beta catenin were also up regulated whereas the RANKL and IL 6 were down regulated in Osteoking treated MC3T3 E1 cells.
   Conclusions: A novel therapeutic mechanism of Osteoking on osteoporosis reveals by present investigation. Clinic effects of Osteoking to treat osteoporosis are closely related to its ability to reduce oxidative stress.
C1 [Qin, Di; Zhang, Huijie; Zhang, Hongfei; Lee, Wen Hui] Chinese Acad Sci, Key Lab Bioact Peptides Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, 32 East JiaoChang Rd, Kunming 650223, Yunnan, Peoples R China.
   [Qin, Di; Zhang, Huijie; Zhang, Hongfei; Sun, Tongyi; Lee, Wen Hui] Weifang Med Univ, Key Lab Biol Med Univ Shandong Prov, Sch Biosci & Technol, Weifang 261053, Shandong, Peoples R China.
   [Zhao, Hongbin] Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China.
C3 Chinese Academy of Sciences; Kunming Institute of Zoology, CAS; Shandong
   Second Medical University; Kunming University of Science & Technology
RP Lee, WH (通讯作者)，Chinese Acad Sci, Key Lab Bioact Peptides Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, 32 East JiaoChang Rd, Kunming 650223, Yunnan, Peoples R China.; Zhao, HB (通讯作者)，Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China.
EM 596829191@qq.com; leewh@mail.kiz.ac.cn
RI Zhao, Hongbin/I 3783 2016
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Aranda A, 2013, TOXICOL IN VITRO, V27, P954, DOI 10.1016/j.tiv.2013.01.016
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bonilla Becerra SM, 2017, LIFE SCI, V179, P120, DOI 10.1016/j.lfs.2017.05.006
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Casati L, 2019, EUR J NUTR, V58, P1019, DOI 10.1007/s00394 018 1618 0
   Chappard D., 2008, Morphologie, V92, P162, DOI 10.1016/j.morpho.2008.10.003
   Dai LF, 2015, MOL MED REP, V12, P1066, DOI 10.3892/mmr.2015.3551
   Dieci E, 2014, AMINO ACIDS, V46, P1715, DOI 10.1007/s00726 014 1734 y
   Fan L, 2014, CHEM NAT COMPD+, V50, P433, DOI 10.1007/s10600 014 0979 8
   Ferreri SL, 2011, BONE, V48, P1095, DOI 10.1016/j.bone.2011.01.002
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Hu Min Hu Min, 2011, China Journal of Traditional Chinese Medicine and Pharmacy, V26, P486
   Jesus A., 2010, DEV DYNAM, V221, P311
   Jilka RL, 2010, AGING CELL, V9, P851, DOI 10.1111/j.1474 9726.2010.00616.x
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kerschan Schindl K, 2008, EXP CLIN ENDOCR DIAB, V116, P491, DOI 10.1055/s 2007 993142
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li HB, 2007, ARCH PHARM RES, V30, P850, DOI 10.1007/BF02978836
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Manolagas SC, 2008, ENDOCRINOLOGY, V149, P3264, DOI 10.1210/en.2008 0402
   Mayo M. W, 2000, FOOD CHEM, V73, P239
   Mayo MW, 2000, BBA REV CANCER, V1470, pM55, DOI 10.1016/S0304 419X(00)00002 0
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014
   Naka K, 2008, ANTIOXID REDOX SIGN, V10, P1883, DOI 10.1089/ars.2008.2114
   Ozgocmen S, 2007, MOL CELL BIOCHEM, V295, P45, DOI 10.1007/s11010 006 9270 z
   Papanicolaou DA, 2000, J CLIN ENDOCR METAB, V85, P1331, DOI 10.1210/jc.85.3.1331
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Sánchez Moreno C, 1998, J SCI FOOD AGR, V76, P270, DOI 10.1002/(SICI)1097 0010(199802)76:2<270::AID JSFA945>3.3.CO;2 0
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   [孙岩 Sun Yan], 2016, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V22, P1513
   Xiao Y, 2012, J FUNCT FOODS, V4, P642, DOI 10.1016/j.jff.2012.04.004
   Yan XF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00007
   Yishake M, 2018, J ORTHOP RES, V36, P937, DOI 10.1002/jor.23682
   Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547
   ZHAO HB, 2007, ZHONGGUO GU SHANG, V20, P757
   Zhao Hong bin, 2005, Chin J Integr Med, V11, P297
   Zhao Hong bin, 2006, Zhongguo Zhong Xi Yi Jie He Za Zhi, V26, P1003
NR 45
TC 62
Z9 65
U1 2
U2 81
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD NOV 15
PY 2019
VL 244
AR 112045
DI 10.1016/j.jep.2019.112045
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA IY4JO
UT WOS:000486357500008
PM 31260757
DA 2025 08 17
ER

PT J
AU Nakamura, Y
   Takarada, T
   Kodama, A
   Hinoi, E
   Yoneda, Y
AF Nakamura, Yukari
   Takarada, Takeshi
   Kodama, Ayumi
   Hinoi, Eiichi
   Yoneda, Yukio
TI Predominant Promotion by Tacrolimus of Chondrogenic Differentiation to
   Proliferating Chondrocytes
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE tacrolimus; ATDC5 cell; metatarsal; chondrocyte; type II collagen
ID AUTOSOMAL SEX REVERSAL; SRY RELATED GENE; RHEUMATOID ARTHRITIS; CHONDRAL
   MINERALIZATION; CAMPOMELIC DYSPLASIA; PARATHYROID HORMONE; PTH/PTHRP
   RECEPTOR; RODENT CARTILAGE; INDIAN HEDGEHOG; GROWTH PLATE
AB Tacrolimus (FK506) has been used as a therapeutic drug beneficial for the treatment of rheumatoid arthritis in humans. In this study, we investigated the effects of FK506 on cellular differentiation in cultured chondrogenic cells. Culture with FK506 led to a significant and concentration dependent increase in Alcian blue staining for matrix proteoglycan at 0.1 to 1,000 ng/ml, but not in alkaline phosphatase (ALP) activity, in ATDC5 cells, a mouse prechondrogenic cell line, cultured for 7 to 28 days, while the non steroidal anti inflammatory drug indomethacin significantly decreased Alcian blue staining in a concentration dependent manner, without altering ALP activity. FK506 significantly increased the expression of mRNA for both type 11 and type X collagen, but not for osteopontin, in ATDC5 cells. Similar promotion was seen in chondrogenic differentiation in both mouse metatarsals and chondrocytes cultured with FK506. However, FK506 failed to significantly affect transcriptional activity of the reporter construct for either sry type HMG box 9 (Sox9) or runt related transcription factor 2 (Runx2), which are both transcription factors responsible for chondrocytic maturation as a master regulator. These results suggest that FK506 may predominantly promote cellular differentiation into proliferating chondrocytes through a mechanism not relevant to the transactivation by either Sox9 or Runx2 in chondrogenic cells.
C1 [Nakamura, Yukari; Takarada, Takeshi; Kodama, Ayumi] Kanazawa Univ, Grad Sch Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.
C3 Kanazawa University
RP Yoneda, Y (通讯作者)，Kanazawa Univ, Grad Sch Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.
EM yyoneda@p.kanazawa u.ac.jp
RI ; Yoneda, Yukio/ABI 1864 2020
OI Takarada, Takeshi/0000 0002 2363 7704; Yoneda,
   Yukio/0000 0002 4624 177X; 
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
   [18053009, 20790250]; Grants in Aid for Scientific Research [20790250,
   18053009] Funding Source: KAKEN
FX This work was supported in part by Grants in Aids for Scientific
   Research to Y.Y. (18053009) and T.T. (20790250) from the Ministry of
   Education, Culture, Sports, Science, and Technology, Japan.
CR Akiyama H, 2005, MATRIX BIOL, V23, P499, DOI 10.1016/j.matbio.2004.10.002
   Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198
   BROZIK M, 1992, J RHEUMATOL, V19, P63
   Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030
   CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   DASGUPTA B, 1992, J RHEUMATOL, V19, P22
   Di Nino DL, 2001, DEV BIOL, V240, P433, DOI 10.1006/dbio.2001.0471
   DUEY P, 1997, CELL, V89, P747
   ELLIOTT MJ, 1995, BAILLIERE CLIN RHEUM, V9, P633, DOI 10.1016/S1521 6942(05)80013 0
   FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0
   Furst DE, 1999, ARTHRITIS RHEUM, V42, pS271
   Guo J, 2006, DEV BIOL, V292, P116, DOI 10.1016/j.ydbio.2005.12.044
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P70, DOI 10.1016/j.bcp.2005.04.025
   Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02 0820fje
   Hinoi E, 2006, GENE DEV, V20, P2937, DOI 10.1101/gad.1482906
   Hinoi E, 2006, J BIOL CHEM, V281, P23632, DOI 10.1074/jbc.M512362200
   HOUSSIAU FA, 1988, ARTHRITIS RHEUM US, V31, P784, DOI 10.1002/art.1780310614
   Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097 0177(199904)214:4<279::AID AJA1>3.0.CO;2 W
   Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Long FX, 1998, DEVELOPMENT, V125, P1067
   Maor G, 2002, J BONE MINER RES, V17, P1034, DOI 10.1359/jbmr.2002.17.6.1034
   Moreland LW, 1997, ARTHRITIS RHEUM, V40, P397, DOI 10.1002/art.1780400302
   Nishigaki F, 2002, EUR J PHARMACOL, V437, P123, DOI 10.1016/S0014 2999(02)01269 4
   Sakuma S, 2000, BRIT J PHARMACOL, V130, P1655, DOI 10.1038/sj.bjp.0703472
   Sakuma S, 2001, INFLAMM RES, V50, P509, DOI 10.1007/PL00000227
   Takarada T, 2008, J PHARMACOL SCI, V106, P536, DOI 10.1254/jphs.FM0070243
   Takarada T, 2008, J CELL PHYSIOL, V215, P320, DOI 10.1002/jcp.21310
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092 8674(94)90041 8
   Wang LY, 2006, J BIOL CHEM, V281, P24553, DOI 10.1074/jbc.M600939200
   Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358
   Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200
NR 37
TC 26
Z9 27
U1 0
U2 7
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAR
PY 2009
VL 109
IS 3
BP 413
EP 423
DI 10.1254/jphs.08315FP
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 424LD
UT WOS:000264567300013
PM 19270431
OA Bronze
DA 2025 08 17
ER

PT J
AU Jones, KB
   Salah, Z
   Del Mare, S
   Galasso, M
   Gaudio, E
   Nuovo, GJ
   Lovat, F
   LeBlanc, K
   Palatini, J
   Randall, RL
   Volinia, S
   Stein, GS
   Croce, CM
   Lian, JB
   Aqeilan, RI
AF Jones, Kevin B.
   Salah, Zaidoun
   Del Mare, Sara
   Galasso, Marco
   Gaudio, Eugenio
   Nuovo, Gerard J.
   Lovat, Francesca
   LeBlanc, Kimberly
   Palatini, Jeff
   Randall, R. Lor
   Volinia, Stefano
   Stein, Gary S.
   Croce, Carlo M.
   Lian, Jane B.
   Aqeilan, Rami I.
TI miRNA Signatures Associate with Pathogenesis and Progression of
   Osteosarcoma
SO CANCER RESEARCH
LA English
DT Article
ID MICRORNA EXPRESSION; OSTEOBLAST DIFFERENTIATION; SUPPRESSES
   TUMORIGENICITY; MESENCHYMAL TRANSITION; PROMOTER METHYLATION; CANCER;
   MECHANISM; APOPTOSIS; SARCOMA; CLUSTER
AB Osteosarcoma remains a leading cause of cancer death in adolescents. Treatment paradigms and survival rates have not improved in two decades. Driving the lack of therapeutic inroads, the molecular etiology of osteosarcoma remains elusive. MicroRNAs (miRNAs) have demonstrated far reaching effects on the cellular biology of development and cancer. Their role in osteosarcomagenesis remains largely unexplored. Here we identify for the first time an miRNA signature reflecting the pathogenesis of osteosarcoma from surgically procured samples from human patients. The signature includes high expression of miR 181a, miR 181b, and miR 181c as well as reduced expression of miR 16, miR 29b, and miR 142 5p. We also demonstrate that miR 181b and miR 29b exhibit restricted expression to distinct cell populations in the tumor tissue. Further, higher expression of miR 27a and miR 181c* in pre treatment biopsy samples characterized patients who developed clinical metastatic disease. In addition, higher expression of miR 451 and miR 15b in pre treatment samples correlated with subsequent positive response to chemotherapy. In vitro and in vivo functional validation in osteosarcoma cell lines confirmed the tumor suppressive role of miR 16 and the pro metastatic role of miR 27a. Furthermore, predicted target genes for miR 16 and miR 27a were confirmed as down regulated by real time PCR. Affymetrix array profiling of cDNAs from the osteosarcoma specimens and controls were interrogated according to predicted targets of miR 16, miR142 5p, miR 29b, miR 181a/b, and miR 27a. This analysis revealed positive and negative correlations highlighting pathways of known importance to osteosarcoma, as well as novel genes. Thus, our findings establish a miRNA signature associated with pathogenesis of osteosarcoma as well as critical pre treatment biomarkers of metastasis and responsiveness to therapy. Cancer Res; 72(7); 1865 77. (C)2012 AACR.
C1 [Jones, Kevin B.; Randall, R. Lor] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA.
   [Jones, Kevin B.; Randall, R. Lor] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT USA.
   [Salah, Zaidoun; Del Mare, Sara; Aqeilan, Rami I.] Hebrew Univ Jerusalem, Hadassah Med Sch, IMRIC, Lautenberg Ctr Immunol & Canc Res, IL 91010 Jerusalem, Israel.
   [Salah, Zaidoun; Del Mare, Sara; Gaudio, Eugenio; Lovat, Francesca; Palatini, Jeff; Volinia, Stefano; Croce, Carlo M.; Aqeilan, Rami I.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA.
   [Galasso, Marco; Volinia, Stefano] Univ Ferrara, Dept Morphol & Embryol, I 44100 Ferrara, Italy.
   [LeBlanc, Kimberly; Stein, Gary S.; Lian, Jane B.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
   [LeBlanc, Kimberly; Stein, Gary S.; Lian, Jane B.] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Huntsman Cancer Institute; Hebrew
   University of Jerusalem; University System of Ohio; Ohio State
   University; James Cancer Hospital & Solove Research Institute; James
   Cancer Hospital & Solove Research Institute; University System of Ohio;
   Ohio State University; University of Ferrara; University of
   Massachusetts System; University of Massachusetts Worcester; University
   of Massachusetts System; University of Massachusetts Worcester
RP Aqeilan, RI (通讯作者)，Hebrew Univ Jerusalem, Lautenberg Ctr, POB 12272, IL 91120 Jerusalem, Israel.
EM kevin.jones@hci.utah.edu; aqeilan@cc.huji.ac.il
RI Volinia, Stefano/A 3029 2010; Aqeilan, Rami/AAT 7785 2020; Galasso,
   Marco/K 2037 2016
OI Volinia, Stefano/0000 0003 0910 3893; Palatini,
   Jeffrey/0000 0001 9280 4417; Galasso, Marco/0000 0003 2655 4792
FU Alex's Lemonade Stand Foundation (ALSF); Israeli Cancer Research Funds
   (ICRF); NIH [K08CA138764]; Huntsman Cancer Foundation; NIH/NIAMS
   [AR039588 19]; AIRC [IG 8588]; MIUR
FX This work was supported, in part, by the Alex's Lemonade Stand
   Foundation (ALSF) "A" Award to R. I. Aqeilan, and Israeli Cancer
   Research Funds (ICRF) to R. I. Aqeilan and Z. Salah. K. B. Jones is
   supported by the NIH K08CA138764 and the Huntsman Cancer Foundation. R.
   L. Randall is supported by the Huntsman Cancer Foundation. G. S. Stein
   and J.B. Lian are supported by NIH/NIAMS AR039588 19. S. Volinia is
   supported by AIRC (IG 8588) and PRIN MIUR 2008.
CR Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69
   Bacci G, 2003, CANCER, V97, P3068, DOI 10.1002/cncr.11456
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111
   Chintharlapalli S, 2009, INT J CANCER, V125, P1965, DOI 10.1002/ijc.24530
   Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008 5472.CAN 10 0638
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024
   Eyholzer M, 2010, BRIT J CANCER, V103, P275, DOI 10.1038/sj.bjc.6605751
   GLASSER DB, 1992, CANCER, V69, P698, DOI 10.1002/1097 0142(19920201)69:3<698::AID CNCR2820690317>3.0.CO;2 G
   Gorlick R, 2009, CANC TREAT, V152, P467, DOI 10.1007/978 1 4419 0284 9_27
   Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715
   Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101
   Karami S, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/879362
   Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Liu CG, 2008, NAT PROTOC, V3, P563, DOI 10.1038/nprot.2008.14
   Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198
   Nuovo GJ, 2009, NAT PROTOC, V4, P107, DOI 10.1038/nprot.2008.215
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Patrick DM, 2010, GENE DEV, V24, P1614, DOI 10.1101/gad.1942810
   Qiang R, 2011, INT J BIOCHEM CELL B, V43, P632, DOI 10.1016/j.biocel.2011.01.002
   Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 320
   Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012
   Randall RL, 2003, CLIN ORTHOP RELAT R, P59, DOI 10.1097/01.blo.0000093897.12372.88
   Sarver AL, 2010, LAB INVEST, V90, P753, DOI 10.1038/labinvest.2010.53
   Sempere LF, 2009, THESCIENTIFICWORLDJO, V9, P626, DOI 10.1100/tsw.2009.88
   Shi R, 2005, BIOTECHNIQUES, V39, P519, DOI 10.2144/000112010
   Simon R, 2007, CANCER INFORM, V3, P11
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Sun QM, 2009, ONCOL REP, V22, P563, DOI 10.3892/or_00000472
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107
   Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600 0609.2009.01348.x
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
   Wu ZY, 2011, MED ONCOL, V28, P1469, DOI 10.1007/s12032 010 9563 7
   Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501
   Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Zhang H, 2010, ONCOL REP, V24, P1363, DOI 10.3892/or_00000994
   Zhang YQ, 2009, WORLD J SURG, V33, P698, DOI 10.1007/s00268 008 9833 0
   Zhang Z, 2009, CELL CYCLE, V8, P2756, DOI 10.4161/cc.8.17.9387
NR 48
TC 336
Z9 361
U1 0
U2 64
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2012
VL 72
IS 7
BP 1865
EP 1877
DI 10.1158/0008 5472.CAN 11 2663
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 922MO
UT WOS:000302551800029
PM 22350417
OA Green Accepted, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Rondanelli, M
   Riva, A
   Morazzoni, P
   Allegrini, P
   Faliva, MA
   Naso, M
   Miccono, A
   Peroni, G
   Degli Agosti, I
   Perna, S
AF Rondanelli, Mariangela
   Riva, Antonella
   Morazzoni, Paolo
   Allegrini, Pietro
   Faliva, Milena Anna
   Naso, Maurizio
   Miccono, Alessandra
   Peroni, Gabriella
   Degli Agosti, Irene
   Perna, Simone
TI The effect and safety of highly standardized Ginger (Zingiber
   officinale) and Echinacea (Echinacea angustifolia) extract
   supplementation on inflammation and chronic pain in NSAIDs poor
   responders. A pilot study in subjects with knee arthrosis
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE Chronic pain; dietary supplement; Echinacea angustifolia; inflammation;
   knee osteoarthritis; Zingiber officinale; ginger; arthritis
ID HYDROALCOHOLIC EXTRACT; ALKAMIDES; RHIZOMES; OSTEOARTHRITIS; TARGET
AB The study aimed to evaluate the effect of Zingiber officinale and Echinacea angustifolia extract supplementation (25mg of ginger and 5mg of Echinacea) for 30days on inflammation and chronic pain in knee osteoarthritis (OA). Consecutive nonsteroidal anti inflammatory drugs (NSAIDs) poor responders with chronic inflammation and pain due to knee arthrosis were assessed (15 subjects, age: 67.2 +/  7.9, body mass index: 30.6 +/  7.1, men/women:2/13). The primary endpoint was to determine pain improvement from baseline to Day 30 by Tegner Lysholm Knee Scoring. The secondary endpoints were the assessment of Visual Analog Scale for Pain, health related quality of life, by the ShortForm36 (SF 36), anthropometric parameters, hydration. After supplementation, a significant improvement of 12.27 points was observed for Lysholm scale score (p<0.05), SF 36 (p<0.05), and a decrease in  0.52cm in knee circumference (left) (p<0.01). This pilot study provides feasibility and safety data for the use of highly standardised ginger and Echinacea extract supplementation in people with knee OA.
   [GRAPHICS]
C1 [Rondanelli, Mariangela; Faliva, Milena Anna; Naso, Maurizio; Miccono, Alessandra; Peroni, Gabriella; Perna, Simone] Univ Pavia, Sect Human Nutr & Dietet, Dept Publ Hlth Expt & Forens Med, Azienda Servizialla Persona Pavia, Pavia, Italy.
   [Riva, Antonella; Morazzoni, Paolo; Allegrini, Pietro] Indena, Res & Dev Unit, Milan, Italy.
   [Degli Agosti, Irene] Ist Santa Margherita, Dept Physiatry, Azienda Serv Persona, Pavia, Italy.
C3 University of Pavia
RP Perna, S (通讯作者)，Univ Pavia, Sect Human Nutr & Dietet, Dept Publ Hlth Expt & Forens Med, Azienda Servizialla Persona Pavia, Pavia, Italy.
EM simoneperna@hotmail.it
RI ; Faliva, Milena Anna/AAC 3653 2022; Rondanelli,
   Mariangela/AGD 6274 2022; Perna, Simone/Y 8892 2018
OI Riva, Antonella/0000 0003 2819 943X; Perna, Simone/0000 0002 2720 1473
CR Aimbire F, 2007, PROSTAG LEUKOTR ESS, V77, P129, DOI 10.1016/j.plefa.2007.08.008
   Ajish KR, 2015, NAT PROD RES, V29, P947, DOI 10.1080/14786419.2014.956741
   Birt DF, 2008, AM J CLIN NUTR, V87, p488S, DOI 10.1093/ajcn/87.2.488S
   Bjordal JM, 2004, BMJ BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63
   Bruyère O, 2016, SEMIN ARTHRITIS RHEU, V45, pS3, DOI 10.1016/j.semarthrit.2015.11.010
   Dall'Acqua S, 2015, EUR J PHARM BIOPHARM, V97, P8, DOI 10.1016/j.ejpb.2015.09.021
   Dedov VN, 2002, BRIT J PHARMACOL, V137, P793, DOI 10.1038/sj.bjp.0704925
   Fouda AMM, 2009, BASIC CLIN PHARMACOL, V104, P262, DOI 10.1111/j.1742 7843.2008.00363.x
   Gertsch J, 2006, J RECEPT SIG TRANSD, V26, P709, DOI 10.1080/10799890600942674
   Guindon J, 2008, BRIT J PHARMACOL, V153, P319, DOI 10.1038/sj.bjp.0707531
   Harvey WF, 2009, MED CLIN N AM, V93, P201, DOI 10.1016/j.mcna.2008.07.010
   Hinz B, 2007, BIOCHEM BIOPH RES CO, V360, P441, DOI 10.1016/j.bbrc.2007.06.073
   Marrelli M, 2015, NAT PROD RES, V29, P2045, DOI 10.1080/14786419.2015.1020491
   Merali S, 2003, PHARM BIOL, V41, P412, DOI 10.1076/phbi.41.6.412.17828
   MULLERJAKIC B, 1994, PLANTA MED, V60, P37, DOI 10.1055/s 2006 959404
   Ojewole JAO, 2006, PHYTOTHER RES, V20, P764, DOI 10.1002/ptr.1952
   Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91
   Raduner S, 2006, J BIOL CHEM, V281, P14192, DOI 10.1074/jbc.M601074200
   Salim M, 2016, NAT PROD RES, V30, P1965, DOI 10.1080/14786419.2015.1094802
   Sang SM, 2009, J AGR FOOD CHEM, V57, P10645, DOI 10.1021/jf9027443
   Semwal RB, 2015, PHYTOCHEMISTRY, V117, P554, DOI 10.1016/j.phytochem.2015.07.012
   Vriens J, 2008, CURR NEUROPHARMACOL, V6, P79, DOI 10.2174/157015908783769644
   Woelkart K, 2005, PLANTA MED, V71, P701, DOI 10.1055/s 2005 871290
   Young HY, 2005, J ETHNOPHARMACOL, V96, P207, DOI 10.1016/j.jep.2004.09.009
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
NR 25
TC 30
Z9 30
U1 0
U2 24
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478 6419
EI 1478 6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PY 2017
VL 31
IS 11
BP 1309
EP 1313
DI 10.1080/14786419.2016.1236097
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA EM2QF
UT WOS:000395160000012
PM 27737573
DA 2025 08 17
ER

PT J
AU Zhang, F
   Yao, YC
   Hao, JH
   Zhou, RJ
   Liu, CZ
   Gong, YH
   Wang, DA
AF Zhang, Feng
   Yao, Yongchang
   Hao, Jinghua
   Zhou, Ruijie
   Liu, Chengzheng
   Gong, Yihong
   Wang, Dong An
TI A dual functioning adenoviral vector encoding both transforming growth
   factor β3 and shRNA silencing type I collagen: Construction and
   controlled release for chondrogenesis
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Adenovirus; Dual functioning; Cartilage regeneration; Transforming
   growth factor; RNA interference
ID MESENCHYMAL STEM CELLS; GENE DELIVERY; RABBIT CHONDROCYTES; BONE;
   CARTILAGE; THERAPY; DIFFERENTIATION; REGENERATION
AB Hyaline articular cartilage degeneration is a common clinical syndrome globally, whereas cell based therapy has proved to be a good solution to such problems. Given that transforming growth factor (TGF beta 3) is helpful in maintaining chondrocytic phenotype or stimulating chondrogenic differentiation of stem cells, vectors containing TGF beta 3 expression cassette can be delivered to therapeutic cells. One problem involved in the application of therapeutic cells in chondrogenesis is the undesirable production of type I collagen in such cells as chondrocytes and synovial mesenchymal stem cells during ex vivo culture, which undermines the mechanical strength of engineered cartilage. RNA interference (RNAi) strategy can be used to knock down its expression to allow better biological and mechanical functions in artificial tissues. In this study, for the first time we report the construction of an adenoviral vector that can express both TGF beta 3 to promote chondrogenesis and short hairpin RNA (shRNA) targeting type I collagen to block its production. This dual functioning vector (Ad dual) Was found to function well in three model cell types: human fibroblast, osteoblast and porcine chondrocyte in terms of the release of TGF beta 3 protein and down regulation of type I collagen production. Besides, we also tested its efficacy in Porcine synovial mesenchymal stem cells, highlighting its potential applications in cell based therapy for the treatment of articular cartilage degeneration. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zhang, Feng; Yao, Yongchang; Hao, Jinghua; Zhou, Ruijie; Liu, Chengzheng; Gong, Yihong; Wang, Dong An] Nanyang Technol Univ, Sch Chem & Biomed Engn, Div BioEngn, Singapore 637457, Singapore.
C3 Nanyang Technological University
RP Wang, DA (通讯作者)，Nanyang Technol Univ, Sch Chem & Biomed Engn, Div BioEngn, 70 Nanyang Dr,N1 3 B2 13, Singapore 637457, Singapore.
EM DAWang@ntu.edu.sg
RI Yao, Yongchang/L 2916 2015; Wang, Dong an/G 6195 2010
OI Yao, Yongchang/0000 0002 4338 2606; Wang, Dong An/0000 0002 7927 1422; 
FU AcRF Tier 1 [RG64/08]; Ministry of Education (MoE), Singapore
FX This research was financially supported by AcRF Tier 1 Grant RG64/08,
   Ministry of Education (MoE), Singapore. We acknowledge Rohan Rajeev
   Varshney for his kind technical support for our work.
CR Aslan H, 2006, TISSUE ENG, V12, P877, DOI 10.1089/ten.2006.12.877
   Bhosale AM, 2008, BRIT MED BULL, V87, P77, DOI 10.1093/bmb/ldn025
   Brantl S, 2002, BBA GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167 4781(02)00280 4
   Buckwalter JA, 2002, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000026073.30435.dc
   Chuang CK, 2007, GENE THER, V14, P1417, DOI 10.1038/sj.gt.3302996
   Fan JB, 2009, TISSUE ENG PART B RE, V15, P75, DOI 10.1089/ten.teb.2008.0586
   Hao JH, 2008, TISSUE ENG PART C ME, V14, P273, DOI 10.1089/ten.tec.2008.0163
   Hosokawa R, 2003, J DENT RES, V82, P558, DOI 10.1177/154405910308200714
   Inoue A, 2005, BIOCHEM BIOPH RES CO, V336, P903, DOI 10.1016/j.bbrc.2005.08.198
   Martin SE, 2006, FEBS LETT, V580, P3694, DOI 10.1016/j.febslet.2006.05.056
   MAYNE R, 1976, P NATL ACAD SCI USA, V73, P1674, DOI 10.1073/pnas.73.5.1674
   Meinel L, 2006, BIOMATERIALS, V27, P4993, DOI 10.1016/j.biomaterials.2006.05.021
   Muneoka Ken, 2008, Birth Defects Research, V84, P265, DOI 10.1002/bdrc.20137
   Na K, 2007, J BIOTECHNOL, V128, P412, DOI 10.1016/j.jbiotec.2006.09.025
   Porteus MH, 2006, PLOS GENET, V2, P1285, DOI 10.1371/journal.pgen.0020133
   Southwood LL, 2004, VET SURG, V33, P565, DOI 10.1111/j.1532 950X.2004.04080.x
   Spector JA, 2000, ANN PLAS SURG, V44, P522, DOI 10.1097/00000637 200044050 00011
   Steinert AF, 2008, INJURY, V39, pS97, DOI 10.1016/j.injury.2008.01.034
   Stoick Cooper CL, 2007, GENE DEV, V21, P1292, DOI 10.1101/gad.1540507
   STRAYER DS, 1993, VIRUS RES, V30, P259, DOI 10.1016/0168 1702(93)90094 4
   Tang TT, 2007, J BONE JOINT SURG BR, V89B, P127, DOI 10.1302/0301 620X.89B1.18350
   Tsai WB, 2006, J MATER SCI MATER M, V17, P337, DOI 10.1007/s10856 006 8234 x
   Yao YC, 2009, PHARM RES DORDR, V26, P263, DOI 10.1007/s11095 008 9772 3
   Yokoyama A, 2005, CELL TISSUE RES, V322, P289, DOI 10.1007/s00441 005 0010 6
   Yun K, 2008, J BIOSCI BIOENG, V105, P122, DOI 10.1263/jbb.105.122
   Zachos T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
NR 26
TC 20
Z9 24
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 25
PY 2010
VL 142
IS 1
BP 70
EP 77
DI 10.1016/j.jconrel.2009.09.027
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 569HH
UT WOS:000275586700011
PM 19822176
DA 2025 08 17
ER

PT J
AU Solanki, P
   Ansari, MD
   Anjali
   Khan, I
   Jahan, RN
   Nikita
   Pandit, J
   Aqil, M
   Ahmad, FJ
   Sultana, Y
AF Solanki, Pavitra
   Ansari, Mohd Danish
   Anjali
   Khan, Iram
   Jahan, Rao Nargis
   Nikita
   Pandit, Jayamanti
   Aqil, Mohd
   Ahmad, Farhan J.
   Sultana, Yasmin
TI Repurposing pentosan polysulfate sodium as hyaluronic acid linked
   polyion complex nanoparticles for the management of osteoarthritis: A
   potential approach
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Hyaluronic acid; Polyion complex nanoparticle; Transdermal delivery;
   Osteoarthritis; Inflammation; Pentosan polysulfate sodium
ID CUTANEOUS APPLICATION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;
   DOUBLE BLIND; CALCIUM; PLASMA; JOINT; PENETRATION; MODEL; KNEE
AB Osteoarthritis is still a disease burden for pharmaceutical scientists and strategy makers. It is associated with the chronic inflammation of joints especially weight bearing joints like knee, hip, backbone, and phalanges. NSAIDs that are used for the management of inflammation associated with osteoarthritis have high side effects related to gastric upset, gastric ulcer, and long term treatment associated with liver and kidney damage. Nanotechnology has gained a huge scope for the management of arthritis as it can reach out to the deep inside the cell and alter cellular physiology as desired. The present study hypothesizes the use of polyion complex nanoparticles of hyaluronic acid linked Pentosan polysulfate sodium, a disease modifying agent for the treatment of osteoarthritis administered through transdermal route. The hypothesis involves the use of drug repurposing as the drug was initially approved for interstitial cystitis, a condition of the urinary bladder associated with pain and swelling. Being very low oral bioavailability and gastric irritation profile, the transdermal route would be beneficial. To overcome the problem associated with the oral route, there is a need for the targeted approach that will particularly reach at inflammatory sites. Thereby transdermal delivery of hyaluronic acid linked Pentosan polysulfate sodium through polyion complex nanoparticle therapy will be a novel therapeutic approach to combat osteoarthritis.
C1 [Solanki, Pavitra; Ansari, Mohd Danish; Anjali; Khan, Iram; Jahan, Rao Nargis; Nikita; Pandit, Jayamanti; Aqil, Mohd; Ahmad, Farhan J.; Sultana, Yasmin] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
C3 Jamia Hamdard University
RP Sultana, Y (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
EM pavitraagra@gmail.com; ysultana@jamiahamdard.ac.in
RI ; Solanki, Dr Pavitra/ABG 4625 2021; Ansari, Mohd/LGZ 1720 2024; Ahmad,
   Farhan/HMO 6565 2023; Aqil, Mohd/M 4371 2015; SOLANKI,
   PAVITRA/ABG 4625 2021; Khan, Iram/J 4017 2012
OI Pandit, Dr Jayamanti/0000 0001 5816 5797; Solanki, Dr
   Pavitra/0000 0002 8032 9513; Ahmad, Farhan/0000 0002 0740 8573; Ansari,
   Dr. Mohd Danish/0009 0006 4035 5377; Solanki,
   Pavitra/0000 0001 9199 9566; 
FU DST Nano Mission [SR/NM/NS 1162/2015]
FX The author is highly thankful to DST Nano Mission for providing
   financial support to Pavitra Solanki in form of research associateship
   file no. SR/NM/NS 1162/2015.
CR Affleck G, 1999, PAIN, V83, P601, DOI 10.1016/S0304 3959(99)00167 0
   Altman R, 2015, DRUGS, V75, P859, DOI 10.1007/s40265 015 0392 z
   Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281 199805000 00018
   Anderson JM, 1997, CURR THER RES CLIN E, V58, P93, DOI 10.1016/S0011 393X(97)80118 X
   Ara R, 2011, J MED, V12, P142
   Aragon CL, 2007, JAVMA J AM VET MED A, V230, P514, DOI 10.2460/javma.230.4.514
   BANSAL MK, 1993, CURR THER RES CLIN E, V54, P714, DOI 10.1016/S0011 393X(05)80702 7
   Bwalya EC., 2017, DIS MODIFYING OSTEOA
   Dong L, 2004, J BIOMAT SCI POLYM E, V15, P671, DOI 10.1163/156856204323046924
   Elmesiry A, 2016, J ARTHRITIS, V5, P2
   Faaij RA, 1999, EUR J CLIN PHARMACOL, V54, P929, DOI 10.1007/s002280050577
   FALL M, 1985, J UROLOGY, V133, P774, DOI 10.1016/S0022 5347(17)49222 6
   Fortin PR, 2002, ARTHRITIS RHEUM, V46, P3327, DOI 10.1002/art.10631
   FRANCIS DJ, 1989, ARTHRITIS RHEUM US, V32, P608, DOI 10.1002/anr.1780320515
   Fuller CJ, 2002, EQUINE VET J, V34, P61, DOI 10.2746/042516402776181123
   Ghosh P, 1996, OSTEOARTHR CARTILAGE, V4, P43, DOI 10.1016/S1063 4584(96)80006 9
   Ghosh P, 2005, CURR THER RES CLIN E, V66, P552, DOI 10.1016/j.curtheres.2005.12.012
   Ghosh P, 1999, SEMIN ARTHRITIS RHEU, V28, P211, DOI 10.1016/S0049 0172(99)80021 3
   Goldring MB, 2012, ARTICULAR CARTILAGE
   GondolphZink B, 1996, AKTUEL RHEUMATOL, V21, P298, DOI 10.1055/s 2008 1043735
   Herrero LJ, 2015, J VIROL, V89, P8063, DOI 10.1128/JVI.00224 15
   How KN, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01105
   Huey DJ, 2012, SCIENCE, V338, P917, DOI 10.1126/science.1222454
   Jepps OG, 2013, ADV DRUG DELIVER REV, V65, P152, DOI 10.1016/j.addr.2012.04.003
   Jung HS, 2014, NANOMEDICINE UK, V9, P743, DOI [10.2217/nnm.14.47, 10.2217/NNM.14.47]
   Kaihara S, 2011, COLLOID SURFACE B, V85, P343, DOI 10.1016/j.colsurfb.2011.03.008
   Koch P, 1996, CONTACT DERMATITIS, V34, P156, DOI 10.1111/j.1600 0536.1996.tb02162.x
   Koenig TJ, 2014, VET SURG, V43, P612, DOI 10.1111/j.1532 950X.2014.12203.x
   Kong M, 2011, CARBOHYD POLYM, V86, P837, DOI 10.1016/j.carbpol.2011.05.027
   Kumagai Kenji, 2010, BMC Clin Pharmacol, V10, P7, DOI 10.1186/1472 6904 10 7
   Li GY, 2011, CHEM ENG J, V174, P199, DOI 10.1016/j.cej.2011.08.079
   Li JT, 2012, TISSUE ENG PART B RE, V18, P270, DOI [10.1089/ten.TEB.2011.0583, 10.1089/ten.teb.2011.0583]
   MACGREGOR IR, 1984, THROMB HAEMOSTASIS, V51, P321
   Meng J, 2010, BIOMED CHROMATOGR, V24, P169, DOI 10.1002/bmc.1266
   Mori M, 2016, INTERN MED J, V46, P15, DOI 10.1111/imj.33_13197
   Nelson AE, 2018, OSTEOARTHR CARTILAGE, V26, P319, DOI 10.1016/j.joca.2017.11.014
   Nickel JC, 2015, J UROLOGY, V193, P857, DOI 10.1016/j.juro.2014.09.036
   RADERMACHER J, 1991, BRIT J CLIN PHARMACO, V31, P537, DOI 10.1111/j.1365 2125.1991.tb05576.x
   Read RA, 1996, J SMALL ANIM PRACT, V37, P108, DOI 10.1111/j.1748 5827.1996.tb02355.x
   SCHEUPLEIN RJ, 1965, J INVEST DERMATOL, V45, P334, DOI 10.1038/jid.1965.140
   Secret E, 2013, ADV HEALTHC MATER, V2, P718, DOI 10.1002/adhm.201200335
   Song H, 2019, INT J NANOMED, V14, P3177, DOI 10.2147/IJN.S188842
   Takahashi I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196625
   Tannenbaum H, 2000, Can J Clin Pharmacol, V7 Suppl A, p4A
   Tao YL, 2015, INT J CLIN EXP PATHO, V8, P15911
   Villaverde G, 2019, BEILSTEIN J NANOTECH, V10, P168, DOI 10.3762/bjnano.10.16
   Walker Bone K, 2000, BMJ BRIT MED J, V321, P936, DOI 10.1136/bmj.321.7266.936
   Wu JH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0723 y
   Yang HJ, 2019, INT J BIOL MACROMOL, V125, P9, DOI 10.1016/j.ijbiomac.2018.11.230
   Yang JA, 2012, BIOMATERIALS, V33, P5947, DOI 10.1016/j.biomaterials.2012.05.003
   Zheng XP, 2012, BIOCHEM BIOPH RES CO, V423, P606, DOI 10.1016/j.bbrc.2012.06.045
NR 51
TC 7
Z9 8
U1 0
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD DEC
PY 2021
VL 157
AR 110713
DI 10.1016/j.mehy.2021.110713
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA YG9WD
UT WOS:000742828400006
PM 34710749
DA 2025 08 17
ER

PT J
AU Bryden, LA
   Nicholson, JR
   Doods, H
   Pekcec, A
AF Bryden, L. A.
   Nicholson, J. R.
   Doods, H.
   Pekcec, A.
TI Deficits in spontaneous burrowing behavior in the rat bilateral
   monosodium iodoacetate model of osteoarthritis: an objective measure of
   pain related behavior and analgesic efficacy
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Burrowing; Monosodium iodoacetate; Spontaneous behavior; Pain; Rat
ID KNEE JOINT INFLAMMATION; PHARMACOLOGICAL CHARACTERIZATION; NEUROPATHIC
   PAIN; NEURONAL INJURY; LABORATORY MICE; NERVE INJURY; RODENT MODEL;
   INHIBITOR; HIP; MONOIODOACETATE
AB Objective: To characterize deficits in burrowing behavior   an ethologically relevant rodent behavior   in the monosodium iodoacetate (MIA) rat model of osteoarthritis (OA), and the sensitivity of these deficits to reversal by analgesic drugs of both prototypical and novel mechanisms of action. A second objective was to compare the burrowing assay to a spontaneous locomotor activity (sLA) assay.
   Method: Male Wistar Han rats (200 220 g) received intrarticular (i.a.) injections of MIA or saline for sham animals. A deficit in the amount of sand burrowed from steel tubes filled with 2.5 kg of sand was used as a measure of pain related behavior, and sensitivity to reversal of these deficits by analgesic drugs was assessed in bilaterally MIA injected rats.
   Results: Bilateral MIA injections induced a significant impairment of burrowing behavior, which was concentration dependent. The temporal pattern of the deficits was biphasic: a large deficit at 3 days post injection, resolving by day 14 and returning at the 21 and 28 day time points. At the 3 day time point ibuprofen, celecoxib and an anti nerve growth factor (NGF) monoclonal antibody (mAb) were able to significantly reinstate burrowing behavior, whereas the fatty acid amide hydrolase (FAAH) inhibitor PF 04457845 and morphine displayed no reversal effect. Morphine impaired burrowing behavior at 3 mg/kg in sham animals. Deficits in rearing frequency in the locomotor activity assay proved irreversible by analgesics.
   Conclusion: Burrowing behavior provides an objective, non reflexive read out for pain related behavior in the MIA model that has predictive validity in detecting analgesic efficacy of nonsteroidal anti inflammatory drugs (NSAIDs) and an anti NGF mAb. (C) 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Bryden, L. A.; Nicholson, J. R.; Doods, H.; Pekcec, A.] Boehringer Ingelheim Pharma GmbH & Co KG, Div Res Germany, D 88397 Biberach, Germany.
C3 Boehringer Ingelheim
RP Pekcec, A (通讯作者)，Boehringer Ingelheim Pharma GmbH & Co KG, Div Res Germany, Birkendorfer Str 65, D 88397 Biberach, Germany.
EM luke.bryden@student.manchester.ac.uk;
   janet.nicholson@boehringer ingelheim.com;
   henri.doods@boehringer ingelheim.com;
   anton.pekcec@boehringer ingelheim.com
OI Bryden, Luke/0000 0002 6803 5715
FU Boehringer Ingelheim Pharma GmbH Co KG
FX All funding was provided by Boehringer Ingelheim Pharma GmbH & Co KG.
CR Ahn K, 2011, J PHARMACOL EXP THER, V338, P114, DOI 10.1124/jpet.111.180257
   Andrews N, 2012, EUR J PAIN, V16, P485, DOI 10.1016/j.ejpain.2011.07.012
   Andrews N, 2011, ANN NY ACAD SCI, V1245, P11, DOI 10.1111/j.1749 6632.2011.06342.x
   Antoniou K, 2007, EXPERT OPIN PHARMACO, V8, P1719, DOI 10.1517/14656566.8.11.1719
   Blackburn Munro G, 2004, TRENDS PHARMACOL SCI, V25, P299, DOI 10.1016/j.tips.2004.04.008
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   Brown MT, 2013, ARTHRITIS RHEUM US, V65, P1795, DOI 10.1002/art.37950
   Cobos EJ, 2012, PAIN, V153, P876, DOI 10.1016/j.pain.2012.01.016
   Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023
   Deacon RMJ, 2006, NAT PROTOC, V1, P118, DOI 10.1038/nprot.2006.19
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Ferreira Gomes J, 2012, MOL PAIN, V8, DOI [10.1186/1744 8069 850, 10.1186/1744 8069 8 50]
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P415, DOI 10.1016/j.joca.2007.12.017
   Hezareh M, 2001, J VIROL, V75, P12161, DOI 10.1128/JVI.75.24.12161 12168.2001
   Hinton R, 2002, AM FAM PHYSICIAN, V65, P841
   Huang WL, 2013, PAIN, V154, P560, DOI 10.1016/j.pain.2012.12.023
   Huggins JP, 2012, PAIN, V153, P1837, DOI 10.1016/j.pain.2012.04.020
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   Jirkof P, 2013, LAB ANIM UK, V47, P274, DOI 10.1177/0023677213493409
   Jirkof P, 2014, J NEUROSCI METH, V234, P139, DOI 10.1016/j.jneumeth.2014.02.001
   Jirkof P, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00165
   Jones CK, 2005, J PHARMACOL EXP THER, V312, P726, DOI 10.1124/jpet.104.075960
   Lau W, 2013, NEUROPHARMACOLOGY, V73, P204, DOI 10.1016/j.neuropharm.2013.05.023
   Le Graverand Gastineau MPH, 2010, CURR DRUG TARGETS, V11, P528
   Liu P, 2011, NEUROSCI LETT, V493, P72, DOI 10.1016/j.neulet.2011.01.027
   Matson DJ, 2007, J PHARMACOL EXP THER, V320, P194, DOI 10.1124/jpet.106.109736
   Mogil JS, 2009, NAT REV NEUROSCI, V10, P283, DOI 10.1038/nrn2606
   Mogil JS, 2004, PAIN, V112, P12, DOI 10.1016/j.pain.2004.09.028
   More AS, 2013, PHARMACOL BIOCHEM BE, V103, P764, DOI 10.1016/j.pbb.2012.12.013
   Nagase H, 2012, J PHARMACOL TOX MET, V65, P29, DOI 10.1016/j.vascn.2011.10.002
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 134
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Rutten K, 2014, EUR J PAIN, V18, P213, DOI 10.1002/j.1532 2149.2013.00359.x
   Rutten K, 2014, EUR J PAIN, V18, P204, DOI 10.1002/j.1532 2149.2013.00358.x
   Sherwin CM, 2004, APPL ANIM BEHAV SCI, V88, P343, DOI 10.1016/j.applanim.2004.03.009
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/nmeth.2935, 10.1038/NMETH.2935]
   Stevenson GW, 2011, PHARMACOL BIOCHEM BE, V98, P35, DOI 10.1016/j.pbb.2010.12.009
   Thakur M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033730
   Vierck CJ, 2008, PAIN, V135, P7, DOI 10.1016/j.pain.2007.12.008
   Whiteside GT, 2008, NEUROPHARMACOLOGY, V54, P767, DOI 10.1016/j.neuropharm.2008.01.001
   Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013
NR 45
TC 47
Z9 50
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD SEP
PY 2015
VL 23
IS 9
BP 1605
EP 1612
DI 10.1016/j.joca.2015.05.001
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA CQ5ON
UT WOS:000360655000019
PM 25966657
OA Bronze
DA 2025 08 17
ER

PT J
AU Romani, AA
   Desenzani, S
   Morganti, MM
   La Monica, S
   Borghetti, AF
   Soliani, P
AF Romani, Antonello A.
   Desenzani, Silvia
   Morganti, Marina M.
   La Monica, Silvia
   Borghetti, Angelo F.
   Soliani, Paolo
TI Zoledronic acid determines S phase arrest but fails to induce apoptosis
   in cholangiocarcinoma cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Cholangiocarcinoma; Zoledronic acid; Cyclins; Cell cycle regulators;
   Bcl xL; GGOH
ID BCL X L; CONTAINING BISPHOSPHONATES INHIBIT; HUMAN OSTEOSARCOMA CELLS;
   PROSTATE CANCER CELLS; IN VITRO; INTRAHEPATIC CHOLANGIOCARCINOMA;
   MEVALONATE PATHWAY; MULTIPLE MYELOMA; GROWTH; EXPRESSION
AB Cholangiocarcinoma is the second most common primary hepatic neoplasia and the only curative therapy is surgical resection or liver transplantation. Biphosphonates (BPs) are an emerging class of drugs widely used to treat bone diseases and also appear to possess direct antitumor activity. In two human cholangiocarcinoma cell lines (TFK 1 and EGI 1) we investigated, for the first time, the activity of zoledronic acid by determining proliferation, cell cycle analysis and apoptosis.
   The results obtained indicate that zoledronic acid induces cell narrowing and growth inhibition, both reversed by 25 mu M GGOH, and significantly affects the colony forming ability of these cells. The inhibition by zoledronic acid of Rap1A prenylation was reversed in cell co treated with GGOH. At 1050 mu M zoledronic acid exerted an S phase cell cycle arrest which was confirmed by changes in the level of cyclins and of regulators p27(KIPI) and pRb. Interestingly, the expression level of cyclin A (putative S phase marker) shows a dose dependent increment in contrast to the decrement of cyclin D1 (putative G1 phase marker). However, neither hypocliploid cells nor cleaved PARP or caspase 3 was detected. The lack of TP53 or loss of its function, the large constitutive expressions of anti apoptotic proteins Bcl xL and HSP27 together with the low level of the pro apoptotic Bax are the likely factors which protect cells from apoptosis.
   In conclusion, our study indicates that zoledronic acid induces S phase arrest and cell narrowing, both reversed by GGOH and, by changing the delicate balance between pro  and anti apoptotic proteins, allows survival of cholangiocarcinoma cells. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Romani, Antonello A.; Desenzani, Silvia; Morganti, Marina M.; La Monica, Silvia; Borghetti, Angelo F.] Univ Parma, Dipartimento Med Sperimentale, Sez Patol Mol & Immunol, I 43100 Parma, Italy.
   [Soliani, Paolo] Univ Parma, Dipartimento Sci Chirurg, Sez Clin Chirurg Gen & Trapianti Organo, I 43100 Parma, Italy.
C3 University of Parma; University of Parma
RP Borghetti, AF (通讯作者)，Univ Parma, Dipartimento Med Sperimentale, Sez Patol Mol & Immunol, Via Volturno 39, I 43100 Parma, Italy.
EM angelo.borghetti@unipr.it
OI La Monica, Silvia/0000 0003 3578 3917
FU Fondazione Cariparma, Parma, Italy
FX This study was supported by RE.GA.STR project (Programma di Ricerca
   Regione Universita 2007 2009, Emilia Romagna, Italy) and FIL grants from
   MIUR (Rome, Italy). Silvia Desenzani was supported by a fellowship from
   Fondazione Cariparma, Parma, Italy. We thank Simona StefAno for her
   precious technical assistance. Conflicts of interest: The authors report
   no conflicts of interest. The authors alone are responsible for the
   content and writing of the paper.
CR Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Blanco Colio LM, 2003, KIDNEY INT, V64, P181, DOI 10.1046/j.1523 1755.2003.00080.x
   Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310
   Borg Å, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260
   Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208
   Caca K, 2002, INT J CANCER, V97, P481, DOI 10.1002/ijc.1639
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Croucher P, 2003, BREAST, V12, pS30, DOI 10.1016/S0960 9776(03)80161 3
   Dive C, 1997, J INTERN MED, V242, P139, DOI 10.1111/joim.1997.242.s740.139
   DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092 8674(88)90205 X
   EASTMAN A, 1993, TOXICOL APPL PHARM, V121, P160, DOI 10.1006/taap.1993.1141
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448
   Gralow Julie, 2005, Clin Breast Cancer, V5 Suppl, pS54, DOI 10.3816/CBC.2005.s.005
   Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845
   Harnois DM, 1997, HEPATOLOGY, V26, P884, DOI 10.1053/jhep.1997.v26.pm0009328309
   Hayward RL, 2003, CLIN CANCER RES, V9, P2856
   Hoesl CE, 2006, UROL INT, V76, P97, DOI 10.1159/000090869
   Huether A, 2007, BIOCHEM PHARMACOL, V73, P1308, DOI 10.1016/j.bcp.2006.12.031
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140 6736(05)67530 7
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349 7006.2004.tb03202.x
   Lee MV, 2001, CANCER RES, V61, P2602
   Li XY, 2001, CANCER RES, V61, P1699
   Li YY, 2008, LUNG CANCER, V59, P180, DOI 10.1016/j.lungcan.2007.08.026
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Malhi H, 2006, J HEPATOL, V45, P856, DOI 10.1016/j.jhep.2006.09.001
   Melisi D, 2005, ENDOCR RELAT CANCER, V12, P1051, DOI 10.1677/erc.1.01061
   Mori Iwamoto S, 2007, INT J ONCOL, V31, P1345
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Okaro AC, 2002, GUT, V51, P556, DOI 10.1136/gut.51.4.556
   Okaro AC, 2001, J CLIN PATHOL, V54, P927, DOI 10.1136/jcp.54.12.927
   Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460 2075.1992.tb05135.x
   Patel T, 2006, NAT CLIN PRACT GASTR, V3, P33, DOI 10.1038/ncpgasthep0389
   Pazdur R, 1999, AM J CLIN ONCOL CANC, V22, P78, DOI 10.1097/00000421 199902000 00019
   Poplin E, 1999, INVEST NEW DRUG, V17, P57, DOI 10.1023/A:1006239200772
   Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555 005 5134 3
   Richards EH, 1996, CANCER RES, V56, P2446
   Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756 3282(96)00318 3
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Romani AA, 2007, BMC CANCER, V7, DOI 10.1186/1471 2407 7 232
   Romani AA, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 255
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Sonnemann J, 2003, ANTI CANCER DRUG, V14, P767, DOI 10.1097/01.cad.0000094848.34612.41
   SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0
   Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955 0674(03)00008 5
   Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721
   Thongprasert S, 2005, ANN ONCOL, V16, P279, DOI 10.1093/annonc/mdi046
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
NR 58
TC 26
Z9 28
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUL 15
PY 2009
VL 78
IS 2
BP 133
EP 141
DI 10.1016/j.bcp.2009.04.004
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 454QI
UT WOS:000266697000004
PM 19464430
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Mulangala, J
   Akers, EJ
   Solly, EL
   Bamhare, PM
   Wilsdon, LA
   Wong, NKP
   Tan, JTM
   Bursill, CA
   Nicholls, SJ
   Di Bartolo, BA
AF Mulangala, Jocelyne
   Akers, Emma J.
   Solly, Emma L.
   Bamhare, Panashe M.
   Wilsdon, Laura A.
   Wong, Nathan K. P.
   Tan, Joanne T. M.
   Bursill, Christina A.
   Nicholls, Stephen J.
   Di Bartolo, Belinda A.
TI Pro Calcific Environment Impairs Ischaemia Driven Angiogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE peripheral arterial disease; angiogenesis; vascular calcification;
   ischaemia
ID PERIPHERAL ARTERIAL DISEASE; ACTIVATION INDUCED CYTOKINE; VASCULAR
   CALCIFICATION; ENDOTHELIAL CELLS; RECEPTOR ACTIVATOR; LIMB ISCHEMIA;
   MOUSE MODEL; OSTEOPROTEGERIN; BONE; BISPHOSPHONATES
AB Peripheral arterial disease (PAD) is characterised by accelerated arterial calcification and impairment in angiogenesis. Studies implicate vascular calcification as a contributor to PAD, but the mechanisms remain unclear. We aimed to determine the effect of calcification on ischaemia driven angiogenesis. Human coronary artery endothelial cells (ECs) were treated with calcification medium (CM: CaCl2 2.7 mM, Na2PO4 2.0 mM) for 24 h and exposed to normoxia (5% CO2) or hypoxia (1.2% O 2; 5% CO2 balanced with N 2). In normoxia, CM significantly inhibited tubule formation and migration and upregulated calcification markers of ALP, BMP2, and Runx2. CM elevated levels of calcification protective gene OPG, demonstrating a compensatory mechanism by ECs. CM failed to induce pro angiogenic regulators VEGFA and HIF 1 alpha in hypoxia and further suppressed the phosphorylation of endothelial nitric oxide synthase (eNOS) that is essential for vascular function. In vivo, osteoprotegerin deficient mice (OPG( / )), a calcification model, were subjected to hind limb ischaemia (HLI) surgery. OPG( / ) mice displayed elevated serum alkaline phosphatase (ALP) activity compared to wild type controls. OPG( / ) mice experienced striking reductions in blood flow reperfusion in both 8 week old and 6 month old mice post HLI. This coincided with significant impairment in tissue ischaemia and reduced limb function as assessed by clinical scoring (Tarlov). This study demonstrated for the first time that a pro calcific environment is detrimental to ischaemia driven angiogenesis. The degree of calcification in patients with PAD can often be a limiting factor with the use of standard therapies. These highly novel findings require further studies for full elucidation of the mechanisms involved and have implications for the development of therapies to suppress calcification in PAD.
C1 [Mulangala, Jocelyne; Akers, Emma J.; Solly, Emma L.; Tan, Joanne T. M.; Bursill, Christina A.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia.
   [Mulangala, Jocelyne; Akers, Emma J.; Solly, Emma L.; Bamhare, Panashe M.; Wilsdon, Laura A.; Wong, Nathan K. P.; Tan, Joanne T. M.; Bursill, Christina A.] South Australian Hlth & Med Res Inst, Vasc Res Ctr, Heart Hlth Theme, Adelaide, SA 5000, Australia.
   [Wong, Nathan K. P.; Di Bartolo, Belinda A.] Univ Sydney, Fac Med & Hlth, Sch Med, Sydney, NSW 2006, Australia.
   [Nicholls, Stephen J.] Monash Univ, Monash Cardiovasc Res Ctr, Victorian Heart Inst, Melbourne, Vic 3168, Australia.
C3 University of Adelaide; South Australian Health & Medical Research
   Institute (SAHMRI); University of Sydney; Monash University
RP Di Bartolo, BA (通讯作者)，Univ Sydney, Fac Med & Hlth, Sch Med, Sydney, NSW 2006, Australia.
EM j.mulangala@centenary.org.au; emma.akers@outlook.com;
   emma.solly@sahmri.com; panashe.bamhare@outlook.com;
   wilsdonlaura@gmail.com; nwon9940@alumni.sydney.edu.au;
   joanne.tan@sahmri.com; christina.bursill@sahmri.com;
   stephen.nicholls@monash.edu; belinda.dibartolo@sydney.edu.au
RI ; Di Bartolo, Belinda/AAF 5153 2021; Tan, Joanne/Y 4423 2019
OI Solly, Emma/0000 0001 9992 1181; Tan, Joanne/0000 0003 1875 4882; Di
   Bartolo, Belinda/0000 0001 8420 0461; Bursill,
   Christina/0000 0002 0682 8760; 
FU AstraZeneca; Amgen Inc; Anthera; Eli Lilly; Novartis; Cerenis; The
   Medicines Company; Resverlogix; InfraReDx; Roche; SanofiRegeneron;
   LipoScience
FX Disclosure: S.J.N. reports receiving research support from AstraZeneca,
   Amgen Inc, Anthera, Eli Lilly, Novartis, Cerenis, The Medicines Company,
   Resverlogix, InfraReDx, Roche, SanofiRegeneron, and LipoScience, as well
   as receiving consulting fees and honoraria from AstraZeneca, Akcea, Eli
   Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi Regeneron,
   CSL Behring, Esperion, and Boehringer Ingelheim.
CR Anand DV, 2006, J AM COLL CARDIOL, V47, P1850, DOI 10.1016/j.jacc.2005.12.054
   Au TB, 2013, AUST FAM PHYSICIAN, V42, P397
   Baud'huin M, 2007, CELL MOL LIFE SCI, V64, P2334, DOI 10.1007/s00018 007 7104 0
   Bennett BJ, 2006, ARTERIOSCL THROM VAS, V26, P2117, DOI 10.1161/01.ATV.0000236428.91125.e6
   Benslimane Ahmim Z, 2011, J THROMB HAEMOST, V9, P834, DOI 10.1111/j.1538 7836.2011.04207.x
   Benslimane Ahmim Z, 2013, ANGIOGENESIS, V16, P575, DOI 10.1007/s10456 013 9337 x
   Brenes RA, 2012, J VASC SURG, V56, P1669, DOI 10.1016/j.jvs.2012.04.067
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Cannizzo CM, 2018, FASEB J, V32, P2911, DOI 10.1096/fj.201700617R
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Collett GDM, 2005, CIRC RES, V96, P930, DOI 10.1161/01.RES.0000163634.51301.0d
   Collinson DJ, 2004, EUR J VASC ENDOVASC, V28, P9, DOI 10.1016/j.ejvs.2004.03.021
   Criqui MH, 2015, CIRC RES, V116, P1509, DOI 10.1161/CIRCRESAHA.116.303849
   Cross SS, 2006, INT J CANCER, V118, P1901, DOI 10.1002/ijc.21606
   Di Bartolo BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074211
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fournier P, 2002, CANCER RES, V62, P6538
   Giallauria F, 2013, CURR GERIATR REP, V2, P255, DOI 10.1007/s13670 013 0063 4
   Golomb BA, 2006, CIRCULATION, V114, P688, DOI 10.1161/CIRCULATIONAHA.105.593442
   Hirsch AT, 2001, JAMA J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317
   Ho CY, 2016, ARTERIOSCL THROM VAS, V36, P1475, DOI 10.1161/ATVBAHA.116.306717
   Karamysheva AF, 2008, BIOCHEMISTRY MOSCOW+, V73, P751, DOI 10.1134/S0006297908070031
   Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kwon TG, 2011, J CELL BIOCHEM, V112, P3582, DOI 10.1002/jcb.23289
   Lee SH, 2012, J BIOL CHEM, V287, P14760, DOI 10.1074/jbc.M112.340232
   Limbourg A, 2009, NAT PROTOC, V4, P1737, DOI 10.1038/nprot.2009.185
   Lotfi S, 2013, ATHEROSCLEROSIS, V227, P1, DOI 10.1016/j.atherosclerosis.2012.10.060
   Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200
   McGonigle JS, 2009, ANGIOGENESIS, V12, P35, DOI 10.1007/s10456 008 9127 z
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood 2006 06 029298
   Min JK, 2003, J BIOL CHEM, V278, P39548, DOI 10.1074/jbc.M300539200
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Morony S, 2008, CIRCULATION, V117, P411, DOI 10.1161/CIRCULATIONAHA.107.707380
   Munaron L, 2006, RECENT PAT ANTI CANC, V1, P105, DOI 10.2174/157489206775246502
   Olszewska Pazdrak B, 2009, AM J PHYSIOL CELL PH, V296, pC1162, DOI 10.1152/ajpcell.00533.2008
   Or C, 2013, BRIT J OPHTHALMOL, V97, P1074, DOI 10.1136/bjophthalmol 2013 303355
   Ouriel K, 2001, LANCET, V358, P1257, DOI 10.1016/S0140 6736(01)06351 6
   Persy V, 2006, KIDNEY INT, V70, P1537, DOI 10.1038/sj.ki.5001899
   Rochette L, 2018, PHARMACOL THERAPEUT, V182, P115, DOI 10.1016/j.pharmthera.2017.08.015
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shroff R, 2013, J AM SOC NEPHROL, V24, P179, DOI 10.1681/ASN.2011121191
   St Hilaire C, 2022, ARTERIOSCL THROM VAS, V42, P253, DOI 10.1161/ATVBAHA.121.316252
   Sun LX, 2001, CANCER RES, V61, P4994
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P3162, DOI 10.1210/jc.86.7.3162
   Tahergorabi Z, 2012, IRAN J BASIC MED SCI, V15, P1110
   Tan JTM, 2015, CARDIOVASC RES, V106, P184, DOI 10.1093/cvr/cvv104
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Yao YC, 2013, CIRC RES, V113, P495, DOI 10.1161/CIRCRESAHA.113.301792
   Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925 4773(01)00428 2
   Zettervall SL, 2018, J VASC SURG, V67, P507, DOI 10.1016/j.jvs.2017.06.086
   Zhu Dongxing, 2012, Front Endocrinol (Lausanne), V3, P95, DOI 10.3389/fendo.2012.00095
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 56
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 6
AR 3363
DI 10.3390/ijms23063363
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0C5MO
UT WOS:000775357300001
PM 35328786
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Niibori, M
   Kudo, Y
   Hayakawa, T
   Ikoma Seki, K
   Kawamata, R
   Sato, A
   Mizumura, K
AF Niibori, Mizuho
   Kudo, Yasushi
   Hayakawa, Takuya
   Ikoma Seki, Keiko
   Kawamata, Ryosuke
   Sato, Atsushi
   Mizumura, Kazue
TI Mechanism of aspirin induced inhibition on the secondary hyperalgesia in
   osteoarthritis model rats
SO HELIYON
LA English
DT Article
DE Osteoarthritis; Acetylsalicylic acid; Secondary hyperalgesia; Monosodium
   iodoacetate; Rat model; Immunology; Pharmaceutical science; Pain
   research; Pharmacology
ID SENSING ION CHANNELS; TNF ALPHA; ACETYLSALICYLIC ACID; KNEE
   OSTEOARTHRITIS; PAIN; EXPRESSION; JOINT; INFLAMMATION; ACTIVATION;
   RESPONSES
AB Aims: The daily activity of osteoarthritis (OA) patients is limited by chronic pain and central sensitization. Although non steroidal anti inflammatory drugs (NSAIDs) and acetaminophen are the first line drugs for the treatment of OA related pain, their efficacy on central sensitization remains unclear. In the present study, we evaluated the effect of acetylsalicylic acid (ASA, Aspirin) using an OA model induced by monosodium iodoacetate (MIA), which has a similar disease progression to human OA.
   Main methods: Secondary hyperalgesia was assessed at the plantar surface of the hind paw by Von Frey test. We evaluated the expression of acid sensing ion channel 3 (ASIC3) in dorsal root ganglia and that of tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL 1 beta) in the spinal cord, which may cause secondary hyperalgesia in OA, by immunohistochemical analysis and real time qPCR.
   Key findings: The administration of ASA attenuated secondary hyperalgesia at 1 3 weeks after MIA, while celecoxib, a selective cyclooxygenase (COX) 2 inhibitor, failed to attenuate secondary hyperalgesia at week 2 after MIA injection, suggesting that ASA exerts its analgesic effect through a COX 2 independent pathway. Immunohistochemical analysis of the dorsal root ganglia indicated that ASA reduced the expression of ASIC3 during OA progression. Expression of TNF alpha mRNA, but not IL 1 beta mRNA, in the spinal cord following MIA injection was suppressed by ASA administration.
   Significance: These findings suggest that ASA may have the ability to attenuate secondary hyperalgesia through suppression of ASIC3 and/or TNF alpha expression. ASA is therefore a clinically useful analgesic drug for treatment of secondary hyperalgesia in OA.
C1 [Niibori, Mizuho; Kudo, Yasushi; Hayakawa, Takuya; Ikoma Seki, Keiko] Lion Corp, Res & Dev Headquarters, Pharmaceut Res Labs, Tokyo, Japan.
   [Kawamata, Ryosuke; Sato, Atsushi] Lion Corp, Res & Dev Headquarters, Adv Analyt Sci Labs, Tokyo, Japan.
   [Mizumura, Kazue] Nihon Univ, Dept Physiol, Sch Dent, Tokyo, Japan.
   [Mizumura, Kazue] Chubu Univ, Coll Life & Hlth Sci, Kasugai, Aichi, Japan.
C3 Lion Corporation; Lion Corporation; Nihon University; Chubu University
RP Niibori, M (通讯作者)，Lion Corp, Res & Dev Headquarters, Pharmaceut Res Labs, Tokyo, Japan.
EM mniibori@lion.co.jp
OI Sato, Atsushi/0009 0005 8775 1687
FU Lion Corporation, Japan
FX This work was fully funded by Lion Corporation, Japan
   (https://www.lion.co.jp/en/). The Lion Corporation provided support in
   the form of salaries for authors M. Niibori, Y. Kudo, T. Hayakawa, K.
   IkomaSeki, R. Kawamata and A. Sato. K. Mizumura received consulting fee
   from Lion Corporation.
CR Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007
   Brunton L.L., 2017, GOODMAN GILMANS PHAR, P691
   Calich ALG, 2010, CLIN RHEUMATOL, V29, P451, DOI 10.1007/s10067 009 1352 3
   Choudhary D., 2018, BMC COMPLEM ALTERN M, V18, P1
   Coderre TJ, 1997, BEHAV BRAIN SCI, V20, P404, DOI 10.1017/S0140525X97251484
   Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023
   Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Gong K, 2011, J FORMOS MED ASSOC, V110, P145, DOI 10.1016/S0929 6646(11)60024 7
   Hakim AW, 2009, J NEUROPHYSIOL, V102, P1551, DOI 10.1152/jn.00326.2009
   Halliday DA, 1998, NEUROCHEM RES, V23, P919, DOI 10.1023/A:1022475432077
   Hanesch U, 1995, J NEUROSCI METH, V63, P55, DOI 10.1016/0165 0270(95)00086 0
   Hu HB, 2016, INT J MOL MED, V38, P1922, DOI 10.3892/ijmm.2016.2770
   HUNSKAAR S, 1986, PAIN, V25, P125, DOI 10.1016/0304 3959(86)90014 X
   Ikeuchi M, 2008, PAIN, V137, P662, DOI 10.1016/j.pain.2008.01.020
   Im HJ, 2010, ARTHRITIS RHEUM US, V62, P2995, DOI 10.1002/art.27608
   Imamura M, 2008, ARTHRIT RHEUM ARTHR, V59, P1424, DOI 10.1002/art.24120
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   Izumi M, 2012, J BIOMED SCI, V19, DOI 10.1186/1423 0127 19 77
   Jeong JW, 2017, EXCLI J, V16, P265, DOI 10.17179/excli2017 119
   KALBHEN DA, 1987, J RHEUMATOL, V14, P130
   Kelly S, 2015, ANN RHEUM DIS, V74, P252, DOI 10.1136/annrheumdis 2013 203413
   Kobayashi K, 2003, J VET MED SCI, V65, P1195, DOI 10.1292/jvms.65.1195
   Kolker SJ, 2010, ANN RHEUM DIS, V69, P903, DOI 10.1136/ard.2009.117168
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   Lee YC, 2011, ARTHRIT CARE RES, V63, P320, DOI 10.1002/acr.20373
   Li ZY, 2016, J ANESTH, V30, P55, DOI 10.1007/s00540 015 2077 x
   Mamet J, 2003, J BIOL CHEM, V278, P48907, DOI 10.1074/jbc.M309468200
   Maurer K, 2014, NEUROSCI LETT, V563, P101, DOI 10.1016/j.neulet.2014.01.050
   Miller RE, 2012, P NATL ACAD SCI USA, V109, P20602, DOI 10.1073/pnas.1209294110
   Murase S, 2010, J NEUROSCI, V30, P3752, DOI 10.1523/JNEUROSCI.3803 09.2010
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 134
   PALMOSKI MJ, 1980, ARTHRITIS RHEUM US, V23, P83, DOI 10.1002/art.1780230114
   Sachs D, 2011, BRIT J PHARMACOL, V162, P72, DOI 10.1111/j.1476 5381.2010.00895.x
   Sagar DR, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 88
   Sakurai Y, 2019, PAIN, V160, P895, DOI 10.1097/j.pain.0000000000001466
   Schaible HG, 2002, ANN NY ACAD SCI, V966, P343, DOI 10.1111/j.1749 6632.2002.tb04234.x
   The National Institute for Health and Care Excellence, 2014, OST CAR MAN OST CAR
   Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21 20 08026.2001
   Wemmie JA, 2013, NAT REV NEUROSCI, V14, P461, DOI 10.1038/nrn3529
   Wluka A, 2015, MATURITAS, V81, P394, DOI 10.1016/j.maturitas.2015.04.015
   Yang YY, 2004, ATHEROSCLEROSIS, V174, P207, DOI 10.1016/j.atherosclerosis.2004.01.024
NR 42
TC 17
Z9 17
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2405 8440
J9 HELIYON
JI Heliyon
PD MAY
PY 2020
VL 6
IS 5
AR e03963
DI 10.1016/j.heliyon.2020.e03963
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LU4TO
UT WOS:000537749900117
PM 32478188
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Morandi, A
   Barbetti, V
   Riverso, M
   Dello Sbarba, P
   Rovida, E
AF Morandi, Andrea
   Barbetti, Valentina
   Riverso, Maria
   Dello Sbarba, Persio
   Rovida, Elisabetta
TI The Colony Stimulating Factor 1 (CSF 1) Receptor Sustains ERK1/2
   Activation and Proliferation in Breast Cancer Cell Lines
SO PLOS ONE
LA English
DT Article
ID C FMS PROTOONCOGENE; GENE EXPRESSION; GROWTH FACTOR; CONSTITUTIVE
   PRODUCTION; SIGNAL TRANSDUCTION; MICROARRAY ANALYSIS; SUPPRESSES GROWTH;
   TUMOR XENOGRAFTS; MAMMARY TUMORS; COPY NUMBER
AB Breast cancer is the second leading cause of cancer related deaths in western countries. Colony Stimulating Factor 1 (CSF 1) and its receptor (CSF 1R) regulate macrophage and osteoclast production, trophoblast implantation and mammary gland development. The expression of CSF 1R and/or CSF 1 strongly correlates with poor prognosis in several human epithelial tumors, including breast carcinomas. We demonstrate that CSF 1 and CSF 1R are expressed, although at different levels, in 16/17 breast cancer cell lines tested with no differences among molecular subtypes. The role of CSF 1/CSF 1R in the proliferation of breast cancer cells was then studied in MDAMB468 and SKBR3 cells belonging to different subtypes. CSF 1 administration induced ERK1/2 phosphorylation and enhanced cell proliferation in both cell lines. Furthermore, the inhibition of CSF 1/CSF 1R signaling, by CSF 1R siRNA or imatinib treatment, impaired CSF 1 induced ERK1/2 activation and cell proliferation. We also demonstrate that c Jun, cyclin D1 and c Myc, known for their involvement in cell proliferation, are downstream CSF 1R in breast cancer cells. The presence of a proliferative CSF 1/CSF 1R autocrine loop involving ERK1/2 was also found. The wide expression of the CSF 1/CSF 1R pair across breast cancer cell subtypes supports CSF 1/CSF 1R targeting in breast cancer therapy.
C1 Univ Florence, Dipartimento Patol & Oncol Sperimentali, Florence, Italy.
   Ist Toscano Tumori, Florence, Italy.
C3 University of Florence; ISPRO Istituto per lo studio, la prevenzione e
   la rete oncologica
RP Morandi, A (通讯作者)，Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
EM persio@unifi.it; erovida@unifi.it
RI Dello Sbarba, Persio/AAX 9887 2020; Rovida, Elisabetta/F 3565 2015;
   Morandi, Andrea/AAC 1901 2022
OI Rovida, Elisabetta/0000 0002 5949 3239; Morandi,
   Andrea/0000 0002 9222 5332
FU Istituto Toscano Tumori; Associazione Italiana per la Ricerca sul Cancro
   (AIRC) [IG5220]; Ministero della Salute (Ricerca Finalizzata); Regione
   Toscana (Programma per la Ricerca in Materia di Salute); Associazione
   Italiana per la lotta contro le Leucemie e i Linfomi; sezione di Prato;
   Fondazione Cassa di Risparmio di Volterra; Federazione Italiana per la
   Ricerca sul Cancro (FIRC/AIRC)
FX This work was supported by Istituto Toscano Tumori (PDS), Associazione
   Italiana per la Ricerca sul Cancro (AIRC, contr.n. IG5220; PDS),
   Ministero della Salute (Ricerca Finalizzata; PDS), Regione Toscana
   (Programma per la Ricerca in Materia di Salute; PDS), Associazione
   Italiana per la lotta contro le Leucemie e i Linfomi (AIL) sezione di
   Prato (PDS), Fondazione Cassa di Risparmio di Volterra (PDS). VB was
   recipient of a fellowship from Federazione Italiana per la Ricerca sul
   Cancro (FIRC/AIRC). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008 5472.CAN 04 0961
   Aharinejad S, 2002, CANCER RES, V62, P5317
   ASHMUN RA, 1989, BLOOD, V73, P827
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585 008 9170 6
   Brownlow N, 2008, LEUKEMIA, V22, P649, DOI 10.1038/sj.leu.2404944
   Cohen PE, 1999, J LEUKOCYTE BIOL, V66, P765, DOI 10.1002/jlb.66.5.765
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065 230X(04)91001 9
   Esparís Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270 285.2002
   Espinosa I, 2009, AM J PATHOL, V174, P2347, DOI 10.2353/ajpath.2009.081037
   FILDERMAN AE, 1992, CANCER RES, V52, P3661
   FlidelRimon O, 1997, J PEDIATR US, V131, P748, DOI 10.1016/S0022 3476(97)70105 7
   Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 96
   Gallet M, 2006, APOPTOSIS, V11, P1909, DOI 10.1007/s10495 006 9507 z
   Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145
   HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006 291X(88)80060 3
   Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099
   KACINSKI BM, 1991, ONCOGENE, V6, P941
   Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098 2795(199701)46:1<71::AID MRD11>3.0.CO;2 6
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kirma N, 2004, CANCER RES, V64, P4162, DOI 10.1158/0008 5472.CAN 03 2971
   Kirma N, 2007, CANCER RES, V67, P1918, DOI 10.1158/0008 5472.CAN 06 1991
   Kluger HM, 2004, LAB INVEST, V84, P320, DOI 10.1038/labinvest.3700044
   Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078 0432.CCR 0699 3
   Lee AWM, 2006, CELL DEATH DIFFER, V13, P1900, DOI 10.1038/sj.cdd.4401884
   Lee AWM, 1999, ONCOGENE, V18, P7477, DOI 10.1038/sj.onc.1203123
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maher MG, 1998, CLIN CANCER RES, V4, P1851
   Mashkani B, 2010, BIOORGAN MED CHEM, V18, P1789, DOI 10.1016/j.bmc.2010.01.056
   Meegalla SK, 2008, BIOORG MED CHEM LETT, V18, P3632, DOI 10.1016/j.bmcl.2008.04.059
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ohno H, 2006, MOL CANCER THER, V5, P2634, DOI 10.1158/1535 7163.MCT 05 0313
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008 5472.CAN 09 1868
   Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008 5472.CAN 05 3523
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Quintás Cardama A, 2009, NAT REV CLIN ONCOL, V6, P535, DOI 10.1038/nrclinonc.2009.112
   RAMAKRISHNAN S, 1989, J CLIN INVEST, V83, P921, DOI 10.1172/JCI113977
   ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015
   Roussel MF, 1997, MOL REPROD DEV, V46, P11, DOI 10.1002/(SICI)1098 2795(199701)46:1<11::AID MRD3>3.0.CO;2 U
   ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924
   Rovida E, 2008, J IMMUNOL, V180, P4166, DOI 10.4049/jimmunol.180.6.4166
   Sapi E, 2004, EXP BIOL MED, V229, P1
   Sapi E, 1996, CANCER RES, V56, P5704
   SCHOLL SM, 1994, JNCI J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120
   SHERR CJ, 1990, BLOOD, V75, P1
   SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092 8674(85)80047 7
   Sims D, 2010, BREAST CANCER RES TR, V124, P567, DOI 10.1007/s10549 010 0945 5
   Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   STANLEY ER, 1985, METHOD ENZYMOL, V116, P564
   Tamimi RM, 2008, CANCER RES, V68, P18, DOI 10.1158/0008 5472.CAN 07 3234
   TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008 5472.CAN 04 1449
   Yee LD, 2000, ANTICANCER RES, V20, P4379
NR 62
TC 45
Z9 55
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 9
PY 2011
VL 6
IS 11
AR e27450
DI 10.1371/journal.pone.0027450
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 852II
UT WOS:000297350800053
PM 22096574
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Ketteler, M
   Wiecek, A
   Rosenkranz, AR
   Ose, C
   Rekowski, J
   Lorenz, H
   Hellmann, B
   Karus, M
   Ruhmann, M
   Ammer, R
AF Ketteler, Markus
   Wiecek, Andrzej
   Rosenkranz, Alexander R.
   Ose, Claudia
   Rekowski, Jan
   Lorenz, Horst
   Hellmann, Burkhard
   Karus, Michael
   Ruhmann, Michaela
   Ammer, Richard
TI Modified release nicotinamide for the treatment of hyperphosphataemia in
   haemodialysis patients: 52 week efficacy and safety results of the phase
   3 randomized controlled NOPHOS trial
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE haemodialysis; hyperphosphataemia; mineral and bone disease;
   nicotinamide; randomized controlled trial
ID HERPES ZOSTER; PHOSPHATE TRANSPORTER; MORTALITY RISK; SERUM CALCIUM;
   DOUBLE BLIND; PHOSPHORUS; NIACIN; DISEASE; SURVIVAL; THROMBOCYTOPENIA
AB Background We previously reported that modified release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here we report outcomes after 52 weeks of treatment. Methods NOPHOS was a phase 3, international, randomized, controlled, double blind trial with a parallel group design. NAMR (250 1500 mg/day) was investigated in comparison to placebo as an add on therapy to an individual therapy with approved phosphate binders. Results In the intention to treat population (NAMR: n = 539; placebo: n = 183), serum phosphate was significantly lower in the NAMR group compared with the placebo group at week 24 (5.40 +/  1.55 versus 5.79 +/  1.37 mg/dl, P < .001) with a mean difference of  0.39 mg/dl [95% confidence interval (CI)  0.66 to  0.13], but was comparable between the groups at week 52 [mean difference  0.08 (95% CI  0.36 0.20)]. In the completer population (n = 358), statistical significance in favour of NAMR was reached at weeks 24 and 52. The treatment effect was reduced in patients with high baseline serum intact parathyroid hormone (iPTH) compared with patients with low baseline serum iPTH. Compliant patients in the NAMR group had a more pronounced and sustained reduction in serum phosphate than non compliant patients. NAMR treatment was associated with a significantly increased risk of thrombocytopenia, pruritus, anaemia, and diarrhoea. Herpes zoster occurred exclusively in patients randomized to NAMR. Conclusions NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Non compliance may have contributed to reduced long term efficacy. Several newly identified safety signals warrant further evaluation.
C1 [Ketteler, Markus] Robert Bosch Krankenhaus, Dept Gen Internal Med & Nephrol, Stuttgart, Germany.
   [Ketteler, Markus] Univ Split, Sch Med, Split, Croatia.
   [Wiecek, Andrzej] Med Univ Silesia, Dept Nephrol Transplantat & Internal Med, Katowice, Poland.
   [Rosenkranz, Alexander R.] Med Univ Graz, Dept Internal Med, Div Nephrol, Graz, Austria.
   [Ose, Claudia; Rekowski, Jan] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Informat Biometry & Epidemiol, Essen, Germany.
   [Ose, Claudia; Rekowski, Jan] Univ Duisburg Essen, Univ Hosp Essen, Ctr Clin Trials, Essen, Germany.
   [Lorenz, Horst] Bur Biometrie & Stat, Neuberg, Germany.
   [Hellmann, Burkhard; Karus, Michael; Ruhmann, Michaela; Ammer, Richard] MEDICE Arzneimittel Putter GmbH & Co KG, Med Dept, Iserlohn, Germany.
   [Ammer, Richard] Univ Hosp Munster, Dept Nephrol, Munster, Germany.
C3 Bosch; Robert Bosch Krankenhaus; University of Split; Medical University
   of Silesia; Medical University of Graz; University of Duisburg Essen;
   University of Duisburg Essen; University of Munster
RP Ammer, R (通讯作者)，MEDICE Arzneimittel Putter GmbH & Co KG, Med Dept, Iserlohn, Germany.; Ammer, R (通讯作者)，Univ Hosp Munster, Dept Nephrol, Munster, Germany.
EM Richard.Ammer@ukmuenster.de
RI Ose, Claudia/AAS 9345 2020
OI Wiecek, Andrzej/0000 0002 8625 4188; Rekowski, Jan/0000 0002 5207 3864
FU MEDICE Arzneimittel Putter GmbH Co.
FX This trial was funded by MEDICE Arzneimittel Putter GmbH & Co. KG.
CR ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Anderson TJ, 2014, NEW ENGL J MED, V371, P288, DOI 10.1056/NEJMc1311039
   [Anonymous], 2012, ADV NAT SCI NANOSCI, DOI DOI 10.3968/J.ANS.1715787020120501.1001
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Cheng SC, 2008, CLIN J AM SOC NEPHRO, V3, P1131, DOI 10.2215/CJN.04211007
   Delanaye P, 2006, KIDNEY INT, V69, P1914, DOI 10.1038/sj.ki.5000381
   Arenas MD, 2010, J NEPHROL, V23, P525
   El Borolossy R, 2016, PEDIATR NEPHROL, V31, P289, DOI 10.1007/s00467 015 3208 1
   Eto N, 2005, NEPHROL DIAL TRANSPL, V20, P1378, DOI 10.1093/ndt/gfh781
   Fissell RB, 2016, HEMODIAL INT, V20, P38, DOI 10.1111/hdi.12315
   Floege J, 2010, NEPHROL DIAL TRANSPL, V25, P1916, DOI 10.1093/ndt/gfp762
   Fouque D, 2018, DRUGS, V78, P1171, DOI 10.1007/s40265 018 0950 2
   FROMKE VL, 1972, MEDICINE, V51, P451, DOI 10.1097/00005792 197211000 00002
   Ghimire S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144119
   Goldie C, 2016, HEART, V102, P198, DOI 10.1136/heartjnl 2015 308055
   Grundy SM, 2002, ARCH INTERN MED, V162, P1568, DOI 10.1001/archinte.162.14.1568
   Hengelbrock J, 2016, PHARM STAT, V15, P315, DOI 10.1002/pst.1757
   Hou Y, 2017, CLIN CHIM ACTA, V474, P108, DOI 10.1016/j.cca.2017.09.005
   Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130
   Ichida Y, 2021, NEPHROL DIAL TRANSPL, V36, P68, DOI 10.1093/ndt/gfaa156
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Karamanidou C, 2008, BMC NEPHROL, V9, DOI 10.1186/1471 2369 9 2
   Katai K, 1999, NEPHROL DIAL TRANSPL, V14, P1195, DOI 10.1093/ndt/14.5.1195
   Ketteler M, 2021, KIDNEY INT REP, V6, P594, DOI 10.1016/j.ekir.2020.12.012
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kuo CC, 2012, AM J KIDNEY DIS, V59, P428, DOI 10.1053/j.ajkd.2011.10.049
   Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955
   Lenglet A, 2017, NEPHROL DIAL TRANSPL, V32, P870, DOI 10.1093/ndt/gfw042
   Liu XY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.228
   Fernandez Martín JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099
   Fernández Martín JL, 2013, NEPHROL DIAL TRANSPL, V28, P1922, DOI 10.1093/ndt/gfs418
   Maccubbin D, 2008, INT J CLIN PRACT, V62, P1959, DOI 10.1111/j.1742 1241.2008.01938.x
   Mareque M, 2019, PUBLIC HEALTH, V167, P136, DOI 10.1016/j.puhe.2018.10.015
   McKenney J, 2010, J CLIN LIPIDOL, V4, P105, DOI 10.1016/j.jacl.2010.02.002
   Muñoz Quiles C, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879 018 3121 x
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   OHKUBO H, 1979, DIGEST DIS SCI, V24, P700, DOI 10.1007/BF01314468
   Papagianni M, 2018, DIABETES THER, V9, P545, DOI 10.1007/s13300 018 0394 4
   Rottembourg JB, 2005, KIDNEY INT, V68, P2911, DOI 10.1111/j.1523 1755.2005.00583_8.x
   Sabbagh Y, 2009, J AM SOC NEPHROL, V20, P2348, DOI 10.1681/ASN.2009050559
   Sato T, 2009, CLIN KIDNEY J, V2, P263, DOI 10.1093/ndtplus/sfp024
   Shahbazian H, 2011, NEFROLOGIA, V31, P58, DOI 10.3265/Nefrologia.pre2010.Nov.10734
   Takahashi Y, 2004, KIDNEY INT, V65, P1099, DOI 10.1111/j.1523 1755.2004.00482.x
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tseng HF, 2016, CLIN INFECT DIS, V62, P462, DOI 10.1093/cid/civ930
   Tsuboi Y, 2020, KIDNEY INT, V98, P343, DOI 10.1016/j.kint.2020.02.040
   Vasantha J, 2011, Indian J Nephrol, V21, P245, DOI 10.4103/0971 4065.83735
   Wu BJ, 2012, CIRCULATION, V125, P150, DOI 10.1161/CIRCULATIONAHA.111.053108
   Young DO, 2009, PERITON DIALYSIS INT, V29, P562
NR 49
TC 6
Z9 7
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAR 31
PY 2023
VL 38
IS 4
BP 982
EP 991
DI 10.1093/ndt/gfac206
EA AUG 2022
PG 10
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA D4LH7
UT WOS:000837545600001
PM 35751625
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Elseweidy, MM
   Zein, N
   Aldhamy, SE
   Elsawy, MM
   Saeid, SA
AF Elseweidy, Mohamed M.
   Zein, Nabila
   Aldhamy, Samih E.
   Elsawy, Marwa M.
   Saeid, Saeid A.
TI Policosanol as a new inhibitor candidate for vascular calcification in
   diabetic hyperlipidemic rats
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Diabetic hyperlipidemia; policosanol; omega 3 fatty acids; atorvastatin;
   inflammation; oxidative stress; aortic calcification
ID II HYPERCHOLESTEROLEMIA; CARDIOVASCULAR DISEASE; PROTEIN EXPRESSION;
   KINASE; CELLS; ATHEROSCLEROSIS; PROGRESSION; MECHANISMS; METFORMIN;
   STATINS
AB This work mainly aimed to investigate the probable changes of aortic calcification by policosanol, omega 3 fatty acids in comparison with atorvastatin and subsequent progression of atherosclerosis in diabetic hyperlipemic rat model. Adult male albino rats of wistar strain (30) were divided into five groups (n=6/group); one was fed normal diet and was used as a normal group, the other groups received alloxan, atherogenic diet (CCT   rat chow diet supplemented with 4% cholesterol, 1% cholic acid, and 0.5% thiouracil) and categorized as follows: the second group received no treatment and kept as control (diabetic hyperlipidemic control group (DHC)). The other groups received daily oral doses of atorvastatin, policosanol (10mg/kg body weight) and omega 3 (50mg/kg body weight), respectively, for eight weeks. Different biomarkers were used for the evaluation that included inflammatory (C reactive protein (CRP), tumor necrosis factor alpha (TNF alpha)), oxidative stress (glutathione (GSH), malondialdehyde (MDA)) bone calcification markers (alkaline phosphatase (ALP), Vitamin D, parathyroid hormone (PTH)), lipogram pattern in addition to histochemical demonstration of calcium in the aorta. Diabetic hyperlipemic group demonstrated significant hyperglycemia, hyperlipidemia, and increased inflammation, oxidative stress, calcification, and finally atherogenesis progression. Treatment of diabetic hyperlipemic rats with, policosanol, omega 3 fatty acids (natural products) and atorvastatin for eight weeks significantly increased high density lipoprotein cholesterol (HDL C), Vitamin D, decreased aortic vacuoles number, and inhibited calcification process. Policosanol induced more remarkable reduction in the density and number of foam cells and improved the intimal lesions of the aorta as compared to atorvastatin. Drugs under study exerted hypoglycemic effect along with an inhibition of inflammation, oxidative stress, and calcium deposition with certain variations but policosanol effect was remarkable in comparison with other drugs.
C1 [Elseweidy, Mohamed M.] Zagazig Univ, Dept Biochem, Fac Pharm, Zagazig 44519, Egypt.
   [Zein, Nabila; Elsawy, Marwa M.] Zagazig Univ, Dept Biochem, Fac Sci, Zagazig 44519, Egypt.
   [Aldhamy, Samih E.] Zagazig Univ, Dept Pharmacognosy, Fac Pharm, Zagazig 44519, Egypt.
   [Saeid, Saeid A.] Zagazig Univ, Dept Chem, Fac Sci, Zagazig 44519, Egypt.
C3 Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian Knowledge
   Bank (EKB); Zagazig University; Egyptian Knowledge Bank (EKB); Zagazig
   University; Egyptian Knowledge Bank (EKB); Zagazig University
RP Elseweidy, MM (通讯作者)，Zagazig Univ, Dept Biochem, Fac Pharm, Zagazig 44519, Egypt.
EM mmelseweidy@yahoo.com
RI ; elsawy, marwa/AAC 3248 2021
OI zein, nabila/0000 0003 0921 6919; 
CR Ahmed MF, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/841090
   Aikawa E, 2007, CIRCULATION, V116, P2841, DOI 10.1161/CIRCULATIONAHA.107.732867
   Al Aly Z, 2007, ARTERIOSCL THROM VAS, V27, P2589, DOI 10.1161/ATVBAHA.107.153668
   ANEIROS E, 1995, CURR THER RES CLIN E, V56, P176, DOI 10.1016/0011 393X(95)85043 0
   Bolego C, 2002, CURR OPIN LIPIDOL, V13, P637, DOI 10.1097/00041433 200212000 00007
   BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   Brown E, 2008, CALCIUM SIGNALLING D, P139
   Budoff MJ, 2005, AM HEART J, V149, P695, DOI 10.1016/j.ahj.2004.07.034
   CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014 5793(87)80292 2
   CARSON WP, 1990, OECOLOGIA, V85, P8, DOI 10.1007/BF00317337
   Castano G, 2005, Drugs R D, V6, P207, DOI 10.2165/00126839 200506040 00003
   Cavalier E, 2010, NEPHROLOGY, V20
   Cola C, 2004, BIOCHEM BIOPH RES CO, V320, P424, DOI 10.1016/j.bbrc.2004.05.181
   Crespo N, 1999, INT J CLIN PHARM RES, V19, P117
   Demer L, 2011, CIRC RES, V108, P1482, DOI 10.1161/CIRCRESAHA.110.234245
   Desco MC, 2002, DIABETES, V51, P1118, DOI 10.2337/diabetes.51.4.1118
   El Said M.E., 1965, OILS FATS WAXES SURF
   Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986
   Fraga V, 1997, ARCH MED RES, V28, P355
   Gruson D, 2014, CLIN CHIM ACTA, V433, P290, DOI 10.1016/j.cca.2014.03.029
   HERNANDEZ F, 1992, CURR THER RES CLIN E, V51, P568
   Iqbal M, 2011, Global J BiotechnolBiochem, V6, P83
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140
   Kizu A, 2004, J CELL BIOCHEM, V93, P1011, DOI 10.1002/jcb.20207
   Lele S, 2012, ISRN AGRON, V2012
   Menendez R, 1997, BRIT J NUTR, V77, P923, DOI 10.1079/BJN19970090
   Menéndez R, 2001, ARCH MED RES, V32, P8, DOI 10.1016/S0188 4409(00)00265 4
   Menendez R., 1994, Biological Research, V27, P199
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   PONS P, 1994, CURR THER RES CLIN E, V55, P1084, DOI 10.1016/S0011 393X(05)80279 6
   Sage AP, 2010, NAT REV CARDIOL, V7, P528, DOI 10.1038/nrcardio.2010.115
   SARIG S, 1994, LAB INVEST, V71, P782
   Schmermund A, 2001, ARTERIOSCL THROM VAS, V21, P421, DOI 10.1161/01.ATV.21.3.421
   Sethi A, 2011, BASIC CLIN PHARMACOL, V108, P371, DOI 10.1111/j.1742 7843.2010.00663.x
   Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781
   Singh DK, 2006, J PHARMACOL EXP THER, V318, P1020, DOI 10.1124/jpet.106.107144
   Sun HJ, 2002, J BIOL CHEM, V277, P47486, DOI 10.1074/jbc.M205814200
   Tomaschitz A, 2012, CARDIOVASC RES, V94, P10, DOI 10.1093/cvr/cvs092
   Varady KA, 2003, NUTR REV, V61, P376, DOI 10.1301/nr.2003.nov.376 383
   Viola F, 2008, MEDITERR J NUTR META, V1, P77, DOI 10.1007/s12349 008 0019 y
   Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 44
TC 20
Z9 21
U1 0
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535 3702
EI 1535 3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD NOV
PY 2016
VL 241
IS 17
BP 1943
EP 1949
DI 10.1177/1535370216659943
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA DZ2EQ
UT WOS:000385655500008
PM 27460718
OA Green Published
DA 2025 08 17
ER

PT J
AU Dharmayanti, C
   Gillam, TA
   Williams, DB
   Blencowe, A
AF Dharmayanti, Cintya
   Gillam, Todd A.
   Williams, Desmond B.
   Blencowe, Anton
TI Drug Eluting Biodegradable Implants for the Sustained Release of
   Bisphosphonates
SO POLYMERS
LA English
DT Article
DE bisphosphonate; implant; osteoporosis; sustained release; poly(lactic
   acid) (PLA); poly(D; L lactide co glycolide) (PLGA); hot melt extrusion
ID HOT MELT EXTRUSION; IN VITRO RELEASE; ALENDRONATE SODIUM; PLGA;
   DELIVERY; PRODRUGS; MICROSPHERES; OSTEOPOROSIS; GANCICLOVIR; MECHANISMS
AB Despite being one of the first line treatments for osteoporosis, the bisphosphonate drug class exhibits an extremely low oral bioavailability (<1%) due to poor absorption from the gastrointestinal tract. To overcome this, and to explore the potential for sustained drug release, bioerodible poly(lactic acid) (PLA) and poly(D,L lactide co glycolide) (PLGA) implants loaded with the bisphosphonate alendronate sodium (ALN) were prepared via hot melt extrusion. The rate of drug release in vitro was modulated by tailoring the ratio of lactide to glycolide in the polymer and by altering the ALN loading of the implants. All investigated implants exhibited sustained ALN release in vitro between 25 to 130 days, where implants of greater glycolide composition and higher ALN loadings released ALN more rapidly. All PLGA implants demonstrated a sigmoidal release profile, characterised by an initial surface dissolution phase, followed by a period of zero order drug diffusion, then relaxation or erosion of the polymer chains that caused accelerated release over the subsequent days. Contrastingly, the PLA implants demonstrated a logarithmic release profile, characterised by a gradual decrease in ALN release over time.
C1 [Dharmayanti, Cintya; Gillam, Todd A.; Blencowe, Anton] Univ South Australia, Clin & Hlth Sci, Appl Chem & Translat Biomat Grp, Adelaide, SA 5000, Australia.
   [Gillam, Todd A.] Univ South Australia, Future Ind Inst, Surface Interact & Soft Matter Grp, Mawson Lakes, SA 5095, Australia.
   [Williams, Desmond B.] Univ South Australia, Clin & Hlth Sci, Pharm & Biomed Sci, Adelaide, SA 5000, Australia.
C3 University of South Australia; University of South Australia; University
   of South Australia
RP Blencowe, A (通讯作者)，Univ South Australia, Clin & Hlth Sci, Appl Chem & Translat Biomat Grp, Adelaide, SA 5000, Australia.
EM Cintya.Dharmayanti@unisa.edu.au; Todd.Gillam@unisa.edu.au;
   Des.Williams@unisa.edu.au; Anton.Blencowe@unisa.edu.au
RI ; Blencowe, anton/B 1214 2011; blencowe, anton/B 1214 2011; Gillam,
   Todd/LPP 9461 2024; Williams, Desmond/B 5896 2013
OI Williams, Desmond/0000 0002 5954 2694; Dharmayanti,
   Cintya/0000 0003 3991 3416; Gillam, Todd/0000 0003 2611 1991; blencowe,
   anton/0000 0002 7630 4874; 
FU Playford Trust (South Australia); Scheer Family
FX C.D. would like to thank both the Playford Trust (South Australia) and
   the Scheer Family for the provision of two Honours Scholarships.
CR Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Aderibigbe BA, 2015, INT J BIOL MACROMOL, V73, P115, DOI 10.1016/j.ijbiomac.2014.10.064
   Albu P, 2017, J THERM ANAL CALORIM, V127, P571, DOI 10.1007/s10973 016 5745 7
   Amann LC, 2010, PHARM RES DORDR, V27, P1730, DOI 10.1007/s11095 010 0152 4
   [Anonymous], 2012, Osteoporosis costing all Australians. A new burden of disease analysis 2012 to 2022
   Avgoustakis K., 2005, Encyclopedia of Biomaterials and Biomedical Engineering, V15, P1
   Ayyoob M, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10101132
   Barrett SE, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.01058 18, 10.1128/AAC.01058 18]
   Bishara A, 2005, J CONTROL RELEASE, V107, P474, DOI 10.1016/j.jconrel.2005.05.026
   Bogazzi F, 2011, J ENDOCRINOL INVEST, V34, pE200, DOI 10.3275/7228
   British Pharmacopoeia, 2020, APP 12 REC DISS TEST, V1
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Chennamaneni SR, 2013, J CONTROL RELEASE, V167, P53, DOI 10.1016/j.jconrel.2013.01.007
   Cossé A, 2017, AAPS PHARMSCITECH, V18, P15, DOI 10.1208/s12249 016 0548 5
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   D'Avila CarvalhoErbetta., 2012, J BIOMATER NANOBIOTE, V03, P208, DOI [10.4236/jbnb.2012.32027, DOI 10.4236/JBNB.2012.32027]
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Engineer C, 2011, CHEM ENG RES DES, V89, P328, DOI 10.1016/j.cherd.2010.06.013
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Fulmer GR, 2010, ORGANOMETALLICS, V29, P2176, DOI 10.1021/om100106e
   Gosau M, 2010, PHARMAZIE, V65, P487, DOI 10.1691/ph.2010.9375
   Guo YT, 2017, PHARM RES DORDR, V34, P2211, DOI 10.1007/s11095 017 2228 x
   Hosny KM, 2013, EXPERT OPIN DRUG DEL, V10, P741, DOI 10.1517/17425247.2013.799136
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142 9612(00)00115 0
   Janoria KG, 2007, INT J PHARM, V338, P133, DOI 10.1016/j.ijpharm.2007.01.038
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kempin W, 2017, EUR J PHARM BIOPHARM, V115, P84, DOI 10.1016/j.ejpb.2017.02.014
   Kiremitçi Gumusderelioglu M, 1999, TURK J CHEM, V23, P153
   KUNOU N, 1995, J CONTROL RELEASE, V37, P143, DOI 10.1016/0168 3659(95)00074 I
   Lan P, 2006, J MACROMOL SCI A, V43, P1887, DOI 10.1080/10601320600941284
   Larson N, 2012, CHEM MATER, V24, P840, DOI 10.1021/cm2031569
   Li DX, 2013, INT J PHARMACEUT, V441, P365, DOI 10.1016/j.ijpharm.2012.11.019
   Li J, 2010, J MATER SCI MATER M, V21, P583, DOI 10.1007/s10856 009 3899 6
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Long KA, 2009, J BIOMAT SCI POLYM E, V20, P653, DOI 10.1163/156856209X426457
   Makadia HK, 2011, POLYMERS BASEL, V3, P1377, DOI 10.3390/polym3031377
   Niemi R, 1998, INT J PHARM, V174, P111, DOI 10.1016/S0378 5173(98)00250 6
   OMELCZUK MO, 1992, PHARMACEUT RES, V9, P26, DOI 10.1023/A:1018967424392
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Park PIP, 2006, J APPL POLYM SCI, V100, P1983, DOI 10.1002/app.22135
   PARK TG, 1994, J CONTROL RELEASE, V30, P161, DOI 10.1016/0168 3659(94)90263 1
   Penczek S, 1998, MACROMOL SYMP, V132, P441, DOI 10.1002/masy.19981320141
   Pignatello R, 2012, J FUNCT BIOMATER, V3, P79, DOI 10.3390/jfb3010079
   Pisa E, 2020, MOL PHARMACEUT, V17, P2021, DOI 10.1021/acs.molpharmaceut.0c00188
   Price JS, 1996, J BIOMED MATER RES, V30, P281, DOI 10.1002/(SICI)1097 4636(199603)30:3<281::AID JBM2>3.0.CO;2 M
   Rajgor N., 2011, Systematic Reviews in Pharmacy, V2, P91, DOI DOI 10.4103/0975 8453.86297
   Ramchandani M, 1998, J CONTROL RELEASE, V54, P167, DOI 10.1016/S0168 3659(97)00113 2
   Ravivarapu H.B., 2000, AAPS PharmSciTech, V1, P1
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Roelofs AJ, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1737, DOI 10.1016/B978 0 12 373884 4.00095 1
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Stewart SA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020105
   Turhanen PA, 2001, PHOSPHORUS SULFUR, V170, P115, DOI 10.1080/10426500108040589
   Vachal P, 2006, J MED CHEM, V49, P3060, DOI 10.1021/jm060398v
   Vannozzi L, 2016, INT J NANOMED, V11, P69, DOI 10.2147/IJN.S92031
   Vepsäläinen JJ, 2002, CURR MED CHEM, V9, P1201, DOI 10.2174/0929867023369998
   Yao H, 2020, DRUG DELIV TRANSL RE, V10, P13, DOI 10.1007/s13346 019 00654 x
NR 60
TC 21
Z9 21
U1 2
U2 30
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4360
J9 POLYMERS BASEL
JI Polymers
PD DEC
PY 2020
VL 12
IS 12
AR 2930
DI 10.3390/polym12122930
PG 14
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA PK6GM
UT WOS:000602540900001
PM 33297466
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shuai, FY
   Yin, YJ
   Yao, YF
   Deng, LZ
   Wen, YH
   Zhao, H
   Han, XL
AF Shuai, Fangyuan
   Yin, Yijia
   Yao, Yufei
   Deng, Lanzhi
   Wen, Yinghui
   Zhao, Hang
   Han, Xianglong
TI A nucleoside based supramolecular hydrogel integrating localized
   self delivery and immunomodulation for periodontitis treatment
SO BIOMATERIALS
LA English
DT Article
ID PURINE; PHOSPHORYLASE; DISEASE; LIPOPOLYSACCHARIDE; 8 AMINOGUANOSINE;
   PATHOGENESIS; INHIBITION; THERAPY; STRESS; TRPM2
AB Periodontitis is a highly prevalent oral disease characterized by bacterial induced hyperactivation of the host immune system, leading to a sustained inflammatory response and osteoclastic activity, which ultimately results in periodontal destruction. In this work, an immunomodulatory supramolecular hydrogel for the topical treatment of periodontitis was synthesized using a simple one pot method. This phenylboronate ester based 8AGPB hydrogel exhibited excellent stability, self healing properties, injectability, and biocompatibility. During degradation, the 8AGPB hydrogel releases immunomodulatory agent 8 aminoguanosine (8AG), which regulates MAPK and NF kappa B signaling pathways by modulation of second messengers in macrophages. In combination with 1,4 phenylenediboronic acid (PBA), which possesses antioxidant properties, 8AG effectively inhibits ROS production and oxidative damage in LPS stimulated macrophages, lowering the M1/M2 macrophage polarization ratio and reducing the secretion of pro inflammatory factors. In an experimental periodontitis model using C57BL/6 mice, periodontal injection of the 8AGPB hydrogel reduced inflammatory infiltration and osteoclastic activity through immunomodulation and inhibition of osteoclast differentiation, thereby ameliorating periodontal destruction during periodontitis progression. Overall, the 8AGPB supramolecular hydrogel, serving as an injectable self delivery platform for 8AG, may represent a promising novel strategy for periodontitis treatment and offer insights for the development of future topical anti inflammatory systems.
C1 [Shuai, Fangyuan; Yin, Yijia; Yao, Yufei; Deng, Lanzhi; Wen, Yinghui; Zhao, Hang; Han, Xianglong] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Shuai, Fangyuan; Yin, Yijia; Yao, Yufei; Deng, Lanzhi; Wen, Yinghui; Zhao, Hang; Han, Xianglong] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Shuai, Fangyuan; Yin, Yijia; Yao, Yufei; Deng, Lanzhi; Wen, Yinghui; Zhao, Hang; Han, Xianglong] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Shuai, Fangyuan; Yin, Yijia; Yao, Yufei; Deng, Lanzhi; Wen, Yinghui; Zhao, Hang; Han, Xianglong] Sichuan Univ, West China Hosp Stomatol, Res Unit Oral Carcinogenesis & Management, Chengdu 610041, Sichuan, Peoples R China.
   [Shuai, Fangyuan; Yin, Yijia; Yao, Yufei; Deng, Lanzhi; Wen, Yinghui; Zhao, Hang; Han, Xianglong] Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University
RP Zhao, H; Han, XL (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Zhao, H; Han, XL (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China.; Zhao, H; Han, XL (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Zhao, H; Han, XL (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Res Unit Oral Carcinogenesis & Management, Chengdu 610041, Sichuan, Peoples R China.; Zhao, H; Han, XL (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China.
EM zhaohangahy@scu.edu.cn; xhan@scu.edu.cn
RI Yao, Yufei/KIA 0679 2024; Zhao, Jianhang/NRB 7570 2025; YIN,
   Yijia/KBB 9124 2024
FU National Natural Science Foundation of China [U24A20712, 82271022,
   82271035]
FX This work was supported by the National Natural Science Foundation of
   China (U24A20712, 82271022, 82271035) .
CR Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327
   Aminu N, 2019, INT J PHARMACEUT, V570, DOI 10.1016/j.ijpharm.2019.118659
   Arnett MC, 2023, J PERIODONTOL, V94, P1133, DOI 10.1002/JPER.23 0002
   Batista EL, 2010, J PERIODONTAL RES, V45, P664, DOI 10.1111/j.1600 0765.2010.01282.x
   Benedyk Machaczka M, 2024, ANTIBIOTICS BASEL, V13, DOI 10.3390/antibiotics13111012
   Benmoussa K, 2018, J MOL BIOL, V430, P3906, DOI 10.1016/j.jmb.2018.07.003
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Birder LA, 2022, NAT REV UROL, V19, P681, DOI 10.1038/s41585 022 00642 w
   Birder LA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140109
   Bzowska A, 2000, PHARMACOL THERAPEUT, V88, P349, DOI 10.1016/S0163 7258(00)00097 8
   Cader MZ, 2020, CELL, V180, P278, DOI [10.1016/j.cell.2019.12.017, 10.1016/j.cell.2020.02.005]
   Canton M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.734229
   Sczepanik FSC, 2020, PERIODONTOL 2000, V84, P45, DOI 10.1111/prd.12342
   Cebatariuniene A, 2019, STEM CELLS DEV, V28, P1037, DOI 10.1089/scd.2019.0021
   Chava VK, 2013, J PERIODONTOL, V84, P1290, DOI 10.1902/jop.2012.120425
   Chen MM, 2020, BIOACT MATER, V5, P880, DOI 10.1016/j.bioactmat.2020.05.004
   Chen YY, 2024, EUR J MED CHEM, V271, DOI 10.1016/j.ejmech.2024.116437
   Choi S, 2007, FREE RADICAL BIO MED, V43, P1594, DOI 10.1016/j.freeradbiomed.2007.08.022
   Cicalau GIP, 2024, BIOMEDICINES, V12, DOI 10.3390/biomedicines12071445
   Díaz Bulnes P, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02951
   Fliegert R, 2007, BIOCHEM SOC T, V35, P109, DOI 10.1042/BST0350109
   Förstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Frencken JE, 2017, J CLIN PERIODONTOL, V44, pS94, DOI 10.1111/jcpe.12677
   Giorgi T, 2003, J AM CHEM SOC, V125, P14741, DOI 10.1021/ja0364827
   Golub LM, 2020, PERIODONTOL 2000, V82, P186, DOI 10.1111/prd.12315
   Guo HL, 2021, ACS APPL MATER INTER, V13, P61638, DOI 10.1021/acsami.1c18701
   Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577 020 00488 6
   Hajishengallis G, 2020, PERIODONTOL 2000, V84, P14, DOI 10.1111/prd.12331
   He XT, 2019, ACTA BIOMATER, V88, P162, DOI 10.1016/j.actbio.2019.02.004
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hu C, 2023, ACS APPL MATER INTER, V15, P9066, DOI 10.1021/acsami.2c21297
   Huang MS, 2022, BIOMATER SCI UK, V10, P6413, DOI 10.1039/d2bm01036d
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jackson EK, 2022, BIOCHEM PHARMACOL, V201, DOI 10.1016/j.bcp.2022.115076
   Jackson EK, 2016, J PHARMACOL EXP THER, V359, P420, DOI 10.1124/jpet.116.237552
   Kassebaum NJ, 2017, J DENT RES, V96, P380, DOI 10.1177/0022034517693566
   Katariya C, 2024, CUREUS J MED SCIENCE, V16, DOI 10.7759/cureus.59109
   KAZMERS IS, 1981, SCIENCE, V214, P1137, DOI 10.1126/science.6795718
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033
   Kwon T, 2021, INT DENT J, V71, P462, DOI 10.1111/idj.12630
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lee JK, 2013, J DERMATOL SCI, V70, P49, DOI 10.1016/j.jdermsci.2013.01.010
   Li JX, 2024, INT J PHARMACEUT, V659, DOI 10.1016/j.ijpharm.2024.124263
   Li MX, 2022, GELS BASEL, V8, DOI 10.3390/gels8100624
   Li N, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100360
   Li QQ, 2024, ACS BIOMATER SCI ENG, V10, P2742, DOI 10.1021/acsbiomaterials.4c00220
   Li WQ, 2024, NAT COMMUN, V15, DOI 10.1038/s41467 024 46866 9
   Liu TN, 2023, MATER TODAY, V62, P71, DOI 10.1016/j.mattod.2022.12.009
   Liu Y, 2024, INT J BIOL MACROMOL, V281, DOI 10.1016/j.ijbiomac.2024.136085
   Liu YY, 2024, SMALL STRUCT, V5, DOI 10.1002/sstr.202300281
   Ma LL, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01247 8
   Ma SQ, 2022, BIOMATER ADV, V142, DOI 10.1016/j.bioadv.2022.213158
   Meenakshi SS, 2021, J ADV ORAL RES, V12, P222, DOI 10.1177/2320206821998574
   Miles RW, 1998, BIOCHEMISTRY US, V37, P8615, DOI 10.1021/bi980658d
   Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524
   MONTGOMERY JA, 1993, MED RES REV, V13, P209, DOI 10.1002/med.2610130302
   Ock CY, 2011, BIOCHEM PHARMACOL, V81, P111, DOI 10.1016/j.bcp.2010.08.023
   Pan QQ, 2025, INT J BIOL MACROMOL, V284, DOI 10.1016/j.ijbiomac.2024.137893
   Park YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00195
   Peng CJ, 2023, POLYM ADVAN TECHNOL, V34, P155, DOI 10.1002/pat.5874
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Qi JJ, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202204273
   Ran SD, 2024, J MATER CHEM B, V12, P6005, DOI 10.1039/d3tb03070a
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Ren JH, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 03990 2
   Rendra E, 2019, IMMUNOBIOLOGY, V224, P242, DOI 10.1016/j.imbio.2018.11.010
   Seim GL, 2022, TRENDS ENDOCRIN MET, V33, P345, DOI 10.1016/j.tem.2022.02.005
   Seim GL, 2019, NAT METAB, V1, P731, DOI 10.1038/s42255 019 0083 2
   Shekhova E, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008470
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Smiley CJ, 2015, J AM DENT ASSOC, V146, P508, DOI 10.1016/j.adaj.2015.01.028
   Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962 8924(02)02294 8
   Sufaru IG, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14081728
   Sumoza Toledo A, 2011, J PHYSIOL LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855
   Sun XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763334
   Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432 1033.2002.03157.x
   Tan HY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2795090
   Tan JL, 2019, ACS NANO, V13, P5616, DOI 10.1021/acsnano.9b00788
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Tominari T, 2024, BIOLOGY BASEL, V13, DOI 10.3390/biology13090692
   Waddington RJ, 2000, ORAL DIS, V6, P138
   Wang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.967193
   Wang YF, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100904
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490
   Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00312 6
   Zambrano LMG, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24866 2
   Zhang GN, 2024, ACS APPL MATER INTER, V16, P45929, DOI 10.1021/acsami.4c07210
   Zhang SB, 2023, REGEN BIOMATER, V10, DOI 10.1093/rb/rbad009
   Zhang T, 2018, J DENT RES, V97, P810, DOI 10.1177/0022034518755688
   Zhang ZH, 2024, PHYTOMEDICINE, V130, DOI 10.1016/j.phymed.2024.155580
   Zhao H, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119598
   Zhao XD, 2022, BIOMATERIALS, V282, DOI 10.1016/j.biomaterials.2022.121387
NR 94
TC 3
Z9 3
U1 32
U2 42
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2025
VL 316
AR 123024
DI 10.1016/j.biomaterials.2024.123024
EA DEC 2024
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA R5Q0A
UT WOS:001391980100001
PM 39705922
DA 2025 08 17
ER

PT J
AU Koulouktsi, C
   Nanaki, S
   Barmpalexis, P
   Kostoglou, M
   Bikiaris, D
AF Koulouktsi, Christina
   Nanaki, Stavroula
   Barmpalexis, Panagiotis
   Kostoglou, Margaritis
   Bikiaris, Dimitrios
TI Preparation and characterization of Alendronate depot microspheres based
   on novel poly( ε caprolactone)/Vitamin E TPGS copolymers
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS X
LA English
DT Article
DE Polycaprolactone; Vitamin E TPGS; Aledronate; Microspheres; Controlled
   release; Long acting injectables
ID VITAMIN E TPGS; ENZYMATIC HYDROLYSIS; CONTROLLED RELEASE;
   BISPHOSPHONATES ACT; IN VITRO; BONE; CARRIERS; BLENDS; BIOAVAILABILITY;
   NANOPARTICLES
AB In the present study, new aledronate (AL) loaded microspheres were prepared with the use of polycaprolactone (PCL)/Vitamin E d alpha tocopheryl poly(ethylene glycol) 1000 succinate (TPGS) copolymers. Specifically, PCL TPGS copolymers, prepared at several PCL to TPGS ratios (namely, 90/10, 80/20, 70/30 and 60/40 w/w) via a ring opening polymerization process, were characterized by intrinsic viscosity, proton nuclear magnetic resonance (H 1 NMR), Fourier transform infrared spectroscopy (FTIR), X ray diffraction (XRD), differential scanning calorimetry (DSC) and enzymatic hydrolysis. Results showed that as TPGS content increases the intrinsic viscosity of the copolymer (and hence, the viscosity average molecular weight) is decreasing, while FTIR analysis showed the formation of hydrogen bonds between the  C=O of PCL and the  OH of TPGS. Additionally, XRD analysis indicated that the prepared copolymers were semi crystalline in nature, while enzymatic hydrolysis studies showed that increasing TGPS content led to increasing copolymer hydrolysis. In the following step, AL drug loaded microspheres were prepared via single emulsification process. Scanning electron microscopy (SEM) revealed the formation of coarse drug loaded microspheres with particle size close to 5 mu m, while XRD analysis showed that the API was amorphously dispersed only in the cases of high TPGS content. Furthermore, FTIR analysis showed that the API did not interact with the copolymer components, while in vitro drug release studies showed that increasing PCL content led to decreasing API release rate. Finally, analysis of the drug release profiles suggested that the API release mechanism was solely governed by the polymer matrix erosion.
C1 [Koulouktsi, Christina; Nanaki, Stavroula; Bikiaris, Dimitrios] Aristotle Univ Thessaloniki, Dept Chem, Lab Polymer Chem & Technol, Thessaloniki 54124, Macedonia, Greece.
   [Barmpalexis, Panagiotis] Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Technol, Thessaloniki 54124, Macedonia, Greece.
   [Kostoglou, Margaritis] Aristotle Univ Thessaloniki, Dept Chem, Lab Gen & Inorgan Chem Technol, GR 54124 Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; Aristotle University of Thessaloniki
RP Bikiaris, D (通讯作者)，Aristotle Univ Thessaloniki, Dept Chem, Lab Polymer Chem & Technol, Thessaloniki 54124, Macedonia, Greece.
EM dbic@chem.auth.gr
OI Barmpalexis, Panagiotis/0000 0002 6765 512X; Bikiaris,
   Dimitrios/0000 0001 8458 4952; kostoglou, Margaritis/0000 0001 7955 0002
CR Abou Zeid DM, 2004, BIOMACROMOLECULES, V5, P1687, DOI 10.1021/bm0499334
   [Anonymous], J SYSTEM ENG ELECT
   Bae J, 2015, INT J PHARMACEUT, V480, P37, DOI 10.1016/j.ijpharm.2015.01.020
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   Bikiaris DN, 2008, MACROMOL BIOSCI, V8, P728, DOI 10.1002/mabi.200800035
   Bikiaris DN, 2012, POLYM DEGRAD STABIL, V97, P2077, DOI 10.1016/j.polymdegradstab.2011.10.024
   Chen SY, 2018, POLYM PLAST TECHNOL, V57, P1873, DOI 10.1080/03602559.2018.1447122
   Ciardelli G, 2005, BIOMACROMOLECULES, V6, P1961, DOI 10.1021/bm0500805
   Dolci LS, 2019, INT J PHARMACEUT, V554, P245, DOI 10.1016/j.ijpharm.2018.11.023
   Dong X, 2018, ARTIF CELL NANOMED B, V46, pS168, DOI 10.1080/21691401.2017.1416390
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Fleisch H., 2000, BISPHOSPHONATES BONE, P67
   Gaba B, 2015, DRUG DELIV, V22, P691, DOI 10.3109/10717544.2014.898110
   Gan ZH, 2001, BIOMACROMOLECULES, V2, P605, DOI 10.1021/bm015535e
   Guo YY, 2013, EUR J PHARM SCI, V49, P175, DOI 10.1016/j.ejps.2013.02.006
   Harada M, 2008, POLYM ENG SCI, V48, P1359, DOI 10.1002/pen.21088
   Hosny KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154926
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kim CW, 2010, J CONTROL RELEASE, V147, P45, DOI 10.1016/j.jconrel.2010.06.016
   KORSMEYER RW, 1983, INT J PHARMACEUT, V15, P25, DOI 10.1016/0378 5173(83)90064 9
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1994, J PHARM SCI US, V83, P1741, DOI 10.1002/jps.2600831218
   Marten E, 2003, POLYM DEGRAD STABIL, V80, P485, DOI 10.1016/S0141 3910(03)00032 6
   Miladi K, 2013, INT J PHARMACEUT, V445, P181, DOI 10.1016/j.ijpharm.2013.01.031
   Miller K, 2013, BIOMATERIALS, V34, P3795, DOI 10.1016/j.biomaterials.2013.01.052
   Miyazaki T, 2014, J BIOMATER APPL, V29, P543, DOI 10.1177/0885328214536243
   Mondal T, 2012, MAT SCI ENG C MATER, V32, P697, DOI 10.1016/j.msec.2012.01.011
   Nafea EH, 2007, J MICROENCAPSUL, V24, P525, DOI 10.1080/02652040701439807
   Nafee N, 2018, J DRUG TARGET, V26, P563, DOI 10.1080/1061186X.2017.1390670
   Nanaki S, 2018, J PHARM SCI US, V107, P2891, DOI 10.1016/j.xphs.2018.07.029
   Nanaki S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030130
   Nanaki SG, 2011, INT J NANOMED, V6, P2981, DOI 10.2147/IJN.S26568
   Nerantzaki M, 2018, MATERIALS, V11, DOI 10.3390/ma11101996
   Neuzil J, 2007, MOL ASPECTS MED, V28, P607, DOI 10.1016/j.mam.2007.02.003
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Parker A, 2000, AICHE J, V46, P1290, DOI 10.1002/aic.690460703
   Qiu ZB, 2003, POLYMER, V44, P2503, DOI 10.1016/S0032 3861(03)00150 2
   Qu GX, 2018, INT J MED SCI, V15, P1458, DOI 10.7150/ijms.27759
   Ramkrishna D., 2000, Theory and applications to particulate systems in engineering
   Rhim SY, 2009, CLIN THER, V31, P1037, DOI 10.1016/j.clinthera.2009.05.001
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Samdancioglu S, 2006, DRUG DEV IND PHARM, V32, P473, DOI 10.1080/03639040500528871
   Sharpe M, 2001, DRUGS, V61, P999, DOI 10.2165/00003495 200161070 00010
   Siafaka PI, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030282
   Solomon OF., 1962, J APPL POLYM SCI, V6, P683, DOI DOI 10.1002/APP.1962.070062414
   Umeki N, 2010, INT J PHARMACEUT, V392, P42, DOI 10.1016/j.ijpharm.2010.03.020
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Williams M. M. R., 1991, Aerosol science: Theory and practice
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Wu HW, 2014, J MATER SCI MATER M, V25, P2649, DOI 10.1007/s10856 014 5289 y
   Yang CL, 2018, THERANOSTICS, V8, P464, DOI 10.7150/thno.22711
   Yuan ML, 2000, MACROMOLECULES, V33, P1613, DOI 10.1021/ma991388p
   Zhang HL, 2015, INT J NANOMED, V10, P2461, DOI 10.2147/IJN.S78988
   Zhang ZP, 2012, BIOMATERIALS, V33, P4889, DOI 10.1016/j.biomaterials.2012.03.046
   Zorba T, 2007, POLYM DEGRAD STABIL, V92, P222, DOI 10.1016/j.polymdegradstab.2006.11.009
NR 56
TC 22
Z9 24
U1 2
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2590 1567
J9 INT J PHARM X
JI Int. J. Pharm. X
PD DEC
PY 2019
VL 1
AR 100014
DI 10.1016/j.ijpx.2019.100014
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LV6SY
UT WOS:000538566300028
PM 31517279
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bonneau, C
   Eliès, A
   Kieffer, Y
   Bourachot, B
   Ladoire, S
   Pelon, F
   Hequet, D
   Guinebretière, JM
   Blanchet, C
   Vincent Salomon, A
   Rouzier, R
   Mechta Grigoriou, F
AF Bonneau, Claire
   Elies, Antoine
   Kieffer, Yann
   Bourachot, Brigitte
   Ladoire, Sylvain
   Pelon, Floriane
   Hequet, Delphine
   Guinebretiere, Jean Marc
   Blanchet, Christophe
   Vincent Salomon, Anne
   Rouzier, Roman
   Mechta Grigoriou, Fatima
TI A subset of activated fibroblasts is associated with distant relapse in
   early luminal breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Luminal breast cancer; Metastases; Cancer associated fibroblasts;
   Stroma; CDH11; Cadherin 11; Tumor infiltrating lymphocytes; TILs; Tumor
   micro environment
ID TUMOR INFILTRATING LYMPHOCYTES; INTERNATIONAL EXPERT CONSENSUS;
   E CADHERIN; STROMAL MYOFIBROBLASTS; DUCTAL CARCINOMA; PRIMARY THERAPY;
   POOR PROGNOSIS; EXPRESSION; GENE; HETEROGENEITY
AB Background Early luminal breast cancer (BC) represents 70% of newly diagnosed BC cases. Among them, small (under 2 cm) BC without lymph node metastasis (classified as T1N0) have been rarely studied, as their prognosis is generally favorable. Nevertheless, up to 5% of luminal T1N0 BC patients relapse with distant metastases that ultimately prove fatal. The aim of our work was to identify the mechanisms involved in metastatic recurrence in these patients. Methods Our study addresses the role that autonomous and non autonomous tumor cell features play with regard to distant recurrence in early luminal BC patients. We created a cohort of T1N0 luminal BC patients (tumors between 0.5 2 cm without lymph node metastasis) with metastatic recurrence ("cases") and corresponding "controls" (without relapse) matched 1:1 on main prognostic factors: age, grade, and proliferation. We deciphered different characteristics of cancer cells and their tumor micro environment (TME) by deep analyses using immunohistochemistry. We performed in vitro functional assays and highlighted a new mechanism of cooperation between cancer cells and one particular subset of cancer associated fibroblasts (CAF). Results We found that specific TME features are indicative of relapse in early luminal BC. Indeed, quantitative histological analyses reveal that "cases" are characterized by significant accumulation of a particular CAF subset (CAF S1) and decrease in CD4(+)T lymphocytes, without any other association with immune cells. In multivariate analysis, TME features, in particular CAF S1 enrichment, remain significantly associated with recurrence, thereby demonstrating their clinical relevance. Finally, by performing functional analyses, we demonstrated that CAF S1 pro metastatic activity is mediated by the CDH11/osteoblast cadherin, consistent with bones being a major site of metastases in luminal BC patients. Conclusions This study shows that distant recurrence in T1N0 BC is strongly associated with the presence of CAF S1 fibroblasts. Moreover, we identify CDH11 as a key player in CAF S1 mediated pro metastatic activity. This is independent of tumor cells and represents a new prognostic factor. These results could assist clinicians in identifying luminal BC patients with high risk of relapse. Targeted therapies against CAF S1 using anti FAP antibody or CDH11 targeting compounds might help in preventing relapse for such patients with activated stroma.
C1 [Bonneau, Claire; Elies, Antoine; Kieffer, Yann; Bourachot, Brigitte; Pelon, Floriane; Mechta Grigoriou, Fatima] PSL Res Univ, Inst Curie, Stress & Canc Lab, Equipe Labelisee Ligue Natl Canc, 26 Rue Ulm, F 75005 Paris, France.
   [Bonneau, Claire; Elies, Antoine; Kieffer, Yann; Bourachot, Brigitte; Pelon, Floriane; Mechta Grigoriou, Fatima] PSL Res Univ, Inst Curie, Inserm U830, 26 Rue Ulm, F 75005 Paris, France.
   [Bonneau, Claire; Elies, Antoine; Hequet, Delphine; Rouzier, Roman] Inst Curie Hosp Grp, Dept Surg, 35 Rue Dailly, F 92210 St Cloud, France.
   [Ladoire, Sylvain; Blanchet, Christophe] Ctr Georges Francois Leclerc, Chemotherapy & Immune Response, Inserm U1231, 1 Rue Prof Marion, F 21000 Dijon, France.
   [Guinebretiere, Jean Marc] Inst Curie Hosp Grp, Dept Pathol, 35 Rue Dailly, F 92210 St Cloud, France.
   [Vincent Salomon, Anne] Inst Curie Hosp Grp, Dept Pathol, 26 Rue Ulm, F 75248 Paris, France.
   [Rouzier, Roman] Inst Curie, Inserm U900, Canc & Genome Bioinformat Biostat & Epiderniol, 35 Rue Dailly, F 92210 St Cloud, France.
   [Rouzier, Roman] Versailles St Quentin Yvelines Univ, Risques Clin & Securite Sante Femmes & Sante Peri, UR 7285, 2 Ave Source Bievre, F 78180 Montigny Le Bretonneux, France.
C3 UNICANCER; Universite PSL; Institut Curie; Universite PSL; UNICANCER;
   Institut Curie; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UNICANCER; Universite PSL; Institut Curie; UNICANCER;
   Universite Bourgogne Europe; Centre Georges Francois Leclerc; Institut
   Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UNICANCER; Universite PSL; Institut Curie; UNICANCER;
   Universite PSL; Institut Curie; Universite PSL; UNICANCER; Institut
   Curie; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Paris Saclay
RP Mechta Grigoriou, F (通讯作者)，PSL Res Univ, Inst Curie, Stress & Canc Lab, Equipe Labelisee Ligue Natl Canc, 26 Rue Ulm, F 75005 Paris, France.; Mechta Grigoriou, F (通讯作者)，PSL Res Univ, Inst Curie, Inserm U830, 26 Rue Ulm, F 75005 Paris, France.
EM fatima.mechta grigoriou@curie.fr
RI ; MECHTA GRIGORIOU, Fatima/C 5253 2017; Bonneau, Claire/GON 5289 2022
OI KIEFFER, Yann/0000 0003 2722 3071; LADOIRE, Sylvain/0000 0002 0331 9194
FU Institut National de la Sante et de la Recherche Medicale (Inserm, Plan
   Cancer  Formation a la recherche translationnelle); association d'aide
   en Cancerologie de Saint Cloud (ARCS); Institut National du Cancer, INCa
   [INCa DGOS 9963, INCa 11692]; SIRIC [INCa DGOS 4654]; Fondation pour la
   Recherche Medicale (FRM); Ligue Nationale Contre le Cancer
   (Labelisation); Inserm [PC201317]; Institut Curie (Incentive and
   Cooperative Program Tumor Micro environment PIC TME/TMEGA, PIC3i CAFi);
   ICGex [ANR 10 EQPX 03]; INCa [STROMAE INCa DGOS 9963, CaLYS INCa 11692,
   INCa DGOS Inserm12554]
FX C.B. was supported by the Institut National de la Sante et de la
   Recherche Medicale (Inserm, Plan Cancer  Formation a la recherche
   translationnelle), A.E. by the association d'aide en Cancerologie de
   Saint Cloud (ARCS), and Y.K. by the Institut National du Cancer, INCa
   (INCa DGOS 9963; INCa 11692), SIRIC (INCa DGOS 4654), and the Fondation
   pour la Recherche Medicale (FRM). The experimental work was supported by
   grants from the Ligue Nationale Contre le Cancer (Labelisation), Inserm
   (PC201317), Institut Curie (Incentive and Cooperative Program Tumor
   Micro environment PIC TME/TMEGA, PIC3i CAFi), ICGex (ANR 10 EQPX 03),
   SIRIC (INCa DGOS 4654), and INCa (STROMAE INCa DGOS 9963, CaLYS
   INCa 11692, INCa DGOS Inserm12554). F.M G acknowledges both the
   Association "Le cancer du sein, Parlons en" and the Simone and Cino del
   Duca Foundation for attribution of their "Grand Prix". F.M G is very
   grateful to all her funders for providing support throughout the years.
CR Asgeirsson KS, 2000, EUR J CANCER, V36, P1098, DOI 10.1016/S0959 8049(00)00062 9
   Assefnia S, 2014, ONCOTARGET, V5, P1458, DOI 10.18632/oncotarget.1538
   Avery D, 2018, MATRIX BIOL, V67, P90, DOI 10.1016/j.matbio.2017.12.003
   Bartoschek M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07582 3
   Bear HD, 2015, LANCET ONCOL, V16, P1037, DOI 10.1016/S1470 2045(15)00041 8
   Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159 8290.CD 18 0710
   Blok EJ, 2018, BREAST CANCER RES TR, V171, P65, DOI 10.1007/s10549 018 4785 z
   Buonomo OC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184680
   Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102
   Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221
   Corso G, 2020, J CELL MOL MED, V24, P5930, DOI 10.1111/jcmm.15140
   Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011
   Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007
   Cremasco V, 2018, CANCER IMMUNOL RES, V6, P1472, DOI 10.1158/2326 6066.CIR 18 0098
   Cui YH, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394
   Desmedt C, 2012, CLIN CANCER RES, V18, P1004, DOI 10.1158/1078 0432.CCR 11 0383
   Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2015, Lancet, V386, P1341, DOI 10.1016/S0140 6736(15)61074 1
   Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110
   Feltes CM, 2002, CANCER RES, V62, P6688
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf
   Frings O, 2013, AM J PATHOL, V182, P2037, DOI 10.1016/j.ajpath.2013.02.018
   Gillett CE, 2001, J PATHOL, V193, P433, DOI 10.1002/path.831
   Giuliano AE, 2017, CA CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393
   Givel AM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03348 z
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Guo XQ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3586
   Hanrahan EO, 2007, J CLIN ONCOL, V25, P4952, DOI 10.1200/JCO.2006.08.0499
   Hanrahan EO, 2006, J CLIN ONCOL, V24, P2113, DOI 10.1200/JCO.2005.02.8035
   Haragan A, 2020, LAB INVEST, V100, P874, DOI 10.1038/s41374 019 0366 y
   Heimann R, 2000, CANCER RES, V60, P298
   Howard EM, 2005, J CANCER RES CLIN, V131, P14, DOI 10.1007/s00432 004 0618 z
   Howard Eugene M, 2004, Int J Clin Oncol, V9, P154
   Ignatov A, 2018, J CANCER RES CLIN, V144, P1347, DOI 10.1007/s00432 018 2644 2
   Ignatov T, 2017, BREAST CANCER RES TR, V163, P111, DOI 10.1007/s10549 017 4168 x
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953
   Kasangian AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189127
   Kawaguchi J, 1999, J BONE MINER RES, V14, P764, DOI 10.1359/jbmr.1999.14.5.764
   Kraby MR, 2015, J CLIN PATHOL, V68, P891, DOI 10.1136/jclinpath 2015 203037
   Laenkholm AV, 2018, J CLIN ONCOL
   Lee DW, 2019, BRIT J CANCER, V121, P230, DOI 10.1038/s41416 019 0511 9
   Lee DM, 2007, SCIENCE, V315, P1006, DOI 10.1126/science.1137306
   Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818
   Li Z, 2017, ONCOTARGET, V8, P16445, DOI 10.18632/oncotarget.14860
   Lim SC, 2002, ONCOL REP, V9, P915
   Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Muenst S, 2013, BREAST CANCER RES TR, V139, P667, DOI 10.1007/s10549 013 2581 3
   Neuzillet C, 2019, J PATHOL, V248, P51, DOI 10.1002/path.5224
   Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078 0432.CCR 10 1282
   Öhlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024
   Ohnstad HO, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0911 9
   OKAZAKI M, 1994, J BIOL CHEM, V269, P12092
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008 5472.CAN 07 2938
   Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586 019 1526 3
   Parker C, 2001, BRIT J CANCER, V85, P1958, DOI 10.1054/bjoc.2001.2178
   Pedersen KB, 2002, BRIT J CANCER, V87, P1281, DOI 10.1038/sj.bjc.6600624
   Pelon F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14134 w
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045
   Pishvaian MJ, 1999, CANCER RES, V59, P947
   Planche A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018640
   Prat A, 2012, BREAST CANCER RES TR, V135, P301, DOI 10.1007/s10549 012 2143 0
   Puré E, 2018, ONCOGENE, V37, P4343, DOI 10.1038/s41388 018 0275 3
   Querzoli P, 2010, BRIT J CANCER, V103, P1835, DOI 10.1038/sj.bjc.6605991
   Rakha EA, 2005, HISTOPATHOLOGY, V46, P685, DOI 10.1111/j.1365 2559.2005.02156.x
   Rothberg BEG, 2006, BREAST CANCER RES TR, V100, P139, DOI 10.1007/s10549 006 9248 2
   Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008 5472.CAN 07 2017
   Sestak L, 2018, JAMA ONCOL, V4, P545, DOI 10.1001/jamaoncol.2017.5524
   Sfikakis PP, 2017, CLIN IMMUNOL, V176, P107, DOI 10.1016/j.clim.2017.01.008
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   St Croix Brad, 1997, Current Opinion in Oncology, V9, P549
   Strell C, 2019, JNCI J NATL CANCER I, V111, P983, DOI 10.1093/jnci/djy234
   Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Surowiak P, 2007, ANTICANCER RES, V27, P2917
   Tamura D, 2008, INT J ONCOL, V33, P17
   Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073
   Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0129 6
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013 0953 SA]
   Yamashita M, 2012, BREAST CANCER TOKYO, V19, P170, DOI 10.1007/s12282 010 0234 5
NR 89
TC 47
Z9 50
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 5411
EI 1465 542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD JUL 14
PY 2020
VL 22
IS 1
AR 76
DI 10.1186/s13058 020 01311 9
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA MQ6ZE
UT WOS:000553042300001
PM 32665033
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kara, M
   Boran, T
   Öztas, E
   Jannuzzi, AT
   Özden, S
   Özhan, G
AF Kara, Mehtap
   Boran, Tugce
   Oztas, Ezgi
   Jannuzzi, Ayse Tarbin
   Ozden, Sibel
   Ozhan, Gul
TI Zoledronic acid induced oxidative damage and endoplasmic reticulum
   stress mediated apoptosis in human embryonic kidney (HEK 293) cells
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE apoptosis; endoplasmic reticulum stress; nephrotoxicity; oxidative
   damage; zoledronic acid
ID NF KAPPA B; CANCER CELLS; INDUCED NEPHROTOXICITY; IN VITRO; L FABP;
   BISPHOSPHONATES; BREAST; CYTOTOXICITY; ACTIVATION; MECHANISMS
AB Zoledronic acid, a nitrogen containing bisphosphonate drug, is used for the treatment of osteoporosis, Paget's disease of bone, and tumor induced osteolysis. Zoledronic acid has also gained a place in cancer treatment due to its cytotoxic and antiproliferative effects in many cancer cells. Although zoledronic acid is considered safe, kidney damage is still one of the concerns in therapeutic doses. In the study, the aim was to assess the nephrotoxic profiles of zoledronic acid in the human embryonic kidney (HEK 293) cells. Cytotoxicity evaluation was performed by 3 [4,5 dimethylthiazol 2 yl] 2,5 diphenyl tetrazolium bromide (MTT) and neutral red uptake tests, while oxidative stress was performed by reactive oxygen species (ROS) production via flow cytometry, and the incomprehensible evaluation of ROS related genes by RT PCR and apoptosis was performed with Annexin PI analysis in flow cytometry. The obtained result showed that zoledronic acid inhibited cell viability (IC50 values were determined as 273.16 by MTT) and cell proliferation in a concentration dependent manner, induced ROS production, caused glutathione depletion, and increased oxidative stress index and endoplasmic reticulum (ER) stress, indicating severe cellular stress. The expression levels of oxidative damage (L fabp, alpha GST, Nrf2, and HMOX1), ER stress (CASP4, IRE1 alpha, GADD153, and GRP78), and apoptosis (Bcl 2, Bax, Cyt c, p53, CASP9, CASP3, NF kappa B, TNF alpha, and JNK) related genes were altered as well as IRE1 alpha protein levels. Herein, we were the first to show that increased oxidative stress and ER stress resulting in apoptosis are the key molecular pathways in zoledronic acid induced nephrotoxicity equivalent to clinically administered concentrations.
C1 [Kara, Mehtap; Boran, Tugce; Oztas, Ezgi; Jannuzzi, Ayse Tarbin; Ozden, Sibel; Ozhan, Gul] Istanbul Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR 34116 Istanbul, Turkey.
C3 Istanbul University
RP Özhan, G (通讯作者)，Istanbul Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR 34116 Istanbul, Turkey.
EM gulozhan@istanbul.edu.tr
RI Boran, Tuğçe/AAD 6094 2020; özhan, gül/AAD 9228 2020; Öztaş,
   Ezgi/MTD 1899 2025; Ozden, Sibel/F 1562 2018; kara,
   mehtap/IQW 7948 2023; Jannuzzi, Ayse Tarbin/A 2634 2016
OI Ozden, Sibel/0000 0002 1662 2504; boran, tugce/0000 0003 4302 1947; 
FU Research Fund of Istanbul University [TSA 2019 35174]
FX This study was funded by the Research Fund of Istanbul University
   (Project No: TSA 2019 35174).
CR Abudayyak M, 2021, TOXICOL IN VITRO, V72, DOI 10.1016/j.tiv.2021.105077
   Bujanda DA, 2007, ANN ONCOL, V18, P556, DOI 10.1093/annonc/mdl408
   Ali AG, 2017, BIOORGAN MED CHEM, V25, P241, DOI 10.1016/j.bmc.2016.10.040
   AMIN D, 1992, J LIPID RES, V33, P1657
   Amoli MM, 2019, PSYCHONEUROENDOCRINO, V99, P265, DOI 10.1016/j.psyneuen.2018.10.009
   Arun MZ, 2016, DRUG DES DEV THER, V10, P1453, DOI 10.2147/DDDT.S103124
   Bahmani P, 2011, IRAN J MED SCI, V36, P260
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Bodmer M, 2007, NEPHROL DIAL TRANSPL, V22, P2366, DOI 10.1093/ndt/gfm209
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Chang JT, 2003, NEW ENGL J MED, V349, P1676
   Chen H, 2010, EUR J PHARMACOL, V627, P69, DOI 10.1016/j.ejphar.2009.10.056
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Czerwinski M, 1997, GENE THER, V4, P268, DOI 10.1038/sj.gt.3300381
   Darling NJ, 2014, BBA MOL CELL RES, V1843, P2150, DOI 10.1016/j.bbamcr.2014.01.009
   Deavall DG, 2012, J TOXICOL US, V2012, DOI 10.1155/2012/645460
   Finianos A, 2019, EXPERT OPIN PHARMACO, V20, P657, DOI 10.1080/14656566.2019.1574754
   Food and Drug Administration [FDA], 2020, DRUG APPR PACKAGEZOM
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Futamura N, 2013, CLIN EXP METASTAS, V30, P595, DOI 10.1007/s10585 012 9563 4
   Gaitanaki C, 2003, J EXP BIOL, V206, P2759, DOI 10.1242/jeb.00483
   Ge X.Y., 2014, PLOS ONE, V9, pe10
   Gobel G, 2013, CANCER GENOM PROTEOM, V10, P81
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245
   Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071 3084.2006
   Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jeong SY, 2010, INT J MOL MED, V25, P31, DOI 10.3892/ijmm_00000310
   Jiang S, 2016, BMC BIOCHEM, V17, DOI 10.1186/s12858 016 0060 2
   Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014 4827(02)00033 2
   Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157
   Karabulut AB, 2010, TRANSPL P, V42, P3820, DOI 10.1016/j.transproceed.2010.06.017
   Khandelwal VKM, 2014, PHYSIOL RES, V63, pS601, DOI 10.33549/physiolres.932934
   Koçer G, 2013, BIOL TRACE ELEM RES, V153, P251, DOI 10.1007/s12011 013 9659 y
   Lan YC, 2013, ANTICANCER RES, V33, P3807
   Lan Z, 2019, HUM EXP TOXICOL, V38, P598, DOI 10.1177/0960327119829527
   Lee OH, 2007, J BIOL CHEM, V282, P36412, DOI 10.1074/jbc.M706517200
   Li S, 2019, NEOPLASMA, V66, P766, DOI 10.4149/neo_2018_181128N904
   Liu H, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201701616
   López E, 2006, FREE RADICAL BIO MED, V40, P940, DOI 10.1016/j.freeradbiomed.2005.10.062
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Mahmoud A, 2016, INT J TOXICOL, V35, P429, DOI 10.1177/1091581816648624
   Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Oakes SA, 2015, ANNU REV PATHOL MECH, V10, P173, DOI 10.1146/annurev pathol 012513 104649
   Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200
   Ohnuki H, 2012, ARCH ORAL BIOL, V57, P906, DOI 10.1016/j.archoralbio.2011.11.015
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Oztas E, 2019, TOXICOL IN VITRO, V55, P101, DOI 10.1016/j.tiv.2018.12.005
   Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004
   Pandha H, 2006, J UROLOGY, V176, P2255, DOI 10.1016/j.juro.2006.07.053
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Prestes AD, 2019, TOXICOL IN VITRO, V55, P33, DOI 10.1016/j.tiv.2018.11.001
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014 5793(02)02289 5
   Recknor C, 2011, EXPERT OPIN PHARMACO, V12, P807, DOI 10.1517/14656566.2011.562201
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rosa SC, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2713
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Seider MJ, 2018, ANN NUCL MED, V32, P553, DOI 10.1007/s12149 018 1278 4
   Sert IU, 2018, ARCH MED SCI, V14, P381, DOI 10.5114/aoms.2016.60227
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Singireesu SSNR, 2018, LIFE SCI, V203, P305, DOI 10.1016/j.lfs.2018.04.059
   Soltau J, 2008, ANTICANCER RES, V28, P933
   Szegezdi, 2006, EMBO REP, V514, P122
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Thomas Philip, 2005, Journal of Pharmacological and Toxicological Methods, V51, P187, DOI 10.1016/j.vascn.2004.08.014
   Ullén A, 2009, SCAND J UROL NEPHROL, V43, P98, DOI 10.1080/00365590802475904
   Verhulst A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121861
   Viganò E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9761
   Wang GQ, 2005, HEPATOLOGY, V42, P871, DOI 10.1002/hep.20857
   Wang IT, 2014, TUMOR BIOL, V35, P11913, DOI 10.1007/s13277 014 2460 5
   Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1109 z
   Waring WS, 2011, CLIN TOXICOL, V49, P720, DOI 10.3109/15563650.2011.615319
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
   Wu CC, 2016, MOLECULES, V21, DOI 10.3390/molecules21121640
   Wu R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170003
   Xu Y, 2015, CLIN CHIM ACTA, V445, P85, DOI 10.1016/j.cca.2015.03.017
   Yazici T, 2018, BIOL TRACE ELEM RES, V184, P358, DOI 10.1007/s12011 017 1187 8
   Zhang P, 2005, INFECT IMMUN, V73, P3990, DOI 10.1128/IAI.73.7.3990 3998.2005
NR 92
TC 13
Z9 13
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1095 6670
EI 1099 0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD AUG
PY 2022
VL 36
IS 8
AR e23083
DI 10.1002/jbt.23083
EA MAY 2022
PG 14
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA 3T6TH
UT WOS:000797463700001
PM 35587103
DA 2025 08 17
ER

PT J
AU De Klerck, B
   Geboes, L
   Hatse, S
   Kelchtermans, H
   Meyvis, Y
   Vermeire, K
   Bridger, G
   Billiau, A
   Schols, D
   Matthys, P
AF De Klerck, B
   Geboes, L
   Hatse, S
   Kelchtermans, H
   Meyvis, Y
   Vermeire, K
   Bridger, G
   Billiau, A
   Schols, D
   Matthys, P
TI Pro inflammatory properties of stromal cell derived factor 1 (CXCL12) in
   collagen induced arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; RHEUMATOID ARTHRITIS; IFN GAMMA; HUMAN
   OSTEOCLASTS; DEFICIENT MICE; HIV 1 ENTRY; T CELLS; MIGRATION; SDF 1;
   MYELOPOIESIS
AB CXCL12 (stromal cell derived factor 1) is a unique biological ligand for the chemokine receptor CXCR4. We previously reported that treatment with a specific CXCR4 antagonist, AMD3100, exerts a beneficial effect on the development of collagen induced arthritis (CIA) in the highly susceptible IFN gamma receptor deficient (IFN gamma R KO) mouse. We concluded that CXCL12 plays a central role in the pathogenesis of CIA in IFN gamma R KO mice by promoting delayed type hypersensitivity against the auto antigen and by interfering with chemotaxis of CXCR4(+) cells to the inflamed joints. Here, we investigated whether AMD3100 can likewise inhibit CIA in wild type mice and analysed the underlying mechanism. Parenteral treatment with the drug at the time of onset of arthritis reduced disease incidence and modestly inhibited severity in affected mice. This beneficial effect was associated with reduced serum concentrations of IL 6. AMD3100 did not affect anti collagen type II antibodies and, in contrast with its action in IFN gamma R KO mice, did not inhibit the delayed type hypersensitivity response against collagen type II, suggesting that the beneficial effect cannot be explained by inhibition of humoral or cellular autoimmune responses. AMD3100 inhibited the in vitro chemotactic effect of CXCL12 on splenocytes, as well as in vivo leukocyte infiltration in CXCL12 containing subcutaneous air pouches. We also demonstrate that, in addition to its effect on cell infiltration, CXCL12 potentiates receptor activator of NF kappa B ligand induced osteoclast differentiation from splenocytes and increases the calcium phosphate resorbing capacity of these osteoclasts, both processes being potently counteracted by AMD3100. Our observations indicate that CXCL12 acts as a pro inflammatory factor in the pathogenesis of autoimmune arthritis by attracting inflammatory cells to joints and by stimulating the differentiation and activation of osteoclasts.
C1 Katholieke Univ Leuven, Rega Inst, Immunobiol Lab, Louvain, Belgium.
   Katholieke Univ Leuven, Rega Inst, Lab Virol & Chemotherapy, Louvain, Belgium.
   AnorMED, Langley, BC, Canada.
C3 KU Leuven; KU Leuven
RP De Klerck, B (通讯作者)，Katholieke Univ Leuven, Rega Inst, Immunobiol Lab, Louvain, Belgium.
EM bert.deklerck@rega.kuleuven.ac.be
RI Matthys, Patrick/B 4813 2018; Schols, Dominique/S 9057 2017; Vermeire,
   Kurt/P 9992 2017
OI Matthys, Patrick/0000 0002 9685 6836; Schols,
   Dominique/0000 0003 3256 5850; Vermeire, Kurt/0000 0003 1123 1907;
   Kelchtermans, Hilde/0000 0002 2724 3438
CR Blades MC, 2002, J IMMUNOL, V168, P4308, DOI 10.4049/jimmunol.168.9.4308
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bradfield PF, 2003, ARTHRITIS RHEUM, V48, P2472, DOI 10.1002/art.11219
   Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423
   Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495
   De Klerck B, 2004, ARTHRITIS RES THER, V6, pR220, DOI 10.1186/ar1167
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Grassi F, 2004, J CELL PHYSIOL, V199, P244, DOI 10.1002/jcp.10445
   Grassi F, 2003, HISTOCHEM CELL BIOL, V120, P391, DOI 10.1007/s00418 003 0587 3
   Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014 5793(02)03143 5
   Kahn J, 2004, BLOOD, V103, P2942, DOI 10.1182/blood 2003 07 2607
   Kanbe K, 2002, ARTHRITIS RHEUM US, V46, P130, DOI 10.1002/1529 0131(200201)46:1<130::AID ART10020>3.0.CO;2 D
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   Matthys P, 1999, J IMMUNOL, V163, P3503
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686
   Matthys P, 2001, TRENDS IMMUNOL, V22, P367, DOI 10.1016/S1471 4906(01)01937 8
   NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305
   Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Tamamura H, 2004, FEBS LETT, V569, P99, DOI 10.1016/j.febslet.2004.05.056
   Vermeire K, 1997, J IMMUNOL, V158, P5507
   Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
NR 26
TC 91
Z9 103
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2005
VL 7
IS 6
BP R1208
EP R1220
DI 10.1186/ar1806
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 997TT
UT WOS:000234272000014
PM 16277673
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tamai, R
   Mashima, I
   Kiyoura, Y
AF Tamai, Riyoko
   Mashima, Izumi
   Kiyoura, Yusuke
TI Alendronate Augments Lipid A Induced IL 1α Release via Activation of ASC
   but Not Caspase 11
SO INFLAMMATION
LA English
DT Article
DE nitrogen containing bisphosphonate (NBP); alendronate; necroptosis;
   caspase 11; apoptosis associated speck like protein containing a CARD
   (ASC); NOD like receptor pyrin domain containing 3 (NLRP3)
ID NONCANONICAL INFLAMMASOME ACTIVATION; NITROGEN CONTAINING
   BISPHOSPHONATES; NLRP3 INFLAMMASOME; IL 1 BETA; INTERLEUKIN 1 ALPHA;
   OSTEONECROSIS; NECROPTOSIS; INHIBITION; EXPRESSION; APOPTOSIS
AB Nitrogen containing bisphosphonates (NBPs), such as alendronate (ALN), are anti bone resorptive drugs that have inflammatory side effects. We previously reported that ALN augmented lipid A induced interleukin (IL) 1 beta production and NOD like receptor pyrin domain containing 3 (NLRP3)/apoptosis associated speck like protein containing a CARD (ASC) dependent cell death. The present study aimed to examine whether ALN augments lipid A induced IL 1 alpha release and necroptosis, which is induced by the activation of receptor interacting protein kinase (RIPK) 3. Treatment of J774.1 cells with ALN augmented lipid A induced IL 1 alpha release, which was not inhibited by Ac IETD CHO, a caspase 8 inhibitor. ALN also activated mixed lineage kinase domain like (MLKL), a key mediator of the necroptosis pathway, and upregulated the expression of caspase 11, a lipid A receptor. GSK'872, a RIPK3 inhibitor, suppressed the ALN upregulated expression of caspase 11 and augmented lipid A induced caspase 8 activation. Moreover, ALN induced the release of NLRP3 and ASC into culture supernatants. GSK'872, but not Ac IETD CHO, reduced the ALN induced release of NLRP3, but not ASC, into culture supernatants, and reduced ALN induced cell death, but not ALN induced LDH release. Antibodies against NLRP3 and ASC upregulated caspase 11 expression in the cytosol by inhibiting ALN induced cell death. However, pretreating cells with an antibody against ASC, but not NLRP3, before ALN addition also inhibited lipid A induced IL 1 alpha release. Pretreating cells with an antibody against caspase 11 before the addition of ALN or lipid A did not downregulate lipid A induced production of IL 1 alpha. Taken together, our fmdings suggest that ALN augments lipid A induced IL 1 alpha release via activation of ASC, but not caspase 11.
C1 [Tamai, Riyoko; Mashima, Izumi; Kiyoura, Yusuke] Ohu Univ, Sch Dent, Dept Oral Med Sci, 31 1 Misumido, Koriyama, Fukushima 9638611, Japan.
RP Tamai, R (通讯作者)，Ohu Univ, Sch Dent, Dept Oral Med Sci, 31 1 Misumido, Koriyama, Fukushima 9638611, Japan.
EM r tamai@den.ohu u.ac.jp
RI ; Tamai, Riyoko/B 7998 2013
OI Mashima, Izumi/0000 0001 6436 1268; Tamai, Riyoko/0000 0002 2782 2763
FU Ohu University School of Dentistry
FX This work was supported by a Grant in Aid for Scientific Research from
   the Ohu University School of Dentistry, including the President's
   discretionary expense.
CR Aachoui Y, 2013, SCIENCE, V339, P975, DOI 10.1126/science.1230751
   Al Moussawi K, 2014, INFECT IMMUN, V82, P4204, DOI 10.1128/IAI.02218 14
   Baroja Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919
   Bochud PY, 2008, NEW ENGL J MED, V359, P1766, DOI 10.1056/NEJMoa0802629
   Casson CN, 2015, P NATL ACAD SCI USA, V112, P6688, DOI 10.1073/pnas.1421699112
   Casson CN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003400
   Chan AH, 2020, J EXP MED, V217, DOI 10.1084/jem.20190314
   Chan JNE, 2020, EUR J IMMUNOL, V50, P1663, DOI 10.1002/eji.201948521
   Coll RC, 2019, NAT CHEM BIOL, V15, P556, DOI 10.1038/s41589 019 0277 7
   Crowley SM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008498
   Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112
   Deng X, 2009, TOXICOL APPL PHARM, V235, P97, DOI 10.1016/j.taap.2008.11.005
   Doerflinger M, 2020, IMMUNITY, V53, P533, DOI 10.1016/j.immuni.2020.07.004
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   England H, 2014, J BIOL CHEM, V289, P15942, DOI 10.1074/jbc.M114.557561
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586 019 1770 6
   Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721
   Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012
   Ishchenko Y, 2017, J PHARMACOL EXP THER, V361, P472, DOI 10.1124/jpet.116.238840
   Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248
   Lee HE, 2016, SCI REP UK, V6, DOI 10.1038/srep38622
   Liao YH, 2013, J LEUKOCYTE BIOL, V93, P289, DOI 10.1189/jlb.0812409
   Malireddi RKS, 2020, J EXP MED, V217, DOI 10.1084/jem.20191644
   Malwal SR, 2018, J AM CHEM SOC, V140, P7568, DOI 10.1021/jacs.8b02363
   Man SM, 2017, SCI REP UK, V7, DOI 10.1038/srep45126
   Manda P, 2018, IMMUNITY, V49, P42, DOI 10.1016/j.immuni.2018.06.011
   Masuda T, 2009, INT IMMUNOPHARMACOL, V9, P1115, DOI 10.1016/j.intimp.2009.05.010
   Medina CB, 2020, NATURE, V580, P130, DOI 10.1038/s41586 020 2121 3
   Meng R, 2019, J BIOL CHEM, V294, P8872, DOI 10.1074/jbc.RA118.007040
   Newton K, 2019, NATURE, V575, P679, DOI 10.1038/s41586 019 1752 8
   Newton K, 2019, NATURE, V574, P428, DOI 10.1038/s41586 019 1548 x
   Papapoulos SE, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115244
   Pontillo A, 2010, EUR J HUM GENET, V18, P844, DOI 10.1038/ejhg.2010.9
   Rathinam VAK, 2016, CELL, V165, P792, DOI 10.1016/j.cell.2016.03.046
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Satoh T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.169
   Silva RO, 2014, NITRIC OXIDE BIOL CH, V40, P22, DOI 10.1016/j.niox.2014.05.002
   Singh AK, 2019, FASEB J, V33, P2526, DOI 10.1096/fj.201801513R
   Tamai R, 2018, LIFE SCI, V198, P8, DOI 10.1016/j.lfs.2018.02.014
   Tamai R, 2010, J ORAL BIOSCI, V52, P268, DOI 10.2330/joralbiosci.52.268
   Tang J, 2020, J EXP MED, V217, DOI 10.1084/jem.20182091
   Tsugawa H, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000813
   Wada N, 2020, MOL METAB, V37, DOI 10.1016/j.molmet.2020.100988
   WANG J, 2018, PLOS PATHOG, V14
   Zanoni I, 2016, SCIENCE, V352, P1232, DOI 10.1126/science.aaf3036
   Zhang QZ, 2015, J BONE MINER RES, V30, P2300, DOI 10.1002/jbmr.2577
NR 47
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360 3997
EI 1573 2576
J9 INFLAMMATION
JI Inflammation
PD OCT
PY 2021
VL 44
IS 5
BP 2132
EP 2141
DI 10.1007/s10753 021 01489 w
EA JUN 2021
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA UU4GN
UT WOS:000657209000002
PM 34080091
DA 2025 08 17
ER

PT J
AU Egger, EK
   Ralser, DJ
   Lindner, K
   Recker, F
   Marinova, M
   Savchenko, O
   Lau, JF
   Mustea, A
AF Egger, Eva Katharina
   Ralser, Damian J.
   Lindner, Kira
   Recker, Florian
   Marinova, Milka
   Savchenko, Oleksandre
   Lau, Jan Frederic
   Mustea, Alexander
TI Diagnostic and Therapeutic Approach in a Metastatic Vaginal
   Adenocarcinoma: A Case Report
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE immune checkpoint blockade; vaginal adenocarcinoma; trastuzumab;
   abscopal effect; mutational burden
ID CHEMOTHERAPY; CANCER
AB Background Vaginal adenocarcinomas (VAC) are most often reported after intrauterine exposition to diethylstilbestrol (DES). Rarely, VACs are reported as a malignant transformation of vaginal adenosis or endometriosis, in the context of chromosomal abnormalities or malformations of the uterus or the vagina. VACs without DES exposition have a poor prognosis and a significantly worse outcome compared to vaginal squamous cell carcinomas or DES associated VACs. Objective Here, we report the case of a primarily metastatic VAC, treated successfully with different lines of chemo , antiangiogenic, antibody, and immunotherapy. Case The 49 year old patient presented in 5/2018 with a primarily pulmonary metastatic VAC. Significant tumor reduction was seen after six cycles of carboplatin AUC5/paclitaxel 175 mg/m(2)/bevacizumab 15 mg/kg q3w. Bevacizumab maintenance therapy and later cisplatin mono 50 mg/m(2) q2w led to local and distant tumor progression. To identify a potential targeted therapy, new tumor biopsies were obtained. Immunohistochemistry revealed ERBB2 expression, and paclitaxel 80 mg/m(2) weekly plus trastuzumab 4 mg/m(2) respectively 2 mg/m(2) q3w was administered. Due to local and pulmonal tumor progression after 6 months and persistent ERBB2 positivity, the therapy was adjusted to trastuzumab emtansine (T DM1) 3.6 mg/kg q3w; however, the patient remained locally progressive after three cycles of T DM1 and additionally showed a new bone metastasis. The new tumor biopsies revealed a combined positive score (CPS) of 2 regarding PD L1, and pembrolizumab 200 mg q3w was initiated. The bone metastasis was radiated and treated with denosumab 120 mg q4w. Extreme tumor regression followed by stable disease was maintained for 9 months. Due to a slow locoregional progress only with new inguinal lymph node and pararectal lymph node metastases, a new tumor biopsy was taken. Molecular profiling showed an ARID1A mutation, a mutational burden of 5.1 mutations per megabase, and no genfusions. Based on these findings, therapy with PD L1 antibodies, PD 1 antibodies, gemcitabine, or dasatinib was suggested. Therefore, administration of pembrolizumab was continued and local radiation therapy was performed. This led to a decrease in local tumor manifestations and a stable systemic disease. Conclusion Our case demonstrates the diagnostic and therapeutic approach in a patient with primary metastatic vaginal adenocarcinoma. By tumorgenetic profiling, different lines of systemic therapy, namely, antiangiogenic therapy, monoclonal antibody therapy, immunotherapy, and local radiation therapy, were identified and successfully administered.
C1 [Egger, Eva Katharina; Ralser, Damian J.; Lindner, Kira; Recker, Florian; Mustea, Alexander] Univ Hosp Bonn, Dept Gynecol & Gynecol Oncol, Bonn, Germany.
   [Marinova, Milka; Savchenko, Oleksandre] Univ Hosp Bonn, Dept Diagnost & Intervent Radiol, Bonn, Germany.
   [Lau, Jan Frederic] Univ Hosp Bonn, Dept Pathol, Bonn, Germany.
C3 University of Bonn; University of Bonn; University of Bonn
RP Egger, EK (通讯作者)，Univ Hosp Bonn, Dept Gynecol & Gynecol Oncol, Bonn, Germany.
EM eva katharina.egger@ukbonn.de
RI Egger, Eva/GSE 1447 2022; Recker, Florian/ABP 4557 2022
OI Recker, Florian/0000 0001 9135 4338
CR Berretta M, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9121182
   Bredin P, 2020, SEMIN ONCOL, V47, P259, DOI 10.1053/j.seminoncol.2020.07.008
   Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265
   Cocetta V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042049
   Cousin S, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0630 4
   Frank SJ, 2007, GYNECOL ONCOL, V105, P470, DOI 10.1016/j.ygyno.2007.01.005
   Hacker NF, 2015, INT J GYNECOL OBSTET, V131, pS84, DOI 10.1016/j.ijgo.2015.06.003
   Halle MK, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.05.068
   HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604
   Liu Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0647 8
   Lorusso D, 2014, GYNECOL ONCOL, V133, P117, DOI 10.1016/j.ygyno.2014.01.042
   Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470 2045(20)30445 9
   Naumann RW, 2019, J CLIN ONCOL, V37, P2825, DOI 10.1200/JCO.19.00739
   Oh DY, 2015, ONCOTARGET, V6, P36219, DOI 10.18632/oncotarget.5283
   Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881
   Pang LH, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6026 1
   Quagliariello V, 2017, ONCOTARGET, V8, P30606, DOI 10.18632/oncotarget.16725
   SANDER R, 1986, INT J GYNECOL PATHOL, V5, P362, DOI 10.1097/00004347 198612000 00008
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   TANAKA H, 1994, GYNECOL ONCOL, V55, P259, DOI 10.1006/gyno.1994.1287
   Tewari KS, 2017, LANCET, V390, P1654, DOI 10.1016/S0140 6736(17)31607 0
   Tewari KS, 2015, CLIN CANCER RES, V21, P5480, DOI 10.1158/1078 0432.CCR 15 1346
   Zhou WL, 2020, ARCH GYNECOL OBSTET, V302, P1429, DOI 10.1007/s00404 020 05737 6
NR 23
TC 5
Z9 5
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 23
PY 2021
VL 12
AR 686879
DI 10.3389/fimmu.2021.686879
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA TV3KP
UT WOS:000681622400001
PM 34367146
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Goktas, M
   Cinar, G
   Orujalipoor, I
   Ide, S
   Tekinay, AB
   Guler, MO
AF Goktas, Melis
   Cinar, Goksu
   Orujalipoor, Ilghar
   Ide, Semra
   Tekinay, Ayse B.
   Guler, Mustafa O.
TI Self Assembled Peptide Amphiphile Nanofibers and PEG Composite Hydrogels
   as Tunable ECM Mimetic Microenvironment
SO BIOMACROMOLECULES
LA English
DT Article
ID POLY(ETHYLENE GLYCOL) HYDROGELS; HYBRID HYDROGELS; OSTEOGENIC
   DIFFERENTIATION; EXTRACELLULAR MATRIX; BONE FORMATION; BIOMATERIALS;
   SCAFFOLDS; MECHANOTRANSDUCTION; OSTEOBLASTS; BIOACTIVITY
AB Natural extracellular matrix (ECM) consists of complex signals interacting with each other to organize cellular behavior and responses. This sophisticated microenvironment can be mimicked by advanced materials presenting essential biochemical and physical properties in a synergistic manner. In this work, we developed a facile fabrication method for a novel nanofibrous self assembled peptide amphiphile (PA) and poly(ethylene glycol) (PEG) composite hydrogel system with independently tunable biochemical, mechanical, and physical cues without any chemical modification of polymer backbone or additional polymer processing techniques to create synthetic ECM analogues. This approach allows noninteracting modification of multiple niche properties (e.g., bioactive ligands, stiffness, porosity), since no covalent conjugation method was used to modify PEG monomers for incorporation of bioactivity and porosity. Combining the self assembled PA nanofibers with a chemically cross linked polymer network simply by facile mixing followed by photopolymerization resulted in the formation of porous bioactive hydrogel systems. The resulting porous network can be functionalized with desired bioactive signaling epitopes by simply altering the amino acid sequence of the self assembling PA molecule. In addition, the mechanical properties of the composite system can be precisely controlled by changing the PEG concentration. Therefore, nanofibrous self assembled PA/PEG composite hydrogels reported in this work can provide new opportunities as versatile synthetic mimics of ECM with independently tunable biological and mechanical properties for tissue engineering and regenerative medicine applications. In addition, such systems could provide useful tools for investigation of how complex niche cues influence cellular behavior and tissue formation both in two dimensional and three dimensional platforms.
C1 [Goktas, Melis; Cinar, Goksu; Tekinay, Ayse B.; Guler, Mustafa O.] Bilkent Univ, Inst Mat Sci & Nanotechnol, Natl Nanotechnol Res Ctr UNAM, TR 06800 Ankara, Turkey.
   [Orujalipoor, Ilghar; Ide, Semra] Hacettepe Univ, Dept Nanotechnol & Nanomed, Natl Nanotechnol Res Ctr UNAM, TR 06800 Ankara, Turkey.
   [Ide, Semra] Hacettepe Univ, Fac Engn, Dept Engn Phys, TR 06800 Ankara, Turkey.
C3 Ihsan Dogramaci Bilkent University; Hacettepe University; Hacettepe
   University
RP Guler, MO (通讯作者)，Bilkent Univ, Inst Mat Sci & Nanotechnol, Natl Nanotechnol Res Ctr UNAM, TR 06800 Ankara, Turkey.
EM atekinay@unam.bilkent.edu.tr; moguler@unam.bilkent.edu.tr
RI ; İde, Semra/L 3501 2018; Guler, Mustafa/C 9453 2011; Tekinay,
   Ayse/A 7212 2015
OI Ide, Semra/0000 0003 1893 4058; Cinar Ciftci, Goksu/0000 0001 9639 577X;
   Tekinay, Ayse/0000 0002 4453 814X; Guler, Mustafa
   O./0000 0003 1168 202X; Goktas, Melis/0000 0001 5616 8900
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [213M406]; TUBITAK BIDEB fellowship; Turkish Academy of Sciences
   Distinguished Young Scientist Award (TUBA GEBIP)
FX This work was supported by the Scientific and Technological Research
   Council of Turkey (TUBITAK), Grant Number 213M406. M.G. and G.C.
   acknowledge support from TUBITAK BIDEB fellowship. M.O.G. and A.B.T.
   acknowledge support from the Turkish Academy of Sciences Distinguished
   Young Scientist Award (TUBA GEBIP). We thank Dr. Hahn Ceylan for helpful
   scientific discussions and Elif Arslan for help in the 3D bioreactor
   setup. Also, we appreciate Mustafa Guler's help with TEM imaging.
CR Alcantar NA, 2000, J BIOMED MATER RES, V51, P343, DOI 10.1002/1097 4636(20000905)51:3<343::AID JBM7>3.0.CO;2 D
   Anderson JM, 2009, BIOMACROMOLECULES, V10, P2935, DOI 10.1021/bm9007452
   Bacioglu A, 2014, MATER CHEM PHYS, V146, P425, DOI 10.1016/j.matchemphys.2014.03.048
   Burdick JA, 2002, BIOMATERIALS, V23, P4315, DOI 10.1016/S0142 9612(02)00176 X
   Ceylan H, 2014, BIOMACROMOLECULES, V15, P2407, DOI 10.1021/bm500248r
   Chen WR, 2006, LANGMUIR, V22, P6539, DOI 10.1021/la0530440
   Chiu YC, 2010, TISSUE ENG PART C ME, V16, P905, DOI 10.1089/ten.TEC.2009.0646
   Choi S, 2015, J MATER CHEM B, V3, P1479, DOI 10.1039/c4tb01852d
   Cui HG, 2010, BIOPOLYMERS, V94, P1, DOI 10.1002/bip.21328
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142 9612(03)00340 5
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Forgacs G, 1998, BIOPHYS J, V74, P2227, DOI 10.1016/S0006 3495(98)77932 9
   Galler KM, 2010, J AM CHEM SOC, V132, P3217, DOI 10.1021/ja910481t
   Guler MO, 2006, BIOMACROMOLECULES, V7, P1855, DOI 10.1021/bm060161g
   Hadjipanayi E, 2009, J TISSUE ENG REGEN M, V3, P77, DOI 10.1002/term.136
   Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999
   Hennessy KM, 2009, BIOMATERIALS, V30, P1898, DOI 10.1016/j.biomaterials.2008.12.053
   Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097 4636(199802)39:2<266::AID JBM14>3.0.CO;2 B
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Hoffman AS, 2012, ADV DRUG DELIVER REV, V64, P18, DOI 10.1016/j.addr.2012.09.010
   Ifkovits JL, 2007, TISSUE ENG, V13, P2369, DOI 10.1089/ten.2007.0093
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Keskar V, 2009, TISSUE ENG PT A, V15, P1695, DOI 10.1089/ten.tea.2008.0238
   Kim IL, 2013, BIOMATERIALS, V34, P5571, DOI 10.1016/j.biomaterials.2013.04.004
   Kleinman HK, 2003, CURR OPIN BIOTECH, V14, P526, DOI 10.1016/j.copbio.2003.08.002
   Kocabey S, 2013, ACTA BIOMATER, V9, P9075, DOI 10.1016/j.actbio.2013.07.007
   Langer R, 2003, AICHE J, V49, P2990, DOI 10.1002/aic.690491202
   Lau HK, 2015, BIOMACROMOLECULES, V16, P28, DOI 10.1021/bm501361c
   Lee HJ, 2006, BIOMATERIALS, V27, P5268, DOI 10.1016/j.biomaterials.2006.06.001
   Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Lutolf MP, 2009, ADV MATER, V21, P3255, DOI 10.1002/adma.200802582
   Lutolf MP, 2003, BIOMACROMOLECULES, V4, P713, DOI 10.1021/bm025744e
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Mabry KM, 2015, BIOMATERIALS, V49, P47, DOI 10.1016/j.biomaterials.2015.01.047
   Marí Buyé N, 2013, TISSUE ENG PT A, V19, P870, DOI [10.1089/ten.tea.2012.0077, 10.1089/ten.TEA.2012.0077]
   Mastrogiacomo M, 2006, BIOMATERIALS, V27, P3230, DOI 10.1016/j.biomaterials.2006.01.031
   Matson JB, 2012, CHEM COMMUN, V48, P26, DOI 10.1039/c1cc15551b
   Missirlis D, 2014, BIOMACROMOLECULES, V15, P195, DOI 10.1021/bm4014827
   Munoz Pinto DJ, 2015, BIOMATERIALS, V40, P32, DOI 10.1016/j.biomaterials.2014.10.051
   Niece KL, 2003, J AM CHEM SOC, V125, P7146, DOI 10.1021/ja028215r
   Paramonov SE, 2006, J AM CHEM SOC, V128, P7291, DOI 10.1021/ja060573x
   Pedersen JS, 1996, MACROMOLECULES, V29, P7602, DOI 10.1021/ma9607630
   Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574
   Ravichandran R, 2014, J MATER CHEM B, V2, P8466, DOI 10.1039/c4tb01095g
   Rnjak Kovacina J, 2011, BIOMATERIALS, V32, P6729, DOI 10.1016/j.biomaterials.2011.05.065
   Saez A, 2007, P NATL ACAD SCI USA, V104, P8281, DOI 10.1073/pnas.0702259104
   Shao Y, 2014, ADV MATER, V26, P1494, DOI 10.1002/adma.201304431
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Shih YRV, 2011, J BONE MINER RES, V26, P730, DOI 10.1002/jbmr.278
   Shin H, 2012, BIOMATERIALS, V33, P3143, DOI 10.1016/j.biomaterials.2011.12.050
   Singh A, 2013, ADV FUNCT MATER, V23, P575, DOI 10.1002/adfm.201201902
   Solon J, 2007, BIOPHYS J, V93, P4453, DOI 10.1529/biophysj.106.101386
   Suh KY, 2004, BIOMATERIALS, V25, P557, DOI 10.1016/S0142 9612(03)00543 X
   Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409
   Sur S, 2015, BIOMATER SCI UK, V3, P520, DOI 10.1039/c4bm00326h
   Sur S, 2012, ACS NANO, V6, P10776, DOI 10.1021/nn304101x
   Thiele J, 2014, ADV MATER, V26, P125, DOI 10.1002/adma.201302958
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161
   Wheeldon I, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/21/212001
   Wu LC, 2011, BIOMATERIALS, V32, P5341, DOI 10.1016/j.biomaterials.2011.04.014
   Xiao JH, 2011, BIOMATERIALS, V32, P6962, DOI 10.1016/j.biomaterials.2011.05.084
   Yang F, 2005, BIOMATERIALS, V26, P5991, DOI 10.1016/j.biomaterials.2005.03.018
   Yang SB, 2012, SOFT MATTER, V8, P8981, DOI 10.1039/c2sm25123j
   Yoo SY, 2011, BIOMACROMOLECULES, V12, P987, DOI 10.1021/bm1013475
   Zhang JT, 2010, ACTA BIOMATER, V6, P1297, DOI 10.1016/j.actbio.2009.11.005
   Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044
NR 69
TC 72
Z9 88
U1 3
U2 144
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD APR
PY 2015
VL 16
IS 4
BP 1247
EP 1258
DI 10.1021/acs.biomac.5b00041
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CG1AS
UT WOS:000353006000019
PM 25751623
DA 2025 08 17
ER

PT J
AU Prel, A
   Caval, V
   Gayon, R
   Ravassard, P
   Duthoit, C
   Payen, E
   Maouche Chretien, L
   Creneguy, A
   Nguyen, TH
   Martin, N
   Piver, E
   Sevrain, R
   Lamouroux, L
   Leboulch, P
   Deschaseaux, F
   Bouillé, P
   Sensébé, L
   Pagès, JC
AF Prel, Anne
   Caval, Vincent
   Gayon, Regis
   Ravassard, Philippe
   Duthoit, Christine
   Payen, Emmanuel
   Maouche Chretien, Leila
   Creneguy, Alison
   Tuan Huy Nguyen
   Martin, Nicolas
   Piver, Eric
   Sevrain, Raphael
   Lamouroux, Lucille
   Leboulch, Philippe
   Deschaseaux, Frederic
   Bouille, Pascale
   Sensebe, Luc
   Pages, Jean Christophe
TI Highly efficient in vitro and in vivo
   delivery of functional RNAs using new versatile MS2 chimeric
   retrovirus like particles
SO MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID PLURIPOTENT STEM CELLS; TRANSGENE EXPRESSION; LENTIVIRAL VECTORS;
   TRANSDUCTION; PROTEIN; EFFICACY; HIV 1; GAG; DIFFERENTIATION; INDUCTION
AB RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell or gene based therapies. Despite significant efforts investigating vector directed RNA transfer, there is still a requirement for better efficiency of delivery to primary cells and in vivo. Retroviral platforms drive RNA delivery, yet retrovirus RNA packaging constraints limit gene transfer to two genome molecules per viral particle. To improve retroviral transfer, we designed a dimerization independent MS2 driven RNA packaging system using MS2 Coat retrovirus chimeras. The engineered chimeric particles promoted effective packaging of several types of RNAs and enabled efficient transfer of biologically active RNAs in various cell types, including human CD34+ and iPS cells. Systemic injection of high titer particles led to gene expression in mouse liver and transferring Cre recombinase mRNA in muscle permitted widespread editing at the ROSA26 locus. We could further show that the VLPs were able to activate an osteoblast differentiation pathway by delivering RUNX2 or DLX5 mRNA into primary human bone marrow mesenchymal stem cells. Thus, the novel chimeric MS2 lentiviral particles are a versatile tool for a wide range of applications including cellular programming or genome editing.
C1 [Prel, Anne; Caval, Vincent; Piver, Eric; Pages, Jean Christophe] Univ Francois Rabelais Tours, INSERM, UMR 966, Tours, France.
   [Prel, Anne; Deschaseaux, Frederic; Sensebe, Luc] UPS, CNRS, INSERM, U1031,UMR 5273,EFS PM, Toulouse, France.
   [Gayon, Regis; Duthoit, Christine; Martin, Nicolas; Sevrain, Raphael; Lamouroux, Lucille; Bouille, Pascale] Vectalys, Toulouse, France.
   [Ravassard, Philippe] Univ Paris 06, ICM, CNRS, UMR7225, Paris, France.
   [Ravassard, Philippe] INSERM, U1127, Biotechnol & Biotherapies Team, Paris, France.
   [Payen, Emmanuel; Maouche Chretien, Leila; Leboulch, Philippe] Univ Paris Sud, CEA, UMR E 007, Inst Emerging Dis & Innovat Therapies iMETI,CEA F, Fontenay Aux Roses, France.
   [Creneguy, Alison; Tuan Huy Nguyen] CHU, Hotel Dieu, INSERM, UMRS 1064, Nantes, France.
   [Creneguy, Alison; Tuan Huy Nguyen] Univ Nantes, ITUN, Nantes, France.
   [Piver, Eric; Pages, Jean Christophe] CHRU Tours, Lab Biochim & Biol Mol, Tours, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Toulouse; Universite Toulouse III   Paul Sabatier; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Centre National de la
   Recherche Scientifique (CNRS); CNRS   National Institute for Biology
   (INSB); Sorbonne Universite; Institut National de la Sante et de la
   Recherche Medicale (Inserm); CEA; Universite Paris Saclay; Nantes
   Universite; CHU de Nantes; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Nantes Universite; CHU Tours
RP Pagès, JC (通讯作者)，Univ Francois Rabelais Tours, INSERM, UMR 966, Tours, France.
EM jean.pages@univ tours.fr
RI ; Ranabhat, Kamal/AAS 6498 2021; Piver, Eric/AAP 8453 2020; maouche,
   leila/E 3887 2017; Payen, Emmanuel/S 5357 2018; Pagès,
   Jean Christophe/IAM 2849 2023
OI Deschaseaux, Frederic/0000 0001 7822 0896; CHRETIEN,
   LEILA/0000 0001 5747 9719; Pages, Jean Christophe/0000 0002 6852 5546;
   Payen, Emmanuel/0000 0002 1329 2327; Lamouroux,
   Lucille/0009 0001 7381 1854; ravassard, philippe/0000 0002 0393 9262; 
FU La Banque Publique d'Investissement (BPI); Region Centre; FEDER Fund;
   IHU Cesti   Nantes Metropole [ANR 10 IBHU 005]; Region Pays de la Loire;
   Chaire Industrielle grant from France's Agence Nationale pour la
   Recherche (ANR)
FX We thank the consortium "MAGenTA", a work supported by a grant from "La
   Banque Publique d'Investissement (BPI)" given to Vectalys for industrial
   implemention of Lentiviral Vectors. The MoDiCSoMe project received
   financial support from the Region Centre and the FEDER Fund. We thank A
   Fourrier for her assistance in cultivating iPS cells, a work supported
   by IHU Cesti, funded by ANR 10 IBHU 005 program, Nantes Metropole and
   Region Pays de la Loire. We thank "Fondation Generale de Sante" and the
   "Assistance Publique Hopitaux de Paris" for human cord blood cells. We
   thank Kanit Bhukhai and Porntip Chaichompoo for their assistance in
   cultivating and transducing CD34+ cells, a work supported by a Chaire
   Industrielle grant from France's Agence Nationale pour la Recherche
   (ANR) given to Philippe Leboulch. We thank E Labat and E Arnaud (UMR
   UPS/CNRS 5273, EFS PM, INSERM U1031) for their assistance. We thank GJ
   Towers, and R Drillien for critical review of the manuscript. J. C. P.
   initiated and supervised the project. A.P., F.D., L.S., P.R., R.G.,
   C.D., E.P., L.M. C., P.L., P.B., and J. C.P. elaborated and supervised
   the experiments. A.P., V.C., R.G., C.D., A.C., T.H.N., E.P., P.R., N.M.,
   R.S., L.L., E. P., L.M. C., and F.D. performed the experiments and
   revised the manuscript. A.P., F.D., C.D., V.C., R.G., E.P., and J. C.P.
   wrote the manuscript.
CR Angel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011756
   [Anonymous], 2014, CURR PROTOC MOL BIOL
   Arruda VR, 2005, BLOOD, V105, P3458, DOI 10.1182/blood 2004 07 2908
   Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534 5807(03)00188 6
   Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097 2765(00)80143 4
   Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev cellbio 100913 013132
   Bloquel C, 2006, FASEB J, V20, P389, DOI 10.1096/fj.05 4737fje
   Bouacida A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048648
   Brown BD, 2006, NAT MED, V12, P585, DOI 10.1038/nm1398
   Chick HE, 2012, HUM GENE THER, V23, P1247, DOI 10.1089/hum.2012.042
   Chiellini C, 2008, BIOCHEM BIOPH RES CO, V374, P64, DOI 10.1016/j.bbrc.2008.06.121
   Cho HJ, 2010, BLOOD, V116, P386, DOI 10.1182/blood 2010 02 269589
   Cordonnier T, 2010, J MATER SCI MATER M, V21, P981, DOI 10.1007/s10856 009 3916 9
   D'Souza V, 2005, NAT REV MICROBIOL, V3, P643, DOI 10.1038/nrmicro1210
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Dorange F, 2004, J GENE MED, V6, P1014, DOI 10.1002/jgm.582
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Feng MZ, 1997, NAT BIOTECHNOL, V15, P866, DOI 10.1038/nbt0997 866
   Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014
   Galaway FA, 2013, MOL PHARMACEUT, V10, P59, DOI 10.1021/mp3003368
   Galla M, 2004, MOL CELL, V16, P309, DOI 10.1016/j.molcel.2004.09.023
   Galla M, 2008, J VIROL, V82, P3069, DOI 10.1128/JVI.01880 07
   Galla Melanie, 2013, Methods Mol Biol, V969, P139, DOI 10.1007/978 1 62703 260 5_10
   Green AA, 2014, CELL, V159, P925, DOI 10.1016/j.cell.2014.10.002
   Hamann MV, 2014, MOL THER, V22, P1460, DOI 10.1038/mt.2014.82
   Houzet L, 2008, NUCLEIC ACIDS RES, V36, P2311, DOI 10.1093/nar/gkn069
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156
   Kanke K, 2014, STEM CELL REP, V2, P751, DOI 10.1016/j.stemcr.2014.04.016
   Kaufmann KB, 2013, EMBO MOL MED, V5, P1642, DOI 10.1002/emmm.201202287
   Kuehle J, 2014, MOL THER, V22, P919, DOI 10.1038/mt.2014.4
   Kutluay SB, 2014, CELL, V159, P1096, DOI 10.1016/j.cell.2014.09.057
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Liu YC, 2013, INT J BIOCHEM CELL B, V45, P2643, DOI 10.1016/j.biocel.2013.09.003
   Lohmann Volker, 2009, V510, P145, DOI 10.1007/978 1 59745 394 3_11
   Mock U, 2014, SCI REP UK, V4, DOI 10.1038/srep06409
   Muriaux D, 2010, RNA BIOL, V7, P744, DOI 10.4161/rna.7.6.14065
   Pan Y, 2012, INT J NANOMED, V7, P5957, DOI 10.2147/IJN.S37990
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Piver E, 2006, J VIROL, V80, P9889, DOI 10.1128/JVI.00664 06
   Poot RA, 1997, P NATL ACAD SCI USA, V94, P10110, DOI 10.1073/pnas.94.19.10110
   Prel A, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472 6750 13 35
   Querido E, 2008, METHOD CELL BIOL, V85, P273
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Scharfmann R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003559
   Schott JW, 2015, CYTOM PART A, V87A, P405, DOI 10.1002/cyto.a.22650
   Singh P, 2015, GENETICS, V199, P1, DOI 10.1534/genetics.114.169771
   Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471 213X 1 4
   Stewart K, 1999, J BONE MINER RES, V14, P1345, DOI 10.1359/jbmr.1999.14.8.1345
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Toromanoff A, 2008, MOL THER, V16, P1291, DOI 10.1038/mt.2008.87
   Uchida N, 2011, GENE THER, V18, P1078, DOI 10.1038/gt.2011.63
   van den Worm SHE, 1998, NUCLEIC ACIDS RES, V26, P1345, DOI 10.1093/nar/26.5.1345
   Voelkel C, 2010, P NATL ACAD SCI USA, V107, P7805, DOI 10.1073/pnas.0914517107
   Westerman KA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742 4690 4 96
   Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004
   Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001
NR 59
TC 61
Z9 81
U1 0
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329 0501
J9 MOL THER METH CLIN D
JI Mol.Ther. Methods Clin. Dev.
PY 2015
VL 2
AR 15039
DI 10.1038/mtm.2015.39
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA V46YE
UT WOS:000209918700051
PM 26528487
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, JJ
   Jha, SK
   Xiao, LD
   Liu, QJ
   Wang, P
   Surya, C
   Yang, M
AF Yu, Jinjiang
   Jha, Shrawan Kumar
   Xiao, Lidan
   Liu, Qingjun
   Wang, Ping
   Surya, Charles
   Yang, Mo
TI AlGaN/GaN heterostructures for non invasive cell electrophysiological
   measurements
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE field effect transistor; extracellular recording; ion channels
ID FIELD EFFECT TRANSISTORS; BIOSENSORS; REPORTER; ISFET
AB Recently, the ability to create bio semiconductor hybrid devices has gained much interest for cell activity analysis. AlGaN material system has been demonstrated to be a promising cell based biosensing platform due to a combination of unique properties, such as chemical inertness, optical transparency and low signal to noise ratios. To investigate the potential application of hybrid cell AlGaN/GaN field effect transistor for cell electrophysiological monitoring, saos 2 human osteoblast like cells were cultured in high density in non metallized gate area of a transparent AlGaN/GaN heterostructure field effect transistor. We implemented and characterized the transistor recording of extracellular voltage in the cell chip junction using the FET chip. The effect of ion channel blocker TEA on transistor signal was explored in order to test the capability of this hybrid chip for in vitro drug screening bioassay. Finally, the effect of cell adhesion on transistor signal was also studied by applying the protein kinase inhibitor H 7. (c) 2007 Elsevier B.V. All rights reserved.
C1 Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Biomed Engn Div, Kowloon, Hong Kong, Peoples R China.
   Hong Kong Polytech Univ, Dept Elect & Informat Engn, Hong Kong, Peoples R China.
   Zhejiang Univ, Dept Biomed Engn, Biosensor Natl Special Lab, Key Lab Biomed Engn,Educ Minist, Hangzhou 310027, Peoples R China.
C3 Hong Kong Polytechnic University; Hong Kong Polytechnic University;
   Zhejiang University
RP Yang, M (通讯作者)，Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Biomed Engn Div, Kowloon, Hong Kong, Peoples R China.
EM htmems@polyu.edu.hk
RI Yang, Mo/K 1274 2012; Liu, Qingjun/AAX 6438 2020
OI Yang, Mo/0000 0002 3863 8187; 
CR Applegate BM, 1998, APPL ENVIRON MICROB, V64, P2730
   Arkhypova VN, 2003, BIOSENS BIOELECTRON, V18, P1047, DOI 10.1016/S0956 5663(02)00222 1
   ASHCROFT FM, 1989, MOL BIOL, V45, P87
   CONNOLLY P, 1990, BIOSENS BIOELECTRON, V5, P223, DOI 10.1016/0956 5663(90)80011 2
   Daunert S, 2000, CHEM REV, V100, P2705, DOI 10.1021/cr990115p
   Denyer MCT, 1998, MED BIOL ENG COMPUT, V36, P638, DOI 10.1007/BF02524437
   Eickhoff M, 2003, GROUP III NITRIDES AND THEIR HETEROSTRUCTURES: GROWTH, CHARACTERIZATION AND APPLICATIONS, P1908, DOI 10.1002/pssc.200303139
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   Kang BS, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.1994951
   Kovacs GTA, 2003, P IEEE, V91, P915, DOI 10.1109/JPROC.2003.813580
   Lehmann M, 2001, BIOSENS BIOELECTRON, V16, P195, DOI 10.1016/S0956 5663(01)00123 3
   Liu QJ, 2007, BIOSENS BIOELECTRON, V22, P810, DOI 10.1016/j.bios.2006.03.006
   Mattiasson B, 1997, RES MICROBIOL, V148, P533, DOI 10.1016/S0923 2508(97)88359 3
   Men H, 2005, SENSOR ACTUAT B CHEM, V110, P350, DOI 10.1016/j.snb.2005.02.032
   Niwa D, 2004, JPN J APPL PHYS 2, V43, pL105, DOI 10.1143/JJAP.43.L105
   Pogorelova SP, 2003, SENSOR ACTUAT B CHEM, V89, P40, DOI 10.1016/S0925 4005(02)00425 2
   ROGERS KR, 1995, BIOSENS BIOELECTRON, V10, P533, DOI 10.1016/0956 5663(95)96929 S
   Schalwig J, 2002, SENSOR ACTUAT B CHEM, V87, P425, DOI 10.1016/S0925 4005(02)00292 7
   Schmidtner M, 2006, BIOPHYS J, V90, P183, DOI 10.1529/biophysj.105.068361
   Schoen I, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2126803
   Spetz AL, 1997, PHYS STATUS SOLIDI A, V162, P493, DOI 10.1002/1521 396X(199707)162:1<493::AID PSSA493>3.0.CO;2 C
   Steinhoff G, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1853531
   Voelker M, 2005, SMALL, V1, P206, DOI 10.1002/smll.200400077
   Wiest J, 2006, ANAL LETT, V39, P1759, DOI 10.1080/00032710600714089
   Wilkins E, 1996, MED ENG PHYS, V18, P273, DOI 10.1016/1350 4533(95)00046 1
   Yang M, 2005, IEEE T BIO MED ENG, V52, P916, DOI 10.1109/TBME.2005.845364
   Yellowley CE, 1998, CALCIFIED TISSUE INT, V62, P122, DOI 10.1007/s002239900405
NR 27
TC 23
Z9 32
U1 0
U2 29
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956 5663
EI 1873 4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD NOV 30
PY 2007
VL 23
IS 4
BP 513
EP 519
DI 10.1016/j.bios.2007.06.014
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology   Other Topics
GA 233WE
UT WOS:000251120200010
PM 17766103
DA 2025 08 17
ER

PT J
AU Petrovic, Z
   Saric, A
   Despotovic, I
   Katic, J
   Peter, R
   Petravic, M
   Petkovic, M
AF Petrovic, Zeljka
   Saric, Ankica
   Despotovic, Ines
   Katic, Jozefina
   Peter, Robert
   Petravic, Mladen
   Petkovic, Marin
TI A New Insight into Coating's Formation Mechanism Between
   TiO2and Alendronate on Titanium Dental Implant
SO MATERIALS
LA English
DT Article
DE titanium dental implant; alendronate sodium; surface coating; DFT; XPS;
   EIS
ID SELF ASSEMBLED MONOLAYERS; STEEL SCREW FIXATION; DENSITY FUNCTIONALS;
   PHOSPHONIC ACID; SURFACES; OSSEOINTEGRATION; PHOSPHATE; ELEMENTS;
   IMMOBILIZATION; DELIVERY
AB Organophosphorus compounds, like bisphosphonates, drugs for treatment and prevention of bone diseases, have been successfully applied in recent years as bioactive and osseoinductive coatings on dental implants. An integrated experimental theoretical approach was utilized in this study to clarify the mechanism of bisphosphonate based coating formation on dental implant surfaces. Experimental validation of the alendronate coating formation on the titanium dental implant surface was carried out by X ray photoelectron spectroscopy and contact angle measurements. Detailed theoretical simulations of all probable molecular implant surface/alendronate interactions were performed employing quantum chemical calculations at the density functional theory level. The calculated Gibbs free energies of (TiO2)(10) alendronate interaction indicate a more spontaneous exergonic process when alendronate molecules interact directly with the titanium surface via two strong bonds, Ti N and Ti O, through simultaneous participation common to both phosphonate and amine branches. Additionally, the stability of the alendronate modified implant during 7 day immersion in a simulated saliva solution has been investigated by using electrochemical impedance spectroscopy. The alendronate coating was stable during immersion in the artificial saliva solution and acted as an additional barrier on the implant with overall resistivity,R similar to 5.9 M Omega cm(2).
C1 [Petrovic, Zeljka] Rudjer Boskovic Inst, Div Mat Chem, Bijenicka Cesta 54, Zagreb 10002, Croatia.
   [Saric, Ankica] Rudjer Boskovic Inst, Ctr Excellence Adv Mat & Sensing Device, Div Mat Phys, Bijenicka Cesta 54, Zagreb 10002, Croatia.
   [Despotovic, Ines] Rudjer Boskovic Inst, Div Phys Chem, Bijenicka Cesta 54, Zagreb 10002, Croatia.
   [Katic, Jozefina] Univ Zagreb, Fac Chem Engn & Technol, Dept Electrochem, Marulicev Trg 19, Zagreb 10000, Croatia.
   [Peter, Robert; Petravic, Mladen] Univ Rijeka, Dept Phys, R Matejcic 2, Rijeka 51000, Croatia.
   [Peter, Robert; Petravic, Mladen] Univ Rijeka, Ctr Micro & Nanosci & Technol, R Matejcic 2, Rijeka 51000, Croatia.
   [Petkovic, Marin] Adentro Dent Studio, Petrova Ul 67, Zagreb 10000, Croatia.
C3 Rudjer Boskovic Institute; Rudjer Boskovic Institute; Rudjer Boskovic
   Institute; University of Zagreb; University of Rijeka; University of
   Rijeka
RP Saric, A (通讯作者)，Rudjer Boskovic Inst, Ctr Excellence Adv Mat & Sensing Device, Div Mat Phys, Bijenicka Cesta 54, Zagreb 10002, Croatia.
EM Zeljka.Petrovic@irb.hr; Ankica.Saric@irb.hr; Ines.Despotovic@irb.hr;
   jkatic@fkit.hr; rpeter@phy.uniri.hr; mpetravic@phy.uniri.hr;
   info@adentro.hr
RI Peter, Robert/R 3216 2018; Petrović, Željka/AAE 8619 2019; Petrovic,
   Zeljka/AAE 8619 2019; Katic, Jozefina/AAP 9800 2020; Petravic,
   Mladen/O 1105 2018
OI Peter, Robert/0000 0002 5669 1985; Katic, Jozefina/0000 0002 4163 9009;
   Petrovic, Zeljka/0000 0001 7609 7863; 
FU SAFU [KK.01.1.1.01.0001]; University of Rijeka [18 144]
FX This work has been partially supported by SAFU, project
   KK.01.1.1.01.0001. The authors would like to thank the Zagreb University
   Computing Centre (SRCE) for generously granting computational resources
   on the ISABELLA cluster (isabella,srce.hr). The authors also thank
   Mirela Leskovac for her valuable comments in wettability measurements.
   Rober Peter and Mladen Petravi acknowledge the University of Rijeka
   support under the project number 18 144.
CR Adden N, 2006, LANGMUIR, V22, P8197, DOI 10.1021/la060754c
   Agarwal R, 2015, BIOMATERIALS, V63, P137, DOI 10.1016/j.biomaterials.2015.06.025
   Aggarwal R, 2016, J INT SOC PREV COMMU, V6, P285, DOI 10.4103/2231 0762.184039
   Agholme F, 2012, J MATER SCI MATER M, V23, P743, DOI 10.1007/s10856 011 4539 5
   Allard MM, 2018, J PHYS CHEM C, V122, P29237, DOI 10.1021/acs.jpcc.8b08641
   [Anonymous], 2019, AIMAll (Version 17.01.25) software TK Gristmill Software
   BADER RF, 1990, ATOMS MOL QUANTUM TH, V22
   Biasetto L, 2016, SURF COAT TECH, V301, P140, DOI 10.1016/j.surfcoat.2016.01.018
   Boubour E, 2000, LANGMUIR, V16, P4222, DOI 10.1021/la991328c
   BOUKAMP BA, 1986, SOLID STATE IONICS, V20, P31, DOI 10.1016/0167 2738(86)90031 7
   BRANEMARK P I, 1969, Scandinavian Journal of Plastic and Reconstructive Surgery, V3, P81
   BRANEMARK PI, 1983, BIOMATERIALS, V4, P25, DOI 10.1016/0142 9612(83)90065 0
   Bronze Uhle ES, 2019, SURF COAT TECH, V357, P36, DOI 10.1016/j.surfcoat.2018.09.038
   BRUG GJ, 1984, J ELECTROANAL CHEM, V176, P275, DOI 10.1016/s0022 0728(84)80324 1
   Cheng DA, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa6521
   Corrado A, 2017, CLIN MED INSIGHTS TH, V9, DOI 10.1177/1179559X17732971
   de Sousa LL, 2017, MATER RES IBERO AM J, V20, P863, DOI [10.1590/1980 5373 MR 2017 0021, 10.1590/1980 5373 mr 2017 0021]
   Elsayed H, 2018, MATERIALS, V11, DOI 10.3390/ma11112234
   Eriksson C, 2004, BIOMATERIALS, V25, P4759, DOI 10.1016/j.biomaterials.2003.12.006
   Frisch M.J., 2016, Gaussian 16, Revision A.03
   Gao Y, 2009, BIOMATERIALS, V30, P1790, DOI 10.1016/j.biomaterials.2008.12.025
   Gaviria L, 2014, J KOR ASSOC ORAL MAX, V40, P50, DOI 10.5125/jkaoms.2014.40.2.50
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Gittens RA, 2014, ACTA BIOMATER, V10, P2907, DOI 10.1016/j.actbio.2014.03.032
   Goodman SB, 2013, BIOMATERIALS, V34, P3174, DOI 10.1016/j.biomaterials.2013.01.074
   He J, 2012, J BIOMED MATER RES A, V100A, P1706, DOI 10.1002/jbm.a.34121
   Hotieba A.A., 2020, ALEX DENT J, V45, P1, DOI [10.21608/adjalexu.2020.79855, DOI 10.21608/ADJALEXU.2020.79855]
   Hu C, 2019, BIOMATERIALS, V219, DOI 10.1016/j.biomaterials.2019.119366
   Ito A, 2005, CURR APPL PHYS, V5, P402, DOI 10.1016/j.cap.2004.10.006
   Karlsson J, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 014 5337 7
   Katic J, 2019, COATINGS, V9, DOI 10.3390/coatings9100612
   Kellesarian SV, 2017, INT J ORAL MAX SURG, V46, P912, DOI 10.1016/j.ijom.2017.03.009
   Kim SE, 2015, J TISSUE ENG REGEN M, V9, pE219, DOI 10.1002/term.1668
   Lee KK, 2019, RSC ADV, V9, P2708, DOI 10.1039/c8ra09729a
   Lee SH, 2018, COATINGS, V8, DOI 10.3390/coatings8010017
   Lin KL, 2011, J MATER CHEM, V21, P16558, DOI 10.1039/c1jm12514a
   Lukaszewska Kuska M, 2018, ADV CLIN EXP MED, V27, P1055, DOI 10.17219/acem/69084
   Mani G, 2008, LANGMUIR, V24, P6774, DOI 10.1021/la8003646
   Marenich AV, 2009, J PHYS CHEM B, V113, P6378, DOI 10.1021/jp810292n
   McLeod K, 2006, APPL SURF SCI, V253, P2644, DOI 10.1016/j.apsusc.2006.05.031
   Mellado Valero A, 2018, MATERIALS, V11, DOI 10.3390/ma11010171
   Mendes V, 2019, INT J ORAL MAX SURG, V48, P373, DOI 10.1016/j.ijom.2018.09.006
   Moon HJ, 2011, BIOCHEM BIOPH RES CO, V413, P194, DOI 10.1016/j.bbrc.2011.08.057
   Orazem ME, 2017, Electrochemical Impedance Spectroscopy Be Replaced by Direct Cur, V2nd, DOI DOI 10.1002/9781119363682
   Pan J, 1996, ELECTROCHIM ACTA, V41, P1143, DOI 10.1016/0013 4686(95)00465 3
   Petravic M, 2014, J APPL PHYS, V115, DOI 10.1063/1.4884835
   Petrovic Z., 2020, INNOV CORROS MAT SCI, V10, P37, DOI [10.2174/2352094910999200407095723, DOI 10.2174/2352094910999200407095723]
   Petrovic Z, 2011, J ELECTROCHEM SOC, V158, pF159, DOI 10.1149/1.3617651
   Pop Georgievski O, 2015, BEILSTEIN J NANOTECH, V6, P617, DOI 10.3762/bjnano.6.63
   Qu ZW, 2007, J PHYS CHEM C, V111, P16808, DOI 10.1021/jp073988t
   Quiñones R, 2007, LANGMUIR, V23, P10123, DOI 10.1021/la701110p
   Rojo L, 2016, SCI REP UK, V6, DOI 10.1038/srep30548
   Scully JR, 2000, CORROSION, V56, P199, DOI 10.5006/1.3280536
   Shen XK, 2019, BIOMATERIALS, V212, P1, DOI 10.1016/j.biomaterials.2019.05.008
   Smeets R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6285620
   Spori DM, 2007, LANGMUIR, V23, P8053, DOI 10.1021/la700474v
   Stanic V, 2010, APPL SURF SCI, V256, P6083, DOI 10.1016/j.apsusc.2010.03.124
   Sun ZL, 1997, J BIOMED MATER RES, V34, P29, DOI 10.1002/(SICI)1097 4636(199701)34:1<29::AID JBM5>3.0.CO;2 P
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Viornery C, 2002, LANGMUIR, V18, P2582, DOI 10.1021/la010908i
   Vohra F, 2014, ARCH ORAL BIOL, V59, P912, DOI 10.1016/j.archoralbio.2014.05.016
   WADT WR, 1985, J CHEM PHYS, V82, P284, DOI 10.1063/1.448800
   Wagstaffe M, 2017, J PHYS CHEM C, V121, P21383, DOI 10.1021/acs.jpcc.7b05818
   Wall I, 2009, BONE, V45, P17, DOI 10.1016/j.bone.2009.03.662
   Yagi R, 2017, MATERIALS, V10, DOI 10.3390/ma10121416
   Yang HO, 2018, MATERIALS, V11, DOI 10.3390/ma11091540
   Yuan HP, 1998, J MATER SCI MATER M, V9, P723, DOI 10.1023/A:1008950902047
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214 007 0310 x
   Zhao Y, 2008, ACCOUNTS CHEM RES, V41, P157, DOI 10.1021/ar700111a
   Zhao Y, 2011, J CHEM THEORY COMPUT, V7, P669, DOI 10.1021/ct1006604
   Zheng D, 2017, J COLLOID INTERF SCI, V487, P1, DOI 10.1016/j.jcis.2016.10.014
NR 71
TC 16
Z9 16
U1 7
U2 34
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1996 1944
J9 MATERIALS
JI Materials
PD JUL
PY 2020
VL 13
IS 14
AR 3220
DI 10.3390/ma13143220
PG 16
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA MS2SM
UT WOS:000554132700001
PM 32698367
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rau, R
AF Rau, R.
TI Efficacy of methotrexate in comparison to biologics in rheumatoid
   arthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE Methotrexate; biologics; rheumatoid arthritis
ID ALPHA MONOCLONAL ANTIBODY; PHASE III TRIAL; DOUBLE BLIND; PLUS
   METHOTREXATE; RANDOMIZED TRIAL; MULTICENTER; PLACEBO; ETANERCEPT;
   THERAPY; COMBINATION
AB This paper reviews trials comparing the efficacy of MTX and biologic agents. So fat; the clinical evaluations of 9 biologics have been published. Three TNF inhibitors   etanercept, adalimumab, golimumab   and the IL 6 receptor inhibitor tocilizumab have been investigated in MTX naive patients using a parallel design. The trials had 3 treatment arms: monotherapies of MTX and of the biologic compound, and the combination of both. The other biologics   infliximab, certolizumab pegol, anakinra, rituximab, and abatacept   were investigated in patients who experienced inadequate response to MTX, and were treated with MTX + biologic agent versus MTX + placebo. That design does not provide a real comparison between MTX and the biologics but may indirectly give an indication of the relative efficacy of the different biologic agents.
   In all trials providing a head to head comparison, MTX and biologics were similarly effective as measured by ACR and EULAR response criteria including clinical remission. In general, improvement started earlier with biologic treatment than with MTX therapy. Inhibition of radiological progression was stronger with biologics probably since TNF inhibitors, in addition to their anti inflammatory effect, directly reduce osteoclast activity. The efficacy of biologics was significantly potentiated when they were combined with MTX.
   Based on the trial results the efficacy of MTX may be underestimated: the initial dose of MTX was too low and was increased only gradually. The trial design with ITT analysis and LOCF may have been disadvantageous for MTX since more patients treated with MTX withdrew and thereby had less time under treatment. Folic acid supplementation may have reduced the efficacy of MTX by interfering with its mechanism of action. Nonetheless, all trials confirmed a surprisingly good performance of MTX in comparison with biologics.
RP Rau, R (通讯作者)，Irisweg 5, D 40489 Dusseldorf, Germany.
EM rau.herborn@t online.de
CR Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Breedveld FC, 2006, ARTHRITIS RHEUM US, V54, P26, DOI 10.1002/art.21519
   Cohen SB, 2004, ANN RHEUM DIS, V63, P1062, DOI 10.1136/ard.2003.016014
   Cohen SB, 2006, ARTHRITIS RHEUM US, V54, P2793, DOI 10.1002/art.22025
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   EMERY P, 2008, LANCET          0716
   Emery P, 2009, ARTHRITIS RHEUM US, V60, P2272, DOI 10.1002/art.24638
   Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308
   Jones G, 2010, ANN RHEUM DIS, V69, P88, DOI 10.1136/ard.2008.105197
   Keystone E, 2008, ARTHRITIS RHEUM, V58, P3319, DOI 10.1002/art.23964
   Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140 6736(04)15640 7
   Kremer JM, 2006, ANN INTERN MED, V144, P865, DOI 10.7326/0003 4819 144 12 200606200 00003
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140 6736(99)05246 0
   Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529 0131(199809)41:9<1552::AID ART5>3.0.CO;2 W
   STENGER AAME, 1992, ANN RHEUM DIS, V51, P1019, DOI 10.1136/ard.51.8.1019
   van der Heijde D, 2007, ARTHRITIS RHEUM, V56, P3928, DOI 10.1002/art.23141
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P1063, DOI 10.1002/art.21655
   van Ede AE, 2001, ARTHRITIS RHEUM US, V44, P1515, DOI 10.1002/1529 0131(200107)44:7<1515::AID ART273>3.0.CO;2 7
NR 18
TC 16
Z9 16
U1 0
U2 6
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD SEP OCT
PY 2010
VL 28
IS 5
SU 61
BP S58
EP S64
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 677XI
UT WOS:000284028500012
PM 21044435
DA 2025 08 17
ER

PT J
AU Amin, N
   Afkhami, A
   Hosseinzadeh, L
   Madrakian, T
AF Amin, Niloufar
   Afkhami, Abbas
   Hosseinzadeh, Leila
   Madrakian, Tayyebeh
TI Green and cost effective synthesis of carbon dots from date kernel and
   their application as a novel switchable fluorescence probe for sensitive
   assay of Zoledronic acid drug in human serum and cellular imaging
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE Nitrogen doped carbon dots; Date kernel; Switchable fluorescence sensor;
   Zoledronic acid drug; Human osteosarcoma cell line; Cell imaging
ID OFF ON FLUORESCENCE; QUANTUM DOTS; CHEMICAL COMPOSITION; NANODOTS;
   NITROGEN; BONE; BISPHOSPHONATES; CHROMATOGRAPHY; INHIBITION; SENSOR
AB A new label free, sensitive and selective off and on signaling fluorescence platform for assay of trace levels of Zoledronic acid (ZA) drug in human biological samples based on nitrogen doped carbon dots (NCDs) ferric ions (Fe3+) was designed. The fluorescence probe, N CDs, was synthesized for the first time through a facile, eco friendly and one step hydrothermal treatment using date kernel as the precursor without any need to use chemical reagents. These CDs exhibited excellent water solubility, ionic and photo stability in various circumstances and a highly relative quantum yield of 12.5%. In the presence of Fe3+, the fluorescence intensity (FL) for N CDs was strongly quenched due to the interaction between ferric ions and the functional groups at the N CDs (switch off). Afterwards, by the addition of ZA, the fluorescence sensor status turned to "ON" (switch on) due to the dominance of ZA in the competition between functional groups on the surface of N CDs and phosphate groups in ZA in the interaction with Fe3+ results in removing Fe3+ from the surface of N CDs. Under the optimized conditions, the proposed fluorescence probe (N CDs Fe3+) exhibited good sensing performance for ZA assay with a linearity from 0.1 mM to 10.0 mM, a detection limit of 0.04 mM and the precision of 2.70%. The developed N CDs Fe3+ sensor was successfully used for the assay of ZA contents with good recoveries and selectivity in human serum samples. Meanwhile, the in vitro cytotoxic activity and cellular uptake of N CDs were investigated on human osteosarcoma (MG 63) cell line. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Amin, Niloufar; Afkhami, Abbas; Madrakian, Tayyebeh] Bu Ali Sina Univ, Fac Chem, Hamadan, Iran.
   [Hosseinzadeh, Leila] Kermanshah Univ Med Sci, Sch Pharm, Pharmaceut Sci Res Ctr, Kermanshah, Iran.
C3 Bu Ali Sina University; Kermanshah University of Medical Sciences
RP Afkhami, A (通讯作者)，Bu Ali Sina Univ, Fac Chem, Hamadan, Iran.
EM afkhami@basu.ac.ir
RI Madrakian, Tayyebeh/C 2780 2018; Afkhami, Abbas/B 3314 2017
OI Madrakian, Tayyebeh/0000 0002 6876 7633; Afkhami,
   Abbas/0000 0002 3559 2080; Amin, Niloufar/0000 0001 9743 0418
CR Amin N, 2018, J LUMIN, V194, P768, DOI 10.1016/j.jlumin.2017.09.048
   Bao L, 2015, ADV MATER, V27, P1663, DOI 10.1002/adma.201405070
   BREDAS JL, 1983, J AM CHEM SOC, V105, P6555, DOI 10.1021/ja00360a004
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Haghshenas E, 2016, ANAL BIOANAL CHEM, V408, P2577, DOI 10.1007/s00216 016 9361 y
   He DG, 2015, CHEM COMMUN, V51, P14764, DOI 10.1039/c5cc05416h
   Holmes LD, 1997, J LIQ CHROMATOGR R T, V20, P123, DOI 10.1080/10826079708010641
   Hossain MZ, 2014, POL J FOOD NUTR SCI, V64, P215, DOI 10.2478/pjfns 2013 0018
   Hsu PC, 2013, J MATER CHEM B, V1, P1774, DOI 10.1039/c3tb00545c
   Hsu PC, 2012, GREEN CHEM, V14, P917, DOI 10.1039/c2gc16451e
   Hu YF, 2017, ACS SUSTAIN CHEM ENG, V5, P4992, DOI 10.1021/acssuschemeng.7b00393
   Huang H, 2014, LANGMUIR, V30, P13542, DOI 10.1021/la503969z
   Huang H, 2013, RSC ADV, V3, P21691, DOI 10.1039/c3ra43452d
   Jhonsi MA, 2017, J LUMIN, V192, P321, DOI 10.1016/j.jlumin.2017.06.056
   Lala R, 2000, ACTA PAEDIATR, V89, P188, DOI 10.1080/080352500750028816
   Li CL, 2014, J MATER CHEM B, V2, P4564, DOI 10.1039/c4tb00216d
   Li XY, 2011, CHEM COMMUN, V47, P932, DOI 10.1039/c0cc03552a
   Liang B, 2006, J MATER CHEM, V16, P1281, DOI 10.1039/b515549e
   Lim SY, 2015, CHEM SOC REV, V44, P362, DOI 10.1039/c4cs00269e
   Liu S, 2012, ADV MATER, V24, P2037, DOI 10.1002/adma.201200164
   Liu W, 2017, SENSOR ACTUAT B CHEM, V241, P190, DOI 10.1016/j.snb.2016.10.068
   Liu YS, 2014, SENSOR ACTUAT B CHEM, V196, P647, DOI 10.1016/j.snb.2014.02.053
   Matuszewski L, 2011, J FAC AGR KYUSHU U, V56, P213
   Miao P, 2015, NANOSCALE, V7, P1586, DOI 10.1039/c4nr05712k
   Park SY, 2014, ACS APPL MATER INTER, V6, P3365, DOI 10.1021/am500159p
   Purbia R, 2016, BIOSENS BIOELECTRON, V79, P467, DOI 10.1016/j.bios.2015.12.087
   Puvvada N, 2012, SCI TECHNOL ADV MAT, V13, DOI 10.1088/1468 6996/13/4/045008
   Raccor BS, 2013, J CHROMATOGR B, V935, P54, DOI 10.1016/j.jchromb.2013.07.019
   Raghu NS, 2011, J LIQ CHROMATOGR R T, V34, P476, DOI 10.1080/10826076.2011.555700
   Rahnemaie R, 2007, LANGMUIR, V23, P3680, DOI 10.1021/la062965n
   Risser F, 1997, J PHARMACEUT BIOMED, V15, P1877, DOI 10.1016/S0731 7085(96)02021 3
   Rose AAN, 2006, B CANCER, V93, P931
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sahoo SK, 2012, CHEM SOC REV, V41, P7195, DOI 10.1039/c2cs35152h
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shi BF, 2016, ACS APPL MATER INTER, V8, P10717, DOI 10.1021/acsami.6b01325
   Simmons JA, 2010, WATER AIR SOIL POLL, V209, P123, DOI 10.1007/s11270 009 0185 7
   Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124
   Sun J, 2015, NANOSCALE, V7, P16372, DOI 10.1039/c5nr04826e
   Suresh S, 2013, J FOOD ENG, V119, P668, DOI 10.1016/j.jfoodeng.2013.06.026
   Tang LB, 2012, ACS NANO, V6, P5102, DOI 10.1021/nn300760g
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Teng XY, 2014, J MATER CHEM B, V2, P4631, DOI 10.1039/c4tb00368c
   Wang CI, 2014, GREEN CHEM, V16, P2509, DOI 10.1039/c3gc42325e
   Wang L, 2014, ANAL CHEM, V86, P8902, DOI 10.1021/ac502646x
   Wang L, 2016, TALANTA, V160, P268, DOI 10.1016/j.talanta.2016.07.020
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Xie Z, 2006, J CHROMATOGR A, V1104, P173, DOI 10.1016/j.chroma.2005.11.113
   Yang GH, 2016, J MATER CHEM A, V4, P12841, DOI 10.1039/c6ta05943k
   Zhai WY, 2014, ANAL CHEM, V86, P12206, DOI 10.1021/ac503215z
   Zhang HJ, 2014, ANAL CHEM, V86, P9846, DOI 10.1021/ac502446m
   Zhang QQ, 2018, BIOSENS BIOELECTRON, V100, P148, DOI 10.1016/j.bios.2017.08.049
   Zhang RZ, 2014, BIOSENS BIOELECTRON, V55, P83, DOI 10.1016/j.bios.2013.11.074
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
   Zhu CZ, 2012, CHEM COMMUN, V48, P9367, DOI 10.1039/c2cc33844k
NR 58
TC 111
Z9 117
U1 4
U2 233
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0003 2670
EI 1873 4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD NOV 7
PY 2018
VL 1030
BP 183
EP 193
DI 10.1016/j.aca.2018.05.014
PG 11
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA GN5NA
UT WOS:000439105500019
PM 30032768
DA 2025 08 17
ER

PT J
AU Gao, S
   Tu, DN
   Li, H
   Jiang, JX
   Cao, X
   You, JB
   Zhou, XQ
AF Gao, Shan
   Tu, Dan Na
   Li, Heng
   Jiang, Jian Xin
   Cao, Xin
   You, Jin Bin
   Zhou, Xiao Qin
TI Pharmacological or genetic inhibition of LDHA reverses tumor progression
   of pediatric osteosarcoma
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE LDHA; Cell proliferation; Cell invasion; ECAR; Warburg effect;
   Osteosarcoma
ID REGULATES AEROBIC GLYCOLYSIS; LACTATE DEHYDROGENASE; GROWTH; METABOLISM
AB Reprogrammed energy metabolism is an emerging hallmark of cancer. Lactate dehydrogenase A (LDHA), a key enzyme involved in anaerobic glycolysis, is frequently deregulated in human malignancies. However, limited knowledge is known about its roles in the progression of osteosarcoma (OS). In this study, we found that LDHA is commonly upregulated in four OS cell lines compared with the normal osteoblast cells (hFOB1.19). Treatment with FX11, a specific inhibitor of LDHA, significantly reduced LDHA activity, and inhibited cell proliferation and invasive potential in a dose dependent manner. Genetic silencing of LDHA resulted in a decreased lactate level in the culture medium, reduced cell viability and decreased cell invasion ability. Meanwhile, silencing of LDHA also compromised tumorigenesis in vivo. Furthermore, knockdown of LDHA remarkably reduced extracellular acidification rate (ECAR) as well as glucose consumption. In the presence of 2 DG, a glycolysis inhibitor, LDHA mediated cell proliferation and invasion were completely blocked, indicating the oncogenic activities of LDHA may dependent on Warburg effect. Finally, pharmacological inhibition of c Myc or HIF1 alpha significantly attenuated LDHA expression. Taken together, upregulated LDHA facilitates tumor progression of OS and might be a potential target for OS treatment. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Gao, Shan; Tu, Dan Na; Li, Heng; Cao, Xin; You, Jin Bin; Zhou, Xiao Qin] Woman & Child Hosp Hubei Prov, Dept Pediat, 745 Wuluo Rd, Wuhan 430070, Peoples R China.
   [Jiang, Jian Xin] Affiliated Hosp Guiyang Med Coll, Dept Biliary Hepat Surg, Guiyang 550001, Peoples R China.
C3 Guizhou Medical University
RP You, JB; Zhou, XQ (通讯作者)，Woman & Child Hosp Hubei Prov, Dept Pediat, 745 Wuluo Rd, Wuhan 430070, Peoples R China.
EM Youjb5813@163.com; 62724838@163.com
RI cao, xin/GLS 7854 2022
FU National Science Foundation of China [81160311]
FX This work was supported by the grant from National Science Foundation of
   China (no. 81160311).
CR Bernthal NM, 2012, CANCER AM CANCER SOC, V118, P5888, DOI 10.1002/cncr.27651
   Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713
   Chen J, 2014, J CANCER RES CLIN, V140, P1205, DOI 10.1007/s00432 014 1644 0
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   Demetrius LA, 2010, THEOR BIOL MED MODEL, V7, DOI 10.1186/1742 4682 7 2
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Girgis H, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 101
   Goodwin Matthew L, 2014, Front Nutr, V1, P27, DOI 10.3389/fnut.2014.00027
   Gorlick R, 2009, CANC TREAT, V152, P467, DOI 10.1007/978 1 4419 0284 9_27
   Haddox Candace L., 2014, Sarcoma, V2014, P402509, DOI 10.1155/2014/402509
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He TL, 2015, MED ONCOL, V32, DOI 10.1007/s12032 015 0633 8
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   Li XY, 2015, MOL MED REP, V11, P577, DOI 10.3892/mmr.2014.2726
   Liu XJ, 2015, ONCOL REP, V33, P157, DOI 10.3892/or.2014.3600
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671
   Ponisovskiy MR, 2010, CRIT REV EUKAR GENE, V20, P325, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.40
   Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Sheng SL, 2012, FEBS J, V279, P3898, DOI 10.1111/j.1742 4658.2012.08748.x
   Shi M, 2014, CLIN CANCER RES, V20, P4370, DOI 10.1158/1078 0432.CCR 14 0186
   Sotgia F, 2012, ONCOTARGET, V3, P1266
   Sun X., 2015, TUMOUR BIOL
   Wang J., 2015, Oncotarget
   WARBURG O, 1956, SCIENCE, V124, P269
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Xian Z. Y., 2015, TUMOUR BIOL
   Zhao YH, 2009, ONCOGENE, V28, P3689, DOI 10.1038/onc.2009.229
NR 30
TC 38
Z9 41
U1 0
U2 26
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2016
VL 81
BP 388
EP 393
DI 10.1016/j.biopha.2016.04.029
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DN8RO
UT WOS:000377347300048
PM 27261617
DA 2025 08 17
ER

PT J
AU Giannoni, P
   Scaglione, S
   Quarto, R
   Narcisi, R
   Parodi, M
   Balleari, E
   Barbieri, F
   Pattarozzi, A
   Florio, T
   Ferrini, S
   Corte, G
   de Totero, D
AF Giannoni, Paolo
   Scaglione, Silvia
   Quarto, Rodolfo
   Narcisi, Roberto
   Parodi, Manuela
   Balleari, Enrico
   Barbieri, Federica
   Pattarozzi, Alessandra
   Florio, Tullio
   Ferrini, Silvano
   Corte, Giorgio
   de Totero, Daniela
TI An interaction between hepatocyte growth factor and its receptor (c MET)
   prolongs the survival of chronic lymphocytic leukemic cells through
   STAT3 phosphorylation: a potential role of mesenchymal cells in the
   disease
SO HAEMATOLOGICA THE HEMATOLOGY JOURNAL
LA English
DT Article
DE chronic lymphocytic leukemia; mesenchymal stem cells; growth factors;
   survival
ID CLL B CELLS; STEM CELLS; NURSELIKE CELLS; EXPRESSION; APOPTOSIS;
   PROLIFERATION; CXCR4; MICROENVIRONMENT; DIFFERENTIATE; ACTIVATION
AB Background
   Chronic lymphocytic leukemia cells are characterized by an apparent longevity in vivo which is lost when they are cultured in vitro. Cellular interactions and factors provided by the microenvironment appear essential to cell survival and may protect leukemic cells from the cytotoxicity of conventional therapies. Understanding the cross talk between leukemic cells and stroma is of interest for identifying signals supporting disease progression and for developing novel therapeutic strategies.
   Design and Methods
   Different cell types, sharing a common mesenchymal origin and representative of various bone marrow components, were used to challenge the viability of leukemic cells in co cultures and in contact free culture systems. Using a bioinformatic approach we searched for genes shared by lineages prolonging leukemic cell survival and further analyzed their biological role in signal transduction experiments.
   Results
   Human bone marrow stromal cells, fibroblasts, trabecular bone derived cells and an osteoblast like cell line strongly enhanced survival of leukemic cells, while endothelial cells and chondrocytes did not. Gene expression profile analysis indicated two soluble factors, hepatocyte growth factor and CXCL12, as potentially involved. We demonstrated that hepatocyte growth factor and CXCL12 are produced only by mesenchymal lineages that sustain the survival of leukemic cells. Indeed chronic lymphocytic leukemic cells express a functional hepatocyte growth factor receptor (c MET) and hepatocyte growth factor enhanced the viability of these cells through STAT3 phosphorylation, which was blocked by a c MET tyrosine kinase inhibitor. The role of hepatocyte growth factor was confirmed by its short interfering RNA mediated knock down in mesenchymal cells.
   Conclusions
   The finding that hepatocyte growth factor prolongs the survival of chronic lymphocytic leukemic cells is novel and we suggest that the interaction between hepatocyte growth factor producing mesenchymal and neoplastic cells contributes to maintenance of the leukemic clone.
C1 [Corte, Giorgio; de Totero, Daniela] Natl Inst Canc Res, Gene Transfer Lab, I 16132 Genoa, Italy.
   [Giannoni, Paolo; Quarto, Rodolfo; Parodi, Manuela] Adv Biotechnol Ctr, Stem Cell Lab, I 16132 Genoa, Italy.
   [Scaglione, Silvia] Univ Genoa, Dept Commun Comp & Syst Sci DIST, I 16132 Genoa, Italy.
   [Quarto, Rodolfo; Narcisi, Roberto] Univ Genoa, Dept Expt Med Di Me S, I 16132 Genoa, Italy.
   [Balleari, Enrico] San Martino Hosp, Dept Hematol, I 16132 Genoa, Italy.
   [Barbieri, Federica; Pattarozzi, Alessandra; Florio, Tullio] Univ Genoa, Pharmacol Lab, Dept Oncol Biol & Genet, I 16132 Genoa, Italy.
   [Ferrini, Silvano] Natl Inst Canc Res, Immunol Therapies Lab, I 16132 Genoa, Italy.
C3 University of Genoa; IRCCS AOU San Martino IST; University of Genoa;
   University of Genoa; University of Genoa; IRCCS AOU San Martino IST;
   University of Genoa; University of Genoa; IRCCS AOU San Martino IST
RP de Totero, D (通讯作者)，Natl Inst Canc Res, Gene Transfer Lab, Largo R Benzi 10, I 16132 Genoa, Italy.
EM daniela.detotero@istge.it
RI Florio, Tullio/A 2211 2012; scaglione, silvia/HKF 6546 2023; Barbieri,
   Federica/L 8753 2015; Ferrini, Silvano/I 4675 2012; Balleari,
   Enrico/R 3119 2016; Quarto, Rodolfo/AAB 2182 2019; De+Totero,
   Daniela/AAB 3481 2019; Giannoni, Paolo/AAE 8170 2021
OI de Totero, Daniela/0000 0002 8481 7848; FLORIO,
   TULLIO/0000 0002 2394 996X; Giannoni, Paolo/0000 0002 7206 376X;
   Scaglione, Silvia/0000 0002 9464 3554; Barbieri,
   Federica/0000 0001 8988 6896; Quarto, Rodolfo/0000 0002 1146 894X;
   Ferrini, Silvano/0000 0001 7254 2616; 
FU Italian Ministry of Health; AIRC (Italian Association for Cancer
   Research)
FX supported by the Italian Ministry of Health project 2007 and AIRC
   (Italian Association for Cancer Research).
CR Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245
   Bau B, 2004, BIOCHEM BIOPH RES CO, V316, P984, DOI 10.1016/j.bbrc.2004.03.001
   Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood 2004 07 2921
   BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140 6736(95)90279 1
   Burger JA, 2009, LEUKEMIA, V23, P43, DOI 10.1038/leu.2008.299
   Burger JA, 2000, BLOOD, V96, P2655
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood 2005 08 3182
   Burger JA, 2007, BRIT J HAEMATOL, V137, P288, DOI 10.1111/j.1365 2141.2007.06590.x
   Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood 2009 06 225326
   Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood 2005 07 2657
   de Totero D, 2006, BLOOD, V107, P3708, DOI 10.1182/blood 2005 09 3535
   de Totero D, 2003, HAEMATOLOGICA, V88, P148
   De Totero D, 2010, HAEMATOL HEMATOL J, V95, P316
   Deaglio S, 2007, BLOOD, V110, P4012, DOI 10.1182/blood 2007 06 094029
   Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875
   Ding W, 2009, BRIT J HAEMATOL, V147, P471, DOI 10.1111/j.1365 2141.2009.07868.x
   Edelmann J, 2008, LEUKEMIA RES, V32, P1565, DOI 10.1016/j.leukres.2008.03.003
   Eksioglu Demiralp E, 2011, CYTOM PART B CLIN CY, V80B, P1, DOI 10.1002/cyto.b.20553
   Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555 007 9107 6
   Giannoni P, 2005, OSTEOARTHR CARTILAGE, V13, P589, DOI 10.1016/j.joca.2005.02.015
   Grugan KD, 2010, P NATL ACAD SCI USA, V107, P11026, DOI 10.1073/pnas.0914295107
   HAN T, 1984, J CLIN ONCOL, V2, P562, DOI 10.1200/JCO.1984.2.6.562
   Kay NE, 2007, LEUKEMIA RES, V31, P899, DOI 10.1016/j.leukres.2006.11.024
   Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood 2009 07 233718
   Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396
   Muraglia A, 2000, J CELL SCI, V113, P1161
   NALDINI L, 1991, ONCOGENE, V6, P501
   Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood 2004 03 0889
   Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Rasmusson I, 2005, EXP CELL RES, V305, P33, DOI 10.1016/j.yexcr.2004.12.013
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Shoham T, 2003, ANN NY ACAD SCI, V996, P245, DOI 10.1111/j.1749 6632.2003.tb03253.x
   Skibinski G, 2001, IMMUNOLOGY, V102, P506, DOI 10.1046/j.1365 2567.2001.01186.x
   Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood 2005 07 2775
   Tabera S, 2008, HAEMATOL HEMATOL J, V93, P1301, DOI 10.3324/haematol.12857
   Tjin EPM, 2006, BLOOD, V107, P760, DOI 10.1182/blood 2005 05 1929
   Tjin EPM, 2005, J IMMUNOL, V175, P2807, DOI 10.4049/jimmunol.175.5.2807
   Tsukada N, 2002, BLOOD, V99, P1030, DOI 10.1182/blood.V99.3.1030
   Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416
   vanderVoort R, 1997, J EXP MED, V185, P2121, DOI 10.1084/jem.185.12.2121
   Xu XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004783
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
NR 44
TC 33
Z9 35
U1 0
U2 5
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390 6078
EI 1592 8721
J9 HAEMATOL HEMATOL J
JI Haematol Hematol. J.
PD JUL
PY 2011
VL 96
IS 7
BP 1015
EP 1023
DI 10.3324/haematol.2010.029736
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 792FX
UT WOS:000292727200012
PM 21486864
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fernández Fresnedo, G
   Rodrigo, E
   Ruiz, JC
   de Francisco, ALM
   Arias, M
AF Fernandez Fresnedo, G.
   Rodrigo, E.
   Ruiz, J. C.
   Martin de Francisco, A. L.
   Arias, M.
TI Bone Metabolism According to Chronic Kidney Disease Stages in Patients
   Undergoing Kidney Transplantation: a 5 Year Database Analysis
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 2nd Annual Meeting of the Madrid Transplantation Society
CY NOV, 2008
CL Madrid, SPAIN
SP Madrid Transplantat Soc
ID PARATHYROID FUNCTION
AB Introduction. While kidney transplantation successfully reverses many complications of uremia that are not corrected with dialysis therapy, elevated parathyroid hormone (PTH) levels and other alterations of mineral metabolism persist in transplant recipients.
   Patients and Methods. A single center cohort retrospective database analysis was performed of 497 consecutive adult patients who underwent first kidney transplantation between 1994 and 2004. At 1  and 5 year follow up, a descriptive analysis was performed of mineral metabolism parameters of chronic kidney disease stage according to NKF KDOQI (National Kidney Foundation Kidney Disease Outcomes Quality Initiative) in patients with a functional graft at I year. Glomerular filtration rate was estimated using the abbreviated MDRD (Modification of Diet in Renal Disease) equation.
   Results.. Most of the transplants (99.2%) were from cadaveric donors. Mean (SD) patient age was 47.7 (13.3) years, and 69% of patients were men. The causes of chronic kidney disease were glomerular (35.4%), congenital (15.4%), systemic (14.1%), vascular (11.3%), interstitial (10.1%), and other (<1%). The percentage of patients in each stage of chronic kidney disease with calcium levels less than 8.5 mg/dL, phosphorus greater than 4.5 mg/dL, and PTHi greater than 150 pg/mL increased as graft function declined. Six posttransplantation parathyroidectomies were performed. Only 130 patients received secondary hyperparathyroidism treatment within 5 years after transplantation: calcium carbonate, 36.9%; calcium acetate, 1.5%; calcium carbonate plus cholecalciferol, 21%; calcitriol, 71%; and calcifediol, 0.8%.
   Conclusions. The prevalence of hypocalcemia, hyperphosphatemia, and elevated PTH level increased with chronic kidney disease stage. Classification of renal transplant recipients by KDOQI stage may enable clinicians to identify patients at increased risk and to target appropriate therapy to improve outcome. There is an opportunity for enhanced management of secondary hyperparathyroidism in these patients.
C1 [Fernandez Fresnedo, G.; Rodrigo, E.; Ruiz, J. C.; Martin de Francisco, A. L.; Arias, M.] Univ Hosp Marques de Valdecilla, Serv Nephrol, Santander, Cantabria, Spain.
C3 Hospital Universitario Marques de Valdecilla (HUMV); Universidad de
   Cantabria
RP Fernández Fresnedo, G (通讯作者)，Hosp Marques de Valdecilla, Serv Nephrol, Avda Valdecilla, Santander 39008, Spain.
EM nefffg@humv.es
RI ; RODRIGO, EMILIO/HNP 4947 2023; RODRIGO, EMILIO/HNP 4947 2023
OI Ruiz, Juan Carlos/0000 0002 7904 8730; RODRIGO,
   EMILIO/0000 0002 2845 5272; RODRIGO, EMILIO/0000 0002 2845 5272
CR Abbud M, 2007, TRANSPLANTATION, V83, pS1, DOI 10.1097/01.tp.0000260765.41275.e2
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Evenepoel P, 2004, NEPHROL DIAL TRANSPL, V19, P1281, DOI 10.1093/ndt/gfh128
   Fernandez Fresnedo G, 2006, TRANSPL P, V38, P2402, DOI 10.1016/j.transproceed.2006.08.051
   Karthikeyan V, 2004, AM J TRANSPLANT, V4, P262, DOI 10.1046/j.1600 6143.2003.00315.x
   Torres A, 1998, NEPHROL DIAL TRANSPL, V13, P94, DOI 10.1093/ndt/13.suppl_3.94
NR 6
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041 1345
EI 1873 2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUL AUG
PY 2009
VL 41
IS 6
BP 2403
EP 2405
DI 10.1016/j.transproceed.2009.06.071
PG 3
WC Immunology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Immunology; Surgery; Transplantation
GA 489IH
UT WOS:000269413200112
PM 19715933
DA 2025 08 17
ER

PT J
AU Su, LP
   Liu, L
   Ji, M
   Hu, XY
   Liang, M
   Lu, ZY
   Wang, ZG
   Guan, YL
   Xiao, JL
   Zhuang, MJ
   Zhu, SS
   Yang, L
   Pu, HW
AF Su, Liping
   Liu, Li
   Ji, Min
   Hu, Xiayun
   Liang, Min
   Lu, Ziyang
   Wang, Zhiguo
   Guan, Yaling
   Xiao, Jinling
   Zhuang, Mengjie
   Zhu, Sensen
   Yang, Long
   Pu, Hongwei
TI Analysis of heroin effects on calcium channels in rat cardiomyocytes
   based on transcriptomics and metabolomics
SO OPEN MEDICINE
LA English
DT Article
DE heroin; transcriptomics; action potential; L calcium channel; arrhythmia
ID HEART FAILURE; MECHANISMS; ARRHYTHMIA; ACTIVATION; RECEPTOR; DELTA
AB Heroin can cause damage to many human organs, possibly leading to different types of arrhythmias and abnormal electrophysiological function of the heart muscle and the steady state of calcium ion channels. We explored cardiomyocytes treated with heroin and the effect on calcium ion channels. Transcriptomics and metabolomics were used to screen for differential genes and metabolite alterations after heroin administration to jointly analyze the effect of heroin on calcium channels in cardiomyocytes. Cardiomyocytes from primary neonatal rats were cultured in vitro and were treated with different concentrations of heroin to observe the changes in morphology and spontaneous beat frequency and rhythm by a patch clamp technique. Transcriptomic studies selected a total of 1,432 differentially expressed genes, 941 upregulated and 491 downregulated genes in rat cardiomyocytes from the control and drug intervention groups. Gene Ontology functional enrichment showed that 1,432 differential genes selected by the two groups were mainly involved in the regulation of the multicellular organismal process, response to external stimulus, myofibril, inflammatory response, muscle system process, cardiac muscle contraction, etc. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis indicated that these genes were mainly concentrated in cardiac muscle contraction, osteoclast differentiation, adrenergic signaling in cardiomyocytes, dilated cardiomyopathy, hypertrophic cardiomyopathy, and other important pathways. Metabolomic testing further suggested that cardiomyocyte metabolism was severely affected after heroin intervention. After the treatment with heroin, the L type calcium channel current I V curve was up shifted, the peak value was significantly lower than that of the control group, action potential duration 90 was significantly increased in the action potential, resting potential negative value was lowered, and action potential amplitude was significantly decreased in cardiomyocytes. In this study, heroin could cause morphological changes in primary cardiomyocytes of neonatal rats and electrophysiological function. Heroin can cause myocardial contraction and calcium channel abnormalities, damage the myocardium, and change the action potential and L type calcium channel.
C1 [Yang, Long] Xinjiang Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Urumqi, Xinjiang, Peoples R China.
   [Pu, Hongwei] Xinjiang Med Univ, Affiliated Hosp 1, Dept Discipline Construct, 137 Liyushan South Rd, Urumqi 830054, Xinjiang, Peoples R China.
   [Su, Liping; Liu, Li; Ji, Min] Xinjiang Med Univ, Affiliated Hosp 1, Dept Pathol, Urumqi, Xinjiang, Peoples R China.
   [Guan, Yaling; Xiao, Jinling; Zhuang, Mengjie; Zhu, Sensen] Xinjiang Med Univ, Sch Basic Med, Urumqi, Xinjiang, Peoples R China.
   [Hu, Xiayun] Shanghai Changhai Hosp, Dept Pathol, Shanghai, Peoples R China.
   [Liang, Min] Xinjiang Med Univ, Affiliated Hosp 1, Discipline Inspect & Supervis Dept, Urumqi, Xinjiang, Peoples R China.
   [Lu, Ziyang] Qilu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China.
   [Wang, Zhiguo] Xinjiang Hengzheng Jud Expertise Ctr, Urumqi, Peoples R China.
C3 Xinjiang Medical University; Xinjiang Medical University; Xinjiang
   Medical University; Xinjiang Medical University; Naval Medical
   University; Xinjiang Medical University; Shandong University
RP Yang, L (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Urumqi, Xinjiang, Peoples R China.; Pu, HW (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 1, Dept Discipline Construct, 137 Liyushan South Rd, Urumqi 830054, Xinjiang, Peoples R China.
EM 1449071175@qq.com; 576250630@qq.com
FU National Science Foundation of China (NSFC), China [81860049, 82160055];
   Science and Nature Foundation of Xinjiang Uyghur Autonomous Region
   [2020D01C257]; State Key Laboratory of Pathogenesis, Prevention, and
   Treatment of Central Asian High Incidence Diseases Fund
   [SKL HIDCA 2022 JZ7]
FX This work was supported by the National Science Foundation of China
   (NSFC), China (Grant numbers: 81860049 and 82160055) and Science and
   Nature Foundation of Xinjiang Uyghur Autonomous Region (Grant number:
   2020D01C257); State Key Laboratory of Pathogenesis, Prevention, and
   Treatment of Central Asian High Incidence Diseases Fund (Grant no.
   SKL HIDCA 2022 JZ7).
CR Ahern BM, 2021, J GEN PHYSIOL, V153, DOI 10.1085/jgp.202012854
   Bell J, 2017, CAN J PSYCHIAT, V62, P451, DOI 10.1177/0706743716673966
   Bridge JHB, 2017, CARDIOVASC RES, V113, P256, DOI 10.1093/cvr/cvx009
   Butler B, 2011, DRUG ALCOHOL REV, V30, P173, DOI 10.1111/j.1465 3362.2010.00213.x
   Doenst T, 2013, CIRC RES, V113, P709, DOI 10.1161/CIRCRESAHA.113.300376
   Dubois N, 2013, ACTA CLIN BELG, V68, P359, DOI 10.2143/ACB.3323
   Dunn KE, 2018, PSYCHOPHARMACOLOGY, V235, P971, DOI 10.1007/s00213 017 4814 3
   Duran J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051508
   Fassina L, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10030640
   Gopinathannair R, 2015, J AM COLL CARDIOL, V66, P1714, DOI 10.1016/j.jacc.2015.08.038
   Guo A, 2018, J MOL CELL CARDIOL, V115, P104, DOI 10.1016/j.yjmcc.2018.01.003
   Houser SR, 2014, CIRC RES, V114, P1320, DOI 10.1161/CIRCRESAHA.114.300569
   Lutz PE, 2014, NEUROPSYCHOPHARMACOL, V39, P2694, DOI 10.1038/npp.2014.126
   Maleki Balajoo S, 2016, BASIC CLIN NEUROSCI, V7, P299, DOI 10.15412/J.BCN.03070403
   Mattiazzi A, 2015, AM J PHYSIOL HEART C, V308, pH1177, DOI 10.1152/ajpheart.00007.2015
   MELANDRI R, 1991, Recenti Progressi in Medicina, V82, P324
   Mukherjee S, 2017, AM J PHYSIOL LUNG C, V312, pL510, DOI 10.1152/ajplung.00084.2016
   Pavlidis P, 2016, AM J FOREN MED PATH, V37, P95, DOI 10.1097/PAF.0000000000000224
   Phillips KA, 2012, J GEN INTERN MED, V27, P1722, DOI 10.1007/s11606 012 2089 2
   Roe ÅT, 2015, CURR PHARM DESIGN, V21, P431
   Solis E, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0151 17.2017
   Solis E, 2017, ACS CHEM NEUROSCI, V8, P265, DOI 10.1021/acschemneuro.6b00246
   Wu TF, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/7328437
NR 23
TC 1
Z9 2
U1 1
U2 7
PU DE GRUYTER POLAND SP Z O O
PI WARSAW
PA BOGUMILA ZUGA 32A STR, 01 811 WARSAW, MAZOVIA, POLAND
SN 2391 5463
J9 OPEN MED WARSAW
JI Open Med.
PD JUL 31
PY 2023
VL 18
IS 1
AR 20230765
DI 10.1515/med 2023 0765
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA O0FJ0
UT WOS:001040661400001
PM 37554148
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hanley, PJ
   Mei, ZY
   Durett, AG
   Cabreira Harrison, MD
   Klis, M
   Li, W
   Zhao, YL
   Yang, B
   Parsha, K
   Mir, O
   Vahidy, F
   Bloom, D
   Rice, RB
   Hematti, P
   Savitz, SI
   Gee, AP
AF Hanley, Patrick J.
   Mei, Zhuyong
   Durett, April G.
   Cabreira Harrison, Marie da Graca
   Klis, Mariola
   Li, Wei
   Zhao, Yali c
   Yang, Bing
   Parsha, Kaushik
   Mir, Osman
   Vahidy, Farhaan
   Bloom, Debra
   Rice, R. Brent
   Hematti, Peiman
   Savitz, Sean I.
   Gee, Adrian P.
TI Efficient manufacturing of therapeutic mesenchymal stromal cells with
   the use of the Quantum Cell Expansion System
SO CYTOTHERAPY
LA English
DT Article
DE cell culture expansion; good manufacturing practices; mesenchymal
   stromal cells; Quantum; stroke
ID BONE MARROW; STEM CELLS; CHILDREN; BLOOD; LIVER
AB Background. The use of bone marrow derived mesenchymal stromal cells (MSCs) as a cellular therapy for various disease's, such as graft versus host disease, diabetes, ischemic cardiomyopathy and Crohn's disease, has produced promising results in early phase clinical trials. However, for widespread application and use in later phase studies, manufacture of these cells must be cost effective, safe and reproducible. Current methods of manufacturing in flasks or cell factories are labor intensive, involve a large number of open procedures and require prolonged culture times. Methods. We evaluated the Quantum Cell Expansion System for the expansion of large numbers of MSCs from unprocessed bone marrow in a functionally closed system and compared the results with a flask based method currently in clinical trials. Results. After only two passages, we were able to expand a mean of 6.6 x 10(8) MSCs from 25 mL of bone marrow reproducibly. The mean expansion time was 21 days, and cells obtained were able to differentiate into all three lineages: chondrocytes, osteoblasts and adipocytes. The Quantum was able to generate the target cell number of 2.0 x 10(8) cells in an average of 9 fewer days and in half the number of passages required during flask based expansion. We estimated that the Quantum would involve 133 open procedures versus 54,400 in flasks when manufacturing for a clinical trial. Quantum expanded MSCs infused into an ischemic stroke rat model were therapeutically active. Conclusions. The Quantum is a novel method of generating high numbers of MSCs in less time and at lower passages when compared with flasks. In the Quantum, the risk of contamination is substantially reduced because of the substantial decrease in open procedures.
C1 [Hanley, Patrick J.; Mei, Zhuyong; Durett, April G.; Klis, Mariola; Li, Wei; Zhao, Yali c; Gee, Adrian P.] Methodist Hosp, Texas Childrens Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
   [Hanley, Patrick J.; Mei, Zhuyong; Durett, April G.; Klis, Mariola; Li, Wei; Zhao, Yali c; Gee, Adrian P.] Baylor Coll Med, Houston, TX 77030 USA.
   [Hanley, Patrick J.] Sheikh Zayed Inst Pediat Surg Innovat, Program Cell Enhancement & Technol Immunotherapy, Washington, DC USA.
   [Hanley, Patrick J.] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, Washington, DC 20010 USA.
   [Cabreira Harrison, Marie da Graca] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA.
   [Yang, Bing; Parsha, Kaushik; Mir, Osman; Vahidy, Farhaan; Savitz, Sean I.] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA.
   [Bloom, Debra; Hematti, Peiman] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
   [Rice, R. Brent] Terumo BCT, Lakewood, CO USA.
C3 Baylor College of Medicine; Baylor College Medical Hospital; Houston
   Methodist; Baylor College of Medicine; Children's National Health
   System; Texas Heart Institute; Saint Lukes Episcopal Hospital;
   University of Texas System; University of Texas Health Science Center
   Houston; University of Wisconsin System; University of Wisconsin Madison
RP Hanley, PJ (通讯作者)，111 Michigan Ave NW,CRI 5th Floor Main,Suite 5200, Washington, DC 20010 USA.
EM phanley@childrensnational.org
RI ; Parsha, Kaushik/AAY 8159 2020; Mir, Osman/JWA 1110 2024; Vahidy, PhD
   MBBS MPH FAHA, Farhaan/I 6050 2019; Li, Wei/AFW 2599 2022
OI Parsha, Kaushik/0000 0001 5230 3095; Hematti,
   Peiman/0000 0001 5836 4497; Mir, Osman/0000 0002 0226 3299; Vahidy,
   Farhaan/0000 0002 3464 2111; Hanley, Patrick/0000 0002 0102 7892; 
FU Production Assistance for Cellular Therapy (PACT) contract from the
   NIH NHLBI [HHSN268201000007C]; Cancer Prevention Research Institute of
   Texas [RP110553]
FX The authors would like to thank Terumo BCT as well as Dr Helen Heslop
   and Dr Malcolm Brenner for their guidance and support of this project.
   This work was funded by a Production Assistance for Cellular Therapy
   (PACT) contract from the NIH NHLBI to Baylor College of Medicine Center
   for Cell and Gene Therapy, Contract No. HHSN268201000007C, as well as a
   Cancer Prevention Research Institute of Texas award RP110553 to Malcolm
   Brenner.
CR Battiwalla M, 2009, CYTOTHERAPY, V11, P503, DOI 10.1080/14653240903193806
   Bieback K., 2011, STEM CELLS INT, V2010
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Connick P, 2011, TRIALS, V12, DOI 10.1186/1745 6215 12 62
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   Götherström C, 2003, BONE MARROW TRANSPL, V32, P265, DOI 10.1038/sj.bmt.1704111
   Hanley PJ, 2013, CYTOTHERAPY, V15, P416, DOI 10.1016/j.jcyt.2012.09.007
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Jean Francois Michiels ME, 2013, GENET ENG BIOTECHNOL, V33, P26
   Jones M, 2013, CYTOTHERAPY, V15, P1323, DOI 10.1016/j.jcyt.2013.05.024
   Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373 004 8183 7
   Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430
   Malgieri A, 2010, INT J CLIN EXP MED, V3, P248
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Newman Robert E., 2009, Inflammation & Allergy Drug Targets, V8, P110
   Nold P, 2013, BIOCHEM BIOPH RES CO, V430, P325, DOI 10.1016/j.bbrc.2012.11.001
   Otsuru S, 2013, CYTOTHERAPY, V15, P146, DOI 10.1016/j.jcyt.2012.10.012
   Philippe B, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/503593
   Pileggi A, 2012, DIABETES, V61, P1355, DOI 10.2337/db12 0355
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reiser J, 2005, EXPERT OPIN BIOL TH, V5, P1571, DOI 10.1517/14712598.5.12.1571
   Rojewski MT, 2013, CELL TRANSPLANT, V22, P1981, DOI 10.3727/096368912X657990
   Sabatino M, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 23
   Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028 3908(00)00005 8
   Schallmoser Katharina, 2009, J Vis Exp, DOI 10.3791/1523
   Sensebé L, 2011, HUM GENE THER, V22, P19, DOI 10.1089/hum.2010.197
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Vidal MA, 2012, STEM CELLS DEV, V21, P273, DOI 10.1089/scd.2010.0589
NR 30
TC 118
Z9 141
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD AUG
PY 2014
VL 16
IS 8
BP 1048
EP 1058
DI 10.1016/j.jcyt.2014.01.417
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA AL0LU
UT WOS:000338819200003
PM 24726657
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gillessen, S
   Attard, G
   Beer, TM
   Beltran, H
   Bossi, A
   Bristow, R
   Carver, B
   Castellano, D
   Chung, BH
   Clarke, N
   Daugaard, G
   Davis, ID
   de Bono, J
   dos Reis, RB
   Drake, CG
   Eeles, R
   Efstathiou, E
   Evans, CP
   Fanti, S
   Feng, F
   Fizazi, K
   Frydenberg, M
   Gleave, M
   Halabi, S
   Heidenreich, A
   Higano, CS
   James, N
   Kantoff, P
   Kellokumpu Lehtinen, PL
   Khauli, RB
   Kramer, G
   Logothetis, C
   Maluf, F
   Morgans, AK
   Morris, MJ
   Mottet, N
   Murthy, V
   Oh, W
   Ost, P
   Padhani, AR
   Parker, C
   Pritchard, CC
   Roach, M
   Rubin, MA
   Ryan, C
   Saad, F
   Sartor, O
   Scher, H
   Sella, A
   Shore, N
   Smith, M
   Soule, H
   Sternberg, CN
   Suzuki, H
   Sweeney, C
   Sydes, MR
   Tannock, I
   Tombal, B
   Valdagni, R
   Wiegel, T
   Omlin, A
AF Gillessen, Silke
   Attard, Gerhardt
   Beer, Tomasz M.
   Beltran, Himisha
   Bossi, Alberto
   Bristow, Rob
   Carver, Brett
   Castellano, Daniel
   Chung, Byung Ha
   Clarke, Noel
   Daugaard, Gedske
   Davis, Ian D.
   de Bono, Johann
   dos Reis, Rodolfo Borges
   Drake, Charles G.
   Eeles, Ros
   Efstathiou, Eleni
   Evans, Christopher P.
   Fanti, Stefano
   Feng, Felix
   Fizazi, Karim
   Frydenberg, Mark
   Gleave, Martin
   Halabi, Susan
   Heidenreich, Axel
   Higano, Celestia S.
   James, Nicolas
   Kantoff, Philip
   Kellokumpu Lehtinen, Pirkko Liisa
   Khauli, Raja B.
   Kramer, Gero
   Logothetis, Chris
   Maluf, Fernando
   Morgans, Alicia K.
   Morris, Michael J.
   Mottet, Nicolas
   Murthy, Vedang
   Oh, William
   Ost, Piet
   Padhani, Anwar R.
   Parker, Chris
   Pritchard, Colin C.
   Roach, Mack
   Rubin, Mark A.
   Ryan, Charles
   Saad, Fred
   Sartor, Oliver
   Scher, Howard
   Sella, Avishay
   Shore, Neal
   Smith, Matthew
   Soule, Howard
   Sternberg, Cora N.
   Suzuki, Hiroyoshi
   Sweeney, Christopher
   Sydes, Matthew R.
   Tannock, Ian
   Tombal, Bertrand
   Valdagni, Riccardo
   Wiegel, Thomas
   Omlin, Aurelius
TI Management of Patients with Advanced Prostate Cancer: The Report of the
   Advanced Prostate Cancer Consensus Conference APCCC 2017
SO EUROPEAN UROLOGY
LA English
DT Article
DE Advanced and high risk localized prostate cancer; Castration naive and
   castration resistant prostate cancer; Therapeutics; Consensus;
   Oligometastatic prostate cancer
ID ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED TRIAL; LYMPH NODE
   DISSECTION; BRCA2 MUTATION CARRIERS; PHASE III TRIAL; SYMPTOMATIC
   SKELETAL EVENTS; METASTASIS FREE SURVIVAL; ESTRO SIOG GUIDELINES;
   OF THE LITERATURE; TERM FOLLOW UP
AB Backgr(o)und: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.
   Objective: To present the report of APCCC 2017.
   Design, setting, and participants: Ten important areas of controversy in APC management were identified: high risk localised and locally advanced prostate cancer; "oligometastatic'' prostate cancer; castration naive and castration resistant prostate cancer; the role of imaging in APC; osteoclast targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions.
   Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process.
   Results and limitations: Voting is based on panellist opinion, and thus is not based on a standard literature review or meta analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data.
   Conclusions: The presented expert voting results can be used for support in areas of management of men with APC where there is no high level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them.
   Patient summary: The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision making process. (C) 2017 European Association of Urology. Published by Elsevier B.V.
C1 [Gillessen, Silke; Omlin, Aurelius] Cantonal Hosp St Gallen, Dept Med Oncol, St Gallen, Switzerland.
   [Gillessen, Silke; Omlin, Aurelius] Univ Bern, Bern, Switzerland.
   [Attard, Gerhardt; de Bono, Johann] Inst Canc Res Royal Marsden, Dept Med Oncol, London, England.
   [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
   [Beltran, Himisha] Weill Cornell Med, Dept Med Oncol, New York, NY USA.
   [Bossi, Alberto] Goustave Roussy, Prostate Brachytherapy Unit, Genito Urinary Oncol, Dept Radiat Oncol, Paris, France.
   [Bristow, Rob] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
   [Bristow, Rob] Univ Toronto, Toronto, ON, Canada.
   [Carver, Brett] Sidney Kimmel Ctr Prostate & Urol Canc, Dept Urol, New York, NY USA.
   [Castellano, Daniel] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain.
   [Chung, Byung Ha] Yonsei Univ Hlth Syst, Gangnam Severance Hosp, Dept Urol, Seoul, South Korea.
   [Clarke, Noel] Christie Hosp, Dept Urol, Manchester, Lancs, England.
   [Clarke, Noel] Salford Royal Hosp, Dept Urol, Manchester, Lancs, England.
   [Daugaard, Gedske] Copenhagen Univ Hosp, Rigshosp, Dept Med Oncol, Copenhagen, Denmark.
   [Davis, Ian D.] Monash Univ, Box Hill, Vic, Australia.
   [Davis, Ian D.] Eastern Hlth Clin Sch, Eastern Hlth, Box Hill, Vic, Australia.
   [dos Reis, Rodolfo Borges] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Urol, Sao Paulo, Brazil.
   [Drake, Charles G.] Columbia Univ, Dept Med Oncol, Div Haematol Oncol, Med Ctr, New York, NY USA.
   [Eeles, Ros] Inst Canc Res, Dept Clin Oncol & Genet, London, England.
   [Eeles, Ros] Royal Marsden NHS Fdn Trust, London, England.
   [Efstathiou, Eleni] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA.
   [Evans, Christopher P.] Univ Calif Davis, Sch Med, Dept Urol, Davis, CA 95616 USA.
   [Fanti, Stefano] Univ Bologna, Policlin S Orsola, Dept Nucl Med, Bologna, Italy.
   [Feng, Felix; Roach, Mack] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
   [Fizazi, Karim] Univ Paris Sud, Gustave Roussy, Dept Med Oncol, Paris, France.
   [Frydenberg, Mark] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Anat & Dev Biol, Dept Surg, Clayton, Vic, Australia.
   [Gleave, Martin] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol, Vancouver, BC, Canada.
   [Halabi, Susan] Duke Univ, Dept Clin trials & Stat, Durham, NC USA.
   [Heidenreich, Axel] Univ Hosp Koln, Dept Urol, Cologne, Germany.
   [Higano, Celestia S.] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA 98195 USA.
   [Higano, Celestia S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [James, Nicolas] Queen Elizabeth Hosp, Clin Oncol, Dept Clin Oncol, Birmingham, W Midlands, England.
   [James, Nicolas] Univ Birmingham, Birmingham, W Midlands, England.
   [Kantoff, Philip] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Kantoff, Philip] Weill Cornell Med Coll, New York, NY USA.
   [Kellokumpu Lehtinen, Pirkko Liisa] Univ Tampere, Tampere Univ Hosp, Fac Med & Life Sci, Dept Clin Oncol, Tampere, Finland.
   [Khauli, Raja B.] Amer Univ Beirut, Med Ctr, Dept Urol, Beirut, Lebanon.
   [Kramer, Gero] Med Univ Vienna, Dept Urol, Vienna, Austria.
   [Logothetis, Chris] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Maluf, Fernando] Hosp Israelita Albert Einstein, Dept Med Oncol, Sao Paulo, Brazil.
   [Maluf, Fernando] Beneficencia Portuguesa Sao Paulo, Dept Med Oncol, Sao Paulo, Brazil.
   [Morgans, Alicia K.] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Dept Med Oncol & Epidemiol, Nashville, TN USA.
   [Morris, Michael J.] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Mottet, Nicolas] Univ Hosp Nord St Etienne, Dept Urol, St Etienne, France.
   [Murthy, Vedang] Tata Mem Hosp, Dept Radiat Oncol, Mumbai, Maharashtra, India.
   [Oh, William] Icahn Sch Med Mt Sinai, Dept Med Oncol, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA.
   [Ost, Piet] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium.
   [Padhani, Anwar R.] Mt Vernon Canc Ctr, Dept Radiol, London, England.
   [Padhani, Anwar R.] Inst Canc Res, London, England.
   [Parker, Chris] Royal Marsden NHS Fdn Trust, Dept Clin Oncol, Sutton, Surrey, England.
   [Pritchard, Colin C.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
   [Rubin, Mark A.] Univ Bern, Dept Pathol, Bern, Switzerland.
   [Rubin, Mark A.] Inselspital Bern, Bern, Switzerland.
   [Ryan, Charles] Univ Calif San Francisco, Dept Med Oncol Clin Med & Urol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Saad, Fred] Ctr Hosp Univ Montreal, Dept Urol, Montreal, PQ, Canada.
   [Sartor, Oliver] Tulane Canc Ctr, Dept Med Oncol, New Orleans, LA USA.
   [Scher, Howard] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA.
   [Sella, Avishay] Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Dept Med Oncol, Zerifin, Israel.
   [Shore, Neal] Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA.
   [Smith, Matthew] Massachusetts Gen Hosp, Ctr Canc, Dept Med Oncol, Boston, MA USA.
   [Soule, Howard] Prostate Canc Fdn, Santa Monica, CA USA.
   [Sternberg, Cora N.] San Camillo Forlanini Hosp, Dept Med Oncol, Rome, Italy.
   [Suzuki, Hiroyoshi] Toho Univ, Sakura Med Ctr, Dept Urol, Sakura, Chiba, Japan.
   [Sweeney, Christopher] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
   [Sweeney, Christopher] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA.
   [Sydes, Matthew R.] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit, London, England.
   [Tannock, Ian] Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada.
   [Tannock, Ian] Univ Toronto, Toronto, ON, Canada.
   [Tombal, Bertrand] Clin Univ St Luc, Dept Urol, Brussels, Belgium.
   [Valdagni, Riccardo] Univ Milan, Dept Oncol & Haematooncol, Radiat Oncol 1, Prostate Canc Program,Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   [Wiegel, Thomas] Univ Klinikum Ulm, Klin Strahlentherapie & Radioonkol, Dept Radiat Oncol, Albert Einstein Allee, Ulm, Germany.
C3 Kantonsspital St. Gallen; University of Bern; Royal Marsden NHS
   Foundation Trust; Oregon Health & Science University; Cornell
   University; Weill Cornell Medicine; University of Toronto; University
   Health Network Toronto; Princess Margaret Cancer Centre; University of
   Toronto; Hospital Universitario 12 de Octubre; Yonsei University; Yonsei
   University Health System; Christie NHS Foundation Trust; Christie
   Hospital; Salford Royal NHS Foundation Trust; Salford Royal Hospital;
   University of Copenhagen; Copenhagen University Hospital;
   Rigshospitalet; Monash University; Eastern Health; Universidade de Sao
   Paulo; Columbia University; Royal Marsden NHS Foundation Trust;
   University of London; Institute of Cancer Research   UK; Royal Marsden
   NHS Foundation Trust; University of Texas System; UTMD Anderson Cancer
   Center; University of California System; University of California Davis;
   IRCCS Azienda Ospedaliero Universitaria di Bologna; University of
   Bologna; University of California System; University of California San
   Francisco; UNICANCER; Gustave Roussy; Universite Paris Saclay; Monash
   University; University of British Columbia; Duke University; University
   of Cologne; University of Washington; University of Washington Seattle;
   Fred Hutchinson Cancer Center; University of Birmingham; University of
   Birmingham; Memorial Sloan Kettering Cancer Center; Cornell University;
   Weill Cornell Medicine; Tampere University; Tampere University Hospital;
   American University of Beirut; Medical University of Vienna; University
   of Texas System; UTMD Anderson Cancer Center; Hospital Israelita Albert
   Einstein; Vanderbilt University; Memorial Sloan Kettering Cancer Center;
   Tata Memorial Centre (TMC); Tata Memorial Hospital; Icahn School of
   Medicine at Mount Sinai; Ghent University; Ghent University Hospital;
   Mount Vernon Cancer Centre; Royal Marsden NHS Foundation Trust;
   University of London; Institute of Cancer Research   UK; Royal Marsden
   NHS Foundation Trust; University of Washington; University of Washington
   Seattle; University of Bern; University of California System; University
   of California San Francisco; UCSF Medical Center; UCSF Helen Diller
   Family Comprehensive Cancer Center; Universite de Montreal; Tulane
   University; Tulane University Hospital; Memorial Sloan Kettering Cancer
   Center; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical
   Center (Assaf Harofeh); Carolina Urologic Research Center; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Azienda Ospedaliera San Camillo Forlanini; Toho University;
   Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Harvard
   Medical School; Medical Research Council Clinical Trials Unit;
   University of London; University College London; University of Toronto;
   University Health Network Toronto; Princess Margaret Cancer Centre;
   University of Toronto; Universite Catholique Louvain; Cliniques
   Universitaires Saint Luc; University of Milan; Fondazione IRCCS Istituto
   Nazionale Tumori Milan; Ulm University
RP Gillessen, S (通讯作者)，Cantonal Hosp St Gallen, Rorschacherstr 95, CH 9007 St Gallen, Switzerland.
EM silke.gillessen@kssg.ch
RI bristow, robert/NES 3364 2025; Halabi, Susan/AFL 7973 2022; Heidenreich,
   Axel/L 1015 2013; Pritchard, Colin/ABF 6086 2022; Valdagni,
   Riccardo/K 1361 2016; Castellano Castillo, Daniel/AAA 8423 2021;
   Gillessen, Silke/C 6093 2019; Wiegel, Thomas/ABB 4372 2020; James,
   Nick/AAL 6802 2020; Rubin, Mark/HCI 4252 2022; Attard,
   Gerhardt/AEY 9874 2022; Daugaard, Gedske/AAD 4009 2019; Reis,
   Rodolfo/F 5877 2014; Padhani, Anwar/KIA 9850 2024; Shore,
   Neal/ABM 5607 2022; Saad, Fred/ADN 9925 2022; Sydes,
   Matthew/C 3373 2008; Davis, Ian/A 1430 2012; Ost, Piet/A 1449 2011;
   Higano, Celestia/ABB 1153 2022; Oh, William/B 9163 2012
OI Kantoff, Philip/0000 0001 7275 0597; James,
   Nicholas/0000 0002 7314 8204; Valdagni, Riccardo/0000 0001 5140 9728; de
   Bono, Johann S/0000 0002 2034 595X; Bristow, Robert/0000 0002 8553 9544;
   Gillessen, Silke/0000 0001 5746 6555; Gleave,
   Martin/0000 0003 4235 0167; Eeles, Rosalind/0000 0002 3698 6241; Morris,
   Michael J./0000 0002 9454 0096; TOMBAL, Bertrand/0000 0002 0093 8408;
   FANTI, STEFANO/0000 0003 1486 2624; Rubin, Mark/0000 0002 8321 9950;
   Padhani, Anwar/0000 0002 5830 5777; Beer, Tomasz
   Michal/0000 0001 5600 9993; Sydes, Matthew/0000 0002 9323 1371; Murthy,
   Vedang/0000 0001 6011 9319; Daugaard, Gedske/0000 0002 9618 9180;
   Halabi, Susan/0000 0003 4135 2777; Oh, William/0000 0001 5113 8147
FU APCCC : City and Canton of St. Gallen; Swiss Cancer Research
   Organisation; European School of Oncology; Swiss Cancer League; Swiss
   Oncology Research Network SAKK; Swiss Cancer Foundation; Prostate Cancer
   Foundation; Movember Foundation; NHMRC Practitioner Fellowship
   [APP1102604]; Cantonal Hospital St. Gallen; EMPA Materials Science and
   Technology; Appenzeller Bier; Egger Gemusebau; Moving light and sound;
   Schwyter; Swiss; Wernli; Astellas; Bayer Health Care; Janssen; Sanofi
   Genzyme; Amgen; Bristol Myers Squibb; Ferring; Roche; Tolmar;
   AstraZeneca; Clovis; Medivation; Orion; Uro Today; MRC [MC_UU_12023/28,
   MC_U122861330] Funding Source: UKRI; Cancer Research UK [19727, 3804,
   17528] Funding Source: researchfish; Medical Research Council
   [MC_U122861330, MC_UU_12023/20, MC_UU_12023/25, MC_UU_12023/28] Funding
   Source: researchfish; National Institute for Health Research
   [NF SI 0510 10096] Funding Source: researchfish; Grants in Aid for
   Scientific Research [16K11030] Funding Source: KAKEN
FX We gratefully acknowledge all the participants in the Advanced Prostate
   Cancer Consensus Conference (APCCC) for their lively, stimulating
   discussions. We thank Thomas Cerny for his support and Stefanie Fischer
   for carefully reading and correcting the manuscript. We gratefully
   acknowledge the financial support of the following nonprofit
   organisations for the APCCC 2017: City and Canton of St. Gallen, Swiss
   Cancer Research Organisation, European School of Oncology, Swiss Cancer
   League, the Swiss Oncology Research Network SAKK, Swiss Cancer
   Foundation, Prostate Cancer Foundation. We would like to thank
   especially the Movember Foundation for generously supporting the APCCC
   2017 conference.IDD is supported by an NHMRC Practitioner Fellowship
   (APP1102604). We would also like to thank the following supporters:
   Cantonal Hospital St. Gallen, EMPA Materials Science and Technology,
   Appenzeller Bier, Egger Gemusebau, Moving light and sound, Schwyter,
   Swiss, Wernli. We also acknowledge sponsorship from several different
   for profit organisations including: Astellas, Bayer Health Care,
   Janssen, Sanofi Genzyme, Amgen, Bristol Myers Squibb, Ferring, Roche,
   Tolmar, AstraZeneca, Clovis, Medivation, Orion, and Uro Today (details
   on www.apccc.org). These for profit organisations supported the
   conference financially but had no input in the scientific content or the
   final publication.
CR Abdollah F, 2015, EUR UROL, V67, P212, DOI 10.1016/j.eururo.2014.05.011
   Abugharib A, 2017, J UROLOGY, V197, P662, DOI 10.1016/j.juro.2016.08.106
   Afshar Oromieh A, 2015, EUR J NUCL MED MOL I, V42, P197, DOI 10.1007/s00259 014 2949 6
   Ahmed M, 2016, FUTUR SCI OA, V2, DOI 10.4155/fso.15.87
   Alibhai SMH, 2010, J CLIN ONCOL, V28, P5030, DOI 10.1200/JCO.2010.30.8742
   Alibhai SMH, 2009, J CLIN ONCOL, V27, P3452, DOI 10.1200/JCO.2008.20.0923
   Annala M, 2017, EUR UROL, V72, P34, DOI 10.1016/j.eururo.2017.02.023
   [Anonymous], 2016, WHO classification of tumours of the urinary system and male genital organs
   [Anonymous], BJUINT2013
   [Anonymous], N ENGL J MED
   Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
   Aparicio AM, 2016, CLIN CANCER RES, V22, P1520, DOI 10.1158/1078 0432.CCR 15 1259
   Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078 0432.CCR 12 3791
   Bach Gansmo T, 2017, J UROLOGY, V197, P676, DOI 10.1016/j.juro.2016.09.117
   Badwe R, 2015, LANCET ONCOL, V16, P1380, DOI 10.1016/S1470 2045(15)00135 7
   Bancroft EK, 2014, EUR UROL, V66, P489, DOI 10.1016/j.eururo.2014.01.003
   Basler L, 2017, LUNG CANCER, V106, P50, DOI 10.1016/j.lungcan.2017.02.007
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045
   Beltran H, 2015, JAMA ONCOL, V1, P466, DOI 10.1001/jamaoncol.2015.1313
   Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078 0432.CCR 13 3309
   Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159 8290.CD 15 1263
   Bjurlin MA, 2015, NAT REV UROL, V12, P617, DOI 10.1038/nrurol.2015.242
   Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140 6736(02)09408 4
   Bolla M, 2012, LANCET, V380, P2018, DOI 10.1016/S0140 6736(12)61253 7
   Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470 2045(10)70223 0
   Briganti A, 2012, EUR UROL, V62, P472, DOI 10.1016/j.eururo.2012.04.056
   Briganti A, 2012, EUR UROL, V61, P480, DOI 10.1016/j.eururo.2011.10.044
   Bryce AH, 2017, PROSTATE CANCER P D, V20, P221, DOI 10.1038/pcan.2016.71
   Buyyounouski MK, 2017, CA CANCER J CLIN, V67, P246, DOI 10.3322/caac.21391
   Carrie C, 2016, LANCET ONCOL, V17, P747, DOI 10.1016/S1470 2045(16)00111 X
   Castro E, 2015, EUR UROL, V68, P186, DOI 10.1016/j.eururo.2014.10.022
   Castro E, 2013, J CLIN ONCOL, V31, P1748, DOI 10.1200/JCO.2012.43.1882
   Chambers SK, 2017, J CLIN ONCOL, V35, P291, DOI 10.1200/JCO.2016.68.8788
   Chambers SK, 2015, PSYCHO ONCOLOGY, V24, P748, DOI 10.1002/pon.3726
   Chambers SK, 2013, PSYCHO ONCOLOGY, V22, P1025, DOI 10.1002/pon.3095
   Cheng HH, 2016, EUR UROL, V69, P992, DOI 10.1016/j.eururo.2015.11.022
   Colombié M, 2015, EUR J NUCL MED MOL I, V42, P1784, DOI 10.1007/s00259 015 3123 5
   Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002
   Cui JS, 2001, AM J HUM GENET, V68, P1207, DOI 10.1086/320114
   Culp SH, 2014, EUR UROL, V65, P1058, DOI 10.1016/j.eururo.2013.11.012
   Dalesio O, 2000, LANCET, V355, P1491
   Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   De Giorgi U, 2015, EUR J NUCL MED MOL I, V42, P1276, DOI 10.1007/s00259 015 3042 5
   Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012
   Dell'Oglio P, 2014, J ENDOUROL, V28, P416, DOI 10.1089/end.2013.0571
   Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002
   Droz JP, 2017, EUR UROL, V72, P521, DOI 10.1016/j.eururo.2016.12.025
   Eiber M, 2015, J NUCL MED, V56, P668, DOI 10.2967/jnumed.115.154153
   Engel J, 2010, EUR UROL, V57, P754, DOI 10.1016/j.eururo.2009.12.034
   Engert A, 2012, LANCET, V379, P1791, DOI 10.1016/S0140 6736(11)61940 5
   Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820
   Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208
   Evangelista L, 2013, CLIN NUCL MED, V38, P305, DOI 10.1097/RLU.0b013e3182867f3c
   Evans MJ, 2011, P NATL ACAD SCI USA, V108, P9578, DOI 10.1073/pnas.1106383108
   Fizazi K, 2015, LANCET ONCOL, V16, P787, DOI 10.1016/S1470 2045(15)00011 X
   Fizazi K, 2012, EUR J CANCER, V48, P209, DOI 10.1016/j.ejca.2011.10.015
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fizazi N, 2017, N ENGL J MED
   Friedenreich CM, 2016, EUR UROL, V70, P576, DOI 10.1016/j.eururo.2015.12.032
   Galvao DA, 2006, MED SCI SPORT EXER, V38, P2045, DOI 10.1249/01.mss.0000233803.48691.8b
   Galvao DA, 2014, EUR UROL, V65, P856, DOI 10.1016/j.eururo.2013.09.041
   Gandaglia G, 2017, EUR UROL, V72, P689, DOI 10.1016/j.eururo.2017.01.039
   GARNICK MB, 1984, NEW ENGL J MED, V311, P1281
   Gillessen S, 2015, ANN ONCOL, V26, P2354, DOI 10.1093/annonc/mdv360
   Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257
   Giovacchini G, 2015, EUR J NUCL MED MOL I, V42, P877, DOI 10.1007/s00259 015 3015 8
   GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Gravis G, 2016, EUR UROL, V70, P256, DOI 10.1016/j.eururo.2015.11.005
   Gravis G, 2015, EUR UROL, V68, P196, DOI 10.1016/j.eururo.2014.09.022
   Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470 2045(12)70560 0
   Hager S, 2016, ANN ONCOL, V27, P975, DOI 10.1093/annonc/mdw156
   HELLMAN S, 1995, J CLIN ONCOL, V13, P8, DOI 10.1200/JCO.1995.13.1.8
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hinev AI, 2014, UROL INT, V92, P300, DOI 10.1159/000354323
   Hofman MS, 2017, PET CLIN, V12, P219, DOI 10.1016/j.cpet.2016.12.004
   Hope TA, 2017, J NUCL MED, V58, P81, DOI 10.2967/jnumed.116.181800
   Hope TA, 2016, FUTURE ONCOL, V12, P2393, DOI 10.2217/fon 2016 0312
   Hövels AM, 2008, CLIN RADIOL, V63, P387, DOI 10.1016/j.crad.2007.05.022
   Jambor I, 2016, ACTA ONCOL, V55, P59, DOI 10.3109/0284186X.2015.1027411
   James ND, 2016, JAMA ONCOL, V2, P493, DOI 10.1001/jamaoncol.2015.5570
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   James ND, 2016, JAMA ONCOL, V2, P348, DOI 10.1001/jamaoncol.2015.4350
   James ND, 2015, EUR UROL, V67, P1028, DOI 10.1016/j.eururo.2014.09.032
   Kalsi T, 2015, BRIT J CANCER, V112, P1435, DOI 10.1038/bjc.2015.120
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kawano M, 2015, SCI REP UK, V5, DOI 10.1038/srep18217
   Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200/JCO.2006.06.2497
   Keating NL, 2012, J NATL CANCER I, V104, P1518, DOI 10.1093/jnci/djs376
   Keating NL, 2010, J NATL CANCER I, V102, P39, DOI 10.1093/jnci/djp404
   Keizman D, 2017, PROSTATE CANCER P D, V20, P289, DOI 10.1038/pcan.2017.6
   Kellokumpu Lehtinen PL, 2013, LANCET ONCOL, V14, P117, DOI 10.1016/S1470 2045(12)70537 5
   Khosrow Khavar F, 2017, J CLIN ONCOL, V35, P201, DOI 10.1200/JCO.2016.69.6203
   Klotz L, 2015, J CLIN ONCOL, V33, P272, DOI 10.1200/JCO.2014.55.1192
   Komura K, 2016, P NATL ACAD SCI USA, V113, P6259, DOI 10.1073/pnas.1600420113
   Kote Jarai Z, 2011, BRIT J CANCER, V105, P1230, DOI 10.1038/bjc.2011.383
   Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199
   Lange E. M, 2010, MALE REPROD CANC EPI
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lecouvet FE, 2012, EUR UROL, V62, P68, DOI 10.1016/j.eururo.2012.02.020
   Lee Joanne, 2007, Cancer Control, V14, P78
   Leongamornlert D, 2014, BRIT J CANCER, V110, P1663, DOI 10.1038/bjc.2014.30
   Leongamornlert D, 2012, BRIT J CANCER, V106, P1697, DOI 10.1038/bjc.2012.146
   Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028
   Lin CC, 2015, J NATL CANC I, V107
   Löppenberg B, 2017, EUR UROL, V72, P14, DOI 10.1016/j.eururo.2016.04.031
   Lorente D, 2014, BRIT J CANCER, V111, P2248, DOI 10.1038/bjc.2014.531
   Lorente D, 2015, NAT REV UROL, V12, P37, DOI 10.1038/nrurol.2014.345
   Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859
   Mateo J, 2017, EUR UROL, V71, P417, DOI 10.1016/j.eururo.2016.08.037
   Meller B, 2015, EJNMMI RES, V5, DOI 10.1186/s13550 015 0145 8
   Minamimoto R, 2015, J NUCL MED, V56, P1862, DOI 10.2967/jnumed.115.162610
   Miyamoto DT, 2012, CANCER DISCOV, V2, P995, DOI 10.1158/2159 8290.CD 12 0222
   Morigi JJ, 2015, J NUCL MED, V56, P1185, DOI 10.2967/jnumed.115.160382
   Morris MJ, 2015, J CLIN ONCOL, V33, P1356, DOI 10.1200/JCO.2014.55.3875
   Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003
   Moul JW, 2014, UROLOGY, V84, P1427, DOI 10.1016/j.urology.2014.07.059
   Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307
   Mucci LA, 2016, JAMA J AM MED ASSOC, V315, P68, DOI 10.1001/jama.2015.17703
   Na R, 2017, EUR UROL, V71, P740, DOI 10.1016/j.eururo.2016.11.033
   Nanni C, 2016, EUR J NUCL MED MOL I, V43, P1601, DOI 10.1007/s00259 016 3329 1
   Narod SA, 2008, BRIT J CANCER, V99, P371, DOI 10.1038/sj.bjc.6604453
   National Comprehensive Cancer Network, 2017, PROSTATE CANC
   Nead KT, 2017, JAMA ONCOL, V3, P49, DOI 10.1001/jamaoncol.2016.3662
   Nead KT, 2016, J CLIN ONCOL, V34, P566, DOI 10.1200/JCO.2015.63.6266
   Nghiem B, 2016, ASIAN J UROL, V3, P223, DOI 10.1016/j.ajur.2016.09.002
   Ost P, 2015, EUR UROL, V67, P852, DOI 10.1016/j.eururo.2014.09.004
   Padhani AR, 2017, EUR UROL, V71, P81, DOI 10.1016/j.eururo.2016.05.033
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Passoni NM, 2014, BJU INT, V114, P503, DOI 10.1111/bju.12342
   Patel V, 2015, Br Dent J, V219, P203, DOI 10.1038/sj.bdj.2015.680
   Perez Lopez R, 2017, RADIOLOGY, V283, P168, DOI 10.1148/radiol.2016160646
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Pezaro CJ, 2014, EUR UROL, V65, P270, DOI 10.1016/j.eururo.2013.10.055
   Pfister D, 2016, EUR J NUCL MED MOL I, V43, P1410, DOI 10.1007/s00259 016 3366 9
   Pilepich MV, 1997, J CLIN ONCOL, V15, P1013, DOI 10.1200/JCO.1997.15.3.1013
   PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090 4295(99)80053 3
   Ploussard G, 2015, J UROLOGY, V194, P983, DOI 10.1016/j.juro.2015.04.103
   Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159 8290.CD 13 0172
   Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144
   Pritchard CC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5988
   Qu FF, 2017, CLIN CANCER RES, V23, P726, DOI 10.1158/1078 0432.CCR 16 1070
   Rao K, 2014, BJU INT, V114, P50, DOI 10.1111/bju.12764
   Reyes DK, 2015, ONCOTARGET, V6, P8491, DOI 10.18632/oncotarget.3455
   Roach M, 2008, J CLIN ONCOL, V26, P585, DOI 10.1200/JCO.2007.13.9881
   Roach Mack III, 2012, Journal of the National Cancer Institute Monographs, P221, DOI 10.1093/jncimonographs/lgs039
   Robinson D, 2015, CELL, V161, P1215, DOI [10.1016/j.cell.2015.06.053, 10.1016/j.cell.2015.05.001]
   Romanel A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9511
   Rowe SP, 2015, TOMOGRAPHY, V1, P81, DOI 10.18383/j.tom.2015.00169
   Rozet F, 2016, WORLD J UROL, V34, P1505, DOI 10.1007/s00345 016 1803 9
   Rusthoven CG, 2016, J CLIN ONCOL, V34, P2835, DOI 10.1200/JCO.2016.67.4788
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad Fred, 2002, Clin Prostate Cancer, V1, P145, DOI 10.3816/CGC.2002.n.016
   Sartor O, 2017, ANN ONCOL, V28, P1090, DOI 10.1093/annonc/mdx044
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828
   Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Schweizer MT, 2016, ONCOTARGET, V7, P82504, DOI 10.18632/oncotarget.12697
   Schwenck J, 2017, EUR J NUCL MED MOL I, V44, P92, DOI 10.1007/s00259 016 3490 6
   Shaikh MP, J CLIN ONCO IN PRESS
   Shen GH, 2014, SKELETAL RADIOL, V43, P1503, DOI 10.1007/s00256 014 1903 9
   Shipley WU, 2017, NEW ENGL J MED, V376, P417, DOI 10.1056/NEJMoa1607529
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2006, J CLIN ENDOCR METAB, V91, P1305, DOI 10.1210/jc.2005 2507
   Smith MR, 2002, J CLIN ENDOCR METAB, V87, P599, DOI 10.1210/jc.87.2.599
   Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228
   Stuchbery R, 2017, NAT REV UROL, V14, P49, DOI 10.1038/nrurol.2016.221
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tendulkar RD, J CLIN ONCO IN PRESS
   Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181
   Thompson IM, 2009, J UROLOGY, V181, P956, DOI 10.1016/j.juro.2008.11.032
   Tombal B, 2014, BJU INT, V113, P189, DOI 10.1111/bju.12469
   Tosoian JJ, 2017, NAT REV UROL, V14, P15, DOI 10.1038/nrurol.2016.175
   Tryggvadóttir L, 2007, JNCI J NATL CANCER I, V99, P929, DOI 10.1093/jnci/djm005
   Ussher JM, 2016, J SEX MED, V13, P425, DOI 10.1016/j.jsxm.2015.12.026
   Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470 2045(15)00489 1
   Waight JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027690
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Welte T, 2016, NAT CELL BIOL, V18, P632, DOI 10.1038/ncb3355
   Wiegel T, 2014, EUR UROL, V66, P243, DOI 10.1016/j.eururo.2014.03.011
   Won ACM, 2013, BJU INT, V112, pE250, DOI 10.1111/bju.12169
   Woo S, 2018, EUR UROL, V73, P81, DOI 10.1016/j.eururo.2017.03.042
   Wright GL, 1996, UROLOGY, V48, P326, DOI 10.1016/S0090 4295(96)00184 7
   Wyatt AW, 2016, JAMA ONCOL, V2, P1598, DOI 10.1001/jamaoncol.2016.0494
   Yu EY, 2012, J UROLOGY, V188, P103, DOI 10.1016/j.juro.2012.03.008
   Zaffuto E, 2017, J UROLOGY, V197, P669, DOI 10.1016/j.juro.2016.09.079
   Zeigler Johnson CM, 2008, CAN J UROL, V15, P4056
NR 196
TC 396
Z9 412
U1 1
U2 89
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302 2838
EI 1873 7560
J9 EUR UROL
JI Eur. Urol.
PD FEB
PY 2018
VL 73
IS 2
BP 178
EP 211
DI 10.1016/j.eururo.2017.06.002
PG 34
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA FS3UG
UT WOS:000419708200013
PM 28655541
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Pakos, EE
   Pitouli, EJ
   Tsekeris, PG
   Papathanasopoulou, V
   Stafilas, K
   Xenakis, TH
AF Pakos, EE
   Pitouli, EJ
   Tsekeris, PG
   Papathanasopoulou, V
   Stafilas, K
   Xenakis, TH
TI Prevention of heterotopic ossification in high risk patients with total
   hip arthroplasty: the experience of a combined therapeutic protocol
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTOPERATIVE IRRADIATION;
   PREOPERATIVE IRRADIATION; ECTOPIC OSSIFICATION; BONE FORMATION;
   REPLACEMENT; PROPHYLAXIS; RADIATION; INDOMETHACIN; VS.
AB The combination of radiotherapy and indomethacin for the prevention of heterotopic ossification (HO) in high risk patients undergoing total hip arthroplasty (THA) has not been reported. The aim of the present study was to present the experience of our department with this combined therapeutic protocol. Fifty four patients who underwent THA received a single dose of 7 Gy of postoperative radiotherapy and 75 mg of indomethacin for 15 days. Patients were analyzed for clinical and radiographical evidence of HO development at 1 year postoperatively. The overall radiographical incidence of HO was 20.4% (95% CI 10.6 33.5%), while only 1 patient with clinically significant HO was seen. Patients with secondary arthritis due to congenital hip disease had a statistically significantly higher incidence of HO compared with those with osteoarthrosis. The clinical assessment with the Merle d'Aubigne score showed that patients with radiographic documentation of HO had a lower mean score compared with those with no evidence of HO. No treatment related side effects were seen. Combined radiotherapy and indomethacin was effective in preventing heterotopic ossification after total hip arthroplasty. The evaluation of this efficacy compared with radiotherapy or NSAIDs alone should be the future target of larger randomized designs.
C1 Univ Ioannina, Univ Hosp Ioannina, Dept Orthopaed Surg, Sch Med, Ioannina, Greece.
   Univ Ioannina, Univ Hosp Ioannina, Dept Radiat Therapy, Sch Med, Ioannina, Greece.
C3 University Hospital Ioannina; University of Ioannina; University
   Hospital Ioannina; University of Ioannina
RP Univ Ioannina, Univ Hosp Ioannina, Dept Orthopaed Surg, Sch Med, Ioannina, Greece.
EM epakos@yahoo.gr
RI Papathanasopoulou, Vasileia/JQI 8851 2023
CR ANTHONY P, 1987, INT J RADIAT ONCOL, V13, P365, DOI 10.1016/0360 3016(87)90010 1
   BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623 197355080 00006
   DAUBIGNE RM, 1954, J BONE JOINT SURG AM, V36 A, P451, DOI 10.2106/00004623 195436030 00001
   Eggli S, 2001, ARCH ORTHOP TRAUM SU, V121, P531, DOI 10.1007/s004020100287
   Fransen M, 2004, Cochrane Database Syst Rev, pCD001160, DOI 10.1002/14651858.CD001160.pub2
   GREGORITCH SJ, 1994, INT J RADIAT ONCOL, V30, P55, DOI 10.1016/0360 3016(94)90519 3
   Haas ML, 1999, INT J RADIAT ONCOL, V45, P461, DOI 10.1016/S0360 3016(99)00191 1
   Handel M, 2004, ARCH ORTHOP TRAUM SU, V124, P483, DOI 10.1007/s00402 004 0699 9
   HEALY WL, 1995, J BONE JOINT SURG AM, V77A, P590, DOI 10.2106/00004623 199504000 00013
   Iorio Richard, 2002, J Am Acad Orthop Surg, V10, P409
   Knelles D, 1997, J BONE JOINT SURG BR, V79B, P596, DOI 10.1302/0301 620X.79B4.6829
   Koelbl O, 2003, STRAHLENTHER ONKOL, V179, P767, DOI 10.1007/s00066 003 1088 y
   Kolbl O, 1997, INT J RADIAT ONCOL, V39, P961, DOI 10.1016/S0360 3016(97)00496 3
   KONSKI A, 1990, INT J RADIAT ONCOL, V18, P1139, DOI 10.1016/0360 3016(90)90450 X
   Lonardi F, 2001, INT ORTHOP, V25, P371, DOI 10.1007/s002640100281
   Moore KD, 1998, J BONE JOINT SURG BR, V80B, P259, DOI 10.1302/0301 620X.80B2.8157
   Pakos EE, 2004, INT J RADIAT ONCOL, V60, P888, DOI 10.1016/j.ijrobp.2003.11.015
   REIS HJ, 1992, INT ORTHOP, V16, P140, DOI 10.1007/BF00180205
   Romanò CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883 5403(03)00279 1
   ROSENDAHL S, 1977, ACTA ORTHOP SCAND, V48, P400, DOI 10.3109/17453677708992016
   Seegenschmiedt MH, 1997, INT J RADIAT ONCOL, V39, P161, DOI 10.1016/S0360 3016(97)00285 X
   Seegenschmiedt MH, 2001, INT J RADIAT ONCOL, V51, P756, DOI 10.1016/S0360 3016(01)01640 6
   van Leeuwen WM, 1998, ACTA ORTHOP SCAND, V69, P116, DOI 10.3109/17453679809117609
   Vielpeau C, 1999, CLIN ORTHOP RELAT R, P279
   Wilkinson JM, 2003, J ORTHOPAED RES, V21, P529, DOI 10.1016/S0736 0266(02)00236 X
NR 25
TC 48
Z9 55
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD APR
PY 2006
VL 30
IS 2
BP 79
EP 83
DI 10.1007/s00264 005 0054 y
PG 5
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 026QN
UT WOS:000236357300002
PM 16482442
OA Green Published
DA 2025 08 17
ER

PT J
AU Kang, EJ
   Kim, HJ
   Choi, JH
   Noh, JR
   Kim, JH
   Lee, IB
   Choi, YK
   Choi, DH
   An, J
   Oh, WK
   Kim, YH
   Lee, CH
AF Kang, Eun Jung
   Kim, Hyun Jong
   Choi, Ji Hyun
   Noh, Jung Ran
   Kim, Jae Hoon
   Lee, In Bok
   Choi, Young Keun
   Choi, Dong Hee
   An, Jinpyo
   Oh, Won Keun
   Kim, Yong Hoon
   Lee, Chul Ho
TI Humulus japonicus extract ameliorates collagen induced arthritis
   in mice through regulation of overall articular inflammation
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Humulus japonicus; rheumatoid arthritis; collagen induced arthritis
   mice; inflammation; therapy
ID RHEUMATOID ARTHRITIS; T CELLS; MACROPHAGES; PATHOGENESIS; CYTOKINES;
   TH1; MECHANISMS; DIAGNOSIS; THERAPY; MODEL
AB Humulus japonicus (HJ) is a widely used herbal medicine in Asia with anti oxidative, anti microbial, and anti inflammatory effects. We investigated the potential therapeutic effects of HJ in rheumatoid arthritis (RA) using a mouse model of collagen induced arthritis (CIA) and a lipopolysaccharide stimulated murine macrophage cell line (RAW 264.7). The CIA mice were administered 300 mg/kg HJ orally starting 3 days prior to second immunization. The clinical and histopathological findings were assessed in the paw of CIA mice. The levels of autoantibodies and inflammatory markers were determined in the plasma and cell culture supernatant, respectively. The expression at mRNA and protein levels was analyzed by reverse transcription quantitative PCR and western blot analysis, respectively. HJ significantly decreased the gross arthritic scores and paw swelling in CIA mice. Furthermore, synovial inflammation, cartilage destruction, and bone erosion were markedly reduced by HJ. It also decreased the expression of inflammatory enzymes in both the paw of mice and RAW 264.7 cells. Moreover, the expression of genes related to all macrophages and pro inflammatory M1 macrophage were significantly decreased, whereas the expression of anti inflammatory M2 macrophage marker was markedly increased in the paw of HJ treated CIA mice. In addition, HJ suppressed the levels of plasma anti type II collagen antibody following the decreased expression of T helper type 1 (Th1) and Th2 cell associated surface markers and cytokines in the paw. HJ also significantly inhibited the expression of IL 6 both in vitro and in vivo, followed by reduced STAT3 phosphorylation and expression in the paw of CIA mice. Finally, the expression of osteoclast related genes was decreased in the paw of HJ treated CIA mice. These findings suggest that HJ can play a role in suppressing the development of CIA by overall regulation of articular inflammation. This study should provide new insights into the use of HJ as a therapeutically effective natural product against RA.
C1 [Kang, Eun Jung; Kim, Hyun Jong; Choi, Ji Hyun; Noh, Jung Ran; Kim, Jae Hoon; Lee, In Bok; Choi, Young Keun; Choi, Dong Hee; Kim, Yong Hoon; Lee, Chul Ho] Korea Res Inst Biosci & Biotechnol, Lab Anim Resource Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea.
   [Choi, Ji Hyun; Kim, Yong Hoon; Lee, Chul Ho] Univ Sci & Technol, Dept Funct Genom, Daejeon 34113, South Korea.
   [An, Jinpyo; Oh, Won Keun] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Korea Bioact Nat Mat Bank, Seoul 08826, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB);
   University of Science & Technology (UST); Seoul National University
   (SNU)
RP Kim, YH; Lee, CH (通讯作者)，Korea Res Inst Biosci & Biotechnol, Lab Anim Resource Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea.
EM yhoonkim@kribb.re.kr; chullee@kribb.re.kr
RI Lee, Chul Ho/MBV 8603 2025; Oh, William/B 9163 2012
FU KRIBB Research Initiative Program; National Research Foundation of Korea
   (NRF); Korean government (MSIP) [NRF 2019R1C1C1005319]; Korea Bioactive
   Natural Material Bank (KBNMB) through the National Research Foundation
   of Korea   Ministry of Science, ICT and Planning [NRF 2017M3A9B8069409]
FX This study was supported by grants from the KRIBB Research Initiative
   Program, a grant from the National Research Foundation of Korea (NRF)
   and the Korean government (MSIP) (NRF 2019R1C1C1005319), and the Korea
   Bioactive Natural Material Bank (KBNMB, NRF 2017M3A9B8069409) through
   the National Research Foundation of Korea, funded by the Ministry of
   Science, ICT and Planning.
CR Aarvak T, 2000, RHEUMATOLOGY, V39, P513, DOI 10.1093/rheumatology/39.5.513
   Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281 199905000 00009
   Bingham CO, 2002, J RHEUMATOL, V29, P3
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brand DD, 2004, METH MOLEC MED, V102, P295
   Bugatti S, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00339
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113
   Cojocaru Manole, 2010, Maedica (Bucur), V5, P286
   Cope AP, 2007, CLIN EXP RHEUMATOL, V25, pS4
   Corry DB, 1999, NATURE, V402, pB18
   Derksen VFAM, 2017, SEMIN IMMUNOPATHOL, V39, P437, DOI 10.1007/s00281 017 0627 z
   Fukui S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01958
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Heidari B, 2011, CASP J INTERN MED, V2, P161
   Jhun JY, 2012, EXP MOL MED, V44, P424, DOI 10.3858/emm.2012.44.7.047
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kaplan C, 2002, ARTHRITIS RES, V4, P54, DOI 10.1186/ar383
   황순이, 2009, [The Journal of Korean Medicine Ophthalmology&Otorhinolaryngology&Dermatology, 한방안이비인후피부과학회지], V22, P92
   Kinne RW, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2333
   Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86
   Laria A, 2016, J INFLAMM RES, V9, P1, DOI 10.2147/JIR.S82320
   Lee CH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12349 9
   Lerner A, 2018, BEST PRACT RES CL RH, V32, P550, DOI 10.1016/j.berh.2019.01.006
   Lieben Liesbet, 2016, Nat Rev Rheumatol, V12, P623, DOI 10.1038/nrrheum.2016.169
   Lim H, 2016, INT J MOL MED, V38, P1101, DOI 10.3892/ijmm.2016.2727
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma YY, 2005, CURR PHARM DESIGN, V11, P569, DOI 10.2174/1381612053381927
   Mukherjee P, 2003, ANN RHEUM DIS, V62, P707, DOI 10.1136/ard.62.8.707
   Munder M, 1998, J IMMUNOL, V160, P5347
   Myasoedova E, 2010, ARTHRITIS RHEUM US, V62, P1576, DOI 10.1002/art.27425
   Nandakumar KS, 2004, ARTHRITIS RES THER, V6, pR544, DOI 10.1186/ar1217
   Oike T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11233 w
   Alvarez JLP, 2009, REUMATOL CLIN, V5, P34, DOI 10.1016/S1699 258X(09)70203 7
   Panagopoulos PK, 2018, J MUSCULOSKEL NEURON, V18, P304
   Park JW, 1999, CLIN EXP ALLERGY, V29, P1080, DOI 10.1046/j.1365 2222.1999.00615.x
   Park S.W., 1994, HANGUK SIKPUM KWAHAK, V26, P464
   Rehman Q, 2001, ARTHRITIS RES, V3, P221, DOI 10.1186/ar305
   Rose BJ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/4895050
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Silman AJ, 2002, ARTHRITIS RES THER, V4, pS265, DOI 10.1186/ar578
   Srirangan S, 2010, THER ADV MUSCULOSKEL, V2, P247, DOI 10.1177/1759720X10378372
   Sun J, 2011, CELL MOL IMMUNOL, V8, P348, DOI 10.1038/cmi.2011.5
   Sung B, 2015, EXP THER MED, V9, P1819, DOI 10.3892/etm.2015.2302
   Suurmond J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3809
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Wang Y, 2017, INT IMMUNOPHARMACOL, V50, P345, DOI 10.1016/j.intimp.2017.07.019
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Yoshida Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/698313
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
NR 52
TC 14
Z9 14
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD FEB
PY 2020
VL 45
IS 2
BP 417
EP 428
DI 10.3892/ijmm.2019.4417
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA KL6UA
UT WOS:000513554900012
PM 31894253
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Lei, XX
   Gao, JP
   Xing, FY
   Zhang, Y
   Ma, Y
   Zhang, GF
AF Lei, Xiongxin
   Gao, Jianping
   Xing, Fangyu
   Zhang, Yang
   Ma, Ye
   Zhang, Guifeng
TI Comparative evaluation of the physicochemical properties of
   nano hydroxyapatite/collagen and natural bone ceramic/collagen scaffolds
   and their osteogenesis promoting effect on MC3T3 E1 cells
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE nano hydroxyapatite; natural bone ceramic; collagen; scaffold; MC3T3 E1;
   osteoblasts
ID SELF ORGANIZATION MECHANISM; CALCIUM PHOSPHATE CEMENTS; IN VITRO;
   DRUG DELIVERY; COLLAGEN; CERAMICS; SPECTROSCOPY; COMPOSITES; MATRICES;
   DEFECTS
AB The use of various types of calcium phosphate has been reported in the preparation of repairing materials for bone defects. However, the physicochemical and biological properties among them might be vastly different. In this study, we prepared two types of calcium phosphates, nano hydroxyapatite (nHA) and natural bone ceramic (NBC), into 3D scaffolds by mixing with type I collagen (CoL), resulting in the nHA/CoL and NBC/CoL scaffolds. We then evaluated and compared the physicochemical and biological properties of these two calcium phosphates and their composite scaffold with CoL. Scanning electron microscopy (SEM), X ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FTIR), X ray diffraction spectroscopy (XRD) and compressive tests were used to, respectively, characterize the morphology, composition, distribution and the effect of nHA and NBC to collagen. Next, we examined the biological properties of the scaffolds using cytotoxicity testing, flow cytometry, immunofluorescence staining, biocompatibility testing, CCK 8 assays and RT PCR. The results reflected that the Ca2+ released from nHA and NBC could bind chemically with collagen and affect its physicochemical properties, including the infrared absorption spectrum and compression modulus, among others. Furthermore, the two kinds of scaffolds could promote the expression of osteo relative genes, but showed different gene induction properties. In short, NBC/CoL could promote the expression of early osteogenic genes, while nHA/CoL could upregulate late osteogenic genes. Conclusively, these two composite scaffolds could provide MC3T3 E1 cells with a biomimetic surface for adhesion, proliferation and the formation of mineralized extracellular matrices. Moreover, nHA/CoL and NBC/CoL had different effects on the period and extent ofMC3T3 E1 cell mineralization.
C1 [Lei, Xiongxin; Gao, Jianping; Zhang, Guifeng] Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100190, Peoples R China.
   [Gao, Jianping; Zhang, Guifeng] Univ Chinese Acad Sci, Sch Chem & Engn, Beijing 100049, Peoples R China.
   [Xing, Fangyu] Shandong Agr Univ, Coll Food Sci & Engn, Tai An 271018, Shandong, Peoples R China.
   [Zhang, Yang] Henan Inst Sci & Technol, Sch Life Sci & Technol, Xinxiang 453003, Henan, Peoples R China.
   [Ma, Ye] Guandong Pharmaceut Univ, Sch Basic Course, Dept Pathogen Biol & Immunol, Guangzhou 510006, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Process Engineering, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Shandong Agricultural University; Henan Institute of Science &
   Technology; Guangdong Pharmaceutical University
RP Zhang, GF (通讯作者)，Inst Proc Engn, Natl Key Lab Biochem Engn, 1 Bei Er Tiao, Beijing 100190, Peoples R China.
EM gfzhang@ipe.ac.cn
RI 马, 业/JKU 7711 2023
FU National Key Research and Development Program of China [2018YFA0108200,
   2018YFC116400]; International Cooperation Project of Hainan Province
   [KJHZ2015 30]; Sci&Tech Program of Guangzhou of China [201803010086]
FX The author(s) disclose receipt of the following financial support for
   the research, authorship and/or publication of this article: the
   National Key Research and Development Program of China (2018YFA0108200,
   2018YFC116400) and the International Cooperation Project of Hainan
   Province (KJHZ2015 30), Sci&Tech Program of Guangzhou of China
   (201803010086).
CR [Anonymous], ANN REV MAT SCI
   [Anonymous], 2016, ALTERNAT MED
   [Anonymous], JAMA J AM MED ASS
   [Anonymous], PLOS ONE
   [Anonymous], DYN BONE CARTILAGE M
   Barba A, 2019, ACS APPL MATER INTER, V11, P8818, DOI 10.1021/acsami.8b20749
   Barth A, 2007, BBA BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Berzina Cimdina L, 2012, INFRARED SPECTROSCOPY   MATERIALS SCIENCE, ENGINEERING AND TECHNOLOGY, P123
   BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999
   Bohner M, 2000, Injury, V31 Suppl 4, P37
   Camacho NP, 2001, BIOPOLYMERS, V62, P1, DOI 10.1002/1097 0282(2001)62:1<1::AID BIP10>3.0.CO;2 O
   Cao S, 2016, J BIOMED MATER RES A, V104, P533, DOI 10.1002/jbm.a.35593
   Chandran PL, 2012, CONNECT TISSUE RES, V53, P285, DOI 10.3109/03008207.2011.640760
   Dai CL, 2011, BIOMATERIALS, V32, P8506, DOI 10.1016/j.biomaterials.2011.07.090
   Dorozhkin SV, 2009, J MATER SCI, V44, P2343, DOI 10.1007/s10853 008 3124 x
   Fleming JE Jr, 2000, ORTHOP CLIN N AM, V31, P357, DOI 10.1016/S0030 5898(05)70156 5
   Ginebra MP, 2006, J CONTROL RELEASE, V113, P102, DOI 10.1016/j.jconrel.2006.04.007
   Ginebra MP, 2006, BIOMATERIALS, V27, P2171, DOI 10.1016/j.biomaterials.2005.11.023
   Ha SW, 2015, BIOMATERIALS, V65, P32, DOI 10.1016/j.biomaterials.2015.06.039
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Hellmich C, 2003, BIOMECH MODEL MECHAN, V2, P21, DOI [10.1007/s10237 002 0025 9, 10.1007/S10237 002 0025 9]
   Hutmacher DW, 2007, J TISSUE ENG REGEN M, V1, P245, DOI 10.1002/term.24
   Inzana JA, 2014, BIOMATERIALS, V35, P4026, DOI 10.1016/j.biomaterials.2014.01.064
   Jäger C, 2006, MAGN RESON CHEM, V44, P573, DOI 10.1002/mrc.1774
   Johnson KD, 1996, J ORTHOP RES, V14, P351, DOI 10.1002/jor.1100140304
   Joschek S, 2000, BIOMATERIALS, V21, P1645, DOI 10.1016/S0142 9612(00)00036 3
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P36, DOI 10.2106/JBJS.G.01260
   Kikuchi M, 2001, BIOMATERIALS, V22, P1705, DOI 10.1016/S0142 9612(00)00305 7
   Kikuchi M, 2004, COMPOS SCI TECHNOL, V64, P819, DOI 10.1016/j.compscitech.2003.09.002
   Koutsopoulos S, 2002, J BIOMED MATER RES, V62, P600, DOI 10.1002/jbm.10280
   Krishnan V, 2016, DENT MATER, V32, P646, DOI 10.1016/j.dental.2016.02.002
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267 6605(93)90049 D
   Li LM, 2015, MATER LETT, V149, P25, DOI 10.1016/j.matlet.2015.02.106
   Lin FH, 1999, BIOMATERIALS, V20, P475, DOI 10.1016/S0142 9612(98)00193 8
   Lin KF, 2016, ACS APPL MATER INTER, V8, P6905, DOI 10.1021/acsami.6b00815
   Liu Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086026, 10.1371/journal.pone.0110611, 10.1371/journal.pone.0095043]
   Ooi CY, 2007, CERAM INT, V33, P1171, DOI 10.1016/j.ceramint.2006.04.001
   Payne JA, 1999, J APPL POLYM SCI, V73, P553, DOI 10.1002/(SICI)1097 4628(19990725)73:4<553::AID APP11>3.0.CO;2 Z
   PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105
   Pedraza CE, 2010, TISSUE ENG PT A, V16, P781, DOI [10.1089/ten.tea.2009.0351, 10.1089/ten.TEA.2009.0351]
   Perrier A, 2010, BONE, V47, P23, DOI 10.1016/j.bone.2010.03.010
   Poinern GE, 2009, ULTRASON SONOCHEM, V16, P469, DOI 10.1016/j.ultsonch.2009.01.007
   Sarikaya B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/576532
   Shi ZL, 2009, ACTA BIOMATER, V5, P338, DOI 10.1016/j.actbio.2008.07.023
   STUPP SI, 1992, J BIOMED MATER RES, V26, P169, DOI 10.1002/jbm.820260204
   Subramaniam S, 2016, BIOMATERIALS, V74, P99, DOI 10.1016/j.biomaterials.2015.09.044
   Tadic D, 2004, BIOMATERIALS, V25, P987, DOI 10.1016/S0142 9612(03)00621 5
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Tran N, 2009, WIRES NANOMED NANOBI, V1, P336, DOI 10.1002/wnan.23
   Vázquez CG, 2005, REV MEX FIS, V51, P284
   Wahl DA, 2006, EUR CELLS MATER, V11, P43, DOI 10.22203/eCM.v011a06
   Wakitani S, 1998, TISSUE ENG, V4, P429, DOI 10.1089/ten.1998.4.429
   Wang T, 2016, FRONT MATER SCI, V10, P122, DOI 10.1007/s11706 016 0333 0
   Wang XF, 2016, RSC ADV, V6, P6832, DOI 10.1039/c5ra21527g
   Yuan T, 2014, J BIOMED MATER RES B, V102, P337, DOI 10.1002/jbm.b.33011
   Zhang SM, 2003, J MATER SCI MATER M, V14, P641, DOI 10.1023/A:1024083309982
   Zhang W, 2003, CHEM MATER, V15, P3221, DOI 10.1021/cm030080g
   Zheng ZH, 2009, J BIOMED MATER RES A, V89A, P453, DOI 10.1002/jbm.a.31979
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zhu Shaihong, 2005, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V22, P980
   Zhu Y, 2017, BIOMATERIALS, V147, P133, DOI 10.1016/j.biomaterials.2017.09.018
NR 61
TC 37
Z9 41
U1 4
U2 61
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD DEC
PY 2019
VL 6
IS 6
BP 361
EP 371
DI 10.1093/rb/rbz026
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA KQ8EC
UT WOS:000517151900005
PM 31827888
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sawada, K
   Takedachi, M
   Yamamoto, S
   Morimoto, C
   Ozasa, M
   Iwayama, T
   Lee, CM
   Okura, H
   Matsuyama, A
   Kitamura, M
   Murakami, S
AF Sawada, Keigo
   Takedachi, Masahide
   Yamamoto, Satomi
   Morimoto, Chiaki
   Ozasa, Masao
   Iwayama, Tomoaki
   Lee, Chun Man
   Okura, Hanayuki
   Matsuyama, Akifumi
   Kitamura, Masahiro
   Murakami, Shinya
TI Trophic factors from adipose tissue derived multi lineage progenitor
   cells promote cytodifferentiation of periodontal ligament cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Adipose tissue; Progenitor cell; Periodontal ligament; Regeneration
ID MESENCHYMAL STEM CELLS; HEPATOCYTE GROWTH FACTOR; PLATELET RICH PLASMA;
   BONE MARROW; BINDING PROTEIN 6; STROMAL CELLS; DIFFERENTIATION;
   REGENERATION; FIBROBLASTS; THERAPY
AB Stem and progenitor cells are currently being investigated for their applicability in cell based therapy for periodontal tissue regeneration. We recently demonstrated that the transplantation of adipose tissue derived multi lineage progenitor cells (ADMPCs) enhances periodontal tissue regeneration in beagle dogs. However, the molecular mechanisms by which transplanted ADMPCs induce periodontal tissue regeneration remain to be elucidated. In this study, trophic factors released by ADMPCs were examined for their paracrine effects on human periodontal ligament cell (HPDL) function. ADMPC conditioned medium (ADMPC CM) up regulated osteoblastic gene expression, alkaline phosphatase activity and calcified nodule formation in HPDLs, but did not significantly affect their proliferative response. ADMPCs secreted a number of growth factors, including insulin like growth factor binding protein 6 (IGFBP6), hepatocyte growth factor and vascular endothelial growth factor. Among these, IGFBP6 was most highly expressed. Interestingly, the positive effects of ADMPC CM on HPDL differentiation were significantly suppressed by transfecting ADMPCs with IGFBP6 siRNA. Our results suggest that ADMPCs transplanted into a defect in periodontal tissue release trophic factors that can stimulate the differentiation of HPDLs to mineralized tissue forming cells, such as osteoblasts and cementoblasts. IGFBP6 may play crucial roles in ADMPC induced periodontal regeneration. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Sawada, Keigo; Takedachi, Masahide; Yamamoto, Satomi; Morimoto, Chiaki; Ozasa, Masao; Iwayama, Tomoaki; Kitamura, Masahiro; Murakami, Shinya] Osaka Univ, Dept Periodontol, Grad Sch Dent, Suita, Osaka 5650871, Japan.
   [Lee, Chun Man] Osaka Univ Hosp, Med Ctr Translat Res, Osaka 553, Japan.
   [Okura, Hanayuki; Matsuyama, Akifumi] Natl Inst Biomed Innovat, Platform Therapeut Rare Dis, Res Dis Bioresources, Osaka, Japan.
C3 University of Osaka; University of Osaka; National Institute of Health
   Sciences   Japan
RP Takedachi, M (通讯作者)，Osaka Univ, Dept Periodontol, Grad Sch Dent, 1 8 Yamadaoka, Suita, Osaka 5650871, Japan.
EM takedati@dent.osaka u.ac.jp
RI ; Iwayama, Tomoaki/H 5921 2019; Sawada, Keigo/MXK 1956 2025; Takedachi,
   Masahide/GVS 6539 2022
OI Sawada, Keigo/0000 0002 9187 2386; Murakami, Shinya/0000 0002 5230 452X;
   Iwayama, Tomoaki/0000 0002 3405 5822; 
FU Ministry of Education, Culture, Sports, Science and Technology
   [26893144]; Ministry of Health, Labour and Welfare of Japan;
   Grants in Aid for Scientific Research [26893144, 25293229, 15J03981]
   Funding Source: KAKEN
FX This study was supported by a Grant in Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology (No.
   26893144) and a Grant in Aid from the Ministry of Health, Labour and
   Welfare of Japan. The authors declare that they have no conflicts of
   interest.
CR [Anonymous], 2014, Inflamm Regen
   BESSEY OA, 1946, J BIOL CHEM, V164, P321
   Cai L, 2007, STEM CELLS, V25, P3234, DOI 10.1634/stemcells.2007 0388
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Chen YC, 2012, ARCH ORAL BIOL, V57, P453, DOI 10.1016/j.archoralbio.2011.10.005
   Cui J, 2011, MOL CELL ENDOCRINOL, V338, P84, DOI 10.1016/j.mce.2011.03.011
   DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727 80 19661
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001 0044
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Headey SJ, 2004, FEBS LETT, V568, P19, DOI 10.1016/j.febslet.2004.04.091
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Katsuno T, 2013, CELL TRANSPLANT, V22, P287, DOI 10.3727/096368912X655019
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim WS, 2007, J DERMATOL SCI, V48, P15, DOI 10.1016/j.jdermsci.2007.05.018
   Kitamura M, 2011, J DENT RES, V90, P35, DOI 10.1177/0022034510384616
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003 2697(80)90165 7
   Lee JH, 2012, CELL TISSUE RES, V348, P475, DOI 10.1007/s00441 012 1392 x
   Mareschi K, 2006, J CELL BIOCHEM, V97, P744, DOI 10.1002/jcb.20681
   Morishita R, 2002, ENDOCR J, V49, P273, DOI 10.1507/endocrj.49.273
   Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d
   Nakanishi C, 2011, CIRC J, V75, P2260, DOI 10.1253/circj.CJ 11 0246
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Okura H, 2010, TISSUE ENG PART C ME, V16, P761, DOI 10.1089/ten.TEC.2009.0208
   Okura H, 2011, TISSUE ENG PART C ME, V17, P145, DOI [10.1089/ten.tec.2010.0139, 10.1089/ten.TEC.2010.0139]
   Taghi GM, 2012, CELL BIOL INT, V36, P1239, DOI 10.1042/CBI20110618
   Vishnubalaji R, 2012, CELL TISSUE RES, V347, P419, DOI 10.1007/s00441 011 1306 3
   Yamada S, 2007, J BIOL CHEM, V282, P23070, DOI 10.1074/jbc.M611181200
   Yamada Y, 2006, INT J PERIODONT REST, V26, P363
   Yamamiya K, 2008, J PERIODONTOL, V79, P811, DOI [10.1902/jop.2008.070518, 10.1902/jop.2008.070518 ]
   Yanagita M, 2014, J DENT RES, V93, P89, DOI 10.1177/0022034513511640
   Zheng W, 2009, TISSUE ENG PT A, V15, P2363, DOI 10.1089/ten.tea.2008.0562
NR 33
TC 20
Z9 21
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 14
PY 2015
VL 464
IS 1
BP 299
EP 305
DI 10.1016/j.bbrc.2015.06.147
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CO5AY
UT WOS:000359173200047
PM 26116772
DA 2025 08 17
ER

PT J
AU Sun, ZY
   Tang, XM
   Li, QY
   Wang, HB
   Sun, HZ
   Tian, JW
AF Sun, Zhongyi
   Tang, Xiaoming
   Li, Qiuyuan
   Wang, Haibin
   Sun, Hongzhi
   Tian, Jiwei
TI Mesenchymal stem cell extracellular vesicles derived microRNA 194 5p
   delays the development of intervertebral disc degeneration by targeting
   TRAF6
SO REGENERATIVE THERAPY
LA English
DT Article
DE Intervertebral disc degeneration; Mesenchymal stem cell extracellular
   vesicles; MicroRNA 194 5p; Tumor receptor associated factor 6;
   Osteoblast differentiation; Apoptosis; Proliferation
ID DIFFERENTIATION; EXOSOMES
AB Objective: Mesenchymal stem cells derived extracellular vesicles (MSCs EVs) can improve intervertebral disc degeneration (IDD). Considering that, their concrete mechanisms from microRNA 194 5p/tumor receptor associated factor 6 (miR 194 5p/TRAF6) axis in IDD ask for disclosure in a scientific way.
   Methods: Nucleus pulposus (NP) cells and MSCs were obtained. EVs were isolated from the obtained MSCs and identified. miR 194 5p expression in MSC EVs was altered by sequence transfection. Subsequently, MSCs EVs were co cultured with NP cells intervened by tumor necrosis factor alpha (TNF alpha). NP cell proliferation and apoptosis, along with their osteogenic differentiation ability were evaluated. miR194 5p and TRAF6 expression and their interaction were determined.
   Results: In TNF alpha intervened NP cells, miR 194 5p was down regulated and TRAF6 was up regulated. Restoring miR 194 5p effectively enhanced proliferation and osteogenic differentiation, and reduced apoptosis of TNF alpha intervened NP cells. miR 194 5p enriched MSCs EVs protected TNF alpha intervened NP cells. miR 194 5p targeted TRAF6, TRAF6 overexpression exerted negatively for the growth of TNF alpha intervened NP cells, and could reduce the protective effects of miR 194 5p on TNF alpha intervened NP cells.
   Conclusion: It is elucidated that miR 194 5p derived from MSCs EVs protects TNF alpha intervened NP cells through restricting TRAF6, replenishing a potential target for IDD treatment. (C) 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Wang, Haibin; Sun, Hongzhi] Nantong Univ, Dept Orthopaed, Affiliated Nanjing Jiangbei Peoples Hosp, Nanjing 210048, Peoples R China.
   [Tang, Xiaoming] Nanjing Med Univ, Affiliated Huaian 1 Peoples Hosp, Huaian 223300, Jiangsu, Peoples R China.
   [Li, Qiuyuan] Nanjing Med Univ, Clin Med Coll, Nanjing 210048, Jiangsu, Peoples R China.
   [Sun, Zhongyi; Tian, Jiwei] Nanjing Med Univ, Dept Orthopaed, Affiliated BenQ Hosp, 71 Hexi St, Nanjing 210048, Jiangsu, Peoples R China.
C3 Nantong University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Tian, JW (通讯作者)，Nanjing Med Univ, Dept Orthopaed, Affiliated BenQ Hosp, 71 Hexi St, Nanjing 210048, Jiangsu, Peoples R China.
EM Tianjiwei8212@163.com
RI Tian, Jiwei/AAH 4331 2020; 杨, 智/KLD 6807 2024; li, qiuyuan/NXB 8214 2025
FU Provincial cultivation project of Nanjing Jiangbei People's Hospital,
   lncrNa Nkila as CERNa mediated Caspase 3 in the role of intervertebral
   disc degeneration and its mechanism [JKK201901]; Provincial cultivation
   project of Nanjing Jiangbei People's Hospital, Mechanism of IL 1
   regulating NF kB/ADAMTS 4 in intervertebral disc degeneration,
   provincial breeding project [JKK201902]
FX This work was supported by Provincial cultivation project of Nanjing
   Jiangbei People's Hospital, lncrNa Nkila as CERNa mediated Caspase 3 in
   the role of intervertebral disc degeneration and its
   mechanism[JKK201901, Jiwei Tian] and Provincial cultivation project of
   Nanjing Jiangbei People's Hospital, Mechanism of IL 1 regulating
   NF kB/ADAMTS 4 in intervertebral disc degeneration, provincial breeding
   project[JKK201902, Zhongyi Sun].
CR Cai J, 2013, J MOL CELL BIOL, V5, P227, DOI 10.1093/jmcb/mjt011
   Chen TS, 2010, NUCLEIC ACIDS RES, V38, P215, DOI 10.1093/nar/gkp857
   Chen XT, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182058
   Chen Z, 2019, J CELL PHYSIOL, V234, P19977, DOI 10.1002/jcp.28595
   Cheng S, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/2785207
   Cheng XF, 2018, J CELL MOL MED, V22, P261, DOI 10.1111/jcmm.13316
   de Sousa MC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246249
   Dong LY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0323 5
   Duan MY, 2020, BLOOD CELL MOL DIS, V82, DOI 10.1016/j.bcmd.2020.102417
   Ge J, 2020, J CELL MOL MED, V24, P8650, DOI 10.1111/jcmm.15496
   Glaeser JD, 2020, JOR SPINE, V3, DOI 10.1002/jsp2.1092
   Gu QQ, 2020, INFLAMM RES, V69, P667, DOI 10.1007/s00011 020 01348 8
   Jeong BC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.485
   Jiao M, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110323
   Kong LL, 2018, MED SCI MONITOR, V24, P3056, DOI 10.12659/MSM.907280
   Li J, 2015, BIOCHEM BIOPH RES CO, V460, P482, DOI 10.1016/j.bbrc.2015.03.059
   Liao ZW, 2019, THERANOSTICS, V9, P4084, DOI 10.7150/thno.33638
   Lu K, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0563 9
   Lv F, 2017, MED SCI MONITOR, V23, P659, DOI 10.12659/MSM.898660
   Mishima K, 2015, EBIOMEDICINE, V2, P2046, DOI 10.1016/j.ebiom.2015.11.024
   Qi L, 2019, J BONE MINER METAB, V37, P455, DOI 10.1007/s00774 018 0953 9
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Sun ZQ, 2018, EUR J PHARMACOL, V837, P96, DOI 10.1016/j.ejphar.2018.08.022
   Tekari A, 2017, EUR CELLS MATER, V33, P197, DOI 10.22203/eCM.v033a15
   Tessier S, 2021, DEV DYNAM, V250, P302, DOI 10.1002/dvdy.217
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang B, 2016, EXP CELL RES, V345, P199, DOI 10.1016/j.yexcr.2016.05.011
   Wang N, 2017, BBA MOL BASIS DIS, V1863, P2085, DOI 10.1016/j.bbadis.2017.02.023
   Wang TY, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0010 2
   Wang XB, 2020, MECH AGEING DEV, V190, DOI 10.1016/j.mad.2020.111293
   Wang YF, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0957 7
   Wei F, 2019, J TISSUE ENG REGEN M, V13, P1978, DOI 10.1002/term.2947
   Xi YH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13364 6
   Xia C, 2019, FREE RADICAL BIO MED, V143, P1, DOI 10.1016/j.freeradbiomed.2019.07.026
   Yang HL, 2010, SPINE J, V10, P802, DOI 10.1016/j.spinee.2010.06.019
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yuan F, 2020, ONCOL LETT, V19, P3643, DOI 10.3892/ol.2020.11474
   Yuan QL, 2020, STEM CELLS DEV, V0, P1038, DOI 10.1089/scd.2020.0083
   Zhao YP, 2020, THERANOSTICS, V10, P7015, DOI 10.7150/thno.45359
   Zhao Z, 2020, ADV CLIN EXP MED, V29, P639, DOI 10.17219/acem/121509
   Zhu GD, 2020, EXP CELL RES, V393, DOI 10.1016/j.yexcr.2020.112109
NR 41
TC 17
Z9 19
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD MAR
PY 2022
VL 19
BP 88
EP 96
DI 10.1016/j.reth.2021.12.001
EA JAN 2022
PG 9
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA ZQ6MD
UT WOS:000767215900009
PM 35127996
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, CH
   Wei, JCC
   Chang, WC
   Chiou, SY
   Chou, CH
   Lin, YJ
   Hung, PH
   Wong, RH
AF Huang, Chun Huang
   Wei, James Cheng Chung
   Chang, Wei Chiao
   Chiou, Shang Yan
   Chou, Chia Hsuan
   Lin, Yu Jie
   Hung, Pei Hsuan
   Wong, Ruey Hong
TI Higher Expression of Whole Blood MicroRNA 21 in Patients with Ankylosing
   Spondylitis Associated with Programmed Cell Death 4 mRNA Expression and
   Collagen Cross linked C telopeptide Concentration
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE ANKYLOSING SPONDYLITIS; MICRORNA 21; PROGRAMMED CELL DEATH 4; COLLAGEN
   CROSS LINKED C TELOPEPTIDE
ID CIRCULATING MICRORNAS; DIAGNOSTIC CRITERIA; DISEASE ACTIVITY;
   DOWN REGULATION; INFLAMMATION; BIOGENESIS; MIR 21; CANCER; CONTRIBUTES;
   MECHANISM
AB Objective. Bone loss is a recognized feature of ankylosing spondylitis (AS). The binding of microRNA 21 (miR 21) to programmed cell death 4 (PDCD4) could inhibit the expression of PDCD4 and further induce the activation of osteoclasts. In the present study, we compared the difference in miR 21 expression between patients with AS and healthy controls, and evaluated the relationships of miR 21, PDCD4 mRNA, and bone erosion in patients with AS. The influences of nonsteroidal antiinflammatory drugs (NSAID) and disease modifying antirheumatic drugs (DMARD) on the expressions of miR 21 and PDCD4 mRNA in patients with AS were also assessed.
   Methods. Whole blood miR 21 and PDCD4 mRNA expression were evaluated by quantitative real time PCR among 122 patients with AS and 122 healthy controls. The serum level of collagen cross linked C telopeptide (CTX) was measured using ELISA.
   Results. When compared to controls, patients with AS had significantly higher levels of miR 21, PDCD4 mRNA, and CTX. MiR 21 expression was negatively correlated with PDCD4 mRNA expression in patients with AS who were taking neither NSAID nor DMARD. Interestingly, significantly positive correlations between miR 21 expression with PDCD4 mRNA expression (r = 0.33, p = 0.01) and CTX level (r = 0.44, p < 0.01) were observed in patients with AS who were taking sulfasalazine. Positive correlations of miR 21 and CTX level were also observed in AS patients with disease duration < 7.0 years (r = 0.36, p = 0.004) and active disease (r = 0.42, p = 0.001).
   Conclusion. The expression of miR 21 might have a role in the development of AS.
C1 Chung Shan Med Univ, Dept Publ Hlth, Inst Med, Taichung 40201, Taiwan.
   Chung Shan Med Univ Hosp, Div Allergy Immunol & Rheumatol, Dept Family & Community Med, Taichung, Taiwan.
   [Chang, Wei Chiao] Taipei Med Univ, Dept Clin Pharm, Taipei, Taiwan.
   [Chang, Wei Chiao] Taipei Med Univ, Wanfang Hosp, Dept Pharm, Taipei, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Taipei Medical University; Taipei Medical
   University; Taipei Municipal WanFang Hospital
RP Wong, RH (通讯作者)，Chung Shan Med Univ, Dept Publ Hlth, 110 Chien Kuo N Rd,Sec 1, Taichung 40201, Taiwan.
EM rueyhong@csmu.edu.tw
RI ; Li, YuJie/JAC 4451 2023; Wei, James/AAL 8947 2020
OI Wei, James Cheng Chung/0000 0002 1235 0679; Chang,
   Wei Chiao/0000 0002 8573 5924; 
FU Chung Shan Medical University Hospital, Taiwan [CSH 2010 C 004];
   National Science Council, Taiwan [NSC100 2815 C 040 036 B]
FX Supported by a grant from the Chung Shan Medical University Hospital,
   Taiwan (CSH 2010 C 004) and the National Science Council, Taiwan
   (NSC100 2815 C 040 036 B).
CR AMOR B, 1995, REV RHUM, V62, P10
   Asaga S, 2011, CLIN CHEM, V57, P84, DOI 10.1373/clinchem.2010.151845
   Asahara H, 1997, ARTHRITIS RHEUM, V40, P912, DOI 10.1002/art.1780400520
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Baskan BM, 2010, RHEUMATOL INT, V30, P375, DOI 10.1007/s00296 009 0975 7
   Braun J, 2003, ANN RHEUM DIS, V62, P817, DOI 10.1136/ard.62.9.817
   Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140 6736(07)60635 7
   BREWERTON DA, 1973, LANCET, V1, P904
   Chen JM, 2006, J RHEUMATOL, V33, P722
   Chou CT, 2001, J IMMUNOL METHODS, V255, P15, DOI 10.1016/S0022 1759(01)00414 8
   Cohen JD, 2006, J RHEUMATOL, V33, P79
   Creemers MCW, 2005, ANN RHEUM DIS, V64, P127, DOI 10.1136/ard.2004.020503
   Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hamilton AJ, 2010, BIOCHEM SOC T, V38, P229, DOI 10.1042/BST0380229
   Kapinas K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3325
   Karberg K, 2005, J RHEUMATOL, V32, P1290
   Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278
   Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560
   Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72
   Maillefert JF, 2001, OSTEOPOROSIS INT, V12, P605, DOI 10.1007/s001980170084
   McDonald JS, 2011, CLIN CHEM, V57, P833, DOI 10.1373/clinchem.2010.157198
   Muntean L, 2011, CLIN RHEUMATOL, V30, P691, DOI 10.1007/s10067 010 1648 3
   Pedersen SJ, 2010, ANN RHEUM DIS, V69, P1065, DOI 10.1136/ard.2009.111187
   Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940 6207.CAPR 11 0370
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Smith MD, 2010, RHEUMATOLOGY, V49, P862, DOI 10.1093/rheumatology/kep467
   Sugatani T, 2013, J CELL BIOCHEM, V114, P1217, DOI 10.1002/jcb.24471
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   Tam LS, 2010, NAT REV RHEUMATOL, V6, P399, DOI 10.1038/nrrheum.2010.79
   Tili E, 2013, IMMUNOL REV, V253, P167, DOI 10.1111/imr.12050
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Wei JCC, 2007, CLIN RHEUMATOL, V26, P1685, DOI 10.1007/s10067 007 0573 6
   Xu JA, 2011, MOL CARCINOGEN, V50, P136, DOI 10.1002/mc.20712
   Yasuda M, 2010, MOL CARCINOGEN, V49, P837, DOI 10.1002/mc.20660
   Zhang Z, 2011, ONCOGENE, V20, P4450
NR 38
TC 38
Z9 43
U1 0
U2 5
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315 162X
EI 1499 2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2014
VL 41
IS 6
BP 1104
EP 1111
DI 10.3899/jrheum.130515
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AI7UU
UT WOS:000337106600010
PM 24786924
OA Bronze
DA 2025 08 17
ER

PT J
AU Wehling, M
   Lösel, R
AF Wehling, Martin
   Loesel, Ralf
TI Non genomic steroid hormone effects:: Membrane or intracellular
   receptors?
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 17th International Symposium of the
   Journal of Steroid Biochemistry and Molecular Biology
CY MAY 31 JUN 03, 2006
CL Seefeld, AUSTRIA
SP Journal Steroid Biochem & Mol Biol
ID PROTEIN COUPLED RECEPTOR; VITAMIN D RECEPTOR; GROWTH FACTOR RECEPTOR;
   RAPID ACTIONS; ESTROGEN; OSTEOBLASTS; RESPONSES; BINDING; GPR30;
   1 ALPHA,25(OH)(2) VITAMIN D 3
AB A controversy regarding the identity of receptors that mediate nongenomic, transcription independent cellular responses to steroids is presently attracting considerable scientific interest. While there is strong evidence for classic receptors belonging to the nuclear receptor superfamily to mediate nongenomic steroid effects in some cases, it does not exist for others. Nongenomic estrogen effects seem to predominantly involve classical estrogen receptors, both residing in cytoplasm and at the cell membrane. On the other hand, there is increasing evidence for the existence of nonrelated membrane receptors for estrogens, mediating CNS effects. Novel membrane receptors for other steroids have been recently cloned, with the demonstration of their biological relevance still largely pending. Recent findings on new and unexpected properties of classic receptors have partially deflected the interest from novel, nonclassic membrane receptors, which are being progressively identified at present. In addition, new findings pose challenges to some of the conclusions drawn from earlier experiments, and potential involvement of receptors and mechanisms of action need to be reconsidered.
   To know the nature of receptors involved will be key to beneficial medical translation of specific and targeted steroid responses. Differential pharmacological exploitation of different steroid receptors seems to become a tangible option. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Heidelberg, Dept Clin Pharmacol, Fac Med, D 68167 Mannheim, Germany.
   AstraZeneca R&D, Molndal, Germany.
C3 Ruprecht Karls University Heidelberg; AstraZeneca
RP Wehling, M (通讯作者)，Univ Heidelberg, Dept Clin Pharmacol, Fac Med, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany.
EM martin.wehling@kpha.ma.uni heidelberg.de
OI Losel, Ralf/0000 0001 9010 5217
CR Bagowski CP, 2001, J BIOL CHEM, V276, P37708, DOI 10.1074/jbc.M104582200
   Barbato JC, 2002, HYPERTENSION, V40, P130, DOI 10.1161/01.HYP.0000025879.29822.24
   Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775
   Boyan BD, 2006, STEROIDS, V71, P286, DOI 10.1016/j.steroids.2005.09.018
   Boyan BD, 2003, J CELL BIOCHEM, V90, P1207, DOI 10.1002/jcb.10716
   CALLACHAN H, 1987, PROC R SOC SER B BIO, V231, P359, DOI 10.1098/rspb.1987.0049
   Centrella M, 2004, MOL ENDOCRINOL, V18, P1120, DOI 10.1210/me.2003 0491
   Falkenstein E, 1999, ENDOCRINOLOGY, V140, P5999, DOI 10.1210/en.140.12.5999
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70
   Hisamoto K, 2005, STEROIDS, V70, P382, DOI 10.1016/j.steroids.2005.02.011
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165 6147(00)89058 6
   Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004 0390
   Lösel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003
   Mendelsohn ME, 2000, CIRC RES, V87, P956, DOI 10.1161/01.RES.87.11.956
   Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603
   Norman AW, 1999, STEROIDS, V64, P120, DOI 10.1016/S0039 128X(98)00091 9
   Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283
   OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006 291X(89)92508 4
   Peluso JJ, 2006, ENDOCRINOLOGY, V147, P3133, DOI 10.1210/en.2006 0114
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Selye H, 1941, P SOC EXP BIOL MED, V46, P116
   Srivastava DP, 2005, J NEUROSCI, V25, P6145, DOI 10.1523/JNEUROSCI.1005 05.2005
   TANG YT, IN PRESS J MOL EVOL
   Vertino AM, 2005, J BIOL CHEM, V280, P14130, DOI 10.1074/jbc.M410720200
   Wali RK, 2003, J CELL BIOCHEM, V88, P794, DOI 10.1002/jcb.10432
   Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699
   Zanello LP, 2004, P NATL ACAD SCI USA, V101, P1589, DOI 10.1073/pnas.0305802101
   ZHU Y, 2002, P ANN M END SOC 84 S, pP1
NR 30
TC 75
Z9 86
U1 0
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD DEC
PY 2006
VL 102
IS 1 5
SI SI
BP 180
EP 183
DI 10.1016/j.jsbmb.2006.09.016
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 117LS
UT WOS:000242875300022
PM 17113980
DA 2025 08 17
ER

PT J
AU Varadi, G
   Zhu, Z
   Blättler, T
   Hösle, M
   Loher, A
   Pokorny, R
   Frey, D
   Carter, SG
AF Varadi, Gyula
   Zhu, Zhen
   Blaettler, Thomas
   Hoesle, Manfred
   Loher, Alfons
   Pokorny, Rolf
   Frey, Diana
   Carter, Stephen G.
TI Randomized Clinical Trial Evaluating Transdermal Ibuprofen for Moderate
   to Severe Knee Osteoarthritis
SO PAIN PHYSICIAN
LA English
DT Article
DE Ibuprofen; transdermal treatment; VALE ibuprofen; knee osteoarthritis;
   Visual Analog Scale; WOMAC score
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TOPICAL IBUPROFEN; ORAL IBUPROFEN;
   DOUBLE BLIND; OLDER PEOPLE; EFFICACY; PAIN; SAFETY; NSAIDS; RISK
AB Background: Osteoarthritis is a common condition, typically treated with orally administered analgesics and non steroidal anti inflammatory drugs (NSAIDs). Chronic administration of NSAIDs, serotonin norepinephrine reuptake inhibitors (SNRIs, i.e., duloxetine), and opioid medications (i.e., tramadole) is regularly associated with multiple, serious side effects, in part due to the route of administration. Transdermal delivery of NSAIDs, such as ibuprofen, represents a potentially alternative treatment for this inflammatory pain condition with a better therapeutic profile.
   Objective: Investigate the safety and efficacy of a novel transdermal ibuprofen formulation (VALE (R) ibuprofen) containing 10% ibuprofen, compared to a placebo in a randomized, double blinded clinical trial, for clinical improvement in patients with moderate to severe painful osteoarthritis of the knee.
   Study Design: A randomized, placebo controlled, double blind, multi center Phase 2 clinical trial.
   Setting: An academic medical center, and private rheumatology and interventional pain management practices in Massachusetts and in Switzerland.
   Methods: The Phase 2 clinical study included patients with primary osteoarthritis in a single knee joint with a progression level of moderate to severe based in part on a grade II or III designation according to the Kellgren and Lawrence classification system. Patients received the corresponding, randomly assigned study formulation (VALE ibuprofen or placebo) for application to the target knee at a dose of 2.0 grams of drug product (200 mg ibuprofen) twice daily for 14 days. The evaluation of the efficacy of the treatments utilized the widely accepted methods of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index and the Visual Analog Scale (VAS) scores for the patients.
   Results: The results indicate that the transdermal VALE ibuprofen formulation was very well tolerated from a safety perspective during the 2 week trial and also produced significant, positive clinical improvements superior to the placebo in all clinical endpoints tested. In particular, the WOMAC(Total) and WOMAC(Physical) Functioning, for the VALE ibuprofen, were superior compared to the placebo (P = 0.0283 and P = 0.0201, respectively). Other clinical endpoints including the WOMAC(Pain), WOMAC(Stiffness), and VAS(Resting) scores were superior to those obtained from the placebo group, trending towards statistical significance compared to placebo (P = 0.0811, 0.1103, and 0.0785, respectively). Based on the Patient and Physician Global Impression of Change survey, patient satisfaction slightly improved across both groups; however, no statistical significance was detectable as compared to the baseline.
   Limitations: The sample size of 64 subjects in the final data analysis and the lack of including an orally administered drug group are limitations of this study.
   Conclusions: The use of transdermal VALE ibuprofen has beneficial clinical effects on the pain levels experienced in some patients with moderate to severe osteoarthritis of the knee as measured by the WOMAC Osteoarthritis Indices for stiffness, pain, physical function, and total. Visual Analog Scales (VAS) tests, VAS(Motion) and VAS(Weight bearing), again while appeared superior to placebo, were not statistically different from placebo.
C1 [Varadi, Gyula; Zhu, Zhen; Carter, Stephen G.] BioChem & Alterix Inc, Dept Res & Dev, Danvers, MA 01923 USA.
   [Pokorny, Rolf] Covance Clin Res Unit AG, Allschwil, Switzerland.
   [Frey, Diana] Univ Zurich, Rheumaklin, Zurich, Switzerland.
   [Frey, Diana] Univ Zurich, Inst Med Phys, Zurich, Switzerland.
C3 University of Zurich; University of Zurich
RP Varadi, G (通讯作者)，BioChem & Alterix Inc, Dept Res & Dev, 99 Rosewood Dr Suite 270, Danvers, MA 01923 USA.
EM gvaradi@biochemics.com
OI Varadi, Gyula/0000 0003 2975 2049
FU BioChemics, Inc., Danvers, Massachusetts
FX Funding for the clinical trial was entirely provided for by BioChemics,
   Inc., Danvers, Massachusetts. The funding organization did not
   participate in any phase of the data generation or data analyses;
   however, researchers at BioChemics did participate in the preparation of
   the manuscript. The principal investigator of the clinical research team
   had full access to the study data.
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003 4819 134 8 200104170 00012
   Benedetti F, 2006, NEUROL SCI, V27, pS100, DOI 10.1007/s10072 006 0580 4
   Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458 05.2005
   Boureau F, 2004, ANN RHEUM DIS, V63, P1028, DOI 10.1136/ard.2003.011403
   BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203
   CAMPBELL J, 1994, J ACCID EMERG MED, V11, P178
   Cross PL, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471 2474 6 55
   Ehrich EW, 2000, J RHEUMATOL, V27, P2635
   Eippert F, 2009, SCIENCE, V326, P404, DOI 10.1126/science.1180142
   EVANS JMM, 1995, BMJ BRIT MED J, V311, P22, DOI 10.1136/bmj.311.6996.22
   FELSON DT, 1995, ARTHRITIS RHEUM US, V38, P1500, DOI 10.1002/art.1780381017
   FELSON DT, 1987, ARTHRITIS RHEUM US, V30, P914, DOI 10.1002/art.1780300811
   FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049 0172(90)90046 I
   GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003 4819 115 10 787
   Griffin MR, 2000, AM J EPIDEMIOL, V151, P488
   Heyneman CA, 2000, DRUGS, V60, P555, DOI 10.2165/00003495 200060030 00004
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Littell RC, 1992, SAS SERIES STAT APPL
   Liu G, 2003, BIO PHARM Q J, V9, P17
   Mason L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 28
   Mason Lorna, 2004, BMC Fam Pract, V5, P10, DOI 10.1186/1471 2296 5 10
   Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333
   Morrison A, 2007, CURR MED RES OPIN, V23, P2395, DOI 10.1185/030079907X219553
   Ondarza A, PLACEBO EFFECTS TRAN
   Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777
   Puopolo A, 2007, OSTEOARTHR CARTILAGE, V15, P1348, DOI 10.1016/j.joca.2007.05.022
   Rovensky J, 2003, DRUG EXP CLIN RES, V29, P85
   Rovensky J, 2001, DRUG EXP CLIN RES, V27, P209
   SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003 4819 115 3 165
   Schaffer D, 2006, MED J AUSTRALIA, V185, P501, DOI 10.5694/j.1326 5377.2006.tb00665.x
   Schiff M, 2004, J RHEUMATOL, V31, P1373
   Schneeweiss S, 2006, ARTHRITIS RHEUM US, V54, P3390, DOI 10.1002/art.22219
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   SOCHOR J, 1994, J CHROMATOGR B, V654, P282, DOI 10.1016/0378 4347(94)00018 2
   Stucki G, 1996, Z RHEUMATOL, V55, P40
   Tiso RL, 2010, PAIN PHYSICIAN, V13, P457
   Trnavsky K, 2004, J RHEUMATOL, V31, P565
   Underwood M, 2008, HEALTH TECHNOL ASSES, V12, pIII
   Underwood MR, 2003, RHEUMATOLOGY, V42, P18
   Underwood M, 2008, BMJ BRIT MED J, V336, P138, DOI 10.1136/bmj.39399.656331.25
   Whitefield M, 2002, J CLIN PHARM THER, V27, P409, DOI 10.1046/j.1365 2710.2002.00439.x
   Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407
NR 44
TC 14
Z9 15
U1 0
U2 15
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533 3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD NOV DEC
PY 2013
VL 16
IS 6
BP E749
EP E762
PG 14
WC Anesthesiology; Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology; Neurosciences & Neurology
GA 259TG
UT WOS:000327548600009
PM 24284856
DA 2025 08 17
ER

PT J
AU Palazzo, B
   Iafisco, M
   Laforgia, M
   Margiotta, N
   Natile, G
   Bianchi, CL
   Walsh, D
   Mann, S
   Roveri, N
AF Palazzo, Barbara
   Iafisco, Michele
   Laforgia, Mariarita
   Margiotta, Nicola
   Natile, Giovanni
   Bianchi, Claudia L.
   Walsh, Dominic
   Mann, Stephen
   Roveri, Norberto
TI Biomimetic hydroxyapatite drug nanocrystals as potential bone
   substitutes with antitumor drug delivery properties
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID IN VITRO; LINKED PHOSPHONATES; SLOW RELEASE; BISPHOSPHONATES;
   ADSORPTION; CISPLATIN; SYSTEMS; CIS DICHLORODIAMMINEPLATINUM(II);
   RESORPTION; MECHANISM
AB This Full Paper investigates the adsorption and desorption of the anticancer drugs cis diamminedichloroplatinum(II) (CDDP, cisplatin) and the new platinum(II) complex di(ethylenediamineplatinum)medronate (DPM), as well as the clinically relevant bisphosphonate alendronate, towards two biomimetic synthetic HA nanocrystalline materials with either plate shaped (HAps) or needle shaped (HAns) morphologies and different chemico physical properties. The adsorption and desorption kinetics are dependent on the specific properties of the drugs and the morphology of the HA nanoparticles. Adsorption of the platinum complexes occurs with retention of the nitrogen ligands but the chloride ligands of cisplatin are displaced. Despite their opposite charges, the negatively charged alendronate bisphosphonate and the positively charged aquated cisplatin are strongly adsorbed, while the neutral DPM complex shows lower affinity towards the negatively charged apatitic surface. The data suggest that adsorption of the two platinum complexes is driven by electrostatic attractions, while interaction between the alendronate and the HA surface takes place by ligand exchange in which the two phosphonate groups of the drug molecule replace two surface phosphate groups. Significantly, adsorption of positively charged hydrolysis species of cisplatin is more favored on the phosphate rich HAns surface while adsorption of negatively charged alendronate is more favored on the calcium rich HAps surface. The latter type of short range electrostatic interactions also appear to dominate the desorption kinetics; consequently, drug release is greater for neutral DPM than for charged alendronate and aquated cisplatin. Moreover, while the release per unit area of charged species is the same for the two types of HAs, the release of DPM is faster from HAns, which is lower in surface calcium, than for HAps. Overall, this work demonstrates that the properties of HA nanocrystals can be modulated in such a way to produce HA/biomolecule conjugates tailored for specific therapeutic applications.
C1 Univ Bologna, Alma Mater Studiorum, Dept Chem, I 40126 Bologna, Italy.
   Univ Bari, Dept Pharm Chem, I 70125 Bari, Italy.
   Univ Milan, Dept Phys Chem & Electrochem, I 20133 Milan, Italy.
   Univ Bristol, Ctr Org Matter Chem, Sch Chem, Bristol, Avon, England.
C3 University of Bologna; Universita degli Studi di Bari Aldo Moro;
   University of Milan; University of Bristol
RP Palazzo, B (通讯作者)，Univ Bologna, Alma Mater Studiorum, Dept Chem, Via Selmi 2, I 40126 Bologna, Italy.
EM norberto.roveri@unibo.it
RI Iafisco, Michele/ABF 7752 2020; Iafisco, Michele/B 4597 2010; Bianchi,
   Claudia/C 7067 2013; Margiotta, Nicola/AAE 3975 2021; Mann,
   Stephen/D 1332 2012; Laforgia, Mariarita/AAD 5348 2020
OI Iafisco, Michele/0000 0002 7813 8347; Bianchi,
   Claudia/0000 0002 9702 6949; Natile, Giovanni/0000 0002 1790 6365; Mann,
   Stephen/0000 0003 3012 8964; Margiotta, Nicola/0000 0003 4034 875X;
   Palazzo, Barbara/0000 0001 5645 3779
CR Aoki H., 1979, BIOMAT MED EV ARTIF, V7, P291
   Barroug A, 2004, J ORTHOP RES, V22, P703, DOI 10.1016/j.orthres.2003.10.016
   Barroug A, 2002, J ORTHOPAED RES, V20, P274, DOI 10.1016/S0736 0266(01)00105 X
   Barroug A, 1998, J COLLOID INTERF SCI, V208, P147, DOI 10.1006/jcis.1998.5759
   BLOEMINK MJ, 1994, INORG CHEM, V33, P1127, DOI 10.1021/ic00084a026
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   DEWAAL WAJ, 1990, J PHARM BIOMED ANAL, V1, P1
   Erkmen ZE, 1999, J BIOMED MATER RES, V48, P861, DOI 10.1002/(SICI)1097 4636(1999)48:6<861::AID JBM15>3.0.CO;2 H
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ferraz M P, 2004, J Appl Biomater Biomech, V2, P74
   Guaber SPA, 2006, EU patent, Patent No. [005 146, 005146]
   Guicheux J, 1997, J BIOMED MATER RES, V34, P165, DOI 10.1002/(SICI)1097 4636(199702)34:2<165::AID JBM4>3.0.CO;2 O
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   KELMAN AD, 1979, CANCER TREAT REP, V63, P1445
   KLENNER T, 1990, J CANCER RES CLIN, V116, P341, DOI 10.1007/BF01612916
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Klenner T, 1993, MET COMPLEXES CANC C, V95
   Landi E, 2000, J EUR CERAM SOC, V20, P2377, DOI 10.1016/S0955 2219(00)00154 0
   Lebugle A, 2002, BIOMATERIALS, V23, P3517, DOI 10.1016/S0142 9612(02)00082 0
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Liou SC, 2004, BIOMATERIALS, V25, P189, DOI 10.1016/S0142 9612(03)00479 4
   MIURA S, 1995, JPN J CLIN ONCOL, V25, P61
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Palazzo B, 2005, MAT SCI ENG C BIO S, V25, P207, DOI 10.1016/j.msec.2005.01.011
   PASINI A, 1993, SYN REACT INORG MET, V23, P1021, DOI 10.1080/15533179308016879
   QUINLAN KP, 1955, ANAL CHEM, V27, P1626, DOI 10.1021/ac60106a039
   Rodríguez Lorenzo LM, 2001, BIOMATERIALS, V22, P1847, DOI 10.1016/S0142 9612(00)00366 5
   ROSENBERG B, 1979, CANCER TREAT REP, V63, P1433
   Roussière H, 2005, J MATER CHEM, V15, P3869, DOI 10.1039/b503680a
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SEGAL E, 1985, CANCER RES, V45, P492
   Taha EA, 2003, CHEM PHARM BULL, V51, P1444, DOI 10.1248/cpb.51.1444
   Tahara Y, 2001, J Orthop Sci, V6, P556, DOI 10.1007/s007760100012
   UCHIDA A, 1992, J ORTHOPAED RES, V10, P440, DOI 10.1002/jor.1100100317
   WINGEN F, 1985, ARZNEIMITTELFORSCH, V35 2, P1565
   Yotsuyanagi T, 2002, INT J PHARMACEUT, V246, P95, DOI 10.1016/S0378 5173(02)00382 4
   YUAN H, 2004, LEARNING NATURE DESI, pCH2
   ZWELLING LA, 1979, CANCER TREAT REP, V63, P1439
NR 39
TC 307
Z9 328
U1 4
U2 160
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD SEP 3
PY 2007
VL 17
IS 13
BP 2180
EP 2188
DI 10.1002/adfm.200600361
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 212ZY
UT WOS:000249636900023
DA 2025 08 17
ER

PT J
AU Nam, OH
   Kim, JH
   Choi, SC
   Kim, Y
AF Nam, Ok Hyung
   Kim, Jae Hwan
   Choi, Sung Chul
   Kim, Young
TI Time Dependent Response of Human Deciduous Tooth Derived Dental Pulp
   Cells Treated with TheraCal LC: Functional Analysis of Gene Interactions
   Compared to MTA
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE gene expression; mineral trioxide aggregate; mRNA sequencing; TheraCal
   LC; vital pulp therapy
ID MINERAL TRIOXIDE AGGREGATE; ACTIVATED PROTEIN KINASE; PROMOTES
   ODONTOBLASTIC DIFFERENTIATION; ACQUIRED IMMUNE RESPONSES; STEM CELLS;
   OSTEOCLAST DIFFERENTIATION; CYTOTOXICITY; BIODENTINE; RESORPTION;
   INDUCTION
AB Pulp capping material should facilitate hard tissue regeneration on the injured pulp tissue. TheraCal LC (TC) was recently developed. Although TC has shown reliable clinical outcomes after direct pulp capping, there are still remaining concerns regarding its detrimental effect on pulp cells. Therefore, this study aimed to identify the gene expression of human deciduous tooth derived dental pulp cells exposed to TC compared to mineral trioxide aggregate (MTA). The cells were cultured and exposed to TC and MTA for 24 and 72 h. Next, total RNA was isolated. QuantSeq 3 ' mRNA sequencing was used to examine differentially expressed genes (DEGs) in exposed to TC and MTA. Functional analysis of DEGs was performed using bioinformatics analysis. In gene ontology (GO) functional enrichment analysis, cells in TC for 24 h presented significantly enriched immune response (p < 0.001) and inflammatory response (p < 0.01) compared to MTA. TC showed enriched positive regulation of cell migration at 72 h (p < 0.001). In Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, neuroactive ligand receptor interaction (p = 1.19 x 10( 7)) and calcium signaling pathway (p = 2.96 x 10( 5)) were confirmed in the shared DEGs in TC. In conclusion, DEGs in TC may be involved in pathways associated with osteoclastogenesis and osteoclastic differentiation.
C1 [Nam, Ok Hyung; Choi, Sung Chul] Kyung Hee Univ, Sch Dent, Dept Pediat Dent, Seoul 02447, South Korea.
   [Kim, Jae Hwan] Chonnam Natl Univ, Sch Dent, Dept Pediat Dent, Gwangju 61186, South Korea.
   [Kim, Young] Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
C3 Kyung Hee University; Chonnam National University; Chonnam National
   University
RP Kim, Y (通讯作者)，Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
EM pedokhyung@gmail.com; jhbcss@hanmail.net; pedochoi@khu.ac.kr;
   youngkim2017@jnu.ac.kr
RI Nam, Ok Hyung/A 9769 2019; CHOI, SUNG/B 4574 2019; NAM, OK
   HYUNG/A 9769 2019
OI Nam, Ok Hyung/0000 0002 6386 803X; 
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2019R1A5A2027521, NRF 2018R1D1A1B07047482]; Chonnam National University
   Hospital Biomedical Research Institute [BCRI19027]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (No. 2019R1A5A2027521
   and NRF 2018R1D1A1B07047482) and a grant of Chonnam National University
   Hospital Biomedical Research Institute (BCRI19027).
CR Alagarsamy S, 2005, NEUROPHARMACOLOGY, V49, P135, DOI 10.1016/j.neuropharm.2005.05.005
   Aminabadi NA, 2016, INT J PAEDIATR DENT, V26, P281, DOI 10.1111/ipd.12196
   Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Arandi NZ, 2018, INT J DENT, V2018, DOI 10.1155/2018/3484653
   Carrotte P, 2004, BRIT DENT J, V197, P735, DOI 10.1038/sj.bdj.4811897
   Chang SW, 2016, ACTA ODONTOL SCAND, V74, P298, DOI 10.3109/00016357.2015.1120882
   Cohenca Nestor, 2013, Dent Clin North Am, V57, P59, DOI 10.1016/j.cden.2012.09.004
   Collado González M, 2017, INT ENDOD J, V50, pE19, DOI 10.1111/iej.12751
   Dammaschke T, 2010, CLIN ORAL INVEST, V14, P559, DOI 10.1007/s00784 009 0326 9
   Erfanparast L, 2018, EUR ARCH PAEDIATR DE, V19, P197, DOI 10.1007/s40368 018 0348 6
   Fuks A B, 2000, Dent Clin North Am, V44, P571
   Gandolfi MG, 2011, DENT MATER, V27, pE134, DOI 10.1016/j.dental.2011.03.011
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Hebling J, 2009, AM J DENT, V22, P137
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jewett A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009874
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kang J, 2016, Genet Mol Res, V15, DOI 10.4238/gmr15047959
   Kim JH, 2019, FOOD SCI BIOTECHNOL, V28, P1801, DOI 10.1007/s10068 019 00609 5
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li X, 2018, DENT MATER, V34, P1410, DOI 10.1016/j.dental.2018.06.016
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Neto NL, 2016, J BIOMED MATER RES B, V104, P165, DOI 10.1002/jbm.b.33379
   Luo ZR, 2014, J ENDODONT, V40, P937, DOI 10.1016/j.joen.2013.11.022
   Lv LW, 2018, CHIN J DENT RES, V21, P101, DOI 10.3290/j.cjdr.a40436
   Ma DD, 2018, J CELL MOL MED, V22, P3442, DOI 10.1111/jcmm.13621
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Mirza R, 2009, AM J PATHOL, V175, P2454, DOI 10.2353/ajpath.2009.090248
   Nakatomi M, 2006, J DENT RES, V85, P427, DOI 10.1177/154405910608500506
   Nilsen BW, 2017, EUR J ORAL SCI, V125, P183, DOI 10.1111/eos.12347
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ranly DM, 2000, J DENT, V28, P153, DOI 10.1016/S0300 5712(99)00065 2
   Rathinam E, 2015, J ENDODONT, V41, P1805, DOI 10.1016/j.joen.2015.07.015
   Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099 1352(199634/12)9:5/6<617::AID JMR310>3.0.CO;2 D
   Roberts HW, 2008, DENT MATER, V24, P149, DOI 10.1016/j.dental.2007.04.007
   Rufas P, 2016, J ENDODONT, V42, P1377, DOI 10.1016/j.joen.2016.06.011
   Schneider TR, 2019, DENT MATER J, V38, P579, DOI 10.4012/dmj.2018 163
   Seo MS, 2013, J ENDODONT, V39, P242, DOI 10.1016/j.joen.2012.11.004
   Smith MJ, 2010, J BIOMED MATER RES A, V93A, P793, DOI 10.1002/jbm.a.32579
   Smith MJ, 2009, BIOMATERIALS, V30, P149, DOI 10.1016/j.biomaterials.2008.09.019
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takita T, 2006, INT ENDOD J, V39, P415, DOI 10.1111/j.1365 2591.2006.01097.x
   TORABINEJAD M, 1995, J ENDODONT, V21, P349, DOI 10.1016/S0099 2399(06)80967 2
   Tuna D, 2008, INT ENDOD J, V41, P273, DOI 10.1111/j.1365 2591.2007.01339.x
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Xia LG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062645
   Xiao Y, 2019, EXP THER MED, V17, P2529, DOI 10.3892/etm.2019.7225
   Xie FR, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00250
   Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378 1119(03)00816 3
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yi XS, 2018, BIOCHEM BIOPH RES CO, V497, P850, DOI 10.1016/j.bbrc.2018.02.125
   Yoldas SE, 2016, J ENDODONT, V42, P1815, DOI 10.1016/j.joen.2016.08.020
   Zakerzadeh Azadeh, 2017, Iran Endod J, V12, P419, DOI 10.22037/iej.v12i4.15104
   Zhao X, 2012, MOL BIOL REP, V39, P215, DOI 10.1007/s11033 011 0728 z
NR 57
TC 10
Z9 10
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2077 0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2020
VL 9
IS 2
AR 531
DI 10.3390/jcm9020531
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA KT2DG
UT WOS:000518823000243
PM 32075286
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Morales, AJA
   DeFreitas, MJ
   Katsoufis, CP
   Seeherunvong, W
   Chandar, J
   Zilleruelo, G
   Freundlich, M
   Abitbol, CL
AF Morales, Aura J. Arenas
   DeFreitas, Marissa J.
   Katsoufis, Chryso P.
   Seeherunvong, Wacharee
   Chandar, Jayanthi
   Zilleruelo, Gaston
   Freundlich, Michael
   Abitbol, Carolyn L.
TI Cinacalcet as rescue therapy for refractory hyperparathyroidism in young
   children with advanced chronic kidney disease
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE Hyperparathyroidism; Pediatric chronic kidney disease; Calcimimetic;
   Cinacalcet; Growth
ID SECONDARY HYPERPARATHYROIDISM; ADJUNCTIVE THERAPY; DIALYSIS;
   CALCIMIMETICS; PARICALCITOL; GROWTH
AB Background Studies in the use of the calcimimetic, cinacalcet, in pediatric chronic kidney disease (CKD) are few and limited to older children with secondary hyperparathyroidism (sHPT), a major morbid complication contributing to poor growth, bone deformities, and cardiovascular disease. Our objectives were to determine a safe and effective dosing regimen of cinacalcet in the treatment of infants and young children with sHPT that was refractory to standard care and to examine their growth during treatment.
   Methods Ten young pediatric patients with advanced CKD were studied retrospectively during 11 courses of treatment with cinacalcet. All had severe sHPT with intact parathyroid hormone (iPTH) levels >= 500 pg/ml and were refractory to standard therapy with phosphate binders and active vitamin D analogs at high doses for >30days. The cinacalcet dose was advanced by 50% every 2 4weeks to achieve a decline in the iPTH to a goal of 150 300pg/ml. Linear growth was assessed at 6 month intervals by change in z scores (triangle SDS) for length before and during cinacalcet therapy.
   Results Median age at initiation of cinacalcet was 18months (IQR 6, 36) with an average starting dose of 0.7 +/  0.2mg/kg/day. Median effective dose required to reach iPTH goal of 150 300 pg/ml was 2.8mg/kg/day (IQR 2.0, 3.1), and time to goal was 112days (IQR 56, 259) with a median overall decline in iPTH of 82% from baseline by 6 months (p<0.0001). No subject experienced a clinical adverse event, although 4 had biochemical asymptomatic hypocalcemia. Linear growth improved significantly during cinacalcet therapy (triangle SDS  0.62 +/  1.2 versus +0.91 +/  1.4; p<0.005). By multiple regression analysis, the primary determinants of growth were concurrent treatment with growth hormone and age <2years (R 2=89.6%; p<0.001). A shorter treatment time required to achieve iPTH goals also was associated with improved growth (r= 0.75; p<0.01).
   Conclusions Cinacalcet may be used effectively and safely in infants and small children with refractory sHPT in advanced CKD using a cautious dosing regimen. Cinacalcet successfully brings iPTH to target level and supports growth when other treatments have been ineffective.
C1 [Morales, Aura J. Arenas; DeFreitas, Marissa J.; Katsoufis, Chryso P.; Seeherunvong, Wacharee; Chandar, Jayanthi; Zilleruelo, Gaston; Freundlich, Michael; Abitbol, Carolyn L.] Univ Miami, Div Pediat Nephrol, Holtz Childrens Hosp, POB 016960, Miami, FL 33130 USA.
C3 University of Miami
RP Abitbol, CL (通讯作者)，Univ Miami, Div Pediat Nephrol, Holtz Childrens Hosp, POB 016960, Miami, FL 33130 USA.
EM cabitbol@med.miami.edu
RI ; Abitbol, Carolyn/ADL 4872 2022; Seeherunvong, Wacharee/AIE 7908 2022
OI Abitbol, Carolyn/0000 0002 0984 3771; 
FU Florida Department of Health Children's Medical Services; 2015 Micah
   Batchelor Children's Research Award
FX This work was supported in part by a grant from the Florida Department
   of Health Children's Medical Services and the 2015 Micah Batchelor
   Children's Research Award.
CR Alharthi AA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000401
   Alon US, 2008, CLIN J AM SOC NEPHRO, V3, P658, DOI 10.2215/CJN.04981107
   Alon US, 2010, PEDIATR NEPHROL, V25, P1747, DOI 10.1007/s00467 010 1547 5
   Edney A, 2013, BUSINESSWEEK
   Freundlich M, 2017, PEDIATR NEPHROL, V32, P1103, DOI 10.1007/s00467 017 3675 7
   Furth SL, 2002, PEDIATRICS, V109, P909, DOI 10.1542/peds.109.5.909
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   Haffner D, 2013, PEDIATR NEPHROL, V28, P537, DOI 10.1007/s00467 012 2270 1
   Joffy S, 2005, AM J KIDNEY DIS, V46, P1, DOI 10.1053/j.ajkd.2005.04.011
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kramer A, 2009, NEPHROL DIAL TRANSPL, V24, P926, DOI 10.1093/ndt/gfn542
   Mitsnefes MM, 2013, JAMA J AM MED ASSOC, V309, P1921, DOI 10.1001/jama.2013.4208
   Muscheites J, 2008, PEDIATR NEPHROL, V23, P1823, DOI 10.1007/s00467 008 0810 5
   Nakagawa K, 2008, NEPHROL DIAL TRANSPL, V23, P2761, DOI 10.1093/ndt/gfn143
   Parfrey PS, 2013, J CLIN ENDOCR METAB, V98, P4834, DOI 10.1210/jc.2013 2975
   Platt C, 2010, PEDIATR NEPHROL, V25, P143, DOI 10.1007/s00467 009 1294 7
   Rees L, 2008, PEDIATR NEPHROL, V23, P179, DOI 10.1007/s00467 007 0684 y
   SALUSKY IB, 1994, KIDNEY INT, V45, P253, DOI 10.1038/ki.1994.31
   Schlieper G, 2008, PEDIATR NEPHROL, V23, P1721, DOI 10.1007/s00467 008 0900 4
   Silverstein DM, 2008, PEDIATR NEPHROL, V23, P1817, DOI 10.1007/s00467 007 0742 5
   Srivastava T, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016 3789
   Srivastava T, 2016, PEDIATR NEPHROL, V31, P795, DOI 10.1007/s00467 015 3271 7
   Srivastava T, 2013, J BONE MINER RES, V28, P992, DOI 10.1002/jbmr.1838
   Webb NJA, 2017, PEDIATR NEPHROL, V32, P1221, DOI 10.1007/s00467 017 3579 6
   Wu SF, 2004, FASEB J, V18, P143, DOI 10.1096/fj.03 0294fje
NR 25
TC 11
Z9 11
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0931 041X
EI 1432 198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD JAN
PY 2019
VL 34
IS 1
BP 129
EP 135
DI 10.1007/s00467 018 4055 7
PG 7
WC Pediatrics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Urology & Nephrology
GA HA7SE
UT WOS:000450482800013
PM 30203374
DA 2025 08 17
ER

PT J
AU Wu, CT
   Fan, W
   Gelinsky, M
   Xiao, Y
   Chang, J
   Friis, T
   Cuniberti, G
AF Wu, Chengtie
   Fan, Wei
   Gelinsky, Michael
   Xiao, Yin
   Chang, Jiang
   Friis, Thor
   Cuniberti, Gianaurelio
TI In situ preparation and protein delivery of silicate alginate
   composite microspheres with core shell structure
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE core shell structure; calcium silicate; alginate; protein delivery;
   bioactivity; microspheres
ID DRUG DELIVERY; BONE RESORPTION; SERUM ALBUMIN; RELEASE; HYDROXYAPATITE;
   SCAFFOLDS; GEL; RECONSTRUCTION; BIOACTIVITY; OSTEOCLAST
AB The efficient loading and sustained release of proteins from bioactive microspheres remain a significant challenge. In this study, we have developed bioactive microspheres which can be loaded with protein and then have a controlled rate of protein release into a surrounding medium. This was achieved by preparing a bioactive microsphere system with core shell structure, combining a calcium silicate (CS) shell with an alginate (A) core by a one step in situ method. The result was to improve the microspheres' protein adsorption and release, which yielded a highly bioactive material with potential uses in bone repair applications. The composition and the core shell structure, as well as the formation mechanism of the obtained CS A microspheres, were investigated by X ray diffraction, optical microscopy, scanning electron microscopy, energy dispersive spectrometer dot and line scanning analysis. The protein loading efficiency reached 75 per cent in CS A microspheres with a core shell structure by the in situ method. This is significantly higher than that of pure A or CS A microspheres prepared by non in situ method, which lack a core shell structure. CS A microspheres with a core shell structure showed a significant decrease in the burst release of proteins, maintaining sustained release profile in phosphate buffered saline (PBS) at both pH 7.4 and 4.3, compared with the controls. The protein release from CS A microspheres is predominantly controlled by a Fickian diffusion mechanism. The CS A microspheres with a core shell structure were shown to have improved apatite mineralization in simulated body fluids compared with the controls, most probably owing to the existence of bioactive CS shell on the surface of the microspheres. Our results indicate that the core shell structure of CS A microspheres play an important role in enhancing protein delivery and mineralization, which makes these composite materials promising candidates for application in bone tissue regeneration.
C1 [Wu, Chengtie; Gelinsky, Michael; Cuniberti, Gianaurelio] Tech Univ Dresden, Inst Mat Sci, D 01069 Dresden, Germany.
   [Wu, Chengtie; Gelinsky, Michael; Cuniberti, Gianaurelio] Tech Univ Dresden, Max Bergmann Ctr Biomat, D 01069 Dresden, Germany.
   [Wu, Chengtie; Fan, Wei; Xiao, Yin; Friis, Thor] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Chang, Jiang] Chinese Acad Sci, Shanghai Inst Ceram, Shanghai 200050, Peoples R China.
   [Cuniberti, Gianaurelio] POSTECH, Natl Ctr Nanomat Technol, Pohang 790784, South Korea.
C3 Technische Universitat Dresden; Technische Universitat Dresden;
   Queensland University of Technology (QUT); Chinese Academy of Sciences;
   Shanghai Institute of Ceramics, CAS; Pohang University of Science &
   Technology (POSTECH)
RP Wu, CT (通讯作者)，Tech Univ Dresden, Inst Mat Sci, Budapester Str 27, D 01069 Dresden, Germany.
EM chengtie.wu@qut.edu.au
RI Cuniberti, Gianaurelio/B 7192 2008; Cuniberti, Gianaurelio
   (Giovanni)/B 7192 2008; Gelinsky, Michael/A 9680 2012; Xiao,
   Yin/AAM 4033 2020
OI Cuniberti, Gianaurelio (Giovanni)/0000 0002 6574 7848; Gelinsky,
   Michael/0000 0001 9075 5121; Xiao, Yin/0000 0003 1785 3491
FU Alexander von Humboldt Foundation; South Korean Ministry of Education,
   Science and Technology [R31 2008 000 10100 0]
FX Funding for this study was provided by a research grant from the
   Alexander von Humboldt Foundation (C.W.) and the South Korean Ministry
   of Education, Science and Technology Programme, Project WCU ITCE no.
   R31 2008 000 10100 0 (G.C.).
CR BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Bi L, 2010, BIOMATERIALS, V31, P3201, DOI 10.1016/j.biomaterials.2010.01.038
   Chang MW, 2011, J R SOC INTERFACE, V8, P451, DOI 10.1098/rsif.2010.0428
   de Aza PN, 2000, J MICROSC OXFORD, V197, P60, DOI 10.1046/j.1365 2818.2000.00647.x
   Halder A, 2005, J MICROENCAPSUL, V22, P67, DOI 10.1080/02652040500045003
   HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0
   Hench LL, 2010, J R SOC INTERFACE, V7, pS379, DOI 10.1098/rsif.2010.0151.focus
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hollinger J, 1996, ORAL SURG ORAL MED O, V82, P594, DOI 10.1016/S1079 2104(96)80431 8
   Hosoya K, 2004, J BIOMED MATER RES A, V71A, P596, DOI 10.1002/jbm.a.30189
   Hsu FY, 1999, BIOMATERIALS, V20, P1931
   Jay SM, 2009, J CONTROL RELEASE, V134, P26, DOI 10.1016/j.jconrel.2008.10.019
   KIBAT PG, 1990, FASEB J, V4, P2533, DOI 10.1096/fasebj.4.8.2110539
   Kikuchi A, 1999, J CONTROL RELEASE, V58, P21, DOI 10.1016/S0168 3659(98)00141 2
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Li HY, 2005, J CONTROL RELEASE, V107, P463, DOI 10.1016/j.jconrel.2005.05.019
   Luciani A, 2008, BIOMATERIALS, V29, P4800, DOI 10.1016/j.biomaterials.2008.09.007
   Malafaya PB, 2008, BIOMATERIALS, V29, P3914, DOI 10.1016/j.biomaterials.2008.06.023
   Matsuno T, 2008, DENT MATER J, V27, P827, DOI 10.4012/dmj.27.827
   Molvinger K, 2004, CHEM MATER, V16, P3367, DOI 10.1021/cm0353299
   Ni SY, 2006, J BIOMED MATER RES A, V76A, P196, DOI 10.1002/jbm.a.30525
   Pareta R, 2006, J R SOC INTERFACE, V3, P573, DOI 10.1098/rsif.2006.0120
   Park K., 1993, BIODEGRADABLE HYDROG, P99
   Ryu J, 2010, ADV FUNCT MATER, V20, P2132, DOI 10.1002/adfm.200902347
   Singh MK, 2008, ADV FUNCT MATER, V18, P694, DOI 10.1002/adfm.200700888
   Siriphannon P, 2002, J EUR CERAM SOC, V22, P511, DOI 10.1016/S0955 2219(01)00301 6
   Soppimath KS, 2007, ADV FUNCT MATER, V17, P355, DOI 10.1002/adfm.200500611
   Tampieri A, 2005, ACTA BIOMATER, V1, P343, DOI 10.1016/j.actbio.2005.01.001
   Turco G, 2009, BIOMACROMOLECULES, V10, P1575, DOI 10.1021/bm900154b
   van de Manakker F, 2009, ADV FUNCT MATER, V19, P2992, DOI 10.1002/adfm.200900603
   WASSELL DTH, 1995, BIOMATERIALS, V16, P697, DOI 10.1016/0142 9612(95)99697 K
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   Wu CT, 2010, J BIOMED MATER RES A, V95A, P476, DOI 10.1002/jbm.a.32873
   Wu CT, 2010, ACTA BIOMATER, V6, P820, DOI 10.1016/j.actbio.2009.09.025
   Wu C, 2009, BIOMATERIALS, V30, P2199, DOI 10.1016/j.biomaterials.2009.01.029
   Xia W, 2006, J CONTROL RELEASE, V110, P522, DOI 10.1016/j.jconrel.2005.11.002
   Xie ML, 2010, ACTA BIOMATER, V6, P3665, DOI 10.1016/j.actbio.2010.03.034
   Xu SW, 2007, J BIOMAT SCI POLYM E, V18, P71, DOI 10.1163/156856207779146141
   Xu S, 2008, BIOMATERIALS, V29, P2588, DOI 10.1016/j.biomaterials.2008.03.013
   Xue WC, 2005, BIOMATERIALS, V26, P3455, DOI 10.1016/j.biomaterials.2004.09.027
   Zhu YF, 2009, MICROPOR MESOPOR MAT, V118, P176, DOI 10.1016/j.micromeso.2008.08.046
NR 43
TC 36
Z9 41
U1 1
U2 64
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742 5689
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD DEC 7
PY 2011
VL 8
IS 65
BP 1804
EP 1814
DI 10.1098/rsif.2011.0201
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 842FK
UT WOS:000296578400012
PM 21613289
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Coulson Thomas, VJ
   Coulson Thomas, YM
   Gesteira, TF
   Kao, WWY
AF Coulson Thomas, Vivien J.
   Coulson Thomas, Yvette M.
   Gesteira, Tarsis F.
   Kao, Winston W.  Y.
TI Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells
   Suppress the Immune System
SO OCULAR SURFACE
LA English
DT Article
DE graft versus host disease; immunity; inflammation; mesenchymal stem
   cells; stem cell transplantation
ID MARROW STROMAL CELLS; VERSUS HOST DISEASE; REGULATORY T CELLS; OCULAR
   SURFACE RECONSTRUCTION; UMBILICAL CORD BLOOD; BONE MARROW; DENDRITIC
   CELLS; IN VITRO; MYOCARDIAL INFARCTION; PROSTAGLANDIN E 2
AB Mesenchymal stem cells (MSCs) are a group of fibroblast like multipotent mesenchymal stromal cells that have the ability to differentiate into osteoblasts, adipocytes, and chondrocytes. Recent studies have demonstrated that MSCs possess a unique ability to exert suppressive and regulatory effects on both adaptive and innate immunity in an autologous and allogeneic manner. A vital step in stem cell transplantation is overcoming the potential graft versus host disease, which is a limiting factor to transplantation success. Given that MSCs attain powerful differentiation capabilities and also present immunosuppressive properties, which enable them to survive host immune rejection, MSCs are of great interest. Due to their ability to differentiate into different cell types and to suppress and modulate the immune system, MSCs are being developed for treating a plethora of diseases, including immune disorders. Moreover, in recent years, MSCs have been genetically engineered to treat and sometimes even cure some diseases, and the use of MSCs for cell therapy presents new perspectives for overcoming tissue rejection. In this review, we discuss the potential extrinsic and intrinsic mechanisms that underlie MSCs' unique ability to modulate inflammation, and both innate and adaptive immunity.
C1 [Coulson Thomas, Vivien J.; Gesteira, Tarsis F.; Kao, Winston W.  Y.] Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA.
   [Coulson Thomas, Vivien J.] Univ Cambridge, John van Geest Ctr Brain Repair, Cambridge, England.
   [Coulson Thomas, Yvette M.] Univ Fed Sao Paulo, Dept Bioquim, Sao Paulo, SP, Brazil.
C3 University System of Ohio; University of Cincinnati; University of
   Cambridge; Universidade Federal de Sao Paulo (UNIFESP)
RP Coulson Thomas, VJ; Kao, WWY (通讯作者)，Univ Cincinnati, Ophthalmol, 3230 Eden Ave,CARE Crawley Suite 5860, Cincinnati, OH 45267 USA.
EM vcoulsonthomas@gmail.com; winston.kao@uc.edu
RI Ferreira, Tarsis/KCK 3229 2024
OI Gesteira Ferreira, Tarsis/0000 0002 0136 0986
FU NIH/NEI [1R01EY021768]; Research to Prevent Blindness, Inc., New York,
   NY; Ohio Lions Eye Research Foundation; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel (CAPES)
FX The review was in part supported by NIH/NEI grant 1R01EY021768, an
   Unrestricted Grant from Research to Prevent Blindness, Inc., New York,
   NY, to the Department of Ophthalmology, University of Cincinnati College
   of Medicine Karl C. Golnik, MD, Chairman, Ohio Lions Eye Research
   Foundation, Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de
   Nivel (CAPES).
CR Abomaray FM, 2015, STEM CELL REV REP, V11, P423, DOI 10.1007/s12015 014 9562 8
   Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Aldridge V, 2012, HEPATOLOGY, V56, P1063, DOI 10.1002/hep.25716
   Almaliotis D, 2015, GRAEF ARCH CLIN EXP, V253, P1121, DOI 10.1007/s00417 015 3042 y
   Alvarez Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Arnalich Montiel F, 2008, STEM CELLS, V26, P570, DOI 10.1634/stemcells.2007 0653
   Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359
   Baker PS, 2009, CURR OPIN OPHTHALMOL, V20, P175, DOI 10.1097/ICU.0b013e328329b5f2
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301 472X(01)00769 X
   Bhakta S, 2006, CARDIOVASC REVASCULA, V7, P19, DOI 10.1016/j.carrev.2005.10.008
   Bian SY, 2014, J MOL MED, V92, P387, DOI 10.1007/s00109 013 1110 5
   Blazquez R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00556
   Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600 0854.2011.01225.x
   Branch MJ, 2012, INVEST OPHTH VIS SCI, V53, P5109, DOI 10.1167/iovs.11 8673
   Bright JJ, 1997, J IMMUNOL, V159, P175
   Bruder SP, 1998, J BONE MINER RES, V13, P655, DOI 10.1359/jbmr.1998.13.4.655
   Cai ZJ, 2012, CELL RES, V22, P607, DOI 10.1038/cr.2011.196
   Campioni D, 2009, CYTOM PART B CLIN CY, V76B, P225, DOI 10.1002/cyto.b.20461
   Casiraghi F, 2008, J IMMUNOL, V181, P3933, DOI 10.4049/jimmunol.181.6.3933
   Cejkova J, 2013, EXP EYE RES, V116, P312, DOI 10.1016/j.exer.2013.10.002
   Chan JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood 2006 01 0057
   Chang W, 2015, MOL CELLS, V38, P643, DOI 10.14348/molcells.2015.0050
   Chanmee T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00180
   Chaput N, 2011, SEMIN IMMUNOPATHOL, V33, P419, DOI 10.1007/s00281 010 0233 9
   Chullikana A, 2015, CYTOTHERAPY, V17, P250, DOI 10.1016/j.jcyt.2014.10.009
   Consentius C, 2015, STEM CELLS, V33, P3087, DOI 10.1002/stem.2104
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood 2005 07 2657
   Corrado C, 2013, INT J MOL SCI, V14, P5338, DOI 10.3390/ijms14035338
   Coulson Thomas VJ, 2010, EXP CELL RES, V316, P3207, DOI 10.1016/j.yexcr.2010.08.005
   Coulson Thomas VJ, 2014, J BIOL CHEM, V289, P25211, DOI 10.1074/jbc.M114.572511
   Coulson Thomas VJ, 2014, J BIOL CHEM, V289, P23465, DOI 10.1074/jbc.M114.557447
   Coulson Thomas VJ, 2013, STEM CELLS, V31, P2116, DOI 10.1002/stem.1481
   Coulson Thomas YM, 2015, HISTOL HISTOPATHOL, V30, P33, DOI 10.14670/HH 30.33
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002 9440(10)63636 X
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Ding DC, 2015, CELL TRANSPLANT, V1263, P321
   Djouad F, 2007, STEM CELLS, V25, P2025, DOI 10.1634/stemcells.2006 0548
   Dong LH, 2015, SCI REP UK, V5, DOI 10.1038/srep08713
   Drew E, 2005, BLOOD, V106, P1885, DOI 10.1182/blood 2005 03 1291
   Du YD, 2005, STEM CELLS, V23, P1266, DOI 10.1634/stemcells.2004 0256
   Dyer DP, 2014, J IMMUNOL, V192, P2177, DOI 10.4049/jimmunol.1300194
   Ekström EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 88
   El Akabawy G, 2015, ANN ANAT, V198, P11, DOI 10.1016/j.aanat.2014.12.002
   English K, 2009, CLIN EXP IMMUNOL, V156, P149, DOI 10.1111/j.1365 2249.2009.03874.x
   Estrada EJ, 2008, CELL TRANSPLANT, V17, P1295, DOI 10.3727/096368908787648119
   Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI200113561
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   García Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350 005 0052 6
   Garzón I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051961
   Gee K, 2004, ARCH IMMUNOL THER EX, V52, P13
   Ghannam S, 2010, J IMMUNOL, V185, P302, DOI 10.4049/jimmunol.0902007
   Gnecchi M, 2009, STEM CELLS, V27, P971, DOI 10.1002/stem.12
   Gonzalez Rey E, 2009, GUT, V58, P929, DOI 10.1136/gut.2008.168534
   Götherström C, 2014, STEM CELL TRANSL MED, V3, P255, DOI 10.5966/sctm.2013 0090
   Gu W, 2015, SCI REP UK, V5, DOI 10.1038/srep08733
   György B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018 011 0689 3
   He XW, 1999, J IMMUNOL, V163, P6173
   Hendricks A, 2000, IMMUNOBIOLOGY, V201, P493, DOI 10.1016/S0171 2985(00)80069 8
   Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946
   Holan V, 2015, STEM CELL TRANSL MED, V4, P1052, DOI 10.5966/sctm.2015 0039
   Holan V, 2013, STEM CELL REV REP, V9, P609, DOI 10.1007/s12015 013 9449 0
   Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Huang C, 2012, J CELL BIOCHEM, V113, P590, DOI 10.1002/jcb.23383
   Huang LB, 2013, OCUL IMMUNOL INFLAMM, V21, P276, DOI 10.3109/09273948.2013.791925
   Huber V, 2008, J TRANSL MED, V6, DOI 10.1186/1479 5876 6 63
   Hue DM, 2010, INT J OPHTHALMOL CHI, V3, P216, DOI 10.3980/j.issn.2222 3959.2010.03.08
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Johnson TV, 2009, EYE, V23, P1980, DOI 10.1038/eye.2008.376
   Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Kang I, 2015, J BIOL CHEM, V290, P21629, DOI 10.1074/jbc.M115.657486
   Kanno Hiroshi, 2013, World J Stem Cells, V5, P163, DOI 10.4252/wjsc.v5.i4.163
   Khan I, 2015, J INFLAMM RES, V8, P1, DOI 10.2147/JIR.S71987
   Kijima N, 2012, NEURO ONCOLOGY, V14, P1254, DOI 10.1093/neuonc/nor202
   Kim JH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/549136
   Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004
   Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015
   Knoop K, 2015, J NUCL MED, V56, P600, DOI 10.2967/jnumed.114.146662
   Kota DJ, 2014, INT J BIOCHEM CELL B, V55, P1, DOI 10.1016/j.biocel.2014.07.022
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood 2002 07 2104
   Krasnodembskaya A, 2012, AM J PHYSIOL LUNG C, V302, pL1003, DOI 10.1152/ajplung.00180.2011
   Lan YN, 2012, INVEST OPHTH VIS SCI, V53, P3638, DOI 10.1167/iovs.11 9311
   Lauer ME, 2015, J BIOL CHEM, V290, P23124, DOI 10.1074/jbc.M115.663823
   Lauer ME, 2014, J BIOL CHEM, V289, P6791, DOI 10.1074/jbc.M113.512491
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111
   LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982
   Leow SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128973
   Lepelletier Y, 2010, STEM CELLS DEV, V19, P1075, DOI 10.1089/scd.2009.0212
   LEUNG KH, 1980, NATURE, V288, P597, DOI 10.1038/288597a0
   Lévesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289
   Li H, 2008, STEM CELLS, V26, P2531, DOI 10.1634/stemcells.2008 0146
   Li YP, 2008, J IMMUNOL, V180, P1598, DOI 10.4049/jimmunol.180.3.1598
   Ling GS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4039
   Liu GY, 2013, CYTOTHERAPY, V15, P1208, DOI 10.1016/j.jcyt.2013.05.011
   Liu W, 2013, THEOR APPL MECH LETT, V3, DOI [10.1186/2045 9912 3 3, 10.1063/2.1306201]
   Lu Y, 2015, BIOCHEM BIOPH RES CO, V464, P541, DOI 10.1016/j.bbrc.2015.07.002
   Machalinska A, 2013, INVEST OPHTH VIS SCI, V54, P8292, DOI 10.1167/iovs.13 12221
   MacKinnon AC, 2012, AM J RESP CRIT CARE, V185, P537, DOI 10.1164/rccm.201106 0965OC
   Maher D, 2004, LANCET, V363, P1911, DOI 10.1016/S0140 6736(04)16377 0
   Maione F, 2012, J CLIN INVEST, V122, P1832, DOI 10.1172/JCI58976
   Maione F, 2009, J CLIN INVEST, V119, P3356, DOI 10.1172/JCI36308
   Marigo I, 2011, SEMIN IMMUNOPATHOL, V33, P593, DOI 10.1007/s00281 011 0267 7
   Mathews S, 2014, J BIOMED MATER RES B, V102, P1825, DOI 10.1002/jbm.b.33152
   Mathieu ME, 2012, STEM CELL REV REP, V8, P1, DOI 10.1007/s12015 011 9261 7
   McGinley LM, 2013, HUM GENE THER, V24, P840, DOI 10.1089/hum.2011.009
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood 2003 11 3909
   Mohammadpour H, 2015, INT IMMUNOPHARMACOL, V28, P1009, DOI 10.1016/j.intimp.2015.07.045
   Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197
   Moretta L, 2002, MICROBES INFECT, V4, P1539, DOI 10.1016/S1286 4579(02)00037 0
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mu YL, 2014, INT J CLIN EXP MED, V7, P3843
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Nasef A, 2008, CELL IMMUNOL, V253, P16, DOI 10.1016/j.cellimm.2008.06.002
   Nemeth CL, 2014, TISSUE ENG PT A, V20, P2817, DOI [10.1089/ten.tea.2013.0614, 10.1089/ten.TEA.2013.0614]
   Németh K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Ng Tsz Kin, 2014, World J Stem Cells, V6, P111, DOI 10.4252/wjsc.v6.i2.111
   Niemeyer P, 2007, TISSUE ENG, V13, P111, DOI 10.1089/ten.2006.0114
   Niu J, 2014, CLIN EXP IMMUNOL, V176, P473, DOI 10.1111/cei.12283
   Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007 0737
   Oh JY, 2014, INVEST OPHTH VIS SCI, V55, P7628, DOI 10.1167/iovs.14 15424
   Oh JY, 2012, MOL THER, V20, P2143, DOI 10.1038/mt.2012.165
   Omoto M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14 15413
   Pan CK, 2013, EXPERT OPIN BIOL TH, V13, P1125, DOI 10.1517/14712598.2013.793304
   Pêche H, 2003, TRANSPLANTATION, V76, P1503, DOI 10.1097/01.TP.0000092494.75313.38
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Poitz DM, 2013, BBA MOL CELL RES, V1833, P3396, DOI 10.1016/j.bbamcr.2013.10.003
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074 7613(94)90093 0
   Qiao B, 2015, DRUG DES DEV THER, V9, P969, DOI 10.2147/DDDT.S77116
   Qin Y, 2015, CELL PHYSIOL BIOCHEM, V37, P117, DOI 10.1159/000430338
   Qu MM, 2015, BIOCHEM BIOPH RES CO, V466, P173, DOI 10.1016/j.bbrc.2015.08.125
   Qu XB, 2012, EXP HEMATOL, V40, P761, DOI 10.1016/j.exphem.2012.05.006
   Quittet MS, 2015, ACTA BIOMATER, V15, P77, DOI 10.1016/j.actbio.2014.12.017
   Rahman MJ, 2014, DIABETES, V63, P1008, DOI 10.2337/db13 0859
   Rasmusson I, 2005, EXP CELL RES, V305, P33, DOI 10.1016/j.yexcr.2004.12.013
   Reinshagen H, 2011, ACTA OPHTHALMOL, V89, P741, DOI 10.1111/j.1755 3768.2009.01812.x
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007
   Rosado MM, 2015, STEM CELLS DEV, V24, P93, DOI 10.1089/scd.2014.0155
   Sadhukha T, 2014, J CONTROL RELEASE, V196, P243, DOI 10.1016/j.jconrel.2014.10.015
   Schulze MSED, 2012, CURR OPIN IMMUNOL, V24, P105, DOI 10.1016/j.coi.2011.11.004
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140 6736(12)60028 2
   Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800
   Sesia SB, 2015, J CELL PHYSIOL, V230, P1258, DOI 10.1002/jcp.24861
   Shen HH, 2015, NANOMEDICINE UK, V10, P2093, DOI [10.2217/NNM.15.47, 10.2217/nnm.15.47]
   Sheng HM, 2008, CELL RES, V18, P846, DOI 10.1038/cr.2008.80
   Shi B, 2014, EXP BIOL MED, V239, P356, DOI 10.1177/1535370213517619
   Shi SJ, 2015, CELL BIOCHEM BIOPHYS, V71, P951, DOI 10.1007/s12013 014 0292 y
   Silverman AM, 2012, CANCER RES, V72, P2228, DOI 10.1158/0008 5472.CAN 11 2165
   Sioud M, 2010, SCAND J IMMUNOL, V71, P267, DOI 10.1111/j.1365 3083.2010.02378.x
   Sivanathan KN, 2014, STEM CELL REV REP, V10, P351, DOI 10.1007/s12015 014 9495 2
   Smith CL, 2015, STEM CELL TRANSL MED, V4, P239, DOI 10.5966/sctm.2014 0149
   Song XL, 2015, INFLAMMATION, V38, P485, DOI 10.1007/s10753 014 9954 6
   Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281 010 0234 8
   Teo GSL, 2015, STEM CELLS, V33, P265, DOI 10.1002/stem.1848
   Torihashi S, 2015, J BIOL CHEM, V290, P22771, DOI 10.1074/jbc.M114.629774
   Treacy O, 2014, AM J TRANSPLANT, V14, P2023, DOI 10.1111/ajt.12828
   Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Uccelli A, 2015, ANN NY ACAD SCI, V1351, P114, DOI 10.1111/nyas.12815
   van Poll D, 2008, HEPATOLOGY, V47, P1634, DOI 10.1002/hep.22236
   Veevers Lowe J, 2011, J CELL SCI, V124, P1288, DOI 10.1242/jcs.076935
   Wang CM, 2014, MOL MED REP, V10, P792, DOI 10.3892/mmr.2014.2236
   Wang HW, 2014, INT J MOL MED, V33, P263, DOI 10.3892/ijmm.2013.1572
   Wang JF, 2004, HAEMATOLOGICA, V89, P837
   Wang M, 2009, IMMUNOLOGY, V126, P220, DOI 10.1111/j.1365 2567.2008.02891.x
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Wang W, 2000, J BIOL CHEM, V275, P22313, DOI 10.1074/jbc.M001461200
   Wang YC, 2013, STEM CELL RES, V11, P721, DOI 10.1016/j.scr.2013.04.009
   Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088
   Wiesmann Anne, 2006, Head Face Med, V2, P8, DOI 10.1186/1746 160X 2 8
   Xie Minghao, 2015, Zhonghua Wei Chang Wai Ke Za Zhi, V18, P58
   Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129
   Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006
   Yagi H, 2010, CELL TRANSPLANT, V19, P823, DOI 10.3727/096368910X508942
   Yagi H, 2010, MOL THER, V18, P1857, DOI 10.1038/mt.2010.155
   Yan H, 2014, BIOCHEM BIOPH RES CO, V448, P212, DOI 10.1016/j.bbrc.2014.04.097
   Yanai A, 2012, CELL TRANSPLANT, V21, P1137, DOI 10.3727/096368911X627435
   Yang CJ, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/573528
   Ye J, 2006, EYE, V20, P482, DOI 10.1038/sj.eye.6701913
   Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001
   Zanier ER, 2015, J NEUROTRAUM, V32, P1
   Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051
   Zeng B, 2008, CELL BIOL INT, V32, P1256, DOI 10.1016/j.cellbi.2008.07.010
   Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479
   Zhang LY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886 015 0138 4
   Zhao J, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957 4484/25/40/405101
   Zhao ZG, 2012, IMMUNOL INVEST, V41, P183, DOI 10.3109/08820139.2011.607877
   Zhu H, 2006, STEM CELLS, V24, P928, DOI 10.1634/stemcells.2005 0186
NR 198
TC 57
Z9 67
U1 1
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1542 0124
EI 1937 5913
J9 OCUL SURF
JI Ocul. Surf.
PD APR
PY 2016
VL 14
IS 2
BP 121
EP 134
DI 10.1016/j.jtos.2015.11.004
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Ophthalmology
GA DK9AR
UT WOS:000375222400007
PM 26804815
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Della Fara, G
   Markovics, A
   Radice, S
   Hamilton, JL
   Chiesa, R
   Sturm, A
   Angenendt, K
   Fischer, A
   Wimmer, MA
AF Della Fara, Greta
   Markovics, Adrienn
   Radice, Simona
   Hamilton, John L.
   Chiesa, Roberto
   Sturm, Andreas
   Angenendt, Katja
   Fischer, Alfons
   Wimmer, Markus A.
TI Electrophoretic deposition of gentamicin and chitosan into titanium
   nanotubes to target periprosthetic joint infection
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE electrophoretic deposition; infection; nanotube; periprosthetic;
   titanium
ID TIO2 NANOTUBES; REVERSE POLARIZATION; GROWTH; ANODIZATION; PHOSPHORUS;
   DELIVERY; RELEASE; CALCIUM; ASSAY
AB Periprosthetic joint infection (PJI) occurs in 1% 2% of primary total hip and knee arthroplasties; the rate can reach 20% in individuals at risk. Due to the low local bioavailability of systemic antibiotics and possible off target effects, localized drug delivery systems are of great importance. Our aim was the electrophoretic deposition (EPD) of gentamicin and chitosan in Titanium (Ti) nanotubes to establish a local, prolonged antibiotic delivery. Nanotubes were created on Ti wire with a two step anodization process. For drug deposition, EPD and the air dry methods were compared. For a prolonged drug release, gentamicin and crosslinked chitosan were deposited in a two step EPD process. Drug release was quantified by fractional volume sampling. The Ti wires were tested against Staphylococcus aureus by agar dilution and liquid culture methods. MC3T3 E1 osteoblastic cell viability was determined with trypan blue. Nanotubes were characterized by a 100 nm diameter and 7 mu m length. EPD allowed a higher amount of gentamicin deposited than the air dry method. Drug deposition was controllable by adjusting the voltage and duration of the EPD process. The cross linked chitosan layer allowed diffusion driven release kinetics for up to 3 days. Gentamicin loaded Ti wires significantly inhibited bacterial growth and resulted in a larger inhibition zone compared to unloaded wires. Twenty four hours of incubation with loaded wires did not have a significant effect on osteoblast viability. Gentamicin loaded Ti nanotubes represent a promising approach for PJI prevention, as well as a valuable preclinical tool for the investigation of localized drug delivery systems created on Ti surface.
C1 [Della Fara, Greta; Markovics, Adrienn; Radice, Simona; Hamilton, John L.; Fischer, Alfons; Wimmer, Markus A.] Rush Univ, Dept Orthoped Surg, Med Ctr, Chicago, IL USA.
   [Chiesa, Roberto] Dept Chem Mat & Chem Engn Giulio Natta, Milan, Italy.
   [Sturm, Andreas; Angenendt, Katja; Fischer, Alfons] Max Planck Inst Eisenforschung GmbH, Dusseldorf, Germany.
   [Markovics, Adrienn] Rush Univ, Med Ctr, 1735 Harrison St, Chicago, IL 60612 USA.
C3 Rush University; Max Planck Society; Rush University
RP Markovics, A (通讯作者)，Rush Univ, Med Ctr, 1735 Harrison St, Chicago, IL 60612 USA.
EM adrienn_markovics@rush.edu
RI ; Roberto, Chiesa/AAV 6476 2021
OI Wimmer, Markus/0000 0001 6169 3873; 
FU Rush Arthritis and Orthopedics Institute
FX The work was supported by the Grainger Directorship of the Rush
   Arthritis and Orthopedics Institute (PI: MAW). This research did not
   receive any specific grant from funding agencies in the public,
   commercial, or not for profit sectors.
CR Allegranzi Benedetta, 2016, Lancet Infect Dis, V16, pe276, DOI 10.1016/S1473 3099(16)30398 X
   Alves SA, 2017, SURF COAT TECH, V324, P153, DOI 10.1016/j.surfcoat.2017.05.073
   Alves SA, 2017, APPL SURF SCI, V399, P682, DOI 10.1016/j.apsusc.2016.12.105
   Barth RE, 2011, INT J ANTIMICROB AG, V38, P371, DOI 10.1016/j.ijantimicag.2011.03.008
   Bernthal NM Stavrakis AI Billi F, PLOS ONE, V5, DOI [10.1371/journal.pone.0012580, DOI 10.1371/JOURNAL.PONE.0012580]
   Çaliskan N, 2014, MAT SCI ENG C MATER, V35, P100, DOI 10.1016/j.msec.2013.10.033
   Cheung RCF, 2015, MAR DRUGS, V13, P5156, DOI 10.3390/md13085156
   Cipriano AF, 2014, J BIOMED NANOTECHNOL, V10, P2977, DOI 10.1166/jbn.2014.1927
   Debmalya G Shahbazian Yassar R Shokuhfar T, J NANOTECH SMART MAT, V1
   Del Pozo JL, 2009, NEW ENGL J MED, V361, P787, DOI 10.1056/NEJMcp0905029
   Diebold U, 2003, APPL PHYS A MATER, V76, P681, DOI 10.1007/s00339 002 2004 5
   Ding P, 2007, INT J BIOL MACROMOL, V41, P125, DOI 10.1016/j.ijbiomac.2006.12.008
   Feng WC, 2016, MAT SCI ENG C MATER, V62, P105, DOI 10.1016/j.msec.2016.01.046
   Fingar KR (Truven Health Analytics) Stocks C (AHRQ) Weiss AJ (Truven Health Analytics) Steiner CA (AHRQ), STAT BRIEF 186 HEALT
   Frutos P, 2000, J PHARMACEUT BIOMED, V21, P1149, DOI 10.1016/S0731 7085(99)00192 2
   Geurts JAP, 2013, ACTA ORTHOP, V84, P509, DOI 10.3109/17453674.2013.858288
   Gulati K, 2015, J PHYS CHEM C, V119, P16033, DOI 10.1021/acs.jpcc.5b03383
   Gupta K Jabrail F, J APPL POLYM SCI, V104, DOI [10.1002/app.25881, DOI 10.1002/APP.25881]
   Hamilton JL, 2021, EUR CELLS MATER, V42, P122, DOI 10.22203/eCM.v042a09
   Heatley NG, 1944, BIOCHEM J, V38, P61, DOI 10.1042/bj0380061
   Izakovicova P, 2019, EFORT OPEN REV, V4, P482, DOI 10.1302/2058 5241.4.180092
   Jie K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223402
   Kaur M, 2019, MAT SCI ENG C MATER, V102, P844, DOI 10.1016/j.msec.2019.04.064
   Kelly MP, 2022, J ARTHROPLASTY, V37, pS989, DOI 10.1016/j.arth.2022.01.027
   Leta TH, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen 2020 041096
   Lin WT Tan HL Duan ZL, INT J NANOMED, V9, DOI [10.2147/IJN.S57875, DOI 10.2147/IJN.S57875]
   Mainardes RM, 2004, CURR DRUG TARGETS, V5, P449, DOI 10.2174/1389450043345407
   Martins AF, 2012, INT J BIOL MACROMOL, V51, P1127, DOI 10.1016/j.ijbiomac.2012.08.032
   Montanaro L, 2011, FUTURE MICROBIOL, V6, P1329, DOI [10.2217/FMB.11.117, 10.2217/fmb.11.117]
   Moriarty TF, 2016, EFORT OPEN REV, V1, P89, DOI 10.1302/2058 5241.1.000037
   Nie BE, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.01766 16, 10.1128/AAC.01766 16]
   Pal D., 2018, Polymers and Polymeric Composites: A Reference Series, P1
   Pawlik A, 2017, COLLOID SURFACE B, V152, P95, DOI 10.1016/j.colsurfb.2017.01.011
   Postler A, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 1977 y
   Regonini D, 2013, MAT SCI ENG R, V74, P377, DOI 10.1016/j.mser.2013.10.001
   Roy P, 2011, ANGEW CHEM INT EDIT, V50, P2904, DOI 10.1002/anie.201001374
   Shen J, 2017, MAT SCI ENG C MATER, V78, P589, DOI 10.1016/j.msec.2017.03.100
   Stavrakis AI, 2013, SCI WORLD J, DOI 10.1155/2013/925906
   Su EP, 2018, BONE JOINT J, V100B, P9, DOI 10.1302/0301 620X.100B1.BJJ 2017 0551.R1
   Tan TL, 2018, J BONE JOINT SURG AM, V100, P777, DOI 10.2106/JBJS.16.01435
   Tande AJ, 2014, CLIN MICROBIOL REV, V27, P302, DOI 10.1128/CMR.00111 13
   Thompson K Petkov S Zeiter S, PLOS ONE, V14, DOI [10.1371/journal.pone.0210402, DOI 10.1371/JOURNAL.PONE.0210402]
   Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521
   Zhang B, 2019, ACS APPL MATER INTER, V11, P28641, DOI 10.1021/acsami.9b07648
   Zhu Y, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11041028
NR 45
TC 3
Z9 3
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD SEP
PY 2023
VL 111
IS 9
BP 1697
EP 1704
DI 10.1002/jbm.b.35267
EA MAY 2023
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA K8RE7
UT WOS:000992260200001
PM 37194725
DA 2025 08 17
ER

PT J
AU Kaygusuz, MA
   Turan, CC
   Aydin, NE
   Temel, I
   Firat, S
   Bulut, T
   Kuku, I
AF Kaygusuz, M. Akif
   Turan, C. Cengiz
   Aydin, N. Engin
   Temel, Ismail
   Firat, Serpil
   Bulut, Taner
   Kuku, Irfan
TI The effects of G CSF and naproxen sodium on the serum TGF β1 level and
   fracture healing in rat tibias
SO LIFE SCIENCES
LA English
DT Article
DE fracture healing; TGF beta 1; G CSF; naproxen
ID COLONY STIMULATING FACTOR; GROWTH FACTOR BETA; HUMAN BONE MARROW;
   NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PERIPHERAL BLOOD; SPINAL FUSION;
   CELL TRANSPLANTATION; HEMATOPOIETIC STEM; TITANIUM IMPLANTS; CANCELLOUS
   BONE
AB Local and systemic release of transforming growth factor beta 1 (TGF beta 1) is known to increase during the process of fracture healing and this cytokine stimulates bone healing. The majority of the non steroidal anti inflammatory drugs (NSAIDs) inhibit fracture healing. Granulocyte colony stimulating factor (G CSF) is a hematopoietic growth factor that stimulates bone marrow. In this study, the effects of the NSAID naproxen sodium, G CSF, and both of them in combination on the TGF beta 1 serum level in rats with tibia fractures were measured and fracture healing was evaluated by histopathologic and radiologic examination. The TGF beta 1 serum levels obtained on day one (24 h after fracture but before administration of naproxen or G CSF) were found to be similar in all of the five groups (p > 0.05). At the end of the first week, TGF beta 1 levels were significantly lower in naproxen treated rats than those of the other groups excluding control (p=0.002). Similar changes in TGF beta 1 levels were found at the end of the second and fourth weeks. TGF beta 1 levels were significantly higher in G CSF treated rats at the end of the first, second and fourth weeks (p < 0.05). Fracture healing scores measured with histopathological and radiological methods were higher in G CSF treated rats than in naproxen treated ones. When both naproxen and G CSF were given, the scores resumed to normal. The results point to the negative effect of naproxen sodium on fracture healing is due to its decreasing effect on the level of TGF beta 1, which may be a new possible mechanism. Moreover, this negative effect can be inhibited by the use of G CSF. (c) 2006 Elsevier Inc. All rights reserved.
C1 Inonu Univ, Fac Med, Dept Orthoped, Malatya, Turkey.
   Inonu Univ, Fac Med, Dept Pathol, Malatya, Turkey.
   Inonu Univ, Fac Med, Dept Biochem, Malatya, Turkey.
   Inonu Univ, Fac Med, Dept Radiol, Malatya, Turkey.
   Inonu Univ, Fac Med, Dept Hematol, Malatya, Turkey.
C3 Inonu University; Inonu University; Inonu University; Inonu University;
   Inonu University
RP Kaygusuz, MA (通讯作者)，Inonu Univ, Fac Med, Dept Orthoped, Malatya, Turkey.
EM makaygusuz@inonu.edu.tr
RI AYDIN, Nasuhi/L 1607 2019; kuku, irfan/ABI 7233 2020; KUKU,
   IRFAN/ABI 7233 2020; AYDIN, Nasuhi/O 9043 2016
OI KUKU, IRFAN/0000 0001 6126 0816; AYDIN, Nasuhi/0000 0003 3145 2432
CR Adachi K, 2003, EXP TOXICOL PATHOL, V55, P21, DOI 10.1078/0940 2993 00297
   Ahmed N, 2001, CELL BIOL INT, V25, P429, DOI 10.1006/cbir.2000.0662
   ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   An YH, 1999, Animal Models in Orthopaedic Research, P204
   Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717
   Besse A, 2000, CYTOKINE, V12, P522, DOI 10.1006/cyto.1999.0580
   Bichara J, 1999, J PERIODONTOL, V70, P869, DOI 10.1902/jop.1999.70.8.869
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS116, DOI 10.1097/00003086 199810001 00013
   Bravenboer N, 2001, J ORTHOP RES, V19, P945, DOI 10.1016/S0736 0266(01)00026 2
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   COHEN AM, 1987, P NATL ACAD SCI USA, V84, P2484, DOI 10.1073/pnas.84.8.2484
   COOK SD, 1995, J ARTHROPLASTY, V10, P351, DOI 10.1016/S0883 5403(05)80184 6
   Corti S, 2002, EXP NEUROL, V177, P443, DOI 10.1006/exnr.2002.8004
   DEMETRI GD, 1991, BLOOD, V78, P2791
   Dimar JR, 1996, SPINE, V21, P1870, DOI 10.1097/00007632 199608150 00006
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Fixe P, 1997, EUR CYTOKINE NETW, V8, P91
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Hirayama Y, 2002, AM J HEMATOL, V69, P138, DOI 10.1002/ajh.10027
   HOGEVOLD HE, 1992, ACTA ORTHOP SCAND, V63, P607
   IBBOTSON KJ, 1989, J BONE MINER RES, V4, P37
   Inano H, 1998, AM J RESP CELL MOL, V19, P167, DOI 10.1165/ajrcmb.19.1.3089
   JOYCE ME, 1990, ORTHOP CLIN N AM, V21, P199
   KELLER JC, 1989, J ORTHOP RES, V7, P28, DOI 10.1002/jor.1100070105
   KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133
   LANE JM, 1987, ORTHOP CLIN N AM, V18, P213
   LANE N, 1990, J BONE MINER RES, V5, P1029
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   LIPSKY PE, 2001, AM J MED, V19, pS1
   Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623 200210000 00004
   MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813
   Natsu ume T, 1997, J ORTHOPAED RES, V15, P837, DOI 10.1002/jor.1100150608
   POJDA Z, 1990, EXP HEMATOL, V18, P1034
   Reuben SS, 2000, ANESTH ANALG, V91, P1221, DOI 10.1097/00000539 200011000 00032
   Riew KD, 2003, J BONE JOINT SURG AM, V85A, P632, DOI 10.2106/00004623 200304000 00007
   ROSEN D, 1994, BONE, V15, P355, DOI 10.1016/8756 3282(94)90300 X
   Rosier R.N., 1998, CLINORTHAND RELRES, V355, P294
   Schmidmaier G, 2002, BONE, V30, P816, DOI 10.1016/S8756 3282(02)00740 8
   Schmitz N, 1996, LANCET, V347, P353, DOI 10.1016/S0140 6736(96)90536 X
   Sciore P, 1998, J ORTHOPAED RES, V16, P429, DOI 10.1002/jor.1100160406
   Seidenberg AB, 2004, PHARMACOL RES, V50, P151, DOI 10.1016/j.phrs.2003.12.017
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   SUDMANN E, 1979, EUR J CLIN INVEST, V9, P333, DOI 10.1111/j.1365 2362.1979.tb00893.x
   TORNKVIST H, 1985, CLIN ORTHOP RELAT R, P264
   TRANCIK T, 1989, CLIN ORTHOP RELAT R, P113
   ULICH TR, 1988, AM J PATHOL, V133, P630
   VAUGHAN J, 1981, LANCET, V2, P133
   Yeung HY, 2002, LIFE SCI, V71, P67, DOI 10.1016/S0024 3205(02)01575 8
   Zhang H, 2003, BIOMATERIALS, V24, P2013, DOI 10.1016/S0142 9612(02)00616 6
NR 51
TC 12
Z9 15
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD DEC 3
PY 2006
VL 80
IS 1
BP 67
EP 73
DI 10.1016/j.lfs.2006.08.023
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 117IE
UT WOS:000242865800009
PM 17023006
DA 2025 08 17
ER

PT J
AU Gunn, NJ
   Kidd, SP
   Solomon, LB
   Yang, DQ
   Roscioli, E
   Atkins, GJ
AF Gunn, Nicholas J.
   Kidd, Stephen P.
   Solomon, Lucian B.
   Yang, Dongqing
   Roscioli, Eugene
   Atkins, Gerald J.
TI Staphylococcus aureus persistence in osteocytes: weathering the
   storm of antibiotics and autophagy/xenophagy
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE antibiotic; autophagy; host pathogen; osteocyte; rifampicin; vancomycin
   Staphylococcus aureus; persister cell
ID IMPLANT RETENTION; AUTOPHAGY; HOST; ELIMINATION; OSTEOBLASTS;
   DEBRIDEMENT; INFECTIONS; MANAGEMENT; RESISTANCE; INDUCTION
AB Staphylococcus aureus is a major causative pathogen of osteomyelitis. Intracellular infections of resident bone cells including osteocytes can persist despite gold standard clinical intervention. The mechanisms by which intracellular S. aureus evades antibiotic therapy are unknown. In this study, we utilised an in vitro S. aureus infection model of human osteocytes to investigate whether antibiotic mediated dysregulation of autophagy contributes to this phenomenon. Infected or non infected osteocyte like cells were exposed to combinations of rifampicin, vancomycin, and modulators of autophagy. Intracellular bacterial growth characteristics were assessed using colony forming unit (CFU) analysis, viable bacterial DNA abundance, and the rate of escape into antibiotic free medium, together with measures of autophagic flux. Rifampicin, alone or in combination with vancomycin, caused a rapid decrease in the culturability of intracellular bacteria, concomitant with stable or increased absolute bacterial DNA levels. Both antibiotics significantly inhibited autophagic flux. However, modulation of autophagic flux did not affect viable bacterial DNA levels. In summary, autophagy was shown to be a factor in the host pathogen relationship in this model, as its modulation affected the growth state of intracellular S. aureus with respect to both their culturability and propensity to escape the intracellular niche. While rifampicin and vancomycin treatments moderately suppressed autophagic flux acutely, this did not explain the paradoxical response of antibiotic treatment in decreasing S. aureus culturability whilst failing to clear bacterial DNA and hence intracellular bacterial load. Thus, off target effects of rifampicin and vancomycin on autophagic flux in osteocyte like cells could not explain the persistent S. aureus infection in these cells.
C1 [Gunn, Nicholas J.; Solomon, Lucian B.; Yang, Dongqing; Atkins, Gerald J.] Univ Adelaide, Fac Hlth & Med Sci, Ctr Orthopaed & Trauma Res, Biomed Orthopaed Res Grp, Adelaide, SA, Australia.
   [Kidd, Stephen P.] Univ Adelaide, Australian Ctr Antimicrobial Resistance Ecol, Adelaide, SA, Australia.
   [Kidd, Stephen P.] Univ Adelaide, Res Ctr Infect Dis, Sch Biol Sci, Adelaide, SA, Australia.
   [Solomon, Lucian B.] Royal Adelaide Hosp, Dept Orthopaed & Trauma, Adelaide, SA, Australia.
   [Roscioli, Eugene] Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA, Australia.
   [Roscioli, Eugene] Univ Adelaide, Fac Hlth & Med Sci, Dept Med, Adelaide, SA, Australia.
   [Roscioli, Eugene] South Australia SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
   [Roscioli, Eugene] Univ South Australia, Adelaide, SA, Australia.
C3 University of Adelaide; University of Adelaide; University of Adelaide;
   Royal Adelaide Hospital; Royal Adelaide Hospital; University of
   Adelaide; Centre for Cancer Biology; University of South Australia
RP Atkins, GJ (通讯作者)，Univ Adelaide, Fac Hlth & Med Sci, Ctr Orthopaed & Trauma Res, Biomed Orthopaed Res Grp, Adelaide, SA, Australia.; Roscioli, E (通讯作者)，Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA, Australia.; Roscioli, E (通讯作者)，Univ Adelaide, Fac Hlth & Med Sci, Dept Med, Adelaide, SA, Australia.; Roscioli, E (通讯作者)，South Australia SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.; Roscioli, E (通讯作者)，Univ South Australia, Adelaide, SA, Australia.
EM Eugene.Roscioli@adelaide.edu.au; Gerald.Atkins@adelaide.edu.au
RI Kidd, Stephen/H 8799 2012; Yang, Dongqing/L 6373 2018
FU Australian Postgraduate Award; Royal Adelaide Research Committee; Royal
   Adelaide Hospital Research Fund; Health Services Charitable Gifts Board;
   Rebecca L Cooper Medical Research Foundation; National Health and
   Medical Research Council of Australia (NHMRC) [2011042]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. NG was supported by an
   Australian Postgraduate Award. ER received support from The Royal
   Adelaide Research Committee, Royal Adelaide Hospital Research Fund, The
   Health Services Charitable Gifts Board, and the Rebecca L Cooper Medical
   Research Foundation. This work was supported by funding to GA, DY, and
   LS from the National Health and Medical Research Council of Australia
   (NHMRC, Grant ID 2011042).
CR Ayrapetyan M, 2018, J BACTERIOL, V200, DOI 10.1128/JB.00249 18
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bosse MJ, 2005, J BONE JOINT SURG AM, V87A, P1343, DOI 10.2106/JBJS.D.02649
   Browning S, 2022, J BONE JOINT INFECT, V7, P203, DOI 10.5194/jbji 7 203 2022
   Bui LMG, 2017, ESSAYS BIOCHEM, V61, P71, DOI 10.1042/EBC20160061
   Day CW, 2022, J CLIN MED, V11, DOI 10.3390/jcm11010122
   Fraunholz M, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00043
   Geng N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00746
   Gunn NJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.781022
   Ha YE, 2015, J ANTIBIOT, V68, P76, DOI 10.1038/ja.2014.112
   Jensen LK, 2023, APMIS, V131, P325, DOI 10.1111/apm.13312
   Kim YJ, 2017, SCI REP UK, V7, DOI 10.1038/srep41356
   King JS, 2012, AUTOPHAGY, V8, P1159, DOI 10.4161/auto.20527
   Kunutsor SK, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0151537, 10.1371/journal.pone.0150866]
   Loos B, 2014, AUTOPHAGY, V10, P2087, DOI 10.4161/15548627.2014.973338
   Malahias MA, 2020, J ARTHROPLASTY, V35, P1154, DOI 10.1016/j.arth.2019.11.026
   Mao K, 2017, AUTOPHAGY, V13, P223, DOI 10.1080/15548627.2016.1267075
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   Mingeot Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P1003, DOI 10.1128/AAC.43.5.1003
   Mitchell G, 2017, CELL HOST MICROBE, V22, P166, DOI 10.1016/j.chom.2017.07.005
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Neumann Y, 2016, AUTOPHAGY, V12, P2069, DOI 10.1080/15548627.2016.1226732
   Nyfeler B, 2012, METHODS MOL BIOL, V821, P239, DOI 10.1007/978 1 61779 430 8_14
   Pais GM, 2020, PHARMACOTHERAPY, V40, P438, DOI 10.1002/phar.2388
   Pantosti A, 2007, FUTURE MICROBIOL, V2, P323, DOI 10.2217/17460913.2.3.323
   Park IH, 2008, IMMUNOPHARM IMMUNOT, V30, P837, DOI [10.1080/08923970802135732, 10.1080/08923970802135732 ]
   Poh WP, 2020, INT J CHRONIC OBSTR, V15, P1253, DOI 10.2147/COPD.S245819
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Riebisch AK, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020110
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rybak MJ, 2009, CLIN INFECT DIS, V49, P325, DOI 10.1086/600877
   Schnaith A, 2007, J BIOL CHEM, V282, P2695, DOI 10.1074/jbc.M609784200
   Sun Q., 2023, eLife, V13, pRP93698, DOI [10.1101/2023.11.21.568051, DOI 10.1101/2023.11.21.568051]
   Tande AJ, 2014, CLIN MICROBIOL REV, V27, P302, DOI 10.1128/CMR.00111 13
   Tsang STJ, 2017, BONE JOINT J, V99B, P1458, DOI [10.1302/0301 620X.99B11.BJJ 2017 0088.R1, 10.1302/0301 620x.99b11.bjj 2017 0088.r1]
   Tu YX, 2022, AUTOPHAGY, V18, P1174, DOI 10.1080/15548627.2021.1965711
   Tuchscherr L, 2016, J ANTIMICROB CHEMOTH, V71, P438, DOI 10.1093/jac/dkv371
   Urish KL, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00932 19
   Wang R, 2021, J DAIRY RES, V88, P293, DOI 10.1017/S0022029921000649
   Yang DQ, 2018, MBIO, V9, DOI 10.1128/mBio.00415 18
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Zelmer AR, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00227 8
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
NR 43
TC 2
Z9 2
U1 2
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2235 2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD JUN 10
PY 2024
VL 14
AR 1403289
DI 10.3389/fcimb.2024.1403289
PG 13
WC Immunology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Microbiology
GA WC5T7
UT WOS:001252690100001
PM 38915921
OA gold
DA 2025 08 17
ER

PT J
AU Raobaikady, B
   Day, JM
   Purohit, A
   Potter, BVL
   Reed, MJ
AF Raobaikady, B
   Day, JM
   Purohit, A
   Potter, BVL
   Reed, MJ
TI The nature of inhibition of steroid sulphatase activity by tibolone and
   its metabolites
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 16th International Symposium of the
   Journal of Steroid Biochemistry and Molecular Biology
CY JUN 05 08, 2004
CL Seefeld, AUSTRIA
SP Journal Steroid Biochem & Mol Biol, Inst Rech Pierre Fabre
DE menopause; hormone replacement therapy; tibolone; steroid; sulphatase
ID HORMONE DEPENDENT MCF 7; BREAST CANCER CELLS; ORG OD14 LIVIAL(R);
   ESTRONE SULFATASE; SULFOTRANSFERASE ACTIVITY; POSTMENOPAUSAL WOMEN;
   TISSUE; T 47D
AB Tibolone is used for hormone replacement therapy and acts in a tissue specific manner being oestrogenic on CNS and bone but not on breast tissues or endometrium. The ability of tibolone and its metabolites to inhibit steroid sulphatase (STS) activity has a crucial role in regulating its tissue specific effects. In this study, we have examined the ability of tibolone and its non sulphated and sulphated metabolites to inhibit STS activity in different enzyme preparations and in intact cells. For this, we have used an 'extracellular' method, which measures the amount of product released into culture medium, and an 'intracellular' method, which assesses the extent of product formation within cells. In addition, the nature by which tibolone and some of its metabolites inhibit STS activity was investigated using intact cells and an enzyme kinetic method. In MCF 7 and T47D breast cancer cells and JEG 3 choriocarcinoma cells, which have high STS activity, tibolone and its metabolites were relatively potent inhibitors of STS activity (33 57% inhibition at 10 mu M) using the extracellular assay method. In HOS TE 85 osteoblast like cells, tibolone and its Delta 4 metabolite were relatively inactive whereas the 3 alpha/3 beta hydroxy metabolites and their sulphated conjugates inhibited activity by 39 55%. When STS activity was assessed in HOS TE 85 cells using an 'intracellular' method tibolone and its 3 beta hydroxy metabolite were inactive. Pre treatment of breast cancer cells and JEG 3 cells, and removal of drugs prior to assaying for STS activity, revealed that in these cells tibolone and its metabolites were acting mainly as reversible inhibitors. This finding was confirmed in an enzyme kinetic study to measure concentration dependent STS inhibition. In HOS TE 85 cells, pre treatment of cells and removal of compounds before assaying for remaining STS activity indicated that some tibolone metabolites appeared to stimulate STS activity. Possible mechanisms by which this might occur are discussed but, if confirmed, this could contribute to the positive oestrogenic effects that tibolone has on bone. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ London Imperial Coll Sci Technol & Med, Fac Med, St Marys Hosp, London W2 1NY, England.
   Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.
C3 Imperial College London; University of Bath
RP Univ London Imperial Coll Sci Technol & Med, Fac Med, St Marys Hosp, Mint Wing,2nd Floor, London W2 1NY, England.
EM b.malini@imperial.ac.uk
RI Potter, Barry/AAX 4781 2020
CR Albertazzi P, 1998, MATURITAS, V30, P295, DOI 10.1016/S0378 5122(98)00059 0
   [Anonymous], J BR MENOPAUSE SOC
   BONNEY RC, 1983, CLIN ENDOCRINOL, V19, P727, DOI 10.1111/j.1365 2265.1983.tb00051.x
   Chetrite G, 1997, ANTICANCER RES, V17, P135
   Chetrite GS, 1999, ANTICANCER RES, V19, P269
   Chetrite GS, 1999, ANTICANCER RES, V19, P261
   de Gooyer ME, 2001, MOL CELL ENDOCRINOL, V183, P55, DOI 10.1016/S0303 7207(01)00606 2
   DELBRESSINE L, 2000, PROG ENDO, P396
   DESREUX J, IN PRESS EFFECTS TIB
   DUNCAN L, 1993, CANCER RES, V53, P298
   Falany JL, 2004, J STEROID BIOCHEM, V88, P383, DOI 10.1016/j.jsbmb.2004.01.005
   HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043 2760(05)80018 9
   HOWARTH NM, 1994, J MED CHEM, V37, P219, DOI 10.1021/jm00028a002
   Kloosterboer HJ, 2001, J STEROID BIOCHEM, V76, P231, DOI 10.1016/S0960 0760(01)00044 9
   MARKIEWICZ L, 1990, J STEROID BIOCHEM, V35, P535, DOI 10.1016/0022 4731(90)90196 Y
   Miki Y, 2002, J CLIN ENDOCR METAB, V87, P5760, DOI 10.1210/jc.2002 020670
   Miyoshi Y, 2003, CLIN CANCER RES, V9, P2288
   Modelska K, 2002, J CLIN ENDOCR METAB, V87, P16, DOI 10.1210/jc.87.1.16
   Moore RA, 1999, BRIT J OBSTET GYNAEC, V106, P1
   Nakata T, 2003, J STEROID BIOCHEM, V86, P455, DOI 10.1016/S0960 0760(03)00357 1
   PUROHIT A, 1995, BIOCHEMISTRY US, V34, P11508, DOI 10.1021/bi00036a025
   Purohit A, 2002, HORM METAB RES, V34, P1, DOI 10.1055/s 2002 19958
   PUROHIT A, 1992, INT J CANCER, V50, P901, DOI 10.1002/ijc.2910500614
   Raeside JI, 2000, BIOCHEM BIOPH RES CO, V273, P505, DOI 10.1006/bbrc.2000.2984
   Reed MJ, 2004, MATURITAS, V48, pS18, DOI 10.1016/j.maturitas.2004.03.007
   Reed MJ, 2004, MATURITAS, V48, pS4, DOI 10.1016/j.maturitas.2004.02.013
   Reed MJ, 1996, ENDOCR RELAT CANCER, V3, P9, DOI 10.1677/erc.0.0030009
   TANG BG, 1993, J STEROID BIOCHEM, V45, P345, DOI 10.1016/0960 0760(93)90003 F
   Valdivia I, 2000, CLIN DRUG INVEST, V20, P101, DOI 10.2165/00044011 200020020 00005
NR 29
TC 12
Z9 14
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD FEB
PY 2005
VL 94
IS 1 3
BP 229
EP 237
DI 10.1016/j.jsbmb.2005.01.021
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 930VP
UT WOS:000229445500026
PM 15862970
DA 2025 08 17
ER

PT J
AU Dai, ZX
   Xie, J
   Lei, PF
   Hu, YH
AF Dai, Zixun
   Xie, Jie
   Lei, Pengfei
   Hu, Yihe
TI 被撤回的出版物: Knockdown of PREX2a inhibits the malignant phenotype of
   osteosarcoma cells (Retracted Article)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE phosphatidylinositol 3,4,5 trisphosphate dependent Rac exchange factor
   2a; osteosarcoma; phosphoinositide 3 kinase; phosphatase and tensin
   homolog deleted on chromosome ten
ID EXCHANGE FACTOR; PI3K/AKT/MTOR PATHWAY; PTEN INHIBITION; CANCER; P REX2;
   INVASION; RAC; PROGRESSION; MIGRATION; THERAPY
AB Phosphatidylinositol 3,4,5 trisphosphate dependent Rac exchange factor 2a (PREX2a), which is a regulator of the small guanosine triphosphatase Rac, has recently been reported to have an oncogenic role via the suppression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) activity, and the subsequent activation of phosphoinositide 3 kinase (PI3K) signaling. However, the detailed role of PREX2a in osteosarcoma (OS) remains unclear. Reverse transcription quantitative polymerase chain reaction and western blotting was used to detect mRNA and protein levels. MTT assay was performed to examine cell proliferation and a Transwell assay and wound healing assay were conducted to examine cell invasion and migration. The present study demonstrated that PREX2a was markedly upregulated in OS cell lines, as compared with in normal osteoblast hFOB1.19 cells. In addition, knockdown of PREX2a expression significantly inhibited OS cell proliferation, whereas overexpression of PREX2a markedly promoted OS cell proliferation. Inhibition of PREX2a also markedly suppressed the invasion and migration of OS cells, at least partly by suppressing the protein expression of matrix metalloproteinase (MMP)2 and MMP9. Conversely, upregulation of PREX2a enhanced OS cell invasion and migration. In addition, PI3K signaling activity was significantly reduced following knockdown of PREX2a, and this was accompanied by an upregulation of PTEN activity. The results of the present study suggested that PREX2a may act as an oncogene in OS via the inhibition of PTEN activity and activation of PI3K signaling.
C1 [Dai, Zixun; Xie, Jie; Lei, Pengfei; Hu, Yihe] Cent S Univ, Xiangya Hosp, Dept Orthoped, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Hu, YH (通讯作者)，Cent S Univ, Xiangya Hosp, Dept Orthoped, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM csuhuyihe@163.com
RI Lei, Peng/NES 1162 2025
FU Fundamental Research Funds for the Central Universities of Central South
   University [2013zzts092]
FX The present study was supported by the Fundamental Research Funds for
   the Central Universities of Central South University (grant no.
   2013zzts092).
CR Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071
   Braccini L., 2012, Advances in Biological Regulation, V52, P389, DOI 10.1016/j.jbior.2012.04.002
   Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280 012 2043 3
   Chen X, 2013, FEBS LETT, V587, P3729, DOI 10.1016/j.febslet.2013.09.044
   Chueh FS, 2014, ENVIRON TOXICOL, V29, P21, DOI 10.1002/tox.20769
   Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096
   Donald S, 2008, P NATL ACAD SCI USA, V105, P4483, DOI 10.1073/pnas.0712324105
   Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257
   Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Guo B, 2014, MOL CANCER RES, V12, P313, DOI 10.1158/1541 7786.MCR 13 0507
   Hodakoski C, 2014, P NATL ACAD SCI USA, V111, P155, DOI 10.1073/pnas.1213773111
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   Leslie NR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.294pe68
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Pandiella A, 2013, CLIN CANCER RES, V19, P4564, DOI 10.1158/1078 0432.CCR 12 1662
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   PosthumaDeBoer J, 2011, CLIN EXP METASTAS, V28, P493, DOI 10.1007/s10585 011 9384 x
   Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30
   Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097
   Thompson LDR, 2013, ENT EAR NOSE THROAT, V92, P288
   Wang JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096571
   Wu P, 2010, CURR MED CHEM, V17, P4326, DOI 10.2174/092986710793361234
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Yang L, 2015, INT J ONCOL, V46, P1651, DOI 10.3892/ijo.2015.2872
NR 27
TC 1
Z9 2
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2016
VL 13
IS 2
BP 1930
EP 1936
DI 10.3892/mmr.2015.4728
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DC9PO
UT WOS:000369553700116
PM 26718453
OA Bronze
DA 2025 08 17
ER

PT J
AU Rosário, F
   Hoet, P
   Nogueira, AJA
   Santos, C
   Oliveira, H
AF Rosario, Fernanda
   Hoet, Peter
   Arsenia Nogueira, Antonio Jose
   Santos, Conceicao
   Oliveira, Helena
TI Differential pulmonary in vitro toxicity of two small sized
   polyvinylpyrrolidone coated silver nanoparticles
SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH PART A CURRENT ISSUES
LA English
DT Article
ID ALVEOLAR EPITHELIAL CELLS; OSTEOBLAST LIKE CELLS; GENE EXPRESSION;
   PARTICLE SIZE; A549 CELLS; GENOTOXICITY; CYTOTOXICITY; LINE; ASSAY; LUNG
AB Silver nanoparticles (AgNP), with their important properties, are being used in a range of sectors from industry to medicine, leading to increased human exposure. Hence, their toxicity potential needs to be comprehensively evaluated. It was postulated that within small sized (20nm) polyvinylpyrrolidone coated silver nanoparticles (PVP AgNP), minor size differences may significantly induce different toxicity profiles and involve varying cellular pathways. Therefore, the aim of this study was to examine the influence of differing size AgNP with 10nm (AgNP10) and 20nm (AgNP20) (up to 100 mu g/ml), as well as to ionic silver as AgNO3 for 24 and 48h, using the human lung cell line A549. The effects on cell viability, proliferation, apoptosis, DNA damage and cell cycle dynamics were assessed. Results for both time periods showed that for low concentrations (<5 mu g/ml), AgNP20 were more cytotoxic than AgNP10, however, at higher doses, AgNP10 exhibited higher toxicity. For concentrations >50 mu g/ml, AgNP10 induced severe DNA damage (comet class 3 4), cell cycle arrest at G(2) phase and late stage apoptosis, while AgNP20 induced cell cycle arrest at S phase and an increase in the percentage sub G(1,) which did not recover after 48h, and late stage apoptosis/necrosis. In longer term exposures, the greater impairment in colony formation due to AgNP exposure than to silver ion supports that nanotoxicity is not exclusively due to the released ion. Data suggest that toxicity mediated by small AgNP (20nm) in lung cells is not only dependent on the level of particle internalization, but also on AgNP size and concentration, which may involve varying pathways as targets.
C1 [Rosario, Fernanda; Arsenia Nogueira, Antonio Jose; Oliveira, Helena] Univ Aveiro, Dept Biol, Aveiro, Portugal.
   [Rosario, Fernanda; Arsenia Nogueira, Antonio Jose; Oliveira, Helena] Univ Aveiro, CESAM, Aveiro, Portugal.
   [Hoet, Peter] Katholieke Univ Leuven, Occupat & Environm Toxicol, Leuven, Belgium.
   [Santos, Conceicao] Univ Porto, Dept Biol, Fac Sci, Porto, Portugal.
   [Oliveira, Helena] Univ Aveiro, CICECO Aveiro Inst Mat, Aveiro, Portugal.
C3 Universidade de Aveiro; Universidade de Aveiro; KU Leuven; Universidade
   do Porto; Universidade de Aveiro
RP Oliveira, H (通讯作者)，Univ Aveiro, Dept Biol, Aveiro, Portugal.; Oliveira, H (通讯作者)，Univ Aveiro, CESAM, Aveiro, Portugal.; Santos, C (通讯作者)，Univ Porto, Dept Biol, Fac Sci, Porto, Portugal.; Oliveira, H (通讯作者)，Univ Aveiro, CICECO Aveiro Inst Mat, Aveiro, Portugal.
EM csantos@fc.up.pt; holiveira@ua.pt
RI Nogueira, Antonio/A 7314 2008; Oliveira, Helena/M 5068 2013; Arsénia
   Nogueira, António José/A 7314 2008; Hoet, Peter/H 9987 2013; Rosário,
   Fernanda/O 9978 2016; Santos, Conceição/ABE 6172 2020
OI Nogueira, Antonio/0000 0001 7089 2508; Oliveira,
   Helena/0000 0002 4673 0696; Hoet, Peter/0000 0002 0292 6603; Rosario,
   Fernanda/0000 0002 1269 8915; 
FU Fundacao para a Ciencia e a Tecnologia [CESAM] [UID/AMB/50017,
   PTDC/AAC AMB/113649, SFRH/BD/91270/2012, SFRH/BPD/111736/2015]; Fundação
   para a Ciência e a Tecnologia [SFRH/BD/91270/2012, SFRH/BPD/111736/2015]
   Funding Source: FCT
FX This work was supported by the Fundacao para a Ciencia e a Tecnologia
   [CESAM (UID/AMB/50017), PTDC/AAC AMB/113649, SFRH/BD/91270/2012,
   SFRH/BPD/111736/2015]
CR Anderson DS, 2015, TOXICOL SCI, V144, P366, DOI 10.1093/toxsci/kfv005
   Williams D., 2006, European Commission Health and Consumer Protection, V246, P79
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Bastos V, 2016, J NANOPART RES, V18, DOI 10.1007/s11051 016 3515 x
   Bastos V, 2016, TOXICOL LETT, V249, P29, DOI 10.1016/j.toxlet.2016.03.005
   Beer C, 2012, TOXICOL LETT, V208, P286, DOI 10.1016/j.toxlet.2011.11.002
   Brzóska K, 2015, MUTAGENESIS, V30, P431, DOI 10.1093/mutage/gev001
   Bunderson Schelvan M, 2017, J TOXICOL ENV HEAL B, V20, P230, DOI 10.1080/10937404.2017.1305924
   Chairuangkitti P, 2013, TOXICOL IN VITRO, V27, P330, DOI 10.1016/j.tiv.2012.08.021
   Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098 2280(1997)30:2<139::AID EM6>3.0.CO;2 I
   COLLINS AR, 1995, MUTAT RES DNA REPAIR, V336, P69, DOI 10.1016/0921 8777(94)00043 6
   De Marzi L, 2013, INT J MOL SCI, V14, P3065, DOI 10.3390/ijms14023065
   Drake PL, 2005, ANN OCCUP HYG, V49, P575, DOI 10.1093/annhyg/mei019
   El Badawy AM, 2012, SCI TOTAL ENVIRON, V429, P325, DOI 10.1016/j.scitotenv.2012.03.041
   Fenech M, 2000, MUTAT RES FUND MOL M, V455, P81, DOI 10.1016/S0027 5107(00)00065 8
   Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77
   Foldbjerg R, 2012, TOXICOL SCI, V130, P145, DOI 10.1093/toxsci/kfs225
   Foldbjerg R, 2011, ARCH TOXICOL, V85, P743, DOI 10.1007/s00204 010 0545 5
   Foster KA, 1998, EXP CELL RES, V243, P359, DOI 10.1006/excr.1998.4172
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Gangwal S, 2011, ENVIRON HEALTH PERSP, V119, P1539, DOI 10.1289/ehp.1103750
   Gliga AR, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743 8977 11 11
   Guo XQ, 2016, NANOTOXICOLOGY, V10, P1373, DOI 10.1080/17435390.2016.1214764
   Haberl N, 2013, BEILSTEIN J NANOTECH, V4, P933, DOI 10.3762/bjnano.4.105
   Herzog F, 2014, BEILSTEIN J NANOTECH, V5, P1357, DOI 10.3762/bjnano.5.149
   Carneiro MFH, 2016, J TOXICOL ENV HEAL B, V19, P129, DOI 10.1080/10937404.2016.1168762
   Kaur J, 2013, FOOD CHEM TOXICOL, V51, P1, DOI 10.1016/j.fct.2012.08.044
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Kaweeteerawat C, 2017, J TOXICOL ENV HEAL A, V80, P1276, DOI 10.1080/15287394.2017.1376727
   Kermanizadeh A, 2016, J TOXICOL ENV HEAL B, V19, P1, DOI 10.1080/10937404.2015.1126210
   Kvítek L, 2008, J PHYS CHEM C, V112, P5825, DOI 10.1021/jp711616v
   Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200
   Lee YK, 2015, INT J NANOMED, V10, P97, DOI 10.2147/IJN.S72998
   Lee YS, 2011, ARCH TOXICOL, V85, P1529, DOI 10.1007/s00204 011 0714 1
   Lévesque M, 2008, TOXICOL APPL PHARM, V231, P308, DOI 10.1016/j.taap.2008.04.016
   Li JD, 2012, J BIOMAT SCI POLYM E, V23, P81, DOI 10.1163/092050610X543159
   Lim Hui Kheng, 2012, Frontiers in Genetics, V3, P104, DOI 10.3389/fgene.2012.00104
   Liu JY, 2010, ENVIRON SCI TECHNOL, V44, P2169, DOI 10.1021/es9035557
   Liu W, 2010, NANOTOXICOLOGY, V4, P319, DOI 10.3109/17435390.2010.483745
   Martins AD Jr, 2017, J TOXICOL ENV HEAL A, V80, P1156, DOI 10.1080/15287394.2017.1357376
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Nymark P, 2013, TOXICOLOGY, V313, P38, DOI 10.1016/j.tox.2012.09.014
   Oberdörster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Oliveira H, 2014, MUTAT RES GEN TOX EN, V775, P38, DOI 10.1016/j.mrgentox.2014.10.002
   Reshma SC, 2016, COLLOID SURFACE B, V140, P104, DOI 10.1016/j.colsurfb.2015.12.030
   Rosário F, 2016, TOXICOLOGY, V368, P103, DOI 10.1016/j.tox.2016.08.020
   Sahu SC, 2014, J APPL TOXICOL, V34, P1155, DOI 10.1002/jat.2994
   SHAPIRO DL, 1978, BIOCHIM BIOPHYS ACTA, V530, P197, DOI 10.1016/0005 2760(78)90005 X
   Singh N, 2009, BIOMATERIALS, V30, P3891, DOI 10.1016/j.biomaterials.2009.04.009
   Suzuki H, 2007, ENVIRON SCI TECHNOL, V41, P3018, DOI 10.1021/es0625632
   Tejamaya M, 2012, ENVIRON SCI TECHNOL, V46, P7011, DOI 10.1021/es2038596
   Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098 2280(2000)35:3<206::AID EM8>3.0.CO;2 J
   Treuel L, 2015, BEILSTEIN J NANOTECH, V6, P857, DOI 10.3762/bjnano.6.88
   U. S EPA, 2010, 505F10008 US EPA
   Vance ME, 2015, BEILSTEIN J NANOTECH, V6, P1769, DOI 10.3762/bjnano.6.181
   Xin LL, 2016, ENVIRON TOXICOL, V31, P1691, DOI 10.1002/tox.22171
   Zhang F, 2015, J APPL TOXICOL, V35, P1114, DOI 10.1002/jat.3138
NR 57
TC 16
Z9 18
U1 1
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1528 7394
EI 1087 2620
J9 J TOXICOL ENV HEAL A
JI J. Toxicol. Env. Health Part A
PY 2018
VL 81
IS 15
BP 675
EP 690
DI 10.1080/15287394.2018.1468837
PG 16
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA GL7BN
UT WOS:000437350100001
PM 29939837
DA 2025 08 17
ER

PT J
AU Capeci, CM
   Tejwani, NC
AF Capeci, Craig M.
   Tejwani, Nirmal C.
TI Bilateral Low Energy Simultaneous or Sequential Femoral Fractures in
   Patients on Long Term Alendronate Therapy
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article
ID SUPPRESSED BONE TURNOVER; SHAFT FRACTURES; MICRODAMAGE ACCUMULATION;
   POSTMENOPAUSAL WOMEN; BIOMECHANICAL PROPERTIES; INTERVENTION TRIAL;
   RANDOMIZED TRIAL; MINERAL DENSITY; OSTEOPOROSIS; BISPHOSPHONATES
AB Background: While alendronate therapy has been shown to decrease the risk of vertebral and femoral neck fractures in postmenopausal osteoporotic patients, recent reports have associated long term alendronate therapy with unilateral low energy subtrochanteric and diaphyseal femoral fractures in a small number of patients. To our knowledge, there has been only one report of sequential bilateral femoral fractures in patients on long term bisphosphonate therapy.
   Methods: We retrospectively reviewed the case log of the senior author over the last four years to identify patients who presented with a subtrochanteric or diaphyseal femoral fracture after a low energy mechanism of injury (a fall from standing height or less) and who had been taking alendronate for more than five years. Radiographs were reviewed, and the fracture patterns were recorded. Serum calcium levels were recorded when available.
   Results: Seven patients who sustained low energy bilateral subtrochanteric or diaphyseal femoral fractures while on long term alendronate therapy were identified. One patient presented with simultaneous bilateral diaphyseal fractures, two patients had sequential subtrochanteric fractures, and four patients had impending contralateral subtrochanteric stress fractures noted at the time of the initial fracture. Of the latter four, one patient had a fracture through the stress site and the other three patients had prophylactic stabilization of the site with internal fixation. No patient had discontinued alendronate therapy prior to the second fracture. All patients were women with an average age of sixty one years, and they had been on alendronate therapy for an average of 8.6 years. All fractures were treated with reamed intramedullary nailing and went on to union at an average of four months.
   Conclusions: In patients on long term alendronate therapy who present with a subtrochanteric or diaphyseal femoral fracture, we recommend radiographs of the contralateral femur and consideration of discontinuing alendronate in consultation with an endocrinologist. If a contralateral stress fracture is found, prophylactic fixation should be considered.
C1 [Capeci, Craig M.; Tejwani, Nirmal C.] NYU, Hosp Joint Dis, Dept Orthopaed Surg, New York, NY 10003 USA.
C3 NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York
   University
RP Capeci, CM (通讯作者)，NYU, Hosp Joint Dis, Dept Orthopaed Surg, 301 E 17th St,Suite 1401, New York, NY 10003 USA.
EM craig.capeci@nyumc.org; nirmal.tejwani@nyumc.org
OI Tejwani, Nirmal/0000 0001 8578 6556
CR [Anonymous], 1998, Hong Kong Med J, V4, P423
   [Anonymous], MULL AO CLASS FRACT
   [Anonymous], DRUGS FDA
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Cheung Ralph K. H., 2007, Hong Kong Medical Journal, V13, P485
   Ciarelli TE, 2003, BONE, V32, P311, DOI 10.1016/S8756 3282(02)00975 4
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Kane RS, 2005, J TRAUMA, V58, P395, DOI 10.1097/01.TA.0000071300.11359.FF
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nork SE, 2003, CLIN ORTHOP RELAT R, P272, DOI 10.1097/01.blo.0000093919.26658.23
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   Stepan JJ, 2007, BONE, V41, P378, DOI 10.1016/j.bone.2007.04.198
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   WU CC, 1992, J TRAUMA, V32, P289, DOI 10.1097/00005373 199203000 00004
NR 24
TC 167
Z9 179
U1 0
U2 3
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021 9355
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD NOV
PY 2009
VL 91A
IS 11
BP 2556
EP 2561
DI 10.2106/JBJS.H.01774
PG 6
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 518DZ
UT WOS:000271671800004
PM 19884427
DA 2025 08 17
ER

PT J
AU Lin, CC
   Chao, PY
   Shen, CY
   Shu, JJ
   Yen, SK
   Huang, CY
   Liu, JY
AF Lin, Chien Chung
   Chao, Pei Yu
   Shen, Chia Yao
   Shu, Jyuan Jen
   Yen, Shiow Kang
   Huang, Chih Yang
   Liu, Jer Yuh
TI Novel Target Genes Responsive to Apoptotic Activity by Ocimum
   gratissimum in Human Osteosarcoma Cells
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Osteosarcoma; Ocimum gratissimum; Apoptosis
ID PROGNOSTIC FACTORS; CANCER CELLS; GROWTH; IDENTIFICATION; GADD34;
   ACTIVATION; INHIBITION; OVEREXPRESSION; SUPPRESSION; SURVIVAL
AB Osteosarcoma (OS) is a type of bone cancer. Eighty percent of this tumor will metastasize to the lungs or liver, and as a result, patients generally need chemotherapy to improve survival possibility. Recently, antitumor activity has been reported in Ocimum gratissimum aqueous extract (OGE), which has been the focus of recent extensive studies on therapeutic strategies due to its antioxidant properties. We performed pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2 OS and HOS cell growth. Cell viability, Western blot and flow cytometry analysis were performed before performing pharmacogenomics analyses for the effect of OGE on human osteosarcoma U2 OS and HOS cell growth, including cDNA microarray and RT PCR assays. Cell viability assays revealed that OGE significantly and dose dependently decreased the viability of U2 OS and HOS cells. Increases in cell shrinkage, Sub G1 fragments and the activation of caspase 3 indicated that OGE induced cell apoptosis in U2 OS and HOS cells. There was no change in human osteoblast hFOS cells. cDNA microarray assay demonstrated that the expression of cell cycle regulators, apoptosis related factors and cell proliferation markers were all modified by OGE treatment. RT PCR analysis also confirmed the down regulation of SKA2 and BUB1B, and the up regulation of PPP1R15A, SQSTM1, HSPA1B, and DDIT4 by OGE treatment. The finding of anticancer activity in OGE and the identification of some potential target genes raise the expectation that OGE may become a useful therapeutic drug for human OS.
C1 [Lin, Chien Chung; Yen, Shiow Kang] Natl Chung Hsing Univ, Dept Mat Sci & Engn, Taichung 40227, Taiwan.
   [Lin, Chien Chung] Armed Forces Gen Hosp, Dept Orthopaed, Taichung, Taiwan.
   [Chao, Pei Yu] Natl Chin Yi Univ Technol, Dept Leisure Ind Management, Taichung, Taiwan.
   [Chao, Pei Yu; Huang, Chih Yang] China Med Univ, Grad Inst Basic Med Sci, Taichung 40402, Taiwan.
   [Huang, Chih Yang] China Med Univ, Grad Inst Chinese Med Sci, Taichung 40402, Taiwan.
   [Liu, Jer Yuh] China Med Univ, Grad Inst Canc Biol, Taichung 40402, Taiwan.
   [Shen, Chia Yao] MeiHo Univ, Dept Nursing, Pingtung, Taiwan.
   [Shu, Jyuan Jen; Liu, Jer Yuh] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan.
   [Huang, Chih Yang] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
C3 National Chung Hsing University; National Chin Yi University of
   Technology; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Hospital   Taiwan; Asia University
   Taiwan
RP Liu, JY (通讯作者)，China Med Univ, Grad Inst Canc Biol, Coll Med, 9F Canc Ctr Bldg,6 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM skyen@dragon.nchu.edu.tw; cyhuang@mail.cmu.edu.tw; jyl@mail.cmu.edu.tw
RI ; Liu, Yu/F 7469 2019; chao, P/GSD 8001 2022; Huang, Kevin
   Chih Yang/Q 4862 2016
OI Huang, Chih Yang/0000 0003 2347 0411; 
FU National Science Council, Republic of China [NSC 99 2632 B 039 001 MY3,
   NSC 102 2320 B 039 049, NSC102 2911 I 002 303];  [CMU98 asia 12]
FX The authors thank Dr. Edwin L. Cooper for reading the paper and making
   suggestions. This work was supported by grants from the National Science
   Council, Republic of China (NSC 99 2632 B 039 001 MY3, NSC
   102 2320 B 039 049 and NSC102 2911 I 002 303) and in part by the
   (CMU98 asia 12), Taiwan, Republic of China. Conceived and designed the
   experiments: Jer Yuh Liu. Performed the experiments: Chia Yao Shen,
   Chien Chung Lin, and Jyuan Jen Shu. Analyzed the data: Chih Yang Huang.
   Contributed reagents/materials/analysis tools: Jer Yuh Liu. Wrote the
   paper: Chien Chung Lin. Provided additional technical assistance and
   contributed to interpretation of the data: Shiow Kang Yen and Pei Yu
   Chao.
CR Abdelfadil E, 2013, AM J CHINESE MED, V41, P683, DOI 10.1142/S0192415X1350047X
   Adler HT, 1999, MOL CELL BIOL, V19, P7050
   Aguiyi JC, 2000, FITOTERAPIA, V71, P444, DOI 10.1016/S0367 326X(00)00143 X
   Ayisi NK, 2003, ANTIVIR RES, V58, P25, DOI 10.1016/S0166 3542(02)00166 3
   Aziba PI, 1999, PHYTOTHER RES, V13, P427, DOI 10.1002/(SICI)1099 1573(199908/09)13:5<427::AID PTR467>3.0.CO;2 T
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Chang HC, 2014, CHINESE J PHYSIOL, V57, P41, DOI 10.4077/CJP.2014.BAB147
   Chen H.M., 2011, EVID BASED COMPL ALT, V2011
   Daigeler A, 2010, ULTRASOUND MED BIOL, V36, P1893, DOI 10.1016/j.ultrasmedbio.2010.08.009
   Detjen KM, 2000, J CELL SCI, V113, P3025
   Ellisen LW, 2005, CELL CYCLE, V4, P1500, DOI 10.4161/cc.4.11.2139
   Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097 2765(02)00706 2
   FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196
   Gehrmann M, 2006, CURR OPIN INVESTIG D, V7, P574
   George S, 2009, J MED FOOD, V12, P1154, DOI 10.1089/jmf.2008.0066
   Hanisch A, 2006, EMBO J, V25, P5504, DOI 10.1038/sj.emboj.7601426
   Hollander MC, 2001, CANCER RES, V61, P2487
   Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097 0215(20010220)96:1<22::AID IJC3>3.0.CO;2 K
   Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567
   Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731
   Hu WS, 2013, AM J CHINESE MED, V41, P1125, DOI 10.1142/S0192415X13500766
   Hwang JM, 2012, AM J CHINESE MED, V40, P1063, DOI [10.1142/s0192415x12500784, 10.1142/S0192415X12500784]
   Ilori MO, 1996, J DIARRHOEAL DIS RES, V14, P283
   Knowles LM, 2008, J BIOL CHEM, V283, P31378, DOI 10.1074/jbc.M803384200
   Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Lamy E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053240
   Lee MJ, 2011, EVID BASED COMPL ALT, V2011, DOI 10.1155/2011/578060
   Li PC, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/139045
   LIN CC, 1995, INT J PHARMACOGN, V33, P139, DOI 10.3109/13880209509055214
   Lisse TS, 2011, FASEB J, V25, P937, DOI 10.1096/fj.10 172577
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823
   Nakatsu N, 2005, MOL CANCER THER, V4, P399
   Nangia Makker P, 2007, INT J CANCER, V121, P884, DOI 10.1002/ijc.22733
   Nangia Makker P, 2013, CANCER BIOL THER, V14, P417, DOI 10.4161/cbt.23762
   Petrilli AS, 2006, J CLIN ONCOL, V24, P1161, DOI 10.1200/JCO.2005.03.5352
   Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107
   Poon Kein Boon, 2004, Kaohsiung Journal of Medical Sciences, V20, P230, DOI 10.1016/S1607 551X(09)70111 1
   Rice L, 2008, J ENDOCRINOL, V198, P499, DOI 10.1677/JOE 08 0019
   Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283 2293.2002
   Stiller CA, 2000, BRIT J CANCER, V82, P1339, DOI 10.1054/bjoc.1999.1101
   Tabuchi Y, 2007, CANCER LETT, V246, P149, DOI 10.1016/j.canlet.2006.02.011
   Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1
   Wan XL, 2012, CANCER RES, V72, P5889, DOI 10.1158/0008 5472.CAN 12 1991
   Wu PK, 2009, JPN J CLIN ONCOL, V39, P514, DOI 10.1093/jjco/hyp057
   Wu TT, 2008, J CELL BIOCHEM, V103, P9, DOI 10.1002/jcb.21378
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Zhang YB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.77
NR 50
TC 34
Z9 36
U1 0
U2 5
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2014
VL 42
IS 3
BP 743
EP 767
DI 10.1142/S0192415X14500487
PG 25
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA AI5SD
UT WOS:000336928500016
PM 24871663
DA 2025 08 17
ER

PT J
AU Ibrahim, NI
   Mohamed, N
   Soelaiman, IN
   Shuid, AN
AF Ibrahim, Nurul 'Izzah
   Mohamed, Norazlina
   Soelaiman, Ima Nirwana
   Shuid, Ahmad Nazrun
TI The Effects of Targeted Deliveries of Lovastatin and Tocotrienol on
   Ossification Related Gene Expressions in Fracture Healing in an
   Osteoporosis Rat Model
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE osteoporotic fracture healing; lovastatin; tocotrienol; targeted
   delivery; fracture healing genes
ID BONE MORPHOGENETIC PROTEINS; ENDOTHELIAL GROWTH FACTOR; MESSENGER RNA;
   ESTROGEN; STATINS; SIMVASTATIN; OSTEOBLAST; RALOXIFENE; DEGRADATION;
   ALENDRONATE
AB Osteoporotic drugs are used to prevent fragility fractures, but their role in fracture healing still remains unknown. Thus, alternative agents with suitable mode of delivery are needed to promote fracture healing. This study was performed to investigate the effects of direct deliveries of lovastatin and tocotrienol to fracture sites on ossification related gene expression in fracture healing in a postmenopausal osteoporosis model. Forty eight Sprague Dawley female rats were divided into six groups. Group I comprised the sham operated rats, while Groups II VI were ovariectomized rats. After 8 weeks, the right tibiae of all rats were fractured and stabilized. Group I and Group II were given two single injections of lovastatin and tocotrienol carriers. Group III was given an estrogen preparation at 64.5 mu g/kg daily via oral gavages. Group IV was injected with lovastatin particles (750 mu g/kg), while Group V was injected with tocotrienol particles (60 mg/kg). Group VI received two single injections of 750 mu g/kg lovastatin particles and 60 mg/kg tocotrienol particles. After 4 weeks, the gene expressions were measured. Group VI showed significantly higher gene expressions of osteocalcin, BMP 2, VEGF , and RUNX 2 compared to Group II. In conclusion, combined treatment of lovastatin and tocotrienol upregulated the expression of genes related to fracture healing.
C1 [Ibrahim, Nurul 'Izzah; Mohamed, Norazlina; Soelaiman, Ima Nirwana; Shuid, Ahmad Nazrun] Univ Kebangsaan Malaysia, Med Ctr, Fac Med, Dept Pharmacol, Kuala Lumpur 56000, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Shuid, AN (通讯作者)，Univ Kebangsaan Malaysia, Med Ctr, Fac Med, Dept Pharmacol, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.
EM nurulizzah88@gmail.com; azlina@ppukm.ukm.edu.my;
   imasoel@ppukm.ukm.edu.my; anazrun@yahoo.com
RI Mohamed, Norazlina/M 7306 2017; Ibrahim, Nurul/X 7167 2019; SHUID,
   AHMAD/AAS 7556 2020; Soelaiman, Ima/C 4289 2017
OI shuid, ahmad nazrun/0000 0003 3526 990X; 
FU Universiti Kebangsaan Malaysia (UKM); Ministry of Higher Education
   [ERGS/1/2012/SKK03/UKM/02/1]
FX The authors would like to thank the Universiti Kebangsaan Malaysia
   (UKM), the Ministry of Higher Education for the grant
   (ERGS/1/2012/SKK03/UKM/02/1) and the Pharmacology Department staffs for
   their technical support. We would also like to acknowledge American
   River Nutrition Inc. for supplying annatto tocotrienol.
CR Abdul Majeed S, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/960742
   Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Alegre DN, 2012, RHEUMATOL INT, V32, P439, DOI 10.1007/s00296 010 1687 8
   [Anonymous], 2010, CLIN GUID PREV TREAT
   BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287
   Bushra Rabia, 2011, Oman Med J, V26, P77, DOI 10.5001/omj.2011.21
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   CHEN JK, 1992, J BONE MINER RES, V7, P987
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   CORRELL CC, 1994, J BIOL CHEM, V269, P633
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Dogan E, 2002, POSTGRAD MED J, V78, P727, DOI 10.1136/pmj.78.926.727
   Doll Bruce, 2008, P39, DOI 10.1007/978 1 59745 239 7_3
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Estai MA, 2011, CLINICS, V66, P2113, DOI 10.1590/S1807 59322011001200018
   Fuentes I, 1998, MED CLIN BARCELONA, V111, P700
   FUERST T, 1995, EUR J RADIOL, V20, P188, DOI 10.1016/0720 048X(95)00650 F
   Goebel S, 2009, J ORTHOP RES, V27, P1141, DOI 10.1002/jor.20857
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Guyton JR, 2006, AM J CARDIOL, V97, p95C, DOI 10.1016/j.amjcard.2005.12.016
   Hagihara M, 2011, J BIOL CHEM, V286, P5157, DOI 10.1074/jbc.M110.180919
   Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165 6147(97)01147 4
   Hatano Hiroshi, 2003, J Orthop Sci, V8, P842, DOI 10.1007/s00776 003 0724 9
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Horiuchi N, 2006, ORAL DIS, V12, P85, DOI 10.1111/j.1601 0825.2005.01172.x
   Ibrahim NI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115595
   Ibrahim NI, 2013, CURR DRUG TARGETS, V14, P1524, DOI 10.2174/13894501113149990195
   Jacobson RH, 1997, JAMA J AM MED ASSOC, V277, P296, DOI 10.1001/jama.277.4.296
   JINGUSHI S, 1992, J BONE MINER RES, V7, P1045
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jorgensen Niklas R, 2011, Curr Osteoporos Rep, V9, P149, DOI 10.1007/s11914 011 0065 0
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Meyer R A, 2001, BMC Musculoskelet Disord, V2, P2, DOI 10.1186/1471 2474 2 2
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 1996, CLIN ORTHOP RELAT R, P24, DOI 10.1097/00003086 199603000 00004
   Njeh CF, 1997, OSTEOPOROSIS INT, V7, P7, DOI 10.1007/BF01623454
   Packer L, 2001, J NUTR, V131, p369S, DOI 10.1093/jn/131.2.369S
   PARKER RA, 1993, J BIOL CHEM, V268, P11230
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pisani P, 2013, WORLD J RADIOL, V5, P398, DOI 10.4329/wjr.v5.i11.398
   Sarahrudi K, 2009, J ORTHOP RES, V27, P1293, DOI 10.1002/jor.20906
   Sato M, 1996, J PHARMACOL EXP THER, V279, P298
   Schmid GJ, 2009, DEV DYNAM, V238, P766, DOI 10.1002/dvdy.21882
   Seraman S, 2010, FOOD BIOPROD PROCESS, V88, P266, DOI 10.1016/j.fbp.2010.01.006
   Sfeir C, 2005, BONE REGENERATION AND REPAIR: BIOLOGY AND CLINICAL APPLICATIONS, P21, DOI 10.1385/1 59259 863 3:021
   Shaik M.R., 2012, International Journal of Pharma Sciences, V2, P112, DOI DOI 10.1016/j.jconrel.2004.04.023
   Sharlina M., 2012, EVID BASED COMPL ALT, V2012, DOI [10.1155/2012/372878, DOI 10.1155/2012/372878]
   Shuid AN, 2013, CURR DRUG TARGETS, V14, P1558, DOI 10.2174/1389450114666131108153905
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Song BL, 2006, J BIOL CHEM, V281, P25054, DOI 10.1074/jbc.M605575200
   Stuermer EK, 2010, LANGENBECK ARCH SURG, V395, P163, DOI 10.1007/s00423 008 0436 x
   TAN B, 2010, TOCOTRIENOLS NEW VIT
   Trimpou P, 2010, EUR J RADIOL, V73, P360, DOI 10.1016/j.ejrad.2008.11.024
   Tsartsalis AN, 2012, HORM INT J ENDOCRINO, V11, P126, DOI 10.14310/horm.2002.1339
   Tsiridis E, 2007, INJURY, V38, pS11, DOI 10.1016/j.injury.2007.02.006
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   YAO KL, 1994, J BONE MINER RES, V9, P231
NR 60
TC 15
Z9 17
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2015
VL 12
IS 10
BP 12958
EP 12976
DI 10.3390/ijerph121012958
PG 19
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA CX1RE
UT WOS:000365472500061
PM 26501302
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Fregnani, ER
   Perez, DED
   de Almeida, OP
   Fonseca, FP
   Soares, FA
   Castro, G
   Alves, FA
AF Fregnani, Eduardo R.
   da Cruz Perez, Danyel E.
   de Almeida, Oslei Paes
   Fonseca, Felipe Paiva
   Soares, Fernando A.
   Castro Junior, Gilberto
   Alves, Fabio A.
TI BRAF V600E expression correlates with ameloblastoma aggressiveness
SO HISTOPATHOLOGY
LA English
DT Article
DE ameloblastoma; BRAF; mitogen activated protein kinase; odontogenic
   tumours
ID ODONTOGENIC TUMORS; PROTEIN PTHRP; MUTATIONS; CARCINOMA; GENE
AB Aims: The aim of this study was to investigate whether the expression of BRAF V600E determines an aggressive clinical and molecular presentation of ameloblastoma.
   Methods and results: Ninety three cases of solid ameloblastomas were arranged in a 1.0 mm tissue microarray (TMA) block. Immunohistochemistry against a large panel of cytokeratins (CK), epidermal growth factor receptor (EGFR), parathyroid hormone related peptide (PTHrP), syndecan 1, Ki67, p53 and BRAF V600E were performed. Clinicopathological parameters, including sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic pattern, vestibular/lingual and basal cortical plates disruption and follow up data, were obtained from patients' medical records. Immuno expression of BRAF V600E was investigated in 73 cases that remained available in TMA sections. Our results indicated that 46.6% (34 cases) demonstrated cytoplasm positivity (six weak and 28 strong positivity). BRAF V600E expression was associated significantly with the expression of CK8 (P = 0.00077), CK16 (P = 0.05), PTHrP (P = 0.0082) and p53 (P = 0.0087). Additionally, a significant association was seen with the presence of recurrences (P = 0.0008), multilocular radiographic appearance (P = 0.044) and disruption of basal bone cortical (P = 0.05). Univariate analysis showed that BRAF positive cases (P = 0.001), EGFR negative/weak positive cases (P = 0.03) and multilocular tumours (P = 0.04) had a significantly lower disease free survival rate, but these parameters were not considered independent prognostic factors in the multivariate analysis (P > 0.05).
   Conclusions: Our findings suggest an association of BRAF V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm.
C1 [Fregnani, Eduardo R.] Sirio Libanes Hosp, Dept Oral Med, Dona Adma Jafet St,115 Bela Vista, BR 01308050 Sao Paulo, SP, Brazil.
   [da Cruz Perez, Danyel E.] Univ Fed Pernambuco, Sch Dent, Oral Pathol, Recife, PE, Brazil.
   [de Almeida, Oslei Paes; Fonseca, Felipe Paiva] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Piracicaba, SP, Brazil.
   [Soares, Fernando A.] Univ Sao Paulo, Fac Med, AC Camargo Canc Ctr, Dept Pathol, BR 05508 Sao Paulo, Brazil.
   [Castro Junior, Gilberto] Univ Sao Paulo, Fac Med, Clin Oncol, Inst Canc Estado Sao Paulo, BR 05508 Sao Paulo, Brazil.
   [Alves, Fabio A.] AC Camargo Canc Ctr, Dept Oral Med, Sao Paulo, Brazil.
C3 Universidade Federal de Pernambuco; Universidade Estadual de Campinas;
   A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade de
   Sao Paulo; A.C.Camargo Cancer Center
RP Fregnani, ER (通讯作者)，Sirio Libanes Hosp, Dept Oral Med, Dona Adma Jafet St,115 Bela Vista, BR 01308050 Sao Paulo, SP, Brazil.
EM eduardofregnani@me.com
RI Fregnani, Eduardo/AAM 4482 2020; Rodrigues Fregnani,
   Eduardo/I 4453 2013; Almeida, Oslei/GOV 5820 2022; de Castro Junior,
   Gilberto/C 1627 2013; da Cruz Perez, Danyel/G 5429 2012; Alves,
   Fabio/B 7892 2011; Soares, Fernando/HLV 7984 2023; Perez,
   Danyel/G 5429 2012; Fonseca, Felipe/C 4158 2012
OI Rodrigues Fregnani, Eduardo/0000 0001 5196 7631; Soares,
   Fernando/0000 0002 1212 9093; Soares, Fernando
   Augusto/0000 0003 1647 7842; de Castro Junior,
   Gilberto/0000 0001 8765 3044; Perez, Danyel/0000 0002 4591 4645;
   Fonseca, Felipe/0000 0002 6657 4547
FU Sao Paulo State Research Foundation (FAPESP/Brazil)
FX This research was supported by grants from the Sao Paulo State Research
   Foundation (FAPESP/Brazil).
CR Abdelsayed RA, 2004, ORAL SURG ORAL MED O, V97, P208, DOI 10.1016/j.tripleo.2003.10.003
   [Anonymous], 2005, World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours
   Brown Noah A, 2015, Biomark Cancer, V7, P19, DOI 10.4137/BIC.S29329
   Brown NA, 2014, CLIN CANCER RES, V20, P5517, DOI 10.1158/1078 0432.CCR 14 1069
   Brunner P, 2015, ORAL ONCOL, V51, pE77, DOI 10.1016/j.oraloncology.2015.07.010
   Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401 011 0841 z
   Castro MAF, 2007, ORL J OTO RHIN LARYN, V69, P146, DOI 10.1159/000099223
   Diniz MG, 2015, TUMOR BIOL, V36, P5649, DOI 10.1007/s13277 015 3238 0
   Fonseca FP, 2016, OR SURG OR MED OR PA, V121, pE154, DOI 10.1016/j.oooo.2015.09.021
   Fregnani ER, 2010, INT J ORAL MAX SURG, V39, P145, DOI 10.1016/j.ijom.2009.11.022
   Heikinheimo K, 2015, J DENT RES, V94, P237, DOI 10.1177/0022034514560373
   Kaye FJ, 2015, JNCI J NATL CANCER I, V107, P1
   Kennedy WR, 2016, EUR ARCH OTO RHINO L, V273, P3293, DOI 10.1007/s00405 016 3899 3
   Kitkumthorn N, 2010, ORAL DIS, V16, P631, DOI 10.1111/j.1601 0825.2010.01664.x
   Kumamoto H, 2004, J ORAL PATHOL MED, V33, P360, DOI 10.1111/j.1600 0714.2004.00141.x
   Kumamoto H, 2004, J ORAL PATHOL MED, V33, P46, DOI 10.1111/j.1600 0714.2004.00204.x
   Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317
   Neves Silva R, 2016, J ORAL PATHOL MED, V45, P704, DOI 10.1111/jop.12428
   Nobusawa A, 2014, OR SURG OR MED OR PA, V118, pE146, DOI 10.1016/j.oooo.2014.03.021
   Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986
   Tan S, 2016, OR SURG OR MED OR PA, V122, pE5, DOI 10.1016/j.oooo.2015.12.016
NR 21
TC 62
Z9 64
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0309 0167
EI 1365 2559
J9 HISTOPATHOLOGY
JI Histopathology
PD FEB
PY 2017
VL 70
IS 3
BP 473
EP 484
DI 10.1111/his.13095
PG 12
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Pathology
GA EM0CG
UT WOS:000394985800015
PM 27681305
DA 2025 08 17
ER

PT J
AU Waller, SB
   Canuto, FJC
   Costa, PPC
   Cavalcanti, EANLD
   Cavalcanti, GAD
   Vasconcelos, M
   Cleff, MB
AF Waller, Stefanie Bressan
   Correia Canuto, Francisco Jucelio
   Correia Costa, Paula Priscila
   Louzada Dias Cavalcanti, Eduarda Alexia Nunes
   Cavalcanti, Guilherme Albuquerque de Oliveira
   Vasconcelos, Marcio
   Cleff, Marlete Brum
TI Maxillomandibular Deformity in a Canine with Fibrous Osteodystrophy
   Secondary to Chronic Kidney Disease
SO ACTA SCIENTIAE VETERINARIAE
LA English
DT Article
DE hyperparathyroidism; chronic renal failure; fibrous osteodystrophy;
   rubber jaw; parathyroid hormone; calcium/phosphorus ratio
ID DOGS; HYPERPARATHYROIDISM; DISORDERS; CALCIUM; BONE
AB Background: Cases of renal fibrous osteodystrophy are usually associated with nutritional causes, which of renal causes are considered uncommon in dogs. This disorder is characterized by the intense proliferation of fibrous connective tissue in bones, impairing bone stiffness. The aim of this study was to report a case of fibrous osteodystrophy secondary to chronic kidney disease in a canine with a "rubber jaw" facial deformity.
   Case: A 4 year old male unneutered mongrel dog weighing 5.2 kg had a history of apathy, progressive weight loss and vomiting for one month, and polyuria and polydipsia for more than three months. In addition, the owner complained about the deformed appearance in the muzzle region of the animal, which was evidenced flexibility of the same, with a displacement of the mandible and maxilla on physical examination, similar to the "rubber jaw". Blood tests revealed macrocytic anemia, elevated total plasma proteins, and lymphopenia associated neutrophilia, as well as hyperphosphatemia (24 mg/dL), uremia (283.6 mg/dL) and increased creatinine (8.6 mg/dL), ALT (143.2 UI/L) and alkaline phosphatase (3222.2 UI/L), while calcium (8.8 mg/dL) and albumin (1.9 g/dL) were decreased. A serological test for visceral leishmaniasis was also performed, which was negative. Abdominal ultrasound imaging revealed kidneys with alterations in tissue architecture, increased thickness and complete loss of cortico medullary relationship, while the parathyroid gland was enlarged and spindle shaped. Cranial radiography showed marked radiopacity of the bilateral maxillary bones, with destruction of the nasal, turbinate and frontal bones, as well as loosening of the teeth and destruction of the mandibular bone matrix, characterizing an aspect of "rubber jaw". Based on the history, history and evidence of azotemia, hyperphosphatemia and loss of facial bone density, the diagnosis of fibrous osteodystrophy secondary to chronic kidney disease associated with hyperparathyroidism was concluded.
   Discussion: The clinical and laboratory findings reported in the present study were similar to those described in dogs with renal fibrous osteodystrophy associated with hyperparathyroidism. In the presence of azotemia, the patient was in stage 4 of chronic kidney disease which, despite investigating the infectious etiology, which was negative, remained unknown. Along with chronic kidney disease, the observation of hyperphosphatemia associated with hypokalemia contributed to the clinical investigation, whose pathophysiological mechanisms of this disorder were discussed in this study. The organic alterations observed in the patient's imaging examination coincided with the pathophysiological processes of renal fibrous osteodystrophy. The findings of renal and parathyroid alterations on ultrasound, as well as the damage to the bone matrix, maxillomandibular deformity and loss of bone support evidenced on cranial radiography, led to the conclusion of the diagnosis of renal fibrous osteodystrophy secondary to hyperparathyroidism. Despite the recommended symptomatic therapy, the patient died within 24 hours of hospitalization, and it was not possible to perform a necropsy. This report is highlighted by the occurrence of bone deformity at the maxillary and mandibular level, as a result of renal dysfunction in a young canine, alerting to the importance of complementary exams for proper diagnosis.
C1 [Waller, Stefanie Bressan; Correia Costa, Paula Priscila; Louzada Dias Cavalcanti, Eduarda Alexia Nunes; Cavalcanti, Guilherme Albuquerque de Oliveira; Cleff, Marlete Brum] Univ Fed Pelotas TPel, Fac Vet, Dept Clin Vet, Pelotas, RS, Brazil.
   [Correia Canuto, Francisco Jucelio; Vasconcelos, Marcio] MV Autonomo, Fortaleza, CE, Brazil.
RP Costa, PPC (通讯作者)，UFPeI, Dept Clin Vet, Ave Eliseu Maciel S N, BR 96160000 Capao Do Leao, RS, Brazil.
EM paulapriscilamv@yahoo.com.br
CR Alves Marcelo A. M. K., 2014, Revista Portuguesa de Ciencias Veterinarias, V109, P51
   Bartges JW, 2012, VET CLIN N AM SMALL, V42, P669, DOI 10.1016/j.cvsm.2012.04.008
   Becker N, 2012, TIERAERZTL PRAX K H, V40, P135
   Brachthäuser L, 2013, TIERAERZTL PRAX K H, V41, P198
   Clark SD, 2019, VET PATHOL, V56, P93, DOI 10.1177/0300985818806050
   Coelho F.S., 2013, CIENCIAS AGRARIAS SA, V9, P82
   Davis EM, 2015, J VET DENT, V32, P87, DOI 10.1177/089875641503200202
   Dittmer KE, 2017, RES VET SCI, V114, P348, DOI 10.1016/j.rvsc.2017.06.013
   Ditzel B.M., 2017, REV ELETRONICA BIOCI, V18, P76
   Elliot J, 2019, Treatment of Vomiting, Nausea and Inappetence in Cats with Chronic Kidney Disease
   Foster JD, 2016, VET CLIN N AM SMALL, V46, P1131, DOI 10.1016/j.cvsm.2016.06.003
   Fraser WD, 2009, LANCET, V374, P145, DOI 10.1016/S0140 6736(09)60507 9
   FREITAS R.A., 2017, BRAZILIAN J VET MED, V39, P215
   IRIS, 2017, IRIS STAG CKD
   Meuten D, 2015, Hematologia e Bioquimica Clinica Veterinaria, V2nd, P689
   Moe SM, 2008, PRIMARY CARE, V35, P215, DOI 10.1016/j.pop.2008.01.007
   Polzin DJ, 2011, NEPHROLOGY AND UROLOGY OF SMALL ANIMALS, P433
   Rusenov A., 2009, Bulgarian Journal of Veterinary Medicine, V12, P212
   Silver J, 2013, NAT REV NEPHROL, V9, P641, DOI 10.1038/nrneph.2013.147
   Thrall MA, 2015, HEMATOLOGIA BIOQUIMI
   Yamamoto S, 2017, J NEPHROL, V30, P623, DOI 10.1007/s40620 017 0406 x
NR 21
TC 1
Z9 1
U1 0
U2 2
PU UNIV FED RIO GRANDE DO SUL
PI PORTO ALEGRE RS
PA FAC VET, CAIXA POSTAL 15017, PORTO ALEGRE RS, 91501 570, BRAZIL
SN 1678 0345
EI 1679 9216
J9 ACTA SCI VET
JI Acta Sci. Vet.
PY 2019
VL 47
SU 1
AR 463
DI 10.22456/1679 9216.98346
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA KI1LX
UT WOS:000511110100112
OA gold
DA 2025 08 17
ER

PT J
AU Upho, N
   Tangtrakulwanich, B
   Pripatnanont, P
   Thitiwongsawet, P
   Ingviya, N
AF Upho, Nisalak
   Tangtrakulwanich, Boonsin
   Pripatnanont, Prisana
   Thitiwongsawet, Patcharaporn
   Ingviya, Natnicha
TI Development of Novel PHBV/PCL and BCP Composite for Musculoskeletal
   Infection: an In Vitro Vancomycin Release and Anti MRSA Effect
SO JOURNAL OF PHARMACEUTICAL INNOVATION
LA English
DT Article
DE Vancomycin; In vitro drug release; Physicochemical characteristics;
   PHBV/PCL and BCP composite; MRSA osteomyelitis
ID CALCIUM PHOSPHATE CERAMICS; SCAFFOLDS; DELIVERY; MICROSPHERES;
   DOXYCYCLINE
AB Antibiotic loaded polymethylmethacrylate has been conventionally used for osteomyelitis treatment, but it requires a second operation for removal. This study aimed to develop and examine the properties of a novel vancomycin loaded composite fabricated from biodegradable poly(epsilon caprolactone)/poly(hydroxybutyrate co hydroxyvalerate)/biphasic calcium phosphate (PCL/PHBV/BCP) for chronic methicillin resistant Staphylococcus aureus (MRSA) osteomyelitis.
   The drug loaded composite was developed using a solvent casting method and fabricated into four formulations: FV1, FV2, FV3, and FV4. The physicochemical characteristics and osteoblast biocompatibility were evaluated. In addition, the drug release profile and anti MRSA activity were examined.
   Vancomycin conserved its antibiotic property and did not form any interactions with the raw materials. A loading efficiency of more than 80 % was achieved with all formulations. FV2, FV3, and FV4 demonstrated cumulative release of more than 90 % over a couple of months. The bactericidal property was assessed to confirm the efficacy of the released vancomycin, and all composites showed antibacterial effects over 28 days. The release kinetics were best fitted with the Korsmeyer Peppas model, and Fickian diffusion was the main transport mechanism. A cytotoxicity test was also performed, and all formulations showed more than 80 % osteoblast viability.
   All of the present in vitro results indicated the effectiveness of the new materials as local vancomycin carriers. In vivo animal models should be evaluated to confirm the efficacy for use in humans in the future.
C1 [Upho, Nisalak; Tangtrakulwanich, Boonsin] Prince Songkla Univ, Dept Orthopaed Surg & Phys Med, Fac Med, Hat Yai 90110, Thailand.
   [Upho, Nisalak] Prince Songkla Univ, Dept Biomed Sci, Fac Med, Hat Yai 90110, Thailand.
   [Pripatnanont, Prisana] Prince Songkla Univ, Dept Surg, Fac Dent, Hat Yai 90110, Thailand.
   [Thitiwongsawet, Patcharaporn] Thammasat Univ, Dept Chem Engn, Fac Engn, Pathum Thani 12121, Thailand.
   [Ingviya, Natnicha] Prince Songkla Univ, Microbiol Unit, Fac Med, Dept Pathol, Hat Yai 90110, Thailand.
C3 Prince of Songkla University; Prince of Songkla University; Prince of
   Songkla University; Thammasat University; Prince of Songkla University
RP Upho, N (通讯作者)，Prince Songkla Univ, Dept Orthopaed Surg & Phys Med, Fac Med, Hat Yai 90110, Thailand.
EM unisalak@medicine.psu.ac.th
RI Wutticharoenmongkol, Patcharaporn/U 8750 2019; Pripatnanont,
   Prisana/K 4879 2012
OI Wutticharoenmongkol, Patcharaporn/0000 0001 6827 0371; Pripatnanont,
   Prisana/0000 0003 3875 8602
FU Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
   [EC 522821142]
FX This work was supported by the Faculty of Medicine, Prince of Songkla
   University, Songkhla, Thailand, under grant EC 522821142. The authors
   would like to thank Dr. Naruporn Monmaturapot from MTEC, Thailand, for
   the BCP syntheses and Assoc. Prof. Dr. Chitchamai Ovartlanporn,
   Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical
   Sciences, Prince of Songkla University, Thailand, for the chemical
   analyses.
CR [Anonymous], 2009, Biological evaluation of medical devices   Part 5: Tests for in vitro cytotoxicity, P1
   Calhoun Jason H, 2009, Semin Plast Surg, V23, P59, DOI 10.1055/s 0029 1214158
   Canut A, 2012, EUR J CLIN MICROBIOL, V31, P2227, DOI 10.1007/s10096 012 1560 7
   Causa F, 2006, J BIOMED MATER RES A, V76A, P151, DOI 10.1002/jbm.a.30528
   Çetin D, 2012, J MATER SCI MATER M, V23, P2803, DOI 10.1007/s10856 012 4726 z
   Dorozhkin Sergey V, 2011, Biomatter, V1, P3, DOI 10.4161/biom.1.1.16782
   Mendes JBE, 2012, SCI WORLD J, DOI 10.1100/2012/542937
   Fellah BH, 2008, BIOMATERIALS, V29, P1177, DOI 10.1016/j.biomaterials.2007.11.034
   Freier T, 2006, ADV POLYM SCI, P1, DOI 10.1007/12_073
   Jiang T, 2014, J MATER SCI MATER M, V25, P131, DOI 10.1007/s10856 013 5057 4
   Kankilic B, 2011, CLIN ORTHOP RELAT R, V469, P3222, DOI 10.1007/s11999 011 2082 9
   KORSMEYER RW, 1983, INT J PHARMACEUT, V15, P25, DOI 10.1016/0378 5173(83)90064 9
   Kumar TSS, 2000, BIOMATERIALS, V21, P1623
   Lazzarini L, 2004, J BONE JOINT SURG AM, V86A, P2305, DOI 10.2106/00004623 200410000 00028
   Li W, 2014, J EUR CERAM SOC, V34, P505, DOI 10.1016/j.jeurceramsoc.2013.08.032
   Lin SS, 1999, CLIN ORTHOP RELAT R, P240
   Mehrabanian M, 2011, INT J NANOMED, V6, P1651, DOI 10.2147/IJN.S21203
   Mundargi RC, 2007, J CONTROL RELEASE, V119, P59, DOI 10.1016/j.jconrel.2007.01.008
   Ranjha NM, 2010, J MATER SCI MATER M, V21, P2805, DOI 10.1007/s10856 010 4134 1
   Rao NL, 2011, PLAST RECONSTR SURG, V127, p177S, DOI 10.1097/PRS.0b013e3182001f0f
   Rossi S, 2004, J ANTIMICROB CHEMOTH, V54, P1013, DOI 10.1093/jac/dkh477
   Sarasua JR, 2011, J MATER SCI MATER M, V22, P2513, DOI 10.1007/s10856 011 4425 1
   Silva GA, 2007, J TISSUE ENG REGEN M, V1, P4, DOI 10.1002/term.2
   Soundrapandian C, 2010, AAPS PHARMSCITECH, V11, P1675, DOI 10.1208/s12249 010 9550 5
   Tang CY, 2008, COMPOS SCI TECHNOL, V68, P1927, DOI 10.1016/j.compscitech.2007.12.003
   Urabe K, 2009, J ORTHOP SCI, V14, P784, DOI 10.1007/s00776 009 1397 9
   Victor SP, 2008, J MATER SCI MATER M, V19, P283, DOI 10.1007/s10856 006 0044 7
   Wang QB, 2011, CERAM SILIKATY, V55, P43
   Xie ZP, 2009, J CONTROL RELEASE, V139, P118, DOI 10.1016/j.jconrel.2009.06.012
   Yang CC, 2013, MAT SCI ENG C MATER, V33, P2203, DOI 10.1016/j.msec.2013.01.038
   Yao QQ, 2013, CERAM INT, V39, P7517, DOI 10.1016/j.ceramint.2013.03.002
   Zhu N., 2013, ADV BIOMATERIALS SCI, P315, DOI DOI 10.5772/54125
   Zhu XD, 2009, ACTA BIOMATER, V5, P1311, DOI 10.1016/j.actbio.2008.11.024
NR 33
TC 3
Z9 3
U1 1
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1872 5120
EI 1939 8042
J9 J PHARM INNOV
JI J. Pharm. Innov.
PD SEP
PY 2015
VL 10
IS 3
BP 211
EP 221
DI 10.1007/s12247 015 9219 4
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CO2WZ
UT WOS:000359019000003
DA 2025 08 17
ER

PT J
AU Dougall, WC
   Aguilera, AR
   Smyth, MJ
AF Dougall, William C.
   Aguilera, Amelia Roman
   Smyth, Mark J.
TI 被撤回的出版物: Dual targeting of RANKL and PD 1 with a bispecific antibody
   improves anti tumor immunity (Retracted article. See vol. 11, 2022)
SO CLINICAL & TRANSLATIONAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE bispecific antibody; metastasis; PD 1; RANKL; TNFSF11; tumor immunity
ID RECEPTOR ACTIVATOR; LIGAND; CELLS; RESISTANCE; BLOCKADE; PROMOTES;
   THERAPY; PATHWAY
AB Objectives The addition of RANKL/RANK blockade to immune checkpoint inhibitors (ICIs) such as anti PD 1/PD L1 and anti CTLA4 antibodies is associated with increased anti tumor immunity in mice. Recent retrospective clinical studies in patients with advanced melanoma and lung cancer suggest the addition of anti RANKL antibody to ICI increases the overall response rate relative to ICI treatment alone. Based on this rationale, we developed a novel bispecific antibody (BsAb) co targeting RANKL and PD 1. Methods We characterized target binding and functional activity of the anti RANKL/PD 1 BsAb in cell based assays. Anti tumor activity was confirmed in experimental lung metastasis models and in mice with established subcutaneously transplanted tumors. Results The anti RANKL/PD 1 BsAb retained binding to both RANKL and PD 1 and blocked the interaction with respective counter structures RANK and PD L1. The inhibitory effect of anti RANKL/PD 1 BsAb was confirmed by demonstrating a complete block of RANKL dependent osteoclast formation. Monotherapy activity of anti RANKL/PD 1 BsAb was observed in anti PD 1 resistant tumors and, when combined with anti CTLA 4 mAb, increased anti tumor responses. An equivalent or superior anti tumor response was observed with the anti RANKL/PD 1 BsAb compared with the combination of parental anti RANKL plus anti PD 1 antibodies depending upon the tumor model. Discussion Mechanistically, the anti tumor activity of anti RANKL/PD 1 BsAb required CD8(+)T cells, host PD 1 and IFN gamma. Targeting RANKL and PD 1 simultaneously within the tumor microenvironment (TME) improved anti tumor efficacy compared with combination of two separate mAbs. Conclusion In summary, the bispecific anti RANKL/PD 1 antibody demonstrates potent tumor growth inhibition in settings of ICI resistance and represents a novel modality for clinical development in advanced cancer.
C1 [Dougall, William C.; Aguilera, Amelia Roman; Smyth, Mark J.] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld 4006, Australia.
C3 QIMR Berghofer Medical Research Institute
RP Smyth, MJ (通讯作者)，QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld 4006, Australia.; Dougall, WC (通讯作者)，Cascadia Drug Dev Grp, 321 High Sch Rd NE Suite D3,386, Bainbridge Isl, WA 98110, Australia.
EM bill@thecddg.com; mark.smyth@qimrberghofer.edu.au
RI ; Smyth, Mark/H 8709 2014
OI Dougall, William/0000 0001 9487 251X; 
FU National Health and Medical Research Council of Australia (NHMRC)
   [1132519, 1078671]; QIMR Berghofer Medical Research Institute Proof of
   Concept Award
FX The authors thank Liam Town, Kate Elder and Brodie Quine for mouse
   genotyping and maintenance during this study. The authors also thank
   GenScript for the production of RANK Fc and recombinant antibodies, and
   the QIMR Berghofer Medical Research Institute animal, flow cytometry and
   histology facilities. MJS was supported by a National Health and Medical
   Research Council of Australia (NH&MRC) Program Grant (1132519) and
   Senior Principal Research Fellowship (1078671). The work was also
   supported by a QIMR Berghofer Medical Research Institute Proof of
   Concept Award.
CR Aguilera AR, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1424677
   Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Ahern E, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431088
   Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bakhru P, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93265
   Bando JK, 2018, IMMUNITY, V48, P1208, DOI 10.1016/j.immuni.2018.04.012
   Blake SJ, 2016, CANCER DISCOV, V6, P446, DOI 10.1158/2159 8290.CD 15 0944
   Chae YK, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0349 3
   Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107
   Dahlen Eva, 2018, Ther Adv Vaccines Immunother, V6, P3, DOI 10.1177/2515135518763280
   Demoulin SA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008334
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Fujimura T, 2015, J INVEST DERMATOL, V135, P2884, DOI 10.1038/jid.2015.209
   Gilfillan S, 2008, J EXP MED, V205, P2965, DOI 10.1084/jem.20081752
   Husain B, 2018, BIODRUGS, V32, P441, DOI 10.1007/s40259 018 0299 9
   Kambayashi Y, 2015, J INVEST DERMATOL, V135, P2547, DOI 10.1038/jid.2015.199
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Khan IS, 2014, J EXP MED, V211, P761, DOI 10.1084/jem.20131889
   Klein C, 2019, METHODS, V154, P21, DOI 10.1016/j.ymeth.2018.11.008
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Liede A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480301
   Mattarollo SR, 2011, CANCER RES, V71, P4809, DOI 10.1158/0008 5472.CAN 11 0753
   Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383
   Ngiow SF, 2015, CANCER RES, V75, P3800, DOI 10.1158/0008 5472.CAN 15 1082
   Nishimura H, 1998, INT IMMUNOL, V10, P1563, DOI 10.1093/intimm/10.10.1563
   O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571 018 0142 8
   O'Donnell JS, 2017, CANCER TREAT REV, V52, P71, DOI 10.1016/j.ctrv.2016.11.007
   Peters S, 2019, CLIN TRANSL ONCOL, V21, P977, DOI 10.1007/s12094 018 02023 5
   Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2
   Sato K, 2018, J IMMUNOL, V200, P3691, DOI 10.4049/jimmunol.1701293
   Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108
   Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520 015 2904 5
   Williamson E, 2002, J IMMUNOL, V169, P3606, DOI 10.4049/jimmunol.169.7.3606
NR 36
TC 25
Z9 29
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2050 0068
J9 CLIN TRANSL IMMUNOL
JI Clin. Transl. Immunol.
PY 2019
VL 8
IS 10
AR e01081
DI 10.1002/cti2.1081
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA JI6EK
UT WOS:000493559900003
PM 31572609
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tandefelt, DG
   Boormans, JL
   van der Korput, HA
   Jenster, GW
   Trapman, J
AF Tandefelt, Delila Gasi
   Boormans, Joost L.
   van der Korput, Hetty A.
   Jenster, Guido W.
   Trapman, Jan
TI A 36 gene Signature Predicts Clinical Progression in a Subgroup of
   ERG positive Prostate Cancers
SO EUROPEAN UROLOGY
LA English
DT Article
DE Prostate cancer; ETS; Predictor; TMPRSS2 ERG; Expression arrays
ID TMPRSS2 ERG GENE FUSION; COPY NUMBER; OVEREXPRESSION; RELEVANT; PATHWAYS
AB Background: The molecular basis of the clinical heterogeneity of prostate cancer (PCa) is not well understood.
   Objective: The purpose of our study was to identify and characterize genes in a clinically relevant gene expression signature in a subgroup of primary PCa positive for transmembrane protease, serine 2 (TMPRSS2) v ets erythroblastosis virus E26 oncogene homolog (avian) (ERG).
   Design, setting, and participants: We studied gene expression profiles by unsupervised hierarchical clustering in 48 primary PCas from patients with a long clinical follow up. Results were correlated with clinical outcome and validated in an independent patient cohort. Selected genes from a defined classifier were tested in vitro for biologic properties.
   Intervention: Initial treatment of primary tumors was radical prostatectomy.
   Outcome measurements and statistical analysis: Associations between clinical and histopathologic variables were evaluated by the Pearson chi(2) test, Mann Whitney U test, or Kruskal Wallis test, where appropriate. The log rank test or Breslow method was used for statistical analysis of Kaplan Meier survival curves.
   Results and limitations: Most tumors that overexpressed ERG clustered separately from other primary PCas. No differences in any clinical end points between ERG positive and ERG negative cancers were detected. Importantly, within the ERG positive samples, two subgroups were identified, which differed significantly in prostate specific antigen recurrence free survival, and cancer specific and overall survival. From our findings, we defined a gene expression classifier of 36 genes. In a second, completely independent tumor set, the classifier also distinguished ERG positive subgroups with different clinical outcome. In both patient cohorts, the classifier was not predictive in ERG negative tumors. Biologic processes regulated by genes in the classifier included cell adhesion and bone remodeling. Tumor growth factor beta signaling was indicated as the main differing signaling pathway between the two ERG subgroups. In vitro biologic assays of two selected genes from the classifier (inhibin, beta A [INHBA] and cadherin 11, type 2, OB cadherin (osteoblast) [CDH11]) supported a functional role in PCa progression. Possible multifocality and limited number of PCa samples can be limitations of the study.
   Conclusions: The classifier identified can contribute to prediction of tumor progression in ERG positive primary prostate tumors and might be instrumental in therapy decisions. (C) 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Tandefelt, Delila Gasi; van der Korput, Hetty A.; Trapman, Jan] Erasmus Univ, Dept Pathol, Med Ctr, Josephine Nefkens Inst, NL 3000 CA Rotterdam, Netherlands.
   [Boormans, Joost L.; Jenster, Guido W.] Erasmus Univ, Dept Urol, Med Ctr, Josephine Nefkens Inst, NL 3000 CA Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC
RP Trapman, J (通讯作者)，Erasmus Univ, Dept Pathol, Med Ctr, POB 2040, NL 3000 CA Rotterdam, Netherlands.
EM j.trapman@erasmusmc.nl
RI ; Tandefelt, Delila/ABI 1558 2020
OI Jenster, Guido/0000 0002 8658 2552; Gasi Tandefelt,
   Delila/0000 0002 9490 6588; Boormans, JL/0000 0002 5127 0436; 
FU European Union; Marie Curie grant "CANCURE"
FX This study was supported by a Marie Curie grant "CANCURE" provided by
   the European Union. The sponsor was involved with the design and conduct
   of the study.
CR Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Brase JC, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 507
   Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370
   Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427
   Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822
   Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843
   Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470 2045(10)70295 3
   Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237
   FitzGerald LM, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 230
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Heemers HV, 2011, CANCER RES, V71, P1978, DOI 10.1158/0008 5472.CAN 10 2512
   Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008 5472.CAN 06 1871
   Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078 0432.CCR 09 1176
   Jhavar S, 2009, BJU INT, V103, P1256, DOI 10.1111/j.1464 410X.2008.08200.x
   Kim HJ, 2010, J CERAM PROCESS RES, V11, P11
   King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371
   Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105
   Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101
   Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008 5472.CAN 07 0673
   Markert EK, 2011, P NATL ACAD SCI USA, V108, P21276, DOI 10.1073/pnas.1117029108
   Penney KL, 2011, J CLIN ONCOL, V29, P2391, DOI 10.1200/JCO.2010.32.6421
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024
   Toubaji A, 2011, MODERN PATHOL, V24, P1511, DOI 10.1038/modpathol.2011.111
   Wikström P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097 0045(19980915)37:1<19::AID PROS4>3.0.CO;2 3
   Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106
NR 28
TC 31
Z9 32
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302 2838
EI 1873 7560
J9 EUR UROL
JI Eur. Urol.
PD DEC
PY 2013
VL 64
IS 6
BP 941
EP 950
DI 10.1016/j.eururo.2013.02.039
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 248EY
UT WOS:000326678100014
PM 23490727
DA 2025 08 17
ER

PT J
AU Breitkreutz, I
   Podar, K
   Figueroa Vazquez, V
   Wilhelm, S
   Hayden, PJ
   Anderson, KC
   Raab, MS
AF Breitkreutz, Iris
   Podar, Klaus
   Figueroa Vazquez, Vianihuini
   Wilhelm, Scott
   Hayden, Patrick J.
   Anderson, Kenneth C.
   Raab, Marc S.
TI The orally available multikinase inhibitor regorafenib (BAY 73 4506) in
   multiple myeloma
SO ANNALS OF HEMATOLOGY
LA English
DT Article
DE Multiple myeloma; Regorafenib; Cell proliferation; Antiangiogenesis
   effects; Osteoclasts
ID ENDOTHELIAL GROWTH FACTOR; CELL GROWTH; PHOSPHATIDYLINOSITOL 3 KINASE;
   COLORECTAL CANCER; KINASE; INTERLEUKIN 6; PLACEBO; ACTIVATION; EFFICACY;
   SAFETY
AB A promising approach to the treatment of multiple myeloma (MM) involves agents that target not only the myeloma cells directly, but also the tumor microenvironment which promotes tumor cell growth, angiogenesis, and MM bone disease. Here we investigate the orally available multikinase inhibitor, regorafenib (BAY 73 4506), for its therapeutic efficacy in MM. Regorafenib is a potent inhibitor of angiogenic (VEGFR 1 3, PDGFR b) as well as oncogenic (c KIT, RET, FGFR, Raf) kinases. We show that regorafenib induces apoptosis in all MM cell lines at below clinically achievable concentrations. Regorafenib overcomes the growth advantage conferred by a stroma cell MM and an endothelial cell MM, co culture systems, and abrogates growth factor stimulated MEK, ERK, and AKT phosphorylation at nanomolar to micromolar concentrations. Moreover, it inhibits endothelial cell growth and tubule formation, abrogates both VEGF secretion and VEGF induced MM cell migration, inhibits osteoclastogenesis, and shows synergistic cytotoxicity with dexamethasone, the immunomodulatory drug pomalidomide, and the p110 delta inhibitor idelalisib. Most importantly, regorafenib significantly delays tumor growth in a xenograft mouse model of human MM. These results provide the rationale for further clinical evaluation of regorafenib, alone and in combination, in the treatment of MM.
C1 [Breitkreutz, Iris; Figueroa Vazquez, Vianihuini; Raab, Marc S.] Univ Heidelberg Hosp, Max Eder Grp Expt Therapies Hematol Malignancies, Heidelberg, Germany.
   [Breitkreutz, Iris; Figueroa Vazquez, Vianihuini; Raab, Marc S.] German Canc Res Ctr, Heidelberg, Germany.
   [Breitkreutz, Iris; Podar, Klaus; Anderson, Kenneth C.; Raab, Marc S.] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
   [Breitkreutz, Iris; Podar, Klaus; Anderson, Kenneth C.; Raab, Marc S.] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA.
   [Breitkreutz, Iris; Raab, Marc S.] Heidelberg Univ Hosp, Dept Med 5, INF 410, D 69120 Heidelberg, Germany.
   [Podar, Klaus] Karl Landsteiner Univ Hlth Sci, Univ Hosp Krems, Dept Internal Med, A 3500 Krems, Austria.
   [Wilhelm, Scott] Bayer HealthCare Pharmaceut, Montville, NJ 07045 USA.
   [Hayden, Patrick J.] Trinity Coll Dublin, St Jamess Hosp, Dept Acad Haematol, Dublin 8, Ireland.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ); Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Harvard University; Harvard University Medical Affiliates;
   Dana Farber Cancer Institute; Harvard Medical School; Ruprecht Karls
   University Heidelberg; Bayer AG; Bayer Healthcare Pharmaceuticals;
   Trinity College Dublin
RP Raab, MS (通讯作者)，Univ Heidelberg Hosp, Max Eder Grp Expt Therapies Hematol Malignancies, Heidelberg, Germany.; Raab, MS (通讯作者)，German Canc Res Ctr, Heidelberg, Germany.; Raab, MS (通讯作者)，Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.; Raab, MS (通讯作者)，Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA.; Raab, MS (通讯作者)，Heidelberg Univ Hosp, Dept Med 5, INF 410, D 69120 Heidelberg, Germany.
EM Iris.Breitkreutz@med.uni heidelberg.de; m.raab@dkfz.de
RI ; Podar, Klaus/ABD 1112 2020; Anderson, Kenneth/ACP 5073 2022
OI Podar, Klaus/0000 0002 7414 3632; Figueroa,
   Vianihuini/0000 0002 0960 8624; Hayden, Patrick/0000 0003 1374 4503; 
FU MMRF senior research grant award; National Institutes of Health [RO CA
   50947, PO 1 CA 78378, P50 CA 100707]; American Cancer Society Clinical
   Research Professor Award; medical faculty of science of the University
   of Heidelberg, Germany
FX This work was supported by a MMRF senior research grant award (to K.P);
   a grant to the Fritz Thyssen foundation (to M.S.R.); National Institutes
   of Health grants RO CA 50947, PO 1 CA 78378, and P50 CA 100707; and the
   American Cancer Society Clinical Research Professor Award (to K.C.A.).
   This work was also supported by the medical faculty of science of the
   University of Heidelberg, Germany.
CR Andrulis M, 2013, CANCER DISCOV, V3, P862, DOI 10.1158/2159 8290.CD 13 0014
   Bellamy WT, 1999, CANCER RES, V59, P728
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Breitkreutz I, 2007, BRIT J HAEMATOL, V139, P55, DOI 10.1111/j.1365 2141.2007.06747.x
   Bruix J, 2016, ANN ONCOL, V27, P140, DOI 10.1093/annonc/mdw237.03
   Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200
   Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007
   Catlett Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074 7613(00)80011 4
   Chang JE, 2014, CURR HEMATOL MALIG R, V9, P33, DOI 10.1007/s11899 013 0189 7
   Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008 5472.CAN 09 1947
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140 6736(12)61857 1
   Fruman DA, 2011, CANCER DISCOV, V1, P562, DOI 10.1158/2159 8290.CD 11 0249
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140 6736(12)61900 X
   Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood 2002 06 1874
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood 2011 05 352492
   Hsu JH, 2004, ONCOGENE, V23, P3368, DOI 10.1038/sj.onc.1207459
   Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood 2009 06 222943
   Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338
   Kumar S, 2003, LEUKEMIA, V17, P2025, DOI 10.1038/sj.leu.2403084
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood 2007 10 116129
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Mir O, 2016, LANCET ONCOL, V17, P1732, DOI 10.1016/S1470 2045(16)30507 1
   Ogata A, 1997, J IMMUNOL, V159, P2212
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008 5472.CAN 04 0124
   Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Raab MS, 2012, CANCER RES, V72, P5374, DOI 10.1158/0008 5472.CAN 12 2026
   Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140 6736(09)60221 X
   Ramakrishnan V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050005
   Miguel JS, 2013, LANCET ONCOL, V14, P1055, DOI 10.1016/S1470 2045(13)70380 2
   Siegel DS, 2012, BLOOD, V120, P2817, DOI 10.1182/blood 2012 05 425934
   Strumberg D, 2012, BRIT J CANCER, V106, P1722, DOI 10.1038/bjc.2012.153
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
NR 39
TC 8
Z9 8
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0939 5555
EI 1432 0584
J9 ANN HEMATOL
JI Ann. Hematol.
PD MAY
PY 2018
VL 97
IS 5
BP 839
EP 849
DI 10.1007/s00277 018 3237 5
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA GB1GM
UT WOS:000428799200011
PM 29359239
DA 2025 08 17
ER

PT J
AU Adams, BL
   Guo, W
   Gors, RT
   Knopp, KL
AF Adams, B. L.
   Guo, W.
   Gors, R. T.
   Knopp, K. L.
TI Pharmacological interrogation of a rodent forced ambulation model:
   leveraging gait impairment as a measure of pain behavior pre clinically
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Gait; Joint pain; Complete Freund's Adjuvant; Functional pain endpoint
ID RAT MODEL; INFLAMMATORY PAIN; TACTILE ALLODYNIA; CATWALK TESTS;
   KNEE BEND; OSTEOARTHRITIS; NOCICEPTION; ANTAGONIST; DICLOFENAC;
   LOCOMOTION
AB Objective: The aim of this study was to investigate whether inflammogen induced temporal and spatial gait changes in a rodent forced ambulation paradigm were sensitive to pharmacological intervention with both clinically validated and novel analgesics.
   Methods: Using the GaitScan ( CleverSys Inc., Reston, VA) treadmill system, we identified four functional endpoints inspired by clinical literature and sensitive to unilateral joint injury induced by intra articular Complete Freund's Adjuvant ( CFA). These endpoints included: range of motion, normalized stance distance, stance/swing ratio, and paw print size as a measure of guarding; collectively, these measures are proposed to serve as a high fidelity index of joint pain. We then examined the ability of known analgesic mechanisms to attenuate gait impairment as measured by this index.
   Results: Clinically efficacious opioids, Nonsteroidal anti inflammatory drugs ( NSAIDs), and the yet unapproved anti NGF antibody dose dependently attenuated the CFA) induced gait deficits, while a TNF alpha fusion protein blocker had no effect on gait, but did produce a reduction in swelling. As well, the time course for gait impairment in the model appears to be distinct from the traditional endpoint of tactile hypersensitivity, offering the potential to assess a novel functional pain phenotype.
   Conclusions: In response to the call for more functional pain measures, we submit this composite gait score as a novel endpoint to interrogate joint pain pre clinically. As the etiology of human osteoarthritis ( OA) remains unclear, this model/endpoint cannot attempt to improve construct validity, but may provide an additional dimension to interrogate pain induced gait deficits. (C) 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Adams, B. L.; Guo, W.; Gors, R. T.; Knopp, K. L.] Lilly Res Labs, Neurosci Res, Indianapolis, IN 46285 USA.
C3 Eli Lilly; Lilly Research Laboratories
RP Knopp, KL (通讯作者)，Lilly Corp Ctr, Lilly Res Labs, Drop Code 0510, Indianapolis, IN 46285 USA.
EM k.knopp@lilly.com
CR Al Zahrani KS, 2002, DISABIL REHABIL, V24, P275, DOI 10.1080/09638280110087098
   Allen KD, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3801
   Amagai Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/540231
   Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 116
   Bellamy N., 1998, Inflammopharmacology, V6, P81, DOI 10.1007/s10787 998 0009 1
   Berryman ER, 2009, J MUSCULOSKEL NEURON, V9, P89
   Boettger MK, 2009, PAIN, V145, P142, DOI 10.1016/j.pain.2009.06.006
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Clark P, 2008, J PHARMACOL EXP THER, V325, P425, DOI 10.1124/jpet.107.134510
   CLARKE KA, 1986, PHYSIOL BEHAV, V38, P345, DOI 10.1016/0031 9384(86)90105 8
   Clarke KA, 1997, PHYSIOL BEHAV, V62, P951, DOI 10.1016/S0031 9384(97)00022 X
   CLARKE KA, 1995, PHYSIOL BEHAV, V58, P415, DOI 10.1016/0031 9384(95)00072 Q
   Cobos EJ, 2012, PAIN, V153, P876, DOI 10.1016/j.pain.2012.01.016
   Cole P, 2004, DRUG TODAY, V40, P281, DOI 10.1358/dot.2004.40.4.820078
   Coulthard P, 2002, J NEUROSCI METH, V116, P197, DOI 10.1016/S0165 0270(02)00042 0
   Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003
   Ferreira Gomes J, 2008, J PAIN, V9, P945, DOI 10.1016/j.jpain.2008.05.012
   Ferreira Gomes J, 2012, PHARMACOL BIOCHEM BE, V101, P617, DOI 10.1016/j.pbb.2012.03.003
   Gök H, 2002, ACTA ORTHOP SCAND, V73, P647, DOI 10.1080/000164702321039606
   Górska T, 2007, J NEUROTRAUM, V24, P1198, DOI 10.1089/neu.2006.0219
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Hunter DJ, 2011, OSTEOARTHR CARTILAGE, V19, P557, DOI 10.1016/j.joca.2010.10.029
   Iosa M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/918642
   Ishikawa G, 2015, OSTEOARTHR CARTILAGE, V23, P925, DOI 10.1016/j.joca.2015.02.002
   Jordan JM, 2013, OSTEOARTHR CARTILAGE, V21, P1143, DOI 10.1016/j.joca.2013.07.006
   Kaufman KR, 2001, J BIOMECH, V34, P907, DOI 10.1016/S0021 9290(01)00036 7
   Malfait AM, 2013, OSTEOARTHR CARTILAGE, V21, P1316, DOI 10.1016/j.joca.2013.06.003
   Matson DJ, 2010, METHODS MOL BIOL, V617, P67, DOI 10.1007/978 1 60327 323 7_6
   Möller KÄ, 2008, J NEUROSCI METH, V174, P1, DOI 10.1016/j.jneumeth.2008.06.017
   Mogil JS, 2010, PAIN, V151, P12, DOI 10.1016/j.pain.2010.07.015
   Möller KÄ, 2015, EUR J PHARMACOL, V756, P75, DOI 10.1016/j.ejphar.2015.02.050
   Möller KÄ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046129
   Nakao K, 2007, J PHARMACOL EXP THER, V322, P686, DOI 10.1124/jpet.107.122010
   Nebel MB, 2009, ARCH PHYS MED REHAB, V90, P1874, DOI 10.1016/j.apmr.2009.07.010
   Parvathy SS, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 14
   Piesla MJ, 2009, BRAIN RES, V1295, P89, DOI 10.1016/j.brainres.2009.07.091
   Reyes Gordillo K, 2007, BIOPHARM DRUG DISPOS, V28, P415, DOI 10.1002/bdd.569
   Schnitzer TJ., 2014, Ann Rheum Dis
   Simjee SU, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2290
   Simjee SU, 2004, PAIN, V109, P453, DOI 10.1016/j.pain.2004.02.022
   Urban R, 2011, PAIN, V152, P990, DOI 10.1016/j.pain.2010.12.003
   Westlund KN, 2012, TRANSL RES, V160, P84, DOI 10.1016/j.trsl.2011.10.003
   Wild KD, 2007, J PHARMACOL EXP THER, V322, P282, DOI 10.1124/jpet.106.116236
NR 44
TC 9
Z9 14
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD NOV
PY 2016
VL 24
IS 11
BP 1928
EP 1939
DI 10.1016/j.joca.2016.05.022
PG 12
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA EA6OE
UT WOS:000386747700012
PM 27450884
OA Bronze
DA 2025 08 17
ER

PT J
AU Nicoletti, F
   Battaglia, G
   Storto, M
   Ngomba, RT
   Iacovelli, L
   Arcella, A
   Gradini, R
   Sale, P
   Rampello, L
   De Vita, T
   Di Marco, R
   Melchiorri, D
   Bruno, V
AF Nicoletti, Ferdinando
   Battaglia, Giuseppe
   Storto, Marianna
   Ngomba, Richard T.
   Iacovelli, Luisa
   Arcella, Antonietta
   Gradini, Roberto
   Sale, Patrizio
   Rampello, Liborio
   De Vita, Teresa
   Di Marco, Roberto
   Melchiorri, Daniela
   Bruno, Valeria
TI Metabotropic glutamate receptors: Beyond the regulation of synaptic
   transmission
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article; Proceedings Paper
CT Lille Summer School in Neuroscience
CY SEP 02 07, 2006
CL Univ Sci tech Lille, Lille, FRANCE
HO Univ Sci tech Lille
DE metabotropic glutamate receptors; brain tumors; stem cells;
   immunological synapse; antigen presenting cells; allosteric modulators
ID T CELL ACTIVATION; NEURAL STEM CELLS; PROGENITOR CELLS; PHARMACOLOGICAL
   BLOCKADE; STRIATAL NEURONS; GLIOMA CELLS; RAT; EXPRESSION; BRAIN; MGLU5
AB Metabotropic glutamate (mGlu) receptors are G protein coupled receptors activated by glutamate, the major excitatory neurotransmitter of the CNS. A growing body of evidence suggests that the function of mGlu receptors is not restricted to the regulation of synaptic transmission. mGlu receptors are expressed in a variety of peripheral cells, including inter alia hepatocytes, pancreatic cells, osteoblasts and immune cells. Within the immunological synapses, mGlu receptors expressed by T cells might contribute to the vast array of signals generated by the antigen presenting cells. mGlu receptors are also found in embryonic and neural stem cells. This suggests their involvement in the pathophysiology of brain tumors, which likely originates from cancer stem cells similar to neural stem cells. Ligands of mGlu3 and mGlu4 receptors are potential candidates for the experimental treatment of malignant gliomas and meduttoblastomas, respectively. (c) 2007 Published by Elsevier Ltd.
C1 Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I 00185 Rome, Italy.
   Ist Neurol Meditrraneo Neuromed, Pozzilli, Italy.
   Univ Roma La Sapienza, Dept Expt Med, I 00185 Rome, Italy.
   Univ Catania, Dept Neurol, I 95124 Catania, Italy.
   IRCCS, Rome, Italy.
C3 Sapienza University Rome; IRCCS Neuromed; Sapienza University Rome;
   University of Catania
RP Nicoletti, F (通讯作者)，Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Piazzale Aldo Moro 5, I 00185 Rome, Italy.
EM ferdinandonicoletti@hotmail.com
RI ; Roberto, Di Marco/G 7765 2012; BRUNO, Valeria Maria
   Gloria/F 3146 2012; Battaglia, Giuseppe/A 7709 2010; Storto,
   Marianna/G 8745 2012; Arcella, Antonietta/A 9806 2013; Nicoletti,
   Ferdinando/T 4898 2019; bruno, Valeria/F 3146 2012; Sale,
   Patrizio/K 8757 2016; Nicoletti, Ferdinando/A 2446 2010; Roberto (Maria
   Antonio), Di Marco/G 7765 2012
OI Ngomba, Richard/0000 0003 3825 3970; BRUNO, Valeria Maria
   Gloria/0000 0003 4231 0739; NICOLETTI, Ferdinando/0000 0003 3366 7269;
   Battaglia, Giuseppe/0000 0001 7571 3417; Arcella,
   Antonietta/0000 0002 0708 8282; marianna, storto/0000 0002 0159 7449;
   IACOVELLI, LUISA/0000 0002 9686 7762; Sale,
   Patrizio/0000 0002 4850 3673; Nicoletti, Ferdinando/0000 0003 0917 443X;
   Roberto (Maria Antonio), Di Marco/0000 0001 5075 4597
CR Arcella A, 2005, NEURO ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961
   Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009
   Boldyrev AA, 2005, J NEUROCHEM, V95, P913, DOI 10.1111/j.1471 4159.2005.03456.x
   Boldyrev AA, 2004, BIOCHEM BIOPH RES CO, V324, P133, DOI 10.1016/j.bbrc.2004.09.019
   Canudas AM, 2004, J NEUROSCI, V24, P10343, DOI 10.1523/JNEUROSCI.3229 04.2004
   Cappitelli F, 2005, MACROMOL BIOSCI, V5, P49, DOI 10.1002/mabi.200400134
   Cappuccio I, 2006, NEUROPHARMACOLOGY, V51, P606, DOI 10.1016/j.neuropharm.2006.05.007
   Chiocchetti A, 2006, BRIT J PHARMACOL, V148, P760, DOI 10.1038/sj.bjp.0706746
   CICERONI C, 2006, AM SOC NEUROSCI, V626, P7
   D'Onofrio M, 2003, J NEUROCHEM, V84, P1288, DOI 10.1046/j.1471 4159.2003.01633.x
   De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165 6147(00)01635 7
   Di Giorgi Gerevini V, 2005, CELL DEATH DIFFER, V12, P1124, DOI 10.1038/sj.cdd.4401639
   Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092 8674(00)80783 7
   Gritti A, 1999, J NEUROSCI, V19, P3287
   Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200
   Hinoi E, 2001, BIOCHEM BIOPH RES CO, V281, P341, DOI 10.1006/bbrc.2001.4355
   Iacovelli L, 2006, J NEUROSCI, V26, P8388, DOI 10.1523/JNEUROSCI.2285 06.2006
   Jong YJI, 2005, J BIOL CHEM, V280, P30469, DOI 10.1074/jbc.M501775200
   Kelland EE, 2001, EUR J PHARMACOL, V424, pR3, DOI 10.1016/S0014 2999(01)01157 8
   Kenny PJ, 2004, TRENDS PHARMACOL SCI, V25, P265, DOI 10.1016/j.tips.2004.03.009
   Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564
   Luyt K, 2004, BIOCHEM BIOPH RES CO, V319, P120, DOI 10.1016/j.bbrc.2004.04.158
   Luyt K, 2003, J NEUROCHEM, V84, P1452, DOI 10.1046/j.1471 4159.2003.01661.x
   Miglio G, 2005, BIOCHEM PHARMACOL, V70, P189, DOI 10.1016/j.bcp.2005.04.038
   NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206
   NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471 4159.1986.tb12922.x
   O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200
   Pacheco R, 2004, J BIOL CHEM, V279, P33352, DOI 10.1074/jbc.M401761200
   Pacheco R, 2006, J IMMUNOL, V177, P6695, DOI 10.4049/jimmunol.177.10.6695
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028 3908(94)00129 G
   Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005
   Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rezzani R, 2003, ACTA HISTOCHEM, V105, P81, DOI 10.1078/0065 1281 00688
   Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666
   Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028 3908(99)00092 1
   Schulenburg A, 2006, CANCER AM CANCER SOC, V107, P2512, DOI 10.1002/cncr.22277
   Shipe WD, 2005, CURR OPIN DRUG DISC, V8, P449
   SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0
   Spinsanti P, 2006, J NEUROCHEM, V99, P299, DOI 10.1111/j.1471 4159.2006.04038.x
   Storto M, 2006, MOL PHARMACOL, V69, P1234, DOI 10.1124/mol.105.018390
   Storto M, 2004, EUR J PHARMACOL, V497, P25, DOI 10.1016/j.ejphar.2004.06.023
   Storto M, 2003, J HEPATOL, V38, P179, DOI 10.1016/S0168 8278(02)00384 7
   Storto M, 2001, J ENDOCRINOL, V170, P71, DOI 10.1677/joe.0.1700071
   Storto M, 2000, J NEUROIMMUNOL, V109, P112, DOI 10.1016/S0165 5728(00)00269 1
   Sureda F, 1997, EUR J PHARMACOL, V338, pR1, DOI 10.1016/S0014 2999(97)81950 4
   Swanson CJ, 2005, NAT REV DRUG DISCOV, V4, P131, DOI 10.1038/nrd1630
   Tong QC, 2002, AM J PHYSIOL ENDOC M, V282, pE1324, DOI 10.1152/ajpendo.00460.2001
   Uehara S, 2004, DIABETES, V53, P998, DOI 10.2337/diabetes.53.4.998
   Varney MA, 2002, CNS NEUROL DISORD DR, V1, P283, DOI 10.2174/1568007023339300
   Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889
   Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358
NR 53
TC 30
Z9 46
U1 0
U2 10
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306 4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD AUG
PY 2007
VL 32
SU 1
BP S40
EP S45
DI 10.1016/j.psyneuen.2007.04.015
PG 6
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 214EK
UT WOS:000249718600009
PM 17651904
DA 2025 08 17
ER

PT J
AU Lorthongpanich, C
   Charoenwongpaiboon, T
   Supakun, P
   Klaewkla, M
   Kheolamai, P
   Issaragrisil, S
AF Lorthongpanich, Chanchao
   Charoenwongpaiboon, Thanapon
   Supakun, Prapasri
   Klaewkla, Methus
   Kheolamai, Pakpoom
   Issaragrisil, Surapol
TI Fisetin Inhibits Osteogenic Differentiation of Mesenchymal Stem Cells
   via the Inhibition of YAP
SO ANTIOXIDANTS
LA English
DT Article
DE fisetin; osteogenic differentiation; mesenchymal stem cells; inhibition;
   YAP; flavonoid
ID OSTEOBLASTIC DIFFERENTIATION; ASSAY; EXPRESSION; APOPTOSIS; THERAPY;
   PROLIFERATION; ACTIVATION; ALIZARIN; ACCURACY; PATHWAY
AB Mesenchymal stem cells (MSCs) are self renewal and capable of differentiating to various functional cell types, including osteocytes, adipocytes, myoblasts, and chondrocytes. They are, therefore, regarded as a potential source for stem cell therapy. Fisetin is a bioactive flavonoid known as an active antioxidant molecule that has been reported to inhibit cell growth in various cell types. Fisetin was shown to play a role in regulating osteogenic differentiation in animal derived MSCs; however, its molecular mechanism is not well understood. We, therefore, studied the effect of fisetin on the biological properties of human MSCs derived from chorion tissue and its role in human osteogenesis using MSCs and osteoblast like cells (SaOs 2) as a model. We found that fisetin inhibited proliferation, migration, and osteogenic differentiation of MSCs as well as human SaOs 2 cells. Fisetin could reduce Yes associated protein (YAP) activity, which results in downregulation of osteogenic genes and upregulation of fibroblast genes. Further analysis using molecular docking and molecular dynamics simulations suggests that fisetin occupied the hydrophobic TEAD pocket preventing YAP from associating with TEA domain (TEAD). This finding supports the potential application of flavonoids like fisetin as a protein protein interaction disruptor and also suggesting an implication of fisetin in regulating human osteogenesis.
C1 [Lorthongpanich, Chanchao; Supakun, Prapasri; Issaragrisil, Surapol] Mahidol Univ, Fac Med Siriraj Hosp, Siriraj Ctr Excellence Stem Cell Res, Dept Med, Bangkok 10700, Thailand.
   [Charoenwongpaiboon, Thanapon] Silpakorn Univ, Dept Chem, Fac Sci, Bangkok 73000, Thailand.
   [Klaewkla, Methus] Chulalongkorn Univ, Dept Biochem, Fac Sci, Bangkok 10330, Thailand.
   [Kheolamai, Pakpoom] Thammasat Univ, Div Cell Biol, Fac Med, Pathum Thani 10120, Thailand.
C3 Mahidol University; Silpakorn University; Chulalongkorn University;
   Thammasat University
RP Lorthongpanich, C (通讯作者)，Mahidol Univ, Fac Med Siriraj Hosp, Siriraj Ctr Excellence Stem Cell Res, Dept Med, Bangkok 10700, Thailand.
EM chanchao.lor@mahidol.ac.th; charoenwongpaib_t@su.ac.th;
   cup14t@gmail.com; methus.kanon@gmail.com; pkheolamai@me.com;
   surapolsi@gmail.com
RI Lorthongpanich, Chanchao/KOD 6786 2024; Charoenwongpaiboon,
   Thanapon/CAI 6460 2022; Kheolamai, Pakpoom/R 8575 2019
OI Lorthongpanich, Chanchao/0000 0003 2206 7065; Charoenwongpaiboon,
   Thanapon/0000 0001 9322 0261; 
FU Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
   Thailand; Siriraj foundation [D003276]
FX This research was funded by a grant from the Faculty of Medicine Siriraj
   Hospital, Mahidol University, Bangkok, Thailand. C.L. and S.I. were
   supported by Siriraj foundation, grant no. D003276.
CR Abo Aziza Faten A M, 2019, Cell Regen, V8, P58, DOI 10.1016/j.cr.2019.11.001
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Brito VGB, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112131
   Bongso A, 2013, STEM CELL REV REP, V9, P226, DOI 10.1007/s12015 012 9418 z
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Coelho MJ, 2000, BIOMATERIALS, V21, P1087, DOI 10.1016/S0142 9612(99)00284 7
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng G, 2016, INFLAMMATION, V39, P148, DOI 10.1007/s10753 015 0233 y
   Frisch M.J., GAUSSIAN 09 REVISION, V2
   Fu CY, 2019, ENVIRON TOXICOL, V34, P902, DOI 10.1002/tox.22761
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Haddad AQ, 2006, PROSTATE CANCER P D, V9, P68, DOI 10.1038/sj.pcan.4500845
   Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Hatakeyama W, 2013, INT J MOL MED, V32, P1255, DOI 10.3892/ijmm.2013.1516
   Heng BC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00735
   Heo JS, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6921703
   Holden JK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107809
   Hong LX, 2018, CELL MOL IMMUNOL, V15, P1003, DOI 10.1038/s41423 018 0007 1
   Hwang KC, 2008, P NATL ACAD SCI USA, V105, P7467, DOI 10.1073/pnas.0802825105
   Jash S.K., 2014, Cardiovasc. Dis, V5, P6
   Je HD, 2016, BIOMOL THER, V24, P57, DOI 10.4062/biomolther.2015.104
   Jeyaraman M, 2021, BBA MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2020.166014
   Jonkman JEN, 2014, CELL ADHES MIGR, V8, P440, DOI 10.4161/cam.36224
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Justus CR, 2014, JOVE J VIS EXP, DOI 10.3791/51046
   Kashyap D, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9050174
   Khan N, 2008, CARCINOGENESIS, V29, P1049, DOI 10.1093/carcin/bgn078
   Kim M, 2019, P NATL ACAD SCI USA, V116, P1569, DOI 10.1073/pnas.1815447116
   Kimira M, 1998, J Epidemiol, V8, P168
   Kucerova L, 2014, GENE THER, V21, P874, DOI 10.1038/gt.2014.66
   Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118
   Lee KM, 2018, BIOCHEM BIOPH RES CO, V503, P116, DOI 10.1016/j.bbrc.2018.05.191
   Lóotoing L, 2014, MOL NUTR FOOD RES, V58, P1239, DOI 10.1002/mnfr.201300836
   Li JM, 2015, BANGL J PHARMACOL, V10, P820, DOI 10.3329/bjp.v10i4.23039
   Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810
   Liou CJ, 2018, CELL PHYSIOL BIOCHEM, V49, P1870, DOI 10.1159/000493650
   Liu S, 2016, NEUROPEPTIDES, V56, P105, DOI 10.1016/j.npep.2015.12.008
   Lorthongpanich C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1494 4
   Macri Pellizzeri L, 2018, TISSUE ENG PART C ME, V24, P171, DOI [10.1089/ten.tec.2017.0400, 10.1089/ten.TEC.2017.0400]
   Maher P, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9111113
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Manochantr S, 2015, NEUROL RES, V37, P545, DOI 10.1179/1743132815Y.0000000019
   McNamara LM, 2009, ANAT REC, V292, P355, DOI 10.1002/ar.20869
   Menon MB, 2009, CELL MOTIL CYTOSKEL, V66, P1041, DOI 10.1002/cm.20418
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Musial Wysocka A, 2019, CELL TRANSPLANT, V28, P801, DOI 10.1177/0963689719837897
   National Center for Biotechnology Information, 2020, PUBCHEM COMP SUMM CI
   Noh EM, 2015, EUR J PHARMACOL, V764, P79, DOI 10.1016/j.ejphar.2015.06.038
   Pan ZJ, 2017, INT J ONCOL, V51, P1055, DOI 10.3892/ijo.2017.4101
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Park HH, 2008, ARCH PHARM RES, V31, P1303, DOI 10.1007/s12272 001 2110 5
   Pearngam P, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00827
   Pevsner Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood 2006 06 028704
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Postiglione L, 2003, J DENT RES, V82, P692, DOI 10.1177/154405910308200907
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Schepers B, 2020, J CHEM PHYS, V152, DOI 10.1063/5.0007630
   Shima WN, 2015, EXP THER MED, V9, P2202, DOI 10.3892/etm.2015.2381
   Smith SA, 2019, J MED CHEM, V62, P1291, DOI 10.1021/acs.jmedchem.8b01402
   Song GB, 2007, COLLOID SURFACE B, V58, P271, DOI 10.1016/j.colsurfb.2007.04.001
   Suh Y, 2009, CARCINOGENESIS, V30, P300, DOI 10.1093/carcin/bgn269
   Sun X, 2018, INT J MOL MED, V42, P811, DOI 10.3892/ijmm.2018.3654
   Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang LS, 2006, J AGR FOOD CHEM, V54, P9798, DOI 10.1021/jf0620719
   Wei YJ, 2011, OSTEOPOROSIS INT, V22, P1469, DOI 10.1007/s00198 010 1352 9
   Wu TY, 2021, J CELL PHYSIOL, V236, P284, DOI 10.1002/jcp.29841
   Wu XW, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0019086
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Yang LL, 2020, BIOMATER SCI UK, V8, P2638, DOI 10.1039/d0bm00264j
   YORK DM, 1993, J CHEM PHYS, V99, P8345, DOI 10.1063/1.465608
   Yu DL, 2017, ONCOTARGETS THER, V10, P4719, DOI 10.2147/OTT.S136840
   Zha KK, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/8830834
   Zheng Qixin, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P674
NR 81
TC 18
Z9 20
U1 1
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD JUN
PY 2021
VL 10
IS 6
AR 879
DI 10.3390/antiox10060879
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA SX5TD
UT WOS:000665266300001
PM 34070903
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lai, KL
   Jiang, W
   Tang, JZ
   Wu, Y
   He, B
   Wang, G
   Gu, ZW
AF Lai, Kuilin
   Jiang, Wen
   Tang, James Z.
   Wu, Yao
   He, Bin
   Wang, Gang
   Gu, Zhongwei
TI Superparamagnetic nano composite scaffolds for promoting bone cell
   proliferation and defect reparation without a magnetic field
SO RSC ADVANCES
LA English
DT Article
ID DOUBLE BLIND; NANOPARTICLES; NANOFIBERS; THERAPY; EFFICACY; GROWTH;
   FORCE; PAIN
AB Apart from chemical molecules, physical regulations also greatly determine the efficiency of healing in regenerating functional tissues. In this study, we fabricated superparamagnetic nano composite scaffolds for tissue engineering and investigated their effects on different bone cells without an external magnetic field. Poly(lactic co glycolic acid) (PLGA) and hydrophobic superparamagnetic magnetite nanoparticles (MNPs) were combined together with different mass ratios in order to construct composite scaffolds using an electrospinning method for the first time. The diameters of the fibers were 400 600 nm with the MNPs uniformly dispersed in them, as shown by transmission (TEM) and scanning (SEM) electron microscopy observations. All composite scaffolds retained superparamagnetism at room temperature, but the saturation magnetization did not increase linearly as the magnetite content increased. The composite scaffolds with different MNP content showed excellent biocompatibility and significantly promoted cell proliferation compared with PLGA nanofibrous scaffold without an external magnetic field. Cell cycle analysis proved that the composite scaffolds decreased cell numbers in G0/G1 phase while increasing those in S phase, which resulted in positive effects on cell proliferation. However, the composite scaffolds had no effect on the differentiation of MC3T3 E1 cells because of the different impact mechanism between proliferation and differentiation. Therefore, the composite scaffolds composed of superparamagnetic MNPs could be considered as an ideal substrate for accelerating osteoblast cell proliferation and tissue repair.
C1 [Lai, Kuilin; Jiang, Wen; Wu, Yao; He, Bin; Wang, Gang; Gu, Zhongwei] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
   [Tang, James Z.] Wolverhampton Univ, Dept Pharm, Sch Appl Sci, Wolverhampton WV1 1SB, England.
C3 Sichuan University; University of Wolverhampton
RP Lai, KL (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
EM Yaowu_amanda@126.com; zwgu@scu.edu.cn
RI wu, yao/IQS 3834 2023; gu, zhongwei/HPC 3816 2023; Lai, KL/C 7236 2013;
   he, bin/AAV 6319 2021
FU National Basic Research Program of China (National 973 program)
   [2011CB606206]; National Natural Science Foundation of China [31070849,
   50830105, 51133004]; Department of Science and Technology of Sichuan
   Province [2009HH0001, 2009SZ0137]; Ministry of Science and Technology
   [2010DFA51550]; European Commission Research and Innovation
   [PIRSES GA 2011 295218]
FX The authors would like to thank National Basic Research Program of China
   (National 973 program, No. 2011CB606206), the National Natural Science
   Foundation of China (31070849, 50830105, 51133004), the Department of
   Science and Technology of Sichuan Province (2009HH0001, 2009SZ0137), the
   Ministry of Science and Technology (2010DFA51550), and European
   Commission Research and Innovation (PIRSES GA 2011 295218)
CR Amna T, 2012, INT J NANOMED, V7, P1659, DOI 10.2147/IJN.S24467
   [Anonymous], BIOMED MAT
   Badami AS, 2006, BIOMATERIALS, V27, P596, DOI 10.1016/j.biomaterials.2005.05.084
   BEAN CP, 1959, J APPL PHYS, V30, P1976, DOI 10.1063/1.1735100
   BERGMEYER HU, 1974, METHOD ENZYMAT AN
   Bersani F, 1997, BIOELECTROMAGNETICS, V18, P463, DOI 10.1002/(SICI)1521 186X(1997)18:7<463::AID BEM1>3.0.CO;2 0
   Boyan BD, 2003, J ORTHOP RES, V21, P638, DOI 10.1016/S0736 0266(02)00261 9
   Bronstein LM, 2007, CHEM MATER, V19, P3624, DOI 10.1021/cm062948j
   Brown CS, 2002, AM J OBSTET GYNECOL, V187, P1581, DOI 10.1067/mob.2002.128026
   Engström S, 2002, BIOELECTROMAGNETICS, V23, P475, DOI 10.1002/bem.10035
   Eremenko T, 1997, BIOELECTROMAGNETICS, V18, P58, DOI 10.1002/(SICI)1521 186X(1997)18:1<58::AID BEM9>3.0.CO;2 4
   Fujihara K, 2005, BIOMATERIALS, V26, P4139, DOI 10.1016/j.biomaterials.2004.09.014
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hong RY, 2006, POWDER TECHNOL, V170, P1, DOI 10.1016/j.powtec.2006.08.017
   Huang ZM, 2003, COMPOS SCI TECHNOL, V63, P2223, DOI 10.1016/S0266 3538(03)00178 7
   Ino K, 2009, BIOTECHNOL BIOENG, V102, P882, DOI 10.1002/bit.22104
   Ito A, 2005, BIOMATERIALS, V26, P6185, DOI 10.1016/j.biomaterials.2005.03.039
   Ito G., 2002, BIOELECTROMAGNETICS, V23, P398
   Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003 0008
   Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e
   Le Renard PE, 2010, BIOMATERIALS, V31, P691, DOI 10.1016/j.biomaterials.2009.09.091
   Liu XH, 2004, ANN BIOMED ENG, V32, P477, DOI 10.1023/B:ABME.0000017544.36001.8e
   Man D, 1999, PLAST RECONSTR SURG, V104, P2261, DOI 10.1097/00006534 199912000 00051
   Markov MS, 1997, BIOELECTROCH BIOENER, V43, P233, DOI 10.1016/S0302 4598(96)02226 X
   Meenach SA, 2010, ACTA BIOMATER, V6, P1039, DOI 10.1016/j.actbio.2009.10.017
   Meng J, 2010, NANOSCALE, V2, P2565, DOI 10.1039/c0nr00178c
   Patel D, 2011, BIOMATERIALS, V32, P1167, DOI 10.1016/j.biomaterials.2010.10.013
   Pilla A. A., 2007, HDB BIOL EFFECTS ELE
   Qiu Li hong, 2004, Shanghai Kou Qiang Yi Xue, V13, P469
   Sazaki G, 1997, J CRYST GROWTH, V173, P231, DOI 10.1016/S0022 0248(96)00777 4
   Sharma B, 2004, ANN BIOMED ENG, V32, P148, DOI 10.1023/B:ABME.0000007799.60142.78
   Shimizu K, 2007, J BIOSCI BIOENG, V103, P472, DOI 10.1263/jbb.103.472
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Song T, 2005, CHEM PHYS LETT, V415, P317, DOI 10.1016/j.cplett.2005.09.035
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Tang ZG, 2006, BIOMATERIALS, V27, P4409, DOI 10.1016/j.biomaterials.2006.04.009
   Vallbona C, 1997, ARCH PHYS MED REHAB, V78, P1200, DOI 10.1016/S0003 9993(97)90332 4
   Wang H, 2009, MATER RES BULL, V44, P1676, DOI 10.1016/j.materresbull.2009.04.006
   Wang SH, 2010, MATER LETT, V64, P9, DOI 10.1016/j.matlet.2009.09.043
   Weintraub MI, 2003, ARCH PHYS MED REHAB, V84, P736, DOI 10.1016/S0003 9993(03)00106 0
   Wolsko PM, 2004, ALTERN THER HEALTH M, V10, P36
   Wu SYH, 2010, J NANOPART RES, V12, P1173, DOI 10.1007/s11051 009 9734 7
   Xu A., 2010, PLASMA SCI TECHNOL, V12, P123
   Yan W., 2011, BIOMED MATER, V6
   Yang ZJ, 1996, BIOMATERIALS, V17, P2131, DOI 10.1016/0142 9612(96)00044 0
   Zeng XB, 2012, INT J NANOMED, V7, P3365, DOI 10.2147/IJN.S32264
   Zhang L, 2006, APPL SURF SCI, V253, P2611, DOI 10.1016/j.apsusc.2006.05.023
NR 47
TC 62
Z9 63
U1 0
U2 74
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2012
VL 2
IS 33
BP 13007
EP 13017
DI 10.1039/c2ra22376g
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 051TF
UT WOS:000312149600068
DA 2025 08 17
ER

PT J
AU Hayashi, Y
   Kawakubo Yasukochi, T
   Mizokami, A
   Hazekawa, M
   Yakura, T
   Naito, M
   Takeuchi, H
   Nakamura, S
   Hirata, M
AF Hayashi, Yoshikazu
   Kawakubo Yasukochi, Tomoyo
   Mizokami, Akiko
   Hazekawa, Mai
   Yakura, Tomiko
   Naito, Munekazu
   Takeuchi, Hiroshi
   Nakamura, Seiji
   Hirata, Masato
TI Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse
   Melanoma Cell Growth
SO JOURNAL OF CANCER
LA English
DT Article
ID RECEPTOR TYROSINE KINASES; INTERFERON GAMMA; IFN GAMMA; IN VIVO; B16
   MELANOMA; TUMOR; ACTIVATION; MECHANISMS; RESISTANCE; INHIBITION
AB Because of the poor response to chemotherapy and radiation therapy, new treatment approaches by immune based therapy involving activated T cells are required for melanoma. We previously reported that the uncarboxylated form of osteocalcin (GluOC), derived from osteoblasts, potentially suppresses human prostate cancer cell proliferation by direct suppression of cell growth. However, the mechanisms in vivo have not been elucidated. In this study, we found that GluOC suppressed tumor growth of B16 mouse melanoma transplants in C57Bl/6N wild type mice. Our data demonstrated that GluOC suppressed cell growth by downregulating phosphorylation levels of receptor tyrosine kinases and inducing apoptosis in vitro. Additionally, stimulation of primary mouse splenocytes with concanavalin A, a polyclonal T cell mitogen, in the presence of GluOC increased T cell proliferation and their interferon gamma production. Taken together, we demonstrate that GluOC exerts multiple antitumor effects not only in vitro, but also in vivo through cellular immunostimulatory effects against B16 mouse melanoma cells.
C1 [Hayashi, Yoshikazu; Kawakubo Yasukochi, Tomoyo; Mizokami, Akiko; Hirata, Masato] Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.
   [Hayashi, Yoshikazu; Nakamura, Seiji] Kyushu Univ, Fac Dent Sci, Sect Oral & Maxillofacial Oncol, Fukuoka 8128582, Japan.
   [Kawakubo Yasukochi, Tomoyo; Hazekawa, Mai] Fukuoka Univ, Fac Pharmaceut Sci, Dept Immunol & Mol Pharmacol, Fukuoka 8140180, Japan.
   [Mizokami, Akiko] Kyushu Univ, Fac Dent Sci, OBT Res Ctr, Fukuoka 8128582, Japan.
   [Yakura, Tomiko; Naito, Munekazu] Aichi Med Univ, Dept Anat, Nagakute, Aichi 4801195, Japan.
   [Takeuchi, Hiroshi] Kyushu Dent Univ, Div Appl Pharmacol, Kitakyushu, Fukuoka 8038580, Japan.
   [Hirata, Masato] Fukuoka Dent Coll, Fukuoka 8140193, Japan.
C3 Kyushu University; Kyushu University; Fukuoka University; Kyushu
   University; Aichi Medical University; Kyushu Dental University; Fukuoka
   Dental College (FDC)
RP Hirata, M (通讯作者)，Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.; Kawakubo Yasukochi, T (通讯作者)，Fukuoka Univ, Fac Pharmaceut Sci, Dept Immunol & Mol Pharmacol, Fukuoka 8140180, Japan.; Hirata, M (通讯作者)，Fukuoka Dent Coll, Fukuoka 8140193, Japan.
EM tomoyoyasu@fukuoka u.ac.jp; hirata1@dent.kyushu u.ac.jp
RI ; Mizokami, Akiko/ABC 5448 2021; Takeuchi, Hiroshi/I 8849 2019
OI YAKURA, TOMIKO/0000 0002 2605 8396; Mizokami, Akiko/0000 0002 7490 5190;
   Takeuchi, Hiroshi/0000 0003 0033 2913; 
FU Japan Society for the Promotion of Science (KAKENHI) [24229009,
   26861554, 16K11496, 26861553, 16K20421]; Central Research Institute of
   Fukuoka University [157103]; Fukuoka Foundation for Sound Health Cancer
   Research Fund; The Iwadare Scholarship Foundation; Morita Scholarship
   Foundation; Grants in Aid for Scientific Research [17K19766, 17K11649,
   16K11496, 17H01595, 16K20421, 26861554, 26861553] Funding Source: KAKEN
FX This work was supported by the Japan Society for the Promotion of
   Science (KAKENHI grants 24229009 to M. Hirata, 26861554 and 16K11496 to
   T. Kawakubo Yasukochi, and 26861553 and 16K20421 to A. Mizokami), the
   Central Research Institute of Fukuoka University (157103 to T.
   Kawakubo Yasukochi. and M. Hazekawa), and Fukuoka Foundation for Sound
   Health Cancer Research Fund. The authors acknowledge useful discussion
   with Prof. M. Nakashima (Fukuoka University). Y. Hayashi was a recipient
   of The Iwadare Scholarship Foundation and Morita Scholarship Foundation.
CR [Anonymous], INT J CANC
   Boone B, 2011, J CUTAN PATHOL, V38, P492, DOI 10.1111/j.1600 0560.2011.01673.x
   BRINKMANN V, 1986, J IMMUNOL, V137, P2991
   Clark JW, 2005, CLIN CANCER RES, V11, P5472, DOI 10.1158/1078 0432.CCR 04 2658
   Clemmensen C, 2014, BRIT J PHARMACOL, V171, P1129, DOI 10.1111/bph.12365
   Davar D, 2016, CANCER TREAT RES, V167, P181, DOI 10.1007/978 3 319 22539 5_7
   Dayer LE, 2015, J ONCOL PHARM PRACT, V21, P224, DOI 10.1177/1078155214524084
   Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570
   Dias DS, 2014, MOLECULES, V19, P12814, DOI 10.3390/molecules190812814
   DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074 7613(94)90087 6
   Easty DJ, 2011, PIGM CELL MELANOMA R, V24, P446, DOI 10.1111/j.1755 148X.2011.00836.x
   GANSBACHER B, 1990, CANCER RES, V50, P7820
   Garay T, 2015, PATHOL ONCOL RES, V21, P957, DOI 10.1007/s12253 015 9916 9
   Gardner TA, 2009, ONCOL REP, V21, P903, DOI 10.3892/or_00000302
   Gioarelli M, 1986, INT J CANCER, V37, P141
   Hayashi Y, 2016, J CANCER, V7, P1605, DOI 10.7150/jca.15523
   Heikkilä K, 2008, EUR J CANCER, V44, P937, DOI 10.1016/j.ejca.2008.02.047
   Hong DS, 2015, ONCOTARGET, V6, P43127, DOI 10.18632/oncotarget.5756
   Kakuta S, 2002, IMMUNOLOGY, V105, P92, DOI 10.1046/j.0019 2805.2001.01342.x
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556
   Kawakubo Yasukochi T, 2016, OBESITY, V24, P895, DOI 10.1002/oby.21447
   Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052
   Kuang DH, 2005, J NEUROCHEM, V93, P383, DOI 10.1111/j.1471 4159.2005.03025.x
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   LI YP, 1992, J IMMUNOL, V148, P788
   Liu SY, 2012, P NATL ACAD SCI USA, V109, P4239, DOI 10.1073/pnas.1114981109
   Lugade AA, 2008, J IMMUNOL, V180, P3132, DOI 10.4049/jimmunol.180.5.3132
   MAEKAWA R, 1988, J INTERFERON RES, V8, P227, DOI 10.1089/jir.1988.8.227
   Marchetti D, 2003, J CELL BIOCHEM, V88, P865, DOI 10.1002/jcb.10473
   Mera P, 2016, MOL METAB, V5, P1042, DOI 10.1016/j.molmet.2016.07.002
   Mizokami A, 2014, BONE, V69, P68, DOI 10.1016/j.bone.2014.09.006
   Mizokami A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057375
   Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6
   MULE JJ, 1992, J IMMUNOL, V148, P2622
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Otani T, 2015, CELL SIGNAL, V27, P532, DOI 10.1016/j.cellsig.2014.12.018
   Owens B, 2014, NATURE, V515, pS109, DOI 10.1038/515S109a
   Pi M, 2011, J BONE MINER RES, V26, P1680, DOI 10.1002/jbmr.390
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Rajabi P, 2012, J RES MED SCI, V17, P534
   Ramirez Montagut T, 2003, ONCOGENE, V22, P3180, DOI 10.1038/sj.onc.1206462
   Rini BI, 2007, EXPERT OPIN PHARMACO, V8, P2359, DOI 10.1517/14656566.8.14.2359
   Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339
   Sanna PS, 2012, HISTOCHEM CELL BIOL, V138, P895
   Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008 5472.CAN 11 0140
   Siska PJ, 2015, TRENDS IMMUNOL, V36, P257, DOI 10.1016/j.it.2015.02.007
   Smyth MJ, 2005, NAT IMMUNOL, V6, P646, DOI 10.1038/ni0705 646
   Tarik R., 2015, CANCERS, V7, P1758
   Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev immunol 031210 101324
   Xu YR, 2015, DRUG DEV IND PHARM, V41, P369, DOI 10.3109/03639045.2013.861480
   Yang LPH, 2012, DRUGS, V72, P2375, DOI 10.2165/11209230 000000000 00000
   Yim JH, 1999, J INTERF CYTOK RES, V19, P723, DOI 10.1089/107999099313569
NR 54
TC 13
Z9 13
U1 0
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837 9664
J9 J CANCER
JI J. Cancer
PY 2017
VL 8
IS 13
BP 2478
EP 2486
DI 10.7150/jca.18648
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FE5HQ
UT WOS:000408243000008
PM 28900485
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Tsuboi, Y
   Ichida, Y
   Murai, A
   Maeda, A
   Iida, M
   Kato, A
   Ohtomo, S
   Horiba, N
AF Tsuboi, Yoshinori
   Ichida, Yasuhiro
   Murai, Atsuko
   Maeda, Akira
   Iida, Manami
   Kato, Atsuhiko
   Ohtomo, Shuichi
   Horiba, Naoshi
TI EOS789, pan phosphate transporter inhibitor, ameliorates the progression
   of kidney injury in anti GBM induced glomerulonephritis rats
SO PHARMACOLOGY RESEARCH & PERSPECTIVES
LA English
DT Article
DE anti GBM nephritis rats; crescent; EOS789; hyperphosphatemia
ID SEVELAMER HYDROCHLORIDE; PHOSPHORUS ABSORPTION; PARATHYROID HORMONE;
   CALCIUM ACETATE; RECEPTOR NURR1; BINDER; SERUM; DISEASE; FGF23;
   HYPERPHOSPHATEMIA
AB Hyperphosphatemia associated with chronic kidney disease (CKD) not only dysregulates mineral metabolism and bone diseases, but also strongly contributes to the progression of kidney disease itself. We have identified a novel drug for hyperphosphatemia, EOS789, that interacts with several sodium dependent phosphate transporters (NaPi IIb, PiT 1, and PiT 2) known to contribute to intestinal phosphate absorption. In this study, we investigated whether EOS789 could ameliorate kidney disease progression in glomerulonephritis rats. Anti glomerular basement membrane (GBM) nephritis was induced in rats by intravenously administering two types of anti rat GBM antibodies. We evaluated the effect of EOS789 administered in food admixture on hyperphosphatemia and kidney disease progression. In an anti GBM nephritis rats, which exhibit a significant increase in serum phosphate and a decline in renal function, EOS789 dose dependently improved hyperphosphatemia and EOS789 at 0.3% food admixture significantly ameliorated kidney dysfunction as shown in the decline of serum creatinine and BUN. Renal histopathology analysis showed that EOS789 significantly decreased crescent formation in glomeruli. To elucidate the mechanism underlying glomerular disease progression, human mesangial cells were used. High phosphate concentration in media significantly increased the expression of Collagen 1A1, 3A1, and alpha SMA mRNA in human mesangial cells and EOS789 dose dependently suppressed these fibrotic markers. These results indicate that EOS789 prevented glomerular crescent formation caused by mesangial fibrosis by ameliorating hyperphosphatemia. In conclusion, EOS789 would not only be useful against hyperphosphatemia but may also have the potential to relieve mesangial proliferative glomerulonephritis with crescent formation.
C1 [Tsuboi, Yoshinori; Ichida, Yasuhiro; Maeda, Akira; Iida, Manami; Horiba, Naoshi] Chugai Pharmaceut Co Ltd, Res Div, Gotemba, Shizuoka, Japan.
   [Murai, Atsuko; Kato, Atsuhiko; Ohtomo, Shuichi] Chugai Pharmaceut Co Ltd, Translat Res Div, Gotemba, Shizuoka, Japan.
C3 Chugai Pharmaceutical Co., Ltd.; Roche Holding; Roche Holding Japan;
   Roche Holding; Roche Holding Japan; Chugai Pharmaceutical Co., Ltd.
RP Tsuboi, Y (通讯作者)，Komakado 1 135, Gotemba, Shizuoka 4128513, Japan.
EM tsuboiysn@chugai pharm.co.jp
CR Berndt T, 2007, P NATL ACAD SCI USA, V104, P11085, DOI 10.1073/pnas.0704446104
   Bleyer AJ, 1999, AM J KIDNEY DIS, V33, P694, DOI 10.1016/S0272 6386(99)70221 0
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Castañeda TR, 2021, J PHARMACOL EXP THER, V376, P190, DOI 10.1124/jpet.120.000285
   Egli Spichtig D, 2019, KIDNEY INT, V96, P890, DOI 10.1016/j.kint.2019.04.009
   Floege J, 2015, NEPHROL DIAL TRANSPL, V30, P1037, DOI 10.1093/ndt/gfv006
   Fouque D, 2011, KIDNEY INT, V80, P348, DOI 10.1038/ki.2011.118
   Gallant KMH, 2021, KIDNEY INT, V99, P1225, DOI 10.1016/j.kint.2020.09.035
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hutchison AJ, 2016, NEPHROLOGY, V21, P987, DOI 10.1111/nep.12864
   ITO M, 1983, JPN J PHARMACOL, V33, P1145, DOI 10.1254/jjp.33.1145
   JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672
   Jing WH, 2018, J PHARMACOL EXP THER, V367, P129, DOI 10.1124/jpet.118.249961
   Kanbay M, 2009, BLOOD PURIFICAT, V27, P220, DOI 10.1159/000197562
   Katai K, 2015, J MED INVESTIG, V62, P68, DOI 10.2152/jmi.62.68
   Katsumata K, 2003, KIDNEY INT, V64, P441, DOI 10.1046/j.1523 1755.2003.00126.x
   Krikken JA, 2009, CURR OPIN NEPHROL HY, V18, P531, DOI 10.1097/MNH.0b013e3283312fc8
   Maeda A, 2019, NEPHRON, V142, P135, DOI 10.1159/000497118
   Matsuo A, 2014, RENAL FAILURE, V36, P1291, DOI 10.3109/0886022X.2014.930491
   McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979
   Meir T, 2014, KIDNEY INT, V86, P1106, DOI 10.1038/ki.2014.215
   Mizuno K., 2012, JP patent, Patent No. [501624B2, 501624]
   Nagano N, 2006, KIDNEY INT, V69, P531, DOI 10.1038/sj.ki.5000020
   Nagano N, 2003, NEPHROL DIAL TRANSPL, V18, P2014, DOI 10.1093/ndt/gfg309
   Ohtake Y., 2016, U.S. patent, Patent No. [2016/0002251 Al, 20160002251]
   Palmer SC, 2011, JAMA J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   Papadimitriou A, 2014, CELL PHYSIOL BIOCHEM, V34, P1260, DOI 10.1159/000366336
   Phan O, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/515606
   Pieper AK, 2006, AM J KIDNEY DIS, V47, P625, DOI 10.1053/j.ajkd.2005.12.039
   SHEIKH MS, 1989, J CLIN INVEST, V83, P66, DOI 10.1172/JCI113886
   Simic P, 2020, J CLIN INVEST, V130, P1513, DOI 10.1172/JCI131190
   Tan XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147816
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Toda N, 2017, SCI REP UK, V7, DOI 10.1038/srep42114
   Tsuboi Y, 2020, KIDNEY INT, V98, P343, DOI 10.1016/j.kint.2020.02.040
   Vegter S, 2012, J AM SOC NEPHROL, V23, P165, DOI 10.1681/ASN.2011040430
   Zhang XY, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1488 5
NR 37
TC 4
Z9 4
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2052 1707
J9 PHARMACOL RES PERSPE
JI Pharmacol. Res. Perspect.
PD JUN
PY 2022
VL 10
IS 3
AR e00973
DI 10.1002/prp2.973
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1N3SK
UT WOS:000800578800001
PM 35621227
OA Green Published
DA 2025 08 17
ER

PT J
AU Mannava, S
   Whitney, KE
   Kennedy, MI
   King, J
   Dornan, GJ
   Klett, K
   Chahla, J
   Evans, TA
   Huard, J
   LaPrade, RF
AF Mannava, Sandeep
   Whitney, Kaitlyn E.
   Kennedy, Mitchell I.
   King, Jill
   Dornan, Grant J.
   Klett, Katarina
   Chahla, Jorge
   Evans, Thos A.
   Huard, Johnny
   LaPrade, Robert F.
TI The Influence of Naproxen on Biological Factors in Leukocyte Rich
   Platelet Rich Plasma: A Prospective Comparative Study
SO ARTHROSCOPY THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GROWTH FACTOR; MUSCULOSKELETAL
   DISEASES; MOLECULAR MECHANISMS; CELLULAR COMPOSITION; BLOOD PRODUCTS;
   INHIBITION; CYTOKINE; BONE; MUSCLE
AB Purpose: To quantify and compare normative catabolic and anabolic factor concentrations in leukocyte rich platelet rich plasma (LR PRP) at various time points, including baseline, 1 week after initiating naproxen use, and after a 1 week washout period. Methods: Asymptomatic healthy donors aged between 18 and 70 years were recruited (average age, 36.6 years; range, 25 64 years). Subjects were excluded from the study if they were actively taking any prescribed medications or nonsteroidal anti inflammatory drugs (NSAIDs) or if they had any of the following at present or previously: blood or immunosuppression disorders, cancer, osteonecrosis, rheumatoid arthritis, avascular necrosis, NSAID intolerance, gastrointestinal or peptic ulcer disease, or kidney dysfunction. The anabolic factors vascular endothelial growth factor, fibroblast growth factor 2, platelet derived growth factor AB (PDGF AB), and platelet derived growth factor AA (PDGF AA) and the catabolic factors interleukin (IL) 1 beta, IL 6, IL 8, and tumor necrosis factor a in LR PRP were measured. Peripheral blood was drawn at 3 time points: baseline, after 1 week of naproxen use, and after a 1 week washout period. Results: The angiogenic factors PDGF AA (44% decrease in median) and PDGF AB (47% decrease) significantly declined from baseline (P < .05) after 1 week of naproxen use. There was a significant recovery (P < .05) of PDGF AA (94% increase) and PDGF AB (153% increase) levels after the 1 week washout period, with a return to baseline levels. The catabolic factor IL 6 also had a significant decline from baseline (77% decrease in median, P < .05) after 1 week of naproxen use. After a 1 week washout period, the IL 6 level was similar to the baseline level (130% increase, P < .05). Conclusions: Naproxen use diminished several biological factors in LR PRP; however, a 1 week washout period was sufficient for the recovery of PDGF AA, PDGF AB, and IL 6 to return to baseline levels. Tumor necrosis factor alpha, IL beta, IL 8, vascular endothelial growth factor, and fibroblast growth factor 2 did not show differences between the 3 time points of data collection. Discontinuing NSAIDs for a minimum of 1 week before LR PRP treatment may improve certain biological factor levels.
C1 [Mannava, Sandeep; Evans, Thos A.; Huard, Johnny; LaPrade, Robert F.] Steadman Philippon Res Inst, Ctr Regenerat Sports Med, Vail, CO USA.
   [Mannava, Sandeep; Whitney, Kaitlyn E.; Kennedy, Mitchell I.; King, Jill; Dornan, Grant J.; Klett, Katarina; Chahla, Jorge; Evans, Thos A.; Huard, Johnny; LaPrade, Robert F.] Steadman Clin, Vail, CO USA.
C3 Steadman Philippon Research Institute
RP LaPrade, RF (通讯作者)，Steadman Philippon Res Inst, 181 W Meadow Dr,Ste 1000, Vail, CO 81657 USA.
EM drlaprade@sprivail.org
RI ; LaPrade, Robert/AFA 8673 2022; Dornan, Grant/ABC 7409 2020
OI Whitney, Kaitlyn/0000 0003 3935 8803; Chahla, Jorge/0000 0002 9194 1150;
   Dornan, Grant/0000 0001 9039 9163; LaPrade, Robert/0000 0002 9823 2306; 
FU Ossur; Smith Nephew; Arthrex
FX J. H. receives royalties from Cook Myosite. R.F.L. receives support from
   Arthrex, Ossur, and Smith & Nephew.
CR Amable PR, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt218
   Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006 8993(97)01204 3
   Braun HJ, 2014, AM J SPORT MED, V42, P1204, DOI 10.1177/0363546514525593
   Castaño E, 2000, J PHARMACOL EXP THER, V293, P509
   Castillo TN, 2011, AM J SPORT MED, V39, P266, DOI 10.1177/0363546510387517
   Chen MR, 2013, KNEE SURG SPORT TR A, V21, P540, DOI 10.1007/s00167 012 2095 2
   Curatolo M, 2001, CLIN J PAIN, V17, P25, DOI 10.1097/00002508 200103000 00005
   de Mos M, 2008, AM J SPORT MED, V36, P1171, DOI 10.1177/0363546508314430
   Di Matteo B, 2014, EUR REV MED PHARMACO, V18, P55
   Dikman A, 2009, ALIMENT PHARM THER, V29, P781, DOI 10.1111/j.1365 2036.2009.03928.x
   Dragoo JL, 2012, AM J SPORT MED, V40, P1274, DOI 10.1177/0363546512442334
   Duggan KC, 2010, J BIOL CHEM, V285, P34950, DOI 10.1074/jbc.M110.162982
   Evanson JR, 2014, MIL MED, V179, P799, DOI 10.7205/MILMED D 13 00336
   Foster TE, 2009, AM J SPORT MED, V37, P2259, DOI 10.1177/0363546509349921
   Gross GJ, 2004, PHARMACOLOGY, V71, P135, DOI 10.1159/000077447
   HANSON SR, 1985, BLOOD, V66, P1105
   Helmick CG, 2008, ARTHRITIS RHEUM US, V58, P15, DOI 10.1002/art.23177
   Hire JM, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 29
   Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437
   Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623 200205000 00022
   Inaoka M, 2006, EXP DERMATOL, V15, P981, DOI 10.1111/j.1600 0625.2006.00505.x
   Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466
   Knijff Dutmer EAJ, 2002, RHEUMATOLOGY, V41, P458, DOI 10.1093/rheumatology/41.4.458
   LaPrade RF, 2016, AM J SPORT MED, V44, P3270, DOI 10.1177/0363546516634674
   Laumonier Thomas, 2016, J Exp Orthop, V3, P15, DOI 10.1186/s40634 016 0051 7
   Magalon J, 2014, ARTHROSCOPY, V30, P629, DOI 10.1016/j.arthro.2014.02.020
   Mannava S, 2017, ARTHROSC TEC, V6, pE763, DOI 10.1016/j.eats.2017.02.001
   Martinez Cairo S, 2001, Rev Alerg Mex, V48, P119
   Mazzocca AD, 2012, AM J SPORT MED, V40, P1742, DOI 10.1177/0363546512452713
   Miroshnychenko O, 2017, AM J SPORT MED, V45, P945, DOI 10.1177/0363546516677547
   Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021
   Murray IR, 2016, BONE JOINT RES, V5, P92, DOI 10.1302/2046 3758.53.BJR 2016 0005
   Murray IR, 2017, J BONE JOINT SURG AM, V99, P809, DOI 10.2106/JBJS.16.00793
   Murray IR, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116636586
   Mussano F, 2016, PLATELETS, V27, P467, DOI 10.3109/09537104.2016.1143922
   Oh JH, 2015, AM J SPORT MED, V43, P3062, DOI 10.1177/0363546515608481
   Paez Espinosa Enma V, 2012, Thrombosis, V2012, P173124, DOI 10.1155/2012/173124
   Page TH, 2010, J IMMUNOL, V185, P3694, DOI 10.4049/jimmunol.1000906
   Reed GL, 2000, BLOOD, V96, P3334
   Robich MP, 2010, J THORAC CARDIOV SUR, V140, P1143, DOI 10.1016/j.jtcvs.2010.06.057
   Sanchez C, 2002, J RHEUMATOL, V29, P772
   SCHAFER AI, 1995, J CLIN PHARMACOL, V35, P209, DOI 10.1002/j.1552 4604.1995.tb04050.x
   Schippinger G, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115588896
   Su B, 2013, J APPL PHYSIOL, V115, P892, DOI 10.1152/japplphysiol.00053.2013
   Sundman EA, 2011, AM J SPORT MED, V39, P2135, DOI 10.1177/0363546511417792
   Tarnawski AS, 2003, J MOL MED, V81, P627, DOI 10.1007/s00109 003 0479 y
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140 6736(07)61602 X
   Whitney K, 2017, PHYSL HOMEOSTASIS MU
   Woolf AD., 2015, BMC Musculoskeletal Disorders, V16, pS3, DOI [DOI 10.1186/1471 2474 16 S1 S3, 10.1186/1471 2474 16 s1 s3]
   Yelin E, 2003, J RHEUMATOL, V30, P8
   Yelin E, 2016, SEMIN ARTHRITIS RHEU, V46, P259, DOI 10.1016/j.semarthrit.2016.07.013
   Zlotnicki JP, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116642433
NR 52
TC 29
Z9 28
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0749 8063
EI 1526 3231
J9 ARTHROSCOPY
JI Arthroscopy
PD JAN
PY 2019
VL 35
IS 1
BP 201
EP 210
DI 10.1016/j.arthro.2018.07.030
PG 10
WC Orthopedics; Sport Sciences; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences; Surgery
GA HG1FA
UT WOS:000454694800040
PM 30472018
DA 2025 08 17
ER

PT J
AU Abe, T
   Sato, T
   Kokabu, S
   Hori, N
   Shimamura, Y
   Sato, T
   Yoda, T
AF Abe, Takahiro
   Sato, Tsuyoshi
   Kokabu, Shoichiro
   Hori, Naoko
   Shimamura, Yumiko
   Sato, Tomoya
   Yoda, Tetsuya
TI Zoledronic acid increases the circulating soluble RANKL level in mice,
   with a further increase in lymphocyte derived soluble RANKL in
   zoledronic acid  and glucocorticoid treated mice stimulated with
   bacterial lipopolysaccharide
SO CYTOKINE
LA English
DT Article
DE Zoledronic acid; Glucocorticoid; sRANKL; Lymphocytes
ID KAPPA B LIGAND; NITROGEN CONTAINING BISPHOSPHONATE; RECEPTOR ACTIVATOR;
   OSTEOPROTEGERIN PRODUCTION; BONE LOSS; T CELLS; EXPRESSION;
   LIGAND/OSTEOPROTEGERIN; OSTEOBLASTS; MECHANISM
AB The nitrogen containing bisphosphonate (BP) zoledronic acid (ZA) is a potent antiresorptive drug used in conjunction with standard cancer therapy to treat osteolysis or hypercalcemia due to malignancy. However, it is unclear how ZA influences the circulating levels of bone remodeling factors. The aim of this study was to evaluate the effects of ZA on the serum levels of soluble receptor activator of NF kB ligand (sRANKL) and osteoprotegerin (OPG). The following four groups of C57BL/6 mice were used (five mice per group): (1) the placebo + phosphate buffered saline (PBS) group, in which placebo treated mice were injected once weekly with PBS for 4 weeks; (2) the placebo + ZA group, in which placebo treated mice were injected once weekly with ZA for 4 weeks; (3) the prednisolone (PSL) + PBS group, in which PSL treated mice were injected once weekly with PBS for 4 weeks; and (4) the PSL + ZA group, in which PSL treated mice were injected once weekly with ZA for 4 weeks. At the 3 week time point, all mice were subjected to oral inflammatory stimulation with bacterial lipopolysaccharide (LPS). The sera of these mice were obtained every week and the levels of sRANKL and OPG were measured using enzyme linked immunosorbent assay. At the time of sacrifice, femurs were prepared for micro computed tomography (micro CT), histological, and histomorphometric analyses. Our data indicated that ZA administration remarkably reduced bone turnover and significantly increased the basal level of sRANKL. Interestingly, the PSL + ZA group showed a dramatically elevated sRANKL level after LPS stimulation. In contrast, the PSL + ZA group in nonobese diabetic mice with severe combined immunodeficiency disease (NOD SCID mice), which are characterized by the absence of functional T  and B lymphocytes, showed no increase in the sRANKL level. Our data suggest that, particularly with combination treatment of ZA and glucocorticoids, surviving lymphocytes might be the source of inflammation induced sRANKL. Thus, circulating sRANXL levels might be modulated by ZA. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Abe, Takahiro; Sato, Tsuyoshi; Hori, Naoko; Shimamura, Yumiko; Yoda, Tetsuya] Saitama Med Univ, Fac Med, Dept Oral & Maxillofacial Surg, Saitama, Japan.
   [Sato, Tomoya] Saitama Med Univ, Fac Med, Dept Plast & Reconstruct Surg, Saitama, Japan.
   [Abe, Takahiro] Univ Tokyo, Dept Oral & Maxillofacial Surg, 7 3 1 Hongo, Tokyo 1138655, Japan.
   [Kokabu, Shoichiro] Kyushu Dent Coll, Dept Mol Signaling & Biochem, Fukuoka, Japan.
C3 Saitama Medical University; Saitama Medical University; University of
   Tokyo; Kyushu Dental University
RP Abe, T (通讯作者)，Univ Tokyo, Dept Oral & Maxillofacial Surg, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138655, Japan.
EM abet ora@h.u tokyo.ac.jp
RI Kokabu, Shoichiro/MDS 5426 2025
OI Abe, Takahiro/0000 0003 1251 7448; Sato, Tsuyoshi/0000 0002 1109 196X
FU JSPS KAKENHI [20791543, 22792009]; Saitama Medical University Research
   Promotion Grant [06 01]; Grants in Aid for Scientific Research
   [25463069, 20791543, 22792009] Funding Source: KAKEN
FX We thank M. Hayakawa for her valuable assistance. Bisphosphonates were
   kindly provided by Novartis Pharma AG, Basel, Switzerland. This work was
   supported by JSPS KAKENHI (grant numbers 20791543 and 22792009) and a
   Saitama Medical University Research Promotion Grant (number 06 01).
CR Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Hofbauer LC, 2001, BIOCHEM BIOPH RES CO, V280, P334, DOI 10.1006/bbrc.2000.4130
   Kananen K, 2006, OSTEOPOROSIS INT, V17, P724, DOI 10.1007/s00198 005 0040 7
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Martini G, 2007, BONE, V40, P457, DOI 10.1016/j.bone.2006.08.003
   Martini G, 2006, HAEMATOLOGICA, V91, P1720
   Naidu A, 2008, ORAL SURG ORAL MED O, V106, P5, DOI 10.1016/j.tripleo.2008.03.036
   Nakamichi Y, 2007, J IMMUNOL, V178, P192, DOI 10.4049/jimmunol.178.1.192
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Rogers A, 2005, J CLIN ENDOCR METAB, V90, P6323, DOI 10.1210/jc.2005 0794
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Simon MJK, 2010, CLIN ORAL INVEST, V14, P51, DOI 10.1007/s00784 009 0312 2
   Stefanik D, 2008, ORAL DIS, V14, P465, DOI 10.1111/j.1601 0825.2007.01402.x
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Yoneda T, 2010, J BONE MINER METAB, V28, P365, DOI 10.1007/s00774 010 0162 7
NR 29
TC 17
Z9 18
U1 0
U2 7
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 4666
EI 1096 0023
J9 CYTOKINE
JI Cytokine
PD JUL
PY 2016
VL 83
BP 1
EP 7
DI 10.1016/j.cyto.2016.03.012
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA DN7AS
UT WOS:000377228300001
PM 26999703
DA 2025 08 17
ER

PT J
AU Naso, LG
   Ferrer, EG
   Butenko, N
   Cavaco, I
   Lezama, L
   Rojo, T
   Etcheverry, SB
   Williams, PAM
AF Naso, Luciana G.
   Ferrer, Evelina G.
   Butenko, Nataliya
   Cavaco, Isabel
   Lezama, Luis
   Rojo, Teofilo
   Etcheverry, Susana B.
   Williams, Patricia A. M.
TI Antioxidant, DNA cleavage, and cellular effects of silibinin and a new
   oxovanadium(IV)/silibinin complex
SO JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
LA English
DT Article
DE Oxovanadium(IV); Silibinin; Osteoblasts; Antioxidant; Antitumoral
ID RADICAL SCAVENGING ACTIVITY; SILYBIN; FLAVONOIDS; VANADIUM; QUERCETIN;
   DERIVATIVES; HYDROXYL; PROLIFERATION; PREVENTION; INHIBITION
AB A new complex of the oxovanadium(IV) cation with the flavolignan silibinin has been synthesized and characterized. Vanadium compounds show interesting biological and pharmacological properties and some of them display antitumoral actions. Flavonoids are part of a larger group of antioxidant compounds called polyphenols which may inhibit the proliferation and growth of cancer cells. The antioxidant and antitumoral effects of silibinin and its oxovanadium(IV) complex were investigated. Silibinin acted as a very strong antioxidant and its complexation with oxovanadium(IV) improved this behavior. Besides, the generation of reactive oxygen species (ROS) by this compound was favored in tumoral (UMR106) cells and correlated with the deleterious behavior in the proliferation of this cell line. Conversely, silibinin did not exert any effect on the proliferation of normal osteoblasts (MC3T3E1). The cytotoxic action and ROS generation of the oxovanadium(IV) complex was more effective in tumoral cells. This behavior was not consistent with cleaving DNA of plasmid DNA pA1 because no significant cleaving activity was observed in both cases. These results suggest that the main deleterious mechanisms may take place through cytotoxic effects more than genotoxic actions. A comparison with our own findings on the behavior of other flavonoids and their vanadyl(IV) complex has also been performed.
C1 [Naso, Luciana G.; Ferrer, Evelina G.; Etcheverry, Susana B.; Williams, Patricia A. M.] Univ Nacl La Plata, Fac Ciencias Exactas, Ctr Quim Inorgan, CEQUINOR,CONICET,UNLP, RA 1900 La Plata, Argentina.
   [Butenko, Nataliya] Univ Algarve, Dept Quim Bioquim & Farmacia, P 8005139 Faro, Portugal.
   [Butenko, Nataliya; Cavaco, Isabel] Univ Tecn Lisboa, Inst Super Tecn, Ctr Quim Estrutural, P 1049001 Lisbon, Portugal.
   [Lezama, Luis; Rojo, Teofilo] Univ Basque Country, Dept Quim Inorgan, Fac Ciencias & Tecnol, E 48080 Bilbao, Spain.
   [Etcheverry, Susana B.] Univ Nacl La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of La Plata; Universidade do Algarve; Universidade
   de Lisboa; University of Basque Country; National University of La Plata
RP Williams, PAM (通讯作者)，Univ Nacl La Plata, Fac Ciencias Exactas, Ctr Quim Inorgan, CEQUINOR,CONICET,UNLP, 47 Y 115, RA 1900 La Plata, Argentina.
EM williams@quimica.unlp.edu.ar
RI Lezama, Luis/M 1544 2013; Cavaco, Isabel/H 9087 2012; Rojo,
   Teofilo/B 5197 2015
OI Lezama, Luis/0000 0001 6183 2052; Williams,
   Patricia/0000 0002 1549 5873; Cavaco, Isabel/0000 0001 8651 9054; 
FU UNLP; CONICET [PIP1125]; ANPCyT [PICT 2008 2218]; CICPBA
FX This work was supported by UNLP, CONICET (PIP1125), ANPCyT (PICT
   2008 2218), and CICPBA. E.G.F. and S.B.E. are members of the Carrera del
   Investigador CONICET. P.A.M.W. is a member of the Carrera del
   Investigador CICPBA, Argentina. L.N. holds a fellowship from CONICET.
CR Arcari M, 1992, Boll Chim Farm, V131, P205
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304 3835(99)00276 1
   Borsari M, 2001, J INORG BIOCHEM, V85, P123, DOI 10.1016/S0162 0134(01)00198 2
   Butenko N, 2009, J INORG BIOCHEM, V103, P622, DOI 10.1016/j.jinorgbio.2009.01.003
   Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891 5849(96)00351 6
   Capella MAM, 2007, CELL BIOL TOXICOL, V23, P413, DOI 10.1007/s10565 007 9003 4
   CHASTEEN ND, 1981, BIOL MAGNETIC RESONA, V3
   CHEN YT, 1990, FREE RADICAL BIO MED, V9, P19, DOI 10.1016/0891 5849(90)90045 K
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   Djordjevic C., 1995, MED CHEM COPPER VANA, V31, P595
   Etcheverry SB, 2008, J BIOL INORG CHEM, V13, P435, DOI 10.1007/s00775 007 0332 9
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Ferrer EG, 2006, J BIOL INORG CHEM, V11, P791, DOI 10.1007/s00775 006 0122 9
   Fisher MB, 1998, ARCH BIOCHEM BIOPHYS, V356, P63, DOI 10.1006/abbi.1998.0742
   Galati G, 2004, FREE RADICAL BIO MED, V37, P287, DOI 10.1016/j.freeradbiomed.2004.04.034
   Gazák R, 2004, BIOORGAN MED CHEM, V12, P5677, DOI 10.1016/j.bmc.2004.07.064
   Gazák R, 2007, CURR MED CHEM, V14, P315, DOI 10.2174/092986707779941159
   Gorinstein S, 2003, MAR POLLUT BULL, V46, P1317, DOI 10.1016/S0025 326X(03)00239 X
   GYORGY I, 1992, RADIAT PHYS CHEM, V39, P81
   HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003 2697(87)90222 3
   HARRIS WR, 1979, J AM CHEM SOC, V101, P6534, DOI 10.1021/ja00516a011
   Hogan FS, 2007, J SURG RES, V143, P58, DOI 10.1016/j.jss.2007.03.080
   Jeong JM, 2007, J PHARM PHARM SCI, V10, P537, DOI 10.18433/J3KW2Z
   Kang JW, 2004, J INORG BIOCHEM, V98, P79, DOI 10.1016/j.jinorgbio.2003.08.015
   Köksal E, 2009, J ENZYM INHIB MED CH, V24, P395, DOI [10.1080/14756360802188081, 10.1080/14756360802188081 ]
   Krejsa CM, 1997, J BIOL CHEM, V272, P11541
   Kren V, 1997, J CHEM SOC PERK T 1, P2467, DOI 10.1039/a703283h
   Kren V, 2000, DRUG METAB DISPOS, V28, P1513
   Kuo CC, 2001, J AGR FOOD CHEM, V49, P1564, DOI 10.1021/jf001215v
   Levchenko LA, 2007, DOKL CHEM, V412, P35, DOI 10.1134/S0012500807020036
   MASCHER H, 1993, J LIQ CHROMATOGR, V16, P2777, DOI 10.1080/10826079308019612
   Meloun M, 2003, ANAL CHIM ACTA, V486, P125, DOI 10.1016/S0003 2670(03)00470 7
   Mladenka P, 2010, FREE RADICAL BIO MED, V49, P963, DOI 10.1016/j.freeradbiomed.2010.06.010
   Moein S, 2007, DARU, V15, P83
   Mokhtari MJ, 2008, CELL BIOL INT, V32, P888, DOI 10.1016/j.cellbi.2008.03.019
   Naso L, 2010, J BIOL INORG CHEM, V15, P889, DOI 10.1007/s00775 010 0652 z
   Okawa M, 2001, BIOL PHARM BULL, V24, P1202, DOI 10.1248/bpb.24.1202
   ONISHI M, 1988, PHOTOMETRIC DETERM 2
   Pessoa JC, 2007, ACS SYM SER, V974, P340
   Pittella F, 2009, INT J MOL SCI, V10, P3713, DOI 10.3390/ijms10093713
   Popescu CM, 2009, CARBOHYD POLYM, V77, P851, DOI 10.1016/j.carbpol.2009.03.011
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891 5849(98)00315 3
   Sáenz AT, 2009, J FOOD COMPOS ANAL, V22, P694, DOI 10.1016/j.jfca.2009.01.021
   Sakao K, 2009, BIOSCI BIOTECH BIOCH, V73, P2048, DOI 10.1271/bbb.90253
   Sálice VC, 1999, MOL CELL BIOCHEM, V198, P119, DOI 10.1023/A:1006997830346
   SHARMA RJ, 2010, INT J BIOTECHNOL APP, V2
   Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605
   Srinivasan P, 2002, INT J ONCOL, V20, P983
   Svagera Z, 2003, PHYTOTHER RES, V17, P524, DOI 10.1002/ptr.1187
   TELLES PDA, 2006, ACTA AMAZON, V36, P513
   Tobi SE, 2002, INT J CANCER, V102, P439, DOI 10.1002/ijc.10730
   Trouillas P, 2008, J PHYS CHEM A, V112, P1054, DOI 10.1021/jp075814h
   Varga Z, 2001, PHYTOTHER RES, V15, P608, DOI 10.1002/ptr.879
   Wang Q, 2010, J BIOL INORG CHEM, V15, P1087, DOI 10.1007/s00775 010 0668 4
   Wilms LC, 2008, TOXICOL IN VITRO, V22, P301, DOI 10.1016/j.tiv.2007.09.002
   Yamaguchi T, 1998, BIOSCI BIOTECH BIOCH, V62, P1201, DOI 10.1271/bbb.62.1201
   Yang LX, 2009, J MED CHEM, V52, P7732, DOI 10.1021/jm900735p
   Zhong ZM, 2007, BIOORGAN MED CHEM, V15, P3775, DOI 10.1016/j.bmc.2007.03.036
   Zulueta A, 2009, FOOD CHEM, V114, P310, DOI 10.1016/j.foodchem.2008.09.033
NR 61
TC 48
Z9 50
U1 0
U2 38
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0949 8257
EI 1432 1327
J9 J BIOL INORG CHEM
JI J. Biol. Inorg. Chem.
PD APR
PY 2011
VL 16
IS 4
BP 653
EP 668
DI 10.1007/s00775 011 0769 8
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 759XY
UT WOS:000290284600012
PM 21399988
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhu, M
   Fejzo, MS
   Anderson, L
   Dering, J
   Ginther, C
   Ramos, L
   Gasson, JC
   Karlan, BY
   Slamon, DJ
AF Zhu, Min
   Fejzo, Marlena S.
   Anderson, Lee
   Dering, Judy
   Ginther, Charles
   Ramos, Lillian
   Gasson, Judith C.
   Karlan, Beth Y.
   Slamon, Dennis J.
TI Periostin promotes ovarian cancer angiogenesis and metastasis
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Periostin; Angiogenesis; Metastasis; Ovarian cancer
ID CELL ADHESION MOLECULE; ENDOTHELIAL GROWTH FACTOR; GENE EXPRESSION;
   FASCICLIN I; OSTEOBLAST; PATHWAY; DIFFERENTIATION; CARCINOMA; PATTERNS;
   INVASION
AB Objective. Perostin (PN) has been found to be overexpressed in a variety of human malignancies including ovarian cancer. In the present study, we investigated PN expression status in a large cohort of ovarian tumors with the focus on biological influence of PN related on ovarian tumor angiogenesis and metastasis.
   Methods. PN expression was determined by cDNA microarray, PN northern blot and PN IHC tissue array analyses. Exogenous PN expression in ovarian cancer cells OVCAR 3 and OV2008 were achieved through retroviral transfection and confirmed by PN western blot and ELISA. The effects of exogenous PN expression on tumor angiogenesis and metastatic growth were accessed in orthotopic mouse models. The in vitro cell adhesion, migration and invasion assays were performed to investigate the potential mechanisms involved in PN's in vivo effects.
   Results. PN was frequently overexpressed in ovarian tumors. Higher PN levels significantly correlated with clinical late stages (III/IV) and cancer recurrence. PN was produced by engineered PN overexpressing cells at levels comparable to that of A2780 cells, an ovarian carcinoma cell line with endogenous PN expression. PN overexpression did not change cell growth rates in vitro; however it significantly promoted intraperitoneal tumor metastatic growth in immunodeficient mice, which was associated with increased tumor angiogenesis and decreased tumor cell apoptosis. In vitro purified PN promoted cell adhesion, migration, and invasion of both human umbilical endothelial cells (HUVECs) and/or ovarian cancer cells.
   Conclusions. Our data indicate PN plays a critical role in both ovarian tumor angiogenesis and metastasis. Thus PN may represent a clinically effective new target for therapy of ovarian cancer. Published by Elsevier Inc.
C1 [Zhu, Min] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA.
   [Zhu, Min; Fejzo, Marlena S.; Anderson, Lee; Dering, Judy; Ginther, Charles; Ramos, Lillian; Gasson, Judith C.; Slamon, Dennis J.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Gasson, Judith C.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Karlan, Beth Y.] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   [Karlan, Beth Y.] Cedars Sinai Med Ctr, Div Gynecol Oncol, Los Angeles, CA 90048 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; UCLA Jonsson Comprehensive Cancer Center;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   Cedars Sinai Medical Center
RP Zhu, M (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Med, Factor Bldg,Rm 11 934,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM MZhu@mednet.ucla.edu
OI Fejzo, Marlena/0000 0001 6800 687X
FU Ovarian Cancer Research Fund
FX We thank Marie Arboleda for the helpful advice with experiments, and Dr.
   Romaine Saxton and Gottfried Konecny for comments on this manuscript.
   This work was supported in part by Ovarian Cancer Research Fund (MZ).
CR Alghisi GC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004449
   Asano Masahiro, 2005, Cell Commun Signal, V3, P11, DOI 10.1186/1478 811X 3 11
   Bamberger ES, 2002, J CLIN PATHOL MOL PA, V55, P348, DOI 10.1136/mp.55.6.348
   Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535 6108(04)00081 9
   Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Gillan L, 2002, CANCER RES, V62, P5358
   Hansen B, 2005, EXP CELL RES, V303, P160, DOI 10.1016/j.yexcr.2004.09.017
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Ismail RS, 2000, CANCER RES, V60, P6744
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Ji XH, 2000, J BONE MINER METAB, V18, P132, DOI 10.1007/s007740050103
   Kanno A, 2008, INT J CANCER, V122, P2707, DOI 10.1002/ijc.23332
   Kashiwagi H, 2000, Hum Cell, V13, P135
   Kertesz Z, 2000, PLACENTA, V21, P150, DOI 10.1053/plac.1999.0476
   KIM CJ, 2005, INT J CANC
   Kruzynska Frejtag A, 2004, DEV DYNAM, V229, P857, DOI 10.1002/dvdy.10453
   Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH 22.1167
   Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008 5472.CAN 05 4540
   Li P, 2004, J APPL PHYSIOL, V97, P1550, DOI 10.1152/japplphysiol.01311.2003
   Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785
   Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002 9440(10)65669 6
   Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131 11144.2005
   Roy S, 2007, P NATL ACAD SCI USA, V104, P14472, DOI 10.1073/pnas.0706793104
   Sasaki H, 2003, BREAST CANCER RES TR, V77, P245, DOI 10.1023/A:1021899904332
   Sasaki H, 2002, J PEDIATR SURG, V37, P1293, DOI 10.1053/jpsu.2002.34985
   Sasaki H, 2001, JPN J CANCER RES, V92, P869, DOI 10.1111/j.1349 7006.2001.tb01174.x
   Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304 3835(01)00633 4
   Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992 4003.2004
   Siriwardena BSMS, 2006, BRIT J CANCER, V95, P1396, DOI 10.1038/sj.bjc.6603431
   Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939
   Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046
   TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271
   Thapa N, 2005, BONE, V36, P232, DOI 10.1016/j.bone.2004.08.007
   Yan W, 2006, J BIOL CHEM, V281, P19700, DOI 10.1074/jbc.M601856200
   ZHONG Y, 1995, J NEUROSCI, V15, P6679
NR 36
TC 88
Z9 95
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0090 8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD NOV
PY 2010
VL 119
IS 2
BP 337
EP 344
DI 10.1016/j.ygyno.2010.07.008
PG 8
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 667PO
UT WOS:000283206300032
PM 20688362
DA 2025 08 17
ER

PT J
AU Ajmal, M
   Mir, A
   Wahid, S
   Khor, CC
   Foo, JN
   Siddiqi, S
   Kauser, M
   Malik, SA
   Nasir, M
AF Ajmal, Muhammad
   Mir, Asif
   Wahid, Sughra
   Khor, Chiea Chuen
   Foo, Jia Nee
   Siddiqi, Saima
   Kauser, Mehran
   Malik, Salman Akbar
   Nasir, Muhammad
TI Identification and in silico characterization of a novel p. P208PfsX1
   mutation in V ATPase a3 subunit associated with autosomal recessive
   osteopetrosis in a Pakistani family
SO BMC MEDICAL GENETICS
LA English
DT Article
DE Infantile malignant osteopetrosis; Human TCIRG1 gene; V ATPase; V0
   domain; a3 subunit
ID INFANTILE MALIGNANT OSTEOPETROSIS; FAST INTERACTION REFINEMENT;
   OSTEOCLAST FUNCTION; SURFACE TOPOGRAPHY; MOLECULAR DOCKING;
   PROTEIN STRUCTURE; COMPUTED ATLAS; TCIRG1; PREDICTION; DISORDERS
AB Background: Osteopetrosis is a rare inherited bone disorder mainly described as an increased bone density caused by defective osteoclastic bone resorption. To date, genetic variants of eleven genes have been reported so far to be associated with different types of osteopetrosis. However, malignant infantile osteopetrosis, a lethal form of the disease, is mostly (50%) caused by mutation(s) in TCIRG1 gene. In this study, we investigated a consanguineous Pakistani family clinically and genetically to elucidate underlying molecular basis of the infantile osteopetrosis.
   Methods: DNA samples from five family members were subjected to SNP array based whole genome homozygosity mapping. Data was analyzed and potentially pathogenic mutation was identified by Sanger sequencing of two affected as well as three phenotypically healthy individuals in the family. The significance of identified pathogenic variation and its impact on protein structure and function was studied using various bioinformatics tools.
   Results: DNA samples from five family members were subjected to genome wide SNP array genotyping and homozygosity mapping which identified similar to 4 Mb region on chr11 harboring the TCIRG1 gene. Sanger sequencing unveiled a novel homozygous deletion c. 624delC in exon 6 of the TCIRG1 gene encodes a3 subunit of V ATPase complex. The identified deletion resulted in a frame shift producing a truncated protein of 208 aa. In silico analysis of premature termination of the a3 subunit of V ATPase complex revealed deleterious effects on the protein structure, predicting impaired or complete loss of V ATPase function causing infantile osteopetrosis.
   Conclusions: Since a3 subunit of V ATPase complex plays a crucial role in bone resorption process, structurally abnormal a3 subunit might have adversely affected bone resorption process, leading to infantile osteopetrosis in Pakistani family. Therefore, the present study not only expands the genotypic spectrum of osteopetrosis but also improve understandings of the role of V ATPase a3 subunit in bone resorption process. Moreover, our findings should help in genetic counseling and provide further insight into the disease pathogenesis and potential targeted therapy.
C1 [Ajmal, Muhammad; Siddiqi, Saima; Kauser, Mehran; Nasir, Muhammad] Inst Biomed & Genet Engn, 24 Mauve Area,G 9 1, Islamabad 44000, Pakistan.
   [Mir, Asif] Int Islamic Univ, Dept Biotechnol, Islamabad, Pakistan.
   [Wahid, Sughra] KRL Gen Hosp, Pediat Dept, 24 Mauve Area,G 9 1, Islamabad 44000, Pakistan.
   [Khor, Chiea Chuen; Foo, Jia Nee] ASTAR, Genome Inst Singapore, Human Genet, Singapore, Singapore.
   [Khor, Chiea Chuen] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore.
   [Foo, Jia Nee] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Malik, Salman Akbar] Quaid I Azam Univ, Dept Biochem, Islamabad 44000, Pakistan.
C3 International Islamic University, Pakistan; Agency for Science
   Technology & Research (A*STAR); A*STAR   Genome Institute of Singapore
   (GIS); National University of Singapore; Nanyang Technological
   University; Quaid I Azam University
RP Nasir, M (通讯作者)，Inst Biomed & Genet Engn, 24 Mauve Area,G 9 1, Islamabad 44000, Pakistan.
EM nasirmalik_soonvalley@yahoo.com
RI Siddiqi, Saima/AAJ 6584 2021; Foo, Jia Nee/D 6069 2014; IDREES,
   MUHAMMAD/JLM 2401 2023; Foo, Jia/D 6069 2014; Mir, Asif/AAD 1788 2021;
   Ajmal, Muhammad/Q 3297 2018
OI Foo, Jia Nee/0000 0001 9899 2308; Nasir, Muhammad/0000 0001 6650 2730; 
FU Government of Pakistan
FX The sample collection and clinical work was supported by Government of
   Pakistan funding to IBGE. The SNP genotyping was supported by the Agency
   for Science, Technology and Research, Singapore (to C.C.K.). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Binkowski TA, 2003, NUCLEIC ACIDS RES, V31, P3352, DOI 10.1093/nar/gkg512
   Bliznetz EA, 2009, EUR J HUM GENET, V17, P664, DOI 10.1038/ejhg.2008.234
   Del FA., 2009, IBMS BONEKEY, V6, P16, DOI [10.1138/20090358, DOI 10.1138/20090358]
   Duhovny D., 2002, Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), V2452
   Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hamdan Abdul Latif H, 2006, Paediatr Child Health, V11, P37
   Hussain R, 1998, J BIOSOC SCI, V30, P261, DOI 10.1017/S0021932098002612
   Jefferies KC, 2008, ARCH BIOCHEM BIOPHYS, V476, P33, DOI 10.1016/j.abb.2008.03.025
   Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011
   Lam DK, 2007, J CAN DENT ASSOC, V73, P839
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404
   Moscatelli I, 2013, BONE, V57, P1, DOI 10.1016/j.bone.2013.07.026
   Palagano E, 2015, J BONE MINER RES, V30, P1814, DOI 10.1002/jbmr.2517
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qin A, 2012, INT J BIOCHEM CELL B, V44, P1422, DOI 10.1016/j.biocel.2012.05.014
   Qin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027155
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   SAMBROOK J, 1989, MOL CLONING
   Schneidman Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Warman ML, 2011, AM J MED GENET A, V155A, P943, DOI 10.1002/ajmg.a.33909
   Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449
   Yuan P, 2011, J BONE MINER METAB, V29, P251, DOI 10.1007/s00774 010 0228 6
   Zeng BH, 2016, GENE, V576, P176, DOI 10.1016/j.gene.2015.10.021
NR 29
TC 6
Z9 9
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD DEC 13
PY 2017
VL 18
AR 148
DI 10.1186/s12881 017 0506 4
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA FQ2GM
UT WOS:000418174900002
PM 29237407
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ross, EA
   Tian, J
   Abboud, H
   Hippensteel, R
   Melnick, JZ
   Pradhan, RS
   Williams, LA
   Hamm, LL
   Sprague, SM
AF Ross, Edward A.
   Tian, Jin
   Abboud, Hanna
   Hippensteel, Richard
   Melnick, Joel Z.
   Pradhan, Rajendra S.
   Williams, Laura A.
   Hamm, L. Lee
   Sprague, Stuart M.
TI Oral paricalcitol for the treatment of secondary hyperparathyroidism in
   patients on hemodialysis or peritoneal dialysis
SO AMERICAN JOURNAL OF NEPHROLOGY
LA English
DT Article
DE paricalcitol; secondary hyperparathyroidism; chronic renal failure;
   chronic renal insufficiency
ID VITAMIN D ANALOGS; RENAL FAILURE; CALCIUM; CALCITRIOL; PHOSPHORUS; D 2;
   SURVIVAL
AB Background/Aims: Secondary hyperparathyroidism is a common complication of chronic kidney disease, resulting from inactivation of vitamin D receptor signaling and phosphate retention. Selective activation of vitamin D receptors with intravenous paricalcitol significantly reduced parathyroid hormone (PTH) levels with no significant hypercalcemia or hyperphosphatemia in predialysis and hemodialysis (HD) patients. This study investigates the effects of oral paricalcitol to reduce PTH in patients receiving chronic HD and peritoneal dialysis (PD). Methods: Eighty eight patients were randomized in double blind fashion to receive paricalcitol or placebo for 12 weeks. The dose of the study drug was adjusted weekly using the previous week's intact PTH (iPTH) level as well as calcium and Ca x P product levels. The primary end points were efficacy (two consecutive iPTH decreases of >= 30%) and safety (two consecutive calcium measurements > 11.0 mg/dl). Markers of biochemical bone activity were followed. Results: Demographic characteristics were similar between treatment groups. The mean paricalcitol doses (three times a week) over the entire treatment period for subjects with baseline iPTH <= 500 pg/ml and iPTH > 500 pg/ml were 3.9 and 7.6 mu g, respectively. A statistically significant decrease in iPTH was seen after week 1, with a mean 30% reduction occurring by week 3. A significantly greater proportion of both HD and PD paricalcitol subjects [83% (33/40) and 100% (18/18), respectively] achieved two consecutive >= 30% decreases in iPTH. The treatment groups were not statistically different in regard to the hypercalcemia safety end point. Phosphate binder use and mean serum phosphorus levels were not different between the treatment groups. The markers of bone activity improved in the treated subjects and worsened in those on placebo. Conclusion: Paricalcitol provides a rapid and sustained reduction of PTH in both HD and PD patients with minimal effect on serum calcium and phosphorus and no significant difference in adverse events as compared with placebo. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Florida, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA.
   Abbott Labs, Abbott Pk, IL 60064 USA.
   Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, San Antonio, TX USA.
   Tulane Univ, Sch Med, Sect Nephrol & Hypertens, New Orleans, LA USA.
   Northwestern Univ, Feinberg Sch Med, Evanston Northwestern Healthcare, Div Nephrol & Hypertens, Evanston, IL USA.
C3 State University System of Florida; University of Florida; Abbott
   Laboratories; University of Texas System; University of Texas Health
   Science Center at San Antonio; Tulane University; NorthShore University
   Health System; Northwestern University; Feinberg School of Medicine
RP Ross, EA (通讯作者)，Univ Florida, Div Nephrol Hypertens & Transplantat, Box 100224, Gainesville, FL 32610 USA.
EM Rossea@medicine.ufl.edu
CR Balint E, 2000, AM J KIDNEY DIS, V36, P789, DOI 10.1053/ajkd.2000.17667
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Brown AJ, 2002, J LAB CLIN MED, V139, P279, DOI 10.1067/mlc.2002.122819
   Chin J, 2000, J AM SOC NEPHROL, V11, P903, DOI 10.1681/ASN.V115903
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Coyne DW, 2002, AM J KIDNEY DIS, V40, P1283, DOI 10.1053/ajkd.2002.36899
   Dobrez DG, 2004, NEPHROL DIAL TRANSPL, V19, P1174, DOI 10.1093/ndt/gfh123
   Ho LT, 2002, SEMIN NEPHROL, V22, P488, DOI 10.1053/snep.2002.35965
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Nakane M, 2006, J STEROID BIOCHEM, V98, P72, DOI 10.1016/j.jsbmb.2005.07.007
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   PITTS TO, 1988, J CLIN ENDOCR METAB, V67, P876, DOI 10.1210/jcem 67 5 876
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   Slatopolsky E, 2002, KIDNEY INT, V62, P1277, DOI 10.1111/j.1523 1755.2002.kid573.x
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
NR 18
TC 58
Z9 62
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0250 8095
EI 1421 9670
J9 AM J NEPHROL
JI Am. J. Nephrol.
PY 2008
VL 28
IS 1
BP 97
EP 106
DI 10.1159/000109398
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 232VO
UT WOS:000251048600013
PM 17914251
DA 2025 08 17
ER

PT J
AU Li, WW
   Wei, YH
   Li, H
   Lai, DM
   Lin, TN
AF Li, Wen Wen
   Wei, Yau Huei
   Li, Hung
   Lai, Dar Ming
   Lin, Teng Nan
TI Isolation and Characterization of a Novel Strain of Mesenchymal Stem
   Cells from Mouse Umbilical Cord: Potential Application in Cell Based
   Therapy
SO PLOS ONE
LA English
DT Article
ID HUMAN BONE MARROW; STROMAL CELLS; ADIPOSE TISSUE; HEPATIC
   DIFFERENTIATION; LIVER FAILURE; IN VITRO; ISCHEMIC STROKE; HUMAN
   PLACENTA; MATRIX CELLS; SPINAL CORD
AB Human umbilical cord derived mesenchymal stem cells (hUC MSCs) have recently been recognized as a potential source for cell based therapy in various preclinical animal models, such as Parkinson's disease, cerebral ischemia, spinal cord injury, and liver failure; however, the precise cellular and molecular mechanisms underlying the beneficial outcomes remain under investigation. There is a growing concern regarding rejection and alteration of genetic code using this xenotransplantation approach. In this study, a novel strain of murine MSCs derived from the umbilical cord of wild type and green fluorescent protein (GFP) transgenic mice have been successfully isolated, expanded, and characterized. After 10 passages, the mUC MSCs developed a rather homogeneous, triangular, spindle shaped morphology, and were sub cultured up to 7 months (over 50 passages) without overt changes in morphology and doubling time. Cell surface markers are quite similar to MSCs isolated from other tissue origins as well as hUC MSCs. These mUC MSCs can differentiate into osteoblasts, adipocytes, neurons, and astrocytes in vitro, as well as hematopoietic lineage cells in vivo. mUC MSCs also possess therapeutic potential against two disease models, focal ischemic stroke induced by middle cerebral artery occlusion (MCAo) and acute hepatic failure. Subtle differences in the expression of cytokine related genes exist between mUC MSCs and hUC MSCs, which may retard and jeopardize the advance of cell therapy. Allografts of these newly established mUC MSCs into various mouse disease models may deepen our insights into the development of more effective cell therapy regimens.
C1 [Li, Wen Wen; Wei, Yau Huei] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Wei, Yau Huei] Mackay Med Coll, Dept Med, New Taipei City, Taiwan.
   [Li, Hung] Acad Sinica, Inst Mol Biol, Taipei, Taiwan.
   [Lai, Dar Ming] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan.
   [Lin, Teng Nan] Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan.
   [Lin, Teng Nan] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; Mackay Medical University;
   Academia Sinica   Taiwan; National Taiwan University; National Taiwan
   University Hospital; National Yang Ming Chiao Tung University; Academia
   Sinica   Taiwan
RP Lai, DM (通讯作者)，Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan.
EM dmdlai@ntu.edu.tw; bmltn@ibms.sinica.edu.tw
RI Lin, Teng nan/Q 4566 2018; Wei, Yau Huei/ABA 6841 2021
OI Lin, Teng nan/0000 0002 4009 0798; Wei, Yau Huei/0000 0002 6429 2546
FU Academia Sinica; National Science Council of Taiwan Government
FX This work was supported by grants from Academia Sinica and National
   Science Council of Taiwan Government. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bai CY, 2013, MOL CELL BIOCHEM, V376, P95, DOI 10.1007/s11010 012 1553 y
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Banas A, 2009, J GASTROEN HEPATOL, V24, P70, DOI 10.1111/j.1440 1746.2008.05496.x
   Ben Ami E, 2011, AUTOIMMUN REV, V10, P410, DOI 10.1016/j.autrev.2011.01.005
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534
   Burdon TJ, 2011, BONE MARROW RES, DOI 10.1155/2011/207326
   Cai JL, 2010, J BIOL CHEM, V285, P11227, DOI 10.1074/jbc.M109.086389
   Cardoso TC, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472 6750 12 18
   Carlin R, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477 7827 4 8
   Castillo MD, 2008, CTS CLIN TRANSL SCI, V1, P27, DOI 10.1111/j.1752 8062.2008.00018.x
   Chao KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001451
   Chao YH, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/759503
   CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738
   Chu MS, 2006, CELL SIGNAL, V18, P519, DOI 10.1016/j.cellsig.2005.05.018
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   de Miranda AS, 2010, ARQ NEURO PSIQUIAT, V68, P597, DOI 10.1590/S0004 282X2010000400022
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Ding DC, 2007, NEUROBIOL DIS, V27, P339, DOI 10.1016/j.nbd.2007.06.010
   Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005 0053
   Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22 5 649
   Greco SJ, 2007, STEM CELLS DEV, V16, P811, DOI 10.1089/scd.2007.0011
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   Harting MT, 2009, STEM CELLS DEV, V18, P127, DOI 10.1089/scd.2008.0046
   Hu Y, 2003, J LAB CLIN MED, V141, P342, DOI 10.1016/S0022 2143(03)00022 2
   Hwang S, 2012, CELL BIOL INT, V36, P279, DOI 10.1042/CBI20110325
   Iacono E, 2012, REPRODUCTION, V143, P455, DOI 10.1530/REP 10 0408
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801
   Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006 0286
   Kim SJ, 2011, J KOREAN SURG SOC, V81, P176, DOI 10.4174/jkss.2011.81.3.176
   Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087
   Lee KS, 2013, RES VET SCI, V94, P144, DOI 10.1016/j.rvsc.2012.07.033
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e
   LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117
   Liu WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055487
   LURIA EA, 1971, TRANSFUSION, V11, P345, DOI 10.1111/j.1537 2995.1971.tb04426.x
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21 1 50
   Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Revell CM, 2009, TISSUE ENG PART B RE, V15, P1, DOI 10.1089/ten.teb.2008.0189
   Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476 9255 2 8
   Sigrist S, 2005, TRANSPL P, V37, P3516, DOI 10.1016/j.transproceed.2005.09.048
   Tögel F, 2007, AM J PHYSIOL RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006
   Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007 0439
   Tsai PC, 2009, LIVER TRANSPLANT, V15, P484, DOI 10.1002/lt.21715
   Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21 6 681
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336
   YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205
   Yu J, 2012, BIOCHEM BIOPH RES CO, V422, P539, DOI 10.1016/j.bbrc.2012.04.156
   Zanini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028175
   Zhang SC, 2012, TISSUE ENG PT A, V18, P1352, DOI [10.1089/ten.tea.2011.0516, 10.1089/ten.TEA.2011.0516]
   Zhao SM, 2010, STEM CELLS DEV, V19, P607, DOI 10.1089/scd.2009.0345
   Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 64
TC 18
Z9 20
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2013
VL 8
IS 8
AR e74478
DI 10.1371/journal.pone.0074478
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 215RU
UT WOS:000324228800120
PM 23991222
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kunrath, MF
   Diz, FM
   Magini, R
   Galárraga Vinueza, ME
AF Kunrath, Marcel F.
   Diz, Fernando M.
   Magini, Ricardo
   Galarraga Vinueza, Maria E.
TI Nanointeraction: The profound influence of nanostructured and nano drug
   delivery biomedical implant surfaces on cell behavior
SO ADVANCES IN COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Biomedical implants; Cell interaction; Drug delivery; Nanostructure;
   Nano scale
ID TITANIUM SURFACES; PERI IMPLANTITIS; DENTAL IMPLANTS; TIO2 NANOTUBES;
   ANTIBACTERIAL PROPERTIES; MACROPHAGE POLARIZATION; SILVER NANOPARTICLES;
   MATRIX ADHESIONS; LOCAL DELIVERY; OSSEOINTEGRATION
AB Nanostructured surfaces feature promising biological properties on biomaterials attracting large interest at basic research, implant industry development, and bioengineering applications. Thou, nanoscale interactions at a molecular and cellular level are not yet completely understood and its biological and clinical implications need to be further elucidated. As follows, the aim of this comprehensive review was to evaluate nanostructured surfaces at biomedical implants focusing on surface development, nanostructuration, and nanoengineered drug delivery systems that can induce specific cell interactions in all relevant aspects of biological, reparative, anti bacterial, anti inflammatory and clinical processes. The methods and the physio chemical properties involved in nanotopography performance, the main cellular characteristics involved at surface/cell interaction, and a summary of results and outlooks reported in studies applying nanostructured surfaces and nano drug delivery systems is presented. The future prospects and commercial translation of this developing field, particularly concerning multifunctional nanostructured surfaces and its clinical implications are further discussed. At a cellular level, nanostructured biomedical implant surfaces can enhance osteogenesis by targeting osteoblasts, osteocytes, and mesenchymal cells, stimulate fibroblast/epithelial cells proliferation and adherence, inhibit bacterial cell proliferation and biofilm accumulation, and act as immune modulating surfaces targeting macrophages and reducing pro inflammatory cytokine expression. Moreover, several methodological options to create drug delivery systems on metallic implant surfaces are available, however, the clinical translation is yet incomplete. The efficiency of which nanostructured/nano delivery surfaces may target specific cell interactions and favor clinical outcomes needs to be further elucidated in pre clinical and clinical studies, along with engineering solutions for commercial translation and approval of controlling agencies. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Kunrath, Marcel F.] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Sch Hlth & Life Sci, Dent Dept, Av Ipiranga,POB 6681, BR 90619900 Porto Alegre, RS, Brazil.
   [Kunrath, Marcel F.] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Mat & Nanosci Lab, Porto Alegre, RS, Brazil.
   [Diz, Fernando M.] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Sch Technol, Program Mat Engn & Technol, Porto Alegre, RS, Brazil.
   [Magini, Ricardo; Galarraga Vinueza, Maria E.] Fed Univ Santa Catarina UFSC, Postgrad Program Implant Dent PPGO, POB 88040 900, Florianopolis, SC, Brazil.
   [Galarraga Vinueza, Maria E.] Univ Amer UDLA, Sch Dent, Quito, Ecuador.
C3 Pontificia Universidade Catolica Do Rio Grande Do Sul; Pontificia
   Universidade Catolica Do Rio Grande Do Sul; Pontificia Universidade
   Catolica Do Rio Grande Do Sul; Universidade Federal de Santa Catarina
   (UFSC); Universidad de Las Americas   Ecuador
RP Kunrath, MF (通讯作者)，Pontifical Catholic Univ Rio Grande do Sul PUCRS, Sch Hlth & Life Sci, Dent Dept, Av Ipiranga,POB 6681, BR 90619900 Porto Alegre, RS, Brazil.; Galárraga Vinueza, ME (通讯作者)，Fed Univ Santa Catarina UFSC, Postgrad Program Implant Dent PPGO, POB 88040 900, Florianopolis, SC, Brazil.
EM marceifkunrath@gmail.com; mariagalarragav@gmail.com
RI ; Diz, Fernando/LTC 5140 2024; Kunrath, Marcel/U 9310 2018
OI Diz, Fernando/0000 0001 7141 2422; Kunrath, Marcel/0000 0003 0493 8891;
   Galarraga Vinueza, Maria Elisa/0000 0002 4060 0444
CR Aguirre R, 2018, J BIOMED MATER RES A, V106, P1341, DOI 10.1002/jbm.a.36331
   Aiyelabegan HT, 2017, BIOMED PHARMACOTHER, V88, P956, DOI 10.1016/j.biopha.2017.01.136
   Albrektsson T, 2016, CLIN IMPLANT DENT R, V18, P840, DOI 10.1111/cid.12427
   Albrektsson Tomas, 2005, J Can Dent Assoc, V71, P327
   Alghamdi HS, 2014, BIOMATERIALS, V35, P5482, DOI 10.1016/j.biomaterials.2014.03.069
   Asa'ad F, 2019, EUR J ORAL SCI, V127, P477, DOI 10.1111/eos.12657
   Aw MS, 2012, CHEM COMMUN, V48, P3348, DOI 10.1039/c2cc17690d
   Awad NK, 2017, MAT SCI ENG C MATER, V76, P1401, DOI 10.1016/j.msec.2017.02.150
   Bachir AI, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a023234
   Bai J, 2019, ACS APPL MATER INTER, V11, P36939, DOI 10.1021/acsami.9b11536
   Bai L, 2018, ACTA BIOMATER, V76, P344, DOI 10.1016/j.actbio.2018.06.023
   Ballo A, 2011, INT J NANOMED, V6, P3415, DOI 10.2147/IJN.S25867
   Bariana M, 2019, INT J NANOMED, V14, P6313, DOI 10.2147/IJN.S202090
   Barik A, 2020, ADV EXP MED BIOL, V1251, P1, DOI 10.1007/5584_2019_447
   Berckmans III B, 2017, U.S. patent application, Patent No. [15/401,740, 15401740]
   Bhadra CM, 2015, SCI REP UK, V5, DOI 10.1038/srep16817
   Bianchini MA, 2019, J PERIODONTICS RESTO, V40, pe1, DOI [10.11607/prd.3849, DOI 10.11607/PRD.3849]
   Bianchini MA, 2019, CLIN IMPLANT DENT R, V21, P758, DOI 10.1111/cid.12773
   Böhrnsen F, 2017, INT J ORAL MAX IMPL, V32, pE175, DOI 10.11607/jomi.5256
   Bose S, 2009, J MATER SCI MATER M, V20, P19, DOI 10.1007/s10856 008 3418 1
   Bosshardt DD, 2017, PERIODONTOL 2000, V73, P22, DOI 10.1111/prd.12179
   Cao YY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19484 x
   Carinci F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163897
   CAVALCANTI JHD, 2019, MAT BASEL, V12, DOI DOI 10.3390/MA12050840
   Chen MH, 2020, ACTA BIOMATER, V105, P304, DOI 10.1016/j.actbio.2020.01.029
   Choi SH, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110049
   Civantos A, 2017, ACS BIOMATER SCI ENG, V3, P1245, DOI 10.1021/acsbiomaterials.6b00604
   Davies D, 2003, NAT REV DRUG DISCOV, V2, P114, DOI 10.1038/nrd1008
   de Cruvinel W. M., 2010, REV BRAS REUMATOL, V50, P434, DOI DOI 10.1590/S0482 50042010000400008
   de Miguel I, 2019, NANO LETT, V19, P2524, DOI 10.1021/acs.nanolett.9b00187
   Delfino MM, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64041 0
   Derks J, 2016, J CLIN PERIODONTOL, V43, P383, DOI 10.1111/jcpe.12535
   Donelli G., 2014, BIOFILM BASED HEALTH, V831, DOI [10.1007/978 3 319 09782 4, DOI 10.1007/978 3 319 09782 4]
   Dong YW, 2017, COLLOID SURFACE B, V158, P127, DOI 10.1016/j.colsurfb.2017.06.034
   Doyle AD, 2016, EXP CELL RES, V343, P60, DOI 10.1016/j.yexcr.2015.10.033
   Elbourne A, 2017, J COLLOID INTERF SCI, V508, P603, DOI 10.1016/j.jcis.2017.07.021
   Esfandiari N, 2014, J BIOMED MATER RES A, V102, P2625, DOI 10.1002/jbm.a.34934
   Esposito M, 2019, INT J ORAL IMPL, V12, P39
   Esposito M, 2012, EUR J ORAL IMPLANTOL, V5, P221
   Fathi M, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109743
   Ferrati S, 2013, J CONTROL RELEASE, V172, P1011, DOI 10.1016/j.jconrel.2013.09.028
   Franz S, 2011, BIOMATERIALS, V32, P6692, DOI 10.1016/j.biomaterials.2011.05.078
   Fretwurst T, 2020, CLIN ORAL IMPLAN RES, V31, P274, DOI 10.1111/clr.13568
   Fu C, 2020, U.S. patent application, Patent No. [16/502,781, 16502781]
   Galarraga Vinueza ME, 2017, J BIOMED MATER RES A, V105, P1994, DOI 10.1002/jbm.a.36056
   Galárraga Vinueza ME, 2020, INT J IMPLANT DENT, V6, DOI 10.1186/s40729 020 00208 8
   Galarraga Vinueza ME, 2018, J BIOMED MATER RES A, V106, P1614, DOI 10.1002/jbm.a.36352
   Gao CD, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.59
   Garlet GP, 2018, J DENT RES, V97, P1079, DOI 10.1177/0022034518785857
   Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402
   Ge X, 2019, BIOACT MATER, V4, P346, DOI 10.1016/j.bioactmat.2019.10.006
   Giljean S, 2011, APPL SURF SCI, V257, P9631, DOI 10.1016/j.apsusc.2011.06.088
   Giljean S, 2014, SCANNING, V36, P2, DOI 10.1002/sca.21061
   Gittens RA, 2014, ACTA BIOMATER, V10, P2907, DOI 10.1016/j.actbio.2014.03.032
   Gnilitskyi I, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102036
   Gong YX, 2018, PHYS SCI REV, V3, DOI 10.1515/psr 2017 0057
   Gultepe E, 2010, ADV DRUG DELIVER REV, V62, P305, DOI 10.1016/j.addr.2009.11.003
   Guo LM, 2009, MAT SCI ENG C BIO S, V29, P1174, DOI 10.1016/j.msec.2008.10.003
   Gupta Saurabh, 2020, Medical Devices & Sensors, V3, DOI 10.1002/mds3.10076
   Harunaga JS, 2011, MATRIX BIOL, V30, P363, DOI 10.1016/j.matbio.2011.06.001
   Hasegawa M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030783
   Hayes JS, 2012, ADV BIOCHEM ENG BIOT, V126, P1, DOI 10.1007/10_2011_110
   Helmus M, 2006, U.S. patent application, Patent No. [11/007,867, 11007867]
   Herman SJ, 2007, U.S. patent application, Patent No. [11/753,330, 11753330]
   Hotchkiss KM, 2016, ACTA BIOMATER, V31, P425, DOI 10.1016/j.actbio.2015.12.003
   Hozumi K, 2015, BIOMATERIALS, V37, P73, DOI 10.1016/j.biomaterials.2014.10.005
   Huang QL, 2019, ACTA BIOMATER, V100, P415, DOI 10.1016/j.actbio.2019.09.030
   Huang QL, 2017, ACTA BIOMATER, V51, P505, DOI 10.1016/j.actbio.2017.01.044
   Huang S, 2010, J CONTROL RELEASE, V142, P149, DOI 10.1016/j.jconrel.2009.10.018
   Huang YZ, 2019, MAT SCI ENG C MATER, V94, P1, DOI 10.1016/j.msec.2018.08.069
   Hunziker EB, 2012, BONE, V51, P98, DOI 10.1016/j.bone.2012.04.004
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333
   Jäger M, 2017, MATERIALS, V10, DOI 10.3390/ma10111302
   Jaggessar A, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951 017 0306 1
   Jarosz M, 2016, COLLOID SURFACE B, V143, P447, DOI 10.1016/j.colsurfb.2016.03.073
   Jepsen S, 2015, J CLIN PERIODONTOL, V42, pS152, DOI 10.1111/jcpe.12369
   Jin SS, 2019, ACS NANO, V13, P6581, DOI 10.1021/acsnano.9b00489
   Kafshgari MH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 49513 2
   Kang H, 2019, NANO LETT, V19, P1963, DOI 10.1021/acs.nanolett.8b05150
   Kato E, 2015, DENT MATER, V31, pE116, DOI 10.1016/j.dental.2015.01.014
   Kaur G, 2016, BIOMATERIALS, V101, P176, DOI 10.1016/j.biomaterials.2016.05.048
   Kierszenbaum A. L., 2015, Histology and Cell Biology: an introduction to pathology E Book
   Konittinen YT, 2006, INT J PERIODONT REST, V26, P135
   Kumar S, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110154
   Kumeria T, 2015, COLLOID SURFACE B, V130, P255, DOI 10.1016/j.colsurfb.2015.04.021
   Kunrath MF, 2019, BIOTECH HISTOCHEM, V94, P261, DOI 10.1080/10520295.2018.1552017
   Kunrath MF, 2020, ARCH ORAL BIOL, V117, DOI 10.1016/j.archoralbio.2020.104824
   Kunrath MF, 2018, CHEMISTRYSELECT, V3, P11180, DOI 10.1002/slct.201801459
   Kunrath MF, 2020, INT J ORAL MAX IMPL, V35, P773, DOI 10.11607/jomi.8069
   Kunrath MF, 2019, AMB EXPRESS, V9, DOI 10.1186/s13568 019 0777 6
   Kunrath MF, 2020, J R SOC INTERFACE, V17
   Lai YK, 2016, SMALL, V12, P2203, DOI 10.1002/smll.201501837
   Lee RSB, 2017, CLIN ORAL IMPLAN RES, V28, pE159, DOI 10.1111/clr.12979
   Lee YH, 2017, NANOMED NANOTECHNOL, V13, P1821, DOI 10.1016/j.nano.2017.02.020
   Li DZ, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900002
   Li J, 2018, CELL CHEM BIOL, V25, P499, DOI 10.1016/j.chembiol.2018.02.005
   Li J, 2017, ACS NANO, V11, P11250, DOI 10.1021/acsnano.7b05620
   Li T, 2018, J COLLOID INTERF SCI, V529, P452, DOI 10.1016/j.jcis.2018.06.004
   Li X, 2019, ACTA BIOMATER, V94, P627, DOI 10.1016/j.actbio.2019.06.023
   Li YQ, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/1569049
   Lin DJ, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110204
   Lindhe J, 2008, J CLIN PERIODONTOL, V35, P282, DOI 10.1111/j.1600 051X.2008.01283.x
   LIU Huinan, 2016, U.S. patent application, Patent No. [14/303,321, 14303321]
   LIU X, 2016, BIOACT MAT, V1, P65
   Long EG, 2019, BIOACT MATER, V4, P249, DOI 10.1016/j.bioactmat.2019.08.001
   Ma QL, 2014, BIOMATERIALS, V35, P9853, DOI 10.1016/j.biomaterials.2014.08.025
   McEver R. P., 2018, HEMATOLOGY, P127, DOI DOI 10.1016/B978 0 323 35762 3.00012 3
   Mendelsohn AD, 2017, U.S. patent, Patent No. [9,770,412, 9770412]
   Miao XC, 2017, INT J NANOMED, V12, P1415, DOI 10.2147/IJN.S126760
   Miralami R, 2019, P I MECH ENG H, V233, P921, DOI 10.1177/0954411919858018
   do Nascimento MHM, 2016, POLIMEROS, V26, P360, DOI 10.1590/0104 1428.1987
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Nanci A, 1998, J BIOMED MATER RES, V40, P324
   Nandi SK, 2018, J BIOMED MATER RES B, V106, P1073, DOI 10.1002/jbm.b.33910
   Ryan DPO, 2017, DENT MATER J, V36, P447, DOI 10.4012/dmj.2016 124
   Padmanabhan J, 2015, WIRES NANOMED NANOBI, V7, P355, DOI 10.1002/wnan.1320
   Pan CJ, 2020, ACS BIOMATER SCI ENG, V6, P2072, DOI 10.1021/acsbiomaterials.0c00187
   Pashkuleva I, 2010, J MATER SCI MATER M, V21, P21, DOI 10.1007/s10856 009 3831 0
   Pawar VD, 2019, U.S. patent, Patent No. [10,413,640, 10413640]
   Pawlik A, 2018, COLLOID SURFACE B, V171, P58, DOI 10.1016/j.colsurfb.2018.07.012
   Pawlik A, 2017, COLLOID SURFACE B, V152, P95, DOI 10.1016/j.colsurfb.2017.01.011
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Pokrowiecki R, 2017, INT J NANOMED, V12, P4285, DOI 10.2147/IJN.S131163
   Pollard T.D., 2016, CELL BIOL E BOOK
   Pranno N, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051568
   Ramasamy M, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1851242
   Renvert S, 2012, CLIN ORAL IMPLAN RES, V23, P84, DOI 10.1111/j.1600 0501.2012.02554.x
   Rezaei NM, 2018, INT J NANOMED, V13, P3381, DOI 10.2147/IJN.S159955
   Richert L, 2010, SURF SCI, V604, P1445, DOI 10.1016/j.susc.2010.05.007
   Rios Pimentel FF, 2019, INT J NANOMED, V14, P3265, DOI 10.2147/IJN.S189323
   Rivera Chacon DM, 2013, J BIOMED NANOTECHNOL, V9, P1092, DOI 10.1166/jbn.2013.1601
   Roguska A, 2018, ACS APPL MATER INTER, V10, P17089, DOI 10.1021/acsami.8b04045
   Rossi S, 2008, CLIN ORAL IMPLAN RES, V19, P348, DOI 10.1111/j.1600 0501.2007.01478.x
   Saha S, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.109982
   Saleh Y. E., 2020, U.S. patent, Patent No. [10,639,402, 10639402]
   Santini J, 2007, U.S. patent application, Patent No. [11/381,646, 11381646]
   Sato M, 2008, J BIOMED MATER RES A, V84A, P265, DOI 10.1002/jbm.a.31469
   Schoenenberger AD, 2016, ACS BIOMATER SCI ENG, V2, P908, DOI 10.1021/acsbiomaterials.6b00006
   Schouten C, 2009, CLIN ORAL IMPLAN RES, V20, P421, DOI 10.1111/j.1600 0501.2008.01657.x
   Schünemann FH, 2019, MAT SCI ENG C MATER, V98, P1294, DOI 10.1016/j.msec.2019.01.062
   Schwarz F, 2018, J CLIN PERIODONTOL, V45, pS246, DOI 10.1111/jcpe.12954
   Sculean A, 2014, J CLIN PERIODONTOL, V41, pS6, DOI 10.1111/jcpe.12206
   Smith GC, 2018, U.S. patent application, Patent No. [15/577,798, 15577798]
   Soon G, 2017, J MECH BEHAV BIOMED, V68, P26, DOI 10.1016/j.jmbbm.2017.01.028
   Souza JCM, 2019, ACTA BIOMATER, V94, P112, DOI 10.1016/j.actbio.2019.05.045
   Su EP, 2018, BONE JOINT J, V100B, P9, DOI 10.1302/0301 620X.100B1.BJJ 2017 0551.R1
   Su YC, 2018, J MECH BEHAV BIOMED, V77, P90, DOI 10.1016/j.jmbbm.2017.08.035
   Sumigray KD, 2015, CURR TOP DEV BIOL, V112, P383, DOI 10.1016/bs.ctdb.2014.11.027
   Sun Y, 2018, APPL SURF SCI, V440, P440, DOI 10.1016/j.apsusc.2018.01.136
   Thakral GK, 2014, J CLIN DIAGN RES, V8, pZE7, DOI 10.7860/JCDR/2014/8764.4355
   Timko BP, 2012, CLIN THER, V34, pS25, DOI 10.1016/j.clinthera.2012.09.012
   Trisi P, 2003, J PERIODONTOL, V74, P945, DOI 10.1902/jop.2003.74.7.945
   Ungai Salánki R, 2019, ADV COLLOID INTERFAC, V269, P309, DOI 10.1016/j.cis.2019.05.005
   Uskokovic V, 2015, CRIT REV THER DRUG, V32, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.2014010920
   Vallet Regí M, 2010, J INTERN MED, V267, P22, DOI 10.1111/j.1365 2796.2009.02190.x
   Wandiyanto JV, 2020, J COLLOID INTERF SCI, V560, P572, DOI 10.1016/j.jcis.2019.10.067
   Wang GS, 2019, MAT SCI ENG C MATER, V95, P114, DOI 10.1016/j.msec.2018.10.068
   Wang JJ, 2018, INT J NANOMED, V13, P4029, DOI 10.2147/IJN.S163956
   Wang K, 2017, ENVIRON SCI NANO, V4, P689, DOI [10.1039/c6en00402d, 10.1039/C6EN00402D]
   Wang K, 2016, ACS APPL MATER INTER, V8, P5082, DOI 10.1021/acsami.5b10531
   Wang YL, 2015, J NANOSCI NANOTECHNO, V15, P4143, DOI 10.1166/jnn.2015.9792
   Wang ZM, 2015, ADV HEALTHC MATER, V4, P927, DOI 10.1002/adhm.201400684
   Wei HY, 2020, COMPOS PART B ENG, V193, DOI 10.1016/j.compositesb.2020.108035
   Wu WG, 2016, J BIOMATER APPL, V31, P250, DOI 10.1177/0885328216640660
   Xia LG, 2013, J MATER CHEM B, V1, P5403, DOI 10.1039/c3tb20945h
   Xia SM, 2017, SEMIN CELL DEV BIOL, V71, P53, DOI 10.1016/j.semcdb.2017.07.029
   Xie CM, 2014, ACS APPL MATER INTER, V6, P8580, DOI 10.1021/am501428e
   Xu RG, 2018, INT J NANOMED, V13, P5045, DOI 10.2147/IJN.S166661
   Yang RG, 2018, EXTREME MECH LETT, V20, P125, DOI 10.1016/j.eml.2017.12.002
   Yeo ISL, 2020, MATERIALS, V13, DOI 10.3390/ma13010089
   Yu YL, 2018, BIOMATERIALS, V167, P44, DOI 10.1016/j.biomaterials.2018.03.024
   Zhang GN, 2019, J MATER RES, V34, P4056, DOI 10.1557/jmr.2019.358
   Zhang LC, 2016, J BIOMED MATER RES B, V104, P1004, DOI 10.1002/jbm.b.33454
   Zhang M, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901031
   Zhang QC, 2015, PROG MATER SCI, V74, P332, DOI 10.1016/j.pmatsci.2015.05.001
   Zhou JB, 2011, THIN SOLID FILMS, V519, P4658, DOI 10.1016/j.tsf.2011.01.012
   Zhou LN, 2019, ORAL DIS, V25, P265, DOI 10.1111/odi.12983
   Zhou P, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab70ee
   Zhou P, 2019, COLLOID SURFACE B, V178, P515, DOI 10.1016/j.colsurfb.2019.03.045
   Zhuang Z, 2019, J DENT RES, V98, P200, DOI 10.1177/0022034518805984
NR 181
TC 41
Z9 43
U1 1
U2 73
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001 8686
EI 1873 3727
J9 ADV COLLOID INTERFAC
JI Adv. Colloid Interface Sci.
PD OCT
PY 2020
VL 284
AR 102265
DI 10.1016/j.cis.2020.102265
PG 18
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA OD2GS
UT WOS:000579672300008
PM 33007580
DA 2025 08 17
ER

PT J
AU Wu, Y
   Qi, YJ
   Liu, H
   Wang, XS
   Zhu, HQ
   Wang, ZG
AF Wu, Yan
   Qi, Yijun
   Liu, Hu
   Wang, Xiaoshan
   Zhu, Huaqing
   Wang, Zhengguang
TI AMPK activator AICAR promotes 5 FU induced apoptosis in gastric cancer
   cells
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE AMPK; Caspase 3; Gastric carcinoma; Multidrug resistance;
   Chemosensitivity
ID LUNG RESISTANCE PROTEIN; D 2 INDUCES APOPTOSIS; KAPPA B PATHWAY;
   MULTIDRUG RESISTANCE; P GLYCOPROTEIN; BREAST CANCER; TRANSCRIPTIONAL
   ACTIVITY; INSULIN SENSITIVITY; SIGNALING PATHWAY; HUMAN OSTEOCLASTS
AB The aim of the present study was to determine the effect of AICAR, an AMPK activator, on apoptosis in gastric carcinoma cells (SGC 7901) with or without 5 fluorouracil (5 FU). SGC 7901 cells were treated with AICAR (0.2 5 mM, for 24 48 h) with or without 5 FU. Cell viability was determined using MTT assay, while apoptosis were measured through the evaluation of active caspase 3 activity and DNA fragmentation. Real time PCR was employed to determine the expression of tumor suppressor and multi drug resistant (mdr1) gene. Cleaved caspase 3 and phosphorylated AMPK (p AMPK) were measured by Western blot. AICAR significant reduced cellular viability but increased apoptosis in a time  and dose dependent manner, which is associated with an increase in p AMPK levels. Importantly, AICAR enhanced the sensitivity to 5 FU induced reduction of cellular viability and increased apoptosis in SGC 7901 cells. Furthermore, AICAR increased tumor suppressor genes [F box and WD repeat domain containing 7 (FBXW7), semaphorin III/F (SEMA3F), and p21(Cip1) (p21)] but reduced mdr1 expression. Finally, p AMPK levels were reduced in 5 FU resistant gastric cancer cells compared to human immortalized gastric epithelial cell line and 5 FU sensitive gastric cancer cells. AICAR not only induces apoptosis alone but also enhances pro apoptotic effect of 5 FU in SGC 7901 cells, which lays an experimental foundation to develop AICAR as a chemotherapeutic sensitizer against gastric cancer.
C1 [Wu, Yan; Qi, Yijun; Liu, Hu; Wang, Xiaoshan; Wang, Zhengguang] Anhui Med Univ, Affiliated Hosp 1, Dept Surg, Hefei, Anhui, Peoples R China.
   [Wu, Yan; Zhu, Huaqing] Anhui Med Univ, Mol Biol Lab, Hefei, Anhui, Peoples R China.
   [Wu, Yan; Zhu, Huaqing] Anhui Med Univ, Dept Biochem, Hefei, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University
RP Wang, ZG (通讯作者)，Anhui Med Univ, Affiliated Hosp 1, Dept Surg, Hefei, Anhui, Peoples R China.; Zhu, HQ (通讯作者)，Anhui Med Univ, Mol Biol Lab, Hefei, Anhui, Peoples R China.; Zhu, HQ (通讯作者)，Anhui Med Univ, Dept Biochem, Hefei, Anhui, Peoples R China.
EM aydzhq@126.com; wangzhengguang@ahmu.edu.cn
FU Natural Science Foundation of Anhui Province, China [1301043054];
   Educational Commission of Anhui Province [kj2011Z210]; Affiliated
   Hospital of Anhui Medical University, Hefei, China
FX This study was supported by the grants from the Natural Science
   Foundation of Anhui Province, China (No. 1301043054), the Educational
   Commission of Anhui Province (Grant No. kj2011Z210), and Affiliated
   Hospital of Anhui Medical University, Hefei, China.
CR Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Calcagno DQ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471 230X 13 141
   Chen D, 2013, EUR REV MED PHARMACO, V17, P1703
   Du J, 2012, INT J MOL SCI, V13, P15755, DOI 10.3390/ijms131215755
   Friedrichsen M, 2013, MOL CELL ENDOCRINOL, V366, P204, DOI 10.1016/j.mce.2012.06.013
   Geng M, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746 1596 8 198
   Herrero R, 2014, BEST PRACT RES CL GA, V28, P1107, DOI 10.1016/j.bpg.2014.10.003
   Hien TT, 2010, MOL NUTR FOOD RES, V54, P918, DOI 10.1002/mnfr.200900146
   Hu WQ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756 9966 28 144
   Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Khalil H, 2012, MOL CELL BIOL, V32, P4523, DOI 10.1128/MCB.00774 12
   Kim HG, 2011, BRIT J PHARMACOL, V162, P1096, DOI 10.1111/j.1476 5381.2010.01101.x
   Kim JG, 2013, ONCOLOGY BASEL, V85, P78, DOI 10.1159/000351234
   Kim YH, 2012, CANCER RES, V72, P2512, DOI 10.1158/0008 5472.CAN 11 3870
   Luo LY, 2013, CANCER LETT, V328, P114, DOI 10.1016/j.canlet.2012.08.034
   Mendes da Cruz DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103405
   MIKULIN T, 1987, EUR J CANCER CLIN ON, V23, P1683, DOI 10.1016/0277 5379(87)90450 0
   Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299
   Park JB, 2012, BIOL PHARM BULL, V35, P1614, DOI 10.1248/bpb.b12 00352
   Qu C, 2014, MOL CELL BIOCHEM, V386, P63, DOI 10.1007/s11010 013 1845 x
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Saitoh M, 2004, BIOCHEM PHARMACOL, V67, P2005, DOI 10.1016/j.bcp.2004.01.020
   Shi HC, 2008, HEPATO GASTROENTEROL, V55, P1530
   Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008 6363(99)00395 8
   Tran TP, 2013, PHYTOMEDICINE, V20, P622, DOI 10.1016/j.phymed.2013.01.014
   Tsai MM, 2014, WORLD J GASTROENTERO, V20, P13791, DOI 10.3748/wjg.v20.i38.13791
   Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567
   Wang JYJ, 2001, CELL DEATH DIFFER, V8, P1047, DOI 10.1038/sj.cdd.4400938
   Wang ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075788
   Wang ZG, 2012, CLIN EXP PHARMACOL P, V39, P227, DOI 10.1111/j.1440 1681.2011.05660.x
   Xiong GF, 2012, CANCER RES, V72, P1728, DOI 10.1158/0008 5472.CAN 11 2762
   Yi B, 2013, ONCOL LETT, V6, P583, DOI 10.3892/ol.2013.1403
   Yue L, 2014, BONE, V60, P112, DOI 10.1016/j.bone.2013.12.011
   Yue L, 2012, BONE, V51, P338, DOI 10.1016/j.bone.2012.06.003
   Zhu HT, 2016, PHARM BIOL, V54, P285, DOI 10.3109/13880209.2015.1033563
NR 36
TC 26
Z9 27
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2016
VL 411
IS 1 2
BP 299
EP 305
DI 10.1007/s11010 015 2592 y
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DD3FX
UT WOS:000369808600030
PM 26497305
DA 2025 08 17
ER

PT J
AU Tan, XQ
   Xiao, H
   Yan, A
   Li, M
   Wang, LF
AF Tan, Xiaoqian
   Xiao, Han
   Yan, An
   Li, Miao
   Wang, Linfeng
TI Effect of Exosomes From Bone Marrow Derived Mesenchymal Stromal Cells
   and Adipose Derived Stromal Cells on Bone Tendon Healing in a Murine
   Rotator Cuff Injury Model
SO ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE
LA English
DT Article
DE adipose derived mesenchymal stromal cell; bone marrow derived
   mesenchymal stromal cell; bone tendon healing; exosomes; rotator cuff
ID INTENSITY PULSED ULTRASOUND; STEM CELLS; REPAIR INTEGRITY; IN VIVO;
   INFLAMMATION; TISSUE
AB Background:Bone tendon injury is characterized by poor self healing. It is established that exosomes are favorable for tissue repair and regeneration. However, their effect on bone tendon healing has not yet been determined.Purpose:To compare the effectiveness of exosomes derived from adipose derived mesenchymal stromal cells (ADSC Exos) and bone marrow derived mesenchymal stromal cells (BMSC Exos) on bone tendon interface healing in murine rotator cuff injury model and explore the underlying mechanisms thereof.Study Design:Controlled laboratory study.Methods:A total of 63 male C57BL6 mice with rotator cuff injuries underwent surgery and were randomly assigned to a control group treated without exosomes (n = 21), an ADSC Exos group (n = 21), or a BMSC Exos group (n = 21). The mice were sacrificed 4 or 8 weeks after surgery, and tissues were collected for histologic examination and radiographic and biomechanical testing. For exosome tracing in vivo, mice were sacrificed 7 days after surgery. A series of functional assays (radiographic evaluation, proliferation assay, Alizarin Red staining, alkaline phosphatase staining and activity, Alcian blue staining, quantitative polymerase chain reaction analyses, and glycosaminoglycans quantification) were conducted to evaluate the effect of exosomes on the cellular behaviors of the BMSCs in vitro. A statistical analysis of multiple group comparisons was performed by 1 way analysis of variance, followed by the Bonferroni post hoc test to assess the differences between the 2 groups.Results:The ADSCs and BMSCs were positive for surface markers CD29 and CD90 and negative for surface markers CD34 and CD45 and could differentiate into osteoblasts, chondrocytes, and adipocytes. Exosomes showed a cup  or sphere shaped morphology and were positive for CD63 and TGS101. Local injection of ADSC Exos and BMSC Exos could recruit BMSCs and promote osteogenesis, chondrogenesis, and bone tendon healing. In vitro, ADSC Exos and BMSC Exos could significantly promote the proliferation, migration, osteogenic differentiation, and chondrogenic differentiation ability of BMSCs. In vivo, ADSC Exos and BMSC Exos significantly accelerated bone tendon injury healing, with no significant statistical difference between them.Conclusion:ADSC Exos and BMSC Exos exhibited similar therapeutic effects on bone tendon healing in our murine animal model.Clinical Relevance:ADSC Exos and BMSC Exos may be used to develop a new cell free therapy method for promoting rotator cuff injury repair.
C1 [Tan, Xiaoqian; Xiao, Han; Yan, An; Li, Miao] Hunan Childrens Hosp, Dept Pediat Orthoped, Changsha, Hunan, Peoples R China.
   [Tan, Xiaoqian; Xiao, Han; Yan, An; Li, Miao] Univ South China, Sch Pediat, Changsha 421001, Hunan, Peoples R China.
   [Tan, Xiaoqian; Xiao, Han; Yan, An; Li, Miao] Hunan Childrens Hosp, Hunan Prov Key Lab Pediat Orthoped, Changsha, Hunan, Peoples R China.
   [Wang, Linfeng] Cent South Univ, Xiangya Hosp, Dept Sports Med, Changsha, Hunan, Peoples R China.
   [Wang, Linfeng] Cent South Univ, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Peoples R China.
C3 University of South China; Central South University; Central South
   University
RP Wang, LF (通讯作者)，Cent South Univ, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Peoples R China.
EM 525311592@qq.com
FU hunan province clinical medical technology innovation guide project;
   Hunan Children's Hospital
FX The authors thank the members of the Hunan Children's Hospital and
   Xiangya Hospital for their support during this study.
CR Baglio SR, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0116 z
   Basu J, 2016, EXPERT OPIN BIOL TH, V16, P489, DOI 10.1517/14712598.2016.1131976
   Benjamin M, 2006, J ANAT, V208, P471, DOI 10.1111/j.1469 7580.2006.00540.x
   Cavallo C, 2011, J CELL BIOCHEM, V112, P1418, DOI 10.1002/jcb.23058
   Chaubey S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0903 4
   Chen C, 2019, ACS APPL MATER INTER, V11, P2891, DOI 10.1021/acsami.8b20563
   Chen CY, 2018, THERANOSTICS, V8, P1607, DOI 10.7150/thno.22958
   Degen RM, 2016, ARTHROSCOPY, V32, P2435, DOI 10.1016/j.arthro.2016.04.019
   Galatz LM, 2004, J BONE JOINT SURG AM, V86A, P219, DOI 10.2106/00004623 200402000 00002
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018 017 2595 9
   Kizil C, 2015, EMBO REP, V16, P416, DOI 10.15252/embr.201439702
   Koga H, 2008, CELL TISSUE RES, V333, P207, DOI 10.1007/s00441 008 0633 5
   Lebaschi AH, 2018, ARTHROSCOPY, V34, P1173, DOI 10.1016/j.arthro.2017.10.045
   Lee HY, 2017, CANCER SCI, V108, P1939, DOI 10.1111/cas.13334
   Leung KS, 2015, AM J SPORT MED, V43, P1413, DOI 10.1177/0363546515576904
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Lu HB, 2016, J ORTHOP RES, V34, P1697, DOI 10.1002/jor.23180
   Lu HB, 2016, AM J SPORT MED, V44, P2706, DOI 10.1177/0363546516651863
   McGonagle D, 2009, J EUR ACAD DERMATOL, V23, P9, DOI 10.1111/j.1468 3083.2009.03363.x
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Oh JH, 2014, J SHOULDER ELB SURG, V23, P445, DOI 10.1016/j.jse.2013.07.054
   Park JS, 2011, BIOMATERIALS, V32, P8139, DOI 10.1016/j.biomaterials.2011.07.043
   Randelli PS., Am J Sports Med, V2019
   Rhee YG, 2014, ARTHROSCOPY, V30, P546, DOI 10.1016/j.arthro.2014.02.006
   Sevivas N, 2018, AM J SPORT MED, V46, P449, DOI 10.1177/0363546517735850
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Vogel G, 2008, SCIENCE, V321, P756, DOI 10.1126/science.321.5890.756b
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Yang RH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1312 z
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Zhang J, 2017, BONE JOINT RES, V6, P231, DOI 10.1302/2046 3758.64.BJR 2017 0268.R1
   Zhang KL, 2019, ARTHROSCOPY, V35, P979, DOI 10.1016/j.arthro.2018.10.126
NR 33
TC 8
Z9 8
U1 2
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
EI 2325 9671
J9 ORTHOP J SPORTS MED
JI Orthop. J. Sports Med.
PD JAN
PY 2024
VL 12
IS 1
AR 23259671231210304
DI 10.1177/23259671231210304
PG 11
WC Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences
GA ED0S2
UT WOS:001136865900001
PM 38188618
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Takagi, K
   Takagi, M
   Kanangat, S
   Warrington, KJ
   Shigemitsu, H
   Postlethwaite, AE
AF Takagi, K
   Takagi, M
   Kanangat, S
   Warrington, KJ
   Shigemitsu, H
   Postlethwaite, AE
TI Modulation of TNF α gene expression by IFN γ and pamidronate in murine
   macrophages:: regulation by STAT1 dependent pathways
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; PROTEIN TYROSINE PHOSPHATASE; NF KAPPA B;
   ACUTE PHASE RESPONSE; MESSENGER RNA STABILITY; INTERFERON GAMMA;
   IN VITRO; C JUN; BISPHOSPHONATES; CELLS
AB Aminobisphosphonates are drugs used in the treatment of hypercalcemia, Paget's disease, osteoporosis, and malignancy. Some patients treated with aminobisphosphonates have a transient febrile reaction that may be caused by an increased serum concentration of proinflammatory cytokines. Aminobisphosphonates induce the production of certain proinflammatory cytokines in vitro, especially in cells of monocytic lineage. A unique feature of aminobisphosphonates is that they bind the Vgamma2Vdelta2 class of T cells, which are found only in primates, and stimulate cytokine production. The effects of aminobisphosphonates on other cells, including macrophages, are incompletely understood. We show in this study that treatment of murine macrophages with pamidronate, a second generation aminobisphosphonate, induces TNF alpha production. Furthermore, pretreatment of murine macrophages with pamidronate before stimulation with IFN gamma significantly augments WN gamma dependent production of TNF alpha. This pamidronate mediated augmentation of TNF a production results in sustained phosphorylation of the tyrosine residue at position 701 of STAT1 after IFN gamma treatment. Our data suggest that this sustained phosphorylation results from inhibition of protein tyrosine phosphatase activity. We also show that pamidronate treatment increases TNF a production in vivo in mice. Pamidronate augmented TNF alpha production by macrophages might be a useful strategy for cytokine based anticancer therapy.
C1 Univ Tennessee, Coll Med, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA.
   Dept Vet Affairs Med Ctr, Memphis, TN 38104 USA.
   Univ Tennessee, Hlth Sci Ctr, Div Connect Tissue Dis, Memphis, TN 38163 USA.
   Univ Tennessee, Hlth Sci Ctr, Div Pulm Med, Memphis, TN 38163 USA.
   St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Memphis VA Medical Center; University of Tennessee
   System; University of Tennessee Health Science Center; University of
   Tennessee System; University of Tennessee Health Science Center; St Jude
   Children's Research Hospital
RP Postlethwaite, AE (通讯作者)，Univ Tennessee, Coll Med, Ctr Hlth Sci, Dept Med, 956 Court Ave,Room G326, Memphis, TN 38163 USA.
EM apostlethwai@utmem.edu
RI Warrington, Kenneth/CAG 1626 2022; Takagi, Masatoshi/F 3713 2011
OI Warrington, Kenneth/0000 0001 7708 2487; 
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Alleva DG, 2002, J LEUKOCYTE BIOL, V71, P677
   Aoki N, 2004, J BIOL CHEM, V279, P10765, DOI 10.1074/jbc.M310401200
   BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791
   BOCHM U, 1997, ANNU REV IMMUNOL, V15, P749
   Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014 5793(00)02084 6
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   CUMIS F, 2002, J CLIN INVEST, V110, P475
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   Endo N, 1996, J BONE MINER RES, V11, P535
   FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909
   HAYES MP, 1995, CYTOKINE, V7, P427, DOI 10.1006/cyto.1995.0058
   IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0
   IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968 0004(94)90026 4
   Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524
   Lee JY, 2001, INFECT IMMUN, V69, P2847, DOI 10.1128/IAI.69.5.2847 2852.2001
   Lejeune FJ, 2002, J CLIN INVEST, V110, P433, DOI 10.1172/JCI200216493
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255
   Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   MELTZER MS, 1982, FED PROC, V41, P2198
   Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092 8674(00)81288 X
   Mueller H, 1998, CELL MOL LIFE SCI, V54, P1291, DOI 10.1007/s000180050255
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   Murakami H, 1997, BONE, V20, P399, DOI 10.1016/S8756 3282(97)00025 2
   NARUMI S, 1990, J BIOL CHEM, V265, P7036
   NARUMI S, 1992, J IMMUNOL, V2, P529
   Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200
   Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598
   Opas EE, 1997, BIOCHEM PHARMACOL, V54, P721, DOI 10.1016/S0006 2952(97)00225 6
   Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974
   Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471 4906(01)02118 4
   Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525
   Rendon Mitchell B, 2003, J IMMUNOL, V170, P3890, DOI 10.4049/jimmunol.170.7.3890
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rose DM, 1997, BIOCHEM BIOPH RES CO, V238, P256, DOI 10.1006/bbrc.1997.7271
   RUDDLE NH, 1992, CURR OPIN IMMUNOL, V4, P327, DOI 10.1016/0952 7915(92)90084 R
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   SCHOOK LB, 1994, J LEUKOCYTE BIOL, V56, P514, DOI 10.1002/jlb.56.4.514
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   Senzer N, 2004, J CLIN ONCOL, V22, P592, DOI 10.1200/JCO.2004.01.227
   Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472
   Sugawara S, 1998, BRIT J PHARMACOL, V125, P735, DOI 10.1038/sj.bjp.0702151
   ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662 5668.2002
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960 894X(02)00106 3
   UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834
   VILCEK J, 1991, J BIOL CHEM, V266, P7313
   Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI200113584
   Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200
   Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795
   ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765
NR 60
TC 29
Z9 32
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2005
VL 174
IS 4
BP 1801
EP 1810
DI 10.4049/jimmunol.174.4.1801
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 897EL
UT WOS:000226986700005
PM 15699106
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, YM
   Shi, F
   Gong, KM
   Liu, Y
   Zhi, W
   Weng, J
   Qu, SX
AF Liu, Yumei
   Shi, Feng
   Gong, Kemeng
   Liu, Yang
   Zhi, Wei
   Weng, Jie
   Qu, Shuxin
TI Study on critical sized ultra high molecular weight polyethylene wear
   particles loaded with alendronate sodium: in vitro release and cell
   response
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID CROSS LINKED POLYETHYLENE; PRO INFLAMMATORY CYTOKINES; TOTAL JOINT
   REPLACEMENT; MACROPHAGE LIKE CELLS; ORTHOPEDIC IMPLANTS; INDUCED
   OSTEOLYSIS; UHMWPE PARTICLES; TOTAL HIP; BISPHOSPHONATES; ARTHROPLASTY
AB The aim of this study was to investigate the in vitro release and the effect of RAW 264.7 macrophages of critical sized wear particles of ultra high molecular weight polyethylene (UHMWPE) loaded with alendronate sodium (ALN), one of the most effective drugs to treat osteoporosis in clinic. The critical sized UHMWPE ALN 0.5 wt.% wear particles were prepared by vacuum gradient filtration combined with Pluronic F 68. In vitro release of ALN from critical sized UHMWPE ALN wear particles was investigated in phosphate buffered saline (PBS) at 37 degrees C with a shaker. Cell morphology, proliferation, lactate dehydrogenase (LDH) leakage and secretions of cytokines were evaluated after co cultured with critical sized UHMWPE ALN wear particles in vitro. Results showed that ALN released from critical sized UHMWPE ALN wear particles included burst release and slow release in vitro. Macrophages would be chemotaxis and aggregated around the critical sized UHMWPE ALN or UHMWPE wear particle, which was phagocytosed with time. The proliferation of macrophages co cultured with critical sized UHMWPE ALN wear particles was significantly decreased compared with that of critical sized UHMWPE group. Meanwhile, the critical sized UHMWPE ALN wear particles significantly induced the LDH leakage of macrophages, which indicated the cell death. The death of macrophages induced by ALN was one of pathways to inhibit their proliferation. The secretions of cytokines interleukin 6 and tumor necrosis factor alpha) in criticalsized UHMWPE ALN group were significantly lower than those in critical sized UHMWPE group due to the released ALN. The present results suggested that UHMWPE ALN had the potential application in clinic to treat osteolysis induced by wear particles.
C1 [Liu, Yumei; Shi, Feng; Gong, Kemeng; Liu, Yang; Zhi, Wei; Weng, Jie; Qu, Shuxin] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, Chengdu 610031, Peoples R China.
C3 Southwest Jiaotong University
RP Qu, SX (通讯作者)，Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, Chengdu 610031, Peoples R China.
EM qushuxin@swjtu.edu.cn
RI Weng, Jie/B 3005 2010; QU, Shuxin/H 3036 2011
OI Weng, Jie/0000 0002 7034 3215; 
FU National Basic Research Program of China (973 Program) [2012CB933602];
   National Natural Science Foundation of China [51372210, 51203130,
   50975239]; Research Fund for the Doctoral Program of Higher Education of
   China [20130184110023]; Basic Research Foundation Key Project of Sichuan
   Province [2016JY0011]; Fundamental Research Funds for the Central
   Universities [2682016YXZT11]; Construction Program for Innovative
   Research Team of University in Sichuan Province [14TD0050]
FX The present study was supported by the National Basic Research Program
   of China (973 Program, 2012CB933602), the National Natural Science
   Foundation of China (51372210, 51203130, 50975239), the Research Fund
   for the Doctoral Program of Higher Education of China (20130184110023),
   the Basic Research Foundation Key Project of Sichuan Province
   (2016JY0011), the Fundamental Research Funds for the Central
   Universities, (2682016YXZT11) and the Construction Program for
   Innovative Research Team of University in Sichuan Province (14TD0050).
CR Alley Carie, 2014, J Long Term Eff Med Implants, V24, P45
   Berkland C, 2007, J PHARM SCI US, V96, P1176, DOI 10.1002/jps.20948
   Bladen CL, 2013, J BIOMED MATER RES B, V101B, P458, DOI 10.1002/jbm.b.32904
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Chang YL, 2011, TOXICOL LETT, V200, P201, DOI 10.1016/j.toxlet.2010.11.016
   Dai M, 2013, J RARE EARTH, V31, P531, DOI 10.1016/S1002 0721(12)60315 9
   Deng YL, 2013, J MATER SCI MATER M, V24, P2085, DOI 10.1007/s10856 013 4970 x
   Dion NT, 2015, ORTHOP CLIN N AM, V46, P321, DOI 10.1016/j.ocl.2015.02.001
   Drees P, 2007, NAT CLIN PRACT RHEUM, V3, P165, DOI 10.1038/ncprheum0428
   Evans CE, 2002, INT J BIOCHEM CELL B, V34, P554, DOI 10.1016/S1357 2725(01)00147 9
   Fang HW, 2006, J BIOCHEM BIOPH METH, V68, P175, DOI 10.1016/j.jbbm.2006.05.011
   Garbuz DS, 2008, J BONE JOINT SURG AM, V90A, P1090, DOI 10.2106/JBJS.G.00415
   Ge SR, 2008, WEAR, V264, P571, DOI 10.1016/j.wear.2007.05.001
   Gong KM, 2016, J MECH BEHAV BIOMED, V61, P334, DOI 10.1016/j.jmbbm.2016.03.023
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Goodman SB, 2009, J BIOMED MATER RES A, V90A, P603, DOI 10.1002/jbm.a.32063
   Hallab NJ, 2012, J BIOMED MATER RES B, V100B, P480, DOI 10.1002/jbm.b.31974
   Hata K, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5472 9
   Huang ZN, 2010, J BIOMED MATER RES A, V94A, P1264, DOI 10.1002/jbm.a.32803
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Jablonski H, 2015, NEUROIMMUNOMODULAT, V22, P152, DOI 10.1159/000360988
   Kurtz SM, 2011, CLIN ORTHOP RELAT R, V469, P2262, DOI 10.1007/s11999 011 1872 4
   Lu YC, 2015, ACTA BIOMATER, V20, P147, DOI 10.1016/j.actbio.2015.03.034
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Cattalini J, 2012, TISSUE ENG PART B RE, V18, P323, DOI 10.1089/ten.teb.2011.0737
   Qu SX, 2013, J BIOMED MATER RES A, V101, P394, DOI 10.1002/jbm.a.34327
   Richards L, 2008, J BONE JOINT SURG BR, V90B, P1106, DOI 10.1302/0301 620X.90B8.20737
   Shen J, 2015, CLIN ORTHOP RELAT R, V473, P760, DOI 10.1007/s11999 014 3850 0
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Sultana S, 2010, CHROMATOGRAPHIA, V72, P321, DOI 10.1365/s10337 010 1656 0
   Wood WJ, 2011, COMPOS PART B ENG, V42, P584, DOI 10.1016/j.compositesb.2010.09.006
   Wu JP, 2013, TRIBOL LETT, V52, P449, DOI 10.1007/s11249 013 0228 5
   Yamazaki T, 2012, BONE, V51, P882, DOI 10.1016/j.bone.2012.08.115
   Yang D, 2012, MAT SCI ENG C MATER, V32, P83, DOI 10.1016/j.msec.2011.09.012
   Zhang YY, 2015, REGEN BIOMATER, V2, P197, DOI 10.1093/rb/rbv002
   Zhang YB, 2010, ACS NANO, V4, P3181, DOI 10.1021/nn1007176
NR 36
TC 6
Z9 6
U1 0
U2 43
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD APR
PY 2017
VL 28
IS 4
AR 56
DI 10.1007/s10856 017 5865 z
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ER7UY
UT WOS:000399020800002
PM 28210968
DA 2025 08 17
ER

PT J
AU León, IE
   Di Virgilio, AL
   Barrio, DA
   Arrambide, G
   Gambino, D
   Etcheverry, SB
AF Leon, Ignacio E.
   Di Virgilio, Ana L.
   Barrio, Daniel A.
   Arrambide, Gabriel
   Gambino, Dinorah
   Etcheverry, Susana B.
TI Hydroxylamido amino acid complexes of oxovanadium(V). Toxicological
   study in cell culture and in a zebrafish model
SO METALLOMICS
LA English
DT Article
ID OSTEOBLAST LIKE CELLS; VANADIUM COMPOUNDS; VANADYL(IV) COMPLEX;
   DNA DAMAGE; ANTITUMOR ACTIVITY; HYDROGEN PEROXIDE; OXIDATIVE STRESS;
   SENSITIVE METHOD; GROWTH FACTOR; POTENTIAL USE
AB Oxovanadium(V) complexes [VO(NH2O)(2)(val)] and [VO(NH2O)(2)(met)] caused inhibition of cell proliferation in two osteoblast cell lines, MC3T3 E1 and UMR106, as well as the viability of zebrafish eggs. In MC3T3 E1, both compounds inhibited cell proliferation (up to ca. 40% at 25 mu M [VO(NH2O)(2)(val)] and 25% at 25 mu M [VO(NH2O)(2)(met)]). This effect occurs in a dose response manner from 2.5 mu M (p < 0.01) with a more deleterious action of [VO(NH2O)(2)(met)]. In UMR106 tumoral cells, [VO(NH2O)(2)(val)] inhibited cell proliferation up to 75% from 25 mu M while [VO(NH2O)(2)(met)] behaved as an inhibitory agent in the whole range of concentrations (p < 0.01). Similar toxic effects were obtained from morphological studies in cell cultures. Moreover, the IC50 values for both complexes in culture studies correlated with the IC50 values obtained with an in vivo model of toxicity (FET test). Besides, the cytotoxicity evaluation in cell culture showed a decrease in mitochondrial activity which was stronger for [VO(NH2O)(2)(met)] than for [VO(NH2O)(2)(val)] (44% vs. 58% at 25 mu M) in both cell lines (p < 0.001). Genotoxicity assessed by micronuclei induction also showed a stronger effect of [VO(NH2O)(2)(met)] in both cell lines. Besides, [VO(NH2O)(2)(val)] caused DNA damage determined by comet formation in MC3T3 E1 cells in the range of 2.5 25 mu M, while this effect could not be observed in the osteosarcoma cells. On the other hand, [VO(NH2O)(2)(val)] enhanced ROS levels over basal up to 225% and 170% at 100 mu M in MC3T3 E1 and UMR106 cells, respectively (p < 0.01). For [VO(NH2O)(2)(met)] a similar situation was observed, suggesting an important role for oxidative stress in the toxicity mechanism of action. Although both complexes showed interesting results that would deserve further drug development [VO(NH2O)(2)(val)] was more stable than [VO(NH2O)(2)(met)] in the solid state. Therefore, we consider that [VO(NH2O)(2)(val)] is a good candidate to be tested in in vivo models as a potential antitumoral agent.
C1 [Leon, Ignacio E.; Di Virgilio, Ana L.; Etcheverry, Susana B.] Univ Nacl La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Buenos Aires, Argentina.
   [Leon, Ignacio E.; Di Virgilio, Ana L.; Etcheverry, Susana B.] Univ Nacl La Plata, Fac Ciencias Exactas, CEQUINOR, RA 1900 La Plata, Buenos Aires, Argentina.
   [Arrambide, Gabriel; Gambino, Dinorah] Univ Republica, Fac Quim, Catedra Quim Inorgan, Montevideo, Uruguay.
C3 National University of La Plata; National University of La Plata;
   Universidad de la Republica, Uruguay
RP Etcheverry, SB (通讯作者)，Univ Nacl La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, 47 & 115, RA 1900 La Plata, Buenos Aires, Argentina.
RI leon, i/GZL 2093 2022; Barrio, Daniel/AAG 6938 2019; Gambino,
   Dinorah/AFL 6104 2022
OI leon, ignacio/0000 0003 1010 3997; Gambino, Dinorah/0000 0001 8678 7374
FU UNLP [11X/554]; CONICET [PIP 1125]; ANPCyT [PICT 2218, PICT 2010 0981];
   CYTED network [209RT0380]; ANPCyT, Argentina
FX This work was partly supported by UNLP (11X/554), CONICET (PIP 1125),
   ANPCyT (PICT 2218 and PICT 2010 0981). The authors would also like to
   thank CYTED network 209RT0380 for mobility funds. ALDV, DAB and SBE are
   members of the Carrera del Investigador, CONICET, Argentina. IEL is a
   fellowship from ANPCyT, Argentina.
CR Arrambide G, 2009, BIOL TRACE ELEM RES, V132, P176, DOI 10.1007/s12011 009 8375 0
   Arrambide G, 2010, BIOL TRACE ELEM RES, V136, P241, DOI 10.1007/s12011 009 8538 z
   Arrambide G, 2009, J COORD CHEM, V62, P63, DOI 10.1080/00958970802474821
   Aureliano M, 2005, J INORG BIOCHEM, V99, P979, DOI 10.1016/j.jinorgbio.2005.02.024
   Baran E. J., 1996, ANAL ACAD NAC CS FIS, V46, P35
   Baran Enrique J., 1997, Acta Farmaceutica Bonaerense, V16, P43
   Barrio DA, 2010, CURR MED CHEM, V17, P3632
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   Barrio DA, 2006, CAN J PHYSIOL PHARM, V84, P765, DOI 10.1139/Y06 021
   Borenfreund E., 1984, Journal of Tissue Culture Methods, V9, P7, DOI [10.1007/BF01666038, DOI 10.1007/BF01666038]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Braunbeck T., 2005, DRAFT DETAILED REV P
   Bruijnincx PCA, 2008, CURR OPIN CHEM BIOL, V12, P197, DOI 10.1016/j.cbpa.2007.11.013
   Capella MAM, 2007, CELL BIOL TOXICOL, V23, P413, DOI 10.1007/s10565 007 9003 4
   Che CM, 2011, CHEM COMMUN, V47, P9554, DOI 10.1039/c1cc10860c
   Cheng JP, 2007, ENVIRON TOXICOL CHEM, V26, P708, DOI 10.1897/06 272R.1
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300 483X(00)00181 5
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n
   Crans D. C., 1998, VANADIUM COMPOUNDS C, P82
   Creton R, 2004, DEV BRAIN RES, V151, P33, DOI 10.1016/j.devbrainres.2004.03.016
   D'Cruz OJ, 2003, BIOCHEM BIOPH RES CO, V302, P253, DOI 10.1016/S0006 291X(03)00161 X
   Di Virgilio AL, 2011, BIOMETALS, V24, P1153, DOI 10.1007/s10534 011 9474 x
   DJORDJEVIC C, 1995, MET IONS BIOL SYST, V31, P595
   DJORDJEVIC C, 1985, J INORG BIOCHEM, V25, P51, DOI 10.1016/0162 0134(85)83007 5
   Domingues I, 2010, COMP BIOCHEM PHYS C, V152, P338, DOI 10.1016/j.cbpc.2010.05.010
   Etcheverry SB, 1997, ARCH BIOCHEM BIOPHYS, V338, P7, DOI 10.1006/abbi.1996.9778
   Etcheverry SB, 2007, BIOORGAN MED CHEM, V15, P6418, DOI 10.1016/j.bmc.2007.06.056
   Etcheverry SB, 2008, J BIOL INORG CHEM, V13, P435, DOI 10.1007/s00775 007 0332 9
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   FENECH M, 1993, MUTAT RES, V285, P35, DOI 10.1016/0027 5107(93)90049 L
   Gambino D, 2011, COORDIN CHEM REV, V255, P2193, DOI 10.1016/j.ccr.2010.12.028
   Hambley TW, 2007, SCIENCE, V318, P1392, DOI 10.1126/science.1150504
   Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865
   HARDING CJ, 1993, ANGEW CHEM INT EDIT, V32, P570, DOI 10.1002/anie.199305701
   Harding MM, 2000, CURR MED CHEM, V7, P1289, DOI 10.2174/0929867003374066
   Holko P, 2008, POL J PATHOL, V59, P3
   Hong CC, 2009, CYTOKINE GROWTH F R, V20, P409, DOI 10.1016/j.cytogfr.2009.10.021
   Jungwirth U, 2011, ANTIOXID REDOX SIGN, V15, P1085, DOI 10.1089/ars.2010.3663
   Keramidas AD, 1997, J AM CHEM SOC, V119, P8901, DOI 10.1021/ja970747y
   Krejsa CM, 1997, J BIOL CHEM, V272, P11541
   Lammer E, 2009, COMP BIOCHEM PHYS C, V149, P196, DOI 10.1016/j.cbpc.2008.11.006
   Li M, 2009, BIOMETALS, V22, P895, DOI 10.1007/s10534 009 9241 4
   Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016
   Majumder S, 2003, EUR J MED CHEM, V38, P893, DOI 10.1016/j.ejmech.2003.08.002
   McNeill JH, 1995, MOL CELL BIOCHEM, V153, P175, DOI 10.1007/BF01075935
   Molinuevo MS, 2005, TOXICOLOGY, V210, P205, DOI 10.1016/j.tox.2005.02.016
   Molinuevo MS, 2004, CANCER CHEMOTH PHARM, V53, P163, DOI 10.1007/s00280 003 0708 7
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mouchet F, 2005, ENVIRON TOXICOL, V20, P74, DOI 10.1002/tox.20080
   Mukherjee R, 2008, CHEM COMMUN, P3783, DOI 10.1039/b806598e
   Nagel R, 2002, ALTEX ALTERN TIEREXP, V19, P38
   Naso L, 2010, J BIOL INORG CHEM, V15, P889, DOI 10.1007/s00775 010 0652 z
   Naso LG, 2011, J BIOL INORG CHEM, V16, P653, DOI 10.1007/s00775 011 0769 8
   NIELSEN FH, 1995, MET IONS BIOL SYST, V31, P543
   OECD, 2006, FISH EMBR TOX TEST
   OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201
   Qin Y, 2008, CELL BIOL INT, V32, P224, DOI 10.1016/j.cellbi.2007.08.028
   Rehder D, 1999, COORDIN CHEM REV, V182, P297, DOI 10.1016/S0010 8545(98)00194 5
   Rehder D, 2002, J BIOL INORG CHEM, V7, P384, DOI 10.1007/s00775 001 0311 5
   Rehder D., 2008, BIOINORGANIC VANADIU, P158
   Rivadeneira J, 2010, MED CHEM, V6, P9, DOI 10.2174/157340610791208754
   Rivadeneira J, 2009, J INORG BIOCHEM, V103, P633, DOI 10.1016/j.jinorgbio.2008.11.009
   Rodríguez Mercado JJ, 2011, TOXICOL IN VITRO, V25, P1996, DOI 10.1016/j.tiv.2011.07.009
   Sálice VC, 1999, MOL CELL BIOCHEM, V198, P119, DOI 10.1023/A:1006997830346
   Scholz S, 2008, ENVIRON SCI POLLUT R, V15, P394, DOI 10.1007/s11356 008 0018 z
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014 4827(88)90265 0
   Smee JJ, 2009, J INORG BIOCHEM, V103, P575, DOI 10.1016/j.jinorgbio.2008.12.015
   Soares SS, 2007, J INORG BIOCHEM, V101, P789, DOI 10.1016/j.jinorgbio.2007.01.012
   Soares SS, 2008, CHEM RES TOXICOL, V21, P607, DOI 10.1021/tx700204r
   Stopper H, 1997, TOXICOL IN VITRO, V11, P661, DOI 10.1016/S0887 2333(97)00084 2
   SUZUKI H, 1969, J ANTIBIOT, V22, P446, DOI 10.7164/antibiotics.22.446
   SUZUKI H, 1968, J ANTIBIOT, V21, P379, DOI 10.7164/antibiotics.21.379
   Thompson KH, 2009, J INORG BIOCHEM, V103, P554, DOI 10.1016/j.jinorgbio.2008.12.003
   Thompson KH, 1999, CHEM REV, V99, P2561, DOI 10.1021/cr980427c
   Thompson KH, 2001, COORDIN CHEM REV, V219, P1033, DOI 10.1016/S0010 8545(01)00395 2
   Thompson KH, 2000, J CHEM SOC DALTON, P2885, DOI 10.1039/b002753g
   Uivarosi V, 2010, MOLECULES, V15, P1578, DOI 10.3390/molecules15031578
   Upreti RK, 1995, MOL CELL BIOCHEM, V153, P167, DOI 10.1007/BF01075934
   Villani P, 2007, TOXICOL LETT, V170, P11, DOI 10.1016/j.toxlet.2006.07.343
   WESTERFIELD M, 1995, ZEBRAFISH BOOK GUIDE
   Williams CH, 2011, INT J MOL SCI, V12, P2262, DOI 10.3390/ijms12042262
   Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585
   YUEN VG, 1993, CAN J PHYSIOL PHARM, V71, P263, DOI 10.1139/y93 041
   Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464
NR 85
TC 19
Z9 20
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1756 5901
EI 1756 591X
J9 METALLOMICS
JI Metallomics
PY 2012
VL 4
IS 12
BP 1287
EP 1296
DI 10.1039/c2mt20091k
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 041PR
UT WOS:000311414200007
PM 23073485
OA Bronze
DA 2025 08 17
ER

PT J
AU Luginina, J
   Kroskins, V
   Lacis, R
   Fedorovska, E
   Demir,Ö
   Dubnika, A
   Loca, D
   Turks, M
AF Luginina, Jevgenija
   Kroskins, Vladislavs
   Lacis, Rihards
   Fedorovska, Elza
   Demir, Oznur
   Dubnika, Arita
   Loca, Dagnija
   Turks, Maris
TI Synthesis and preliminary cytotoxicity evaluation of water soluble
   pentacyclic triterpenoid phosphonates
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Pentacyclic triterpenoids; Phosphonates; Cytotoxicity; Aqueous
   solubility
ID OLEANOLIC ACID; BETULINIC ACID; URSOLIC ACID; DERIVATIVES SYNTHESIS;
   CELL CYCLE; PRODRUGS; MITOCHONDRIA; INHIBITION; ACTIVATION; PHOSPHATE
AB Synthesis, solubility and cytotoxicity evaluation of anionic phosphonates derived from betulin, betulinic acid, oleanolic acid and ursolic acid is reported. Phosphonate moieties were successfully installed at terpenoid C28 by carboxylic acid deprotonation/alkylation sequence using (dimethoxyphosphoryl)methyl trifluoromethanesulfonate as alkylation reagent. Also, betulin derived and ether linked bis phosphonate is obtained and characterized. After demethylation in the presence of TMSI the resulting phosphonic acids were transformed into their disodium salts. All target compounds display excellent water solubility, which was determined by qNMR in D2O. Cytotoxicity tests were performed in different concentrations of each compound (10 50 mu M) against human osteosarcoma cell line MG 63 and osteoblast precursor cell line MC3T3 E1. Improved aqueous solubility and low cytotoxicity profile of the newly designed triterpenoid phosphonates reveal high potential for various medicinal chemistry and pharmacological applications in the future.
C1 [Luginina, Jevgenija; Kroskins, Vladislavs; Lacis, Rihards; Fedorovska, Elza; Turks, Maris] Riga Tech Univ, Inst Chem & Chem Technol, Fac Nat Sci & Technol, 3 P Valdena St, LV 1048 Riga, Latvia.
   [Demir, Oznur; Dubnika, Arita; Loca, Dagnija] Riga Tech Univ, Inst Biomat & Bioengn, Fac Nat Sci & Technol, 3 Pulka St, LV 1048 Riga, Latvia.
   [Demir, Oznur; Dubnika, Arita; Loca, Dagnija] Riga Tech Univ, Balt Biomat Ctr Excellence, Riga, Latvia.
C3 Riga Technical University; Riga Technical University; Riga Technical
   University
RP Turks, M (通讯作者)，Riga Tech Univ, Inst Chem & Chem Technol, Fac Nat Sci & Technol, 3 P Valdena St, LV 1048 Riga, Latvia.
EM maris.turks@rtu.lv
RI ; Oğuz, Öznur/ABH 1286 2020
OI Demir, Oznur/0000 0002 1783 7582; 
FU Ministry of Economics Republic of Latvia
   [VPP EM BIOMEDICINA 2022/1 0001]; European Union [857287]
FX The authors acknowledge financial support from the Ministry of Economics
   Republic of Latvia project "State research project in the field of
   biomedicine, medical technologies and pharmacy", project No.
   VPP EM BIOMEDICINA 2022/1 0001 (BioMedPharm). D.L., A.D. and OE.D.
   acknowledge the financial support, access to the infrastructure and
   expertise of the BBCE   Baltic Biomaterials Centre of Excellence
   (European Union's Horizon 2020 research and innovation programme under
   the grant agreement No. 857287).
CR ALY O A, 1982, Environment International, V7, P373, DOI 10.1016/0160 4120(82)90152 0
   Amiri S, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2019.06.008
   Bag BG, 2016, RSC ADV, V6, P17290, DOI 10.1039/c5ra25167b
   Basu A, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15061611
   Berger M, 2020, CHEM US, V6, P1183, DOI 10.1016/j.chempr.2020.04.007
   Boryczka S, 2013, MOLECULES, V18, P4526, DOI 10.3390/molecules18044526
   Bureeva S, 2007, BIOORGAN MED CHEM, V15, P3489, DOI 10.1016/j.bmc.2007.03.002
   Cerreia Vioglio P, 2017, ADV DRUG DELIVER REV, V117, P86, DOI 10.1016/j.addr.2017.07.001
   Chodurek E, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242216487
   Chrobak E, 2021, MOLECULES, V26, DOI 10.3390/molecules26030737
   Chrobak E, 2019, BIOORG CHEM, V87, P613, DOI 10.1016/j.bioorg.2019.03.060
   Chrobak E, 2016, MOLECULES, V21, DOI 10.3390/molecules21091123
   Cruz Cabeza AJ, 2012, CRYSTENGCOMM, V14, P6362, DOI 10.1039/c2ce26055g
   Dang Q, 2006, EXPERT OPIN THER PAT, V16, P343, DOI 10.1517/13543776.16.3.343
   Dehaen W, 2011, MOLECULES, V16, P2443, DOI 10.3390/molecules16032443
   Deng SL, 2007, PHOSPHORUS SULFUR, V182, P951, DOI 10.1080/10426500601088838
   Dzhemileva LU, 2023, CANCERS, V15, DOI 10.3390/cancers15030756
   Fan JP, 2021, J MOL LIQ, V332, DOI 10.1016/j.molliq.2021.115837
   Flekhter OB, 2004, RUSS J BIOORG CHEM+, V30, P80, DOI 10.1023/B:RUBI.0000015778.77887.f1
   Franz RD, 2001, AAPS PHARMSCI, V3
   Fu LF, 2013, ORG LETT, V15, P1622, DOI 10.1021/ol400399x
   Ghante MH, 2019, J PHARMACOPUNCT, V22, P55
   Hu KS, 2011, ATMOS CHEM PHYS, V11, P8307, DOI 10.5194/acp 11 8307 2011
   Huang LY, 2024, WIRES NANOMED NANOBI, V16, DOI 10.1002/wnan.1967
   Jäger S, 2007, PLANTA MED, V73, P157, DOI 10.1055/s 2007 967106
   Jäger S, 2009, MOLECULES, V14, P2016, DOI 10.3390/molecules14062016
   Jannus F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158158
   Jaroszewski B, 2024, BIOMEDICINES, V12, DOI 10.3390/biomedicines12061168
   Kazachenko AS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031602
   Krasutsky P., 2002, World Patent Appl., Patent No. [WO0226762A1, 0226762]
   Krasutsky P., 2002, World Patent Appl., Patent No. [WO0226761A1, 0226761]
   Krecmerova M, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.889737
   Lee EH, 2011, RUSS J BIOORG CHEM+, V37, P569, DOI 10.1134/S1068162011050050
   Levdanskii VA, 2014, CHEM NAT COMPD+, V50, P1029, DOI 10.1007/s10600 014 1152 0
   Lewinska A, 2017, APOPTOSIS, V22, P800, DOI 10.1007/s10495 017 1353 7
   Liu H, 2005, J ETHNOPHARMACOL, V100, P92, DOI 10.1016/j.jep.2005.05.024
   Lombrea A, 2023, PLANTS BASEL, V12, DOI 10.3390/plants12061253
   Lombrea A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073676
   Luginina J, 2021, EUR J ORG CHEM, V2021, P2557, DOI 10.1002/ejoc.202100293
   Mao XR, 2024, MOL BIOL REP, V51, DOI 10.1007/s11033 024 09596 1
   McClements DJ, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2018.08.004
   MEKSURIYEN D, 1986, PHYTOCHEMISTRY, V25, P1685, DOI 10.1016/S0031 9422(00)81236 4
   Melnikova NB, 2018, MOLECULES, V23, DOI 10.3390/molecules23051175
   Michaudel Q, 2014, ANGEW CHEM INT EDIT, V53, P12091, DOI 10.1002/anie.201407016
   Mierina I, 2020, CURR MED CHEM, V27, P1308, DOI 10.2174/0929867325666180530095657
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Oboh M, 2021, MOLECULES, V26, DOI 10.3390/molecules26237243
   Ochiai M., 2006, World Patent Appl., Patent No. [WO2006132033A1, 2006132033]
   Oliveira Costa JF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.883857
   Orchel A, 2021, MOLECULES, V26, DOI 10.3390/molecules26030615
   Pertusati Fabrizio, 2012, Antiviral Chemistry & Chemotherapy, V22, P181, DOI 10.3851/IMP2012
   Petrova AV, 2024, CHEM BIOL DRUG DES, V103, DOI 10.1111/cbdd.14506
   Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006 2952(96)00654 5
   Popov SA, 2021, SYNTHETIC COMMUN, V51, P2466, DOI 10.1080/00397911.2021.1939057
   Popov SA, 2020, STEROIDS, V162, DOI 10.1016/j.steroids.2020.108698
   Pradere U, 2014, CHEM REV, V114, P9154, DOI 10.1021/cr5002035
   Roy S, 2024, PHYTOMEDICINE, V129, DOI 10.1016/j.phymed.2024.155638
   Safarzadeh E, 2014, ADV PHARM BULL, V4, P421, DOI 10.5681/apb.2014.062
   Safayhi H, 1997, PLANTA MED, V63, P487, DOI 10.1055/s 2006 957748
   Salvador JAR, 2017, EUR J MED CHEM, V142, P95, DOI 10.1016/j.ejmech.2017.07.013
   Sathya S, 2014, LIFE SCI, V95, P53, DOI 10.1016/j.lfs.2013.11.019
   Serajuddin ATM, 2007, ADV DRUG DELIVER REV, V59, P603, DOI 10.1016/j.addr.2007.05.010
   Shai LJ, 2008, J ETHNOPHARMACOL, V119, P238, DOI 10.1016/j.jep.2008.06.036
   Shu C, 2019, SCI HORTIC AMSTERDAM, V256, DOI 10.1016/j.scienta.2019.108636
   Similie D, 2024, ANTIOXIDANTS BASEL, V13, DOI 10.3390/antiox13080952
   Sousa JLC, 2019, MOLECULES, V24, DOI 10.3390/molecules24020355
   Spivak AY, 2013, RUSS CHEM B+, V62, P188, DOI 10.1007/s11172 013 0028 y
   Spivak A, 2018, MOLECULES, V23, DOI 10.3390/molecules23113000
   Spivak AY, 2017, MED CHEM RES, V26, P518, DOI 10.1007/s00044 016 1771 z
   Tsepaeva OV, 2021, RUSS CHEM B+, V70, P179, DOI 10.1007/s11172 021 3074 x
   Tubek B, 2012, SYNTHETIC COMMUN, V42, P3648, DOI 10.1080/00397911.2011.588817
   Wang CM, 2016, MOLECULES, V21, DOI 10.3390/molecules21020139
   Wang X, 2013, CARCINOGENESIS, V34, P1323, DOI 10.1093/carcin/bgt058
   Wolfram RK, 2018, EUR J MED CHEM, V155, P869, DOI 10.1016/j.ejmech.2018.06.051
   Wolfram RK, 2018, EUR J MED CHEM, V152, P21, DOI 10.1016/j.ejmech.2018.04.031
   Wu PP, 2021, BIOORG CHEM, V109, DOI 10.1016/j.bioorg.2021.104692
   Xiao SL, 2014, CHEMMEDCHEM, V9, P1060, DOI 10.1002/cmdc.201300545
   Xu Y, 2006, J AM CHEM SOC, V128, P885, DOI 10.1021/ja0554716
   Yli Kauhaluoma J., 2007, World Patent Appl., Patent No. [WO2007141391A1, 2007141391]
   Yu ZJ, 2016, MOL PHARMACEUT, V13, P1699, DOI 10.1021/acs.molpharmaceut.6b00129
   Zhou M, 2017, EUR J MED CHEM, V131, P222, DOI 10.1016/j.ejmech.2017.03.005
NR 81
TC 3
Z9 3
U1 2
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 14
PY 2024
VL 14
IS 1
AR 28031
DI 10.1038/s41598 024 76816 w
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA M2K5J
UT WOS:001355879400006
PM 39543237
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Carlisle, P
   Marrs, J
   Gaviria, L
   Silliman, DT
   Decker, JF
   Baer, PB
   Guda, T
AF Carlisle, Patricia
   Marrs, Jeffrey
   Gaviria, Laura
   Silliman, David T.
   Decker, John F.
   Baer, Pamela Brown
   Guda, Teja
TI Quantifying Vascular Changes Surrounding Bone Regeneration in a Porcine
   Mandibular Defect Using Computed Tomography
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE CT; bone regeneration; vascular morphology; mandible; pig
ID ENDOTHELIAL GROWTH FACTOR; MESENCHYMAL STEM CELLS; TISSUE ENGINEERED
   BONE; MORPHOGENETIC PROTEIN 2; IN VIVO; CRANIOMAXILLOFACIAL INJURIES;
   OSTEOBLAST DIFFERENTIATION; ANGIOGENIC FACTORS; PROGENITOR CELLS; VEGF
AB Angiogenesis is a critical process essential for optimal bone healing. Several in vitro and in vivo systems have been previously used to elucidate some of the mechanisms involved in the process of angiogenesis, and at the same time, to test potential therapeutic agents and bioactive factors that play important roles in neovascularization. Computed tomography (CT) is a noninvasive imaging technique that has recently allowed investigators to obtain a diverse range of high resolution, three dimensional characterization of structures, such as bone formation within bony defects. Unfortunately, to date, angiogenesis evaluation relies primarily on histology, or ex vivo imaging and few studies have utilized CT to qualitatively and quantitatively study the vascular response during bone repair. In the current study a clinical CT based technique was used to evaluate the effects of rhBMP 2 eluting graft treatment on soft tissue vascular architecture surrounding a large segmental bone defect model in the minipig mandible. The objective of this study was to demonstrate the efficacy of contrast enhanced, clinical 64 slice CT technology in extracting quantitative metrics of vascular architecture over a 12 week period. The results of this study show that the presence of rhBMP 2 had a positive effect on vessel volume from 4 to 12 weeks, which was explained by a concurrent increase in vessel number, which was also significantly higher at 4 weeks for the rhBMP 2 treatment. More importantly, analysis of vessel architecture showed no changes throughout the duration of the study, indicating therapeutic safety. This study validates CT analysis as a relevant imaging method for quantitative and qualitative analysis of morphological characteristics of vascular tissue around a bone healing site. Also important, the study shows that CT technology can be used in large animal models and potentially be translated into clinical models for the development of improved methods to evaluate tissue healing and vascular adaptation processes over the course of therapy. This methodology has demonstrated sensitivity to tracking spatial and temporal changes in vascularization and has the potential to be applied to studying changes in other high contrast tissues as well.
C1 [Carlisle, Patricia; Marrs, Jeffrey; Silliman, David T.; Decker, John F.; Baer, Pamela Brown] US Army Inst Surg Res, Dent Trauma & Res Detachment, San Antonio, TX USA.
   [Carlisle, Patricia] Prytime Med Devices Inc, Boerne, TX USA.
   [Marrs, Jeffrey] Univ Texas Hlth Sci Ctr San Antonio, Sch Dent, San Antonio, TX 78229 USA.
   [Gaviria, Laura; Guda, Teja] Univ Texas San Antonio, Dept Biomed Engn, One UTSA Circle,AET 1 356, San Antonio, TX 78249 USA.
   [Baer, Pamela Brown] GenCure, Clin Operat & New Prod Commercializat, San Antonio, TX USA.
   US Army Inst Surg Res, Ft Sam Houston, TX USA.
   Univ Texas San Antonio, San Antonio, TX USA.
C3 United States Department of Defense; United States Army; University of
   Texas System; University of Texas Health Science Center at San Antonio;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas at San Antonio (UTSA); United States
   Department of Defense; United States Army; University of Texas System;
   University of Texas at San Antonio (UTSA)
RP Guda, T (通讯作者)，Univ Texas San Antonio, Dept Biomed Engn, One UTSA Circle,AET 1 356, San Antonio, TX 78249 USA.
EM teja.guda@utsa.edu
RI Guda, Teja/A 7286 2009
FU United States Army Medical Research and Materiel Command; United States
   Department of Defense; National Science Foundation [1847103];
   Directorate For Engineering; Div Of Chem, Bioeng, Env, & Transp Sys
   [1847103] Funding Source: National Science Foundation
FX This study was primarily supported by funding from the United States
   Army Medical Research and Materiel Command and the Department of
   Defense. TG was also supported by National Science Foundation award
   #1847103.
CR An G, 2017, EUR REV MED PHARMACO, V21, P2316
   Arkudas A, 2010, TISSUE ENG PART C ME, V16, P1503, DOI 10.1089/ten.tec.2010.0016
   Baer PRB, 2012, CRANIOMAX TRAUM REC, V5, P243, DOI 10.1055/s 0032 1329542
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown KV, 2011, TISSUE ENG PT A, V17, P1735, DOI [10.1089/ten.TEA.2010.0446, 10.1089/ten.tea.2010.0446]
   Buyukdereli G, 2006, ANN NUCL MED, V20, P89, DOI 10.1007/BF02985619
   Cao LY, 2014, BIOMATERIALS, V35, P684, DOI 10.1016/j.biomaterials.2013.10.005
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Carlisle P, 2019, J BIOMED MATER RES B, V107, P1491, DOI 10.1002/jbm.b.34241
   Chan RK, 2012, J TRAUMA ACUTE CARE, V73, pS453, DOI 10.1097/TA.0b013e3182754868
   Chenard KE, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601549
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev cellbio 092910 154002
   Clarkin CE, 2013, CELL BIOCHEM FUNCT, V31, P1, DOI 10.1002/cbf.2911
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Dellian M, 1996, AM J PATHOL, V149, P59
   Dumas JE, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/2/024112
   Duvall CL, 2004, AM J PHYSIOL HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003
   Fang TD, 2005, J BONE MINER RES, V20, P1114, DOI 10.1359/JBMR.050301
   Fedorovich NE, 2010, TISSUE ENG PT A, V16, P2355, DOI [10.1089/ten.tea.2009.0603, 10.1089/ten.TEA.2009.0603]
   Giannoudis P, 2007, INJURY, V38, pS81, DOI 10.1016/j.injury.2007.02.013
   Giannoudis PV, 2008, INJURY, V39, pS5, DOI 10.1016/S0020 1383(08)70010 X
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Guda T, 2014, TISSUE ENG PART C ME, V20, P749, DOI [10.1089/ten.tec.2013.0581, 10.1089/ten.TEC.2013.0581]
   Guldberg RE, 2003, IEEE ENG MED BIOL, V22, P77, DOI 10.1109/MEMB.2003.1256276
   Guldberg Robert E, 2004, Birth Defects Res C Embryo Today, V72, P250, DOI 10.1002/bdrc.20016
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1817, DOI 10.1007/s10529 009 0099 x
   Hale Robert G, 2010, Singapore Dent J, V31, P1, DOI 10.1016/S0377 5291(12)70002 0
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   He XN, 2013, TISSUE ENG PT A, V19, P508, DOI [10.1089/ten.tea.2012.0244, 10.1089/ten.TEA.2012.0244]
   Henkel J, 2013, BONE RES, V1, P216, DOI 10.4248/BR201303002
   Horner EA, 2010, TISSUE ENG PART B RE, V16, P263, DOI [10.1089/ten.teb.2009.0224, 10.1089/ten.TEB.2009.0224]
   Howie RN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132520
   Hu K, 2017, DEV DYNAM, V246, P227, DOI 10.1002/dvdy.24463
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang YC, 2005, J BONE MINER RES, V20, P848, DOI 10.1359/JBMR.041226
   Hussein KA, 2012, TISSUE ENG PT A, V18, P665, DOI [10.1089/ten.tea.2011.0148, 10.1089/ten.TEA.2011.0148]
   Irvin MW, 2014, EXP BIOL MED, V239, P1476, DOI 10.1177/1535370214529386
   Jia F, 2010, ANAT REC, V293, P215, DOI 10.1002/ar.21054
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   Kigami R, 2013, IMPLANT DENT, V22, P422, DOI 10.1097/ID.0b013e31829d19f0
   Kleinheinz J, 2005, J ORAL MAXIL SURG, V63, P1310, DOI 10.1016/j.joms.2005.05.303
   Kline TL, 2010, ANN BIOMED ENG, V38, P2851, DOI 10.1007/s10439 010 0058 7
   Kneser U, 2006, TISSUE ENG, V12, P1721, DOI 10.1089/ten.2006.12.1721
   Leong Poi H, 2009, CARDIOVASC RES, V84, P190, DOI 10.1093/cvr/cvp248
   Lethaus B, 2013, CLIN ORAL IMPLAN RES, V24, P746, DOI 10.1111/j.1600 0501.2012.02480.x
   Lew TA, 2010, J ORAL MAXIL SURG, V68, P3, DOI 10.1016/j.joms.2009.06.006
   Li B, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2869572
   Liu YM, 2014, TISSUE ENG PT A, V20, P3189, DOI [10.1089/ten.tea.2013.0653, 10.1089/ten.TEA.2013.0653]
   Madson AQ, 2013, J CRANIO MAXILL SURG, V41, P816, DOI 10.1016/j.jcms.2013.01.035
   Mahmoud AM, 2013, ULTRASONICS, V53, P727, DOI 10.1016/j.ultras.2012.10.017
   Nebuloni L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086562
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pacicca DM, 2003, BONE, V33, P889, DOI 10.1016/j.bone.2003.06.002
   Rai B, 2007, J BIOMED MATER RES A, V81A, P888, DOI 10.1002/jbm.a.31142
   Raida M, 2006, INT J MOL MED, V18, P735
   Rouwkema J, 2006, TISSUE ENG, V12, P2685, DOI 10.1089/ten.2006.12.2685
   Roux BM, 2015, J CELL MOL MED, V19, P903, DOI 10.1111/jcmm.12569
   Saka B, 2002, J CRANIO MAXILL SURG, V30, P41, DOI 10.1054/jcms.2001.0257
   Samee M, 2008, J PHARMACOL SCI, V108, P18, DOI 10.1254/jphs.08036FP
   Santoni BG, 2012, CLIN ORTHOP RELAT R, V470, P2478, DOI 10.1007/s11999 012 2349 9
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Schroeder JE, 2011, INJURY, V42, P609, DOI 10.1016/j.injury.2011.03.029
   Seo Y, 2008, PHYS MED BIOL, V53, pN99, DOI 10.1088/0031 9155/53/7/N01
   Simons M, 2015, CIRC RES, V116, pE99, DOI 10.1161/RES.0000000000000054
   Sivakumar B, 2004, JAMA J AM MED ASSOC, V292, P972, DOI 10.1001/jama.292.8.972
   Tatara AM, 2014, J DENT RES, V93, P1196, DOI 10.1177/0022034514547763
   Upputuri PK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/783983
   van den Wijngaard JPHM, 2013, J BIOMECH, V46, P229, DOI 10.1016/j.jbiomech.2012.11.027
   Wang H, 2012, EUR J RADIOL, V81, P104, DOI 10.1016/j.ejrad.2010.03.022
   Weigand A, 2015, TISSUE ENG PT A, V21, P1680, DOI [10.1089/ten.tea.2014.0568, 10.1089/ten.TEA.2014.0568]
   Wikesjö UME, 2004, CLIN ORAL IMPLAN RES, V15, P194, DOI 10.1111/j.1600 0501.2004.00971.x
   Wolf DE, 2012, PROC SPIE, V8222, DOI 10.1117/12.909032
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Xiao CW, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/1/015013
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yin J, 2018, BIOMED PHARMACOTHER, V105, P932, DOI 10.1016/j.biopha.2018.06.078
   Young S, 2008, TISSUE ENG PART B RE, V14, P295, DOI 10.1089/ten.teb.2008.0153
   Yudell RM, 2000, J ORAL MAXIL SURG, V58, P761, DOI 10.1053/joms.2000.7261
   Zagorchev Lyubomir, 2010, J Angiogenes Res, V2, P7, DOI 10.1186/2040 2384 2 7
   Zhang WJ, 2014, EUR CELLS MATER, V27, P1
   Zhao FJ, 2016, MED BIOL ENG COMPUT, V54, P511, DOI 10.1007/s11517 015 1337 0
   Zhao FJ, 2014, PHYS MED BIOL, V59, P7777, DOI 10.1088/0031 9155/59/24/7777
NR 83
TC 3
Z9 4
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD DEC
PY 2019
VL 25
IS 12
BP 721
EP 731
DI 10.1089/ten.tec.2019.0205
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA KM1RJ
UT WOS:000513897500003
PM 31850839
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, Z
   Zhang, MY
   Luo, B
   Jing, HY
   Yu, Y
   Wang, SQ
   Luo, SW
AF Yu, Zheng
   Zhang, Meiying
   Luo, Bin
   Jing, Hongyang
   Yu, Yue
   Wang, Shunqi
   Luo, Shiwen
TI Lrp4 in hippocampal astrocytes serves as a negative feedback factor in
   seizures
SO CELL AND BIOSCIENCE
LA English
DT Article
DE Low density lipoprotein receptor related protein 4; Epilepsy; microRNA;
   Astrocytic NMDA receptor; The threshold of seizure
ID PILOCARPINE MODEL; PROTEIN 4; EPILEPSY; RECEPTOR; EXPRESSION; BRAIN;
   OSTEOBLASTS; SCLEROSTIN; PATHWAYS; CLUSTERS
AB Background Epilepsy is characterized by the typical symptom of seizure, and anti seizure medications are the main therapeutic method in clinical, but the effects of these therapy have not been satisfactory. To find a better treatment, it makes sense to further explore the regulatory mechanisms of seizures at genetic level. Lrp4 regionally expresses in mice hippocampus where is key to limbic epileptogenesis. It is well known that neurons release a high level of glutamate during seizures, and it has been reported that Lrp4 in astrocytes down regulates glutamate released from neurons. However, it is still unclear whether there is a relationship between Lrp4 expression level and seizures, and whether Lrp4 plays a role in seizures. Results We found that seizures induced by pilocarpine decreased Lrp4 expression level and increased miR 351 5p expression level in mice hippocampus. Glutamate reduced Lrp4 expression and enhanced miR 351 5p expression in cultured hippocampal astrocytes, and these effects can be partially attenuated by AP5. Furthermore, miR 351 5p inhibitor lessened the reduction of Lrp4 expression in glutamate treated hippocampal astrocytes. Local reduction of Lrp4 in hippocampus by sh Lrp4 lentivirus injection in hippocampus increased the threshold of seizures in pilocarpine or pentylenetetrazol (PTZ) injected mice. Conclusions These results indicated that high released glutamate induced by seizures down regulated astrocytic Lrp4 through increasing miR 351 5p in hippocampal astrocytes via activating astrocytic NMDA receptor, and locally reduction of Lrp4 in hippocampus increased the threshold of seizures. Lrp4 in hippocampal astrocytes appears to serve as a negative feedback factor in seizures. This provides a new potential therapeutic target for seizures regulation.
C1 [Yu, Zheng; Luo, Shiwen] Nanchang Univ, Affiliated Hosp 1, Ctr Expt Med, Nanchang 330006, Jiangxi, Peoples R China.
   [Yu, Zheng; Luo, Bin; Jing, Hongyang; Wang, Shunqi] Nanchang Univ, Inst Life Sci, Nanchang 330006, Jiangxi, Peoples R China.
   [Yu, Zheng; Luo, Bin; Jing, Hongyang; Wang, Shunqi] Nanchang Univ, Sch Life Sci, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhang, Meiying] Nanchang Univ, Nanchang Univ Hosp, Nanchang 330006, Jiangxi, Peoples R China.
   [Yu, Yue] Teensen Genesis Sch, Nanchang 330006, Jiangxi, Peoples R China.
   [Luo, Shiwen] Jiangxi Key Lab Mol Diagnost & Precis Med, 17 Yongwai St, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Luo, SW (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Ctr Expt Med, Nanchang 330006, Jiangxi, Peoples R China.
EM shiwenluo@ncu.edu.cn
RI ; Zhang, Meiying/GQP 8902 2022; Wang, Shunqi/JAC 6266 2023; jing,
   hongyang/JDW 6791 2023
OI Jing, Hongyang/0000 0003 2811 1266; 
FU National Natural Science Foundation of China [31460260]
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (31671476 to Shiwen Luo), and National
   Natural Science Foundation of China (31460260 to Shunqi Wang).
CR Ahn Y, 2013, DEVELOPMENT, V140, P583, DOI 10.1242/dev.085118
   Alachkar A, 2019, MOLECULES, V24, DOI 10.3390/molecules24224106
   Baj G, 2013, HIPPOCAMPUS, V23, P413, DOI 10.1002/hipo.22100
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Basu S, 2015, MOL BIOL CELL, V26, P938, DOI 10.1091/mbc.E14 06 1158
   Biagini G, 2001, J NEUROCHEM, V76, P1814, DOI 10.1046/j.1471 4159.2001.00163.x
   Binder DK, 2001, TRENDS NEUROSCI, V24, P47, DOI 10.1016/S0166 2236(00)01682 9
   Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002
   Brenner HR, 2014, DEV BIOL, V394, P122, DOI 10.1016/j.ydbio.2014.07.018
   CAVALHEIRO EA, 1995, ITAL J NEUROL SCI, V16, P33, DOI 10.1007/BF02229072
   Cho KO, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7606
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Costa MS, 2004, NEUROSCI LETT, V356, P41, DOI 10.1016/j.neulet.2003.11.019
   Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019
   Devinsky O, 2016, NEUROLOGY, V86, P779, DOI 10.1212/WNL.0000000000002253
   Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140 6736(06)68477 8
   Eilam R, 1998, P NATL ACAD SCI USA, V95, P1888, DOI 10.1073/pnas.95.4.1888
   ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896 6273(91)90084 D
   Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550
   Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013 9580.2005.66104.x
   Fukata Y, 2017, CURR OPIN NEUROBIOL, V45, P1, DOI 10.1016/j.conb.2017.02.001
   Gorter JA, 2014, NEUROBIOL DIS, V62, P508, DOI 10.1016/j.nbd.2013.10.026
   Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092 8674(93)90529 Y
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li L, 2018, ANNU REV PHYSIOL, V80, P159, DOI 10.1146/annurev physiol 022516 034255
   Liu GM, 2013, NEURON, V79, P31, DOI 10.1016/j.neuron.2013.04.027
   Liu XH, 2011, J NEUROSCI, V31, P8491, DOI 10.1523/JNEUROSCI.5317 10.2011
   Mohseni P, 2011, J NEUROSCI, V31, P11547, DOI 10.1523/JNEUROSCI.4396 10.2011
   Oyrer J, 2018, PHARMACOL REV, V70, P142, DOI 10.1124/pr.117.014456
   Patel DC, 2019, NAT REV NEUROSCI, V20, P282, DOI 10.1038/s41583 019 0126 4
   Pohlkamp T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116701
   Pun RYK, 2012, NEURON, V75, P1022, DOI 10.1016/j.neuron.2012.08.002
   Saxena Shekhar, 2017, Epilepsia Open, V2, P153, DOI 10.1002/epi4.12010
   Shen CY, 2013, J CLIN INVEST, V123, P5190, DOI 10.1172/JCI66039
   Smolders I, 1997, BRIT J PHARMACOL, V121, P1171, DOI 10.1038/sj.bjp.0701231
   Sun XD, 2016, NAT NEUROSCI, V19, P1010, DOI 10.1038/nn.4326
   Tan GH, 2012, NAT NEUROSCI, V15, P258, DOI 10.1038/nn.3005
   Tanahashi H, 2016, SCI REP UK, V6, DOI 10.1038/srep20241
   Tian N, 2018, MMWR MORBID MORTAL W, V67, P437, DOI 10.15585/mmwr.mm6715a1
   Vezzani Annamaria, 2007, Epilepsy Curr, V7, P45, DOI 10.1111/j.1535 7511.2007.00165.x
   Woo RS, 2007, NEURON, V54, P599, DOI 10.1016/j.neuron.2007.04.009
   Wu H, 2004, J NEUROSCI RES, V76, P76, DOI 10.1002/jnr.20060
   Wu HT, 2010, DEVELOPMENT, V137, P1017, DOI 10.1242/dev.038711
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
   Zhang B, 2008, NEURON, V60, P285, DOI 10.1016/j.neuron.2008.10.006
   Zhang B, 2012, ARCH NEUROL CHICAGO, V69, P445, DOI 10.1001/archneurol.2011.2393
   Zhang HS, 2019, ELIFE, V8, DOI 10.7554/eLife.45303
NR 48
TC 7
Z9 7
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045 3701
J9 CELL BIOSCI
JI Cell Biosci.
PD NOV 23
PY 2020
VL 10
IS 1
AR 135
DI 10.1186/s13578 020 00498 w
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA PA5NS
UT WOS:000595682800002
PM 33292473
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Farid, R
   Mirfeizi, Z
   Mirheidari, M
   Rezaieyazdi, Z
   Mansouri, H
   Esmaelli, H
   Zibadi, S
   Rohdewald, P
   Watson, RR
AF Farid, Reza
   Mirfeizi, Zahra
   Mirheidari, Mahyar
   Rezaieyazdi, Zahra
   Mansouri, Hassan
   Esmaelli, Habib
   Zibadi, Sherma
   Rohdewald, Peter
   Watson, Ronald Ross
TI Pycnogenol supplementation reduces pain and stiffness and improves
   physical function in adults with knee osteoarthritis
SO NUTRITION RESEARCH
LA English
DT Article
DE osteoarthritis; knee; pycnogenol; flavonoid; antioxidant
ID NITRIC OXIDE; MATRIX METALLOPROTEINASES; ANTIOXIDANT ACTIVITY; BARK;
   ARTHRITIS; EXTRACT
AB Knee osteoarthritis (OA) is a common degenerative joint disorder and a major cause of pain and disability. The purpose of this study was to investigate the potential effect of Pycnogenol (Horphag Research, Ltd, Geneva, Switzerland), a flavonoid rich dietary supplement, on the symptoms of knee OA. Thirty seven osteoarthritic patients were enrolled in a randomized, double blind, placebo controlled trial with parallel group design. Patients received either placebo or Pycnogenol pills (50 mg, three times daily) in a blinded fashion for 3 months. Osteoarthritis clinical symptoms were evaluated monthly with Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Nonsteroidal anti inflammatory drugs (NSAIDs) or selective cyclooxygenase 2 (COX 2) inhibitors usage was also assessed. In the Pycnogenol group, there was a significant improvement in total WOMAC score and WOMAC subscale score of pain and physical function at 60 and 90 days of treatment. At 90 days, significant reduction of 43%, 35%, 52%, and 49% in self reported pain, stiffness, physical function, and composite WOMAC score, respectively, were reported in Pycnogenol group, whereas the placebo group showed no significant changes. The dosage and frequency of NSAIDs or COX 2 inhibitors usage were increased in placebo group, which were significantly less in Pycnogenol group. The results of this study indicate the efficacy of Pycnogenol in alleviating osteoarthritis symptoms and reducing the need for NSAIDs or COX 2 inhibitors administration. This beneficial effect of Pycnogenol might be due to its antioxidant and anti inflammatory properties. Further research is warranted to determine the underlying mechanism associated with this apparent effect. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Arizona, Mel & Enid Zuckerman Arizona Coll Publ Hlth, Tucson, AZ 85724 USA.
   Univ Arizona, Sch Med, Tucson, AZ 85724 USA.
   Mashhad Univ Sch Med, Ghaem Gen Hosp, Dept Rheumatol, Mashhad 9176699199, Iran.
   Univ Munster, Coll Pharm, Munster, Germany.
C3 University of Arizona; University of Arizona; Mashhad University of
   Medical Sciences; University of Munster
RP Watson, RR (通讯作者)，Univ Arizona, Mel & Enid Zuckerman Arizona Coll Publ Hlth, POB 245155, Tucson, AZ 85724 USA.
EM rwatson@email.arizona.edu
RI ebrahimi, mansour/D 9950 2011; Esmaily, Habibollah/N 8264 2016
OI Esmaily, Habibollah/0000 0003 4139 546X
CR Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926 001 0069 3
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   [Anonymous], 2005, Encyclopedia of Dietary Supplements
   Bayeta E, 2000, NUTR RES, V20, P249, DOI 10.1016/S0271 5317(99)00157 8
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   di Cesare P.E., 2005, KELLYS TXB RHEUMATOL, P1493
   Felson DT, 2004, RADIOL CLIN N AM, V42, P1, DOI 10.1016/S0033 8389(03)00161 1
   Grimm T, 2004, FREE RADICAL BIO MED, V36, P811, DOI 10.1016/j.freeradbiomed.2003.12.017
   Hayashi T, 1997, ARTHRITIS RHEUM, V40, P261, DOI 10.1002/art.1780400210
   Hirai Y, 2001, LIFE SCI, V68, P913, DOI 10.1016/S0024 3205(00)00998 X
   McAlindon TE, 1996, ARTHRITIS RHEUM US, V39, P648, DOI 10.1002/art.1780390417
   Packer L, 1999, FREE RADICAL BIO MED, V27, P704, DOI 10.1016/S0891 5849(99)00090 8
   Pelletier JP, 1996, OSTEOARTHR CARTILAGE, V4, P77, DOI 10.1016/S1063 4584(96)80009 4
   Rohdewald P, 2002, INT J CLIN PHARM TH, V40, P158
   Saliou C, 2001, FREE RADICAL BIO MED, V30, P154, DOI 10.1016/S0891 5849(00)00445 7
   Spiegel BMR, 2005, ARTHRIT RHEUM ARTHR, V53, P185, DOI 10.1002/art.21065
   SPRINTHALL RC, 2003, BASIC STAT ANAL, P550
   *SPSS I INC, 2002, SPSS WIND VERS 11 5
   Stefanescu M, 2001, PHYTOTHER RES, V15, P698, DOI 10.1002/ptr.915
   VIRGILI F, 1998, ANTIOX HEALTH DIS, V7, P421
   Wang XF, 2004, AM J PATHOL, V165, P1375, DOI 10.1016/S0002 9440(10)63395 0
   Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407
   Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455
NR 23
TC 45
Z9 46
U1 0
U2 12
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271 5317
J9 NUTR RES
JI Nutr. Res.
PD NOV
PY 2007
VL 27
IS 11
BP 692
EP 697
DI 10.1016/j.nutres.2007.09.007
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 236BC
UT WOS:000251277000005
DA 2025 08 17
ER

PT J
AU Hirata Tsuchiya, S
   Suzuki, S
   Okamoto, K
   Saito, N
   Yuan, H
   Yamada, S
   Jimi, E
   Shiba, H
   Kitamura, C
AF Hirata Tsuchiya, Shizu
   Suzuki, Shigeki
   Okamoto, Kazuki
   Saito, Noriko
   Yuan, Hang
   Yamada, Satoru
   Jimi, Eijiro
   Shiba, Hideki
   Kitamura, Chiaki
TI A small nuclear acidic protein (MTI II, Zn<SUP>2+</SUP> binding protein,
   parathymosin) attenuates TNF α inhibition of BMP induced osteogenesis by
   enhancing accessibility of the Smad4 NF κB p65 complex to Smad binding
   element
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE MTI II; Osteogenesis; Inflammation; Smad4; p65
ID NF KAPPA B; BONE MORPHOGENETIC PROTEIN 2; INFLAMMATION; DIFFERENTIATION;
   OSTEOBLAST; GENE; SUBUNIT
AB Pro inflammatory cytokines prevent bone regeneration in vivo and activation of nuclear factor kappa B (NF kappa B) signaling has been proposed to lead to suppression of bone morphogenetic protein (BMP) induced osteogenesis via direct binding of p65 to Smad4 in vitro. Application of a small nuclear acidic protein (MTI II) and its delivered peptide, MPAID (MTI II peptide anti inflammatory drug) has been described to elicit therapeutic potential via strong anti inflammatory action following the physical association of MTI II and MPAID with p65. However, it is unclear whether MTI II attenuates tumor necrosis factor (TNF) alpha inhibition of BMP induced osteogenesis. Herein, we found that TNF alpha mediated suppression of responses associated with BMP4 induced osteogenesis, including expression of the osteocalcin encoding gene Ocn, Smad binding element (SBE) dependent luciferase activity, alkaline phosphatase activity, and alizarin red S staining were largely restored by MTI II and MPAID in MC3T3 E1 cells. Mechanistically, MTI II and MPAID did not inhibit nuclear translocation of p65 or disassociate Smad4 from p65. Further, results from chromatin immunoprecipitation (ChIP) analyses revealed that Smad4 enrichment in cells over expressing MTI II and treated with TNF alpha was equivalent to that in cells without TNF alpha treatment. Alternatively, Smad4 enrichment was considerably decreased following TNF alpha treatment in control cells. Moreover, p65 enrichment in the Id 1 promoter SBE was detected only when cells over expressing MTI II were stimulated with TNF alpha. Overall, our study concludes that MTI II restored TNF alpha inhibited suppression of BMP Smad induced osteogenic differentiation by enhancing accessibility of the Smad4 p65 complex to the SBE rather than by liberating Smad4 from p65.
C1 [Hirata Tsuchiya, Shizu; Suzuki, Shigeki; Saito, Noriko; Shiba, Hideki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Biol Endodont, Hiroshima 7348553, Japan.
   [Hirata Tsuchiya, Shizu; Kitamura, Chiaki] Kyushu Dent Univ, Dept Oral Funct, Div Endodont & Restorat Dent, Fukuoka 8038580, Japan.
   [Suzuki, Shigeki; Yuan, Hang; Yamada, Satoru] Tohoku Univ, Dept Periodontol & Endodontol, Grad Sch Dent, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
   [Okamoto, Kazuki] Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan.
   [Jimi, Eijiro] Kyushu Univ, Fac Dent Sci, Oral Hlth Brain Hlth Total Hlth Res Ctr, Fukuoka 8128582, Japan.
C3 Hiroshima University; Kyushu Dental University; Tohoku University;
   University of Osaka; Kyushu University
RP Suzuki, S (通讯作者)，Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Biol Endodont, Hiroshima 7348553, Japan.; Suzuki, S (通讯作者)，Tohoku Univ, Dept Periodontol & Endodontol, Grad Sch Dent, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM shigeki.suzuki.b1@tohoku.ac.jp
RI Yuan, Hang/JDD 4563 2023; Shiba, Hideki/G 6446 2019
OI Suzuki, Shigeki/0000 0003 0888 4050
FU Grants in Aid for Scientific Research [16K11551, 17K11706, 20K09956,
   20H03866, 20H03855] Funding Source: KAKEN; Grants in Aid for Scientific
   Research [17K11706, 16K11551] Funding Source: Medline
CR Baum R, 2014, CURR OSTEOPOROS REP, V12, P9, DOI 10.1007/s11914 013 0183 y
   Bernardini C, 2010, GENE EXPRESSION, V15, P27, DOI 10.3727/105221610X12819686555097
   Bitzer M, 2000, GENE DEV, V14, P187
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956
   Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200
   Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Headland SE, 2015, SEMIN IMMUNOL, V27, P149, DOI 10.1016/j.smim.2015.03.014
   Hirata Tsuchiya S, 2016, J ORAL BIOSCI, V58, P73, DOI 10.1016/j.job.2016.02.003
   Hirata Tsuchiya S, 2014, MOL ENDOCRINOL, V28, P1460, DOI 10.1210/me.2014 1094
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365 2443.2002.00573.x
   Kozawa O, 2002, J CELL BIOCHEM, V84, P583, DOI 10.1002/jcb.10056.abs
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   Nakayama K, 2016, J CELL BIOCHEM, V117, P2552, DOI 10.1002/jcb.25548
   Ohte S, 2011, BIOCHEM BIOPH RES CO, V407, P213, DOI 10.1016/j.bbrc.2011.03.001
   Okamoto K, 2005, J BIOL CHEM, V280, P36986, DOI 10.1074/jbc.M506056200
   Okamoto K, 2016, ENDOCRINOLOGY, V157, P4973, DOI 10.1210/en.2016 1746
   Pola E, 2004, GENE THER, V11, P683, DOI 10.1038/sj.gt.3302207
   RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752
   ROSEN V, 1994, J BONE MINER RES, V9, P1759
   Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364
   Tarapore RS, 2016, J BONE MINER RES, V31, P52, DOI 10.1002/jbmr.2592
   Urata M, 2018, J CELL PHYSIOL, V233, P7356, DOI 10.1002/jcp.26571
   Vareli K, 2000, EXP CELL RES, V257, P152, DOI 10.1006/excr.2000.4857
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yan JY, 2018, J BIOL CHEM, V293, P9162, DOI 10.1074/jbc.RA118.001825
   Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597
NR 34
TC 11
Z9 11
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JUN
PY 2020
VL 469
IS 1 2
BP 133
EP 142
DI 10.1007/s11010 020 03734 6
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LQ3CP
UT WOS:000534884800013
PM 32304006
DA 2025 08 17
ER

PT J
AU Na, C
   Ao, D
   Chen, HT
AF Na, Cikedaoerji
   Ao, Denggaowa
   Chen, Hongtao
TI MiR 331 3p facilitates osteoporosis and may promote osteoporotic
   fractures by modulating NRP2 expression
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Osteoporosis; Fracture; miR 331 3p; NPR2
ID THERAPY
AB BackgroundOsteoporosis (OP) is a high incidence bone disease that is prone to osteoporotic fractures (OF), so it has attracted widespread attention.AimThis study investigated the specific expression and role of miR 331 in patients with OP and OF. The findings have profound implications for the clinical prevention and treatment of these conditions.MethodsThe study included 60 OP patients, 46 OF patients, and 40 healthy controls. The expression level of miR 331 3p was detected using RT qPCR. BMP2 was used to stimulate differentiation in MC3T3 E1 cells. After induction, the expression activity of osteogenic differentiation related gene markers was detected using RT qPCR. The target gene analysis was conducted using a luciferase reporter assay.ResultsThe levels of miR 331 3p were significantly elevated, while NRP2 levels were significantly reduced in OF patients. Post surgery, miR 331 3p levels decreased over time. MiR 331 3p was found to negatively regulate the luciferase activity of NPR2 in MC3T3 E1 cells. Furthermore, overexpression of miR 331 3p inhibited cell proliferation and decreased the levels of osteoblast differentiation markers.ConclusionThe up regulation of miR 331 3p can promote OP and might also encourage the occurrence of OF by regulating NRP2. However, this needs further verification.
C1 [Na, Cikedaoerji; Chen, Hongtao] Xinjiang Med Univ, Affiliated Hosp 6, Sports Med Dept, 39 Wuxing South Rd, Urumqi 830000, Peoples R China.
   [Ao, Denggaowa] Xinjiang Med Univ, Affiliated Hosp 1, Oncol Dept, Urumqi 830000, Peoples R China.
C3 Xinjiang Medical University; Xinjiang Medical University
RP Chen, HT (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 6, Sports Med Dept, 39 Wuxing South Rd, Urumqi 830000, Peoples R China.
EM hongtaochen5632@163.com
FU Xinjiang Uygur Autonomous Region "Tianshan Talents" Training Program for
   High level Talents in Medicine and Health [TSYC202301B077]
FX The study is supported by the Xinjiang Uygur Autonomous Region "Tianshan
   Talents" Training Program for High level Talents in Medicine and Health
   (No:TSYC202301B077)
CR Buranjiang G, 2019, ARCH MED SCI, V15, P1520, DOI 10.5114/aoms.2018.77858
   Conti V, 2015, INT J MOL SCI, V16, P5452, DOI 10.3390/ijms16035452
   Du FY, 2015, EXP THER MED, V10, P207, DOI 10.3892/etm.2015.2477
   Fujii T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081351
   Gargano G, 2023, BRIT MED BULL, V148, P58, DOI 10.1093/bmb/ldad023
   Gargano G, 2022, BRIT MED BULL, V142, P34, DOI 10.1093/bmb/ldac012
   Gargano G, 2021, BRIT MED BULL, V138, P58, DOI 10.1093/bmb/ldaa040
   Gautvik KM, 2020, J BONE MINER RES, V35, P1065, DOI 10.1002/jbmr.3974
   Giordano L, 2020, BRIT MED BULL, V133, P79, DOI 10.1093/bmb/ldaa002
   Helmrich G, 2013, CLIN OBSTET GYNECOL, V56, P659, DOI 10.1097/GRF.0b013e3182a99814
   Hensley AP, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115760
   Karinkanta S, 2010, NAT REV ENDOCRINOL, V6, P396, DOI 10.1038/nrendo.2010.70
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Li X, 2020, J BONE MINER RES, V35, P469, DOI 10.1002/jbmr.3903
   Liu YQ, 2015, MOL MED REP, V12, P6584, DOI 10.3892/mmr.2015.4283
   Migliorini F, 2022, BRIT MED BULL, V143, P46, DOI 10.1093/bmb/ldac017
   Migliorini F, 2021, EXPERT REV CLIN PHAR, V14, P105, DOI 10.1080/17512433.2021.1851192
   Migliorini F, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57101119
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02497 0
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02474 7
   Miyakoshi N, 2017, ASIAN SPINE J, V11, P756, DOI 10.4184/asj.2017.11.5.756
   Mohanapriya R, 2022, Biochimie
   Musette P, 2010, OSTEOPOROSIS INT, V21, P723, DOI 10.1007/s00198 009 1097 5
   Oliviero A, 2019, BRIT MED BULL, V130, P137, DOI 10.1093/bmb/ldz015
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Sun P, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.964103
   Sun Q, 2019, J Dent, P8291
   Tian QQ, 2020, Cancer Manag Res.
   Verlinden L, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1223021
   Verlinden L, 2013, BONE, V55, P465, DOI 10.1016/j.bone.2013.03.023
   Waki T, 2016, BMC Musculoskelet Disord, P1783
   Wang H, 2024, Front Endocrinol (Lausanne)
   Wang JC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1309 7
   Wang T, 2024, BIOFACTORS, V50, P6, DOI 10.1002/biof.1994
   Wong CP, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00808 2
   Yao JL, 2024, INJURY, V55, DOI 10.1016/j.injury.2024.111410
   Yuan Y, 2019, INT J SPORTS MED, V40, P931, DOI 10.1055/a 1015 0285
   Zhang C, 2023, Int J Nanomed, P18781
   Zhang HY, 2019, ONCOL LETT, V18, P6501, DOI 10.3892/ol.2019.11029
   Zhao JG, 2017, JAMA J AM MED ASSOC, V318, P2466, DOI 10.1001/jama.2017.19344
   Zheng ZZ, 2023, LIFE SCI, V323, DOI 10.1016/j.lfs.2023.121693
NR 42
TC 2
Z9 2
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD AUG 17
PY 2024
VL 19
IS 1
AR 487
DI 10.1186/s13018 024 04959 7
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA C9G2W
UT WOS:001292368500003
PM 39154011
OA gold
DA 2025 08 17
ER

PT J
AU Gunji, H
   Kunimatsu, R
   Tsuka, Y
   Yoshimi, Y
   Sumi, K
   Awada, T
   Nakajima, K
   Kimura, A
   Hiraki, T
   Hirose, N
   Yanoshita, M
   Tanimoto, K
AF Gunji, Hidemi
   Kunimatsu, Ryo
   Tsuka, Yuji
   Yoshimi, Yuki
   Sumi, Keisuke
   Awada, Tetsuya
   Nakajima, Kengo
   Kimura, Aya
   Hiraki, Tomoka
   Hirose, Naoto
   Yanoshita, Makoto
   Tanimoto, Kotaro
TI Effect of high frequency near infrared diode laser irradiation on
   periodontal tissues during experimental tooth movement in rats
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE lasers; orthodontics; accelerated tooth movement; periodontal tissue
   regeneration
ID RANDOMIZED CLINICAL TRIAL; BONE EXTRACELLULAR MATRIX; ORTHODONTIC
   MOVEMENT; THERAPY; PROLIFERATION; VELOCITY; CELLS; METABOLISM;
   EXPRESSION; PROMOTES
AB Background and ObjectivesTooth movement during orthodontic treatment is associated with bone neoplasticity and bone resorption on the tension and pressure sides. Previous clinical studies have suggested that low power laser irradiation can accelerate tooth movement during orthodontic treatment, although the underlying mechanism remains unclear. In this study, we used a high frequency near infrared diode laser that generates less heat and examined the histologic changes in periodontal tissue during experimental tooth movement with laser irradiation.
   MethodsA nickel titanium closed coil was mounted between the maxillary left side first molar and incisor of rats to model experimental tooth movement. The laser irradiation and the control groups were set, and the amount of movement of the first molar on 7th and 14th days after the start of pulling of the first molar tooth on the maxillary left was measured by three dimensional analysis of mu CT. After tooth movement, tissue samples from the mesial and tension sides were collected, and successive horizontal sections were prepared and examined using hematoxylin eosin and TRAP staining and immunohistochemical staining for RANKL, OPG, ALP, and proliferating cell nuclear antigen (PCNA). Changes in tissue temperature following laser irradiation were also examined.
   ResultsLaser irradiation significantly increased tooth movement compared with non irradiated controls. Histologic staining of the pressure side mesial root in laser irradiated rats revealed enhanced RANKL expression and increased numbers of TRAP positive cells compared with controls. By contrast, on the tension side, laser irradiation led to increased expression of ALP and PCNA. These data indicate that high frequency near infrared diode laser irradiation on the pressure side upregulates RANKL expression and accelerates osteoclast differentiation, facilitating bone resorption, whereas bone formation is induced on the tension side.
   ConclusionThis study demonstrates that high frequency near infrared diode laser irradiation of periodontal tissue leads to metabolic activation, which ultimately increases the rate of tooth movement. Lasers Surg. Med. 50:772 780, 2018. (c) 2018 Wiley Periodicals, Inc.
C1 [Gunji, Hidemi; Kunimatsu, Ryo; Tsuka, Yuji; Yoshimi, Yuki; Sumi, Keisuke; Awada, Tetsuya; Nakajima, Kengo; Kimura, Aya; Hiraki, Tomoka; Hirose, Naoto; Yanoshita, Makoto; Tanimoto, Kotaro] Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
C3 Hiroshima University
RP Kunimatsu, R (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthodont & Craniofacial Dev Biol, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
EM ryoukunimatu@hiroshima u.ac.jp
FU JSPS KAKENHI [16K11790, 16K20644, 25862016, 17K17327, 15K20595];
   Grants in Aid for Scientific Research [17K17330, 25862016, 16K11790,
   15K20595, 17K17327, 16K20644] Funding Source: KAKEN
FX Contract grant sponsor: JSPS KAKENHI; Contract grant numbers: 16K11790,
   16K20644, 25862016, 17K17327, 15K20595.
CR Alzoman HA, 2016, INT J DENT HYG, V14, P261, DOI 10.1111/idh.12169
   Aoki A, 2004, PERIODONTOL 2000, V36, P59, DOI 10.1111/j.1600 0757.2004.03679.x
   Awazu K, 2002, C T COL I S, V3, P95
   Bloise N, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128006
   Capon A, 2003, AM J CLIN DERMATOL, V4, P1, DOI 10.2165/00128071 200304010 00001
   Carvalho Lobato P, 2014, PHOTOMED LASER SURG, V32, P302, DOI 10.1089/pho.2012.3439
   Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140 6736(09)61522 1
   Cruz DR, 2004, LASER SURG MED, V35, P117, DOI 10.1002/lsm.20076
   Merli LAD, 2012, PHOTOCHEM PHOTOBIOL, V88, P1293, DOI 10.1111/j.1751 1097.2012.01172.x
   Ejiri K, 2014, LASER MED SCI, V29, P1339, DOI 10.1007/s10103 013 1292 7
   Ekizer A, 2016, LASER SURG MED, V48, P936, DOI 10.1002/lsm.22516
   Fabre HSC, 2015, J PHYS THER SCI, V27, P1645, DOI 10.1589/jpts.27.1645
   Fujita S, 2008, ORTHOD CRANIOFAC RES, V11, P143, DOI 10.1111/j.1601 6343.2008.00423.x
   GARCIA RL, 1989, AM J PATHOL, V134, P733
   Graver L, 2011, ORTHODONTICS CURRENT, V8 9, P253
   Gupta A, 2015, J BIOPHOTONICS, V8, P489, DOI 10.1002/jbio.201400058
   Hayashi H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100066
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Kim WT, 2013, ANGLE ORTHOD, V83, P611, DOI 10.2319/082012 665.1
   Kucuk BB, 2010, J OROFAC PAIN, V24, P293
   Noda M, 2016, LASER SURG MED, V48, P955, DOI 10.1002/lsm.22560
   Santinoni CD, 2017, J PHOTOCH PHOTOBIO B, V169, P83, DOI 10.1016/j.jphotobiol.2017.03.004
   Sayed N, 2014, J MAXILLOFAC ORAL SU, V13, P444, DOI 10.1007/s12663 013 0544 1
   Schwarz F, 2009, PERIODONTOL 2000, V51, P79, DOI 10.1111/j.1600 0757.2009.00301.x
   Seiryu M, 2010, J DENT RES, V89, P537, DOI 10.1177/0022034510363230
   Sgolastra F, 2013, J DENT RES, V92, P492, DOI 10.1177/0022034513487212
   Shirazi M, 2015, LASER MED SCI, V30, P713, DOI 10.1007/s10103 013 1407 1
   Soares DM, 2015, LASER MED SCI, V30, P1171, DOI 10.1007/s10103 013 1436 9
   Suzuki R, 2016, LASER MED SCI, V31, P1683, DOI 10.1007/s10103 016 2038 0
   Suzuki SS, 2016, J BIOPHOTONICS, V9, P1222, DOI 10.1002/jbio.201600016
   Tortamano A, 2009, AM J ORTHOD DENTOFAC, V136, P662, DOI 10.1016/j.ajodo.2008.06.028
   Tsuka Y, 2016, J LASERS MED SCI, V7, P40, DOI 10.15171/jlms.2016.09
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Wagner VP, 2016, LASER MED SCI, V31, P665, DOI 10.1007/s10103 016 1904 0
   Walsh LJ, 1997, AUST DENT J, V42, P302, DOI 10.1111/j.1834 7819.1997.tb00134.x
   Wu JY, 2013, INT J ORAL SCI, V5, P85, DOI 10.1038/ijos.2013.38
   Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044027, 10.1371/journal.pone.0046393]
   Yadav A, 2016, J PHOTOCH PHOTOBIO B, V162, P77, DOI 10.1016/j.jphotobiol.2016.06.031
   Yoshida T, 2009, ORTHOD CRANIOFAC RES, V12, P289, DOI 10.1111/j.1601 6343.2009.01464.x
   Youssef M, 2008, LASER MED SCI, V23, P27, DOI 10.1007/s10103 007 0449 7
   Zhu JX, 2001, HISTOCHEM J, V33, P25, DOI 10.1023/A:1017587712914
NR 41
TC 14
Z9 14
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0196 8092
EI 1096 9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD SEP
PY 2018
VL 50
IS 7
BP 772
EP 780
DI 10.1002/lsm.22797
PG 9
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Surgery
GA GR0OE
UT WOS:000442217400010
PM 29399884
DA 2025 08 17
ER

PT J
AU Xu, GW
   Zhang, LY
   Ren, GW
   Yuan, ZR
   Zhang, YY
   Zhao, RC
   Shi, YF
AF Xu, Guangwu
   Zhang, Liying
   Ren, Guangwen
   Yuan, Zengrong
   Zhang, Yingyu
   Zhao, Robert C.
   Shi, Yufang
TI Immunosuppressive properties of cloned bone marrow mesenchymal stem
   cells
SO CELL RESEARCH
LA English
DT Article
DE suppression; T cells; cytokines; stem cells; transplantation
ID INHIBIT LYMPHOCYTE PROLIFERATION; ANTIGEN PRESENTING CELL;
   NATURAL KILLER CELLS; VERSUS HOST DISEASE; STROMAL CELLS; IN VITRO;
   T CELLS; CHONDROGENIC DIFFERENTIATION; INTERFERON GAMMA; RESPONSES
AB Mesenchymal stem cells (MSCs), derived from adult tissues, are multipotent progenitor cells, which hold great promise for regenerative medicine. Recent studies have shown that MSCs are immunosuppressive in vivo and in vitro in both animals and humans. However, the mechanisms that govern these immune modulatory functions of MSCs remain largely elusive. Some studies with bulk populations of MSCs indicated that soluble factors such as PGE2 and TGF beta are important, while others support a role for cell cell contact. In this study, we intended to clarify these issues by examining immunosuppressive effects of cloned MSCs. We derived MSC clones from mouse bone marrow and showed that the majority of these clones were able to differentiate into adipocytes and osteoblast like cells. Importantly, cells from these clones exhibited strong inhibitory effects on TCR activation induced T cell proliferation in vitro, and injection of a small number of these cells promoted the survival of allogeneic skin grafts in mice. Conditioned medium from MSC cultures showed some inhibitory effect on anti CD3 induced lymphocyte proliferation independent of PGE2 and TGF beta. In comparison, direct co culture of MSCs with stimulated lymphocytes resulted in much stronger immunosuppressive effect. Interestingly, the suppression was bi directional, as MSC proliferation was also reduced in the presence of lympbocytes. Taking together, our findings with cloned MSCs demonstrate that these cells exert their immunosuppressive effects through both soluble factor(s) and cell cell contact, and that lymphocytes and MSCs are mutually inhibitory on their respective proliferation.
C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol & Immunol, Piscataway, NJ 08854 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences
RP Shi, YF (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol & Immunol, 661 Hoes Lane, Piscataway, NJ 08854 USA.
EM shiyu@umdnj.edu
RI Shi, Yufang/AAE 4431 2020; Ren, Guangwen/D 8895 2012; zhao,
   chunhua/MZR 1130 2025
OI Shi, Yufang/0000 0001 8964 319X; Ren, Guangwen/0000 0003 2436 9593; 
FU NIAID NIH HHS [AI50222, AI43384, AI057596] Funding Source: Medline
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Augello A, 2005, EUR J IMMUNOL, V35, P1482, DOI 10.1002/eji.200425405
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301 472X(01)00769 X
   Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood 2004 07 2921
   Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934
   Chan JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood 2006 01 0057
   Deng WM, 2004, EXP HEMATOL, V32, P861, DOI 10.1016/j.exphem.2004.06.009
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood 2003 04 1193
   Drukker M, 2004, TRENDS BIOTECHNOL, V22, P136, DOI 10.1016/j.tibtech.2004.01.003
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood 2004 09 3696
   Groh ME, 2005, EXP HEMATOL, V33, P928, DOI 10.1016/j.exphem.2005.05.002
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood 2004 02 0586
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood 2002 07 2104
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365 3083.2003.01176.x
   Le Blanc K, 2005, BIOL BLOOD MARROW TR, V11, P321, DOI 10.1016/j.bbmt.2005.01.005
   Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864
   Liu Li hui, 2005, Zhonghua Xue Ye Xue Za Zhi, V26, P385
   Mais A, 2006, J CELL BIOCHEM, V98, P798, DOI 10.1002/jcb.20786
   Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400
   Majumdar MK, 2003, J BIOMED SCI, V10, P228, DOI 10.1159/000068710
   McFarlin K, 2006, WOUND REPAIR REGEN, V14, P471, DOI 10.1111/j.1743 6109.2006.00153.x
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood 2003 11 3909
   Ogawa R, 2004, BIOCHEM BIOPH RES CO, V319, P511, DOI 10.1016/j.bbrc.2004.05.021
   Potian JA, 2003, J IMMUNOL, V171, P3426, DOI 10.4049/jimmunol.171.7.3426
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80
   Rasmusson I, 2005, EXP CELL RES, V305, P33, DOI 10.1016/j.yexcr.2004.12.013
   Rasmusson I, 2006, EXP CELL RES, V312, P2169, DOI 10.1016/j.yexcr.2006.03.019
   Ringdén O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004 0359
   Stagg J, 2006, BLOOD, V107, P2570, DOI 10.1182/blood 2005 07 2793
   Sudres M, 2006, J IMMUNOL, V176, P7761, DOI 10.4049/jimmunol.176.12.7761
   Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9
   Uccelli A, 2006, EXPERT OPIN BIOL TH, V6, P17, DOI 10.1517/14712598.6.1.17
   Vodyanik MA, 2006, BLOOD, V108, P2095, DOI 10.1182/blood 2006 02 003327
   Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood 2005 04 1496
   Zheng B, 2006, TISSUE ENG, V12, P1891, DOI 10.1089/ten.2006.12.1891
NR 41
TC 118
Z9 148
U1 1
U2 30
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001 0602
EI 1748 7838
J9 CELL RES
JI Cell Res.
PD MAR
PY 2007
VL 17
IS 3
BP 240
EP 248
DI 10.1038/cr.2007.4
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 162ZM
UT WOS:000246128100006
PM 17325691
OA Bronze
DA 2025 08 17
ER

PT J
AU Jin, YP
   Yang, L
   Li, X
AF Jin, Yongping
   Yang, Liu
   Li, Xia
TI MicroRNA 652 promotes cell proliferation and osteosarcoma invasion by
   directly targeting KLF9
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE microRNA 652; osteosarcoma; kruppel like factor 9; proliferation;
   invasion
ID COLORECTAL CANCER; DOWN REGULATION; LUNG CANCER; SUPPRESSES; GROWTH;
   TRANSCRIPTION; METASTASIS; EXPRESSION; PROGNOSIS; THERAPY
AB Previous studies have demonstrated that various microRNAs (miRNAs or miRs) are abnormally expressed in osteosarcoma (OS) and serve roles in its malignant development. An in depth understanding of the specific roles of dysregulated miRNAs in OS may be important for cancer research and the identification of novel therapeutic targets. In the current study, reverse transcription quantitative PCR was performed to determine miR 652 expression in OS tissues and cell lines. Cell Counting Kit 8 and Transwell invasion assays were used for assessing the effect of miR 652 on the proliferation and invasion of OS cells. Herein, miR 652 expression was assessed in OS and the effects and molecular mechanisms of miR 652 in OS cells were examined. The results revealed that miR 652 expression was significantly upregulated in OS tissues and cell lines compared with adjacent normal tissues and a normal human osteoblast cell line. Furthermore, miR 652 downregulation inhibited the proliferation and invasion of OS cells. miR 652 was also demonstrated to directly interact with the 3' untranslated region of kruppel like factor 9 (KLF9) and miR 652 negatively regulated KLF9 expression in OS cells. miR 652 and KLF9 mRNA levels were also revealed to be inversely correlated in OS tissues. Treatment with KLF9 small interfering RNA abolished the suppression of OS proliferation and invasion induced by miR 652 downregulation. miR 652 may serve an oncogenic role in OS cells by targeting KLF9 directly. The results also indicated that miR 652 may be an effective novel therapeutic target for the treatment of patients with OS.
C1 [Jin, Yongping; Li, Xia] Henan Univ, Coll Nursing & Hlth Sci, Inst Nursing Allied Hlth Sci, North Sect Jinming Rd, Kaifeng 475001, Henan, Peoples R China.
   [Yang, Liu] Kaifeng Hlth Sch, Dept Nursing, Kaifeng 475001, Henan, Peoples R China.
C3 Henan University
RP Li, X (通讯作者)，Henan Univ, Coll Nursing & Hlth Sci, Inst Nursing Allied Hlth Sci, North Sect Jinming Rd, Kaifeng 475001, Henan, Peoples R China.
EM lixia_henan@163.com
CR Ando Kosei, 2012, Sarcoma, V2012, P523432, DOI 10.1155/2012/523432
   Bai XY, 2018, CANCER LETT, V412, P224, DOI 10.1016/j.canlet.2017.10.027
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Chen XL, 2018, CELL PHYSIOL BIOCHEM, V48, P815, DOI 10.1159/000491911
   Deng SC, 2015, ONCOTARGET, V6, P39661, DOI 10.18632/oncotarget.5350
   Ferrari S, 2009, CANCER TREAT RES, V152, P275, DOI 10.1007/978 1 4419 0284 9_14
   Han K, 2015, ONCOTARGET, V6, P8875, DOI 10.18632/oncotarget.3560
   Huang SY, 2015, CANCER LETT, V356, P547, DOI 10.1016/j.canlet.2014.10.007
   Kang L, 2008, PATHOL INT, V58, P334, DOI 10.1111/j.1440 1827.2008.02233.x
   Kim YH, 2017, ONCOTARGET, V8, P8726, DOI 10.18632/oncotarget.14429
   Leichter AL, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0584 0
   Liu K, 2017, LIFE SCI, V188, P141, DOI 10.1016/j.lfs.2017.09.003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma C, 2018, ONCOL RES, V26, P765, DOI 10.3727/096504017X15021536183535
   Mao ZF, 2017, ANTICANCER RES, V37, P3795, DOI 10.21873/anticanres.11756
   McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009
   Pan Y, 2018, HEREDITAS, V155, DOI 10.1186/s41065 018 0061 9
   Peng NN, 2018, BIOCHEM CELL BIOL, V96, P515, DOI 10.1139/bcb 2017 0186
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Sampson VB, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00069
   Sharma N, 2019, CLIN TRANSL ONCOL, V21, P126, DOI 10.1007/s12094 018 1910 8
   Shen PL, 2014, PROSTATE, V74, P946, DOI 10.1002/pros.22812
   Smolle MA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091960
   Sun JB, 2014, CANCER LETT, V355, P25, DOI 10.1016/j.canlet.2014.09.022
   Tan ML, 2009, CANCER BIOL THER, V8, P106, DOI 10.4161/cbt.8.2.7385
   Tao YM, 2018, J CANCER, V9, P2317, DOI 10.7150/jca.25427
   To KKW, 2018, WORLD J GASTROENTERO, V24, P2949, DOI 10.3748/wjg.v24.i27.2949
   Wang ZL, 2017, EXP THER MED, V14, P1547, DOI 10.3892/etm.2017.4648
   Wu YQ, 2018, BIOMED PHARMACOTHER, V105, P1325, DOI 10.1016/j.biopha.2018.06.033
   Yang JZ, 2018, EUR REV MED PHARMACO, V22, P4156, DOI 10.26355/eurrev_201807_15408
   Yang WH, 2016, ONCOTARGET, V7, P16703, DOI 10.18632/oncotarget.7697
   Yao J, 2017, ONCOL LETT, V14, P1097, DOI 10.3892/ol.2017.6200
   Yuan HL, 2018, ONCOTARGETS THER, V11, P3891, DOI 10.2147/OTT.S156921
   Zhang QH, 2015, ARCH GYNECOL OBSTET, V291, P377, DOI 10.1007/s00404 014 3405 3
NR 34
TC 12
Z9 12
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD OCT
PY 2020
VL 20
IS 4
BP 2953
EP 2960
DI 10.3892/etm.2020.9037
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA NW4UQ
UT WOS:000575004100003
PM 32855660
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Schulz, P
   Werner, J
   Stauber, T
   Henriksen, K
   Fendler, K
AF Schulz, Patrick
   Werner, Johannes
   Stauber, Tobias
   Henriksen, Kim
   Fendler, Klaus
TI The G215R Mutation in the Cl<SUP> </SUP>/H<SUP>+</SUP> Antiporter ClC 7
   Found in ADO II Osteopetrosis Does Not Abolish Function but Causes a
   Severe Trafficking Defect
SO PLOS ONE
LA English
DT Article
ID AUTOSOMAL DOMINANT OSTEOPETROSIS; LYSOSOMAL STORAGE DISEASE; CLCN7
   GENE MUTATIONS; CHLORIDE CHANNELS; PROKARYOTIC HOMOLOG; BONE RESORPTION;
   BETA SUBUNIT; OSTEOCLASTS; ACIDIFICATION; TRANSPORTERS
AB Background: ClC 7 is a ubiquitous transporter which is broadly expressed in mammalian tissues. It is implied in the pathogenesis of lysosomal storage disease and osteopetrosis. Because of its endosomal/lysosomal localization it is still poorly characterized.
   Methodology/Principal Findings: An electrophysiological characterization of rat ClC 7 using solid supported membrane based electrophysiology is presented. The measured currents show the characteristics of ClC 7 and confirm its function as a Cl /H+ antiporter. We have used rat ClC 7 in CHO cells as a model system to investigate the functionality and cellular localization of the wt transporter and its variant G213R ClC 7 which is the analogue of human G215R ClC 7 responsible for autosomal dominant osteopetrosis type II. Our study shows that rat G213R ClC 7 is functional but has a localization defect in CHO cells which prevents it from being correctly targeted to the lysosomal membrane. The electrophysiological assay is tested as a tool for drug discovery. The assay is validated with a number of drug candidates. It is shown that ClC 7 is inhibited by DIDS, NPPB and NS5818 at micromolar concentrations.
   Conclusions/Significance: It is suggested that the scenario found in the CHO model system also applies to the human transporter and that mislocalization rather than impaired functionality of G215R ClC 7 is the primary cause of the related autosomal dominant osteopetrosis type II. Furthermore, the robust solid supported membrane based electrophysiological assay is proposed for rapid screening for potential ClC 7 inhibitors which are discussed for treatment of osteoporosis.
C1 [Schulz, Patrick; Werner, Johannes; Fendler, Klaus] Max Planck Inst Biophys, Dept Biophys Chem, Frankfurt, Germany.
   [Stauber, Tobias] Leibniz Inst Mol Pharmakol FMP, Berlin, Germany.
   [Stauber, Tobias] Max Delbruck Ctr Mol Med MDC, Berlin, Germany.
   [Henriksen, Kim] Nord Biosci, Herlev, Denmark.
C3 Max Planck Society; Leibniz Association; Leibniz Forschungsinstitut furr
   Molekulare Pharmakologie (FMP); Helmholtz Association; Max Delbruck
   Center for Molecular Medicine; Nordic Bioscience
RP Schulz, P (通讯作者)，Max Planck Inst Biophys, Dept Biophys Chem, Frankfurt, Germany.
EM klaus.fendler@biophys.mpg.de
RI Werner, Johannes/U 4724 2019; Stauber, Tobias/E 4005 2010
OI Stauber, Tobias/0000 0003 0727 6109; Werner,
   Johannes/0000 0001 7322 4433; Fendler, Klaus/0000 0002 5699 7060
FU Max Planck Gesellschaft zur Foerderung der Wissenschaften e.V., 80084
   Munchen, Germany; Deutsche Forschungsgemeinschaft, 53170 Bonn, Germany
   [SFB 807, SFB 740]; Nordic Biosciences, 2730 Herlev, Denmark; Nordic
   Biosciences
FX This work was funded by the Max Planck Gesellschaft zur Foerderung der
   Wissenschaften e.V., 80084 Munchen, Germany (P.S., J.W., K.F.), the
   Deutsche Forschungsgemeinschaft, SFB 807 to K.F. (P.S.) and SFB 740 to
   Thomas J. Jentsch (T. S.), 53170 Bonn, Germany, and Nordic Biosciences,
   2730 Herlev, Denmark (K.H.). As Nordic Biosciences have employed K.H.
   they did have a role in reading the manuscript and decision to publish.
   Apart from that Nordic Biosciences had no role in study design, data
   collection and analysis and have no financial interest in the
   manuscript. Kim Hendriksen is an employee of Nordic Biosciences. Nordic
   Biosciences supported the study through salaries and materials but had
   no role in the study design or performance and have no financial
   interest of the results. This does not alter the authors' adherence to
   all the PLoS ONE policies on sharing data and materials.
CR Abramoff M.D., 2004, J. Biophot. Int., V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Accardi A, 2004, J GEN PHYSIOL, V123, P109, DOI 10.1085/jgp.200308935
   Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314
   AUTUORI F, 1982, J CELL SCI, V57, P1
   Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014 5793(95)01298 2
   Campos Xavier AB, 2003, HUM GENET, V112, P186, DOI 10.1007/s00439 002 0861 9
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Diewald L, 2002, BIOCHEM BIOPH RES CO, V291, P421, DOI 10.1006/bbrc.2002.6462
   Estévez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   Freundt EC, 2007, CELL RES, V17, P956, DOI 10.1038/cr.2007.80
   Garcia Celma JJ, 2007, LANGMUIR, V23, P10074, DOI 10.1021/la701188f
   Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Henriksen K, 2008, CALCIFIED TISSUE INT, V83, P230, DOI 10.1007/s00223 008 9168 8
   Henriksen K, 2009, BIOCHEM BIOPH RES CO, V378, P804, DOI 10.1016/j.bbrc.2008.11.145
   HUNTER MJ, 1961, BIOCHIM BIOPHYS ACTA, V47, P580, DOI 10.1016/0006 3002(61)90553 4
   Jentsch TJ, 2008, CRIT REV BIOCHEM MOL, V43, P3, DOI [10.1080/10409230701829110, 10.1080/10409230701829110 ]
   Kajiya H, 2009, PFLUG ARCH EUR J PHY, V458, P1049, DOI 10.1007/s00424 009 0689 4
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Maritzen T, 2008, J NEUROSCI, V28, P10587, DOI 10.1523/JNEUROSCI.3750 08.2008
   Matsuda JJ, 2008, AM J PHYSIOL CELL PH, V294, pC251, DOI 10.1152/ajpcell.00338.2007
   MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663
   Neagoe I, 2010, J BIOL CHEM, V285, P21689, DOI 10.1074/jbc.M110.125971
   Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365 201X.2003.01060.x
   Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720
   Plans V, 2009, PFLUG ARCH EUR J PHY, V458, P23, DOI 10.1007/s00424 008 0597 z
   Poët M, 2006, P NATL ACAD SCI USA, V103, P13854, DOI 10.1073/pnas.0606137103
   Schaller S, 2005, DRUG NEWS PERSPECT, V18, P489, DOI 10.1358/dnp.2005.18.8.944546
   Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]
   Schulz P, 2008, METHODS, V46, P97, DOI 10.1016/j.ymeth.2008.07.002
   Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172
   Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516
   VENTURI M, 2003, MEMBRANE PROTEIN PUR
   Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780
   Waguespack SG, 2003, J BONE MINER RES, V18, P1513, DOI 10.1359/jbmr.2003.18.8.1513
   Waguespack SG, 2007, J CLIN ENDOCR METAB, V92, P771, DOI 10.1210/jc.2006 1986
   Wartosch L, 2009, FASEB J, V23, P4056, DOI 10.1096/fj.09 130880
   Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhao QX, 2009, BIOCHEM BIOPH RES CO, V384, P277, DOI 10.1016/j.bbrc.2009.04.088
   Zifarelli G, 2007, REV PHYSIOL BIOCH P, V158, P23, DOI 10.1007/112_2006_0605
NR 45
TC 44
Z9 53
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 7
PY 2010
VL 5
IS 9
AR e12585
DI 10.1371/journal.pone.0012585
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 647PO
UT WOS:000281631300014
PM 20830208
OA Green Published, gold, Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Shiv, R
   Rakeswari
   Farjana, N
   Subbiah, U
   Ajith, A
   Balaji, A
   Mohanasatheesh, S
AF Shiv, Ragul
   Rakeswari
   Farjana, Nilofer
   Subbiah, Usha
   Ajith, Athira
   Balaji, Anitha
   Mohanasatheesh, S.
TI Characterization of missense nonsynonymous single nucleotide
   polymorphism of runt related transcription factor 2 gene   An in
   silico approach
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE In silico approach; missense; protein; runt related transcription
   factor 2; single nucleotide polymorphism
ID EVOLUTIONARY CONSERVATION; MUTATIONS; BINDING; DISEASE
AB OBJECTIVES: Single nucleotide polymorphism (SNP) codes for multiple amino acids, impacting protein functions and disease prognosis. Runt related transcription factor 2 (RUNX2), a transcription factor linked to osteoblast differentiation, regulates cell proliferation in endothelium and osteoblastic cells. Understanding Runx2's role in nonosseous tissues is rapidly advancing. This study aims to identify harmful SNPs of the RUNX2 gene that may alter disease susceptibility using computational techniques.
   METHODS: The study uses various in silico methods to identify nonsynonymous SNPs (nsSNPs) of the RUNX2 gene, which could potentially alter protein structure and functions, with further analyses by I Mutant, ConSurf, Netsurf 3.0, GeneMANIA, and Have (y)Our Protein Explained.
   RESULTS: Six missense nsSNPs were identified as potentially harmful, disease causing, and damaging. Four were found to be unstable, while five were conserved. All six nsSNPs had a coiled secondary structure. Five nsSNPs were found to be destabilized.
   CONCLUSION: The RUNX2 gene's deleterious missense nsSNPs were identified by this study, and they may be exploited in future experimental studies. These high risk nsSNPs might be considered target molecules in therapeutic and diagnostic therapies in teeth and bone development.
C1 [Shiv, Ragul; Rakeswari; Farjana, Nilofer; Balaji, Anitha; Mohanasatheesh, S.] Bharath Inst Higher Educ & Res, Sree Balaji Dent Coll & Hosp, Dept Periodont, Chennai, Tamil Nadu, India.
   [Subbiah, Usha; Ajith, Athira] Bharath Inst Higher Educ & Res, Sree Balaji Dent Coll & Hosp, Human Genet Res Ctr, Chennai 600100, Tamil Nadu, India.
C3 Bharath Institute of Higher Education & Research; Sree Balaji Dental
   College & Hospital; Bharath Institute of Higher Education & Research;
   Sree Balaji Dental College & Hospital
RP Subbiah, U (通讯作者)，Bharath Inst Higher Educ & Res, Sree Balaji Dent Coll & Hosp, Human Genet Res Ctr, Chennai 600100, Tamil Nadu, India.
EM ushat75@yahoo.com
RI subbiah, usha/HTL 2793 2023
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070
   Bisht K., 2020, Int J Curr Res Rev, V12, P193
   Boillée S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018
   Bromberg Y, 2007, NUCLEIC ACIDS RES, V35, P3823, DOI 10.1093/nar/gkm238
   Capriotti E, 2006, BIOINFORMATICS, V22, P2729, DOI 10.1093/bioinformatics/btl423
   Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
   Elkhattabi L, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/4951627
   Gao XR, 2019, HEREDITAS, V156, DOI 10.1186/s41065 019 0107 7
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lihua N., 2021, Exploratory Research and Hypothesis in Medicine, V6, P87
   Morava É, 2002, EUR J PEDIATR, V161, P619, DOI 10.1007/s00431 002 0977 x
   Quack I, 1999, AM J HUM GENET, V65, P1268, DOI 10.1086/302622
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Sneha P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174953
   Subbiah HV, 2020, EGYPTIAN J MED HUMAN, V21, DOI 10.1186/s43042 020 00110 3
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tang HM, 2016, BIOINFORMATICS, V32, P2230, DOI 10.1093/bioinformatics/btw222
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0253 7613
EI 1998 3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD MAY JUN
PY 2024
VL 56
IS 3
BP 198
EP 205
DI 10.4103/ijp.ijp_533_23
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA G4X9S
UT WOS:001316697300008
PM 39078184
OA Green Published
DA 2025 08 17
ER

PT J
AU Peng, TY
   Lin, DJ
   Mine, Y
   Tasi, CY
   Li, PJ
   Shih, YH
   Chiu, KC
   Wang, TH
   Hsia, SM
   Shieh, TM
AF Peng, Tzu Yu
   Lin, Dan Jae
   Mine, Yuichi
   Tasi, Chi Yang
   Li, Po Jung
   Shih, Yin Hwa
   Chiu, Kuo Chou
   Wang, Tong Hong
   Hsia, Shih Min
   Shieh, Tzong Ming
TI Biofilm Formation on the Surface of (Poly)Ether Ether Ketone and In
   Vitro Antimicrobial Efficacy of Photodynamic Therapy on Peri Implant
   Mucositis
SO POLYMERS
LA English
DT Article
DE dentistry; polyetheretherketone; biofilm; peri implant mucositis;
   photodynamic therapy; antimicrobial activity
ID ZIRCONIA IMPLANTS; PEEK; TITANIUM; ALL ON 4; PATIENT; RESTORATIONS;
   BIOMATERIALS; MECHANISMS; DENTISTRY; DENTURE
AB Poly ether ether ketone (PEEK) is an aesthetically pleasing natural material with good biocompatibility and shock absorption characteristics. The application of PEEK as a dental implant or abutment is expected to reduce the risk of failure and enhance aesthetics. Given that approximately one in 15 patients have allergic reactions to antibiotics, photodynamic therapy (PDT) has been gaining attention as an alternative treatment. Herein, the applicability of PEEK dental implants or abutments was investigated using material analyses, biofilm formation assay, and cell viability tests. The possible use of PDT for peri implant mucositis was evaluated with the biofilm removal assay. The obtained data were analyzed based on the multivariate analysis of variance, paired t tests, and the Pearson correlation coefficient (alpha = 0.05). The results revealed that PEEK was significantly less conducive to the formation of biofilms with S. mutans and A. actinomycetemcomitan (p < 0.001) but exhibited comparable MG 63 (human osteoblast like) osteoblast cell viability (p > 0.05) to the other materials. PDT had similar antimicrobial efficacy and yielded similar biofilm removal effects to antibiotics. Altogether, these findings suggest that PEEK has attractive features and can serve as an alternative material for dental implants or abutments. In cases where peri implant mucositis occurs, PDT can be used as an accessible therapeutic approach.
C1 [Peng, Tzu Yu; Lin, Dan Jae; Li, Po Jung; Shieh, Tzong Ming] China Med Univ, Coll Dent, Sch Dent, Taichung 40402, Taiwan.
   [Mine, Yuichi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Med Syst Engn, Hiroshima, Hiroshima 7348553, Japan.
   [Tasi, Chi Yang] Taipei Med Univ Hosp, Dept Dent, Taipei 11031, Taiwan.
   [Shih, Yin Hwa] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung 41354, Taiwan.
   [Chiu, Kuo Chou] Triserv Gen Hosp, Natl Def Med Ctr, Div Oral Diag & Family Dent, Taipei 11490, Taiwan.
   [Wang, Tong Hong] Chang Gung Univ, Chang Gung Mem Hosp, Tissue Bank, Taoyuan 33305, Taiwan.
   [Hsia, Shih Min] Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei 11031, Taiwan.
C3 China Medical University Taiwan; Hiroshima University; Taipei Medical
   University; Taipei Medical University Hospital; Asia University Taiwan;
   National Defense Medical University; Tri Service General Hospital; Chang
   Gung Memorial Hospital; Chang Gung University; Taipei Medical University
RP Shieh, TM (通讯作者)，China Med Univ, Coll Dent, Sch Dent, Taichung 40402, Taiwan.; Chiu, KC (通讯作者)，Triserv Gen Hosp, Natl Def Med Ctr, Div Oral Diag & Family Dent, Taipei 11490, Taiwan.
EM typ@mail.cmu.edu.tw; djlin@mail.cmu.edu.tw; mine@hiroshima u.ac.jp;
   cytsai@tmu.edu.tw; ll820731@gmail.com; evashih@asia.edu.tw;
   scalinghoner@yahoo.com.tw; cellww@adm.cgmh.org.tw; bryanhsia@tmu.edu.tw;
   tmshieh@mail.cmu.edu.tw
RI Hsia, Shih Min/AAL 2026 2020; Shih, Yin Hwa/AAD 1492 2020; Lin,
   Dan Jae/D 6901 2013; Mine, Yuichi/HHN 1257 2022
OI Hsia, Shih Min/0000 0003 2888 2618; Peng, Tzu Yu/0000 0002 7168 9429;
   Wang, Tong Hong/0000 0001 9248 9031; Lin, Dan Jae/0000 0001 8967 7090;
   Mine, Yuichi/0000 0002 7057 1955
FU Ministry of Science and Technology, Taiwan [MOST 108 2314 B 039 009 MY3,
   MOST 109 2811 B 039 527, MOST 109 2314 B 039 008]; China Medical
   University, Taiwan [CMU109 MF 32, CMU109 S 17]
FX This research was funded by the Ministry of Science and Technology,
   Taiwan (MOST 108 2314 B 039 009 MY3; MOST 109 2811 B 039 527; MOST
   109 2314 B 039 008) and China Medical University, Taiwan (CMU109 MF 32;
   CMU109 S 17).
CR Allison RR, 2013, CLIN ENDOSC, V46, P24, DOI 10.5946/ce.2013.46.1.24
   Anguiano Sanchez J, 2016, COMPUT MATH METHOD M, V2016, DOI 10.1155/2016/6183679
   Azizi B, 2018, PHOTODIAGN PHOTODYN, V21, P328, DOI 10.1016/j.pdpdt.2018.01.017
   Barkarmo S, 2019, CLIN EXP DENT RES, V5, P427, DOI 10.1002/cre2.205
   Cabello Domínguez G, 2020, J PROSTHET DENT, V124, P403, DOI 10.1016/j.prosdent.2019.10.002
   Chiu KC, 2021, J FORMOS MED ASSOC, V120, P827, DOI 10.1016/j.jfma.2020.09.002
   D'Ercole S, 2020, J MATER SCI MATER M, V31, DOI 10.1007/s10856 020 06408 3
   Daubert DM, 2019, PERIODONTOL 2000, V81, P29, DOI 10.1111/prd.12280
   De la Pinta I, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6281 3
   Gama LT, 2020, DENT MATER, V36, pE93, DOI 10.1016/j.dental.2020.01.002
   Gursoy H, 2013, CLIN ORAL INVEST, V17, P1113, DOI 10.1007/s00784 012 0845 7
   Hahnel S, 2015, CLIN ORAL IMPLAN RES, V26, P1297, DOI 10.1111/clr.12454
   Han AF, 2016, INT J ADHES ADHES, V69, P58, DOI 10.1016/j.ijadhadh.2016.03.022
   Horita S, 2017, J PROSTHODONT RES, V61, P123, DOI 10.1016/j.jpor.2016.08.002
   Kondo T, 2019, J PROSTHODONT RES, V63, P140, DOI 10.1016/j.jpor.2018.10.006
   Konopka K, 2007, J DENT RES, V86, P694, DOI 10.1177/154405910708600803
   Kurtz SM, 2019, PEEK biomaterials handbook, DOI [10.1016/C2016 0 02479 8, DOI 10.1016/C2016 0 02479 8]
   Kurtz SM, 2007, BIOMATERIALS, V28, P4845, DOI 10.1016/j.biomaterials.2007.07.013
   Kyomoto M, 2013, BIOMATERIALS, V34, P7829, DOI 10.1016/j.biomaterials.2013.07.023
   Ma R, 2014, INT J MOL SCI, V15, P5426, DOI 10.3390/ijms15045426
   Ma XK, 2017, MATER DESIGN, V114, P271, DOI 10.1016/j.matdes.2016.11.028
   Parmigiani Izquierdo JM, 2017, INT J IMPLANT DENT, V3, DOI 10.1186/s40729 016 0062 2
   Martins R, 2018, J PERIODONTAL RES, V53, P210, DOI 10.1111/jre.12508
   Mellado Valero A, 2013, MED ORAL PATOL ORAL, V18, pE869, DOI 10.4317/medoral.19420
   National Health Service (NHS.UK), Antibiotics
   Nogueira TE, 2017, J ORAL REHABIL, V44, P1004, DOI 10.1111/joor.12550
   Peng TY, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13040543
   Prikrylová J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2519205
   Puig CP, 2010, EUR J ORAL IMPLANTOL, V3, P155
   Qin LD, 2021, MATERIALS, V14, DOI 10.3390/ma14020408
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   Rupp F, 2018, DENT MATER, V34, P40, DOI 10.1016/j.dental.2017.09.007
   Schünemann FH, 2019, MAT SCI ENG C MATER, V98, P1294, DOI 10.1016/j.msec.2019.01.062
   Sibata CH, 2000, BRAZ J MED BIOL RES, V33, P869, DOI 10.1590/S0100 879X2000000800002
   Soon G, 2016, CERAM INT, V42, P12543, DOI 10.1016/j.ceramint.2016.05.077
   Sperandio Felipe F, 2013, Recent Pat Antiinfect Drug Discov, V8, P108
   Meza Siccha AS, 2019, INT J DENT, V2019, DOI 10.1155/2019/4292976
   Steinemann SG, 1998, PERIODONTOL 2000, V17, P7, DOI 10.1111/j.1600 0757.1998.tb00119.x
   Wandiyanto JV, 2019, MATERIALS, V12, DOI 10.3390/ma12101575
   Wang AQ, 2018, J MICROSC OXFORD, V270, P53, DOI 10.1111/jmi.12649
   Yan HJ, 2018, CLIN CASE REP, V6, P1972, DOI 10.1002/ccr3.1753
   Yuan B, 2018, BIOMATERIALS, V170, P116, DOI 10.1016/j.biomaterials.2018.04.014
   Zhao XD, 2020, J MECH BEHAV BIOMED, V112, DOI 10.1016/j.jmbbm.2020.104032
   Zoidis P, 2018, J PROSTHET DENT, V119, P516, DOI 10.1016/j.prosdent.2017.04.020
   Zotti F, 2020, CLIN COSMET INV DENT, V12, P377, DOI 10.2147/CCIDE.S274669
NR 45
TC 23
Z9 23
U1 5
U2 30
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4360
J9 POLYMERS BASEL
JI Polymers
PD MAR
PY 2021
VL 13
IS 6
AR 940
DI 10.3390/polym13060940
PG 12
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA SE3HR
UT WOS:000651962400001
PM 33803736
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, F
   Akiyama, Y
   Tai, S
   Maruyama, K
   Kawaguchi, Y
   Muramatsu, K
   Yamaguchi, K
AF Liu, Feng
   Akiyama, Yasuto
   Tai, Sachiko
   Maruyama, Kouji
   Kawaguchi, Yoshihiro
   Muramatsu, Kouji
   Yamaguchi, Ken
TI Changes in the expression of CD106, osteogenic genes, and transcription
   factors involved in the osteogenic differentiation of human bone marrow
   mesenchymal stem cells
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE mesenchymal stem cell; osteogenic differentiation; FACS; real time PCR
ID MESODERMAL PROGENITOR CELLS; ADHESION MOLECULE 1; IN VITRO; HUMAN
   OSTEOBLASTS; STROMAL CELLS; GROWTH; INDUCTION; EXPANSION; THERAPY;
   VCAM 1
AB Mesenchymal stem cells (MSCs) are well known to possess multipotential differentiation and are becoming a good tool for clinical research. However, specific markers for their purification and the mechanism of their osteogenic differentiation remain to be elucidated. In the present study, we compared the expression of CD106, and osteogenic differentiation related proteins and genes in human bone marrow (BM) derived MSCs, before and after differentiation by FACS, histochemical staining, immunohistochemical staining, RT PCR, and real time PCR. It was found that MSCs were positive for CD13, CD29, CD44, CD73, CD90, CD105, and CD166, but negative for CD14, CD31, CD34, CD62E, CD45, and GlyA. Notably, CD106 was detected before osteogenic induction, but its expression was downregulated 10 fold after 2 weeks of osteogenic differentiation as determined by flow cytometry. The results of RT PCR and real time PCR revealed that the expression of CD106 mRNA in MSCs significantly decreased by 7.1 , 4.2 , and 5.1 fold, respectively after osteogenic, chondrogenic, and adipogenic differentiation. In contrast, other MSC positive markers described above did not change significantly even after differentiation. Compared to levels in control cells, after 2 weeks of osteogenic differentiation, mRNA levels of alkaline phosphatase, bone sialoprotein, osteocalcin, and transcript factors RUNX2 and Osterix showed more than 2 fold, 5 fold, 1.5 fold, 2 fold, and 5 fold increase, respectively. Thus, we speculate that CD106 might be a useful surface marker for BMMSCs. Moreover, alkaline phosphatase, type I collagen, osteonectin, osteopontin, and biglycin were expressed in the early stages of osteogenic differentiation before bone sialoprotein and osteocalcin. The present study should help to provide a novel marker for isolating purified MSCs and characterizing osteogenic differentiation.
C1 [Liu, Feng; Akiyama, Yasuto; Tai, Sachiko; Maruyama, Kouji; Kawaguchi, Yoshihiro; Yamaguchi, Ken] Shizuoka Canc Ctr Res Inst, Div Immunotherapy, Nagaizumi, Shizuoka 4118777, Japan.
   [Muramatsu, Kouji] Shizuoka Canc Ctr Res Inst, Canc Diagnost Res Div, Shizuoka, Japan.
C3 Shizuoka Cancer Center; Shizuoka Cancer Center
RP Akiyama, Y (通讯作者)，Shizuoka Canc Ctr Res Inst, Div Immunotherapy, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan.
EM y.akiyama@scchr.jp
CR Akiyama Y, 2004, IMMUNOL LETT, V95, P199, DOI 10.1016/j.imlet.2004.07.010
   Akiyama Y, 2004, ANTICANCER RES, V24, P571
   Ali S, 2000, AM J PATHOL, V157, P313, DOI 10.1016/S0002 9440(10)64542 7
   BANKS RE, 1993, BRIT J CANCER, V68, P122, DOI 10.1038/bjc.1993.298
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood 2003 04 1193
   Franceschi RT, 2005, J DENT RES, V84, P1093, DOI 10.1177/154405910508401204
   FRIDENSHTEIN AY, 1982, ARK PATOL, V44, P3
   Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Hung SC, 2002, STEM CELLS, V20, P249, DOI 10.1634/stemcells.20 3 249
   Ikeda R, 2005, J BIOL CHEM, V280, P8523, DOI 10.1074/jbc.M409442200
   Karlsson C, 2007, J ORTHOP RES, V25, P152, DOI 10.1002/jor.20287
   Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097 4644(19971201)67:3<386::AID JCB10>3.3.CO;2 5
   Lin KY, 2007, CANCER RES, V67, P1832, DOI 10.1158/0008 5472.CAN 06 3014
   Madras N, 2002, STEM CELLS, V20, P230, DOI 10.1634/stemcells.20 3 230
   Maurer CA, 1998, INT J CANCER, V79, P76, DOI 10.1002/(SICI)1097 0215(19980220)79:1<76::AID IJC15>3.3.CO;2 Y
   Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   SABATINI F, 2005, LAB INVEST, V30, P1
   Shahdadfar A, 2005, STEM CELLS, V23, P1357, DOI 10.1634/stemcells.2005 0094
   Shur I, 2001, J CELL BIOCHEM, V83, P547, DOI 10.1002/jcb.1249
   Solchaga LA, 2005, J CELL PHYSIOL, V203, P398, DOI 10.1002/jcp.20238
   Stewart K, 2003, CELL TISSUE RES, V313, P281, DOI 10.1007/s00441 003 0762 9
   Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220
   Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092 8674(03)00847 X
NR 29
TC 65
Z9 89
U1 0
U2 12
PU SPRINGER TOKYO
PI TOKYO
PA 1 11 11 KUDAN KITA, CHIYODA KU, TOKYO, 102 0073, JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2008
VL 26
IS 4
BP 312
EP 320
DI 10.1007/s00774 007 0842 0
PG 9
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 322RG
UT WOS:000257392400002
PM 18600396
DA 2025 08 17
ER

PT J
AU Ern, C
   Berger, T
   Frasheri, I
   Heym, R
   Hickel, R
   Folwaczny, M
AF Ern, Christina
   Berger, Tamara
   Frasheri, Iris
   Heym, Richard
   Hickel, Reinhard
   Folwaczny, Matthias
TI Differentiation of hMSC and hPDLSC induced by PGE2 or BMP 7 in 3D models
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Periodontitis; Scaffold; hTERT; BMP 7; Mesenchymal stem cell;
   Periodontal ligament stem cell
ID HUMAN PERIODONTAL LIGAMENT; BONE MORPHOGENETIC PROTEIN 7; GINGIVAL
   CREVICULAR FLUID; MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION;
   INFLAMMATORY MEDIATORS; EP2/EP4 SUBTYPES; PGE(2) RECEPTORS;
   PROSTAGLANDIN E; GROWTH FACTOR
AB Regenerative therapies of pathogenic tissue defects are gaining increasing importance in periodontology. Among others, the osteogenic effect of BMP 7 seems to play a major role in the development of teeth and alveolar bone. Human periodontal ligament stem cells (hPDLSC), as well as human mesenchymal stem cells (hMSC), show the ability to differentiate into various types of tissues. Regarding prostaglandin E2, many studies have confirmed that it is involved in the inflammation associated to periodontitis stimulating osteoclasts, which ultimately leads to resorption of tooth supporting bone. Herein, we aimed to investigate how PGE2 influences regenerative processes.
   The influence of PGE2 and BMP 7 on the osteogenic differentiation of hMSC and hPDLSC was determined in a 3D cell culture model using qRT PCR, immunocytochemistry and REM. BMP 7 enhanced the expression of osteogenic markers in hMSC and lowered it in hPDLSC TERT. BMP 7 had a lower osteogenic effect on hPDLSC hTERT than on hMSC, while PGE2 decreases the osteogenic differentiation in both cell types, thus, inhibiting anabolic processes. Both cell types presented good proliferation and adhesion onto the scaffolds. The well developed structural morphology and the support of osteogenic differentiation suggest that the scaffolds are potential candidate materials for bone regeneration. The positivity for Cap in hPDLSC and more in hMSC immunostaining samples indicates the initiation of neocementogenesis as part of periodontal regeneration.
   In conclusion, BMP7, in particular combined with MSC, seems to have a favourable application also in periodontal regeneration. Our results show that inflammation plays an important role in periodontal regeneration. PGE2 is a key mediator, which stimulates bone resorption also via a mechanism involving the inhibition of osteogenic differentiation of MSC as well as PDLSC. Therefore, regenerative approaches should always be conducted in combination with anti inflammatory measures oriented to control inflammation.
C1 [Ern, Christina; Berger, Tamara; Frasheri, Iris; Heym, Richard; Hickel, Reinhard; Folwaczny, Matthias] Ludwig Maximilian Univ Munchen, Univ Hosp, Dept Operat Dent & Periodontol, Munich, Germany.
   [Berger, Tamara] Max Planck Inst Psychiat, Munich, Germany.
C3 University of Munich; Max Planck Society
RP Ern, C (通讯作者)，Ludwig Maximilian Univ Munchen, Univ Hosp, Dept Operat Dent & Periodontol, Munich, Germany.
EM chrisern@dent.med.uni muenchen.de; berger_tamara@gmx.de;
   irisfrasheri@yahoo.it; rheym@dent.med.uni muenchen.de;
   hickel@dent.med.uni muenchen.de; mfolwa@dent.med.uni muenchen.de
FU FoFoLe Grant [716/618]
FX We gratefully acknowledge the financial support by FoFoLe Grant 716/618.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agard M, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00045
   Amano S, 1996, J IMMUNOL, V156, P1931
   Boon MR, 2011, CYTOKINE GROWTH F R, V22, P221, DOI 10.1016/j.cytogfr.2011.08.001
   CHAMBERS TJ, 1983, J PATHOL, V139, P383, DOI 10.1002/path.1711390313
   Chubinskaya S, 2003, INT J BIOCHEM CELL B, V35, P1323, DOI 10.1016/S1357 2725(03)00035 9
   Diefenderfer D. L., 2003, CONNECT TISSUE RE S1, V44
   Docheva D, 2010, EUR CELLS MATER, V19, P228, DOI 10.22203/eCM.v019a22
   Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952 3278(03)00027 9
   GOTTLOW J, 1984, J CLIN PERIODONTOL, V11, P494, DOI 10.1111/j.1600 051X.1984.tb00901.x
   Grzesik WJ, 2002, CRIT REV ORAL BIOL M, V13, P474, DOI 10.1177/154411130201300605
   HAKEDA Y, 1987, ENDOCRINOLOGY, V121, P1966, DOI 10.1210/endo 121 6 1966
   Helder MN, 1998, J DENT RES, V77, P545, DOI 10.1177/00220345980770040701
   Jönsson D, 2011, J PERIODONTAL RES, V46, P153, DOI 10.1111/j.1600 0765.2010.01331.x
   KANAKARIS NK, 2009, INJURY S3, V40, P21, DOI DOI 10.1016/50020 1383(09)70007 5
   Kim CK, 2014, J MICROBIOL BIOTECHN, V24, P188, DOI 10.4014/jmb.1308.08005
   Kim K, 2010, J DENT RES, V89, P842, DOI 10.1177/0022034510370803
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Leibur E, 1999, ORAL DIS, V5, P223
   Machtei EE, 2008, QUINTESSENCE INT, V39, P811
   Matarasso M, 2015, CLIN ORAL INVEST, V19, P1581, DOI 10.1007/s00784 015 1491 7
   NAKASHIMA K, 1994, J CLIN PERIODONTOL, V21, P327, DOI 10.1111/j.1600 051X.1994.tb00721.x
   Noguchi K, 2005, ORAL DIS, V11, P157, DOI 10.1111/j.1601 0825.2005.01059.x
   Nukaga J, 2004, J PERIODONTOL, V75, P249, DOI 10.1902/jop.2004.75.2.249
   NYMAN S, 1982, J CLIN PERIODONTOL, V9, P257, DOI 10.1111/j.1600 051X.1982.tb02065.x
   OFFENBACHER S, 1981, J CLIN PERIODONTOL, V8, P359, DOI 10.1111/j.1600 051X.1981.tb02045.x
   OFFENBACHER S, 1993, J PERIODONTOL, V64, P432, DOI 10.1902/jop.1993.64.5s.432
   Pitaru S, 2002, CONNECT TISSUE RES, V43, P257, DOI 10.1080/03008200290001276
   Pountos I, 2010, J ORTHOP TRAUMA, V24, P552, DOI 10.1097/BOT.0b013e3181efa8fe
   Preshaw PM, 2002, J CLIN PERIODONTOL, V29, P15, DOI 10.1034/j.1600 051x.2002.290103.x
   Rajan GP, 2006, J TRAUMA, V60, P1322, DOI 10.1097/01.ta.0000195977.18035.40
   Ramseier CA, 2012, PERIODONTOL 2000, V59, P185, DOI 10.1111/j.1600 0757.2011.00432.x
   Sakuma Y, 2000, J BONE MINER RES, V15, P218, DOI 10.1359/jbmr.2000.15.2.218
   Salvi GE, 1998, J PERIODONTAL RES, V33, P212, DOI 10.1111/j.1600 0765.1998.tb02193.x
   Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shen BJ, 2010, J CELL BIOCHEM, V109, P406, DOI 10.1002/jcb.22412
   SOMERMAN MJ, 1990, ARCH ORAL BIOL, V35, P241, DOI 10.1016/0003 9969(90)90062 F
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Urist M. R., 1965, SCIENCES, V150
   Weinreb M, 2006, PROSTAG LEUKOTR ESS, V75, P81, DOI 10.1016/j.plefa.2006.06.004
   White RP, 2002, J ORAL MAXIL SURG, V60, P1241, DOI 10.1053/joms.2002.35719
   YAMAGUCHI DT, 1989, AM J PHYSL, V257
   Yan MM, 2005, J PERIODONTOL, V76, P929, DOI 10.1902/jop.2005.76.6.929
   Zhang YF, 2007, BIOMATERIALS, V28, P4635, DOI 10.1016/j.biomaterials.2007.07.009
   Zhu WT, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0719 2
NR 45
TC 11
Z9 12
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952 3278
EI 1532 2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD JUL
PY 2017
VL 122
BP 30
EP 37
DI 10.1016/j.plefa.2017.06.005
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA FD6WH
UT WOS:000407668100005
PM 28735626
DA 2025 08 17
ER

PT J
AU Lepore, S
   Milillo, L
   Trotta, T
   Castellani, S
   Porro, C
   Panaro, MA
   Santarelli, A
   Bambini, F
   Lo Muzio, L
   Conese, M
   Maffione, AB
AF Lepore, S.
   Milillo, L.
   Trotta, T.
   Castellani, S.
   Porro, C.
   Panaro, M. A.
   Santarelli, A.
   Bambini, F.
   Lo Muzio, L.
   Conese, M.
   Maffione, A. B.
TI ADHESION AND GROWTH OF OSTEOBLAST LIKE CELLS ON LASER ENGINEERED POROUS
   TITANIUM SURFACE: EXPRESSION AND LOCALIZATION OF N CADHERIN AND
   β CATENIN
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE titanium surface; MG63; biomaterials; dental implants
ID ORAL IMPLANT SURFACES; DIFFERENTIATION; ROUGHNESS; STRAINS
AB Response of different types of cells on biomaterials is crucial for the applications of tissue engineering and regenerative medicine. It is recognized that cell behaviour depends largely on material surface characteristics. The purpose of this study was to define the biologic response of MG63 cells to the innovative patented surface SYNTHEGRA (R). MG63 morphology and distribution on the three different titanium disk surfaces (sandblasted, smooth, and laser treated) were evaluated by microscopy analysis after staining with hematoxylin and eosin. Cell adhesion was determined by crystal violet assay at 48 h while proliferation and cytotoxicity were performed by MTT assay at 24, 48, 72 and 240 h. The expression and localization of N cadherin and beta catenin were studied by immunfluorescence and confocal microscopy. At 48 h the adhesion was similar in all titanium surfaces, no difference in cell viability were observed in all titanium disks when compared with controls, while the cell growth on laser treated disks was significantly higher at 240 h than at 24 and 72 h. Morphological analysis show that cells are aligned along the grooves and inside the cavities. beta catenin signal appeared more diffuse and localized underneath the cell membrane, while N cadherin signal was fainter in cells grown on SYNTHEGRA (R) surface. This work put into evidence the performance of newly designed laser micromachined surface for adhesion, growth and distribution of human osteoblast like cells. SYNTHEGRA (R) surface inducing modification of N cadherin and beta catenin expression and localization, are suggestive of cells undergoing differentiation towards osteocytes and could be particularly suited for immediate load implant procedures.
C1 [Lepore, S.] IRCCS CROB, Lab Preclin & Translat Res, Rionero In Vulture, Italy.
   [Milillo, L.; Trotta, T.; Porro, C.; Lo Muzio, L.; Maffione, A. B.] Univ Foggia, Dept Clin & Expt Med, I 71122 Foggia, Italy.
   [Castellani, S.; Conese, M.] Univ Foggia, Dept Med & Surg Sci, I 71122 Foggia, Italy.
   [Panaro, M. A.] Univ Bari, Dept Basic Med Sci, I 70121 Bari, Italy.
   [Santarelli, A.; Bambini, F.] Univ Ancona, Dept Clin & Dent Sci, I 60128 Ancona, Italy.
C3 IRCCS CROB; University of Foggia; University of Foggia; Universita degli
   Studi di Bari Aldo Moro; Marche Polytechnic University
RP Lo Muzio, L (通讯作者)，Univ Foggia, Dept Clin & Expt Med, Via Rovelli 48, I 71122 Foggia, Italy.
EM l.lomuzio@unifg.it
RI Lo Muzio, Lorenzo/C 8533 2011; Santarelli, Andrea/P 6310 2014; Lepore,
   Silvia/AAB 8005 2020; PORRO, CHIARA/G 7849 2018; Conese,
   Massimo/AAB 7926 2019; Porro, Chiara/G 7849 2018; Castellani,
   Stefano/AAR 4143 2021; Panaro, Maria/AFS 7875 2022; Muzio,
   Lorenzo/C 8533 2011; Maffione, angela bruna/AAC 2193 2022
OI Lo Muzio, Lorenzo/0000 0003 4633 4893; Santarelli,
   Andrea/0000 0003 4218 3354; Lepore, Silvia/0000 0002 1918 8547; Conese,
   Massimo/0000 0003 3465 6641; castellani, stefano/0000 0003 0201 7298;
   PORRO, CHIARA/0000 0002 7526 6968; 
CR Albrektsson T, 2004, INT J PROSTHODONT, V17, P544
   Albrektsson T, 2004, INT J PROSTHODONT, V17, P536
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Berardi D, 2009, INT J IMMUNOPATH PH, V22, P125, DOI 10.1177/039463200902200114
   Browne M, 2000, BIOMATERIALS, V21, P385, DOI 10.1016/S0142 9612(99)00200 8
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   Cei S, 2011, IMPLANT DENT, V20, P285, DOI 10.1097/ID.0b013e31821bfa9f
   Cretel E, 2008, CELL MOL BIOENG, V1, P5, DOI 10.1007/s12195 008 0009 7
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Di Palma F, 2005, BIOMATERIALS, V26, P4249, DOI 10.1016/j.biomaterials.2004.10.041
   Di Palma F, 2003, BIOMATERIALS, V24, P3139, DOI 10.1016/S0142 9612(03)00152 2
   Ferrari SL, 2000, J BONE MINER RES, V15, P198, DOI 10.1359/jbmr.2000.15.2.198
   Glauser R., 2011, CLIN IMPLANT DENT R, V10, P1708
   Hansson S, 1999, J BIOMECH, V32, P829, DOI 10.1016/S0021 9290(99)00058 5
   Head WC, 1995, CLIN ORTHOP RELAT RE, P85
   Javed F, 2010, J DENT, V38, P612, DOI 10.1016/j.jdent.2010.05.013
   Kawaguchi J, 2001, J BONE MINER RES, V16, P260, DOI 10.1359/jbmr.2001.16.2.260
   Liñares A, 2011, CLIN ORAL IMPLAN RES, V22, P38, DOI 10.1111/j.1600 0501.2010.01988.x
   Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142 9612(98)00144 6
   Mangano C, 2009, J OSSEOINTEGRATION, V1, P2
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Marie PJ, J CELL PHYSL, V190, P297
   Puleo David A, 2006, Dent Clin North Am, V50, P323, DOI 10.1016/j.cden.2006.03.001
   RICCI JL, 1991, BONE BIOMATERIAL INTERFACE, P334
   Rosa AL, 2009, CLIN ORAL IMPLAN RES, V20, P472, DOI 10.1111/j.1600 0501.2008.01662.x
   Ryan G, 2006, BIOMATERIALS, V27, P2651, DOI 10.1016/j.biomaterials.2005.12.002
   Stangl R., 2001, European Cells & Materials, V2, P1
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955 0674(95)80102 2
   Wennerberg A, 2009, CLIN ORAL IMPLAN RES, V20, P172, DOI 10.1111/j.1600 0501.2009.01775.x
   Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955 0674(97)80155 X
   Zinger O, 2005, BIOMATERIALS, V26, P1837, DOI 10.1016/j.biomaterials.2004.06.035
   Zinger O, 2004, BIOMATERIALS, V25, P2695, DOI 10.1016/j.biomaterials.2003.09.111
NR 32
TC 12
Z9 12
U1 0
U2 16
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD APR JUN
PY 2013
VL 27
IS 2
BP 531
EP 541
PG 11
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA 189TH
UT WOS:000322290700024
PM 23830402
DA 2025 08 17
ER

PT J
AU Zhou, N
   Chen, CC
   Liu, YB
   Yu, ZL
   Bello, AK
   Chen, YH
   Liu, P
AF Zhou, Na
   Chen, Chengchuan
   Liu, Yubei
   Yu, Zhaolan
   Bello, Aminu K.
   Chen, Yanhua
   Liu, Ping
TI Assessing the quality of CKD care using process quality indicators: A
   scoping review
SO PLOS ONE
LA English
DT Article
ID CHRONIC KIDNEY DISEASE; OF CARE; MANAGEMENT; GUIDELINES; HEALTH
AB Introduction Assessing the quality of chronic kidney disease (CKD) management is crucial for optimal care and identifying care gaps. It is largely unknown which quality indicators have been widely used and the potential variations in the quality of CKD care. We sought to summarize process quality indicators for CKD and assess the quality of CKD care.Methods We searched databases including Medline (Ovid), PubMed, Cochrane Library, Web of Science, CINAHL, and Scopus from inception to June 20, 2024. Two reviewers screened the identified records, extracted relevant data, and classified categories and themes of quality indicators.Results We included 24 studies, extracted 30 quality indicators, and classified them into three categories with nine themes. The three categories included laboratory measures and monitoring of CKD progression and/or complications (monitoring of kidney markers, CKD mineral and bone disorder, anemia and malnutrition, electrolytes, and volume), use of guideline recommended therapeutic agents (use of medications), and attainment of therapeutic targets (blood pressure, glycemia, and lipids). Among the frequently reported quality indicators (in five or more studies), the following have a median proportion of study participants achieving that quality indicator exceeding 50%: monitoring of kidney markers (Scr/eGFR), use of medications (ACEIs/ARBs, avoiding non steroidal anti inflammatory drugs (NSAIDs)), management of blood pressure (with a target of <= 140/90, or without specific targets), and monitoring for glycated hemoglobin A1c (HbA1c)). The presence of diabetes, hypertension, cardiovascular disease, or proteinuria was associated with higher achievement in indicators of monitoring of kidney markers, use of recommended medications, and management of blood pressure and glycemia.Conclusion The quality of CKD management varies with quality indicators. A more consistent and complete reporting of key quality indicators is needed for future studies assessing CKD care quality.
C1 [Zhou, Na; Liu, Yubei; Chen, Yanhua; Liu, Ping] Southwest Med Univ, Sch Nursing, Luzhou, Sichuan Prov, Peoples R China.
   [Zhou, Na] Chengdu Med Coll, Affiliated Hosp 1, Dept Cardiol, Chengdu, Sichuan Prov, Peoples R China.
   [Chen, Chengchuan] Chengdu Qingbaijiang Dist Tradit Chinese Med Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China.
   [Yu, Zhaolan] Southwest Med Univ, Affiliated Hosp, Dept Nephrol, Luzhou, Sichuan Prov, Peoples R China.
   [Bello, Aminu K.] Univ Alberta, Fac Med & Dent, Div Nephrol & Immunol, Edmonton, AB, Canada.
   [Chen, Yanhua] Southwest Med Univ, Affiliated Hosp, Dept Nursing, Luzhou, Sichuan Prov, Peoples R China.
   [Liu, Ping] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada.
   [Liu, Ping] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.
C3 Southwest Medical University; Chengdu Medical College; Southwest Medical
   University; University of Alberta; Southwest Medical University;
   University of Calgary; University of Calgary
RP Chen, YH (通讯作者)，Southwest Med Univ, Sch Nursing, Luzhou, Sichuan Prov, Peoples R China.
EM chen_yanhua25@163.com; ping.liu1@ucalgary.ca
RI Liu, Ping/L 9975 2014; Bello, Aminu/D 2213 2013
OI Liu, Ping/0000 0003 2238 7528; 
FU Kidney Research Scientist Core Education and National Training
   (KRESCENT) Program New Investigator Award [FRN 2023KNIA 1058404]; Kidney
   Foundation of Canada and Canadian Institutes of Health Research
FX PL was supported by a Kidney Research Scientist Core Education and
   National Training (KRESCENT) Program New Investigator Award (FRN
   2023KNIA 1058404), which is co sponsored by the Kidney Foundation of
   Canada and Canadian Institutes of Health Research).
CR Agvall BA O., 2023, Characteristics, management and outcomes in patients with CKD in a healthcare region in Sweden: a population based, observational study
   Allen AS, 2011, J GEN INTERN MED, V26, P386, DOI 10.1007/s11606 010 1523 6
   Ang GY, 2013, ANN ACAD MED SINGAP, V42, P632
   [Anonymous], 2021, KIDNEY INT, V99, pS26, DOI 10.1016/j.kint.2020.11.003
   [Anonymous], 2012, Kidney Int Suppl, V2, P283
   [Anonymous], 2021, NICE guideline NG203
   Bansal S, 2020, KIDNEY360, V1, P904, DOI 10.34067/KID.0000532020
   Bello AK, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10704
   Bezabhe WM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030783
   Bikbov B, 2020, LANCET, V395, P709, DOI 10.1016/S0140 6736(20)30045 3
   Chen TK, 2019, JAMA J AM MED ASSOC, V322, P1294, DOI 10.1001/jama.2019.14745
   de Boer IH, 2022, KIDNEY INT, V102, pS1, DOI 10.1016/j.kint.2022.06.008
   Dzau VJ, 2017, JAMA J AM MED ASSOC, V317, P1461, DOI 10.1001/jama.2017.1964
   Eckardt KU, TRENDS PERSP IMPR Q, P1523
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Expert Group on Kidney Clinical Quality Control Center in Shanghai, 2022, Chin J Nephrol, V38, P735, DOI [10.19538/j.nk2022090108, DOI 10.19538/J.NK2022090108]
   Fukuma S, 2020, MED CARE, V58, P625, DOI 10.1097/MLR.0000000000001301
   Hemmelgarn BR, 2010, JAMA J AM MED ASSOC, V303, P423, DOI 10.1001/jama.2010.39
   Herget Rosenthal S, 2006, INT J CLIN PRACT, V60, P941, DOI 10.1111/j.1742 1241.2006.01028.x
   Jaeger L, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0272662
   Jamaluddin Jazlan, 2021, Malays Fam Physician, V16, P68, DOI 10.51866/oa1171
   Kalay Z, 2023, CLIN KIDNEY J, V16, P52, DOI 10.1093/ckj/sfac189
   Khanam MA, 2019, AUST J GEN PRACT, V48, P132, DOI 10.31128/AJGP 07 18 4630
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, Kidney Int, V3, P1, DOI [DOI 10.1016/J.KINT.2023.10.018, DOI 10.1038/KISUP.2012.73]
   Levin A, 2008, CAN MED ASSOC J, V179, P1154, DOI 10.1503/cmaj.080351
   Ling JM, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.869899
   Liu P, 2021, JAMA INTERN MED, V181, P1359, DOI 10.1001/jamainternmed.2021.4813
   Lopez Heydeck Sandra Maricruz, 2020, Rev Med Inst Mex Seguro Soc, V58, P305, DOI 10.24875/RMIMSS.M20000035
   Luk AO, 2016, DIABETIC MED, V33, P1230, DOI 10.1111/dme.13014
   Manns L, 2017, CLIN J AM SOC NEPHRO, V12, P727, DOI 10.2215/CJN.08720816
   Mende CW, 2022, ADV THER, V39, P148, DOI 10.1007/s12325 021 01994 2
   Mendu ML, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882 019 1260 y
   Mendu ML, 2014, CLIN J AM SOC NEPHRO, V9, P1526, DOI 10.2215/CJN.01660214
   Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874 018 0611 x
   Nash Danielle M, 2017, Can J Kidney Health Dis, V4, p2054358117703059, DOI 10.1177/2054358117703059
   Neale EP, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882 020 01731 x
   Nihat A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen 2015 008480
   Pasternak M, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.25821
   Pugh D, 2019, DRUGS, V79, P365, DOI 10.1007/s40265 019 1064 1
   Ricardo AC, 2016, J GEN INTERN MED, V31, P22, DOI 10.1007/s11606 015 3452 x
   Roger M, 2022, NEFROLOGIA, V42, P65, DOI 10.1016/j.nefro.2021.09.004
   Rovin BH, 2021, KIDNEY INT, V100, pS1, DOI 10.1016/j.kint.2021.05.021
   Rucker D, 2011, KIDNEY INT, V79, P210, DOI 10.1038/ki.2010.376
   Samal L, 2014, BMC NEPHROL, V15, DOI 10.1186/1471 2369 15 70
   Singh S, 2023, CURR OPIN NEPHROL HY, V32, P434, DOI 10.1097/MNH.0000000000000907
   Smits KPJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 025784
   Smits KPJ, 2016, INT J CLIN PRACT, V70, P861, DOI 10.1111/ijcp.12878
   Sperati CJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221325
   Stevens PE, 2024, KIDNEY INT, V105, pS117, DOI 10.1016/j.kint.2023.10.018
   Swartling O, 2022, J AM SOC NEPHROL, V33, P1903, DOI 10.1681/ASN.2022030373
   Tesfaye WH, 2021, J NEPHROL, V34, P1091, DOI 10.1007/s40620 020 00895 x
   Thomas MC, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.18
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18 0850
   Tsai WC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003013
   Tu Karen, 2017, CMAJ Open, V5, pE74, DOI 10.9778/cmajo.20160113
   Tylicki L, 2015, J RENIN ANGIO ALDO S, V16, P145, DOI 10.1177/1470320314550018
   Van den Bulck SA, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882 020 01788 8
   van Dipten C, 2017, FAM PRACT, V34, P459, DOI 10.1093/fampra/cmx002
   Van Gelder VA, 2016, SCAND J PRIM HEALTH, V34, P73, DOI 10.3109/02813432.2015.1132885
   Vassalotti JA, 2016, AM J MED, V129, P153, DOI 10.1016/j.amjmed.2015.08.025
   Weckmann GFC, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882 018 1048 5
   Yuen J, 2023, AM J KIDNEY DIS, V81, P247, DOI 10.1053/j.ajkd.2022.07.009
NR 63
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2024
VL 19
IS 12
AR e0309973
DI 10.1371/journal.pone.0309973
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA P1F0N
UT WOS:001375443900028
PM 39656690
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Koonrungsesomboon, N
   Teekachunhatean, S
   Chansakaow, S
   Hanprasertpong, N
AF Koonrungsesomboon, Nut
   Teekachunhatean, Supanimit
   Chansakaow, Sunee
   Hanprasertpong, Nutthiya
TI Clinical Efficacy and Safety of Yellow Oil Formulations 3 and 4 versus
   Indomethacin Solution in Patients with Symptomatic Osteoarthritis of the
   Knee: A Randomized Controlled Trial
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OUTCOME SCORE KOOS; HIP
   OSTEOARTHRITIS; VISUAL ANALOG; RATING SCALE; PAIN; METAANALYSIS;
   CRITERIA; RECOMMENDATIONS; EXPRESSION
AB Background. Topical nonsteroidal anti inflammatory drugs (NSAIDs) are widely prescribed for the treatment of symptomatic osteoarthritis (OA) of the knee. However, searching for alternatives such as locally available medicinal herbs to manage OA knee pain remains of clinical value. The objective of the present study was to evaluate the efficacy and safety of two yellow oil formulations in patients with OA of the knee.Methods. This prospective, randomized, single blind, active controlled, noninferiority study enrolled 102 patients with OA of the knee. Eligible patients were randomly assigned to apply either yellow oil formulation 3 (YOF3), yellow oil formulation 4 (YOF4), or indomethacin solution (INDO) topically four times daily for four weeks. Outcomes were assessed on a biweekly basis. The primary efficacy outcome measure was a 100 mm visual analog scale (VAS) of pain, while secondary endpoints included knee function, physical performance assessments, and safety parameters. Modified intention to treat and per protocol analyses were applied. Assessment of noninferiority was done with a prespecified margin of 10 mm for VAS pain.Results. Of 102 patients enrolled, 86 completed the study: 29/34 in the YOF3 group, 25/34 in the YOF4 group, and 32/34 in the INDO group. The absolute reduction in VAS pain at the final evaluation was  25.06 +/  13.91,  18.50 +/  16.06, and  23.38 +/  10.05 mm in the YOF3, YOF4, and INDO groups, respectively (p=0.169). Only YOF3 was found to be noninferior to INDO. Other efficacy outcomes were significantly improved in all three groups. All the interventions were well tolerated; no skin rash was observed in any of the three groups.Conclusions. YOF3 was shown to be noninferior to INDO in relieving knee pain and should be considered an alternative for the treatment of symptomatic OA of the knee. Further research into the mechanism of action of YOF3 and its long term efficacy and safety is required.
C1 [Koonrungsesomboon, Nut; Teekachunhatean, Supanimit; Hanprasertpong, Nutthiya] Chiang Mai Univ, Fac Med, Dept Pharmacol, Chiang Mai 50200, Thailand.
   [Koonrungsesomboon, Nut] Chiang Mai Univ, Musculoskeletal Sci & Translat Res Ctr, Chiang Mai 50200, Thailand.
   [Teekachunhatean, Supanimit] Chiang Mai Univ, Fac Med, Ctr Thai Tradit & Complementary Med, Chiang Mai 50200, Thailand.
   [Chansakaow, Sunee] Chiang Mai Univ, Dept Pharmaceut Sci, Chiang Mai 50200, Thailand.
   [Chansakaow, Sunee] Chiang Mai Univ, Fac Pharm, Med Plant Innovat Ctr, Chiang Mai 50200, Thailand.
C3 Chiang Mai University; Chiang Mai University; Chiang Mai University;
   Chiang Mai University; Chiang Mai University
RP Hanprasertpong, N (通讯作者)，Chiang Mai Univ, Fac Med, Dept Pharmacol, Chiang Mai 50200, Thailand.
EM nutthiya.h@cmu.ac.th
RI Koonrungsesomboon, Nut/L 2805 2013; Chansakaow, Sunee/AAQ 6551 2020
OI Koonrungsesomboon, Nut/0000 0003 4649 597X; Hanprasertpong,
   Nutthiya/0000 0002 3739 4723
FU Department of Thai Traditional and Alternative Medicine, Ministry of
   Public Health
FX The authors are grateful to the editorial assistance of Dr. G. Lamar
   Robert, English language consultant, the Department of Pharmacology,
   Faculty of Medicine, Chiang Mai University. The authors would also like
   to extend their thanks to Ms. Sujitra Techatoei for her secretarial
   assistance. This work was conducted under the project of Northern Herb
   Innovation Park in 2016 and was supported by the Department of Thai
   Traditional and Alternative Medicine, Ministry of Public Health.
CR Alghadir AH, 2018, J PAIN RES, V11, P851, DOI 10.2147/JPR.S158847
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   [Anonymous], 2010, Mahasarakham Hospital Journal
   Askari A, 2019, COMPLEMENT THER MED, V47, DOI 10.1016/j.ctim.2019.08.017
   Bachiega TF, 2012, J PHARM PHARMACOL, V64, P610, DOI 10.1111/j.2042 7158.2011.01440.x
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Bennell K, 2011, ARTHRIT CARE RES, V63, pS350, DOI 10.1002/acr.20538
   Bigdeli Shamloo M. B., 2015, ANESTH PAIN MED, V5, DOI 10.5812/aapm.25085v2
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Bjordal JM, 2007, EUR J PAIN, V11, P125, DOI 10.1016/j.ejpain.2006.02.013
   Cameron M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010538
   Cameron M, 2009, PHYTOTHER RES, V23, P1497, DOI 10.1002/ptr.3007
   Chaipinyo K., 2009, THAI J PHYS THER, V31, P67
   Chaiwongsa R, 2013, AFR J TRADIT COMPLEM, V10, P40, DOI 10.4314/ajtcam.v10i1.7
   Chang SH, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/3165125
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chrubasik JE, 2007, PHYTOTHER RES, V21, P675, DOI 10.1002/ptr.2142
   Collins NJ, 2016, OSTEOARTHR CARTILAGE, V24, P1317, DOI 10.1016/j.joca.2016.03.010
   Collins NJ, 2011, ARTHRIT CARE RES, V63, pS208, DOI 10.1002/acr.20632
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140 6736(17)31744 0
   Deng ZH, 2016, CLIN RHEUMATOL, V35, P1253, DOI 10.1007/s10067 015 3021 z
   Dougados M, 2000, OSTEOARTHR CARTILAGE, V8, P395, DOI 10.1053/joca.2000.0361
   Dworkin RH, 2011, OSTEOARTHR CARTILAGE, V19, P483, DOI 10.1016/j.joca.2011.02.020
   Gregori D, 2018, JAMA J AM MED ASSOC, V320, P2564, DOI 10.1001/jama.2018.19319
   Almeida JRGD, 2013, SCI WORLD J, DOI 10.1155/2013/808460
   Hanprasertpong N, 2017, J HERB MED, V7, P18, DOI 10.1016/j.hermed.2017.01.001
   Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543
   Honvo G, 2019, DRUG AGING, V36, P45, DOI 10.1007/s40266 019 00661 0
   Huang ZY, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1951 6
   Jeenapongsa R, 2003, J ETHNOPHARMACOL, V87, P143, DOI 10.1016/S0378 8741(03)00098 9
   Juergens U R, 1998, Eur J Med Res, V3, P539
   Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783
   Karcioglu O, 2018, AM J EMERG MED, V36, P707, DOI 10.1016/j.ajem.2018.01.008
   Kim SS, 2003, LIFE SCI, V73, P337, DOI 10.1016/S0024 3205(03)00288 1
   Kolasinski SL, 2019, Arthritis Care Res. (Hoboken), V72, P149
   Koonrungsesomboon N, 2016, PHYTOMEDICINE, V23, P1090, DOI 10.1016/j.phymed.2015.10.017
   Lee HJ, 2006, J ETHNOPHARMACOL, V103, P208, DOI 10.1016/j.jep.2005.08.009
   Lee S, 2018, KOREAN J ANESTHESIOL, V71, P353, DOI 10.4097/kja.d.18.00242
   Liao JC, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/429320
   Lin FY, 2004, BMJ BRIT MED J, V329, P324, DOI 10.1136/bmj.38159.639028.7C
   Litwic A, 2013, BRIT MED BULL, V105, P185, DOI 10.1093/bmb/lds038
   McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005
   Murphy L, 2008, ARTHRIT RHEUM ARTHR, V59, P1207, DOI 10.1002/art.24021
   Panthong A, 1997, PHYTOMEDICINE, V4, P207, DOI 10.1016/S0944 7113(97)80069 4
   PANTHONG A, 1986, J ETHNOPHARMACOL, V18, P213, DOI 10.1016/0378 8741(86)90001 2
   Persson MSM, 2020, RHEUMATOLOGY, V59, P2207, DOI 10.1093/rheumatology/keaa113
   Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001
   Rafanan BS, 2018, PAIN MANAG, V8, P115, DOI 10.2217/pmt 2017 0047
   Scott DL, 2000, RHEUMATOLOGY, V39, P1095, DOI 10.1093/rheumatology/39.10.1095
   Steinmeyer J, 2018, ORTHOP REV, V10, P147, DOI 10.4081/or.2018.7782
   Sun L, 2016, J ETHNOPHARMACOL, V194, P904, DOI 10.1016/j.jep.2016.10.064
   Tsai CC, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/297458
   Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905
   Wang XZ, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/171706
   World Medical Association Declaration of Helsinki, 2013, Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, V310, P2191, DOI 10.1001/jama.2013.281053
   Zeng C, 2018, BRIT J SPORT MED, V52, P642, DOI 10.1136/bjsports 2017 098043
   Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis 2015 208387
NR 58
TC 11
Z9 11
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD JUL 25
PY 2020
VL 2020
AR 5782178
DI 10.1155/2020/5782178
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA MZ4VE
UT WOS:000559122000002
PM 32774422
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Melo, FG
   Ocarino, NM
   Reis, AMS
   Gimeno, EJ
   Massone, AR
   Melo, MM
   Botelho, AFM
   Stehmann, JR
   Serakides, R
AF Melo, Fabricio Gomes
   Ocarino, Natalia Melo
   Reis, Amanda Maria Sena
   Gimeno, Eduardo Juan
   Massone, Adriana Raquel
   Melo, Marilia Martins
   Botelho, Ana Flavia Machado
   Stehmann, Joao Renato
   Serakides, Rogeria
TI The Solanum glaucophyllum Desf. extract reduces
   mineralized matrix synthesis in osteogenically differentiated rat
   mesenchymal stem cells in vitro
SO JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION
LA English
DT Article
DE calcinogenic plant; enzootic calcinosis; osteogenic differentiation;
   stem cell
ID HUMAN ADIPOSE TISSUE; ENZOOTIC CALCINOSIS; BONE MARROW;
   NIEREMBERGIA VEITCHII; STROMAL CELLS; MALACOXYLON;
   1,25 DIHYDROXYCHOLECALCIFEROL; CALCIUM; OSTEOPONTIN; TOXICITY
AB The Solanum glaucophyllum Desf. has been used to treat and prevent diseases in human and veterinary medicine. On the other hand, plant poisoning causes several bone diseases, among them osteoporosis, which is characterized by osteoblastic hypoplasia. Because the osteoblast is a cell derived from the differentiation of mesenchymal stem cells (MSCs) from bone marrow, the hypothesis is that the plant reduces the osteogenic differentiation of MSCs. The objective of this study was to evaluate the effects of S. glaucophyllum Desf. extract on MSCs cultured in osteogenic differentiation medium. We determined by liquid chromatography that 1 ml of plant extract contained 3.8 mu l of 1,25(OH)(2)D 3 (calcitriol). Four groups of MSCs cultivated in osteogenic medium were evaluated as follows: (a) treated with 100 mu l of extract/L containing 0.4 mu g/L of calcitriol; (b) treated with 1 ml of extract/L containing 4 mu g/L of calcitriol; (c) treated with 5 ml of extract/L containing 20 mu g/L of calcitriol; and (d) a control group without extract. We performed alkaline phosphatase activity assay, analysis of MTT conversion to formazan, and evaluated the percentage of cells, and number and diameter of mineralization nodules. The expression of gene transcripts for osteopontin, bone sialoprotein and BMP 2 was analysed by RT qPCR. After 21 days, there was a significant reduction in MTT conversion to formazan in treated groups, of the cellularity in the group with 5 ml of extract/L, and in the number and size of mineralization nodules in the groups treated with 1 and 5 ml of extract/L. The 5 ml extract/L concentration also reduced transcript expression of osteopontin. It is concluded that S. glaucophyllum Desf. at concentrations of 1 and 5 ml extract/L reduced mineralized matrix synthesis in MSCs cultivated in osteogenic differentiation medium, which suggests that this is one of the mechanisms by which osteoporosis occurs in intoxicated animals.
C1 [Melo, Fabricio Gomes; Ocarino, Natalia Melo; Reis, Amanda Maria Sena; Melo, Marilia Martins; Stehmann, Joao Renato; Serakides, Rogeria] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Gimeno, Eduardo Juan; Massone, Adriana Raquel] Univ La Plata, La Plata, Argentina.
   [Botelho, Ana Flavia Machado] Univ Fed Goias, Goiania, Go, Brazil.
C3 Universidade Federal de Minas Gerais; National University of La Plata;
   Universidade Federal de Goias
RP Serakides, R (通讯作者)，Univ Fed Minas Gerais Belo Horizonte, Escola Vet, NCT TCA, Ave Antonio Carlos 6627, BR 31270901 Belo Horizonte, MG, Brazil.
EM serakidesufmg@gmail.com
RI Melo, Marília/I 8283 2018; Reis, Amanda/AAQ 5039 2020; Stehmann,
   Joao/C 2611 2009; Serakides, Rogéria/C 7571 2016; Stehmann, Joao
   Renato/C 2611 2009; Serakides, Rogeria/C 7571 2016
OI Reis, AlessanRSS/0000 0001 8486 7469; Stehmann, Joao
   Renato/0000 0002 9504 5441; Serakides, Rogeria/0000 0001 5374 6242
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
CR Alves EGL, 2016, PESQUI VET BRASIL, V36, P21, DOI 10.1590/S0100 736X201600130004
   ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   Bachmann H, 2013, BRIT POULTRY SCI, V54, P642, DOI 10.1080/00071668.2013.825692
   Bachmann H, 2013, J STEROID BIOCHEM, V136, P333, DOI 10.1016/j.jsbmb.2012.09.016
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Boeloni JN, 2009, HORM RES, V72, P88, DOI 10.1159/000232161
   Boeloni JN, 2013, PATHOL RES PRACT, V209, P44, DOI 10.1016/j.prp.2012.10.004
   Dobereiner J., 1971, Pesquisa Agropecuaria Brasileira, Serie Veterinaria, V6, P91
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fricke R., 1985, UNTERSUCHUNGEN PROPH, P214
   Gallego S. E., 1979, RIA INTA, V14, P67
   GAST DR, 1979, J DAIRY SCI, V62, P1009, DOI 10.3168/jds.S0022 0302(79)83364 0
   Guedes KMR, 2011, PESQUISA VET BRASIL, V31, P643, DOI 10.1590/S0100 736X2011000800002
   HASCHEK WM, 1978, CORNELL VET, V68, P324
   HERRATH DV, 1974, DEUT MED WOCHENSCHR, V99, P2407
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   LISKOVAKIAR M, 1978, CALC TISS RES, V26, P39, DOI 10.1007/BF02013232
   LOU YR, 2017, SCI REP, V7, P1
   MAUTALEN CA, 1977, CALC TISS RES, V22, P534
   McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097 0029(19960201)33:2<141::AID JEMT5>3.0.CO;2 W
   Micheloud J.F., 2012, Rev Med Vet, V93, P59
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   NOGUEIRADOSSANTOS M, 1976, CORNELL VET, V66, P566
   Ocarino NM, 2008, NITRIC OXIDE BIOL CH, V19, P320, DOI 10.1016/j.niox.2008.08.004
   Odriozola ER, 2018, J VET DIAGN INVEST, V30, P286, DOI 10.1177/1040638717746447
   OKADA KA, 1977, ECON BOT, V31, P225, DOI 10.1007/BF02866593
   PETERLIK M, 1975, FED PROC, V34, P887
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Posa F, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9150819
   PUCHE RC, 1974, CALC TISS RES, V16, P219, DOI 10.1007/BF02008229
   RAPPAPORTT I, 1977, PHYTOCHEMISTRY, V16, P1115, DOI 10.1016/S0031 9422(00)86765 5
   RIETCORREA F, 1981, PESQUI AGROPECU BRAS, V16, P727
   RIETCORREA F, 1987, PESQUI VET BRASIL, V7, P85
   ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088
   Reis AMS, 2016, CONNECT TISSUE RES, V57, P131, DOI 10.3109/03008207.2015.1117075
   STERN PH, 1978, MOL PHARMACOL, V14, P357
   Vieites FM, 2018, SEMIN CIENC AGRAR, V39, P2205, DOI 10.5433/1679 0359.2018v39n5p2205
   Vieites FM, 2014, SEMIN CIENC AGRAR, V35, P1617, DOI 10.5433/1679 0359.2014v35n3p1617
   WASSERMAN RH, 1976, SCIENCE, V194, P853, DOI 10.1126/science.982048
   WORKER NA, 1967, NATURE, V215, P72, DOI 10.1038/215072a0
   Zhou YS, 2006, CHINESE MED J PEKING, V119, P1278, DOI 10.1097/00029330 200608010 00008
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 43
TC 3
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0931 2439
EI 1439 0396
J9 J ANIM PHYSIOL AN N
JI J. Anim. Physiol. Anim. Nutr.
PD SEP
PY 2020
VL 104
IS 5
BP 1256
EP 1266
DI 10.1111/jpn.13366
EA APR 2020
PG 11
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Veterinary Sciences
GA PI2QE
UT WOS:000525997500001
PM 32281708
DA 2025 08 17
ER

PT J
AU Kafka, M
   Gruber, R
   Neuwirt, H
   Ladurner, M
   Eder, IE
AF Kafka, Mona
   Gruber, Rebecca
   Neuwirt, Hannes
   Ladurner, Michael
   Eder, Iris E.
TI Long Term Treatment with Simvastatin Leads to Reduced Migration Capacity
   of Prostate Cancer Cells
SO BIOMEDICINES
LA English
DT Article
DE statins; prostate cancer; metastasis; cell migration; adhesion;
   cholesterol; long term treatment
ID NATIONAL HEALTH; STATIN DRUGS; PROGRESSION; RISK; CHOLESTEROL;
   BIOMARKERS; THERAPY; ANTIGEN; TIME
AB Statins have been shown to improve survival of metastatic prostate cancer (mPCa). Nevertheless, their therapeutic use is still under debate. In the present study, we investigated the short term effects of three different statins (simvastatin, atorvastatin and rosuvastatin) in various PCa cell lines mimicking androgen sensitive and  insensitive PCa. Moreover, we generated three new PCa cell lines (LNCaPsim, ABLsim, PC 3sim) that were cultured with simvastatin over several months. Our data showed that the three statins expressed highly diverse short term effects, with the strongest growth inhibitory effect from simvastatin in PC 3 cells and almost no effect from rosuvastatin in any of the cell lines. Long term treatment with simvastatin resulted in a loss of response to statins in all three cell lines, which was associated with an upregulation of cholesterol and fatty acid pathways as revealed through RNA sequencing. Despite that, long term treated cells exhibited diminished spheroid growth and significantly reduced migration capacity per se and to differentiated osteoclasts. These findings were strengthened by reduced expression of genes annotated to cell adhesion and migration after long term simvastatin treatment. Notably, mPCa patients taking statins were found to have lower numbers of circulating tumor cells in their blood with reduced levels of PSA and alkaline phosphatase. Our data suggest that long term usage of simvastatin hampers the metastatic potential of PCa cells and may therefore be a potential therapeutic drug for mPCa.
C1 [Kafka, Mona; Gruber, Rebecca; Ladurner, Michael; Eder, Iris E.] Med Univ Innsbruck, Dept Urol, Anichstr 35, A 6020 Innsbruck, Austria.
   [Neuwirt, Hannes] Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, Anichstr 35, A 6020 Innsbruck, Austria.
C3 Medical University of Innsbruck; Medical University of Innsbruck
RP Eder, IE (通讯作者)，Med Univ Innsbruck, Dept Urol, Anichstr 35, A 6020 Innsbruck, Austria.
EM iris.eder@i med.ac.at
RI ; Neuwirt, Hannes/AAF 1090 2019
OI Ladurner, Michael/0000 0003 2396 9175; Gruber,
   Rebecca/0009 0008 9003 5093; Neuwirt, Hannes/0000 0003 1064 0098
CR Althanoon Z., 2020, Syst Rev Pharm, V11, P167, DOI 10.31838/srp.2020.7.27
   Bluemn EG, 2012, CURR OPIN ONCOL, V24, P251, DOI 10.1097/CCO.0b013e32835105b3
   Pavan LMC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130476
   Caro Maldonado A, 2018, ONCOTARGET, V9, P1494, DOI 10.18632/oncotarget.22217
   Chang CC, 2011, PROSTATE, V71, P1818, DOI 10.1002/pros.21401
   Chang SL, 2010, J CLIN ONCOL, V28, P3951, DOI 10.1200/JCO.2009.27.9406
   Craig EL, 2022, PROSTATE CANCER P D, V25, P641, DOI 10.1038/s41391 022 00554 1
   Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684
   Dai C, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a030452
   Flick ED, 2007, CANCER EPIDEM BIOMAR, V16, P2218, DOI 10.1158/1055 9965.EPI 07 0197
   Geng JH, 2022, PROSTATE CANCER P D, V25, P320, DOI 10.1038/s41391 022 00494 w
   Göbel A, 2016, CANCER LETT, V375, P162, DOI 10.1016/j.canlet.2016.03.004
   Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010
   Hamilton Robert J, 2008, J Natl Cancer Inst, V100, P1511, DOI 10.1093/jnci/djn362
   Harshman LC, 2015, JAMA ONCOL, V1, P495, DOI 10.1001/jamaoncol.2015.0829
   Heidegger I, 2017, TARGET ONCOL, V12, P37, DOI 10.1007/s11523 016 0461 6
   Holstein SA, 2006, CANCER CHEMOTH PHARM, V57, P155, DOI 10.1007/s00280 005 0013 8
   Jacobs EJ, 2007, CANCER EPIDEM BIOMAR, V16, P2213, DOI 10.1158/1055 9965.EPI 07 0448
   Kafka M, 2020, UROL ONCOL SEMIN ORI, V38, P801, DOI 10.1016/j.urolonc.2020.05.025
   Ladurner M, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081004
   Longo J, 2019, MOL METAB, V25, P119, DOI 10.1016/j.molmet.2019.04.003
   Mangelinck A, 2021, CANCERS, V13, DOI 10.3390/cancers13225869
   Mariano R, 2022, EINSTEIN SAO PAULO, V20, DOI [10.31744/einstein_journal/2022RW6339, 10.31744/einstein_journal/2022rw6339]
   Menter DG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028813
   Mondul AM, 2010, CANCER CAUSE CONTROL, V21, P671, DOI 10.1007/s10552 009 9494 9
   Neuwirt H, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 019 0505 5
   Peltomaa AI, 2021, PROSTATE CANCER P D, V24, P917, DOI 10.1038/s41391 021 00351 2
   Platz EA, 2006, JNCI J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499
   Pon D, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883 014 0474 5
   Roussy G., 2021, NCT03819101
   Sekine Y, 2018, ONCOL LETT, V15, P3167, DOI 10.3892/ol.2017.7721
   Siltari A, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen 2021 050264
   Syvälä H, 2016, BIOCHEM BIOPH RES CO, V481, P46, DOI 10.1016/j.bbrc.2016.11.021
   Xue LY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01510
   Yin P, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000028513
   Zhou CK, 2016, INT J CANCER, V138, P1388, DOI 10.1002/ijc.29894
   Zhu ZM, 2022, INVESTIG CLIN UROL, V63, P350, DOI 10.4111/icu.20210411
NR 37
TC 9
Z9 11
U1 0
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD JAN
PY 2023
VL 11
IS 1
AR 29
DI 10.3390/biomedicines11010029
PG 18
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 7X7QW
UT WOS:000914393200001
PM 36672537
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pasandideh, Z
   Tajabadi, M
   Javadpour, J
   Mirkazemi, SM
AF Pasandideh, Zahra
   Tajabadi, Maryam
   Javadpour, Jafar
   Mirkazemi, Seyed Mohammad
TI The effects of Fe<SUP>3+</SUP> and Co<SUP>2+</SUP> substitution in
   Ca10 x yFexCoy(PO4)6</s
   ub>(OH)2 hydroxyapatite nanoparticles: Magnetic,
   antibacterial, and improved drug release behavior
SO CERAMICS INTERNATIONAL
LA English
DT Article
DE Nano hydroxyapatite (nHA); Hydrothermal; Iron doped hydroxyapatite;
   Cobalt doped hydroxyapatite; Dually doped hydroxyapatite; Antibacterial;
   Drug release; Magnetic properties
ID DOPED HYDROXYAPATITE; SILVER NANOPARTICLES; HYDROTHERMAL SYNTHESIS;
   HYPERTHERMIA; COMPOSITE; MECHANISM; IONS; IRON; ZN
AB The mineral constituent of the bone contains non stoichiometric hydroxyapatite with various substitutional ions. Iron (Fe) and cobalt (Co) are fundamental cofactors, which influence cell respiration and mitosis, respectively. In this study, undoped, Fe3+ , Co2+ , and dually doped HA nanoparticles (NPs) were synthesized by the hydrothermal method. The molar ratio was varied between 0.02 and 0.2. Samples were analyzed using X ray diffraction (XRD), field emission scanning electron microscopy (FESEM), vibrating sample magnetometry (VSM), Fourier transformed infrared spectroscopy (FT IR), inductively coupled plasma optical emission spectroscopy (ICP OES), and biological assessment. XRD results confirmed the formation of the hexagonal HA crystal structure. The crystallite size was reduced from 34.6 nm to 4.4 nm. Also, the c axis dimension and the degree of crystallinity were reduced in all the doped samples. The FESEM results showed a change of morphology from rod like in the undoped nHA into a sphere like morphology in the doped samples. With the addition of ferromagnetic dopant, the magnetic behavior of samples altered from diamagnetic to paramagnetic like and ferromagnetic behavior. Bioactivity assessment indicated the formation of the HA particle on the surface of all synthesized materials. The antibacterial test demonstrated antibacterial activity against gram negative ( ) E. coli. Moreover, the antibiotic impregnated samples had a synergistic effect on both gram ( ), E. coli, as well as gram (+), S. aureus, bacteria. The MTT evaluation revealed the enhanced cell viability of osteoblast like cells in the dually doped NPs. Based on this survey, we can strongly emphasize the potential for bone bioactivity and antibacterial feature of these newly developed samples.
C1 [Pasandideh, Zahra; Tajabadi, Maryam; Javadpour, Jafar; Mirkazemi, Seyed Mohammad] Iran Univ Sci & Technol IUST, Sch Met & Mat Engn, Tehran 16844, Iran.
C3 Iran University Science & Technology
RP Tajabadi, M (通讯作者)，Iran Univ Sci & Technol IUST, Sch Met & Mat Engn, Tehran 16844, Iran.
EM mtajabadi@iust.ac.ir
RI ; Tajabadi, Maryam/X 5243 2018; Javadpour, Jafar/X 5715 2018; Mirkazemi,
   Seyed Mohammad/T 5744 2018
OI Mirkazemi, S. Mohammad/0000 0002 4899 891X; 
CR Allenstein U, 2015, ACS APPL MATER INTER, V7, P15331, DOI 10.1021/acsami.5b03189
   [Anonymous], 2018, 19749 ISODIS
   Arsad MS, 2011, 2 INT C BIOT FOOD SC
   Bajpai AK, 2011, J MATER SCI MATER M, V22, P357, DOI 10.1007/s10856 010 4214 2
   Balakrishnan S, 2019, J AUST CERAM SOC, V55, P953, DOI 10.1007/s41779 019 00307 9
   Barmparis GD, 2015, BEILSTEIN J NANOTECH, V6, P361, DOI 10.3762/bjnano.6.35
   Basu S, 2018, ACS BIOMATER SCI ENG, V4, P857, DOI 10.1021/acsbiomaterials.7b00813
   Berzina Cimdina L, 2012, INFRARED SPECTROSCOPY   MATERIALS SCIENCE, ENGINEERING AND TECHNOLOGY, P123
   Cacciotti I, 2009, J EUR CERAM SOC, V29, P2969, DOI 10.1016/j.jeurceramsoc.2009.04.038
   Cairo G, 2006, GENES NUTR, V1, P25, DOI 10.1007/BF02829934
   Cawthray JF, 2015, INORG CHEM, V54, P1440, DOI 10.1021/ic502425e
   Chandra VS, 2012, ACS APPL MATER INTER, V4, P1200, DOI 10.1021/am300140q
   Cho HY, 2018, ACS APPL MATER INTER, V10, P9301, DOI 10.1021/acsami.7b19255
   Czarnek K, 2015, CENT EUR J IMMUNOL, V40, P236, DOI 10.5114/ceji.2015.52837
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Devi Lamabam Sophiya, 2012, Mycobiology, V40, P27, DOI 10.5941/MYCO.2012.40.1.027
   Dorozhkin Sergey V, 2011, Biomatter, V1, P121, DOI 10.4161/biom.18790
   Eanes E., 1998, CALCIUM PHOSPHATES B, P21, DOI [10.1007/978 1 4615 5517 92, DOI 10.1007/978 1 4615 5517 9_2]
   Elayaraja K, 2012, MATER CHEM PHYS, V134, P464, DOI 10.1016/j.matchemphys.2012.03.018
   Elkabouss K, 2004, J CATAL, V226, P16, DOI 10.1016/j.jcat.2004.05.007
   Farzadi A, 2014, CERAM INT, V40, P6021, DOI 10.1016/j.ceramint.2013.11.051
   Hezma, 2015, PHYS SCI INT J, V7, P137, DOI [10.9734/PSIJ/2015/18676, DOI 10.9734/PSIJ/2015/18676]
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Iafisco M, 2013, CHEM MATER, V25, P2610, DOI 10.1021/cm4007298
   Iannotti V, 2017, INORG CHEM, V56, P4446, DOI 10.1021/acs.inorgchem.6b03143
   Iwasaki T, 2013, INT J MOL SCI, V14, P9365, DOI 10.3390/ijms14059365
   Jankovic A, 2015, J ALLOY COMPD, V624, P148, DOI 10.1016/j.jallcom.2014.11.078
   Joshy MIA, 2011, CURR APPL PHYS, V11, P1100, DOI 10.1016/j.cap.2011.02.003
   Kabir S.F., 2012, BANGLADESH J SCI IND, V47, P1
   Ke Qingdong, 2005, Int J Environ Res Public Health, V2, P10, DOI 10.3390/ijerph2005010010
   Kim HM, 2004, J ROY SOC INTERFACE, V1, P17, DOI 10.1098/rsif.2004.0003
   Kramer E, 2014, CERAM INT, V40, P13471, DOI 10.1016/j.ceramint.2014.05.072
   Kulanthaivel S, 2016, MAT SCI ENG C MATER, V58, P648, DOI 10.1016/j.msec.2015.08.052
   Kulanthaivel S, 2015, CERAM INT, V41, P11323, DOI 10.1016/j.ceramint.2015.05.090
   Laurencin D, 2011, BIOMATERIALS, V32, P1826, DOI 10.1016/j.biomaterials.2010.11.017
   Liao JA, 2010, INT J NANOMED, V5, P261
   Lieu Pauline T., 2001, Molecular Aspects of Medicine, V22, P1, DOI 10.1016/S0098 2997(00)00006 6
   Lin ZY, 2017, SPECTROCHIM ACTA A, V173, P527, DOI 10.1016/j.saa.2016.09.050
   Liu G, 2010, ENVIRON SCI TECHNOL, V44, P1366, DOI 10.1021/es9015734
   Lu JX, 2011, J MATER SCI MATER M, V22, P607, DOI 10.1007/s10856 011 4228 4
   Mazzoli A, 2012, POWDER TECHNOL, V225, P65, DOI 10.1016/j.powtec.2012.03.033
   Miculescu F, 2017, ACS SUSTAIN CHEM ENG, V5, P8491, DOI 10.1021/acssuschemeng.7b02314
   Nouri Felekori M, 2019, MATER LETT, V243, P120, DOI 10.1016/j.matlet.2019.01.147
   Ota N., 2014, ARXIV14014504
   Panseri S, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477 3155 10 32
   Petchsang N, 2009, J MAGN MAGN MATER, V321, P1990, DOI 10.1016/j.jmmm.2008.12.027
   Poinern GEJ, 2014, SCI REP UK, V4, DOI 10.1038/srep06235
   Prabhu Y.T., 2014, WORLD J NANOSCI ENG, V2014
   Serrano JR, 2017, ADV MECH ENG, V9, DOI 10.1177/1687814017728242
   Ramya JR, 2014, CERAM INT, V40, P16707, DOI 10.1016/j.ceramint.2014.08.035
   Rau JV, 2014, APPL SURF SCI, V307, P301, DOI 10.1016/j.apsusc.2014.04.030
   Robles Aguila MJ, 2017, CERAM INT, V43, P12705, DOI 10.1016/j.ceramint.2017.06.154
   Sarwar A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123084
   Saxena V, 2018, MATER TECHNOL, V33, P79, DOI 10.1080/10667857.2017.1377972
   Smekalova M, 2016, VET J, V209, P174, DOI 10.1016/j.tvjl.2015.10.032
   Stojanovic Z, 2009, MATER MANUF PROCESS, V24, P1096, DOI 10.1080/10426910903032113
   Suganthi RV, 2011, MAT SCI ENG C MATER, V31, P593, DOI 10.1016/j.msec.2010.11.025
   Sun W, 2018, ACS APPL MATER INTER, V10, P7832, DOI 10.1021/acsami.7b19281
   Tampieri A, 2012, ACTA BIOMATER, V8, P843, DOI 10.1016/j.actbio.2011.09.032
   Tank KP, 2013, J NANOPART RES, V15, DOI 10.1007/s11051 013 1644 z
   Türk S, 2019, MAT SCI ENG C MATER, V99, P986, DOI 10.1016/j.msec.2019.02.025
   Ullah I, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110633
   Ullah I, 2020, ACS BIOMATER SCI ENG, V6, P375, DOI 10.1021/acsbiomaterials.9b01666
   Ullah I, 2018, CERAM INT, V44, P21338, DOI 10.1016/j.ceramint.2018.08.187
   Veerla SC, 2019, MAT SCI ENG C MATER, V98, P311, DOI 10.1016/j.msec.2018.12.148
   Wei LX, 2019, J MATER SCI, V54, P2514, DOI 10.1007/s10853 018 2951 7
   WEINER S, 1990, J ARCHAEOL SCI, V17, P187, DOI 10.1016/0305 4403(90)90058 D
   Whitesides GM, 2005, SMALL, V1, P172, DOI 10.1002/smll.200400130
   Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042
   Wu SYH, 2010, J NANOPART RES, V12, P1173, DOI 10.1007/s11051 009 9734 7
   Wu Y, 2010, BIOMED MATER, V5, DOI 10.1088/1748 6041/5/1/015001
   Xia YN, 2009, ANGEW CHEM INT EDIT, V48, P60, DOI 10.1002/anie.200802248
   Xu Y, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0184 y
   Yazdani N, 2019, IRAN J MATER SCI ENG, V16, P39, DOI 10.22068/ijmse.16.1.39
   Zhao L, 2015, W INDIAN MED J, V64, P506, DOI 10.7727/wimj.2016.179
   Zhao Y, 2007, J BIOMED MATER RES B, V83B, P121, DOI 10.1002/jbm.b.30774
NR 76
TC 23
Z9 23
U1 0
U2 42
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272 8842
EI 1873 3956
J9 CERAM INT
JI Ceram. Int.
PD JUL
PY 2020
VL 46
IS 10
BP 16104
EP 16118
DI 10.1016/j.ceramint.2020.03.163
PN B
PG 15
WC Materials Science, Ceramics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LO3EN
UT WOS:000533512000045
DA 2025 08 17
ER

PT J
AU Zaric, J
   Rüegg, C
AF Zaric, J
   Rüegg, C
TI Integrin mediated adhesion and soluble ligand binding stabilize COX 2
   protein levels in endothelial cells by inducing expression and
   preventing degradation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CYCLOOXYGENASE 2 GENE EXPRESSION; FLUID SHEAR STRESS; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; TRANSCRIPTIONAL REGULATION; PROTEASOME
   INHIBITION; MC3T3 E1 OSTEOBLASTS; UP REGULATION; ANGIOGENESIS;
   INDUCTION; KINASE
AB Cyclooxygenase 2 (COX 2), a key enzyme in prostaglandin synthesis, is highly expressed during inflammation and cellular transformation and promotes tumor progression and angiogenesis. We have previously demonstrated that endothelial cell COX 2 is required for integrin alpha(V)beta(3) dependent activation of Rac 1 and Cdc 42 and for endothelial cell spreading, migration, and angiogenesis (Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. (2001) Nat. Med. 7, 1041 1047; Dormond, O., Bezzi, M., Mariotti, A., and Ruegg, C. (2002) J. Biol. Chem. 277, 45838 45846). In this study, we addressed the question of whether integrin mediated cell adhesion may regulate COX 2 expression in endothelial cells. We report that cell detachment from the substrate caused rapid degradation of COX 2 protein in human umbilical vein endothelial cells (HUVEC) independent of serum stimulation. This effect was prevented by broad inhibition of cellular proteinases and by neutralizing lysosomal activity but not by inhibiting the proteasome. HUVEC adhesion to laminin, collagen I, fibronectin, or vitronectin induced rapid COX 2 protein expression with peak levels reached within 2 h and increased COX 2 dependent prostaglandin E 2 production. In contrast, nonspecific adhesion to poly L lysine was ineffective in inducing COX 2 expression. Furthermore, the addition of matrix proteins in solution promoted COX 2 protein expression in suspended or poly L lysine attached HUVEC. Adhesion induced COX 2 expression was strongly suppressed by pharmacological inhibition of c Src, phosphatidylinositol 3 kinase, p38, extracellular regulated kinase 1/2, and, to a lesser extent, protein kinase C and by the inhibition of mRNA or protein synthesis. In conclusion, this work demonstrates that integrin mediated cell adhesion and soluble integrin ligands contribute to maintaining COX 2 steady state levels in endothelial cells by the combined prevention of lysosomal dependent degradation and the stimulation of mRNA synthesis involving multiple signaling pathways.
C1 Swiss Inst Expt Canc Res, Ctr Pluridisciplinaire Oncol, CH 1066 Epalinges, Switzerland.
   Swiss Inst Expt Canc Res, Natl Ctr Competence Res, CH 1066 Epalinges, Switzerland.
C3 Swiss Institute Experimental Cancer Research; Swiss Institute
   Experimental Cancer Research
RP Swiss Inst Expt Canc Res, Ctr Pluridisciplinaire Oncol, 155 Chemin Boveresses, CH 1066 Epalinges, Switzerland.
EM curzio.ruegg@isrec.ch
CR Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960 9822(02)70714 8
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530
   Cho MK, 2004, BIOCHEM PHARMACOL, V67, P2239, DOI 10.1016/j.bcp.2004.02.024
   Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200
   COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97
   Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050
   Dimberg J, 2001, ANTICANCER RES, V21, P911
   Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171
   Dixon DA, 2003, J EXP MED, V198, P475, DOI 10.1084/jem.20030616
   Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200
   Dormond O, 2003, THROMB HAEMOSTASIS, V90, P577, DOI 10.1160/TH03 03 0196
   Dormond O, 2001, DRUG RESIST UPDATE, V4, P314, DOI 10.1054/drup.2001.0219
   Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901 1041
   Doroudi R, 2000, BIOCHEM BIOPH RES CO, V269, P257, DOI 10.1006/bbrc.2000.2279
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109 003 0422 2
   Engelse MA, 2004, SEMIN THROMB HEMOST, V30, P71
   FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382
   Figueiredo Pereira ME, 2002, J BIOL CHEM, V277, P25283, DOI 10.1074/jbc.M109145200
   FRELINGER AL, 1991, J BIOL CHEM, V266, P17106
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955 0674(00)00251 9
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Gilroy DW, 2001, AM J PHYSIOL CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188
   Han SW, 2004, INT J CANCER, V111, P322, DOI 10.1002/ijc.20281
   Hashimoto Y, 2004, HISTOPATHOLOGY, V44, P353, DOI 10.1111/j.1365 2559.2004.01853.x
   Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962 8924(99)01667 0
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092 8674(92)90115 S
   Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13
   Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998
   Jones MK, 1999, NAT MED, V5, P1418
   Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200
   Kim SJ, 2003, J BIOL CHEM, V278, P42448, DOI 10.1074/jbc.M304887200
   Kirtikara K, 2000, MOL CELL BIOCHEM, V203, P41, DOI 10.1023/A:1007045600664
   Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200
   Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165 6147(99)01385 1
   McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603 713
   Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097 2765(03)00012 1
   Müller Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799
   Murphy JF, 2003, BRIT J HAEMATOL, V121, P157, DOI 10.1046/j.1365 2141.2003.04247.x
   Nakagawa T, 1999, J CELL PHYSIOL, V179, P226, DOI 10.1002/(SICI)1097 4652(199905)179:2<226::AID JCP13>3.3.CO;2 H
   Nina M, 2000, EUR BIOPHYS J BIOPHY, V29, P439, DOI 10.1007/PL00006649
   Norvell SM, 2004, J APPL PHYSIOL, V96, P957, DOI 10.1152/japplphysiol.00869.2003
   Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922
   Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092 8674(00)81988 1
   PAVALKO FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591, DOI DOI 10.1152/ajpcell.1998.275.6.C1591
   Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003
   Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59
   RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021
   Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646
   Rüegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018 003 2297 3
   Rüegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498 408
   Rüegg C, 2003, ANN MED, V35, P476, DOI 10.1080/07853890310017053
   Rüegg C, 2004, BBA REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003
   Sawyer SJ, 2001, AM J PHYSIOL CELL PH, V281, pC1038, DOI 10.1152/ajpcell.2001.281.3.C1038
   Schmedtje JF, 1997, J BIOL CHEM, V272, P601
   Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962 8924(01)02152 3
   SEGLEN PO, 1976, EXP CELL RES, V100, P276, DOI 10.1016/0014 4827(76)90148 8
   Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200
   Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120
   Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18
   SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178
   Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100
   Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Stinson MW, 2003, INFECT IMMUN, V71, P2365, DOI 10.1128/IAI.71.5.2365 2372.2003
   Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838
   Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911
   Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200
   Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3504, DOI 10.1210/jc.87.7.3504
   Tang QB, 2001, CANCER RES, V61, P4329
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092 8674(00)81433 6
   Uracz W, 2002, J PHYSIOL PHARMACOL, V53, P643
   Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Weaver SA, 2001, GASTROENTEROLOGY, V120, P1117, DOI 10.1053/gast.2001.23257
   Wickström SA, 2003, CANCER CELL, V3, P513, DOI 10.1016/S1535 6108(03)00143 0
   Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang CM, 2002, CELL SIGNAL, V14, P899, DOI 10.1016/S0898 6568(02)00037 2
NR 81
TC 50
Z9 61
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 14
PY 2005
VL 280
IS 2
BP 1077
EP 1085
DI 10.1074/jbc.M410006200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 885ZF
UT WOS:000226195200028
PM 15525653
OA hybrid
DA 2025 08 17
ER

PT J
AU Metz, RL
   Patel, PS
   Hameed, M
   Bryan, M
   Rameshwar, P
AF Metz, Rebecca L.
   Patel, Prem S.
   Hameed, Meera
   Bryan, Margaret
   Rameshwar, Pranela
TI Role of human HGFIN/nmb in breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID BONE MARROW; TRANSMEMBRANE PROTEIN; GROWTH FACTOR; SUBSTANCE P; DC HIL;
   CELLS; P53; EXPRESSION; GENE; OSTEOACTIVIN
AB Introduction HGFIN, previously identified as nmb, and its homolog osteoactivin are single transmembrane proteins that are expressed in differentiated immune cells. These proteins exhibit properties that could potentiate tumorigenesis or decrease invasiveness. These seemingly opposing roles of HGFIN suggest that this protein might be central to malignancies and might also behave as a tumor suppressor. Consistent with the reported roles for HGFIN is the fact that this gene is regulated by p53 through multiple binding sites in the 5' flanking region, and is expressed in osteoblasts.
   Methods This study used siRNA to knock out HGFIN in non tumorigenic breast cells and ectopically expressed HGFIN in breast cancer cells. In addition, in situ hybridization studies analyzed primary breast tissues from archived breast surgeries. Reporter gene assays studied the untranslated exon 1 of HGFIN.
   Results HGFIN expression led to reduced cell growth of breast cancer cells and reduced migration. At the molecular level, reporter gene analyses determined the untranslated exon 1 to be a negative regulator of the upstream enhancing effect. Ectopic expression of wild  type p53 in breast cancer cells that expressed endogenous mutant p53 resulted in increased HGFIN reporter gene activities.
   Conclusion As the majority of cancer cells have mutations in p53, further studies on the relationship between p53 and HGFIN expression, and its role in tumor genesis and bone invasion, might uncover novel therapy targets for breast and other cancers. The results show a central role for p53 in HGFIN expression, which appears to determine the behavior of the cancer cells.
C1 [Metz, Rebecca L.; Bryan, Margaret; Rameshwar, Pranela] Univ Med & Dent New Jersey, Sch Med, Dept Med, Newark, NJ 07103 USA.
   [Metz, Rebecca L.] Univ Med & Dent New Jersey, Sch Med, Dept Obstet Gynecol & Womens Hlth, Newark, NJ USA.
   [Patel, Prem S.] Brookdate Univ Hosp, Med Ctr, Div Trauma, Brooklyn, NY USA.
   [Hameed, Meera] Univ Med & Dent New Jersey, Sch Med, Dept Lab Med & Pathol, Newark, NJ USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers University System; Rutgers University New Brunswick;
   Rutgers University Biomedical & Health Sciences
RP Rameshwar, P (通讯作者)，Univ Med & Dent New Jersey, Sch Med, Dept Med, Newark, NJ 07103 USA.
EM rameshwa@umdnj.edu
CR Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841
   Bandari PS, 2003, REGUL PEPTIDES, V111, P169, DOI 10.1016/S0167 0115(02)00288 4
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Chung JS, 2007, BLOOD, V109, P4320, DOI 10.1182/blood 2006 11 053769
   Corcoran KE, 2005, BIOL PROCED ONLINE, V7, P8, DOI 10.1251/bpo100
   Gregg TR, 2003, BRAIN RES, V994, P55, DOI 10.1016/j.brainres.2003.09.024
   Haralanova Ilieva B, 2005, J HEPATOL, V42, P565, DOI 10.1016/j.jhep.2004.12.021
   Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735
   Kastan MB, 2007, NAT CELL BIOL, V9, P489, DOI 10.1038/ncb0507 489
   Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078 0432.CCR 05 2797
   Metz RL, 2005, CELL CYCLE, V4, P315
   Ogawa T, 2005, AM J PHYSIOL CELL PH, V289, pC697, DOI 10.1152/ajpcell.00565.2004
   Patel HJ, 2005, P NATL ACAD SCI USA, V102, P17436, DOI 10.1073/pnas.0506351102
   Qian J, 2001, J IMMUNOL, V166, P2553, DOI 10.4049/jimmunol.166.4.2553
   RAMESHWAR P, 1994, J IMMUNOL, V153, P2819
   Rameshwar P, 1997, J IMMUNOL, V158, P3417
   Rao G, 2004, CANCER RES, V64, P2874, DOI 10.1158/0008 5472.CAN 03 3121
   Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200
   Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557
   Schmidt Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100
   Selim AA, 2003, CRIT REV EUKAR GENE, V13, P265, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
   SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206
   Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200
   Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388
   Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571
   Vishalakumar S, 2006, CELL SIGNAL, V18, P422, DOI 10.1016/j.cellsig.2005.05.002
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
NR 27
TC 30
Z9 36
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 542X
EI 1465 5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2007
VL 9
IS 5
AR R58
DI 10.1186/bcr1764
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 264KI
UT WOS:000253285800007
PM 17845721
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rosado, A
   Borrás, A
   Sánchez Soto, M
   Labíková, M
   Hettegger, H
   Ramírez Jiménez, RA
   Rojo, L
   García Fernández, L
   Aguilar, MR
   Liebner, F
   López Periago, AM
   Ayllón, JA
   Domingo, C
AF Rosado, Albert
   Borras, Alejandro
   Sanchez Soto, Miguel
   Labikova, Magdalena
   Hettegger, Hubert
   Ramirez Jimenez, Rosa Ana
   Rojo, Luis
   Garcia Fernandez, Luis
   Aguilar, Maria Rosa
   Liebner, Falk
   Lopez Periago, Ana M.
   Ayllon, Jose A.
   Domingo, Concepcion
TI BioMOF@cellulose Glycerogel Scaffold with Multifold Bioactivity:
   Perspective in Bone Tissue Repair
SO GELS
LA English
DT Article
DE glycerogel; cellulose; bioMOF; composite; scaffold; tissue repair
ID METAL ORGANIC FRAMEWORKS; RELEASE; MICROENVIRONMENT; ADSORPTION;
   DELIVERY
AB The development of new biomaterials for musculoskeletal tissue repair is currently an important branch in biomedicine research. The approach presented here is centered around the development of a prototypic synthetic glycerogel scaffold for bone regeneration, which simultaneously features therapeutic activity. The main novelty of this work lies in the combination of an open meso and macroporous nanocrystalline cellulose (NCC) based glycerogel with a fully biocompatible microporous bioMOF system (CaSyr 1) composed of calcium ions and syringic acid. The bioMOF framework is further impregnated with a third bioactive component, i.e., ibuprofen (ibu), to generate a multifold bioactive system. The integrated CaSyr 1(ibu) serves as a reservoir for bioactive compounds delivery, while the NCC scaffold is the proposed matrix for cell ingrowth, proliferation and differentiation. The measured drug delivery profiles, studied in a phosphate buffered saline solution at 310 K, indicate that the bioactive components are released concurrently with bioMOF dissolution after ca. 30 min following a pseudo first order kinetic model. Furthermore, according to the semi empirical Korsmeyer Peppas kinetic model, this release is governed by a case II mechanism, suggesting that the molecular transport is influenced by the relaxation of the NCC matrix. Preliminary in vitro results denote that the initial high concentration of glycerol in the NCC scaffold can be toxic in direct contact with human osteoblasts (HObs). However, when the excess of glycerol is diluted in the system (after the second day of the experiment), the direct and indirect assays confirm full biocompatibility and suitability for HOb proliferation.
C1 [Rosado, Albert; Borras, Alejandro; Lopez Periago, Ana M.; Domingo, Concepcion] CSIC, Inst Ciencia Mat Barcelona ICMAB, Campus UAB S N, Bellaterra 08193, Spain.
   [Sanchez Soto, Miguel] Univ Politecn Catalunya Barcelona Tech UPC, Dept Ciencia & Engn Mat, Escola Engn Barcelona Est EEBE, Barcelona 08019, Spain.
   [Labikova, Magdalena; Hettegger, Hubert; Liebner, Falk] Univ Nat Resources & Life Sci, Inst Chem Renewable Resources, Vienna BOKU, Konrad Lorenz Str 24, A 3430 Tulln An Der Donau, Austria.
   [Labikova, Magdalena] Univ Chem & Technol, Dept Organ Chem, Prague UCT, Technicka 5, Prague 6, Czech Republic.
   [Hettegger, Hubert] Univ Nat Resources & Life Sci, Christian Doppler Lab Cellulose High Tech Mat, Vienna BOKU, Konrad Lorenz Str 24, A 3430 Tulln An Der Donau, Austria.
   [Ramirez Jimenez, Rosa Ana; Rojo, Luis; Garcia Fernandez, Luis; Aguilar, Maria Rosa] CSIC, Inst Ciencia & Tecnol Polimeros ICTP, C Juan Cierva 3, Madrid 28006, Spain.
   [Ramirez Jimenez, Rosa Ana; Rojo, Luis; Garcia Fernandez, Luis; Aguilar, Maria Rosa] Networking Biomed Res Ctr Bioengn Biomat & Nanomed, Ave Monforte Lemos 3 5, Madrid 28029, Spain.
   [Ayllon, Jose A.] Univ Autonoma Barcelona UAB, Dept Quim, Campus UAB S N, Bellaterra 08193, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Instituto
   de Ciencia de Materiales de Barcelona (ICMAB); Universitat Politecnica
   de Catalunya; BOKU University; University of Chemistry & Technology,
   Prague; BOKU University; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC   Instituto de Ciencia & Tecnologia de Polimeros (ICTP);
   Autonomous University of Barcelona
RP Rosado, A; Domingo, C (通讯作者)，CSIC, Inst Ciencia Mat Barcelona ICMAB, Campus UAB S N, Bellaterra 08193, Spain.
EM arosado@icmab.es; aborras@icmab.es; m.sanchez soto@upc.edu;
   magdalena.labikova@vscht.cz; hubert.hettegger@boku.ac.at;
   raramirez@ictp.csic.es; rojodelolmo@ictp.csic.es; luis.garcia@csic.es;
   mraguilar@ictp.csic.es; falk.liebner@boku.ac.at; amlopez@icmab.es;
   joseantonio.ayllon@uab.es; conchi@icmab.es
RI JIMENEZ, ROSA/ABH 8794 2020; Soto, Miguel/H 7312 2016; Rojo,
   Luis/B 3073 2009; Rojo del Olmo, Luis/B 3073 2009; Garcia Fernandez,
   Luis/A 7629 2012; García Fernández, Luis/A 7629 2012; Ayllon,
   José/L 1639 2014; Liebner, Falk/B 4690 2011; Domingo,
   Concepcion/L 1241 2014; Aguilar, Maria Rosa/C 2593 2014; Sanchez Soto,
   Miguel/H 7312 2016; Lopez Periago, Ana M./I 5567 2012
OI Hettegger, Hubert/0000 0002 9343 5673; RAMIREZ JIMENEZ, ROSA
   ANA/0000 0001 7563 2553; Rojo del Olmo, Luis/0000 0001 6334 6736;
   Rosado, Albert/0000 0003 3222 9566; Garcia Fernandez,
   Luis/0000 0002 4179 2556; Liebner, Falk/0000 0002 8244 8153; Domingo,
   Concepcion/0000 0002 6976 8283; Aguilar, Maria Rosa/0000 0001 7395 5754;
   Sanchez Soto, Miguel/0000 0002 0023 5059; Lopez Periago, Ana
   M./0000 0002 3777 3205; Labikova, Magdalena/0009 0004 8900 6675
FU Spanish Ministry of Science and Innovation (MICINN) [CEX2019 000917 S];
   Spanish National Plan of Research [PID2020 115631GB I00,
   PID2020 114086RB I00, PID2019 106518RB I00]; CIBER (Spain) Consorcio
   Centro de Investigacion Biomedica en Red [CB06/01/0013]; Instituto de
   Salud Carlos III [202180E048]; Austrian Czech Project   Austrian Agency
   for Education and International is ation (OeAD) [CZ 17/2023];
   Generalitat de Catalunya [2021SGR01042]; AERoGELS Cost Action [CA18125]
FX This work was funded by the Spanish Ministry of Science and Innovation
   (MICINN) through the Severo Ochoa Program for Centers of Excellence
   (CEX2019 000917 S) with the Spanish National Plan of Research projects
   PID2020 115631GB I00, PID2020 114086RB I00 and PID2019 106518RB I00, and
   also CIBER (Spain) Consorcio Centro de Investigacion Biomedica en Red
   (CB06/01/0013), Instituto de Salud Carlos III. This research work was
   performed in the framework of the Nanomedicine CSIC HUB (202180E048).
   Furthermore, financial support through the Austrian Czech Project CZ
   17/2023 (M.L., H.H.), funded by the Austrian Agency for Education and
   International is ation (OeAD), is thankfully acknowledged. M.S. S.
   thanks the Generalitat de Catalunya for the grant 2021SGR01042. This
   work has been performed in the framework of the doctoral program
   "Chemistry" of the UAB by A.R. that acknowledges the financial support
   of a FPI 2019 grant and AERoGELS Cost Action (CA18125) with regards to a
   Short Term Scientific Mission (STSM).
CR Ahmed L., 2019, INT J LATEST TECHNOL, V8, P52
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Andersen FA, 2005, INT J TOXICOL, V24, P1, DOI 10.1080/10915810590953833
   [Anonymous], 2018, Cutting Edge Enabling Technologies for Regenerative Medicine
   ARMITAGE WJ, 1986, CRYOBIOLOGY, V23, P116, DOI 10.1016/0011 2240(86)90002 7
   ARMITAGE WJ, 1984, AM J PHYSIOL, V247, pC382, DOI 10.1152/ajpcell.1984.247.5.C382
   Arumugam B, 2018, J CELL COMMUN SIGNAL, V12, P561, DOI 10.1007/s12079 018 0449 3
   Bon V, 2015, PHYS CHEM CHEM PHYS, V17, P17471, DOI 10.1039/c5cp02180d
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Charlier A, 2000, INT J PHARM, V200, P115, DOI 10.1016/S0378 5173(00)00356 2
   Chavooshi R, 2023, CELL J, V25, P158, DOI [10.22074/CELLJ.2023.559011.1095, 10.22074/cellj.2023.559011.1095]
   Cheemanapalli S, 2018, BIOMED PHARMACOTHER, V108, P547, DOI 10.1016/j.biopha.2018.09.069
   Chen HJ, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13452 2
   Chen XY, 2020, BIOPHYS J, V119, P502, DOI 10.1016/j.bpj.2020.06.026
   Chiarello E, 2013, AGING CLIN EXP RES, V25, pS101, DOI 10.1007/s40520 013 0088 8
   Chimpibul W, 2020, J MATER CHEM B, V8, P7904, DOI 10.1039/d0tb01015d
   Dhua S, 2023, INT J BIOL MACROMOL, V242, DOI 10.1016/j.ijbiomac.2023.125102
   Fardjahromi MA, 2022, MATER TODAY CHEM, V23, DOI 10.1016/j.mtchem.2021.100670
   Ferracini R, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030122
   FRANK MSB, 1981, PHARMACOTHERAPY, V1, P147
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   García JI, 2010, GREEN CHEM, V12, P426, DOI 10.1039/b923631g
   Ghassemi T, 2018, ARCH BONE JT SURG AB, V6, P90
   Guo JQ, 2017, BIOMACROMOLECULES, V18, P2045, DOI 10.1021/acs.biomac.7b00306
   Iravani S, 2022, MOLECULES, V27, DOI 10.3390/molecules27248830
   Janmohammadi M, 2023, BIOACT MATER, V20, P137, DOI 10.1016/j.bioactmat.2022.05.018
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Kuznetsova IV, 2013, RUSS J PHYS CHEM B+, V7, P814, DOI 10.1134/S1990793113070105
   Lawson HD, 2021, ACS APPL MATER INTER, V13, P7004, DOI 10.1021/acsami.1c01089
   Lee J, 2022, THERANOSTICS, V12, P4051, DOI 10.7150/thno.73146
   López Periago AM, 2018, J SUPERCRIT FLUID, V134, P204, DOI 10.1016/j.supflu.2017.11.011
   McKinlay AC, 2010, ANGEW CHEM INT EDIT, V49, P6260, DOI 10.1002/anie.201000048
   Mestre AS, 2007, CARBON, V45, P1979, DOI 10.1016/j.carbon.2007.06.005
   Nikolova MP, 2019, BIOACT MATER, V4, P271, DOI 10.1016/j.bioactmat.2019.10.005
   Osorio DA, 2019, ACTA BIOMATER, V87, P152, DOI 10.1016/j.actbio.2019.01.049
   PEPPAS NA, 1989, INT J PHARMACEUT, V57, P169, DOI 10.1016/0378 5173(89)90306 2
   Rechberger F, 2017, NANOSCALE HORIZ, V2, P6, DOI 10.1039/c6nh00077k
   Rojas S, 2017, J MATER CHEM B, V5, P2560, DOI 10.1039/c6tb03217f
   Rosa MF, 2010, CARBOHYD POLYM, V81, P83, DOI 10.1016/j.carbpol.2010.01.059
   Rosado A, 2023, INORG CHEM FRONT, V10, P2165, DOI 10.1039/d2qi02639b
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Schneemann A, 2014, CHEM SOC REV, V43, P6062, DOI 10.1039/c4cs00101j
   Seo Y, 2020, ACS APPL MATER INTER, V12, P13040, DOI 10.1021/acsami.9b21697
   Smirnova I, 2018, J SUPERCRIT FLUID, V134, P228, DOI 10.1016/j.supflu.2017.12.037
   Tobiszewski M, 2017, GREEN CHEM, V19, P1034, DOI 10.1039/c6gc03424a
   Trucillo P, 2022, PROCESSES, V10, DOI 10.3390/pr10061094
   Wang C, 2020, BIOFABRICATION, V12, DOI 10.1088/1758 5090/abab5b
   Watanabe M, 2021, J BIOMED MATER RES B, V109, P921, DOI 10.1002/jbm.b.34756
   WIEBE JP, 1991, LIFE SCI, V48, P1511, DOI 10.1016/0024 3205(91)90275 G
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Wu MX, 2017, ADV MATER, V29, DOI 10.1002/adma.201606134
   Zhang YG, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15102323
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
NR 55
TC 2
Z9 2
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2310 2861
J9 GELS BASEL
JI Gels
PD OCT
PY 2024
VL 10
IS 10
AR 631
DI 10.3390/gels10100631
PG 16
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA K3Q5G
UT WOS:001343055900001
PM 39451284
OA gold
DA 2025 08 17
ER

PT J
AU Dideriksen, K
   Reitelseder, S
   Agergaard, J
   Boesen, AP
   Aas, SN
   Raastad, T
   Holm, L
AF Dideriksen, K.
   Reitelseder, S.
   Agergaard, J.
   Boesen, A. P.
   Aas, S. N.
   Raastad, T.
   Holm, Lars
TI Muscle protein breakdown is impaired during immobilization compared to
   during a subsequent retraining period in older men: no effect of
   anti inflammatory medication
SO PFLUGERS ARCHIV EUROPEAN JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE Deuterated water; Deuterated alanine; Muscle degradation; Muscle disuse;
   Muscle recovery; NSAID
ID HUMAN SKELETAL MUSCLE; RESISTANCE EXERCISE; UBIQUITIN LIGASES;
   PROTEOLYTIC SYSTEM; GENE EXPRESSION; GROWTH HORMONE; AMINO ACIDS;
   ATROPHY; IBUPROFEN; ADAPTATIONS
AB Muscle inactivity reduces muscle protein synthesis (MPS), whereas a subsequent period of rehabilitation resistance training (retraining) increases MPS. However, less is known regarding muscle protein breakdown (MPB) during such conditions. Furthermore, nonsteroidal anti inflammatory drugs (NSAIDs) may have a dampening effect on MPB during periods of inactivity in older individuals. Thus, we measured the average MPB, by use of the deuterated water methodology, during an immobilization period and a subsequent retraining period in older individuals with and without NSAID treatment. Eighteen men (60 80 years: range) were randomly assigned to ibuprofen (1200 mg/d, Ibu) or placebo (Plc). One lower limb was immobilized in a cast for 2 weeks and retrained for 2 weeks, and 2 x 20 g of whey protein was ingested daily during both periods. Besides MPB, the protein expression of different muscle degradation signaling molecules was investigated. MPB was lower during immobilization compared to retraining (p < 0.01). NSAID treatment did not affect the MPB rate during immobilization or retraining (p > 0.05). The protein expression of muscle degradation signaling molecules changed during the study intervention but were unaffected by NSAID treatment. The finding that MPB was lower during immobilization than during retraining indicates that an increased MPB may play an important role in the muscle protein remodeling processes taking place within the initial retraining period. Moreover, NSAID treatment did not significantly influence the MPB rate during 2 weeks of lower limb immobilization or during 2 weeks of subsequent retraining in older individuals.
C1 [Dideriksen, K.; Reitelseder, S.; Agergaard, J.; Boesen, A. P.; Holm, Lars] Univ Copenhagen, Ctr Hlthy Aging, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Dideriksen, K.; Reitelseder, S.; Agergaard, J.; Boesen, A. P.; Holm, Lars] Univ Copenhagen, Inst Sports Med Copenhagen, Dept Orthoped, M Bispebjerg Hosp, Copenhagen, Denmark.
   [Reitelseder, S.; Holm, Lars] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark.
   [Aas, S. N.; Raastad, T.] Norwegian Sch Sport Sci, Dept Phys Performance, Oslo, Norway.
   [Holm, Lars] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; Norwegian School of Sport Sciences; University of Birmingham
RP Holm, L (通讯作者)，Univ Copenhagen, Ctr Hlthy Aging, Fac Hlth & Med Sci, Copenhagen, Denmark.; Holm, L (通讯作者)，Univ Copenhagen, Inst Sports Med Copenhagen, Dept Orthoped, M Bispebjerg Hosp, Copenhagen, Denmark.; Holm, L (通讯作者)，Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.
EM L.Holm@bham.ac.uk
RI ; Raastad, Truls/AFP 1474 2022; Agergaard, Jakob/ABF 2729 2020; Holm,
   Lars/G 8181 2017; Holm, Lars/AAI 1320 2020
OI Agergaard, Jakob/0000 0003 3401 3144; Holm, Lars/0000 0002 4392 9616; 
CR Atherton PJ, 2016, AM J PHYSIOL ENDOC M, V311, pE594, DOI 10.1152/ajpendo.00257.2016
   Bemelmans WJE, 2004, EUR J CLIN NUTR, V58, P1083, DOI 10.1038/sj.ejcn.1601938
   BIOLO G, 1995, AM J PHYSIOL ENDOC M, V268, pE514
   Boesen AP, 2014, J APPL PHYSIOL, V116, P192, DOI 10.1152/japplphysiol.01077.2013
   Boesen AP, 2013, J PHYSIOL LONDON, V591, P6039, DOI 10.1113/jphysiol.2013.261263
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Breen L, 2013, J CLIN ENDOCR METAB, V98, P2604, DOI 10.1210/jc.2013 1502
   Brook MS, 2015, FASEB J, V29, P4485, DOI 10.1096/fj.15 273755
   Damas F, 2016, J PHYSL, V58, P7250
   Davis TW, 2004, J PHARMACOL EXP THER, V308, P929, DOI 10.1124/jpet.103.063099
   den Kamp CMO, 2013, AM J CLIN NUTR, V98, P738, DOI 10.3945/ajcn.113.058388
   Dideriksen K, 2016, EXP GERONTOL, V82, P8, DOI 10.1016/j.exger.2016.05.009
   Dideriksen K, 2017, J APPL PHYSIOL, V122, P273, DOI 10.1152/japplphysiol.00809.2015
   Drummond MJ, 2012, AM J PHYSIOL ENDOC M, V302, pE1113, DOI 10.1152/ajpendo.00603.2011
   Ferrando AA, 1996, AM J PHYSIOL ENDOC M, V270, pE627, DOI 10.1152/ajpendo.1996.270.4.E627
   Glover EI, 2010, APPL PHYSIOL NUTR ME, V35, P125, DOI 10.1139/H09 137
   He K, 2009, AM J CARDIOL, V103, P1238, DOI 10.1016/j.amjcard.2009.01.016
   Holm L, 2014, AM J PHYSIOL ENDOC M, V306, pE1330, DOI 10.1152/ajpendo.00084.2014
   Holm L, 2013, AM J PHYSIOL ENDOC M, V304, pE895, DOI 10.1152/ajpendo.00579.2012
   Hoppeler H, 2016, J EXP BIOL, V219, P205, DOI 10.1242/jeb.128207
   Jackman RW, 2013, EXP PHYSIOL, V98, P19, DOI 10.1113/expphysiol.2011.063321
   Jurdana M, 2015, AGE, V37, DOI 10.1007/s11357 015 9848 z
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Mantovani G, 2010, J MOL MED JMM, V88, P85, DOI 10.1007/s00109 009 0547 z
   Markworth JF, 2014, J APPL PHYSIOL, V117, P20, DOI 10.1152/japplphysiol.01299.2013
   McCarthy DO, 2004, RES NURS HEALTH, V27, P174, DOI 10.1002/nur.20019
   McFarlane C, 2006, J CELL PHYSIOL, V209, P501, DOI 10.1002/jcp.20757
   Peterson JM, 2003, MED SCI SPORT EXER, V35, P892, DOI 10.1249/01.MSS.0000069917.51742.98
   Phillips SM, 1997, AM J PHYSIOL ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99
   Phillips SM, 1999, AM J PHYSIOL ENDOC M, V276, pE118
   Rennie MJ, 2010, SCAND J MED SCI SPOR, V20, P5, DOI 10.1111/j.1600 0838.2009.00967.x
   Rieu I, 2009, J PHYSIOL LONDON, V587, P5483, DOI 10.1113/jphysiol.2009.178319
   Rudrappa SS, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00361
   Sacheck JM, 2004, AM J PHYSIOL ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004
   Sandri M, 2008, PHYSIOLOGY, V23, P160, DOI 10.1152/physiol.00041.2007
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Standley RA, 2013, PROSTAG LEUKOTR ESS, V88, P361, DOI 10.1016/j.plefa.2013.02.004
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097 2765(04)00211 4
   Suetta C, 2009, J APPL PHYSIOL, V107, P1172, DOI 10.1152/japplphysiol.00290.2009
   Suetta C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051238
   Symons TB, 2009, J APPL PHYSIOL, V107, P34, DOI 10.1152/japplphysiol.91137.2008
   Tardif N, 2013, AM J CLIN NUTR, V98, P1485, DOI 10.3945/ajcn.113.063859
   Tesch PA, 2008, J APPL PHYSIOL, V105, P902, DOI 10.1152/japplphysiol.90558.2008
   Trappe TA, 2013, AM J PHYSIOL REG I, V304, pR198, DOI 10.1152/ajpregu.00245.2012
   Trappe TA, 2011, AM J PHYSIOL REG I, V300, pR655, DOI 10.1152/ajpregu.00611.2010
   van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167
   Vella L, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12172
   Vella L, 2012, AM J PHYSIOL REG I, V302, pR667, DOI 10.1152/ajpregu.00336.2011
   Wall BT, 2013, AGEING RES REV, V12, P898, DOI 10.1016/j.arr.2013.07.003
   Wilkinson DJ, 2014, AM J PHYSIOL ENDOC M, V306, pE571, DOI 10.1152/ajpendo.00650.2013
   You JS, 2010, APPL PHYSIOL NUTR ME, V35, P310, DOI 10.1139/H10 022
   You JS, 2010, J NUTR BIOCHEM, V21, P929, DOI 10.1016/j.jnutbio.2009.07.007
NR 52
TC 4
Z9 4
U1 2
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0031 6768
EI 1432 2013
J9 PFLUG ARCH EUR J PHY
JI Pflugers Arch.
PD FEB
PY 2020
VL 472
IS 2
SI SI
BP 281
EP 292
DI 10.1007/s00424 020 02353 w
PG 12
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA KO1LI
UT WOS:000515309600012
PM 32025814
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Migliore, A
   Massafra, U
   Bizzi, E
   Argento, G
   Diamanti, AP
   Germano, V
   Tormenta, S
   Arduini, F
   Iannessi, F
   Granata, M
   Laganà, B
AF Migliore, A.
   Massafra, U.
   Bizzi, E.
   Argento, G.
   Diamanti, A. Picchianti
   Germano, V.
   Tormenta, S.
   Arduini, F.
   Iannessi, F.
   Granata, M.
   Lagana, B.
TI May Etanercept and PTH (1 34) association heal erosions in early
   rheumatoid arthritis? A pilot study
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Anti TNF; Rheumatoid Arthritis; Erosions; Etanercept; Teriparatide
ID PARATHYROID HORMONE 1 34; RECEIVING CONCOMITANT METHOTREXATE; RA MRI
   SCORE; POSTMENOPAUSAL WOMEN; MONOCLONAL ANTIBODY; BONE LOSS; EFFICACY;
   OSTEOPOROSIS; TERIPARATIDE; FRACTURES
AB Introduction: Rheumatoid arthritis (RA) is characterized by the formation in the joints of an inflammatory tissue, which causes the appearance of localized erosions on the margins of the joints. The molecular mechanism that causes the bone erosion is multifactorial. Inflammatory cytokines imbalance and OPG RANK L system are involved.
   Objective of the Study: The aim of the study is to evaluate the possibility of inducing healing or reduction in the number of erosions in Rheumatoid Arthritis patients treated with anti TNF alpha adding Teriparatide (PTH1 34) to standard treatment with anti TNF.
   Patients and Methods: Twenty adult patients with active RA diagnosed according to American Rheumatism Association (ARA) criteria at least 6 months before study begin were enrolled. Only patients affected by established RA (6 to 18 months from symptoms beginning) were recruited. Eligible patients were randomized to receive a standard dosage of etanercept (50 mg/week) or etanercept at same dosage with an addition of teriparatide (20 mg). Evaluation of eventual healing of arthritic erosions by magnetic resonance imaging was performed at time zero and then at twelve months. The following evaluation was assessed at baseline and after 12 months according to the Outcome Measures in Rheumatology Clinical Trials (OMERACT) definitions: number of erosion and presence or absence of synovitis, effusion and bone oedema. A comparative examination of quantitative and qualitative assessment of each parameter was applied. Plain radiographs of the hands were obtained at baseline and 52 weeks. Radiographs were scored blindly using the van der Heijde modification of the Sharp method. Safety of each treatment was evaluated by means of the adverse events (AES) evaluation and report.
   Results: There were no significant differences in baseline characteristics between the groups. The study did not achieve its primary endpoint of healing erosions. In the active arm no healing of erosions was found. At 52 weeks, there were no new MRI erosions in two arms. Bone oedema scores were significantly improved at 52 weeks in favour of both treatments versus baseline scores, without inter groups differences.
   X ray patterns were unchanged in all patients of both groups. No new erosions or previous erosions' healing were observed. No AEs were reported. Patients from both groups demonstrated a significant reduction in the DAS 28 scores at 52 weeks (p < 0.005) if compared with baseline values.
   Conclusions: These data confirm rapid control of inflammation and MRI damage benefits after Etanercept administration without a significant improvement in MRI findings after concomitant addition of teriparatide. Even though these results could seem to suggest to avoid the simultaneous use of these two drugs to treat RA erosions, further studies might be suggested to asses if sequential adminstration of an anabolic agent such as Teriparatide, after achieving clinical remission, may be able to improve bone damage.
C1 [Migliore, A.; Massafra, U.; Bizzi, E.] San Pietro Fatebenefratelli Hosp, Operat Unit Rheumatol, Rome, Italy.
   [Migliore, A.; Massafra, U.; Bizzi, E.] San Pietro Fatebenefratelli Hosp, Res Ctr, Rome, Italy.
   [Argento, G.] Univ Roma La Sapienza, S Andrea Hosp, Dept Radiol, Rome, Italy.
   [Diamanti, A. Picchianti; Germano, V.; Lagana, B.] Univ Roma La Sapienza, Operat Unit Autoimmune Dis, S Andrea Hosp, Rome, Italy.
   [Tormenta, S.; Arduini, F.; Iannessi, F.] San Pietro Fatebenefratelli Hosp, Dept Radiol, Rome, Italy.
   [Granata, M.] San Filippo Neri Hosp, Operat Unit Rheumatol, Rome, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza
   University Rome; Azienda Ospedaliera Sant'Andrea; San Filippo Neri
   Hospital
RP Bizzi, E (通讯作者)，San Pietro Fatebenefratelli Hosp, Operat Unit Rheumatol, Rome, Italy.
EM ebizzi@email.it
RI Alberto, Migliore/AAX 9382 2020; Bizzi, Emanuele/AAG 6552 2021; Argento,
   Giacomo/NFP 4630 2025; Diamanti, Andrea/P 9022 2016
OI Bizzi, Emanuele/0000 0001 8560 5866; Picchianti Diamanti,
   Andrea/0000 0002 8552 4641
CR Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bird P, 2003, J RHEUMATOL, V30, P1380
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Bukata Susan V, 2010, Curr Osteoporos Rep, V8, P28, DOI 10.1007/s11914 010 0006 3
   Christodoulou C, 2006, CLIN EXP MED, V6, P13, DOI 10.1007/s10238 006 0088 5
   Cipriano Cara A, 2009, HSS J, V5, P149, DOI 10.1007/s11420 009 9109 8
   Cobo Ibáñez T, 2007, EXPERT OPIN PHARMACO, V8, P1373, DOI 10.1517/14656566.8.9.1373
   Conaghan P, 2003, J RHEUMATOL, V30, P1376
   Conaghan P, 2001, J RHEUMATOL, V28, P1158
   Ejbjerg BJ, 2005, ARTHRITIS RHEUM US, V52, P2300, DOI 10.1002/art.21207
   Emery P, 2010, ARTHRITIS RHEUM US, V62, P674, DOI 10.1002/art.27268
   Furst DE, 2009, NAT CLIN PRACT RHEUM, V5, P134, DOI 10.1038/ncprheum1004
   Grunke Mathias, 2005, Expert Rev Clin Immunol, V1, P313, DOI 10.1586/1744666X.1.3.313
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Kay J, 2009, CORE EVID, V4, P159
   Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217
   Klareskog L, 2011, CLIN EXP RHEUMATOL, V29, P238
   Lassere M, 2003, J RHEUMATOL, V30, P1366
   Lau AN, 2010, THER CLIN RISK MANAG, V6, P497, DOI 10.2147/TCRM.S7776
   Leibbrandt A, 2010, ADV EXP MED BIOL, V658, P77, DOI 10.1007/978 1 4419 1050 9_9
   Leibbrandt A, 2009, ADV EXP MED BIOL, V647, P130, DOI 10.1007/978 0 387 89520 8_9
   Leibbrandt A, 2009, ADV EXP MED BIOL, V649, P100
   Lisbona MP, 2008, J RHEUMATOL, V35, P394
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140 6736(99)05246 0
   McQueen F, 2003, J RHEUMATOL, V30, P1387
   Migliore Alberto, 2007, Aging Clin Exp Res, V19, P18
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Peterfy C, 2003, J RHEUMATOL, V30, P1364
   Reginster JY, 2011, DRUGS, V71, P65, DOI 10.2165/11587570 000000000 00000
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Senel S, 2011, CLIN RHEUMATOL, V30, P1369, DOI 10.1007/s10067 011 1782 6
   Sikon A, 2010, INT J WOMENS HEALTH, V2, P37
   Sowa Hideaki, 2011, Clin Calcium, V21, P9, DOI CliCa1101916
   Swinkels HL, 2001, SEMIN ARTHRITIS RHEU, V31, P176, DOI 10.1053/sarh.2001.28304
   WEINBLATT ME, 2010, ARTHRITIS CARE  1018
NR 35
TC 10
Z9 10
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2012
VL 16
IS 3
BP 363
EP 369
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 926RQ
UT WOS:000302849100012
PM 22530354
DA 2025 08 17
ER

PT J
AU Forsberg, PA
   Mark, TM
AF Forsberg, Peter A.
   Mark, Tomer M.
TI Pomalidomide in the treatment of relapsed multiple myeloma
SO FUTURE ONCOLOGY
LA English
DT Article
DE IMiD; multiple myeloma; pomalidomide; refractory; relapsed
ID LENALIDOMIDE PLUS DEXAMETHASONE; STEM CELL TRANSPLANTATION; ENDOTHELIAL
   GROWTH FACTOR; LOW DOSE DEXAMETHASONE; THALIDOMIDE ANALOGS; OSTEOCLAST
   FORMATION; CEREBLON EXPRESSION; INDUCE APOPTOSIS; DOWN REGULATION;
   RENAL FAILURE
AB The novel agents bortezomib and lenalidomide improve outcomes in multiple myeloma, yet most patients will relapse after exhausting treatment. Management of relapsed and refractory multiple myeloma (RRMM) is challenging owing to disease , patient  and treatment related factors, and new therapies for these patients are required. Pomalidomide (POM) is an immunomodulatory compound that has been recently approved in the USA for the treatment of RRMM after two prior therapies, including lenalidomide and bortezomib. POM has several potential mechanisms of action and has a unique pharmacokinetic profile. Several trials demonstrate the efficacy and safety of POM in RRMM, including subjects refractory to lenalidomide and bortezomib. Herein, POM is reviewed as a clinically active new treatment option for RRMM.
C1 [Forsberg, Peter A.; Mark, Tomer M.] New York Presbyterian Hosp, Cornell Med Ctr, Div Hematol & Med Oncol, Dept Med,Weill Cornell Med Coll, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medical Center; NewYork Presbyterian
   Hospital; Weill Cornell Medicine
RP Mark, TM (通讯作者)，New York Presbyterian Hosp, Cornell Med Ctr, Div Hematol & Med Oncol, Dept Med,Weill Cornell Med Coll, 428 East 72nd St, New York, NY 10021 USA.
EM tom9009@med.cornell.edu
FU Celgene Inc.; Onyx Inc.
FX TM Mark has received honoraria for speakers bureau activities, advisory
   board membership and research funding from Celgene Inc. TM Mark has also
   received honoraria for speakers bureau activities and research funding
   from Onyx Inc., and honoraria for speakers bureau activities and
   advisory board membership from Millenium Inc. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   [Anonymous], SEER Cancer Statistics Review 1975 2008
   Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204
   Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138
   Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323
   Bolzoni M, 2013, EXP HEMATOL, V41, P387, DOI 10.1016/j.exphem.2012.11.005
   Broyl A, 2013, BLOOD, V121, P624, DOI 10.1182/blood 2012 06 438101
   Chen NH, 2012, CANCER CHEMOTH PHARM, V69, P789, DOI 10.1007/s00280 011 1760 3
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   Corral LG, 1999, J IMMUNOL, V163, P380
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210
   Dimopoulos MA, 2012, AM SOC HEM M ATL GA
   Dimopoulos MA, 2010, J CLIN ONCOL, V28, P4976, DOI 10.1200/JCO.2010.30.8791
   Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607
   Dredge K, 2002, J IMMUNOL, V168, P4914, DOI 10.4049/jimmunol.168.10.4914
   Dreisbach AW, 2008, EXPERT OPIN DRUG MET, V4, P1065, DOI [10.1517/17425255.4.8.1065, 10.1517/17425255.4.8.1065 ]
   Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood 2012 01 405977
   Eleutherakis Papaiakovou V, 2007, LEUKEMIA LYMPHOMA, V48, P337, DOI 10.1080/10428190601126602
   Escoubet Lozach L, 2009, CANCER RES, V69, P7347, DOI 10.1158/0008 5472.CAN 08 4898
   Galustian C, 2009, CANCER IMMUNOL IMMUN, V58, P1033, DOI 10.1007/s00262 008 0620 4
   Gandhi AK, 2010, CURR CANCER DRUG TAR, V10, P155
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Harousseau JL, 2010, HAEMATOL HEMATOL J, V95, P1738, DOI 10.3324/haematol.2009.015917
   Henry JY, 2013, IMMUNOLOGY, V139, P377, DOI 10.1111/imm.12087
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hoffmann M, 2013, CANCER CHEMOTH PHARM, V71, P489, DOI 10.1007/s00280 012 2040 6
   Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319
   Jagannath S, 2012, AM SOC HEM ANN M ATL
   Knight R, 2005, SEMIN ONCOL, V32, pS24, DOI 10.1053/j.seminoncol.2005.06.018
   Kropff M, 2012, HAEMATOL HEMATOL J, V97, P784, DOI 10.3324/haematol.2011.044271
   Kumar SK, 2012, LEUKEMIA, V26, P149, DOI 10.1038/leu.2011.196
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood 2007 10 116129
   Lacy MQ, 2010, LEUKEMIA, V24, P1934, DOI 10.1038/leu.2010.190
   Lacy MQ, 2011, BLOOD, V118, P2970, DOI 10.1182/blood 2011 04 348896
   Lacy MQ, 2009, J CLIN ONCOL, V27, P5008, DOI 10.1200/JCO.2009.23.6802
   Lacy MQ, 2012, AM SOC HEM M ATL GA
   Leleu X, 2013, BLOOD, V121, P1968, DOI 10.1182/blood 2012 09 452375
   Leleu XL, 2012, 17 C EUR HEM ASS AMS
   Li SR, 2011, BLOOD, V117, P5157, DOI 10.1182/blood 2010 10 314278
   Lopez Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119
   Lu L, 2009, MICROVASC RES, V77, P78, DOI 10.1016/j.mvr.2008.08.003
   Mark TM, 2012, AM SOC HEM M ATL GA
   Matsuoka N, 1996, CLIN EXP IMMUNOL, V104, P501, DOI 10.1046/j.1365 2249.1996.46752.x
   McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083
   Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525
   Nakamura M, 2010, INT J ONCOL, V37, P815, DOI 10.3892/ijo_00000731
   Nucci M, 2009, CLIN INFECT DIS, V49, P1211, DOI 10.1086/605664
   Ohara T, 2004, ANTICANCER RES, V24, P3723
   Pal R, 2010, BLOOD, V115, P605, DOI 10.1182/blood 2009 05 221077
   Palumbo A, 2009, LEUKEMIA, V23, P449, DOI 10.1038/leu.2008.325
   Palumbo A, 2012, AM SOC HEM M ATL GA
   Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704
   Pratt G, 2007, BRIT J HAEMATOL, V138, P563, DOI 10.1111/j.1365 2141.2007.06705.x
   Quach H, 2010, LEUKEMIA, V24, P22, DOI 10.1038/leu.2009.236
   Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221
   Rajkumar SV, 2005, BLOOD, V106, P4050, DOI 10.1182/blood 2005 07 2817
   Richardson P, 2011, 13 INT MYEL WORKSH P
   Richardson PG, 2009, J CLIN ONCOL, V27, P3518, DOI 10.1200/JCO.2008.18.3087
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Richardson PG, 2012, AM SOC HEM M ATL GA
   Richardson PG, 2013, 14 INT MYEL WORKSH K
   Rossi A, 2013, BLOOD, V121, P1982, DOI 10.1182/blood 2012 08 448563
   Rychak E, 2011, 13 INT MYEL WORKSH P
   SCAGLIONE F, 1993, J CHEMOTHERAPY, V5, P228
   Schey SA, 2004, J CLIN ONCOL, V22, P3269, DOI 10.1200/JCO.2004.10.052
   Schütt P, 2006, LEUKEMIA LYMPHOMA, V47, P1570, DOI 10.1080/10428190500472503
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Stewart A, 2007, LEUKEMIA, V21, P2358, DOI 10.1038/sj.leu.2404800
   Streetly MJ, 2008, BRIT J HAEMATOL, V141, P41, DOI 10.1111/j.1365 2141.2008.07013.x
   TAKIZAWA H, 1995, BIOCHEM BIOPH RES CO, V210, P781, DOI 10.1006/bbrc.1995.1727
   Tosi P, 2005, EUR J HAEMATOL, V74, P212, DOI 10.1111/j.1600 0609.2004.00382.x
   Verhelle D, 2007, CANCER RES, V67, P746, DOI 10.1158/0008 5472.CAN 06 2317
   Vij R, 2012, AM SOC CLIN ONC ANN
   Xu YB, 2009, BLOOD, V114, P338, DOI 10.1182/blood 2009 02 200543
   Zhu D, 2008, CANCER IMMUNOL IMMUN, V57, P1849, DOI 10.1007/s00262 008 0512 7
   Zhu YX, 2013, LEUKEMIA LYMPHOMA, V54, P683, DOI 10.3109/10428194.2012.728597
   Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood 2011 05 356063
NR 78
TC 3
Z9 4
U1 0
U2 7
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479 6694
EI 1744 8301
J9 FUTURE ONCOL
JI Future Oncol.
PD JUL
PY 2013
VL 9
IS 7
BP 939
EP 948
DI 10.2217/FON.13.105
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 292XA
UT WOS:000329934800009
PM 23837756
DA 2025 08 17
ER

PT J
AU Chen, JQ
   Sang, YM
   Li, JY
   Zhao, T
   Liu, B
   Xie, SJ
   Sun, WB
AF Chen, Jiaqi
   Sang, Yimeng
   Li, Jiaying
   Zhao, Tian
   Liu, Bin
   Xie, Sijing
   Sun, Weibin
TI Low level controllable blue LEDs irradiation enhances human dental pulp
   stem cells osteogenic differentiation via transient receptor potential
   vanilloid 1
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY
LA English
DT Article
DE Blue LEDs; Photobiomodulation; Human dental pulp cells; TRPV1;
   Osteogenic differentiation
ID LASER IRRADIATION; EXTRACELLULAR CALCIFICATION; PHOTOBIOMODULATION
   THERAPY; OSTEOBLAST PROLIFERATION; GROWTH FACTOR; BONE REPAIR;
   WAVELENGTH; EXPRESSION; APOPTOSIS; INCREASE
AB Human dental pulp stem cells (hDPSCs) have attracted tremendous attention in tissue regeneration engineering due to their excellent multidirectional differentiation potential. Photobiomodulation (PBM) using low level light emitting diodes (LEDs) or lasers has been proved to promote the osteogenesis of mesenchymal stem cells. However, the effect of LEDs on osteogenic differentiation of hDPSCs has little published data. In this work, the effect of blue LEDs with different energy densities of 2, 4, 6, 8, 10 J/cm(2) on osteogenic differentiation of hDPSCs was examined by using in vitro ALP staining, ALP activity, mineralization, and real time PCR. The results showed that compared with the control group, osteogenic differentiation was significantly enhanced in blue LEDs treated groups. As the energy density increased, the level of osteogenesis initially increased and then decreased reaching the highest level at 6 J/cm(2). Transient receptor potential vanilloid 1 (TRPV1), a Ca2+ ion channel, was believed to be a potential player in osteogenesis by photobiomodulation. By immunofluorescence assay, calcium influx assay, PCR, and ALP staining, it was shown that blue LEDs irradiation can increase the activity of TRPV1 and intracellular calcium levels similarly to the agonist of TRPV1 capsaicin. Additionally, pretreatment with capsazepine, a selective TRPV1 inhibitor, was able to abrogate the osteogenic effect of blue LEDs. In conclusion, these findings proposed that blue LEDs can promote the osteogenesis of hDPSCs within the appropriate range (4 8 J/cm(2)) during culture of osteogenic medium, and TRPV1/Ca2+ may be an essential signaling pathway involved in blue LEDs induced osteogenesis, providing new insights for the use of hDPSCs in tissue regeneration engineering.
C1 [Chen, Jiaqi; Li, Jiaying; Zhao, Tian; Xie, Sijing; Sun, Weibin] Nanjing Univ, Nanjing Stomatol Hosp, Med Sch, 30 Zhongyang Rd, Nanjing 210008, Jiangsu, Peoples R China.
   [Sang, Yimeng; Liu, Bin] Nanjing Univ, Sch Elect Sci & Engn, Jiangsu Prov Key Lab Adv Photon & Elect Mat, Nanjing 210093, Jiangsu, Peoples R China.
   [Chen, Jiaqi; Li, Jiaying; Zhao, Tian] Nanjing Univ, Nanjing Stomatol Hosp, Cent Lab Stomatol, Med Sch, Nanjing 210008, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Xie, SJ; Sun, WB (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Med Sch, 30 Zhongyang Rd, Nanjing 210008, Jiangsu, Peoples R China.
EM xiesj@nju.edu.cn; wbsun@nju.edu.cn
RI liu, bin/E 5431 2016; Chen, Jiaqi/HTT 0960 2023
FU National Key R & D Program of China [2021YFB3601000, 2021YFB3601002];
   National Natural Science Foundation of China [81801401]; Medical Science
   and Technology Development Foundation, Nanjing Department of Health
   [ZKX21055]
FX The work was supported by the National Key R & D Program of China
   (2021YFB3601000, 2021YFB3601002) ; the National Natural Science
   Foundation of China (81801401) ; and the Key Project supported by
   Medical Science and Technology Development Foundation, Nanjing
   Department of Health (ZKX21055) .
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Amid R, 2014, J LASERS MED SCI, V5, P163
   Ash C, 2017, LASER MED SCI, V32, P1909, DOI 10.1007/s10103 017 2317 4
   Barbosa D, 2013, LASER MED SCI, V28, P651, DOI 10.1007/s10103 012 1125 0
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Basso FG, 2013, LASER MED SCI, V28, P367, DOI 10.1007/s10103 012 1057 8
   Byrnes KR, 2005, LASER SURG MED, V37, P161, DOI 10.1002/lsm.20202
   Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fujimoto K, 2010, LASER SURG MED, V42, P519, DOI 10.1002/lsm.20880
   Ge XY, 2020, J CELL PHYSIOL, V235, P1209, DOI 10.1002/jcp.29034
   Grajales Reyes JG, 2021, NAT PROTOC, V16, P3072, DOI 10.1038/s41596 021 00532 2
   Heiskanen V, 2018, PHOTOCH PHOTOBIO SCI, V17, P1003, DOI [10.1039/c8pp00176f, 10.1039/c8pp90049c]
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751 1097.2008.00394.x
   Kim CY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20803 y
   Kim JE, 2017, LASER SURG MED, V49, P940, DOI 10.1002/lsm.22736
   Kipshidze N, 2001, LASER SURG MED, V28, P355, DOI 10.1002/lsm.1062
   Kirino I, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 79067 7
   Kiyosaki T, 2010, PHOTOMED LASER SURG, V28, pS167, DOI 10.1089/pho.2009.2693
   Kulkarni S, 2020, LASER MED SCI, V35, P1889, DOI 10.1007/s10103 020 03071 6
   Kumar A, 2018, BIOCHIMIE, V155, P129, DOI 10.1016/j.biochi.2018.10.014
   Kushibiki Toshihiro, 2008, Int J Med Sci, V5, P319
   Kushibiki T, 2009, PHOTOMED LASER SURG, V27, P493, DOI 10.1089/pho.2008.2343
   Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214
   Lipovsky A, 2010, LASER SURG MED, V42, P467, DOI 10.1002/lsm.20948
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Migliario M, 2014, LASER MED SCI, V29, P1463, DOI 10.1007/s10103 014 1556 x
   Mikami R, 2018, LASER SURG MED, V50, P340, DOI 10.1002/lsm.22775
   Mohan, 2019, LASERS DENT SCI, V3, P175, DOI [10.1007/s41547 019 00066 7, DOI 10.1007/S41547 019 00066 7]
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Oliveira FA, 2016, J PHOTOCH PHOTOBIO B, V163, P14, DOI 10.1016/j.jphotobiol.2016.08.006
   Pan LT, 2013, EUR J PHARMACOL, V715, P280, DOI 10.1016/j.ejphar.2013.05.009
   Park SI, 2015, NAT BIOTECHNOL, V33, P1280, DOI 10.1038/nbt.3415
   Pasternak Mnich K, 2019, LASER SURG MED, V51, P824, DOI 10.1002/lsm.23107
   Pereira MCMC, 2010, J PHOTOCH PHOTOBIO B, V98, P188, DOI 10.1016/j.jphotobiol.2009.12.005
   Pinheiro CCG, 2018, TISSUE ENG PT A, V24, P569, DOI [10.1089/ten.tea.2017.0115, 10.1089/ten.TEA.2017.0115]
   Pruitt T, 2022, METABOLITES, V12, DOI 10.3390/metabo12020103
   Qiu XY, 2021, ACTA BIOMATER, V135, P593, DOI 10.1016/j.actbio.2021.08.009
   Saracino S, 2009, LASER SURG MED, V41, P298, DOI 10.1002/lsm.20762
   Sassoli C, 2016, LASER SURG MED, V48, P318, DOI 10.1002/lsm.22441
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   Sun L, 2021, ACS NANO, V15, P12475, DOI 10.1021/acsnano.1c03614
   Wang YG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07525 w
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   Wu ZH, 2010, LASER SURG MED, V42, P503, DOI 10.1002/lsm.20924
   Yakushenko A, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.11.111402
   Yamagishi K, 2019, NAT BIOMED ENG, V3, P27, DOI 10.1038/s41551 018 0261 7
   Yan GG, 2018, INT J BIOCHEM CELL B, V103, P81, DOI 10.1016/j.biocel.2018.08.006
   Yang YY, 2020, LASER MED SCI, V35, P1981, DOI 10.1007/s10103 020 02995 3
   Yoo JA, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/8871745
   Yuan Y, 2017, CELL PHYSIOL BIOCHEM, V43, P237, DOI 10.1159/000480344
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhu TT, 2019, LASER MED SCI, V34, P1473, DOI 10.1007/s10103 019 02750 3
NR 56
TC 15
Z9 15
U1 1
U2 20
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011 1344
EI 1873 2682
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B Biol.
PD AUG
PY 2022
VL 233
AR 112472
DI 10.1016/j.jphotobiol.2022.112472
EA JUN 2022
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 3I8WL
UT WOS:000832989400002
PM 35660312
OA hybrid
DA 2025 08 17
ER

PT J
AU Botz, B
   Bölcskei, K
   Kereskai, L
   Kovács, M
   Németh, T
   Szigeti, K
   Horváth, I
   Máthé, D
   Kovács, N
   Hashimoto, H
   Reglodi, D
   Szolcsányi, J
   Pintér, E
   Mócsai, A
   Helyes, Z
AF Botz, Balint
   Bolcskei, Kata
   Kereskai, Laszlo
   Kovacs, Miklos
   Nemeth, Tamas
   Szigeti, Krisztian
   Horvath, Ildiko
   Mathe, Domokos
   Kovacs, Noemi
   Hashimoto, Hitoshi
   Reglodi, Dora
   Szolcsanyi, Janos
   Pinter, Erika
   Mocsai, Attila
   Helyes, Zsuzsanna
TI Differential Regulatory Role of Pituitary Adenylate Cyclase Activating
   Polypeptide in the Serum Transfer Arthritis Model
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; INDOCYANINE GREEN; CALVARIAL OSTEOBLASTS;
   LUTZOMYIA LONGIPALPIS; PLASMA LEAKAGE; PACAP; RECEPTORS; VIP;
   EXPRESSION; VASODILATOR
AB ObjectivePituitary adenylate cyclase activating polypeptide (PACAP) expressed in capsaicin sensitive sensory neurons and immune cells has divergent functions in inflammatory and pain processes. This study was undertaken to investigate the involvement of PACAP in a mouse model of rheumatoid arthritis.
   MethodsArthritis was induced in PACAP( / ) and wild type (PACAP(+/+)) mice by K/BxN serum transfer. General features of the disease were investigated by semiquantitative scoring, plethysmometry, and histopathologic analysis. Mechano  and thermonociceptive thresholds and motor functions were also evaluated. Metabolic activity was assessed by positron emission tomography. Bone morphology was measured by in vivo micro computed tomography, myeloperoxidase activity and superoxide production by bioluminescence imaging with luminol and lucigenin, respectively, and vascular permeability by fluorescent indocyanine green dye study.
   ResultsPACAP(+/+) mice developed notable joint swelling, reduced grasping ability, and mechanical (but not thermal) hyperalgesia after K/BxN serum transfer. In PACAP( / ) mice clinical scores and edema were significantly reduced, and mechanical hyperalgesia and motor impairment were absent, throughout the 2 week period of observation. Metabolic activity and superoxide production increased in the tibiotarsal joints of wild type mice but were significantly lower in PACAP( / ) animals. Myeloperoxidase activity in the ankle joints of PACAP( / ) mice was significantly reduced in the early phase of arthritis, but increased in the late phase. Synovial hyperplasia was also significantly increased, and progressive bone spur formation was observed in PACAP deficient mice only.
   ConclusionIn PACAP deficient mice with serum transfer arthritis, joint swelling, vascular leakage, hyperalgesia, and early inflammatory cell accumulation are reduced; in the later phase of the disease, immune cell function and bone neoformation are increased. Elucidation of the underlying pathways of PACAP activity may open promising new avenues for development of therapy in inflammatory arthritis.
C1 [Botz, Balint; Bolcskei, Kata; Szolcsanyi, Janos; Pinter, Erika; Helyes, Zsuzsanna] Univ Pecs, Sch Med, Dept Pharmacol & Pharmacotherapy, H 7624 Pecs, Hungary.
   [Botz, Balint; Bolcskei, Kata; Pinter, Erika; Helyes, Zsuzsanna] Univ Pecs, Janos Szentagothai Res Ctr, Mol Pharmacol Res Team, Pecs, Hungary.
   [Kereskai, Laszlo] Univ Pecs, Sch Med, Dept Pathol, H 7624 Pecs, Hungary.
   [Kovacs, Miklos; Nemeth, Tamas; Mocsai, Attila] Semmelweis Univ, Sch Med, Dept Physiol, Budapest, Hungary.
   [Kovacs, Miklos; Nemeth, Tamas; Mocsai, Attila] MTA SE Lendulet Inflammat Physiol Res Grp, Budapest, Hungary.
   [Szigeti, Krisztian; Horvath, Ildiko; Mathe, Domokos] Semmelweis Univ, Dept Biophys & Radiat Biol, Ctr Nanobiotechnol & Vivo Imaging, H 1085 Budapest, Hungary.
   [Mathe, Domokos; Kovacs, Noemi] CROmed Ltd, Budapest, Hungary.
   [Hashimoto, Hitoshi] Osaka Univ, Grad Sch Pharmaceut Sci, Osaka, Japan.
   [Reglodi, Dora] Univ Pecs, Sch Med, Dept Anat, Pecs, Hungary.
   [Reglodi, Dora] MTA PTE PACAP Lendulet Res Grp, Pecs, Hungary.
C3 University of Pecs; University of Pecs; University of Pecs; Semmelweis
   University; Semmelweis University; University of Osaka; University of
   Pecs
RP Helyes, Z (通讯作者)，Univ Pecs, Sch Med, Dept Pharmacol & Pharmacotherapy, Szigeti U 12, H 7624 Pecs, Hungary.
EM zsuzsanna.helyes@aok.pte.hu
RI ; Németh, Tamás/O 1968 2017; Horvath, Ildiko/HTQ 0256 2023; Bölcskei,
   Kata/KQV 4528 2024; Zsuzsanna, Helyes/GLU 8236 2022; Hashimoto,
   Hitoshi/D 1209 2010; Mocsai, Attila/B 2792 2008
OI Helyes, Zsuzsanna/0000 0003 2435 4367; Nemeth,
   Tamas/0000 0001 6854 4301; Hashimoto, Hitoshi/0000 0001 6548 4016;
   Kovacs, Miklos/0000 0001 9650 3363; Mathe, Domokos/0000 0001 7343 0413;
   Mocsai, Attila/0000 0002 0512 1157
FU European Research Council [206283]; Wellcome Trust [087782]; National
   Excellence Program of the European Union; State of Hungary [TAMOP 4.2.4.
   A/2 11 1 2012 0001]; European Social Fund; Hungarian Academy of Sciences
   Lendulet Program [OTKA K104984]; Arimura Foundation; 
   [SROP 4.2.2.A 11/1/KONV 2012 0024]; Grants in Aid for Scientific
   Research [26670122] Funding Source: KAKEN
FX Supported by the European Research Council (Starting Independent
   Investigator Award 206283 to Dr. Mocsai) and the Wellcome Trust
   (International Senior Research Fellowship 087782 to Dr. Mocsai). Dr.
   Botz' work was supported by the National Excellence Program of the
   European Union and the State of Hungary (award TAMOP 4.2.4.
   A/2 11 1 2012 0001) and cofunded by the European Social Fund. Dr.
   Reglodi's work was supported by the Hungarian Academy of Sciences
   Lendulet Program (grant OTKA K104984) and the Arimura Foundation. The
   research was supported by SROP 4.2.2.A 11/1/KONV 2012 0024.
CR Abad C, 2001, J IMMUNOL, V167, P3182, DOI 10.4049/jimmunol.167.6.3182
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Asquith DL, 2009, EUR J IMMUNOL, V39, P2040, DOI 10.1002/eji.200939578
   Botz B, 2013, PEPTIDES, V43, P105, DOI 10.1016/j.peptides.2013.03.003
   Davis Taber R, 2008, J PAIN, V9, P449, DOI 10.1016/j.jpain.2008.01.329
   Delgado M, 2003, ANN NY ACAD SCI, V992, P141, DOI 10.1111/j.1749 6632.2003.tb03145.x
   El Zein N, 2008, J LEUKOCYTE BIOL, V83, P972, DOI 10.1189/jlb.0507327
   Gross S, 2009, NAT MED, V15, P455, DOI 10.1038/nm.1886
   Hardy RS, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4158
   Harfi I, 2004, J IMMUNOL, V173, P4154, DOI 10.4049/jimmunol.173.6.4154
   Hashimoto H, 2006, ANN NY ACAD SCI, V1070, P75, DOI 10.1196/annals.1317.038
   Helyes Z, 2004, ARTHRITIS RHEUM US, V50, P1677, DOI 10.1002/art.20184
   Jakus Z, 2010, ARTHRITIS RHEUM US, V62, P1899, DOI 10.1002/art.27438
   Juhász T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091541
   Kanno Y, 2005, MOL CELL ENDOCRINOL, V229, P75, DOI 10.1016/j.mce.2004.09.004
   Kelchtermans H, 2007, J LEUKOCYTE BIOL, V81, P1044, DOI 10.1189/jlb.0806486
   Kellogg DL, 2012, J APPL PHYSIOL, V113, P1512, DOI 10.1152/japplphysiol.00859.2012
   Kim TH, 2010, PHARM RES DORDR, V27, P1900, DOI 10.1007/s11095 010 0190 y
   Kim Y, 2006, J IMMUNOL, V176, P2969, DOI 10.4049/jimmunol.176.5.2969
   Kinhult J, 2002, PEPTIDES, V23, P1735, DOI 10.1016/S0196 9781(02)00149 3
   Kirchherr AK, 2009, MOL PHARMACEUT, V6, P480, DOI 10.1021/mp8001649
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Laburthe M, 2007, PEPTIDES, V28, P1631, DOI 10.1016/j.peptides.2007.04.026
   Le YY, 2000, IMMUNOL REV, V177, P185, DOI 10.1034/j.1600 065X.2000.17704.x
   LEVINE JD, 1985, J IMMUNOL, V135, pS843
   Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339
   Mabuchi T, 2004, J NEUROSCI, V24, P7283, DOI 10.1523/JNEUROSCI.0983 04.2004
   Matsui T, 2009, J NUCL MED, V50, P920, DOI 10.2967/jnumed.108.060103
   McDougall JJ, 2006, PAIN, V123, P98, DOI 10.1016/j.pain.2006.02.015
   Meier R, 2010, ARTHRITIS RHEUM US, V62, P2322, DOI 10.1002/art.27542
   MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006 291X(89)91757 9
   Nagata A, 2009, J CELL PHYSIOL, V221, P75, DOI 10.1002/jcp.21831
   Ohsawa M, 2002, PAIN, V100, P27, DOI 10.1016/S0304 3959(02)00207 5
   Persson E, 2005, BIOCHEM BIOPH RES CO, V335, P705, DOI 10.1016/j.bbrc.2005.07.135
   Persson E, 2011, J CELL BIOCHEM, V112, P3732, DOI 10.1002/jcb.23304
   Pozo D, 1997, BBA MOL CELL RES, V1359, P250, DOI 10.1016/S0167 4889(97)00104 3
   Ransjö M, 2000, BIOCHEM BIOPH RES CO, V274, P400, DOI 10.1006/bbrc.2000.3151
   Sándor K, 2010, NEUROPEPTIDES, V44, P363, DOI 10.1016/j.npep.2010.06.004
   Sándor K, 2009, PAIN, V141, P143, DOI 10.1016/j.pain.2008.10.028
   Schmidt Choudhury A, 1999, REGUL PEPTIDES, V82, P65, DOI 10.1016/S0167 0115(99)00041 5
   Schytz HW, 2010, J HEADACHE PAIN, V11, P309, DOI 10.1007/s10194 010 0214 3
   Schytz HW, 2009, BRAIN, V132, P16, DOI 10.1093/brain/awn307
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Svensjö E, 2012, MICROVASC RES, V83, P185, DOI 10.1016/j.mvr.2011.10.003
   Svensjö E, 2009, J VASC RES, V46, P435, DOI 10.1159/000197866
   Tan YV, 2009, P NATL ACAD SCI USA, V106, P2012, DOI 10.1073/pnas.0812257106
   Tseng JC, 2012, CHEM BIOL, V19, P1199, DOI 10.1016/j.chembiol.2012.08.007
   Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370
   WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476 5381.1992.tb14336.x
   Werner SG, 2012, ANN RHEUM DIS, V71, P504, DOI 10.1136/annrheumdis 2010 148288
NR 50
TC 42
Z9 42
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD OCT
PY 2014
VL 66
IS 10
BP 2739
EP 2750
DI 10.1002/art.38772
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AQ4DZ
UT WOS:000342744300011
PM 25048575
OA Green Published
DA 2025 08 17
ER

PT J
AU Baraliakos, X
   de Jongh, J
   Poddubnyy, D
   Zwezerijnen, GJC
   Hemke, R
   Glatt, S
   Shaw, S
   Ionescu, L
   el Baghdady, A
   Mann, J
   Maguire, RP
   Vaux, T
   de Peyrecave, N
   Oortgiesen, M
   Baeten, D
   van der Laken, C
AF Baraliakos, Xenofon
   de Jongh, Jerney
   Poddubnyy, Denis
   Zwezerijnen, Gerben J. C.
   Hemke, Robert
   Glatt, Sophie
   Shaw, Stevan
   Ionescu, Lucian
   el Baghdady, Assem
   Mann, Joanne
   Maguire, Ralph Paul
   Vaux, Tom
   de Peyrecave, Natasha
   Oortgiesen, Marga
   Baeten, Dominique
   van der Laken, Conny
TI Impact of bimekizumab and certolizumab pegol on efficacy, safety and
   osteoblastic activity in radiographic axial spondyloarthritis: results
   from a phase IIa, multicentre, randomised, double blind, exploratory
   study with PET CT imaging
SO THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
LA English
DT Article
DE ankylosing spondylitis; axial spondyloarthritis; bDMARDs; bimekizumab;
   bone; IL 17 inhibitors; imaging; osteoblast; PET CT; TNF inhibitors
ID TUMOR NECROSIS FACTOR; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS;
   PREDICT; LESIONS
AB Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL) 17F in addition to IL 17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation is possible using 18F fluoride positron emission tomography computerised tomography (PET CT) imaging to quantitatively monitor osteoblastic activity.Objectives: This exploratory study, initiated before phase IIb/III studies, assessed the efficacy and safety of BKZ in patients with radiographic (r )axSpA and its effect on new bone formation.Design: Patients were randomised 2:1 to BKZ 160 mg every 2 weeks (Q2W; Weeks 0 10) then 320 mg Q4W (Weeks 12 44), or the reference drug: certolizumab pegol (CZP) 400 mg Q2W (Weeks 0 4), then 200 mg Q2W (Weeks 6 10), 400 mg Q4W (Weeks 12 44).Methods: Primary (Axial Spondyloarthritis Disease Activity Score (ASDAS) change from baseline (CfB)) and secondary endpoints (ASDAS ID, ASDAS MI) were assessed at Week 12. PET positive axSpA lesion counts and osteoblastic activity quantification (mean SUVauc) were performed at baseline and Weeks 12 and 48 in the sacroiliac joints and spine (PET CT substudy; not powered to evaluate differences).Results: In total, 76 patients were randomised; 26/76 entered the PET CT substudy. At Week 12, the mean ASDAS CfB with BKZ was  2.1 (CZP:  1.8); ASDAS ID and ASDAS MI were achieved by 23.9% (11/46) (CZP: 20.8% (5/24)) and 60.9% (28/46) (CZP: 45.8% (11/24)) patients. Across treatments, clinical efficacy was maintained or increased further at Week 48. In the PET CT substudy, the total number of PET positive axSpA lesions and mean SUVauc were substantially reduced from baseline at Week 12 with BKZ and CZP, with reductions maintained or further reduced at Week 48. Treatments were well tolerated with no new safety signals.Conclusion: Dual inhibition of IL 17A and IL 17F with BKZ resulted in improved clinical outcomes and reduced osteoblastic activity in patients with r axSpA, suggesting the potential of BKZ to reduce disease activity and new bone formation within 12 weeks of treatment. CZP findings were consistent with previous data. No new safety signals were identified.Trial registration: ClinicalTrials.gov, NCT03215277 (https://clinicaltrials.gov/study/NCT03215277).
C1 [Baraliakos, Xenofon] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany.
   [de Jongh, Jerney; van der Laken, Conny] Amsterdam UMC, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, De Boelelaan 1117, NL 1081 HV Amsterdam, Netherlands.
   [Poddubnyy, Denis] Charite Univ Med Berlin, Dept Gastroenterol Infect Dis & Rheumatol, Berlin, Germany.
   [Poddubnyy, Denis] German Rheumatism Res Ctr, Dept Epidemiol, Berlin, Germany.
   [Zwezerijnen, Gerben J. C.; Hemke, Robert] Amsterdam UMC, Dept Radiol & Nucl Med, Amsterdam, Netherlands.
   [Glatt, Sophie; Ionescu, Lucian; Maguire, Ralph Paul; de Peyrecave, Natasha] UCB, Brussels, Belgium.
   [Shaw, Stevan; Mann, Joanne; Vaux, Tom] UCB, Slough, England.
C3 Ruhr University Bochum; Rheumazentrum Ruhrgebiet; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Leibniz Association; Deutsches Rheuma Forschungszentrum (DRFZ);
   University of Amsterdam; UCB Pharma SA; UCB Pharma SA
RP van der Laken, C (通讯作者)，Amsterdam UMC, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, De Boelelaan 1117, NL 1081 HV Amsterdam, Netherlands.
EM j.vanderlaken@amsterdamumc.nl
RI Zwezerijnen, Gerben/MSW 0702 2025; Baraliakos, Xenofon/AAF 7346 2019;
   Poddubnyy, Denis/V 1985 2019; Maguire, Ralph/GYV 1278 2022
OI Baraliakos, Xenofon/0000 0002 9475 9362; Maguire, Ralph
   Paul/0000 0003 3937 6622; Poddubnyy, Denis/0000 0002 4537 6015; 
FU UCB; UCB
FX The authors thank the patients and their caregivers in addition to all
   the investigators and their teams who contributed to these studies. The
   authors also acknowledge Raphael Teichmann, PhD, UCB, Monheim, Germany,
   for global clinical project management of the study, Celia Menckeberg,
   PhD, UCB, Breda, The Netherlands, for publication coordination and
   editorial assistance and Evelyn Turner, BSc, Costello Medical,
   Cambridge, UK, for medical writing and editorial assistance. This study
   was funded by UCB.
CR Baraliakos X, 2005, ANN RHEUM DIS, V64, P1462, DOI 10.1136/ard.2004.033472
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P1819, DOI 10.1136/annrheumdis 2013 203425
   Baraliakos X, 2024, ANN RHEUM DIS, V83, P199, DOI 10.1136/ard 2023 224803
   Baraliakos X, 2022, ARTHRITIS RHEUMATOL, V74, P1943, DOI 10.1002/art.42282
   Baraliakos X, 2022, RHEUMATOLOGY, V61, P2875, DOI 10.1093/rheumatology/keab841
   Baraliakos X, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2496
   Boel A, 2019, ANN RHEUM DIS, V78, P1545, DOI 10.1136/annrheumdis 2019 215707
   Boellaard R, 2018, J NUCL MED, V59
   Braun J, 2023, ARTHRITIS RES THER, V25, DOI 10.1186/s13075 023 03051 5
   Braun J, 2019, RHEUMATOLOGY, V58, P859, DOI 10.1093/rheumatology/key375
   Braun J, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen 2017 000430
   Bruijnen STG, 2018, RHEUMATOLOGY, V57, P631, DOI 10.1093/rheumatology/kex448
   Campbell CM, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000697
   de Jongh J, 2023, EUR J NUCL MED MOL I, V50, P1351, DOI 10.1007/s00259 022 06080 5
   Deodhar A, 2019, ARTHRITIS RHEUMATOL, V71, P599, DOI 10.1002/art.40753
   European Medicines Agency (EMA), 2021, Bimekizumab summary of product characteristics
   European Medicines Agency (EMA), 2010, Certolizumab pegol summary of product characteristics
   Food and Drugs Administration (FDA), 2017, Certolizumab pegol prescribing information
   Frost ML, 2013, J BONE MINER RES, V28, P1337, DOI 10.1002/jbmr.1862
   Glatt S, 2018, ANN RHEUM DIS, V77, P523, DOI 10.1136/annrheumdis 2017 212127
   Landewé R, 2014, ANN RHEUM DIS, V73, P39, DOI 10.1136/annrheumdis 2013 204231
   Lukas C, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2017 000586
   Maksymowych WP, 2018, RHEUMATOLOGY, V57, P1390, DOI 10.1093/rheumatology/key104
   Maksymowych WP, 2009, ARTHRITIS RHEUM US, V60, P93, DOI 10.1002/art.24132
   McInnes I, 2022, ANN RHEUM DIS, V81, P206, DOI 10.1136/annrheumdis 2022 eular.5016
   Merola JF, 2022, ANN RHEUM DIS, V81, P167, DOI 10.1136/annrheumdis 2022 eular.2265
   Nakamura A, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2020.101491
   National Library of Medicine (NIH), Syndesmophyte
   Navarro Compán V, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1191782
   Navarro Compán V, 2021, ANN RHEUM DIS, V80, P1511, DOI 10.1136/annrheumdis 2021 221035
   Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365 2567.2011.03465.x
   Park EK, 2017, RHEUMATOL INT, V37, P765, DOI 10.1007/s00296 017 3660 2
   Poddubnyy D, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0681 5
   Ramiro S, 2022, ARTHRITIS RHEUMATOL, V74, P1094, DOI 10.1136/ard 2022 223296
   Reich K, 2021, NEW ENGL J MED, V385, P142, DOI 10.1056/NEJMoa2102383
   Reich K, 2021, LANCET, V397, P487, DOI 10.1016/S0140 6736(21)00125 2
   Rudwaleit M, 2023, ANN RHEUM DIS, V82, P614, DOI 10.1136/annrheumdis 2023 eular.1702
   Rudwaleit M, 2005, ARTHRITIS RHEUM, V52, P1000, DOI 10.1002/art.20990
   Shah M, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen 2020 001306
   Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140 6736(16)31591 4
   Torgutalp M, 2022, ANN RHEUM DIS, V81, P1252, DOI 10.1136/annrheumdis 2022 222324
   van der Heijde D, 2009, ANN RHEUM DIS, V68, P1811, DOI 10.1136/ard.2008.100826
   van der Heijde D, 2023, ANN RHEUM DIS, V82, P515, DOI 10.1136/ard 2022 223595
   van der Heijde D, 2020, ANN RHEUM DIS, V79, P595, DOI 10.1136/annrheumdis 2020 216980
   van der Heijde D, 2018, ANN RHEUM DIS, V77, P699, DOI 10.1136/annrheumdis 2017 212377
   van der Heijde D, 2017, RHEUMATOLOGY, V56, P1498, DOI 10.1093/rheumatology/kex174
   van der Heijde D, 2017, ANN RHEUM DIS, V76, P978, DOI 10.1136/annrheumdis 2016 210770
   van der Horst Bruinsma IE, 2021, THER ADV MUSCULOSKEL, V13, DOI 10.1177/1759720X211003803
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Ward MM, 2019, ARTHRITIS RHEUMATOL, V71, P1599, DOI [10.1002/art.41042, 10.1002/acr.24025]
   Warren RB, 2021, NEW ENGL J MED, V385, P130, DOI 10.1056/NEJMoa2102388
NR 51
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759 720X
EI 1759 7218
J9 THER ADV MUSCULOSKEL
JI Ther. Adv. Musculoskelet. Dis.
PY 2024
VL 16
AR 1759720X241293944
DI 10.1177/1759720X241293944
PG 18
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA N7V9Q
UT WOS:001366379000001
PM 39620046
OA gold
DA 2025 08 17
ER

PT J
AU Proulx, ST
   Kwok, E
   You, Z
   Papuga, MO
   Beck, CA
   Shealy, DJ
   Calvi, LM
   Ritchlin, CT
   Awad, HA
   Boyce, BF
   Xing, L
   Schwarz, EM
AF Proulx, Steven T.
   Kwok, Edmund
   You, Zhigang
   Papuga, M. Owen
   Beck, Christopher A.
   Shealy, David J.
   Calvi, Laura M.
   Ritchlin, Christopher T.
   Awad, Hani A.
   Boyce, Brendan F.
   Xing, Lianping
   Schwarz, Edward M.
TI Elucidating bone marrow edema and myelopoiesis in murine arthritis using
   contrast enhanced magnetic resonance imaging
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID TUMOR NECROSIS FACTOR; EARLY RHEUMATOID ARTHRITIS; NF KAPPA B;
   ANKYLOSING SPONDYLITIS; INFLAMMATORY ARTHRITIS; OSTEOCLAST PRECURSORS;
   STROMAL CELLS; JOINT DAMAGE; LYMPH NODE; MRI
AB Objective. While bone marrow edema (BME) detected by magnetic resonance imaging (MRI) is a biomarker of arthritis, its nature remains poorly understood due to the limitations of clinical studies. In this study, MRI of murine arthritis was used to elucidate its cellular composition and vascular involvement.
   Methods. BME was quantified using normalized bone marrow intensity (NBMI) from precontrast MRI and normalized marrow contrast enhancement (NMCE) following intravenous administration of gadopentate dimeglumine. Wild type (WT) and tumor necrosis factor (TNF) transgenic mice were scanned from 2 to 5 months of age, followed by histologic or fluorescence activated cell sorting (FACS) analysis of marrow. In efficacy studies, TNF transgenic mice were treated with anti TNF or placebo for 8 weeks, and then were studied using bimonthly MRI and histologic analysis.
   Results. NBMI values were similar in WT and TNF transgenic mice at 2 months. The values in WT mice steadily decreased thereafter, with mean values becoming significantly different from those of TNF transgenic mice at 3.5 months (mean +/  SD 0.29 +/  0.08 versus 0.46 +/  0.13; P < 0.05). Red to yellow marrow transformation occurred in WT but not TNF transgenic mice, as observed histologically at 5 months. The marrow of TNF transgenic mice that received anti TNF therapy converted to yellow marrow, with lower NBMI values versus placebo at 6 weeks (mean SD 0.26 +/  0.07 versus 0.61 +/  0.22; P < 0.05). FACS analysis of bone marrow revealed a significant correlation between NBMI values and CD11b+ monocytes (R 2 = 0.91, p = 0.0028). Thresholds for "normal" red marrow versus pathologic BME were established, and it was also found that inflammatory marrow is highly permeable to contrast agent.
   Conclusion. BME signals in TNF transgenic mice are caused by yellow to red marrow conversion, With increased myelopoiesis and increased marrow permeability. The factors that mediate these changes warrant further investigation.
C1 [Proulx, Steven T.; Kwok, Edmund; You, Zhigang; Papuga, M. Owen; Beck, Christopher A.; Calvi, Laura M.; Ritchlin, Christopher T.; Awad, Hani A.; Boyce, Brendan F.; Xing, Lianping; Schwarz, Edward M.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
   [Shealy, David J.] Centocor Res & Dev, Radnor, PA USA.
C3 University of Rochester; Johnson & Johnson; Johnson & Johnson USA
RP Schwarz, EM (通讯作者)，Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.
EM Edward_Schwarz@URMC.Rochester.edu
RI ; Kwok, Edmund/N 9544 2019; Mostafa, Taymour/H 6834 2019; Awad,
   Hani/G 6976 2014; Calvi, Laura/P 6988 2019
OI Proulx, Steven/0000 0003 2154 8502; ritchlin,
   christopher/0000 0002 2602 1219; Calvi, Laura Maria/0000 0001 6969 239X;
   Awad, Hani/0000 0003 2197 2610; 
FU NIAMS NIH HHS [R01 AR051469, AR 51469, R01 AR043510, R01 AR046545,
   AR 48697, P50 AR054041, AR 54041, AR 43510, AR 46545, R01 AR048697]
   Funding Source: Medline; NIDCR NIH HHS [DE 17096, R21 DE017096] Funding
   Source: Medline; NIDDK NIH HHS [DK 64381, R01 DK076876, K08 DK064381]
   Funding Source: Medline
CR Appel H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2035
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P2845, DOI 10.1002/art.22060
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P1805, DOI 10.1002/art.21907
   Braun J, 2006, ARTHRITIS RHEUM, V54, P1646, DOI 10.1002/art.21790
   Bugatti S, 2005, ARTHRITIS RHEUM US, V52, P3448, DOI 10.1002/art.21377
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Daldrup Link HE, 2007, EUR RADIOL, V17, P743, DOI 10.1007/s00330 006 0404 1
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Görtz B, 2004, J BONE MINER RES, V19, P990, DOI 10.1359/JBMR.040205
   Haavardsholm EA, 2008, ANN RHEUM DIS, V67, P794, DOI 10.1136/ard.2007.071977
   Hodgson R, 2008, ANN RHEUM DIS, V67, P270, DOI 10.1136/ard.2007.077271
   Hofmann S, 2004, ORTHOP CLIN N AM, V35, P321, DOI 10.1016/j.ocl.2004.04.005
   Jimenez Boj E, 2005, J IMMUNOL, V175, P2579, DOI 10.4049/jimmunol.175.4.2579
   Jimenez Boj E, 2007, ARTHRITIS RHEUM US, V56, P1118, DOI 10.1002/art.22496
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Kornaat PR, 2006, RADIOLOGY, V239, P811, DOI 10.1148/radiol.2393050253
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281 003 0125 3
   McQueen FM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2075
   McQueen FM, 1998, ANN RHEUM DIS, V57, P350, DOI 10.1136/ard.57.6.350
   McQueen FM, 2003, ARTHRITIS RHEUM, V48, P1814, DOI 10.1002/art.11162
   McQueen FM, 2000, RHEUMATOLOGY, V39, P700, DOI 10.1093/rheumatology/39.7.700
   Ostergaard M, 2003, J RHEUMATOL, V30, P1385
   Papadaki HA, 2002, BLOOD, V99, P1610, DOI 10.1182/blood.V99.5.1610
   Proulx ST, 2007, ANN NY ACAD SCI, V1117, P106, DOI 10.1196/annals.1402.016
   Proulx ST, 2007, ARTHRITIS RHEUM US, V56, P4024, DOI 10.1002/art.23128
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Shealy DJ, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar430
   Tomita T, 1997, J RHEUMATOL, V24, P465
   Tomita T, 1999, RHEUMATOLOGY, V38, P854, DOI 10.1093/rheumatology/38.9.854
   Van der Heijde D, 2006, ARTHRIT RHEUM ARTHR, V55, P569, DOI 10.1002/art.22097
   VOGLER JB, 1988, RADIOLOGY, V168, P679, DOI 10.1148/radiology.168.3.3043546
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
NR 40
TC 37
Z9 45
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD JUL
PY 2008
VL 58
IS 7
BP 2019
EP 2029
DI 10.1002/art.23546
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 323SX
UT WOS:000257469800017
PM 18576355
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chang, CH
   Yang, SJ
   Young, TH
   Yao, WC
AF Chang, Chih Hao
   Yang, Shu Jyuan
   Young, Tai Horng
   Yao, Wei Cheng
TI Effect of co loaded vitamin D3 on intravenous injectable raloxifene
   delivery system
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Nanomedicine; Osteoporosis; Raloxifene; Human serum albumin; Vitamin D3
ID ALKALINE PHOSPHATASE ACTIVITY; ALBUMIN BASED NANOPARTICLES;
   POSTMENOPAUSAL WOMEN; DRUG DELIVERY; HYDROCHLORIDE; OSTEOPOROSIS;
   MECHANISMS; STABILITY; THERAPY; D 3
AB Owing to its promising advantages, including improved drug bioavailability and therapeutic efficiency at low doses and frequency, increased patient convenience and compliance, and prolonged storage life, nanomedicine has received heightened attention over conventional pharmaceuticals. Human serum albumin (HSA) based nanoparticles have been used as drug carriers in injectable formulations, with great success and versatility. In this study, raloxifene and vitamin D3 were co encapsulated in HSA based nanoparticles (Ral/VitaD/HSA/PSS NPs) as an intravenously injected pharmaceutical formulation in order to enhance their availability in the body. The lyophilization hydration method was utilized to develop the Ral/VitaD/HSA/PSS NPs. In addition, the characteristics and stability of the NP and the effect of the co loading of vitamin D3 on raloxifene release in vitro and in vivo were discussed. The raloxifene and vitamin D3 molecules were successfully encapsulated and well dispersed in an amorphous state within Ral/VitaD/HSA/PSS NPs. The prepared Ral/VitaD/HSA/PSS NPs were lyophilized for long term storage and were both biocompatible and hemocompatible, enhancing alkaline phosphtase activity in osteoblasts. Delivered via intravenous injection, Ral/VitaD/HSA/PSS NPs addressed the low bioavailability of raloxifene and vitamin D3 caused by oral administration, and improved their compatibility and residence time in the body. Overall, the established raloxifene vitamin D3 co loaded NPs may be a potential nanomedicine contender for treating postmenopausal osteoporosis.
C1 [Chang, Chih Hao] Natl Taiwan Univ Hosp, Dept Orthoped, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.
   [Chang, Chih Hao] Natl Taiwan Univ, Coll Med, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.
   [Yang, Shu Jyuan; Young, Tai Horng] Natl Taiwan Univ, Inst Biomed Engn, Coll Med, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.
   [Yang, Shu Jyuan; Young, Tai Horng] Natl Taiwan Univ, Coll Engn, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.
   [Yao, Wei Cheng] Min Sheng Gen Hosp, Dept Anesthesiol & Pain Med, 168 Jingguo Rd, Taoyuan City 330, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University; National Taiwan
   University
RP Chang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Orthoped, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.; Chang, CH (通讯作者)，Natl Taiwan Univ, Coll Med, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.; Yang, SJ (通讯作者)，Natl Taiwan Univ, Inst Biomed Engn, Coll Med, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.; Yang, SJ (通讯作者)，Natl Taiwan Univ, Coll Engn, 1 Sect 1,Jen Ai Rd, Taipei 100, Taiwan.
EM handchang@ntu.edu.tw; sjyang@ntuh.gov.tw
RI 赵, 超/HIR 5342 2022; Chen, Jung Chih/JPY 0107 2023
FU National Science and Technology Council (NSTC) [111 2622 B 002 013,
   112 2314 B 002 217 ]; Tajen University Industry Cooperation and
   Incubation Center
FX This work was supported by the National Science and Technology Council
   (NSTC 111 2622 B 002 013  and 112 2314 B 002 217 ) , and Tajen
   University Industry Cooperation and Incubation Center. The authors also
   acknowledge the Good Liver Foundation and the transmission electron
   microscopy technical research services of Technology Commons, College of
   Life Science, National Taiwan University.
CR Abbas MA, 2017, J STEROID BIOCHEM, V165, P369, DOI 10.1016/j.jsbmb.2016.08.004
   Ahmed OAA, 2018, INT J NANOMED, V13, P6325, DOI 10.2147/IJN.S181587
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Borel P, 2015, CRIT REV FOOD SCI, V55, P1193, DOI 10.1080/10408398.2012.688897
   Chauhan DS, 2019, LANGMUIR, V35, P7805, DOI 10.1021/acs.langmuir.8b03460
   Chen Y, 2010, MOLECULES, V15, P8478, DOI 10.3390/molecules15118478
   Cooper C, 2012, CURR MED RES OPIN, V28, P475, DOI 10.1185/03007995.2012.663750
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Du BJ, 2018, NAT REV MATER, V3, P358, DOI 10.1038/s41578 018 0038 3
   Duque G, 2004, BIOGERONTOLOGY, V5, P421, DOI 10.1007/s10522 004 3192 5
   Elzoghby AO, 2012, J CONTROL RELEASE, V157, P168, DOI 10.1016/j.jconrel.2011.07.031
   Fontana MC, 2019, BRAZ J PHARM SCI, V55, DOI 10.1590/s2175 97902019000118052
   Fuenzalida JP, 2014, J PHYS CHEM B, V118, P9782, DOI 10.1021/jp5037553
   Gradauer K, 2013, J CONTROL RELEASE, V165, P207, DOI 10.1016/j.jconrel.2012.12.001
   Guttoff M, 2015, FOOD CHEM, V171, P117, DOI 10.1016/j.foodchem.2014.08.087
   Hemery YM, 2015, FOOD CHEM, V184, P90, DOI 10.1016/j.foodchem.2015.03.096
   Hochner Celnikier D, 1999, EUR J OBSTET GYN R B, V85, P23, DOI 10.1016/S0301 2115(98)00278 4
   Hu SQ, 2015, J CONTROL RELEASE, V220, P175, DOI 10.1016/j.jconrel.2015.10.031
   Iglesias J, 2009, BREAST CANCER RES, V11, pS9, DOI 10.1186/bcr2282
   Jagadish B, 2010, CHEM PHARM BULL, V58, P293, DOI 10.1248/cpb.58.293
   Kelder C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093202
   Klymchenko AS, 2013, PROG MOL BIOL TRANSL, V113, P35, DOI 10.1016/B978 0 12 386932 6.00002 8
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Kuru L, 1999, J PERIODONTAL RES, V34, P123, DOI 10.1111/j.1600 0765.1999.tb02231.x
   Lee DY, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11298 2
   Lee SY, 2020, ACS APPL MATER INTER, V12, P4254, DOI 10.1021/acsami.9b18855
   Lee S, 2018, INT J PHARMACEUT, V553, P363, DOI 10.1016/j.ijpharm.2018.10.063
   Lo Muzio L, 2013, EUR J INFLAMM, V11, P797
   Loewen A, 2018, FOOD CHEM, V240, P472, DOI 10.1016/j.foodchem.2017.07.126
   Malabanan AO, 2003, J WOMEN HEALTH GEN B, V12, P151, DOI 10.1089/154099903321576547
   Maurya VK, 2017, J FOOD SCI TECH MYS, V54, P3753, DOI 10.1007/s13197 017 2840 0
   Modi A, 2016, OSTEOPOROSIS INT, V27, P1227, DOI 10.1007/s00198 015 3388 3
   Moulas AN, 2018, J BIOTECHNOL, V285, P91, DOI 10.1016/j.jbiotec.2018.08.010
   Murthy A, 2020, INT J PHARMACEUT, V588, DOI 10.1016/j.ijpharm.2020.119731
   O'Donnell EF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.549
   Orive G, 2003, CURR OPIN BIOTECH, V14, P659, DOI 10.1016/j.copbio.2003.10.007
   Pabbathi A, 2013, CHEMPHYSCHEM, V14, P2441, DOI 10.1002/cphc.201300313
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Pike JW, 2017, ENDOCRIN METAB CLIN, V46, P815, DOI 10.1016/j.ecl.2017.07.001
   Rezaei A, 2019, FOOD HYDROCOLLOID, V88, P146, DOI 10.1016/j.foodhyd.2018.10.003
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Saini D, 2015, DRUG DELIV, V22, P823, DOI 10.3109/10717544.2014.900153
   SCCS members. Electronic address: sante c2 scientific committees@ec.europa.eu, 2020, Regul Toxicol Pharmacol, V112, P104611, DOI 10.1016/j.yrtph.2020.104611
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Sinha VK, 2008, CLIN PHARMACOKINET, V47, P35, DOI 10.2165/00003088 200847010 00004
   Snyder KR, 2000, AM J HEALTH SYST PH, V57, P1669, DOI 10.1093/ajhp/57.18.1669
   Tan YL, 2018, DRUG DISCOV TODAY, V23, P1108, DOI 10.1016/j.drudis.2018.01.051
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Temova Z, 2016, J CHROMATOGR SCI, V54, P1180, DOI 10.1093/chromsci/bmw048
   Tirkey B, 2017, MAT SCI ENG C MATER, V73, P507, DOI 10.1016/j.msec.2016.12.108
   Trontelj J, 2005, PHARMACOL RES, V52, P334, DOI 10.1016/j.phrs.2005.05.007
   Tsai MH, 2017, MOL PHARMACEUT, V14, P2766, DOI 10.1021/acs.molpharmaceut.7b00315
   Ulbrich K, 2016, CHEM REV, V116, P5338, DOI 10.1021/acs.chemrev.5b00589
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Waters EA, 2012, BREAST CANCER RES TR, V134, P875, DOI 10.1007/s10549 012 2089 2
   Wilson LR, 2016, P NUTR SOC, V75, pE116, DOI 10.1017/S0029665116001312
   Woods A, 2015, J CONTROL RELEASE, V210, P1, DOI 10.1016/j.jconrel.2015.05.269
   Yang SJ, 2023, CANCER NANOTECHNOL, V14, DOI 10.1186/s12645 022 00151 w
   Yang SJ, 2022, DRUG DELIV, V29, P2685, DOI 10.1080/10717544.2022.2111479
   Yang SY, 2022, NANOMEDICINE UK, V17, P23, DOI 10.2217/nnm 2021 0187
   Yang SJ, 2020, INT J NANOMED, V15, P10331, DOI 10.2147/IJN.S281029
   Zhang RX, 2016, J CONTROL RELEASE, V240, P489, DOI 10.1016/j.jconrel.2016.06.012
   Zhang YN, 2016, J CONTROL RELEASE, V240, P332, DOI 10.1016/j.jconrel.2016.01.020
   Zhou Z, 2017, J NUTR SCI VITAMINOL, V63, P161, DOI 10.3177/jnsv.63.161
   Ziani K, 2012, FOOD CHEM, V134, P1106, DOI 10.1016/j.foodchem.2012.03.027
NR 66
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD FEB
PY 2025
VL 246
AR 114379
DI 10.1016/j.colsurfb.2024.114379
EA NOV 2024
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA N0Y9F
UT WOS:001361699000001
PM 39566355
DA 2025 08 17
ER

PT J
AU Chi, H
   Zhang, X
   Chen, XQ
   Fang, S
   Ding, Q
   Gao, ZB
AF Chi, Hao
   Zhang, Xian
   Chen, Xueqin
   Fang, Sui
   Ding, Qiang
   Gao, Zhaobing
TI Sanguinarine is an agonist of TRPA1 channel
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Sanguinarine; Alkaloid; TRPA1; Agonist; Pain
ID ANKYRIN 1 TRPA1; NF KAPPA B; EXPRESSION; RECEPTOR; CHELERYTHRINE; TRPV1
AB Sanguinarine, a benzyl isoquinoline alkaloid extracted from the root of Papaveraceae plants, shows extensive pharmacological activities including anti microbial, anti trypanosoma, anti tumor, antiplatelet, anti hypertensive effects, as well as inhibition of osteoclast formation. Here we demonstrate that TRPA1 channel (Transient receptor potential cation channel, member Al) is a potential target for sanguinarine. Electrophysiological recordings show that sanguinarine activates TRPA1 channel potently with an EC50 0.09 (0.04 0.13) mu M, but has no effects on other examined TRP channels. Sanguinarine increases the intracellular calcium levels and upregulates the excitability of mouse dorsal root ganglion (DRG) neurons in vitro significantly. Plantar injection of sanguinarine evokes nociceptive behaviors similar to that elicited by allyl isothiocyanate (AITC), a classic agonist of TRPA1. Both the enhancement of excitability of DRG neurons and the nociceptive behaviors can be attenuated by treatment of TRPA1 channel antagonist HC030031 or knockout of trpa1 gene. Taken together, our data demonstrate that sanguinarine is a potent and relatively selective agonist of TRPA1 channel. (C) 2020 Published by Elsevier Inc.
C1 [Chi, Hao; Zhang, Xian; Chen, Xueqin; Fang, Sui; Ding, Qiang; Gao, Zhaobing] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, CAS Key Lab Receptor Res, Shanghai, Peoples R China.
   [Chi, Hao; Zhang, Xian; Gao, Zhaobing] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Ding, Qiang] Shanghai Leado Pharmatech Co Ltd, Shanghai, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS
RP Ding, Q; Gao, ZB (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, CAS Key Lab Receptor Res, Shanghai, Peoples R China.
EM zbgao@simm.ac.cn
RI Chen, Yu Ju/E 9481 2015
OI chen, xueqin/0000 0001 6444 4928
FU National Science Fund of Distinguished Young Scholars [81825021];
   National Natural Science Foundation of China [81773707]; Strategic
   Leading Science and Technology Projects of Chinese Academy of Sciences
   [XDA12050308]; Fund of National Science and Technology Major Project
   [2018ZX09711002 002 006]
FX We thank Dr David Julius (University of California, San Francisco) and
   Dr Zhuan Zhou (Peking University) for providing trpa1<SUP> / </SUP>
   mice. This work was supported by grants from the National Science Fund
   of Distinguished Young Scholars [81825021], the National Natural Science
   Foundation of China [81773707], the Strategic Leading Science and
   Technology Projects of Chinese Academy of Sciences (XDA12050308) and
   Fund of National Science and Technology Major Project
   (2018ZX09711002 002 006).
CR Alpizar YA, 2014, PFLUG ARCH EUR J PHY, V466, P507, DOI 10.1007/s00424 013 1334 9
   Balestrini L, 2017, INT J DEV BIOL, V61, P43, DOI 10.1387/ijdb.160169rb
   Berta T, 2017, EXPERT OPIN THER TAR, V21, P695, DOI 10.1080/14728222.2017.1328057
   Beuria TK, 2005, BIOCHEMISTRY US, V44, P16584, DOI 10.1021/bi050767+
   del Camino D, 2010, J NEUROSCI, V30, P15165, DOI 10.1523/JNEUROSCI.2580 10.2010
   Ding Q, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.24
   Fuentes E, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/861786
   Gupta R, 2016, SCI REP UK, V6, DOI 10.1038/srep37460
   Haas ET, 2011, ARCH ORAL BIOL, V56, P1604, DOI 10.1016/j.archoralbio.2011.06.014
   Hondoh A, 2010, BRAIN RES, V1319, P60, DOI 10.1016/j.brainres.2010.01.016
   Hossain M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018333
   Hu HZ, 2010, PFLUG ARCH EUR J PHY, V459, P579, DOI 10.1007/s00424 009 0749 9
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Li TB, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56639 w
   Liu BY, 2013, PULM PHARMACOL THER, V26, P364, DOI 10.1016/j.pupt.2013.01.010
   Luo XB, 2006, PHYTOCHEM ANALYSIS, V17, P431, DOI 10.1002/pca.945
   Mackraj I, 2008, CARDIOVASC THER, V26, P75, DOI 10.1111/j.1527 3466.2007.00037.x
   Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461
   Marwaha L, 2016, INFLAMMOPHARMACOLOGY, V24, P305, DOI 10.1007/s10787 016 0288 x
   McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104
   Moran MM, 2018, ANNU REV PHARMACOL, V58, P309, DOI 10.1146/annurev pharmtox 010617 052832
   Mukhopadhyay I, 2011, J RECEPT SIG TRANSD, V31, P350, DOI 10.3109/10799893.2011.602413
   Nozawa K, 2009, P NATL ACAD SCI USA, V106, P3408, DOI 10.1073/pnas.0805323106
   Omar S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171681
   Sadofsky LR, 2011, PHARMACOL RES, V63, P30, DOI 10.1016/j.phrs.2010.11.004
   Skerratt S, 2017, Prog Med Chem, V56, P81, DOI 10.1016/bs.pmch.2016.11.003
   Stanford KR, 2019, BRAIN RES, V1715, P94, DOI 10.1016/j.brainres.2019.03.029
   Sugiyama D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170410
   Takahashi N, 2014, ACTA PHYSIOL, V210, P705, DOI 10.1111/apha.12251
   Takahashi N, 2011, NAT CHEM BIOL, V7, P701, DOI [10.1038/nchembio.640, 10.1038/NCHEMBIO.640]
   Talavera K, 2020, PHYSIOL REV, V100, P725, DOI 10.1152/physrev.00005.2019
   Tani M, 2015, J NEUROPHYSIOL, V114, P989, DOI 10.1152/jn.00282.2015
   Ückert S, 2015, INT J IMPOT RES, V27, P16, DOI 10.1038/ijir.2014.23
   Vrba J, 2008, CELL BIOL TOXICOL, V24, P39, DOI 10.1007/s10565 007 9014 1
   Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789
   Yang H, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.896557
   Yao JY, 2010, PARASITOL RES, V107, P1035, DOI 10.1007/s00436 010 1966 z
   Zhang SX, 2018, BIOMED PHARMACOTHER, V102, P302, DOI 10.1016/j.biopha.2018.03.071
   Zhang Y, 2019, MOL MED REP, V19, P4449, DOI 10.3892/mmr.2019.10087
NR 39
TC 9
Z9 9
U1 1
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2021
VL 534
BP 226
EP 232
DI 10.1016/j.bbrc.2020.11.107
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA PR5UX
UT WOS:000607302500009
PM 33272574
DA 2025 08 17
ER

PT J
AU Lee, SY
   Huang, GW
   Shiung, JN
   Huang, YH
   Jeng, JH
   Kuo, TF
   Yang, JC
   Yang, WCV
AF Lee, Sheng Yang
   Huang, Guo Wei
   Shiung, Jau Nan
   Huang, Yen Hua
   Jeng, Jiiang Huei
   Kuo, Tzong Fu
   Yang, Jen Chang
   Yang, Wei Chung Vivian
TI Magnetic Cryopreservation for Dental Pulp Stem Cells
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Dental pulp stem cell; Magnetic cryopreservation; Stem cells
ID OSTEOGENIC DIFFERENTIATION; VITRIFICATION SOLUTION; CLINICAL USE;
   OSTEOBLASTS; TOXICITY; TISSUES; MINERALIZATION; MECHANISMS; EXPANSION;
   PROTEINS
AB Magnetic cryopreservation has been successfully used for tooth banking with satisfactory implantation outcomes, suggesting that the method preserves human periodontal ligament cells and dental pulp stem cells (DPSCs). Therefore, magnetic cryopreservation may be applied for the preservation of DPSCs; however, this method has not been evaluated yet. A reliable cryopreservation method for live cell preservation is important for the clinical applications of regenerative medicine. The conventional slow freezing procedure with 10% dimethylsulfoxide (DMSO) may not be appropriate for stem cell based therapies because DMSO is cytotoxic. The objective of this study was to investigate whether magnetic cryopreservation can be applied for DPSC cryopreservation. Cells isolated from human dental pulp were subjected to magnetic cryopreservation. Postthawing cell viability, adhesion, proliferation, expression of markers for mesenchymal stem cells (MSCs), differentiation ability of magnetically cryopreserved DPSCs and DNA stability were compared to those of cells subjected to the conventional slow freezing method. The results indicated that a serum free cryopreservation medium (SFM) containing 3% DMSO is optimal for magnetic cryopreservation. Post thaw magnetically cryopreserved DPSCs express MSC markers, and perform osteogenesis and adipogenesis after induction similarly to fresh MSCs. No significant DNA damage was found in magnetically cryopreserved DPSCs. Magnetic cryopreservation is thus a reliable and effective method for storage of DPSCs. The smaller amount of DMSO required in SFM for cryopreservation is beneficial for the clinical applications of post thaw cells in regenerative medicine. Copyright (C) 2012 S. Karger AG, Basel
C1 [Yang, Wei Chung Vivian] Taipei Med Univ, PhD Program Translat Med, Coll Med Sci & Technol, Taipei 110, Taiwan.
   [Yang, Wei Chung Vivian] Taipei Med Univ, Ctr Translat Med, Taipei 110, Taiwan.
   [Yang, Wei Chung Vivian] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Coll Med Sci & Technol, Taipei 110, Taiwan.
   [Lee, Sheng Yang; Huang, Guo Wei; Shiung, Jau Nan] Taipei Med Univ, Sch Dent, Coll Oral Med, Taipei 110, Taiwan.
   [Lee, Sheng Yang; Shiung, Jau Nan] Taipei Med Univ, Dept Dent, Wan Fang Med Ctr, Taipei 110, Taiwan.
   [Lee, Sheng Yang; Shiung, Jau Nan] Taipei Med Univ, Ctr Teeth Bank & Dent Stem Cell Technol, Taipei 110, Taiwan.
   [Huang, Yen Hua] Taipei Med Univ, Dept Biochem, Grad Inst Med Sci, Sch Med, Taipei 110, Taiwan.
   [Yang, Jen Chang] Taipei Med Univ, Sch Dent Technol, Coll Oral Med, Taipei 110, Taiwan.
   [Kuo, Tzong Fu] Natl Taiwan Univ, Dept Vet Med, Sch Vet Med, Taipei 10764, Taiwan.
   [Jeng, Jiiang Huei] Natl Taiwan Univ Hosp, Dept Dent, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Taipei Medical
   University; Taipei Medical University; Taipei Medical University; Taipei
   Municipal WanFang Hospital; Taipei Medical University; Taipei Medical
   University; Taipei Medical University; National Taiwan University;
   National Taiwan University; National Taiwan University Hospital
RP Yang, WCV (通讯作者)，Taipei Med Univ, PhD Program Translat Med, Coll Med Sci & Technol, 250 Wu Hsin St, Taipei 110, Taiwan.
EM vyang@tmu.edu.tw
OI KUO, TZONG FU/0000 0002 6328 8967; Jeng, Jiiang Huei/0000 0002 2068 5380
FU Center for Teeth Bank and Dental Stem Cell, Taipei Medical University,
   Taiwan; Li Jian Biotechnology Corporation Limited [98TMU IIC 035]
FX This work was supported by Center for Teeth Bank and Dental Stem Cell,
   Taipei Medical University, Taiwan and a grant from Li Jian Biotechnology
   Corporation Limited (98TMU IIC 035).
CR Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Bruder SP, 1998, J BONE MINER RES, V13, P655, DOI 10.1359/jbmr.1998.13.4.655
   Brunner D, 2010, ALTEX ALTERN ANIM EX, V27, P53
   Carvalho KAT, 2008, TRANSPL P, V40, P839, DOI 10.1016/j.transproceed.2008.03.004
   Chase LG, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt8
   Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   d'Aquino R, 2008, STEM CELL REV, V4, P21, DOI 10.1007/s12015 008 9013 5
   d'Aquino R, 2009, J EXP ZOOL PART B, V312B, P408, DOI 10.1002/jez.b.21263
   DAVIS JM, 1990, BLOOD, V75, P781
   De Rosa A, 2009, TISSUE ENG PART C ME, V15, P659, DOI [10.1089/ten.tec.2008.0674, 10.1089/ten.TEC.2008.0674]
   FAHY GM, 1990, CRYOBIOLOGY, V27, P247, DOI 10.1016/0011 2240(90)90025 Y
   Fahy GM, 2004, CRYOBIOLOGY, V48, P157, DOI 10.1016/j.cryobiol.2004.02.002
   Fahy GM, 2004, CRYOBIOLOGY, V48, P22, DOI 10.1016/j.cryobiol.2003.11.004
   Fowler A, 2005, ANN NY ACAD SCI, V1066, P119, DOI 10.1196/annals.1363.010
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Haack Sorensen M, 2007, CYTOTHERAPY, V9, P328, DOI 10.1080/14653240701322235
   Heng BC, 2009, BIOL PROCED ONLINE, V11, P161, DOI 10.1007/s12575 009 9001 4
   Heng BC, 2009, TISSUE CELL, V41, P376, DOI 10.1016/j.tice.2009.01.004
   Hidalgo Bastida LA, 2010, TISSUE ENG PART B RE, V16, P405, DOI [10.1089/ten.teb.2009.0714, 10.1089/ten.TEB.2009.0714]
   Honda S, 2001, BIOCHEM BIOPH RES CO, V282, P493, DOI 10.1006/bbrc.2001.4585
   Hsu SH, 2010, CYTOTECHNOLOGY, V62, P143, DOI 10.1007/s10616 010 9271 3
   Hubel A, 1997, TRANSFUS MED REV, V11, P224, DOI 10.1053/tmrv.1997.0110224
   Hunt Charles J, 2007, Methods Mol Biol, V368, P261
   Jo YY, 2007, TISSUE ENG, V13, P767, DOI 10.1089/ten.2006.0192
   Kaku M, 2010, CRYOBIOLOGY, V61, P73, DOI 10.1016/j.cryobiol.2010.05.003
   Kami D, 2008, CRYOBIOLOGY, V57, P242, DOI 10.1016/j.cryobiol.2008.09.003
   Kuwayama M, 2007, THERIOGENOLOGY, V67, P73, DOI 10.1016/j.theriogenology.2006.09.014
   Lee SY, 2010, J ENDODONT, V36, P1336, DOI 10.1016/j.joen.2010.04.015
   Li XY, 2009, HUM REPROD, V24, P580, DOI 10.1093/humrep/den404
   Papaccio G, 2006, J CELL PHYSIOL, V208, P319, DOI 10.1002/jcp.20667
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Schmidt Mende J, 2000, J IMMUNOL METHODS, V245, P91, DOI 10.1016/S0022 1759(00)00285 4
   Seo BM, 2005, J DENT RES, V84, P907, DOI 10.1177/154405910508401007
   Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601 6343.2005.00331.x
   Stachowiak EM, 2009, REPROD DOMEST ANIM, V44, P653, DOI 10.1111/j.1439 0531.2007.01042.x
   Wang JH, 2000, CRYOBIOLOGY, V41, P1, DOI 10.1006/cryo.2000.2265
   Woods EJ, 2004, CRYOBIOLOGY, V48, P146, DOI 10.1016/j.cryobiol.2004.03.002
   Woods EJ, 2009, CRYOBIOLOGY, V59, P150, DOI 10.1016/j.cryobiol.2009.06.005
   Yang Y, 2010, BIOELECTROMAGNETICS, V31, P277, DOI 10.1002/bem.20560
   Zhang WB, 2006, TISSUE ENG, V12, P2813, DOI 10.1089/ten.2006.12.2813
   Zhao ZG, 2008, CANCER INVEST, V26, P391, DOI 10.1080/07357900701788049
NR 43
TC 56
Z9 67
U1 1
U2 36
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2012
VL 196
IS 1
BP 23
EP 33
DI 10.1159/000331247
PG 11
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 957VA
UT WOS:000305192100003
PM 22285908
DA 2025 08 17
ER

PT J
AU Efe, T
   Sagnak, E
   Roessler, PP
   Getgood, A
   Patzer, T
   Fuchs Winkelmann, S
   Peterlein, CD
   Schofer, MD
AF Efe, Turgay
   Sagnak, Ercan
   Roessler, Philip P.
   Getgood, Alan
   Patzer, Thilo
   Fuchs Winkelmann, Susanne
   Peterlein, Christian D.
   Schofer, Markus D.
TI Penetration of topical diclofenac sodium 4 % spray gel into the synovial
   tissue and synovial fluid of the knee: a randomised clinical trial
SO KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
LA English
DT Article
DE Diclofenac sodium; Knee; Non steroidal anti inflammatory drug;
   Penetration; Spray gel Synovial; Topical
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STANDING COMMITTEE; TASK FORCE;
   OSTEOARTHRITIS; RECOMMENDATIONS; MANAGEMENT; PLASMA; NSAIDS
AB The present study was designed to evaluate the penetration of diclofenac sodium 4 % spray gel in synovial tissue, synovial fluid and blood plasma after topical application in subjects with joint effusions and planned total knee arthroplasty (TKA) due to osteoarthritis.
   A total of 39 patients were randomised to two  or three times daily application of diclofenac sodium 4 % spray gel to knees requiring surgery over a treatment period of 3 days. Within 8 h after the last application, TKA was conducted, and the diclofenac concentrations in synovial tissue, synovial fluid and blood plasma were measured by liquid chromatography.
   The median diclofenac concentration was approximately 10 20 fold higher in synovial tissue (36.2 and 42.8 ng/g) than in synovial fluid (2.6 and 2.8 ng/mL) or plasma (3.9 and 4.1 ng/mL) in both treatment groups. Dose proportionality for any compartment or treatment groups could not be detected. Treatment related adverse events were noted in two cases and limited to skin reactions.
   Diclofenac sodium 4 % spray gel was found to penetrate the skin locally in substantial amounts and thus reach the desired target tissue. Concentrations were not dose dependent, and application was well tolerated by 97.4 % of patients. Topical application of diclofenac should be considered a valuable alternative to systemic NSAID therapy in the initial treatment of osteoarthritis.
C1 [Efe, Turgay; Sagnak, Ercan; Roessler, Philip P.; Patzer, Thilo; Fuchs Winkelmann, Susanne; Peterlein, Christian D.; Schofer, Markus D.] Univ Hosp Marburg, Dept Orthopaed & Rheumatol, D 35043 Marburg, Germany.
   [Sagnak, Ercan] Univ Hosp Schleswig Holstein, Dept Orthopaed & Trauma, Lubeck, Germany.
   [Getgood, Alan] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England.
   [Patzer, Thilo] Univ Hosp Dusseldorf, Dept Orthopaed, Dusseldorf, Germany.
   [Schofer, Markus D.] ORTHOmed Gelenkzentrum Frankfurt Offenbach, Offenbach, Germany.
C3 University Hospital of Giessen & Marburg; University of Kiel; Schleswig
   Holstein University Hospital; University of Warwick; Heinrich Heine
   University Dusseldorf; Heinrich Heine University Dusseldorf Hospital
RP Efe, T (通讯作者)，Univ Hosp Marburg, Dept Orthopaed & Rheumatol, Baldingerstr, D 35043 Marburg, Germany.
EM efet@med.uni marburg.de
RI Getgood, Alan/D 1147 2015
OI Roessler, Philip Peter/0000 0002 1574 0111
FU MIKA Pharma
FX T.E. and M.D.S. are consultants to Smith and Nephew, Endoscopy. The
   study was supported by MIKA Pharma.
CR Arcangeli P, 1996, Riv Eur Sci Med Farmacol, V18, P217
   Barron MC, 2007, J AM OSTEOPATH ASSOC, V107, pES21
   BENSON MD, 1985, SEMIN ARTHRITIS RHEU, V15, P65, DOI 10.1016/S0049 0172(85)80013 5
   Brune K, 2007, CURR MED RES OPIN, V23, P2985, DOI 10.1185/030079907X242584
   Brunner M, 2005, BRIT J CLIN PHARMACO, V60, P573, DOI 10.1111/j.1365 2125.2005.02484.x
   Courtney P, 2002, ANN RHEUM DIS, V61, P767, DOI 10.1136/ard.61.9.767
   Davies NM, 1997, CLIN PHARMACOKINET, V33, P184, DOI 10.2165/00003088 199733030 00003
   ELMQUIST WF, 1994, PHARMACEUT RES, V11, P1689, DOI 10.1023/A:1018994712387
   Escribano E, 2003, EUR J PHARM SCI, V19, P203, DOI 10.1016/S0928 0987(03)00103 9
   Felson DT, 2004, ARTHRITIS RHEUM US, V50, P341, DOI 10.1002/art.20051
   FOWLER PD, 1983, EUR J CLIN PHARMACOL, V25, P389, DOI 10.1007/BF01037953
   Hamad M, 1994, J DRUG RES, V21, P133
   Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Liauw H L, 1985, Agents Actions Suppl, V17, P195
   Mason L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 28
   Mason Lorna, 2004, BMC Fam Pract, V5, P10, DOI 10.1186/1471 2296 5 10
   Miyatake S, 2009, BRIT J CLIN PHARMACO, V67, P125, DOI 10.1111/j.1365 2125.2008.03333.x
   Moore RA, 2004, J RHEUMATOL, V31, P1893
   Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333
   NISHIHATA T, 1987, CHEM PHARM BULL, V35, P3807
   RADERMACHER J, 1991, BRIT J CLIN PHARMACO, V31, P537, DOI 10.1111/j.1365 2125.1991.tb05576.x
   RIESS W, 1986, ARZNEIMITTELFORSCH, V36 2, P1092
   SHERERTZ EF, 1987, J INVEST DERMATOL, V89, P147, DOI 10.1111/1523 1747.ep12470550
   Taylor RS, 2011, CURR MED RES OPIN, V27, P605, DOI 10.1185/03007995.2010.550606
   Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014
   Zhang W, 2007, ANN RHEUM DIS, V66, P377, DOI 10.1136/ard.2006.062091
NR 27
TC 25
Z9 30
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942 2056
EI 1433 7347
J9 KNEE SURG SPORT TR A
JI Knee Surg. Sports Traumatol. Arthrosc.
PD FEB
PY 2014
VL 22
IS 2
BP 345
EP 350
DI 10.1007/s00167 013 2408 0
PG 6
WC Orthopedics; Sport Sciences; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences; Surgery
GA AA1EA
UT WOS:000330837900015
PM 23338668
DA 2025 08 17
ER

PT J
AU Narula, S
   Kelly, D
   Welthy, L
   Prosser, G
   Mattin, A
   Yates, PJ
   Seymour, H
AF Narula, Siddarth
   Kelly, David
   Welthy, Lisa
   Prosser, Gareth
   Mattin, Andrew
   Yates, Piers Jason
   Seymour, Hannah
TI Implementation of a clinical pathway for osteoporosis management within
   an Orthopaedic Fracture Clinic
SO ANZ JOURNAL OF SURGERY
LA English
DT Article
DE fracture liaison service; fragility fracture; minimal trauma fracture;
   orthogeriatric medicine; osteopenia; osteoporosis
ID POSTMENOPAUSAL WOMEN; DENOSUMAB
AB Background A fracture liaison service (FLS) is a multidisciplinary system approach to reducing subsequent fracture risk in patients with a recent fragility fracture. This study investigated the utility of an alternate model delivered by orthopaedic surgeons in increasing the investigation and treatment of osteoporosis within an orthopaedic fracture clinic in a tertiary hospital. Method We established a pathway of treatment (FLS) for women >= 50 years old with a minimal trauma fracture (MTF) in the orthopaedic fracture clinic using existing clinic resources to identify patients. All female patients >= 50 years old with upper limb MTFs during the study period were included and compared with historical controls prior to the intervention. The intervention and control groups were compared to assess the capacity of the new model of care to identify suitable patients and deliver best practice care. Results After the intervention the cumulative rate of osteoporosis screening increased from 52/173 to 201/318 (P < 0.001). Among the patients who were screened for osteoporosis the treatment rate increased from 25/52 to 126/201 (P < 0.001). The intervention resulted in a significant reduction in patients who were not screened after MTF from 87/173 to 40/318 (P < 0.001). Conclusion We have developed a low cost pathway developed by the orthogeriatric team integrated into an orthopaedic fracture clinic that leads to increased screening and treatment of osteoporosis. This model was implemented in a tertiary hospital with an integrated inpatient orthogeriatric service and highly engaged orthopaedic surgeons and may not be applicable in other settings.
C1 [Narula, Siddarth; Kelly, David; Prosser, Gareth; Mattin, Andrew; Yates, Piers Jason] Fiona Stanley Hosp, Dept Orthopaed Surg, Robin Warren Dr, Perth, WA 6150, Australia.
   [Welthy, Lisa; Seymour, Hannah] Fiona Stanley Hosp, Dept Geriatr, Perth, WA, Australia.
C3 South Metropolitan Health Service; Fiona Stanley Fremantle Hospitals
   Group; Fiona Stanley Hospital; South Metropolitan Health Service; Fiona
   Stanley Fremantle Hospitals Group; Fiona Stanley Hospital
RP Narula, S (通讯作者)，Fiona Stanley Hosp, Dept Orthopaed Surg, Robin Warren Dr, Perth, WA 6150, Australia.
EM siddarth.narula@health.wa.gov.au
RI ; Seymour, Hannah/KDN 7165 2024
OI Narula, Sid/0000 0003 1661 8617; 
CR Ambrose AF, 2015, MATURITAS, V82, P85, DOI 10.1016/j.maturitas.2015.06.035
   [Anonymous], 2013, Osteoporosis Costing all Australians A New Burden of Disease Analysis 2012 to 2022
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Boonen S, 2011, J CLIN ENDOCR METAB, V96, P1727, DOI 10.1210/jc.2010 2784
   Bunta AD, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.15.01494
   Bunta AD, 2011, OSTEOPOROSIS INT, V22, pS477, DOI 10.1007/s00198 011 1704 0
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delbar A, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115838
   Eisman J, 2004, J BONE MINER RES, V19, P1969, DOI 10.1359/JBMR.040905
   Kuo I, 2007, OSTEOPOROSIS INT, V18, P1633, DOI 10.1007/s00198 007 0418 9
   Marsh D, 2011, OSTEOPOROSIS INT, V22, P2051, DOI 10.1007/s00198 011 1642 x
   Miki RA, 2008, J BONE JOINT SURG AM, V90A, P2346, DOI 10.2106/JBJS.G.01246
   Nakayama A, 2016, OSTEOPOROSIS INT, V27, P873, DOI 10.1007/s00198 015 3443 0
   Nguyen TV, 2004, MED J AUSTRALIA, V180, pS18
   Queally JM, 2013, OSTEOPOROSIS INT, V24, P1089, DOI 10.1007/s00198 012 2238 9
   Tosi LL, 2008, J BONE JOINT SURG AM, V90A, P163, DOI 10.2106/JBJS.G.00682
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
NR 17
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1445 1433
EI 1445 2197
J9 ANZ J SURG
JI ANZ J. Surg.
PD OCT
PY 2022
VL 92
IS 10
BP 2661
EP 2666
DI 10.1111/ans.17876
EA JUL 2022
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 5E8PQ
UT WOS:000819832900001
PM 35779016
DA 2025 08 17
ER

PT J
AU Huang, B
   Zhao, MY
   Yang, MZ
   Rao, L
   Wu, CZ
   Hu, YZ
   Chen, HQ
   Li, YS
AF Huang, Bin
   Zhao, Mengyao
   Yang, Mingzhe
   Rao, Lu
   Wu, Chizhou
   Hu, Yuzhu
   Chen, Huangqin
   Li, Yuesheng
TI Osmanthus Fragrans Loaded NIPAAM Hydrogel Promotes Osteogenic
   Differentiation of MC3T3 E1
SO GELS
LA English
DT Article
DE osmanthus fragrans loaded NIPAAM; hydrogel; electron beam radiation;
   osteogenic differentiation; network pharmacology; molecular docking
ID TOTAL PHENOLIC CONTENTS; ANTIOXIDANT CAPACITIES; AUTOPHAGY; FLOWERS;
   BMSCS
AB There is an urgent need to find long acting, natural osteogenesis promoting drug systems. In this study, first the potential targets and mechanism of osmanthus fragrans (O. fragrans) extract in regulating osteogenic differentiation based on autophagy were analyzed by network pharmacology and molecular docking. Then, osmanthus fragrans was extracted using the ethanol reflux method and an osmanthus fragrans extract loaded Poly N isopropylacrylamide (OF/NIPAAM) hydrogel was prepared by electron beam radiation. The chemical components of the osmanthus fragrans extract and the microstructure of OF/NIPAAM hydrogels were characterized by ultraviolet visible spectrophotometry (UV Vis) and X ray diffraction (XRD), respectively. Mouse embryonic osteoblast precursor cells MC3T3 E1 were cultured with different concentrations of OF/NIPAAM hydrogel to discover cell proliferation activity by CCK 8 assay. Alkaline phosphatase (ALP) staining and alizarin red staining were used to observe the differentiation and calcification. Through experimental exploration, we found that a total of 11 targets were predicted, which are TP53, CASP3, SIRT1, etc., and osmanthus fragrans had good binding activity to TP53. In vitro, except for proliferation promotion, OF/NIPAAM hydrogel enhanced ALP activity and formation of mineralized nodules of MC3T3 E1 cells at a concentration equal to or less than 62.5 mu g/mL (p < 0.05). The addition of autophagy inhibitor 3 methyladenine (3 MA) reduced ALP activity and mineralized nodule formation.
C1 [Huang, Bin; Zhao, Mengyao; Yang, Mingzhe; Wu, Chizhou; Hu, Yuzhu; Chen, Huangqin] Hubei Univ Sci & Technol, Xianing Med Coll, Sch Stomatol & Ophthalmol, Dept Stomatol, Xianning 437100, Peoples R China.
   [Rao, Lu; Li, Yuesheng] Hubei Univ Sci & Technol, Nonpower Nucl Technol Collaborat Innovat Ctr, Hubei Key Lab Radiat Chem & Funct Mat, Xianning 437100, Peoples R China.
C3 Hubei University of Science & Technology; Hubei University of Science &
   Technology
RP Chen, HQ (通讯作者)，Hubei Univ Sci & Technol, Xianing Med Coll, Sch Stomatol & Ophthalmol, Dept Stomatol, Xianning 437100, Peoples R China.; Li, YS (通讯作者)，Hubei Univ Sci & Technol, Nonpower Nucl Technol Collaborat Innovat Ctr, Hubei Key Lab Radiat Chem & Funct Mat, Xianning 437100, Peoples R China.
EM chenhuangqin79@163.com; frank78929@163.com
RI Zhu, Yan/A 1548 2017; Li, Yuesheng/F 6728 2019
FU Hubei Provincial Colleges and Universities Outstanding Young and
   Middle Aged Technological Innovation Team Project [T2020022]; Xianning
   City Key Program of Science Technology [2021GXYF021]; PhD start up fund
   of Hubei University of Science and Technology [2018 20XB012]; Special
   Fund of the School of Stomatology and Ophthalmology of Hubei University
   of Science and Technology [2020XZ32, 2020WG01]; Science Development
   Foundation of Hubei University of Science Technology [2020TD01,
   2021ZX01, 2022FH09]; Provincial College Students Innovation Training
   Program [S202210927030, S202210927031]
FX This work was supported by the Hubei Provincial Colleges and
   Universities Outstanding Young and Middle Aged Technological Innovation
   Team Project (No.T2020022), Xianning City Key Program of Science &
   Technology (No. 2021GXYF021), PhD start up fund of Hubei University of
   Science and Technology (2018 20XB012), Special Fund of the School of
   Stomatology and Ophthalmology of Hubei University of Science and
   Technology (2020XZ32, 2020WG01), the Science Development Foundation of
   Hubei University of Science & Technology (No.2020TD01, 2021ZX01,
   2022FH09), and Provincial College Students Innovation Training Program
   (S202210927030, S202210927031).
CR Adamova E, 2016, IN VITRO CELL DEV AN, V52, P144, DOI 10.1007/s11626 015 9964 1
   Adams M, 2007, J ETHNOPHARMACOL, V113, P363, DOI 10.1016/j.jep.2007.07.016
   Ahmadi A, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106414
   Bian Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020684
   Chen GL, 2018, IND CROP PROD, V111, P430, DOI 10.1016/j.indcrop.2017.10.051
   Chen HG, 2021, HORTIC RES ENGLAND, V8, DOI 10.1038/s41438 021 00531 0
   [邓荣华 Deng Ronghua], 2013, [食品科学, Food Science], V34, P85
   Feldman F, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020672
   He YX, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.01621
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Huang B, 2015, ARCH ORAL BIOL, V60, P1030, DOI 10.1016/j.archoralbio.2015.02.026
   Jiang YR, 2016, J AGR FOOD CHEM, V64, P2459, DOI 10.1021/acs.jafc.5b03474
   Jiang YX, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100287
   Kim YW, 2022, GELS BASEL, V8, DOI 10.3390/gels8050324
   Li AN, 2014, J FUNCT FOODS, V6, P319, DOI 10.1016/j.jff.2013.10.022
   Li Kuoyu, 2013, Taiwanese Journal of Agricultural Chemistry and Food Science, V51, P7
   Li M, 2018, J CELL BIOCHEM, V119, P4928, DOI 10.1002/jcb.26730
   Lin JT, 2020, BIOCHEM BIOPH RES CO, V531, P228, DOI 10.1016/j.bbrc.2020.06.146
   Liu J, 2015, J NAT MED TOKYO, V69, P135, DOI 10.1007/s11418 014 0869 1
   Liu Y, 2022, J AGR FOOD CHEM, V70, P1148, DOI 10.1021/acs.jafc.1c07583
   Sun JH, 2013, J AGR FOOD CHEM, V61, P10960, DOI 10.1021/jf401802n
   Sun ST, 2011, J MATER CHEM, V21, P4095, DOI 10.1039/c1jm10276a
   Wu LP, 2022, FOOD CHEM, V377, DOI 10.1016/j.foodchem.2021.131853
   Yamagata K, 2019, CURR PHARM DESIGN, V25, P2443, DOI 10.2174/1381612825666190722100504
   Yang XH, 2020, J MOL HISTOL, V51, P55, DOI 10.1007/s10735 020 09856 x
   Yang YH, 2021, FREE RADICAL BIO MED, V166, P226, DOI 10.1016/j.freeradbiomed.2021.02.025
   Zang DeKui Zang DeKui, 2004, Journal of Nanjing Forestry University (Natural Sciences Edition), V28, P7
   Zhang K, 2019, ARCH ORAL BIOL, V101, P172, DOI 10.1016/j.archoralbio.2019.03.020
   Zhao Rongguang., 2015, A History Of Food Culture In China
   Zhou F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10411 0
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
NR 31
TC 4
Z9 4
U1 1
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2310 2861
J9 GELS BASEL
JI Gels
PD OCT
PY 2022
VL 8
IS 10
AR 659
DI 10.3390/gels8100659
PG 13
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA 5S4VH
UT WOS:000875189000001
PM 36286160
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, BL
   Song, XM
   Guo, WJ
   Hou, YF
   Hu, HY
   Ge, WP
   Fan, TF
   Han, ZF
   Li, ZW
   Yang, PR
   Gao, R
   Zhao, HM
   Wang, J
AF Li, Bolun
   Song, Xiaomin
   Guo, Wenjun
   Hou, Yangfeng
   Hu, Huiyuan
   Ge, Weipeng
   Fan, Tianfei
   Han, Zhifa
   Li, Zhiwei
   Yang, Peiran
   Gao, Ran
   Zhao, Hongmei
   Wang, Jing
TI Single Cell Transcriptome Profiles Reveal Fibrocytes as Potential
   Targets of Cell Therapies for Abdominal Aortic Aneurysm
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE abdominal aortic aneurysm; single cell sequencing; fibrocytes; cell
   therapy; cell atlas
ID EXPRESSION; MACROPHAGES; ACTIVATION; DIFFERENTIATION; INHIBITOR;
   IMMUNOMETABOLISM; MYOFIBROBLASTS; HETEROGENEITY; LOCALIZATION;
   FIBROBLASTS
AB Abdominal aortic aneurysm (AAA) is potentially life threatening in aging population due to the risk of aortic rupture and a lack of optimal treatment. The roles of different vascular and immune cells in AAA formation and pathogenesis remain to be future characterized. Single cell RNA sequencing was performed on an angiotensin (Ang) II induced mouse model of AAA. Macrophages, B cells, T cells, fibroblasts, smooth muscle cells and endothelial cells were identified through bioinformatic analyses. The discovery of multiple subtypes of macrophages, such as the re polarization of Trem2(+)Acp5(+) osteoclast like and M2 like macrophages toward the M1 type macrophages, indicates the heterogenous nature of macrophages during AAA development. More interestingly, we defined CD45(+)COL1(+) fibrocytes, which was further validated by flow cytometry and immunostaining in mouse and human AAA tissues. We then reconstituted these fibrocytes into mice with Ang II induced AAA and found the recruitment of these fibrocytes in mouse AAA. More importantly, the fibrocyte treatment exhibited a protective effect against AAA development, perhaps through modulating extracellular matrix production and thus enhancing aortic stability. Our study reveals the heterogeneity of macrophages and the involvement of a novel cell type, fibrocyte, in AAA. Fibrocyte may represent a potential cell therapy target for AAA.
C1 [Li, Bolun; Song, Xiaomin; Guo, Wenjun; Hou, Yangfeng; Hu, Huiyuan; Ge, Weipeng; Fan, Tianfei; Han, Zhifa; Li, Zhiwei; Gao, Ran; Zhao, Hongmei; Wang, Jing] Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Med Mol Biol, Dept Pathophysiol,Inst Basic Med Sci, Beijing, Peoples R China.
   [Hu, Huiyuan] Xi An Jiao Tong Univ, Clin Coll 1, Xian, Shaanxi, Peoples R China.
   [Han, Zhifa] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing, Peoples R China.
   [Yang, Peiran] Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, State Key Lab Med Mol Biol,Dept Physiol, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Xi'an Jiaotong University; Tsinghua
   University; Chinese Academy of Medical Sciences   Peking Union Medical
   College; Peking Union Medical College
RP Gao, R; Zhao, HM (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Med Mol Biol, Dept Pathophysiol,Inst Basic Med Sci, Beijing, Peoples R China.
EM hongmeizhao@ibms.pumc.edu.cn; ggrr1991@outlook.com
RI ; hu, huiyuan/LZG 8151 2025; wang, jian/HRB 9588 2023
OI li, bolun/0000 0002 7078 7107; Hou, Yangfeng/0000 0002 5341 7999; 
FU Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
   [2021 1 I2M 016]; National Natural Science Foundation of China
   [82100514]; National Key Research and Development Program of China
   [2019YFA0801804]; Thousand Young Talents Program of China
FX Funding This study was financially supported by Chinese Academy of
   Medical Sciences Innovation Fund for Medical Sciences (2021 1 I2M 016)
   (to RG); the National Natural Science Foundation of China Grants
   82100514 (to RG); the National Key Research and Development Program of
   China grants 2019YFA0801804 (to JW); Thousand Young Talents Program of
   China (to JW).
CR Akhmetshina A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1734
   An SJ, 2007, CARDIOVASC RES, V75, P702, DOI 10.1016/j.cardiores.2007.02.015
   Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Byon CH, 2011, ARTERIOSCL THROM VAS, V31, P1387, DOI 10.1161/ATVBAHA.110.222547
   Cochain C, 2018, CIRC RES, V122, P1661, DOI 10.1161/CIRCRESAHA.117.312509
   Crawford JR, 2010, J IMMUNOL METHODS, V363, P9, DOI 10.1016/j.jim.2010.09.025
   Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182
   Dale MA, 2015, ARTERIOSCL THROM VAS, V35, P1746, DOI 10.1161/ATVBAHA.115.305269
   Enzerink A, 2011, J THROMB HAEMOST, V9, P619, DOI 10.1111/j.1538 7836.2011.04209.x
   Furusho A, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007750
   Galle C, 2005, CLIN EXP IMMUNOL, V142, P519, DOI 10.1111/j.1365 2249.2005.02938.x
   Haudek SB, 2006, P NATL ACAD SCI USA, V103, P18284, DOI 10.1073/pnas.0608799103
   Hillebrands JL, 2005, TRENDS CARDIOVAS MED, V15, P1, DOI 10.1016/j.tcm.2004.10.002
   Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004
   Huang SCC, 2014, NAT IMMUNOL, V15, P846, DOI 10.1038/ni.2956
   Isselbacher EM, 2005, CIRCULATION, V111, P816, DOI 10.1161/01.CIR.0000154569.08857.7A
   Just SA, 2017, RESP RES, V18, DOI 10.1186/s12931 017 0623 9
   Kao HK, 2011, ANN SURG, V254, P1066, DOI 10.1097/SLA.0b013e3182251559
   Karthikesalingam A, 2014, LANCET, V383, P963, DOI 10.1016/S0140 6736(14)60109 4
   Keeley EC, 2010, INT J BIOCHEM CELL B, V42, P535, DOI 10.1016/j.biocel.2009.10.014
   Kim K, 2018, CIRC RES, V123, P1127, DOI 10.1161/CIRCRESAHA.118.312804
   Krishna SM, 2017, ARTERIOSCL THROM VAS, V37, P553, DOI 10.1161/ATVBAHA.116.308723
   Lemaître V, 2003, CIRCULATION, V107, P333, DOI 10.1161/01.CIR.0000044915.37074.5C
   Li YM, 2020, CIRCULATION, V142, P1374, DOI 10.1161/CIRCULATIONAHA.120.046528
   Liao XD, 2011, J CLIN INVEST, V121, P2736, DOI 10.1172/JCI45444
   Liu ZY, 2012, CIRC RES, V111, P1261, DOI [10.1161/circresaha.112.270520, 10.1161/CIRCRESAHA.112.270520]
   LopezCandales A, 1997, AM J PATHOL, V150, P993
   Maekawa T, 2017, LEUKEMIA, V31, P2709, DOI 10.1038/leu.2017.112
   Mäyränpää MI, 2009, J VASC SURG, V50, P388, DOI 10.1016/j.jvs.2009.03.055
   McAnulty RJ, 2007, INT J BIOCHEM CELL B, V39, P666, DOI 10.1016/j.biocel.2006.11.005
   Medbury HJ, 2008, INT ANGIOL, V27, P114
   Meher AK, 2014, AM J PATHOL, V184, P3130, DOI 10.1016/j.ajpath.2014.07.006
   Misra S, 2010, J VASC INTERV RADIOL, V21, P896, DOI 10.1016/j.jvir.2010.02.030
   Nikam VS, 2010, EUR RESPIR J, V36, P1302, DOI 10.1183/09031936.00028009
   O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570
   Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931
   Qin YW, 2012, CARDIOVASC RES, V96, P401, DOI 10.1093/cvr/cvs263
   Quintana RA, 2019, CIRC RES, V124, P607, DOI 10.1161/CIRCRESAHA.118.313187
   Raffort J, 2017, NAT REV CARDIOL, V14, P457, DOI 10.1038/nrcardio.2017.52
   Russell DG, 2019, NAT REV IMMUNOL, V19, P291, DOI 10.1038/s41577 019 0124 9
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Schaheen B, 2016, ARTERIOSCL THROM VAS, V36, P2191, DOI 10.1161/ATVBAHA.116.307559
   Shi Y, 1996, ARTERIOSCL THROM VAS, V16, P1298, DOI 10.1161/01.ATV.16.10.1298
   Takei Y, 2016, ARTERIOSCL THROM VAS, V36, P1962, DOI 10.1161/ATVBAHA.116.307715
   THOMPSON RW, 1995, J CLIN INVEST, V96, P318, DOI 10.1172/JCI118037
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Tsuruda T, 2008, CIRC RES, V102, P1368, DOI 10.1161/CIRCRESAHA.108.173682
   van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375 019 0404 1
   van Puijvelde GHM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190962
   Xie T, 2018, CELL REP, V22, P3625, DOI 10.1016/j.celrep.2018.03.010
   Yang H, 2021, ARTERIOSCL THROM VAS, V41, P1158, DOI 10.1161/ATVBAHA.120.315607
   Yu B, 2017, ARTERIOSCL THROM VAS, V37, P1698, DOI 10.1161/ATVBAHA.117.309859
   Zhao GZ, 2021, CARDIOVASC RES, V117, P1402, DOI 10.1093/cvr/cvaa214
   Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049
   Zulli A, 2005, HISTOCHEM CELL BIOL, V124, P517, DOI 10.1007/s00418 005 0072 2
NR 56
TC 21
Z9 23
U1 3
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2297 055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD NOV 24
PY 2021
VL 8
AR 753711
DI 10.3389/fcvm.2021.753711
PG 15
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA YA2YM
UT WOS:000738205000001
PM 34901214
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Strong, AL
   Gimble, JM
   Bunnell, BA
AF Strong, Amy L.
   Gimble, Jeffrey M.
   Bunnell, Bruce A.
TI Analysis of the Pro  and Anti Inflammatory Cytokines Secreted by Adult
   Stem Cells during Differentiation
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID HUMAN ADIPOSE TISSUE
AB Adipose derived stromal/stem cells (ASCs) are adult stem cells that have the potential to differentiate into mesenchymal lineage cells. The abundance of ASCs in adipose tissue and easy accessibility with relatively little donor site morbidity make them attractive candidate cells for tissue engineering and regenerative medicine. However, the underlying inflammatory process that occurs during ASC differentiation into adipocytes and osteoblast has not been extensively investigated. ASCs cultured in osteogenic and adipogenic differentiation medium were characterized by oil red o staining and alizarin red staining, respectively. ASCs undergoing osteogenic and adipogenic differentiation were isolated on days 7, 14, and 21 and assessed by qRT PCR for the expression of pro and anti inflammatory cytokines. ASCs undergoing osteogenic differentiation expressed a distinct panel of cytokines that differed from the cytokine profile of ASCs undergoing adipogenic differentiation at each of the time points analyzed. Mapping the cytokine expression profile during ASC differentiation will provide insight into the role of inflammation in this process and identify potential targets that may aid in enhancing osteogenic or adipogenic differentiation for the purposes of tissue engineering and regenerative medicine.
C1 [Strong, Amy L.; Gimble, Jeffrey M.; Bunnell, Bruce A.] Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA.
   [Gimble, Jeffrey M.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA.
   [Gimble, Jeffrey M.] Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA.
   [Bunnell, Bruce A.] Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA.
C3 Tulane University; Tulane University; Tulane University; Tulane
   University
RP Bunnell, BA (通讯作者)，Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM bbunnell@tulane.edu
OI Strong, Amy/0000 0002 2581 2481; Bunnell, Bruce/0000 0001 6196 3722
FU NIH HHS [P51 OD011104] Funding Source: Medline
CR Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Ferreira E, 2013, J BIOL CHEM, V288, P29494, DOI 10.1074/jbc.M113.471268
   Forsberg JA, 2014, CLIN ORTHOP RELAT R, V472, P2845, DOI 10.1007/s11999 014 3694 7
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Iyer A, 2010, NAT REV ENDOCRINOL, V6, P71, DOI 10.1038/nrendo.2009.264
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee J, 2010, J CRANIOFAC SURG, V21, P1136, DOI 10.1097/SCS.0b013e3181e488d6
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00425
   Peterson JR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008810
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007
   Shao JS, 2010, HYPERTENSION, V55, P579, DOI 10.1161/HYPERTENSIONAHA.109.134205
   Sonomoto K, 2012, ARTHRITIS RHEUM US, V64, P3355, DOI 10.1002/art.34555
   Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942
   Trayhurn P, 2013, PHYSIOL REV, V93, P1, DOI 10.1152/physrev.00017.2012
   Vallée M, 2009, PATHOL BIOL, V57, P309, DOI 10.1016/j.patbio.2008.04.010
   Vermette M, 2007, BIOMATERIALS, V28, P2850, DOI 10.1016/j.biomaterials.2007.02.030
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 22
TC 21
Z9 26
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2015
VL 2015
AR 412467
DI 10.1155/2015/412467
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CP0IU
UT WOS:000359559800001
PM 26300921
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Vural, P
   Canbaz, M
   Akgul, C
AF Vural, P
   Canbaz, M
   Akgul, C
TI Effects of menopause and postmenopausal tibolone treatment on plasma
   TNFα, IL 4, IL 10, IL 12 cytokine pattern and some bone turnover markers
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE postmenopause; cytokines; bone turnover; tibolone; hormone replacement
   therapy
ID TUMOR NECROSIS FACTORS; INTERLEUKIN 6 PRODUCTION; REPLACEMENT THERAPY;
   OSTEOBLASTIC CELLS; STROMAL CELLS; ESTROGEN; RESORPTION; WOMEN;
   OSTEOPOROSIS; INVITRO
AB Objective: To asses plasma TNF alpha, IL 4, IL 10, IL 12; urinay hydroxyproline (Hyp) and calcium as bone resorption markers in healthy postmenopausal women compared with premenopausal ones, and to observe the effect of tibolone (2.5 mg/day for 6 months) upon above mentioned parameters.
   Patients and methods: The study involved 24 healthy postmenopausal women (study group) and 25 premenopausal women (control group). Plasma TNF alpha, IL 4, IL 10 and IL 12 concentrations were measured using ELISA kits. Fasting urinary Hyp was measured by Ehrlich's spectrophotometric reaction. Calcium was determined by oxalate precipitation and the redox titration procedure. Statistical significance was analysed by the Mann Whitney U test for unpaired data, Wilcoxon Signed Rank test for paired data, and Pearson correlation test.
   Results: Postmenopausal women (both before and after tibolone treatment) have increased (p < 0.001) plasma TNF alpha, IL 4, IL 10, IL 12; and increased urinary Hyp (p < 0.05) and calcium (p < 0.001) concentrations in comparison with premenopausal individuals. Tibolone treatment has no effect on reversing the increased postmenopausal plasma TNF alpha, IL 4, IL 10 and IL 12, but decreases urinary Hyp and calcium to premenopausal levels. There is a weak positive correlation (r=0.532;p < 0.05) between TNF alpha and IL 4 levels in postmenopausal women.
   Conclusions: The results show that plasma TNF alpha, IL 4, IL 10, IL 12, urinary Hyp and calcium increase with menopause. The increase of anti inflammatory IL 10, IL 12 and especially IL 4 is probably a compensatory mechanism, by which these cytokines conteract to pro inflammatory TNF alpha, and thus balance its osteoclast activating and oxidative stress inducing effects. Tibolone is successful in decreasing of bone resorption markers (urinary Hyp and calcium), but has no effect on reversing the impact of menopause on plasma TNF alpha, as well as IL 4, IL 10, IL 12. The last effect probably is related with progestogenic and androgenic properties of tibolone. Clearly, further studies are necessary to establish a risk/benefit ratio for tibolone in view of its effects on bone turnover as a new hormone replacement rationale. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Istanbul Fac Med, Dept Biochem, Istanbul, Turkey.
   Istanbul Fac Med, Dept Obstet & Gynecol, Istanbul, Turkey.
C3 Istanbul University; Istanbul University
RP Hakan Apt 4 4, TR 34310 Istanbul, Turkey.
EM pervinvural@yahoo.com
RI Akgül, Cemil/AAP 6327 2020; Vural, Pervin/AAD 9095 2020
CR Akgül C, 1998, MATURITAS, V30, P79, DOI 10.1016/S0378 5122(98)00046 2
   Albertazzi P, 1998, MATURITAS, V30, P295, DOI 10.1016/S0378 5122(98)00059 0
   [Anonymous], 1996, ADV IMMUNOLOGY
   Berger S, 1996, EUR J IMMUNOL, V26, P1297, DOI 10.1002/eji.1830260618
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Boissonnault WG, 2001, J ORTHOP SPORT PHYS, V31, P359, DOI 10.2519/jospt.2001.31.7.359
   Cioffi M, 2002, MATURITAS, V41, P187, DOI 10.1016/S0378 5122(01)00286 9
   COHENSOLAL ME, 1993, J CLIN ENDOCR METAB, V77, P1648, DOI 10.1210/jc.77.6.1648
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   FAULKNER WR, 1982, FUNDAMENTALS CLIN CH, P975
   Gambacciani M, 2004, GYNECOL ENDOCRINOL, V18, P9, DOI 10.1080/09513590310001651722
   GENCI S, 2000, J CLIN INVEST, V106, P1229
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   GOWEN M, 1985, J CLIN INVEST, V75, P1223, DOI 10.1172/JCI111819
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Inanir A, 2004, J INT MED RES, V32, P570, DOI 10.1177/147323000403200602
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   JOHNSON RA, 1989, ENDOCRINOLOGY, V124, P1424, DOI 10.1210/endo 124 3 1424
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Kumru S, 2004, J REPROD IMMUNOL, V63, P31, DOI 10.1016/j.jri.2004.02.001
   Löfman O, 2005, CLIN CHIM ACTA, V356, P67, DOI 10.1016/j.cccn.2004.12.014
   LORENZO JA, 1987, ENDOCRINOLOGY, V121, P1164, DOI 10.1210/endo 121 3 1164
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MCKANE WR, 1994, J BONE MINER RES, V9, P1313
   Ohta H, 2002, MATURITAS, V43, P27, DOI 10.1016/S0378 5122(02)00180 9
   Onoe Y, 1996, J IMMUNOL, V156, P758
   OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   PACIFICI R, 1990, J BONE MINER RES, V5, P145
   PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822
   Peris P, 2002, CLIN EXP RHEUMATOL, V20, P697
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   REVILARD JP, 1995, IMMUNOLOGIE
   Sandmand M, 2002, CLIN EXP IMMUNOL, V127, P107, DOI 10.1046/j.1365 2249.2002.01736.x
   Saucedo R, 2002, GYNECOL OBSTET INVES, V53, P114, DOI 10.1159/000053005
   SCHNEIDER GB, 1989, BONE MINER, V5, P129, DOI 10.1016/0169 6009(89)90091 3
   Shearer GM, 1997, MECH AGEING DEV, V94, P1
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   SWITZER BR, 1991, J NUTR BIOCHEM, V2, P229, DOI 10.1016/0955 2863(91)90021 V
   TAKAHASHI N, 1991, J BONE MINER RES, V6, P977
   THOMSON BM, 1987, J IMMUNOL, V138, P775
   TIETZ NW, 1982, FUNDAMENTALS CLIN CH, P849
   Vural P, 2005, ANN CLIN BIOCHEM, V42, P220, DOI 10.1258/0004563053857941
   Yagi K, 1997, ACTA BIOCHIM POL, V44, P701, DOI 10.18388/abp.1997_4372
NR 46
TC 34
Z9 38
U1 0
U2 1
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD APR
PY 2006
VL 53
IS 4
BP 367
EP 371
DI 10.1016/j.phrs.2006.01.005
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 041BR
UT WOS:000237428500008
PM 16503406
DA 2025 08 17
ER

PT J
AU Hammed, A
   Matagrin, B
   Spohn, G
   Prouillac, C
   Benoit, E
   Lattard, V
AF Hammed, Abdessalem
   Matagrin, Benjamin
   Spohn, Gabriele
   Prouillac, Caroline
   Benoit, Etienne
   Lattard, Virginie
TI VKORC1L1, an Enzyme Rescuing the Vitamin K 2,3 Epoxide Reductase
   Activity in Some Extrahepatic Tissues during Anticoagulation Therapy
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Drug Resistance; Enzyme Inhibitors; Enzyme Kinetics; Hemostasis; Vitamin
   K; VKORC1; VKORC1L1; Vitamin K Antagonist; Vitamin K Epoxide Reductase
ID GAMMA CARBOXYGLUTAMIC ACID; MATRIX GLA PROTEIN; WARFARIN RESISTANCE;
   DEPENDENT PROTEINS; GENE EXPRESSION; BONE; DEFICIENCY; KIDNEY;
   CALCIFICATION; PROTHROMBIN
AB Vitamin K is involved in the  carboxylation of the vitamin K dependent proteins, and vitamin K epoxide is a by product of this reaction. Due to the limited intake of vitamin K, its regeneration is necessary and involves vitamin K 2,3 epoxide reductase (VKOR) activity. This activity is known to be supported by VKORC1 protein, but recently a second gene, VKORC1L1, appears to be able to support this activity when the encoded protein is expressed in HEK293T cells. Nevertheless, this protein was described as being responsible for driving the vitamin K mediated antioxidation pathways. In this paper we precisely analyzed the catalytic properties of VKORC1L1 when expressed in Pichia pastoris and more particularly its susceptibility to vitamin K antagonists. Vitamin K antagonists are also inhibitors of VKORC1L1, but this enzyme appears to be 50 fold more resistant to vitamin K antagonists than VKORC1. The expression of Vkorc1l1 mRNA was observed in all tissues assayed, i.e. in C57BL/6 wild type and VKORC1 deficient mouse liver, lung, and testis and rat liver, lung, brain, kidney, testis, and osteoblastic cells. The characterization of VKOR activity in extrahepatic tissues demonstrated that a part of the VKOR activity, more or less important according to the tissue, may be supported by VKORC1L1 enzyme especially in testis, lung, and osteoblasts. Therefore, the involvement of VKORC1L1 in VKOR activity partly explains the low susceptibility of some extrahepatic tissues to vitamin K antagonists and the lack of effects of vitamin K antagonists on the functionality of the vitamin K dependent protein produced by extrahepatic tissues such as matrix Gla protein or osteocalcin.
C1 [Hammed, Abdessalem; Matagrin, Benjamin; Prouillac, Caroline; Benoit, Etienne; Lattard, Virginie] Inst Natl Rech Agron INRA Vetagro Sup, Vet Sch Lyon, Unite Contrat USC 1233, F 69280 Marcy Letoile, France.
   [Spohn, Gabriele] Goethe Univ Frankfurt, German Red Cross Blood Serv, D 60528 Frankfurt, Germany.
   [Spohn, Gabriele] Goethe Univ Frankfurt, Inst Transfus Med & Immunohematol, D 60528 Frankfurt, Germany.
C3 VetAgro Sup; INRAE; Goethe University Frankfurt; Goethe University
   Frankfurt
RP Lattard, V (通讯作者)，Inst Natl Rech Agron INRA Vetagro Sup, Vet Sch Lyon, Unite Contrat USC 1233, F 69280 Marcy Letoile, France.
EM virginie.lattard@vetagro sup.fr
RI Prouillac, Caroline/H 1667 2011; Lattard, Virginie/NGR 4838 2025;
   HAMMED, Abdessalem/ABF 8875 2021
OI HAMMED, Abdessalem/0000 0001 8714 2789; Prouillac,
   Caroline/0000 0002 7244 6162; 
FU Agence Nationale pour la Recherche [RODENT 2009 CESA 008 03]; Direction
   Generale de l'Enseignement et de la Recherche (DGER)
FX This work was supported by Agence Nationale pour la Recherche Grant
   RODENT 2009 CESA 008 03 and by Direction Generale de l'Enseignement et
   de la Recherche (DGER).
CR Binkley N, 2007, J BONE MINER RES, V22, P695, DOI 10.1359/JBMR.070208
   Cadavid JC, 2011, CHEST, V139, P1503, DOI 10.1378/chest.10 1322
   Chatrou MLL, 2011, HAMOSTASEOLOGIE, V31, P251, DOI 10.5482/ha 1157
   Chu PH, 2006, P NATL ACAD SCI USA, V103, P19308, DOI 10.1073/pnas.0609401103
   Coutu DL, 2008, J BIOL CHEM, V283, P17991, DOI 10.1074/jbc.M708029200
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Gilbert KA, 2004, AM J PHYSIOL LUNG C, V286, pL1179, DOI 10.1152/ajplung.00188.2003
   Grover PK, 2000, EUR J BIOCHEM, V267, P61, DOI 10.1046/j.1432 1327.2000.00954.x
   Hara K, 2005, J BONE MINER METAB, V23, P366, DOI 10.1007/s00774 005 0614 7
   Hodroge A, 2012, J THROMB HAEMOST, V10, P2535, DOI 10.1111/jth.12019
   Hodroge A, 2011, ARCH BIOCHEM BIOPHYS, V515, P14, DOI 10.1016/j.abb.2011.08.010
   Knapen MHJ, 2012, BRIT J NUTR, V108, P1017, DOI 10.1017/S000711451100626X
   Lasseur R, 2005, J BIOCHEM MOL TOXIC, V19, P379, DOI 10.1002/jbt.20104
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254
   Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387
   Oldenburg J, 2008, VITAM HORM, V78, P35, DOI 10.1016/S0083 6729(07)00003 9
   Oury F, 2011, CELL, V144, P796, DOI 10.1016/j.cell.2011.02.004
   PRICE PA, 1982, P NATL ACAD SCI BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734
   PRICE PA, 1987, THROMB RES, V46, P121, DOI 10.1016/0049 3848(87)90212 X
   PRICE PA, 1976, P NATL ACAD SCI USA, V73, P3374, DOI 10.1073/pnas.73.10.3374
   Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400
   PRICE PA, 1981, J BIOL CHEM, V256, P2754
   PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006 291X(83)91663 7
   PRICE PA, 1981, J BIOL CHEM, V256, P2760
   RANNELS SR, 1993, AM J PHYSIOL, V265, pL270, DOI 10.1152/ajplung.1993.265.3.L270
   Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214
   Schurgers LJ, 2007, BLOOD, V109, P2823, DOI 10.1182/blood 2006 07 035345
   Schurgers LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043229
   Schurgers LJ, 2005, ARTERIOSCL THROM VAS, V25, P1629, DOI 10.1161/01.ATV.0000173313.46222.43
   Spohn G, 2009, THROMB HAEMOSTASIS, V101, P1044, DOI 10.1160/TH09 03 0204
   Stapleton AMF, 1998, BRIT J UROL, V81, P666
   Stenova E, 2011, BRATISL MED J, V112, P71
   Viegas CSB, 2008, J BIOL CHEM, V283, P36655, DOI 10.1074/jbc.M802761200
   Villines TC, 2009, CALCIFIED TISSUE INT, V85, P494, DOI 10.1007/s00223 009 9300 4
   Westhofen P, 2011, J BIOL CHEM, V286, P15085, DOI 10.1074/jbc.M110.210971
   Wysowski DK, 2007, ARCH INTERN MED, V167, P1414, DOI 10.1001/archinte.167.13.1414
   Zhu AH, 2007, BLOOD, V109, P5270, DOI 10.1182/blood 2006 12 064188
NR 38
TC 55
Z9 65
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 4
PY 2013
VL 288
IS 40
BP 28733
EP 28742
DI 10.1074/jbc.M113.457119
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 298BL
UT WOS:000330298800027
PM 23928358
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Balaphas, A
   Meyer, J
   Buchs, NC
   Modarressi, A
   Bühler, LH
   Toso, C
   Gonelle Gispert, C
   Ris, F
AF Balaphas, Alexandre
   Meyer, Jeremy
   Buchs, Nicolas C.
   Modarressi, Ali
   Buhler, Leo H.
   Toso, Christian
   Gonelle Gispert, Carmen
   Ris, Frederic
TI Isolation and Characterization of Stem Cells from the Anal Canal
   Transition Zone in Pigs
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Anal canal transition zone; Mesenchymal stem cells; Stem cells; Stromal
   cells; Pig; Incontinence
ID ADIPOSE TISSUE; STROMAL CELLS; INCONTINENCE; THERAPY; CANCER
AB Background Utilization of autologous stem cells has been proposed for the treatment of anal incontinence despite a lack of understanding of their mechanism of action and of the physiological healing process of anal sphincters after injury. Aims We aim to develop a technique allowing isolation and further study of local mesenchymal stem cells, directly from anal canal transition zone in pig. Methods Anal canal was resected "en bloc" from two young pigs and further microdissected. The anal canal transition zone was washed and digested with 0.1% type I collagenase for 45 min at 37 degrees C. The isolated cells were plated on dishes in mesenchymal stem cell medium and trypsinized when confluent. Cells were further used for flow cytometry analysis and differentiation assays. Results The anal canal transition zone localization was confirmed with H&E staining. Following culture, cells exhibited a typical "fibroblast like" morphology typical of stem cells. Isolated cells were positive for CD90 and CD44 but negative for CD14, CD34, CD45, CD105, CD106, and SLA DR. Following incubation with specific differentiation medium, isolated cells differentiated into adipocytes, osteoblasts, and chondrocytes, confirming in vitro multipotency. Conclusions Herein, we report for the first time the presence of mesenchymal stem cells in the anal canal transition zone in pigs and the feasibility of their isolation. This preliminary study opens the path to the isolation of human anal canal transition zone mesenchymal stem cells that might be used to study sphincters healing and to treat anal incontinence.
C1 [Balaphas, Alexandre; Meyer, Jeremy; Buchs, Nicolas C.; Toso, Christian; Ris, Frederic] Univ Hosp Geneva, Div Digest Surg, Rue Gabrielle Perret Gentil 4, CH 1211 Geneva 14, Switzerland.
   [Modarressi, Ali] Univ Hosp Geneva, Div Plast Reconstruct & Aesthet Surg, Rue Gabrielle Perret Gentil 4, CH 1211 Geneva 14, Switzerland.
   [Buhler, Leo H.; Gonelle Gispert, Carmen] Univ Fribourg, Fac Sci & Med, Sect Med, Route Albert Gockel 1, CH 1700 Fribourg, Switzerland.
C3 University of Geneva; University of Geneva; University of Fribourg
RP Balaphas, A (通讯作者)，Univ Hosp Geneva, Div Digest Surg, Rue Gabrielle Perret Gentil 4, CH 1211 Geneva 14, Switzerland.
EM alexandre.balaphas@hcuge.ch
RI ; Toso, Christian/E 7785 2018; Meyer, Jeremy/AAP 3367 2020; Ris,
   Frederic/H 7030 2019
OI /0000 0003 3789 6464; Toso, Christian/0000 0003 1652 4522; 
FU University of Geneva; University Hospital of Geneva "Projet Recherche et
   Developpement" [19 I 2020]
FX Open access funding provided by University of Geneva. University
   Hospital of Geneva "Projet Recherche et Developpement" 19 I 2020.
CR Asteria CR, 2016, TECH COLOPROCTOL, V20, P299, DOI 10.1007/s10151 016 1458 y
   Balaphas A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082086
   Dadhich P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54440 3
   De Ligny WR, 2019, AM J OBSTET GYNECOL, V220, P142, DOI 10.1016/j.ajog.2018.09.009
   De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165 2478(03)00108 1
   Eiro N, 2014, ONCOTARGET, V5, P10692, DOI 10.18632/oncotarget.2530
   Frudinger A, 2015, COLORECTAL DIS, V17, P794, DOI 10.1111/codi.12947
   Frudinger A, 2010, GUT, V59, P55, DOI 10.1136/gut.2009.181347
   Frudinger A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0978 y
   Gräs S, 2017, INT UROGYNECOL J, V28, P341, DOI 10.1007/s00192 016 3064 y
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Mitoyan L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23034 x
   Montanari E, 2021, XENOTRANSPLANTATION, V28, DOI 10.1111/xen.12666
   Nakashima J, 2020, STATPEARLS
   Noël D, 2008, EXP CELL RES, V314, P1575, DOI 10.1016/j.yexcr.2007.12.022
   Park J, 2020, OBSTET GYNECOL SCI, V63, P594, DOI 10.5468/ogs.20073
   Pochampally Radhika, 2008, V449, P83, DOI 10.1007/978 1 60327 169 1_6
   Schneider J, 2016, CANCER GENOM PROTEOM, V13, P331
   Son IT, 2019, COLORECTAL DIS, V21, P38, DOI 10.1111/codi.14351
   Trébol J, 2018, WORLD J STEM CELLS, V10, P82, DOI 10.4252/wjsc.v10.i7.82
   Yang EJ, 2015, MODERN PATHOL, V28, P994, DOI 10.1038/modpathol.2015.54
   Yang ZX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059354
   Zoulamoglou M, 2017, ANN MED SURG, V24, P31, DOI 10.1016/j.amsu.2017.10.004
NR 23
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163 2116
EI 1573 2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2023
VL 68
IS 2
BP 471
EP 477
DI 10.1007/s10620 022 07690 7
EA SEP 2022
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 8W3SU
UT WOS:000855634100003
PM 36125591
OA Green Published
DA 2025 08 17
ER

PT J
AU Rana, N
   Suliman, S
   Mohamed Ahmed, S
   Gavasso, S
   Gjertsen, BT
   Mustafa, K
AF Rana, Neha
   Suliman, Salwa
   Mohamed Ahmed, Samih
   Gavasso, Sonia
   Gjertsen, Bjorn Tore
   Mustafa, Kamal
TI Systemic and local innate immune responses to surgical
   co transplantation of mesenchymal stromal cells and biphasic calcium
   phosphate for bone regeneration
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Mesenchymal stromal cells; Biphasic calcium phosphate; Innate immune
   response; Critical sized bone defects; Monocyte macrophages;
   Neutrophils; Osteogenesis
ID STEM CELLS; OSTEOCLAST DIFFERENTIATION; INFLAMMATION; MACROPHAGES;
   CYTOKINE; SCAFFOLDS; TRIGGER; LIGAND
AB Bone regeneration from mesenchymal stromal cells (MSC) is attributed to comprehensive immune modulation mediated by the MSC. However, the temporal and spatial regulation of these immune responses has not yet been described. The aim of the present study was to assess the local and systemic innate immune responses to implantation of biphasic calcium phosphate biomaterial (BCP) alone, or with bone marrow derived MSC (BCP + MSC), in critical sized calvarial bone defects of Lewis rats. Four weeks after implantation, flow cytometry analysis of innate immune cells revealed increased numbers of circulating classical monocyte macrophages (MM) and decreased non classical MM in the BCP + MSC group. At week 8, this differential systemic MM response was associated with an increased presence of local tissue anti inflammatory macrophages expressing CD68 and CD163 markers (M2 like). In the BCP group without MSC, NK cells increased at weeks 1 and 4, and neutrophils increased in circulation at weeks 2 and 8. At week 8, the increase in number of neutrophils in circulation was associated with decreased local tissue neutrophils, in the BCP + MSC group. Gene expression analysis of tissue biopsies from defects implanted with BCP + MSC, in comparison to BCP alone, revealed upregulated expression of early osteogenesis genes along with macrophage differentiation related genes at weeks 1 and 8 and neutrophil chemotaxis related genes at week 1. This study is the first to demonstrate that surgical implantation of BCP or BCP + MSC grafts differentially regulate both systemic and local tissue innate immune responses which enhance bone formation. The results provide new insights into immune mechanisms underlying MSC mediated bone regeneration.
   Statement of significance
   The suitability of biphasic calcium phosphate and mesenchymal stromal cell construct (BCP+ MSC) transplantation is evident from their progress in clinical trials for treating challenging maxillofacial bone defects. But less is known about the overall immune response generated by this surgical process and how it later impacts the bone formation. To this end, it is crucial to understand for both clinicians and researchers, the systemic immune response to transplanting MSC in patients for ensuring both the safety and efficacy of cell therapies. In this study, we used rat calvarial bone defect model and showed that both systemic and local innate immunes responses (monocyte macrophages and neutrophils) are favorably directed towards enhanced bone formation in BCP+ MSC implanted defects, as compared to BCP alone. (c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Rana, Neha; Suliman, Salwa; Mohamed Ahmed, Samih; Mustafa, Kamal] Univ Bergen, Ctr Translat Oral Res TOR, Tissue Engn Res Grp, Dept Clin Dent,Fac Med, Arstadsveien 19, N 5058 Bergen, Norway.
   [Gavasso, Sonia] Haukeland Hosp, Dept Neurol, Neuro SysMed, Bergen, Norway.
   [Gavasso, Sonia] Univ Bergen, Dept Clin Med, Bergen, Norway.
   [Gjertsen, Bjorn Tore] Univ Bergen, Ctr Canc Biomarkers, Dept Clin Sci, Bergen, Norway.
   [Gjertsen, Bjorn Tore] Haukeland Hosp, Dept Med, Hematol Sect, Bergen, Norway.
C3 University of Bergen; University of Bergen; Haukeland University
   Hospital; University of Bergen; University of Bergen; University of
   Bergen; Haukeland University Hospital
RP Mustafa, K (通讯作者)，Univ Bergen, Ctr Translat Oral Res TOR, Tissue Engn Res Grp, Dept Clin Dent,Fac Med, Arstadsveien 19, N 5058 Bergen, Norway.
EM kamal.mustafa@uib.no
RI Rana, Neha/X 9603 2019; Mustafa, Kamal/ABD 4458 2020; Gjertsen, Bjorn
   T/O 1542 2015
OI Rana, Neha/0000 0001 6017 983X; Mustafa, Kamal/0000 0002 2968 2856;
   Suliman, Salwa/0000 0003 0385 6157
FU Research Council of Norway [BEHANDLING/273551]; Trond Mohn Foundation
   [BFS2018TMT10, TMS2021STG03]; MAXIBONE EU H2020 project [779322]; H2020
   Societal Challenges Programme [779322] Funding Source: H2020 Societal
   Challenges Programme
FX The authors gratefully acknowledge Research Council of Nor way
   (BEHANDLING/273551) , Trond Mohn Foundation (Grant No. BFS2018TMT10 and
   TMS2021STG03) and MAXIBONE EU H2020 project no. 779322 for the financial
   support of the study. We also acknowledge Biomatlante Biologics
   Solution, France for providing the MBCP +TM biomaterial. Flow cytometry
   analysis was performed at the Flow Cytometry Core Facility, Dept. of
   Clinical Science, Uni versity of Bergen. The authors thank Dr. JOrn
   Skavland and Dr. Brith Bergum (Flow Cytometry Core Facility, University
   of Bergen) for their excellent support and Dr. Cecilie Gjerde (Section
   of Oral and Maxillofacial Surgery) for guidance and help during surgery.
   Dr. Harsh Dongre (Experimental Pathology Research Group, Dept. of
   Clinical Medicine, University of Bergen) is acknowledged for his
   assistance with immunohistochemical digital analysis and for pro viding
   licensed application (cited as; Created with BioRender.com ) , used to
   create graphical figures in this manuscript.
CR Aratani Y, 2018, ARCH BIOCHEM BIOPHYS, V640, P47, DOI 10.1016/j.abb.2018.01.004
   Barnett Vanes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0142520
   Barrère F, 2006, INT J NANOMED, V1, P317
   Bastian OW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00945
   Batoon L, 2017, CURR OSTEOPOROS REP, V15, P385, DOI 10.1007/s11914 017 0384 x
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Brennan MA, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt504
   Chu CY, 2017, TISSUE ENG PART B RE, V23, P421, DOI [10.1089/ten.teb.2016.0463, 10.1089/ten.TEB.2016.0463]
   de Witte SFH, 2018, STEM CELLS, V36, P602, DOI 10.1002/stem.2779
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fingerhut L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124523
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Galleu A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7828
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Gao Q, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9050499
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Gjerde C, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0951 9
   Gómez Barrena E, 2020, INJURY, V51, pS63, DOI 10.1016/j.injury.2020.02.070
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Heinrich J, 2005, ARCH ORAL BIOL, V50, P897, DOI 10.1016/j.archoralbio.2005.02.007
   Humbert P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00663
   Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562
   Jhunjhunwala S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137550
   Julier Z, 2017, ACTA BIOMATER, V53, P13, DOI 10.1016/j.actbio.2017.01.056
   Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004
   Ko JH, 2020, CELL REP, V30, P3806, DOI 10.1016/j.celrep.2020.02.062
   Kondo N, 2006, BIOMATERIALS, V27, P4419, DOI 10.1016/j.biomaterials.2006.04.016
   Kota DJ, 2014, SCI REP UK, V4, DOI 10.1038/srep04565
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Lin RZ, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 017 0081
   Liu J, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02014 w
   Maggini J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009252
   Melgert BN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045229
   Menges P, 2012, EUR SURG RES, V48, P180, DOI 10.1159/000338196
   Mohamed Ahmed S, 2021, CELL TISSUE RES, V383, P1061, DOI 10.1007/s00441 020 03315 5
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Noronha ND, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1259 0
   Pabst R, 2020, CELL TISSUE RES, V380, P287, DOI 10.1007/s00441 020 03206 9
   Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528
   Prockop DJ, 2016, MATRIX BIOL, V51, P7, DOI 10.1016/j.matbio.2016.01.010
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270 007 9372 6
   Scapini P, 2016, IMMUNOL REV, V273, P48, DOI 10.1111/imr.12448
   Seebach E, 2014, ACTA BIOMATER, V10, P4730, DOI 10.1016/j.actbio.2014.07.017
   Shin RLY, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/8835156
   Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004 0359
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006
   Sun JC, 2009, EUR J IMMUNOL, V39, P2059, DOI 10.1002/eji.200939435
   Takano K, 2001, INFLAMM RES, V50, P503, DOI 10.1007/PL00000226
   Tanneberger AM, 2021, CLIN ORAL INVEST, V25, P859, DOI 10.1007/s00784 020 03373 7
   Tasso R, 2013, STEM CELLS DEV, V22, P3178, DOI 10.1089/scd.2013.0313
   Tour G, 2014, J TISSUE ENG REGEN M, V8, P841, DOI 10.1002/term.1574
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wang MY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3057624
   Wendler S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00713
   Wise AF, 2014, AM J PHYSIOL RENAL, V306, pF1222, DOI 10.1152/ajprenal.00675.2013
   Wu CL, 2020, OSTEOARTHR CARTILAGE, V28, P544, DOI 10.1016/j.joca.2019.12.007
   Xie YJ, 2020, REGEN BIOMATER, V7, P233, DOI 10.1093/rb/rbaa006
   Yassin MA, 2015, J BIOMED MATER RES A, V103, P3649, DOI 10.1002/jbm.a.35505
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yu XY, 2017, IMMUNITY, V47, P903, DOI 10.1016/j.immuni.2017.10.007
   Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441 017 2598 8
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 68
TC 14
Z9 17
U1 1
U2 21
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 15
PY 2022
VL 141
BP 440
EP 453
DI 10.1016/j.actbio.2021.12.027
EA MAR 2022
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 2Q0IK
UT WOS:000820112900007
PM 34968726
DA 2025 08 17
ER

PT J
AU Lecaille, F
   Chazeirat, T
   Bojarski, KK
   Renault, J
   Saidi, A
   Prasad, VGNV
   Samsonov, S
   Lalmanach, G
AF Lecaille, Fabien
   Chazeirat, Thibault
   Bojarski, Krzysztof K.
   Renault, Justine
   Saidi, Ahlame
   Prasad, V. Gangadhara N. V.
   Samsonov, Sergey
   Lalmanach, Gilles
TI Rat cathepsin K: Enzymatic specificity and regulation of its
   collagenolytic activity
SO BIOCHIMICA ET BIOPHYSICA ACTA PROTEINS AND PROTEOMICS
LA English
DT Article
DE Cathepsin K; Chondroitin 4 sulfate; Collagen; Cysteinc protease;
   Protein glycosaminoglycan interactions; T kininogen
ID T KININOGEN; COLLAGENASE ACTIVITY; SELECTIVE INHIBITION; CYSTEINE
   PROTEASE; FORCE FIELD; UNIQUE; OSTEOPOROSIS; THIOSTATIN; EXPRESSION;
   SULFATE
AB Human cathepsin K (hCatK), which is highly expressed in osteoclasts, has the noteworthy ability to cleave type I and II collagens in their helical domain. Its collagenase potency depends strictly on the formation of an oligomeric complex with chondroitin 4 sulfate (C4 S). Accordingly, hCatK is a pivotal protease involved in bone resorption and is an attractive target for the treatment of osteoporosis. As rat is a common animal model for the evaluation of hCatK inhibitors, we conducted a comparative analysis of rat CatK (rCatK) and hCatK, which share a high degree of identity (88%) and similarity (93%). The pH activity profile of both enzymes displayed a similar bell shaped curve (optimal pH: 6.4). Presence of Ser134 and Val160 in the S2 pocket of rCatK instead of Ala and Leu residues, respectively, in hCatK, led to a weaker peptidase activity, as observed for mouse CatK. Also, regardless of the presence of C4 S, rCatK cleaved in the nonhelical telopeptide regions of both type I (tail) and type II (articular joint) rat collagens. Structure based computational analyses (electrostatic potential, molecular docking, molecular dynamics, free energy calculations) sustained that the C4 S mediated collagenolytic activity of rCatK obeys distinct molecular interactions from those of hCatK. Additionally, T kininogen (a.k.a. thiostatin), a unique rat serum acute phase molecule, acted as a tight binding inhibitor of hCatK (Ki = 0.11 +/  0.05 nM). Taken into account the increase of T Kininogen level in inflamed rat sera, this may raise the question of the appropriateness to evaluate pharmacological hCatK inhibitors in this peculiar animal model.
C1 [Lecaille, Fabien; Chazeirat, Thibault; Renault, Justine; Saidi, Ahlame; Lalmanach, Gilles] Univ Tours, F 37032 Tours, France.
   [Lecaille, Fabien; Chazeirat, Thibault; Renault, Justine; Saidi, Ahlame; Lalmanach, Gilles] INSERM, Team Proteolyt Mech Inflammat, Res Ctr Resp Dis CEPR, UMR 1100, Tours, France.
   [Bojarski, Krzysztof K.; Samsonov, Sergey] Univ Gdansk, Fac Chem, Wita Stwosza 63, PL 80308 Gdansk, Poland.
   [Prasad, V. Gangadhara N. V.] Coll Vet Sci, Dept Vet Pharmacol & Toxicol, Hyderabad, India.
   [Renault, Justine] Univ Paris Diderot Paris7, CNRS UMR 8251, Biol Fonct & Adaptat, Paris, France.
C3 Universite de Tours; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Fahrenheit Universities; University of Gdansk;
   Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); CNRS   National Institute for Biology (INSB)
RP Lecaille, F; Lalmanach, G (通讯作者)，Univ Tours, Fac Med, INSERM, UMR 1100,CEPR, 10 Blvd Tonnelle, F 37032 Tours, France.
EM fabien.lecaille@univ tours.fr; gilles.lalmanach@univ tours.fr
RI ; Bojarski, Krzysztof Kamil/ISA 6428 2023; Lecaille,
   Fabien/GRY 5313 2022; AHLAME, SAIDI/ABU 3656 2022
OI Saidi, Ahlame/0000 0002 0282 2476; Lalmanach,
   Gilles/0000 0001 8562 4821; Bojarski, Krzysztof
   Kamil/0000 0002 2066 1522; Lecaille, Fabien/0000 0003 1060 4222;
   Samsonov, Sergey/0000 0002 5166 4849
FU Institut National de la Sante et de la Recherche Medicale (INSERM);
   University of Tours; GagoSciences (Structure, function and regulation of
   glycosaminoglycans) [GDR 3739]; RTR (Thematic Research Network)
   MotivHealth (Region Centre Val de Loire, France); MESRI (Ministere de
   l'Enseignement Superieur, de la Recherche et de l'Innovation, France);
   Faculty of Chemistry, University of Gdansk [BMN 538 8370 B249 18];
   National Science Center of Poland (Narodowe Cenrtum Nauki)
   [UMO 2018/31/N/ST4/01677]; National Science Center of Poland (Narodowe
   Centrum Nauki) [UMO 2018/30/E/ST4/00037]
FX Authors acknowledge Prof. Dieter Bromme (Department of Oral Biological
   and Medical Sciences, The University of British Columbia, Vancouver,
   British Columbia, Canada) for providing human recombinant cathepsin K.
   This work was supported by institutional fundings from the Institut
   National de la Sante et de la Recherche Medicale (INSERM), the
   University of Tours and GagoSciences (Structure, function and regulation
   of glycosaminoglycans; GDR 3739, Centre National de la Recherche
   Scientifique). We acknowledge the RTR (Thematic Research Network)
   MotivHealth (Region Centre Val de Loire, France) for support. TC holds a
   doctoral fellowship from MESRI (Ministere de l'Enseignement Superieur,
   de la Recherche et de l'Innovation, France). KKB holds a BMN (Badania
   Miodych Naukowcow) grant from the Faculty of Chemistry, University of
   Gdansk (BMN 538 8370 B249 18) and a grant (UMO 2018/31/N/ST4/01677) from
   the National Science Center of Poland (Narodowe Cenrtum Nauki). SS
   received funding (grant UMO 2018/30/E/ST4/00037) from the National
   Science Center of Poland (Narodowe Centrum Nauki). A friendly and warmly
   grateful thought to Dr. Francis Gauthier, Professor Emeritus at the
   University of Tours.
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   BARLAS A, 1985, BIOCHEM BIOPH RES CO, V129, P280, DOI 10.1016/0006 291X(85)91434 2
   BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189
   Bojarski K. K., 2019, BIOPOLYMERS, V110
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200
   Darden T. A., 2016, AMBER 2017
   ESNARD F, 1983, J BIOL CHEM, V258, P2443
   Ester M., 1996, KDD 96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P226
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   GAUTHIER F, 1988, BIOL CHEM H S, V369, P251
   Godat E, 2004, BIOCHEM J, V383, P501, DOI 10.1042/BJ20040864
   GORDON AH, 1969, BIOCHEM J, V113, P481, DOI 10.1042/bj1130481
   Hou WS, 1999, J CLIN INVEST, V103, P731, DOI 10.1172/JCI653
   HUIGE CJM, 1995, J COMPUT CHEM, V16, P56, DOI 10.1002/jcc.540160106
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820
   LALMANACH G, 1991, EUR J BIOCHEM, V196, P73, DOI 10.1111/j.1432 1033.1991.tb15787.x
   Lalmanach G, 2010, BIOCHIMIE, V92, P1568, DOI 10.1016/j.biochi.2010.03.011
   Lauer Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201
   LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003 2697(66)90246 6
   Law S, 2019, BIOCHEM J, V476, P499, DOI 10.1042/BCJ20180851
   Law S, 2017, BIOCHEM J, V474, P851, DOI 10.1042/BCJ20160985
   Lecaille F, 2003, BIOCHEM J, V375, P307, DOI 10.1042/BJ20030468
   Lecaille F, 2002, BIOCHEMISTRY US, V41, P8447, DOI 10.1021/bi025638x
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Li WZ, 2015, NUCLEIC ACIDS RES, V43, pW580, DOI 10.1093/nar/gkv279
   Li ZQ, 2008, J MOL BIOL, V383, P78, DOI 10.1016/j.jmb.2008.07.038
   Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200
   Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200
   Li ZQ, 2000, BIOCHEMISTRY US, V39, P529, DOI 10.1021/bi992251u
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   Marquis RW, 2001, J MED CHEM, V44, P1380, DOI 10.1021/jm000481x
   MOREAU T, 1988, EUR J BIOCHEM, V173, P185, DOI 10.1111/j.1432 1033.1988.tb13983.x
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096 987X(19981115)19:14<1639::AID JCC10>3.0.CO;2 B
   Nallaseth FS, 2013, BIOCHEMISTRY US, V52, P7742, DOI 10.1021/bi401051j
   Naudin C, 2010, J MOL BIOL, V400, P1022, DOI 10.1016/j.jmb.2010.06.006
   Novinec M, 2016, FEBS LETT, V590, P4507, DOI 10.1002/1873 3468.12495
   Novinec M, 2010, BIOCHEM J, V429, P379, DOI 10.1042/BJ20100337
   Panwar P, 2018, BRIT J PHARMACOL, V175, P902, DOI 10.1111/bph.14133
   Panwar P, 2017, J BONE MINER RES, V32, P2415, DOI 10.1002/jbmr.3227
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pichert A, 2012, GLYCOBIOLOGY, V22, P134, DOI 10.1093/glycob/cwr120
   Prasad VGNV, 2015, EUR J DRUG METAB PH, V40, P23, DOI 10.1007/s13318 013 0172 7
   Sage J, 2013, BIOCHEMISTRY US, V52, P6487, DOI 10.1021/bi400925g
   Selent J, 2007, J BIOL CHEM, V282, P16492, DOI 10.1074/jbc.M700242200
   Tada S, 2008, J BIOCHEM, V144, P499, DOI 10.1093/jb/mvn093
   Turk V, 2012, BBA PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   URBAN J, 1979, J BIOL CHEM, V254, P565
   Vizovisek M, 2019, MATRIX BIOL, V75 76, P141, DOI 10.1016/j.matbio.2018.01.024
   Walter R, 1998, MECH AGEING DEV, V106, P129, DOI 10.1016/S0047 6374(98)00107 9
NR 53
TC 12
Z9 12
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1570 9639
EI 1878 1454
J9 BBA PROTEINS PROTEOM
JI BBA Proteins Proteomics
PD FEB
PY 2020
VL 1868
IS 2
AR 140318
DI 10.1016/j.bbapap.2019.140318
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA KE7OB
UT WOS:000508739900016
PM 31740411
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Brody, A
   Scheich, B
   Dobo Nagy, C
AF Brody, Andrea
   Scheich, Balint
   Dobo Nagy, Csaba
TI Targeted histological evaluation shows high incidence of actinomyces
   infection in medication related osteonecrosis of the jaws
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; RISK FACTORS; OSTEOMYELITIS;
   OSTEORADIONECROSIS; SECONDARY; CANCER
AB Medication Related Osteonecrosis of the Jaws (MRONJ) is a difficult to treat complication of the therapy of osteoporosis and some malignancies cured with bisphosphonates and antiresorptive drugs. The pathomechanism is unclear, but there is increasing observation that Actinomyces infection may play a role in its development and progression. The aim of our study was to demonstrate that histological examination using a validated triple staining procedure for Actinomyces bacteria strains can detect a high rate of Actinomyces infection in patient's samples with MRONJ. 112 previously hematoxylin eosin (HE) stained samples submitted with the clinical diagnosis of MRONJ were re evaluated histologically using an appropriate triple special staining validated for the identification of Actinomyces infection. During the first evaluation, when pathologists did not specifically look for Actinomyces, only 8.93% of the samples were reported as positive. In contrast, re evaluation with triple staining provided a yield of 93.7% positive samples, therefore, we suggest the triple special staining to be standard in MRONJ histology evaluation. These results show that if the clinician suspects Actinomyces infection and brings this to the attention of the pathologist, it could significantly increase the number of correct diagnoses. It serves as an aid for clinicians in therapeutic success of MRONJ by selecting a long term adequate antibiotic medication which is suitable for the elimination of actinomyces infection.
C1 [Brody, Andrea; Dobo Nagy, Csaba] Semmelweis Univ, Fac Dent, Dept Oral Diagnost, Szentkiralyi U 47, H 1088 Budapest, Hungary.
   [Scheich, Balint] Semmelweis Univ, Fac Med, Dept Pathol & Expt Canc Res, Ulloi Ut 26, H 1085 Budapest, Hungary.
C3 Semmelweis University; Semmelweis University
RP Brody, A (通讯作者)，Semmelweis Univ, Fac Dent, Dept Oral Diagnost, Szentkiralyi U 47, H 1088 Budapest, Hungary.
EM brody.andrea@gmail.com
RI Dobo Nagy, Csaba/X 6971 2019; Bródy, Andrea/M 7724 2018
FU Semmelweis University
FX Open access funding provided by Semmelweis University.
CR Akashi M, 2018, ORAL MAXILLOFAC SURG, V22, P59, DOI 10.1007/s10006 017 0667 5
   Anavi Lev K, 2013, OR SURG OR MED OR PA, V115, P660, DOI 10.1016/j.oooo.2013.03.001
   Anette S., 2020, FOGORV SZ, V113, P96
   Caso JAA, 2012, MED CLIN BARCELONA, V139, P676, DOI 10.1016/j.medcli.2012.05.039
   Brody A, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0843 0
   Cerrato A., 2020, J STOMATOL ORAL MAXI, V2, P2
   Curi MM, 2000, ORAL ONCOL, V36, P294, DOI 10.1016/S1368 8375(99)00080 9
   De Ceulaer J, 2014, EUR J CLIN MICROBIOL, V33, P1873, DOI 10.1007/s10096 014 2160 5
   Domah F., 2018, Oral Surgery, V11, p250, DOI [DOI 10.1111/ORS.12329, 10.1111/ors.12329]
   Franco Pretto E, 2014, OR SURG OR MED OR PA, V118, P408, DOI 10.1016/j.oooo.2014.04.017
   Gabbert TI, 2015, J CANCER RES CLIN, V141, P749, DOI 10.1007/s00432 014 1853 6
   Gajdács M, 2019, DENT J BASEL, V7, DOI 10.3390/dj7030085
   Gaweda A., 2018, J PRECLIN CLIN RES, V12, P82
   Gupta N., 2020, BMJ CASE REP, V13, P2
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hansen T, 2006, HUM PATHOL, V37, P61, DOI 10.1016/j.humpath.2005.09.018
   Hansen T, 2007, VIRCHOWS ARCH, V451, P1009, DOI 10.1007/s00428 007 0516 2
   Hinson AM, 2014, INT J DENT, V2014, DOI 10.1155/2014/452737
   Itzhak B., 2021, TREATMENT ACTINOMYCO
   Kaplan I, 2009, ORAL SURG ORAL MED O, V108, P738, DOI 10.1016/j.tripleo.2009.06.019
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198 015 3335 3
   Koerdt S, 2014, J ORAL PATHOL MED, V43, P448, DOI 10.1111/jop.12156
   Könönen E, 2015, CLIN MICROBIOL REV, V28, P419, DOI 10.1128/CMR.00100 14
   Kos M, 2010, INT J ORAL MAX SURG, V39, P1097, DOI 10.1016/j.ijom.2010.04.054
   Kotán EV, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 025600
   Lee CYS., 2011, IMPLANT DENT, V20, P2
   Lugassy G, 2004, AM J MED, V117, P440, DOI 10.1016/j.amjmed.2004.04.015
   Mallmann Lídia, 2020, Rev. Estomatol. Herediana, V30, P126, DOI 10.20453/reh.v30i2.3765
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   MARX RE, 1994, J ORAL MAXIL SURG, V52, P26, DOI 10.1016/0278 2391(94)90008 6
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mulcahy LE, 2015, EUR CELLS MATER, V30, P271, DOI 10.22203/eCM.v030a19
   Nagler R, 1997, ORAL SURG ORAL MED O, V83, P652, DOI 10.1016/S1079 2104(97)90313 9
   Naik NH, 2009, CLIN INFECT DIS, V49, P1729, DOI 10.1086/648075
   Oostman Olga, 2005, Curr Infect Dis Rep, V7, P170, DOI 10.1007/s11908 005 0030 0
   Panya S, 2017, J CRANIO MAXILL SURG, V45, P357, DOI 10.1016/j.jcms.2017.01.006
   Patel V, 2011, BRIT J ORAL MAX SURG, V49, P251, DOI 10.1016/j.bjoms.2010.05.007
   Raguse JD, 2020, OR SURG OR MED OR PA, V129, pE257, DOI 10.1016/j.oooo.2019.10.008
   Rosenberg A., 2016, DIAGN HISTOPATHOL, V22, P355, DOI [10.1016/j.mpdhp.2016.09.005, DOI 10.1016/J.MPDHP.2016.09.005]
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russmueller G, 2016, SCI REP UK, V6, DOI 10.1038/srep31604
   Schipmann S, 2013, J ORAL PATHOL MED, V42, P587, DOI 10.1111/jop.12038
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P1259, DOI 10.14219/jada.archive.2009.0049
   Sezer Bahar, 2017, J Dent Sci, V12, P301, DOI 10.1016/j.jds.2013.02.031
   Shuster A, 2019, INT J ORAL MAX SURG, V48, P17, DOI 10.1016/j.ijom.2018.07.002
   Smith AJ, 2005, J ANTIMICROB CHEMOTH, V56, P407, DOI 10.1093/jac/dki206
   Smith MH, 2011, BMC ORAL HEALTH, V11, DOI 10.1186/1472 6831 11 21
   Stajer A., 2020, ANTIBIOTICS BASEL, V9, P2
   Store G, 2005, INT J ORAL MAX SURG, V34, P193, DOI 10.1016/j.ijom.2004.06.010
   Szentpéteri S, 2020, ORVOSI HETILAP, V161, P283, DOI 10.1556/650.2019.31621
   Vereb T, 2020, ORVOSI HETILAP, V161, P214, DOI 10.1556/650.2020.31633
   Zirk M, 2019, CLIN ORAL INVEST, V23, P2143, DOI 10.1007/s00784 018 2655 z
NR 53
TC 8
Z9 8
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 1
PY 2022
VL 12
IS 1
AR 3406
DI 10.1038/s41598 022 07375 1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ZK5EF
UT WOS:000763010000036
PM 35233034
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Singhal, M
   Seaton, CC
   Surtees, A
   Katsikogianni, MG
AF Singhal, Mitali
   Seaton, Colin C.
   Surtees, Alexander
   Katsikogianni, Maria G.
TI Formulation, Characterisation, and Biocompatibility Assessment of
   Rifampicin Loaded Poly(d,l lactide co glycolide) Composites for Local
   Treatment of Orthopaedic and Wound Infections
SO PHARMACEUTICS
LA English
DT Article
DE composites; biodegradable; polymer; antimicrobial; cytocompatibility;
   rifampicin; PLGA
ID PROSTHETIC JOINT INFECTIONS; ANTIBACTERIAL ACTIVITY EVALUATION;
   DRUG DELIVERY; NANOPARTICLES; RELEASE; COMBINATION; FRACTURES;
   CYTOCOMPATIBILITY; ARTHROPLASTY; MICROSPHERES
AB Background/Objectives: The escalating challenge of antimicrobial resistance (AMR) necessitates the development of targeted antibiotic delivery platforms, minimising systemic administration. Polymer based drug delivery emerges as a promising solution, ensuring sustained release and prolonged efficacy of bioactive compounds, ensuring long term efficacy. Methods: This study focuses on encapsulating rifampicin (RIF), a key antibiotic for orthopaedic and wound related infections, within Poly(d,l lactide co glycolide) (PLGA), a biodegradable polymer, through solvent casting, to formulate a PLGA RIF composite membrane. Comprehensive characterisation, employing Fourier transformed infrared spectroscopy (FT IR), scanning electron microscopy (SEM), thermal analysis and X ray Diffraction (XRD), confirmed the integrity of both the starting and produced materials. UV Vis spectroscopy revealed a controlled drug release profile over 21 days in various media, with the chosen media influencing the drug release, notably the tryptic soya broth (TSB) caused the highest release. The quantitative assessment of the antimicrobial efficacy of the developed PLGA RIF composite was conducted by measuring the size of the inhibition zones against both Gram negative and Gram positive bacteria. Results: The results confirmed the composite's potential as a robust antibacterial biomaterial, demonstrating a rapid and effective antibacterial response. Cytocompatibility tests incorporated human fibroblast and osteoblast like cell lines and demonstrated that the RIF:PLGA (1:8) formulation maintained eukaryotic cell viability, indicating the composite's potential for targeted medical applications in combating bacterial infections with minimal systemic impact. Conclusions: This study presents the significance of investigating drug release within appropriate and relevant physiological media. A key novelty of this work therefore lies in the exploration of drug release dynamics across different media, allowing for a comprehensive understanding of how varying physiological conditions may influence drug release and its effect on biological responses.
C1 [Singhal, Mitali] Univ Bradford, Inst Canc Therapeut, Sch Pharm & Med Sci, Bradford BD7 1DP, England.
   [Seaton, Colin C.; Katsikogianni, Maria G.] Univ Bradford, Sch Chem & Biosci, Bradford BD7 1DP, England.
   [Surtees, Alexander] Univ Bradford, Sch Archaeol & Forens Sci, Bradford BD7 1DP, England.
C3 University of Bradford; University of Bradford; University of Bradford
RP Katsikogianni, MG (通讯作者)，Univ Bradford, Sch Chem & Biosci, Bradford BD7 1DP, England.
EM mitali3005@gmail.com; c.seaton@bradford.ac.uk; a.surtees@bradford.ac.uk;
   m.katsikogianni@bradford.ac.uk
OI Singhal, Mitali/0000 0002 3111 417X; Katsikogianni,
   Maria/0000 0002 1560 3993
CR Agrawal S, 2004, EUR J PHARM SCI, V22, P127, DOI 10.1016/j.ejps.2004.02.011
   Ahlborg HG, 1999, ACTA ORTHOP SCAND, V70, P116, DOI 10.3109/17453679909011246
   Alp E, 2016, J INFECT PUBLIC HEAL, V9, P494, DOI 10.1016/j.jiph.2015.12.014
   Alsaab HO, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122728
   Asadpour Zeynali K, 2016, IRAN J PHARM RES, V15, P713
   Badaraev AD, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15030939
   Baelo A, 2015, J CONTROL RELEASE, V209, P150, DOI 10.1016/j.jconrel.2015.04.028
   Barros CHN, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00851 2
   Busscher HJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004528
   Calderon LGM, 2023, ACS APPL MATER INTER, V15, P40213, DOI 10.1021/acsami.3c07367
   Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092 8674(01)00286 0
   Canaparo R, 2019, MOLECULES, V24, DOI 10.3390/molecules24101991
   Cao Y, 2018, MATERIALS, V11, DOI 10.3390/ma11040589
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Silva ISD, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249 019 1576 8
   Deepika MS, 2020, ACS APPL BIO MATER, V3, P385, DOI 10.1021/acsabm.9b00850
   DENKBAS EB, 1995, J BIOMAT SCI POLYM E, V6, P815, DOI 10.1163/156856295X00201
   Donaldson LJ, 2008, J EPIDEMIOL COMMUN H, V62, P174, DOI 10.1136/jech.2006.056622
   Dutt M, 2001, J ANTIMICROB CHEMOTH, V47, P829, DOI 10.1093/jac/47.6.829
   Elashnikov R, 2015, REACT FUNCT POLYM, V93, P163, DOI 10.1016/j.reactfunctpolym.2015.06.010
   Ernst J, 2018, EUR J PHARM BIOPHARM, V131, P120, DOI 10.1016/j.ejpb.2018.07.025
   Esmaeili F, 2007, NANOMED NANOTECHNOL, V3, P161, DOI 10.1016/j.nano.2007.03.003
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Gajendiran M, 2013, CURR DRUG DELIV, V10, P722, DOI 10.2174/15672018113109990002
   Gruppuso M, 2022, ACS APPL MATER INTER, V14, P27599, DOI 10.1021/acsami.2c04849
   Guégan C, 2014, COLLOID SURFACE B, V114, P193, DOI 10.1016/j.colsurfb.2013.10.010
   Hasan S, 2017, J MATER CHEM B, V5, P1005, DOI 10.1039/c6tb03290g
   Hellmark B, 2009, CLIN MICROBIOL INFEC, V15, P238, DOI 10.1111/j.1469 0691.2008.02663.x
   Hu CH, 2012, COLLOID SURFACE B, V95, P162, DOI 10.1016/j.colsurfb.2012.02.030
   Huang YP, 2018, IND ENG CHEM RES, V57, P17048, DOI 10.1021/acs.iecr.8b03122
   Ichioka Y, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 02220 3
   International Organization for Standardization, 2021, ISO 10993 12:2021
   Kolewe KW, 2015, ACS APPL MATER INTER, V7, P19562, DOI 10.1021/acsami.5b04269
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Lentino JR, 2003, CLIN INFECT DIS, V36, P1157, DOI 10.1086/374554
   Liang QZ, 2020, INT J NANOMED, V15, P7491, DOI 10.2147/IJN.S257758
   Lichter JA, 2008, BIOMACROMOLECULES, V9, P1571, DOI 10.1021/bm701430y
   Lindau TR, 1999, ACTA ORTHOP SCAND, V70, P124, DOI 10.3109/17453679909011248
   Liu H, 2021, J INCL PHENOM MACRO, V101, P111, DOI 10.1007/s10847 021 01093 3
   Liu M, 2017, ACS APPL MATER INTER, V9, P41512, DOI 10.1021/acsami.7b15826
   Loureiro JA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090903
   Marmor S, 2016, ORTHOP TRAUMATOL SUR, V102, pS113, DOI 10.1016/j.otsr.2015.05.012
   Masquelet A, 2019, J BONE JOINT SURG AM, V101, P1024, DOI 10.2106/JBJS.18.00842
   Mok S, 2023, J ANTIMICROB CHEMOTH, V78, P2637, DOI 10.1093/jac/dkad252
   Munita JM, 2016, MICROBIOL SPECTR, V4, DOI [10.1128/microbiolspec.VMBF 0016 2015, 10.3389/fmicb.2015.00034]
   NAJI A, 1991, BIOMATERIALS, V12, P690, DOI 10.1016/0142 9612(91)90118 T
   Ogawara H, 2019, MOLECULES, V24, DOI 10.3390/molecules24193430
   Palacios J, 2013, POLYM ENG SCI, V53, P1414, DOI 10.1002/pen.23396
   Peñuelas Urquides K, 2013, BRAZ J MICROBIOL, V44, P287, DOI 10.1590/S1517 83822013000100042
   Pillai O, 2001, CURR OPIN CHEM BIOL, V5, P447, DOI 10.1016/S1367 5931(00)00227 1
   Ponnusamy Thiruselvam, 2012, Biomatter, V2, P77, DOI 10.4161/biom.20390
   Qiao ZW, 2019, ARTIF CELL NANOMED B, V47, P790, DOI 10.1080/21691401.2019.1581792
   Rahal EA, 2011, INT J ANTIMICROB AG, V37, P135, DOI 10.1016/j.ijantimicag.2010.10.009
   Reinbold J, 2017, MOLECULES, V22, DOI 10.3390/molecules22091570
   Ruediger T, 2012, DENT MATER, V28, pE239, DOI 10.1016/j.dental.2012.05.008
   Saez V, 2016, MACROMOL SYMP, V368, P116, DOI 10.1002/masy.201500181
   Shariati A, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.926363
   Singhal M, 2024, APPL SCI BASEL, V14, DOI 10.3390/app14051902
   Smith R, 2020, ANTIBIOTICS BASEL, V9, DOI 10.3390/antibiotics9020056
   Snejdrova E, 2022, J DRUG DELIV SCI TEC, V73, DOI 10.1016/j.jddst.2022.103435
   Straub H, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801323
   Tande AJ, 2014, CLIN MICROBIOL REV, V27, P302, DOI 10.1128/CMR.00111 13
   THORNSBERRY C, 1983, REV INFECT DIS, V5, pS412
   Timms A, 2013, INT J ORTHOP TRAUMA, V17, P19, DOI 10.1016/j.ijotn.2012.04.005
   Tripodi MF, 2007, INT J ANTIMICROB AG, V30, P537, DOI 10.1016/j.ijantimicag.2007.07.007
   Tsai MH, 2023, GELS BASEL, V9, DOI 10.3390/gels9070562
   Wang WZ, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/ac2a8c
   WHO, 2020, WHO consolidated guidelines on tuberculosis. Module 1: prevention tuberculosis preventive treatment
   Yoo Chae Kyung, 2016, Maxillofac Plast Reconstr Surg, V38, P17, DOI 10.1186/s40902 016 0062 4
   Yoo J, 2020, ACS BIOMATER SCI ENG, V6, P6053, DOI 10.1021/acsbiomaterials.0c01228
   Zheng XK, 2021, INFECT DRUG RESIST, V14, P1527, DOI 10.2147/IDR.S301863
   Zhu GQ, 2013, POLIMEROS, V23, P619
NR 72
TC 1
Z9 1
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD NOV
PY 2024
VL 16
IS 11
AR 1467
DI 10.3390/pharmaceutics16111467
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA N7C5X
UT WOS:001365875300001
PM 39598590
OA gold
DA 2025 08 17
ER

PT J
AU Liu, X
   Zhu, SJ
   Cui, JF
   Shao, HG
   Zhang, W
   Yang, HL
   Xu, YZ
   Geng, DC
   Yu, L
AF Liu, Xing
   Zhu, Shijun
   Cui, Jingfu
   Shao, Hongguo
   Zhang, Wen
   Yang, Huilin
   Xu, Yaozeng
   Geng, Dechun
   Yu, Long
TI Strontium ranelate inhibits titanium particle induced osteolysis, by
   restraining inflammatory osteoclastogenesis in vivo
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Aseptic loosening; Wear particle; Strontium ranelate; RANKL; TNF alpha
ID TOTAL HIP ARTHROPLASTY; WEAR DEBRIS; RANK LIGAND; BONE MASS; TNF ALPHA;
   EXPRESSION; OSTEOBLASTS; OSTEOPROTEGERIN; OSTEOPOROSIS; MECHANISMS
AB Wear particle induced osteolysis is considered to be the main reason for revision after arthroplasty. Although the exact mechanism remains unclear, inflammatory osteoclastogenesis plays an important role in this process. Strontium ranelate (SR) was found to have a therapeutic effect on osteoporosis in postmenopausal women. Based on prior studies, the present authors hypothesized that SR prevents wear particle induced osteolysis through restraining inflammatory osteoclastogenesis. The present study used 80 male C57BL/J6 mice to test this hypothesis in a murine osteolysis model. All experimental animals were randomly divided into four groups: a control group; a SR group; a titanium group; and a titanium + SR group. Once titanium particles had been implanted in mice, the mice were administered SR (900 mg kg( 1) day( 1)) by gavage for 14 days. After 14 days, the calvaria were collected for micro computed tomography (mu CT), histological and molecular analysis. The results of mu CT and histomorphometric analysis demonstrated that SR markedly inhibited bone resorption and the generation of tartrate resistant acid phosphatase positive cells in vivo, compared with titanium stimulated calvaria. Reverse transcription polymerase chain reaction and ELISAs showed that SR stimulated the mRNA and protein expression of osteoprotegerin, and inhibited gene and protein expression of receptor activators of nuclear factor kappa B ligand in titanium particle charged calvaria. In addition, SR obviously reduced the secretion of tumor necrosis factor a and interleukin 1 beta in the calvaria of the titanium group. It was concluded that SR inhibits titanium induced osteolysis by restraining inflammatory osteoclastogenesis, and that it could be developed as a new drug to prevent and treat aseptic loosening. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Liu, Xing; Yu, Long] Fudan Univ, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Zhu, Shijun; Cui, Jingfu; Shao, Hongguo; Yang, Huilin; Xu, Yaozeng; Geng, Dechun] Suzhou Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Peoples R China.
   [Zhang, Wen] Suzhou Univ, Inst Orthoped, Suzhou 215006, Peoples R China.
C3 Fudan University
RP Geng, DC (通讯作者)，Suzhou Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shi Zi Rd, Suzhou 215006, Peoples R China.
EM szgengdc@163.com; yulong201@aliyun.com
RI Geng, Dechun/LMO 1733 2024; Zhang, Wen/CAA 2126 2022
FU Jiangsu Province's Key Medical center, Jiangsu Provincial Special
   Program of Medical Science [BL2012004]; National Nature Science
   Foundation of China [81372018, 81272018, 81101399]; Nature Science
   Foundation of Jiangsu Province [BK2011303]; Project of Jiangsu College
   graduate research and innovation program [CXZZ13_0835]
FX This work was supported by the Jiangsu Province's Key Medical center,
   Jiangsu Provincial Special Program of Medical Science (BL2012004), the
   National Nature Science Foundation of China (Grant no. 81372018,
   81272018 and 81101399), the Nature Science Foundation of Jiangsu
   Province (Grant no. BK2011303) and the Project of Jiangsu College
   graduate research and innovation program (CXZZ13_0835).
CR Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Body JJ, 2012, OSTEOPOROSIS INT, V23, pS1, DOI 10.1007/s00198 011 1891 8
   Braux J, 2011, ACTA BIOMATER, V7, P2593, DOI 10.1016/j.actbio.2011.02.013
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Buache E, 2012, ACTA BIOMATER, V8, P3113, DOI 10.1016/j.actbio.2012.04.045
   Chavassieux P, 2014, J BONE MINER RES, V29, P618, DOI 10.1002/jbmr.2074
   Delannoy P, 2002, METABOLISM, V51, P906, DOI 10.1053/meta.2002.33360
   Della Valle CJ, 2009, J BONE JOINT SURG AM, V91A, P1130, DOI 10.2106/JBJS.H.00168
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Dorr LD, 2005, J BONE JOINT SURG AM, V87A, P1816, DOI 10.2106/JBJS.D.01915
   Duffy GP, 2001, J ARTHROPLASTY, V16, P140, DOI 10.1054/arth.2001.28716
   Fujii J, 2011, HIP INT, V21, P231, DOI 10.5301/HIP.2011.7977
   Geng DC, 2011, ACTA BIOMATER, V7, P3216, DOI 10.1016/j.actbio.2011.05.007
   Geng DC, 2010, BIOMATERIALS, V31, P1996, DOI 10.1016/j.biomaterials.2009.11.069
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Muratoglu OK, 2002, BIOMATERIALS, V23, P717, DOI 10.1016/S0142 9612(01)00176 4
   Nich C, 2013, BIOMATERIALS, V34, P641, DOI 10.1016/j.biomaterials.2012.10.030
   Nich Christophe, 2011, Arthritis Res Ther, V13, pR100, DOI 10.1186/ar3381
   Pearl JI, 2011, BIOMATERIALS, V32, P5535, DOI 10.1016/j.biomaterials.2011.04.046
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Rao AJ, 2013, J BIOMED MATER RES A, V101, P1925, DOI 10.1002/jbm.a.34486
   Rao AJ, 2012, ACTA BIOMATER, V8, P2815, DOI 10.1016/j.actbio.2012.03.042
   Ren WP, 2006, BIOMATERIALS, V27, P5161, DOI 10.1016/j.biomaterials.2006.04.004
   Ren WP, 2003, BIOMATERIALS, V24, P4819, DOI 10.1016/S0142 9612(03)00384 3
   Rizzoli R, 2012, OSTEOPOROSIS INT, V23, P305, DOI 10.1007/s00198 011 1758 z
   Rizzoli Rene, 2011, Expert Rev Clin Pharmacol, V4, P593
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   Shahnazari M, 2006, J BONE MINER RES, V21, P1696, DOI 10.1359/JBMR.060724
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Wang R, 2013, BIOMATERIALS, V34, P2611, DOI 10.1016/j.biomaterials.2013.01.025
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
NR 37
TC 49
Z9 54
U1 0
U2 41
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2014
VL 10
IS 11
BP 4912
EP 4918
DI 10.1016/j.actbio.2014.07.025
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AR8XJ
UT WOS:000343854400037
PM 25078426
DA 2025 08 17
ER

PT J
AU Gubensek, J
   Buturovic Ponikvar, J
   Knap, B
   Pernat, AM
   Benedik, M
   Ponikvar, R
AF Gubensek, Jakob
   Buturovic Ponikvar, Jadranka
   Knap, Bojan
   Pernat, Andreja Marn
   Benedik, Miha
   Ponikvar, Rafael
TI Effect of Switching to Nocturnal Thrice Weekly Hemodialysis on Clinical
   and Laboratory Parameters: Our Experience
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Anemia; Hemodialysis; Hypertension; Outcome assessment; Phosphates;
   Nocturnal; Metabolic and bone disease
ID STAGE RENAL DISEASE; QUALITY OF LIFE; HOME HEMODIALYSIS; CARDIOVASCULAR
   PARAMETERS; CONVENTIONAL HEMODIALYSIS; LONG TERM; DIALYSIS; FREQUENT;
   SURVIVAL; TRIAL
AB Long or frequent hemodialysis schedules are reported to improve clinical outcomes. We report here our experience with an in center, nocturnal, thrice weekly hemodialysis program. We retrospectively analyzed the effect of switching 10 patients (8 male, age 45 +/  11 years, renal replacement therapy vintage 12 +/  8 years) from regular, 4 5 h, thrice weekly hemodialysis to 8 h nocturnal, in center hemodialysis as regards dialysis efficiency, chronic kidney disease metabolic and bone disease (CKD MBD) parameters, blood pressure, and anemia. With more intense dialysis, the mean predialysis creatinine and urea decreased significantly (1092 +/  195 vs. 961 +/  154 mu mol/L, P < 0.01 and 30.8 +/  4.6 vs. 25.5 +/  2.9 mmol/L, P < 0.01), while the decrease in potassium was insignificant (5.9 +/  0.7 vs. 5.6 +/  0.5 mmol/L), but in 3/10 patients, dialysate potassium was increased. Three months after starting nocturnal hemodialysis, no significant influence on pre dialysis blood pressure was observed (143/80 vs. 140/80 mmHg), but antihypertensive medications were reduced in two patients. The mean dry weight reduced (74 +/  12 to 72 +/  12 kg) and the mean ultrafiltration increased insignificantly (3123 +/  1174 to 3434 +/  1341 mL). Serum calcium was stable, while phosphate reduced insignificantly (1.5 +/  0.5 to 1.2 +/  0.2 mmol/L), but 6/10 patients were able to discontinue phosphate binders, the dose was reduced in one, and phosphate was added to dialysate in 3/10 patients. Intact parathyroid hormone values were within the target range, except in patients post parathyroidectomy. There were no differences in hemoglobin (121 +/  6 vs. 122 +/  8 g/L), and the mean epoetin dose decreased insignificantly (5950 +/  3947 vs. 5250 +/  4238 IU/week). To conclude, improved phosphate and potassium control and reduction in phosphate binders were observed after switching to nocturnal hemodialysis. There was an insignificant reduction of epoetin dose and antihypertensive medications.
C1 [Gubensek, Jakob; Buturovic Ponikvar, Jadranka; Knap, Bojan; Pernat, Andreja Marn; Benedik, Miha; Ponikvar, Rafael] Univ Med Ctr Ljubljana, Dept Nephrol, Ljubljana 1000, Slovenia.
C3 University Medical Centre Ljubljana
RP Gubensek, J (通讯作者)，Univ Med Ctr Ljubljana, Zaloska 7, Ljubljana 1000, Slovenia.
EM jakob.gubensek@kclj.si
RI Gubensek, Jakob/A 5077 2010
OI Gubensek, Jakob/0000 0002 5394 3729; Buturovic Ponikvar,
   Jadranka/0000 0001 7473 3731
FU University Medical Center Ljubljana [20110059]
FX This study was partially funded by a tertiary research project no.
   20110059 by University Medical Center Ljubljana.
CR Charra B, 1996, AM J NEPHROL, V16, P35, DOI 10.1159/000168968
   Chiu YW, 2009, CLIN J AM SOC NEPHRO, V4, P1089, DOI 10.2215/CJN.00290109
   Culleton BF, 2007, JAMA J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291
   Karamanidou C, 2008, BMC NEPHROL, V9, DOI 10.1186/1471 2369 9 2
   Lacson E, 2012, J AM SOC NEPHROL, V23, P687, DOI 10.1681/ASN.2011070674
   Mahadevan K, 2006, NEPHROLOGY, V11, P413, DOI 10.1111/j.1440 1797.2006.00670.x
   Powell JR, 2009, CLIN J AM SOC NEPHRO, V4, P1097, DOI 10.2215/CJN.06651208
   Rocco MV, 2011, KIDNEY INT, V80, P1080, DOI 10.1038/ki.2011.213
   Saad E, 2004, SEMIN DIALYSIS, V17, P295, DOI 10.1111/j.0894 0959.2004.17330.x
   Schwartz DI, 2005, CLIN NEPHROL, V63, P202
   Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P689, DOI 10.1053/j.ajkd.2011.12.020
   Ting GO, 2003, AM J KIDNEY DIS, V42, P1020, DOI 10.1016/j.ajkd.2003.07.020
   Van Eps CL, 2007, NEPHROLOGY, V12, P224, DOI 10.1111/j.1440 1797.2006.00712.x
   Weinreich T, 2006, CLIN NEPHROL, V66, P433
NR 14
TC 10
Z9 11
U1 0
U2 24
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD AUG
PY 2013
VL 17
IS 4
SI SI
BP 412
EP 415
DI 10.1111/1744 9987.12088
PG 4
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 198IW
UT WOS:000322917100012
PM 23931881
DA 2025 08 17
ER

PT J
AU Karras, D
   Stoykov, I
   Lems, WF
   Langdahl, BL
   Ljunggren, Ö
   Barrett, A
   Walsh, JB
   Fahrleitner Pammer, A
   Rajzbaum, G
   Jakob, F
   Marin, F
AF Karras, Dimitrios
   Stoykov, Ivaylo
   Lems, Willem F.
   Langdahl, Bente L.
   Ljunggren, Oesten
   Barrett, Annabel
   Walsh, J. Bernard
   Fahrleitner Pammer, Astrid
   Rajzbaum, Gerald
   Jakob, Franz
   Marin, Fernando
TI Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis
   and Glucocorticoid Use: 3 Year Results from the EFOS Study
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GLUCOCORTICOIDS; OSTEOPOROSIS; TERIPARATIDE; FRACTURE; BACK PAIN;
   QUALITY OF LIFE
ID PARATHYROID HORMONE; BONE FORMATION; ALENDRONATE; FRACTURES; PREVENTION;
   MECHANISMS; THERAPY; DENSITY; RISK
AB Objective. To describe clinical fracture rates, back pain, and health related quality of life (HROOL) in postmenopausal women with osteoporosis who are receiving glucocorticoids (GC), during a 36 month study of teriparatide treatment for up to 18 months, with an additional 18 month followup period when patients were receiving other osteoporosis medications.
   Methods. A prospective, multinational, observational study. Data for clinical fractures, back pain (by visual analog scale; VAS) and HRQOL (by EQ 5D) were collected over 36 months. Fracture data were summarized in 6 month segments and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ VAS were analyzed.
   Results. Of 1581 enrolled women with followup data, 294 (18.6%) had antecedents of GC use. Of these, 49 (16.7%) patients sustained a total of 69 fractures during the 36 month study period. Adjusted odds of fracture were significantly decreased during the last year of followup compared with the first 6 months of teriparatide treatment: an 81% decrease in the 24 to < 30 month period (p < 0.05), and an 89% decrease in the 30 to < 36 month period (p < 0.05). There were significant reductions in back pain and improvements in HRQOL in both groups of GC users and nonusers.
   Conclusion. Postmenopausal women with severe osteoporosis receiving GC, who were treated with teriparatide for up to 18 months, showed a reduced incidence of clinical fractures during the third year while receiving sequential osteoporosis treatments compared with the first 6 months, together with reduced back pain and improved HRQOL. Our results should be interpreted in the context of an uncontrolled observational study in a routine clinical setting. (First Release Jan 15 2012; J Rheumatol 2012;39:600 9; doi:10.3899/jrheum.110947)
C1 [Karras, Dimitrios] Vet Adm Hosp, Dept Rheumatol, Athens 11473, Greece.
   Eli Lilly & Co, Dept Med Res, Brussels, Belgium.
   [Lems, Willem F.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
   [Langdahl, Bente L.] Aarhus Univ Hosp, Skejby, Denmark.
   Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
   [Stoykov, Ivaylo; Barrett, Annabel; Marin, Fernando] Lilly Res Ctr Ltd, Windlesham GU20 6PH, Surrey, England.
   [Walsh, J. Bernard] Trinity Coll Dublin, Dublin, Ireland.
   [Rajzbaum, Gerald] Hop St Joseph, F 75674 Paris, France.
   [Fahrleitner Pammer, Astrid] Med Univ, Graz, Austria.
   [Jakob, Franz] Julius Maximilians Univ, Wurzburg, Germany.
   [Ljunggren, Oesten] Univ Uppsala Hosp, Uppsala, Sweden.
C3 Eli Lilly; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER;
   Aarhus University; Uppsala University; Eli Lilly; Lilly Research
   Laboratories; Trinity College Dublin; Universite Paris Cite; Hopital
   Paris Saint Joseph; Medical University of Graz; University of Wurzburg;
   Uppsala University; Uppsala University Hospital
RP Karras, D (通讯作者)，Vet Adm Hosp, Dept Rheumatol, Kallidromiou 50, Athens 11473, Greece.
EM dkarras@ath.forthnet.gr
RI Fahrleitner Pammer, Astrid/JQX 1538 2023; Jakob, Franz/D 8526 2015;
   Marin, Fernando/K 7666 2019
FU Eli Lilly and Company
FX The EFOS study is funded by Eli Lilly and Company.
CR [Anonymous], 2011, FORST TER SUMM PROD
   [Anonymous], 2000, Applied logistic regression
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Fahrleitner Pammer A, 2011, OSTEOPOROSIS INT, V22, P2709, DOI 10.1007/s00198 010 1498 5
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Graeff C, 2009, J BONE MINER RES, V24, P1672, DOI [10.1359/JBMR.090416, 10.1359/jbmr.090416]
   Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
   HOMIK J, 2000, COCHRANE DB SYST REV, V2
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Langdahl BL, 2009, OSTEOPOROSIS INT, V20, P2095, DOI 10.1007/s00198 009 0917 y
   Langdahl BL, 2009, CALCIFIED TISSUE INT, V85, P484, DOI 10.1007/s00223 009 9299 6
   Lems WF, 2007, ARTHRITIS RHEUM US, V56, P3518, DOI 10.1002/art.22975
   Liang YK, 1986, BIOMETRIKA, V73, P13, DOI DOI 10.1093/BIOMET/73.1.13
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Rajzbaum G, 2008, CURR MED RES OPIN, V24, P377, DOI 10.1185/030079908X261087
   Rizzoli R, 2008, NAT CLIN PRACT ENDOC, V4, P372, DOI 10.1038/ncpendmet0838
   Ross Philip D., 1997, American Journal of Medicine, V103, p30S, DOI 10.1016/S0002 9343(97)90025 5
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Silverman Stuart L, 2009, Curr Osteoporos Rep, V7, P23
   Silverman SL, 2009, AM J MED, V122, P114, DOI 10.1016/j.amjmed.2008.09.030
   Szende A., 2004, Measuring self reported population health:an international perspective based on EQ 5D
   Teitelbaum SL, 2011, ARTHRITIS RHEUM US, V63, P325, DOI 10.1002/art.30135
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Weinstein RS, 2010, BONE, V46, P564, DOI 10.1016/j.bone.2009.06.030
NR 35
TC 25
Z9 28
U1 0
U2 5
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315 162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAR
PY 2012
VL 39
IS 3
BP 600
EP 609
DI 10.3899/jrheum.110947
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 915PB
UT WOS:000302038800024
PM 22247365
OA Bronze
DA 2025 08 17
ER

PT J
AU Pillai, L
   Burnett, BP
   Levy, RM
AF Pillai, Lakshmi
   Burnett, Bruce P.
   Levy, Robert M.
TI GOAL: multicenter, open label, post marketing study of flavocoxid, a
   novel dual pathway inhibitor anti inflammatory agent of botanical origin
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE 5 lipoxygenase; Cyclooxygenase; Flavocoxid Gastrointestinal; Limbrel;
   Osteoarthritis
ID PROTON PUMP INHIBITORS; 2 PERCENT FIXED COMBINATION; GASTROINTESTINAL
   TOXICITY; RHEUMATOID ARTHRITIS; SCUTELLARIA BAICALENSIS; SELECTIVE
   INHIBITORS; CONTROLLED TRIAL; ACACIA CATECHU; DRUGS; OSTEOARTHRITIS
AB Objectives:
   GOAL (Gauging Osteoarthritis [OA] with Limbrel*), an open label, post marketing study was performed to determine the overall efficacy and gastrointestinal (GI) tolerability of flavocoxid, a novel, plant based, anti inflammatory medication, in a 'real world' clinical practice setting. To this end, the study enrolled several unique patient types including nonsteroidal anti inflammatory drug (NSAID) naive patients, those who had used NSAIDs in the past, regardless of outcome (positive or negative), and those who had previously taken a gastroprotective medication to improve GI tolerability or continued to take it as a precautionary measure to prevent NSAID associated GI damage.
   Methods:
   A total of 1067 individuals at 41 rheumatology practices were enrolled and prescribed flavocoxid, 500 mg b.i.d., for 60 days. The Physician Global Assessment of Disease (PGAD) visual analog scale (VAS) was used as a global measure to assess the signs and symptoms of OA, including joint discomfort, functional stiffness, functional mobility and quality of life. In addition, overall tolerability and upper GI tolerability were assessed by individual questions scored on a 5 part Likert scale. The physicians also monitored any interruption in, or cessation of use of flavocoxid due to a GI issue as well as changes in the use of gastroprotective medications. Adverse event (AE) monitoring was also conducted.
   Results:
   Of the 1005 patients who completed all follow up visits, physicians recorded an average improvement in VAS scores from 60.1 +/  18.8 at baseline to 42.5 +/  21.9 at 8 weeks (p<0.001) in 65.8% of patients. The PGAD VAS noted the most significant improvement in those patients with moderate to severe OA (baseline VAS [0 least severe, 100 most severe]: 0 25mm,  3.5 +/  6.9; 26 50 mm,  10.1 +/  17.0; 51 75 mm,  19.3 +/  19.5; 76 100 mm,  29.6 +/  23.6; p<0.001) and in those patients who were historically non responders to NSAIDs (40.3 +/  21.1 vs. 66.3 +/  17.7 at baseline; p<0.001). Patients who had previously responded well to NSAIDs had VAS scores of 42.6 +/  19.8 vs. 58.0 +/  18.0 (p<0.001) and NSAID naive subjects showed improvement in VAS scores from 60.5 +/  18.0 at baseline to 46.3 +/  23.7 (p<0.001). The study recorded a low incidence (similar to 10%) of AEs reported to physicians and good overall tolerability to flavocoxid. Flavocoxid showed improved upper GI tolerability in almost 50% of previous NSAID users (p<0.001) and reduced therapy interruption in similar to 90% of previous NSAID users with a history of GI related therapy interruptions (p 0.0001). Finally, the use of flavocoxid resulted in a>30% reduction in or cessation of the use of gastroprotective medications such as proton pump inhibitors (PPI) or histamine 2 receptor antagonists (H2s) in subjects (p<0.001).
   Conclusions:
   Within a 'real world' clinical rheumatology practice setting, flavocoxid demonstrated significant efficacy in the management of OA in multiple patient types and displayed significant potential for reducing the possibility of adverse GI side effects and use of gastroprotective agents associated with more traditional OA medications. A limitation of this study was that it was open label and not rigorously controlled. The large population may compensate for this lack of control.
C1 [Pillai, Lakshmi; Burnett, Bruce P.; Levy, Robert M.] Primus Pharmaceut Inc, Scottsdale, AZ 85251 USA.
RP Pillai, L (通讯作者)，Primus Pharmaceut Inc, 4725 N Scottsdale Rd,Suite 200, Scottsdale, AZ 85251 USA.
EM lpillai@primusrx.com
FU Primus Pharmaceuticals, Inc
FX Primus Pharmaceuticals, Inc. was the financial sponsor of this study.
CR Altavilla D, 2009, BRIT J PHARMACOL, V157, P1410, DOI 10.1111/j.1476 5381.2009.00322.x
   Altman RD, 2000, SEMIN ARTHRITIS RHEU, V30, P11, DOI 10.1053/sarh.2000.0248
   ANDREWS FJ, 1994, AM J PHYSIOL, V266, pG657, DOI 10.1152/ajpgi.1994.266.4.G657
   [Anonymous], 2009, GASTROENTEROL CLIN N, DOI DOI 10.1016/J.GTC.2009.03.007
   ASAKO H, 1992, AM J PHYSIOL, V262, pG903, DOI 10.1152/ajpgi.1992.262.5.G903
   Baatar D, 2002, AM J PATHOL, V160, P963, DOI 10.1016/S0002 9440(10)64918 8
   Bent S, 2006, ANN INTERN MED, V144, P257, DOI 10.7326/0003 4819 144 4 200602210 00007
   Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Burnett BP, 2007, J MED FOOD, V10, P442, DOI 10.1089/jmf.2006.255
   Burnett BP, 2007, J FOOD BIOCHEM, V31, P797, DOI 10.1111/j.1745 4514.2007.00142.x
   Burnett Bruce P, 2006, J Knee Surg, V19, P191
   BUTT JH, 1988, ALIMENT PHARM THERAP, V2, P121
   Carvajal A, 2004, EUR J CLIN PHARMACOL, V60, P439, DOI 10.1007/s00228 004 0782 8
   CRONBERG S, 1984, SCAND J HAEMATOL, V33, P155
   Day DG, 2005, EUR J OPHTHALMOL, V15, P336, DOI 10.1177/112067210501500304
   Dial S, 2004, CAN MED ASSOC J, V171, P33, DOI 10.1503/cmaj.1040876
   FRIES JF, 1991, J RHEUMATOL, V18, P6
   Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291
   Hippisley Cox J, 2005, BMJ BRIT MED J, V330, P1366, DOI 10.1136/bmj.330.7504.1366
   Huang JQ, 2002, LANCET, V359, P14, DOI 10.1016/S0140 6736(02)07273 2
   HUDSON N, 1993, GUT, V34, P742, DOI 10.1136/gut.34.6.742
   Jones CW, 1996, BRIT J CLIN PRACT, V50, P390
   Jüni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287
   Kaluzny JJ, 2003, ACTA OPHTHALMOL SCAN, V81, P349, DOI 10.1034/j.1600 0420.2003.00097.x
   Kimmey MB, 2004, ALIMENT PHARM THER, V19, P60, DOI 10.1111/j.0953 0673.2004.01840.x
   Langman M, 2001, PHARMACOEPIDEM DR S, V10, P517, DOI 10.1002/pds.653
   LAPENNA D, 1994, EUR J CLIN INVEST, V24, P476, DOI 10.1111/j.1365 2362.1994.tb02378.x
   LARKAI EN, 1989, J CLIN GASTROENTEROL, V11, P158, DOI 10.1097/00004836 198904000 00009
   LEUFKENS HG, 1990, PHARM WEEKBLAD, V12, P97, DOI 10.1007/BF01967602
   LEVY RM, 2010, EFFICACY SAFET UNPUB
   Levy RM, 2009, NUTR RES, V29, P298, DOI 10.1016/j.nutres.2009.04.003
   LU HL, STAT REV BRIEFING DO
   Martel Pelletier J, 1999, OSTEOARTHR CARTILAGE, V7, P315, DOI 10.1053/joca.1998.0177
   Martel Pelletier J, 2003, ANN RHEUM DIS, V62, P501, DOI 10.1136/ard.62.6.501
   Martel Pelletier J, 2004, ARTHRITIS RHEUM US, V50, P3925, DOI 10.1002/art.20632
   Moore RA, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 79
   MORGAN SL, 2008, J MED FOOD, V12, P1
   Nardino RJ, 2000, AM J GASTROENTEROL, V95, P3118
   Naunton M, 2000, J CLIN PHARM THER, V25, P333, DOI 10.1046/j.1365 2710.2000.00312.x
   Ofman JJ, 2004, AM J MED, V116, P835, DOI 10.1016/j.amjmed.2004.02.028
   PAULUS HE, 1988, ARTHRITIS RHEUM, V31, P1450, DOI 10.1002/art.1780311118
   PESKAR BM, 1991, GASTROENTEROLOGY, V100, P619, DOI 10.1016/0016 5085(91)80005 T
   PHAM CQD, 2006, PHARMACOL THERAPEUT, V31, P159
   RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140 6736(94)91843 0
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530
   Singh G., 1998, Am J Med, V105, p31S, DOI DOI 10.1016/S0002 9343(98)00072 2
   Singh Vijay Pal, 2005, Indian Journal of Experimental Biology, V43, P247
   Smalley WE, 1996, GASTROENTEROL CLIN N, V25, P373, DOI 10.1016/S0889 8553(05)70253 3
   Smalley WE, 1996, J GEN INTERN MED, V11, P461, DOI 10.1007/BF02599040
   Stewart WC, 2004, EYE, V18, P905, DOI 10.1038/sj.eye.6701353
   Stockl Karen, 2005, J Manag Care Pharm, V11, P550
   Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   VECKA M, 2008, BIOCH METAB, V16, P27
   WALKER AM, 1992, J CLIN EPIDEMIOL, V45, P187, DOI 10.1016/0895 4356(92)90015 F
   Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264
   Waller R., 2000, Collect. Forum, V14, P1
   Wright JM, 2002, CAN MED ASSOC J, V167, P1131
   Wright MJ, 2008, NUTR REV, V66, P103, DOI 10.1111/j.1753 4887.2008.00015.x
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
   Zimmermann KC, 1998, MOL PHARMACOL, V54, P536, DOI 10.1124/mol.54.3.536
NR 63
TC 21
Z9 21
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD MAY
PY 2010
VL 26
IS 5
BP 1055
EP 1063
DI 10.1185/03007991003694522
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 583MO
UT WOS:000276680900007
PM 20225990
DA 2025 08 17
ER

PT J
AU Guimaraes, GM
   Tesser Gamba, F
   Petrilli, AS
   Alves, MTS
   Garcia, RJ
   Oliveira, R
   Toledo, SRC
AF Guimaraes, G. M.
   Tesser Gamba, F.
   Petrilli, A. S.
   Alves, M. T. S.
   Garcia Filho, R. J.
   Oliveira, R.
   Toledo, S. R. C.
TI IGFBP5 in osteosarcoma tumorigenesis: Gene expression profile
   among metastatic and non metastatic patients
SO GENE
LA English
DT Article
DE Osteosarcoma; Pulmonary metastasis; IGFBP5 gene; Gene expression; MAPKs
   Pathway
ID FACTOR BINDING PROTEIN 5; GROWTH FACTOR I; PROGNOSTIC FACTORS;
   CHEMOTHERAPY; PROGRESSION; RESISTANCE; IMPACT; MAPK7
AB Osteosarcoma (OS) is the most frequent primary malignant bone tumor among children and adolescents, with a peak of incidence in the second decade of life. The presence of metastasis at diagnosis in OS patients significantly decreases the chances of survival and new therapy approaches are needed. The IGFBP5 gene is related to osteoblasts metabolism and some studies have pointed out a role of its low expressions in OS development and metastasis. In this study, we aimed to establish an IGFBP5 gene expression profile among metastatic and nonmetastatic OS patients throughout the treatment and development of the disease. Fresh frozen tumor samples were obtained from 40 patients admitted to treatment at the Pediatric Oncology Institute (IOP/GRAACC/UNIFESP) and divided by clinical status: metastatic or non metastatic disease. For each patient, samples before and after chemotherapy treatment were obtained, as well as metastasis and lung tissue surrounding metastasis samples from the metastatic patients. A quantitative real time PCR was used to investigate IGFBP5 expression. Our analyses demonstrate that non metastatic patients presented lower IGFBP5 expression in their prechemotherapy samples compared with metastatic patients, suggesting that low expressions of this gene could help triggering the OS tumorigenesis but that its action alone is not sufficient to activate the metastatic process. Heterogeneity in IGFBP5 expressions within groups was also seen. We observed that IGFBP5 and two MAPK genes, a downstream pathway in the IGFBP5 axis, are differentially expressed in OS samples of non metastatic patients. Further investigation about these genes' modulations might lead to a better understanding of metastasis development in OS.
C1 [Guimaraes, G. M.; Tesser Gamba, F.; Petrilli, A. S.; Alves, M. T. S.; Garcia Filho, R. J.; Oliveira, R.; Toledo, S. R. C.] Univ Fed Sao Paulo, Pediat Oncol Inst GRAACC, Dept Pediat, Sao Paulo, SP, Brazil.
   [Alves, M. T. S.] Univ Fed Sao Paulo, Pathol Dept, Sao Paulo, SP, Brazil.
   [Garcia Filho, R. J.] Univ Fed Sao Paulo, Orthoped & Traumatol Dept, Oncol Orthoped Grp, Sao Paulo, SP, Brazil.
   [Oliveira, R.] Univ Fed Sao Paulo, Surg Dept, Sao Paulo, SP, Brazil.
   [Guimaraes, G. M.; Toledo, S. R. C.] Univ Fed Sao Paulo, Morphol & Genet Dept, Genet Discipline, Sao Paulo, SP, Brazil.
   [Tesser Gamba, F.; Toledo, S. R. C.] Natl Sci & Technol Inst Childrens Canc Biol & Pedi, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP);
   Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP)
RP Tesser Gamba, F (通讯作者)，UNIFESP Univ Fed Sao Paulo, Inst Oncol Pediat, Programa Neurooncol, GRAACC Grp Apoio Ao Adolescente & Crianca Com Canc, 743,8th floor,Vila Clementino, BR 04023062 Sao Paulo, SP, Brazil.
EM francinegamba@graacc.org.br
RI Toledo, Silvia/C 2470 2012; Petrilli, Antonio/B 7906 2012; Gamba,
   Francine/E 2237 2015
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, DF,
   Brazil) [123760/2017 8, 125612/2018 4]; IOP GRAACC/UNIFESP (Grupo de
   Apoio ao Adolescente e a Crianca com Cancer, SP, Brazil)
FX This work was supported by CNPq (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, DF, Brazil, no. 123760/2017 8 and
   125612/2018 4) and IOP GRAACC/UNIFESP (Grupo de Apoio ao Adolescente e a
   Crianca com Cancer, SP, Brazil) .
CR Bacci G, 2003, CANCER, V97, P3068, DOI 10.1002/cncr.11456
   Batchu S, 2020, ONCOLOGY BASEL, V98, P814, DOI 10.1159/000508720
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   CAMPANACCI M, 1992, Z ORTHOP GRENZGEB, V130, P259, DOI 10.1055/s 2008 1039613
   Chen CL, 2021, CANCER LETT, V500, P1, DOI 10.1016/j.canlet.2020.12.024
   Chiappetta C, 2017, ONCOTARGET, V8, P80416, DOI 10.18632/oncotarget.19010
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Cormier JN, 2004, CA CANCER J CLIN, V54, P94, DOI 10.3322/canjclin.54.2.94
   Dankner M, 2018, Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations, V37, P3183
   Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001 0033
   Gorlick R., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P549
   Govoni KE, 2005, PEDIATR NEPHROL, V20, P261, DOI 10.1007/s00467 004 1658 y
   Güllü G, 2012, CHIN J CANCER, V31, P266, DOI 10.5732/cjc.011.10405
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Herzlieb N, 2000, CELL MOL BIOL, V46, P71
   Jaffe N, 2009, CANCER TREAT RES, V152, P239, DOI 10.1007/978 1 4419 0284 9_12
   Jentzsch T, 2014, ANTICANCER RES, V34, P3881
   JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   KAPPEL CC, 1994, CANCER RES, V54, P2803
   LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304 3835(03)00159 9
   Li SY, 2015, TUMOR BIOL, V36, P1329, DOI 10.1007/s13277 015 3181 0
   Luther GA, 2013, CANCER LETT, V336, P222, DOI 10.1016/j.canlet.2013.05.002
   Marko TA, 2016, PEDIATR BLOOD CANCER, V63, P1006, DOI 10.1002/pbc.25963
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Mirabello L, 2015, CANCER DISCOV, V5, P920, DOI 10.1158/2159 8290.CD 15 0125
   Mukherjee A, 2007, GROWTH HORM IGF RES, V17, P179, DOI 10.1016/j.ghir.2007.01.005
   Pérez Casellas LA, 2009, BBA GENE REGUL MECH, V1789, P78, DOI 10.1016/j.bbagrm.2008.08.013
   Petrilli AS, 2006, J CLIN ONCOL, V24, P1161, DOI 10.1200/JCO.2005.03.5352
   Roudi R, 2024, EUR RADIOL EXP, V8, DOI 10.1186/s41747 024 00467 9
   Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Tesser Gamba F, 2016, MOL CARCINOGEN, V55, P1700, DOI 10.1002/mc.22420
   Tesser Gamba F, 2012, HUM PATHOL, V43, P994, DOI 10.1016/j.humpath.2011.08.003
   Trujillo Paolillo A, 2017, ONCOTARGET, V8, P38530, DOI 10.18632/oncotarget.15869
   Wang YH, 2012, J SURG ONCOL, V105, P235, DOI 10.1002/jso.22077
   Xu JF, 2015, ONCOTARGET, V6, P23662, DOI 10.18632/oncotarget.4282
NR 37
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD JAN 20
PY 2025
VL 934
AR 149026
DI 10.1016/j.gene.2024.149026
EA OCT 2024
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA K8S5W
UT WOS:001346542200001
PM 39442824
DA 2025 08 17
ER

PT J
AU Lee, SH
   Ding, Y
   Yan, XT
   Kim, YH
   Jang, HD
AF Lee, Sang Hyun
   Ding, Yan
   Yan, Xi Tao
   Kim, Young Ho
   Jang, Hae Dong
TI Scopoletin and Scopolin Isolated from Artemisia iwayomogi
   Suppress Differentiation of Osteoclastic Macrophage RAW 264.7 Cells by
   Scavenging Reactive Oxygen Species
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID INHIBITORY ACTIVITY; STRESS
AB Artemisia iwayomogi has been used as a folk medicine for treating various diseases including inflammatory and immune related diseases. Scopoletin (1) and scopolin (2) were isolated from this species. Scopoletin (1) showed more potent peroxyl radical scavenging capacity, reducing capacity, and cellular antioxidant capacity compared to scopolin (2). The inhibitory effect of 1 on the receptor activator of nuclear factor kappa B ligand induced osteoclastic differentiation of RAW 264.7 macrophage cells was also more potent than that of 2. The production of general reactive oxygen species (ROS) and superoxide anions during differentiation of preosteodastic RAW 264.7 cells into osteoclasts was attenuated by compounds 1 and 2. These findings indicate that the suppressive effects of 1 and 2 on the differentiation of preosteoclastic RAW 264.7 cells is partially due to their intracellular antioxidant capacity, as they can scavenge ROS and play an important signaling role in the differentiation process.
C1 [Lee, Sang Hyun; Jang, Hae Dong] Hannam Univ, Dept Food & Nutr, Taejon 305811, South Korea.
   [Ding, Yan; Yan, Xi Tao; Kim, Young Ho] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea.
C3 Hannam University; Chungnam National University
RP Kim, YH (通讯作者)，Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea.
EM yhk@cnu.ac.kr; haedong@hnu.kr
RI Kang, Hyun Seung/J 5365 2012; kim, youngho/AAG 5029 2020
OI Kim, Young Ho/0000 0003 0703 1136; Yan, Xi Tao/0000 0001 8439 9087; ,
   Young Ho/0000 0002 7441 9459
FU Ministry for Food, Agriculture, Forestry, and Fisheries, Republic of
   Korea through the High Value Added Food Technology Development Program
FX This study was financially supported by the Ministry for Food,
   Agriculture, Forestry, and Fisheries, Republic of Korea, through the
   High Value Added Food Technology Development Program.
CR Aruoma OI, 1998, J AGR FOOD CHEM, V46, P5181, DOI 10.1021/jf980649b
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Ding Y, 2010, BIOL PHARM BULL, V33, P1448, DOI 10.1248/bpb.33.1448
   Han YH, 2008, INT J ONCOL, V33, P1099, DOI 10.3892/ijo_00000099
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   KAZUMA K, 1998, PHYTOCHEMISTRY, V49, P1421
   Kim AR, 2004, PHYTOTHER RES, V18, P1, DOI 10.1002/ptr.1358
   Kim GN, 2011, TOXICOL IN VITRO, V25, P138, DOI 10.1016/j.tiv.2010.10.005
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kim SS, 1997, ARCH PHARM RES, V20, P148, DOI 10.1007/BF02974002
   Koo Kyoung Ah, 1994, Archives of Pharmacal Research (Seoul), V17, P371, DOI 10.1007/BF02974179
   Kurihara H, 2004, BIOL PHARM BULL, V27, P1093, DOI 10.1248/bpb.27.1093
   Lautraite S, 2003, TOXICOL IN VITRO, V17, P207, DOI 10.1016/S0887 2333(03)00005 5
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Lee JA, 2008, INT IMMUNOPHARMACOL, V8, P117, DOI 10.1016/j.intimp.2007.10.022
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Moon HJ, 2012, BIOCHEM BIOPH RES CO, V418, P247, DOI 10.1016/j.bbrc.2012.01.005
   Moon PD, 2007, EUR J PHARMACOL, V555, P218, DOI 10.1016/j.ejphar.2006.10.021
   Qin Y, 2008, CELL BIOL INT, V32, P224, DOI 10.1016/j.cellbi.2007.08.028
   Rollinger JM, 2004, J MED CHEM, V47, P6248, DOI 10.1021/jm049655r
   Ryu JH, 2003, PHYTOTHER RES, V17, P485, DOI 10.1002/ptr.1180
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Srinivasan S, 2010, ANN NY ACAD SCI, V1192, P245, DOI 10.1111/j.1749 6632.2009.05377.x
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tian XJ, 2009, INT J PHARMACEUT, V367, P58, DOI 10.1016/j.ijpharm.2008.09.023
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
NR 30
TC 56
Z9 63
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163 3864
EI 1520 6025
J9 J NAT PROD
JI J. Nat. Prod.
PD APR
PY 2013
VL 76
IS 4
BP 615
EP 620
DI 10.1021/np300824h
PG 6
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA 135CX
UT WOS:000318264700019
PM 23510022
DA 2025 08 17
ER

PT J
AU Takada, Y
   Gresh, L
   Bozec, A
   Ikeda, E
   Kamiya, K
   Watanabe, M
   Kobayashi, K
   Asano, K
   Toyama, Y
   Wagner, EF
   Matsuo, K
AF Takada, Y.
   Gresh, L.
   Bozec, A.
   Ikeda, E.
   Kamiya, K.
   Watanabe, M.
   Kobayashi, K.
   Asano, K.
   Toyama, Y.
   Wagner, E. F.
   Matsuo, K.
TI Interstitial lung disease induced by gefitinib and Toll like receptor
   ligands is mediated by Fra 1
SO ONCOGENE
LA English
DT Article
DE Fra 1; gefitinib; interstitial lung disease; MCP 1; AP 1; TLR
ID SYSTEMIC INFLAMMATORY RESPONSE; DOUBLE EDGED SWORD; NF KAPPA B;
   PULMONARY FIBROSIS; C FOS; OSTEOCLAST DIFFERENTIATION; TYROSINE KINASE;
   INNATE IMMUNITY; BONE FORMATION; JUN PROTEINS
AB The role of the AP 1 transcription factor Fra 1 (encoded by Fosl1) in inflammatory responses associated with lung disease is largely unknown. Here, we show that Fra 1 overexpression in mice reduced proinflammatory cytokine production in response to injection of lipopolysaccharide (LPS), a Toll like receptor (TLR) ligand. Unexpectedly, Fra 1 transgenic mice died rapidly following LPS treatment, showing severe interstitial lung disease and displaying massive accumulation of macrophages and overproduction of several chemokines, including macrophage chemoattractant protein 1 (MCP 1, encoded by Ccl2). To assess the clinical relevance of Fra 1 in lung pathology, mice were treated with the anticancer drug gefitinib (Iressa), which can lead to interstitial lung disease in patients. Gefitinib treated mice showed increased Fosl1 and Ccl2 expression and developed interstitial lung disease in response to LPS, endogenous TLR ligands and chemotherapy. Moreover, deletion of Fra 1 or blocking MCP 1 receptor signaling in mice attenuated gefitinib enhanced lethality in response to LPS. Importantly, human alveolar macrophages showed enhanced LPS induced FOSL1 and CCL2 expression after gefitinib treatment. These results indicate that Fra 1 is an important mediator of interstitial lung disease following gefitinib treatment. Oncogene (2011) 30, 3821 3832;doi:10.1038/onc.2011.101; published online 4 April 2011
C1 [Matsuo, K.] Keio Univ, Lab Cell & Tissue Biol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Gresh, L.] Res Inst Mol Pathol IMP, Vienna, Austria.
   [Bozec, A.; Wagner, E. F.] Spanish Natl Canc Res Ctr CNIO, Canc Cell Biol Programme, Madrid, Spain.
   [Ikeda, E.] Keio Univ, Dept Pathol, Sch Med, Tokyo 1608582, Japan.
   [Kamiya, K.; Watanabe, M.; Kobayashi, K.] Keio Univ, Dept Surg, Sch Med, Tokyo 1608582, Japan.
   [Asano, K.] Keio Univ, Dept Med, Sch Med, Tokyo 1608582, Japan.
   [Toyama, Y.] Keio Univ, Dept Orthopaed Surg, Sch Med, Tokyo 1608582, Japan.
C3 Keio University; Vienna Biocenter (VBC); Research Institute of Molecular
   Pathology (IMP); Centro Nacional de Investigaciones Oncologicas (CNIO);
   Keio University; Keio University; Keio University; Keio University
RP Matsuo, K (通讯作者)，Keio Univ, Lab Cell & Tissue Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM matsuo@sc.itc.keio.ac.jp
RI Matsuo, Koichi/AFP 4369 2022; Matsuo, Koichi/K 5695 2012; Bozec,
   Aline/M 6942 2015; Toyama, Yoshiaki/K 5743 2013; takada, y/HKE 5714 2023
OI Matsuo, Koichi/0000 0002 1490 8955; Wagner, Erwin F/0000 0001 7872 0196;
   Gresh, Lionel/0000 0002 2333 1748; 
FU global COE; MEXT of Japan [21390425]; Naito Foundation; EMBO; Boehringer
   Ingelheim; Grants in Aid for Scientific Research [23791663, 21390425]
   Funding Source: KAKEN
FX We thank A Oide, M Asakawa and S Fukuse for technical support; T
   Yamaguchi for Fra 1 mouse maintenance; A Dent, A Ueda and M Busslinger
   for plasmids; H Daub for AX14596; and H Handa, S Sakamoto, K Maruyama, T
   Mitsudomi and L Bakiri for helpful input. We thank the Core
   Instrumentation Facility, Keio University School of Medicine, for
   technical assistance. This work was funded by a grant in aid from the
   global COE program, a grant in aid for Scientific Research (B) from MEXT
   of Japan (21390425), and a grant in aid for Scientific Research on
   Priority Areas and the Naito Foundation (YT). LG was funded by an EMBO
   Long Term Fellowship. IMP is funded by Boehringer Ingelheim.
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Bakiri L, 2007, BONE, V40, P867, DOI 10.1016/j.bone.2006.11.005
   BERGERS G, 1995, MOL CELL BIOL, V15, P3748
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111
   Brehmer D, 2005, CANCER RES, V65, P379
   Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8 4 303
   De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Eferl R, 2008, P NATL ACAD SCI USA, V105, P10525, DOI 10.1073/pnas.0801414105
   Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643
   Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038
   Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001
   Guinea Viniegra J, 2009, GENE DEV, V23, P2663, DOI 10.1101/gad.543109
   Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274
   Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140 6736(03)12190 3
   Ishii Y, 2006, AM J RESP CRIT CARE, V174, P550, DOI 10.1164/rccm.200509 1534OC
   Ishizaka A, 2001, CRIT CARE MED, V29, P896, DOI 10.1097/00003246 200104000 00043
   Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20
   Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kida H, 2005, AM J PHYSIOL LUNG C, V288, pL342, DOI 10.1152/ajplung.00016.2004
   Kris MG, 2003, JAMA J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149
   Lee DH, 2010, CLIN CANCER RES, V16, P1307, DOI 10.1158/1078 0432.CCR 09 1903
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08
   Morishita H, 2009, INT IMMUNOL, V21, P457, DOI 10.1093/intimm/dxp015
   PAINE R, 1993, J IMMUNOL, V150, P4561
   PETERSGOLDEN M, 1987, AM REV RESPIR DIS, V135, P1020
   Pircher A, 2010, LUNG CANCER, V69, P265, DOI 10.1016/j.lungcan.2010.01.017
   Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004
   Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928
   Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899
   Suzuki H, 2003, CANCER RES, V63, P5054
   Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200
   Takada Y, 2010, J IMMUNOL, V184, P1014, DOI 10.4049/jimmunol.0901196
   Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526 968X(200002)26:2<113::AID GENE3>3.0.CO;2 2
   Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749
   ULICH TR, 1991, AM J PATHOL, V138, P1485
   Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638
   Watanabe M, 2003, ANN THORAC SURG, V76, P1668, DOI 10.1016/S0003 4975(03)01015 4
   Wolter S, 2008, MOL CELL BIOL, V28, P4407, DOI 10.1128/MCB.00535 07
   Yamaguchi T, 2009, J BONE MINER RES, V24, P2056, DOI [10.1359/JBMR.090603, 10.1359/jbmr.090603]
   Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963
   Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 51
TC 23
Z9 25
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
J9 ONCOGENE
JI Oncogene
PD SEP
PY 2011
VL 30
IS 36
BP 3821
EP 3832
DI 10.1038/onc.2011.101
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 817PV
UT WOS:000294687200001
PM 21460858
DA 2025 08 17
ER

PT J
AU Kaiafa, G
   Perifanis, V
   Kakaletsis, N
   Chalvatzi, K
   Hatzitolios, AI
AF Kaiafa, G.
   Perifanis, V
   Kakaletsis, N.
   Chalvatzi, K.
   Hatzitolios, A., I
TI Hypercalcemia and multiple osteolytic lesions in an adult patient with
   relapsed pre B acute lymphoblastic leukemia: a case report
SO HIPPOKRATIA
LA English
DT Article
DE Precursor B acute lymphoblastic leukemia; relapse; hypercalcemia;
   osteolysis; multiple osteolytic lesions; adult
AB Background: Hypercalcemia and severe osteolytic lesions are rare complications of acute lymphoblastic leukemia (ALL) in childhood, and those cases share similar clinical features. Similarly, hypercalcemia is a rare feature in adult ALL. Here, we report an uncommon case of an adult patient with relapsed precursor B ALL (pre B ALL) who developed multiple osteolytic lesions and hypercalcemia.
   Case description: A 24 year old male patient, diagnosed with pre B ALL, was admitted in our hospital due to severe lumbar pain. After reviewing laboratory, radiological and clinical findings, the patient was diagnosed as having relapse of a mixed phenotype acute leukemia, according to bone marrow aspiration (9% blasts) and cytogenetic analysis, with multiple osteolytic lesions in all lumbar vertebrae, sacrum and ilium and severe hypercalcemia (13.3 mg/dL). Thus, FLAG IDA rescue therapy and hydration plus furosemide, corticoids and bisphosphonates were administered. Despite initial amelioration, his hematological condition deteriorated and he died due to severe sepsis as a result of severe immunosuppression.
   Conclusion: Two possible mechanisms have been suggested for hypercalcemia in hematological malignancy, either the leukemic infiltration or the paraneoplastic production of a variety of humoral factors and proinflammatory cytokines. However, hypercalcemia and severe osteolytic lesions are rare features in ALL adult patients and their combination may be indicator of poor prognosis.
C1 [Kaiafa, G.; Perifanis, V; Kakaletsis, N.; Hatzitolios, A., I] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Sch Med, Propedeut Dept Internal Med 1, Thessaloniki 54636, Greece.
   [Chalvatzi, K.] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Sch Med, Dept Immunol,Lab Microbiol, Thessaloniki 54636, Greece.
C3 Aristotle University of Thessaloniki; Ahepa University Hospital;
   Aristotle University of Thessaloniki; Ahepa University Hospital
RP Kakaletsis, N (通讯作者)，Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Sch Med, Propedeut Dept Internal Med 1, 1 Stilponos Kyriakidi St, Thessaloniki 54636, Greece.
EM kakaletsisnikos@yahoo.gr
RI Perifanis, Vasileios/S 1666 2019; Kakaletsis, Nikolaos/I 4072 2014
OI Kakaletsis, Nikolaos/0000 0002 5263 1803; Perifanis,
   Vasileios/0000 0002 7841 4428
CR [Anonymous], 2008, WHO CLASSIFICATION T
   [Anonymous], KOREAN J HEMATOL
   Antunovic P, 1998, MED ONCOL, V15, P58, DOI 10.1007/BF02787346
   Bassan R, 2004, CRIT REV ONCOL HEMAT, V50, P223, DOI 10.1016/j.critrevonc.2003.11.003
   Esbrit P, 2001, Clin Lab, V47, P67
   Fukasawa H, 2001, AM J MED SCI, V322, P109, DOI 10.1097/00000441 200108000 00009
   JACOBSON JO, 1989, CANCER AM CANCER SOC, V63, P917, DOI 10.1002/1097 0142(19890301)63:5<917::AID CNCR2820630522>3.0.CO;2 E
   Margolin J.F., 2002, Principles and practice of pediatric oncology, V4th, P489
   Maruyama H, 1992, Rinsho Ketsueki, V33, P514
   Mori Akio, 2007, Rinsho Ketsueki, V48, P559
   Niizuma H, 2007, PEDIATR BLOOD CANCER, V49, P990, DOI 10.1002/pbc.20782
   Ogihara T, 1995, Rinsho Ketsueki, V36, P29
   Shimonodan H, 2005, PEDIATR BLOOD CANCER, V45, P333, DOI 10.1002/pbc.20357
   SONI PN, 1993, POSTGRAD MED J, V69, P483, DOI 10.1136/pgmj.69.812.483
   STEIN A, 1988, BRIT J HAEMATOL, V70, P503, DOI 10.1111/j.1365 2141.1988.tb02526.x
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Verma SP, 2014, INDIAN J HEMATOL BLO, V30, pS24, DOI 10.1007/s12288 012 0221 4
NR 17
TC 11
Z9 12
U1 0
U2 0
PU LITHOGRAPHIA
PI THESSALONIKI
PA ANTONIADIS I PSARRAS TH G P, NEA REDESTOS, THESSALONIKI, 00000, GREECE
SN 1108 4189
J9 HIPPOKRATIA
JI Hippokratia
PY 2015
VL 19
IS 1
BP 78
EP 81
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CL0JM
UT WOS:000356628700016
PM 26435654
DA 2025 08 17
ER

PT J
AU Wang, WW
   Wang, SS
   Pan, L
AF Wang, Weiwei
   Wang, Shanshan
   Pan, Lei
TI Identification of key differentially expressed mRNAs and microRNAs in
   non small cell lung cancer using bioinformatics analysis
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE non small cell lung cancer; bioinformatics; microRNA; miRNA mRNA
   network; Kaplan Meier plot
ID POOR PROGNOSIS; GENE EXPRESSION; THERAPEUTIC TARGET; OVEREXPRESSION;
   UBCH10; CDC20; SIGNATURE; CARCINOMA; MIR 134; TOP2A
AB Non small cell lung cancer (NSCLC) is a leading cause of mortality worldwide. However, the pathogenesis of NSCLC remains to be fully elucidated. Therefore, the present study aimed to explore the differential expression of mRNAs and microRNAs (miRNAs/miRs) in NSCLC and to determine how these RNA molecules interact with one another to affect disease progression. Differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were identified from the GSE18842, GSE32863 and GSE29250 datasets downloaded from the Gene Expression Omnibus (GEO database). Functional and pathway enrichment analysis were performed based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. STRING, Cytoscape and MCODE were applied to construct a protein protein interaction (PPI) network and to screen hub genes. The interactions between miRNAs and mRNAs were predicted using miRWalk 3.0 and a miRNA mRNA regulatory network was constructed. The prognostic value of the identified hub genes was then evaluated via Kaplan Meier survival analyses using datasets from The Cancer Genome Atlas. A total of 782 DEGs and 46 DEMs were identified from the 3 GEO datasets. The enriched pathways and functions of the DEGs and target genes of the DEMs included osteoclast differentiation, cell adhesion, response to a drug, plasma membrane, extracellular exosome and protein binding. A subnetwork composed of 11 genes was extracted from the PPI network and the genes in this subnetwork were mainly involved in the cell cycle, cell division and DNA replication. A miRNA gene regulatory network was constructed with 247 miRNA gene pairs based on 6 DEMs and 210 DEGs. Kaplan Meier survival analysis indicated that the expression of ubiquitin E2 ligase C, cell division cycle protein 20, DNA topoisomerase II alpha, aurora kinase A and B, cyclin B2, maternal embryonic leucine zipper kinase, slit guidance ligand 3, phosphoglucomutase 5, endomucin, cysteine dioxygenase type 1, dihydropyrimidinase like 2, miR 130b, miR 1181 and miR 127 was significantly associated with overall survival of patients with lung adenocarcinoma. In the present study, a miRNA mRNA regulatory network in NSCLC was established, which may provide future avenues for scientific exploration and therapeutic targeting of NSCLC.
C1 [Wang, Weiwei; Wang, Shanshan; Pan, Lei] Capital Med Univ, Beijing Shijitan Hosp, Dept Pulm & Crit Care Med, 10 Tieyi Rd, Beijing 100038, Peoples R China.
C3 Capital Medical University
RP Pan, L (通讯作者)，Capital Med Univ, Beijing Shijitan Hosp, Dept Pulm & Crit Care Med, 10 Tieyi Rd, Beijing 100038, Peoples R China.
EM panlei@bjsjth.cn
RI Wang, Weiwei/N 7890 2017; Wang, Shan Shan/S 8186 2019
FU Beijing Municipal Science and Technology Commission Fund [2018 A20]
FX The present study was supported by Beijing Municipal Science and
   Technology Commission Fund (grant no. 2018 A20).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Azad FM, 2016, GENE, V577, P221, DOI 10.1016/j.gene.2015.11.040
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Berlingieri MT, 2007, ONCOGENE, V26, P2136, DOI 10.1038/sj.onc.1210010
   Bumbaca B, 2018, ACTA PHARM SIN B, V8, P518, DOI 10.1016/j.apsb.2018.04.007
   Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861
   Cellai D, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.175703
   Chen D, 2017, UROLOGY, V102, DOI 10.1016/j.urology.2016.12.050
   Choi YL, 2001, J KOREAN MED SCI, V16, P424, DOI 10.3346/jkms.2001.16.4.424
   Dettmer MS, 2014, J MOL ENDOCRINOL, V52, P181, DOI 10.1530/JME 13 0266
   Diboun I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 252
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fort RS, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164 018 0102 0
   Ganguly R, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169 014 0045 y
   Gao XH, 2016, EUR J PHARMACOL, V791, P603, DOI 10.1016/j.ejphar.2016.09.025
   Goswami RS, 2013, J CLIN ONCOL, V31, P2903, DOI 10.1200/JCO.2012.45.3050
   Guglietta S, 2016, SEMIN IMMUNOL, V28, P578, DOI 10.1016/j.smim.2016.10.011
   Guo JW, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389 018 0054 6
   Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555
   Hua X, 2019, EUR REV MED PHARMACO, V23, P1077, DOI 10.26355/eurrev_201902_16996
   Jemal A, 2010, CA CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
   Kato T, 2012, J SURG ONCOL, V106, P423, DOI 10.1002/jso.23109
   Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799
   Kovarikova V, 2016, ZYGOTE, V24, P326, DOI 10.1017/S0967199415000222
   Lan J, 2014, TUMOR BIOL, V35, P179, DOI 10.1007/s13277 013 1022 6
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692
   Li S, 2016, ONCOTARGET, V7, P6266, DOI 10.18632/oncotarget.6673
   Liu T, 2019, MOL ONCOL, V13, P1047, DOI 10.1002/1878 0261.12457
   Lou WY, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00066
   Lv K, 2019, EXP THER MED, V18, P451, DOI 10.3892/etm.2019.7619
   Ma LN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026502
   Mo ML, 2010, INT J BIOL MARKER, V25, P236, DOI 10.5301/JBM.2010.6088
   Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100
   Nam EJ, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755 8794 5 18
   Okamoto Y, 2003, CANCER RES, V63, P4167
   Osmani L, 2018, SEMIN CANCER BIOL, V52, P103, DOI 10.1016/j.semcancer.2017.11.019
   Pan JY, 2017, MOL THER NUCL ACIDS, V6, P140, DOI 10.1016/j.omtn.2016.11.003
   Parris TZ, 2014, INT J CANCER, V134, P1617, DOI 10.1002/ijc.28497
   Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111
   Qian XT, 2015, BIOMED PHARMACOTHER, V74, P222, DOI 10.1016/j.biopha.2015.08.004
   Qin Q, 2016, J CELL MOL MED, V20, P1974, DOI 10.1111/jcmm.12889
   Ruiz Martinez M, 2016, ONCOTARGET, V7, P51515, DOI 10.18632/oncotarget.9862
   Sanchez Palencia A, 2011, INT J CANCER, V129, P355, DOI 10.1002/ijc.25704
   Scardoni G, 2009, BIOINFORMATICS, V25, P2857, DOI 10.1093/bioinformatics/btp517
   Schneider MA, 2017, INT J ONCOL, V50, P365, DOI 10.3892/ijo.2017.3834
   Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111
   Sempere LF, 2011, EXPERT REV MOL DIAGN, V11, P813, DOI [10.1586/ERM.11.69, 10.1586/erm.11.69]
   Shi L, 2017, ONCOGENE, V36, P1631, DOI 10.1038/onc.2016.332
   Speers C, 2016, CLIN CANCER RES, V22, P5864, DOI 10.1158/1078 0432.CCR 15 2711
   Sun CC, 2016, ONCOTARGET, V7, P35960, DOI 10.18632/oncotarget.8482
   Takashima S, 2014, TUMOR BIOL, V35, P4257, DOI 10.1007/s13277 013 1556 7
   Takeshita M, 2013, LUNG CANCER, V80, P85, DOI 10.1016/j.lungcan.2012.12.018
   Tang JN, 2018, PEERJ, V6, DOI 10.7717/peerj.4674
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Tripathi V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003368
   van Ree JH, 2010, J CELL BIOL, V188, P83, DOI 10.1083/jcb.200906147
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang C, 2015, INT J MOL SCI, V16, P4698, DOI 10.3390/ijms16034698
   Wang J, 2017, WORLD J GASTROENTERO, V23, P1594, DOI 10.3748/wjg.v23.i9.1594
   Wang J, 2018, CANCER MED US, V7, P5665, DOI 10.1002/cam4.1816
   Wang LX, 2015, PHARMACOL THERAPEUT, V151, P141, DOI 10.1016/j.pharmthera.2015.04.002
   Wang TL, 2017, MED SCI MONITOR, V23, P984, DOI 10.12659/MSM.899060
   Wesierska Gadek J, 2012, FUTURE MED CHEM, V4, P51, DOI [10.4155/FMC.11.175, 10.4155/fmc.11.175]
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Wu F, 2018, CANCER CHEMOTH PHARM, V81, P999, DOI 10.1007/s00280 018 3578 8
   Wu T, 2010, J BIOL CHEM, V285, P18291, DOI 10.1074/jbc.M110.106575
   Wu Y, 2019, J ONCOL, V2019, DOI 10.1155/2019/8607859
   Xu ZJ, 2009, J CELL BIOL, V187, P637, DOI 10.1083/jcb.200906053
   Zhang HQ, 2018, EUR REV MED PHARMACO, V22, P1665, DOI 10.26355/eurrev_201803_14578
   Zheng HM, 2016, INT J NANOMED, V11, P5519, DOI 10.2147/IJN.S111594
   Zhong ZY, 2018, CANCERS, V10, DOI 10.3390/cancers10060180
NR 73
TC 4
Z9 4
U1 1
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD OCT
PY 2020
VL 20
IS 4
BP 3720
EP 3732
DI 10.3892/etm.2020.9105
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA NW4UQ
UT WOS:000575004100100
PM 32855723
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Elron Gross, I
   Glucksam, Y
   Margalit, R
AF Elron Gross, Inbar
   Glucksam, Yifat
   Margalit, Rimona
TI Liposomal dexamethasone diclofenac combinations for local osteoarthritis
   treatment
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Liposome; Osteoarthritis; Diclofenac; Dexamethasone; Cyclooxygenase; MRI
ID DRUG DELIVERY; IN VITRO; TARGETED DELIVERY; CO ENCAPSULATION;
   BIOADHESIVE; RELEASE; CARRIERS; SODIUM; CELLS; MODEL
AB Conventional chronic and acute treatments for osteoarthritis (CIA) are by oral NSAIDs (such as diclofenac) and intra articular injected glucocorticosteroids (such as dexamethasone). In free form, diclofenac and dexamethasone generate severe adverse effects with risks of toxicity. To reduce these drawbacks, we investigated local injections of liposomal formulations for diclofenac and dexamethasone (each alone, and their combination). Bioadhesive liposomes carrying hyaluronan (HA BAL) or collagen (COL BAL) as their surface anchored ligand were used for the task. Each drug alone or their combination showed high efficiency encapsulations (>= 80%) and performance as slow release depots (half lives in the range of 1 3 days under the fastest conditions). Employing RIA and immunoblot assay techniques, it was verified that the encapsulated drugs retained their biological activities: inhibitions of Cyclooxygenases enzyme activity (diclofenac) and of Cyclooxygenases protein expression (dexamethasone). Using live animal MRI, a single intra articular injection of each liposome drug(s) formulation sufficed to reduce knee joint inflammation in OA rats over a time span of 17 days, HA BAL better than COL BAL The most effective treatment was by the combination of both drugs in HA BAL, a single dose reducing the inflammation volume down to 12.9% from initial over that time span. We find all three HA BAL formulations worthy of further studies. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Elron Gross, Inbar; Glucksam, Yifat; Margalit, Rimona] Tel Aviv Univ, Dept Biochem, IL 69978 Tel Aviv, Israel.
C3 Tel Aviv University
RP Margalit, R (通讯作者)，Tel Aviv Univ, Dept Biochem, IL 69978 Tel Aviv, Israel.
EM rimona@post.tau.ac.il
CR Asgeirdóttir SA, 2007, MOL PHARMACOL, V72, P121, DOI 10.1124/mol.107.034140
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   Braunwald E., 2001, Harrisons Principles of Internal Medicine
   Butoescu N, 2008, J MICROENCAPSUL, V25, P339, DOI 10.1080/02652040801999551
   Butoescu N, 2009, BIOMATERIALS, V30, P1772, DOI 10.1016/j.biomaterials.2008.12.017
   Cevc G, 2008, INT J PHARMACEUT, V360, P29, DOI 10.1016/j.ijpharm.2008.01.051
   Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110
   Elron Gross I, 2008, BBA BIOMEMBRANES, V1778, P931, DOI 10.1016/j.bbamem.2008.01.002
   Elron Gross I, 2009, J CONTROL RELEASE, V135, P65, DOI 10.1016/j.jconrel.2008.12.005
   Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003 4819 133 9 200011070 00015
   Ferreira H, 2005, ANAL BIOANAL CHEM, V382, P1256, DOI 10.1007/s00216 005 3251 z
   GALLAGHER S, 2008, CURR PROTOC IMMUNOL, pCH8
   Ge ZG, 2006, ARTHRIT RHEUM ARTHR, V55, P493, DOI 10.1002/art.21994
   Gerwin N, 2006, ADV DRUG DELIVER REV, V58, P226, DOI 10.1016/j.addr.2006.01.018
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Gürsoy A, 2004, INT J PHARMACEUT, V271, P115, DOI 10.1016/j.ijpharm.2003.10.033
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   Holla VR, 2005, J BIOL CHEM, V280, P476, DOI 10.1074/jbc.M407403200
   Hunter DJ, 2006, BMJ BRIT MED J, V332, P639, DOI 10.1136/bmj.332.7542.639
   Jiang Y., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P45
   Kallinteri P, 2002, BIOMATERIALS, V23, P4819, DOI 10.1016/S0142 9612(02)00233 8
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   Kim HS, 2003, EXP MOL MED, V35, P203, DOI 10.1038/emm.2003.28
   Koning GA, 2006, ARTHRITIS RHEUM US, V54, P1198, DOI 10.1002/art.21719
   Larsen C, 2008, J PHARM SCI US, V97, P4622, DOI 10.1002/jps.21346
   Levin G, 2000, CHEMOTHERAPY, V46, P429, DOI 10.1159/000007323
   Loeuille D, 1997, J RHEUMATOL, V24, P133
   Lopes LB, 2004, COLLOID SURFACE B, V39, P151, DOI 10.1016/j.colsurfb.2004.09.004
   MARGALIT R, 1991, J CONTROL RELEASE, V17, P285, DOI 10.1016/0168 3659(91)90147 6
   MARGALIT R, 1995, CRIT REV THER DRUG, V12, P233, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2 3.30
   MENASSE R, 1978, SCAND J RHEUMATOL, P5
   Peer D, 2000, ARCH BIOCHEM BIOPHYS, V383, P185, DOI 10.1006/abbi.2000.2046
   Peer D, 2003, BBA BIOMEMBRANES, V1612, P76, DOI 10.1016/S0005 2736(03)00106 8
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Saravanan M, 2004, INT J PHARM, V283, P71, DOI 10.1016/j.ijpharm.2004.06.023
   Sarzi Puttini P, 2005, SEMIN ARTHRITIS RHEU, V35, P1, DOI 10.1016/j.semarthrit.2005.01.013
   Schumacher HR, 2005, AM J MED, V118, P1208, DOI 10.1016/j.amjmed.2005.05.003
   Schumacher I, 1997, J PHARM SCI, V86, P635, DOI 10.1021/js9503690
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Stöve J, 2002, ACTA ORTHOP SCAND, V73, P562, DOI 10.1080/000164702321022857
   Tardi PG, 2007, BBA BIOMEMBRANES, V1768, P678, DOI 10.1016/j.bbamem.2006.11.014
   Thakkar H, 2005, AAPS PHARMSCITECH, V6
   Towheed TE, 2006, J RHEUMATOL, V33, P567
   Tunçay M, 2000, J MICROENCAPSUL, V17, P145
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   YERUSHALMI N, 1994, ARCH BIOCHEM BIOPHYS, V313, P267, DOI 10.1006/abbi.1994.1387
   YERUSHALMI N, 1994, BBA BIOMEMBRANES, V1189, P13, DOI 10.1016/0005 2736(94)90274 7
   Yerushalmi N, 1998, ARCH BIOCHEM BIOPHYS, V349, P21, DOI 10.1006/abbi.1997.0356
NR 49
TC 88
Z9 99
U1 1
U2 40
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUL 6
PY 2009
VL 376
IS 1 2
BP 84
EP 91
DI 10.1016/j.ijpharm.2009.04.025
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 468CI
UT WOS:000267790800011
PM 19409466
DA 2025 08 17
ER

EF